https://www.biopharmawatch.com/news/CAMP/camp4-reports-third-quarter-2024-financial-results-completed-initial-public-offering-ipo-o-camp-20241121monthly0.5https://www.biopharmawatch.com/news/RNA/information-statement-atrium-therapeutics-inc-distribution-of-common-stock-0-001-par-value-rna-20260226monthly0.5https://www.biopharmawatch.com/news/CNTX/forward-looking-statements-this-press-release-contains-forward-looking-statements-within-t-cntx-20260518monthly0.5https://www.biopharmawatch.com/news/CNTX/important-notice-and-disclaimers-except-for-statements-of-historical-fact-any-information--cntx-20241202monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-oncology-reports-first-quarter-2026-financial-results-and-provides-business-update-chrs-20260511monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-oncology-reports-full-year-and-fourth-quarter-2025-financial-results-and-provides--chrs-20260309monthly0.5https://www.biopharmawatch.com/news/CHRS/xa9-2026-coherus-oncology-inc-coherus-oncology-value-proposition-shareholder-value-creatio-chrs-20251231monthly0.5https://www.biopharmawatch.com/news/CHRS/cautionary-statement-regarding-forward-looking-statements-certain-matters-discussed-herein-chrs-20251113monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-oncology-reports-second-quarter-2025-financial-results-and-provides-business-updat-chrs-20250807monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-first-quarter-2025-financial-results-and-provides-business-upd-chrs-20250512monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-completes-strategic-transformation-with-successful-divestiture-of-udenyca-franchis-chrs-20250414monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-repurchase-of-approximately-170-million-of-convertible-notes-remaining-6-chrs-20250401monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-fourth-quarter-full-year-2024-financial-results-and-provides-b-chrs-20250311monthly0.5https://www.biopharmawatch.com/news/CHRS/preliminary-revenues-and-cash-xa9-2025-coherus-biosciences-39-2024-total-year-expected-net-chrs-20250113monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-agreement-to-divest-udenyca-franchise-for-up-to-558-million-to-intas-pha-chrs-20241203monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-third-quarter-2024-financial-results-and-provides-business-upd-chrs-20241106monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-second-quarter-2024-financial-results-and-provides-business-up-chrs-20240808monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-divestiture-of-yusimry-adalimumab-aqvh-in-a-40-million-upfro-chrs-20240627monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-first-quarter-2024-financial-results-and-provides-business-upd-chrs-20240509monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-fourth-quarter-full-year-2023-financial-results-and-provides-c-chrs-20240307monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-completes-divestiture-of-ophthalmology-franchise-upfront-cash-payment-of-170-milli-chrs-20240304monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-amends-term-loan-agreement-with-pharmakon-advisors-lp-estimated-balance-of-75-mill-chrs-20240205monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-agreement-to-divest-ophthalmology-franchise-to-sandoz-in-170-million-upf-chrs-20240122monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-third-quarter-2023-financial-results-and-business-highlights-n-chrs-20231106monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-and-junshi-biosciences-announce-fda-approval-of-loqtorzi-toripalimab-tpzi-in-all-l-chrs-20231027monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-completes-surface-oncology-acquisition-clinical-stage-product-candidates-casdozoki-chrs-20230908monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-second-quarter-2023-financial-results-and-business-highlights--chrs-20230802monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-to-acquire-surface-oncology-surface-acquisition-and-potential-toripalimab-approval-chrs-20230616monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-first-quarter-2023-financial-results-and-business-highlights-u-chrs-20230508monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-fourth-quarter-and-full-year-2022-results-net-product-sales-of-chrs-20230306monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-third-quarter-2022-results-and-provides-business-update-udenyc-chrs-20221108monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-second-quarter-2022-results-and-provides-business-update-comme-chrs-20220804monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-first-quarter-2022-results-cimerli-bla-review-progressing-towa-chrs-20220505monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-fourth-quarter-and-full-year-2021-results-yusimry-adalimumab-a-chrs-20220217monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-and-junshi-biosciences-expand-immuno-oncology-collaboration-to-include-tigit-targe-chrs-20220110monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-secures-credit-financing-with-pharmakon-advisors-balance-sheet-strengt-chrs-20220107monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-third-quarter-2021-results-key-milestones-achieved-driving-nea-chrs-20211108monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-mourns-the-passing-of-board-member-alan-c-mendelson-chrs-20211011monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-mourns-the-passing-of-board-member-dr-samuel-nussbaum-chrs-20210929monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-second-quarter-2021-financial-results-and-immuno-oncology-and--chrs-20210805monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-first-quarter-2021-financial-results-and-immuno-oncology-and-b-chrs-20210506monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-fourth-quarter-and-full-year-2020-financial-results-product-re-chrs-20210224monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-to-expand-late-stage-pipeline-to-immuno-oncology-with-in-license-of-ju-chrs-20210201monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-appoints-alan-mendelson-and-mark-stolper-to-board-of-directors-chrs-20210107monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-third-quarter-2020-financial-results-third-quarter-udenyca-net-chrs-20201105monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-appoints-kimberly-tzoumakas-j-d-to-board-of-directors-chrs-20200803monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-second-quarter-2020-financial-results-second-quarter-udenyca-n-chrs-20200806monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-first-quarter-2020-financial-results-first-quarter-udenyca-net-chrs-20200507monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-proposed-convertible-senior-subordinated-notes-offering-chrs-20200414monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-fourth-quarter-and-full-year-2019-financial-results-full-year--chrs-20200227monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-corporate-highlights-and-third-quarter-2019-financial-results-chrs-20191106monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-corporate-highlights-and-second-quarter-2019-financial-results-chrs-20190801monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-unaudited-second-quarter-2019-udenyca-net-sales-of-79-millio-chrs-20190708monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-corporate-highlights-and-first-quarter-2019-financial-results-chrs-20190509monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-and-amgen-settle-trade-secrets-action-coherus-continues-to-commerciali-chrs-20190502monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-unaudited-first-quarter-2019-udenyca-net-sales-chrs-20190405monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-receives-transitional-pass-through-status-from-chrs-20190318monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-fourth-quarter-and-full-year-2018-financial-results-chrs-20190228monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-corporate-highlights-and-third-quarter-2018-financial-results-chrs-20181108monthly0.5https://www.biopharmawatch.com/news/CHRS/u-s-fda-approves-udenyca-pegfilgrastim-cbqv-chrs-20181102monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-receives-european-commission-approval-for-udenyca-pegfilgrastim-biosim-chrs-20180925monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-corporate-highlights-and-second-quarter-2018-financial-results-chrs-20180808monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-receives-positive-chmp-opinion-for-udenyca-pegfilgrastim-biosimilar-ca-chrs-20180727monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-proposed-public-offering-of-common-stock-chrs-20180521monthly0.5https://www.biopharmawatch.com/news/CHRS/u-s-food-and-drug-administration-accepts-and-acknowledges-coherus-biosciences-biologics-li-chrs-20180514monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-appoints-samuel-nussbaum-m-d-to-board-of-directors-chrs-20180510monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-corporate-highlights-and-first-quarter-2018-financial-results-chrs-20180510monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-re-submits-biologics-license-application-for-chs-1701-pegfilgrastim-bi-chrs-20180503monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-fourth-quarter-and-full-year-2017-financial-results-chrs-20180308monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-third-quarter-2017-operating-and-financial-results-chrs-20171106monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-provides-update-on-619-ipr-institution-decision-patent-trial-and-appea-chrs-20170907monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-positive-topline-results-for-clinical-pharmacokinetic-bioequ-chrs-20170828monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-secures-private-placement-from-temasek-first-tranche-of-75-million-secured-chrs-20170821monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-second-quarter-2017-corporate-highlights-and-financial-results-chrs-20170807monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-receives-complete-response-letter-from-fda-for-its-biologics-license-a-chrs-20170612monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-prevails-in-135-ipr-decision-patent-trial-and-appeal-board-invalidates-chrs-20170516monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-first-quarter-2017-corporate-highlights-and-financial-results-chrs-20170508monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-completes-patent-dance-exchange-with-amgen-for-neulasta-biosimilar-chrs-20170425monthly0.5https://www.biopharmawatch.com/news/CHRS/c-oherus-b-iosciences-i-nc-e-xecutive-c-hange-in-c-ontrol-and-s-everance-p-lan-and-s-ummar-chrs-20170405monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-fourth-quarter-and-full-year-2016-corporate-highlights-and-fin-chrs-20170313monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-chs-1420-chrs-20170302monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-proposed-public-offering-of-common-stock-chrs-20170207monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-files-four-petitions-for-inter-partes-review-against-abbvie-s-humira-f-chrs-20170131monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-marketing-authorization-application-to-european-medicines-agency-for-chs-1701-pegf-chrs-20161129monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-third-quarter-2016-operating-and-financial-results-continued-e-chrs-20161109monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-receives-decision-denying-institution-of-the-166-ipr-related-to-abbvie-chrs-20161107monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-fda-acceptance-of-351-k-biologics-license-application-to-u-s-chrs-20161006monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-completes-two-pharmacokinetic-bioequivalence-studies-of-chs-0214-chrs-20161006monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-second-quarter-2016-financial-and-operating-results-continued--chrs-20160809monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-positive-topline-results-for-chs-1701-pegfilgrastim-biosimilar-candidate-chrs-20160711monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-positive-phase-2b-efficacy-data-on-novel-oral-therapy-in-relapsing-remit-chrs-20160628monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-provides-update-on-iprs-patent-trial-and-appeal-board-institutes-two-a-chrs-20160613monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-proposed-public-offering-of-common-stock-chrs-20160523monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-provides-update-on-135-ipr-patent-trial-and-appeal-board-institutes-chrs-20160517monthly0.5https://www.biopharmawatch.com/news/CHRS/forward-looking-statements-except-for-the-historical-information-contained-herein-the-matt-chrs-20160511monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-first-quarter-2016-financial-and-operating-results-chs-1420-ad-chrs-20160509monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-fourth-quarter-and-year-end-2015-financial-and-operating-resul-chrs-20160229monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-chs-1701-neulasta-biosimilar-met-both-primary-endpoints-in-registration--chrs-20160201monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-and-baxalta-announce-chs-0214-investigational-etanercept-biosimilar-met-primary-ef-chrs-20160111monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-signs-strategic-manufacturing-agreement-with-kbi-biopharma-for-commerc-chrs-20151221monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-update-to-chs-1701-program-pegfilgrastim-follow-on-pk-pd-study-chrs-20151208monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-third-quarter-2015-financial-and-operating-results-and-corpora-chrs-20151109monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-announces-topline-results-of-chs-1701-pharmacokinetic-and-pharmacodynamic-biosimil-chrs-20151001monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-provides-updates-on-clinical-studies-increases-enrollment-in-chs-1701-immunogenici-chrs-20150903monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-second-quarter-2015-financial-and-operating-results-pegfilgras-chrs-20150810monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-first-quarter-2015-financial-and-operating-results-pegfilgrast-chrs-20150511monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-and-baxter-announce-amendment-to-etanercept-biosimilar-collaboration-a-chrs-20150415monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-fourth-quarter-and-year-end-2014-financial-and-operating-resul-chrs-20150323monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-finalizes-chs-1701-bla-enabling-clinical-program-and-initiates-pivotal-pharmacokin-chrs-20150317monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-reports-third-quarter-2014-financial-and-operating-results-management--chrs-20141215monthly0.5https://www.biopharmawatch.com/news/CHRS/coherus-biosciences-announces-closing-of-initial-public-offering-and-exercise-of-underwrit-chrs-20141112monthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-reports-fourth-quarter-2025-preliminary-unaudited-financial-results-and--lenz-20260107monthly0.5https://www.biopharmawatch.com/news/LENZ/corxel-and-lenz-therapeutics-announce-positive-topline-data-from-china-phase-3-presbyopia--lenz-20241027monthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-announces-submission-of-new-drug-application-to-u-s-food-and-drug-admini-lenz-20240812monthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-announces-30-million-investment-from-ridgeback-capital-lenz-20240715monthly0.5https://www.biopharmawatch.com/news/LENZ/document-lenz-therapeutics-announces-positive-topline-data-from-phase-3-clarity-presbyopia-lenz-20240403monthly0.5https://www.biopharmawatch.com/news/LENZ/document-report-of-independent-registered-public-accounting-firm-to-the-shareholders-and-t-lenz-20240322monthly0.5https://www.biopharmawatch.com/news/LENZ/graphite-bio-declares-special-dividend-in-connection-with-proposed-merger-with-lenz-therap-lenz-20240308monthly0.5https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-and-graphite-bio-announce-merger-agreement-merger-to-create-nasdaq-liste-lenz-20231115monthly0.5https://www.biopharmawatch.com/news/LENZ/graphite-bio-announces-departure-of-chief-financial-officer-lenz-20230623monthly0.5https://www.biopharmawatch.com/news/LENZ/graphite-bio-reports-recent-business-progress-and-fourth-quarter-and-fiscal-year-2022-fina-lenz-20230320monthly0.5https://www.biopharmawatch.com/news/LENZ/graphite-bio-announces-process-to-explore-strategic-alternatives-and-corporate-restructuri-lenz-20230222monthly0.5https://www.biopharmawatch.com/news/LENZ/graphite-bio-announces-voluntary-pause-of-phase-1-2-cedar-study-of-nulabeglogene-autogedte-lenz-20230105monthly0.5https://www.biopharmawatch.com/news/LENZ/graphite-bio-presents-preclinical-data-for-novel-sequencing-method-used-to-determine-gene--lenz-20221211monthly0.5https://www.biopharmawatch.com/news/LENZ/graphite-bio-reports-recent-business-progress-and-third-quarter-2022-financial-results-dos-lenz-20221109monthly0.5https://www.biopharmawatch.com/news/LENZ/graphite-bio-announces-abstracts-accepted-for-upcoming-64-th-ash-annual-meeting-and-exposi-lenz-20221103monthly0.5https://www.biopharmawatch.com/news/LENZ/graphite-bio-reports-recent-business-progress-and-second-quarter-2022-financial-results-do-lenz-20220811monthly0.5https://www.biopharmawatch.com/news/LENZ/graphite-bio-doses-first-patient-with-investigational-gene-editing-therapy-gph101-for-sick-lenz-20220811monthly0.5https://www.biopharmawatch.com/news/LENZ/graphite-bio-presents-preclinical-gene-replacement-data-for-gph102-for-beta-thalassemia-at-lenz-20220713monthly0.5https://www.biopharmawatch.com/news/LENZ/graphite-bio-presents-preclinical-gene-replacement-data-for-gph102-for-beta-thalassemia-at-lenz-20220516monthly0.5https://www.biopharmawatch.com/news/LENZ/graphite-bio-reports-recent-business-progress-and-first-quarter-2022-financial-results-gph-lenz-20220512monthly0.5https://www.biopharmawatch.com/news/LENZ/graphite-bio-reports-recent-business-progress-and-fourth-quarter-and-fiscal-year-2021-fina-lenz-20220321monthly0.5https://www.biopharmawatch.com/news/LENZ/learn-more-about-graphite-bio-by-visiting-www-graphitebio-com-and-following-the-company-on-lenz-20220302monthly0.5https://www.biopharmawatch.com/news/LENZ/graphite-bio-enrolls-first-patient-in-phase-1-2-clinical-trial-of-gph101-for-sickle-cell-d-lenz-20211117monthly0.5https://www.biopharmawatch.com/news/LENZ/graphite-bio-reports-recent-business-progress-and-third-quarter-2021-financial-results-rec-lenz-20211110monthly0.5https://www.biopharmawatch.com/news/LENZ/graphite-bio-reports-recent-business-progress-and-second-quarter-2021-financial-results-on-lenz-20210812monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-2oti-proprietary-disclaimers-forward-looking-statements-this-pres-osur-20260506monthly0.5https://www.biopharmawatch.com/news/OSUR/strategy-growth-outlook-orasure-is-executing-a-focused-strategy-with-near-term-catalysts-e-osur-20260330monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-2oti-proprietary-disclaimers-forward-looking-statements-this-pres-osur-20260225monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-media-contact-jason-plagman-amy-koch-vp-investor-relations-director-corpo-osur-20260105monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-2oti-proprietary-disclaimers-forward-looking-statements-this-pres-osur-20251105monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-jason-plagman-vp-investor-relations-investorinfo-orasure-com-media-contac-osur-20250324monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-2-this-presentation-contains-certain-forward-looking-statements-w-osur-20241219monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-2-this-presentation-contains-certain-forward-looking-statements-w-osur-20240104monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-scott-gleason-svp-investor-relations-corp-communications-484-425-0588-sgl-osur-20230510monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-scott-gleason-svp-investor-relations-corporate-communications-484-425-058-osur-20230214monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-scott-gleason-svp-investor-relations-corp-communications-484-425-0588-sgl-osur-20221108monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-scott-gleason-svp-investor-relations-corp-communications-484-425-0588-sgl-osur-20220809monthly0.5https://www.biopharmawatch.com/news/OSUR/carrie-eglinton-manner-appointed-chief-executive-officer-of-orasure-osur-20220523monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-scott-gleason-interim-cfo-svp-investor-relations-corp-communications-484--osur-20220510monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-scott-gleason-interim-cfo-svp-investor-relations-corp-communications-484--osur-20220223monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-scott-gleason-interim-cfo-svp-investor-relations-corp-communications-484--osur-20211109monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-scott-gleason-interim-cfo-svp-investor-relations-corp-communications-484--osur-20211103monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-scott-gleason-svp-investor-relations-corporate-communications-484-425-058-osur-20211004monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-scott-gleason-interim-cfo-svp-investor-relations-corp-communications-484--osur-20210923monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-scott-gleason-interim-cfo-svp-investor-relations-corp-communications-484--osur-20210920monthly0.5https://www.biopharmawatch.com/news/OSUR/forward-looking-statements-disclaimer-this-presentation-contains-certain-forward-looking-s-osur-20210908monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-scott-gleason-interim-cfo-svp-investor-relations-corporate-communications-osur-20210902monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-scott-gleason-svp-investor-relations-corporate-communications-484-425-058-osur-20210803monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-sam-martin-argot-partners-212-600-1902-orasure-argotpartners-com-media-co-osur-20210505monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-sam-martin-argot-partners-212-600-1902-orasure-argotpartners-com-media-co-osur-20210301monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-media-contact-sam-martin-jeanne-mell-argot-partners-vp-corporate-communic-osur-20201221monthly0.5https://www.biopharmawatch.com/news/OSUR/forward-looking-statements-disclaimer-this-presentation-contains-certain-forward-looking-s-osur-20201105monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-media-contact-sam-martin-jeanne-mell-argot-partners-vp-corporate-communic-osur-20201104monthly0.5https://www.biopharmawatch.com/news/OSUR/forward-looking-statements-disclaimer-this-presentation-contains-certain-forward-looking-s-osur-20200901monthly0.5https://www.biopharmawatch.com/news/OSUR/forward-looking-statements-disclaimer-this-presentation-contains-certain-forward-looking-s-osur-20200825monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-sam-martin-argot-partners-212-600-1902-orasure-argotpartners-com-media-co-osur-20200805monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-media-contact-sam-martin-jeanne-mell-argot-partners-vp-corporate-communic-osur-20200602monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-sam-martin-argot-partners-212-600-1902-orasure-argotpartners-com-media-co-osur-20200529monthly0.5https://www.biopharmawatch.com/news/OSUR/s-roberto-cuca-jeanne-mell-chief-financial-officer-610-882-1820-vp-corporate-communication-osur-20200506monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-roberto-cuca-chief-financial-officer-610-882-1820-investorinfo-orasure-co-osur-20200505monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-robert-cuca-chief-financial-officer-610-882-1820-investorinfo-orasure-com-osur-20200408monthly0.5https://www.biopharmawatch.com/news/OSUR/s-roberto-cuca-chief-financial-officer-610-882-1820-investorinfo-orasure-com-jeanne-mell-v-osur-20200406monthly0.5https://www.biopharmawatch.com/news/OSUR/s-roberto-cuca-jeanne-mell-chief-financial-officer-610-882-1820-vp-corporate-communication-osur-20200219monthly0.5https://www.biopharmawatch.com/news/OSUR/roberto-cuca-jeanne-mell-chief-financial-officer-610-882-1820-vp-corporate-communications--osur-20191106monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-roberto-cuca-chief-financial-officer-610-882-1820-investorinfo-orasure-co-osur-20190819monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-robert-cuca-chief-financial-officer-610-882-1820-investorinfo-orasure-com-osur-20190814monthly0.5https://www.biopharmawatch.com/news/OSUR/roberto-cuca-jeanne-mell-chief-financial-officer-610-882-1820-vp-corporate-communications--osur-20190806monthly0.5https://www.biopharmawatch.com/news/OSUR/roberto-cuca-jeanne-mell-chief-financial-officer-610-882-1820-vp-corporate-communications--osur-20190508monthly0.5https://www.biopharmawatch.com/news/OSUR/roberto-cuca-jeanne-mell-chief-financial-officer-610-882-1820-vp-corporate-communications--osur-20190206monthly0.5https://www.biopharmawatch.com/news/OSUR/roberto-cuca-jeanne-mell-chief-financial-officer-vp-corporate-communications-610-882-1820--osur-20190104monthly0.5https://www.biopharmawatch.com/news/OSUR/roberto-cuca-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-com-osur-20181107monthly0.5https://www.biopharmawatch.com/news/OSUR/roberto-cuca-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-com-osur-20180808monthly0.5https://www.biopharmawatch.com/news/OSUR/shauna-white-corporate-marketing-manager-484-353-1575-media-orasure-com-www-orasure-com-or-osur-20180504monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20180502monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20180207monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-shauna-white-chief-financial-officer-corporate-marketing-manager-610-882-18-osur-20180202monthly0.5https://www.biopharmawatch.com/news/OSUR/jack-e-jerrett-senior-vice-president-general-counsel-and-secretary-610-882-1820-jjerrett-o-osur-20180104monthly0.5https://www.biopharmawatch.com/news/OSUR/first-amendment-to-credit-agreement-this-first-amendment-to-credit-agreement-this-amendmen-osur-20171220monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20171101monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20170802monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-shauna-white-chief-financial-officer-corporate-marketing-manager-610-882-18-osur-20170622monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20170503monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20170224monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20170208monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-shauna-white-chief-financial-officer-corporate-marketing-manager-610-882-18-osur-20170206monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-analyst-day-osur-20161129monthly0.5https://www.biopharmawatch.com/news/OSUR/ronny-lancaster-has-been-appointed-to-replace-dr-tang-as-chairman-of-the-compensation-comm-osur-20161115monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20161102monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20160803monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-and-abbvie-agree-to-an-early-termination-of-hcv-co-promotion-agreemen-osur-20160701monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20160504monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure--osur-20160323monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20160203monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20151104monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20150805monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20150506monthly0.5https://www.biopharmawatch.com/news/OSUR/amendment-no-3-to-employment-agreement-this-amendment-no-3-to-employment-agreement-entered-osur-20150327monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20150204monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20141105monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20140806monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-media-contact-chief-financial-officer-jennifer-moritz-610-882-1820-zer0-to--osur-20140625monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-jennifer-moritz-chief-financial-officer-zer0-to-5ive-for-orasure-technologi-osur-20140611monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20140507monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20140205monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-media-contact-ron-spair-jennifer-moritz-orasure-technologies-zer0-to-5ive-osur-20140107monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-ron-spair-orasure-technologies-610-882-1820-investorinfo-orasure-com-oras-osur-20131125monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-media-contact-ron-spair-jennifer-moritz-orasure-technologies-zer0-to-5ive-osur-20131121monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20131106monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20130807monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20130508monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20130206monthly0.5https://www.biopharmawatch.com/news/OSUR/jennifer-moritz-zer0-to-5ive-for-orasure-technologies-917-748-4006-jmoritz-0to5-com-orasur-osur-20121128monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20121107monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20120807monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-orasure-techn-osur-20120710monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-analyst-investor-conference-call-osur-20120705monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure--osur-20120703monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure--osur-20120515monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20120502monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-media-contact-ronald-h-spair-ashley-buford-chief-financial-officer-golinh-osur-20120404monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20120208monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-media-contact-ronald-h-spair-ashley-buford-chief-financial-officer-golinh-osur-20120103monthly0.5https://www.biopharmawatch.com/news/OSUR/the-corporate-plan-for-retirement-sm-executive-p-lan-basic-plan-document-important-note-th-osur-20111221monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-media-contact-ronald-h-spair-jennifer-moritz-chief-financial-officer-zer0-osur-20111129monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-media-contact-ronald-h-spair-jennifer-moritz-chief-financial-officer-zer0-osur-20111110monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20111102monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-media-contact-ronald-h-spair-jennifer-moritz-chief-financial-officer-zer0-osur-20110818monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-2011-second-quarter-analyst-investor-conference-call-osur-20110803monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-announces-2011-second-quarter-financial-results-osur-20110803monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-media-contact-ronald-h-spair-jennifer-moritz-chief-financial-officer-zer0-osur-20110725monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-2011-first-quarter-analyst-investor-conference-call-osur-20110504monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20110504monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure--osur-20110407monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-2010-fourth-quarter-and-full-year-analyst-investor-conference-cal-osur-20110209monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20110209monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-media-contact-ronald-h-spair-jennifer-moritz-chief-financial-officer-zer0-osur-20110104monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-2010-third-quarter-analyst-investor-conference-call-osur-20101109monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20101109monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-2010-second-quarter-analyst-investor-conference-call-osur-20100804monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20100804monthly0.5https://www.biopharmawatch.com/news/OSUR/investor-contact-media-contact-ronald-h-spair-jennifer-moritz-chief-financial-officer-zer0-osur-20100625monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-2010-first-quarter-analyst-investor-conference-call-osur-20100505monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20100505monthly0.5https://www.biopharmawatch.com/news/OSUR/orasure-technologies-inc-2009-fourth-quarter-and-full-year-analyst-investor-conference-cal-osur-20100210monthly0.5https://www.biopharmawatch.com/news/OSUR/ronald-h-spair-chief-financial-officer-610-882-1820-investorinfo-orasure-com-www-orasure-c-osur-20100210monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-provides-first-quarter-2026-financial-results-and-business-updates-c-nerv-20260505monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-announces-leadership-transition-jim-o-connor-joins-as-chief-business-officer-and-g-nerv-20260402monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-fourth-quarter-and-fiscal-year-2025-financial-results-and-bu-nerv-20260311monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-appoints-dr-inderjit-kaul-to-the-company-s-board-of-directors-nerv-20251119monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-financing-of-up-to-200-million-to-advance-roluperidone-for-nerv-20251021monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-receives-complete-response-letter-from-fda-for-new-drug-application--nerv-20240227monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-20-million-in-private-placement-priced-at-a-premium-to-mar-nerv-20230628monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-the-nda-filing-for-roluperidone-for-the-treatment-of-negat-nerv-20230501monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-update-on-its-new-drug-application-nda-for-roluperidone-fo-nerv-20221228monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-receives-refusal-to-file-letter-from-fda-for-its-new-drug-applicatio-nerv-20221017monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-listing-transfer-to-nasdaq-capital-market-nerv-20220909monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-submits-new-drug-application-to-fda-for-roluperidone-for-the-treatme-nerv-20220822monthly0.5https://www.biopharmawatch.com/news/NERV/disclaimer-this-presentation-contains-forward-looking-statements-which-are-subject-to-the--nerv-20220413monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-provides-update-from-type-c-meeting-with-fda-and-next-steps-in-prepa-nerv-20220407monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-publication-of-roluperidone-phase-3-study-results-in-schiz-nerv-20220228monthly0.5https://www.biopharmawatch.com/news/NERV/forward-looking-statement-safe-harbor-forward-looking-safe-harbor-statement-this-presentat-nerv-20220105monthly0.5https://www.biopharmawatch.com/news/NERV/abstract-objective-in-a-previous-large-multi-national-trial-roluperidone-min-101-a-compoun-nerv-20211208monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-fda-recommendation-for-type-c-meeting-to-discuss-evidence--nerv-20211103monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-promotion-of-geoff-race-to-president-frederick-ahlholm-is--nerv-20211011monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-study-results-demonstrating-bioequivalence-of-phase-2b-pha-nerv-20210930monthly0.5https://www.biopharmawatch.com/news/NERV/william-b-boni-vp-investor-relations-corp-communications-minerva-neurosciences-inc-617-600-nerv-20210908monthly0.5https://www.biopharmawatch.com/news/NERV/william-b-boni-minerva-neurosciences-inc-617-600-7376-royalty-pharma-plc-212-883-2295-for--nerv-20210119monthly0.5https://www.biopharmawatch.com/news/NERV/william-b-boni-vp-investor-relations-corp-communications-minerva-neurosciences-inc-617-600-nerv-20201201monthly0.5https://www.biopharmawatch.com/news/NERV/william-b-boni-vp-investor-relations-corp-communications-minerva-neurosciences-inc-617-600-nerv-20200701monthly0.5https://www.biopharmawatch.com/news/NERV/forward-looking-statement-safe-harbor-this-presentation-contains-forward-looking-statement-nerv-20200605monthly0.5https://www.biopharmawatch.com/news/NERV/william-b-boni-vp-investor-relations-corp-communications-minerva-neurosciences-inc-617-600-nerv-20200529monthly0.5https://www.biopharmawatch.com/news/NERV/all-trademarks-trade-names-and-service-marks-appearing-in-this-presentation-are-the-proper-nerv-20200401monthly0.5https://www.biopharmawatch.com/news/NERV/william-b-boni-vp-investor-relations-corp-communications-minerva-neurosciences-inc-617-600-nerv-20200309monthly0.5https://www.biopharmawatch.com/news/NERV/william-b-boni-vp-investor-relations-corp-communications-minerva-neurosciences-inc-617-600-nerv-20200205monthly0.5https://www.biopharmawatch.com/news/NERV/william-b-boni-vp-investor-relations-corp-communications-minerva-neurosciences-inc-617-600-nerv-20200106monthly0.5https://www.biopharmawatch.com/news/NERV/william-b-boni-vp-investor-relations-corp-communications-minerva-neurosciences-inc-617-600-nerv-20191218monthly0.5https://www.biopharmawatch.com/news/NERV/william-b-boni-vp-investor-relations-corp-communications-minerva-neurosciences-inc-617-600-nerv-20191001monthly0.5https://www.biopharmawatch.com/news/NERV/catalent-and-minerva-neurosciences-enter-commercial-supply-agreement-for-schizophrenia-dru-nerv-20190923monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-achievement-of-primary-and-key-secondary-objectives-in-pha-nerv-20190624monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-positive-top-line-results-in-phase-2b-clinical-trial-with--nerv-20190513monthly0.5https://www.biopharmawatch.com/news/NERV/william-b-boni-vp-investor-relations-corp-communications-minerva-neurosciences-inc-617-600-nerv-20180717monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-inc-amended-and-restated-2013-equity-incentive-plan-amended-and-rest-nerv-20180611monthly0.5https://www.biopharmawatch.com/news/NERV/all-trademarks-trade-names-and-service-marks-appearing-in-this-presentation-are-the-proper-nerv-20180322monthly0.5https://www.biopharmawatch.com/news/NERV/all-trademarks-trade-names-and-service-marks-appearing-in-this-presentation-are-the-proper-nerv-20180221monthly0.5https://www.biopharmawatch.com/news/NERV/william-b-boni-vp-investor-relations-corp-communications-minerva-neurosciences-inc-617-600-nerv-20180205monthly0.5https://www.biopharmawatch.com/news/NERV/all-trademarks-trade-names-and-service-marks-appearing-in-this-presentation-are-the-proper-nerv-20180108monthly0.5https://www.biopharmawatch.com/news/NERV/william-b-boni-vp-investor-relations-corp-communications-minerva-neurosciences-inc-617-600-nerv-20171211monthly0.5https://www.biopharmawatch.com/news/NERV/william-b-boni-vp-investor-relations-corp-communications-minerva-neurosciences-inc-617-600-nerv-20170825monthly0.5https://www.biopharmawatch.com/news/NERV/william-b-boni-vp-investor-relations-corp-communications-minerva-neurosciences-inc-617-600-nerv-20170724monthly0.5https://www.biopharmawatch.com/news/NERV/william-b-boni-vp-investor-relations-corp-communications-minerva-neurosciences-inc-617-600-nerv-20170627monthly0.5https://www.biopharmawatch.com/news/NERV/william-b-boni-vp-investor-relations-corp-communications-minerva-neurosciences-inc-617-600-nerv-20170531monthly0.5https://www.biopharmawatch.com/news/NERV/william-b-boni-vp-investor-relations-corp-communications-minerva-neurosciences-inc-617-600-nerv-20170515monthly0.5https://www.biopharmawatch.com/news/NERV/this-presentation-contains-certain-forward-looking-statements-about-minerva-neurosciences--nerv-20170227monthly0.5https://www.biopharmawatch.com/news/NERV/william-b-boni-vp-investor-relations-corp-communications-minerva-neurosciences-inc-617-600-nerv-20170120monthly0.5https://www.biopharmawatch.com/news/NERV/this-presentation-contains-certain-forward-looking-statements-about-minerva-neurosciences--nerv-20170106monthly0.5https://www.biopharmawatch.com/news/NERV/william-b-boni-vp-investor-relations-corp-communications-minerva-neurosciences-inc-617-600-nerv-20161205monthly0.5https://www.biopharmawatch.com/news/NERV/william-b-boni-vp-investor-relations-corp-communications-minerva-neurosciences-inc-617-600-nerv-20161026monthly0.5https://www.biopharmawatch.com/news/NERV/william-b-boni-vp-investor-relations-corp-communications-minerva-neurosciences-inc-617-600-nerv-20160926monthly0.5https://www.biopharmawatch.com/news/NERV/william-b-boni-vp-investor-relations-corp-communications-minerva-neurosciences-inc-617-600-nerv-20160613monthly0.5https://www.biopharmawatch.com/news/NERV/june-2016-innovative-cns-therapies-to-address-unmet-medical-needs-this-presentation-contai-nerv-20160613monthly0.5https://www.biopharmawatch.com/news/NERV/this-presentation-contains-certain-forward-looking-statements-about-minerva-neurosciences--nerv-20160606monthly0.5https://www.biopharmawatch.com/news/NERV/william-b-boni-vp-investor-relations-corp-communications-minerva-neurosciences-inc-617-600-nerv-20160526monthly0.5https://www.biopharmawatch.com/news/NERV/william-b-boni-vp-investor-relations-corp-communications-minerva-neurosciences-inc-617-600-nerv-20160311monthly0.5https://www.biopharmawatch.com/news/NERV/william-b-boni-vp-investor-relations-corp-communications-minerva-neurosciences-inc-617-600-nerv-20160222monthly0.5https://www.biopharmawatch.com/news/NERV/william-b-boni-vp-investor-relations-corp-communications-minerva-neurosciences-inc-617-600-nerv-20160201monthly0.5https://www.biopharmawatch.com/news/NERV/william-b-boni-vp-investor-relations-corp-communications-minerva-neurosciences-inc-617-600-nerv-20160111monthly0.5https://www.biopharmawatch.com/news/NERV/william-b-boni-vp-investor-relations-corp-communications-minerva-neurosciences-inc-617-600-nerv-20151229monthly0.5https://www.biopharmawatch.com/news/NERV/william-b-boni-vp-investor-relations-corp-communications-minerva-neurosciences-inc-617-600-nerv-20151218monthly0.5https://www.biopharmawatch.com/news/NERV/william-b-boni-vp-investor-relations-corp-communications-minerva-neurosciences-inc-617-600-nerv-20151209monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-appointment-of-dr-david-kupfer-to-its-board-of-directors-nerv-20151102monthly0.5https://www.biopharmawatch.com/news/NERV/william-b-boni-vp-investor-relations-corp-communications-minerva-neurosciences-inc-617-600-nerv-20150924monthly0.5https://www.biopharmawatch.com/news/NERV/william-b-boni-vp-investor-relations-corp-communications-minerva-neurosciences-inc-617-600-nerv-20150616monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-fourth-quarter-and-full-year-2014-financial-results-min-101--nerv-20150326monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-completes-private-placement-raises-31-million-nerv-20150318monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-31-million-financing-nerv-20150313monthly0.5https://www.biopharmawatch.com/news/NERV/all-trademarks-trade-names-and-service-marks-appearing-in-this-presentation-are-the-proper-nerv-20150303monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-positive-phase-1-data-with-min-202-selective-orexin-2-antago-nerv-20150121monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-15-million-debt-facility-with-oxford-finance-llc-and-silic-nerv-20150120monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-positive-data-showing-an-analog-of-minerva-s-min-301-compoun-nerv-20150105monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-announces-completion-of-development-and-final-selection-of-once-dail-nerv-20141203monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-appoints-dr-remy-luthringer-as-ceo-waltham-ma-nerv-20141125monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-third-quarter-2014-financial-results-advanced-lead-compound--nerv-20141106monthly0.5https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-reports-second-quarter-2014-financial-results-advanced-lead-compound-nerv-20140807monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-expands-commercial-and-business-development-opportunities-through-realignment-of--huma-20260424monthly0.5https://www.biopharmawatch.com/news/HUMA/universally-implantable-regenerative-human-tissue-2-disclaimer-these-slides-and-the-accomp-huma-20260319monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-p-ricing-of-60-0-million-oversubscribed-registered-direct-offering-durh-huma-20251007monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-second-quarter-2025-financial-results-and-provides-business-update-tota-huma-20250811monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-first-quarter-2025-financial-results-and-provides-business-update-comme-huma-20250513monthly0.5https://www.biopharmawatch.com/news/HUMA/document-humacyte-statement-on-recent-attacks-durham-n-c-huma-20250417monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-fourth-quarter-and-year-end-2024-financial-results-and-provides-busines-huma-20250328monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-statement-on-new-york-times-article-durham-n-c-huma-20250327monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-inc-announces-proposed-public-offering-of-common-stock-durham-n-c-huma-20250325monthly0.5https://www.biopharmawatch.com/news/HUMA/universally-implantable-regenerative-human-tissue-2-disclaimer-these-slides-and-the-accomp-huma-20250325monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-fda-approval-of-symvess-acellular-tissue-engineered-vessel-tyod-for-the-huma-20241219monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-pricing-of-15-0-million-registered-direct-offering-durham-n-c-huma-20241114monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-third-quarter-2024-financial-results-and-business-update-fda-review-of-acellular--huma-20241108monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-presentation-of-positive-results-from-v007-phase-3-av-access-clinical-t-huma-20241028monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-pricing-of-30-0-million-registered-direct-offering-durham-n-c-huma-20241004monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-fda-communication-of-additional-time-required-to-complete-review-of-ace-huma-20240809monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-acellular-tissue-engineered-vessel-atev-meets-primary-endpoints-in-v007-phase-3-c-huma-20240731monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-first-quarter-2024-financial-results-and-business-update-biologics-license-applic-huma-20240510monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-fourth-quarter-and-year-end-2023-financial-results-and-business-update-biologics--huma-20240322monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-inc-announces-proposed-public-offering-of-common-stock-durham-n-c-huma-20240229monthly0.5https://www.biopharmawatch.com/news/HUMA/disclaimer-these-slides-and-the-accompanying-oral-presentation-contain-forward-looking-sta-huma-20240229monthly0.5https://www.biopharmawatch.com/news/HUMA/human-acellular-vessel-hav-biologics-license-application-granted-priority-review-by-u-s-fd-huma-20240209monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-submits-biologics-license-application-bla-to-u-s-fda-seeking-approval-of-human-ac-huma-20231212monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-third-quarter-2023-financial-results-and-business-update-positive-top-line-result-huma-20231109monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-positive-top-line-results-from-phase-2-3-trial-of-human-acellular-vesse-huma-20230912monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-second-quarter-2023-financial-results-and-business-update-completed-enrollment-in-huma-20230814monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-completes-enrollment-in-phase-2-3-trial-of-human-acellular-vessel-hav-for-vascula-huma-20230726monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-first-quarter-2023-financial-results-and-business-update-human-acellular-vessel-h-huma-20230512monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-fourth-quarter-and-year-end-2022-financial-results-and-business-update--huma-20230324monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-third-quarter-2022-financial-results-and-business-update-progress-continues-in-cl-huma-20221110monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-expands-board-of-directors-and-leadership-team-with-new-appointments-lt-general-b-huma-20220920monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-second-quarter-2022-financial-results-and-business-update-human-acellular-vessels-huma-20220812monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-first-quarter-2022-financial-results-and-business-update-human-acellular-vessels--huma-20220513monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-reports-fourth-quarter-and-year-end-2021-financial-results-and-provides-business--huma-20220329monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-inc-universally-implantable-regenerative-human-tissue-2-disclaimer-these-slides-a-huma-20220110monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-presents-new-12-month-data-from-havs-produced-using-commercial-scale-manufacturin-huma-20211115monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-reports-third-quarter-2021-financial-results-and-provides-business-highlights-com-huma-20211112monthly0.5https://www.biopharmawatch.com/news/HUMA/report-of-independent-registered-public-accounting-firm-to-the-board-of-directors-and-stoc-huma-20210830monthly0.5https://www.biopharmawatch.com/news/HUMA/alpha-healthcare-acquisition-corp-announces-shareholder-approval-of-business-combination-w-huma-20210824monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-addition-of-chief-commercial-officer-and-integration-of-commercial-scal-huma-20210817monthly0.5https://www.biopharmawatch.com/news/HUMA/alpha-healthcare-acquisition-corp-sets-huma-20210804monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-provide-investor-update-on-june-7-durham-n-c-huma-20210604monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-presentation-by-principal-investigator-highlighting-clinical-experience-huma-20210522monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-ceo-dr-laura-niklason-presents-advances-in-whole-lung-engineering-laboratory-and--huma-20210521monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-appoints-dale-sander-as-chief-financial-officer-proven-cfo-with-extensive-financi-huma-20210519monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-leadership-and-investigators-to-present-at-five-scientific-events-in-may-durham-n-huma-20210506monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-announces-positive-long-term-follow-up-data-from-phase-2-vascular-access-trial-fi-huma-20210420monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-secures-50-million-debt-facility-with-silicon-valley-bank-durham-n-c-huma-20210414monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-to-present-long-term-follow-up-data-from-phase-2-vascular-access-trial-at-charing-huma-20210305monthly0.5https://www.biopharmawatch.com/news/HUMA/alpha-healthcare-humacyte-merger-announcement-presentation-transcription-huma-20210217monthly0.5https://www.biopharmawatch.com/news/HUMA/humacyte-a-transformative-biotechnology-platform-company-capable-of-manufacturing-universa-huma-20210217monthly0.5https://www.biopharmawatch.com/news/HUMA/alpha-healthcare-acquisition-corp-announces-the-separate-trading-of-its-class-a-common-sto-huma-20201109monthly0.5https://www.biopharmawatch.com/news/HUMA/alpha-healthcare-acquisition-corp-index-to-financial-statement-page-report-of-independent--huma-20200922monthly0.5https://www.biopharmawatch.com/news/HUMA/alpha-healthcare-acquisition-corp-announces-pricing-of-100-000-000-initial-public-offering-huma-20200917monthly0.5https://www.biopharmawatch.com/news/IKT/corporate-overview-november-2025-disclaimer-this-presentation-contains-information-that-ma-ikt-20251120monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-announces-third-quarter-2025-financial-results-and-highlights-rece-ikt-20251114monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-announces-first-quarter-2025-financial-results-and-highlights-rece-ikt-20250514monthly0.5https://www.biopharmawatch.com/news/IKT/consulting-agreement-this-agreement-is-made-and-entered-into-as-of-ikt-20250411monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-announces-2024-financial-results-and-highlights-recent-activity-ne-ikt-20250327monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-announces-closing-of-up-to-275-million-financing-and-advancement-o-ikt-20241021monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-announces-pricing-of-110-million-private-placement-to-advance-ikt--ikt-20241009monthly0.5https://www.biopharmawatch.com/news/IKT/pah-business-presentation-clinical-development-of-disease-modifying-therapeutics-for-pulmo-ikt-20241009monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-announces-pricing-of-registered-direct-offering-and-warrant-induce-ikt-20240520monthly0.5https://www.biopharmawatch.com/news/IKT/q24-business-presentation-clinical-development-of-disease-modifying-therapeutics-for-neuro-ikt-20240429monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-issues-letter-to-shareholders-and-provides-update-on-development-p-ikt-20240418monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-inc-employment-agreement-this-employment-agreement-this-agreement--ikt-20240402monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-announces-preliminary-outcomes-of-its-pre-nda-meeting-with-the-fda-ikt-20240207monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-announces-planned-retirement-of-chief-financial-officer-joseph-fra-ikt-20240116monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-issues-a-letter-to-shareholders-and-comments-on-recent-trading-act-ikt-20230920monthly0.5https://www.biopharmawatch.com/news/IKT/by-electronic-delivery-to-mhwerner-inhibikase-com-jfrattaroli-inhibikase-com-ikt-20230717monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-announces-a-1-for-6-reverse-stock-split-boston-and-atlanta-ikt-20230629monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-announces-10-million-concurrent-registered-direct-offering-and-pri-ikt-20230125monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-announces-fda-has-lifted-the-full-clinical-hold-on-ikt-148009-in-p-ikt-20230125monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-reports-third-quarter-2022-financial-results-and-highlights-recent-ikt-20221115monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-announces-fda-clinical-hold-on-ikt-148009-programs-boston-and-atla-ikt-20221107monthly0.5https://www.biopharmawatch.com/news/IKT/ikt-148009-as-a-potential-disease-modifying-therapy-in-parkinson-s-disease-poster-789-wern-ikt-20220916monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-appoints-gisele-dion-to-board-of-directors-boston-and-atlanta-ikt-20220901monthly0.5https://www.biopharmawatch.com/news/IKT/q-2022-business-presentation-clinical-development-of-disease-modifying-therapeutics-for-ne-ikt-20220815monthly0.5https://www.biopharmawatch.com/news/IKT/this-presentation-shall-not-constitute-an-offer-to-sell-or-a-solicitation-of-an-offer-to-b-ikt-20220421monthly0.5https://www.biopharmawatch.com/news/IKT/ikt-parkinson-s-disease-modification-through-abl-kinase-inhibition-ad-pd-2022-march-18-202-ikt-20220324monthly0.5https://www.biopharmawatch.com/news/IKT/clinical-development-of-therapies-intended-to-reverse-the-functional-loss-in-parkinson-s-a-ikt-20220120monthly0.5https://www.biopharmawatch.com/news/IKT/clinical-development-of-therapies-intended-to-reverse-the-functional-loss-in-parkinson-s-a-ikt-20211019monthly0.5https://www.biopharmawatch.com/news/IKT/ikt-clinical-development-of-therapies-intended-to-reverse-the-functional-loss-in-parkinson-ikt-20210817monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-announces-closing-of-follow-on-offering-of-common-stock-atlanta-ikt-20210618monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-prices-follow-on-public-offering-of-common-stock-atlanta-ikt-20210615monthly0.5https://www.biopharmawatch.com/news/IKT/ikt-clinical-development-of-therapies-intended-to-reverse-the-functional-loss-in-parkinson-ikt-20210601monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and-hi-ikt-20210401monthly0.5https://www.biopharmawatch.com/news/IKT/therapies-in-clinical-development-to-reverse-the-progression-of-neurodegeneration-in-parki-ikt-20210208monthly0.5https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-inc-announces-pricing-of-its-initial-public-offering-atlanta-ikt-20201222monthly0.5https://www.biopharmawatch.com/news/ACIU/nasdaq-aciu-agm-presentation-aciu-20260611monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-receive-research-grant-from-goradia-family-for-development-of-aci-7104-in-par-aciu-20260611monthly0.5https://www.biopharmawatch.com/news/ACIU/to-the-company-s-form-6-k-on-13-march-2026-can-be-downloaded-from-the-company-s-website-at-aciu-20260515monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-first-quarter-2026-financial-and-corporate-updates-dosed-first-subjects-in-phase-aciu-20260430monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-initiates-final-cohort-in-ongoing-phase-1b-2-abate-trial-of-anti-abeta-active-im-aciu-20260430monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-announces-amendment-to-morphomer-tau-license-and-collaboration-agreement-with-li-aciu-20260407monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-initiates-phase-1-clinical-trial-of-nlrp3-inhibitor-aci-19764-is-an-orally-avail-aciu-20260224monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-positive-interim-phase-2-data-on-aci-7104-056-support-potential-slowing-of-progr-aciu-20251211monthly0.5https://www.biopharmawatch.com/news/ACIU/condensed-consolidated-balance-sheets-unaudited-in-chf-thousands-as-of-september-30-decemb-aciu-20251104monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-sharpens-pipeline-focus-with-operational-efficiencies-extending-cash-runway-stra-aciu-20250904monthly0.5https://www.biopharmawatch.com/news/ACIU/condensed-consolidated-balance-sheets-unaudited-in-chf-thousands-as-of-june-30-december-31-aciu-20250805monthly0.5https://www.biopharmawatch.com/news/ACIU/nasdaq-aciu-agm-presentation-june-2025-2025-ac-immune-not-to-be-used-or-reproduced-without-aciu-20250619monthly0.5https://www.biopharmawatch.com/news/ACIU/to-the-company-s-form-6-k-on-aciu-20250519monthly0.5https://www.biopharmawatch.com/news/ACIU/condensed-consolidated-balance-sheets-unaudited-in-chf-thousands-as-of-march-31-december-3-aciu-20250430monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-full-year-2024-financial-results-and-provides-a-corporate-update-landmar-aciu-20250313monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-interim-safety-data-from-phase-1b-2-abate-trial-of-aci-24-060-in-down-sy-aciu-20241210monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-positive-interim-results-from-phase-2-trial-of-aci-7104-056-active-immun-aciu-20241114monthly0.5https://www.biopharmawatch.com/news/ACIU/condensed-consolidated-balance-sheets-unaudited-in-chf-thousands-as-of-september-30-decemb-aciu-20241105monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-receives-second-milestone-payment-following-progress-in-phase-2b-re-ain-trial-of-aciu-20240917monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-s-pi-2620-tau-pet-diagnostic-in-phase-3-receives-fast-track-designation-in-three-aciu-20240828monthly0.5https://www.biopharmawatch.com/news/ACIU/condensed-consolidated-balance-sheets-unaudited-in-chf-thousands-as-of-june-30-december-31-aciu-20240806monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-unveils-novel-therapeutic-antibody-drug-conjugate-adc-technology-for-improved-ef-aciu-20240731monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-s-aci-35-030-now-jnj-2056-granted-fda-fast-track-designation-for-alzheimer-s-dis-aciu-20240725monthly0.5https://www.biopharmawatch.com/news/ACIU/nasdaq-aciu-agm-presentation-june-2024-2024-ac-immune-not-to-be-used-or-reproduced-without-aciu-20240620monthly0.5https://www.biopharmawatch.com/news/ACIU/to-the-company-s-form-6-k-on-14-march-2024-can-be-downloaded-from-the-company-s-website-ir-aciu-20240521monthly0.5https://www.biopharmawatch.com/news/ACIU/condensed-consolidated-balance-sheets-unaudited-in-chf-thousands-as-of-march-31-december-3-aciu-20240513monthly0.5https://www.biopharmawatch.com/news/ACIU/bettter-health-brighter-future-news-release-ac-immune-and-takeda-sign-exclusive-option-and-aciu-20240513monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-full-year-2023-financial-results-and-provides-a-corporate-update-aci-24--aciu-20240314monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-regain-global-rights-to-crenezumab-and-semorinemab-company-s-strategy-is-focu-aciu-20240122monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-progress-update-on-phase-2-active-immunotherapy-clinical-pipeline-for-alzheimer--aciu-20240103monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-s-targeted-anti-ptau-active-immunotherapy-for-alzheimer-s-disease-advances-into--aciu-20231215monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-strengthens-management-appoints-madiha-derouazi-as-cso-and-christopher-roberts-a-aciu-20231201monthly0.5https://www.biopharmawatch.com/news/ACIU/condensed-consolidated-balance-sheets-unaudited-in-chf-thousands-as-of-september-30-decemb-aciu-20231103monthly0.5https://www.biopharmawatch.com/news/ACIU/condensed-consolidated-balance-sheets-unaudited-in-chf-thousands-x200b-x200b-x200b-x200b-x-aciu-20230804monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-sa-appoints-new-chief-medical-officer-nuno-mendon-a-md-appointed-new-chief-medic-aciu-20230726monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-receives-fda-fast-track-designation-for-anti-amyloid-beta-active-immunotherapy-a-aciu-20230627monthly0.5https://www.biopharmawatch.com/news/ACIU/nasdaq-aciu-agm-presentation-june-2023-2023-ac-immune-not-to-be-used-or-reproduced-without-aciu-20230623monthly0.5https://www.biopharmawatch.com/news/ACIU/to-the-company-s-form-6-k-on-16-march-2023-can-be-downloaded-from-the-company-s-website-ht-aciu-20230524monthly0.5https://www.biopharmawatch.com/news/ACIU/condensed-consolidated-balance-sheets-unaudited-in-chf-thousands-as-of-march-31-december-3-aciu-20230428monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update-clinical--aciu-20230316monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-s-aci-24-060-anti-amyloid-beta-vaccine-for-alzheimer-s-shows-positive-initial-in-aciu-20230126monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-s-alzheimer-s-disease-vaccine-candidate-aci-35-030-selected-for-further-developm-aciu-20221130monthly0.5https://www.biopharmawatch.com/news/ACIU/condensed-consolidated-balance-sheets-unaudited-in-chf-thousands-x200b-x200b-x200b-x200b-x-aciu-20221028monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-partner-lmi-progresses-tau-pet-tracer-pi-2620-into-late-stage-development-in-alz-aciu-20220926monthly0.5https://www.biopharmawatch.com/news/ACIU/detailed-data-from-the-phase-ii-crenezumab-alzheimer-s-prevention-initiative-study-in-auto-aciu-20220802monthly0.5https://www.biopharmawatch.com/news/ACIU/condensed-consolidated-balance-sheets-unaudited-in-chf-thousands-balance-sheets-notes-as-o-aciu-20220728monthly0.5https://www.biopharmawatch.com/news/ACIU/nasdaq-aciu-annual-general-meeting-june-2022-2022-ac-immune-not-to-be-used-or-reproduced-w-aciu-20220624monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-provides-update-on-alzheimer-s-prevention-initiative-study-evaluating-crenezumab-aciu-20220616monthly0.5https://www.biopharmawatch.com/news/ACIU/to-the-company-s-form-6-k-on-22-march-2022-can-be-downloaded-from-the-company-s-website-ht-aciu-20220525monthly0.5https://www.biopharmawatch.com/news/ACIU/condensed-consolidated-balance-sheets-unaudited-in-chf-thousands-balance-sheets-notes-as-o-aciu-20220428monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-full-year-2021-financial-results-and-provides-corporate-update-seven-cli-aciu-20220322monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-first-live-images-of-alpha-synuclein-in-human-brain-with-new-pet-tracer--aciu-20220316monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-announces-interim-phase-1b-2a-data-showing-that-its-aci-35-030-anti-ptau-alzheim-aciu-20211112monthly0.5https://www.biopharmawatch.com/news/ACIU/condensed-consolidated-balance-sheets-unaudited-in-chf-thousands-balance-sheets-notes-as-o-aciu-20211108monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-holds-its-extraordinary-general-meeting-and-appoints-monica-shaw-m-d-and-prof-mo-aciu-20211029monthly0.5https://www.biopharmawatch.com/news/ACIU/notice-of-the-extraordinary-general-meeting-egm-of-29-october-2021-to-the-shareholders-of--aciu-20211007monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-announces-first-positive-cognitive-results-for-a-tau-targeting-monoclonal-antibo-aciu-20210831monthly0.5https://www.biopharmawatch.com/news/ACIU/condensed-consolidated-balance-sheets-unaudited-in-chf-thousands-balance-sheets-notes-as-o-aciu-20210804monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-announces-strategic-acquisition-of-industry-leading-parkinson-s-disease-vaccine--aciu-20210727monthly0.5https://www.biopharmawatch.com/news/ACIU/nasdaq-aciu-annual-general-meeting-2021-2021-ac-immune-not-to-be-used-or-reproduced-withou-aciu-20210625monthly0.5https://www.biopharmawatch.com/news/ACIU/notice-of-the-annual-general-meeting-2021-to-the-shareholders-of-ac-immune-sa-1-date-frida-aciu-20210521monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-sa-balance-sheets-in-chf-thousands-notes-as-of-aciu-20210428monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-appoints-experienced-biotech-and-investment-executive-dr-alan-colowick-to-board--aciu-20210331monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-full-year-2020-financial-results-and-provides-2021-r-d-outlook-anti-ptau-aciu-20210323monthly0.5https://www.biopharmawatch.com/news/ACIU/lausanne-26-february-2021-invitation-to-the-extraordinary-shareholders-meeting-date-wednes-aciu-20210226monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-s-alzheimer-s-vaccine-generates-potent-anti-ptau-antibody-response-in-a-phase-1b-aciu-20210211monthly0.5https://www.biopharmawatch.com/news/ACIU/immunotherapy-pioneer-prof-carl-h-june-joins-ac-immune-s-board-of-directors-prof-june-is-a-aciu-20201120monthly0.5https://www.biopharmawatch.com/news/ACIU/neurologist-and-psychiatrist-prof-johannes-rolf-streffer-md-joins-ac-immune-sa-as-chief-me-aciu-20201118monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-sa-balance-sheets-in-chf-thousands-notes-as-of-aciu-20201113monthly0.5https://www.biopharmawatch.com/news/ACIU/lausanne-19-october-2020-invitation-to-the-extraordinary-shareholders-meeting-date-friday--aciu-20201021monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-top-line-results-from-tauriel-phase-2-trial-evaluating-semorinemab-in-ea-aciu-20200923monthly0.5https://www.biopharmawatch.com/news/ACIU/balance-sheets-in-chf-thousands-notes-as-of-aciu-20200805monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-advances-phospho-tau-alzheimer-s-vaccine-in-phase-1b-2a-study-interim-data-confi-aciu-20200716monthly0.5https://www.biopharmawatch.com/news/ACIU/pioneering-precision-medicine-for-neurodegeneration-nasdaq-aciu-annual-general-meeting-aciu-20200626monthly0.5https://www.biopharmawatch.com/news/ACIU/lausanne-19-may-2020-invitation-to-the-ordinary-shareholders-meeting-date-friday-26-june-2-aciu-20200504monthly0.5https://www.biopharmawatch.com/news/ACIU/interim-condensed-financial-statements-unaudited-interim-condensed-financial-statements-un-aciu-20200504monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-presents-the-latest-preclinical-data-on-novel-drug-targets-for-neurodegenerative-aciu-20200402monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-full-year-2019-financial-results-and-provides-2020-r-d-outlook-ongoing-s-aciu-20200330monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-receives-second-milestone-and-new-milestone-to-increase-the-potential-deal-value-aciu-20200323monthly0.5https://www.biopharmawatch.com/news/ACIU/interim-condensed-financial-statements-unaudited-interim-condensed-financial-statements-un-aciu-20191113monthly0.5https://www.biopharmawatch.com/news/ACIU/www-acimmune-com-2019-ac-immune-not-to-be-used-or-reproduced-without-permission-novel-ther-aciu-20191106monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-receives-first-milestone-payment-from-lilly-in-small-molecule-tau-morphomer-prog-aciu-20190920monthly0.5https://www.biopharmawatch.com/news/ACIU/interim-condensed-financial-statements-unaudited-interim-condensed-financial-statements-un-aciu-20190814monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-initiates-ph1b-2a-study-of-anti-phospho-tau-vaccine-in-alzheimer-s-disease-clini-aciu-20190801monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-initiates-phase-1-study-of-aci-3024-small-molecule-tau-morphomer-an-investigatio-aciu-20190717monthly0.5https://www.biopharmawatch.com/news/ACIU/www-acimmune-com-2019-ac-immune-not-to-be-used-or-reproduced-without-permission-aci-24-a-n-aciu-20190626monthly0.5https://www.biopharmawatch.com/news/ACIU/www-acimmune-com-2019-ac-immune-not-to-be-used-or-reproduced-without-permission-roadmap-to-aciu-20190628monthly0.5https://www.biopharmawatch.com/news/ACIU/lausanne-31-may-2019-invitation-to-the-ordinary-shareholders-meeting-date-28-june-2019-at--aciu-20190604monthly0.5https://www.biopharmawatch.com/news/ACIU/interim-condensed-financial-statements-unaudited-interim-condensed-financial-statements-un-aciu-20190515monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-full-year-2018-financial-results-and-provides-business-update-chf-300-mi-aciu-20190321monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-announces-anti-tau-monoclonal-antibody-entering-second-phase-2-trial-in-moderate-aciu-20190220monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-makes-two-appointments-to-executive-committee-to-accelerate-product-development--aciu-20190207monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-discontinuation-of-phase-iii-cread-1-and-2-studies-of-crenezumab-in-alzh-aciu-20190130monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-announces-appointment-of-dr-marie-kosco-vilbois-as-chief-scientific-officer-laus-aciu-20190103monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-and-lilly-announce-license-and-collaboration-agreement-multi-year-agreement-focu-aciu-20181212monthly0.5https://www.biopharmawatch.com/news/ACIU/in-memoriam-dr-andreas-muhs-cso-scientific-leader-and-friend-has-passed-away-lausanne-swit-aciu-20181207monthly0.5https://www.biopharmawatch.com/news/ACIU/interim-condensed-financial-statements-unaudited-interim-condensed-financial-statements-un-aciu-20181113monthly0.5https://www.biopharmawatch.com/news/ACIU/www-acimmune-com-2018-ac-immune-not-to-be-used-or-reproduced-without-permission-targeting--aciu-20181026monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-announces-dr-andreas-muhs-chief-scientific-officer-to-take-medical-leave-of-abse-aciu-20181022monthly0.5https://www.biopharmawatch.com/news/ACIU/interim-condensed-financial-statements-unaudited-interim-condensed-financial-statements-un-aciu-20180808monthly0.5https://www.biopharmawatch.com/news/ACIU/crenezumab-s-second-phase-3-trial-cread-2-fully-recruited-updates-on-ac-immune-s-pipeline--aciu-20180717monthly0.5https://www.biopharmawatch.com/news/ACIU/becoming-a-global-leader-in-precision-medicine-of-neurodegenerative-diseases-2018-ac-immun-aciu-20180706monthly0.5https://www.biopharmawatch.com/news/ACIU/lausanne-6-june-2018-invitation-to-the-ordinary-shareholders-meeting-date-6-july-2018-at-1-aciu-20180607monthly0.5https://www.biopharmawatch.com/news/ACIU/interim-condensed-financial-statements-unaudited-interim-condensed-financial-statements-un-aciu-20180502monthly0.5https://www.biopharmawatch.com/news/ACIU/novel-therapeutics-and-diagnostics-for-alzheimer-s-and-other-neurodegenerative-diseases-20-aciu-20180427monthly0.5https://www.biopharmawatch.com/news/ACIU/lausanne-22-march-2018-invitation-to-the-extraordinary-shareholders-meeting-date-27-april--aciu-20180322monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-full-year-2017-financial-results-successful-first-year-as-a-public-compa-aciu-20180320monthly0.5https://www.biopharmawatch.com/news/ACIU/interim-condensed-financial-statements-unaudited-interim-condensed-financial-statements-un-aciu-20171113monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-receive-milestone-payment-for-anti-tau-antibody-moving-into-phase-2-trial-for-aciu-20171102monthly0.5https://www.biopharmawatch.com/news/ACIU/novel-therapies-and-diagnostics-for-neurodegenerative-diseases-with-focus-on-alzheimer-s-w-aciu-20170628monthly0.5https://www.biopharmawatch.com/news/ACIU/lausanne-30-may-2017-invitation-to-the-ordinary-shareholders-meeting-date-28-june-2017-at--aciu-20170601monthly0.5https://www.biopharmawatch.com/news/ACIU/interim-condensed-financial-statements-unaudited-interim-condensed-financial-statements-un-aciu-20170511monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-full-year-2016-financial-results-and-r-d-update-strong-cash-position-of--aciu-20170317monthly0.5https://www.biopharmawatch.com/news/ACIU/crenezumab-phase-i-study-2016-ac-immune-not-to-be-used-or-reproduced-without-permission-20-aciu-20161216monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-appoints-experienced-life-science-professional-as-new-chief-financial-officer-la-aciu-20161123monthly0.5https://www.biopharmawatch.com/news/ACIU/www-acimmune-com-2016-ac-immune-not-to-be-used-or-reproduced-without-permission-novel-ther-aciu-20161115monthly0.5https://www.biopharmawatch.com/news/ACIU/unaudited-interim-condensed-financial-statements-unaudited-interim-condensed-financial-sta-aciu-20161114monthly0.5https://www.biopharmawatch.com/news/ACIU/lausanne-7-october-2016-invitation-to-the-ordinary-shareholders-meeting-date-15-november-2-aciu-20161013monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-reports-fourth-quarter-and-full-year-2025-financial-and-operating-results-transfor-vygr-20260309monthly0.5https://www.biopharmawatch.com/news/VYGR/leveraging-genetics-to-treat-neurological-diseases-corporate-deck-january-2026-2-forward-l-vygr-20260108monthly0.5https://www.biopharmawatch.com/news/VYGR/leveraging-genetics-to-treat-neurological-diseases-citi-2025-biopharma-back-to-school-conf-vygr-20250902monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-reports-second-quarter-2025-financial-and-operating-results-cash-runway-extended-i-vygr-20250806monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-reports-first-quarter-2025-financial-and-operating-results-tau-silencing-gene-ther-vygr-20250506monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-reports-fourth-quarter-and-full-year-2024-financial-and-operating-results-tau-sile-vygr-20250311monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-reports-third-quarter-2024-financial-and-operating-results-enrollment-and-dosing-c-vygr-20241112monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-reports-second-quarter-2024-financial-and-operating-results-top-line--vygr-20240806monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-reports-first-quarter-2024-financial-and-operating-results-company-an-vygr-20240513monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-and-operating-res-vygr-20240228monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-pricing-of-public-offering-lexington-mass-january-4-2024-vo-vygr-20240109monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-selection-of-development-candidate-for-sod1-amyotrophic-lat-vygr-20231206monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-reports-third-quarter-2023-financial-and-operating-results-glp-toxico-vygr-20231106monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-reports-second-quarter-2023-financial-and-operating-results-introduce-vygr-20230803monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-reports-first-quarter-2023-financial-and-operating-results-neurocrine-vygr-20230509monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-and-operating-res-vygr-20230307monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-reports-third-quarter-2022-financial-and-operating-results-voyager-s--vygr-20221108monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-prioritizes-pipeline-and-reports-second-quarter-2022-financial-and-op-vygr-20220804monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-reports-first-quarter-2022-financial-and-operating-results-company-to-vygr-20220504monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-and-operating-res-vygr-20220308monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-reports-third-quarter-2021-financial-and-operating-results-license-op-vygr-20211102monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-transforms-pipeline-and-increases-investment-in-next-generation-trace-vygr-20210809monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-first-quarter-2021-financial-results-and-corporate-updates--vygr-20210510monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-fourth-quarter-and-full-year-2020-financial-results-and-cor-vygr-20210225monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-third-quarter-2020-financial-results-and-corporate-updates--vygr-20201109monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-second-quarter-2020-financial-results-and-corporate-updates-vygr-20200810monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-first-quarter-2020-financial-results-and-corporate-updates--vygr-20200506monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-fourth-quarter-and-full-year-2019-financial-results-and-cor-vygr-20200303monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-third-quarter-2019-financial-results-and-corporate-highligh-vygr-20191106monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-reports-second-quarter-2019-financial-results-and-corporate-highlight-vygr-20190809monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-reports-first-quarter-2019-financial-results-and-corporate-highlights-vygr-20190507monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-reports-fourth-quarter-and-full-year-2018-financial-results-and-corpo-vygr-20190226monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-third-quarter-2018-financial-results-and-corporate-highligh-vygr-20181107monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-second-quarter-2018-financial-results-and-corporate-highlig-vygr-20180807monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-first-quarter-2018-financial-results-and-corporate-highligh-vygr-20180510monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-reports-fourth-quarter-and-full-year-2017-financial-results-vy-aadc-f-vygr-20180314monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-ceo-succession-plan-for-2018-cambridge-mass-vygr-20180131monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-pricing-of-public-offering-of-common-stock-cambridge-mass-vygr-20171107monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-reports-third-quarter-2017-financial-results-and-corporate-highlights-vygr-20171102monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-reports-second-quarter-2017-financial-results-and-corporate-highlight-vygr-20170808monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-reports-first-quarter-2017-financial-results-and-corporate-highlights-vygr-20170509monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-reports-fourth-quarter-and-full-year-2016-financial-results-and-corpo-vygr-20170315monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-announces-positive-interim-results-from-phase-1b-trial-of-vy-aadc01-f-vygr-20161207monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-provides-third-quarter-2016-investor-update-vygr-20161110monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-provides-second-quarter-2016-investor-update-vy-aadc01-phase-1b-study-vygr-20160811monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-provides-first-quarter-2016-investor-update-enrollment-completed-in-2-vygr-20160512monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-provides-fourth-quarter-and-full-year-2015-investor-update-top-line-c-vygr-20160317monthly0.5https://www.biopharmawatch.com/news/VYGR/voyager-therapeutics-reports-third-quarter-2015-financial-results-i-nitia-l-public-offerin-vygr-20151217monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-provides-business-update-and-reports-first-quarter-2026-financial-result-lucd-20260514monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-announces-proposed-public-offering-of-common-stock-lucd-20250909monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-provides-business-update-and-reports-second-quarter-2025-financial-resul-lucd-20250813monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-provides-business-update-and-reports-first-quarter-2025-financial-result-lucd-20250514monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-announces-closing-of-public-offering-of-common-stock-lucd-20250411monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-announces-proposed-public-offering-of-common-stock-lucd-20250409monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-provides-business-update-and-reports-fourth-quarter-and-full-year-2024-f-lucd-20250324monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering-lucd-20250305monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-announces-15-3-million-registered-direct-offering-lucd-20250304monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-provides-business-update-and-third-quarter-2024-financial-results-esogua-lucd-20241113monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-provides-business-update-and-second-quarter-2024-financial-results-esogu-lucd-20240812monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-provides-business-update-and-first-quarter-2024-financial-results-quarte-lucd-20240514monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-closes-series-b-b-1-preferred-stock-offering-and-appoints-healthcare-ind-lucd-20240507monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-announces-peer-reviewed-publication-of-positive-data-from-national-cance-lucd-20240502monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-provides-business-update-and-third-quarter-financial-results-quarterly-e-lucd-20231113monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-provides-update-on-newly-published-future-effective-medicare-local-cover-lucd-20230403monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-provides-business-update-and-fourth-quarter-and-full-year-2022-financial-lucd-20230313monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-holds-first-checkyourfoodtube-precancer-testing-event-partners-with-san--lucd-20230215monthly0.5https://www.biopharmawatch.com/news/LUCD/pavmed-and-lucid-diagnostics-provide-strategic-business-update-strategic-resource-realloca-lucd-20230117monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-provides-business-update-and-third-quarter-2022-financial-results-esogua-lucd-20221114monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-provides-business-update-and-preliminary-second-quarter-2022-financial-r-lucd-20220815monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-provides-business-update-and-preliminary-first-quarter-2022-financial-re-lucd-20220511monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-laboratory-executes-participating-provider-agreement-with-medincrease-he-lucd-20220509monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-provides-updates-on-newly-published-esophageal-precancer-clinical-guidel-lucd-20220404monthly0.5https://www.biopharmawatch.com/news/LUCD/pavmed-provides-business-update-and-preliminary-fourth-quarter-and-full-year-2021-financia-lucd-20220329monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-provides-business-update-and-preliminary-fourth-quarter-and-full-year-20-lucd-20220328monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-to-hold-a-business-update-conference-call-on-lucd-20220307monthly0.5https://www.biopharmawatch.com/news/LUCD/pavmed-subsidiary-lucid-diagnostics-launches-luciddx-labs-to-accommodate-esoguard-testing--lucd-20220303monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-to-participate-in-a-fireside-chat-at-the-24th-annual-needham-virtual-gro-lucd-20220107monthly0.5https://www.biopharmawatch.com/news/LUCD/pavmed-subsidiary-lucid-diagnostics-launches-next-phase-of-lucid-test-centers-patients-in--lucd-20211111monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-esoguard-esophageal-dna-test-wins-diagnostics-innovation-of-the-year-awa-lucd-20211028monthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-announces-87-5m-private-placement-equity-financing-morristown-nj-whwk-20260513monthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-reports-first-quarter-2026-financial-results-and-recent-highlights--whwk-20260507monthly0.5https://www.biopharmawatch.com/news/WHWK/three-months-ended-december-31-twelve-months-ended-whwk-20260312monthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-inc-condensed-statements-of-operations-in-thousands-except-share-da-whwk-20251106monthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-inc-condensed-statements-of-operations-in-thousands-except-share-da-whwk-20250807monthly0.5https://www.biopharmawatch.com/news/WHWK/aadi-bioscience-relaunches-as-whitehawk-therapeutics-marking-evolution-into-adc-company-ne-whwk-20250319monthly0.5https://www.biopharmawatch.com/news/WHWK/aadi-bioscience-announces-closing-of-100-million-pipe-financing-morristown-nj-whwk-20250304monthly0.5https://www.biopharmawatch.com/news/WHWK/aadi-bioscience-transforms-with-in-licensing-of-novel-adc-portfolio-100-million-sale-of-fy-whwk-20241219monthly0.5https://www.biopharmawatch.com/news/WHWK/aadi-bioscience-announces-financial-results-for-the-third-quarter-2024-and-provides-corpor-whwk-20241106monthly0.5https://www.biopharmawatch.com/news/WHWK/aadi-bioscience-provides-precision1-trial-and-corporate-updates-precision1-tumor-agnostic--whwk-20240820monthly0.5https://www.biopharmawatch.com/news/WHWK/aadi-bioscience-announces-financial-results-for-the-second-quarter-2024-and-provides-corpo-whwk-20240807monthly0.5https://www.biopharmawatch.com/news/WHWK/aadi-bioscience-announces-financial-results-for-the-first-quarter-2024-and-provides-corpor-whwk-20240508monthly0.5https://www.biopharmawatch.com/news/WHWK/aadi-bioscience-announces-financial-results-for-the-fourth-quarter-and-full-year-2023-and--whwk-20240313monthly0.5https://www.biopharmawatch.com/news/WHWK/aadi-bioscience-reports-interim-results-from-precision1-trial-of-nab-sirolimus-demonstrati-whwk-20231214monthly0.5https://www.biopharmawatch.com/news/WHWK/aadi-bioscience-reports-financial-results-for-the-third-quarter-2023-and-provides-corporat-whwk-20231108monthly0.5https://www.biopharmawatch.com/news/WHWK/aadi-bioscience-appoints-dave-lennon-ph-d-as-president-and-chief-executive-officer-dr-lenn-whwk-20231002monthly0.5https://www.biopharmawatch.com/news/WHWK/aadi-bioscience-announces-financial-results-for-the-second-quarter-2023-and-provides-corpo-whwk-20230809monthly0.5https://www.biopharmawatch.com/news/WHWK/aadi-bioscience-announces-financial-results-and-operational-update-for-the-first-quarter-2-whwk-20230510monthly0.5https://www.biopharmawatch.com/news/WHWK/aadi-bioscience-announces-financial-results-for-the-fourth-quarter-and-full-year-2022-and--whwk-20230328monthly0.5https://www.biopharmawatch.com/news/WHWK/aadi-bioscience-announces-leadership-transition-whwk-20230303monthly0.5https://www.biopharmawatch.com/news/WHWK/aadi-bioscience-announces-financial-results-for-the-third-quarter-of-2022-and-provides-cor-whwk-20221109monthly0.5https://www.biopharmawatch.com/news/WHWK/aadi-bioscience-announces-72-5-million-private-placement-equity-financing-whwk-20220922monthly0.5https://www.biopharmawatch.com/news/WHWK/aadi-bioscience-announces-financial-results-for-the-second-quarter-of-2022-and-provides-co-whwk-20220810monthly0.5https://www.biopharmawatch.com/news/WHWK/aadi-bioscience-reports-first-quarter-2022-financial-results-and-provides-a-corporate-upda-whwk-20220512monthly0.5https://www.biopharmawatch.com/news/WHWK/aadi-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-business-upd-whwk-20220317monthly0.5https://www.biopharmawatch.com/news/WHWK/aadi-bioscience-announces-fda-approval-of-its-first-product-fyarro-for-patients-with-local-whwk-20211123monthly0.5https://www.biopharmawatch.com/news/WHWK/aadi-reports-third-quarter-2021-financial-results-and-provides-business-update-fyarro-unde-whwk-20211110monthly0.5https://www.biopharmawatch.com/news/WHWK/aadi-bioscience-appoints-scott-giacobello-as-chief-financial-officer-whwk-20211101monthly0.5https://www.biopharmawatch.com/news/WHWK/aadi-bioscience-appoints-brendan-delaney-as-chief-operating-officer-whwk-20210920monthly0.5https://www.biopharmawatch.com/news/WHWK/aadi-bioscience-appoints-emma-reeve-to-its-board-of-directors-whwk-20210913monthly0.5https://www.biopharmawatch.com/news/WHWK/corporate-overview-august-2021-nasdaq-aadi-www-aadibio-com-aadi-bioscience-inc-pacific-pal-whwk-20210827monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-reports-second-quarter-2021-financial-results-and-provides-business-update-ended-se-whwk-20210811monthly0.5https://www.biopharmawatch.com/news/WHWK/aadi-bioscience-announces-fda-acceptance-and-priority-review-for-the-new-drug-application--whwk-20210726monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-provides-second-update-on-aadi-bioscience-presentation-at-the-asco-2021-virtual-mee-whwk-20210604monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-provides-update-on-aadi-bioscience-presentation-at-the-asco-2021-virtual-meeting-whwk-20210519monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-reports-first-quarter-2021-financial-results-and-provides-business-update-ended-fir-whwk-20210517monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-pharmaceuticals-and-aadi-bioscience-enter-into-a-definitive-merger-agreement-transa-whwk-20210517monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-business-u-whwk-20210311monthly0.5https://www.biopharmawatch.com/news/WHWK/quantum-leap-healthcare-collaborative-discontinues-testing-of-aerpio-pharmaceutical-s-razu-whwk-20210305monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-announces-strategic-review-after-topline-results-from-razuprotafib-glaucoma-phase-2-whwk-20210105monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-announces-statistically-significant-topline-results-from-razuprotafib-glaucoma-phas-whwk-20201211monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-reports-third-quarter-2020-financial-results-and-provides-business-update-enrollmen-whwk-20201110monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-reports-second-quarter-2020-financial-results-and-provides-business-update-initiate-whwk-20200812monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-pharmaceuticals-inc-announces-a-second-clinical-trial-with-funding-from-mtec-to-eva-whwk-20200804monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-announces-initiation-of-28-day-phase-2-razuprotafib-glaucoma-trial-cincinnati-whwk-20200624monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-pharmaceuticals-inc-and-quantum-leap-healthcare-collaborative-announce-the-selectio-whwk-20200527monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-announces-amended-licensing-deal-with-gossamer-bio-on-its-inflammatory-bowel-diseas-whwk-20200512monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-reports-first-quarter-2020-financial-results-and-provides-business-update-razuprota-whwk-20200507monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides-business-u-whwk-20200316monthly0.5https://www.biopharmawatch.com/news/WHWK/topical-ocular-formulation-of-aerpio-pharmaceutical-s-akb-9778-product-candidate-produced--whwk-20200108monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-reports-third-quarter-2019-financial-results-and-provides-business-update-cincinnat-whwk-20191107monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-pharmaceuticals-announces-interim-results-from-its-phase-1b-clinical-trial-of-topic-whwk-20191010monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-reports-second-quarter-2019-financial-results-and-provides-business-update-cincinna-whwk-20190808monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-reports-first-quarter-2019-financial-results-and-provides-business-update-on-track--whwk-20190509monthly0.5https://www.biopharmawatch.com/news/WHWK/forward-looking-statements-this-presentation-has-been-prepared-by-aerpio-pharmaceuticals-w-whwk-20190410monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-pharmaceuticals-announces-results-from-time-2b-study-of-akb-9778-in-diabetic-retino-whwk-20190318monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-reports-fourth-quarter-and-full-year-2018-financial-results-and-provides-business-u-whwk-20190305monthly0.5https://www.biopharmawatch.com/news/WHWK/forward-looking-statements-this-presentation-has-been-prepared-by-aerpio-pharmaceuticals-w-whwk-20190107monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-reports-third-quarter-2018-financial-results-and-provides-business-update-time-2b-c-whwk-20181107monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-reports-second-quarter-2018-financial-results-and-provides-business-update-time-2b--whwk-20180814monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-pharmaceuticals-announces-proposed-public-offering-of-common-stock-and-uplisting-to-whwk-20180627monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-announces-exclusive-license-agreement-with-gossamer-bio-for-akb-4924-a-first-in-cla-whwk-20180625monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-announces-initiation-of-dosing-in-a-phase-1a-multiple-ascending-dose-study-of-akb-4-whwk-20180529monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-reports-first-quarter-2018-financial-results-and-provides-company-update-time-2b-cl-whwk-20180515monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-reports-fourth-quarter-and-full-year-2017-financial-results-and-provides-business-u-whwk-20180313monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-pharmaceuticals-forward-looking-statement-this-presentation-has-been-prepared-by-ae-whwk-20180108monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-pharmaceuticals-announces-appointment-of-michael-rogers-as-chief-financial-officer--whwk-20171115monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-pharmaceuticals-announces-appointment-of-stephen-hoffman-m-d-ph-d-as-chief-executiv-whwk-20171010monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-pharmaceuticals-commences-trading-on-the-otcqb-market-the-company-will-trade-under--whwk-20170808monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-announces-initiation-of-patient-dosing-in-the-time-2b-study-a-phase-2b-clinical-tri-whwk-20170629monthly0.5https://www.biopharmawatch.com/news/WHWK/aerpio-reports-first-quarter-2017-financial-results-whwk-20170516monthly0.5https://www.biopharmawatch.com/news/WHWK/f-inancial-s-tatements-aerpio-therapeutics-inc-years-ended-whwk-20170317monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-reports-second-quarter-2025-financial-results-and-corporate-highlights-x2022-initia-nktx-20250812monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-reports-first-quarter-2025-financial-results-and-corporate-highlights-x2022-enrollm-nktx-20250514monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-reports-fourth-quarter-and-full-year-2024-financial-results-and-corporate-highlight-nktx-20250326monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-reports-third-quarter-2024-financial-results-and-corporate-highlights-x2022-first-p-nktx-20241107monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-reports-second-quarter-2024-financial-results-and-corporate-highlights-x2022-enroll-nktx-20240816monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-reports-second-quarter-2024-financial-results-and-corporate-highlights-x2022-enroll-nktx-20240813monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-announces-leadership-updates-appoints-nadir-mahmood-as-president-nktx-20240716monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-initiates-clinical-trial-of-nkx019-in-lupus-nephritis-with-first-patient-in-screeni-nktx-20240627monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-adds-experienced-leader-in-autoimmune-r-d-george-vratsanos-m-d-facr-to-board-of-dir-nktx-20240613monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-reports-first-quarter-2024-financial-results-and-corporate-highlights-x2022-dosing--nktx-20240509monthly0.5https://www.biopharmawatch.com/news/NKTX/forward-looking-statements-this-presentation-contains-forward-x2010-looking-statements-wit-nktx-20240325monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-reports-fourth-quarter-and-full-year-2023-financial-results-and-corporate-highlight-nktx-20240321monthly0.5https://www.biopharmawatch.com/news/NKTX/forward-looking-statements-this-presentation-contains-forward-x2010-looking-statements-wit-nktx-20240108monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-reports-third-quarter-2023-financial-results-and-corporate-highlights-x2022-fda-cle-nktx-20231109monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-receives-fda-clearance-of-ind-application-for-nkx019-in-lupus-nephritis-new-pipelin-nktx-20230930monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-to-host-conference-call-on-tuesday-october-17-at-8am-et-to-discuss-expansion-of-cli-nktx-20231017monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-reports-second-quarter-2023-financial-results-and-corporate-highlights-x2022-nkx101-nktx-20230810monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-appoints-alyssa-levin-chief-financial-and-business-officer-nktx-20230705monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-updates-clinical-progress-of-car-nk-cell-therapy-nkx101-for-patients-with-relapsed--nktx-20230627monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-to-host-conference-call-to-discuss-updated-clinical-data-from-nkx101-nk-cell-therap-nktx-20230627monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-reports-first-quarter-2023-financial-results-and-corporate-highlights-x2022-clinica-nktx-20230511monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-announces-departure-of-chief-financial-business-officer-x2022-clinical-updates-on-t-nktx-20230330monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-reports-fourth-quarter-and-full-year-2022-financial-results-and-corporate-highlight-nktx-20230316monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-promotes-david-r-shook-m-d-to-chief-medical-officer-nktx-20230109monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-announces-updated-clinical-data-on-anti-cd19-allogeneic-car-nk-cell-therapy-nkx019--nktx-20221205monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-to-host-conference-call-to-discuss-updated-clinical-data-from-nkx019-nk-cell-therap-nktx-20221205monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-reports-third-quarter-2022-financial-results-and-corporate-highlights-x2022-nkx101--nktx-20221109monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-reports-second-quarter-2022-financial-results-and-corporate-highlights-x2022-positi-nktx-20220811monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-appoints-david-r-shook-md-as-vice-president-clinical-development-nktx-20220516monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-reports-first-quarter-2022-financial-results-and-corporate-highlights-x2022-positiv-nktx-20220512monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-announces-positive-preliminary-dose-finding-data-for-two-lead-engineered-natural-ki-nktx-20220425monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-to-host-conference-call-highlighting-preliminary-clinical-data-from-two-lead-nk-cel-nktx-20220425monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-appoints-manufacturing-technology-executive-angela-thedinga-to-board-of-directors-a-nktx-20220329monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-reports-fourth-quarter-and-full-year-2021-financial-results-and-corporate-highlight-nktx-20220317monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-reports-third-quarter-2021-financial-results-and-business-update-initial-data-expec-nktx-20211110monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-announces-updates-to-nkx019-and-nkx101-clinical-development-programs-first-patients-nktx-20211007monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-reports-second-quarter-2021-financial-results-and-business-progress-initial-data-fr-nktx-20210812monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-establishes-new-combined-nk-cell-therapy-manufacturing-facility-company-headquarter-nktx-20210714monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-reports-first-quarter-2021-financial-results-and-business-progress-nkx019-ind-recei-nktx-20210513monthly0.5https://www.biopharmawatch.com/news/NKTX/crispr-therapeutics-and-nkarta-announce-global-collaboration-to-develop-gene-edited-cell-t-nktx-20210506monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-receives-nkx019-ind-clearance-from-u-s-food-and-drug-administration-for-treatment-o-nktx-20210428monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-reports-fourth-quarter-and-full-year-2020-financial-results-and-highlights-business-nktx-20210325monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-reports-third-quarter-2020-financial-results-x2022-first-patient-dosed-in-clinical--nktx-20201112monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-announces-leadership-changes-nadir-mahmood-ph-d-named-to-expanded-role-as-chief-fin-nktx-20201005monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-reports-second-quarter-2020-financial-results-x2022-co-lead-programs-on-track-nkx10-nktx-20200820monthly0.5https://www.biopharmawatch.com/news/NKTX/nkarta-announces-closing-of-upsized-initial-public-offering-and-exercise-in-full-of-underw-nktx-20200714monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-third-quarter-2025-financial-update-and-pipeline-progress--arct-20251110monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-second-quarter-2025-financial-update-and-pipeline-progress-arct-20250811monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-positive-interim-phase-2-multiple-dose-data-for-ornithine--arct-20250630monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-first-quarter-2025-financial-update-and-pipeline-progress--arct-20250512monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-fourth-quarter-and-fiscal-year-2024-financial-update-and-p-arct-20250306monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-second-quarter-2024-financial-update-and-pipeline-progress-arct-20240805monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-appoints-moncef-slaoui-ph-d-to-board-of-directors-previously-chief-s-arct-20240620monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-first-quarter-2024-financial-update-and-pipeline-progress--arct-20240508monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-fourth-quarter-and-fiscal-year-2023-financial-update-and-p-arct-20240307monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-third-quarter-2023-financial-update-and-pipeline-progress--arct-20231114monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-and-cystic-fibrosis-foundation-extend-agreement-to-advance-arct-032--arct-20230926monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-joint-venture-mrna-manufacturing-partner-arcalis-awarded-115-million-arct-20230814monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-second-quarter-2023-financial-update-and-pipeline-progress-arct-20230807monthly0.5https://www.biopharmawatch.com/news/ARCT/june-30-2023-name-of-company-meiji-holdings-co-ltd-name-of-representative-kazuo-kawamura-c-arct-20230630monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-first-quarter-2023-financial-update-and-pipeline-progress--arct-20230509monthly0.5https://www.biopharmawatch.com/news/ARCT/dated-april-28-2023-arct-20230428monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-fourth-quarter-2022-financial-update-and-pipeline-progress-arct-20230328monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-appoints-john-markels-ph-d-to-its-board-of-directors-dr-markels-accomplished-and--arct-20221213monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-third-quarter-2022-financial-update-and-pipeline-progress--arct-20221109monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-announces-collaboration-with-csl-to-develop-and-commercialize-self-amplifying-mrn-arct-20221101monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-announces-63-2-million-award-from-the-u-s-government-to-support-development-of-se-arct-20220901monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-second-quarter-2022-financial-update-and-pipeline-progress-arct-20220809monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-first-quarter-2022-financial-update-and-pipeline-progress--arct-20220509monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-announces-self-amplifying-covid-19-mrna-vaccine-candidate-arct-154-meets-primary--arct-20220420monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-fourth-quarter-and-full-year-2021-financial-update-and-pip-arct-20220228monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-appoints-jing-marantz-m-d-ph-d-m-b-a-to-its-board-of-directors-san-d-arct-20211213monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-third-quarter-2021-financial-update-and-pipeline-progress--arct-20211108monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-second-quarter-2021-financial-results-and-mrna-vaccine-and-arct-20210809monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-first-quarter-2021-company-overview-and-financial-results--arct-20210510monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-fourth-quarter-and-full-year-2020-financial-results-and-po-arct-20210301monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-acquires-exclusive-license-to-mrna-manufacturing-technology-from-ale-arct-20210222monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-pricing-of-150-million-public-offering-of-common-stock-arct-20201207monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-third-quarter-2020-financial-results-and-positive-clinical-arct-20201109monthly0.5https://www.biopharmawatch.com/news/ARCT/israel-secures-rights-to-stockpile-and-reserve-doses-of-lunar-cov19-for-its-citizens-israe-arct-20200723monthly0.5https://www.biopharmawatch.com/news/ARCT/ultragenyx-announces-exercise-of-option-to-purchase-additional-stock-of-arcturus-therapeut-arct-20200521monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-first-quarter-2020-financial-results-and-provides-a-corpor-arct-20200507monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-reports-fourth-quarter-and-year-end-2019-financial-results-ind-filed-arct-20200311monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-and-duke-nus-medical-school-partner-to-develop-a-coronavirus-covid-1-arct-20200304monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-third-quarter-financial-results-and-provides-corporate-upd-arct-20191107monthly0.5https://www.biopharmawatch.com/news/ARCT/forward-looking-statements-arcturus-therapeutics-this-presentation-contains-forward-lookin-arct-20191107monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-9-8-million-registered-direct-offering-of-common-stock-san-arct-20190926monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-appointment-of-dr-edward-holmes-m-d-and-re-appointment-of--arct-20190923monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-second-quarter-financial-results-and-provides-a-corporate--arct-20190815monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-2-3-million-additional-registered-direct-offering-of-commo-arct-20190802monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-announces-10-9-million-registered-direct-offering-of-common-stock-sa-arct-20190801monthly0.5https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-receives-up-to-15-million-commitment-from-the-cystic-fibrosis-founda-arct-20190801monthly0.5https://www.biopharmawatch.com/news/ARCT/ultragenyx-and-arcturus-therapeutics-expand-existing-research-collaboration-and-license-ag-arct-20190619monthly0.5https://www.biopharmawatch.com/news/ARCT/forward-looking-statements-arcturus-therapeutics-this-presentation-contains-forward-lookin-arct-20190619monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-therapeutics-announces-first-quarter-2026-financial-results-and-provides-busines-uncy-20260512monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-therapeutics-announces-full-year-2025-financial-results-and-provides-business-up-uncy-20260330monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-therapeutics-announces-third-quarter-2025-financial-results-and-provides-busines-uncy-20251112monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-therapeutics-provides-update-from-fda-type-a-meeting-and-expects-to-resubmit-olc-uncy-20251028monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-therapeutics-announces-second-quarter-2025-financial-results-and-provides-busine-uncy-20250814monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-nasdaq-uncy-20250617monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-therapeutics-announces-receipt-of-complete-response-letter-for-oxylanthanum-carb-uncy-20250630monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-therapeutics-inc-announces-reverse-stock-split-shares-expected-to-begin-trading--uncy-20250620monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-provides-update-on-new-drug-application-for-oxylanthanum-carbonate-to-treat-hype-uncy-20250610monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-therapeutics-announces-time-change-for-2025-annual-meeting-of-stockholders-uncy-20250521monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-therapeutics-announces-first-quarter-2025-financial-results-and-provides-busines-uncy-20250514monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-therapeutics-announces-full-year-2024-financial-results-and-provides-business-up-uncy-20250331monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-announces-third-quarter-2024-financial-results-and-provides-business-update-olc--uncy-20241113monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-therapeutics-announces-u-s-fda-acceptance-of-the-new-drug-application-nda-for-ox-uncy-20241112monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-announces-second-quarter-2024-financial-results-and-provides-business-update-on--uncy-20240814monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-therapeutics-achieves-study-objective-in-oxylanthanum-carbonate-olc-pivotal-clin-uncy-20240625monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-announces-first-quarter-2024-financial-results-and-provides-business-update-on-t-uncy-20240513monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-announces-full-year-2023-financial-results-and-provides-business-update-oxylanth-uncy-20240328monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-announces-50-million-private-placement-unicycive-therapeutics-inc-thu-uncy-20240314monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-announces-third-quarter-2023-financial-results-and-provides-business-update-reac-uncy-20231114monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-therapeutics-reaches-alignment-with-the-fda-on-path-to-file-new-drug-application-uncy-20231023monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-therapeutics-strengthens-board-of-directors-with-appointment-of-sara-kenkare-mit-uncy-20230906monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-announces-second-quarter-2023-financial-results-and-provides-business-update-rec-uncy-20230814monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-therapeutics-provides-regulatory-update-on-lanthanum-dioxycarbonate-program-uncy-20230629monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-announces-first-quarter-2023-financial-results-and-provides-business-update-clos-uncy-20230516monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-announces-full-year-2022-financial-results-and-provides-business-update-closed-t-uncy-20230331monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-announces-up-to-130-million-financing-to-commercialize-and-launch-investigationa-uncy-20230306monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-announces-exclusive-license-and-development-agreement-with-lotus-for-renazorb-in-uncy-20230202monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-achieves-primary-endpoint-in-pivotal-bioequivalence-study-of-renazorb-renazorb-d-uncy-20221228monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-announces-third-quarter-financial-results-and-provides-business-update-topline-r-uncy-20221114monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-announces-second-quarter-financial-results-and-provides-business-update-advancin-uncy-20220815monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-announces-exclusive-license-and-development-agreement-with-lee-s-pharmaceutical--uncy-20220718monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-announces-first-quarter-financial-results-and-provides-business-update-on-track--uncy-20220512monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-announces-full-year-2021-financial-results-and-provides-business-update-on-track-uncy-20220331monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-therapeutics-receives-confirmatory-guidance-on-renazorb-regulatory-pathway-on-tr-uncy-20211129monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-therapeutics-announces-third-quarter-2021-financial-results-expect-to-receive-co-uncy-20211111monthly0.5https://www.biopharmawatch.com/news/UNCY/unicycive-therapeutics-announces-second-quarter-2021-financial-results-completed-initial-p-uncy-20210816monthly0.5https://www.biopharmawatch.com/news/OABI/omniab-reports-third-quarter-2025-financial-results-and-business-highlights-conference-cal-oabi-20251104monthly0.5https://www.biopharmawatch.com/news/OABI/omniab-announces-30-million-private-placement-emeryville-calif-oabi-20250825monthly0.5https://www.biopharmawatch.com/news/OABI/omniab-reports-second-quarter-2025-financial-results-and-business-highlights-conference-ca-oabi-20250806monthly0.5https://www.biopharmawatch.com/news/OABI/omniab-reports-first-quarter-2025-financial-results-and-business-highlights-conference-cal-oabi-20250508monthly0.5https://www.biopharmawatch.com/news/OABI/omniab-reports-fourth-quarter-and-full-year-2024-financial-results-and-business-highlights-oabi-20250318monthly0.5https://www.biopharmawatch.com/news/OABI/omniab-reports-third-quarter-2024-financial-results-and-business-highlights-conference-cal-oabi-20241112monthly0.5https://www.biopharmawatch.com/news/OABI/omniab-reports-second-quarter-2024-financial-results-and-business-highlights-conference-ca-oabi-20240808monthly0.5https://www.biopharmawatch.com/news/OABI/omniab-reports-first-quarter-2024-financial-results-and-business-highlights-conference-cal-oabi-20240509monthly0.5https://www.biopharmawatch.com/news/OABI/omniab-reports-fourth-quarter-and-full-year-2023-financial-results-and-business-highlights-oabi-20240320monthly0.5https://www.biopharmawatch.com/news/OABI/omniab-reports-third-quarter-2023-financial-results-and-business-highlights-webcast-includ-oabi-20231109monthly0.5https://www.biopharmawatch.com/news/OABI/omniab-reports-second-quarter-2023-financial-results-and-business-highlights-conference-ca-oabi-20230810monthly0.5https://www.biopharmawatch.com/news/OABI/omniab-reports-first-quarter-2023-financial-results-and-business-highlights-conference-cal-oabi-20230511monthly0.5https://www.biopharmawatch.com/news/OABI/omniab-reports-fourth-quarter-and-full-year-2022-financial-results-and-business-highlights-oabi-20230330monthly0.5https://www.biopharmawatch.com/news/OABI/we-caution-you-that-this-presentation-contains-forward-looking-statements-all-statements-o-oabi-20230109monthly0.5https://www.biopharmawatch.com/news/OABI/omniab-reports-third-quarter-2022-financial-results-and-business-highlights-emeryville-cal-oabi-20221115monthly0.5https://www.biopharmawatch.com/news/OABI/have-the-same-meaning-as-terms-defined-and-included-elsewhere-in-the-current-report-on-for-oabi-20221107monthly0.5https://www.biopharmawatch.com/news/OABI/analyst-teach-in-oabi-20220621monthly0.5https://www.biopharmawatch.com/news/OABI/ligand-to-spin-off-its-omniab-business-through-merger-with-avista-public-acquisition-corp--oabi-20220323monthly0.5https://www.biopharmawatch.com/news/OABI/avista-public-acquisition-corp-ii-index-to-financial-statement-report-of-independent-regis-oabi-20220128monthly0.5https://www.biopharmawatch.com/news/OABI/avista-public-acquisition-corp-ii-announces-the-separate-trading-of-its-class-a-ordinary-s-oabi-20210930monthly0.5https://www.biopharmawatch.com/news/OABI/avista-public-acquisition-corp-ii-index-to-financial-statement-report-of-independent-regis-oabi-20210812monthly0.5https://www.biopharmawatch.com/news/OABI/avista-public-acquisition-corp-ii-announces-pricing-of-200-million-initial-public-offering-oabi-20210809monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-reports-first-quarter-2026-financial-results-and-provides-business-update-advancin-alec-20260507monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business--alec-20260225monthly0.5https://www.biopharmawatch.com/news/ALEC/is-headquartered-in-south-san-francisco-california-for-more-information-please-visit-www-a-alec-20251212monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-reports-third-quarter-2025-financial-results-and-provides-business-update-selected-alec-20251106monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-announces-topline-results-from-latozinemab-phase-3-trial-in-individuals-with-front-alec-20251021monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-reports-second-quarter-2025-financial-results-and-provides-business-update-on-trac-alec-20250807monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-provides-executive-leadership-update-neil-berkley-m-b-a-appointed-interim-chief-fi-alec-20250613monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-reports-first-quarter-2025-financial-results-and-provides-business-update-topline--alec-20250508monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-business--alec-20250226monthly0.5https://www.biopharmawatch.com/news/ALEC/in-alector-s-quarterly-report-on-form-10-q-filed-on-alec-20241106monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-secures-flexible-credit-facility-for-up-to-50-million-from-hercules-capital-south--alec-20241114monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-reports-third-quarter-2024-financial-results-and-provides-business-update-data-fro-alec-20241106monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-reports-second-quarter-2024-financial-results-and-provides-business-update-data-fr-alec-20240807monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-reports-first-quarter-2024-financial-results-and-provides-business-update-data-fro-alec-20240508monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-business--alec-20240227monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-announces-pricing-of-public-offering-of-common-stock-south-san-francisco-calif-alec-20240117monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-reports-third-quarter-2023-financial-results-and-provides-business-update-achieved-alec-20231107monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-reports-second-quarter-2023-financial-results-and-provides-business-update-closed--alec-20230803monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-reports-first-quarter-2023-financial-results-and-provides-business-update-on-track-alec-20230504monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-corporate-alec-20230228monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-reports-third-quarter-2022-financial-results-and-provides-business-update-progress-alec-20221108monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-reports-second-quarter-2022-financial-results-and-provides-business-update-investi-alec-20220804monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-reports-first-quarter-2022-financial-results-and-provides-business-update-data-fro-alec-20220505monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-announces-appointment-of-gary-romano-m-d-ph-d-as-chief-medical-officer-south-san-f-alec-20220329monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-reports-fourth-quarter-and-full-year-2021-financial-results-ctad-and-sitc-presenta-alec-20220224monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-announces-appointment-of-marc-grasso-m-d-as-chief-financial-officer-south-san-fran-alec-20220207monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-reports-third-quarter-2021-financial-results-initiated-phase-2-clinical-trial-of-a-alec-20211104monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-announces-appointment-of-elizabeth-a-garofalo-m-d-to-its-board-of-directors-south--alec-20210928monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-provides-executive-leadership-update-planned-transitions-announced-for-shehnaaz-su-alec-20210907monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-reports-second-quarter-2021-financial-results-presented-twelve-month-data-from-ong-alec-20210803monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-presents-12-month-results-from-the-infront-2-phase-2-open-label-clinical-study-of--alec-20210729monthly0.5https://www.biopharmawatch.com/news/ALEC/for-media-and-investors-only-issued-7-30am-et-2-july-2021-london-uk-alector-and-gsk-announ-alec-20210707monthly0.5https://www.biopharmawatch.com/news/ALEC/media-1ab-dan-budwick-973-271-6085-dan-1abmedia-com-or-investors-alector-inc-ir-alector-co-alec-20210505monthly0.5https://www.biopharmawatch.com/news/ALEC/media-erica-jefferson-vice-president-communications-and-public-affairs-alector-inc-301-928-alec-20210225monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-announces-departure-of-chief-business-officer-sabah-oney-steps-down-as-from-a-role-alec-20210120monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-reports-third-quarter-2020-financial-results-and-provides-corporate-update-global--alec-20201110monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-reports-second-quarter-2020-financial-results-and-provides-corporate-update-pivota-alec-20200811monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-reports-2020-first-quarter-financial-results-and-business-highlights-x2022-provide-alec-20200513monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-reports-2019-fourth-quarter-and-full-year-financial-results-and-business-highlight-alec-20200324monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwri-alec-20200203monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-showcases-progress-in-immuno-neurology-clinical-programs-and-research-portfolio-at-alec-20191213monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-reports-recent-business-highlights-and-third-quarter-2019-financial-results-initia-alec-20191112monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-reports-recent-business-highlights-and-second-quarter-2019-financial-results-compl-alec-20190812monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-announces-the-addition-of-kristine-yaffe-m-d-to-the-board-of-directors-south-san-f-alec-20190812monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-reports-recent-business-highlights-and-first-quarter-2019-financial-results-dosed--alec-20190513monthly0.5https://www.biopharmawatch.com/news/ALEC/alector-reports-recent-business-highlights-and-fourth-quarter-and-full-year-2018-financial-alec-20190326monthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-reports-first-quarter-2026-financial-results-first-quarter-2026-total-revenue-was--tkno-20260506monthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-reports-second-quarter-2025-financial-results-second-quarter-2025-total-revenue-wa-tkno-20250807monthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-reports-first-quarter-2025-financial-results-first-quarter-2025-total-revenue-was--tkno-20250508monthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-reports-fourth-quarter-and-full-year-2024-financial-results-full-year-2024-total-r-tkno-20250304monthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-reports-third-quarter-2024-financial-results-third-quarter-2024-total-revenue-was--tkno-20241107monthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-reports-second-quarter-2024-financial-results-second-quarter-2024-total-revenue-wa-tkno-20240813monthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-announces-15-4-million-private-placement-tkno-20240711monthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-provides-strategic-business-update-and-announces-preliminary-second-quarter-2024-r-tkno-20240630monthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-reports-first-quarter-2024-financial-results-first-quarter-2024-total-revenue-was--tkno-20240513monthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-reports-fourth-quarter-and-full-year-2023-financial-results-full-year-2023-total-r-tkno-20240311monthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-reports-third-quarter-2023-financial-results-raised-22-9-million-of-equity-capital-tkno-20231109monthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-announces-up-to-22-9-million-concurrent-registered-direct-offering-and-private-pla-tkno-20230918monthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-reports-second-quarter-2023-financial-results-second-quarter-2023-total-revenue-wa-tkno-20230810monthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-reports-first-quarter-2023-financial-results-first-quarter-2023-total-revenue-was--tkno-20230510monthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-reports-fourth-quarter-and-full-year-2022-financial-results-full-year-2022-total-r-tkno-20230315monthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-reports-third-quarter-2022-financial-results-third-quarter-2022-total-revenue-was--tkno-20221109monthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-reports-second-quarter-2022-financial-results-second-quarter-2022-total-revenue-wa-tkno-20220810monthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-reports-first-quarter-2022-financial-results-first-quarter-2022-total-revenue-was--tkno-20220511monthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-reports-fourth-quarter-and-full-year-2021-financial-results-full-year-2021-total-r-tkno-20220315monthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-expands-leadership-team-with-the-appointments-of-ken-gelhaus-as-chief-commercial-o-tkno-20211110monthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-reports-third-quarter-2021-financial-results-9-4-million-in-total-revenue-up-5-yea-tkno-20211110monthly0.5https://www.biopharmawatch.com/news/TKNO/teknova-reports-second-quarter-2021-financial-results-8-3-million-in-total-revenue-up-38-y-tkno-20210811monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-appoints-charles-newton-to-its-board-of-directors-kros-20260226monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-announces-participation-at-upcoming-healthcare-conferences-kros-20260218monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-reports-second-quarter-2025-financial-results-kros-20250806monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-announces-participation-at-goldman-sachs-46-th-annual-global-healthcare-kros-20250606monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-announces-tropos-topline-data-and-corporate-restructuring-discontinues--kros-20250529monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-announces-participation-at-bank-of-america-2025-global-healthcare-confe-kros-20250512monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-reports-recent-first-quarter-2025-financial-results-kros-20250506monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-announces-review-of-strategic-alternatives-adopts-limited-duration-stoc-kros-20250410monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-announces-initial-topline-results-from-the-phase-1-clinical-trial-of-ke-kros-20250331monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-announces-participation-at-upcoming-healthcare-conferences-kros-20250228monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-reports-recent-business-highlights-and-fourth-quarter-and-full-year-202-kros-20250226monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-the-guggenheim-smid-cap-biotech-conference-kros-20250130monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-announces-effectiveness-of-global-license-agreement-with-takeda-to-adva-kros-20250121monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-announces-additional-update-on-the-phase-2-tropos-trial-kros-20250115monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-announces-update-on-the-phase-2-tropos-trial-keros-will-host-an-update--kros-20241212monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-presents-clinical-data-from-its-elritercept-program-at-the-66th-america-kros-20241209monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-announces-global-license-agreement-with-takeda-to-advance-elritercept-k-kros-20241203monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-announces-participation-at-upcoming-healthcare-conferences-kros-20241126monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-reports-recent-business-highlights-and-third-quarter-2024-financial-res-kros-20241106monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-the-guggenheim-healthcare-innovation-conference-kros-20241106monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-appoints-yung-h-chyung-m-d-as-chief-medical-officer-kros-20241016monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-announces-update-on-enrollment-in-the-phase-2-tropos-trial-kros-20240903monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-announces-participation-at-upcoming-healthcare-conferences-kros-20240828monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-reports-second-quarter-2024-financial-results-kros-20240807monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-announces-leadership-updates-kros-20240617monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-presents-clinical-data-from-its-elritercept-ker-050-program-at-the-29th-kros-20240617monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-host-a-corporate-update-conference-call-and-webcast-kros-20240604monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-goldman-sachs-45th-annual-global-healthcare-conference-kros-20240603monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-appoints-jean-jacques-bienaim-to-its-board-of-directors-kros-20240528monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-reports-recent-business-highlights-and-first-quarter-2024-financial-res-kros-20240508monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-announces-u-s-fda-fast-track-designation-for-ker-050-in-lower-risk-myel-kros-20240314monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-leerink-partners-2024-global-biopharma-conference-kros-20240305monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-reports-recent-business-highlights-and-fourth-quarter-and-full-year-202-kros-20240228monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-announces-closing-of-upsized-public-offering-of-common-stock-kros-20240109monthly0.5https://www.biopharmawatch.com/news/KROS/january-2024-corporate-presentation-corporate-presentation-2-statements-contained-in-this--kros-20240103monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-presents-clinical-data-from-its-ker-050-program-at-the-65th-american-so-kros-20231211monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-upcoming-healthcare-conferences-kros-20231107monthly0.5https://www.biopharmawatch.com/news/KROS/november-2023-corporate-presentation-corporate-presentation-2-statements-contained-in-this-kros-20231106monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-reports-recent-business-highlights-and-third-quarter-2023-financial-res-kros-20231106monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-presents-preclinical-data-from-its-ker-065-program-at-the-28th-internat-kros-20231004monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-upcoming-healthcare-conferences-kros-20230905monthly0.5https://www.biopharmawatch.com/news/KROS/august-2023-corporate-presentation-corporate-presentation-2-statements-contained-in-this-p-kros-20230807monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-reports-recent-business-highlights-and-second-quarter-2023-financial-re-kros-20230807monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-host-conference-call-and-webcast-to-provide-an-overview-of-tropos-th-kros-20230724monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-presents-clinical-trial-and-preclinical-study-results-from-its-ker-050--kros-20230609monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-goldman-sach-s-44-th-annual-global-healthcare-conference-kros-20230607monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-presents-preclinical-and-clinical-data-from-its-ker-012-program-at-the--kros-20230522monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-reports-recent-business-highlights-and-first-quarter-2023-financial-res-kros-20230504monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-appoints-alpna-seth-ph-d-to-its-board-of-directors-kros-20230419monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-reports-recent-business-highlights-and-fourth-quarter-and-full-year-202-kros-20230303monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-cowen-s-43-rd-annual-health-care-conference-kros-20230301monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference-kros-20230207monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-presents-clinical-data-from-its-ker-050-and-ker-047-programs-and-precli-kros-20221212monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-upcoming-healthcare-conferences-kros-20221122monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-presents-preclinical-data-from-its-ker-012-program-at-the-american-hear-kros-20221107monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-the-64th-american-society-of-hematology-annual-meeting-an-kros-20221103monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-reports-recent-business-highlights-and-third-quarter-2022-financial-res-kros-20221103monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-presents-additional-clinical-data-from-its-ker-012-program-and-preclini-kros-20220912monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-the-morgan-stanley-20-th-annual-global-healthcare-confere-kros-20220906monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-reports-recent-business-highlights-and-second-quarter-2022-financial-re-kros-20220804monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-presents-results-from-a-preclinical-study-of-rker-012-in-pulmonary-arte-kros-20220613monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-presents-clinical-trial-and-preclinical-study-results-from-its-ker-050--kros-20220610monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-announces-preliminary-topline-results-from-its-ongoing-phase-1-clinical-kros-20220518monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-presents-results-from-a-preclinical-study-of-rker-012-in-pulmonary-arte-kros-20220517monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-reports-first-quarter-2022-financial-results-lexington-mass-kros-20220505monthly0.5https://www.biopharmawatch.com/news/KROS/march-2022-corporate-presentation-disclaimer-statements-contained-in-this-presentation-reg-kros-20220309monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-reports-recent-business-highlights-and-fourth-quarter-and-full-year-202-kros-20220309monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-the-11th-annual-svb-leerink-global-healthcare-conference--kros-20220211monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-appoints-christopher-rovaldi-as-chief-operating-officer-kros-20220131monthly0.5https://www.biopharmawatch.com/news/KROS/corrected-keros-therapeutics-presents-clinical-trial-and-preclinical-study-results-from-it-kros-20211213monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-presents-clinical-trial-and-preclinical-study-results-from-its-ker-050--kros-20211213monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-announces-licensing-agreement-and-strategic-partnership-with-hansoh-pha-kros-20211213monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-the-piper-sandler-33-rd-annual-virtual-healthcare-confere-kros-20211122monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-presents-results-from-a-preclinical-study-of-rker-012-at-the-american-h-kros-20211115monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-the-jefferies-virtual-london-healthcare-conference-lexing-kros-20211111monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-reports-recent-business-highlights-and-third-quarter-2021-financial-res-kros-20211104monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-presents-results-from-a-preclinical-study-of-rker-012-in-pulmonary-arte-kros-20211004monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-participate-in-two-upcoming-healthcare-conferences-lexington-mass-kros-20210902monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-reports-recent-business-highlights-and-second-quarter-2021-financial-re-kros-20210805monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-appoints-simon-cooper-m-b-b-s-as-chief-medical-officer-kros-20210802monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-announces-preliminary-results-from-its-phase-2-clinical-trial-evaluatin-kros-20210622monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-presents-preclinical-data-from-alk2-and-ker-050-hematology-programs-at--kros-20210611monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-the-jefferies-virtual-healthcare-conference-lexington-mas-kros-20210527monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-announces-issuance-of-u-s-patent-for-use-of-therapeutic-proteins-in-tre-kros-20210525monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-presents-results-from-preclinical-study-of-ker-012-in-pulmonary-arteria-kros-20210514monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-the-virtual-26th-annual-congress-of-the-european-hematolo-kros-20210512monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-reports-recent-business-highlights-and-first-quarter-2021-financial-res-kros-20210506monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-reports-recent-business-highlights-and-fourth-quarter-and-full-year-202-kros-20210325monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-presents-results-from-preclinical-studies-of-ker-050-and-alk2-inhibitor-kros-20210305monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-2021-virtual-conf-kros-20210302monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-to-present-at-the-10-th-annual-svb-leerink-global-healthcare-conference-kros-20210217monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-announces-addition-to-nasdaq-biotechnology-index-lexington-massachusett-kros-20201221monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-appoints-mary-ann-gray-ph-d-to-its-board-of-directors-lexington-massach-kros-20201217monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-presents-clinical-trial-and-preclinical-study-results-from-its-alk2-inh-kros-20201207monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-announces-closing-of-public-offering-of-common-stock-and-full-exercise--kros-20201117monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-announces-pricing-of-public-offering-of-common-stock-lexington-massachu-kros-20201112monthly0.5https://www.biopharmawatch.com/news/KROS/business-overview-we-are-a-clinical-stage-biopharmaceutical-company-focused-on-the-discove-kros-20201026monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-reports-recent-business-highlights-and-third-quarter-2020-financial-res-kros-20201110monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-inc-announces-dosing-of-first-participants-in-phase-2-clinical-trial-of-kros-20201020monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-presents-results-from-preclinical-studies-investigating-ker-012-at-the--kros-20200911monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-reports-recent-business-highlights-and-second-quarter-2020-financial-re-kros-20200813monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-inc-announces-completion-of-dosing-of-planned-cohorts-in-ker-047-phase--kros-20200804monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-set-to-join-russell-2000-index-lexington-massachusetts-kros-20200626monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-presents-results-from-clinical-and-preclinical-studies-investigating-ke-kros-20200612monthly0.5https://www.biopharmawatch.com/news/KROS/keros-therapeutics-reports-recent-business-highlights-and-first-quarter-2020-financial-res-kros-20200522monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-a-corporation-x201c-sa-x201d-with-a-share-capital-of-5-029-549-70-euros-register-clls-20260521monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-m-clls-20260511monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-nine-mo-clls-20251107monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-r-d-day-highlights-lasme-cel-s-potential-to-address-significant-unmet-need-for-p-clls-20251016monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-six-mon-clls-20251014monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-six-mon-clls-20250804monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-clls-20250626monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-a-corporation-x201c-sa-x201d-with-a-share-capital-of-5-014-561-35-euros-register-clls-20250521monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-m-clls-20250512monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-a-clls-20241104monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-a-clls-20240911monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-a-clls-20240806monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-annual-shareholders-meeting-june-28-2024-vote-results-ordinary-resolutions-nb-re-clls-20240628monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-m-clls-20240528monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-a-corporation-sa-with-a-share-capital-of-4-997-776-75-euros-headquarters-8-rue-d-clls-20240524monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-appoints-arthur-stril-as-interim-chief-financial-officer-new-york-ny-clls-20240502monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-shareholders-meeting-clls-20231222monthly0.5https://www.biopharmawatch.com/news/CLLS/time-sensitive-materials-depositary-s-notice-of-combined-ordinary-and-extraordinary-genera-clls-20231128monthly0.5https://www.biopharmawatch.com/news/CLLS/english-language-translation-for-information-purpose-only-cellectis-french-soci-t-anonyme--clls-20231117monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-the-execution-of-the-subsequent-investment-agreement-with-astrazeneca--clls-20231101monthly0.5https://www.biopharmawatch.com/news/CLLS/confidential-certain-information-in-this-exhibit-identified-by-is-confidential-and-has-bee-clls-20231101monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-a-clls-20231106monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-strategic-collaboration-and-investment-agreements-with-astrazeneca-col-clls-20231101monthly0.5https://www.biopharmawatch.com/news/CLLS/translation-for-information-purposes-only-cellectis-french-soci-t-anonyme-corporation-with-clls-20231031monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-a-clls-20230905monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-a-clls-20230807monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-s-a-reports-results-from-annual-shareholders-general-meeting-held-on-clls-20230627monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-a-corporation-sa-with-a-share-capital-of-2-779-188-40-euros-headquarters-8-rue-d-clls-20230522monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-m-clls-20230504monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-enters-into-warrant-agreement-with-the-european-investment-bank-related-to-credi-clls-20230404monthly0.5https://www.biopharmawatch.com/news/CLLS/this-presentation-together-with-the-corresponding-webcast-this-presentation-contains-forwa-clls-20221213monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-a-clls-20221103monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-a-clls-20220831monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-a-clls-20220804monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-s-a-reports-results-from-annual-shareholders-general-meeting-held-on-clls-20220628monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-annual-shareholders-general-meeting-to-be-held-on-clls-20220523monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-a-corporation-sa-with-a-share-capital-of-2-274-215-50-euros-headquarters-8-rue-d-clls-20220523monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-m-clls-20220512monthly0.5https://www.biopharmawatch.com/news/CLLS/business-company-overview-calyxt-inc-was-founded-in-2010-and-incorporated-in-delaware-caly-clls-20220218monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-appoints-bing-wang-phd-mba-as-chief-financial-officer-clls-20220210monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-licensed-partner-allogene-therapeutics-announces-removal-of-fda-clinical-hold-on-clls-20220110monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-provides-business-objectives-for-2022-and-updates-its-corporate-presentation-clls-20220104monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-a-clls-20211104monthly0.5https://www.biopharmawatch.com/news/CLLS/calyxt-announces-new-strategic-direction-to-provide-sustainable-plant-based-synthetic-biol-clls-20211005monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-a-clls-20210831monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-a-clls-20210805monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-s-a-reports-results-from-annual-shareholders-general-meeting-held-on-clls-20210601monthly0.5https://www.biopharmawatch.com/news/CLLS/non-binding-unofficial-english-translation-for-information-purposes-only-original-in-frenc-clls-20210519monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-m-clls-20210506monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-a-french-limited-liability-company-soci-t-anonyme-with-a-share-capital-of-2-272--clls-20210427monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-completes-sale-of-47-million-through-its-atm-program-new-york-ny-clls-20210409monthly0.5https://www.biopharmawatch.com/news/CLLS/calyxt-announces-dr-yves-ribeill-appointed-as-executive-chair-replacing-ceo-jim-blome-rose-clls-20210219monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-nine-mo-clls-20201105monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-general-assembly-11-04-2020-vote-results-ordinary-resolutions-for-against-vote-w-clls-20201105monthly0.5https://www.biopharmawatch.com/news/CLLS/time-sensitive-materials-depositary-s-notice-of-combined-ordinary-and-extraordinary-genera-clls-20201006monthly0.5https://www.biopharmawatch.com/news/CLLS/translation-for-information-purposes-only-cellectis-a-french-limited-liability-company-soc-clls-20201001monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-six-mon-clls-20200909monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-six-mon-clls-20200805monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-s-a-reports-results-from-annual-shareholders-general-meeting-held-on-clls-20200629monthly0.5https://www.biopharmawatch.com/news/CLLS/translation-for-information-purposes-only-cellectis-a-french-limited-liability-company-soc-clls-20200508monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-m-clls-20200506monthly0.5https://www.biopharmawatch.com/news/CLLS/us-patent-covering-crispr-edited-allogeneic-car-t-cells-granted-to-cellectis-following-ser-clls-20200310monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-provides-business-update-and-reports-4th-quarter-and-full-year-2019-financial-re-clls-20200304monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-and-servier-execute-the-amendment-confirming-the-expansion-of-their-collaboratio-clls-20200304monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-hold-fourth-quarter-and-full-year-2019-earnings-call-on-thursday-clls-20200225monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-and-servier-expand-collaboration-on-ucart19-products-cellectis-grants-additional-clls-20200218monthly0.5https://www.biopharmawatch.com/news/CLLS/first-patient-dosed-with-cellectis-new-allogeneic-ucart123-product-candidate-for-relapsed--clls-20200115monthly0.5https://www.biopharmawatch.com/news/CLLS/iovance-biotherapeutics-and-cellectis-enter-into-a-research-collaboration-and-exclusive-wo-clls-20200112monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-an-expert-review-on-allogeneic-car-t-for-cancer-published-in-nature-reviews-drug-clls-20200106monthly0.5https://www.biopharmawatch.com/news/CLLS/st-patient-dosed-with-cellectis-allogeneic-ucart22-in-relapsed-refractory-b-cell-acute-lym-clls-20191202monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-wins-patent-challenge-in-europe-for-a-method-using-crispr-cas9-for-gene-editing--clls-20191120monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-publishes-creation-of-smart-car-t-cells-for-potentially-safer-more-effective-tre-clls-20191113monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-m-clls-20191106monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-financial-results-for-third-quarter-and-first-nine-months-2019-first-pat-clls-20191106monthly0.5https://www.biopharmawatch.com/news/CLLS/first-patient-dosed-with-off-the-shelf-ucartcs1-product-candidate-for-relapsed-refractory--clls-20191029monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-and-lonza-enter-cgmp-manufacturing-service-agreement-for-cellectis-allogeneic-uc-clls-20191001monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-m-clls-20190806monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-financial-results-for-second-quarter-and-first-six-months-2019-fda-appro-clls-20190806monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-publishes-new-car-design-to-control-car-t-cells-in-non-lethal-way-swiff-car-a-ne-clls-20190708monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-s-a-reports-results-from-combined-shareholders-meeting-held-on-clls-20190625monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-as-of-and-for-t-clls-20190508monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-financial-results-for-first-quarter-2019-started-construction-of-in-hous-clls-20190507monthly0.5https://www.biopharmawatch.com/news/CLLS/non-binding-unofficial-english-translation-for-information-purposes-only-original-in-frenc-clls-20190503monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-oral-and-poster-presentations-of-allogeneic-car-t-cell-programs-at-the-clls-20190417monthly0.5https://www.biopharmawatch.com/news/CLLS/fda-clears-the-ind-for-ucartcs1-the-first-allogeneic-car-t-to-treat-multiple-myeloma-patie-clls-20190402monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-4th-quarter-and-full-year-2018-financial-results-ucart123-in-phase-1-dos-clls-20190312monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-enters-lease-agreement-to-build-manufacturing-facility-advancing-towards-commerc-clls-20190307monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-publishes-novel-methods-to-improve-the-safety-of-car-t-cell-therapy-and-prevent--clls-20190225monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-appoints-william-monteith-as-senior-vice-president-u-s-manufacturing-new-york-bu-clls-20181210monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-financial-results-for-3-rd-quarter-and-first-nine-months-2018-ucart123-i-clls-20181113monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-m-clls-20181113monthly0.5https://www.biopharmawatch.com/news/CLLS/car-t-pioneer-dr-stephan-a-grupp-to-join-cellectis-clinical-advisory-board-new-york-busine-clls-20180919monthly0.5https://www.biopharmawatch.com/news/CLLS/calyxt-appoints-ceo-jim-blome-former-president-ceo-of-bayer-cropscience-lp-minneapolis-st--clls-20180918monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-calyxt-names-biotech-veteran-and-board-of-directors-member-dr-yves-j-ribeill-as--clls-20180822monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-appoints-stefan-scherer-m-d-ph-d-as-senior-vice-president-clinical-development-a-clls-20180802monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-condensed-consolidated-financial-statements-for-the-three-m-clls-20180801monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-financial-results-for-2-nd-quarter-and-first-six-months-2018-fda-approve-clls-20180801monthly0.5https://www.biopharmawatch.com/news/CLLS/translation-for-information-purposes-only-cellectis-a-french-soci-t-anonyme-corporation-wi-clls-20180626monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-s-a-reports-results-from-annual-general-meeting-held-on-clls-20180626monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-publishes-novel-methods-to-improve-the-clinical-use-of-chimeric-antigen-receptor-clls-20180612monthly0.5https://www.biopharmawatch.com/news/CLLS/fda-grants-cellectis-ind-approval-for-ucart22-in-b-all-cellectis-3-rd-talen-based-gene-edi-clls-20180604monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-approval-of-ucart123-amendment-in-aml-to-accelerate-clinical-development-increas-clls-20180522monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-present-data-at-the-2018-asgct-annual-meeting-new-york-business-wire-clls-20180510monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-a-french-limited-liability-company-soci-t-anonyme-with-share-capital-of-2-080-27-clls-20180509monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-these-unaudited-condensed-interim-consolidated-financial-statements-for-t-clls-20180507monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-1-st-quarter-2018-financial-results-ind-filed-for-ucart22-clinical-inves-clls-20180507monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-files-ind-for-ucart22-in-acute-lymphoblastic-leukemia-b-all-this-is-the-3-rd-ind-clls-20180502monthly0.5https://www.biopharmawatch.com/news/CLLS/harvard-s-wyss-institute-partners-with-cellectis-to-recode-the-human-genome-recode-project-clls-20180501monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-present-data-at-the-2018-aacr-annual-meeting-new-york-business-wire-clls-20180411monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-closing-of-follow-on-offering-new-york-business-wire-clls-20180410monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-pricing-of-follow-on-offering-new-york-business-wire-clls-20180404monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-launch-of-follow-on-offering-new-york-business-wire-clls-20180403monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-and-allogene-therapeutics-intend-to-continue-strategic-cancer-immunotherapy-coll-clls-20180403monthly0.5https://www.biopharmawatch.com/news/CLLS/dr-mathieu-simon-to-retire-as-cellectis-chief-operating-officer-elsy-boglioli-named-as-suc-clls-20180313monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-4-th-quarter-and-full-year-2017-financial-results-first-dose-cohort-of-p-clls-20180228monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-servier-and-pfizer-announce-results-of-ucart19-first-in-human-trials-to-be-prese-clls-20180308monthly0.5https://www.biopharmawatch.com/news/CLLS/two-issued-u-s-patents-granted-to-cellectis-for-crispr-use-in-t-cells-new-york-business-wi-clls-20180213monthly0.5https://www.biopharmawatch.com/news/CLLS/translation-for-information-purposes-only-cellectis-a-french-soci-t-anonyme-corporation-wi-clls-20180109monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-data-from-servier-and-pfizer-s-ucart19-product-candidate-shows-high-complete-r-clls-20171212monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-appoints-immuno-oncology-leader-st-phane-depil-to-position-of-senior-vice-presid-clls-20171204monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-appoints-elsy-boglioli-to-executive-vice-president-strategy-and-corporate-develo-clls-20171204monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-demonstrates-fine-and-predictable-tuning-of-talen-gene-editing-targeting-to-impr-clls-20171120monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-condensed-interim-consolidated-financial-statements-for-the-clls-20171113monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-financial-results-for-third-quarter-and-first-nine-months-of-2017-fda-ha-clls-20171113monthly0.5https://www.biopharmawatch.com/news/CLLS/fda-lifts-clinical-hold-on-cellectis-phase-1-clinical-trials-with-ucart123-in-aml-and-bpdc-clls-20171106monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-two-oral-presentations-and-one-poster-presentation-at-the-2017-ash-ann-clls-20171101monthly0.5https://www.biopharmawatch.com/news/CLLS/servier-and-pfizer-announce-preliminary-results-of-the-first-in-human-trials-of-ucart19-wi-clls-20171101monthly0.5https://www.biopharmawatch.com/news/CLLS/mathieu-simon-m-d-cellectis-evp-chief-operating-officer-to-serve-as-interim-chief-medical--clls-20171004monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-clinical-hold-of-ucart123-studies-new-york-business-wire-clls-20170904monthly0.5https://www.biopharmawatch.com/news/CLLS/segment-financial-information-supplement-to-cellectis-s-a-s-interim-report-for-the-quarter-clls-20170901monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-ucart123-administered-to-first-patient-with-bpdcn-in-phase-i-clinical-trial-at-m-clls-20170817monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-condensed-interim-consolidated-financial-statements-for-the-clls-20170802monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-financial-results-for-2-nd-quarter-and-first-six-months-2017-first-aml-p-clls-20170725monthly0.5https://www.biopharmawatch.com/news/CLLS/calyxt-announces-full-exercise-of-over-allotment-option-and-closing-of-its-initial-public--clls-20170725monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-s-a-calyxt-announces-full-exercise-of-over-allotment-option-and-closing-of-its-i-clls-20170725monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-granted-patent-for-crispr-use-in-t-cells-new-york-business-wire-clls-20170724monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-s-a-calyxt-announces-pricing-of-56-0-million-initial-public-offering-st-paul-min-clls-20170719monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-calyxt-announces-proposed-initial-public-offering-of-100-0-million-st-paul-minn--clls-20170710monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-appoints-rainer-boehm-m-d-and-herv-hoppenot-to-board-of-directors-new-york-busin-clls-20170628monthly0.5https://www.biopharmawatch.com/news/CLLS/first-in-human-administration-of-ucart123-in-cellectis-aml-phase-i-clinical-trial-at-weill-clls-20170627monthly0.5https://www.biopharmawatch.com/news/CLLS/explanatory-note-the-board-of-directors-recommended-a-vote-in-favor-of-all-resolutions-wit-clls-20170626monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-s-a-reports-results-from-annual-general-meeting-held-on-clls-20170626monthly0.5https://www.biopharmawatch.com/news/CLLS/calyxt-files-registration-statement-for-proposed-initial-public-offering-st-paul-minn-new--clls-20170623monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-annual-general-meeting-of-clls-20170609monthly0.5https://www.biopharmawatch.com/news/CLLS/calyxt-names-joseph-b-saluri-as-general-counsel-evp-corporate-development-st-paul-minn-bus-clls-20170607monthly0.5https://www.biopharmawatch.com/news/CLLS/calyxt-launches-u-s-field-trials-with-university-of-minnesota-for-powdery-mildew-resistant-clls-20170516monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-patent-encompassing-broad-uses-of-gene-editing-technologies-maintained-by-uspto--clls-20170510monthly0.5https://www.biopharmawatch.com/news/CLLS/calyxt-patent-encompassing-broad-uses-of-plant-gene-editing-technologies-maintained-by-usp-clls-20170510monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-first-quarter-consolidated-financial-statements-included-he-clls-20170509monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-1-st-quarter-2017-financial-results-clinical-trial-approval-by-the-fda-f-clls-20170509monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-ceo-selected-as-speaker-for-2017-milken-institute-global-conference-dr-andr-chou-clls-20170427monthly0.5https://www.biopharmawatch.com/news/CLLS/correcting-and-replacing-cellectis-to-present-at-the-american-society-of-gene-cell-therapy-clls-20170425monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-present-at-the-american-society-of-gene-cell-therapy-annual-meeting-new-york--clls-20170425monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-s-a-to-explore-possible-initial-public-offering-of-calyxt-inc-new-york-business--clls-20170412monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-present-at-the-2017-annual-conference-of-the-american-association-for-cancer--clls-20170329monthly0.5https://www.biopharmawatch.com/news/CLLS/calyxt-hires-cargill-executive-manoj-sahoo-as-chief-commercial-officer-st-paul-minn-busine-clls-20170321monthly0.5https://www.biopharmawatch.com/news/CLLS/calyxt-announces-new-technology-framework-agreement-with-plant-bioscience-limited-to-expan-clls-20170309monthly0.5https://www.biopharmawatch.com/news/CLLS/servier-and-pfizer-announce-fda-clearance-of-ind-application-for-ucart19-in-adult-relapsed-clls-20170309monthly0.5https://www.biopharmawatch.com/news/CLLS/five-additional-leading-physicians-to-join-cellectis-clinical-advisory-board-new-board-mem-clls-20170307monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-4-th-quarter-and-full-year-2016-financial-results-fda-approval-to-conduc-clls-20170306monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-present-at-the-leerink-partners-6th-annual-global-healthcare-conference-on-th-clls-20170207monthly0.5https://www.biopharmawatch.com/news/CLLS/fda-grants-cellectis-ind-approval-to-proceed-with-the-clinical-development-of-ucart123-the-clls-20170206monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-four-prominent-physicians-to-join-cellectis-clinical-advisory-board-new-board-me-clls-20170123monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-studies-safety-in-new-car-architecture-controlling-car-t-cell-functions-publicat-clls-20170122monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-present-at-the-35th-annual-j-p-morgan-healthcare-conference-on-monday-clls-20170104monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-submits-ind-application-for-ucart123-an-allogeneic-gene-edited-car-t-cell-produc-clls-20170103monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-recombinant-dna-advisory-committee-s-rac-unanimous-approval-of-ucart12-clls-20161215monthly0.5https://www.biopharmawatch.com/news/CLLS/calyxt-appoints-seed-trait-veteran-bryan-corkal-to-new-chief-financial-officer-role-expans-clls-20161205monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-these-unaudited-condensed-interim-consolidated-financial-statements-for-t-clls-20161122monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-financial-results-for-3-rd-quarter-and-first-nine-months-2016-ucart19-ph-clls-20161122monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-participate-in-oppenheimer-life-sciences-summit-ny-in-piper-jaffray-28th-annu-clls-20161121monthly0.5https://www.biopharmawatch.com/news/CLLS/calyxt-produces-1-200-tons-of-high-oleic-soybeans-in-u-s-minneapolis-st-paul-minn-business-clls-20161115monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-successful-cgmp-manufacturing-for-second-product-candidate-ucart123-ne-clls-20161115monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-two-oral-presentations-and-one-poster-at-the-2016-ash-annual-meeting-n-clls-20161107monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-hosts-world-s-first-gene-edited-dinner-in-nyc-new-york-business-wire-clls-20161031monthly0.5https://www.biopharmawatch.com/news/CLLS/calyxt-generating-healthier-high-oleic-low-linolenic-soybean-variety-with-increased-oxidat-clls-20161031monthly0.5https://www.biopharmawatch.com/news/CLLS/calyxt-expands-its-patent-portfolio-now-encompassing-broad-uses-of-technologies-such-as-cr-clls-20161004monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-the-issuance-of-u-s-patent-9-458-439-following-u-s-patent-8-921-332-is-clls-20161004monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-wins-2016-most-innovative-european-biotech-sme-award-for-healthcare-new-york-bus-clls-20160927monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-2-nd-quarter-and-first-half-year-2016-financial-results-first-patient-do-clls-20160908monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-these-unaudited-condensed-consolidated-financial-statements-for-the-three-clls-20160908monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-named-2016-technology-pioneer-by-the-world-economic-forum-new-york-business-wire-clls-20160627monthly0.5https://www.biopharmawatch.com/news/CLLS/mit-technology-review-names-cellectis-on-annual-list-of-50-smartest-companies-for-second-c-clls-20160627monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-first-patient-treated-in-phase-1-trial-of-ucart19-in-pediatric-acute-b-clls-20160620monthly0.5https://www.biopharmawatch.com/news/CLLS/calyxt-appoints-federico-a-tripodi-to-new-role-of-ceo-st-paul-minn-business-wire-clls-20160523monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-first-quarter-consolidated-financial-statements-included-he-clls-20160511monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-first-quarter-2016-financial-results-initiated-ucart123-gmp-production-c-clls-20160511monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-to-present-data-on-its-allogeneic-car-t-cell-programs-at-the-19-th-american-soci-clls-20160502monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-a-french-limited-liability-company-soci-t-anonyme-with-share-capital-of-1-758-93-clls-20160428monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-and-mabquest-announce-immunotherapy-partnership-on-new-class-of-pd-1-antagonist--clls-20160316monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-fourth-quarter-and-full-year-2015-financial-results-on-track-with-submis-clls-20160314monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-presentation-at-the-cowen-and-company-36th-annual-health-care-conferen-clls-20160307monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-subsidiary-calyxt-acquires-land-for-new-headquarters-facility-new-york-business--clls-20160301monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-enters-into-new-agreement-with-cell-for-cure-for-the-cgmp-manufacturing-of-ucart-clls-20160119monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-a-new-car-architecture-controlling-car-t-cell-functions-publication-in-clls-20160111monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-chief-medical-officer-appointment-to-senior-leadership-team-new-york-b-clls-20160107monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-files-first-clinical-trial-application-for-ucart19-an-allogeneic-gene-edited-car-clls-20151223monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-presentation-at-the-34th-annual-j-p-morgan-healthcare-conference-in-sa-clls-20151221monthly0.5https://www.biopharmawatch.com/news/CLLS/calyxt-announces-research-collaboration-and-licensing-agreement-for-trait-development-in-w-clls-20151216monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-third-quarter-and-first-nine-months-2015-financial-results-new-york-busi-clls-20151116monthly0.5https://www.biopharmawatch.com/news/CLLS/servier-exercises-exclusive-worldwide-licensing-option-with-cellectis-for-ucart19-an-allog-clls-20151118monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-ucart19-first-in-man-proof-of-concept-to-be-presented-at-2015-ash-annual-meeting-clls-20151105monthly0.5https://www.biopharmawatch.com/news/CLLS/calyxt-completes-the-first-field-trials-of-its-cold-storable-potato-product-new-brighton-m-clls-20151102monthly0.5https://www.biopharmawatch.com/news/CLLS/calyxt-completes-second-year-of-field-trials-of-its-high-oleic-soybean-product-new-brighto-clls-20151102monthly0.5https://www.biopharmawatch.com/news/CLLS/successful-gmp-production-process-for-ucart19-new-york-business-wire-clls-20151028monthly0.5https://www.biopharmawatch.com/news/CLLS/preliminary-note-the-unaudited-half-year-consolidated-financial-statements-included-herein-clls-20150908monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-second-quarter-and-first-half-year-2015-financial-results-paris-business-clls-20150908monthly0.5https://www.biopharmawatch.com/news/CLLS/md-anderson-cancer-center-and-cellectis-announce-a-broad-preclinical-and-clinical-strategi-clls-20150903monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-announces-publication-of-an-article-in-cancer-research-on-allogeneic-car-t-cell--clls-20150716monthly0.5https://www.biopharmawatch.com/news/CLLS/calyxt-launches-field-trials-of-its-cold-storable-potato-new-brighton-minn-business-wire-clls-20150708monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reaches-milestone-in-servier-collaboration-new-york-business-wire-clls-20150708monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-reports-first-quarter-2015-financial-results-paris-business-wire-clls-20150609monthly0.5https://www.biopharmawatch.com/news/CLLS/weill-cornell-medical-college-and-cellectis-announce-research-alliance-advancing-drug-disc-clls-20150602monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-sa-combined-general-shareholders-meeting-of-clls-20150518monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-s-a-to-present-data-on-its-allogeneic-car-t-cell-programs-at-american-society-of-clls-20150507monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-s-a-announces-calyxt-is-new-name-for-its-plant-sciences-subsidiary-paris-busines-clls-20150504monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-a-soci-t-anonyme-with-a-share-capital-of-1-751-443-70-registered-office-8-rue-de-clls-20150428monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-plant-sciences-inc-locks-early-crispr-intellectual-property-uses-in-plants-celle-clls-20150415monthly0.5https://www.biopharmawatch.com/news/CLLS/cellectis-plant-sciences-inc-publishes-a-study-demonstrating-reduced-acrylamide-in-fried-p-clls-20150414monthly0.5https://www.biopharmawatch.com/news/ACH/project-huskies-management-presentation-may-2026-this-presentation-may-contain-material-no-ach-20260511monthly0.5https://www.biopharmawatch.com/news/ACH/accendra-health-reports-fourth-quarter-2025-financial-results-completed-sale-of-products-h-ach-20260219monthly0.5https://www.biopharmawatch.com/news/ACH/owens-minor-inc-completes-sale-of-products-healthcare-services-business-to-platinum-equity-ach-20251231monthly0.5https://www.biopharmawatch.com/news/ACH/owens-minor-announces-corporate-name-change-to-accendra-health-inc-accendra-health-to-trad-ach-20251218monthly0.5https://www.biopharmawatch.com/news/ACH/owens-minor-to-present-at-upcoming-investor-conferences-on-ach-20251202monthly0.5https://www.biopharmawatch.com/news/ACH/owens-minor-reports-third-quarter-2025-financial-results-signed-definitive-agreement-for-t-ach-20251030monthly0.5https://www.biopharmawatch.com/news/ACH/owens-minor-announces-definitive-agreement-to-divest-products-healthcare-services-segment--ach-20251007monthly0.5https://www.biopharmawatch.com/news/ACH/owens-minor-reports-second-quarter-2025-financial-results-classified-products-healthcare-s-ach-20250811monthly0.5https://www.biopharmawatch.com/news/ACH/owens-minor-and-rotech-healthcare-mutually-agree-to-terminate-previously-announced-acquisi-ach-20250605monthly0.5https://www.biopharmawatch.com/news/ACH/owens-minor-reports-first-quarter-2025-financial-results-top-line-growth-led-by-the-patien-ach-20250508monthly0.5https://www.biopharmawatch.com/news/ACH/owens-minor-announces-upsize-and-pricing-of-senior-secured-notes-offering-ach-20250402monthly0.5https://www.biopharmawatch.com/news/ACH/owens-minor-announces-launch-of-senior-secured-notes-offering-ach-20250326monthly0.5https://www.biopharmawatch.com/news/ACH/disclaimer-forward-looking-statements-this-presentation-contains-certain-forward-looking-s-ach-20250320monthly0.5https://www.biopharmawatch.com/news/ACH/owens-minor-reports-fourth-quarter-full-year-financial-results-and-announces-sale-process--ach-20250228monthly0.5https://www.biopharmawatch.com/news/ACH/owens-minor-launches-financing-for-rotech-acquisition-and-provides-preliminary-fourth-quar-ach-20250203monthly0.5https://www.biopharmawatch.com/news/ACH/owens-minor-reports-third-quarter-2024-financial-results-top-line-growth-driven-by-continu-ach-20241104monthly0.5https://www.biopharmawatch.com/news/ACH/owens-minor-names-jonathan-leon-executive-vice-president-chief-financial-officer-richmond--ach-20240923monthly0.5https://www.biopharmawatch.com/news/ACH/owens-minor-reports-second-quarter-2024-financial-results-top-line-expansion-driven-by-sol-ach-20240802monthly0.5https://www.biopharmawatch.com/news/ACH/owens-minor-inc-signs-definitive-agreement-to-acquire-rotech-healthcare-holdings-inc-for-1-ach-20240723monthly0.5https://www.biopharmawatch.com/news/ACH/owens-minor-inc-releases-preliminary-second-quarter-2024-financial-results-reaffirms-2024--ach-20240723monthly0.5https://www.biopharmawatch.com/news/ACH/owens-minor-reports-first-quarter-2024-financial-results-gross-margin-expansion-of-79-basi-ach-20240503monthly0.5https://www.biopharmawatch.com/news/ACH/owens-minor-reports-fourth-quarter-and-full-year-2023-financial-results-business-delivered-ach-20240220monthly0.5https://www.biopharmawatch.com/news/ACH/owens-minor-owens-minor-unveils-long-term-strategy-at-investor-day-today-outlines-new-five-ach-20231206monthly0.5https://www.biopharmawatch.com/news/ACH/owens-minor-announces-executive-leadership-team-changes-company-also-provides-preliminary--ach-20221012monthly0.5https://www.biopharmawatch.com/news/ACH/index-to-financial-statements-audited-consolidated-financial-statements-of-apria-inc-repor-ach-20220329monthly0.5https://www.biopharmawatch.com/news/ACH/owens-minor-announces-upsize-and-pricing-of-600-million-of-senior-notes-due-2030-richmond--ach-20220323monthly0.5https://www.biopharmawatch.com/news/ACH/owens-minor-announces-launch-of-senior-notes-offering-richmond-va-business-wire-ach-20220318monthly0.5https://www.biopharmawatch.com/news/ACH/investor-presentation-ach-20220228monthly0.5https://www.biopharmawatch.com/news/ACH/owens-minor-inc-signs-definitive-agreement-to-acquire-apria-inc-highly-complementary-trans-ach-20220110monthly0.5https://www.biopharmawatch.com/news/ACH/owens-minor-announces-pricing-of-500-million-of-senior-notes-due-2029-richmond-va-ach-20210304monthly0.5https://www.biopharmawatch.com/news/ACH/owens-minor-announces-launch-of-senior-notes-offering-richmond-va-ach-20210302monthly0.5https://www.biopharmawatch.com/news/ACH/document-two-new-members-elected-to-owens-minor-board-of-directors-ach-20210224monthly0.5https://www.biopharmawatch.com/news/ACH/use-of-non-gaap-measures-the-foregoing-tables-contain-financial-measures-that-are-not-calc-ach-20200305monthly0.5https://www.biopharmawatch.com/news/ACH/owens-minor-names-board-member-robert-sledd-chairman-and-interim-president-and-ceo-company-ach-20181108monthly0.5https://www.biopharmawatch.com/news/ACH/safe-harbor-this-presentation-is-intended-to-be-disclosure-through-methods-reasonably-desi-ach-20180409monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-reports-long-term-vispa-cel-data-in-second-line-large-b-cell-lymphoma--crbu-20260612monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-reports-first-quarter-2026-financial-results-and-provides-business-upd-crbu-20260507monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-announces-the-fda-granted-regenerative-medicine-advanced-therapy-rmat--crbu-20260331monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provid-crbu-20260305monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-reports-third-quarter-2025-financial-results-and-provides-business-upd-crbu-20251112monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-announces-positive-data-from-antler-phase-1-trial-demonstrating-effica-crbu-20251103monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-reports-second-quarter-2025-financial-results-and-provides-business-up-crbu-20250812monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-reports-first-quarter-2025-financial-results-and-provides-business-upd-crbu-20250508monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-announces-strategic-pipeline-prioritization-with-focus-on-cb-010-and-c-crbu-20250424monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-reports-fourth-quarter-and-full-year-2024-financial-results-and-provid-crbu-20250310monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-initiates-the-cb-010-gallop-phase-1-trial-in-lupus-and-provides-outloo-crbu-20250112monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-appoints-sri-ryali-as-chief-financial-officer-crbu-20250102monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-reports-third-quarter-2024-financial-results-and-provides-business-upd-crbu-20241106monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-appoints-tina-albertson-md-phd-as-chief-medical-officer-highly-experie-crbu-20240812monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-reports-second-quarter-2024-financial-results-and-provides-business-up-crbu-20240806monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-presents-encouraging-clinical-data-from-cb-010-antler-phase-1-trial-in-crbu-20240602monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-reports-first-quarter-2024-financial-results-and-provides-business-upd-crbu-20240507monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-expands-clinical-development-of-cb-010-with-fda-clearance-of-ind-in-lu-crbu-20240404monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-reports-fourth-quarter-and-full-year-2023-financial-results-and-provid-crbu-20240311monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-appoints-tim-kelly-as-chief-technology-officer-and-highlights-multiple-crbu-20240107monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-provides-regulatory-update-on-cb-010-pivotal-plan-with-phase-3-trial-i-crbu-20231212monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-reports-third-quarter-2023-financial-results-and-provides-business-upd-crbu-20231107monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-announces-fda-clearance-of-ind-application-for-cb-012-an-allogeneic-an-crbu-20231018monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-reports-second-quarter-2023-financial-results-and-provides-business-up-crbu-20230808monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-announces-proposed-public-offering-of-common-stock-berkeley-ca-crbu-20230713monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-reports-positive-clinical-data-from-dose-escalation-of-cb-010-antler-p-crbu-20230713monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-announces-25-million-equity-investment-from-pfizer-pfizer-purchases-25-crbu-20230706monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-reports-first-quarter-2023-financial-results-and-provides-business-upd-crbu-20230509monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-announces-fda-granted-fast-track-designation-to-cb-011-an-allogeneic-c-crbu-20230404monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-announces-dosing-of-first-patient-in-the-cammouflage-phase-1-trial-of--crbu-20230328monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-initiates-dose-expansion-portion-of-cb-010-antler-phase-1-trial-in-sec-crbu-20230329monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-reports-fourth-quarter-and-full-year-2022-financial-results-and-provid-crbu-20230309monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-reports-cb-010-antler-phase-1-trial-progress-long-term-durability-obse-crbu-20221212monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-announces-the-fda-granted-regenerative-medicine-advanced-therapy-rmat--crbu-20221129monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-announces-fda-clearance-of-ind-application-for-cb-011-an-allogeneic-an-crbu-20221121monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-reports-third-quarter-2022-financial-results-and-provides-business-upd-crbu-20221108monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-to-present-antler-trial-in-progress-poster-at-the-64th-american-societ-crbu-20221103monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-presents-case-report-on-long-term-follow-up-of-first-patient-dosed-in--crbu-20221018monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-reports-second-quarter-2022-financial-results-and-provides-business-up-crbu-20220809monthly0.5https://www.biopharmawatch.com/news/CRBU/x201c-caribou-biosciences-x201d-and-the-caribou-logo-are-registered-trademarks-of-caribou--crbu-20220610monthly0.5https://www.biopharmawatch.com/news/CRBU/current-and-future-research-and-development-programs-preclinical-studies-and-clinical-tria-crbu-20220601monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-announces-positive-initial-data-for-cb-010-anti-cd19-allogeneic-car-t--crbu-20220512monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-announces-appointment-of-david-johnson-to-its-board-of-directors-mr-jo-crbu-20220511monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-reports-first-quarter-2022-financial-results-and-provides-business-upd-crbu-20220509monthly0.5https://www.biopharmawatch.com/news/CRBU/enhanced-persistence-caribou-is-advancing-a-pipeline-of-off-the-shelf-car-t-and-car-nk-cel-crbu-20220425monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-reports-fourth-quarter-and-full-year-2021-financial-results-and-provid-crbu-20220321monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-appoints-syed-rizvi-m-d-as-chief-medical-officer-dr-rizvi-brings-signi-crbu-20220118monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-provides-business-update-and-reports-third-quarter-2021-financial-resu-crbu-20211109monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-appoints-dara-richardson-heron-m-d-to-its-board-of-directors-and-ruhi--crbu-20211108monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-appoints-biotechnology-industry-veteran-ran-zheng-to-its-board-of-dire-crbu-20210929monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-provides-business-update-and-reports-second-quarter-2021-financial-res-crbu-20210902monthly0.5https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-appoints-nancy-whiting-pharm-d-to-its-board-of-directors-berkeley-ca-x-crbu-20210825monthly0.5https://www.biopharmawatch.com/news/EMBC/dated-may-15-2026-embecta-completes-acquisition-of-owen-mumford-holdings-limited-parsippan-embc-20260515monthly0.5https://www.biopharmawatch.com/news/EMBC/document-for-immediate-release-embecta-corp-reports-second-quarter-fiscal-2026-financial-r-embc-20260505monthly0.5https://www.biopharmawatch.com/news/EMBC/embecta-announces-definitive-agreement-to-acquire-owen-mumford-holdings-limited-acquisitio-embc-20260319monthly0.5https://www.biopharmawatch.com/news/EMBC/document-for-immediate-release-embecta-corp-reports-first-quarter-fiscal-2026-financial-re-embc-20260205monthly0.5https://www.biopharmawatch.com/news/EMBC/embecta-corp-reports-fiscal-2025-fourth-quarter-and-full-year-financial-results-provides-i-embc-20251125monthly0.5https://www.biopharmawatch.com/news/EMBC/embecta-announces-changes-to-board-of-directors-parsippany-n-j-embc-20251117monthly0.5https://www.biopharmawatch.com/news/EMBC/document-for-immediate-release-embecta-corp-reports-third-quarter-fiscal-2025-financial-re-embc-20250808monthly0.5https://www.biopharmawatch.com/news/EMBC/document-for-immediate-release-embecta-corp-reports-second-quarter-fiscal-2025-financial-r-embc-20250509monthly0.5https://www.biopharmawatch.com/news/EMBC/document-for-immediate-release-embecta-corp-reports-first-quarter-fiscal-2025-financial-re-embc-20250206monthly0.5https://www.biopharmawatch.com/news/EMBC/embecta-corp-reports-fiscal-2024-fourth-quarter-and-full-year-financial-results-provides-i-embc-20241126monthly0.5https://www.biopharmawatch.com/news/EMBC/document-for-immediate-release-embecta-corp-reports-third-quarter-fiscal-2024-financial-re-embc-20240809monthly0.5https://www.biopharmawatch.com/news/EMBC/document-for-immediate-release-embecta-corp-reports-second-quarter-fiscal-2024-financial-r-embc-20240509monthly0.5https://www.biopharmawatch.com/news/EMBC/document-for-immediate-release-embecta-corp-reports-first-quarter-fiscal-2024-financial-re-embc-20240209monthly0.5https://www.biopharmawatch.com/news/EMBC/embecta-corp-reports-fiscal-2023-fourth-quarter-and-full-year-financial-results-and-provid-embc-20231121monthly0.5https://www.biopharmawatch.com/news/EMBC/embecta-corp-reports-third-quarter-fiscal-2023-financial-results-parsippany-n-j-embc-20230808monthly0.5https://www.biopharmawatch.com/news/EMBC/embecta-corp-reports-second-quarter-fiscal-2023-financial-results-parsippany-n-j-embc-20230512monthly0.5https://www.biopharmawatch.com/news/EMBC/embecta-corp-reports-first-quarter-fiscal-2023-financial-results-parsippany-n-j-embc-20230214monthly0.5https://www.biopharmawatch.com/news/EMBC/to-our-current-report-on-form-8-k-and-our-most-recent-annual-report-on-form-10-k-as-furthe-embc-20221220monthly0.5https://www.biopharmawatch.com/news/EMBC/to-our-current-report-on-form-8-k-except-as-required-by-law-we-undertake-no-obligation-to--embc-20220815monthly0.5https://www.biopharmawatch.com/news/EMBC/to-our-current-report-on-form-8-k-except-as-required-by-law-we-undertake-no-obligation-to--embc-20220513monthly0.5https://www.biopharmawatch.com/news/EMBC/embecta-completes-spin-off-from-bd-and-lists-on-nasdaq-as-a-global-leader-in-diabetes-care-embc-20220401monthly0.5https://www.biopharmawatch.com/news/EMBC/unaudited-pro-forma-condensed-combined-financial-information-references-in-this-section-to-embc-20220323monthly0.5https://www.biopharmawatch.com/news/EMBC/forward-looking-statements-this-presentation-contains-certain-estimates-and-other-forward--embc-20220307monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-reports-second-quarter-2025-financial-results-unaudited-net-revenue-inc-smti-20250813monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-reports-first-quarter-2025-financial-results-unaudited-q1-net-revenue-i-smti-20250514monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-reports-fourth-quarter-and-full-year-2024-financial-results-unaudited-q-smti-20250325monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-expands-executive-leadership-team-with-new-appointments-elizabeth-taylo-smti-20250121monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-exclusive-license-and-distribution-agreement-with-and-minorit-smti-20250121monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-reports-unaudited-preliminary-results-for-the-fourth-quarter-and-full-y-smti-20250121monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-reports-third-quarter-2024-results-fort-worth-tx-globenewswire-smti-20241112monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-changes-to-its-board-of-directors-fort-worth-tx-accesswire-smti-20241007monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-and-infusystem-holdings-inc-announce-exclusive-united-states-distributi-smti-20240911monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-second-quarter-2024-results-fort-worth-tx-globenewswire-smti-20240812monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-first-quarter-2024-results-fort-worth-tx-globenewswire-smti-20240513monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-55-million-debt-facility-fort-worth-tx-globenewswire-smti-20240418monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-the-appointments-of-jake-waldrop-as-chief-operating-officer-a-smti-20240405monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-fourth-quarter-and-full-year-2023-results-fort-worth-tx-globe-smti-20240325monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-unaudited-preliminary-results-for-the-fourth-quarter-and-full-smti-20240222monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-third-quarter-2023-results-fort-worth-tx-globenewswire-smti-20231113monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-second-quarter-2023-results-fort-worth-tx-globenewswire-smti-20230814monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-the-acquisition-of-certain-assets-related-to-its-collagen-pro-smti-20230802monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-first-quarter-2023-results-fort-worth-tx-globenewswire-smti-20230515monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-fourth-quarter-and-full-year-2022-results-fort-worth-tx-globe-smti-20230320monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-unaudited-preliminary-results-for-the-fourth-quarter-and-full-smti-20230222monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-third-quarter-2022-results-fort-worth-tx-globenewswire-smti-20221114monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-second-quarter-2022-results-fort-worth-tx-accesswire-smti-20220815monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-closing-of-scendia-biologics-llc-acquisition-fort-worth-tx-smti-20220705monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-first-quarter-2022-results-fort-worth-tx-smti-20220516monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-closing-of-merger-to-acquire-precision-healing-inc-fort-worth-smti-20220404monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-entry-into-merger-agreement-to-acquire-precision-healing-inc--smti-20220404monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-fourth-quarter-and-full-year-2021-results-fort-worth-tx-globe-smti-20220330monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-unaudited-preliminary-results-for-the-fourth-quarter-and-full-smti-20220222monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-the-appointment-of-zachary-b-fleming-as-chief-executive-offic-smti-20211228monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-the-retirement-of-j-michael-carmena-and-appointment-of-eric-t-smti-20211222monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-the-appointment-of-roszell-mack-iii-to-its-board-of-directors-smti-20211215monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-third-quarter-2021-results-and-business-update-fort-worth-tx--smti-20211112monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-second-quarter-2021-results-and-business-update-fort-worth-tx-smti-20210816monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-the-purchase-of-certain-assets-from-rochal-industries-llc-for-smti-20210719monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-exclusive-partnership-with-pixalere-healthcare-inc-to-advance-smti-20210604monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-proposed-public-offering-of-common-stock-fort-worth-tx-access-smti-20210211monthly0.5https://www.biopharmawatch.com/news/SMTI/smti-ex991-sanara-medtech-inc-announces-preliminary-results-for-the-fourth-quarter-and-ful-smti-20210125monthly0.5https://www.biopharmawatch.com/news/SMTI/additional-exhibits-smti-ex991-smti-20201223monthly0.5https://www.biopharmawatch.com/news/SMTI/smti-ex991-smti-20201029monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-the-appointment-of-bob-desutter-to-its-board-of-directors-for-smti-20201015monthly0.5https://www.biopharmawatch.com/news/SMTI/smti-ex991-smti-20200417monthly0.5https://www.biopharmawatch.com/news/SMTI/sanara-medtech-inc-announces-closing-of-10-000-000-private-placement-of-common-stock-fort--smti-20191016monthly0.5https://www.biopharmawatch.com/news/SMTI/wound-management-technologies-reports-preliminary-financial-results-for-the-third-quarter--smti-20151007monthly0.5https://www.biopharmawatch.com/news/SMTI/wound-management-technologies-inc-schedules-first-quarter-2015-earnings-call-for-wednesday-smti-20150422monthly0.5https://www.biopharmawatch.com/news/SMTI/letter-to-shareholders-wmti8kex991053012-htm-news-bulletin-from-wound-management-technolog-smti-20120529monthly0.5https://www.biopharmawatch.com/news/SMTI/presentation-wmti8kex991092711-htm-smti-20110928monthly0.5https://www.biopharmawatch.com/news/SMTI/presentation-materials-wmti8kex991111110-htm-smti-20101112monthly0.5https://www.biopharmawatch.com/news/SMTI/presentation-materials-wmit8kex992100610-htm-smti-20101006monthly0.5https://www.biopharmawatch.com/news/SMTI/presentation-wmti8kex991050610-htm-smti-20100506monthly0.5https://www.biopharmawatch.com/news/SMTI/wound-management-technologies-acquires-resorbable-orthopedics-specialty-medical-products-c-smti-20091002monthly0.5https://www.biopharmawatch.com/news/SMTI/news-bulletin-re-wound-management-technologies-inc-777-main-street-suite-3100-fort-worth-t-smti-20090616monthly0.5https://www.biopharmawatch.com/news/SMTI/mbsb-announces-exclusive-worldwide-human-health-care-license-rights-to-its-external-wound--smti-20071130monthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-reports-full-year-2025-financial-results-and-recent-business-highli-artv-20260310monthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-reports-second-quarter-2025-financial-results-recent-business-highl-artv-20250806monthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-reports-first-quarter-2025-financial-results-recent-business-highli-artv-20250508monthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-reports-full-year-2024-financial-results-and-recent-business-highli-artv-20250324monthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-reports-third-quarter-2024-financial-results-and-recent-business-hi-artv-20241112monthly0.5https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-reports-second-quarter-2024-financial-results-and-recent-business-h-artv-20240829monthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-proposes-public-offering-westminster-colo-business-wire-tlsi-20260219monthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-announces-expiration-and-results-of-exchange-offer-and-consent-soli-tlsi-20250724monthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-announces-chief-financial-officer-transition-with-appointment-of-da-tlsi-20250530monthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-announces-22-0-million-private-placement-preliminary-q1-2025-unaudi-tlsi-20250430monthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-announces-leadership-changes-james-young-appointed-chief-financial-officer-richar-tlsi-20250108monthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-reports-q3-2024-financial-results-and-provides-business-update-reported-q3-and-ni-tlsi-20241114monthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-reports-q2-2024-financial-results-and-business-update-reported-revenues-of-7-4-mi-tlsi-20240815monthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-announces-completion-of-exchange-offer-and-consent-solicitation-wes-tlsi-20240701monthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-announces-expiration-and-results-of-exchange-offer-and-consent-soli-tlsi-20240626monthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-announces-commencement-of-exchange-offer-and-consent-solicitation-r-tlsi-20240524monthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-reports-q1-2024-financial-results-and-business-update-reported-revenues-of-6-5-mi-tlsi-20240515monthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-secures-up-to-50-million-of-debt-financing-with-orbimed-to-support--tlsi-20240430monthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-reports-q4-and-full-year-2023-financial-results-and-business-update-reported-reve-tlsi-20240401monthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-january-2024-2-disclaimer-certain-statements-in-this-presentation-m-tlsi-20231231monthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-reports-third-quarter-2023-financial-results-and-provides-business-update-complet-tlsi-20231114monthly0.5https://www.biopharmawatch.com/news/TLSI/standby-equity-purchase-agreement-this-standby-equity-purchase-agreement-this-agreement-da-tlsi-20231002monthly0.5https://www.biopharmawatch.com/news/TLSI/our-mission-trisalus-life-sciences-seeks-to-transform-the-way-liver-and-pancreatic-tumors--tlsi-20230901monthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-inc-condensed-consolidated-balance-sheets-unaudited-in-thousands-ex-tlsi-20230816monthly0.5https://www.biopharmawatch.com/news/TLSI/medtech-acquisition-corporation-adjourns-special-meeting-of-stockholders-tlsi-20230802monthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-presents-additional-data-for-sd-101-delivered-by-the-proprietary-pe-tlsi-20230612monthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-presents-new-data-at-aacr-for-sd-101-delivered-by-the-proprietary-p-tlsi-20230420monthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-appoints-james-alecxih-to-lead-device-technology-business-denver-an-tlsi-20230221monthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-posts-updated-investor-presentation-highlighting-additional-phase-1-tlsi-20230216monthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-video-transcript-text-on-screen-dr-carvajal-is-a-member-of-the-trisalus-scientifi-tlsi-20221221monthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-highlights-pressure-enabled-regional-immuno-oncology-perio-clinical-tlsi-20221215monthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-provides-updates-on-pressure-enabled-regional-immuno-oncology-perio-tlsi-20221121monthly0.5https://www.biopharmawatch.com/news/TLSI/list-of-participants-chris-dewey-chief-executive-officer-medtech-acquisition-corporation-m-tlsi-20221114monthly0.5https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-to-become-publicly-traded-through-merger-with-medtech-acquisition-c-tlsi-20221114monthly0.5https://www.biopharmawatch.com/news/TLSI/medtech-acquisition-corporation-and-memic-innovative-surgery-ltd-mutually-agree-to-termina-tlsi-20220310monthly0.5https://www.biopharmawatch.com/news/TLSI/memic-innovative-surgery-ltd-and-medtech-acquisition-corporation-announce-proposed-busines-tlsi-20210813monthly0.5https://www.biopharmawatch.com/news/TLSI/medtech-acquisition-corporation-announces-receipt-of-notice-from-nasdaq-regarding-late-fil-tlsi-20210602monthly0.5https://www.biopharmawatch.com/news/TLSI/medtech-acquisition-corporation-announces-separate-trading-of-its-class-a-common-stock-and-tlsi-20210208monthly0.5https://www.biopharmawatch.com/news/TLSI/medtech-acquisition-corporation-index-to-financial-statement-page-audited-financial-statem-tlsi-20201222monthly0.5https://www.biopharmawatch.com/news/TLSI/medtech-acquisition-corporation-announces-pricing-of-upsized-220-000-000-initial-public-of-tlsi-20201217monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-last-patient-first-visit-in-canyon-1-study-of-crb-913-for-crbp-20260414monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-broad-alignment-with-fda-on-registration-path-for-crb-701-crbp-20260407monthly0.5https://www.biopharmawatch.com/news/CRBP/this-presentation-contains-certain-forward-looking-statements-within-the-meaning-of-sectio-crbp-20260225monthly0.5https://www.biopharmawatch.com/news/CRBP/this-presentation-contains-certain-forward-looking-statements-within-the-meaning-of-sectio-crbp-20260112monthly0.5https://www.biopharmawatch.com/news/CRBP/future-events-or-our-financial-performance-and-involve-known-and-unknown-risks-uncertainti-crbp-20250916monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides-a-corpor-crbp-20250805monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-first-quarter-2025-financial-results-and-provides-a-corpora-crbp-20250506monthly0.5https://www.biopharmawatch.com/news/CRBP/appendix-99-1-corbus-pharmaceuticals-reports-q4-and-2024-financial-results-and-provides-a--crbp-20250311monthly0.5https://www.biopharmawatch.com/news/CRBP/crb-701-sys6002-a-next-generation-nectin-4-targeting-adc-demonstrates-encouraging-safety-a-crbp-20250214monthly0.5https://www.biopharmawatch.com/news/CRBP/fda-grants-fast-track-designation-to-crb-701-for-the-treatment-of-relapsed-or-refractory-m-crbp-20241203monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-3-rd-quarter-2024-financial-results-and-provides-a-corporat-crbp-20241107monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-presents-new-crb-913-pre-clinical-data-at-obesity-week-2024-x2022-c-crbp-20241104monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-strengthens-board-of-directors-with-appointment-of-winston-kung-nor-crbp-20240820monthly0.5https://www.biopharmawatch.com/news/CRBP/this-presentation-contains-certain-forward-looking-statements-within-the-meaning-of-sectio-crbp-20240806monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-second-quarter-2024-financial-results-and-provides-a-corpor-crbp-20240806monthly0.5https://www.biopharmawatch.com/news/CRBP/sys6002-crb-701-a-next-generation-nectin-4-targeting-antibody-drug-conjugate-continues-to--crbp-20240601monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-first-quarter-2024-financial-results-and-provides-corporate-crbp-20240507monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-fourth-quarter-and-year-end-2023-financial-results-and-prov-crbp-20240312monthly0.5https://www.biopharmawatch.com/news/CRBP/forward-looking-statements-this-presentation-contains-certain-forward-looking-statements-w-crbp-20240205monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-proposed-public-offering-norwood-ma-crbp-20240130monthly0.5https://www.biopharmawatch.com/news/CRBP/crb-701-sys6002-a-next-generation-nectin-4-targeting-antibody-drug-conjugate-demonstrates--crbp-20240126monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-fda-clearance-of-ind-application-for-its-anti-x3b1-v-x3b2-crbp-20240109monthly0.5https://www.biopharmawatch.com/news/CRBP/forward-looking-statements-this-presentation-contains-certain-forward-looking-statements-w-crbp-20231114monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-third-quarter-2023-financial-results-and-provides-corporate-crbp-20231107monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-second-quarter-2023-financial-results-and-provides-corporat-crbp-20230808monthly0.5https://www.biopharmawatch.com/news/CRBP/forward-looking-statements-this-presentation-contains-certain-forward-looking-statements-w-crbp-20230803monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-first-quarter-2023-financial-results-and-provides-corporate-crbp-20230509monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-fourth-quarter-2022-and-year-end-financial-results-and-prov-crbp-20230307monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-expands-board-of-directors-with-appointment-of-yong-ben-m-d-mba-nor-crbp-20230306monthly0.5https://www.biopharmawatch.com/news/CRBP/forward-looking-statements-this-press-release-contains-certain-forward-looking-statements--crbp-20230213monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-third-quarter-2022-financial-results-and-provides-corporate-crbp-20221221monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-appoints-anne-altmeyer-phd-to-board-of-directors-norwood-ma-crbp-20220926monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-second-quarter-2022-financial-results-and-provides-corporat-crbp-20220809monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-first-quarter-2022-financial-results-and-provides-corporate-crbp-20220510monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-presents-first-preclinical-data-for-crb-601-at-the-american-association-for-cancer--crbp-20220408monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-fourth-quarter-and-year-end-2021-financial-results-and-prov-crbp-20220308monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-third-quarter-2021-financial-results-and-provides-corporate-crbp-20211112monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-second-quarter-2021-financial-results-and-provides-corporat-crbp-20210812monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-topline-results-from-d-eter-m-ine-phase-3-study-of-lenaba-crbp-20210624monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-licenses-two-integrin-targeting-mabs-further-expanding-pipeline-int-crbp-20210601monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-first-quarter-2021-financial-results-and-provides-corporate-crbp-20210513monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-fourth-quarter-and-year-end-2020-financial-results-phase-3--crbp-20210315monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-third-quarter-financial-results-and-provides-corporate-upda-crbp-20201110monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-corporate-restructuring-and-pipeline-portfolio-updates-co-crbp-20201008monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-phase-2b-study-of-lenabasum-for-treatment-of-cystic-fibro-crbp-20201006monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-topline-results-from-resolve-1-phase-3-study-of-lenabasum-crbp-20200908monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-second-quarter-financial-results-and-corporate-updates-reso-crbp-20200806monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-strengthens-balance-sheet-with-up-to-121-million-in-new-capital-agg-crbp-20200729monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-appoints-george-golumbeski-ph-d-to-board-of-directors-dr-golumbeski-crbp-20200708monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-first-quarter-financial-results-and-corporate-updates-topli-crbp-20200511monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-fourth-quarter-and-year-end-2019-financial-results-topline--crbp-20200312monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-changes-to-its-board-and-appointment-of-pete-salzmann-m-d-crbp-20200310monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-proposed-public-offering-of-common-stock-norwood-ma-crbp-20200206monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-2019-third-quarter-financial-results-and-provides-clinical--crbp-20191107monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-2019-second-quarter-financial-results-and-provides-clinical-crbp-20190808monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-2019-first-quarter-financial-results-and-provides-clinical--crbp-20190509monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-appoints-rachelle-jacques-to-board-of-directors-appointment-brings--crbp-20190408monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-fourth-quarter-and-full-year-2018-financial-results-and-pro-crbp-20190312monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-proposed-public-offering-of-common-stock-norwood-ma-crbp-20190124monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-strategic-collaboration-with-kaken-pharmaceutical-co-ltd--crbp-20190103monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-third-quarter-2018-financial-results-and-provides-business--crbp-20181108monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-2018-second-quarter-financial-results-and-provides-business-crbp-20180808monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-presents-1-year-systemic-sclerosis-and-6-month-dermatomyositis-data-crbp-20180613monthly0.5https://www.biopharmawatch.com/news/CRBP/confidential-draft-not-for-immediate-release-corbus-pharmaceuticals-appoints-former-direct-crbp-20180606monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-2018-first-quarter-financial-results-and-provides-business--crbp-20180510monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-2017-financial-results-and-provides-clinical-update-advanci-crbp-20180312monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-holdings-inc-announces-exercise-of-option-to-purchase-additional-sh-crbp-20171127monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-2017-third-quarter-financial-results-and-highlights-recent--crbp-20171108monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-holdings-inc-announces-proposed-public-offering-of-common-stock-nor-crbp-20171023monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-positive-topline-results-from-phase-2-study-in-rare-autoimm-crbp-20171019monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-appoints-paris-panayiotopoulos-to-its-board-of-directors-norwood-ma-crbp-20171017monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-2017-second-quarter-financial-results-and-provides-business-crbp-20170809monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-2017-first-quarter-financial-results-and-provides-business--crbp-20170509monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-positive-topline-data-demonstrating-anabasum-reduces-acute--crbp-20170330monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-2016-financial-results-and-provides-2017-business-update-q4-crbp-20170309monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-27-2-million-registered-direct-offering-norwood-ma-crbp-20170228monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-positive-topline-results-showing-clear-signal-of-clinical-b-crbp-20161114monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-2016-third-quarter-financial-results-and-provides-business--crbp-20161110monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-2016-second-quarter-financial-results-and-provides-business-crbp-20160815monthly0.5https://www.biopharmawatch.com/news/CRBP/this-presentation-contains-certain-forward-looking-statements-including-those-relating-to--crbp-20160616monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-15-million-registered-direct-offering-norwood-ma-crbp-20160610monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-2016-first-quarter-financial-results-and-provides-business--crbp-20160516monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-2015-financial-results-and-provides-2016-business-update-20-crbp-20160329monthly0.5https://www.biopharmawatch.com/news/CRBP/this-presentation-contains-certain-forward-looking-statements-including-those-relating-to--crbp-20160107monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-2015-third-quarter-financial-results-company-launched-three-crbp-20151111monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-successfully-completes-warrant-call-raises-11-3-mm-in-total-from-10-crbp-20150827monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-2015-second-quarter-financial-results-and-provides-business-crbp-20150813monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-call-notice-for-exercise-of-warrants-use-of-proceeds-to-a-crbp-20150727monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-2015-first-quarter-financial-results-and-provides-business--crbp-20150513monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-receives-5-million-development-award-from-cystic-fibrosis-foundatio-crbp-20150422monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-2014-financial-results-and-provides-2015-business-update-no-crbp-20150210monthly0.5https://www.biopharmawatch.com/news/CRBP/forward-looking-statements-this-presentation-contains-certain-forward-looking-statements-i-crbp-20150209monthly0.5https://www.biopharmawatch.com/news/CRBP/forward-looking-statements-this-presentation-contains-certain-forward-looking-statements-i-crbp-20141125monthly0.5https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-reports-2014-third-quarter-results-and-business-update-norwood-ma-crbp-20141113monthly0.5https://www.biopharmawatch.com/news/CRBP/forward-looking-statement-2-this-presentation-contains-certain-forward-looking-statements--crbp-20141110monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-reports-financial-performance-for-first-quarter-2026-contact-bri-utmd-20260423monthly0.5https://www.biopharmawatch.com/news/UTMD/utmd-reports-year-2025-and-fourth-quarter-financial-performance-contact-brian-koopman-801--utmd-20260129monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-appoints-director-and-increases-quarterly-dividend-contact-brian-utmd-20251104monthly0.5https://www.biopharmawatch.com/news/UTMD/utmd-reports-financial-performance-for-third-calendar-quarter-and-nine-months-2025-contact-utmd-20251023monthly0.5https://www.biopharmawatch.com/news/UTMD/utmd-reports-financial-performance-for-second-calendar-quarter-and-first-half-2025-contact-utmd-20250724monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-reports-financial-performance-for-first-quarter-2025-contact-bri-utmd-20250429monthly0.5https://www.biopharmawatch.com/news/UTMD/utmd-reports-year-2024-and-fourth-quarter-financial-performance-contact-brian-koopman-801--utmd-20250128monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-appoints-director-and-increases-quarterly-dividend-contact-brian-utmd-20241105monthly0.5https://www.biopharmawatch.com/news/UTMD/utmd-reports-financial-performance-for-third-calendar-quarter-and-nine-months-2024-contact-utmd-20241029monthly0.5https://www.biopharmawatch.com/news/UTMD/utmd-reports-audited-year-2023-and-fourth-quarter-financial-performance-contact-brian-koop-utmd-20240130monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-increases-regular-quarterly-dividend-contact-brian-koopman-utmd-20231031monthly0.5https://www.biopharmawatch.com/news/UTMD/utmd-reports-financial-performance-for-third-calendar-quarter-and-nine-months-2023-contact-utmd-20231026monthly0.5https://www.biopharmawatch.com/news/UTMD/utmd-reports-financial-performance-for-second-calendar-quarter-and-first-half-2023-contact-utmd-20230725monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-reports-financial-performance-for-first-quarter-2023-contact-bri-utmd-20230425monthly0.5https://www.biopharmawatch.com/news/UTMD/utmd-reports-audited-year-2022-and-fourth-quarter-financial-performance-contact-brian-koop-utmd-20230131monthly0.5https://www.biopharmawatch.com/news/UTMD/utmd-reports-financial-performance-for-third-calendar-quarter-and-nine-months-2022-contact-utmd-20221025monthly0.5https://www.biopharmawatch.com/news/UTMD/utmd-reports-financial-performance-for-second-calendar-quarter-and-first-half-2022-contact-utmd-20220726monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-reports-financial-performance-for-first-quarter-2022-contact-cry-utmd-20220426monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-announces-quarterly-dividend-contact-crystal-rios-utmd-20220208monthly0.5https://www.biopharmawatch.com/news/UTMD/utmd-reports-audited-year-2021-and-fourth-quarter-financial-performance-contact-crystal-ri-utmd-20220201monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-announces-special-dividend-contact-crystal-rios-utmd-20211102monthly0.5https://www.biopharmawatch.com/news/UTMD/utmd-reports-financial-performance-for-third-calendar-quarter-and-nine-months-2021-contact-utmd-20211026monthly0.5https://www.biopharmawatch.com/news/UTMD/utmd-reports-financial-performance-for-second-calendar-quarter-and-first-half-2021-contact-utmd-20210722monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-reports-financial-performance-for-first-quarter-2021-contact-cry-utmd-20210422monthly0.5https://www.biopharmawatch.com/news/UTMD/utmd-reports-audited-year-2020-and-fourth-quarter-financial-performance-contact-crystal-ri-utmd-20210128monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-increases-quarterly-dividend-contact-crystal-rios-utmd-20201103monthly0.5https://www.biopharmawatch.com/news/UTMD/utmd-reports-financial-performance-for-third-quarter-and-nine-months-of-year-2020-contact--utmd-20201027monthly0.5https://www.biopharmawatch.com/news/UTMD/utmd-reports-financial-performance-for-second-calendar-quarter-and-first-half-2020-contact-utmd-20200728monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-reports-financial-performance-for-first-quarter-2020-contact-cry-utmd-20200423monthly0.5https://www.biopharmawatch.com/news/UTMD/utmd-postpones-its-2020-annual-stockholders-meeting-for-three-months-contact-crystal-rios-utmd-20200323monthly0.5https://www.biopharmawatch.com/news/UTMD/utmd-reports-audited-year-2019-and-fourth-quarter-financial-performance-contact-crystal-ri-utmd-20200130monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-announces-that-its-board-of-dire-utmd-20191105monthly0.5https://www.biopharmawatch.com/news/UTMD/utmd-reports-financial-performance-for-third-quarter-and-nine-months-of-year-2019-contact--utmd-20191024monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-reports-financial-performance-for-second-quarter-2019-contact-cr-utmd-20190730monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-reports-financial-performance-for-first-quarter-2019-contact-cry-utmd-20190425monthly0.5https://www.biopharmawatch.com/news/UTMD/utmd-reports-audited-year-2018-and-fourth-quarter-financial-performance-contact-crystal-ri-utmd-20190131monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-announces-that-its-board-of-dire-utmd-20181030monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-7043-south-300-west-midvale-utah-84047-telephone-801-566-1200-fa-utmd-20180426monthly0.5https://www.biopharmawatch.com/news/UTMD/utmd-reports-audited-financial-performance-for-fourth-quarter-and-year-2017-contact-paul-r-utmd-20180130monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-announces-that-its-board-of-dire-utmd-20171031monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-reports-financial-performance-for-third-quarter-2017-contact-pau-utmd-20171024monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-reports-financial-performance-for-second-quarter-2017-contact-pa-utmd-20170725monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-reports-financial-performance-for-first-quarter-2017-contact-pau-utmd-20170425monthly0.5https://www.biopharmawatch.com/news/UTMD/utmd-reports-audited-financial-performance-for-fourth-quarter-and-year-2016-contact-paul-r-utmd-20170131monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-reports-financial-performance-for-third-quarter-2016-contact-pau-utmd-20161025monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-reports-financial-performance-for-second-quarter-2016-contact-pa-utmd-20160726monthly0.5https://www.biopharmawatch.com/news/UTMD/utmd-reports-audited-financial-performance-for-fourth-quarter-and-year-2015-contact-paul-r-utmd-20160202monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-announces-that-its-board-of-dire-utmd-20151103monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-reports-financial-performance-for-second-quarter-2015-contact-pa-utmd-20150723monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-reports-financial-performance-for-first-quarter-2015-contact-pau-utmd-20150423monthly0.5https://www.biopharmawatch.com/news/UTMD/utmd-reports-financial-performance-for-fourth-quarter-and-year-2014-contact-paul-richins-utmd-20150129monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-announces-that-its-board-of-dire-utmd-20141104monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-reports-financial-performance-for-third-quarter-2014-contact-pau-utmd-20141023monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-reports-financial-performance-for-second-quarter-2014-contact-pa-utmd-20140724monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-reports-financial-performance-for-first-quarter-2014-contact-pau-utmd-20140424monthly0.5https://www.biopharmawatch.com/news/UTMD/utmd-reports-financial-performance-for-fourth-quarter-and-year-2013-contact-paul-richins-utmd-20140130monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-announces-that-its-board-of-dire-utmd-20131029monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-reports-financial-performance-for-third-quarter-2013-contact-pau-utmd-20131024monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-reports-financial-performance-for-second-quarter-2013-contact-pa-utmd-20130725monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-reports-financial-performance-for-first-quarter-2013-contact-pau-utmd-20130425monthly0.5https://www.biopharmawatch.com/news/UTMD/utmd-reports-financial-performance-for-fourth-quarter-and-year-2012-contact-paul-richins-utmd-20130131monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-announces-that-its-board-of-dire-utmd-20121108monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-reports-financial-performance-for-third-quarter-2012-contact-pau-utmd-20121025monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-reports-financial-performance-for-second-quarter-2012-contact-pa-utmd-20120726monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-reports-financial-performance-for-first-quarter-2012-contact-pau-utmd-20120425monthly0.5https://www.biopharmawatch.com/news/UTMD/utmd-reports-financial-performance-for-fourth-quarter-and-year-2011-contact-paul-richins-utmd-20120131monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-announces-that-its-board-of-dire-utmd-20111101monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-reports-financial-performance-for-third-quarter-2011-contact-pau-utmd-20111020monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-reports-financial-performance-for-second-quarter-2011-salt-lake--utmd-20110726monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-reports-financial-performance-for-first-quarter-2011-contact-pau-utmd-20110428monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-acquires-femcare-group-limited-contact-paul-richins-utmd-20110318monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-reports-financial-performance-for-fourth-quarter-and-year-2010-s-utmd-20110127monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-announces-that-its-board-of-dire-utmd-20101102monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-reports-financial-performance-for-third-quarter-2010-salt-lake-c-utmd-20100930monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-reports-financial-performance-for-second-quarter-2010-salt-lake--utmd-20100722monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-reports-financial-performance-for-first-quarter-2010-salt-lake-c-utmd-20100422monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-announces-that-two-fda-investiga-utmd-20100322monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-reports-financial-performance-for-fourth-quarter-and-year-2009-s-utmd-20100128monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-announces-that-its-board-of-dire-utmd-20091103monthly0.5https://www.biopharmawatch.com/news/UTMD/utah-medical-products-inc-reports-financial-performance-for-third-quarter-2009-salt-lake-c-utmd-20091022monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-in-the-second-calendar-quarter-2q-and-first-half-1h-of-2009-utah-medic-utmd-20090723monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-achieved-its-targeted-profit-mar-utmd-20090428monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-s-nasdaq-utmd-financial-results-for-fourth-q-utmd-20090127monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-announces-that-its-board-of-dire-utmd-20081030monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-in-the-third-calendar-quarter-3q-and-three-quarters-year-to-date-or-ni-utmd-20081023monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-in-the-second-calendar-quarter-2q-and-first-half-1h-of-2008-utah-medic-utmd-20080724monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-reports-that-it-achieved-the-fol-utmd-20080430monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-s-nasdaq-utmd-financial-results-for-2007-wer-utmd-20080129monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-announces-that-its-board-of-dire-utmd-20071030monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-reports-that-for-the-third-calen-utmd-20071023monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-in-the-second-calendar-quarter-2q-of-2007-utah-medical-products-inc-s--utmd-20070724monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-reports-changes-in-measures-of-f-utmd-20070424monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-announces-that-its-board-of-dire-utmd-20070130monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-in-the-fourth-quarter-4q-of-2006-utah-medical-products-inc-s-nasdaq-ut-utmd-20070123monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-announces-that-its-board-of-dire-utmd-20061031monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-reports-that-for-the-third-calen-utmd-20060930monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-on-utmd-20060807monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-announces-that-its-board-of-dire-utmd-20060802monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-on-utmd-20060725monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-in-the-second-calendar-quarter-2q-of-2006-utah-medical-products-inc-s--utmd-20060630monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-announces-that-its-board-of-dire-utmd-20060502monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-reports-that-all-primary-income--utmd-20060419monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-on-utmd-20060215monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-announces-that-its-board-of-dire-utmd-20060131monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-in-the-fourth-quarter-4q-of-2005-utah-medical-products-inc-s-nasdaq-ut-utmd-20060124monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-announces-that-its-legal-counsel-utmd-20051215monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-on-utmd-20051116monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-announces-that-on-utmd-20051103monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-announces-that-its-board-of-dire-utmd-20051101monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-the-outcome-of-the-u-s-food-drug-administration-s-fda-or-agency-lawsui-utmd-20051025monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-utmd-announces-that-the-u-s-federal-district-utmd-20051021monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-in-the-third-quarter-3q-of-2005-utah-medical-products-inc-s-nasdaq-utm-utmd-20050930monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-announces-that-the-trial-for-the-utmd-20051005monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-the-trial-of-the-lawsuit-filed-in-august-2004-on-behalf-of-the-u-s-foo-utmd-20050913monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-on-utmd-20050831monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-on-utmd-20050819monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-in-the-second-calendar-quarter-2q-of-2005-utah-medical-products-inc-s--utmd-20050630monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-on-utmd-20050630monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-announces-that-since-the-drop-in-utmd-20050519monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-announces-that-its-board-of-dire-utmd-20050511monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-in-the-first-calendar-quarter-of-2005-1q-2005-utah-medical-products-in-utmd-20050421monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-will-release-its-financial-resul-utmd-20050331monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-is-a-defendant-in-a-lawsuit-file-utmd-20050126monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-is-a-defendant-in-a-lawsuit-file-utmd-20041215monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-utah-medical-products-inc-nasdaq-utmd-is-a-defendant-in-a-complaint-fi-utmd-20041116monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-since-august-20-utah-medical-products-inc-nasdaq-utmd-has-recognized-i-utmd-20041021monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-in-the-third-calendar-quarter-of-2004-3q-2004-utah-medical-products-in-utmd-20040930monthly0.5https://www.biopharmawatch.com/news/UTMD/the-reports-of-my-death-are-greatly-exaggerated-mark-twain-salt-lake-city-utah-in-august-u-utmd-20041012monthly0.5https://www.biopharmawatch.com/news/UTMD/salt-lake-city-utah-on-utmd-20040810monthly0.5https://www.biopharmawatch.com/news/NBP/novabridge-announces-productive-fda-type-b-meeting-on-potential-accelerated-approval-pathw-nbp-20260316monthly0.5https://www.biopharmawatch.com/news/NBP/company-presentation-february-2026-disclaimer-this-presentation-has-been-prepared-by-novab-nbp-20260225monthly0.5https://www.biopharmawatch.com/news/NBP/novabridge-appoints-biotech-leader-emmett-t-cunningham-jr-md-phd-mph-as-vice-chairman-of-t-nbp-20260219monthly0.5https://www.biopharmawatch.com/news/NBP/company-presentation-february-2026-disclaimer-this-presentation-has-been-prepared-by-novab-nbp-20260206monthly0.5https://www.biopharmawatch.com/news/NBP/novabridge-presents-positive-givastomig-dose-expansion-data-from-the-phase-1b-combination--nbp-20260106monthly0.5https://www.biopharmawatch.com/news/NBP/novabridge-announces-presentation-of-ragistomig-expanded-phase-1-data-at-esmo-io-x2022-rag-nbp-20251204monthly0.5https://www.biopharmawatch.com/news/NBP/novabridge-biosciences-supplemental-and-updated-disclosures-novabridge-biosciences-the-com-nbp-20251031monthly0.5https://www.biopharmawatch.com/news/NBP/novabridge-subsidiary-visara-assigns-its-exclusive-license-to-everest-medicines-for-vis-10-nbp-20251029monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-nasdaq-imab-transitions-to-novabridge-biosciences-nasdaq-nbp-with-trading-effective-nbp-20251030monthly0.5https://www.biopharmawatch.com/news/NBP/updated-safety-efficacy-and-biomarker-analysis-from-the-phase-i-monotherapy-study-of-givas-nbp-20251024monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-to-present-positive-updated-givastomig-monotherapy-data-at-2025-aacr-nci-eortc-molec-nbp-20251023monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-intention-to-undertake-strategic-transformation-to-global-biotech-platform-nbp-20251016monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-x5929-x5883-x751f-x7269-2440-research-boulevard-suite-400-rockville-md-20850-proxy-s-nbp-20250924monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-acceleration-of-givastomig-investment-and-leadership-appointments-x2022-ex-nbp-20250908monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-the-appointment-of-seasoned-biotech-executives-to-the-board-of-directors-a-nbp-20250825monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-reports-second-quarter-2025-financial-results-and-provides-business-update-x2022-pos-nbp-20250820monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-completes-enrollment-in-planned-phase-1b-dose-expansion-study-for-givastomig-in-comb-nbp-20250811monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-pricing-of-65-million-underwritten-offering-of-american-depositary-shares--nbp-20250801monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-strengthens-givastomig-intellectual-property-portfolio-through-acquisition-of-bridge-nbp-20250717monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-presents-positive-givastomig-phase-1b-dose-escalation-data-in-combination-with-immun-nbp-20250702monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-highlights-positive-givastomig-phase-1b-dose-escalation-data-in-combination-with-imm-nbp-20250626monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-regains-compliance-with-nasdaq-minimum-bid-price-requirement-rockville-md-nbp-20250612monthly0.5https://www.biopharmawatch.com/news/NBP/transforming-potential-into-reality-i-mab-biopharma-june-2025-legal-disclaimer-this-presen-nbp-20250602monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-reports-first-quarter-2025-financial-results-and-provides-business-update-x2022-prio-nbp-20250515monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-givastomig-abstract-accepted-for-oral-presentation-at-esmo-gi-2025-the-esm-nbp-20250430monthly0.5https://www.biopharmawatch.com/news/NBP/transforming-potential-into-reality-i-mab-biopharma-april-2025-legal-disclaimer-this-prese-nbp-20250404monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-reports-full-year-2024-financial-results-and-provides-business-update-x2022-continue-nbp-20250403monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requiremen-nbp-20250321monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-accelerated-givastomig-phase-1b-study-progress-x2022-enrollment-completed--nbp-20250307monthly0.5https://www.biopharmawatch.com/news/NBP/transforming-potential-into-reality-i-mab-biopharma-february-2025-legal-disclaimer-this-pr-nbp-20250227monthly0.5https://www.biopharmawatch.com/news/NBP/transforming-potential-into-reality-i-mab-biopharma-january-2025-legal-disclaimer-this-pre-nbp-20250113monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-open-market-purchases-of-company-american-depositary-shares-by-board-membe-nbp-20250108monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-portfolio-prioritization-of-givastomig-cldn18-2-x-4-1bb-bispecific-antibod-nbp-20250106monthly0.5https://www.biopharmawatch.com/news/NBP/transforming-potential-into-reality-i-mab-biopharma-nbp-20241203monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-reports-third-quarter-2024-results-x2022-givastomig-data-presented-at-esmo-2024-and--nbp-20241101monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-appoints-sean-fu-phd-mba-as-chief-executive-officer-rockville-md-nbp-20241106monthly0.5https://www.biopharmawatch.com/news/NBP/transforming-potential-into-reality-i-mab-biopharma-nbp-20241024monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-presents-updated-phase-1-givastomig-data-at-esmo-2024-expanded-phase-1-monotherapy-s-nbp-20240916monthly0.5https://www.biopharmawatch.com/news/NBP/secondment-agreement-this-secondment-agreement-the-x201c-agreement-x201d-is-made-effective-nbp-20240828monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-reports-1h-2024-financial-results-pipeline-progress-and-business-updates-x2022-compl-nbp-20240828monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-appoints-u-s-auditor-pricewaterhousecoopers-llp-pwc-engagement-is-part-of-i-mab-s-co-nbp-20240807monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-leadership-transitions-rockville-md-nbp-20240715monthly0.5https://www.biopharmawatch.com/news/NBP/transforming-potential-into-reality-i-mab-biopharma-nbp-20240605monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-collaboration-with-bristol-myers-squibb-to-evaluate-givastomig-in-a-combin-nbp-20240605monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-encouraging-phase-1-clinical-data-of-pd-l1x4-1bb-bispecific-antibody-ragis-nbp-20240523monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-closing-of-the-divestiture-of-business-operations-in-china-rockville-md-nbp-20240402monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-reports-full-year-2023-financial-results-and-business-update-recently-announced-agre-nbp-20240315monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-signs-agreement-to-divest-its-assets-and-business-operations-in-china-agreement-mark-nbp-20240207monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-and-abl-bio-announce-latest-updates-of-pd-l1-and-4-1bb-bispecific-antibody-tj-l14b-a-nbp-20231010monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-provides-mid-year-2023-financial-results-business-and-corporate-updates-significant--nbp-20230817monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-the-appointment-of-raj-kannan-as-ceo-gaithersburg-md-and-shanghai-china-nbp-20230622monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-encouraging-phase-1b-2-study-results-of-patients-with-advanced-nsclc-recei-nbp-20230525monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-provides-business-and-corporate-updates-and-reports-financial-results-for-the-year-e-nbp-20230501monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-first-patient-dosed-in-phase-3-registrational-study-of-cd47-antibody-lemzo-nbp-20230424monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-positive-outcome-in-arbitration-relating-to-agreements-with-tracon-award-i-nbp-20230425monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-provides-business-and-corporate-updates-and-reports-financial-results-for-the-year-e-nbp-20230331monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-index-to-consolidated-financial-statements-unaudited-interim-condensed-consolidated--nbp-20221110monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-positive-phase-2-data-of-lemzoparlimab-in-combination-with-azacitidine-aza-nbp-20220910monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-provides-business-and-corporate-updates-and-reports-financial-results-for-the-six-mo-nbp-20220830monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-reports-latest-phase-2-clinical-data-of-its-differentiated-cd73-antibody-uliledlimab-nbp-20220526monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-provides-updates-on-status-under-holding-foreign-companies-accountable-act-shanghai--nbp-20220505monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-provides-business-and-corporate-updates-and-reports-financial-results-for-the-year-e-nbp-20220428monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-appointments-of-richard-yeh-as-chief-operating-officer-and-john-hayslip-as-nbp-20220428monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-voluntary-lock-ups-by-key-shareholders-and-senior-management-for-long-term-nbp-20220331monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-provides-business-and-corporate-updates-and-reports-financial-results-for-the-year-e-nbp-20220331monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-provides-business-and-corporate-updates-and-reports-financial-results-for-the-year-e-nbp-20220329monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-receives-fda-orphan-drug-designation-for-its-novel-claudin-18-2-x-4-1bb-bispecific-a-nbp-20220303monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-s-announcement-on-unusual-price-movement-shanghai-china-and-gaithersburg-md-i-mab-th-nbp-20220128monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-strengthens-management-team-designed-to-accelerate-global-pipeline-development-and-t-nbp-20211221monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-presents-interim-clinical-data-of-lemzoparlimab-in-combination-with-rituximab-in-rel-nbp-20211214monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-to-pursue-dual-listing-plan-on-the-main-board-of-the-stock-exchange-of-hong-kong-lim-nbp-20211207monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-first-two-patients-dosed-in-u-s-phase-2-combination-trial-of-uliledlimab-w-nbp-20211203monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-index-to-consolidated-financial-statements-unaudited-interim-condensed-consolidated--nbp-20211112monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-and-abl-bio-report-preclinical-data-of-4-1bb-targeting-bispecific-antibodies-at-2021-nbp-20211109monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-to-present-clinical-data-of-lemzoparlimab-in-combination-with-rituximab-in-non-hodgk-nbp-20211105monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-strengthens-senior-executive-team-with-new-chief-financial-officer-and-chief-strateg-nbp-20211101monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-ind-approval-for-phase-2-clinical-trial-of-efineptakin-alfa-in-combination-nbp-20211018monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-advances-late-stage-development-of-its-differentiated-cd38-antibody-felzartamab-tj20-nbp-20211013monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-reports-multiple-positive-clinical-updates-of-differentiated-cd47-antibody-lemzoparl-nbp-20210930monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-provides-business-and-corporate-updates-and-reports-financial-results-for-the-six-mo-nbp-20210831monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-establishment-of-environmental-social-and-governance-committee-i-mab-recei-nbp-20210819monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-reports-positive-interim-analysis-from-phase-2-3-study-of-its-gm-csf-antibody-plonma-nbp-20210811monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-ind-acceptance-for-phase-2-clinical-trial-of-efineptakin-alfa-in-combinati-nbp-20210722monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-authorization-of-a-renewed-stock-repurchase-program-by-the-company-up-to-u-nbp-20210729monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-preliminary-proposal-for-potential-dual-listing-on-the-star-market-of-the--nbp-20210727monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-china-nmpa-approval-for-phase-1b-trial-of-felzartamab-in-systemic-lupus-er-nbp-20210625monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-first-patient-dosed-in-china-phase-2-combination-trial-of-lemzoparlimab-wi-nbp-20210518monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-positive-topline-phase-2-results-for-olamkicept-in-ulcerative-colitis-shan-nbp-20210426monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-and-abl-bio-announce-first-patient-dosed-in-phase-1-trial-of-bispecific-antibody-tj--nbp-20210406monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-reports-financial-results-for-full-year-of-2020-and-provides-business-updates-18-sig-nbp-20210329monthly0.5https://www.biopharmawatch.com/news/NBP/registered-secondary-public-offering-of-american-depositary-shares-by-certain-pre-ipo-shar-nbp-20210209monthly0.5https://www.biopharmawatch.com/news/NBP/proposed-registered-secondary-public-offering-of-american-depositary-shares-by-certain-pre-nbp-20210205monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-index-to-consolidated-financial-statements-unaudited-interim-condensed-consolidated--nbp-20210205monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-multiple-clinical-advancements-of-its-differentiated-cd73-antibody-uliledl-nbp-20210205monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-to-hold-investor-call-and-expand-clinical-data-analysis-on-efficacy-signal-of-lemzop-nbp-20201112monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-preclinical-data-on-differentiated-anti-c5ar-antibody-tj210-mor210-at-sitc-nbp-20201111monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-reports-phase-1-clinical-trial-data-of-highly-differentiated-anti-cd47-monoclonal-an-nbp-20201109monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-receives-china-cde-approval-to-initiate-phase-3-clinical-trial-of-eftansomatropin-in-nbp-20201005monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-china-nmpa-clearance-for-phase-1-clinical-trial-of-lemzoparlimab-in-relaps-nbp-20200921monthly0.5https://www.biopharmawatch.com/news/NBP/morphosys-and-i-mab-announce-fda-clearance-of-ind-application-for-mor210-tj210-in-patients-nbp-20200917monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-418-million-private-placement-with-hillhouse-capital-led-consortium-ordina-nbp-20200904monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-reports-financial-results-for-the-six-months-ended-june-30-and-provides-corporate-up-nbp-20200831monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-first-patient-dosed-in-phase-1b-study-of-plonmarlimab-in-rheumatoid-arthri-nbp-20200817monthly0.5https://www.biopharmawatch.com/news/NBP/china-nmpa-accepts-ind-application-for-eftansomatropin-pivotal-trial-in-pediatric-patients-nbp-20200804monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-drives-commercialization-strategy-with-appointment-of-ivan-yifei-zhu-as-chief-commer-nbp-20200728monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-authorization-of-stock-repurchase-program-up-to-20-million-shanghai-china--nbp-20200715monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-and-abl-bio-to-present-preclinical-data-for-joint-bispecific-antibody-program-at-the-nbp-20200612monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-reports-interim-results-from-part-1-study-for-anti-gm-csf-antibody-tjm2-to-treat-cov-nbp-20200528monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-and-genexine-announce-china-nmpa-clearance-for-phase-2-clinical-trial-of-tj107-hyleu-nbp-20200521monthly0.5https://www.biopharmawatch.com/news/NBP/first-patient-dosed-with-i-mab-s-cd73-antibody-tjd5-in-phase-1-2-clinical-trial-in-china-f-nbp-20200513monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-and-morphosys-announce-first-patient-dosed-in-phase-3-clinical-trial-of-tj202-mor202-nbp-20200427monthly0.5https://www.biopharmawatch.com/news/NBP/april-2020-i-mab-presentation-disclaimer-this-presentation-has-been-prepared-by-i-mab-the--nbp-20200408monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-ind-clearance-from-fda-for-tjm2-to-treat-cytokine-release-syndrome-crs-ass-nbp-20200403monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-first-patient-dosed-in-phase-1-2a-clinical-trial-of-anti-cd47-antibody-tjc-nbp-20200402monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-financial-results-for-the-full-year-ended-nbp-20200331monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-enters-into-strategic-regional-partnership-with-kalbe-genexine-biologics-for-commerc-nbp-20200330monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-expands-global-out-licensing-and-business-development-efforts-fernando-j-sall-s-ph-d-nbp-20200327monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-appoints-gigi-feng-as-vice-president-and-global-head-of-corporate-communications-sha-nbp-20200323monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-biopharma-announces-development-of-tjm2-to-treat-cytokine-release-syndrome-associate-nbp-20200313monthly0.5https://www.biopharmawatch.com/news/NBP/i-mab-announces-partial-exercise-of-over-allotment-option-in-initial-public-offering-shang-nbp-20200210monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-reports-second-quarter-2025-financial-results-and-provides-business-rnac-20250807monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-reports-first-quarter-2025-financial-results-and-provides-business--rnac-20250508monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-descartes-08-observed-to-provide-deep-and-sustained-benefits-throug-rnac-20250408monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-reports-full-year-2024-financial-results-and-provides-business-upda-rnac-20250313monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business--rnac-20241107monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-reports-second-quarter-2024-financial-results-and-provides-business-rnac-20240808monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-announces-130-million-private-placement-equity-financing-gaithersbu-rnac-20240702monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-reports-first-quarter-2024-financial-results-and-provides-business--rnac-20240508monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-announces-approval-of-conversion-of-series-a-convertible-preferred--rnac-20240327monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-reports-full-year-2023-financial-results-and-provides-business-upda-rnac-20240307monthly0.5https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-establishes-new-corporate-headquarters-and-state-of-the-art-mrna-ce-rnac-20240305monthly0.5https://www.biopharmawatch.com/news/RNAC/therapeutics-pioneering-mrna-cell-therapy-for-autoimmunity-january-2024-c-a-r-t-es-i-an-t--rnac-20240108monthly0.5https://www.biopharmawatch.com/news/RNAC/disclosures-for-the-purposes-of-this-notice-the-presentation-that-follows-shall-mean-and-i-rnac-20231113monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-reports-second-quarter-2023-financial-results-and-updates-on-strategic-rnac-20230817monthly0.5https://www.biopharmawatch.com/news/RNAC/phase-3-dissolve-program-of-sel-212-in-chronic-refractory-gout-meets-primary-endpoint-resp-rnac-20230321monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-and-astellas-announce-exclusive-licensing-and-development-agreement-fo-rnac-20230109monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-announces-next-generation-iga-protease-clinical-candidate-selection-fo-rnac-20221214monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-announces-appointment-of-blaine-davis-as-chief-financial-officer-rnac-20221128monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-reports-third-quarter-2022-financial-results-and-provides-business-upd-rnac-20221103monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-reports-second-quarter-2022-financial-results-and-provides-business-up-rnac-20220804monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-announces-partnership-advancements-and-clinical-trial-updates-sarepta--rnac-20220613monthly0.5https://www.biopharmawatch.com/news/RNAC/in-the-court-of-chancery-of-the-state-of-delaware-anthony-franchi-derivatively-on-behalf-o-rnac-20220518monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-reports-first-quarter-2022-financial-results-and-provides-business-upd-rnac-20220505monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-announces-38-7-million-underwritten-offering-rnac-20220406monthly0.5https://www.biopharmawatch.com/news/RNAC/selb-april-2022-any-statements-in-this-presentation-about-the-future-expectations-plans-an-rnac-20220406monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-reports-fourth-quarter-and-full-year-2021-financial-results-and-provid-rnac-20220310monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-provides-update-on-phase-1-2-clinical-trial-of-sel-302-for-the-treatme-rnac-20211124monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-reports-third-quarter-2021-financial-results-and-provides-business-upd-rnac-20211109monthly0.5https://www.biopharmawatch.com/news/RNAC/selb-aav8-empty-capsid-plus-immtor-sel-399-human-proof-of-concept-study-t-op-line-data-rep-rnac-20211108monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-reports-second-quarter-2021-financial-results-and-provides-business-up-rnac-20210812monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-reports-first-quarter-2021-financial-results-and-provides-business-upd-rnac-20210513monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-and-askbio-announce-updates-to-methylmalonic-acidemia-mma-101-program--rnac-20210429monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-reports-recent-business-highlights-and-fourth-quarter-and-full-year-20-rnac-20210311monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-announces-data-in-non-human-primates-further-validating-multiple-poten-rnac-20210106monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-reports-third-quarter-2020-financial-results-and-provides-corporate-up-rnac-20201105monthly0.5https://www.biopharmawatch.com/news/RNAC/phase-2-compare-trial-topline-data-presentation-rnac-20200930monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-reports-second-quarter-2020-financial-results-and-provides-corporate-u-rnac-20200806monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-reports-first-quarter-2020-financial-results-topline-data-announcement-rnac-20200507monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-reports-fourth-quarter-2019-and-year-end-financial-results-topline-res-rnac-20200312monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-reports-third-quarter-2019-financial-results-and-provides-corporate-up-rnac-20191108monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-reports-second-quarter-2019-financial-results-and-provides-corporate-u-rnac-20190808monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-combines-immtor-platform-with-askbio-s-industry-leading-gene-therapy-p-rnac-20190807monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-reports-first-quarter-2019-financial-results-and-provides-corporate-up-rnac-20190509monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-announces-fourth-quarter-and-year-end-2018-financial-results-and-provi-rnac-20190315monthly0.5https://www.biopharmawatch.com/news/RNAC/january2019jpm-company-presentation-january-2019-selb-1-safe-harbor-disclaimer-any-stateme-rnac-20190107monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-expands-potential-for-immtor-platform-and-streamlined-structure-under--rnac-20190103monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-announces-third-quarter-2018-financial-results-and-provides-corporate--rnac-20181108monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-presents-new-interim-data-from-phase-2-trial-of-sel-212-in-development-rnac-20181023monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-announces-second-quarter-2018-financial-results-and-provides-corporate-rnac-20180808monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-presents-data-from-ongoing-phase-2-trial-of-sel-212-in-development-for-rnac-20180615monthly0.5https://www.biopharmawatch.com/news/RNAC/jefferiesinvestorpr-jefferies-presentation-nasdaq-selb-june-2018-safe-harbor-disclaimer-an-rnac-20180604monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-announces-first-quarter-2018-financial-results-and-provides-corporate--rnac-20180509monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-presents-positive-new-data-from-ongoing-phase-2-trial-of-sel-212-in-de-rnac-20180410monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-announces-fourth-quarter-and-year-end-2017-financial-results-and-provi-rnac-20180315monthly0.5https://www.biopharmawatch.com/news/RNAC/jan2018investo-investor-presentation-nasdaq-selb-january-2018-safe-harbor-disclaimer-2-any-rnac-20180108monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-announces-third-quarter-2017-financial-results-and-provides-corporate--rnac-20171107monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-announces-important-additions-to-senior-leadership-team-rnac-20171026monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-announces-second-quarter-2017-financial-results-and-provides-corporate-rnac-20170811monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-reports-data-from-ongoing-phase-2-trial-of-lead-candidate-sel-212-in-d-rnac-20170615monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-announces-first-quarter-2017-financial-results-and-provides-corporate--rnac-20170511monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-announces-fourth-quarter-and-year-end-2016-financial-results-and-provi-rnac-20170327monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-announces-third-quarter-2016-financial-results-and-provides-corporate--rnac-20161110monthly0.5https://www.biopharmawatch.com/news/RNAC/selecta-biosciences-announces-second-quarter-2016-financial-results-and-provides-corporate-rnac-20160809monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-announces-10-0-million-registered-direct-offering-priced-at-the-market-eltx-20250130monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-announces-completion-of-phase-2-amplify-7p-study-enrollment-phase-2-ra-eltx-20241203monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-announces-closing-of-private-placement-of-20-0-million-convertible-not-eltx-20240812monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-announces-pricing-of-11-5-million-underwritten-public-offering-boston-eltx-20240628monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-announces-preliminary-disease-free-survival-analysis-from-the-ongoing--eltx-20240627monthly0.5https://www.biopharmawatch.com/news/ELTX/nature-medicine-publishes-updated-preliminary-phase-1-data-from-elicio-therapeutic-s-ampli-eltx-20240109monthly0.5https://www.biopharmawatch.com/news/ELTX/document-elicio-therapeutics-presents-updated-preliminary-data-including-promising-relapse-eltx-20230928monthly0.5https://www.biopharmawatch.com/news/ELTX/document-elicio-therapeutics-receives-2-6-million-grant-from-the-gastro-intestinal-gi-rese-eltx-20230907monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-announces-positive-interim-data-from-the-phase-1-study-of-an-investiga-eltx-20230603monthly0.5https://www.biopharmawatch.com/news/ELTX/angion-biomedia-corp-announces-1-for-10-reverse-stock-split-eltx-20230601monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-to-present-interim-data-from-the-ongoing-phase-1-study-of-investigatio-eltx-20230501monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-announces-first-patient-dosed-in-phase-1-2-study-of-lymph-node-targete-eltx-20230427monthly0.5https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-and-angion-enter-into-definitive-merger-agreement-merger-to-result-in--eltx-20230117monthly0.5https://www.biopharmawatch.com/news/ELTX/document-angion-provides-corporate-update-and-reports-second-quarter-2022-financial-result-eltx-20220815monthly0.5https://www.biopharmawatch.com/news/ELTX/document-angion-provides-corporate-update-and-reports-first-quarter-2022-financial-results-eltx-20220516monthly0.5https://www.biopharmawatch.com/news/ELTX/document-angion-provides-corporate-update-and-reports-full-year-2021-financial-results-enr-eltx-20220330monthly0.5https://www.biopharmawatch.com/news/ELTX/document-angion-provides-corporate-update-and-reports-third-quarter-2021-financial-results-eltx-20211112monthly0.5https://www.biopharmawatch.com/news/ELTX/document-angion-provides-corporate-update-and-reports-second-quarter-2021-financial-result-eltx-20210812monthly0.5https://www.biopharmawatch.com/news/ELTX/document-angion-provides-corporate-update-and-reports-first-quarter-2021-financial-results-eltx-20210517monthly0.5https://www.biopharmawatch.com/news/ELTX/document-angion-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2020-fi-eltx-20210330monthly0.5https://www.biopharmawatch.com/news/ELTX/angion-biomedica-corp-announces-closing-of-117-million-initial-public-offering-and-concurr-eltx-20210209monthly0.5https://www.biopharmawatch.com/news/IMDX/imdx-announces-26-0-imdx-20260211monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-changes-name-to-insight-molecular-diagnostics-inc-imdx-moves-headquarters-to-nash-imdx-20250617monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-reports-q1-2025-results-and-business-progress-q1-2025-pharma-services-revenue-of--imdx-20250512monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-reports-successful-2024-sets-stage-for-2025-catalysts-q4-2024-revenue-of-1-5-mill-imdx-20250324monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-prices-29-1-million-equity-offering-proceeds-expected-to-fund-transplant-assay-th-imdx-20250210monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-reports-commercial-launch-progress-on-track-to-sign-20-transplant-centers-by-end--imdx-20241112monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-announces-successful-graftassure-tm-beta-launch-and-q2-2024-results-interest-in-k-imdx-20240808monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-appoints-andrea-james-as-chief-financial-officer-imdx-20240617monthly0.5https://www.biopharmawatch.com/news/IMDX/e-xhibit-99-1-oncocyte-reports-first-quarter-2024-financial-results-conference-call-on-wed-imdx-20240515monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-corporation-announces-15-8-million-private-placement-of-securities-priced-at-the--imdx-20240411monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-and-bio-rad-partner-on-global-launch-of-transplant-assay-bio-rad-expects-to-make--imdx-20240411monthly0.5https://www.biopharmawatch.com/news/IMDX/now-officially-available-we-are-excited-to-announce-the-official-launch-of-vitagraft-kidne-imdx-20240123monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-reports-third-quarter-2023-financial-results-launching-first-products-in-1h-2024--imdx-20231109monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-reports-second-quarter-2023-financial-results-conference-call-on-thursday-imdx-20230810monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-announces-1-for-20-reverse-stock-split-imdx-20230724monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-reports-first-quarter-2023-financial-results-nearing-manufacturing-start-up-of-fi-imdx-20230511monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-reports-preliminary-fourth-quarter-and-full-year-2022-financial-results-and-plans-imdx-20230331monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-appoints-joshua-riggs-as-president-and-chief-executive-officer-imdx-20230302monthly0.5https://www.biopharmawatch.com/news/IMDX/were-derived-from-the-company-s-historical-consolidated-financial-statements-and-are-being-imdx-20230223monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-announces-initiatives-to-focus-corporate-strategy-imdx-20221216monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-reports-third-quarter-2022-financial-results-irvine-calif-imdx-20221110monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-reports-second-quarter-2022-financial-results-irvine-calif-imdx-20220810monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-announces-the-appointment-of-john-peter-gutfreund-as-independent-member-of-its-bo-imdx-20220728monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-reports-first-quarter-2022-financial-results-irvine-calif-imdx-20220511monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-imdx-20220413monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-corporation-announces-pricing-of-registered-direct-offering-of-11-765-shares-of-s-imdx-20220413monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-corporat-imdx-20220310monthly0.5https://www.biopharmawatch.com/news/IMDX/news-oncocyte-announces-development-and-co-marketing-agreement-with-thermo-fisher-scientif-imdx-20220118monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-and-burning-rock-complete-technology-transfer-part-two-and-prepare-for-scaled-dis-imdx-20211208monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-reports-third-quarter-2021-financial-results-and-provides-corporate-update-clinic-imdx-20211109monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-announces-the-clinical-launch-of-determaio-immunotherapy-response-prediction-test-imdx-20211104monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-strengthens-transplant-intellectual-property-portfolio-with-us-patent-covering-di-imdx-20211027monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-appoints-gisela-a-paulsen-as-chief-operating-officer-irvine-calif-imdx-20211007monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-announces-oral-presentation-of-new-data-on-its-determaio-immunotherapy-response-t-imdx-20210920monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-reports-second-quarter-2021-financial-results-and-provides-corporate-update-deter-imdx-20210810monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-reports-first-quarter-2021-financial-results-and-provides-corporate-update-oncocy-imdx-20210517monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-enters-the-rapidly-growing-immune-therapy-monitoring-market-with-the-closing-of-t-imdx-20210419monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-provides-corporate-update-and-reports-fourth-quarter-and-annual-2020-financial-re-imdx-20210316monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-to-begin-trading-on-the-nasdaq-stock-market-on-imdx-20210225monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-announces-pricing-of-35-million-public-offering-of-common-stock-irvine-calif-imdx-20210205monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-announces-definitive-agreement-to-acquire-chronix-biomedical-inc-transaction-incl-imdx-20210202monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-announces-25-million-registered-offering-offering-led-by-current-shareholder-and--imdx-20210120monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-imdx-20201215monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-reports-third-quarter-2020-financial-results-and-provides-corporate-update-determ-imdx-20201112monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-provides-corporate-update-and-reports-second-quarter-2020-financial-results-secur-imdx-20200729monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-provides-corporate-update-and-reports-first-quarter-2020-financial-results-announ-imdx-20200512monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-announces-10-7-million-registered-offering-further-strengthens-balance-sheet-to-s-imdx-20200424monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2019-financial-imdx-20200325monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-closes-merger-agreement-to-acquire-insight-genetics-acquisition-broadens-suite-of-imdx-20200205monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-announces-definitive-agreement-to-acquire-insight-genetics-acquisition-includes-a-imdx-20200110monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-announces-7-6-million-registered-offering-proceeds-strengthen-balance-sheet-to-su-imdx-20200102monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-provides-corporate-update-and-reports-third-quarter-2019-financial-results-determ-imdx-20191114monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-closes-initial-investment-in-razor-genomics-and-acquires-rights-to-commercialize--imdx-20191001monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-announces-definitive-agreement-to-acquire-razor-genomics-acquisition-of-razor-s-t-imdx-20190905monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-provides-corporate-update-and-reports-second-quarter-2019-financial-results-molec-imdx-20190814monthly0.5https://www.biopharmawatch.com/news/IMDX/amendment-to-oncocyte-corporation-2018-equity-incentive-plan-approved-by-shareholders-imdx-20190717monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-announces-chief-executive-officer-transition-appoints-diagnostic-industry-veteran-imdx-20190606monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-provides-corporate-update-and-reports-first-quarter-2019-financial-results-comple-imdx-20190514monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2018-financial-imdx-20190401monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-announces-proposed-public-offering-of-common-stock-imdx-20190207monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-announces-successful-results-of-determavu-r-d-validation-study-results-show-90-se-imdx-20190129monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-reports-third-quarter-2018-financial-results-and-progress-in-determavu-developmen-imdx-20181113monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-completes-successful-transition-to-new-diagnostic-testing-platform-and-initiates--imdx-20181029monthly0.5https://www.biopharmawatch.com/news/IMDX/equity-incentive-plan-oncocyte-corporation-1-purpose-eligibility-1-1-general-purpose-the-n-imdx-20180829monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-reports-second-quarter-2018-financial-results-and-positive-corporate-developments-imdx-20180814monthly0.5https://www.biopharmawatch.com/news/IMDX/seasoned-healthcare-executive-albert-p-parker-appointed-chief-operating-officer-of-oncocyt-imdx-20180809monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-announces-at-market-3-59-million-offering-of-common-stock-and-warrants-alameda-ca-imdx-20180727monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-reports-encouraging-new-study-results-for-lung-cancer-blood-test-results-suggest--imdx-20180709monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-reports-first-quarter-2018-financial-results-conference-call-today-at-4-30-pm-imdx-20180515monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-reports-fourth-quarter-and-full-year-2017-financial-results-development-of-determ-imdx-20180402monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-announces-the-closing-of-a-10-million-private-placement-of-common-stock-alameda-c-imdx-20180328monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-announces-initial-results-of-determavu-feasibility-on-new-platforms-enhancements--imdx-20180308monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-initiates-search-for-new-independent-director-imdx-20171129monthly0.5https://www.biopharmawatch.com/news/IMDX/seasoned-financial-executive-joins-oncocyte-as-chief-financial-officer-imdx-20171115monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-reports-third-quarter-2017-financial-results-conference-call-today-at-4-30-pm-et-imdx-20171114monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-confirms-launch-plans-for-lung-cancer-diagnostic-test-reports-progress-toward-cli-imdx-20170814monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-receives-5-74-million-in-proceeds-from-exercise-of-warrants-alameda-california-imdx-20170725monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-continues-to-make-progress-towards-commercialization-reports-first-quarter-2017-r-imdx-20170428monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-reports-successful-results-of-lung-cancer-diagnostic-test-study-targets-2017-prod-imdx-20170306monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-corporation-reports-fourth-quarter-and-full-year-2016-financial-results-enters-in-imdx-20170227monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-receives-2-million-in-proceeds-from-early-exercise-of-warrants-completes-sample-c-imdx-20170221monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-reports-third-quarter-2016-financial-results-currently-processing-samples-and-ana-imdx-20161110monthly0.5https://www.biopharmawatch.com/news/IMDX/liquid-biopsies-next-generation-cancer-molecular-diagnostics-william-annettchief-executive-imdx-20160908monthly0.5https://www.biopharmawatch.com/news/IMDX/don-m-bailey-appointed-to-oncocyte-corporation-s-board-of-directors-experienced-senior-exe-imdx-20160829monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-corporation-announces-the-closing-of-two-private-placement-transactions-generatin-imdx-20160829monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-reports-second-quarter-2016-financial-results-conference-call-to-discuss-the-resu-imdx-20160811monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-reports-first-quarter-2016-financial-results-conference-call-to-discuss-the-resul-imdx-20160518monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-corporation-reports-full-year-2015-financial-results-alameda-ca-imdx-20160330monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-corporation-and-the-wistar-institute-enter-into-global-licensing-agreement-exclus-imdx-20160127monthly0.5https://www.biopharmawatch.com/news/IMDX/oncocyte-corporation-initiates-trading-on-the-nyse-mkt-company-s-common-stock-listed-under-imdx-20160104monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20260430monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-pdex-20260212monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20260129monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-pdex-20251219monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20251030monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20250904monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20250501monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20250130monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20241031monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20240905monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20240502monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20240208monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20231102monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20231013monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20230504monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20230202monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20221103monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20220825monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20220505monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20220203monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20211115monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20210826monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20210506monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20210204monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20201105monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20200827monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20200507monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20200324monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20200206monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20191218monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20191107monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20190829monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20190509monthly0.5https://www.biopharmawatch.com/news/PDEX/investor-presentation-presented-by-rick-van-kirk-ceo-safe-harbor-statement-statements-made-pdex-20190501monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20190207monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20181108monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20180830monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20180510monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20180208monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20171109monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20170905monthly0.5https://www.biopharmawatch.com/news/PDEX/investor-presentation-presented-by-rick-van-kirk-ceo-safe-harbor-statement-statements-made-pdex-20170627monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20170511monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20170209monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-pdex-20170130monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20161110monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20160915monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20160512monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20160211monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20151110monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20150917monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20150514monthly0.5https://www.biopharmawatch.com/news/PDEX/richard-l-van-kirk-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc--pdex-20150210monthly0.5https://www.biopharmawatch.com/news/PDEX/harold-a-hurwitz-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc-an-pdex-20141113monthly0.5https://www.biopharmawatch.com/news/PDEX/harold-a-hurwitz-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc-an-pdex-20140918monthly0.5https://www.biopharmawatch.com/news/PDEX/harold-a-hurwitz-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc-an-pdex-20140512monthly0.5https://www.biopharmawatch.com/news/PDEX/harold-a-hurwitz-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-pdex-20140501monthly0.5https://www.biopharmawatch.com/news/PDEX/harold-a-hurwitz-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-pdex-20140324monthly0.5https://www.biopharmawatch.com/news/PDEX/harold-a-hurwitz-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-pdex-20140310monthly0.5https://www.biopharmawatch.com/news/PDEX/harold-a-hurwitz-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc-an-pdex-20140206monthly0.5https://www.biopharmawatch.com/news/PDEX/harold-a-hurwitz-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-pdex-20131217monthly0.5https://www.biopharmawatch.com/news/PDEX/harold-a-hurwitz-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc-an-pdex-20131113monthly0.5https://www.biopharmawatch.com/news/PDEX/harold-a-hurwitz-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc-an-pdex-20130925monthly0.5https://www.biopharmawatch.com/news/PDEX/harold-a-hurwitz-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc-an-pdex-20130711monthly0.5https://www.biopharmawatch.com/news/PDEX/mr-nick-swenson-pdex-20130607monthly0.5https://www.biopharmawatch.com/news/PDEX/harold-a-hurwitz-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc-an-pdex-20130513monthly0.5https://www.biopharmawatch.com/news/PDEX/michael-j-berthelot-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc-pdex-20130110monthly0.5https://www.biopharmawatch.com/news/PDEX/michael-j-berthelot-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc-pdex-20121025monthly0.5https://www.biopharmawatch.com/news/PDEX/michael-j-berthelot-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc-pdex-20120904monthly0.5https://www.biopharmawatch.com/news/PDEX/michael-j-berthelot-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-pro-pdex-20120806monthly0.5https://www.biopharmawatch.com/news/PDEX/michael-j-berthelot-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-pdex-20120504monthly0.5https://www.biopharmawatch.com/news/PDEX/mark-murphy-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-pdex-20120206monthly0.5https://www.biopharmawatch.com/news/PDEX/mark-murphy-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc-announc-pdex-20111109monthly0.5https://www.biopharmawatch.com/news/PDEX/mark-murphy-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc-announc-pdex-20110914monthly0.5https://www.biopharmawatch.com/news/PDEX/mark-murphy-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc-announc-pdex-20110510monthly0.5https://www.biopharmawatch.com/news/PDEX/mark-murphy-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-pdex-20110411monthly0.5https://www.biopharmawatch.com/news/PDEX/mark-murphy-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc-announc-pdex-20110210monthly0.5https://www.biopharmawatch.com/news/PDEX/mark-murphy-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-pdex-20101109monthly0.5https://www.biopharmawatch.com/news/PDEX/pro-dex-inc-announces-fiscal-year-2010-fourth-quarter-and-full-year-results-irvine-calif-s-pdex-20100928monthly0.5https://www.biopharmawatch.com/news/PDEX/mark-murphy-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-pdex-20100707monthly0.5https://www.biopharmawatch.com/news/PDEX/mark-murphy-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc-announc-pdex-20100429monthly0.5https://www.biopharmawatch.com/news/PDEX/unassociated-document-contact-mark-murphy-chief-executive-officer-949-769-3200-for-immedia-pdex-20100407monthly0.5https://www.biopharmawatch.com/news/PDEX/mark-murphy-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc-announc-pdex-20100204monthly0.5https://www.biopharmawatch.com/news/PDEX/mark-murphy-chief-executive-officer-949-769-3200-for-immediate-release-customer-elects-to--pdex-20100122monthly0.5https://www.biopharmawatch.com/news/PDEX/mark-murphy-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc-receive-pdex-20100113monthly0.5https://www.biopharmawatch.com/news/PDEX/unassociated-document-contact-mark-murphy-chief-executive-officer-949-769-3200-for-immedia-pdex-20091204monthly0.5https://www.biopharmawatch.com/news/PDEX/mark-murphy-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc-announc-pdex-20091029monthly0.5https://www.biopharmawatch.com/news/PDEX/mark-murphy-chief-executive-officer-949-769-3200-for-immediate-release-pro-dex-inc-announc-pdex-20090917monthly0.5https://www.biopharmawatch.com/news/PDEX/mark-murphy-chief-executive-officer-949-769-3200-jeff-stanlis-investor-relations-hayden-ir-pdex-20090514monthly0.5https://www.biopharmawatch.com/news/PDEX/v139830-ex99-1-txt-logo-contact-mark-murphy-chief-executive-officer-949-769-3200-jeff-stan-pdex-20090213monthly0.5https://www.biopharmawatch.com/news/PDEX/mark-murphy-chief-executive-officer-949-769-3200-jeff-stanlis-investor-relations-hayden-co-pdex-20081113monthly0.5https://www.biopharmawatch.com/news/PDEX/pro-dex-inc-receives-nasdaq-letter-irvine-california-pdex-20080924monthly0.5https://www.biopharmawatch.com/news/PDEX/pro-dex-inc-and-subsidiaries-consolidated-balance-sheets-30-jun-08-30-jun-07-assets-curren-pdex-20080922monthly0.5https://www.biopharmawatch.com/news/PDEX/mark-murphy-chief-executive-officer-949-769-3200-jeff-stanlis-investor-relations-hayden-co-pdex-20080918monthly0.5https://www.biopharmawatch.com/news/PDEX/mark-murphy-chief-executive-officer-949-769-3200-jeff-stanlis-investor-relations-hayden-co-pdex-20080515monthly0.5https://www.biopharmawatch.com/news/PDEX/mark-murphy-chief-executive-officer-714-241-4411-jeff-stanlis-investor-relations-hayden-co-pdex-20080214monthly0.5https://www.biopharmawatch.com/news/PDEX/mark-murphy-chief-executive-officer-714-241-4411-brett-maas-investor-relations-hayden-comm-pdex-20080115monthly0.5https://www.biopharmawatch.com/news/PDEX/v094586-ex99-1-txt-pro-dex-inc-announces-fiscal-first-quarter-2008-financial-results-and-n-pdex-20071115monthly0.5https://www.biopharmawatch.com/news/PDEX/v093846-ex99-1-txt-pro-dex-inc-announces-fiscal-first-quarter-2008-financial-results-and-n-pdex-20071114monthly0.5https://www.biopharmawatch.com/news/PDEX/unassociated-document-contact-mark-murphy-chief-executive-officer-714-241-4411-brett-maas--pdex-20070913monthly0.5https://www.biopharmawatch.com/news/PDEX/mark-murphy-chief-executive-officer-714-241-4411-brett-maas-investor-relations-hayden-comm-pdex-20070515monthly0.5https://www.biopharmawatch.com/news/PDEX/mark-murphy-chief-executive-officer-714-241-4411-brett-maas-investor-relations-hayden-comm-pdex-20070213monthly0.5https://www.biopharmawatch.com/news/PDEX/mark-murphy-chief-executive-officer-714-241-4411-brett-maas-investor-relations-hayden-comm-pdex-20061114monthly0.5https://www.biopharmawatch.com/news/PDEX/mark-murphy-chief-executive-officer-714-241-4411-brett-maas-investor-relations-hayden-comm-pdex-20060927monthly0.5https://www.biopharmawatch.com/news/PDEX/pro-dex-inc-provides-preliminary-fiscal-2006-year-end-update-company-expects-annual-sales--pdex-20060814monthly0.5https://www.biopharmawatch.com/news/PDEX/jeff-ritchey-ceo-cfo-secretary-714-241-4411-matthew-hayden-investor-relations-hayden-commu-pdex-20060522monthly0.5https://www.biopharmawatch.com/news/PDEX/pro-dex-inc-announces-revised-outlook-management-restructuring-expects-revenue-of-4-2-mill-pdex-20060331monthly0.5https://www.biopharmawatch.com/news/PDEX/logo-of-pro-dex-contact-patrick-johnson-president-ceo-714-241-4411-matthew-hayden-investor-pdex-20060209monthly0.5https://www.biopharmawatch.com/news/PDEX/patrick-johnson-president-ceo-714-241-4411-matthew-hayden-investor-relations-hayden-commun-pdex-20060105monthly0.5https://www.biopharmawatch.com/news/PDEX/logo-of-pro-dex-contact-patrick-johnson-president-ceo-714-241-4411-matthew-hayden-investor-pdex-20051114monthly0.5https://www.biopharmawatch.com/news/PDEX/patrick-johnson-president-ceo-714-241-4411-matthew-hayden-investor-relations-hayden-commun-pdex-20051102monthly0.5https://www.biopharmawatch.com/news/PDEX/pro-dex-inc-announces-fourth-fiscal-quarter-and-fiscal-2005-results-sales-increase-19-for--pdex-20050906monthly0.5https://www.biopharmawatch.com/news/PDEX/patrick-johnson-president-ceo-714-241-4411-matthew-hayden-investor-relations-for-immediate-pdex-20050707monthly0.5https://www.biopharmawatch.com/news/PDEX/patrick-johnson-president-ceo-714-241-4411-matthew-hayden-investor-relations-hayden-commun-pdex-20050512monthly0.5https://www.biopharmawatch.com/news/PDEX/patrick-johnson-president-ceo-714-241-4411-matthew-hayden-investor-relations-hayden-commun-pdex-20050214monthly0.5https://www.biopharmawatch.com/news/PDEX/pro-dex-reports-financial-results-by-edgar2-com-contact-patrick-johnson-president-ceo-714--pdex-20041028monthly0.5https://www.biopharmawatch.com/news/PDEX/patrick-johnson-president-ceo-714-241-4411-for-immediate-release-jim-white-investor-relati-pdex-20040908monthly0.5https://www.biopharmawatch.com/news/ZEPP/zepp-health-corporation-reports-fourth-quarter-and-full-year-2025-unaudited-financial-resu-zepp-20260316monthly0.5https://www.biopharmawatch.com/news/ZEPP/zepp-health-corporation-reports-third-quarter-2025-unaudited-financial-results-milpitas-ca-zepp-20251105monthly0.5https://www.biopharmawatch.com/news/ZEPP/zepp-health-corporation-reports-second-quarter-2025-unaudited-financial-results-zepp-20250803monthly0.5https://www.biopharmawatch.com/news/ZEPP/zepp-health-corporation-reports-first-quarter-2025-unaudited-financial-results-zepp-20250519monthly0.5https://www.biopharmawatch.com/news/ZEPP/zepp-health-corporation-reports-fourth-quarter-and-full-year-2024-unaudited-financial-resu-zepp-20250326monthly0.5https://www.biopharmawatch.com/news/ZEPP/zepp-health-corporation-reports-third-quarter-2024-unaudited-financial-results-zepp-20241118monthly0.5https://www.biopharmawatch.com/news/ZEPP/zepp-regains-compliance-with-nyse-minimum-price-continued-listing-criterion-zepp-20241002monthly0.5https://www.biopharmawatch.com/news/ZEPP/zepp-health-corporation-announces-plan-to-implement-ads-ratio-change-zepp-20240906monthly0.5https://www.biopharmawatch.com/news/ZEPP/zepp-health-corporation-announces-board-changes-zepp-20240903monthly0.5https://www.biopharmawatch.com/news/ZEPP/zepp-health-corporation-reports-second-quarter-2024-unaudited-financial-results-zepp-20240821monthly0.5https://www.biopharmawatch.com/news/ZEPP/zepp-health-corporation-reports-first-quarter-2024-unaudited-financial-results-zepp-20240520monthly0.5https://www.biopharmawatch.com/news/ZEPP/zepp-health-corporation-reports-fourth-quarter-and-full-year-2023-unaudited-financial-resu-zepp-20240318monthly0.5https://www.biopharmawatch.com/news/ZEPP/zepp-health-corporation-reports-third-quarter-2023-unaudited-financial-results-amsterdam-t-zepp-20231120monthly0.5https://www.biopharmawatch.com/news/ZEPP/zepp-health-corporation-reports-second-quarter-2023-unaudited-financial-results-amsterdam-zepp-20230821monthly0.5https://www.biopharmawatch.com/news/ZEPP/zepp-health-corporation-reports-first-quarter-2023-unaudited-financial-results-beijing-zepp-20230523monthly0.5https://www.biopharmawatch.com/news/ZEPP/zepp-health-corporation-reports-fourth-quarter-and-full-year-2022-unaudited-financial-resu-zepp-20230321monthly0.5https://www.biopharmawatch.com/news/ZEPP/zepp-health-corporation-2023-share-incentive-plan-article-1-purpose-the-purpose-of-this-20-zepp-20230111monthly0.5https://www.biopharmawatch.com/news/ZEPP/zepp-health-corporation-reports-third-quarter-2022-unaudited-financial-results-beijing-zepp-20221121monthly0.5https://www.biopharmawatch.com/news/ZEPP/zepp-health-corporation-reports-second-quarter-2022-unaudited-financial-results-beijing-zepp-20220825monthly0.5https://www.biopharmawatch.com/news/ZEPP/zepp-health-corporation-to-hold-annual-general-meeting-on-zepp-20220615monthly0.5https://www.biopharmawatch.com/news/ZEPP/zepp-health-corporation-reports-first-quarter-2022-unaudited-financial-results-beijing-zepp-20220524monthly0.5https://www.biopharmawatch.com/news/ZEPP/zepp-health-corporation-reports-fourth-quarter-and-full-year-2021-unaudited-financial-resu-zepp-20220317monthly0.5https://www.biopharmawatch.com/news/ZEPP/zepp-health-provides-updates-to-guidance-and-share-repurchases-beijing-zepp-20211231monthly0.5https://www.biopharmawatch.com/news/ZEPP/zepp-health-corporation-reports-third-quarter-2021-unaudited-financial-results-beijing-zepp-20211116monthly0.5https://www.biopharmawatch.com/news/ZEPP/zepp-health-corporation-reports-second-quarter-2021-unaudited-financial-results-beijing-zepp-20210819monthly0.5https://www.biopharmawatch.com/news/ZEPP/zepp-health-corp-reports-first-quarter-2021-unaudited-financial-results-beijing-zepp-20210513monthly0.5https://www.biopharmawatch.com/news/ZEPP/zepp-health-corp-reports-fourth-quarter-and-full-year-2020-unaudited-financial-results-bei-zepp-20210315monthly0.5https://www.biopharmawatch.com/news/ZEPP/huami-corporation-announces-name-change-to-zepp-health-new-name-reflects-company-s-expandi-zepp-20210225monthly0.5https://www.biopharmawatch.com/news/ZEPP/huami-corporation-to-hold-2020-annual-general-meeting-on-zepp-20210126monthly0.5https://www.biopharmawatch.com/news/ZEPP/huami-enters-in-definitive-agreement-to-acquire-a-minority-stake-in-jiangsu-yitong-high-te-zepp-20210105monthly0.5https://www.biopharmawatch.com/news/ZEPP/former-texas-instruments-executive-bing-xie-joins-huami-s-board-as-independent-director-be-zepp-20201122monthly0.5https://www.biopharmawatch.com/news/ZEPP/huami-corp-announces-change-of-chief-financial-officer-effective-zepp-20200901monthly0.5https://www.biopharmawatch.com/news/ZEPP/huami-corporation-reports-second-quarter-2020-unaudited-financial-results-beijing-zepp-20200818monthly0.5https://www.biopharmawatch.com/news/ZEPP/huami-corporation-reports-first-quarter-2020-unaudited-financial-results-quarterly-revenue-zepp-20200512monthly0.5https://www.biopharmawatch.com/news/ZEPP/huami-corporation-files-2019-annual-report-on-form-20-f-beijing-zepp-20200423monthly0.5https://www.biopharmawatch.com/news/ZEPP/huami-corporation-reports-fourth-quarter-and-full-year-2019-unaudited-financial-results-qu-zepp-20200313monthly0.5https://www.biopharmawatch.com/news/ZEPP/huami-corporation-announced-corporate-mission-connect-health-with-technology-recaps-2019-a-zepp-20191204monthly0.5https://www.biopharmawatch.com/news/ZEPP/huami-corporation-to-hold-2019-annual-general-meeting-on-zepp-20191129monthly0.5https://www.biopharmawatch.com/news/ZEPP/huami-corporation-reports-third-quarter-2019-unaudited-financial-results-quarterly-revenue-zepp-20191112monthly0.5https://www.biopharmawatch.com/news/ZEPP/huami-corporation-announces-change-of-board-composition-zepp-20190830monthly0.5https://www.biopharmawatch.com/news/ZEPP/huami-corporation-reports-second-quarter-2019-unaudited-financial-results-quarterly-revenu-zepp-20190819monthly0.5https://www.biopharmawatch.com/news/ZEPP/huami-corporation-reports-first-quarter-2019-unaudited-financial-results-quarterly-revenue-zepp-20190603monthly0.5https://www.biopharmawatch.com/news/ZEPP/huami-corporation-announces-proposed-follow-on-public-offering-of-american-depositary-shar-zepp-20190424monthly0.5https://www.biopharmawatch.com/news/ZEPP/huami-corporation-reports-fourth-quarter-and-full-year-2018-unaudited-financial-results-qu-zepp-20190314monthly0.5https://www.biopharmawatch.com/news/ZEPP/huami-corporation-reports-third-quarter-2018-unaudited-financial-results-revenues-up-126-7-zepp-20181126monthly0.5https://www.biopharmawatch.com/news/ZEPP/huami-corporation-reports-second-quarter-2018-unaudited-financial-results-revenues-up-54-8-zepp-20180820monthly0.5https://www.biopharmawatch.com/news/ZEPP/huami-corporation-announces-official-launch-of-mi-band-3-beijing-zepp-20180531monthly0.5https://www.biopharmawatch.com/news/ZEPP/huami-corporation-reports-first-quarter-2018-unaudited-financial-results-revenues-up-77-0--zepp-20180521monthly0.5https://www.biopharmawatch.com/news/ZEPP/huami-corporation-reports-fourth-quarter-and-full-year-2017-unaudited-financial-results-be-zepp-20180326monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-announces-leadership-transition-stephen-steve-griffin-current-chief-fin-anik-20260108monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-anik-20230921monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-enters-into-cooperation-agreement-with-caligan-partners-gary-fischetti-joins-anika-b-anik-20230413monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-to-acquire-parcus-medical-and-arthrosurface-accelerates-revenue-growth--anik-20200106monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-third-quarter-2019-financial-results-total-revenue-increases-11-and-net-inco-anik-20191024monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-second-quarter-2019-financial-results-delivers-strong-bottom-line-performanc-anik-20190724monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-first-quarter-2019-financial-results-total-revenue-increased-16-year-over-ye-anik-20190502monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-fourth-quarter-and-full-year-2018-financial-results-strong-bottom-line-perfo-anik-20190221monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-third-quarter-2018-financial-results-cingal-drives-strong-international-visc-anik-20181024monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-second-quarter-2018-financial-results-solid-top-and-bottom-line-performance--anik-20180725monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-announces-top-line-results-from-cingal-16-02-clinical-trial-in-knee-ost-anik-20180619monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-first-quarter-2018-financial-results-successful-leadership-transition-in-evo-anik-20180502monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-fourth-quarter-and-full-year-2017-financial-results-monovisc-global-revenue--anik-20180221monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-third-quarter-2017-financial-results-completed-enrollment-in-cingal-phase-ii-anik-20171025monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-announces-appointment-of-joseph-darling-as-president-track-record-of-successful-prod-anik-20170727monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-strong-second-quarter-2017-financial-results-monovisc-u-s-end-user-sales-exc-anik-20170726monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-fourth-quarter-and-full-year-2016-financial-results-worldwide-orthobiologics-anik-20170215monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-third-quarter-2016-financial-results-worldwide-orthobiologics-revenue-increa-anik-20161026monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-second-quarter-2016-financial-results-total-revenue-increases-16-year-over-y-anik-20160727monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-reports-first-quarter-2016-financial-results-total-revenue-increased-44-year-over-ye-anik-20160427monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-delivers-strong-performance-with-record-product-revenue-for-the-fourth--anik-20160224monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-announces-decision-to-proceed-with-cingal-premarket-review-through-fda--anik-20151209monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-robust-financial-performance-and-continued-progress-on-key-fron-anik-20151028monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-delivers-solid-second-quarter-2015-financial-results-and-continued-pipe-anik-20150729monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-fourth-quarter-and-full-year-2014-financial-results-monovisc-re-anik-20150225monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-appoints-dr-glenn-larsen-to-its-board-of-directors-bedford-mass-busines-anik-20150219monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-third-quarter-2014-financial-results-third-quarter-total-revenu-anik-20141029monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-second-quarter-2014-financial-results-total-revenue-grows-26-to-anik-20140730monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-first-quarter-2014-financial-results-receives-17-5-million-in-m-anik-20140429monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-announces-dismissal-of-monovisc-u-s-patent-infringement-lawsuit-bedford-anik-20140313monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-fourth-quarter-and-full-year-2013-financial-results-monovisc-ac-anik-20140226monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-20-total-revenue-growth-and-record-third-quarter-earnings-total-anik-20131030monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-appoints-industry-recognized-r-d-executive-john-w-sheets-jr-ph-d-as-chi-anik-20131002monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-record-second-quarter-revenue-and-earnings-net-income-grows-58--anik-20130731monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-first-quarter-2013-financial-results-achieves-net-income-growth-anik-20130501monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-fourth-quarter-and-full-year-2012-financial-results-fourth-quar-anik-20130227monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-names-sylvia-cheung-as-chief-financial-officer-provides-summary-of-four-anik-20130122monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-announces-monovisc-pma-news-bedford-mass-business-wire-anik-20121204monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-third-quarter-financial-results-achieves-revenue-of-14-8-millio-anik-20121030monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-record-second-quarter-revenue-and-earnings-total-revenue-grows--anik-20120801monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-record-first-quarter-revenue-and-earnings-total-revenue-grows-2-anik-20120503monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-25-increase-in-fourth-quarter-revenue-earnings-more-than-double-anik-20120229monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-announces-u-s-monovisc-license-and-supply-agreement-with-depuy-mitek-in-anik-20111221monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-33-revenue-growth-in-third-quarter-2011-earnings-per-share-grow-anik-20111102monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-second-quarter-2011-financial-results-second-quarter-and-six-mo-anik-20110804monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-first-quarter-2011-financial-results-orthobiologics-revenue-ris-anik-20110504monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-comments-on-patent-litigation-bedford-mass-business-wire-anik-20110426monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-39-total-revenue-growth-in-fourth-quarter-2010-orthobiologics-r-anik-20110309monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-announces-date-of-fourth-quarter-and-year-end-2010-financial-results-co-anik-20110214monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-appoints-industry-veteran-jeffery-s-thompson-to-board-of-directors-comp-anik-20110120monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-29-total-revenue-growth-in-third-quarter-2010-fab-integration-a-anik-20101108monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-52-total-revenue-growth-in-second-quarter-2010-orthovisc-sales--anik-20100809monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-35-total-revenue-growth-in-first-quarter-2010-strong-domestic-s-anik-20100510monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-18-revenue-growth-in-fourth-quarter-2009-domestic-unit-sales-of-anik-20100316monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-inc-charles-h-sherwood-ph-d-ceo-kevin-w-quinlan-cfo-tel-781-457-9000-an-anik-20091231monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-17-revenue-growth-in-third-quarter-2009-net-income-increases-37-anik-20091027monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-second-quarter-2009-results-domestic-unit-sales-of-orthovisc-gr-anik-20090722monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-appoints-frank-j-luppino-as-chief-operating-officer-seasoned-operations-anik-20090526monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-first-quarter-2009-results-revenues-rise-8-led-by-strong-orthov-anik-20090429monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-record-revenue-for-2008-total-revenue-grows-16-as-product-reven-anik-20090305monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-17-increase-in-third-quarter-product-revenue-company-reports-st-anik-20081103monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-28-increase-in-revenue-for-second-quarter-2008-joint-health-rev-anik-20080723monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-strong-revenue-growth-for-first-quarter-2008-revenues-rise-39-w-anik-20080501monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-inc-renews-shareholder-rights-plan-bedford-mass-business-wire-anika-the-anik-20080407monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-record-product-revenues-for-2007-strong-fourth-quarter-leads-to-anik-20080305monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-and-galderma-agree-to-terminate-license-development-and-supply-agreemen-anik-20071120monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-33-percent-increase-in-third-quarter-product-revenues-in-negoti-anik-20071105monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-inc-charles-h-sherwood-ph-d-ceo-kevin-w-quinlan-cfo-781-932-6616-anika--anik-20070918monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-second-quarter-fiscal-2007-financial-results-orthovisc-domestic-anik-20070724monthly0.5https://www.biopharmawatch.com/news/ANIK/v072803-ex99-1-txt-anika-therapeutics-reports-first-quarter-fiscal-2007-financial-results--anik-20070427monthly0.5https://www.biopharmawatch.com/news/ANIK/charles-h-sherwood-ph-d-ceo-kevin-w-quinlan-cfo-anika-therapeutics-inc-781-932-6616-anika--anik-20070228monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-appoints-orthopedics-veteran-john-c-moran-to-board-of-directors-woburn--anik-20061220monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-inc-rodman-renshaw-8-th-annual-healthcare-conference-anik-20061107monthly0.5https://www.biopharmawatch.com/news/ANIK/charles-h-sherwood-ph-d-ceo-kevin-w-quinlan-cfo-anika-therapeutics-inc-781-932-6616-anika--anik-20061024monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-inc-ubs-global-life-sciences-conference-anik-20060927monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-second-quarter-2006-financial-results-reports-record-product-re-anik-20060725monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-announces-worldwide-development-and-commercialization-agreement-with-ga-anik-20060707monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-first-quarter-2006-financial-results-woburn-mass-april-25-prnew-anik-20060426monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-reports-fourth-quarter-and-full-year-2005-financial-results-anik-20060302monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-inc-charles-h-sherwood-ph-d-ceo-kevin-w-quinlan-cfo-781-932-6616-anika--anik-20060125monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-inc-pondelwilkinson-inc-charles-h-sherwood-ph-d-ceo-rob-whetstone-310-2-anik-20051018monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-announces-termination-of-worldwide-development-and-commercialization-pa-anik-20050901monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-inc-pondelwilkinson-inc-charles-h-sherwood-ph-d-ceo-rob-whetstone-310-2-anik-20050727monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-inc-pondelwilkinson-inc-charles-h-sherwood-ph-d-ceo-rob-whetstone-310-2-anik-20050712monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-inc-pondelwilkinson-charles-h-sherwood-ph-d-susan-klein-508-358-4315-ch-anik-20050427monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-inc-pondelwilkinson-klein-charles-sherwood-ph-d-ceo-susan-klein-508-358-anik-20050223monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-inc-pondelwilkinson-klein-charles-sherwood-ph-d-ceo-susan-klein-508-358-anik-20041220monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-inc-pondelwilkinson-klein-charles-sherwood-ph-d-ceo-susan-klein-508-358-anik-20041116monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-inc-pondelwilkinson-klein-charles-sherwood-ph-d-ceo-susan-klein-508-358-anik-20041029monthly0.5https://www.biopharmawatch.com/news/ANIK/anika-therapeutics-inc-pondelwilkinson-klein-charles-sherwood-ph-d-ceo-susan-klein-508-358-anik-20041005monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-reports-preliminary-q4-and-full-year-2025-results-achieves-record-rev-krmd-20260112monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-announces-27-q3-revenue-growth-and-raises-2025-krmd-20251112monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-announces-q2-2025-financial-results-including-record-double-digit-rev-krmd-20250806monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-announces-record-q1-2025-financial-results-and-raises-2025-krmd-20250507monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-announces-fourth-quarter-and-full-year-2024-financial-results-with-re-krmd-20250312monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-reports-preliminary-fourth-quarter-and-full-year-2024-results-achieve-krmd-20250113monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-inc-announces-2024-q3-financial-results-third-consecutive-quarter-of--krmd-20241113monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-inc-announces-2024-q2-financial-results-a-record-quarter-with-22-reve-krmd-20240807monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-inc-announces-2024-first-quarter-financial-results-delivering-double--krmd-20240501monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-announces-successful-appeal-in-eu-notified-body-review-mahwah-nj-krmd-20240411monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-inc-announces-2023-fourth-quarter-full-year-financial-results-and-202-krmd-20240313monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-inc-announces-2023-third-quarter-financial-results-and-updates-full-y-krmd-20231108monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-krmd-20231004monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-inc-announces-2023-second-quarter-financial-results-and-updates-full--krmd-20230809monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-inc-announces-preliminary-second-quarter-2023-revenues-and-provides-b-krmd-20230802monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-krmd-20230627monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-inc-announces-2023-first-quarter-financial-results-strong-start-to-20-krmd-20230504monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-announces-2022-q4-and-full-year-financial-results-accelerating-to-19--krmd-20230308monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-announces-2022-third-quarter-financial-results-mahwah-nj-krmd-20221109monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-announces-2022-second-quarter-financial-results-mahwah-nj-krmd-20220803monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-announces-2022-first-quarter-financial-results-chester-ny-krmd-20220504monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-announces-2021-q4-krmd-20220302monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-to-unveil-updated-strategic-plan-at-investor-day-krmd-20211201monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-announces-2021-krmd-20211110monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-announces-2021-second-quarter-financial-results-chester-ny-krmd-20210811monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-announces-2021-krmd-20210512monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-reports-fourth-quarter-and-full-year-2020-financial-results-chester-n-krmd-20210323monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-announces-new-chief-executive-officer-chester-ny-krmd-20210319monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-reports-preliminary-full-year-2020-results-announces-ceo-transition-c-krmd-20210125monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-announces-financial-results-for-third-quarter-2020-chester-ny-krmd-20201103monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-announces-2020-second-quarter-financial-results-record-net-sales-of-7-krmd-20200804monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-commences-public-offering-of-common-stock-chester-ny-krmd-20200618monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-announces-2020-first-quarter-financial-results-q1-2020-summary-net-sa-krmd-20200504monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-announces-record-2019-fourth-quarter-and-full-year-financial-results--krmd-20200225monthly0.5https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-announces-record-2019-third-quarter-financial-results-conference-call-krmd-20191105monthly0.5https://www.biopharmawatch.com/news/KRMD/rms-medical-products-announces-rebranding-to-koru-medical-systems-new-ticker-symbol-krmd-c-krmd-20191023monthly0.5https://www.biopharmawatch.com/news/KRMD/rms-medical-products-appoints-healthcare-industry-veteran-r-john-fletcher-to-board-of-dire-krmd-20190508monthly0.5https://www.biopharmawatch.com/news/KRMD/rms-medical-products-announces-2019-first-quarter-financial-results-record-quarterly-net-s-krmd-20190501monthly0.5https://www.biopharmawatch.com/news/KRMD/rms-medical-products-announces-record-revenue-and-profitability-for-2018-outlines-plan-for-krmd-20190212monthly0.5https://www.biopharmawatch.com/news/KRMD/rms-medical-announces-new-ceo-strategic-plan-and-upcoming-schedule-don-pettigrew-promoted--krmd-20190204monthly0.5https://www.biopharmawatch.com/news/KRMD/rms-medical-products-announces-private-placement-transaction-between-shareholders-chester--krmd-20181217monthly0.5https://www.biopharmawatch.com/news/KRMD/rms-medical-products-announces-new-board-members-chester-ny-krmd-20181206monthly0.5https://www.biopharmawatch.com/news/KRMD/rms-medical-products-third-quarter-2018-results-conference-call-october-24-2018-confirmati-krmd-20181024monthly0.5https://www.biopharmawatch.com/news/KRMD/rms-medical-products-announces-second-straight-record-quarterly-net-sales-and-net-income-n-krmd-20181024monthly0.5https://www.biopharmawatch.com/news/KRMD/rms-medical-products-announces-record-quarterly-sales-and-net-income-net-sales-for-the-qua-krmd-20180806monthly0.5https://www.biopharmawatch.com/news/KRMD/rms-medical-pre-announces-strong-quarterly-sales-growth-and-change-in-leadership-quarterly-krmd-20180726monthly0.5https://www.biopharmawatch.com/news/KRMD/rms-medical-products-victory-as-u-s-federal-circuit-court-of-appeals-invalidates-emed-tech-krmd-20180409monthly0.5https://www.biopharmawatch.com/news/KRMD/rms-medical-products-announces-results-for-three-ten-and-twelve-months-ending-krmd-20180213monthly0.5https://www.biopharmawatch.com/news/KRMD/rms-medical-products-announces-new-fda-clearance-warning-letter-closed-and-organizational--krmd-20171122monthly0.5https://www.biopharmawatch.com/news/KRMD/rms-medical-products-posts-strong-results-for-four-month-period-ending-krmd-20170727monthly0.5https://www.biopharmawatch.com/news/KRMD/rms-medical-products-posts-third-quarter-2017-results-ongoing-growth-in-revenue-both-domes-krmd-20161227monthly0.5https://www.biopharmawatch.com/news/KRMD/rms-medical-products-posts-second-quarter-2017-results-continued-growth-in-core-business-m-krmd-20160923monthly0.5https://www.biopharmawatch.com/news/KRMD/rms-medical-products-posts-first-quarter-2017-results-double-digit-growth-in-revenue-and-a-krmd-20160627monthly0.5https://www.biopharmawatch.com/news/KRMD/repro-med-systems-inc-posts-fourth-quarter-and-fiscal-year-2016-results-and-announces-new--krmd-20160518monthly0.5https://www.biopharmawatch.com/news/KRMD/repro-med-systems-inc-gives-business-update-including-preliminary-revenue-results-for-q4-2-krmd-20160331monthly0.5https://www.biopharmawatch.com/news/KRMD/repro-med-systems-inc-posts-strong-revenue-growth-productivity-gains-and-announces-new-int-krmd-20151223monthly0.5https://www.biopharmawatch.com/news/KRMD/repro-med-systems-inc-repr-announces-strong-results-for-third-quarter-ended-krmd-20141223monthly0.5https://www.biopharmawatch.com/news/KRMD/rms-medical-products-secures-additional-growth-capital-chester-ny-accesswire-krmd-20140811monthly0.5https://www.biopharmawatch.com/news/KRMD/for-further-information-contact-andrew-i-sealfon-president-and-ceo-845-469-2042-rms-announ-krmd-20140612monthly0.5https://www.biopharmawatch.com/news/KRMD/repro-med-announces-board-changes-stock-buy-back-plan-chester-ny-krmd-20131204monthly0.5https://www.biopharmawatch.com/news/KRMD/repro-med-systems-inc-reports-29-9-increase-in-sales-for-fiscal-year-ended-february-29-201-krmd-20120607monthly0.5https://www.biopharmawatch.com/news/KRMD/for-further-information-andrew-i-sealfon-president-rms-medical-products-24-carpenter-road--krmd-20110531monthly0.5https://www.biopharmawatch.com/news/KRMD/repro-med-systems-inc-reports-30-increase-in-revenue-for-fiscal-year-ended-february-28-201-krmd-20110331monthly0.5https://www.biopharmawatch.com/news/KRMD/medicare-clarification-reimbursing-the-freedom60-krmd-20070904monthly0.5https://www.biopharmawatch.com/news/TMCI/treace-medical-concepts-reports-first-quarter-2026-financial-results-ponte-vedra-fla-x2013-tmci-20260508monthly0.5https://www.biopharmawatch.com/news/TMCI/treace-medical-concepts-reports-fourth-quarter-and-full-year-2025-financial-results-ponte--tmci-20260227monthly0.5https://www.biopharmawatch.com/news/TMCI/treace-announces-preliminary-unaudited-fourth-quarter-and-full-year-2025-revenue-tmci-20260113monthly0.5https://www.biopharmawatch.com/news/TMCI/treace-medical-secures-up-to-175-million-in-debt-financing-new-5-year-agreement-provides-c-tmci-20251218monthly0.5https://www.biopharmawatch.com/news/TMCI/treace-medical-concepts-reports-third-quarter-2025-financial-results-ponte-vedra-fla-x2013-tmci-20251106monthly0.5https://www.biopharmawatch.com/news/TMCI/treace-medical-concepts-reports-second-quarter-2025-financial-results-announces-full-marke-tmci-20250807monthly0.5https://www.biopharmawatch.com/news/TMCI/treace-medical-concepts-reports-first-quarter-2025-financial-results-ponte-vedra-fla-x2013-tmci-20250508monthly0.5https://www.biopharmawatch.com/news/TMCI/treace-announces-upcoming-board-chair-transition-tmci-20250407monthly0.5https://www.biopharmawatch.com/news/TMCI/treace-medical-concepts-reports-fourth-quarter-and-full-year-2024-financial-results-ponte--tmci-20250227monthly0.5https://www.biopharmawatch.com/news/TMCI/treace-announces-preliminary-unaudited-fourth-quarter-and-full-year-2024-revenue-tmci-20250113monthly0.5https://www.biopharmawatch.com/news/TMCI/treace-medical-concepts-reports-third-quarter-2024-financial-results-ponte-vedra-fla-x2013-tmci-20241105monthly0.5https://www.biopharmawatch.com/news/TMCI/treace-files-patent-infringement-and-unfair-competition-suit-to-protect-lapiplasty-bunion--tmci-20241014monthly0.5https://www.biopharmawatch.com/news/TMCI/treace-medical-concepts-reports-second-quarter-2024-financial-results-ponte-vedra-fla-x201-tmci-20240806monthly0.5https://www.biopharmawatch.com/news/TMCI/treace-medical-concepts-reports-first-quarter-2024-financial-results-ponte-vedra-fla-x2013-tmci-20240507monthly0.5https://www.biopharmawatch.com/news/TMCI/treace-medical-concepts-reports-fourth-quarter-and-full-year-2023-financial-results-and-pr-tmci-20240227monthly0.5https://www.biopharmawatch.com/news/TMCI/nd-annual-j-p-morgan-healthcare-conference-john-t-treace-ceo-founder-tmci-20240109monthly0.5https://www.biopharmawatch.com/news/TMCI/treace-announces-preliminary-unaudited-fourth-quarter-and-full-year-2023-revenue-company-t-tmci-20240109monthly0.5https://www.biopharmawatch.com/news/TMCI/treace-medical-concepts-reports-third-quarter-2023-financial-results-ponte-vedra-fla-x2013-tmci-20231109monthly0.5https://www.biopharmawatch.com/news/TMCI/treace-medical-concepts-reports-second-quarter-2023-financial-results-ponte-vedra-fla-x201-tmci-20230808monthly0.5https://www.biopharmawatch.com/news/TMCI/june-1-2023-forward-looking-statements-and-other-cautions-this-presentation-may-include-fo-tmci-20230601monthly0.5https://www.biopharmawatch.com/news/TMCI/treace-medical-concepts-reports-first-quarter-2023-financial-results-ponte-vedra-fla-x2013-tmci-20230508monthly0.5https://www.biopharmawatch.com/news/TMCI/treace-medical-concepts-reports-fourth-quarter-and-full-year-2022-financial-results-ponte--tmci-20230307monthly0.5https://www.biopharmawatch.com/news/TMCI/treace-medical-concepts-provides-2022-preliminary-unaudited-revenue-tmci-20230109monthly0.5https://www.biopharmawatch.com/news/TMCI/treace-medical-concepts-reports-third-quarter-2022-financial-results-ponte-vedra-fla-x2013-tmci-20221108monthly0.5https://www.biopharmawatch.com/news/TMCI/treace-medical-concepts-appoints-new-directors-ponte-vedra-fla-x2013-tmci-20220927monthly0.5https://www.biopharmawatch.com/news/TMCI/treace-medical-concepts-reports-second-quarter-2022-financial-results-ponte-vedra-fla-x201-tmci-20220809monthly0.5https://www.biopharmawatch.com/news/TMCI/treace-medical-concepts-reports-first-quarter-2022-financial-results-ponte-vedra-fla-x2013-tmci-20220505monthly0.5https://www.biopharmawatch.com/news/TMCI/treace-secures-up-to-150-million-in-debt-financing-tmci-20220502monthly0.5https://www.biopharmawatch.com/news/TMCI/treace-medical-concepts-reports-fourth-quarter-and-full-year-2021-financial-results-ponte--tmci-20220303monthly0.5https://www.biopharmawatch.com/news/TMCI/treace-medical-concepts-provides-2021-preliminary-sales-results-tmci-20220110monthly0.5https://www.biopharmawatch.com/news/TMCI/treace-medical-concepts-reports-third-quarter-2021-financial-results-tmci-20211104monthly0.5https://www.biopharmawatch.com/news/TMCI/treace-medical-concepts-appoints-new-directors-tmci-20211004monthly0.5https://www.biopharmawatch.com/news/TMCI/treace-medical-concepts-reports-second-quarter-2021-financial-results-tmci-20210805monthly0.5https://www.biopharmawatch.com/news/TMCI/treace-medical-concepts-reports-first-quarter-2021-financial-results-tmci-20210525monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2025-full-year-financial-results-st-louis-mo-stxs-20260309monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2025-second-quarter-financial-results-st-louis-mo-stxs-20250807monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-12-5-million-registered-direct-offering-of-common-stock-led-by-strat-stxs-20250717monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2025-first-quarter-financial-results-st-louis-mo-stxs-20250512monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2024-full-year-financial-results-st-louis-mo-stxs-20250303monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2024-third-quarter-financial-results-st-louis-stxs-20241111monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2024-second-quarter-financial-results-stxs-20240812monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-strengthens-board-of-directors-with-appointment-of-nachum-shamir-st-louis-stxs-20240718monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2024-first-quarter-financial-results-stxs-20240513monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2023-full-year-financial-results-stxs-20240304monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2023-third-quarter-financial-results-stxs-20231109monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2023-second-quarter-financial-results-stxs-20230810monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-to-initiate-first-in-human-trial-to-support-ce-mark-application-of-magic-cathe-stxs-20230615monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2023-first-quarter-financial-results-stxs-20230509monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2022-full-year-financial-results-stxs-20230303monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2022-third-quarter-financial-results-stxs-20221110monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2022-second-quarter-financial-results-stxs-20220809monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2022-first-quarter-financial-results-stxs-20220510monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2021-full-year-financial-results-stxs-20220303monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2021-third-quarter-financial-results-stxs-20211111monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2021-second-quarter-financial-results-stxs-20210810monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-strengthens-board-of-directors-with-appointment-of-myriam-j-curet-m-d-st-louis-stxs-20210726monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2021-first-quarter-financial-results-stxs-20210510monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2020-full-year-financial-results-st-louis-stxs-20210225monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-long-term-ceo-performance-stock-award-st-louis-stxs-20210224monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2020-third-quarter-financial-results-stxs-20201109monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2020-second-quarter-financial-results-st-louis-mo-stxs-20200806monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-15-million-common-stock-financing-stxs-20200526monthly0.5https://www.biopharmawatch.com/news/STXS/separation-agreement-and-release-of-all-claims-this-separation-agreement-and-release-of-al-stxs-20200507monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2020-first-quarter-financial-results-stxs-20200505monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2019-full-year-financial-results-stxs-20200310monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2019-third-quarter-financial-results-stxs-20191114monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-cfo-transition-stxs-20190916monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-inc-balance-sheet-unaudited-actual-and-as-adjusted-june-30-2019-stxs-20190822monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2019-second-quarter-financial-results-stxs-20190808monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-25-million-private-placement-stxs-20190808monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2019-first-quarter-financial-operational-results-stxs-20190509monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2018-full-year-financial-results-record-high-annual-recurring-revenue--stxs-20190312monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2018-third-quarter-financial-results-continued-progress-on-strategic-i-stxs-20181112monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2018-second-quarter-financial-results-progress-on-strategic-internal-i-stxs-20180807monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-and-johnson-johnson-s-biosense-webster-extend-development-alliance-and-supply--stxs-20180625monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-changes-to-its-board-of-directors-stxs-20180604monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2018-first-quarter-financial-results-3-year-over-year-growth-in-recurr-stxs-20180514monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2017-fourth-quarter-and-full-year-financial-results-7-year-over-year-g-stxs-20180306monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-preliminary-fourth-quarter-2017-revenue-results-revenue-of-7-6-million-stxs-20180108monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-third-quarter-2017-financial-results-3-year-over-year-growth-in-recurr-stxs-20171109monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-second-quarter-2017-financial-results-stable-recurring-revenue-and-2-y-stxs-20170810monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2017-first-quarter-financial-results-procedures-stable-with-gain-in-ve-stxs-20170508monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-management-transition-and-2016-financial-results-resignation-of-will-stxs-20170206monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2016-third-quarter-financial-results-completed-24-million-private-plac-stxs-20161107monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-completes-private-placement-of-24-million-stxs-20160929monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-multiple-positive-strategic-updates-24-million-equity-investment-rec-stxs-20160927monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2016-second-quarter-financial-results-ventricular-tachycardia-procedur-stxs-20160809monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-common-stock-to-begin-trading-on-otcqx-on-stxs-20160804monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2016-first-quarter-financial-results-ventricular-tachycardia-procedure-stxs-20160509monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2015-fourth-quarter-and-full-year-financial-results-new-capital-orders-stxs-20160222monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2015-third-quarter-financial-results-total-quarterly-revenue-increased-stxs-20151103monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-results-of-warrants-offering-stxs-20151008monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-extends-warrants-offering-subscription-period-company-ceo-and-cfo-fully-exerci-stxs-20150928monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-ex-warrants-date-of-stxs-20150915monthly0.5https://www.biopharmawatch.com/news/STXS/form-of-instructions-as-to-use-of-stereotaxis-inc-warrants-certificates-consult-the-warran-stxs-20150904monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2015-second-quarter-financial-results-total-revenue-increased-20-over--stxs-20150804monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2015-first-quarter-financial-results-total-revenue-increased-14-over-p-stxs-20150506monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-elects-medical-device-industry-veteran-duane-desisto-to-board-of-directors-stxs-20150504monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-extends-silicon-valley-bank-credit-facility-by-three-years-stxs-20150330monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2014-fourth-quarter-and-full-year-financial-results-achieves-first-qua-stxs-20150225monthly0.5https://www.biopharmawatch.com/news/STXS/fy-2014-q3-earnings-release-conference-call-transcript-stxs-20141105monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2014-third-quarter-financial-results-improves-system-revenue-89-sequen-stxs-20141105monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2014-second-quarter-financial-results-achieves-second-consecutive-quar-stxs-20140804monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-2014-first-quarter-financial-results-records-7-million-in-recurring-re-stxs-20140506monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-results-of-rights-offering-stxs-20131127monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-announces-record-date-for-rights-offering-stxs-20131029monthly0.5https://www.biopharmawatch.com/news/STXS/stereotaxis-reports-second-quarter-2013-financial-results-announces-capital-transactions-a-stxs-20130808monthly0.5https://www.biopharmawatch.com/news/STXS/dan-johnston-chief-financial-officer-314-678-6007-investor-contact-evc-group-inc-doug-sher-stxs-20110505monthly0.5https://www.biopharmawatch.com/news/STXS/dan-johnston-chief-financial-officer-314-678-6007-investor-contact-evc-group-inc-douglas-s-stxs-20110228monthly0.5https://www.biopharmawatch.com/news/STXS/dan-johnston-chief-financial-officer-314-678-6007-investor-contact-evc-group-inc-doug-sher-stxs-20110222monthly0.5https://www.biopharmawatch.com/news/STXS/dan-johnston-chief-financial-officer-314-678-6007-investor-contact-evc-group-inc-doug-sher-stxs-20110105monthly0.5https://www.biopharmawatch.com/news/STXS/dan-johnston-chief-financial-officer-314-678-6007-investor-contact-evc-group-inc-doug-sher-stxs-20101110monthly0.5https://www.biopharmawatch.com/news/IFRX/this-is-a-translation-into-english-of-the-deed-of-amendment-to-the-articles-of-association-ifrx-20260423monthly0.5https://www.biopharmawatch.com/news/IFRX/convening-notice-this-is-the-convening-notice-for-the-2026-annual-general-meeting-of-share-ifrx-20260402monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-reports-full-year-2025-results-and-highlights-key-achievements-and-expected-milest-ifrx-20260319monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirem-ifrx-20260313monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-strategy-focused-on-capital-efficient-execution-with-izicopan-and-near-t-ifrx-20260108monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-unaudited-condensed-consolidated-financial-statements-september-30-2025-these--ifrx-20251110monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-unaudited-condensed-consolidated-financial-statements-june-30-2025-these-unaud-ifrx-20250807monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-unaudited-condensed-consolidated-financial-statements-march-31-2025-these-unau-ifrx-20250507monthly0.5https://www.biopharmawatch.com/news/IFRX/this-is-a-translation-into-english-of-the-deed-of-amendment-to-the-articles-of-association-ifrx-20250424monthly0.5https://www.biopharmawatch.com/news/IFRX/convening-notice-this-is-the-convening-notice-for-the-2025-annual-general-meeting-of-share-ifrx-20250403monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-reports-full-year-2024-results-and-highlights-key-achievements-and-expected-milest-ifrx-20250320monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-receives-european-commission-approval-for-gohibic-vilobelimab-for-the-treatment-of-ifrx-20250115monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-first-patient-dosed-in-phase-2a-study-for-oral-c5ar-inhibitor-inf904-jen-ifrx-20241220monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-receives-positive-chmp-opinion-for-gohibic-vilobelimab-for-the-treatment-of-sars-c-ifrx-20241115monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-unaudited-condensed-consolidated-financial-statements-september-30-2024-these--ifrx-20241108monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-unaudited-condensed-consolidated-financial-statements-ifrx-20240808monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-ordinary-shares-nominal-value-0-12-per-share-ifrx-20240628monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-s-gohibic-vilobelimab-selected-for-first-barda-sponsored-clinical-trial-to-evaluat-ifrx-20240624monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-hosts-r-d-event-highlighting-the-promise-of-inf904-thought-leaders-in-complement-i-ifrx-20240605monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-presents-new-analysis-of-panamo-phase-iii-trial-in-severe-covid-19-at-ats-2024-sho-ifrx-20240521monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-unaudited-condensed-consolidated-financial-statements-ifrx-20240508monthly0.5https://www.biopharmawatch.com/news/IFRX/this-is-a-translation-into-english-of-the-deed-of-amendment-to-the-articles-of-association-ifrx-20240425monthly0.5https://www.biopharmawatch.com/news/IFRX/convening-notice-this-is-the-convening-notice-for-the-2024-annual-general-meeting-of-share-ifrx-20240404monthly0.5https://www.biopharmawatch.com/news/IFRX/corporate-presentation-march-2024-important-notice-and-disclaimer-this-presentation-has-be-ifrx-20240321monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-reports-full-year-2023-results-and-announces-inf904-development-plans-inflarx-will-ifrx-20240321monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-initiation-of-its-commitment-program-for-gohibic-vilobelimab-to-help-bro-ifrx-20240125monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-positive-topline-results-from-the-multiple-ascending-dose-mad-phase-i-st-ifrx-20240104monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-first-patient-dosed-in-phase-iii-trial-with-vilobelimab-in-pyoderma-gang-ifrx-20231106monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-unaudited-condensed-consolidated-financial-statements-september-30-2023-these--ifrx-20231101monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-positive-topline-results-from-the-single-ascending-dose-sad-phase-i-stud-ifrx-20230911monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-s-marketing-authorization-application-maa-for-vilobelimab-for-treatment-of-critica-ifrx-20230830monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-unaudited-condensed-consolidated-financial-statements-ifrx-20230810monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-appoints-dr-camilla-chong-as-chief-medical-officer-camilla-chong-m-d-joins-the-tea-ifrx-20230628monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-commercial-launch-of-gohibic-vilobelimab-in-the-u-s-for-the-treatment-of-ifrx-20230621monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-unaudited-condensed-consolidated-financial-statements-march-31-2023-these-unau-ifrx-20230511monthly0.5https://www.biopharmawatch.com/news/IFRX/convening-notice-this-is-the-convening-notice-for-the-2023-annual-general-meeting-of-share-ifrx-20230405monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-receives-fda-emergency-use-authorization-for-gohibic-vilobelimab-for-treatment-of--ifrx-20230404monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-reports-full-year-2022-financial-and-operating-results-major-progress-in-developme-ifrx-20230322monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-provides-update-on-planned-phase-iii-study-design-in-pyoderma-gangrenosum-with-vil-ifrx-20230105monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-amendment-of-co-development-agreement-and-additional-equity-investment-b-ifrx-20221221monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-initiates-first-in-human-study-with-small-molecule-c5ar-inhibitor-inf904-randomize-ifrx-20221109monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-unaudited-condensed-consolidated-financial-statements-september-30-2022-these--ifrx-20221109monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-submits-request-for-emergency-use-authorization-to-us-fda-for-vilobelimab-for-trea-ifrx-20220929monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-vilobelimab-phase-iii-results-in-critically-ill-covid-19-patients-publis-ifrx-20220908monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-unaudited-condensed-consolidated-financial-statements-june-30-2022-these-unaud-ifrx-20220805monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-plans-to-apply-for-emergency-use-authorization-from-the-us-fda-for-vilob-ifrx-20220726monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-receives-fda-fast-track-designation-for-treatment-of-ulcerative-pyoderma-gangrenos-ifrx-20220706monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-provides-development-update-for-vilobelimab-in-pyoderma-gangrenosum-and-severe-cov-ifrx-20220629monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-unaudited-condensed-consolidated-financial-statements-march-31-2022-these-unau-ifrx-20220512monthly0.5https://www.biopharmawatch.com/news/IFRX/convening-notice-this-is-the-convening-notice-for-the-2022-annual-general-meeting-of-share-ifrx-20220407monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-encouraging-phase-iii-topline-results-from-panamo-trial-of-vilobelimab-i-ifrx-20220331monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-reports-full-year-2021-financial-and-operating-results-company-received-corrected--ifrx-20220324monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-receives-corrected-advice-letter-from-fda-related-to-phase-iii-program-for-vilobel-ifrx-20220317monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-vilobelimab-trial-in-pyoderma-gangrenosum-selected-for-late-breaker-oral-ifrx-20220308monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-provides-update-on-development-plans-for-vilobelimab-in-hidradenitis-suppurativa-j-ifrx-20220228monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-reports-progress-in-ongoing-phase-ii-clinical-trial-with-vilobelimab-in-cutaneous--ifrx-20220216monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-new-pipeline-program-oral-c5ar-inhibitor-regulatory-discussions-on-phase-ifrx-20220110monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-initiates-phase-iii-clinical-program-with-vilobelimab-in-hidradenitis-suppurativa--ifrx-20220105monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-positive-data-from-phase-ii-ixchange-study-with-vilobelimab-in-anca-asso-ifrx-20211115monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-unaudited-interim-condensed-consolidated-financial-statements-september-30-202-ifrx-20211105monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-positive-data-from-third-cohort-of-phase-iia-open-label-study-with-vilob-ifrx-20211027monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-awarded-up-to-eur-43-7-million-usd-50-7-million-grant-by-german-government-to-adva-ifrx-20211019monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-completes-enrollment-of-vilobelimab-phase-iii-study-in-severe-covid-19-study-has-e-ifrx-20211012monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-to-proceed-with-pivotal-development-for-vilobelimab-in-hidradenitis-suppurativa-wi-ifrx-20210908monthly0.5https://www.biopharmawatch.com/news/IFRX/this-is-a-translation-into-english-of-the-deed-of-amendment-to-the-articles-of-association-ifrx-20210826monthly0.5https://www.biopharmawatch.com/news/IFRX/convening-notice-this-is-the-convening-notice-for-the-extraordinary-general-meeting-of-sha-ifrx-20210810monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-positive-data-from-second-interim-analysis-of-ongoing-phase-iia-open-lab-ifrx-20210810monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-unaudited-condensed-consolidated-financial-statements-june-30-2021-these-unaud-ifrx-20210805monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-doses-first-patient-in-multicenter-phase-ii-clinical-trial-in-cutaneous-squamous-c-ifrx-20210608monthly0.5https://www.biopharmawatch.com/news/IFRX/tony-gibney-joins-inflarx-board-of-directors-jena-germany-ifrx-20210521monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-unaudited-condensed-consolidated-financial-statements-march-31-2021-these-unau-ifrx-20210512monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-positive-topline-results-for-vilobelimab-from-the-u-s-phase-ii-anca-asso-ifrx-20210511monthly0.5https://www.biopharmawatch.com/news/IFRX/convening-notice-this-is-the-convening-notice-for-the-2021-annual-general-meeting-of-share-ifrx-20210503monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-completes-enrollment-of-vilobelimab-phase-iia-study-in-pyoderma-gangraenosum-targe-ifrx-20210415monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-reports-full-year-2020-financial-operating-results-submitted-a-special-protocol-as-ifrx-20210325monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-15-000-000-common-shares-warrants-to-purchase-up-to-15-000-000-common-shares-u-ifrx-20210225monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-provides-update-on-vilobelimab-ifx-1-development-multiple-data-readouts-expected-i-ifrx-20210111monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-completes-enrollment-in-vilobelimab-ifx-1-european-phase-ii-study-in-anca-associat-ifrx-20210105monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-unaudited-condensed-consolidated-financial-statements-september-30-2020-these--ifrx-20201029monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-leadership-team-additions-with-new-cfo-and-newly-created-position-of-chi-ifrx-20200917monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-initiation-of-phase-iii-part-of-phase-ii-iii-clinical-trial-with-ifx-1-i-ifrx-20200914monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-to-present-at-upcoming-virtual-investor-events-jena-germany-ifrx-20200806monthly0.5https://www.biopharmawatch.com/news/IFRX/announces-decision-to-enter-phase-iii-development-of-ifx-1-in-severe-covid-19-induced-pneu-ifrx-20200721monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-common-shares-nominal-value-0-12-per-share-ifrx-20200720monthly0.5https://www.biopharmawatch.com/news/IFRX/convening-notice-this-is-the-convening-notice-for-the-2020-annual-general-meeting-of-share-ifrx-20200630monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-reports-encouraging-topline-results-from-the-exploratory-phase-ii-part-of-the-adap-ifrx-20200617monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-unaudited-condensed-consolidated-financial-statements-march-31-2020-these-unau-ifrx-20200521monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-reports-full-year-2019-financial-operating-results-end-of-phase-2-fda-meeting-sche-ifrx-20200429monthly0.5https://www.biopharmawatch.com/news/IFRX/controlling-inflammation-lifesci-capital-alpha-series-conference-2020-important-notice-and-ifrx-20200409monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-doses-first-patient-in-multicenter-randomized-clinical-trial-in-severe-progressed--ifrx-20200331monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-positive-initial-data-from-ongoing-phase-iia-open-label-study-with-ifx-1-ifrx-20200226monthly0.5https://www.biopharmawatch.com/news/IFRX/controlling-inflammation-jp-morgan-corporate-presentation-january-2020-important-notice-an-ifrx-20200116monthly0.5https://www.biopharmawatch.com/news/IFRX/ifx-1-c5a-controlling-inflammation-developing-the-first-in-class-anti-c5a-antibody-ifx-1-l-ifrx-20191114monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-unaudited-condensed-consolidated-financial-statements-september-30-2019-these--ifrx-20191107monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-unaudited-condensed-consolidated-financial-statements-june-30-2019-these-unaud-ifrx-20190814monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-reports-additional-analysis-of-the-shine-phase-iib-results-for-ifx-1-in-hidradenit-ifrx-20190719monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-treats-first-patient-in-phase-iia-clinical-trial-with-lead-candidate-ifx-1-in-pyod-ifrx-20190613monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-top-line-shine-phase-iib-results-for-ifx-1-in-hidradenitis-suppurativa-i-ifrx-20190605monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-unaudited-condensed-consolidated-financial-statements-march-31-2019-these-unau-ifrx-20190523monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-commences-second-phase-ii-clinical-trial-of-ifx-1-in-anca-associated-vasculitis-wi-ifrx-20190514monthly0.5https://www.biopharmawatch.com/news/IFRX/ifx-1-c5a-controlling-inflammation-corporate-presentation-may-2019-important-notice-and-di-ifrx-20190501monthly0.5https://www.biopharmawatch.com/news/IFRX/convening-notice-this-is-the-convening-notice-for-the-2019-annual-general-meeting-of-share-ifrx-20190503monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-full-year-2018-financial-operating-results-62-9-million-53-0-million-raised-in-a-f-ifrx-20190328monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-receives-approval-to-initiate-phase-iia-clinical-trial-with-lead-candidate-ifx-1-i-ifrx-20190227monthly0.5https://www.biopharmawatch.com/news/IFRX/richard-brudnick-to-join-inflarx-board-of-directors-jena-germany-ifrx-20190214monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-presentation-of-new-clinical-data-with-lead-candidate-ifx-1-in-hidradeni-ifrx-20190206monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-continues-u-s-expansion-with-addition-of-new-york-city-corporate-office-and-additi-ifrx-20190103monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-receives-european-approval-to-initiate-phase-ii-clinical-trial-with-ifx-1-in-anca--ifrx-20181219monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-amsterdam-condensed-consolidated-interim-financial-statements-inflarx-n-v-and--ifrx-20181121monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-completes-enrollment-in-phase-iib-clinical-trial-with-lead-candidate-ifx-1-in-hidr-ifrx-20181108monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-initiates-phase-ii-clinical-trial-with-ifx-1-in-anca-associated-vasculitis-with-fi-ifrx-20181030monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-announces-appointment-of-jens-holstein-to-board-of-directors-jena-germany-ifrx-20180921monthly0.5https://www.biopharmawatch.com/news/IFRX/convening-notice-this-is-the-convening-notice-for-the-extraordinary-general-meeting-of-sha-ifrx-20180822monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-amsterdam-condensed-consolidated-interim-financial-statements-inflarx-n-v-and--ifrx-20180809monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-receives-ind-approval-from-the-fda-to-start-its-phase-ii-clinical-trial-of-ifx-1-i-ifrx-20180628monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-opens-new-research-facility-in-ann-arbor-r-d-activities-will-focus-on-proprietary--ifrx-20180605monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-n-v-amsterdam-unaudited-condensed-consolidated-financial-statements-inflarx-n-v-an-ifrx-20180517monthly0.5https://www.biopharmawatch.com/news/IFRX/convening-notice-this-is-the-convening-notice-for-the-annual-general-meeting-of-shareholde-ifrx-20180504monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-full-year-2017-financial-operating-results-ifx-1-positive-phase-iia-data-in-hidrad-ifrx-20180329monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-first-patient-enrolled-in-phase-iib-trial-with-lead-candidate-ifx-1-in-h-ifrx-20180308monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-announces-appointment-of-tony-gibney-to-inflarx-s-board-jena-germany-ifrx-20180206monthly0.5https://www.biopharmawatch.com/news/IFRX/convening-notice-this-is-the-convening-notice-for-the-extraordinary-general-meeting-of-sha-ifrx-20180122monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-receives-ind-acceptance-to-proceed-with-a-phase-iib-trial-with-lead-candidate-ifx--ifrx-20180109monthly0.5https://www.biopharmawatch.com/news/IFRX/inflarx-gmbh-index-to-unaudited-interim-condensed-consolidated-financial-statements-unaudi-ifrx-20171221monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-reports-fourth-quarter-and-fiscal-year-2025-financial-results-and-pr-dtil-20260312monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-reports-third-quarter-2025-financial-results-and-provides-business-u-dtil-20251103monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-reports-second-quarter-2025-financial-results-and-provides-business--dtil-20250807monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-announces-phase-1-safety-and-efficacy-for-cohort-1-lowest-dose-level-dtil-20250806monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-reports-first-quarter-2025-financial-results-and-provides-business-u-dtil-20250515monthly0.5https://www.biopharmawatch.com/news/DTIL/all-forward-looking-statements-speak-only-as-of-the-date-of-this-press-release-and-except--dtil-20250514monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-reports-fourth-quarter-and-fiscal-year-2024-financial-results-and-pr-dtil-20250326monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-reports-third-quarter-2024-financial-results-and-provides-business-u-dtil-20241104monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-receives-first-approval-of-clinical-trial-application-to-initiate-pb-dtil-20241024monthly0.5https://www.biopharmawatch.com/news/DTIL/ownership-of-our-common-stock-including-fluctuations-in-our-stock-price-our-ability-to-mee-dtil-20240912monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-receives-13-million-in-proceeds-from-imugene-convertible-note-maturi-dtil-20240903monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-reports-second-quarter-2024-financial-results-and-provides-business--dtil-20240801monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-reports-first-quarter-2024-financial-results-and-provides-business-u-dtil-20240513monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-announces-return-of-programs-and-conclusion-of-collaboration-with-pr-dtil-20240416monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-reports-fourth-quarter-and-fiscal-year-2023-financial-results-and-pr-dtil-20240327monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-announces-40-0-million-offering-of-common-stock-and-warrants-durham--dtil-20240301monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-completes-license-deal-with-tg-therapeutics-for-cell-therapy-azer-ce-dtil-20240109monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-reports-third-quarter-2023-financial-results-and-provides-business-u-dtil-20231107monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-hosts-virtual-r-d-day-highlighting-its-proprietary-arcus-technology--dtil-20230912monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-completes-strategic-transaction-with-imugene-for-azer-cel-in-cancer--dtil-20230815monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-reports-second-quarter-2023-financial-results-and-provides-business--dtil-20230804monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-provides-update-on-allogeneic-car-t-programs-and-regulatory-path-for-dtil-20230531monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-reports-first-quarter-2023-financial-results-and-provides-business-u-dtil-20230509monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-announces-late-breaking-abstract-of-preclinical-in-vivo-gene-editing-dtil-20230418monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-reports-fourth-quarter-and-fiscal-year-2022-financial-results-and-pr-dtil-20230309monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-announces-senior-leadership-promotions-and-organizational-changes-ne-dtil-20230224monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-recaps-2022-accomplishments-and-outlines-2023-corporate-priorities-a-dtil-20230109monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-announces-change-to-its-board-of-directors-raymond-f-schinazi-ph-d-t-dtil-20221110monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-reports-third-quarter-2022-financial-results-and-provides-business-u-dtil-20221108monthly0.5https://www.biopharmawatch.com/news/DTIL/those-expenses-will-be-precision-s-limited-operating-history-the-success-of-its-programs-a-dtil-20220902monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-reports-second-quarter-2022-financial-results-and-provides-business--dtil-20220808monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-announces-50-million-offering-of-common-stock-durham-n-c-dtil-20220621monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-announces-in-vivo-gene-editing-collaboration-with-novartis-to-develo-dtil-20220622monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-provides-update-on-allogeneic-car-t-programs-and-path-forward-with-i-dtil-20220608monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-appoints-melinda-brown-to-board-of-directors-new-director-brings-pro-dtil-20220531monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-reports-first-quarter-2022-financial-results-and-provides-business-u-dtil-20220509monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-reports-fourth-quarter-and-fiscal-year-2021-financial-results-and-pr-dtil-20220315monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-to-present-at-the-40-th-annual-j-p-morgan-health-care-conference-dur-dtil-20220104monthly0.5https://www.biopharmawatch.com/news/DTIL/greenhouse-studies-and-clinical-or-field-trials-public-perception-about-genome-editing-tec-dtil-20211221monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-reports-third-quarter-2021-financial-results-and-provides-business-u-dtil-20211110monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-appoints-sam-wadsworth-ph-d-and-shari-lisa-pir-j-d-to-board-of-direc-dtil-20211108monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-to-present-at-the-jefferies-virtual-gene-therapy-editing-summit-on-t-dtil-20211021monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-appoints-michael-amoroso-chief-executive-officer-durham-n-c-dtil-20210927monthly0.5https://www.biopharmawatch.com/news/DTIL/investor-contact-alex-kelly-chief-financial-officer-alex-kelly-precisionbiosciences-com-me-dtil-20210909monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-reports-second-quarter-2021-financial-results-and-provides-business--dtil-20210812monthly0.5https://www.biopharmawatch.com/news/DTIL/certain-information-marked-as-has-been-excluded-from-this-exhibit-because-it-is-both-not-m-dtil-20210702monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-reports-progress-on-two-strategies-designed-to-optimize-durability-o-dtil-20210604monthly0.5https://www.biopharmawatch.com/news/DTIL/senior-director-corporate-communications-maurissa-messier-precisionbiosciences-com-dtil-20210527monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-reports-first-quarter-and-2021-financial-results-and-provides-busine-dtil-20210513monthly0.5https://www.biopharmawatch.com/news/DTIL/public-perception-about-genome-editing-technology-and-its-applications-competition-in-the--dtil-20210415monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-reacquires-global-rights-to-its-allogeneic-car-t-programs-precision--dtil-20210415monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-reports-fourth-quarter-and-fiscal-year-2020-financial-results-and-pr-dtil-20210318monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-announces-3-year-pre-clinical-study-results-showing-long-term-durability-and-saf-dtil-20210219monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-receives-notice-of-allowance-for-u-s-patent-application-covering-pbc-dtil-20210125monthly0.5https://www.biopharmawatch.com/news/DTIL/all-forward-looking-statements-speak-only-as-of-the-date-of-this-press-release-and-except--dtil-20210107monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-announces-executive-leadership-change-durham-n-c-dtil-20201214monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-reports-positive-interim-results-from-pbcar0191-phase-1-2a-trial-in--dtil-20201204monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-reports-third-quarter-2020-financial-results-and-provides-business-u-dtil-20201110monthly0.5https://www.biopharmawatch.com/news/DTIL/conditions-or-circumstances-on-which-any-such-statements-may-be-based-or-that-may-affect-t-dtil-20200921monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-and-servier-expand-car-t-oncology-development-collaboration-with-fou-dtil-20200917monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-reports-second-quarter-2020-financial-results-and-provides-business--dtil-20200813monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-regains-rights-to-in-vivo-hepatitis-b-virus-program-durham-n-c-dtil-20200706monthly0.5https://www.biopharmawatch.com/news/DTIL/this-presentation-together-with-any-other-statements-or-information-that-we-may-make-in-co-dtil-20200602monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-reports-first-quarter-2020-financial-results-and-provides-business-u-dtil-20200515monthly0.5https://www.biopharmawatch.com/news/DTIL/this-presentation-together-with-any-other-statements-or-information-that-we-may-make-in-co-dtil-20200312monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-strengthens-board-of-directors-with-appointment-of-geno-germano-durh-dtil-20200311monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-reports-fourth-quarter-and-fiscal-year-2019-financial-results-and-pr-dtil-20200310monthly0.5https://www.biopharmawatch.com/news/DTIL/dtil-ex991-6-pptx-htm-38th-annual-j-p-morgan-healthcare-conference-dtil-20200115monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-welcomes-healthcare-industry-expert-kevin-j-buehler-to-its-board-of--dtil-20191113monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-reports-third-quarter-2019-financial-results-and-highlights-ongoing--dtil-20191112monthly0.5https://www.biopharmawatch.com/news/DTIL/dedicated-to-improving-life-overcome-cancer-cure-genetic-disease-feed-the-planet-deliverin-dtil-20191112monthly0.5https://www.biopharmawatch.com/news/DTIL/dedicated-to-improving-life-overcome-cancer-cure-genetic-disease-feed-the-planet-deliverin-dtil-20191002monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-appoints-david-thomson-phd-as-chief-operating-officer-durham-n-c-dtil-20190923monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-reports-second-quarter-2019-financial-results-and-highlights-ongoing-dtil-20190814monthly0.5https://www.biopharmawatch.com/news/DTIL/this-presentation-together-with-any-other-statements-or-information-that-we-may-make-in-co-dtil-20190607monthly0.5https://www.biopharmawatch.com/news/DTIL/precision-biosciences-reports-first-quarter-2019-financial-results-durham-north-carolina-dtil-20190429monthly0.5https://www.biopharmawatch.com/news/OGI/to-and-incorporated-by-reference-into-the-company-s-annual-report-on-form-40-f-for-the-fis-ogi-20260309monthly0.5https://www.biopharmawatch.com/news/OGI/document-dated-ogi-20260218monthly0.5https://www.biopharmawatch.com/news/OGI/pressreleased-organigram-to-report-fourth-quarter-fiscal-2025-results-on-ogi-20251205monthly0.5https://www.biopharmawatch.com/news/OGI/materialchang-form-51-102f3-material-change-report-item-1-name-and-address-of-company-orga-ogi-20251125monthly0.5https://www.biopharmawatch.com/news/OGI/document-organigram-unveils-bold-new-brand-identity-reflecting-market-leadership-position--ogi-20250326monthly0.5https://www.biopharmawatch.com/news/OGI/document-organigram-announces-results-of-annual-and-special-meeting-including-shareholder--ogi-20250324monthly0.5https://www.biopharmawatch.com/news/OGI/to-and-incorporated-by-reference-into-the-company-s-annual-report-on-form-40-f-for-the-fis-ogi-20250303monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-organigram-closes-third-tranche-of-previously-announced-bat-priv-ogi-20250303monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-1-name-and-address-of--ogi-20241206monthly0.5https://www.biopharmawatch.com/news/OGI/document-notice-of-change-of-auditor-national-instrument-51-102-to-kpmg-llp-and-to-ontario-ogi-20240416monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-one-name-and-address-o-ogi-20240402monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-execution-version-certain-portions-of-this-exhibit-have-been-red-ogi-20240402monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-organigram-successfully-closes-previously-announced-underwritten-ogi-20240402monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-certain-portions-of-this-exhibit-have-been-redacted-as-they-are--ogi-20240327monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-organigram-announces-pricing-of-overnight-marketed-public-offeri-ogi-20240327monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-organigram-announces-launch-of-overnight-marketed-public-offerin-ogi-20240326monthly0.5https://www.biopharmawatch.com/news/OGI/document-form-52-109f2-certification-of-interim-filings-full-certificate-i-beena-goldenber-ogi-20240213monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-to-report-first-quarter-fiscal-2024-results-on-ogi-20240207monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-completes-first-shipment-to-germany-extending-its-international-reach-toronto-b-ogi-20240131monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-amended-and-restated-investor-rights-agreement-between-bt-de-inv-ogi-20240123monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-announces-the-first-tranche-closing-from-bat-investment-toronto-business-wire-ogi-20240124monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-announces-appointment-of-karina-gehring-to-board-of-directors-toronto-business--ogi-20240119monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-announces-results-of-annual-and-special-meeting-including-shareholder-approval--ogi-20240118monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-announces-mailing-of-management-information-circular-in-connection-with-annual--ogi-20231229monthly0.5https://www.biopharmawatch.com/news/OGI/notice-of-annual-general-and-special-meeting-of-shareholders-to-be-held-on-ogi-20231227monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-announces-appointment-of-greg-guyatt-as-chief-financial-officer-toronto-busines-ogi-20231218monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-to-report-fourth-quarter-and-fiscal-2023-results-on-ogi-20231214monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-wins-kind-magazine-s-innovation-of-the-year-for-shred-x-rip-strips-hash-organig-ogi-20231213monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-increases-investment-in-phylos-after-successful-milestone-achievement-organigra-ogi-20231128monthly0.5https://www.biopharmawatch.com/news/OGI/form-51-102f3-material-change-report-item-one-name-and-address-of-company-organigram-holdi-ogi-20231105monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-announces-interim-chief-financial-officer-toronto-business-wire-ogi-20231110monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-subscription-agreement-between-bt-de-investments-inc-and-ogi-20231105monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-announces-c-124-6-million-investment-from-bat-and-creation-of-jupiter-strategic-ogi-20231106monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-provides-corporate-update-achieves-2-market-share-over-the-last-two-months-toro-ogi-20231018monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-holdings-inc-files-final-base-shelf-prospectus-toronto-business-wire-ogi-20231011monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-holdings-inc-files-preliminary-base-shelf-prospectus-toronto-business-wire-ogi-20230925monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-announces-resignation-of-board-member-toronto-business-wire-ogi-20230901monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-launches-first-range-of-thcv-products-derived-from-moncton-grown-whole-flower-f-ogi-20230828monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-relaunches-one-of-canada-s-first-cannabis-brands-trailblazer-trailblazer-return-ogi-20230821monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-to-enter-the-united-kingdom-with-agreement-to-supply-medical-cannabis-to-4c-lab-ogi-20230815monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-s-application-for-judicial-review-on-jolts-ingestible-extract-granted-toronto-b-ogi-20230810monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-launches-new-tube-style-pre-rolls-shred-dartz-and-holy-smokes-both-shred-dartz--ogi-20230802monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-to-report-third-quarter-fiscal-2023-results-on-ogi-20230713monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-organigram-announces-completion-of-share-consolidation-toronto-b-ogi-20230705monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-introduces-ultra-high-thc-infused-pre-rolls-shred-x-heavies-shred-x-heavies-is--ogi-20230621monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-announces-effective-date-of-share-consolidation-toronto-business-wire-ogi-20230619monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-makes-first-strategic-u-s-investment-in-phylos-bioscience-to-commercialize-thcv-ogi-20230525monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-to-enter-german-market-supplying-sanity-group-organigram-to-supply-the-medical--ogi-20230523monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-announces-achievement-of-earnout-by-the-edibles-and-infusions-corporation-toron-ogi-20230519monthly0.5https://www.biopharmawatch.com/news/OGI/notice-of-change-in-year-end-pursuant-to-section-4-8-of-national-instrument-51-102-organig-ogi-20230515monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-to-report-second-quarter-fiscal-2023-results-on-ogi-20230404monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-accelerates-focus-on-vapes-with-strategic-investment-in-greentank-organigram-s--ogi-20230331monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-announces-director-appointment-toronto-business-wire-ogi-20230321monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-provides-edison-jolts-product-update-toronto-business-wire-ogi-20230313monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-holdings-inc-announces-election-of-directors-toronto-ontario-business-wire-ogi-20230228monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-revolutionizes-hash-with-shred-x-rip-strip-hash-shred-aims-to-introduce-hash-to-ogi-20230227monthly0.5https://www.biopharmawatch.com/news/OGI/notice-of-annual-general-and-special-meeting-of-shareholders-to-be-held-on-ogi-20230127monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-provides-nasdaq-listing-update-toronto-business-wire-ogi-20230126monthly0.5https://www.biopharmawatch.com/news/OGI/certification-form-52-109f2-certification-of-interim-filings-full-certificate-i-beena-gold-ogi-20230112monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-to-report-first-quarter-fiscal-2023-results-on-ogi-20230105monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-ogi-20221219monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-wins-kind-magazine-s-cannabis-company-of-the-year-award-and-most-innovative-pro-ogi-20221208monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-launches-holy-mountain-to-further-support-its-strong-position-in-the-dried-flow-ogi-20221123monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-to-report-annual-fiscal-2022-results-on-ogi-20221118monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-and-intercure-dba-canndoc-sign-new-international-strategic-agreement-representi-ogi-20221117monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-introduction-this-management-s-discussion-and-analysis-dated-ogi-20220713monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-to-report-third-quarter-2022-results-on-ogi-20220714monthly0.5https://www.biopharmawatch.com/news/OGI/proposed-settlement-reached-in-2016-class-action-toronto-business-wire-ogi-20220623monthly0.5https://www.biopharmawatch.com/news/OGI/certification-form-52-109f2-certification-of-interim-filings-full-certificate-i-beena-gold-ogi-20220412monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-to-report-second-quarter-2022-results-on-ogi-20220401monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-provides-corporate-update-and-announces-new-product-launches-toronto-business-w-ogi-20220324monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-joins-the-pledge-1-movement-launches-its-social-impact-strategy-organigram-oper-ogi-20220317monthly0.5https://www.biopharmawatch.com/news/OGI/bat-exercises-top-up-rights-to-invest-6-3-million-resulting-in-an-increase-in-equity-posit-ogi-20220228monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-holdings-inc-announces-election-of-directors-bat-s-simon-ashton-appointed-to-th-ogi-20220223monthly0.5https://www.biopharmawatch.com/news/OGI/notice-of-annual-general-meeting-of-shareholders-to-be-held-on-ogi-20220202monthly0.5https://www.biopharmawatch.com/news/OGI/certification-form-52-109f2-certification-of-interim-filings-full-certificate-i-beena-gold-ogi-20220111monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-to-report-first-quarter-fiscal-2022-results-on-ogi-20220105monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-one-name-and-address-o-ogi-20211221monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-makes-additional-2-5-million-investment-in-hyasynth-biologicals-a-leading-canna-ogi-20211222monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-acquires-quebec-based-laurentian-organic-inc-in-accretive-transaction-leading-p-ogi-20211221monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-launches-new-wellness-brand-monjour-monjour-s-cbd-forward-product-assortment-is-ogi-20211118monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-to-report-fourth-quarter-and-full-year-fiscal-2021-results-on-ogi-20211115monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-provides-corporate-update-moncton-new-brunswick-business-wire-ogi-20211101monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-holdings-inc-files-final-base-shelf-prospectus-moncton-new-brunswick-business-w-ogi-20210831monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-extends-popular-shred-product-portfolio-with-high-quality-value-priced-shred-em-ogi-20210825monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-launches-edison-jolts-reinvents-the-ingestible-extract-a-first-to-market-produc-ogi-20210817monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-one-name-and-address-o-ogi-20210804monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-appoints-beena-goldenberg-as-chief-executive-officer-moncton-new-brunswick-busi-ogi-20210804monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-launches-cannabis-innovators-panel-panel-supports-company-s-ongoing-commitment--ogi-20210715monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-introduction-this-management-s-discussion-and-analysis-dated-ogi-20210712monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-to-report-third-quarter-fiscal-2021-results-on-ogi-20210706monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-organigram-holdings-inc-files-preliminary-base-shelf-prospectus--ogi-20210624monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-recruits-for-as-many-as-75-roles-based-in-moncton-new-brunswick-company-hiring--ogi-20210603monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-appoints-senior-vice-president-of-marketing-moncton-new-brunswick-business-wire-ogi-20210531monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-launches-big-bag-o-buds-indoor-grown-strain-specific-dried-flower-in-28g-value--ogi-20210518monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-appoints-vice-president-of-innovation-moncton-new-brunswick-business-wire-ogi-20210510monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-one-name-and-address-o-ogi-20210430monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-ceo-steps-away-from-role-will-continue-to-act-as-a-special-advisor-to-the-board-ogi-20210503monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-expands-edison-cannabis-co-dried-flower-portfolio-with-two-new-high-thc-strains-ogi-20210422monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-one-name-and-address-o-ogi-20210406monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-introduction-this-management-s-discussion-and-analysis-dated-ogi-20210411monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-acquires-soft-chew-manufacturer-edibles-infusions-corporation-a-cannabis-proces-ogi-20210406monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-to-report-second-quarter-fiscal-2021-results-on-ogi-20210406monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-repays-credit-facilities-with-bank-of-montreal-in-discussions-for-new-revolving-ogi-20210401monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-launches-indi-an-indica-only-brand-and-three-new-edison-indica-pre-rolls-black--ogi-20210330monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-one-name-and-address-o-ogi-20210310monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-and-bat-form-product-development-collaboration-includes-strategic-investment-fr-ogi-20210311monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-launches-shred-tropic-thunder-jar-of-j-s-jar-of-joints-and-trailblazer-snax-mil-ogi-20210302monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-organigram-holdings-inc-announces-election-of-directors-moncton--ogi-20210223monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-announces-executive-changes-moncton-new-brunswick-business-wire-ogi-20210202monthly0.5https://www.biopharmawatch.com/news/OGI/notice-of-annual-general-meeting-of-shareholders-to-be-held-on-ogi-20210201monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-introduction-this-management-s-discussion-and-analysis-dated-ogi-20210110monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-appoints-marni-wieshofer-to-the-board-of-directors-california-based-former-chie-ogi-20210111monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-to-report-first-quarter-fiscal-2021-results-on-ogi-20210105monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-ogi-20201221monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-expands-edison-portfolio-with-three-new-indica-genetics-black-cherry-punch-ice--ogi-20201222monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-notice-of-change-of-auditor-national-instrument-51-102-to-deloit-ogi-20201214monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-launches-new-1g-trailblazer-torch-vape-cartridges-trailblazer-spark-flicker-and-ogi-20201216monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-one-name-and-address-o-ogi-20201127monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-reports-fourth-quarter-2020-results-q4-2020-net-revenue-increased-25-to-20-4-mi-ogi-20201130monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-to-report-fourth-quarter-and-full-year-fiscal-2020-results-on-ogi-20201125monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-launches-edison-re-mix-rapid-dissolvable-cannabis-powder-rapid-dissolving-and-d-ogi-20201117monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-one-name-and-address-o-ogi-20201112monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-organigram-holdings-inc-as-the-corporation-and-tsx-trust-company-ogi-20201112monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-closes-previously-announced-underwritten-public-offering-moncton-new-brunswick--ogi-20201112monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-ogi-20201110monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-launches-trailblazer-kushmas-stix-and-edison-bytes-gingerbread-truffles-two-new-ogi-20201109monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-ceo-joins-canadian-chamber-of-commerce-board-of-directors-moncton-new-brunswick-ogi-20201030monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-confirms-additional-2-5-million-investment-in-hyasynth-biologicals-inc-as-biosy-ogi-20201023monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-expands-strong-value-portfolio-with-launch-of-shred-high-quality-high-potency-a-ogi-20200917monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-joins-medical-cannabis-by-shoppers-inc-and-trutrace-in-effort-to-track-source-a-ogi-20200818monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-sends-first-shipment-of-indoor-grown-dried-flower-to-israeli-cannabis-producer--ogi-20200814monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-strengthens-edison-flower-portfolio-with-three-new-high-potency-strains-the-gen-ogi-20200804monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-launches-trailblazer-snax-the-largest-competitively-priced-cannabis-infused-cho-ogi-20200728monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-table-of-contents-management-s-responsibility-for-the-financial--ogi-20200717monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-announces-executive-change-moncton-new-brunswick-business-wire-ogi-20200720monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-one-name-and-address-o-ogi-20200703monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-provides-update-on-covid-19-corporate-action-plan-and-timing-for-q3-results-mon-ogi-20200703monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-holdings-inc-provides-corporate-updates-moncton-new-brunswick-business-wire-ogi-20200623monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-and-canndoc-sign-international-strategic-agreement-organigram-to-supply-israeli-ogi-20200609monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-execution-copy-second-amendment-to-credit-agreement-this-agreeme-ogi-20200528monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-one-name-and-address-o-ogi-20200528monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-successfully-completes-amendment-to-credit-facilities-with-bank-of-montreal-mai-ogi-20200529monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-rolls-out-cannabis-2-0-products-to-medical-consumers-edison-cannabis-company-va-ogi-20200528monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-announces-first-phase-of-return-to-work-strategy-company-recalls-approximately--ogi-20200514monthly0.5https://www.biopharmawatch.com/news/OGI/court-significantly-reduces-scope-of-class-action-moncton-new-brunswick-business-wire-ogi-20200430monthly0.5https://www.biopharmawatch.com/news/OGI/consumer-research-drives-enhancements-to-organigram-adult-recreational-commercial-portfoli-ogi-20200423monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-organigram-holdings-inc-49-000-000-ogi-20200422monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-organigram-s-portfolio-of-adult-recreational-cannabis-brands-the-ogi-20200414monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-one-name-and-address-o-ogi-20200406monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-provides-update-on-corporate-action-plan-in-response-to-covid-19-pandemic-also--ogi-20200407monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-receives-health-canada-license-renewal-and-expansion-for-final-elements-of-phas-ogi-20200323monthly0.5https://www.biopharmawatch.com/news/OGI/ideal-potency-of-edible-products-5mgs-of-thc-or-less-organigram-consumer-research-survey-c-ogi-20200310monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-expands-leadership-team-with-the-appointment-of-chief-strategy-officer-and-newl-ogi-20200304monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-1a-the-articles-of-organigram-holdings-inc-the-corporation-be-am-ogi-20200227monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-holdings-inc-announces-election-of-directors-moncton-new-brunswick-business-wir-ogi-20200225monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-continues-cannabis-2-0-roll-out-releases-edison-vape-pens-powered-by-feather-an-ogi-20200220monthly0.5https://www.biopharmawatch.com/news/OGI/notice-of-annual-and-special-meeting-of-shareholders-to-be-held-on-ogi-20200203monthly0.5https://www.biopharmawatch.com/news/OGI/edison-la-strada-selected-favourite-thc-flower-in-canada-2019-leafly-readers-choice-awards-ogi-20200123monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-secures-supply-agreement-with-medical-cannabis-by-shoppers-agreement-highlights-ogi-20200116monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-organigram-holdings-inc-management-s-discussion-and-analysis-of--ogi-20200115monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-selected-by-canada-s-top-100-employers-atlantic-canada-s-top-employer-competiti-ogi-20200109monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-to-report-first-quarter-fiscal-2020-results-on-january-14-th-2020-and-operation-ogi-20200103monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-trailblazer-torch-vape-cartridges-among-first-cannabis-2-0-products-company-dis-ogi-20191223monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-receives-licensing-for-chocolate-production-and-packaging-area-increased-produc-ogi-20191213monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-organigram-holdings-inc-55-000-000-ogi-20191204monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-reports-fourth-quarter-and-2019-fiscal-year-results-2019-net-revenue-grew-547-t-ogi-20191125monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-one-name-and-address-o-ogi-20191111monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-wins-top-product-award-in-high-thc-bottled-oil-category-at-2019-canadian-cannab-ogi-20191111monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-provides-corporate-update-announces-earnings-call-for-fiscal-q4-and-full-year-2-ogi-20191111monthly0.5https://www.biopharmawatch.com/news/OGI/a-strong-step-forward-for-the-legal-cannabis-market-in-ontario-organigram-expects-enhanced-ogi-20191107monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-awarded-excellence-in-manufacturing-consortium-award-company-recognized-in-outs-ogi-20191010monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-assumes-board-positions-on-international-cannabis-industry-advocacy-organizatio-ogi-20191007monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-receives-health-canada-approval-to-bring-total-licensed-production-capacity-to--ogi-20190909monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-announces-trading-date-for-graduation-to-tsx-moncton-new-brunswick-business-wir-ogi-20190820monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-conditionally-approved-to-graduate-to-the-tsx-moncton-new-brunswick-business-wi-ogi-20190808monthly0.5https://www.biopharmawatch.com/news/OGI/organigram-signs-new-agreement-for-access-to-60-000kg-of-cbd-rich-hemp-new-advance-purchas-ogi-20190726monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-organigram-s-portfolio-of-adult-recreational-cannabis-brands-1-i-ogi-20190712monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-organigram-and-lift-co-enhance-education-of-cannabis-frontline-s-ogi-20190710monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-organigram-announces-expanded-development-of-rapid-onset-nano-em-ogi-20190708monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-organigram-holdings-inc-to-report-third-quarter-fiscal-2019-resu-ogi-20190702monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-organigram-receives-health-canada-approval-for-an-additional-17--ogi-20190624monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-organigram-sends-first-shipment-to-quebec-organigram-products-no-ogi-20190620monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-organigram-becomes-exclusive-canadian-supplier-of-feather-compan-ogi-20190618monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-organigram-holdings-inc-as-borrower-and-the-lenders-from-time-to-ogi-20190531monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-organigram-secures-partnership-with-pax-as-brand-partner-partner-ogi-20190607monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-organigram-closes-140-million-credit-facility-with-bank-of-montr-ogi-20190531monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-organigram-receives-organic-certification-for-recreational-canna-ogi-20190531monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-organigram-fulfills-gap-in-canadian-cbd-market-with-edison-cbd-o-ogi-20190529monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-change-of-status-report-pursuant-to-section-11-2-of-national-ins-ogi-20190521monthly0.5https://www.biopharmawatch.com/news/OGI/filed-by-newsfilecorp-com-organigram-announces-may-21-st-as-inaugural-date-of-trading-on-t-ogi-20190517monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-first-quarter-2026-financial-results-and-completion-of-phase-3-endometr-kpti-20260514monthly0.5https://www.biopharmawatch.com/news/KPTI/believers-in-the-extraordinary-karyopharm-s-phase-3-sentry-trial-in-myelofibrosis-met-firs-kpti-20260324monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-preliminary-unaudited-2025-revenue-and-reiterates-expectation-of-deli-kpti-20260112monthly0.5https://www.biopharmawatch.com/news/KPTI/believers-in-the-extraordinary-karyopharm-announces-strategic-financing-transactions-to-su-kpti-20251008monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-second-quarter-2025-financial-results-and-highlights-recent-company-pro-kpti-20250811monthly0.5https://www.biopharmawatch.com/news/KPTI/confidential-investor-presentation-july-2025-2025-karyopharm-therapeutics-inc-confidential-kpti-20250711monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-first-quarter-2025-financial-results-and-announces-new-data-in-myelofib-kpti-20250512monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-fourth-quarter-and-full-year-2024-financial-results-announces-update-to-kpti-20250219monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-preliminary-unaudited-2024-revenue-and-2025-objectives-x2013-opportun-kpti-20250113monthly0.5https://www.biopharmawatch.com/news/KPTI/believers-in-the-extraordinary-karyopharm-therapeutics-provides-endometrial-cancer-program-kpti-20241203monthly0.5https://www.biopharmawatch.com/news/KPTI/believers-in-the-extraordinary-karyopharm-reports-third-quarter-2024-financial-results-and-kpti-20241105monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-announces-favorable-change-in-co-primary--kpti-20241031monthly0.5https://www.biopharmawatch.com/news/KPTI/believers-in-the-extraordinary-karyopharm-reports-second-quarter-2024-financial-results-an-kpti-20240806monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-announces-significant-refinancing-transac-kpti-20240508monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-first-quarter-2024-financial-resu-kpti-20240508monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-poreh3-karyopharm-reports-fourth-quarter-and-full-year-20-kpti-20240229monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-announces-preliminary-unaudited-2023-reve-kpti-20240108monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-third-quarter-2023-financial-resu-kpti-20231102monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-second-quarter-2023-financial-res-kpti-20230802monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-first-quarter-2023-financial-resu-kpti-20230504monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-fourth-quarter-and-full-year-2022-kpti-20230215monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-announces-preliminary-unaudited-fourth-qu-kpti-20230109monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-announces-165-million-private-placement-kpti-20221205monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-third-quarter-2022-financial-resu-kpti-20221103monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-second-quarter-2022-financial-res-kpti-20220804monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-first-quarter-2022-financial-resu-kpti-20220505monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-strong-fourth-quarter-and-full-ye-kpti-20220208monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-announces-preliminary-unaudited-fourth-qu-kpti-20220110monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-strong-third-quarter-2021-financi-kpti-20211103monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-business-highlights-and-second-qu-kpti-20210805monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-first-quarter-2021-financial-resu-kpti-20210503monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-fourth-quarter-and-full-year-2020-kpti-20210211monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-announces-preliminary-unaudited-fourth-qu-kpti-20210111monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-announces-fda-approval-of-xpovio-selinexo-kpti-20201218monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-third-quarter-2020-financial-resu-kpti-20201102monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-second-quarter-2020-financial-res-kpti-20200804monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-announces-preliminary-unaudited-second-qu-kpti-20200714monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-first-quarter-2020-financial-resu-kpti-20200505monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-pricing-of-public-offering-of-common-stock-newton-mass-kpti-20200303monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-announces-phase-3-boston-study-meets-prim-kpti-20200302monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-fourth-quarter-and-full-year-2019-kpti-20200213monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-announces-preliminary-unaudited-fourth-qu-kpti-20200113monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-new-and-updated-xpovio-selinexor--kpti-20191207monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-third-quarter-2019-financial-resu-kpti-20191104monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-enters-into-royalty-agreement-with-health-kpti-20190916monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-second-quarter-2019-financial-res-kpti-20190806monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-fda-approval-of-xpovio-tm-selinexor-for-the-treatment-of-patients-wit-kpti-20190703monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-updated-data-from-the-phase-2b-sa-kpti-20190619monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-new-and-updated-selinexor-combina-kpti-20190614monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-first-quarter-2019-financial-resu-kpti-20190509monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-announces-fda-extension-of-review-period--kpti-20190315monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-therapeutics-inc-consolidated-statements--kpti-20190228monthly0.5https://www.biopharmawatch.com/news/KPTI/forward-looking-statements-and-other-important-information-this-presentation-contains-forw-kpti-20190107monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-positive-top-line-phase-2b-sadal--kpti-20181201monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-third-quarter-2018-financial-resu-kpti-20181108monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-therapeutics-announces-pricing-of-150-mil-kpti-20181011monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-therapeutics-announces-proposed-private-o-kpti-20181009monthly0.5https://www.biopharmawatch.com/news/KPTI/u-s-food-and-drug-administration-accepts-karyopharm-s-new-drug-application-for-selinexor-a-kpti-20181009monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-phase-2b-storm-data-evaluating-selinexor-in-patients-kpti-20180914monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-second-quarter-2018-financial-res-kpti-20180807monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-completes-rolling-submission-of-new-drug--kpti-20180807monthly0.5https://www.biopharmawatch.com/news/KPTI/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-kpti-20180620monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-corporate-presentation-june-2018-forward-looking-sta-kpti-20180607monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-and-antengene-sign-exclusive-license-agreement-to-develop-and-commercialize-sel-kpti-20180524monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-first-quarter-2018-financial-resu-kpti-20180510monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-therapeutics-announces-pricing-of-public--kpti-20180502monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-announces-positive-top-line-data-from-pha-kpti-20180501monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-fourth-quarter-and-full-year-2017-kpti-20180315monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-announces-agreement-for-biogen-to-acquire-kpt-350-for-the-treatment-of-neurolog-kpti-20180125monthly0.5https://www.biopharmawatch.com/news/KPTI/th-annual-j-p-morgan-healthcare-conference-january-8-11-2018-forward-looking-statements-th-kpti-20180108monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-presents-positive-selinexor-data-from-the-kpti-20171210monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-third-quarter-2017-financial-resu-kpti-20171102monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-and-ono-pharmaceutical-co-ltd-sign-exclus-kpti-20171012monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-announces-successful-outcome-from-phase-2-kpti-20170920monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-second-quarter-2017-financial-res-kpti-20170808monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-updated-phase-2b-sadal-data-for-s-kpti-20170623monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-first-quarter-2017-financial-resu-kpti-20170504monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-therapeutics-announces-proposed-public-of-kpti-20170424monthly0.5https://www.biopharmawatch.com/news/KPTI/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-kpti-20170405monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-interim-phase-2b-sadal-data-at-th-kpti-20170404monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-fourth-quarter-and-full-year-2016-kpti-20170316monthly0.5https://www.biopharmawatch.com/news/KPTI/corporate-presentation-january-2017-karyopharm-therapeutics-inc-targetting-disease-at-the--kpti-20170109monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-presents-updated-phase-2b-storm-data-at-t-kpti-20161205monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-third-quarter-2016-financial-resu-kpti-20161107monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-positive-top-line-phase-2b-storm--kpti-20160906monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-second-quarter-2016-financial-res-kpti-20160804monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-first-quarter-2016-financial-resu-kpti-20160509monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-fourth-quarter-and-full-year-2015-kpti-20160314monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-initiates-clinical-trial-of-oral-selinexo-kpti-20160114monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-presents-positive-clinical-data-on-the-activity-of-selinexor-in-co-kpti-20151207monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-inc-forward-looking-statements-this-presentation-contains-forward--kpti-20151110monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-third-quarter-2015-financial-resu-kpti-20151109monthly0.5https://www.biopharmawatch.com/news/KPTI/nasdaq-kpti-corporate-presentation-august-2015-targeting-disease-at-the-nuclear-pore-forwa-kpti-20150810monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-second-quarter-2015-financial-res-kpti-20150810monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-presents-hematologic-cancer-data-on-lead--kpti-20150615monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-presents-clinical-data-for-selinexor-kpt--kpti-20150530monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-first-quarter-2015-financial-resu-kpti-20150511monthly0.5https://www.biopharmawatch.com/news/KPTI/targeting-disease-at-the-nuclear-pore-karyopharm-reports-fourth-quarter-and-full-year-2014-kpti-20150316monthly0.5https://www.biopharmawatch.com/news/KPTI/karyopharm-therapeutics-announces-pricing-of-public-offering-of-common-stock-kpti-20150106monthly0.5https://www.biopharmawatch.com/news/KPTI/risk-factors-investing-in-our-common-stock-involves-a-high-degree-of-risk-before-investing-kpti-20150105monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-reports-financial-results-for-the-first-quarter-ended-lfcr-20260506monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-reports-financial-results-for-the-fourth-quarter-and-transition-period-lfcr-20260316monthly0.5https://www.biopharmawatch.com/news/LFCR/lfcrpresentation-august-2025-2-important-information-regarding-forward-looking-statements--lfcr-20250812monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-reports-fourth-quarter-and-fiscal-year-2025-financial-results-and-prov-lfcr-20250807monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-reports-third-quarter-fiscal-2025-financial-results-and-provides-corpo-lfcr-20250403monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-announces-special-stockholder-meeting-company-seeking-to-remove-conver-lfcr-20250117monthly0.5https://www.biopharmawatch.com/news/LFCR/document-lifecore-biomedical-further-strengthens-financial-position-through-sale-of-excess-lfcr-20250107monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-reports-second-quarter-fiscal-2025-financial-results-and-provides-corp-lfcr-20250102monthly0.5https://www.biopharmawatch.com/news/LFCR/lfcrq1fy25ear-lifecore-biomedical-reports-first-quarter-of-fiscal-2025-financial-results-a-lfcr-20241004monthly0.5https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-announces-cooperation-agreement-with-22nw-provides-for-the-addition-of-lfcr-20240701monthly0.5https://www.biopharmawatch.com/news/LFCR/expressions-are-used-to-identify-forward-looking-statements-forward-looking-statements-in--lfcr-20230523monthly0.5https://www.biopharmawatch.com/news/LFCR/information-investor-relations-jeff-sonnek-646-277-1263-jeff-sonnek-icrinc-com-landec-corp-lfcr-20220810monthly0.5https://www.biopharmawatch.com/news/LFCR/landec-corporation-mourns-the-passing-of-board-member-charles-macaluso-lfcr-20210224monthly0.5https://www.biopharmawatch.com/news/LFCR/landec-appoints-new-chief-financial-officer-lfcr-20210119monthly0.5https://www.biopharmawatch.com/news/LFCR/as-a-result-of-refinancing-the-company-s-existing-credit-facilities-with-these-new-credit--lfcr-20210105monthly0.5https://www.biopharmawatch.com/news/LFCR/landec-continues-progression-of-transformation-plan-for-curation-foods-announcing-agreemen-lfcr-20200825monthly0.5https://www.biopharmawatch.com/news/LFCR/landec-nominates-three-new-members-to-its-board-of-directors-providing-deep-expertise-to-b-lfcr-20200824monthly0.5https://www.biopharmawatch.com/news/LFCR/landec-corporation-amends-credit-agreement-lfcr-20200716monthly0.5https://www.biopharmawatch.com/news/LFCR/landec-corporation-amends-credit-agreement-appoints-brian-mclaughlin-chief-financial-offic-lfcr-20200325monthly0.5https://www.biopharmawatch.com/news/LFCR/information-investor-relations-jeff-sonnek-646-277-1263-jeff-sonnek-icrinc-com-landec-corp-lfcr-20200102monthly0.5https://www.biopharmawatch.com/news/LFCR/information-at-the-company-investor-relations-gregory-s-skinner-jeff-sonnek-executive-vice-lfcr-20191001monthly0.5https://www.biopharmawatch.com/news/LFCR/information-at-the-company-investor-relations-gregory-s-skinner-jeff-sonnek-executive-vice-lfcr-20190730monthly0.5https://www.biopharmawatch.com/news/LFCR/diversified-health-and-wellness-solutions-for-immediate-release-contact-information-at-the-lfcr-20190528monthly0.5https://www.biopharmawatch.com/news/LFCR/information-at-the-company-investor-relations-gregory-s-skinner-john-mills-partner-vice-pr-lfcr-20190403monthly0.5https://www.biopharmawatch.com/news/LFCR/information-at-the-company-gregory-s-skinner-vice-president-finance-and-cfo-650-261-3677-i-lfcr-20170725monthly0.5https://www.biopharmawatch.com/news/LFCR/information-at-the-company-investor-relations-gregory-s-skinner-john-mills-partner-vice-pr-lfcr-20170404monthly0.5https://www.biopharmawatch.com/news/LFCR/information-at-the-company-investor-relations-gregory-s-skinner-john-mills-partner-vice-pr-lfcr-20170104monthly0.5https://www.biopharmawatch.com/news/LFCR/information-at-the-company-investor-relations-gregory-s-skinner-john-mills-partner-vice-pr-lfcr-20160927monthly0.5https://www.biopharmawatch.com/news/LFCR/information-at-the-company-investor-relations-gregory-s-skinner-vice-president-finance-and-lfcr-20160726monthly0.5https://www.biopharmawatch.com/news/LFCR/information-at-the-company-gregory-s-skinner-vice-president-finance-and-cfo-650-261-3677-i-lfcr-20160329monthly0.5https://www.biopharmawatch.com/news/LFCR/information-at-the-company-investor-relations-gregory-s-skinner-matt-glover-vice-president-lfcr-20160105monthly0.5https://www.biopharmawatch.com/news/LFCR/information-at-the-company-investor-relations-gregory-s-skinner-matt-glover-vice-president-lfcr-20150929monthly0.5https://www.biopharmawatch.com/news/LFCR/information-at-the-company-investor-relations-gregory-s-skinner-matt-glover-or-michael-koe-lfcr-20150728monthly0.5https://www.biopharmawatch.com/news/LFCR/fourth-amendment-to-credit-agreement-fourth-amendment-to-credit-agreement-amendment-dated--lfcr-20150527monthly0.5https://www.biopharmawatch.com/news/LFCR/information-at-the-company-investor-relations-gregory-s-skinner-matt-glover-or-michael-koe-lfcr-20150521monthly0.5https://www.biopharmawatch.com/news/LFCR/information-at-the-company-investor-relations-gregory-s-skinner-matt-glover-or-michael-koe-lfcr-20150331monthly0.5https://www.biopharmawatch.com/news/LFCR/information-at-the-company-investor-relations-gregory-s-skinner-matt-glover-or-michael-koe-lfcr-20150205monthly0.5https://www.biopharmawatch.com/news/LFCR/information-at-the-company-investor-relations-gregory-s-skinner-matt-glover-or-michael-koe-lfcr-20150106monthly0.5https://www.biopharmawatch.com/news/LFCR/information-at-the-company-investor-relations-gregory-s-skinner-matt-glover-or-michael-koe-lfcr-20141031monthly0.5https://www.biopharmawatch.com/news/LFCR/information-at-the-company-investor-relations-gregory-s-skinner-vice-president-finance-and-lfcr-20141007monthly0.5https://www.biopharmawatch.com/news/LFCR/information-at-the-company-investor-relations-gregory-s-skinner-matt-glover-or-michael-koe-lfcr-20140903monthly0.5https://www.biopharmawatch.com/news/LFCR/information-at-the-company-investor-relations-gregory-s-skinner-matt-glover-or-michael-koe-lfcr-20140729monthly0.5https://www.biopharmawatch.com/news/LFCR/information-at-the-company-investor-relations-gregory-s-skinner-matt-glover-or-michael-koe-lfcr-20140718monthly0.5https://www.biopharmawatch.com/news/LFCR/information-at-the-company-investor-relations-gregory-s-skinner-matt-glover-or-michael-koe-lfcr-20140325monthly0.5https://www.biopharmawatch.com/news/LFCR/information-at-the-company-investor-relations-gregory-s-skinner-matt-glover-or-michael-koe-lfcr-20140103monthly0.5https://www.biopharmawatch.com/news/LFCR/landec-corporation-2013-stock-incentive-plan-section-1-introduction-1-the-landec-corporati-lfcr-20131011monthly0.5https://www.biopharmawatch.com/news/LFCR/information-at-the-company-investor-relations-gregory-s-skinner-justin-vaicek-vice-preside-lfcr-20130924monthly0.5https://www.biopharmawatch.com/news/LFCR/information-at-the-company-gregory-s-skinner-vice-president-finance-and-cfo-650-261-3677-l-lfcr-20130731monthly0.5https://www.biopharmawatch.com/news/LFCR/information-at-the-company-gregory-s-skinner-vice-president-finance-and-cfo-650-261-3677-l-lfcr-20130326monthly0.5https://www.biopharmawatch.com/news/LFCR/information-at-the-company-gregory-s-skinner-vice-president-finance-and-cfo-650-261-3677-l-lfcr-20130102monthly0.5https://www.biopharmawatch.com/news/LFCR/information-at-the-company-gregory-s-skinner-vice-president-finance-and-cfo-650-261-3677-l-lfcr-20120926monthly0.5https://www.biopharmawatch.com/news/LFCR/information-at-the-company-gregory-s-skinner-vice-president-finance-and-cfo-650-261-3677-l-lfcr-20120731monthly0.5https://www.biopharmawatch.com/news/LFCR/information-at-the-company-gregory-s-skinner-vice-president-finance-and-cfo-650-261-3677-lfcr-20120626monthly0.5https://www.biopharmawatch.com/news/LFCR/information-at-the-company-gregory-s-skinner-vice-president-finance-and-cfo-650-261-3677-l-lfcr-20120423monthly0.5https://www.biopharmawatch.com/news/LFCR/information-at-the-company-gregory-s-skinner-vice-president-finance-and-cfo-650-261-3677-l-lfcr-20120326monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-announces-acceptance-of-marketing-authorization-application-for--mist-20260106monthly0.5https://www.biopharmawatch.com/news/MIST/fda-approval-investor-call-mist-20251215monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides-regul-mist-20250812monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-reports-first-quarter-2025-financial-results-and-provides-regula-mist-20250514monthly0.5https://www.biopharmawatch.com/news/MIST/fda-issues-complete-response-letter-for-etripamil-for-psvt-crl-focused-on-cmc-no-clinical--mist-20250328monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-financial-results-and--mist-20250313monthly0.5https://www.biopharmawatch.com/news/MIST/commercial-investor-event-preparation-for-potential-launch-of-cardamyst-etripamil-nasal-sp-mist-20250225monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides-regula-mist-20241112monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-appoints-industry-veteran-joseph-papa-to-its-board-of-directors--mist-20240904monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-reports-second-quarter-2024-financial-results-and-provides-regul-mist-20240808monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-refreshes-board-of-directors-two-new-independent-directors-stuar-mist-20240715monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-announces-fda-acceptance-of-new-drug-application-for-cardamyst-m-mist-20240526monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-reports-first-quarter-2024-financial-results-and-provides-regula-mist-20240513monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-announces-etripamil-data-demonstrating-patients-ability-to-self--mist-20240408monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-announces-resubmission-of-new-drug-application-for-etripamil-for-mist-20240328monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results-and--mist-20240321monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-announces-proposed-public-offering-of-common-shares-and-pre-fund-mist-20240304monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-announces-plan-to-resubmit-nda-for-etripamil-for-the-treatment-o-mist-20240226monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-receives-refusal-to-file-letter-from-u-s-fda-for-new-drug-applic-mist-20231226monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-reports-third-quarter-2023-financial-results-and-provides-clinic-mist-20231113monthly0.5https://www.biopharmawatch.com/news/MIST/company-overview-confidential-atrial-fibrillation-program-update-november-2023-forward-loo-mist-20231113monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-to-host-investor-and-analyst-webcast-to-review-data-from-revera--mist-20231107monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-announces-submission-of-new-drug-application-to-the-u-s-fda-for--mist-20231024monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-reports-second-quarter-2023-financial-results-and-provides-clini-mist-20230810monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-reports-first-quarter-2023-financial-results-and-provides-clinic-mist-20230511monthly0.5https://www.biopharmawatch.com/news/MIST/company-overview-mist-20230330monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-reports-fourth-quarter-and-full-year-2022-financial-results-and--mist-20230329monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-announces-125-million-strategic-financing-with-rtw-investments-t-mist-20230328monthly0.5https://www.biopharmawatch.com/news/MIST/corporate-overview-march-2023-forward-looking-statement-2-milestone-corporate-overview-the-mist-20230307monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-reports-third-quarter-2022-financial-results-and-provides-clinic-mist-20221110monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-announces-positive-results-from-phase-3-rapid-clinical-trial-of--mist-20221017monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-reports-second-quarter-2022-financial-results-and-provides-clini-mist-20220810monthly0.5https://www.biopharmawatch.com/news/MIST/index-to-consolidated-financial-statements-report-of-independent-registered-public-account-mist-20220324monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-announces-appointment-of-david-bharucha-m-d-ph-d-as-chief-medica-mist-20220216monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-reports-third-quarter-2021-financial-results-and-provides-clinic-mist-20211112monthly0.5https://www.biopharmawatch.com/news/MIST/joseph-oliveto-president-ceo-corporate-overview-june-2021-disclaimers-the-presentation-con-mist-20210602monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-announces-exclusive-license-agreement-with-ji-xing-pharmaceutica-mist-20210517monthly0.5https://www.biopharmawatch.com/news/MIST/item-8-financial-statements-report-of-independent-registered-public-accounting-firm-to-the-mist-20210330monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-announces-pricing-of-a-public-offering-of-45-million-of-common-s-mist-20201023monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-strengthens-board-of-directors-with-two-new-appointments-montrea-mist-20200922monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-announces-regulatory-guidance-and-updated-clinical-development-p-mist-20200723monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-announces-topline-results-from-first-of-its-kind-phase-3-node-30-mist-20200323monthly0.5https://www.biopharmawatch.com/news/MIST/corporate-overview-december-2019-joseph-oliveto-chief-executive-officer-disclaimers-this-p-mist-20191217monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-reports-third-quarter-2019-financial-results-and-provides-clinic-mist-20191113monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-announces-appointment-of-amit-hasija-as-chief-financial-officer--mist-20190910monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-provides-positive-regulatory-updates-for-etripamil-pivotal-progr-mist-20190813monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-inc-condensed-consolidated-financial-statements-unaudited-three--mist-20190524monthly0.5https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-announces-closing-of-initial-public-offering-montreal-qc-ca-and--mist-20190513monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-announces-35-75-million-private-placement-to-advance-potential-best-abos-20260316monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-reports-second-quarter-2025-financial-results-and-business-highligh-abos-20250812monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-reports-first-quarter-2025-financial-results-and-business-highlight-abos-20250513monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-reports-financial-results-for-the-year-ended-abos-20250327monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-reports-third-quarter-2024-financial-results-and-business-highlight-abos-20241112monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-reports-second-quarter-2024-financial-results-and-business-highligh-abos-20240813monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-reports-first-quarter-2024-financial-results-and-business-highlight-abos-20240514monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-reports-third-quarter-2023-financial-results-and-business-highlight-abos-20231113monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-reports-second-quarter-2023-financial-results-and-business-highligh-abos-20230808monthly0.5https://www.biopharmawatch.com/news/ABOS/part-ii-information-not-required-in-prospectus-item-14-other-expenses-of-issuance-and-dist-abos-20230720monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-presents-positive-topline-results-from-first-in-human-phase-1-study-abos-20230716monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-reports-first-quarter-2023-financial-results-and-business-highlight-abos-20230509monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-reports-financial-results-for-full-year-ended-abos-20230327monthly0.5https://www.biopharmawatch.com/news/ABOS/corporate-presentation-february-2023-1-forward-looking-statements-this-presentation-contai-abos-20230201monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-reports-third-quarter-2022-financial-results-and-business-highlight-abos-20221114monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-s-acu193-an-anti-amyloid-beta-oligomer-antibody-granted-fda-fast-track-designation--abos-20221024monthly0.5https://www.biopharmawatch.com/news/ABOS/corporate-overview-september-2022-1-forward-looking-statements-this-presentation-contains--abos-20220912monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-reports-financial-results-for-second-quarter-2022-and-business-high-abos-20220815monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-presents-poster-describing-method-to-standardize-amyloid-beta-oligomer-assays-suppo-abos-20220801monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-reports-financial-results-for-first-quarter-2022-and-business-highl-abos-20220516monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-reports-financial-results-for-full-year-ended-abos-20220328monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-reports-financial-results-for-third-quarter-2021-and-business-highl-abos-20211115monthly0.5https://www.biopharmawatch.com/news/ABOS/forward-looking-statements-and-notes-regarding-this-presentation-this-presentation-may-con-abos-20211110monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-announces-first-patient-dosed-in-a-phase-1-clinical-trial-of-acu193-a-monoclonal-an-abos-20211007monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-safe-harbor-statement-notes-regarding-this-presentation-this-presentation-may-conta-abos-20210816monthly0.5https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-reports-financial-results-for-second-quarter-2021-and-business-high-abos-20210816monthly0.5https://www.biopharmawatch.com/news/ACB/burrard-st-3rd-floor-date-acb-20260521monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-advances-global-medical-cannabis-portfolio-with-new-product-launches-across-key-int-acb-20260428monthly0.5https://www.biopharmawatch.com/news/ACB/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aurora-cannabis-in-acb-20260415monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-to-participate-in-the-td-cowen-46th-annual-health-care-conference-nasdaq-tsx-acb-ca-acb-20260217monthly0.5https://www.biopharmawatch.com/news/ACB/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aurora-cannabis-in-acb-20260203monthly0.5https://www.biopharmawatch.com/news/ACB/execution-version-acb-20260204monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-filing-of-prospectus-supplement-for-at-the-market-offering-progr-acb-20260204monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-fiscal-2026-third-quarter-results-nasdaq-tsx-acb-expands-yoy-tot-acb-20260204monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-host-third-quarter-2026-investor-conference-call-nasdaq-tsx-acb-20260121monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-achieves-significant-progress-in-disease-resistance-research-nasdaq-tsx-acb-as-a-le-acb-20260114monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-fiscal-2026-second-quarter-results-expands-yoy-global-medical-ca-acb-20251105monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-host-second-quarter-2026-investor-conference-call-nasdaq-tsx-acb-20251022monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-announces-investment-into-german-manufacturing-facility-nasdaq-tsx-acb-facility-inv-acb-20250918monthly0.5https://www.biopharmawatch.com/news/ACB/annual-general-and-special-meeting-of-shareholders-of-aurora-cannabis-inc-the-company-acb-20250808monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-inc-announces-results-of-2025-annual-general-and-special-meeting-nasdaq-ts-acb-20250808monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-fiscal-2026-first-quarter-results-nasdaq-tsx-acb-expands-yoy-glo-acb-20250806monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-inc-reminds-shareholders-to-vote-in-advance-of-the-proxy-voting-deadline-f-acb-20250730monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-host-first-quarter-2026-investor-conference-call-nasdaq-tsx-acb-20250723monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-completes-first-ever-eu-gmp-certification-for-the-company-s-dedicated-distribution--acb-20250714monthly0.5https://www.biopharmawatch.com/news/ACB/letter-from-our-executive-chairman-and-ceo-dear-fellow-shareholders-we-are-pleased-to-invi-acb-20250709monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-inc-announces-filing-and-mailing-of-the-management-information-circular-in-acb-20250709monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-advises-of-second-false-article-from-investing-com-nasdaq-tsx-acb-20250619monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-denies-news-of-acquisition-of-medleaf-therapeutics-nasdaq-tsx-acb-20250618monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-files-full-year-results-and-announces-fiscal-2025-fourth-quarter-nasdaq-ts-acb-20250618monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-host-fourth-quarter-and-fiscal-year-2025-investor-conference-call-and-f-acb-20250603monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-breakthrough-discovery-of-powdery-mildew-resistant-cultivars-nas-acb-20250320monthly0.5https://www.biopharmawatch.com/news/ACB/breaking-down-barriers-aurora-cannabis-eases-patient-access-to-high-quality-medical-cannab-acb-20250214monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-supply-agreement-with-sndl-nasdaq-tsx-acb-agreement-complements--acb-20250206monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-fiscal-2025-third-quarter-results-nasdaq-tsx-acb-reports-total-n-acb-20250205monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-host-third-quarter-2025-investor-conference-call-nasdaq-tsx-acb-20250122monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-fiscal-2025-second-quarter-results-nasdaq-tsx-acb-record-adjuste-acb-20241106monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-host-second-quarter-2025-investor-conference-call-nasdaq-tsx-acb-20241024monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-ceo-miguel-martin-takes-on-additional-role-as-executive-chairman-of-board-of-direct-acb-20240920monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-advances-auto-flowering-research-unveiling-key-insights-for-future-cultiva-acb-20240917monthly0.5https://www.biopharmawatch.com/news/ACB/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aurora-cannabis-in-acb-20240826monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-results-of-2024-annual-general-and-special-meeting-nasdaq-tsx-acb-20240812monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-fiscal-2025-first-quarter-results-and-delivers-positive-free-cas-acb-20240807monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-and-vectura-fertin-pharma-inc-announce-commercial-collaboration-collaborat-acb-20240801monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-host-first-quarter-2025-investor-conference-call-nasdaq-tsx-acb-20240729monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-receives-expanded-cultivation-and-unique-research-licenses-for-german-facility-nasd-acb-20240725monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-inc-announces-filing-and-mailing-of-management-information-circular-in-con-acb-20240709monthly0.5https://www.biopharmawatch.com/news/ACB/ceo-letter-to-shareholders-dear-shareholders-we-are-pleased-to-invite-you-to-the-2024-annu-acb-20240709monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-inc-notice-of-change-of-auditor-to-ernst-young-llp-1133-melville-street-su-acb-20240625monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-files-full-year-results-and-announces-fiscal-2024-fourth-quarter-delivers--acb-20240620monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-host-fourth-quarter-and-fiscal-year-2024-investor-conference-call-and-f-acb-20240607monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-appointment-of-new-director-nasdaq-tsx-acb-newly-created-directo-acb-20240515monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-marks-first-shipment-of-medical-cannabis-to-the-new-zealand-market-nasdaq-tsx-acb-c-acb-20240508monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-inc-notice-of-change-of-auditor-to-kpmg-llp-po-box-10426-777-dunsmuir-stre-acb-20240417monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-completes-final-repayment-of-convertible-senior-notes-representing-465-million-in-t-acb-20240229monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-cfo-transition-and-completion-of-previously-announced-share-cons-acb-20240220monthly0.5https://www.biopharmawatch.com/news/ACB/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aurora-cannabis-in-acb-20240208monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-fiscal-2024-third-quarter-results-generates-record-adjusted-ebit-acb-20240208monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-acquires-medreleaf-australia-nasdaq-tsx-acb-aurora-becomes-the-largest-glo-acb-20240208monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-provides-business-update-and-announces-date-of-third-quarter-fiscal-year-2-acb-20240131monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-fiscal-2024-second-quarter-results-and-delivers-record-positive--acb-20231109monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-host-second-quarter-fiscal-year-2024-investor-conference-call-nasdaq-ts-acb-20231026monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-confirms-approval-of-transfer-to-nasdaq-capital-market-enters-into-agreement-to-rep-acb-20230919monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-repurchases-us-9-0-million-principal-amount-of-convertible-notes-continues-progress-acb-20230908monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-results-of-2023-annual-general-meeting-nasdaq-tsx-acb-20230814monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-inc-condensed-consolidated-interim-financial-statements-unaudited-for-the--acb-20230810monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-fiscal-2024-first-quarter-results-and-delivers-record-positive-a-acb-20230810monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-host-first-quarter-fiscal-year-2024-investor-conference-call-nasdaq-tsx-acb-20230727monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-sale-of-aurora-sun-facility-to-bevo-expected-to-provide-incremen-acb-20230724monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-inc-announces-filing-and-mailing-of-the-management-information-circular-in-acb-20230719monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-fiscal-2023-third-quarter-and-files-full-year-results-nasdaq-tsx-acb-20230614monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-host-third-quarter-and-fiscal-year-2023-investor-conference-call-and-fi-acb-20230607monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-expands-medical-cannabis-portfolio-in-germany-new-flower-varieties-for-patients-wit-acb-20230428monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-repurchases-22-million-principal-amount-of-convertible-notes-saving-1-2-million-in--acb-20230424monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-repurchases-47-million-principal-amount-of-convertible-notes-saving-2-6-million-in--acb-20230330monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-provides-update-on-nasdaq-listing-nasdaq-tsx-acb-20230324monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-filing-of-preliminary-base-shelf-prospectus-nasdaq-tsx-acb-20230317monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-and-medreleaf-australia-launch-new-medical-cannabis-brand-craftplant-nasdaq-tsx-acb-acb-20230222monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-inc-condensed-consolidated-interim-financial-statements-unaudited-for-the--acb-20230210monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-fiscal-2023-second-quarter-results-nasdaq-tsx-acb-cannabis-reven-acb-20230209monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-host-second-quarter-fiscal-year-2023-investor-conference-call-edmonton--acb-20230126monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-sale-of-polaris-facility-balance-sheet-remains-among-strongest-i-acb-20230104monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-repurchases-103-million-principal-amount-of-convertible-notes-balance-shee-acb-20221205monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-inc-and-computershare-trust-company-of-canada-warrant-indenture-providing--acb-20221128monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-results-of-2022-annual-general-and-special-meeting-nasdaq-tsx-acb-20221114monthly0.5https://www.biopharmawatch.com/news/ACB/annual-general-and-special-meeting-of-shareholders-of-aurora-cannabis-inc-the-company-acb-20221114monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-inc-condensed-consolidated-interim-financial-statements-unaudited-for-the--acb-20221114monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-fiscal-2023-first-quarter-results-nasdaq-tsx-acb-reiterates-reac-acb-20221110monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-host-first-quarter-fiscal-year-2023-investor-conference-call-nasdaq-tsx-acb-20221027monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-mailing-of-management-information-circular-for-the-annual-and-sp-acb-20221018monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-repurchases-us-23-million-principal-amount-of-convertible-notes-balance-sh-acb-20221007monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-fiscal-2022-fourth-quarter-and-full-year-results-remains-1-canad-acb-20220920monthly0.5https://www.biopharmawatch.com/news/ACB/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aurora-cannabis-in-acb-20220825monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-host-fourth-quarter-and-full-fiscal-year-2022-investor-conference-call--acb-20220829monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-acquires-controlling-interest-in-bevo-farms-nasdaq-tsx-acb-long-term-inves-acb-20220825monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-repurchases-us-20-million-of-convertible-notes-aurora-further-strengthens--acb-20220603monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-inc-and-computershare-trust-company-of-canada-warrant-indenture-providing--acb-20220601monthly0.5https://www.biopharmawatch.com/news/ACB/execution-version-61-225-000-units-aurora-cannabis-inc-acb-20220527monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-inc-announces-us-125-million-bought-deal-financing-edmonton-ab-acb-20220526monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-strengthens-leadership-position-in-germany-with-eu-gmp-certification-at-preeminent--acb-20220518monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-inc-condensed-consolidated-interim-financial-statements-unaudited-for-the--acb-20220513monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-fiscal-2022-third-quarter-results-increasing-original-target-for-acb-20220512monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-advances-premiumization-strategy-by-completing-acquisition-of-thrive-canna-acb-20220505monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-host-third-quarter-fiscal-year-2022-investor-conference-call-edmonton-a-acb-20220503monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-advances-premiumization-strategy-by-acquiring-thrive-cannabis-and-its-awar-acb-20220322monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-inc-condensed-consolidated-interim-financial-statements-unaudited-for-the--acb-20220211monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-fiscal-2022-second-quarter-results-global-cannabis-net-revenue-o-acb-20220210monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-s-reliva-expands-portfolio-with-new-cbd-brand-kg7-nasdaq-tsx-acb-sports-or-acb-20220203monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-host-second-quarter-fiscal-year-2022-investor-conference-call-nasdaq-ts-acb-20220201monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-delivers-10-million-shipment-of-medical-cannabis-to-israel-nasdaq-tsx-acb--acb-20220104monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-new-director-and-updates-to-the-board-newly-created-directorship-acb-20220104monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-and-22nd-century-group-license-foundational-biosynthesis-ip-to-cronos-group-licensi-acb-20211214monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-builds-on-a-decade-of-global-leadership-in-plant-genetics-with-the-launch-of-occo-g-acb-20211116monthly0.5https://www.biopharmawatch.com/news/ACB/annual-general-meeting-of-shareholders-of-aurora-cannabis-inc-the-company-acb-20211112monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-results-of-2021-annual-general-meeting-nasdaq-tsx-acb-20211112monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-inc-condensed-consolidated-interim-financial-statements-unaudited-for-the--acb-20211110monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-fiscal-2022-first-quarter-results-transformation-plan-on-track-a-acb-20211109monthly0.5https://www.biopharmawatch.com/news/ACB/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aurora-cannabis-in-acb-20211108monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-acquires-a-significant-equity-stake-in-growery-b-v-one-of-10-successful-ap-acb-20211108monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-announces-manufacturing-agreement-with-the-valens-company-new-seasonal-offerings-sl-acb-20211028monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-host-first-quarter-fiscal-year-2022-investor-conference-call-edmonton-a-acb-20211026monthly0.5https://www.biopharmawatch.com/news/ACB/what-s-inside-letter-to-shareholders-notice-of-annual-general-meeting-of-shareholders-soli-acb-20211006monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-fiscal-2021-fourth-quarter-results-nasdaq-tsx-acb-1-canadian-lp--acb-20210927monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-reschedules-fourth-quarter-and-full-fiscal-year-2021-investor-conference-c-acb-20210920monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-host-fourth-quarter-and-full-fiscal-year-2021-investor-conference-call--acb-20210907monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-marks-successful-inaugural-fulfillment-for-french-pilot-program-nasdaq-tsx-acb-20210825monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-appointment-of-new-independent-director-distinguished-senior-hea-acb-20210726monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-delivers-8-million-shipment-of-cannabis-to-israel-shipment-is-part-of-the--acb-20210715monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-completes-balance-sheet-restructuring-full-repayment-of-credit-facility-re-acb-20210601monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-participate-in-three-upcoming-virtual-investor-conferences-nasdaq-tsx-acb-20210528monthly0.5https://www.biopharmawatch.com/news/ACB/new-science-innovation-business-unit-to-advance-aurora-s-leadership-in-biosynthesis-and-pl-acb-20210527monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-begin-trading-on-the-the-nasdaq-global-select-market-on-acb-20210525monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-announces-filing-of-prospectus-supplement-for-at-the-market-offering-program-nyse-t-acb-20210520monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-to-participate-in-bmo-capital-markets-farm-to-market-virtual-conference-edmonton-ab-acb-20210514monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-inc-condensed-consolidated-interim-financial-statements-unaudited-for-the--acb-20210514monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-fiscal-2021-third-quarter-results-domestic-medical-net-revenue-s-acb-20210512monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-host-third-quarter-fiscal-year-2021-investor-conference-call-nyse-tsx-acb-20210430monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-filing-of-preliminary-base-shelf-prospectus-nyse-tsx-acb-20210310monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-inc-condensed-consolidated-interim-financial-statements-unaudited-for-the--acb-20210211monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-fiscal-2021-second-quarter-results-total-cannabis-net-revenue-of-acb-20210210monthly0.5https://www.biopharmawatch.com/news/ACB/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aurora-cannabis-in-acb-20210126monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-host-second-quarter-fiscal-year-2021-investor-conference-call-nyse-tsx-acb-20210128monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-and-medreleaf-australia-announce-strategic-agreement-broadest-medical-cann-acb-20210127monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-inc-and-computershare-trust-company-of-canada-warrant-indenture-providing--acb-20210126monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-closes-previously-announced-bought-deal-financing-over-allotment-option-ex-acb-20210126monthly0.5https://www.biopharmawatch.com/news/ACB/execution-version-12-000-000-units-aurora-cannabis-inc-acb-20210122monthly0.5https://www.biopharmawatch.com/news/ACB/filed-by-newsfilecorp-com-aurora-cannabis-inc-as-borrower-and-the-lenders-from-time-to-tim-acb-20210122monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-inc-announces-us-125-million-bought-deal-financing-nyse-tsx-acb-20210121monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-operational-balance-sheet-improvements-revised-credit-facility-t-acb-20201216monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-israeli-medical-supply-agreement-with-cantek-aurora-strategicall-acb-20201125monthly0.5https://www.biopharmawatch.com/news/ACB/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aurora-cannabis-in-acb-20201116monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-closes-previously-announced-upsized-underwritten-public-offering-over-allo-acb-20201116monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-announces-results-of-2020-annual-general-and-special-meeting-nyse-tsx-acb-20201116monthly0.5https://www.biopharmawatch.com/news/ACB/execution-version-20-000-000-units-aurora-cannabis-inc-acb-20201111monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-inc-condensed-consolidated-interim-financial-statements-unaudited-for-the--acb-20201109monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-fiscal-first-quarter-2021-results-1-canadian-medical-position-by-acb-20201109monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-obtains-receipt-for-final-base-shelf-prospectus-reiterates-fiscal-q1-guida-acb-20201030monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-host-first-quarter-fiscal-year-2021-investor-conference-call-nyse-tsx-acb-20201028monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-filing-of-preliminary-base-shelf-prospectus-and-provides-update--acb-20201027monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-inc-the-company-notice-of-annual-general-and-special-meeting-of-shareholde-acb-20201001monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-date-of-annual-general-meeting-nyse-tsx-acb-20200928monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-fiscal-fourth-quarter-2020-results-continued-adjusted-ebitda-imp-acb-20200922monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-host-fourth-quarter-and-full-fiscal-year-2020-investor-conference-call--acb-20200914monthly0.5https://www.biopharmawatch.com/news/ACB/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aurora-cannabis-in-acb-20200908monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-provides-business-updates-and-announces-new-ceo-appoints-miguel-martin-as--acb-20200908monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-appoints-miguel-martin-as-ceo-nyse-tsx-acb-20200908monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-appoints-international-consumer-packaged-goods-executive-miguel-martin-as--acb-20200706monthly0.5https://www.biopharmawatch.com/news/ACB/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aurora-cannabis-in-acb-20200626monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-retirement-of-terry-booth-from-board-of-directors-nyse-tsx-acb-20200629monthly0.5https://www.biopharmawatch.com/news/ACB/alcanna-inc-completes-27-6-million-secondary-bought-deal-offering-by-aurora-cannabis-inc-acb-20200624monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-provides-key-updates-on-business-transformation-plan-nyse-tsx-acb-continue-acb-20200623monthly0.5https://www.biopharmawatch.com/news/ACB/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aurora-cannabis-in-acb-20200616monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-retirement-of-co-founder-and-president-steve-dobler-nyse-tsx-acb-20200616monthly0.5https://www.biopharmawatch.com/news/ACB/execution-copy-first-amended-and-restated-credit-agreement-this-agreement-dated-acb-20200612monthly0.5https://www.biopharmawatch.com/news/ACB/filed-by-newsfilecorp-com-alcanna-inc-announces-27-6-million-secondary-bought-deal-offerin-acb-20200603monthly0.5https://www.biopharmawatch.com/news/ACB/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aurora-cannabis-in-acb-20200528monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-strategically-enter-the-united-states-with-acquisition-of-reliva-llc-a--acb-20200520monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-inc-condensed-consolidated-interim-financial-statements-unaudited-for-the--acb-20200515monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-fiscal-third-quarter-2020-results-operational-reset-update-net-r-acb-20200514monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-confirms-share-consolidation-effective-date-nyse-tsx-acb-common-shares-of--acb-20200511monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-host-third-quarter-2020-investor-conference-call-nyse-tsx-acb-20200501monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-inc-the-corporation-information-notice-consolidation-of-shares-to-investor-acb-20200412monthly0.5https://www.biopharmawatch.com/news/ACB/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aurora-cannabis-in-acb-20200413monthly0.5https://www.biopharmawatch.com/news/ACB/execution-acb-20200415monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-provides-update-on-initiatives-to-strengthen-liquidity-business-transforma-acb-20200413monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-share-sale-by-founder-terry-booth-transaction-in-connection-with-acb-20200316monthly0.5https://www.biopharmawatch.com/news/ACB/execution-copy-aurora-cannabis-inc-and-anandia-laboratories-inc-arrangement-agreement-date-acb-20200225monthly0.5https://www.biopharmawatch.com/news/ACB/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aurora-cannabis-in-acb-20200206monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-inc-condensed-consolidated-interim-financial-statements-unaudited-for-the--acb-20200213monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-second-quarter-2020-results-net-revenue-of-66-6-million-excludin-acb-20200213monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-host-second-quarter-2020-investor-conference-call-nyse-tsx-acb-20200210monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-appointment-of-two-new-independent-directors-friedmann-and-detle-acb-20200206monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-ceo-retirement-and-succession-board-of-directors-expansion-and-b-acb-20200207monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-receives-eu-gmp-certification-for-its-aurora-river-facility-achievement-in-acb-20200203monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-provides-corporate-update-and-confirms-cannabis-2-0-roll-out-nyse-tsx-acb--acb-20191223monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-change-to-executive-team-cam-battley-steps-away-from-his-role-as-acb-20191221monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-achieves-highest-cannabis-corporate-boards-ranking-in-2019-globe-mail-boar-acb-20191202monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-receives-first-approval-for-medicinal-cannabis-product-in-ireland-tsx-nyse-acb-20191202monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-opens-experiential-flagship-store-in-north-america-s-largest-mall-11-000-s-acb-20191127monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-strengthens-leadership-team-adding-chief-product-officer-and-chief-integra-acb-20191120monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-inc-condensed-consolidated-interim-financial-statements-unaudited-for-the--acb-20191114monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-first-quarter-2020-results-corporate-action-plan-nyse-tsx-acb-re-acb-20191114monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-temporary-amended-early-conversion-privilege-for-its-2020-conver-acb-20191114monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-2019-agm-voting-results-all-items-of-business-approved-edmonton-acb-20191111monthly0.5https://www.biopharmawatch.com/news/ACB/consumer-legalization-one-year-later-aurora-cannabis-reveals-sneak-peek-of-plans-for-nextg-acb-20191016monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-and-ctt-pharmaceutical-announce-launch-of-sublingual-cannabis-wafers-disso-acb-20191008monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-provides-update-on-global-operations-and-growth-initiatives-tsx-acb-nyse-a-acb-20191003monthly0.5https://www.biopharmawatch.com/news/ACB/notice-of-annual-general-meeting-of-shareholders-we-are-pleased-to-invite-you-to-the-annua-acb-20190923monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-date-of-annual-general-meeting-tsx-acb-nyse-acb-20190920monthly0.5https://www.biopharmawatch.com/news/ACB/liquor-stores-n-a-ltd-and-aurora-cannabis-inc-and-2095173-acb-20190920monthly0.5https://www.biopharmawatch.com/news/ACB/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aurora-cannabis-in-acb-20190909monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-financial-results-for-the-fourth-quarter-and-2019-fiscal-year-ge-acb-20190911monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-closes-expanded-c-360-million-us-280-million-credit-facility-nyse-tsx-acb-20190909monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-sale-of-remaining-shares-in-the-green-organic-dutchman-sale-of-n-acb-20190904monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-host-fourth-quarter-2019-investor-conference-call-nyse-acb-tsx-acb-20190903monthly0.5https://www.biopharmawatch.com/news/ACB/burrard-st-3rd-floor-date-acb-20190815monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-completes-hempco-food-and-fibre-acquisition-nyse-tsx-acb-introduces-aurora-acb-20190819monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-upsizing-of-credit-facility-to-approximately-c-360-million-us-28-acb-20190815monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-provides-corporate-update-for-the-fourth-quarter-of-fiscal-2019-tsx-nyse-acb-20190806monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-and-ufc-launch-clinical-research-on-use-of-hemp-derived-cbd-products-by-mm-acb-20190724monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-selected-as-sole-winner-in-italian-cannabis-tender-secures-two-year-contra-acb-20190718monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-obtains-two-licences-for-outdoor-growing-operations-new-outdoor-research-s-acb-20190715monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-prepared-for-expansion-of-canada-s-cannabis-market-efficient-distribution--acb-20190621monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-and-ufc-join-forces-to-advance-cbd-research-education-and-product-developm-acb-20190521monthly0.5https://www.biopharmawatch.com/news/ACB/execution-acb-20190514monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-inc-condensed-consolidated-interim-financial-statements-unaudited-for-the--acb-20190515monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-financial-results-for-the-third-quarter-of-fiscal-2019-solid-net-acb-20190514monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-and-radient-technologies-announce-first-commercial-delivery-of-cannabis-de-acb-20190513monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-extends-exclusive-supply-relationship-with-luxembourg-tsx-nyse-acb-20190509monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-host-third-quarter-2019-investor-conference-call-on-acb-20190506monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-and-enwave-corporation-enter-global-licensing-arrangements-establish-intel-acb-20190426monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-bolsters-anandia-s-testing-capabilities-through-acquisition-of-chemi-pharmaceutical-acb-20190425monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-provides-update-on-german-cannabis-production-tender-public-appeal-process-acb-20190418monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-acquire-remaining-interest-in-hempco-food-and-fiber-inc-strengthens-exe-acb-20190416monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-provides-construction-update-on-aurora-sun-facility-footprint-increased-to-acb-20190410monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-awarded-maximum-number-of-lots-in-german-cannabis-production-tender-compan-acb-20190405monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-expands-management-team-to-support-strategic-initiatives-tsx-nyse-acb-appo-acb-20190404monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-files-preliminary-base-shelf-prospectus-tsx-acb-nyse-acb-provides-flexibility-to-ex-acb-20190402monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-appoints-nelson-peltz-as-strategic-advisor-nyse-tsx-acb-edmonton-and-acb-20190313monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-commences-cannabis-oil-sales-to-german-pharmacies-high-margin-derivative-products-a-acb-20190311monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-provides-update-on-its-strategic-investment-in-choom-tsx-nyse-acb-20190307monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-completes-whistler-medical-acquisition-adding-iconic-organic-certified-premium-cann-acb-20190304monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-expands-into-portugal-enhancing-european-market-leadership-new-production--acb-20190226monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-receives-health-canada-licensing-of-aurora-sky-and-medreleaf-bradford-sky--acb-20190225monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-broadens-senior-leadership-team-tsx-nyse-acb-darren-karasiuk-promoted-to-c-acb-20190221monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-key-changes-to-its-board-of-directors-tsx-nyse-acb-20190220monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-provides-update-on-its-strategic-investment-in-high-tide-inc-tsx-nyse-acb-20190213monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-construction-of-aurora-polaris-centre-of-excellence-for-value-ad-acb-20190212monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-makes-first-commercial-export-to-the-united-kingdom-tsx-acb-nyse-acb-20190211monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-inc-condensed-consolidated-interim-financial-statements-unaudited-for-the--acb-20190212monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-financial-results-for-the-second-quarter-of-fiscal-2019-83-seque-acb-20190211monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-confirmed-time-for-its-conference-call-to-discuss-second-quarter-acb-20190207monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-partner-radient-technologies-receives-standard-processing-license-nyse-tsx-acb-20190204monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-inc-and-glas-trust-company-llc-as-trustee-indenture-dated-as-of-acb-20190124monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-closes-offering-of-convertible-senior-notes-nyse-acb-tsx-acb-20190124monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-prices-offering-of-convertible-senior-notes-tsx-acb-nyse-acb-20190118monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-private-offering-of-us-250-million-of-convertible-senior-notes-d-acb-20190116monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-to-acquire-whistler-a-company-with-an-iconic-brand-offering-organic-certified-canna-acb-20190114monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-provides-guidance-for-the-second-quarter-of-fiscal-2019-anticipating-net-r-acb-20190108monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-inc-code-of-business-conduct-and-ethics-purpose-this-code-of-business-cond-acb-20181227monthly0.5https://www.biopharmawatch.com/news/ACB/annual-general-and-special-meeting-of-aurora-cannabis-inc-the-company-acb-20181224monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-expands-retail-exposure-through-strategic-investment-in-high-tide-particip-acb-20181213monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-acquire-mexico-s-farmacias-magistrales-s-a-first-license-to-import-manu-acb-20181210monthly0.5https://www.biopharmawatch.com/news/ACB/form-51-102f3-material-change-report-item-1-name-and-address-of-company-aurora-cannabis-in-acb-20181210monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-enter-mexico-market-via-exclusive-supply-arrangement-with-farmacias-mag-acb-20181207monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-increases-eu-footprint-with-medical-cannabis-shipment-to-luxembourg-receives-import-acb-20181206monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-inc-500-10355-jasper-avenue-edmonton-alberta-canada-t5j-1y6-tel-1-855-279--acb-20181130monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-2018-agm-voting-results-all-items-of-business-approved-tsx-nyse-acb-20181204monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-market-launch-of-softgel-capsules-tsx-nyse-acb-20181203monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-completes-australis-distribution-to-non-resident-shareholders-tsx-nyse-acb-20181128monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-ship-medical-cannabis-to-the-czech-republic-international-expansion-ext-acb-20181127monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-receives-final-regulatory-approval-and-completes-acquisition-of-icc-labs-e-acb-20181122monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-appoints-dr-jonathan-page-as-chief-science-officer-promotes-dr-shane-morri-acb-20181114monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-inc-condensed-interim-consolidated-financial-statements-unaudited-for-the--acb-20181113monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-financial-results-for-the-first-quarter-of-fiscal-2019-260-reven-acb-20181112monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-to-host-first-quarter-2019-investor-conference-call-on-acb-20181112monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-announces-grand-opening-of-aurora-eau-a-new-indoor-premium-cannabis-produc-acb-20181105monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-increases-cornerstone-investment-in-cannabis-retailer-choom-with-additiona-acb-20181105monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-receives-lenders-consent-for-proposed-acquisition-of-icc-milestone-towards-acb-20181101monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-receives-first-cannabis-import-permit-from-polish-ministry-of-health-first-acb-20181025monthly0.5https://www.biopharmawatch.com/news/ACB/aurora-cannabis-files-early-warning-report-in-connection-with-tgod-holding-tsx-acb-20181018monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-reports-second-quarter-2025-financial-results-and-provides-corporate-update-vi-imux-20250807monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-pricing-of-oversubscribed-65-million-underwritten-public-offering-imux-20250529monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-proposed-public-offering-imux-20250528monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-announces-vidofludimus-calcium-reduced-risk-of-disability-worsening-by-30-in-prima-imux-20250430monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-pricing-of-5-1-million-registered-direct-offering-led-by-aberdeen-in-imux-20250409monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-s-oral-imu-856-demonstrated-dose-dependent-increase-of-glp-1-in-celiac-disease-pat-imux-20250220monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-reports-third-quarter-2024-financial-results-and-provides-corporate-update-pos-imux-20241107monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-announces-positive-outcome-of-interim-analysis-of-phase-3-ensure-program-of-vidofl-imux-20241022monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-reports-second-quarter-2024-financial-results-and-provides-corporate-update-ja-imux-20240808monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-strengthens-its-board-of-directors-with-the-appointment-of-experienced-pharmac-imux-20240724monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-appoints-jason-tardio-as-chief-operating-officer-and-president-former-novartis-and-imux-20240709monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-reports-first-quarter-2024-financial-results-and-provides-corporate-update-sub-imux-20240508monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-reports-year-end-2023-financial-results-and-provides-corporate-update-signific-imux-20240222monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-private-placement-of-up-to-240-million-imux-20240105monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-reports-third-quarter-2023-financial-results-and-provides-corporate-update-pos-imux-20231114monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-reports-positive-interim-data-from-phase-2-calliper-trial-of-vidofludimus-calcium--imux-20231010monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-reports-second-quarter-2023-financial-results-and-provides-corporate-update-pr-imux-20230803monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-reports-first-quarter-2023-financial-results-and-provides-corporate-update-pos-imux-20230511monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-reports-positive-results-from-phase-1b-clinical-trial-of-imu-856-in-celiac-disease-imux-20230504monthly0.5https://www.biopharmawatch.com/news/IMUX/dated-april-27-2023-immunic-inc-strengthens-its-board-of-directors-with-the-appointment-of-imux-20230427monthly0.5https://www.biopharmawatch.com/news/IMUX/dated-april-5-2023-immunic-reports-positive-data-from-maintenance-phase-of-phase-2-caldose-imux-20230405monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-reports-year-end-2022-financial-results-and-provides-corporate-update-initial--imux-20230223monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-to-host-virtual-celiac-disease-r-d-day-to-highlight-current-pathways-for-drug-deve-imux-20230209monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-reports-new-data-from-phase-2-emphasis-trial-of-vidofludimus-calcium-in-relapsing--imux-20221117monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-reports-third-quarter-2022-financial-results-and-provides-corporate-update-72--imux-20221103monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-reports-pre-planned-phase-1b-interim-analysis-of-imu-935-in-psoriasis-patients-con-imux-20221020monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-60-0-million-oversubscribed-private-placement-equity-financing-imux-20221010monthly0.5https://www.biopharmawatch.com/news/IMUX/dated-september-20-2022-immunic-announces-positive-results-from-single-and-multiple-ascend-imux-20220920monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-reports-second-quarter-2022-financial-results-and-provides-corporate-update-in-imux-20220804monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-strengthens-its-board-of-directors-with-the-appointment-of-maria-t-rns-n-globa-imux-20220706monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-reports-top-line-data-from-phase-2-caldose-1-trial-of-vidofludimus-calcium-in--imux-20220531monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-reports-first-quarter-2022-financial-results-and-provides-corporate-update-top-imux-20220510monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-reports-year-end-2021-financial-results-and-highlights-recent-activity-initiat-imux-20220224monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-present-preclinical-data-for-vidofludimus-calcium-at-the-17th-congress-of-e-imux-20220218monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-publishes-positive-results-from-the-single-and-multiple-ascending-dose-parts-o-imux-20211214monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-reports-third-quarter-2021-financial-results-and-highlights-recent-activity-fu-imux-20211104monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-reports-second-quarter-2021-financial-results-and-highlights-recent-activity-r-imux-20210806monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-host-virtual-r-d-day-today-to-provide-an-update-on-the-preclinical-and-clin-imux-20210712monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-fda-clearance-to-begin-imu-838-phase-3-ensure-studies-in-relapsing-r-imux-20210701monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-reports-first-quarter-2021-financial-results-and-highlights-recent-activity-em-imux-20210506monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-and-4sc-ag-sign-agreement-regarding-the-settlement-of-royalty-obligations-for-immu-imux-20210331monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-reports-year-end-2020-financial-results-and-highlights-recent-activity-phase-3-imux-20210226monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-that-oral-treatment-imu-838-shows-evidence-of-clinical-activity-in-m-imux-20210218monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-reports-third-quarter-2020-financial-results-and-provides-corporate-update-rel-imux-20201105monthly0.5https://www.biopharmawatch.com/news/IMUX/eib-provides-immunic-with-up-to-24-5-million-to-support-ongoing-development-of-a-potential-imux-20201020monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-publishes-full-unblinded-clinical-data-from-phase-2-emphasis-trial-of-imu-838--imux-20200914monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-reports-positive-top-line-data-from-phase-2-emphasis-trial-of-imu-838-in-patie-imux-20200803monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-first-patients-enrolled-in-investigator-sponsored-phase-2-clinical-t-imux-20200727monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-first-patients-dosed-in-its-phase-2-calvid-1-clinical-trial-of-imu-8-imux-20200615monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-pricing-of-25-million-public-offering-of-common-stock-imux-20200610monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-host-virtual-r-d-day-today-imux-20200519monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-receives-first-regulatory-approval-from-german-health-authority-bfarm-to-initi-imux-20200513monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-reports-first-quarter-2020-financial-results-and-highlights-recent-activity-imux-20200508monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-pricing-of-15-million-financing-imux-20200423monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-reports-that-imu-838-a-selective-oral-dhodh-inhibitor-has-demonstrated-preclin-imux-20200422monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-reports-year-end-2019-financial-results-and-highlights-recent-achievements-top-imux-20200316monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-reports-third-quarter-2019-financial-results-and-highlights-recent-activity-imux-20191107monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-s-interim-dosing-analysis-of-imu-838-as-part-of-its-ongoing-phase-2-caldose-1--imux-20190905monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-reports-second-quarter-2019-financial-results-and-highlights-recent-activity-imux-20190808monthly0.5https://www.biopharmawatch.com/news/IMUX/updated-unaudited-pro-forma-condensed-combined-financial-information-on-imux-20190717monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-files-financial-statements-and-pro-forma-financial-information-in-accordance-w-imux-20190621monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-present-newly-available-preclinical-data-for-imu-935-in-poster-presentation-imux-20190604monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-therapeutics-and-vital-therapies-complete-transaction-creating-nasdaq-listed-compa-imux-20190415monthly0.5https://www.biopharmawatch.com/news/IMUX/investment-and-subscription-agreement-imux-20190107monthly0.5https://www.biopharmawatch.com/news/IMUX/vital-therapies-announces-third-quarter-2015-imux-20151105monthly0.5https://www.biopharmawatch.com/news/IMUX/vital-therapies-provides-corporate-imux-20151016monthly0.5https://www.biopharmawatch.com/news/IMUX/vital-therapies-outlines-plans-for-new-phase-3-trial-of-elad-r-in-alcohol-induced-liver-de-imux-20150928monthly0.5https://www.biopharmawatch.com/news/IMUX/additional-data-from-vti-208-presented-at-rostock-conference-imux-20150831monthly0.5https://www.biopharmawatch.com/news/IMUX/vital-therapies-announces-that-topline-results-of-vti-208-fail-to-achieve-primary-or-secon-imux-20150821monthly0.5https://www.biopharmawatch.com/news/IMUX/vital-therapies-reports-on-clinical-trial-progress-and-eu-regulatory-advice-san-diego-cali-imux-20140709monthly0.5https://www.biopharmawatch.com/news/IMUX/vital-therapies-announces-first-quarter-2014-financial-results-and-provides-operational-up-imux-20140528monthly0.5https://www.biopharmawatch.com/news/IMUX/vital-therapies-announces-full-exercise-of-underwriters-option-to-purchase-additional-shar-imux-20140506monthly0.5https://www.biopharmawatch.com/news/IMUX/vital-therapies-inc-reaches-midpoint-for-enrollment-in-vti-208-san-diego-ca-marketwire-imux-20140501monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-first-quarter-2026-financial-results-reported-first-quarter-year-over-yea-ingn-20260507monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-the-appointment-of-vafa-jamali-to-board-of-directors-ingn-20260406monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-leadership-appointments-designed-to-accelerate-next-phase-of-growth-jason-ingn-20260330monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-fourth-quarter-and-full-year-2025-financial-results-and-provides-2026-fin-ingn-20260224monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-preliminary-revenue-results-for-fourth-quarter-and-full-year-2025-inogen--ingn-20260112monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-third-quarter-2025-financial-results-delivered-seventh-consecutive-quarte-ingn-20251105monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-second-quarter-2025-financial-results-delivered-strong-top-line-results-r-ingn-20250807monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-first-quarter-2025-financial-results-ingn-20250507monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-fourth-quarter-and-full-year-2024-financial-results-x2022-results-reflect-ingn-20250225monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-appointment-of-mira-kirti-sahney-to-board-of-directors-and-retirement-of--ingn-20250203monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-expands-product-portfolio-global-reach-and-innovation-pipeline-through-strategic-co-ingn-20250126monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-preliminary-fourth-quarter-and-full-year-2024-revenue-ingn-20250113monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-receives-fda-510-k-clearance-for-simeox-200-airway-clearance-device-goleta-calif-x2-ingn-20241230monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-third-quarter-2024-financial-results-goleta-calif-x2013-ingn-20241107monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-second-quarter-2024-financial-results-goleta-calif-x2013-ingn-20240806monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-strengthens-leadership-team-with-appointment-of-new-general-counsel-and-executive-v-ingn-20240703monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-first-quarter-2024-financial-results-goleta-calif-x2013-ingn-20240507monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-fourth-quarter-and-full-year-2023-financial-results-fourth-quarter-2023-r-ingn-20240227monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-names-michael-bourque-as-new-chief-financial-officer-goleta-ca-x2013-ingn-20240124monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-leadership-change-with-the-appointment-of-kevin-smith-as-president-and-ce-ingn-20231113monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-third-quarter-2023-financial-results-ingn-20231107monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-completes-acquisition-of-physio-assist-acquisition-expands-inogen-s-global-respirat-ingn-20230918monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-cfo-transition-plan-x2013-names-mike-sergesketter-as-interim-chief-financ-ingn-20230907monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-second-quarter-2023-financial-results-ingn-20230807monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-expands-its-respiratory-product-portfolio-with-acquisition-of-physio-assist-acquisi-ingn-20230713monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-first-quarter-2023-financial-results-total-revenue-of-72-2-million-in-lin-ingn-20230504monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-appointment-of-tom-west-to-board-of-directors-and-retirement-of-board-mem-ingn-20230322monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-fourth-quarter-and-full-year-2022-financial-results-fourth-quarter-year-o-ingn-20230223monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-preliminary-fourth-quarter-and-full-year-2022-revenue-within-company-expe-ingn-20230110monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-third-quarter-2022-financial-results-double-digit-year-over-year-revenue--ingn-20221102monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-second-quarter-2022-financial-results-robust-sequential-revenue-growth-dr-ingn-20220804monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-first-quarter-2022-financial-results-q1-2022-total-revenue-of-80-4-millio-ingn-20220505monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-board-of-director-changes-glenn-boehnlein-kevin-king-and-mary-kay-ladone--ingn-20220323monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-names-kristin-caltrider-as-chief-financial-officer-goleta-california-ingn-20220304monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-fourth-quarter-and-full-year-2021-financial-results-q4-2021-total-revenue-ingn-20220224monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-preliminary-unaudited-full-year-and-fourth-quarter-2021-revenue-results-q-ingn-20220110monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-appoints-elizabeth-mora-as-board-chairperson-ray-huggenberger-retires-from-board-go-ingn-20211230monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-cfo-transition-plan-names-mike-sergesketter-as-interim-chief-financial-of-ingn-20211213monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-third-quarter-2021-financial-results-q3-2021-total-revenue-increased-25-3-ingn-20211104monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-second-quarter-2021-financial-results-q2-2021-record-total-revenue-of-101-ingn-20210804monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-strengthens-board-of-directors-with-addition-of-elizabeth-mora-goleta-california-ingn-20210524monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-first-quarter-2021-financial-results-q1-2021-total-revenue-of-86-9-millio-ingn-20210504monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-appointment-of-chief-commercial-officer-transition-of-certain-officers-an-ingn-20210407monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-fourth-quarter-2020-financial-results-q4-2020-total-revenue-of-74-0-milli-ingn-20210224monthly0.5https://www.biopharmawatch.com/news/INGN/about-inogen-we-are-a-medical-technology-company-offering-innovative-respiratory-products--ingn-20210216monthly0.5https://www.biopharmawatch.com/news/INGN/notice-regarding-forward-looking-statements-these-slides-and-the-accompanying-oral-present-ingn-20210111monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-third-quarter-2020-financial-results-q3-2020-total-revenue-of-74-3-millio-ingn-20201104monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-second-quarter-2020-financial-results-q2-2020-total-revenue-of-71-7-milli-ingn-20200804monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-ceo-announces-intent-to-retire-before-end-of-2021-inogen-commences-search-for-succe-ingn-20200609monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-first-quarter-2020-financial-results-q1-2020-total-revenue-of-88-5-millio-ingn-20200505monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-fourth-quarter-and-full-year-2019-financial-results-and-updates-2020-guid-ingn-20200225monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-preliminary-unaudited-full-year-and-fourth-quarter-2019-revenue-results-q-ingn-20200113monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-third-quarter-2019-financial-results-q3-2019-total-revenue-of-91-8-millio-ingn-20191105monthly0.5https://www.biopharmawatch.com/news/INGN/notice-regarding-forward-looking-statements-these-slides-and-the-accompanying-oral-present-ingn-20190909monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-second-quarter-2019-financial-results-and-updates-2019-guidance-q2-2019-r-ingn-20190807monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-first-quarter-2019-financial-results-and-updates-2019-guidance-q1-2019-sa-ingn-20190507monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-fourth-quarter-and-full-year-2018-financial-results-and-updates-2019-guid-ingn-20190226monthly0.5https://www.biopharmawatch.com/news/INGN/notice-regarding-forward-looking-statements-these-slides-and-the-accompanying-oral-present-ingn-20190107monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-third-quarter-2018-financial-results-q3-2018-sales-revenue-up-42-1-over-t-ingn-20181106monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-management-changes-goleta-california-ingn-20180828monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-record-second-quarter-2018-financial-results-and-increases-2018-guidance--ingn-20180807monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-record-first-quarter-2018-financial-results-and-increases-2018-guidance-q-ingn-20180430monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-fourth-quarter-and-full-year-2017-financial-results-and-updates-2018-guid-ingn-20180227monthly0.5https://www.biopharmawatch.com/news/INGN/notice-regarding-forward-looking-statements-these-slides-and-the-accompanying-oral-present-ingn-20180108monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-record-third-quarter-2017-financial-results-q3-2017-sales-revenue-up-33-8-ingn-20171107monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-record-second-quarter-2017-financial-results-q2-2017-sales-revenue-up-27--ingn-20170803monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-first-quarter-2017-financial-results-q1-2017-sales-revenue-up-40-1-over-t-ingn-20170509monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-fourth-quarter-and-full-year-2016-financial-results-and-updates-2017-guid-ingn-20170228monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-provides-impact-from-21-st-century-cures-act-impact-of-21-st-century-cures-act-expe-ingn-20170109monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-management-transitions-and-expanded-board-of-directors-scott-wilkinson-to-ingn-20161206monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-third-quarter-2016-financial-results-q3-2016-sales-revenue-up-61-3-over-t-ingn-20161103monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-second-quarter-2016-financial-results-record-revenue-and-net-income-quart-ingn-20160804monthly0.5https://www.biopharmawatch.com/news/INGN/correction-by-inogen-inc-goleta-calif-business-wire-in-the-news-release-inogen-announces-f-ingn-20160509monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-first-quarter-2016-financial-results-q1-2016-sales-revenue-up-42-4-over-t-ingn-20160509monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-fourth-quarter-and-full-year-2015-financial-results-and-updates-2016-guid-ingn-20160314monthly0.5https://www.biopharmawatch.com/news/INGN/company-overview-january-2016-notice-regarding-forward-looking-statements-these-slides-and-ingn-20160111monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-provides-additional-full-year-2016-guidance-reaffirms-2015-guidance-ingn-20151130monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-third-quarter-2015-financial-results-q3-2015-revenue-growth-of-38-7-over--ingn-20151110monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-second-quarter-2015-financial-results-record-q2-2015-total-revenue-adjust-ingn-20150811monthly0.5https://www.biopharmawatch.com/news/INGN/r-scott-greer-joins-inogen-board-of-directors-goleta-california-ingn-20150806monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-first-quarter-2015-financial-results-record-q1-2015-total-revenue-growth--ingn-20150512monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-fourth-quarter-and-full-year-2014-financial-results-and-updates-2015-outl-ingn-20150427monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-receives-expected-nasdaq-notice-related-to-delay-in-form-10-k-filing-goleta-califor-ingn-20150420monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-delays-filing-of-form-10-k-goleta-california-ingn-20150414monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-reaffirms-2015-guidance-announces-audit-committee-investigation-into-accounting-mat-ingn-20150311monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-discusses-oxygen-therapy-market-and-future-growth-drivers-at-investor-analyst-day-r-ingn-20141215monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-releases-third-quarter-2014-financial-results-q3-2014-revenues-reflect-48-6-year-ov-ingn-20141111monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-selects-jpmorgan-chase-co-for-primary-banking-relationship-new-agreement-enables-jp-ingn-20141110monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-announces-preliminary-unaudited-third-quarter-2014-revenue-goleta-california-ingn-20141027monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-releases-second-quarter-2014-financial-results-record-q2-2014-revenues-reflect-51-g-ingn-20140812monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-strengthens-board-of-directors-with-addition-of-heather-d-rider-goleta-california-ingn-20140807monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-releases-first-quarter-2014-financial-results-strong-q1-2014-revenue-growth-of-50-y-ingn-20140513monthly0.5https://www.biopharmawatch.com/news/INGN/inogen-releases-fourth-quarter-and-full-year-2013-financial-results-and-provides-2014-outl-ingn-20140327monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-reports-unaudited-fourth-quarter-and-full-year-2025-financial-results-bnr-20260312monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-announces-results-of-2025-annual-general-meeting-bnr-20251223monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-reports-third-quarter-2025-financial-results-bnr-20251120monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-reports-second-quarter-2025-financial-results-bnr-20250908monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-reports-first-quarter-2025-financial-results-bnr-20250606monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-reports-unaudited-fourth-quarter-and-full-year-2024-financial-results-bnr-20250325monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-announces-results-of-2024-annual-general-meeting-bnr-20241231monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-reports-third-quarter-2024-financial-results-bnr-20241204monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-announces-2024-annual-general-meeting-to-be-held-on-bnr-20241203monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-announces-changes-to-management-and-board-of-directors-bnr-20240927monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-reports-second-quarter-2024-financial-results-bnr-20240823monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-regains-compliance-with-nasdaq-minimum-bid-price-requirement-bnr-20240603monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-reports-first-quarter-2024-financial-results-bnr-20240529monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-announces-ads-ratio-change-to-be-effective-on-bnr-20240515monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-announces-ads-ratio-change-bnr-20240426monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-reports-fourth-quarter-and-full-year-2023-financial-results-bnr-20240329monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-announces-receipt-of-notification-from-bnr-20240104monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-announces-results-of-2023-annual-general-meeting-bnr-20231220monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-reports-third-quarter-2023-financial-results-bnr-20231130monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-announces-2023-annual-general-meeting-to-be-held-on-bnr-20231122monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-reports-second-quarter-2023-financial-results-bnr-20230831monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-announces-resignation-and-appointment-of-directors-bnr-20230628monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-reports-first-quarter-2023-financial-results-bnr-20230530monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-reports-fourth-quarter-and-full-year-2022-financial-results-bnr-20230328monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-provides-an-update-on-2022-revenue-guidance-bnr-20230118monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-received-fda-breakthrough-device-designation-for-its-overc-multi-cancer-detec-bnr-20230104monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-reports-third-quarter-2022-financial-results-bnr-20221116monthly0.5https://www.biopharmawatch.com/news/BNR/management-s-discussion-and-analysis-of-financial-condition-and-results-of-operations-disc-bnr-20221107monthly0.5https://www.biopharmawatch.com/news/BNR/not-for-release-publication-or-distribution-in-whole-or-part-directly-or-indirectly-in-or--bnr-20221102monthly0.5https://www.biopharmawatch.com/news/BNR/not-for-release-publication-or-distribution-in-whole-or-part-directly-or-indirectly-in-or--bnr-20221027monthly0.5https://www.biopharmawatch.com/news/BNR/not-for-release-publication-or-distribution-in-whole-or-part-directly-or-indirectly-in-or--bnr-20221021monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-announces-results-of-2022-annual-general-meeting-bnr-20220908monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-reports-second-quarter-2022-financial-results-bnr-20220831monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-announces-2022-annual-general-meeting-to-be-held-on-bnr-20220803monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-announces-resignation-of-director-bnr-20220715monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-announces-changes-to-board-composition-bnr-20220624monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-announces-us-10-million-share-repurchase-program-bnr-20220621monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-announces-plan-to-pursue-an-alternative-listing-bnr-20220621monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-reports-first-quarter-2022-financial-results-bnr-20220531monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-reports-fourth-quarter-and-full-year-2021-financial-results-bnr-20220322monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-announces-results-of-2021-annual-general-meeting-bnr-20211228monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-reports-third-quarter-2021-financial-results-bnr-20211116monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-reports-second-quarter-2021-financial-results-bnr-20210831monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-reports-first-quarter-2021-financial-results-bnr-20210525monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-reports-fourth-quarter-and-full-year-2020-financial-results-bnr-20210311monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-announces-proposed-registered-secondary-public-offering-of-american-depositar-bnr-20201202monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-reports-third-quarter-2020-financial-results-bnr-20201120monthly0.5https://www.biopharmawatch.com/news/BNR/burning-rock-reports-second-quarter-2020-financial-results-bnr-20200811monthly0.5https://www.biopharmawatch.com/news/OKUR/onkure-therapeutics-reports-second-quarter-2025-financial-results-and-provides-a-business--okur-20250812monthly0.5https://www.biopharmawatch.com/news/OKUR/legends-forward-looking-statements-this-presentation-contains-forward-looking-statements-t-okur-20250626monthly0.5https://www.biopharmawatch.com/news/OKUR/onkure-therapeutics-reports-first-quarter-2025-financial-results-and-business-highlights-c-okur-20250506monthly0.5https://www.biopharmawatch.com/news/OKUR/onkure-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-okur-20250310monthly0.5https://www.biopharmawatch.com/news/OKUR/onkure-announces-encouraging-preliminary-safety-tolerability-and-pharmacokinetic-pk-data-f-okur-20241210monthly0.5https://www.biopharmawatch.com/news/OKUR/index-to-unaudited-condensed-financial-statements-unaudited-condensed-financial-statements-okur-20241107monthly0.5https://www.biopharmawatch.com/news/OKUR/report-of-independent-registered-public-accounting-firm-to-the-board-of-directors-and-stoc-okur-20241008monthly0.5https://www.biopharmawatch.com/news/OKUR/reneo-pharmaceuticals-reports-second-quarter-2024-financial-results-okur-20240813monthly0.5https://www.biopharmawatch.com/news/OKUR/reneo-pharmaceuticals-and-onkure-announce-proposed-merger-merger-to-create-a-nasdaq-listed-okur-20240513monthly0.5https://www.biopharmawatch.com/news/OKUR/reneo-pharmaceuticals-reports-first-quarter-2024-financial-results-okur-20240507monthly0.5https://www.biopharmawatch.com/news/OKUR/reneo-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results-and-busi-okur-20240328monthly0.5https://www.biopharmawatch.com/news/OKUR/reneo-pharmaceuticals-reports-third-quarter-2023-financial-results-topline-data-results-fr-okur-20231113monthly0.5https://www.biopharmawatch.com/news/OKUR/focused-on-improving-the-lives-of-patients-with-rare-genetic-mitochondrial-diseases-k-ke-e-okur-20231009monthly0.5https://www.biopharmawatch.com/news/OKUR/reneo-pharmaceuticals-reports-second-quarter-2023-financial-results-topline-results-of-the-okur-20230810monthly0.5https://www.biopharmawatch.com/news/OKUR/reneo-pharmaceuticals-reports-first-quarter-2023-financial-results-x2022-completed-enrollm-okur-20230511monthly0.5https://www.biopharmawatch.com/news/OKUR/reneo-pharmaceuticals-announces-proposed-public-offering-of-common-stock-okur-20230503monthly0.5https://www.biopharmawatch.com/news/OKUR/focused-on-improving-the-lives-of-patients-with-rare-genetic-mitochondrial-diseases-nasdaq-okur-20230503monthly0.5https://www.biopharmawatch.com/news/OKUR/reneo-pharmaceuticals-reports-fourth-quarter-and-full-year-2022-financial-results-and-prov-okur-20230327monthly0.5https://www.biopharmawatch.com/news/OKUR/forward-looking-statements-this-presentation-contains-forward-looking-statements-that-are--okur-20230109monthly0.5https://www.biopharmawatch.com/news/OKUR/reneo-pharmaceuticals-reports-third-quarter-2022-financial-results-okur-20221108monthly0.5https://www.biopharmawatch.com/news/OKUR/reneo-pharmaceuticals-reports-second-quarter-2022-financial-results-okur-20220809monthly0.5https://www.biopharmawatch.com/news/OKUR/reneo-pharmaceuticals-reports-first-quarter-2022-financial-results-okur-20220510monthly0.5https://www.biopharmawatch.com/news/OKUR/reneo-pharmaceuticals-reports-fourth-quarter-and-full-year-2021-financial-results-and-prov-okur-20220323monthly0.5https://www.biopharmawatch.com/news/OKUR/reneo-pharmaceuticals-reports-third-quarter-2021-financial-results-irvine-calif-okur-20211111monthly0.5https://www.biopharmawatch.com/news/OKUR/nasdaq-rphm-august-2021-focused-on-improving-the-lives-of-patients-with-rare-genetic-mitoc-okur-20210811monthly0.5https://www.biopharmawatch.com/news/OKUR/reneo-pharmaceuticals-reports-second-quarter-2021-financial-results-first-patient-dosed-in-okur-20210811monthly0.5https://www.biopharmawatch.com/news/OKUR/reneo-pharmaceuticals-reports-first-quarter-2021-financial-results-okur-20210520monthly0.5https://www.biopharmawatch.com/news/NGEN/form-51-102f3-material-change-report-item-1-name-and-address-of-company-nervgen-pharma-cor-ngen-20260521monthly0.5https://www.biopharmawatch.com/news/NGEN/condensed-consolidated-interim-financial-statements-of-nervgen-pharma-corp-expressed-in-ca-ngen-20260515monthly0.5https://www.biopharmawatch.com/news/NGEN/form-51-102f3-material-change-report-item-1-name-and-address-of-reporting-issuer-nervgen-p-ngen-20260312monthly0.5https://www.biopharmawatch.com/news/NGEN/form-51-102f3-material-change-report-item-1-name-and-address-of-reporting-issuer-nervgen-p-ngen-20260108monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provid-tnya-20260311monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-reports-second-quarter-2025-financial-results-and-provides-business-up-tnya-20250806monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-reports-first-quarter-2025-financial-results-and-provides-business-upd-tnya-20250507monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-provid-tnya-20250310monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-announces-pricing-of-public-offering-south-san-francisco-calif-tnya-20250303monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-reports-promising-early-data-from-mypeak-1-phase-1b-2-clinical-trial-o-tnya-20241217monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-upd-tnya-20241106monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-reports-second-quarter-2024-financial-results-and-provides-business-up-tnya-20240808monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-reports-first-quarter-2024-financial-results-and-provides-business-upd-tnya-20240514monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-provid-tnya-20240318monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-announces-pricing-of-underwritten-offering-south-san-francisco-calif-tnya-20240208monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-reports-third-quarter-2023-financial-results-and-provides-business-upd-tnya-20231108monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-reports-second-quarter-2023-financial-results-and-provides-business-up-tnya-20230809monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-reports-first-quarter-2023-financial-results-and-provides-business-upd-tnya-20230510monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-provid-tnya-20230308monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-appoints-amy-burroughs-to-board-of-directors-south-san-francisco-calif-tnya-20221207monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-announces-pricing-of-public-offering-south-san-francisco-calif-tnya-20221117monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-reports-third-quarter-2022-financial-results-and-provides-business-upd-tnya-20221110monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-reports-second-quarter-2022-financial-results-and-provides-business-up-tnya-20220810monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-reports-first-quarter-2022-financial-results-and-provides-business-upd-tnya-20220511monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-reports-fourth-quarter-and-year-end-2021-financial-results-and-provide-tnya-20220323monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-appoints-karah-parschauer-j-d-to-its-board-of-directors-and-joanna-auc-tnya-20211222monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-announces-the-addition-of-dr-june-lee-to-its-board-of-directors-south--tnya-20211122monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-reports-third-quarter-2021-financial-results-and-provides-business-upd-tnya-20211110monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-reports-second-quarter-2021-financial-results-and-provides-business-up-tnya-20210908monthly0.5https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-announces-closing-of-upsized-initial-public-offering-and-exercise-in-f-tnya-20210803monthly0.5https://www.biopharmawatch.com/news/IPHA/number-of-shares-and-voting-rights-of-innate-pharma-as-of-ipha-20260512monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-conference-call-and-webcast-for-q1-2026-business-update-marseille--ipha-20260506monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-to-participate-in-the-d-boral-capital-global-conference-marseille-france-ipha-20260423monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-to-present-matisse-phase-2-interim-results-of-iph5201-in-clinical-trials-ple-ipha-20260417monthly0.5https://www.biopharmawatch.com/news/IPHA/number-of-shares-and-voting-rights-of-innate-pharma-as-of-ipha-20260409monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-files-its-2025-universal-registration-document-document-d-enregistrement-uni-ipha-20260402monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-conference-call-and-webcast-for-full-year-2025-financial-results-m-ipha-20260319monthly0.5https://www.biopharmawatch.com/news/IPHA/number-of-shares-and-voting-rights-of-innate-pharma-as-of-december-31-2025-marseille-franc-ipha-20260107monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-to-present-at-jefferies-global-healthcare-conference-marseille-france-ipha-20251117monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-reports-third-quarter-2025-business-update-and-financial-results-marseille-f-ipha-20251113monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-fda-clearance-to-proceed-with-tellomak-3-a-confirmatory-phase-3-tr-ipha-20251110monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-conference-call-and-webcast-for-third-quarter-2025-results-and-bus-ipha-20251105monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-to-host-analyst-and-investor-event-on-lacutamab-on-october-28-2025-marseille-ipha-20251014monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-its-participation-in-the-25th-edition-of-the-european-midcap-event-ipha-20250915monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-conference-call-and-webcast-for-first-half-2025-financial-results--ipha-20250910monthly0.5https://www.biopharmawatch.com/news/IPHA/number-of-shares-and-voting-rights-of-innate-pharma-as-of-september-1-2025-marseille-franc-ipha-20250902monthly0.5https://www.biopharmawatch.com/news/IPHA/number-of-shares-and-voting-rights-of-innate-pharma-as-of-august-1-2025-marseille-france-ipha-20250804monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-its-participation-in-btig-virtual-biotechnology-conference-marseil-ipha-20250729monthly0.5https://www.biopharmawatch.com/news/IPHA/number-of-shares-and-voting-rights-of-innate-pharma-as-of-july-3-2025-marseille-france-ipha-20250704monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-its-participation-in-h-c-wainwright-and-wolfe-research-healthcare--ipha-20250617monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-highlights-preclinical-antitumor-activity-of-iph6501-in-diffuse-large-b-cell-ipha-20250613monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-its-participation-in-jefferies-and-goldman-sachs-healthcare-confer-ipha-20250527monthly0.5https://www.biopharmawatch.com/news/IPHA/outcome-of-innate-pharma-s-2025-annual-general-meeting-marseille-france-ipha-20250523monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-highlights-durable-responses-to-lacutamab-in-sezary-syndrome-and-mycosis-fun-ipha-20250523monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-highlights-abstracts-selected-for-asco-2025-annual-meeting-marseille-france-ipha-20250519monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-highlights-anket-abstracts-selected-for-the-eha-2025-congress-marseille-fran-ipha-20250515monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-reports-first-quarter-2025-business-update-and-financial-results-marseille-f-ipha-20250513monthly0.5https://www.biopharmawatch.com/news/IPHA/number-of-shares-and-voting-rights-of-innate-pharma-as-of-may-5-2025-marseille-france-ipha-20250512monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-conference-call-and-webcast-for-q1-2025-business-update-marseille--ipha-20250506monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-files-its-2024-universal-registration-document-document-d-enregistrement-uni-ipha-20250430monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-highlights-preclinical-anti-tumor-efficacy-data-of-its-antibody-drug-conjuga-ipha-20250429monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-files-its-2024-universal-registration-document-document-d-enregistrement-uni-ipha-20250428monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-15m-investment-by-sanofi-marseille-france-ipha-20250424monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-regains-its-rights-on-cd123-targeting-anket-and-announces-sanofi-s-intention-ipha-20250423monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-to-hold-its-annual-general-meeting-of-shareholders-on-may-22-2025-marseille--ipha-20250416monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-proposes-to-its-shareholders-to-transform-its-corporate-governance-structure-ipha-20250416monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-to-participate-in-the-2025-stifel-virtual-targeted-oncology-forum-marseille--ipha-20250403monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-reports-full-year-2024-financial-results-and-business-update-marseille-franc-ipha-20250327monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-highlights-antibody-drug-conjugate-iph4502-abstract-selected-for-the-aacr-20-ipha-20250326monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-its-participation-in-the-life-sciences-van-lanschot-kempen-confere-ipha-20250325monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-conference-call-and-webcast-for-full-year-2024-financial-results-m-ipha-20250320monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-to-participate-in-the-2025-leerink-partners-global-healthcare-conference-mar-ipha-20250227monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-u-s-fda-granted-breakthrough-therapy-designation-to-lacutamab-for--ipha-20250217monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-first-patient-dosed-in-phase-1-study-of-its-nectin-4-targeting-ant-ipha-20250127monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-nectin-4-antibody-drug-conjugate-investor-and-analyst-event-in-new-ipha-20250121monthly0.5https://www.biopharmawatch.com/news/IPHA/number-of-shares-and-voting-rights-of-innate-pharma-as-of-december-31-2024-marseille-franc-ipha-20250116monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-transformative-strategy-to-accelerate-growth-marseille-france-ipha-20250110monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-to-participate-in-the-43-rd-annual-j-p-morgan-healthcare-conference-marseill-ipha-20241220monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-presents-lacutamab-improved-health-related-quality-of-life-data-at-ash-2024--ipha-20241209monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-and-the-institute-for-follicular-lymphoma-innovation-ifli-announce-up-to-7-9-ipha-20241206monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-highlights-abstracts-selected-for-the-ash-annual-meeting-2024-marseille-fran-ipha-20241203monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-releases-its-2025-financial-calendar-marseille-france-ipha-20241120monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-publication-in-science-immunology-highlighting-innovative-next-gen-ipha-20241119monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-reports-third-quarter-2024-business-update-and-financial-results-marseille-f-ipha-20241113monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-highlights-data-from-its-innovative-oncology-portfolio-selected-for-the-sitc-ipha-20241108monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-conference-call-and-webcast-for-third-quarter-2024-results-and-bus-ipha-20241107monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-marseille-franc-ipha-20241029monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-appoints-jonathan-dickinson-as-new-chief-executive-officer-and-chairman-of-t-ipha-20241014monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-to-host-kol-scientific-symposium-on-immunotherapy-in-new-york-on-ipha-20241003monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-fda-clearance-of-the-ind-for-iph4502-a-nectin-4-adc-to-be-develope-ipha-20240923monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-reports-first-half-2024-business-update-and-financial-results-marseille-fran-ipha-20240912monthly0.5https://www.biopharmawatch.com/news/IPHA/monalizumab-data-from-neocoast-2-phase-2-study-in-early-stage-nsclc-presented-at-the-wclc--ipha-20240909monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-conference-call-and-webcast-for-first-half-2024-financial-results--ipha-20240905monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-its-participation-in-the-h-c-wainwright-26th-annual-global-investm-ipha-20240904monthly0.5https://www.biopharmawatch.com/news/IPHA/number-of-shares-and-voting-rights-of-innate-pharma-as-of-ipha-20240710monthly0.5https://www.biopharmawatch.com/news/IPHA/number-of-shares-and-voting-rights-of-innate-pharma-as-of-ipha-20240610monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-shares-updated-results-from-the-sanofi-developed-blood-cancer-phase-1-2-sar4-ipha-20240617monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-presents-positive-results-from-tellomak-phase-2-study-with-lacutamab-in-myco-ipha-20240604monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-its-participation-in-upcoming-investor-conferences-marseille-franc-ipha-20240528monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-highlights-abstracts-selected-for-asco-2024-annual-meeting-marseille-france-ipha-20240524monthly0.5https://www.biopharmawatch.com/news/IPHA/outcome-of-innate-pharma-s-2024-annual-general-meeting-marseille-france-ipha-20240523monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-highlights-abstracts-selected-for-eha-2024-congress-marseille-france-ipha-20240515monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-reports-first-quarter-2024-business-update-and-financial-results-marseille-f-ipha-20240514monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-conference-call-and-webcast-for-q1-2024-business-update-marseille--ipha-20240507monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-advancement-of-sanofi-developed-nk-cell-engager-sar443579-iph6101--ipha-20240415monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-to-hold-its-annual-general-meeting-of-shareholders-on-ipha-20240415monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-presents-at-aacr-2024-preclinical-efficacy-of-its-pre-ind-drug-candidate-iph-ipha-20240410monthly0.5https://www.biopharmawatch.com/news/IPHA/summary-of-consolidated-financial-statements-and-notes-as-of-ipha-20240321monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-reports-full-year-2023-financial-results-and-business-update-positive-final--ipha-20240321monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-its-participation-to-upcoming-investor-conference-marseille-france-ipha-20240319monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-conference-call-and-webcast-for-full-year-2023-financial-results-m-ipha-20240314monthly0.5https://www.biopharmawatch.com/news/IPHA/first-patient-dosed-in-phase-1-2-study-of-iph6501-in-relapsed-refractory-b-cell-non-hodgki-ipha-20240306monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-to-present-nectin-4-antibody-drug-conjugate-iph45-preclinical-data-at-aacr-2-ipha-20240306monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-its-participation-to-upcoming-investor-conference-marseille-france-ipha-20240221monthly0.5https://www.biopharmawatch.com/news/IPHA/number-of-shares-and-voting-rights-of-innate-pharma-as-of-ipha-20240101monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-u-s-fda-lifts-partial-clinical-hold-on-lacutamab-clinical-program--ipha-20240104monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-strengthens-leadership-and-appoints-two-new-members-to-its-executive-board-t-ipha-20240104monthly0.5https://www.biopharmawatch.com/news/IPHA/recent-developments-since-ipha-20231220monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-licensing-of-a-fourth-natural-killer-cell-engager-in-oncology-to-s-ipha-20231219monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-leadership-change-current-ceo-mondher-mahjoubi-to-leave-innate-pha-ipha-20231218monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-presents-positive-results-from-tellomak-phase-2-study-with-lacutamab-in-pati-ipha-20231212monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-shares-efficacy-and-safety-phase-1-2-results-of-nk-cell-engager-sar443579-ip-ipha-20231211monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-to-host-virtual-kol-event-on-lacutamab-the-event-will-highlight-positive-res-ipha-20231127monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-reports-third-quarter-2023-financial-results-and-business-update-positive-fi-ipha-20231114monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-conference-call-for-third-quarter-2023-business-update-marseille-f-ipha-20231107monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-new-clinical-data-for-lacutamab-and-sar443579-iph6101-at-ash-2023--ipha-20231103monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-marseille-franc-ipha-20231027monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-2024-financial-calendar-marseille-france-business-wire-ipha-20231019monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-abstracts-selected-for-esmo-congress-2023-sanofi-s-ongoing-sar-579-ipha-20231016monthly0.5https://www.biopharmawatch.com/news/IPHA/number-of-shares-and-voting-rights-of-innate-pharma-as-of-ipha-20231003monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-provides-update-on-lacutamab-clinical-program-phase-2-tellomak-trial-fully-r-ipha-20231005monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-encore-presentation-of-interim-results-of-phase-2-tellomak-study-w-ipha-20230922monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-reports-first-half-2023-financial-results-and-business-update-phase-1-2-dose-ipha-20230914monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-and-conference--ipha-20230829monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-to-participate-in-upcoming-investor-conference-marseille-france-business-wir-ipha-20230810monthly0.5https://www.biopharmawatch.com/news/IPHA/first-patient-dosed-in-sar-514-iph6401-phase-1-2-clinical-trial-in-relapsed-refractory-mul-ipha-20230711monthly0.5https://www.biopharmawatch.com/news/IPHA/number-of-shares-and-voting-rights-of-innate-pharma-as-of-ipha-20230701monthly0.5https://www.biopharmawatch.com/news/IPHA/first-patient-dosed-in-phase-2-matisse-trial-of-iph5201-in-early-stage-lung-cancer-phase-2-ipha-20230626monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-highlights-increased-lacutamab-clinical-activity-from-interim-results-of-pha-ipha-20230616monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-to-present-updated-interim-phase-2-efficacy-results-of-lacutamab-in-mycosis--ipha-20230612monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-highlights-proprietary-tetra-specific-anket-nk-cell-engager-iph6501-at-the-e-ipha-20230610monthly0.5https://www.biopharmawatch.com/news/IPHA/sar-579-iph6101-receives-fda-fast-track-designation-in-the-us-for-the-treatment-of-hematol-ipha-20230608monthly0.5https://www.biopharmawatch.com/news/IPHA/number-of-shares-and-voting-rights-of-innate-pharma-as-of-ipha-20230601monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-highlights-phase-1-2-dose-escalation-safety-and-preliminary-efficacy-of-sano-ipha-20230526monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-to-participate-in-upcoming-investor-conferences-marseille-france-business-wi-ipha-20230523monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-to-present-iph6501-preclinical-data-at-the-eha-2023-congress-iph6501-a-first-ipha-20230515monthly0.5https://www.biopharmawatch.com/news/IPHA/outcome-of-innate-pharma-s-2023-annual-general-meeting-marseille-france-business-wire-ipha-20230512monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-reports-first-quarter-2023-financial-results-and-business-update-exclusive-w-ipha-20230510monthly0.5https://www.biopharmawatch.com/news/IPHA/number-of-shares-and-voting-rights-of-innate-pharma-as-of-ipha-20230501monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-conference-call-and-webcast-for-q1-business-update-marseille-franc-ipha-20230503monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-highlights-clinical-abstracts-selected-for-asco-2023-annual-meeting-oral-pre-ipha-20230503monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-establishes-a-new-at-the-market-atm-program-on-nasdaq-marseille-france-busin-ipha-20230426monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-to-participate-in-upcoming-investor-conference-marseille-france-business-wir-ipha-20230421monthly0.5https://www.biopharmawatch.com/news/IPHA/number-of-shares-and-voting-rights-of-innate-pharma-as-of-ipha-20230401monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-to-hold-its-annual-general-meeting-of-shareholders-on-ipha-20230407monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-files-its-2022-universal-registration-document-d-ocument-d-enregistrement-un-ipha-20230406monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-exclusive-license-of-antibodies-to-takeda-for-celiac-disease-resea-ipha-20230403monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-reports-full-year-2022-1-financial-results-and-business-update-sanofi-collab-ipha-20230323monthly0.5https://www.biopharmawatch.com/news/IPHA/number-of-shares-and-voting-rights-of-innate-pharma-as-of-ipha-20230301monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-conference-call-and-webcast-for-full-year-2022-financial-results-m-ipha-20230316monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-provides-update-on-silicon-valley-bank-exposure-innate-pharma-does-not-have--ipha-20230313monthly0.5https://www.biopharmawatch.com/news/IPHA/number-of-shares-and-voting-rights-of-innate-pharma-as-of-ipha-20230201monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-to-participate-in-upcoming-investor-conferences-marseille-france-business-wi-ipha-20230207monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-hsr-clearance-regarding-expansion-of-its-collaboration-with-sanofi-ipha-20230125monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-publication-of-preclinical-data-with-a-trifunctional-nk-cell-engag-ipha-20230116monthly0.5https://www.biopharmawatch.com/news/IPHA/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-onco-ipha-20221219monthly0.5https://www.biopharmawatch.com/news/IPHA/number-of-shares-and-voting-rights-of-innate-pharma-as-of-december-1-2022-marseille-france-ipha-20221212monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-presents-data-from-ongoing-phase-2-tellomak-trial-demonstrating-clinical-act-ipha-20221210monthly0.5https://www.biopharmawatch.com/news/IPHA/number-of-shares-and-voting-rights-of-innate-pharma-as-of-ipha-20221201monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-to-present-adenosine-franchise-iph5201-and-iph5301-at-esmo-io-2022-phase-1-d-ipha-20221201monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-reports-third-quarter-financial-results-preliminary-data-from-ongoing-phase--ipha-20221114monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-conference-call-and-webcast-for-third-quarter-2022-business-update-ipha-20221107monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-to-present-results-from-a-preliminary-analysis-of-the-tellomak-phase-2-trial-ipha-20221104monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-to-participate-in-upcoming-investor-conferences-marseille-france-business-wi-ipha-20221102monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-2023-financial-calendar-marseille-france-business-wire-ipha-20221020monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-presents-data-from-ongoing-phase-2-tellomak-trial-demonstrating-clinical-act-ipha-20220923monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-conference-call-and-webcast-for-first-half-2022-business-update-ma-ipha-20220908monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-to-present-lacutamab-ptcl-phase-1b-design-and-anket-platform-at-esmo-2022-po-ipha-20220905monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-to-participate-in-upcoming-investor-conferences-marseille-france-business-wi-ipha-20220823monthly0.5https://www.biopharmawatch.com/news/IPHA/number-of-shares-and-voting-rights-of-innate-pharma-as-of-ipha-20220801monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-provides-update-on-astrazeneca-sponsored-interlink-1-phase-3-study-marseille-ipha-20220801monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-to-participate-in-upcoming-investor-conference-marseille-france-business-wir-ipha-20220728monthly0.5https://www.biopharmawatch.com/news/IPHA/second-innate-pharma-nk-cell-engager-selected-by-sanofi-as-drug-candidate-for-development--ipha-20220721monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-to-participate-in-upcoming-investor-conference-marseille-france-business-wir-ipha-20220623monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-iph5201-phase-2-study-in-lung-cancer-anti-cd39-monoclonal-antibody-ipha-20220603monthly0.5https://www.biopharmawatch.com/news/IPHA/outcome-of-innate-pharma-s-2022-annual-general-meeting-appointment-of-dr-sally-bennett-to--ipha-20220520monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-to-participate-in-upcoming-investor-conferences-marseille-france-business-wi-ipha-20220511monthly0.5https://www.biopharmawatch.com/news/IPHA/number-of-shares-and-voting-rights-of-innate-pharma-as-of-ipha-20220501monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-reports-first-quarter-2022-financial-results-and-business-update-first-patie-ipha-20220510monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-establishes-an-at-the-market-atm-program-on-nasdaq-marseille-france-business-ipha-20220503monthly0.5https://www.biopharmawatch.com/news/IPHA/6xk-2020-innate-pharma-all-rights-reserved-paris-iph-pa-nasdaq-ipha-company-overview-april-ipha-20220503monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-conference-call-and-webcast-for-q1-2022-business-update-marseille--ipha-20220503monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-first-patient-dosed-in-monalizumab-phase-3-lung-cancer-clinical-trial-trigge-ipha-20220429monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-to-hold-its-annual-general-meeting-of-shareholders-on-ipha-20220408monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-files-its-2021-universal-registration-document-document-d-enregistrement-uni-ipha-20220405monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-reports-full-year-2021-financial-results-and-business-update-monalizumab-pro-ipha-20220324monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-conference-call-and-webcast-for-full-year-2021-financial-results-m-ipha-20220317monthly0.5https://www.biopharmawatch.com/news/IPHA/number-of-shares-and-voting-rights-of-innate-pharma-as-of-ipha-20220301monthly0.5https://www.biopharmawatch.com/news/IPHA/number-of-shares-and-voting-rights-of-innate-pharma-as-of-ipha-20220201monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-to-participate-in-upcoming-investor-conferences-marseille-france-business-wi-ipha-20220204monthly0.5https://www.biopharmawatch.com/news/IPHA/number-of-shares-and-voting-rights-of-innate-pharma-as-of-ipha-20220124monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-obtains-28-7m-in-non-dilutive-financing-in-the-form-of-state-guaranteed-loan-ipha-20220105monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-to-participate-in-upcoming-investor-conferences-marseille-france-business-wi-ipha-20220104monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-first-patient-dosed-in-iph6101-sar443579-phase-1-2-clinical-trial-in-various-ipha-20211216monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-monalizumab-combined-with-cetuximab-and-durvalumab-demonstrates-anti-tumor-a-ipha-20211209monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-to-present-monalizumab-data-at-esmo-immuno-oncology-2021-congress-innate-to--ipha-20211202monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-to-participate-in-the-evercore-isi-4-th-annual-healthconx-virtual-conference-ipha-20211124monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-third-quarter-2021-report-monalizumab-in-combination-with-durvalumab-signifi-ipha-20211116monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-highlights-new-nk-cell-engager-data-with-partner-sanofi-at-sitc-annual-meeti-ipha-20211112monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-announces-conference-call-and-webcast-for-q3-2021-business-update-marseille--ipha-20211109monthly0.5https://www.biopharmawatch.com/news/IPHA/innate-pharma-2022-financial-calendar-marseille-france-business-wire-ipha-20211026monthly0.5https://www.biopharmawatch.com/news/IPHA/number-of-shares-and-voting-rights-of-innate-pharma-as-of-ipha-20211001monthly0.5https://www.biopharmawatch.com/news/ALPS/alps-group-inc-expands-mygenome-accreditation-to-include-whole-genome-sequencing-under-ms--alps-20260609monthly0.5https://www.biopharmawatch.com/news/ALPS/alps-group-inc-publishes-clinical-safety-tolerability-and-effectiveness-data-supporting-ad-alps-20260223monthly0.5https://www.biopharmawatch.com/news/ALPS/unaudited-pro-forma-condensed-combined-financial-information-unless-the-context-otherwise--alps-20260205monthly0.5https://www.biopharmawatch.com/news/ALPS/alps-group-inc-announces-potential-pipeline-expansion-beyond-celesome-following-publicatio-alps-20260130monthly0.5https://www.biopharmawatch.com/news/ALPS/alps-group-inc-appoints-cheing-lye-ping-as-chief-financial-officer-alps-20260108monthly0.5https://www.biopharmawatch.com/news/ALPS/alps-announces-closing-of-business-combination-with-globalink-investment-inc-alps-ordinary-alps-20251031monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-secures-second-commercial-payer-agreement-for-tonmya-expanding-total-tnxp-20260601monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-tnx-4800-a-long-acting-bactericidal-human-monoclonal-an-tnxp-20260515monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presents-updates-on-preclinical-immuno-oncology-programs-at-the-amer-tnxp-20260423monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presented-post-hoc-analyses-of-phase-3-data-on-tonmya-tm-at-the-8th--tnxp-20260310monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-tnxp-20260303monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-8-k-tonix-pharmaceuticals-announces-licensing-tnx-4900--tnxp-20251216monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-tnxp-20251007monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-further-strengthens-commercial-leadership-team-with-appointment-of-g-tnxp-20250930monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-plans-to-initiate-prader-willi-syndrome-phase-2-trial-of-tnx-2900-in-tnxp-20250929monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-positive-pre-ind-meeting-with-fda-for-tnx-102-sl-for-the-t-tnxp-20250918monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-in-licensing-phase-2-3-ready-monoclonal-antibody-designed--tnxp-20250917monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-tnxp-20250818monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-fda-approval-of-tonmya-tm-cyclobenzaprine-hcl-sublingual-t-tnxp-20250818monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-second-quarter-2025-financial-results-and-operational-highli-tnxp-20250811monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-the-launch-of-the-move-fibro-forward-campaign-to-bring-awa-tnxp-20250721monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-corporate-presentation-july-2025-nasdaq-tnxp-po6091-jul-tnxp-20250716monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-presentation-of-new-data-on-mpox-and-smallpox-vaccine-cand-tnxp-20250710monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-on-line-publication-of-phase-3-resilient-trial-results-of--tnxp-20250709monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-peer-reviewed-publication-in-cancer-cell-journal-highlight-tnxp-20250702monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presented-data-and-analyses-of-tnx-102-sl-treatment-effects-on-fibro-tnxp-20250616monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-appointment-of-commercial-industry-veteran-james-jim-hunte-tnxp-20250613monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-first-patient-dosed-in-phase-2-oasis-study-of-tnx-102-sl-f-tnxp-20250521monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-appointment-of-joseph-hand-esq-as-general-counsel-and-exec-tnxp-20250514monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-first-quarter-2025-financial-results-and-operational-highlig-tnxp-20250512monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presented-preclinical-data-on-gastric-cancer-models-at-the-american--tnxp-20250429monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presented-data-on-potential-mpox-vaccine-tnx-801-at-world-vaccine-co-tnxp-20250424monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-and-makana-therapeutics-announce-collaboration-combining-tonix-s-ant-tnxp-20250409monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-launches-tonix-one-tm-a-fully-integrated-digital-platform-designed-t-tnxp-20250401monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-that-fda-will-not-require-an-advisory-committee-meeting-to-tnxp-20250324monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-financial-results-and-oper-tnxp-20250318monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-grant-by-medical-cbrn-defense-consortium-mcdc-for-developm-tnxp-20250310monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presented-data-and-analyses-of-tnx-102-sl-treatment-effects-on-fibro-tnxp-20250304monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-recently-announced-preliminary-full-year-2024-operating-results-and--tnxp-20250207monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-positive-topline-results-from-phase-1-trial-for-tnx-1500-a-tnxp-20250206monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-promotes-siobhan-fogarty-to-chief-technical-officer-ms-fogarty-has-s-tnxp-20250204monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-1-for-100-reverse-stock-split-chatham-n-j-tnxp-20250203monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-further-strengthens-commercial-leadership-team-with-appointment-of-g-tnxp-20250108monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-pdufa-goal-date-of-tnxp-20241223monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-fda-acceptance-of-the-new-drug-application-nda-for-tnx-102-tnxp-20241217monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-expansion-of-leadership-team-with-two-strategic-hires-toni-tnxp-20241203monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-peer-reviewed-publication-in-msphere-journal-highlighting--tnxp-20241113monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-third-quarter-2024-financial-results-and-operational-highlig-tnxp-20241112monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-2024-tonix-pharmaceuticals-holding-corp-tnx-1700-gastri-tnxp-20241105monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-research-agreement-with-kenya-medical-research-institute-k-tnxp-20241104monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presented-data-on-potential-mpox-vaccine-tnx-801-at-world-vaccine-co-tnxp-20241101monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-receives-first-contract-payment-from-u-s-department-of-defense-for-a-tnxp-20241017monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-submission-of-the-tnx-102-sl-new-drug-application-nda-for--tnxp-20241016monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-ai-collaboration-with-x-chem-to-develop-broad-spectrum-ant-tnxp-20241008monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-issuance-of-u-s-patent-covering-the-subcutaneous-delivery--tnxp-20240927monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-data-presentations-on-tnx-102-sl-for-fibromyalgia-at-the-1-tnxp-20240923monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-issuance-of-u-s-patent-by-the-united-states-patent-and-tra-tnxp-20240919monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-that-its-single-dose-mpox-vaccine-candidate-tnx-801-aligns-tnxp-20240916monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-appointment-of-thomas-englese-as-executive-vice-president--tnxp-20240910monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presented-data-on-the-potential-mpox-vaccine-tnx-801-in-using-synthe-tnxp-20240909monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presented-data-from-two-posters-on-tnx-102-sl-for-reduction-of-acute-tnxp-20240829monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-and-bilthoven-biologicals-to-collaborate-on-advancing-development-of-tnxp-20240826monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-first-patient-enrolled-in-phase-2-catalyst-study-of-tnx-13-tnxp-20240820monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-second-quarter-2024-financial-results-and-operational-highli-tnxp-20240819monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presented-data-and-analyses-of-tnx-102-sl-treatment-effects-on-fibro-tnxp-20240812monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-granted-fast-track-designation-by-fda-for-tonmya-for-fibromyalgia-fa-tnxp-20240725monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-corporate-presentation-abbreviated-july-2024-nasdaq-tnx-tnxp-20240716monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-proposed-public-offering-chatham-n-j-tnxp-20240708monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-final-positive-pre-nda-meeting-with-fda-for-tonmya-for-the-m-tnxp-20240708monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-proposed-public-offering-chatham-n-j-tnxp-20240626monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-requirement-chatham-tnxp-20240626monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-positive-pre-nda-cmc-meeting-with-fda-for-tonmya-for-the-m-tnxp-20240620monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-proposed-public-offering-chatham-n-j-tnxp-20240611monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-corporate-presentation-focus-on-tonmya-tnx-102-sl-in-de-tnxp-20240610monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-1-for-32-reverse-stock-split-chatham-n-j-tnxp-20240606monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-two-oral-presentations-and-one-poster-presentation-involvi-tnxp-20240606monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presented-new-data-on-tonmya-suggesting-activity-for-improvement-in--tnxp-20240603monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-two-poster-presentations-of-tnx-102-sl-sublingual-cycloben-tnxp-20240530monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-deliver-an-oral-presentation-and-present-two-posters-at-the-ameri-tnxp-20240522monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-key-findings-from-initial-phase-of-eversana-market-opportu-tnxp-20240521monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-first-quarter-2024-financial-results-and-operational-highlig-tnxp-20240513monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results-and-oper-tnxp-20240401monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-pricing-of-4-4-million-registered-direct-offering-chatham--tnxp-20240328monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-receives-rare-pediatric-disease-designation-from-the-fda-for-tnx-290-tnxp-20240325monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-poster-presentation-describing-discovery-of-novel-next-gen-tnxp-20240321monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-selection-of-two-contract-manufacturing-organizations-for--tnxp-20240320monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-transition-to-fully-integrated-biopharmaceutical-company-e-tnxp-20240319monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-improvement-in-brain-fog-in-fibromyalgia-patients-treated-wi-tnxp-20240311monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-publication-in-psychiatry-research-showing-activity-of-bed-tnxp-20240307monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-selects-eversana-to-support-launch-strategy-and-commercialization-pl-tnxp-20240306monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-translation-of-preclinical-pharmacokinetic-parameters-of-t-tnxp-20240305monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-completes-clinical-stage-of-phase-1-trial-for-tnx-1500-fc-modified-h-tnxp-20240228monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-positive-results-from-clinical-pharmacokinetic-bridging-st-tnxp-20240227monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-engagement-of-rho-as-cro-to-support-submission-of-new-drug-tnxp-20240213monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-fda-ind-clearance-for-dod-funded-trial-of-tnx-102-sl-for-t-tnxp-20240212monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-research-indicating-pre-existing-fibromyalgia-type-symptom-tnxp-20240131monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-conditional-acceptance-of-tonmya-as-trade-name-for-tnx-102-tnxp-20240129monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-biotech-showcase-focus-on-tnx-102-sl-in-development-for-tnxp-20240108monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-corporate-presentation-focus-on-tnx-102-sl-in-developme-tnxp-20240102monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-registered-direct-offering-of-up-to-144-million-led-by-hea-tnxp-20231220monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-highly-statistically-significant-and-clinically-meaningful-tnxp-20231220monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-corporate-presentation-december-2023-nasdaq-tnxp-versio-tnxp-20231211monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-ind-clearance-by-the-fda-for-phase-2-trial-of-tnx-2900-for-tnxp-20231204monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-completes-clinical-stage-of-phase-3-resilient-study-of-tnx-102-sl-fo-tnxp-20231115monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-enrollment-initiated-in-mass-general-brigham-phase-2-inves-tnxp-20231113monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-third-quarter-2023-financial-results-and-operational-highlig-tnxp-20231109monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-vaccine-candidate-tnx-1800-selected-by-nih-niaid-project-nextgen-for-tnxp-20231102monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-topline-results-from-phase-2-proof-of-concept-study-of-tnx-tnxp-20231031monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-new-data-involving-tnx-1500-fc-modified-dimeric-anti-cd40l-tnxp-20231030monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-completes-clinical-stage-of-phase-2-prevention-study-of-tnx-1900-for-tnxp-20231026monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presents-data-from-its-horsepox-based-vaccine-development-platform-a-tnxp-20231019monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-publication-of-data-in-the-journal-nature-involving-tnx-15-tnxp-20231018monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-corporate-presentation-october-2023-nasdaq-tnxp-version-tnxp-20231016monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-completes-clinical-stage-of-phase-2-uplift-study-of-tnx-601-er-for-t-tnxp-20231016monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-issuance-of-eu-patent-covering-intranasal-potentiated-oxyt-tnxp-20231004monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-proposed-public-offering-chatham-n-j-tnxp-20230928monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-department-of-defense-grant-to-support-the-university-of-n-tnxp-20230927monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-investor-presentation-nasdaq-tnxp-version-p04-88-septem-tnxp-20230925monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-tnxp-20230921monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-presentation-of-non-clinical-studies-supporting-the-mechan-tnxp-20230918monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-poster-presentation-involving-tnx-1700-in-preclinical-colo-tnxp-20230914monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-investor-presentation-nasdaq-tnxp-version-p0482-tnxp-20230911monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-commitment-to-supply-tosymra-sumatriptan-nasal-spray-10-mg-tnxp-20230906monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-topline-results-from-phase-2-prevail-proof-of-concept-stud-tnxp-20230905monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-results-of-pre-ind-meeting-with-fda-for-tnx-801-as-a-poten-tnxp-20230821monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-initiates-phase-1-trial-of-tnx-1500-fc-modified-humanized-anti-cd40l-tnxp-20230816monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-second-quarter-2023-financial-results-and-operational-highli-tnxp-20230810monthly0.5https://www.biopharmawatch.com/news/TNXP/gif87a-0-w-software-microsoft-office-0-r-z-s-z-j-b-j-r-n-k-s-o-z-1c-bs-r-z-1k-j-j-c-b-j-o--tnxp-20230807monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-completes-clinical-phase-of-prevail-proof-of-concept-study-of-tnx-10-tnxp-20230807monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-completes-enrollment-in-potentially-nda-enabling-phase-3-resilient-t-tnxp-20230801monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-enrollment-initiated-in-the-mgh-phase-2-strobe-study-of-tn-tnxp-20230731monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-proposed-public-offering-chatham-n-j-tnxp-20230727monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-accelerating-completion-of-enrollment-in-phase-2-uplift-st-tnxp-20230726monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-data-supporting-the-memory-and-cognition-enhancing-effects-tnxp-20230724monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-agreement-and-initiation-of-enrollment-in-phase-2-trial-wi-tnxp-20230717monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-investor-presentation-nasdaq-tnxp-version-p0461-tnxp-20230712monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-initiation-of-enrollment-in-the-mgh-phase-2-power-study-of-tnxp-20230710monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-completes-acquisition-of-two-fda-approved-marketed-migraine-products-tnxp-20230703monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-investor-presentation-nasdaq-tnxp-version-p0456-tnxp-20230626monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-enters-into-agreement-to-acquire-two-fda-approved-marketed-migraine--tnxp-20230626monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-publication-of-results-from-phase-3-relief-trial-of-tnx-10-tnxp-20230615monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-2023-tonix-pharmaceuticals-holding-corp-tnx-1700-gastri-tnxp-20230613monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-data-presentations-involving-tnx-1500-anti-cd40l-mab-for-t-tnxp-20230607monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-presentation-of-data-supporting-development-of-racemic-and-tnxp-20230605monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-investor-presentation-nasdaq-tnxp-version-p0447-tnxp-20230601monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-presentations-involving-tnx-1500-anti-cd40l-mab-at-the-202-tnxp-20230531monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-requirement-chatham-tnxp-20230525monthly0.5https://www.biopharmawatch.com/news/TNXP/confidential-tonix-pharmaceuticals-announces-poster-presentation-at-the-2023-american-soci-tnxp-20230525monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-the-isolation-and-characterization-of-the-s-isomer-of-tian-tnxp-20230523monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-clinical-proof-of-concept-study-of-tnx-1900-intranasal-pot-tnxp-20230522monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-pharmacology-and-medicinal-chemistry-results-that-reveal-t-tnxp-20230517monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-1-for-6-25-reverse-stock-split-chatham-n-j-tnxp-20230509monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-first-quarter-2023-financial-results-and-operational-highlig-tnxp-20230508monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-ind-clearance-for-tnx-1500-anti-cd40l-mab-for-the-preventi-tnxp-20230504monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-investor-presentation-nasdaq-tnxp-version-p0-440-tnxp-20230501monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-presentations-of-pre-clinical-data-on-tnx-1700-in-syngenei-tnxp-20230419monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-two-publications-of-data-in-american-journal-of-transplant-tnxp-20230417monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-expedites-fibromyalgia-and-chronic-migraine-programs-streamlining-ph-tnxp-20230413monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presents-data-from-its-vaccine-development-program-at-the-world-vacc-tnxp-20230406monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-poster-presentations-at-the-american-association-for-cance-tnxp-20230405monthly0.5https://www.biopharmawatch.com/news/TNXP/confidential-tonix-pharmaceuticals-announces-pipeline-prioritization-update-for-2023-prior-tnxp-20230404monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presents-positive-efficacy-and-safety-data-from-phase-3-relief-study-tnxp-20230330monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presents-non-clinical-data-on-tnx-2900-for-the-potential-treatment-o-tnxp-20230323monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-investor-presentation-nasdaq-tnxp-version-p0424-march-2-tnxp-20230320monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-initiates-enrollment-in-phase-2-uplift-study-of-tnx-601-er-tianeptin-tnxp-20230316monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-investor-presentation-nasdaq-tnxp-version-p0419-march-1-tnxp-20230313monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-fourth-quarter-and-full-year-2022-financial-results-and-oper-tnxp-20230313monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-results-from-a-preclinical-study-of-murine-tnx-1700-presen-tnxp-20230307monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-investor-presentation-nasdaq-tnxp-version-p0414-februar-tnxp-20230227monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-new-board-member-r-newcomb-stillwell-chatham-n-j-tnxp-20230223monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-exclusive-license-of-potential-therapeutic-or-preventative-tnxp-20230213monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-publication-of-paper-in-viruses-highlighting-the-company-s-tnxp-20230209monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-investor-presentation-the-wall-street-conference-nasdaq-tnxp-20230207monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-initiates-enrollment-in-phase-2-prevention-study-of-potentiated-intr-tnxp-20230206monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-acquisition-of-preclinical-infectious-disease-portfolio-fr-tnxp-20230202monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-research-agreement-with-university-of-maryland-baltimore-t-tnxp-20230201monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-presentation-of-clinical-and-non-clinical-tnx-1900-data-at-tnxp-20230131monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-requirement-chatham-tnxp-20230130monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-presentation-of-licensed-antiviral-drug-technology-at-the--tnxp-20230126monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-publication-of-paper-in-antiviral-research-highlighting-th-tnxp-20230124monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-biotech-showcase-covid-antiviral-agents-anti-sars-cov-2-tnxp-20230107monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-appoints-zeil-rosenberg-m-d-m-p-h-as-executive-vice-president-medica-tnxp-20230104monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-achieves-enrollment-of-first-50-percent-of-participants-in-the-resil-tnxp-20221219monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-investor-presentation-nasdaq-tnxp-version-p0399-decembe-tnxp-20221214monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-exclusive-license-of-potential-therapeutic-or-preventative-tnxp-20221212monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-collaboration-with-boston-children-s-hospital-to-study-tnx-tnxp-20221205monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presents-development-update-on-potential-smallpox-and-monkeypox-vacc-tnxp-20221201monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announced-data-from-its-fully-human-anti-sars-cov-2-monoclonal-antib-tnxp-20221130monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-data-from-an-in-vitro-study-of-the-impact-of-oxytocin-on-h-tnxp-20221116monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-third-quarter-2022-financial-results-and-operational-highlig-tnxp-20221107monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-pricing-of-15-million-private-placement-of-convertible-red-tnxp-20221025monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-investor-presentation-nasdaq-tnxp-version-p0382-tnxp-20221003monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-ind-clearance-for-tnx-601-er-as-a-potential-treatment-for--tnxp-20221003monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-presents-data-from-retrospective-observational-database-study-on-the-tnxp-20220922monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-tnxp-20220915monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-investor-presentation-nasdaq-tnxp-version-p0376-tnxp-20220906monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-initiates-enrollment-in-phase-2-prevail-study-of-tnx-102-sl-for-the--tnxp-20220822monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-second-quarter-2022-financial-results-and-operational-highli-tnxp-20220808monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-receives-federal-grant-from-the-national-institute-on-drug-abuse-nid-tnxp-20220802monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-issuance-of-u-s-patent-covering-potentiated-intranasal-oxy-tnxp-20220801monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-collaboration-with-kenya-medical-research-institute-to-dev-tnxp-20220728monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-appointment-of-sina-bavari-ph-d-as-executive-vice-presiden-tnxp-20220725monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-tnx-2900-intranasal-oxytocin-magnesium-in-development-f-tnxp-20220711monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-development-of-tnx-601-er-a-potential-abuse-deterrent-exte-tnxp-20220711monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-investor-presentation-nasdaq-tnxp-version-p0361-tnxp-20220705monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-trial-design-of-new-phase-2-clinical-study-of-tnx-1300-for-tnxp-20220627monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-investor-presentation-nasdaq-tnxp-version-p0360-tnxp-20220622monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-pricing-of-30-million-private-placement-of-convertible-red-tnxp-20220622monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-publication-of-paper-in-pharmaceutics-on-the-enhancing-eff-tnxp-20220621monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-data-presentations-involving-tnx-1500-fc-modified-anti-cd4-tnxp-20220609monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-presentation-on-tnx-801-vaccine-protection-against-monkeyp-tnxp-20220608monthly0.5https://www.biopharmawatch.com/news/TNXP/investor-presentation-nasdaq-tnxp-2022-tonix-pharmaceuticals-holding-corp-version-p03-53-j-tnxp-20220607monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-requirement-chatham-tnxp-20220602monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-issuance-of-u-s-patent-for-tnx-801-smallpox-and-monkeypox--tnxp-20220601monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-share-repurchase-program-chatham-n-j-tnxp-20220531monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-two-oral-presentations-involving-tnx-1500-fc-modified-anti-tnxp-20220531monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-extends-research-collaboration-with-the-university-of-alberta-to-dev-tnxp-20220518monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-1-for-32-reverse-stock-split-chatham-n-j-tnxp-20220516monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-first-quarter-2022-financial-results-and-operational-highlig-tnxp-20220509monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-results-of-retrospective-observational-database-study-in-o-tnxp-20220420monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-initiates-enrollment-in-the-resilient-study-a-potentially-pivotal-ph-tnxp-20220407monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-ind-clearance-for-tnx-102-sl-as-a-potential-treatment-for--tnxp-20220406monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-extension-of-sponsored-research-agreement-with-kansas-stat-tnxp-20220405monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-investor-presentation-nasdaq-tnxp-version-p0345-tnxp-20220328monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-investor-presentation-nasdaq-tnxp-version-p0343-tnxp-20220322monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-phase-3-rally-study-results-for-tnx-102-sl-5-6-mg-for-the--tnxp-20220321monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-fourth-quarter-and-full-year-2021-financial-results-and-oper-tnxp-20220314monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-appointment-of-jeffrey-rosenfeld-ph-d-as-executive-directo-tnxp-20220309monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-investor-presentation-nasdaq-tnxp-version-p0338-tnxp-20220308monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-collaboration-with-massachusetts-general-hospital-to-evalu-tnxp-20220307monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-fda-orphan-drug-designation-for-tnx-2900-for-the-treatment-tnxp-20220303monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-research-agreement-with-the-french-national-institute-of-h-tnxp-20220228monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-investor-presentation-nasdaq-tnxp-version-p0335-tnxp-20220111monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-initiates-enrollment-in-clinical-trial-of-tnx-2100-a-diagnostic-skin-tnxp-20220111monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-exclusive-option-and-research-collaboration-with-kansas-st-tnxp-20220104monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-added-to-the-nasdaq-biotechnology-index-chatham-n-j-tnxp-20211215monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-ind-clearance-for-skin-test-tnx-2100-to-measure-sars-cov-2-tnxp-20211214monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-research-collaboration-with-columbia-university-to-study-r-tnxp-20211213monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-fda-clearance-of-the-ind-for-potentiated-intranasal-oxytoc-tnxp-20211123monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-publication-of-paper-on-antiviral-sars-cov-2-inhibitor-tnx-tnxp-20211122monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-issuance-of-u-s-patent-for-use-of-tnx-1700-a-stabilized-re-tnxp-20211115monthly0.5https://www.biopharmawatch.com/news/TNXP/tnx-601-cr-a-once-daily-formulation-of-tianeptine-in-development-for-the-treatment-of-majo-tnxp-20211109monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-third-quarter-2021-financial-results-and-operational-highlig-tnxp-20211108monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-ribbon-cutting-ceremony-for-its-infectious-disease-r-d-cen-tnxp-20211015monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-investor-presentation-nasdaq-tnxp-version-p0326-tnxp-20211012monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-completion-of-acquisition-of-infectious-disease-r-d-center-tnxp-20211004monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-expands-research-collaboration-to-develop-precision-medicine-techniq-tnxp-20210923monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-tnxp-20210921monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-results-of-pre-ind-meeting-with-fda-for-tnx-1800-as-a-pote-tnxp-20210913monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-tnxp-20210827monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-results-of-pre-ind-meeting-with-fda-for-tnx-102-sl-as-a-po-tnxp-20210824monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-second-quarter-2021-financial-results-and-operational-highli-tnxp-20210809monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-tnxp-20210802monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-agreement-to-acquire-infectious-disease-r-d-facility-to-ac-tnxp-20210727monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-outcome-of-interim-analysis-of-phase-3-rally-study-of-tnx--tnxp-20210723monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-new-board-member-carolyn-e-taylor-tnxp-20210719monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-1-june-2021-version-p0306-6-28-2021-doc-0854-investor-p-tnxp-20210628monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-1-june-2021-version-p0304-6-22-2021-doc-0852-investor-p-tnxp-20210622monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-program-to-develop-tnx-102-sl-for-the-treatment-of-long-co-tnxp-20210621monthly0.5https://www.biopharmawatch.com/news/TNXP/results-discussion-conclusions-figures-6-7-mcfb-in-promis-sleep-disturbance-and-promis-fat-tnxp-20210603monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-first-quarter-2021-financial-results-and-operational-highlig-tnxp-20210510monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-1-may-2021-version-p0293-5-3-2021-doc-0829-investor-pre-tnxp-20210503monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-1-april-2021-version-p0289-4-19-2021-doc-0822-investor--tnxp-20210419monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-enters-into-exclusive-worldwide-licensing-agreement-with-oyagen-to-d-tnxp-20210419monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-tnxp-20210419monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-results-of-pre-ind-meeting-with-fda-on-tnx-601-cr-for-the--tnxp-20210322monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-issuance-of-u-s-patent-for-compositions-and-uses-of-tianep-tnxp-20210319monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-positive-covid-19-vaccine-efficacy-results-in-non-human-prim-tnxp-20210317monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-fourth-quarter-and-full-year-2020-financial-results-and-oper-tnxp-20210315monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-1-march-2021-version-p0280-3-11-2021-doc-0796-investor--tnxp-20210315monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-requirement-chatham-tnxp-20210304monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-1-march-2021-version-p0276-3-3-2021-doc-0789-investor-p-tnxp-20210303monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-1-february-2021-version-p0274-2-19-2021-doc-0787-invest-tnxp-20210219monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-licenses-technology-for-treating-prader-willi-syndrome-a-rare-geneti-tnxp-20210211monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-1-february-2021-version-p0271-2-09-2021-doc-0774-invest-tnxp-20210210monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holdings-corp-prices-70m-common-stock-offering-priced-at-the-market-tnxp-20210208monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-develop-covid-19-skin-test-tnx-2100-to-measure-sars-cov-2-exposur-tnxp-20210208monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-publication-of-patent-application-for-tnx-1500-monoclonal--tnxp-20210114monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holdings-corp-prices-40m-common-stock-offering-priced-at-the-market-tnxp-20210111monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-and-massachusetts-general-hospital-mgh-enter-into-research-collabora-tnxp-20210105monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-plans-commercial-scale-vaccine-manufacturing-facility-hamilton-mt-fa-tnxp-20201223monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-acquires-exclusive-license-to-university-of-geneva-technology-for-ox-tnxp-20201222monthly0.5https://www.biopharmawatch.com/news/TNXP/confidential-not-for-distribution-tonix-pharmaceuticals-reports-topline-results-from-phase-tnxp-20201221monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-1-december-2020-version-p0264-12-14-2020-doc-0747-inves-tnxp-20201214monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-1-december-2020-version-p0261-12-8-2020-doc-0743-invest-tnxp-20201208monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-positive-phase-3-relief-study-results-for-tnx-102-sl-5-6-m-tnxp-20201207monthly0.5https://www.biopharmawatch.com/news/TNXP/vaccine-genome-researchers-report-99-7-colinear-identity-between-a-u-s-civil-war-era-small-tnxp-20201204monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-tnxp-20201116monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-tnxp-20201112monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-1-november-2020-version-p0253-11-10-20-doc-0726-investo-tnxp-20201110monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-third-quarter-2020-financial-results-and-operational-highlig-tnxp-20201109monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-1-october-2020-nasdaq-tnxp-version-p0252-doc-0725-tnx-1-tnxp-20201102monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-enrolls-first-participant-in-the-precision-study-an-observational-st-tnxp-20201015monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-completes-purchase-of-facility-to-house-advanced-development-center--tnxp-20200928monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-tnxp-20200916monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-enrolls-first-patient-in-cov-logic-an-observational-study-to-assess--tnxp-20200915monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-1-september-2020-version-p0246-9-3-20-doc-0699-investor-tnxp-20200903monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-1-august-2020-version-p0244-8-17-20-doc-0695-investor-p-tnxp-20200817monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-second-quarter-2020-financial-results-and-operational-highli-tnxp-20200810monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-clearance-of-ind-for-tnx-102-sl-for-treatment-of-alcohol-u-tnxp-20200806monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-requirement-tnxp-20200804monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-1-august-2020-version-p0239-8-3-20-doc-0679-investor-pr-tnxp-20200803monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-research-collaboration-to-develop-precision-medicine-techn-tnxp-20200716monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-closes-10-5-tnxp-20200715monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-prices-10-500-000-tnxp-20200713monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-enters-into-research-and-exclusive-license-option-agreement-with-kan-tnxp-20200713monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-completes-enrollment-in-phase-3-relief-trial-of-tnx-102-sl-for-manag-tnxp-20200710monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-plans-massachusetts-r-d-facility-to-accelerate-clinical-development--tnxp-20200707monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-enrollment-of-phase-3-relief-trial-of-tnx-102-sl-for-manag-tnxp-20200629monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-and-southern-research-announce-expansion-of-covid-19-vaccine-collabo-tnxp-20200618monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-acquisition-of-non-addictive-migraine-and-pain-treatment-p-tnxp-20200611monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-appointment-of-richard-h-bagger-to-board-of-directors-tnxp-20200610monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-tnxp-20200605monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-fujifilm-diosynth-biotechnologies-to-be-manufacturing-part-tnxp-20200601monthly0.5https://www.biopharmawatch.com/news/TNXP/jfif-xicc-profile-hlino-mntrrgb-xyz-1-acspmsft-iec-srgb-hp-cprt-p-3desc-lwtpt-bkpt-rxyz-tnxp-20200521monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-appointment-of-herbert-harris-m-d-ph-d-as-executive-vice-p-tnxp-20200519monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-tnxp-20200515monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-first-quarter-2020-financial-results-and-operational-highlig-tnxp-20200512monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-enters-into-research-collaboration-and-exclusive-license-agreement-w-tnxp-20200507monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-1-april-2020-version-p0229-4-24-20-doc-0625-investor-pr-tnxp-20200424monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-tnxp-20200422monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-tnxp-20200420monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-tnxp-20200413monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-fourth-quarter-and-full-year-2019-financial-results-and-oper-tnxp-20200324monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-1-march-2020-version-p0222-2-28-20-doc-0604-investor-pr-tnxp-20200303monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-inc-prices-16-005-000-common-stock-offering-priced-at-the-market-new-tnxp-20200228monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-research-collaboration-with-southern-research-to-develop-a-tnxp-20200226monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-closing-of-7-5-million-public-offering-tnxp-20200211monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-prices-7-5-million-public-offering-tnxp-20200207monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-1-february-2020-version-p0220-2-5-20-doc-0593-investor--tnxp-20200129monthly0.5https://www.biopharmawatch.com/news/TNXP/synthetic-chimeric-horsepox-virus-schpxv-vaccination-protects-macaques-from-monkeypox-ryan-tnxp-20200129monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-successful-completion-of-a-fed-fasting-and-dose-proportion-tnxp-20200124monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-to-present-results-from-preclinical-study-of-tnx-801-in-a-poster-pre-tnxp-20200123monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-1-biotech-showcase-2020-version-p0217-1-13-20-doc-0584--tnxp-20200113monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-january-2020-version-p0215-1-6-20-doc-0580-investor-pre-tnxp-20200106monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-december-2019-version-p0213-12-17-19-doc-0577-investor--tnxp-20191218monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-plan-to-develop-tnx-601-cr-tablets-for-once-daily-treatmen-tnxp-20191216monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-new-european-patent-for-the-composition-and-formulation-of-tnxp-20191211monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-enrolls-first-patient-in-phase-3-relief-study-of-tnx-102-sl-for-the--tnxp-20191210monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-requirement-tnxp-20191203monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-november-2019-version-p0206-11-26-19-doc-0560-investor--tnxp-20191127monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-completes-pre-ind-meeting-with-fda-for-tnx-102-sl-as-a-clinical-cand-tnxp-20191120monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-closing-of-9-0-million-public-offering-tnxp-20191120monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-prices-9-0-million-public-offering-tnxp-20191115monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-third-quarter-2019-financial-results-and-operational-highlig-tnxp-20191108monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-november-2019-version-p0203-11-4-19-doc-0549-investor-p-tnxp-20191104monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-12-week-primary-endpoint-and-addition-of-adaptive-design-f-tnxp-20191104monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-confidential-do-not-duplicate-or-distribute-1-tnxp-20191101monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-1-for-10-reverse-stock-split-tnxp-20191031monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-issuance-of-u-s-patent-for-crystalline-tianeptine-oxalate--tnxp-20191023monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-october-2019-version-p0201-10-16-19-doc-0544-investor-p-tnxp-20191016monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-that-the-european-patent-office-opposition-division-has-up-tnxp-20191007monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-completion-of-long-term-exposure-studies-in-participants-w-tnxp-20191003monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-licensing-agreement-with-columbia-university-for-the-devel-tnxp-20190916monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-publication-of-paper-on-triple-reuptake-inhibitor-tnx-1600-tnxp-20190916monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-doses-participants-in-phase-1-study-evaluating-tnx-601-for-the-dayti-tnxp-20190904monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-august-2019-version-p0193-8-21-19-doc-0521-investor-pre-tnxp-20190821monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-and-massachusetts-general-hospital-enter-into-research-collaboration-tnxp-20190821monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-expands-preclinical-pipeline-with-triple-reuptake-inhibitor-tnx-1600-tnxp-20190820monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-second-quarter-2019-financial-results-and-operational-highli-tnxp-20190812monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-director-stepping-down-tnxp-20190802monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-issuance-of-u-s-patent-for-the-composition-and-formulation-tnxp-20190725monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock-tnxp-20190716monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-issuance-of-patent-in-china-for-the-composition-and-formul-tnxp-20190613monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-june-2019-version-p0185-6-3-19-doc-0496-investor-presen-tnxp-20190603monthly0.5https://www.biopharmawatch.com/news/TNXP/steady-state-pharmacokinetic-properties-of-a-sublingual-formulation-of-cyclobenzaprine-cbp-tnxp-20190530monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-expands-pipeline-with-mid-stage-biologic-candidate-tnx-1300-for-coca-tnxp-20190523monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-director-stepping-down-tnxp-20190517monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-first-quarter-2019-financial-results-and-operational-highlig-tnxp-20190513monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-new-board-member-daniel-goodman-m-d-tnxp-20190508monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-update-on-the-collaborative-research-and-development-agree-tnxp-20190423monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-that-breakthrough-therapy-designation-remains-in-effect-fo-tnxp-20190422monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-plans-to-expand-tnx-102-sl-phase-3-program-beyond-ptsd-to-include-fi-tnxp-20190404monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-fourth-quarter-and-full-year-2018-financial-results-and-oper-tnxp-20190318monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-enrolls-first-participant-in-the-recovery-study-a-new-phase-3-trial--tnxp-20190311monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-tnxp-20190305monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-provides-update-on-tonmya-for-the-treatment-of-posttraumatic-stress--tnxp-20190301monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-share-repurchase-program-tnxp-20190301monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-new-board-member-james-treco-tnxp-20190219monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-requirement-tnxp-20181218monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-prices-15-000-000-public-offering-tnxp-20181207monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-november-2018-version-p0149-11-30-18-doc-0420-investor--tnxp-20181126monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-additional-details-of-the-new-phase-3-study-of-tonmya-for--tnxp-20181129monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-1-for-10-reverse-stock-split-tnxp-20181127monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-third-quarter-2018-financial-results-and-operational-highlig-tnxp-20181109monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-new-patent-coverage-protecting-tonmya-tnxp-20181107monthly0.5https://www.biopharmawatch.com/news/TNXP/time-since-trauma-in-ptsd-phase-3-multi-center-double-blind-placebo-controlled-trial-of-tn-tnxp-20181106monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-november-2018-version-p0143-11-1-18-doc-0406-investor-p-tnxp-20181029monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-innovative-design-in-next-phase-3-study-of-tonmya-for-ptsd-tnxp-20181031monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-october-2018-version-p0140-10-1-18-doc-0401-investor-pr-tnxp-20181002monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-september-2018-version-p0137-9-10-18-doc-0395-investor--tnxp-20180910monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-new-board-member-oye-olukotun-m-d-new-york-september-7-201-tnxp-20180907monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-director-stepping-down-tnxp-20180822monthly0.5https://www.biopharmawatch.com/news/TNXP/effect-of-time-since-trauma-on-response-to-tnx-102-sl-cyclobenzaprine-sublingual-tablets-i-tnxp-20180821monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-second-quarter-2018-financial-results-and-operational-highli-tnxp-20180813monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-outcome-of-interim-analysis-for-phase-3-honor-study-of-ton-tnxp-20180727monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-receives-fast-track-designation-from-the-u-s-fda-for-tnx-102-sl-for--tnxp-20180716monthly0.5https://www.biopharmawatch.com/news/TNXP/an-afsp-ascp-workshop-inclusion-of-suicidal-individuals-in-treatment-trials-now-is-the-tim-tnxp-20180531monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-preliminary-results-from-a-phase-1-pivotal-multiple-dose-bri-tnxp-20180524monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-first-quarter-2018-financial-results-and-provides-programs-u-tnxp-20180514monthly0.5https://www.biopharmawatch.com/news/TNXP/jfif-6exif-mm-b-j-1-r-2-i-adobe-photoshop-cs3-windows-2018-04-12-21-37-25-4-tnxp-20180413monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-april-2018-version-p0106-4-3-18-doc-0334-investor-prese-tnxp-20180403monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-fourth-quarter-and-full-year-2017-financial-results-and-prov-tnxp-20180312monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-appoints-david-l-grange-to-the-board-of-directors-tnxp-20180215monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-receives-notice-of-allowance-for-new-u-s-patent-for-the-active-ingre-tnxp-20180123monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-january-2018-version-p0094-1-19-18-doc-0313-investor-pr-tnxp-20180122monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-publication-reporting-synthesis-construction-and-character-tnxp-20180119monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-appoints-jessica-morris-as-chief-operating-officer-tnxp-20180109monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-december-2017-version-p0089-12-12-17-doc-0303-investor--tnxp-20171212monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-third-quarter-2017-financial-results-and-provides-programs-u-tnxp-20171107monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-receives-european-patent-for-the-active-ingredient-in-tonmya-cyclobe-tnxp-20170914monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-elects-margaret-smith-bell-to-the-board-of-directors-tnxp-20170914monthly0.5https://www.biopharmawatch.com/news/TNXP/phase-2-trial-of-a-low-dose-bedtime-proprietary-sublingual-formulation-of-cyclobenzaprine--tnxp-20170829monthly0.5https://www.biopharmawatch.com/news/TNXP/interim-analysis-of-phase-3-honor-study-of-tnxp-20170814monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-july-2017-version-p0072-7-6-17-investor-presentation-20-tnxp-20170706monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-conditional-acceptance-of-tonmya-as-proposed-brand-name-fo-tnxp-20170706monthly0.5https://www.biopharmawatch.com/news/TNXP/seth-lederman-1-gregory-sullivan-1-judy-gendreau-1-r-michael-gendreau-2-ashild-peters-1-pe-tnxp-20170615monthly0.5https://www.biopharmawatch.com/news/TNXP/2017-tonix-pharmaceuticals-holding-corp-tnxp-20170530monthly0.5https://www.biopharmawatch.com/news/TNXP/jfif-d-d-ducky-d-adobe-d-4-4-8-tnxp-20170522monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-first-quarter-tnxp-20170515monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-holding-corp-may-2017-version-p0061-5-1-17-investor-presentation-201-tnxp-20170501monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-fourth-tnxp-20170417monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-full-tnxp-20170413monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-reports-results-from-tnxp-20170411monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-completes-8-tnxp-20170404monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-requirement-tnxp-20170403monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-proposed-tnxp-20170330monthly0.5https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-enrolls-first-participant-tnxp-20170328monthly0.5https://www.biopharmawatch.com/news/TNXP/jfif-6exif-mm-b-j-1-r-2-i-adobe-photoshop-cs3-windows-2017-03-20-17-14-53-4-tnxp-20170320monthly0.5https://www.biopharmawatch.com/news/FOCL/2026-investor-day-nasdaq-focl-june-1-2026-1-focl-20260601monthly0.5https://www.biopharmawatch.com/news/FOCL/the-global-leader-in-therapeutic-ultrasound-1-focl-20260318monthly0.5https://www.biopharmawatch.com/news/FOCL/edap-announces-preliminary-record-fourth-quarter-and-focl-20260112monthly0.5https://www.biopharmawatch.com/news/FOCL/securities-and-exchange-commission-focl-20250909monthly0.5https://www.biopharmawatch.com/news/KRRO/forward-looking-statements-and-disclaimers-forward-looking-statements-certain-statements-i-krro-20260127monthly0.5https://www.biopharmawatch.com/news/KRRO/concept-program-indication-delivery-discovery-preclinical-development-phase-1-phase-2-phas-krro-20260115monthly0.5https://www.biopharmawatch.com/news/KRRO/korro-reports-first-quarter-2025-financial-results-and-provides-business-updates-x2014-int-krro-20250507monthly0.5https://www.biopharmawatch.com/news/KRRO/korro-bio-announces-dosing-of-first-participants-in-rewrite-phase-1-2a-study-of-krro-110-f-krro-20250113monthly0.5https://www.biopharmawatch.com/news/KRRO/korro-receives-australian-hrec-approval-and-ctn-clearance-to-initiate-phase-1-2a-clinical--krro-20241121monthly0.5https://www.biopharmawatch.com/news/KRRO/korro-reports-third-quarter-2024-financial-results-and-provides-business-updates-x2014-sub-krro-20241112monthly0.5https://www.biopharmawatch.com/news/KRRO/korro-announces-regulatory-filing-for-initiation-of-krro-110-first-in-human-study-and-form-krro-20241104monthly0.5https://www.biopharmawatch.com/news/KRRO/korro-bio-announces-collaboration-with-novo-nordisk-to-develop-two-therapeutic-candidates--krro-20240916monthly0.5https://www.biopharmawatch.com/news/KRRO/korro-reports-second-quarter-2024-financial-results-and-provides-business-updates-x2014-re-krro-20240813monthly0.5https://www.biopharmawatch.com/news/KRRO/korro-reports-first-quarter-2024-financial-results-and-appointment-of-kemi-olugemo-m-d-as--krro-20240514monthly0.5https://www.biopharmawatch.com/news/KRRO/korro-announces-70-million-private-placement-financing-led-by-deep-track-capital-with-part-krro-20240418monthly0.5https://www.biopharmawatch.com/news/KRRO/korro-reports-full-year-2023-financial-results-and-highlights-recent-progress-on-track-for-krro-20240326monthly0.5https://www.biopharmawatch.com/news/KRRO/to-its-current-report-on-form-8-k-filed-with-the-sec-on-krro-20240109monthly0.5https://www.biopharmawatch.com/news/KRRO/update-korro-bio-and-frequency-therapeutics-announce-closing-of-merger-and-private-placeme-krro-20231106monthly0.5https://www.biopharmawatch.com/news/KRRO/frequency-therapeutics-provides-business-updates-and-second-quarter-2023-financial-results-krro-20230810monthly0.5https://www.biopharmawatch.com/news/KRRO/korro-bio-and-frequency-therapeutics-announce-merger-agreement-merger-to-create-a-nasdaq-l-krro-20230714monthly0.5https://www.biopharmawatch.com/news/KRRO/frequency-therapeutics-provides-business-updates-and-first-quarter-2023-financial-results-krro-20230512monthly0.5https://www.biopharmawatch.com/news/KRRO/frequency-therapeutics-provides-business-updates-and-fourth-quarter-and-full-year-2022-fin-krro-20230310monthly0.5https://www.biopharmawatch.com/news/KRRO/forward-looking-statements-and-other-disclaimers-this-presentation-contains-forward-lookin-krro-20230213monthly0.5https://www.biopharmawatch.com/news/KRRO/forward-looking-statements-and-other-disclaimers-this-presentation-contains-forward-lookin-krro-20221213monthly0.5https://www.biopharmawatch.com/news/KRRO/frequency-therapeutics-provides-business-updates-and-third-quarter-2022-financial-results--krro-20221108monthly0.5https://www.biopharmawatch.com/news/KRRO/pioneering-a-new-category-in-regenerative-medicine-frequency-therapeutics-corporate-presen-krro-20220912monthly0.5https://www.biopharmawatch.com/news/KRRO/frequency-therapeutics-provides-business-updates-and-second-quarter-2022-financial-results-krro-20220809monthly0.5https://www.biopharmawatch.com/news/KRRO/frequency-therapeutics-provides-business-updates-and-first-quarter-2022-financial-results--krro-20220504monthly0.5https://www.biopharmawatch.com/news/KRRO/pioneering-a-new-category-in-regenerative-medicine-frequency-therapeutics-corporate-presen-krro-20220408monthly0.5https://www.biopharmawatch.com/news/KRRO/pioneering-a-new-category-in-regenerative-medicine-frequency-therapeutics-corporate-presen-krro-20220315monthly0.5https://www.biopharmawatch.com/news/KRRO/frequency-therapeutics-provides-business-updates-and-reports-fourth-quarter-and-full-year--krro-20220315monthly0.5https://www.biopharmawatch.com/news/KRRO/pioneering-a-new-category-in-regenerative-medicine-frequency-therapeutics-corporate-presen-krro-20220113monthly0.5https://www.biopharmawatch.com/news/KRRO/pioneering-a-new-category-in-regenerative-medicine-frequency-therapeutics-corporate-presen-krro-20211209monthly0.5https://www.biopharmawatch.com/news/KRRO/frequency-therapeutics-provides-business-updates-and-third-quarter-2021-financial-results--krro-20211115monthly0.5https://www.biopharmawatch.com/news/KRRO/pioneering-a-new-category-in-regenerative-medicine-frequency-therapeutics-corporate-presen-krro-20211109monthly0.5https://www.biopharmawatch.com/news/KRRO/leading-a-new-category-in-regenerative-medicine-advancing-novel-approaches-to-hearing-rest-krro-20210922monthly0.5https://www.biopharmawatch.com/news/KRRO/this-presentation-contains-forward-looking-statements-within-the-meaning-of-the-private-se-krro-20210812monthly0.5https://www.biopharmawatch.com/news/KRRO/this-presentation-contains-forward-looking-statements-within-the-meaning-of-the-private-se-krro-20210630monthly0.5https://www.biopharmawatch.com/news/KRRO/frequency-therapeutics-provides-business-updates-and-reports-first-quarter-2021-financial--krro-20210513monthly0.5https://www.biopharmawatch.com/news/KRRO/frequency-therapeutics-provides-business-updates-and-reports-fourth-quarter-and-full-year--krro-20210329monthly0.5https://www.biopharmawatch.com/news/KRRO/this-presentation-contains-forward-looking-statements-within-the-meaning-of-the-private-se-krro-20210323monthly0.5https://www.biopharmawatch.com/news/KRRO/frequency-therapeutics-announces-publication-of-phase-1-2-data-showing-hearing-improvement-krro-20210222monthly0.5https://www.biopharmawatch.com/news/KRRO/reimagining-the-treatment-of-hearing-loss-corporate-overview-january-2021-forward-looking--krro-20210111monthly0.5https://www.biopharmawatch.com/news/KRRO/frequency-therapeutics-appoints-peter-pfreundschuh-as-chief-financial-officer-krro-20201201monthly0.5https://www.biopharmawatch.com/news/KRRO/frequency-therapeutics-provides-business-updates-and-reports-third-quarter-2020-financial--krro-20201116monthly0.5https://www.biopharmawatch.com/news/KRRO/forward-looking-statements-and-other-disclaimers-this-presentation-contains-forward-lookin-krro-20201029monthly0.5https://www.biopharmawatch.com/news/KRRO/frequency-therapeutics-appoints-cynthia-feldmann-to-its-board-of-directors-krro-20200925monthly0.5https://www.biopharmawatch.com/news/KRRO/frequency-therapeutics-provides-business-updates-and-reports-second-quarter-2020-financial-krro-20200812monthly0.5https://www.biopharmawatch.com/news/KRRO/frequency-therapeutics-provides-business-updates-and-reports-first-quarter-2020-financial--krro-20200514monthly0.5https://www.biopharmawatch.com/news/KRRO/a-letter-from-david-l-lucchino-chief-executive-officer-dear-fellow-shareholders-this-past--krro-20200430monthly0.5https://www.biopharmawatch.com/news/KRRO/frequency-therapeutics-provides-business-updates-and-reports-fourth-quarter-and-full-year--krro-20200326monthly0.5https://www.biopharmawatch.com/news/KRRO/frequency-therapeutics-provides-business-updates-and-reports-third-quarter-2019-financial--krro-20191118monthly0.5https://www.biopharmawatch.com/news/MENS/jyong-biotech-limited-unaudited-interim-condensed-consolidated-balance-sheets-in-thousand--mens-20260109monthly0.5https://www.biopharmawatch.com/news/MENS/jyong-biotech-ltd-announces-pricing-of-20-million-initial-public-offering-new-taipei-city--mens-20250616monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-contact-b-infu-20260518monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-contact-b-infu-20260507monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20260430monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-contact-b-infu-20260316monthly0.5https://www.biopharmawatch.com/news/INFU/q25investorpr-investor-presentation-infu-20260227monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-contact-b-infu-20260224monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20260217monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20251210monthly0.5https://www.biopharmawatch.com/news/INFU/q25investorpr-investor-presentation-infu-20251113monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20251110monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-contact-j-infu-20251104monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20251028monthly0.5https://www.biopharmawatch.com/news/INFU/q25investorpr-investor-presentation-infu-20251006monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20250925monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-contact-j-infu-20250805monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20250729monthly0.5https://www.biopharmawatch.com/news/INFU/q25investorpr-investor-presentation-infu-20250509monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-contact-j-infu-20250508monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20250501monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20250401monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-contact-j-infu-20250304monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20250225monthly0.5https://www.biopharmawatch.com/news/INFU/q24investorpr-investor-presentation-infu-20241204monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20241122monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20241118monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-contact-j-infu-20241107monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20241031monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20240927monthly0.5https://www.biopharmawatch.com/news/INFU/q24investorpr-investor-presentation-infu-20240912monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20240911monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20240904monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-contact-j-infu-20240808monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20240806monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20240802monthly0.5https://www.biopharmawatch.com/news/INFU/q24investorpr-investor-presentation-infu-20240612monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20240604monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20240520monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-contact-j-infu-20240509monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20240502monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20240403monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-contact-j-infu-20240314monthly0.5https://www.biopharmawatch.com/news/INFU/cooperation-agreement-this-cooperation-agreement-this-agreement-is-made-as-of-infu-20240308monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20240308monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20231128monthly0.5https://www.biopharmawatch.com/news/INFU/q23investorpr-investor-presentation-infu-20231109monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20231109monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-contact-j-infu-20231107monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20231031monthly0.5https://www.biopharmawatch.com/news/INFU/q23investorpr-investor-presentation-infu-20230914monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20230905monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-contact-j-infu-20230803monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20230727monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20230621monthly0.5https://www.biopharmawatch.com/news/INFU/q23investorpr-investor-presentation-infu-20230511monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20230505monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20230427monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20230425monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-contact-j-infu-20230315monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20221110monthly0.5https://www.biopharmawatch.com/news/INFU/q22investorpr-investor-presentation-november-8-2022-l-nyse-american-infu-enabling-continui-infu-20221103monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-contact-j-infu-20221108monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20221103monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20220923monthly0.5https://www.biopharmawatch.com/news/INFU/q22investorpr-investor-presentation-september-8-2022-l-nyse-american-infu-enabling-continu-infu-20220908monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20220907monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-contact-j-infu-20220804monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20220729monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20220614monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20220526monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-contact-j-infu-20220505monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20220428monthly0.5https://www.biopharmawatch.com/news/INFU/q21investorpr-investor-presentation-infu-20220323monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20220222monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-contact-j-infu-20220210monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20220113monthly0.5https://www.biopharmawatch.com/news/INFU/q21investorpr-investor-presentation-november-15-2021-l-nyse-american-infu-enabling-continu-infu-20211110monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-contact-j-infu-20211115monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20211103monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-3851-w-hamlin-road-rochester-hills-mi-48309-248-291-1210-for-immed-infu-20210908monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-co-infu-20180207monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-co-infu-20180131monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-ri-infu-20171116monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-co-infu-20171110monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-michigan-48071-248-291-1-infu-20171031monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-co-infu-20170809monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-michigan-48071-248-291-1-infu-20170804monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-in-infu-20170629monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-in-infu-20170622monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-in-infu-20170619monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-in-infu-20170518monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-co-infu-20170511monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-michigan-48071-248-291-1-infu-20170414monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-we-infu-20170322monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-michigan-48071-248-291-1-infu-20170317monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-co-infu-20161213monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-mo-infu-20161128monthly0.5https://www.biopharmawatch.com/news/INFU/safe-harbor-statement-innovation-teamwork-integrity-focus-people-first-certain-statements--infu-20160926monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-co-infu-20160810monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-michigan-48071-248-291-1-infu-20160803monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-co-infu-20160729monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-co-infu-20160510monthly0.5https://www.biopharmawatch.com/news/INFU/safe-harbor-statement-innovation-teamwork-integrity-focus-people-first-certain-statements--infu-20160314monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-we-infu-20160309monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-michigan-48071-248-291-1-infu-20160302monthly0.5https://www.biopharmawatch.com/news/INFU/safe-harbor-statement-2-innovation-teamwork-integrity-focus-people-first-certain-statement-infu-20160202monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-contact-joe-dor-infu-20151112monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-michigan-48071-248-291-1-infu-20151105monthly0.5https://www.biopharmawatch.com/news/INFU/safe-harbor-statement-2-innovation-teamwork-integrity-focus-people-first-certain-statement-infu-20150930monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-co-infu-20150813monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-michigan-48071-248-291-1-infu-20150806monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-co-infu-20150515monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-for-immediate-r-infu-20150512monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-michigan-48071-248-291-1-infu-20150505monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-co-infu-20150421monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-shareholder-presentation-as-of-infu-20150415monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-co-infu-20150326monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-mo-infu-20150309monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-michigan-48071-248-291-1-infu-20150304monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-fo-infu-20150106monthly0.5https://www.biopharmawatch.com/news/INFU/safe-harbor-statement-certain-statements-contained-in-this-presentation-are-forward-lookin-infu-20141202monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-for-immediate-release-monday-infu-20141110monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-michigan-48071-248-291-1-infu-20141030monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-for-immediate-r-infu-20140801monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-michigan-48071-248-291-1-infu-20140709monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-fo-infu-20140519monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-shareholder-presentation-as-of-infu-20140519monthly0.5https://www.biopharmawatch.com/news/INFU/to-the-company-s-current-report-on-form-8-k-filed-with-the-securities-and-exchange-commiss-infu-20140516monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-fo-infu-20140509monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-fo-infu-20140505monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-michigan-48071-248-291-1-infu-20140428monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-for-immediate-release-wednesday-infu-20140423monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-for-immediate-release-31700-research-park-drive-madison-heights-mi-infu-20140409monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-for-immediate-r-infu-20140311monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-michigan-48071-248-291-1-infu-20140226monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-michigan-48071-248-291-1-infu-20140212monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-sidoti-company-llc-conference-infu-20140113monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-fo-infu-20140109monthly0.5https://www.biopharmawatch.com/news/INFU/safe-harbor-statement-certain-statements-contained-in-this-release-are-forward-looking-sta-infu-20131205monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-shareholders-q3-13-presentation-infu-20131118monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-for-immediate-r-infu-20131112monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-michigan-48071-248-291-1-infu-20131105monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-fo-infu-20131003monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-post-shareholders-meeting-infu-20130829monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-fo-infu-20130826monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-fo-infu-20130815monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-fo-infu-20130813monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-michigan-48071-248-291-1-infu-20130805monthly0.5https://www.biopharmawatch.com/news/INFU/ryan-j-morris-rmorris-mesoncapital-com-607-279-5382-www-mesoncapital-com-infu-20130717monthly0.5https://www.biopharmawatch.com/news/INFU/ryan-j-morris-rmorris-mesoncapital-com-607-279-5382-www-mesoncapital-com-infu-20130513monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-fo-infu-20130513monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-infu-20130502monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-for-immediate-r-infu-20130328monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-infu-20130314monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-fo-infu-20130103monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-fo-infu-20121203monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-announces-third-quarter-fiscal-2012-results-infusystem-holdings-in-infu-20121114monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-michigan-48071-248-291-1-infu-20121102monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-announces-second-quarter-fiscal-2012-results-infusystem-holdings-i-infu-20120807monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-michigan-48071-248-291-1-infu-20120801monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-in-infu-20120608monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-in-infu-20120521monthly0.5https://www.biopharmawatch.com/news/INFU/investor-contact-jonathan-p-foster-chief-financial-officer-info-infusystem-com-248-291-121-infu-20120515monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-announces-agreement-with-investor-group-regarding-2012-annual-meeting-of-stockh-infu-20120424monthly0.5https://www.biopharmawatch.com/news/INFU/investor-contact-pat-lavecchia-vice-chairman-info-infusystem-com-tel-800-962-9656-media-co-infu-20120316monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-2450-south-shore-blvd-suite-402-league-city-texas-77573-248-291-12-infu-20120315monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-investor-contact-madison-heights-mi-4807-infu-20120206monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-in-infu-20111110monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-in-infu-20110811monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-madison-heights-mi-48071-248-291-1210-in-infu-20110512monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-31700-research-park-drive-investor-contact-madison-heights-mi-4807-infu-20110310monthly0.5https://www.biopharmawatch.com/news/INFU/infusystem-holdings-inc-248-291-1210-investor-contacts-asher-dewhurst-bob-east-westwicke-p-infu-20101210monthly0.5https://www.biopharmawatch.com/news/INFU/sean-whelan-cfo-infusystem-248-291-1210-investor-contacts-asher-dewhurst-bob-east-westwick-infu-20100615monthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-corporation-reports-first-quarter-2026-financial-results-and-recent-corpor-derm-20260513monthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-corporation-secures-contract-with-third-major-gpo-for-emrosi-payer-access--derm-20260401monthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-corporation-reports-second-quarter-2025-financial-results-and-recent-corpo-derm-20250812monthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-to-join-russell-2000-and-russell-3000-indexes-scottsdale-az-derm-20250624monthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-corporation-reports-first-quarter-2025-financial-results-and-recent-corpor-derm-20250514monthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-corporation-appoints-ramsey-alloush-as-chief-operating-officer-scottsdale--derm-20250401monthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-corporation-reports-full-year-2024-financial-results-and-recent-corporate--derm-20250326monthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-corporation-launches-emrosi-40-mg-minocycline-hydrochloride-modified-relea-derm-20250324monthly0.5https://www.biopharmawatch.com/news/DERM/2025-journey-medical-corporation-all-rights-reserved-emrosi-derm-20250205monthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-corporation-reports-third-quarter-2024-financial-results-and-recent-corpor-derm-20241112monthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-corporation-announces-u-s-fda-approval-of-emrosi-minocycline-hydrochloride-derm-20241104monthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-corporation-reports-second-quarter-2024-financial-results-and-recent-corpo-derm-20240812monthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-corporation-reports-first-quarter-2024-financial-results-and-recent-corpor-derm-20240513monthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-corporation-appoints-joseph-benesch-as-chief-financial-officer-scottsdale--derm-20240501monthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-corporation-reports-full-year-2023-financial-results-and-recent-corporate--derm-20240321monthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-corporation-secures-credit-facility-with-swk-holdings-for-up-to-20-million-derm-20240102monthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-corporation-reports-third-quarter-2023-financial-results-and-recent-corpor-derm-20231107monthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-corporation-enters-into-an-exclusive-license-agreement-with-maruho-co-ltd--derm-20230906monthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-corporation-reports-second-quarter-2023-financial-results-and-recent-corpo-derm-20230808monthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-corporation-reports-first-quarter-2023-financial-results-and-recent-corpor-derm-20230522monthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-corporation-reports-full-year-2022-financial-results-and-recent-corporate--derm-20230329monthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-corporation-appoints-joseph-benesch-as-interim-chief-financial-officer-sco-derm-20230120monthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-corporation-reports-third-quarter-2022-financial-results-and-recent-corpor-derm-20221110monthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-corporation-reports-second-quarter-2022-financial-results-and-recent-corpo-derm-20220809monthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-corporation-reports-first-quarter-2022-financial-results-and-recent-corpor-derm-20220510monthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-corporation-reports-full-year-2021-financial-results-and-recent-corporate--derm-20220323monthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-corporation-acquires-two-fda-approved-topical-minocycline-products-and-mol-derm-20220113monthly0.5https://www.biopharmawatch.com/news/DERM/journey-medical-corporation-reports-third-quarter-2021-financial-results-and-recent-corpor-derm-20211210monthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-reports-first-quarter-2026-results-first-quarter-2026-revenue-of-50-2-million-and-a-lfmd-20260506monthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-appoints-veteran-healthcare-finance-executive-as-chief-financial-officer-and-expand-lfmd-20260316monthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-reports-fourth-quarter-and-full-year-2025-results-full-year-2025-revenue-grew-25-to-lfmd-20260309monthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-announces-closing-of-50-million-revolving-credit-facility-with-citizens-bank-lfmd-20260106monthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-reports-third-quarter-2025-results-total-revenue-increased-13-year-over-year-to-60--lfmd-20251117monthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-reschedules-third-quarter-2025-earnings-release-and-conference-call-to-november-17-lfmd-20251105monthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-divests-majority-interest-in-worksimpli-software-positioning-company-as-a-pure-play-lfmd-20251104monthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-reports-second-quarter-2025-results-total-revenue-increased-23-year-over-year-to-62-lfmd-20250805monthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-names-coo-and-promotes-two-executives-lfmd-20250731monthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-reports-first-quarter-2025-results-and-raises-full-year-2025-guidance-total-revenue-lfmd-20250506monthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-reports-fourth-quarter-2024-results-consolidated-revenues-increased-43-year-over-ye-lfmd-20250310monthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-appoints-dr-calum-macrae-to-its-board-of-directors-lfmd-20240429monthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-and-medifast-partner-to-offer-transformative-weight-management-solution-collaborati-lfmd-20231213monthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-appoints-william-j-febbo-to-its-board-of-directors-lfmd-20230620monthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-inc-announces-closing-of-new-40-million-credit-facility-lfmd-20230322monthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-appoints-dr-joan-larovere-to-its-board-of-directors-lfmd-20230210monthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-appoints-bobby-jindal-to-the-board-of-directors-lfmd-20220920monthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-provides-initial-fy2022-guidance-and-announces-preliminary-fy2021-revenues-total-fy-lfmd-20220119monthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-announces-launch-of-public-offering-of-common-stock-lfmd-20210928monthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-appoints-seasoned-investor-naveen-bhatia-to-board-of-directors-industry-veteran-bri-lfmd-20210913monthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-teams-with-a-leading-provider-of-diagnostic-services-and-axle-health-to-deliver-tel-lfmd-20210715monthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-names-experienced-pharma-executive-alexander-mironov-as-president-a-seasoned-indust-lfmd-20210611monthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-tm-completes-15m-debt-financing-financing-significantly-bolsters-liquidity-position-lfmd-20210603monthly0.5https://www.biopharmawatch.com/news/LFMD/plaintiffs-in-shareholder-suits-drop-claims-against-lifemd-cases-voluntarily-dismissed-com-lfmd-20210528monthly0.5https://www.biopharmawatch.com/news/LFMD/star-actresses-kate-del-castillo-and-bellamy-young-partner-with-lifemd-as-brand-ambassador-lfmd-20210518monthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-reports-q1-2021-revenue-up-323-to-record-18-2m-raises-full-year-revenue-guidance-to-lfmd-20210513monthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-announces-expected-record-revenue-of-18-2m-for-q1-21-up-323-vs-q1-20-due-to-growth--lfmd-20210419monthly0.5https://www.biopharmawatch.com/news/LFMD/short-seller-s-note-is-short-on-credibility-lifemd-says-company-cites-errors-distortions-i-lfmd-20210416monthly0.5https://www.biopharmawatch.com/news/LFMD/lifemd-responds-to-anonymous-short-report-lfmd-20210415monthly0.5https://www.biopharmawatch.com/news/LFMD/conversion-labs-begins-trading-under-new-company-name-lifemd-and-ticker-symbol-lfmd-20210222monthly0.5https://www.biopharmawatch.com/news/LFMD/conversion-labs-to-become-life-md-with-launch-of-new-concierge-telehealth-services-company-lfmd-20210212monthly0.5https://www.biopharmawatch.com/news/LFMD/conversion-labs-appoints-seasoned-financial-and-operational-executive-marc-benathen-as-chi-lfmd-20210205monthly0.5https://www.biopharmawatch.com/news/LFMD/conversion-labs-expects-2020-revenue-up-205-to-record-38-0-million-subscription-arr-up-525-lfmd-20210119monthly0.5https://www.biopharmawatch.com/news/LFMD/conversion-labs-appoints-leading-telehealth-professional-dr-anthony-puopolo-as-chief-medic-lfmd-20210111monthly0.5https://www.biopharmawatch.com/news/LFMD/conversion-labs-appoints-digital-marketing-executive-bryant-hussey-as-chief-digital-office-lfmd-20210105monthly0.5https://www.biopharmawatch.com/news/LFMD/conversion-labs-appoints-expert-life-sciences-attorney-eric-h-yecies-as-chief-compliance-o-lfmd-20201120monthly0.5https://www.biopharmawatch.com/news/LFMD/conversion-labs-inc-condensed-consolidated-balance-sheet-unaudited-lfmd-20201117monthly0.5https://www.biopharmawatch.com/news/LFMD/conversion-labs-appoints-wex-cfo-and-former-revlon-cfo-roberto-simon-to-board-of-directors-lfmd-20201110monthly0.5https://www.biopharmawatch.com/news/LFMD/conversion-labs-closes-initial-round-of-15-million-private-placement-with-institutional-in-lfmd-20201104monthly0.5https://www.biopharmawatch.com/news/LFMD/conversion-labs-appoints-former-white-house-physician-and-u-s-navy-rear-admiral-dr-connie--lfmd-20201021monthly0.5https://www.biopharmawatch.com/news/LFMD/jfif-c-1-3-mqypdx-egc-c-cb8bcccccccccccccccccccccccccccccccccccccccccccccccccc-1a-qa-q-2-lfmd-20191211monthly0.5https://www.biopharmawatch.com/news/LFMD/jfif-6-6-424-lddl-z-6-6-424-lddl-z-1aq-lfmd-20190911monthly0.5https://www.biopharmawatch.com/news/LFMD/conversion-labs-strengthens-board-of-directors-with-appointment-of-two-new-directors-lfmd-20190611monthly0.5https://www.biopharmawatch.com/news/LFMD/jfif-c-7-01444-9-82-s-i-bh-4-d-l-2v-m-p-gz-2p-d-h-8-n-p-m-9-h-8-f-n-p-8-ii-z-lfmd-20190514monthly0.5https://www.biopharmawatch.com/news/LFMD/conversion-labs-announces-sean-fitzpatrick-as-chief-acquisition-officer-lfmd-20181029monthly0.5https://www.biopharmawatch.com/news/LFMD/immudyne-inc-q2-2018-corporate-presentation-please-note-our-name-will-be-changing-to-conve-lfmd-20180619monthly0.5https://www.biopharmawatch.com/news/LFMD/immudyne-announces-management-changes-sale-of-legacy-manufacturing-business-new-york-n-y-lfmd-20180130monthly0.5https://www.biopharmawatch.com/news/LFMD/immudyne-provides-2017-business-outlook-lfmd-20170306monthly0.5https://www.biopharmawatch.com/news/LFMD/investor-presentation-q4-2016-otcqb-immd-www-immudyne-com-statements-in-this-presentation--lfmd-20161012monthly0.5https://www.biopharmawatch.com/news/LFMD/immudyne-announces-q2-2016-net-sales-up-343-adjusted-non-gaap-net-income-lfmd-20160815monthly0.5https://www.biopharmawatch.com/news/LFMD/immudyne-announces-q1-2016-net-sales-up-470-q2-changes-to-drive-growth-profitability-immud-lfmd-20160517monthly0.5https://www.biopharmawatch.com/news/LFMD/immudyne-pre-announces-full-year-2015-revenues-up-73-guides-for-10m-in-fiscal-2016-fiscal--lfmd-20160307monthly0.5https://www.biopharmawatch.com/news/LFMD/immudyne-corporate-presentation-lfmd-20130418monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-announces-chief-financial-officer-transition-minneapolis-cvrx-20260609monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-reports-fourth-quarter-and-full-year-2025-financial-and-operating-results-minneapolis-cvrx-20260212monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-reports-preliminary-fourth-quarter-and-fiscal-year-2025-financial-results-and-issues--cvrx-20260101monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-reports-second-quarter-2025-financial-and-operating-results-minneapolis-cvrx-20250804monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-reports-first-quarter-2025-financial-and-operating-results-minneapolis-cvrx-20250508monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-reports-preliminary-first-quarter-2025-financial-results-first-quarter-revenue-expect-cvrx-20250407monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-reports-fourth-quarter-and-full-year-2024-financial-and-operating-results-minneapolis-cvrx-20250204monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-reports-preliminary-fourth-quarter-and-fiscal-year-2024-financial-results-and-issues--cvrx-20250113monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-reports-third-quarter-2024-financial-and-operating-results-minneapolis-cvrx-20241029monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-reports-second-quarter-2024-financial-and-operating-results-minneapolis-cvrx-20240729monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-reports-first-quarter-2024-financial-and-operating-results-minneapolis-cvrx-20240430monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-announces-appointment-of-kevin-hykes-as-president-and-chief-executive-officer-appoint-cvrx-20240131monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-reports-fourth-quarter-and-full-year-2023-financial-and-operating-results-minneapolis-cvrx-20240125monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-reports-preliminary-fourth-quarter-and-fiscal-year-2023-financial-results-and-announc-cvrx-20240108monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-receives-fda-approval-for-expanded-labeling-of-barostim-u-s-annual-market-opportunity-cvrx-20231226monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-reports-third-quarter-2023-financial-and-operating-results-minneapolis-cvrx-20231026monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-reports-second-quarter-2023-financial-and-operating-results-minneapolis-cvrx-20230725monthly0.5https://www.biopharmawatch.com/news/CVRX/rd-annual-william-blair-growth-stock-conference-june-2023-2-cautionary-note-regarding-forw-cvrx-20230608monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-reports-first-quarter-2023-financial-and-operating-results-minneapolis-cvrx-20230427monthly0.5https://www.biopharmawatch.com/news/CVRX/totality-of-evidence-from-beat-hf-study-shows-cvrx-s-barostim-provides-long-term-benefits--cvrx-20230321monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-reports-preliminary-results-of-the-beat-hf-post-market-randomized-clinical-trial-the--cvrx-20230221monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-reports-fourth-quarter-and-full-year-2022-financial-and-operating-results-fourth-quar-cvrx-20230126monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-reports-preliminary-fourth-quarter-and-fiscal-year-2022-financial-results-minneapolis-cvrx-20230109monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-reports-third-quarter-2022-financial-and-operating-results-third-quarter-2022-revenue-cvrx-20221101monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-reports-second-quarter-2022-financial-and-operating-results-second-quarter-2022-reven-cvrx-20220728monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-reports-first-quarter-2022-financial-and-operating-results-first-quarter-2022-revenue-cvrx-20220425monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-reports-fourth-quarter-and-full-year-2021-financial-and-operating-results-fourth-quar-cvrx-20220215monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-reports-preliminary-fourth-quarter-and-fiscal-year-2021-financial-results-minneapolis-cvrx-20220110monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-reports-third-quarter-2021-financial-and-operating-results-third-quarter-2021-revenue-cvrx-20211104monthly0.5https://www.biopharmawatch.com/news/CVRX/cvrx-reports-second-quarter-2021-financial-and-operating-results-second-quarter-2021-reven-cvrx-20210804monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-announces-pricing-of-20-million-underwritten-offering-zurich-schlieren--moln-20241025monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-reports-corporate-highlights-and-h1-2022-financials-moln-20220825monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-publishes-invitation-to-annual-general-meeting-2022-moln-20220317monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-and-novartis-report-positive-topline-data-from-phase-2-study-for-ensovi-moln-20220110monthly0.5https://www.biopharmawatch.com/news/MOLN/custom-built-biology-for-patients-1-oncology-day-2021-molecular-p-artners-a-g-s-witzerland-moln-20211215monthly0.5https://www.biopharmawatch.com/news/MOLN/molecular-partners-reports-corporate-highlights-and-key-financials-for-h1-2021-moln-20210826monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-second-regulatory-approval-for-phase-2b-trial-of-allocetra-in-age-relate-enlv-20260421monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-21-million-debt-financing-decentralized-prediction-markets-rain-token-re-enlv-20260320monthly0.5https://www.biopharmawatch.com/news/ENLV/quality-longevity-company-enlivex-receives-investigational-new-drug-ind-clearance-from-the-enlv-20260323monthly0.5https://www.biopharmawatch.com/news/ENLV/certificate-of-change-of-name-this-is-to-certify-that-the-company-company-number-514716489-enlv-20260223monthly0.5https://www.biopharmawatch.com/news/ENLV/articles-of-association-of-enlivex-therapeutics-ltd-a-company-limited-by-shares-under-the--enlv-20260203monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-treasury-portfolio-update-listing-of-the-rain-token-on-kucoin-a-leading-cryptocurr-enlv-20260107monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-notice-of-extraordinary-general-meeting-of-shareholders-to-be-hel-enlv-20251218monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-management-to-host-fireside-chat-on-december-11-to-discuss-rain-token-strategy-and-enlv-20251204monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-closing-of-previously-announced-212-000-000-private-placement-enlivex-ha-enlv-20251125monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-condensed-consolidated-financial-statements-as-of-september-30-20-enlv-20251114monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-notice-of-annual-general-meeting-of-shareholders-to-be-held-on-no-enlv-20250925monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-condensed-consolidated-financial-statements-as-of-june-30-2025-an-enlv-20250829monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-phase-iia-topline-results-aug-2025-these-slides-and-the-accompanying--enlv-20250818monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-reaffirms-enlv-20250728monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-condensed-consolidated-financial-statements-as-of-march-31-2025-a-enlv-20250530monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-completion-of-enrollment-in-the-phase-ii-stage-of-its-phase-i-ii-trial-e-enlv-20250421monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-the-dosing-of-the-first-patient-in-a-phase-i-trial-evaluating-allocetra--enlv-20250403monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-financial-statements-as-of-december-31-2024-enlivex-therapeutics--enlv-20250331monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-receives-notice-of-allowance-for-chinese-patent-application-covering-the-use-of-al-enlv-20250317monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-announces-investor-webinar-to-discuss-positive-interim-data-from-phas-enlv-20250304monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-positive-interim-data-statistically-significant-47-0-durable-and-persist-enlv-20250303monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-issues-urgent-statement-on-fraudulent-news-dissemination-ness-ziona-israel-enlv-20250218monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-receives-regulatory-authorization-for-the-initiation-of-a-phase-i-trial-evaluating-enlv-20241211monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-positive-interim-efficacy-data-from-allocetra-trial-in-patients-with-mod-enlv-20241203monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-condensed-consolidated-financial-statements-as-of-september-30-20-enlv-20241129monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-adopts-bitcoin-treasury-reserve-strategy-nes-ziona-israel-enlv-20241120monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-the-dosing-of-the-first-patient-in-a-phase-i-clinical-trial-evaluating-a-enlv-20241114monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-the-enrollment-and-dosing-of-the-first-10-patient-in-the-randomized-phas-enlv-20241111monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-receives-notice-of-allowance-for-japanese-patent-application-covering-the-use-of-a-enlv-20241030monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-the-company-amended-and-restated-compensation-policy-for-company--enlv-20241015monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-receives-authorization-from-the-danish-medicines-agency-to-initiate-the-phase-ii-s-enlv-20240926monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-positive-dsmb-recommendation-to-initiate-the-phase-ii-stage-of-its-phase-enlv-20240924monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-notice-of-annual-general-meeting-of-shareholders-to-be-held-on-oc-enlv-20240911monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-condensed-consolidated-financial-statements-as-of-june-30-2024-an-enlv-20240830monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-receives-regulatory-authorization-for-the-initiation-of-a-phase-i-clinical-trial-t-enlv-20240723monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-the-dosing-of-the-first-patient-in-a-randomized-placebo-controlled-phase-enlv-20240624monthly0.5https://www.biopharmawatch.com/news/ENLV/join-enlivex-therapeutics-chief-executive-officer-for-a-live-investor-webinar-and-q-a-sess-enlv-20240620monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-positive-interim-data-readout-from-a-phase-i-ii-trial-evaluating-allocet-enlv-20240617monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-condensed-consolidated-financial-statements-as-of-march-31-2024-a-enlv-20240614monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-receives-regulatory-authorization-for-the-initiation-of-a-placebo-controlled-phase-enlv-20240603monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-closes-up-to-15-million-registered-direct-offering-nes-ziona-israel-enlv-20240529monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-announces-up-to-15-million-registered-direct-offering-single-healthca-enlv-20240528monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-ceo-issues-letter-to-shareholders-perspectives-on-recent-events-nes-ziona-israel-enlv-20240429monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-dosing-of-first-two-patients-in-its-randomized-controlled-phase-i-ii-tri-enlv-20240422monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-authorization-from-the-danish-regulatory-agency-for-the-company-s-random-enlv-20240416monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-topline-results-of-its-phase-ii-trial-evaluating-allocetra-in-patients-w-enlv-20240411monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-financial-statements-as-of-december-31-2023-enlivex-therapeutics--enlv-20240329monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-issuance-of-new-u-s-patent-covering-allocetra-cells-and-their-manufactur-enlv-20240207monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-receives-imoh-regulatory-authorization-for-the-initiation-of-a-multi-country-rando-enlv-20240117monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-completion-of-enrollment-of-its-phase-ii-trial-evaluating-allocetra-in-p-enlv-20231219monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-condensed-consolidated-financial-statements-as-of-september-30-20-enlv-20231109monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-notice-of-annual-general-meeting-of-shareholders-to-be-held-on-enlv-20230913monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-reprioritization-plan-and-second-quarter-2023-financial-results-the-comp-enlv-20230911monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-condensed-consolidated-financial-statements-as-of-june-30-2023-an-enlv-20230901monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-peer-reviewed-publication-in-frontiers-in-immunology-of-clinical-data-de-enlv-20230802monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-dosing-of-first-patient-under-the-amended-protocol-of-its-phase-ii-trial-enlv-20230731monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-first-quarter-2023-financial-results-and-provides-a-business-update-enro-enlv-20230626monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-condensed-consolidated-financial-statements-as-of-march-31-2023-a-enlv-20230616monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-selected-for-an-elevator-pitch-presentation-and-two-additional-poster-presentation-enlv-20230531monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-issuance-of-european-patent-covering-the-use-of-allocetra-to-prevent-cyt-enlv-20230508monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-receives-notice-of-allowance-for-u-s-patent-application-covering-the-use-of-alloce-enlv-20230419monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-appoints-andrew-singer-to-its-board-of-directors-mr-singer-brings-over-25-years-of-enlv-20230417monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-tislelizumab-clinical-collaboration-full-year-2022-financial-results-and-enlv-20230403monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-clinical-collaboration-to-evaluate-combinations-of-allocetra-and-pd-1-in-enlv-20230403monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-financial-statements-as-of-december-31-2022-enlivex-therapeutics--enlv-20230331monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-receives-positive-dsmb-recommendation-and-imoh-clearance-to-continue-phase-i-ii-tr-enlv-20230320monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-receives-clearance-from-spanish-agency-of-medicines-and-medical-devices-for-treatm-enlv-20230223monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-issuance-of-israeli-patent-covering-the-use-of-allocetra-to-prevent-cyto-enlv-20230215monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-positive-dsmb-recommendation-and-imoh-clearance-to-continue-phase-i-ii-t-enlv-20230125monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-receives-authorizations-from-french-and-belgian-regulatory-agencies-to-expand-its--enlv-20230104monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-third-quarter-2022-financial-results-and-provides-a-business-update-rece-enlv-20221205monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-condensed-consolidated-financial-statements-as-of-september-30-20-enlv-20221202monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-receives-allocetra-ind-clearance-from-the-u-s-food-and-drug-administration-for-tre-enlv-20221128monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-dosing-of-the-first-patient-in-phase-i-ii-trial-evaluating-allocetra-alo-enlv-20221115monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-notice-of-annual-general-meeting-of-shareholders-to-be-held-on-enlv-20221005monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-new-preclinical-data-in-murine-mesothelioma-model-showing-a-substantial--enlv-20220912monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-receives-notice-of-allowance-for-u-s-patent-application-covering-the-use-of-alloce-enlv-20220906monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-receives-notice-of-allowance-for-japanese-patent-application-covering-allocetra-de-enlv-20220829monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-regulatory-clearance-in-multiple-countries-for-integration-of-frozen-all-enlv-20220824monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-condensed-consolidated-financial-statements-as-of-june-30-2022-an-enlv-20220822monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-receives-israeli-ministry-of-health-approval-for-the-initiation-of-a-phase-i-ii-tr-enlv-20220816monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-receives-notice-of-allowance-for-u-s-patent-application-covering-methods-of-treati-enlv-20220803monthly0.5https://www.biopharmawatch.com/news/ENLV/sheba-medical-center-and-enlivex-announce-dosing-of-the-first-patient-in-phase-i-ii-trial--enlv-20220706monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-receives-israeli-ministry-of-health-authorization-for-the-initiation-of-a-phase-i--enlv-20220606monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-new-preclinical-data-in-ovarian-cancer-showing-a-substantial-survival-be-enlv-20220531monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-condensed-consolidated-financial-statements-as-of-march-31-2022-a-enlv-20220527monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-awarded-its-third-non-dilutive-israel-innovation-authority-grant-to-support-the-cl-enlv-20220525monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-appoints-dr-roger-j-pomerantz-to-its-board-of-directors-as-vice-chairman-former-wo-enlv-20220523monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-presented-substantial-survival-benefit-of-allocetra-in-combination-with-immune-che-enlv-20220509monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-issuance-of-two-u-s-patents-covering-methods-of-treating-sepsis-with-all-enlv-20220505monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-full-year-2021-financial-results-completion-of-development-of-frozen-for-enlv-20220429monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-issuance-of-israeli-patent-covering-allocetra-derived-from-pooled-donor--enlv-20220308monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-strengthens-management-team-with-the-appointment-of-biotech-industry-veteran-einat-enlv-20220222monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-receives-regulatory-authorization-to-expand-its-phase-iib-trial-evaluating-allocet-enlv-20211213monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-receives-regulatory-authorization-to-expand-its-phase-ii-sepsis-trial-into-greece--enlv-20211207monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-receives-notice-of-allowance-for-u-s-patent-application-covering-the-treatment-of--enlv-20211206monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-third-quarter-2021-financial-results-and-provides-a-business-update-init-enlv-20211122monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-condensed-consolidated-financial-statements-as-of-september-30-20-enlv-20211119monthly0.5https://www.biopharmawatch.com/news/ENLV/spanish-regulator-grants-enlivex-authorization-to-expand-its-phase-iib-trial-evaluating-al-enlv-20211110monthly0.5https://www.biopharmawatch.com/news/ENLV/spanish-regulator-grants-enlivex-authorization-to-expand-its-sepsis-phase-ii-into-spain-ne-enlv-20211104monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-receives-notice-of-allowance-for-israeli-patent-application-covering-allocetra-der-enlv-20211005monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-the-peer-reviewed-publication-in-frontiers-in-immunology-of-clinical-dat-enlv-20211004monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-notice-of-annual-and-extraordinary-general-meeting-of-shareholder-enlv-20210930monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-doses-first-patient-in-placebo-controlled-phase-iib-clinical-trial-evaluating-allo-enlv-20210922monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-after-review-of-phase-ii-data-israeli-ministry-of-health-authorizes-initiation-of--enlv-20210815monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-second-quarter-2021-financial-results-and-provides-a-business-update-top-enlv-20210809monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-condensed-consolidated-financial-statements-as-of-june-30-2021-an-enlv-20210806monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-hires-biotech-industry-veteran-tzvi-palash-to-lead-the-design-and-construction-of--enlv-20210802monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-initiates-design-and-construction-process-for-a-new-cgmp-allocetra-manufacturing-p-enlv-20210712monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-issuance-of-new-european-patent-covering-therapeutic-compositions-of-all-enlv-20210615monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-issuance-of-new-canadian-patent-covering-pharmaceutical-compositions-man-enlv-20210601monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-condensed-consolidated-financial-statements-as-of-march-31-2021-a-enlv-20210528monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-awarded-second-israel-innovation-authority-grant-to-support-the-clinical-developme-enlv-20210518monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-research-collaboration-with-yale-cancer-center-to-assess-synergistic-eff-enlv-20210322monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-receives-notice-of-allowance-for-japanese-patent-application-covering-the-use-of-a-enlv-20210308monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-and-mount-sinai-health-system-announce-research-collaboration-for-the-development--enlv-20210301monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-receives-notice-of-allowance-for-chinese-patent-application-covering-allocetra-imm-enlv-20210222monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-exercise-of-underwriter-s-option-to-purchase-additional-shares-nes-ziona-enlv-20210218monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-issuance-of-new-u-s-patent-covering-methods-of-treating-gout-inflammator-enlv-20210216monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-closing-of-previously-announced-bought-deal-offering-of-approximately-46-enlv-20210212monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-reports-positive-top-line-results-from-phase-ii-clinical-trial-evaluating-allocetr-enlv-20210203monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-pre-print-publication-of-full-results-from-phase-ib-severe-sepsis-trial--enlv-20201221monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-issuance-of-new-chinese-patent-covering-allocetra-immunotherapy-nes-zion-enlv-20201207monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-reports-positive-interim-results-from-phase-ii-clinical-trial-evaluating-allocetra-enlv-20201203monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-reports-positive-two-year-clinical-outcome-for-a-hospitalized-patient-with-erosive-enlv-20201118monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-appoints-former-arqule-inc-executive-dr-brian-schwartz-to-the-company-s-board-of-d-enlv-20201117monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-to-present-schedule-for-sepsis-covid-19-and-solid-cancer-programs-at-h-c-wainwrigh-enlv-20201111monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-receives-notice-of-allowance-for-u-s-patent-application-covering-methods-of-treati-enlv-20201105monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-israeli-ministry-of-health-authorizes-initiation-of-phase-iib-clinical-trial-evalu-enlv-20201103monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-condensed-consolidated-financial-statements-as-of-september-30-20-enlv-20201030monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-to-host-covid-19-webinar-the-staging-of-a-new-disease-and-its-implications-for-tre-enlv-20201027monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-reports-dosing-of-first-two-patients-in-phase-ii-clinical-trial-evaluating-allocet-enlv-20201022monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-after-expedited-review-israeli-ministry-of-health-authorizes-initiation-of-phase-i-enlv-20201013monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-condensed-consolidated-financial-statements-as-of-june-30-2020-an-enlv-20201013monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-reports-positive-allocetra-trial-results-in-covid-19-patients-in-severe-critical-c-enlv-20201001monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-allowance-of-new-chinese-patent-covering-allocetra-immunotherapy-nes-zio-enlv-20200916monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-allowance-of-new-u-s-patent-covering-allocetra-immunotherapy-nes-ziona-i-enlv-20200824monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-condensed-consolidated-financial-statements-as-of-june-30-2020-an-enlv-20200814monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-dosing-of-first-patient-in-clinical-trial-of-allocetra-in-covid-19-patie-enlv-20200809monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-allowance-of-new-japanese-patent-application-covering-allocetra-immunoth-enlv-20200618monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-presents-new-clinical-data-demonstrating-early-resolution-of-cytokine-storms-in-se-enlv-20200528monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-notice-of-annual-and-extraordinary-general-meeting-of-shareholder-enlv-20200519monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-condensed-consolidated-financial-statements-as-of-march-31-2020-a-enlv-20200518monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-initiation-of-multi-center-phase-ii-investigator-initiated-clinical-tria-enlv-20200506monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-selected-by-the-israel-innovation-authority-to-receive-1-5-million-grant-to-fund-c-enlv-20200413monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-announces-positive-final-safety-and-efficacy-data-from-clinical-trial-of-off-the-s-enlv-20200318monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-confirms-public-statements-made-by-the-head-of-israel-economic-and-co-enlv-20200303monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-closes-8-0-million-registered-direct-offering-nes-ziona-israel-enlv-20200226monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-announces-plan-for-increased-production-capacity-of-allocetra-tm-in-p-enlv-20200224monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-condensed-consolidated-financial-statements-as-of-september-30-20-enlv-20191114monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-announces-positive-interim-safety-and-efficacy-data-from-ongoing-tria-enlv-20191104monthly0.5https://www.biopharmawatch.com/news/ENLV/jfif-6-6-424-lddl-z-6-6-424-lddl-z-16-enlv-20190909monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-announces-positive-outcome-from-safety-committee-s-review-of-six-pati-enlv-20190819monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-condensed-consolidated-financial-statements-as-of-june-30-2019-an-enlv-20190726monthly0.5https://www.biopharmawatch.com/news/ENLV/immunotherapy-company-enlivex-announces-dual-listing-on-the-tel-aviv-stock-exchange-the-co-enlv-20190716monthly0.5https://www.biopharmawatch.com/news/ENLV/enlivex-therapeutics-ltd-condensed-consolidated-financial-statements-as-of-march-31-2019-a-enlv-20190520monthly0.5https://www.biopharmawatch.com/news/ENLV/execution-version-enlv-20190311monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-announces-effectiveness-of-eight-to-one-reverse-split-ordinary-shares-will-begin--enlv-20190306monthly0.5https://www.biopharmawatch.com/news/ENLV/asset-purchase-agreement-this-asset-purchase-agreement-this-agreement-is-made-as-of-enlv-20190215monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-ltd-notice-of-extraordinary-general-meeting-of-the-shareholders-general-no-enlv-20190219monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-ltd-notice-of-extraordinary-general-meeting-of-the-shareholders-general-no-enlv-20190131monthly0.5https://www.biopharmawatch.com/news/ENLV/unaudited-financial-information-as-of-and-for-the-six-months-ended-enlv-20181231monthly0.5https://www.biopharmawatch.com/news/ENLV/to-such-report-and-copies-of-which-are-attached-as-annexes-a-and-b-respectively-to-the-pro-enlv-20181206monthly0.5https://www.biopharmawatch.com/news/ENLV/to-the-6-k-report-2-the-transaction-will-not-be-completed-if-item-no-1-is-not-approved-2-t-enlv-20181121monthly0.5https://www.biopharmawatch.com/news/ENLV/execution-version-agreement-and-plan-of-merger-by-and-among-bioblast-pharma-ltd-treblast-l-enlv-20181119monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-ltd-corporate-and-management-update-tel-aviv-israel-and-new-york-new-york-enlv-20180726monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-ltd-notice-of-annual-and-extraordinary-general-meeting-of-the-shareholders-enlv-20171116monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-reports-third-quarter-2017-financial-results-tel-aviv-israel-enlv-20171102monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-announces-effectiveness-of-five-to-one-reverse-split-ordinary-shares-will-begin-t-enlv-20170925monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-ltd-notice-of-extraordinary-general-meeting-of-the-shareholders-notice-is--enlv-20170814monthly0.5https://www.biopharmawatch.com/news/ENLV/investor-contact-jsb-partners-contact-matthew-p-duffy-wolfgang-stoiber-managing-director-m-enlv-20170804monthly0.5https://www.biopharmawatch.com/news/ENLV/investor-contact-jsb-partners-contact-matthew-p-duffy-wolfgang-stoiber-managing-director-m-enlv-20170605monthly0.5https://www.biopharmawatch.com/news/ENLV/investor-contact-matthew-p-duffy-managing-director-lifesci-advisors-llc-telephone-212-915--enlv-20170526monthly0.5https://www.biopharmawatch.com/news/ENLV/investor-contact-matthew-p-duffy-managing-director-lifesci-advisors-llc-matthew-lifesciadv-enlv-20170417monthly0.5https://www.biopharmawatch.com/news/ENLV/matthew-lifesciadvisors-com-enlv-20170310monthly0.5https://www.biopharmawatch.com/news/ENLV/investor-contact-matthew-p-duffy-managing-director-lifesci-advisors-llc-matthew-lifesciadv-enlv-20170224monthly0.5https://www.biopharmawatch.com/news/ENLV/investor-contact-matthew-p-duffy-managing-director-lifesci-advisors-llc-phone-212-915-0685-enlv-20170118monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-reports-third-quarter-2016-financial-results-tel-aviv-israel-enlv-20161129monthly0.5https://www.biopharmawatch.com/news/ENLV/investor-contact-matthew-p-duffy-managing-director-lifesci-advisors-llc-telephone-212-915--enlv-20161024monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-reports-results-of-a-clinical-trial-of-trehalose-in-oculopharyngeal-muscul-enlv-20160912monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-reports-second-quarter-2016-financial-results-tel-aviv-israel-enlv-20160825monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-ltd-notice-of-annual-general-meeting-of-the-shareholders-notice-is-hereby--enlv-20160705monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-updates-corporate-plans-trehalose-phase-2b-trial-in-oculopharyngeal-muscul-enlv-20160609monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-reports-first-quarter-2016-financial-results-new-haven-connecticut-enlv-20160525monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-announces-pricing-of-6-7-million-registered-direct-offering-new-haven-ct-enlv-20160317monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-ltd-consolidated-interim-financial-statements-as-of-june-30-2015-u-s-dolla-enlv-20160317monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-announces-positive-final-results-from-hopemd-phase-2-open-label-clinical-s-enlv-20160316monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-reports-fourth-quarter-and-full-year-2015-financial-results-new-haven-conn-enlv-20160223monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-ltd-notice-of-extraordinary-general-meeting-of-shareholders-notice-is-here-enlv-20160119monthly0.5https://www.biopharmawatch.com/news/ENLV/jfif-6exif-mm-b-j-1-r-2-i-adobe-photoshop-cs3-windows-2016-01-10-21-03-50-enlv-20160111monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-enhances-leadership-team-appoints-industry-veteran-robert-w-cook-as-chief--enlv-20160111monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-ltd-notice-of-extraordinary-general-meeting-of-shareholders-notice-is-here-enlv-20151222monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-enlv-20151209monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-reports-third-quarter-financial-results-tel-aviv-israel-enlv-20151117monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-strengthens-leadership-team-and-announces-key-organizational-changes-signi-enlv-20151116monthly0.5https://www.biopharmawatch.com/news/ENLV/announces-positive-interim-results-from-hopemd-phase-2-clinical-study-of-cabaletta-in-ocul-enlv-20151027monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-augments-leadership-team-appoints-former-aptalis-and-novartis-executive-th-enlv-20151009monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-announces-appointment-of-tom-dubin-former-alexion-svp-chief-legal-officer--enlv-20150916monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-granted-patent-from-uspto-for-cabaletta-for-the-treatment-of-spinocerebellar-atax-enlv-20150914monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-augments-leadership-team-and-establishes-u-s-headquarters-in-new-haven-con-enlv-20150910monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-reports-second-quarter-financial-results-tel-aviv-israel-enlv-20150821monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-receives-orphan-drug-designation-from-the-european-commission-for-cabalett-enlv-20150629monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-receives-orphan-drug-designation-from-the-european-commission-for-cabalett-enlv-20150625monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-announces-positive-preclinical-proof-of-concept-results-of-its-novel-read-through-enlv-20150622monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-announces-the-start-of-a-phase-3-study-for-cabaletta-in-oculopharyngeal-muscular--enlv-20150615monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-reports-first-quarter-financial-results-tel-aviv-israel-enlv-20150519monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-announces-granting-of-fast-track-designation-by-the-fda-for-cabaletta-in-o-enlv-20150409monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-ltd-notice-of-annual-general-meeting-of-the-shareholders-notice-is-hereby--enlv-20150331monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-announces-positive-in-vivo-preclinical-proof-of-concept-results-of-its-cab-enlv-20150330monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-announces-positive-preclinical-proof-of-concept-results-of-its-novel-mitoc-enlv-20150326monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-receives-ind-clearance-to-commence-clinical-trial-for-cabaletta-for-the-treatment-enlv-20150312monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-reports-fourth-quarter-financial-results-tel-aviv-israel-february-17-201-5-enlv-20150217monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-ltd-notice-of-extraordinary-general-meeting-of-shareholders-notice-is-here-enlv-20150210monthly0.5https://www.biopharmawatch.com/news/ENLV/bio-blast-announces-key-leadership-changes-enlv-20150202monthly0.5https://www.biopharmawatch.com/news/ENLV/bio-blast-provides-update-on-clinical-trial-of-cabaletta-for-occulopharyngeal-muscular-dys-enlv-20150108monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-receives-notice-of-patent-issuance-from-uspto-for-its-novel-fusion-protein-based--enlv-20141217monthly0.5https://www.biopharmawatch.com/news/ENLV/bio-blast-pharma-reports-third-quarter-financial-results-tel-aviv-israel-enlv-20141121monthly0.5https://www.biopharmawatch.com/news/ENLV/bio-blast-pharma-receives-orphan-drug-designation-from-u-s-fda-for-cabaletta-for-the-treat-enlv-20141119monthly0.5https://www.biopharmawatch.com/news/ENLV/bio-blast-pharma-ltd-notice-of-extraordinary-general-meeting-of-shareholders-notice-is-her-enlv-20140923monthly0.5https://www.biopharmawatch.com/news/ENLV/bio-blast-pharma-announces-initiation-of-its-canadian-opmd-clinical-study-center-at-mcgill-enlv-20140922monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-announces-preclinical-and-clinical-pharmacokinetic-results-with-cabaletta--enlv-20140917monthly0.5https://www.biopharmawatch.com/news/ENLV/bioblast-pharma-reports-second-quarter-financial-results-tel-aviv-israel-enlv-20140829monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-fully-enrolls-its-phase-2-placebo-controlled-multiple-sclerosis-trial-boston-ma-tlsa-20260521monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-reports-reduced-brain-inflammation-in-multiple-system-atrophy-patients-treated-wit-tlsa-20260514monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-late-breaking-poster-accepted-for-presentation-at-the-7-th-tlsa-20260414monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-closing-of-oversubscribed-8-8-million-registered-direct-of-tlsa-20260116monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-to-dose-first-patient-in-phase-2-alzheimer-s-trial-first-patient-exp-tlsa-20251212monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-ltd-tiziana-or-the-company-update-and-interim-results-for-the-six-mo-tlsa-20251003monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-purchase-of-shares-by-chairman-boston-ma-tlsa-20250905monthly0.5https://www.biopharmawatch.com/news/TLSA/fda-approves-tiziana-life-sciences-phase-2-ind-for-multiple-system-atrophy-tlsa-20250811monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-immunologic-analysis-of-nasal-foralumab-in-moderate-alzhei-tlsa-20250721monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-expands-phase-2-clinical-trial-of-intranasal-foralumab-with-commence-tlsa-20250613monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-to-present-at-the-bio-international-convention-tlsa-20250613monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-interview-highlighting-intranasal-foralumab-for-the-treatm-tlsa-20250523monthly0.5https://www.biopharmawatch.com/news/TLSA/journal-of-clinical-nuclear-medicine-publishes-results-of-tiziana-s-nasal-foralumab-in-stu-tlsa-20250515monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-purchase-of-shares-by-chairman-new-york-tlsa-20250512monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-significant-reduction-in-microglia-activation-in-pet-scan--tlsa-20250509monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-comprehensive-positive-results-from-study-of-nasal-foralum-tlsa-20250506monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-university-of-massachusetts-commences-dosing-intranasal-fo-tlsa-20250423monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-johns-hopkins-university-commences-dosing-nasal-foralumab--tlsa-20250402monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-yale-university-commences-intranasal-foralumab-dosing-in-p-tlsa-20250325monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-to-present-at-the-37-th-annual-roth-conference-tlsa-20250317monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-regains-compliance-with-nasdaq-listing-minimum-bid-price-rule-tlsa-20250314monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-files-investigational-new-drug-application-with-fda-for-als-phase-2--tlsa-20250304monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-groundbreaking-study-published-in-nature-neuroscience-demo-tlsa-20250227monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-long-covid-study-to-complete-in-second-quarter-tlsa-20250225monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-agreement-for-product-development-services-with-renaissanc-tlsa-20250221monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-dosing-of-additional-patients-in-multiple-sclerosis-expand-tlsa-20250218monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-tv-interview-with-first-patient-dosed-with-moderate-alzhei-tlsa-20250211monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-positive-results-in-treating-spinal-cord-injury-with-nasal-tlsa-20250123monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-discovery-of-new-immune-biomarkers-in-multiple-sclerosis-p-tlsa-20250122monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-announces-reduction-of-side-effects-commonly-seen-with-discontinuation-of-glp-1-ag-tlsa-20250110monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-review-article-published-in-nature-highlighting-foralumab--tlsa-20250108monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-first-patient-with-moderate-alzheimer-s-disease-dosed-with-tlsa-20241217monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-expands-phase-2-clinical-trial-for-non-active-secondary-progressive--tlsa-20241204monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-groundbreaking-als-trial-grant-awarded-by-the-als-associat-tlsa-20241119monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-to-participate-in-bio-europe-2024-to-discuss-recent-clinical-advance-tlsa-20241101monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-registered-direct-offering-of-up-to-approximately-10-milli-tlsa-20241030monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-positive-results-from-ozempic-and-nasal-anti-cd3-combinati-tlsa-20241030monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-ltd-tiziana-or-the-company-update-and-interim-results-for-the-six-mo-tlsa-20241018monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-4-million-grant-awarded-by-national-institutes-of-health-t-tlsa-20240919monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-appoints-new-chief-executive-officer-tlsa-20240819monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-regains-compliance-with-nasdaq-listing-minimum-bid-price-rule-tlsa-20240814monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-granted-fda-fast-track-designation-tlsa-20240724monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-receives-3-4-million-in-non-dilutive-funding-tlsa-20240628monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-to-dose-first-patient-with-moderate-alzheimer-s-disease-with-foralum-tlsa-20240626monthly0.5https://www.biopharmawatch.com/news/TLSA/fda-accepts-tiziana-life-sciences-fast-track-designation-submission-for-treatment-of-multi-tlsa-20240611monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-six-month-qualitative-improvement-in-neuroimaging-in-80-of-tlsa-20240606monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-submits-grant-application-to-als-association-to-fund-clinical-trial--tlsa-20240604monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-scientific-board-chairman-to-receive-prestigious-award-for-multiple--tlsa-20240530monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-files-for-orphan-drug-designation-for-intranasal-foralumab-tlsa-20240513monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-reports-positive-3-month-neuroimaging-scores-in-multiple-sclerosis-p-tlsa-20240425monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-fda-allowance-for-additional-twenty-patients-to-be-enrolle-tlsa-20240423monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-additional-clinical-improvements-among-multiple-sclerosis--tlsa-20240422monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-study-results-from-intranasal-anti-cd3-foralumab-in-multip-tlsa-20240419monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-new-quantitative-pet-imaging-data-on-foralumab-at-the-annu-tlsa-20240418monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-platform-presentation-of-new-quantitative-pet-imaging-data-tlsa-20240411monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-podium-presentation-at-ad-pd-of-nasal-anti-cd3-in-alzheime-tlsa-20240305monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-updated-clinical-and-pet-scan-findings-for-intranasal-fora-tlsa-20240108monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-to-present-at-biotech-showcase-conference-in-san-francisco-january-8-tlsa-20240105monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-files-new-patent-application-for-combination-therapy-of-anti-cd3-for-tlsa-20240105monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-ltd-tiziana-or-the-company-updated-interim-results-for-the-six-month-tlsa-20231229monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-doses-first-patient-in-phase-2a-trial-of-intranasal-foralumab-in-mul-tlsa-20231219monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-to-present-at-the-webull-live-with-corporate-connect-biotech-investm-tlsa-20231204monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-ltd-notice-of-annual-general-meeting-of-shareholders-on-thursday-14t-tlsa-20231201monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-foralumab-dosing-of-four-new-patients-in-the-expanded-acce-tlsa-20231130monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-to-present-recent-clinical-updates-at-bio-europe-in-munich-germany-n-tlsa-20231101monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-allowance-by-fda-for-at-home-dosing-of-intranasal-foraluma-tlsa-20231018monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-positive-six-month-clinical-results-in-multiple-sclerosis--tlsa-20231011monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-announces-positive-qualitative-six-month-pet-scan-results-with-intranasal-foraluma-tlsa-20231013monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-announces-presentation-of-six-month-safety-and-biomarker-data-for-intranasal-foral-tlsa-20231011monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-initiates-multi-center-phase-2a-clinical-trial-of-intranasal-foralum-tlsa-20230926monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-to-participate-in-the-h-c-wainwright-25-th-annual-global-investment--tlsa-20230908monthly0.5https://www.biopharmawatch.com/news/TLSA/study-validating-moa-of-intranasal-foralumab-in-alzheimer-s-disease-published-in-the-prest-tlsa-20230906monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-appointment-of-william-a-clementi-as-chief-development-off-tlsa-20230823monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-foralumab-presentation-by-dr-howard-weiner-at-the-annual-m-tlsa-20230824monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-live-bloomberg-tv-interview-of-renowned-scientist-dr-howar-tlsa-20230817monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-fda-ind-clearance-of-intranasal-foralumab-for-the-treatmen-tlsa-20230815monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-ltd-receives-nasdaq-deficiency-notice-new-york-tlsa-20230721monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-promotes-matthew-w-davis-md-rph-to-chief-operating-officer-tlsa-20230613monthly0.5https://www.biopharmawatch.com/news/TLSA/t-iziana-life-sciences-announces-reduction-in-microglial-activation-in-a-total-of-5-out-of-tlsa-20230605monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-to-host-kol-webinar-on-foralumab-in-non-active-secondary-progressive-tlsa-20230525monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-participation-on-the-webull-corporate-communications-servi-tlsa-20230523monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-chief-medical-officer-invited-to-give-presentation-on-intr-tlsa-20230517monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-findings-from-intranasal-anti-cd3-mab-treatment-in-intrace-tlsa-20230427monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-ltd-reports-annual-results-for-the-twelve-months-ended-tlsa-20230426monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-ltd-regains-compliance-with-nasdaq-listing-minimum-bid-price-rule-tlsa-20230424monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-to-file-alzheimer-s-ind-for-intranasal-foralumab-in-q2-2023-applicat-tlsa-20230420monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-initiates-program-to-develop-intranasal-foralumab-in-type-1-diabetes-tlsa-20230418monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-to-pursue-development-of-intranasal-foralumab-for-the-treatment-of-l-tlsa-20230413monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-presentations-on-intranasal-foralumab-at-the-preserving-th-tlsa-20230410monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-invitation-for-podium-presentation-of-research-on-intranas-tlsa-20230404monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-announces-positive-data-on-intranasal-anti-cd3-monoclonal-antibody-in-intracerebra-tlsa-20230404monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-anti-cd3-mab-research-for-the-treatment-of-alzheimer-s-dis-tlsa-20230331monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-to-proceed-with-phase-2-clinical-trial-in-patients-with-non-active-s-tlsa-20230328monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-purchase-of-tlsa-20230322monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-purchase-of-common-shares-by-chairman-and-acting-ceo-new-y-tlsa-20230321monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-highlighted-in-forbes-article-article-entitled-new-t-cell-antibody-t-tlsa-20230317monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-purchase-of-common-shares-by-chairman-and-acting-tlsa-20230317monthly0.5https://www.biopharmawatch.com/news/TLSA/grant-of-share-options-tlsa-20230315monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-publication-in-proceedings-of-the-national-academy-of-scie-tlsa-20230308monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-ind-filed-for-phase-2-study-of-milciclib-in-combination-wi-tlsa-20230104monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-additional-clinical-improvements-in-the-second-patient-wit-tlsa-20230103monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-ltd-tiziana-or-the-company-updated-interim-results-for-the-six-month-tlsa-20221230monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-ltd-tiziana-or-the-company-result-of-annual-general-meeting-london-2-tlsa-20221229monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-ltd-tiziana-or-the-company-interim-results-for-the-six-months-ended--tlsa-20221228monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-to-participate-in-january-investor-meetings-new-york-tlsa-20221216monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-completion-of-prerequisite-pre-clinical-safety-study-tlsa-20221215monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-ltd-granted-180-day-extension-by-nasdaq-to-meet-minimum-bid-price-re-tlsa-20221214monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-ltd-notice-of-annual-general-meeting-of-shareholders-to-be-held-via--tlsa-20221206monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-announces-publication-of-a-peer-reviewed-article-on-the-intranasal-administration--tlsa-20221123monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-near-term-strategic-focus-on-intranasal-foralumab-for-dise-tlsa-20221110monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-to-host-investor-call-tlsa-20221104monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-purchase-of-common-shares-by-executive-chairman-new-york-tlsa-20221103monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-completes-enrollment-of-the-first-patient-cohort-for-its-intermediat-tlsa-20221102monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-starts-enrollment-of-the-first-patient-cohort-in-its-intermediate-si-tlsa-20221026monthly0.5https://www.biopharmawatch.com/news/TLSA/enabling-breakthrough-immunomodulation-approaches-to-enhance-the-functionality-of-treg-bas-tlsa-20221025monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-ltd-invites-you-to-join-us-at-the-thinkequity-conference-new-york-tlsa-20221019monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plans-to-submit-ind-for-phase-1-trial-of-intranasal-foralumab-in-alz-tlsa-20221012monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-new-yor-tlsa-20220929monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-presentations-on-intranasal-foralumab-at-the-preserving-th-tlsa-20220928monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-new-yor-tlsa-20220923monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-purchase-of-common-shares-by-executive-chairman-new-york-tlsa-20220921monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-continued-clinical-improvements-in-the-second-patient-with-tlsa-20220920monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-purchase-of-common-shares-by-executive-chairman-new-york-tlsa-20220916monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-grant-received-by-the-brigham-and-women-s-hospital-to-expl-tlsa-20220915monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-new-yor-tlsa-20220909monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-purchase-of-common-shares-by-executive-chairman-new-york-tlsa-20220825monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-purchase-of-common-shares-by-executive-chairman-new-york-tlsa-20220817monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-presentation-at-alzheimer-s-association-international-conf-tlsa-20220801monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-appoints-matthew-w-davis-md-rph-as-chief-medical-officer-and-acting--tlsa-20220718monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-resignation-of-ceo-new-york-tlsa-20220715monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-to-participate-in-a-fireside-chat-at-the-b-riley-securities-2022-vir-tlsa-20220427monthly0.5https://www.biopharmawatch.com/news/TLSA/fda-grants-permission-to-enroll-up-to-8-additional-secondary-progressive-multiple-sclerosi-tlsa-20220405monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-announces-initiation-of-phase-1b-clinical-trial-in-crohn-s-disease-patients-to-eva-tlsa-20220325monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-announces-availability-of-march-14-kol-event-replay-new-york-tlsa-20220315monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-hosting-key-opinion-leader-virtual-event-to-discuss-the-intranasal-d-tlsa-20220311monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-announces-positive-clinical-data-from-a-secondary-progressive-multiple-sclerosis-p-tlsa-20220310monthly0.5https://www.biopharmawatch.com/news/TLSA/stemprinter-demonstrates-prognostic-utility-in-transatac-cohort-new-york-tlsa-20220301monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-interim-results-for-the-six-months-ended--tlsa-20220222monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-ceo-to-present-at-annual-bio-ceo-investor-conference-tlsa-20220210monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-announces-submission-of-amendment-to-investigational-new-drug-application-to-advan-tlsa-20220204monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-to-participate-in-a-fireside-chat-at-the-b-riley-securities-2022-onc-tlsa-20220126monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-ltd-to-implement-stock-repurchase-program-for-up-to-5-million-new-yo-tlsa-20220124monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-death-of-director-new-york-tlsa-20220113monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-enrolls-second-patient-in-ongoing-intranasal-foralumab-evaluation-for-secondary-pr-tlsa-20220110monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-to-participate-in-2022-biotech-showcase-virtual-investor-conference-tlsa-20220106monthly0.5https://www.biopharmawatch.com/news/TLSA/this-announcement-contains-inside-information-for-the-purposes-of-article-7-of-regulation--tlsa-20211021monthly0.5https://www.biopharmawatch.com/news/TLSA/pdmr-dealing-london-new-york-20-october-2021-tiziana-life-sciences-plc-nasdaq-tlsa-lse-til-tlsa-20211020monthly0.5https://www.biopharmawatch.com/news/TLSA/this-announcement-contains-inside-information-for-the-purposes-of-article-7-of-regulation--tlsa-20211019monthly0.5https://www.biopharmawatch.com/news/TLSA/pdmr-dealing-london-new-york-6-october-2021-tiziana-life-sciences-plc-nasdaq-tlsa-lse-tils-tlsa-20211006monthly0.5https://www.biopharmawatch.com/news/TLSA/pdmr-dealing-london-new-york-5-october-2021-tiziana-life-sciences-plc-nasdaq-tlsa-lse-tils-tlsa-20211005monthly0.5https://www.biopharmawatch.com/news/TLSA/pdmr-dealing-london-new-york-4-october-2021-tiziana-life-sciences-plc-nasdaq-tlsa-aim-tils-tlsa-20211004monthly0.5https://www.biopharmawatch.com/news/TLSA/pdmr-dealing-london-new-york-28-september-2021-tiziana-life-sciences-plc-nasdaq-tlsa-aim-t-tlsa-20210928monthly0.5https://www.biopharmawatch.com/news/TLSA/september-2021-results-of-court-meeting-and-general-meeting-on-20-august-2021-tiziana-life-tlsa-20210927monthly0.5https://www.biopharmawatch.com/news/TLSA/notes-to-the-interim-financial-statements-for-the-six-month-period-to-30-june-2021-tiziana-tlsa-20210924monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-change-of-registered-office-london-new-york-7-september-2021-tiz-tlsa-20210907monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-to-host-investor-call-to-discuss-exclusive-license-agreement-to-evaluate-foralumab-tlsa-20210907monthly0.5https://www.biopharmawatch.com/news/TLSA/this-announcement-contains-inside-information-for-the-purposes-of-article-7-of-regulation--tlsa-20210903monthly0.5https://www.biopharmawatch.com/news/TLSA/precision-biosciences-and-tiziana-life-sciences-announce-exclusive-license-agreement-to-ev-tlsa-20210902monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-files-scheme-of-arrangement-to-effect-a-corporate-reorganisation-tlsa-20210820monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-announces-publication-of-a-peer-reviewed-article-on-data-from-the-clinical-trial-w-tlsa-20210817monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-invites-you-to-join-us-at-the-q3-virtual-investor-summit-new-yor-tlsa-20210816monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-ads-ex-dividend-date-scheduled-for-july-09-2021-this-announcemen-tlsa-20210709monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-distribution-dates-for-shares-and-adrs-in-accustem-sciences-limi-tlsa-20210702monthly0.5https://www.biopharmawatch.com/news/TLSA/dr-howard-weiner-chairman-of-the-tiziana-scientific-advisory-board-to-give-an-interview-on-tlsa-20210630monthly0.5https://www.biopharmawatch.com/news/TLSA/the-information-contained-in-this-announcement-is-inside-information-for-the-purposes-of-a-tlsa-20210625monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-enters-a-collaboration-agreement-with-fhi-clinical-to-conduct-a-phase-2-clinical-t-tlsa-20210623monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-appoints-dr-kevin-schutz-as-vice-president-of-regulatory-affairs-new-york-london-tlsa-20210621monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-responds-to-uk-call-for-development-of-innovative-take-home-treatments-for-covid-1-tlsa-20210617monthly0.5https://www.biopharmawatch.com/news/TLSA/not-for-release-publication-or-distribution-in-whole-or-in-part-directly-or-indirectly-in--tlsa-20210602monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-reports-data-indicating-significant-immunomodulation-effects-on-immune-and-inflamm-tlsa-20210526monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-initiation-of-clinical-trial-in-a-secondary-progressive-mu-tlsa-20210524monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-science-plc-pdmr-dealing-london-new-york-21-may-2021-tiziana-life-sciences-pl-tlsa-20210521monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-interview-to-air-on-bloomberg-television-u-s-on-the-redchip-money-re-tlsa-20210507monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-announces-strategic-initiative-with-takanawa-japan-k-k-pharma-team-to-identify-a-p-tlsa-20210505monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-to-participate-in-a-fireside-chat-on-28-april-2021-at-10-30-a-m-edt--tlsa-20210427monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-tiziana-life-sciences-plc-announces-plans-tlsa-20210413monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-announces-the-fda-has-allowed-treatment-for-a-secondary-progressive-multiple-scler-tlsa-20210330monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-plans-phase-2-clinical-study-in-moderate-to-severe-covid-19-patients-with-nasal-ad-tlsa-20210330monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-updated-gabriele-cerrone-chairman-of-tizi-tlsa-20210329monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-gabriele-cerrone-chairman-of-tiziana-life-tlsa-20210329monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-tiziana-life-sciences-interview-to-air-on-tlsa-20210227monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-tiziana-life-sciences-to-present-at-the-b-tlsa-20210216monthly0.5https://www.biopharmawatch.com/news/TLSA/pdmr-dealing-5-february-2021-new-york-and-london-tlsa-20210205monthly0.5https://www.biopharmawatch.com/news/TLSA/appointment-of-director-5-february-2021-new-york-and-london-tlsa-20210205monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-ceo-discusses-covid-19-trial-data-in-exclusive-interview-new-york-an-tlsa-20210203monthly0.5https://www.biopharmawatch.com/news/TLSA/this-announcement-includes-inside-information-tiziana-reports-positive-data-from-the-clini-tlsa-20210202monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-tiziana-files-registration-statement-on-f-tlsa-20210127monthly0.5https://www.biopharmawatch.com/news/TLSA/updated-corporate-presentation-26-january-2021-new-york-london-26-january-2021-tiziana-lif-tlsa-20210126monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-tiziana-life-sciences-to-participate-in-a-tlsa-20210120monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-aim-delisting-and-admission-to-the-standa-tlsa-20210120monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-tiziana-announces-appointment-of-dr-neil--tlsa-20210113monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-tiziana-life-sciences-to-participate-at-j-tlsa-20210111monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-tiziana-announces-completion-of-the-clini-tlsa-20210104monthly0.5https://www.biopharmawatch.com/news/TLSA/this-announcement-is-an-advertisement-and-not-a-prospectus-neither-this-announcement-nor-a-tlsa-20201218monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-notification-of-proposed-admission-to-the-tlsa-20201217monthly0.5https://www.biopharmawatch.com/news/TLSA/pdmr-dealing-london-new-york-10-december-2020-tiziana-life-sciences-plc-nasdaq-tlsa-aim-ti-tlsa-20201210monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-to-host-investor-update-call-on-2-december-2020-at-4-15-p-m-et-new-y-tlsa-20201201monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-pdmr-dealing-london-new-york-18-november--tlsa-20201118monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-phase-1b-2-clinical-trial-crohn-s-disease-tlsa-20201112monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-tiziana-announces-initiation-of-clinical--tlsa-20201102monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-exercise-of-options-issue-of-equity-pdmr--tlsa-20201029monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-demerger-update-and-timetable-confirmatio-tlsa-20201029monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-issue-of-equity-on-exercise-of-warrants-l-tlsa-20201028monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-timetable-of-demerger-of-accustem-for-holders-of-tiziana-a-tlsa-20201027monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-exercise-of-options-issue-of-equity-pdmr--tlsa-20201026monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-issue-of-equity-on-exercise-of-warrants-l-tlsa-20201022monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-exercise-of-options-issue-of-equity-pdmr--tlsa-20201021monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-issue-of-equity-on-exercise-of-warrants-l-tlsa-20201020monthly0.5https://www.biopharmawatch.com/news/TLSA/the-information-contained-in-this-announcement-is-inside-information-for-the-purposes-of-a-tlsa-20201002monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-interim-results-for-the-six-months-ended--tlsa-20200930monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-tiziana-life-sciences-interview-to-air-on-tlsa-20200925monthly0.5https://www.biopharmawatch.com/news/TLSA/publication-of-research-note-london-new-york-21-september-2020-tiziana-life-sciences-plc-n-tlsa-20200921monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-issue-of-equity-and-total-voting-rights-l-tlsa-20200921monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-tiziana-to-conduct-a-clinical-study-with--tlsa-20200917monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-announces-planned-spin-out-of-stemprinter-into-a-new-publicly-listed-tlsa-20200916monthly0.5https://www.biopharmawatch.com/news/TLSA/tr-1-standard-form-for-notification-of-major-holdings-notification-of-major-holdings-to-be-tlsa-20200828monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-tiziana-life-sciences-clarifies-reason-fo-tlsa-20200828monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-exercise-of-warrants-and-issue-of-equity--tlsa-20200827monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-grant-of-options-director-dealings-london-tlsa-20200826monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-granted-a-patent-on-methods-and-use-of-anti-il-6-il-6-receptor-monoclonal-antibodi-tlsa-20200824monthly0.5https://www.biopharmawatch.com/news/TLSA/this-announcement-contains-inside-information-for-the-purposes-of-article-7-of-eu-regulati-tlsa-20200821monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-tiziana-granted-a-patent-on-methods-and-u-tlsa-20200818monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-to-present-at-btig-s-virtual-biotechnology-conference-new-york-and-l-tlsa-20200811monthly0.5https://www.biopharmawatch.com/news/TLSA/tr-1-standard-form-for-notification-of-major-holdings-notification-of-major-holdings-to-be-tlsa-20200810monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-life-sciences-plc-announces-closing-of-57-25-million-off-tlsa-20200805monthly0.5https://www.biopharmawatch.com/news/TLSA/this-announcement-contains-inside-information-for-the-purposes-of-article-7-of-regulation--tlsa-20200803monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-tiziana-life-sciences-announces-an-expedi-tlsa-20200804monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-total-voting-rights-london-new-york-31-ju-tlsa-20200731monthly0.5https://www.biopharmawatch.com/news/TLSA/this-announcement-contains-inside-information-for-the-purposes-of-article-7-of-regulation--tlsa-20200731monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-early-notification-of-proposed-admission--tlsa-20200730monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-update-on-timings-and-corporate-actions-n-tlsa-20200730monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-exercise-of-warrants-and-issue-of-equity--tlsa-20200724monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-director-appointment-new-york-london-20-j-tlsa-20200720monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-results-of-annual-general-meeting-london--tlsa-20200716monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-tiziana-announces-submission-of-patent-ap-tlsa-20200716monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-tiziana-life-sciences-interview-to-air-on-tlsa-20200710monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-total-voting-rights-and-stemprinter-demer-tlsa-20200701monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-agreement-with-stc-biologics-tiziana-life-tlsa-20200629monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-annual-general-meeting-london-new-york-23-tlsa-20200623monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-exercise-of-warrants-and-issue-of-equity--tlsa-20200622monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-tiziana-granted-first-ever-patent-on-a-tr-tlsa-20200619monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-directorate-change-london-new-york-18-jun-tlsa-20200618monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-final-results-for-the-year-ended-31-decem-tlsa-20200618monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-tiziana-life-sciences-announces-that-its--tlsa-20200604monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-correction-exercise-of-warrants-and-issue-tlsa-20200602monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-exercise-of-warrants-and-issue-of-equity--tlsa-20200602monthly0.5https://www.biopharmawatch.com/news/TLSA/june-2020-tiziana-life-science-plc-appointment-of-broker-tiziana-life-sciences-plc-aim-til-tlsa-20200601monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-tiziana-life-sciences-announces-intention-tlsa-20200522monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-tiziana-life-sciences-announces-online-pu-tlsa-20200514monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-tiziana-life-sciences-to-present-two-stud-tlsa-20200511monthly0.5https://www.biopharmawatch.com/news/TLSA/the-information-contained-in-this-announcement-is-inside-information-for-the-purposes-of-a-tlsa-20200506monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-tiziana-life-sciences-files-patent-on-com-tlsa-20200427monthly0.5https://www.biopharmawatch.com/news/TLSA/april-2020-tiziana-life-sciences-plc-tiziana-or-the-company-tiziana-life-sciences-acquires-tlsa-20200424monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-issue-of-equity-and-resulting-total-votin-tlsa-20200424monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-issue-of-equity-and-resulting-total-votin-tlsa-20200415monthly0.5https://www.biopharmawatch.com/news/TLSA/this-announcement-contains-inside-information-for-the-purposes-of-article-7-of-regulation--tlsa-20200409monthly0.5https://www.biopharmawatch.com/news/TLSA/this-announcement-contains-inside-information-for-the-purposes-of-article-7-of-regulation--tlsa-20200316monthly0.5https://www.biopharmawatch.com/news/TLSA/this-announcement-contains-inside-information-for-the-purposes-of-article-7-of-regulation--tlsa-20200311monthly0.5https://www.biopharmawatch.com/news/TLSA/the-information-contained-in-this-announcement-is-inside-information-for-the-purposes-of-a-tlsa-20200311monthly0.5https://www.biopharmawatch.com/news/TLSA/the-information-contained-in-this-announcement-is-inside-information-for-the-purposes-of-a-tlsa-20200220monthly0.5https://www.biopharmawatch.com/news/TLSA/this-announcement-contains-inside-information-for-the-purposes-of-article-7-of-regulation--tlsa-20200217monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-science-plc-pdmr-dealing-new-york-london-4-february-2020-tiziana-life-science-tlsa-20200204monthly0.5https://www.biopharmawatch.com/news/TLSA/the-information-contained-in-this-announcement-is-inside-information-for-the-purposes-of-a-tlsa-20200203monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-tiziana-life-sciences-announces-f-3-filin-tlsa-20200123monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-tiziana-life-sciences-announces-appointme-tlsa-20200121monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-science-plc-the-company-proposed-cancellation-from-aim-new-york-london-13-jan-tlsa-20200113monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-tiziana-reports-phase-1-clinical-data-dem-tlsa-20200109monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-tiziana-announces-initiation-of-a-phase-1-tlsa-20191204monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-issue-of-equity-and-directorate-change-th-tlsa-20191120monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-issue-of-convertible-unsecured-loan-notes-tlsa-20191101monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-change-to-ads-ratio-london-30-october-2019-tiziana-life-sciences-tlsa-20191030monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-or-the-company-tlsa-20190930monthly0.5https://www.biopharmawatch.com/news/TLSA/the-information-contained-in-this-announcement-is-deemed-by-the-company-to-constitute-insi-tlsa-20190916monthly0.5https://www.biopharmawatch.com/news/TLSA/the-information-contained-in-this-announcement-is-deemed-by-the-company-to-constitute-insi-tlsa-20190910monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-life-sciences-or-the-company-tiziana-life-sciences-repor-tlsa-20190904monthly0.5https://www.biopharmawatch.com/news/TLSA/this-announcement-contains-inside-information-for-the-purposes-of-article-7-of-regulation--tlsa-20190806monthly0.5https://www.biopharmawatch.com/news/TLSA/the-information-contained-in-this-announcement-is-deemed-by-the-company-to-constitute-insi-tlsa-20190722monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-independent-third-party-article-in-new-england-journal-of-medici-tlsa-20190701monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-newly-published-article-reporting-clinical-activity-of-orally-ad-tlsa-20190624monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-incorporated-in-england-and-wales-with-company-number-09665181-p-tlsa-20190603monthly0.5https://www.biopharmawatch.com/news/TLSA/may-2019-tiziana-life-sciences-plc-the-company-results-of-annual-general-meeting-tiziana-l-tlsa-20190531monthly0.5https://www.biopharmawatch.com/news/TLSA/may-2019-tiziana-life-sciences-plc-the-company-notice-of-annual-general-meeting-tiziana-li-tlsa-20190507monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-incorporated-in-england-and-wales-with-company-number-09665181-p-tlsa-20190502monthly0.5https://www.biopharmawatch.com/news/TLSA/the-information-contained-in-this-announcement-is-deemed-by-the-company-to-constitute-insi-tlsa-20190501monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-incorporated-in-england-and-wales-with-company-number-09665181-p-tlsa-20190425monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-tiziana-reports-encouraging-interim-clini-tlsa-20190424monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-financial-results-for-the-year-ended-31-d-tlsa-20190404monthly0.5https://www.biopharmawatch.com/news/TLSA/this-announcement-contains-inside-information-for-the-purposes-of-article-7-of-regulation--tlsa-20190207monthly0.5https://www.biopharmawatch.com/news/TLSA/this-announcement-contains-inside-information-for-the-purposes-of-article-7-of-regulation--tlsa-20181211monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-tiziana-completes-patient-enrollment-in-a-tlsa-20181203monthly0.5https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-plc-tiziana-or-the-company-tiziana-announces-initiation-of-phase-1-c-tlsa-20181128monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-presents-two-posters-at-aacr-2026-with-new-data-highlighting-muzastotug-s-potentia-adag-20260417monthly0.5https://www.biopharmawatch.com/news/ADAG/confidential-adagene-announces-clinical-collaboration-with-incyte-to-evaluate-muzastotug-a-adag-20260402monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-reports-full-year-2025-financial-results-and-provides-corporate-update-in-2025-muz-adag-20260401monthly0.5https://www.biopharmawatch.com/news/ADAG/internal-adagene-announces-up-to-25-million-strategic-investment-from-sanofi-sanofi-to-exe-adag-20250701monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-updated-data-from-phase-1b-2-study-of-muzastotug-adg126-in-combination-w-adag-20250522monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-reports-full-year-2024-financial-results-and-provides-corporate-update-muzastotug--adag-20250324monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-updated-data-from-phase-1b-2-study-of-muzastotug-in-combination-with-key-adag-20250127monthly0.5https://www.biopharmawatch.com/news/ADAG/securities-and-exchange-commission-adag-20241107monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-presents-results-at-esmo-congress-that-show-best-in-class-therapeutic-potential-fo-adag-20240916monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-reports-six-month-financial-results-for-2024-and-provides-corporate-update-potenti-adag-20240725monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-reports-full-year-2023-financial-results-and-provides-corporate-update-data-for-ma-adag-20240329monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-progress-and-expansion-of-clinical-collaboration-program-for-masked-anti-adag-20240209monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-presents-interim-results-reinforcing-best-in-class-profile-of-masked-anti-ctla-4-s-adag-20240116monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-presents-data-demonstrating-the-best-in-class-therapeutic-index-for-masked-anti-ct-adag-20231103monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-reports-six-month-financial-results-for-2023-and-provides-corporate-update-best-in-adag-20230831monthly0.5https://www.biopharmawatch.com/news/ADAG/unleashing-anti-ctla-4-therapy-by-enhancing-the-therapeutic-index-july-2023-disclaimer-and-adag-20230707monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-achieves-3-million-milestone-in-collaboration-with-exelixis-for-successful-nominat-adag-20230504monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-updates-to-its-board-of-directors-san-diego-and-adag-20230428monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-presents-clinical-data-for-anti-ctla-4-safebody-adg126-reinforcing-best-in-class-s-adag-20230418monthly0.5https://www.biopharmawatch.com/news/ADAG/march-adagene-reports-full-year-2022-financial-results-and-provides-corporate-update-clini-adag-20230328monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-interim-data-demonstrating-safety-and-confirmed-clinical-responses-of-an-adag-20230109monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-clinical-trial-collaboration-to-evaluate-anti-ctla-4-safebody-adg126-in--adag-20221216monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-appoints-cuong-do-to-board-of-directors-and-audit-committee-san-diego-and-adag-20221121monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-presents-interim-monotherapy-data-at-esmo-2022-showing-compelling-safety-anti-tumo-adag-20220910monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-reports-financial-results-for-the-six-months-ended-adag-20220831monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-authorization-of-share-repurchase-program-up-to-us-10-million-san-diego--adag-20220629monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-publication-at-asco-of-interim-monotherapy-dose-escalation-data-showing--adag-20220526monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-presents-data-demonstrating-first-and-best-in-class-potential-for-differentiated-p-adag-20220408monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-reports-full-year-2021-financial-results-and-provides-corporate-update-2022-clinic-adag-20220331monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-fda-clearance-to-proceed-with-phase-1b-2-trial-of-anti-ctla-4-adg126-saf-adag-20220316monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-four-poster-presentations-on-robust-preclinical-pipeline-of-antibody-bas-adag-20220308monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-safebody-multi-target-collaboration-with-sanofi-for-novel-masked-immuno--adag-20220302monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-board-and-management-appointments-to-support-pipeline-growth-san-diego-a-adag-20220202monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-first-patient-dosed-with-novel-proprietary-combination-of-anti-cd137-ago-adag-20220127monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-expands-scientific-and-strategic-advisory-board-with-appointment-of-david-gandara--adag-20220119monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-first-patients-with-advanced-non-small-cell-lung-cancer-dosed-in-phase-1-adag-20220113monthly0.5https://www.biopharmawatch.com/news/ADAG/company-overview-january-2022-disclaimer-and-cautionary-note-on-forward-looking-statements-adag-20220112monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-achieves-key-milestone-in-collaboration-with-exelixis-for-safebody-novel-masked-an-adag-20211222monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-presents-preclinical-data-showcasing-best-in-class-profiles-for-adg153-an-anti-cd4-adag-20211213monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-presents-clinical-data-demonstrating-strong-safety-and-early-signals-of-efficacy-i-adag-20211206monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-fda-clearance-of-ind-for-phase-1b-2-trial-of-anti-ctla-4-monoclonal-anti-adag-20211129monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-poster-presentations-of-clinical-data-for-two-novel-antibody-programs-at-adag-20211122monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-unveils-preclinical-data-from-two-transformative-antibody-programs-at-upcoming-ame-adag-20211104monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-establishes-collaboration-for-clinical-trial-of-adg106-in-combination-with-nivolum-adag-20211027monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-reports-financial-results-for-the-six-months-ended-adag-20210826monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137--adag-20210819monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-appointment-of-interim-chief-medical-officer-and-new-members-of-scientif-adag-20210812monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-clinical-trial-collaboration-with-merck-to-advance-two-anti-ctla-4-monoc-adag-20210722monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-authorization-of-share-repurchase-program-up-to-us-20-million-san-franci-adag-20210707monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-presents-clinical-data-from-neobody-tm-program-adg106-anti-cd137-agonist-in-an-abs-adag-20210519monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-presents-preclinical-data-from-lead-safebody-tm-program-adg126-at-the-american-ass-adag-20210413monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-reports-full-year-2020-financial-results-and-provides-corporate-updates-successful-adag-20210331monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-clinical-advancement-for-adg116-neobody-product-candidate-adg116-has-bee-adag-20210329monthly0.5https://www.biopharmawatch.com/news/ADAG/adagene-announces-first-patients-dosed-in-global-phase-1-clinical-trial-of-adg126-lead-saf-adag-20210316monthly0.5https://www.biopharmawatch.com/news/TTRX/jefferies-global-healthcare-conference-june-2026-2-disclaimer-except-for-historical-inform-ttrx-20260603monthly0.5https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-announces-peer-reviewed-publication-in-journal-of-dermatological-treatme-ttrx-20260527monthly0.5https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-to-present-at-jefferies-global-healthcare-conference-2026-westlake-villa-ttrx-20260519monthly0.5https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-appoints-physician-scientist-and-former-fda-commissioner-dr-stephen-m-ha-ttrx-20260518monthly0.5https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-upda-ttrx-20260511monthly0.5https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-announces-corporate-and-pipeline-updates-and-2026-outlook-ahead-of-the-4-ttrx-20260112monthly0.5https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-appoints-martin-dewhurst-to-its-board-of-directors-mr-dewhurst-brings-ov-ttrx-20260107monthly0.5https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-reports-third-quarter-2025-financial-results-and-provides-corporate-upda-ttrx-20251113monthly0.5https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-gx-03-technology-named-as-one-of-five-novel-mechanisms-reshaping-atopic--ttrx-20251111monthly0.5https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-appoints-veteran-capital-markets-executive-andrew-scott-as-vice-presiden-ttrx-20251104monthly0.5https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-enters-global-supply-development-and-license-agreement-with-leading-medi-ttrx-20251030monthly0.5https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-provides-shareholder-update-highlighting-continued-execution-across-clin-ttrx-20251022monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20260512monthly0.5https://www.biopharmawatch.com/news/PRQR/expanding-the-axiomer-rna-editing-opportunity-beyond-ax-0810-nasdaq-prqr-prqr-20260408monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-encouraging-ax-0810-phase-1-safety-and-pk-data-development-candidate-selec-prqr-20260108monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20251106monthly0.5https://www.biopharmawatch.com/news/PRQR/entering-the-clinic-with-ax-0810-prqr-20251103monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20250807monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20250508monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-strengthens-leadership-with-appointments-of-cfo-and-cmo-to-support-next-phase-of-gro-prqr-20250414monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-year-end-2024-operating-and-financial-results-axiomer-adar-mediated-rna-ed-prqr-20250313monthly0.5https://www.biopharmawatch.com/news/PRQR/investor-prqr-20241211monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-announces-8-1-million-in-new-funding-from-rett-syndrome-research-trust--prqr-20241211monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-appoints-peter-a-beal-phd-as-chief-adar-scientist-leiden-netherlands-prqr-20241210monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-to-host-virtual-analyst-and-investor-event-on-prqr-20241205monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20241107monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-proposed-underwritten-public-offering-of-ordinary-shares-leiden-netherland-prqr-20241022monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20240808monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20240509monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-nominates-martin-maier-phd-to-board-and-announces-annual-meeting-of-shareholders-to--prqr-20240423monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-achieves-successful-defense-of-new-challenge-to-its-axiomer-ip-portfolio-leiden-neth-prqr-20240419monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-year-end-2023-operating-and-financial-results-preclinical-and-translationa-prqr-20240313monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-japanese-axiomer-patent-upheld-following-opposition-against-its-leading-ip-prqr-20240215monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-highlights-new-platform-data-from-presentation-on-axiomer-rna-editing-technology-at--prqr-20240119monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-and-rett-syndrome-research-trust-join-forces-with-axiomer-rna-editing-collaboration--prqr-20240105monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-announces-transaction-completed-for-th-a-to-acquire-sepofarsen-and-ulte-prqr-20231208monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20231107monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-provides-update-on-ophthalmic-assets-leiden-netherlands-prqr-20230927monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20230803monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-and-laboratoires-th-a-announce-agreement-for-th-a-to-acquire-proqr-s-se-prqr-20230801monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20230516monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-annual-meeting-of-shareholders-to-be-held-prqr-20230418monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-initial-pipeline-targets-and-highlights-axiomer-rna-editing-platform-techn-prqr-20230329monthly0.5https://www.biopharmawatch.com/news/PRQR/lilly-and-proqr-to-expand-rna-editing-collaboration-new-agreement-supports-the-discovery-a-prqr-20221222monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20221109monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-to-focus-exclusively-on-axiomer-rna-editing-technology-and-partner-ophthalmology-pro-prqr-20220811monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20220804monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-annual-general-meeting-of-shareholders-and-provides-leadership-updates-ann-prqr-20220601monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20220505monthly0.5https://www.biopharmawatch.com/news/PRQR/strategy-update-nasdaq-prqr-date-prqr-20220413monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-additional-sepofarsen-illuminate-trial-analyses-and-provides-update-on-com-prqr-20220413monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20220224monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-top-line-results-from-phase-2-3-illuminate-trial-of-sepofarsen-in-cep290-m-prqr-20220211monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-amendment-to-convertible-debt-financing-agreement-with-pontifax-ventures-a-prqr-20211230monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-first-patients-dosed-in-phase-2-3-pivotal-trials-of-qr-421a-for-ush2a-medi-prqr-20211216monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-highlights-from-analyst-event-leiden-netherlands-prqr-20211118monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20211104monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-appoints-theresa-heggie-as-chief-commercial-officer-senior-leader-with-extensive-glo-prqr-20211004monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-axiomer-rna-editing-licensing-and-research-collaboration-with-lilly-compan-prqr-20210908monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20210805monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20210506monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-and-yarrow-biotechnology-an-rtw-investments-lp-incubated-company-announ-prqr-20210504monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-annual-meeting-of-shareholders-leiden-netherlands-prqr-20210420monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-prices-90-million-underwritten-public-offering-of-ordinary-shares-leiden-netherlands-prqr-20210330monthly0.5https://www.biopharmawatch.com/news/PRQR/qr-421a-stellar-trial-results-prqr-20210324monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-positive-results-from-clinical-trial-of-qr-421a-in-usher-syndrome-and-plan-prqr-20210324monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20210225monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-completes-enrollment-of-its-pivotal-trial-of-sepofarsen-for-the-treatment-of-lca10-t-prqr-20210107monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20201116monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-appoints-naveed-shams-md-phd-as-chief-scientific-officer-yuml-proven-leader-with-dee-prqr-20201005monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20200806monthly0.5https://www.biopharmawatch.com/news/PRQR/forward-looking-statements-this-press-release-contains-forward-looking-statements-all-stat-prqr-20200720monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-30-million-strategic-convertible-debt-financing-agreement-with-pontifax-ve-prqr-20200714monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-annual-meeting-of-shareholders-leiden-netherlands-prqr-20200525monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20200507monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-positive-findings-from-an-interim-analysis-in-the-phase-1-2-trial-of-qr-42-prqr-20200331monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20200226monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-receives-rare-pediatric-disease-designation-from-fda-for-qr-421a-designation-is-for--prqr-20200130monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-first-patient-dosed-in-phase-1-2-aurora-trial-of-qr-1123-for-autosomal-dom-prqr-20191211monthly0.5https://www.biopharmawatch.com/news/PRQR/final-for-release-proqr-receives-orphan-drug-designation-from-fda-for-qr-1123-for-autosoma-prqr-20191121monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20191112monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-prices-50-million-underwritten-public-offering-of-ordinary-shares-leiden-the-netherl-prqr-20191015monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-proposed-underwritten-public-offering-of-ordinary-shares-leiden-netherland-prqr-20191015monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-positive-top-line-results-from-the-phase-1-2-study-of-sepofarsen-in-lca10--prqr-20191010monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-receives-fast-track-designation-from-fda-for-qr-1123-for-autosomal-dominant-retiniti-prqr-20190909monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-clearance-of-ind-to-start-clinical-trial-of-qr-1123-in-patients-with-autos-prqr-20190812monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20190807monthly0.5https://www.biopharmawatch.com/news/PRQR/european-medicines-agency-grants-prime-access-to-proqr-s-sepofarsen-for-leber-s-congenital-prqr-20190729monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-financial-results-for-the-first-quarter-of-2019-leiden-netherlands-prqr-20190508monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-annual-meeting-of-shareholders-leiden-netherlands-and-prqr-20190418monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-doses-first-patient-in-phase-2-3-illuminate-trial-of-sepofarsen-for-lca10-leiden-net-prqr-20190415monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-spins-out-all-dystrophic-epidermolysis-bullosa-activities-into-newly-formed-wings-th-prqr-20190326monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-doses-first-patient-in-phase-1-2-stellar-trial-of-qr-421a-for-usher-syndrome-type-2--prqr-20190311monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-reports-fourth-quarter-and-full-year-2018-operating-and-financial-results-leiden-net-prqr-20190227monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-proqr-vision-2023-strategy-at-its-annual-r-d-day-leiden-the-netherlands-prqr-20190129monthly0.5https://www.biopharmawatch.com/news/PRQR/final-for-release-proqr-reaches-agreement-with-the-fda-on-design-of-phase-2-3-pivotal-tria-prqr-20190107monthly0.5https://www.biopharmawatch.com/news/PRQR/final-for-release-proqr-announces-strategic-changes-to-the-management-team-and-key-new-hir-prqr-20181213monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-receives-4-7-million-in-innovation-credit-from-dutch-government-for-qr-110-for-lca10-prqr-20181210monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-clearance-of-ind-to-start-clinical-trial-of-qr-421a-in-usher-syndrome-type-prqr-20181204monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20181107monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-press-release-prqr-20181029monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-prices-90-6-million-underwritten-public-offering-of-ordinary-shares-leiden-netherlan-prqr-20180906monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-proposed-underwritten-public-offering-of-ordinary-shares-leiden-netherland-prqr-20180905monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-positive-interim-results-from-phase-1-2-clinical-trial-of-qr-110-in-lca10--prqr-20180905monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20180808monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-press-release-prqr-20180629monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-press-release-prqr-20180612monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-unaudited-condensed-consolidated-statement-of-financial-position-prqr-20180510monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-press-release-prqr-20180423monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-annual-meeting-of-shareholders-leiden-the-netherlands-prqr-20180411monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20180228monthly0.5https://www.biopharmawatch.com/news/PRQR/foundation-fighting-blindness-proqr-therapeutics-n-v-press-release-prqr-20180212monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-press-release-prqr-20171227monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-press-release-prqr-20171129monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20171120monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-press-release-prqr-20171114monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-press-release-prqr-20171026monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-press-release-prqr-20170925monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-press-release-prqr-20170921monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-press-release-prqr-20170919monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-press-release-prqr-20170912monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-press-release-september-5-2017-final-for-release-proqr-s-drug-candi-prqr-20170905monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-press-release-prqr-20170829monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20170816monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-press-release-prqr-20170705monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-press-release-prqr-20170615monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-press-release-prqr-20170608monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-press-release-prqr-20170531monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20170517monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-press-release-prqr-20170427monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-annual-meeting-of-shareholders-leiden-the-netherlands-prqr-20170410monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-press-release-prqr-20170403monthly0.5https://www.biopharmawatch.com/news/PRQR/final-for-release-proqr-appoints-david-m-rodman-md-as-chief-development-strategy-officer-l-prqr-20170327monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20170228monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-unaudited-condensed-consolidated-statement-of-financial-position-prqr-20161114monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-analyst-investor-event-nacfc-2016-orlando-florida-date-presenters-october-27th-2016--prqr-20161028monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-press-release-prqr-20161027monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-press-release-prqr-20160927monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20160817monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-press-release-prqr-20160719monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-press-release-prqr-20160621monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-press-release-prqr-20160601monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20160518monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-annual-meeting-of-shareholders-leiden-the-netherlands-prqr-20160407monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20160217monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-interim-financial-stateme-prqr-20151123monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-a-proof-of-concept-nasal-potential-difference-study-of-qr-010-is-open-for--prqr-20150914monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-interim-financial-stateme-prqr-20150819monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-announces-enrollment-has-started-in-global-phase-1b-study-of-qr-010-in-cystic-fibros-prqr-20150626monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-interim-financial-statements-page-unau-prqr-20150521monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-announces-annual-shareholder-meeting-leiden-the-netherlands-prqr-20150429monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-financial-statements-page-unaudited-co-prqr-20150226monthly0.5https://www.biopharmawatch.com/news/PRQR/proqr-therapeutics-n-v-index-to-unaudited-condensed-consolidated-financial-statements-page-prqr-20141124monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-announces-proposed-public-offering-of-common-stock-apyx-20251117monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-reports-third-quarter-2024-financial-results-updates-full-year-20-apyx-20241108monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-reports-second-quarter-2024-financial-results-updates-full-year-2-apyx-20240808monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-reports-first-quarter-2024-financial-results-reaffirms-full-year--apyx-20240509monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-reports-fourth-quarter-and-full-year-2023-financial-results-intro-apyx-20240321monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-announces-renuvion-to-be-featured-in-educational-sessions-at-the--apyx-20240221monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-announces-peer-reviewed-clinical-publication-evaluating-the-safet-apyx-20240122monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-reports-preliminary-fourth-quarter-and-full-year-2023-revenue-res-apyx-20240108monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-announces-new-debt-facility-with-perceptive-advisors-new-facility-apyx-20231109monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-reports-third-quarter-2023-financial-results-and-updates-full-yea-apyx-20231109monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-reports-second-quarter-2023-financial-results-and-reaffirms-full--apyx-20230810monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-reports-first-quarter-2023-financial-results-and-updates-full-yea-apyx-20230511monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-reports-fourth-quarter-and-full-year-2022-financial-results-intro-apyx-20230316monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-announces-new-five-year-credit-agreement-with-midcap-financial-fa-apyx-20230221monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-reports-preliminary-fourth-quarter-and-full-year-2022-revenue-res-apyx-20230110monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-reports-third-quarter-2022-financial-results-and-updates-full-yea-apyx-20221110monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-reports-second-quarter-2022-financial-results-and-updates-full-ye-apyx-20220811monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-reports-first-quarter-2022-financial-results-and-updates-full-yea-apyx-20220512monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-reports-fourth-quarter-and-full-year-2021-financial-results-intro-apyx-20220317monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-reports-third-quarter-2021-financial-results-and-updates-full-yea-apyx-20211111monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-reports-second-quarter-2021-financial-results-and-updates-full-ye-apyx-20210812monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-reports-first-quarter-2021-financial-results-and-updates-full-yea-apyx-20210512monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-reports-fourth-quarter-and-full-year-2020-financial-results-intro-apyx-20210331monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-reports-third-quarter-2020-financial-results-clearwater-fl-novemb-apyx-20201109monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-reports-first-quarter-2020-financial-results-clearwater-fl-may-11-apyx-20200511monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-reports-fourth-quarter-and-full-year-of-2019-preliminary-unaudite-apyx-20200319monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-reports-preliminary-full-year-and-fourth-quarter-2019-revenue-res-apyx-20191231monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-announces-subject-enrollment-initiated-in-new-study-evaluating-th-apyx-20191203monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-reports-third-quarter-of-2019-financial-results-and-updates-fisca-apyx-20191112monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-announces-subject-enrollment-initiated-in-study-evaluating-the-us-apyx-20191015monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-reports-second-quarter-and-first-half-of-2019-financial-results-a-apyx-20190807monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-announces-appointment-of-minnie-baylor-henry-to-the-company-s-boa-apyx-20190801monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-reports-first-quarter-2019-financial-results-and-updates-fiscal-y-apyx-20190508monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-provides-update-on-the-premarket-notification-510-k-submission-to-apyx-20190404monthly0.5https://www.biopharmawatch.com/news/APYX/apyx-medical-corporation-reports-preliminary-full-year-and-fourth-quarter-2018-revenue-res-apyx-20181231monthly0.5https://www.biopharmawatch.com/news/APYX/bovie-medical-corporation-announces-appointment-of-tara-h-semb-as-chief-financial-officer--apyx-20181217monthly0.5https://www.biopharmawatch.com/news/APYX/bovie-medical-corporation-announces-corporate-name-change-to-apyx-medical-corporation-and--apyx-20181212monthly0.5https://www.biopharmawatch.com/news/APYX/bovie-medical-corporation-announces-future-retirement-of-jay-d-ewers-chief-financial-offic-apyx-20181113monthly0.5https://www.biopharmawatch.com/news/APYX/bovie-medical-corporation-reports-third-quarter-2018-financial-results-and-updates-fiscal--apyx-20181101monthly0.5https://www.biopharmawatch.com/news/APYX/bovie-medical-corporation-updates-fiscal-year-2018-financial-outlook-now-expect-advanced-e-apyx-20180905monthly0.5https://www.biopharmawatch.com/news/APYX/bovie-medical-corporation-announces-completion-of-core-business-segment-sale-to-symmetry-s-apyx-20180830monthly0.5https://www.biopharmawatch.com/news/APYX/bovie-medical-corporation-reports-second-quarter-2018-financial-results-advanced-energy-sa-apyx-20180801monthly0.5https://www.biopharmawatch.com/news/APYX/bovie-medical-corporation-announces-preliminary-second-quarter-2018-revenue-results-advanc-apyx-20180630monthly0.5https://www.biopharmawatch.com/news/APYX/bovie-medical-corporation-announces-appointment-of-craig-a-swandal-to-board-of-directors-c-apyx-20180309monthly0.5https://www.biopharmawatch.com/news/APYX/bovie-medical-corporation-reports-fourth-quarter-and-full-year-2017-financial-results-prov-apyx-20180312monthly0.5https://www.biopharmawatch.com/news/APYX/bovie-medical-corporation-appoints-charles-d-goodwin-chief-executive-officer-updates-2017--apyx-20171215monthly0.5https://www.biopharmawatch.com/news/APYX/bovie-medical-corporation-reports-third-quarter-2017-financial-results-and-updates-fiscal--apyx-20171102monthly0.5https://www.biopharmawatch.com/news/APYX/bovie-medical-corporation-reports-second-quarter-2017-financial-results-and-reaffirms-fisc-apyx-20170802monthly0.5https://www.biopharmawatch.com/news/APYX/bovie-medical-corporation-reports-first-quarter-2017-financial-results-and-introduce-fisca-apyx-20170515monthly0.5https://www.biopharmawatch.com/news/APYX/bovie-medical-corporation-reports-fourth-quarter-and-full-year-2016-results-record-full-ye-apyx-20170310monthly0.5https://www.biopharmawatch.com/news/APYX/bovie-medical-prices-public-offerings-of-common-stock-clearwater-fl-apyx-20161110monthly0.5https://www.biopharmawatch.com/news/APYX/unassociated-document-bovie-medical-corporation-reports-second-quarter-and-first-half-2016-apyx-20160801monthly0.5https://www.biopharmawatch.com/news/APYX/htm-bovie-medical-corporation-reports-first-quarter-2016-results-first-quarter-highlights--apyx-20160511monthly0.5https://www.biopharmawatch.com/news/APYX/bovie-medical-corporation-reports-fourth-quarter-and-full-year-2015-results-2015-highlight-apyx-20160318monthly0.5https://www.biopharmawatch.com/news/APYX/3rd-qtr-earnings-exhibit991-htm-bovie-medical-reports-third-quarter-2015-results-total-sal-apyx-20151105monthly0.5https://www.biopharmawatch.com/news/APYX/quarter-results-exhibit991-htm-bovie-medical-reports-second-quarter-2015-results-sales-inc-apyx-20150806monthly0.5https://www.biopharmawatch.com/news/APYX/bovie-medical-corporation-announces-closing-of-over-allotment-apyx-20150331monthly0.5https://www.biopharmawatch.com/news/APYX/bovie-medical-corporation-reports-fourth-quarter-and-full-year-2014-results-fourth-quarter-apyx-20150227monthly0.5https://www.biopharmawatch.com/news/APYX/htm-bovie-medical-corporation-reports-third-quarter-2014-results-third-quarter-2014-highli-apyx-20141106monthly0.5https://www.biopharmawatch.com/news/APYX/bovie-medical-reports-second-quarter-2014-results-second-quarter-2014-highlights-sales-inc-apyx-20140805monthly0.5https://www.biopharmawatch.com/news/APYX/amended-order-preliminary-approving-settlement-exhibit991-htm-in-the-united-states-distric-apyx-20140702monthly0.5https://www.biopharmawatch.com/news/APYX/htm-bovie-medical-names-peter-donato-chief-financial-officer-clearwater-fl-apyx-20140506monthly0.5https://www.biopharmawatch.com/news/APYX/bovie-medical-reports-fourth-quarter-and-full-year-2013-results-names-jack-mccarthy-chief--apyx-20140331monthly0.5https://www.biopharmawatch.com/news/APYX/bovie-medical-corporation-closes-strategic-7-0m-equity-investment-through-great-point-part-apyx-20131213monthly0.5https://www.biopharmawatch.com/news/APYX/settlement-agreement-exhibit991-htm-confidential-settlement-agreement-and-mutual-general-r-apyx-20120228monthly0.5https://www.biopharmawatch.com/news/APYX/bovie-medical-corporation-names-j-robert-saron-president-appoints-two-new-members-to-its-b-apyx-20110321monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-second-quarter-2025-operating-results-and-provides-a-business-spro-20250812monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-first-quarter-2025-operating-results-and-provides-a-business--spro-20250513monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-fourth-quarter-and-full-year-2024-operating-results-and-provi-spro-20250327monthly0.5https://www.biopharmawatch.com/news/SPRO/corporate-presentation-january-2025-forward-looking-statement-this-presentation-contains-f-spro-20250110monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-third-quarter-2024-operating-results-and-provides-a-business--spro-20241114monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-spr720-phase-2a-interim-results-and-provides-a-business-updat-spro-20241029monthly0.5https://www.biopharmawatch.com/news/SPRO/corporate-presentation-sept-2024-forward-looking-statement-this-presentation-contains-forw-spro-20240910monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-second-quarter-2024-operating-results-and-provides-a-business-spro-20240805monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-first-quarter-2024-operating-results-and-provides-a-business--spro-20240515monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-fourth-quarter-and-full-year-2023-operating-results-and-provi-spro-20240313monthly0.5https://www.biopharmawatch.com/news/SPRO/forward-looking-statement-this-presentation-contains-forward-looking-statements-as-defined-spro-20240108monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-provides-corporate-update-and-2024-outlook-in-2h-2024-expect-to-provide-spro-20240105monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-first-patient-first-visit-for-phase-3-pivot-po-trial-evaluati-spro-20240102monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-third-quarter-2023-operating-results-and-provides-a-business--spro-20231113monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-appoints-esther-rajavelu-as-chief-financial-officer-and-chief-business--spro-20231101monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-second-quarter-2023-operating-results-and-provides-a-business-spro-20230810monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-special-protocol-assessment-agreement-with-fda-for-phase-3-pi-spro-20230731monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-appoints-sath-shukla-as-president-chief-executive-officer-sath-shukla-c-spro-20230614monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-first-quarter-2023-operating-results-and-provides-a-business--spro-20230511monthly0.5https://www.biopharmawatch.com/news/SPRO/exhbit-99-1-spero-therapeutics-announces-fourth-quarter-and-full-year-2022-operating-resul-spro-20230330monthly0.5https://www.biopharmawatch.com/news/SPRO/forward-looking-statement-this-presentation-contains-forward-looking-statements-as-defined-spro-20221231monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-third-quarter-2022-operating-results-and-provides-business-up-spro-20221114monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-closing-of-exclusive-license-agreement-with-gsk-for-tebipenem-spro-20221108monthly0.5https://www.biopharmawatch.com/news/SPRO/gsk-and-spero-therapeutics-announce-exclusive-license-agreement-for-late-stage-antibiotic--spro-20220922monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-provides-tebipenem-hbr-program-update-following-type-a-meeting-with-the-spro-20220906monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-second-quarter-2022-operating-results-and-provides-business-u-spro-20220810monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-receives-complete-response-letter-from-u-s-food-and-drug-administration-spro-20220627monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-first-quarter-2022-operating-results-and-provides-business-up-spro-20220516monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-new-strategic-direction-focusing-on-advancing-promising-clini-spro-20220503monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-tebipenem-pivoxil-hydrobromide-phase-3-data-published-in-the-new-englan-spro-20220406monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-fourth-quarter-and-full-year-2021-operating-results-and-provi-spro-20220331monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-positive-topline-results-from-phase-1-bronchoalveolar-lavage--spro-20220216monthly0.5https://www.biopharmawatch.com/news/SPRO/forward-looking-statements-this-presentation-contains-forward-looking-statements-as-define-spro-20220125monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-awarded-up-to-an-additional-12-9-million-by-barda-to-support-the-develo-spro-20220119monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-fda-acceptance-and-priority-review-of-new-drug-application-fo-spro-20220104monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-third-quarter-2021-operating-results-and-provides-business-up-spro-20211110monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-submits-new-drug-application-to-u-s-fda-for-tebipenem-hbr-for-the-treat-spro-20211028monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-appoints-kathleen-tregoning-to-its-board-of-directors-ms-tregoning-brin-spro-20211012monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-second-quarter-2021-operating-results-and-provides-business-u-spro-20210805monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-40-million-equity-investment-from-pfizer-inc-and-licensing-ag-spro-20210630monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-first-quarter-2021-operating-results-and-provides-business-up-spro-20210506monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-fourth-quarter-and-full-year-2020-operating-results-and-provi-spro-20210311monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-provides-update-on-spr720-phase-2a-clinical-trial-spro-20210205monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-appointment-of-sath-shukla-as-chief-financial-officer-spro-20201217monthly0.5https://www.biopharmawatch.com/news/SPRO/forward-looking-statements-this-presentation-contains-forward-looking-statements-as-define-spro-20201203monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-third-quarter-2020-operating-results-and-provides-business-up-spro-20201105monthly0.5https://www.biopharmawatch.com/news/SPRO/forward-looking-statements-this-presentation-contains-forward-looking-statements-as-define-spro-20200908monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-second-quarter-2020-operating-results-and-provides-business-u-spro-20200806monthly0.5https://www.biopharmawatch.com/news/SPRO/forward-looking-statements-this-presentation-contains-forward-looking-statements-as-define-spro-20200604monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-first-quarter-2020-operating-results-and-provides-business-up-spro-20200508monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-announces-appointment-of-scott-jackson-to-its-board-of-directors-spero-brings-signif-spro-20200416monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-fourth-quarter-and-full-year-2019-operating-results-and-provi-spro-20200316monthly0.5https://www.biopharmawatch.com/news/SPRO/form-of-instructions-as-to-use-of-spero-therapeutics-inc-subscription-rights-certificates--spro-20200211monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-proposed-rights-offering-30-million-fully-backstopped-rights--spro-20200130monthly0.5https://www.biopharmawatch.com/news/SPRO/second-amendment-to-lease-agreement-this-second-amendment-to-lease-the-second-amendment-da-spro-20191219monthly0.5https://www.biopharmawatch.com/news/SPRO/forward-looking-statements-this-presentation-contains-forward-looking-statements-as-define-spro-20191205monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-third-quarter-2019-operating-results-and-provides-pipeline-re-spro-20191104monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-positive-recommendation-to-continue-phase-3-clinical-trial-of-spro-20191003monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-second-quarter-2019-operating-results-and-provides-pipeline-u-spro-20190808monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-announces-10-million-registered-direct-offering-of-common-stock-novo-holdings-a-s-th-spro-20190613monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-first-quarter-2019-operating-results-and-provides-pipeline-re-spro-20190509monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-announces-appointment-of-cynthia-smith-to-its-board-of-directors-spero-adds-signific-spro-20190319monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-fourth-quarter-and-full-year-2018-operating-results-and-provi-spro-20190314monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-signs-license-agreement-with-everest-medicines-to-develop-manufacture-a-spro-20190107monthly0.5https://www.biopharmawatch.com/news/SPRO/forward-looking-statements-this-presentation-contains-forward-looking-statements-as-define-spro-20181113monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-third-quarter-2018-financial-results-and-pipeline-overview-pi-spro-20181108monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-announces-positive-spr994-phase-1-sad-mad-final-results-multiple-ascending-dose-clin-spro-20180927monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-announces-appointment-of-john-c-pottage-jr-md-to-its-board-of-directors-spero-adds-b-spro-20180814monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-second-quarter-2018-financial-results-and-pipeline-overview-p-spro-20180809monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-awarded-up-to-54-million-by-barda-and-dtra-to-support-spr994-development-inter-agenc-spro-20180716monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-proposed-offering-of-common-stock-spro-20180709monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-announces-positive-interim-phase-1-sad-mad-results-for-spr994-clinical-data-demonstr-spro-20180709monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-first-quarter-2018-financial-results-and-pipeline-update-mult-spro-20180510monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-fourth-quarter-and-full-year-2017-operating-results-and-provi-spro-20180402monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-announces-appointment-of-david-p-southwell-to-its-board-of-directors-broad-leadershi-spro-20180201monthly0.5https://www.biopharmawatch.com/news/SPRO/first-amendment-to-lease-agreement-this-first-amendment-to-lease-the-amendment-dated-this--spro-20180123monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-3q17-operating-results-and-pipeline-update-raised-approximate-spro-20171214monthly0.5https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-closing-of-initial-public-offering-spro-20171106monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-letter-to-shareholders-initiating-phase-3-oral-insulin-trial-in-the-united-states-u-ormp-20240220monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-announces-101-875-000-short-term-senior-secured-note-transaction-with-scilex-holdin-ormp-20230921monthly0.5https://www.biopharmawatch.com/news/ORMP/execution-version-non-binding-ormp-20230911monthly0.5https://www.biopharmawatch.com/news/ORMP/execution-version-stalking-horse-stock-purchase-term-sheet-this-term-sheet-this-stalking-h-ormp-20230807monthly0.5https://www.biopharmawatch.com/news/ORMP/addressing-the-multibillion-dollar-injectable-drug-markets-with-oral-formulations-december-ormp-20221212monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-reports-third-quarter-2022-financial-results-ormp-20221110monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-letter-to-shareholders-169-million-in-cash-and-investments-pivotal-phase-3-oral-ins-ormp-20220707monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-issues-annual-message-to-shareholders-oral-insulin-program-continues-to-advance-wit-ormp-20220112monthly0.5https://www.biopharmawatch.com/news/ORMP/addressing-the-multibillion-dollar-injectable-drug-markets-with-oral-formulations-december-ormp-20211203monthly0.5https://www.biopharmawatch.com/news/ORMP/addressing-the-multibillion-dollar-injectable-drug-markets-with-oral-formulations-august-2-ormp-20210802monthly0.5https://www.biopharmawatch.com/news/ORMP/addressing-the-multibillion-dollar-injectable-drug-markets-with-oral-formulations-march-20-ormp-20210319monthly0.5https://www.biopharmawatch.com/news/ORMP/addressing-the-multibillion-dollar-injectable-drug-markets-with-oral-formulations-october--ormp-20201022monthly0.5https://www.biopharmawatch.com/news/ORMP/ora-d-007-randomized-double-blind-placebo-controlled-study-to-assess-the-safety-and-effica-ormp-20160728monthly0.5https://www.biopharmawatch.com/news/ORMP/addressing-the-multibillion-dollar-injectable-drug-markets-with-oral-formulations-may-2016-ormp-20160523monthly0.5https://www.biopharmawatch.com/news/ORMP/addressing-the-multibillion-dollar-injectable-drug-markets-with-oral-formulations-january--ormp-20160114monthly0.5https://www.biopharmawatch.com/news/ORMP/nasdaq-ormp-july-2015-corporate-presentation-safe-harbor-certain-statements-contained-in-t-ormp-20150702monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-to-present-at-the-1-st-asia-pacific-congress-on-controversies-to-co-ormp-20110518monthly0.5https://www.biopharmawatch.com/news/ORMP/unassociated-document-oramed-pharmaceuticals-to-present-at-the-10th-national-life-science--ormp-20110512monthly0.5https://www.biopharmawatch.com/news/ORMP/unassociated-document-oramed-pharmaceuticals-announces-completion-of-3-4-million-private-p-ormp-20110406monthly0.5https://www.biopharmawatch.com/news/ORMP/unassociated-document-oramed-successfully-completes-toxicity-study-for-ormd-0801-jerusalem-ormp-20110323monthly0.5https://www.biopharmawatch.com/news/ORMP/unassociated-document-oramed-pharmaceuticals-sells-its-stake-in-entera-bio-for-1-15-millio-ormp-20110228monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-chosen-to-lecture-at-the-fourth-international-conference-on-advanced-technologies-a-ormp-20110215monthly0.5https://www.biopharmawatch.com/news/ORMP/pharmaceuticals-was-awarded-a-nis-2-9-million-grant-from-the-israeli-office-of-ormp-20101227monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-announces-publication-in-the-journal-of-diabetes-science-and-techno-ormp-20101201monthly0.5https://www.biopharmawatch.com/news/ORMP/unassociated-document-oramed-pharmaceuticals-presents-results-of-its-phase-iib-clinical-tr-ormp-20101115monthly0.5https://www.biopharmawatch.com/news/ORMP/unassociated-document-oramed-pharmaceuticals-to-present-results-of-an-oral-insulin-adminis-ormp-20101026monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-announces-successful-results-of-a-novel-exploratory-clinical-study--ormp-20100914monthly0.5https://www.biopharmawatch.com/news/ORMP/unassociated-document-this-presentation-may-contain-forward-looking-statements-including-s-ormp-20100908monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-and-sanofi-aventis-enter-into-an-agreement-for-the-insulin-supply-o-ormp-20100707monthly0.5https://www.biopharmawatch.com/news/ORMP/unassociated-document-oramed-pharmaceuticals-to-present-at-the-70-th-scientific-sessions-o-ormp-20100628monthly0.5https://www.biopharmawatch.com/news/ORMP/unassociated-document-oramed-pharmaceuticals-was-chosen-to-present-two-abstracts-at-the-70-ormp-20100615monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-to-present-at-the-9th-national-life-science-technology-week-ilsi-bi-ormp-20100608monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-forms-joint-venture-launches-entera-bio-ltd-jerusalem-israel-ormp-20100602monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-announces-publication-of-research-article-on-its-oral-insulin-capsu-ormp-20100526monthly0.5https://www.biopharmawatch.com/news/ORMP/unassociated-document-oramed-pharmaceuticals-announces-that-dr-michael-berelowitz-senior-v-ormp-20100518monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-reports-results-in-phase-2b-trial-of-oral-insulin-administration-to-ormp-20100506monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-expands-scientific-advisory-board-with-the-appointment-of-john-amat-ormp-20100216monthly0.5https://www.biopharmawatch.com/news/ORMP/unassociated-document-oramed-s-chief-scientific-officer-miriam-kidron-ph-d-chosen-to-lectu-ormp-20100210monthly0.5https://www.biopharmawatch.com/news/ORMP/unassociated-document-oramed-pharmaceuticals-announces-completion-of-patient-enrollment-fo-ormp-20100120monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-announces-filing-of-two-registration-statements-ormp-20100111monthly0.5https://www.biopharmawatch.com/news/ORMP/dear-shareholder-as-we-are-about-to-begin-2010-i-would-like-to-take-the-opportunity-to-loo-ormp-20100104monthly0.5https://www.biopharmawatch.com/news/ORMP/unassociated-document-oramed-s-dr-roy-eldor-was-chosen-to-lecture-at-the-first-internation-ormp-20091221monthly0.5https://www.biopharmawatch.com/news/ORMP/unassociated-document-oramed-pharmaceuticals-was-chosen-to-present-results-of-a-glp-1-anal-ormp-20091020monthly0.5https://www.biopharmawatch.com/news/ORMP/unassociated-document-oramed-pharmaceuticals-commences-human-clinical-trials-of-an-oral-gl-ormp-20090909monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-to-present-at-rodman-renshaw-11-th-annual-healthcare-conference-ormp-20090903monthly0.5https://www.biopharmawatch.com/news/ORMP/unassociated-document-frost-and-sullivan-honors-oramed-pharmaceuticals-with-the-2009-europ-ormp-20090825monthly0.5https://www.biopharmawatch.com/news/ORMP/unassociated-document-oramed-s-chief-scientific-officer-miriam-kidron-ph-d-chosen-to-lectu-ormp-20090818monthly0.5https://www.biopharmawatch.com/news/ORMP/unassociated-document-oramed-pharmaceuticals-was-awarded-an-nis-3-1-million-grant-from-the-ormp-20090804monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-reports-positive-results-from-a-study-of-oral-insulin-capsule-on-ty-ormp-20090721monthly0.5https://www.biopharmawatch.com/news/ORMP/unassociated-document-oramed-pharmaceuticals-to-present-at-the-8th-national-life-science-t-ormp-20090610monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-announces-launch-of-phase-2b-clinical-trials-in-south-africa-of-its-ormp-20090505monthly0.5https://www.biopharmawatch.com/news/ORMP/unassociated-document-oramed-pharmaceuticals-to-present-oral-insulin-phase-2a-trial-result-ormp-20090325monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-presents-results-of-oral-administration-of-exenatide-4-proof-of-con-ormp-20081114monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-launches-phase-1a-trials-of-its-insulin-suppository-an-insulin-supp-ormp-20081023monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-commences-phase-2a-trials-of-its-oral-insulin-capsule-on-type-1-dia-ormp-20080924monthly0.5https://www.biopharmawatch.com/news/ORMP/unassociated-document-oramed-pharmaceuticals-launches-glp1-analog-program-based-on-its-pro-ormp-20080916monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-partners-with-eti-karle-clinical-to-conduct-phase-2b-trials-on-its--ormp-20080909monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-announces-successful-phase-2a-clinical-trial-of-its-oral-insulin-ca-ormp-20080806monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-raises-5-million-through-a-private-placement-the-equity-financing-w-ormp-20080715monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-partners-with-onq-consulting-for-phase-2b-trials-on-its-oral-insuli-ormp-20080417monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-commences-phase-2a-clinical-trials-in-israel-oramed-begins-studies--ormp-20080414monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-granted-approval-to-conduct-phase-2a-trials-of-its-oral-insulin-cap-ormp-20080318monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-successfully-completes-phase-1b-clinical-trials-of-oral-insulin-cap-ormp-20080311monthly0.5https://www.biopharmawatch.com/news/ORMP/source-oramed-pharmaceuticals-inc-oramed-pharmaceuticals-teams-up-with-onq-consulting-wedn-ormp-20080201monthly0.5https://www.biopharmawatch.com/news/ORMP/oramed-pharmaceuticals-signs-manufacturing-agreement-for-oral-insulin-pill-jerusalem-israe-ormp-20061102monthly0.5https://www.biopharmawatch.com/news/ORMP/integrated-security-technologies-inc-1500-885-west-georgia-street-vancouver-b-c-v6c-3e8-ormp-20060217monthly0.5https://www.biopharmawatch.com/news/ORMP/form8-kfeb806exh99-1-pdf-converted-by-secpublisher-4-0-created-by-bcl-technologies-inc-for-ormp-20060209monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-c-o-r-p-o-r-a-t-e-p-r-e-s-e-n-t-a-t-i-o-n-j-u-n-e-2024-protalix-b-plx-20260521monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-first-quarter-2026-financial-and-business-results-company-plx-20260513monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-fiscal-year-2025-financial-and-business-results-company-t-plx-20260318monthly0.5https://www.biopharmawatch.com/news/PLX/forward-looking-statements-this-presentation-contains-forward-looking-statements-that-invo-plx-20260211monthly0.5https://www.biopharmawatch.com/news/PLX/chiesi-global-rare-diseases-and-protalix-biotherapeutics-receive-positive-chmp-opinion-for-plx-20260130monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-letter-to-stockholders-plx-20260105monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-third-quarter-2025-financial-and-business-results-company-plx-20251113monthly0.5https://www.biopharmawatch.com/news/PLX/chiesi-global-rare-diseases-and-protalix-biotherapeutics-seek-re-examination-from-the-ema--plx-20251103monthly0.5https://www.biopharmawatch.com/news/PLX/forward-looking-statements-this-presentation-contains-forward-looking-statements-that-invo-plx-20251017monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-second-quarter-2025-financial-and-business-results-compan-plx-20250814monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-appoints-gilad-mamlok-as-its-new-senior-vice-president-and-chief--plx-20250721monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-first-quarter-2025-financial-and-business-results-company-plx-20250509monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-fiscal-year-2024-financial-and-business-results-company-t-plx-20250317monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-issues-2025-letter-to-stockholders-plx-20241223monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-third-quarter-2024-financial-and-business-results-company-plx-20241114monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-to-present-phase-i-prx-115-data-in-late-breaking-poster-at-acr-co-plx-20241025monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-second-quarter-2024-financial-and-business-results-compan-plx-20240814monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-first-quarter-2024-financial-and-business-results-company-plx-20240510monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-fiscal-year-2023-financial-and-business-results-company-t-plx-20240314monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-issues-2024-letter-to-stockholders-plx-20231226monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-third-quarter-2023-financial-and-business-results-company-plx-20231106monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-appoints-eliot-richard-forster-ph-d-as-chairman-of-its-board-of-d-plx-20230914monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-second-quarter-2023-financial-and-business-results-compan-plx-20230807monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-issues-letter-to-stockholders-plx-20230530monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-20-million-milestone-payment-from-chiesi-global-rare-di-plx-20230518monthly0.5https://www.biopharmawatch.com/news/PLX/chiesi-global-rare-diseases-and-protalix-biotherapeutics-announce-fda-approval-of-elfabrio-plx-20230510monthly0.5https://www.biopharmawatch.com/news/PLX/chiesi-global-rare-diseases-and-protalix-biotherapeutics-announce-european-commission-auth-plx-20230505monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-first-quarter-2023-financial-and-business-results-company-plx-20230504monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-fiscal-year-2022-financial-and-business-results-company-t-plx-20230227monthly0.5https://www.biopharmawatch.com/news/PLX/chiesi-global-rare-diseases-and-protalix-biotherapeutics-receive-positive-chmp-opinion-for-plx-20230224monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-issues-2023-letter-to-stockholders-plx-20230103monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-to-delist-its-common-stock-from-the-tel-aviv-stock-exchange-the-c-plx-20221221monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-second-quarter-2022-financial-and-business-results-compan-plx-20220815monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-poster-presentations-at-the-2022-program-7th-update-on--plx-20220526monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-first-quarter-2022-financial-and-business-results-company-plx-20220516monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-and-chiesi-global-rare-diseases-announce-topline-results-from-the-plx-20220404monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-fiscal-year-2021-financial-and-business-results-company-t-plx-20220331monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-and-chiesi-global-rare-diseases-announce-the-submission-of-a-mark-plx-20220224monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-issues-2021-letter-to-stockholders-plx-20211222monthly0.5https://www.biopharmawatch.com/news/PLX/biotherapeutics-reports-third-quarter-2021-financial-results-and-provides-financial-and-bu-plx-20211115monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-and-chiesi-global-rare-diseases-provide-regulatory-update-on-prx--plx-20211012monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-closing-of-private-note-exchange-plx-20210826monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-second-quarter-2021-financial-results-and-financial-and-b-plx-20210816monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-private-note-exchange-plx-20210813monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-and-chiesi-global-rare-diseases-provide-update-regarding-clinical-plx-20210602monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-first-quarter-2021-financial-results-and-business-update--plx-20210514monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-and-chiesi-global-rare-diseases-receive-complete-response-letter--plx-20210428monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-fiscal-year-2020-financial-and-business-results-in-februa-plx-20210330monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-and-chiesi-global-rare-diseases-announce-positive-topline-results-plx-20210223monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-proposed-public-offering-of-common-stock-plx-20210211monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-third-quarter-2020-financial-results-and-provides-busines-plx-20201029monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-regains-compliance-with-nyse-american-continued-listing-standards-plx-20200908monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-and-chiesi-global-rare-diseases-announce-u-s-food-and-drug-admini-plx-20200811monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-second-quarter-2020-financial-results-and-provides-busine-plx-20200810monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-appoints-yael-hayon-ph-d-as-its-new-vice-president-research-and-d-plx-20200608monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-first-quarter-2020-financial-results-and-business-update--plx-20200601monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-and-chiesi-global-rare-diseases-announce-submission-of-biologics--plx-20200528monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-positive-topline-results-from-the-bridge-phase-iii-open-plx-20200511monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-closing-of-43-7-million-private-placement-plx-20200318monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-fourth-quarter-and-full-year-2019-financial-and-business--plx-20200312monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-43-7-million-in-financing-to-further-advance-its-progra-plx-20200312monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-presents-key-clinical-data-of-pegunigalsidase-alfa-for-the-treatm-plx-20200210monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-and-chiesi-farmaceutici-announce-receipt-of-agreement-letter-for--plx-20200206monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-adds-two-accomplished-biopharmaceutical-executives-to-its-board-o-plx-20191219monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-1-for-10-reverse-stock-split-plx-20191209monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-and-chiesi-farmaceutici-announce-successful-pre-bla-meeting-with--plx-20191118monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-third-quarter-2019-results-and-provides-corporate-update-plx-20191107monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-positive-12-month-interim-data-from-the-bridge-phase-ii-plx-20191017monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-and-chiesi-group-complete-enrollment-in-the-third-phase-iii-clini-plx-20190924monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-second-quarter-2019-results-and-provides-corporate-update-plx-20190808monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-and-chiesi-farmaceutici-s-p-a-to-apply-for-accelerated-approval-o-plx-20190606monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-2019-first-quarter-results-and-provides-corporate-update-plx-20190506monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-2018-full-year-results-and-provides-corporate-update-plx-20190318monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-presents-preliminary-data-from-the-bright-study-of-pegunigalsidas-plx-20190205monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-corporate-update-january-2019-this-presentation-contains-forward--plx-20181231monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-the-completion-of-enrollment-in-the-phase-iii-bridge-cl-plx-20181217monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-2018-third-quarter-results-and-provides-corporate-update-plx-20181107monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-presents-positive-preliminary-data-from-the-bridge-study-of-pegun-plx-20181005monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-positive-preliminary-data-from-the-bridge-study-of-peguni-plx-20180921monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-appoints-david-granot-to-its-board-of-directors-carmiel-israel-plx-20180813monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-2018-second-quarter-results-and-provides-corporate-update-plx-20180809monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-expands-partnership-with-chiesi-farmaceutici-to-include-exclusive-plx-20180724monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-announces-exchange-and-discharge-of-remaining-2018-notes-plx-20180524monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-2018-first-quarter-results-and-provides-corporate-update-plx-20180509monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-corporate-update-march-2018-this-presentation-contains-forward-lo-plx-20180321monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-2017-full-year-results-and-provides-corporate-update-enro-plx-20180306monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-pegunigalsidase-alfa-receives-fast-track-designation-from-the-u-s-plx-20180131monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-corporate-update-january-2018-this-presentation-contains-forward--plx-20171231monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-presents-positive-results-from-the-phase-i-ii-open-label-extensio-plx-20171127monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-receives-positive-opinion-for-orphan-designation-for-prx-102-for--plx-20171113monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-2017-third-quarter-results-and-provides-corporate-update--plx-20171108monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-enters-into-an-exclusive-ex-us-partnership-with-chiesi-farmaceuti-plx-20171018monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-2017-second-quarter-results-and-provides-corporate-update-plx-20170809monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-completes-private-plx-20170725monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-phase-ii-clinical-trial-results-for-alidornase-alfa-in--plx-20170607monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-2017-first-quarter-results-and-provides-corporate-update--plx-20170510monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-announces-fda-investigational-new-drug-clearance-to-commence-once-monthly-dosing--plx-20170509monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-new-preclinical-results-demonstrating-a-positive-effect-plx-20170418monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-positive-results-from-phase-ii-clinical-trial-of-alidor-plx-20170412monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-2016-full-year-results-and-provides-corporate-update-curr-plx-20170316monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-provides-review-of-2016-and-strategic-outlook-for-2017-full-switc-plx-20170109monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-positive-interim-results-from-phase-ii-clinical-trial-o-plx-20170103monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-receives-confirmation-of-order-for-over-24-million-of-alfataligli-plx-20161227monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-receives-letter-detailing-intended-purchases-of-approximately-24--plx-20161214monthly0.5https://www.biopharmawatch.com/news/PLX/company-presentation-december-2016-www-protalix-com-8-181-153-37-93-168-3-173-235-49-132-1-plx-20161202monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-enrolls-first-patient-in-phase-ii-clinical-trial-of-oprx-106-for--plx-20161130monthly0.5https://www.biopharmawatch.com/news/PLX/alfataliglicerase-approved-for-pediatric-indications-in-brazil-for-the-treatment-of-gauche-plx-20161122monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-provides-update-and-reports-2016-third-quarter-results-patient-en-plx-20161109monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-doses-first-patient-in-global-phase-iii-clinical-trial-of-prx-102-plx-20161025monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-additional-positive-data-from-its-phase-i-ii-clinical-t-plx-20160810monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-second-quarter-2016-financial-results-patient-screening-u-plx-20160808monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-first-patient-dosed-in-the-air-dnase-tm-phase-ii-clinic-plx-20160707monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-corporate-update-june-2016-this-presentation-contains-forward-loo-plx-20160607monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-initiates-prx-102-global-phase-iii-clinical-trial-of-fabry-diseas-plx-20160606monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-first-quarter-2016-financial-results-and-provides-corpora-plx-20160509monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-fiscal-year-2015-financial-results-and-provides-corporate-plx-20160308monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-presents-positive-six-and-twelve-month-interim-clinical-data-on-p-plx-20160303monthly0.5https://www.biopharmawatch.com/news/PLX/prx-102-prh-galactosidase-a-novel-enzyme-replacement-therapy-for-the-treatment-of-patients-plx-20151123monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-to-conduct-phase-iii-clinical-trial-for-prx-102-for-the-treatment-plx-20151116monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-third-quarter-2015-financial-results-net-losses-narrowed--plx-20151109monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-positive-long-term-data-on-prx-102-for-fabry-disease-sign-plx-20151019monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-sells-its-share-in-collaboration-agreement-for-elelyso-and-a-6-eq-plx-20151013monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-positive-phase-i-ii-interim-clinical-data-on-the-1mg-kg-c-plx-20150909monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-second-quarter-2015-financial-results-net-losses-narrowed-plx-20150810monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-first-quarter-2015-financial-results-losses-narrowed-by-1-plx-20150507monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-full-year-2014-financial-results-and-provides-corporate-u-plx-20150312monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-presents-additional-positive-phase-i-ii-interim-clinical-data-on--plx-20150212monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-completes-enrollment-in-phase-i-ii-clinical-trial-of-prx-102-for--plx-20150202monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reports-positive-interim-data-from-phase-i-ii-clinical-trial-of-p-plx-20150108monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-new-strategy-for-accelerated-growth-prioritizing-pipeli-plx-20150105monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-appoints-moshe-manor-as-president-and-chief-executive-officer-car-plx-20140929monthly0.5https://www.biopharmawatch.com/news/PLX/media-contact-plx-20140828monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-names-shlomo-yanai-as-chairman-of-the-board-of-directors-carmiel--plx-20140724monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-announces-new-data-on-elelyso-taliglucerase-alfa-presented-at-the-european-workin-plx-20140627monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-initiates-phase-ii-study-with-prx-112-an-orally-administered-enzy-plx-20140618monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-president-and-chief-executive-officer-david-aviezer-ph-d-will-ret-plx-20140613monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-announces-elelyso-taliglucerase-alfa-approved-in-canada-for-the-treatment-of-gauc-plx-20140530monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-announces-elelyso-taliglucerase-alfa-approved-in-australia-for-the-treatment-of-g-plx-20140522monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-oral-gcd-data-to-be-presented-at-world-symposium-2014-plx-20140212monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-provides-full-year-2014-strategic-outlook-dr-aviezer-to-present-a-plx-20140113monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-positive-phase-i-clinical-trial-results-for-oral-gcd-in-plx-20131014monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-plx-20130918monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-proposed-60-million-offering-of-convertible-notes-plx-20130911monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-discloses-three-new-compounds-in-development-oral-prx-106-for-imm-plx-20130620monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-and-brazil-s-ministry-of-health-enter-into-supply-and-technology--plx-20130619monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-to-host-analyst-event-in-new-york-city-plx-20130612monthly0.5https://www.biopharmawatch.com/news/PLX/uplyso-alfataliglicerase-approved-in-mexico-and-chile-for-the-treatment-of-gaucher-disease-plx-20130429monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-treats-first-gaucher-patient-in-phase-i-study-with-prx-112-an-ora-plx-20130402monthly0.5https://www.biopharmawatch.com/news/PLX/pfizer-contacts-plx-20130318monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-receives-approval-to-initiate-phase-i-study-in-gaucher-patients-w-plx-20130307monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-announces-new-clinical-data-on-elelyso-to-be-presented-at-the-world-symposium-201-plx-20130213monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-reviewing-partnering-and-other-alternatives-plx-20130205monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-first-patient-treated-in-phase-i-ii-study-of-fabry-pati-plx-20121210monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-signs-clinical-development-agreement-with-pfizer-for-elelyso-tm-t-plx-20121206monthly0.5https://www.biopharmawatch.com/news/PLX/pfizer-contacts-plx-20121101monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-receives-marketing-authorization-for-elelyso-tm-for-the-treatment-plx-20120927monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-receives-fda-ind-clearance-to-initiate-a-phase-i-ii-study-of-fabr-plx-20120813monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-to-present-at-the-canaccord-genuity-32-nd-annual-growth-conferenc-plx-20120809monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-new-clinical-data-on-taliglucerase-alfa-presented-at-th-plx-20120702monthly0.5https://www.biopharmawatch.com/news/PLX/new-clinical-data-on-elelyso-taliglucerase-alfa-to-be-presented-at-the-10-th-annual-europe-plx-20120625monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-to-review-chmp-opinion-for-elelyso-conference-call-and-webcast-sc-plx-20120622monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-receives-a-25-million-milestone-payment-for-u-s-approval-of-elelyso-carmiel-israe-plx-20120611monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-to-present-at-three-upcoming-healthcare-conferences-plx-20120529monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-to-present-at-three-upcoming-healthcare-conferences-plx-20120510monthly0.5https://www.biopharmawatch.com/news/PLX/pfizer-and-protalix-biotherapeutics-announce-plx-20120501monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-sets-record-date-for-annual-meeting-of-shareholders-plx-20120316monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-to-participate-at-two-upcoming-global-healthcare-conferences-plx-20120223monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-the-pricing-of-public-offering-of-common-stock-plx-20120216monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-proposed-public-offering-of-common-stock-plx-20120215monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-announces-new-clinical-data-on-taliglucerase-alfa-to-be-presented-at-the-world-ly-plx-20120209monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-announces-new-clinical-data-on-taliglucerase-alfa-to-be-presented-at-the-world-ly-plx-20120126monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-to-present-at-the-oppenheimer-22nd-annual-healthcare-conference-plx-20111213monthly0.5https://www.biopharmawatch.com/news/PLX/fda-extends-taliglucerase-alfa-pdufa-date-to-plx-20111206monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-announces-successful-european-gmp-audit-plx-20111201monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-s-acetylcholinesterase-demonstrates-potential-role-in-the-treatment-of-parkinson--plx-20111110monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-to-present-at-four-upcoming-conferences-plx-20111026monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-to-present-at-the-jefferies-2011-global-healthcare-conference-plx-20110921monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-to-present-at-the-ubs-global-life-sciences-conference-plx-20110913monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-taliglucerase-alfa-phase-iii-results-published-in-blood-the-journ-plx-20110908monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-fda-accepts-for-review-complete-response-resubmission-f-plx-20110817monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-submits-reply-to-fda-complete-response-letter-for-taliglucerase-alfa-and-reports--plx-20110801monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-announces-successful-gmp-manufacturing-audit-by-brazil-s-national-health-surveill-plx-20110615monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-to-present-at-four-upcoming-healthcare-conferences-plx-20110512monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-to-present-at-the-bio-manguinhos-international-symposium-on-immun-plx-20110427monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-to-present-at-the-tel-aviv-stock-exchange-100-investment-conferen-plx-20110407monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-the-pricing-of-public-offering-of-common-stock-plx-20110318monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-proposed-public-offering-of-common-stock-plx-20110317monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-to-present-new-data-on-taliglucerase-alfa-and-preclinical-data-on-oral-enzyme-glu-plx-20110218monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-january-2011-confidential-note-regarding-forward-looking-statemen-plx-20110127monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-announces-oral-presentations-at-the-world-lysosomal-disease-network-symposium-plx-20110124monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-presents-data-on-the-company-s-fabry-program-and-oral-enzyme-gauc-plx-20110119monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-presentation-of-prx-105-data-at-the-barda-industry-day-plx-20110104monthly0.5https://www.biopharmawatch.com/news/PLX/pfizer-and-protalix-biotherapeutics-announce-submission-of-taliglucerase-alfa-for-european-plx-20101129monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-preliminary-top-line-positive-data-from-taliglucerase-a-plx-20101102monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-to-present-at-two-upcoming-healthcare-conferences-plx-20101025monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-to-present-at-the-ubs-global-life-sciences-conference-plx-20100913monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-names-tzvi-palash-chief-operating-officer-plx-20100907monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-to-dual-list-on-tel-aviv-stock-exchange-common-stock-to-list-on-b-plx-20100830monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-french-atu-granted-for-taliglucerase-alfa-for-the-treat-plx-20100713monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-receives-pdufa-date-for-taliglucerase-alfa-carmiel-israel-july-12-plx-20100712monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-completes-phase-i-clinical-trial-for-prx-105-plx-20100608monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-receives-research-grant-of-up-to-4-1-million-from-the-israeli-gov-plx-20100517monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-submits-validation-data-on-manufacturing-process-to-fda-carmiel-israel-april-27-p-plx-20100427monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-initiates-a-phase-i-clinical-trial-of-acetylcholinesterase-for-biodefense-indicat-plx-20100317monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-appoints-mr-zeev-bronfeld-interim-chairman-of-the-board-of-directors-carmiel-isra-plx-20100309monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-announces-successful-gmp-manufacturing-audit-by-israel-s-ministry-of-health-plx-20100303monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-presents-additional-phase-iii-data-for-taliglucerase-alfa-at-the-world-symposium-plx-20100211monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-announces-presentation-of-phase-iii-taliglucerase-alfa-data-at-world-lysosomal-di-plx-20100204monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-announces-nda-submission-update-for-taliglucerase-alfa-for-the-treatment-of-gauch-plx-20100202monthly0.5https://www.biopharmawatch.com/news/PLX/european-medicines-agency-s-comp-adopts-positive-opinion-for-the-orphan-drug-designation-f-plx-20100113monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-names-sandra-lauterbach-vice-president-of-sales-and-commercial-affairs-plx-20091217monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-completes-nda-submission-for-taliglucerase-alfa-for-the-treatment-of-gaucher-s-di-plx-20091201monthly0.5https://www.biopharmawatch.com/news/PLX/pfizer-contacts-plx-20091201monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-positive-top-line-results-from-its-phase-iii-clinical-t-plx-20091015monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-reports-preclinical-data-on-anti-tnf-follow-on-biologic-arthritis-drug-plx-20090922monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-completes-pivotal-phase-iii-trial-for-prgcd-for-the-treatment-of-gaucher-disease--plx-20090914monthly0.5https://www.biopharmawatch.com/news/PLX/fda-grants-protalix-orphan-drug-designation-for-prgcd-plx-20090908monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-receives-fda-fast-track-designation-for-prgcd-plx-20090825monthly0.5https://www.biopharmawatch.com/news/PLX/u-s-food-and-drug-administration-approves-protalix-s-treatment-protocol-for-prgcd-plx-20090817monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-holds-pre-nda-meeting-with-fda-for-prgcd-plx-20090714monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-approached-by-the-fda-to-consider-submitting-a-treatment-protocol-for-the-use-of--plx-20090706monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-initiates-a-home-care-treatment-program-for-gaucher-patients-in-the-phase-iii-ext-plx-20090625monthly0.5https://www.biopharmawatch.com/news/PLX/frost-sullivan-presents-protalix-biotherapeutics-with-its-2009-european-orphan-diseases-ma-plx-20090604monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-to-present-at-three-upcoming-healthcare-conferences-plx-20090601monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-receives-research-grant-of-over-6-million-from-the-israeli-govern-plx-20090311monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-to-present-at-the-world-lysosomal-disease-network-symposium-2009-plx-20090213monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-announces-first-patient-enrolled-in-open-label-switchover-trial-o-plx-20081219monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-to-present-at-the-piper-jaffray-20th-annual-health-care-conferenc-plx-20081125monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-to-present-at-to-present-at-oppenheimer-annual-healthcare-confere-plx-20081028monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-to-present-at-the-ubs-global-life-sciences-conference-plx-20080917monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-sets-record-date-for-annual-meeting-of-shareholders-plx-20080908monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-to-present-at-the-oppenheimer-small-and-mid-cap-clinical-and-regu-plx-20080731monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-to-present-at-ubs-global-life-sciences-conference-plx-20070919monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-added-to-russell-3000-index-carmiel-israel-plx-20070626monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-plans-to-offer-common-stock-to-the-public-carmiel-israel-plx-20070620monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-appoints-dr-ernest-beutler-to-its-scientific-advisory-board-carmi-plx-20070604monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-to-present-at-the-bio-international-convention-on-plx-20070507monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-inc-receives-approval-from-the-fda-to-initiate-a-phase-iii-clinic-plx-20070418monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-inc-to-commence-trading-on-the-american-stock-exchange-shares-to--plx-20070309monthly0.5https://www.biopharmawatch.com/news/PLX/orthodontix-announces-name-change-to-protalix-biotherapeutics-inc-carmiel-israel-plx-20070301monthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-reports-positive-enabling-data-supporting-advancement-of-oral-an2-502998--antx-20260604monthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-reports-third-quarter-2025-financial-results-and-recent-business-and-scie-antx-20251112monthly0.5https://www.biopharmawatch.com/news/ANTX/investor-overview-june-2025-a-n-2-t-h-e-r-a-p-e-u-t-i-c-s-c-o-m-forward-looking-statements-antx-20250611monthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-reports-data-from-the-phase-3-portion-of-previously-terminated-ebo-301-st-antx-20250501monthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-bu-antx-20250325monthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-reports-third-quarter-2024-financial-results-provides-important-ebo-301-u-antx-20241113monthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-adopts-limited-duration-stockholder-rights-plan-antx-20240816monthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-reports-second-quarter-2024-financial-results-and-recent-business-and-sci-antx-20240813monthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-provides-update-on-ebo-301-phase-2-3-study-evaluating-epetraborole-for-tr-antx-20240808monthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-reports-first-quarter-2024-financial-results-and-recent-business-and-scie-antx-20240514monthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-recent-bu-antx-20240328monthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-reports-third-quarter-2023-financial-results-and-recent-business-and-scie-antx-20231109monthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-commences-phase-3-part-of-phase-2-3-clinical-trial-evaluating-epetraborol-antx-20230913monthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-announces-pricing-of-70-0-million-underwritten-offering-of-common-stock-m-antx-20230815monthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-reports-second-quarter-2023-financial-results-and-recent-highlights-suffi-antx-20230810monthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-reports-first-quarter-2023-financial-results-and-recent-highlights-x2022--antx-20230511monthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-recent-hi-antx-20230329monthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-reports-third-quarter-2022-financial-results-and-provides-business-update-antx-20221109monthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-provides-update-on-epetraborole-ex-u-s-development-plan-in-treatment-refr-antx-20221006monthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-reports-second-quarter-2022-financial-results-and-provides-business-updat-antx-20220811monthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-initiates-pivotal-phase-2-3-trial-evaluating-epetraborole-for-treatment-r-antx-20220629monthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-reports-first-quarter-2022-financial-results-and-provides-business-update-antx-20220510monthly0.5https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-appoints-maggie-fitzpatrick-to-its-board-of-directors-menlo-park-ca-antx-20220509monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-galt-20260515monthly0.5https://www.biopharmawatch.com/news/GALT/thanks-kevin-since-i-became-president-and-ceo-of-galectin-therapeutics-i-can-honestly-say--galt-20251203monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-financial-results-for-the-quarter-ended-galt-20251114monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeuticscorporate-overviewseptember-2025-2-this-presentation-contains-in-addi-galt-20250908monthly0.5https://www.biopharmawatch.com/news/GALT/belapectin-for-mash-cirrhosis-and-portal-hypertension-june-2025-khurram-today-s-agenda-01--galt-20250616monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-2024-financial-results-and-provides-business-update-norcross-galt-20250515monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeuticscorporate-overviewmay-2025-2-this-presentation-contains-in-addition-t-galt-20250512monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-2024-financial-results-and-provides-business-update-norcross-galt-20250331monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeuticscorporate-overviewfebruary-2025-2-this-presentation-contains-in-addit-galt-20250305monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-significant-reduction-in-new-varices-with-belapectin-in-u-s--galt-20250218monthly0.5https://www.biopharmawatch.com/news/GALT/thank-you-kevin-and-thank-you-to-everyone-for-joining-the-call-this-morning-please-note-th-galt-20250123monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeuticscorporate-overviewjanuary-2025-2-this-presentation-contains-in-additi-galt-20250113monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-top-line-results-of-navigate-clinical-trial-evaluating-bel-galt-20241220monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeuticscorporate-overviewnovember-2024-2-this-presentation-contains-in-addit-galt-20241114monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-financial-results-for-the-quarter-ended-galt-20241114monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeuticscorporate-overviewaugust-2024-2-this-presentation-contains-in-additio-galt-20240909monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-financial-results-for-the-quarter-ended-galt-20240813monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-appoints-khurram-jamil-m-d-to-chief-medical-officer-norcross-ga-galt-20240801monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-financial-results-for-the-quarter-ended-galt-20240515monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-2023-financial-results-and-provides-business-update-norcross-galt-20240329monthly0.5https://www.biopharmawatch.com/news/GALT/thanks-kevin-and-thank-you-to-everyone-joining-us-today-please-note-that-certain-statement-galt-20231207monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-financial-results-for-the-quarter-ended-galt-20231113monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-financial-results-for-the-quarter-ended-galt-20230814monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-financial-results-for-the-quarter-ended-galt-20230515monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-2022-financial-results-and-provides-business-update-norcross-galt-20230330monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-provides-final-randomization-status-of-navigate-its-seamless-adaptiv-galt-20230302monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-the-end-of-enrollment-of-navigate-its-seamless-adaptive-ph-galt-20230105monthly0.5https://www.biopharmawatch.com/news/GALT/thanks-kevin-and-thank-you-to-everyone-joining-us-today-out-of-an-abundance-of-caution-man-galt-20221201monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-financial-results-for-the-quarter-ended-galt-20221114monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-receives-fda-approval-to-proceed-with-combination-immunotherapy-tria-galt-20221012monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-the-positive-outcome-of-the-second-data-and-safety-monitorin-galt-20221006monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-financial-results-for-the-quarter-ended-galt-20220815monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-60-million-credit-line-from-richard-e-uihlein-sufficient-t-galt-20220726monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-financial-results-for-the-quarter-ended-galt-20220516monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-the-positive-outcome-of-the-first-data-and-safety-monitoring-galt-20220414monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-2021-financial-results-and-provides-business-update-norcross-galt-20220331monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-closing-of-10-million-in-debt-financing-from-its-chairman--galt-20211221monthly0.5https://www.biopharmawatch.com/news/GALT/thanks-kevin-and-thank-you-to-everyone-joining-us-virtually-today-unfortunately-we-are-sti-galt-20211203monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-financial-results-for-the-quarter-ended-galt-20211115monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-20-million-convertible-debt-financing-from-its-chairman-ri-galt-20210921monthly0.5https://www.biopharmawatch.com/news/GALT/this-presentation-contains-in-addition-to-historical-information-forward-looking-statement-galt-20210913monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-financial-results-for-the-quarter-ended-galt-20210816monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-positive-top-line-results-from-a-phase-1b-clinical-trial-e-galt-20210709monthly0.5https://www.biopharmawatch.com/news/GALT/d-r-a-f-t-galectin-therapeutics-reports-financial-results-for-the-quarter-ended-galt-20210517monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-fiscal-2020-financial-results-and-provides-business-update-n-galt-20210331monthly0.5https://www.biopharmawatch.com/news/GALT/this-presentation-contains-in-addition-to-historical-information-forward-looking-statement-galt-20210309monthly0.5https://www.biopharmawatch.com/news/GALT/thanks-kevin-i-want-to-thank-jack-and-beth-for-putting-together-our-virtual-annual-meeting-galt-20201203monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-provides-business-update-and-reports-financial-results-for-the-quart-galt-20201109monthly0.5https://www.biopharmawatch.com/news/GALT/this-presentation-contains-in-addition-to-historical-information-forward-looking-statement-galt-20200929monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-investor-conference-call-and-webinar-on-galt-20200922monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-appoints-joel-lewis-as-chief-executive-officer-dr-harold-shlevin-ret-galt-20200902monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-financial-results-for-the-quarter-ended-galt-20200810monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-commencement-of-patient-enrollment-of-the-adaptively-desig-galt-20200630monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-financial-results-for-the-quarter-ended-galt-20200511monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-submits-seamless-adaptively-designed-phase-2b-3-nash-rx-protocol-in--galt-20200430monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-fiscal-2019-financial-results-and-provides-business-update-a-galt-20200316monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-appoints-seasoned-biopharmaceutical-executive-pol-f-boudes-m-d-as-ch-galt-20200220monthly0.5https://www.biopharmawatch.com/news/GALT/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-galt-20191204monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-webcast-corporate-update-on-galt-20191126monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-q3-2019-financial-results-provides-update-on-nash-rx-trial-p-galt-20191112monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-inc-and-providence-cancer-institute-receive-patent-on-the-use-of-bel-galt-20190917monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-q2-2019-financial-results-and-provides-business-update-norcr-galt-20190809monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-submits-phase-3-nash-rx-protocol-in-nash-cirrhosis-to-fda-norcross-g-galt-20190805monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-raises-44-5-million-in-rights-offering-and-2-5-million-from-warrant--galt-20190528monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-releases-richard-e-uihlein-s-open-letter-to-stockholders-dated-galt-20190510monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-inc-announces-record-date-subscription-pricing-galt-20190415monthly0.5https://www.biopharmawatch.com/news/GALT/this-presentation-contains-in-addition-to-historical-information-forward-looking-statement-galt-20190321monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-releases-richard-e-uihlein-s-open-letter-to-stockholders-norcross-ga-galt-20190306monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-files-registration-statement-for-stockholder-rights-offering-of-comm-galt-20190306monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-fiscal-2018-financial-results-and-provides-business-update-p-galt-20190306monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-largest-institutional-shareholder-converts-existing-series-b-preferr-galt-20190115monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-extension-of-10-million-line-credit-norcross-ga-galt-20181220monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-2018-third-quarter-financial-results-and-provides-business-u-galt-20181113monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-inc-announces-positive-preliminary-results-from-phase-1b-clinical-tr-galt-20180920monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-2018-second-quarter-financial-results-and-provides-business--galt-20180814monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-inc-announces-new-galt-20180612monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-proceeds-to-phase-3-development-of-gr-md-02-for-nash-cirrhosis-follo-galt-20180514monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-2018-first-quarter-financial-results-and-provides-business-u-galt-20180511monthly0.5https://www.biopharmawatch.com/news/GALT/rationale-for-galectin-3-inhibition-in-nash-gal-3-is-a-lectin-protein-that-binds-to-galact-galt-20180416monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-2017-financial-results-and-provides-business-update-norcross-galt-20180329monthly0.5https://www.biopharmawatch.com/news/GALT/this-presentation-contains-in-addition-to-historical-information-forward-looking-statement-galt-20180206monthly0.5https://www.biopharmawatch.com/news/GALT/forward-looking-statements-this-presentation-contains-in-addition-to-historical-informatio-galt-20180104monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-10-million-credit-line-from-richard-e-uihlein-sufficient-t-galt-20171219monthly0.5https://www.biopharmawatch.com/news/GALT/forward-looking-statements-this-presentation-contains-in-addition-to-historical-informatio-galt-20171205monthly0.5https://www.biopharmawatch.com/news/GALT/combination-immunotherapy-of-pembrolizumab-with-the-galectin-3-inhibitor-gr-md-02-shows-pr-galt-20171113monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-2017-third-quarter-financial-results-and-provides-business-u-galt-20171107monthly0.5https://www.biopharmawatch.com/news/GALT/clarification-galectin-therapeutics-reports-2017-second-quarter-financial-results-and-prov-galt-20170818monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-2017-second-quarter-financial-results-and-provides-business--galt-20170814monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-2017-first-quarter-financial-results-and-provides-business-u-galt-20170515monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-2016-financial-results-and-provides-business-update-norcross-galt-20170328monthly0.5https://www.biopharmawatch.com/news/GALT/gr-md-02-demonstrates-clinically-significant-effect-in-patients-with-severe-and-refractory-galt-20170314monthly0.5https://www.biopharmawatch.com/news/GALT/combination-immunotherapy-with-galectin-3-inhibitor-gr-md-02-enhances-effects-in-pre-clini-galt-20170207monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-nasdaq-galt-this-presentation-contains-in-addition-to-historical-inf-galt-20170202monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-achievement-of-key-milestones-related-to-nash-cx-clinical--galt-20170201monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-4-million-in-new-equity-financings-common-and-preferred-pr-galt-20161229monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-positive-new-psoriasis-and-atopic-dermatitis-clinical-data-galt-20161110monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-third-quarter-2016-financial-results-and-provides-business-u-galt-20161108monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-top-line-data-from-exploratory-phase-2a-pilot-trial-nash-f-galt-20160927monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-results-from-12-week-extension-of-phase-2a-psoriasis-clini-galt-20160825monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-second-quarter-2016-financial-results-and-provides-business--galt-20160809monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-completion-of-patient-recruitment-in-its-phase-2-trial-wit-galt-20160802monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-positive-interim-results-from-phase-2a-trial-with-gr-md-02-galt-20160516monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-complete-enrollment-in-its-phase-2-trial-with-gr-md-02-in--galt-20160511monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-first-quarter-2016-financial-results-and-provides-business-u-galt-20160510monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-2015-financial-results-and-provides-business-update-conferen-galt-20160315monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-appoints-dr-marc-rubin-chairman-of-the-board-of-directors-norcross-g-galt-20160108monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-posts-2015-2016-progress-and-possibilities-to-corporate-website-norc-galt-20160107monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-dismissals-of-federal-securities-class-action-and-sharehol-galt-20160105monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-pricing-of-9-8-million-registered-direct-offering-norcross-galt-20151120monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-third-quarter-2015-financial-results-and-provides-business-u-galt-20151109monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-gr-md-02-to-be-studied-in-combination-with-keytruda-in-patients-with-galt-20151019monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-start-of-phase-2-clinical-trial-with-gr-md-02-in-nash-with-galt-20150916monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-nasdaq-galt-this-presentation-contains-in-addition-to-historical-inf-galt-20150910monthly0.5https://www.biopharmawatch.com/news/GALT/clinical-trial-to-establish-efficacy-of-gr-md-02-in-nash-cirrhosis-in-late-june-2015-galec-galt-20150902monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-provides-phase-2-nash-program-update-and-reports-second-quarter-2015-galt-20150810monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-no-drug-drug-interaction-between-gr-md-02-and-midazolam-phas-galt-20150514monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-nasdaq-galt-this-presentation-contains-in-addition-to-historical-inf-galt-20150511monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-first-quarter-2015-financial-results-provides-business-updat-galt-20150511monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-2014-financial-results-provides-business-update-norcross-ga-galt-20150318monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-engages-ppd-to-conduct-gr-md-02-phase-2-trial-in-nash-submits-specia-galt-20150312monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-nasdaq-galt-this-presentation-contains-in-addition-to-historical-inf-galt-20150224monthly0.5https://www.biopharmawatch.com/news/GALT/final-draft-february-23-2015-galectin-therapeutics-announces-details-of-the-design-of-its--galt-20150224monthly0.5https://www.biopharmawatch.com/news/GALT/final-draft-2-january-6-2015-final-phase-1-trial-results-demonstrate-galectin-therapeutics-galt-20150107monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-nasdaq-galt-forward-looking-statements-this-presentation-contains-in-galt-20150107monthly0.5https://www.biopharmawatch.com/news/GALT/author-disclosures-stephen-a-harrison-advisory-committees-or-review-panels-merck-nimbus-di-galt-20141110monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-third-quarter-2014-financial-results-and-provides-update-on--galt-20141110monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-issuance-of-u-s-patent-for-gr-md-02-in-diabetic-nephropath-galt-20140915monthly0.5https://www.biopharmawatch.com/news/GALT/forward-looking-statement-disclaimer-2-2014-galectin-therapeutics-nasdaq-galt-this-present-galt-20140912monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-second-quarter-2014-financial-results-norcross-ga-galt-20140807monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-receives-u-s-patent-for-gr-md-02-composition-of-matter-patent-covers-galt-20140805monthly0.5https://www.biopharmawatch.com/news/GALT/forward-looking-statement-this-presentation-contains-in-addition-to-historical-information-galt-20140729monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-first-patient-dosed-in-cohort-1-of-phase-1b-clinical-trial-galt-20140722monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-receives-u-s-patent-for-gr-md-02-in-diabetic-nephropathy-a-progressi-galt-20140528monthly0.5https://www.biopharmawatch.com/news/GALT/forward-looking-statement-disclaimer-this-presentation-contains-in-addition-to-historical--galt-20140514monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-first-quarter-2014-financial-results-norcross-ga-galt-20140513monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-hold-conference-call-to-provide-corporate-update-following-compan-galt-20140508monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-completes-enrollment-of-second-cohort-of-phase-1-trial-of-galt-20140423monthly0.5https://www.biopharmawatch.com/news/GALT/forward-looking-statement-this-presentation-contains-in-addition-to-historical-information-galt-20140331monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-announce-results-from-first-cohort-of-phase-1-clinical-trial-in-f-galt-20140325monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-2013-financial-results-norcross-ga-galt-20140321monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-secures-u-s-patent-for-its-proprietary-galectin-inhibitor-gr-md-02-i-galt-20140226monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-ceo-serves-on-cancer-immunotherapy-panel-at-bio-ceo-investor-confere-galt-20140213monthly0.5https://www.biopharmawatch.com/news/GALT/forward-looking-statements-this-presentation-contains-in-addition-to-historical-informatio-galt-20140207monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-present-at-16-th-annual-bio-ceo-investor-conference-norcross-ga-galt-20140205monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-and-providence-portland-medical-center-receive-ok-from-fda-to-procee-galt-20140203monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-inc-and-sbh-sciences-inc-announce-the-formation-of-galectin-sciences-galt-20140127monthly0.5https://www.biopharmawatch.com/news/GALT/preclinical-study-demonstrates-effect-of-galectin-inhibitor-on-serum-biomarker-in-fatty-li-galt-20140121monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-supports-investigational-new-drug-ind-application-for-its-galectin-i-galt-20140115monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-completion-of-enrollment-in-first-cohort-of-phase-1-trial--galt-20140113monthly0.5https://www.biopharmawatch.com/news/GALT/corporate-presentation-january-2014-nasdaq-galt-2014-galectin-therapeutics-www-galectinthe-galt-20140109monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-update-on-financing-activities-and-cash-of-32-3-million-no-galt-20140110monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-on-key-2013-scientific-development-and-regulatory-milestones-galt-20140108monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-receives-us-patent-for-combination-treatment-for-liver-fibrosis-norc-galt-20140106monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-update-on-enrollment-of-first-cohort-of-phase-1-clinical-tri-galt-20131112monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-early-warrant-exercise-by-10x-fund-provides-update-on-cash-galt-20131017monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-preclinical-data-published-in-plos-one-show-its-galectin-inhibitors--galt-20131010monthly0.5https://www.biopharmawatch.com/news/GALT/forward-looking-statements-this-presentation-contains-in-addition-to-historical-informatio-galt-20130920monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-leadership-to-present-at-three-upcoming-conferences-norcross-ga-galt-20130923monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-receives-us-patent-for-potential-ground-breaking-treatment-for-fatty-galt-20130910monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-update-on-warrant-exercises-norcross-ga-galt-20130828monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-3-million-private-placement-of-restricted-stock-norcross-g-galt-20130821monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-second-quarter-2013-financial-results-norcross-ga-galt-20130814monthly0.5https://www.biopharmawatch.com/news/GALT/final-for-release-monday-galt-20130812monthly0.5https://www.biopharmawatch.com/news/GALT/reduction-in-lung-fibrosis-with-the-anti-galectin-drug-gr-md-02-revealed-in-preclinical-da-galt-20130805monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-first-patient-dosed-in-phase-1-trial-of-gr-md-02-a-potenti-galt-20130724monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-submits-fast-track-application-to-fda-for-gr-md-02-in-treatment-of-f-galt-20130701monthly0.5https://www.biopharmawatch.com/news/GALT/tumor-immunotherapy-efficacy-increased-in-both-breast-and-prostate-cancer-preclinical-mode-galt-20130612monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-hold-conference-call-to-provide-update-following-company-s-annual-galt-20130523monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-to-hold-conference-call-to-provide-update-following-company-s-annual-galt-20130515monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-first-quarter-2013-financial-results-norcross-ga-galt-20130510monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-inhibitors-reverse-liver-cirrhosis-in-preclinical-studies-galectin-therapeutics-a-galt-20130429monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-full-year-and-fourth-quarter-2012-financial-results-norcross-galt-20130329monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-corporate-summary-galt-20130311monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-inc-for-immediate-release-galectin-therapeutics-inc-receives-ok-from-galt-20130305monthly0.5https://www.biopharmawatch.com/news/GALT/forward-looking-statements-this-presentation-contains-in-addition-to-historical-informatio-galt-20130205monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-inc-announces-submission-of-an-investigational-new-drug-ind-applicat-galt-20130131monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-presents-new-data-on-the-treatment-of-fatty-liver-disease-and-fibros-galt-20121112monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-third-quarter-2012-financial-results-norcross-ga-galt-20121109monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-appoints-harold-h-shlevin-phd-bioscience-industry-executive-as-chief-galt-20120829monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-second-quarter-2012-financial-results-newton-mass-galt-20120810monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-first-quarter-2012-financial-results-newton-mass-galt-20120511monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-announces-long-term-engagement-of-dr-scott-friedman-to-advise-on-liv-galt-20120501monthly0.5https://www.biopharmawatch.com/news/GALT/forward-looking-statements-this-presentation-contains-in-addition-to-historical-informatio-galt-20120411monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-reports-full-year-and-fourth-quarter-2011-financial-results-newton-m-galt-20120330monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-inc-announces-pricing-of-public-offering-of-1-159-445-units-listing--galt-20120322monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-inc-appoints-thomas-a-mcgauley-as-acting-chief-financial-officer-and-galt-20120305monthly0.5https://www.biopharmawatch.com/news/GALT/forward-looking-statements-this-presentation-contains-in-addition-to-historical-informatio-galt-20120214monthly0.5https://www.biopharmawatch.com/news/GALT/forward-looking-statements-this-presentation-contains-in-addition-to-historical-informatio-galt-20120109monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-provides-corporate-update-newton-ma-galt-20111219monthly0.5https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-elects-dr-marc-rubin-to-its-board-of-directors-newton-ma-galt-20111012monthly0.5https://www.biopharmawatch.com/news/GALT/forward-looking-statements-this-presentation-contains-in-addition-to-historical-informatio-galt-20110920monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-announces-enrollment-in-phase-2-seabreeze-stat-studies-will-continue-as--cntb-20260423monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-s-exclusive-licensee-in-china-simcere-pharmaceutical-announced-submissio-cntb-20250709monthly0.5https://www.biopharmawatch.com/news/CNTB/product-candidates-if-approved-by-physicians-patients-healthcare-payors-and-others-in-the--cntb-20250514monthly0.5https://www.biopharmawatch.com/news/CNTB/existing-patent-terms-where-available-our-continued-reliance-on-third-parties-to-conduct-a-cntb-20250513monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-pric-cntb-20250328monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-announces-positive-rademikibart-global-phase-2b-topline-results-in-adult-cntb-20231212monthly0.5https://www.biopharmawatch.com/news/CNTB/exclusive-license-and-collaboration-agreement-by-and-between-connect-biopharma-hongkong-li-cntb-20231121monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-reports-first-half-2023-financial-results-and-provides-business-update-x-cntb-20230912monthly0.5https://www.biopharmawatch.com/news/CNTB/house-lease-contract-lessor-taicang-science-and-technology-venture-park-co-ltd-hereinafter-cntb-20230623monthly0.5https://www.biopharmawatch.com/news/CNTB/corporate-presentation-june-2023-nasdaq-cntb-developing-next-generation-therapeutics-for-t-cntb-20230605monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-announces-positive-long-term-data-from-the-maintenance-period-through-we-cntb-20230601monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-reports-full-year-2022-financial-results-and-provides-business-update-cd-cntb-20230411monthly0.5https://www.biopharmawatch.com/news/CNTB/view-source-version-on-businesswire-com-https-www-businesswire-com-news-home-2023031700507-cntb-20230321monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-reports-cbp-201-global-phase-2-asthma-trial-achieves-full-enrollment-san-cntb-20230209monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-provides-business-and-clinical-development-program-update-cash-runway-no-cntb-20221230monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-reports-first-half-2022-financial-results-and-provides-business-update-x-cntb-20220913monthly0.5https://www.biopharmawatch.com/news/CNTB/forward-looking-statements-this-presentation-regarding-connect-biopharma-holdings-limited--cntb-20220610monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-announces-week-12-top-line-results-from-phase-2-cbp-307-trial-in-patient-cntb-20220503monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-reports-full-year-2021-financial-results-and-provides-business-update-gl-cntb-20220331monthly0.5https://www.biopharmawatch.com/news/CNTB/forward-looking-statements-this-presentation-regarding-connect-biopharma-holdings-limited--cntb-20220216monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-reports-detailed-positive-dataset-from-the-global-phase-2b-trial-of-cbp--cntb-20220105monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-completes-enrollment-of-cbp-307-global-phase-2-clinical-trial-in-moderat-cntb-20211119monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-reports-positive-top-line-results-from-the-global-phase-2-clinical-trial-cntb-20211118monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-announces-first-subject-dosed-in-phase-2-trial-evaluating-cbp-201-in-adu-cntb-20210908monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-announces-first-patient-dosed-in-china-pivotal-trial-evaluating-cbp-201--cntb-20210902monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-holdings-limited-index-to-the-unaudited-interim-condensed-consolidated-f-cntb-20210831monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-announces-first-subject-dosed-in-phase-i-trial-evaluating-safety-tolerab-cntb-20210525monthly0.5https://www.biopharmawatch.com/news/CNTB/connect-biopharma-announces-first-patient-dosed-in-phase-2-trial-evaluating-cbp-201-in-adu-cntb-20210512monthly0.5https://www.biopharmawatch.com/news/HRTX/u-s-district-court-issues-decision-regarding-cinvanti-patents-x2014-after-reviewing-the-ru-hrtx-20260602monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-first-quarter-2026-financial-results-and-reaffirms-guidance-q-hrtx-20260511monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-zynrelef--hrtx-20260226monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-preliminary-unaudited-q4-and-full-year-2025-net-revenue-zynre-hrtx-20260109monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-q3-2025-financial-results-and-highlights-commercial-progress--hrtx-20251104monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors-cary-n-c-hrtx-20251029monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-corporate-headquarters-relocation-to-cary-north-carolina-hrtx-20241223monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-third-quarter-2024-financial-results-and-narrows-financial-gu-hrtx-20241112monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-appointment-of-michael-kaseta-to-board-of-directors-hrtx-20241104monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-second-quarter-2024-financial-results-and-narrows-financial-g-hrtx-20240806monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-acceptance-of-the-prior-approval-supplement-application-for-z-hrtx-20240702monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-prior-approval-supplement-submission-to-the-fda-for-zynrelef--hrtx-20240529monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-first-quarter-2024-financial-results-and-highlights-recent-co-hrtx-20240507monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-fourth-quarter-and-full-year-2023-financial-results-and-highl-hrtx-20240312monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-fda-approval-of-zynrelef-indication-expansion-to-include-addi-hrtx-20240123monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-partnership-with-crosslink-life-sciences-to-expand-promotiona-hrtx-20240107monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-third-quarter-2023-financial-results-and-updates-financial-gu-hrtx-20231114monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-second-quarter-2023-financial-results-and-provides-corporate--hrtx-20230814monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-30-million-private-placement-financing-hrtx-20230724monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-appointment-of-william-forbes-pharm-d-as-chief-development-of-hrtx-20230612monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-financial-results-for-the-three-months-ended-hrtx-20230511monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-commercial-leadership-changes-hrtx-20230420monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-new-ceo-and-board-chairman-craig-collard-appointed-ceo-adam-m-hrtx-20230403monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-financial-results-for-the-three-and-twelve-months-ended-hrtx-20230323monthly0.5https://www.biopharmawatch.com/news/HRTX/forward-looking-statements-this-news-release-contains-forward-looking-statements-as-define-hrtx-20230313monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-u-s-commercial-launch-of-aponvie-tm-for-the-management-of-pos-hrtx-20230306monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-enters-into-cooperation-agreement-with-rubric-capital-and-velan-capital-hrtx-20230222monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-highlights-progress-in-acute-care-and-oncology-care-franchises-prelimin-hrtx-20230109monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-filing-of-an-efficacy-supplement-for-zynrelef-and-provision-i-hrtx-20221229monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-financial-results-for-the-three-and-nine-months-ended-hrtx-20221108monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-u-s-fda-approval-of-aponvie-tm-htx-019-for-the-prevention-of--hrtx-20220916monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-financial-results-for-the-three-and-six-months-ended-hrtx-20220809monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-publication-showing-zynrelef-as-the-foundation-of-a-periopera-hrtx-20220614monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-financial-results-for-the-three-months-ended-hrtx-20220509monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-secures-pass-through-payment-status-for-zynrelef-from-centers-for-medic-hrtx-20220325monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-approval-of-zynrelef-by-health-canada-for-the-management-of-p-hrtx-20220317monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-financial-results-for-the-three-and-twelve-months-ended-hrtx-20220228monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-fda-approval-of-a-significant-indication-expansion-for-zynrel-hrtx-20211209monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-submission-of-htx-019-nda-for-the-prevention-of-postoperative-hrtx-20211118monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-financial-results-for-the-three-and-nine-months-ended-hrtx-20211103monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-filing-of-a-supplemental-new-drug-application-for-significant-hrtx-20211004monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-financial-results-for-the-three-and-six-months-ended-hrtx-20210809monthly0.5https://www.biopharmawatch.com/news/HRTX/this-presentation-contains-forward-looking-statements-as-defined-by-the-private-securities-hrtx-20210513monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-financial-results-for-the-three-months-ended-hrtx-20210510monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-financial-results-for-the-three-and-twelve-months-ended-hrtx-20210224monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-publication-of-results-from-epoch-1-follow-on-study-of-htx-01-hrtx-20210121monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-highlights-progress-in-pain-management-and-cinv-franchises-and-announce-hrtx-20210111monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-resubmits-new-drug-application-to-fda-for-htx-011-for-the-treatment-of--hrtx-20201113monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-financial-results-for-the-three-and-nine-months-ended-hrtx-20201105monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-receives-european-commission-authorization-for-zynrelef-tm-htx-011-for--hrtx-20200928monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-publication-of-results-from-epoch-2-follow-on-study-a-phase-2-hrtx-20200916monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-successful-outcome-of-fda-type-a-meeting-to-discuss-htx-011-f-hrtx-20200908monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-financial-results-for-the-three-and-six-months-ended-hrtx-20200805monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-receives-positive-chmp-opinion-for-zynrelef-htx-011-for-the-management--hrtx-20200724monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-initiation-of-phase-2-clinical-study-of-cinvanti-for-the-trea-hrtx-20200716monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-receives-complete-response-letter-for-htx-011-for-the-management-of-pos-hrtx-20200629monthly0.5https://www.biopharmawatch.com/news/HRTX/about-heron-therapeutics-inc-heron-therapeutics-inc-is-a-commercial-stage-biotechnology-co-hrtx-20200604monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-initiation-of-phase-1b-2-clinical-study-of-htx-034-for-the-tr-hrtx-20200518monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-financial-results-for-the-three-months-ended-hrtx-20200506monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-financial-results-for-the-three-and-twelve-months-ended-hrtx-20200302monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-fda-extension-of-review-period-for-nda-for-htx-011-for-the-ma-hrtx-20200219monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-highlights-progress-in-pain-management-and-cinv-franchises-marketing-ap-hrtx-20191231monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-publication-of-the-mechanism-of-action-data-for-htx-011-a-d-u-hrtx-20191216monthly0.5https://www.biopharmawatch.com/news/HRTX/health-canada-grants-priority-review-status-for-heron-therapeutics-new-drug-submission-for-hrtx-20191203monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-financial-results-for-the-three-and-nine-months-ended-hrtx-20191112monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-fda-acceptance-of-new-drug-application-resubmission-for-htx-0-hrtx-20191028monthly0.5https://www.biopharmawatch.com/news/HRTX/forward-looking-statements-this-news-release-contains-forward-looking-statements-as-define-hrtx-20191022monthly0.5https://www.biopharmawatch.com/news/HRTX/forward-looking-statements-this-news-release-contains-forward-looking-statements-as-define-hrtx-20191002monthly0.5https://www.biopharmawatch.com/news/HRTX/statements-reflect-our-analysis-only-on-their-stated-date-and-heron-takes-no-obligation-to-hrtx-20191001monthly0.5https://www.biopharmawatch.com/news/HRTX/except-as-may-be-required-by-law-investor-relations-and-media-contact-david-szekeres-senio-hrtx-20191001monthly0.5https://www.biopharmawatch.com/news/HRTX/about-heron-therapeutics-inc-heron-therapeutics-inc-is-a-commercial-stage-biotechnology-co-hrtx-20191001monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-publication-of-results-from-epoch-2-a-phase-3-study-of-htx-01-hrtx-20190820monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-financial-results-for-the-three-and-six-months-ended-hrtx-20190805monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-publication-of-results-from-phase-3-epoch-1-study-of-htx-011--hrtx-20190521monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-presents-new-results-from-real-world-study-showing-95-of-postoperative--hrtx-20190514monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-financial-results-for-the-three-months-ended-hrtx-20190509monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-receives-complete-response-letter-for-htx-011-for-the-management-of-pos-hrtx-20190501monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-announces-european-medicines-agency-validation-of-marketing-authorisation-applicatio-hrtx-20190401monthly0.5https://www.biopharmawatch.com/news/HRTX/of-patients-remain-opioid-free-when-htx-011-is-given-with-an-over-the-counter-analgesic-re-hrtx-20190311monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-announces-fda-approval-of-supplemental-new-drug-application-to-expand-cinvanti-label-hrtx-20190226monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-financial-results-for-the-three-and-twelve-months-ended-hrtx-20190222monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-highlights-progress-in-pain-management-and-cinv-franchises-acceptance-o-hrtx-20190107monthly0.5https://www.biopharmawatch.com/news/HRTX/of-patients-remain-opioid-free-when-htx-011-is-given-with-an-over-the-counter-analgesic-re-hrtx-20190103monthly0.5https://www.biopharmawatch.com/news/HRTX/fda-grants-priority-review-designation-for-heron-therapeutics-nda-for-htx-011-a-non-opioid-hrtx-20181231monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-financial-results-for-the-three-and-nine-months-ended-hrtx-20181107monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-financial-results-for-the-three-and-six-months-ended-hrtx-20180808monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-announces-positive-topline-results-from-phase-2b-clinical-studies-of-htx-011-in-tota-hrtx-20180621monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-announces-positive-topline-results-from-pivotal-phase-3-clinical-trials-of-htx-011-i-hrtx-20180319monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-highlights-progress-in-cinv-and-pain-management-franchises-sustol-fourt-hrtx-20180108monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-u-s-fda-approval-of-cinvanti-tm-aprepitant-injectable-emulsio-hrtx-20171109monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-initiation-of-phase-3-program-for-htx-011-in-postoperative-pa-hrtx-20170809monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-positive-topline-results-from-phase-2-clinical-trial-of-htx-0-hrtx-20170105monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-u-s-fda-approval-of-sustol-granisetron-extended-release-injec-hrtx-20160810monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-reports-positive-top-line-results-from-phase-2-studies-of-htx-011-for-m-hrtx-20160801monthly0.5https://www.biopharmawatch.com/news/HRTX/legal-disclaimer-this-presentation-contains-forward-looking-statements-as-defined-by-the-p-hrtx-20160111monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-reports-positive-top-line-results-from-phase-2-study-of-htx-011-in-the--hrtx-20150922monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-positive-results-from-phase-3-magic-study-of-sustol-primary-e-hrtx-20150528monthly0.5https://www.biopharmawatch.com/news/HRTX/legal-disclaimer-this-presentation-contains-forward-looking-statements-as-defined-by-the-p-hrtx-20150513monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-reports-positive-results-from-phase-1-study-of-htx-011-results-support--hrtx-20150319monthly0.5https://www.biopharmawatch.com/news/HRTX/legal-disclaimer-this-presentation-contains-forward-looking-statements-as-defined-by-the-p-hrtx-20141210monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-provides-update-on-sustol-program-sustol-phase-3-study-in-delayed-hec-p-hrtx-20140602monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-reports-positive-results-for-post-surgical-pain-program-advanced-biochr-hrtx-20140514monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-announces-fourth-quarter-and-full-year-2013-financial-results-and-highl-hrtx-20140305monthly0.5https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-inc-all-rights-reserved-confidential-2-legal-disclaimer-this-presentati-hrtx-20140113monthly0.5https://www.biopharmawatch.com/news/HRTX/a-p-pharma-announces-third-quarter-2013-financial-results-and-highlights-recent-corporate--hrtx-20131112monthly0.5https://www.biopharmawatch.com/news/HRTX/a-p-pharma-announces-second-quarter-2013-financial-results-and-highlights-recent-corporate-hrtx-20130808monthly0.5https://www.biopharmawatch.com/news/HRTX/legal-disclaimer-this-presentation-contains-forward-looking-statements-as-defined-by-the-p-hrtx-20130709monthly0.5https://www.biopharmawatch.com/news/HRTX/a-p-pharma-announces-first-quarter-2013-financial-results-and-highlights-recent-corporate--hrtx-20130510monthly0.5https://www.biopharmawatch.com/news/HRTX/a-p-pharma-receives-fda-complete-response-letter-for-apf530-company-revises-projected-laun-hrtx-20130328monthly0.5https://www.biopharmawatch.com/news/HRTX/a-p-pharma-appoints-jesse-hollingsworth-as-vice-president-of-sales-hrtx-20130228monthly0.5https://www.biopharmawatch.com/news/HRTX/legal-disclaimer-this-presentation-contains-forward-looking-statements-as-defined-by-the-p-hrtx-20130107monthly0.5https://www.biopharmawatch.com/news/HRTX/a-p-pharma-makes-key-appointments-in-preparation-of-potential-fda-approval-of-lead-product-hrtx-20121217monthly0.5https://www.biopharmawatch.com/news/HRTX/a-p-pharma-names-mark-s-gelder-m-d-as-senior-vice-president-and-chief-medical-officer-hrtx-20121213monthly0.5https://www.biopharmawatch.com/news/HRTX/a-p-pharma-announces-third-quarter-2012-financial-results-and-highlights-recent-corporate--hrtx-20121105monthly0.5https://www.biopharmawatch.com/news/HRTX/a-p-pharma-appoints-robert-rosen-as-senior-vice-president-and-chief-commercial-officer-hrtx-20121018monthly0.5https://www.biopharmawatch.com/news/HRTX/a-p-pharma-announces-pdufa-action-date-for-apf530-new-drug-application-resubmission-hrtx-20121016monthly0.5https://www.biopharmawatch.com/news/HRTX/a-p-pharma-resubmits-new-drug-application-for-apf530-a-product-candidate-for-the-preventio-hrtx-20120928monthly0.5https://www.biopharmawatch.com/news/HRTX/a-p-pharma-appoints-thomas-pitler-ph-d-as-vice-president-of-business-development-hrtx-20120910monthly0.5https://www.biopharmawatch.com/news/HRTX/a-p-pharma-announces-second-quarter-2012-financial-results-and-highlights-recent-corporate-hrtx-20120802monthly0.5https://www.biopharmawatch.com/news/HRTX/a-p-pharma-appoints-robert-rosen-to-its-board-of-directors-hrtx-20120731monthly0.5https://www.biopharmawatch.com/news/HRTX/a-p-pharma-to-raise-53-6-million-in-common-stock-offering-hrtx-20120725monthly0.5https://www.biopharmawatch.com/news/HRTX/a-p-pharma-announces-the-allowance-of-three-patents-covering-apf530-apf530-patent-protecti-hrtx-20120710monthly0.5https://www.biopharmawatch.com/news/HRTX/a-p-pharma-announces-positive-apf530-patient-satisfaction-data-from-phase-3-study-in-patie-hrtx-20120629monthly0.5https://www.biopharmawatch.com/news/HRTX/a-p-pharma-to-present-apf530-patient-satisfaction-data-from-phase-3-study-poster-at-the-mu-hrtx-20120620monthly0.5https://www.biopharmawatch.com/news/HRTX/a-p-pharma-announces-study-finding-continuous-exposure-to-a-5-ht3-antagonist-using-apf530--hrtx-20120531monthly0.5https://www.biopharmawatch.com/news/HRTX/a-p-pharma-announces-first-quarter-2012-financial-results-and-recent-corporate-progress-hrtx-20120510monthly0.5https://www.biopharmawatch.com/news/HRTX/legal-disclaimer-march-2012-2012-a-p-pharma-inc-all-rights-reserved-2-this-presentation-co-hrtx-20120326monthly0.5https://www.biopharmawatch.com/news/HRTX/a-p-pharma-announces-fourth-quarter-and-full-year-2011-financial-results-and-provides-upda-hrtx-20120326monthly0.5https://www.biopharmawatch.com/news/HRTX/a-p-pharma-announces-third-quarter-2011-financial-results-and-recent-corporate-progress-hrtx-20111107monthly0.5https://www.biopharmawatch.com/news/HRTX/legal-disclaimer-september-2011-2011-a-p-pharma-inc-all-rights-reserved-2-this-presentatio-hrtx-20110920monthly0.5https://www.biopharmawatch.com/news/HRTX/a-p-pharma-announces-second-quarter-2011-financial-results-and-reports-on-recent-corporate-hrtx-20110808monthly0.5https://www.biopharmawatch.com/news/HRTX/a-p-pharma-to-raise-24-million-in-private-placement-of-common-stock-and-warrants-proceeds--hrtx-20110629monthly0.5https://www.biopharmawatch.com/news/HRTX/a-p-pharma-announces-first-quarter-2011-financial-results-and-recent-corporate-progress-hrtx-20110516monthly0.5https://www.biopharmawatch.com/news/HRTX/a-p-pharma-announces-financing-of-up-to-4-5-million-and-names-ceo-and-hrtx-20110425monthly0.5https://www.biopharmawatch.com/news/HRTX/a-p-pharma-announces-fourth-quarter-and-full-year-2010-financial-results-and-provides-corp-hrtx-20110328monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-inc-reports-fourth-quarter-and-full-year-2025-financial-results-hypr-20260318monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-reports-preliminary-unaudited-fourth-quarter-and-full-year-2025-financial-result-hypr-20260112monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-inc-reports-third-quarter-2025-financial-results-hypr-20251113monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-announces-pricing-of-17-5-million-public-offering-guilford-ct-hypr-20251016monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-reports-preliminary-unaudited-results-for-third-quarter-2025-signaling-strong-bu-hypr-20251015monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-inc-reports-first-quarter-2025-financial-results-hypr-20250513monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-inc-reports-fourth-quarter-and-full-year-2024-financial-results-hypr-20250317monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-announces-6-0-million-registered-direct-offering-guilford-ct-hypr-20250211monthly0.5https://www.biopharmawatch.com/news/HYPR/ai-powered-portable-brain-mri-the-swoop-portable-mr-imaging-system-is-driving-the-future-o-hypr-20250211monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-inc-reports-third-quarter-2024-financial-results-hypr-20241112monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-inc-reports-record-quarterly-revenue-and-raises-fy-2024-revenue-guidance-x2500-r-hypr-20240808monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-inc-reports-first-quarter-2024-financial-results-hypr-20240513monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-inc-reports-fourth-quarter-and-full-year-2023-financial-results-hypr-20240321monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-inc-reports-third-quarter-2023-financial-results-hypr-20231109monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-inc-reports-second-quarter-2023-financial-results-hypr-20230814monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-inc-announces-promotion-of-tom-teisseyre-ph-d-to-chief-operating-officer-guilfor-hypr-20230718monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-inc-reports-first-quarter-2023-financial-results-hypr-20230511monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-inc-reports-fourth-quarter-and-full-year-2022-financial-results-hypr-20230321monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-inc-swoop-portable-mr-imaging-system-receives-ce-marking-after-meeting-comprehen-hypr-20230221monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-inc-announces-brett-hale-as-new-chief-administrative-officer-chief-financial-off-hypr-20230208monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-reports-third-quarter-2022-financial-results-hypr-20221110monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-names-maria-sainz-president-and-chief-executive-officer-hypr-20221006monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-reports-second-quarter-2022-financial-results-hypr-20220810monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-announces-ceo-transition-launches-global-search-for-long-term-ceo-with-scott-hue-hypr-20220629monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-reports-first-quarter-2022-financial-results-hypr-20220511monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-reports-fourth-quarter-and-full-year-2021-financial-results-hypr-20220323monthly0.5https://www.biopharmawatch.com/news/HYPR/defining-the-future-of-life-saving-diagnostics-at-the-point-of-care-corporate-presentation-hypr-20220309monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-reports-preliminary-unaudited-2021-revenue-and-swoop-system-installations-hypr-20220110monthly0.5https://www.biopharmawatch.com/news/HYPR/unaudited-pro-forma-condensed-combined-financial-information-defined-terms-included-below--hypr-20211228monthly0.5https://www.biopharmawatch.com/news/HYPR/hyperfine-inc-creator-of-the-first-fda-cleared-portable-mri-device-and-liminal-sciences-in-hypr-20210708monthly0.5https://www.biopharmawatch.com/news/HYPR/index-to-financial-statement-audited-financial-statements-for-healthcor-catalio-acquisitio-hypr-20210129monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-reports-positive-one-year-reveal-1-open-label-results-showing-sustained-pos-guts-20260604monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-appoints-lara-smith-weber-as-chief-financial-officer-to-support-commercial--guts-20260106monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-announces-second-quarter-2025-financial-results-and-business-updates-random-guts-20250812monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-reports-positive-3-month-reveal-1-cohort-data-showing-revita-sustained-weig-guts-20250623monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-reinforces-intellectual-property-leadership-in-metabolic-disease-with-two-n-guts-20250618monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-advances-rejuva-gene-therapy-platform-with-submission-of-first-clinical-tri-guts-20250519monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-unveils-new-rejuva-smart-glp-1-tm-pancreatic-gene-therapy-preclinical-data--guts-20250517monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-announces-first-quarter-2025-financial-results-and-business-updates-reveal--guts-20250513monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-reports-positive-early-data-showing-revita-has-potential-to-prevent-weight--guts-20250401monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-announces-fourth-quarter-and-full-year-2024-financial-results-and-business--guts-20250303monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-announces-increased-focus-on-groundbreaking-revita-weight-maintenance-and-r-guts-20250131monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-announces-positive-initial-clinical-results-demonstrating-weight-maintenanc-guts-20250113monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-reports-third-quarter-2024-financial-results-and-provides-business-updates--guts-20241112monthly0.5https://www.biopharmawatch.com/news/GUTS/about-rejuva-fractyl-health-s-rejuva-x2009-platform-focuses-on-developing-next-generation--guts-20241104monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-reports-second-quarter-2024-financial-results-and-provides-business-updates-guts-20240814monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-receives-fda-breakthrough-device-designation-for-revita-in-weight-maintenan-guts-20240730monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-announces-advancement-in-weight-maintenance-pipeline-and-business-updates-c-guts-20240624monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-reports-first-quarter-2024-financial-results-and-provides-business-updates--guts-20240513monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-bu-guts-20240401monthly0.5https://www.biopharmawatch.com/news/GUTS/fractyl-health-receives-fda-ide-approval-for-the-revita-remain-1-pivotal-study-of-weight-m-guts-20240401monthly0.5https://www.biopharmawatch.com/news/MSLE/notice-of-meeting-and-management-information-circular-relating-to-the-msle-20260520monthly0.5https://www.biopharmawatch.com/news/MSLE/form-51-102f3-material-change-report-1-name-and-address-of-company-satellos-bioscience-inc-msle-20260205monthly0.5https://www.biopharmawatch.com/news/MSLE/satellos-announces-first-participant-dosed-in-phase-2-pediatric-study-of-sat-3247-for-duch-msle-20260212monthly0.5https://www.biopharmawatch.com/news/MSLE/satellos-bioscience-inc-4-455-445-common-shares-pre-funded-warrants-to-purchase-up-to-495--msle-20260205monthly0.5https://www.biopharmawatch.com/news/NTHI/neonc-technologies-secures-uae-ind-approval-for-neo212-following-successful-phase-1-comple-nthi-20260616monthly0.5https://www.biopharmawatch.com/news/NTHI/neonc-provides-business-update-and-reports-q1-2026-financial-results-nthi-20260518monthly0.5https://www.biopharmawatch.com/news/NTHI/neonc-technologies-holdings-inc-announces-300-000-in-insider-purchases-of-nthi-stock-by-ch-nthi-20260414monthly0.5https://www.biopharmawatch.com/news/NTHI/neonc-provides-business-update-and-reports-q4-2025-financial-results-nthi-20260401monthly0.5https://www.biopharmawatch.com/news/NTHI/neonc-technologies-appoints-david-choi-as-chief-accounting-officer-nthi-20260313monthly0.5https://www.biopharmawatch.com/news/NTHI/neonc-technologies-reports-phase-1-dose-escalation-results-for-dosing-and-toxicity-and-det-nthi-20260304monthly0.5https://www.biopharmawatch.com/news/NTHI/neonc-technologies-nasdaq-nthi-to-host-investor-conference-call-to-present-dose-escalation-nthi-20260227monthly0.5https://www.biopharmawatch.com/news/NTHI/neonc-technologies-reports-updated-clinical-results-expanded-clinical-experience-demonstra-nthi-20251215monthly0.5https://www.biopharmawatch.com/news/NTHI/neonc-technologies-nasdaq-nthi-announces-ai-driven-findings-showing-ultrasound-enhances-th-nthi-20251201monthly0.5https://www.biopharmawatch.com/news/NTHI/neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides-operational-up-nthi-20251114monthly0.5https://www.biopharmawatch.com/news/NTHI/neonc-technologies-reports-updated-clinical-results-results-of-clinical-trials-provide-evi-nthi-20251112monthly0.5https://www.biopharmawatch.com/news/NTHI/neonc-technologies-nasdaq-nthi-to-host-investor-conference-call-to-present-data-updates-fr-nthi-20251107monthly0.5https://www.biopharmawatch.com/news/NTHI/neonc-technologies-appoints-amir-heshmatpour-as-chief-executive-officer-to-drive-next-phas-nthi-20251104monthly0.5https://www.biopharmawatch.com/news/NTHI/his-highness-sheikh-nahyan-bin-zayed-al-nahyan-assumes-executive-chairmanship-of-neonc-tec-nthi-20251028monthly0.5https://www.biopharmawatch.com/news/NTHI/neonc-technologies-and-quazar-investment-set-to-close-50-million-strategic-partnership-by--nthi-20251006monthly0.5https://www.biopharmawatch.com/news/NTHI/neonc-technologies-subsidiary-neuromena-signs-master-services-agreement-with-m42-s-iros-an-nthi-20251009monthly0.5https://www.biopharmawatch.com/news/NTHI/neonc-technologies-receives-fda-authorization-to-proceed-with-phase-ii-clinical-trial-of-n-nthi-20250910monthly0.5https://www.biopharmawatch.com/news/NTHI/neonc-technologies-holdings-reports-second-quarter-2025-results-and-provides-operational-u-nthi-20250819monthly0.5https://www.biopharmawatch.com/news/NTHI/neonc-technologies-awarded-2-5-million-in-nih-sttr-grants-to-advance-neo212-in-gliomas-and-nthi-20250807monthly0.5https://www.biopharmawatch.com/news/NTHI/neonc-technologies-signs-definitive-agreement-for-50-million-strategic-partnership-with-qu-nthi-20250729monthly0.5https://www.biopharmawatch.com/news/NTHI/neonc-technologies-executes-sub-license-agreement-marking-key-milestone-toward-closing-50--nthi-20250722monthly0.5https://www.biopharmawatch.com/news/NTHI/neonc-technologies-signs-50-million-non-binding-strategic-term-sheet-with-quazar-investmen-nthi-20250708monthly0.5https://www.biopharmawatch.com/news/NTHI/neonc-technologies-holdings-inc-appoints-dr-josh-neman-as-chief-clinical-officer-to-advanc-nthi-20250606monthly0.5https://www.biopharmawatch.com/news/NTHI/neonc-technologies-holdings-inc-executive-chairman-amir-heshmatpour-assumes-expanded-leade-nthi-20250410monthly0.5https://www.biopharmawatch.com/news/NTHI/neonc-technologies-expands-global-clinical-trial-network-with-cbcc-global-research-to-acce-nthi-20250327monthly0.5https://www.biopharmawatch.com/news/NTHI/neonc-technologies-holdings-announces-effectiveness-nthi-20250327monthly0.5https://www.biopharmawatch.com/news/HURA/unaudited-pro-forma-condensed-combined-financial-information-unless-the-context-indicates--hura-20260430monthly0.5https://www.biopharmawatch.com/news/HURA/unaudited-pro-forma-condensed-combined-financial-information-unless-the-context-indicates--hura-20260408monthly0.5https://www.biopharmawatch.com/news/HURA/unaudited-pro-forma-condensed-combined-financial-information-unless-the-context-indicates--hura-20251118monthly0.5https://www.biopharmawatch.com/news/HURA/business-except-as-otherwise-specified-or-indicated-by-the-context-references-to-we-us-our-hura-20251103monthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-inc-reports-second-quarter-2025-financial-results-and-provides-a-corpor-hura-20250814monthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-inc-and-kineta-inc-stockholders-approve-proposed-merger-and-all-related-hura-20250623monthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-inc-enters-into-12-5-million-equity-financing-transaction-and-receives--hura-20250603monthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-inc-reports-first-quarter-2025-financial-results-and-provides-a-corpora-hura-20250515monthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-inc-reports-financial-results-for-fiscal-year-2024-and-provides-corpora-hura-20250401monthly0.5https://www.biopharmawatch.com/news/HURA/overcoming-resistance-to-cancer-immunotherapy-presentation-march-2025-tuhurabio-com-filed--hura-20250318monthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-inc-appoints-craig-l-tendler-m-d-former-vice-president-oncology-clinica-hura-20250311monthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-inc-enters-into-definitive-merger-agreement-to-acquire-kineta-inc-oppor-hura-20241212monthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-inc-nasdaq-hura-outlines-development-pathway-for-single-phase-3-acceler-hura-20241125monthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-completes-merger-transaction-with-kintara-therapeutics-x2022-combined-c-hura-20241018monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-announces-correction-to-prior-announcement-regarding-cvr-issuance-in--hura-20241018monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-announces-record-date-for-cvr-issuance-in-connection-with-the-propose-hura-20241018monthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-inc-and-subsidiary-condensed-consolidated-financial-statements-as-of-hura-20241008monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-announces-fiscal-2024-financial-results-and-provides-corporate-update-hura-20241008monthly0.5https://www.biopharmawatch.com/news/HURA/it-is-imperative-for-all-stockholders-to-vote-your-shares-voting-deadline-is-october-3-rd--hura-20240924monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-announces-adjournment-of-special-meeting-of-stockholders-until-hura-20240920monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-reminds-stockholders-to-vote-by-thursday-to-allow-for-completion-of-t-hura-20240919monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-provides-update-on-corporate-developments-and-rem-001-clinical-study-hura-20240911monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-to-hold-special-meeting-of-stockholders-to-allow-for-completion-of-th-hura-20240909monthly0.5https://www.biopharmawatch.com/news/HURA/we-ask-that-all-kintara-stockholders-vote-their-shares-today-voting-deadline-is-september--hura-20240819monthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-and-kintara-therapeutics-announce-kineta-inc-reopens-enrollment-for-vis-hura-20240819monthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-enters-into-exclusivity-and-right-of-first-offer-agreement-for-kineta-i-hura-20240708monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-and-tuhura-biosciences-provide-update-on-recent-corporate-and-clinica-hura-20240701monthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-and-kintara-therapeutics-announce-positive-results-from-phase-1b-trial--hura-20240603monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-announces-fiscal-2024-third-quarter-financial-results-hura-20240514monthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-to-present-its-ifx-2-0-personalized-cancer-vaccine-clinical-trial-resul-hura-20240425monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-and-tuhura-biosciences-enter-into-definitive-merger-agreement-x2022-t-hura-20240403monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-announces-fiscal-2024-second-quarter-financial-results-and-provides-c-hura-20240214monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-announces-initiation-of-rem-001-clinical-trial-for-the-treatment-of-c-hura-20240212monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-announces-review-of-strategic-alternatives-ladenburg-thalmann-hired-a-hura-20231207monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-granted-extension-by-nasdaq-to-regain-compliance-with-the-stockholder-hura-20231205monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-announces-fiscal-2024-first-quarter-financial-results-and-provides-co-hura-20231113monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-announces-preliminary-topline-results-from-gbm-agile-study-val-083-di-hura-20231031monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-announces-fiscal-2023-year-financial-results-and-provides-corporate-u-hura-20230918monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-announces-fiscal-2023-third-quarter-financial-results-and-provides-co-hura-20230511monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-announces-fiscal-2023-second-quarter-financial-results-and-provides-c-hura-20230214monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-hura-20221130monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-announces-fiscal-2023-first-quarter-financial-results-and-provides-co-hura-20221109monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-pauses-rem-001-program-to-conserve-funds-to-support-val-083-internati-hura-20221019monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-announces-fiscal-2022-financial-results-and-provides-corporate-update-hura-20220927monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-enters-into-equity-purchase-agreement-for-up-to-20-million-with-linco-hura-20220803monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-granted-fast-track-designation-from-the-fda-for-val-083-for-newly-dia-hura-20220615monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-granted-180-day-extension-to-meet-nasdaq-minimum-bid-price-requirement-hura-20220603monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-announces-fiscal-2022-third-quarter-financial-results-and-provides-co-hura-20220513monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-announces-8-6-million-registered-direct-offering-priced-at-the-market-under-nasdaq-hura-20220412monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-announces-fiscal-2022-second-quarter-financial-results-and-provides-c-hura-20220211monthly0.5https://www.biopharmawatch.com/news/HURA/forward-looking-statements-2-this-presentation-contains-forward-looking-statements-based-u-hura-20220110monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-announces-fiscal-2022-first-quarter-financial-results-and-provides-co-hura-20211115monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-announces-fiscal-year-2021-financial-results-and-provides-corporate-u-hura-20210929monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-announces-15-0-million-offering-of-common-stock-and-warrants-priced-at-a-premium-t-hura-20210924monthly0.5https://www.biopharmawatch.com/news/HURA/forward-looking-statements-2-this-presentation-contains-forward-looking-statements-based-u-hura-20210907monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-announces-fiscal-third-quarter-2021-financial-results-and-provides-co-hura-20210514monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-announces-fiscal-second-quarter-2021-financial-results-and-provides-c-hura-20210212monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-announces-first-fiscal-quarter-2021-financial-results-and-recent-corp-hura-20201113monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-announces-fiscal-year-2020-financial-results-and-recent-corporate-upd-hura-20200921monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-completes-final-closing-of-previously-announced-private-placement-for-hura-20200901monthly0.5https://www.biopharmawatch.com/news/HURA/kintara-therapeutics-announces-additional-2-4-million-private-placement-priced-at-the-mark-hura-20200821monthly0.5https://www.biopharmawatch.com/news/HURA/delmar-announces-19-6-million-private-placement-priced-at-the-market-hura-20200818monthly0.5https://www.biopharmawatch.com/news/HURA/delmar-announces-approval-of-merger-by-stockholders-hura-20200817monthly0.5https://www.biopharmawatch.com/news/HURA/forward-looking-statements-and-confidentiality-any-statements-contained-in-this-presentati-hura-20200624monthly0.5https://www.biopharmawatch.com/news/HURA/delmar-to-acquire-adgero-biopharmaceuticals-expands-late-stage-oncology-pipeline-combinati-hura-20200610monthly0.5https://www.biopharmawatch.com/news/HURA/delmar-pharmaceuticals-announces-fiscal-third-quarter-2020-financial-results-and-recent-co-hura-20200513monthly0.5https://www.biopharmawatch.com/news/HURA/delmar-pharmaceuticals-receives-nasdaq-bid-price-extension-hura-20200326monthly0.5https://www.biopharmawatch.com/news/HURA/pharmaceuticals-announces-fiscal-second-quarter-2020-financial-results-and-recent-corporat-hura-20200213monthly0.5https://www.biopharmawatch.com/news/HURA/delmar-pharmaceuticals-inc-edited-transcript-of-key-opinion-leader-event-hura-20200107monthly0.5https://www.biopharmawatch.com/news/HURA/current-standard-of-care-for-glioblastoma-gbm-includes-surgery-followed-by-concurrent-ther-hura-20191122monthly0.5https://www.biopharmawatch.com/news/HURA/pharmaceuticals-announces-fiscal-year-2019-hura-20190910monthly0.5https://www.biopharmawatch.com/news/HURA/delmar-pharmaceuticals-reports-full-hura-20190909monthly0.5https://www.biopharmawatch.com/news/HURA/breakthrough-cancer-therapeutics-val-083-validated-dna-targeting-agent-for-multiple-drug-r-hura-20190828monthly0.5https://www.biopharmawatch.com/news/HURA/delmar-pharmaceuticals-announces-pricing-hura-20190815monthly0.5https://www.biopharmawatch.com/news/HURA/delmar-pharmaceuticals-announces-3-6-hura-20190603monthly0.5https://www.biopharmawatch.com/news/HURA/financial-statements-of-delmar-pharmaceuticals-inc-delmar-pharmaceuticals-inc-index-to-fin-hura-20190603monthly0.5https://www.biopharmawatch.com/news/HURA/delmar-pharmaceuticals-announces-third-hura-20190515monthly0.5https://www.biopharmawatch.com/news/HURA/delmar-pharmaceuticals-announces-1-for-10-reverse-stock-split-vancouver-british-columbia-a-hura-20190507monthly0.5https://www.biopharmawatch.com/news/HURA/pharmaceuticals-announces-second-quarter-hura-20190212monthly0.5https://www.biopharmawatch.com/news/HURA/pharmaceuticals-announces-first-quarter-fiscal-year-2019-financial-results-hura-20181114monthly0.5https://www.biopharmawatch.com/news/HURA/delmar-pharmaceuticals-announces-fiscal-year-2018-annual-financial-results-company-will-ho-hura-20180925monthly0.5https://www.biopharmawatch.com/news/HURA/appoints-saiid-zarrabian-to-full-time-president-and-ceo-hura-20180522monthly0.5https://www.biopharmawatch.com/news/HURA/delmar-pharmaceuticals-announces-hura-20180517monthly0.5https://www.biopharmawatch.com/news/HURA/delmar-pharmaceuticals-announces-second-quarter-fiscal-year-2018-financial-results-company-hura-20180215monthly0.5https://www.biopharmawatch.com/news/HURA/delmar-presents-positive-interim-results-from-val-083-study-in-mgmt-unmethylated-recurrent-hura-20171121monthly0.5https://www.biopharmawatch.com/news/HURA/delmar-pharmaceuticals-appoints-saiid-zarrabian-as-interim-chief-executive-officer-vancouv-hura-20171107monthly0.5https://www.biopharmawatch.com/news/HURA/copyright-2017-delmar-pharmaceuticals-all-rights-reserved-seeking-new-horizons-for-cancer--hura-20171004monthly0.5https://www.biopharmawatch.com/news/HURA/pharmaceuticals-announces-10-million-registered-direct-hura-20170921monthly0.5https://www.biopharmawatch.com/news/HURA/pharmaceuticals-announces-pricing-of-9-000-000-million-public-hura-20170413monthly0.5https://www.biopharmawatch.com/news/HURA/delmar-pharmaceuticals-announces-first-quarter-fiscal-year-2017-financial-results-and-corp-hura-20161115monthly0.5https://www.biopharmawatch.com/news/HURA/delmar-pharmaceuticals-announces-third-quarter-fiscal-year-2016-financial-results-and-corp-hura-20160519monthly0.5https://www.biopharmawatch.com/news/HURA/delmar-pharmaceuticals-reports-first-quarter-fiscal-year-2016-financial-results-and-provid-hura-20151123monthly0.5https://www.biopharmawatch.com/news/HURA/delmar-pharmaceuticals-announces-third-quarter-fiscal-year-2015-financial-results-and-prov-hura-20150518monthly0.5https://www.biopharmawatch.com/news/HURA/jfif-c-1-3-mqypdx-egc-c-cb8bcccccccccccccccccccccccccccccccccccccccccccccccccc-1a-qa-q-2-hura-20150218monthly0.5https://www.biopharmawatch.com/news/HURA/delmar-pharmaceuticals-completes-offer-to-exchange-common-stock-for-outstanding-warrants-v-hura-20150210monthly0.5https://www.biopharmawatch.com/news/HURA/delmar-pharmaceuticals-commences-offer-to-exchange-common-stock-for-outstanding-warrants-v-hura-20150108monthly0.5https://www.biopharmawatch.com/news/HURA/delmar-pharmaceuticals-inc-hura-20141125monthly0.5https://www.biopharmawatch.com/news/HURA/election-to-exercise-warrants-to-2014-delmar-pharmaceuticals-inc-suite-720-999-west-broadw-hura-20140530monthly0.5https://www.biopharmawatch.com/news/HURA/berry-only-inc-pro-forma-consolidated-financial-statements-unaudited-expressed-in-united-s-hura-20130131monthly0.5https://www.biopharmawatch.com/news/SPRB/long-term-data-presented-at-the-22-nd-annual-world-symposium-highlights-tralesinidase-alfa-sprb-20260205monthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-secures-up-to-50-million-in-growth-capital-from-avenue-capital-initial--sprb-20260108monthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-reports-third-quarter-2025-financial-results-and-provides-corporate-upd-sprb-20251110monthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-reports-second-quarter-2025-financial-results-and-provides-corporate-up-sprb-20250814monthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-announces-reverse-stock-split-spruce-s-common-stock-to-begin-trading-on-sprb-20250724monthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-reports-first-quarter-2025-financial-results-and-provides-corporate-upd-sprb-20250506monthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-announces-new-corporate-strategy-and-acquisition-of-tralesinidase-alfa--sprb-20250415monthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-reports-third-quarter-2024-financial-results-and-provides-corporate-upd-sprb-20241111monthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-reports-second-quarter-2024-financial-results-and-provides-corporate-up-sprb-20240812monthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-reports-first-quarter-2024-financial-results-and-provides-corporate-upd-sprb-20240513monthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-reports-full-year-2023-financial-results-and-provides-corporate-updates-sprb-20240313monthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-provides-clinical-program-updates-and-outlook-for-2024-catalyst-heavy-2-sprb-20240104monthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-reports-third-quarter-2023-financial-results-and-provides-corporate-upd-sprb-20231113monthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-reports-second-quarter-2023-financial-results-and-provides-corporate-up-sprb-20230814monthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-reports-first-quarter-2023-financial-results-and-provides-corporate-upd-sprb-20230515monthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-reports-full-year-2022-financial-results-and-provides-corporate-updates-sprb-20230316monthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-reports-third-quarter-2022-financial-results-and-provides-corporate-upd-sprb-20221110monthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-reports-second-quarter-2022-financial-results-and-provides-corporate-up-sprb-20220810monthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-reports-first-quarter-2022-financial-results-and-provides-corporate-upd-sprb-20220511monthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-reports-fourth-quarter-and-full-year-2021-financial-results-and-provide-sprb-20220314monthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-appoints-javier-szwarcberg-m-d-mph-as-chief-executive-officer-samir-gha-sprb-20220105monthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-reports-third-quarter-2021-financial-results-and-provides-corporate-upd-sprb-20211115monthly0.5https://www.biopharmawatch.com/news/SPRB/forward-looking-statements-2-this-presentation-contains-forward-looking-statements-about-s-sprb-20210915monthly0.5https://www.biopharmawatch.com/news/SPRB/forward-looking-statements-this-presentation-contains-forward-looking-statements-about-spr-sprb-20210825monthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-reports-second-quarter-2021-financial-results-and-provides-corporate-up-sprb-20210810monthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-reports-first-quarter-2021-financial-results-and-provides-corporate-upd-sprb-20210512monthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-reports-fourth-quarter-and-full-year-2020-financial-results-and-provide-sprb-20210322monthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-provides-corporate-update-and-outlines-milestones-for-2021-cahmelia-adu-sprb-20210106monthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-reports-third-quarter-2020-financial-results-and-provides-corporate-upd-sprb-20201118monthly0.5https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-announces-closing-of-upsized-initial-public-offering-and-full-exercise--sprb-20201014monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-provides-clinical-update-decoy20-monotherapy-induces-partial-respons-indp-20250904monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate-indp-20250813monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-inc-announces-sale-of-2-3-million-in-private-placement-of-convertibl-indp-20250613monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-reports-first-quarter-2025-financial-results-and-provides-corporate--indp-20250514monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-reports-fourth-quarter-and-year-end-2024-financial-results-and-provi-indp-20250313monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-inc-announces-2-25-million-private-placement-priced-at-the-market-un-indp-20250113monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-inc-announces-2-135-million-registered-direct-offering-and-concurren-indp-20241122monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-reports-third-quarter-2024-financial-results-and-provides-corporate--indp-20241112monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-reports-second-quarter-2024-financial-results-and-provides-corporate-indp-20240812monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-inc-announces-3-0-million-registered-direct-offering-and-concurrent--indp-20240807monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-reports-first-quarter-2024-financial-results-and-provides-corporate--indp-20240508monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-reports-fourth-quarter-and-year-end-2023-financial-results-and-provi-indp-20240313monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-reports-third-quarter-2023-financial-results-and-provides-corporate--indp-20231106monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-reports-second-quarter-2023-financial-results-and-provides-corporate-indp-20230814monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-reports-first-quarter-2023-financial-results-and-provides-corporate--indp-20230511monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-reports-fourth-quarter-and-year-end-2022-financial-results-and-provi-indp-20230317monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-reports-third-quarter-2022-financial-results-and-provides-corporate--indp-20221110monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-reports-second-quarter-2022-financial-results-and-provides-corporate-indp-20220808monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-to-i-indp-20220519monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-reports-first-quarter-2022-financial-results-and-provides-corporate--indp-20220512monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-reports-fourth-quarter-and-year-end-2021-financial-results-and-provi-indp-20220321monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-announces-appointment-of-boyan-litchev-m-d-as-chief-medical-officer--indp-20220103monthly0.5https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-reports-third-quarter-2021-financial-results-and-provides-corporate--indp-20211115monthly0.5https://www.biopharmawatch.com/news/INDP/intec-closes-merger-with-decoy-biosystems-completes-30-million-private-placement-changes-c-indp-20210803monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-reports-first-quarter-2026-financial-results-and-corporate-highlights-phase-1-pr-eq-20260513monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-reports-third-quarter-2025-financial-results-and-provides-operational-update-clo-eq-20251113monthly0.5https://www.biopharmawatch.com/news/EQ/august-2025-equillium-announces-strategic-expansion-of-cryptocurrency-treasury-reserve-str-eq-20250804monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-announces-feedback-from-the-u-s-food-and-drug-administration-eq-20250424monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-corporate-eq-20250327monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-reports-third-quarter-2024-financial-results-and-provides-corporate-and-clinical-eq-20241113monthly0.5https://www.biopharmawatch.com/news/EQ/itolizumab-update-eq-20241031monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-reports-second-quarter-2024-financial-results-and-provides-recent-corporate-and--eq-20240808monthly0.5https://www.biopharmawatch.com/news/EQ/this-presentation-contains-forward-looking-statements-about-equillium-inc-the-company-in-s-eq-20240604monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-reports-first-quarter-2024-financial-results-and-provides-recent-clinical-highli-eq-20240509monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-reports-on-fourth-quarter-and-full-year-2023-financial-results-and-corporate-and-eq-20240325monthly0.5https://www.biopharmawatch.com/news/EQ/e-quillium-i-nc-2024-i-nducement-p-lan-a-dopted-by-the-b-oard-of-d-irectors-eq-20240306monthly0.5https://www.biopharmawatch.com/news/EQ/risk-that-studies-will-not-be-completed-as-planned-equillium-s-plans-and-product-developme-eq-20231108monthly0.5https://www.biopharmawatch.com/news/EQ/analyst-investor-day-with-dr-arash-mostaghimi-eq-20231016monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-reports-second-quarter-2023-financial-results-and-provides-corporate-and-clinica-eq-20230809monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-reports-first-quarter-2023-financial-results-and-provides-clinical-updates-62-0--eq-20230511monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-corpora-eq-20230323monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-and-metacrine-mutually-agree-to-terminate-definitive-merger-agreement-eq-20221223monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-and-ono-pharmaceutical-announce-exclusive-option-and-asset-purchase-agreement-fo-eq-20221206monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-reports-third-quarter-2022-financial-results-and-provides-corporate-and-clinical-eq-20221114monthly0.5https://www.biopharmawatch.com/news/EQ/safe-harbor-statement-this-presentation-contains-forward-looking-statements-about-equilliu-eq-20220927monthly0.5https://www.biopharmawatch.com/news/EQ/report-of-independent-registered-public-accounting-firm-to-the-stockholders-and-the-board--eq-20220926monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-to-acquire-metacrine-in-all-stock-transaction-expected-to-add-33-million-in-cash-eq-20220906monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-reports-second-quarter-2022-financial-results-and-provides-clinical-development--eq-20220815monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-reports-first-quarter-2022-financial-results-and-provides-corporate-and-clinical-eq-20220512monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-corpora-eq-20220323monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-announces-initiation-of-the-phase-3-equator-study-of-itolizumab-in-first-line-ac-eq-20220304monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-announces-appointment-of-barbara-troupin-to-board-of-directors-eq-20220301monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-acquires-bioniz-therapeutics-significantly-expanding-pipeline-of-novel-immunomod-eq-20220216monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-reports-third-quarter-2021-financial-results-and-provides-clinical-development-u-eq-20211110monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-reports-second-quarter-2021-financial-results-and-provides-clinical-development--eq-20210810monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-announces-plans-to-initiate-phase-3-pivotal-study-of-itolizumab-in-first-line-tr-eq-20210712monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-announces-positive-topline-results-from-the-equate-study-in-first-line-treatment-eq-20210611monthly0.5https://www.biopharmawatch.com/news/EQ/forward-looking-statements-statements-contained-in-this-press-release-regarding-matters-th-eq-20210610monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-to-collaborate-with-oxford-university-and-kennedy-institute-of-rheumatology-to-i-eq-20210607monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-reports-first-quarter-2021-financial-results-and-provides-clinical-development-u-eq-20210513monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-announces-favorable-data-from-phase-1b-equalise-study-in-systemic-lupus-erythema-eq-20210330monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-clinica-eq-20210324monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-announces-positive-data-for-itolizumab-in-acute-graft-versus-host-disease-in-two-eq-20210315monthly0.5https://www.biopharmawatch.com/news/EQ/safe-harbor-statement-this-presentation-contains-forward-looking-statements-about-equilliu-eq-20210309monthly0.5https://www.biopharmawatch.com/news/EQ/john-koreth-alison-w-loren-ryotaro-nakamura-marco-mielcarek-trent-wang-george-l-chen-sarah-eq-20210212monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-announces-pricing-of-30-million-registered-direct-offering-eq-20210204monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-appoints-industry-veteran-dolca-thomas-m-d-as-executive-vice-president-of-resear-eq-20201221monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-presents-translational-data-demonstrating-impact-of-itolizumab-on-effector-t-cel-eq-20201207monthly0.5https://www.biopharmawatch.com/news/EQ/safe-harbor-statement-this-presentation-contains-forward-looking-statements-about-equilliu-eq-20201204monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-to-host-virtual-investor-and-analyst-day-on-eq-20201130monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-provides-itolizumab-covid-19-program-update-analyst-day-scheduled-for-eq-20201125monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-reports-third-quarter-2020-financial-results-and-business-highlights-eq-20201110monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-receives-fda-clearance-of-covid-19-ind-for-phase-3-trial-equillium-plans-to-init-eq-20201029monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-announces-proposed-public-offering-of-common-stock-eq-20200813monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-reports-second-quarter-2020-financial-results-and-recent-highlights-eq-20200812monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-announces-positive-interim-data-with-itolizumab-in-acute-gvhd-study-complete-res-eq-20200810monthly0.5https://www.biopharmawatch.com/news/EQ/clinical-trial-shows-itolizumab-reduces-mortality-in-patients-hospitalized-with-covid-19-e-eq-20200713monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-reports-first-quarter-2020-financial-results-eq-20200513monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides-busines-eq-20200326monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-biocon-expand-exclusive-licensing-agreement-for-itolizumab-to-include-australia--eq-20191212monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-reports-third-quarter-2019-financial-results-and-recent-highlights-eq-20191112monthly0.5https://www.biopharmawatch.com/news/EQ/company-logo-harnessing-novel-immunobiology-october-2019-www-equilliumbio-com-safe-harbor--eq-20191001monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-reports-second-quarter-2019-financial-results-and-recent-highlights-initiated-ph-eq-20190812monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-reports-first-quarter-2019-financial-results-and-recent-highlights-equate-phase--eq-20190513monthly0.5https://www.biopharmawatch.com/news/EQ/safe-harbor-statement-this-presentation-contains-forward-looking-statements-about-equilliu-eq-20190501monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-reports-fourth-quarter-and-full-year-2018-financial-results-and-recent-highlight-eq-20190327monthly0.5https://www.biopharmawatch.com/news/EQ/safe-harbor-statement-this-presentation-contains-forward-looking-statements-about-equilliu-eq-20190226monthly0.5https://www.biopharmawatch.com/news/EQ/equillium-reports-third-quarter-2018-financial-results-and-recent-highlights-completes-suc-eq-20181115monthly0.5https://www.biopharmawatch.com/news/EQ/harnessing-novel-immunobiology-november-2018-safe-harbor-statement-this-presentation-conta-eq-20181113monthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-inc-602-2265-upper-middle-road-east-oakville-on-canada-l6h-0g5-notice-crdl-20260526monthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-inc-condensed-interim-consolidated-financial-statements-three-months--crdl-20260511monthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-phase-ii-maveric-results-accepted-for-publication-in-the-journal-of-t-crdl-20260507monthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-expands-u-s-maveric-phase-iii-trial-network-to-address-growing-intere-crdl-20260428monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-to-highlight-maveric-phase-iii-trial-and-re-crdl-20260414monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-announces-year-end-2025-update-on-operation-crdl-20260401monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-to-present-at-td-cowen-46th-annual-health-c-crdl-20260225monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-archer-phase-ii-study-results-published-in--crdl-20260210monthly0.5https://www.biopharmawatch.com/news/CRDL/execution-version-crdl-20260123monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-1-name-and-address-of--crdl-20260116monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-announces-closing-of-bought-deal-financing--crdl-20260123monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-announces-bought-deal-financing-for-gross-p-crdl-20260116monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-achieves-key-50-patient-enrollment-mileston-crdl-20260113monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-new-data-from-the-phase-ii-archer-trial-demonstrate-cardiolrx-im-crdl-20251201monthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-inc-condensed-interim-consolidated-financial-statements-three-and-nin-crdl-20251113monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-receives-u-s-patent-allowance-broadly-prote-crdl-20251113monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-phase-ii-archer-trial-results-to-be-present-crdl-20251105monthly0.5https://www.biopharmawatch.com/news/CRDL/form-45-106f1-report-of-exempt-distribution-item-1-x2013-report-type-x2612-new-report-x261-crdl-20251028monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-1-name-and-address-of--crdl-20251017monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-completes-us-11-4-million-financing-and-ext-crdl-20251021monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-secures-us-11-million-financing-and-extends-crdl-20251017monthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-inc-condensed-interim-consolidated-financial-statements-three-and-six-crdl-20250814monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-to-participate-in-fireside-chat-at-canaccor-crdl-20250811monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-announces-topline-results-from-the-phase-ii-crdl-20250806monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-announces-database-lock-for-phase-ii-archer-crdl-20250722monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-reports-results-of-2025-annual-general-meet-crdl-20250529monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-o-crdl-20250527monthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-inc-condensed-interim-consolidated-financial-statements-three-months--crdl-20250514monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-nominates-dr-timothy-garnett-to-its-board-o-crdl-20250429monthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-inc-602-2265-upper-middle-road-east-oakville-on-canada-l6h-0g5-notice-crdl-20250428monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-enrolls-first-patient-in-pivotal-phase-iii--crdl-20250416monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-announces-year-end-2024-update-on-operation-crdl-20250401monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-to-present-at-td-cowen-45th-annual-health-c-crdl-20250303monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-announces-publication-of-research-in-the-jo-crdl-20250220monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-to-present-at-oppenheimer-35-th-annual-heal-crdl-20250204monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-phase-ii-maveric-pilot-clinical-results-in--crdl-20241118monthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-inc-condensed-interim-consolidated-financial-statements-three-and-nin-crdl-20241114monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-to-advance-cardiolrx-into-a-late-stage-tria-crdl-20241022monthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-announces-exercise-and-closing-of-over-allotment-option-oakville-on-crdl-20241011monthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-announces-closing-of-us-13-5-million-public-offering-of-common-shares-crdl-20241010monthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-inc-8-437-500-common-shares-crdl-20241009monthly0.5https://www.biopharmawatch.com/news/CRDL/borden-ladner-gervais-llp-bay-adelaide-centre-east-tower-22-adelaide-street-west-toronto-o-crdl-20241008monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-achieves-target-patient-enrollment-in-its-p-crdl-20240924monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-announces-completion-of-the-maveric-phase-i-crdl-20240910monthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-inc-condensed-interim-consolidated-financial-statements-three-and-six-crdl-20240812monthly0.5https://www.biopharmawatch.com/news/CRDL/borden-ladner-gervais-llp-bay-adelaide-centre-east-tower-22-adelaide-street-west-toronto-o-crdl-20240716monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-reports-results-of-2024-annual-general-and--crdl-20240627monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-to-webcast-virtual-annual-general-and-speci-crdl-20240625monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-announces-positive-topline-data-from-its-ph-crdl-20240613monthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-inc-602-2265-upper-middle-road-east-oakville-on-canada-l6h-0g5-notice-crdl-20240528monthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-inc-condensed-interim-consolidated-financial-statements-three-months--crdl-20240514monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-announces-phase-ii-archer-trial-presented-a-crdl-20240514monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-crdl-20240418monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-announces-year-end-2023-update-on-operation-crdl-20240402monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-1-name-and-address-of--crdl-20240214monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-completes-patient-enrollment-in-its-phase-i-crdl-20240221monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-granted-orphan-drug-designation-for-its-lea-crdl-20240215monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-regains-compliance-with-all-applicable-list-crdl-20240124monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-announces-it-has-exceeded-50-enrollment-in--crdl-20240109monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-announces-massachusetts-general-hospital-la-crdl-20231205monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-announces-study-results-presented-at-the-20-crdl-20231116monthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-inc-condensed-interim-consolidated-financial-statements-three-and-nin-crdl-20231114monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-announces-it-has-exceeded-50-enrollment-in--crdl-20231101monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-receives-nasdaq-deficiency-notice-regarding-crdl-20231020monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-1-name-and-address-of--crdl-20231010monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-announces-positive-study-results-demonstrat-crdl-20231010monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-to-present-at-cantor-fitzgerald-2023-global-crdl-20230926monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-1-name-and-address-of--crdl-20230919monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-announces-all-collaborating-clinical-resear-crdl-20230919monthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-inc-condensed-interim-consolidated-financial-statements-three-and-six-crdl-20230810monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-to-present-at-canaccord-genuity-43-rd-annua-crdl-20230809monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-regains-compliance-with-all-applicable-list-crdl-20230808monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-reports-results-of-2023-annual-general-meet-crdl-20230629monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-o-crdl-20230627monthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-inc-602-2265-upper-middle-road-east-oakville-on-canada-l6h-0g5-notice-crdl-20230518monthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-inc-condensed-interim-consolidated-financial-statements-three-months--crdl-20230515monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-2265-upper-middle-road-east-suite-602-oakville-on-l6h-0g5-canada-crdl-20230329monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-2265-upper-middle-road-east-suite-602-oakville-on-l6h-0g5-canada-crdl-20230307monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-2265-upper-middle-road-east-suite-602-oakville-on-l6h-0g5-canada-crdl-20230117monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-2265-upper-middle-road-east-suite-602-oakville-on-l6h-0g5-canada-crdl-20221212monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-2265-upper-middle-road-east-suite-602-oakville-on-l6h-0g5-canada-crdl-20221114monthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-inc-condensed-interim-consolidated-financial-statements-three-and-nin-crdl-20221110monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-2265-upper-middle-road-east-suite-602-oakville-on-l6h-0g5-canada-crdl-20221107monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-1-name-and-address-of--crdl-20221025monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-2265-upper-middle-road-east-suite-602-oakville-on-l6h-0g5-canada-crdl-20221025monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-2265-upper-middle-road-east-suite-602-oakville-on-l6h-0g5-canada-crdl-20221003monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-2265-upper-middle-road-east-suite-602-oakville-on-l6h-0g5-canada-crdl-20220928monthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-inc-condensed-interim-consolidated-financial-statements-three-and-six-crdl-20220810monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-announces-first-patient-enrolled-in-archer--crdl-20220803monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-2265-upper-middle-road-east-suite-602-oakville-on-l6h-0g5-canada-crdl-20220629monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-2265-upper-middle-road-east-suite-602-oakville-on-l6h-0g5-canada-crdl-20220627monthly0.5https://www.biopharmawatch.com/news/CRDL/borden-ladner-gervais-llp-bay-adelaide-centre-east-tower-22-adelaide-street-west-toronto-o-crdl-20220609monthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-inc-602-2265-upper-middle-road-east-oakville-on-canada-l6h-0g5-notice-crdl-20220524monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-2265-upper-middle-road-east-suite-602-oakville-on-l6h-0g5-canada-crdl-20220519monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-2265-upper-middle-road-east-suite-602-oakville-on-l6h-0g5-canada-crdl-20220517monthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-inc-condensed-interim-consolidated-financial-statements-three-months--crdl-20220516monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-2265-upper-middle-road-east-suite-602-oakville-on-l6h-0g5-canada-crdl-20220324monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-2265-upper-middle-road-east-suite-602-oakville-on-l6h-0g5-canada-crdl-20220322monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-2265-upper-middle-road-east-suite-602-oakville-on-l6h-0g5-canada-crdl-20220315monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-cardiol-therapeutics-receives-clearance-from-the-fda-and-regulat-crdl-20220301monthly0.5https://www.biopharmawatch.com/news/CRDL/troutman-pepper-hamilton-sanders-llp-401-9th-street-nw-suite-1000-washington-dc-20004-trou-crdl-20220208monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-2265-upper-middle-road-east-suite-602-oakville-on-l6h-0g5-canada-crdl-20220119monthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-inc-condensed-interim-financial-statements-three-and-nine-months-ende-crdl-20211115monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-1-name-and-address-of--crdl-20211103monthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-inc-and-computershare-trust-company-of-canada-warrant-indenture-novem-crdl-20211105monthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-inc-16-350-000-units-crdl-20211103monthly0.5https://www.biopharmawatch.com/news/CRDL/upper-middle-road-east-suite-602-oakville-on-l6h-0g5-canada-cardiol-therapeutics-files-pre-crdl-20211102monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-2265-upper-middle-road-east-suite-602-oakville-on-l6h-0g5-canada-crdl-20211025monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-2265-upper-middle-road-east-suite-602-oakville-on-l6h-0g5-canada-crdl-20211018monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-2265-upper-middle-road-east-suite-602-oakville-on-l6h-0g5-canada-crdl-20210916monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-2265-upper-middle-road-east-suite-602-oakville-on-l6h-0g5-canada-crdl-20210910monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-2265-upper-middle-road-east-suite-602-oakville-on-l6h-0g5-canada-crdl-20210907monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-material-change-report-form-51-102f3-item-1-name-and-address-of--crdl-20210823monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-2265-upper-middle-road-east-suite-602-oakville-on-l6h-0g5-canada-crdl-20210824monthly0.5https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-inc-condensed-interim-financial-statements-three-and-six-months-ended-crdl-20210817monthly0.5https://www.biopharmawatch.com/news/CRDL/filed-by-newsfilecorp-com-2265-upper-middle-road-east-suite-602-oakville-on-l6h-0g5-canada-crdl-20210809monthly0.5https://www.biopharmawatch.com/news/DH/definitive-healthcare-reports-financial-results-for-first-quarter-2026-first-quarter-reven-dh-20260507monthly0.5https://www.biopharmawatch.com/news/DH/definitive-healthcare-reports-financial-results-for-fourth-quarter-and-full-fiscal-year-20-dh-20260226monthly0.5https://www.biopharmawatch.com/news/DH/definitive-healthcare-reports-financial-results-for-third-quarter-fiscal-year-2025-third-q-dh-20251106monthly0.5https://www.biopharmawatch.com/news/DH/definitive-healthcare-reports-financial-results-for-second-quarter-fiscal-year-2025-second-dh-20250807monthly0.5https://www.biopharmawatch.com/news/DH/definitive-healthcare-reports-financial-results-for-first-quarter-fiscal-year-2025-first-q-dh-20250508monthly0.5https://www.biopharmawatch.com/news/DH/definitive-healthcare-reports-financial-results-for-fourth-quarter-and-full-fiscal-year-20-dh-20250227monthly0.5https://www.biopharmawatch.com/news/DH/definitive-healthcare-reports-financial-results-for-third-quarter-fiscal-year-2024-third-q-dh-20241107monthly0.5https://www.biopharmawatch.com/news/DH/definitive-healthcare-reports-financial-results-for-second-quarter-fiscal-year-2024-second-dh-20240805monthly0.5https://www.biopharmawatch.com/news/DH/definitive-healthcare-reports-financial-results-for-first-quarter-fiscal-year-2024-first-q-dh-20240507monthly0.5https://www.biopharmawatch.com/news/DH/definitive-healthcare-reports-financial-results-for-fourth-quarter-and-full-fiscal-year-20-dh-20240228monthly0.5https://www.biopharmawatch.com/news/DH/definitive-healthcare-announces-ceo-transition-jason-krantz-founder-and-executive-chairman-dh-20240116monthly0.5https://www.biopharmawatch.com/news/DH/team-as-we-embark-upon-this-new-year-i-m-writing-to-share-some-critical-and-difficult-chan-dh-20240104monthly0.5https://www.biopharmawatch.com/news/DH/definitive-healthcare-reports-financial-results-for-third-quarter-fiscal-year-2023-third-q-dh-20231102monthly0.5https://www.biopharmawatch.com/news/DH/definitive-healthcare-names-carrie-lazorchak-as-chief-revenue-officer-framingham-ma-dh-20231005monthly0.5https://www.biopharmawatch.com/news/DH/definitive-healthcare-welcomes-scott-stephenson-to-board-of-directors-framingham-ma-dh-20230908monthly0.5https://www.biopharmawatch.com/news/DH/definitive-healthcare-reports-financial-results-for-second-quarter-fiscal-year-2023-second-dh-20230814monthly0.5https://www.biopharmawatch.com/news/DH/definitive-healthcare-reports-preliminary-financial-results-for-second-quarter-fiscal-year-dh-20230801monthly0.5https://www.biopharmawatch.com/news/DH/definitive-healthcare-reports-financial-results-for-first-quarter-fiscal-year-2023-first-q-dh-20230504monthly0.5https://www.biopharmawatch.com/news/DH/definitive-healthcare-reports-financial-results-for-fourth-quarter-and-full-fiscal-year-20-dh-20230223monthly0.5https://www.biopharmawatch.com/news/DH/email-to-employees-definitive-healthcare-team-today-i-m-announcing-the-most-difficult-deci-dh-20230112monthly0.5https://www.biopharmawatch.com/news/DH/definitive-healthcare-reports-financial-results-for-third-quarter-fiscal-year-2022-third-q-dh-20221103monthly0.5https://www.biopharmawatch.com/news/DH/definitive-healthcare-announces-changes-to-board-of-directors-sastry-chilukuri-joins-board-dh-20221003monthly0.5https://www.biopharmawatch.com/news/DH/definitive-healthcare-reports-financial-results-for-second-quarter-fiscal-year-2022-second-dh-20220804monthly0.5https://www.biopharmawatch.com/news/DH/definitive-healthcare-reports-financial-results-for-first-quarter-fiscal-year-2022-first-q-dh-20220505monthly0.5https://www.biopharmawatch.com/news/DH/definitive-healthcare-reports-financial-results-for-fourth-quarter-and-full-year-fiscal-20-dh-20220223monthly0.5https://www.biopharmawatch.com/news/DH/definitive-healthcare-reports-financial-results-for-third-quarter-fiscal-year-2021-third-q-dh-20211108monthly0.5https://www.biopharmawatch.com/news/DH/robert-musslewhite-joins-definitive-healthcare-as-president-framingham-ma-dh-20211007monthly0.5https://www.biopharmawatch.com/news/DH/definitive-healthcare-appoints-kathleen-a-winters-to-board-of-directors-framingham-ma-dh-20211001monthly0.5https://www.biopharmawatch.com/news/DH/definitive-healthcare-announces-closing-of-public-offering-framingham-ma-dh-20210920monthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-cognition-inc-nasdaq-acog-1452-hughes-road-ste-200-grapevine-tx-65051-www-alphacogni-acog-20260326monthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-cognition-inc-announces-proposed-public-offering-of-common-shares-vancouver-bc-and-d-acog-20250930monthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-cognition-inc-c-o-1200-750-west-pender-street-vancouver-bc-v6c-2t8-management-inform-acog-20240821monthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-cognition-inc-cse-acog-1200-750-w-pender-st-vancouver-bc-v6c-2t8-www-alphacognition--acog-20240812monthly0.5https://www.biopharmawatch.com/news/ACOG/alpha-cognition-inc-cse-acog-otcqb-acogf-301-1228-hamilton-street-vancouver-bc-v6b-6l2-www-acog-20240729monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-reports-second-quarter-2025-financial-results-provides-corporate-update--rani-20250807monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-reports-first-quarter-2025-financial-results-provides-corporate-update-a-rani-20250513monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-provides-cor-rani-20250331monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-reports-third-quarter-2024-financial-results-provides-corporate-update-c-rani-20241114monthly0.5https://www.biopharmawatch.com/news/RANI/this-presentation-and-the-accompanying-oral-statements-contain-forward-looking-statements--rani-20240624monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-reports-first-quarter-2024-financial-results-provides-corporate-update-a-rani-20240506monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-provides-cor-rani-20240320monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-announces-positive-topline-results-from-phase-1-study-of-an-oral-anti-in-rani-20240205monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-reports-third-quarter-2023-financial-results-provides-corporate-update-c-rani-20231108monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-announces-strategic-program-prioritization-expansion-of-manufacturing-an-rani-20231101monthly0.5https://www.biopharmawatch.com/news/RANI/the-ranipill-capsule-rani-therapeutics-oral-delivery-platform-was-well-tolerated-in-60-day-rani-20231025monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-announces-successful-drug-delivery-of-high-capacity-pill-in-preclinical--rani-20230907monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-reports-second-quarter-2023-financial-results-provides-corporate-update--rani-20230811monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-provides-cor-rani-20230322monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-receives-feedback-from-pre-ind-meeting-with-fda-provides-pipeline-update-rani-20230105monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-announces-repeat-dose-topline-results-from-rt-102-phase-1-study-rt-102-a-rani-20221206monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-reports-third-quarter-2022-financial-results-and-provides-corporate-upda-rani-20221110monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-announces-new-rt-111-development-program-and-provides-corporate-update-r-rani-20221024monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-reports-second-quarter-2022-financial-results-provides-corporate-update--rani-20220810monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-reports-first-quarter-2022-financial-results-provides-corporate-update-i-rani-20220511monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-provides-cor-rani-20220329monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-unveils-high-capacity-ranipill-device-for-oral-delivery-of-biologics-rep-rani-20220223monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-reports-third-quarter-2021-financial-results-provides-corporate-update-rani-20211115monthly0.5https://www.biopharmawatch.com/news/RANI/this-presentation-and-the-accompanying-oral-statements-contain-forward-looking-statements--rani-20210929monthly0.5https://www.biopharmawatch.com/news/RANI/rani-therapeutics-reports-second-quarter-2021-financial-results-provides-corporate-update--rani-20210913monthly0.5https://www.biopharmawatch.com/news/GNLX/genelux-corporation-announces-proposed-public-offering-of-common-stock-gnlx-20260107monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-reports-first-quarter-2026-financial-results-rcel-20260514monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-names-cary-vance-as-chief-executive-officer-x2022-board-appoints-cary-vance--rcel-20260430monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-reports-fourth-quarter-and-full-year-2025-financial-results-rcel-20260212monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-announces-ceo-transition-x2022-board-chairman-cary-vance-appointed-interim-c-rcel-20251016monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-successfully-completes-australian-equity-raise-x2022-private-placement-of-ap-rcel-20250812monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-reports-second-quarter-2025-financial-results-updates-full-year-guidance-and-rcel-20250807monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-announces-appointment-of-michael-tarnoff-md-facs-to-its-board-of-directors-a-rcel-20250806monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-reports-first-quarter-2025-financial-results-rcel-20250508monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-announces-exclusive-manufacturing-and-distribution-agreements-with-stedical--rcel-20250317monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-reports-fourth-quarter-and-full-year-2024-financial-results-rcel-20250213monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-updates-expected-fourth-quarter-and-full-year-2024-revenue-provides-2025-fin-rcel-20250107monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-reports-third-quarter-financial-results-rcel-20241107monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-reports-second-quarter-financial-results-rcel-20240808monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-expands-portfolio-with-unique-dermal-matrix-to-advance-wound-care-exclusive--rcel-20240731monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-appoints-nicole-kelsey-as-chief-legal-and-compliance-officer-and-corporate-s-rcel-20240701monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-announces-fda-approval-of-rcel-20240530monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-reports-first-quarter-financial-results-rcel-20240513monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-updates-expected-first-quarter-2024-revenue-rcel-20240410monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-202-rcel-20240222monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-announces-preliminary-2023-financial-highlights-provides-2024-financial-guid-rcel-20240110monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-reports-third-quarter-financial-results-with-51-revenue-growth-over-the-same-rcel-20231109monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-announces-preliminary-third-quarter-2023-financial-highlights-and-secures-up-rcel-20231018monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-reports-second-quarter-financial-results-rcel-20230810monthly0.5https://www.biopharmawatch.com/news/RCEL/full-thickness-skin-defects-ftsd-market-sizing-june-2023-update-market-size-additional-mar-rcel-20230626monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-announces-appointment-of-david-o-toole-as-chief-financial-officer-rcel-20230615monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-reports-first-quarter-financial-results-and-affirms-full-year-guidance-rcel-20230511monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-announce-first-quarter-2023-financial-results-valencia-calif-rcel-20230420monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-appoints-new-non-executive-member-to-the-board-of-directors-rcel-20230323monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-appoints-new-non-executive-member-to-the-board-of-directors-rcel-20230316monthly0.5https://www.biopharmawatch.com/news/RCEL/certain-statements-in-this-presentation-and-the-accompanying-oral-commentary-are-forward-l-rcel-20230302monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-announce-fourth-quarter-and-full-year-2022-financial-results-and-provide--rcel-20230209monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-announces-management-changes-and-fourth-quarter-2022-earnings-conference-cal-rcel-20230119monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-submits-fda-pma-application-to-expand-indication-to-vitiligo-valencia-calif--rcel-20221219monthly0.5https://www.biopharmawatch.com/news/RCEL/mr-lou-panaccio-chairman-of-the-board-of-avita-medical-inc-call-to-order-brief-company-ove-rcel-20221214monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-reports-third-quarter-2022-financial-results-rcel-20221110monthly0.5https://www.biopharmawatch.com/news/RCEL/asx-news-release-avita-medical-announces-fda-breakthrough-device-designations-for-the-rece-rcel-20221103monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-appoints-industry-leader-james-corbett-as-chief-executive-officer-rcel-20220928monthly0.5https://www.biopharmawatch.com/news/RCEL/certain-statements-in-this-presentation-and-the-accompanying-oral-commentary-are-forward-l-rcel-20220922monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-achieves-positive-topline-pivotal-trial-results-for-treatment-of-stable-viti-rcel-20220913monthly0.5https://www.biopharmawatch.com/news/RCEL/recell-system-insurance-coverage-begins-in-japan-for-treatment-of-acute-burns-reimbursemen-rcel-20220902monthly0.5https://www.biopharmawatch.com/news/RCEL/certain-statements-in-this-presentation-and-the-accompanying-oral-commentary-are-forward-l-rcel-20220830monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-reports-second-quarter-2022-financial-results-rcel-20220811monthly0.5https://www.biopharmawatch.com/news/RCEL/asx-news-release-avita-medical-inc-substantial-holder-notice-valencia-calif-usa-and-melbou-rcel-20220722monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-reports-first-quarter-2022-financial-results-rcel-20220512monthly0.5https://www.biopharmawatch.com/news/RCEL/recell-system-to-be-highlighted-at-upcoming-music-city-scale-multidisciplinary-dermatology-rcel-20220510monthly0.5https://www.biopharmawatch.com/news/RCEL/asx-news-release-avita-medical-to-announce-first-quarter-2022-financial-results-valencia-c-rcel-20220428monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-inc-announces-resignation-of-louis-drapeau-from-board-of-directors-valencia--rcel-20220421monthly0.5https://www.biopharmawatch.com/news/RCEL/recell-system-data-to-be-presented-at-the-american-burn-association-annual-meeting-rcel-20220404monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-announces-modification-of-barda-contract-to-advance-development-of-recell-sy-rcel-20220321monthly0.5https://www.biopharmawatch.com/news/RCEL/february-2022-nasdaq-rcel-asx-avh-copyright-2022-avita-medical-all-rights-reserved-legal-d-rcel-20220309monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-inc-signs-agreement-with-premier-inc-to-supply-the-recell-system-to-hospital-rcel-20220304monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-reports-quarter-ending-rcel-20220301monthly0.5https://www.biopharmawatch.com/news/RCEL/the-recell-system-receives-pmda-approval-in-japan-and-avita-medical-will-commercialize-in--rcel-20220224monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-announces-fda-approval-of-new-recell-system-with-improved-ease-of-use-system-rcel-20220218monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-present-at-the-btig-medtech-digital-health-life-science-diagnostic-tools--rcel-20220202monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-announces-preliminary-unaudited-results-for-the-quarter-ended-rcel-20211231monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-inc-results-of-2021-annual-meeting-of-shareholders-rcel-20211222monthly0.5https://www.biopharmawatch.com/news/RCEL/certain-statements-in-this-presentation-and-the-accompanying-oral-commentary-are-forward-l-rcel-20211215monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-inc-announces-adjournment-of-2021-annual-stockholder-meeting-valencia-calif--rcel-20211214monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-reports-first-fiscal-quarter-2022-financial-results-rcel-20211108monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-reports-fourth-quarter-and-fiscal-year-2021-financial-results-rcel-20210826monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-to-announce-fiscal-fourth-quarter-2021-financial-results-rcel-20210812monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-announces-inclusion-in-the-russell-3000-index-valencia-calif-usa-rcel-20210629monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-announces-preliminary-fourth-quarter-2021-financial-results-valencia-calif-u-rcel-20210615monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-inc-appoints-two-new-non-executive-rcel-20210601monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-reports-third-quarter-2021-financial-results-rcel-20210513monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-inc-names-michael-holder-as-chief-financial-officer-rcel-20210322monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-inc-announces-closing-of-offering-of-3-214-250-rcel-20210301monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-rcel-20210224monthly0.5https://www.biopharmawatch.com/news/RCEL/asx-news-release-avita-medical-announces-preliminary-fiscal-second-quarter-2021-results-va-rcel-20210112monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-therapeutics-appoints-kathy-mcgee-as-chief-operating-officer-valencia-calif-usa-and--rcel-20201201monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-therapeutics-and-the-houston-methodist-research-institute-enter-into-collaboration-t-rcel-20201109monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-therapeutics-inc-announces-executive-change-valencia-calif-usa-rcel-20201105monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-therapeutics-inc-announces-correction-of-time-for-the-adjourned-2020-annual-stockhol-rcel-20201104monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-therapeutics-inc-announces-adjournment-of-2020-annual-stockholder-meeting-rcel-20201029monthly0.5https://www.biopharmawatch.com/news/RCEL/shelf-registration-statement-filed-with-sec-valencia-calif-usa-and-melbourne-australia-rcel-20201012monthly0.5https://www.biopharmawatch.com/news/RCEL/appendix-4e-preliminary-final-report-30-june-2020-avita-therapeutics-inc-arbn-641-288-155--rcel-20200831monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-therapeutics-provides-company-update-and-revised-corporate-presentation-valencia-cal-rcel-20200826monthly0.5https://www.biopharmawatch.com/news/RCEL/barda-to-initiate-procurement-of-the-recell-system-for-emergency-response-preparedness-val-rcel-20200713monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-therapeutics-provides-company-update-and-preliminary-unaudited-results-for-the-fourt-rcel-20200709monthly0.5https://www.biopharmawatch.com/news/RCEL/asx-news-release-avita-medical-limited-proposed-redomiciliation-to-the-united-states-of-am-rcel-20200622monthly0.5https://www.biopharmawatch.com/news/RCEL/asx-news-release-avita-medical-limited-proposed-redomiciliation-to-the-united-states-of-am-rcel-20200615monthly0.5https://www.biopharmawatch.com/news/RCEL/asx-news-release-avita-medical-limited-proposed-redomiciliation-to-the-united-states-of-am-rcel-20200611monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-limited-proposed-redomiciliation-to-the-united-states-of-america-registratio-rcel-20200512monthly0.5https://www.biopharmawatch.com/news/RCEL/asx-news-release-avita-medical-limited-proposed-redomiciliation-to-the-united-states-of-am-rcel-20200511monthly0.5https://www.biopharmawatch.com/news/RCEL/asx-news-release-avita-medical-reports-third-quarter-fiscal-2020-financial-results-and-com-rcel-20200429monthly0.5https://www.biopharmawatch.com/news/RCEL/asx-news-release-avita-medical-announces-intention-to-redomicile-to-the-united-states-of-a-rcel-20200420monthly0.5https://www.biopharmawatch.com/news/RCEL/asx-news-release-avita-medical-provides-preliminary-top-line-results-for-the-third-quarter-rcel-20200415monthly0.5https://www.biopharmawatch.com/news/RCEL/asx-news-release-avita-medical-half-year-financial-report-for-fiscal-2020-valencia-calif-u-rcel-20200219monthly0.5https://www.biopharmawatch.com/news/RCEL/asx-news-release-avita-medical-reports-second-quarter-fiscal-2020-financial-results-and-co-rcel-20200203monthly0.5https://www.biopharmawatch.com/news/RCEL/december-2019-registered-office-avita-medical-limited-c-o-mertons-corporate-services-pty-l-rcel-20191206monthly0.5https://www.biopharmawatch.com/news/RCEL/asx-news-release-avita-medical-names-david-mcintyre-as-chief-financial-officer-appointment-rcel-20191118monthly0.5https://www.biopharmawatch.com/news/RCEL/asx-news-release-avita-medical-announces-institutional-placement-of-a-120-0-million-to-sup-rcel-20191113monthly0.5https://www.biopharmawatch.com/news/RCEL/asx-news-release-avita-medical-reports-first-quarter-fiscal-2020-financial-results-and-com-rcel-20191101monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-limited-acn-058-466-523-notice-of-2019-annual-general-meeting-notice-is-give-rcel-20191101monthly0.5https://www.biopharmawatch.com/news/RCEL/contents-corporate-information-3-letter-from-the-chairman-and-ceo-4-5-directors-report-6-2-rcel-20191011monthly0.5https://www.biopharmawatch.com/news/RCEL/avita-medical-limited-a-b-n-28-058-466-523-full-financial-report-for-the-year-ended-30-jun-rcel-20190930monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-first-quarter-2026-financial-results-and-highlights-bot-bal-execution-acros-agen-20260511monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-2025-results-bot-bal-advances-to-phase-3-and-early-access-programs-expand-g-agen-20260316monthly0.5https://www.biopharmawatch.com/news/AGEN/about-balstilimab-bal-balstilimab-is-a-novel-fully-human-monoclonal-immunoglobulin-g4-igg4-agen-20260116monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-q3-2025-results-showcasing-clinical-and-regulatory-advances-x2022-france-gr-agen-20251110monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-is-dedicated-to-making-investigational-medicines-available-to-patients-with-cancer--agen-20250811monthly0.5https://www.biopharmawatch.com/news/AGEN/pd-l2-it-has-been-evaluated-in-900-patients-to-date-and-has-demonstrated-clinical-activity-agen-20250604monthly0.5https://www.biopharmawatch.com/news/AGEN/information-that-may-be-important-to-investors-will-be-routinely-posted-on-our-website-and-agen-20250512monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-q4-and-year-end-2024-results-strategic-operational-improvements-and-signifi-agen-20250311monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-secures-22-million-mortgage-and-announces-strategic-operational-realignment-lexingt-agen-20241127monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-third-quarter-2024-financial-results-and-strategic-advancements-in-bot-bal--agen-20241112monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-second-quarter-2024-operational-and-financial-results-robust-phase-2-data-v-agen-20240808monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-announces-appointment-of-dr-jennifer-buell-to-its-board-of-directors-6-17-2024-stra-agen-20240611monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-first-quarter-2024-results-100m-royalty-financing-agreement-with-ligand-ann-agen-20240507monthly0.5https://www.biopharmawatch.com/news/AGEN/ligand-and-agenus-enter-into-100-million-royalty-financing-agreement-capital-infusion-will-agen-20240507monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-fourth-quarter-and-full-year-2023-results-fda-grants-fast-track-designation-agen-20240314monthly0.5https://www.biopharmawatch.com/news/AGEN/expressions-are-intended-to-identify-forward-looking-statements-these-forward-looking-stat-agen-20240215monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-third-quarter-2023-results-conference-call-on-tuesday-agen-20231107monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-second-quarter-2023-results-lexington-mass-business-wire-agen-20230808monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-provides-corporate-update-and-first-quarter-2023-financial-results-at-a-late-breaki-agen-20230509monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-announces-dividend-of-5-million-shares-of-mink-therapeutics-agen-20230330monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-corporate-update-and-fourth-quarter-full-year-2021-financial-report-botensilimab-fc-agen-20220301monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-provides-update-on-balstilimab-development-company-voluntarily-withdraws-bla-at-fda-agen-20211022monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-and-bristol-myers-squibb-announce-exclusive-global-license-for-agenus-anti-tigit-bi-agen-20210518monthly0.5https://www.biopharmawatch.com/news/AGEN/susan-hirsch-joins-agenus-board-of-directors-agen-20201013monthly0.5https://www.biopharmawatch.com/news/AGEN/paul-clark-joins-agenus-board-of-directors-agen-20200831monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-provides-r-d-update-second-quarter-financial-report-dr-chuck-drake-dr-bree-wilky-to-agen-20200806monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-receives-35m-in-immuno-oncology-transaction-with-betta-pharmaceuticals-lexington-ma-agen-20200728monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-and-betta-pharmaceuticals-enter-into-a-license-agreement-for-balstilimab-and-zalifr-agen-20200622monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-first-quarter-results-and-update-agen1181-nextgen-ctla-4-balstilimab-anti-pd-1-show-agen-20200507monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides-corporate--agen-20200312monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-announces-the-appointment-of-dr-jennifer-buell-to-the-position-of-president-and-agen-20200109monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-provides-corporate-update-with-third-quarter-2019-financial-results-pd-1-plus-ctla--agen-20191104monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-second-quarter-2019-financial-results-and-provides-corporate-update-enrollm-agen-20190808monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-first-quarter-2019-financial-results-and-provides-corporate-update-gilead-p-agen-20190509monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-fourth-quarter-and-full-year-2018-financial-results-and-provides-corporate--agen-20190314monthly0.5https://www.biopharmawatch.com/news/AGEN/impact-of-tokens-on-agen2034-economics-illustrative-us-net-sales-of-agen2034-illustrative--agen-20190221monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-closes-150-million-immuno-oncology-transaction-with-gilead-lexington-mass-agen-20190124monthly0.5https://www.biopharmawatch.com/news/AGEN/gilead-contacts-sung-lee-investors-650-524-7792-nathan-kaiser-media-650-522-1853-agenus-co-agen-20181220monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-third-quarter-2018-financial-results-and-provides-corporate-update-130-pati-agen-20181106monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-second-quarter-2018-financial-results-and-provides-corporate-update-cash-mi-agen-20180809monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-first-quarter-2018-financial-results-and-provides-corporate-update-agenus-t-agen-20180507monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-fourth-quarter-and-full-year-2017-financial-results-and-provides-corporate--agen-20180315monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-inc-announces-230-million-royalty-monetization-with-healthcare-royalty-partners-lex-agen-20180108monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-receives-license-fee-of-4-million-usd-from-merck-entitled-up-to-an-additional-99-mi-agen-20171115monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-second-quarter-2017-financial-results-and-provides-corporate-update-earning-agen-20170803monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-first-quarter-2017-financial-results-and-provides-corporate-update-substant-agen-20170504monthly0.5https://www.biopharmawatch.com/news/AGEN/phase-1-2-clinical-trial-of-agenus-anti-pd-1-antibody-begins-first-patient-dosed-combinati-agen-20170420monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-restructures-business-to-sharpen-focus-on-clinical-development-of-cancer-therapies--agen-20170330monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-fourth-quarter-and-full-year-2016-results-will-host-update-conference-call--agen-20170309monthly0.5https://www.biopharmawatch.com/news/AGEN/incyte-and-agenus-amend-collaboration-agreement-incyte-secures-global-clinical-development-agen-20170214monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-announces-collaboration-with-the-national-cancer-institute-to-evaluate-the-combinat-agen-20170117monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-announces-commencement-of-phase-1-2-clinical-trial-of-anti-ox40-checkpoint-antibody-agen-20161130monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-third-quarter-financial-results-and-recent-highlights-company-to-host-confe-agen-20161027monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-second-quarter-2016-financial-results-and-operational-progress-company-to-h-agen-20160728monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-appoints-jean-marie-cuillerot-m-d-as-vice-president-and-global-head-of-clinical-dev-agen-20160706monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-announces-commencement-of-phase-1-2-clinical-trial-of-anti-gitr-checkpoint-antibody-agen-20160622monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-announces-lead-product-candidate-selection-in-its-collaboration-with-merck-received-agen-20160609monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-first-quarter-2016-financial-results-and-operational-progress-company-to-ho-agen-20160428monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-commences-phase-1-clinical-trial-of-its-ctla-4-checkpoint-antibody-to-treat-solid-t-agen-20160427monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-fourth-quarter-and-full-year-2015-financial-and-operational-results-and-rec-agen-20160303monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-announces-clearance-of-investigational-new-drug-applications-by-the-fda-for-anti-ct-agen-20160121monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-completes-xoma-antibody-manufacturing-pilot-plant-acquisition-agen-20160104monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-acquires-phosimmune-with-a-novel-class-of-cancer-neoantigens-offers-the-potential-f-agen-20151223monthly0.5https://www.biopharmawatch.com/news/AGEN/forward-looking-statements-this-presentation-contains-forward-looking-statements-including-agen-20151119monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-to-acquire-antibody-manufacturing-capability-expands-antibody-discovery-and-adds-ce-agen-20151105monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-third-quarter-2015-financial-results-corporate-update-conference-call-at-11-agen-20151027monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-inc-completes-115-million-non-dilutive-royalty-transaction-with-oberland-capital-le-agen-20150909monthly0.5https://www.biopharmawatch.com/news/AGEN/gsk-s-malaria-vaccine-containing-agenus-qs-21-stimulon-receives-positive-opinion-from-euro-agen-20150724monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-second-quarter-2015-financial-results-corporate-update-conference-call-at-1-agen-20150723monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-acquires-novel-antibodies-to-immuno-oncology-target-ceacam1-target-expressed-on-lym-agen-20150720monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-appoints-c-evan-ballantyne-as-chief-financial-officer-lexington-mass-business-wire-agen-20150617monthly0.5https://www.biopharmawatch.com/news/AGEN/merck-extends-immuno-oncology-collaboration-with-agenus-collaboration-involves-two-proprie-agen-20150603monthly0.5https://www.biopharmawatch.com/news/AGEN/updated-phase-2-data-of-prophage-in-newly-diagnosed-gbm-presented-at-asco-show-improvement-agen-20150601monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-announces-closing-of-public-offering-and-exercise-in-full-of-underwriters-option-to-agen-20150527monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-announces-proposed-public-offering-of-common-stock-agen-20150520monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-r-d-day-may-14th-2015-driving-the-immune-a-system-to-fight-cancer-and-infectious-di-agen-20150501monthly0.5https://www.biopharmawatch.com/news/AGEN/nejm-publishes-study-showing-gsk-s-shingles-vaccine-containing-agenus-qs-21-stimulon-adjuv-agen-20150428monthly0.5https://www.biopharmawatch.com/news/AGEN/gsk-s-malaria-vaccine-phase-3-study-containing-agenus-qs-21-published-in-the-lancet-final--agen-20150424monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-first-quarter-2015-financial-results-corporate-update-conference-call-at-11-agen-20150423monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-acquires-celexion-assets-and-expands-its-antibody-discovery-platform-secant-yeast-d-agen-20150408monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-fourth-quarter-and-full-year-2014-financial-results-agenus-to-host-conferen-agen-20150226monthly0.5https://www.biopharmawatch.com/news/AGEN/incyte-and-agenus-announce-global-alliance-to-develop-novel-immuno-oncology-antibodies-all-agen-20150109monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-third-quarter-2014-financial-results-agenus-to-host-conference-call-beginni-agen-20141031monthly0.5https://www.biopharmawatch.com/news/AGEN/first-vaccine-candidate-for-malaria-is-accepted-for-eu-regulatory-review-gsk-s-rts-s-is-th-agen-20140724monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-second-quarter-2014-financial-results-agenus-to-host-conference-call-beginn-agen-20140724monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-brain-cancer-vaccine-shows-extended-survival-in-phase-2-final-data-analysis-median--agen-20140701monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-vaccine-shows-significant-reduction-in-viral-burden-after-herpv-generated-immune-ac-agen-20140626monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-selected-for-inclusion-in-the-russell-3000-index-and-global-index-lexington-mass-bu-agen-20140616monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-first-quarter-2014-financial-results-agenus-to-host-conference-call-beginni-agen-20140508monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-announces-collaboration-and-license-agreement-with-merck-for-novel-checkpoint-antib-agen-20140428monthly0.5https://www.biopharmawatch.com/news/AGEN/update-on-gsk-s-mage-a3-cancer-immunotherapeutic-phase-3-study-in-non-small-cell-lung-canc-agen-20140402monthly0.5https://www.biopharmawatch.com/news/AGEN/gsk-s-mage-a3-cancer-immunotherapeutic-phase-3-study-in-non-small-cell-lung-cancer-misses--agen-20140320monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-reports-fourth-quarter-and-full-year-2013-financial-results-agenus-to-host-conferen-agen-20140305monthly0.5https://www.biopharmawatch.com/news/AGEN/agenus-completes-acquisition-of-4-antibody-agenus-gains-powerful-platform-for-rapid-discov-agen-20140213monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-announces-first-quarter-2026-results-and-highlights-delivered-25-6-million-in-rev-bdsx-20260504monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-announces-fourth-quarter-and-fiscal-year-2025-results-and-highlights-delivered-41-bdsx-20260226monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-announces-preliminary-fourth-quarter-and-full-year-2025-results-unaudited-estimat-bdsx-20260112monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-announces-third-quarter-2025-results-and-highlights-q3-2025-revenue-of-21-8-milli-bdsx-20251103monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-announces-one-for-twenty-reverse-stock-split-louisville-co-bdsx-20250911monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-announces-second-quarter-2025-results-and-highlights-q2-2025-revenue-of-20-0-mill-bdsx-20250807monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-announces-first-quarter-2025-results-and-highlights-total-q1-2025-revenue-of-18-0-bdsx-20250513monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-announces-fourth-quarter-and-fiscal-year-2024-results-total-revenue-of-71-3-milli-bdsx-20250303monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-announces-preliminary-fourth-quarter-and-full-year-2024-results-unaudited-grew-fu-bdsx-20250110monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-announces-third-quarter-2024-results-and-highlights-q3-2024-revenue-grew-35-over--bdsx-20241101monthly0.5https://www.biopharmawatch.com/news/BDSX/corporate-presentation-biodesix-is-a-blood-based-lung-diagnostic-company-addressing-a-larg-bdsx-20240815monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-announces-second-quarter-2024-results-and-highlights-q2-2024-revenue-grew-51-over-bdsx-20240807monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-announces-first-quarter-2024-results-driven-by-growth-in-lung-diagnostic-testing--bdsx-20240508monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-announces-pricing-of-oversubscribed-and-upsized-underwritten-offering-of-common-s-bdsx-20240405monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-announces-fourth-quarter-and-fiscal-year-2023-results-and-business-highlights-per-bdsx-20240301monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-announces-third-quarter-2023-results-and-highlights-third-quarter-2023-lung-diagn-bdsx-20231107monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-announces-second-quarter-2023-results-and-highlights-second-quarter-2023-core-lun-bdsx-20230807monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-announces-first-quarter-2023-results-and-highlights-first-quarter-2023-core-lung--bdsx-20230511monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-announces-fourth-quarter-and-fiscal-year-end-2022-results-and-highlights-fourth-q-bdsx-20230306monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-s-most-recent-annual-report-on-form-10-k-filed-bdsx-20221216monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-announces-senior-secured-financing-agreement-with-perceptive-advisors-for-up-to-5-bdsx-20221116monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-announces-third-quarter-2022-results-and-highlights-third-quarter-2022-core-lung--bdsx-20221103monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-announces-preliminary-revenue-for-third-quarter-2022-third-quarter-2022-core-lung-bdsx-20221011monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-announces-second-quarter-2022-results-and-highlights-second-quarter-2022-core-lun-bdsx-20220804monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-announces-first-quarter-2022-results-and-highlights-first-quarter-2022-core-lung--bdsx-20220511monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-strengthens-financial-position-with-equity-issuance-and-amendment-to-term-loan-ap-bdsx-20220411monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-announces-fourth-quarter-and-year-end-2021-results-and-highlights-fourth-quarter--bdsx-20220314monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-announces-common-stock-purchase-agreement-for-up-to-50-million-with-lincoln-park--bdsx-20220307monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-announces-preliminary-fourth-quarter-and-full-year-2021-revenue-unaudited-core-lu-bdsx-20220214monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-strengthens-financial-position-with-equity-issuance-and-amendment-to-term-loan-ap-bdsx-20220104monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-announces-appointment-of-successful-innovator-and-scientific-professional-jon-fai-bdsx-20211208monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-announces-third-quarter-2021-results-and-highlights-third-quarter-2021-lung-diagn-bdsx-20211115monthly0.5https://www.biopharmawatch.com/news/BDSX/this-presentation-and-the-accompanying-oral-presentation-have-been-prepared-by-biodesix-in-bdsx-20210909monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-announces-second-quarter-2021-results-and-highlights-second-quarter-2021-revenue--bdsx-20210810monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-inc-condensed-balance-sheets-unaudited-in-thousands-bdsx-20210511monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-announces-closing-of-new-30-million-term-loan-increases-company-s-net-liquidity-p-bdsx-20210323monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-inc-condensed-statements-of-operations-unaudited-in-thousands-except-per-share-da-bdsx-20210316monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-anticipates-strong-preliminary-fourth-quarter-2020-revenue-unaudited-record-quart-bdsx-20210108monthly0.5https://www.biopharmawatch.com/news/BDSX/and-uncertainties-actual-results-and-performance-could-differ-materially-from-those-projec-bdsx-20210105monthly0.5https://www.biopharmawatch.com/news/BDSX/biodesix-announces-third-quarter-2020-results-and-provides-corporate-update-generates-reco-bdsx-20201210monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-preliminary-q1-2026-revenue-of-9-6-9-7-million-up-3-4-year-over-ye-snwv-20260331monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-q3-fy2025-financial-results-q3-2025-revenues-were-11-5-million-up-22-fr-snwv-20251107monthly0.5https://www.biopharmawatch.com/news/SNWV/document-sanuwave-announces-strategic-debt-refinancing-with-new-credit-facility-credit-fac-snwv-20250926monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-q2-fy2025-financial-results-q2-2025-revenues-were-10-2-million-up-42-fr-snwv-20250808monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-preliminary-revenue-results-for-the-second-quarter-2025-ended-snwv-20250630monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-q1-fy2025-financial-results-q1-2025-revenues-were-9-3-million-up-61-fro-snwv-20250509monthly0.5https://www.biopharmawatch.com/news/SNWV/document-sanuwave-health-announces-preliminary-revenue-results-for-the-first-quarter-2025--snwv-20250331monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-record-quarterly-revenues-q4-fy2024-financial-results-q4-2024-revenues--snwv-20250321monthly0.5https://www.biopharmawatch.com/news/SNWV/document-sanuwave-health-to-uplist-to-the-nasdaq-global-market-trading-under-the-ticker-sn-snwv-20250307monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-preliminary-revenue-results-for-the-fourth-quarter-2024-ended-snwv-20241231monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-record-quarterly-revenues-q3-fy2024-financial-results-q3-2024-revenues--snwv-20241108monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-1-for-375-reverse-stock-split-common-stock-will-begin-trading-on-snwv-20241018monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-record-quarterly-revenues-q2-fy2024-financial-results-q2-2024-revenues--snwv-20240813monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-preliminary-revenue-results-for-the-second-quarter-2024-ended-snwv-20240630monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-termination-of-merger-agreement-with-sep-acquisition-corp-company-to-pu-snwv-20240626monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-provides-corporate-update-sanuwave-pays-off-6-3-million-celularity-note-and-inter-snwv-20240604monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-preliminary-revenue-results-for-the-first-quarter-2024-ended-snwv-20240331monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-appoints-industry-veteran-peter-sorensen-as-chief-financial-officer-sanuwa-snwv-20240401monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-record-q4-and-fy2023-revenue-q4-2023-revenues-were-a-record-7-0-million-snwv-20240322monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-preliminary-revenue-results-for-the-fourth-quarter-and-fiscal-ye-snwv-20231231monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-q3-2023-financial-results-eden-prairie-mn-november-10-2023-sanuwave-hea-snwv-20231113monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-preliminary-revenue-results-for-the-third-quarter-ended-snwv-20230930monthly0.5https://www.biopharmawatch.com/news/SNWV/investor-presentation-september-2023-this-presentation-presentation-is-for-informational-p-snwv-20230925monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-inc-a-leading-provider-of-fda-approved-next-generation-wound-care-products-snwv-20230823monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-q2-2023-financial-results-eden-prairie-mn-august-11-2023-sanuwave-healt-snwv-20230811monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-appoints-industry-veteran-andrew-walko-as-president-sanuwave-health-inc-snwv-20230731monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-preliminary-revenue-results-for-the-second-quarter-ended-snwv-20230630monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-inc-appoints-morgan-frank-as-chief-executive-officer-published-snwv-20230524monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-q1-2023-financial-results-sanuwave-health-inc-snwv-20230512monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-fourth-quarter-and-full-year-2022-results-and-provides-corporate-update-snwv-20230403monthly0.5https://www.biopharmawatch.com/news/SNWV/kevin-richardson-ii-chief-executive-officer-investors-sanuwave-com-sanuwave-announces-q3-e-snwv-20221114monthly0.5https://www.biopharmawatch.com/news/SNWV/investor-presentation-october-2022-forward-looking-statements-this-presentation-may-contai-snwv-20221013monthly0.5https://www.biopharmawatch.com/news/SNWV/sabrina-ruelle-senior-director-marketing-program-management-sabrina-ruelle-sanuwave-com-sa-snwv-20220808monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-new-board-leadership-sanuwave-announces-addition-of-three-new-board-mem-snwv-20220412monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-3-million-financing-capital-to-accelerate-the-company-s-near-ter-snwv-20210428monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-completes-acquisition-of-snwv-20200812monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-to-provide-update-on-recently-acquired-wound-care-snwv-20200812monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-enters-into-exclusive-letter-of-intent-to-acquire-celularity-s-ultramist-x-snwv-20200610monthly0.5https://www.biopharmawatch.com/news/SNWV/securities-and-exchange-commission-snwv-20200601monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-inc-conference-call-to-discuss-first-quarter-2020-financial-results-and-pr-snwv-20200527monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-partners-with-the-mobile-health-company-a-snwv-20200518monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-first-quarter-2020-snwv-20200518monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-inc-conference-call-to-discuss-fourth-quarter-and-full-fiscal-year-2019-fi-snwv-20200330monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-snwv-20200207monthly0.5https://www.biopharmawatch.com/news/SNWV/management-presentation-untitled-document-snwv-20191211monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-third-quarter-2019-snwv-20191115monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-second-quarter-2019-snwv-20190815monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-record-2018-financial-results-full-year-revenue-increased-over-150-snwv-20190329monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-record-third-quarter-revenue-total-revenue-increase-of-269-initial-snwv-20181120monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-strong-third-quarter-revenue-product-revenue-increase-of-99-for-9--snwv-20181115monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-record-second-quarter-revenue-increase-and-significant-milestones--snwv-20180814monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-hires-shri-parikh-as-president-for-global-healthcare-division-suwanee-ga-june-4-2-snwv-20180531monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-first-quarter-financial-results-and-provides-a-snwv-20180516monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-signs-1-million-equipment-financing-line-with-nfs-leasing-suwanee-ga-february-12--snwv-20180216monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-strategic-partnership-with-premier-shockwave-dermapace-enters-va-indian-snwv-20180216monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-third-quarter-financial-results-and-provides-a-snwv-20171120monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-second-quarter-financial-results-and-provides-a-business-update-su-snwv-20170817monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-snwv-20170803monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-appoints-maj-britt-kaltoft-to-its-board-of-directors-extensive-internation-snwv-20170727monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-first-quarter-financial-results-and-provides-a-snwv-20170516monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-record-revenue-in-2016-and-provides-a-snwv-20170404monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-third-quarter-financial-results-and-provides-a-business-update-suw-snwv-20161114monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-second-quarter-financial-results-and-provides-a-business-update-al-snwv-20160817monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-first-quarter-financial-results-and-provides-a-snwv-20160517monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-appoints-orthopaedic-and-podiatric-shockwave-executive-a-michael-stolarski-snwv-20160419monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-2015-financial-results-and-provides-a-snwv-20160330monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-closes-1-5-million-equity-offering-alpharetta-ga-march-14-2016-sanuwave-health-in-snwv-20160317monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-third-quarter-financial-results-and-provides-a-snwv-20151112monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-second-quarter-financial-results-and-provides-a-snwv-20150811monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-cfo-transition-alpharetta-ga-july-20-2015-sanuwave-health-inc-ot-snwv-20150720monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-provides-an-update-on-the-dermapace-clinical-trial-alpharetta-ga-june-30-2-snwv-20150630monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-strengthening-of-balance-sheet-with-amendment-and-extension-of-promisso-snwv-20150618monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-provides-an-update-on-the-dermapace-clinical-trial-alpharetta-ga-may-6-201-snwv-20150507monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-2014-financial-results-and-provides-a-snwv-20150303monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-third-quarter-financial-results-and-provides-a-business-update-alp-snwv-20141114monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-first-quarter-financial-results-and-provides-a-business-update-alp-snwv-20140513monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-executive-changes-alpharetta-ga-snwv-20140421monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-2013-financial-results-and-provides-a-clinical-trial-and-funding-u-snwv-20140331monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-closes-10-1m-private-placement-led-by-ra-capital-management-alpharetta-ga-snwv-20140318monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-reports-third-quarter-2013-snwv-20131112monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-appoints-life-sciences-industry-executive-alan-l-rubino-to-its-board-alpharetta-g-snwv-20130904monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-reports-second-quarter-2013-snwv-20130814monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-announces-conversion-of-all-senior-snwv-20130805monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-reports-first-quarter-2013-snwv-20130514monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-reports-2012-snwv-20130326monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-receives-full-approval-from-the-fda-to-conduct-the-dermapace-pivotal-clini-snwv-20130313monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-announces-the-appointment-of-ceo-and-closing-of-its-2-0-snwv-20130226monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-reports-third-quarter-2012-snwv-20121114monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-reports-second-quarter-2012-financial-results-and-provides-a-business-update-comp-snwv-20120808monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-reports-2011-snwv-20120314monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-inc-barry-jenkins-cfo-bernie-laurel-vp-of-sales-and-marketing-678-578-0103-snwv-20111221monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-inc-barry-jenkins-cfo-bernie-laurel-vp-of-sales-and-marketing-678-578-0103-snwv-20111114monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-inc-barry-jenkins-cfo-bernie-laurel-vp-of-sales-and-marketing-678-578-0103-snwv-20110929monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-inc-lippert-heilshorn-associates-barry-jenkins-cfo-anne-marie-fields-inves-snwv-20110921monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-inc-barry-jenkins-cfo-bernie-laurel-vp-of-sales-and-marketing-678-578-0103-snwv-20110810monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-inc-barry-jenkins-cfo-bernie-laurel-vp-of-sales-and-marketing-678-578-0103-snwv-20110712monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-inc-lippert-heilshorn-associates-barry-jenkins-cfo-anne-marie-fields-berni-snwv-20110328monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-inc-lippert-heilshorn-associates-barry-jenkins-cfo-anne-marie-fields-berni-snwv-20101112monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-health-inc-lippert-heilshorn-associates-barry-jenkins-cfo-anne-marie-fields-berni-snwv-20100813monthly0.5https://www.biopharmawatch.com/news/SNWV/sanuwave-inc-and-subsidiaries-consolidated-financial-statements-years-ended-snwv-20090930monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-and-provide-vtvt-20260310monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate-upda-vtvt-20250812monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-2025-first-quarter-financial-results-and-provides-corporate-upd-vtvt-20250515monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-2024-fourth-quarter-and-full-year-financial-results-and-provide-vtvt-20250320monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-2024-third-quarter-financial-results-and-provides-corporate-upd-vtvt-20241112monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-2024-second-quarter-financial-results-and-provides-corporate-up-vtvt-20240808monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-2024-first-quarter-financial-results-and-provides-corporate-upd-vtvt-20240509monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-2023-fourth-quarter-and-full-year-financial-results-and-provide-vtvt-20240313monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-51-million-private-placement-from-healthcare-focused-institutio-vtvt-20240228monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-sale-of-shares-in-reneo-pharmaceuticals-for-proceeds-of-4-4-mil-vtvt-20231101monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-2023-second-quarter-financial-results-and-provides-corporate-up-vtvt-20230811monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-2023-first-quarter-financial-results-and-provides-corporate-upd-vtvt-20230511monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-2022-fourth-quarter-and-full-year-financial-results-and-provide-vtvt-20230306monthly0.5https://www.biopharmawatch.com/news/VTVT/elizabeth-keiley-selected-as-executive-vice-president-and-general-counsel-of-vtv-therapeut-vtvt-20230201monthly0.5https://www.biopharmawatch.com/news/VTVT/nasdaq-vtvt-improving-the-lives-of-millions-of-patients-with-type-1-diabetes-non-confident-vtvt-20230106monthly0.5https://www.biopharmawatch.com/news/VTVT/steven-tuch-chief-financial-officer-vtv-therapeutics-appoints-biotech-industry-veteran-ste-vtvt-20221213monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-2022-third-quarter-financial-results-and-provides-corporate-upd-vtvt-20221110monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-2022-second-quarter-financial-results-and-provides-corporate-up-vtvt-20220815monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-paul-sekhri-as-new-president-and-chief-executive-officer-high-p-vtvt-20220727monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-investment-by-cinrx-pharma-high-point-n-c-globe-newswire-vtvt-20220725monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-investment-by-and-entry-into-collaboration-and-license-agreemen-vtvt-20220601monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-2022-first-quarter-financial-results-and-provides-corporate-upd-vtvt-20220512monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-2021-fourth-quarter-and-full-year-financial-results-and-provide-vtvt-20220329monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-2021-third-quarter-financial-results-and-provides-corporate-upd-vtvt-20211109monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-deepa-prasad-as-new-president-and-vtvt-20211020monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-2021-second-quarter-financial-results-and-provides-corporate-up-vtvt-20210804monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-2021-first-quarter-financial-results-and-provides-corporate-upd-vtvt-20210505monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-2020-fourth-quarter-and-full-year-financial-results-and-provide-vtvt-20210224monthly0.5https://www.biopharmawatch.com/news/VTVT/forward-looking-statements-this-release-contains-forward-looking-statements-which-involve--vtvt-20201124monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-2020-third-quarter-financial-results-and-update-high-point-n-c--vtvt-20201105monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-2020-second-quarter-financial-results-and-update-high-point-n-c-vtvt-20200803monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-2020-first-quarter-financial-results-and-update-high-point-n-c--vtvt-20200507monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-2019-fourth-quarter-and-full-year-financial-results-and-provide-vtvt-20200220monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-2019-third-quarter-financial-results-and-update-simplicit-1-stu-vtvt-20191030monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-2019-second-quarter-financial-results-and-update-high-point-n-c-vtvt-20190731monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-2019-first-quarter-financial-results-and-update-high-point-n-c--vtvt-20190501monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-15-million-of-class-a-common-stock-financings-proceeds-will-fun-vtvt-20190318monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-2018-fourth-quarter-and-full-year-financial-results-and-update--vtvt-20190227monthly0.5https://www.biopharmawatch.com/news/VTVT/disclosure-notice-the-statements-made-in-this-presentation-may-include-forward-looking-sta-vtvt-20190219monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-third-quarter-2018-results-and-update-high-point-n-c-business-w-vtvt-20181108monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-transfer-of-listing-to-the-nasdaq-capital-market-high-point-n-c-vtvt-20181029monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-second-quarter-2018-results-and-update-high-point-n-c-business--vtvt-20180803monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-topline-results-from-part-b-of-phase-3-steadfast-study-high-poi-vtvt-20180612monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-reports-2018-first-quarter-financial-and-operational-results-and-recent-h-vtvt-20180515monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-topline-results-from-the-first-steadfast-phase-3-study-evaluati-vtvt-20180409monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-reports-2017-fourth-quarter-and-full-year-financial-and-operational-resul-vtvt-20180227monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-reports-third-quarter-2017-financial-and-operational-results-high-point-n-vtvt-20171101monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-reports-second-quarter-2017-financial-and-operational-results-high-point--vtvt-20170802monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-reports-first-quarter-2017-financial-and-operational-results-high-point-n-vtvt-20170503monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-reports-2016-fourth-quarter-and-full-year-financial-and-operational-resul-vtvt-20170227monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-positive-topline-results-from-phase-2-study-of-ttp273-in-type-2-vtvt-20161214monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-reports-third-quarter-financial-and-operational-results-and-recent-highli-vtvt-20161102monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-completes-enrollment-of-phase-2-trial-evaluating-ttp273-for-the-treatment-vtvt-20160816monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-announces-positive-topline-results-from-phase-2b-study-of-glucokinase-act-vtvt-20160810monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-reports-first-quarter-financial-and-operational-results-high-point-n-c-vtvt-20160512monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-reports-fourth-quarter-and-full-year-2015-financial-and-operational-resul-vtvt-20160301monthly0.5https://www.biopharmawatch.com/news/VTVT/disclaimer-the-statements-made-in-this-presentation-may-include-forward-looking-statements-vtvt-20151117monthly0.5https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-reports-financial-results-for-the-third-quarter-ended-vtvt-20151112monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-announces-fourth-quarter-of-2025-financial-results-and-provides-business-updates-adv-nnox-20260420monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-announces-15-million-registered-direct-offering-of-common-stock-nnox-20251123monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-announces-third-quarter-of-2025-financial-results-and-provides-business-update-manag-nnox-20251120monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-reaches-agreement-with-vaso-corporation-to-acquire-vasohealthcare-it-accelerating-u--nnox-20251119monthly0.5https://www.biopharmawatch.com/news/NNOX/nano-x-imaging-ltd-the-ofer-tech-park-94-shlomo-shmeltzer-road-petach-tikva-israel-4970602-nnox-20251117monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-announces-first-quarter-2025-financial-results-and-provides-business-updates-managem-nnox-20250522monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-receives-fda-clearance-for-general-use-of-new-imaging-system-nanox-arc-x-first-fda-c-nnox-20250417monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-announces-fourth-quarter-of-2024-financial-results-and-provides-business-updates-rec-nnox-20250331monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-arc-imaging-system-receives-ce-mark-expanding-medical-imaging-offering-in-european-m-nnox-20250225monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-arc-imaging-system-receives-fda-clearance-for-general-use-including-pulmonary-indica-nnox-20241205monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-announces-third-quarter-of-2024-financial-results-and-provides-business-update-made--nnox-20241121monthly0.5https://www.biopharmawatch.com/news/NNOX/nano-x-imaging-ltd-the-ofer-tech-park-94-shlomo-shmeltzer-road-petach-tikva-israel-4970602-nnox-20241029monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-announces-second-quarter-of-2024-financial-results-and-provides-business-update-acce-nnox-20240820monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-announces-first-quarter-of-2024-financial-results-and-provides-business-update-accel-nnox-20240528monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-files-2023-annual-report-on-form-20-f-petach-tikva-israel-business-wire-nnox-20240422monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-announces-fourth-quarter-of-2023-financial-results-and-provides-business-update-nano-nnox-20240401monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-receives-fda-clearance-for-healthfld-an-advanced-ai-based-software-empowering-clinic-nnox-20240213monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-mourns-death-of-its-founder-ran-poliakine-nnox-20240116monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-announces-third-quarter-of-2023-financial-results-and-provides-business-update-repor-nnox-20231128monthly0.5https://www.biopharmawatch.com/news/NNOX/nano-x-imaging-ltd-the-communications-center-neve-ilan-israel-9085000-notice-of-annual-gen-nnox-20231116monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-announces-strategic-manufacturing-agreement-with-varex-imaging-corporation-to-advanc-nnox-20231003monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-announces-second-quarter-of-2023-financial-results-and-provides-business-update-repo-nnox-20230817monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-announces-30-nnox-20230724monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-announces-first-quarter-of-2023-financial-results-and-provides-business-update-repor-nnox-20230522monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-arc-imaging-system-receives-fda-clearance-pioneering-a-new-era-in-medical-imaging-na-nnox-20230501monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-files-2022-annual-report-on-form-20-f-neve-ilan-israel-business-wire-nnox-20230501monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-announces-fourth-quarter-2022-financial-results-and-provides-business-update-reports-nnox-20230309monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-to-report-fourth-quarter-2022-financial-results-on-nnox-20230223monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-ai-connects-to-nuance-precision-imaging-network-to-improve-early-detection-of-chroni-nnox-20230214monthly0.5https://www.biopharmawatch.com/news/NNOX/nano-x-imaging-ltd-the-communications-center-neve-ilan-israel-9085000-notice-of-annual-gen-nnox-20221110monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-announces-third-quarter-2022-financial-results-and-provides-business-update-reports--nnox-20221110monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-announces-second-quarter-2022-financial-results-and-provides-business-update-reports-nnox-20220816monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-announces-its-first-quarter-of-2022-financial-results-and-provides-business-update-r-nnox-20220519monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-opens-south-korean-fabrication-plant-to-produce-semiconductor-chips-for-novel-digita-nnox-20220405monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-announces-fourth-quarter-2021-financial-results-and-provides-business-update-managem-nnox-20220331monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-announces-third-quarter-2021-financial-results-and-provides-business-update-reports--nnox-20211117monthly0.5https://www.biopharmawatch.com/news/NNOX/nano-x-imaging-ltd-the-communications-center-neve-ilan-israel-9085000-telephone-972-2-5360-nnox-20210930monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-enters-into-acquisition-via-merger-agreement-with-zebra-medical-vision-ltd-and-annou-nnox-20210810monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-signs-msaas-agreement-for-the-deployment-of-1-000-nanox-systems-in-nigeria-making-it-nnox-20210712monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-announces-fda-510-k-submission-for-first-version-of-multi-source-nanox-arc-510-k-cla-nnox-20210617monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-announces-first-quarter-2021-results-and-provides-business-update-announced-fda-510--nnox-20210511monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-announces-fda-clearance-of-510-k-for-single-source-nanox-arc-digital-x-ray-nnox-20210402monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-announces-fourth-quarter-2020-results-and-provides-business-update-successfully-demo-nnox-20210302monthly0.5https://www.biopharmawatch.com/news/NNOX/nano-x-imaging-ltd-the-communications-center-neve-ilan-israel-9085000-telephone-972-2-536--nnox-20201231monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-announces-third-quarter-2020-results-and-provides-business-update-on-track-to-obtain-nnox-20201109monthly0.5https://www.biopharmawatch.com/news/NNOX/dawn-of-early-detection-healthcare-investor-presentationseptember-2020-1-disclaimers-nothi-nnox-20200922monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-issues-statement-on-unusual-trading-activities-neve-ilan-israel-nnox-20200916monthly0.5https://www.biopharmawatch.com/news/NNOX/nanox-s-igns-a-greement-with-spi-medical-for-the-d-eployment-of-630-nanox-arc-u-nits-in-me-nnox-20200909monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-appoints-everett-cunningham-as-president-and-ceo-effective-qtrx-20260108monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-announces-board-and-leadership-changes-to-support-next-stage-of-growth-appoints--qtrx-20251120monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-releases-financial-results-for-the-third-quarter-of-2025-qtrx-20251110monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-releases-financial-results-for-the-second-quarter-of-2025-qtrx-20250807monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-completes-acquisition-of-akoya-biosciences-creating-the-first-integrated-platfor-qtrx-20250708monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-releases-financial-results-for-the-first-quarter-of-2025-qtrx-20250512monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-and-akoya-biosciences-announce-amended-merger-agreement-quanterix-files-updated--qtrx-20250429monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-releases-financial-results-for-the-fourth-quarter-of-2024-delivers-seventh-conse-qtrx-20250317monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-provides-update-on-financial-performance-company-announced-preliminary-q4-2024-r-qtrx-20250114monthly0.5https://www.biopharmawatch.com/news/QTRX/operator-hello-and-welcome-to-today-s-call-to-discuss-quanterix-s-acquisition-of-akoya-bio-qtrx-20250110monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-to-acquire-akoya-biosciences-creating-the-first-integrated-solution-for-ultra-se-qtrx-20250110monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-expands-capabilities-with-strategic-acquisition-of-emission-builds-technology-ca-qtrx-20241217monthly0.5https://www.biopharmawatch.com/news/QTRX/document-quanterix-releases-preliminary-financial-results-for-the-third-quarter-of-2024-si-qtrx-20241112monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-welcomes-ivana-magov-evi-liebisch-ph-d-j-d-to-board-of-directors-qtrx-20241002monthly0.5https://www.biopharmawatch.com/news/QTRX/jeffrey-elliott-appointed-to-quanterix-s-board-of-directors-qtrx-20240819monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-releases-financial-results-for-the-second-quarter-of-2024-qtrx-20240808monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-releases-financial-results-for-the-first-quarter-of-2024-billerica-mass-may-7-20-qtrx-20240507monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-releases-operating-results-for-fourth-quarter-and-full-year-2023-billerica-mass--qtrx-20240229monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-reschedules-q4-and-full-year-2023-earnings-conference-call-reaffirms-2023-guidan-qtrx-20240226monthly0.5https://www.biopharmawatch.com/news/QTRX/create-the-tools-enabling-discovery-and-better-health-o-u-r-m-i-s-s-i-o-n-1-1-preliminary--qtrx-20240111monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-releases-operating-results-for-third-quarter-2023-qtrx-20231106monthly0.5https://www.biopharmawatch.com/news/QTRX/william-p-donnelly-appointed-to-quanterix-s-board-of-directors-billerica-mass-qtrx-20230821monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-appoints-vandana-sriram-as-chief-financial-officer-billerica-mass-qtrx-20230809monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-releases-operating-results-for-second-quarter-2023-qtrx-20230807monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-releases-operating-results-for-first-quarter-2023-qtrx-20230509monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-releases-operating-results-for-fourth-quarter-and-full-year-2022-aligned-with-ex-qtrx-20230306monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-announces-appointment-of-brian-blaser-to-board-of-directors-billerica-mass-qtrx-20230109monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-corporation-releases-operating-results-for-third-quarter-2022-billerica-mass-qtrx-20221108monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-corporation-releases-operating-results-for-second-quarter-2022-announces-busines-qtrx-20220808monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-announces-appointment-of-karen-a-flynn-to-board-of-directors-qtrx-20220606monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-corporation-releases-operating-results-for-first-quarter-2022-quanterix-reports--qtrx-20220510monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-corporation-releases-operating-results-for-fourth-quarter-and-full-year-2021-com-qtrx-20220301monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-provides-operational-and-preliminary-financial-highlights-expects-q4-2021-revenu-qtrx-20220113monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-corporation-releases-operating-results-for-third-quarter-of-2021-third-quarter-r-qtrx-20211104monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-corporation-releases-operating-results-for-second-quarter-of-2021-q2-gaap-revenu-qtrx-20210805monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-appoints-michael-doyle-as-chief-financial-officer-doyle-brings-strong-financial--qtrx-20210628monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-appoints-masoud-toloue-as-president-of-quanterix-and-diagnostics-toloue-brings-d-qtrx-20210511monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-corporation-releases-operating-results-for-first-quarter-2021-q1-gaap-revenue-in-qtrx-20210505monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-appoints-laurie-olson-to-board-of-directors-pharmaceutical-veteran-adds-deep-exp-qtrx-20210428monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-announces-appointment-of-interim-chief-financial-officer-billerica-mass-qtrx-20210421monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-corporation-releases-operating-results-for-fourth-quarter-and-full-year-2020-q4--qtrx-20210302monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-prices-public-offering-of-common-stock-billerica-mass-business-wire-qtrx-20210204monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-provides-operational-and-preliminary-financial-highlights-expects-q4-2020-gaap-r-qtrx-20210113monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-appoints-william-geist-as-chief-operating-officer-geist-brings-operational-exper-qtrx-20201118monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-corporation-releases-operating-results-for-third-quarter-2020-gaap-revenue-inclu-qtrx-20201105monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-enters-into-a-license-agreement-that-grants-abbott-access-to-portfolio-of-bead-b-qtrx-20201005monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-announces-closing-of-public-offering-including-exercise-in-full-of-underwriters--qtrx-20200811monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-prices-public-offering-of-common-stock-billerica-mass-business-wire-qtrx-20200806monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-corporation-releases-operating-results-for-second-quarter-2020-1h-revenue-up-12--qtrx-20200804monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-corporation-releases-operating-results-for-first-quarter-2020-15-7m-revenues-27--qtrx-20200505monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-corporation-releases-operating-results-for-fourth-quarter-and-full-year-2019-46--qtrx-20200309monthly0.5https://www.biopharmawatch.com/news/QTRX/j-p-morgan-healthcare-conference-qtrx-20200115monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-corporation-releases-operating-results-for-third-quarter-2019-strong-revenue-gro-qtrx-20191106monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-prices-public-offering-of-common-stock-qtrx-20190809monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-corporation-releases-operating-results-for-second-quarter-2019-13-5m-revenues-57-qtrx-20190806monthly0.5https://www.biopharmawatch.com/news/QTRX/sarah-hlavinka-elected-to-quanterix-board-of-directors-adds-broad-based-experience-growing-qtrx-20190726monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-announces-agreement-to-acquire-umandiagnostics-world-s-leading-neurofilament-lig-qtrx-20190626monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-raises-49-7-million-and-announces-introduction-of-latest-model-simoa-hd-x-analyz-qtrx-20190604monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-corporation-releases-operating-results-for-first-quarter-2019-64-q1-revenue-grow-qtrx-20190509monthly0.5https://www.biopharmawatch.com/news/QTRX/amendment-no-7-to-loan-and-security-agreement-this-amendment-no-7-to-loan-and-security-agr-qtrx-20190415monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-appoints-amol-chaubal-as-chief-financial-officer-amol-brings-global-pharmaceutic-qtrx-20190328monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-corporation-releases-operating-results-for-fourth-quarter-and-full-year-2018-65--qtrx-20190307monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-corporation-releases-operating-results-for-third-quarter-2018-85-revenue-growth--qtrx-20181101monthly0.5https://www.biopharmawatch.com/news/QTRX/lease-agreement-between-ssi-900-middlesex-ma-lp-as-landlord-and-quanterix-corporation-as-t-qtrx-20181002monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-corporation-releases-operating-results-for-second-quarter-2018-66-revenue-growth-qtrx-20180808monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-corporation-releases-operating-results-for-first-quarter-2018-41-revenue-growth--qtrx-20180509monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-corporation-releases-operating-results-for-fourth-quarter-and-fiscal-year-2017-r-qtrx-20180314monthly0.5https://www.biopharmawatch.com/news/QTRX/rapid-growth-with-compelling-consumable-pull-through-three-year-growth-in-millions-grew-fr-qtrx-20180111monthly0.5https://www.biopharmawatch.com/news/QTRX/quanterix-corporation-announces-closing-of-initial-public-offering-qtrx-20171211monthly0.5https://www.biopharmawatch.com/news/BDTX/document-black-diamond-therapeutics-reports-first-quarter-2026-financial-results-and-provi-bdtx-20260507monthly0.5https://www.biopharmawatch.com/news/BDTX/document-black-diamond-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-re-bdtx-20260316monthly0.5https://www.biopharmawatch.com/news/BDTX/document-black-diamond-therapeutics-reports-third-quarter-2025-financial-results-and-provi-bdtx-20251106monthly0.5https://www.biopharmawatch.com/news/BDTX/document-black-diamond-therapeutics-reports-second-quarter-2025-financial-results-and-prov-bdtx-20250807monthly0.5https://www.biopharmawatch.com/news/BDTX/document-black-diamond-therapeutics-reports-first-quarter-2025-financial-results-and-provi-bdtx-20250512monthly0.5https://www.biopharmawatch.com/news/BDTX/document-black-diamond-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-re-bdtx-20250306monthly0.5https://www.biopharmawatch.com/news/BDTX/document-black-diamond-therapeutics-reports-third-quarter-2024-financial-results-and-provi-bdtx-20241105monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-announces-restructuring-plan-to-focus-resources-on-bdtx-1535-an-bdtx-20241007monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-announces-initial-phase-2-data-demonstrating-robust-anti-tumor--bdtx-20240923monthly0.5https://www.biopharmawatch.com/news/BDTX/document-black-diamond-therapeutics-reports-second-quarter-2024-financial-results-and-prov-bdtx-20240806monthly0.5https://www.biopharmawatch.com/news/BDTX/document-black-diamond-therapeutics-reports-first-quarter-2024-financial-results-and-provi-bdtx-20240509monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-announces-changes-to-board-of-directors-cambridge-mass-bdtx-20240411monthly0.5https://www.biopharmawatch.com/news/BDTX/document-black-diamond-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-re-bdtx-20240312monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-announces-corporate-update-and-expected-2024-milestones-fda-fee-bdtx-20240104monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-announces-topline-results-from-phase-1-dose-escalation-trial-of-bdtx-20231213monthly0.5https://www.biopharmawatch.com/news/BDTX/document-black-diamond-therapeutics-reports-third-quarter-2023-financial-results-and-provi-bdtx-20231106monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-announces-ceo-transition-current-chairman-of-the-board-and-indu-bdtx-20230918monthly0.5https://www.biopharmawatch.com/news/BDTX/document-black-diamond-therapeutics-reports-second-quarter-2023-financial-results-and-prov-bdtx-20230811monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-announces-initial-dose-escalation-data-demonstrating-anti-tumor-bdtx-20230627monthly0.5https://www.biopharmawatch.com/news/BDTX/document-black-diamond-therapeutics-reports-first-quarter-2023-financial-results-and-provi-bdtx-20230509monthly0.5https://www.biopharmawatch.com/news/BDTX/document-black-diamond-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-re-bdtx-20230309monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-announces-changes-to-board-of-directors-cambridge-mass-and-bdtx-20221219monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-announces-spinout-of-launchpad-therapeutics-inc-an-antibody-foc-bdtx-20221212monthly0.5https://www.biopharmawatch.com/news/BDTX/document-black-diamond-therapeutics-reports-third-quarter-2022-financial-results-and-provi-bdtx-20221108monthly0.5https://www.biopharmawatch.com/news/BDTX/document-black-diamond-therapeutics-reports-second-quarter-2022-financial-results-and-prov-bdtx-20220809monthly0.5https://www.biopharmawatch.com/news/BDTX/document-black-diamond-therapeutics-reports-first-quarter-2022-financial-results-and-provi-bdtx-20220511monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-announces-pipeline-prioritization-and-workforce-realignment-str-bdtx-20220425monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-appoints-wendy-l-dixon-to-its-board-of-directors-cambridge-mass-bdtx-20220407monthly0.5https://www.biopharmawatch.com/news/BDTX/document-black-diamond-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-re-bdtx-20220317monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-announces-strategic-priorities-and-expected-milestones-for-2022-bdtx-20220110monthly0.5https://www.biopharmawatch.com/news/BDTX/document-black-diamond-therapeutics-reports-third-quarter-2021-financial-results-and-provi-bdtx-20211108monthly0.5https://www.biopharmawatch.com/news/BDTX/document-black-diamond-therapeutics-reports-second-quarter-2021-financial-results-and-prov-bdtx-20210812monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-announces-appointment-of-mark-velleca-m-d-ph-d-to-board-of-dire-bdtx-20210810monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-presents-phase-1-pharmacokinetic-safety-and-preliminary-efficac-bdtx-20210519monthly0.5https://www.biopharmawatch.com/news/BDTX/document-black-diamond-therapeutics-reports-first-quarter-2021-financial-results-and-provi-bdtx-20210507monthly0.5https://www.biopharmawatch.com/news/BDTX/document-black-diamond-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-re-bdtx-20210325monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-announces-appointment-of-oncology-clinical-development-veteran--bdtx-20210120monthly0.5https://www.biopharmawatch.com/news/BDTX/document-black-diamond-therapeutics-reports-third-quarter-2020-financial-results-and-provi-bdtx-20201110monthly0.5https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-announces-the-appointment-of-biopharmaceutical-veteran-robert-a-bdtx-20200929monthly0.5https://www.biopharmawatch.com/news/BDTX/document-black-diamond-therapeutics-reports-second-quarter-2020-financial-results-and-prov-bdtx-20200811monthly0.5https://www.biopharmawatch.com/news/BDTX/document-black-diamond-therapeutics-reports-first-quarter-2020-financial-results-and-corpo-bdtx-20200512monthly0.5https://www.biopharmawatch.com/news/BDTX/document-black-diamond-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-re-bdtx-20200324monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-reports-first-quarter-2026-financial-results-and-advances-micvo-toward-key--pyxs-20260514monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-announces-positive-preliminary-phase-1-data-for-micvotabart-pelidotin-micvo-pyxs-20251218monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-provides-business-update-and-reports-third-quarter-2025-financial-results-pyxs-20251103monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-reports-second-quarter-2025-financial-results-and-provides-business-update--pyxs-20250814monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-reports-first-quarter-2025-financial-results-and-provides-business-update-a-pyxs-20250515monthly0.5https://www.biopharmawatch.com/news/PYXS/forward-looking-statement-this-presentation-contains-forward-looking-statements-for-the-pu-pyxs-20250318monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-bu-pyxs-20250318monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-granted-fda-fast-track-designation-for-pyx-201-monotherapy-in-patients-with-pyxs-20250226monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-initiates-new-pyx-201-combination-trial-and-initiates-cohort-expansions-of--pyxs-20250204monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-announces-portfolio-prioritization-focusing-resources-on-its-lead-clinical--pyxs-20241219monthly0.5https://www.biopharmawatch.com/news/PYXS/pyx-201-phase-1-dose-escalation-study-data-disclosure-november-2024-forward-looking-statem-pyxs-20241120monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-provides-corporate-update-and-reports-financial-results-for-third-quarter-2-pyxs-20241112monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-provides-corporate-update-and-reports-financial-results-for-second-quarter--pyxs-20240814monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-expands-board-of-directors-with-appointment-of-michael-a-metzger-pyxs-20240610monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-provides-corporate-update-and-reports-financial-results-for-first-quarter-2-pyxs-20240514monthly0.5https://www.biopharmawatch.com/news/PYXS/unaudited-pro-forma-condensed-combined-financial-information-the-merger-on-pyxs-20240327monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-obtains-8-million-payment-for-the-sale-of-royalty-rights-pyxs-20240327monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-provides-corporate-update-and-reports-financial-results-for-fourth-quarter--pyxs-20240321monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-expands-board-of-directors-with-appointment-of-santhosh-palani-ph-d-cfa-pyxs-20240313monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-announces-50-million-private-placement-pyxs-20240227monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-announces-appointment-of-ken-kobayashi-m-d-f-a-c-p-as-chief-medical-officer-pyxs-20231128monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-announces-initiatives-to-prioritize-lead-adc-program-reports-financial-resu-pyxs-20231107monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-successfully-completes-acquisition-of-apexigen-pyxs-20230823monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-reports-financial-results-for-second-quarter-2023-and-provides-corporate-up-pyxs-20230811monthly0.5https://www.biopharmawatch.com/news/PYXS/unaudited-pro-forma-condensed-combined-financial-information-the-merger-on-pyxs-20230811monthly0.5https://www.biopharmawatch.com/news/PYXS/this-presentation-contains-forward-looking-statements-for-the-purposes-of-the-safe-harbor--pyxs-20230524monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-to-acquire-apexigen-pyxis-oncology-positioned-at-forefront-of-antibody-drug-pyxs-20230524monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-reports-financial-results-for-the-first-quarter-2023-and-provides-corporate-pyxs-20230511monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-reports-financial-results-for-the-fiscal-year-ended-pyxs-20230322monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-announces-dosing-of-first-subject-in-phase-1-trial-of-pyx-201-a-novel-adc-f-pyxs-20230316monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-announces-fda-clearance-of-two-ind-applications-fda-grants-ind-clearances-o-pyxs-20221201monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-reports-financial-results-for-the-quarter-ended-pyxs-20221101monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-reports-financial-results-for-the-second-quarter-ended-pyxs-20220815monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-reports-financial-results-for-the-quarter-ended-pyxs-20220513monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-announces-leadership-changes-pyxs-20220413monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-provides-corporate-and-financial-update-announces-expansion-of-novel-immuno-pyxs-20220329monthly0.5https://www.biopharmawatch.com/news/PYXS/pyxis-reports-financial-results-for-the-third-quarter-of-2021-and-provides-business-update-pyxs-20211115monthly0.5https://www.biopharmawatch.com/news/NYXH/information-on-the-total-number-of-voting-rights-and-shares-nyxh-20260610monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-nyxh-20260508monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-nyxoah-reports-fourth-quarter-and-full-year-2025-financial-and-opera-nyxh-20260319monthly0.5https://www.biopharmawatch.com/news/NYXH/publication-relating-to-transparency-notifications-nyxh-20251202monthly0.5https://www.biopharmawatch.com/news/NYXH/interim-financial-report-third-quarter-2025-table-of-contents-interim-financial-report-3-1-nyxh-20251117monthly0.5https://www.biopharmawatch.com/news/NYXH/interim-financial-report-third-quarter-2025-table-of-contents-interim-financial-report-3-1-nyxh-20251113monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-provides-update-on-expanded-middle-east-presence-new-centers-in-dubai-kuwait-and-ab-nyxh-20250923monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-inside-information-nyxoah-announces-proposed-offering-of-ordinary-sh-nyxh-20250918monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-files-patent-infringement-lawsuit-against-inspire-medical-systems-inc-mont-saint-gu-nyxh-20250915monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-publication-relating-to-transparency-notifications-mont-saint-guiber-nyxh-20250905monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-nyxoah-reports-second-quarter-financial-and-operating-results-fda-ap-nyxh-20250818monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-receives-approval-from-fda-for-genio-system-for-the-treatment-of-obstructive-sleep--nyxh-20250808monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-nyxh-20250613monthly0.5https://www.biopharmawatch.com/news/NYXH/information-on-the-total-number-of-voting-rights-and-shares-nyxh-20250523monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-nyxoah-reports-first-quarter-financial-and-operating-results-company-nyxh-20250514monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-publication-relating-to-transparency-notifications-mont-saint-guiber-nyxh-20250509monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-sa-euronext-brussels-nyxh-rue-edouard-belin-12-1435-mont-saint-guibert-belgium-here-nyxh-20250509monthly0.5https://www.biopharmawatch.com/news/NYXH/inside-information-regulated-information-conditional-issuance-of-shares-mont-saint-guibert-nyxh-20250416monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-provides-update-on-fda-approvable-letter-for-genio-system-expects-to-meet-final-fda-nyxh-20250408monthly0.5https://www.biopharmawatch.com/news/NYXH/inside-information-regulated-information-fda-issues-nyxoah-an-approvable-letter-for-its-ge-nyxh-20250326monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-nyxoah-reports-fourth-quarter-and-financial-year-2024-financial-and--nyxh-20250313monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-publication-relating-to-transparency-notifications-mont-saint-guiber-nyxh-20241220monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-commercial-launch-of-genio-innovative-therapy-in-england-nyxh-20241213monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-information-on-the-total-number-of-voting-rights-and-shares-mont-sai-nyxh-20241127monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-nyxh-20241119monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-publication-relating-to-transparency-notifications-mont-saint-guiber-nyxh-20241118monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-nyxoah-reports-third-quarter-financial-and-operating-results-fda-app-nyxh-20241106monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-appoints-john-landry-as-chief-financial-officer-current-cfo-lo-c-moreau-to-transiti-nyxh-20241104monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-publication-relating-to-transparency-notifications-mont-saint-guiber-nyxh-20241025monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-publication-relating-to-transparency-notifications-mont-saint-guiber-nyxh-20241015monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-publication-relating-to-transparency-notifications-mont-saint-guiber-nyxh-20241009monthly0.5https://www.biopharmawatch.com/news/NYXH/inside-information-regulated-information-nyxoah-raises-27-million-through-its-at-the-marke-nyxh-20241007monthly0.5https://www.biopharmawatch.com/news/NYXH/publication-relating-to-transparency-notifications-nyxh-20240927monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-nyxoah-reports-second-quarter-and-first-half-2024-financial-and-oper-nyxh-20240806monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-appoints-scott-holstine-as-chief-commercial-officer-nyxh-20240715monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-inside-information-nyxoah-has-signed-a-37-5-million-loan-facility-ag-nyxh-20240703monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-submits-fourth-and-final-module-in-pma-application-for-genio-to-the-nyxh-20240701monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-information-on-the-total-number-of-voting-rights-and-shares-mont-sai-nyxh-20240628monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-publication-relating-to-transparency-notifications-mont-saint-guiber-nyxh-20240603monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-closing-of-offering-and-partial-exercise-of-option-to-purchase-additional-nyxh-20240531monthly0.5https://www.biopharmawatch.com/news/NYXH/information-on-the-total-number-of-voting-rights-and-shares-nyxh-20240528monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-inside-information-nyxoah-announces-pricing-of-offering-mont-saint-g-nyxh-20240523monthly0.5https://www.biopharmawatch.com/news/NYXH/reduction-of-the-maximum-amount-available-under-its-at-the-market-equity-offering-program-nyxh-20240522monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-nyxoah-reports-first-quarter-2024-financial-and-operating-results-an-nyxh-20240514monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-appoints-dr-maurits-s-boon-md-as-chief-medical-officer-nyxh-20240411monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-inside-information-nyxoah-announces-dream-u-s-pivotal-study-meets-pr-nyxh-20240319monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-nyxoah-reports-fourth-quarter-and-financial-year-2023-financial-and--nyxh-20240305monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-2024-strategic-priorities-mont-saint-guibert-belgium-nyxh-20240117monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-preliminary-results-for-the-fourth-quarter-and-full-year-2023-mont-saint--nyxh-20240109monthly0.5https://www.biopharmawatch.com/news/NYXH/publication-relating-to-a-transparency-notification-nyxh-20231208monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-nyxoah-reports-third-quarter-2023-financial-and-operating-results-pa-nyxh-20231108monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-partnership-with-resmed-in-germany-nyxh-20230928monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-nyxoah-reports-second-quarter-and-first-half-2023-financial-and-oper-nyxh-20230808monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-information-on-the-total-number-of-voting-rights-and-shares-mont-sai-nyxh-20230727monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-nyxoah-reports-first-quarter-2023-financial-and-operating-results-mo-nyxh-20230516monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-nyxh-20230512monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-appoints-christoph-eigenmann-as-chief-commercial-officer-nyxh-20230510monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-infomation-publication-relating-to-transparency-notifications-mont-saint-guibert-nyxh-20230420monthly0.5https://www.biopharmawatch.com/news/NYXH/inside-information-regulated-information-nyxoah-raises-3-million-from-its-at-the-market-eq-nyxh-20230413monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-raises-3-million-from-an-at-the-market-equity-offering-nyxh-20230327monthly0.5https://www.biopharmawatch.com/news/NYXH/inside-information-regulated-information-nyxoah-announces-a-15-million-private-placement-f-nyxh-20230323monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-nyxoah-reports-fourth-quarter-and-full-year-2022-financial-and-opera-nyxh-20230322monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-achievement-of-key-clinical-and-regulatory-milestones-nyxh-20230306monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-appoints-mr-daniel-wildman-to-its-board-of-directors-mont-saint-guibert-belgium-nyxh-20230109monthly0.5https://www.biopharmawatch.com/news/NYXH/information-on-the-total-number-of-voting-rights-and-shares-nyxh-20221229monthly0.5https://www.biopharmawatch.com/news/NYXH/inside-information-regulated-information-nyxoah-files-shelf-registration-statement-and-ann-nyxh-20221222monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-nyxoah-reports-third-quarter-2022-financial-and-operating-results-dr-nyxh-20221108monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-change-to-board-of-directors-mont-saint-guibert-belgium-nyxh-20221024monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-release-third-quarter-financial-results-on-nyxh-20221019monthly0.5https://www.biopharmawatch.com/news/NYXH/information-on-the-total-number-of-voting-rights-and-shares-nyxh-20220930monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-nyxoah-reports-second-quarter-and-first-half-2022-financial-and-oper-nyxh-20220808monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-and-acurable-enter-into-distribution-agreement-in-germany-for-the-acupebble-sa100-h-nyxh-20220802monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-release-second-quarter-and-first-half-2022-financial-results-on-nyxh-20220720monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-announces-ce-mark-approval-for-genio-2-1-nyxh-20220718monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-receives-fda-ide-approval-to-initiate-the-acccess-study-of-genio-in-complete-concen-nyxh-20220711monthly0.5https://www.biopharmawatch.com/news/NYXH/information-on-the-total-number-of-voting-rights-and-shares-nyxh-20220630monthly0.5https://www.biopharmawatch.com/news/NYXH/fda-approves-genio-2-1-for-use-in-dream-u-s-ide-pivotal-study-new-smartphone-application-u-nyxh-20220601monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-nyxoah-reports-first-quarter-2022-financial-and-operating-results-mo-nyxh-20220510monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-nyxh-20220506monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-nyxoah-reports-full-year-2021-operating-and-financial-results-mont-s-nyxh-20220324monthly0.5https://www.biopharmawatch.com/news/NYXH/better-sleep-achieves-primary-endpoint-across-all-patient-cohorts-nyxh-20220314monthly0.5https://www.biopharmawatch.com/news/NYXH/information-on-the-total-number-of-voting-rights-and-shares-nyxh-20220211monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-provides-general-corporate-update-nyxh-20220110monthly0.5https://www.biopharmawatch.com/news/NYXH/information-on-the-total-number-of-voting-rights-and-shares-nyxh-20211126monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-appoints-new-cfo-nyxh-20211108monthly0.5https://www.biopharmawatch.com/news/NYXH/information-on-the-total-number-of-voting-rights-and-shares-nyxh-20211029monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-information-on-the-total-number-of-voting-rights-and-shares-mont-sai-nyxh-20211001monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-information-on-the-total-number-of-voting-rights-and-shares-mont-sai-nyxh-20210912monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-publication-relating-to-transparency-notifications-mont-saint-guiber-nyxh-20210901monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-nyxoah-issues-first-half-2021-financial-results-mont-saint-guibert-b-nyxh-20210831monthly0.5https://www.biopharmawatch.com/news/NYXH/nyxoah-to-release-first-half-2021-financial-results-on-august-31-and-host-earnings-confere-nyxh-20210827monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-infomation-publication-relating-to-a-transparency-notification-mont-saint-guiber-nyxh-20210714monthly0.5https://www.biopharmawatch.com/news/NYXH/regulated-information-information-on-the-total-number-of-voting-rights-and-shares-mont-sai-nyxh-20210707monthly0.5https://www.biopharmawatch.com/news/CYPH/cypherpunk-accelerates-zcash-accumulation-increa-ses-treasury-holdings-to-290-062-67-zec-c-cyph-20251230monthly0.5https://www.biopharmawatch.com/news/CYPH/c-ypherpunk-purchases-additional-18-million-of-zec-bringing-total-network-percentage-to-1--cyph-20251118monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-rebrands-as-cypherpunk-expands-leadership-team-to-drive-new-zcash-treasu-cyph-20251112monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-presents-final-data-from-defiance-study-at-esmo-2025-sirexatamab-demonst-cyph-20251020monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-announces-closing-of-58-88-million-private-placement-in-cash-led-by-wink-cyph-20251009monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-announces-58-88-million-private-placement-in-cash-commitments-led-by-win-cyph-20251006monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-second-quarter-2025-financial-results-cambridge-ma-cyph-20250814monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-updated-clinical-data-from-sirexatamab-colorectal-cancer-study-a-cyph-20250623monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-first-quarter-2025-financial-results-cambridge-ma-cyph-20250513monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-leap-to-host-cyph-20250326monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-initial-clinical-data-from-part-b-of-the-defiance-study-and-part-cyph-20250128monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-third-quarter-2024-financial-results-cambridge-ma-cyph-20241113monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-announces-completion-of-enrollment-in-part-b-of-the-defiance-study-of-dk-cyph-20240930monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-second-quarter-2024-financial-results-cambridge-ma-cyph-20240812monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-first-quarter-2024-financial-results-cambridge-ma-cyph-20240513monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-announces-40-million-private-placement-net-proceeds-along-with-existing--cyph-20240411monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-cambridge-ma-cyph-20240318monthly0.5https://www.biopharmawatch.com/news/CYPH/company-presentation-cyph-20240123monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-to-present-new-clinical-data-from-part-a-of-defiance-study-at-the-2024-a-cyph-20240116monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-third-quarter-2023-financial-results-cambridge-ma-cyph-20231113monthly0.5https://www.biopharmawatch.com/news/CYPH/company-presentation-cyph-20230913monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-second-quarter-2023-financial-results-cambridge-ma-cyph-20230814monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-announces-initiation-of-randomized-controlled-part-b-of-the-defiance-stu-cyph-20230712monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-announces-reverse-stock-split-cambridge-ma-cyph-20230620monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-to-present-updated-data-from-part-a-of-the-distinguish-study-of-dkn-01-p-cyph-20230525monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-first-quarter-2023-financial-results-cambridge-ma-cyph-20230515monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-to-present-updated-data-from-part-a-of-the-distinguish-study-of-dkn-01-p-cyph-20230426monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-announces-completion-of-enrollment-in-part-a-of-the-defiance-study-of-dk-cyph-20230412monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-cambridge-ma-cyph-20230324monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-provides-update-on-beigene-option-agreement-for-dkn-01-distinguish-trial-cyph-20230316monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-acquires-flame-biosciences-adds-fl-301-clinical-stage-anti-claudin18-2-a-cyph-20230117monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-third-quarter-2022-financial-results-cyph-20221114monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-to-present-updated-data-from-the-distinguish-study-of-dkn-01-plus-tislel-cyph-20221107monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-announces-appointment-of-richard-l-schilsky-md-to-its-board-of-directors-cyph-20220906monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-second-quarter-2022-financial-results-cyph-20220812monthly0.5https://www.biopharmawatch.com/news/CYPH/company-presentation-leap-therapeutics-dkn-01-r-d-day-cyph-20220712monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-first-quarter-2022-cyph-20220513monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-cambridge-ma-cyph-20220311monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-to-present-positive-new-data-from-the-distinguish-study-of-dkn-01-plus-t-cyph-20220121monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-third-quarter-2021-financial-results-cambridge-ma-cyph-20211112monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-announces-closing-of-public-offering-of-common-stock-and-pre-funded-warr-cyph-20210924monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-announces-pricing-of-90-million-of-common-stock-and-pre-funded-warrants--cyph-20210922monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-announces-proposed-public-offering-of-common-stock-and-pre-funded-warran-cyph-20210921monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-presents-updated-positive-data-from-the-distinguish-study-of-dkn-01-plus-cyph-20210917monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-to-present-new-data-from-the-distinguish-study-of-dkn-01-plus-tislelizum-cyph-20210913monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-second-quarter-2021-financial-results-and-upcoming-data-presenta-cyph-20210813monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-first-quarter-2021-financial-results-cambridge-ma-cyph-20210514monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-announces-completion-of-enrollment-for-first-line-patient-cohort-in-stud-cyph-20210401monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-presents-dkn-01-clinical-data-at-the-society-of-gynecologic-oncology-202-cyph-20210322monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-cambridge-ma-cyph-20210312monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-third-quarter-2020-financial-results-cambridge-ma-cyph-20201112monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-presents-updated-data-for-dkn-01-in-esophagogastric-cancer-patients-at-s-cyph-20201109monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-announces-fda-fast-track-designation-granted-to-dkn-01-for-the-treatment-cyph-20200924monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-and-beigene-announce-first-patient-dosed-in-study-of-dkn-01-in-combinati-cyph-20200921monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-second-quarter-2020-financial-results-cambridge-ma-cyph-20200813monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-announces-full-exercise-of-underwriters-option-to-purchase-additional-sh-cyph-20200625monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-announces-closing-of-public-offering-of-common-stock-and-pre-funded-warr-cyph-20200622monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-announces-pricing-of-45-million-of-common-stock-and-pre-funded-warrants--cyph-20200618monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-announces-proposed-public-offering-of-common-stock-and-pre-funded-warran-cyph-20200617monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-announces-oprhan-drug-designation-of-dkn-01-for-the-treatment-of-gastric-cyph-20200611monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-first-quarter-2020-financial-results-cambridge-ma-cyph-20200514monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-to-present-updated-data-for-dkn-01-monotherapy-and-paclitaxel-combinatio-cyph-20200423monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-announces-executive-leadership-changes-cambridge-ma-cyph-20200318monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-cambridge-ma-cyph-20200316monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-announces-closing-of-previously-announced-equity-financing-cambridge-ma-cyph-20200107monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-and-beigene-announce-exclusive-option-and-license-agreement-for-dkn-01-a-cyph-20200103monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-third-quarter-2019-financial-results-dkn-01-data-continues-to-sh-cyph-20191114monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-to-present-updated-data-for-dkn-01-monotherapy-and-paclitaxel-combinatio-cyph-20190917monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-second-quarter-2019-financial-results-positive-data-from-dkn-01--cyph-20190809monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-presents-positive-clinical-results-for-the-combination-of-dkn-01-plus-keytruda-and-pr-cyph-20190806monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-announces-common-stock-purchase-agreements-for-up-to-21-million-with-lin-cyph-20190711monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-first-quarter-2019-financial-results-strong-clinical-trial-enrol-cyph-20190515monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-clinical-update-and-2018-financial-results-cambridge-ma-cyph-20190401monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-presents-at-society-of-gynecologic-oncology-50-th-annual-meeting-on-wome-cyph-20190318monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-announces-closing-of-public-offering-and-full-exercise-of-underwriters-o-cyph-20190205monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-announces-pricing-of-11-5-million-public-offering-of-common-stock-and-wa-cyph-20190201monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-announces-proposed-public-offering-of-common-stock-and-warrants-cambridg-cyph-20190131monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-announces-an-investigator-initiated-study-of-dkn-01-in-patients-with-dkk-cyph-20190114monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-presents-trx518-data-at-esmo-immuno-oncology-congress-2018-and-updated-d-cyph-20181214monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-third-quarter-2018-business-update-and-financial-results-cambrid-cyph-20181109monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-presents-esophagogastric-cancer-data-at-esmo-2018-annual-congress-live-c-cyph-20181021monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-second-quarter-2018-business-update-and-financial-results-cambri-cyph-20180808monthly0.5https://www.biopharmawatch.com/news/CYPH/company-update-july-2018-forward-looking-this-presentation-contains-forward-looking-statem-cyph-20180723monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-first-quarter-2018-financial-results-conference-call-with-dkn-01-cyph-20180511monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-presents-nonclinical-and-clinical-data-on-dkn-01-at-aacr-2018-annual-mee-cyph-20180416monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-announces-closing-of-public-offering-of-common-stock-and-full-exercise-o-cyph-20180327monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-announces-pricing-of-14-million-public-offering-of-common-stock-cambridg-cyph-20180323monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-announces-proposed-public-offering-of-common-stock-cambridge-ma-cyph-20180322monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-leap-therapeutics-provides-dkn-01-program-update-and-announces-scientifi-cyph-20180314monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-fourth-quarter-and-full-year-2017-financial-results-and-announce-cyph-20180223monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-announces-18-million-private-placement-offering-cyph-20171115monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-third-quarter-2017-financial-results-and-announces-first-patient-cyph-20171113monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-second-quarter-2017-financial-results-cambridge-ma-cyph-20170811monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-announces-collaboration-with-merck-to-evaluate-keytruda-pembrolizumab-in-cyph-20170621monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-first-quarter-2017-financial-results-company-announces-investiga-cyph-20170512monthly0.5https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-reports-full-year-2016-financial-results-and-progression-free-survival-d-cyph-20170331monthly0.5https://www.biopharmawatch.com/news/HSDT/solana-company-reports-first-quarter-2026-financial-results-newtown-pa-hsdt-20260515monthly0.5https://www.biopharmawatch.com/news/HSDT/solana-company-hsdt-solana-company-nasdaq-hsdt-announces-registered-direct-offering-of-com-hsdt-20260427monthly0.5https://www.biopharmawatch.com/news/HSDT/solana-company-hsdt-solana-company-nasdaq-hsdt-appoints-madelene-gani-as-chief-operating-o-hsdt-20260409monthly0.5https://www.biopharmawatch.com/news/HSDT/solana-company-reports-third-quarter-2025-financial-results-newtown-pa-hsdt-20251118monthly0.5https://www.biopharmawatch.com/news/HSDT/x-2-disclaimer-this-presentation-has-been-prepared-by-solana-company-the-x201c-company-x20-hsdt-20251103monthly0.5https://www.biopharmawatch.com/news/HSDT/solana-company-announces-updated-sol-holdings-and-industry-leading-staking-yield-newtown-p-hsdt-20251029monthly0.5https://www.biopharmawatch.com/news/HSDT/solana-company-executive-chairman-s-message-october-20th-2025-newtown-pa-hsdt-20251020monthly0.5https://www.biopharmawatch.com/news/HSDT/preeminent-sol-treasury-company-helius-nasdaq-hsdt-announces-corporate-name-change-to-sola-hsdt-20250929monthly0.5https://www.biopharmawatch.com/news/HSDT/cautionary-disclaimer-statement-certain-statements-in-this-news-release-are-not-based-on-h-hsdt-20250925monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-nasdaq-hsdt-begins-purchases-of-sol-the-native-asset-of-solana-blockchain-newtown-p-hsdt-20250922monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-nasdaq-hsdt-in-partnership-with-pantera-capital-and-summer-capital-closes-over-500--hsdt-20250918monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-nasdaq-hsdt-in-partnership-with-pantera-capital-and-summer-capital-announces-over-5-hsdt-20250915monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-unaudited-condensed-interim-consolidated-balance-sheet-the-hsdt-20250617monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-compliant-with-nasdaq-bid-price-rule-listing-criteria-comp-hsdt-20250604monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-announces-reverse-stock-split-newtown-pa-hsdt-20250430monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-announces-exercise-of-warrants-and-issuance-of-new-warrant-hsdt-20250121monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-announces-first-portable-neuromodulation-stimulator-pons-system-sale-to-the-veteran-hsdt-20241223monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-announces-exploration-of-strategic-alternatives-newtown-pa-hsdt-20241118monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-reports-second-quarter-2024-financial-results-company-to-h-hsdt-20240812monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-reports-first-quarter-2024-financial-results-company-to-ho-hsdt-20240513monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-announces-pricing-of-6-4-million-public-offering-newtown-p-hsdt-20240506monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-announces-preliminary-cms-payment-determination-of-reimbur-hsdt-20240506monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-reports-fourth-quarter-and-full-year-2023-financial-result-hsdt-20240328monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-secures-hcpcs-codes-for-portable-neuromodulation-stimulato-hsdt-20240304monthly0.5https://www.biopharmawatch.com/news/HSDT/empowering-neuroplasticity-pons-therapytm-for-balance-and-gait-deficits-in-patients-with-n-hsdt-20231204monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-reports-third-quarter-2023-financial-results-cash-runway-e-hsdt-20231109monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-to-release-third-quarter-2023-financial-results-on-hsdt-20231102monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-receives-upc-numbers-for-its-pons-system-and-mouthpiece-up-hsdt-20230928monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-compliant-with-all-applicable-nasdaq-listing-criteria-newt-hsdt-20230905monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-announces-reverse-stock-split-newtown-pa-hsdt-20230816monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-reports-second-quarter-2023-financial-results-total-q2-rev-hsdt-20230810monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-reports-first-quarter-2023-financial-results-company-to-ho-hsdt-20230511monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-announces-distribution-of-series-b-preferred-stock-to-hold-hsdt-20230323monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-reports-fourth-quarter-and-full-year-2022-financial-result-hsdt-20230309monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-announces-preliminary-results-for-the-fourth-quarter-and-f-hsdt-20230123monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-reports-third-quarter-2022-financial-results-total-q3-reve-hsdt-20221114monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-reports-second-quarter-2022-financial-results-net-proceeds-hsdt-20220815monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-announces-pricing-of-18-million-public-offering-newtown-pa-hsdt-20220805monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-reports-first-quarter-2022-financial-results-and-provides--hsdt-20220512monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-fulfills-first-u-s-prescriptions-for-pons-first-patients-h-hsdt-20220427monthly0.5https://www.biopharmawatch.com/news/HSDT/legal-disclaimers-this-presentation-contains-forward-looking-statements-including-statemen-hsdt-20220401monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-reports-fourth-quarter-and-full-year-2021-financial-result-hsdt-20220314monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-provides-corporate-update-fourth-quarter-2021-revenue-proj-hsdt-20220126monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-announces-proposed-underwritten-public-offering-of-common--hsdt-20211109monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-reports-third-quarter-2021-financial-results-newtown-pa-hsdt-20211110monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-receives-pons-market-authorization-in-australia-newtown-pa-hsdt-20211104monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-appoints-paul-buckman-to-its-board-of-directors-newtown-pa-hsdt-20210914monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-announces-voluntary-de-listing-from-toronto-stock-exchange-hsdt-20210825monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-announces-fda-breakthrough-device-designation-for-the-trea-hsdt-20210817monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-reports-second-quarter-2021-financial-results-newtown-pa-hsdt-20210812monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-expands-executive-leadership-team-with-the-appointment-of--hsdt-20210615monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-reports-first-quarter-2021-financial-results-newtown-pa-hsdt-20210517monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-inc-receives-u-s-marketing-authorization-for-the-pons-device-first-and-only-hsdt-20210329monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-reports-fourth-quarter-and-full-year-2020-financial-result-hsdt-20210310monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-announces-pricing-of-9-6-million-underwritten-public-offer-hsdt-20210128monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-regains-compliance-with-nasdaq-listing-standards-the-compa-hsdt-20210119monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-submits-response-to-u-s-fda-in-pursuit-of-de-novo-classifi-hsdt-20210111monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-announces-reverse-stock-split-newtown-pa-hsdt-20201231monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-reports-third-quarter-of-fiscal-year-2020-financial-result-hsdt-20201112monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-announces-closing-of-3-4-million-private-placement-newtown-pa-hsdt-20201026monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-announces-3-4-million-private-placement-newtown-pa-hsdt-20201021monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-provides-update-on-fda-s-review-of-its-request-for-de-novo-hsdt-20201019monthly0.5https://www.biopharmawatch.com/news/HSDT/the-last-frontier-in-healthcare-empowering-the-natural-healing-process-of-the-brain-septem-hsdt-20200909monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-announces-departure-of-president-chief-executive-officer-a-hsdt-20200825monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-reports-second-quarter-of-fiscal-year-2020-financial-resul-hsdt-20200812monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-submits-request-for-fda-clearance-for-pons-tm-device-repor-hsdt-20200806monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-announces-the-dismissal-of-the-shareholder-class-action-lawsui-hsdt-20200714monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-announces-fda-has-granted-the-pons-device-breakthrough-dev-hsdt-20200512monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-reports-first-quarter-of-full-year-2020-financial-results--hsdt-20200507monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-announces-publication-of-its-pons-registrational-clinical--hsdt-20200430monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-appoints-jeffrey-s-mathiesen-to-its-board-of-directors-newtown-hsdt-20200422monthly0.5https://www.biopharmawatch.com/news/HSDT/legal-disclaimers-www-heliusmedical-com-nasdaq-hsdt-tsx-hsm-this-presentation-contains-for-hsdt-20200324monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-announces-2-2-million-registered-direct-offering-newtown-pa-hsdt-20200318monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-reports-fourth-quarter-and-full-year-2019-financial-result-hsdt-20200312monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-reports-preliminary-unaudited-fourth-quarter-and-full-year-una-hsdt-20200302monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-announces-proposed-public-offering-newtown-pa-hsdt-20191121monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-reports-third-quarter-2019-financial-results-and-provides--hsdt-20191112monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-announces-update-on-us-regulatory-strategy-following-pre-s-hsdt-20191024monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-reports-second-quarter-2019-financial-results-and-provides-hsdt-20190808monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-reports-first-quarter-2019-financial-results-and-provides--hsdt-20190509monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-provides-update-on-fda-s-review-of-its-request-for-de-novo-hsdt-20190410monthly0.5https://www.biopharmawatch.com/news/HSDT/legal-disclaimers-this-presentation-contains-forward-looking-statements-including-statemen-hsdt-20190320monthly0.5https://www.biopharmawatch.com/news/HSDT/exhit-helius-medical-technologies-inc-reports-fourth-quarter-and-full-year-2018-financial--hsdt-20190314monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-provides-update-on-fda-s-review-of-its-request-for-de-novo-hsdt-20190125monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-submits-ce-mark-application-for-pons-device-newtown-pa-hsdt-20181212monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-announces-proposed-public-offering-of-class-a-common-stock-hsdt-20181114monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-reports-third-quarter-2018-financial-results-newtown-pa-hsdt-20181108monthly0.5https://www.biopharmawatch.com/news/HSDT/ex-99-1-helius-medical-technologies-receives-medical-device-license-clearance-from-health--hsdt-20181022monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-submits-request-for-fda-510-k-clearance-of-the-pons-device-new-hsdt-20180904monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-names-jennifer-laux-as-chief-commercialization-officer-new-hsdt-20180712monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-announces-uplisting-to-nasdaq-and-pricing-of-public-offeri-hsdt-20180411monthly0.5https://www.biopharmawatch.com/news/HSDT/and-other-factors-many-of-which-are-beyond-the-control-of-the-company-including-the-compan-hsdt-20180123monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-selects-key-tronic-corporation-as-its-commercial-contract-manu-hsdt-20180105monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-contacts-investor-relations-josh-berg-415-205-7891-info-heliusmedical-com-hsdt-20180104monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-announces-closing-of-second-tranche-of-private-placement-newto-hsdt-20171228monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-announces-closing-of-first-tranche-of-private-placement-newtow-hsdt-20171222monthly0.5https://www.biopharmawatch.com/news/HSDT/hsdt-ex991-6-pptx-htm-a-revolution-in-mind-hsdt-20171109monthly0.5https://www.biopharmawatch.com/news/HSDT/fact-sheet-hsdt-20170710monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-announces-closing-of-cad-7-0-million-private-placement-newtown-pa-hsdt-20170627monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-a-revolution-in-mind-may-2017-helius-medical-technologies-www--hsdt-20170523monthly0.5https://www.biopharmawatch.com/news/HSDT/fact-sheet-hsdt-20170515monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-announces-cad-10-8-million-public-offering-of-class-a-hsdt-20170209monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inc-announces-proposed-public-offering-of-class-a-hsdt-20170208monthly0.5https://www.biopharmawatch.com/news/HSDT/resignation-of-director-to-helius-medical-technologies-inc-the-company-i-hereby-resign-as--hsdt-20170130monthly0.5https://www.biopharmawatch.com/news/HSDT/filed-by-newsfilecorp-com-helius-medical-technologies-and-u-s-army-extend-sole-source-cont-hsdt-20161121monthly0.5https://www.biopharmawatch.com/news/HSDT/focused-on-the-treatment-of-neurological-symptoms-caused-by-disease-or-trauma-helius-medic-hsdt-20160808monthly0.5https://www.biopharmawatch.com/news/HSDT/filed-by-newsfilecorp-com-helius-medical-announces-proceeds-of-1-4-million-from-exercise-o-hsdt-20160606monthly0.5https://www.biopharmawatch.com/news/HSDT/filed-by-newsfilecorp-com-helius-medical-technologies-restates-and-re-files-historical-fin-hsdt-20160426monthly0.5https://www.biopharmawatch.com/news/HSDT/filed-by-newsfilecorp-com-helius-medical-technologies-announces-allowances-of-10-new-paten-hsdt-20160104monthly0.5https://www.biopharmawatch.com/news/HSDT/filed-by-newsfilecorp-com-helius-medical-technologies-announces-receipt-of-remainder-of-a--hsdt-20151231monthly0.5https://www.biopharmawatch.com/news/HSDT/filed-by-newsfilecorp-com-helius-medical-technologies-names-joyce-laviscount-as-cfo-coo-ne-hsdt-20151022monthly0.5https://www.biopharmawatch.com/news/HSDT/filed-by-newsfilecorp-com-helius-medical-technologies-inc-and-a-b-company-limited-enter-in-hsdt-20151013monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-inventors-granted-us-patent-no-9-072-889-systems-for-providing-hsdt-20150715monthly0.5https://www.biopharmawatch.com/news/HSDT/helius-medical-technologies-announces-clinical-device-readiness-for-pons-4-0-newtown-pa-ju-hsdt-20150625monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-reports-third-quarter-financial-results-and-provides-a-corporate-update--coya-20251112monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-announces-proposed-public-offering-of-common-stock-houston-tx-coya-20251023monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-reports-second-quarter-financial-results-and-provides-a-corporate-update-coya-20250812monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-reports-first-quarter-financial-results-and-provides-a-corporate-update--coya-20250513monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-provides-a-corporate-update-and-reports-fiscal-2024-financial-results-ho-coya-20250318monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-provides-a-corporate-update-and-reports-unaudited-third-quarter-2024-fin-coya-20241106monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-announces-positive-results-of-a-double-blind-study-of-subcutaneous-low-d-coya-20241029monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-announces-10-0-million-private-placement-majority-of-investors-in-offeri-coya-20241022monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-promotes-arun-swaminathan-ph-d-to-chief-executive-officer-effective-nove-coya-20240819monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-provides-a-corporate-update-and-reports-unaudited-second-quarter-2024-fi-coya-20240812monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-announces-5-million-strategic-investment-by-the-alzheimer-s-drug-discove-coya-20240520monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-provides-a-corporate-update-and-reports-unaudited-first-quarter-2024-fin-coya-20240509monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-provides-a-corporate-update-and-reports-fiscal-2023-financial-results-ho-coya-20240319monthly0.5https://www.biopharmawatch.com/news/COYA/mr-wilbur-l-ross-former-united-states-secretary-of-commerce-joins-board-of-coya-therapeuti-coya-20231220monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-inc-and-dr-reddy-s-laboratories-enter-into-an-exclusive-collaboration-fo-coya-20231206monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-inc-provides-business-update-and-reports-q3-2023-unaudited-financial-res-coya-20231108monthly0.5https://www.biopharmawatch.com/news/COYA/former-ceo-and-chairman-of-the-board-of-bayer-pharma-ag-dieter-weinand-joins-coya-s-board--coya-20230821monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-inc-provides-business-update-and-reports-q2-2023-unaudited-financial-res-coya-20230808monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-ceo-dr-howard-berman-s-letter-to-stockholders-houston-business-wire-coya-coya-20230612monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-coya-301-increased-treg-function-and-halted-cognitive-decline-in-an-open-coya-20230516monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-inc-provides-business-update-and-reports-q1-2023-unaudited-financial-res-coya-20230510monthly0.5https://www.biopharmawatch.com/news/COYA/coya-therapeutics-inc-provides-business-update-and-reports-fy-2022-unaudited-financial-res-coya-20230329monthly0.5https://www.biopharmawatch.com/news/COYA/disclosures-mitsubishi-tanabe-pharma-member-of-clinical-advisory-board-eledon-pharmaceutic-coya-20230321monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-announces-preliminary-unaudited-fourth-quarter-and-full-year-2025-financial-result-mxct-20260112monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-reports-preliminary-third-quarter-2025-financial-results-and-reiterates-full-year--mxct-20251105monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-reports-second-quarter-2025-financial-results-and-updates-full-year-2025-guidance--mxct-20250806monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-reports-first-quarter-2025-financial-results-and-reiterates-full-year-2025-guidanc-mxct-20250507monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-full-year-mxct-20250311monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-acquires-sequre-dx-to-broaden-cell-engineering-offerings-with-on-target-and-off-ta-mxct-20250130monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-announces-preliminary-unaudited-fourth-quarter-and-full-year-2024-financial-result-mxct-20250113monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-announces-retirement-of-board-member-art-mandell-rockville-md-mxct-20241222monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-announces-streamlined-operations-and-raises-2024-revenue-guidance-rockville-md-mxct-20241209monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-reports-third-quarter-2024-financial-results-and-updates-full-year-2024-guidance-r-mxct-20241106monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-appoints-cynthia-collins-to-its-board-of-directors-rockville-md-mxct-20241015monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-reports-second-quarter-and-half-year-2024-financial-results-and-updates-full-year--mxct-20240806monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-reports-first-quarter-2024-financial-results-and-updates-2024-guidance-rockville-m-mxct-20240507monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-reports-fourth-quarter-and-full-year-2023-financial-results-and-reiterates-2024-gu-mxct-20240312monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-initiates-full-year-2024-guidance-and-reaffirms-2023-preliminary-results-rockville-mxct-20240304monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-announces-preliminary-unaudited-fourth-quarter-and-full-year-2023-financial-result-mxct-20240108monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-announces-ceo-transition-and-updates-revenue-guidance-for-2023-doug-doerfler-presi-mxct-20231211monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-reports-third-quarter-2023-financial-results-and-reiterates-full-year-2023-revenue-mxct-20231108monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-announces-preliminary-third-quarter-2023-revenue-and-updates-full-year-2023-revenu-mxct-20231004monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-reports-second-quarter-and-half-year-2023-financial-results-and-updates-full-year--mxct-20230809monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-reports-first-quarter-2023-financial-results-and-updates-full-year-2023-guidance-r-mxct-20230510monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-appoints-douglas-swirsky-as-chief-financial-officer-rockville-md-mxct-20230327monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-reports-fourth-quarter-and-full-year-2022-financial-results-31-total-revenue-growt-mxct-20230315monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-announces-preliminary-unaudited-fourth-quarter-and-full-year-2022-revenue-results--mxct-20230306monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-appoints-patrick-j-balthrop-as-non-executive-director-rockville-md-1-december-2022-mxct-20221201monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-reports-third-quarter-2022-financial-results-22-year-over-year-core-business-reven-mxct-20221109monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-reports-second-quarter-and-half-year-2022-financial-results-45-year-over-year-core-mxct-20220810monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-reports-first-quarter-financial-results-maxcyte-increases-2022-core-revenue-growth-mxct-20220509monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-announces-departure-of-cfo-and-appointment-of-ron-holtz-as-interim-cfo-announces-p-mxct-20220412monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-reports-fourth-quarter-and-full-year-financial-results-maxcyte-provides-initial-20-mxct-20220322monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-announces-strong-preliminary-unaudited-fourth-quarter-and-full-year-2021-revenue-r-mxct-20220124monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-reports-third-quarter-financial-results-gaithersburg-md-mxct-20211110monthly0.5https://www.biopharmawatch.com/news/MXCT/maxcyte-reports-second-quarter-and-half-year-2021-financial-results-provides-preliminary-2-mxct-20210913monthly0.5https://www.biopharmawatch.com/news/CGTX/https-cogrx-com-cognition-therapeutics-nasdaq-cgtx-an-investigational-oral-therapy-advanci-cgtx-20260604monthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-completes-meeting-with-fda-for-zervimesine-ct1812-in-dementia-with--cgtx-20260521monthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-reports-financial-results-for-the-first-quarter-2026-and-provides-b-cgtx-20260507monthly0.5https://www.biopharmawatch.com/news/CGTX/september-2025-zervimesine-a-once-daily-oral-therapeutic-advancing-towards-phase-3-2-forwa-cgtx-20250915monthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-reports-financial-results-for-the-second-quarter-2025-and-highlight-cgtx-20250807monthly0.5https://www.biopharmawatch.com/news/CGTX/philanthropic-donor-funds-cognition-therapeutics-expanded-access-program-for-zervimesine-c-cgtx-20250603monthly0.5https://www.biopharmawatch.com/news/CGTX/targeting-pathogenic-oligomers-june-2025-a-disruptive-approach-to-the-treatment-of-neurode-cgtx-20250602monthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-reports-topline-results-showing-oral-zervimesine-ct1812-reduced-les-cgtx-20250508monthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-reports-financial-results-for-the-first-quarter-2025-and-provides-b-cgtx-20250507monthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-reports-year-end-2024-financial-results-and-provides-business-updat-cgtx-20250320monthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-successfully-passes-pre-defined-futility-analysis-of-phase-2-study--cgtx-20250226monthly0.5https://www.biopharmawatch.com/news/CGTX/targeting-pathogenic-oligomers-january-2025-a-disruptive-approach-to-the-treatment-of-neur-cgtx-20250128monthly0.5https://www.biopharmawatch.com/news/CGTX/targeting-pathogenic-oligomers-january-2025-a-disruptive-approach-to-the-treatment-of-neur-cgtx-20250113monthly0.5https://www.biopharmawatch.com/news/CGTX/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-cgtx-20241218monthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-reports-financial-results-for-the-third-quarter-2024-and-provides-b-cgtx-20241113monthly0.5https://www.biopharmawatch.com/news/CGTX/targeting-amyloid-beta-oligomers-a-disruptive-approach-to-the-treatment-of-cns-disorders-s-cgtx-20241001monthly0.5https://www.biopharmawatch.com/news/CGTX/targeting-amyloid-beta-oligomers-a-disruptive-approach-to-the-treatment-of-alzheimer-s-dis-cgtx-20240828monthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-reports-financial-results-for-the-second-quarter-2024-and-provides--cgtx-20240808monthly0.5https://www.biopharmawatch.com/news/CGTX/results-from-the-proof-of-concept-phase-2-x2018-shine-study-of-ct1812-in-mild-to-moderate--cgtx-20240729monthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-reports-financial-results-for-the-first-quarter-2024-and-provides-b-cgtx-20240507monthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-reports-year-end-2023-financial-results-and-provides-business-updat-cgtx-20240326monthly0.5https://www.biopharmawatch.com/news/CGTX/the-field-allows-up-to-17-characters-cgtx-20240104monthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-reports-third-quarter-2023-financial-results-and-provides-business--cgtx-20231102monthly0.5https://www.biopharmawatch.com/news/CGTX/disease-modifying-medicines-for-neurodegenerative-disorders-cgtx-20230909monthly0.5https://www.biopharmawatch.com/news/CGTX/disease-modifying-medicines-for-neurodegenerative-disorders-perspective-from-a-pre-commerc-cgtx-20230824monthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-reports-second-quarter-2023-financial-results-and-business-update-a-cgtx-20230808monthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-announces-positive-topline-results-for-ct1812-phase-2-sequel-study--cgtx-20230628monthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-reports-first-quarter-2023-financial-results-and-provides-business--cgtx-20230504monthly0.5https://www.biopharmawatch.com/news/CGTX/developing-disease-modifying-medicines-for-degenerative-disorders-analyst-breakfast-april--cgtx-20230419monthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-presents-proteomic-biomarker-data-demonstrating-prominent-effects-o-cgtx-20230328monthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-reports-year-end-2022-financial-results-and-provides-business-updat-cgtx-20230323monthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-announces-development-plans-for-oral-ct1812-in-geographic-atrophy-s-cgtx-20230315monthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-and-actc-receive-fda-clearance-for-phase-2-start-study-of-oral-ct18-cgtx-20230222monthly0.5https://www.biopharmawatch.com/news/CGTX/developing-disease-modifying-medicines-for-degenerative-disorders-november-2022-2-forward--cgtx-20221116monthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-reports-third-quarter-2022-financial-results-and-provides-business--cgtx-20221114monthly0.5https://www.biopharmawatch.com/news/CGTX/developing-disease-modifying-medicines-for-degenerative-disorders-august-2022-2-this-prese-cgtx-20220829monthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-reports-second-quarter-2022-financial-results-and-provides-business-cgtx-20220809monthly0.5https://www.biopharmawatch.com/news/CGTX/disease-modifying-medicines-for-degenerative-disorders-jmp-securities-life-sciences-confer-cgtx-20220616monthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-reports-first-quarter-2022-financial-results-and-provides-business--cgtx-20220511monthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-reports-year-end-2021-financial-results-and-provides-business-updat-cgtx-20220330monthly0.5https://www.biopharmawatch.com/news/CGTX/experimental-therapeutic-ct1812-demonstrates-target-engagement-in-a-phase-1b-clinical-tria-cgtx-20220315monthly0.5https://www.biopharmawatch.com/news/CGTX/disease-modifying-medicines-for-degenerative-disorders-january-2022-2-this-presentation-co-cgtx-20220110monthly0.5https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-reports-third-quarter-financial-results-and-company-highlights-capi-cgtx-20211118monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-nasdaq-nrxp-appoints-neuroscience-information-technology-and-medical-t-nrxp-20240618monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-nasdaq-nrxp-reports-first-quarter-2024-financial-results-and-provides--nrxp-20240514monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-announces-proposed-underwritten-public-offering-of-common-stock-ra-nrxp-20240417monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-nasdaq-nrxp-reports-fourth-quarter-and-full-year-2023-financial-result-nrxp-20240401monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-announces-reverse-stock-split-to-maintain-nasdaq-listing-common-stock--nrxp-20240328monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-announces-results-of-the-vote-held-during-the-special-meeting-of-share-nrxp-20240321monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-announces-proposed-underwritten-public-offering-of-common-stock-ra-nrxp-20240226monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-announces-advance-of-5-million-milestone-payment-from--nrxp-20240212monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-nasdaq-nrxp-announces-receipt-of-positive-nasdaq-listing-determina-nrxp-20240117monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-reports-third-quarter-2023-financial-results-and-provides-business-upd-nrxp-20231114monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-announces-agreement-with-lifesci-associates-to-provide-financial-servi-nrxp-20230914monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-announces-definitive-purchase-agreement-for-preferred-shares-at-0-40-p-nrxp-20230829monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-announces-6-28-million-registered-direct-offering-radnor-pa-nrxp-20230606monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-lotus-pharmaceuticals-and-alvogen-inc-announce-collaboration-to-develo-nrxp-20230605monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-reports-full-year-2022-financial-results-and-provides-business-update--nrxp-20230331monthly0.5https://www.biopharmawatch.com/news/NRXP/announces-close-of-2-9-million-registered-direct-offering-nrxp-20230314monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-announces-close-of-2-9-million-registered-direct-offering-nrx-pharmace-nrxp-20230309monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-reports-minutes-of-recent-u-s-food-and-drug-administration-fda-meeting-nrxp-20230213monthly0.5https://www.biopharmawatch.com/news/NRXP/ad-hoc-announcement-pursuant-to-art-53-lr-relief-therapeutics-holding-sa-and-nrx-pharmaceu-nrxp-20221114monthly0.5https://www.biopharmawatch.com/news/NRXP/release-of-an-ad-hoc-announcement-pursuant-to-art-53-lr-relief-therapeutics-holding-sa-and-nrxp-20220822monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-announces-the-appointment-of-stephen-willard-chief-executive-officer-a-nrxp-20220713monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-appoints-seth-van-voorhees-phd-as-chief-financial-officer-and-treasure-nrxp-20220607monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-announces-data-safety-monitoring-board-dsmb-update-on-u-s-national-ins-nrxp-20220525monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-appoints-ira-strassberg-as-chief-financial-officer-and-treasurer-radno-nrxp-20220318monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-announces-leadership-transition-robert-besthof-head-of-operations-and--nrxp-20220308monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-announces-closing-of-25-million-private-placement-priced-at-a-premium--nrxp-20220202monthly0.5https://www.biopharmawatch.com/news/NRXP/dear-shareholders-of-nrx-pharmaceuticals-inc-i-am-writing-to-you-about-the-recent-lawsuit--nrxp-20211013monthly0.5https://www.biopharmawatch.com/news/NRXP/business-company-overview-nrx-is-a-clinical-stage-pharmaceutical-company-which-develops-th-nrxp-20210910monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-announces-closing-of-30-million-private-placement-radnor-pa-nrxp-20210824monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-announces-30-million-private-placement-radnor-pa-nrxp-20210819monthly0.5https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-inc-commences-trading-on-nasdaq-as-nrxp-following-merger-between-neuro-nrxp-20210525monthly0.5https://www.biopharmawatch.com/news/NRXP/big-rock-partners-acquisition-corp-announces-effectiveness-of-registration-statement-confi-nrxp-20210524monthly0.5https://www.biopharmawatch.com/news/NRXP/neurorx-and-georgian-ministry-of-health-agree-to-initiate-expanded-access-program-of-zyesa-nrxp-20210428monthly0.5https://www.biopharmawatch.com/news/NRXP/neurorx-responds-to-issues-raised-by-relief-therapeutics-regarding-zyesami-development-rad-nrxp-20210419monthly0.5https://www.biopharmawatch.com/news/NRXP/neurorx-and-tff-pharmaceuticals-announce-entering-into-feasibility-collaboration-feasibili-nrxp-20210309monthly0.5https://www.biopharmawatch.com/news/NRXP/neurorx-inc-and-big-rock-partners-acquisition-corp-announce-committed-10-million-pipe-to-s-nrxp-20210315monthly0.5https://www.biopharmawatch.com/news/NRXP/neurorx-announces-that-zyesami-x2122-aviptadil-has-successfully-demonstrated-10-day-accele-nrxp-20210223monthly0.5https://www.biopharmawatch.com/news/NRXP/neurorx-reports-initial-phase-2b-3-study-results-demonstrating-significant-benefit-of-zyes-nrxp-20210209monthly0.5https://www.biopharmawatch.com/news/NRXP/neurorx-relief-and-quantum-leap-announce-the-inclusion-of-zyesami-x2122-rlf-100-x2122-avip-nrxp-20210111monthly0.5https://www.biopharmawatch.com/news/NRXP/big-rock-partners-acquisition-corp-announces-merger-with-neurorx-inc-combined-company-to-h-nrxp-20201214monthly0.5https://www.biopharmawatch.com/news/NRXP/big-rock-partners-acquisition-corp-announces-extension-of-time-to-consummate-business-comb-nrxp-20190222monthly0.5https://www.biopharmawatch.com/news/NRXP/big-rock-partners-acquisition-corp-announces-intent-to-extend-deadline-to-complete-busines-nrxp-20181119monthly0.5https://www.biopharmawatch.com/news/NRXP/big-rock-partners-acquisition-corp-index-to-financial-statements-f-page-report-of-independ-nrxp-20171122monthly0.5https://www.biopharmawatch.com/news/NRXP/big-rock-partners-acquisition-corp-announces-pricing-of-60-million-initial-public-offering-nrxp-20171120monthly0.5https://www.biopharmawatch.com/news/KLRS/kalaris-reports-first-quarter-2026-financial-results-and-provides-business-updates-patient-klrs-20260512monthly0.5https://www.biopharmawatch.com/news/KLRS/kalaris-reports-full-year-2025-financial-results-and-provides-business-updates-positive-in-klrs-20260317monthly0.5https://www.biopharmawatch.com/news/KLRS/forward-looking-statements-disclaimer-this-presentation-contains-forward-looking-statement-klrs-20260309monthly0.5https://www.biopharmawatch.com/news/KLRS/kalaris-therapeutics-announces-oversubscribed-50-0-million-private-placement-klrs-20251217monthly0.5https://www.biopharmawatch.com/news/KLRS/kalaris-therapeutics-reports-initial-positive-phase-1a-data-for-th103-in-treatment-na-ve-n-klrs-20251217monthly0.5https://www.biopharmawatch.com/news/KLRS/kalaris-reports-third-quarter-2025-financial-results-and-provides-business-updates-phase-1-klrs-20251112monthly0.5https://www.biopharmawatch.com/news/KLRS/kalaris-reports-second-quarter-2025-financial-results-and-provides-business-updates-contin-klrs-20250813monthly0.5https://www.biopharmawatch.com/news/KLRS/kalaris-reports-first-quarter-2025-financial-results-and-provides-business-highlights-acti-klrs-20250514monthly0.5https://www.biopharmawatch.com/news/KLRS/kalaris-announces-closing-of-merger-with-allovir-kalaris-is-focused-on-developing-th103-a--klrs-20250319monthly0.5https://www.biopharmawatch.com/news/KLRS/kalaris-and-allovir-announce-stockholder-approval-of-merger-combined-company-expected-to-t-klrs-20250312monthly0.5https://www.biopharmawatch.com/news/KLRS/allovir-and-kalaris-therapeutics-announce-agreement-for-transformational-merger-to-create--klrs-20241108monthly0.5https://www.biopharmawatch.com/news/KLRS/allovir-provides-updates-on-phase-3-clinical-development-program-for-posoleucel-an-allogen-klrs-20231222monthly0.5https://www.biopharmawatch.com/news/KLRS/allovir-reports-third-quarter-2023-financial-results-posoleucel-a-highly-innovative-off-th-klrs-20231102monthly0.5https://www.biopharmawatch.com/news/KLRS/allovir-reports-second-quarter-2023-financial-results-company-s-three-phase-3-global-regis-klrs-20230803monthly0.5https://www.biopharmawatch.com/news/KLRS/allovir-announces-proposed-public-offering-of-common-stock-cambridge-mass-klrs-20230621monthly0.5https://www.biopharmawatch.com/news/KLRS/allovir-reports-first-quarter-2023-financial-results-company-s-three-posoleucel-phase-3-gl-klrs-20230504monthly0.5https://www.biopharmawatch.com/news/KLRS/allovir-appoints-derek-adams-ph-d-to-board-of-directors-waltham-mass-klrs-20230223monthly0.5https://www.biopharmawatch.com/news/KLRS/allovir-reports-full-year-2022-financial-results-and-2023-outlook-completion-of-enrollment-klrs-20230215monthly0.5https://www.biopharmawatch.com/news/KLRS/allovir-announces-plans-to-complete-enrollment-in-three-phase-3-posoleucel-studies-in-2023-klrs-20230109monthly0.5https://www.biopharmawatch.com/news/KLRS/allovir-reports-third-quarter-2022-financial-results-posoleucel-continues-to-advance-in-th-klrs-20221103monthly0.5https://www.biopharmawatch.com/news/KLRS/allovir-reports-second-quarter-2022-financial-results-three-phase-3-posoleucel-registratio-klrs-20220804monthly0.5https://www.biopharmawatch.com/news/KLRS/allovir-announces-126-6-million-registered-direct-offering-proceeds-support-the-completion-klrs-20220727monthly0.5https://www.biopharmawatch.com/news/KLRS/allovir-reports-first-quarter-2022-financial-results-initiated-posoleucel-registrational-s-klrs-20220505monthly0.5https://www.biopharmawatch.com/news/KLRS/allovir-appoints-shawn-tomasello-to-its-board-of-directors-waltham-mass-klrs-20220331monthly0.5https://www.biopharmawatch.com/news/KLRS/allovir-reports-full-year-2021-financial-results-and-2022-outlook-three-ongoing-phase-3-re-klrs-20220210monthly0.5https://www.biopharmawatch.com/news/KLRS/a-leader-in-allogeneic-off-the-shelf-virus-specific-t-cell-therapies-j-p-morgan-healthcare-klrs-20220110monthly0.5https://www.biopharmawatch.com/news/KLRS/allovir-announces-departure-of-chief-medical-officer-agustin-melian-waltham-mass-klrs-20211216monthly0.5https://www.biopharmawatch.com/news/KLRS/allovir-announces-positive-preliminary-data-from-the-ongoing-phase-2-posoleucel-multi-viru-klrs-20211211monthly0.5https://www.biopharmawatch.com/news/KLRS/a-leader-in-allogeneic-off-the-shelf-virus-specific-t-cell-therapies-november-2021-confide-klrs-20211115monthly0.5https://www.biopharmawatch.com/news/KLRS/allovir-reports-third-quarter-2021-financial-results-company-is-prioritizing-prevention-an-klrs-20211105monthly0.5https://www.biopharmawatch.com/news/KLRS/allovir-reports-second-quarter-2021-financial-results-posoleucel-viralym-m-alvr105-proof-o-klrs-20210806monthly0.5https://www.biopharmawatch.com/news/KLRS/allovir-reports-first-quarter-2021-financial-results-viralym-m-pivotal-trial-in-virus-asso-klrs-20210506monthly0.5https://www.biopharmawatch.com/news/KLRS/allovir-appoints-diana-m-brainard-m-d-as-chief-executive-officer-effective-klrs-20210322monthly0.5https://www.biopharmawatch.com/news/KLRS/allovir-reports-full-year-2020-financial-results-initiated-phase-3-pivotal-clinical-trial--klrs-20210211monthly0.5https://www.biopharmawatch.com/news/KLRS/disclaimer-this-presentation-has-been-prepared-by-allovir-inc-we-us-our-allovir-or-the-com-klrs-20210114monthly0.5https://www.biopharmawatch.com/news/KLRS/allovir-announces-fda-clearance-of-investigational-new-drug-application-for-alvr106-an-all-klrs-20201217monthly0.5https://www.biopharmawatch.com/news/KLRS/positive-phase-2-proof-of-concept-data-for-viralym-m-and-burden-of-disease-data-presented--klrs-20201207monthly0.5https://www.biopharmawatch.com/news/KLRS/preclinical-data-demonstrate-anti-viral-activity-of-allovir-s-alvr109-an-allogeneic-off-th-klrs-20201205monthly0.5https://www.biopharmawatch.com/news/KLRS/allovir-reports-third-quarter-2020-financial-results-completed-initial-public-offering-rai-klrs-20201110monthly0.5https://www.biopharmawatch.com/news/KLRS/allovir-announces-the-fda-clearance-of-investigational-new-drug-application-ind-for-alvr10-klrs-20200917monthly0.5https://www.biopharmawatch.com/news/KLRS/allovir-reports-second-quarter-2020-financial-results-cambridge-mass-klrs-20200902monthly0.5https://www.biopharmawatch.com/news/PEPG/company-presentation-may-2026-forward-looking-statements-this-presentation-contains-forwar-pepg-20260521monthly0.5https://www.biopharmawatch.com/news/PEPG/march-2026-company-presentation-forward-looking-statements-this-presentation-contains-forw-pepg-20260304monthly0.5https://www.biopharmawatch.com/news/PEPG/julia-deutsch-lyra-strategic-advisory-jdeutsch-lyraadvisory-com-pepg-20251208monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-reports-third-quarter-2025-financial-results-and-recent-corporate-highlights-x2013--pepg-20251112monthly0.5https://www.biopharmawatch.com/news/PEPG/october-2025-company-presentation-forward-looking-statements-this-presentation-contains-fo-pepg-20251001monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-announces-proposed-public-offering-pepg-20250924monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-announces-highest-mean-splicing-correction-reported-in-dm1-patients-53-7-mean-splic-pepg-20250924monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-reports-second-quarter-2025-financial-results-and-recent-corporate-highlights-x2013-pepg-20250807monthly0.5https://www.biopharmawatch.com/news/PEPG/forward-looking-statements-these-risks-and-uncertainties-include-but-are-not-limited-to-ri-pepg-20250528monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-reports-first-quarter-2025-financial-results-and-recent-corporate-highlights-x2013--pepg-20250508monthly0.5https://www.biopharmawatch.com/news/PEPG/about-pepgen-pepgen-is-a-clinical-stage-biotechnology-company-advancing-the-next-generatio-pepg-20250331monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-announces-update-to-phase-2-connect2-edo51-study-in-patients-with-dmd-company-will--pepg-20250304monthly0.5https://www.biopharmawatch.com/news/PEPG/condensed-consolidated-balance-sheets-unaudited-in-thousands-december-31-pepg-20250224monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-announces-connect-program-updates-boston-x2014-pepg-20250129monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-announces-clinical-hold-in-the-u-s-on-ind-application-to-initiate-connect2-edo51-ph-pepg-20241216monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-reports-third-quarter-2024-financial-results-and-recent-corporate-highlights-x2013--pepg-20241107monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-announces-presentations-at-the-29-th-annual-congress-of-the-world-muscle-society-bo-pepg-20241008monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-announces-christopher-ashton-phd-to-retire-from-its-board-of-directors-boston-pepg-20240919monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-appoints-paul-streck-m-d-mba-as-executive-vice-president-head-of-research-developme-pepg-20240820monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-reports-second-quarter-2024-financial-results-and-recent-corporate-highlights-x2013-pepg-20240808monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-announces-positive-data-from-low-dose-cohort-of-pgn-edo51-in-ongoing-connect1-edo51-pepg-20240730monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-appoints-afsaneh-mohebbi-ph-d-as-svp-portfolio-and-program-management-and-dave-bora-pepg-20240702monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-announces-executive-team-promotions-michelle-mellion-m-d-promoted-to-chief-medical--pepg-20240611monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-reports-first-quarter-2024-financial-results-and-recent-corporate-highlights-x2013--pepg-20240514monthly0.5https://www.biopharmawatch.com/news/PEPG/t-pepgen-receives-u-s-fda-orphan-drug-and-rare-pediatric-disease-designations-for-pgn-edo5-pepg-20240313monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-reports-fourth-quarter-and-full-year-2023-financial-results-and-recent-corporate-de-pepg-20240306monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-announces-clearance-of-cta-by-uk-medicines-healthcare-products-regulatory-agency-to-pepg-20240304monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-receives-u-s-fda-fast-track-designation-for-pgn-edodm1-for-the-treatment-of-myotoni-pepg-20240220monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-announces-pricing-of-80-1-million-underwritten-offering-of-common-stock-boston-pepg-20240207monthly0.5https://www.biopharmawatch.com/news/PEPG/mary-beth-delena-joins-pepgen-as-general-counsel-and-secretary-boston-pepg-20240117monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-announces-first-patient-dosed-in-connect1-edo51-phase-2-clinical-trial-of-pgn-edo51-pepg-20240108monthly0.5https://www.biopharmawatch.com/news/PEPG/including-development-pathway-for-our-product-candidates-and-our-financial-resources-and-c-pepg-20231218monthly0.5https://www.biopharmawatch.com/news/PEPG/x201c-aims-x201d-x201c-anticipates-x201d-x201c-believes-x201d-x201c-could-x201d-x201c-esti-pepg-20231115monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-inc-announces-fda-has-lifted-the-clinical-hold-on-its-investigational-new-drug-appl-pepg-20231012monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-inc-announces-clearance-of-cta-by-health-canada-to-begin-the-freedom-dm1-phase-1-st-pepg-20230906monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-inc-presents-pgn-edodm1-preclinical-data-supporting-the-company-s-enhanced-delivery-pepg-20230906monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-reports-second-quarter-2023-financial-results-and-recent-corporate-developments-x20-pepg-20230808monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-inc-provides-update-on-planned-initiation-of-phase-1-study-of-pgn-edodm1-in-myotoni-pepg-20230613monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-inc-announces-clinical-hold-in-the-u-s-on-ind-application-to-initiate-a-phase-1-stu-pepg-20230530monthly0.5https://www.biopharmawatch.com/news/PEPG/sarah-sutton-argot-partners-pepgen-argotpartners-com-pepg-20230518monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-reports-first-quarter-2023-financial-results-and-recent-corporate-developments-x201-pepg-20230511monthly0.5https://www.biopharmawatch.com/news/PEPG/empowering-oligonucleotide-therapeutics-company-presentation-march-2023-disclaimers-this-p-pepg-20230327monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-reports-fourth-quarter-and-full-year-2022-financial-results-and-recent-corporate-de-pepg-20230323monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-presents-clinical-and-nonclinical-data-at-the-2023-annual-muscular-dystrophy-associ-pepg-20230322monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-announces-ind-enabling-preclinical-data-supporting-progression-of-pgn-edodm1-into-c-pepg-20221207monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-announces-positive-preclinical-data-for-pgn-edo53-pgn-edo45-and-pgn-edo44-three-nov-pepg-20221114monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-reports-third-quarter-2022-financial-results-and-recent-corporate-developments-bost-pepg-20221110monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-reports-positive-data-from-phase-1-trial-of-pgn-edo51-for-the-treatment-of-duchenne-pepg-20220928monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-appoints-habib-dable-to-board-of-directors-boston-pepg-20220922monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-reports-second-quarter-2022-financial-results-and-recent-corporate-developments-bos-pepg-20220812monthly0.5https://www.biopharmawatch.com/news/PEPG/pepgen-reports-first-quarter-2022-financial-results-and-recent-corporate-developments-bost-pepg-20220616monthly0.5https://www.biopharmawatch.com/news/EXOZ/exozymes-inc-announces-closing-of-6-million-public-offering-los-angeles-ca-exoz-20260617monthly0.5https://www.biopharmawatch.com/news/EXOZ/exozymes-inc-announces-pricing-of-public-offering-of-common-stock-and-warrants-los-angeles-exoz-20260608monthly0.5https://www.biopharmawatch.com/news/EXOZ/exozymes-advancing-commercial-readiness-with-profound-production-metrics-on-initial-nct-pi-exoz-20260129monthly0.5https://www.biopharmawatch.com/news/EXOZ/exozymes-achieves-100-scale-up-of-nct-production-using-exozymes-demonstrating-near-perfect-exoz-20251211monthly0.5https://www.biopharmawatch.com/news/EXOZ/exozymes-selected-as-core-industry-partner-in-9m-nsf-funded-initiative-to-advance-modular--exoz-20250626monthly0.5https://www.biopharmawatch.com/news/EXOZ/exozymes-provides-fourth-quarter-and-full-year-2024-update-management-to-host-conference-c-exoz-20250402monthly0.5https://www.biopharmawatch.com/news/EXOZ/exozymes-appoints-experienced-biomanufacturing-executive-damien-perriman-as-cco-expanded-l-exoz-20250402monthly0.5https://www.biopharmawatch.com/news/EXOZ/invizyne-technologies-announces-pricing-of-15-million-initial-public-offering-shares-to-be-exoz-20241112monthly0.5https://www.biopharmawatch.com/news/KZIA/nasdaq-kzia-x-kaziatx-beyond-inhibition-reprogramming-cancer-control-2026-corporate-overvi-kzia-20260427monthly0.5https://www.biopharmawatch.com/news/KZIA/nasdaq-kzia-x-kaziatx-beyond-inhibition-reprogramming-cancer-control-2026-corporate-overvi-kzia-20260331monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-limited-abn-37-063-259-754-half-yearly-report-31-december-2025-kazia-th-kzia-20260330monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-limited-abn-37-063-259-754-half-yearly-report-31-december-2025-kazia-th-kzia-20260319monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-announces-transformative-preclinical-data-demonstrating-paxalisib-s-pot-kzia-20250611monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-limited-abn-37-063-259-754-half-yearly-report-31-december-2024-kazia-th-kzia-20250610monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-announces-first-patient-dosed-in-phase-1b-trial-of-paxalisib-in-advance-kzia-20250605monthly0.5https://www.biopharmawatch.com/news/KZIA/may-2025-kazia-therapeutics-highlights-recent-progress-and-provides-business-update-awarde-kzia-20250515monthly0.5https://www.biopharmawatch.com/news/KZIA/march-2025-kazia-therapeutics-announces-sale-of-intellectual-property-and-trademarks-right-kzia-20250331monthly0.5https://www.biopharmawatch.com/news/KZIA/annual-report-contents-2-4-6-chairman-and-key-about-gbm-ceo-s-letter-milestones-8-12-envir-kzia-20250313monthly0.5https://www.biopharmawatch.com/news/KZIA/february-2025-kazia-therapeutics-and-the-hebrew-university-of-jerusalem-receives-a-grant-f-kzia-20250220monthly0.5https://www.biopharmawatch.com/news/KZIA/a-diversified-oncology-drug-development-company-kazia-corporate-overview-january-2025-nasd-kzia-20250203monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-announces-the-launch-of-a-groundbreaking-trial-with-paxalisib-in-combin-kzia-20250130monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-announces-2-0-million-registered-direct-offering-kzia-20250110monthly0.5https://www.biopharmawatch.com/news/KZIA/december-2024-kazia-therapeutics-provides-update-on-paxalisib-regulatory-pathway-following-kzia-20241231monthly0.5https://www.biopharmawatch.com/news/KZIA/december-2024-kazia-therapeutics-to-present-data-highlighting-synergistic-activity-between-kzia-20241211monthly0.5https://www.biopharmawatch.com/news/KZIA/november-2024-kazia-therapeutics-announces-granting-of-type-c-meeting-with-fda-to-discuss--kzia-20241104monthly0.5https://www.biopharmawatch.com/news/KZIA/october-2024-kazia-therapeutics-announces-presentation-of-promising-phase-i-data-evaluatin-kzia-20241002monthly0.5https://www.biopharmawatch.com/news/KZIA/september-2024-kazia-therapeutics-announces-presentation-of-evt801-clinical-data-at-15-th--kzia-20240923monthly0.5https://www.biopharmawatch.com/news/KZIA/september-2024-kazia-executes-licensing-agreement-with-qimr-berghofer-sydney-kzia-20240912monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-announces-phase-ii-iii-clinical-trial-results-for-paxalisib-in-glioblas-kzia-20240710monthly0.5https://www.biopharmawatch.com/news/KZIA/may-2024-kazia-reports-successful-stage-1-completion-of-the-evt801-phase-1-clinical-trial--kzia-20240501monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-limited-abn-37-063-259-754-half-yearly-report-31-december-2023-kazia-th-kzia-20240327monthly0.5https://www.biopharmawatch.com/news/KZIA/march-2024-kazia-therapeutics-licenses-paxalisib-to-sovargen-for-intractable-seizures-in-r-kzia-20240321monthly0.5https://www.biopharmawatch.com/news/KZIA/february-2024-kazia-therapeutics-reports-early-conclusion-of-clinical-trial-after-reaching-kzia-20240221monthly0.5https://www.biopharmawatch.com/news/KZIA/january-2024-kazia-continues-board-renewal-with-two-new-appointments-18-january-2024-kazia-kzia-20240118monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-announces-closing-of-2-million-registered-direct-offering-kzia-20231205monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-announces-2-million-registered-direct-offering-kzia-20231201monthly0.5https://www.biopharmawatch.com/news/KZIA/november-2023-kazia-announces-non-binding-letter-of-intent-for-the-proposed-granting-of-ri-kzia-20231129monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-limited-abn-37-063-259-754-this-document-is-important-and-requires-your-kzia-20231129monthly0.5https://www.biopharmawatch.com/news/KZIA/november-2023-kazia-provides-overview-of-paxalisib-related-presentations-from-the-society--kzia-20231121monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-announces-receipt-of-nasdaq-minimum-bid-notification-sydney-kzia-20231120monthly0.5https://www.biopharmawatch.com/news/KZIA/november-2023-kazia-announces-the-release-of-pnoc022-clinical-study-abstract-highlighting--kzia-20231115monthly0.5https://www.biopharmawatch.com/news/KZIA/november-2023-kazia-announces-publication-in-molecular-cancer-therapeutics-highlighting-pa-kzia-20231114monthly0.5https://www.biopharmawatch.com/news/KZIA/asx-release-01-nov-2023-kazia-therapeutics-provides-preliminary-update-from-ongoing-phase--kzia-20231101monthly0.5https://www.biopharmawatch.com/news/KZIA/asx-release-23-oct-2023-kazia-therapeutics-announces-clinical-data-at-esmo-2023-from-ongoi-kzia-20231023monthly0.5https://www.biopharmawatch.com/news/KZIA/asx-release-13-october-2023-shareholder-communication-on-the-de-listing-process-sydney-13--kzia-20231013monthly0.5https://www.biopharmawatch.com/news/KZIA/asx-release-11-october-2023-kazia-announces-voluntary-delisting-from-asx-sydney-11-october-kzia-20231011monthly0.5https://www.biopharmawatch.com/news/KZIA/market-announcement-10-october-2023-kazia-therapeutics-limited-asx-kza-suspension-from-quo-kzia-20231010monthly0.5https://www.biopharmawatch.com/news/KZIA/october-2023-ms-lisa-bahn-senior-adviser-listings-compliance-asx-limited-20-bridge-street--kzia-20231006monthly0.5https://www.biopharmawatch.com/news/KZIA/asx-release-29-september-2023-kazia-therapeutics-announces-acceptance-of-late-breaking-abs-kzia-20230929monthly0.5https://www.biopharmawatch.com/news/KZIA/annual-report-2023-contents-chairman-and-ceo-s-letter-key-milestones-introduction-to-kazia-kzia-20230905monthly0.5https://www.biopharmawatch.com/news/KZIA/asx-release-11-august-2023-kazia-therapeutics-announces-change-to-board-of-directors-sydne-kzia-20230811monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-s-paxalisib-receives-fast-track-designation-from-fda-for-treatment-of-solid-tumor-br-kzia-20230706monthly0.5https://www.biopharmawatch.com/news/KZIA/asx-announcement-26-june-2023-kazia-corporate-update-and-corporate-presentation-sydney-26--kzia-20230626monthly0.5https://www.biopharmawatch.com/news/KZIA/asx-announcement-5-june-2023-kazia-expands-board-of-directors-with-appointment-of-ebru-dav-kzia-20230605monthly0.5https://www.biopharmawatch.com/news/KZIA/asx-announcement-1-st-may-2023-kazia-announces-executive-leadership-changes-dr-john-friend-kzia-20230501monthly0.5https://www.biopharmawatch.com/news/KZIA/asx-announcement-14-april-2023-kazia-regains-compliance-with-nasdaq-minimum-bid-price-requ-kzia-20230414monthly0.5https://www.biopharmawatch.com/news/KZIA/asx-announcement-4-april-2023-kazia-presents-new-data-for-paxalisib-and-evt801-at-aacr-ann-kzia-20230404monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-limited-appendix-4d-half-year-report-1-company-details-name-of-entity-k-kzia-20230309monthly0.5https://www.biopharmawatch.com/news/KZIA/asx-announcement-7-march-2023-kazia-therapeutics-announces-clinical-collaboration-for-aust-kzia-20230307monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-limited-appendix-4d-half-year-report-1-company-details-name-of-entity-k-kzia-20230228monthly0.5https://www.biopharmawatch.com/news/KZIA/asx-announcement-24-february-2023-results-of-egm-sydney-24-february-2023-kazia-therapeutic-kzia-20230224monthly0.5https://www.biopharmawatch.com/news/KZIA/asx-announcement-24-february-2023-change-in-auditor-s-y-dn-ey-2-4-fe-b-ru-a-r-y-2-0-2-3-ka-kzia-20230224monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-limited-abn-37-063-259-754-this-document-is-important-and-requires-your-kzia-20230120monthly0.5https://www.biopharmawatch.com/news/KZIA/asx-announcement-15-december-2022-kazia-launches-preclinical-collaboration-with-qimr-bergh-kzia-20221215monthly0.5https://www.biopharmawatch.com/news/KZIA/december-2022-kazia-announces-receipt-of-nasdaq-minimum-bid-notification-sydney-12-d-ecemb-kzia-20221209monthly0.5https://www.biopharmawatch.com/news/KZIA/asx-announcement-1-december-2022-compelling-preclinical-data-for-kazia-s-evt801-published--kzia-20221201monthly0.5https://www.biopharmawatch.com/news/KZIA/asx-release-16-november-2022-agm-materials-sydney-16-november-2022-kazia-therapeutics-limi-kzia-20221116monthly0.5https://www.biopharmawatch.com/news/KZIA/asx-announcement-3-november-2022-withdrawal-of-resolution-from-agm-sydney-3-november-2022--kzia-20221103monthly0.5https://www.biopharmawatch.com/news/KZIA/october-27-th-2022-kazia-s-paxalisib-demonstrates-positive-monotherapy-efficacy-signals-in-kzia-20221027monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-limited-abn-37-063-259-754-this-document-is-important-and-requires-your-kzia-20221014monthly0.5https://www.biopharmawatch.com/news/KZIA/a-diversified-oncology-drug-development-company-presentation-to-hc-wainwright-global-inves-kzia-20220915monthly0.5https://www.biopharmawatch.com/news/KZIA/appendix3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-directo-kzia-20220908monthly0.5https://www.biopharmawatch.com/news/KZIA/annual-report-2022-annual-report-2022-contents-2022-at-a-glance-2-chairman-s-letter-4-ceo--kzia-20220901monthly0.5https://www.biopharmawatch.com/news/KZIA/asx-release-5-august-2022-kazia-therapeutics-reports-promising-interim-data-from-combinati-kzia-20220805monthly0.5https://www.biopharmawatch.com/news/KZIA/asx-release-1-august-2022-kazia-provides-progress-update-on-gbm-agile-pivotal-study-sydney-kzia-20220801monthly0.5https://www.biopharmawatch.com/news/KZIA/asx-release-17-june-2022-us-fda-awards-orphan-drug-designation-odd-to-paxalisib-for-at-rt--kzia-20220617monthly0.5https://www.biopharmawatch.com/news/KZIA/novogen-announces-results-of-general-meeting-of-shareholders-sydney-kzia-20140813monthly0.5https://www.biopharmawatch.com/news/KZIA/novogen-and-cantx-announce-potency-of-intra-peritoneal-trx-1-confirmed-against-chemo-resis-kzia-20140617monthly0.5https://www.biopharmawatch.com/news/KZIA/novogen-and-genea-announce-partnership-to-investigate-promising-new-approach-to-neurodegen-kzia-20140502monthly0.5https://www.biopharmawatch.com/news/KZIA/novogen-and-cantx-experimental-drug-trx-1-proves-effective-in-vivo-experimental-drug-desig-kzia-20140318monthly0.5https://www.biopharmawatch.com/news/KZIA/asx-media-release-2-may-2011-marshall-edwards-announces-private-placement-novogen-limited--kzia-20110503monthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-plans-to-unblind-hero-and-ole-data-to-inform-path-forward-following--aard-20260514monthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-u-aard-20260507monthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-inc-consolidated-balance-sheets-in-thousands-except-share-amounts-aard-20260323monthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-announces-voluntary-pause-of-phase-3-hero-trial-in-prader-willi-synd-aard-20260227monthly0.5https://www.biopharmawatch.com/news/AARD/disclaimer-aardvark-therapeutics-inc-the-x201c-company-x201d-does-not-nor-its-respective-a-aard-20260112monthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-reports-third-quarter-2025-financial-results-and-provides-pipeline-a-aard-20251113monthly0.5https://www.biopharmawatch.com/news/AARD/disclaimer-aardvark-therapeutics-inc-the-x201c-company-x201d-does-not-nor-their-respective-aard-20251106monthly0.5https://www.biopharmawatch.com/news/AARD/forward-looking-statement-whether-as-a-result-of-new-information-future-events-or-otherwis-aard-20251009monthly0.5https://www.biopharmawatch.com/news/AARD/corporate-presentation-september-2025-disclaimer-aardvark-therapeutics-inc-the-x201c-compa-aard-20250903monthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-announces-ard-201-preclinical-obesity-data-showing-significant-weigh-aard-20250812monthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-reports-first-quarter-2025-financial-results-and-provides-business-h-aard-20250514monthly0.5https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-reports-full-year-2024-financial-results-and-provides-business-highl-aard-20250331monthly0.5https://www.biopharmawatch.com/news/BMEA/certain-statements-in-this-presentation-and-the-accompanying-oral-commentary-are-forward-l-bmea-20260428monthly0.5https://www.biopharmawatch.com/news/BMEA/st-1-quarter-2026-biomea-fusion-corporate-presentation-1-legal-disclaimer-forward-looking--bmea-20260225monthly0.5https://www.biopharmawatch.com/news/BMEA/legal-disclaimer-forward-looking-statements-certain-statements-in-this-presentation-and-th-bmea-20260114monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-proposed-public-offering-of-securities-bmea-20251006monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-reports-second-quarter-2025-financial-results-and-corporate-highlights-x2022-bmea-20250805monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-appoints-julianne-averill-to-its-board-of-directors-bmea-20250724monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-proposed-public-offering-of-securities-bmea-20250617monthly0.5https://www.biopharmawatch.com/news/BMEA/corporate-update-june-2025-slide-1-legal-disclaimer-forward-looking-statement-certain-stat-bmea-20250617monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-reports-first-quarter-2025-financial-results-and-corporate-highlights-compan-bmea-20250505monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-reports-fourth-quarter-and-full-year-2024-financial-results-and-corporate-hi-bmea-20250331monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-leadership-transition-board-member-mick-hitchcock-named-interim-ce-bmea-20250325monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-to-become-a-diabetes-obesity-medicines-company-bmea-20250113monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-positive-topline-results-from-ongoing-phase-ii-covalent-111-study--bmea-20241217monthly0.5https://www.biopharmawatch.com/news/BMEA/legal-disclaimer-forward-looking-statements-certain-statements-in-this-presentation-and-th-bmea-20241031monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-reports-third-quarter-2024-financial-results-and-corporate-highlights-x2022--bmea-20241029monthly0.5https://www.biopharmawatch.com/news/BMEA/fda-lifts-clinical-hold-on-bmf-219-in-type-2-and-type-1-diabetes-trials-bmea-20240926monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-reports-second-quarter-2024-financial-results-and-corporate-highlights-x2022-bmea-20240731monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-bmf-219-in-diabetes-placed-on-clinical-hold-bmea-20240606monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-reports-first-quarter-2024-financial-results-and-corporate-highlights-x2022--bmea-20240502monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-highlights-initial-data-from-the-first-two-type-1-diabetes-patients-dosed-wi-bmea-20240401monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-reports-fourth-quarter-and-full-year-2023-financial-results-and-corporate-hi-bmea-20240401monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-presents-patient-cohorts-in-covalent-111-displaying-a-durable-placebo-adjust-bmea-20240307monthly0.5https://www.biopharmawatch.com/news/BMEA/jp-morgan-2024-corporate-presentation-page-1-disclaimer-legal-disclaimer-forward-looking-s-bmea-20240110monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-reports-third-quarter-2023-financial-results-and-corporate-highlights-x2022--bmea-20231030monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-reports-second-quarter-2023-financial-results-and-corporate-highlights-x2022-bmea-20230731monthly0.5https://www.biopharmawatch.com/news/BMEA/bmf-219-induces-complete-responses-in-target-acute-myeloid-leukemia-aml-patient-population-bmea-20230724monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-fda-clearance-of-investigational-new-drug-ind-application-for-cova-bmea-20230501monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-reports-first-quarter-2023-financial-results-and-corporate-highlights-x2022--bmea-20230502monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-proposed-public-offering-of-common-stock-bmea-20230329monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-positive-data-from-initial-cohorts-of-ongoing-phase-ii-study-coval-bmea-20230328monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-reports-fourth-quarter-and-full-year-2022-financial-results-and-corporate-hi-bmea-20230328monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-to-present-at-41-st-annual-j-p-morgan-healthcare-conference-and-highlight-20-bmea-20230109monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-fda-clearance-of-investigational-new-drug-ind-application-for-cova-bmea-20221214monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-presents-at-the-2022-ash-annual-meeting-preclinical-data-on-bmf-500-supporti-bmea-20221212monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-reports-third-quarter-2022-financial-results-and-business-highlights-x2022-c-bmea-20221107monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-dosing-of-first-patient-with-type-2-diabetes-and-completion-of-pha-bmea-20221031monthly0.5https://www.biopharmawatch.com/news/BMEA/bmf-219-enters-the-clinic-for-kras-solid-tumors-biomea-fusion-announces-fda-clearance-of-i-bmea-20221018monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-presents-new-translational-data-at-the-european-association-for-the-study-of-bmea-20220922monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-presents-new-preclinical-data-at-the-european-association-for-the-study-of-d-bmea-20220920monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-presents-additional-preclinical-data-demonstrating-anti-tumor-activity-and-m-bmea-20220826monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-reports-second-quarter-2022-financial-results-and-business-highlights-x2022--bmea-20220801monthly0.5https://www.biopharmawatch.com/news/BMEA/preclinical-activity-of-irreversible-menin-inhibitor-bmf-219-in-chronic-lymphocytic-leukem-bmea-20220606monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-reports-first-quarter-2022-financial-results-and-business-highlights-x2022-c-bmea-20220516monthly0.5https://www.biopharmawatch.com/news/BMEA/first-amendment-to-change-in-control-and-severance-agreement-this-first-amendment-to-chang-bmea-20220422monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-reports-preclinical-data-on-bmf-219-and-trial-in-progress-presentations-at-a-bmea-20220408monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-reports-fourth-quarter-and-full-year-2021-financial-results-and-corporate-hi-bmea-20220228monthly0.5https://www.biopharmawatch.com/news/BMEA/corporate-presentation-january-2022-1-disclaimer-and-forward-looking-statement-certain-sta-bmea-20220112monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-tm-corporate-presentation-november-2021-disclaimer-and-forward-looking-state-bmea-20211115monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-reports-third-quarter-2021-financial-results-and-business-highlights-announc-bmea-20211103monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-announces-fda-clearance-of-investigational-new-drug-application-for-irrevers-bmea-20210916monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-reports-second-quarter-2021-financial-results-and-business-highlights-comple-bmea-20210811monthly0.5https://www.biopharmawatch.com/news/BMEA/corporate-presentation-july-2021-disclaimer-and-forward-looking-statement-certain-statemen-bmea-20210719monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-fusion-reports-first-quarter-2021-financial-results-and-business-highlights-receive-bmea-20210527monthly0.5https://www.biopharmawatch.com/news/BMEA/biomea-announces-closing-of-initial-public-offering-redwood-city-california-bmea-20210420monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-ycanth-vrca-20260311monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-reports-third-quarter-2025-financial-results-company-reports-14-3--vrca-20251117monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-reports-quarterly-2025-financial-results-company-reports-3-4-milli-vrca-20250513monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-financial-results-compan-vrca-20250311monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-announces-pricing-of-42-0-million-public-offering-vrca-20241121monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-announces-proposed-public-offering-vrca-20241120monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-reports-third-quarter-2024-financial-results-and-announces-leaders-vrca-20241104monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-reports-second-quarter-2024-financial-results-reports-ycanth-reven-vrca-20240814monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-amendment-to-company-s-collaboration-and-license-agreeme-vrca-20240515monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-reports-first-quarter-2024-financial-results-reports-ycanth-revenu-vrca-20240513monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results-report-vrca-20240229monthly0.5https://www.biopharmawatch.com/news/VRCA/company-overview-january-2024-copyright-2024-verrica-pharmaceuticals-all-rights-reserved-n-vrca-20240108monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-reports-third-quarter-2023-financial-results-strong-awareness-and--vrca-20231109monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-reports-second-quarter-2023-financial-results-in-july-fda-approved-vrca-20230808monthly0.5https://www.biopharmawatch.com/news/VRCA/disclaimer-certain-information-contained-in-this-presentation-and-statements-made-orally-d-vrca-20230727monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-closing-of-125-million-debt-financing-with-orbimed-verri-vrca-20230721monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-fda-approval-of-ycanth-cantharidin-topical-solution-as-t-vrca-20230721monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-reports-first-quarter-2023-financial-results-new-drug-application--vrca-20230509monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-reports-fourth-quarter-and-full-year-2022-financial-results-new-dr-vrca-20230306monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-announces-pricing-of-32-5-million-underwritten-offering-of-common-stock-and-pre-fu-vrca-20230221monthly0.5https://www.biopharmawatch.com/news/VRCA/disclaimer-certain-information-contained-in-this-presentation-and-statements-made-orally-d-vrca-20230202monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-reports-third-quarter-2022-financial-results-reiterates-expectatio-vrca-20221107monthly0.5https://www.biopharmawatch.com/news/VRCA/disclaimer-certain-information-contained-in-this-presentation-and-statements-made-orally-d-vrca-20220914monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-reports-second-quarter-2022-financial-results-verrica-held-type-a--vrca-20220811monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-announces-proposed-public-offering-of-common-stock-west-chester-pa-vrca-20220629monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-reports-first-quarter-2022-financial-results-upcoming-pdufa-date-o-vrca-20220509monthly0.5https://www.biopharmawatch.com/news/VRCA/disclaimer-certain-information-contained-in-this-presentation-and-statements-made-orally-d-vrca-20220407monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-reports-fourth-quarter-and-full-year-2021-financial-results-nda-fo-vrca-20220302monthly0.5https://www.biopharmawatch.com/news/VRCA/disclaimer-certain-information-contained-in-this-presentation-and-statements-made-orally-d-vrca-20211129monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-reports-third-quarter-2021-financial-results-contract-manufacturer-vrca-20211112monthly0.5https://www.biopharmawatch.com/news/VRCA/disclaimer-certain-information-contained-in-this-presentation-and-statements-made-orally-d-vrca-20210929monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-reports-second-quarter-2021-financial-results-vrca-20210810monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-vrca-20210528monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-reports-first-quarter-2021-financial-results-expanded-commercial-t-vrca-20210507monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-announces-proposed-public-offering-of-common-stock-west-chester-pa-vrca-20210322monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-reports-fourth-quarter-and-full-year-2020-financial-results-fda-ac-vrca-20210304monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-fda-filing-acceptance-of-resubmitted-new-drug-applicatio-vrca-20210217monthly0.5https://www.biopharmawatch.com/news/VRCA/company-overview-january-2021-1-disclaimer-certain-information-contained-in-this-presentat-vrca-20210106monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-positive-topline-results-in-phase-2-clinical-study-of-vp-vrca-20201110monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-reports-third-quarter-2020-financial-results-verrica-completes-typ-vrca-20201109monthly0.5https://www.biopharmawatch.com/news/VRCA/company-overview-september-2020-copyright-2020-verrica-pharmaceuticals-all-rights-reserved-vrca-20200908monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-reports-second-quarter-2020-financial-results-company-intends-to-r-vrca-20200805monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-clinical-and-drug-development-leadership-changes-dr-gary-vrca-20200723monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-receives-complete-response-letter-from-the-fda-for-its-new-drug-ap-vrca-20200714monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-provides-regulatory-update-on-vp-102-vrca-20200629monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-appoints-diem-nguyen-ph-d-m-b-a-to-its-board-of-directors-global-b-vrca-20200610monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-reports-first-quarter-2020-financial-results-secured-55-million-in-vrca-20200507monthly0.5https://www.biopharmawatch.com/news/VRCA/certain-information-contained-in-this-presentation-and-statements-made-orally-during-this--vrca-20200417monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-reports-fourth-quarter-and-full-year-2019-financial-results-new-dr-vrca-20200313monthly0.5https://www.biopharmawatch.com/news/VRCA/certain-information-contained-in-this-presentation-and-statements-made-orally-during-this--vrca-20200302monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-reports-third-quarter-2019-financial-results-submitted-new-drug-ap-vrca-20191106monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-announces-presentation-of-positive-data-from-clinical-trials-of-vp-vrca-20191018monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-reports-second-quarter-2019-financial-results-achieved-positive-to-vrca-20190807monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-achieves-positive-topline-results-in-phase-2-clinical-study-of-vp--vrca-20190626monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-reports-first-quarter-2019-financial-results-reported-positive-top-vrca-20190507monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-reports-fourth-quarter-and-full-year-2018-financial-results-vrca-20190307monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-achieves-positive-topline-results-from-two-pivotal-phase-3-clinical-trials-of-vp-1-vrca-20190103monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-reports-third-quarter-2018-financial-results-vrca-20181107monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-announces-successful-phase-2-innovate-trial-and-complete-enrollment-of-phase-3-tri-vrca-20180912monthly0.5https://www.biopharmawatch.com/news/VRCA/verrica-reports-second-quarter-2018-financial-results-vrca-20180807monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-corporation-nasdaq-kequ-special-note-regarding-forward-looking-stateme-kequ-20250827monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-corporation-completes-acquisition-of-nu-aire-exchange-nasdaq-kequ-cont-kequ-20241101monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-corporation-nasdaq-kequ-special-note-regarding-forward-looking-stateme-kequ-20240828monthly0.5https://www.biopharmawatch.com/news/KEQU/annual-shareholder-meeting-encouraging-new-discovery-worldwide-kequ-20230823monthly0.5https://www.biopharmawatch.com/news/KEQU/certain-statements-in-this-document-constitute-forward-looking-statements-within-the-meani-kequ-20220824monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-second-quarter-of-fiscal-year-2022-exchange-nasdaq-kequ-20211216monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-first-quarter-of-fiscal-year-2022-exchange-nasdaq--kequ-20210908monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-fiscal-year-and-fourth-quarter-exchange-nasdaq-keq-kequ-20210708monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-third-quarter-of-fiscal-year-2021-exchange-nasdaq--kequ-20210310monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-second-quarter-of-fiscal-year-2021-exchange-nasdaq-kequ-20201209monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-first-quarter-of-fiscal-year-2021-exchange-nasdaq--kequ-20200908monthly0.5https://www.biopharmawatch.com/news/KEQU/special-note-regarding-forward-looking-statements-certain-statements-in-this-document-cons-kequ-20200826monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-corporation-accelerates-growth-in-the-middle-east-africa-market-by-est-kequ-20200721monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-fiscal-year-and-fourth-quarter-exchange-nasdaq-keq-kequ-20200721monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-announces-the-appointment-of-a-new-vice-president-of-manufacturing-ope-kequ-20200601monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-third-quarter-exchange-nasdaq-kequ-contact-donald--kequ-20200303monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-second-quarter-suspension-of-dividend-exchange-nas-kequ-20191216monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-announces-release-date-to-report-results-for-second-quarter-fiscal-yea-kequ-20191126monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-corporation-nasdaq-kequ-encouraging-new-discovery-worldwide-1-1-specia-kequ-20190828monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-first-quarter-exchange-nasdaq-kequ-contact-donald--kequ-20190827monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-fiscal-year-and-fourth-quarter-exchange-nasdaq-keq-kequ-20190618monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-announces-the-appointment-of-a-new-vice-president-of-finance-cfo-excha-kequ-20190429monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-corporation-announces-resignation-of-chief-executive-and-election-of-n-kequ-20190311monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-declares-quarterly-dividend-and-reports-results-for-third-quarter-exch-kequ-20190226monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-announces-appointment-of-chairman-of-the-board-exchange-nasdaq-kequ-co-kequ-20190201monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-second-quarter-exchange-nasdaq-kequ-contact-thomas-kequ-20181204monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-first-quarter-statesville-n-c-kequ-20180828monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-corporation-nasdaq-kequ-encouraging-new-discovery-worldwide-special-no-kequ-20180829monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-fiscal-year-and-fourth-quarter-statesville-n-c-kequ-20180626monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-third-quarter-statesville-n-c-kequ-20180227monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-second-quarter-statesville-n-c-kequ-20171205monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-first-quarter-statesville-n-c-kequ-20170829monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-fourth-quarter-and-fiscal-year-statesville-n-c-kequ-20170620monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-third-quarter-statesville-n-c-kequ-20170228monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-second-quarter-statesville-n-c-kequ-20161206monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-awarded-18-5-million-contract-in-kuwait-exchange-nasdaq-kequ-contact-t-kequ-20160919monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-first-quarter-statesville-n-c-kequ-20160830monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-fourth-quarter-and-fiscal-year-statesville-n-c-kequ-20160621monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-announces-the-appointment-of-a-new-vice-president-of-manufacturing-ope-kequ-20160502monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-third-quarter-statesville-n-c-kequ-20160301monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-second-quarter-statesville-n-c-kequ-20151208monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-announces-the-appointment-of-a-new-vice-president-of-finance-cfo-excha-kequ-20151102monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-first-quarter-statesville-n-c-kequ-20150825monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-announces-cfo-retirement-exchange-nasdaq-kequ-contact-d-michael-parker-kequ-20150716monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-year-and-fourth-quarter-statesville-n-c-kequ-20150623monthly0.5https://www.biopharmawatch.com/news/KEQU/keith-m-gehl-elected-to-kewaunee-scientific-board-of-directors-exchange-nasdaq-kequ-contac-kequ-20150505monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-third-quarter-statesville-n-c-kequ-20150303monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-second-quarter-statesville-n-c-kequ-20141202monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-first-quarter-statesville-n-c-kequ-20140826monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-year-and-fourth-quarter-statesville-n-c-kequ-20140624monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-corporation-announces-china-expansion-plans-exchange-nasdaq-kequ-conta-kequ-20140522monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-third-quarter-statesville-n-c-kequ-20140304monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-second-quarter-statesville-n-c-kequ-20131203monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-record-sales-and-earnings-for-first-quarter-statesville-n-c-kequ-20130827monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-announces-buyout-of-its-international-operations-minority-shares-excha-kequ-20130708monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-record-sales-for-year-and-fourth-quarter-statesville-n-c-kequ-20130625monthly0.5https://www.biopharmawatch.com/news/KEQU/donald-f-shaw-elected-to-kewaunee-scientific-board-of-directors-exchange-nasdaq-kequ-conta-kequ-20130603monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-announces-ceo-retirement-and-appointment-of-successor-exchange-nasdaq--kequ-20130429monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-improved-results-for-third-quarter-statesville-n-c-kequ-20130226monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-record-sales-for-second-quarter-statesville-n-c-kequ-20121127monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-improved-sales-and-earnings-for-first-quarter-statesville-n-c-kequ-20120821monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-significantly-improved-results-for-fourth-quarter-statesville--kequ-20120626monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-announces-promotion-of-david-m-rausch-exchange-nasdaq-kequ-contact-d-m-kequ-20120313monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-announces-results-for-third-quarter-statesville-n-c-kequ-20120228monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-announces-results-for-second-quarter-statesville-n-c-kequ-20111130monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-sales-and-earnings-for-first-quarter-statesville-n-c-kequ-20110824monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-announces-results-for-third-quarter-statesville-n-c-kequ-20110302monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-announces-results-for-second-quarter-statesville-n-c-kequ-20101202monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-sales-and-earnings-for-first-quarter-statesville-n-c-aug-24-pr-kequ-20100826monthly0.5https://www.biopharmawatch.com/news/KEQU/unassociated-document-kewaunee-scientific-reports-results-for-year-and-fourth-quarter-stat-kequ-20100625monthly0.5https://www.biopharmawatch.com/news/KEQU/ross-w-mccanless-elected-to-kewaunee-scientific-board-of-directors-exchange-nasdaq-kequ-co-kequ-20100422monthly0.5https://www.biopharmawatch.com/news/KEQU/unassociated-document-kewaunee-scientific-announces-results-for-third-quarter-and-quarterl-kequ-20100225monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-announces-results-for-second-quarter-statesville-n-c-kequ-20091203monthly0.5https://www.biopharmawatch.com/news/KEQU/unassociated-document-kewaunee-scientific-reports-increased-sales-and-earnings-for-first-q-kequ-20090825monthly0.5https://www.biopharmawatch.com/news/KEQU/unassociated-document-kewaunee-scientific-reports-record-results-net-earnings-for-year-inc-kequ-20090624monthly0.5https://www.biopharmawatch.com/news/KEQU/patrick-l-mccrory-elected-to-kewaunee-scientific-board-of-directors-exchange-nasdaq-kequ-c-kequ-20090527monthly0.5https://www.biopharmawatch.com/news/KEQU/unassociated-document-kewaunee-scientific-announces-higher-third-quarter-sales-and-earning-kequ-20090226monthly0.5https://www.biopharmawatch.com/news/KEQU/unassociated-document-kewaunee-scientific-announces-record-sales-and-earnings-for-second-q-kequ-20081203monthly0.5https://www.biopharmawatch.com/news/KEQU/v124793-ex99-1-txt-kewaunee-scientific-announces-improved-first-quarter-results-exchange-n-kequ-20080826monthly0.5https://www.biopharmawatch.com/news/KEQU/v118083-ex99-1-txt-kewaunee-scientific-reports-results-net-earnings-for-year-increase-104--kequ-20080624monthly0.5https://www.biopharmawatch.com/news/KEQU/v105058-ex99-1-txt-kewaunee-scientific-reports-third-quarter-results-net-earnings-increase-kequ-20080227monthly0.5https://www.biopharmawatch.com/news/KEQU/v085742-ex99-1-txt-kewaunee-scientific-announces-first-quarter-results-and-quarterly-divid-kequ-20070822monthly0.5https://www.biopharmawatch.com/news/KEQU/v079267-ex99-1-txt-kewaunee-scientific-reports-results-for-year-and-fourth-quarter-exchang-kequ-20070626monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-announces-third-quarter-results-and-quarterly-dividend-statesville-n-c-kequ-20070301monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-the-second-quarter-and-quarterly-dividend-statesvi-kequ-20061130monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-first-quarter-and-quarterly-dividend-statesville-n-kequ-20060824monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-year-and-fourth-quarter-statesville-n-c-june-21-pr-kequ-20060622monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-announces-third-quarter-results-and-quarterly-dividend-statesville-n-c-kequ-20060222monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-second-quarter-statesville-n-c-nov-22-prnewswire-f-kequ-20051122monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-first-quarter-statesville-n-c-aug-24-prnewswire-fi-kequ-20050825monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-year-and-fourth-quarter-statesville-n-c-june-15-pr-kequ-20050617monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-corporation-announces-sale-of-texas-facility-statesville-n-c-may-18-pr-kequ-20050513monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-announces-third-quarter-results-and-quarterly-dividend-statesville-n-c-kequ-20050223monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-announces-second-quarter-results-statesville-n-c-nov-22-prnewswire-fir-kequ-20041124monthly0.5https://www.biopharmawatch.com/news/KEQU/kewaunee-scientific-reports-results-for-first-quarter-statesville-n-c-aug-25-prnewswire-fi-kequ-20040826monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-second-quarter-2025-financial-results-and-recent-business-highlights-on-tra-ino-20250812monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-proposed-public-offering-ino-20250702monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-first-quarter-2025-financial-results-and-recent-business-highlights-on-trac-ino-20250513monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-fourth-quarter-and-full-year-2024-financial-results-and-operational-highlig-ino-20250318monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-pricing-of-30-million-public-offering-ino-20241213monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-third-quarter-2024-financial-results-and-recent-business-highlights-new-imm-ino-20241114monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-second-quarter-2024-financial-results-and-recent-business-highlights-ino-20240808monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-first-quarter-2024-financial-results-and-recent-business-highlights-bla-sub-ino-20240513monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-pricing-of-approximately-36-million-underwritten-offering-of-common-stock-ino-20240415monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-third-quarter-2023-financial-results-and-operational-highlights-achieved-si-ino-20231109monthly0.5https://www.biopharmawatch.com/news/INO/inovio-receives-fda-feedback-that-data-from-completed-phase-1-2-trial-of-ino-3107-can-be-u-ino-20231010monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-second-quarter-2023-financial-results-and-provides-strategic-update-prepa-ino-20230809monthly0.5https://www.biopharmawatch.com/news/INO/united-states-district-court-eastern-district-of-pennsylvania-in-re-inovio-pharmaceuticals-ino-20230623monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-first-quarter-2023-financial-results-and-operational-highlights-announced-a-ino-20230510monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-fourth-quarter-and-full-year-2022-financial-results-and-clinical-highlights-ino-20230301monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-strategic-reorganization-continues-efforts-to-focus-on-promising-dna-medi-ino-20230131monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-financial-results-and-highlights-for-the-third-quarter-2022-announced-posit-ino-20221108monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-financial-results-and-highlights-for-the-second-quarter-2022-increased-cash-ino-20220809monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-corporate-reorganization-to-reduce-operational-expenses-and-focus-on-oppo-ino-20220719monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-first-quarter-2022-financial-results-and-program-developments-announces-pri-ino-20220510monthly0.5https://www.biopharmawatch.com/news/INO/inovio-expands-partnership-with-advaccine-to-conduct-global-phase-3-efficacy-trial-of-covi-ino-20210608monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-appointment-of-roger-dansey-m-d-to-its-board-of-directors-dr-dansey-seage-ino-20210517monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-fourth-quarter-2020-and-year-end-financial-results-investor-call-today-at-4-ino-20210301monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-proposed-public-offering-of-common-stock-ino-20210120monthly0.5https://www.biopharmawatch.com/news/INO/in-the-preliminary-prospectus-supplement-to-be-used-in-connection-with-a-proposed-public-o-ino-20210120monthly0.5https://www.biopharmawatch.com/news/INO/inovio-and-advaccine-announce-exclusive-partnership-to-commercialize-covid-19-dna-vaccine--ino-20210104monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-initiation-of-phase-2-segment-of-its-phase-2-3-clinical-trial-for-its-cov-ino-20201116monthly0.5https://www.biopharmawatch.com/news/INO/inovio-reports-fda-partial-clinical-hold-for-planned-phase-2-3-trial-of-covid-19-vaccine-c-ino-20200928monthly0.5https://www.biopharmawatch.com/news/INO/inovio-receives-71-million-contract-from-u-s-department-of-defense-to-scale-up-manufacture-ino-20200623monthly0.5https://www.biopharmawatch.com/news/INO/investors-ben-matone-484-362-0076-ben-matone-inovio-com-media-jeff-richardson-267-440-4211-ino-20200115monthly0.5https://www.biopharmawatch.com/news/INO/execution-version-inovio-pharmaceuticals-inc-krw18-000-000-1-00-convertible-bonds-due-2024-ino-20190731monthly0.5https://www.biopharmawatch.com/news/INO/investors-ben-matone-484-362-0076-ben-matone-inovio-com-media-jeff-richardson-267-440-4211-ino-20190716monthly0.5https://www.biopharmawatch.com/news/INO/investors-ben-matone-inovio-484-362-0076-ben-matone-inovio-com-media-jeff-richardson-inovi-ino-20190325monthly0.5https://www.biopharmawatch.com/news/INO/investors-ben-matone-inovio-484-362-0076-ben-matone-inovio-com-media-jeff-richardson-inovi-ino-20190312monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-prices-65-0-million-convertible-senior-notes-offering-ino-20190214monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-announces-proposed-convertible-senior-notes-offering-ino-20190213monthly0.5https://www.biopharmawatch.com/news/INO/investors-ben-matone-484-362-0076-ben-matone-inovio-com-media-jeff-richardson-267-440-4211-ino-20190103monthly0.5https://www.biopharmawatch.com/news/INO/inovio-awarded-up-to-56-million-from-cepi-to-advance-dna-vaccines-against-lassa-fever-and--ino-20180411monthly0.5https://www.biopharmawatch.com/news/INO/immediate-release-contacts-investors-ben-matone-inovio-484-362-0076-ben-matone-inovio-com--ino-20180108monthly0.5https://www.biopharmawatch.com/news/INO/immediate-release-contacts-investors-ben-matone-inovio-484-362-0076-ben-matone-inovio-com--ino-20180102monthly0.5https://www.biopharmawatch.com/news/INO/immediate-release-contacts-investors-media-jeff-richardson-inovio-pharmaceuticals-267-440--ino-20171205monthly0.5https://www.biopharmawatch.com/news/INO/inovio-announces-proposed-public-offering-of-common-stock-ino-20170718monthly0.5https://www.biopharmawatch.com/news/INO/immediate-release-contacts-investors-bernie-hertel-inovio-pharmaceuticals-858-410-3101-bhe-ino-20170608monthly0.5https://www.biopharmawatch.com/news/INO/immediate-release-contacts-investors-bernie-hertel-inovio-pharmaceuticals-858-410-3101-bhe-ino-20170321monthly0.5https://www.biopharmawatch.com/news/INO/immediate-release-contacts-investors-bernie-hertel-inovio-pharmaceuticals-858-410-3101-bhe-ino-20170213monthly0.5https://www.biopharmawatch.com/news/INO/immediate-release-contacts-investors-bernie-hertel-inovio-pharmaceuticals-858-410-3101-bhe-ino-20161024monthly0.5https://www.biopharmawatch.com/news/INO/immediate-release-contacts-investors-bernie-hertel-inovio-pharmaceuticals-858-410-3101-bhe-ino-20160803monthly0.5https://www.biopharmawatch.com/news/INO/immediate-release-contacts-investors-bernie-hertel-inovio-pharmaceuticals-858-410-3101-bhe-ino-20160311monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-enters-into-strategic-cancer-vaccine-collaboration-and-license-agre-ino-20150810monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-closes-87-4-million-underwritten-financing-ino-20150505monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-announces-public-offering-of-common-stock-ino-20150429monthly0.5https://www.biopharmawatch.com/news/INO/immediate-release-inovio-pharmaceuticals-welcomes-nancy-wysenski-to-its-board-of-directors-ino-20150310monthly0.5https://www.biopharmawatch.com/news/INO/immediate-release-contacts-investors-bernie-hertel-inovio-pharmaceuticals-858-410-3101-bhe-ino-20140904monthly0.5https://www.biopharmawatch.com/news/INO/immediate-release-contacts-investors-bernie-hertel-inovio-pharmaceuticals-858-410-3101-bhe-ino-20140723monthly0.5https://www.biopharmawatch.com/news/INO/immediate-release-contacts-investors-bernie-hertel-inovio-pharmaceuticals-858-410-3101-bhe-ino-20140317monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-closes-63-3-million-underwritten-financing-ino-20140304monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock-ino-20140227monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-inc-overview-we-are-engaged-in-the-discovery-and-development-of-a-n-ino-20140226monthly0.5https://www.biopharmawatch.com/news/INO/basel-switzerland-and-blue-bell-pa-usa-10-september-2013-roche-and-inovio-pharmaceuticals--ino-20130910monthly0.5https://www.biopharmawatch.com/news/INO/inovio-pharmaceuticals-prices-15-1-million-offering-of-common-stock-and-warrants-ino-20130306monthly0.5https://www.biopharmawatch.com/news/INO/immediate-release-contacts-investors-bernie-hertel-inovio-pharmaceuticals-858-410-3101-med-ino-20120601monthly0.5https://www.biopharmawatch.com/news/INO/investors-bernie-hertel-inovio-pharmaceuticals-858-410-3101-bhertel-inovio-com-media-jeff--ino-20120104monthly0.5https://www.biopharmawatch.com/news/INO/investors-bernie-hertel-inovio-pharmaceuticals-858-410-3101-bhertel-inovio-com-media-jeff--ino-20111207monthly0.5https://www.biopharmawatch.com/news/INO/investors-bernie-hertel-inovio-pharmaceuticals-858-410-3101-bhertel-inovio-com-media-jeff--ino-20111201monthly0.5https://www.biopharmawatch.com/news/INO/investors-bernie-hertel-inovio-pharmaceuticals-858-410-3101-bhertel-inovio-com-media-jeff--ino-20111010monthly0.5https://www.biopharmawatch.com/news/INO/investors-bernie-hertel-inovio-pharmaceuticals-858-410-3101-bhertel-inovio-com-media-jeff--ino-20110701monthly0.5https://www.biopharmawatch.com/news/INO/investors-bernie-hertel-inovio-pharmaceuticals-858-410-3101-bhertel-inovio-com-media-jeff--ino-20110124monthly0.5https://www.biopharmawatch.com/news/INO/investors-bernie-hertel-inovio-biomedical-858-410-3101-media-jeff-richardson-richardson-as-ino-20091026monthly0.5https://www.biopharmawatch.com/news/INO/immediate-release-contacts-investors-bernie-hertel-inovio-biomedical-858-410-3101-media-je-ino-20090730monthly0.5https://www.biopharmawatch.com/news/INO/immediate-release-contacts-investors-bernie-hertel-inovio-biomedical-858-410-3101-media-je-ino-20090529monthly0.5https://www.biopharmawatch.com/news/INO/investors-bernie-hertel-inovio-biomedical-858-410-3101-media-jeff-richardson-richardson-as-ino-20090514monthly0.5https://www.biopharmawatch.com/news/INO/exhitit-99-1-news-release-immediate-release-contacts-investors-bernie-hertel-inovio-biomed-ino-20090501monthly0.5https://www.biopharmawatch.com/news/INO/investors-bernie-hertel-inovio-biomedical-858-410-3101-media-jeff-richardson-richardson-as-ino-20090406monthly0.5https://www.biopharmawatch.com/news/INO/investors-bernie-hertel-inovio-biomedical-858-410-3101-media-jeff-richardson-richardson-as-ino-20090331monthly0.5https://www.biopharmawatch.com/news/INO/vgx-pharmaceuticals-logo-vgx-pharmaceuticals-oral-anti-inflammatory-drug-safe-in-phase-i-s-ino-20090326monthly0.5https://www.biopharmawatch.com/news/INO/investors-bernie-hertel-858-410-3101-media-jeff-richardson-805-491-8313-director-resigns-f-ino-20090206monthly0.5https://www.biopharmawatch.com/news/INO/investors-bernie-hertel-inovio-biomedical-858-410-3101-media-ron-trahan-ronald-trahan-asso-ino-20081204monthly0.5https://www.biopharmawatch.com/news/INO/investors-bernie-hertel-inovio-biomedical-858-410-3101-media-ron-trahan-ronald-trahan-asso-ino-20081208monthly0.5https://www.biopharmawatch.com/news/INO/investor-relations-media-relations-bernie-hertel-ronald-trahan-phone-858-410-3101-phone-50-ino-20081107monthly0.5https://www.biopharmawatch.com/news/INO/vgx-pharmaceuticals-awarded-23-5-million-nih-contract-to-develop-dna-based-preventive-hiv--ino-20081001monthly0.5https://www.biopharmawatch.com/news/INO/investors-bernie-hertel-inovio-biomedical-858-410-3101-media-ron-trahan-ronald-trahan-asso-ino-20080923monthly0.5https://www.biopharmawatch.com/news/INO/transcript-of-inovio-biomedical-corporation-ino-investor-conference-call-ino-20080708monthly0.5https://www.biopharmawatch.com/news/INO/investors-bernie-hertel-inovio-biomedical-858-410-3101-media-ron-trahan-ronald-trahan-asso-ino-20080707monthly0.5https://www.biopharmawatch.com/news/INO/this-employment-agreement-the-agreement-is-made-as-of-the-12-th-day-of-march-2008-among-in-ino-20080314monthly0.5https://www.biopharmawatch.com/news/INO/investors-bernie-hertel-inovio-biomedical-858-410-3101-media-ron-trahan-ronald-trahan-asso-ino-20080220monthly0.5https://www.biopharmawatch.com/news/INO/immediate-release-contacts-investor-relations-media-relations-bernie-hertel-ronald-trahan--ino-20080130monthly0.5https://www.biopharmawatch.com/news/PCSC/perceptive-capital-solutions-corp-and-freenome-announce-effectiveness-of-registration-stat-pcsc-20260618monthly0.5https://www.biopharmawatch.com/news/PCSC/freenome-and-perceptive-capital-solutions-corp-announce-business-combination-agreement-to--pcsc-20251205monthly0.5https://www.biopharmawatch.com/news/PCSC/index-to-financial-statement-page-balance-sheet-of-perceptive-capital-solutions-corp-repor-pcsc-20240808monthly0.5https://www.biopharmawatch.com/news/PCSC/index-to-financial-statement-page-balance-sheet-of-perceptive-capital-solutions-corp-repor-pcsc-20240613monthly0.5https://www.biopharmawatch.com/news/PCSC/perceptive-capital-solutions-corp-announces-pricing-of-75-million-initial-public-offering-pcsc-20240612monthly0.5https://www.biopharmawatch.com/news/SEER/seer-confirms-receipt-of-unsolicited-proposal-and-director-candidate-nominations-from-rado-seer-20260413monthly0.5https://www.biopharmawatch.com/news/SEER/seer-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-full-year-20-seer-20260226monthly0.5https://www.biopharmawatch.com/news/SEER/seer-reports-first-quarter-2025-financial-results-and-reiterates-full-year-2025-outlook-re-seer-20250513monthly0.5https://www.biopharmawatch.com/news/SEER/seer-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-full-year-20-seer-20250227monthly0.5https://www.biopharmawatch.com/news/SEER/seer-reports-third-quarter-2024-financial-results-growing-enthusiasm-for-proteograph-produ-seer-20241106monthly0.5https://www.biopharmawatch.com/news/SEER/seer-appoints-nicolas-roelofs-to-its-board-of-directors-seer-20241007monthly0.5https://www.biopharmawatch.com/news/SEER/seer-appoints-nicolas-roelofs-to-its-board-of-directors-seer-20240814monthly0.5https://www.biopharmawatch.com/news/SEER/seer-reports-second-quarter-2024-financial-results-launched-stac-in-europe-and-additional--seer-20240808monthly0.5https://www.biopharmawatch.com/news/SEER/seer-reports-first-quarter-2024-financial-results-demonstrated-the-power-of-the-proteograp-seer-20240508monthly0.5https://www.biopharmawatch.com/news/SEER/seer-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-full-year-20-seer-20240229monthly0.5https://www.biopharmawatch.com/news/SEER/document-ex-99-1-seer-appoints-deep-nishar-and-mostafa-ronaghi-ph-d-to-its-board-of-direct-seer-20210217monthly0.5https://www.biopharmawatch.com/news/SEER/seer-announces-proposed-public-offering-of-common-stock-redwood-city-calif-seer-20210125monthly0.5https://www.biopharmawatch.com/news/SEER/seer-announces-closing-of-initial-public-offering-and-full-exercise-of-underwriters-option-seer-20201208monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-reports-fourth-quarter-2025-financial-results-and-provides-corporate-update-comple-qttb-20260310monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-announces-10-5-million-registered-direct-offering-qttb-20260217monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-sells-complement-inhibitor-adx-097-asset-sale-further-enables-company-s-strategic--qttb-20251201monthly0.5https://www.biopharmawatch.com/news/QTTB/xfeff-q32-bio-reports-second-quarter-2025-financial-results-and-provides-corporate-update--qttb-20250806monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-reports-first-quarter-2025-financial-results-and-provides-corporate-update-first-p-qttb-20250508monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-reports-fourth-quarter-2024-financial-results-and-provides-corporate-update-presen-qttb-20250311monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-presents-results-from-signal-aa-part-a-clinical-trial-evaluating-bempikibart-in-pa-qttb-20250308monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-announces-strategic-restructuring-to-focus-on-advancement-of-bempikibart-in-patien-qttb-20250210monthly0.5https://www.biopharmawatch.com/news/QTTB/building-the-future-of-immune-therapeutics-company-overview-january-2025-forward-looking-s-qttb-20250113monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-provides-bempikibart-program-update-including-next-steps-for-advancing-alopecia-ar-qttb-20241210monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-reports-third-quarter-2024-financial-results-and-provides-corporate-update-bempiki-qttb-20241107monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-reports-second-quarter-2024-financial-results-and-provides-corporate-update-comple-qttb-20240808monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-announces-completion-of-enrollment-in-the-signal-ad-phase-2-clinical-trial-of-bemp-qttb-20240709monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-reports-first-quarter-2024-financial-results-and-provides-corporate-update-complet-qttb-20240509monthly0.5https://www.biopharmawatch.com/news/QTTB/confidential-q32-bio-announces-closing-of-merger-with-homology-medicines-and-concurrent-pr-qttb-20240326monthly0.5https://www.biopharmawatch.com/news/QTTB/building-the-future-of-immune-therapeutics-company-overview-january-2024-disclaimers-impor-qttb-20240126monthly0.5https://www.biopharmawatch.com/news/QTTB/homology-medicines-receives-nasdaq-notification-regarding-minimum-bid-price-deficiency-hom-qttb-20240103monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-and-homology-medicines-announce-merger-agreement-the-combined-company-will-operate-qttb-20231116monthly0.5https://www.biopharmawatch.com/news/QTTB/copyright-2023-homology-medicines-inc-all-rights-reserved-forward-looking-statements-this--qttb-20231010monthly0.5https://www.biopharmawatch.com/news/QTTB/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-qttb-20230104monthly0.5https://www.biopharmawatch.com/news/QTTB/homology-medicines-inc-unaudited-condensed-consolidated-pro-forma-financial-information-on-qttb-20220310monthly0.5https://www.biopharmawatch.com/news/QTTB/homology-medicines-provides-an-update-on-phenix-gene-therapy-trial-for-adults-with-qttb-20220218monthly0.5https://www.biopharmawatch.com/news/QTTB/oxford-biomedica-broadens-leading-viral-vector-offerings-by-incorporating-homology-medicin-qttb-20220128monthly0.5https://www.biopharmawatch.com/news/QTTB/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-qttb-20210208monthly0.5https://www.biopharmawatch.com/news/QTTB/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-qttb-20210106monthly0.5https://www.biopharmawatch.com/news/QTTB/homology-medicines-announces-60-million-equity-investment-from-pfizer-inc-qttb-20201109monthly0.5https://www.biopharmawatch.com/news/QTTB/homology-medicines-appoints-alise-reicin-m-d-to-the-board-of-directors-celgene-executive-w-qttb-20190715monthly0.5https://www.biopharmawatch.com/news/QTTB/homology-medicines-announces-leadership-updates-sam-rasty-ph-d-departs-as-chief-operating--qttb-20190627monthly0.5https://www.biopharmawatch.com/news/LONA/leonabio-reports-first-quarter-2026-financial-results-and-provides-business-update-advanci-lona-20260507monthly0.5https://www.biopharmawatch.com/news/LONA/julie-rathbun-leonabio-com-206-769-9219-lona-20260109monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-announces-exclusive-license-to-lasofoxifene-phase-3-development-program-for--lona-20251218monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-reports-third-quarter-2025-financial-results-and-provides-business-update-co-lona-20251106monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-reports-second-quarter-2025-financial-results-and-provides-business-update-d-lona-20250807monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-reports-first-quarter-2025-financial-results-and-pipeline-and-business-updat-lona-20250509monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-reports-full-year-2024-financial-results-and-pipeline-and-business-updates-c-lona-20250227monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-reports-third-quarter-2024-financial-results-and-pipeline-and-business-updat-lona-20241107monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-to-focus-on-advancement-of-ath-1105-for-the-treatment-of-neurodegenerative-d-lona-20240917monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-announces-topline-results-from-phase-2-3-lift-ad-clinical-trial-of-fosgonime-lona-20240903monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-reports-second-quarter-2024-financial-results-and-pipeline-and-business-upda-lona-20240801monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-announces-proposed-settlement-of-stockholder-derivative-action-bothell-wa-lona-20240517monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-reports-first-quarter-2024-financial-results-and-pipeline-and-business-updat-lona-20240515monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-reports-full-year-2023-financial-results-and-pipeline-and-business-updates-e-lona-20240222monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-provides-2024-clinical-pipeline-outlook-and-business-update-completed-enroll-lona-20240108monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-reports-third-quarter-2023-financial-results-and-pipeline-and-business-updat-lona-20231109monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-reports-second-quarter-2023-financial-results-and-pipeline-and-business-upda-lona-20230810monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-appoints-andrew-gengos-as-chief-financial-officer-and-chief-business-officer-lona-20230522monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-reports-first-quarter-2023-financial-results-and-recent-pipeline-and-busines-lona-20230511monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-reports-full-year-2022-financial-results-and-recent-pipeline-and-business-up-lona-20230323monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-reports-third-quarter-2022-financial-results-and-recent-clinical-and-corpora-lona-20221110monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-advances-phase-2-3-lift-ad-clinical-study-of-fosgonimeton-in-mild-to-moderat-lona-20221017monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-reports-second-quarter-2022-financial-results-and-recent-clinical-and-corpor-lona-20220815monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-announces-topline-results-from-act-ad-phase-2-proof-of-concept-study-of-fosg-lona-20220622monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-reports-first-quarter-2022-financial-results-and-provides-pipeline-and-busin-lona-20220512monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-reports-full-year-2021-financial-results-and-provides-clinical-update-on-tra-lona-20220324monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-announces-appointment-of-dr-michael-a-panzara-to-its-board-of-directors-indu-lona-20220321monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-announces-appointment-of-grant-pickering-to-its-board-of-directors-lona-20220131monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-reports-third-quarter-2021-financial-results-and-business-update-x2013-compl-lona-20211110monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-announces-leadership-changes-mark-litton-ph-d-m-b-a-named-president-and-chie-lona-20211021monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-reports-second-quarter-2021-financial-results-and-business-update-initiated--lona-20210816monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-mourns-the-loss-of-chair-of-board-of-directors-tadataka-yamada-lona-20210805monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-chief-operating-officer-mark-litton-assumes-day-to-day-leadership-responsibi-lona-20210617monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-reports-first-quarter-2021-financial-results-and-provides-business-highlight-lona-20210513monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-bus-lona-20210325monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors-bothell-wa-lona-20210308monthly0.5https://www.biopharmawatch.com/news/LONA/this-presentation-and-the-accompanying-oral-commentary-contain-forward-looking-statements--lona-20210111monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-announces-appointment-of-kelly-a-romano-to-its-board-of-directors-seattle-lona-20201214monthly0.5https://www.biopharmawatch.com/news/LONA/athira-pharma-reports-third-quarter-2020-financial-results-and-provides-business-highlight-lona-20201112monthly0.5https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-reports-record-fourth-quarter-and-full-year-2025-financial-results--rpid-20260312monthly0.5https://www.biopharmawatch.com/news/RPID/document-rapid-micro-biosystems-announces-record-preliminary-unaudited-fourth-quarter-and--rpid-20260113monthly0.5https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-reports-third-quarter-2025-financial-results-announces-record-multi-rpid-20251107monthly0.5https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-reports-second-quarter-2025-financial-results-reports-second-quarte-rpid-20250812monthly0.5https://www.biopharmawatch.com/news/RPID/dear-rmb-team-members-and-shareholders-i-am-writing-on-a-personal-note-to-let-you-know-tha-rpid-20250617monthly0.5https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-reports-first-quarter-2025-financial-results-reports-first-quarter--rpid-20250509monthly0.5https://www.biopharmawatch.com/news/RPID/rpidxpresentation-rapid-micro-biosystems-td-cowen-45th-annual-health-care-conference-rober-rpid-20250304monthly0.5https://www.biopharmawatch.com/news/RPID/document-rapid-micro-biosystems-announces-global-distribution-and-collaboration-agreement--rpid-20250227monthly0.5https://www.biopharmawatch.com/news/RPID/rpidxpresentation-rapid-micro-biosystems-43rd-annual-j-p-morgan-healthcare-conference-rob--rpid-20250116monthly0.5https://www.biopharmawatch.com/news/RPID/document-rapid-micro-biosystems-announces-preliminary-unaudited-fourth-quarter-and-full-ye-rpid-20250114monthly0.5https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-reports-third-quarter-2024-financial-results-reports-record-third-q-rpid-20241101monthly0.5https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-reports-second-quarter-2024-financial-results-record-second-quarter-rpid-20240802monthly0.5https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-reports-first-quarter-2024-financial-results-reports-first-quarter--rpid-20240503monthly0.5https://www.biopharmawatch.com/news/RPID/document-rapid-micro-biosystems-announces-preliminary-unaudited-fourth-quarter-and-full-ye-rpid-20240111monthly0.5https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-reports-third-quarter-2023-financial-results-reports-third-quarter--rpid-20231103monthly0.5https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-reports-second-quarter-2023-financial-results-reports-second-quarte-rpid-20230804monthly0.5https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-reports-first-quarter-2023-financial-results-reports-first-quarter--rpid-20230505monthly0.5https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-announces-preliminary-unaudited-fourth-quarter-and-full-year-2022-r-rpid-20230112monthly0.5https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-concludes-review-of-strategic-alternatives-rpid-20221201monthly0.5https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-reports-third-quarter-2022-financial-results-reports-third-quarter--rpid-20221110monthly0.5https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-provides-business-update-and-reports-second-quarter-2022-financial--rpid-20220812monthly0.5https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-reports-first-quarter-2022-financial-results-reports-first-quarter--rpid-20220510monthly0.5https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-reports-fourth-quarter-and-full-year-2021-financial-results-and-rea-rpid-20220304monthly0.5https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-announces-preliminary-unaudited-fourth-quarter-and-full-year-2021-r-rpid-20220113monthly0.5https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-announces-appointment-of-inese-lowenstein-to-board-of-directors-rpid-20211223monthly0.5https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-reports-third-quarter-2021-financial-results-reports-third-quarter--rpid-20211111monthly0.5https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-reports-second-quarter-2021-financial-results-and-provides-business-rpid-20210826monthly0.5https://www.biopharmawatch.com/news/BHST/dated-june-18-2026-news-release-dated-bhst-20260618monthly0.5https://www.biopharmawatch.com/news/BHST/jfif-c-7-01444-9-82-f-x-w-foa-s-kt-t-2y-s-one6-i-zx-i-b-lb4-c-7-k-z-yq-g-x-x-a-4-w-bhst-20260528monthly0.5https://www.biopharmawatch.com/news/BHST/bioharvest-sciences-reports-first-quarter-2026-financial-results-bhst-20260514monthly0.5https://www.biopharmawatch.com/news/BHST/unaudited-interim-condensed-consolidated-financial-statements-bhst-20260514monthly0.5https://www.biopharmawatch.com/news/BHST/material-change-report-dated-may-13-2026-news-release-dated-bhst-20260513monthly0.5https://www.biopharmawatch.com/news/BHST/bioharvest-sciences-signs-1-2m-cdmo-stage-2-contract-for-the-development-of-a-rare-fragran-bhst-20260512monthly0.5https://www.biopharmawatch.com/news/BHST/material-change-report-dated-may-11-2026-material-change-report-dated-bhst-20260511monthly0.5https://www.biopharmawatch.com/news/BHST/dated-april-30-2026-news-release-dated-bhst-20260430monthly0.5https://www.biopharmawatch.com/news/BHST/dated-april-29-2026-news-release-dated-bhst-20260429monthly0.5https://www.biopharmawatch.com/news/BHST/dated-march-26-2026-news-release-dated-bhst-20260326monthly0.5https://www.biopharmawatch.com/news/BHST/dated-march-17-2026-news-release-dated-bhst-20260317monthly0.5https://www.biopharmawatch.com/news/BHST/dated-march-13-2026-news-release-dated-bhst-20260313monthly0.5https://www.biopharmawatch.com/news/BHST/material-change-report-dated-march-6-2026-material-change-report-dated-bhst-20260306monthly0.5https://www.biopharmawatch.com/news/BHST/bioharvest-sciences-announces-board-transition-and-appointment-of-prof-bhst-20260305monthly0.5https://www.biopharmawatch.com/news/BHST/dated-march-3-2026-news-release-dated-bhst-20260303monthly0.5https://www.biopharmawatch.com/news/BHST/bioharvest-sciences-issues-year-end-shareholder-letter-bhst-20260107monthly0.5https://www.biopharmawatch.com/news/BHST/dated-december-18-2025-news-release-dated-bhst-20251218monthly0.5https://www.biopharmawatch.com/news/BHST/bioharvest-sciences-announces-launch-of-vinia-blood-flow-hydration-product-bhst-20251203monthly0.5https://www.biopharmawatch.com/news/BHST/unaudited-interim-condensed-consolidated-financial-statements-unaudited-interim-condensed--bhst-20251113monthly0.5https://www.biopharmawatch.com/news/BHST/dated-november-12-2025-news-release-dated-bhst-20251112monthly0.5https://www.biopharmawatch.com/news/BHST/dated-november-10-2025-news-release-dated-bhst-20251110monthly0.5https://www.biopharmawatch.com/news/BHST/material-change-report-material-change-report-form-51-102f3-material-change-report-item-1--bhst-20251107monthly0.5https://www.biopharmawatch.com/news/BHST/bioharvest-sciences-to-host-third-quarter-earnings-call-on-november-13-at-4-30-p-m-bhst-20251104monthly0.5https://www.biopharmawatch.com/news/BHST/material-change-report-dated-october-31-2025-material-change-report-dated-bhst-20251031monthly0.5https://www.biopharmawatch.com/news/BHST/dated-october-30-2025-news-release-dated-bhst-20251030monthly0.5https://www.biopharmawatch.com/news/BHST/material-change-report-dated-september-23-2025-material-change-report-dated-september-23-2-bhst-20250922monthly0.5https://www.biopharmawatch.com/news/BHST/dated-september-22-2025-news-release-dated-bhst-20250922monthly0.5https://www.biopharmawatch.com/news/BHST/dated-september-10-2025-news-release-dated-bhst-20250910monthly0.5https://www.biopharmawatch.com/news/BHST/material-change-report-dated-september-9-2025-material-change-report-dated-september-9-202-bhst-20250908monthly0.5https://www.biopharmawatch.com/news/BHST/bioharvest-sciences-inc-bhst-20250909monthly0.5https://www.biopharmawatch.com/news/BHST/dated-september-2-2025-news-release-dated-bhst-20250902monthly0.5https://www.biopharmawatch.com/news/BHST/material-change-report-dated-august-14-2025-material-change-report-dated-bhst-20250814monthly0.5https://www.biopharmawatch.com/news/BHST/bioharvest-sciences-amended-insider-trading-policy-bhst-20250813monthly0.5https://www.biopharmawatch.com/news/BHST/dated-august-11-2025-news-release-dated-bhst-20250811monthly0.5https://www.biopharmawatch.com/news/BHST/unaudited-interim-condensed-consolidated-financial-statements-unaudited-interim-condensed--bhst-20250811monthly0.5https://www.biopharmawatch.com/news/BHST/bioharvest-sciences-to-host-second-quarter-2025-earnings-call-on-august-11-at-8-00-a-m-bhst-20250805monthly0.5https://www.biopharmawatch.com/news/BHST/dated-july-23-2025-news-release-dated-bhst-20250723monthly0.5https://www.biopharmawatch.com/news/BHST/material-change-report-dated-july-4-2025-material-change-report-dated-bhst-20250704monthly0.5https://www.biopharmawatch.com/news/BHST/rehovot-israel-july-2-2025-bioharvest-sciences-inc-bhst-20250703monthly0.5https://www.biopharmawatch.com/news/BHST/to-all-applicable-regulators-and-exchanges-bhst-20250610monthly0.5https://www.biopharmawatch.com/news/BHST/dated-june-4-2025-news-release-dated-bhst-20250604monthly0.5https://www.biopharmawatch.com/news/BHST/dated-may-21-2025-news-release-dated-bhst-20250521monthly0.5https://www.biopharmawatch.com/news/BHST/dated-may-15-2025-news-release-dated-bhst-20250515monthly0.5https://www.biopharmawatch.com/news/BHST/unaudited-interim-condensed-consolidated-financial-statements-unaudited-interim-condensed--bhst-20250515monthly0.5https://www.biopharmawatch.com/news/BHST/dated-may-12-2025-news-release-dated-bhst-20250512monthly0.5https://www.biopharmawatch.com/news/BHST/dated-may-1-2025-news-release-dated-bhst-20250501monthly0.5https://www.biopharmawatch.com/news/BHST/certification-of-annual-filings-ceo-certification-of-annual-filings-ceo-form-52-109f1-cert-bhst-20250401monthly0.5https://www.biopharmawatch.com/news/BHST/dated-march-31-2025-news-release-dated-bhst-20250331monthly0.5https://www.biopharmawatch.com/news/BHST/dated-march-17-2025-press-release-dated-bhst-20250317monthly0.5https://www.biopharmawatch.com/news/BHST/dated-march-6-2025-press-release-dated-bhst-20250306monthly0.5https://www.biopharmawatch.com/news/BHST/dated-march-4-2025-press-release-dated-bhst-20250304monthly0.5https://www.biopharmawatch.com/news/BHST/dated-february-18-2025-press-release-dated-bhst-20250218monthly0.5https://www.biopharmawatch.com/news/BHST/material-change-report-dated-february-14-2025-material-change-report-dated-bhst-20250214monthly0.5https://www.biopharmawatch.com/news/BHST/dated-february-12-2025-news-release-dated-bhst-20250212monthly0.5https://www.biopharmawatch.com/news/BHST/dated-february-10-2025-press-release-dated-bhst-20250210monthly0.5https://www.biopharmawatch.com/news/BHST/item-1-name-and-address-of-company-bhst-20250123monthly0.5https://www.biopharmawatch.com/news/BHST/dated-january-8-2025-news-release-dated-bhst-20250108monthly0.5https://www.biopharmawatch.com/news/BHST/-bhst-20241211monthly0.5https://www.biopharmawatch.com/news/BHST/dated-november-25-2024-news-release-dated-bhst-20241125monthly0.5https://www.biopharmawatch.com/news/BHST/bioharvest-launches-vinia-superfood-functional-tea-line-bhst-20241125monthly0.5https://www.biopharmawatch.com/news/BHST/unaudited-interim-condensed-consolidated-financial-statements-unaudited-interim-condensed--bhst-20241125monthly0.5https://www.biopharmawatch.com/news/BHST/dated-november-21-2024-news-release-dated-bhst-20241121monthly0.5https://www.biopharmawatch.com/news/BHST/dated-november-18-2024-news-release-dated-bhst-20241118monthly0.5https://www.biopharmawatch.com/news/BHST/vancouver-canada-and-rehovot-israel-november-15-2024-bioharvest-sciences-inc-bhst-20241118monthly0.5https://www.biopharmawatch.com/news/BHST/dated-november-12-2024-news-release-dated-bhst-20241112monthly0.5https://www.biopharmawatch.com/news/BHST/dated-november-7-2024-news-release-dated-bhst-20241107monthly0.5https://www.biopharmawatch.com/news/BHST/item-1-name-and-address-of-company-bhst-20241029monthly0.5https://www.biopharmawatch.com/news/BHST/bioharvest-sciences-announces-record-preliminary-third-quarter-2024-financial-results-bhst-20241023monthly0.5https://www.biopharmawatch.com/news/BHST/dated-october-16-2024-news-release-dated-bhst-20241016monthly0.5https://www.biopharmawatch.com/news/BHST/material-change-report-dated-september-20-2024-material-change-report-dated-bhst-20240920monthly0.5https://www.biopharmawatch.com/news/BHST/vancouver-british-columbia-and-rehovot-israel-september-20-2024-bioharvest-sciences-inc-bhst-20240920monthly0.5https://www.biopharmawatch.com/news/BHST/dated-september-12-2024-press-release-dated-bhst-20240912monthly0.5https://www.biopharmawatch.com/news/BHST/monthly-progress-report-dated-september-5-2024-monthly-progress-report-dated-bhst-20240905monthly0.5https://www.biopharmawatch.com/news/BHST/dated-september-4-2024-news-release-dated-bhst-20240904monthly0.5https://www.biopharmawatch.com/news/BHST/bioharvest-sciences-surpasses-usd-1-0-million-in-cumulative-direct-sales-of-coffee-with-vi-bhst-20240829monthly0.5https://www.biopharmawatch.com/news/BHST/unaudited-interim-condensed-consolidated-financial-statements-unaudited-interim-condensed--bhst-20240829monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-reports-first-quarter-2026-financial-results-and-provides-business-update-i-vani-20260513monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-inc-announces-pricing-of-common-stock-offering-alameda-calif-january-25-202-vani-20260127monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-inc-announces-pricing-of-common-stock-offering-alameda-calif-october-26-202-vani-20251028monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-announces-rapid-advancement-of-npm-139-a-novel-semaglutide-implant-followin-vani-20250805monthly0.5https://www.biopharmawatch.com/news/VANI/exenatide-implant-reduces-liver-fat-by-82-in-obese-mice-after-12-weeks-liver-fat-reduction-vani-20250617monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-appoint-s-anthony-baldor-as-chief-financial-officer-alameda-calif-june-11-2-vani-20250611monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-a-nnounces-filing-of-form-10-registration-statement-for-planned-s-pin-off-o-vani-20250529monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-provides-business-update-including-3m-equity-financing-and-reports-first-qu-vani-20250513monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-and-okava-expand-collaboration-to-develop-okv-119-for-dogs-targeting-metabo-vani-20250331monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-provides-business-update-and-reports-fourth-quarter-and-full-year-2024-fina-vani-20250331monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-announces-8-25m-private-placement-equity-financing-financing-strengthens-ba-vani-20250326monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-announces-positive-preclinical-weight-loss-data-for-npm-139-semaglutide-imp-vani-20250326monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-announces-intent-to-spin-off-cortigent-neurostimulation-business-planned-co-vani-20250313monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-provides-business-update-including-5-m-equity-financing-and-reports-third-q-vani-20241113monthly0.5https://www.biopharmawatch.com/news/VANI/v-ivani-m-edical-to-present-at-the-partnership-opportunities-in-drug-de-livery-podd-event--vani-20241022monthly0.5https://www.biopharmawatch.com/news/VANI/v-ivani-medical-receives-regulatory-approval-to-initiate-first-in-human-clinical-trial-wit-vani-20240926monthly0.5https://www.biopharmawatch.com/news/VANI/v-ivani-m-edical-to-present-at-the-emerging-growth-conference-on-september-2-5-2024-a-lame-vani-20240925monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-announces-positive-preclinical-liver-fat-results-with-miniature-ultra-long--vani-20240904monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-provides-business-update-and-reports-second-quarter-2024-financial-results--vani-20240813monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-provides-update-on-clinical-development-plans-for-miniature-long-term-glp-1-vani-20240711monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-announces-fda-clears-investigational-new-drug-application-and-lifts-clinica-vani-20240613monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-provides-business-update-and-reports-first-quarter-2024-financial-results-c-vani-20240513monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-provides-business-update-and-reports-fourth-quarter-and-full-year-2023-fina-vani-20240326monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-appoints-daniel-bradbury-to-its-board-of-directors-appointment-comes-as-viv-vani-20240306monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-announces-pricing-of-15-0-million-registered-direct-offering-of-common-stoc-vani-20240301monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-announces-positive-npm-115-preclinical-weight-loss-data-comparable-to-ozemp-vani-20240228monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-inc-guaranteed-adherence-better-outcomes-nasdaq-vani-vani-20231114monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-inc-guaranteed-adherence-better-outcomes-nasdaq-vani-vani-20230918monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-inc-guaranteed-adherence-better-outcomes-nasdaq-vani-vani-20230828monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-inc-plan-of-conversion-this-plan-of-conversion-this-plan-sets-forth-certain-vani-20230710monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-inc-guaranteed-adherence-better-outcomes-nasdaq-vani-vani-20230515monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-inc-guaranteed-adherence-better-outcomes-nasdaq-vani-vani-20230321monthly0.5https://www.biopharmawatch.com/news/VANI/included-in-form-8-k-filed-with-the-sec-on-vani-20230217monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-inc-guaranteed-adherence-better-outcomes-nasdaq-vani-vani-20230106monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-medical-reports-third-quarter-2022-results-and-provides-business-updates-emeryville-vani-20221114monthly0.5https://www.biopharmawatch.com/news/VANI/medical-inc-vani-20221017monthly0.5https://www.biopharmawatch.com/news/VANI/included-in-form-8-k-filed-with-the-sec-on-vani-20220902monthly0.5https://www.biopharmawatch.com/news/VANI/vivani-announces-trading-under-new-ticker-symbol-nasdaq-vani-emeryville-ca-business-newswi-vani-20220831monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-medical-products-inc-announces-shareholder-approval-for-proposed-merger-with--vani-20220729monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-medical-products-announces-year-four-nih-funding-of-its-orion-study-grant-pro-vani-20220718monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-medical-products-and-nano-precision-medical-announce-merger-agreement-to-crea-vani-20220208monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-medical-products-announces-closing-of-public-offering-los-angeles-ca-business-vani-20210608monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-medical-products-announces-proposed-public-offering-of-common-stock-los-angel-vani-20210622monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-medical-products-announces-results-of-its-2021-annual-meeting-los-angeles-ca--vani-20210601monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-medical-products-names-dean-baker-and-alexandra-larson-to-its-board-of-direct-vani-20210406monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-medical-products-names-scott-dunbar-acting-ceo-vani-20210401monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-medical-products-announces-closing-of-27-9-million-private-placement-of-commo-vani-20210326monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-medical-products-announces-27-9-million-private-placement-of-common-stock-vani-20210324monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-medical-products-inc-receives-fda-approval-for-the-argus-2s-retinal-prosthesi-vani-20210305monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-medical-products-matthew-j-pfeffer-chief-executive-officer-publicrelations-se-vani-20210106monthly0.5https://www.biopharmawatch.com/news/VANI/investor-relations-in-site-communications-inc-lisa-wilson-president-t-212-452-2793-e-lwils-vani-20200925monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-medical-products-inc-announces-closing-of-public-offering-of-common-stock-vani-20200505monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-medical-products-announces-pricing-of-public-offering-of-common-stock-vani-20200430monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-medical-products-provides-business-update-los-angeles-vani-20200428monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-announces-employee-layoffs-intent-to-wind-down-operations-and-appointment-of--vani-20200330monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-reports-fourth-quarter-and-full-year-2019-financial-results-received-ce-mark--vani-20200319monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-announces-departure-of-will-mcguire-president-and-ceo-and-appointment-of-greg-vani-20200312monthly0.5https://www.biopharmawatch.com/news/VANI/ex-99-1-for-immediate-release-second-sight-reports-third-quarter-2019-financial-results-re-vani-20191114monthly0.5https://www.biopharmawatch.com/news/VANI/eyes-ex991-6-pptx-htm-second-sight-medical-products-inc-nasdaq-eyes-discover-life-in-a-new-vani-20190904monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-reports-second-quarter-2019-financial-results-r-d-and-clinical-programs-for-o-vani-20190806monthly0.5https://www.biopharmawatch.com/news/VANI/researchers-present-latest-positive-results-of-second-sight-s-orion-visual-cortical-prosth-vani-20190625monthly0.5https://www.biopharmawatch.com/news/VANI/eyes-ex991-6-pptx-htm-second-sight-medical-products-inc-nasdaq-eyes-discover-life-in-a-new-vani-20190523monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-reports-first-quarter-2019-financial-results-company-to-accelerate-developmen-vani-20190515monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-to-accelerate-development-of-orion-visual-cortical-prosthesis-system-positive-vani-20190515monthly0.5https://www.biopharmawatch.com/news/VANI/o-observations-from-rehabilitation-sessions-include-that-subjects-are-able-to-use-orion-to-vani-20190411monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-reports-fourth-quarter-and-full-year-2018-financial-results-los-angeles-ca-vani-20190313monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-medical-products-inc-announces-completion-of-rights-offering-expiration-date--vani-20190222monthly0.5https://www.biopharmawatch.com/news/VANI/nasdaq-eyes-enriching-the-lives-of-the-blind-may-2018-nasdaq-eyes-nasdaq-eyes-forward-look-vani-20180524monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-reports-first-quarter-2018-financial-results-orion-feasibility-study-on-track-vani-20180510monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-completes-10-million-private-placement-of-common-stock-with-gregg-williams-ch-vani-20180507monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-announces-dr-robert-greenberg-s-resignation-from-board-of-directors-and-as-an-vani-20180409monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-appoints-john-t-blake-chief-financial-officer-sylmar-ca-vani-20180322monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-appoints-gregg-williams-as-chairman-of-the-board-of-directors-sylmar-ca-vani-20180316monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-announces-latest-expansion-of-medicare-coverage-for-argus-ii-retinal-prosthes-vani-20180306monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-reports-fourth-quarter-and-full-year-2017-financial-results-year-over-year-ne-vani-20180307monthly0.5https://www.biopharmawatch.com/news/VANI/nasdaq-eyes-enriching-the-lives-of-the-blind-march-2018-nasdaq-eyes-nasdaq-eyes-forward-lo-vani-20180307monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-announces-record-number-of-argus-ii-retinal-prosthesis-systems-implants-and-c-vani-20180205monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-announces-market-entry-into-iran-with-first-two-implants-of-argus-ii-retinal--vani-20171208monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-receives-fda-expedited-access-pathway-designation-for-the-orion-cortical-visu-vani-20171113monthly0.5https://www.biopharmawatch.com/news/VANI/ontario-health-technology-advisory-committee-recommends-public-funding-for-second-sight-s--vani-20171113monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-reports-third-quarter-2017-financial-results-sylmar-ca-vani-20171102monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-receives-full-fda-approval-to-begin-first-orion-human-clinical-study-second-s-vani-20171107monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-announces-final-medicare-hospital-outpatient-payment-rate-for-2018-for-the-ar-vani-20171106monthly0.5https://www.biopharmawatch.com/news/VANI/jfif-6exif-mm-b-j-1-r-2-i-adobe-photoshop-cs3-windows-2017-09-12-22-11-13-4-vani-20170912monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-receives-conditional-fda-approval-to-begin-first-orion-human-clinical-study-s-vani-20170831monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-announces-market-entry-into-russia-with-first-implant-of-argus-ii-retinal-pro-vani-20170728monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-announces-market-entry-into-south-korea-with-two-vani-20170710monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-announces-expansion-of-medicare-coverage-for-argus-ii-retinal-prosthesis-syst-vani-20170706monthly0.5https://www.biopharmawatch.com/news/VANI/nasdaq-eyes-a-better-way-of-life-for-patients-may-2017-nasdaq-eyes-vani-20170525monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-reports-first-quarter-2017-financial-results-sylmar-calif-business-wire-secon-vani-20170504monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-medical-products-vani-20170331monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-reports-fourth-quarter-and-vani-20170315monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-medical-products-inc-announces-completion-of-oversubscribed-rights-offering-s-vani-20170309monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-appoints-david-jacques-as-vice-president-of-research-and-development-sylmar-c-vani-20170306monthly0.5https://www.biopharmawatch.com/news/VANI/uk-government-announces-funding-for-second-sight-s-argus-ii-bionic-eye-vani-20161222monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-medical-products-inc-vani-20161208monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-reports-third-quarter-2016-financial-results-sylmar-calif-business-wire-secon-vani-20161104monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-announces-final-cms-hospital-outpatient-payment-rate-for-2017-and-two-new-cpt-vani-20161103monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-announces-successful-implantation-and-activation-of-wireless-visual-cortical--vani-20161028monthly0.5https://www.biopharmawatch.com/news/VANI/jfif-6exif-mm-b-j-1-r-2-i-adobe-photoshop-cs3-windows-2016-10-25-22-45-19-4-vani-20161025monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-reports-second-quarter-2016-financial-results-sylmar-ca-vani-20160728monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-announces-positive-five-year-data-from-argus-ii-retinal-prosthesis-system-stu-vani-20160725monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-medical-products-inc-announces-completion-of-oversubscribed-rights-offering-vani-20160601monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-reports-first-quarter-2016-financial-results-sylmar-ca-vani-20160428monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-appoints-steven-d-okland-jr-as-commercial-vice-president-u-s-and-canada-sylma-vani-20160324monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-reports-fourth-quarter-and-year-end-2015-financial-results-sylmar-ca-vani-20160303monthly0.5https://www.biopharmawatch.com/news/VANI/nasdaq-eyes-investor-presentation-2016-nasdaq-eyes-nasdaq-eyes-forward-looking-statements--vani-20160223monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-announces-publication-of-positive-results-in-3-year-flora-study-of-the-argus--vani-20160222monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-provides-business-update-and-key-performance-metrics-for-full-year-2015-recor-vani-20160111monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-medical-products-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-vani-20151204monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-reports-third-quarter-2015-financial-results-sylmar-ca-vani-20151029monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-reports-second-quarter-2015-financial-results-sylmar-ca-vani-20150804monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-announces-first-age-related-macular-degeneration-patient-receives-the-argus-i-vani-20150724monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-appoints-will-mcguire-as-vani-20150625monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-appoints-matthew-j-pfeffer-to-its-board-of-directors-sylmar-ca-vani-20150603monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-reports-first-quarter-2015-financial-results-sylmar-ca-vani-20150513monthly0.5https://www.biopharmawatch.com/news/VANI/announces-exclusive-agreement-with-gulf-medical-company-to-distribute-the-argus-ii-retinal-vani-20150513monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-announces-senior-management-appointments-in-commercialization-and-manufacturi-vani-20150501monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-reports-fourth-quarter-and-year-end-2014-financial-results-and-provides-busin-vani-20150311monthly0.5https://www.biopharmawatch.com/news/VANI/second-sight-receives-highest-priority-reimbursement-for-argus-ii-in-germany-sylmar-ca-vani-20150203monthly0.5https://www.biopharmawatch.com/news/VANI/nasdaq-eyes-investor-presentation-nasdaq-eyes-january-2015-nasdaq-eyes-forward-looking-sta-vani-20150113monthly0.5https://www.biopharmawatch.com/news/STEX/streamex-corp-and-orca-announce-launch-of-24-7-decentralized-secondary-liquidity-infrastru-stex-20260527monthly0.5https://www.biopharmawatch.com/news/STEX/streamex-corp-appoints-former-microsoft-and-paypal-lead-product-designer-kori-handy-as-vic-stex-20260526monthly0.5https://www.biopharmawatch.com/news/STEX/streamex-corp-clarifies-and-refutes-inaccurate-claims-regarding-lock-up-agreements-co-foun-stex-20260327monthly0.5https://www.biopharmawatch.com/news/STEX/streamex-corp-appoints-christine-plummer-former-global-controller-at-coinbase-and-managing-stex-20260316monthly0.5https://www.biopharmawatch.com/news/STEX/streamex-corp-appoints-shawn-matthews-former-ceo-of-cantor-fitzgerald-co-founder-and-cio-o-stex-20260303monthly0.5https://www.biopharmawatch.com/news/STEX/streamex-corp-nasdaq-stex-appoints-morgan-lekstrom-as-executive-chairman-announces-complet-stex-20260209monthly0.5https://www.biopharmawatch.com/news/STEX/streamex-corp-nasdaq-stex-appoints-anthony-marciano-clinical-professor-of-finance-at-nyu-s-stex-20260204monthly0.5https://www.biopharmawatch.com/news/STEX/streamex-corp-nasdaq-stex-announces-proposed-public-offering-winter-park-fl-stex-20260122monthly0.5https://www.biopharmawatch.com/news/STEX/streamex-corp-nasdaq-stex-announces-issuance-of-prepayment-notice-for-previously-announced-stex-20260123monthly0.5https://www.biopharmawatch.com/news/STEX/streamex-corp-nasdaq-stex-acquires-9-9-strategic-equity-stake-in-royalty-and-streaming-fir-stex-20251211monthly0.5https://www.biopharmawatch.com/news/STEX/streamex-corp-nasdaq-stex-announces-appointment-of-kevin-gopaul-global-financial-executive-stex-20251118monthly0.5https://www.biopharmawatch.com/news/STEX/streamex-corp-nasdaq-stex-announces-gold-bullion-purchases-closing-of-initial-usd-25-000-0-stex-20251105monthly0.5https://www.biopharmawatch.com/news/STEX/streamex-corp-nasdaq-stex-announces-nasdaq-approval-for-continued-listing-on-nasdaq-capita-stex-20251031monthly0.5https://www.biopharmawatch.com/news/STEX/biosig-technologies-inc-announces-corporate-rebrand-to-streamex-corp-strategic-rebranding--stex-20250910monthly0.5https://www.biopharmawatch.com/news/STEX/biosig-technologies-inc-announces-proposed-public-offering-los-angeles-ca-stex-20250813monthly0.5https://www.biopharmawatch.com/news/STEX/biosig-technologies-inc-and-streamex-exchange-corporation-announce-definitive-agreements-f-stex-20250707monthly0.5https://www.biopharmawatch.com/news/STEX/streamex-and-biosig-announce-the-successful-closing-of-share-exchange-transaction-and-exec-stex-20250528monthly0.5https://www.biopharmawatch.com/news/STEX/biosig-technologies-inc-signs-definitive-share-exchange-agreement-with-streamex-exchange-c-stex-20250523monthly0.5https://www.biopharmawatch.com/news/STEX/confidential-letter-of-intent-stex-20250505monthly0.5https://www.biopharmawatch.com/news/STEX/biosig-regains-compliance-with-nasdaq-s-minimum-bid-price-requirement-los-angeles-ca-stex-20241113monthly0.5https://www.biopharmawatch.com/news/STEX/biosig-technologies-appoints-mr-ferdinand-groenewald-to-position-of-interim-chief-financia-stex-20240610monthly0.5https://www.biopharmawatch.com/news/STEX/biosig-announces-3-million-registered-direct-offering-priced-at-the-market-under-nasdaq-ru-stex-20240530monthly0.5https://www.biopharmawatch.com/news/STEX/biosig-technologies-inc-announces-new-appointments-to-its-now-fully-constituted-board-of-d-stex-20240503monthly0.5https://www.biopharmawatch.com/news/STEX/biosig-technologies-inc-appoints-mr-anthony-amato-to-position-of-chief-executive-officer-e-stex-20240430monthly0.5https://www.biopharmawatch.com/news/STEX/biosig-s-pure-ep-platform-with-new-near-field-tracking-algorithm-surpasses-100-patient-cas-stex-20240206monthly0.5https://www.biopharmawatch.com/news/STEX/biosig-announces-reverse-stock-split-common-stock-will-begin-trading-on-split-adjusted-bas-stex-20240202monthly0.5https://www.biopharmawatch.com/news/STEX/biosig-announces-cost-reductions-to-improve-its-financial-standing-and-shifts-its-core-str-stex-20240130monthly0.5https://www.biopharmawatch.com/news/STEX/letter-to-shareholders-december-2023-dear-fellow-shareholders-as-we-approach-the-end-of-20-stex-20231206monthly0.5https://www.biopharmawatch.com/news/STEX/biosig-announces-2-5-million-registered-direct-offering-priced-at-the-market-under-nasdaq--stex-20231113monthly0.5https://www.biopharmawatch.com/news/STEX/biosig-announces-2-5-million-registered-direct-offering-priced-at-the-market-under-nasdaq--stex-20231109monthly0.5https://www.biopharmawatch.com/news/STEX/biosig-appoints-global-medtech-leader-fred-hrkac-as-new-executive-vp-32-year-career-in-med-stex-20231107monthly0.5https://www.biopharmawatch.com/news/STEX/securities-and-exchange-commission-stex-20230428monthly0.5https://www.biopharmawatch.com/news/STEX/securities-and-exchange-commission-stex-20210412monthly0.5https://www.biopharmawatch.com/news/STEX/securities-and-exchange-commission-stex-20210325monthly0.5https://www.biopharmawatch.com/news/STEX/securities-and-exchange-commission-stex-20210225monthly0.5https://www.biopharmawatch.com/news/STEX/securities-and-exchange-commission-stex-20210223monthly0.5https://www.biopharmawatch.com/news/STEX/securities-and-exchange-commission-stex-20210113monthly0.5https://www.biopharmawatch.com/news/STEX/securities-and-exchange-commission-stex-20201214monthly0.5https://www.biopharmawatch.com/news/STEX/securities-and-exchange-commission-stex-20201106monthly0.5https://www.biopharmawatch.com/news/STEX/securities-and-exchange-commission-stex-20200727monthly0.5https://www.biopharmawatch.com/news/STEX/securities-and-exchange-commission-stex-20200330monthly0.5https://www.biopharmawatch.com/news/STEX/letter-to-shareholders-the-year-in-review-what-a-difference-12-months-make-dear-biosig-sha-stex-20180404monthly0.5https://www.biopharmawatch.com/news/STEX/biosig-technologies-inc-shareholder-letter-december-2017-dear-biosig-technologies-inc-shar-stex-20171220monthly0.5https://www.biopharmawatch.com/news/STEX/ip-veteran-andrew-filler-joins-biosig-technologies-board-of-directors-santa-monica-ca-stex-20171110monthly0.5https://www.biopharmawatch.com/news/STEX/biosig-technologies-inc-shareholder-letter-april-2017-dear-biosig-technologies-inc-shareho-stex-20170424monthly0.5https://www.biopharmawatch.com/news/STEX/biosig-technologies-announces-strategic-partnership-with-mayo-clinic-ten-year-agreement-pr-stex-20170317monthly0.5https://www.biopharmawatch.com/news/STEX/corporate-presentation-2017-symbol-bsgm-disclaimer-symbol-bsgm-this-presentation-contains--stex-20170222monthly0.5https://www.biopharmawatch.com/news/STEX/biosig-technologies-announces-advanced-research-program-with-mayo-clinic-minneapolis-mn-stex-20160323monthly0.5https://www.biopharmawatch.com/news/STEX/fourth-amendment-to-the-biosig-technologies-inc-2012-equity-incentive-plan-this-fourth-ame-stex-20150522monthly0.5https://www.biopharmawatch.com/news/STEX/biosig-appoints-patrick-gallagher-to-its-board-of-directors-los-angeles-ca-stex-20140722monthly0.5https://www.biopharmawatch.com/news/STEX/biosig-names-med-devices-veteran-exec-gregory-d-cash-ceo-president-director-los-angeles-ca-stex-20140721monthly0.5https://www.biopharmawatch.com/news/ALDX/expectations-regarding-competition-aldeyra-s-anticipated-growth-strategies-aldeyra-s-abili-aldx-20260610monthly0.5https://www.biopharmawatch.com/news/ALDX/future-studies-or-clinical-trials-involving-aldeyra-s-product-candidates-in-clinical-trial-aldx-20260317monthly0.5https://www.biopharmawatch.com/news/ALDX/indications-the-scope-progress-expansion-and-costs-of-developing-and-commercializing-aldey-aldx-20251216monthly0.5https://www.biopharmawatch.com/news/ALDX/disclaimers-and-forward-looking-statements-this-presentation-contains-forward-looking-stat-aldx-20251113monthly0.5https://www.biopharmawatch.com/news/ALDX/candidates-aldeyra-s-expectations-regarding-competition-aldeyra-s-anticipated-growth-strat-aldx-20251028monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-fda-acceptance-for-review-of-reproxalap-new-drug-applicatio-aldx-20250717monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-receives-special-protocol-assessment-agreement-letter-from-the-u-s-fo-aldx-20250626monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-resubmits-reproxalap-new-drug-application-for-the-treatment-of-dry-ey-aldx-20250617monthly0.5https://www.biopharmawatch.com/news/ALDX/disclaimers-and-forward-looking-statements-this-presentation-contains-forward-looking-stat-aldx-20250506monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-appoints-chip-clark-to-board-of-directors-lexington-mass-aldx-20250417monthly0.5https://www.biopharmawatch.com/news/ALDX/c-o-n-f-e-r-e-n-c-e-c-a-l-l-reproxalap-for-the-potential-treatment-of-dry-eye-disease-regu-aldx-20250403monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-fda-acceptance-for-review-of-reproxalap-new-drug-applicatio-aldx-20241118monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-resubmits-reproxalap-new-drug-application-for-the-treatment-of-dry-ey-aldx-20241003monthly0.5https://www.biopharmawatch.com/news/ALDX/dry-eye-disease-chamber-phase-3-clinical-trial-of-reproxalap-aldx-20240808monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-advancement-of-new-rasp-modulators-and-recent-preclinical-d-aldx-20240620monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-completes-enrollment-in-phase-3-clinical-trial-of-reproxalap-in-dry-e-aldx-20240613monthly0.5https://www.biopharmawatch.com/news/ALDX/r-e-s-e-a-r-c-h-d-e-v-e-l-o-p-m-e-n-t-d-a-y-c-o-r-p-o-a-t-e-o-a-p-r-i-l-25-202-4-nasdaq-al-aldx-20240425monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-clinical-development-plan-for-resubmission-of-new-drug-appl-aldx-20240328monthly0.5https://www.biopharmawatch.com/news/ALDX/innovative-therapeuticsfor-immune-mediated-diseases-corporate-overview-february-2024-nasda-aldx-20240213monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-provides-clinical-and-regulatory-update-and-announces-advancement-of--aldx-20240104monthly0.5https://www.biopharmawatch.com/news/ALDX/top-line-results-from-thephase-2-clinical-trial-of-adx-629in-atopic-dermatitis-aldx-20231219monthly0.5https://www.biopharmawatch.com/news/ALDX/c-o-n-f-e-r-e-n-c-e-c-a-l-l-reproxalap-for-the-treatment-of-dry-eye-disease-regulatory-upd-aldx-20231128monthly0.5https://www.biopharmawatch.com/news/ALDX/top-line-results-from-thephase-2-clinical-trial-of-adx-2191-in-retinitis-pigmentosa-aldx-20230629monthly0.5https://www.biopharmawatch.com/news/ALDX/top-line-results-from-thephase-2-clinical-trial-ofadx-629-in-chronic-cough-aldx-20230627monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-provides-regulatory-update-on-adx-2191-based-on-u-s-food-drug-adminis-aldx-20230621monthly0.5https://www.biopharmawatch.com/news/ALDX/top-line-results-from-thephase-3-invigorate-2-trial-in-allergic-conjunctivitis-aldx-20230615monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-reports-first-quarter-2023-financial-results-and-recent-corporate-hig-aldx-20230504monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-reports-full-year-2022-financial-results-and-recent-corporate-highlig-aldx-20230309monthly0.5https://www.biopharmawatch.com/news/ALDX/fda-accepts-for-priority-review-adx-2191-new-drug-application-for-the-treatment-of-primary-aldx-20230302monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-fda-acceptance-of-new-drug-application-for-reproxalap-for-t-aldx-20230207monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-submits-new-drug-application-to-the-u-s-food-and-drug-administration--aldx-20221221monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-positive-primary-vitreoretinal-lymphoma-pre-nda-meeting-wit-aldx-20221201monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-submits-new-drug-application-to-the-u-s-food-and-drug-administration--aldx-20221129monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-reports-third-quarter-2022-financial-results-and-recent-corporate-hig-aldx-20221110monthly0.5https://www.biopharmawatch.com/news/ALDX/top-line-results-from-part-1-of-the-phase-3-guard-trial-of-adx-2191-in-proliferative-vitre-aldx-20221006monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-positive-dry-eye-disease-pre-nda-meeting-with-the-fda-and-h-aldx-20220914monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-reports-second-quarter-2022-financial-results-and-recent-corporate-hi-aldx-20220805monthly0.5https://www.biopharmawatch.com/news/ALDX/top-line-results-from-thedry-eye-disease-chamber-crossover-trial-of-reproxalap-aldx-20220712monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-top-line-results-from-the-phase-3-tranquility-2-trial-in-dry-eye-disease-aldx-20220608monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-designates-schirmer-test-as-sole-primary-endpoint-in-phase-3-tranquil-aldx-20220524monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-that-post-hoc-analysis-using-computer-automated-grading-of--aldx-20220518monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-reports-first-quarter-2022-financial-results-and-recent-corporate-hig-aldx-20220505monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-chief-financial-officer-transition-lexington-mass-business--aldx-20220428monthly0.5https://www.biopharmawatch.com/news/ALDX/welcome-and-opening-remarks-todd-c-brady-m-d-ph-d-chief-executive-officer-aldx-20220329monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-reports-full-year-2021-financial-results-and-recent-corporate-highlig-aldx-20220317monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-completion-of-enrollment-in-phase-3-tranquility-trial-in-pa-aldx-20211109monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-achievement-of-primary-endpoint-of-ocular-redness-in-random-aldx-20211102monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-reports-third-quarter-2021-financial-results-and-recent-corporate-hig-aldx-20211028monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-reports-second-quarter-2021-financial-results-and-recent-corporate-hi-aldx-20210805monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-reports-first-quarter-2021-financial-results-and-recent-business-high-aldx-20210506monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-inc-announces-proposed-125-million-public-offering-of-common-stock-aldx-20210427monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-reports-full-year-2020-financial-results-and-recent-business-highligh-aldx-20210311monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-inc-announces-proposed-public-offering-of-common-stock-aldx-20210113monthly0.5https://www.biopharmawatch.com/news/ALDX/disclaimers-and-forward-looking-statements-this-presentation-and-various-remarks-which-may-aldx-20210107monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-third-quarter-2020-financial-results-and-provides-corporate-aldx-20201105monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-second-quarter-2020-financial-results-and-provides-corporat-aldx-20200806monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-stock-sales-to-perceptive-advisors-and-avidity-partners-gro-aldx-20200714monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-new-drug-application-nda-development-plans-for-dry-eye-dise-aldx-20200707monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-reaches-agreement-with-the-us-food-and-drug-administration-for-the-us-aldx-20200604monthly0.5https://www.biopharmawatch.com/news/ALDX/disclaimers-and-forward-looking-statements-this-presentation-and-various-remarks-which-may-aldx-20200520monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-reports-first-quarter-2020-financial-results-and-announces-new-clinic-aldx-20200507monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-announces-positive-top-line-phase-1-clinical-trial-results-and-clinical-developmen-aldx-20200414monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-reports-full-year-2019-financial-results-and-provides-updates-on-anti-aldx-20200312monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-to-provide-update-on-late-stage-clinical-development-pipeline-at-2020-aldx-20200224monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-appoints-nancy-miller-rich-to-board-of-directors-addition-of-35-year--aldx-20200114monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-positive-top-line-results-from-part-1-of-adaptive-phase-3-r-aldx-20191203monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-reports-third-quarter-2019-financial-results-and-provides-updates-on--aldx-20191107monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-receives-fast-track-designation-for-adx-2191-for-the-prevention-of-pr-aldx-20190924monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-second-quarter-2019-financial-results-and-provides-corporat-aldx-20190808monthly0.5https://www.biopharmawatch.com/news/ALDX/disclaimers-and-forward-looking-statements-this-presentation-and-various-remarks-which-may-aldx-20190625monthly0.5https://www.biopharmawatch.com/news/ALDX/disclaimers-and-forward-looking-statements-this-presentation-and-various-remarks-which-may-aldx-20190606monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-first-quarter-2019-financial-results-and-provides-corporate-aldx-20190509monthly0.5https://www.biopharmawatch.com/news/ALDX/disclaimers-and-forward-looking-statements-this-presentation-and-various-remarks-which-may-aldx-20190326monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-year-end-2018-financial-results-results-from-the-alleviate--aldx-20190308monthly0.5https://www.biopharmawatch.com/news/ALDX/disclaimers-and-forward-looking-statements-this-presentation-and-various-remarks-which-may-aldx-20190228monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-expands-retinal-disease-pipeline-with-acquisition-of-helio-vision-add-aldx-20190129monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-third-quarter-2018-financial-results-reported-positive-data-aldx-20181114monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-inc-announces-proposed-public-offering-of-common-stock-aldx-20180926monthly0.5https://www.biopharmawatch.com/news/ALDX/disclaimers-and-forward-looking-statements-this-presentation-and-various-remarks-which-may-aldx-20180926monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-positive-mesothelioma-investigator-sponsored-clinical-trial-aldx-20180925monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-second-quarter-2018-financial-results-and-provides-corporat-aldx-20180809monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-appoints-joshua-reed-as-chief-financial-officer-aldx-20180731monthly0.5https://www.biopharmawatch.com/news/ALDX/disclaimers-and-forward-looking-statements-this-presentation-and-various-remarks-which-may-aldx-20180626monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-first-quarter-2018-financial-results-aldx-20180515monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-year-end-2017-financial-results-aldx-20180329monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-agreement-with-johnson-johnson-innovation-to-advance-novel--aldx-20180227monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-third-quarter-2017-financial-results-aldx-20171109monthly0.5https://www.biopharmawatch.com/news/ALDX/disclaimers-and-forward-looking-statements-this-presentation-and-various-remarks-which-may-aldx-20171010monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-inc-announces-closing-of-public-offering-of-common-stock-and-full-exe-aldx-20170921monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-inc-announces-pricing-of-public-offering-of-common-stock-aldx-20170919monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-inc-announces-proposed-public-offering-of-common-stock-aldx-20170918monthly0.5https://www.biopharmawatch.com/news/ALDX/disclaimers-and-forward-looking-statements-this-presentation-and-various-remarks-which-may-aldx-20170912monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-second-quarter-2017-financial-results-lexington-ma-aldx-20170808monthly0.5https://www.biopharmawatch.com/news/ALDX/disclaimers-and-forward-looking-statements-this-presentation-and-various-remarks-which-may-aldx-20170614monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-provides-corporate-update-and-announces-first-quarter-2017-financial--aldx-20170515monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-reports-full-year-2016-financial-results-lexington-ma-aldx-20170330monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-inc-announces-closing-of-public-offering-of-common-stock-and-full-exe-aldx-20170217monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-inc-prices-public-offering-of-common-stock-aldx-20170214monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-inc-proposes-public-offering-of-common-stock-aldx-20170213monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-clinical-development-update-for-phase-3-programs-noninfecti-aldx-20170125monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-third-quarter-2016-financial-results-on-track-to-initiate-t-aldx-20161114monthly0.5https://www.biopharmawatch.com/news/ALDX/disclaimers-and-forward-looking-statements-this-presentation-and-various-remarks-which-may-aldx-20160926monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-appoints-richard-h-douglas-to-its-board-of-directors-lexington-ma-mar-aldx-20160914monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-second-quarter-2016-financial-results-and-provides-corporat-aldx-20160810monthly0.5https://www.biopharmawatch.com/news/ALDX/disclaimers-and-forward-looking-statements-this-presentation-contains-forward-looking-stat-aldx-20160809monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-inc-prices-public-offering-of-common-stock-aldx-20160526monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-positive-results-from-phase-ii-clinical-trial-in-subjects-w-aldx-20160509monthly0.5https://www.biopharmawatch.com/news/ALDX/disclaimers-and-forward-looking-statements-2-this-presentation-contains-forward-looking-st-aldx-20160331monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-reports-full-year-2015-financial-results-lexington-ma-aldx-20160330monthly0.5https://www.biopharmawatch.com/news/ALDX/disclaimers-and-forward-looking-statements-this-presentation-contains-forward-looking-stat-aldx-20160309monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-reports-third-quarter-and-year-to-date-2015-financial-and-operating-r-aldx-20151112monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-reports-second-quarter-and-year-to-date-2015-financial-results-and-pr-aldx-20150811monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-reports-first-quarter-2015-financial-and-operating-results-initiated--aldx-20150513monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-reports-full-year-2014-financial-results-lexington-ma-aldx-20150319monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-opens-enrollment-in-sj-gren-larsson-syndrome-clinical-trial-and-final-aldx-20150317monthly0.5https://www.biopharmawatch.com/news/ALDX/xxxxx-x-forward-looking-statements-this-presentation-contains-forward-looking-statements-w-aldx-20150302monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-completes-2-0-million-private-placement-lexington-ma-aldx-20150122monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-2-0-million-private-placement-lexington-ma-aldx-20150120monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-completes-7-79-million-private-placement-lexington-ma-aldx-20150115monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-announces-7-79-million-private-placement-lexington-ma-aldx-20150113monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-submits-fda-ind-filing-for-noninfectious-anterior-uveitis-lexington-m-aldx-20141218monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-reports-third-quarter-and-year-to-date-2014-financial-results-lexingt-aldx-20141110monthly0.5https://www.biopharmawatch.com/news/ALDX/forward-looking-statements-this-presentation-includes-statements-contains-forward-looking--aldx-20140905monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-expands-drug-development-team-in-advance-of-ns2-clinical-trials-burli-aldx-20140902monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-reports-second-quarter-2014-financial-results-burlington-ma-aldx-20140804monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-to-join-russell-microcap-index-burlington-ma-aldx-20140626monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-appoints-stephen-tulipano-chief-financial-officer-burlington-ma-aldx-20140619monthly0.5https://www.biopharmawatch.com/news/ALDX/aldeyra-therapeutics-reports-first-quarter-2014-financial-results-burlington-ma-aldx-20140611monthly0.5https://www.biopharmawatch.com/news/ALDX/ns2-a-novel-aldehyde-trap-decreases-aldehyde-levels-in-dry-skin-and-eye-models-scott-l-you-aldx-20140508monthly0.5https://www.biopharmawatch.com/news/PTHS/legal-disclaimer-this-presentation-of-pelthos-therapeutics-inc-we-us-our-or-the-company-co-pths-20260528monthly0.5https://www.biopharmawatch.com/news/PTHS/corporate-presentation-q1-2026-2-legal-disclaimer-this-presentation-of-pelthos-therapeutic-pths-20260112monthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-acquires-xeglyze-abametapir-topical-treatment-for-head-lice-acquisiti-pths-20260105monthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-expands-board-of-directors-with-the-appointment-of-andrew-einhorn-sea-pths-20251223monthly0.5https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-acquires-xepi-ozenoxacin-cream-1-and-announces-18-million-private-con-pths-20251107monthly0.5https://www.biopharmawatch.com/news/PTHS/corporate-presentation-q-4-2-02-5-1-legal-disclaimer-this-presentation-of-pelthos-therapeu-pths-20251014monthly0.5https://www.biopharmawatch.com/news/PTHS/lnhc-inc-condensed-balance-sheets-in-thousands-unaudited-pths-20250916monthly0.5https://www.biopharmawatch.com/news/PTHS/q-3-2-0-2-5-1-legal-disclaimer-this-presentation-of-pelthos-therapeutics-inc-we-us-our-or--pths-20250903monthly0.5https://www.biopharmawatch.com/news/PTHS/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-ameri-pths-20250501monthly0.5https://www.biopharmawatch.com/news/PTHS/ot-pelthos-therapeuties-corporate-corporate-presentation-presentation-q-2-2-0-2-5-so-nsd-n-pths-20250417monthly0.5https://www.biopharmawatch.com/news/PTHS/chromocell-announces-name-change-to-channel-therapeutics-corporation-and-provides-therapeu-pths-20241121monthly0.5https://www.biopharmawatch.com/news/PTHS/chromocell-announces-stock-repurchase-plan-freehold-n-j-pths-20241024monthly0.5https://www.biopharmawatch.com/news/PTHS/chromocell-announces-stock-repurchase-plan-freehold-n-j-pths-20240807monthly0.5https://www.biopharmawatch.com/news/PTHS/chromocell-therapeutics-corporation-1-chromocell-therapeutics-corporation-potential-breakt-pths-20240729monthly0.5https://www.biopharmawatch.com/news/PTHS/chromocell-issues-letter-to-stockholders-from-chief-executive-officer-freehold-n-j-pths-20240409monthly0.5https://www.biopharmawatch.com/news/PTHS/chromocell-announces-formal-launch-of-eye-pain-treatment-program-and-hiring-of-dr-simon-ch-pths-20240321monthly0.5https://www.biopharmawatch.com/news/PTHS/chromocell-names-frank-knuettel-as-chief-executive-officer-removing-interim-status-held-si-pths-20240318monthly0.5https://www.biopharmawatch.com/news/PTHS/chromocell-therapeutics-corporation-1-chromocell-therapeutics-corporation-potential-breakt-pths-20240313monthly0.5https://www.biopharmawatch.com/news/PTHS/chromocell-therapeutics-announces-pricing-of-upsized-6-6-initial-public-offering-freehold--pths-20240216monthly0.5https://www.biopharmawatch.com/news/FTLF/fitlife-brands-begins-trading-on-the-otcqx-market-omaha-ne-x2013-ftlf-20210503monthly0.5https://www.biopharmawatch.com/news/FTLF/fitlife-brands-acquires-nutrology-omaha-ne-x2013-ftlf-20210413monthly0.5https://www.biopharmawatch.com/news/FTLF/fitlife-brands-announces-second-quarter-2020-results-omaha-ne-x2013-ftlf-20200813monthly0.5https://www.biopharmawatch.com/news/FTLF/fitlife-brands-announces-first-quarter-2020-results-omaha-ne-x2013-ftlf-20200515monthly0.5https://www.biopharmawatch.com/news/FTLF/fitlife-brands-provides-preliminary-first-quarter-results-and-operational-update-omaha-ne-ftlf-20200403monthly0.5https://www.biopharmawatch.com/news/FTLF/fitlife-brands-announces-first-quarter-2019-results-omaha-ne-x2013-ftlf-20190515monthly0.5https://www.biopharmawatch.com/news/FTLF/fitlife-brands-announces-preliminary-third-quarter-and-nine-month-2016-results-ftlf-20161108monthly0.5https://www.biopharmawatch.com/news/FTLF/secconnect-com-fitlife-brands-announces-fiscal-second-quarter-201-6-results-ftlf-20160815monthly0.5https://www.biopharmawatch.com/news/FTLF/investor-presentation-materials-dated-march-2016-ex99-1-htm-ftlf-20160315monthly0.5https://www.biopharmawatch.com/news/FTLF/secconnect-com-fitlife-brands-announces-preliminary-fourth-quarter-and-full-year-2015-resu-ftlf-20160310monthly0.5https://www.biopharmawatch.com/news/FTLF/secconnect-com-fitlife-brands-inc-closes-merger-with-isatori-inc-omaha-ne-ftlf-20151001monthly0.5https://www.biopharmawatch.com/news/FTLF/fitlife-brands-inc-and-isatori-inc-announce-exchange-ratio-for-merger-omaha-ne-and-golden--ftlf-20150925monthly0.5https://www.biopharmawatch.com/news/FTLF/fitlife-brands-to-present-at-the-midwest-ideas-investor-conference-on-august-26-th-in-chic-ftlf-20150824monthly0.5https://www.biopharmawatch.com/news/FTLF/fitlife-brands-frequently-asked-questions-regarding-proposed-merger-with-isatori-omaha-ne--ftlf-20150602monthly0.5https://www.biopharmawatch.com/news/FTLF/fitlife-brands-inc-isatori-inc-agree-to-merger-strategic-combination-will-create-a-formida-ftlf-20150519monthly0.5https://www.biopharmawatch.com/news/FTLF/fitlife-brands-announces-fiscal-first-quarter-2015-results-omaha-ne-business-wire-ftlf-20150514monthly0.5https://www.biopharmawatch.com/news/FTLF/fitlife-brands-board-of-directors-authorizes-an-extension-of-its-share-repurchase-program--ftlf-20150309monthly0.5https://www.biopharmawatch.com/news/FTLF/fitlife-brands-announces-preliminary-financial-results-for-fiscal-year-2014-expects-net-in-ftlf-20150224monthly0.5https://www.biopharmawatch.com/news/FTLF/fitlife-brands-reports-third-quarter-2014-financial-results-posts-12-and-16-increases-in-r-ftlf-20141113monthly0.5https://www.biopharmawatch.com/news/FTLF/dated-august-7-2014-ex99-1-htm-fitlife-brands-reports-second-quarter-2014-financial-result-ftlf-20140807monthly0.5https://www.biopharmawatch.com/news/FTLF/fitlife-brands-reports-first-quarter-2014-results-company-reports-record-quarterly-revenue-ftlf-20140430monthly0.5https://www.biopharmawatch.com/news/FTLF/fitlife-brands-presents-at-microcapclub-invitational-omaha-ne-business-wire-ftlf-20140107monthly0.5https://www.biopharmawatch.com/news/FTLF/1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-ftlf-20131205monthly0.5https://www.biopharmawatch.com/news/FTLF/secconnect-com-fitlife-brands-announces-new-directors-omaha-ne-business-wire-tuesday-novem-ftlf-20131105monthly0.5https://www.biopharmawatch.com/news/FTLF/secconnect-com-bond-labs-completes-recapitalization-and-name-change-omaha-ne-business-wire-ftlf-20130926monthly0.5https://www.biopharmawatch.com/news/FTLF/secconnect-com-bond-labs-to-simplify-capital-structure-all-outstanding-preferred-stock-red-ftlf-20130910monthly0.5https://www.biopharmawatch.com/news/FTLF/secconnect-com-notice-of-redemption-issued-to-holders-of-10-cumulative-perpetual-series-b--ftlf-20130906monthly0.5https://www.biopharmawatch.com/news/FTLF/secconnect-com-bond-labs-reports-3rd-quarter-and-ytd-results-continued-strong-revenue-and--ftlf-20121115monthly0.5https://www.biopharmawatch.com/news/FTLF/secconnect-com-bond-labs-achieves-turnaround-generating-record-2011-results-press-release--ftlf-20120131monthly0.5https://www.biopharmawatch.com/news/FTLF/secconnect-com-bond-labs-reports-profitable-3-rd-quarter-and-ytd-results-omaha-neb-busines-ftlf-20111114monthly0.5https://www.biopharmawatch.com/news/FTLF/secconnect-com-consulting-agreement-for-services-between-bond-laboratories-inc-and-burnham-ftlf-20110829monthly0.5https://www.biopharmawatch.com/news/FTLF/secconnect-com-bond-labs-recaps-profitable-and-successful-2-nd-quarter-omaha-neb-ftlf-20110816monthly0.5https://www.biopharmawatch.com/news/FTLF/secconnect-com-bond-labs-reports-profitable-quarter-and-ytd-results-ftlf-20110720monthly0.5https://www.biopharmawatch.com/news/FTLF/bond-labs-reports-strong-april-results-extends-impressive-growth-trend-omaha-neb-business--ftlf-20110518monthly0.5https://www.biopharmawatch.com/news/FTLF/secconnect-com-bond-labs-reports-profitable-q1-results-omaha-ne-ftlf-20110510monthly0.5https://www.biopharmawatch.com/news/FTLF/secconnect-com-bond-labs-generates-significant-growth-for-month-and-quarter-monthly-and-qu-ftlf-20110404monthly0.5https://www.biopharmawatch.com/news/FTLF/secconnect-com-bond-labs-reports-record-revenue-at-its-nds-division-boasts-increase-of-mor-ftlf-20110309monthly0.5https://www.biopharmawatch.com/news/FTLF/secconnect-com-bond-labs-nds-division-again-increases-revenue-over-prior-year-period-nds-j-ftlf-20110208monthly0.5https://www.biopharmawatch.com/news/FTLF/secconnect-com-bond-labs-nds-division-generates-35-revenue-increase-in-december-nds-quarte-ftlf-20110113monthly0.5https://www.biopharmawatch.com/news/FTLF/secconnect-com-for-immediate-release-bond-labs-nds-nutrition-increases-sales-by-35-for-the-ftlf-20100923monthly0.5https://www.biopharmawatch.com/news/FTLF/secconnect-com-consulting-agreement-for-services-between-bond-laboratories-inc-and-burnham-ftlf-20100823monthly0.5https://www.biopharmawatch.com/news/FTLF/bond-labs-announces-increased-revenue-for-first-quarter-period-highlighted-by-22-growth-in-ftlf-20100504monthly0.5https://www.biopharmawatch.com/news/FTLF/bond-announces-1-st-qtr-growth-of-21-for-nds-division-outperforms-nutritional-supplement-i-ftlf-20100331monthly0.5https://www.biopharmawatch.com/news/FTLF/bond-labs-announces-245-revenue-growth-for-2009-year-highlighted-by-launch-of-industry-lea-ftlf-20100406monthly0.5https://www.biopharmawatch.com/news/FTLF/bond-labs-announces-70-increase-in-revenue-for-the-fourth-quarter-thu-jan-28-11-53-am-omah-ftlf-20100201monthly0.5https://www.biopharmawatch.com/news/FTLF/bond-labs-reports-strong-revenue-growth-during-first-year-of-nds-nutrition-products-inc-ow-ftlf-20100120monthly0.5https://www.biopharmawatch.com/news/FTLF/consulting-agreement-for-services-between-bond-laboratories-inc-and-burnham-hill-advisors--ftlf-20090826monthly0.5https://www.biopharmawatch.com/news/FTLF/bond-laboratories-inc-completes-3-million-dollar-common-stock-private-placement-solana-bea-ftlf-20080701monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-receives-its-first-international-regulatory-approval-for-the-commercializ-mbot-20260526monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-to-hold-conference-call-to-review-recent-progress-executive-team-to-be-joined-by--mbot-20260514monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-successfully-transitions-to-commercial-operations-as-it-records-revenue-r-mbot-20260514monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-s-liberty-endovascular-robotic-system-is-now-adopted-by-multiple-accounts-mbot-20260505monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-the-addition-of-senior-commercial-executive-with-proven-track-r-mbot-20260430monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-to-participate-at-the-oppenheimer-36th-annual-healthcare-medtech-services-mbot-20260310monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-s-liberty-endovascular-robotic-system-continues-to-expand-market-visibili-mbot-20260219monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-ceo-to-discuss-recent-fda-clearance-of-the-liberty-endovascular-robotic-s-mbot-20250923monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-receives-fda-510-k-clearance-for-its-liberty-endovascular-robotic-system--mbot-20250909monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-granted-u-s-patent-that-significantly-expands-potential-market-applicatio-mbot-20250820monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-receives-non-dilutive-grant-to-enhance-operational-capabilities-strengthe-mbot-20250805monthly0.5https://www.biopharmawatch.com/news/MBOT/e-xhibit-99-1-microbot-medical-expands-commercial-leadership-with-appointment-of-christina-mbot-20250722monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-to-open-inaugural-endovascular-robotics-session-at-the-society-of-robotic-mbot-20250708monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-added-to-the-russell-microcap-index-automatic-inclusion-in-the-appropriat-mbot-20250630monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-strengthens-global-ip-portfolio-with-newly-granted-patent-in-china-signif-mbot-20250617monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-continues-to-strengthen-commercial-capabilities-in-preparation-for-the-an-mbot-20250609monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-selected-for-preliminary-inclusion-to-russell-microcap-index-mbot-20250605monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-bolsters-commercial-leadership-team-with-the-addition-of-experienced-heal-mbot-20250423monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-shares-results-from-its-pivotal-clinical-trial-achieving-100-robotic-navi-mbot-20250409monthly0.5https://www.biopharmawatch.com/news/MBOT/reminder-microbot-medical-announces-data-from-the-company-s-access-pvi-trial-will-be-prese-mbot-20250401monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-appoints-seasoned-endovascular-sales-executive-to-lead-its-u-s-sales-acti-mbot-20250304monthly0.5https://www.biopharmawatch.com/news/MBOT/robotic-telesurgery-data-from-collaboration-with-corewell-health-accepted-for-presentation-mbot-20250225monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-closes-13-million-registered-direct-offering-mbot-20250211monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-13-million-registered-direct-offering-priced-at-the-market-unde-mbot-20250210monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-late-breaking-abstract-acceptance-at-the-society-of-interventio-mbot-20250204monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-strengthens-its-management-team-in-support-of-the-anticipated-commercial--mbot-20250121monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-8-6-million-registered-direct-offering-priced-at-the-market-und-mbot-20250108monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-7-million-registered-direct-offering-priced-at-the-market-under-mbot-20250106monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-concludes-2024-by-achieving-key-milestones-culminating-in-fda-submission--mbot-20241230monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-fda-submission-for-the-commercialization-of-the-liberty-endovas-mbot-20241210monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-the-successful-completion-of-its-pivotal-human-clinical-trial-a-mbot-20241015monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-accelerates-patient-enrollment-of-its-pivotal-human-clinical-trial-expect-mbot-20240930monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-the-successful-enrollment-of-50-of-the-patients-in-its-pivotal--mbot-20240917monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-signs-phase-2-collaboration-agreement-with-corewell-health-to-advance-rem-mbot-20240822monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-receives-quality-certification-to-support-future-regulatory-submissions-a-mbot-20240813monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-and-emory-university-to-evaluate-the-future-autonomous-capabilities-of-th-mbot-20240801monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-completes-the-enrollment-of-clinical-sites-in-its-pivotal-human-clinical--mbot-20240718monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-continues-to-ramp-up-patient-enrollment-in-its-pivotal-human-clinical-tri-mbot-20240709monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-enrolled-the-first-patient-in-its-pivotal-human-clinical-trial-the-first--mbot-20240708monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-partners-with-baptist-hospital-of-miami-to-participate-in-its-pivotal-hum-mbot-20240703monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-brigham-and-women-s-hospital-as-a-site-for-its-pivotal-human-cl-mbot-20240617monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-2-35-million-registered-direct-offering-priced-at-the-market-un-mbot-20240603monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-has-received-fda-approval-to-proceed-with-its-pivotal-human-clinical-tria-mbot-20240603monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-positive-results-from-the-first-phase-of-its-collaboration-with-mbot-20240429monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-shares-status-following-recent-geopolitical-events-all-regulatory-clinica-mbot-20240415monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-settlement-and-release-agreement-effectively-resolving-all-asso-mbot-20240130monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-expands-us-clinical-infrastructure-in-support-of-the-upcoming-ide-submiss-mbot-20240118monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-exercise-of-outstanding-preferred-investment-options-for-2-73-m-mbot-20231229monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-and-corewell-health-forge-collaboration-to-establish-the-liberty-endovasc-mbot-20231214monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-the-successful-completion-of-its-glp-pivotal-pre-clinical-study-mbot-20231207monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-appoints-seasoned-medical-expert-dr-juan-diaz-cartelle-as-its-new-chief-m-mbot-20231121monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-successfully-completed-integral-part-of-the-verification-and-validation-p-mbot-20231113monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-granted-registered-trademark-from-the-u-s-patent-and-trademark-office-mbot-20231108monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-reveals-successful-short-term-follow-up-outcomes-from-its-pivotal-pre-cli-mbot-20231031monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-received-confirmation-for-the-commencement-of-its-ce-mark-approval-proces-mbot-20231024monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-grant-of-summary-judgment-in-its-favor-and-dismissal-of-counter-mbot-20231019monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-successful-initial-outcomes-from-its-pivotal-pre-clinical-study-mbot-20231017monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-engages-cro-to-support-its-upcoming-u-s-pivotal-clinical-trial-the-engage-mbot-20230927monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-gains-global-recognition-professor-vincent-vidal-to-present-an-abstract-o-mbot-20230908monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-boosts-manufacturing-and-commercialization-capabilities-for-its-robotic-s-mbot-20230815monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-strengthens-its-position-among-us-interventional-radiologists-by-appointi-mbot-20230810monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-engaging-with-a-leading-notified-body-to-secure-ce-mark-for-sales-in-euro-mbot-20230725monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-expands-its-physician-support-with-the-addition-of-leading-italian-interv-mbot-20230711monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-successfully-completes-an-extensive-pre-clinical-study-performed-in-the-u-mbot-20230629monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-2-million-registered-direct-offering-priced-at-the-market-under-mbot-20230627monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-expand-ip-protection-in-japan-received-grant-of-protection-for-a-design-p-mbot-20230622monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-multiple-peer-reviewed-abstracts-accepted-by-the-cardiovascular-mbot-20230616monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-1-5-million-registered-direct-offering-priced-at-the-market-und-mbot-20230602monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-receives-a-non-dilutive-grant-from-the-israel-innovation-authority-suppor-mbot-20230602monthly0.5https://www.biopharmawatch.com/news/MBOT/liberty-robotic-surgical-system-achieved-additional-milestone-in-its-path-to-first-in-huma-mbot-20230531monthly0.5https://www.biopharmawatch.com/news/MBOT/lahey-hospital-medical-center-agrees-to-become-one-of-u-s-sites-for-the-liberty-robotic-sy-mbot-20230525monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-2-66-million-registered-direct-offering-of-common-stock-priced--mbot-20230523monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-1-4-million-registered-direct-offering-of-common-stock-priced-a-mbot-20230522monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-achieved-100-success-rate-for-liberty-in-extensive-pre-clinical-animal-st-mbot-20230522monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-to-enhance-focus-on-its-core-business-and-prioritize-preparations-for-reg-mbot-20230518monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-initiates-preparations-for-first-in-human-fih-cases-in-brazil-for-the-lib-mbot-20230508monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-final-data-from-its-recent-animal-study-data-supports-next-regu-mbot-20230505monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-s-liberty-robotic-system-surpasses-100-th-catheterization-95-success-rate-mbot-20230503monthly0.5https://www.biopharmawatch.com/news/MBOT/gerry-o-sullivan-the-latest-member-to-join-microbot-medical-s-scientific-advisory-board-to-mbot-20230323monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-launches-presence-in-the-united-kingdom-as-highly-accomplished-consultant-mbot-20230316monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-increases-presence-in-the-eu-with-the-addition-of-greece-based-key-opinio-mbot-20230313monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-s-chief-medical-officer-dr-eyal-morag-to-highlight-performance-safety-and-mbot-20230309monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-leverages-recently-awarded-non-dilutive-grant-from-the-israeli-government-mbot-20230302monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-meeting-with-key-opinion-leaders-hospital-administrators-and-potential-st-mbot-20230228monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-expands-its-geographic-presence-to-south-america-with-the-addition-of-fra-mbot-20230227monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-s-remote-controller-for-the-liberty-robotic-system-receives-design-patent-mbot-20230223monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-medtech-industry-veteran-joe-mullings-will-moderate-the-next-ac-mbot-20230106monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-the-participation-of-a-key-opinion-leader-in-the-endovascular-r-mbot-20221214monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-s-proprietary-liberty-robotic-system-receives-third-patent-allowance-in-i-mbot-20221208monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-s-novel-liberty-robotic-system-continues-to-be-validated-with-latest-u-s--mbot-20221118monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-new-webinar-series-to-engage-stakeholders-with-experts-in-the-h-mbot-20221115monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-receives-additional-patent-allowance-in-israel-for-the-liberty-robotic-sy-mbot-20221103monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-5-million-registered-direct-offering-priced-at-the-market-under-mbot-20221021monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-accomplishes-the-next-step-in-the-regulatory-process-for-the-liberty-robo-mbot-20221018monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-completes-glp-animal-study-for-the-liberty-robotic-system-mbot-20221013monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-receives-patent-allowance-in-israel-for-the-liberty-robotic-system-comple-mbot-20221010monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-strengthens-liberty-robotic-system-portfolio-with-acquisition-of-novel-fd-mbot-20221007monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announce-strategic-addition-to-scientific-advisory-board-appointment-awar-mbot-20221004monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-attracts-another-leading-physician-and-expands-capabilities-of-its-scient-mbot-20220919monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-enhances-its-scientific-advisory-board-sab-with-its-newest-member-dr-vinc-mbot-20220915monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-to-review-recent-progress-d-uring-h-c-wainwright-s-24th-annual-global-inv-mbot-20220913monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-commenced-its-first-step-in-the-anticipated-regulatory-process-for-its-li-mbot-20220912monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-strengthen-its-scientific-advisory-board-with-the-recent-addition-of-dr-s-mbot-20220908monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-secures-design-patent-grant-in-europe-for-the-liberty-robotic-system-mbot-20220906monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-confirms-glp-pre-clinical-trial-is-on-track-to-commence-later-this-month-mbot-20220902monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-to-present-the-self-cleaning-shunt-at-the-16-th-asian-australasian-congre-mbot-20220818monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-to-review-recent-progress-during-needham-s-virtual-healthcare-conference-mbot-20220411monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-continues-to-strengthen-management-team-as-rachel-vaknin-promoted-to-chie-mbot-20220406monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-achieves-significant-regulatory-milestone-for-the-liberty-robotic-system--mbot-20220331monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-strategic-collaboration-with-stryker-corporation-to-develop-the-mbot-20211227monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-secures-third-patent-for-the-liberty-robotic-system-in-the-united-states--mbot-20211223monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-initiates-search-for-u-s-clinical-sites-for-the-liberty-robotic-system-mbot-20211222monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-achieves-design-freeze-of-the-liberty-robotic-system-meets-previously-sta-mbot-20211215monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-secures-additional-patent-for-the-liberty-robotic-system-in-the-united-st-mbot-20211119monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-secures-patent-for-liberty-robotic-system-in-the-united-states-mbot-20211006monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-secures-patent-allowance-in-china-third-global-jurisdiction-in-2021-to-re-mbot-20210629monthly0.5https://www.biopharmawatch.com/news/MBOT/leading-interventional-cardiologist-dr-giora-weisz-joins-microbot-medical-s-scientific-adv-mbot-20210607monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-secures-additional-protection-for-the-one-and-done-guidewire-technology-w-mbot-20210604monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-granted-patent-allowance-in-japan-global-jurisdictions-recognizing-novel--mbot-20210204monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-successful-outcome-of-its-discussions-with-fda-regarding-regula-mbot-20210127monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-enhances-scientific-advisory-board-with-world-renowned-interventional-rad-mbot-20210121monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-positive-results-of-additional-animal-feasibility-study-with-li-mbot-20210114monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-demonstrates-significant-progress-in-2020-outlines-anticipated-milestones-mbot-20210111monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-to-share-current-progress-and-expected-2021-milestones-at-upcoming-confer-mbot-20210107monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-secures-patents-in-multiple-global-jurisdictions-mbot-20201117monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-to-highlight-progress-and-recent-achievements-at-h-c-wainwright-6th-annua-mbot-20201109monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-receives-notice-of-allowance-for-u-s-patent-covering-a-system-for-reducin-mbot-20201007monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-schedules-virtual-meeting-to-address-increased-interest-following-its-rec-mbot-20200819monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-successful-animal-study-utilizing-its-liberty-tm-robotic-system-mbot-20200817monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-to-share-current-results-of-a-feasibility-animal-study-utilizing-the-libe-mbot-20200813monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-appoints-the-co-founder-of-corindus-vascular-robotics-to-its-board-of-dir-mbot-20200803monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-appoints-aileen-stockburger-to-the-board-of-directors-proven-track-record-mbot-20200401monthly0.5https://www.biopharmawatch.com/news/MBOT/correcting-and-replacing-microbot-medical-appoints-eyal-morag-m-d-as-chief-medical-officer-mbot-20200303monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-appoints-eyal-morag-m-d-as-chief-medical-officer-mbot-20200303monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-receives-intention-to-grant-from-european-patent-office-for-a-patent-appl-mbot-20200108monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-inc-announces-10-million-registered-direct-offering-priced-at-the-market--mbot-20191230monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-inc-announces-10-million-registered-direct-offering-priced-at-the-market--mbot-20191227monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-inc-announces-9-59-million-registered-direct-offering-priced-at-the-marke-mbot-20191226monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-to-unveil-world-s-first-fully-disposable-robotic-system-for-endovascular--mbot-20191223monthly0.5https://www.biopharmawatch.com/news/MBOT/global-jurisdictions-continue-to-recognize-microbot-medical-s-innovative-technology-receiv-mbot-20191125monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-receives-notice-of-allowance-for-u-s-patent-covering-its-tipcat-technology-platfo-mbot-20191030monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-outcome-of-annual-meeting-of-shareholders-maintains-regulatory--mbot-20190913monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-s-self-cleaning-shunt-scs-clearly-demonstrated-the-ability-to-prevent-shu-mbot-20190910monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-to-demonstrate-a-working-prototype-of-its-self-cleaning-shunt-at-the-rodm-mbot-20190905monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-receives-notice-of-allowance-from-the-israel-patent-office-for-a-patent-a-mbot-20190724monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-strengthens-global-ip-portfolio-with-canadian-notice-of-allowance-for-a-p-mbot-20190423monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-notice-of-intention-to-grant-of-european-patent-for-adjustable--mbot-20190304monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-maintains-2019-milestone-targets-following-recent-court-decision-hingham--mbot-20190301monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-inc-announces-2-5-million-registered-direct-offering-priced-at-the-market-mbot-20190123monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-inc-announces-5-9-million-registered-direct-offering-priced-at-the-market-mbot-20190115monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-showcases-a-working-prototype-of-its-self-cleaning-shunt-hingham-ma-mbot-20190117monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-inc-announces-3-million-registered-direct-offering-priced-at-the-market-mbot-20190115monthly0.5https://www.biopharmawatch.com/news/MBOT/overview-our-company-microbot-is-a-pre-clinical-medical-device-company-specializing-in-the-mbot-20190114monthly0.5https://www.biopharmawatch.com/news/MBOT/recent-study-validates-the-operational-effectiveness-of-microbot-medical-s-self-cleaning-s-mbot-20190114monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-fda-pre-submission-milestones-for-2019-regulatory-pre-submissio-mbot-20190107monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-inc-to-present-at-the-ladenburg-thalmann-healthcare-conference-hingham-ma-mbot-20181001monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-commencement-of-pivotal-study-for-its-self-cleaning-shunt-large-mbot-20181001monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-strengthens-global-ip-with-issued-patent-in-india-covering-the-company-s--mbot-20180625monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-inc-announces-european-patent-office-s-intent-to-grant-patent-for-device--mbot-20180618monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-inc-schedules-its-periodical-townhall-meeting-for-monday-june-4th-at-9-00-mbot-20180530monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-successful-completion-of-pre-clinical-study-performed-at-washin-mbot-20180529monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-closes-acquisition-of-novel-technology-from-cardiosert-ltd-hingham-ma-mbot-20180525monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-receiving-a-notification-of-granting-a-patent-right-for-its-vir-mbot-20180523monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-successfully-completes-pre-clinical-study-for-its-self-cleaning-shunt-dat-mbot-20180521monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-receiving-notice-of-allowance-for-a-u-s-patent-covering-its-sel-mbot-20180509monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-exercises-option-to-acquire-novel-technology-from-cardiosert-ltd-expands--mbot-20180416monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-s-self-cleaning-shunt-awarded-a-grant-by-the-european-commission-non-dilu-mbot-20180412monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-appointment-of-chief-technology-officer-hingham-ma-mbot-20180405monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-inc-to-initiate-townhall-meetings-initial-event-planned-for-thursday-febr-mbot-20180131monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-enters-into-agreement-to-acquire-novel-technology-to-enhance-existing-tec-mbot-20180108monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-receives-notice-of-allowance-for-u-s-patent-covering-its-tipcat-technology-platfo-mbot-20171214monthly0.5https://www.biopharmawatch.com/news/MBOT/p-laxmin-laxminarain-appointed-to-microbot-medical-s-board-of-directors-medical-device-exe-mbot-20171212monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-inc-receives-additional-government-grant-for-development-of-its-self-clea-mbot-20171108monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-inc-to-present-at-the-ladenburg-thalmann-healthcare-conference-hingham-ma-mbot-20170925monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-inc-expands-global-ip-portfolio-as-patent-in-india-covering-the-company-s-mbot-20170915monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-inc-to-present-at-the-rodman-renshaw-annual-global-investment-conference--mbot-20170907monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-inc-reports-second-quarter-2017-financial-results-and-recent-development--mbot-20170814monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-inc-to-report-second-quarter-results-on-mbot-20170814monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-inc-continues-to-solidify-ip-portfolio-with-us-patent-for-previously-disc-mbot-20170614monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-closing-of-10-million-registered-direct-offering-of-common-stoc-mbot-20170609monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-announces-10-million-registered-direct-offering-of-common-stock-hingham-m-mbot-20170605monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-inc-announces-issuance-of-a-canadian-patent-covering-a-self-cleaning-shun-mbot-20170531monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-inc-reports-first-quarter-2017-financial-results-and-recent-development-p-mbot-20170515monthly0.5https://www.biopharmawatch.com/news/MBOT/final-microbot-medical-inc-announces-investor-briefing-conference-call-and-webcast-schedul-mbot-20170329monthly0.5https://www.biopharmawatch.com/news/MBOT/re-patent-exhibit991-htm-microbot-medical-for-immediate-release-microbot-medical-inc-annou-mbot-20170222monthly0.5https://www.biopharmawatch.com/news/MBOT/htm-microbot-medical-for-immediate-release-microbot-medical-inc-strengthens-board-of-direc-mbot-20170207monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-inc-announces-research-collaboration-agreement-with-washington-university-mbot-20170130monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-inc-announces-3-5-million-registered-direct-offering-net-proceeds-to-be-u-mbot-20170105monthly0.5https://www.biopharmawatch.com/news/MBOT/independent-auditors-report-to-the-shareholders-of-microbot-medical-ltd-we-have-audited-th-mbot-20170104monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-powerpoint-presentation-exhibit99-htm-transforming-medical-treatments-through-mic-mbot-20161219monthly0.5https://www.biopharmawatch.com/news/MBOT/htm-microbot-medical-for-immediate-release-microbot-medical-inc-announces-first-investor-b-mbot-20161215monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-press-release-exhibit991-htm-microbot-medical-microbot-medical-appoints-hezi-hime-mbot-20161206monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-closes-asset-sale-proceeds-will-be-used-to-further-develop-its-innovative-mbot-20161201monthly0.5https://www.biopharmawatch.com/news/MBOT/microbot-medical-closes-merger-transaction-initiates-trading-on-nasdaq-as-mbot-innovative--mbot-20161128monthly0.5https://www.biopharmawatch.com/news/MBOT/stemcells-inc-and-microbot-medical-ltd-announce-strategic-merger-companies-plan-to-pursue--mbot-20160816monthly0.5https://www.biopharmawatch.com/news/MBOT/important-information-and-where-to-find-it-this-communication-does-not-constitute-an-offer-mbot-20160815monthly0.5https://www.biopharmawatch.com/news/MBOT/stemcells-inc-announces-proposed-public-offering-of-common-stock-and-warrants-newark-calif-mbot-20160308monthly0.5https://www.biopharmawatch.com/news/MBOT/stemcells-inc-announces-proposed-public-offering-of-common-stock-and-warrants-newark-calif-mbot-20150423monthly0.5https://www.biopharmawatch.com/news/MBOT/securities-purchase-agreement-this-securities-purchase-agreement-this-agreement-is-dated-a-mbot-20140714monthly0.5https://www.biopharmawatch.com/news/MBOT/stemcells-inc-announces-proposed-public-offering-of-common-stock-and-warrants-newark-calif-mbot-20131001monthly0.5https://www.biopharmawatch.com/news/MBOT/purchase-agreement-purchase-agreement-the-agreement-dated-as-of-mbot-20130603monthly0.5https://www.biopharmawatch.com/news/MBOT/stemcells-inc-reports-fourth-quarter-and-year-end-2011-financial-results-and-provides-busi-mbot-20120313monthly0.5https://www.biopharmawatch.com/news/MBOT/rodney-young-chief-financial-officer-510-456-4128-stemcells-mbot-20111215monthly0.5https://www.biopharmawatch.com/news/MBOT/rodney-young-chief-financial-officer-510-456-4128-stemcells-inc-provides-business-update-a-mbot-20111101monthly0.5https://www.biopharmawatch.com/news/MBOT/rodney-young-chief-financial-officer-510-456-4128-stemcells-inc-reports-second-quarter-fin-mbot-20110728monthly0.5https://www.biopharmawatch.com/news/PYPD/notice-for-the-annual-and-extraordinary-general-meeting-to-be-held-on-july-15-2026-e-xhibi-pypd-20260610monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-completes-new-drug-application-submission-to-fda-for-d-plex-100-if-approved-d-plex-pypd-20260601monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-initiates-d-plex-nda-submission-to-the-fda-polypid-submits-first-modules-as-part-o-pypd-20260331monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-ltd-notice-of-extraordinary-general-meeting-of-shareholders-to-be-held-on-february-pypd-20251231monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-appoints-veteran-medtech-leader-brooke-story-as-chairman-of-the-board-of-directors-pypd-20251216monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-positive-fda-pre-nda-meeting-minutes-for-d-plex-100-supporting-nda-submi-pypd-20251203monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-ltd-and-its-subsidiaries-interim-condensed-consolidated-financial-statements-as-of-pypd-20250813monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-provides-corporate-update-and-reports-second-quarter-2025-financial-results-positi-pypd-20250813monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-unveils-a-long-acting-glp-1-receptor-agonists-delivery-platform-targeting-the-diab-pypd-20250715monthly0.5https://www.biopharmawatch.com/news/PYPD/compensation-policy-polypid-ltd-the-company-compensation-policy-for-officers-and-directors-pypd-20250625monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-secures-26-7-million-through-warrant-exercise-following-successful-shield-ii-phase-pypd-20250616monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-positive-topline-results-from-phase-3-shield-ii-trial-d-plex-100-demonst-pypd-20250609monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-ltd-amended-and-restated-2012-share-option-plan-1-definitions-as-used-herein-capit-pypd-20250530monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-ltd-notice-of-annual-and-extraordinary-general-meeting-of-shareholders-to-be-held--pypd-20250521monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-provides-corporate-update-and-reports-first-quarter-2025-financial-results-polypid-pypd-20250514monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-successful-completion-of-enrollment-in-phase-3-shield-ii-trial-of-d-plex-pypd-20250311monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2024-financial--pypd-20250212monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-positive-recommendation-by-dsmb-to-continue-enrollment-of-phase-3-shield-pypd-20241223monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-research-and-development-collaboration-with-immunogenesis-leveraging-ple-pypd-20241211monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-receipt-of-nasdaq-notification-of-minimum-stockholders-equity-non-compli-pypd-20241129monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-provides-corporate-update-and-reports-third-quarter-2024-financial-results-last-pa-pypd-20241113monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-last-patient-in-for-planned-unblinded-interim-analysis-in-the-ongoing-sh-pypd-20241001monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-ltd-and-its-subsidiaries-interim-condensed-consolidated-financial-statements-as-of-pypd-20240814monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-provides-corporate-update-and-reports-second-quarter-2024-financial-results-approx-pypd-20240814monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-private-placement-for-up-to-14-million-in-gross-proceeds-funding-extends-pypd-20240801monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-ltd-amended-and-restated-2012-share-option-plan-1-definitions-as-used-herein-capit-pypd-20240702monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-hosts-kol-call-to-discuss-significant-unmet-medical-need-in-surgical-site-infectio-pypd-20240618monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-ltd-notice-of-annual-and-extraordinary-general-meeting-of-shareholders-to-be-held--pypd-20240528monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-ltd-amended-and-restated-2012-share-option-plan-1-definitions-as-used-herein-capit-pypd-20240517monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-provides-corporate-update-and-reports-first-quarter-2024-financial-results-more-th-pypd-20240508monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-enrollment-of-200-th-patient-in-ongoing-shield-ii-phase-3-trial-evaluati-pypd-20240430monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2023-financial--pypd-20240214monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-enrollment-of-the-100-th-patient-in-the-ongoing-shield-ii-phase-3-trial--pypd-20240212monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-private-placement-for-16-million-in-gross-proceeds-financing-led-by-lead-pypd-20240104monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-provides-corporate-update-and-reports-third-quarter-2023-financial-results-total-o-pypd-20231108monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-the-addition-of-dr-nurit-tweezer-zaks-to-its-board-of-directors-biopharm-pypd-20231107monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-regains-compliance-with-nasdaq-minimum-closing-bid-price-rule-pypd-20231011monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-ltd-amended-and-restated-2012-share-option-plan-1-definitions-as-used-herein-capit-pypd-20231010monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-reverse-share-split-pypd-20230920monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-ltd-notice-of-extraordinary-general-meeting-of-shareholders-to-be-held-on-october--pypd-20230901monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-ltd-and-its-subsidiaries-interim-condensed-consolidated-financial-statements-as-of-pypd-20230809monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-provides-corporate-update-and-reports-second-quarter-2023-financial-results-reache-pypd-20230809monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-recruitment-of-first-patient-in-revised-shield-ii-phase-3-trial-evaluati-pypd-20230622monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-180-day-extension-to-regain-compliance-with-nasdaq-minimum-bid-requireme-pypd-20230606monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-fda-agreement-on-the-design-of-shield-ii-phase-3-trial-evaluating-d-plex-pypd-20230522monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-provides-corporate-update-and-reports-first-quarter-2023-financial-results-submitt-pypd-20230510monthly0.5https://www.biopharmawatch.com/news/PYPD/articles-of-association-of-polypid-ltd-as-amended-and-restated-on-pypd-20230505monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-receipt-of-nasdaq-notification-of-minimum-stockholders-equity-non-compli-pypd-20230414monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-proposed-underwritten-public-offering-of-ordinary-shares-pypd-20230328monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-ltd-notice-of-annual-and-extraordinary-general-meeting-of-shareholders-to-be-held--pypd-20230331monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2022-financial--pypd-20230208monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-provides-positive-regulatory-update-for-d-plex-for-the-prevention-of-surgical-site-pypd-20230124monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-publication-in-the-american-journal-of-surgery-of-phase-2-clinical-trial-pypd-20230103monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-scheduling-of-type-d-meeting-with-u-s-fda-to-discuss-shield-i-phase-3-re-pypd-20221212monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-receipt-of-nasdaq-minimum-bid-price-notification-petach-tikva-israel-dec-pypd-20221209monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-provides-corporate-update-and-reports-third-quarter-2022-financial-results-company-pypd-20221109monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-cost-reduction-plan-reduction-of-approximately-20-in-organization-headco-pypd-20221020monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-eligibility-for-european-medicines-agency-centralized-procedure-for-d-pl-pypd-20220928monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-top-line-results-of-phase-3-shield-i-trial-of-d-plex-for-the-prevention--pypd-20220902monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-ltd-amended-and-restated-2012-share-option-plan-1-definitions-as-used-herein-capit-pypd-20220810monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-ltd-and-its-subsidiaries-interim-condensed-consolidated-financial-statements-as-of-pypd-20220810monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-provides-corporate-update-and-reports-second-quarter-2022-financial-results-signed-pypd-20220810monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-exclusive-licensing-agreement-with-advanz-pharma-for-the-commercializati-pypd-20220803monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-dikla-czaczkes-akselbrad-assumes-role-of-ceo-company-previously-announce-pypd-20220705monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-completion-of-enrollment-in-phase-3-shield-i-trial-of-d-plex-100-for-pre-pypd-20220531monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-recommendation-by-data-safety-monitoring-board-to-conclude-enrollment-of-pypd-20220523monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-provides-corporate-update-and-reports-first-quarter-2022-financial-results-planned-pypd-20220511monthly0.5https://www.biopharmawatch.com/news/PYPD/articles-of-association-of-polypid-ltd-as-amended-and-restated-on-pypd-20220503monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-secures-15-million-non-dilutive-secured-term-loan-facility-secured-loan-facility-w-pypd-20220406monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-ltd-notice-of-annual-and-extraordinary-general-meeting-of-shareholders-to-be-held--pypd-20220328monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-750-th-patient-enrolled-in-shield-i-phase-3-clinical-trial-of-d-plex-100-pypd-20220302monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2021-financial--pypd-20220209monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-planned-ceo-transition-current-evp-cfo-dikla-czaczkes-akselbrad-appointe-pypd-20220103monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-500-th-patient-enrolled-in-shield-i-phase-3-clinical-trial-of-d-plex-100-pypd-20211118monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-ltd-reports-third-quarter-2021-financial-results-and-provides-corporate-update-rec-pypd-20211110monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-positive-preclinical-data-of-its-intra-tumoral-oncoplex-in-brain-cancer--pypd-20210913monthly0.5https://www.biopharmawatch.com/news/PYPD/true-12-31-q2-2021-2021-06-30-6-k-a-0001611842-001-38428-polypid-ltd-0001611842-2021-01-01-pypd-20210830monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-ltd-and-its-subsidiary-interim-condensed-consolidated-financial-statements-as-of-j-pypd-20210811monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-ltd-reports-second-quarter-2021-financial-results-and-provides-corporate-update-re-pypd-20210811monthly0.5https://www.biopharmawatch.com/news/PYPD/this-presentation-of-polypid-ltd-the-company-contains-forward-looking-statements-within-th-pypd-20210702monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-positive-fda-type-b-meeting-feedback-for-d-plex-100-development-program--pypd-20210519monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-ltd-reports-first-quarter-2021-financial-results-and-provides-corporate-update-rec-pypd-20210512monthly0.5https://www.biopharmawatch.com/news/PYPD/compensation-policy-polypid-ltd-the-company-compensation-policy-for-executive-officers-and-pypd-20210413monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-ltd-notice-of-annual-general-meeting-of-shareholders-notice-is-hereby-given-that-a-pypd-20210305monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-100-th-patient-enrolled-in-shield-i-phase-3-clinical-trial-of-d-plex-100-pypd-20210216monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-ltd-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2020-financ-pypd-20210210monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-announces-positive-preclinical-data-from-oncoplex-intra-tumoral-cancer-therapy-pro-pypd-20201222monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-initiates-shield-ii-second-phase-3-clinical-trial-of-d-plex-100-for-the-prevention-pypd-20201216monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-granted-breakthrough-therapy-designation-from-fda-for-d-plex-100-for-the-preventio-pypd-20201124monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-ltd-provides-corporate-update-and-reports-third-quarter-2020-financial-results-ove-pypd-20201112monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-ltd-provides-corporate-update-and-reports-second-quarter-2020-financial-results-in-pypd-20200819monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-granted-fast-track-designation-from-fda-for-d-plex-100-for-prevention-of-surgical--pypd-20200803monthly0.5https://www.biopharmawatch.com/news/PYPD/polypid-ltd-announces-closing-of-initial-public-offering-and-full-exercise-of-underwriters-pypd-20200630monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-announces-5-0-million-registered-direct-offering-nrxs-20250521monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-inc-announces-strong-preliminary-unaudited-fourth-quarter-2024-results-revenues-i-nrxs-20250108monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-reports-strong-third-quarter-2024-financial-results-driven-by-a-40-increase-in-re-nrxs-20241112monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-reports-second-quarter-2024-financial-results-conference-call-will-be-held-today--nrxs-20240809monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-reports-fourth-quarter-and-fiscal-year-2023-financial-results-carmel-ind-nrxs-20240409monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-appoints-timothy-henrichs-as-chief-financial-officer-nrxs-20240131monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-secures-3-million-financing-carmel-ind-nrxs-20231114monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-reports-second-quarter-2023-financial-results-carmel-ind-nrxs-20230921monthly0.5https://www.biopharmawatch.com/news/NRXS/neuraxis-announces-pricing-of-initial-public-offering-carmel-in-nrxs-20230809monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-reports-first-quarter-2026-results-and-provides-business-update-completed-crdf-20260514monthly0.5https://www.biopharmawatch.com/news/CRDF/february-2026-company-overview-the-onvansertib-opportunity-forward-looking-statements-cert-crdf-20260225monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-reports-second-quarter-2025-results-and-provides-business-update-appointe-crdf-20250729monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-reports-first-quarter-2025-results-and-provides-business-update-completed-crdf-20250508monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-reports-fourth-quarter-and-full-year-2024-results-and-provides-business-u-crdf-20250227monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-prices-oversubscribed-40-million-underwritten-registered-direct-offering-crdf-20241210monthly0.5https://www.biopharmawatch.com/news/CRDF/december-10-2024-crdf-004-trial-1st-line-ras-mutated-mcrc-initial-data-release-forward-loo-crdf-20241210monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-reports-third-quarter-2024-results-and-provides-business-update-published-crdf-20241107monthly0.5https://www.biopharmawatch.com/news/CRDF/au-gu-st-7-2-0-2-3-mcrc-program-update-and-clinical-development-plan-pfizer-we-expect-clin-crdf-20230807monthly0.5https://www.biopharmawatch.com/news/CRDF/document-cardiff-oncology-announces-proposed-public-offering-san-diego-crdf-20200929monthly0.5https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-enters-agreement-with-poc-capital-to-fund-phase-2-clinical-trial-of-onvan-crdf-20200513monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-5-0-million-private-placement-priced-at-the-market-san-diego-crdf-20191025monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-successful-completion-of-phase-1b-trial-of-onvansertib-in-acute-myeloi-crdf-20190919monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-to-present-at-the-h-c-crdf-20190903monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-presents-positive-clinical-data-from-ongoing-phase-2-study-of-onvansertib-in-met-crdf-20190826monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-to-present-new-data-from-onvansertib-phase-2-study-in-metastatic-castration-resi-crdf-20190815monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-second-quarter-2019-results-and-highlights-crdf-20190808monthly0.5https://www.biopharmawatch.com/news/CRDF/esmo-accepts-trovagene-aml-clinical-trial-abstract-for-oral-presentation-acute-myeloid-leu-crdf-20190722monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-commences-non-deal-investor-roadshow-management-team-to-meet-with-investment-ins-crdf-20190715monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-initiation-of-enrollment-for-phase-1b-2-clinical-trial-in-kras-mutated-crdf-20190709monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-company-update-conference-call-script-friday-crdf-20190607monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-to-host-business-update-conference-call-on-crdf-20190531monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-research-collaboration-with-nektar-therapeutics-to-evaluate-efficacy-o-crdf-20190523monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-equity-investment-of-1-5-million-at-premium-to-market-price-from-insti-crdf-20190513monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-first-quarter-2019-results-and-highlights-crdf-20190507monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-data-demonstrating-significant-synergy-of-onvansertib-in-combination-w-crdf-20190423monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-1-5-million-equity-investment-at-premium-to-market-from-institutional--crdf-20190405monthly0.5https://www.biopharmawatch.com/news/CRDF/early-data-from-phase-2-trial-indicates-activity-of-onvansertib-in-prostate-cancer-patient-crdf-20190402monthly0.5https://www.biopharmawatch.com/news/CRDF/phase-1b-2-dose-escalation-trial-of-onvansertib-in-relapsed-refractory-aml-demonstrates-sa-crdf-20190401monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-receives-approximately-3-0-million-from-exercise-of-warrants-crdf-20190313monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-regains-compliance-with-nasdaq-listing-requirements-crdf-20190312monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-fourth-quarter-and-full-year-2018-results-crdf-20190306monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-to-present-data-from-lead-clinical-programs-of-onvansertib-in-aml-and-mcrpc-at-t-crdf-20190228monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-inc-announces-reverse-stock-split-reverse-stock-split-intended-to-bring-company--crdf-20190219monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-presents-update-on-phase-2-study-of-onvansertib-in-combination-with-zytiga-in-pa-crdf-20190214monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-and-poc-capital-enter-agreement-to-fund-clinical-development-of-onvansertib-in-m-crdf-20190129monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-new-patent-issued-for-combination-of-onvansertib-with-anti-androgen-dr-crdf-20190123monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-adjournment-of-special-meeting-of-stockholders-until-crdf-20190115monthly0.5https://www.biopharmawatch.com/news/CRDF/new-data-from-phase-1b-2-study-of-onvansertib-in-combination-with-ldac-or-decitabine-demon-crdf-20181203monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-inc-receives-positive-nasdaq-listing-decision-crdf-20181115monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-launch-of-new-company-website-new-website-offers-visitors-greater-insi-crdf-20181113monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-third-quarter-2018-highlights-and-financial-results-crdf-20181107monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-to-present-data-from-lead-clinical-program-of-onvansertib-in-acute-myeloid-leuke-crdf-20181101monthly0.5https://www.biopharmawatch.com/news/CRDF/licensed-drug-candidate-from-nms-onvansertib-polo-like-kinase-1-plk1-inhibitor-largest-onc-crdf-20181024monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-to-provide-update-on-onvansertib-clinical-development-program-on-wednesday-crdf-20181018monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-exclusive-license-agreement-with-mit-for-combination-therapy-of-anti-a-crdf-20181003monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-completion-of-dosing-cohort-of-patients-treated-with-onvansertib-in-co-crdf-20180927monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-participation-at-the-microcap-conference-on-october-1-st-and-2-nd-at-t-crdf-20180918monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-predictive-clinical-biomarker-approach-to-identify-acute-myeloid-leuke-crdf-20180905monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-european-commission-grants-orphan-drug-designation-to-onvansertib-pcm--crdf-20180829monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-completion-of-second-dosing-cohort-of-patients-treated-with-onvanserti-crdf-20180816monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-receives-usan-approval-for-onvansertib-as-nonproprietary-name-for-first-in-class-crdf-20180815monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-second-quarter-2018-highlights-and-financial-results-crdf-20180803monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-receives-positive-opinion-for-orphan-drug-designation-in-the-european-union-for--crdf-20180801monthly0.5https://www.biopharmawatch.com/news/CRDF/forward-looking-statements-certain-statements-in-this-presentation-are-forward-looking-wit-crdf-20180717monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-presents-outlook-for-second-half-of-2018-crdf-20180709monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-preliminary-clinical-data-from-first-dosing-cohort-demonstrating-durab-crdf-20180627monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-leadership-change-william-welch-has-resigned-as-ceo-and-director-dr-th-crdf-20180622monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-the-start-of-recruitment-and-enrollment-for-phase-2-clinical-trial-of--crdf-20180621monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-completion-of-first-dosing-cohort-of-patients-treated-with-pcm-075-in--crdf-20180615monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-inc-announces-closing-of-18-million-public-offering-crdf-20180612monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-inc-announces-reverse-stock-split-san-diego-may-31-2018-trovagene-inc-nasdaq-tro-crdf-20180601monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-completion-of-first-dosing-cohort-of-patients-in-ongoing-phase-1b-2-tr-crdf-20180517monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-first-quarter-2018-highlights-and-financial-results-crdf-20180508monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-presents-data-at-aacr-meeting-2018-on-pharmacodynamic-and-tumor-biomarkers-durin-crdf-20180417monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-presents-data-at-aacr-meeting-2018-showing-synergy-of-pcm-075-in-combination-wit-crdf-20180416monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-presentations-at-the-american-association-for-cancer-research-aacr-ann-crdf-20180413monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-to-present-at-the-26-th-annual-wall-street-investor-conference-crdf-20180320monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-first-patient-successfully-completes-cycle-1-of-treatment-with-pcm-075-crdf-20180305monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-fourth-quarter-and-full-year-2017-results-crdf-20180226monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-activation-of-two-additional-clinical-trial-sites-to-conduct-its-phase-crdf-20180213monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-presents-data-showing-synergy-of-pcm-075-in-combination-with-zytiga-in-castratio-crdf-20180209monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-completion-of-cycle-one-dosing-in-first-patient-enrolled-in-its-phase--crdf-20180206monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-initiation-of-unite-phase-2-clinical-trial-of-pcm-075-in-patients-with-crdf-20180124monthly0.5https://www.biopharmawatch.com/news/CRDF/forward-looking-statements-certain-statements-in-this-presentation-are-forward-looking-wit-crdf-20180108monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-to-present-at-the-biotech-showcase-annual-conference-crdf-20180103monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-activation-of-second-clinical-trial-site-in-phase-1b-2-acute-myeloid-l-crdf-20171221monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-prices-4-5-million-public-offering-crdf-20171215monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-submits-protocol-to-fda-for-phase-2-clinical-trial-of-pcm-075-in-combination-wit-crdf-20171214monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-the-launch-of-nextcollect-urine-collection-and-dna-preservation-kit-to-crdf-20171212monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-presents-data-showing-sensitivity-of-triple-negative-breast-cancer-tnbc-cell-lin-crdf-20171207monthly0.5https://www.biopharmawatch.com/news/CRDF/transforming-oncology-with-precision-cancer-therapeutics-company-overview-november-2017-co-crdf-20171128monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-activation-of-first-clinical-trial-site-in-phase-1b-2-acute-myeloid-le-crdf-20171113monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-third-quarter-2017-company-highlights-and-financial-results-crdf-20171109monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-s-plk1-inhibitor-pcm-075-demonstrates-synergy-with-zytiga-abiraterone-acetate-in-crdf-20171018monthly0.5https://www.biopharmawatch.com/news/CRDF/fda-grants-orphan-drug-designation-to-trovagene-s-plk1-inhibitor-pcm-075-for-the-treatment-crdf-20171009monthly0.5https://www.biopharmawatch.com/news/CRDF/transforming-oncology-with-precision-cancer-therapeutics-company-overview-september-2017-c-crdf-20170921monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-strengthens-board-of-directors-with-appointment-of-oncology-development-veteran--crdf-20170920monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-participation-at-the-19-th-annual-rodman-renshaw-global-investment-con-crdf-20170831monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-s-plk1-inhibitor-pcm-075-demonstrates-synergy-with-a-hdac-inhibitor-in-non-hodgk-crdf-20170821monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-s-plk1-inhibitor-pcm-075-in-preclinical-aml-data-significantly-enhances-the-effi-crdf-20170816monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-second-quarter-2017-company-highlights-and-financial-results-crdf-20170809monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-antonius-schuh-and-stephen-zaniboni-resolve-employment-dispute-crdf-20170728monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-fda-approval-of-ind-for-phase-1b-2-trial-of-pcm-075-in-patients-with-a-crdf-20170727monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-peer-reviewed-publication-of-first-in-human-phase-1-trial-results-with-crdf-20170725monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-7-1-million-registered-direct-offering-crdf-20170714monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-agreement-with-novogene-for-nextcollect-in-china-crdf-20170712monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-inc-regains-compliance-with-nasdaq-listing-requirements-crdf-20170710monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-engages-cro-to-conduct-phase-1b-2-trial-of-pcm-075-in-crdf-20170706monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-manufacturing-agreement-with-nerpharma-for-supply-of-pcm-075-for-aml-t-crdf-20170629monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-submission-of-investigational-new-drug-application-to-initiate-phase-1-crdf-20170627monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-expansion-of-key-claims-for-its-npm1-patent-portfolio-for-acute-myeloi-crdf-20170626monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-agreement-with-global-biopharmaceutical-company-to-utilize-trovera-ctd-crdf-20170622monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-enters-into-agreement-with-astrazeneca-to-utilize-trovera-ctdna-test-and-service-crdf-20170612monthly0.5https://www.biopharmawatch.com/news/CRDF/phase-1-safety-study-supports-planned-development-of-pcm-075-in-aml-study-evaluated-safety-crdf-20170525monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-to-present-at-the-7th-annual-ld-micro-invitational-conference-on-crdf-20170523monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-first-quarter-2017-company-highlights-and-financial-results-crdf-20170510monthly0.5https://www.biopharmawatch.com/news/CRDF/transforming-oncology-with-precision-cancer-therapeutics-company-overview-may-2017-company-crdf-20170501monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-to-announce-first-quarter-2017-financial-results-and-host-conference-call-on-wed-crdf-20170426monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-to-present-at-the-pioneers-2017-joseph-gunnar-conference-on-crdf-20170425monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-the-addition-of-dr-sandra-silberman-to-its-clinical-advisory-board-crdf-20170413monthly0.5https://www.biopharmawatch.com/news/CRDF/transforming-oncology-with-precision-cancer-therapeutics-company-overview-march-2017-compa-crdf-20170328monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-to-present-at-the-microcap-conference-on-crdf-20170327monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-to-present-at-the-sidoti-company-spring-2017-convention-crdf-20170321monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-reports-fourth-quarter-and-year-end-2016-financial-results-announces-restructuri-crdf-20170315monthly0.5https://www.biopharmawatch.com/news/CRDF/trovera-tm-egfr-urine-liquid-biopsy-test-predictive-of-clinical-response-to-therapy-case-s-crdf-20170307monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-to-announce-fourth-quarter-and-year-end-2016-financial-results-and-accomplishmen-crdf-20170302monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-to-attend-the-29th-annual-roth-conference-crdf-20170228monthly0.5https://www.biopharmawatch.com/news/CRDF/publication-of-trovera-kras-liquid-biopsy-test-demonstrates-clinical-utility-in-advanced-c-crdf-20170124monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-broadening-network-of-commercial-distributors-seven-new-partners-to-co-crdf-20170112monthly0.5https://www.biopharmawatch.com/news/CRDF/transforming-oncology-with-precision-medicine-solutions-company-overview-january-2017-forw-crdf-20170109monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-a-reorganization-to-accelerate-global-distribution-of-liquid-biopsy-te-crdf-20161213monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-and-boreal-genomics-announce-strategic-partnership-companies-to-develop-and-comm-crdf-20161130monthly0.5https://www.biopharmawatch.com/news/CRDF/world-lung-conference-features-data-demonstrating-clinical-utility-and-cost-effectiveness--crdf-20161128monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-to-attend-the-28th-annual-piper-jaffray-healthcare-conference-crdf-20161122monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-reports-third-quarter-2016-financial-results-and-accomplishments-crdf-20161109monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-hpv-patent-issuance-by-u-s-patent-and-trademark-office-broadening-its--crdf-20161107monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-schedules-release-of-third-quarter-2016-financial-results-and-investor-conferenc-crdf-20161102monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-s-liquid-biopsy-in-ground-breaking-national-initiative-to-transform-outcomes-for-crdf-20161004monthly0.5https://www.biopharmawatch.com/news/CRDF/overview-forward-looking-statements-statements-in-this-presentation-about-the-company-s-ex-crdf-20160926monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-to-present-at-the-3rd-annual-precision-medicine-congress-crdf-20160909monthly0.5https://www.biopharmawatch.com/news/CRDF/blue-cross-blue-shield-illinois-to-cover-trovera-liquid-biopsy-tests-bcbs-illinois-expands-crdf-20160817monthly0.5https://www.biopharmawatch.com/news/CRDF/trovera-urine-liquid-biopsy-test-provides-egfr-status-to-inconclusive-tissue-biopsy-case-r-crdf-20160809monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-reports-second-quarter-2016-financial-results-and-accomplishments-crdf-20160804monthly0.5https://www.biopharmawatch.com/news/CRDF/diagnostic-performance-of-urinary-egfr-testing-in-lung-cancer-patients-published-in-journa-crdf-20160726monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-and-usc-norris-comprehensive-cancer-center-collaborate-to-standardize-the-use-of-crdf-20160712monthly0.5https://www.biopharmawatch.com/news/CRDF/overview-forward-looking-statements-statements-in-this-presentation-about-the-company-s-ex-crdf-20160711monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-and-university-of-michigan-enter-into-collaboration-for-monitoring-and-early-det-crdf-20160706monthly0.5https://www.biopharmawatch.com/news/CRDF/asco-oral-presentation-demonstrates-trovagene-s-liquid-biopsy-urine-test-detects-egfr-t790-crdf-20160606monthly0.5https://www.biopharmawatch.com/news/CRDF/large-clinical-data-set-in-lung-cancer-featuring-trovagene-s-precision-cancer-monitoring-p-crdf-20160519monthly0.5https://www.biopharmawatch.com/news/CRDF/large-clinical-study-demonstrates-high-detection-rate-and-ability-to-monitor-kras-mutation-crdf-20160513monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-first-quarter-2016-financial-results-crdf-20160510monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-appoints-bill-welch-as-chief-executive-officer-crdf-20160425monthly0.5https://www.biopharmawatch.com/news/CRDF/patient-case-report-demonstrating-the-ability-of-trovagene-s-precision-cancer-monitoring-p-crdf-20160415monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-enters-into-preferred-provider-agreement-with-stratose-ppo-network-crdf-20160411monthly0.5https://www.biopharmawatch.com/news/CRDF/clinical-data-featuring-trovagene-s-precision-cancer-monitoring-platform-to-be-presented-a-crdf-20160407monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-terminates-the-employment-of-ceo-antonius-schuh-and-cfo-stephen-zaniboni-for-cau-crdf-20160328monthly0.5https://www.biopharmawatch.com/news/CRDF/clinical-study-results-featuring-trovagene-s-precision-cancer-monitoring-platform-to-be-pr-crdf-20160324monthly0.5https://www.biopharmawatch.com/news/CRDF/c-o-r-r-e-c-t-i-o-n-trovagene-inc-in-the-news-release-trovagene-announces-fourth-quarter-a-crdf-20160311monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-fourth-quarter-and-year-end-2015-financial-results-crdf-20160310monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-enters-into-preferred-provider-agreement-with-multiplan-inc-agreement-expands-in-crdf-20160301monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-schedules-release-of-fourth-quarter-and-year-end-2015-financial-results-and-inve-crdf-20160229monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-enters-into-preferred-provider-agreement-with-three-rivers-provider-network-crdf-20160224monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-enters-into-preferred-provider-agreement-with-fortified-provider-network-crdf-20160222monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-to-present-at-leerink-partners-5th-annual-global-healthcare-conference-crdf-20160208monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-enters-into-agreement-with-fedmed-inc-and-significantly-expands-patient-access-t-crdf-20160201monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-agreement-with-america-s-choice-provider-network-to-offer-patients-acc-crdf-20160121monthly0.5https://www.biopharmawatch.com/news/CRDF/january-2016-better-cancer-monitoring-with-cell-free-dna-forward-looking-statements-statem-crdf-20160113monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-dna-november-2015-better-cancer-monitoring-with-cell-free-forward-looking-statem-crdf-20160111monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-patent-issuance-broadening-its-precision-cancer-monitoring-ip-portfoli-crdf-20151216monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-to-present-at-27-th-annual-piper-jaffray-healthcare-conference-and-attend-everco-crdf-20151125monthly0.5https://www.biopharmawatch.com/news/CRDF/november-2015-better-cancer-monitoring-with-cell-free-dna-forward-looking-statements-state-crdf-20151116monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-inc-announces-third-quarter-2015-financial-results-crdf-20151109monthly0.5https://www.biopharmawatch.com/news/CRDF/clinical-data-featuring-trovagene-s-precision-cancer-monitoring-platform-to-be-presented-a-crdf-20151106monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-s-urine-based-liquid-biopsy-platform-shows-clinical-sensitivity-of-93-percent-in-crdf-20151027monthly0.5https://www.biopharmawatch.com/news/CRDF/clinical-data-for-trovagene-s-precision-cancer-monitoring-platform-presented-at-the-europe-crdf-20150924monthly0.5https://www.biopharmawatch.com/news/CRDF/results-from-second-large-scale-clinical-trial-for-trovagene-s-urine-based-hpv-test-releas-crdf-20150921monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-forms-european-institute-with-alberto-bardelli-ph-d-core-technologies-transferre-crdf-20150910monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-s-urine-based-liquid-biopsy-platform-shown-to-detect-impact-of-cancer-therapy-wi-crdf-20150909monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-to-present-clinical-data-and-capabilities-of-its-urine-based-liquid-biopsy-platf-crdf-20150818monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-inc-announces-second-quarter-2015-financial-results-crdf-20150810monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-inc-announces-closing-of-public-offering-of-common-stock-san-diego-ca-crdf-20150722monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-inc-announces-pricing-of-public-offering-of-common-stock-crdf-20150717monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-inc-announces-public-offering-of-common-stock-crdf-20150716monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-initiates-study-to-monitor-response-to-immunotherapy-in-melanoma-patients-using--crdf-20150708monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-inc-to-present-at-cantor-fitzgerald-s-inaugural-healthcare-conference-crdf-20150707monthly0.5https://www.biopharmawatch.com/news/CRDF/july-2015-better-cancer-monitoring-with-cell-free-dna-forward-looking-statements-statement-crdf-20150706monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-upgraded-to-russell-3000-small-cap-and-global-indexes-crdf-20150629monthly0.5https://www.biopharmawatch.com/news/CRDF/clinical-data-featuring-trovagene-s-urine-based-liquid-biopsy-platform-to-be-presented-at--crdf-20150608monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-launches-commercial-marketing-campaign-at-the-2015-american-society-of-clinical--crdf-20150528monthly0.5https://www.biopharmawatch.com/news/CRDF/may-2015-better-cancer-monitoring-with-cell-free-dna-forward-looking-statements-statements-crdf-20150519monthly0.5https://www.biopharmawatch.com/news/CRDF/clinical-utility-of-trovagene-s-urine-based-liquid-biopsy-platform-to-be-highlighted-at-th-crdf-20150513monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-inc-announces-first-quarter-2015-financial-results-company-moves-three-egfr-muta-crdf-20150505monthly0.5https://www.biopharmawatch.com/news/CRDF/cost-benefit-analysis-of-trovagene-s-precision-cancer-monitoring-solution-to-be-presented--crdf-20150504monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-schedules-release-of-first-quarter-2015-financial-results-and-investor-conferenc-crdf-20150428monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-s-urine-based-hpv-assay-to-be-featured-in-presentation-at-the-13-th-annual-cervi-crdf-20150423monthly0.5https://www.biopharmawatch.com/news/CRDF/poster-presentations-at-2015-aacr-annual-meeting-to-highlight-clinical-utilities-and-advan-crdf-20150420monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-s-urinary-ctdna-assay-outperforms-tissue-biopsy-in-clinical-study-for-the-detect-crdf-20150417monthly0.5https://www.biopharmawatch.com/news/CRDF/matthew-posard-joins-trovagene-s-executive-management-team-as-chief-commercial-officer-ind-crdf-20150318monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-inc-reports-fourth-quarter-and-full-year-2014-financial-results-advancing-its-pr-crdf-20150312monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-inc-to-present-at-leerink-global-healthcare-conference-crdf-20150210monthly0.5https://www.biopharmawatch.com/news/CRDF/clinical-results-demonstrate-high-sensitivity-of-trovagene-s-urine-based-hpv-assay-for-the-crdf-20150209monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-inc-announces-pricing-of-public-offering-of-common-stock-crdf-20150206monthly0.5https://www.biopharmawatch.com/news/CRDF/better-cancer-monitoring-with-cell-free-dna-february-2015-forward-looking-statements-state-crdf-20150205monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-s-chief-scientific-officer-to-present-precision-cancer-monitoring-sm-platform-ov-crdf-20150126monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-expands-collaboration-with-genomac-to-demonstrate-clinical-utility-in-lung-and-c-crdf-20150121monthly0.5https://www.biopharmawatch.com/news/CRDF/clinical-study-results-presented-at-the-2015-gastrointestinal-cancer-symposium-support-uti-crdf-20150120monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-collaborates-with-uc-san-diego-moores-cancer-center-to-demonstrate-clinical-util-crdf-20150112monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-and-city-of-hope-collaborate-to-monitor-egfr-mutational-status-in-lung-cancer-pa-crdf-20150108monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-to-present-at-the-7-th-annual-biotech-showcase-conference-crdf-20150107monthly0.5https://www.biopharmawatch.com/news/CRDF/former-president-of-bio-joins-trovagene-s-board-of-directors-crdf-20150106monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-presentation-of-clinical-data-at-the-56-th-annual-american-society-of--crdf-20141204monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-releases-clinical-study-results-for-the-detection-and-monitoring-of-kras-mutatio-crdf-20141120monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-inc-announces-third-quarter-2014-financial-results-crdf-20141106monthly0.5https://www.biopharmawatch.com/news/CRDF/better-cancer-monitoring-with-cell-free-dna-october-2014-forward-looking-statements-statem-crdf-20141003monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-provides-update-on-its-urine-based-hpv-test-crdf-20140820monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-inc-announces-second-quarter-2014-financial-results-crdf-20140807monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-secures-15-million-in-debt-financing-from-silicon-valley-bank-and-oxford-finance-crdf-20140701monthly0.5https://www.biopharmawatch.com/news/CRDF/stephen-zaniboni-chief-financial-officer-jefferies-2014-global-healthcare-conference-crdf-20140602monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-s-precision-cancer-monitoring-technology-referenced-in-multi-disciplinary-clinic-crdf-20140528monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-publication-of-data-from-clinical-validation-program-using-its-precisi-crdf-20140520monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-inc-announces-first-quarter-2014-financial-results-crdf-20140512monthly0.5https://www.biopharmawatch.com/news/CRDF/antonius-schuh-ph-d-chief-executive-officer-april-2014-better-cancer-monitoring-with-cell--crdf-20140414monthly0.5https://www.biopharmawatch.com/news/CRDF/clinical-data-presented-at-aacr-demonstrate-ability-of-trovagene-s-molecular-diagnostic-pl-crdf-20140408monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-inc-reports-fourth-quarter-and-full-year-2013-financial-results-expanding-cancer-crdf-20140317monthly0.5https://www.biopharmawatch.com/news/CRDF/dr-rodney-s-markin-joins-trovagene-s-board-of-directors-crdf-20140219monthly0.5https://www.biopharmawatch.com/news/CRDF/antonius-schuh-ph-d-chief-executive-officer-february-2014-better-cancer-monitoring-with-ce-crdf-20140211monthly0.5https://www.biopharmawatch.com/news/CRDF/better-cancer-monitoring-with-cell-free-dna-in-urine-antonius-schuh-ph-d-chief-executive-o-crdf-20140113monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-and-us-oncology-research-collaborate-on-a-prospective-study-for-urine-based-kras-crdf-20140106monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-inc-reports-third-quarter-2013-financial-results-first-clinical-results-presente-crdf-20131114monthly0.5https://www.biopharmawatch.com/news/CRDF/dr-paul-billings-joins-trovagene-s-board-of-directors-crdf-20131030monthly0.5https://www.biopharmawatch.com/news/CRDF/a-better-clinical-pathway-for-cancer-monitoring-antonius-schuh-ph-d-chief-executive-office-crdf-20131022monthly0.5https://www.biopharmawatch.com/news/CRDF/first-prospective-cancer-monitoring-data-released-indicating-that-oncogene-mutation-signal-crdf-20131021monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-collaborates-with-usc-in-a-clinical-study-evaluating-cancer-monitoring-technolog-crdf-20130906monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-inc-announces-second-quarter-2013-earnings-crdf-20130814monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-inc-announces-closing-of-15-million-registered-direct-offering-of-common-stock-crdf-20130731monthly0.5https://www.biopharmawatch.com/news/CRDF/raindrop-system-unlocks-power-of-trovagene-s-urine-based-mutation-detection-technology-dig-crdf-20130729monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-issuance-of-broad-microrna-patent-patent-covers-methods-of-detecting-c-crdf-20130724monthly0.5https://www.biopharmawatch.com/news/CRDF/a-better-clinical-pathway-for-cancer-monitoring-antonius-schuh-ph-d-chief-executive-office-crdf-20130723monthly0.5https://www.biopharmawatch.com/news/CRDF/urine-based-cancer-detection-technology-validated-trovagene-develops-ultra-sensitive-cell--crdf-20130722monthly0.5https://www.biopharmawatch.com/news/CRDF/a-better-clinical-pathway-for-cancer-monitoring-antonius-schuh-ph-d-chief-executive-office-crdf-20130626monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-inc-announces-first-quarter-2013-earnings-crdf-20130514monthly0.5https://www.biopharmawatch.com/news/CRDF/introduction-to-trovagene-inc-antonius-schuh-ph-d-chief-executive-officer-april-2013-forwa-crdf-20130422monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-inc-announces-fourth-quarter-and-year-end-2012-earnings-crdf-20130401monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-launches-urine-based-hpv-test-new-non-invasive-molecular-diagnostic-test-is-easy-crdf-20130327monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-appoints-mark-erlander-ph-d-as-chief-scientific-officer-crdf-20130304monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-commercial-launch-timelines-for-hpv-carrier-and-oncogene-mutation-test-crdf-20130212monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-to-study-transrenal-braf-mutations-in-primary-and-metastatic-cancers-study-with--crdf-20130103monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-inc-grants-license-for-npm1-marker-for-acute-myelogenous-leukemia-to-leading-aca-crdf-20121227monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-inc-continues-to-expand-npm1-licensing-program-for-acute-myelogenous-leukemia-crdf-20121220monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-closing-of-private-placement-of-3-76-million-from-the-sale-of-restrict-crdf-20121121monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-inc-announces-third-quarter-and-year-to-date-earnings-provides-milestone-update-crdf-20121114monthly0.5https://www.biopharmawatch.com/news/CRDF/introduction-to-trovagene-inc-antonius-schuh-phd-chief-executive-officer-november-2012-for-crdf-20121106monthly0.5https://www.biopharmawatch.com/news/CRDF/introduction-to-trovagene-inc-antonius-schuh-phd-chief-executive-officer-august-2012-forwa-crdf-20120829monthly0.5https://www.biopharmawatch.com/news/CRDF/for-release-at-6-00-am-est-august-15-2012-trovagene-inc-announces-second-quarter-and-year--crdf-20120815monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-inc-announces-pricing-of-public-offering-of-1-150-000-units-listing-on-nasdaq-an-crdf-20120530monthly0.5https://www.biopharmawatch.com/news/CRDF/trovagene-announces-validation-program-for-trans-renal-k-ras-mutation-detection-in-pancrea-crdf-20120430monthly0.5https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-announces-peer-reviewed-publication-in-biomedicine-pharmacotherapy-telo-20260615monthly0.5https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-reports-peer-reviewed-publication-of-telomir-zn-data-demonstrating-telo-20260520monthly0.5https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-announces-pricing-of-initial-public-offering-baltimore-maryland-telo-20240208monthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-wins-u-k-approval-to-launch-phase-2-clinical-trial-of-lti-03-in-idiopath-rntx-20250819monthly0.5https://www.biopharmawatch.com/news/RNTX/aileron-therapeutics-reports-third-quarter-2024-financial-results-and-recent-business-high-rntx-20241114monthly0.5https://www.biopharmawatch.com/news/RNTX/aileron-therapeutics-reports-second-quarter-2024-financial-results-and-business-highlights-rntx-20240814monthly0.5https://www.biopharmawatch.com/news/RNTX/aileron-therapeutics-announces-pricing-of-underwritten-registered-direct-offering-priced-a-rntx-20240501monthly0.5https://www.biopharmawatch.com/news/RNTX/aileron-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-provi-rntx-20240415monthly0.5https://www.biopharmawatch.com/news/RNTX/aileron-therapeutics-announces-ceo-transition-current-president-and-chief-operating-office-rntx-20240312monthly0.5https://www.biopharmawatch.com/news/RNTX/aileron-therapeutics-announces-acquisition-of-lung-therapeutics-acquisition-includes-multi-rntx-20231031monthly0.5https://www.biopharmawatch.com/news/RNTX/aileron-therapeutics-inc-2021-stock-incentive-plan-1-purpose-the-purpose-of-this-2021-stoc-rntx-20210617monthly0.5https://www.biopharmawatch.com/news/RNTX/aileron-therapeutics-announces-35-9-million-registered-direct-offering-rntx-20210106monthly0.5https://www.biopharmawatch.com/news/RNTX/prevention-of-chemotherapy-induced-myelosuppression-in-sclc-patients-treated-with-the-dual-rntx-20201025monthly0.5https://www.biopharmawatch.com/news/RNTX/aileron-therapeutics-announces-common-stock-purchase-agreement-for-up-to-15-million-with-l-rntx-20200921monthly0.5https://www.biopharmawatch.com/news/RNTX/aileron-therapeutics-announces-pricing-of-public-offering-of-common-stock-rntx-20200604monthly0.5https://www.biopharmawatch.com/news/RNTX/alrn-6924-ongoing-ph1b-clinical-trial-in-small-cell-lung-cancer-patients-receiving-topotec-rntx-20200601monthly0.5https://www.biopharmawatch.com/news/RNTX/aileron-therapeutics-announces-management-change-watertown-mass-rntx-20190909monthly0.5https://www.biopharmawatch.com/news/RNTX/aileron-therapeutics-strengthens-board-of-directors-with-appointments-of-william-t-mckee-a-rntx-20190624monthly0.5https://www.biopharmawatch.com/news/RNTX/aileron-therapeutics-completes-26m-private-placement-satter-medical-technology-partners-le-rntx-20190403monthly0.5https://www.biopharmawatch.com/news/RNTX/aileron-therapeutics-announces-pricing-of-26m-private-placement-rntx-20190329monthly0.5https://www.biopharmawatch.com/news/RNTX/aileron-therapeutics-announces-the-appointment-of-dr-manuel-aivado-as-chief-executive-offi-rntx-20180906monthly0.5https://www.biopharmawatch.com/news/RNTX/aileron-therapeutics-announces-changes-to-management-cambridge-ma-rntx-20180515monthly0.5https://www.biopharmawatch.com/news/RNTX/aileron-therapeutics-appoints-jeffrey-a-bailey-to-its-board-of-directors-rntx-20180319monthly0.5https://www.biopharmawatch.com/news/SKIN/skinhealth-systems-reports-first-quarter-2026-financial-results-long-beach-calif-skin-20260507monthly0.5https://www.biopharmawatch.com/news/SKIN/document-the-beauty-health-company-announces-corporate-rebrand-to-skinhealth-systems-refle-skin-20260422monthly0.5https://www.biopharmawatch.com/news/SKIN/beautyhealth-reports-full-year-and-fourth-quarter-2025-financial-results-long-beach-calif-skin-20260312monthly0.5https://www.biopharmawatch.com/news/SKIN/beautyhealth-reports-third-quarter-2025-financial-results-long-beach-calif-skin-20251106monthly0.5https://www.biopharmawatch.com/news/SKIN/document-beautyhealth-appoints-philippe-schaison-pharmad-to-board-of-directors-global-aest-skin-20251103monthly0.5https://www.biopharmawatch.com/news/SKIN/document-the-beauty-health-company-names-pedro-malha-president-and-chief-executive-officer-skin-20250930monthly0.5https://www.biopharmawatch.com/news/SKIN/beautyhealth-reports-second-quarter-2025-financial-results-raises-guidance-on-strong-execu-skin-20250807monthly0.5https://www.biopharmawatch.com/news/SKIN/the-beautyhealth-company-announces-convertible-debt-refinancing-refinancing-extends-maturi-skin-20250521monthly0.5https://www.biopharmawatch.com/news/SKIN/beautyhealth-reports-first-quarter-2025-financial-results-long-beach-calif-skin-20250508monthly0.5https://www.biopharmawatch.com/news/SKIN/beautyhealth-reports-full-year-and-fourth-quarter-2024-financial-results-delivers-fourth-q-skin-20250312monthly0.5https://www.biopharmawatch.com/news/SKIN/document-the-beauty-health-company-strengthens-commercial-leadership-team-with-chief-reven-skin-20250228monthly0.5https://www.biopharmawatch.com/news/SKIN/document-beautyhealth-appoints-stephen-j-fanning-to-board-of-directors-medical-aesthetics--skin-20241217monthly0.5https://www.biopharmawatch.com/news/SKIN/beautyhealth-reports-third-quarter-2024-financial-results-delivers-third-quarter-net-sales-skin-20241112monthly0.5https://www.biopharmawatch.com/news/SKIN/beautyhealth-reports-second-quarter-2024-financial-results-delivers-second-quarter-net-sal-skin-20240808monthly0.5https://www.biopharmawatch.com/news/SKIN/beautyhealth-reports-first-quarter-2024-financial-results-delivers-first-quarter-net-sales-skin-20240509monthly0.5https://www.biopharmawatch.com/news/SKIN/beautyhealth-reports-full-year-and-fourth-quarter-2023-financial-results-delivers-net-sale-skin-20240312monthly0.5https://www.biopharmawatch.com/news/SKIN/document-beautyhealth-announces-appointment-of-marla-beck-as-chief-executive-officer-skin-20240312monthly0.5https://www.biopharmawatch.com/news/SKIN/beautyhealth-reports-third-quarter-2023-financial-results-revises-financial-guidance-on-lo-skin-20231113monthly0.5https://www.biopharmawatch.com/news/SKIN/pressrelease12sep2-beautyhealth-announces-business-transformation-program-to-drive-profita-skin-20230912monthly0.5https://www.biopharmawatch.com/news/SKIN/beautyhealth-reports-second-quarter-2023-financial-results-delivers-double-digit-net-sales-skin-20230809monthly0.5https://www.biopharmawatch.com/news/SKIN/document-beautyhealth-names-michael-monahan-chief-financial-officer-skin-20230809monthly0.5https://www.biopharmawatch.com/news/SKIN/beautyhealth-reports-first-quarter-2023-financial-results-on-strong-consumer-demand-delive-skin-20230510monthly0.5https://www.biopharmawatch.com/news/SKIN/maturing-into-a-multi-brand-ecosystem-beautyhealth-appoints-aesthetics-veteran-brad-hauser-skin-20230419monthly0.5https://www.biopharmawatch.com/news/SKIN/beautyhealth-reports-full-year-and-fourth-quarter-2022-financial-results-delivers-41-year--skin-20230228monthly0.5https://www.biopharmawatch.com/news/SKIN/beautyhealth-to-acquire-skinstylus-fda-cleared-microneedling-device-acquisition-is-a-strat-skin-20230228monthly0.5https://www.biopharmawatch.com/news/SKIN/beautyhealth-enters-into-100-million-accelerated-share-repurchase-agreement-long-beach-cal-skin-20221110monthly0.5https://www.biopharmawatch.com/news/SKIN/beautyhealth-reports-third-quarter-2022-financial-results-net-sales-beat-expectations-for--skin-20221108monthly0.5https://www.biopharmawatch.com/news/SKIN/beautyhealth-announces-200-million-share-repurchase-authorization-enters-into-100-million--skin-20220927monthly0.5https://www.biopharmawatch.com/news/SKIN/a-harbinger-of-beauty-industry-resiliency-beautyhealth-announces-three-year-plan-to-double-skin-20220915monthly0.5https://www.biopharmawatch.com/news/SKIN/beautyhealth-reports-record-second-quarter-2022-financial-results-all-time-high-quarterly--skin-20220809monthly0.5https://www.biopharmawatch.com/news/SKIN/beautyhealth-skin-20220606monthly0.5https://www.biopharmawatch.com/news/SKIN/the-beauty-health-company-reports-strong-first-quarter-2022-financial-results-increases-20-skin-20220510monthly0.5https://www.biopharmawatch.com/news/SKIN/the-beauty-health-company-introduces-new-digitally-connected-hydrafacial-syndeo-delivery-s-skin-20220307monthly0.5https://www.biopharmawatch.com/news/SKIN/the-beauty-health-company-reports-record-fourth-quarter-and-fiscal-year-2021-financial-res-skin-20220222monthly0.5https://www.biopharmawatch.com/news/SKIN/the-beauty-health-company-announces-appointment-of-andrew-stanleick-as-president-and-chief-skin-20220120monthly0.5https://www.biopharmawatch.com/news/SKIN/the-beauty-health-company-confirms-fiscal-2021-outlook-ahead-of-the-2022-icr-conference-ex-skin-20220110monthly0.5https://www.biopharmawatch.com/news/SKIN/the-beauty-health-company-reports-record-third-quarter-2021-financial-results-raises-full--skin-20211109monthly0.5https://www.biopharmawatch.com/news/SKIN/the-beauty-health-company-announces-the-results-of-the-completed-redemption-of-all-outstan-skin-20211108monthly0.5https://www.biopharmawatch.com/news/SKIN/the-beauty-health-company-reminds-investors-of-redemption-of-public-warrants-approximately-skin-20211018monthly0.5https://www.biopharmawatch.com/news/SKIN/the-beauty-health-company-announces-redemption-of-all-outstanding-warrants-long-beach-cali-skin-20211004monthly0.5https://www.biopharmawatch.com/news/SKIN/the-beauty-health-company-prices-upsized-650-million-convertible-senior-notes-offering-lon-skin-20210909monthly0.5https://www.biopharmawatch.com/news/SKIN/the-beauty-health-company-announces-proposed-convertible-senior-notes-offering-long-beach--skin-20210908monthly0.5https://www.biopharmawatch.com/news/SKIN/the-beauty-health-company-reports-record-second-quarter-2021-financial-results-raises-full-skin-20210810monthly0.5https://www.biopharmawatch.com/news/SKIN/hydrafacial-and-vesper-healthcare-announce-closing-of-business-combination-combined-compan-skin-20210505monthly0.5https://www.biopharmawatch.com/news/SKIN/hydrafacial-announces-record-first-quarter-fiscal-2021-preliminary-net-sales-first-quarter-skin-20210421monthly0.5https://www.biopharmawatch.com/news/SKIN/hydrafacial-a-beauty-health-company-announces-2020-preliminary-net-sales-on-track-to-compl-skin-20210222monthly0.5https://www.biopharmawatch.com/news/SKIN/hydrafacial-an-experiential-beauty-health-company-and-vesper-healthcare-announce-business--skin-20201209monthly0.5https://www.biopharmawatch.com/news/SKIN/vesper-healthcare-acquisition-corp-index-to-financial-statement-page-report-of-independent-skin-20201002monthly0.5https://www.biopharmawatch.com/news/SKIN/vesper-healthcare-acquisition-corp-announces-pricing-of-400-million-initial-public-offerin-skin-20200929monthly0.5https://www.biopharmawatch.com/news/EDSA/barda-selects-edesa-biotech-s-drug-for-u-s-funded-platform-trial-in-general-ards-this-phas-edsa-20240624monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-reports-fiscal-2nd-quarter-2024-results-toronto-on-accesswire-edsa-20240510monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-reports-fiscal-1st-quarter-2024-results-toronto-on-accesswire-edsa-20240209monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-reports-fiscal-year-2023-results-toronto-on-accesswire-edsa-20231215monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-to-receive-up-to-c-23-million-in-funding-from-federal-government-toronto-on--edsa-20231012monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-announces-one-for-seven-reverse-share-split-toronto-on-accesswire-edsa-20231010monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-reports-fiscal-third-quarter-2023-results-toronto-on-accesswire-edsa-20230809monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-appoints-biotech-deal-veteran-to-cfo-role-toronto-on-accesswire-edsa-20230627monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-reports-fiscal-2nd-quarter-2023-results-toronto-on-accesswire-edsa-20230511monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-reports-fiscal-1st-quarter-2023-results-toronto-on-accesswire-edsa-20230210monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-reports-fiscal-year-2022-results-toronto-on-accesswire-edsa-20221216monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-announces-closing-of-3-0-million-private-placement-priced-at-the-market-toro-edsa-20221103monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-reports-fiscal-3rd-quarter-2022-results-phase-3-ards-drug-study-in-hospitali-edsa-20220812monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-reports-fiscal-2nd-quarter-2022-results-toronto-on-accesswire-edsa-20220513monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-announces-10-0-million-registered-direct-offering-priced-at-the-market-under-edsa-20220322monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-reports-fiscal-1st-quarter-2022-results-toronto-on-accesswire-edsa-20220214monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-reports-fiscal-year-2021-results-toronto-on-accesswire-edsa-20211228monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-reports-fiscal-3rd-quarter-2021-financial-results-toronto-on-accesswire-edsa-20210813monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-reports-fiscal-2nd-quarter-2021-results-toronto-on-accesswire-edsa-20210514monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-announces-3-5-million-bought-deal-offering-of-common-shares-toronto-on-acces-edsa-20210225monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-reports-fiscal-first-quarter-2021-results-toronto-on-accesswire-edsa-20210216monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-receives-c-14-million-for-covid-19-study-toronto-on-accesswire-edsa-20210202monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-reports-fiscal-year-2020-results-toronto-on-accesswire-edsa-20201207monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-reports-fiscal-3rd-quarter-2020-results-toronto-on-accesswire-edsa-20200812monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-reports-fiscal-2nd-quarter-2020-results-toronto-on-accesswire-edsa-20200515monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-and-light-chain-bioscience-sign-license-agreement-to-develop-treatments-for--edsa-20200420monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-reports-fiscal-1st-quarter-2020-results-toronto-on-accesswire-edsa-20200213monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-announces-4-36-million-registered-direct-offering-toronto-on-accesswire-edsa-20200106monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-reports-financial-results-for-short-period-fiscal-year-toronto-on-accesswire-edsa-20191212monthly0.5https://www.biopharmawatch.com/news/EDSA/date-of-earliest-event-reported-august-30-edsa-20190830monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-reports-quarterly-financial-results-toronto-on-accesswire-edsa-20190814monthly0.5https://www.biopharmawatch.com/news/EDSA/edesa-biotech-and-stellar-biotechnologies-complete-business-combination-toronto-edsa-20190607monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-reports-second-quarter-financial-results-edsa-20190508monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-and-edesa-biotech-sign-share-exchange-agreement-edsa-20190308monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-reports-first-quarter-financial-results-edsa-20190205monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-reports-fiscal-year-2018-financial-results-edsa-20181130monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-reports-third-quarter-financial-results-edsa-20180808monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-announces-pricing-of-5-5-million-public-offering-edsa-20180511monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-reports-second-quarter-financial-results-edsa-20180507monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-announces-one-for-seven-reverse-split-edsa-20180427monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-reports-first-quarter-2018-financial-results-edsa-20180207monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-appoints-pharma-licensing-expert-to-board-of-directors-edsa-20180125monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-reports-fiscal-year-2017-financial-results-company-prepares-to-sup-edsa-20171201monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-reports-third-quarter-2017-financial-results-company-prepares-for--edsa-20170809monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-reports-second-quarter-2017-financial-results-late-stage-customer--edsa-20170509monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-and-matrivax-sign-agreement-to-transfer-vaccine-technology-stellar-edsa-20170313monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-reports-first-quarter-2017-financial-results-company-continues-sca-edsa-20170206monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-reports-fiscal-year-2016-financial-results-broader-customer-base-d-edsa-20161214monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-appoints-pharma-and-capital-markets-experts-to-board-of-directors-edsa-20161209monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-announces-pricing-of-6-75-million-registered-direct-offering-port--edsa-20160630monthly0.5https://www.biopharmawatch.com/news/EDSA/and-neovacs-sign-joint-venture-agreement-to-edsa-20160517monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-reports-second-quarter-2016-financial-results-and-operational-high-edsa-20160510monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-announces-results-of-special-meeting-of-shareholders-port-hueneme--edsa-20151029monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-issues-corporate-update-port-hueneme-ca-10-23-15-stellar-biotechno-edsa-20151027monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-provides-update-on-anticipated-listing-on-the-nasdaq-capital-marke-edsa-20150915monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-announces-reverse-stock-split-in-preparation-for-proposed-uplistin-edsa-20150828monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-reports-third-quarter-2015-financial-results-and-operational-highl-edsa-20150810monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-signs-collaboration-agreement-to-expand-klh-aquaculture-operations-edsa-20150728monthly0.5https://www.biopharmawatch.com/news/EDSA/stock-options-granted-port-hueneme-ca-edsa-20150612monthly0.5https://www.biopharmawatch.com/news/EDSA/corporate-presentation-otcqb-sbotf-tsx-v-klh-www-stellarbiotech-com-www-klhsite-org-safe-h-edsa-20150112monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-and-araclon-biotech-sign-exclusive-klh-supply-agreement-for-clinic-edsa-20141111monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-reports-year-end-2014-financial-results-company-to-hold-conference-edsa-20141113monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-and-biovest-international-sign-klh-supply-agreement-for-biovaxid-i-edsa-20141023monthly0.5https://www.biopharmawatch.com/news/EDSA/notice-of-change-of-financial-year-end-edsa-20140828monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-inc-audit-committee-charter-1-charter-this-charter-this-charter-go-edsa-20140814monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-reports-third-quarter-2014-financial-results-and-recent-corporate--edsa-20140710monthly0.5https://www.biopharmawatch.com/news/EDSA/condensed-interim-consolidated-financial-edsa-20140710monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-inc-corporate-presentation-june-2014-www-stellarbiotech-com-www-kl-edsa-20140625monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-inc-332-e-scott-street-port-hueneme-california-93041-the-company-n-edsa-20140603monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-appoints-two-members-to-scientific-advisory-board-port-hueneme-ca-edsa-20140606monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-releases-corporate-video-port-hueneme-ca-edsa-20140520monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-to-present-at-two-upcoming-conferences-port-hueneme-ca-edsa-20140515monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-retains-stonegate-for-institutional-outreach-port-hueneme-ca-edsa-20140507monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-launches-new-corporate-website-the-new-website-showcases-stellar-s-edsa-20140502monthly0.5https://www.biopharmawatch.com/news/EDSA/condensed-interim-consolidated-financial-edsa-20140410monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-to-host-corporate-update-and-second-quarter-2014-results-conferenc-edsa-20140404monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-presenting-today-at-2014-tsx-venture-50-spotlight-event-port-huene-edsa-20140401monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-presents-poster-on-klh-achievements-at-gordon-research-conference--edsa-20140303monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-to-present-at-the-26-th-annual-roth-capital-growth-conference-port-edsa-20140227monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-reports-on-annual-general-and-special-meeting-port-hueneme-ca-edsa-20140218monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-named-2014-tsx-venture-50-company-port-hueneme-ca-edsa-20140213monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-presents-klh-verification-method-at-aquaculture-america-conference-edsa-20140212monthly0.5https://www.biopharmawatch.com/news/EDSA/condensed-interim-consolidated-financial-edsa-20140130monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-inc-to-present-at-two-investor-conferences-in-january-port-hueneme-edsa-20140106monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-issues-year-end-results-and-highlights-from-2013-port-hueneme-ca-edsa-20140102monthly0.5https://www.biopharmawatch.com/news/EDSA/stellar-biotechnologies-inc-announces-meeting-and-record-date-and-approval-of-advance-noti-edsa-20131227monthly0.5https://www.biopharmawatch.com/news/JATT/jatt-ii-acquisition-corp-index-to-financial-statement-page-financial-statement-of-jatt-ii--jatt-20260420monthly0.5https://www.biopharmawatch.com/news/JATT/jatt-ii-acquisition-corp-announces-pricing-of-60-000-000-initial-public-offering-westfield-jatt-20260416monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-shortlists-ai-tenants-for-41-5mw-norway-ai-data-center-after-receiving-multiple--vivo-20260521monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-becomes-ebitda-profitable-31-million-revenue-10-million-ebitda-from-completion-o-vivo-20260421monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-launches-lease-bidding-after-receiving-strong-interest-from-ai-operators-for-41--vivo-20260423monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-commences-strategic-share-conversion-program-initial-2-96-million-listed-class-a-vivo-20260320monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-terminates-180-million-f-3-registration-statement-decision-reflects-commitment-t-vivo-20260318monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-announces-effectiveness-of-new-stock-ticker-vivo-and-corporate-name-change-londo-vivo-20260316monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-announces-new-stock-ticker-vivo-and-corporate-name-change-in-alignment-with-its--vivo-20260310monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-announces-leadership-changes-london-vivo-20260219monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-secures-30-million-pipe-at-6-80-conversion-price-to-accelerate-sovereign-ai-data-vivo-20260212monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-completes-definitive-agreement-with-kweather-advances-strategic-exit-from-digita-vivo-20260205monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-international-plc-announces-termination-of-at-the-market-atm-equity-offering-agr-vivo-20260202monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-announces-shareholder-approval-of-all-resolutions-at-extraordinary-general-meeti-vivo-20260130monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-s-tembo-secures-strategic-partnership-in-us-11-billion-australian-utility-pick-u-vivo-20260116monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-receives-nasdaq-letter-confirming-it-is-in-compliance-with-nasdaq-listing-standa-vivo-20250701monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-believes-it-meets-nasdaq-equity-requirement-following-reg-s-investment-company-b-vivo-20250626monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-announces-xrp-focused-digital-asset-treasury-strategy-and-us-121-million-private-vivo-20250528monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-provides-clarification-re-us-180-million-enterprise-value-takeover-proposal-prop-vivo-20250414monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-s-tembo-signs-definitive-distribution-agreement-with-the-kingdom-of-saudi-arabia-vivo-20250411monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-receives-non-binding-all-cash-takeover-offer-at-enterprise-value-of-us-120-milli-vivo-20250324monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-activates-and-extends-stock-buyback-program-of-up-to-us-5-million-stock-buyback--vivo-20250307monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-s-caret-digital-secures-cad-140m-definitive-binding-investment-commitment-from-g-vivo-20250113monthly0.5https://www.biopharmawatch.com/news/VIVO/results-of-annual-general-meeting-all-six-resolutions-were-approved-by-the-majority-of-sha-vivo-20250102monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-completes-filing-of-2024-annual-report-on-form-20-f-filing-follows-successful-co-vivo-20241219monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-receives-notification-of-recompliance-with-nasdaq-s-minimum-bid-price-rule-londo-vivo-20241211monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-s-tembo-secures-full-on-road-homologation-for-its-tembo-tusker-100-electric-vehi-vivo-20241118monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-s-caret-digital-to-develop-up-to-55mw-of-its-solar-farm-portfolio-for-digital-as-vivo-20241114monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-s-tembo-announces-definitive-agreement-with-pre-eminent-jeepney-group-sarao-moto-vivo-20241003monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-decides-to-close-f-1-offering-after-successfully-raising-4m-in-gross-proceeds-fr-vivo-20240930monthly0.5https://www.biopharmawatch.com/news/VIVO/updated-vivopower-and-future-automotive-solutions-technologies-fast-proforma-1-13bn-merged-vivo-20240926monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-and-future-automotive-solutions-and-technologies-fast-pro-forma-us-1-13bn-merged-vivo-20240925monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-announces-strategic-merger-heads-of-agreement-with-fast-at-a-pro-forma-combined--vivo-20240917monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-secures-mpox-diagnostic-tests-distribution-heads-of-agreement-for-singapore-hong-vivo-20240916monthly0.5https://www.biopharmawatch.com/news/VIVO/business-combination-agreement-by-and-among-cactus-acquisition-corp-1-limited-vivopower-in-vivo-20240829monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-international-plc-reports-preliminary-estimated-unaudited-financial-results-for--vivo-20240830monthly0.5https://www.biopharmawatch.com/news/VIVO/tembo-e-lv-a-subsidiary-of-nasdaq-listed-vivopower-international-plc-vvpr-executes-a-defin-vivo-20240829monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-s-tembo-extends-heads-of-agreement-exclusivity-for-us-838m-merger-with-ccts-excl-vivo-20240729monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-secures-extension-for-us-34m-loan-financing-facility-agreement-agreement-consoli-vivo-20240709monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-s-tembo-confirms-heads-of-agreement-exclusivity-extension-for-us-838m-merger-wit-vivo-20240702monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-vivo-20240702monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-s-tembo-secures-200-tuskers-worth-us-10m-tembo-has-secured-a-minimum-of-200-tusk-vivo-20240618monthly0.5https://www.biopharmawatch.com/news/VIVO/vivopower-s-tembo-launches-the-full-electric-tembo-tusker-with-first-50-committed-orders-i-vivo-20240605monthly0.5https://www.biopharmawatch.com/news/VIVO/notice-of-annual-general-meeting-to-be-held-on-5-september-2017-vivopower-international-pl-vivo-20170731monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-provides-regulatory-update-on-tabelecleucel-thousand-oaks-calif-busi-atra-20260507monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-inc-consolidated-statements-of-operations-and-comprehensive-income-l-atra-20260316monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-provides-a-business-update-atara-renegotiates-one-time-milestone-pay-atra-20260223monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-provides-regulatory-and-business-update-on-ebvallo-tabelecleucel-u-s-atra-20251231monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-third-quarter-financial-results-and-operational-progress-t-atra-20251112monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-second-quarter-financial-results-and-operational-progress--atra-20250811monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-provides-regulatory-and-business-updates-on-tabelecleucel-tab-cel-at-atra-20250630monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-first-quarter-financial-results-and-operational-progress-a-atra-20250515monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-fourth-quarter-and-full-year-2024-financial-results-and-op-atra-20250307monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-provides-update-on-clinical-programs-related-to-ebvallo-tm-tabelecle-atra-20250121monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-provides-regulatory-and-business-update-on-ebvallo-tm-tabelecleucel--atra-20250116monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-third-quarter-2024-financial-results-and-operational-progr-atra-20241112monthly0.5https://www.biopharmawatch.com/news/ATRA/securities-purchase-agreement-this-securities-purchase-agreement-this-agreement-is-dated-a-atra-20240903monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-inc-condensed-consolidated-statements-of-operations-and-comprehensiv-atra-20240812monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-u-s-fda-acceptance-and-priority-review-of-the-biologics-li-atra-20240717monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-1-for-25-reverse-stock-split-atra-20240617monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-first-quarter-2024-financial-results-and-operational-progr-atra-20240509monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-fourth-quarter-and-full-year-2023-financial-results-and-op-atra-20240328monthly0.5https://www.biopharmawatch.com/news/ATRA/forward-looking-statements-this-presentation-and-the-accompanying-oral-presentation-contai-atra-20240108monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-closing-of-expanded-global-tab-cel-partnership-with-pierre-atra-20231220monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-primary-analysis-data-from-phase-2-embold-clinical-trial-o-atra-20231108monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-expanded-global-tab-cel-partnership-with-pierre-fabre-labo-atra-20231101monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-plans-to-submit-tab-cel-bla-in-q2-2024-following-fda-agree-atra-20230919monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-second-quarter-2023-financial-results-and-operational-prog-atra-20230808monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-first-quarter-2023-financial-results-and-operational-progr-atra-20230508monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-fourth-quarter-and-full-year-2022-financial-results-and-op-atra-20230208monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-third-quarter-2022-financial-results-and-operational-progr-atra-20221108monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-second-quarter-2022-financial-results-and-corporate-strate-atra-20220808monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-first-quarter-2022-financial-results-and-operational-progr-atra-20220505monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-fourth-quarter-and-full-year-2021-financial-results-and-op-atra-20220228monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-enters-strategic-manufacturing-partnership-with-fujifilm-fujifilm-to-atra-20220126monthly0.5https://www.biopharmawatch.com/news/ATRA/ola-ebv-ptld-advocate-atara-bio-investor-presentation-jp-morgan-healthcare-conference-atra-20220110monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-third-quarter-2021-financial-results-and-operational-progr-atra-20211104monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-second-quarter-2021-financial-results-and-operational-prog-atra-20210809monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-first-quarter-2021-financial-results-and-operational-progr-atra-20210504monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-fourth-quarter-and-full-year-2020-financial-results-and-op-atra-20210301monthly0.5https://www.biopharmawatch.com/news/ATRA/forward-looking-statements-this-presentation-and-the-accompanying-oral-presentation-contai-atra-20210111monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-third-quarter-2020-financial-results-and-operational-progr-atra-20201109monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-second-quarter-2020-financial-results-and-operational-prog-atra-20200805monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-first-quarter-2020-financial-results-and-operational-progr-atra-20200506monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-third-quarter-2019-financial-results-and-recent-clinical-o-atra-20191107monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-second-quarter-2019-financial-results-and-recent-operation-atra-20190808monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-first-quarter-2019-financial-results-and-recent-operationa-atra-20190509monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-fourth-quarter-and-full-year-2018-financial-results-and-re-atra-20190226monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-third-quarter-2018-financial-results-and-recent-operationa-atra-20181106monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-second-quarter-2018-financial-results-and-recent-operation-atra-20180801monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-first-quarter-2018-financial-results-and-recent-operationa-atra-20180508monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-fourth-quarter-and-full-year-2017-financial-results-and-re-atra-20180227monthly0.5https://www.biopharmawatch.com/news/ATRA/whether-as-a-result-of-any-new-information-future-events-changed-circumstances-or-otherwis-atra-20180104monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-fda-clearance-to-initiate-two-phase-3-clinical-studies-to--atra-20171229monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-third-quarter-2017-financial-results-and-recent-highlights-atra-20171109monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-second-quarter-2017-financial-results-and-recent-highlight-atra-20170807monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-first-quarter-2017-financial-results-and-recent-highlights-atra-20170504monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-announces-positive-interim-results-from-ongoing-phase-1-trial-of-the-autologous--atra-20170420monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-announces-fourth-quarter-and-full-year-2016-financial-results-and-recent-highlig-atra-20170309monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-announces-third-quarter-2016-financial-results-and-recent-highlights-atra-20161104monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-announces-second-quarter-2016-financial-results-and-recent-highlights-atra-20160808monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-announces-first-quarter-2016-financial-results-and-recent-highlights-atra-20160505monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-announces-fourth-quarter-and-full-year-2015-financial-results-and-recent-highlig-atra-20160303monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-bio-announces-results-from-the-phase-2-proof-of-concept-pinta-745-clinical-trial-for-atra-20151214monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-third-quarter-2015-financial-results-south-san-francisco-c-atra-20151105monthly0.5https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-announces-second-quarter-2015-results-south-san-francisco-calif-atra-20150806monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-expands-pipeline-with-exclusive-license-from-ascendant-health-sciences-ltd-f-cue-20260430monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-reports-second-quarter-2025-financial-results-and-recent-business-highlights-cue-20250812monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-inc-2025-stock-incentive-plan-1-purpose-the-purpose-of-this-2025-stock-incen-cue-20250610monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-reports-first-quarter-2025-financial-results-and-recent-business-highlights--cue-20250515monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-pricing-of-approximately-20-million-public-offering-cue-20250414monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-reports-fourth-quarter-and-full-year-2024-financial-results-and-business-hig-cue-20250331monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-reports-third-quarter-2024-financial-results-and-recent-business-highlights-cue-20241114monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-pricing-of-12-0-million-public-offering-cue-20240926monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-strategic-prioritization-of-autoimmune-programs-enabling-optimizat-cue-20240725monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-reports-first-quarter-2024-financial-results-and-recent-business-highlights-cue-20240509monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-30-million-private-investment-in-public-equity-pipe-financing-bost-cue-20221114monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-forward-looking-statements-disclosure-this-presentation-has-been-prepared-by-cue-20211115monthly0.5https://www.biopharmawatch.com/news/CUE/forward-looking-statements-disclaimer-this-presentation-has-been-prepared-by-cue-biopharma-cue-20210318monthly0.5https://www.biopharmawatch.com/news/CUE/nasdaq-cue-corporate-presentation-cue-20200605monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-reports-first-quarter-2020-results-updates-of-cue-101-phase-1-dose-escalatio-cue-20200519monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-reports-fourth-quarter-and-full-year-2019-financial-results-and-recent-busin-cue-20200317monthly0.5https://www.biopharmawatch.com/news/CUE/nasdaq-cue-march-2020-corporate-cue-20200302monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-reports-third-quarter-2019-financial-results-and-recent-business-highlights--cue-20191112monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-and-lg-chem-life-sciences-announce-wt1-as-the-next-immuno-stat-target-in-onc-cue-20181220monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-announces-strategic-collaboration-with-lg-chem-life-sciences-for-immuno-stat-cue-20181108monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-produces-immuno-stat-tm-biologic-candidate-for-treatment-of-autoimmune-disea-cue-20180712monthly0.5https://www.biopharmawatch.com/news/CUE/cue-biopharma-inc-notice-of-change-of-location-and-time-of-annual-meeting-of-stockholders-cue-20180529monthly0.5https://www.biopharmawatch.com/news/CUE/copyright-2018-cue-20180517monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-reports-q3-fiscal-year-2026-financial-results-and-provides-corporate-update-received--ibio-20260512monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-appoints-distinguished-biotech-leader-elizabeth-stoner-to-its-board-of-directors-san--ibio-20260508monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-received-regulatory-clearance-to-initiate-its-phase-1-clinical-trial-of-ibio-600-in-a-ibio-20260408monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-reports-preclinical-body-composition-data-from-obese-non-human-primates-treated-with--ibio-20260309monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-reports-q2-fiscal-year-2026-financial-results-and-provides-corporate-update-secured-2-ibio-20260210monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-announces-26-million-private-placement-ibio-20260109monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-reports-q1-fiscal-year-2026-financial-results-and-provides-corporate-update-strengthe-ibio-20251112monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-unveils-new-non-human-primate-data-on-ibio-610-an-activin-e-antibody-with-strong-ther-ibio-20251030monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-reports-fiscal-year-2025-financial-results-and-provides-corporate-update-san-diego-ca-ibio-20250905monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-announces-proposed-public-offering-ibio-20250818monthly0.5https://www.biopharmawatch.com/news/IBIO/breakthrough-antibodies-for-obesity-and-cardiometabolic-diseases-corporate-presentation-au-ibio-20250818monthly0.5https://www.biopharmawatch.com/news/IBIO/breakthrough-antibodies-for-obesity-and-cardiometabolic-diseases-corporate-presentation-ju-ibio-20250624monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-reports-fiscal-third-quarter-2025-financial-results-ibio-20250502monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-expands-cardiometabolic-and-obesity-pipeline-through-licensing-of-first-in-class-anti-ibio-20250422monthly0.5https://www.biopharmawatch.com/news/IBIO/breakthrough-antibodies-for-obesity-and-cardiometabolic-diseases-enabled-by-an-ai-platform-ibio-20250408monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-announces-ibio-600-non-human-primate-data-showing-extended-half-life-and-muscle-growt-ibio-20250407monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-to-begin-trading-on-the-nasdaq-stock-exchange-ibio-20250219monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-reports-fiscal-second-quarter-2025-financial-results-ibio-20250210monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-announces-new-investments-from-board-members-and-officers-ibio-20250113monthly0.5https://www.biopharmawatch.com/news/IBIO/breakthrough-antibodies-for-obesity-and-cardiometabolic-diseases-enabled-by-an-ai-platform-ibio-20250110monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-expands-cardiometabolic-and-obesity-program-with-anti-myostatin-antibody-discovered-u-ibio-20250102monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-strengthens-board-with-appointment-of-two-new-independent-directors-ibio-20241125monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-reports-fiscal-first-quarter-202-5-financial-results-advanced-myostatin-program-with--ibio-20241112monthly0.5https://www.biopharmawatch.com/news/IBIO/october-2024-tomorrow-s-precision-antibody-therapeutics-powered-by-machine-learning-2-forw-ibio-20241023monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-reports-fiscal-year-2024-financial-results-and-provides-corporate-update-san-diego-ca-ibio-20240920monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-closes-sale-of-manufacturing-facility-in-texas-the-sale-of-the-facility-eliminates-13-ibio-20240603monthly0.5https://www.biopharmawatch.com/news/IBIO/june-2024-tomorrow-s-precision-antibody-therapeutics-powered-by-machine-learning-2-forward-ibio-20240603monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-reports-fiscal-third-quarter-2024-financial-results-and-provides-corporate-update-str-ibio-20240513monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-announces-15-0-million-private-placement-purchase-price-of-2-85-represents-a-premium--ibio-20240326monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-announces-sale-of-preclinical-pd-1-agonist-antibody-program-to-otsuka-deal-includes-1-ibio-20240226monthly0.5https://www.biopharmawatch.com/news/IBIO/january-2024-tomorrow-s-precision-antibody-therapeutics-powered-by-machine-learning-2-forw-ibio-20240108monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-amends-and-extends-maturity-of-credit-agreement-extends-maturity-date-to-ibio-20231226monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-inc-announces-pricing-of-4-5-million-public-offering-bryan-texas-and-ibio-20231205monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-announces-reverse-stock-split-bryan-texas-and-ibio-20231127monthly0.5https://www.biopharmawatch.com/news/IBIO/october-2023-ai-powered-precision-antibody-therapeutics-2-forward-looking-statements-certa-ibio-20231002monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-announces-filing-of-2023-annual-report-on-sec-form-10-k-bryan-texas-and-san-diego-cal-ibio-20230927monthly0.5https://www.biopharmawatch.com/news/IBIO/pro-forma-condensed-consolidated-financial-statements-of-ibio-inc-unaudited-on-ibio-20230915monthly0.5https://www.biopharmawatch.com/news/IBIO/july-2023-ai-powered-precision-antibody-therapeutics-2-forward-looking-statements-certain--ibio-20230710monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-appoints-dr-martin-brenner-as-ceo-felipe-duran-as-cfo-to-oversee-company-s-next-stage-ibio-20230627monthly0.5https://www.biopharmawatch.com/news/IBIO/april-2023-forward-looking-statements-certain-statements-in-this-presentation-constitute-f-ibio-20230424monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-announces-closing-of-3-5-million-underwritten-public-offering-ibio-20221209monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-announces-proposed-underwritten-public-offering-ibio-20221206monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-announces-ceo-departure-bryan-texas-ibio-20221202monthly0.5https://www.biopharmawatch.com/news/IBIO/november-2022-xa9-ibio-inc-all-right-reserved-forward-looking-statements-certain-statement-ibio-20221103monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-accelerates-transformation-to-ai-powered-biotech-divesting-cdmo-business-and-cgmp-bio-ibio-20221103monthly0.5https://www.biopharmawatch.com/news/IBIO/growingtomorrow-s-biologics-corporate-presentation-october-2022-tom-isett-chairman-ceo-202-ibio-20221003monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-reports-preliminary-unaudited-fiscal-year-2022-financial-results-and-provides-corpora-ibio-20220927monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-acquires-rubryc-therapeutics-ai-drug-discovery-platform-and-pipeline-positions-compan-ibio-20220921monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-provides-update-on-development-of-next-gen-covid-19-vaccine-candidate-manufactured-fi-ibio-20220816monthly0.5https://www.biopharmawatch.com/news/IBIO/growing-tomorrow-s-biologics-corporate-presentation-may-2022-tom-isett-chairman-ceo-2022-i-ibio-20220516monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-reports-fiscal-third-quarter-2022-financial-results-and-provides-corporate-update-bry-ibio-20220512monthly0.5https://www.biopharmawatch.com/news/IBIO/growing-tomorrow-s-biologics-corporate-presentation-march-2022-tom-isett-chairman-ceo-xa9--ibio-20220318monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-reports-fiscal-second-quarter-2022-financial-results-and-provides-corporate-update-br-ibio-20220214monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-announces-progression-of-vaccine-program-for-multi-variant-covid-19-disease-ibio-202--ibio-20220126monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-announces-partial-adjournment-of-annual-meeting-of-shareholders-to-ibio-20211222monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-announces-partial-adjournment-of-annual-meeting-to-december-22-shareholders-presently-ibio-20211210monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-reports-fiscal-first-quarter-2022-financial-results-and-provides-corporate-update-add-ibio-20211115monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-acquires-fastpharming-manufacturing-facility-takes-sole-ownership-of-cdmo-subsidiary--ibio-20211103monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-reports-fourth-quarter-and-fiscal-year-2021-financial-results-and-provides-corporate--ibio-20210927monthly0.5https://www.biopharmawatch.com/news/IBIO/growing-a-next-gen-biologics-pipeline-corporate-presentation-august-2021-tom-isett-chairma-ibio-20210830monthly0.5https://www.biopharmawatch.com/news/IBIO/third-amended-and-restated-certificate-of-incorporation-of-rubryc-therapeutics-inc-pursuan-ibio-20210827monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-appoints-william-d-clark-to-its-board-of-directors-industry-veteran-adds-deep-experti-ibio-20210826monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-reports-successful-preclinical-immunization-studies-with-next-gen-nucleocapsid-covid--ibio-20210715monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-further-strengthens-board-with-appointment-of-veteran-biopharmaceutical-executive-eef-ibio-20210609monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-reports-fiscal-third-quarter-2021-financial-results-and-provides-corporate-update-bry-ibio-20210517monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-reports-successful-covid-19-vaccine-toxicology-study-results-and-announces-next-gen-c-ibio-20210506monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-reports-fiscal-second-quarter-2021-financial-results-and-provides-corporate-update-br-ibio-20210216monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-appoints-robert-m-lutz-as-chief-financial-business-officer-bryan-texas-ibio-20210216monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-appoints-dr-martin-b-brenner-as-chief-scientific-officer-bryan-texas-ibio-20201228monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-announces-closing-of-its-public-offering-of-common-stock-bryan-texas-ibio-20201210monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-announces-proposed-public-offering-of-common-stock-bryan-texas-ibio-20201207monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-reports-fiscal-first-quarter-2021-financial-results-and-provides-corporate-update-bry-ibio-20201116monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-announces-appointment-of-randy-j-maddux-as-chief-operating-officer-brings-20-years-of-ibio-20201103monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-announces-appointment-of-dr-linda-armstrong-to-board-of-directors-accomplished-biopha-ibio-20201014monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-announces-financial-results-for-fiscal-year-ended-ibio-20201013monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-enters-into-agreement-with-safi-biosolutions-to-develop-growth-factors-and-cytokines--ibio-20201002monthly0.5https://www.biopharmawatch.com/news/IBIO/group-1-group-2-group-3-group-4-group-5-group-6-group-7-0-0-0-2-0-4-0-6-0-8-1-0-a-b-s-i-g--ibio-20200729monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-expands-covid-19-vaccine-collaboration-to-include-the-infectious-disease-research-ins-ibio-20200409monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-announces-advancement-of-covid-19-vaccine-program-preclinical-immunization-studies-at-ibio-20200326monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-announces-development-of-proprietary-covid-19-vaccine-candidates-several-provisional--ibio-20200318monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-inc-announces-postponement-of-annual-meeting-new-york-new-york-february-6-2020-ibio-i-ibio-20200206monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-inc-announces-nyse-american-acceptance-of-plan-of-compliance-new-york-new-york-januar-ibio-20200116monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-inc-reports-on-nyse-american-noncompliance-notice-and-compliance-plan-new-york-ibio-20191213monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-inc-prices-5-000-000-public-offering-new-york-new-york-october-25-2019-ibio-inc-nyse--ibio-20191024monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-inc-reports-on-nyse-american-noncompliance-notice-and-compliance-plan-new-york-new-yo-ibio-20191016monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-announces-appointment-of-thomas-f-isett-to-board-of-directors-accomplished-life-scien-ibio-20190401monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-inc-announces-nyse-american-acceptance-of-plan-of-compliance-new-york-new-york-august-ibio-20180822monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-inc-closes-16-000-000-public-offering-new-york-new-york-june-26-2018-ibio-inc-nyse-am-ibio-20180626monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-inc-prices-16-000-000-public-offering-new-york-new-york-june-22-2018-ibio-inc-nyse-am-ibio-20180622monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-inc-reports-on-nyse-american-noncompliance-notice-and-compliance-plan-new-york-new-yo-ibio-20180606monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-inc-announces-reverse-stock-split-new-york-new-york-may-31-2018-ibio-inc-nyse-america-ibio-20180531monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-inc-provides-corporate-update-new-york-new-york-january-5-2018-ibio-inc-nyse-american-ibio-20180105monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-inc-closes-4-500-000-offering-of-common-stock-new-york-new-york-november-30-2017-ibio-ibio-20171201monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-inc-prices-4-500-000-firm-commitment-offering-of-common-stock-new-york-new-york-novem-ibio-20171130monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-inc-initiates-litigation-against-fraunhofer-gesellschaft-in-delaware-chancery-court-n-ibio-20171106monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-inc-enters-into-common-stock-purchase-agreement-for-up-to-16-0-million-with-lincoln-p-ibio-20170724monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-inc-holds-annual-meeting-in-college-station-texas-new-york-ny-marketwired-ibio-20160407monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-forms-joint-venture-cmo-for-large-scale-pharmaceuticals-manufacturing-in-green-plants-ibio-20160114monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-enters-into-10-million-common-ibio-20140826monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-inc-receives-notice-that-nyse-mkt-accepted-the-company-s-plan-to-regain-compliance-wi-ibio-20130605monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-inc-announces-proposed-public-offering-newark-del-ibio-20130422monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-inc-receives-notice-from-nyse-mkt-staff-that-company-currently-is-not-in-compliance-w-ibio-20130422monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-inc-receives-anticipated-notice-from-nyse-mkt-that-company-is-below-certain-continued-ibio-20130304monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-announces-at-the-market-equity-offering-ibio-20130201monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-inc-receives-notice-from-nyse-mkt-staff-that-company-currently-is-below-certain-conti-ibio-20121123monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-inc-announces-proposed-public-offering-ibio-20120109monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-inc-receives-notice-from-nyse-amex-staff-that-company-currently-is-below-certain-cont-ibio-20111104monthly0.5https://www.biopharmawatch.com/news/IBIO/jules-a-m-sing-joins-ibio-s-board-of-directors-newark-del-business-wire-ibio-inc-nyse-amex-ibio-20110623monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-appoints-douglas-beck-chief-financial-officer-newark-del-business-wire-ibio-inc-nyse--ibio-20110504monthly0.5https://www.biopharmawatch.com/news/IBIO/game-changing-technology-for-the-vaccine-and-therapeutic-biologics-business-noble-financia-ibio-20100604monthly0.5https://www.biopharmawatch.com/news/IBIO/ibio-inc-announces-agreement-in-principle-for-licensing-large-scale-vaccine-production-fac-ibio-20100226monthly0.5https://www.biopharmawatch.com/news/IBIO/robert-erwin-melody-carey-president-co-president-ibio-inc-rx-communications-inc-302-355-23-ibio-20090915monthly0.5https://www.biopharmawatch.com/news/IBIO/demand-and-the-company-s-ability-to-obtain-new-contracts-and-accurately-estimate-net-reven-ibio-20080820monthly0.5https://www.biopharmawatch.com/news/IBIO/demand-and-the-company-s-ability-to-obtain-new-contracts-and-accurately-estimate-net-reven-ibio-20080818monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-unaudited-financial-results-for-the-quarter-ended-iccc-20250814monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-bank-debt-refinancing-for-immediate-release-iccc-20250812monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-preliminary-unaudited-sales-results-for-q2-of-2025-for-immedia-iccc-20250709monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-embarks-on-ceo-succession-planning-process-for-immediate-release-iccc-20250625monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-unaudited-financial-results-for-the-quarter-ended-iccc-20250514monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-preliminary-unaudited-sales-results-for-q1-of-2025-for-immedia-iccc-20250408monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-hires-chief-financial-officer-for-immediate-release-iccc-20250407monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-unaudited-financial-results-for-the-quarter-and-year-ended-iccc-20250225monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-settlement-of-insurance-claim-related-to-previously-disclosed-productio-iccc-20250116monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-preliminary-unaudited-sales-results-for-q4-and-full-year-2024--iccc-20250109monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-unaudited-financial-results-for-the-quarter-ended-iccc-20241113monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-preliminary-unaudited-sales-results-for-q3-2024-for-immediate--iccc-20241008monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-unaudited-financial-results-for-the-quarter-ended-iccc-20240813monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-preliminary-unaudited-sales-results-for-q2-2024-for-immediate--iccc-20240709monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-provides-update-on-regulatory-status-of-product-development-initiative-f-iccc-20240605monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-unaudited-financial-results-for-the-quarter-ended-iccc-20240514monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-preliminary-unaudited-sales-results-for-q1-2024-for-immediate--iccc-20240409monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-unaudited-financial-results-for-the-quarter-and-year-ended-iccc-20240227monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-preliminary-unaudited-sales-results-for-q4-2023-for-immediate-release-iccc-20240108monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-unaudited-financial-results-for-the-quarter-ended-iccc-20231113monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-preliminary-unaudited-sales-results-for-q3-2023-for-immediate--iccc-20231005monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-unaudited-financial-results-for-the-quarter-ended-iccc-20230810monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-preliminary-unaudited-sales-results-for-q2-2023-for-immediate--iccc-20230711monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-change-in-timing-of-anticipated-fda-submission-iccc-20230628monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-appoints-bryan-k-gathagan-to-board-of-directors-for-immediate-release-iccc-20230621monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-unaudited-financial-results-for-the-quarter-ended-iccc-20230511monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-preliminary-unaudited-sales-results-for-q1-2023-for-immediate--iccc-20230405monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-unaudited-financial-results-for-the-year-ended-iccc-20230221monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-preliminary-unaudited-sales-results-for-the-year-ended-iccc-20221231monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-unaudited-financial-results-for-the-quarter-ended-iccc-20221121monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-to-announce-unaudited-financial-results-for-the-quarter-ended-iccc-20221110monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-preliminary-unaudited-sales-results-for-third-quarter-of-2022--iccc-20221005monthly0.5https://www.biopharmawatch.com/news/ICCC/second-amendment-of-lease-this-is-a-second-amendment-of-lease-this-amendment-is-dated-as-o-iccc-20220817monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-unaudited-financial-results-for-the-quarter-ended-iccc-20220811monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-receives-technical-section-incomplete-letter-from-fda-pertaining-to-re-t-iccc-20220727monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-preliminary-unaudited-sales-results-for-second-quarter-of-2022-iccc-20220707monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-unaudited-financial-results-for-the-quarter-ended-iccc-20220512monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-record-preliminary-unaudited-sales-results-for-first-quarter-o-iccc-20220411monthly0.5https://www.biopharmawatch.com/news/ICCC/allonge-to-and-amendment-of-term-note-loan-no-8160005131-this-allonge-to-and-amendment-of--iccc-20220324monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-unaudited-financial-results-for-the-quarter-and-year-ended-iccc-20220222monthly0.5https://www.biopharmawatch.com/news/ICCC/independent-contractor-agreement-this-independent-contractor-agreement-agreement-is-made-a-iccc-20220211monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-record-preliminary-unaudited-sales-results-for-the-year-ended-iccc-20211231monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-unaudited-financial-results-for-the-third-quarter-ended-iccc-20211115monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-record-preliminary-unaudited-sales-results-for-third-quarter-o-iccc-20211006monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-required-to-prepare-second-submission-of-final-major-technical-section-f-iccc-20210824monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-unaudited-financial-results-for-the-second-quarter-ended-iccc-20210812monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-strong-preliminary-unaudited-sales-results-for-second-quarter--iccc-20210707monthly0.5https://www.biopharmawatch.com/news/ICCC/note-purchase-agreement-this-note-purchase-agreement-agreement-is-made-as-of-iccc-20210630monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-unaudited-financial-results-for-the-first-quarter-ended-iccc-20210513monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-closes-4-250-000-equity-financing-iccc-20210414monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-preliminary-unaudited-sales-results-for-first-quarter-of-2021--iccc-20210407monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-makes-important-regulatory-submission-and-announces-unaudited-financial--iccc-20210223monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-preliminary-unaudited-sales-results-for-the-year-ended-iccc-20201231monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-restructuring-of-its-bank-debt-for-immediate-release-iccc-20201215monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-unaudited-financial-results-for-the-third-quarter-ended-iccc-20201112monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-preliminary-unaudited-sales-results-for-the-quarter-ended-iccc-20200930monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-unaudited-financial-results-for-the-second-quarter-ended-iccc-20200812monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-preliminary-unaudited-sales-results-for-the-second-quarter-end-iccc-20200630monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-receives-500-000-loan-from-the-maine-technology-institute-for-immediate-release-iccc-20200616monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-corporation-to-present-at-lytham-partners-virtual-investor-conference-on-tuesday--iccc-20200514monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-to-hold-virtual-only-annual-meeting-of-stockholders-for-immediate-releas-iccc-20200514monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-unaudited-financial-results-for-the-first-quarter-ended-iccc-20200513monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-receives-938-000-in-support-under-the-paycheck-protection-program-for-im-iccc-20200414monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-preliminary-unaudited-product-sales-results-for-the-quarter-en-iccc-20200331monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-refinancing-of-its-bank-debt-for-immediate-release-iccc-20200311monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-correction-to-its-reported-unaudited-loss-per-share-from-0-06--iccc-20200219monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-unaudited-financial-results-for-the-year-ended-iccc-20200218monthly0.5https://www.biopharmawatch.com/news/ICCC/announces-preliminary-unaudited-product-sales-results-iccc-20200122monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-unaudited-financial-results-for-third-quarter-of-2019-for-imme-iccc-20191111monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-enters-into-lease-agreement-for-a-facility-to-expand-first-defense-produ-iccc-20190917monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-an-agreement-covering-the-formulation-and-aseptic-filling-of-s-iccc-20190911monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-receives-fda-response-to-first-cmc-submission-for-re-tain-second-submiss-iccc-20190829monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-unaudited-financial-results-for-second-quarter-of-2019-for-imm-iccc-20190812monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-unaudited-financial-results-for-first-quarter-of-2019-for-imme-iccc-20190513monthly0.5https://www.biopharmawatch.com/news/ICCC/amended-and-restated-incentive-compensation-agreement-this-amended-and-restated-incentive--iccc-20190411monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-corporation-announces-commencement-of-public-offering-of-common-stock-fo-iccc-20190326monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-submission-of-manufacturing-technical-section-for-its-purified-iccc-20190228monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-preliminary-financial-results-for-fourth-quarter-and-full-year-iccc-20190213monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-usda-approval-of-dual-force-first-defense-for-immediate-releas-iccc-20181211monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-financial-results-for-third-quarter-of-2018-for-immediate-rele-iccc-20181113monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-issuance-of-human-food-safety-technical-section-complete-lette-iccc-20180925monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-financial-results-for-second-quarter-of-2018-for-immediate-rel-iccc-20180813monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-sale-of-certain-non-core-assets-for-immediate-release-iccc-20180725monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-preliminary-sales-results-for-second-quarter-of-2018-for-immed-iccc-20180710monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-financial-results-for-first-quarter-of-2018-for-immediate-rele-iccc-20180514monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-preliminary-financial-results-for-fourth-quarter-and-full-year-iccc-20180208monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-appoints-two-new-members-to-its-board-of-directors-for-immediate-release-iccc-20180130monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-corporation-announces-closing-of-3-million-public-offering-of-common-sto-iccc-20171221monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-corporation-announces-pricing-of-3-million-public-offering-of-common-sha-iccc-20171219monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-announces-financial-results-for-third-quarter-of-2017-iccc-20171113monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-achieves-usda-approval-of-new-product-claim-to-prevent-rotavirus-infecti-iccc-20171113monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-september-1-2017-michael-brigham-president-immucell-corporation-56-evergreen-dr-p-iccc-20170905monthly0.5https://www.biopharmawatch.com/news/ICCC/announces-financial-results-for-second-quarter-of-2017-iccc-20170814monthly0.5https://www.biopharmawatch.com/news/ICCC/memo-to-board-of-directors-immucell-from-linda-rhodes-vmd-phd-date-iccc-20170810monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-immucell-closes-1-000-000-equity-investment-iccc-20170727monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-for-immediate-release-immucell-announces-financial-results-for-first-quarter-of-2-iccc-20170511monthly0.5https://www.biopharmawatch.com/news/ICCC/bobbi-jo-brockmann-is-appointed-to-board-of-directors-of-immucell-corporation-for-immediat-iccc-20170308monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-preliminary-2016-financial-results-portland-me-marketwired-iccc-20170209monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-not-for-release-immucell-corporation-announces-closing-of-3-5-million-private-pla-iccc-20161021monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-to-raise-3-5-million-in-private-placement-portland-me-marketwired-iccc-20161018monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-preliminary-third-quarter-2016-financial-results-portland-me-marketwire-iccc-20161018monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-breaks-ground-for-mast-out-r-facility-portland-me-marketwired-iccc-20161011monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-first-quarter-2016-financial-results-portland-me-marketwired-iccc-20160511monthly0.5https://www.biopharmawatch.com/news/ICCC/second-amended-and-restated-loan-agreement-this-agreement-is-entered-into-this-28th-day-of-iccc-20160331monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-full-year-2015-financial-results-q4-sales-up-22-full-year-sales-up-35-q-iccc-20160210monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-corporation-announces-closing-of-5-9-million-public-offering-of-common-stock-port-iccc-20160203monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-corporation-announces-pricing-of-5-9-million-public-offering-of-common-shares-con-iccc-20160129monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-corporation-announces-proposed-public-offering-of-common-stock-and-preliminary-fu-iccc-20160128monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-acquires-certain-assets-from-minnesota-firm-contact-michael-f-brigham-president-a-iccc-20160106monthly0.5https://www.biopharmawatch.com/news/ICCC/product-development-contract-manufacture-agreement-this-agreement-is-dated-17-th-of-decemb-iccc-20151222monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-results-for-third-quarter-of-2015-total-sales-increase-40-during-third--iccc-20151112monthly0.5https://www.biopharmawatch.com/news/ICCC/amended-and-restated-loan-agreement-this-agreement-is-entered-into-this-21-st-day-of-septe-iccc-20150924monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-corporation-press-release-immucell-announces-results-for-second-quarter-of-2015-t-iccc-20150813monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-corporation-press-release-immucell-corp-increases-sales-guidance-for-second-quart-iccc-20150708monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-announces-results-for-first-quarter-of-2015-total-sales-during-first-quarter-incr-iccc-20150512monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-board-of-directors-amends-its-common-stock-rights-plan-portland-me-marketwired-iccc-20150415monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-nasdaqcm-iccc-corporate-presentation-may-2014-forward-looking-statements-this-pre-iccc-20140519monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-presents-mast-out-r-product-offering-at-world-animal-health-congress-portland-me--iccc-20111208monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-appoints-david-s-cunningham-to-board-of-directors-iccc-20110907monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-comments-on-status-of-zero-milk-discard-claim-for-mast-out-portland-me-marketwire-iccc-20110609monthly0.5https://www.biopharmawatch.com/news/ICCC/immucell-iccc-20110216monthly0.5https://www.biopharmawatch.com/news/ICCC/robert-c-bruce-c-o-oakmont-advisory-group-477-congress-street-portland-maine-04102-tel-207-iccc-20101220monthly0.5https://www.biopharmawatch.com/news/ICCC/contact-michael-f-brigham-iccc-20050822monthly0.5https://www.biopharmawatch.com/news/ICCC/contact-michael-f-brigham-iccc-20041221monthly0.5https://www.biopharmawatch.com/news/ICCC/contact-michael-f-brigham-iccc-20041117monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-announces-2025-fourth-quarter-and-full-year-financial-results-and-introduces-r-mdai-20260325monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-announces-2025-second-quarter-financial-results-q2-overview-research-developme-mdai-20250812monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-announces-voting-results-from-2025-annual-meeting-of-stockholders-dallas-tx-mdai-20250529monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-announces-2025-first-quarter-financial-results-q1-overview-research-developmen-mdai-20250513monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-announces-2024-fourth-quarter-and-full-year-financial-results-2024-research-de-mdai-20250327monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-raises-up-to-15-million-of-debt-financing-and-strengthens-financial-position-f-mdai-20250324monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-announces-successful-results-from-its-burn-validation-study-of-the-deepview-sy-mdai-20250317monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-announces-confirmation-of-compliance-of-its-nasdaq-listing-requirements-dallas-mdai-20241223monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-inc-announces-return-of-founder-dr-j-michael-dimaio-as-chairman-of-the-board-o-mdai-20241014monthly0.5https://www.biopharmawatch.com/news/MDAI/predictive-wound-healing-ai-multispectral-imaging-faster-more-accurate-treatment-decisions-mdai-20240809monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-continues-support-of-naked-short-selling-inquiry-dallas-tx-mdai-20240715monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-supports-naked-short-selling-inquiry-dallas-tx-mdai-20240624monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-appoints-jeremiah-sparks-as-chief-commercialization-officer-mdai-20240401monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-announces-2023-fourth-quarter-and-full-year-financial-results-2023-research-de-mdai-20240327monthly0.5https://www.biopharmawatch.com/news/MDAI/standby-equity-purchase-agreement-this-standby-equity-purchase-agreement-this-agreement-da-mdai-20240320monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-appoints-peter-m-carlson-as-ceo-appointment-paves-the-way-for-company-s-next-c-mdai-20240229monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-receives-ukca-authorization-for-burn-indication-expected-commercialization-2-nd-h-mdai-20240222monthly0.5https://www.biopharmawatch.com/news/MDAI/predictive-wound-healing-ai-multispectral-imaging-faster-more-accurate-treatment-decisions-mdai-20240201monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-appoints-dr-j-michael-dimaio-to-board-of-directors-the-company-s-two-largest-s-mdai-20240212monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-names-industry-veteran-and-former-top-mimedx-financial-executive-peter-m-carls-mdai-20231219monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-appoints-erich-spangenberg-as-chairman-of-the-executive-committee-of-the-board-mdai-20231127monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-ai-announces-2023-third-quarter-financial-results-highlights-continuing-progress--mdai-20231113monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-md-awarded-barda-project-bioshield-contract-valued-at-149-million-for-ai-driven-d-mdai-20230928monthly0.5https://www.biopharmawatch.com/news/MDAI/spectral-s-management-s-discussion-and-analysis-of-financial-condition-and-results-of-oper-mdai-20230915monthly0.5https://www.biopharmawatch.com/news/MDAI/an-artificial-intelligence-company-focusing-on-medical-diagnostics-to-deliver-faster-and-m-mdai-20230622monthly0.5https://www.biopharmawatch.com/news/MDAI/index-to-financial-statement-page-audited-financial-statement-of-rosecliff-acquisition-cor-mdai-20220324monthly0.5https://www.biopharmawatch.com/news/MDAI/gett-and-rosecliff-acquisition-corp-agree-to-terminate-the-business-combination-agreement--mdai-20220311monthly0.5https://www.biopharmawatch.com/news/MDAI/gett-category-leading-corporate-ground-transportation-management-platform-to-list-on-nasda-mdai-20211110monthly0.5https://www.biopharmawatch.com/news/MDAI/rosecliff-acquisition-corp-i-receives-expected-notice-from-nasdaq-regarding-delayed-filing-mdai-20210604monthly0.5https://www.biopharmawatch.com/news/MDAI/rosecliff-acquisition-corp-i-announces-the-separate-trading-of-its-class-a-common-stock-an-mdai-20210326monthly0.5https://www.biopharmawatch.com/news/MDAI/index-to-financial-statement-page-audited-financial-statement-of-rosecliff-acquisition-cor-mdai-20210217monthly0.5https://www.biopharmawatch.com/news/MDAI/rosecliff-acquisition-corp-i-announces-pricing-of-upsized-220-million-initial-public-offer-mdai-20210211monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-and-cleveland-clinic-present-new-updated-positive-data-from-phase-1-stud-anix-20241108monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-inc-3150-almaden-expressway-suite-250-san-jose-ca-95118-408-708-9808-nas-anix-20240508monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-inc-3150-almaden-expressway-suite-250-san-jose-ca-95118-408-708-9808-nas-anix-20231206monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-inc-3150-almaden-expressway-suite-250-san-jose-ca-95118-408-708-9808-nas-anix-20230417monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-announces-strategic-program-realignment-focused-on-advancement-of-its-therapeutic-an-anix-20200702monthly0.5https://www.biopharmawatch.com/news/ANIX/in-the-court-of-chancery-of-the-state-of-delaware-thomas-s-howland-jr-derivatively-on-beha-anix-20190827monthly0.5https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-conference-call-recording-available-on-company-website-anix-20190125monthly0.5https://www.biopharmawatch.com/news/ANIX/itus-corporation-forms-alliance-with-serametrix-corporation-anix-20180305monthly0.5https://www.biopharmawatch.com/news/ANIX/itus-receives-notice-of-nasdaq-continued-listing-compliance-anix-20171003monthly0.5https://www.biopharmawatch.com/news/ANIX/itus-announces-closing-of-rights-offering-anix-20170404monthly0.5https://www.biopharmawatch.com/news/ANIX/itus-extends-ownership-period-and-changes-record-date-for-stock-rights-offering-anix-20170210monthly0.5https://www.biopharmawatch.com/news/ANIX/itus-announces-common-stock-rights-offering-and-ownership-day-anix-20170119monthly0.5https://www.biopharmawatch.com/news/ANIX/itus-announces-cchek-preliminary-cancer-patient-efficacy-study-results-anix-20161207monthly0.5https://www.biopharmawatch.com/news/ANIX/itus-receives-notice-of-nasdaq-continued-listing-compliance-anix-20161017monthly0.5https://www.biopharmawatch.com/news/ANIX/itus-announces-uplisting-to-anix-20150709monthly0.5https://www.biopharmawatch.com/news/ANIX/itus-announces-formation-of-cancer-diagnostics-subsidiary-anix-20150623monthly0.5https://www.biopharmawatch.com/news/ANIX/itus-settles-lawsuit-with-au-optronics-melville-ny-january-5-201-5-itus-corporation-itus-o-anix-20150105monthly0.5https://www.biopharmawatch.com/news/ANIX/itus-restructures-convertible-debt-melville-ny-anix-20140910monthly0.5https://www.biopharmawatch.com/news/ANIX/itus-and-videocon-enter-into-termination-agreement-and-agree-to-effectuate-return-of-itus--anix-20140903monthly0.5https://www.biopharmawatch.com/news/ANIX/copytele-changing-company-name-and-stock-ticker-symbol-to-anix-20140827monthly0.5https://www.biopharmawatch.com/news/ANIX/copytele-raises-4-million-in-registered-direct-offering-melville-ny-anix-20140715monthly0.5https://www.biopharmawatch.com/news/ANIX/copytele-announces-anix-20140714monthly0.5https://www.biopharmawatch.com/news/ANIX/copytele-announces-3-5-million-financing-from-institutional-investor-melville-ny-anix-20131112monthly0.5https://www.biopharmawatch.com/news/ANIX/copytele-acquires-rights-to-patent-portfolio-covering-loyalty-programs-melville-ny-anix-20130403monthly0.5https://www.biopharmawatch.com/news/ANIX/copytele-announces-private-placement-melville-ny-anix-20130125monthly0.5https://www.biopharmawatch.com/news/ANIX/copytele-presenting-at-the-15-th-annual-redchip-fall-small-cap-conference-melville-ny-anix-20121002monthly0.5https://www.biopharmawatch.com/news/ANIX/copytele-adds-experienced-patent-monetization-team-and-appoints-new-ceo-melville-ny-anix-20120919monthly0.5https://www.biopharmawatch.com/news/ANIX/copytele-announces-private-placement-melville-ny-anix-20120913monthly0.5https://www.biopharmawatch.com/news/ANIX/copytele-appoints-bruce-johnson-to-the-company-s-board-of-directors-melville-ny-anix-20120904monthly0.5https://www.biopharmawatch.com/news/ANIX/copytele-terminates-denis-a-krusos-as-chief-executive-officer-lewis-h-titterton-jr-appoint-anix-20120822monthly0.5https://www.biopharmawatch.com/news/ANIX/copytele-licenses-technology-to-auo-for-e-paper-and-nano-displays-melville-n-y-business-wi-anix-20110531monthly0.5https://www.biopharmawatch.com/news/ANIX/copytele-announces-private-placement-melville-n-y-business-wire-anix-20110210monthly0.5https://www.biopharmawatch.com/news/ANIX/copytele-announces-agreement-with-zqx-advisors-llc-to-seek-business-opportunities-and-lice-anix-20090824monthly0.5https://www.biopharmawatch.com/news/ANIX/copytele-inc-announces-annual-meeting-of-stockholders-melville-n-y-anix-20040922monthly0.5https://www.biopharmawatch.com/news/RLYB/rallybio-reports-third-quarter-2025-financial-results-and-provides-business-updates-rlyb11-rlyb-20251106monthly0.5https://www.biopharmawatch.com/news/RLYB/rallybio-reports-second-quarter-2025-financial-results-and-provides-business-updates-data--rlyb-20250807monthly0.5https://www.biopharmawatch.com/news/RLYB/rallybio-reports-first-quarter-2025-financial-results-and-provides-business-updates-on-tra-rlyb-20250508monthly0.5https://www.biopharmawatch.com/news/RLYB/rallybio-to-discontinue-development-of-rlyb212-for-prevention-of-fnait-rlyb212-phase-2-pk--rlyb-20250408monthly0.5https://www.biopharmawatch.com/news/RLYB/rallybio-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-business-rlyb-20250313monthly0.5https://www.biopharmawatch.com/news/RLYB/rallybio-reports-third-quarter-2024-financial-results-and-provides-business-updates-cta-ap-rlyb-20241107monthly0.5https://www.biopharmawatch.com/news/RLYB/rallybio-reports-second-quarter-2024-financial-results-and-provides-business-updates-on-tr-rlyb-20240808monthly0.5https://www.biopharmawatch.com/news/RLYB/rallybio-reports-first-quarter-2024-financial-results-and-provides-business-updates-on-tra-rlyb-20240509monthly0.5https://www.biopharmawatch.com/news/RLYB/rallybio-announces-collaboration-to-advance-therapeutic-solutions-for-pregnant-individuals-rlyb-20240410monthly0.5https://www.biopharmawatch.com/news/RLYB/rallybio-reports-fourth-quarter-and-full-year-2023-financial-results-received-protocol-ass-rlyb-20240312monthly0.5https://www.biopharmawatch.com/news/RLYB/rallybio-announces-portfolio-prioritization-and-provides-corporate-update-prioritization-o-rlyb-20240206monthly0.5https://www.biopharmawatch.com/news/RLYB/rallybio-announces-preliminary-phase-1-multiple-ascending-dose-data-for-rlyb116-an-innovat-rlyb-20231220monthly0.5https://www.biopharmawatch.com/news/RLYB/rallybio-reports-third-quarter-2023-financial-results-and-provides-business-updates-rlyb21-rlyb-20231109monthly0.5https://www.biopharmawatch.com/news/RLYB/rallybio-reports-second-quarter-2023-financial-results-and-provides-business-updates-rlyb2-rlyb-20230808monthly0.5https://www.biopharmawatch.com/news/RLYB/rallybio-announces-succession-plan-appoints-stephen-uden-m-d-as-chief-executive-officer-ef-rlyb-20230629monthly0.5https://www.biopharmawatch.com/news/RLYB/rallybio-reports-first-quarter-2023-financial-results-rlyb212-phase-1b-proof-of-concept-st-rlyb-20230509monthly0.5https://www.biopharmawatch.com/news/RLYB/rallybio-reports-fourth-quarter-and-full-year-2022-financial-results-proof-of-concept-achi-rlyb-20230306monthly0.5https://www.biopharmawatch.com/news/RLYB/rallybio-announces-appointment-of-jonathan-i-lieber-as-chief-financial-officer-rlyb-20230131monthly0.5https://www.biopharmawatch.com/news/RLYB/rallybio-reports-third-quarter-2022-financial-results-preliminary-results-from-phase-1b-st-rlyb-20221107monthly0.5https://www.biopharmawatch.com/news/RLYB/rallybio-announces-positive-preliminary-results-for-rlyb212-an-anti-hpa-1a-monoclonal-anti-rlyb-20220928monthly0.5https://www.biopharmawatch.com/news/RLYB/rallybio-reports-second-quarter-2022-financial-results-emerging-data-from-phase-1b-study-o-rlyb-20220808monthly0.5https://www.biopharmawatch.com/news/RLYB/rallybio-appoints-wendy-k-chung-m-d-ph-d-to-its-board-of-directors-rlyb-20220802monthly0.5https://www.biopharmawatch.com/news/RLYB/rallybio-announces-retirement-of-jeffrey-fryer-cpa-chief-financial-officer-company-initiat-rlyb-20220602monthly0.5https://www.biopharmawatch.com/news/RLYB/rallybio-reports-first-quarter-2022-financial-results-initiated-phase-1b-proof-of-concept--rlyb-20220510monthly0.5https://www.biopharmawatch.com/news/RLYB/rallybio-appoints-christine-a-nash-and-hui-liu-ph-d-to-its-board-of-directors-tim-shannon--rlyb-20220404monthly0.5https://www.biopharmawatch.com/news/RLYB/rallybio-reports-fourth-quarter-and-full-year-2021-financial-results-phase-1b-proof-of-con-rlyb-20220315monthly0.5https://www.biopharmawatch.com/news/RLYB/march-2022-taking-a-devastating-disease-x2013-and-devastating-it-we-re-going-there-corpora-rlyb-20220307monthly0.5https://www.biopharmawatch.com/news/RLYB/rallybio-corporation-reports-third-quarter-2021-financial-results-and-recent-business-high-rlyb-20211110monthly0.5https://www.biopharmawatch.com/news/RLYB/rallybio-corporation-reports-second-quarter-2021-financial-results-and-recent-business-hig-rlyb-20210909monthly0.5https://www.biopharmawatch.com/news/CLNN/clnn-commonstock00001parvaluecustommember-clnn-20241023monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-announces-closing-of-5-million-debt-facility-from-the-state-of-maryland-funding-demo-clnn-20221212monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-third-quarter-2022-financial-results-and-recent-operating-highlights-x2022-s-clnn-20221107monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-announces-10-8-million-registered-direct-offering-and-5-million-debt-facility-from-t-clnn-20221031monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-topline-results-demonstrating-survival-signal-for-cnm-au8-in-healey-als-plat-clnn-20221003monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-second-quarter-2022-financial-results-and-recent-operating-highlights-x2022--clnn-20220815monthly0.5https://www.biopharmawatch.com/news/CLNN/forward-looking-statements-this-presentation-contains-x201c-forward-looking-statements-x20-clnn-20220721monthly0.5https://www.biopharmawatch.com/news/CLNN/forward-looking-statements-this-presentation-contains-x201c-forward-looking-statements-x20-clnn-20220714monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-receives-3-million-loan-from-state-of-maryland-to-support-development-of-commercial--clnn-20220519monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-first-quarter-2022-financial-results-and-recent-operating-highlights-x2022-c-clnn-20220509monthly0.5https://www.biopharmawatch.com/news/CLNN/disclosures-acknowledgements-mck-and-the-university-of-sydney-have-received-research-fundi-clnn-20220405monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-nanomedicine-presents-updated-clinical-data-from-phase-2-rescue-als-and-repair-trial-clnn-20220314monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-full-year-2021-financial-results-and-recent-operating-highlights-x2022-cash--clnn-20220311monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-nanomedicine-presents-data-from-two-phase-2-multiple-sclerosis-trials-at-actrims-for-clnn-20220224monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-nanomedicine-provides-clinical-program-update-x2022-healey-als-platform-trial-fully--clnn-20220214monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-announces-new-chief-financial-officer-morgan-brown-clnn-20220201monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-nanomedicine-s-second-asset-cnm-znag-completes-50-patient-enrollment-in-covid-19-tri-clnn-20220118monthly0.5https://www.biopharmawatch.com/news/CLNN/clnn-nasdaq-clnn-20211214monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-nanomedicine-s-facility-improvement-project-receives-1-million-grant-award-from-the--clnn-20211213monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-nanomedicine-presents-updated-data-from-rescue-als-phase-2-study-at-4-th-annual-als--clnn-20211201monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-announces-completion-of-patient-enrollment-in-the-healey-als-platform-trial-registra-clnn-20211115monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-third-quarter-2021-operating-and-financial-highlights-recently-announced-top-clnn-20211109monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-nanomedicine-announces-top-line-results-from-phase-2-rescue-als-clinical-trial-rescu-clnn-20211102monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-nanomedicine-presents-blinded-interim-update-from-visionary-ms-and-positive-results--clnn-20211014monthly0.5https://www.biopharmawatch.com/news/CLNN/clnn-nasdaq-clnn-20211006monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-announces-initiation-of-a-second-fda-expanded-access-program-with-cnm-au8-for-people-clnn-20210923monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-presents-phase-2-cnm-au8-cns-target-engagement-data-at-the-international-parkinson-a-clnn-20210917monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-completes-final-patient-visit-in-phase-2-rescue-als-study-topline-data-readout-expec-clnn-20210909monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-enters-into-two-leases-to-materially-expand-manufacturing-capacity-of-its-lead-asset-clnn-20210811monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-second-quarter-2021-operating-and-financial-highlights-phase-2-repair-progra-clnn-20210810monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-nanomedicine-appoints-dr-vallerie-mclaughlin-to-its-board-of-directors-clnn-20210805monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-positive-top-line-results-from-its-phase-2-repair-clinical-trials-in-parkins-clnn-20210805monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-announces-plan-to-expand-its-manufacturing-capacity-of-cnm-au8-closing-of-up-to-30-m-clnn-20210524monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-appoints-david-j-matlin-as-chairman-of-the-board-clnn-20210519monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-first-quarter-2021-operating-and-financial-highlights-interim-phase-2-data-i-clnn-20210512monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-reports-full-year-2020-operating-and-financial-highlights-interim-phase-2-data-indic-clnn-20210329monthly0.5https://www.biopharmawatch.com/news/CLNN/robert-glanzman-md-faan-for-the-visionary-ms-investigators-r-g-l-a-n-z-m-a-n-m-d-f-aa-n-1--clnn-20210226monthly0.5https://www.biopharmawatch.com/news/CLNN/clene-nanomedicine-closes-merger-with-tottenham-acquisition-i-limited-and-provides-corpora-clnn-20201231monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-first-quarter-2026-financial-results-and-recent-corporate-highlig-fbio-20260514monthly0.5https://www.biopharmawatch.com/news/FBIO/streams-if-at-all-our-ability-to-identify-acquire-close-and-integrate-product-candidates-s-fbio-20260223monthly0.5https://www.biopharmawatch.com/news/FBIO/predicts-should-or-will-or-the-negative-of-these-terms-or-other-comparable-terminology-are-fbio-20251215monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-third-quarter-2025-financial-results-and-recent-corporate-highlig-fbio-20251114monthly0.5https://www.biopharmawatch.com/news/FBIO/statements-are-based-on-management-s-current-expectations-and-are-subject-to-risks-and-unc-fbio-20251001monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-first-quarter-2025-financial-results-and-recent-corporate-highlig-fbio-20250515monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-2024-financial-results-and-recent-corporate-highlights-emrosi-app-fbio-20250331monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-third-quarter-2024-financial-results-and-recent-corporate-highlig-fbio-20241114monthly0.5https://www.biopharmawatch.com/news/FBIO/biotech-announces-pricing-of-8-million-registered-direct-offering-and-concurrent-private-p-fbio-20240923monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-second-quarter-2024-financial-results-and-recent-corporate-highli-fbio-20240813monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reduces-total-debt-and-enters-into-new-35-million-term-loan-with-oaktree--fbio-20240725monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-pause-in-payment-of-dividends-on-9-375-series-a-cumulative-rede-fbio-20240705monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-first-quarter-2024-financial-results-and-recent-corporate-highlig-fbio-20240515monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-2023-financial-results-and-recent-corporate-highlights-record-con-fbio-20240328monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-pricing-of-11-million-registered-direct-offering-priced-at-the--fbio-20231229monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-third-quarter-2023-financial-results-and-recent-corporate-highlig-fbio-20231114monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-launch-of-proposed-public-offering-miami-fl-fbio-20231109monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-reverse-stock-split-miami-fl-fbio-20231009monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-second-quarter-2023-financial-results-and-recent-corporate-highli-fbio-20230814monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-first-quarter-2023-financial-results-and-recent-corporate-highlig-fbio-20230515monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-record-2022-financial-results-and-recent-corporate-highlights-for-fbio-20230330monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-pricing-of-13-9-million-registered-direct-offering-priced-at-th-fbio-20230208monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-appoints-lucy-lu-m-d-to-its-board-of-directors-miami-fl-fbio-20221219monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-third-quarter-2022-financial-results-and-recent-corporate-highlig-fbio-20221114monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-second-quarter-2022-financial-results-and-recent-corporate-highli-fbio-20220811monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-appoints-david-jin-as-chief-financial-officer-miami-fl-fbio-20220722monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-first-quarter-2022-financial-results-and-recent-corporate-highlig-fbio-20220512monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-record-2021-financial-results-and-recent-corporate-highlights-rec-fbio-20220328monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-record-third-quarter-2021-financial-results-and-recent-corporate--fbio-20211115monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-closing-of-acquisition-of-caelum-biosciences-by-astrazeneca-tri-fbio-20211006monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-record-second-quarter-2021-financial-results-and-recent-corporate-fbio-20210816monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-first-quarter-2021-financial-results-and-recent-corporate-highlig-fbio-20210516monthly0.5https://www.biopharmawatch.com/news/FBIO/journey-medical-corporation-enters-into-a-definitive-agreement-with-dermira-inc-a-wholly-o-fbio-20210401monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-record-2020-financial-results-and-recent-corporate-highlights-rev-fbio-20210331monthly0.5https://www.biopharmawatch.com/news/FBIO/cyprium-therapeutics-a-fortress-biotech-partner-company-and-sentynl-therapeutics-a-wholly--fbio-20210224monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-third-quarter-2020-financial-results-and-recent-corporate-highlig-fbio-20201109monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-pricing-of-series-a-preferred-stock-offering-new-york-ny-fbio-20200826monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-second-quarter-2020-financial-results-and-recent-corporate-highli-fbio-20200810monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-pricing-of-series-a-preferred-stock-offering-new-york-ny-fbio-20200526monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-record-first-quarter-2020-financial-results-and-recent-corporate--fbio-20200511monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-up-to-5-million-series-a-cumulative-redeemable-perpetual-prefer-fbio-20200323monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-record-fourth-quarter-and-full-year-2019-financial-results-and-re-fbio-20200316monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-pricing-of-series-a-preferred-stock-offering-new-york-ny-fbio-20200211monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-pricing-of-series-a-preferred-stock-offering-new-york-ny-fbio-20191125monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-third-quarter-2019-financial-results-and-recent-corporate-highlig-fbio-20191112monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-appointment-of-kevin-l-lorenz-j-d-to-board-of-directors-new-yor-fbio-20190819monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-second-quarter-2019-financial-results-and-recent-corporate-highli-fbio-20190809monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-first-quarter-2019-financial-results-and-recent-corporate-highlig-fbio-20190510monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-fourth-quarter-and-full-year-2018-financial-results-and-recent-co-fbio-20190318monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-completes-final-stage-closing-of-the-sale-of-its-remaining-shares-of-nati-fbio-20190212monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-agreement-to-sell-its-majority-stake-in-national-holdings-corpo-fbio-20181119monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-third-quarter-2018-financial-results-and-recent-corporate-highlig-fbio-20181109monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-second-quarter-2018-financial-results-and-recent-corporate-highli-fbio-20180809monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-first-quarter-2018-financial-results-and-recent-corporate-highlig-fbio-20180510monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-fourth-quarter-and-full-year-2017-financial-results-and-recent-co-fbio-20180316monthly0.5https://www.biopharmawatch.com/news/FBIO/non-confidential-materials-corporate-presentation-december-2017-non-confidential-materials-fbio-20171214monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-third-quarter-2017-financial-results-and-recent-corporate-highlig-fbio-20171109monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-second-quarter-2017-financial-results-and-recent-corporate-highli-fbio-20170809monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-first-quarter-2017-financial-results-and-recent-corporate-highlig-fbio-20170510monthly0.5https://www.biopharmawatch.com/news/FBIO/proprietary-materials-corporate-presentation-may-2017-proprietary-materials-forward-lookin-fbio-20170502monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-financial-results-for-the-fourth-quarter-and-full-year-ended-fbio-20170316monthly0.5https://www.biopharmawatch.com/news/FBIO/proprietary-materials-corporate-presentation-lindsay-a-rosenwald-md-president-and-ceo-chai-fbio-20170301monthly0.5https://www.biopharmawatch.com/news/FBIO/corporate-overview-march-2017-caelum-biosciences-forward-looking-statements-2-statements-i-fbio-20170228monthly0.5https://www.biopharmawatch.com/news/FBIO/proprietary-materials-corporate-presentation-lindsay-a-fbio-20170214monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-announces-that-its-subsidiary-mustang-bio-closes-94-5-million-private-pla-fbio-20170202monthly0.5https://www.biopharmawatch.com/news/FBIO/unaudited-pro-forma-combined-financial-statements-the-accompanying-unaudited-pro-forma-con-fbio-20161206monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-third-quarter-2016-financial-results-and-recent-corporate-highlig-fbio-20161109monthly0.5https://www.biopharmawatch.com/news/FBIO/corporate-overview-nasdaq-fbio-october-2016-fbio-20161024monthly0.5https://www.biopharmawatch.com/news/FBIO/corporate-overview-nasdaq-fbio-october-2016-fbio-20161020monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-second-quarter-2016-financial-results-and-recent-corporate-highli-fbio-20160809monthly0.5https://www.biopharmawatch.com/news/FBIO/checkpoint-therapeutics-inc-2-gansevoort-street-9-th-floor-new-york-ny-10014-tel-1-781-652-fbio-20160527monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-first-quarter-2016-financial-results-and-recent-corporate-highlig-fbio-20160510monthly0.5https://www.biopharmawatch.com/news/FBIO/mustang-bio-announces-oral-presentation-of-initial-clinical-data-for-mb-101-il13r-2-specif-fbio-20160505monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-and-national-holdings-announce-agreement-subsidiary-of-fortress-biotech-t-fbio-20160428monthly0.5https://www.biopharmawatch.com/news/FBIO/helocyte-announces-corporate-and-clinical-milestones-frank-taffy-appointed-president-and-c-fbio-20160421monthly0.5https://www.biopharmawatch.com/news/FBIO/mustang-bio-announces-presentations-of-mb-101-a-novel-il13r-2-specific-car-t-cells-product-fbio-20160418monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-financial-results-for-the-fourth-quarter-and-year-ended-fbio-20160315monthly0.5https://www.biopharmawatch.com/news/FBIO/teva-and-checkpoint-therapeutics-announce-license-agreement-for-oral-parp-inhibitor-checkp-fbio-20160107monthly0.5https://www.biopharmawatch.com/news/FBIO/avenue-therapeutics-files-to-become-a-public-reporting-company-new-york-ny-fbio-20151230monthly0.5https://www.biopharmawatch.com/news/FBIO/checkpoint-therapeutics-closes-58m-in-private-placement-financing-new-york-ny-fbio-20151221monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-financial-results-for-the-third-quarter-2015-ended-september-30-2-fbio-20151109monthly0.5https://www.biopharmawatch.com/news/FBIO/avenue-therapeutics-inc-corporate-overview-october-2015-forward-looking-statements-stateme-fbio-20151020monthly0.5https://www.biopharmawatch.com/news/FBIO/checkpoint-therapeutics-files-to-become-a-public-reporting-company-new-york-ny-fbio-20150908monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-financial-results-for-the-second-quarter-2015-ended-june-30-2015--fbio-20150810monthly0.5https://www.biopharmawatch.com/news/FBIO/fortress-biotech-reports-financial-results-for-the-first-quarter-2015-ended-march-31-2015--fbio-20150511monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-reports-financial-results-for-the-fourth-quarter-and-year-ended-decem-fbio-20150316monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-closes-10-million-private-placement-financing-burlington-ma-fbio-20150303monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-raises-3-500-000-fbio-20141110monthly0.5https://www.biopharmawatch.com/news/FBIO/altamira-bio-inc-fbio-20141107monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-reports-financial-results-burlington-ma-fbio-20141106monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-reports-financial-results-burlington-ma-fbio-20140811monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-reports-topline-results-from-investigator-initiated-pilot-study-of-ts-fbio-20140626monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-initiates-phase-2a-clinical-study-of-tso-in-pediatric-patients-with-a-fbio-20140514monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-reports-financial-results-for-the-first-quarter-ended-march-31-2014-b-fbio-20140512monthly0.5https://www.biopharmawatch.com/news/FBIO/nasdaq-cndo-april-2014-lindsay-a-rosenwald-md-chairman-president-and-ceo-statements-in-thi-fbio-20140414monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-announces-initiation-of-investigator-initiated-study-evaluating-tso-i-fbio-20140410monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-reports-financial-results-for-the-fourth-quarter-and-year-ended-decem-fbio-20140314monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-granted-a-second-key-patent-for-cndo-109-an-activator-of-natural-kill-fbio-20140206monthly0.5https://www.biopharmawatch.com/news/FBIO/statements-in-this-presentation-that-are-not-descriptions-of-historical-facts-are-forward--fbio-20131224monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-announces-management-changes-burlington-ma-fbio-20131220monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-announces-presentation-of-interim-data-from-autism-study-at-neuropsyc-fbio-20131212monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-announces-ind-submission-for-tso-for-the-treatment-of-moderate-to-sev-fbio-20131209monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-announces-independent-data-monitoring-committee-recommendation-to-dis-fbio-20131106monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-announces-personnel-realignment-including-appointment-of-kevin-horgan-fbio-20131106monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-reports-financial-results-for-the-third-quarter-ended-fbio-20131101monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-announces-top-line-results-from-its-trust-i-phase-2-clinical-trial-of-fbio-20131014monthly0.5https://www.biopharmawatch.com/news/FBIO/statements-in-this-presentation-that-are-not-descriptions-of-historical-facts-are-forward--fbio-20130830monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-reports-financial-results-for-the-second-quarter-ended-june-30-2013-b-fbio-20130805monthly0.5https://www.biopharmawatch.com/news/FBIO/statements-in-this-presentation-that-are-not-descriptions-of-historical-facts-are-forward--fbio-20130729monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-announces-completion-of-enrollment-in-trust-i-phase-2-clinical-trial--fbio-20130701monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-appoints-george-avgerinos-ph-d-as-senior-vice-president-biologics-ope-fbio-20130604monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-reports-financial-results-for-the-first-quarter-ended-march-31-2013-b-fbio-20130508monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-announces-departure-of-dr-bobby-w-sandage-jr-burlington-ma-fbio-20130424monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-announces-sale-of-common-stock-in-its-at-the-market-public-offering-b-fbio-20130411monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-reports-financial-results-for-the-fourth-quarter-and-year-ended-decem-fbio-20130314monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-signs-research-collaboration-and-license-agreement-with-freie-univers-fbio-20130222monthly0.5https://www.biopharmawatch.com/news/FBIO/statements-in-this-presentation-that-are-not-descriptions-of-historical-facts-are-forward--fbio-20130107monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-announces-key-addition-to-management-team-burlington-ma-fbio-20130102monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-acquires-tso-manufacturing-rights-from-ovamed-burlington-ma-fbio-20121227monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-reports-financial-results-for-the-third-quarter-ended-fbio-20121114monthly0.5https://www.biopharmawatch.com/news/FBIO/september-2012-bobby-w-sandage-jr-phd-president-chief-executive-officer-developing-unique--fbio-20120904monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-secures-15-million-loan-facility-from-hercules-technology-growth-capi-fbio-20120829monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-reports-financial-results-for-the-second-quarter-ended-fbio-20120808monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-inc-announces-the-pricing-of-public-offering-of-common-stock-burlingt-fbio-20120622monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-reports-financial-results-for-the-first-quarter-ended-fbio-20120515monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-announces-independent-data-monitoring-committee-recommendation-to-con-fbio-20120424monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-reports-financial-results-for-the-fourth-quarter-and-year-ended-fbio-20120329monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-signs-collaboration-agreement-with-dr-falk-pharma-and-ovamed-for-the--fbio-20120322monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-signs-binding-terms-of-agreement-to-enter-into-collaboration-for-deve-fbio-20111222monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-approved-for-listing-on-nasdaq-burlington-ma-fbio-20111215monthly0.5https://www.biopharmawatch.com/news/FBIO/coronado-biosciences-commences-public-trading-on-the-otc-bulletin-board-form-s-1-registrat-fbio-20111117monthly0.5https://www.biopharmawatch.com/news/CPIX/document-cumberland-pharmaceuticals-reports-q1-2026-financial-results-company-update-enter-cpix-20260505monthly0.5https://www.biopharmawatch.com/news/CPIX/document-cumberland-pharmaceuticals-reports-31-1-fourth-quarter-2025-revenue-growth-cumber-cpix-20260303monthly0.5https://www.biopharmawatch.com/news/CPIX/document-cumberland-pharmaceuticals-receives-fda-fast-track-designation-for-its-ifetroban--cpix-20260204monthly0.5https://www.biopharmawatch.com/news/CPIX/document-cumberland-pharmaceuticals-reports-12-year-to-date-revenue-growth-nashville-tenn-cpix-20251104monthly0.5https://www.biopharmawatch.com/news/CPIX/document-cumberland-pharmaceuticals-reports-23-revenue-growth-year-to-date-nashville-tenn--cpix-20250805monthly0.5https://www.biopharmawatch.com/news/CPIX/document-cumberland-pharmaceuticals-reports-38-revenue-growth-in-q1-2025-nashville-tenn-tu-cpix-20250506monthly0.5https://www.biopharmawatch.com/news/CPIX/document-cumberland-pharmaceuticals-reports-11-6-fourth-quarter-2024-revenue-growth-2024-h-cpix-20250304monthly0.5https://www.biopharmawatch.com/news/CPIX/document-cumberland-pharmaceuticals-reports-third-quarter-2024-financial-results-and-compa-cpix-20241107monthly0.5https://www.biopharmawatch.com/news/CPIX/document-cumberland-pharmaceuticals-reports-16-sequential-revenue-growth-in-second-quarter-cpix-20240806monthly0.5https://www.biopharmawatch.com/news/CPIX/document-cumberland-pharmaceuticals-reports-first-quarter-2024-financial-results-company-u-cpix-20240507monthly0.5https://www.biopharmawatch.com/news/CPIX/document-cumberland-pharmaceuticals-reports-annual-2023-financial-results-2023-highlights--cpix-20240305monthly0.5https://www.biopharmawatch.com/news/CPIX/document-cumberland-pharmaceuticals-reports-third-quarter-2023-financial-results-nashville-cpix-20231107monthly0.5https://www.biopharmawatch.com/news/CPIX/document-cumberland-pharmaceuticals-reports-revenue-and-earnings-growth-second-quarter-202-cpix-20230808monthly0.5https://www.biopharmawatch.com/news/CPIX/document-cumberland-pharmaceuticals-reports-first-quarter-2023-financial-results-company-u-cpix-20230509monthly0.5https://www.biopharmawatch.com/news/CPIX/document-cumberland-pharmaceuticals-reports-17-revenue-growth-for-full-year-2022-2022-high-cpix-20230307monthly0.5https://www.biopharmawatch.com/news/CPIX/document-cumberland-pharmaceuticals-reports-41-revenue-growth-company-also-delivers-growin-cpix-20221108monthly0.5https://www.biopharmawatch.com/news/CPIX/document-cumberland-pharmaceuticals-reports-14-revenue-growth-expanding-portfolio-of-fda-a-cpix-20220809monthly0.5https://www.biopharmawatch.com/news/CPIX/document-cumberland-pharmaceuticals-reports-6-revenue-growth-the-nashville-based-specialty-cpix-20220510monthly0.5https://www.biopharmawatch.com/news/CPIX/document-cumberland-pharmaceuticals-reports-2021-financial-results-company-update-2021-hig-cpix-20220308monthly0.5https://www.biopharmawatch.com/news/CPIX/document-cumberland-pharmaceuticals-acquires-sancuso-from-kyowa-kirin-north-america-nashvi-cpix-20220104monthly0.5https://www.biopharmawatch.com/news/CPIX/document-caldolor-now-fda-approved-for-pre-operative-administration-dosed-prior-to-surgery-cpix-20211129monthly0.5https://www.biopharmawatch.com/news/CPIX/document-cpix-20211116monthly0.5https://www.biopharmawatch.com/news/CPIX/document-cumberland-pharmaceuticals-reports-third-quarter-2021-financial-results-company-u-cpix-20211109monthly0.5https://www.biopharmawatch.com/news/CPIX/document-cumberland-pharmaceuticals-reports-second-quarter-2021-financial-results-company--cpix-20210810monthly0.5https://www.biopharmawatch.com/news/CPIX/document-cumberland-pharmaceuticals-reports-first-quarter-2021-financial-results-company-u-cpix-20210511monthly0.5https://www.biopharmawatch.com/news/CPIX/document-cumberland-pharmaceuticals-reports-9-revenue-growth-in-2020-nashville-tennessee-t-cpix-20210309monthly0.5https://www.biopharmawatch.com/news/CPIX/this-press-release-may-contain-statements-that-are-forward-looking-within-the-meaning-of-s-cpix-20201110monthly0.5https://www.biopharmawatch.com/news/CPIX/in-april-2020-cumberland-released-its-inaugural-sustainability-report-cpix-20200811monthly0.5https://www.biopharmawatch.com/news/CPIX/exhibit-new-publication-reveals-real-world-usage-of-vibativ-in-patients-with-bacteremia-or-cpix-20200529monthly0.5https://www.biopharmawatch.com/news/CPIX/in-april-2020-cumberland-released-its-first-sustainability-report-cpix-20200520monthly0.5https://www.biopharmawatch.com/news/CPIX/fourth-quarter-and-annual-highlights-cpix-20200318monthly0.5https://www.biopharmawatch.com/news/CPIX/exhibit-new-study-reveals-real-world-usage-of-vibativ-in-a-variety-of-infections-nashville-cpix-20191125monthly0.5https://www.biopharmawatch.com/news/CPIX/this-press-release-may-contain-statements-that-are-forward-looking-within-the-meaning-of-s-cpix-20191112monthly0.5https://www.biopharmawatch.com/news/CPIX/exhibit-new-study-reveals-superiority-of-vibativ-over-vancomycin-in-select-patients-with-b-cpix-20191015monthly0.5https://www.biopharmawatch.com/news/CPIX/this-release-contains-forward-looking-statements-within-the-meaning-of-the-federal-securit-cpix-20190814monthly0.5https://www.biopharmawatch.com/news/CPIX/this-release-contains-forward-looking-statements-within-the-meaning-of-the-federal-securit-cpix-20190514monthly0.5https://www.biopharmawatch.com/news/CPIX/fourth-quarter-highlights-cpix-20190226monthly0.5https://www.biopharmawatch.com/news/CPIX/this-release-contains-forward-looking-statements-within-the-meaning-of-the-federal-securit-cpix-20181113monthly0.5https://www.biopharmawatch.com/news/CPIX/this-release-contains-forward-looking-statements-within-the-meaning-of-the-federal-securit-cpix-20180814monthly0.5https://www.biopharmawatch.com/news/CPIX/q1-2018-earnings-release-exhibit-cumberland-pharmaceuticals-reports-first-quarter-2018-fin-cpix-20180508monthly0.5https://www.biopharmawatch.com/news/CPIX/q4-earnings-release-exhibit-cumberland-pharmaceuticals-reports-25-revenue-growth-for-the-f-cpix-20180306monthly0.5https://www.biopharmawatch.com/news/CPIX/earnings-release-q3-2017-exhibit-cumberland-pharmaceutical-reports-27-revenue-growth-in-th-cpix-20171108monthly0.5https://www.biopharmawatch.com/news/CPIX/q2-2017-earnings-release-exhibit-cumberland-pharmaceutical-reports-double-digit-revenue-gr-cpix-20170808monthly0.5https://www.biopharmawatch.com/news/CPIX/earnings-release-q1-exhibit-cumberland-pharmaceuticals-reports-revenue-growth-of-25-in-fir-cpix-20170515monthly0.5https://www.biopharmawatch.com/news/CPIX/q4-earnings-release-exhibit-cumberland-pharmaceuticals-reports-fourth-quarter-and-full-yea-cpix-20170307monthly0.5https://www.biopharmawatch.com/news/CPIX/earnings-release-exhibit-cumberland-pharmaceuticals-reports-third-quarter-year-to-date-201-cpix-20161101monthly0.5https://www.biopharmawatch.com/news/CPIX/exhibit-cumberland-pharmaceuticals-reports-second-quarter-2016-financial-results-entered-i-cpix-20160802monthly0.5https://www.biopharmawatch.com/news/CPIX/sec-exhibit-cumberland-pharmaceuticals-reports-first-quarter-2016-financial-results-caldol-cpix-20160510monthly0.5https://www.biopharmawatch.com/news/CPIX/exhibit-cumberland-pharmaceuticals-reports-fourth-quarter-and-full-year-2015-financial-res-cpix-20160303monthly0.5https://www.biopharmawatch.com/news/CPIX/hepatoren-and-boxaban-phase-ii-clinical-studies-complete-cpix-20151103monthly0.5https://www.biopharmawatch.com/news/CPIX/q2-2015-ex-99-1-earnings-release-cumberland-pharmaceuticals-reports-second-quarter-year-to-cpix-20150804monthly0.5https://www.biopharmawatch.com/news/CPIX/q1-2015-ex-99-1-earnings-release-cumberland-pharmaceuticals-reports-first-quarter-2015-fin-cpix-20150507monthly0.5https://www.biopharmawatch.com/news/CPIX/earnings-release-cumberland-pharmaceuticals-announces-return-to-growth-and-profitability-i-cpix-20150303monthly0.5https://www.biopharmawatch.com/news/CPIX/clinical-cumberland-pharmaceuticals-reports-clinical-and-regualtory-milestones-initial-hep-cpix-20150303monthly0.5https://www.biopharmawatch.com/news/CPIX/earnings-release-q3-2014-ex-99-1-earnings-release-cumberland-pharmaceuticals-reports-third-cpix-20141104monthly0.5https://www.biopharmawatch.com/news/CPIX/earnings-release-q2-2014-ex-99-1-earnings-release-cumberland-pharmaceuticals-reports-secon-cpix-20140805monthly0.5https://www.biopharmawatch.com/news/CPIX/earnings-release-q1-2014-ex-99-1-earnings-release-cumberland-pharmaceuticals-reports-first-cpix-20140513monthly0.5https://www.biopharmawatch.com/news/CPIX/cet-investment-for-immediate-distribution-cumberland-pharmaceuticals-and-gloria-pharmaceut-cpix-20140506monthly0.5https://www.biopharmawatch.com/news/CPIX/an-inability-of-manufacturers-to-produce-cumberland-s-products-on-a-timely-basis-or-failur-cpix-20140307monthly0.5https://www.biopharmawatch.com/news/CPIX/q3-2013-ex-99-1-earnings-release-cumberland-pharmaceuticals-reports-third-quarter-financia-cpix-20131105monthly0.5https://www.biopharmawatch.com/news/CPIX/first-amendment-to-fourth-amended-and-restated-loan-agreement-this-first-amendment-to-four-cpix-20101005monthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-highlights-phase-1-data-in-an-investigator-initiated-study-of-lymphir-deni-ctor-20260530monthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-ships-first-international-order-of-lymphir-to-europe-order-fulfilment-expa-ctor-20260429monthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-announces-positive-topline-results-from-investigator-initiated-phase-1-stu-ctor-20260310monthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-inc-reports-fiscal-year-2025-financial-results-and-provides-business-updat-ctor-20251210monthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-announces-18-million-concurrent-registered-direct-offering-and-private-pla-ctor-20251209monthly0.5https://www.biopharmawatch.com/news/CTOR/corporate-overview-nasdaq-ctor-december-2025-forward-looking-language-nasdaq-ctor-2-this-p-ctor-20251201monthly0.5https://www.biopharmawatch.com/news/CTOR/forward-looking-language-this-presentation-has-been-prepared-by-citius-oncology-inc-the-co-ctor-20251023monthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-announces-pricing-of-9-0-million-registered-direct-offering-and-concurrent-ctor-20250909monthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-announces-pricing-of-9-0-million-public-offering-cranford-n-j-ctor-20250716monthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-anticipates-commercial-launch-of-lymphir-in-2025-cranford-n-j-ctor-20250617monthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-inc-reports-fiscal-second-quarter-2025-financial-results-and-provides-busi-ctor-20250514monthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-inc-reports-fiscal-first-quarter-2025-financial-results-and-provides-busin-ctor-20250214monthly0.5https://www.biopharmawatch.com/news/CTOR/citius-pharmaceuticals-and-citius-oncology-announce-unique-permanent-j-code-issued-for-lym-ctor-20250206monthly0.5https://www.biopharmawatch.com/news/CTOR/citius-pharmaceuticals-and-citius-oncology-highlight-lymphir-commercial-launch-planned-for-ctor-20250107monthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-engages-jefferies-as-exclusive-financial-advisor-to-explore-strategic-alte-ctor-20250106monthly0.5https://www.biopharmawatch.com/news/CTOR/citius-oncology-inc-reports-fiscal-full-year-2024-financial-results-and-provides-business--ctor-20241227monthly0.5https://www.biopharmawatch.com/news/CTOR/citius-pharmaceuticals-inc-and-citius-oncology-inc-announce-promising-preliminary-results--ctor-20241111monthly0.5https://www.biopharmawatch.com/news/CTOR/citius-pharmaceuticals-inc-and-citius-oncology-inc-announce-lymphir-denileukin-diftitox-cx-ctor-20240905monthly0.5https://www.biopharmawatch.com/news/CTOR/tenx-keane-acquisition-announces-contribution-to-trust-account-in-connection-with-extensio-ctor-20240110monthly0.5https://www.biopharmawatch.com/news/CTOR/citius-pharmaceuticals-executes-definitive-agreement-to-merge-wholly-owned-subsidiary-with-ctor-20231024monthly0.5https://www.biopharmawatch.com/news/CTOR/tenx-keane-acquisition-announces-extension-of-the-deadline-for-an-initial-business-combina-ctor-20231018monthly0.5https://www.biopharmawatch.com/news/CTOR/tenx-keane-acquisition-announces-extension-of-the-deadline-for-an-initial-business-combina-ctor-20230718monthly0.5https://www.biopharmawatch.com/news/CTOR/tenx-keane-acquisition-announces-the-separate-trading-of-its-ordinary-shares-and-rights-co-ctor-20221208monthly0.5https://www.biopharmawatch.com/news/CTOR/index-to-financial-statements-page-audited-financial-statements-of-tenx-keane-acquisition--ctor-20221018monthly0.5https://www.biopharmawatch.com/news/CTOR/tenx-keane-acquisition-announces-pricing-of-60-million-initial-public-offering-new-york-ctor-20221013monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-reports-first-quarter-results-san-jose-ca-x2013-om-20260507monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-reports-third-quarter-results-san-jose-ca-x2013-om-20251110monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-appoints-renee-gaeta-as-chief-financial-officer-san-jose-ca-om-20250603monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-appoints-industry-veteran-kevin-o-boyle-to-its-board-of-directors-san-jose--om-20250514monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-first-quarter-results-demonstrate-strong-growth-in-console-and-recurring-re-om-20250507monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-announces-one-for-fifteen-reverse-stock-split-san-jose-ca-om-20250318monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-inc-index-to-financial-statements-page-reports-of-independent-registered-pu-om-20250226monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-reports-fourth-quarter-and-full-year-2024-financial-results-san-jose-ca-x20-om-20250219monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-announces-169-million-private-placement-financing-from-leading-mutual-funds-om-20250106monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-reports-third-quarter-2024-financial-results-san-jose-ca-x2013-om-20241106monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-reports-second-quarter-2024-financial-results-san-jose-ca-x2013-om-20240807monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-reports-first-quarter-2024-financial-results-san-jose-ca-x2013-om-20240508monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-s-tablocart-with-prefiltration-receives-fda-510-k-clearance-san-jose-calif--om-20240506monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-announces-appointment-of-medical-technology-veteran-brent-d-lang-to-its-boa-om-20240313monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-reports-fourth-quarter-and-full-year-2023-financial-results-san-jose-ca-x20-om-20240221monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-reports-unaudited-fourth-quarter-and-2023-revenue-provides-2024-revenue-and-om-20240108monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-reports-third-quarter-2023-financial-results-reiterates-updated-2023-revenu-om-20231107monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-reports-preliminary-third-quarter-2023-financial-results-conference-call-sc-om-20231012monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-reports-second-quarter-2023-financial-results-sequential-revenue-growth-of--om-20230802monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-reports-first-quarter-2023-financial-results-increases-revenue-and-gross-ma-om-20230503monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-reports-fourth-quarter-and-full-year-2022-financial-results-san-jose-ca-x20-om-20230213monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-reports-expected-fourth-quarter-and-full-year-2022-revenue-provides-2023-re-om-20230109monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-reports-third-quarter-2022-financial-results-revenue-grows-10-8-from-q2-to--om-20221108monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-secures-up-to-300-million-in-debt-financing-san-jose-ca-x2013-om-20221104monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-resumes-shipment-of-tablo-systems-for-home-use-reports-second-quarter-2022--om-20220801monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-announces-shipment-hold-on-new-tablo-systems-for-home-use-pending-fda-revie-om-20220613monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-reports-first-quarter-2022-financial-results-revenue-grows-33-3-to-30-6-mil-om-20220504monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-names-business-leader-dale-e-jones-to-board-of-directors-san-jose-ca-x2013-om-20220425monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-reports-fourth-quarter-and-full-year-2021-financial-results-record-annual-r-om-20220216monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-reports-third-quarter-2021-financial-results-2021-revenue-guidance-range-el-om-20211103monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-reports-second-quarter-2021-financial-results-2021-revenue-guidance-range-u-om-20210805monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-announces-departure-of-cfo-and-appointment-of-nabeel-ahmed-as-interim-cfo-r-om-20210701monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-appoints-medtech-executive-katie-szyman-to-board-of-directors-om-20210524monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-reports-first-quarter-2021-financial-results-san-jose-ca-om-20210505monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-announces-pricing-of-primary-and-upsized-secondary-public-offering-om-20210409monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-announces-primary-and-secondary-offering-of-common-stock-san-jose-ca-om-20210406monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-appoints-global-consumer-brand-builder-andrea-saia-to-board-of-directors-om-20210324monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-reports-fourth-quarter-and-full-year-2020-financial-results-san-jose-ca-om-20210309monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-appoints-karen-drexler-to-board-of-directors-healthcare-industry-veteran-br-om-20210112monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-announces-secondary-offering-of-common-stock-san-jose-ca-om-20201130monthly0.5https://www.biopharmawatch.com/news/OM/outset-medical-reports-third-quarter-2020-financial-results-strong-quarter-driven-by-accel-om-20201111monthly0.5https://www.biopharmawatch.com/news/SPAI/safe-pro-awarded-u-s-army-order-for-ai-powered-threat-analysis-kit-together-with-red-cat-b-spai-20260602monthly0.5https://www.biopharmawatch.com/news/SPAI/safe-pro-reports-record-560-revenue-growth-in-first-quarter-as-artificial-intelligence-sal-spai-20260515monthly0.5https://www.biopharmawatch.com/news/SPAI/safe-pro-awarded-contract-to-provide-u-s-government-with-ai-powered-edge-processing-system-spai-20260220monthly0.5https://www.biopharmawatch.com/news/SPAI/safe-pro-group-reports-102-revenue-growth-in-third-quarter-2024-nine-month-revenues-increa-spai-20241114monthly0.5https://www.biopharmawatch.com/news/SPAI/safe-pro-group-reports-record-524-revenue-increase-in-second-quarter-of-2024-2024-second-q-spai-20240926monthly0.5https://www.biopharmawatch.com/news/QTI/investorpresentati-quantitative-transmission-imaging-breast-acoustic-ct-scanner-may-2026-n-qti-20260521monthly0.5https://www.biopharmawatch.com/news/QTI/document-qt-imaging-reports-first-quarter-2026-revenue-of-6-5-million-revenue-of-6-5-milli-qti-20260513monthly0.5https://www.biopharmawatch.com/news/QTI/document-qt-imaging-reports-2025-fourth-quarter-and-full-year-financial-results-2025-reven-qti-20260325monthly0.5https://www.biopharmawatch.com/news/QTI/document-qt-imaging-reports-preliminary-unaudited-fourth-quarter-and-full-year-2025-financ-qti-20260218monthly0.5https://www.biopharmawatch.com/news/QTI/document-qt-imaging-holdings-inc-audited-consolidated-financial-statements-as-of-and-for-t-qti-20260206monthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-announces-uplisting-to-nasdaq-novato-calif-qti-20260127monthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-holdings-inc-unaudited-pro-forma-condensed-consolidated-balance-sheet-as-of-sep-qti-20260123monthly0.5https://www.biopharmawatch.com/news/QTI/document-qt-imaging-announces-exclusive-distribution-agreement-with-al-naghi-medical-for-t-qti-20260120monthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-holdings-inc-unaudited-pro-forma-condensed-consolidated-statement-of-operations-qti-20251223monthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-holdings-inc-unaudited-pro-forma-condensed-consolidated-balance-sheet-as-of-sep-qti-20251211monthly0.5https://www.biopharmawatch.com/news/QTI/document-qt-imaging-reports-strong-third-quarter-2025-financial-results-generated-revenue--qti-20251110monthly0.5https://www.biopharmawatch.com/news/QTI/document-qt-imaging-3-1-reverse-stock-split-market-effective-on-qti-20251024monthly0.5https://www.biopharmawatch.com/news/QTI/document-qt-imaging-announces-plans-to-relist-on-nasdaq-company-to-effect-3-1-reverse-stoc-qti-20251020monthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-holdings-inc-unaudited-pro-forma-condensed-consolidated-balance-sheet-as-of-jun-qti-20250930monthly0.5https://www.biopharmawatch.com/news/QTI/this-press-release-shall-not-constitute-an-offer-to-sell-or-the-solicitation-of-an-offer-t-qti-20251001monthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-receives-5-0-million-in-new-funding-from-lynrock-lake-to-repurchase-and-cancel--qti-20250827monthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-holdings-inc-unaudited-pro-forma-condensed-consolidated-balance-sheet-as-of-mar-qti-20250611monthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-holdings-receives-10-1-million-in-new-funding-to-support-working-capital-and-re-qti-20250227monthly0.5https://www.biopharmawatch.com/news/QTI/quantitative-transmission-imaging-breast-acoustic-ct-scanner-investor-presentation-april-2-qti-20240401monthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-holdings-names-dr-raluca-dinu-as-acting-chief-executive-officer-and-anastas-bud-qti-20240318monthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-holdings-announces-new-ticker-symbol-for-otc-warrants-and-delisting-of-units-no-qti-20240315monthly0.5https://www.biopharmawatch.com/news/QTI/unaudited-pro-forma-condensed-combined-financial-information-qt-imaging-holdings-inc-f-k-a-qti-20240304monthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-pioneers-patient-centric-breast-imaging-technology-through-strategic-partnershi-qti-20240307monthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-holdings-announces-completion-of-business-combination-with-gigcapital5-combined-qti-20240305monthly0.5https://www.biopharmawatch.com/news/QTI/gigcapital5-inc-announces-closing-date-for-business-combination-with-qt-imaging-qt-imaging-qti-20240229monthly0.5https://www.biopharmawatch.com/news/QTI/gigcapital5-inc-announces-shareholder-approval-of-business-combination-palo-alto-ca-qti-20240222monthly0.5https://www.biopharmawatch.com/news/QTI/united-states-securities-and-exchange-commission-washington-d-c-20549-schedule-14a-proxy-s-qti-20240216monthly0.5https://www.biopharmawatch.com/news/QTI/united-states-securities-and-exchange-commission-washington-d-c-20549-schedule-14a-a-proxy-qti-20240207monthly0.5https://www.biopharmawatch.com/news/QTI/gigcapital5-inc-announces-stockholder-approval-of-extension-amendment-to-the-amended-and-r-qti-20231229monthly0.5https://www.biopharmawatch.com/news/QTI/united-states-securities-and-exchange-commission-washington-d-c-20549-schedule-14a-a-proxy-qti-20231226monthly0.5https://www.biopharmawatch.com/news/QTI/united-states-securities-and-exchange-commission-washington-d-c-20549-schedule-14a-proxy-s-qti-20231219monthly0.5https://www.biopharmawatch.com/news/QTI/gigcapital5-inc-confirms-receipt-of-sponsor-funds-for-additional-working-capital-palo-alto-qti-20231031monthly0.5https://www.biopharmawatch.com/news/QTI/gigcapital5-inc-announces-stockholder-approval-of-extension-amendment-to-the-amended-and-r-qti-20230929monthly0.5https://www.biopharmawatch.com/news/QTI/united-states-securities-and-exchange-commission-washington-d-c-20549-schedule-14a-proxy-s-qti-20230927monthly0.5https://www.biopharmawatch.com/news/QTI/gigcapital5-inc-confirms-consideration-for-non-redemption-agreements-palo-alto-ca-qti-20230922monthly0.5https://www.biopharmawatch.com/news/QTI/gigcapital5-inc-confirms-receipt-of-sponsor-funds-to-extend-period-of-time-to-consummate-b-qti-20230725monthly0.5https://www.biopharmawatch.com/news/QTI/gigcapital5-inc-confirms-receipt-of-sponsor-funds-to-extend-period-of-time-to-consummate-b-qti-20230626monthly0.5https://www.biopharmawatch.com/news/QTI/gigcapital5-inc-confirms-receipt-of-sponsor-funds-to-extend-period-of-time-to-consummate-b-qti-20230427monthly0.5https://www.biopharmawatch.com/news/QTI/gigcapital5-inc-announces-transfer-of-listing-to-nasdaq-qti-20230411monthly0.5https://www.biopharmawatch.com/news/QTI/gigcapital5-inc-announces-stockholder-approval-of-extension-amendment-to-the-amended-and-r-qti-20230328monthly0.5https://www.biopharmawatch.com/news/QTI/gigcapital5-inc-confirms-receipt-of-sponsor-funds-to-extend-period-of-time-to-consummate-b-qti-20230227monthly0.5https://www.biopharmawatch.com/news/QTI/gigcapital5-inc-confirms-receipt-of-sponsor-funds-to-extend-period-of-time-to-consummate-b-qti-20230126monthly0.5https://www.biopharmawatch.com/news/QTI/gigcapital5-inc-confirms-receipt-of-sponsor-funds-to-extend-period-of-time-to-consummate-b-qti-20221228monthly0.5https://www.biopharmawatch.com/news/QTI/qt-imaging-and-gigcapital5-announce-signing-of-business-combination-agreement-to-bring-bre-qti-20221212monthly0.5https://www.biopharmawatch.com/news/QTI/gigcapital5-inc-confirms-receipt-of-sponsor-funds-to-extend-period-of-time-to-consummate-b-qti-20221128monthly0.5https://www.biopharmawatch.com/news/QTI/gigcapital5-inc-confirms-receipt-of-sponsor-funds-to-extend-period-of-time-to-consummate-b-qti-20221026monthly0.5https://www.biopharmawatch.com/news/QTI/gigcapital5-and-qt-imaging-sign-an-exclusive-term-sheet-for-a-business-combination-qt-imag-qti-20221003monthly0.5https://www.biopharmawatch.com/news/QTI/gigcapital5-inc-announces-a-one-month-extension-of-the-combination-period-palo-alto-ca-qti-20220926monthly0.5https://www.biopharmawatch.com/news/QTI/gigcapital5-inc-announces-stockholder-approval-of-extension-amendments-to-the-amended-and--qti-20220923monthly0.5https://www.biopharmawatch.com/news/QTI/dr-sharmila-makhija-joins-gigcapital5-board-of-directors-qti-20220105monthly0.5https://www.biopharmawatch.com/news/QTI/gigcapital5-inc-announces-the-separate-trading-of-its-common-stock-and-warrants-commencing-qti-20211104monthly0.5https://www.biopharmawatch.com/news/QTI/gigcapital5-inc-index-to-balance-sheet-and-notes-to-balance-sheet-report-of-lndependent-re-qti-20210929monthly0.5https://www.biopharmawatch.com/news/QTI/gigcapital5-inc-announces-pricing-of-200-000-000-initial-public-offering-qti-20210923monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-second-quarter-2025-financial-and-operating-results-delivered-38-1-mil-stim-20250715monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-appoints-new-chief-financial-officer-steven-pfanstiel-a-seasoned-financial-exe-stim-20250715monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-first-quarter-2025-financial-and-operating-results-malvern-pa-may-6-20-stim-20250506monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-updated-fourth-quarter-and-full-year-2024-financial-and-operating-resu-stim-20250327monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-fourth-quarter-and-full-year-2024-financial-and-operating-results-malv-stim-20250304monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-launch-of-underwritten-public-offering-of-common-stock-malvern-pa-stim-20250206monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-provides-business-update-and-issues-2025-guidance-preliminary-unaudited-fourth-stim-20250113monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-and-greenbrook-tms-announce-closing-of-transaction-malvern-pa-and-toronto-on-stim-20241210monthly0.5https://www.biopharmawatch.com/news/STIM/correction-neuronetics-reports-record-third-quarter-2024-financial-and-operating-results-m-stim-20241112monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-record-third-quarter-2024-financial-and-operating-results-malvern-pa-stim-20241112monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-and-greenbrook-tms-announce-receipt-of-interim-order-in-respect-of-proposed-ar-stim-20241004monthly0.5https://www.biopharmawatch.com/news/STIM/understanding-the-benefits-of-neuronetics-greenbrook-acquisition-stim-20241002monthly0.5https://www.biopharmawatch.com/news/STIM/fireside-chat-keith-sullivan-president-ceo-neuronetics-inc-bill-leonard-president-ceo-gree-stim-20240815monthly0.5https://www.biopharmawatch.com/news/STIM/forward-looking-statements-this-presentation-contains-estimates-and-other-statistical-data-stim-20240814monthly0.5https://www.biopharmawatch.com/news/STIM/presentation-operator-good-day-and-thank-you-for-standing-by-welcome-to-the-neuronetics-se-stim-20240812monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-record-second-quarter-2024-financial-and-operating-results-malvern-pa-stim-20240812monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-the-closing-of-up-to-90-million-senior-secured-credit-facility-with--stim-20240730monthly0.5https://www.biopharmawatch.com/news/STIM/william-blair-th-44-annual-growth-stock-conference-stim-20240606monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-record-first-quarter-2024-financial-and-operating-results-malvern-pa-stim-20240507monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-record-fourth-quarter-and-record-full-year-2023-financial-and-operatin-stim-20240305monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-preliminary-fourth-quarter-and-fiscal-year-2023-financial-results-malv-stim-20240108monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-third-quarter-2023-financial-and-operating-results-malvern-pa-stim-20231107monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-draws-down-remaining-22-5-million-available-under-credit-facility-malvern-pa-stim-20231003monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-record-second-quarter-2023-financial-and-operating-results-malvern-pa-stim-20230808monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-record-first-quarter-2023-financial-and-operating-results-malvern-pa-stim-20230509monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-secures-up-to-60-million-in-new-debt-financing-with-slr-capital-partners-provi-stim-20230404monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-record-fourth-quarter-and-record-full-year-2022-financial-and-operatin-stim-20230307monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-preliminary-fourth-quarter-and-fiscal-year-2022-financial-results-malv-stim-20230109monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-third-quarter-2022-financial-and-operating-results-malvern-pa-stim-20221108monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-second-quarter-2022-financial-and-operating-results-malvern-pa-stim-20220802monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-first-quarter-2022-financial-and-operating-results-malvern-pa-stim-20220512monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-fourth-quarter-and-full-year-2021-financial-and-operating-results-malv-stim-20220308monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-amendment-of-credit-facility-with-slr-investment-corp-malvern-pa-stim-20220222monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-preliminary-fourth-quarter-and-fiscal-year-2021-financial-results-malv-stim-20220110monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-third-quarter-2021-financial-and-operating-results-malvern-pa-stim-20211109monthly0.5https://www.biopharmawatch.com/news/STIM/correction-neuronetics-announces-preliminary-revenue-for-third-quarter-2021-malvern-pa-stim-20211019monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-preliminary-revenue-for-third-quarter-2021-malvern-pa-stim-20211012monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-appointment-of-megan-rosengarten-to-its-board-of-directors-malvern-p-stim-20210805monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-second-quarter-2021-financial-and-operating-results-malvern-pa-stim-20210803monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-first-quarter-2021-financial-and-operating-results-malvern-pa-stim-20210504monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-retirement-of-brian-farley-and-appointment-of-robert-cascella-as-cha-stim-20210414monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-appointment-of-robert-cascella-to-its-board-of-directors-malvern-pa--stim-20210401monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-fourth-quarter-and-full-year-2020-financial-and-operating-results-malv-stim-20210302monthly0.5https://www.biopharmawatch.com/news/STIM/disclaimers-this-presentation-has-been-prepared-solely-for-use-at-this-meeting-the-materia-stim-20210128monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-preliminary-fourth-quarter-and-fiscal-year-2020-financial-results-malv-stim-20210112monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-the-amendment-of-credit-facility-with-solar-capital-partners-amendme-stim-20201208monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-third-quarter-2020-financial-and-operating-results-malvern-pa-stim-20201102monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-second-quarter-2020-financial-and-operating-results-malvern-pa-stim-20200804monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-the-appointment-of-keith-j-sullivan-as-president-and-chief-executive-stim-20200714monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-appointment-of-bruce-j-shook-to-its-board-of-directors-malvern-pa-stim-20200626monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-first-quarter-2020-financial-and-operating-results-malvern-pa-stim-20200505monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-inc-announces-preliminary-first-quarter-2020-revenue-corporate-restructuring-a-stim-20200408monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-inc-adopts-limited-duration-shareholder-rights-plan-malvern-pa-stim-20200408monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-inc-announces-chris-thatcher-will-step-down-as-president-and-stim-20200305monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-fourth-quarter-and-full-year-2019-financial-and-operating-results-malv-stim-20200303monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-third-quarter-2019-financial-and-operating-results-malvern-pa-stim-20191105monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-appointment-of-sheryl-conley-to-its-board-of-directors-malvern-pa-stim-20191101monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-second-quarter-2019-financial-and-operating-results-malvern-pa-stim-20190806monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-appoints-stephen-furlong-as-chief-financial-officer-malvern-pa-stim-20190702monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-first-quarter-2019-financial-and-operating-results-malvern-pa-stim-20190507monthly0.5https://www.biopharmawatch.com/news/STIM/neurostar-advanced-therapy-to-receive-reimbursement-approval-in-japan-proven-breakthrough--stim-20190327monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-fourth-quarter-and-full-year-2018-financial-and-operating-results-malv-stim-20190305monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-inc-announces-appointment-of-dr-cheryl-r-blanchard-to-its-board-of-directors-d-stim-20190215monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-announces-preliminary-fourth-quarter-and-full-year-revenue-preliminary-full-ye-stim-20190107monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-third-quarter-2018-financial-and-operating-results-malvern-pa-stim-20181106monthly0.5https://www.biopharmawatch.com/news/STIM/neuronetics-reports-second-quarter-2018-financial-and-operating-results-malvern-pa-stim-20180814monthly0.5https://www.biopharmawatch.com/news/OSTX/os-therapies-announces-ema-initiates-rolling-review-of-conditional-marketing-authorization-ostx-20260430monthly0.5https://www.biopharmawatch.com/news/OSTX/os-therapies-completes-5-25m-registered-direct-offering-primarily-with-pre-existing-high-n-ostx-20260402monthly0.5https://www.biopharmawatch.com/news/OSTX/os-therapies-enters-into-warrant-inducement-agreements-7-53m-gross-proceeds-raised-from-pr-ostx-20260112monthly0.5https://www.biopharmawatch.com/news/OSTX/nyse-american-ostx-corporate-presentation-october-2025-nyse-american-ostx-2-safe-harbor-st-ostx-20251017monthly0.5https://www.biopharmawatch.com/news/OSTX/os-therapies-completes-exercise-inducement-and-exchange-offer-for-all-remaining-outstandin-ostx-20250902monthly0.5https://www.biopharmawatch.com/news/OSTX/os-therapies-terminates-equity-line-of-credit-new-york-ny-ostx-20250825monthly0.5https://www.biopharmawatch.com/news/OSTX/os-therapies-reports-second-quarter-2025-financial-results-and-provides-business-update-u--ostx-20250819monthly0.5https://www.biopharmawatch.com/news/OSTX/os-therapies-closes-4-2-million-in-warrant-exercise-inducement-and-exchange-offer-cash-run-ostx-20250714monthly0.5https://www.biopharmawatch.com/news/OSTX/os-therapies-announces-warrant-exercise-inducement-exchange-offer-current-holders-of-five--ostx-20250624monthly0.5https://www.biopharmawatch.com/news/OSTX/os-therapies-reports-first-quarter-2025-financial-results-and-provides-business-update-fee-ostx-20250516monthly0.5https://www.biopharmawatch.com/news/OSTX/os-therapies-completes-acquisition-of-advaxis-immunotherapies-clinical-pre-clinical-and-ip-ostx-20250409monthly0.5https://www.biopharmawatch.com/news/OSTX/os-therapies-reports-full-year-2024-financial-results-and-provides-business-update-full-da-ostx-20250331monthly0.5https://www.biopharmawatch.com/news/OSTX/os-therapies-announces-closing-of-6-million-private-placement-funding-expected-to-provide--ostx-20241231monthly0.5https://www.biopharmawatch.com/news/OSTX/os-therapies-announces-pricing-of-6-million-private-placement-funding-will-provide-company-ostx-20241224monthly0.5https://www.biopharmawatch.com/news/OSTX/os-therapies-reports-third-quarter-2024-financial-results-and-provides-business-update-top-ostx-20241115monthly0.5https://www.biopharmawatch.com/news/OSTX/os-therapies-appoints-two-bio-pharmaceutical-industry-veterans-to-the-board-of-directors-c-ostx-20241028monthly0.5https://www.biopharmawatch.com/news/OSTX/os-therapies-clarifies-cusip-of-common-stock-new-york-ny-ostx-20240822monthly0.5https://www.biopharmawatch.com/news/OSTX/os-therapies-reports-second-quarter-2024-financial-results-successful-ipo-that-raised-6-4--ostx-20240731monthly0.5https://www.biopharmawatch.com/news/CSBR/about-champions-oncology-inc-champions-oncology-is-a-global-preclinical-and-clinical-resea-csbr-20260312monthly0.5https://www.biopharmawatch.com/news/CSBR/not-be-considered-in-isolation-or-as-a-substitute-for-gaap-measures-such-as-operating-inco-csbr-20251215monthly0.5https://www.biopharmawatch.com/news/CSBR/through-its-large-portfolio-of-cutting-edge-bioanalytical-platforms-groundbreaking-data-pl-csbr-20250915monthly0.5https://www.biopharmawatch.com/news/CSBR/this-press-release-to-conform-these-statements-to-actual-results-or-to-changes-in-champion-csbr-20250723monthly0.5https://www.biopharmawatch.com/news/CSBR/on-these-forward-looking-statements-the-company-s-actual-results-could-differ-materially-f-csbr-20250311monthly0.5https://www.biopharmawatch.com/news/CSBR/non-gaap-financial-information-see-the-attached-reconciliation-of-gaap-net-income-loss-to--csbr-20241211monthly0.5https://www.biopharmawatch.com/news/CSBR/non-gaap-financial-information-see-the-attached-reconciliation-of-gaap-net-income-loss-to--csbr-20240911monthly0.5https://www.biopharmawatch.com/news/CSBR/about-champions-oncology-inc-champions-oncology-is-a-global-preclinical-and-clinical-resea-csbr-20240718monthly0.5https://www.biopharmawatch.com/news/CSBR/loss-divided-by-the-weighted-average-number-of-diluted-shares-outstanding-champions-defini-csbr-20240312monthly0.5https://www.biopharmawatch.com/news/CSBR/see-the-attached-reconciliation-of-gaap-net-loss-to-non-gaap-net-income-loss-for-an-explan-csbr-20231212monthly0.5https://www.biopharmawatch.com/news/CSBR/website-www-championsoncology-com-facebook-https-www-facebook-com-championsoncology-linked-csbr-20231017monthly0.5https://www.biopharmawatch.com/news/CSBR/full-details-of-the-company-s-financial-results-will-be-available-by-csbr-20230914monthly0.5https://www.biopharmawatch.com/news/CSBR/share-amounts-as-non-gaap-net-income-loss-divided-by-the-weighted-average-number-of-dilute-csbr-20230724monthly0.5https://www.biopharmawatch.com/news/CSBR/about-champions-oncology-inc-champions-oncology-is-a-technology-driven-research-organizati-csbr-20230405monthly0.5https://www.biopharmawatch.com/news/CSBR/performance-and-trends-that-facilitate-comparisons-between-periods-before-and-after-certai-csbr-20230315monthly0.5https://www.biopharmawatch.com/news/CSBR/management-does-not-believe-affect-the-company-s-basic-operations-do-not-meet-the-gaap-def-csbr-20221213monthly0.5https://www.biopharmawatch.com/news/CSBR/see-the-attached-reconciliation-of-gaap-net-income-loss-to-non-gaap-net-income-for-an-expl-csbr-20220908monthly0.5https://www.biopharmawatch.com/news/CSBR/champions-oncology-is-a-technology-driven-research-organization-that-develops-innovative-t-csbr-20220721monthly0.5https://www.biopharmawatch.com/news/CSBR/trends-that-facilitate-comparisons-between-periods-before-and-after-certain-items-that-wou-csbr-20220315monthly0.5https://www.biopharmawatch.com/news/CSBR/a-substitute-for-similar-gaap-items-champions-defines-non-gaap-dilutive-earnings-per-share-csbr-20211213monthly0.5https://www.biopharmawatch.com/news/CSBR/see-the-attached-reconciliation-of-gaap-net-income-loss-to-non-gaap-net-income-for-an-expl-csbr-20210913monthly0.5https://www.biopharmawatch.com/news/CSBR/champions-oncology-is-a-technology-driven-research-organization-that-provides-end-to-end-r-csbr-20210722monthly0.5https://www.biopharmawatch.com/news/CSBR/non-gaap-financial-information-see-the-attached-reconciliation-of-gaap-net-income-to-non-g-csbr-20210311monthly0.5https://www.biopharmawatch.com/news/CSBR/see-the-attached-reconciliation-of-gaap-net-income-loss-to-non-gaap-net-income-loss-for-an-csbr-20201214monthly0.5https://www.biopharmawatch.com/news/CSBR/earnings-loss-per-share-amounts-for-the-three-months-ended-csbr-20200914monthly0.5https://www.biopharmawatch.com/news/CSBR/engraftments-or-tumorgrafts-in-a-manner-that-preserves-the-biological-characteristics-of-t-csbr-20200727monthly0.5https://www.biopharmawatch.com/news/CSBR/about-champions-oncology-inc-about-champions-oncology-champions-oncology-inc-is-engaged-in-csbr-20200312monthly0.5https://www.biopharmawatch.com/news/CSBR/about-champions-oncology-inc-about-champions-oncology-champions-oncology-inc-is-engaged-in-csbr-20191216monthly0.5https://www.biopharmawatch.com/news/CSBR/trends-that-facilitate-comparisons-between-periods-before-and-after-certain-items-that-wou-csbr-20190916monthly0.5https://www.biopharmawatch.com/news/CSBR/oncology-generally-uses-words-such-as-believe-may-could-will-intend-expect-anticipate-plan-csbr-20190715monthly0.5https://www.biopharmawatch.com/news/CSBR/gaap-net-income-loss-and-non-gaap-earnings-loss-per-share-are-not-and-should-not-be-viewed-csbr-20190318monthly0.5https://www.biopharmawatch.com/news/CSBR/about-champions-oncology-inc-champions-oncology-inc-is-engaged-in-the-development-of-advan-csbr-20181217monthly0.5https://www.biopharmawatch.com/news/CSBR/platform-is-a-novel-approach-to-personalizing-cancer-care-based-upon-the-implantation-of-p-csbr-20180913monthly0.5https://www.biopharmawatch.com/news/CSBR/companies-seeking-personalized-approaches-to-drug-development-can-lower-the-cost-and-incre-csbr-20180726monthly0.5https://www.biopharmawatch.com/news/CSBR/see-the-attached-reconciliation-of-gaap-net-loss-to-non-gaap-net-loss-for-an-explanation-o-csbr-20180315monthly0.5https://www.biopharmawatch.com/news/CSBR/see-the-attached-reconciliation-of-gaap-net-loss-to-non-gaap-net-loss-for-an-explanation-o-csbr-20171207monthly0.5https://www.biopharmawatch.com/news/CSBR/treatment-plans-and-translational-oncology-solutions-in-which-pharmaceutical-and-biotechno-csbr-20170914monthly0.5https://www.biopharmawatch.com/news/CSBR/this-press-release-may-contain-forward-looking-statements-within-the-meaning-of-the-privat-csbr-20170727monthly0.5https://www.biopharmawatch.com/news/CSBR/recurring-items-non-gaap-net-loss-and-non-gaap-loss-per-share-are-not-and-should-not-be-vi-csbr-20161129monthly0.5https://www.biopharmawatch.com/news/CSBR/on-a-gaap-basis-certain-unusual-or-non-recurring-items-that-management-does-not-believe-af-csbr-20160909monthly0.5https://www.biopharmawatch.com/news/CSBR/champions-oncology-inc-susan-foreman-sforeman-championsoncology-com-telephone-410-369-0365-csbr-20160609monthly0.5https://www.biopharmawatch.com/news/CSBR/investor-presentation-may-2016-2-notice-of-forward-looking-statements-thispresentationcont-csbr-20160511monthly0.5https://www.biopharmawatch.com/news/CSBR/news-one-university-plaza-suite-307-hackensack-nj-07601-tel-201-808-8400-for-immediate-rel-csbr-20160412monthly0.5https://www.biopharmawatch.com/news/CSBR/one-university-plaza-suite-csbr-20160315monthly0.5https://www.biopharmawatch.com/news/CSBR/investor-presentation-march-2016-2-notice-of-forward-looking-statements-this-presentation--csbr-20160307monthly0.5https://www.biopharmawatch.com/news/CSBR/champions-oncology-reports-csbr-20151214monthly0.5https://www.biopharmawatch.com/news/CSBR/champions-oncology-reports-csbr-20150910monthly0.5https://www.biopharmawatch.com/news/CSBR/one-university-plaza-suite-307-hackensack-nj-07601-phone-201-808-8400-www-championsoncolog-csbr-20150821monthly0.5https://www.biopharmawatch.com/news/CSBR/champions-oncology-announces-reverse-stock-split-in-preparation-for-uplisting-to-nasdaq-ha-csbr-20150812monthly0.5https://www.biopharmawatch.com/news/CSBR/news-one-university-plaza-suite-307-hackensack-nj-07601-tel-201-808-8400-champions-oncolog-csbr-20150728monthly0.5https://www.biopharmawatch.com/news/CSBR/news-one-university-plaza-suite-307-hackensack-nj-07601-tel-201-808-8400-champions-oncolog-csbr-20150317monthly0.5https://www.biopharmawatch.com/news/CSBR/champions-oncology-announces-14-million-capital-raise-hackensack-nj-march-12-2015-champion-csbr-20150312monthly0.5https://www.biopharmawatch.com/news/CSBR/champions-oncology-closes-convertible-debt-financing-hackensack-nj-csbr-20150302monthly0.5https://www.biopharmawatch.com/news/CSBR/one-university-plaza-suite-csbr-20141212monthly0.5https://www.biopharmawatch.com/news/CSBR/champions-oncology-closes-convertible-debt-financing-hackensack-nj-csbr-20141205monthly0.5https://www.biopharmawatch.com/news/CSBR/news-one-university-plaza-suite-307-hackensack-nj-07601-tel-201-808-8400-champions-oncolog-csbr-20140911monthly0.5https://www.biopharmawatch.com/news/CSBR/news-one-university-plaza-suite-307-hackensack-nj-07601-tel-201-808-8400-champions-oncolog-csbr-20140313monthly0.5https://www.biopharmawatch.com/news/CSBR/news-one-university-plaza-suite-307-hackensack-nj-07601-tel-201-808-8400-for-immediate-rel-csbr-20130913monthly0.5https://www.biopharmawatch.com/news/CSBR/news-one-university-plaza-suite-307-hackensack-nj-07601-tel-201-808-8400-for-immediate-rel-csbr-20130612monthly0.5https://www.biopharmawatch.com/news/CSBR/news-one-university-plaza-suite-307-hackensack-nj-07601-tel-201-808-8400-for-immediate-rel-csbr-20130314monthly0.5https://www.biopharmawatch.com/news/CSBR/news-one-university-plaza-suite-307-hackensack-nj-07601-tel-201-808-8400-for-immediate-rel-csbr-20130305monthly0.5https://www.biopharmawatch.com/news/CSBR/news-one-university-plaza-suite-307-hackensack-nj-07601-tel-201-808-8400-for-immediate-rel-csbr-20130129monthly0.5https://www.biopharmawatch.com/news/CSBR/a-proprietary-in-vivo-testing-and-information-platform-for-personalizing-cancer-care-janua-csbr-20130107monthly0.5https://www.biopharmawatch.com/news/CSBR/news-one-university-plaza-suite-307-hackensack-nj-07601-tel-201-808-8400-for-immediate-rel-csbr-20120803monthly0.5https://www.biopharmawatch.com/news/CSBR/champions-oncology-inc-news-1-university-plaza-suite-307-hackensack-nj-usa-tel-410-369-036-csbr-20111101monthly0.5https://www.biopharmawatch.com/news/CSBR/champions-biotechnology-inc-news-855-n-wolfe-street-suite-619-baltimore-maryland-21205-usa-csbr-20110718monthly0.5https://www.biopharmawatch.com/news/CSBR/champions-oncology-formerly-champions-biotechnology-completes-9-4-million-financing-baltim-csbr-20110405monthly0.5https://www.biopharmawatch.com/news/CSBR/champions-biotechnology-inc-news-855-n-wolfe-street-suite-619-baltimore-maryland-21205-usa-csbr-20110114monthly0.5https://www.biopharmawatch.com/news/CSBR/champions-biotechnology-inc-news-855-n-wolfe-street-suite-619-baltimore-maryland-21205-usa-csbr-20101213monthly0.5https://www.biopharmawatch.com/news/CSBR/champions-biotechnology-inc-news-855-n-wolfe-street-suite-619-baltimore-maryland-21205-usa-csbr-20101102monthly0.5https://www.biopharmawatch.com/news/CSBR/champions-biotechnology-inc-news-855-n-wolfe-street-suite-619-baltimore-maryland-21205-usa-csbr-20101028monthly0.5https://www.biopharmawatch.com/news/CSBR/champions-biotechnology-inc-news-855-n-wolfe-street-suite-619-baltimore-maryland-21205-usa-csbr-20100910monthly0.5https://www.biopharmawatch.com/news/CSBR/champions-biotechnology-inc-news-855-n-wolfe-street-suite-619-baltimore-maryland-21205-usa-csbr-20100728monthly0.5https://www.biopharmawatch.com/news/CSBR/news-champions-biotechnology-reports-fiscal-2010-third-quarter-financial-results-baltimore-csbr-20100317monthly0.5https://www.biopharmawatch.com/news/CSBR/champions-biotechnology-reports-fiscal-2010-second-quarter-financial-results-baltimore-md-csbr-20091215monthly0.5https://www.biopharmawatch.com/news/CSBR/news-champions-biotechnology-reports-fiscal-2010-first-quarter-financial-results-baltimore-csbr-20090914monthly0.5https://www.biopharmawatch.com/news/CSBR/champions-biotechnology-inc-news-1400-north-14-th-street-arlington-virginia-22209-usa-tel--csbr-20080730monthly0.5https://www.biopharmawatch.com/news/CSBR/champions-sports-inc-champions-biotechnology-inc-2200-wilson-boulevard-suite-102-316-arlin-csbr-20070214monthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-announces-board-transition-salt-lake-city-x2013-sera-20260601monthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-reports-fourth-quarter-2025-financial-results-salt-lake-city-x2013-sera-20260318monthly0.5https://www.biopharmawatch.com/news/SERA/january-2026-we-are-redefining-pregnancy-care-to-reduce-the-burden-of-preterm-birth-this-p-sera-20260108monthly0.5https://www.biopharmawatch.com/news/SERA/landmark-study-finds-pretrm-blood-test-reduces-earliest-preterm-births-and-newborn-complic-sera-20260107monthly0.5https://www.biopharmawatch.com/news/SERA/sera-announces-publication-acceptance-for-prime-study-the-prime-study-one-of-the-largest-s-sera-20251124monthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-reports-third-quarter-2025-financial-results-salt-lake-city-x2013-sera-20251113monthly0.5https://www.biopharmawatch.com/news/SERA/this-presentation-contains-forward-looking-statements-that-involve-substantial-risks-and-u-sera-20250905monthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-reports-second-quarter-2025-financial-results-salt-lake-city-x2013-sera-20250806monthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-appoints-lee-anderson-as-chief-commercial-officer-industry-veteran-to-spe-sera-20250508monthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-reports-first-quarter-2025-financial-results-salt-lake-city-x2013-sera-20250507monthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-reports-fourth-quarter-2024-financial-results-salt-lake-city-x2013-sera-20250319monthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-announces-proposed-public-offering-salt-lake-city-sera-20250210monthly0.5https://www.biopharmawatch.com/news/SERA/we-at-sera-aim-to-change-pregnancy-care-in-order-to-transform-the-experience-into-one-with-sera-20250131monthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-inc-all-rights-reserved-pretrm-sera-prognostics-and-their-logos-are-trade-sera-20250113monthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-reports-third-quarter-2024-financial-results-salt-lake-city-x2013-sera-20241106monthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-reports-second-quarter-2024-financial-results-salt-lake-city-sera-20240807monthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-reports-first-quarter-2024-financial-results-salt-lake-city-sera-20240508monthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-reports-fourth-quarter-2023-financial-results-salt-lake-city-sera-20240320monthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-announces-primary-endpoint-criteria-met-in-pivotal-prime-study-interim-lo-sera-20231206monthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-reports-third-quarter-2023-financial-results-salt-lake-city-sera-20231108monthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-inc-all-rights-reserved-pretrm-sera-prognostics-and-their-logos-are-trade-sera-20230925monthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-reports-second-quarter-2023-financial-results-salt-lake-city-sera-20230809monthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-announces-commercial-changes-and-actions-to-optimize-business-for-market--sera-20230525monthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-announces-retirement-of-president-and-ceo-dr-greg-critchfield-and-appoint-sera-20230515monthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-reports-first-quarter-2023-financial-results-salt-lake-city-sera-20230510monthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-reports-fourth-quarter-2022-financial-results-salt-lake-city-sera-20230322monthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-reports-third-quarter-2022-financial-results-salt-lake-city-sera-20221109monthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-reports-second-quarter-2022-financial-results-salt-lake-city-sera-20220810monthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-reports-first-quarter-2022-financial-results-salt-lake-city-sera-20220510monthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-announces-the-appointment-of-dr-jane-f-barlow-to-the-sera-prognostics-boa-sera-20220412monthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-reports-fourth-quarter-2021-financial-results-salt-lake-city-sera-20220329monthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-announces-the-appointment-of-sandra-a-j-lawrence-to-the-sera-prognostics--sera-20211130monthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-reports-third-quarter-2021-financial-results-salt-lake-city-sera-20211109monthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-announces-the-appointment-of-zhenya-lindgardt-to-the-board-noted-healthca-sera-20211108monthly0.5https://www.biopharmawatch.com/news/SERA/sera-prognostics-reports-second-quarter-2021-financial-results-salt-lake-city-sera-20210830monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-fire-safety-reports-fiscal-first-quarter-2027-results-q1-fy27-net-sales-of-47-4-m-lake-20260609monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-fire-safety-reports-fiscal-fourth-quarter-and-full-year-2026-financial-results-q4-lake-20260416monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-fire-safety-completes-sale-of-hpfr-and-hiviz-product-line-sale-to-national-safety-lake-20260330monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-fire-safety-appoints-lee-d-rudow-to-the-board-of-directors-current-ceo-of-transca-lake-20260223monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-fire-safety-appoints-calven-swinea-as-chief-financial-officer-financial-and-accou-lake-20260217monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-fire-safety-issues-shareholder-letter-and-provides-corporate-update-huntsville-al-lake-20260126monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-fire-safety-reports-fiscal-third-quarter-2026-financial-results-q3-26-net-sales-i-lake-20251209monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-fire-safety-declares-cash-dividend-for-fourth-quarter-2026-huntsville-al-x2013-20-lake-20251103monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-fire-safety-completes-acquisitions-of-arizona-ppe-recon-inc-and-california-ppe-re-lake-20250915monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-fire-safety-fiscal-second-quarter-2026-financial-results-conference-call-lake-20250909monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-fire-safety-reports-fiscal-second-quarter-2026-financial-results-q2-26-net-sales--lake-20250909monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-fire-safety-declares-cash-dividend-for-third-quarter-2026-huntsville-al-lake-20250801monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-reports-fiscal-first-quarter-2026-financial-results-q1-26-net-sales-in-lake-20250609monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-fire-safety-declares-cash-dividend-for-second-quarter-2026-huntsville-al-lake-20250501monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-reports-fiscal-fourth-quarter-and-full-year-2025-financial-results-q4--lake-20250409monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-fire-safety-issues-shareholder-letter-and-provides-corporate-update-huntsville-al-lake-20250211monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-fire-safety-declares-cash-dividend-for-first-quarter-2026-huntsville-al-lake-20250203monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-fire-safety-announces-proposed-public-offering-of-common-stock-huntsville-al-lake-20250122monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-fire-safety-completes-acquisition-of-veridian-strategic-acquisition-expands-lakel-lake-20241216monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-reports-fiscal-year-2025-third-quarter-financial-results-net-sales-inc-lake-20241206monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-engages-mz-group-to-lead-strategic-investor-relations-and-shareholder--lake-20241016monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-inc-reports-fiscal-202-5-second-quarter-financial-results-net-sales-of-lake-20240904monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-declares-cash-dividend-for-third-quarter-2025-huntsville-al-accesswire-lake-20240801monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-announces-filing-of-s-3-shelf-registration-statement-huntsville-al-lake-20240712monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-completes-acquisition-of-lhd-group-strategic-acquisition-enhances-lake-lake-20240701monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-inc-reports-fiscal-202-5-first-quarter-financial-results-net-sales-of--lake-20240604monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-appoints-james-m-jenkins-as-new-president-and-ceo-as-the-new-ceo-james-lake-20240520monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-declares-cash-dividend-for-second-quarter-2025-huntsville-al-accesswir-lake-20240501monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-to-participate-in-the-planet-microcap-showcase-vegas-2024-conference-h-lake-20240429monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-inc-reports-fiscal-202-4-fourth-quarter-financial-and-full-year-financ-lake-20240410monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-announces-the-acquisition-of-the-fire-and-rescue-business-of-the-lhd-g-lake-20240402monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-announces-the-acquisition-of-jolly-scarpe-footwear-strategic-acquisiti-lake-20240205monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-declares-cash-dividend-for-first-quarter-2025-huntsville-al-accesswire-lake-20240201monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-inc-reports-fiscal-202-4-third-quarter-financial-results-net-sales-of--lake-20231206monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-to-present-and-host-1x1-investor-meetings-at-the-sidoti-virtual-micro--lake-20231113monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-declares-cash-dividend-for-fourth-quarter-2024-huntsville-al-accesswir-lake-20231101monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-announces-executive-leadership-changes-charlie-roberson-to-step-down-a-lake-20231019monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-inc-reports-fiscal-202-4-second-quarter-financial-results-net-sales-of-lake-20230906monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-declares-cash-dividend-for-third-quarter-2024-huntsville-al-accesswire-lake-20230801monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-inc-reports-fiscal-202-4-first-quarter-financial-results-net-sales-of--lake-20230607monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-declares-cash-dividend-for-second-quarter-2024-huntsville-al-accesswir-lake-20230501monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-inc-reports-fiscal-2023-fourth-quarter-and-full-year-financial-results-lake-20230413monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-announces-management-changes-allen-dillard-to-retire-helena-an-promote-lake-20230410monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-announces-cfo-transition-huntsville-al-accesswire-lake-20230202monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-announces-the-initiation-of-a-quarterly-dividend-program-huntsville-al-lake-20230201monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-finalizes-previously-announced-board-transition-huntsville-al-accesswi-lake-20230126monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-inc-reports-fiscal-202-3-third-quarter-financial-results-net-sales-of--lake-20221208monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-enhances-its-global-fire-protection-business-with-the-acquisition-of-e-lake-20221205monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-inc-reports-fiscal-202-3-second-quarter-financial-results-net-sales-of-lake-20220908monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-announces-board-leadership-changes-in-line-with-existing-board-success-lake-20220622monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-inc-reports-fiscal-202-3-first-quarter-financial-results-first-quarter-lake-20220609monthly0.5https://www.biopharmawatch.com/news/LAKE/transcript-of-lakeland-industries-inc-lakeland-industries-inc-preliminary-fiscal-2022-four-lake-20220418monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-inc-reports-preliminary-fiscal-2022-fourth-quarter-and-year-end-financ-lake-20220418monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-announces-new-5-million-stock-repurchase-program-huntsville-al-accessw-lake-20220413monthly0.5https://www.biopharmawatch.com/news/LAKE/perimeter-parkway-suite-325-huntsville-al-35806-256-350-3873-www-lakeland-com-lakeland-ind-lake-20211216monthly0.5https://www.biopharmawatch.com/news/LAKE/perimeter-parkway-suite-325-huntsville-al-35806-256-350-3873-www-lakeland-com-lakeland-ind-lake-20211209monthly0.5https://www.biopharmawatch.com/news/LAKE/perimeter-parkway-huntsville-al-35806-256-350-3873-www-lakeland-com-lakeland-industries-ma-lake-20211019monthly0.5https://www.biopharmawatch.com/news/LAKE/pride-lane-sw-decatur-al-35603-256-350-3873-www-lakeland-com-lakeland-industries-inc-repor-lake-20210909monthly0.5https://www.biopharmawatch.com/news/LAKE/pride-lane-sw-decatur-al-35603-256-350-3873-www-lakeland-com-lakeland-industries-announces-lake-20210707monthly0.5https://www.biopharmawatch.com/news/LAKE/pride-lane-sw-decatur-al-35603-256-350-3873-www-lakeland-com-lakeland-industries-inc-repor-lake-20210609monthly0.5https://www.biopharmawatch.com/news/LAKE/pride-lane-sw-decatur-al-35603-256-350-3873-www-lakeland-com-lakeland-industries-inc-repor-lake-20210415monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-appoints-investment-industry-veteran-nikki-hamblin-to-board-of-directo-lake-20210224monthly0.5https://www.biopharmawatch.com/news/LAKE/pride-lane-sw-decatur-al-35603-256-350-3873-www-lakeland-com-lakeland-industries-bolsters--lake-20201230monthly0.5https://www.biopharmawatch.com/news/LAKE/pride-lane-sw-decatur-al-35603-256-350-3873-www-lakeland-com-lakeland-industries-inc-repor-lake-20201210monthly0.5https://www.biopharmawatch.com/news/LAKE/lake-ex991-202-pride-lane-sw-decatur-al-35603-256-350-3873-www-lakeland-com-lakeland-indus-lake-20200909monthly0.5https://www.biopharmawatch.com/news/LAKE/pride-lane-sw-decatur-al-35603-256-350-3873-www-lakeland-com-lakeland-industries-announces-lake-20200701monthly0.5https://www.biopharmawatch.com/news/LAKE/pride-lane-sw-decatur-al-35603-256-350-3873-www-lakeland-com-lakeland-industries-inc-repor-lake-20200609monthly0.5https://www.biopharmawatch.com/news/LAKE/pride-lane-sw-decatur-al-35603-256-350-3873-www-lakeland-com-lakeland-industries-inc-repor-lake-20200415monthly0.5https://www.biopharmawatch.com/news/LAKE/blueprint-3555-veterans-memorial-highway-suite-c-ronkonkoma-ny-11779-631-981-9700-www-lake-lake-20191209monthly0.5https://www.biopharmawatch.com/news/LAKE/veterans-memorial-highway-suite-c-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakela-lake-20190909monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-inc-reports-fiscal-2020-first-quarter-financial-results-ronkonkoma-ny--lake-20190610monthly0.5https://www.biopharmawatch.com/news/LAKE/veterans-memorial-highway-suite-c-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakela-lake-20190416monthly0.5https://www.biopharmawatch.com/news/LAKE/veterans-memorial-highway-suite-c-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakela-lake-20181217monthly0.5https://www.biopharmawatch.com/news/LAKE/veterans-memorial-hwy-suite-c-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakeland-i-lake-20181206monthly0.5https://www.biopharmawatch.com/news/LAKE/veterans-memorial-highway-suite-c-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakela-lake-20180910monthly0.5https://www.biopharmawatch.com/news/LAKE/veterans-memorial-highway-suite-c-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakela-lake-20180712monthly0.5https://www.biopharmawatch.com/news/LAKE/veterans-memorial-highway-suite-c-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakela-lake-20180608monthly0.5https://www.biopharmawatch.com/news/LAKE/veterans-memorial-highway-suite-c-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakela-lake-20180416monthly0.5https://www.biopharmawatch.com/news/LAKE/veterans-memorial-highway-suite-c-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakela-lake-20171215monthly0.5https://www.biopharmawatch.com/news/LAKE/veterans-memorial-highway-suite-c-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakela-lake-20170913monthly0.5https://www.biopharmawatch.com/news/LAKE/veterans-memorial-highway-suite-c-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakela-lake-20170822monthly0.5https://www.biopharmawatch.com/news/LAKE/veterans-memorial-highway-suite-c-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakela-lake-20170816monthly0.5https://www.biopharmawatch.com/news/LAKE/veterans-memorial-highway-suite-c-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakela-lake-20170614monthly0.5https://www.biopharmawatch.com/news/LAKE/veterans-memorial-highway-suite-c-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakela-lake-20170426monthly0.5https://www.biopharmawatch.com/news/LAKE/veterans-memorial-highway-suite-c-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakela-lake-20161214monthly0.5https://www.biopharmawatch.com/news/LAKE/veterans-memorial-highway-suite-c-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakela-lake-20160914monthly0.5https://www.biopharmawatch.com/news/LAKE/veterans-memorial-highway-suite-c-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakela-lake-20160614monthly0.5https://www.biopharmawatch.com/news/LAKE/veterans-memorial-highway-suite-c-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakela-lake-20160421monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-inc-reports-fiscal-2016-third-quarter-financial-results-significant-im-lake-20151215monthly0.5https://www.biopharmawatch.com/news/LAKE/veterans-memorial-highway-suite-c-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakela-lake-20150916monthly0.5https://www.biopharmawatch.com/news/LAKE/veterans-memorial-hwy-suite-c-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakeland-i-lake-20150723monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-announces-early-payoff-of-arbitration-settlement-to-accelerate-exit-fr-lake-20150622monthly0.5https://www.biopharmawatch.com/news/LAKE/veterans-memorial-highway-suite-c-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakela-lake-20150615monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-inc-reports-fiscal-2015-fourth-quarter-and-year-end-financial-results--lake-20150518monthly0.5https://www.biopharmawatch.com/news/LAKE/koehler-avenue-suite-7-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakeland-industri-lake-20150402monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-inc-reports-fiscal-2015-third-quarter-financial-results-consolidated-s-lake-20141210monthly0.5https://www.biopharmawatch.com/news/LAKE/koehler-avenue-suite-7-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakeland-industri-lake-20141029monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-announces-11-2-million-lake-20141024monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-inc-reports-fiscal-2015-second-quarter-financial-results-manufacturing-lake-20140910monthly0.5https://www.biopharmawatch.com/news/LAKE/701-7-koehler-avenue-suite-7-ronkonkoma-lake-20140828monthly0.5https://www.biopharmawatch.com/news/LAKE/koehler-avenue-suite-7-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakeland-industri-lake-20140730monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-inc-reports-fiscal-2015-first-quarter-financial-results-in-fiscal-2015-lake-20140612monthly0.5https://www.biopharmawatch.com/news/LAKE/koehler-avenue-suite-7-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakeland-industri-lake-20140428monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-inc-reports-fiscal-2014-third-quarter-financial-results-reports-consol-lake-20131212monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-clarifies-statements-made-in-the-media-ronkonkoma-ny-lake-20130916monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-inc-reports-fiscal-2014-second-quarter-financial-results-reports-opera-lake-20130912monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-inc-announces-completion-of-financing-ronkonkoma-ny-lake-20130701monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-inc-reports-fiscal-2014-first-quarter-financial-results-ronkonkoma-ny-lake-20130613monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-inc-reports-fiscal-2013-fourth-quarter-and-full-year-financial-results-lake-20130521monthly0.5https://www.biopharmawatch.com/news/LAKE/koehler-avenue-suite-7-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakeland-industri-lake-20130501monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-inc-reports-fiscal-2013-third-quarter-financial-results-reports-net-in-lake-20121213monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-inc-announces-amendments-to-its-credit-facility-all-defaults-waived-co-lake-20121017monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-inc-reports-fiscal-2013-second-quarter-financial-results-settlement-re-lake-20120913monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-inc-reports-fiscal-2013-first-quarter-financial-results-ronkonkoma-ny-lake-20120614monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-retains-raymond-james-lake-20120612monthly0.5https://www.biopharmawatch.com/news/LAKE/koehler-avenue-suite-7-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakeland-industri-lake-20120418monthly0.5https://www.biopharmawatch.com/news/LAKE/701-7-koehler-avenue-suite-7-ronkonkoma-lake-20120413monthly0.5https://www.biopharmawatch.com/news/LAKE/unassociated-document-701-7-koehler-avenue-suite-7-ronkonkoma-ny-11779-631-981-9700-www-la-lake-20111228monthly0.5https://www.biopharmawatch.com/news/LAKE/unassociated-document-701-7-koehler-avenue-suite-7-ronkonkoma-ny-11779-631-981-9700-www-la-lake-20111207monthly0.5https://www.biopharmawatch.com/news/LAKE/unassociated-document-701-7-koehler-avenue-suite-7-ronkonkoma-ny-11779-631-981-9700-www-la-lake-20110908monthly0.5https://www.biopharmawatch.com/news/LAKE/koehler-avenue-suite-7-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-for-immediate-rel-lake-20110629monthly0.5https://www.biopharmawatch.com/news/LAKE/koehler-avenue-suite-7-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakeland-industri-lake-20110608monthly0.5https://www.biopharmawatch.com/news/LAKE/unassociated-document-701-7-koehler-avenue-suite-7-ronkonkoma-ny-11779-631-981-9700-www-la-lake-20110407monthly0.5https://www.biopharmawatch.com/news/LAKE/koehler-avenue-suite-7-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-for-immediate-rel-lake-20110228monthly0.5https://www.biopharmawatch.com/news/LAKE/koehler-avenue-suite-7-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-for-immediate-rel-lake-20101213monthly0.5https://www.biopharmawatch.com/news/LAKE/unassociated-document-amendment-no-2-dated-as-of-lake-20101130monthly0.5https://www.biopharmawatch.com/news/LAKE/koehler-avenue-suite-7-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakeland-industri-lake-20100914monthly0.5https://www.biopharmawatch.com/news/LAKE/koehler-avenue-suite-7-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakeland-industri-lake-20100614monthly0.5https://www.biopharmawatch.com/news/LAKE/koehler-avenue-suite-7-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakeland-industri-lake-20100416monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-industries-closes-23-5-million-bank-revolver-with-td-bank-lake-20100115monthly0.5https://www.biopharmawatch.com/news/LAKE/koehler-avenue-suite-7-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-for-immediate-rel-lake-20091210monthly0.5https://www.biopharmawatch.com/news/LAKE/koehler-avenue-suite-7-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-for-immediate-rel-lake-20090909monthly0.5https://www.biopharmawatch.com/news/LAKE/koehler-avenue-suite-7-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakeland-industri-lake-20090609monthly0.5https://www.biopharmawatch.com/news/LAKE/koehler-avenue-suite-7-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakeland-industri-lake-20090415monthly0.5https://www.biopharmawatch.com/news/LAKE/koehler-avenue-suite-7-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakeland-industri-lake-20081210monthly0.5https://www.biopharmawatch.com/news/LAKE/koehler-avenue-suite-7-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-for-immediate-rel-lake-20080909monthly0.5https://www.biopharmawatch.com/news/LAKE/koehler-avenue-suite-7-ronkonkoma-ny-11779-631-981-9700-www-lakeland-com-lakeland-industri-lake-20080609monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-lake-20080516monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-lake-20080422monthly0.5https://www.biopharmawatch.com/news/LAKE/lakeland-lake-20080416monthly0.5https://www.biopharmawatch.com/news/HIT/q1-2026-earnings-conference-call-hit-20260513monthly0.5https://www.biopharmawatch.com/news/HIT/an-ai-powered-marketplace-platform-helping-smbs-access-better-self-funded-health-plans-dis-hit-20260513monthly0.5https://www.biopharmawatch.com/news/HIT/an-ai-powered-marketplace-platform-helping-smbs-access-better-self-funded-health-plans-dis-hit-20260327monthly0.5https://www.biopharmawatch.com/news/HIT/health-in-tech-announces-closing-of-7-0-million-private-placement-stuart-fl-hit-20260327monthly0.5https://www.biopharmawatch.com/news/HIT/health-in-tech-announces-7-0-million-private-placement-stuart-fl-hit-20260325monthly0.5https://www.biopharmawatch.com/news/HIT/health-in-tech-announces-fourth-quarter-and-full-year-2025-financial-results-full-year-202-hit-20260325monthly0.5https://www.biopharmawatch.com/news/HIT/health-in-tech-announces-voluntary-extension-of-lock-up-period-stuart-fl-hit-20251202monthly0.5https://www.biopharmawatch.com/news/HIT/q3-2025-earnings-conference-call-hit-20251110monthly0.5https://www.biopharmawatch.com/news/HIT/health-in-tech-announces-third-quarter-2025-financial-results-revenue-reached-8-5-million--hit-20251110monthly0.5https://www.biopharmawatch.com/news/HIT/nasdaq-hit-this-presentation-has-been-prepared-by-the-company-solely-for-informational-pur-hit-20251112monthly0.5https://www.biopharmawatch.com/news/HIT/this-presentation-has-been-prepared-by-the-company-solely-for-informational-purposes-the-i-hit-20250630monthly0.5https://www.biopharmawatch.com/news/HIT/health-in-tech-announces-second-quarter-2025-financial-results-revenues-of-9-3-million-up--hit-20250721monthly0.5https://www.biopharmawatch.com/news/HIT/this-presentation-has-been-prepared-by-the-company-solely-for-informational-purposes-the-i-hit-20250331monthly0.5https://www.biopharmawatch.com/news/HIT/health-in-tech-announces-first-quarter-2025-financial-results-revenues-increased-56-over-t-hit-20250331monthly0.5https://www.biopharmawatch.com/news/HIT/health-in-tech-announces-appointment-of-sanjay-shrestha-to-board-of-directors-stuart-fl-hit-20250410monthly0.5https://www.biopharmawatch.com/news/HIT/this-presentation-has-been-prepared-by-the-company-solely-for-informational-purposes-the-i-hit-20250317monthly0.5https://www.biopharmawatch.com/news/HIT/health-in-tech-announces-fourth-quarter-and-full-year-2024-financial-results-total-audited-hit-20250317monthly0.5https://www.biopharmawatch.com/news/HIT/health-in-tech-inc-announces-pricing-of-initial-public-offering-stuart-fl-hit-20241220monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-activates-first-u-s-site-for-ongoing-international-phase-2-expansion-tr-maia-20260416monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-expects-recent-33-million-capital-raise-to-fully-fund-ongoing-pivotal-p-maia-20260408monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-reports-overall-survival-exceeding-two-years-for-eight-patients-in-ongo-maia-20260331monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-announces-1-51-million-private-placement-chicago-il-maia-20251216monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-announces-2-25-million-private-placement-chicago-il-maia-20250929monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-receives-fda-s-fast-track-designation-for-ateganosine-as-a-treatment-fo-maia-20250728monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-announces-peer-reviewed-journal-publication-of-data-validating-second-g-maia-20250717monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-announces-first-patient-dosed-in-expansion-of-phase-2-trial-for-ategano-maia-20250709monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-welcomes-leading-hepatocellular-carcinoma-clinician-scientists-to-scien-maia-20250624monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-announces-master-clinical-supply-agreement-with-roche-for-hard-to-treat-maia-20250618monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-announces-positive-efficacy-update-for-phase-2-thio-101-clinical-trial--maia-20250605monthly0.5https://www.biopharmawatch.com/news/MAIA/correcting-and-replacing-maia-biotechnology-announces-695-000-private-placement-this-is-a--maia-20250527monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-announces-1-08-million-private-placement-chicago-il-maia-20250505monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-receives-usan-council-approval-for-ateganosine-as-nonproprietary-name-f-maia-20250319monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-to-initiate-phase-3-pivotal-trial-of-thio-sequenced-with-checkpoint-inh-maia-20250227monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-announces-non-brokered-private-placement-of-approximately-1-43-million--maia-20250224monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-announces-private-placement-of-2-715-000-chicago-maia-20250218monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-announces-positive-efficacy-updates-for-phase-2-thio-101-trial-in-advan-maia-20250204monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-granted-fda-rare-pediatric-disease-designation-for-thio-as-a-treatment--maia-20241216monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-announces-private-placement-of-approximately-950-000-chicago-maia-20241209monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-selected-for-oral--maia-20241105monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-announces-2-44-million-private-placement-chicago-maia-20241028monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-announces-new-updates-from-phase-2-trial-of-novel-cancer-treatment-agen-maia-20240723monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-announces-year-to-date-achievements-and-highlights-recent-clinical-prog-maia-20240606monthly0.5https://www.biopharmawatch.com/news/MAIA/telomere-targeting-immunotherapies-for-cancer-nyse-american-maia-june-2024-forward-looking-maia-20240604monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-announces-1-00-million-private-placement-chicago-il-maia-20240423monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-announces-1-33-million-private-placement-chicago-il-maia-20240326monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-announces-strong-efficacy-of-thio-as-third-line-treatment-for-non-small-maia-20240306monthly0.5https://www.biopharmawatch.com/news/MAIA/march-2024-dear-fellow-shareholders-at-maia-biotechnology-our-tenacious-pursuit-of-innovat-maia-20240219monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-appoints-leading-immuno-oncology-scientist-dr-remus-vezan-as-scientific-maia-20240227monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-completes-enrollment-in-thio-101-phase-2-clinical-trial-for-non-small-c-maia-20240222monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-announces-publication-of-international-pct-patent-application-covering--maia-20240124monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-provides-positive-phase-2-clinical-updates-for-lead-anticancer-agent-an-maia-20240117monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-announces-dose-selection-in-thio-101-phase-2-clinical-trial-for-non-sma-maia-20231219monthly0.5https://www.biopharmawatch.com/news/MAIA/fda-grants-orphan-drug-designation-to-maia-biotechnology-for-thio-as-a-treatment-for-gliob-maia-20231110monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-reports-third-quarter-2023-financial-results-and-highlights-recent-deve-maia-20231107monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-announces-100-disease-control-in-second-line-non-small-cell-lung-cancer-maia-20231024monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-announces-share-repurchase-program-chicago-il-maia-20230928monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-reports-second-quarter-2023-financial-results-and-provides-updates-for--maia-20230808monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-reports-updates-on-disease-control-rates-for-thio-101-phase-2-trial-for-maia-20230711monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-reports-updates-on-preliminary-survival-data-for-thio-101-phase-2-trial-maia-20230710monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-announces-updates-in-enrollment-in-phase-ii-clinical-trial-thio-101-has-maia-20230620monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-reports-first-quarter-2023-financial-results-and-provides-corporate-upd-maia-20230508monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-inc-announces-pricing-of-public-offering-new-york-maia-20230424monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-reports-preliminary-survival-data-in-part-a-of-thio-101-phase-2-trial-f-maia-20230420monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-announces-excellent-efficacy-of-thio-in-liver-cancer-models-study-showe-maia-20230418monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-reports-positive-topline-data-from-part-a-safety-lead-in-of-thio-101-ph-maia-20230411monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-reports-full-year-2022-financial-results-and-provides-corporate-update--maia-20230324monthly0.5https://www.biopharmawatch.com/news/MAIA/west-lake-street-suite-1700-chicago-il-60606-usa-www-maiabiotech-com-1-312-416-8592-main-m-maia-20230213monthly0.5https://www.biopharmawatch.com/news/MAIA/exhibit-99-1-444-west-lake-street-suite-1700-chicago-il-60606-usa-www-maiabiotech-com-1-31-maia-20230213monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-reports-third-quarter-2022-financial-results-and-provides-corporate-upd-maia-20221109monthly0.5https://www.biopharmawatch.com/news/MAIA/all-statements-in-this-presentation-other-than-those-relating-to-historical-facts-are-forw-maia-20220907monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-reports-second-quarter-2022-financial-results-and-provides-corporate-up-maia-20220822monthly0.5https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-announces-pricing-of-initial-public-offering-chicago-il-maia-20220727monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-scientific-advisory-board-meeting-and-urcosimod-data-presentation-du-okyo-20260407monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-chairman-and-founder-acquires-shares-london-and-new-york-ny-okyo-20260319monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-director-acquires-shares-london-and-new-york-ny-okyo-20260319monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-chief-development-officer-and-director-acquires-shares-london-and-ne-okyo-20260319monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-reports-new-phase-2-data-demonstrating-meaningful-improvements-in-patient-repo-okyo-20260318monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-abstract-selected-for-presentation-at-premier-global-ophthalmology-congress-london-an-okyo-20260223monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-pricing-of-20-million-public-offering-of-ordinary-shares-london-and--okyo-20260212monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-public-offering-of-ordinary-shares-london-and-new-york-ny-okyo-20260212monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-interim-results-for-the-six-months-ended-30-september-2025-london-and-new-york-okyo-20260130monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-to-ring-the-opening-bell-at-nasdaq-london-and-new-york-ny-okyo-20251219monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-chairman-and-founder-acquires-shares-london-and-new-york-ny-okyo-20251203monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-to-present-at-ois-xv-in-san-diego-london-and-new-york-ny-okyo-20251118monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-unveils-strong-phase-2-clinical-trial-results-for-urcosimod-to-treat-neuropath-okyo-20250716monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-plans-to-accelerate-the-clinical-development-of-urcosimod-to-treat-n-okyo-20250430monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-files-for-fast-track-designation-with-fda-for-urcosimod-to-treat-neuropathic-c-okyo-20250310monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-ok-101-officially-assigned-usan-urcosimod-london-and-new-york-ny-okyo-20250212monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-chairman-and-ceo-acquire-shares-london-and-new-york-ny-okyo-20250131monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-to-complete-enrollment-of-neuropathic-corneal-pain-trial-by-end-of-second-quar-okyo-20250129monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-receives-1-4-million-in-non-dilutive-funding-london-and-new-york-ny-okyo-20250122monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-to-participate-at-the-4-th-annual-btig-ophthalmology-conference-london-and-new-okyo-20241126monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-to-present-at-international-tear-film-and-ocular-surface-society-conference-lo-okyo-20241030monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-first-patient-dosed-in-the-first-clinical-trial-to-treat-neuropathic-okyo-20241023monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-start-of-phase-2-clinical-trial-to-treat-patients-with-neuropathic-c-okyo-20241016monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-chairman-acquires-shares-london-and-new-york-ny-okyo-20240910monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-chairman-acquires-shares-london-and-new-york-ny-okyo-20240905monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-granted-u-s-patent-covering-ok-101-s-potential-for-treating-symptoms-of-dry-ey-okyo-20240827monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-ceo-interview-to-air-on-bloomberg-tv-london-and-new-york-ny-okyo-20240823monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-chairman-acquires-shares-london-and-new-york-ny-okyo-20240823monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-chairman-acquires-shares-london-and-new-york-ny-okyo-20240821monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-participates-in-h-c-wainwright-4-th-annual-ophthalmology-virtual-conference-lo-okyo-20240815monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-granted-european-patent-covering-ok-101-chemerin-analogs-and-their-method-of-u-okyo-20240806monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-to-initiate-neuropathic-corneal-pain-trial-for-ok-101-phase-2-randomized-place-okyo-20240711monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-promising-categorical-data-from-ok-101-phase-2-trial-in-dry-eye-dise-okyo-20240710monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-participation-in-may-2024-investor-conferences-london-and-new-york-n-okyo-20240508monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-upcoming-presentation-of-ok-101-phase-2-data-for-dry-eye-disease-at--okyo-20240430monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-to-reschedule-key-opinion-leader-event-in-dry-eye-disease-to-may-2024-london-a-okyo-20240408monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-upcoming-presentation-of-ok-101-phase-2-data-for-dry-eye-disease-at--okyo-20240402monthly0.5https://www.biopharmawatch.com/news/OKYO/london-and-new-york-ny-okyo-20240329monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-ok-101-successfully-achieved-statistical-significance-for-multiple-s-okyo-20240322monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-to-host-key-opinion-leader-event-to-discuss-new-and-comprehensive-data-from-ph-okyo-20240321monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-to-release-new-and-comprehensive-data-from-phase-2-dry-eye-disease-trial-and-h-okyo-20240322monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-receives-fda-approval-of-ind-for-ok-101-in-neuropathic-corneal-pain-ok-101-is--okyo-20240209monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-distinguished-ophthalmologists-with-expertise-in-the-medical-and-sur-okyo-20240131monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-ok-101-successfully-achieved-statistical-significance-for-both-sign--okyo-20240108monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-to-present-at-the-biotech-showcase-conference-in-san-francisco-january-8-10-20-okyo-20240105monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-last-patient-enrolled-in-ok-101-phase-2-clinical-trial-to-treat-dry--okyo-20231204monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-5-84-million-cash-raise-and-payables-reduction-pricing-of-a-register-okyo-20231031monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-filing-of-an-investigational-new-drug-ind-application-for-ok-101-to--okyo-20231009monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-positive-safety-data-profile-for-the-ongoing-ok-101-phase-2-clinical-okyo-20231005monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-closing-of-4-0-million-registered-direct-offering-of-ordinary-shares-okyo-20230915monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-pricing-of-4-0-million-registered-direct-offering-of-ordinary-shares-okyo-20230914monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-announces-withdrawal-of-public-offering-london-and-okyo-20230914monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-public-offering-of-ordinary-shares-london-and-new-york-ny-okyo-20230913monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-completes-enrollment-in-phase-2-clinical-trial-of-ok-101-to-treat-dry-eye-dise-okyo-20230908monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-achieves-90-enrollment-in-240-patient-phase-2-clinical-trial-of-ok-101-to-trea-okyo-20230830monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-regains-compliance-with-nasdaq-listing-minimum-market-value-rule-new-y-okyo-20230829monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-reports-annual-results-for-the-twelve-months-ended-okyo-20230815monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-announces-withdrawal-of-public-offering-london-and-okyo-20230731monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-proposed-public-offering-of-ordinary-shares-london-and-new-york-ny-okyo-20230728monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-receives-nasdaq-deficiency-notice-new-york-okyo-20230728monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-plans-to-initiate-phase-2-trial-of-ok-101-in-neuropathic-corneal-pain-ncp-foll-okyo-20230728monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-appointment-of-william-a-clementi-as-chief-operating-officer-london--okyo-20230727monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-randomized-segment-now-underway-in-phase-2-clinical-trial-of-topical-okyo-20230606monthly0.5https://www.biopharmawatch.com/news/OKYO/may-2023-okyo-pharma-limited-okyo-or-company-london-stock-exchange-delisting-further-to-th-okyo-20230522monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-ads-program-collapse-commencement-of-trading-of-new-ordinary-shares-on-okyo-20230519monthly0.5https://www.biopharmawatch.com/news/OKYO/exihibit-99-1-okyo-pharma-limited-okyo-or-company-change-of-record-time-and-last-day-of-de-okyo-20230515monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-now-participating-on-the-webull-corporate-communications-service-platform-webu-okyo-20230511monthly0.5https://www.biopharmawatch.com/news/OKYO/may-2023-okyo-pharma-limited-okyo-or-company-change-of-delisting-date-to-22-may-2023-the-b-okyo-20230511monthly0.5https://www.biopharmawatch.com/news/OKYO/may-2023-okyo-pharma-limited-okyo-or-company-result-of-general-meeting-the-board-of-direct-okyo-20230503monthly0.5https://www.biopharmawatch.com/news/OKYO/this-announcement-contains-inside-information-for-the-purposes-of-article-7-of-regulation--okyo-20230503monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-first-patient-first-visit-for-phase-2-trial-evaluating-efficacy-and--okyo-20230502monthly0.5https://www.biopharmawatch.com/news/OKYO/this-announcement-contains-inside-information-for-the-purposes-of-article-7-of-regulation--okyo-20230425monthly0.5https://www.biopharmawatch.com/news/OKYO/not-for-release-publication-or-distribution-in-whole-or-in-part-directly-or-indirectly-in--okyo-20230405monthly0.5https://www.biopharmawatch.com/news/OKYO/this-announcement-contains-inside-information-for-the-purposes-of-article-7-of-regulation--okyo-20230404monthly0.5https://www.biopharmawatch.com/news/OKYO/director-acquires-shares-london-and-new-york-ny-30-march-2023-okyo-pharma-limited-nasdaq-o-okyo-20230330monthly0.5https://www.biopharmawatch.com/news/OKYO/director-acquires-shares-london-and-new-york-ny-29-march-2023-okyo-pharma-limited-nasdaq-o-okyo-20230329monthly0.5https://www.biopharmawatch.com/news/OKYO/pdmr-dealing-london-and-new-york-ny-24-march-2023-okyo-pharma-limited-nasdaq-okyo-lse-okyo-okyo-20230324monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-phase-2-trial-of-ok-101-drug-to-treat-dry-eye-disease-is-now-listed--okyo-20230316monthly0.5https://www.biopharmawatch.com/news/OKYO/this-announcement-contains-inside-information-for-the-purposes-of-article-7-of-regulation--okyo-20230315monthly0.5https://www.biopharmawatch.com/news/OKYO/not-for-publication-distribution-or-release-directly-or-indirectly-in-whole-or-in-part-in--okyo-20230314monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-prices-5-3-million-offering-of-adss-london-okyo-20230313monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-okyo-okyo-pharma-or-the-company-okyo-pharma-announces-custom-clearance-okyo-20230228monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-announces-appointment-of-dr-jay-s-pepose-to-its-scientific-advisory-board-worl-okyo-20230223monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-okyo-okyo-pharma-or-the-company-okyo-pharma-to-present-at-the-second-a-okyo-20230221monthly0.5https://www.biopharmawatch.com/news/OKYO/february-2023-okyo-pharma-limited-okyo-or-the-company-allotment-of-ordinary-shares-and-tot-okyo-20230214monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-okyo-or-the-company-interim-results-availability-the-okyo-pharma-inter-okyo-20230103monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-interim-results-for-the-six-months-ending-30-september-2022-london-and-okyo-20221230monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-okyo-or-the-company-okyo-pharma-announces-u-s-fda-clearance-of-ind-app-okyo-20221222monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-okyo-or-the-company-okyo-to-participate-at-biotech-showcase-london-and-okyo-20221221monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-okyo-or-the-company-okyo-publicly-files-a-registration-statement-with--okyo-20221206monthly0.5https://www.biopharmawatch.com/news/OKYO/this-announcement-contains-inside-information-for-the-purposes-of-article-7-of-regulation--okyo-20221201monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-okyo-or-the-company-grant-of-options-pdmr-dealing-london-and-boston-m--okyo-20221125monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-okyo-or-the-company-okyo-pharma-announces-u-s-ind-filing-on-ok-101-for-okyo-20221121monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-hosting-key-opinion-leader-event-introducing-ok-101-as-a-potential-treatment-f-okyo-20221110monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-ltd-announces-participation-in-the-thinkequity-conference-new-york-new-york-okyo-20221020monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-interview-to-air-on-bloomberg-u-s-on-the-redchip-money-report-new-york-okyo-20220908monthly0.5https://www.biopharmawatch.com/news/OKYO/september-2022-okyo-pharma-limited-okyo-or-company-result-of-annual-general-meeting-the-bo-okyo-20220907monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-plans-q4-2022-ind-filing-of-ok-101-to-treat-dry-eye-disease-with-subsequent-ph-okyo-20220830monthly0.5https://www.biopharmawatch.com/news/OKYO/august-2022-okyo-pharma-limited-okyo-or-the-company-notice-of-annual-general-meeting-okyo--okyo-20220819monthly0.5https://www.biopharmawatch.com/news/OKYO/okyo-pharma-limited-final-audited-results-for-the-year-ended-31-march-2022-london-and-okyo-20220816monthly0.5https://www.biopharmawatch.com/news/OKYO/pdmr-dealing-london-and-new-york-9-june-2022-okyo-pharma-limited-lse-okyo-nasdaq-okyo-a-bi-okyo-20220609monthly0.5https://www.biopharmawatch.com/news/OKYO/pdmr-dealing-london-and-boston-ma-20-may-2022-okyo-pharma-limited-lse-okyo-nasdaq-okyo-a-l-okyo-20220520monthly0.5https://www.biopharmawatch.com/news/OKYO/this-announcement-contains-inside-information-for-the-purpose-of-article-7-of-regulation-2-okyo-20220519monthly0.5https://www.biopharmawatch.com/news/OKYO/pdmr-dealing-london-and-new-york-ny-18-may-2022-okyo-pharma-limited-lse-okyo-nasdaq-okyo-a-okyo-20220518monthly0.5https://www.biopharmawatch.com/news/XBIT/xbiotech-announces-outcome-of-ema-s-oral-explanation-meeting-xbit-20170421monthly0.5https://www.biopharmawatch.com/news/XBIT/corporate-presentation-2016-nasdaq-xbit-creating-breakthrough-therapies-from-natural-human-xbit-20161205monthly0.5https://www.biopharmawatch.com/news/XBIT/xbiotech-closes-initial-public-offering-austin-tx-xbit-20150417monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-presents-additional-clinical-and-biomarker-data-from-phase-1b-clinical-s-ganx-20260318monthly0.5https://www.biopharmawatch.com/news/GANX/corporate-presentation-september-2024-gain-therapeutics-corporate-deck-february-2026-nasda-ganx-20260203monthly0.5https://www.biopharmawatch.com/news/GANX/corporate-presentation-september-2024-gain-therapeutics-parkinson-s-disease-kol-event-biom-ganx-20251014monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-reports-financial-results-for-second-quarter-2025-and-provides-corporate-ganx-20250812monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-announces-proposed-public-offering-bethesda-md-ganx-20250715monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-reports-financial-results-for-first-quarter-2025-and-provides-corporate--ganx-20250514monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-presents-additional-preclinical-data-and-design-of-phase-1b-clinical-stu-ganx-20250410monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-reports-financial-results-for-the-fourth-quarter-and-year-end-2024-and-p-ganx-20250327monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-ceo-gene-mack-issues-letter-to-shareholders-and-provides-operational-upd-ganx-20250206monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-appoints-gene-mack-as-chief-executive-officer-and-director-gene-mack-has-ganx-20250107monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-initiates-phase-1b-clinical-trial-of-lead-candidate-gt-02287-in-people-w-ganx-20241223monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-reports-financial-results-for-third-quarter-2024-and-provides-corporate--ganx-20241114monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-presents-preclinical-gt-02287-data-at-neuroscience-2024-gt-02287-demonst-ganx-20241007monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-reports-financial-results-for-second-quarter-2024-and-provides-corporate-ganx-20240808monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-announces-the-completion-of-dosing-in-the-multiple-ascending-dose-mad-of-ganx-20240709monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-inc-appoints-gene-mack-as-interim-ceo-mr-mack-is-the-company-s-current-c-ganx-20240627monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-announces-proposed-public-offering-bethesda-md-ganx-20240613monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-reports-financial-results-for-first-quarter-2024-and-provides-corporate--ganx-20240514monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-bolsters-management-team-with-the-appointment-of-gene-mack-as-chief-fina-ganx-20240408monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-reports-financial-results-for-year-end-2023-and-provides-corporate-updat-ganx-20240326monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-ganx-20240131monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-announces-proposed-public-offering-bethesda-md-ganx-20231120monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-announces-third-quarter-2023-financial-results-and-business-update-phase-ganx-20231114monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-announces-second-quarter-2023-financial-results-and-business-update-hrec-ganx-20230810monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-reports-first-quarter-2023-financial-results-and-business-update-success-ganx-20230512monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-appoints-c-evan-ballantyne-as-chief-financial-officer-bethesda-md-ganx-20230412monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-reports-full-year-2022-financial-results-and-business-update-company-exp-ganx-20230323monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-inc-reports-third-quarter-2022-financial-results-and-business-update-pre-ganx-20221110monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-announces-promotion-of-matthias-alder-to-chief-executive-officer-outgoin-ganx-20220920monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-inc-reports-second-quarter-2022-financial-results-and-business-update-pr-ganx-20220808monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-inc-reports-first-quarter-2022-financial-results-and-business-update-pre-ganx-20220516monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-inc-reports-full-year-2021-financial-results-and-business-update-36-88-m-ganx-20220324monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bethesda-md-ganx-20211228monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-inc-reports-third-quarter-2021-financial-results-and-business-update-dat-ganx-20211112monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-appoints-matthias-alder-as-chief-operating-officer-bethesda-md-ganx-20211019monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-inc-reports-second-quarter-2021-financial-results-and-business-update-an-ganx-20210811monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-inc-reports-first-quarter-2021-financial-results-completed-successful-in-ganx-20210510monthly0.5https://www.biopharmawatch.com/news/GANX/gain-therapeutics-inc-4800-hampden-ln-st-200-bethesda-md-20814-www-gaintherapeutics-com-ga-ganx-20210503monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-first-quarter-2026-financial-res-plrx-20260511monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-fourth-quarter-2025-financial-re-plrx-20260311monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-first-quarter-2025-financial-res-plrx-20250508monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-fourth-quarter-2024-financial-re-plrx-20250303monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-next-steps-following-dsmb-recommendation-on-beacon-ipf-a-pha-plrx-20250213monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-provides-update-on-beacon-ipf-a-phase-2b-3-trial-in-patients-with-idio-plrx-20250207monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-third-quarter-2024-financial-res-plrx-20241107monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-second-quarter-2024-financial-re-plrx-20240807monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-positive-long-term-data-from-the-integris-psc-phase-2a-trial-plrx-20240715monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-positive-topline-data-from-a-phase-2a-collagen-pet-imaging-c-plrx-20240514monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-first-quarter-2024-financial-res-plrx-20240506monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-accelerated-bexotegrast-development-plan-for-the-treatment-o-plrx-20240312monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-fourth-quarter-2023-financial-re-plrx-20240227monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-positive-safety-and-exploratory-efficacy-data-from-the-integ-plrx-20240204monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-third-quarter-2023-financial-res-plrx-20231109monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-positive-safety-and-exploratory-efficacy-data-from-phase-2a--plrx-20230926monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-second-quarter-2023-financial-re-plrx-20230809monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-first-quarter-2023-financial-res-plrx-20230509monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-positive-long-term-data-from-the-integris-ipf-phase-2a-trial-plrx-20230430monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-fourth-quarter-2022-financial-re-plrx-20230309monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-positive-data-from-the-integris-ipf-phase-2a-trial-demonstra-plrx-20230122monthly0.5https://www.biopharmawatch.com/news/PLRX/developing-novel-treatments-for-fibrotic-diseases-january-2023-2023-pliant-therapeutics-di-plrx-20230109monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-third-quarter-2022-financial-res-plrx-20221108monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-second-quarter-2022-financial-re-plrx-20220808monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-announces-positive-safety-and-efficacy-data-from-phase-2a-integris-ipf-plrx-20220710monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-first-quarter-2022-financial-res-plrx-20220509monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-202-plrx-20220228monthly0.5https://www.biopharmawatch.com/news/PLRX/developing-novel-treatments-for-fibrotic-diseases-corporate-presentation-january-2022-disc-plrx-20220110monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-third-quarter-2021-financial-res-plrx-20211109monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-reports-positive-interim-results-from-phase-2a-pet-imaging-clinical-tr-plrx-20210907monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-second-quarter-2021-financial-re-plrx-20210809monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-first-quarter-2021-financial-res-plrx-20210510monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-202-plrx-20210316monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-third-quarter-2020-financial-res-plrx-20201110monthly0.5https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-announces-second-quarter-2020-financial--plrx-20200811monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-announces-termination-of-merger-agreement-with-alcon-research-llc-company-to-report-lnsr-20260317monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-reports-second-quarter-2025-results-and-provides-business-update-18-ally-robotic-ca-lnsr-20250807monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-reports-first-quarter-2025-results-and-provides-business-update-14-ally-robotic-las-lnsr-20250508monthly0.5https://www.biopharmawatch.com/news/LNSR/communique-aux-medias-medienmitteilung-alcon-agrees-to-acquire-lensar-inc-acquisition-of-a-lnsr-20250324monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-reports-fourth-quarter-and-full-year-2024-results-and-provides-business-update-31-a-lnsr-20250227monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-reports-third-quarter-2024-results-and-provides-business-update-24-ally-robotic-las-lnsr-20241107monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-reports-second-quarter-2024-results-and-provides-business-update-17-new-ally-adapti-lnsr-20240808monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-reports-first-quarter-2024-results-and-provides-business-update-total-revenue-incre-lnsr-20240509monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-reports-fourth-quarter-and-full-year-2023-results-and-provides-business-update-44-a-lnsr-20240304monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-reports-third-quarter-2023-results-and-provides-business-update-increased-ally-adap-lnsr-20231109monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-reports-second-quarter-2023-results-and-provides-business-update-increased-ally-ada-lnsr-20230809monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-reports-first-quarter-2023-results-and-provides-business-update-increased-ally-adap-lnsr-20230512monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-reports-fourth-quarter-and-full-year-2022-results-and-provides-business-update-inst-lnsr-20230316monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-announces-preliminary-fourth-quarter-and-full-year-2022-results-installed-ten-ally--lnsr-20230214monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-reports-third-quarter-2022-financial-results-and-provides-business-update-company-l-lnsr-20221109monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-announces-application-for-certification-of-the-ally-adaptive-cataract-treatment-sys-lnsr-20220908monthly0.5https://www.biopharmawatch.com/news/LNSR/first-patients-treated-with-lensar-s-ally-adaptive-cataract-treatment-system-lnsr-20220816monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-reports-second-quarter-2022-financial-results-and-provides-business-update-company--lnsr-20220808monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-receives-u-s-fda-clearance-of-ally-adaptive-cataract-treatment-system-lnsr-20220613monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-reports-first-quarter-2022-financial-results-and-provides-business-update-first-qua-lnsr-20220509monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-business-u-lnsr-20220303monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-reports-third-quarter-2021-financial-results-and-provides-business-update-third-qua-lnsr-20211108monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-inc-statements-of-operations-in-thousands-except-per-share-amounts-three-months-end-lnsr-20210805monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-reports-first-quarter-2021-financial-results-and-provides-business-update-first-qua-lnsr-20210505monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-business-u-lnsr-20210310monthly0.5https://www.biopharmawatch.com/news/LNSR/lensar-expands-board-of-directors-with-the-appointments-of-aimee-s-weisner-and-elizabeth-g-lnsr-20210201monthly0.5https://www.biopharmawatch.com/news/LNSR/discovery-drive-orlando-fl-32826-lensar-reports-third-quarter-2020-financial-results-and-p-lnsr-20201109monthly0.5https://www.biopharmawatch.com/news/LNSR/thomas-r-staab-ii-ir-contact-lensar-com-lensar-inc-begins-trading-on-nasdaq-orlando-fl-lnsr-20201002monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-announces-two-transactions-to-strengthen-balance-sheet-reduce-operating-mcrb-20260605monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-upda-mcrb-20260505monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-second-quarter-2025-financial-results-and-provides-business-upd-mcrb-20250806monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-first-quarter-2025-financial-results-and-provides-business-upda-mcrb-20250507monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-provide-mcrb-20250313monthly0.5https://www.biopharmawatch.com/news/MCRB/j-p-morgan-conference-seres-therapeutics-investor-presentation-mcrb-20250116monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-announces-new-translational-biomarker-results-from-ser-155-phase-1b-cli-mcrb-20250109monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-upda-mcrb-20241113monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-announces-completion-of-vowst-asset-sale-to-soci-t-des-produits-nestl-s-mcrb-20240930monthly0.5https://www.biopharmawatch.com/news/MCRB/ser-155-phase-1b-readout-mcrb-20240912monthly0.5https://www.biopharmawatch.com/news/MCRB/index-to-consolidated-financial-statements-page-report-of-independent-registered-public-ac-mcrb-20240815monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-second-quarter-2024-financial-results-and-provides-business-upd-mcrb-20240813monthly0.5https://www.biopharmawatch.com/news/MCRB/form-of-support-agreement-this-support-agreement-this-agreement-is-made-as-of-mcrb-20240805monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-announces-signing-of-vowst-asset-purchase-agreement-with-nestl-health-s-mcrb-20240806monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-first-quarter-2024-financial-results-and-provides-business-upda-mcrb-20240508monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-provide-mcrb-20240305monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-announces-vowst-commercial-launch-update-and-us-fda-fast-track-designat-mcrb-20240110monthly0.5https://www.biopharmawatch.com/news/MCRB/some-of-the-statements-in-this-presentation-constitute-forward-looking-statements-under-th-mcrb-20240109monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-third-quarter-2023-financial-results-including-vowst-net-sales--mcrb-20231102monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-second-quarter-2023-financial-results-and-provides-business-upd-mcrb-20230808monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-june-2023-corporate-overview-forward-looking-statements-some-of-the-sta-mcrb-20230628monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-first-quarter-2023-financial-results-and-provides-business-upda-mcrb-20230509monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-provide-mcrb-20230307monthly0.5https://www.biopharmawatch.com/news/MCRB/some-of-the-statements-in-this-presentation-constitute-forward-looking-statements-under-th-mcrb-20230109monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-third-quarter-2022-financial-results-and-provides-business-upda-mcrb-20221102monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-second-quarter-2022-financial-results-and-provides-business-upd-mcrb-20220803monthly0.5https://www.biopharmawatch.com/news/MCRB/some-of-the-statements-in-this-presentation-constitute-forward-looking-statements-under-th-mcrb-20220607monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-first-quarter-2022-financial-results-and-provides-business-upda-mcrb-20220504monthly0.5https://www.biopharmawatch.com/news/MCRB/some-of-the-statements-in-this-presentation-constitute-forward-looking-statements-under-th-mcrb-20220406monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-provide-mcrb-20220301monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-third-quarter-2021-financial-results-and-provides-business-upda-mcrb-20211110monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-second-quarter-2021-financial-results-and-provides-business-upd-mcrb-20210803monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-announces-topline-results-for-ser-287-phase-2b-study-in-mild-to-moderat-mcrb-20210722monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-announces-david-arkowitz-to-join-as-executive-vice-president-chief-fina-mcrb-20210520monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-first-quarter-2021-financial-results-and-provides-business-upda-mcrb-20210504monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and-provide-mcrb-20210302monthly0.5https://www.biopharmawatch.com/news/MCRB/some-of-the-statements-in-this-presentation-constitute-forward-looking-statements-under-th-mcrb-20210111monthly0.5https://www.biopharmawatch.com/news/MCRB/some-of-the-statements-in-this-presentation-constitute-forward-looking-statements-under-th-mcrb-20201109monthly0.5https://www.biopharmawatch.com/news/MCRB/forward-looking-statements-some-of-the-statements-in-this-presentation-constitute-forward--mcrb-20200728monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-first-quarter-2020-financial-results-and-provides-business-upda-mcrb-20200507monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-and-corpora-mcrb-20200302monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-third-quarter-financial-results-and-provides-business-update-tw-mcrb-20191105monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-second-quarter-financial-results-and-provides-progress-update-f-mcrb-20190806monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-first-quarter-financial-results-and-provides-clinical-pipeline--mcrb-20190502monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-fourth-quarter-and-full-year-financial-results-and-provides-ope-mcrb-20190306monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-third-quarter-financial-results-and-provides-operational-update-mcrb-20181108monthly0.5https://www.biopharmawatch.com/news/MCRB/some-of-the-statements-in-this-presentation-constitute-forward-looking-statements-under-th-mcrb-20180802monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-second-quarter-financial-results-and-provides-operational-updat-mcrb-20180802monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-first-quarter-financial-results-and-provides-operational-update-mcrb-20180509monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-fourth-quarter-and-full-year-2017-financial-results-and-provide-mcrb-20180308monthly0.5https://www.biopharmawatch.com/news/MCRB/some-of-the-statements-in-this-presentation-constitute-forward-looking-statements-under-th-mcrb-20180108monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-third-quarter-2017-financial-results-and-provides-update-on-ope-mcrb-20171108monthly0.5https://www.biopharmawatch.com/news/MCRB/forward-looking-statements-some-of-the-statements-in-this-presentation-constitute-forward--mcrb-20171016monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-second-quarter-2017-financial-results-and-provides-update-on-op-mcrb-20170803monthly0.5https://www.biopharmawatch.com/news/MCRB/forward-looking-statements-some-of-the-statements-in-this-presentation-constitute-forward--mcrb-20170612monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-first-quarter-2017-financial-results-and-provides-update-on-ope-mcrb-20170504monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-fourth-quarter-and-full-year-2016-financial-results-and-provide-mcrb-20170316monthly0.5https://www.biopharmawatch.com/news/MCRB/forward-looking-statements-some-of-the-statements-in-this-presentation-constitute-forward--mcrb-20170131monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-fourth-quarter-and-full-year-2015-financial-results-and-provide-mcrb-20160225monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-third-quarter-2015-financial-results-and-provides-business-upda-mcrb-20151110monthly0.5https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-reports-second-quarter-2015-financial-results-and-provides-business-upd-mcrb-20150806monthly0.5https://www.biopharmawatch.com/news/XGN/exagen-inc-announces-closing-of-20-2-million-public-offering-including-full-exercise-of-un-xgn-20250509monthly0.5https://www.biopharmawatch.com/news/XGN/exagen-inc-announces-proposed-public-offering-of-common-stock-xgn-20250507monthly0.5https://www.biopharmawatch.com/news/XGN/exagen-inc-announces-senior-secured-credit-facility-with-perceptive-advisors-25-million-fu-xgn-20250428monthly0.5https://www.biopharmawatch.com/news/XGN/exagen-inc-announces-27-2-million-debt-refinancing-xgn-20211025monthly0.5https://www.biopharmawatch.com/news/XGN/exagen-inc-announces-proposed-public-offering-of-common-stock-xgn-20210322monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-to-divest-vitalware-for-147-million-accelerating-strategic-transformation--hcat-20260604monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-reports-first-quarter-2026-results-hcat-20260511monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-appoints-steve-nelson-president-of-aetna-to-its-board-of-directors-nelson--hcat-20260430monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-appoints-ben-albert-as-chief-executive-officer-albert-to-sharpen-focus-on--hcat-20260218monthly0.5https://www.biopharmawatch.com/news/HCAT/matt-arens-ceo-and-founder-of-health-catalyst-s-largest-shareholder-first-light-asset-mana-hcat-20251202monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-reports-third-quarter-2025-results-hcat-20251110monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-appoints-ben-albert-to-the-role-of-president-and-coo-albert-appointed-to-d-hcat-20250910monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-reports-second-quarter-2025-results-hcat-20250807monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-reports-first-quarter-2025-results-hcat-20250507monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-reports-fourth-quarter-and-year-end-2024-results-hcat-20250226monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-signs-definitive-agreement-to-acquire-upfront-healthcare-services-hcat-20250113monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-reports-third-quarter-2024-results-hcat-20241106monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-reports-second-quarter-2024-results-hcat-20240807monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-announces-new-credit-facility-for-up-to-225-000-000-salt-lake-city-utah-hcat-20240718monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-reports-first-quarter-2024-results-hcat-20240509monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-reports-fourth-quarter-and-year-end-2023-results-hcat-20240222monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-reports-third-quarter-2023-results-hcat-20231102monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-reports-third-quarter-2023-preliminary-results-hcat-20231027monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-reports-second-quarter-2023-results-hcat-20230808monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-reports-first-quarter-2023-results-hcat-20230509monthly0.5https://www.biopharmawatch.com/news/HCAT/innovative-healthcare-executive-and-carle-health-coo-matthew-kolb-joins-health-catalyst-bo-hcat-20230228monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-reports-fourth-quarter-and-year-end-2022-results-hcat-20230228monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-announces-new-external-leadership-assignment-for-paul-horstmeier-salt-lake-hcat-20230106monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-reports-third-quarter-2022-results-hcat-20221108monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-announces-new-leadership-assignments-in-support-of-strategic-focus-areas-a-hcat-20220907monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-announces-40-million-share-repurchase-program-hcat-20220804monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-reports-second-quarter-2022-results-hcat-20220804monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-reports-first-quarter-2022-results-hcat-20220510monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-reports-fourth-quarter-and-year-end-2021-results-hcat-20220301monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-reports-third-quarter-2021-results-hcat-20211109monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-reports-second-quarter-2021-results-hcat-20210805monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-announces-agreement-to-acquire-twistle-twistle-a-patient-engagement-saas-t-hcat-20210624monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-reports-first-quarter-2021-results-hcat-20210506monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-reports-fourth-quarter-and-year-end-2020-results-hcat-20210225monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-reports-third-quarter-2020-results-hcat-20201110monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-completes-hosting-of-the-largest-ever-healthcare-analytics-summit-and-anno-hcat-20200908monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-announces-agreement-to-acquire-vitalware-a-revenue-workflow-optimization-a-hcat-20200811monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-reports-second-quarter-2020-results-hcat-20200811monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-reports-first-quarter-2020-results-hcat-20200512monthly0.5https://www.biopharmawatch.com/news/HCAT/mark-templeton-appointed-to-health-catalyst-board-of-directors-hcat-20200512monthly0.5https://www.biopharmawatch.com/news/HCAT/about-health-catalyst-health-catalyst-is-a-leading-provider-of-data-and-analytics-technolo-hcat-20200409monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-reports-fourth-quarter-and-year-end-2019-results-hcat-20200227monthly0.5https://www.biopharmawatch.com/news/HCAT/experienced-technology-executives-julie-larson-green-and-s-dawn-smith-appointed-to-health--hcat-20191112monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-reports-third-quarter-2019-results-hcat-20191112monthly0.5https://www.biopharmawatch.com/news/HCAT/health-catalyst-reports-second-quarter-2019-results-hcat-20190822monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-inc-condensed-consolidated-balance-sheet-data-unaudited-in-thousands-ex-tcrx-20260506monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-inc-condensed-consolidated-balance-sheet-data-unaudited-in-thousands-ex-tcrx-20260304monthly0.5https://www.biopharmawatch.com/news/TCRX/disclaimers-and-forward-looking-statements-this-presentation-and-the-accompanying-discussi-tcrx-20260112monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-inc-condensed-consolidated-balance-sheet-data-unaudited-in-thousands-ex-tcrx-20251112monthly0.5https://www.biopharmawatch.com/news/TCRX/company-presentation-september-2025-disclaimers-and-forward-looking-statements-this-presen-tcrx-20250909monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate-up-tcrx-20250812monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-reports-first-quarter-2025-financial-results-and-provides-corporate-upd-tcrx-20250506monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-provide-tcrx-20250305monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-refinances-existing-convertible-debt-facility-with-term-loan-for-up-to--tcrx-20241223monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-to-present-updated-data-from-the-ongoing-alloha-phase-1-heme-trial-duri-tcrx-20241210monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-reports-third-quarter-2024-financial-results-and-provides-corporate-upd-tcrx-20241112monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-reports-second-quarter-2024-financial-results-and-provides-corporate-up-tcrx-20240812monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-updates-to-its-board-of-directors-garry-a-nicholson-an-experi-tcrx-20240614monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-reports-first-quarter-2024-financial-results-and-provides-corporate-upd-tcrx-20240513monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-launch-of-125-million-proposed-public-offering-tcrx-20240416monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-provides-clinical-pipeline-update-and-highlights-near-term-priorities-o-tcrx-20240416monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-appoints-seasoned-hematology-and-oncology-expert-chrystal-u-louis-m-d-m-tcrx-20240408monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-provide-tcrx-20240306monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-appoints-seasoned-industry-executive-jason-a-amello-as-chief-financial--tcrx-20240129monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-presents-initial-phase-1-clinical-results-on-tsc-100-and-tsc-101-at-the-tcrx-20231209monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-appoints-r-keith-woods-to-its-board-of-directors-bringing-expertise-in--tcrx-20231207monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-reports-third-quarter-2023-financial-results-and-provides-corporate-upd-tcrx-20231109monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-reports-second-quarter-2023-financial-results-and-provides-corporate-up-tcrx-20230810monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-transition-of-chief-financial-officer-tcrx-20230629monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-launch-of-proposed-public-offering-tcrx-20230525monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-appoints-gavin-macbeath-ph-d-as-chief-executive-officer-and-as-a-member-tcrx-20230524monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-presents-preliminary-phase-1-clinical-results-on-tsc-100-and-tsc-101-at-tcrx-20230517monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-reports-first-quarter-2023-financial-results-and-provides-corporate-upd-tcrx-20230510monthly0.5https://www.biopharmawatch.com/news/TCRX/amgen-and-tscan-therapeutics-announce-collaboration-to-identify-novel-targets-in-crohn-s-d-tcrx-20230509monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-appointment-of-barbara-klencke-m-d-to-its-board-of-directors--tcrx-20230410monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-ceo-transition-david-southwell-steps-down-gavin-macbeath-ph-d-tcrx-20230328monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-highlig-tcrx-20230308monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-fda-clearance-of-three-investigational-new-drug-applications--tcrx-20230123monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-reports-third-quarter-2022-financial-results-and-provides-business-upda-tcrx-20221109monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-secures-convertible-debt-facility-for-up-to-60-million-with-k2-healthve-tcrx-20220912monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-reports-second-quarter-2022-financial-results-and-highlights-recent-pro-tcrx-20220810monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-tsc-tcrx-20220531monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-reports-first-quarter-2022-financial-results-and-upcoming-anticipated-m-tcrx-20220509monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-reports-full-year-2021-financial-results-and-highlights-key-2022-priori-tcrx-20220309monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-tsc-tcrx-20220124monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-reports-third-quarter-2021-financial-results-and-highlights-recent-comp-tcrx-20211110monthly0.5https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-reports-second-quarter-2021-financial-results-and-highlights-recent-com-tcrx-20210819monthly0.5https://www.biopharmawatch.com/news/ACRV/acrivon-reports-first-quarter-2026-financial-results-and-highlights-progress-towards-key-2-acrv-20260513monthly0.5https://www.biopharmawatch.com/news/ACRV/acrivon-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recen-acrv-20260319monthly0.5https://www.biopharmawatch.com/news/ACRV/forward-looking-statements-certain-information-contained-in-this-presentation-and-related--acrv-20260227monthly0.5https://www.biopharmawatch.com/news/ACRV/acr-368-and-acr-2316-clinical-data-and-ap3-acrv-20260108monthly0.5https://www.biopharmawatch.com/news/ACRV/acrivon-therapeutics-announces-positive-acr-368-phase-2b-endometrial-cancer-clinical-data--acrv-20260108monthly0.5https://www.biopharmawatch.com/news/ACRV/acrivon-therapeutics-reports-third-quarter-2025-financial-results-and-business-highlights--acrv-20251113monthly0.5https://www.biopharmawatch.com/news/ACRV/forward-looking-statements-certain-information-contained-in-this-presentation-includes-for-acrv-20250905monthly0.5https://www.biopharmawatch.com/news/ACRV/acrivon-therapeutics-reports-second-quarter-2025-financial-results-and-business-highlights-acrv-20250813monthly0.5https://www.biopharmawatch.com/news/ACRV/acrivon-therapeutics-reports-first-quarter-2025-financial-results-and-business-highlights--acrv-20250514monthly0.5https://www.biopharmawatch.com/news/ACRV/acrivon-therapeutics-appoints-world-renowned-oncology-key-opinion-leader-and-clinical-inve-acrv-20250407monthly0.5https://www.biopharmawatch.com/news/ACRV/acrivon-therapeutics-provides-program-updates-and-fourth-quarter-and-full-year-2024-financ-acrv-20250327monthly0.5https://www.biopharmawatch.com/news/ACRV/corporate-r-d-event-acrv-20250325monthly0.5https://www.biopharmawatch.com/news/ACRV/acrivon-therapeutics-reports-third-quarter-2024-financial-results-and-business-highlights--acrv-20241113monthly0.5https://www.biopharmawatch.com/news/ACRV/acrivon-therapeutics-announces-initial-patient-dosing-in-phase-1-trial-of-acr-2316-a-novel-acrv-20241011monthly0.5https://www.biopharmawatch.com/news/ACRV/acrivon-therapeutics-reports-positive-endometrial-cancer-data-from-ongoing-acr-368-registr-acrv-20240914monthly0.5https://www.biopharmawatch.com/news/ACRV/acrivon-therapeutics-reports-second-quarter-2024-financial-results-and-business-highlights-acrv-20240813monthly0.5https://www.biopharmawatch.com/news/ACRV/acrivon-therapeutics-reports-first-quarter-2024-financial-results-and-business-highlights-acrv-20240514monthly0.5https://www.biopharmawatch.com/news/ACRV/corporate-r-d-event-april-24-2024-acrivon-predictive-precision-proteomics-ap3-overcoming-l-acrv-20240424monthly0.5https://www.biopharmawatch.com/news/ACRV/acrivon-therapeutics-announces-130-million-private-placement-financing-acrv-20240409monthly0.5https://www.biopharmawatch.com/news/ACRV/acrivon-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-busin-acrv-20240328monthly0.5https://www.biopharmawatch.com/news/ACRV/acrivon-therapeutics-appoints-santhosh-palani-ph-d-cfa-experienced-board-member-and-health-acrv-20240304monthly0.5https://www.biopharmawatch.com/news/ACRV/acrivon-therapeutics-appoints-seasoned-industry-executive-ivana-magov-evi-liebisch-ph-d-j--acrv-20240208monthly0.5https://www.biopharmawatch.com/news/ACRV/forward-looking-statements-certain-information-contained-in-this-presentation-includes-for-acrv-20240108monthly0.5https://www.biopharmawatch.com/news/ACRV/acrivon-therapeutics-reports-third-quarter-2023-financial-results-and-business-highlights-acrv-20231109monthly0.5https://www.biopharmawatch.com/news/ACRV/acrivon-therapeutics-announces-acr-2316-a-novel-dual-wee1-and-pkmyt1-inhibitor-development-acrv-20230905monthly0.5https://www.biopharmawatch.com/news/ACRV/acrivon-therapeutics-reports-second-quarter-2023-financial-results-and-business-highlights-acrv-20230811monthly0.5https://www.biopharmawatch.com/news/ACRV/acrivon-therapeutics-reports-first-quarter-2023-financial-results-and-business-highlights-acrv-20230509monthly0.5https://www.biopharmawatch.com/news/ACRV/a-acr-criv-ivon-on-t-t-h-h-e-e-r-r-a-a-p-p-e-e-u-u-t-t-ii-c-c-s-s-acrivon-predictive-preci-acrv-20230501monthly0.5https://www.biopharmawatch.com/news/ACRV/acriv-acrivon-on-thera-therapeutics-peutics-acrivon-predictive-precision-proteomics-ap3-dr-acrv-20230425monthly0.5https://www.biopharmawatch.com/news/ACRV/acrivon-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-busin-acrv-20230328monthly0.5https://www.biopharmawatch.com/news/ACRV/acriv-acrivon-on-thera-therapeutics-peutics-acrivon-predictive-precision-proteomics-ap3-dr-acrv-20230313monthly0.5https://www.biopharmawatch.com/news/ACRV/share-purchase-agreement-this-share-purchase-agreement-this-agreement-is-entered-into-as-o-acrv-20221114monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-provides-corporate-update-and-highlights-expected-2026-milestones-successfully--acet-20260107monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-reports-third-quarter-2025-financial-results-and-provides-business-updates-anno-acet-20251105monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-announces-positive-preliminary-data-from-adi-001-phase-1-study-in-patients-with-acet-20251007monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-reports-second-quarter-2025-financial-results-and-provides-business-updates-act-acet-20250807monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-reports-first-quarter-2025-financial-results-and-provides-business-updates-two--acet-20250506monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-appoints-michael-grissinger-to-the-board-of-directors-mr-grissinger-brings-more-acet-20250417monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-reports-fourth-quarter-and-full-year-2024-financial-results-and-highlights-rece-acet-20250306monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-announces-first-patient-dosed-in-the-phase-1-clinical-trial-of-adi-270-in-metas-acet-20241219monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-opens-enrollment-for-adi-270-phase-1-clinical-trial-in-metastatic-advanced-clear-ce-acet-20241118monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-reports-third-quarter-2024-financial-results-and-provides-business-updates-adi-001--acet-20241106monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-announces-fda-clearance-of-ind-amendment-to-evaluate-adi-001-in-idiopathic-infl-acet-20241016monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-opens-enrollment-for-adi-001-phase-1-clinical-trial-in-autoimmune-diseases-activate-acet-20240930monthly0.5https://www.biopharmawatch.com/news/ACET/adi-001-clinical-biomarker-data-demonstrate-robust-tissue-trafficking-and-complete-b-cell--acet-20240919monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-appoints-lloyd-klickstein-m-d-ph-d-to-the-board-of-directors-redwood-city-calif-bos-acet-20240819monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-reports-second-quarter-2024-financial-results-and-provides-business-updates-adi-001-acet-20240813monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-receives-fda-fast-track-designation-for-adi-270-in-metastatic-advanced-clear-ce-acet-20240708monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-announces-fda-clearance-of-ind-application-for-adi-270-in-renal-cell-carcinoma--acet-20240624monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-receives-fda-fast-track-designation-for-adi-001-in-lupus-nephritis-redwood-city-acet-20240605monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-reports-first-quarter-2024-financial-results-and-provides-business-updates-on-track-acet-20240514monthly0.5https://www.biopharmawatch.com/news/ACET/adi-270-an-armored-allogeneic-anti-cd70-car-x3b3-x3b4-t-cell-therapy-candidate-designed-fo-acet-20240510monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-highlights-preclinical-data-supporting-ind-readiness-for-adi-270-in-an-oral-pre-acet-20240422monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-reports-fourth-quarter-and-full-year-2023-financial-results-and-highlights-recent-c-acet-20240319monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-inc-announces-proposed-public-offering-redwood-city-calif-boston-acet-20240122monthly0.5https://www.biopharmawatch.com/news/ACET/leaders-in-developing-allogeneic-car-x3b3-x3b4-1-cell-therapies-to-fight-autoimmune-diseas-acet-20240116monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-provides-corporate-update-and-highlights-strategic-priorities-for-2024-expanding-cl-acet-20240104monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-reports-third-quarter-2023-financial-results-and-provides-business-updates-initiate-acet-20231108monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-reports-second-quarter-2023-financial-results-and-provides-business-updates-announc-acet-20230809monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-announces-appointment-of-katie-peng-to-the-board-of-directors-redwood-city-calif-bo-acet-20230711monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-reports-positive-data-from-ongoing-adi-001-phase-1-trial-in-patients-with-relap-acet-20230626monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-presents-positive-preclinical-data-on-adi-270-at-the-american-society-of-gene-a-acet-20230518monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-reports-first-quarter-2023-financial-results-and-provides-business-updates-on-track-acet-20230509monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-reports-fourth-quarter-and-full-year-2022-financial-results-and-highlights-recent-c-acet-20230315monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-reports-positive-data-from-ongoing-adi-001-phase-1-trial-in-patients-with-relap-acet-20221205monthly0.5https://www.biopharmawatch.com/news/ACET/virtual-r-d-event-acet-20221110monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-reports-third-quarter-2022-financial-results-and-provides-business-updates-as-of-as-acet-20221108monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-reports-ash-abstract-data-from-ongoing-adi-001-phase-1-trial-in-relapsed-or-ref-acet-20221103monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-reports-second-quarter-2022-financial-results-and-provides-business-updates-adi-001-acet-20220810monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-reports-emerging-data-from-adi-001-phase-1-trial-at-the-american-society-of-cli-acet-20220531monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-reports-positive-clinical-update-from-adi-001-phase-1-trial-in-relapsed-refract-acet-20220526monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-reports-first-quarter-2022-financial-results-and-provides-business-updates-interim--acet-20220512monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-presents-preclinical-data-at-the-isct-annual-meeting-highlighting-potential-advanta-acet-20220505monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-receives-fda-fast-track-designation-for-lead-candidate-adi-001-menlo-park-ca-an-acet-20220419monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-reports-fourth-quarter-and-full-year-2021-financial-results-and-highlights-recent-c-acet-20220315monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-inc-announces-proposed-follow-on-offering-of-common-stock-menlo-park-calif-and-acet-20211207monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-announces-appointment-of-dr-michael-g-kauffman-to-the-board-of-directors-menlo-park-acet-20211118monthly0.5https://www.biopharmawatch.com/news/ACET/about-adicet-bio-inc-adicet-bio-inc-is-a-biotechnology-company-discovering-and-developing--acet-20211112monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-reports-third-quarter-2021-financial-results-and-provides-business-updates-xf0b7-on-acet-20211110monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-collaborates-with-twist-bioscience-to-accelerate-discovery-of-gamma-delta-t-cel-acet-20210913monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-reports-second-quarter-2021-financial-results-and-provides-business-updates-on-trac-acet-20210812monthly0.5https://www.biopharmawatch.com/news/ACET/balance-sheet-data-in-thousands-unaudited-acet-20210517monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-business-u-acet-20210311monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-announces-initiation-of-its-first-in-human-phase-1-trial-of-adi-001-for-the-tre-acet-20210310monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-appoints-dr-andrew-sinclair-to-its-board-of-directors-menlo-park-ca-and-boston--acet-20210304monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-bio-inc-announces-proposed-public-offering-of-common-stock-and-concurrent-private-p-acet-20210209monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-announces-appointment-of-dr-bastiano-sanna-to-its-board-of-directors-menlo-park-ca--acet-20201201monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-reports-third-quarter-2020-financial-results-and-provides-business-update-menlo-par-acet-20201105monthly0.5https://www.biopharmawatch.com/news/ACET/employment-agreement-this-employment-agreement-agreement-is-made-between-adicet-therapeuti-acet-20201026monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-announces-fda-clearance-of-ind-application-for-first-in-class-allogeneic-car-gamma--acet-20201022monthly0.5https://www.biopharmawatch.com/news/ACET/management-following-the-merger-executive-officers-and-directors-of-the-combined-company-f-acet-20200918monthly0.5https://www.biopharmawatch.com/news/ACET/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-acet-20200916monthly0.5https://www.biopharmawatch.com/news/ACET/adicet-announces-completion-of-merger-with-restorbio-adicet-emerges-as-a-leading-allogenei-acet-20200916monthly0.5https://www.biopharmawatch.com/news/ACET/restorbio-provides-corporate-update-and-reports-second-quarter-2020-financial-results-acet-20200730monthly0.5https://www.biopharmawatch.com/news/ACET/forward-looking-statements-this-communication-contains-forward-looking-statements-within-t-acet-20200728monthly0.5https://www.biopharmawatch.com/news/ACET/forward-looking-statements-this-communication-contains-forward-looking-statements-within-t-acet-20200623monthly0.5https://www.biopharmawatch.com/news/ACET/forward-looking-statements-this-communication-contains-forward-looking-statements-within-t-acet-20200602monthly0.5https://www.biopharmawatch.com/news/ACET/this-press-release-which-are-not-strictly-historical-statements-including-without-limitati-acet-20200528monthly0.5https://www.biopharmawatch.com/news/ACET/restorbio-provides-corporate-update-and-reports-first-quarter-2020-financial-results-acet-20200507monthly0.5https://www.biopharmawatch.com/news/ACET/restorbio-and-adicet-bio-announce-merger-agreement-to-advance-allogeneic-gamma-delta-car-t-acet-20200429monthly0.5https://www.biopharmawatch.com/news/ACET/restorbio-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides-corpora-acet-20200312monthly0.5https://www.biopharmawatch.com/news/ACET/forward-looking-statements-this-presentation-has-been-prepared-by-restorbio-inc-we-us-our--acet-20200219monthly0.5https://www.biopharmawatch.com/news/ACET/forward-looking-statements-this-presentation-has-been-prepared-by-restorbio-inc-we-us-our--acet-20191203monthly0.5https://www.biopharmawatch.com/news/ACET/this-presentation-has-been-prepared-by-restorbio-inc-we-us-our-restorbio-or-the-company-an-acet-20191118monthly0.5https://www.biopharmawatch.com/news/ACET/restorbio-announces-that-the-phase-3-protector-1-trial-of-rtb101-in-clinically-symptomatic-acet-20191115monthly0.5https://www.biopharmawatch.com/news/ACET/restorbio-reports-third-quarter-2019-financial-results-and-corporate-update-top-line-data--acet-20191105monthly0.5https://www.biopharmawatch.com/news/ACET/this-presentation-has-been-prepared-by-restorbio-inc-we-us-our-restorbio-or-the-company-an-acet-20191003monthly0.5https://www.biopharmawatch.com/news/ACET/restorbio-reports-second-quarter-2019-financial-results-and-corporate-update-quarter-highl-acet-20190814monthly0.5https://www.biopharmawatch.com/news/ACET/restorbio-announces-early-completion-of-enrollment-of-phase-3-protector-1-trial-with-rtb10-acet-20190723monthly0.5https://www.biopharmawatch.com/news/ACET/restorbio-reports-first-quarter-2019-financial-results-and-corporate-update-initiated-firs-acet-20190515monthly0.5https://www.biopharmawatch.com/news/ACET/restorbio-announces-initiation-of-phase-3-clinical-program-of-rtb101-in-clinically-symptom-acet-20190509monthly0.5https://www.biopharmawatch.com/news/ACET/restorbio-inc-announces-pricing-of-public-offering-of-common-stock-acet-20190319monthly0.5https://www.biopharmawatch.com/news/ACET/restorbio-reports-fourth-quarter-and-full-year-2018-financial-results-positive-end-of-phas-acet-20190318monthly0.5https://www.biopharmawatch.com/news/ACET/this-presentation-may-contain-forward-looking-statements-within-the-meaning-of-the-private-acet-20190318monthly0.5https://www.biopharmawatch.com/news/ACET/this-presentation-may-contain-forward-looking-statements-within-the-meaning-of-the-private-acet-20190207monthly0.5https://www.biopharmawatch.com/news/ACET/this-presentation-may-contain-forward-looking-statements-within-the-meaning-of-the-private-acet-20190107monthly0.5https://www.biopharmawatch.com/news/ACET/restorbio-reports-third-quarter-2018-financial-results-additional-positive-data-from-phase-acet-20181113monthly0.5https://www.biopharmawatch.com/news/ACET/restorbio-appoints-michael-grissinger-to-its-board-of-directors-brings-extensive-business--acet-20181106monthly0.5https://www.biopharmawatch.com/news/ACET/this-presentation-may-contain-forward-looking-statements-within-the-meaning-of-the-private-acet-20181016monthly0.5https://www.biopharmawatch.com/news/ACET/restorbio-inc-employment-agreement-this-employment-agreement-agreement-is-made-as-of-the-3-acet-20180917monthly0.5https://www.biopharmawatch.com/news/ACET/restorbio-appoints-jeffrey-chodakewitz-m-d-to-its-board-of-directors-brings-extensive-expe-acet-20180815monthly0.5https://www.biopharmawatch.com/news/ACET/restorbio-reports-second-quarter-2018-financial-results-phase-2b-results-identify-dose-and-acet-20180809monthly0.5https://www.biopharmawatch.com/news/ACET/this-presentation-may-contain-forward-looking-statements-within-the-meaning-of-the-private-acet-20180730monthly0.5https://www.biopharmawatch.com/news/ACET/restorbio-announces-positive-topline-results-in-phase-2b-trial-of-rtb101-statistically-sig-acet-20180725monthly0.5https://www.biopharmawatch.com/news/ACET/restorbio-reports-first-quarter-2018-financial-results-last-patient-dosed-in-phase-2b-tria-acet-20180510monthly0.5https://www.biopharmawatch.com/news/ACET/restorbio-completes-dosing-of-patients-in-phase-2b-study-to-reduce-the-incidence-of-respir-acet-20180509monthly0.5https://www.biopharmawatch.com/news/ACET/restorbio-reports-fourth-quarter-and-full-year-2017-financial-results-acet-20180329monthly0.5https://www.biopharmawatch.com/news/SRXH/srx-health-solutions-invests-in-astro-investment-xvii-an-affiliate-of-astro-capital-compan-srxh-20260422monthly0.5https://www.biopharmawatch.com/news/SRXH/tony-frouge-chief-regulatory-officer-new-york-stock-exchange-11-wall-street-new-york-ny-10-srxh-20260218monthly0.5https://www.biopharmawatch.com/news/SRXH/srx-health-solutions-redeems-series-a-preferred-stock-and-cancels-approximately-125-000-00-srxh-20260211monthly0.5https://www.biopharmawatch.com/news/SRXH/srx-health-solutions-regains-compliance-with-srxh-20260108monthly0.5https://www.biopharmawatch.com/news/SRXH/srx-health-enters-into-definitive-agreement-to-acquire-emjx-to-establish-next-generation-d-srxh-20251216monthly0.5https://www.biopharmawatch.com/news/SRXH/srx-health-solutions-appoints-sammy-dorf-to-board-of-directors-tampa-fl-srxh-20251110monthly0.5https://www.biopharmawatch.com/news/SRXH/srx-health-solutions-received-nyse-american-notification-letter-regarding-stockholders-equ-srxh-20251017monthly0.5https://www.biopharmawatch.com/news/SRXH/srx-health-solutions-appoints-joshua-epstein-to-board-of-directors-and-compensation-commit-srxh-20251001monthly0.5https://www.biopharmawatch.com/news/SRXH/srx-health-solutions-announces-the-cancellation-of-approximately-18-8-million-shares-of-it-srxh-20250814monthly0.5https://www.biopharmawatch.com/news/SRXH/srx-health-solutions-initiates-restructuring-proceedings-under-ccaa-for-its-canadian-subsi-srxh-20250812monthly0.5https://www.biopharmawatch.com/news/SRXH/srx-health-solutions-announces-management-and-board-changes-tampa-fl-srxh-20250714monthly0.5https://www.biopharmawatch.com/news/SRXH/srx-health-completes-7-3-million-financing-led-by-insiders-and-existing-investors-and-anno-srxh-20250708monthly0.5https://www.biopharmawatch.com/news/SRXH/srx-health-solutions-announces-management-and-board-changes-tampa-fl-srxh-20250611monthly0.5https://www.biopharmawatch.com/news/SRXH/better-choice-company-announces-closing-of-the-srx-health-merger-name-symbol-change-and-co-srxh-20250425monthly0.5https://www.biopharmawatch.com/news/SRXH/srx-health-solutions-inc-formerly-known-as-better-choice-company-inc-announces-halo-spin-o-srxh-20250423monthly0.5https://www.biopharmawatch.com/news/SRXH/source-better-choice-company-inc-srxh-20250416monthly0.5https://www.biopharmawatch.com/news/SRXH/better-choice-company-adjourns-special-meeting-of-stockholders-to-srxh-20250220monthly0.5https://www.biopharmawatch.com/news/SRXH/better-choice-company-chairman-issues-letter-to-shareholders-as-company-continues-to-make--srxh-20241018monthly0.5https://www.biopharmawatch.com/news/SRXH/better-choice-company-inc-announces-second-quarter-2024-results-net-income-increased-190-t-srxh-20240813monthly0.5https://www.biopharmawatch.com/news/SRXH/better-choice-company-announces-notification-of-noncompliance-with-additional-nyse-america-srxh-20240429monthly0.5https://www.biopharmawatch.com/news/SRXH/better-choice-company-inc-announces-fourth-quarter-and-full-year-2023-results-gross-margin-srxh-20240412monthly0.5https://www.biopharmawatch.com/news/SRXH/better-choice-company-board-of-directors-authorize-stock-repurchase-program-srxh-20240416monthly0.5https://www.biopharmawatch.com/news/SRXH/better-choice-company-inc-announces-third-quarter-2023-results-third-quarter-2023-revenue--srxh-20231113monthly0.5https://www.biopharmawatch.com/news/SRXH/document-better-choice-company-inc-announces-second-quarter-2023-results-enhanced-operatio-srxh-20230821monthly0.5https://www.biopharmawatch.com/news/SRXH/document-better-choice-company-reports-first-quarter-2023-financial-results-gross-margin-i-srxh-20230512monthly0.5https://www.biopharmawatch.com/news/SRXH/document-better-choice-announces-streamlining-of-operations-and-reduction-in-workforce-srxh-20230302monthly0.5https://www.biopharmawatch.com/news/SRXH/document-better-choice-company-reports-third-quarter-2022-financial-results-and-provides-o-srxh-20221110monthly0.5https://www.biopharmawatch.com/news/SRXH/document-better-choice-company-reports-record-second-quarter-2022-gross-sales-and-provides-srxh-20220811monthly0.5https://www.biopharmawatch.com/news/SRXH/document-better-choice-company-board-of-directors-authorize-stock-repurchase-program-srxh-20220512monthly0.5https://www.biopharmawatch.com/news/SRXH/document-better-choice-company-reports-record-first-quarter-2022-gross-sales-of-19-7-milli-srxh-20220512monthly0.5https://www.biopharmawatch.com/news/SRXH/document-better-choice-company-reports-fourth-quarter-and-full-year-2021-financial-results-srxh-20220329monthly0.5https://www.biopharmawatch.com/news/SRXH/document-better-choice-company-reports-record-third-quarter-2021-financial-results-and-pro-srxh-20211110monthly0.5https://www.biopharmawatch.com/news/SRXH/document-better-choice-company-appoints-lionel-conacher-and-arlene-dickinson-to-the-board--srxh-20211001monthly0.5https://www.biopharmawatch.com/news/SRXH/document-srxh-20210817monthly0.5https://www.biopharmawatch.com/news/SRXH/document-better-choice-company-reports-second-quarter-2021-financial-results-srxh-20210812monthly0.5https://www.biopharmawatch.com/news/SRXH/document-better-choice-company-reports-first-quarter-2021-financial-results-srxh-20210513monthly0.5https://www.biopharmawatch.com/news/SRXH/document-better-choice-announces-appointment-of-former-blue-buffalo-founding-shareholder-g-srxh-20210426monthly0.5https://www.biopharmawatch.com/news/SRXH/document-better-choice-announces-19-growth-in-q1-2021-gross-sales-relative-to-q4-2020-gros-srxh-20210420monthly0.5https://www.biopharmawatch.com/news/SRXH/document-better-choice-company-reports-fourth-quarter-and-full-year-2020-financial-results-srxh-20210331monthly0.5https://www.biopharmawatch.com/news/SRXH/document-better-choice-company-retains-emerging-markets-consulting-llc-emc-srxh-20210217monthly0.5https://www.biopharmawatch.com/news/SRXH/document-better-choice-secures-new-credit-facility-partnership-new-long-term-credit-relati-srxh-20210111monthly0.5https://www.biopharmawatch.com/news/SRXH/document-better-choice-appoints-consumer-packaged-goods-industry-veteran-scott-lerner-as-n-srxh-20210104monthly0.5https://www.biopharmawatch.com/news/SRXH/better-choice-company-reports-third-quarter-and-year-to-date-2020-financial-results-srxh-20201118monthly0.5https://www.biopharmawatch.com/news/SRXH/better-choice-closes-third-tranche-of-series-f-and-completes-equity-raise-totaling-cumulat-srxh-20201027monthly0.5https://www.biopharmawatch.com/news/SRXH/better-choice-announces-closing-of-expanded-series-f-financing-and-acceleration-of-asian-e-srxh-20201013monthly0.5https://www.biopharmawatch.com/news/SRXH/better-choice-closes-17-8m-insider-led-financing-to-expand-its-rapidly-growing-e-commerce--srxh-20201002monthly0.5https://www.biopharmawatch.com/news/SRXH/better-choice-company-reports-second-quarter-2020-financial-results-srxh-20200818monthly0.5https://www.biopharmawatch.com/news/SRXH/investor-presentation-srxh-20200804monthly0.5https://www.biopharmawatch.com/news/SRXH/better-choice-company-announces-new-7-5-million-revolving-credit-facility-with-citizens-ba-srxh-20200720monthly0.5https://www.biopharmawatch.com/news/SRXH/better-choice-company-reports-first-quarter-2020-financial-results-including-12-3-million--srxh-20200625monthly0.5https://www.biopharmawatch.com/news/SRXH/better-choice-company-reports-full-year-2019-financial-results-and-provides-a-shareholder--srxh-20200507monthly0.5https://www.biopharmawatch.com/news/SRXH/better-choice-company-appoints-pet-and-consumer-packaged-goods-industry-veteran-werner-von-srxh-20200211monthly0.5https://www.biopharmawatch.com/news/SRXH/bruce-linton-joins-better-choice-company-as-special-advisor-management-the-board-and-key-s-srxh-20190917monthly0.5https://www.biopharmawatch.com/news/SRXH/better-choice-company-appoints-walmart-and-pepsico-veteran-andreas-schulmeyer-as-chief-fin-srxh-20190709monthly0.5https://www.biopharmawatch.com/news/SRXH/increasing-liquidity-and-institutional-participation-in-the-cryptocurrency-markets-april-2-srxh-20180404monthly0.5https://www.biopharmawatch.com/news/BDMD/baird-medical-investment-holdings-limited-index-to-financial-statements-page-baird-medical-bdmd-20251205monthly0.5https://www.biopharmawatch.com/news/BDMD/baird-medical-and-excelfin-acquisition-corp-complete-business-combination-bdmd-20241001monthly0.5https://www.biopharmawatch.com/news/HYFT/mindwalk-s-preclinical-dengue-data-support-a-hyft-computational-prediction-immunogens-desi-hyft-20260602monthly0.5https://www.biopharmawatch.com/news/HYFT/the-biology-came-first-over-20-partner-owned-drug-programs-have-reached-clinical-trials-as-hyft-20260518monthly0.5https://www.biopharmawatch.com/news/HYFT/sedi-insider-activity-report-period-march-18-27-2026-source-sedi-issuer-no-5542-all-prices-hyft-20260331monthly0.5https://www.biopharmawatch.com/news/HYFT/sedi-insider-activity-report-period-march-16-x2013-20-2026-source-sedi-issuer-no-5542-all--hyft-20260321monthly0.5https://www.biopharmawatch.com/news/HYFT/the-following-management-s-discussion-and-analysis-x201c-md-a-x201d-should-be-read-in-conj-hyft-20260312monthly0.5https://www.biopharmawatch.com/news/HYFT/mindwalk-holdings-corp-reports-q3-fiscal-2026-financial-results-third-consecutive-quarter--hyft-20260312monthly0.5https://www.biopharmawatch.com/news/HYFT/mindwalk-announces-b-cell-llama-a-nanobody-discovery-platform-designed-for-the-bispecific--hyft-20260306monthly0.5https://www.biopharmawatch.com/news/HYFT/mindwalk-advances-universal-influenza-program-with-a-breakthrough-functional-insight-valid-hyft-20260112monthly0.5https://www.biopharmawatch.com/news/HYFT/the-following-management-s-discussion-and-analysis-x201c-md-a-x201d-should-be-read-in-conj-hyft-20251215monthly0.5https://www.biopharmawatch.com/news/HYFT/mindwalk-reports-record-growth-and-announces-strategic-progress-on-its-ai-asset-pipeline-v-hyft-20251215monthly0.5https://www.biopharmawatch.com/news/HYFT/mindwalk-holdings-corp-to-report-financial-results-and-recent-business-highlights-for-seco-hyft-20251208monthly0.5https://www.biopharmawatch.com/news/HYFT/mindwalk-cto-dr-dirk-van-hyfte-to-join-fireside-chat-at-ai-drug-discovery-development-summ-hyft-20251113monthly0.5https://www.biopharmawatch.com/news/HYFT/mindwalk-holdings-corp-the-x201c-company-x201d-revised-statement-of-executive-compensation-hyft-20251106monthly0.5https://www.biopharmawatch.com/news/HYFT/report-of-voting-results-submitted-pursuant-to-section-11-3-of-national-instrument-51-102--hyft-20251009monthly0.5https://www.biopharmawatch.com/news/HYFT/mindwalk-appoints-r-scott-areglado-as-chief-financial-officer-to-strengthen-financial-lead-hyft-20251020monthly0.5https://www.biopharmawatch.com/news/HYFT/mindwalk-appoints-dr-thomas-w-lynch-as-chief-business-officer-to-accelerate-commercial-exp-hyft-20251015monthly0.5https://www.biopharmawatch.com/news/HYFT/unaudited-pro-forma-financial-information-overview-on-hyft-20251014monthly0.5https://www.biopharmawatch.com/news/HYFT/mindwalk-announces-share-repurchase-program-austin-texas-x2013-mindwalk-holdings-corp-x201-hyft-20251009monthly0.5https://www.biopharmawatch.com/news/HYFT/mindwalk-advances-ai-designed-glp-1-program-with-first-in-class-dual-pathway-regimen-for-a-hyft-20250922monthly0.5https://www.biopharmawatch.com/news/HYFT/mindwalk-holdings-corp-tm-formerly-immunoprecise-antibodiestm-reports-record-7-6-million-q-hyft-20250915monthly0.5https://www.biopharmawatch.com/news/HYFT/the-following-management-s-discussion-and-analysis-x201c-md-a-x201d-should-be-read-in-conj-hyft-20250915monthly0.5https://www.biopharmawatch.com/news/HYFT/mindwalk-to-report-financial-results-and-recent-business-highlights-for-first-quarter-fisc-hyft-20250910monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-rebrands-as-mindwalk-announces-nasdaq-ticker-change-to-x201c-hyft-x201d-an-e-hyft-20250903monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-to-participate-at-h-c-wainwright-s-27th-annual-global-investment--hyft-20250902monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-advances-ai-discovered-and-developed-universal-dengue-vaccine-initiative-mov-hyft-20250827monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-ltd-divests-netherlands-facilities-to-avs-bio-to-accelerate-bio-n-hyft-20250806monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-ltd-3204-4464-markham-street-victoria-bc-canada-v8z-7x8-ph-1-250--hyft-20250801monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-ipa-reports-record-full-fiscal-year-2025-results-record-fourth-qu-hyft-20250729monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-releases-new-findings-showing-lens-ai-quickly-flags-anti-drug-antibody-risk--hyft-20250724monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-appoints-healthcare-data-visionary-jeff-fried-to-advisory-board-austin-texas-hyft-20250721monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-regains-compliance-with-nasdaq-minimum-bid-price-requirement-austin-texas-x2-hyft-20250711monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors-austin-hyft-20250707monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-validates-lens-ai-epitope-mapping-platform-across-broad-range-of-unseen-ther-hyft-20250703monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-advances-universal-dengue-vaccine-confirming-safety-immune-activation-and-st-hyft-20250605monthly0.5https://www.biopharmawatch.com/news/HYFT/ai-designed-glp-1-peptides-from-immunoprecise-antibodies-surpass-semaglutide-in-receptor-a-hyft-20250612monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-announces-ai-driven-breakthrough-in-universal-dengue-vaccine-discovery-lens--hyft-20250605monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-engages-core-ir-to-enhance-investor-engagement-efforts-hyft-20250521monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-s-lens-ai-platform-delivers-x-ray-x2013-level-epitope-mapping-insights-in-hours-matchi-hyft-20250512monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-highlights-alignment-of-proprietary-ai-driven-platform-lensai-wit-hyft-20250411monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-and-ribopro-partner-to-advance-mrna-driven-antibody-discovery-unlocking-new-frontiers--hyft-20250410monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-ipa-reports-financial-results-and-recent-business-highlights-for--hyft-20250328monthly0.5https://www.biopharmawatch.com/news/HYFT/the-following-management-s-discussion-and-analysis-x201c-md-a-x201d-should-be-read-in-conj-hyft-20250328monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-and-a-global-biotechnology-leader-enter-into-a-usd-8m-10m-partner-hyft-20250313monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-to-reschedule-financial-results-and-recent-business-highlights-for-third-quarter-fisca-hyft-20250312monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-announces-key-leadership-changes-austin-texas-x2013-immunoprecise-hyft-20250224monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-ipa-announces-completion-of-at-the-market-equity-offering-and-ful-hyft-20250203monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-ipa-announces-completion-of-at-the-market-equity-offering-and-ful-hyft-20250127monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-immunoprecise-antibodies-pioneers-ai-designed-glp-1-therapies-a-potential-new-chapter--hyft-20250122monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-realigns-pipeline-strategy-empowering-drug-discovery-with-ai-and--hyft-20250117monthly0.5https://www.biopharmawatch.com/news/HYFT/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-1-name-and-address-of--hyft-20241231monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-ipa-demonstrates-strong-market-confidence-with-insider-share-purc-hyft-20241223monthly0.5https://www.biopharmawatch.com/news/HYFT/the-following-management-s-discussion-and-analysis-x201c-md-a-x201d-should-be-read-in-conj-hyft-20241210monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-ipa-reports-financial-results-and-recent-business-highlights-for--hyft-20241210monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-to-report-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-ye-hyft-20241203monthly0.5https://www.biopharmawatch.com/news/HYFT/report-of-voting-results-submitted-pursuant-to-section-11-3-of-national-instrument-51-102--hyft-20241114monthly0.5https://www.biopharmawatch.com/news/HYFT/billion-market-breakthrough-ipa-pioneers-high-impact-antibody-development-for-next-generat-hyft-20241113monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-to-host-techday-cutting-edge-ai-and-biologics-innovation-victoria-british-co-hyft-20241104monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-advances-anti-aging-research-with-mayo-clinic-study-poised-to-tap-into-81-bi-hyft-20241028monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-to-participate-at-the-ai-driven-drug-discovery-summit-usa-2024-vi-hyft-20241021monthly0.5https://www.biopharmawatch.com/news/HYFT/filed-by-newsfilecorp-com-date-hyft-20241010monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-celebrates-nobel-prize-in-chemistry-advances-in-ai-powered-protei-hyft-20241010monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-subsidiary-signs-material-transfer-agreement-with-biotheus-talem-therapeutic-hyft-20241002monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-advances-therapeutic-innovation-with-groundbreaking-rabbit-antibo-hyft-20240926monthly0.5https://www.biopharmawatch.com/news/HYFT/filed-by-newsfilecorp-com-date-hyft-20240920monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-ltd-3204-4464-markham-street-victoria-british-columbia-v8z-7x8-hyft-20240917monthly0.5https://www.biopharmawatch.com/news/HYFT/the-following-management-s-discussion-and-analysis-x201c-md-a-x201d-should-be-read-in-conj-hyft-20240916monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-ipa-reports-financial-results-and-recent-business-highlights-for--hyft-20240916monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-to-report-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-ye-hyft-20240910monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-to-participate-at-h-c-wainwright-s-26th-annual-global-investment--hyft-20240826monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-receives-nasdaq-notification-regarding-minimum-bid-requirements-v-hyft-20240823monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-successfully-engineers-in-silico-antibodies-to-elusive-tumor-prot-hyft-20240819monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-ipa-reports-financial-results-and-business-updates-for-fourth-qua-hyft-20240729monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-to-reschedule-financial-results-and-recent-business-highlights-re-hyft-20240723monthly0.5https://www.biopharmawatch.com/news/HYFT/filed-by-newsfilecorp-com-immunoprecise-announces-financing-agreement-with-yorkville-advis-hyft-20240716monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-to-report-financial-results-and-recent-business-highlights-for-fourth-quarter-and-fisc-hyft-20240715monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-appoints-kristin-taylor-as-chief-financial-officer-victoria-british-columbia-hyft-20240627monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-s-subsidiary-biostrand-and-pgxai-announce-strategic-collaboration-to-develop-first-in--hyft-20240625monthly0.5https://www.biopharmawatch.com/news/HYFT/filed-by-newsfilecorp-com-immunoprecise-antibodies-ltd-subsidiary-biostrand-receives-prest-hyft-20240612monthly0.5https://www.biopharmawatch.com/news/HYFT/filed-by-newsfilecorp-com-biostrand-immunoprecise-antibodies-subsidiary-announces-immediat-hyft-20240610monthly0.5https://www.biopharmawatch.com/news/HYFT/filed-by-newsfilecorp-com-ipa-s-subsidiary-biostrand-announces-advanced-large-language-mod-hyft-20240603monthly0.5https://www.biopharmawatch.com/news/HYFT/filed-by-newsfilecorp-com-intersystems-and-ipa-s-subsidiary-biostrand-unveil-the-innovativ-hyft-20240328monthly0.5https://www.biopharmawatch.com/news/HYFT/filed-by-newsfilecorp-com-ipa-acquires-the-carterra-lsa-instrument-to-enhance-antibody-dis-hyft-20240320monthly0.5https://www.biopharmawatch.com/news/HYFT/filed-by-newsfilecorp-com-ipa-reports-financial-results-and-recent-business-highlights-for-hyft-20240314monthly0.5https://www.biopharmawatch.com/news/HYFT/the-following-management-s-discussion-and-analysis-x201c-md-a-x201d-should-be-read-in-conj-hyft-20240314monthly0.5https://www.biopharmawatch.com/news/HYFT/filed-by-newsfilecorp-com-ipa-s-subsidiary-biostrand-unveils-major-breakthrough-in-life-sc-hyft-20240307monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-ltd-condensed-interim-consolidated-financial-statements-for-the-t-hyft-20240215monthly0.5https://www.biopharmawatch.com/news/HYFT/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-1-name-and-address-of--hyft-20231208monthly0.5https://www.biopharmawatch.com/news/HYFT/the-following-management-s-discussion-and-analysis-md-a-should-be-read-in-conjunction-with-hyft-20231214monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-reports-financial-results-and-recent-business-highlights-for-second-quarter-fiscal-yea-hyft-20231214monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-announces-closing-of-1-265-million-public-offering-of-common-shares-victoria-british-c-hyft-20231208monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-announces-pricing-of-1-1-million-public-offering-of-common-shares-victoria-british-col-hyft-20231206monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-announces-proposed-public-offering-of-common-shares-victoria-british-columbia-business-hyft-20231205monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-ltd-announces-key-board-and-board-committee-chair-appointments-an-hyft-20231127monthly0.5https://www.biopharmawatch.com/news/HYFT/filed-by-newsfilecorp-com-report-of-voting-results-submitted-pursuant-to-section-11-3-of-n-hyft-20231109monthly0.5https://www.biopharmawatch.com/news/HYFT/biostrand-unveils-a-revolutionary-approach-to-biological-sequence-retrieval-a-fusion-of-na-hyft-20231113monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-s-subsidiary-biostrand-provides-an-update-on-lens-ai-biostrand-unveils-groundbreaking--hyft-20231025monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-provides-update-on-growth-strategy-and-recent-share-price-movement-victoria-british-co-hyft-20231023monthly0.5https://www.biopharmawatch.com/news/HYFT/filed-by-newsfilecorp-com-immunoprecise-antibodies-ltd-unit-3204-4464-markham-street-victo-hyft-20231016monthly0.5https://www.biopharmawatch.com/news/HYFT/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-1-name-and-address-of--hyft-20230919monthly0.5https://www.biopharmawatch.com/news/HYFT/filed-by-newsfilecorp-com-date-hyft-20230922monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-announces-cfo-transition-brad-mcconn-to-step-down-later-this-mont-hyft-20230919monthly0.5https://www.biopharmawatch.com/news/HYFT/filed-by-newsfilecorp-com-immunoprecise-antibodies-ltd-3204-4464-markham-street-victoria-b-hyft-20230915monthly0.5https://www.biopharmawatch.com/news/HYFT/the-following-management-s-discussion-and-analysis-x201c-md-a-x201d-should-be-read-in-conj-hyft-20230914monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-hyft-20230914monthly0.5https://www.biopharmawatch.com/news/HYFT/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-1-name-and-address-of--hyft-20230905monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-to-report-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-ye-hyft-20230908monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-announces-board-refreshment-ipa-appoints-barry-a-springer-dirk-witters-and-chris-buyse-hyft-20230905monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-responds-to-13d-filing-ipa-responds-to-13d-filing-by-ingalls-snyder-llc-victoria-briti-hyft-20230809monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-invites-investors-and-stakeholders-to-exclusive-interview-with-ma-hyft-20230714monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-reports-financial-results-and-recent-business-highlights-for-full-fiscal-yea-hyft-20230707monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-to-report-financial-results-and-recent-business-highlights-for-fourth-quarter-and-fisc-hyft-20230629monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-s-subsidiary-biostrand-unveils-use-case-for-solving-the-information-integration-dilemm-hyft-20230613monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-releases-new-hyft-powered-in-silico-humanization-platform-aims-to-disrupt-the-transgen-hyft-20230606monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-s-subsidiary-biostrand-solves-the-information-integration-dilemma-iid-for-systems-biol-hyft-20230530monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-to-present-at-jefferies-healthcare-conference-2023-victoria-british-columbia-business--hyft-20230517monthly0.5https://www.biopharmawatch.com/news/HYFT/filed-by-newsfilecorp-com-immunoprecise-antibodies-ltd-stock-option-plan-1-purpose-of-plan-hyft-20230424monthly0.5https://www.biopharmawatch.com/news/HYFT/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-1-name-and-address-of--hyft-20230316monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-s-subsidiary-talem-enters-into-exclusive-research-collaboration-and-license--hyft-20230330monthly0.5https://www.biopharmawatch.com/news/HYFT/european-patent-office-to-grant-biokey-s-patent-application-for-foundational-hyft-technolo-hyft-20230327monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-presents-novel-t-cell-engaging-bispecific-antibodies-addressing-a-unique-onc-hyft-20230323monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-reports-financial-results-and-recent-business-highlights-for-third-quarter-fiscal-year-hyft-20230316monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-ltd-management-discussion-and-analysis-for-the-nine-months-ended--hyft-20230316monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-subsidiary-talem-therapeutics-announces-a-multi-target-ai-driven--hyft-20230315monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-to-report-financial-results-and-recent-business-highlights-for-third-quarter-fiscal-ye-hyft-20230307monthly0.5https://www.biopharmawatch.com/news/HYFT/filed-by-newsfilecorp-com-report-of-voting-results-submitted-pursuant-to-section-11-3-of-n-hyft-20230105monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-reports-financial-results-and-recent-business-highlights-for-second-quarter-fiscal-yea-hyft-20221215monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-ltd-management-discussion-and-analysis-for-the-six-months-ended-o-hyft-20221215monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-s-subsidiary-biostrand-completes-integration-of-20-million-proprietary-structural-hyft-hyft-20221208monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-to-report-financial-results-and-recent-business-highlights-for-second-quarter-fiscal-y-hyft-20221205monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-s-subsidiary-biostrand-and-briacell-announce-artificial-intelligence-collaboration-and-hyft-20221130monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-ltd-announces-voluntary-delisting-from-tsx-venture-exchange-victo-hyft-20221122monthly0.5https://www.biopharmawatch.com/news/HYFT/filed-by-newsfilecorp-com-2-immunoprecise-antibodies-ltd-unit-3204-4464-markham-street-vic-hyft-20221117monthly0.5https://www.biopharmawatch.com/news/HYFT/filed-by-newsfilecorp-com-immunoprecise-antibodies-ltd-3204-4464-markham-street-victoria-b-hyft-20221028monthly0.5https://www.biopharmawatch.com/news/HYFT/filed-by-newsfilecorp-com-hyft-20221014monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-s-subsidiary-talem-therapeutics-licenses-antibodies-for-three-omnichicken-derived-prog-hyft-20221012monthly0.5https://www.biopharmawatch.com/news/HYFT/niaid-confirms-ipa-s-polytope-tatx-03-neutralizing-activity-against-the-currently-spreadin-hyft-20220914monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-ltd-management-discussion-and-analysis-for-the-three-months-ended-hyft-20220914monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-reports-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-year-hyft-20220914monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-to-report-financial-results-and-recent-business-highlights-for-first-quarter-fiscal-ye-hyft-20220908monthly0.5https://www.biopharmawatch.com/news/HYFT/live-virus-assays-at-ludwig-maximilians-universit-t-m-nchen-confirm-polytope-s-efficacy-ag-hyft-20220829monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-reports-financial-results-and-recent-business-highlights-for-full-fiscal-yea-hyft-20220729monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-to-report-financial-results-and-recent-business-highlights-for-fourth-quarter-and-full-hyft-20220729monthly0.5https://www.biopharmawatch.com/news/HYFT/histopathology-data-of-preclinical-repeated-dose-toxicity-study-and-ex-vivo-human-tissue-c-hyft-20220712monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-s-subsidiary-biostrand-secures-second-vlaio-research-grant-ipa-subsidiary-biostrand-re-hyft-20220509monthly0.5https://www.biopharmawatch.com/news/HYFT/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-1-name-and-address-of--hyft-20220413monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-s-advanced-polytope-tatx-03-a-multi-antibody-cocktail-potently-prevents-in-vitro-infec-hyft-20220420monthly0.5https://www.biopharmawatch.com/news/HYFT/filed-by-newsfilecorp-com-ipa-announces-agreement-to-acquire-biostrand-bv-revolutionizing--hyft-20220329monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-completes-acquisition-of-belgian-technology-companies-biostrand-biokey-and-bioclue-add-hyft-20220414monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-announces-agreement-to-acquire-biostrand-bv-revolutionizing-biotherapeutics-with-metho-hyft-20220329monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-reports-financial-results-and-recent-business-highlights-for-third-quarter-f-hyft-20220316monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-ltd-management-discussion-and-analysis-for-the-nine-months-ended--hyft-20220316monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-updates-on-investigational-new-drug-ind-enabling-program-for-polytope-tatx-03-in-vivo--hyft-20220309monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-selected-to-work-with-elektrofi-on-covid-19-therapeutic-delivery-and-future-pandemic-p-hyft-20220314monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-sets-third-quarter-fiscal-2022-financial-results-and-recent-business-highlig-hyft-20220308monthly0.5https://www.biopharmawatch.com/news/HYFT/immunotherapeutic-polytope-from-immunoprecise-ipa-potently-neutralizes-the-sars-cov-2-omic-hyft-20220127monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-relocates-european-subsidiary-to-leed-certified-campus-to-continue-to-advanc-hyft-20220118monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-announces-grant-of-stock-options-victoria-british-columbia-busine-hyft-20220117monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-announces-grant-of-stock-options-victoria-british-columbia-busine-hyft-20220111monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-announces-grant-of-stock-options-victoria-british-columbia-busine-hyft-20220103monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-and-chempartner-biologics-announce-polytope-tatx-03-antibody-cock-hyft-20211220monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-ltd-management-discussion-and-analysis-for-the-six-months-ended-o-hyft-20211213monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-reports-financial-results-and-recent-business-highlights-for-second-quarter--hyft-20211213monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-reports-financial-results-and-recent-business-highlights-for-second-quarter--hyft-20211207monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-update-on-its-sars-cov-2-polytope-multi-antibody-cocktail-development-progra-hyft-20211130monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-to-present-at-the-benchmark-company-s-discovery-one-on-one-virtual-video-inv-hyft-20211124monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-ltd-unit-3204-4464-markham-street-victoria-bc-v8z-7x8-notice-of-a-hyft-20211029monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-announces-resignation-of-director-victoria-british-columbia-business-wire-hyft-20211109monthly0.5https://www.biopharmawatch.com/news/HYFT/notice-of-change-of-auditor-to-grant-thornton-llp-crowe-mackay-llp-and-to-british-columbia-hyft-20211101monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-announces-at-the-market-facility-of-up-to-us-50-million-victoria-british-col-hyft-20211013monthly0.5https://www.biopharmawatch.com/news/HYFT/talem-therapeutics-announces-multi-target-antibody-discovery-research-collaboration-with-p-hyft-20211007monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-f-hyft-20210909monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-ltd-management-discussion-and-analysis-for-the-three-months-ended-hyft-20210909monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-s-dutch-subsidiary-receives-french-research-tax-credit-cir-accreditation-vic-hyft-20210908monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-announces-participation-at-the-h-c-wainwright-23-nd-annual-global-investment-hyft-20210907monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-reports-financial-results-and-recent-business-highlights-for-first-quarter-f-hyft-20210903monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-welcomes-vice-president-of-client-relations-and-vice-president-of-marketing--hyft-20210804monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-reports-financial-results-and-recent-business-highlights-for-full-fiscal-yea-hyft-20210728monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-s-polytope-tatx-03-antibody-cocktail-potently-neutralizes-sars-cov-2-delta-v-hyft-20210722monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-to-report-financial-results-and-business-highlights-for-fiscal-year-2021-the-hyft-20210715monthly0.5https://www.biopharmawatch.com/news/HYFT/eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-disco-hyft-20210622monthly0.5https://www.biopharmawatch.com/news/HYFT/histopathology-preclinical-data-from-immunoprecise-s-polytope-program-confirms-lung-inflam-hyft-20210617monthly0.5https://www.biopharmawatch.com/news/HYFT/preclinical-data-from-immunoprecise-s-drug-pipeline-to-be-presented-during-the-bio-interna-hyft-20210615monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-announces-appointment-of-dr-ilse-roodink-to-the-role-of-chief-scientific-off-hyft-20210602monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-names-dr-dion-neame-to-strategic-advisory-board-victoria-british-columbia-bu-hyft-20210525monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-moves-sars-cov-2-polytope-cocktail-program-s-path-toward-ind-filing-demonstr-hyft-20210520monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-selects-lifesci-advisors-as-investor-relations-agent-of-record-victoria-brit-hyft-20210421monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-launches-tatx-112-candidate-antibody-program-for-the-treatment-of-cancer-and-hyft-20210408monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-identifies-a-unique-antibody-23-h7-that-demonstrates-in-vivo-efficacy-an-alt-hyft-20210325monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-ltd-management-discussion-and-analysis-for-the-nine-months-ended--hyft-20210318monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-reports-financial-results-and-recent-business-highlights-for-third-quarter-o-hyft-20210317monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-announces-results-from-a-comprehensive-screening-of-27-proprietar-hyft-20210316monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-announces-participation-at-the-h-c-wainwright-global-life-sciences-conferenc-hyft-20210304monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-announces-data-from-preclinical-study-of-tatx-03-polytope-monoclonal-antibod-hyft-20210219monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-announces-closing-of-over-allotment-option-associated-with-the-recently-completed-boug-hyft-20210210monthly0.5https://www.biopharmawatch.com/news/HYFT/ipa-announces-closing-of-21-7-million-bought-deal-offering-of-common-shares-victoria-briti-hyft-20210208monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-ltd-condensed-interim-consolidated-financial-statements-for-the-t-hyft-20210203monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-announces-grant-of-stock-options-victoria-british-columbia-busine-hyft-20210106monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-antibodies-to-participate-in-january-conferences-victoria-british-columbia-b-hyft-20210106monthly0.5https://www.biopharmawatch.com/news/HYFT/immunoprecise-partners-on-launch-of-sars-cov-2-nanomedicine-therapy-program-innovative-nov-hyft-20201230monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-inc-condensed-consolidated-statements-of-operations-and-comprehensive--pmvp-20260512monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-inc-condensed-consolidated-statements-of-opera-tions-and-comprehensive-pmvp-20260306monthly0.5https://www.biopharmawatch.com/news/PMVP/disclaimer-forward-looking-statements-this-presentation-contains-forward-looking-statement-pmvp-20250910monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-reports-second-quarter-2025-financial-results-and-corporate-highlights-pmvp-20250807monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-reports-first-quarter-2025-financial-results-and-corporate-highlights--pmvp-20250509monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-reports-full-year-2024-financial-results-and-corporate-highlights-x202-pmvp-20250303monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-reports-third-quarter-2024-financial-results-x2022-enrollment-on-track-pmvp-20241107monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-reports-second-quarter-2024-financial-results-and-provides-a-progress--pmvp-20240808monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-reports-first-quarter-2024-financial-results-and-corporate-highlights--pmvp-20240509monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-reports-full-year-2023-financial-results-and-corporate-highlights-x202-pmvp-20240229monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-announces-prioritization-of-pc14586-clinical-development-and-extended--pmvp-20231231monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-strengthens-leadership-with-key-appointments-as-company-advances-into--pmvp-20240105monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-inc-condensed-statements-of-opera-tions-and-comprehensive-loss-unaudit-pmvp-20231109monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-updated-pc14586-phase-1-data-demonstrated-anti-tumor-activity-across-m-pmvp-20231012monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-to-present-updated-phase-1-data-on-pc14586-at-the-2023-aacr-nci-eortc--pmvp-20231011monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-reports-second-quarter-2023-financial-results-and-corporate-highlights-pmvp-20230809monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-reports-first-quarter-2023-financial-results-and-corporate-highlights--pmvp-20230510monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-reports-full-year-2022-financial-results-and-corporate-highlights-x202-pmvp-20230301monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-reports-third-quarter-2022-financial-results-and-corporate-highlights--pmvp-20221108monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-appoints-industry-veteran-dr-carol-gallagher-to-board-of-directors-cra-pmvp-20221104monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-reports-second-quarter-2022-financial-results-and-corporate-highlights-pmvp-20220809monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-initial-pc14586-phase-1-data-presented-at-asco-demonstrated-anti-tumor-pmvp-20220607monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-announces-initial-pc14586-phase-1-clinical-data-to-be-presented-at-the-pmvp-20220526monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-reports-first-quarter-2022-financial-results-and-corporate-highlights--pmvp-20220510monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-reports-fourth-quarter-and-full-year-2021-financial-results-and-corpor-pmvp-20220301monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharma-announces-changes-to-its-board-of-directors-cranbury-nj-pmvp-20220106monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-inc-condensed-statements-of-operations-and-comprehensive-loss-unaudite-pmvp-20211112monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-inc-condensed-statements-of-operations-and-comprehensive-loss-unaudite-pmvp-20210813monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-reports-first-quarter-2021-financial-results-and-corporate-highlights--pmvp-20210514monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharma-strengthens-board-of-directors-with-appointment-of-dr-charles-baum-cranbury-nj-pmvp-20210406monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-reports-fourth-quarter-and-full-year-2020-financial-results-and-corpor-pmvp-20210303monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-reports-third-quarter-2020-financial-results-and-corporate-highlights-pmvp-20201113monthly0.5https://www.biopharmawatch.com/news/PMVP/pmv-pharma-announces-closing-of-243-5-million-initial-public-offering-and-exercise-in-full-pmvp-20200929monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-holdings-inc-announces-closing-of-approximately-16-6-million-registere-lixt-20260604monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-announces-strategic-transformation-into-ai-energy-infrastructure-equip-lixt-20260601monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-acquires-liora-technologies-proprietary-proton-therapy-platform-for-ca-lixt-20251125monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-holdings-makes-2-6-million-initial-purchase-of-digital-currency-to-div-lixt-20250910monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-holdings-updates-corporate-treasury-policy-to-include-cryptocurrency-lixt-20250813monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-holdings-regains-compliance-with-nasdaq-s-continued-listing-requiremen-lixt-20250716monthly0.5https://www.biopharmawatch.com/news/LIXT/new-clinical-findings-published-in-scientific-journal-nature-validate-lixte-s-ongoing-ovar-lixt-20250709monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-holdings-inc-announces-5-0-million-private-placement-priced-at-the-mar-lixt-20250701monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-launches-new-study-to-determine-if-certain-pre-cancerous-cells-found-in-an-aging-pop-lixt-20250331monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-provides-update-on-progress-with-proprietary-compound-lb-100-to-treat--lixt-20250327monthly0.5https://www.biopharmawatch.com/news/LIXT/new-findings-show-how-lixte-s-lead-clinical-compound-lb-100-is-metabolized-to-its-active-f-lixt-20250310monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-adds-northwestern-university-s-lurie-cancer-center-as-second-site-in-ongoing-clinica-lixt-20250225monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-announces-1-05-million-registered-direct-offering-priced-at-the-market-lixt-20250211monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-receives-u-s-patent-issue-notification-for-immune-oncology-patent-covers-combining-l-lixt-20240904monthly0.5https://www.biopharmawatch.com/news/LIXT/first-patient-dosed-with-lixte-s-lb-100-in-new-clinical-trial-to-treat-colorectal-cancer-c-lixt-20240826monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-holdings-to-present-at-two-investor-conferences-company-to-present-aug-lixt-20240815monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-holdings-announces-collaboration-on-a-new-colon-cancer-clinical-trial--lixt-20240614monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-holdings-names-distinguished-oncologist-jan-schellens-as-chief-medical-lixt-20240603monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-holdings-provides-update-on-recent-activities-publishing-of-findings-i-lixt-20240520monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-co-sponsoring-international-scientific-conference-on-therapeutic-over--lixt-20240508monthly0.5https://www.biopharmawatch.com/news/LIXT/new-scientific-publication-shows-lb-100-lixte-s-lead-clinical-compound-can-force-cancer-ce-lixt-20240327monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-provides-update-on-progress-with-lb-100-as-a-pp2a-inhibitor-to-enhance-chemotherapy--lixt-20240321monthly0.5https://www.biopharmawatch.com/news/LIXT/professor-ren-bernards-to-present-new-pre-clinical-data-on-lixte-s-lb-100-at-joint-confere-lixt-20240227monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-enters-into-exclusive-immune-oncology-patent-license-agreement-with-ni-lixt-20240226monthly0.5https://www.biopharmawatch.com/news/LIXT/first-patient-dosed-with-lixte-s-lb-100-and-gsk-s-immunotherapy-dostarlimab-gxly-in-ovaria-lixt-20240129monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-provides-update-on-clinical-progress-and-expanding-collaborations-lixt-20231113monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-netherlands-cancer-institute-and-oncode-institute-to-expand-collaboration-extension--lixt-20231016monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-appoints-bas-van-der-baan-as-president-and-chief-executive-officer-biotechnology-vet-lixt-20230926monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-announces-a-supported-collaborative-trial-to-study-lixte-s-first-in-cl-lixt-20230920monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-announces-closing-of-3-5-million-registered-direct-offering-and-concur-lixt-20230720monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-announces-pricing-of-3-5-million-registered-direct-offering-and-concur-lixt-20230718monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-holdings-inc-regains-compliance-with-nasdaq-continued-listing-requirem-lixt-20230623monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-reports-first-spanish-site-activated-to-begin-accrual-of-patients-for--lixt-20230424monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-announces-sarah-cannon-research-institute-joins-city-of-hope-s-ongoing-lixt-20230404monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-holdings-reports-newly-published-independent-pre-clinical-research-the-lixt-20230214monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-holdings-inc-reports-that-its-lead-clinical-compound-lb-100-can-kill-c-lixt-20230207monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-holdings-to-present-at-planet-microcap-showcase-virtual-2022-investor--lixt-20221130monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-announces-approval-of-a-phase-1b-2-randomized-trial-of-doxorubicin-lb--lixt-20221013monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-announces-appointment-of-bas-van-der-baan-internationally-recognized-b-lixt-20220621monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-announces-appointment-of-professor-ren-eacute-bernards-to-its-board-of-lixt-20220615monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-announces-5-8-million-registered-direct-offering-priced-at-the-market--lixt-20220412monthly0.5https://www.biopharmawatch.com/news/LIXT/inactivating-mutations-in-scaffold-component-of-pp2a-the-target-enzyme-of-lixte-biotechnol-lixt-20220322monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-announces-collaboration-with-netherlands-cancer-institute-amsterdam-an-lixt-20211013monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-and-city-of-hope-enroll-first-patient-in-phase-1b-trial-of-lead-compou-lixt-20210602monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-holdings-inc-announces-the-appointment-of-regina-brown-to-its-board-of-lixt-20210512monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-holdings-inc-announces-the-appointment-of-gil-n-schwartzberg-to-its-bo-lixt-20210413monthly0.5https://www.biopharmawatch.com/news/LIXT/vi-lixte-biotechnology-announces-4-19-million-registered-direct-offering-email-print-frien-lixt-20210301monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-and-city-of-hope-to-initiate-phase-1b-clinical-trial-of-lixte-s-lead-c-lixt-20210119monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-holdings-inc-announces-closing-of-public-offering-and-uplisting-to-nas-lixt-20201201monthly0.5https://www.biopharmawatch.com/news/LIXT/source-lixte-biotechnology-holdings-inc-lixt-20201125monthly0.5https://www.biopharmawatch.com/news/LIXT/the-spanish-sarcoma-group-will-lead-a-european-consortium-to-evaluate-the-ability-of-lixte-lixt-20190806monthly0.5https://www.biopharmawatch.com/news/LIXT/fda-approves-lixte-biotechnology-s-ind-to-conduct-a-phase-1b-2-trial-of-lb-100-in-patients-lixt-20181105monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-announces-a-clinical-trial-agreement-with-moffitt-cancer-center-to-ini-lixt-20180821monthly0.5https://www.biopharmawatch.com/news/LIXT/yun-yen-md-phd-and-winson-sze-chun-ho-md-join-lixte-biotechnology-s-board-of-directors-eas-lixt-20180808monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-holdings-inc-announces-exclusive-licensing-of-their-lead-anti-cancer-c-lixt-20151230monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-holdings-inc-announces-that-its-novel-protein-phosphatase-2a-inhibitor-lixt-20151106monthly0.5https://www.biopharmawatch.com/news/LIXT/lixte-biotechnology-s-lead-compound-reported-to-be-active-against-hematologic-cancers-in-p-lixt-20150225monthly0.5https://www.biopharmawatch.com/news/LIXT/via-pr-newswire-lixt-20150123monthly0.5https://www.biopharmawatch.com/news/LIXT/east-setauket-ny-lixt-20071217monthly0.5https://www.biopharmawatch.com/news/LIXT/east-setauket-new-york-lixt-20070111monthly0.5https://www.biopharmawatch.com/news/LUNG/the-preliminary-unaudited-revenue-results-described-in-this-press-release-are-estimates-on-lung-20251027monthly0.5https://www.biopharmawatch.com/news/LUNG/pulmonx-announces-appointment-of-mehul-joshi-as-chief-financial-officer-redwood-city-ca-lung-20240402monthly0.5https://www.biopharmawatch.com/news/LUNG/pulmonx-announces-cfo-transition-and-record-preliminary-third-quarter-2023-revenue-derrick-lung-20231010monthly0.5https://www.biopharmawatch.com/news/IMA/imagenebio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-compan-ima-20260310monthly0.5https://www.biopharmawatch.com/news/IMA/imagenebio-corporate-overview-fourth-quarter-2025-disclaimer-and-forward-looking-statement-ima-20251119monthly0.5https://www.biopharmawatch.com/news/IMA/imagenebio-reports-third-quarter-2025-financial-results-and-provides-img-007-program-updat-ima-20251112monthly0.5https://www.biopharmawatch.com/news/IMA/i-magene-b-io-i-nc-2025-e-quity-i-nducement-p-lan-a-dopted-by-the-b-oard-of-d-irectors-j-u-ima-20250801monthly0.5https://www.biopharmawatch.com/news/IMA/corporate-overview-july-2025-disclaimer-this-presentation-contains-forward-looking-stateme-ima-20250729monthly0.5https://www.biopharmawatch.com/news/IMA/inmagene-biopharmaceuticals-announces-completion-of-merger-with-ikena-oncology-and-concurr-ima-20250728monthly0.5https://www.biopharmawatch.com/news/IMA/ikena-oncology-announces-stockholder-approval-of-merger-with-inmagene-biopharmaceuticals-c-ima-20250715monthly0.5https://www.biopharmawatch.com/news/IMA/ikena-oncology-announces-iss-and-glass-lewis-recommend-stockholders-vote-for-proposed-merg-ima-20250711monthly0.5https://www.biopharmawatch.com/news/IMA/inmagene-doses-first-patient-in-the-adaptive-phase-2b-trial-of-img-007-a-nondepleting-anti-ima-20250701monthly0.5https://www.biopharmawatch.com/news/IMA/additional-information-and-where-to-find-it-investors-and-security-holders-will-be-able-to-ima-20241223monthly0.5https://www.biopharmawatch.com/news/IMA/ikena-oncology-announces-strategic-update-ikena-to-discontinue-development-of-ik-930-ik-59-ima-20240528monthly0.5https://www.biopharmawatch.com/news/IMA/ikena-oncology-appoints-caroline-germa-m-d-as-chief-medical-officer-caroline-germa-m-d-an--ima-20240221monthly0.5https://www.biopharmawatch.com/news/IMA/ikena-oncology-outlines-key-priorities-and-provides-corporate-updates-ik-930-optimized-for-ima-20240118monthly0.5https://www.biopharmawatch.com/news/IMA/ikena-oncology-shares-initial-positive-and-differentiated-dose-escalation-data-from-ik-930-ima-20231109monthly0.5https://www.biopharmawatch.com/news/IMA/ikena-oncology-acquires-pionyr-immunotherapeutics-in-all-stock-transaction-ikena-receives--ima-20230807monthly0.5https://www.biopharmawatch.com/news/IMA/ikena-oncology-reports-first-quarter-2023-financial-results-and-highlights-advancements-ac-ima-20230515monthly0.5https://www.biopharmawatch.com/news/IMA/ikena-oncology-shares-differentiation-profile-of-ik-930-a-novel-hippo-pathway-inhibitor-in-ima-20230417monthly0.5https://www.biopharmawatch.com/news/IMA/ikena-oncology-appoints-owen-hughes-as-board-chair-owen-hughes-joins-ikena-board-as-indepe-ima-20221219monthly0.5https://www.biopharmawatch.com/news/IMA/ikena-oncology-announces-new-program-in-next-generation-mek-raf-inhibition-and-provides-co-ima-20221128monthly0.5https://www.biopharmawatch.com/news/IMA/ikena-oncology-announces-initial-clinical-data-from-ik-175-program-in-urothelial-carcinoma-ima-20221110monthly0.5https://www.biopharmawatch.com/news/IMA/ikena-appoints-jotin-marango-m-d-ph-d-as-chief-financial-officer-and-head-of-corporate-dev-ima-20220413monthly0.5https://www.biopharmawatch.com/news/IMA/ikena-appoints-richard-wooster-ph-d-to-its-board-of-directors-boston-ima-20220126monthly0.5https://www.biopharmawatch.com/news/IMA/november-2021-disclaimer-this-presentation-contains-forward-looking-statements-and-informa-ima-20211110monthly0.5https://www.biopharmawatch.com/news/IMA/ikena-oncology-reports-second-quarter-2021-financial-results-and-provides-update-on-key-pr-ima-20210812monthly0.5https://www.biopharmawatch.com/news/IMA/ikena-oncology-reports-first-quarter-2021-financial-results-and-outlines-key-corporate-obj-ima-20210513monthly0.5https://www.biopharmawatch.com/news/IMA/ikena-oncology-appoints-dr-maria-koehler-to-its-board-of-directors-boston-ma-ima-20210415monthly0.5https://www.biopharmawatch.com/news/HAO/haoxi-health-technology-ltd-a-cayman-islands-exempted-company-with-limited-liability-nasda-hao-20260521monthly0.5https://www.biopharmawatch.com/news/HAO/haoxi-health-technology-limited-index-to-unaudited-condensed-consolidated-financial-statem-hao-20260422monthly0.5https://www.biopharmawatch.com/news/HAO/haoxi-health-technology-ltd-a-cayman-islands-exempted-company-with-limited-liability-nasda-hao-20251112monthly0.5https://www.biopharmawatch.com/news/HAO/securities-purchase-agreement-this-securities-purchase-agreement-this-agreement-is-dated-a-hao-20251013monthly0.5https://www.biopharmawatch.com/news/HAO/haoxi-health-technology-limited-index-to-consolidated-financial-statements-contents-page-s-hao-20250423monthly0.5https://www.biopharmawatch.com/news/HAO/haoxi-health-technology-ltd-a-cayman-islands-exempted-company-with-limited-liability-nasda-hao-20241219monthly0.5https://www.biopharmawatch.com/news/HAO/haoxi-health-technology-limited-receives-nasdaq-notification-letter-regarding-minimum-bid--hao-20241106monthly0.5https://www.biopharmawatch.com/news/HAO/haoxi-health-technology-limited-reports-unaudited-financial-results-for-the-six-months-end-hao-20240531monthly0.5https://www.biopharmawatch.com/news/HAO/haoxi-health-technology-limited-enters-into-rebate-agreement-with-clients-on-advertising-p-hao-20240507monthly0.5https://www.biopharmawatch.com/news/HAO/haoxi-health-technology-limited-enters-into-advertising-placement-service-framework-contra-hao-20240503monthly0.5https://www.biopharmawatch.com/news/HAO/haoxi-health-technology-limited-announces-pricing-of-its-initial-public-offering-beijing-hao-20240125monthly0.5https://www.biopharmawatch.com/news/LFVN/lifevantage-announces-financial-results-for-the-third-quarter-of-fiscal-2026-salt-lake-cit-lfvn-20260506monthly0.5https://www.biopharmawatch.com/news/LFVN/lifevantage-appointing-terrence-moorehead-as-chief-executive-officer-salt-lake-city-ut-lfvn-20260416monthly0.5https://www.biopharmawatch.com/news/LFVN/document-lifevantage-appoints-cindy-latham-to-board-of-directors-salt-lake-city-ut-lfvn-20220217monthly0.5https://www.biopharmawatch.com/news/LFVN/document-lifevantage-appoints-carl-aure-as-chief-financial-officer-salt-lake-city-ut-lfvn-20211025monthly0.5https://www.biopharmawatch.com/news/LFVN/document-lifevantage-announces-appointment-of-chief-executive-officer-steven-r-fife-named--lfvn-20210202monthly0.5https://www.biopharmawatch.com/news/LFVN/document-lifevantage-announces-management-transition-steven-fife-appointed-interim-chief-e-lfvn-20200908monthly0.5https://www.biopharmawatch.com/news/LFVN/exhibit-lifevantage-reports-record-second-quarter-preliminary-revenue-q2-preliminary-reven-lfvn-20190109monthly0.5https://www.biopharmawatch.com/news/LFVN/exhibit-lifevantage-corporation-indemnification-agreement-this-indemnification-agreement-e-lfvn-20180313monthly0.5https://www.biopharmawatch.com/news/LFVN/exhibit-lifevantage-further-enhances-management-team-with-appointment-of-steven-r-fife-as--lfvn-20170313monthly0.5https://www.biopharmawatch.com/news/LFVN/exhibit-lifevantage-strengthens-management-team-with-appointment-of-charles-j-wach-as-chie-lfvn-20170309monthly0.5https://www.biopharmawatch.com/news/LFVN/exhibit-lifevantage-announces-management-change-gary-koos-to-assume-role-as-interim-chief--lfvn-20170118monthly0.5https://www.biopharmawatch.com/news/LFVN/exhibit-lifevantage-announces-financial-results-for-fiscal-year-2016-and-the-first-quarter-lfvn-20161212monthly0.5https://www.biopharmawatch.com/news/LFVN/exhibit-lifevantage-corp-receives-nasdaq-letter-related-to-delay-in-filing-form-10-q-lfvn-20161118monthly0.5https://www.biopharmawatch.com/news/LFVN/exhibit-lifevantage-receives-limited-waiver-and-extension-under-credit-facility-lfvn-20161026monthly0.5https://www.biopharmawatch.com/news/LFVN/exhibit-lifevantage-corp-receives-nasdaq-letter-related-to-delay-in-filing-form-10-k-lfvn-20160930monthly0.5https://www.biopharmawatch.com/news/LFVN/exhibit-lifevantage-appoints-wsrp-llc-as-its-new-independent-auditor-the-company-dismissed-lfvn-20160713monthly0.5https://www.biopharmawatch.com/news/LFVN/exhibit-lifevantage-announces-third-quarter-fiscal-year-2016-results-reports-record-quarte-lfvn-20160504monthly0.5https://www.biopharmawatch.com/news/LFVN/exhibit-lifevantage-announces-refinancing-of-term-loan-new-three-year-term-loan-with-zions-lfvn-20160404monthly0.5https://www.biopharmawatch.com/news/LFVN/exhibit-lifevantage-announces-second-quarter-fiscal-year-2016-results-second-quarter-reven-lfvn-20160209monthly0.5https://www.biopharmawatch.com/news/LFVN/exhibit-lifevantage-announces-first-quarter-fiscal-year-2016-results-first-quarter-revenue-lfvn-20151104monthly0.5https://www.biopharmawatch.com/news/LFVN/exhibit-lifevantage-announces-7-1-reverse-stock-split-company-reiterates-fiscal-year-2016--lfvn-20151016monthly0.5https://www.biopharmawatch.com/news/LFVN/earnings-release-exhibit-lifevantage-announces-fourth-quarter-and-full-fiscal-year-2015-re-lfvn-20150901monthly0.5https://www.biopharmawatch.com/news/LFVN/exhibit-lifevantage-appoints-mark-jaggi-new-chief-financial-officer-salt-lake-city-ut-lfvn-20150824monthly0.5https://www.biopharmawatch.com/news/LFVN/exhibit-exhibit991-earningsrelease-lifevantage-announces-third-quarter-fiscal-year-2013-re-lfvn-20130509monthly0.5https://www.biopharmawatch.com/news/LFVN/lifevantage-announces-additional-share-repurchase-program-company-s-board-authorizes-repur-lfvn-20130322monthly0.5https://www.biopharmawatch.com/news/LFVN/lifevantage-announces-second-quarter-fiscal-year-2013-results-second-quarter-net-revenue-i-lfvn-20130207monthly0.5https://www.biopharmawatch.com/news/LFVN/lifevantage-launches-protandim-the-nrf2-synergizer-in-japan-in-country-operations-formally-lfvn-20130114monthly0.5https://www.biopharmawatch.com/news/LFVN/lifevantage-formally-expands-its-global-operations-to-hong-kong-lfvn-20121219monthly0.5https://www.biopharmawatch.com/news/LFVN/lifevantage-announces-shares-repurchase-program-company-authorized-repurchase-of-up-to-5-m-lfvn-20121214monthly0.5https://www.biopharmawatch.com/news/LFVN/wedbush-13th-annual-consumer-conference-lfvn-20121211monthly0.5https://www.biopharmawatch.com/news/LFVN/lifevantage-corporation-announces-voluntary-recall-and-replacement-of-select-lots-of-prota-lfvn-20121205monthly0.5https://www.biopharmawatch.com/news/LFVN/lifevantage-announces-dismissal-of-lawsuit-lfvn-20121114monthly0.5https://www.biopharmawatch.com/news/LFVN/lifevantage-announces-strong-first-quarter-fiscal-year-2013-results-first-quarter-net-reve-lfvn-20121108monthly0.5https://www.biopharmawatch.com/news/LFVN/lifevantage-corporation-announces-appointment-of-head-of-asia-operations-company-appoints--lfvn-20121025monthly0.5https://www.biopharmawatch.com/news/LFVN/lifevantage-appoints-darlene-r-walley-ph-d-as-new-chief-science-officer-company-expands-re-lfvn-20121012monthly0.5https://www.biopharmawatch.com/news/LFVN/lifevantage-announces-continued-international-expansion-salt-lake-city-ut-lfvn-20120919monthly0.5https://www.biopharmawatch.com/news/LFVN/lifevantage-announces-record-fourth-quarter-and-full-fiscal-year-2012-results-company-rece-lfvn-20120910monthly0.5https://www.biopharmawatch.com/news/LFVN/lifevantage-corporation-completes-previously-announced-cfo-transition-company-appoints-dav-lfvn-20120801monthly0.5https://www.biopharmawatch.com/news/LFVN/lifevantage-announces-record-third-quarter-fiscal-year-2012-net-revenue-increases-263-over-lfvn-20120515monthly0.5https://www.biopharmawatch.com/news/LFVN/lifevantage-corporation-makes-charitable-donation-to-traffic-jam-salt-lake-city-ut-lfvn-20120420monthly0.5https://www.biopharmawatch.com/news/LFVN/lifevantage-announces-record-second-quarter-fiscal-year-2012-net-revenue-increases-239-ove-lfvn-20120214monthly0.5https://www.biopharmawatch.com/news/LFVN/lifevantage-to-announce-fiscal-second-quarter-2012-results-on-lfvn-20120207monthly0.5https://www.biopharmawatch.com/news/LFVN/lifevantage-expands-board-of-directors-and-announces-approval-of-tender-offer-to-modify-wa-lfvn-20120117monthly0.5https://www.biopharmawatch.com/news/LFVN/lifevantage-provides-corporate-update-announces-adoption-of-rule-10b5-1-stock-repurchase-p-lfvn-20111219monthly0.5https://www.biopharmawatch.com/news/LFVN/lifevantage-announces-record-first-quarter-fiscal-year-2012-results-net-revenue-increases--lfvn-20111114monthly0.5https://www.biopharmawatch.com/news/LFVN/f-inal-t-ranscript-conference-call-transcript-lfvn-q4-2011-lifevantage-corp-earnings-confe-lfvn-20110928monthly0.5https://www.biopharmawatch.com/news/LFVN/lifevantage-announces-record-fiscal-year-2011-results-and-provides-fiscal-year-2012-guidan-lfvn-20110928monthly0.5https://www.biopharmawatch.com/news/LFVN/life-vantage-corporation-investor-presentation-accredited-members-summer-2011-investment-r-lfvn-20110613monthly0.5https://www.biopharmawatch.com/news/LFVN/lifevantage-announces-fiscal-third-quarter-2011-results-record-third-quarter-net-revenue-i-lfvn-20110517monthly0.5https://www.biopharmawatch.com/news/LFVN/lifevantage-announces-appointment-of-new-president-and-chief-executive-officer-douglas-c-r-lfvn-20110314monthly0.5https://www.biopharmawatch.com/news/LFVN/lifevantage-announces-preliminary-unaudited-second-quarter-2011-results-company-anticipate-lfvn-20110119monthly0.5https://www.biopharmawatch.com/news/LFVN/lifevantage-announces-unaudited-first-quarter-fiscal-2011-financial-and-operating-results--lfvn-20101110monthly0.5https://www.biopharmawatch.com/news/LFVN/lifevantage-announces-unaudited-second-quarter-fiscal-2010-financial-and-operating-results-lfvn-20100216monthly0.5https://www.biopharmawatch.com/news/LFVN/lifevantage-announces-preliminary-unaudited-first-quarter-revenue-company-anticipates-seco-lfvn-20091015monthly0.5https://www.biopharmawatch.com/news/LFVN/lifevantage-announces-fourth-quarter-and-fiscal-year-2009-financial-and-operating-results--lfvn-20090929monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-announces-6-million-registered-direct-offering-of-common-stock-malvern-pa-anvs-20251010monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-provides-corporate-updates-and-reports-second-quarter-2025-financial-results-malve-anvs-20250812monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-announces-nyse-acceptance-of-plan-to-regain-listing-compliance-malvern-pa-anvs-20250619monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-provides-corporate-updates-and-reports-first-quarter-2025-financial-results-malver-anvs-20250513monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-inc-anvs-20250327monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-provides-corporate-updates-and-reports-fourth-quarter-and-fiscal-year-2024-financi-anvs-20250321monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-announces-first-patients-entered-into-pivotal-phase-3-study-of-buntanetap-for-earl-anvs-20250205monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-inc-announces-proposed-public-offering-malvern-pa-anvs-20250131monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-reports-third-quarter-financial-results-and-provides-business-update-malvern-p-anvs-20241111monthly0.5https://www.biopharmawatch.com/news/ANVS/fda-clears-annovis-to-launch-pivotal-phase-3-alzheimer-s-studies-paving-the-way-to-ndas-ma-anvs-20241015monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-files-three-new-patents-for-combination-therapies-involving-buntanetap-trulicity-a-anvs-20240930monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-reports-second-quarter-financial-results-and-provides-business-update-malvern--anvs-20240815monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-lead-compound-enhances-cognition-synergistically-with-glp-1-agonist-malvern-pa-anvs-20240806monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-receives-fda-approval-to-transition-to-new-crystal-form-of-buntanetap-malvern--anvs-20240716monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-announces-new-data-from-phase-iii-parkinson-s-study-highlighting-improvements--anvs-20240702monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-s-buntanetap-found-safe-and-effective-in-high-risk-alzheimer-s-patients-join-o-anvs-20240611monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-inc-nyse-anvs-schedules-investor-webcast-malvern-pa-anvs-20240605monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-announces-new-publication-in-a-peer-reviewed-journal-malvern-pa-anvs-20240521monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-provides-corporate-updates-and-announces-first-quarter-2024-financial-results--anvs-20240513monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-announces-unblinding-of-the-buntanetap-phase-iii-data-in-parkinson-s-disease-malve-anvs-20240509monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-ceo-maria-maccecchini-issues-letter-to-stockholders-malvern-pa-anvs-20240506monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-provides-corporate-updates-and-reports-fourth-quarter-and-full-year-2023-finan-anvs-20240402monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-provides-data-announcement-update-for-the-phase-ii-iii-study-of-buntanetap-in--anvs-20240320monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-announces-launch-of-proposed-public-offering-berwyn-pennsylvania-anvs-20231030monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-receives-positive-recommendation-to-continue-phase-2-3-trial-of-buntanetap-for-anvs-20231030monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-announces-positive-interim-independent-analysis-for-statistical-power-in-its-a-anvs-20231012monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-announces-fourth-quarter-and-full-year-2022-financial-anvs-20230403monthly0.5https://www.biopharmawatch.com/news/ANVS/attacks-neurodegeneration-alzheimer-s-and-parkinson-s-diseases-by-improving-the-informatio-anvs-20230213monthly0.5https://www.biopharmawatch.com/news/ANVS/attacks-neurodegeneration-alzheimer-s-and-parkinson-s-diseases-by-improving-the-informatio-anvs-20230106monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-appoints-henry-hagopian-iii-as-chief-financial-officer-berwyn-pa-anvs-20220829monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-announces-second-quarter-2022-results-and-provides-corporate-update-berwyn-pen-anvs-20220808monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-announces-first-quarter-2022-results-and-provides-corporate-update-berwyn-penn-anvs-20220504monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-announces-transfer-of-listing-to-the-new-york-stock-exchange-trading-to-begin-anvs-20211118monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-presented-at-the-14-th-clinical-trials-on-alzheimer-s-disease-conference-with--anvs-20211112monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-announces-positive-phase-2-efficacy-data-for-the-treatment-of-parkinson-s-dise-anvs-20211005monthly0.5https://www.biopharmawatch.com/news/ANVS/frequently-asked-questions-annovis-bio-phase-2a-data-results-1-what-interim-results-from-t-anvs-20210811monthly0.5https://www.biopharmawatch.com/news/ANVS/aaic-panel-july-28-2021-symbol-anvs-nyse-american-anvs-20210729monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-inc-announces-proposed-public-offering-of-common-stock-berwyn-pa-anvs-20210521monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-appoints-reid-mccarthy-to-board-and-to-role-of-audit-committee-chairman-berwyn-anvs-20210415monthly0.5https://www.biopharmawatch.com/news/ANVS/attacks-alzheimer-s-disease-and-neurodegeneration-by-improving-the-information-highway-of--anvs-20210323monthly0.5https://www.biopharmawatch.com/news/ANVS/annovis-bio-to-present-at-the-june-2020-virtual-summer-investor-summit-berwyn-pa-anvs-20200609monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-announces-patent-licensing-agreement-with-mit-for-small-molecules-to-impro-rfl-20260422monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-reports-second-quarter-fiscal-2026-financial-results-newark-nj-rfl-20260316monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-reports-first-quarter-fiscal-2026-financial-results-newark-nj-rfl-20251211monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-reports-fourth-quarter-and-full-year-fiscal-2025-financial-results-cyclo-t-rfl-20251029monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-mourns-the-passing-of-lead-independent-director-stephen-greenberg-and-anno-rfl-20251028monthly0.5https://www.biopharmawatch.com/news/RFL/nasdaq-rfl-october-2025-investor-presentation-forward-looking-statements-some-of-the-infor-rfl-20251010monthly0.5https://www.biopharmawatch.com/news/RFL/fourth-amended-and-restated-by-laws-of-rafael-holdings-inc-hereinafter-called-the-corporat-rfl-20250714monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-announces-continuation-of-its-phase-3-study-for-the-treatment-of-niemann-p-rfl-20250618monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-reports-third-quarter-fiscal-2025-financial-results-cyclo-therapeutics-tra-rfl-20250611monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-inc-announces-final-results-and-closing-of-rights-offering-newark-nj-rfl-20250604monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-inc-provides-update-to-the-description-of-subscription-rights-related-to-i-rfl-20250520monthly0.5https://www.biopharmawatch.com/news/RFL/standby-purchase-agreement-this-standby-purchase-agreement-this-agreement-is-made-and-ente-rfl-20250506monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-inc-announces-revised-subscription-rights-in-connection-with-its-previousl-rfl-20250505monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-inc-announces-proposed-terms-of-a-25-million-rights-offering-to-support-it-rfl-20250429monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-strengthens-its-focus-on-the-development-of-trappsol-cyclo-and-announces-c-rfl-20250424monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-completes-merger-with-cyclo-therapeutics-following-shareholder-approvals-c-rfl-20250326monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-reports-second-quarter-fiscal-2025-financial-results-the-planned-merger-wi-rfl-20250313monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-reports-first-quarter-fiscal-2025-financial-results-upon-completion-of-our-rfl-20241211monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-reports-fourth-quarter-and-full-year-fiscal-2024-financial-results-our-pro-rfl-20241106monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-and-cyclo-therapeutics-enter-into-a-definitive-merger-agreement-cyclo-ther-rfl-20240822monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-reports-third-quarter-fiscal-2024-financial-results-strategically-focused--rfl-20240614monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-reports-second-quarter-fiscal-2024-financial-results-company-remains-focus-rfl-20240313monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-reports-first-quarter-fiscal-2024-financial-results-company-remains-focuse-rfl-20231214monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-reports-fourth-quarter-and-full-year-fiscal-2023-financial-results-company-rfl-20231030monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-reports-third-quarter-fiscal-2023-financial-results-and-provides-business--rfl-20230613monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-announces-up-to-5-million-share-repurchase-program-announces-expanded-sear-rfl-20230404monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-reports-second-quarter-fiscal-2023-financial-results-newark-nj-rfl-20230314monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-reports-first-quarter-fiscal-2023-financial-results-newark-nj-rfl-20221213monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-to-focus-on-strategic-business-development-initiatives-and-curtail-early-s-rfl-20221115monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-reports-fourth-quarter-fiscal-2022-financial-results-newark-nj-rfl-20221031monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-reports-third-quarter-fiscal-2022-financial-results-newark-nj-rfl-20220614monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-reports-second-quarter-fiscal-2022-financial-results-newark-nj-rfl-20220317monthly0.5https://www.biopharmawatch.com/news/RFL/william-bill-conkling-to-assume-the-role-of-chief-executive-officer-as-of-rfl-20220121monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-reports-first-quarter-fiscal-2022-financial-and-operating-results-newark-n-rfl-20211215monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-realigns-leadership-team-to-support-earlier-stage-pipeline-focus-ameet-mal-rfl-20211122monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-provides-update-on-rafael-pharmaceuticals-two-phase-3-trials-of-cpi-613-de-rfl-20211028monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-reports-fourth-quarter-and-full-year-fiscal-2021-financial-and-operating-r-rfl-20211018monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-appoints-patrick-fabbio-as-chief-financial-officer-newark-nj-rfl-20210914monthly0.5https://www.biopharmawatch.com/news/RFL/harnessing-the-power-of-cancer-metabolism-to-develop-innovative-therapeutics-that-improve--rfl-20210810monthly0.5https://www.biopharmawatch.com/news/RFL/harnessing-the-power-of-cancer-metabolism-to-develop-innovative-therapeutics-that-improve--rfl-20210714monthly0.5https://www.biopharmawatch.com/news/RFL/harnessing-the-power-of-cancer-metabolism-to-develop-innovative-therapeutics-that-improve--rfl-20210618monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-announces-strategic-merger-with-rafael-pharmaceuticals-to-form-a-focused-l-rfl-20210621monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-reports-third-quarter-fiscal-year-2021-results-newark-nj-rfl-20210614monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-reports-second-quarter-fiscal-year-2021-results-newark-nj-rfl-20210317monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-enhances-senior-management-team-with-additions-of-ameet-mallik-ceo-and-wil-rfl-20210311monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-reports-first-quarter-fiscal-year-2021-results-newark-nj-rfl-20201215monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-reports-fourth-quarter-and-full-fiscal-year-2020-results-newark-nj-rfl-20201029monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-reports-third-quarter-fiscal-year-2020-results-newark-nj-rfl-20200609monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-reports-second-quarter-fiscal-year-2020-results-newark-nj-rfl-20200305monthly0.5https://www.biopharmawatch.com/news/RFL/jfif-c-1-3-mqypdx-egc-c-cb8bcccccccccccccccccccccccccccccccccccccccccccccccccc-e-1a-qa-q-2-rfl-20191210monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-reports-first-quarter-fiscal-year-2020-results-highlights-developments-in--rfl-20191209monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-to-begin-trading-on-rfl-20191118monthly0.5https://www.biopharmawatch.com/news/RFL/holdings-reports-fourth-quarter-and-full-fiscal-year-2019-results-rfl-20191004monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-reports-third-quarter-rfl-20190605monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-reports-second-quarter-fiscal-year-2019-results-newark-nj-rfl-20190312monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-acquires-majority-stake-in-rafael-pharma-rafael-pharma-will-utilize-the-in-rfl-20190123monthly0.5https://www.biopharmawatch.com/news/RFL/rafael-holdings-reports-first-quarter-rfl-20181210monthly0.5https://www.biopharmawatch.com/news/RFL/december-6-2018-ld-micro-2018-conference-rfl-20181206monthly0.5https://www.biopharmawatch.com/news/RFL/holdings-reports-fourth-quarter-and-full-fiscal-year-2018-results-rfl-20181015monthly0.5https://www.biopharmawatch.com/news/RFL/holdings-increases-stake-in-rafael-pharma-rfl-20180907monthly0.5https://www.biopharmawatch.com/news/RFL/holdings-reports-third-quarter-fiscal-year-2018-results-rfl-20180611monthly0.5https://www.biopharmawatch.com/news/BYSI/seed-therapeutics-seed-enters-into-strategic-research-collaboration-with-eisai-co-ltd-to-d-bysi-20240806monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-regains-compliance-with-nasdaq-minimum-bid-price-and-periodic-filing-requirem-bysi-20240226monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-receives-nasdaq-delinquency-notice-regarding-late-filing-of-its-form-6-k-bysi-20240110monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-receives-nasdaq-notice-regarding-minimum-bid-price-requirements-bysi-20231218monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-regains-compliance-with-nasdaq-minimum-bid-price-requirement-bysi-20231030monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-receives-nasdaq-notice-regarding-minimum-bid-price-requirements-bysi-20231004monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-receives-notifications-from-nasdaq-regarding-compliance-with-listing-rules-bysi-20230109monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-receives-nasdaq-notice-regarding-minimum-bid-price-requirements-bysi-20221123monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-organizational-streamlining-resources-to-be-focused-on-highest-valu-bysi-20220111monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-appoints-commercial-leader-mark-santos-to-its-board-of-directors-bysi-20211110monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-pharmaceuticals-announces-positive-final-phase-3-dublin-3-data-with-the-plina-bysi-20210920monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-exclusive-commercialization-and-co-development-agreement-with-jiang-bysi-20210826monthly0.5https://www.biopharmawatch.com/news/BYSI/plinabulin-dublin-3-nsclc-topline-data-august-5-2021-nasdaq-bysi-disclaimer-this-presentat-bysi-20210805monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-positive-topline-results-from-its-dublin-3-registrational-trial-of--bysi-20210804monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-strengthens-board-with-the-addition-of-ex-immunomedics-and-constellation-comm-bysi-20210714monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-first-quarter-2021-financial-results-and-provides-a-corporate-updat-bysi-20210616monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-submission-of-new-drug-application-to-u-s-fda-and-china-nmpa-for-pl-bysi-20210331monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-inc-proxy-statement-general-the-board-of-directors-of-beyondspring-inc-the-co-bysi-20210209monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-the-appointment-of-dr-jeffrey-vacirca-to-its-board-of-directors-bysi-20201217monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-third-quarter-2020-financial-results-and-provides-business-updates--bysi-20201117monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-positive-topline-results-from-its-protective-2-phase-3-registration-bysi-20201116monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-subsidiary-seed-therapeutics-announces-research-collaboration-and-license-agr-bysi-20201113monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-appoints-elizabeth-czerepak-as-chief-financial-officer-new-subsidiary-focused-bysi-20200922monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-provides-second-quarter-2020-financial-results-and-business-updates-reported--bysi-20200903monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-appoints-forty-seven-inc-co-founder-and-stanford-hematology-veteran-dr-ravind-bysi-20200818monthly0.5https://www.biopharmawatch.com/news/BYSI/amendment-to-the-beyondspring-inc-2017-omnibus-incentive-plan-this-amendment-this-amendmen-bysi-20200724monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-positive-topline-interim-results-from-protective-2-study-106-phase--bysi-20200615monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-reports-first-quarter-2020-financial-results-and-operational-update-protectiv-bysi-20200611monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-files-for-patent-protection-on-bpi-002-for-the-treatment-of-viral-infections--bysi-20200311monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-provides-third-quarter-2019-operational-and-financial-results-update-preparin-bysi-20191218monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-provides-operational-update-and-second-quarter-2019-financial-results-to-subm-bysi-20190918monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-provides-operational-update-and-first-quarter-2019-financial-results-new-and--bysi-20190710monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-announces-top-line-positive-efficacy-and-safety-data-from-phase-2-study-106-w-bysi-20181023monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-provides-operational-update-and-second-quarter-2018-financial-results-reporte-bysi-20181023monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-appoints-richard-j-daly-as-chief-operating-officer-to-lead-the-transition-to--bysi-20180801monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-reports-operational-updates-and-first-quarter-2018-financial-results-bysi-20180621monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-appoints-life-sciences-veteran-patrick-fabbio-to-board-of-directors-as-an-ind-bysi-20180129monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-reports-third-quarter-2017-operational-and-financial-results-new-york-n-y-bysi-20171109monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-provides-operational-update-for-second-quarter-of-2017-new-york-n-y-bysi-20170821monthly0.5https://www.biopharmawatch.com/news/BYSI/transformational-science-advancing-oncology-disclaimer-this-presentation-contains-forward--bysi-20170524monthly0.5https://www.biopharmawatch.com/news/BYSI/beyondspring-reports-first-quarter-2017-financial-results-new-york-n-y-may-22-2017-beyonds-bysi-20170522monthly0.5https://www.biopharmawatch.com/news/BYSI/transformational-science-advancing-oncology-bysi-20170504monthly0.5https://www.biopharmawatch.com/news/IBO/dr-ashleys-limited-and-impact-biomedical-inc-announce-strategic-merger-a-strategic-move-to-ibo-20250621monthly0.5https://www.biopharmawatch.com/news/IBO/impact-biomedical-inc-announces-pricing-of-initial-public-offering-ibo-20240916monthly0.5https://www.biopharmawatch.com/news/BTMD/transforming-healthy-aging-2-transforming-healthy-aging-forward-looking-statements-forward-btmd-20260403monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-reports-fourth-quarter-and-full-year-2025-financial-results-executing-efficiently-on-btmd-20260311monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-reports-third-quarter-2025-financial-results-continued-progress-against-strategic-pr-btmd-20251105monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-reports-second-quarter-2025-financial-results-q2-financial-performance-driven-by-str-btmd-20250806monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-names-rich-barrera-to-board-of-directors-irving-tx-btmd-20250609monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-reports-first-quarter-2025-financial-results-strong-financial-performance-driven-in--btmd-20250507monthly0.5https://www.biopharmawatch.com/news/BTMD/transforming-healthy-aging-2-transforming-healthy-aging-forward-looking-statements-forward-btmd-20250317monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-reports-fourth-quarter-and-full-year-2024-financial-results-strengthened-business-wi-btmd-20250312monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-announces-ceo-retirement-and-succession-plan-terry-weber-retiring-as-ceo-and-directo-btmd-20250130monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-reports-third-quarter-2024-financial-results-continued-profitable-growth-vertical-in-btmd-20241112monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-reports-second-quarter-2024-financial-results-procedure-revenue-growth-accelerates-s-btmd-20240808monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-announces-60-million-agreement-to-repurchase-8-3-million-shares-and-cancel-approxima-btmd-20240620monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-reports-first-quarter-2024-financial-results-procedure-revenue-growth-and-strengthen-btmd-20240507monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-announces-definitive-settlement-with-founder-company-to-repurchase-all-of-founder-s--btmd-20240429monthly0.5https://www.biopharmawatch.com/news/BTMD/transforming-healthy-aging-2-transforming-healthy-aging-forward-looking-statements-forward-btmd-20240314monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-reports-fourth-quarter-and-full-year-2023-financial-results-grew-practitioner-networ-btmd-20240312monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-announces-agreement-to-resolve-litigation-and-repurchase-all-of-founder-s-shares-com-btmd-20240220monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-announces-20-million-share-repurchase-authorization-irving-tx-btmd-20240125monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-provides-preliminary-2023-results-and-initial-2024-guidance-irving-tx-btmd-20240117monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-names-robert-peterson-as-chief-financial-officer-irving-tx-btmd-20240111monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-reports-third-quarter-2023-financial-results-achieves-progress-in-test-of-complement-btmd-20231107monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-reports-second-quarter-2023-financial-results-solid-second-quarter-revenue-growth-co-btmd-20230810monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-announces-expiration-and-results-of-exchange-offer-and-consent-solicitation-relating-btmd-20230608monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-reports-first-quarter-2023-financial-results-new-initiative-targets-long-term-growth-btmd-20230509monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-reports-fourth-quarter-and-full-year-2022-financial-results-achieved-full-year-2022--btmd-20230328monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-reports-third-quarter-financial-results-strong-third-quarter-revenue-of-42-million-d-btmd-20221108monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-appoints-debby-morris-to-board-of-directors-irving-tx-btmd-20221107monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-releases-updated-corporate-presentation-for-october-2022-btmd-20221010monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-announces-approval-to-relist-on-the-nasdaq-stock-market-company-will-resume-trading--btmd-20220825monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-appoints-samar-kamdar-as-chief-financial-officer-irving-tx-btmd-20220824monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-issues-correction-to-second-quarter-operating-loss-and-net-income-irving-tx-btmd-20220815monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-reports-second-quarter-2022-financial-results-company-generates-accelerated-revenue--btmd-20220809monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-holdings-llc-unaudited-quarterly-financial-results-for-2021-biote-corp-the-company-i-btmd-20220609monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-holdings-llc-condensed-consolidated-financial-statements-quarterly-period-ended-btmd-20220602monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-debuts-as-publicly-traded-company-focused-on-transforming-hormone-optimization-indus-btmd-20220526monthly0.5https://www.biopharmawatch.com/news/BTMD/haymaker-acquisition-corp-iii-announces-stockholder-approval-of-business-combination-with--btmd-20220524monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-reports-first-quarter-2022-financial-results-and-provides-corporate-update-company-a-btmd-20220511monthly0.5https://www.biopharmawatch.com/news/BTMD/to-this-current-report-on-form-8-k-transaction-costs-amounted-to-16-973-945-consisting-of--btmd-20220504monthly0.5https://www.biopharmawatch.com/news/BTMD/this-promissory-note-note-has-not-been-registered-under-the-securities-act-of-1933-as-amen-btmd-20220228monthly0.5https://www.biopharmawatch.com/news/BTMD/andy-heyer-welcome-to-the-biote-corporate-presentation-this-is-andy-heyer-from-haymaker-ii-btmd-20211214monthly0.5https://www.biopharmawatch.com/news/BTMD/biote-to-be-listed-on-nasdaq-through-a-business-combination-with-haymaker-acquisition-corp-btmd-20211213monthly0.5https://www.biopharmawatch.com/news/BTMD/haymaker-acquisition-corp-iii-announces-the-separate-trading-of-its-class-a-common-stock-a-btmd-20210422monthly0.5https://www.biopharmawatch.com/news/BTMD/to-this-current-report-on-form-8-k-transaction-costs-amounted-to-16-973-945-consisting-of--btmd-20210311monthly0.5https://www.biopharmawatch.com/news/BTMD/haymaker-acquisition-corp-iii-announces-pricing-of-300-million-initial-public-offering-btmd-20210301monthly0.5https://www.biopharmawatch.com/news/ONCY/third-quarter-interim-financial-statements-document-condensed-interim-consolidated-financi-oncy-20251112monthly0.5https://www.biopharmawatch.com/news/ONCY/forward-looking-statements-overview-neither-the-securities-and-exchange-commission-nor-any-oncy-20251010monthly0.5https://www.biopharmawatch.com/news/ONCY/second-quarter-interim-financial-statements-document-condensed-interim-consolidated-financ-oncy-20250808monthly0.5https://www.biopharmawatch.com/news/ONCY/first-quarter-interim-financial-statement-document-condensed-interim-consolidated-financia-oncy-20250514monthly0.5https://www.biopharmawatch.com/news/ONCY/purchase-agreement-purchase-agreement-this-agreement-dated-as-of-oncy-20250410monthly0.5https://www.biopharmawatch.com/news/ONCY/third-quarter-interim-financial-statement-document-condensed-interim-consolidated-financia-oncy-20241112monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-us-50-000-000-equity-distribution-agreement-oncy-20240802monthly0.5https://www.biopharmawatch.com/news/ONCY/second-quarter-interim-financial-statements-document-condensed-interim-consolidated-financ-oncy-20240801monthly0.5https://www.biopharmawatch.com/news/ONCY/first-quarter-interim-financial-statements-document-condensed-interim-consolidated-financi-oncy-20240509monthly0.5https://www.biopharmawatch.com/news/ONCY/third-quarter-interim-financial-statements-document-condensed-interim-consolidated-financi-oncy-20231103monthly0.5https://www.biopharmawatch.com/news/ONCY/second-quarter-interim-financial-statements-document-condensed-interim-consolidated-financ-oncy-20230814monthly0.5https://www.biopharmawatch.com/news/ONCY/first-quarter-interim-financial-statements-document-condensed-interim-consolidated-financi-oncy-20230505monthly0.5https://www.biopharmawatch.com/news/ONCY/third-quarter-interim-financial-statements-document-condensed-interim-consolidated-financi-oncy-20221107monthly0.5https://www.biopharmawatch.com/news/ONCY/second-quarter-interim-financial-statements-document-condensed-interim-consolidated-financ-oncy-20220811monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-us-65-000-000-equity-distribution-agreement-oncy-20220617monthly0.5https://www.biopharmawatch.com/news/ONCY/first-quarter-interim-financial-statements-document-condensed-interim-consolidated-financi-oncy-20220505monthly0.5https://www.biopharmawatch.com/news/ONCY/third-quarter-interim-financial-statements-document-interim-consolidated-financial-stateme-oncy-20211105monthly0.5https://www.biopharmawatch.com/news/ONCY/second-quarter-interim-financial-statements-document-interim-consolidated-financial-statem-oncy-20210806monthly0.5https://www.biopharmawatch.com/news/ONCY/first-quarter-interim-financial-statements-document-interim-consolidated-financial-stateme-oncy-20210507monthly0.5https://www.biopharmawatch.com/news/ONCY/execution-copy-oncolytics-biotech-inc-80-000-000-equity-distribution-agreement-oncy-20210305monthly0.5https://www.biopharmawatch.com/news/ONCY/third-quarter-interim-financial-statements-document-interim-consolidated-financial-stateme-oncy-20201112monthly0.5https://www.biopharmawatch.com/news/ONCY/second-quarter-interim-financial-statements-document-interim-consolidated-financial-statem-oncy-20200804monthly0.5https://www.biopharmawatch.com/news/ONCY/execution-version-oncolytics-biotech-inc-40-000-000-equity-distribution-agreement-oncy-20200615monthly0.5https://www.biopharmawatch.com/news/ONCY/first-quarter-interim-financial-statements-exhibit-interim-consolidated-financial-statemen-oncy-20200508monthly0.5https://www.biopharmawatch.com/news/ONCY/notice-of-annual-general-meeting-of-shareholders-to-be-held-on-may-7-2020-and-oncy-20200417monthly0.5https://www.biopharmawatch.com/news/ONCY/third-quarter-interim-financial-statements-exhibit-interim-consolidated-financial-statemen-oncy-20191112monthly0.5https://www.biopharmawatch.com/news/ONCY/underwriting-agreement-4-619-773-common-shares-and-4-619-773-warrants-oncolytics-biotech-i-oncy-20190814monthly0.5https://www.biopharmawatch.com/news/ONCY/second-quarter-interim-financial-statements-exhibit-interim-consolidated-financial-stateme-oncy-20190813monthly0.5https://www.biopharmawatch.com/news/ONCY/first-quarter-interim-financial-statements-exhibit-interim-consolidated-financial-statemen-oncy-20190503monthly0.5https://www.biopharmawatch.com/news/ONCY/third-quarter-interim-financial-statements-exhibit-interim-consolidated-financial-statemen-oncy-20181113monthly0.5https://www.biopharmawatch.com/news/ONCY/execution-copy-oncolytics-biotech-inc-30-000-000-equity-distribution-agreement-oncy-20181024monthly0.5https://www.biopharmawatch.com/news/ONCY/purchase-agreement-this-purchase-agreement-the-agreement-dated-as-of-oncy-20180927monthly0.5https://www.biopharmawatch.com/news/ONCY/second-quarter-interim-financial-statements-exhibit-interim-consolidated-financial-stateme-oncy-20180803monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-poster-presentation-demonstrating-the-ability-of-reolysin-to--oncy-20180604monthly0.5https://www.biopharmawatch.com/news/ONCY/execution-version-underwriting-agreement-1-372-213-common-shares-oncolytics-biotech-inc-in-oncy-20180601monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-listing-on-nasdaq-capital-market-calgary-ab-and-oncy-20180601monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-public-offering-of-common-shares-calgary-ab-and-oncy-20180531monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-publication-of-reolysin-abstract-for-the-asco-2018-annual-mee-oncy-20180516monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-details-of-2018-annual-general-meeting-of-shareholders-calgar-oncy-20180426monthly0.5https://www.biopharmawatch.com/news/ONCY/first-quarter-interim-financial-statements-exhibit-interim-consolidated-financial-statemen-oncy-20180514monthly0.5https://www.biopharmawatch.com/news/ONCY/notice-of-annual-general-meeting-of-shareholders-to-be-held-on-may-3-2018-and-oncy-20180425monthly0.5https://www.biopharmawatch.com/news/ONCY/dated-february-1-2018-exhibit-oncolytics-biotech-to-host-conference-call-outlining-the-tre-oncy-20180201monthly0.5https://www.biopharmawatch.com/news/ONCY/dated-january-29-2018-exhibit-oncolytics-biotech-inc-announces-plans-to-apply-to-list-comm-oncy-20180129monthly0.5https://www.biopharmawatch.com/news/ONCY/exhibit-oncolytics-biotech-named-to-the-2018-otcqx-best-50-calgary-ab-and-oncy-20180125monthly0.5https://www.biopharmawatch.com/news/ONCY/exhibit-oncolytics-biotech-announces-poster-presentation-at-the-2018-gastrointestinal-canc-oncy-20180119monthly0.5https://www.biopharmawatch.com/news/ONCY/exhibit-oncolytics-biotech-announces-abstract-for-poster-presentation-at-the-2018-gastroin-oncy-20180116monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-poster-presentation-at-the-2018-gastrointestinal-cancers-symp-oncy-20171227monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-receives-favorable-final-advice-letter-from-the-european-medicines-agen-oncy-20171205monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-present-at-the-oncolytic-virotherapy-summit-dr-matt-coffey-oncolytic-oncy-20171204monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-establishes-scientific-advisory-board-focused-on-reolysin-registration--oncy-20171130monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-and-adlai-nortye-enter-into-usd-86-6-million-regional-licensing-agr-oncy-20171117monthly0.5https://www.biopharmawatch.com/news/ONCY/third-quarter-interim-financial-statements-exhibit-interim-consolidated-financial-statemen-oncy-20171108monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-2017-third-quarter-results-calgary-and-oncy-20171108monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-appoints-deborah-brown-to-board-of-directors-calgary-and-oncy-20171102monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-present-at-the-2017-bio-investor-forum-presenting-clinical-data-of-r-oncy-20171011monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-present-at-the-phacilitate-immuno-oncology-frontiers-conference-dr-a-oncy-20170919monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-successful-end-of-phase-2-meeting-with-fda-for-reolysin-in-me-oncy-20170918monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-first-patient-treated-in-muk-eleven-study-calgary-and-oncy-20170914monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-the-presentation-of-reolysin-clinical-data-at-esmo-2017-congr-oncy-20170911monthly0.5https://www.biopharmawatch.com/news/ONCY/second-quarter-interim-financial-statements-exhibit-interim-consolidated-financial-stateme-oncy-20170816monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-2017-second-quarter-results-calgary-and-oncy-20170803monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-to-present-at-the-canaccord-genuity-37th-annual-growth-conference-c-oncy-20170801monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-to-present-reolysin-safety-data-in-combination-with-chemotherapy-at-esm-oncy-20170726monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-appoints-andrew-de-guttadauro-president-of-oncolytics-biotech-u-s-i-oncy-20170629monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-opens-u-s-based-office-in-san-diego-calgary-and-oncy-20170627monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-closing-of-public-offering-of-units-calgary-oncy-20170601monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-prices-public-offering-of-units-calgary-oncy-20170524monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-proposed-public-offering-calgary-oncy-20170523monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-participation-in-world-immunotherapy-congress-usa-2017-ca-oncy-20170523monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-announces-asco-abstracts-and-preliminary-data-for-studies-in-pancreatic-oncy-20170517monthly0.5https://www.biopharmawatch.com/news/ONCY/first-quarter-interim-financial-statements-exhibit-interim-consolidated-financial-statemen-oncy-20170508monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-fda-fast-track-designation-for-reolysin-in-metastatic-bre-oncy-20170508monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-2017-first-quarter-results-calgary-oncy-20170505monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-voting-results-from-its-annual-meeting-of-shareholders-ca-oncy-20170504monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-details-of-2017-annual-meeting-of-shareholders-calgary-oncy-20170427monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-to-present-at-the-sixth-annual-bloom-burton-co-healthcare-investor--oncy-20170426monthly0.5https://www.biopharmawatch.com/news/ONCY/notice-of-annual-general-meeting-of-shareholders-to-be-held-on-may-4-2017-and-oncy-20170414monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-registration-pathway-and-clinical-development-plan-initia-oncy-20170412monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-s-reolysin-more-than-doubles-overall-survival-in-patients-with-muta-oncy-20170405monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-s-reolysin-provides-statistically-significant-improvement-in-overal-oncy-20170331monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-enters-into-first-in-class-collaboration-with-myeloma-uk-and-celgen-oncy-20170316monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-2016-year-end-results-calgary-oncy-20170310monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-canadian-cancer-trials-group-to-present-final-randomized--oncy-20170302monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-appoints-dr-matt-coffey-to-the-role-of-president-and-oncy-20170119monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-change-to-board-of-directors-calgary-oncy-20161206monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-collaborators-present-initial-results-from-reo-019-study-in-multipl-oncy-20161206monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-appointment-of-new-chief-medical-officer-andres-a-gutierr-oncy-20161110monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-2016-third-quarter-results-calgary-oncy-20161103monthly0.5https://www.biopharmawatch.com/news/ONCY/interim-financial-statements-september-30-2016-exhibit-interim-consolidated-financial-stat-oncy-20161103monthly0.5https://www.biopharmawatch.com/news/ONCY/media-advisory-oncolytics-biotech-inc-announces-management-team-changes-calgary-oncy-20161102monthly0.5https://www.biopharmawatch.com/news/ONCY/media-advisory-oncolytics-biotech-inc-announces-participation-in-the-2016-bio-investor-for-oncy-20161018monthly0.5https://www.biopharmawatch.com/news/ONCY/media-advisory-oncolytics-biotech-inc-announces-participation-in-the-4th-annual-immuno-onc-oncy-20160830monthly0.5https://www.biopharmawatch.com/news/ONCY/media-advisory-oncolytics-biotech-inc-announces-participation-in-the-canaccord-genuity-36t-oncy-20160810monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-reports-additional-data-from-randomized-phase-ii-study-of-reolysin--oncy-20160810monthly0.5https://www.biopharmawatch.com/news/ONCY/second-quarter-interim-financial-statements-exhibit-interim-consolidated-financial-stateme-oncy-20160804monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-2016-second-quarter-results-calgary-oncy-20160804monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-phase-2-study-in-female-patients-with-colorectal-cancer-m-oncy-20160629monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-reports-preliminary-data-from-randomized-phase-ii-study-of-reolysin-oncy-20160519monthly0.5https://www.biopharmawatch.com/news/ONCY/first-quarter-fs-exhibit-interim-consolidated-financial-statements-unaudited-oncolytics-bi-oncy-20160506monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-voting-results-from-its-annual-meeting-of-shareholders-ca-oncy-20160506monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-2016-first-quarter-results-calgary-oncy-20160506monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-presentation-of-reolysin-preclinical-research-at-the-2016-oncy-20160505monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-details-of-2016-annual-meeting-of-shareholders-calgary-oncy-20160503monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-to-participate-in-the-bloom-burton-co-healthcare-investor-conferenc-oncy-20160429monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-formation-of-science-and-technology-committee-calgary-oncy-20160429monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-collaborators-present-reolysin-preclinical-research-at-the-2016-aac-oncy-20160418monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-reports-updated-data-from-randomized-phase-2-study-of-reolysin-in-p-oncy-20160414monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-filing-of-management-information-circular-and-details-of--oncy-20160324monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-reports-data-from-randomized-phase-2-study-of-reolysin-in-ovarian-c-oncy-20160321monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-r-inc-announces-2015-year-end-results-calgary-oncy-20160311monthly0.5https://www.biopharmawatch.com/news/ONCY/1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-release-not-for-distri-oncy-20160225monthly0.5https://www.biopharmawatch.com/news/ONCY/media-advisory-oncolytics-biotech-inc-announces-participation-in-upcoming-conferences-calg-oncy-20160208monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-first-patients-treated-in-phase-1b-study-in-advanced-panc-oncy-20160119monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-collaborators-present-multiple-myeloma-data-at-57th-american-societ-oncy-20151208monthly0.5https://www.biopharmawatch.com/news/ONCY/media-advisory-oncolytics-biotech-inc-to-present-at-ld-micro-growth-conference-calgary-oncy-20151202monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-start-of-enrollment-in-phase-1b-study-of-multiple-myeloma-oncy-20151118monthly0.5https://www.biopharmawatch.com/news/ONCY/third-quarter-financial-statements-exhibit-interim-consolidated-financial-statements-unaud-oncy-20151105monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-2015-third-quarter-results-calgary-oncy-20151105monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-receipt-of-qualification-for-trading-on-the-otcqx-and-nas-oncy-20151029monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-phase-1b-study-in-advanced-pancreatic-cancer-first-clinic-oncy-20151020monthly0.5https://www.biopharmawatch.com/news/ONCY/media-advisory-oncolytics-biotech-inc-to-participate-in-the-14th-annual-bio-investor-forum-oncy-20151020monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-completion-of-enrollment-in-randomized-phase-ii-prostate--oncy-20151006monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-collaborators-present-data-from-clinical-study-in-multiple-myeloma--oncy-20150925monthly0.5https://www.biopharmawatch.com/news/ONCY/media-advisory-oncolytics-biotech-inc-to-participate-in-the-baird-2015-healthcare-conferen-oncy-20150909monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-collaborators-to-present-survival-data-from-reo-016-study-in-non-sm-oncy-20150827monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-completion-of-enrollment-in-randomized-phase-ii-non-small-oncy-20150826monthly0.5https://www.biopharmawatch.com/news/ONCY/media-advisory-oncolytics-biotech-inc-to-participate-in-the-35th-annual-canaccord-genuity--oncy-20150812monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-2015-second-quarter-results-calgary-oncy-20150806monthly0.5https://www.biopharmawatch.com/news/ONCY/second-quarter-fs-ex-99-1-interim-financial-statements-oncy-20150806monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-collaborators-present-final-data-from-reo-017-clinical-study-in-pan-oncy-20150706monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-collaborators-present-reolysin-preclinical-data-at-the-9th-internat-oncy-20150615monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-voting-results-from-its-annual-meeting-of-shareholders-ca-oncy-20150612monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-director-election-results-from-its-annual-meeting-of-shar-oncy-20150609monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-provides-update-at-agm-on-planned-registration-program-for-oncy-20150608monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-details-of-2015-annual-meeting-of-shareholders-calgary-oncy-20150605monthly0.5https://www.biopharmawatch.com/news/ONCY/media-advisory-oncolytics-biotech-inc-to-participate-in-the-ld-micro-invitational-conferen-oncy-20150602monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-phase-1-study-in-pediatric-patients-with-brain-tumors-cal-oncy-20150519monthly0.5https://www.biopharmawatch.com/news/ONCY/of-shareholders-to-be-held-on-june-8-2015-oncy-20150515monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-2015-first-quarter-results-calgary-oncy-20150507monthly0.5https://www.biopharmawatch.com/news/ONCY/march-31-2015-financial-statements-ex-99-1-interim-financial-statements-oncy-20150507monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-receipt-of-orphan-drug-designation-from-the-u-s-fda-for-g-oncy-20150506monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-receipt-of-orphan-drug-status-from-the-ema-for-pancreatic-oncy-20150429monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-extension-to-regain-compliance-with-nasdaq-s-minimum-bid--oncy-20150428monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-collaborators-present-reolysin-preclinical-data-at-the-2015-aacr-an-oncy-20150420monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-receipt-of-orphan-drug-designation-from-the-u-s-fda-for-m-oncy-20150417monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-presents-at-uk-immuno-oncology-meeting-calgary-oncy-20150415monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-filing-for-orphan-drug-designation-with-the-u-s-fda-for-g-oncy-20150407monthly0.5https://www.biopharmawatch.com/news/ONCY/media-advisory-oncolytics-biotech-inc-to-participate-in-the-14th-annual-needham-healthcare-oncy-20150413monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-presents-at-the-2015-immune-checkpoint-inhibitors-meeting-calgary-oncy-20150326monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-receipt-of-orphan-drug-status-from-the-ema-for-ovarian-ca-oncy-20150325monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-2014-year-end-results-calgary-oncy-20150316monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-collaborators-present-preclinical-data-on-the-combination-of-reolys-oncy-20150305monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-receipt-of-orphan-drug-designation-from-the-u-s-fda-for-p-oncy-20150303monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-completion-of-enrollment-in-randomized-phase-ii-colorecta-oncy-20150218monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-receipt-of-orphan-drug-designation-from-the-u-s-fda-for-p-oncy-20150217monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-receipt-of-orphan-drug-designation-from-the-u-s-fda-for-o-oncy-20150211monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-filing-for-orphan-drug-designation-with-the-u-s-fda-for-h-oncy-20150209monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-filing-for-orphan-designation-with-the-ema-for-pancreatic-oncy-20141222monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-collaborators-present-reolysin-and-checkpoint-inhibitor-combination-oncy-20141204monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-filing-for-orphan-drug-designation-with-the-u-s-fda-for-p-oncy-20141202monthly0.5https://www.biopharmawatch.com/news/ONCY/media-advisory-oncolytics-biotech-inc-to-participate-in-the-stifel-2014-healthcare-confere-oncy-20141118monthly0.5https://www.biopharmawatch.com/news/ONCY/september-30-2014-interim-fs-ex-99-1-interim-financial-statements-oncy-20141106monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-third-quarter-2014-results-calgary-oncy-20141106monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-receipt-of-nasdaq-notice-of-deficiency-calgary-oncy-20141104monthly0.5https://www.biopharmawatch.com/news/ONCY/execution-copy-oncolytics-biotech-inc-20-000-000-oncy-20141024monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-entry-into-20-million-at-the-market-equity-distribution-a-oncy-20141024monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-amendment-to-common-share-purchase-agreement-with-lincoln-oncy-20141020monthly0.5https://www.biopharmawatch.com/news/ONCY/amendment-no-2-to-purchase-agreement-this-amendment-no-2-the-amendment-is-entered-into-thi-oncy-20141020monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-announces-overall-and-kras-mutated-patient-data-from-u-s-randomized-oncy-20140916monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-press-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canad-oncy-20140903monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-press-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canad-oncy-20140811monthly0.5https://www.biopharmawatch.com/news/ONCY/amendment-no-1-to-purchase-agreement-this-amendment-no-1-the-amendment-is-entered-into-thi-oncy-20140808monthly0.5https://www.biopharmawatch.com/news/ONCY/interim-financial-statements-june-30-2014-ex-99-1-interim-financial-statements-oncy-20140807monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n--oncy-20140807monthly0.5https://www.biopharmawatch.com/news/ONCY/information-circular-ex-99-1-2014-information-circular-notice-of-annual-meeting-of-shareho-oncy-20140725monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-press-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canad-oncy-20140708monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-press-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canad-oncy-20140619monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-press-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canad-oncy-20140616monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-press-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canad-oncy-20140602monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-press-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canad-oncy-20140521monthly0.5https://www.biopharmawatch.com/news/ONCY/q1-2014-financial-statements-ex-99-1-interim-financial-statements-oncy-20140509monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-press-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canad-oncy-20140508monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-press-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canad-oncy-20140414monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-press-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canad-oncy-20140411monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-6k-form-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n--oncy-20140408monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-press-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canad-oncy-20140407monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-press-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canad-oncy-20140313monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-press-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canad-oncy-20140304monthly0.5https://www.biopharmawatch.com/news/ONCY/e-xecution-v-ersion-purchase-agreement-purchase-agreement-the-agreement-dated-as-of-oncy-20140227monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-press-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canad-oncy-20140225monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-press-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canad-oncy-20131203monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-press-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canad-oncy-20131121monthly0.5https://www.biopharmawatch.com/news/ONCY/third-quarter-2013-interim-financial-statements-ex-99-1-interim-financial-statements-oncy-20131107monthly0.5https://www.biopharmawatch.com/news/ONCY/third-quarter-2013-press-release-ex99-1-press-release-q3-2013-210-1167-kensington-cr-n-w-c-oncy-20131107monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-press-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canad-oncy-20131028monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-press-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canad-oncy-20131022monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-press-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canad-oncy-20131001monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-press-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canad-oncy-20130909monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-press-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canad-oncy-20130813monthly0.5https://www.biopharmawatch.com/news/ONCY/june-30-2013-interim-financial-statements-ex-99-1-interim-financial-statements-oncy-20130801monthly0.5https://www.biopharmawatch.com/news/ONCY/q2-2013-press-release-ex99-1-press-release-q2-2013-210-1167-kensington-cr-n-w-calgary-albe-oncy-20130801monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-press-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canad-oncy-20130522monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-6k-form-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n--oncy-20130514monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-press-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canad-oncy-20130510monthly0.5https://www.biopharmawatch.com/news/ONCY/march-31-2013-financial-statements-ex-99-1-interim-financial-statements-oncy-20130509monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-press-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canad-oncy-20130506monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-press-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canad-oncy-20130429monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-press-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canad-oncy-20130328monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-press-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canad-oncy-20130314monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-press-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canad-oncy-20130305monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-press-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canad-oncy-20130225monthly0.5https://www.biopharmawatch.com/news/ONCY/1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-release-oncolytics-bio-oncy-20130225monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-press-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canad-oncy-20130220monthly0.5https://www.biopharmawatch.com/news/ONCY/consent-of-norton-rose-canada-llp-we-hereby-consent-to-the-use-of-our-name-in-the-prospect-oncy-20130220monthly0.5https://www.biopharmawatch.com/news/ONCY/1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-release-oncolytics-bio-oncy-20130220monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n--oncy-20130208monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-press-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canad-oncy-20130128monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n--oncy-20121213monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n--oncy-20121112monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n--oncy-20121109monthly0.5https://www.biopharmawatch.com/news/ONCY/third-quarter-2012-financial-statements-ex-99-1-interim-financial-statements-oncy-20121108monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n--oncy-20121024monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n--oncy-20120928monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n--oncy-20120913monthly0.5https://www.biopharmawatch.com/news/ONCY/charter-2-ex99-htm-release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n--oncy-20120816monthly0.5https://www.biopharmawatch.com/news/ONCY/june-30-2012-financial-statements-ex-99-1-interim-financial-statements-oncy-20120802monthly0.5https://www.biopharmawatch.com/news/ONCY/second-quarter-2012-press-release-ex-99-1-second-quarter-2012-press-release-210-1167-kensi-oncy-20120802monthly0.5https://www.biopharmawatch.com/news/ONCY/htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-release-oncoly-oncy-20120621monthly0.5https://www.biopharmawatch.com/news/ONCY/htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-media-advisory-oncolytics-bi-oncy-20120618monthly0.5https://www.biopharmawatch.com/news/ONCY/htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-release-oncoly-oncy-20120615monthly0.5https://www.biopharmawatch.com/news/ONCY/htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-release-oncoly-oncy-20120613monthly0.5https://www.biopharmawatch.com/news/ONCY/notice-of-annual-and-special-meeting-of-shareholders-june-20-2012-to-the-shareholders-of-o-oncy-20120529monthly0.5https://www.biopharmawatch.com/news/ONCY/q1-2012-press-release-ex-99-1-q1-2012-press-release-210-1167-kensington-cr-n-w-calgary-alb-oncy-20120510monthly0.5https://www.biopharmawatch.com/news/ONCY/march-31-2012-financial-statements-ex-99-1-interim-financial-statements-oncy-20120510monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20120503monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-media-advisory--oncy-20120404monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20120402monthly0.5https://www.biopharmawatch.com/news/ONCY/htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-release-oncoly-oncy-20120329monthly0.5https://www.biopharmawatch.com/news/ONCY/year-end-press-release-ex-99-1-12-31-2011-year-end-results-press-release-210-1167-kensingt-oncy-20120319monthly0.5https://www.biopharmawatch.com/news/ONCY/management-discussion-analysis-ex-99-1-2011-md-a-2011-management-discussion-analysis-2011--oncy-20120314monthly0.5https://www.biopharmawatch.com/news/ONCY/financial-statements-ex-99-1-audited-financial-statements-consolidated-financial-statement-oncy-20120319monthly0.5https://www.biopharmawatch.com/news/ONCY/1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-media-advisory-oncolytics-biotech-in-oncy-20120302monthly0.5https://www.biopharmawatch.com/news/ONCY/210-1167-kensington-cr-oncy-20120223monthly0.5https://www.biopharmawatch.com/news/ONCY/1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-oncolytics-biotech-inc-closes-bought-oncy-20120208monthly0.5https://www.biopharmawatch.com/news/ONCY/1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-oncolytics-biotech-inc-announces-inc-oncy-20120124monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20111202monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20111121monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20111114monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20111111monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-form-52-109f2-certification-of-interim-filings-full-certificate-i-brad-th-oncy-20111114monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-q3-2011-message-to-shareholders-oncy-20111114monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-media-advisory--oncy-20110922monthly0.5https://www.biopharmawatch.com/news/ONCY/210-1167-kensington-cr-oncy-20110811monthly0.5https://www.biopharmawatch.com/news/ONCY/q2-certificates-ex99-htm-form-52-109f2-certification-of-interim-filings-full-certificate-i-oncy-20110803monthly0.5https://www.biopharmawatch.com/news/ONCY/210-1167-kensington-cr-oncy-20110803monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-message-to-shareholders-oncy-20110729monthly0.5https://www.biopharmawatch.com/news/ONCY/210-1167-kensington-cr-oncy-20110728monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20110706monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20110608monthly0.5https://www.biopharmawatch.com/news/ONCY/voting-results-ex99-htm-oncolytics-biotech-inc-annual-general-meeting-held-on-oncy-20110603monthly0.5https://www.biopharmawatch.com/news/ONCY/q1-certificates-ex99-htm-form-52-109f2-certification-of-interim-filings-full-certificate-i-oncy-20110603monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-media-advisory--oncy-20110602monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20110512monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-message-to-shareholders-oncy-20110513monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20110510monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20110505monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20110420monthly0.5https://www.biopharmawatch.com/news/ONCY/notice-of-annual-general-meeting-of-shareholders-may-11-2011-to-the-shareholders-of-oncoly-oncy-20110407monthly0.5https://www.biopharmawatch.com/news/ONCY/technology-changing-life-annual-report-2010-table-of-contents-oncolytics-biotech-inc-is-fo-oncy-20110407monthly0.5https://www.biopharmawatch.com/news/ONCY/8th-avenue-sw-6th-floor-date-oncy-20110407monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-media-advisory--oncy-20110331monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20110324monthly0.5https://www.biopharmawatch.com/news/ONCY/financial-statements-ex99-htm-consolidated-financial-statements-oncolytics-biotech-inc-oncy-20110318monthly0.5https://www.biopharmawatch.com/news/ONCY/md-a-ex99-htm-management-discussion-analysis-2010-table-of-contents-forward-looking-statem-oncy-20110316monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20110317monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-media-advisory--oncy-20110303monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20110301monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-media-advisory--oncy-20110224monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20110216monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20110214monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-media-advisory--oncy-20110210monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20110125monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20110118monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20110110monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20101223monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20101201monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-for-immediate-release-oncolytics-biotech-inc-announces-publication-of-pha-oncy-20101129monthly0.5https://www.biopharmawatch.com/news/ONCY/210-1167-kensington-cr-oncy-20101118monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-q3-2010-message-to-shareholders-oncy-20101112monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-form-52-109f2-certification-of-interim-filings-full-certificate-i-brad-th-oncy-20101112monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20101110monthly0.5https://www.biopharmawatch.com/news/ONCY/exv99w1-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-oncolytics-biotech-inc-c-oncy-20101108monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20101101monthly0.5https://www.biopharmawatch.com/news/ONCY/exv99w1-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-oncolytics-biotech-inc-a-oncy-20101028monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20101026monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-media-advisory--oncy-20101004monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20100928monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-media-advisory--oncy-20100909monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20100902monthly0.5https://www.biopharmawatch.com/news/ONCY/210-1167-kensington-cr-oncy-20100805monthly0.5https://www.biopharmawatch.com/news/ONCY/q2-certificates-ex99-htm-form-52-109f2-certification-of-interim-filings-full-certificate-i-oncy-20100730monthly0.5https://www.biopharmawatch.com/news/ONCY/for-the-quarter-ended-june-30-2010-oncy-20100730monthly0.5https://www.biopharmawatch.com/news/ONCY/210-1167-kensington-cr-oncy-20100729monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20100719monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20100617monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20100607monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20100604monthly0.5https://www.biopharmawatch.com/news/ONCY/form-ex99-htm-oncolytics-biotech-inc-annual-and-special-meeting-held-on-oncy-20100603monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20100601monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-for-immediate-release-oncolytics-biotech-inc-announces-start-of-enrolment-oncy-20100526monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20100525monthly0.5https://www.biopharmawatch.com/news/ONCY/210-1167-kensington-cr-oncy-20100521monthly0.5https://www.biopharmawatch.com/news/ONCY/us-gaap-note-q1-2010-ex99-htm-oncolytics-biotech-inc-oncy-20100520monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20100519monthly0.5https://www.biopharmawatch.com/news/ONCY/certification-ex99-htm-form-52-109f2-certification-of-interim-filings-full-certificate-i-b-oncy-20100513monthly0.5https://www.biopharmawatch.com/news/ONCY/for-the-quarter-ended-march-31-2010-oncy-20100513monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20100512monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20100507monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20100423monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20100414monthly0.5https://www.biopharmawatch.com/news/ONCY/notice-of-annual-and-special-meeting-of-shareholders-may-11-2010-to-the-shareholders-of-on-oncy-20100409monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-technology-changing-life-annual-report-2009-oncolytics-biotech-inc--oncy-20100409monthly0.5https://www.biopharmawatch.com/news/ONCY/date-01-03-2010-530-8th-avenue-sw-6th-floor-calgary-ab-t2p-3s8-www-computershare-com-to-al-oncy-20100409monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-for-immediate-release-oncolytics-biotech-inc-announces-publication-of-pre-oncy-20100408monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-media-advisory--oncy-20100406monthly0.5https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-inc-oncy-20100330monthly0.5https://www.biopharmawatch.com/news/ONCY/announces-2009-year-end-results-oncy-20100309monthly0.5https://www.biopharmawatch.com/news/ONCY/approval-from-the-u-k-oncy-20100216monthly0.5https://www.biopharmawatch.com/news/ONCY/annual-bio-ceo-investor-conference-oncy-20100204monthly0.5https://www.biopharmawatch.com/news/ONCY/to-present-at-biopartnering-north-america-oncy-20100121monthly0.5https://www.biopharmawatch.com/news/ONCY/senior-vice-president-global-licensing-and-business-development-oncy-20091211monthly0.5https://www.biopharmawatch.com/news/ONCY/exercise-of-underwriters-over-allotment-option-oncy-20091202monthly0.5https://www.biopharmawatch.com/news/ONCY/us-12-75-million-unit-offering-oncy-20091123monthly0.5https://www.biopharmawatch.com/news/ONCY/exv99w1-oncolytics-biotech-inc-4-250-000-shares-1-700-000-warrants-oncy-20091118monthly0.5https://www.biopharmawatch.com/news/ONCY/calgary-ab-november-18-2009-oncy-20091118monthly0.5https://www.biopharmawatch.com/news/ONCY/collaborators-to-present-updated-phase-i-ii-trial-results-in-advanced-solid-oncy-20091116monthly0.5https://www.biopharmawatch.com/news/ONCY/gaap-note-ex99-htm-oncolytics-biotech-inc-oncy-20091112monthly0.5https://www.biopharmawatch.com/news/ONCY/certificates-ex99-htm-form-52-109f2-certification-of-interim-filings-full-certificate-i-br-oncy-20091110monthly0.5https://www.biopharmawatch.com/news/ONCY/collaborators-present-positive-phase-ii-sarcoma-trial-results-at-ctos-annual-oncy-20091106monthly0.5https://www.biopharmawatch.com/news/ONCY/the-quarter-ended-september-30-2009-oncy-20091106monthly0.5https://www.biopharmawatch.com/news/ONCY/results-of-second-warrant-expiry-date-acceleration-program-oncy-20091103monthly0.5https://www.biopharmawatch.com/news/ONCY/collaborators-to-present-phase-ii-sarcoma-trial-results-at-ctos-annual-oncy-20091030monthly0.5https://www.biopharmawatch.com/news/ONCY/biotech-inc-oncy-20091027monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20091026monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-media-advisory--oncy-20091023monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20091020monthly0.5https://www.biopharmawatch.com/news/ONCY/htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-media-advisory-oncolytics-bi-oncy-20091007monthly0.5https://www.biopharmawatch.com/news/ONCY/htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-release-oncoly-oncy-20091002monthly0.5https://www.biopharmawatch.com/news/ONCY/210-1167-kensington-cr-oncy-20091002monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20091001monthly0.5https://www.biopharmawatch.com/news/ONCY/210-1167-kensington-crescent-nw-oncy-20090924monthly0.5https://www.biopharmawatch.com/news/ONCY/htm-for-immediate-release-oncolytics-biotech-inc-announces-start-of-enrolment-in-u-s-phase-oncy-20090924monthly0.5https://www.biopharmawatch.com/news/ONCY/htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-release-oncoly-oncy-20090923monthly0.5https://www.biopharmawatch.com/news/ONCY/210-1167-kensington-cr-oncy-20090918monthly0.5https://www.biopharmawatch.com/news/ONCY/htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-media-advisory-oncolytics-bi-oncy-20090908monthly0.5https://www.biopharmawatch.com/news/ONCY/htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-release-oncoly-oncy-20090901monthly0.5https://www.biopharmawatch.com/news/ONCY/q2-certs-ex99-htm-form-52-109f2-certification-of-interim-filings-full-certificate-i-brad-t-oncy-20090811monthly0.5https://www.biopharmawatch.com/news/ONCY/gaap-note-ex99-htm-oncolytics-biotech-inc-oncy-20090731monthly0.5https://www.biopharmawatch.com/news/ONCY/for-the-quarter-ended-june-30-2009-oncy-20090730monthly0.5https://www.biopharmawatch.com/news/ONCY/q2-press-release-exhibit99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-f-oncy-20090729monthly0.5https://www.biopharmawatch.com/news/ONCY/release-ex99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-r-oncy-20090727monthly0.5https://www.biopharmawatch.com/news/ONCY/210-1167-kensington-cr-oncy-20090720monthly0.5https://www.biopharmawatch.com/news/ONCY/htm-210-1167-kensington-crescent-nw-calgary-alberta-canada-t2n-1x7-for-immediate-release-o-oncy-20090714monthly0.5https://www.biopharmawatch.com/news/ONCY/htm-for-immediate-release-oncolytics-biotech-inc-research-collaborators-present-glioma-reo-oncy-20090715monthly0.5https://www.biopharmawatch.com/news/ONCY/july-2-2009-exhibit99-htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-im-oncy-20090702monthly0.5https://www.biopharmawatch.com/news/ONCY/voting-results-exhibit99-htm-oncolytics-biotech-inc-annual-and-special-meeting-of-holders--oncy-20090602monthly0.5https://www.biopharmawatch.com/news/ONCY/htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-release-oncoly-oncy-20090601monthly0.5https://www.biopharmawatch.com/news/ONCY/underwriting-agreement-oncy-20090506monthly0.5https://www.biopharmawatch.com/news/ONCY/htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-release-oncoly-oncy-20090514monthly0.5https://www.biopharmawatch.com/news/ONCY/q1-2009-certifications-exhibit99-htm-form-52-109f2-certification-of-interim-filings-full-c-oncy-20090506monthly0.5https://www.biopharmawatch.com/news/ONCY/us-gaap-note-ex99-htm-oncolytics-biotech-inc-oncy-20090506monthly0.5https://www.biopharmawatch.com/news/ONCY/the-quarter-ended-march-31-2009-oncy-20090506monthly0.5https://www.biopharmawatch.com/news/ONCY/2009-first-quarter-results-oncy-20090506monthly0.5https://www.biopharmawatch.com/news/ONCY/biotech-inc-oncy-20090430monthly0.5https://www.biopharmawatch.com/news/ONCY/htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-f-or-immediate-release-oncol-oncy-20090427monthly0.5https://www.biopharmawatch.com/news/ONCY/information-circular-ex99-1-htm-notice-of-annual-and-special-meeting-of-shareholders-to-be-oncy-20090318monthly0.5https://www.biopharmawatch.com/news/ONCY/htm-210-1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-f-or-immediate-release-oncol-oncy-20090407monthly0.5https://www.biopharmawatch.com/news/ONCY/1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-f-or-immediate-release-oncolytics-bi-oncy-20090325monthly0.5https://www.biopharmawatch.com/news/ONCY/1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-f-or-immediate-release-oncolytics-bi-oncy-20090323monthly0.5https://www.biopharmawatch.com/news/ONCY/1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-release-oncolytics-bio-oncy-20090320monthly0.5https://www.biopharmawatch.com/news/ONCY/1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-release-oncolytics-bio-oncy-20090316monthly0.5https://www.biopharmawatch.com/news/ONCY/1167-kensington-cres-nw-calgary-alberta-canada-t2n-1x7-for-immediate-release-oncolytics-bi-oncy-20090312monthly0.5https://www.biopharmawatch.com/news/ONCY/1167-kensington-cr-n-w-calgary-alberta-canada-t2n-1x7-for-immediate-release-oncolytics-bio-oncy-20090304monthly0.5https://www.biopharmawatch.com/news/ONCY/via-canada-newswire-toronto-416-863-9350-attention-business-editors-media-advisory-oncolyt-oncy-20090205monthly0.5https://www.biopharmawatch.com/news/ONCY/via-canada-newswire-toronto-416-863-9350-attention-business-medical-editors-oncolytics-bio-oncy-20090127monthly0.5https://www.biopharmawatch.com/news/ONCY/via-canada-newswire-toronto-416-863-9350-attention-business-editors-oncolytics-biotech-inc-oncy-20090113monthly0.5https://www.biopharmawatch.com/news/ONCY/underwriting-agreement-oncy-20081201monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-corporate-presentation-march-2025-forward-looking-statements-statements-in-this-mnov-20250311monthly0.5https://www.biopharmawatch.com/news/MNOV/services-agreement-this-agreement-is-entered-into-mnov-20210801monthly0.5https://www.biopharmawatch.com/news/MNOV/lease-between-the-irvine-company-llc-and-medicinova-inc-lease-short-form-this-lease-is-mad-mnov-20210720monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-closing-of-us-20-million-private-placement-transaction-mnov-20210131monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-enters-into-us-20-million-securities-purchase-agreement-with-a-fund-managed-by--mnov-20210111monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-appoints-carolyn-beaver-to-its-board-of-directors-and-as-audit-committee-chair-mnov-20201021monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-appoints-kazuko-matsuda-to-its-board-of-directors-mnov-20190724monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-proposed-underwritten-public-offering-of-common-stock-mnov-20180207monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-appoints-hideki-nagao-to-its-board-of-directors-mnov-20171109monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-the-presentation-of-additional-positive-top-line-results-from-the-spr-mnov-20171030monthly0.5https://www.biopharmawatch.com/news/MNOV/corporate-presentation-november-2016-forward-looking-statements-statements-in-this-present-mnov-20161110monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-inc-2015-statements-in-this-presentation-that-are-not-historical-in-nature-cons-mnov-20150925monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-closing-of-underwritten-public-offering-of-common-stock-mnov-20150824monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-proposed-underwritten-public-offering-of-common-stock-mnov-20150818monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-inc-2014-medicinova-inc-2014-statements-in-this-presentation-that-are-not-histo-mnov-20141017monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-positive-interim-results-of-phase-2a-study-of-mn-166-ibudilast-in-opi-mnov-20140818monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-appoints-yoshio-ishizaka-to-its-board-of-directors-mnov-20140408monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-appoints-yutaka-kobayashi-to-its-board-of-directors-mnov-20131016monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-inc-2013-statements-in-this-presentation-that-are-not-historical-in-nature-cons-mnov-20130717monthly0.5https://www.biopharmawatch.com/news/MNOV/m-edici-n-ova-i-nc-2013-e-quity-i-ncentive-p-lan-a-dopted-by-the-b-oard-of-d-irectors-a-pr-mnov-20130617monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-fourth-quarter-and-full-year-2012-results-mnov-20130328monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-enters-into-a-20-million-common-stock-purchase-agreement-with-aspire-capital-fu-mnov-20120820monthly0.5https://www.biopharmawatch.com/news/MNOV/a-ccelerating-statements-in-this-presentation-that-are-not-historical-in-nature-constitute-mnov-20120705monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-appoints-david-o-toole-cpa-to-its-board-of-directors-mnov-20120410monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-fourth-quarter-and-full-year-2011-results-medicinova-management-to-host-mnov-20120329monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-inc-2012-forward-looking-statements-statements-in-this-presentation-that-are-no-mnov-20120215monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-third-quarter-2011-results-medicinova-management-to-host-a-conference-c-mnov-20111115monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-second-quarter-2011-results-medicinova-management-to-host-a-conference--mnov-20110816monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-first-quarter-2011-results-medicinova-management-to-host-a-conference-c-mnov-20110517monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-fourth-quarter-and-full-year-2010-results-mnov-20110331monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-proposed-public-offering-of-common-stock-and-warrants-san-diego-ca-mnov-20110323monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-inc-2011-statements-in-this-presentation-that-are-not-historical-in-nature-cons-mnov-20110207monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-inc-2011-forward-looking-statements-forward-looking-statements-statements-in-th-mnov-20110107monthly0.5https://www.biopharmawatch.com/news/MNOV/columbia-university-new-york-state-psychiatric-institute-and-medicinova-report-preliminary-mnov-20101213monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-third-quarter-2010-results-mnov-20101115monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-inc-2010-forward-looking-statements-forward-looking-statements-2-statements-in--mnov-20101004monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-inc-2010-forward-looking-statements-forward-looking-statements-statements-in-th-mnov-20100914monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-second-quarter-2010-results-mnov-20100816monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-nets-9-5-million-from-settlement-of-auction-rate-securities-held-by-mnov-20100706monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-first-quarter-2010-results-mnov-20100517monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-secures-15-million-debt-facility-from-oxford-finance-corporation-mnov-20100511monthly0.5https://www.biopharmawatch.com/news/MNOV/superior-court-for-the-state-of-california-for-the-county-of-alameda-the-pennsylvania-aven-mnov-20100412monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-fourth-quarter-and-full-year-2009-results-mnov-20100324monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-inc-2010-statements-in-this-presentation-that-are-not-historical-in-nature-cons-mnov-20100318monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-reports-positive-preliminary-results-from-a-phase-ib-clinical-trial-of-mn-221-i-mnov-20100317monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-inc-2010-statements-in-this-presentation-that-are-not-historical-in-nature-cons-mnov-20100309monthly0.5https://www.biopharmawatch.com/news/MNOV/accelerating-the-global-development-and-commercialization-of-innovative-pharmaceuticals-me-mnov-20100111monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-extends-conversion-deadline-to-mnov-20100105monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-and-avigen-stockholders-approve-merger-san-diego-calif-and-mnov-20091217monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-and-avigen-confirm-stockholder-election-deadline-san-diego-calif-and-mnov-20091215monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-and-avigen-announce-stockholder-election-deadline-and-update-to-estimated-merge-mnov-20091209monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-inc-2009-forward-looking-statements-forward-looking-statements-statements-in-th-mnov-20091117monthly0.5https://www.biopharmawatch.com/news/MNOV/shintaro-asako-chief-financial-officer-phone-858-373-1500-e-mail-info-medicinova-com-for-i-mnov-20091112monthly0.5https://www.biopharmawatch.com/news/MNOV/shintaro-asako-chief-financial-officer-phone-858-373-1500-e-mail-info-medicinova-com-rhond-mnov-20090916monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-inc-2009-statements-in-this-presentation-that-are-not-historical-in-nature-cons-mnov-20090904monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-and-avigen-enter-into-definitive-agreement-for-business-combination-san-diego-c-mnov-20090821monthly0.5https://www.biopharmawatch.com/news/MNOV/shintaro-asako-chief-financial-officer-phone-858-373-1500-e-mail-info-medicinova-com-rhond-mnov-20090814monthly0.5https://www.biopharmawatch.com/news/MNOV/shintaro-asako-chief-financial-officer-phone-858-373-1500-e-mail-info-medicinova-com-rhond-mnov-20090713monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-and-avigen-confirm-understanding-for-key-terms-for-a-business-combination-san-d-mnov-20090625monthly0.5https://www.biopharmawatch.com/news/MNOV/shintaro-asako-chief-financial-officer-phone-858-373-1500-e-mail-info-medicinova-com-rhond-mnov-20090622monthly0.5https://www.biopharmawatch.com/news/MNOV/shintaro-asako-chief-financial-officer-phone-858-373-1500-e-mail-info-medicinova-com-rhond-mnov-20090528monthly0.5https://www.biopharmawatch.com/news/MNOV/shintaro-asako-chief-financial-officer-phone-858-373-1500-e-mail-info-medicinova-com-rhond-mnov-20090515monthly0.5https://www.biopharmawatch.com/news/MNOV/shintaro-asako-chief-financial-officer-phone-858-373-1500-e-mail-info-medicinova-com-rhond-mnov-20090331monthly0.5https://www.biopharmawatch.com/news/MNOV/shintaro-asako-chief-financial-officer-phone-858-373-1500-e-mail-info-medicinova-com-for-i-mnov-20090324monthly0.5https://www.biopharmawatch.com/news/MNOV/shintaro-asako-chief-financial-officer-phone-858-373-1500-e-mail-info-medicinova-com-for-i-mnov-20090319monthly0.5https://www.biopharmawatch.com/news/MNOV/shintaro-asako-chief-financial-officer-phone-858-373-1500-e-mail-info-medicinova-com-for-i-mnov-20090312monthly0.5https://www.biopharmawatch.com/news/MNOV/shintaro-asako-chief-financial-officer-phone-858-373-1500-e-mail-info-medicinova-com-for-i-mnov-20090209monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-inc-2009-statements-in-this-presentation-that-are-not-historical-in-nature-cons-mnov-20090112monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-inc-4350-la-jolla-village-drive-suite-950-san-diego-ca-92122-mnov-20081222monthly0.5https://www.biopharmawatch.com/news/MNOV/shintaro-asako-chief-financial-officer-phone-858-373-1500-e-mail-info-medicinova-com-rhond-mnov-20081110monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-inc-2008-statements-in-this-presentation-that-are-not-historical-in-nature-cons-mnov-20081110monthly0.5https://www.biopharmawatch.com/news/MNOV/shintaro-asako-chief-financial-officer-phone-858-373-1500-e-mail-info-medicinova-com-rhond-mnov-20080811monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-inc-2008-statements-in-this-presentation-that-are-not-historical-in-nature-cons-mnov-20080625monthly0.5https://www.biopharmawatch.com/news/MNOV/shintaro-asako-chief-financial-officer-phone-858-373-1500-e-mail-info-medicinova-com-rhond-mnov-20080512monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-inc-2008-2-statements-in-this-presentation-that-are-not-historical-in-nature-co-mnov-20080429monthly0.5https://www.biopharmawatch.com/news/MNOV/shintaro-asako-chief-financial-officer-phone-858-373-1500-e-mail-info-medicinova-com-rhond-mnov-20080317monthly0.5https://www.biopharmawatch.com/news/MNOV/shintaro-asako-chief-financial-officer-phone-858-373-1500-e-mail-info-medicinova-com-rhond-mnov-20080208monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-inc-2008-2-this-presentation-contains-forward-looking-statements-that-involve-r-mnov-20080107monthly0.5https://www.biopharmawatch.com/news/MNOV/shintaro-asako-chief-financial-officer-phone-858-373-1500-e-mail-info-medicinova-com-rhond-mnov-20071109monthly0.5https://www.biopharmawatch.com/news/MNOV/shintaro-asako-chief-financial-officer-medicinova-inc-phone-858-373-1500-e-mail-info-medic-mnov-20071108monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-inc-2007-2-this-presentation-contains-forward-looking-statements-that-involve-r-mnov-20071010monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-inc-2007-2-this-presentation-contains-forward-looking-statements-that-involve-r-mnov-20070926monthly0.5https://www.biopharmawatch.com/news/MNOV/shintaro-asako-chief-financial-officer-phone-858-373-1500-e-mail-info-medicinova-com-rhond-mnov-20070809monthly0.5https://www.biopharmawatch.com/news/MNOV/non-confidential-presentation-july-2007-2-this-presentation-contains-forward-looking-state-mnov-20070724monthly0.5https://www.biopharmawatch.com/news/MNOV/shintaro-asako-chief-financial-officer-phone-858-373-1500-e-mail-info-medicinova-com-rhond-mnov-20070626monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-inc-2007-this-presentation-may-contain-forward-looking-statements-within-the-me-mnov-20070530monthly0.5https://www.biopharmawatch.com/news/MNOV/shintaro-asako-chief-financial-officer-phone-858-373-1500-info-medicinova-com-bonnie-feldm-mnov-20070510monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-inc-mnov-20070329monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-inc-2007-this-presentation-may-contain-forward-looking-statements-within-the-me-mnov-20070330monthly0.5https://www.biopharmawatch.com/news/MNOV/kenneth-w-locke-ph-d-chief-business-officer-e-mail-locke-medicinova-com-bonnie-feldman-d-d-mnov-20070329monthly0.5https://www.biopharmawatch.com/news/MNOV/bonnie-feldman-vice-president-of-investor-relations-medicinova-inc-phone-858-373-8000-e-ma-mnov-20070129monthly0.5https://www.biopharmawatch.com/news/MNOV/shintaro-asako-vice-president-and-cfo-medicinova-inc-phone-858-373-1500-e-mail-info-medici-mnov-20061109monthly0.5https://www.biopharmawatch.com/news/MNOV/kenneth-w-locke-ph-d-chief-business-officer-medicinova-inc-phone-858-373-1200-e-mail-locke-mnov-20061031monthly0.5https://www.biopharmawatch.com/news/MNOV/shintaro-asako-medicinova-inc-phone-858-373-1500-e-mail-asako-medicinova-com-for-immediate-mnov-20061015monthly0.5https://www.biopharmawatch.com/news/MNOV/shintaro-asako-medicinova-inc-phone-858-373-1500-e-mail-asako-medicinova-com-for-immediate-mnov-20060614monthly0.5https://www.biopharmawatch.com/news/MNOV/kenneth-w-locke-ph-d-chief-business-officer-medicinova-inc-phone-858-373-1200-e-mail-locke-mnov-20060613monthly0.5https://www.biopharmawatch.com/news/MNOV/kenneth-w-locke-ph-d-chief-business-officer-medicinova-inc-phone-858-373-1200-e-mail-locke-mnov-20060611monthly0.5https://www.biopharmawatch.com/news/MNOV/kenneth-w-locke-ph-d-chief-business-officer-medicinova-inc-phone-858-373-1200-e-mail-locke-mnov-20060604monthly0.5https://www.biopharmawatch.com/news/MNOV/shintaro-asako-medicinova-inc-phone-858-373-1500-e-mail-asako-medicinova-com-for-immediate-mnov-20060511monthly0.5https://www.biopharmawatch.com/news/MNOV/shintaro-asako-medicinova-inc-phone-858-373-1500-e-mail-asako-medicinova-com-for-immediate-mnov-20060112monthly0.5https://www.biopharmawatch.com/news/MNOV/kenneth-w-locke-ph-d-chief-business-officer-medicinova-inc-phone-858-373-1200-e-mail-locke-mnov-20051213monthly0.5https://www.biopharmawatch.com/news/MNOV/shintaro-asako-medicinova-inc-phone-858-373-1500-e-mail-asako-medicinova-com-for-immediate-mnov-20051205monthly0.5https://www.biopharmawatch.com/news/MNOV/shintaro-asako-medicinova-inc-phone-858-373-1500-email-asako-medicinova-com-for-immediate--mnov-20050930monthly0.5https://www.biopharmawatch.com/news/MNOV/brian-anderson-medicinova-inc-phone-858-622-9752-email-banderson-medicinova-com-for-immedi-mnov-20050921monthly0.5https://www.biopharmawatch.com/news/MNOV/brian-anderson-medicinova-inc-phone-858-622-9752-email-banderson-medicinova-com-for-immedi-mnov-20050907monthly0.5https://www.biopharmawatch.com/news/MNOV/financial-statements-for-the-six-months-ended-mnov-20050815monthly0.5https://www.biopharmawatch.com/news/MNOV/brian-anderson-medicinova-inc-phone-858-622-9752-email-banderson-medicinova-com-for-immedi-mnov-20050802monthly0.5https://www.biopharmawatch.com/news/MNOV/brian-anderson-medicinova-inc-phone-858-622-9752-email-banderson-medicinova-com-for-immedi-mnov-20050725monthly0.5https://www.biopharmawatch.com/news/MNOV/brian-anderson-medicinova-inc-phone-858-622-9752-email-banderson-medicinova-com-for-immedi-mnov-20050617monthly0.5https://www.biopharmawatch.com/news/MNOV/brian-anderson-medicinova-inc-phone-858-622-9752-email-banderson-medicinova-com-for-immedi-mnov-20050524monthly0.5https://www.biopharmawatch.com/news/MNOV/brian-anderson-medicinova-inc-phone-858-622-9752-email-banderson-medicinova-com-for-immedi-mnov-20050328monthly0.5https://www.biopharmawatch.com/news/MNOV/brian-anderson-medicinova-inc-phone-858-622-9752-email-banderson-medicinova-com-for-immedi-mnov-20050322monthly0.5https://www.biopharmawatch.com/news/MNOV/financial-statements-for-the-year-ended-mnov-20050322monthly0.5https://www.biopharmawatch.com/news/MNOV/brian-anderson-medicinova-inc-phone-858-622-9752-email-banderson-medicinova-com-for-immedi-mnov-20050314monthly0.5https://www.biopharmawatch.com/news/MNOV/brian-anderson-medicinova-inc-phone-858-622-9752-email-banderson-medicinova-com-for-immedi-mnov-20050310monthly0.5https://www.biopharmawatch.com/news/MNOV/brian-anderson-medicinova-inc-phone-858-622-9752-email-banderson-medicinova-com-for-immedi-mnov-20050308monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-announces-the-start-of-a-phase-ii-clinical-trial-with-novel-anti-anxiety-agent--mnov-20050301monthly0.5https://www.biopharmawatch.com/news/MNOV/medicinova-inc-closes-initial-public-offering-san-diego-mnov-20050208monthly0.5https://www.biopharmawatch.com/news/ENTX/entera-bio-announces-management-changes-boston-massachusetts-jerusalem-israel-entx-20200810monthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-announces-first-quarter-2026-financial-results-halneuron-phase-2b-tri-dwtx-20260514monthly0.5https://www.biopharmawatch.com/news/DWTX/ceo-letter-to-dogwood-therapeutics-shareholders-first-quarter-2026-progress-report-alphare-dwtx-20260326monthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-atlanta-g-dwtx-20260318monthly0.5https://www.biopharmawatch.com/news/DWTX/ceo-letter-to-dogwood-therapeutics-shareholders-the-year-in-review-the-year-ahead-alpharet-dwtx-20260120monthly0.5https://www.biopharmawatch.com/news/DWTX/nasdaq-dwtx-q4-2025-update-deep-commitment-to-advancing-first-in-class-new-therapeutic-tre-dwtx-20251009monthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-reports-second-quarter-2025-financial-results-enrollment-to-date-of-5-dwtx-20250813monthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-announces-first-quarter-2025-financial-results-dogwood-therapeutics-i-dwtx-20250508monthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-inc-regains-nasdaq-compliance-atlanta-ga-dwtx-20250403monthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-announces-fourth-quarter-and-full-year-2024-financial-results-dogwood-dwtx-20250331monthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-inc-announces-pricing-of-4-8-million-registered-direct-offering-of-co-dwtx-20250313monthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-inc-announces-conversion-of-existing-19-5m-in-debt-to-equity-strength-dwtx-20250312monthly0.5https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-announces-third-quarter-2024-financial-results-dogwood-therapeutics-i-dwtx-20241107monthly0.5https://www.biopharmawatch.com/news/DWTX/facebook-https-www-facebook-com-dogwoodther-forward-looking-statements-statements-in-this--dwtx-20241030monthly0.5https://www.biopharmawatch.com/news/DWTX/virios-therapeutics-inc-and-wex-pharmaceuticals-inc-announce-business-combination-to-form--dwtx-20241009monthly0.5https://www.biopharmawatch.com/news/DWTX/virios-therapeutics-announces-second-quarter-2024-financial-results-bateman-horne-center-c-dwtx-20240808monthly0.5https://www.biopharmawatch.com/news/DWTX/virios-therapeutics-announces-pricing-of-1-7-million-public-offering-of-common-stock-to-co-dwtx-20240519monthly0.5https://www.biopharmawatch.com/news/DWTX/virios-therapeutics-announces-first-quarter-2024-financial-results-and-provides-corporate--dwtx-20240509monthly0.5https://www.biopharmawatch.com/news/DWTX/virios-therapeutics-announces-fourth-quarter-and-full-year-2023-financial-results-atlanta--dwtx-20240229monthly0.5https://www.biopharmawatch.com/news/DWTX/virios-therapeutics-announces-third-quarter-2023-financial-results-and-provides-corporate--dwtx-20231113monthly0.5https://www.biopharmawatch.com/news/DWTX/virios-therapeutics-announces-second-quarter-2023-financial-results-and-provides-corporate-dwtx-20230810monthly0.5https://www.biopharmawatch.com/news/DWTX/virios-therapeutics-announces-plans-to-advance-lead-candidate-imc-1-to-phase-3-development-dwtx-20230809monthly0.5https://www.biopharmawatch.com/news/DWTX/virios-therapeutics-announces-positive-data-demonstrating-improvement-in-multiple-long-cov-dwtx-20230717monthly0.5https://www.biopharmawatch.com/news/DWTX/sent-via-electronic-delivery-to-angela-virios-com-dwtx-20230524monthly0.5https://www.biopharmawatch.com/news/DWTX/virios-therapeutics-announces-first-quarter-2023-financial-results-atlanta-ga-dwtx-20230511monthly0.5https://www.biopharmawatch.com/news/DWTX/virios-therapeutics-announces-fourth-quarter-and-full-year-2022-financial-results-atlanta--dwtx-20230314monthly0.5https://www.biopharmawatch.com/news/DWTX/new-scientific-paradigm-exploring-herpes-virus-activation-as-potential-underlying-cause-of-dwtx-20221116monthly0.5https://www.biopharmawatch.com/news/DWTX/virios-therapeutics-announces-third-quarter-2022-financial-results-and-provides-corporate--dwtx-20221114monthly0.5https://www.biopharmawatch.com/news/DWTX/virios-therapeutics-inc-announces-proposed-public-offering-atlanta-ga-dwtx-20220919monthly0.5https://www.biopharmawatch.com/news/DWTX/virios-therapeutics-announces-top-line-results-from-phase-2b-study-of-imc-1-in-fibromyalgi-dwtx-20220919monthly0.5https://www.biopharmawatch.com/news/DWTX/virios-therapeutics-announces-second-quarter-2022-financial-results-and-provides-corporate-dwtx-20220811monthly0.5https://www.biopharmawatch.com/news/DWTX/virios-therapeutics-announces-first-quarter-2022-financial-results-and-provides-corporate--dwtx-20220512monthly0.5https://www.biopharmawatch.com/news/DWTX/virios-therapeutics-announces-fourth-quarter-and-full-year-2021-financial-results-and-prov-dwtx-20220317monthly0.5https://www.biopharmawatch.com/news/DWTX/hsv-1virus-virios-therapeutics-inc-nasdaq-virinew-scientific-paradigm-exploringherpes-viru-dwtx-20220301monthly0.5https://www.biopharmawatch.com/news/DWTX/virios-therapeutics-announces-third-quarter-2021-financial-results-and-provides-corporate--dwtx-20211111monthly0.5https://www.biopharmawatch.com/news/DWTX/hsv-x2010-1-virus-virios-therapeutics-inc-nasdaq-x201c-viri-x201d-new-scientific-paradigm--dwtx-20211012monthly0.5https://www.biopharmawatch.com/news/DWTX/virios-therapeutics-announces-second-quarter-2021-financial-results-and-provides-corporate-dwtx-20210812monthly0.5https://www.biopharmawatch.com/news/DWTX/hsv-1-virus-virios-therapeutics-inc-nasdaq-x201c-viri-x201d-new-scientific-paradigm-explor-dwtx-20210514monthly0.5https://www.biopharmawatch.com/news/DWTX/virios-therapeutics-announces-first-quarter-2021-financial-results-and-provides-corporate--dwtx-20210513monthly0.5https://www.biopharmawatch.com/news/DWTX/hsv-1-virus-virios-therapeutics-inc-nasdaq-x201c-viri-x201d-new-scientific-paradigm-explor-dwtx-20210323monthly0.5https://www.biopharmawatch.com/news/DWTX/virios-therapeutics-announces-fourth-quarter-and-full-year-2020-financial-results-and-prov-dwtx-20210318monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-announces-key-appointment-of-industry-veteran-to-board-of-directors-m-actu-20260506monthly0.5https://www.biopharmawatch.com/news/ACTU/transcript-of-key-opinion-leader-event-event-details-date-2025-05-31-company-actuate-thera-actu-20250605monthly0.5https://www.biopharmawatch.com/news/ACTU/corporate-overview-actu-20250531monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-announces-statistically-significant-topline-results-from-global-phase-actu-20250506monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-announces-positive-interim-phase-2-data-of-elraglusib-in-first-line-t-actu-20241217monthly0.5https://www.biopharmawatch.com/news/ACTU/actuate-announces-fda-rare-pediatric-disease-designation-granted-to-elraglusib-for-treatme-actu-20241112monthly0.5https://www.biopharmawatch.com/news/FLNA/cassava-sciences-announces-50-million-registered-direct-offering-of-common-stock-xfeff-aus-flna-20221122monthly0.5https://www.biopharmawatch.com/news/FLNA/cassava-sciences-files-lawsuit-against-perpetrators-of-x201c-short-and-distort-x201d-campa-flna-20221103monthly0.5https://www.biopharmawatch.com/news/FLNA/cassava-sciences-announces-expansion-of-leadership-team-xfeff-xb7-chris-cook-a-skilled-lit-flna-20221027monthly0.5https://www.biopharmawatch.com/news/FLNA/xfeff-encouraging-interim-results-at-9-months-from-an-open-label-study-of-simufilam-in-pat-flna-20210803monthly0.5https://www.biopharmawatch.com/news/FLNA/xfeff-xfeff-xfeff-cassava-sciences-selects-clinical-research-organization-for-phase-3-clin-flna-20210621monthly0.5https://www.biopharmawatch.com/news/FLNA/xfeff-cassava-sciences-announces-the-appointment-of-xfeff-richard-j-barry-to-its-board-of--flna-20210611monthly0.5https://www.biopharmawatch.com/news/FLNA/xfeff-xfeff-cassava-sciences-announces-pharmaceutical-supply-agreement-for-simufilam-xfeff-flna-20210311monthly0.5https://www.biopharmawatch.com/news/FLNA/xfeff-cassava-sciences-announces-200-million-registered-direct-offering-of-common-stock-xf-flna-20210210monthly0.5https://www.biopharmawatch.com/news/FLNA/xfeff-cassava-sciences-we-focus-on-alzheimer-s-disease-february-2021-cassava-sciences-1-xf-flna-20210208monthly0.5https://www.biopharmawatch.com/news/FLNA/xfeff-cassava-sciences-appoints-dr-james-kupiec-as-chief-clinical-development-officer-xfef-flna-20210104monthly0.5https://www.biopharmawatch.com/news/FLNA/xfeff-cassava-sciences-announces-proposed-public-offering-of-common-stock-xfeff-austin-tex-flna-20201113monthly0.5https://www.biopharmawatch.com/news/FLNA/xfeff-sumifilam-significantly-improves-eleven-csf-biomarkers-in-a-randomized-placebo-contr-flna-20201107monthly0.5https://www.biopharmawatch.com/news/FLNA/xfeff-cassava-sciences-final-results-of-a-phase-2b-study-of-sumifilam-in-alzheimer-s-disea-flna-20200914monthly0.5https://www.biopharmawatch.com/news/FLNA/xfeff-cassava-sciences-one-month-oral-treatment-with-pti-125-a-new-drug-candidate-reduces--flna-20191205monthly0.5https://www.biopharmawatch.com/news/FLNA/pain-therapeutics-inc-xfeff-xfeff-xfeff-xfeff-pain-therapeutics-announces-name-change-to-c-flna-20190328monthly0.5https://www.biopharmawatch.com/news/FLNA/xfeff-xfeff-pain-therapeutics-inc-xfeff-xfeff-pain-therapeutics-announces-feedback-from-re-flna-20190131monthly0.5https://www.biopharmawatch.com/news/FLNA/xfeff-pain-therapeutics-inc-xfeff-for-more-information-contact-ruth-araya-pain-therapeutic-flna-20181011monthly0.5https://www.biopharmawatch.com/news/FLNA/xfeff-xfeff-pain-therapeutics-inc-overview-of-neuroprotection-program-non-confidential-oct-flna-20181004monthly0.5https://www.biopharmawatch.com/news/FLNA/xfeff-pain-therapeutics-inc-xfeff-xfeff-for-more-information-contact-ruth-araya-pain-thera-flna-20180820monthly0.5https://www.biopharmawatch.com/news/FLNA/xfeff-pain-therapeutics-inc-xfeff-for-more-information-contact-ruth-araya-pain-therapeutic-flna-20170510monthly0.5https://www.biopharmawatch.com/news/FLNA/jfif-d-d-ducky-2-adobe-d-flna-20130510monthly0.5https://www.biopharmawatch.com/news/FLNA/v073384-ex991-txt-pain-therapeutics-announces-first-quarter-2007-financial-results-south-s-flna-20070502monthly0.5https://www.biopharmawatch.com/news/FLNA/pain-therapeutics-announces-fourth-quarter-and-year-end-2006-financial-results-south-san-f-flna-20070205monthly0.5https://www.biopharmawatch.com/news/FLNA/pain-therapeutics-announces-third-quarter-2006-flna-20061025monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-inc-reports-first-quarter-2026-financial-results-and-provides-an-update-of-comme-cing-20260514monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-inc-reports-fourth-quarter-and-full-year-2025-financial-results-and-operational--cing-20260318monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-inc-reports-second-quarter-2025-financial-results-and-provides-recent-highlights-cing-20250819monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-inc-reports-first-quarter-2025-financial-results-and-provides-an-updated-timelin-cing-20250508monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-receives-3-million-grant-from-private-foundation-to-accelerate-development-of-an-cing-20250409monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-inc-reports-full-year-2024-fourth-quarter-results-and-provides-development-updat-cing-20250326monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-reports-safety-results-from-final-phase-3-trials-for-lead-adhd-asset-ctx-1301-on-cing-20250304monthly0.5https://www.biopharmawatch.com/news/CING/final-study-completed-for-cingulate-s-lead-asset-ctx-1301-no-serious-adverse-events-report-cing-20250107monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-completes-financing-transaction-for-net-proceeds-of-5-000-000-cash-runway-extend-cing-20241223monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-reports-third-quarter-2024-financial-results-reflecting-19-5-million-increase-in-cing-20241107monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-initiates-final-study-for-lead-adhd-asset-ctx-1301-10-million-of-additional-capi-cing-20240912monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-reports-second-quarter-2024-financial-results-and-provides-development-update-on-cing-20240813monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-announces-exercise-of-warrants-for-1-86-million-gross-proceeds-kansas-city-kan-cing-20240628monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-reports-first-quarter-2024-financial-results-and-provides-clinical-and-business--cing-20240508monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-inc-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-cli-cing-20240401monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-appoints-jay-roberts-bryan-lawrence-and-jeff-ervin-to-its-board-of-directors-ann-cing-20240213monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-announces-pricing-of-7-5-million-public-offering-cing-20240202monthly0.5https://www.biopharmawatch.com/news/CING/werth-family-investment-associates-converts-remaining-3-3m-of-debt-and-accrued-interest-in-cing-20240129monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-inc-reports-third-quarter-2023-financial-results-and-provides-clinical-and-busin-cing-20231113monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-to-host-cns-key-opinion-leader-panel-in-new-york-city-expert-analysis-of-cingula-cing-20231017monthly0.5https://www.biopharmawatch.com/news/CING/werth-family-investment-associates-converts-5-8-million-of-debt-into-cingulate-equity-at-a-cing-20230908monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-inc-reports-second-quarter-2023-financial-results-and-provides-clinical-and-busi-cing-20230814monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-announces-positive-top-line-results-from-phase-3-adult-efficacy-and-safety-trial-cing-20230711monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-successfully-manufactures-clinical-supply-initiation-of-pediatric-phase-3-studie-cing-20230629monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-completes-phase-3-adult-trial-of-ctx-1301-dexmethylphenidate-for-adhd-study-asse-cing-20230608monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-inc-reports-first-quarter-2023-financial-results-and-provides-clinical-and-busin-cing-20230510monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-announces-successful-transfer-of-ctx-1301-dexmethylphenidate-proprietary-ptr-man-cing-20230503monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-inc-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-cli-cing-20230310monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-inc-reports-third-quarter-2022-financial-results-and-provides-clinical-and-busin-cing-20221114monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-announces-agreement-with-societal-cdmo-and-provides-clinical-update-new-partners-cing-20221024monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-inc-reports-second-quarter-2022-financial-results-and-provides-clinical-and-busi-cing-20220811monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-inc-reports-first-quarter-2022-results-and-provides-clinical-and-business-update-cing-20220512monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-inc-reports-fourth-quarter-and-full-year-2021-results-and-provides-clinical-and--cing-20220310monthly0.5https://www.biopharmawatch.com/news/CING/cingulate-provides-2022-clinical-plan-for-ctx-1301-an-investigational-medication-for-atten-cing-20220208monthly0.5https://www.biopharmawatch.com/news/SCYX/advancing-innovative-solutions-for-severe-rare-diseases-corporate-deck-march-2026-legal-di-scyx-20260331monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-40-0-million-private-placement-scyx-20260331monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-completes-transformative-acquisition-of-pxl-770-an-innovative-highly-selective-di-scyx-20260331monthly0.5https://www.biopharmawatch.com/news/SCYX/a-dynamic-force-in-the-fight-against-infectious-disease-september-2024-forward-looking-sta-scyx-20240910monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-full-year-2023-financial-results-and-provides-corporate-update-x2022-scy--scyx-20240328monthly0.5https://www.biopharmawatch.com/news/SCYX/a-dynamic-force-in-the-fight-against-infectious-disease-january-2024-forward-looking-state-scyx-20240105monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-third-quarter-2022-financial-results-and-provides-corporate-update-x2022--scyx-20221109monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-second-quarter-2022-financial-results-and-provides-corporate-update-brexa-scyx-20220815monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-first-quarter-2022-financial-results-and-provides-corporate-update-brexaf-scyx-20220512monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-corporat-scyx-20220329monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-reports-third-quarter-2021-financial-results-and-provides-corporate-update-brexaf-scyx-20211110monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-announces-positive-top-line-results-from-its-second-pivotal-phase-3-study-vanish--scyx-20200421monthly0.5https://www.biopharmawatch.com/news/SCYX/scyx-ex991-6-pptx-htm-corporate-presentation-aug-2018-ibrexafungerp-formerly-scy-078-first-scyx-20180809monthly0.5https://www.biopharmawatch.com/news/SCYX/scyx-ex991-6-pptx-htm-scy-078-first-representative-of-a-novel-oral-iv-triterpenoid-antifun-scyx-20180305monthly0.5https://www.biopharmawatch.com/news/SCYX/scyx-ex991-72-pptx-htm-scy-078-first-representative-of-a-novel-oral-iv-triterpenoid-antifu-scyx-20180108monthly0.5https://www.biopharmawatch.com/news/SCYX/employment-agreement-this-employment-agreement-agreement-effecti-v-e-a-s-o-f-scyx-20151101monthly0.5https://www.biopharmawatch.com/news/SCYX/to-form-8-k-the-fair-value-of-the-warrants-issued-in-connection-with-our-series-d-2-prefer-scyx-20151030monthly0.5https://www.biopharmawatch.com/news/SCYX/unaudited-condensed-pro-forma-financial-statements-as-disclosed-within-the-current-report--scyx-20150723monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-unaudited-pro-forma-condensed-financial-statements-as-disclosed-in-our-annual-scyx-20150409monthly0.5https://www.biopharmawatch.com/news/SCYX/scynexis-inc-january-2015-1-certain-statements-regarding-scynexis-inc-the-company-made-in--scyx-20150109monthly0.5https://www.biopharmawatch.com/news/TIL/document-instil-bio-reports-third-quarter-2022-financial-results-and-provides-corporate-up-til-20221114monthly0.5https://www.biopharmawatch.com/news/TIL/document-instil-bio-reports-second-quarter-2022-financial-results-and-provides-corporate-u-til-20220812monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-first-quarter-2026-unaudited-financial-results-continuing-transition-toward--yi-20260604monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-fourth-quarter-and-fiscal-year-2025-financial-results-continuing-transition--yi-20260409monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-third-quarter-2025-unaudited-financial-results-transition-from-an-asset-heav-yi-20251217monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-second-quarter-2025-unaudited-financial-results-maintained-quarterly-operati-yi-20250917monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-first-quarter-2025-unaudited-financial-results-maintained-quarterly-operatio-yi-20250619monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-fourth-quarter-and-fiscal-year-2024-financial-results-achieved-first-ever-an-yi-20250320monthly0.5https://www.biopharmawatch.com/news/YI/inc-regains-compliance-with-nasdaq-requirement-shanghai-yi-20250211monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-ads-ratio-change-shanghai-yi-20250108monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-third-quarter-2024-unaudited-financial-results-maintained-operational-profit-yi-20241127monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-change-to-board-of-directors-shanghai-yi-20241104monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-second-quarter-2024-unaudited-financial-results-maintained-operational-profi-yi-20240829monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-first-quarter-2024-unaudited-financial-results-turned-to-quarterly-operation-yi-20240523monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-fourth-quarter-and-fiscal-year-2023-financial-results-shanghai-yi-20240321monthly0.5https://www.biopharmawatch.com/news/YI/announces-receipt-of-withdrawal-of-going-private-proposal-111-inc-111-or-the-company-nasda-yi-20240227monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-third-quarter-2023-unaudited-financial-results-shanghai-yi-20231130monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-second-quarter-2023-unaudited-financial-results-shanghai-yi-20230824monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-first-quarter-2023-unaudited-financial-results-shanghai-yi-20230615monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-fourth-quarter-and-fiscal-year-2022-financial-results-shanghai-yi-20230323monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-third-quarter-2022-unaudited-financial-results-shanghai-yi-20221201monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-appointment-of-independent-financial-advisor-and-legal-counsel-to-the-specia-yi-20220923monthly0.5https://www.biopharmawatch.com/news/YI/inc-receives-unsolicited-preliminary-non-binding-proposal-to-acquire-the-company-shanghai-yi-20220909monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-second-quarter-2022-unaudited-financial-results-shanghai-yi-20220825monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-first-quarter-2022-unaudited-financial-results-shanghai-yi-20220616monthly0.5https://www.biopharmawatch.com/news/YI/inc-provides-updates-on-its-status-under-the-holding-foreign-companies-accountable-act-sha-yi-20220505monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-fourth-quarter-and-fiscal-year-2021-financial-results-shanghai-yi-20220317monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-third-quarter-2021-unaudited-financial-results-shanghai-yi-20211119monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-10-million-share-repurchase-program-shanghai-sept-7-2021-prnewswire-111-inc--yi-20210907monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-second-quarter-2021-unaudited-financial-results-shanghai-yi-20210827monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-first-quarter-2021-unaudited-financial-results-shanghai-yi-20210519monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-fourth-quarter-and-fiscal-year-2020-unaudited-financial-results-shanghai-yi-20210318monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-additional-round-of-new-capital-injection-led-by-esteemed-list-of-technology-yi-20201222monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-third-quarter-2020-unaudited-financial-results-shanghai-yi-20201119monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-new-capital-injection-and-strategic-plan-to-expand-access-to-china-s-capital-yi-20200820monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-first-quarter-2020-unaudited-financial-results-shanghai-yi-20200521monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-fourth-quarter-and-fiscal-year-2019-unaudited-financial-results-shanghai-chi-yi-20200312monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-third-quarter-2019-unaudited-financial-results-shanghai-china-november-14-20-yi-20191115monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-second-quarter-2019-unaudited-financial-results-and-us-10-million-share-repu-yi-20190815monthly0.5https://www.biopharmawatch.com/news/YI/announces-changes-to-its-board-of-directors-shanghai-yi-20190516monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-first-quarter-2019-unaudited-financial-results-shanghai-china-may-16-2019-11-yi-20190516monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-fourth-quarter-and-fiscal-year-2018-unaudited-financial-results-shanghai-chi-yi-20190307monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-the-appointment-of-a-new-chief-financial-officer-yi-20190227monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-management-and-board-changes-yi-20190118monthly0.5https://www.biopharmawatch.com/news/YI/inc-announces-third-quarter-2018-unaudited-financial-results-shanghai-china-yi-20181108monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-17-5-million-private-placement-of-common-stock-priced-at-the-market--drio-20250922monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-20-to-1-reverse-stock-split-drio-20250825monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-appoints-healthcare-industry-leader-larry-leisure-to-board-of-directors-health-drio-20250227monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-25-6m-private-placement-positioning-the-company-to-execute-on-strate-drio-20250121monthly0.5https://www.biopharmawatch.com/news/DRIO/a-comprehensive-user-centric-digital-health-platform-dariohealth-corp-feb-21st-2024-2-01-t-drio-20240222monthly0.5https://www.biopharmawatch.com/news/DRIO/investors-day-dariohealth-corp-nasdaq-drio-october-17th-2023-01-this-presentation-of-dario-drio-20231017monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-launches-agreement-with-large-regional-health-plan-and-announces-preliminary-results-drio-20230724monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-14-3-million-private-placement-newly-designated-convertible-preferre-drio-20230502monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-appoints-industry-veteran-jon-kaplan-to-board-mr-kaplan-brings-a-wealth-of-experienc-drio-20230223monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-preliminary-fourth-quarter-and-full-year-2022-operating-results-prel-drio-20230206monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-second-quarter-2022-financial-and-operating-results-q2-revenue-of-6-2--drio-20220815monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-secures-50-million-dollar-non-dilutive-credit-facility-with-orbimed-investment-drio-20220609monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-enters-into-strategic-agreement-with-sanofi-u-s-novel-strategic-agreement-focu-drio-20220301monthly0.5https://www.biopharmawatch.com/news/DRIO/dario-health-investors-day-jan-19-th-2022-this-presentation-and-the-statements-of-represen-drio-20211231monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-strong-second-quarter-2021-results-and-operational-highlights-total-q2-drio-20210816monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-closing-of-wayforward-acquisition-new-york-june-8-2021-dariohealth-c-drio-20210608monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-corp-nasdaq-drio-ai-powered-digital-solutions-that-drive-durable-behavior-chan-drio-20210204monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-announces-acquisition-of-leading-digital-musculoskeletal-company-upright-techn-drio-20210127monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-corp-live-therapeutics-for-better-life-forward-looking-statements-this-present-drio-20190521monthly0.5https://www.biopharmawatch.com/news/DRIO/dariohealth-corp-prices-offering-of-1-450-000-drio-20170331monthly0.5https://www.biopharmawatch.com/news/DRIO/digital-health-innovators-company-overview-july-2016-drio-20160727monthly0.5https://www.biopharmawatch.com/news/DRIO/labstyle-innovations-corp-drio-20150515monthly0.5https://www.biopharmawatch.com/news/DRIO/labstyle-innovations-raises-1-6-million-in-a-non-brokered-private-placement-financing-proc-drio-20150225monthly0.5https://www.biopharmawatch.com/news/DRIO/labstyle-innovations-appoints-zvi-ben-david-as-new-chief-financial-officer-brings-25-years-drio-20150108monthly0.5https://www.biopharmawatch.com/news/DRIO/labstyle-innovations-closes-4-2-million-drio-20140924monthly0.5https://www.biopharmawatch.com/news/DRIO/labstyle-innovations-corp-9-halamish-street-caesarea-industrial-park-38900-israel-suppleme-drio-20140519monthly0.5https://www.biopharmawatch.com/news/DRIO/labstyle-innovations-corp-9-halamish-street-caesarea-industrial-park-38900-israel-drio-20140508monthly0.5https://www.biopharmawatch.com/news/DRIO/labstyle-innovations-announces-pricing-of-4-19-million-private-placement-financing-caesare-drio-20140213monthly0.5https://www.biopharmawatch.com/news/DRIO/labstyle-innovations-appoints-mr-gadi-levin-as-chief-financial-officer-experienced-public--drio-20131127monthly0.5https://www.biopharmawatch.com/news/DRIO/marjie-hadad-press-investor-relations-labstyle-innovations-booke-and-company-inc-972-54-53-drio-20131114monthly0.5https://www.biopharmawatch.com/news/DRIO/labstyle-innovations-announces-internal-management-changes-in-anticipation-of-commercial-l-drio-20130812monthly0.5https://www.biopharmawatch.com/news/DRIO/labstyle-innovations-appoints-renowned-diabetes-expert-to-its-board-of-directors-appointme-drio-20130625monthly0.5https://www.biopharmawatch.com/news/DRIO/labstyle-innovations-closes-10-million-financing-funds-will-support-the-anticipated-europe-drio-20130510monthly0.5https://www.biopharmawatch.com/news/DRIO/labstyle-innovations-signs-distribution-agreement-for-dario-in-the-united-kingdom-with-far-drio-20130425monthly0.5https://www.biopharmawatch.com/news/DRIO/jfif-c-c-y-1a-qa-q-2-b-r-3br-456789-cdef-drio-20130412monthly0.5https://www.biopharmawatch.com/news/RADX/appendix-3h-notification-of-cessation-of-securities-announcement-summary-entity-name-radio-radx-20260603monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-1-may-2026-financial-services-and-company-secretary-changes-sydney-austra-radx-20260501monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-23-april-2026-radiopharm-theranostics-reports-business-update-completed-e-radx-20260423monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-radx-20260420monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-16-april-2026-radiopharm-theranostics-completes-enrollment-in-u-s-phase-2-radx-20260416monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-radx-20260408monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-7-april-2026-radiopharm-theranostics-and-siemens-healthineers-sign-clinic-radx-20260407monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-27-march-2026-radiopharm-theranostics-doses-first-patient-in-phase-1-clin-radx-20260327monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-24-march-2026-radiopharm-theranostics-achieves-primary-endpoint-in-90-of--radx-20260324monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-19-march-2026-radiopharm-to-present-at-nwr-virtual-healthcare-conference--radx-20260319monthly0.5https://www.biopharmawatch.com/news/RADX/rad-theranostics-radiopharm-interim-report-half-year-ended-31december-2025-radx-20260227monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-24-february-2026-radiopharm-theranostics-doses-first-patient-in-phase-1-2-radx-20260224monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-28-january-2026-radiopharm-theranostics-reports-half-year-financial-resul-radx-20260128monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-12-january-2026-rad-increases-ownership-in-radiopharm-ventures-to-87-5-ra-radx-20260112monthly0.5https://www.biopharmawatch.com/news/RADX/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-radx-20251219monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-15-december-2025-radiopharm-theranostics-achieves-primary-endpoint-in-92--radx-20251215monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-3-december-2025-results-of-general-meeting-sydney-australia-wednesday-3-d-radx-20251204monthly0.5https://www.biopharmawatch.com/news/RADX/appendix-3z-final-director-s-interest-notice-rule-3-19a-3-appendix-3z-final-director-s-int-radx-20251125monthly0.5https://www.biopharmawatch.com/news/RADX/november-20-202-5-nasdaq-radx-asx-rad-annual-general-meeting-notice-disclaimer-2-the-infor-radx-20251120monthly0.5https://www.biopharmawatch.com/news/RADX/appendix-3x-initial-director-s-interest-notice-rule-3-19a-1-appendix-3x-initial-director-s-radx-20251119monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-18-november-2025-radiopharm-theranostics-receives-approval-to-initiate-ph-radx-20251118monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-17-november-2025-radiopharm-theranostics-announces-50-enrollment-in-phase-radx-20251117monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-12-november-2025-radiopharm-theranostics-starts-enrollment-of-the-third-c-radx-20251112monthly0.5https://www.biopharmawatch.com/news/RADX/notice-of-extraordinary-general-meeting-radiopharm-theranostics-limited-acn-647-877-889-no-radx-20251104monthly0.5https://www.biopharmawatch.com/news/RADX/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-radx-20251103monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-28-october-2025-quarterly-activities-and-cash-flow-report-quarter-ended-3-radx-20251028monthly0.5https://www.biopharmawatch.com/news/RADX/notice-of-annual-general-meeting-radiopharm-theranostics-limited-acn-647-877-889-notice-of-radx-20251023monthly0.5https://www.biopharmawatch.com/news/RADX/radiopharm-theranostics-completes-a-35-million-placement-and-launches-a-a-5-million-share--radx-20250930monthly0.5https://www.biopharmawatch.com/news/RADX/appendix-3g-notification-of-issue-conversion-or-payment-up-of-unquoted-equity-securities-a-radx-20251007monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-october-1-st-2025-radiopharm-theranostics-receives-positive-recommendatio-radx-20251001monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-radiopharm-theranostics-partners-with-starpharma-on-research-and-option-a-radx-20250930monthly0.5https://www.biopharmawatch.com/news/RADX/radiopharm-theranostics-limited-corporate-governance-statement-30-june-2025-this-corporate-radx-20250917monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-15-september-2025-radiopharm-to-host-pivalate-brain-mets-key-opinion-lead-radx-20250915monthly0.5https://www.biopharmawatch.com/news/RADX/radiopharm-theranostics-limited-appendix-4e-preliminary-final-report-1-company-details-nam-radx-20250829monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-21-august-2025-radiopharm-to-host-key-opinion-leader-webinar-series-sydne-radx-20250821monthly0.5https://www.biopharmawatch.com/news/RADX/appendix-3g-notification-of-issue-conversion-or-payment-up-of-unquoted-equity-securities-a-radx-20250801monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-29-july-2025-radiopharm-theranostics-reports-fiscal-year-2025-financial-r-radx-20250729monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-radiopharm-theranostics-receives-ind-approval-from-us-fda-to-initiate-pha-radx-20250728monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-22-july-2025-dr-oliver-sartor-appointed-to-radiopharm-scientific-advisory-radx-20250722monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-radiopharm-receives-4-5m-r-d-tax-incentive-sydney-australia-16-july-2025--radx-20250716monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-radiopharm-theranostics-and-cyclotek-sign-clinical-supply-agreement-for-1-radx-20250624monthly0.5https://www.biopharmawatch.com/news/RADX/appendix-2a-application-for-quotation-of-securities-announcement-summary-entity-name-radio-radx-20250611monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-11-june-2025-radiopharm-theranostics-granted-u-s-food-and-drug-administra-radx-20250611monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-4-june-2025-radiopharm-theranostics-doses-first-patient-in-phase-1-heat-t-radx-20250604monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-radiopharm-theranostics-reports-preclinical-lu177-b7h3-mab-data-demonstra-radx-20250602monthly0.5https://www.biopharmawatch.com/news/RADX/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-radx-20250530monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-19-may-2025-itm-and-radiopharm-sign-supply-agreement-for-n-c-a-lutetium-1-radx-20250519monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-12-may-2025-radiopharm-theranostics-accelerates-177lu-rad204-phase-1-dose-radx-20250512monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-29-april-2025-quarterly-activities-and-cash-flow-report-quarter-ended-31--radx-20250429monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-28-april-2025-radiopharm-theranostics-doses-first-patient-with-18f-rad101-radx-20250428monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-17-march-2025-new-rad202-data-confirms-positive-tumor-uptake-and-favorabl-radx-20250317monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-13-march-2025-radiopharm-participation-in-leerink-nwr-healthcare-conferen-radx-20250313monthly0.5https://www.biopharmawatch.com/news/RADX/appendix-3g-notification-of-issue-conversion-or-payment-up-of-unquoted-equity-securities-u-radx-20250307monthly0.5https://www.biopharmawatch.com/news/RADX/radiopharm-theranostics-limited-appendix-4d-half-year-report-1-company-details-name-of-ent-radx-20250228monthly0.5https://www.biopharmawatch.com/news/RADX/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-radx-20250225monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-24-february-2025-radiopharm-to-present-at-td-cowen-annual-healthcare-conf-radx-20250224monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-18-february-2025-rad-to-participate-in-b-riley-securities-precision-oncol-radx-20250218monthly0.5https://www.biopharmawatch.com/news/RADX/new-clinical-trial-data-highlights-rad-101-18f-pivalate-successfully-detects-brain-metasta-radx-20250210monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-30-january-2025-quarterly-activities-and-cash-flow-report-quarter-ended-3-radx-20250130monthly0.5https://www.biopharmawatch.com/news/RADX/appendix-2a-application-for-quotation-of-securities-announcement-summary-entity-name-radio-radx-20250121monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-09-january-2025-lantheus-increases-to-12-16-shareholding-in-radiopharm-wi-radx-20250110monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-30-december-2024-radiopharm-announces-strategic-co-development-partnershi-radx-20241230monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-20-december-2024-rad-202-receives-approval-to-start-phase-1-therapeutic-t-radx-20241220monthly0.5https://www.biopharmawatch.com/news/RADX/appendix-2a-application-for-quotation-of-securities-announcement-summary-entity-name-radio-radx-20241219monthly0.5https://www.biopharmawatch.com/news/RADX/asx-announcement-10-december-2024-completion-of-preclinical-data-package-for-klk3-targetin-radx-20241210monthly0.5https://www.biopharmawatch.com/news/PDSB/precision-designed-science-for-cancer-patients-nasdaq-pdsb-april-2026-forward-looking-stat-pdsb-20260424monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-publication-of-positive-pds01adc-interim-phase-2-clinical-trial-data-pdsb-20260415monthly0.5https://www.biopharmawatch.com/news/PDSB/precision-designed-science-for-cancer-patients-nasdaq-pdsb-february-2026-forward-looking-s-pdsb-20260223monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-new-composition-of-matter-patent-for-pds0101-in-japan-new-patent-gra-pdsb-20251209monthly0.5https://www.biopharmawatch.com/news/PDSB/precision-designed-science-for-cancer-patients-nasdaq-pdsb-august-2025-forward-looking-sta-pdsb-20250825monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-reports-second-quarter-2025-financial-results-and-provides-clinical-programs-u-pdsb-20250813monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-colorectal-cancer-cohort-of-phase-2-clinical-trial-with-pds01adc-met-pdsb-20250710monthly0.5https://www.biopharmawatch.com/news/PDSB/addressing-the-growing-incidence-of-hpv16-related-cancers-nasdaq-pdsb-june-2025-precision--pdsb-20250625monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-unveils-updated-positive-data-from-versatile-002-trial-and-additional-trials-e-pdsb-20250602monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-positive-extended-follow-up-data-for-versatile-002-and-additional-tr-pdsb-20250522monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-reports-first-quarter-2025-financial-results-and-provides-clinical-programs-an-pdsb-20250514monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-additional-details-on-two-preclinical-universal-influenza-presentati-pdsb-20250508monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-reports-full-year-2024-financial-results-and-provides-clinical-programs-update-pdsb-20250327monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-fda-clearance-of-ind-application-for-combination-of-versamune-muc1-a-pdsb-20250313monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-initiates-versatile-003-phase-3-clinical-trial-evaluating-versamune-hpv-in-hpv-pdsb-20250307monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-up-to-22-million-registered-direct-offering-priced-at-the-market-und-pdsb-20250227monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-positive-clinical-data-demonstrating-compelling-survival-and-clinica-pdsb-20250226monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-circulating-tumor-dna-results-for-versamune-hpv-in-immunocerv-trial--pdsb-20250224monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-reaffirms-guidance-for-first-quarter-initiation-of-versatile-003-phase-3-clini-pdsb-20250205monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-provides-clinical-programs-update-and-reports-third-quarter-2024-financial-res-pdsb-20241114monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-36-month-overall-survival-rate-of-84-4-in-locally-advanced-cervical--pdsb-20241002monthly0.5https://www.biopharmawatch.com/news/PDSB/transforming-how-the-immune-system-targets-and-fights-cancer-to-promote-survival-nasdaq-pd-pdsb-20240826monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-updated-results-from-versatile-002-phase-2-clinical-trial-presented--pdsb-20240916monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-provides-business-update-and-reports-second-quarter-2024-financial-results-pri-pdsb-20240813monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-abstract-accepted-for-oral-presentation-at-2024-astro-annual-meeting-pdsb-20240808monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-to-announce-second-quarter-financial-results-on-pdsb-20240807monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-abstract-accepted-for-presentation-at-esmo-congress-2024-princeton-n-pdsb-20240805monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-aligns-with-fda-on-phase-3-trial-in-hpv16-positive-first-line-recurrent-or-met-pdsb-20240801monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-provides-data-update-from-ongoing-versatile-002-phase-2-clinical-trial-in-head-pdsb-20240612monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-provides-business-update-and-reports-first-quarter-2024-financial-results-prov-pdsb-20240515monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-versatile-002-phase-2-clinical-trial-meets-primary-study-endpoints-in-first-li-pdsb-20240509monthly0.5https://www.biopharmawatch.com/news/PDSB/transforming-how-the-immune-system-targets-and-fights-cancer-to-promote-survival-2024-pds--pdsb-20240508monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-appoints-stephan-toutain-as-chief-operating-officer-reports-inducement-grant-u-pdsb-20240502monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-clinical-strategy-update-and-reports-full-year-2023-financial-result-pdsb-20240327monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-publication-of-preclinical-research-and-grant-of-u-s-composition-of--pdsb-20240313monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-retirement-of-lauren-v-wood-m-d-and-appointment-of-kirk-v-shepard-m--pdsb-20240122monthly0.5https://www.biopharmawatch.com/news/PDSB/developing-transformational-immunotherapies-for-cancer-nasdaq-pdsb-december-2023-forward-l-pdsb-20231204monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-appoints-lars-boesgaard-as-chief-financial-officer-princeton-n-j-november-28-2-pdsb-20231128monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-reports-third-quarter-2023-financial-results-and-provides-business-update-anno-pdsb-20231114monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-updated-survival-data-from-nci-led-phase-2-clinical-trial-of-pds0101-pdsb-20231109monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-preliminary-biomarker-study-results-in-subset-of-advanced-hpv-positi-pdsb-20231023monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-interim-safety-and-immune-response-data-from-phase-1-2-clinical-tria-pdsb-20231011monthly0.5https://www.biopharmawatch.com/news/PDSB/developing-transformational-immunotherapies-for-cancer-nasdaq-pdsb-october-2023-forward-lo-pdsb-20231003monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-interim-24-month-survival-rate-of-74-in-immune-checkpoint-inhibitor--pdsb-20231003monthly0.5https://www.biopharmawatch.com/news/PDSB/pds0101-in-hpv16-head-and-neck-cancer-kol-roundtable-nasdaq-pdsb-pdsb-20231003monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-pds0101-combined-with-chemoradiotherapy-associated-with-rapid-declin-pdsb-20231002monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-pds0202-elicits-active-neutralization-of-multiple-influenza-strains--pdsb-20230920monthly0.5https://www.biopharmawatch.com/news/PDSB/developing-transformational-immunotherapies-for-cancer-nasdaq-pdsb-september-2023-forward--pdsb-20230911monthly0.5https://www.biopharmawatch.com/news/PDSB/pds0202-universal-influenza-preclinical-ferret-data-to-be-presented-in-oral-lecture-at-9th-pdsb-20230906monthly0.5https://www.biopharmawatch.com/news/PDSB/developing-transformational-immunotherapies-for-cancer-nasdaq-pdsb-august-2023-forward-loo-pdsb-20230818monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-data-from-immunocerv-phase-2-trial-investigating-pds0101-and-chemora-pdsb-20230816monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-submission-of-phase-3-protocol-to-fda-to-initiate-versatile-003-tria-pdsb-20230814monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-reports-second-quarter-2023-financial-results-and-provides-business-update-suc-pdsb-20230814monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-to-present-updated-immune-response-data-from-combination-of-pds0101-and-keytru-pdsb-20230725monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-acceptance-of-abstract-on-combination-of-pds0301-with-docetaxel-in-m-pdsb-20230717monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-strengthens-intellectual-property-portfolio-governing-a-combination-of-versamu-pdsb-20230711monthly0.5https://www.biopharmawatch.com/news/PDSB/developing-transformational-immunotherapies-for-cancer-nasdaq-pdsb-june-2023-forward-looki-pdsb-20230614monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-announces-achievement-of-efficacy-threshold-in-stage-2-of-the-versatile--pdsb-20230614monthly0.5https://www.biopharmawatch.com/news/PDSB/developing-transformational-immunotherapies-for-cancer-nasdaq-pdsb-may-2023-forward-lookin-pdsb-20230601monthly0.5https://www.biopharmawatch.com/news/PDSB/developing-transformational-immunotherapies-for-cancer-nasdaq-pdsb-may-2023-forward-lookin-pdsb-20230525monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-interim-data-demonstrates-12-month-survival-rate-of-87-with-pds0101--pdsb-20230525monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-completes-enrollment-in-immune-checkpoint-inhibitor-na-ve-arm-of-versatile-002-pdsb-20230518monthly0.5https://www.biopharmawatch.com/news/PDSB/precision-designed-science-for-immunotherapy-investor-presentation-nasdaq-pdsb-may-2023-2--pdsb-20230517monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-provides-business-update-and-reports-first-quarter-2023-financial-results-upda-pdsb-20230515monthly0.5https://www.biopharmawatch.com/news/PDSB/precision-designed-science-for-immunotherapy-investor-presentation-nasdaq-pdsb-april-2023--pdsb-20230427monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-to-present-updated-data-at-2023-american-society-of-clinical-oncology-asco-ann-pdsb-20230427monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-receives-1-4-million-after-selling-its-net-operating-loss-tax-benefits-through-pdsb-20230424monthly0.5https://www.biopharmawatch.com/news/PDSB/interleukin-12-il-12-kol-roundtable-nasdaq-pdsb-pdsb-20230421monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-to-host-interleukin-12-il-12-immunocytokine-focused-kol-roundtable-on-pdsb-20230412monthly0.5https://www.biopharmawatch.com/news/PDSB/precision-designed-science-for-immunotherapy-investor-presentation-nasdaq-pdsb-april-2023--pdsb-20230406monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-plan-to-initiate-phase-3-study-evaluating-pds0101-in-combination-wit-pdsb-20230330monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-provides-business-update-and-reports-fourth-quarter-and-full-year-2022-financi-pdsb-20230328monthly0.5https://www.biopharmawatch.com/news/PDSB/precision-designed-science-for-immunotherapy-investor-presentation-nasdaq-pdsb-march-2023--pdsb-20230314monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-the-publication-of-pds0301-study-linking-induced-changes-in-immune-r-pdsb-20230301monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-completes-successful-meeting-with-fda-for-triple-combination-of-pds0101-pds030-pdsb-20230227monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-preclinical-publication-in-peer-reviewed-viruses-journal-showing-sup-pdsb-20230216monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-publication-of-preclinical-infectimune-based-vaccine-studies-demonst-pdsb-20230208monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-abstract-accepted-for-presentation-at-esmo-targeted-anticancer-thera-pdsb-20230206monthly0.5https://www.biopharmawatch.com/news/PDSB/precision-designed-science-for-immunotherapy-oncology-platforms-and-clinical-data-summary--pdsb-20230119monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-exclusive-global-license-agreement-for-investigational-il-12-tumor-t-pdsb-20230103monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-reports-median-overall-survival-os-of-21-months-in-advanced-refractory-cancer--pdsb-20221228monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-completes-first-stage-of-enrollment-in-checkpoint-inhibitor-refractory-arm-of--pdsb-20221215monthly0.5https://www.biopharmawatch.com/news/PDSB/precision-designed-science-for-immunotherapy-investor-presentation-nasdaq-pdsb-december-20-pdsb-20221212monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-executives-to-present-an-overview-of-oncology-and-infectious-disease-programs--pdsb-20221121monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-reports-third-quarter-2022-financial-results-and-provides-business-update-anno-pdsb-20221114monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-presentation-of-preliminary-pds0101-efficacy-safety-and-immunology-d-pdsb-20221107monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-provides-highlights-from-head-and-neck-cancer-kol-roundtable-jared-weiss-md-le-pdsb-20221027monthly0.5https://www.biopharmawatch.com/news/PDSB/head-and-neck-cancer-kol-roundtable-nasdaq-pdsb-pdsb-20221026monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-abstract-demonstrating-versatility-of-the-versamune-platform-in-onco-pdsb-20221017monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-to-host-head-and-neck-cancer-kol-roundtable-on-pdsb-20221012monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-expanded-interim-data-in-pds0101-triple-combination-phase-2-trial-ta-pdsb-20221011monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-abstracts-involving-research-of-pds0101-accepted-for-presentation-at-pdsb-20221005monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-successful-end-of-phase-2-meeting-with-the-fda-and-preparation-for-t-pdsb-20221003monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-and-national-cancer-institute-identify-optimal-patient-group-for-advancing-pds-pdsb-20220921monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-completes-35-million-financing-agreement-led-by-horizon-technology-finance-ini-pdsb-20220825monthly0.5https://www.biopharmawatch.com/news/PDSB/precision-designed-science-for-immunotherapy-investor-presentation-nasdaq-pdsb-august-2022-pdsb-20220810monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-reports-second-quarter-2022-financial-results-and-provides-business-update-ann-pdsb-20220808monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-independent-data-monitoring-committee-recommends-versatile-002-trial-continuat-pdsb-20220804monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-announces-presentation-of-universal-flu-vaccine-preclinical-data-at-the--pdsb-20220714monthly0.5https://www.biopharmawatch.com/news/PDSB/precision-designed-science-for-immunotherapy-investor-presentation-nasdaq-pdsb-june-2022-2-pdsb-20220607monthly0.5https://www.biopharmawatch.com/news/PDSB/precision-designed-science-for-immunotherapy-post-asco-presentation-nasdaq-pdsb-pdsb-20220607monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-granted-fda-fast-track-designation-for-lead-candidate-pds0101-pds-biotec-pdsb-20220602monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-expansion-of-its-versatile-002-clinical-trial-into-europe-promising--pdsb-20220531monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-presentation-of-efficacy-and-safety-data-from-versatile-002-phase-2--pdsb-20220526monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-presentation-of-data-from-nci-led-triple-combination-phase-2-clinica-pdsb-20220526monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-provides-business-update-and-reports-first-quarter-2022-financial-results-comp-pdsb-20220511monthly0.5https://www.biopharmawatch.com/news/PDSB/confidential-pds-biotech-announces-two-abstracts-accepted-for-presentation-at-the-2022-ame-pdsb-20220427monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-receives-1-2-million-after-selling-its-net-operating-loss-tax-benefits-through-pdsb-20220419monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-provides-business-update-and-reports-fourth-quarter-and-full-year-2021-financi-pdsb-20220331monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-achievement-of-an-enrollment-objective-in-national-cancer-institute--pdsb-20220315monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-preliminary-safety-data-on-pds0101-in-combination-with-keytruda-pemb-pdsb-20220224monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-clinical-trial-with-mayo-clinic-to-study-pds0101-in-early-stage-pre--pdsb-20220215monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-preliminary-efficacy-achievement-in-versatile-002-phase-2-trial-of-p-pdsb-20220202monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-preclinical-data-for-pds0202-universal-influenza-vaccine-pds0202-inf-pdsb-20220127monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-granted-patent-for-its-novel-hpv16-immunotherapy-extends-patent-protection-of--pdsb-20220110monthly0.5https://www.biopharmawatch.com/news/PDSB/investor-presentation-frank-bedu-addo-ph-d-president-ceo-january-2022-2-this-presentation--pdsb-20220107monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-provides-recruitment-update-for-national-cancer-institute-led-phase-2-clinical-pdsb-20211206monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-provides-business-update-and-reports-third-quarter-2021-financial-results-pdsb-20211110monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-provides-update-on-national-cancer-institute-led-phase-2-clinical-trial-of-pds-pdsb-20211021monthly0.5https://www.biopharmawatch.com/news/PDSB/corporate-overview-frank-bedu-addo-ph-d-president-ceo-october-2021-2-forward-looking-state-pdsb-20211018monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-enrolls-first-stage-of-checkpoint-inhibitor-na-ve-patient-arm-of-phase-2-clini-pdsb-20211004monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-achieves-safety-requirement-milestone-for-the-first-12-patients-in-the-versati-pdsb-20210920monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-completes-enrollment-of-lead-in-safety-cohort-in-versatile-002-phase-2-combina-pdsb-20210909monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-provides-business-update-and-reports-second-quarter-2021-financial-results-pdsb-20210812monthly0.5https://www.biopharmawatch.com/news/PDSB/corporate-overview-frank-bedu-addo-ph-d-president-ceo-august-2021-forward-looking-statemen-pdsb-20210809monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-proposed-offering-of-common-stock-florham-park-nj-pdsb-20210614monthly0.5https://www.biopharmawatch.com/news/PDSB/corporate-overview-frank-bedu-addo-ph-d-president-ceo-june-2021-2-forward-looking-statemen-pdsb-20210608monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-expands-versatile-002-study-of-pds0101-and-keytruda-in-advanced-head-and-pdsb-20210603monthly0.5https://www.biopharmawatch.com/news/PDSB/corporate-overview-frank-bedu-addo-ph-d-president-ceo-may-2021-2-forward-looking-statement-pdsb-20210525monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-release-of-abstract-for-pds0101-in-nci-led-phase-2-clinical-study-fo-pdsb-20210520monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-receives-4-5m-after-selling-its-net-operating-loss-tax-benefits-through-the-ne-pdsb-20210517monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-provides-business-update-and-reports-first-quarter-2021-financial-results-pdsb-20210513monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-oral-presentation-of-pds0101-data-by-the-national-cancer-institute-a-pdsb-20210429monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-reports-financial-results-for-the-year-ended-pdsb-20210318monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-that-its-covid-19-vaccine-consortium-received-a-commitment-from-the--pdsb-20210311monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-and-farmacore-announce-blanver-to-join-consortium-to-commercialize-novel-versa-pdsb-20210222monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-preliminary-efficacy-achievement-in-phase-2-combination-trial-of-pds-pdsb-20210203monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-releases-white-paper-detailing-the-potential-of-the-versamune-platform-in-over-pdsb-20210114monthly0.5https://www.biopharmawatch.com/news/PDSB/corporate-overview-frank-bedu-addo-ph-d-president-ceo-january-2021-2-forward-looking-state-pdsb-20210107monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-mount-sinai-publication-of-studies-showing-superior-induction-of-ant-pdsb-20201221monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-appoints-seth-van-voorhees-as-chief-financial-officer-florham-park-nj-pdsb-20201209monthly0.5https://www.biopharmawatch.com/news/PDSB/corporate-overview-frank-bedu-addo-ph-d-president-ceo-november-2020-2-forward-looking-stat-pdsb-20201116monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-reports-financial-results-for-the-third-quarter-2020-and-provides-busine-pdsb-20201111monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-appoints-renowned-oncologist-otis-brawley-m-d-to-its-board-of-directors--pdsb-20201105monthly0.5https://www.biopharmawatch.com/news/PDSB/corporate-presentation-frank-bedu-addo-ph-d-president-ceo-september-2020-2-forward-looking-pdsb-20200911monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-corporation-announces-proposed-public-offering-of-common-stock-florham-p-pdsb-20200810monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-reports-financial-results-for-the-second-quarter-2020-and-provides-busin-pdsb-20200813monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-preclinical-data-for-pds0203-a-t-cell-activating-recombinant-protein-pdsb-20200727monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-collaborator-granted-niaid-award-to-accelerate-development-of-versamune-based--pdsb-20200714monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-publication-of-preclinical-results-of-pds0101-combination-by-the-nat-pdsb-20200622monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-initiation-of-phase-2-trial-of-pds0101-led-by-the-national-cancer-in-pdsb-20200615monthly0.5https://www.biopharmawatch.com/news/PDSB/corporate-presentation-frank-bedu-addo-ph-d-president-ceo-june-2020-2-forward-looking-stat-pdsb-20200609monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotech-announces-clinical-trial-of-its-lead-immunotherapy-product-pds0101-in-combinat-pdsb-20200604monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-announces-publication-at-american-society-of-clinical-oncology-asco-2020-pdsb-20200513monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-reports-financial-results-for-the-first-quarter-2020-and-provides-busine-pdsb-20200513monthly0.5https://www.biopharmawatch.com/news/PDSB/corporate-presentation-frank-bedu-addo-ph-d-president-ceo-april-2020-2-forward-looking-sta-pdsb-20200331monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-initiates-novel-vaccine-development-programs-for-covid-19-and-universal--pdsb-20200416monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-appoints-dr-ilian-iliev-to-board-of-directors-princeton-nj-pdsb-20200409monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-reports-full-year-2019-financial-results-and-provides-business-update-pr-pdsb-20200327monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-announces-resignation-of-andrew-saik-as-cfo-princeton-nj-pdsb-20200323monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-appoints-kamil-ali-jackson-esq-to-board-of-directors-princeton-nj-pdsb-20200224monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-corporation-announces-pricing-of-public-offering-of-approximately-12-mil-pdsb-20200214monthly0.5https://www.biopharmawatch.com/news/PDSB/corporate-presentation-frank-bedu-addo-ph-d-president-ceo-january-2020-2-forward-looking-s-pdsb-20200113monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-announces-principal-investigator-and-independent-data-monitoring-committ-pdsb-20191211monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-announces-resignation-of-james-loughlin-from-board-of-directors-princeto-pdsb-20191211monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-to-present-at-the-12th-annual-ld-micro-main-event-princeton-nj-pdsb-20191203monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-to-present-at-the-world-vaccine-immunotherapy-congress-west-coast-2019-p-pdsb-20191125monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-reports-third-quarter-2019-financial-results-and-provides-business-updat-pdsb-20191107monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-accepted-for-oral-presentation-at-the-34th-annual-society-for-immunother-pdsb-20191106monthly0.5https://www.biopharmawatch.com/news/PDSB/a-new-generation-of-multi-functional-cancer-immunotherapies-october-2019products-clinical--pdsb-20191029monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-completes-manufacturing-of-clinical-batches-of-pds0101-clinical-batches--pdsb-20191022monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-corp-announces-clinical-collaboration-with-merck-pds0101-keytruda-pembro-pdsb-20191003monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-prioritizes-development-of-pds0101-in-advanced-cancers-following-promisi-pdsb-20191001monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-reports-clinical-data-for-its-novel-immunotherapy-pds0101-in-follow-up-t-pdsb-20190918monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-reports-second-quarter-2019-financial-results-and-provides-business-upda-pdsb-20190801monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-reports-first-quarter-2019-financial-results-and-provides-business-updat-pdsb-20190514monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-appoints-stephen-glover-to-its-board-of-directors-berkeley-heights-nj-pdsb-20190408monthly0.5https://www.biopharmawatch.com/news/PDSB/pds-biotechnology-completes-merger-with-edge-therapeutics-shares-of-combined-company-to-co-pdsb-20190318monthly0.5https://www.biopharmawatch.com/news/PDSB/edge-therapeutics-announces-full-year-2018-financial-results-pdsb-20190221monthly0.5https://www.biopharmawatch.com/news/PDSB/edge-therapeutics-enters-into-merger-agreement-with-pds-biotechnology-to-form-clinical-sta-pdsb-20181126monthly0.5https://www.biopharmawatch.com/news/PDSB/edge-therapeutics-reports-third-quarter-2018-financial-results-pdsb-20181101monthly0.5https://www.biopharmawatch.com/news/PDSB/edge-therapeutics-reports-second-quarter-2018-financial-results-pdsb-20180801monthly0.5https://www.biopharmawatch.com/news/PDSB/edge-therapeutics-reports-first-quarter-2018-financial-results-pdsb-20180501monthly0.5https://www.biopharmawatch.com/news/PDSB/edge-therapeutics-announces-review-of-strategic-alternatives-pdsb-20180430monthly0.5https://www.biopharmawatch.com/news/PDSB/edge-therapeutics-provides-update-following-interim-analysis-of-phase-3-newton-2-study-of--pdsb-20180328monthly0.5https://www.biopharmawatch.com/news/PDSB/edge-therapeutics-reports-fourth-quarter-and-full-year-2017-financial-results-interim-anal-pdsb-20180301monthly0.5https://www.biopharmawatch.com/news/PDSB/corporate-presentation-february-2018-disclaimer-this-presentation-and-any-statements-of-re-pdsb-20180215monthly0.5https://www.biopharmawatch.com/news/PDSB/corporate-presentation-january-2018-disclaimer-this-presentation-and-any-statements-of-rep-pdsb-20180108monthly0.5https://www.biopharmawatch.com/news/PDSB/edge-s-eg-1962-phase-3-newton-2-study-continues-as-planned-following-completion-of-futilit-pdsb-20171229monthly0.5https://www.biopharmawatch.com/news/PDSB/december-2017-nasdaq-edge-disclaimer-this-presentation-and-any-statements-of-representativ-pdsb-20171213monthly0.5https://www.biopharmawatch.com/news/PDSB/edge-therapeutics-reports-third-quarter-2017-financial-results-pdsb-20171101monthly0.5https://www.biopharmawatch.com/news/PDSB/edge-therapeutics-appoints-rosemary-a-crane-pharmaceutical-industry-leader-to-its-board-of-pdsb-20170919monthly0.5https://www.biopharmawatch.com/news/PDSB/edge-therapeutics-reports-second-quarter-2017-financial-results-and-continued-operational--pdsb-20170801monthly0.5https://www.biopharmawatch.com/news/PDSB/edge-therapeutics-announces-commercial-supply-agreement-for-eg-1962-with-oakwood-laborator-pdsb-20170706monthly0.5https://www.biopharmawatch.com/news/PDSB/exhbit-99-1-edge-therapeutics-receives-pediatric-investigation-plan-waiver-from-the-europe-pdsb-20170608monthly0.5https://www.biopharmawatch.com/news/PDSB/edge-therapeutics-reports-first-quarter-2017-financial-results-and-continued-operational-p-pdsb-20170503monthly0.5https://www.biopharmawatch.com/news/PDSB/edge-therapeutics-announces-18-million-registered-direct-offering-of-common-stock-offering-pdsb-20170419monthly0.5https://www.biopharmawatch.com/news/PDSB/edge-therapeutics-announces-first-patient-randomized-in-study-of-intracisternal-administra-pdsb-20170313monthly0.5https://www.biopharmawatch.com/news/PDSB/edge-therapeutics-reports-fourth-quarter-and-full-year-2016-financial-results-pdsb-20170302monthly0.5https://www.biopharmawatch.com/news/PDSB/edge-therapeutics-reports-third-quarter-financial-results-pdsb-20161101monthly0.5https://www.biopharmawatch.com/news/PDSB/edge-therapeutics-appoints-chief-operating-officer-and-makes-inducement-grant-under-nasdaq-pdsb-20161017monthly0.5https://www.biopharmawatch.com/news/PDSB/edge-therapeutics-reports-second-quarter-financial-results-and-recent-highlights-initiates-pdsb-20160803monthly0.5https://www.biopharmawatch.com/news/PDSB/edge-therapeutics-announces-closing-of-20-million-debt-facility-with-hercules-capital-inc-pdsb-20160802monthly0.5https://www.biopharmawatch.com/news/PDSB/edge-therapeutics-announces-first-patient-treated-in-phase-3-newton-2-study-of-eg-1962-in--pdsb-20160729monthly0.5https://www.biopharmawatch.com/news/PDSB/edge-therapeutics-receives-fda-fast-track-designation-for-eg-1962-for-the-treatment-of-sub-pdsb-20160513monthly0.5https://www.biopharmawatch.com/news/PDSB/edge-therapeutics-reports-first-quarter-2016-financial-results-conference-call-today-at-8--pdsb-20160503monthly0.5https://www.biopharmawatch.com/news/PDSB/edge-therapeutics-reports-fourth-quarter-and-full-year-2015-financial-results-conference-c-pdsb-20160308monthly0.5https://www.biopharmawatch.com/news/PDSB/phase-1-2a-multicenter-controlled-randomized-open-label-dose-escalation-safety-tolerabilit-pdsb-20160219monthly0.5https://www.biopharmawatch.com/news/PDSB/edge-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-pdsb-20151120monthly0.5https://www.biopharmawatch.com/news/PDSB/edge-therapeutics-reports-third-quarter-2015-financial-results-successfully-completed-init-pdsb-20151106monthly0.5https://www.biopharmawatch.com/news/PDSB/edge-therapeutics-names-w-bradford-middlekauff-as-senior-vice-president-general-counsel-an-pdsb-20151105monthly0.5https://www.biopharmawatch.com/news/PDSB/october-2015-disclaimer-this-presentation-contains-forward-looking-statements-that-involve-pdsb-20151028monthly0.5https://www.biopharmawatch.com/news/PDSB/edge-therapeutics-receives-european-commission-orphan-drug-designation-for-eg-1962-in-the--pdsb-20151012monthly0.5https://www.biopharmawatch.com/news/PDSB/edge-therapeutics-announces-closing-of-initial-public-offering-and-full-exercise-of-over-a-pdsb-20151006monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-first-quarter-2026-financial-results-first-quarter-2026-net-sales-of-ecor-20260506monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-full-year-2025-financial-results-and-organizational-changes-record-f-ecor-20260319monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-provides-preliminary-full-year-2025-business-update-expects-26-revenue-growth--ecor-20251231monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-appoints-elena-bonfiglioli-to-board-of-directors-rockaway-n-j-ecor-20250903monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-second-quarter-2025-financial-results-net-sales-of-7-4-million-incre-ecor-20250806monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-first-quarter-2025-financial-results-first-quarter-2025-net-sales-of-ecor-20250507monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-completes-acquisition-of-neurometrix-gaining-access-to-its-quell-platform-crea-ecor-20250502monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-full-year-2024-financial-results-record-f-ull-year-2024-net-sales-of-ecor-20250312monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-to-acquire-neurometrix-gaining-access-to-its-quell-platform-and-positioning-it-ecor-20241217monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-third-quarter-2024-financial-results-record-quarterly-revenues-drive-ecor-20241113monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-second-quarter-2024-financial-results-seventh-consecutive-record-qua-ecor-20240807monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-200-forge-way-suite-205-rockaway-nj-07866-ecor-20240711monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-9-3-million-registered-direct-offering-and-concurrent-private-pl-ecor-20240603monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-first-quarter-2024-financial-results-record-first-quarter-2024-net-s-ecor-20240508monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-fourth-quarter-and-full-year-2023-financial-results-record-f-ull-yea-ecor-20240313monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-third-quarter-2023-financial-results-record-third-quarter-2023-net-s-ecor-20231108monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-second-quarter-2023-financial-results-record-second-quarter-2023-net-ecor-20230809monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-8-145-million-registered-direct-offering-and-concurrent-private--ecor-20230731monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-provides-select-second-quarter-2023-financial-guidance-record-revenue-of-appro-ecor-20230630monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-rockaway-nj-ecor-20230522monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-first-quarter-2023-financial-results-record-first-quarter-2023-net-s-ecor-20230503monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-provides-select-first-quarter-2023-financial-guidance-record-revenue-of-approx-ecor-20230331monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-fourth-quarter-and-full-year-2022-financial-results-record-f-ull-yea-ecor-20230308monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-reverse-stock-split-rockaway-n-j-ecor-20230214monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-expected-record-4q-2022-revenue-of-2-5m-provides-business-update-rec-ecor-20221231monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-third-quarter-2022-financial-results-third-quarter-2022-revenue-grew-ecor-20221103monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-provides-select-third-quarter-2022-financial-guidance-revenue-will-be-approxim-ecor-20220930monthly0.5https://www.biopharmawatch.com/news/ECOR/dated-september-20-2022-electrocore-announces-date-for-fiscal-year-2022-ecor-20220920monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-record-second-quarter-2022-financial-results-record-second-quarter-2-ecor-20220804monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-provides-select-second-quarter-2022-financial-guidance-record-r-evenue-will-be-ecor-20220630monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-listing-transfer-to-the-nasdaq-capital-market-rockaway-n-j-ecor-20220623monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-record-first-quarter-2022-financial-results-first-quarter-2022-net-s-ecor-20220505monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-provides-business-update-and-select-first-quarter-2022-financial-guidance-reco-ecor-20220331monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-fourth-quarter-and-full-year-2021-financial-results-full-year-2021-n-ecor-20220310monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-changes-to-its-board-of-directors-julie-bruzzone-goldstein-and-trici-ecor-20220309monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-shareholder-letter-and-full-year-2021-business-update-company-antici-ecor-20220118monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-third-quarter-2021-financial-results-third-quarter-2021-revenue-grew-ecor-20211104monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-provides-business-update-and-select-third-quarter-2021-financial-guidance-thir-ecor-20211012monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-peter-cuneo-as-board-chairman-rockaway-nj-ecor-20210920monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-second-quarter-2021-financial-results-second-quarter-2021-net-sales--ecor-20210805monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-pricing-of-18-0-million-public-offering-of-common-stock-rockaway-nj-ecor-20210630monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-first-quarter-2021-financial-results-record-first-quarter-2021-net-s-ecor-20210506monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-provides-business-update-and-select-first-quarter-2021-financial-guidance-firs-ecor-20210413monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-fourth-quarter-and-full-year-2020-financial-results-full-year-2020-n-ecor-20210311monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-510-k-clearance-of-gammacore-tm-non-invasive-vagus-nerve-stimulation-ecor-20210216monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-the-establishment-of-a-unique-level-ii-hcpcs-code-for-non-invasi-ecor-20210119monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-provides-business-update-and-select-financial-guidance-full-year-2020-revenue--ecor-20201231monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-third-quarter-financial-results-revenue-growth-of-44-over-the-second-ecor-20201112monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-provides-business-update-and-select-financial-guidance-third-quarter-2020-reve-ecor-20201013monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-second-quarter-financial-results-received-eua-and-initiated-gammacor-ecor-20200813monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-provides-update-on-availability-of-gammacore-sapphire-cv-for-the-acute-treatme-ecor-20200730monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-provides-business-update-and-select-financial-guidance-ecor-20200714monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-fda-emergency-use-authorization-for-use-of-gammacore-sapphire-cv-for-ecor-20200713monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-first-quarter-financial-results-generated-first-quarter-revenue-of-7-ecor-20200514monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-provides-update-on-covid-19-clinical-initiatives-randomized-controlled-investi-ecor-20200427monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-provides-business-update-and-select-first-quarter-2020-guidance-ecor-20200417monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-submits-emergency-use-authorization-application-to-allow-the-study-and-use-of--ecor-20200402monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-changes-to-its-board-of-directors-john-gandolfo-tom-patton-and-peter-ecor-20200326monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-fourth-quarter-and-full-year-2019-financial-results-continued-growth-ecor-20200323monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-provides-business-update-and-select-financial-guidance-ecor-20200113monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-board-of-directors-transition-ecor-20191227monthly0.5https://www.biopharmawatch.com/news/ECOR/to-the-company-s-form-8-k-furnished-with-the-sec-on-ecor-20191113monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-third-quarter-2019-financial-results-continued-growth-in-prescribing-ecor-20191113monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-provides-update-on-510-k-submission-seeking-expanded-indication-for-gammacore--ecor-20190925monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-second-quarter-2019-financial-results-sequential-growth-reported-in--ecor-20190813monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-files-registration-statement-on-form-s-3-ecor-20190715monthly0.5https://www.biopharmawatch.com/news/ECOR/separation-and-release-agreement-this-separation-and-release-agreement-this-agreement-is-e-ecor-20190610monthly0.5https://www.biopharmawatch.com/news/ECOR/disclaimers-this-presentation-contains-forward-looking-statements-these-statements-identif-ecor-20190530monthly0.5https://www.biopharmawatch.com/news/ECOR/separation-and-release-agreement-this-separation-and-release-agreement-this-agreement-is-e-ecor-20190604monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-comprehensive-redeployment-and-cost-reduction-plan-management-to-hos-ecor-20190529monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-first-quarter-2019-financial-results-continues-to-deliver-sequential-ecor-20190514monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-announces-fourth-quarter-and-full-year-2018-financial-results-fourth-quarter-2-ecor-20190327monthly0.5https://www.biopharmawatch.com/news/ECOR/commercial-stage-bioelectronic-medicine-company-corporate-presentation-january-2019-discla-ecor-20190104monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-recieves-fda-clearance-for-gammacore-nvns-for-adjunctive-use-for-the-preventiv-ecor-20181128monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-third-quarter-financial-results-ecor-20181113monthly0.5https://www.biopharmawatch.com/news/ECOR/electrocore-inc-announces-second-quarter-financial-results-ecor-20180813monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-is-a-clinical-stage-biopharmaceutical-company-pioneering-the-development-inkt-20251208monthly0.5https://www.biopharmawatch.com/news/INKT/mink-therapeutics-announces-appointment-of-dr-robert-kadlec-to-board-of-directors-inkt-20241031monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-appoints-joseph-m-manko-to-its-board-of-directors-burlington-ma-myo-20260513monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-appoints-william-j-febbo-to-its-board-of-directors-burlington-ma-myo-20260416monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-reports-fourth-quarter-and-full-year-2025-financial-and-operating-results-fourth-qua-myo-20260309monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-reports-third-quarter-2025-financial-and-operating-results-revenue-of-10-1-million-2-myo-20251110monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-reports-second-quarter-2025-financial-and-operating-results-revenue-of-9-7-million-8-myo-20250811monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-provides-highlights-of-today-s-investor-analyst-day-event-senior-executives-to-provi-myo-20250618monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-reports-first-quarter-2025-financial-and-operating-results-revenue-of-9-8-million-re-myo-20250507monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-announces-upcoming-changes-to-its-board-of-directors-burlington-mass-myo-20250410monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-s-fourth-quarter-financial-results-feature-record-revenue-of-12-1-million-generated--myo-20250310monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-reports-record-third-quarter-financial-and-operating-results-9-2-million-in-revenue--myo-20241106monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-reports-second-quarter-2024-financial-results-record-revenue-of-7-5-million-record-2-myo-20240806monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-reports-preliminary-second-quarter-2024-revenues-and-operating-metrics-expects-recor-myo-20240708monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-reports-first-quarter-2024-financial-results-record-275-patients-in-backlog-includes-myo-20240508monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-announces-first-lump-sum-reimbursements-for-myopros-delivered-to-medicare-part-b-ben-myo-20240506monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-appoints-heather-getz-to-its-board-of-directors-boston-myo-20240328monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-reports-fourth-quarter-and-full-year-2023-financial-results-q4-total-revenue-of-4-8--myo-20240307monthly0.5https://www.biopharmawatch.com/news/MYO/cms-posts-final-medicare-dmepos-fee-schedule-rate-for-the-myopro-fees-for-codes-l8701-and--myo-20240301monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-reports-preliminary-fourth-quarter-revenue-and-backlog-boston-myo-20240117monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-reports-third-quarter-2023-financial-results-featuring-record-product-revenue-and-au-myo-20231107monthly0.5https://www.biopharmawatch.com/news/MYO/cms-posts-proposed-medicare-dmepos-fee-schedule-rate-for-the-myopro-for-review-at-the-upco-myo-20231106monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-announces-that-cms-has-classified-the-myopro-orthosis-under-the-brace-benefit-catego-myo-20231102monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-receives-medicare-part-b-reimbursement-for-first-myopro-claims-appropriate-payment-a-myo-20230824monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-reports-second-quarter-2023-financial-results-featuring-year-over-year-growth-in-rev-myo-20230809monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-reports-first-quarter-2023-financial-results-featuring-20-year-over-year-increase-in-myo-20230510monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-receives-technology-license-fee-payment-from-china-joint-venture-company-payment-of--myo-20230410monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-reports-fourth-quarter-and-full-year-2022-financial-results-fourth-quarter-revenue-w-myo-20230313monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-appoints-yitzchak-jacobovitz-to-its-board-of-directors-boston-myo-20230130monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-announces-initiative-to-reduce-cash-burn-undertakes-a-reduction-in-force-to-enhance--myo-20230110monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-reports-third-quarter-2022-financial-results-featuring-strong-authorizations-and-ord-myo-20221110monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-reports-second-quarter-2022-financial-results-and-record-number-of-patient-pipeline--myo-20220803monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-announces-second-quarter-preliminary-revenue-and-record-pipeline-additions-boston-myo-20220707monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-reports-first-quarter-2022-financial-results-revenue-of-3-9-million-up-66-over-prior-myo-20220511monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-reports-progress-with-china-joint-venture-receives-partial-payment-of-technology-lic-myo-20220404monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-reports-fourth-quarter-and-full-year-2021-financial-results-fourth-quarter-revenue-o-myo-20220309monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-provides-update-on-myopro-insurance-reimbursement-boston-mass-myo-20220110monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-third-quarter-2021-financial-results-feature-record-revenue-revenue-of-4-4-million-u-myo-20211110monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-inc-announces-agreements-for-exercise-of-2020-investor-warrants-boston-mass-myo-20211015monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-second-quarter-2021-financial-results-feature-significant-increases-in-revenue-and-g-myo-20210809monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-provides-update-on-cms-discussions-boston-mass-myo-20210608monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-reports-first-quarter-2021-financial-results-revenue-of-2-3-million-up-132-over-prio-myo-20210505monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-reports-fourth-quarter-and-full-year-2020-financial-results-record-q4-2020-revenue-o-myo-20210310monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-reports-preliminary-fourth-quarter-and-full-year-2020-results-fourth-quarter-2020-re-myo-20210111monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-third-quarter-financial-results-feature-record-revenue-of-1-9-million-up-218-over-th-myo-20201110monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-reports-2020-second-quarter-financial-results-revenue-exceeds-projection-as-covid-19-myo-20200811monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-resumes-fitting-myopro-patients-and-deliveries-as-states-begin-to-re-open-after-covi-myo-20200622monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-reports-2020-first-quarter-financial-results-21-year-over-year-revenue-growth-51-seq-myo-20200514monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-reports-accelerating-growth-in-myopro-pipeline-and-record-backlog-in-the-first-quart-myo-20200408monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-reports-preliminary-fourth-quarter-and-full-year-2019-results-cambridge-ma-myo-20200206monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-reports-third-quarter-2019-results-growth-metrics-accelerating-timing-of-insurance-p-myo-20191112monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-reports-second-quarter-2019-results-record-quarterly-revenues-and-28-sequential-expa-myo-20190808monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-reports-first-quarter-2019-results-reports-165-year-over-year-revenue-growth-and-con-myo-20190513monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-reports-fourth-quarter-and-year-end-2018-financial-results-reports-record-revenues-a-myo-20190307monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-inc-announces-proposed-public-offering-of-common-stock-myo-20190207monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-announces-cfo-succession-myo-20190206monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-announces-third-quarter-2018-financial-results-achieved-revenue-growth-of-25-and-rep-myo-20181105monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-announces-second-quarter-2018-financial-results-achieved-revenue-growth-of-106-myo-20180807monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-appoints-micah-mitchell-as-chief-commercial-officer-company-establishes-new-executiv-myo-20180709monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-application-for-medicare-codes-receives-favorable-preliminary-decision-myo-20180514monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-reports-first-quarter-2018-results-myo-20180509monthly0.5https://www.biopharmawatch.com/news/MYO/revised-news-release-myomo-reports-fourth-quarter-and-year-end-2017-results-myo-20180316monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-reports-fourth-quarter-and-year-end-2017-results-myo-20180307monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-inc-announces-pricing-of-public-offering-myo-20171130monthly0.5https://www.biopharmawatch.com/news/MYO/myomo-inc-reports-third-quarter-2017-results-myo-20171106monthly0.5https://www.biopharmawatch.com/news/MYO/inc-myo-20170814monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-reports-landmark-accomplishments-advancing-toward-fda-approval-of-first-of-i-coch-20260511monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-reports-full-year-2025-financial-results-received-fda-approval-to-expand-ful-coch-20260323monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-regains-compliance-with-nasdaq-listing-requirement-white-bear-lake-minnesota-coch-20260224monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-announces-closing-of-up-to-78-0-million-upsized-public-offering-30-0-million-coch-20260212monthly0.5https://www.biopharmawatch.com/news/COCH/investor-presentation-december-2025-www-envoymedical-com-nasdaq-coch-hear-for-life-nasdaq--coch-20251216monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-reports-third-quarter-2025-financial-and-operational-results-transformationa-coch-20251110monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-receives-positive-listing-determination-from-nasdaq-white-bear-lake-mn-coch-20251027monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-announces-up-to-16-million-registered-direct-offering-priced-at-the-market-u-coch-20251008monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-receives-fda-approval-to-advance-its-pivotal-clinical-trial-to-final-stage-b-coch-20251007monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-announces-2-5-million-registered-direct-offering-priced-at-the-market-under--coch-20250922monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-expands-patent-portfolio-by-securing-additional-european-patent-for-breakthr-coch-20250919monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-extinguishes-over-32-million-in-debt-strengthening-balance-sheet-announces-r-coch-20250826monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-reports-on-second-quarter-2025-results-white-bear-lake-minnesota-coch-20250731monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-reports-on-first-quarter-2025-results-company-provides-update-on-its-pivotal-coch-20250501monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-reports-fourth-quarter-and-full-year-2024-financial-results-company-provides-coch-20250331monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-secures-10-million-in-funding-to-advance-pivotal-clinical-trial-of-breakthro-coch-20250312monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-reports-third-quarter-2024-results-and-other-exciting-events-fda-approval-to-coch-20241114monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-secures-lending-facility-of-10m-glen-taylor-committed-investor-and-believer--coch-20240828monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-reports-second-quarter-2024-results-and-provides-business-update-company-con-coch-20240812monthly0.5https://www.biopharmawatch.com/news/COCH/bipartisan-senate-bill-seeks-to-clarify-that-implanted-active-middle-ear-hearing-devices-a-coch-20240731monthly0.5https://www.biopharmawatch.com/news/COCH/investor-presentation-july-2024-www-envoymedical-com-nasdaq-coch-hear-for-life-nasdaq-coch-coch-20240715monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-announces-addition-of-medical-device-manufacturing-experience-to-its-board-o-coch-20240611monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-reports-first-quarter-2024-results-the-company-a-current-leader-in-fully-imp-coch-20240515monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-secures-up-to-10-million-term-debt-financing-to-advance-upcoming-clinical-tr-coch-20240304monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-announces-settlement-contract-outstanding-shareholder-claims-resolved-coch-20231010monthly0.5https://www.biopharmawatch.com/news/COCH/shall-have-the-meanings-ascribed-to-them-in-the-current-report-on-form-8-k-the-form-8-k-to-coch-20230914monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-corporation-and-anzu-special-acquisition-corp-i-complete-business-combinatio-coch-20230929monthly0.5https://www.biopharmawatch.com/news/COCH/anzu-special-acquisition-corp-i-stockholders-approve-business-combination-with-envoy-medic-coch-20230927monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-1-investor-presentation-hear-for-life-september-2023-envoy-medical-2-forward-coch-20230914monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-1-investor-presentation-hear-for-life-envoy-medical-2-this-presentation-this-coch-20230222monthly0.5https://www.biopharmawatch.com/news/COCH/anzu-special-acquisition-corp-i-announces-adjournment-of-special-meeting-of-stockholders-a-coch-20230221monthly0.5https://www.biopharmawatch.com/news/COCH/anzu-special-acquisition-corp-i-announces-adjournment-of-special-meeting-of-stockholders-t-coch-20230209monthly0.5https://www.biopharmawatch.com/news/COCH/envoy-medical-1-investor-presentation-hear-for-life-envoy-medical-2-this-presentation-this-coch-20230120monthly0.5https://www.biopharmawatch.com/news/COCH/anzu-special-acquisition-corp-i-announces-forward-purchase-agreements-of-up-to-120-million-coch-20211207monthly0.5https://www.biopharmawatch.com/news/COCH/anzu-special-acquisition-corp-i-announces-the-separate-trading-of-its-class-a-common-stock-coch-20210422monthly0.5https://www.biopharmawatch.com/news/COCH/anzu-special-acquisition-corp-i-coch-20210420monthly0.5https://www.biopharmawatch.com/news/COCH/anzu-special-acquisition-corp-i-page-report-of-independent-registered-public-accounting-fi-coch-20210304monthly0.5https://www.biopharmawatch.com/news/AGPU/1-this-presentation-contains-forward-looking-statements-as-de-ned-by-the-private-securitie-agpu-20251117monthly0.5https://www.biopharmawatch.com/news/AGPU/securities-purchase-agreement-agpu-20250930monthly0.5https://www.biopharmawatch.com/news/AGPU/corporate-overview-cancer-quest-2020-project-september-2019-predictive-oncology-p-o-a-i-agpu-20190926monthly0.5https://www.biopharmawatch.com/news/AGPU/a-leader-in-artificial-intelligence-ai-driven-knowledge-based-precision-medicine-aipt-corp-agpu-20190517monthly0.5https://www.biopharmawatch.com/news/AGPU/precision-therapeutics-reports-first-quarter-2019-financial-results-and-provides-corporate-agpu-20190515monthly0.5https://www.biopharmawatch.com/news/AGPU/corporate-mission-to-apply-artificial-intelligence-ai-to-personalized-medicine-and-drug-di-agpu-20181030monthly0.5https://www.biopharmawatch.com/news/AGPU/committed-to-providing-products-and-services-that-ensure-the-best-possible-patient-outcome-agpu-20170815monthly0.5https://www.biopharmawatch.com/news/AGPU/skyline-medical-signs-binding-letter-of-intent-for-merger-transaction-with-cytobioscience-agpu-20170802monthly0.5https://www.biopharmawatch.com/news/AGPU/skyline-medical-announces-results-for-year-end-2014-minneapolis-mn-agpu-20150430monthly0.5https://www.biopharmawatch.com/news/AGPU/skyline-medical-announces-results-for-third-quarter-and-first-nine-months-of-2014-increase-agpu-20141112monthly0.5https://www.biopharmawatch.com/news/AGPU/skyline-medical-inc-announces-second-quarter-2014-results-17-streamway-units-sold-17-trial-agpu-20140808monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-holdings-inc-unaudited-pro-forma-condensed-consolidated-financial-informatio-xtnt-20251203monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-reports-second-quarter-2025-financial-results-total-revenue-of-35-4-million--xtnt-20250812monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-definitive-agreements-for-the-sale-of-its-coflex-and-cofix-spinal--xtnt-20250707monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-reports-first-quarter-2025-financial-results-revenue-increases-18-year-over--xtnt-20250512monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-secondary-private-sale-of-existing-shares-by-orbimed-and-prelimina-xtnt-20250416monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-reports-fourth-quarter-and-full-year-2024-financial-results-full-year-2024-r-xtnt-20250306monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-reports-third-quarter-2024-financial-results-third-quarter-revenue-growth-of-xtnt-20241112monthly0.5https://www.biopharmawatch.com/news/XTNT/surgalign-holdings-inc-and-subsidiaries-condensed-consolidated-balance-sheets-unaudited-in-xtnt-20240903monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-5-0-million-private-placement-belgrade-mt-xtnt-20240808monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-reports-second-quarter-2024-revenue-growth-of-48-xtnt-20240808monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-reports-first-quarter-2024-revenue-growth-of-55-and-raises-full-year-2024-re-xtnt-20240515monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-record-third-quarter-revenue-of-25-million-raises-2023-annual-reve-xtnt-20231109monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-completes-acquisition-of-surgalign-s-hardware-and-biologics-business-belgrad-xtnt-20230810monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-second-quarter-revenue-growth-of-32-raises-2023-annual-revenue-gui-xtnt-20230801monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-wins-auction-for-surgalign-s-hardware-and-biologics-business-acquisition-to--xtnt-20230728monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-appoints-lori-mitchell-keller-to-board-of-directors-belgrade-mt-xtnt-20230518monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-first-quarter-2023-revenue-growth-of-38-and-full-year-2023-revenue-xtnt-20230504monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-fourth-quarter-and-full-year-2022-financial-results-belgrade-mt-xtnt-20230307monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-acquires-coflex-product-line-from-surgalign-for-17-million-expands-xtant-s-p-xtnt-20230301monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-appoints-mark-schallenberger-as-chief-operations-officer-belgrade-mt-xtnt-20230109monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-third-quarter-2022-financial-results-belgrade-mt-xtnt-20221103monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-closing-of-second-tranche-of-9-75-million-private-investment-belgr-xtnt-20221011monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-closing-of-first-tranche-of-9-75-million-private-investment-belgra-xtnt-20220831monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-9-75-million-private-investment-upon-completion-of-first-closing-s-xtnt-20220824monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-second-quarter-2022-financial-results-belgrade-mt-xtnt-20220804monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-first-quarter-2022-financial-results-belgrade-mt-xtnt-20220505monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-fourth-quarter-and-full-year-2021-financial-results-belgrade-mt-xtnt-20220308monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-appoints-scott-neils-interim-chief-financial-officer-belgrade-mt-xtnt-20220103monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-third-quarter-2021-financial-results-belgrade-mt-xtnt-20211112monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-second-quarter-2021-financial-results-belgrade-mt-xtnt-20210805monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-first-quarter-2021-financial-results-belgrade-mt-xtnt-20210511monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-fourth-quarter-and-full-year-2020-financial-results-belgrade-mt-xtnt-20210224monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-20-xtnt-20210222monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-expiration-of-rights-offering-belgrade-mt-xtnt-20201207monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-third-quarter-2020-financial-results-belgrade-mt-xtnt-20201029monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-record-date-and-other-key-dates-for-proposed-15-million-rights-off-xtnt-20201022monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-regains-compliance-with-nyse-american-continued-listing-standards-belgrade-m-xtnt-20201006monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-closing-of-debt-restructuring-belgrade-mt-xtnt-20201001monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-debt-restructuring-belgrade-mt-xtnt-20200810monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-second-quarter-2020-financial-results-belgrade-mt-xtnt-20200803monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-first-quarter-2020-financial-results-belgrade-mt-xtnt-20200507monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-fourth-quarter-and-full-year-2019-financial-results-belgrade-mt-xtnt-20200305monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-third-quarter-2019-financial-results-belgrade-mt-xtnt-20191107monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-names-sean-browne-president-and-chief-executive-officer-belgrade-mt-xtnt-20191007monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-second-quarter-2019-financial-results-belgrade-mt-xtnt-20190808monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-nyse-american-acceptance-of-plan-to-regain-compliance-with-continu-xtnt-20190528monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-first-quarter-2019-financial-results-belgrade-mt-xtnt-20190515monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-receives-noncompliance-notice-from-nyse-american-belgrade-mt-xtnt-20190405monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-fourth-quarter-and-2018-financial-results-belgrade-mt-xtnt-20190401monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-third-quarter-2018-financial-results-belgrade-mt-xtnt-20181114monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-appointment-of-interim-ceo-belgrade-mt-xtnt-20181015monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-amendments-to-credit-facility-and-issuance-of-warrants-belgrade-mt-xtnt-20180917monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-appointment-of-chief-financial-officer-belgrade-mt-aug-xx-2018-xta-xtnt-20180820monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-second-quarter-2018-financial-results-belgrade-mt-xtnt-20180807monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-appoints-kevin-brandt-as-chief-commercial-officer-belgrade-mt-xtnt-20180710monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-holdings-inc-announces-expiration-of-rights-offering-belgrade-mt-xtnt-20180619monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-receives-fda-510-k-clearance-for-intice-c-porous-titanium-cervical-interbody-xtnt-20180521monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-holdings-inc-announces-record-date-for-proposed-rights-offering-belgrade-mt--xtnt-20180417monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-announces-fourth-quarter-and-year-end-2017-financial-results-xtnt-20180402monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-to-issue-fourth-quarter-and-full-year-2017-financial-results-monday-april-2-xtnt-20180327monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-exchange-of-outstanding-convertible-notes-and-closing-of-private-p-xtnt-20180214monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-results-of-special-meeting-of-stockholders-approval-of-the-issuanc-xtnt-20180213monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-enters-into-restructuring-and-exchange-agreement-with-all-holders-of-outstan-xtnt-20180118monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-reports-third-quarter-2017-financial-results-company-restructuring-efforts-c-xtnt-20171122monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-postpones-release-of-third-quarter-2017-financial-results-xtnt-20171109monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-enters-into-a-distribution-agreement-with-curasan-inc-bringing-matriform-to--xtnt-20171101monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-to-announce-third-quarter-2017-results-on-wednesday-november-8th-xtnt-20171027monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-to-feature-product-portfolio-at-the-2017-north-american-spine-society-annual-xtnt-20171025monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-consolidation-of-fixation-operations-to-montana-and-closure-of-day-xtnt-20171006monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-receives-510k-clearance-for-expanded-indications-of-irix-a-xtnt-20170912monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-reports-second-quarter-2017-financial-results-company-continues-to-take-step-xtnt-20170809monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-receives-fda-clearance-for-calix-c-cervical-interbody-line-extension-and-exp-xtnt-20170809monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-to-announce-second-quarter-2017-results-on-august-9th-2017-belgrade-mt-xtnt-20170724monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-rescheduling-of-annual-meeting-xtnt-20170526monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-enters-into-licensing-agreement-for-sites-medical-s-osteosync-ti-technology-xtnt-20170516monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-orbimed-financing-and-engagement-of-aurora-management-partners-xtnt-20170512monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-reports-first-quarter-revenue-of-22-1-million-5-growth-compared-to-the-prior-xtnt-20170509monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-sets-annual-meeting-and-record-dates-xtnt-20170505monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-release-of-first-quarter-2017-results-on-xtnt-20170502monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-recognized-as-montana-ambassador-business-of-the-year-xtnt-20170425monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-receives-going-concern-opinion-belgrade-mt-xtnt-20170405monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-reports-record-fourth-quarter-revenue-of-24-5-million-10-growth-compared-to--xtnt-20170309monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-to-announce-fourth-quarter-and-full-year-2016-results-on-march-9th-2017-belg-xtnt-20170301monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-appointment-of-carl-o-connell-to-permanent-xtnt-20170222monthly0.5https://www.biopharmawatch.com/news/XTNT/belgrade-mont-xtnt-20170123monthly0.5https://www.biopharmawatch.com/news/XTNT/xtnt-announces-issuance-of-pik-notes-xtnt-20170119monthly0.5https://www.biopharmawatch.com/news/XTNT/xtnt-announces-closing-of-registered-direct-offering-xtnt-20170118monthly0.5https://www.biopharmawatch.com/news/XTNT/xtnt-announces-registered-direct-offering-xtnt-20170113monthly0.5https://www.biopharmawatch.com/news/XTNT/xtnt-announces-preliminary-fourth-quarter-and-full-year-2016-revenue-adjusted-ebitda-recor-xtnt-20170111monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-receives-fda-clearance-for-the-xsert-lumbar-expandable-interbody-system-xtnt-20161123monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-closes-rights-offering-for-gross-proceeds-of-3-8-million-xtnt-20161117monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-receives-fda-clearance-to-use-allografts-in-the-stand-alone-irix-c-cervical--xtnt-20161115monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-reminds-shareholders-of-upcoming-expiration-of-rights-offering-subscription--xtnt-20161111monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-adjustment-to-subscription-price-of-rights-offering-xtnt-20161109monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-holdings-reports-record-third-quarter-2016-results-see-footnote-about-the-us-xtnt-20161107monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-receives-approval-of-compliance-plan-from-xtnt-20161101monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-reminds-shareholders-that-rights-offering-ownership-day-is-tuesday-xtnt-20161018monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-pre-announces-record-third-quarter-2016-revenue-see-footnote-about-the-use-o-xtnt-20161011monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-the-appointment-of-carl-o-connell-as-president-belgrade-mt-xtnt-20161006monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-files-s-1-registration-statement-for-rights-offering-to-shareholders-xtnt-20160829monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-receives-non-compliance-notice-from-xtnt-20160819monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-expands-ar-credit-facility-with-silicon-valley-bank-expanded-credit-facility-xtnt-20160816monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-reports-second-quarter-2016-results-see-footnote-about-the-use-of-pro-forma--xtnt-20160801monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-the-operations-expansion-of-montana-s-tissue-processing-rooms-belg-xtnt-20160726monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-pre-announces-second-quarter-2016-revenue-and-ebitda-second-quarter-2016-rev-xtnt-20160720monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-changes-to-its-executive-management-and-board-of-directors-xtnt-20160616monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-completes-new-credit-facility-project-xtnt-svb-facility-pr-xtant-medical-ver-xtnt-20160526monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-sets-annual-meeting-and-record-dates-xtnt-20160513monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-pre-announces-first-quarter-2016-revenue-core-recurring-revenue-to-increase--xtnt-20160419monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-fda-clearance-of-the-xspan-laminoplasty-fixation-system-xtnt-20160329monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-distribution-agreement-with-vivex-biomedical-bringing-osteovive-a--xtnt-20160324monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-reports-record-22-3-million-revenue-and-14-1-growth-for-the-fourth-quarter-2-xtnt-20160315monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-receives-ce-mark-for-its-aranax-cervical-plating-system-and-irix-a-stand-alo-xtnt-20160303monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-to-present-at-the-canaccord-genuity-2016-musculoskeletal-conference-xtnt-20160216monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-to-present-at-the-source-capital-2016-disruptive-growth-healthcare-conferenc-xtnt-20160203monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-holdings-inc-reports-preliminary-fourth-quarter-2015-financial-results-belgr-xtnt-20160112monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-first-surgical-procedure-with-the-aranax-cervical-plating-system-b-xtnt-20151215monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-first-surgical-case-of-atrix-c-cervical-allograft-interbody-spacer-xtnt-20151209monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-the-global-launch-for-the-certex-oct-spinal-fixation-system-belgra-xtnt-20151208monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-to-present-at-icv-manhattan-belgrade-mont-dec-3-2015-globe-newswire-xtant-me-xtnt-20151203monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-and-montana-state-university-develop-custom-3d-printer-for-prototyping-recon-xtnt-20151202monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-receives-clearance-of-expanded-indication-for-ilium-fixation-and-deformity-xtnt-20151201monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-to-present-at-the-8th-annual-ld-micro-conference-xtnt-20151124monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-holdings-inc-reports-third-quarter-2015-results-third-quarter-2015-consolida-xtnt-20151111monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-first-surgical-use-of-osteoselect-plus-dbm-putty-xtnt-20151103monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-holdings-inc-to-report-third-quarter-2015-financial-results-on-xtnt-20151104monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-holdings-begins-trading-on-nyse-mkt-under-symbol-xtnt-xtnt-20151019monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-holdings-announces-uplisting-to-xtnt-20151015monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-tm-announces-preliminary-third-quarter-2015-revenue-third-quarter-2015-pro-forma-com-xtnt-20151013monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-exhibits-at-north-american-spine-society-nass-meeting-belgrade-mont-xtnt-20151012monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-awarded-grant-from-the-montana-board-of-research-and-commercialization-techn-xtnt-20151006monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-exhibits-at-the-congress-of-neurological-surgeons-annual-meeting-belgrade-mt-xtnt-20150928monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-tm-medical-announces-expanded-patent-coverage-of-core-technologies-xtnt-20150922monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-fda-clearance-of-the-aranax-cervical-plate-belgrade-mt-business-wi-xtnt-20150909monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-to-exhibit-at-eurospine-2015-belgrade-mt-usa-xtant-medical-holdings-inc-otcq-xtnt-20150901monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-to-present-at-the-rodman-renshaw-17th-annual-global-investment-conference-xtnt-20150827monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-announces-fda-approval-of-osteoselect-xtnt-20150825monthly0.5https://www.biopharmawatch.com/news/XTNT/x-spine-systems-inc-consolidated-financial-report-reviewed-xtnt-20150814monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-reports-first-half-2015-financial-results-first-half-xtant-tm-medical-pro-fo-xtnt-20150731monthly0.5https://www.biopharmawatch.com/news/XTNT/xtant-medical-holdings-inc-to-report-second-quarter-2015-financial-results-on-xtnt-20150804monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-closes-purchase-of-the-outstanding-common-stock-of-x-spine-systems-inc-combines-b-xtnt-20150731monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-to-purchase-the-outstanding-common-stock-of-x-spine-systems-inc-creating-xtant-me-xtnt-20150728monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-annouces-preliminary-second-quarter-revenue-second-quarter-total-revenue-in-the-r-xtnt-20150709monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-international-holdings-inc-awarded-agreement-with-premier-inc-xtnt-20150624monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-international-announces-signing-of-agreement-with-yankee-alliance-xtnt-20150619monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-the-launch-of-arthrofuse-xtnt-20150603monthly0.5https://www.biopharmawatch.com/news/XTNT/correcting-and-replacing-bacterin-sets-annual-meeting-and-record-dates-belgrade-mont-busin-xtnt-20150515monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-record-announces-first-quarter-2015-results-company-continues-to-see-record-reven-xtnt-20150505monthly0.5https://www.biopharmawatch.com/news/XTNT/wire-may-4-2015-bacterin-international-holdings-inc-xtnt-20150504monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-international-receives-coverage-from-medicare-administrative-contractor-mac-for-h-xtnt-20150428monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-to-report-first-quarter-2015-financial-results-on-xtnt-20150423monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-preliminary-first-quarter-2015-results-first-quarter-total-revenue-expe-xtnt-20150409monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-international-to-begin-trading-on-otcqx-marketplace-belgrade-mont-xtnt-20150408monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-osteosponge-patent-belgrade-mt-xtnt-20150406monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-fourth-quarter-and-year-end-2014-results-fourth-quarter-highlights-tota-xtnt-20150317monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-contract-extension-with-novation-xtnt-20150316monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-to-present-at-the-canaccord-genuity-musculoskeletal-conference-xtnt-20150311monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-distribution-agreement-with-spartan-medical-for-dod-and-va-medical-cent-xtnt-20150310monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-to-report-fourth-quarter-2014-financial-results-on-xtnt-20150302monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-to-present-at-the-27th-annual-roth-conference-belgrade-mt-xtnt-20150224monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-1000-th-lot-of-osteoselect-dbm-putty-belgrade-mt-business-wire-xtnt-20150217monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-preliminary-fourth-quarter-2014-revenue-fourth-quarter-total-revenue-in-xtnt-20150112monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-to-present-at-the-7-th-annual-ld-micro-conference-belgrade-mt-xtnt-20141126monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-to-present-at-the-singular-research-9th-annual-best-of-the-uncovereds-conference--xtnt-20141117monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-receives-delisting-notice-from-xtnt-20141114monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-ceo-dan-goldberger-to-be-guest-on-fox-business-network-s-after-the-bell-with-liz--xtnt-20141111monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-third-quarter-2014-results-company-increases-year-over-year-sales-impro-xtnt-20141105monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-further-expansion-of-its-sales-force-belgrade-mt-globe-new-swire-xtnt-20141105monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-to-showcase-new-product-line-at-the-north-american-spine-society-annual-meeting-b-xtnt-20141104monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-awarded-grant-from-the-montana-board-of-research-and-commercialization-technology-xtnt-20141027monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-to-report-third-quarter-2014-financial-results-on-xtnt-20141023monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-presents-preclinical-results-of-an-efficacious-antimicrobial-orthopedic-device-co-xtnt-20141022monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-3demin-cortical-fibers-belgrade-mt-business-wire-xtnt-20141020monthly0.5https://www.biopharmawatch.com/news/XTNT/correcting-and-replacing-bacterin-announces-preliminary-third-quarter-2014-revenue-third-q-xtnt-20141016monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-international-announces-sales-team-expansion-bacterin-attracts-industry-top-sales-xtnt-20141016monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-preliminary-third-quarter-2014-revenue-third-quarter-total-revenue-expe-xtnt-20141014monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-ceo-dan-goldberger-to-be-guest-on-fox-business-network-s-opening-bell-with-maria--xtnt-20141002monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-to-present-at-the-singular-research-9th-annual-best-of-the-uncovereds-conference--xtnt-20140918monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-the-appointment-of-new-board-member-belgrade-mont-business-wire-xtnt-20140813monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-second-quarter-2014-results-second-quarter-2014-revenues-increase-appro-xtnt-20140812monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-publication-in-the-spine-journal-featuring-osteoselect-dbm-putty-xtnt-20140812monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-closing-of-public-offering-of-common-stock-belgrade-mt-xtnt-20140806monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-clinical-results-on-the-use-of-osteosponge-sc-allograft-published-in-th-xtnt-20140805monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-pricing-of-public-offering-of-common-stock-belgrade-mt-xtnt-20140801monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-public-offering-of-common-stock-belgrade-mt-xtnt-20140731monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-to-report-second-quarter-2014-financial-results-on-xtnt-20140729monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-reverse-split-of-common-stock-xtnt-20140723monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-preliminary-second-quarter-2014-results-second-quarter-total-revenue-ex-xtnt-20140721monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-the-appointment-of-robert-di-silvio-as-president-belgrade-mont-business-xtnt-20140701monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-to-present-at-the-2014-newport-coast-securities-inc-annual-equity-national-sales--xtnt-20140610monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-first-quarter-2014-results-company-reports-record-core-recurring-biolog-xtnt-20140506monthly0.5https://www.biopharmawatch.com/news/XTNT/the-appointment-of-a-vice-president-of-sales-xtnt-20140501monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-to-report-first-quarter-2014-financial-results-on-xtnt-20140428monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-preclinical-results-on-the-use-of-osteoselect-dbm-putty-published-in-th-xtnt-20140423monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-preliminary-first-quarter-2014-revenue-core-recurring-biologics-revenue-xtnt-20140421monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-the-addition-of-two-vice-presidents-belgrade-mont-business-wire-xtnt-20140408monthly0.5https://www.biopharmawatch.com/news/XTNT/clinical-results-on-the-use-of-bacterin-s-osteosponge-for-foot-and-ankle-arthrodeses-proce-xtnt-20140320monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-full-year-2013-results-belgrade-mont-business-wire-xtnt-20140319monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-the-launch-of-osteostx-a-novel-biologic-product-belgrade-mt-xtnt-20140313monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-secures-additional-orbimed-financing-belgrade-mt-xtnt-20140310monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-to-present-at-the-canaccord-genuity-musculoskeletal-conference-xtnt-20140305monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-earnings-release-and-conference-call-date-for-2013-fourth-quarter-and-f-xtnt-20140225monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-to-present-at-the-canaccord-genuity-musculoskeletal-conference-belgrade-mt-xtnt-20140219monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-to-present-at-the-leerink-global-healthcare-conference-belgrade-mt-xtnt-20140204monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-preliminary-fourth-quarter-2013-revenue-fourth-quarter-revenue-in-the-r-xtnt-20140123monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-to-present-at-the-noble-financial-tenth-annual-equity-conference-belgrade-mt-xtnt-20140115monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-2014-donate-life-rose-parade-float-living-donor-honoree-belgrade-mont-b-xtnt-20140101monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-international-holdings-inc-ceo-dan-goldberger-to-be-interviewed-on-clear-channel--xtnt-20131220monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-xtnt-20131218monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-2014-xtnt-20131205monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-to-present-at-the-ld-micro-conference-belgrade-mt-xtnt-20131126monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-receives-deficiency-notice-from-xtnt-20131122monthly0.5https://www.biopharmawatch.com/news/XTNT/positive-clinical-results-on-the-use-of-bacterin-s-osteosponge-for-transforaminal-lumbar-i-xtnt-20131121monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-ranked-in-deloitte-s-technology-fast-500-belgrade-mt-xtnt-20131119monthly0.5https://www.biopharmawatch.com/news/XTNT/third-quarter-2013-results-xtnt-20131107monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-strategic-alliance-to-distribute-products-into-european-markets-belgrad-xtnt-20131107monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-awarded-patent-for-method-to-produce-demineralized-bone-matrix-belgrade-mt-xtnt-20131106monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-earnings-release-and-conference-call-date-for-2013-third-quarter-result-xtnt-20131022monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-to-host-initial-investor-call-with-ceo-dan-goldberger-belgrade-mt-xtnt-20130904monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-to-present-at-the-rodman-renshaw-annual-global-investment-conference-belgrade-mt-xtnt-20130827monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-reports-inducement-grant-in-accordance-with-section-711-a-of-the-nyse-mkt-company-xtnt-20130821monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-new-xtnt-20130807monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-second-quarter-2013-results-highlights-revenue-increased-to-8-3-million-xtnt-20130807monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-earnings-release-and-conference-call-date-for-2013-second-quarter-resul-xtnt-20130724monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-s-osteoselect-dbm-putty-approved-for-spinal-fusion-applications-xtnt-20130716monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-receives-acceptance-of-plan-to-regain-compliance-from-xtnt-20130625monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-international-announces-financing-belgrade-mt-xtnt-20130605monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-receives-compliance-notice-from-xtnt-20130516monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-first-quarter-2013-revenue-of-8-6-million-first-quarter-2013-highlights-xtnt-20130509monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-earnings-release-and-conference-call-date-for-2013-first-quarter-result-xtnt-20130430monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-selection-of-executive-search-firm-belgrade-mt-xtnt-20130426monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-provides-update-on-executive-leadership-transition-plans-company-in-final-stages--xtnt-20130417monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-transition-of-executive-leadership-company-has-begun-process-to-identif-xtnt-20130401monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-record-2012-revenue-of-33-million-full-year-2012-highlights-revenue-inc-xtnt-20130326monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-earnings-release-and-conference-call-date-for-2012-fourth-quarter-year--xtnt-20130313monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-international-holdings-inc-announces-iso-certification-belgrade-mt-xtnt-20130226monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-international-holdings-inc-announces-fourth-quarter-revenues-belgrade-mt-xtnt-20130220monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-s-osteosponge-product-generates-positive-clinical-results-clinical-results-for-fo-xtnt-20130122monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-reports-third-quarter-2012-financial-results-revenue-increases-18-company-reports-xtnt-20121107monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-international-holdings-inc-schedules-third-quarter-2012-financial-earnings-confer-xtnt-20121023monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-to-present-at-7th-annual-singular-research-conference-xtnt-20121023monthly0.5https://www.biopharmawatch.com/news/XTNT/john-deedrick-joins-bacterin-board-of-directors-xtnt-20120912monthly0.5https://www.biopharmawatch.com/news/XTNT/positive-clinical-results-on-the-use-of-bacterin-s-osteosponge-sc-product-for-regeneration-xtnt-20120911monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-international-to-present-at-stifel-nicolaus-2012-healthcare-conference-on-xtnt-20120831monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-secures-25-million-financing-with-orbimed-funding-provides-significant-flexibilit-xtnt-20120828monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-international-announces-second-quarter-and-six-months-2012-financial-results-seco-xtnt-20120809monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-international-holdings-inc-schedules-second-quarter-2012-financial-earnings-confe-xtnt-20120727monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-international-signs-its-fourth-national-gpo-contract-with-the-premier-healthcare--xtnt-20120710monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-receives-letter-from-nyse-mkt-llc-regarding-timely-notice-of-record-date-for-2012-xtnt-20120702monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-to-present-at-the-jefferies-2012-global-healthcare-conference-xtnt-20120530monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-international-signs-its-third-national-gpo-contract-with-novation-xtnt-20120508monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-first-quarter-2012-revenue-of-7-8-million-up-29-year-over-year-on-gross-xtnt-20120503monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-international-holdings-inc-schedules-first-quarter-2012-financial-earnings-confer-xtnt-20120424monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-secures-accounts-receivable-credit-facility-xtnt-20120424monthly0.5https://www.biopharmawatch.com/news/XTNT/peer-review-determines-bacterin-s-osteosponge-superior-to-autograft-and-ideal-for-bone-reg-xtnt-20120404monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-announces-record-2011-revenue-of-30-1-million-up-96-year-over-year-conference-cal-xtnt-20120322monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-to-present-at-the-5th-annual-maxim-group-growth-conference-on-xtnt-20120312monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-international-holdings-inc-schedules-fourth-quarter-2011-financial-earnings-confe-xtnt-20120224monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-study-at-aaos-2012-annual-meeting-shows-osteosponge-equivalence-to-rhbmp-2-in-spi-xtnt-20120210monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-promotes-seasoned-healthcare-sales-professional-to-national-sales-manager-xtnt-20120207monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-retains-hayden-ir-to-develop-strategic-investor-relations-program-seeks-to-expand-xtnt-20120201monthly0.5https://www.biopharmawatch.com/news/XTNT/unassociated-document-bacterin-to-present-at-the-noble-8th-annual-equity-conference-on-xtnt-20120111monthly0.5https://www.biopharmawatch.com/news/XTNT/unassociated-document-bacterin-signs-distribution-agreement-with-jeil-for-lef-rte-cranioma-xtnt-20111128monthly0.5https://www.biopharmawatch.com/news/XTNT/unassociated-document-bacterin-to-present-at-4th-annual-ld-micro-conference-on-xtnt-20111122monthly0.5https://www.biopharmawatch.com/news/XTNT/unassociated-document-bacterin-reports-third-quarter-2011-results-record-revenues-of-7-5-m-xtnt-20111110monthly0.5https://www.biopharmawatch.com/news/XTNT/unassociated-document-bacterin-becomes-premier-founding-sponsor-of-rmec-s-new-osteobiologi-xtnt-20111103monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-to-present-at-lazard-capital-markets-8th-annual-healthcare-conference-on-xtnt-20111031monthly0.5https://www.biopharmawatch.com/news/XTNT/unassociated-document-bacterin-sponsors-the-2012-donate-life-rose-parade-float-in-recognit-xtnt-20111028monthly0.5https://www.biopharmawatch.com/news/XTNT/unassociated-document-bacterin-study-shows-osteosponge-equivalence-to-rhbmp-2-in-spinal-fu-xtnt-20111025monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterinawarded-approved-vendor-status-for-american-medical-concepts-network-of-hospitals--xtnt-20111024monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-international-sets-third-quarter-2011-conference-call-for-thursday-xtnt-20111017monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-international-to-present-at-stifel-nicolaus-2011-healthcare-conference-on-xtnt-20110824monthly0.5https://www.biopharmawatch.com/news/XTNT/unassociated-document-bacterin-international-to-present-at-rodman-renshaw-annual-global-in-xtnt-20110823monthly0.5https://www.biopharmawatch.com/news/XTNT/unassociated-document-bacterin-second-quarter-2011-revenues-up-135-over-prior-year-driving-xtnt-20110811monthly0.5https://www.biopharmawatch.com/news/XTNT/unassociated-document-bacterin-reports-new-hires-and-management-reorganization-driving-mos-xtnt-20110805monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-secures-15-million-credit-facility-with-midcap-financial-and-silicon-valley-bank--xtnt-20110801monthly0.5https://www.biopharmawatch.com/news/XTNT/unassociated-document-bacterin-sets-second-quarter-2011-conference-call-for-thursday-xtnt-20110726monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-acquires-assets-of-robinson-medsurg-xtnt-20110718monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-joins-russell-3000-russell-microcap-and-russell-global-indexes-belgrade-mt-xtnt-20110627monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-engages-liolios-group-to-lead-investor-relations-program-belgrade-mt-xtnt-20110621monthly0.5https://www.biopharmawatch.com/news/XTNT/bacterin-international-signs-its-second-national-gpo-contract-for-xtnt-20110614monthly0.5https://www.biopharmawatch.com/news/BGM/bgm-group-ltd-no-152-hongliang-east-1st-street-no-1703-tianfu-new-district-chengdu-prc-610-bgm-20260617monthly0.5https://www.biopharmawatch.com/news/BGM/acting-in-concert-agreement-this-acting-in-concert-agreement-the-agreement-is-executed-on-bgm-20250814monthly0.5https://www.biopharmawatch.com/news/BGM/bgm-group-ltd-index-to-unaudited-condensed-consolidated-financial-statements-table-of-cont-bgm-20250724monthly0.5https://www.biopharmawatch.com/news/BGM/from-virtual-agents-to-embodied-and-industry-specific-ai-bgm-acquires-xingdao-intelligent--bgm-20250528monthly0.5https://www.biopharmawatch.com/news/BGM/bgm-group-announces-strategic-acquisition-of-hm-management-to-expand-ai-application-ecosys-bgm-20250502monthly0.5https://www.biopharmawatch.com/news/BGM/bgm-group-acquires-wonder-dragon-to-accelerate-healthcare-strategy-bgm-20250421monthly0.5https://www.biopharmawatch.com/news/BGM/rons-intelligent-technology-beijing-co-ltd-and-shenzhen-xinbao-investment-management-co-lt-bgm-20250328monthly0.5https://www.biopharmawatch.com/news/BGM/bgm-acquires-yx-to-strengthen-ai-strategy-for-its-intelligent-platform-bgm-20250319monthly0.5https://www.biopharmawatch.com/news/BGM/bgm-group-ltd-no-152-hongliang-east-1st-street-no-1703-tianfu-new-district-chengdu-610200--bgm-20250301monthly0.5https://www.biopharmawatch.com/news/BGM/transaction-agreement-by-and-among-bgm-group-ltd-cisg-holding-ltd-patrition-limited-gm-man-bgm-20241127monthly0.5https://www.biopharmawatch.com/news/BGM/share-subscription-agreement-this-agreement-is-made-on-bgm-20241127monthly0.5https://www.biopharmawatch.com/news/BGM/qilian-international-holding-group-limited-no-152-hongliang-east-1st-street-no-1703-tianfu-bgm-20240909monthly0.5https://www.biopharmawatch.com/news/BGM/qilian-international-holding-group-limited-index-to-condensed-consolidated-financial-state-bgm-20240814monthly0.5https://www.biopharmawatch.com/news/BGM/qilian-international-holding-group-limited-no-152-hongliang-east-1st-street-no-1703-tianfu-bgm-20240311monthly0.5https://www.biopharmawatch.com/news/BGM/qilian-international-holding-group-limited-no-152-hongliang-east-1st-street-no-1703-tianfu-bgm-20231031monthly0.5https://www.biopharmawatch.com/news/BGM/financial-highlights-for-the-six-months-ended-bgm-20230804monthly0.5https://www.biopharmawatch.com/news/BGM/qilian-received-a-letter-from-nasdaq-related-to-regain-compliance-bgm-20230426monthly0.5https://www.biopharmawatch.com/news/BGM/qilian-received-notification-of-deficiency-from-nasdaq-related-to-not-timely-filing-of-ann-bgm-20230223monthly0.5https://www.biopharmawatch.com/news/BGM/qilian-international-holding-group-ltd-declares-special-cash-dividends-to-shareholders-jiu-bgm-20230216monthly0.5https://www.biopharmawatch.com/news/BGM/qilian-international-holding-group-limited-reports-financial-results-for-the-first-six-mon-bgm-20220930monthly0.5https://www.biopharmawatch.com/news/BGM/qilian-international-holding-group-ltd-jiuquan-economic-and-technological-development-zone-bgm-20220829monthly0.5https://www.biopharmawatch.com/news/BGM/qilian-international-holding-group-limited-reports-fiscal-year-2021-financial-results-jiuq-bgm-20220211monthly0.5https://www.biopharmawatch.com/news/BGM/qilian-international-holding-group-limited-reports-financial-results-for-the-first-six-mon-bgm-20210916monthly0.5https://www.biopharmawatch.com/news/BGM/qilian-international-holding-group-limited-reports-fiscal-year-2020-financial-results-jiuq-bgm-20210211monthly0.5https://www.biopharmawatch.com/news/BGM/qilian-international-holding-group-limited-announces-full-exercise-of-underwriters-over-al-bgm-20210119monthly0.5https://www.biopharmawatch.com/news/BGM/qilian-international-holding-group-limited-announces-pricing-of-initial-public-offering-ji-bgm-20210111monthly0.5https://www.biopharmawatch.com/news/HYPD/hyperion-defi-reports-1q-2026-financial-results-with-record-net-income-and-raises-guidance-hypd-20260514monthly0.5https://www.biopharmawatch.com/news/HYPD/hyperion-defi-reports-third-quarter-2025-financial-results-with-record-net-income-of-6-6-m-hypd-20251031monthly0.5https://www.biopharmawatch.com/news/HYPD/hyperion-defi-announces-strategic-partnership-with-felix-to-launch-hip-3-powered-perpetual-hypd-20251029monthly0.5https://www.biopharmawatch.com/news/HYPD/hyperion-defi-announces-appointment-of-david-knox-as-chief-financial-officer-paypal-s-form-hypd-20250929monthly0.5https://www.biopharmawatch.com/news/HYPD/hyperion-defi-provides-corporate-update-and-reports-second-quarter-2025-financial-results--hypd-20250813monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-announces-rebranding-and-corporate-name-change-to-hyperion-defi-inc-name-change-r-hypd-20250702monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-announces-co-branded-validator-with-kinetiq-kinetiq-x-hyperion-provides-a-premier-hypd-20250625monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-announces-50-million-investment-to-launch-a-hyperliquid-hype-token-cryptocurrency-hypd-20250617monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-provides-updates-on-potential-merger-with-betaliq-and-development-of-the-optejet--hypd-20250519monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-enters-into-non-binding-letter-of-intent-to-effect-reverse-merger-with-betaliq-co-hypd-20250320monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-announces-1-for-80-reverse-stock-split-reverse-stock-split-when-effective-is-inte-hypd-20250128monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-inc-announces-pricing-of-1-9-million-registered-direct-offering-hypd-20241206monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-inc-announces-pricing-of-1-3-million-registered-direct-offering-hypd-20241125monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-provides-update-on-phase-3-chaperone-study-a-review-of-study-data-by-an-independe-hypd-20241115monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-reports-third-quarter-2024-financial-results-and-provides-corporate-update-advanc-hypd-20241112monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-inc-announces-pricing-of-4-million-registered-direct-offering-hypd-20240927monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-announces-appointment-of-experienced-finance-and-accounting-executive-andrew-jone-hypd-20240903monthly0.5https://www.biopharmawatch.com/news/HYPD/august-2024-our-vision-is-to-improve-yours-with-topical-ophthalmic-therapies-that-are-easi-hypd-20240823monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-inc-announces-proposed-public-offering-hypd-20240820monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-reports-second-quarter-2024-financial-results-and-provides-corporate-update-follo-hypd-20240812monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-announces-pricing-of-5m-registered-direct-offering-hypd-20240628monthly0.5https://www.biopharmawatch.com/news/HYPD/june-2024-we-are-the-optejet-company-developing-and-commercializing-ophthalmic-therapeutic-hypd-20240604monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-reports-first-quarter-2024-financial-results-and-provides-updates-on-its-myopia-p-hypd-20240515monthly0.5https://www.biopharmawatch.com/news/HYPD/march-2024-we-are-the-optejet-xae-company-developing-and-commercializing-ophthalmic-therap-hypd-20240319monthly0.5https://www.biopharmawatch.com/news/HYPD/january-2024-we-are-the-optejet-company-developing-and-commercializing-ophthalmic-drug-dev-hypd-20240131monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-re-acquires-development-and-commercialization-rights-to-micropine-in-the-u-s-and--hypd-20240116monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-reports-third-quarter-2023-financial-results-and-provides-business-update-acquire-hypd-20231113monthly0.5https://www.biopharmawatch.com/news/HYPD/september-2023-eyen-com-v2-0012-1-forward-looking-statements-except-for-historical-informa-hypd-20230920monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-announces-12-hypd-20230824monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-acquires-u-s-commercial-rights-to-app13007-clobetasol-propionate-ophthalmic-nanos-hypd-20230816monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-reports-second-quarter-2023-financial-results-and-provides-business-update-announ-hypd-20230810monthly0.5https://www.biopharmawatch.com/news/HYPD/annual-meeting-1-forward-looking-statements-except-for-historical-information-all-the-stat-hypd-20230627monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-reports-first-quarter-2023-financial-results-and-provides-business-update-announc-hypd-20230511monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-announces-fda-approval-of-mydcombi-the-first-ophthalmic-spray-for-mydriasis-which-hypd-20230508monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-reports-fourth-quarter-2022-financial-results-and-provides-business-update-announ-hypd-20230330monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-announces-independent-director-stephen-benjamin-to-step-down-to-assume-role-of-he-hypd-20230228monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-announces-development-collaboration-agreement-with-formosa-pharmaceuticals-collab-hypd-20230215monthly0.5https://www.biopharmawatch.com/news/HYPD/making-it-possible-february-2023-eyenovia-com-1-except-for-historical-information-all-the--hypd-20230130monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-announces-fda-acceptance-of-new-drug-application-for-mydcombi-for-in-office-pupil-hypd-20221213monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-announces-promotion-of-bren-kern-to-chief-operating-officer-and-corporate-vice-pr-hypd-20221208monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-announces-15-million-credit-facility-with-avenue-venture-debt-fund-transaction-pr-hypd-20221129monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-reports-third-quarter-2022-financial-results-and-provides-business-update-announc-hypd-20221110monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-announces-positive-results-from-vision-2-phase-3-study-of-microline-as-a-potentia-hypd-20221020monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-announces-planned-retirement-of-lead-independent-director-ken-lee-jr-hypd-20220930monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-reports-second-quarter-2022-financial-results-announced-appointment-of-michael-ro-hypd-20220810monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-announces-appointment-of-ophthalmic-industry-veteran-michael-rowe-as-chief-execut-hypd-20220727monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-announces-appointments-of-dr-ellen-strahlman-and-dr-ram-palanki-as-new-and-indepe-hypd-20220707monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-announces-planned-chief-executive-officer-transition-ceo-dr-sean-ianchulev-will-t-hypd-20220607monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-reports-first-quarter-2022-financial-results-mydcombi-nda-resubmission-on-track-f-hypd-20220512monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-inc-stock-ownership-guidelines-purpose-the-board-of-directors-board-of-eyenovia-i-hypd-20220512monthly0.5https://www.biopharmawatch.com/news/HYPD/making-it-possible-april-2022-eyenovia-com-1-except-for-historical-information-all-the-sta-hypd-20220404monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-reports-fourth-quarter-and-full-year-2021-financial-results-successfully-complete-hypd-20220328monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-strengthens-balance-sheet-with-a-15-million-institutional-capital-investment-from-hypd-20220304monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-concludes-type-a-meeting-with-fda-related-to-mydcombi-nda-resubmission-no-additio-hypd-20220208monthly0.5https://www.biopharmawatch.com/news/HYPD/making-it-possible-december-2021-eyenovia-com-1-except-for-historical-information-all-the--hypd-20211206monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-reports-third-quarter-2021-financial-results-on-track-with-vision-2-phase-3-presb-hypd-20211110monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-announces-first-patient-enrolled-in-phase-3-vision-2-trial-of-microline-for-presb-hypd-20211104monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-announces-reclassification-of-mydcombi-tm-as-drug-device-combination-product-by-f-hypd-20211025monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-reports-second-quarter-2021-financial-results-announced-positive-topline-data-fro-hypd-20210811monthly0.5https://www.biopharmawatch.com/news/HYPD/making-it-possible-june-2021-except-for-historical-information-all-of-the-statements-expec-hypd-20210621monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-highlights-recent-progress-in-three-phase-3-programs-nda-review-progress-and-lice-hypd-20210615monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-announces-positive-topline-results-from-vision-1-phase-3-clinical-study-of-microl-hypd-20210525monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-reports-first-quarter-2021-financial-results-mydcombi-pdufa-date-confirmed-for-hypd-20210512monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-announces-new-25-million-credit-facility-with-silicon-valley-bank-hypd-20210510monthly0.5https://www.biopharmawatch.com/news/HYPD/making-it-possible-may-2021-except-for-historical-information-all-of-the-statements-expect-hypd-20210505monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-announces-appointment-of-renowned-ophthalmologist-and-scientific-leader-dr-julia--hypd-20210401monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-reports-fourth-quarter-and-full-year-2020-financial-results-announces-mydcombi-ex-hypd-20210325monthly0.5https://www.biopharmawatch.com/news/HYPD/making-it-possible-march-2021-except-for-historical-information-all-of-the-statements-expe-hypd-20210315monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-announces-fda-acceptance-of-the-mydcombi-nda-pdufa-date-expected-4q-2021-hypd-20210302monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-submits-new-drug-application-to-fda-for-pharmacologic-mydriasis-with-mydcombi-tar-hypd-20201229monthly0.5https://www.biopharmawatch.com/news/HYPD/making-it-possible-december-18-2020-hypd-20201218monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-announces-first-patients-enrolled-in-phase-3-study-of-microline-for-presbyopia-to-hypd-20201216monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-announces-fda-acceptance-of-ind-for-microline-for-presbyopia-clearing-path-to-ini-hypd-20201203monthly0.5https://www.biopharmawatch.com/news/HYPD/making-it-possible-december-2020-except-for-historical-information-all-of-the-statements-e-hypd-20201110monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-reports-third-quarter-2020-financial-results-company-to-host-conference-call-and--hypd-20201110monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-investor-contacts-john-gandolfo-jgandolfo-eyenovia-com-917-289-1117-eric-ribner-l-hypd-20201012monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-inc-announces-proposed-public-offering-of-common-stock-hypd-20200818monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-reports-second-quarter-2020-financial-results-new-york-ny-hypd-20200812monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-and-arctic-vision-announce-exclusive-collaboration-and-license-agreement-to-devel-hypd-20200811monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-resumes-recruitment-of-phase-iii-chaperone-study-for-progressive-myopia-new-york--hypd-20200630monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-reports-first-quarter-2020-financial-results-new-york-ny-hypd-20200513monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-reports-fourth-quarter-and-full-year-2019-financial-results-new-york-ny-hypd-20200325monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-inc-announces-approximately-6-0-million-private-placement-new-york-ny-hypd-20200323monthly0.5https://www.biopharmawatch.com/news/HYPD/making-it-possible-november-2019-except-for-historical-information-all-of-the-statements-e-hypd-20191119monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-reports-third-quarter-2019-financial-results-new-york-ny-hypd-20191113monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-advances-microline-for-the-treatment-of-presbyopia-towards-phase-iii-development--hypd-20191029monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-reports-second-quarter-2019-financial-results-new-york-ny-hypd-20190812monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-inc-announces-proposed-public-offering-of-common-stock-hypd-20190710monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-enrolls-first-patient-in-phase-iii-chaperone-study-for-progressive-myopia-program-hypd-20190604monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-reports-first-quarter-2019-financial-results-new-york-ny-hypd-20190514monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-reports-fourth-quarter-and-full-year-2018-financial-results-new-york-ny-hypd-20190327monthly0.5https://www.biopharmawatch.com/news/HYPD/making-it-possible-analyst-investor-lunch-february-27-2019-hypd-20190227monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-announces-confirmatory-results-from-second-microstat-phase-iii-registration-study-hypd-20190225monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-confirms-expanded-microprost-phase-iii-indication-to-enroll-broad-patient-populat-hypd-20190213monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-announces-fda-acceptance-of-ind-application-for-micropine-to-reduce-the-progressi-hypd-20190206monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-announces-positive-results-in-the-microstat-mist-1-phase-iii-registration-study-f-hypd-20190130monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-prices-public-offering-of-common-stock-new-york-new-york-hypd-20181219monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-completes-patient-enrollment-in-microstat-mist-1-study-and-enrolls-first-patient--hypd-20181203monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-initiates-phase-iii-microstat-program-for-pharmacologic-mydriasis-enrolls-first-p-hypd-20181126monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-reports-third-quarter-2018-financial-results-new-york-ny-hypd-20181113monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-reports-second-quarter-2018-financial-results-new-york-ny-hypd-20180814monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-s-eyn-pg21-trial-evaluating-high-precision-microdose-of-latanoprost-demonstrates--hypd-20180813monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-reports-first-quarter-2018-financial-results-and-completion-of-eyn-pg21-study-new-hypd-20180509monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-announces-fourth-quarter-and-full-year-2017-financial-results-successfully-comple-hypd-20180402monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-appoints-three-industry-veterans-to-board-of-directors-new-york-ny-hypd-20180326monthly0.5https://www.biopharmawatch.com/news/HYPD/eyenovia-announces-pricing-of-initial-public-offering-new-york-ny-hypd-20180125monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-22-east-broadway-gardner-massachusetts-01440-3338-telephone-9-poci-20250320monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-22-east-broadway-gardner-massachusetts-01440-3338-telephone-9-poci-20250304monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-22-east-broadway-gardner-massachusetts-01440-3338-telephone-9-poci-20250220monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-22-east-broadway-gardner-massachusetts-01440-3338-telephone-9-poci-20240930monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-announces-pricing-of-1-4-million-registered-direct-offering-of-common-sto-poci-20240814monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-22-east-broadway-gardner-massachusetts-01440-3338-telephone-9-poci-20230615monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-22-east-broadway-gardner-massachusetts-01440-3338-telephone-9-poci-20230612monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-22-east-broadway-gardner-massachusetts-01440-3338-telephone-9-poci-20230607monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-22-east-broadway-gardner-massachusetts-01440-3338-telephone-9-poci-20230509monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-22-east-broadway-gardner-massachusetts-01440-3338-telephone-9-poci-20221020monthly0.5https://www.biopharmawatch.com/news/POCI/corporate-presentation-october-2019-otcqb-peye-forward-looking-statements-this-presentatio-poci-20191003monthly0.5https://www.biopharmawatch.com/news/POCI/ross-opitcal-industries-inc-financial-statements-for-the-years-ended-poci-20190708monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-22-east-broadway-gardner-massachusetts-01440-3338-telephone-9-poci-20180731monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-22-east-broadway-gardner-massachusetts-01440-3338-telephone-9-poci-20071120monthly0.5https://www.biopharmawatch.com/news/POCI/unassociated-document-precision-optics-corporation-22-east-broadway-gardner-massachusetts--poci-20071001monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-22-east-broadway-gardner-massachusetts-01440-3338-telephone-9-poci-20070515monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-22-east-broadway-gardner-massachusetts-01440-3338-telephone-9-poci-20070215monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-22-east-broadway-gardner-massachusetts-01440-3338-telephone-9-poci-20070201monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-inc-2006-equity-incentive-plan-1-defined-terms-exhibit-a-whic-poci-20061204monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-22-east-broadway-gardner-massachusetts-01440-3338-telephone-9-poci-20061115monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-22-east-broadway-gardner-massachusetts-01440-3338-telephone-9-poci-20060929monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-22-east-broadway-gardner-massachusetts-01440-3338-telephone-9-poci-20060920monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-22-east-broadway-gardner-massachusetts-01440-3338-telephone-9-poci-20060511monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-22-east-broadway-gardner-massachusetts-01440-3338-telephone-9-poci-20060419monthly0.5https://www.biopharmawatch.com/news/POCI/unassociated-document-news-release-page-1-of-4-poci-20060210monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-22-east-broadway-gardner-massachusetts-01440-3338-telephone-9-poci-20051123monthly0.5https://www.biopharmawatch.com/news/POCI/page-1-of-4-poci-20051114monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-22-east-broadway-gardner-massachusetts-01440-3338-telephone-9-poci-20050928monthly0.5https://www.biopharmawatch.com/news/POCI/unassociated-document-precision-optics-corporation-22-east-broadway-gardner-massachusetts--poci-20050805monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-22-east-broadway-gardner-massachusetts-01440-3338-telephone-9-poci-20050620monthly0.5https://www.biopharmawatch.com/news/POCI/unassociated-document-precision-optics-corporation-22-east-broadway-gardner-massachusetts--poci-20050609monthly0.5https://www.biopharmawatch.com/news/POCI/monday-poci-20050509monthly0.5https://www.biopharmawatch.com/news/POCI/unassociated-document-precision-optics-corporation-22-east-broadway-gardner-massachusetts--poci-20050120monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-22-east-broadway-gardner-massachusetts-01440-3338-telephone-9-poci-20041222monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-inc-amended-and-restated-1997-incentive-plan-1-defined-terms--poci-20041130monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-22-east-broadway-gardner-massachusetts-01440-3338-telephone-9-poci-20041110monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-22-east-broadway-gardner-massachusetts-01440-3338-telephone-9-poci-20041021monthly0.5https://www.biopharmawatch.com/news/POCI/precision-optics-corporation-22-east-broadway-gardner-massachusetts-01440-3338-telephone-9-poci-20040903monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ltd-announces-financial-results-for-the-third-quarter--apt-20171108monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ltd-announces-financial-results-for-the-second-quarter-apt-20170802monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ltd-announces-financial-results-for-the-first-quarter--apt-20170509monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-james-w-a-buchan-to-join-the-board-of-directors-for-immediate-release-apt-20170316monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ltd-announces-financial-results-for-the-fourth-quarter-apt-20170307monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ltd-announces-financial-results-for-the-third-quarter--apt-20161102monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ltd-announces-financial-results-for-the-second-quarter-apt-20160803monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ltd-announces-first-quarter-financial-results-first-qu-apt-20160504monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ltd-announces-financial-results-for-the-fourth-quarter-apt-20160302monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-realigns-executive-titles-lloyd-hoffman-named-ceo-and--apt-20151229monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ltd-announces-financial-results-for-the-third-quarter--apt-20151104monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ceo-sheldon-hoffman-retires-company-president-al-milla-apt-20150923monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ltd-announces-financial-results-for-the-2015-second-qu-apt-20150804monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ltd-announces-financial-results-for-the-2015-first-qua-apt-20150506monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ltd-announces-financial-results-for-the-fourth-quarter-apt-20150305monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ltd-announces-financial-results-for-the-third-quarter--apt-20141023monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ltd-announces-financial-results-for-the-second-quarter-apt-20140805monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-ltd-l-t-d-alpha-pro-tech-ltd-announces-financial-results-for-the-first-quar-apt-20140506monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ltd-announces-financial-results-for-the-fourth-quarter-apt-20140305monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ltd-announces-financial-results-for-the-third-quarter--apt-20131105monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ltd-announces-financial-results-for-the-second-quarter-apt-20130806monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ltd-announces-financial-results-for-the-first-quarter--apt-20130506monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ltd-announces-financial-results-for-the-fourth-quarter-apt-20130305monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ltd-announces-financial-results-for-the-third-quarter--apt-20121106monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ltd-announces-financial-results-for-the-second-quarter-apt-20120807monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ltd-announces-financial-results-for-the-first-quarter--apt-20120507monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ltd-announces-financial-results-for-the-fourth-quarter-apt-20120314monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ltd-announces-financial-results-for-the-third-quarter--apt-20111109monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ltd-announces-financial-results-for-the-second-quarter-apt-20110803monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ltd-announces-first-quarter-2011-financial-results-bui-apt-20110506monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-alpha-pro-tech-ltd-announces-fourth-quarter-and-full-year-2010-financial-re-apt-20110315monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ltd-announces-third-quarter-2010-financial-results-com-apt-20101109monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-ltd-alpha-pro-tech-ltd-announces-financial-results-for-the-second-quarter-a-apt-20100810monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ltd-announces-first-quarter-2010-financial-results-fir-apt-20100506monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ltd-revises-disposable-protective-apparel-distribution-apt-20100329monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ltd-announces-fourth-quarter-and-full-year-financial-r-apt-20100309monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ltd-announces-financial-results-for-the-third-quarter--apt-20091027monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ltd-announces-financial-results-for-the-second-quarter-apt-20090805monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-ltd-alpha-pro-tech-ltd-signs-three-year-renewable-contract-with-fortune-500-apt-20080909monthly0.5https://www.biopharmawatch.com/news/APT/alpha-pro-tech-l-t-d-alpha-pro-tech-ltd-to-announce-2008-second-quarter-results-on-august--apt-20080731monthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-therapeutics-reports-business-updates-and-first-quarter-2026-financial-results--mgx-20260511monthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-therapeutics-reports-business-updates-and-full-year-2025-financial-results-comp-mgx-20260305monthly0.5https://www.biopharmawatch.com/news/MGX/xfeff-metagenomi-announces-corporate-name-change-to-metagenomi-therapeutics-inc-and-highli-mgx-20260112monthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-reports-business-updates-and-first-quarter-2025-financial-results-nonhuman-prim-mgx-20250513monthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-reports-business-updates-and-full-year-2024-financial-results-hemophilia-a-pres-mgx-20250317monthly0.5https://www.biopharmawatch.com/news/MGX/rd-annual-j-p-morgan-healthcare-conference-nasdaq-mgx-january-2025-unlocking-4-billion-yea-mgx-20250116monthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-presents-updated-preclinical-data-in-hemophilia-a-at-american-society-of-hemato-mgx-20241209monthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-reports-business-updates-and-third-quarter-2024-financial-results-initiating-in-mgx-20241113monthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-announces-preclinical-data-for-lead-hemophilia-a-program-demonstrating-durable--mgx-20240903monthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-reports-business-updates-and-second-quarter-2024-financial-results-declared-dev-mgx-20240814monthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-presents-data-at-scientific-conferences-and-first-quarter-2024-financial-result-mgx-20240514monthly0.5https://www.biopharmawatch.com/news/MGX/nasdaq-listed-mgx-business-update-call-may-1st-2024-5pm-et-unlocking-4-billion-years-of-mi-mgx-20240501monthly0.5https://www.biopharmawatch.com/news/MGX/metagenomi-reports-business-updates-and-full-year-2023-financial-results-demonstrated-nonh-mgx-20240327monthly0.5https://www.biopharmawatch.com/news/DCGO/docgo-announces-first-quarter-2026-results-company-increases-2026-revenue-guidance-based-o-dcgo-20260511monthly0.5https://www.biopharmawatch.com/news/DCGO/docgo-announces-fourth-quarter-and-full-year-2025-results-company-raises-2026-revenue-and--dcgo-20260316monthly0.5https://www.biopharmawatch.com/news/DCGO/docgo-announces-third-quarter-2025-results-company-achieves-record-volumes-across-all-majo-dcgo-20251110monthly0.5https://www.biopharmawatch.com/news/DCGO/docgo-acquires-virtual-care-platform-steadymd-expands-telehealth-services-across-all-50-st-dcgo-20250930monthly0.5https://www.biopharmawatch.com/news/DCGO/docgo-announces-second-quarter-2025-results-company-reiterates-2025-revenue-and-adjusted-e-dcgo-20250807monthly0.5https://www.biopharmawatch.com/news/DCGO/docgo-announces-first-quarter-2025-results-company-focuses-on-growing-medical-transportati-dcgo-20250508monthly0.5https://www.biopharmawatch.com/news/DCGO/docgo-announces-fourth-quarter-and-full-year-2024-results-company-surpasses-700-000-total--dcgo-20250227monthly0.5https://www.biopharmawatch.com/news/DCGO/docgo-announces-third-quarter-2024-results-company-significantly-expands-operations-on-the-dcgo-20241107monthly0.5https://www.biopharmawatch.com/news/DCGO/docgo-appoints-healthcare-visionary-dr-stephen-k-klasko-as-chair-of-the-board-dcgo-20240930monthly0.5https://www.biopharmawatch.com/news/DCGO/docgo-announces-strong-second-quarter-2024-results-company-raises-cash-flow-from-operation-dcgo-20240807monthly0.5https://www.biopharmawatch.com/news/DCGO/docgo-announces-strong-first-quarter-2024-results-company-reports-first-quarter-net-income-dcgo-20240508monthly0.5https://www.biopharmawatch.com/news/DCGO/document-docgo-announces-record-fourth-quarter-and-full-year-2023-results-company-updates--dcgo-20240228monthly0.5https://www.biopharmawatch.com/news/DCGO/docgo-announces-share-buyback-program-dcgo-20240131monthly0.5https://www.biopharmawatch.com/news/DCGO/document-docgo-provides-additional-information-to-refute-misleading-short-seller-report-ne-dcgo-20240116monthly0.5https://www.biopharmawatch.com/news/DCGO/document-docgo-rejects-short-seller-report-and-releases-preliminary-2024-revenue-guidance--dcgo-20240110monthly0.5https://www.biopharmawatch.com/news/DCGO/docgo-announces-record-third-quarter-2023-results-company-raises-2023-revenue-guidance-to--dcgo-20231106monthly0.5https://www.biopharmawatch.com/news/DCGO/adolfo-carri-oacute-n-jr-commissioner-office-of-the-commissioner-100-gold-street-new-york--dcgo-20230906monthly0.5https://www.biopharmawatch.com/news/DCGO/docgo-announces-record-second-quarter-2023-results-company-raises-2023-revenue-guidance-to-dcgo-20230807monthly0.5https://www.biopharmawatch.com/news/DCGO/proactive-health-care-revolution-05-06-07-08-excellence-in-operations-care-delivery-growth-dcgo-20230620monthly0.5https://www.biopharmawatch.com/news/DCGO/docgo-announces-first-quarter-2023-results-company-reiterates-2023-revenue-guidance-of-500-dcgo-20230508monthly0.5https://www.biopharmawatch.com/news/DCGO/docgo-announces-fourth-quarter-and-full-year-2022-results-2022-revenue-increased-to-440-5--dcgo-20230313monthly0.5https://www.biopharmawatch.com/news/DCGO/docgo-announces-stan-vashovsky-to-continue-to-serve-as-chairman-of-its-board-of-directors--dcgo-20221229monthly0.5https://www.biopharmawatch.com/news/DCGO/docgo-appoints-veteran-technology-human-resources-executive-vina-leite-ms-to-its-board-of--dcgo-20221114monthly0.5https://www.biopharmawatch.com/news/DCGO/docgo-announces-strong-third-quarter-2022-results-q3-revenue-of-104-3-million-up-22-year-o-dcgo-20221107monthly0.5https://www.biopharmawatch.com/news/DCGO/docgo-announces-90-million-line-of-credit-with-citibank-n-a-available-funds-to-be-used-for-dcgo-20221102monthly0.5https://www.biopharmawatch.com/news/DCGO/docgo-announces-redemption-of-all-outstanding-warrants-dcgo-20220815monthly0.5https://www.biopharmawatch.com/news/DCGO/docgo-announces-strong-second-quarter-2022-results-q2-revenue-of-109-5-million-up-76-year--dcgo-20220808monthly0.5https://www.biopharmawatch.com/news/DCGO/docgo-announces-share-repurchase-program-of-up-to-40-million-dcgo-20220524monthly0.5https://www.biopharmawatch.com/news/DCGO/docgo-announces-strong-first-quarter-2022-results-q1-revenue-of-118-million-up-137-over-co-dcgo-20220509monthly0.5https://www.biopharmawatch.com/news/DCGO/docgo-names-lee-bienstock-as-chief-operating-officer-to-drive-strategic-expansion-bienstoc-dcgo-20220314monthly0.5https://www.biopharmawatch.com/news/DCGO/docgo-announces-record-fourth-quarter-and-full-year-2021-results-q4-and-full-year-revenue--dcgo-20220314monthly0.5https://www.biopharmawatch.com/news/DCGO/docgo-announces-record-preliminary-fourth-quarter-2021-revenue-full-year-and-fourth-quarte-dcgo-20220128monthly0.5https://www.biopharmawatch.com/news/DCGO/docgo-announces-increase-in-full-year-2021-guidance-annual-revenues-expected-to-reach-over-dcgo-20211201monthly0.5https://www.biopharmawatch.com/news/DCGO/ambulnz-inc-and-subsidiaries-condensed-consolidated-financial-statements-for-the-periods-e-dcgo-20211115monthly0.5https://www.biopharmawatch.com/news/DCGO/unaudited-pro-forma-condensed-combined-financial-statements-defined-terms-included-below-h-dcgo-20211112monthly0.5https://www.biopharmawatch.com/news/DCGO/motion-acquisition-corp-and-docgo-announce-shareholder-approval-of-business-combination-dcgo-20211102monthly0.5https://www.biopharmawatch.com/news/DCGO/motion-acquisition-corp-and-docgo-announce-docgo-s-record-preliminary-second-quarter-2021--dcgo-20210720monthly0.5https://www.biopharmawatch.com/news/DCGO/motion-acquisition-corp-receives-nasdaq-notification-of-non-compliance-with-listing-rules--dcgo-20210528monthly0.5https://www.biopharmawatch.com/news/DCGO/a-l-l-r-i-g-h-t-s-r-e-s-e-r-v-e-d-d-o-c-g-o-investor-p-r-ese-n-t-a-tio-n-may-2021-where-te-dcgo-20210521monthly0.5https://www.biopharmawatch.com/news/DCGO/motion-acquisition-corp-and-docgo-announce-docgo-s-record-preliminary-first-quarter-2021-r-dcgo-20210428monthly0.5https://www.biopharmawatch.com/news/DCGO/set-forth-below-is-a-transcript-of-a-recorded-investor-presentation-made-by-officers-of-mo-dcgo-20210308monthly0.5https://www.biopharmawatch.com/news/DCGO/ambulnz-dba-docgo-a-leading-provider-of-last-mile-telehealth-and-integrated-medical-mobili-dcgo-20210309monthly0.5https://www.biopharmawatch.com/news/DCGO/motion-acquisition-corp-report-of-independent-registered-public-accounting-firm-f-2-balanc-dcgo-20201019monthly0.5https://www.biopharmawatch.com/news/DCGO/motion-acquisition-corp-announces-pricing-of-115-000-000-initial-public-offering-new-york--dcgo-20201015monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-fourth-quarter-2025-financial-results-highlighted-by-publication-srts-20260212monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-appoints-larry-biscotti-to-its-board-of-directors-boca-raton-fla-sensus--srts-20260112monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-appoints-eric-sachetta-to-its-board-of-directors-seasoned-financial-exec-srts-20251112monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-third-quarter-2025-financial-results-centers-for-medicare-medica-srts-20251106monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-second-quarter-2025-financial-results-shipped-19-srt-systems-dur-srts-20250807monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-first-quarter-2025-financial-results-21-srt-systems-shipped-duri-srts-20250515monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-buys-back-shares-boca-raton-fla-srts-20250211monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-fourth-quarter-and-full-year-2024-financial-results-shipped-a-re-srts-20250205monthly0.5https://www.biopharmawatch.com/news/SRTS/this-revised-news-release-replaces-the-one-issued-on-srts-20241114monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-third-quarter-2024-financial-res-ults-with-revenues-more-than-do-srts-20241114monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-second-quarter-2024-financial-results-with-revenues-more-than-do-srts-20240808monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-first-quarter-2024-financial-results-with-revenues-up-more-than--srts-20240509monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-fourth-quarter-and-full-year-2023-financial-results-fourth-quart-srts-20240208monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-third-quarter-2023-financial-results-revenues-of-3-9-million-ref-srts-20231109monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-second-quarter-2023-financial-results-revenues-increased-33-and--srts-20230803monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-first-quarter-2023-financial-results-lower-demand-for-srt-system-srts-20230503monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-fourth-quarter-2022-financial-results-include-quarterly-revenues-of-13-1-srts-20230209monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-announces-preliminary-fourth-quarter-2022-revenues-fourth-quarter-revenu-srts-20230105monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-third-quarter-2022-financial-results-profitability-continues-wit-srts-20221103monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-second-quarter-2022-financial-results-feature-revenue-growth-of-124-dilu-srts-20220804monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-first-quarter-2022-financial-results-feature-revenue-growth-of-237-dilut-srts-20220505monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-announces-share-repurchase-program-boca-raton-fla-srts-20220309monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-record-sales-and-earnings-for-the-2021-fourth-quarter-4q21-dilut-srts-20220210monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-expects-record-4q-2021-sales-and-continued-growth-in-1q-2022-profiles-ne-srts-20220105monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-third-quarter-2021-financial-results-achieves-profitability-on-r-srts-20211104monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-second-quarter-2021-financial-results-revenues-of-5-4-million-up-srts-20210805monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-first-quarter-2021-financial-results-revenues-up-83-year-over-ye-srts-20210506monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-fourth-quarter-and-full-year-2020-financial-results-achieves-fou-srts-20210225monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-third-quarter-2020-financial-results-conference-call-begins-at-4-srts-20201105monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-second-quarter-2020-financial-results-conference-call-begins-at--srts-20200806monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-acquires-two-mobile-aesthetic-laser-companies-in-florida-establishes-new-srts-20200804monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-first-quarter-2020-financial-results-conference-call-begins-at-4-srts-20200507monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-fourth-quarter-and-full-year-2019-financial-results-fourth-quart-srts-20200213monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-third-quarter-srts-20191106monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-second-quarter-srts-20190808monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-first-quarter-2019-financial-results-premier-inc-adds-srt-to-its-srts-20190509monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-fourth-quarter-financial-results-feature-record-revenue-and-continued-do-srts-20190214monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-third-quarter-financial-results-feature-revenue-growth-of-32-shipped-18--srts-20181101monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-inc-announces-underwriters-exercise-of-option-srts-20180921monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-second-quarter-financial-results-feature-continued-strong-revenue-growth-srts-20180802monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-first-quarter-financial-results-featuring-37-revenue-growth-ship-srts-20180503monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-record-revenue-for-2017-fourth-quarter-and-full-year-ninth-conse-srts-20180201monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-third-quarter-financial-results-featuring-revenue-up-44-marks-ei-srts-20171102monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-record-second-quarter-financial-results-revenue-growth-of-39-mar-srts-20170803monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-first-quarter-financial-srts-20170504monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-fourth-quarter-and-full-year-2016-results-record-quarterly-reven-srts-20170202monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-third-quarter-2016-results-q3-revenues-increased-58-year-over-ye-srts-20161103monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-reports-second-quarter-2016-results-q2-revenues-increased-49-year-over-y-srts-20160804monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-inc-announces-separation-of-units-sold-in-srts-20160721monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-inc-appoints-dr-darrell-rigel-to-its-board-of-directors-past-president-o-srts-20160613monthly0.5https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-inc-announces-completion-of-initial-public-offering-including-underwrite-srts-20160608monthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-reports-broad-metabolic-improvements-with-aln1003-in-obese-mouse-studies-x2022-aln-tcrt-20260526monthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-reports-preclinical-aln1003-data-showing-effects-on-insulin-resistance-related-bio-tcrt-20260518monthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-announces-second-quarter-2023-financial-results-interim-clinical-data-tcrt-20230814monthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-reports-first-quarter-2023-financial-results-actively-enrolling-patie-tcrt-20230510monthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-generated-tcrt-20230307monthly0.5https://www.biopharmawatch.com/news/TCRT/attacking-solid-tumors-with-novel-tcr-t-cell-therapies-january-2023-forward-looking-statem-tcrt-20230109monthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-announces-proposed-public-offering-of-common-stock-tcrt-20221128monthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-reports-third-quarter-2022-financial-results-presented-early-data-hig-tcrt-20221114monthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-to-present-data-highlighting-its-huntr-tcr-discovery-platform-at-the--tcrt-20221107monthly0.5https://www.biopharmawatch.com/news/TCRT/objective-clinical-response-by-kras-mutation-specific-tcr-t-cell-therapy-in-previously-tre-tcrt-20220930monthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-highlights-data-from-tcr-t-library-phase-1-2-trial-at-the-cri-enci-aa-tcrt-20220921monthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-announces-early-clinical-data-showing-objective-clinical-response-usi-tcrt-20220906monthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-to-present-at-the-cri-enci-aacr-sixth-international-cancer-immunother-tcrt-20220824monthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-reports-second-quarter-2022-financial-results-advancing-tcr-t-library-tcrt-20220815monthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-appoints-abhishek-srivastava-ph-d-as-vice-president-technical-operati-tcrt-20220804monthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-and-the-national-cancer-institute-extend-cooperative-research-and-dev-tcrt-20220627monthly0.5https://www.biopharmawatch.com/news/TCRT/h-c-wainwright-global-investment-conference-tcrt-20220524monthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-reports-first-quarter-2022-financial-results-successfully-dosed-first-tcrt-20220516monthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-to-present-at-american-society-of-gene-and-cell-therapy-25th-annual-m-tcrt-20220502monthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-doses-first-patient-in-tcr-t-library-phase-1-2-trial-for-the-treatmen-tcrt-20220502monthly0.5https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-phase-1-2-tcrt-20220330monthly0.5https://www.biopharmawatch.com/news/TCRT/attacking-solid-tumors-with-novel-tcr-t-cell-therapies-oppenheimer-32nd-annual-healthcare--tcrt-20220317monthly0.5https://www.biopharmawatch.com/news/TCRT/attacking-solid-tumors-with-novel-tcr-t-cell-therapies-january-2022-forward-looking-statem-tcrt-20220126monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-announces-strategic-reduction-in-workforce-and-extension-in-cash-runway--tcrt-20210927monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-appoints-kevin-s-boyle-sr-as-chief-executive-officer-and-announces-other-tcrt-20210830monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-provides-second-quarter-2021-corporate-updates-accomplished-key-mileston-tcrt-20210809monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-reinforces-clear-and-bold-vision-for-delivering-value-at-annual-sharehol-tcrt-20210519monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-reports-first-quarter-2021-financial-results-and-provides-corporate-upda-tcrt-20210506monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-provides-leadership-and-corporate-updates-reports-fourth-quarter-and-ful-tcrt-20210225monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-announces-election-of-robert-postma-to-its-board-of-directors-boston-tcrt-20210205monthly0.5https://www.biopharmawatch.com/news/TCRT/forward-looking-statements-this-presentation-contains-certain-forward-looking-information--tcrt-20210114monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-comments-on-consent-solicitation-results-jaime-vieser-and-holger-weis-elected-to--tcrt-20201216monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-announces-chief-financial-officer-to-step-down-boston-tcrt-20201214monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-appoints-mary-thistle-to-board-of-directors-special-advisor-and-former-c-tcrt-20201116monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-reports-third-quarter-2020-financial-results-and-provides-corporate-upda-tcrt-20201105monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-appoints-kevin-buchi-to-its-board-of-directors-life-sciences-industry-ve-tcrt-20200922monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-reports-second-quarter-2020-financial-results-and-provides-corporate-upd-tcrt-20200806monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-presents-encouraging-clinical-data-for-controlled-il-12-for-the-treatmen-tcrt-20200529monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-reports-first-quarter-2020-financial-results-and-provides-corporate-upda-tcrt-20200507monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-reports-financial-results-for-fourth-quarter-and-full-year-2019-emergenc-tcrt-20200302monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-announces-pricing-of-public-offering-of-common-stock-boston-ma-tcrt-20200205monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-announces-proposed-public-offering-of-common-stock-boston-ma-tcrt-20200204monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-presents-encouraging-clinical-data-for-controlled-il-12-for-the-treatmen-tcrt-20191123monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-reports-third-quarter-2019-financial-results-phase-2-trial-of-sleeping-b-tcrt-20191107monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-and-md-anderson-cancer-center-announce-new-r-d-agreement-to-expand-tcr-t-tcrt-20191028monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-announces-fda-clearance-of-ind-for-rapid-personalized-manufacture-of-cd1-tcrt-20191001monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-reports-second-quarter-2019-financial-results-fda-cleared-ind-for-phase--tcrt-20190808monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-announces-45-million-warrant-exercise-by-existing-shareholders-in-a-priv-tcrt-20190729monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-names-nci-s-dr-drew-deniger-to-direct-tcr-t-cell-therapy-program-dr-deni-tcrt-20190703monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-initiates-phase-2-trial-evaluating-combination-therapy-of-controlled-il--tcrt-20190627monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-completes-enrollment-of-controlled-il-12-plus-opdivo-nivolumab-phase-1-c-tcrt-20190626monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-reports-first-quarter-2019-financial-results-and-reaffirms-clinical-time-tcrt-20190508monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-reports-fourth-quarter-and-full-year-2018-financial-results-and-provides-tcrt-20190305monthly0.5https://www.biopharmawatch.com/news/TCRT/forward-looking-statement-this-presentation-contains-certain-forward-looking-information-a-tcrt-20190110monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-posts-letter-to-stockholders-boston-ma-tcrt-20190107monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-announces-50-million-private-placement-boston-tcrt-20181112monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-announces-changes-to-board-of-directors-and-management-team-ceo-laurence-tcrt-20181016monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-and-precigen-redefine-relationships-announce-new-license-agreement-ziopharm-to-ho-tcrt-20181009monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-reports-second-quarter-2018-financial-results-and-provides-corporate-upd-tcrt-20180808monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-reports-on-status-of-investigational-new-drug-application-for-phase-1-tr-tcrt-20180618monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-reports-first-quarter-2018-financial-results-and-provides-corporate-upda-tcrt-20180510monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-reports-fourth-quarter-and-full-year-2017-financial-results-and-provides-tcrt-20180301monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-addresses-rumors-and-stock-volatility-affirms-2018-guidance-boston-ma-tcrt-20180206monthly0.5https://www.biopharmawatch.com/news/TCRT/this-presentation-contains-certain-forward-looking-information-about-ziopharm-oncology-inc-tcrt-20180111monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-provides-update-on-standout-technologies-during-the-36-th-annual-j-p-mor-tcrt-20180109monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-reports-third-quarter-2017-financial-results-and-provides-update-on-rece-tcrt-20171106monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-appoints-david-mauney-m-d-as-evp-and-chief-business-officer-boston-ma-tcrt-20170928monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-reports-second-quarter-2017-financial-results-and-provides-update-on-rec-tcrt-20170731monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-announces-positive-updated-results-of-ad-rts-hil-12-veledimex-in-recurre-tcrt-20170605monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-announces-pricing-of-50-million-follow-on-tcrt-20170512monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-announces-fda-acceptance-of-ind-for-cd33-specific-car-t-cell-therapy-tar-tcrt-20170502monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-reports-first-quarter-2017-financial-results-and-provides-update-on-rece-tcrt-20170501monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-announces-successful-end-of-phase-2-meeting-with-fda-for-ad-rts-hil-12-gene-thera-tcrt-20170327monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-reports-fourth-quarter-2016-financial-results-and-provides-update-on-recent-activ-tcrt-20170216monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-35th-annual-j-p-morgan-healthcare-conference-tcrt-20170111monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-and-intrexon-announce-cooperative-research-and-development-agreement-with-the-nat-tcrt-20170110monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-announces-clinical-data-on-ad-rts-hil-12-demonstrates-survival-benefits-in-patien-tcrt-20161117monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-reports-third-quarter-2016-financial-results-and-provides-update-on-recent-activi-tcrt-20161109monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-reports-second-quarter-2016-financial-results-and-provides-update-on-recent-activ-tcrt-20160809monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-issues-statement-clarifying-speculation-on-financing-activity-boston-ma-tcrt-20160720monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-provides-update-regarding-phase-i-study-of-gene-therapy-candidate-ad-rts-hil-12-i-tcrt-20160719monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-issues-statement-regarding-phase-i-study-of-gene-therapy-candidate-ad-rts-hil-12--tcrt-20160715monthly0.5https://www.biopharmawatch.com/news/TCRT/this-presentation-contains-certain-forward-looking-information-about-ziopharm-oncology-inc-tcrt-20160714monthly0.5https://www.biopharmawatch.com/news/TCRT/intrexon-and-ziopharm-amend-exclusive-channel-collaborations-to-improve-alignment-as-progr-tcrt-20160630monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-completes-enrollment-in-second-patient-cohort-and-initiates-enrollment-in-third-c-tcrt-20160627monthly0.5https://www.biopharmawatch.com/news/TCRT/this-presentation-contains-certain-forward-looking-information-about-ziopharm-oncology-inc-tcrt-20160609monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-announces-clinical-data-highlighting-favorable-interim-survival-results-with-gene-tcrt-20160518monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-reports-first-quarter-2016-financial-results-and-provides-update-on-recent-activi-tcrt-20160510monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-jefferies-immuno-oncology-summit-april-2016-forward-looking-statements-this-prese-tcrt-20160407monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-reports-fourth-quarter-2015-financial-results-and-provides-update-on-recent-activ-tcrt-20160224monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-announces-first-patient-treated-in-the-dose-escalation-portion-of-the-phase-1-stu-tcrt-20160224monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-34th-annual-j-p-morgan-healthcare-conference-january-2016-ziopharm-oncology-forwa-tcrt-20160111monthly0.5https://www.biopharmawatch.com/news/TCRT/this-presentation-contains-certain-forward-looking-information-about-ziopharm-oncology-inc-tcrt-20151216monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-announces-presentation-of-phase-1b-2-study-of-ad-rts-hil-12-gene-therapy-in-patie-tcrt-20151210monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-announces-presentation-of-data-from-cd19-specific-car-t-cell-therapy-programs-at--tcrt-20151207monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-announces-data-highlighting-ad-rts-hil-12-activity-in-glioma-at-sno-early-clinica-tcrt-20151119monthly0.5https://www.biopharmawatch.com/news/TCRT/synthetic-biology-leads-to-powerful-engineering-of-immune-system-immune-cells-are-capable--tcrt-20151112monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-reports-third-quarter-2015-financial-results-and-recent-activities-boston-ma-tcrt-20151102monthly0.5https://www.biopharmawatch.com/news/TCRT/intrexon-and-ziopharm-to-develop-immunotherapies-for-treatment-of-graft-versus-host-diseas-tcrt-20150928monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-appoints-scott-tarriff-to-its-board-of-directors-boston-tcrt-20150928monthly0.5https://www.biopharmawatch.com/news/TCRT/forward-looking-statements-this-presentation-contains-certain-forward-looking-information--tcrt-20150910monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-reports-second-quarter-2015-financial-results-and-recent-activities-boston-ma-tcrt-20150810monthly0.5https://www.biopharmawatch.com/news/TCRT/this-presentation-contains-certain-forward-looking-information-about-ziopharm-oncology-tha-tcrt-20150618monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-announces-caesar-j-belbel-chief-legal-officer-appointed-chief-operating-officer-b-tcrt-20150602monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-reports-first-quarter-2015-financial-results-and-recent-activities-boston-ma-tcrt-20150507monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-appoints-laurence-j-n-cooper-m-d-ph-d-chief-executive-officer-boston-ma-tcrt-20150507monthly0.5https://www.biopharmawatch.com/news/TCRT/exhibit-no-99-1-ziopharm-announces-initiation-of-phase-1b-2-study-of-ad-rts-hil-12-gene-th-tcrt-20150427monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-intrexon-synthetic-immuno-oncology-programs-strengthened-through-collaboration-wi-tcrt-20150330monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-reports-fourth-quarter-and-full-year-2014-financial-results-and-recent-activities-tcrt-20150226monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-announces-exercise-of-option-to-purchase-additional-shares-tcrt-20150212monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-announces-pricing-of-public-offering-of-common-stock-tcrt-20150203monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-announces-proposed-public-offering-of-common-stock-tcrt-20150202monthly0.5https://www.biopharmawatch.com/news/TCRT/the-future-of-cancer-therapy-jp-morgan-33rd-annual-healthcare-conference-january2015-www-z-tcrt-20150114monthly0.5https://www.biopharmawatch.com/news/TCRT/intrexon-ziopharm-and-md-anderson-in-exclusive-car-t-pact-exclusive-licensing-agreement-fo-tcrt-20150113monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-and-intrexon-present-clinical-and-preclinical-data-from-immuno-oncology-programs--tcrt-20141203monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-reports-third-quarter-2014-financial-results-provides-overview-of-activities-bost-tcrt-20141030monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-reports-second-quarter-2014-financial-results-and-reviews-recent-activities-bosto-tcrt-20140807monthly0.5https://www.biopharmawatch.com/news/TCRT/exhibit-no-99-1-ziopharm-oncology-and-solasia-pharma-announce-global-license-and-collabora-tcrt-20140731monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-announces-oral-presentation-highlighting-ad-rts-il-12-results-correlated-with-red-tcrt-20140522monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-reports-first-quarter-2014-financial-results-and-reviews-recent-activities-boston-tcrt-20140508monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-presents-preclinical-data-at-aacr-annual-meeting-supporting-controlled-dna-based--tcrt-20140408monthly0.5https://www.biopharmawatch.com/news/TCRT/this-presentation-contains-certain-forward-looking-information-about-ziopharm-oncology-tha-tcrt-20140328monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-reports-fourth-quarter-and-full-year-2013-financial-results-and-reviews-recent-ac-tcrt-20140303monthly0.5https://www.biopharmawatch.com/news/TCRT/the-future-of-cancer-therapy-bio-ceo-investor-conference-february-2014-www-ziopharm-com-fo-tcrt-20140210monthly0.5https://www.biopharmawatch.com/news/TCRT/this-presentation-contains-certain-forward-looking-information-about-ziopharm-oncology-tha-tcrt-20140115monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-reports-positive-interim-results-in-patients-with-advanced-melanoma-from-ongoing--tcrt-20131207monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-announces-unanimous-recombinant-dna-advisory-committee-rac-approval-for-phase-1-s-tcrt-20131206monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-prices-public-offering-of-common-stock-tcrt-20131024monthly0.5https://www.biopharmawatch.com/news/TCRT/mesoblast-intrexon-and-ziopharm-to-target-cancers-partnership-combines-mesoblast-s-cell-an-tcrt-20131023monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-announces-proposed-public-offering-of-common-stock-tcrt-20131022monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-announces-third-quarter-financial-results-and-updates-key-development-activities--tcrt-20131022monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-and-intrexon-announce-presentation-of-data-highlighting-regulated-gene-expression-tcrt-20131022monthly0.5https://www.biopharmawatch.com/news/TCRT/september-2013-forward-looking-statements-this-presentation-contains-certain-forward-looki-tcrt-20130927monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-announces-second-quarter-financial-results-and-updates-key-development-activities-tcrt-20130808monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-announces-first-quarter-financial-results-and-key-developments-highlights-include-tcrt-20130507monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-terminates-development-of-palifosfamide-in-metastatic-soft-tissue-sarcoma-restruc-tcrt-20130326monthly0.5https://www.biopharmawatch.com/news/TCRT/phase-3-trial-of-ziopharm-s-palifosfamide-in-first-line-metastatic-soft-tissue-sarcoma-rea-tcrt-20130212monthly0.5https://www.biopharmawatch.com/news/TCRT/indemnity-agreement-this-indemnity-agreement-this-agreement-dated-as-of-2012-is-made-by-an-tcrt-20130131monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-announces-compelling-clinical-activity-in-phase-1-study-of-ad-rts-il-12--tcrt-20121025monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-announces-third-quarter-financial-results-and-key-developments-highlights-include-tcrt-20121108monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-issues-statement-regarding-misleading-blog-post-tcrt-20121019monthly0.5https://www.biopharmawatch.com/news/TCRT/better-cancer-medicine-19-th-annual-newsmakers-in-the-biotech-industry-conference-forward--tcrt-20120907monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-announces-second-quarter-financial-results-and-key-developments-highlights-includ-tcrt-20120802monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-announces-new-executive-team-tcrt-20120716monthly0.5https://www.biopharmawatch.com/news/TCRT/jonathan-lewis-md-phd-chief-executive-officer-2012-research-development-day-tcrt-20120619monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-completes-enrollment-in-picasso-3-trial-evaluating-palifosfamide-in-fron-tcrt-20120602monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-appoints-jason-a-amello-as-executive-vice-president-and-chief-financial--tcrt-20120508monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-reports-first-quarter-financial-results-tcrt-20120503monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-presents-compelling-data-showing-palifosfamide-activity-in-breast-cancer-tcrt-20120403monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-presents-preclinical-data-at-aacr-meeting-demonstrating-significant-anti-tcrt-20120402monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-provides-update-on-picasso-3-trial-highly-rigorous-progression-free-surv-tcrt-20120402monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-reports-fourth-quarter-and-full-year-2011-financial-results-significant-progress--tcrt-20120229monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-reports-positive-preliminary-palifosfamide-overall-survival-data-from-ra-tcrt-20120213monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-prices-public-offering-of-common-stock-tcrt-20120120monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-announces-proposed-public-offering-of-common-stock-new-york-ny-tcrt-20120119monthly0.5https://www.biopharmawatch.com/news/TCRT/th-annual-j-p-morgan-healthcare-conference-jonathan-lewis-md-phd-chief-executive-officer-b-tcrt-20120111monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-granted-european-patent-allowance-for-palifosfamide-additional-patent-issuance-fo-tcrt-20111207monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-presents-preclinical-data-for-darinaparsin-effect-on-hedgehog-signaling--tcrt-20111113monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-reports-third-quarter-financial-results-and-highlights-ends-quarter-with-119-mill-tcrt-20111103monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-presents-promising-preclinical-pediatric-sarcoma-data-with-oral-and-iv-palifosfam-tcrt-20111028monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-reports-second-quarter-financial-results-and-highlights-ends-quarter-with-130-mil-tcrt-20110801monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-announces-acceptance-of-investigational-new-drug-application-for-zin-ati-tcrt-20110610monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-announces-initial-positive-data-presented-at-2011-asco-annual-meeting-from-first--tcrt-20110606monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-and-intrexon-announce-preclinical-study-results-at-2011-asgct-meeting-from-contro-tcrt-20110520monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-to-present-data-at-2011-asco-annual-meeting-from-first-ever-treatment-de-tcrt-20110519monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-files-investigational-new-drug-application-for-ad-rts-il-12-a-novel-dna--tcrt-20110513monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-reports-first-quarter-financial-results-and-highlights-ends-quarter-with-124-mill-tcrt-20110505monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-reports-fourth-quarter-and-full-year-2010-financial-results-new-york-ny-tcrt-20110301monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-announces-full-exercise-of-underwriter-s-option-tcrt-20110208monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-tcrt-20110203monthly0.5https://www.biopharmawatch.com/news/TCRT/announces-proposed-public-offering-of-common-stock-tcrt-20110203monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-receives-positive-opinion-for-orphan-drug-designation-for-darinaparsin-from-europ-tcrt-20110120monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-and-intrexon-announce-worldwide-partnership-for-synthetic-biology-dna-ba-tcrt-20110106monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-oncology-announces-first-patient-dosed-in-phase-i-study-of-palifosfamide-in-small-tcrt-20101229monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-tcrt-20101104monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-granted-japanese-patent-for-darinaparsin-new-york-ny-september-27-2010-ziopharm-o-tcrt-20100927monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-receives-fda-orphan-drug-designation-for-darinaparsin-in-the-treatment-of-periphe-tcrt-20100923monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-announces-initiation-of-palifosfamide-pivotal-study-front-line-therapy-trial-for--tcrt-20100719monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-provides-guidance-on-planned-pivotal-phase-iii-study-of-palifosfamide-in-metastat-tcrt-20100621monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-presents-positive-palifosfamide-picasso-phase-ii-results-in-oral-session-at-asco--tcrt-20100607monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-announces-proposed-public-offering-of-common-stock-tcrt-20100526monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-to-present-further-palifosfamide-picasso-phase-ii-results-in-oral-session-at-asco-tcrt-20100521monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-reports-first-quarter-financial-results-decreased-cash-burn-from-operations-conti-tcrt-20100430monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-elects-george-b-abercrombie-former-ceo-of-hoffmann-la-roche-to-board-of-directors-tcrt-20100406monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-reports-fourth-quarter-and-full-year-2009-tcrt-20100317monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-receives-important-palifosfamide-u-s-patent-allowance-additional-patent-issuances-tcrt-20100126monthly0.5https://www.biopharmawatch.com/news/TCRT/ziopharm-tcrt-20091203monthly0.5https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-announces-8-0-million-registered-direct-offering-and-concurrent-priv-esla-20260106monthly0.5https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-completes-second-dose-cohort-in-starlight-1-trial-of-eb103-with-comp-esla-20251106monthly0.5https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-announces-activation-of-additional-site-for-phase-i-ii-starlight-1-t-esla-20250605monthly0.5https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-announces-approximately-3-35-million-private-placement-equity-financ-esla-20250603monthly0.5https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-initiates-second-cohort-and-doses-first-patient-in-starlight-1-trial-esla-20250529monthly0.5https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-completes-first-dose-cohort-in-starlight-1-trial-and-receives-approv-esla-20250219monthly0.5https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-announces-appointment-of-hong-zhang-as-chairperson-and-board-member-esla-20240814monthly0.5https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-doses-first-patient-in-phase-i-ii-trial-of-anti-cd19-artemis-t-cells-esla-20240731monthly0.5https://www.biopharmawatch.com/news/ESLA/developing-cd19-redirected-artemis-t-cell-therapy-for-cancers-and-autoimmune-diseases-esla-20240410monthly0.5https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-announces-1-million-share-repurchase-authorization-emeryville-esla-20240130monthly0.5https://www.biopharmawatch.com/news/ESLA/description-of-the-business-combination-on-esla-20230929monthly0.5https://www.biopharmawatch.com/news/ESLA/tradeup-acquisition-corp-announces-extension-of-the-deadline-for-an-initial-business-combi-esla-20230918monthly0.5https://www.biopharmawatch.com/news/ESLA/tradeup-acquisition-corp-announces-extension-of-the-deadline-for-an-initial-business-combi-esla-20230818monthly0.5https://www.biopharmawatch.com/news/ESLA/tradeup-acquisition-corp-announces-extension-of-the-deadline-for-an-initial-business-combi-esla-20230718monthly0.5https://www.biopharmawatch.com/news/ESLA/tradeup-acquisition-corp-announces-meeting-date-for-stockholders-to-approve-the-business-c-esla-20230712monthly0.5https://www.biopharmawatch.com/news/ESLA/tradeup-acquisition-corp-announces-extension-of-the-deadline-for-an-initial-business-combi-esla-20230620monthly0.5https://www.biopharmawatch.com/news/ESLA/tradeup-acquisition-corp-announces-extension-of-the-deadline-for-an-initial-business-combi-esla-20230519monthly0.5https://www.biopharmawatch.com/news/ESLA/tradeup-acquisition-corp-announces-extension-of-the-deadline-for-an-initial-business-combi-esla-20230413monthly0.5https://www.biopharmawatch.com/news/ESLA/tradeup-acquisition-corp-announces-extension-of-the-deadline-for-an-initial-business-combi-esla-20230317monthly0.5https://www.biopharmawatch.com/news/ESLA/tradeup-acquisition-corp-announces-extension-of-the-deadline-for-an-initial-business-combi-esla-20230217monthly0.5https://www.biopharmawatch.com/news/ESLA/tradeup-acquisition-corp-announces-extension-of-the-deadline-for-an-initial-business-combi-esla-20230120monthly0.5https://www.biopharmawatch.com/news/ESLA/estrella-biopharma-inc-a-biopharmaceutical-company-to-become-a-publicly-traded-company-via-esla-20221003monthly0.5https://www.biopharmawatch.com/news/ESLA/tradeup-acquisition-corp-announces-the-separate-trading-of-its-common-stock-and-warrants-c-esla-20210903monthly0.5https://www.biopharmawatch.com/news/ESLA/to-this-current-report-on-form-8-k-f-11-esla-20210722monthly0.5https://www.biopharmawatch.com/news/ESLA/tradeup-acquisition-corp-announces-pricing-of-40-million-initial-public-offering-esla-20210714monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-inc-condensed-consolidated-statements-of-operations-and-comprehensive-l-xlo-20260512monthly0.5https://www.biopharmawatch.com/news/XLO/unlocking-the-potential-of-immuno-oncology-therapies-xlo-20260309monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-late-breaking-phase-2-data-for-vilastobart-in-patients-with-m-xlo-20251110monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-pipeline-and-business-updates-and-second-quarter-2025-financi-xlo-20250814monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-pricing-of-50-0-million-public-offering-xlo-20250602monthly0.5https://www.biopharmawatch.com/news/XLO/unleashing-the-potential-of-immuno-oncology-therapies-xlo-20250531monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-pipeline-and-business-updates-and-first-quarter-2025-financia-xlo-20250508monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-pipeline-and-business-updates-and-fourth-quarter-and-full-yea-xlo-20250311monthly0.5https://www.biopharmawatch.com/news/XLO/abbvie-and-xilio-therapeutics-announce-collaboration-and-option-agreement-to-develop-novel-xlo-20250212monthly0.5https://www.biopharmawatch.com/news/XLO/this-presentation-contains-forward-looking-statements-within-the-meaning-of-the-private-se-xlo-20250113monthly0.5https://www.biopharmawatch.com/news/XLO/unleashing-the-potential-of-immuno-oncology-therapies-xlo-20241219monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-pipeline-and-business-updates-and-third-quarter-2024-financia-xlo-20241107monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-pipeline-and-business-updates-and-second-quarter-2024-financi-xlo-20240808monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-pipeline-and-business-updates-and-first-quarter-2024-financia-xlo-20240514monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-pipeline-and-business-updates-and-fourth-quarter-and-full-yea-xlo-20240401monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-info-investors-melissa-forst-argot-partners-xilio-argotpartners-com-media-dan-budwic-xlo-20240328monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-initiation-of-enrollment-for-phase-1-combination-trial-of-xtx-xlo-20231207monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-pipeline-and-business-updates-and-third-quarter-2023-financia-xlo-20231109monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-announces-initial-monotherapy-safety-and-anti-tumor-activity-data-for-xtx202-a-tumor-xlo-20231106monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-promotion-of-katarina-luptakova-m-d-to-chief-medical-officer--xlo-20230905monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-pipeline-and-business-updates-and-second-quarter-2023-financi-xlo-20230817monthly0.5https://www.biopharmawatch.com/news/XLO/unleashing-the-potential-of-immuno-oncology-therapies-xlo-20230525monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-pipeline-and-business-updates-and-first-quarter-2023-financia-xlo-20230509monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-pipeline-and-business-updates-for-the-fourth-quarter-and-full-xlo-20230302monthly0.5https://www.biopharmawatch.com/news/XLO/unleashing-the-potential-of-immuno-oncology-therapies-xlo-20230109monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-pipeline-and-business-updates-and-third-quarter-2022-financia-xlo-20221109monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-encouraging-preliminary-phase-1-dose-escalation-data-for-xtx1-xlo-20220809monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-reports-pipeline-and-business-highlights-and-first-quarter-2022-financi-xlo-20220512monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-reports-pipeline-and-business-progress-and-fourth-quarter-and-full-year-xlo-20220301monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-appoints-yuan-xu-ph-d-to-its-board-of-directors-xlo-20220106monthly0.5https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-reports-pipeline-and-business-progress-and-third-quarter-2021-financial-xlo-20211202monthly0.5https://www.biopharmawatch.com/news/SCLX/dear-scilex-holding-company-stockholders-and-other-holders-of-scilex-holding-company-secur-sclx-20260430monthly0.5https://www.biopharmawatch.com/news/SCLX/kasowitz-llp-daniel-a-saunders-sbn-161051-dsaunders-kasowitz-com-robert-w-bosslet-sbn-2780-sclx-20260313monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-17-million-registered-direct-offering-sclx-20241212monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-15-million-registered-direct-offering-sclx-20240424monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-announces-10-million-bought-deal-offering-sclx-20240229monthly0.5https://www.biopharmawatch.com/news/SCLX/execution-version-non-binding-sclx-20230911monthly0.5https://www.biopharmawatch.com/news/SCLX/safe-harbor-statements-forward-looking-statements-certain-statements-contained-in-this-cor-sclx-20230622monthly0.5https://www.biopharmawatch.com/news/SCLX/note-to-stockholders-of-scilex-holding-company-scilex-in-connection-with-the-dividend-by-s-sclx-20230129monthly0.5https://www.biopharmawatch.com/news/SCLX/scilex-holding-company-a-majority-owned-subsidiary-of-sorrento-therapeutics-inc-nasdaq-srn-sclx-20221111monthly0.5https://www.biopharmawatch.com/news/SCLX/vickers-vantage-corp-i-announces-shareholder-approval-of-extension-of-deadline-to-complete-sclx-20220705monthly0.5https://www.biopharmawatch.com/news/SCLX/vickers-vantage-corp-i-sclx-20220411monthly0.5https://www.biopharmawatch.com/news/SCLX/c-c-on-on-f-f-i-i-den-de-t-nt-i-i-al-al-f-f-or-or-i-in-nt-te-er-r-na-na-l-l-s-s-c-c-i-i-l--sclx-20220218monthly0.5https://www.biopharmawatch.com/news/SCLX/vickers-vantage-corp-i-sclx-20220107monthly0.5https://www.biopharmawatch.com/news/SCLX/vickers-vantage-corp-i-receives-nasdaq-notification-of-non-compliance-sclx-20210601monthly0.5https://www.biopharmawatch.com/news/SCLX/vickers-vantage-corp-i-index-to-financial-statement-page-audited-financial-statements-of-v-sclx-20210111monthly0.5https://www.biopharmawatch.com/news/SCLX/vickers-vantage-corp-i-announces-pricing-of-upsized-120-000-000-initial-public-offering-sclx-20210106monthly0.5https://www.biopharmawatch.com/news/BEAT/heartbeam-announces-proposed-public-offering-of-common-stock-beat-20260414monthly0.5https://www.biopharmawatch.com/news/BEAT/heartbeam-appoints-ceo-robert-eno-to-board-of-directors-to-support-u-s-commercialization-a-beat-20250505monthly0.5https://www.biopharmawatch.com/news/BEAT/heartbeam-announces-exercise-and-closing-of-underwriter-s-over-allotment-option-for-public-beat-20250225monthly0.5https://www.biopharmawatch.com/news/BEAT/settings-that-provides-a-3d-comparison-of-baseline-and-symptomatic-12-lead-ecg-to-more-acc-beat-20230726monthly0.5https://www.biopharmawatch.com/news/BEAT/document-heartbeam-appoints-ken-nelson-and-mark-strome-to-the-board-of-directors-accomplis-beat-20230608monthly0.5https://www.biopharmawatch.com/news/BEAT/document-heartbeam-completes-25-million-capital-raise-and-updates-2023-strategic-focus-and-beat-20230503monthly0.5https://www.biopharmawatch.com/news/BEAT/breakthrough-cardiac-health-monitoring-always-by-your-side-1-disclaimers-this-presentation-beat-20230313monthly0.5https://www.biopharmawatch.com/news/BEAT/heartbeam-announces-senior-leadership-change-robert-eno-assumes-duties-of-chief-business-o-beat-20230308monthly0.5https://www.biopharmawatch.com/news/BEAT/document-heartbeam-appoints-robert-eno-as-president-senior-medical-technology-executive-to-beat-20230124monthly0.5https://www.biopharmawatch.com/news/BEAT/heartbeam-names-ken-persen-as-chief-technology-officer-company-hires-cardiac-industry-vete-beat-20220804monthly0.5https://www.biopharmawatch.com/news/BEAT/document-heartbeam-partners-with-triple-ring-technologies-to-co-develop-telehealth-solutio-beat-20220310monthly0.5https://www.biopharmawatch.com/news/BEAT/document-heartbeam-appoints-alan-baumel-as-chief-operating-officer-commercial-medical-devi-beat-20211222monthly0.5https://www.biopharmawatch.com/news/BEAT/heartbeam-announces-pricing-of-16-5-million-initial-public-offering-santa-clara-calif-busi-beat-20211111monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-reports-fourth-quarter-and-full-year-2025-financial-results-initiates-nxt-41-regula-elut-20260311monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-reports-preliminary-fourth-quarter-2025-results-strengthened-financial-position-and-elut-20260112monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-announces-sale-of-bioenvelope-business-to-boston-scientific-corporation-for-88-mill-elut-20250909monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-delivers-robust-growth-on-the-strength-elut-20250814monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-announces-strong-first-quarter-2025-financial-results-driven-by-84-sequential-growt-elut-20250508monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-transitions-to-direct-distribution-of-its-cardiovascular-product-portfolio-move-exp-elut-20250501monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-announces-fourth-quarter-and-full-year-2024-financial-results-strong-demand-for-elu-elut-20250306monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-announces-15-0-million-registered-direct-offering-elut-20250203monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-announces-strong-third-quarter-results-accelerating-toward-full-launch-of-elupro-an-elut-20241114monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-announces-second-quarter-2024-results-launch-production-of-elupro-underway-commerci-elut-20240807monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-announces-13-26-million-registered-direct-offering-elut-20240617monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-announces-fda-clearance-of-elupro-the-first-antibiotic-eluting-bioenvelope-designed-elut-20240617monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-announces-first-quarter-2024-results-simpliderm-sales-increase-55-cangaroo-rm-on-tr-elut-20240509monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-reports-fourth-quarter-and-full-year-2023-financial-results-anticipates-cangaroorm--elut-20240307monthly0.5https://www.biopharmawatch.com/news/ELUT/management-s-discussion-and-analysis-of-financial-condition-and-results-of-operations-with-elut-20231120monthly0.5https://www.biopharmawatch.com/news/ELUT/unaudited-pro-forma-condensed-consolidated-financial-statements-on-elut-20231108monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-reports-26-year-over-year-sales-growth-of-proprietary-products-and-strengthened-bal-elut-20231113monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-completes-divestiture-of-orthobiologics-business-unit-for-cash-proceeds-of-up-to-35-elut-20231109monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-announces-private-placement-for-proceeds-up-to-26-million-combined-proceeds-of-fina-elut-20230919monthly0.5https://www.biopharmawatch.com/news/ELUT/elutia-announces-sale-of-orthobiologics-business-unit-for-cash-proceeds-of-up-to-35-millio-elut-20230918monthly0.5https://www.biopharmawatch.com/news/ELUT/aziyo-biologics-rebrands-as-elutia-to-reflect-strategic-focus-on-drug-eluting-biomatrices--elut-20230906monthly0.5https://www.biopharmawatch.com/news/ELUT/aziyo-biologics-reports-second-quarter-2023-financial-results-transformation-continues-to--elut-20230814monthly0.5https://www.biopharmawatch.com/news/ELUT/aziyo-biologics-announces-voluntary-recall-of-viable-bone-matrix-products-elut-20230713monthly0.5https://www.biopharmawatch.com/news/ELUT/aziyo-biologics-reports-highest-sales-and-gross-profit-in-company-history-all-four-busines-elut-20230510monthly0.5https://www.biopharmawatch.com/news/ELUT/aziyo-biologics-and-lemaitre-vascular-partner-for-the-distribution-of-aziyo-s-cardiovascul-elut-20230420monthly0.5https://www.biopharmawatch.com/news/ELUT/aziyo-biologics-reports-record-full-year-2022-revenues-elut-20230322monthly0.5https://www.biopharmawatch.com/news/ELUT/aziyo-biologics-provides-update-on-fda-submission-for-cangaroo-rm-antibacterial-envelope-elut-20230320monthly0.5https://www.biopharmawatch.com/news/ELUT/aziyo-biologics-announces-record-annual-net-sales-in-preliminary-unaudited-fourth-quarter--elut-20230109monthly0.5https://www.biopharmawatch.com/news/ELUT/aziyo-biologics-reports-strong-third-quarter-2022-revenue-positive-meeting-with-fda-provid-elut-20221114monthly0.5https://www.biopharmawatch.com/news/ELUT/aziyo-biologics-appoints-seasoned-healthcare-executive-david-colpman-to-board-of-directors-elut-20221024monthly0.5https://www.biopharmawatch.com/news/ELUT/aziyo-biologics-inc-index-to-financial-statements-report-of-independent-registered-public--elut-20220831monthly0.5https://www.biopharmawatch.com/news/ELUT/aziyo-biologics-announces-second-quarter-2022-financial-results-and-recent-business-achiev-elut-20220811monthly0.5https://www.biopharmawatch.com/news/ELUT/aziyo-biologics-provides-business-update-and-reports-first-quarter-2022-financial-results-elut-20220509monthly0.5https://www.biopharmawatch.com/news/ELUT/azy0-q4-2021-earnings-press-release-aziyo-biologics-reports-fourth-quarter-and-full-year-2-elut-20220303monthly0.5https://www.biopharmawatch.com/news/ELUT/aziyo-biologics-announces-14-0-million-private-placement-silver-spring-md-elut-20211206monthly0.5https://www.biopharmawatch.com/news/ELUT/aziyo-biologics-reports-third-quarter-2021-financial-results-elut-20211109monthly0.5https://www.biopharmawatch.com/news/ELUT/aziyo-biologics-provides-business-update-and-preliminary-third-quarter-2021-revenue-result-elut-20211025monthly0.5https://www.biopharmawatch.com/news/ELUT/aziyo-biologics-reports-second-quarter-2021-financial-results-elut-20210809monthly0.5https://www.biopharmawatch.com/news/ELUT/aziyo-biologics-comments-on-june-2nd-elut-20210607monthly0.5https://www.biopharmawatch.com/news/ELUT/aziyo-biologics-reports-first-quarter-2021-financial-results-and-increases-2021-revenue-gu-elut-20210504monthly0.5https://www.biopharmawatch.com/news/ELUT/aziyo-biologics-reports-fourth-quarter-and-full-year-2020-financial-results-elut-20210301monthly0.5https://www.biopharmawatch.com/news/ELUT/aziyo-biologics-reports-third-quarter-2020-financial-results-elut-20201119monthly0.5https://www.biopharmawatch.com/news/QUCY/n-a-s-d-a-q-q-u-c-y-c-o-r-p-o-r-a-t-e-p-r-e-s-e-n-t-a-t-i-o-n-j-u-n-e-2-0-2-6-autonomous-d-qucy-20260514monthly0.5https://www.biopharmawatch.com/news/QUCY/quantum-cyber-aligns-strategy-with-trump-administration-s-national-cyber-security-framewor-qucy-20260317monthly0.5https://www.biopharmawatch.com/news/QUCY/mainz-biomed-announces-appointment-of-robert-liscouski-as-chairman-of-the-board-of-directo-qucy-20260311monthly0.5https://www.biopharmawatch.com/news/QUCY/mainz-biomed-announces-6-0-usd-million-private-placement-and-strategic-update-company-to-f-qucy-20260217monthly0.5https://www.biopharmawatch.com/news/QUCY/to-this-form-6-k-this-discussion-and-analysis-contains-forward-looking-statements-based-up-qucy-20250926monthly0.5https://www.biopharmawatch.com/news/QUCY/minutes-of-the-proceedings-at-the-annual-general-meeting-of-mainz-biomed-n-v-a-public-comp-qucy-20250605monthly0.5https://www.biopharmawatch.com/news/QUCY/notice-of-annual-general-meeting-of-mainz-biomed-n-v-notice-is-given-that-an-annual-genera-qucy-20250502monthly0.5https://www.biopharmawatch.com/news/QUCY/mainz-biomed-reports-2024-financial-results-and-provides-corporate-update-lab-network-reve-qucy-20250401monthly0.5https://www.biopharmawatch.com/news/QUCY/mainz-biomed-and-liquid-biosciences-make-groundbreaking-discovery-of-mrna-biomarkers-for-b-qucy-20250313monthly0.5https://www.biopharmawatch.com/news/QUCY/mainz-biomed-n-v-regains-compliance-with-nasdaq-capital-market-listing-requirements-berkel-qucy-20250127monthly0.5https://www.biopharmawatch.com/news/QUCY/mainz-biomed-announces-closing-of-8-0-million-follow-on-offering-berkeley-us-and-qucy-20241216monthly0.5https://www.biopharmawatch.com/news/QUCY/mainz-biomed-announces-pricing-of-8-0-million-follow-on-offering-priced-at-the-market-unde-qucy-20241212monthly0.5https://www.biopharmawatch.com/news/QUCY/mainz-biomed-announces-stock-split-berkeley-us-and-qucy-20241129monthly0.5https://www.biopharmawatch.com/news/QUCY/minutes-of-the-proceedings-at-the-extraordinary-general-meeting-of-mainz-biomed-n-v-a-publ-qucy-20241115monthly0.5https://www.biopharmawatch.com/news/QUCY/mainz-biomed-and-thermo-fisher-scientific-sign-a-collaboration-agreement-for-the-developme-qucy-20241112monthly0.5https://www.biopharmawatch.com/news/QUCY/mainz-biomed-reports-mid-year-2024-financial-results-and-provides-corporate-update-revenue-qucy-20241021monthly0.5https://www.biopharmawatch.com/news/QUCY/to-this-form-6-k-this-discussion-and-analysis-contains-forward-looking-statements-based-up-qucy-20241018monthly0.5https://www.biopharmawatch.com/news/QUCY/mainz-biomed-reports-results-of-2024-annual-general-meeting-berkeley-us-qucy-20240531monthly0.5https://www.biopharmawatch.com/news/QUCY/announcement-of-annual-general-meeting-of-mainz-biomed-n-v-23-april-2024-mainz-biomed-n-v--qucy-20240424monthly0.5https://www.biopharmawatch.com/news/QUCY/mainz-biomed-usa-inc-carve-out-plan-1-purpose-the-mainz-biomed-usa-inc-carve-out-plan-as-m-qucy-20240223monthly0.5https://www.biopharmawatch.com/news/QUCY/to-this-form-6-k-this-discussion-and-analysis-contain-forward-looking-statements-based-upo-qucy-20231116monthly0.5https://www.biopharmawatch.com/news/QUCY/mainz-biomed-announces-pricing-of-5-0-million-registered-direct-offering-berkeley-calif-an-qucy-20231113monthly0.5https://www.biopharmawatch.com/news/QUCY/mainz-biomed-s-colofuture-study-evaluating-its-novel-mrna-biomarkers-reports-groundbreakin-qucy-20230913monthly0.5https://www.biopharmawatch.com/news/QUCY/to-this-form-6-k-this-discussion-and-analysis-contain-forward-looking-statements-based-upo-qucy-20230815monthly0.5https://www.biopharmawatch.com/news/QUCY/minutes-of-the-proceedings-at-the-annual-general-meeting-of-mainz-biomed-n-v-a-public-comp-qucy-20230628monthly0.5https://www.biopharmawatch.com/news/QUCY/announcement-annual-general-meeting-mainz-biomed-n-v-qucy-20230519monthly0.5https://www.biopharmawatch.com/news/QUCY/to-this-form-6-k-this-discussion-and-analysis-contain-forward-looking-statements-based-upo-qucy-20230516monthly0.5https://www.biopharmawatch.com/news/QUCY/mainz-biomed-acquires-entire-intellectual-property-portfolio-for-its-colorectal-cancer-dia-qucy-20230221monthly0.5https://www.biopharmawatch.com/news/QUCY/this-document-is-an-unofficial-english-translation-of-a-document-prepared-in-dutch-in-prep-qucy-20221220monthly0.5https://www.biopharmawatch.com/news/QUCY/announcement-extraordinary-general-meeting-mainz-biomed-n-v-3-november-2022-mainz-biomed-n-qucy-20221104monthly0.5https://www.biopharmawatch.com/news/QUCY/mainz-biomed-strengthens-board-of-directors-with-nomination-of-dr-heiner-dreismann-and-gre-qucy-20220928monthly0.5https://www.biopharmawatch.com/news/QUCY/to-this-form-6-k-this-discussion-and-analysis-contain-forward-looking-statements-based-upo-qucy-20220907monthly0.5https://www.biopharmawatch.com/news/QUCY/minutes-of-the-proceedings-at-the-annual-general-meeting-of-mainz-biomed-n-v-a-public-comp-qucy-20220701monthly0.5https://www.biopharmawatch.com/news/QUCY/announcement-annual-general-meeting-mainz-biomed-n-v-20-may-2022-mainz-biomed-n-v-announce-qucy-20220603monthly0.5https://www.biopharmawatch.com/news/QUCY/mainz-biomed-announces-pricing-of-follow-on-offering-berkeley-calif-and-qucy-20220125monthly0.5https://www.biopharmawatch.com/news/QUCY/mainz-biomed-acquires-exclusive-rights-to-novel-mrna-biomarkers-potential-for-coloalert-to-qucy-20220106monthly0.5https://www.biopharmawatch.com/news/QUCY/mynz-shares-have-commenced-trading-on-the-nasdaq-capital-market-berkeley-us-mainz-germany--qucy-20211104monthly0.5https://www.biopharmawatch.com/news/BKHA/vesicor-therapeutics-appoints-michael-tolentino-m-d-as-chief-executive-officer-blackhawk-c-bkha-20260317monthly0.5https://www.biopharmawatch.com/news/BKHA/black-hawk-acquisition-corporation-amends-its-definitive-proxy-statement-bkha-20250707monthly0.5https://www.biopharmawatch.com/news/BKHA/black-hawk-acquisition-corporation-amends-its-definitive-proxy-statement-bkha-20250620monthly0.5https://www.biopharmawatch.com/news/BKHA/vesicor-therapeutics-inc-and-black-hawk-acquisition-corporation-enter-into-a-business-comb-bkha-20250428monthly0.5https://www.biopharmawatch.com/news/BKHA/black-hawk-acquisition-corporation-welcomes-mr-jonathan-ginsberg-to-board-danville-ca-bkha-20240423monthly0.5https://www.biopharmawatch.com/news/BKHA/black-hawk-acquisition-corporation-index-to-financial-statement-page-report-of-independent-bkha-20240322monthly0.5https://www.biopharmawatch.com/news/BKHA/black-hawk-acquisition-corporation-announces-pricing-of-69-000-000-upsized-initial-public--bkha-20240320monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-third-quarter-2025-financial-results-and-provides-business-update-t-goss-20251105monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-second-quarter-2025-financial-results-and-provides-business-update--goss-20250805monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-completion-of-enrollment-in-registrational-phase-3-prosera-study-fo-goss-20250616monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-first-quarter-2025-financial-results-and-provides-business-update-i-goss-20250515monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-fourth-quarter-and-full-year-2024-financial-results-and-provides-bu-goss-20250313monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-third-quarter-2024-financial-results-and-provides-business-update-3-goss-20241107monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-second-quarter-2024-financial-results-and-provides-business-update--goss-20240812monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-first-quarter-2024-financial-results-and-provides-business-update-t-goss-20240507monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-and-chiesi-group-announce-transformative-global-collaboration-to-develop-and--goss-20240506monthly0.5https://www.biopharmawatch.com/news/GOSS/document-gossamer-bio-announces-appointment-of-steven-d-nathan-m-d-and-skye-drynan-to-its--goss-20240312monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-fourth-quarter-and-full-year-2023-financial-results-and-provides-bu-goss-20240305monthly0.5https://www.biopharmawatch.com/news/GOSS/document-gossamer-bio-announces-appointment-of-john-quisel-j-d-ph-d-to-its-board-of-direct-goss-20231129monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-third-quarter-2023-financial-results-and-provides-business-update-p-goss-20231109monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-second-quarter-2023-financial-results-and-provides-business-update--goss-20230808monthly0.5https://www.biopharmawatch.com/news/GOSS/for-investors-and-media-bryan-giraudo-chief-operating-officer-and-chief-financial-officer--goss-20230720monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-first-quarter-2023-financial-results-and-provides-business-update-f-goss-20230509monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-fourth-quarter-and-full-year-2022-financial-results-and-provides-bu-goss-20230317monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-third-quarter-2022-financial-results-and-provides-business-update-s-goss-20221103monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-second-quarter-2022-financial-results-and-provides-business-update--goss-20220809monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-120-million-private-placement-financing-goss-20220713monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-first-quarter-2022-financial-results-and-provides-business-update-s-goss-20220510monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-fourth-quarter-and-full-year-2021-financial-results-and-provides-bu-goss-20220303monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-third-quarter-2021-financial-results-and-provides-corporate-update--goss-20211108monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-addition-of-two-cns-penetrant-btk-inhibitors-to-its-product-candida-goss-20211011monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-appointment-of-bryan-giraudo-as-chief-operating-officer-in-addition-goss-20210921monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-second-quarter-2021-financial-results-and-provides-corporate-update-goss-20210809monthly0.5https://www.biopharmawatch.com/news/GOSS/document-gossamer-bio-announces-appointment-of-sandra-milligan-m-d-j-d-to-its-board-of-dir-goss-20210614monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-first-quarter-2021-financial-results-and-provides-corporate-update--goss-20210506monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-executive-management-transition-and-promotion-of-laura-carter-ph-d--goss-20210420monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-fourth-quarter-and-full-year-2020-financial-results-and-provides-bu-goss-20210225monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-third-quarter-2020-financial-results-and-provides-corporate-update--goss-20201110monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-topline-results-for-phase-2-trials-of-oral-gb001-in-asthma-and-chro-goss-20201013monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-second-quarter-2020-financial-results-and-provides-corporate-update-goss-20200811monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-proposed-concurrent-public-offerings-of-common-stock-and-convertibl-goss-20200518monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-first-quarter-2020-financial-results-and-provides-corporate-update--goss-20200512monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-fourth-quarter-and-full-year-2019-financial-results-and-provides-bu-goss-20200324monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-third-quarter-2019-financial-results-clinical-programs-on-track-for-goss-20191112monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-second-quarter-2019-financial-results-immuno-oncology-candidate-gb1-goss-20190808monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-first-quarter-2019-financial-results-multiple-trial-initiations-and-goss-20190514monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-secures-debt-facility-for-up-to-150-million-goss-20190502monthly0.5https://www.biopharmawatch.com/news/GOSS/gossamer-bio-announces-2018-annual-financial-results-goss-20190322monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-announces-2025-results-with-nis-270-million-in-revenue-and-positive-operating-ca-incr-20260501monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-receives-nasdaq-notification-regarding-minimum-bid-requirement-new-york-and-incr-20260303monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-announces-preliminary-estimated-2025-revenue-of-nis-265-million-positive-adjuste-incr-20260219monthly0.5https://www.biopharmawatch.com/news/INCR/notice-of-annual-general-meeting-of-shareholders-to-be-held-on-december-30-2025-to-the-sha-incr-20251125monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance--incr-20251103monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-reports-first-half-2025-results-with-nis-130-million-in-revenue-and-positive-ope-incr-20251008monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-announces-strategic-acquisition-of-ishi-unlocking-access-to-premium-u-s-cannabis-incr-20250919monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-announces-fy2024-results-and-provides-q1-2025-update-revenue-of-nis-239-million--incr-20250501monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-names-alexander-rabinovich-as-chairman-replacing-ehud-barak-new-york-incr-20250212monthly0.5https://www.biopharmawatch.com/news/INCR/notice-of-extraordinary-general-meeting-of-shareholders-to-be-held-on-january-27-2025-to-t-incr-20250127monthly0.5https://www.biopharmawatch.com/news/INCR/notice-of-extraordinary-general-meeting-of-shareholders-to-be-held-on-january-27-2025-to-t-incr-20241220monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-has-secured-funding-of-nis-66m-to-support-the-recovery-of-nir-oz-facility-the-fu-incr-20241220monthly0.5https://www.biopharmawatch.com/news/INCR/notice-of-annual-general-meeting-of-shareholders-to-be-held-on-december-30-2024-to-the-sha-incr-20241125monthly0.5https://www.biopharmawatch.com/news/INCR/notice-of-extraordinary-general-meeting-of-shareholders-to-be-held-on-october-28-2024-to-t-incr-20240917monthly0.5https://www.biopharmawatch.com/news/INCR/notice-of-extraordinary-general-meeting-of-shareholders-to-be-held-on-october-28-2024-to-t-incr-20240913monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-announces-first-half-of-2024-results-revenue-of-nis-126-million-and-adjusted-ebi-incr-20240829monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-announces-expansion-of-its-strategic-partnership-with-cookies-to-germany-intercu-incr-20240828monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-provides-update-following-class-action-dismissal-the-tel-aviv-yafo-district-cour-incr-20240521monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-announces-fy2023-results-revenue-of-nis-356-million-and-adjusted-ebitda-of-nis-6-incr-20240501monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-announces-preliminary-estimated-2023-revenue-of-nis-351-million-and-ebidta-of-ov-incr-20240401monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-provides-an-update-regarding-nir-oz-facility-new-york-and-incr-20240213monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-signs-definitive-agreement-to-acquire-leon-cannabis-pharmacy-chain-new-york-and-incr-20240131monthly0.5https://www.biopharmawatch.com/news/INCR/notice-of-annual-general-meeting-of-shareholders-to-be-held-on-december-14-2023-to-the-sha-incr-20231108monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-wins-cannolam-arbitration-proceeding-new-york-and-incr-20231031monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-provides-an-update-regarding-the-security-situation-in-israel-new-york-and-incr-20231017monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-announces-record-revenues-first-half-of-2023-with-over-14-growth-yoy-achieved-re-incr-20230831monthly0.5https://www.biopharmawatch.com/news/INCR/notice-of-special-meeting-of-shareholders-to-be-held-on-august-14-2023-notice-is-hereby-gi-incr-20230724monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-ltd-announces-proposed-voluntary-delisting-from-the-toronto-stock-exchange-and-s-incr-20230710monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-provides-an-update-about-the-lawsuit-it-filed-against-cann-pharmaceuticals-to-re-incr-20230609monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-announces-record-breaking-first-quarter-revenues-with-22-growth-yoy-achieved-rec-incr-20230515monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-informs-that-a-lawsuit-was-filed-against-the-company-by-minority-shareholders-of-incr-20230425monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-informs-that-an-application-to-approve-a-class-action-against-26-cannabis-compan-incr-20230425monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-ltd-partners-with-tyson-2-0-in-israel-australia-united-kingdom-germany-and-other-incr-20230420monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-announces-reschedules-2022-full-year-results-conference-call-new-york-toronto-an-incr-20230403monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-announces-record-fourth-quarter-and-fiscal-year-end-2022-results-record-fiscal-y-incr-20230331monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-files-lawsuit-against-cann-pharmacuticals-to-recover-funds-following-failed-merg-incr-20230214monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-announces-the-termination-of-its-acquisition-agreement-with-cann-pharmaceutical--incr-20230201monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-announces-exclusive-international-partnership-agreement-with-award-winning-canna-incr-20221219monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-announces-the-withdrawal-of-a-class-action-lawsuit-against-it-new-york-toronto-a-incr-20221205monthly0.5https://www.biopharmawatch.com/news/INCR/update-regarding-better-transaction-new-york-toronto-and-herzliya-israel-november-23-2022--incr-20221123monthly0.5https://www.biopharmawatch.com/news/INCR/organigram-and-intercure-dba-canndoc-sign-new-international-strategic-agreement-representi-incr-20221117monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-ltd-condensed-consolidated-interim-financial-statements-as-of-incr-20221116monthly0.5https://www.biopharmawatch.com/news/INCR/notice-of-annual-and-special-meeting-of-shareholders-to-be-held-on-september-15-2022-notic-incr-20220818monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-begins-2022-with-record-breaking-first-quarter-financial-results-record-revenue--incr-20220524monthly0.5https://www.biopharmawatch.com/news/INCR/annual-information-form-for-the-year-ended-incr-20220407monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-reports-record-preliminary-2021-fourth-quarter-revenue-3-times-yoy-and-24-qoq-gr-incr-20220208monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-ltd-intercure-extraordinary-general-meeting-of-shareholders-of-intercure-ltd-hel-incr-20211230monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-announces-european-expansion-with-international-cannabis-brand-cookies-leading-g-incr-20211202monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-expands-pharmacy-chain-in-israel-surpasses-one-ton-medical-cannabis-products-dis-incr-20211115monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-announces-record-preliminary-third-quarter-revenue-of-cad-24-million-3-times-yoy-incr-20211025monthly0.5https://www.biopharmawatch.com/news/INCR/intercure-announces-record-breaking-second-quarter-financial-results-with-4-times-yoy-reve-incr-20210816monthly0.5https://www.biopharmawatch.com/news/ATYR/forward-looking-statements-the-following-slides-and-any-accompanying-oral-presentation-con-atyr-20260601monthly0.5https://www.biopharmawatch.com/news/ATYR/ashlee-dunston-sr-director-investor-relations-and-public-affairs-adunston-atyrpharma-com-a-atyr-20260515monthly0.5https://www.biopharmawatch.com/news/ATYR/forward-looking-statements-the-following-slides-and-any-accompanying-oral-presentation-con-atyr-20260511monthly0.5https://www.biopharmawatch.com/news/ATYR/ashlee-dunston-sr-director-investor-relations-and-public-affairs-adunston-atyrpharma-com-a-atyr-20260305monthly0.5https://www.biopharmawatch.com/news/ATYR/ashlee-dunston-sr-director-investor-relations-and-public-affairs-adunston-atyrpharma-com-a-atyr-20251106monthly0.5https://www.biopharmawatch.com/news/ATYR/forward-looking-statements-the-following-slides-and-any-accompanying-oral-presentation-con-atyr-20250915monthly0.5https://www.biopharmawatch.com/news/ATYR/ashlee-dunston-sr-director-investor-relations-and-public-affairs-adunston-atyrpharma-com-a-atyr-20250807monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-ashlee-dunston-sr-director-investor-relations-and-public-affairs-atyr-20250507monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-ashlee-dunston-sr-director-investor-relations-and-public-affairs-atyr-20250313monthly0.5https://www.biopharmawatch.com/news/ATYR/atyr-pharma-inc-non-employee-director-compensation-policy-the-purpose-of-this-non-employee-atyr-20241212monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-ashlee-dunston-director-investor-relations-and-public-affairs-ad-atyr-20241107monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-ashlee-dunston-director-investor-relations-and-public-affairs-ad-atyr-20240813monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-ashlee-dunston-director-investor-relations-and-public-affairs-ad-atyr-20240502monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-ashlee-dunston-director-investor-relations-and-public-affairs-ad-atyr-20240314monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-ashlee-dunston-director-investor-relations-and-public-affairs-ad-atyr-20231109monthly0.5https://www.biopharmawatch.com/news/ATYR/forward-looking-statements-the-following-slides-and-any-accompanying-oral-presentation-con-atyr-20230926monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-ashlee-dunston-director-investor-relations-and-public-affairs-ad-atyr-20230809monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-ashlee-dunston-director-investor-relations-and-corporate-communi-atyr-20230509monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-ashlee-dunston-director-investor-relations-and-corporate-communi-atyr-20230309monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-ashlee-dunston-director-investor-relations-and-corporate-communi-atyr-20221110monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-ashlee-dunston-director-investor-relations-and-corporate-communi-atyr-20220815monthly0.5https://www.biopharmawatch.com/news/ATYR/forward-looking-statements-the-following-slides-and-any-accompanying-oral-presentation-con-atyr-20220517monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-ashlee-dunston-director-investor-relations-and-corporate-communi-atyr-20220509monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-ashlee-dunston-director-investor-relations-and-corporate-communi-atyr-20220314monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-ashlee-dunston-director-investor-relations-and-corporate-communi-atyr-20210916monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-ashlee-dunston-director-investor-relations-and-corporate-communi-atyr-20210913monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-ashlee-dunston-director-investor-relations-and-corporate-communi-atyr-20210513monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-ashlee-dunston-director-investor-relations-and-corporate-communi-atyr-20210323monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-ashlee-dunston-director-investor-relations-and-corporate-communi-atyr-20210315monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-ashlee-dunston-director-investor-relations-and-corporate-communi-atyr-20210125monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-ashlee-dunston-director-investor-relations-and-corporate-communi-atyr-20210122monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-ashlee-dunston-director-investor-relations-and-corporate-communi-atyr-20210114monthly0.5https://www.biopharmawatch.com/news/ATYR/forward-looking-statements-the-following-slides-and-any-accompanying-oral-presentation-con-atyr-20210111monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-ashlee-dunston-director-investor-relations-and-corporate-communi-atyr-20210104monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-ashlee-dunston-director-investor-relations-and-corporate-communi-atyr-20201112monthly0.5https://www.biopharmawatch.com/news/ATYR/schedules-schedule-3-a-subsidiaries-schedule-3-c-capitalization-schedule-3-e-conflicts-sch-atyr-20200910monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-ashlee-dunston-investor-relations-atyr-pharma-adunston-atyrpharm-atyr-20200813monthly0.5https://www.biopharmawatch.com/news/ATYR/forward-looking-statements-the-following-slides-and-any-accompanying-oral-presentation-con-atyr-20200518monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-joyce-allaire-managing-director-lifesci-advisors-llc-jallaire-li-atyr-20200512monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-joyce-allaire-managing-director-lifesci-advisors-llc-jallaire-li-atyr-20200421monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-joyce-allaire-managing-director-lifesci-advisors-llc-jallaire-li-atyr-20200326monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-joyce-allaire-managing-director-lifesci-advisors-llc-jallaire-li-atyr-20200106monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-joyce-allaire-managing-director-lifesci-advisors-llc-jallaire-li-atyr-20191212monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-joyce-allaire-managing-director-lifesci-advisors-llc-jallaire-li-atyr-20191114monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-joyce-allaire-managing-director-lifesci-advisors-llc-jallaire-li-atyr-20190814monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-joyce-allaire-managing-director-lifesci-advisors-llc-jallaire-li-atyr-20190701monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-joyce-allaire-managing-director-lifesci-advisors-llc-jallaire-li-atyr-20190628monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-joyce-allaire-managing-director-lifesci-advisors-llc-jallaire-li-atyr-20190513monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-joyce-allaire-managing-director-lifesci-advisors-llc-jallaire-li-atyr-20190411monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-joyce-allaire-managing-director-lifesci-advisors-llc-jallaire-li-atyr-20190325monthly0.5https://www.biopharmawatch.com/news/ATYR/corporate-presentation-march-2019-forward-looking-statements-the-following-slides-and-any--atyr-20190311monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-joyce-allaire-managing-director-lifesci-advisors-llc-jallaire-li-atyr-20190227monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-jason-spark-managing-director-canale-communications-inc-jason-ca-atyr-20181113monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-jason-spark-managing-director-canale-communications-inc-jason-ca-atyr-20181015monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-mark-johnson-sr-director-investor-relations-mjohnson-atyrpharma--atyr-20180814monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-mark-johnson-sr-director-investor-relations-mjohnson-atyrpharma--atyr-20180726monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-mark-johnson-sr-director-investor-relations-mjohnson-atyrpharma--atyr-20180626monthly0.5https://www.biopharmawatch.com/news/ATYR/forward-looking-statements-the-following-slides-and-any-accompanying-oral-presentation-con-atyr-20180604monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-mark-johnson-sr-director-investor-relations-mjohnson-atyrpharma--atyr-20180514monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-mark-johnson-sr-director-investor-relations-mjohnson-atyrpharma--atyr-20180319monthly0.5https://www.biopharmawatch.com/news/ATYR/identification-of-novel-liquid-biopsy-biomarker-for-monitoring-the-immune-set-point-in-bot-atyr-20180125monthly0.5https://www.biopharmawatch.com/news/ATYR/forward-looking-statements-the-following-slides-and-any-accompanying-oral-presentation-con-atyr-20180108monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-mark-johnson-sr-director-investor-relations-mjohnson-atyrpharma--atyr-20171114monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-mark-johnson-sr-director-investor-relations-mjohnson-atyrpharma--atyr-20171101monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-mark-johnson-sr-director-investor-relations-mjohnson-atyrpharma--atyr-20170828monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-mark-johnson-sr-director-investor-relations-mjohnson-atyrpharma--atyr-20170814monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-mark-johnson-sr-director-investor-relations-mjohnson-atyrpharma--atyr-20170810monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-mark-johnson-sr-director-investor-relations-mjohnson-atyrpharma--atyr-20170511monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-mark-johnson-sr-director-investor-relations-mjohnson-atyrpharma--atyr-20170424monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-mark-johnson-sr-director-investor-relations-mjohnson-atyrpharma--atyr-20170316monthly0.5https://www.biopharmawatch.com/news/ATYR/forward-looking-statements-the-following-slides-and-any-accompanying-oral-presentation-con-atyr-20170109monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-mark-johnson-sr-director-investor-relations-mjohnson-atyrpharma--atyr-20161213monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-mark-johnson-sr-director-investor-relations-mjohnson-atyrpharma--atyr-20161114monthly0.5https://www.biopharmawatch.com/news/ATYR/life-ex991-110-pptx-htm-new-hope-for-severe-rare-muscle-lung-disease-patients-building-a-n-atyr-20161107monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-mark-johnson-sr-director-investor-relations-mjohnson-atyrpharma--atyr-20161006monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-mark-johnson-sr-director-investor-relations-mjohnson-atyrpharma--atyr-20160810monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-mark-johnson-jessica-rowlands-sr-director-investor-relations-fei-atyr-20160511monthly0.5https://www.biopharmawatch.com/news/ATYR/life-ex991-110-pptx-htm-building-a-new-class-of-medicines-physiocrine-based-therapeutics-1-atyr-20160413monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-sanuj-k-ravindran-md-and-jessica-rowlands-chief-business-officer-atyr-20160330monthly0.5https://www.biopharmawatch.com/news/ATYR/life-ex991-6-pptx-htm-new-promise-for-rare-disease-patients-with-immune-fibrotic-pathologi-atyr-20160111monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-marcy-graham-jessica-rowlands-vice-president-investor-relations--atyr-20151110monthly0.5https://www.biopharmawatch.com/news/ATYR/immediate-release-contact-marcy-graham-jessica-rowlands-vice-president-investor-relations--atyr-20150812monthly0.5https://www.biopharmawatch.com/news/ATYR/marcy-graham-jessica-rowlands-vice-president-investor-relations-corporate-communications-f-atyr-20150720monthly0.5https://www.biopharmawatch.com/news/ATYR/marcy-graham-jessica-rowlands-vice-president-investor-relations-corporate-communications-m-atyr-20150713monthly0.5https://www.biopharmawatch.com/news/ATYR/marcy-graham-jessica-rowlands-vice-president-investor-relations-corporate-communications-f-atyr-20150618monthly0.5https://www.biopharmawatch.com/news/QNTM/this-news-release-is-intended-for-distribution-in-canada-only-and-is-qntm-20260602monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-ltd-formerly-fsd-pharma-inc-condensed-consolidated-interim-financial-sta-qntm-20260506monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-ltd-provides-corporate-update-toronto-qntm-20251222monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-ltd-formerly-fsd-pharma-inc-condensed-consolidated-interim-financial-sta-qntm-20251106monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-1-name-and-address-of--qntm-20251029monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-qntm-20251029monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-quantum-biopharma-to-present-at-global-growth-and-investment-con-qntm-20251029monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-announces-filing-of-year-end-2023-results-toronto-on-qntm-20251028monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-announces-dr-sanjiv-chopra-is-elected-to-fsd-pharma-b-qntm-20251028monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-ltd-formerly-fsd-pharma-inc-condensed-consolidated-interim-financial-sta-qntm-20250807monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-ltd-formerly-fsd-pharma-inc-condensed-consolidated-interim-financial-sta-qntm-20250616monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-ltd-formerly-fsd-pharma-inc-condensed-consolidated-interim-financial-sta-qntm-20250514monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-quantum-biopharma-corporate-update-toronto-ontario-qntm-20250418monthly0.5https://www.biopharmawatch.com/news/QNTM/form-7-monthly-progress-report-name-of-listed-issuer-quantum-biopharma-ltd-the-issuer-or-q-qntm-20250107monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-in-court-with-dr-raza-bokhari-on-january-24-2025-seeking-a-court-order-t-qntm-20250117monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-ltd-now-trading-on-upstream-under-qntm-toronto-on-accesswire-qntm-20250114monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-ltd-approved-to-dual-list-on-upstream-trading-to-become-available-januar-qntm-20250107monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-diversifies-treasury-with-the-purchase-of-usd-1-000-000-of-bitcoin-btc-a-qntm-20241220monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-previously-known-as-fsd-pharma-nasdaq-huge-cse-huge-invites-shareholders-qntm-20241125monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-ltd-formerly-fsd-pharma-inc-condensed-consolidated-interim-financial-sta-qntm-20241112monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-announces-that-sentinel-dosing-has-started-the-phase-1-multiple-ascendin-qntm-20241029monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-nasdaq-qntm-posts-link-on-its-website-to-access-the-filed-complaint-agai-qntm-20241022monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-nasdaq-qntm-files-a-us-federal-lawsuit-against-cibc-world-markets-rbc-do-qntm-20241021monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-ltd-provides-update-from-celly-nutrition-signing-a-master-distribution-a-qntm-20241007monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-provides-corporate-update-toronto-on-qntm-20240927monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-closes-private-placement-offering-toronto-qntm-20240913monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-signs-an-agreement-with-ingenu-cro-to-conduct-a-clinical-study-to-observ-qntm-20240909monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-receives-nasdaq-notification-of-regaining-compliance-with-nasdaq-s-minim-qntm-20240906monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-announces-celly-nutrition-launches-unbuzzd-grab-and-go-stick-packs-on-am-qntm-20240830monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-announces-intention-to-complete-debt-settlements-and-provides-corporate--qntm-20240823monthly0.5https://www.biopharmawatch.com/news/QNTM/quantum-biopharma-ltd-condensed-consolidated-interim-financial-statements-for-the-three-an-qntm-20240819monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-completes-name-change-to-quantum-biopharma-and-65-1-consolidation-trading-under-qntm-20240815monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-inc-condensed-consolidated-interim-financial-statements-for-the-three-and-six-m-qntm-20240814monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-announces-share-consolidation-and-name-change-toronto-qntm-20240809monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-provides-update-on-its-investment-in-celly-nutrition-corp-who-secures-additiona-qntm-20240809monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-inc-notice-of-annual-general-and-special-meeting-of-the-shareholders-to-be-held-qntm-20240708monthly0.5https://www.biopharmawatch.com/news/QNTM/form-51-102f3-amended-and-restated-material-change-report-note-to-reader-this-amended-and--qntm-20240708monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-provides-corporate-update-toronto-qntm-20240628monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-inc-wins-final-judgment-to-confirm-arbitration-award-of-3-059-998-plus-interest-qntm-20240628monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-receives-ethics-committee-approval-for-a-phase-1-multiple-ascending-doses-clini-qntm-20240627monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-enters-into-an-exclusive-option-agreement-with-the-university-of-southern-calif-qntm-20240613monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-receives-institutional-review-board-approval-to-study-the-safety-and-efficacy-o-qntm-20240604monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-inc-wins-petition-to-confirm-arbitration-awards-entered-against-dr-raza-bokhari-qntm-20240531monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-submits-a-clinical-trial-protocol-to-study-the-safety-and-efficacy-of-unbuzzd-i-qntm-20240528monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-provides-corporate-update-toronto-on-qntm-20240524monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-provides-update-on-celly-nu-s-new-packaging-for-unbuzzd-tm-toronto-on-accesswir-qntm-20240516monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-inc-condensed-consolidated-interim-financial-statements-for-the-three-months-en-qntm-20240515monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-submits-a-phase-1-multiple-ascending-doses-clinical-trial-application-for-lucid-qntm-20240507monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-signs-agreement-with-applied-science-and-performance-institute-aspi-to-conduct--qntm-20240430monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-provides-update-from-celly-nu-s-partnership-with-six-one-for-unbuzzd-toronto-on-qntm-20240425monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-provides-another-update-on-celly-nu-s-anticipated-launch-of-unbuzzd-toronto-on-qntm-20240422monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-expands-investigative-pipeline-to-include-potential-weight-loss-and-liver-healt-qntm-20240417monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-announces-filing-of-year-end-2023-results-toronto-on-qntm-20240328monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-provides-update-on-its-investment-in-celly-nutrition-corp-a-company-launching-a-qntm-20240415monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-inc-receives-nasdaq-notification-regarding-minimum-bi-qntm-20240405monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-signs-the-agreement-with-ingenu-cro-to-conduct-a-clinical-study-to-assess-the-s-qntm-20240327monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-submits-a-phase-1b-clinical-trial-application-for-ethics-committee-for-its-prop-qntm-20240311monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-presents-positive-results-on-first-in-human-phase-1-study-of-lucid-21-302-lucid-qntm-20240305monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-announces-debt-settlement-toronto-on-qntm-20240228monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-signs-agreement-with-ingenu-cro-to-conduct-a-clinical-trial-to-determine-the-sa-qntm-20240226monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-announces-us-atm-offering-toronto-on-qntm-20240216monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-announces-dr-sanjiv-chopra-is-elected-to-fsd-pharma-board-of-directors-and-corp-qntm-20240129monthly0.5https://www.biopharmawatch.com/news/QNTM/court-of-appeal-dismisses-motion-for-leave-to-appeal-brought-by-dr-raza-bokhari-fsd-pharma-qntm-20240206monthly0.5https://www.biopharmawatch.com/news/QNTM/update-provided-on-gbb-drink-lab-inc-litigation-and-safety-shot-toronto-qntm-20240116monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-files-final-base-shelf-prospectus-to-replace-expired-base-shelf-prospectus-and--qntm-20231222monthly0.5https://www.biopharmawatch.com/news/QNTM/form-51-102f3-material-change-report-item-1-name-and-address-of-company-fsd-pharma-inc-fsd-qntm-20231221monthly0.5https://www.biopharmawatch.com/news/QNTM/form-51-102f3-material-change-report-item-1-name-and-address-of-company-fsd-pharma-inc-the-qntm-20231204monthly0.5https://www.biopharmawatch.com/news/QNTM/form-51-102f3-material-change-report-item-1-name-and-address-of-company-fsd-pharma-inc-the-qntm-20231215monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-inc-announces-closing-of-private-placement-toronto-qntm-20231205monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-inc-and-celly-nutrition-corp-announce-completion-of-plan-of-arrangement-toronto-qntm-20231130monthly0.5https://www.biopharmawatch.com/news/QNTM/update-provided-on-gbb-drink-lab-inc-litigation-and-safety-shot-previously-known-as-jupite-qntm-20231128monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-inc-obtains-final-order-for-plan-of-arrangement-toronto-qntm-20231127monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-inc-199-bay-st-suite-4000-toronto-on-m5l-1a9-www-fsdpharma-com-supplement-to-th-qntm-20231115monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-announces-distribution-date-for-distribution-of-celly-shares-pursuant-to-plan-o-qntm-20231117monthly0.5https://www.biopharmawatch.com/news/QNTM/form-51-102f3-material-change-report-item-1-name-and-address-of-company-fsd-pharma-inc-the-qntm-20231116monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-files-supplement-to-management-information-circular-in-connection-with-special--qntm-20231115monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-inc-condensed-consolidated-interim-financial-statemen-qntm-20231115monthly0.5https://www.biopharmawatch.com/news/QNTM/form-51-102f3-material-change-report-item-1-name-and-address-of-company-fsd-pharma-inc-the-qntm-20231107monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-announces-interim-results-from-first-in-human-clinical-trial-of-lucid-ms-lucid--qntm-20231107monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-files-preliminary-base-shelf-prospectus-to-replace-expired-base-shelf-prospectu-qntm-20231106monthly0.5https://www.biopharmawatch.com/news/QNTM/arrangement-agreement-this-arrangement-agreement-agreement-is-made-as-of-the-4-th-day-of-o-qntm-20231107monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-files-management-information-circular-for-proposed-arrangement-with-celly-nu-to-qntm-20231023monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-rebuts-claims-of-gbb-drink-lab-now-acquired-by-jupiter-wellness-inc-trading-und-qntm-20230825monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-signs-definitive-agreement-to-launch-unbuzzd-a-revolu-qntm-20230825monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-inc-condensed-consolidated-interim-financial-statemen-qntm-20230630monthly0.5https://www.biopharmawatch.com/news/QNTM/arbitration-panel-finds-that-syneos-health-nasdaq-synh-failed-to-use-commercially-reasonab-qntm-20230717monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-retains-christian-attar-law-and-team-of-experts-to-lead-preliminary-investigati-qntm-20230710monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-appoints-zeeshan-saeed-as-chief-executive-officer-anthony-durkacz-to-serve-as-e-qntm-20230704monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-inc-announces-results-of-annual-general-and-special-meeting-of-shareholders-tor-qntm-20230630monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-announces-agreement-to-grant-exclusive-rights-to-revolutionary-recreational-alc-qntm-20230620monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-appoints-former-ontario-minister-of-health-doctor-eric-hoskins-to-board-of-dire-qntm-20230525monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-inc-condensed-consolidated-interim-financial-statemen-qntm-20230515monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-announces-receipt-of-court-action-and-update-on-spin-out-and-distribution-toron-qntm-20230512monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-awarded-2-81-million-in-cost-awards-from-dr-raza-bokhari-toronto-business-wire-qntm-20230511monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-dr-qntm-20230510monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-to-present-at-sidoti-virtual-investor-conference-may-10-11-toronto-business-wir-qntm-20230508monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-achieves-milestone-in-completion-of-dosing-of-sentinel-subjects-in-first-in-hum-qntm-20230417monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-announces-plan-to-spin-out-subsidiary-as-distribution-to-shareholders-sharehold-qntm-20230412monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-announces-filing-of-year-end-2022-results-toronto-business-wire-qntm-20230331monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-adds-former-celsius-holdings-ceo-gerry-david-to-board-of-advisors-previously-he-qntm-20230330monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-announces-its-australian-entity-receives-approval-to-proceed-with-phase-1-clini-qntm-20230322monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-symbol-huge-renews-shareholder-intelligence-services-to-investigate-possible-na-qntm-20230314monthly0.5https://www.biopharmawatch.com/news/QNTM/original-shark-and-iconic-entrepreneur-kevin-harrington-joins-fsd-pharma-advisory-board-ha-qntm-20230228monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-presenting-two-scientific-posters-on-preclinical-toxicology-and-efficacy-data-o-qntm-20230221monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-regains-compliance-with-nasdaq-continued-listing-requirements-toronto-business--qntm-20230215monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-launches-a-new-research-and-development-program-targeting-unmet-medical-needs-f-qntm-20230214monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-receives-regulatory-clearance-for-its-proposed-phase-1-clinical-trial-of-lucid--qntm-20230207monthly0.5https://www.biopharmawatch.com/news/QNTM/recruiting-underway-in-fsd-pharma-s-phase-2-trial-of-fsd-pea-fsd201-for-the-treatment-of-c-qntm-20230130monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-submits-its-phase-1-clinical-trial-application-for-lucid-ms-lucid-21-302-for-fi-qntm-20230117monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-announces-share-repurchase-program-toronto-business-wire-qntm-20230113monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-inc-incorporates-new-subsidiary-to-capitalize-on-drug-development-incentives-in-qntm-20230109monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-to-attend-41st-annual-j-p-morgan-healthcare-conference-2023-toronto-business-wi-qntm-20230106monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-announces-changes-to-the-board-of-directors-toronto-business-wire-qntm-20221128monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-inc-condensed-consolidated-interim-financial-statemen-qntm-20221114monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-announces-arbitrator-dismisses-claims-by-former-ceo-dr-raza-bokhari-toronto-bus-qntm-20221110monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-inc-receives-nasdaq-notification-regarding-minimum-bid-price-deficiency-toronto-qntm-20220929monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-participating-in-h-c-wainwright-24th-annual-global-investment-conference-on-dem-qntm-20220912monthly0.5https://www.biopharmawatch.com/news/QNTM/fda-and-health-canada-clear-ind-for-fsd-pharma-to-proceed-with-phase-2-trial-of-fsd201-for-qntm-20220906monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-inc-condensed-consolidated-interim-financial-statemen-qntm-20220812monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-subsidiary-lucid-psycheceuticals-files-for-patent-on-novel-formulations-of-palm-qntm-20220713monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-inc-announces-results-of-annual-general-meeting-of-shareholders-and-other-corpo-qntm-20220627monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-files-investigational-new-drug-application-ind-with-fda-and-health-canada-for-p-qntm-20220531monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-issues-circular-adopts-incentive-plan-and-grants-psus-toronto-business-wire-qntm-20220524monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-inc-notice-of-annual-general-meeting-of-the-sharehold-qntm-20220523monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-inc-condensed-consolidated-interim-financial-statemen-qntm-20220513monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-closes-cad-16-4-million-sale-of-non-core-assets-nets-cad-15-480-780-cash-in-non-qntm-20220510monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-may-3-2022-to-all-applicable-exchanges-and-commissions-re-fsd-ph-qntm-20220506monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-announces-dismissal-of-derivative-complaint-toronto-business-wire-qntm-20220506monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-announces-engagement-with-tekkfund-capital-and-share-issuance-to-crystal-resear-qntm-20220502monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-appoints-julia-levy-award-recipient-david-allan-and-dr-john-mcgraw-to-advisory--qntm-20220421monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-announces-cancellation-of-certain-shares-issued-to-former-chief-executive-offic-qntm-20220408monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-issues-corporate-updates-toronto-business-wire-qntm-20220406monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-announces-filing-of-year-end-2021-results-toronto-business-wire-qntm-20220331monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-announces-executive-informational-overview-report-produced-by-crystal-research--qntm-20220315monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-announces-agreement-for-sale-of-cobourg-facility-for-cad-16-500-000-toronto-bus-qntm-20220225monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-announces-launch-of-new-corporate-website-new-website-shares-fsd-s-unique-drug--qntm-20220120monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-congratulates-dr-eleanor-fish-on-being-named-to-the-order-of-canada-toronto-bus-qntm-20220118monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-to-present-at-the-h-c-wainwright-bioconnect-conference-on-january-10-13-th-toro-qntm-20220104monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-announces-share-repurchase-program-toronto-business-wire-qntm-20211230monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-establishes-new-regulatory-advisory-board-with-the-appointment-of-joga-gobburu--qntm-20211209monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-to-present-at-the-h-c-wainwright-2-nd-annual-psychedelics-virtual-conference-on-qntm-20211203monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-unveils-videos-demonstrating-positive-effects-of-lucid-ms-in-treating-multiple--qntm-20211202monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-expands-research-and-clinical-advisory-board-with-appointment-of-world-renowned-qntm-20211116monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-inc-management-s-discussion-and-analysis-of-financial-qntm-20211115monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-qntm-20211029monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-signs-agreement-with-covar-pharmaceuticals-to-support-the-development-of-lucid--qntm-20211019monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-1-name-and-address-of--qntm-20210921monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-announces-engagement-with-capital-markets-communications-providers-and-market-m-qntm-20210922monthly0.5https://www.biopharmawatch.com/news/QNTM/master-agreement-this-agreement-made-as-of-the-25th-day-of-august-2021-among-fsd-pharma-in-qntm-20210921monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-form-51-102f3-material-change-report-item-1-name-and-address-of--qntm-20210824monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-inc-announces-termination-of-fsd-201-phase-2-clinical-trial-however-will-contin-qntm-20210824monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-announces-definitive-agreement-to-acquire-lucid-psycheceuticals-acquisition-adv-qntm-20210825monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-inc-management-s-discussion-and-analysis-of-financial-qntm-20210813monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-inc-announces-termination-of-chief-executive-officer-dr-raza-bokhari-for-cause--qntm-20210727monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-inc-appoints-a-new-independent-director-toronto-business-wire-qntm-20210603monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-inc-announces-results-of-the-annual-general-and-special-meeting-of-shareholders-qntm-20210517monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-announces-filing-of-criminal-complaint-against-former-chief-financial-officer-t-qntm-20210513monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-announces-investigational-new-animal-drug-filing-with-the-fda-to-treat-dogs-wit-qntm-20210512monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-inc-condensed-consolidated-interim-financial-statemen-qntm-20210507monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-announces-that-iss-recommends-shareholders-vote-for-the-company-s-nominees-to-t-qntm-20210505monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-these-materials-are-important-and-require-your-immediate-attenti-qntm-20210505monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-announces-appointment-of-interim-chief-financial-officer-toronto-business-wire-qntm-20210505monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-issues-important-message-to-shareholders-and-response-to-dissident-circular-man-qntm-20210503monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-these-materials-are-important-and-require-your-immediate-attenti-qntm-20210423monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-files-proxy-materials-and-sends-letter-to-shareholders-management-director-nomi-qntm-20210423monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-qntm-20210407monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-commences-proceedings-against-dissident-shareholders-proceedings-intended-to-ap-qntm-20210331monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-enters-into-license-agreement-to-develop-fda-approved-veterinary-drugs-for-the--qntm-20210316monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-announces-us-20m-at-the-market-offering-toronto-business-wire-qntm-20210211monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-execution-version-fsd-pharma-inc-class-b-qntm-20210211monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-inc-form-51-102f3-material-change-report-1-name-and-address-of-company-fsd-phar-qntm-20210126monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-provides-corporate-update-toronto-business-wire-qntm-20210126monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-sets-date-for-annual-meeting-toronto-business-wire-qntm-20210122monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-announces-first-patient-randomized-in-phase-2-trial-of-fsd201-for-the-treatment-qntm-20201215monthly0.5https://www.biopharmawatch.com/news/QNTM/fsd-pharma-inc-management-s-discussion-and-analysis-of-financial-condition-and-results-of--qntm-20201116monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-announces-settlement-of-class-action-proceeding-toron-qntm-20201029monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-inc-form-51-102f3-material-change-report-1-name-and-a-qntm-20201020monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-inc-announces-closing-of-us-9-5-million-registered-di-qntm-20201021monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-inc-announces-us-9-5-million-registered-direct-offeri-qntm-20201016monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-inc-form-51-102f3-material-change-report-1-name-and-a-qntm-20200928monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-begins-phase-2-clinical-trial-to-evaluate-fsd201-for--qntm-20200928monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-announces-phase-2-clinical-trial-ind-filing-with-the--qntm-20200831monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-inc-form-51-102f3-material-change-report-1-name-and-a-qntm-20200806monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-inc-management-s-discussion-and-analysis-of-financial-qntm-20200811monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-inc-announces-closing-of-us-10-million-registered-dir-qntm-20200806monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-inc-form-51-102f3-material-change-report-1-name-and-a-qntm-20200730monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-inc-announces-us-10-million-registered-direct-offerin-qntm-20200731monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-announces-decision-to-surrender-health-canada-license-qntm-20200730monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-announces-us-20m-at-the-market-offering-toronto-qntm-20200713monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-execution-version-fsd-pharma-inc-class-b-qntm-20200710monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-reports-favorable-topline-results-from-phase-1-first--qntm-20200622monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-inc-form-51-102f3-material-change-report-item-1-name--qntm-20200603monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-announces-closing-of-c-10-125-million-private-placeme-qntm-20200609monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-inc-announces-c-10-125-million-private-placement-toro-qntm-20200604monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-receives-u-s-fda-approval-to-design-a-phase-2a-clinic-qntm-20200603monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-monetizes-non-core-asset-with-sale-of-partial-equity--qntm-20200521monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-inc-management-s-discussion-and-analysis-of-financial-qntm-20200515monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-takes-steps-to-mitigate-the-impact-of-covid-19-on-its-qntm-20200323monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-12-13-in-witness-whereof-the-parties-have-executed-this-agreemen-qntm-20200318monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-begins-phase-1-in-human-safety-and-tolerability-study-qntm-20200309monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-to-ring-the-opening-bell-of-the-canadian-securities-e-qntm-20200306monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-generates-7-7-million-in-proceeds-and-670-return-on-i-qntm-20200220monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-and-solarvest-enhance-commitment-to-cbd-research-proj-qntm-20200204monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-seasoned-healthcare-executive-and-academic-luminary-larry-kaiser-qntm-20200122monthly0.5https://www.biopharmawatch.com/news/QNTM/filed-by-newsfilecorp-com-fsd-pharma-to-commence-trading-on-nasdaq-capital-market-under-sy-qntm-20200109monthly0.5https://www.biopharmawatch.com/news/ZYBT/zhengye-biotechnology-holding-limited-notice-of-2026-annual-general-meeting-of-shareholder-zybt-20260302monthly0.5https://www.biopharmawatch.com/news/ZYBT/zhengye-biotechnology-holding-limited-unaudited-condensed-consolidated-balance-sheets-amou-zybt-20251212monthly0.5https://www.biopharmawatch.com/news/ZYBT/zhengye-biotechnology-holding-limited-receives-nasdaq-notice-related-to-late-filing-of-for-zybt-20250523monthly0.5https://www.biopharmawatch.com/news/ZYBT/zhengye-biotechnology-holding-limited-announces-full-exercise-of-underwriters-over-allotme-zybt-20250114monthly0.5https://www.biopharmawatch.com/news/ZYBT/zhengye-biotechnology-holding-limited-announces-pricing-of-initial-public-offering-jilin-c-zybt-20250106monthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-announces-reverse-stock-split-common-stock-will-begin-trading-on-split-adjusted-b-kala-20260507monthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-settles-approximately-10-6-million-of-debt-kala-20260105monthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-announces-10-million-registered-direct-offering-of-common-stock-priced-at-the-mar-kala-20251204monthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-reports-first-quarter-2025-financial-results-and-provides-corporate-update-ongoin-kala-20250514monthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-corporat-kala-20250331monthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-announces-10-750-000-private-placement-kala-20241230monthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-reports-third-quarter-2024-financial-results-and-provides-corporate-update-ongoin-kala-20241112monthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-reports-second-quarter-2024-financial-results-and-provides-corporate-update-close-kala-20240806monthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-announces-12-500-000-private-placement-kala-20240627monthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-reports-first-quarter-2024-financial-results-and-provides-corporate-update-patien-kala-20240514monthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-corporat-kala-20240329monthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-reports-third-quarter-2023-financial-results-and-provides-corporate-update-enroll-kala-20231113monthly0.5https://www.biopharmawatch.com/news/KALA/kala-bio-reports-second-quarter-2023-financial-results-and-provides-corporate-update-activ-kala-20230804monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-reports-first-quarter-2023-financial-results-and-provides-corporate-u-kala-20230509monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-reports-fourth-quarter-and-full-year-2022-financial-results-and-provi-kala-20230303monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-reports-third-quarter-2022-financial-results-and-provides-corporate-u-kala-20221108monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-announces-reverse-stock-split-common-stock-will-begin-trading-on-spli-kala-20221021monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-announces-distribution-of-series-d-preferred-stock-to-holders-of-its--kala-20220818monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-reports-second-quarter-2022-financial-results-and-provides-corporate--kala-20220811monthly0.5https://www.biopharmawatch.com/news/KALA/kala-reports-first-quarter-2022-financial-results-and-provides-corporate-update-expanded-c-kala-20220516monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-reports-fourth-quarter-and-full-year-2021-financial-results-and-provi-kala-20220329monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-reports-third-quarter-2021-financial-results-and-provides-corporate-u-kala-20211115monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-reports-second-quarter-2021-financial-results-and-provides-corporate--kala-20210805monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-reports-first-quarter-2021-financial-results-and-provides-corporate-u-kala-20210505monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-reports-fourth-quarter-and-full-year-2020-financial-results-and-provi-kala-20210225monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-announces-availability-of-eysuvis-tm-for-the-treatment-of-dry-eye-dis-kala-20201231monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-reports-third-quarter-2020-financial-results-and-provides-corporate-u-kala-20201105monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-announces-fda-approval-of-eysuvis-for-the-short-term-treatment-of-the-kala-20201027monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-reports-second-quarter-2020-financial-results-and-provides-corporate--kala-20200806monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-inc-2017-equity-incentive-plan-1-purpose-the-purpose-of-this-2017-equ-kala-20200626monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-reports-first-quarter-2020-financial-results-and-provides-corporate-u-kala-20200507monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-announces-pricing-of-public-offering-of-16-000-000-shares-of-common-s-kala-20200310monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-reports-fourth-quarter-and-full-year-2019-financial-results-x2013-com-kala-20200212monthly0.5https://www.biopharmawatch.com/news/KALA/not-for-promotional-use-key-highlights-3-proprietary-ampplify-drug-delivery-technology-to--kala-20191231monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-reports-third-quarter-2019-financial-results-x2013-conference-call-an-kala-20191107monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-receives-fda-complete-response-letter-for-kpi-121-0-25-nda-and-plans--kala-20190808monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-reports-second-quarter-2019-financial-results-x2013-conference-call-a-kala-20190806monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-reports-first-quarter-2019-financial-results-x2013-conference-call-an-kala-20190509monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-reports-fourth-quarter-and-full-year-2018-financial-results-xb7-invel-kala-20190311monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-reports-third-quarter-2018-financial-results-x2013-inveltys-tm-launch-kala-20181108monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-announces-full-exercise-of-underwriters-option-to-purchase-additional-kala-20181011monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-announces-pricing-of-public-offering-of-7-500-000-shares-of-common-st-kala-20181003monthly0.5https://www.biopharmawatch.com/news/KALA/risk-factors-kala-pharmaceuticals-inc-we-us-or-our-is-filing-information-for-the-purpose-o-kala-20181002monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-announces-financing-from-athyrium-capital-management-totaling-110-mil-kala-20181002monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-announces-fda-approval-of-inveltys-tm-for-the-treatment-of-post-opera-kala-20180823monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-reports-second-quarter-2018-financial-results-x2013-pdufa-target-acti-kala-20180809monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-reports-first-quarter-2018-financial-results-waltham-ma-x2013-kala-20180510monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-reports-fourth-quarter-and-full-year-2017-financial-results-update-on-kala-20180326monthly0.5https://www.biopharmawatch.com/news/KALA/innovation-in-ophthalmology-corporate-overview-january-2018-disclaimers-and-notices-this-p-kala-20171231monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-announces-topline-results-for-two-phase-3-trials-stride-1-and-stride--kala-20180105monthly0.5https://www.biopharmawatch.com/news/KALA/kala-pharmaceuticals-reports-third-quarter-2017-financial-results-and-provides-business-up-kala-20171107monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-provides-business-update-and-reports-first-quarter-2026-financial-results-veris-hea-pavm-20260515monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-provides-business-update-and-reports-fourth-quarter-and-full-year-2025-financial-re-pavm-20260330monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-closes-preferred-stock-and-senior-secured-note-financings-eliminating-all-previousl-pavm-20260204monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-announces-reverse-stock-split-pavm-20251230monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-provides-business-update-and-reports-third-quarter-2025-financial-results-veris-hea-pavm-20251113monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-provides-business-update-and-reports-second-quarter-2025-financial-results-lucid-pr-pavm-20250814monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-provides-business-update-and-reports-first-quarter-2025-financial-results-lucid-sec-pavm-20250515monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-provides-business-update-and-reports-fourth-quarter-and-full-year-2024-financial-re-pavm-20250325monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-provides-business-update-and-third-quarter-2024-financial-results-lucid-reports-rec-pavm-20241114monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-announces-efforts-to-regain-compliance-with-nasdaq-listing-requirements-efforts-inc-pavm-20240916monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-provides-business-update-and-second-quarter-2024-financial-results-lucid-reports-re-pavm-20240813monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-provides-business-update-and-first-quarter-2024-financial-results-lucid-strengthens-pavm-20240514monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-subsidiary-veris-health-signs-memorandum-of-understanding-with-the-ohio-state-unive-pavm-20240430monthly0.5https://www.biopharmawatch.com/news/PAVM/madison-avenue-25th-floor-new-york-new-york-10017-pavm-20240209monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-announces-dividend-of-lucid-diagnostics-common-stock-and-reverse-stock-split-pavmed-pavm-20231205monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-provides-business-update-and-third-quarter-financial-results-lucid-s-quarterly-reve-pavm-20231114monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-provides-business-update-and-preliminary-fourth-quarter-and-full-year-2022-financia-pavm-20230314monthly0.5https://www.biopharmawatch.com/news/PAVM/lucid-diagnostics-holds-first-checkyourfoodtube-precancer-testing-event-partners-with-san--pavm-20230215monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-and-lucid-diagnostics-provide-strategic-business-update-strategic-resource-realloca-pavm-20230117monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-provides-business-update-and-third-quarter-2022-financial-results-esoguard-test-vol-pavm-20221115monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-provides-business-update-and-preliminary-second-quarter-2022-financial-results-luci-pavm-20220816monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-provides-business-update-and-preliminary-first-quarter-2022-financial-results-confe-pavm-20220512monthly0.5https://www.biopharmawatch.com/news/PAVM/in-the-court-of-chancery-of-the-state-of-delaware-george-a-spritzer-on-behalf-of-himself-a-pavm-20220426monthly0.5https://www.biopharmawatch.com/news/PAVM/lucid-diagnostics-provides-updates-on-newly-published-esophageal-precancer-clinical-guidel-pavm-20220404monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-provides-business-update-and-preliminary-fourth-quarter-and-full-year-2021-financia-pavm-20220329monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-to-hold-a-business-update-conference-call-on-pavm-20220308monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-appoints-shaun-o-neil-as-chief-operating-officer-pavm-20220224monthly0.5https://www.biopharmawatch.com/news/PAVM/evernorth-executive-and-healthcare-services-industry-leader-joan-harvey-named-to-pavmed-bo-pavm-20220215monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-and-lucid-to-hold-joint-business-update-conference-call-on-pavm-20211104monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-digital-health-subsidiary-veris-health-appoints-sunny-webb-as-chief-technology-offi-pavm-20211025monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-acquires-esophacap-manufacturer-capnostics-pavm-20211007monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-provides-business-update-and-preliminary-second-quarter-2021-financial-results-conf-pavm-20210812monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-subsidiary-lucid-diagnostics-launches-first-lucid-test-centers-patients-undergoing--pavm-20210810monthly0.5https://www.biopharmawatch.com/news/PAVM/global-industry-executive-aster-angagaw-joins-pavmed-subsidiary-lucid-diagnostics-board-of-pavm-20210803monthly0.5https://www.biopharmawatch.com/news/PAVM/stanley-lapidus-founder-and-former-chairman-ceo-of-exact-sciences-joins-pavmed-subsidiary--pavm-20210728monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-subsidiary-lucid-diagnostics-launches-strategic-partnership-with-direct-to-consumer-pavm-20210722monthly0.5https://www.biopharmawatch.com/news/PAVM/tim-baxter-former-ceo-of-samsung-electronics-north-america-and-global-technology-industry--pavm-20210614monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-subsidiary-lucid-diagnostics-completes-european-ce-mark-certification-of-its-esogua-pavm-20210610monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-launches-digital-health-company-veris-health-inc-new-subsidiary-veris-acquires-priv-pavm-20210602monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-subsidiary-lucid-diagnostics-receives-ce-mark-certification-for-its-esocheck-esopha-pavm-20210526monthly0.5https://www.biopharmawatch.com/news/PAVM/data-presented-at-digestive-disease-week-2021-support-clinical-utility-of-pavmed-subsidiar-pavm-20210524monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-provides-business-update-and-first-quarter-2021-financial-results-conference-call-t-pavm-20210517monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-subsidiary-lucid-diagnostics-announces-upcoming-presentation-at-digestive-disease-w-pavm-20210513monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-subsidiary-lucid-diagnostics-expands-commercial-leadership-team-four-new-senior-exe-pavm-20210506monthly0.5https://www.biopharmawatch.com/news/PAVM/dr-jacque-sokolov-joins-pavmed-subsidiary-lucid-diagnostics-board-of-directors-pavm-20210429monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-announces-closing-of-its-public-offering-of-common-stock-pavm-20210225monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-announces-proposed-public-offering-of-common-stock-pavm-20210222monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-provides-business-update-and-preliminary-fourth-quarter-2020-financial-results-anno-pavm-20210222monthly0.5https://www.biopharmawatch.com/news/PAVM/first-u-s-patient-undergoes-successful-minimally-invasive-carpal-tunnel-release-using-pavm-pavm-20210216monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-closes-13-4-million-common-stock-registered-direct-offering-priced-at-the-market-un-pavm-20210108monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-announces-registered-direct-offering-of-its-common-stock-priced-at-the-market-under-pavm-20210106monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-closes-additional-8-1-million-common-stock-registered-direct-offering-pavm-20201222monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-announces-pricing-of-additional-8-1-million-common-stock-registered-direct-offering-pavm-20201218monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-announces-registered-direct-offering-of-its-common-stock-pavm-20201211monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-reports-third-quarter-2020-financial-results-and-provides-business-update-conferenc-pavm-20201117monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-reports-second-quarter-2020-financial-results-and-provides-business-update-conferen-pavm-20200818monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-to-join-the-russell-2000-and-russell-3000-indexes-pavm-20200617monthly0.5https://www.biopharmawatch.com/news/PAVM/founder-and-former-chairman-ceo-of-exact-sciences-stanley-lapidus-joins-pavmed-subsidiary--pavm-20200615monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-subsidiary-lucid-diagnostics-receives-preliminary-payment-determination-for-esoguar-pavm-20200611monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-collaborates-with-canon-on-disappear-pediatric-ear-tubes-executed-loi-with-canon-vi-pavm-20200603monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-reports-preliminary-first-quarter-2020-financial-results-and-provides-business-upda-pavm-20200521monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-receives-fda-510-k-clearance-for-its-carpx-minimally-invasive-carpal-tunnel-device-pavm-20200421monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-reports-preliminary-fourth-quarter-2019-financial-results-and-provides-business-upd-pavm-20200409monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-subsidiary-lucid-diagnostics-esocheck-esophageal-cell-collection-device-receives-pr-pavm-20200402monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-receives-6-3-million-in-gross-proceeds-from-completion-of-november-2019-financing-pavm-20200331monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-announces-fda-510-k-re-submission-for-its-carpx-minimally-invasive-carpal-tunnel-de-pavm-20200309monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-subsidiary-lucid-diagnostics-partners-with-university-of-pennsylvania-to-evaluate-e-pavm-20200302monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-subsidiary-lucid-diagnostics-partners-with-fred-hutchinson-cancer-research-center-t-pavm-20200220monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-adds-esocure-esophageal-ablation-device-with-patented-caldus-technology-to-commerci-pavm-20200218monthly0.5https://www.biopharmawatch.com/news/PAVM/u-s-fda-grants-pavmed-subsidiary-lucid-diagnostics-breakthrough-device-designation-for-its-pavm-20200211monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-receives-formal-notification-of-nasdaq-continued-listing-compliance-pavm-20200113monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-announces-first-human-carpx-procedures-first-nine-patients-undergo-successful-carpx-pavm-20190520monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-reports-excellent-disappear-animal-study-results-resorbable-pediatric-ear-tube-expe-pavm-20190424monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-announces-registered-direct-offering-of-its-common-stock-pavm-20190412monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-announces-nextflo-breakthrough-groundbreaking-disposable-gravity-driven-intravenous-pavm-20190320monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-provides-business-update-pavm-20190110monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-closes-oversubscribed-rights-offering-for-gross-proceeds-of-10-350-000-new-york-pavm-20180612monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-to-receive-10-4-million-in-gross-proceeds-from-oversubscribed-rights-offering-new-y-pavm-20180608monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-to-offer-opportunity-to-exchange-outstanding-warrants-new-warrants-to-be-identical--pavm-20180212monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-announces-closing-of-over-allotment-option-with-respect-to-firm-commitment-common-s-pavm-20180125monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-announces-closing-of-firm-commitment-common-stock-offering-new-york-pavm-20180123monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-announces-firm-commitment-public-offering-of-common-stock-new-york-pavm-20180118monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-announces-temporary-offer-allowing-warrants-to-be-exercised-at-a-reduced-price-new--pavm-20171228monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-reports-first-quarter-2017-financial-results-and-provides-business-update-conferenc-pavm-20170525monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-announces-filing-of-exchange-offer-registration-statement-with-the-sec-exchange-str-pavm-20170410monthly0.5https://www.biopharmawatch.com/news/PAVM/tm-nasdaq-pavm-lishan-aklog-md-chairman-and-ceo-apr-2017-2-disclaimers-this-presentation-c-pavm-20170404monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-announces-closing-of-additional-financing-aggregate-private-placement-proceeds-exce-pavm-20170309monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-announces-exchange-offer-exchange-to-provide-incentives-for-long-term-ownership-by--pavm-20170223monthly0.5https://www.biopharmawatch.com/news/PAVM/tm-nasdaq-pavm-corporate-presentation-fall-2016-1-disclaimers-this-presentation-contains-c-pavm-20161122monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-partners-with-leading-academic-institutions-to-develop-revolutionary-ear-device-agr-pavm-20161104monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-inc-pavm-20160816monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-successfully-completes-carpx-pavm-20160622monthly0.5https://www.biopharmawatch.com/news/PAVM/marcum-microcap-conference-june-2-2016-new-york-ny-lishan-pavm-20160602monthly0.5https://www.biopharmawatch.com/news/PAVM/pavmed-inc-pavm-20160503monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-fourth-quarter-and-fiscal-2025-financial-results-strong-service-growth-deb-aray-20250813monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-convertible-notes-exchange-and-refinancing-of-existing-credit-facilities-aray-20250606monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-fiscal-2025-third-quarter-financial-results-aray-20250430monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-strong-fiscal-2025-second-quarter-financial-results-raises-guidance-aray-20250205monthly0.5https://www.biopharmawatch.com/news/ARAY/bkaplan-accuray-com-investor-contact-aman-patel-cfa-investor-relations-icr-westwicke-1-443-aray-20250121monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-fiscal-2025-first-quarter-financial-results-strong-start-to-fiscal-year-ra-aray-20241106monthly0.5https://www.biopharmawatch.com/news/ARAY/beth-kaplan-accuray-1-408-789-4426-bkaplan-accuray-com-investor-contact-aman-patel-cfa-inv-aray-20241021monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-president-and-chief-executive-officer-suzanne-winter-returns-from-medical-leave-of-aray-20241015monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-president-and-chief-executive-officer-suzanne-winter-to-take-temporary-medical-lea-aray-20240903monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-fourth-quarter-and-fiscal-2024-financial-results-14-revenue-and-8-orders-g-aray-20240814monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-fiscal-2024-third-quarter-financial-results-aray-20240501monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-fiscal-2024-second-quarter-financial-results-19-order-growth-yoy-8-service-aray-20240131monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-fiscal-2024-first-quarter-financial-results-company-achieves-8-revenue-gro-aray-20231107monthly0.5https://www.biopharmawatch.com/news/ARAY/forward-looking-statements-this-presentation-is-intended-exclusively-for-investors-2-propr-aray-20231003monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-fourth-quarter-and-fiscal-2023-financial-results-8-q4-revenue-growth-recor-aray-20230809monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-fiscal-2023-third-quarter-financial-results-company-delivers-record-quarte-aray-20230426monthly0.5https://www.biopharmawatch.com/news/ARAY/proprietary-and-confidential-property-of-accuray-safe-harbor-statement-statements-in-this--aray-20230306monthly0.5https://www.biopharmawatch.com/news/ARAY/proprietary-and-confidential-property-of-accuray-safe-harbor-statement-statements-in-this--aray-20230202monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-fiscal-2023-second-quarter-financial-results-delivered-strong-q2-performan-aray-20230201monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-fiscal-2023-first-quarter-financial-results-strong-customer-demand-navigat-aray-20221102monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-fourth-quarter-and-fiscal-2022-financial-results-8-5-fy22-revenue-growth-c-aray-20220810monthly0.5https://www.biopharmawatch.com/news/ARAY/actual-results-could-differ-materially-from-the-results-expressed-or-implied-by-these-forw-aray-20220615monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-fiscal-2022-third-quarter-financial-results-aray-20220427monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-reports-fiscal-2022-second-quarter-financial-results-record-revenue-for-second-qua-aray-20220126monthly0.5https://www.biopharmawatch.com/news/ARAY/joseph-diaz-beth-kaplan-managing-partner-investor-relations-lytham-partners-llc-public-rel-aray-20211103monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-transforming-patient-care-through-innovation-investor-day-aray-20211025monthly0.5https://www.biopharmawatch.com/news/ARAY/joe-diaz-beth-kaplan-investor-relations-lytham-partners-public-relations-director-accuray--aray-20211021monthly0.5https://www.biopharmawatch.com/news/ARAY/investor-contact-joe-diaz-investor-relations-lytham-partners-1-602-889-9700-diaz-lythampar-aray-20210823monthly0.5https://www.biopharmawatch.com/news/ARAY/joe-diaz-beth-kaplan-investor-relations-lytham-partners-public-relations-director-accuray--aray-20210811monthly0.5https://www.biopharmawatch.com/news/ARAY/to-accelerated-revenue-growth-expectations-related-to-the-impact-of-the-company-s-vision-a-aray-20210622monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-convertible-notes-exchange-and-subscription-aray-20210506monthly0.5https://www.biopharmawatch.com/news/ARAY/joe-diaz-beth-kaplan-investor-relations-lytham-partners-public-relations-director-accuray--aray-20210427monthly0.5https://www.biopharmawatch.com/news/ARAY/joe-diaz-investor-relations-accuray-tel-1-602-717-7804-e-mail-jdiaz-accuray-com-aray-20210219monthly0.5https://www.biopharmawatch.com/news/ARAY/joe-diaz-beth-kaplan-investor-relations-lytham-partners-public-relations-director-accuray--aray-20210127monthly0.5https://www.biopharmawatch.com/news/ARAY/safe-harbor-statement-statements-in-this-presentation-including-the-oral-commentary-that-a-aray-20210114monthly0.5https://www.biopharmawatch.com/news/ARAY/joe-diaz-beth-kaplan-investor-relations-lytham-partners-public-relations-director-accuray--aray-20201029monthly0.5https://www.biopharmawatch.com/news/ARAY/safe-harbor-statement-statements-in-this-presentation-including-the-oral-commentary-that-a-aray-20201026monthly0.5https://www.biopharmawatch.com/news/ARAY/joe-diaz-beth-kaplan-investor-relations-lytham-partners-public-relations-director-accuray--aray-20200813monthly0.5https://www.biopharmawatch.com/news/ARAY/including-new-product-offerings-the-c-ompany-s-ability-to-effectively-integrate-and-execut-aray-20200722monthly0.5https://www.biopharmawatch.com/news/ARAY/joe-diaz-beth-kaplan-investor-relations-lytham-partners-public-relations-director-accuray--aray-20200428monthly0.5https://www.biopharmawatch.com/news/ARAY/joe-diaz-beth-kaplan-investor-relations-lytham-partners-public-relations-director-accuray--aray-20200128monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-to-discuss-revenue-growth-expectations-for-the-next-three-fiscal-years-at-the-jp-m-aray-20200115monthly0.5https://www.biopharmawatch.com/news/ARAY/michael-polyviou-beth-kaplan-investor-relations-evc-group-public-relations-director-accura-aray-20191029monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-appoints-medtech-veteran-suzanne-winter-as-chief-commercial-officer-aray-20191021monthly0.5https://www.biopharmawatch.com/news/ARAY/china-announces-tariff-exclusion-for-medical-linear-accelerators-aray-20190916monthly0.5https://www.biopharmawatch.com/news/ARAY/such-other-risks-identified-under-the-heading-risk-factors-in-the-company-s-annual-report--aray-20190823monthly0.5https://www.biopharmawatch.com/news/ARAY/michael-polyviou-beth-kaplan-investor-relations-evc-group-public-relations-director-accura-aray-20190815monthly0.5https://www.biopharmawatch.com/news/ARAY/doug-sherk-beth-kaplan-investor-relations-evc-group-public-relations-director-accuray-1-41-aray-20190423monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-and-china-isotope-and-radiation-corporation-enter-joint-venture-contract-to-manufa-aray-20190128monthly0.5https://www.biopharmawatch.com/news/ARAY/doug-sherk-beth-kaplan-investor-relations-evc-group-public-relations-director-accuray-1-41-aray-20190122monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-appoints-shig-hamamatsu-chief-financial-officer-aray-20181119monthly0.5https://www.biopharmawatch.com/news/ARAY/todd-kehrli-beth-kaplan-investor-relations-evc-group-public-relations-director-accuray-1-3-aray-20181030monthly0.5https://www.biopharmawatch.com/news/ARAY/todd-kehrli-beth-kaplan-investor-relations-evc-group-public-relations-director-accuray-1-3-aray-20180816monthly0.5https://www.biopharmawatch.com/news/ARAY/joseph-e-whitters-appointed-to-accuray-board-of-directors-aray-20180719monthly0.5https://www.biopharmawatch.com/news/ARAY/doug-sherk-beth-kaplan-investor-relations-evc-group-public-relations-director-accuray-1-41-aray-20180430monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-retires-february-2018-convertible-notes-company-continues-to-execute-strategies-to-aray-20180205monthly0.5https://www.biopharmawatch.com/news/ARAY/doug-sherk-beth-kaplan-investor-relations-evc-group-public-relations-director-accuray-1-41-aray-20180123monthly0.5https://www.biopharmawatch.com/news/ARAY/beverly-a-huss-joins-accuray-board-of-directors-aray-20180111monthly0.5https://www.biopharmawatch.com/news/ARAY/th-annual-j-p-morgan-healthcare-conference-aray-20180110monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-elects-net-share-settlement-for-3-50-series-a-convertible-senior-notes-due-2018-co-aray-20180103monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-enters-into-40-million-term-loan-company-intends-to-retire-principal-amount-of-feb-aray-20171221monthly0.5https://www.biopharmawatch.com/news/ARAY/doug-sherk-investor-relations-evc-group-1-415-652-9100-dsherk-evcgroup-com-beth-kaplan-pub-aray-20171024monthly0.5https://www.biopharmawatch.com/news/ARAY/doug-sherk-investor-relations-evc-group-1-415-652-9100-dsherk-evcgroup-com-beth-kaplan-pub-aray-20170822monthly0.5https://www.biopharmawatch.com/news/ARAY/confidential-07-27-17-accuray-enhances-capital-structure-through-convertible-debt-transact-aray-20170728monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-preliminary-fourth-quarter-and-fiscal-year-2017-results-q4-revenue-expec-aray-20170717monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-enters-into-new-revolving-loan-agreement-new-loan-expected-to-reduce-interest-cost-aray-20170615monthly0.5https://www.biopharmawatch.com/news/ARAY/doug-sherk-beth-kaplan-investor-relations-evc-group-public-relations-director-accuray-1-41-aray-20170427monthly0.5https://www.biopharmawatch.com/news/ARAY/doug-sherk-investor-relations-evc-group-1-415-652-9100-dsherk-evcgroup-com-beth-kaplan-pub-aray-20170131monthly0.5https://www.biopharmawatch.com/news/ARAY/th-annual-jp-morgan-healthcare-conference-aray-20170111monthly0.5https://www.biopharmawatch.com/news/ARAY/doug-sherk-investor-relations-evc-group-1-415-652-9100-dsherk-evcgroup-com-beth-kaplan-pub-aray-20161027monthly0.5https://www.biopharmawatch.com/news/ARAY/doug-sherk-investor-relations-evc-group-1-415-652-9100-dsherk-evcgroup-com-beth-kaplan-pub-aray-20160817monthly0.5https://www.biopharmawatch.com/news/ARAY/kevin-waters-senior-vice-president-chief-financial-officer-1-aray-20160520monthly0.5https://www.biopharmawatch.com/news/ARAY/doug-sherk-beth-kaplan-investor-relations-evc-group-public-relations-director-accuray-1-41-aray-20160426monthly0.5https://www.biopharmawatch.com/news/ARAY/doug-sherk-beth-kaplan-investor-relations-evc-group-public-relations-director-accuray-1-41-aray-20160128monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-announces-repurchases-of-convertible-debt-aray-20160119monthly0.5https://www.biopharmawatch.com/news/ARAY/j-p-morgan-healthcare-conference-january-2016-accuray-and-or-its-affiliates-all-rights-res-aray-20160111monthly0.5https://www.biopharmawatch.com/news/ARAY/doug-sherk-investor-relations-evc-group-1-415-652-9100-dsherk-evcgroup-com-beth-kaplan-pub-aray-20160111monthly0.5https://www.biopharmawatch.com/news/ARAY/doug-sherk-beth-kaplan-investor-relations-evc-group-public-relations-director-accuray-1-41-aray-20151029monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-2007-incentive-award-plan-2016-market-stock-unit-grant-notice-accuray-aray-20151002monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-josh-levine-president-and-ceo-morgan-stanley-healthcare-conference-se-aray-20150828monthly0.5https://www.biopharmawatch.com/news/ARAY/kevin-waters-named-chief-financial-officer-of-accuray-succeeds-retiring-cfo-greg-lichtward-aray-20150915monthly0.5https://www.biopharmawatch.com/news/ARAY/doug-sherk-investor-relations-evc-group-1-415-652-9100-dsherk-evcgroup-com-beth-kaplan-pub-aray-20150820monthly0.5https://www.biopharmawatch.com/news/ARAY/doug-sherk-investor-relations-evc-group-1-415-652-9100-dsherk-evcgroup-com-beth-kaplan-pub-aray-20150430monthly0.5https://www.biopharmawatch.com/news/ARAY/doug-sherk-investor-relations-evc-group-1-415-652-9100-dsherk-evcgroup-com-beth-kaplan-pub-aray-20150127monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-j-p-morgan-healthcare-conference-january-2015-nasdaq-aray-safe-harbor-aray-20150112monthly0.5https://www.biopharmawatch.com/news/ARAY/lynn-pieper-investor-relations-westwicke-partners-1-415-202-5678-lynn-pieper-westwicke-com-aray-20141029monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-2007-incentive-award-plan-restricted-stock-unit-grant-notice-the-part-aray-20140902monthly0.5https://www.biopharmawatch.com/news/ARAY/jamar-ismail-investor-relations-westwicke-partners-1-415-202-5678-jamar-ismail-westwicke-c-aray-20140821monthly0.5https://www.biopharmawatch.com/news/ARAY/lynn-pieper-investor-relations-1-415-202-5678-lynn-pieper-westwicke-com-madelyn-homick-man-aray-20140430monthly0.5https://www.biopharmawatch.com/news/ARAY/lynn-pieper-investor-relations-1-415-202-5678-lynn-pieper-westwicke-com-rebecca-phillips-p-aray-20140130monthly0.5https://www.biopharmawatch.com/news/ARAY/lynn-pieper-rebecca-phillips-investor-relations-public-relations-manager-1-415-202-5678-1--aray-20131107monthly0.5https://www.biopharmawatch.com/news/ARAY/page-1-of-19-accuray-incorporated-2007-incentive-award-plan-2014-market-stock-unit-grant-n-aray-20130927monthly0.5https://www.biopharmawatch.com/news/ARAY/lynn-pieper-investor-relations-1-415-202-5678-lynn-pieper-westwicke-com-rebecca-phillips-p-aray-20130903monthly0.5https://www.biopharmawatch.com/news/ARAY/lynn-pieper-investor-relations-1-415-202-5678-lynn-pieper-westwicke-com-rebecca-phillips-p-aray-20130827monthly0.5https://www.biopharmawatch.com/news/ARAY/lynn-pieper-investor-relations-1-415-202-5678-lynn-pieper-westwicke-com-rebecca-phillips-p-aray-20130507monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-company-overview-about-accuray-accuray-is-a-radiation-oncology-company-that-develo-aray-20130208monthly0.5https://www.biopharmawatch.com/news/ARAY/tom-rathjen-vice-president-investor-relations-1-408-789-4458-trathjen-accuray-com-rebecca--aray-20130206monthly0.5https://www.biopharmawatch.com/news/ARAY/tom-rathjen-stephanie-tomei-vice-president-investor-relations-director-corporate-communica-aray-20130103monthly0.5https://www.biopharmawatch.com/news/ARAY/tom-rathjen-vice-president-investor-relations-1-408-789-4458-trathjen-accuray-com-stephani-aray-20121107monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-2007-incentive-award-plan-market-stock-unit-grant-notice-accuray-inco-aray-20121017monthly0.5https://www.biopharmawatch.com/news/ARAY/investor-contact-tom-rathjen-vice-president-investor-relations-1-408-789-4458-trathjen-acc-aray-20121012monthly0.5https://www.biopharmawatch.com/news/ARAY/tom-rathjen-vice-president-investor-relations-1-408-789-4458-trathjen-accuray-com-stephani-aray-20120906monthly0.5https://www.biopharmawatch.com/news/ARAY/rebecca-phillips-helen-shik-public-relations-manager-accuray-schwartz-msl-1-408-716-4773-1-aray-20120517monthly0.5https://www.biopharmawatch.com/news/ARAY/tom-rathjen-stephanie-tomei-vice-president-investor-relations-director-corporate-communica-aray-20120508monthly0.5https://www.biopharmawatch.com/news/ARAY/final-contacts-tom-rathjen-stephanie-tomei-vice-president-investor-relations-director-corp-aray-20120208monthly0.5https://www.biopharmawatch.com/news/ARAY/accuray-incorporated-2007-incentive-award-plan-performance-stock-unit-grant-notice-the-par-aray-20111123monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-q1-2026-shareholder-update-call-conference-call-will-be-held-on-may-18t-prpo-20260506monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-q3-2025-shareholder-update-call-conference-call-to-be-held-on-november--prpo-20251106monthly0.5https://www.biopharmawatch.com/news/PRPO/diagnostics-biotech-company-nasdaq-prpo-founded-in-2011-hq-new-haven-ct-disclaim-er-t-his--prpo-20250818monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-q2-2025-shareholder-update-call-conference-call-to-be-held-on-august-14-prpo-20250731monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-its-q1-2025-financial-results-conference-call-to-follow-tomorrow-may-15-prpo-20250515monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-q1-2025-shareholder-update-call-conference-call-to-be-held-on-may-15-th-prpo-20250506monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-q4-and-year-end-2024-shareholder-update-call-conference-call-to-be-held-prpo-20250317monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-grants-senior-management-performance-based-awards-instead-of-traditional-time-ves-prpo-20250116monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-q3-2024-shareholder-update-call-conference-call-to-be-held-on-prpo-20241107monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-q2-2024-shareholder-update-call-conference-call-to-be-held-on-prpo-20240815monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-secures-a-short-term-500k-credit-facility-loan-will-supplement-any-temporary-cash-prpo-20240506monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-year-end-2023-shareholder-update-call-conference-call-to-be-held-on-apr-prpo-20240326monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-christina-valauri-joins-the-board-of-directors-douglas-fisher-md-will-s-prpo-20240102monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-management-shares-thoughts-on-2023-and-looks-ahead-to-2024-new-haven-ct-globenews-prpo-20231214monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-q3-2023-shareholder-update-call-conference-call-to-be-held-on-november--prpo-20231116monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-takes-final-step-towards-regaining-nasdaq-compliance-company-announces-1-for-20-r-prpo-20230921monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-q2-2023-shareholder-update-call-conference-call-to-be-held-on-prpo-20230817monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-inc-announces-pricing-of-2-million-registered-direct-offering-and-concurrent-priv-prpo-20230612monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-q1-2023-shareholder-update-call-conference-call-to-be-held-on-prpo-20230517monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-granted-180-day-extension-from-nasdaq-to-regain-compliance-extension-will-enable--prpo-20230427monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-2022-fourth-quarter-and-year-end-shareholder-update-call-conference-cal-prpo-20230329monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-third-quarter-shareholder-update-call-conference-call-to-be-held-on-mon-prpo-20221104monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-second-quarter-shareholder-update-call-conference-call-to-be-held-on-mo-prpo-20220808monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-to-distribute-hemescreen-through-fisher-healthcare-channel-agreement-enhances-pre-prpo-20220721monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-requests-that-all-stockholders-that-have-not-yet-voted-proceed-to-cast-their-vote-prpo-20220614monthly0.5https://www.biopharmawatch.com/news/PRPO/page-nasdaq-prpo-a-cancer-diagnostics-solutions-company-2022-corporate-presentation-discla-prpo-20220613monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-2021-fourth-quarter-and-year-end-shareholder-update-call-conference-cal-prpo-20220323monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-inc-announces-the-resignation-of-its-chief-financial-officer-and-appointment-of-i-prpo-20220321monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-releases-year-end-2021-preliminary-unaudited-results-and-outlook-for-2022-new-hav-prpo-20220224monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-q3-2021-shareholder-update-call-conference-call-to-be-held-on-monday-no-prpo-20211102monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-reschedules-q2-2021-shareholder-update-call-due-to-a-schedule-conflict-the-call-i-prpo-20210823monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-q2-2021-shareholder-update-call-conference-call-to-be-held-on-monday-au-prpo-20210813monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-preliminary-unaudited-q2-2021-revenues-of-2-3m-increase-of-65-yoy-and-2-prpo-20210728monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-q1-2021-and-year-end-shareholder-update-call-conference-call-to-be-held-prpo-20210517monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-q4-2020-and-year-end-shareholder-update-call-conference-call-to-be-held-prpo-20210318monthly0.5https://www.biopharmawatch.com/news/PRPO/mr-richard-sandberg-is-appointed-chairman-of-precipio-s-board-of-directors-new-haven-ct-prpo-20210303monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-q3-2020-shareholder-update-call-conference-call-to-be-held-on-thursday--prpo-20201112monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-a-shareholder-call-to-discuss-its-covid-19-progress-and-future-plans-il-prpo-20200907monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-q2-2020-corporate-update-call-for-shareholders-conference-call-to-be-he-prpo-20200807monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-q2-2020-unaudited-pathology-services-revenue-increased-approximately-50-prpo-20200722monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-q1-2020-corporate-update-call-for-shareholders-conference-call-to-be-he-prpo-20200513monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-completes-the-transaction-with-poplar-healthcare-s-oncometrix-hematopathology-div-prpo-20200316monthly0.5https://www.biopharmawatch.com/news/PRPO/prpo-8k-99-1-poplar-partenrship-precipio-in-advanced-discussions-with-poplar-healthcare-to-prpo-20200218monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-shareholder-update-call-to-kick-off-2020-new-haven-ct-prpo-20200113monthly0.5https://www.biopharmawatch.com/news/PRPO/prpo-8k-99-1-press-release-dated-dec-4-2019-precipio-announces-the-resignation-of-samuel-r-prpo-20191204monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-q3-2019-corporate-update-call-for-shareholders-conference-call-to-be-he-prpo-20191105monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-shareholder-update-call-on-commercial-progress-conference-call-to-be-he-prpo-20191002monthly0.5https://www.biopharmawatch.com/news/PRPO/prpo-8k-99-1press-release-dated-prpo-20190926monthly0.5https://www.biopharmawatch.com/news/PRPO/prpo-8k-august-13-2019-press-release-letter-to-shareholders-precipio-announces-q2-2019-cor-prpo-20190813monthly0.5https://www.biopharmawatch.com/news/PRPO/prpo-8k-991-press-release-letter-to-shareholders-june-19-2019-precipio-ceo-provides-update-prpo-20190617monthly0.5https://www.biopharmawatch.com/news/PRPO/prpo-8k-991-press-release-nasdaq-compliance-precipio-regains-nasdaq-listing-compliance-new-prpo-20190515monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-takes-final-step-towards-regaining-nasdaq-compliance-company-announces-1-for-15-r-prpo-20190426monthly0.5https://www.biopharmawatch.com/news/PRPO/prpo-8k-regulation-fd-99-1-discl-letter-to-shareholders-precipio-ceo-issues-shareholder-up-prpo-20190311monthly0.5https://www.biopharmawatch.com/news/PRPO/prpo-8k-99-1-for-preliminary-results-q4-precipio-2018-revenues-increase-66-over-2017-compa-prpo-20190214monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-third-quarter-2018-corporate-update-call-for-shareholders-conference-ca-prpo-20181119monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-third-quarter-2018-revenues-estimated-to-be-2-4-times-third-quarter-of--prpo-20181016monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-granted-180-day-nasdaq-extension-to-regain-compliance-enables-company-to-execute--prpo-20180927monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-second-quarter-2018-financial-results-and-provides-corporate-update-con-prpo-20180823monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-appoints-new-board-member-to-replace-departing-director-kathy-laporte-brings-30-y-prpo-20180809monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-213-year-over-year-revenue-growth-in-preliminary-q2-2018-results-third--prpo-20180718monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-inc-announces-adjournment-of-annual-meeting-of-shareholders-new-haven-ct-prpo-20180615monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announce-s-preliminary-q-1-2018-year-over-year-revenue-increase-of-286-growth-res-prpo-20180514monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-participation-details-for-upcoming-shareholder-conference-call-new-have-prpo-20180426monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-q4-2017-revenue-at-350-of-previous-quarter-first-post-merger-quarter-to-prpo-20180209monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-third-quarter-2017-financial-results-and-provides-corporate-update-conf-prpo-20171121monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-appoints-samuel-d-riccitelli-as-chairman-of-the-board-of-directors-and-elects-dav-prpo-20171114monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-inc-announces-closing-of-2-748-000-prpo-20171113monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-inc-announces-pricing-of-2-748-000-registered-direct-offering-new-haven-ct-novemb-prpo-20171103monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-elects-jeffrey-cossman-md-and-douglas-fisher-md-to-its-board-of-directors-new-hav-prpo-20171002monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-provides-shareholder-update-letter-new-haven-conn-prpo-20170906monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-inc-announces-closing-of-public-offering-new-haven-ct-prpo-20170831monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-inc-prices-6-000-000-public-offering-new-haven-ct-prpo-20170823monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-announces-proposed-public-offering-new-haven-conn-prpo-20170801monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-diagnostics-llc-index-unaudited-condensed-financial-statements-2-condensed-balanc-prpo-20170731monthly0.5https://www.biopharmawatch.com/news/PRPO/precipio-diagnostics-and-transgenomic-complete-merger-company-renamed-precipio-inc-to-comm-prpo-20170630monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-stockholders-and-precipio-diagnostics-members-approve-merger-omaha-neb-and-ne-prpo-20170606monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-board-confirms-date-and-location-of-special-meeting-of-stockholders-and-annou-prpo-20170525monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-closes-bridge-financing-proceeds-intended-to-facilitate-completion-of-merger--prpo-20170417monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-provides-update-on-its-planned-merger-and-reports-change-in-listing-status-om-prpo-20170221monthly0.5https://www.biopharmawatch.com/news/PRPO/voting-agreement-this-voting-agreement-this-agreement-dated-as-of-october-2016-is-made-by--prpo-20161013monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-reports-second-quarter-2016-financial-results-conference-call-to-be-held-at-5-prpo-20160812monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-announces-private-placement-financing-omaha-neb-prpo-20160111monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-announces-conversion-of-series-a-and-b-preferred-securities-and-extension-of--prpo-20160111monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-finalizes-divestment-of-its-genetic-assays-platforms-business-unit-divestitur-prpo-20151201monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-reports-third-quarter-2015-financial-results-conference-call-to-be-held-at-5--prpo-20151112monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-signs-binding-term-sheet-to-divest-genetic-assays-platforms-business-unit-tra-prpo-20150930monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-sells-ion-chromatography-product-line-and-assets-to-edge-biosystems-inc-2-1-m-prpo-20150909monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-reports-second-quarter-2015-financial-results-conference-call-to-be-held-at-5-prpo-20150813monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-announces-private-placement-financing-omaha-neb-prpo-20150701monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-announces-plans-to-launch-liquid-biopsy-cancer-test-pipeline-during-2015-plan-prpo-20150622monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-expands-board-of-directors-and-executive-team-new-director-mya-thomae-is-regu-prpo-20150609monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-reports-first-quarter-2015-financial-results-conference-call-to-be-held-at-5--prpo-20150514monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-provides-financial-and-business-update-conference-call-to-be-held-at-5-00-pm--prpo-20150415monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-announces-commencement-of-public-offering-of-common-stock-omaha-neb-prpo-20150226monthly0.5https://www.biopharmawatch.com/news/PRPO/1-investor-presentation-improving-cancer-outcomes-with-groundbreaking-precision-in-molecul-prpo-20150114monthly0.5https://www.biopharmawatch.com/news/PRPO/strategic-update-advancing-outcomes-in-oncology-with-groundbreaking-molecular-testing-tech-prpo-20141211monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-announces-executive-changes-omaha-neb-prpo-20141105monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-reports-third-quarter-2014-financial-results-conference-call-to-be-held-at-8--prpo-20141030monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-announces-2-375-million-private-placement-financing-omaha-neb-prpo-20141022monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-reports-second-quarter-2014-financial-results-conference-call-to-be-held-at-5-prpo-20140806monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-sells-rights-to-surveyor-mutation-detection-technology-and-assets-to-integrat-prpo-20140702monthly0.5https://www.biopharmawatch.com/news/PRPO/john-d-thompson-joins-transgenomic-s-board-of-directors-omaha-neb-prpo-20140515monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-reports-first-quarter-2014-financial-results-conference-call-to-be-held-at-5--prpo-20140507monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-announces-uplisting-to-the-nasdaq-capital-market-omaha-neb-prpo-20140506monthly0.5https://www.biopharmawatch.com/news/PRPO/dr-michael-a-luther-joins-transgenomic-s-board-of-directors-omaha-neb-prpo-20140319monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-reports-fourth-quarter-and-fiscal-year-2013-financial-results-conference-call-prpo-20140312monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-announces-7-million-convertible-preferred-stock-financing-omaha-neb-prpo-20140306monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-files-application-for-the-nasdaq-capital-market-listing-and-board-approves-re-prpo-20140116monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-reports-third-quarter-2013-financial-results-conference-call-to-be-held-at-5--prpo-20131106monthly0.5https://www.biopharmawatch.com/news/PRPO/pdi-media-and-investor-contact-melody-carey-rx-communications-group-llc-917-322-2571-mcare-prpo-20131015monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-announces-executive-changes-paul-kinnon-named-president-chief-executive-offic-prpo-20130930monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-reports-second-quarter-2013-financial-results-conference-call-to-be-held-at-5-prpo-20130806monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-reports-first-quarter-2013-financial-results-conference-call-to-be-held-today-prpo-20130508monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-reports-fourth-quarter-and-fiscal-year-2012-financial-results-conference-call-prpo-20130313monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-secures-8-0-million-credit-facility-omaha-neb-prpo-20130313monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-announces-8-3-million-private-placement-financing-omaha-neb-prpo-20130125monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-reports-third-quarter-2012-financial-results-conference-call-to-be-held-today-prpo-20121107monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-announces-appointment-of-mark-p-colonnese-as-chief-financial-officer-omaha-ne-prpo-20120913monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-acquires-scoliscore-adolescent-idiopathic-scoliosis-prognostic-test-from-axia-prpo-20120828monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-reports-second-quarter-2012-financial-results-conference-call-to-be-held-toda-prpo-20120801monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-reports-first-quarter-2012-financial-results-conference-call-to-be-held-at-5--prpo-20120508monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-reports-fiscal-year-2011-financial-results-annual-revenues-increase-59-year-o-prpo-20120307monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-announces-22-0-million-private-placement-financing-omaha-neb-prpo-20120203monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-announces-3-million-convertible-note-financing-omaha-neb-prpo-20120106monthly0.5https://www.biopharmawatch.com/news/PRPO/unassociated-document-transgenomic-reports-third-quarter-financial-results-quarterly-reven-prpo-20111109monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-inc-craig-hallum-2nd-annual-alpha-select-conference-prpo-20111006monthly0.5https://www.biopharmawatch.com/news/PRPO/investor-presentation-slides-transgenomic-inc-rodman-renshaw-13th-annual-healthcare-confer-prpo-20110916monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-reports-first-quarter-financial-results-net-sales-of-7-5-million-up-37-percen-prpo-20110512monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-reports-fourth-quarter-financial-results-conference-call-begins-at-11-00-a-m--prpo-20110310monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-announces-closing-of-the-acquisition-of-clinical-data-s-diagnostic-business-a-prpo-20101229monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-inc-to-purchase-clinical-data-inc-s-diagnostic-business-addition-of-high-grow-prpo-20101130monthly0.5https://www.biopharmawatch.com/news/PRPO/transgenomic-reports-second-quarter-financial-results-conference-call-begins-at-5-00-p-m-e-prpo-20100812monthly0.5https://www.biopharmawatch.com/news/PRPO/unassociated-document-transgenomic-reports-first-quarter-financial-results-conference-call-prpo-20100505monthly0.5https://www.biopharmawatch.com/news/PRPO/unassociated-document-transgenomic-reports-fourth-quarter-financial-results-conference-cal-prpo-20100224monthly0.5https://www.biopharmawatch.com/news/PRPO/thursday-prpo-20091105monthly0.5https://www.biopharmawatch.com/news/PRPO/wednesday-prpo-20090812monthly0.5https://www.biopharmawatch.com/news/PRPO/unassociated-document-friday-prpo-20090522monthly0.5https://www.biopharmawatch.com/news/PRPO/wednesday-prpo-20090513monthly0.5https://www.biopharmawatch.com/news/PRPO/unassociated-document-wednesday-prpo-20090318monthly0.5https://www.biopharmawatch.com/news/PRPO/wednesday-prpo-20081029monthly0.5https://www.biopharmawatch.com/news/PRPO/v113094-ex99-txt-wednesday-prpo-20080507monthly0.5https://www.biopharmawatch.com/news/PRPO/v105339-ex99-1-txt-to-business-and-medical-editors-transgenomic-inc-reports-fourth-quarter-prpo-20080228monthly0.5https://www.biopharmawatch.com/news/PRPO/v102065-ex99-1-txt-transgenomic-appoints-david-pauluzzi-to-board-of-directors-former-quest-prpo-20080205monthly0.5https://www.biopharmawatch.com/news/ONMD/onemednet-regains-compliance-with-nasdaq-periodic-filing-requirements-minneapolis-onmd-20241230monthly0.5https://www.biopharmawatch.com/news/ONMD/onemednet-announces-receipt-of-nasdaq-notice-regarding-delayed-form-10-q-minneapolis-onmd-20241127monthly0.5https://www.biopharmawatch.com/news/ONMD/onemednet-announces-board-member-transition-to-drive-growth-post-ipo-minneapolis-october-2-onmd-20241007monthly0.5https://www.biopharmawatch.com/news/ONMD/onemednet-announces-additional-1-7-million-private-placement-minneapolis-onmd-20240926monthly0.5https://www.biopharmawatch.com/news/ONMD/onemednet-announces-receipt-of-nasdaq-notices-regarding-delayed-forms-10-q-minneapolis-onmd-20240912monthly0.5https://www.biopharmawatch.com/news/ONMD/onemednet-announces-4-6-million-private-placement-institutional-investors-include-affiliat-onmd-20240726monthly0.5https://www.biopharmawatch.com/news/ONMD/onemednet-provides-updates-on-auditor-change-and-announces-related-receipt-of-nasdaq-notic-onmd-20240624monthly0.5https://www.biopharmawatch.com/news/ONMD/onemednet-announces-ceo-succession-plan-president-aaron-green-assumes-role-of-chief-execut-onmd-20240402monthly0.5https://www.biopharmawatch.com/news/ONMD/onemednet-announces-participation-as-an-exhibitor-in-the-ai-showcase-during-the-rsna-2023--onmd-20231120monthly0.5https://www.biopharmawatch.com/news/ONMD/unaudited-pro-forma-condensed-combined-financial-information-defined-terms-included-below--onmd-20231113monthly0.5https://www.biopharmawatch.com/news/ONMD/data-knights-acquisition-corp-confirms-funding-to-extend-period-to-consummate-initial-busi-onmd-20231012monthly0.5https://www.biopharmawatch.com/news/ONMD/data-knights-acquisition-corp-please-do-not-return-the-proxy-card-if-you-are-voting-electr-onmd-20231010monthly0.5https://www.biopharmawatch.com/news/ONMD/onemednet-corporation-and-data-knights-acquisition-corp-announce-effectiveness-of-registra-onmd-20230925monthly0.5https://www.biopharmawatch.com/news/ONMD/data-knights-acquisition-corp-confirms-funding-to-extend-period-to-consummate-initial-busi-onmd-20230918monthly0.5https://www.biopharmawatch.com/news/ONMD/data-knights-acquisition-corp-confirms-funding-to-extend-period-to-consummate-initial-busi-onmd-20230811monthly0.5https://www.biopharmawatch.com/news/ONMD/data-knights-acquisition-corp-announces-charter-and-trust-agreement-amendments-and-extensi-onmd-20230811monthly0.5https://www.biopharmawatch.com/news/ONMD/data-knights-acquisition-corp-announces-calling-of-special-meeting-of-stockholders-minneap-onmd-20230731monthly0.5https://www.biopharmawatch.com/news/ONMD/data-knights-acquisition-corp-confirms-funding-to-extend-period-to-consummate-initial-busi-onmd-20230712monthly0.5https://www.biopharmawatch.com/news/ONMD/data-knights-acquisition-corp-confirms-funding-to-extend-period-to-consummate-initial-busi-onmd-20230612monthly0.5https://www.biopharmawatch.com/news/ONMD/onemednet-announces-filing-of-registration-statement-on-form-s-4-in-connection-with-its-pr-onmd-20220722monthly0.5https://www.biopharmawatch.com/news/ONMD/extracting-and-refining-medical-real-world-data-p-aul-c-asey-ceo-j-effrey-y-u-md-f-ounder--onmd-20220520monthly0.5https://www.biopharmawatch.com/news/ONMD/extracting-and-refining-medical-real-world-data-p-aul-c-asey-ceo-j-effrey-y-u-md-f-ounder--onmd-20220512monthly0.5https://www.biopharmawatch.com/news/ONMD/data-knights-acquisition-corp-confirms-funding-to-extend-period-to-consummate-initial-busi-onmd-20220505monthly0.5https://www.biopharmawatch.com/news/ONMD/onemednet-an-expert-and-leader-in-clinical-imaging-innovation-and-data-solutions-to-become-onmd-20220425monthly0.5https://www.biopharmawatch.com/news/ONMD/data-knights-acquisition-corp-announces-the-separate-trading-of-its-class-a-common-stock-a-onmd-20210622monthly0.5https://www.biopharmawatch.com/news/ONMD/index-to-financial-statements-page-report-of-independent-registered-public-accounting-firm-onmd-20210511monthly0.5https://www.biopharmawatch.com/news/ONMD/data-knights-acquisition-corp-announces-pricing-of-100-000-000-initial-public-offering-and-onmd-20210506monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-selects-commercial-brand-name-for-its-abuse-deterrent-fentanyl-patch-nutriband-h-ntrb-20260330monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-inc-signs-agreement-to-sell-majority-stake-of-subsidiary-pocono-pharmaceutical-f-ntrb-20251231monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-announces-successful-meeting-completed-with-united-states-fda-for-its-abuse-dete-ntrb-20251028monthly0.5https://www.biopharmawatch.com/news/NTRB/issued-april-4-2025-e-xhibit-99-1-nutriband-signs-associate-partnership-with-charlotte-fc--ntrb-20250404monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-and-kindeva-formalize-exclusive-product-development-partnership-and-long-term-co-ntrb-20250213monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-receives-notice-of-allowance-for-new-u-s-patent-covering-its-transdermal-abuse-d-ntrb-20250207monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-extends-chinese-patent-to-macao-for-its-aversa-abuse-deterrent-transdermal-techn-ntrb-20241227monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-inc-issued-full-patent-from-the-chinese-national-intellectual-property-administr-ntrb-20241031monthly0.5https://www.biopharmawatch.com/news/NTRB/issued-september-16-2024-e-xhibit-99-1-nutriband-inc-announces-1-million-share-buyback-pro-ntrb-20240916monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-signs-commercial-development-and-clinical-supply-agreement-with-kindeva-drug-del-ntrb-20240104monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-secures-2-million-line-of-credit-financing-facility-to-be-used-for-commercializa-ntrb-20230328monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-inc-commences-trading-on-upstream-under-ntrb-nutriband-among-the-first-issuers-t-ntrb-20230105monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-inc-announces-application-for-dual-listing-on-upstream-ntrb-20221003monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-inc-details-of-seven-for-six-forward-stock-split-ntrb-20220810monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-receives-notice-of-allowance-from-the-canadian-intellectual-property-office-for--ntrb-20220801monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-inc-announces-seven-for-six-forward-stock-split-ntrb-20220727monthly0.5https://www.biopharmawatch.com/news/NTRB/m-shares-of-nutriband-inc-to-be-cancelled-from-total-outstanding-shares-following-final-co-ntrb-20220726monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-inc-successfully-obtains-court-verdict-for-recovery-of-shares-constituting-15-of-ntrb-20220715monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-issued-full-us-patent-for-its-aversa-abuse-deterrent-transdermal-platform-by-uni-ntrb-20220128monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-inc-expands-product-development-pipeline-for-its-aversa-platform-abuse-deterrent-ntrb-20220118monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-inc-and-kindeva-drug-delivery-sign-feasibility-agreement-to-develop-aversa-fenta-ntrb-20220110monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-inc-issued-full-patent-from-korean-intellectual-property-office-kipo-for-its-abu-ntrb-20211231monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-inc-announces-1-million-share-repurchase-authorization-ntrb-20211229monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-inc-receives-patent-protection-from-australia-russia-and-mexico-ntrb-20200318monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-inc-s-abuse-deterrent-transdermal-technology-patent-granted-by-japan-s-patent-of-ntrb-20190423monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-inc-s-abuse-deterrent-transdermal-technology-patent-granted-by-european-patent-o-ntrb-20190326monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-inc-granted-prioritized-examination-from-the-united-states-patent-and-trademark--ntrb-20190129monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-inc-receives-intention-to-grant-notice-from-european-patent-office-for-abuse-det-ntrb-20181031monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-inc-signs-acquisition-agreement-of-carmel-biosciences-and-fda-approved-prexxarta-ntrb-20180926monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-inc-announces-the-appointment-of-larry-dillaha-md-as-chief-medical-officer-and-t-ntrb-20180802monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-inc-completes-acquisition-of-4p-therapeutics-inc-ntrb-20180801monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-inc-signs-20-year-90-million-dollar-exclusive-distribution-agreement-with-best-c-ntrb-20180510monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-inc-acquires-4p-therapeutics-inc-orlando-fla-ntrb-20180410monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-inc-announces-the-appointment-of-sean-gallagher-as-company-president-orlando-flo-ntrb-20180213monthly0.5https://www.biopharmawatch.com/news/NTRB/mutual-rescission-and-release-agreement-nutriband-inc-and-emi-11-09-2017-this-mutual-recis-ntrb-20171110monthly0.5https://www.biopharmawatch.com/news/NTRB/nutriband-inc-announces-the-acquisition-of-edgemark-innovation-inc-oviedo-fla-ntrb-20171005monthly0.5https://www.biopharmawatch.com/news/NTRB/in-analyzing-the-six-following-provisional-patents-ntrb-20170818monthly0.5https://www.biopharmawatch.com/news/NTRB/share-exchange-agreement-this-share-exchange-agreement-the-agreement-is-made-and-entered-i-ntrb-20170523monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-granted-u-s-fda-orphan-drug-designation-to-reyobiq-in-pediatric-malignan-pstv-20260408monthly0.5https://www.biopharmawatch.com/news/PSTV/result-from-the-treatment-of-fractional-shares-the-potential-for-the-company-to-regain-com-pstv-20260402monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-c-corporate-orporate-up-update-date-ja-january-nuary-2-2026-026-p-power--pstv-20260122monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-granted-180-day-extension-to-regain-compliance-with-nasdaq-s-minimum-bid-pstv-20251117monthly0.5https://www.biopharmawatch.com/news/PSTV/the-unaudited-pro-forma-balance-sheet-has-been-filed-in-order-to-show-compliance-with-the--pstv-20250814monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reports-second-quarter-financial-results-and-recent-business-highlights--pstv-20250814monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reports-first-quarter-financial-results-and-recent-business-highlights-c-pstv-20250530monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-inc-receives-notification-of-deficiency-from-nasdaq-related-to-delayed-f-pstv-20250523monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-b-pstv-20250327monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reports-third-quarter-2024-financial-results-and-recent-business-highlig-pstv-20241114monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reports-second-quarter-2024-financial-results-and-recent-business-highli-pstv-20240814monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reports-first-quarter-2024-financial-results-and-recent-business-highlig-pstv-20240515monthly0.5https://www.biopharmawatch.com/news/PSTV/corporate-presentation-march-2024-forward-looking-statement-this-presentation-contains-sta-pstv-20240313monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-business-pstv-20240305monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reports-new-interim-respect-gbm-phase-2-trial-data-at-the-society-for-ne-pstv-20231120monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reports-third-quarter-2023-financial-results-and-business-highlights-new-pstv-20231031monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reports-second-quarter-2023-financial-results-and-business-highlights-re-pstv-20230814monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-regains-compliance-with-nasdaq-listing-requirements-pstv-20230516monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-announces-reverse-stock-split-pstv-20230428monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reports-first-quarter-2023-financial-results-and-business-highlights-plu-pstv-20230420monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-business-pstv-20230223monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reports-third-quarter-2022-financial-results-and-business-highlights-awa-pstv-20221020monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-executes-17-6-million-award-contract-with-cancer-prevention-research-ins-pstv-20220922monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reports-second-quarter-2022-financial-results-and-business-highlights-co-pstv-20220721monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reports-first-quarter-2022-financial-results-and-business-highlights-fir-pstv-20220421monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-and-medidata-announce-expanded-clinical-trial-partnership-companies-coll-pstv-20220405monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-business-pstv-20220224monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-significantly-expands-investigational-oncology-drug-pipeline-licenses-ta-pstv-20220106monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-announces-positive-interim-data-from-respect-gbm-phase-1-clinical-trial--pstv-20211118monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reports-third-quarter-2021-financial-results-and-business-highlights-man-pstv-20211021monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-announces-the-appointment-of-industry-veteran-norman-lafrance-m-d-as-the-pstv-20210913monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reports-second-quarter-2021-financial-results-and-business-highlights-ma-pstv-20210722monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reports-first-quarter-2021-financial-results-and-business-highlights-man-pstv-20210422monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and-business-pstv-20210222monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reports-third-quarter-2020-financial-results-and-business-highlights-rec-pstv-20201022monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-receives-fast-track-designation-for-its-novel-glioblastoma-treatment-pstv-20200915monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reports-second-quarter-2020-financial-and-business-results-pstv-20200810monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reports-first-quarter-2020-financial-and-business-results-pstv-20200514monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-announces-closing-of-agreement-to-license-novel-oncology-platform-pstv-20200511monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-reports-fourth-quarter-and-full-fiscal-year-2019-financial-and-business--pstv-20200330monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-licenses-novel-oncology-platform-expands-pipeline-multiple-clinical-prec-pstv-20200330monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-welcomes-two-new-directors-dr-robert-lenk-and-mr-howard-clowes-pstv-20200312monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-announces-changes-to-its-board-of-directors-pstv-20200206monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-appoints-dr-an-van-es-johansson-to-board-of-directors-pstv-20200102monthly0.5https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-inc-announces-pricing-of-15-million-underwritten-public-offering-pstv-20190923monthly0.5https://www.biopharmawatch.com/news/PSTV/to-our-current-report-on-form-8-k-this-exhibit-to-revise-and-recast-our-historical-consoli-pstv-20190910monthly0.5https://www.biopharmawatch.com/news/PSTV/our-need-and-ability-to-raise-additional-cash-the-outcome-of-our-partnering-licensing-effo-pstv-20190716monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-announces-new-annual-stockholders-meeting-date-for-july-11-annual-meeting-adjourned-pstv-20190627monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-announces-new-annual-stockholders-meeting-date-for-june-27-annual-meeting-adjourned-pstv-20190618monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-to-present-new-strategic-direction-company-to-announce-new-therapeutic-area-focus-a-pstv-20190613monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-announces-new-annual-stockholders-meeting-date-for-june-18-may-28-meeting-adjourned-pstv-20190530monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-therapeutics-contact-gary-titus-1-858-458-0900-ir-cytori-com-cytori-reports-q1-2019-pstv-20190514monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-reports-fourth-quarter-and-full-year-2018-business-and-financial-results-strategic--pstv-20190401monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-therapeutics-contact-tiago-girao-1-858-458-0900-ir-cytori-com-cytori-reports-q3-201-pstv-20181114monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-therapeutics-contact-tiago-girao-1-858-458-0900-ir-cytori-com-cytori-reports-q2-201-pstv-20180814monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-therapeutics-contact-tiago-girao-1-858-458-0900-ir-cytori-com-cytori-reports-q1-201-pstv-20180510monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-therapeutics-contact-tiago-girao-1-858-458-0900-ir-cytori-com-cytori-reports-fourth-pstv-20180308monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-reports-third-quarter-2017-business-and-financial-results-pstv-20171109monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-therapeutics-contact-tiago-girao-1-858-458-0900-ir-cytori-com-cytori-reports-second-pstv-20170810monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-therapeutics-contact-tiago-girao-1-858-458-0900-ir-cytori-com-cytori-reports-first--pstv-20170511monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-announces-proposed-public-offering-of-common-stock-pstv-20170410monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-therapeutics-contact-tiago-girao-1-858-458-0900-ir-cytori-com-cytori-reports-fourth-pstv-20170323monthly0.5https://www.biopharmawatch.com/news/PSTV/forward-looking-statements-and-disclaimers-33-15-11-22-19-other-usa-eu-japan-asia-pacific--pstv-20170110monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-therapeutics-contact-tiago-girao-1-858-458-0900-ir-cytori-com-cytori-reports-third--pstv-20161109monthly0.5https://www.biopharmawatch.com/news/PSTV/barda-increases-contract-option-with-cytori-to-advance-countermeasure-clinical-trial-incre-pstv-20160919monthly0.5https://www.biopharmawatch.com/news/PSTV/forward-looking-statements-and-disclaimers-33-15-11-22-19-other-usa-eu-japan-asia-pacific--pstv-20160913monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-therapeutics-inc-press-release-dated-june-13-2016-cytori-announces-expiration-of-ri-pstv-20160613monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-therapeutics-inc-press-release-dated-june-6-2016-cytori-extends-rights-offering-sub-pstv-20160606monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-therapeutics-inc-press-release-dated-may-31-2016-cytori-announces-commencement-of-s-pstv-20160531monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-therapeutics-contact-tiago-girao-1-858-458-0900-ir-cytori-com-cytori-reports-fourth-pstv-20160303monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-therapeutics-investor-presentation-material-cytori-therapeutics-nasdaq-cytx-enhanci-pstv-20160112monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-amends-corporate-warrant-agreements-simplifying-capital-structure-and-updates-on-20-pstv-20151218monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-therapeutics-contact-tiago-girao-1-858-458-0900-ir-cytori-com-cytori-reports-third--pstv-20151105monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-restructures-its-debt-to-a-17-7-million-term-loan-june-1-st-2015-san-diego-ca-cytor-pstv-20150529monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-prices-registered-direct-offering-providing-for-up-to-25-million-in-equity-financin-pstv-20150508monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-provides-twelve-month-data-update-on-scleradec-i-trial-pstv-20150413monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-therapeuticsnasdaq-cytxcorporate-updatemarch-2015-nasdaq-cytx-restoring-lives-forwa-pstv-20150304monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-therapeutics-nasdaq-cytx-investor-update-january-2015-nasdaq-cytx-restoring-lives-f-pstv-20150112monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-therapeutics-contact-megan-mccormick-1-858-875-5279-mmccormick-cytori-com-cytori-th-pstv-20140530monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-press-release-exhibit991-pressrelease-htm-cytori-therapeutics-contact-megan-mccormi-pstv-20140402monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-press-release-exhibit991-pressrelease-htm-cytori-therapeutics-contact-megan-mccormi-pstv-20140311monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-press-release-exhibit991-pressrelease-htm-pstv-20130307monthly0.5https://www.biopharmawatch.com/news/PSTV/dated-2-25-cytori-exhibit991-htm-pstv-20130225monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-press-release-exhibit991-pressrelease-htm-pstv-20121108monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-press-release-exhibit991-pressrelease-htm-pstv-20120808monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-press-release-exhibit991-pressrelease-htm-pstv-20120509monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-press-release-exhibit991-pressrelease-htm-pstv-20120308monthly0.5https://www.biopharmawatch.com/news/PSTV/exhbit-99-1-cytori-press-release-11-3-2011-exhibit991-pressrelease-htm-pstv-20111103monthly0.5https://www.biopharmawatch.com/news/PSTV/exhbit-99-1-cytori-press-release-8-9-2011-exhibit991-pressrelease-htm-pstv-20110809monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-press-release-5-5-2011-exhibit991-pressrelease-htm-pstv-20110505monthly0.5https://www.biopharmawatch.com/news/PSTV/cytori-press-release-3-10-2011-exhibit991-pressrelease-htm-pstv-20110310monthly0.5https://www.biopharmawatch.com/news/PETS/document-petmeds-extends-existing-shareholder-rights-plan-pets-20251126monthly0.5https://www.biopharmawatch.com/news/PETS/petmeds-files-form-10-k-for-fiscal-2025-delray-beach-florida-pets-20251014monthly0.5https://www.biopharmawatch.com/news/PETS/petmed-express-inc-announces-management-changes-delray-beach-florida-pets-20250812monthly0.5https://www.biopharmawatch.com/news/PETS/document-pets-20250724monthly0.5https://www.biopharmawatch.com/news/PETS/petmed-express-receives-notification-of-deficiency-from-nasdaq-related-to-delayed-filing-o-pets-20250703monthly0.5https://www.biopharmawatch.com/news/PETS/petmed-express-inc-provides-update-on-status-of-fourth-quarter-and-fy-2025-results-and-for-pets-20250701monthly0.5https://www.biopharmawatch.com/news/PETS/petmed-express-inc-announces-preliminary-fourth-quarter-and-fy-2025-results-and-filing-of--pets-20250616monthly0.5https://www.biopharmawatch.com/news/PETS/petmed-express-inc-announces-appointment-of-peter-batushansky-to-board-of-directors-former-pets-20250409monthly0.5https://www.biopharmawatch.com/news/PETS/page-8-of-8-pets-20250210monthly0.5https://www.biopharmawatch.com/news/PETS/petmeds-adopts-limited-duration-shareholder-rights-plan-delray-beach-florida-pets-20241203monthly0.5https://www.biopharmawatch.com/news/PETS/page-8-of-8-pets-20241106monthly0.5https://www.biopharmawatch.com/news/PETS/petmed-express-inc-announces-appointment-of-robyn-d-elia-as-chief-financial-officer-d-elia-pets-20240912monthly0.5https://www.biopharmawatch.com/news/PETS/page-7-of-7-pets-20240806monthly0.5https://www.biopharmawatch.com/news/PETS/petmed-express-inc-announces-appointment-of-doug-krulik-as-chief-accounting-officer-krulik-pets-20240805monthly0.5https://www.biopharmawatch.com/news/PETS/petmed-express-inc-announces-appointment-of-leah-solivan-to-board-of-directors-visionary-f-pets-20240624monthly0.5https://www.biopharmawatch.com/news/PETS/petmeds-announces-its-fourth-quarter-and-fiscal-year-end-financial-results-delray-beach-fl-pets-20240611monthly0.5https://www.biopharmawatch.com/news/PETS/petmed-express-inc-announces-appointment-of-justin-mennen-to-board-of-directors-veteran-te-pets-20240520monthly0.5https://www.biopharmawatch.com/news/PETS/petmed-express-inc-names-sandra-campos-as-new-chief-executive-officer-and-president-sandra-pets-20240429monthly0.5https://www.biopharmawatch.com/news/PETS/page-8-of-7-pets-20240415monthly0.5https://www.biopharmawatch.com/news/PETS/page-2-of-1-pets-20240215monthly0.5https://www.biopharmawatch.com/news/PETS/page-3-of-3-pets-20240208monthly0.5https://www.biopharmawatch.com/news/PETS/page-7-of-7-pets-20231030monthly0.5https://www.biopharmawatch.com/news/PETS/page-7-of-7-pets-20230731monthly0.5https://www.biopharmawatch.com/news/PETS/petmed-express-inc-quarter-and-year-ended-march-31-2023-conference-call-transcript-may-22--pets-20230526monthly0.5https://www.biopharmawatch.com/news/PETS/petmeds-announces-its-fourth-quarter-and-fiscal-year-end-financial-results-and-declares-a--pets-20230522monthly0.5https://www.biopharmawatch.com/news/PETS/petmeds-appoints-sandra-y-campos-to-its-board-of-directors-ms-campos-joins-as-an-independe-pets-20230518monthly0.5https://www.biopharmawatch.com/news/PETS/document-pets-20230403monthly0.5https://www.biopharmawatch.com/news/PETS/page-7-of-7-pets-20230206monthly0.5https://www.biopharmawatch.com/news/PETS/petmeds-to-acquire-petcarerx-the-acquisition-is-expected-to-accelerate-revenue-growth-and--pets-20230117monthly0.5https://www.biopharmawatch.com/news/PETS/page-6-of-6-pets-20221107monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20170825monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20170823monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20170726monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20170717monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20170510monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20170502monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20170125monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20170118monthly0.5https://www.biopharmawatch.com/news/PETS/page-2-of-2-pets-20161026monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20161026monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20161018monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20160727monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20160719monthly0.5https://www.biopharmawatch.com/news/PETS/page-5-of-5-pets-20160511monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20160510monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20160504monthly0.5https://www.biopharmawatch.com/news/PETS/page-5-of-5-pets-20160127monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20160126monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20160120monthly0.5https://www.biopharmawatch.com/news/PETS/page-5-of-5-pets-20151021monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20151020monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20151013monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20150722monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20150720monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20150715monthly0.5https://www.biopharmawatch.com/news/PETS/page-5-of-5-pets-20150506monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20150506monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20150428monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20150122monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20150120monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20150116monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20150114monthly0.5https://www.biopharmawatch.com/news/PETS/page-6-of-6-pets-20141021monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20141020monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20141014monthly0.5https://www.biopharmawatch.com/news/PETS/page-5-of-5-pets-20140723monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20140721monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20140718monthly0.5https://www.biopharmawatch.com/news/PETS/page-7-of-7-pets-20140507monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20140505monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20140428monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20140131monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20140123monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20140115monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20131028monthly0.5https://www.biopharmawatch.com/news/PETS/page-6-of-6-pets-20131023monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20131021monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20131016monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20130726monthly0.5https://www.biopharmawatch.com/news/PETS/page-5-of-5-pets-20130724monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20130722monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20130718monthly0.5https://www.biopharmawatch.com/news/PETS/page-6-of-6-pets-20130508monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20130506monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20130506monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20130430monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20130128monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20130124monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20130115monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20121203monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20121031monthly0.5https://www.biopharmawatch.com/news/PETS/page-5-of-5-pets-20121024monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20121023monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20121015monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20120730monthly0.5https://www.biopharmawatch.com/news/PETS/page-7-of-7-pets-20120725monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20120724monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20120717monthly0.5https://www.biopharmawatch.com/news/PETS/page-6-of-6-pets-20120509monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20120508monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20120508monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20120430monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20120130monthly0.5https://www.biopharmawatch.com/news/PETS/page-7-of-7-pets-20120125monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20120124monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20120119monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20111031monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20111024monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20111019monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20110801monthly0.5https://www.biopharmawatch.com/news/PETS/page-7-of-7-pets-20110720monthly0.5https://www.biopharmawatch.com/news/PETS/page-5-of-5-pets-20110511monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20110509monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20110509monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20110504monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20110131monthly0.5https://www.biopharmawatch.com/news/PETS/page-6-of-6-pets-20110126monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20110125monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20110120monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20101101monthly0.5https://www.biopharmawatch.com/news/PETS/page-7-of-7-pets-20101020monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20101019monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20101018monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20100802monthly0.5https://www.biopharmawatch.com/news/PETS/page-9-of-9-pets-20100721monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20100720monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20100713monthly0.5https://www.biopharmawatch.com/news/PETS/page-8-of-8-pets-20100512monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20100510monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20100504monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20100201monthly0.5https://www.biopharmawatch.com/news/PETS/page-8-of-8-pets-20100121monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20100120monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20100112monthly0.5https://www.biopharmawatch.com/news/PETS/page-7-of-7-pets-20091021monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20091020monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20091013monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20090803monthly0.5https://www.biopharmawatch.com/news/PETS/page-7-of-7-pets-20090722monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20090721monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20090714monthly0.5https://www.biopharmawatch.com/news/PETS/page-7-of-7-pets-20090513monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20090512monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20090511monthly0.5https://www.biopharmawatch.com/news/PETS/page-5-of-5-pets-20090122monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20090120monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20090114monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20081103monthly0.5https://www.biopharmawatch.com/news/PETS/page-6-of-6-pets-20081022monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20081021monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20081021monthly0.5https://www.biopharmawatch.com/news/PETS/page-7-of-7-pets-20080723monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20080721monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20080716monthly0.5https://www.biopharmawatch.com/news/PETS/page-9-of-9-pets-20080515monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20080513monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20080513monthly0.5https://www.biopharmawatch.com/news/PETS/page-7-of-7-pets-20080125monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20080124monthly0.5https://www.biopharmawatch.com/news/PETS/page-5-of-5-pets-20071024monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20071022monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20071015monthly0.5https://www.biopharmawatch.com/news/PETS/page-5-of-5-pets-20070725monthly0.5https://www.biopharmawatch.com/news/PETS/page-4-of-4-pets-20070723monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-of-1-pets-20070718monthly0.5https://www.biopharmawatch.com/news/PETS/page-6-of-6-pets-20070516monthly0.5https://www.biopharmawatch.com/news/PETS/page-7-7-pets-20070124monthly0.5https://www.biopharmawatch.com/news/PETS/petmed-express-d-b-a-1-800-petmeds-announces-third-quarter-financial-results-net-sales-inc-pets-20070122monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-1-pets-20070116monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-1-pets-20070104monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-1-pets-20061108monthly0.5https://www.biopharmawatch.com/news/PETS/page-7-7-pets-20061025monthly0.5https://www.biopharmawatch.com/news/PETS/petmed-express-d-b-a-1-800-petmeds-announces-second-quarter-financial-results-net-income-i-pets-20061023monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-1-pets-20061018monthly0.5https://www.biopharmawatch.com/news/PETS/page-7-7-pets-20060727monthly0.5https://www.biopharmawatch.com/news/PETS/petmed-express-d-b-a-1-800-petmeds-announces-first-quarter-financial-results-net-income-in-pets-20060724monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-1-pets-20060719monthly0.5https://www.biopharmawatch.com/news/PETS/page-8-8-pets-20060517monthly0.5https://www.biopharmawatch.com/news/PETS/page-1-1-pets-20060509monthly0.5https://www.biopharmawatch.com/news/PETS/page-7-7-pets-20060126monthly0.5https://www.biopharmawatch.com/news/PETS/page-3-3-pets-20051028monthly0.5https://www.biopharmawatch.com/news/MIRA/mira-pharmaceuticals-submits-phase-2a-clinical-trial-protocol-to-fda-for-ketamir-2-in-chem-mira-20260617monthly0.5https://www.biopharmawatch.com/news/MIRA/mira-pharmaceuticals-secures-worldwide-exclusive-rights-to-mira-55-and-skny-1-agreement-es-mira-20260604monthly0.5https://www.biopharmawatch.com/news/MIRA/mira-pharmaceuticals-secures-worldwide-rights-for-ketamir-2-expanding-global-ip-portfolio--mira-20260527monthly0.5https://www.biopharmawatch.com/news/MIRA/mira-pharmaceuticals-announces-exclusive-licensing-agreement-for-oral-ketamine-analog-keta-mira-20231120monthly0.5https://www.biopharmawatch.com/news/MIRA/mira-pharmaceuticals-inc-announces-pricing-of-8-9-million-initial-public-offering-and-nasd-mira-20230802monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-reports-full-year-2025-financial-results-and-provides-corporate-highlights-mreo-20260319monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-provides-corporate-update-additional-data-analyses-from-orbit-and-cosmic-p-mreo-20251231monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-reports-second-quarter-2025-financial-results-and-provides-corporate-highl-mreo-20250812monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-reports-first-quarter-2025-financial-results-and-provides-corporate-highli-mreo-20250513monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-reports-full-year-2024-financial-results-and-provides-corporate-highlights-mreo-20250326monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-reports-third-quarter-2024-financial-results-and-provides-corporate-update-mreo-20241112monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-reports-second-quarter-2024-financial-results-and-provides-corporate-updat-mreo-20240813monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-announces-pricing-of-50-million-underwritten-registered-direct-offering-of-mreo-20240614monthly0.5https://www.biopharmawatch.com/news/MREO/ultragenyx-and-mereo-biopharma-announce-new-phase-2-data-from-phase-2-3-orbit-study-demons-mreo-20240611monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-reports-first-quarter-2024-financial-results-and-provides-corporate-update-mreo-20240515monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-reports-full-year-2023-financial-results-and-provides-corporate-update-pha-mreo-20240327monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-provides-update-on-pipeline-progress-and-corporate-developments-phase-3-po-mreo-20240108monthly0.5https://www.biopharmawatch.com/news/MREO/this-document-is-important-and-requires-your-immediate-attention-if-you-are-in-any-doubt-a-mreo-20231116monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-reports-on-recent-program-developments-and-provides-financial-update-londo-mreo-20231023monthly0.5https://www.biopharmawatch.com/news/MREO/ultragenyx-and-mereo-biopharma-announce-interim-phase-2-data-from-phase-2-3-orbit-study-de-mreo-20231014monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-group-plc-condensed-consolidated-statements-of-comprehensive-loss-unaudite-mreo-20230907monthly0.5https://www.biopharmawatch.com/news/MREO/ultragenyx-announces-first-patients-dosed-in-phase-3-program-evaluating-setrusumab-ux143-f-mreo-20230706monthly0.5https://www.biopharmawatch.com/news/MREO/ultragenyx-and-mereo-biopharma-announce-positive-data-from-the-ongoing-phase-2-3-orbit-stu-mreo-20230605monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-regains-compliance-with-nasdaq-minimum-bid-price-requirement-london-mreo-20230508monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-announces-listing-transfer-to-nasdaq-capital-market-london-mreo-20230505monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-reports-full-year-2022-financial-results-and-recent-highlights-london-mreo-20230328monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-provides-regulatory-updates-on-alvelestat-for-the-treatment-of-alpha-1-ant-mreo-20230321monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-group-plc-condensed-consolidated-statements-of-comprehensive-loss-income-u-mreo-20221102monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-received-notification-of-nasdaq-minimum-bid-price-deficiency-london-mreo-20221102monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-reaches-cooperation-agreement-with-rubric-capital-management-mereo-to-appo-mreo-20221028monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-files-shareholder-circular-for-upcoming-general-meeting-reiterates-quality-mreo-20221021monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-announces-updated-operating-plan-to-maximize-shareholder-value-targets-40--mreo-20221018monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-receives-fda-fast-track-designation-for-alvelestat-for-treatment-of-alpha--mreo-20221017monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-confirms-receipt-of-a-valid-notice-requiring-it-to-convene-a-general-meeti-mreo-20221003monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-offered-to-settle-proxy-contest-with-rubric-capital-management-by-putting--mreo-20220926monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-reports-clinical-update-and-interim-biomarker-analysis-presented-at-esmo-2-mreo-20220912monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-sends-letter-to-rubric-capital-management-letter-reiterates-mereo-s-update-mreo-20220831monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-sends-letter-to-rubric-capital-management-notifies-rubric-of-certain-defic-mreo-20220822monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-regains-compliance-with-nasdaq-minimum-bid-price-requirement-london-and-mo-mreo-20220705monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-to-present-data-update-for-the-phase-1b-2-study-activate-of-etigilimab-and-mreo-20220602monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-announces-the-presentation-of-updated-data-from-a-phase-1b-2-study-of-etig-mreo-20220526monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-announces-appointment-of-dr-abdul-mullick-to-board-of-directors-london-and-mreo-20220517monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-announces-positive-top-line-efficacy-and-safety-data-from-astraeus-phase-2-mreo-20220509monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-reports-full-year-2021-financial-results-and-recent-highlights-london-and--mreo-20220331monthly0.5https://www.biopharmawatch.com/news/MREO/disclaimer-this-presentation-has-been-prepared-by-mereo-biopharma-group-plc-the-company-so-mreo-20220314monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-announces-appointment-of-anne-hyland-to-board-of-directors-london-and-redw-mreo-20220301monthly0.5https://www.biopharmawatch.com/news/MREO/uab-and-mereo-announce-positive-top-line-results-from-costa-a-phase-1b-2-trial-of-alvelest-mreo-20211222monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-reports-interim-data-from-activate-phase-1b-2-open-label-study-of-etigilim-mreo-20211130monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-group-plc-condensed-consolidated-statement-of-comprehensive-income-unaudit-mreo-20211102monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-receives-u-s-orphan-drug-designation-for-alvelestat-in-the-treatment-of-al-mreo-20211026monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-and-ultragenyx-present-data-from-the-phase-2b-asteroid-study-of-ux143-setr-mreo-20211001monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-announces-appointment-of-pierre-jacquet-m-d-ph-d-to-board-of-directors-lon-mreo-20210920monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-announces-positive-desmosine-biomarker-data-from-an-interim-analysis-of-an-mreo-20210602monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-and-cancer-focus-fund-announce-partnership-for-phase-1b-2-study-of-etigili-mreo-20210430monthly0.5https://www.biopharmawatch.com/news/MREO/this-document-is-important-and-requires-your-immediate-attention-if-you-are-in-any-doubt-a-mreo-20210416monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-reports-full-year-2020-financial-results-and-recent-highlights-ultragenyx--mreo-20210331monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-group-plc-announces-closing-of-public-offering-of-american-depositary-shar-mreo-20210212monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-group-plc-announces-proposed-public-offering-of-american-depositary-shares-mreo-20210209monthly0.5https://www.biopharmawatch.com/news/MREO/this-document-is-important-and-requires-your-immediate-attention-if-you-are-in-any-doubt-a-mreo-20210114monthly0.5https://www.biopharmawatch.com/news/MREO/this-announcement-contains-inside-information-as-defined-under-the-market-abuse-regulation-mreo-20201217monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-provides-update-on-aim-delisting-and-continued-listing-of-its-adss-on-nasd-mreo-20201215monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-to-hold-virtual-r-d-day-on-tuesday-mreo-20201116monthly0.5https://www.biopharmawatch.com/news/MREO/this-announcement-contains-inside-information-as-defined-under-the-market-abuse-regulation-mreo-20201111monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-appoints-christine-fox-as-chief-financial-officer-and-heidi-petersen-as-se-mreo-20201020monthly0.5https://www.biopharmawatch.com/news/MREO/this-announcement-contains-inside-information-as-defined-under-the-market-abuse-regulation-mreo-20201019monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-group-plc-pdmr-notification-london-and-redwood-city-calif-mreo-20201012monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-group-plc-director-and-pdmr-dealings-london-and-redwood-city-calif-mreo-20201009monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-files-registration-statement-on-form-f-3-with-u-s-securities-and-exchange--mreo-20201006monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-announces-interim-financial-results-for-the-six-months-ended-mreo-20200929monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-group-plc-mereo-or-the-company-or-the-group-result-of-general-meeting-lond-mreo-20200928monthly0.5https://www.biopharmawatch.com/news/MREO/this-announcement-contains-inside-information-as-defined-under-the-market-abuse-regulation-mreo-20201001monthly0.5https://www.biopharmawatch.com/news/MREO/this-announcement-contains-inside-information-as-defined-under-the-market-abuse-regulation-mreo-20200924monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-group-plc-notice-of-general-meeting-london-and-redwood-city-calif-mreo-20200904monthly0.5https://www.biopharmawatch.com/news/MREO/this-announcement-contains-inside-information-as-defined-under-the-market-abuse-regulation-mreo-20200825monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-group-plc-mereo-or-the-company-or-the-group-result-of-annual-general-meeti-mreo-20200629monthly0.5https://www.biopharmawatch.com/news/MREO/publication-of-circular-and-notice-of-general-meeting-london-and-redwood-city-calif-mreo-20200609monthly0.5https://www.biopharmawatch.com/news/MREO/this-announcement-contains-inside-information-as-defined-under-the-market-abuse-regulation-mreo-20200604monthly0.5https://www.biopharmawatch.com/news/MREO/notice-of-annual-general-meeting-london-and-redwood-city-calif-mreo-20200527monthly0.5https://www.biopharmawatch.com/news/MREO/annual-general-meeting-london-and-redwood-city-calif-mreo-20200522monthly0.5https://www.biopharmawatch.com/news/MREO/this-announcement-contains-inside-information-as-defined-under-the-market-abuse-regulation-mreo-20200327monthly0.5https://www.biopharmawatch.com/news/MREO/this-announcement-contains-inside-information-as-defined-under-the-market-abuse-regulation-mreo-20200228monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-group-plc-mereo-or-the-company-notification-of-director-and-other-pdmr-dea-mreo-20200220monthly0.5https://www.biopharmawatch.com/news/MREO/this-announcement-contains-inside-information-as-defined-under-the-market-abuse-regulation-mreo-20200218monthly0.5https://www.biopharmawatch.com/news/MREO/unaudited-pro-forma-condensed-combined-financial-information-of-mereo-biopharma-group-plc--mreo-20200218monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-announces-update-on-distribution-related-to-contingent-value-rights-follow-mreo-20200212monthly0.5https://www.biopharmawatch.com/news/MREO/this-announcement-contains-inside-information-as-defined-under-the-market-abuse-regulation-mreo-20200210monthly0.5https://www.biopharmawatch.com/news/MREO/this-announcement-contains-inside-information-as-defined-under-the-market-abuse-regulation-mreo-20200114monthly0.5https://www.biopharmawatch.com/news/MREO/this-announcement-contains-inside-information-as-defined-under-the-market-abuse-regulation-mreo-20191111monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-receives-fda-fast-track-designation-for-navicixizumab-for-the-treatment-of-mreo-20191007monthly0.5https://www.biopharmawatch.com/news/MREO/mereo-biopharma-announces-interim-financial-results-for-the-six-months-ended-mreo-20190917monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-board-to-evaluate-potential-one-time-special-cash-dividend-to-shareholders-tvgn-20260130monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-finalizes-agreement-for-company-s-own-cell-therapy-production-facility-the-agr-tvgn-20250417monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-enters-agreement-to-receive-up-to-10-million-of-non-dilutive-grant-funding-the-tvgn-20250128monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-ceo-highlights-expected-reporting-of-a-94-9-million-liability-elimination-ai-i-tvgn-20240426monthly0.5https://www.biopharmawatch.com/news/TVGN/semper-paratus-acquisition-corporation-s-shareholders-approve-business-combination-with-te-tvgn-20240201monthly0.5https://www.biopharmawatch.com/news/TVGN/semper-paratus-acquisition-corporation-announces-anticipated-listing-of-tevogen-bio-holdin-tvgn-20240124monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-inc-and-semper-paratus-acquisition-corporation-announce-effectiveness-of-regis-tvgn-20240105monthly0.5https://www.biopharmawatch.com/news/TVGN/semper-paratus-acquisition-corporation-regains-compliance-with-certain-nasdaq-listing-requ-tvgn-20230929monthly0.5https://www.biopharmawatch.com/news/TVGN/semper-paratus-acquisition-corporation-files-registration-statement-on-form-s-4-in-connect-tvgn-20230914monthly0.5https://www.biopharmawatch.com/news/TVGN/tevogen-bio-to-become-publicly-listed-on-nyse-via-business-combination-with-semper-paratus-tvgn-20230629monthly0.5https://www.biopharmawatch.com/news/TVGN/semper-paratus-acquisition-corporation-announces-the-separate-trading-of-its-class-a-ordin-tvgn-20211230monthly0.5https://www.biopharmawatch.com/news/TVGN/report-of-independent-registered-public-accounting-firm-to-the-shareholders-and-board-of-d-tvgn-20211108monthly0.5https://www.biopharmawatch.com/news/TVGN/semper-paratus-acquisition-corporation-announces-pricing-of-300-million-initial-public-off-tvgn-20211103monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-q1-2026-results-conference-call-with-q-a-today-at-4-30-pm-et-22-30-mdxh-20260513monthly0.5https://www.biopharmawatch.com/news/MDXH/unofficial-english-translation-for-informational-purposes-only-mdxhealth-sa-limited-liabil-mdxh-20260430monthly0.5https://www.biopharmawatch.com/news/MDXH/exosome-diagnostics-inc-financial-statements-mdxh-20260211monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-preliminary-fourth-quarter-and-full-year-2025-revenues-issues-2026-reven-mdxh-20260112monthly0.5https://www.biopharmawatch.com/news/MDXH/interim-report-table-of-contents-i-interim-management-report-2-ii-interim-condensed-unaudi-mdxh-20250814monthly0.5https://www.biopharmawatch.com/news/MDXH/unofficial-english-translation-for-informational-purposes-only-mdxhealth-sa-limited-liabil-mdxh-20250606monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-sa-and-subsidiaries-unaudited-condensed-consolidated-statement-of-profit-or-loss-mdxh-20250514monthly0.5https://www.biopharmawatch.com/news/MDXH/report-of-the-board-of-directors-this-report-of-the-board-of-directors-has-been-prepared-i-mdxh-20250506monthly0.5https://www.biopharmawatch.com/news/MDXH/unofficial-english-translation-for-informational-purposes-only-mdxhealth-sa-limited-liabil-mdxh-20250502monthly0.5https://www.biopharmawatch.com/news/MDXH/condensed-unaudited-consolidated-statement-of-profit-or-loss-three-months-ended-september--mdxh-20241106monthly0.5https://www.biopharmawatch.com/news/MDXH/securities-purchase-agreement-this-securities-purchase-agreement-this-agreement-is-dated-a-mdxh-20240925monthly0.5https://www.biopharmawatch.com/news/MDXH/interim-report-table-of-contents-i-interim-management-report-1-ii-interim-condensed-unaudi-mdxh-20240821monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-appoints-sanford-j-siegel-m-d-to-board-of-directors-irvine-ca-and-herstal-belgiu-mdxh-20240708monthly0.5https://www.biopharmawatch.com/news/MDXH/unofficial-english-translation-for-informational-purposes-only-mdxhealth-sa-limited-liabil-mdxh-20240605monthly0.5https://www.biopharmawatch.com/news/MDXH/neither-this-security-nor-the-securities-for-which-this-security-is-exercisable-have-been--mdxh-20240516monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-q1-2024-results-and-announces-growth-capital-from-orbimed-year-over-year-mdxh-20240501monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-sa-and-subsidiaries-unaudited-condensed-consolidated-statement-of-profit-or-loss-mdxh-20240501monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-adds-hereditary-prostate-cancer-genetic-test-to-prostate-cancer-offering-irvine--mdxh-20240312monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-fourth-quarter-and-full-year-2023-financial-results-2023-revenue-grew--mdxh-20240306monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-announces-resignation-of-board-member-irvine-ca-and-herstal-belgium-mdxh-20240216monthly0.5https://www.biopharmawatch.com/news/MDXH/mdxhealth-reports-preliminary-fourth-quarter-and-full-year-2023-revenues-and-issues-2024-r-mdxh-20240108monthly0.5https://www.biopharmawatch.com/news/MDXH/regulated-information-december-18-2023-1-00-am-et-07-00-am-cet-mdxhealth-announces-complet-mdxh-20231218monthly0.5https://www.biopharmawatch.com/news/MDXH/regulated-information-november-27-2023-1-00-am-et-7-00-am-cet-mdxhealth-announces-completi-mdxh-20231127monthly0.5https://www.biopharmawatch.com/news/MDXH/regulated-information-inside-information-november-13-2023-4-00-pm-et-22-00-cet-mdxhealth-a-mdxh-20231113monthly0.5https://www.biopharmawatch.com/news/MDXH/regulated-information-8-november-2023-4-00pm-edt-22-00-cet-mdxhealth-reports-results-for-t-mdxh-20231108monthly0.5https://www.biopharmawatch.com/news/MDXH/regulated-information-inside-information-november-6-2023-1-00-am-et-7-00-cet-mdxhealth-ann-mdxh-20231106monthly0.5https://www.biopharmawatch.com/news/MDXH/news-release-mdxh-20231020monthly0.5https://www.biopharmawatch.com/news/MDXH/inside-and-regulated-information-9-october-2023-4pm-et-22-00-cet-mdxhealth-reports-prelimi-mdxh-20231009monthly0.5https://www.biopharmawatch.com/news/MDXH/free-english-translation-for-information-purposes-only-mdxhealth-sa-limited-liability-comp-mdxh-20231003monthly0.5https://www.biopharmawatch.com/news/MDXH/interim-report-table-of-contents-i-interim-management-report-2-ii-interim-condensed-unaudi-mdxh-20230823monthly0.5https://www.biopharmawatch.com/news/MDXH/august-2023-4pm-et-22-00-cet-cigna-expands-commercial-and-medicare-advantage-coverage-to-i-mdxh-20230809monthly0.5https://www.biopharmawatch.com/news/MDXH/regulated-information-30-june-2023-10-00-p-m-cest-mdxhealth-announces-results-of-its-extra-mdxh-20230703monthly0.5https://www.biopharmawatch.com/news/MDXH/unofficial-english-translation-for-informational-purposes-only-mdxhealth-sa-limited-liabil-mdxh-20230606monthly0.5https://www.biopharmawatch.com/news/MDXH/regulated-information-25-may-2023-22-30-cet-mdxhealth-announces-results-of-its-annual-and--mdxh-20230526monthly0.5https://www.biopharmawatch.com/news/MDXH/regulated-information-15-may-2023-4-00pm-edt-22-00-cet-mdxhealth-reports-q1-2023-results-y-mdxh-20230515monthly0.5https://www.biopharmawatch.com/news/MDXH/regulated-information-april-25-2023-4-00-pm-et-22-00-cet-mdxhealth-announces-its-ordinary--mdxh-20230425monthly0.5https://www.biopharmawatch.com/news/MDXH/news-release-mdxh-20230419monthly0.5https://www.biopharmawatch.com/news/MDXH/regulated-information-april-7-2023-4-30-pm-et-22-30-cet-mdxhealth-shareholder-transparency-mdxh-20230407monthly0.5https://www.biopharmawatch.com/news/MDXH/regulated-information-march-2-2023-4-30-pm-et-22-30-cet-mdxhealth-shareholder-transparency-mdxh-20230309monthly0.5https://www.biopharmawatch.com/news/MDXH/regulated-information-february-21-2023-4-30-pm-et-22-30-cet-mdxhealth-shareholder-transpar-mdxh-20230223monthly0.5https://www.biopharmawatch.com/news/MDXH/february-2023-4-00pm-et-22-00-cet-mdxhealth-announces-unitedhealthcare-to-provide-commerci-mdxh-20230213monthly0.5https://www.biopharmawatch.com/news/MDXH/regulated-information-inside-information-february-1-2023-4pm-et-22-00-cet-mdxhealth-announ-mdxh-20230201monthly0.5https://www.biopharmawatch.com/news/MDXH/to-form-6-k-with-the-securities-and-exchange-commission-updated-unaudited-pro-forma-combin-mdxh-20230120monthly0.5https://www.biopharmawatch.com/news/MDXH/inside-and-regulated-information-9-january-2023-4pm-et-22-00-cet-mdxhealth-reports-prelimi-mdxh-20230109monthly0.5https://www.biopharmawatch.com/news/MDXH/report-of-independent-auditors-to-the-management-of-exact-sciences-corporation-opinion-we--mdxh-20221219monthly0.5https://www.biopharmawatch.com/news/MDXH/inside-and-regulated-information-29-november-2022-4-00pm-edt-22-00-cet-mdxhealth-provides--mdxh-20221129monthly0.5https://www.biopharmawatch.com/news/MDXH/regulated-information-27-october-2022-4-00pm-edt-22-00-cet-mdxhealth-reports-q3-2022-resul-mdxh-20221027monthly0.5https://www.biopharmawatch.com/news/MDXH/interim-report-table-of-contents-i-interim-management-report-2-ii-interim-condensed-unaudi-mdxh-20220826monthly0.5https://www.biopharmawatch.com/news/MDXH/regulated-information-25-august-2022-4-00pm-edt-22-00-cet-mdxhealth-reports-half-year-2022-mdxh-20220825monthly0.5https://www.biopharmawatch.com/news/MDXH/news-release-mdxh-20220819monthly0.5https://www.biopharmawatch.com/news/MDXH/news-release-mdxh-20220802monthly0.5https://www.biopharmawatch.com/news/MDXH/regulated-information-25-may-2022-4-00-p-m-edt-22-00-cet-mdxhealth-announces-results-of-it-mdxh-20220527monthly0.5https://www.biopharmawatch.com/news/MDXH/news-release-mdxh-20220519monthly0.5https://www.biopharmawatch.com/news/MDXH/unofficial-english-translation-for-informational-purposes-only-mdxhealth-sa-limited-liabil-mdxh-20220428monthly0.5https://www.biopharmawatch.com/news/MDXH/regulated-information-27-april-2022-4-00pm-edt-22-00-cet-mdxhealth-reports-q1-2022-results-mdxh-20220427monthly0.5https://www.biopharmawatch.com/news/MDXH/regulated-information-2-march-2022-4-00-pm-est-22-00-cet-mdxhealth-reports-financial-year--mdxh-20220302monthly0.5https://www.biopharmawatch.com/news/MDXH/regulated-information-10-december-2021-23-55-cet-mdxhealth-shareholder-transparency-declar-mdxh-20211213monthly0.5https://www.biopharmawatch.com/news/MDXH/regulated-information-22-november-2021-11-00-p-m-cet-mdxhealth-shareholder-transparency-de-mdxh-20211123monthly0.5https://www.biopharmawatch.com/news/MDXH/regulated-information-15-november-2021-11-00-p-m-cet-mdxhealth-shareholder-transparency-de-mdxh-20211115monthly0.5https://www.biopharmawatch.com/news/MDXH/regulated-information-november-8-2021-22-30-cet-mdxhealth-announces-completion-of-initial--mdxh-20211108monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-reports-record-first-quarter-2026-increasing-revenue-by-136-quarter-over-quarter--rnxt-20260514monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-reports-full-year-2025-financial-results-and-provides-business-update-renovocath--rnxt-20260330monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-announces-10-million-at-market-private-placement-bolstered-cash-position-expected-rnxt-20260318monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-reports-commercial-revenue-growth-in-the-second-quarter-2025-and-announces-positi-rnxt-20250814monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-reports-first-quarter-2025-financial-results-and-business-highlights-q1-2025-reno-rnxt-20250515monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-reports-initial-revenues-from-renovocath-commercialization-and-provides-update-on-rnxt-20250401monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-announces-proposed-public-offering-rnxt-20250206monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-reports-third-quarter-2024-financial-results-and-operational-highlights-near-term-rnxt-20241114monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-increases-production-of-fda-cleared-renovocath-delivery-system-in-response-to-str-rnxt-20240925monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-regains-compliance-with-nasdaq-stockholders-equity-requirement-rnxt-20240418monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-closes-11-1-million-private-placement-providing-cash-runway-into-2026-with-17-2-m-rnxt-20240415monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-announces-11-1-million-at-market-private-placement-cash-position-now-expected-to--rnxt-20240408monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-closes-6-1-million-private-placement-with-material-participation-from-insiders-of-rnxt-20240129monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-reports-third-quarter-2023-financial-results-and-operational-highlights-collabora-rnxt-20231114monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-reports-second-quarter-2023-financial-results-and-operational-highlights-presente-rnxt-20230817monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-reports-first-quarter-2023-financial-results-and-operational-highlights-announced-rnxt-20230515monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-appoints-former-chief-medical-officer-of-schering-plough-robert-j-spiegel-md-facp-rnxt-20230427monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-inc-announces-5-million-registered-direct-offering-priced-at-the-market-under-nas-rnxt-20230330monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-reports-full-year-2022-financial-results-and-achievement-of-important-phase-iii-c-rnxt-20230302monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-announces-initial-results-in-pharmacokinetic-pk-substudy-data-on-renovogem-tm-sup-rnxt-20230118monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-reports-third-quarter-2022-financial-results-los-altos-ca-rnxt-20221114monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-appoints-angela-gill-nelms-as-chief-operating-officer-los-altos-ca-rnxt-20220919monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-reports-second-quarter-2022-financial-results-los-altos-ca-rnxt-20220815monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-appoints-james-ahlers-as-chief-financial-officer-expands-finance-team-with-additi-rnxt-20220719monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-reports-first-quarter-2022-financial-results-los-altos-ca-rnxt-20220516monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-reports-full-year-2021-financial-results-los-altos-ca-rnxt-20220330monthly0.5https://www.biopharmawatch.com/news/RNXT/renovorx-announces-third-quarter-2021-financial-results-los-altos-ca-rnxt-20211115monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-receives-fda-x201c-study-may-proceed-x201d-letter-for-z-endoxifen-inve-atos-20260106monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-regulatory-strategy-aimed-at-accelerating-development-of-low-atos-20250908monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-second-quarter-2025-financial-results-and-provides-a-corpora-atos-20250812monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-first-quarter-2025-financial-results-and-provides-a-corporat-atos-20250513monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-to-present-pharmacokinetic-and-tolerability-data-from-phase-2-evangeli-atos-20241210monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-third-quarter-2024-financial-results-and-provides-corporate--atos-20241112monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-reports-positive-karisma-endoxifen-trial-results-z-endoxifen-shown-to--atos-20241104monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-second-quarter-2024-financial-results-and-provides-corporate-atos-20240812monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-first-quarter-2024-financial-results-and-provides-corporate--atos-20240513monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-announces-year-end-2023-financial-results-and-provides-corporate-updat-atos-20240401monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-appoints-breast-cancer-specialist-tessa-cigler-m-d-m-p-h-to-its-board--atos-20240312monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-preliminary-results-from-male-phase-1-study-of-topical-endoxifen-atos-20180913monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-second-quarter-2018-financial-results-and-provides-company-updat-atos-20180813monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-first-quarter-2018-financial-results-and-provides-company-update-atos-20180514monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-2017-financial-results-and-provides-company-update-seattle-atos-20180308monthly0.5https://www.biopharmawatch.com/news/ATOS/nasdaq-atos-www-atossagenetics-com-2018-a-tossa-g-enetics-i-nc-a-ll-r-ights-r-eserved-c-or-atos-20180221monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-presents-additional-findings-from-its-phase-1-study-of-oral-endoxifen-conf-atos-20180201monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-third-quarter-2017-financial-results-and-provides-company-update-atos-20171114monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-pricing-of-5-1-million-public-offering-of-common-stock-seattle-atos-20171026monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-preliminary-results-from-phase-1-study-of-oral-endoxifen-all-obj-atos-20171025monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-preliminary-results-from-phase-1-study-of-topical-endoxifen-all--atos-20170914monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-second-quarter-2017-financial-results-and-provides-company-updat-atos-20170814monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-first-quarter-atos-20170511monthly0.5https://www.biopharmawatch.com/news/ATOS/ot3-02-08-open-label-phase-2-safety-efficacy-and-pharmacokinetic-study-of-pre-surgical-int-atos-20161212monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-third-quarter-2016-financial-results-and-provides-company-update-atos-20161114monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-inc-prices-underwritten-public-offering-of-1-150-000-common-shares-seattle-atos-20160902monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-second-quarter-2016-financial-results-and-provides-company-updat-atos-20160815monthly0.5https://www.biopharmawatch.com/news/ATOS/nasdaq-atos-www-atossagenetics-com-2016-a-tossa-g-enetics-i-nc-a-ll-r-ights-r-eserved-c-or-atos-20160727monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-10-million-at-the-market-common-stock-purchase-agreement-with-as-atos-20160527monthly0.5https://www.biopharmawatch.com/news/ATOS/ex-10-1-2-v440599-ex99-1-htm-exhibit-10-1-exhibit-10-1-amended-and-restated-employment-agr-atos-20160518monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-first-quarter-2016-financial-results-and-provides-company-update-atos-20160505monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-2015-financial-results-and-provides-company-update-conference-ca-atos-20160330monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-third-quarter-2015-financial-results-and-provides-company-update-atos-20151112monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-inc-announces-appointment-of-scott-youmans-as-chief-operating-officer-seat-atos-20150902monthly0.5https://www.biopharmawatch.com/news/ATOS/announces-second-quarter-2015-financial-results-atos-20150806monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-inc-to-raise-approximately-6-220-000-from-institutional-healthcare-investo-atos-20150605monthly0.5https://www.biopharmawatch.com/news/ATOS/common-stock-purchase-agreement-atos-20150528monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-first-quarter-2015-financial-results-and-provides-company-update-atos-20150513monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-2014-financial-results-and-provides-company-update-conference-ca-atos-20150330monthly0.5https://www.biopharmawatch.com/news/ATOS/1-the-breast-care-company-nasdaq-atos-www-atos-20150115monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-third-quarter-2014-financial-results-and-provides-company-update-atos-20141112monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-inc-provides-regulatory-and-commercial-update-on-its-forecyte-breast-aspir-atos-20140924monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-second-quarter-2014-financial-results-and-provides-company-updat-atos-20140812monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-adopts-stockholder-rights-agreement-seattle-atos-20140522monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-first-quarter-2014-financial-results-and-provides-company-update-atos-20140514monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-2013-financial-results-and-provides-company-update-conference-ca-atos-20140327monthly0.5https://www.biopharmawatch.com/news/ATOS/license-and-services-agreement-this-license-and-services-agreement-agreement-is-made-and-e-atos-20131216monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-reports-third-quarter-2013-results-and-provides-company-update-announces-s-atos-20131112monthly0.5https://www.biopharmawatch.com/news/ATOS/medical-device-voluntary-recall-news-release-forecyte-breast-health-test-mammary-aspiratio-atos-20131004monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-reports-second-quarter-2013-results-and-operating-highlights-second-quarte-atos-20130814monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-national-agreement-with-network-provider-fedmed-more-than-40-mil-atos-20130313monthly0.5https://www.biopharmawatch.com/news/ATOS/atossa-genetics-announces-third-quarter-2012-financial-results-prepares-for-national-roll--atos-20121220monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-reports-first-quarter-2026-financial-results-and-provides-business-updates--ltrn-20260515monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-inc-announces-up-to-9-25-million-registered-direct-offering-with-existing-h-ltrn-20260514monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-bu-ltrn-20260330monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-reports-third-quarter-2025-financial-results-and-provides-business-updates--ltrn-20251113monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-reports-second-quarter-2025-financial-results-and-business-updates-major-mi-ltrn-20250813monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-reports-first-quarter-2025-financial-results-and-business-updates-completio-ltrn-20250515monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-provides-business-updates-and-fourth-quarter-year-end-2024-financial-result-ltrn-20250327monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-reports-third-quarter-2024-financial-results-and-business-updates-lantern-i-ltrn-20241107monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-reports-second-quarter-2024-financial-results-and-business-updates-active-c-ltrn-20240808monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-reports-first-quarter-2024-financial-results-and-business-highlights-active-ltrn-20240509monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-reports-fourth-quarter-fiscal-year-2023-financial-results-and-business-high-ltrn-20240318monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-reports-third-quarter-2023-financial-results-and-operational-highlights-rec-ltrn-20231108monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-reports-second-quarter-2023-financial-results-and-operational-highlights-ob-ltrn-20230809monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-reports-first-quarter-2023-financial-results-and-operational-highlights-dos-ltrn-20230509monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-reports-fourth-quarter-and-fiscal-year-2022-financial-results-and-operation-ltrn-20230320monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-reports-third-quarter-2022-financial-results-and-operational-highlights-the-ltrn-20221107monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-reports-second-quarter-2022-financial-results-and-operational-highlights-la-ltrn-20220808monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-reports-first-quarter-2022-financial-results-and-operational-highlights-rad-ltrn-20220503monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-s-board-of-directors-names-maria-maccecchini-ph-d-as-a-director-nominee-to--ltrn-20220426monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-announces-extension-of-existing-share-repurchase-program-dallas-ltrn-20220322monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-reports-fourth-quarter-and-fiscal-year-2021-financial-results-and-operation-ltrn-20220310monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-receives-rare-pediatric-disease-and-orphan-drug-designations-for-lp-184-for-ltrn-20220124monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-announces-share-repurchase-program-dallas-ltrn-20211122monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-reports-third-quarter-2021-financial-results-and-operating-highlights-radr--ltrn-20211101monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-reports-second-quarter-2021-financial-results-and-operational-highlights-ob-ltrn-20210729monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-reports-first-quarter-2021-financial-results-and-operational-highlights-rad-ltrn-20210503monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-reports-fourth-quarter-and-year-end-2020-financial-results-and-operational--ltrn-20210310monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-reports-third-quarter-2020-financial-results-continued-operational-progress-ltrn-20201029monthly0.5https://www.biopharmawatch.com/news/LTRN/amended-and-restated-lantern-pharma-inc-2018-equity-incentive-plan-i-general-provisions-1--ltrn-20200821monthly0.5https://www.biopharmawatch.com/news/LTRN/lantern-pharma-reports-second-quarter-2020-financial-results-and-continued-corporate-progr-ltrn-20200730monthly0.5https://www.biopharmawatch.com/news/LTRN/monday-ltrn-20200615monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-reports-second-quarter-2025-financial-results-malvern-pa-tela-20250811monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-appoints-jeffrey-blizard-as-president-company-further-strengthens-executive-leade-tela-20250602monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-reports-first-quarter-2025-financial-results-malvern-pa-tela-20250508monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-u-s-commercial-launch-of-larger-sizes-of-ovitex-prs-for-plastic-and-rec-tela-20250331monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-reports-fourth-quarter-and-full-year-tela-20250320monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-reports-third-quarter-2024-financial-results-reiterates-2024-revenue-guidance-and-tela-20241107monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-reports-second-quarter-2024-financial-results-and-reiterates-full-year-2024-reven-tela-20240812monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-appoints-jeffrey-blizard-to-its-board-of-directors-malvern-pa-tela-20240604monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-appoints-greg-firestone-as-chief-commercial-officer-malvern-pa-tela-20240520monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-reports-first-quarter-2024-financial-results-malvern-pa-tela-20240509monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-u-s-commercial-launch-of-robotic-compatible-ovitex-ihr-addressing-the-n-tela-20240415monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-achieves-record-fourth-quarter-and-full-year-2023-revenues-and-reports-complete-f-tela-20240321monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-sale-of-distribution-rights-for-wound-care-product-to-mimedx-tela-bio-t-tela-20240320monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-reports-third-quarter-2023-financial-results-malvern-pa-tela-20231109monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-u-s-commercial-launch-of-ovitex-prs-long-term-resorbable-for-plastic-an-tela-20230816monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-reports-second-quarter-2023-financial-results-malvern-pa-tela-20230809monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-reports-first-quarter-2023-financial-results-malvern-pa-tela-20230511monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-510-k-clearance-for-ovitex-prs-long-term-resorbable-for-plastic-and-rec-tela-20230323monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-reports-fourth-quarter-and-full-year-2022-financial-results-malvern-pa-tela-20230321monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-u-s-commercial-launch-of-two-new-ovitex-lpr-device-configurations-to-re-tela-20230221monthly0.5https://www.biopharmawatch.com/news/TELA/investor-presentation-january-2023-forward-looking-statements-this-presentation-contains-f-tela-20230110monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-u-s-commercial-launch-of-nivis-tm-fibrillar-collagen-pack-the-natural-r-tela-20230109monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-reports-third-quarter-2022-financial-results-malvern-pa-tela-20221109monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-publication-of-24-month-bravo-study-results-demonstrating-benefits-of-o-tela-20221026monthly0.5https://www.biopharmawatch.com/news/TELA/investor-presentation-august-2022-forward-looking-statements-this-presentation-contains-fo-tela-20220815monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-reports-second-quarter-2022-financial-results-malvern-pa-tela-20220810monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-reports-first-quarter-2022-financial-results-malvern-pa-tela-20220510monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-reports-fourth-quarter-and-full-year-2021-financial-results-malvern-pa-tela-20220321monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-u-s-commercial-launch-of-siteguard-tm-no-rinse-antimicrobial-solution-c-tela-20220303monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-reports-strong-third-quarter-2021-revenues-reflecting-continued-growth-driven-by--tela-20211110monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-publication-of-12-month-results-from-the-bravo-study-with-continued-pos-tela-20211109monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-and-next-science-enter-into-exclusive-distribution-agreement-in-the-plastic-recon-tela-20211101monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-reports-record-second-quarter-2021-revenues-driven-by-increased-demand-malvern-pa-tela-20210811monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-initiates-bravo-ii-study-of-ovitex-for-the-robotic-repair-of-ventral-hernias-malv-tela-20210519monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-first-quarter-2021-financial-results-malvern-pa-tela-20210513monthly0.5https://www.biopharmawatch.com/news/TELA/advancing-soft-tissue-reconstruction-investor-presentation-january-2021-2-forward-looking--tela-20210329monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-fourth-quarter-and-full-year-2020-financial-results-malvern-pa-tela-20210324monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-reports-preliminary-results-for-fourth-quarter-and-full-year-2020-malvern-pa-tela-20210114monthly0.5https://www.biopharmawatch.com/news/TELA/advancing-soft-tissue-reconstruction-investor-presentation-november-2020-2-forward-looking-tela-20201117monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-third-quarter-2020-financial-results-malvern-pa-tela-20201111monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-presents-additional-data-from-bravo-study-of-ovitex-for-ventral-hernia-repair-mal-tela-20200925monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-second-quarter-2020-financial-results-malvern-pa-tela-20200812monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-interim-analysis-from-bravo-study-of-ovitex-for-ventral-hernia-repair-m-tela-20200709monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-pricing-of-public-offering-of-common-stock-tela-20200625monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-inc-announces-poster-presentations-at-the-2020-minimally-invasive-surgery-symposi-tela-20200615monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-advancing-soft-tissue-reconstruction-may-2020-2-forward-looking-statements-this-p-tela-20200522monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-first-quarter-2020-financial-results-malvern-pa-tela-20200512monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-changes-to-its-board-of-directors-malvern-pa-tela-20200423monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-advancing-soft-tissue-reconstruction-april-2020-2-forward-looking-statements-this-tela-20200401monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-fourth-quarter-and-full-year-2019-financial-results-malvern-pa-tela-20200327monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-appointment-of-new-chief-commercial-officer-malvern-pa-tela-20200129monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-preliminary-revenue-for-fourth-quarter-and-full-year-2019-preliminary-f-tela-20200110monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-announces-third-quarter-2019-financial-results-revenue-increased-80-year-over-yea-tela-20191218monthly0.5https://www.biopharmawatch.com/news/TELA/tela-bio-awarded-contract-with-healthtrust-purchasing-group-malvern-pa-tela-20191206monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-receives-a-6-0-million-r-d-tax-incentive-refund-for-fy25-further-strengthening-ba-ixhl-20260610monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-announces-initiation-of-research-coverage-by-alliance-global-partners-melbourne-a-ixhl-20260609monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-healthcare-officially-commences-dreamzz-clinical-study-for-ihl-42x-in-obstructive-ixhl-20260514monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-healthcare-wins-medtech-breakthrough-award-for-ihl-42x-underscoring-leadership-in-ixhl-20260512monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-healthcare-psx-001-program-aligns-with-white-house-executive-order-accelerating-a-ixhl-20260422monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-reactivates-share-repurchase-program-underscoring-confidence-in-valuation-and-str-ixhl-20260327monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-healthcare-announces-partnership-with-the-aasm-foundation-in-support-of-sleep-apn-ixhl-20260325monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-highlights-strong-balance-sheet-with-approximately-75-million-in-cash-and-no-debt-ixhl-20260318monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-regains-compliance-with-nasdaq-minimum-bid-price-requirement-melbourne-and-new-yo-ixhl-20260317monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-healthcare-inc-announces-pricing-of-10-million-registered-direct-offering-priced--ixhl-20260312monthly0.5https://www.biopharmawatch.com/news/IXHL/innovating-new-pathways-to-relief-nasdaq-ixhl-investor-presentation-february-2026-2-corpor-ixhl-20260312monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-announces-reverse-stock-split-incannex-s-common-stock-is-expected-to-begin-tradin-ixhl-20260227monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-healthcare-announces-additional-appointments-to-clinical-advisory-board-expands-c-ixhl-20260129monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-healthcare-announces-formation-of-clinical-advisory-board-for-psx-001-program-str-ixhl-20260122monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-healthcare-wins-research-and-development-award-for-obstructive-sleep-apnea-progra-ixhl-20260115monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-healthcare-delivers-transformational-2025-progress-and-outlines-well-funded-outlo-ixhl-20260114monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-granted-fda-fast-track-designation-for-ihl-42x-in-obstructive-sleep-apnea-osa-mel-ixhl-20251203monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-provides-shareholder-update-highlighting-clinical-progress-capital-discipline-and-ixhl-20251030monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-minimum-bid-price-r-ixhl-20251022monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-reports-positive-results-from-phase-2-clinical-trial-of-psx-001-psi-gad-for-gener-ixhl-20250826monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-healthcare-authorizes-20-million-share-repurchase-program-melbourne-australia-and-ixhl-20250822monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-receives-positive-patient-reported-outcomes-and-compelling-phase-2-efficacy-data--ixhl-20250808monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-confirms-strong-cash-position-no-plans-or-requirement-to-fully-utilise-atm-in-nea-ixhl-20250731monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-reports-positive-topline-results-from-reposa-phase-2-trial-of-ihl-42x-statistical-ixhl-20250730monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-healthcare-expands-clinical-advisory-board-to-support-obstructive-sleep-apnea-pro-ixhl-20250725monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-healthcare-expands-clinical-advisory-board-to-support-obstructive-sleep-apnea-pro-ixhl-20250624monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-achieves-key-milestone-with-database-lock-for-reposa-phase-2-trial-of-ihl-42x-top-ixhl-20250618monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-healthcare-forms-joint-venture-with-mind-medicine-australia-to-expand-access-to-p-ixhl-20250617monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-healthcare-cancels-all-outstanding-series-a-warrants-following-strategic-atm-exec-ixhl-20250612monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-healthcare-inc-expands-ihl-42x-clinical-advisory-board-with-appointments-of-four--ixhl-20250603monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-healthcare-inc-advances-ihl-42x-reposa-trial-to-phase-3-following-fda-protocol-cl-ixhl-20250529monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-enters-agreement-to-cancel-remaining-series-a-warrants-eliminating-up-to-347-2-mi-ixhl-20250528monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-healthcare-inc-executes-strategic-cancellation-of-50-4-of-series-a-warrants-signi-ixhl-20250520monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-announces-potential-reduction-of-up-to-50-4-of-its-series-a-warrants-new-york-and-ixhl-20250516monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-healthcare-inc-reports-fiscal-third-quarter-2025-financial-results-and-business-u-ixhl-20250515monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-healthcare-inc-provides-clinical-program-update-on-ihl-42x-an-oral-once-daily-tre-ixhl-20250517monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-healthcare-completes-phase-2-enrollment-in-reposa-phase-2-3-trial-of-ihl-42x-an-o-ixhl-20250403monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-healthcare-inc-announces-pricing-of-12-5-million-private-placement-priced-at-the--ixhl-20250307monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-healthcare-inc-reports-fiscal-second-quarter-2025-financial-results-and-business--ixhl-20250214monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-healthcare-appoints-alison-wimms-ph-d-to-newly-formed-ihl-42x-obstructive-sleep-a-ixhl-20250204monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-healthcare-announces-positive-topline-results-from-pharmacokinetics-pk-study-of-i-ixhl-20250123monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-healthcare-inc-reports-fiscal-full-year-2024-financial-results-and-business-updat-ixhl-20240930monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-healthcare-announces-strategic-financing-for-up-to-60-million-with-arena-investor-ixhl-20240910monthly0.5https://www.biopharmawatch.com/news/IXHL/description-of-capital-stock-the-following-description-of-the-capital-stock-of-incannex-he-ixhl-20231129monthly0.5https://www.biopharmawatch.com/news/IXHL/market-announcement-17-november-2023-incannex-healthcare-limited-asx-ihl-suspension-from-q-ixhl-20231120monthly0.5https://www.biopharmawatch.com/news/IXHL/date-17-november-2023-public-announcement-nasdaq-ixhl-asx-ihl-computershare-will-be-appoin-ixhl-20231117monthly0.5https://www.biopharmawatch.com/news/IXHL/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-ixhl-20231107monthly0.5https://www.biopharmawatch.com/news/IXHL/date-26-october-2023-public-announcement-asx-ihl-nasdaq-ixhl-incannex-healthcare-september-ixhl-20231026monthly0.5https://www.biopharmawatch.com/news/IXHL/rules-4-7-3-and-4-10-3-appendix-4g-key-to-disclosures-corporate-governance-council-princip-ixhl-20230901monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-healthcare-limited-abn-93-096-635-246-appendix-4e-for-the-year-ended-30-june-2023-ixhl-20230901monthly0.5https://www.biopharmawatch.com/news/IXHL/date-28-july-2023-public-announcement-asx-ihl-nasdaq-ixhl-incannex-healthcare-june-2023-qu-ixhl-20230728monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-healthcare-limited-abn-93-093-635-246-level-39-rialto-south-tower-525-collins-str-ixhl-20230630monthly0.5https://www.biopharmawatch.com/news/IXHL/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-ixhl-20230607monthly0.5https://www.biopharmawatch.com/news/IXHL/p-s-y-c-h-en-n-e-x-p-t-y-l-td-c-o-m-p-a-n-y-u-p-d-a-t-e-market-update-may-2023-psychennex--ixhl-20230518monthly0.5https://www.biopharmawatch.com/news/IXHL/ihl-675a-p-h-a-s-e-1-c-li-n-i-c-a-l-t-r-i-a-l-t-o-a-s-s-e-s-s-s-a-f-e-t-y-an-d-p-h-a-r-m-a-ixhl-20230503monthly0.5https://www.biopharmawatch.com/news/IXHL/date-27-april-2023-public-announcement-asx-ihl-nasdaq-ixhl-incannex-healthcare-march-2023--ixhl-20230427monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-healthcare-limited-abn-93-096-635-246-and-controlled-entities-half-year-informati-ixhl-20230227monthly0.5https://www.biopharmawatch.com/news/IXHL/market-announcement-1-december-2022-incannex-healthcare-limited-asx-ihl-trading-halt-descr-ixhl-20221201monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-healthcare-limited-acn-096-635-246-addendum-to-notice-of-annual-general-meeting-f-ixhl-20221121monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-healthcare-limited-acn-096-635-246-notice-of-annual-general-meeting-for-the-annua-ixhl-20221021monthly0.5https://www.biopharmawatch.com/news/IXHL/annual-report-incannex-healthcare-limited-asx-ihl-nasdaq-ixhl-limitless-p-o-t-e-n-t-i-a-l--ixhl-20220920monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-healthcare-limited-abn-93-096-635-246-appendix-4e-preliminary-final-report-for-th-ixhl-20220901monthly0.5https://www.biopharmawatch.com/news/IXHL/company-overview-asx-ticker-ihl-nasdaq-ticker-ixhl-disclaimer-disclosure-and-disclaimer-th-ixhl-20220809monthly0.5https://www.biopharmawatch.com/news/IXHL/notice-of-extraordinary-general-meeting-and-explanatory-statement-incannex-healthcare-limi-ixhl-20220512monthly0.5https://www.biopharmawatch.com/news/IXHL/incannex-healthcare-limited-abn-93-096-635-246-and-controlled-entities-half-year-informati-ixhl-20220321monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-announces-revised-merger-agreement-with-tetraphase-under-revised-te-tlph-20200529monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-announces-revised-merger-agreement-with-tetraphase-under-revised-te-tlph-20200527monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-announces-dsuvia-milestone-c-approval-and-provides-business-update-milestone-c-deci-tlph-20200430monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-reports-second-quarter-2017-financial-results-and-provides-corporat-tlph-20170801monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-appoints-raffi-asadorian-as-chief-financial-officer-tlph-20170719monthly0.5https://www.biopharmawatch.com/news/TLPH/event-id-event-name-acrx-acelrx-1q17-financial-results-event-date-2017-05-08-officers-and--tlph-20170510monthly0.5https://www.biopharmawatch.com/news/TLPH/event-id-event-name-acrx-acelrx-4q16-and-fy16-financial-results-event-date-2017-03-02-offi-tlph-20170307monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-submits-new-drug-application-for-arx-04-for-the-treatment-of-modera-tlph-20161213monthly0.5https://www.biopharmawatch.com/news/TLPH/event-id-event-name-acrx-acelrx-3q16-results-call-event-date-2016-11-01-officers-and-speak-tlph-20161103monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-conference-call-september-15-2016-confirmation-13645416-page-1-acelrx-pharmaceutica-tlph-20160919monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-reports-positive-results-for-arx-04-sufentanil-sublingual-tablet-30-mcg-including-i-tlph-20160915monthly0.5https://www.biopharmawatch.com/news/TLPH/event-id-event-name-acrx-acelrx-second-quarter-2016-financial-results-event-date-2016-07-2-tlph-20160802monthly0.5https://www.biopharmawatch.com/news/TLPH/event-id-event-name-acrx-acelrx-q1-results-call-event-date-2016-05-02-officers-and-speaker-tlph-20160504monthly0.5https://www.biopharmawatch.com/news/TLPH/event-id-event-name-acrx-acelrx-conference-call-event-date-2016-03-29-officers-and-speaker-tlph-20160331monthly0.5https://www.biopharmawatch.com/news/TLPH/event-id-event-name-acelrx-pharmaceuticals-annual-2015-financial-results-event-date-2016-0-tlph-20160309monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-completes-protocol-review-with-fda-and-plans-to-initiate-phase-3-open-label-study-i-tlph-20160108monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-conducts-pre-nda-meeting-with-u-s-food-and-drug-administration-for--tlph-20151214monthly0.5https://www.biopharmawatch.com/news/TLPH/event-id-event-name-acrx-acelrx-3q15-financial-results-event-date-2015-10-29-officers-and--tlph-20151102monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-provides-business-update-and-reports-third-quarter-and-nine-months--tlph-20151029monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-provides-regulatory-update-on-zalviso-redwood-city-calif-october-8--tlph-20151008monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-reports-that-the-european-commission-has-granted-marketing-authoriz-tlph-20150922monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-arx-04-meets-all-endpoints-in-pivotal-phase-3-study-for-moderate-to-tlph-20150909monthly0.5https://www.biopharmawatch.com/news/TLPH/event-id-event-name-acrx-acelrx-2q15-financial-results-event-date-2015-08-03-officers-and--tlph-20150804monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-announce-s-positive-chmp-opinion-for-zalviso-in-the-management-of-acute-moderate-to-tlph-20150724monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-first-quarter-2015-financial-results-tlph-20150504monthly0.5https://www.biopharmawatch.com/news/TLPH/event-id-event-name-acrx-acelrx-fourth-quarter-and-annual-financial-results-event-date-201-tlph-20150309monthly0.5https://www.biopharmawatch.com/news/TLPH/forward-looking-statements-2-this-presentation-contains-forward-looking-statements-includi-tlph-20150209monthly0.5https://www.biopharmawatch.com/news/TLPH/january-2015-forward-looking-statements-this-presentation-contains-forward-looking-stateme-tlph-20150113monthly0.5https://www.biopharmawatch.com/news/TLPH/event-id-event-name-acrx-acelrx-q3-financial-results-event-date-2014-11-10-officers-and-sp-tlph-20141113monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-reports-third-quarter-2014-financial-results-tlph-20141110monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-provides-regulatory-update-on-zalviso-tlph-20140926monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-receives-complete-response-letter-from-fda-for-new-drug-application-tlph-20140725monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-appoints-timothy-e-morris-as-chief-financial-officer-tlph-20140325monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-reports-fourth-quarter-and-full-year-2013-financial-results-tlph-20140303monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-secures-40-million-credit-facility-with-hercules-technology-growth-capital-tlph-20131219monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-and-gr-nenthal-announce-collaboration-for-eu-commercialization-of-zalviso-tm-fda-es-tlph-20131219monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-adds-new-board-member-tlph-20131211monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-submits-new-drug-application-to-the-fda-for-zalviso-zalviso-nda-sub-tlph-20130930monthly0.5https://www.biopharmawatch.com/news/TLPH/forward-looking-statements-this-current-report-on-form-8-k-or-form-8-k-contains-forward-lo-tlph-20130701monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-reports-first-quarter-2013-financial-results-tlph-20130508monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-reports-fourth-quarter-and-full-year-2012-financial-results-tlph-20130312monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-top-line-data-show-primary-endpoint-achieved-in-pivotal-phase-3-study-of-sufentanil-tlph-20130304monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-appoints-adrian-adams-to-board-of-directors-as-chairman-tlph-20130212monthly0.5https://www.biopharmawatch.com/news/TLPH/risk-factors-our-business-is-subject-to-various-risks-including-those-described-below-you--tlph-20121207monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-announces-primary-endpoint-met-in-phase-3-non-inferiority-study-of-sublingual-sufen-tlph-20121115monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-reports-third-quarter-2012-financial-results-tlph-20121106monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-initiates-third-phase-3-clinical-trial-for-arx-01-the-sufentanil-na-tlph-20120823monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-reports-second-quarter-2012-financial-results-tlph-20120809monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-receives-two-additional-u-s-patents-for-small-volume-oral-transmuco-tlph-20120801monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-completes-private-placement-of-10-0-million-tlph-20120604monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-announces-pricing-of-a-10-0-million-pipe-financing-tlph-20120530monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-reports-first-quarter-2012-financial-results-tlph-20120508monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-receives-two-notices-of-allowance-for-small-volume-oral-transmucosa-tlph-20120411monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-reports-fourth-quarter-and-full-year-2011-financial-results-tlph-20120320monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-reports-third-quarter-2011-financial-results-tlph-20111108monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-appoints-mark-g-edwards-to-its-board-of-directors-tlph-20110928monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-reports-second-quarter-2011-financial-results-remains-on-track-to-i-tlph-20110811monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-secures-20-million-loan-financing-agreement-expected-to-extend-its-operating-cash-r-tlph-20110630monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-announces-5-6-million-department-of-defense-grant-to-develop-arx-04-a-new-acute-pai-tlph-20110531monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-reports-first-quarter-2011-financial-results-initiation-of-phase-3--tlph-20110512monthly0.5https://www.biopharmawatch.com/news/TLPH/acelrx-pharmaceuticals-reports-fourth-quarter-and-full-year-2010-financial-results-plans-t-tlph-20110324monthly0.5https://www.biopharmawatch.com/news/GRML/greenland-mines-ltd-nasdaq-grml-visit-greenlandmines-com-for-more-information-may-13-14-20-grml-20260514monthly0.5https://www.biopharmawatch.com/news/GRML/greenland-mines-secures-additional-180-day-period-for-nasdaq-bid-price-compliance-extensio-grml-20260323monthly0.5https://www.biopharmawatch.com/news/GRML/klotho-neurosciences-completes-rebranding-to-greenland-mines-ltd-and-change-of-nasdaq-tick-grml-20260312monthly0.5https://www.biopharmawatch.com/news/GRML/investor-webcast-grml-20260312monthly0.5https://www.biopharmawatch.com/news/GRML/klotho-neurosciences-acquires-greenland-mines-corp-securing-control-of-a-68-billion-pallad-grml-20260304monthly0.5https://www.biopharmawatch.com/news/GRML/klotho-neurosciences-inc-klotho-initiates-manufacturing-of-klto-202-product-candidate-usin-grml-20250812monthly0.5https://www.biopharmawatch.com/news/GRML/klotho-neurosciences-inc-partners-with-aavnergene-inc-to-make-klotho-s-gene-therapy-assets-grml-20250722monthly0.5https://www.biopharmawatch.com/news/GRML/klotho-neurosciences-inc-regains-full-compliance-with-nasdaq-minimum-closing-bid-price-and-grml-20250716monthly0.5https://www.biopharmawatch.com/news/GRML/klotho-neurosciences-inc-granted-fda-orphan-drug-designation-for-klto-202-for-treatment-of-grml-20250710monthly0.5https://www.biopharmawatch.com/news/GRML/klotho-neurosciences-moves-forward-with-manufacturing-gene-therapy-for-the-treatment-of-grml-20250630monthly0.5https://www.biopharmawatch.com/news/GRML/klotho-neurosciences-raises-over-11-million-retires-all-debt-and-exceeds-nasdaq-stockholde-grml-20250616monthly0.5https://www.biopharmawatch.com/news/GRML/klotho-neuroscience-inc-announces-an-approach-to-increase-longevity-and-healthy-life-span--grml-20250609monthly0.5https://www.biopharmawatch.com/news/GRML/dr-robert-langer-co-founder-of-moderna-joins-scientific-advisory-board-of-klotho-neuroscie-grml-20240930monthly0.5https://www.biopharmawatch.com/news/GRML/strategic-asset-leasing-inc-13576-walnut-street-omaha-ne-68144-financial-statements-and-no-grml-20240620monthly0.5https://www.biopharmawatch.com/news/GRML/using-gene-therapy-to-address-the-aging-process-investor-presentation-q3-2023-disclaimer-2-grml-20230811monthly0.5https://www.biopharmawatch.com/news/GRML/anew-medical-inc-enters-into-definitive-merger-agreement-with-redwoods-acquisition-corp-an-grml-20230530monthly0.5https://www.biopharmawatch.com/news/GRML/redwoods-acquisition-corp-announces-receipt-of-nasdaq-listing-delinquency-letter-and-nasda-grml-20230531monthly0.5https://www.biopharmawatch.com/news/GRML/index-to-unaudited-pro-forma-financial-statement-unaudited-pro-forma-balance-sheet-as-of-grml-20220407monthly0.5https://www.biopharmawatch.com/news/GRML/index-to-financial-statement-report-of-independent-registered-public-accounting-firm-f-2-f-grml-20220404monthly0.5https://www.biopharmawatch.com/news/EHTH/document-ehealth-inc-announces-first-quarter-2026-results-q1-2026-results-ahead-of-expecta-ehth-20260506monthly0.5https://www.biopharmawatch.com/news/EHTH/document-andrea-brimmer-to-transition-from-ehealth-board-of-directors-indianapolis-ehth-20260331monthly0.5https://www.biopharmawatch.com/news/EHTH/document-ehealth-inc-announces-fourth-quarter-and-fiscal-year-2025-results-achieves-record-ehth-20260225monthly0.5https://www.biopharmawatch.com/news/EHTH/document-ehealth-announces-125-million-asset-based-revolving-credit-facility-deal-further--ehth-20260106monthly0.5https://www.biopharmawatch.com/news/EHTH/document-press-release-ehealth-inc-updates-guidance-for-fiscal-year-2025-following-strong--ehth-20251218monthly0.5https://www.biopharmawatch.com/news/EHTH/document-ehealth-inc-announces-third-quarter-2025-results-raises-2025-annual-earnings-guid-ehth-20251105monthly0.5https://www.biopharmawatch.com/news/EHTH/document-ehealth-announces-extension-of-blue-torch-term-loan-ehealth-reaffirms-its-commitm-ehth-20251007monthly0.5https://www.biopharmawatch.com/news/EHTH/document-ehealth-inc-announces-second-quarter-2025-results-q2-2025-results-reflect-strateg-ehth-20250806monthly0.5https://www.biopharmawatch.com/news/EHTH/document-ehealth-announces-ceo-succession-derrick-duke-appointed-chief-executive-officer-a-ehth-20250729monthly0.5https://www.biopharmawatch.com/news/EHTH/document-ehealth-inc-announces-first-quarter-2025-results-strong-first-quarter-results-wit-ehth-20250507monthly0.5https://www.biopharmawatch.com/news/EHTH/document-ehealth-inc-announces-fourth-quarter-and-fiscal-year-2024-results-reports-record--ehth-20250226monthly0.5https://www.biopharmawatch.com/news/EHTH/document-press-release-ehealth-inc-updates-guidance-for-fiscal-year-2024-following-strong--ehth-20241217monthly0.5https://www.biopharmawatch.com/news/EHTH/document-ehealth-inc-announces-third-quarter-2024-results-third-quarter-performance-driven-ehth-20241106monthly0.5https://www.biopharmawatch.com/news/EHTH/document-ehealth-inc-announces-second-quarter-2024-results-strong-second-quarter-results-d-ehth-20240807monthly0.5https://www.biopharmawatch.com/news/EHTH/document-ehealth-inc-announces-first-quarter-2024-results-strong-first-quarter-results-wit-ehth-20240507monthly0.5https://www.biopharmawatch.com/news/EHTH/document-ehealth-inc-announces-fourth-quarter-and-fiscal-year-2023-results-fourth-quarter--ehth-20240227monthly0.5https://www.biopharmawatch.com/news/EHTH/document-press-release-ehealth-inc-announces-preliminary-results-for-the-fourth-quarter-an-ehth-20240126monthly0.5https://www.biopharmawatch.com/news/EHTH/document-ehealth-inc-announces-third-quarter-2023-results-entered-aep-on-strong-financial--ehth-20231108monthly0.5https://www.biopharmawatch.com/news/EHTH/document-ehealth-inc-announces-second-quarter-2023-results-strong-second-quarter-results-2-ehth-20230808monthly0.5https://www.biopharmawatch.com/news/EHTH/document-ehealth-inc-announces-first-quarter-2023-results-strong-first-quarter-performance-ehth-20230509monthly0.5https://www.biopharmawatch.com/news/EHTH/document-ehealth-inc-announces-fourth-quarter-and-fiscal-year-2022-results-ehth-20230228monthly0.5https://www.biopharmawatch.com/news/EHTH/document-ehealth-inc-announces-preliminary-results-for-the-fourth-quarter-and-fiscal-year--ehth-20230124monthly0.5https://www.biopharmawatch.com/news/EHTH/document-ehealth-inc-announces-third-quarter-2022-results-ehth-20221107monthly0.5https://www.biopharmawatch.com/news/EHTH/document-ehealth-inc-announces-second-quarter-2022-results-ehth-20220808monthly0.5https://www.biopharmawatch.com/news/EHTH/document-ehealth-inc-announces-first-quarter-2022-results-ehth-20220503monthly0.5https://www.biopharmawatch.com/news/EHTH/document-c-o-r-r-e-c-t-i-o-n-ehealth-inc-ehealth-inc-is-correcting-misstatements-regarding-ehth-20220302monthly0.5https://www.biopharmawatch.com/news/EHTH/document-ehealth-inc-announces-fourth-quarter-and-fiscal-year-2021-results-ehth-20220301monthly0.5https://www.biopharmawatch.com/news/EHTH/document-ehealth-inc-announces-third-quarter-2021-results-ehth-20211108monthly0.5https://www.biopharmawatch.com/news/EHTH/document-ehealth-inc-announces-second-quarter-2021-results-ehth-20210729monthly0.5https://www.biopharmawatch.com/news/EHTH/document-ehealth-enters-into-cooperation-agreement-with-starboard-value-ehealth-to-nominat-ehth-20210513monthly0.5https://www.biopharmawatch.com/news/EHTH/document-ehealth-inc-announces-first-quarter-2021-results-ehth-20210429monthly0.5https://www.biopharmawatch.com/news/EHTH/document-for-immediate-release-ehealth-enters-into-cooperation-agreement-with-hudson-execu-ehth-20210311monthly0.5https://www.biopharmawatch.com/news/EHTH/ehealth-inc-announces-fourth-quarter-2020-and-fiscal-2020-results-fourth-quarter-2020-over-ehth-20210218monthly0.5https://www.biopharmawatch.com/news/EHTH/document-ehealth-inc-announces-strategic-investment-from-h-i-g-capital-h-i-g-capital-commi-ehth-20210129monthly0.5https://www.biopharmawatch.com/news/EHTH/document-ehealth-inc-announces-preliminary-results-for-the-fourth-quarter-and-fiscal-year--ehth-20210129monthly0.5https://www.biopharmawatch.com/news/EHTH/ehealth-inc-announces-third-quarter-2020-results-third-quarter-2020-overview-revenue-for-t-ehth-20201022monthly0.5https://www.biopharmawatch.com/news/EHTH/ehealth-inc-announces-second-quarter-2020-results-second-quarter-2020-overview-revenue-for-ehth-20200723monthly0.5https://www.biopharmawatch.com/news/EHTH/ehealth-inc-announces-first-quarter-2020-results-first-quarter-2020-overview-revenue-for-t-ehth-20200423monthly0.5https://www.biopharmawatch.com/news/EHTH/ehealth-inc-announces-fourth-quarter-2019-and-fiscal-2019-results-fourth-quarter-2019-over-ehth-20200220monthly0.5https://www.biopharmawatch.com/news/EHTH/exhibit-ehealth-inc-announces-preliminary-results-for-the-fourth-quarter-and-fiscal-year-2-ehth-20200123monthly0.5https://www.biopharmawatch.com/news/EHTH/ehealth-inc-announces-third-quarter-2019-results-third-quarter-2019-overview-revenue-for-t-ehth-20191024monthly0.5https://www.biopharmawatch.com/news/EHTH/ehealth-inc-announces-second-quarter-2019-results-second-quarter-2019-overview-revenue-for-ehth-20190725monthly0.5https://www.biopharmawatch.com/news/EHTH/ehealth-inc-announces-first-quarter-2019-results-first-quarter-2019-overview-revenue-for-t-ehth-20190425monthly0.5https://www.biopharmawatch.com/news/EHTH/exhibit-ehealth-inc-announces-fourth-quarter-and-fiscal-2018-results-fourth-quarter-2018-o-ehth-20190221monthly0.5https://www.biopharmawatch.com/news/EHTH/ehealth-inc-announces-preliminary-results-for-the-fourth-quarter-and-fiscal-year-2018-and--ehth-20190122monthly0.5https://www.biopharmawatch.com/news/EHTH/of-form-8-k-our-future-capital-requirements-will-depend-on-many-factors-including-our-expe-ehth-20181217monthly0.5https://www.biopharmawatch.com/news/EHTH/ehealth-inc-announces-third-quarter-2018-results-third-quarter-2018-overview-revenue-for-t-ehth-20181025monthly0.5https://www.biopharmawatch.com/news/EHTH/ehealth-inc-announces-second-quarter-2018-results-second-quarter-2018-overview-revenue-for-ehth-20180726monthly0.5https://www.biopharmawatch.com/news/EHTH/ehealth-appoints-derek-n-yung-as-chief-financial-officer-ehth-20180604monthly0.5https://www.biopharmawatch.com/news/EHTH/ehealth-inc-announces-first-quarter-2018-results-first-quarter-2018-overview-revenue-for-t-ehth-20180426monthly0.5https://www.biopharmawatch.com/news/EHTH/ehealth-inc-announces-acquisition-of-gomedigap-to-further-accelerate-expansion-of-medicare-ehth-20180116monthly0.5https://www.biopharmawatch.com/news/EHTH/proxydirectenr-ehth-20171031monthly0.5https://www.biopharmawatch.com/news/EHTH/ehealth-inc-announces-third-quarter-2017-results-third-quarter-2017-overview-revenue-for-t-ehth-20171026monthly0.5https://www.biopharmawatch.com/news/EHTH/ehealth-inc-announces-second-quarter-2017-results-second-quarter-2017-overview-revenue-for-ehth-20170727monthly0.5https://www.biopharmawatch.com/news/EHTH/ehealth-inc-announces-first-quarter-2017-results-first-quarter-2017-overview-revenue-for-t-ehth-20170427monthly0.5https://www.biopharmawatch.com/news/EHTH/ehealth-inc-announces-completion-of-strategic-alternatives-review-company-plans-to-host-an-ehth-20170324monthly0.5https://www.biopharmawatch.com/news/EHTH/correcting-and-replacing-ehealth-inc-announces-fourth-quarter-and-fiscal-2016-results-moun-ehth-20170227monthly0.5https://www.biopharmawatch.com/news/EHTH/ehealth-inc-announces-fourth-quarter-and-fiscal-2016-results-fourth-quarter-2016-overview--ehth-20170224monthly0.5https://www.biopharmawatch.com/news/EHTH/agreementbetwe-1-agreement-between-web-based-entity-and-the-centers-for-medicare-medicaid--ehth-20161103monthly0.5https://www.biopharmawatch.com/news/EHTH/ehealth-inc-announces-third-quarter-2016-results-third-quarter-2016-overview-revenue-for-t-ehth-20161027monthly0.5https://www.biopharmawatch.com/news/EHTH/ehealth-inc-announces-second-quarter-2016-results-second-quarter-2016-overview-revenue-for-ehth-20160728monthly0.5https://www.biopharmawatch.com/news/EHTH/ehealth-inc-announces-first-quarter-2016-results-first-quarter-2016-overview-revenue-for-f-ehth-20160428monthly0.5https://www.biopharmawatch.com/news/EHTH/ehealth-inc-announces-fourth-quarter-and-fiscal-2015-results-fourth-quarter-2015-overview--ehth-20160223monthly0.5https://www.biopharmawatch.com/news/EHTH/wbecmsagreemen-1-agreement-between-web-broker-entity-and-the-centers-for-medicare-and-medi-ehth-20151110monthly0.5https://www.biopharmawatch.com/news/EHTH/ehealth-inc-announces-third-quarter-2015-results-third-quarter-2015-overview-revenue-of-38-ehth-20151029monthly0.5https://www.biopharmawatch.com/news/EHTH/ehealth-inc-announces-second-quarter-2015-results-second-quarter-2015-overview-revenue-of--ehth-20150729monthly0.5https://www.biopharmawatch.com/news/EHTH/ehealth-inc-announces-first-quarter-2015-results-first-quarter-2015-overview-revenue-of-61-ehth-20150424monthly0.5https://www.biopharmawatch.com/news/EHTH/ex-10-1-2-exhibit991-031915-htm-exhibit-10-1-exhibit-10-1-03-23-15-exhibit-10-1-ehealth-in-ehth-20150323monthly0.5https://www.biopharmawatch.com/news/EHTH/ehealth-inc-announces-strategic-cost-reduction-program-estimated-15-reduction-in-its-workf-ehth-20150311monthly0.5https://www.biopharmawatch.com/news/EHTH/ehealth-inc-announces-fourth-quarter-and-fiscal-2014-results-fourth-quarter-2014-overview--ehth-20150225monthly0.5https://www.biopharmawatch.com/news/EHTH/ehealth-inc-announces-preliminary-results-for-the-fourth-quarter-and-fiscal-year-2014-conf-ehth-20150115monthly0.5https://www.biopharmawatch.com/news/EHTH/ehealth-inc-announces-third-quarter-2014-results-third-quarter-2014-overview-revenue-of-41-ehth-20141030monthly0.5https://www.biopharmawatch.com/news/EHTH/exhibit-ehthexhibit992-1-agent-broker-general-agreement-for-the-federally-facilitated-exch-ehth-20140929monthly0.5https://www.biopharmawatch.com/news/EHTH/ehealth-inc-announces-second-quarter-2014-results-second-quarter-2014-overview-revenue-of--ehth-20140730monthly0.5https://www.biopharmawatch.com/news/EHTH/ehealth-inc-ehth-20140501monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-first-quarter-2026-financial-results-reports-total-q1-2026-revenue-of-3--nspr-20260504monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-initiates-voluntary-u-s-recall-of-cguard-prime-135-cm-carotid-stent-delivery-sys-nspr-20260501monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-fourth-quarter-and-full-year-2025-financial-results-miami-fl-nspr-20260318monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-second-quarter-2025-financial-results-management-to-host-investor-confer-nspr-20250805monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-u-s-commercial-launch-of-cguard-prime-carotid-stent-system-for-the-pre-nspr-20250709monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-fda-approval-for-cguard-prime-carotid-stent-system-for-the-prevention--nspr-20250624monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-ce-mark-approval-for-cguard-prime-embolic-prevention-system-eps-under--nspr-20250613monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-appointment-of-michael-lawless-as-chief-financial-officer-reports-indu-nspr-20250603monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-first-quarter-2025-financial-results-management-to-host-investor-confere-nspr-20250509monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-fourth-quarter-and-full-year-2024-financial-results-management-to-host-i-nspr-20250312monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-expected-retirement-of-its-cfo-craig-shore-and-cfo-transition-in-2025--nspr-20241212monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-first-patient-enrolled-in-the-cguardians-ii-pivotal-study-of-the-cguar-nspr-20241209monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-appointment-of-accomplished-medical-technology-executive-scott-r-ward--nspr-20241125monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-third-quarter-2024-financial-results-and-provides-business-update-submit-nspr-20241112monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-establishment-of-global-headquarters-in-miami-florida-to-support-antic-nspr-20241015monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-approval-of-investigational-device-exemption-ide-application-for-cguar-nspr-20241007monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-submission-of-premarket-approval-application-to-fda-seeking-u-s-regula-nspr-20240916monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-second-quarter-2024-financial-results-and-provides-business-update-annou-nspr-20240806monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-full-exercise-of-series-h-warrant-tranche-for-gross-proceeds-of-17-9-m-nspr-20240701monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-presentation-of-positive-one-year-follow-up-results-from-the-c-guardia-nspr-20240528monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-first-quarter-2024-financial-results-and-provides-business-update-genera-nspr-20240514monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-abstract-of-one-year-follow-up-results-from-the-c-guardians-u-s-invest-nspr-20240326monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-busines-nspr-20240306monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-receives-ce-mark-recertification-under-eu-s-new-medical-device-regulation-mdr-re-nspr-20240131monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-issuance-of-key-u-s-patent-covering-its-switchguard-tm-neuroprotection-nspr-20231220monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-strategic-agreement-with-jacobs-institute-to-execute-early-feasibility-nspr-20231127monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-third-quarter-2023-financial-results-and-provides-business-update-presen-nspr-20231106monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-presents-positive-30-day-follow-up-results-from-the-c-guardians-u-s-investigatio-nspr-20231101monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-supports-cms-final-national-coverage-determination-ncd-expanding-coverage-of-car-nspr-20231012monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-abstract-of-30-day-results-from-the-c-guardians-u-s-investigational-de-nspr-20230831monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-second-quarter-2023-financial-results-and-provides-business-update-compl-nspr-20230808monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-completion-of-enrollment-in-c-guardians-u-s-investigational-device-exe-nspr-20230626monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-first-quarter-2023-financial-results-and-provides-business-update-comple-nspr-20230516monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-private-placement-of-up-to-113-6-million-led-by-marshall-wace-with-par-nspr-20230515monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-fourth-quarter-and-year-end-2022-financial-results-and-provides-business-nspr-20230330monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-promotion-of-andrea-tommasoli-to-chief-operating-officer-mr-tommasoli--nspr-20230320monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-third-quarter-2022-financial-results-and-provides-business-update-genera-nspr-20221108monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-second-quarter-2022-financial-results-and-provides-business-update-gener-nspr-20220809monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-first-quarter-2022-financial-results-and-business-update-20-growth-in-cg-nspr-20220510monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-fourth-quarter-and-year-end-2021-financial-results-cguard-revenue-genera-nspr-20220308monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-the-inclusion-of-its-cguard-carotid-stent-in-crest-2-trial-following-f-nspr-20220228monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-third-quarter-2021-financial-results-and-provides-corporate-update-cguar-nspr-20211109monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-publication-of-12-month-results-of-cguard-eps-siberia-trial-in-journal-nspr-20211103monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-receives-reimbursement-approval-for-cguard-embolic-prevention-system-from-the-fr-nspr-20211013monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-strong-second-quarter-2021-financial-results-revenue-rebound-strong-pr-nspr-20210810monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-enrolls-and-treats-first-patients-at-ballad-health-system-in-u-s-registration-c--nspr-20210723monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-warrants-exchange-listing-transfer-to-nasdaq-tickers-to-be-nsprw-and-n-nspr-20210527monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-appointment-of-katie-arnold-to-board-of-directors-tel-aviv-israel-nspr-20210512monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-first-quarter-2021-financial-results-company-completes-up-list-to-nasd-nspr-20210511monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-stock-exchange-listing-transfer-to-nasdaq-ticker-to-remain-nspr-tel-av-nspr-20210510monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-provides-corporate-update-for-shareholders-tel-aviv-israel-nspr-20210419monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-1-for-15-reverse-stock-split-tel-aviv-israel-nspr-20210414monthly0.5https://www.biopharmawatch.com/news/NSPR/e-xhibit-99-1-inspiremd-announces-fourth-quarter-and-year-end-2020-financial-results-manag-nspr-20210309monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-pricing-of-upsized-18-million-underwritten-public-offering-tel-aviv-is-nspr-20210204monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-third-quarter-2020-financial-results-third-quarter-2020-revenue-return-nspr-20201109monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-inc-appoints-andrea-tommasoli-senior-vice-president-of-global-sales-and-marketin-nspr-20201103monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-renowned-interventional-cardiologist-gary-s-roubin-m-d-ph-d-to-join-bo-nspr-20201013monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-inc-appoints-patrick-jamnik-as-vice-president-of-business-development-and-strate-nspr-20201006monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-approval-of-investigational-device-exemption-ide-for-pivotal-study-of--nspr-20200908monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-the-european-society-of-cardiology-2020-best-poster-award-for-updated--nspr-20200903monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-regains-compliance-with-nyse-american-listing-standards-tel-aviv-israel-nspr-20200810monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-second-quarter-2020-financial-results-in-the-second-quarter-the-compan-nspr-20200805monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-gains-registration-clearance-of-its-cguard-embolic-prevention-system-eps-in-braz-nspr-20200723monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-late-breaking-presentation-of-early-siberia-clinical-trial-results-to--nspr-20200625monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-publication-of-12-month-results-of-cguard-eps-paradigm-trial-in-euroin-nspr-20200610monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-inc-announces-pricing-of-10-million-underwritten-public-offering-tel-aviv-israel-nspr-20200603monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-first-quarter-2020-financial-results-first-quarter-revenue-growth-driv-nspr-20200512monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-fourth-quarter-and-year-end-2019-financial-results-robust-cguard-eps-y-nspr-20200310monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-successful-live-clinical-case-transmissions-featuring-cguard-eps-at-th-nspr-20200129monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-s-cguard-embolic-prevention-system-to-be-prominently-featured-in-live-case-trans-nspr-20200127monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-strong-preliminary-fourth-quarter-2019-revenue-and-reports-inducement--nspr-20200106monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-planned-leadership-transition-life-sciences-industry-veteran-marvin-sl-nspr-20191210monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-updated-positive-cguard-eps-data-presented-at-veith-2019-cguard-eps-clin-nspr-20191126monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-third-quarter-2019-financial-results-strong-revenue-driven-by-record-o-nspr-20191112monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-inc-announces-pricing-of-5-million-underwritten-public-offering-tel-aviv-israel-nspr-20190919monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-provides-business-update-tel-aviv-israel-nspr-20190909monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-notification-of-nyse-american-listing-deficiency-tel-aviv-israel-nspr-20190809monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-second-quarter-2019-financial-results-u-s-investigational-device-exemp-nspr-20190806monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-first-quarter-2019-financial-results-on-track-to-submit-u-s-ide-expect-nspr-20190514monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-inc-announces-proposed-public-offering-of-common-stock-tel-aviv-israel-nspr-20190403monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-1-for-50-reverse-stock-split-tel-aviv-israel-nspr-20190326monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-provides-amended-disclosure-tel-aviv-israel-nspr-20190322monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-fourth-quarter-2018-financial-results-2018-cguard-tm-eps-annual-sales--nspr-20190219monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-report-fourth-quarter-and-fiscal-2018-financial-results-and-provide-business--nspr-20190207monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-two-successful-live-clinical-case-transmissions-featuring-cguard-eps-a-nspr-20190123monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-s-cguard-embolic-prevention-system-to-be-prominently-featured-in-live-case-trans-nspr-20190118monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-the-distribution-of-cguard-embolic-prevention-system-in-south-africa-g-nspr-20190114monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-receives-noncompliance-notice-from-nyse-american-tel-aviv-israel-nspr-20190111monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-publication-of-meta-analysis-citing-benefits-of-next-generation-mesh-c-nspr-20181218monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-positive-long-term-safety-and-efficacy-data-from-ongoing-cguard-eps-re-nspr-20181129monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-regulatory-and-reimbursement-approval-of-cguard-embolic-prevention-sys-nspr-20181128monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-upcoming-presentations-at-the-45th-annual-symposium-on-vascular-and-en-nspr-20181113monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-third-quarter-2018-financial-results-and-provides-corporate-update-pre-nspr-20181106monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-regulatory-approval-of-cguard-embolic-prevention-system-in-mexico-comm-nspr-20180924monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-issuance-of-two-new-u-s-patents-covering-proprietary-micronet-stent-ja-nspr-20180917monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-94-increase-in-cguard-eps-revenues-for-the-second-quarter-of-2018-tel-av-nspr-20180806monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-opening-of-first-two-cguard-eps-centers-of-excellence-tel-aviv-israel-nspr-20180723monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-inc-announces-pricing-of-10-million-underwritten-public-offering-tel-aviv-israel-nspr-20180629monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-s-cguard-eps-prominently-featured-at-the-10th-international-congress-of-the-poli-nspr-20180618monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-s-cguard-micronet-eps-featured-in-a-live-case-transmission-to-the-2-nd-dga-inter-nspr-20180611monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-on-expanded-2-year-follow-up-results-from-the-paradigm-clinical-study-us-nspr-20180524monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-receives-regulatory-approval-for-both-cguard-eps-and-mguard-prime-in-ecuador-tel-nspr-20180516monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-132-increase-in-cguard-eps-sales-for-the-first-quarter-of-2018-tel-aviv--nspr-20180507monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-regulatory-approval-and-reimbursement-to-commercialize-both-cguard-eps-nspr-20180430monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-s-cguard-embolic-prevention-system-to-be-featured-at-icca-stroke-2018-in-warsaw--nspr-20180419monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-anticipates-fifth-consecutive-quarter-of-sequential-double-digit-growth-projects-nspr-20180403monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-inc-announces-proposed-public-offering-of-common-stock-tel-aviv-israel-nspr-20180327monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-receives-regulatory-approval-for-both-cguard-eps-and-mguard-prime-in-peru-tel-av-nspr-20180327monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-first-patient-treated-with-cguard-tm-eps-in-india-patient-with-severe--nspr-20180305monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-expansion-of-its-distribution-network-signs-exclusive-distributors-for-nspr-20180301monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-inc-announces-pricing-of-public-offering-of-common-stock-tel-aviv-israel-nspr-20180227monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-inc-announces-proposed-public-offering-of-common-stock-tel-aviv-israel-nspr-20180226monthly0.5https://www.biopharmawatch.com/news/NSPR/i-nspiremd-announces-exclusive-distribution-sales-and-marketing-agreement-for-cguard-eps-i-nspr-20180222monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-commercial-launch-and-first-sales-of-cguard-eps-in-india-tel-aviv-isra-nspr-20180220monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-fourth-quarter-and-year-end-2017-results-cguard-eps-fourth-quarter-sal-nspr-20180214monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-1-for-35-reverse-stock-split-tel-aviv-israel-nspr-20180207monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-s-cguard-embolic-prevention-system-featured-in-successful-live-case-transmission-nspr-20180130monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-s-cguard-embolic-prevention-system-to-be-prominently-featured-in-two-live-case-t-nspr-20180126monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-publication-of-an-independent-imaging-study-highlighting-the-advantage-nspr-20180119monthly0.5https://www.biopharmawatch.com/news/NSPR/crescendo-communications-llc-to-jim-barry-craig-shore-from-david-waldman-natalya-rudman-su-nspr-20180110monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-projects-211-increase-in-cguard-eps-sales-for-the-fourth-quarter-of-2017-confere-nspr-20180110monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-schedules-conference-call-to-discuss-recent-developments-preliminary-sales-resul-nspr-20180103monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-regulatory-approval-of-cguard-eps-in-india-signs-agreement-with-leadin-nspr-20180103monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-s-cguard-embolic-prevention-system-once-again-featured-in-a-successful-live-clin-nspr-20171218monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-preliminary-2-year-follow-up-results-from-the-paradigm-clinical-study--nspr-20171205monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-expansion-of-its-distribution-network-for-cguard-eps-in-australia-new--nspr-20171204monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-planned-recapitalization-tel-aviv-israel-nspr-20171129monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-third-quarter-2017-results-cguard-revenue-increases-90-versus-same-per-nspr-20171107monthly0.5https://www.biopharmawatch.com/news/NSPR/new-york-stock-exchange-accepts-inspiremd-s-plan-to-regain-compliance-tel-aviv-israel-nspr-20171024monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-the-start-of-patient-enrollment-in-an-investigator-initiated-trial-of--nspr-20171009monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-postpones-special-meeting-of-stockholders-to-nspr-20171004monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-distribution-agreement-for-cguard-tm-eps-in-portugal-tel-aviv-israel-nspr-20170921monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-distribution-agreement-for-cguard-tm-eps-in-switzerland-tel-aviv-israe-nspr-20170825monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-shares-cguard-tm-eps-video-testimonials-from-european-key-opinion-leaders-tel-av-nspr-20170822monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-double-digit-sequential-and-year-over-year-revenue-growth-for-the-second-nspr-20170808monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-publication-of-an-independent-clinical-review-authored-by-leading-u-s--nspr-20170807monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-s-cguard-carotid-embolic-prevention-system-featured-at-the-solaci-caci-congress--nspr-20170803monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-completion-of-transition-from-exclusive-european-distributor-to-inspir-nspr-20170613monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-distribution-agreement-for-cguard-eps-in-taiwan-tel-aviv-israel-nspr-20170608monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-the-publication-of-an-investigator-initiated-clinical-registry-reaffir-nspr-20170607monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-distribution-agreement-for-cguard-tm-eps-in-poland-tel-aviv-israel-nspr-20170605monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-appointment-of-paul-stuka-as-chairman-of-the-board-tel-aviv-israel-nspr-20170602monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-first-two-patients-in-hong-kong-successfully-treated-with-cguard-eps-t-nspr-20170530monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-s-cguard-carotid-embolic-prevention-system-featured-in-live-case-transmission-at-nspr-20170518monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-publication-of-the-iron-guard-registry-in-eurointervention-zero-incide-nspr-20170517monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-distribution-agreements-for-cguard-eps-and-mguard-prime-eps-in-peru-an-nspr-20170515monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-provides-business-update-for-the-first-quarter-of-2017-new-commercial-roll-out-o-nspr-20170509monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-distribution-agreement-for-cguard-tm-eps-in-germany-tel-aviv-nspr-20170501monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-listing-of-series-b-warrants-on-the-nyse-mkt-tel-aviv-nspr-20170405monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-commercial-launch-of-cguard-eps-in-the-russian-federation-at-the-icca--nspr-20170330monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-repays-term-note-ahead-of-schedule-tel-aviv-nspr-20170322monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-cguard-tm-distribution-agreement-for-the-russian-federation-tel-aviv-nspr-20170320monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-closing-of-public-offering-of-approximately-6-8-million-boston-ma-nspr-20170314monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-pricing-of-public-offering-of-up-to-7-5-million-boston-ma-nspr-20170309monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-provides-year-end-business-update-and-reports-financial-results-for-the-fourth-q-nspr-20170221monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-financial-results-for-the-third-quarter-ended-nspr-20161114monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-appointment-of-medical-device-industry-veteran-agustin-gago-as-chief-c-nspr-20161026monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-independent-study-published-in-the-journal-of-endovascular-therapy-tha-nspr-20161017monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-adjustments-to-shares-receivable-upon-warrant-exercise-and-exercise-pr-nspr-20161006monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-1-for-25-reverse-stock-split-boston-ma-nspr-20160928monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-appoints-thomas-kester-to-board-of-directors-boston-ma-nspr-20160907monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-financial-results-for-the-second-quarter-ended-nspr-20160809monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-regains-compliance-with-nyse-mkt-listing-standards-boston-ma-nspr-20160721monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-closing-of-public-offering-of-approximately-14-6-million-boston-ma-nspr-20160707monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-pricing-of-public-offering-of-approximately-14-6-million-boston-ma-nspr-20160630monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-amendment-to-loan-security-agreement-with-hercules-capital-principal-p-nspr-20160614monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-names-dr-james-barry-as-president-and-ceo-medical-device-veteran-brings-broad-in-nspr-20160607monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-s-cguard-tm-highlighted-at-the-late-breaking-clinical-trial-session-at-the-europ-nspr-20160517monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-financial-results-for-the-first-quarter-ended-nspr-20160510monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-pricing-of-public-offering-boston-ma-nspr-20160316monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-aligns-operations-and-leadership-team-appoints-isaac-blech-as-vice-chairman-of-t-nspr-20160122monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-receives-eu-regulatory-approval-for-additional-supplier-of-cguard-tm-delivery-ca-nspr-20151202monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-positive-twelve-month-follow-up-carenet-trial-data-at-veith-symposium--nspr-20151120monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-financial-results-for-the-third-quarter-ended-nspr-20151110monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-cguard-tm-approval-in-argentina-cguard-tm-clinical-data-presented-at-t-nspr-20151019monthly0.5https://www.biopharmawatch.com/news/NSPR/nyse-mkt-nspr-october-2015-forward-looking-statements-2-this-presentation-contains-forward-nspr-20151015monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-cguard-tm-approval-in-colombia-boston-ma-nspr-20151005monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-one-for-ten-reverse-stock-split-boston-ma-nspr-20151001monthly0.5https://www.biopharmawatch.com/news/NSPR/nyse-mkt-nspr-september-2015-forward-looking-statements-2-this-presentation-contains-forwa-nspr-20150909monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-financial-results-for-the-second-quarter-ended-nspr-20150805monthly0.5https://www.biopharmawatch.com/news/NSPR/p-rospective-evaluation-of-a-ll-comer-pe-r-cutaneous-c-a-roti-d-revascularization-i-n-symp-nspr-20150522monthly0.5https://www.biopharmawatch.com/news/NSPR/announces-clinical-presentations-on-cguard-and-mguard-nspr-20150512monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-financial-results-for-the-first-quarter-ended-nspr-20150511monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-mguard-prime-approval-in-brazil-boston-ma-nspr-20150427monthly0.5https://www.biopharmawatch.com/news/NSPR/completion-of-sales-restructuring-program-nspr-20150415monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-plan-of-compliance-accepted-by-nspr-20150316monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-financial-results-for-the-nspr-20150313monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-closing-of-public-offering-for-approximately-13-7-million-boston-ma-nspr-20150309monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-public-offering-for-approximately-13-5-million-boston-ma-nspr-20150304monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-proposed-public-offering-of-common-stock-and-warrants-boston-ma-nspr-20150303monthly0.5https://www.biopharmawatch.com/news/NSPR/nyse-mkt-nspr-february-2015-nspr-20150227monthly0.5https://www.biopharmawatch.com/news/NSPR/nyse-mkt-nspr-february-2015-nspr-20150220monthly0.5https://www.biopharmawatch.com/news/NSPR/piotr-musialek-md-dphil-fesc-jagiellonian-university-dept-of-cardiac-vascular-diseases-joh-nspr-20150127monthly0.5https://www.biopharmawatch.com/news/NSPR/notification-of-nyse-mkt-listing-deficiency-nspr-20150121monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-announce-positive-six-month-results-from-the-cguard-tm-carenet-trial-at-linc--nspr-20150113monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-pre-announces-a-fourth-quarter-nspr-20150106monthly0.5https://www.biopharmawatch.com/news/NSPR/the-master-ii-trial-comparison-of-the-mguard-embolic-protection-stent-with-standard-stents-nspr-20141215monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-financial-results-nspr-20141112monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-completes-8-1-million-registered-direct-offering-boston-ma-nspr-20141107monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-registered-direct-offering-for-approximately-8-million-boston-ma-nspr-20141104monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-investigational-device-exemption-ide-amendment-approved-by-the-fda-validation-of-nspr-20141029monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-resumes-mguard-prime-sales-and-prioritizes-des-and-carotid-new-product-programs--nspr-20141014monthly0.5https://www.biopharmawatch.com/news/NSPR/initial-commercial-sales-of-the-cguardtm-eps-nspr-20141001monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-host-conference-call-and-webinar-and-to-discuss-recently-released-results-of--nspr-20140916monthly0.5https://www.biopharmawatch.com/news/NSPR/joachim-schofer-pi-piotr-musialek-co-pi-on-behalf-of-the-carenet-investigators-evaluation--nspr-20140916monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-announce-results-of-cguard-carenet-trial-at-the-tct-innovation-session-on-lat-nspr-20140811monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-financial-results-for-nspr-20140724monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-appoints-dr-nspr-20140718monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-successful-completion-of-cguard-tm-carenet-car-otid-e-mbolic-protectio-nspr-20140708monthly0.5https://www.biopharmawatch.com/news/NSPR/european-regulatory-approval-to-resume-manufacturing-and-distribution-of-mguardtm-prime-ep-nspr-20140623monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-showcase-embolic-systems-with-micronet-tm-technology-and-results-from-master--nspr-20140520monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-financial-results-for-the-first-quarter-ended-nspr-20140508monthly0.5https://www.biopharmawatch.com/news/NSPR/voluntary-field-action-for-mguardtm-prime-eps-nspr-20140430monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-first-patient-enrolled-into-new-cguard-tm-carenet-car-otid-e-mbolic-pr-nspr-20140319monthly0.5https://www.biopharmawatch.com/news/NSPR/2-this-presentation-contains-forward-looking-statements-nspr-20140305monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-financial-results-for-the-quarter-and-six-month-period-ended-nspr-20140227monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-report-financial-results-for-six-month-period-ended-nspr-20140218monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-successful-implantation-of-the-new-cguard-tm-carotid-embolic-system-with-nspr-20140205monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-appoints-rick-olson-as-vice-president-of-global-sales-operations-company-strengt-nspr-20131202monthly0.5https://www.biopharmawatch.com/news/NSPR/exhbit-99-1-for-immediate-release-inspiremd-reports-financial-results-for-quarter-ended-nspr-20131112monthly0.5https://www.biopharmawatch.com/news/NSPR/november-2013-nyse-mkt-nspr-forward-looking-statements-this-presentation-contains-forward--nspr-20131029monthly0.5https://www.biopharmawatch.com/news/NSPR/master-trial-12-month-results-prof-nspr-20131029monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-ring-opening-bell-at-new-york-stock-exchange-on-thursday-october-24th-boston--nspr-20131023monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-fourth-quarter-and-fiscal-year-2013-results-boston-ma-nspr-20130917monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-report-fiscal-year-2013-results-on-september-17-th-boston-ma-nspr-20130909monthly0.5https://www.biopharmawatch.com/news/NSPR/september-2013-v50-46-nyse-mkt-nspr-forward-looking-statements-this-presentation-contains--nspr-20130910monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-new-appointment-to-the-board-of-directors-boston-ma-nspr-20130904monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-participation-in-two-investor-conferences-in-september-presenting-at-r-nspr-20130829monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-completes-first-phase-of-manufacturing-upgrade-and-partners-with-healthlink-for--nspr-20130826monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-first-patient-enrolled-in-u-s-registration-trial-for-mguard-prime-eps--nspr-20130729monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-present-at-8-th-annual-jmp-healthcare-conference-boston-and-nspr-20130703monthly0.5https://www.biopharmawatch.com/news/NSPR/forward-looking-statements-this-presentation-contains-forward-looking-statements-nspr-20130529monthly0.5https://www.biopharmawatch.com/news/NSPR/master-trial-update-6-month-results-prof-nspr-20130523monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-to-announce-six-month-results-from-the-mguard-embolic-protection-stent-eps-maste-nspr-20130523monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-reimbursement-coverage-for-mguard-coronary-embolic-protection-stent-ep-nspr-20130516monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-financial-results-for-period-ended-nspr-20130508monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-hires-vice-president-of-corporate-development-former-covidien-executive-gwen-bam-nspr-20130423monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-closes-25-million-underwritten-public-offering-tel-aviv-israel-apr-16-inspiremd--nspr-20130418monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-pricing-of-underwritten-public-offering-of-common-stock-and-listing-on-nspr-20130411monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-receives-ce-mark-approval-for-carotid-embolic-protection-stent-inspiremd-s-carot-nspr-20130315monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-files-amended-registration-statement-for-proposed-public-offering-of-common-stoc-nspr-20130311monthly0.5https://www.biopharmawatch.com/news/NSPR/michael-berman-joins-inspiremd-board-former-boston-scientific-executive-and-cofounder-of-n-nspr-20130212monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-results-for-period-ended-nspr-20130204monthly0.5https://www.biopharmawatch.com/news/NSPR/inspiremd-names-alan-milinazzo-president-and-ceo-former-medtronic-and-boston-scientific-ex-nspr-20130103monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-quarterly-activities-report-appendix-4c-q3-fy26-following-idmc-r-immp-20260501monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-limited-abn-90-009-237-889-appendix-4d-half-year-financial-report-for-the-half-yea-immp-20260226monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-quarterly-activities-report-appendix-4c-q2-fy26-entered-into-str-immp-20260130monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-strong-operational-progress-in-global-tacti-004-keynote-f91-phase-iii-an-immp-20251216monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-and-dr-reddy-s-enters-into-strategic-collaboration-for-commercialisation-of-an-inn-immp-20251208monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-receives-a-4-6-million-r-d-tax-incentive-from-french-government--immp-20251104monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-quarterly-activities-report-appendix-4c-q1-fy26-pivotal-tacti-00-immp-20251030monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-limited-preliminary-final-report-appendix-4e-preliminary-final-report-1-company-de-immp-20250903monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-receives-positive-feedback-from-fda-on-late-stage-clinical-development-of-eftilagi-immp-20250807monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-quarterly-activities-report-appendix-4c-q4-fy25-the-pivotal-tact-immp-20250731monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-positive-update-from-phase-i-study-of-imp761-a-first-in-class-lag-3-agon-immp-20250623monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-s-efti-with-radiotherapy-keytruda-pembrolizumab-meets-primary-endpoint-in-phase-ii-immp-20250526monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-s-efti-with-keytruda-pembrolizumab-chemotherapy-achieves-high-response-rates-in-fi-immp-20250515monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-s-efti-in-combination-with-keytruda-pembrolizumab-drives-strong-overall-survival-i-immp-20250505monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-quarterly-activities-report-appendix-4c-q3-fy25-first-patient-sa-immp-20250430monthly0.5https://www.biopharmawatch.com/news/IMMP/first-patient-dosed-in-immutep-s-tacti-004-phase-iii-trial-in-first-line-non-small-cell-lu-immp-20250325monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-limited-abn-90-009-237-889-appendix-4d-half-year-financial-report-for-the-half-yea-immp-20250227monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-quarterly-activities-report-appendix-4c-q2-fy25-marking-immutep--immp-20250203monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-initial-safety-data-from-first-in-human-phase-i-trial-evaluating-imp761--immp-20241217monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-reports-promising-new-data-in-head-and-neck-cancer-at-esmo-immuno-oncology-2024-da-immp-20241212monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-initiation-of-tacti-004-phase-iii-trial-in-first-line-non-small-cell-lun-immp-20241210monthly0.5https://www.biopharmawatch.com/news/IMMP/positive-data-from-phase-ii-trial-in-soft-tissue-sarcoma-presented-at-ctos-2024-annual-mee-immp-20241115monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-s-efti-shows-excellent-survival-data-from-insight-003-trial-in-non-small-cell-lung-immp-20241114monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-quarterly-activities-report-appendix-4c-q1-fy25-positive-feedbac-immp-20241030monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-completes-patient-enrolment-in-randomised-phase-ii-of-aipac-003-trial-in-metastati-immp-20241003monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-receives-a-3-6-million-r-d-tax-incentive-from-french-government--immp-20240924monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-s-efti-in-combination-with-msd-s-keytruda-leads-to-positive-efficacy-with-favourab-immp-20240916monthly0.5https://www.biopharmawatch.com/news/IMMP/index-announcement-s-p-dow-jones-indices-announces-september-2024-quarterly-rebalance-of-t-immp-20240910monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-limited-preliminary-final-report-appendix-4e-preliminary-final-report-1-company-de-immp-20240903monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-late-breaking-abstract-in-head-neck-cancer-selected-fo-immp-20240821monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-first-participant-dosed-in-phase-i-study-of-imp761-a-f-immp-20240815monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-quarterly-activities-report-appendix-4c-q4-fy24-entered-into-thi-immp-20240801monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-successful-meeting-with-fda-on-phase-iii-design-in-non-immp-20240723monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-receives-regulatory-clearance-for-phase-i-study-of-first-in-clas-immp-20240717monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-reports-positive-results-in-first-line-head-and-neck-squamous-cell-carcinoma-patie-immp-20240712monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-details-for-oral-presentation-at-esmo-virtual-plenary-session-and-webcas-immp-20240703monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-reports-positive-topline-results-from-tacti-003-phase-iib-trial-in-first-line-head-immp-20240627monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-signs-exclusive-license-agreement-with-cardiff-university-for-ne-immp-20240625monthly0.5https://www.biopharmawatch.com/news/IMMP/not-for-distribution-or-release-to-u-s-wire-services-in-the-united-states-24-june-2024-imm-immp-20240625monthly0.5https://www.biopharmawatch.com/news/IMMP/june-2024-immutep-successfully-completes-institutional-placement-and-institutional-compone-immp-20240606monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-clinical-collaboration-with-msd-to-evaluate-efti-in-combination-with-key-immp-20240604monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-presents-data-from-safety-lead-in-phase-of-aipac-003-at-esmo-breast-2024-confirmed-immp-20240515monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-positive-initial-clinical-data-reported-from-immutep-s-efti-combined-wit-immp-20240503monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-quarterly-activities-report-appendix-4c-q3-fy24-first-clinical-d-immp-20240430monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-positive-preliminary-topline-results-from-tacti-003-phase-iib-trial-eval-immp-20240424monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-appoints-leading-research-institute-to-conduct-first-in-human-ph-immp-20240419monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-first-clinical-data-from-90mg-dosing-of-efti-data-from-the-safety-lead-i-immp-20240305monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-limited-abn-90-009-237-889-appendix-4d-half-year-financial-report-for-the-half-yea-immp-20240229monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-quarterly-activities-report-appendix-4c-q2-fy24-excellent-clinic-immp-20240130monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-receives-constructive-regulatory-feedback-on-tacti-004-registrational-trial-in-met-immp-20231221monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-receives-a-2-6-million-r-d-tax-incentive-from-french-government--immp-20231208monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-completes-enrollment-in-tacti-003-phase-iib-trial-of-efti-and-ke-immp-20231109monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-completion-of-the-safety-lead-in-and-opening-of-the-ra-immp-20231106monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-new-biomarker-data-from-tacti-002-phase-ii-in-first-li-immp-20231103monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-quarterly-activities-report-appendix-4c-q1-fy24-excellent-surviv-immp-20231101monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-25-october-2023-immutep-receives-a-1-13-million-immp-20231025monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-reports-promising-clinical-data-from-insight-003-trial-at-esmo-c-immp-20231025monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-s-efti-in-combination-with-keytruda-generates-excellent-overall--immp-20231024monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-publication-of-abstracts-at-esmo-congress-2023-new-upd-immp-20231017monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-commercial-manufacturing-of-eftilagimod-alpha-at-2000l-scale-granted-aut-immp-20230921monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-receives-positive-scientific-advice-from-european-medicines-agen-immp-20230802monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-quarterly-activities-report-appendix-4c-q4-fy23-late-stage-regis-immp-20230801monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-announcement-first-patient-dosed-in-chemotherapy-free-triple-combination-phase-ii-tria-immp-20230728monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-secures-third-united-states-patent-for-eftilagimod-alpha-in-comb-immp-20230628monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-granted-united-states-patent-for-imp761-a-first-in-class-agonist-immp-20230621monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-reports-final-positive-data-in-2nd-line-head-and-neck-squamous-c-immp-20230606monthly0.5https://www.biopharmawatch.com/news/IMMP/june-2023-immutep-successfully-completes-institutional-placement-and-institutional-compone-immp-20230605monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-selects-charles-river-laboratories-for-imp761-s-glp-toxicology-s-immp-20230531monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-publication-of-abstracts-for-asco-2023-annual-meeting--immp-20230526monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-doses-first-patient-in-aipac-003-phase-ii-iii-trial-for-metastat-immp-20230525monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-promising-new-clinical-data-from-triple-combination-th-immp-20230525monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-s-efti-in-combination-with-pembrolizumab-achieves-excellent-init-immp-20230517monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-receives-positive-feedback-from-fda-on-late-stage-clinical-devel-immp-20230516monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-receives-approval-to-initiate-insight-005-trial-evaluating-eftil-immp-20230502monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-quarterly-activities-report-appendix-4c-q3-fy23-initiation-of-in-immp-20230428monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-initiation-of-investigator-initiated-phase-ii-trial-in-immp-20230418monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-changes-to-the-board-sydney-australia-11-april-2023-im-immp-20230411monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-positive-final-data-in-2-nd-line-metastatic-nsclc-pati-immp-20230403monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-expansion-of-triple-combination-therapy-in-1-st-line-n-immp-20230331monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-initiation-of-phase-ii-iii-trial-for-eftilagimod-alpha-immp-20230314monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-limited-abn-90-009-237-889-appendix-4d-half-year-financial-report-for-the-half-yea-immp-20230227monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-reaches-enrolment-target-for-insight-003-trial-in-1-st-line-nscl-immp-20230206monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-quarterly-activities-report-appendix-4c-q2-fy23-second-us-fda-fa-immp-20230131monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-achieves-50-enrollment-milestone-in-randomised-phase-iib-tacti-0-immp-20230104monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-successful-meeting-with-the-fda-on-eftilagimod-alpha-p-immp-20230104monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-successfully-achieves-commercial-scale-in-manufacturing-of-eftil-immp-20221208monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-gmp-manufacturing-process-developed-for-imp761-a-first-immp-20221207monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-enters-into-second-clinical-trial-collaboration-agreement-with-merck-kgaa-darmstad-immp-20221129monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-14-november-2022-immutep-receives-australian-r--immp-20221115monthly0.5https://www.biopharmawatch.com/news/IMMP/the-purpose-of-the-presentation-is-to-provide-an-update-of-the-business-of-immutep-limited-immp-20221114monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-compelling-clinical-results-from-phase-ii-trial-utiliz-immp-20221114monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-promising-initial-clinical-data-from-insight-003-at-si-immp-20221114monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-granted-new-patents-in-japan-and-south-korea-for-first-in-class--immp-20221109monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-abstract-highlighting-eftilagimod-alpha-selected-for-s-immp-20221104monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-late-breaking-abstract-accepted-for-oral-presentation-on-first-i-immp-20221104monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-independent-data-monitoring-committee-positive-recomme-immp-20221028monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-quarterly-activities-report-appendix-4c-clinical-development-str-immp-20221026monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-abstracts-accepted-for-presentation-at-the-society-for-immp-20221006monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-receives-fda-fast-track-designation-for-lag-3-therapeutic-eftila-immp-20221005monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-receives-a-2-7-million-r-d-tax-incentive-from-french-government--immp-20220923monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-clinical-development-update-for-its-first-in-class-lag-3-antigen-immp-20220915monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-appoints-lag-3-pioneer-fr-d-ric-triebel-to-board-sydney-australi-immp-20220914monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-announcement-immutep-announces-investigator-initiated-phase-ii-trial-evaluating--immp-20220907monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-limited-preliminary-final-report-appendix-4e-preliminary-final-report-1-company-de-immp-20220901monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-granted-japanese-patent-for-eftilagimod-alpha-a-soluble-lag-3-pr-immp-20220831monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-reports-new-positive-interim-data-from-its-phase-ii-study-of-lag-immp-20220802monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-quarterly-activities-report-appendix-4c-phase-ii-tacti-002-trial-immp-20220729monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-granted-japanese-patent-for-imp761-a-first-in-class-immunosuppre-immp-20220707monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-to-announce-new-tacti-002-data-at-the-2022-world-conference-on-l-immp-20220628monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-reports-positive-overall-response-rate-in-its-phase-ii-clinical--immp-20220607monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-publication-of-tacti-002-and-tacti-003-abstracts-at-as-immp-20220531monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-appoints-leading-oncologists-to-its-clinical-advisory-board-sydn-immp-20220518monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-presents-new-and-significant-data-from-the-aipac-study-statistic-immp-20220505monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-quarterly-activities-report-appendix-4c-new-interim-tacti-002-da-immp-20220502monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-to-announce-new-tacti-002-data-in-an-oral-presentation-at-the-as-immp-20220428monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-s-efti-in-combination-with-msd-s-pembrolizumab-shows-encouraging-immp-20220331monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-publication-of-tacti-002-abstract-at-esmo-s-european-l-immp-20220325monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-second-japanese-patent-grant-for-lag-3-antagonist-anti-immp-20220321monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-receives-constructive-feedback-from-us-fda-on-its-clinical-devel-immp-20220310monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-granted-australian-patent-for-eftilagimod-alpha-a-soluble-lag-3--immp-20220224monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-limited-abn-90-009-237-889-appendix-4d-half-year-financial-report-for-the-half-yea-immp-20220224monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-quarterly-activities-report-appendix-4c-final-overall-survival-d-immp-20220125monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-advances-imp761-manufacturing-sydney-australia-16-december-2021--immp-20211216monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-reports-good-safety-from-first-five-patients-in-triple-combinati-immp-20211203monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-successfully-completes-recruitment-for-phase-ii-tacti-002-study--immp-20211122monthly0.5https://www.biopharmawatch.com/news/IMMP/sitc-2021-results-management-update-global-webcast-date-time-8-00-am-aedt-sydney-wednesday-immp-20211118monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-publishes-aipac-tacti-002-and-tacti-003-trial-posters-at-sitc-wi-immp-20211115monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-publication-of-aipac-tacti-002-and-tacti-003-abstracts-immp-20211112monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-granted-chinese-patent-for-eftilagimod-alpha-a-soluble-lag-3-pro-immp-20211103monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-receives-positive-ema-scientific-advice-for-further-clinical-dev-immp-20211029monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-quarterly-activities-report-appendix-4c-received-competent-autho-immp-20211028monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-receives-a-3-4-million-r-d-tax-incentive-from-french-government--immp-20210929monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-completes-recruitment-of-2-nd-line-pd-1-pd-l1-refractory-nsclc-p-immp-20210902monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-limited-preliminary-final-report-appendix-4e-preliminary-final-report-1-company-de-immp-20210901monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-s-chinese-partner-eoc-pharma-expands-efti-trial-pipeline-sydney--immp-20210831monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-chinese-patent-grant-for-lag-3-antagonist-antibody-lag-immp-20210827monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-reports-dosing-of-first-patient-for-triple-combination-efti-anti-immp-20210805monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-completes-tranche-2-of-its-previously-announced-placement-sydney-australia-immp-20210730monthly0.5https://www.biopharmawatch.com/news/IMMP/not-for-release-to-us-wire-services-or-distribution-in-the-united-states-asx-media-release-immp-20210721monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-quarterly-activities-report-appendix-4c-immutep-entered-late-sta-immp-20210714monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-receives-fda-and-irb-approval-in-the-us-for-phase-iib-tacti-003--immp-20210707monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-to-evaluate-efti-in-triple-combination-therapy-phase-i-study-wit-immp-20210622monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-reveals-a-new-anti-lag-3-research-program-sydney-australia-8-jun-immp-20210609monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-reports-positive-data-from-its-tacti-002-phase-ii-study-of-lag-3-immp-20210607monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-reports-positive-final-data-from-the-insight-004-phase-i-study-o-immp-20210607monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-secures-second-european-patent-for-eftilagimod-alpha-a-soluble-l-immp-20210603monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-enters-into-a-new-collaboration-with-merck-kgaa-darmstadt-german-immp-20210602monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-granted-chinese-patent-for-eftilagimod-alpha-in-chemo-immunother-immp-20210527monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-publication-of-tacti-002-and-insight-004-abstracts-for-immp-20210521monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-operational-update-aipac-reaches-72-of-events-and-tacti-002-recr-immp-20210510monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-to-announce-new-tacti-002-and-insight-004-data-in-poster-present-immp-20210430monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-quarterly-activities-report-appendix-4c-highlights-safely-dosed--immp-20210331monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-16-april-2021-immutep-receives-a-1-155-055-r-d--immp-20210419monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-achieves-fast-track-designation-from-us-fda-for-efti-a-soluble-l-immp-20210409monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-european-patent-grant-for-lag525-antibody-in-combinati-immp-20210408monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-enters-second-collaboration-with-msd-for-a-new-randomised-phase--immp-20210317monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-secures-second-united-states-patent-grant-for-eftilagimod-alpha--immp-20210310monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-expands-part-b-of-tacti-002-study-follows-positive-efficacy-and--immp-20210305monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-limited-abn-90-009-237-889-appendix-4d-half-year-financial-report-for-the-half-yea-immp-20210224monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-advancement-of-phase-ii-trial-for-eftilagimod-alpha-in-immp-20210128monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-quarterly-activities-report-appendix-4c-highlights-encouraging-e-immp-20210125monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase--immp-20210108monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-secures-united-states-patent-for-eftilagimod-alpha-in-combinatio-immp-20201231monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-upscales-efti-manufacturing-sydney-australia-immp-20201216monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-operational-update-efti-clinical-trial-status-updates-excellent--immp-20201215monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-reports-statistically-significant-survival-benefit-for-key-patie-immp-20201211monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-s-chinese-partner-eoc-pharma-to-start-phase-ii-metastatic-breast-immp-20201211monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-completes-a-a-29-6-million-placement-to-accelerate-and-broaden-its-clinical-develo-immp-20201119monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-expansion-of-tacti-002-collaboration-trial-additional--immp-20201120monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-s-phase-ii-tacti-002-study-reports-encouraging-data-at-sitc-over-immp-20201112monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-australian-patent-grant-for-imp701-antibody-sydney-aus-immp-20201110monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-announcement-immutep-s-tacti-002-data-to-be-presented-at-society-for-immunotherapy-of--immp-20201104monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-to-collaborate-with-labcorp-to-develop-oncology-services-and-pro-immp-20201103monthly0.5https://www.biopharmawatch.com/news/IMMP/the-purpose-of-the-presentation-is-to-provide-an-update-of-the-business-of-immutep-limited-immp-20201028monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-announcement-immutep-announces-the-start-of-an-investigator-initiated-phase-ii-s-immp-20201026monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-quarterly-activities-report-appendix-4c-encouraging-clinical-res-immp-20201023monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-granted-european-patent-for-imp761-sydney-australia-21-october-2-immp-20201022monthly0.5https://www.biopharmawatch.com/news/IMMP/this-appendix-is-not-available-as-an-online-form-please-fill-in-and-submit-as-a-pdf-announ-immp-20201007monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-reports-improving-results-from-insight-004-trial-41-7-of-patient-immp-20200921monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-and-monash-university-receive-grant-funding-for-lag-3-project-sy-immp-20200901monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-limited-preliminary-final-report-appendix-4e-preliminary-final-report-1-company-de-immp-20200827monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-announcement-immutep-completes-recruitment-for-stage-1-of-part-b-in-tacti-002-study-23-immp-20200818monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-granted-united-states-patent-for-eftilagimod-alpha-in-chemo-immu-immp-20200812monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-announcement-immutep-quarterly-activities-report-appendix-4c-very-encouraging-data-for-immp-20200723monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-united-states-patent-grant-for-imp701-antibody-sydney--immp-20200716monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-announcement-immutep-completes-recruitment-for-part-a-of-phase-ii-tacti-002-study-comp-immp-20200629monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-22-june-2020-immutep-receives-a-1-437-826-r-d-t-immp-20200623monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-improving-data-from-the-phase-ii-tacti-002-study-first-immp-20200602monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-receives-a-3-6-million-r-d-tax-incentive-from-french-government--immp-20200601monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-global-webcast-to-present-new-data-from-2020-asco-annual-meeting-immp-20200528monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-granted-japanese-patent-for-eftilagimod-alpha-in-chemo-immunothe-immp-20200508monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-announcement-immutep-announces-first-insight-004-data-and-new-tacti-002-data-to--immp-20200430monthly0.5https://www.biopharmawatch.com/news/IMMP/not-for-release-to-us-wire-services-or-distribution-in-the-united-states-asx-media-release-immp-20200430monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-announcement-immutep-reports-positive-phase-ii-tacti-002-data-increasing-benefit-immp-20200428monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-enrollment-completed-for-the-insight-004-study-sydney-australia-immp-20200422monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-announcement-immutep-quarterly-activities-report-appendix-4c-highly-encouraging--immp-20200420monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-limited-level-12-95-pitt-street-sydney-nsw-2000-abn-90-009-237-889-asx-media-annou-immp-20200416monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-announcement-immutep-tacti-002-data-presentation-at-the-aacr-virtual-annual-meet-immp-20200414monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-announcement-immutep-s-partner-eoc-pharma-continues-to-advance-efti-in-breast-ca-immp-20200408monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-aipac-phase-iib-clinical-results-update-global-webcast-slides-sydney-australia-immp-20200326monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-announcement-immutep-reports-supportive-efficacy-data-from-the-phase-iib-aipac-s-immp-20200325monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-announcement-immutep-s-partner-eoc-pharma-reports-completion-of-recruitment-of-p-immp-20200320monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-immp-20200317monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-announcement-immutep-receives-second-ind-approval-for-efti-from-us-fda-enables-i-immp-20200309monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-limited-abn-90-009-237-889-appendix-4d-interim-financial-report-for-the-half-year--immp-20200224monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-announcement-immutep-reports-positive-tacti-002-data-encouraging-overall-respons-immp-20200221monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-to-present-tacti-002-interim-data-at-german-cancer-congress-sydn-immp-20200205monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-4c-quarterly-report-for-entities-subject-to-listing-rule-4-7b-rule-4-7b-appendix--immp-20200130monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-announcement-immutep-corporate-presentation-sydney-australia-immp-20200110monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-announcement-immutep-expands-part-c-of-tacti-002-due-to-positive-data-recruitment-comp-immp-20200109monthly0.5https://www.biopharmawatch.com/news/IMMP/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-immp-20200106monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-insight-004-clinical-trial-update-recruitment-commenced-for-second-cohor-immp-20191219monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-immp-20191210monthly0.5https://www.biopharmawatch.com/news/IMMP/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-immp-20191204monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-european-patent-grant-for-lag525-antibody-sydney-austr-immp-20191115monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-presents-positive-interim-data-from-phase-ii-tacti-002-trial-at--immp-20191108monthly0.5https://www.biopharmawatch.com/news/IMMP/chairman-s-address-2019-annual-general-meeting-dr-russell-howard-1-november-2019-ladies-an-immp-20191104monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-operational-update-tacti-002-patient-recruitment-update-six-patients-now-immp-20191028monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-4c-quarterly-report-for-entities-subject-to-listing-rule-4-7b-rule-4-7b-appendix--immp-20191023monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-immutep-reports-positive-final-efficacy-data-fr-immp-20191015monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-immutep-announces-data-presentations-at-upcomin-immp-20191010monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-immp-20191009monthly0.5https://www.biopharmawatch.com/news/IMMP/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-immp-20191004monthly0.5https://www.biopharmawatch.com/news/IMMP/rules-4-7-3-and-4-10-3-1-appendix-4g-key-to-disclosures-corporate-governance-council-princ-immp-20191001monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-expansion-of-part-a-of-tacti-002-phase-ii-clinical-tri-immp-20190926monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-immutep-to-receive-4m-milestone-payment-from-gs-immp-20190924monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-announces-japanese-patent-grant-for-lag525-antibody-sydney-austr-immp-20190918monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-immutep-granted-european-patent-for-eftilagimod-immp-20190822monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-limited-preliminary-final-report-appendix-4e-preliminary-final-report-1-company-de-immp-20190821monthly0.5https://www.biopharmawatch.com/news/IMMP/not-for-release-to-us-wire-services-or-distribution-in-the-united-states-asx-media-release-immp-20190814monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-immp-20190814monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-release-immutep-completes-a-6m-immp-20190806monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-4c-quarterly-report-for-entities-subject-to-listing-rule-4-7b-rule-4-7b-appendix--immp-20190730monthly0.5https://www.biopharmawatch.com/news/IMMP/market-announcement-5-july-2019-immutep-limited-asx-imm-trading-halt-description-the-secur-immp-20190708monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-completes-patient-enrolment-of-the-aipac-phase-iib-clinical-tria-immp-20190625monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-immutep-announces-australian-patent-granted-for-immp-20190621monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-completes-recruitment-of-initial-cohort-in-1-st-line-nsclc-patie-immp-20190613monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-insight-first-patient-dosed-in-the-4-th-arm-called-insight-004-highlight-immp-20190606monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-presentation-at-asco-2019-sydney-australia-3-june-2019-immutep-l-immp-20190604monthly0.5https://www.biopharmawatch.com/news/IMMP/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-immp-20190605monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-immutep-announces-european-patent-grant-for-eft-immp-20190523monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-immutep-announces-data-from-ongoing-tacti-mel-p-immp-20190517monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-immutep-announces-upcoming-industry-conference--immp-20190513monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-operational-update-highlights-recruitment-for-the-aipac-study-expected-t-immp-20190430monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-4c-quarterly-report-for-entities-subject-to-listing-rule-4-7b-rule-4-7b-appendix--immp-20190426monthly0.5https://www.biopharmawatch.com/news/IMMP/the-purpose-of-the-presentation-is-to-provide-an-update-of-the-business-of-immutep-limited-immp-20190328monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-immutep-to-host-eftilagimod-alpha-clinical-deve-immp-20190327monthly0.5https://www.biopharmawatch.com/news/IMMP/the-purpose-of-the-presentation-is-to-provide-an-update-of-the-business-of-immutep-limited-immp-20190326monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-immutep-announces-united-states-patent-grant-fo-immp-20190322monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-immutep-to-present-imp761-preclinical-results-i-immp-20190319monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-immutep-presents-positive-imp761-preclinical-re-immp-20190311monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-immutep-announces-data-from-ongoing-tacti-mel-p-immp-20190307monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-doses-first-patient-in-tacti-002-phase-ii-trial-the-first-patien-immp-20190306monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-immutep-to-present-at-oppenheimer-s-29th-annual-immp-20190305monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-limited-abn-90-009-237-889-appendix-4d-interim-financial-report-for-the-half-year--immp-20190228monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-immutep-to-present-at-upcoming-industry-confere-immp-20190227monthly0.5https://www.biopharmawatch.com/news/IMMP/investor-update-january-2019-in-this-issue-message-from-the-ceo-industry-conferences-and-p-immp-20190129monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-immutep-enters-into-clinical-trial-collaboration-service-and-supply-agre-immp-20190108monthly0.5https://www.biopharmawatch.com/news/IMMP/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-immp-20190103monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-limited-abn-90-009-237-889-prospectus-for-the-issue-by-the-company-of-2-080-000-wa-immp-20181221monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-21-december-2018-disclosure-under-listing-rules-immp-20181221monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-immutep-announces-us-5-2-million-financing-led--immp-20181219monthly0.5https://www.biopharmawatch.com/news/IMMP/securities-purchase-agreement-this-securities-purchase-agreement-this-agreement-dated-as-o-immp-20181218monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-immp-20181129monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-immutep-granted-european-patent-for-eftilagimod-immp-20181128monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-new-data-from-ongoing-tacti-mel-study-in-unrese-immp-20181127monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-immp-20181127monthly0.5https://www.biopharmawatch.com/news/IMMP/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-immp-20181123monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-announcement-16-november-2018-results-of-annual-general-meeting-the-results-of-immutep-immp-20181119monthly0.5https://www.biopharmawatch.com/news/IMMP/the-purpose-of-the-presentation-is-to-provide-an-update-of-the-business-of-immutep-limited-immp-20181105monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-immutep-presents-positive-new-data-from-ongoing-immp-20181112monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-operational-update-highlights-site-selection-pr-immp-20181101monthly0.5https://www.biopharmawatch.com/news/IMMP/the-purpose-of-the-presentation-is-to-provide-an-update-of-the-business-of-immutep-limited-immp-20181031monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-4c-quarterly-report-for-entities-subject-to-listing-rule-4-7b-rule-4-7b-appendix--immp-20181026monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-immutep-announces-data-presentations-at-upcomin-immp-20181024monthly0.5https://www.biopharmawatch.com/news/IMMP/letter-from-the-chairman-dear-fellow-shareholder-i-invite-you-to-join-our-board-and-manage-immp-20181017monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-lag-3-immunotherapy-i-annual-report-2018-reporting-period-year-ended-30-june-2018--immp-20181017monthly0.5https://www.biopharmawatch.com/news/IMMP/rules-4-7-3-and-4-10-3-1-appendix-4g-key-to-disclosures-corporate-governance-council-princ-immp-20181017monthly0.5https://www.biopharmawatch.com/news/IMMP/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-immp-20181005monthly0.5https://www.biopharmawatch.com/news/IMMP/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-cleansing-notice-appendix-3b-new-issue-announcem-immp-20181004monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-immutep-announces-presentations-at-society-for--immp-20181002monthly0.5https://www.biopharmawatch.com/news/IMMP/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-immp-20181001monthly0.5https://www.biopharmawatch.com/news/IMMP/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-immp-20180928monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-immutep-to-present-at-ladenburg-thalmann-2018-h-immp-20180926monthly0.5https://www.biopharmawatch.com/news/IMMP/th-2-the-purpose-of-the-presentation-is-to-provide-an-update-of-the-business-of-immutep-li-immp-20180910monthly0.5https://www.biopharmawatch.com/news/IMMP/code-asx-imm-nasdaq-immp-3-september-2018-progress-towards-clinical-development-of-imp761--immp-20180905monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-immutep-receives-a-1-9-million-research-and-dev-immp-20180821monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-immutep-to-present-at-the-biocentury-25th-annua-immp-20180816monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-tacti-mel-patient-recruitment-complete-and-oper-immp-20180807monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-30-july-2018-immutep-s-lag-3-immunostimulant-pr-immp-20180801monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-4c-quarterly-report-for-entities-subject-to-listing-rule-4-7b-rule-4-7b-appendix--immp-20180731monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-2-july-2018-immutep-submits-investigational-new-immp-20180703monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-19-june-2018-mid-point-of-patient-enrolment-rea-immp-20180620monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-4-june-2018-immutep-presentations-at-asco-sydne-immp-20180605monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-positive-new-data-from-ongoing-tacti-mel-study--immp-20180530monthly0.5https://www.biopharmawatch.com/news/IMMP/two-active-immunotherapies-in-melanoma-tacti-mel-results-of-a-phase-i-trial-with-metastati-immp-20180525monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-immutep-to-present-interim-results-from-tacti-m-immp-20180517monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-4-may-2018-immutep-to-present-at-2018-asco-annu-immp-20180507monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-4c-quarterly-report-for-entities-subject-to-listing-rule-4-7b-rule-4-7b-appendix--immp-20180426monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-13-april-2018-immutep-completes-6-31-million-sh-immp-20180413monthly0.5https://www.biopharmawatch.com/news/IMMP/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-immp-20180413monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-3-april-2018-operational-update-first-two-patie-immp-20180404monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-22-march-2018-immutep-commences-patient-dosing--immp-20180323monthly0.5https://www.biopharmawatch.com/news/IMMP/form-603-corporations-act-2001-section-671b-notice-of-initial-substantial-holder-to-compan-immp-20180320monthly0.5https://www.biopharmawatch.com/news/IMMP/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-immp-20180316monthly0.5https://www.biopharmawatch.com/news/IMMP/march-2018-dear-fellow-shareholder-it-is-with-pleasure-that-i-write-to-invite-certain-elig-immp-20180316monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-12-march-2018-immutep-enters-into-clinical-tria-immp-20180313monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-6-march-2018-immutep-announces-united-states-pa-immp-20180307monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-5-march-2018-immutep-receives-a-686-704-r-d-tax-immp-20180306monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-limited-abn-90-009-237-889-appendix-4d-interim-financial-report-for-the-half-year--immp-20180223monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-9-february-2018-outcome-from-dsmb-safety-review-immp-20180209monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-1-february-2018-immutep-limited-announces-miles-immp-20180202monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-4c-quarterly-report-for-entities-subject-to-listing-rule-4-7b-rule-4-7b-appendix--immp-20180123monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-immp-20171226monthly0.5https://www.biopharmawatch.com/news/IMMP/investor-updates-december-2017-in-this-issue-message-from-the-chair-message-from-the-ceo-s-immp-20171221monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-imm-nasdaq-immp-12-december-2017-operational-update-sydney-aust-immp-20171213monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-4-december-2017-release-of-securities-from-escrow-appendix-3b-cleansing--immp-20171205monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-28-november-2017-prima-biomed-becomes-immutep-sydney-28-november-2017-we-immp-20171201monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-3z-final-director-s-interest-notice-rule-3-19a-3-appendix-3z-final-director-s-int-immp-20171124monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-22-november-2017-prima-secures-european-patent--immp-20171122monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-20-november-2017-prima-biomed-changes-its-name--immp-20171121monthly0.5https://www.biopharmawatch.com/news/IMMP/chairman-s-address-2017-annual-general-meeting-lucy-turnbull-ao-17-november-2017-dear-fell-immp-20171120monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-announcement-17-november-2017-results-of-annual-general-meeting-the-results-of-prima-b-immp-20171120monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-15-november-2017-eftilagimod-alpha-lag-3ig-or-i-immp-20171116monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-9-november-2017-new-eftilagimod-alpha-lag-3ig-o-immp-20171109monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-1-november-2017-dr-fr-eacute-d-eacute-ric-trieb-immp-20171031monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-20-october-2017-dr-fr-eacute-d-eacute-ric-trieb-immp-20171020monthly0.5https://www.biopharmawatch.com/news/IMMP/a-message-from-the-chairman-dear-fellow-shareholder-i-invite-you-to-join-our-board-and-man-immp-20171018monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-17-october-2017-imp321-new-data-accepted-for-pr-immp-20171017monthly0.5https://www.biopharmawatch.com/news/IMMP/investor-update-by-edition-21-october-2017-message-from-the-ceo-business-overview-lag-3-co-immp-20171012monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-4c-quarterly-report-for-entities-subject-to-listing-rule-4-7b-rule-4-7b-appendix--immp-20171012monthly0.5https://www.biopharmawatch.com/news/IMMP/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-immp-20171005monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-8-september-2017-prima-secures-japanese-patent--immp-20170911monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-5-september-2017-prima-secures-japanese-patent--immp-20170906monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-30-august-2017-prima-biomed-and-monash-universi-immp-20170831monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-ltd-preliminary-final-report-appendix-4e-preliminary-final-report-1-company-d-immp-20170830monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-21-august-2017-prima-biomed-appoints-non-execut-immp-20170822monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-16-august-2017-prima-biomed-receives-a-1-3-mill-immp-20170817monthly0.5https://www.biopharmawatch.com/news/IMMP/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-immp-20170808monthly0.5https://www.biopharmawatch.com/news/IMMP/investor-update-by-edition-20-august-2017-message-from-the-ceo-dear-fellow-shareholders-as-immp-20170804monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-18-july-2017-financial-update-2h17-sydney-austr-immp-20170719monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-4c-quarterly-report-for-entities-subject-to-listing-rule-4-7b-rule-4-7b-appendix--immp-20170718monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-17-july-2017-prima-biomed-announces-second-mile-immp-20170718monthly0.5https://www.biopharmawatch.com/news/IMMP/code-asx-prr-nasdaq-pbmd-10-july-2017-prima-biomed-announces-approval-for-the-initiation-o-immp-20170711monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-release-code-asx-prr-nasdaq-pbmd-6-july-2017-disclosure-under-listing-rules-3-10-5a-an-immp-20170707monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-release-code-asx-prr-nasdaq-pbmd-4-july-2017-appendix-3b-us-5m-capital-raising-sydney--immp-20170707monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-29-june-2017-prima-biomed-announces-pricing-of--immp-20170629monthly0.5https://www.biopharmawatch.com/news/IMMP/interim-financial-report-for-the-nine-and-three-months-periods-ended-31-march-2017-previou-immp-20170629monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-26-june-2017-operational-update-sydney-australi-immp-20170627monthly0.5https://www.biopharmawatch.com/news/IMMP/june-2017-asx-market-announcements-australia-securities-exchange-expiry-of-options-waiver--immp-20170609monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-5-june-2017-lag-3ig-imp321-demonstrates-positiv-immp-20170605monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-1-june-2017-prima-biomed-announces-formation-of-immp-20170602monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-18-may-2017-data-from-prima-biomed-aipac-clinic-immp-20170519monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-19-april-2017-prima-biomed-receives-approval-fo-immp-20170419monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-4c-quarterly-report-for-entities-subject-to-listing-rule-4-7b-rule-4-7b-appendix--immp-20170413monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-12-april-2017-prima-biomed-receives-a-492-144-t-immp-20170413monthly0.5https://www.biopharmawatch.com/news/IMMP/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-immp-20170317monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-15-march-2017-prima-biomed-completes-recruitmen-immp-20170315monthly0.5https://www.biopharmawatch.com/news/IMMP/investor-update-by-prima-biomed-edition19-march-2017-marc-voigt-ceo-lucy-turnbull-ao-messa-immp-20170308monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-1-march-2017-usa-patent-grants-for-imp321-in-ca-immp-20170301monthly0.5https://www.biopharmawatch.com/news/IMMP/abn-90-009-237-889-appendix-4d-interim-financial-report-for-the-half-year-ended-31-decembe-immp-20170301monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-24-february-2017-first-half-2017-operational-up-immp-20170224monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-13-february-2017-prima-biomed-receives-a-860-00-immp-20170215monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-23-january-2017-prima-biomed-to-present-at-2nd--immp-20170124monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-20-january-2017-prima-biomed-commences-randomis-immp-20161230monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-18-january-2017-prima-biomed-to-maintain-nasdaq-immp-20170118monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-12-january-2017-prima-biomed-commences-recruitm-immp-20170112monthly0.5https://www.biopharmawatch.com/news/IMMP/nasdaq-pbmd-asx-prr-january-2017-corporate-presentation-notice-forward-looking-statements--immp-20170109monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-4c-quarterly-report-for-entities-subject-to-listing-rule-4-7b-rule-4-7b-appendix--immp-20170106monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-5-january-2017-prima-biomed-enters-new-material-immp-20170105monthly0.5https://www.biopharmawatch.com/news/IMMP/code-asx-prr-nasdaq-pbmd-3-january-2017-prima-announces-new-product-candidate-imp761-a-lag-immp-20170104monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-29-december-2016-prima-biomed-announces-first-c-immp-20161229monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-22-december-2016-prima-biomed-announces-data-fr-immp-20161222monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-20-december-2016-prima-biomed-receives-uk-appro-immp-20161221monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-19-december-2016-prima-biomed-announces-adr-rat-immp-20161220monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-3b-new-issue-announcement-rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-ann-immp-20161207monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-3b-new-issue-announcement-rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-ann-immp-20161201monthly0.5https://www.biopharmawatch.com/news/IMMP/chairman-s-address-2016-annual-general-meeting-lucy-turnbull-ao-25-november-2016-dear-fell-immp-20161128monthly0.5https://www.biopharmawatch.com/news/IMMP/code-asx-prr-nasdaq-pbmd-23-november-2016-wuxi-biologics-and-prima-sign-mou-and-announce-s-immp-20161123monthly0.5https://www.biopharmawatch.com/news/IMMP/sitc-2016-national-harbor-md-november-9-13-2016-an-apc-activator-imp321-or-lag-3ig-combine-immp-20161114monthly0.5https://www.biopharmawatch.com/news/IMMP/investor-update-by-prima-biomed-edition-18-november-2016-marc-voigt-ceo-message-from-the-c-immp-20161114monthly0.5https://www.biopharmawatch.com/news/IMMP/acn-009-237-889-n-otice-of-2016-a-nnual-g-eneral-m-eeting-including-explanatory-notes-and--immp-20161027monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-4c-quarterly-report-for-entities-subject-to-listing-rule-4-7b-rule-4-7b-appendix--immp-20161021monthly0.5https://www.biopharmawatch.com/news/IMMP/code-asx-prr-nasdaq-pbmd-13-october-2016-prima-to-present-at-2016-society-for-immunotherap-immp-20161013monthly0.5https://www.biopharmawatch.com/news/IMMP/code-asx-prr-nasdaq-pbmd-6-october-2016-prima-abstracts-accepted-for-poster-presentation-a-immp-20161007monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-4-october-2016-appendix-3b-cleansing-notice-syd-immp-20161004monthly0.5https://www.biopharmawatch.com/news/IMMP/annual-report-2016-reporting-period-year-ended-30-june-2016-previous-corresponding-period--immp-20160929monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-2-september-2016-appendix-3b-cleansing-notice-s-immp-20160906monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-ltd-preliminary-final-report-appendix-4e-preliminary-final-report-1-company-d-immp-20160901monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-25-august-2016-european-patent-grants-for-imp73-immp-20160825monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-18-august-2016-operational-update-sydney-austra-immp-20160818monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-nasdaq-pbmd-asx-prr-10-august-2016-prima-biomed-receives-nasdaq-not-immp-20160811monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-4c-quarterly-report-for-entities-admitted-on-the-basis-of-commitments-appendix-4c-immp-20160728monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-12-july-2016-prima-biomed-collaborates-in-inves-immp-20160713monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-22-june-2016-prima-biomed-announces-first-safet-immp-20160623monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-7-june-2016-prima-biomed-to-maintain-nasdaq-lis-immp-20160607monthly0.5https://www.biopharmawatch.com/news/IMMP/abn-90-009-237-889-interim-financial-report-for-the-half-year-ended-31-december-2015-previ-immp-20160527monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-12-may-2016-prima-biomed-enters-into-sale-and-l-immp-20160513monthly0.5https://www.biopharmawatch.com/news/IMMP/message-from-the-chair-dear-fellow-shareholders-the-prima-board-and-management-recently-an-immp-20160513monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-2-may-2016-japanese-patent-grants-for-imp321-in-immp-20160503monthly0.5https://www.biopharmawatch.com/news/IMMP/april-2016-asx-compliance-pty-ltd-20-bridge-street-sydney-nsw-2000-prima-biomed-ltd-asx-pr-immp-20160422monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-4c-quarterly-report-for-entities-admitted-on-the-basis-of-commitments-appendix-4c-immp-20160411monthly0.5https://www.biopharmawatch.com/news/IMMP/march-2016-imp321-safety-and-immune-monitoring-data-published-in-clinical-cancer-research--immp-20160316monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-8-march-2016-appointment-of-joint-company-secre-immp-20160308monthly0.5https://www.biopharmawatch.com/news/IMMP/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-immp-20160307monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-med-ia-relea-s-e-code-nasdaq-pbmd-asx-prr-4-march-2016-prima-biomed-receives-nasdaq-no-immp-20160304monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-and-wuxi-biologics-announce-first-dose-of-chinese-manufactured-biologic-in-eu-immp-20160302monthly0.5https://www.biopharmawatch.com/news/IMMP/abn-90-009-237-889-appendix-4d-interim-financial-report-for-the-half-year-ended-31-decembe-immp-20160301monthly0.5https://www.biopharmawatch.com/news/IMMP/lucy-turnbull-ao-message-from-the-chair-dear-shareholders-welcome-to-our-first-newsletter--immp-20160211monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-28-january-2016-us-patent-grants-for-imp731-ant-immp-20160201monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-27-january-2016-prima-biomed-initiates-phase-i--immp-20160128monthly0.5https://www.biopharmawatch.com/news/IMMP/january-2016-asx-compliance-pty-ltd-20-bridge-street-sydney-nsw-2000-dear-stephanie-prima--immp-20160111monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-4c-quarterly-reports-for-entities-admitted-on-the-basis-of-commitments-appendix-4-immp-20160107monthly0.5https://www.biopharmawatch.com/news/IMMP/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-immp-20151229monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-22-december-2015-prima-biomed-initiates-phase-i-immp-20151222monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-11-december-2015-prima-biomed-progresses-japane-immp-20151211monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-26-november-2015-prima-biomed-receives-tax-reba-immp-20151130monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-ltd-2015-annual-general-meeting-address-by-russell-howard-non-executive-direc-immp-20151125monthly0.5https://www.biopharmawatch.com/news/IMMP/lucy-turnbull-ao-message-from-the-chair-dear-fellow-shareholders-as-this-constitutes-the-f-immp-20151124monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-18-november-2015-prima-biomed-unveils-phase-i-c-immp-20151118monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-5-november-2015-prima-biomed-will-present-at-th-immp-20151105monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-30-october-2015-prima-biomed-raises-a-2-0-milli-immp-20151102monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-27-october-2015-prima-biomed-gains-belgian-regu-immp-20151027monthly0.5https://www.biopharmawatch.com/news/IMMP/acn-009-237-889-n-otice-of-2015-a-nnual-g-eneral-m-eeting-including-explanatory-notes-and--immp-20151023monthly0.5https://www.biopharmawatch.com/news/IMMP/october-2015-change-of-address-in-accordance-with-listing-rule-3-14-prima-biomed-limited-a-immp-20151020monthly0.5https://www.biopharmawatch.com/news/IMMP/october-2015-information-required-under-listing-rule-3-10-5a-further-to-the-appendix-3b-lo-immp-20151015monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-13-october-2015-prima-biomed-raises-a-1-55m-thr-immp-20151013monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-9-october-2015-prima-biomed-receives-grant-from-immp-20151013monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-4c-quarterly-report-for-entities-admitted-on-the-basis-of-commitments-appendix-4c-immp-20151008monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-immp-20151005monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-25-september-2015-prima-biomed-to-present-at-le-immp-20150925monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-ltd-preliminary-final-report-appendix-4e-preliminary-final-report-1-company-d-immp-20150831monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-14-august-2015-prima-biomed-announces-commencem-immp-20150817monthly0.5https://www.biopharmawatch.com/news/IMMP/july-2015-the-manager-australian-stock-exchange-company-announcements-office-level-4-excha-immp-20150805monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-4-august-2015-prima-biomed-terminates-investmen-immp-20150805monthly0.5https://www.biopharmawatch.com/news/IMMP/notice-forward-looking-statements-the-purpose-of-the-presentation-is-to-provide-an-update--immp-20150805monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-31-july-2015-chairman-s-address-prima-biomed-lt-immp-20150804monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-immp-20150804monthly0.5https://www.biopharmawatch.com/news/IMMP/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-immp-20150730monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-4c-quarterly-report-for-entities-admitted-on-the-basis-of-commitments-appendix-4c-immp-20150729monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-24-july-2015-prima-biomed-raises-a-10m-through--immp-20150727monthly0.5https://www.biopharmawatch.com/news/IMMP/july-2015-ms-stephanie-so-senior-adviser-listings-compliance-sydney-asx-compliance-pty-ltd-immp-20150714monthly0.5https://www.biopharmawatch.com/news/IMMP/code-asx-prr-nasdaq-pbmd-10-july-2015-share-purchase-plan-offer-documents-prima-biomed-ltd-immp-20150713monthly0.5https://www.biopharmawatch.com/news/IMMP/message-from-the-chair-investor-update-dear-fellow-shareholders-a-lot-has-happened-for-pri-immp-20150710monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-7-july-2015-prima-biomed-announces-share-purcha-immp-20150707monthly0.5https://www.biopharmawatch.com/news/IMMP/a-message-from-the-chairman-dear-fellow-shareholders-of-prima-biomed-it-is-with-great-plea-immp-20150706monthly0.5https://www.biopharmawatch.com/news/IMMP/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-immp-20150624monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-12-june-2015-prima-biomed-to-present-at-the-201-immp-20150615monthly0.5https://www.biopharmawatch.com/news/IMMP/june-2015-company-announcements-office-australian-securities-exchange-notice-under-section-immp-20150615monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-11-june-2015-prima-biomed-receives-a-research-t-immp-20150611monthly0.5https://www.biopharmawatch.com/news/IMMP/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-immp-20150611monthly0.5https://www.biopharmawatch.com/news/IMMP/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-immp-20150608monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-4-june-2015-prima-biomed-to-maintain-nasdaq-lis-immp-20150608monthly0.5https://www.biopharmawatch.com/news/IMMP/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-immp-20150605monthly0.5https://www.biopharmawatch.com/news/IMMP/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-immp-20150602monthly0.5https://www.biopharmawatch.com/news/IMMP/form-603-corporations-act-2001-section-671b-notice-of-initial-substantial-holder-to-compan-immp-20150529monthly0.5https://www.biopharmawatch.com/news/IMMP/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-immp-20150529monthly0.5https://www.biopharmawatch.com/news/IMMP/th-may-2015-company-announcements-office-australian-securities-exchange-n-o-t-i-c-e-und-e--immp-20150528monthly0.5https://www.biopharmawatch.com/news/IMMP/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-immp-20150527monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-25-may-2015-prima-biomed-to-present-at-proactiv-immp-20150527monthly0.5https://www.biopharmawatch.com/news/IMMP/may-2015-company-announcements-office-australian-securities-exchange-notice-under-section--immp-20150520monthly0.5https://www.biopharmawatch.com/news/IMMP/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-immp-20150518monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-11-may-2015-prima-biomed-announces-japanese-col-immp-20150512monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-29-april-2015-prima-biomed-to-present-at-canary-immp-20150430monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-4c-quarterly-report-for-entities-admitted-on-the-basis-of-commitments-appendix-4c-immp-20150423monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-nasdaq-pbmd-asx-prr-introductory-corporate-presentation-27-february-2015-marc-immp-20150227monthly0.5https://www.biopharmawatch.com/news/IMMP/abn-90-009-237-889-appendix-4d-interim-financial-report-for-the-half-year-ended-31-decembe-immp-20150227monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-4c-quarterly-report-for-entities-admitted-on-the-basis-of-commitments-appendix-4c-immp-20150130monthly0.5https://www.biopharmawatch.com/news/IMMP/january-2015-company-announcements-office-australian-securities-exchange-notice-under-sect-immp-20150126monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-20-january-2015-777k-r-d-tax-incentive-refund-r-immp-20150120monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-immp-20150107monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-med-ia-relea-s-e-code-nasdaq-pbmd-asx-prr-29-december-2014-prima-biomed-receives-nasda-immp-20141223monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-22-december-2014-prima-biomed-announces-immutep-immp-20141222monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-17-december-2014-prima-biomed-completes-immutep-immp-20141217monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-15-december-2014-prima-initiates-pancreatic-cli-immp-20141215monthly0.5https://www.biopharmawatch.com/news/IMMP/december-2014-company-announcements-office-australian-securities-exchange-notice-under-sec-immp-20141211monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-5-december-2014-prima-enhances-cvac-manufacturi-immp-20141205monthly0.5https://www.biopharmawatch.com/news/IMMP/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-immp-20141201monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-14-november-2014-chairman-s-address-prima-biome-immp-20141117monthly0.5https://www.biopharmawatch.com/news/IMMP/ceo-presentation-annual-general-meeting-marc-voigt-ceo-14-november-2014-asx-prr-nasdaq-pbm-immp-20141114monthly0.5https://www.biopharmawatch.com/news/IMMP/p85-trial-evaluating-overall-survival-in-epithelial-ovarian-cancer-eoc-patients-in-second--immp-20141112monthly0.5https://www.biopharmawatch.com/news/IMMP/november-2014-company-announcements-office-australian-securities-exchange-notice-under-sec-immp-20141106monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-6-november-2014-cvac-demonstrates-overall-survi-immp-20141106monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-21-october-2014-prima-biomed-conference-call-we-immp-20141021monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-4c-quarterly-report-for-entities-admitted-on-the-basis-of-commitments-appendix-4c-immp-20141021monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-14-october-2014-prima-announces-immutep-s-imp32-immp-20141014monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-ltd-australian-cancer-treatment-company-acn-009-237-889-notice-of-2014-annual-immp-20141014monthly0.5https://www.biopharmawatch.com/news/IMMP/annual-report-2014-abn-90-009-237-889-prima-biomed-contents-03-corporate-directory-04-chai-immp-20141014monthly0.5https://www.biopharmawatch.com/news/IMMP/october-2014-company-announcements-office-australian-securities-exchange-notice-under-sect-immp-20141003monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-2-october-2014-prima-secures-us-37-4m-investmen-immp-20141003monthly0.5https://www.biopharmawatch.com/news/IMMP/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-immp-20140922monthly0.5https://www.biopharmawatch.com/news/IMMP/company-announcements-australian-stock-exchange-sydney-27-august-2014-announcement-of-resu-immp-20140828monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-19-august-2014-cvac-can-003-a-immp-20140819monthly0.5https://www.biopharmawatch.com/news/IMMP/investor-update-by-prima-biomed-edition-12-july-2014-message-from-the-ceo-ceo-marc-voigt-w-immp-20140731monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-22-july-2014-summary-of-key-employment-terms-fo-immp-20140724monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-16-july-2014-prima-receives-us-patent-grant-for-immp-20140716monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-3x-initial-director-s-interest-notice-rule-3-19a-1-appendix-3x-initial-director-s-immp-20140715monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-9-july-2014-prima-biomed-appoints-new-chief-exe-immp-20140711monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-23-june-2014-prima-biomed-s-can-002-cvac-trial--immp-20140624monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-19-june-2014-prima-biomed-to-present-at-2014-wa-immp-20140620monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-discusses-can-003-abstract-presented-at-asco-transcript-speakers-dr-heidi-gra-immp-20140605monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-2-june-2014-cvac-demonstrates-positive-trend-in-immp-20140603monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-30-may-2014-prima-biomed-to-host-conference-cal-immp-20140531monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-26-may-2014-prima-s-cvac-patent-application-rec-immp-20140527monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-15-may-2014-cvac-demonstrates-improvement-in-pr-immp-20140516monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-09-may-2014-prima-biomed-s-cvac-granted-fast-tr-immp-20140509monthly0.5https://www.biopharmawatch.com/news/IMMP/message-from-the-ceo-welcome-to-the-first-issue-of-the-prima-biomed-investor-update-for-20-immp-20140509monthly0.5https://www.biopharmawatch.com/news/IMMP/rd-quarter-results-for-fy-2014-period-ended-31-march-2014-supplemental-information-to-mana-immp-20140506monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-29-april-2014-prima-biomed-th-immp-20140429monthly0.5https://www.biopharmawatch.com/news/IMMP/draft-asx-media-release-code-asx-prr-nasdaq-pbmd-28-april-2014-prima-biomed-s-can-004-phas-immp-20140429monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-7-april-2014-prima-biomed-to-present-at-13-th-a-immp-20140409monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-28-march-2014-prima-biomed-s-cvac-data-demonstr-immp-20140328monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-25-march-2014-prima-biomed-announces-significan-immp-20140325monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-5-march-2014-1-6-million-r-d-tax-incentive-refu-immp-20140305monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-27-february-2014-prima-biomed-to-present-at-24--immp-20140227monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-21-february-2014-prima-biomed-and-neopharm-grou-immp-20140221monthly0.5https://www.biopharmawatch.com/news/IMMP/abn-90-009-237-889-appendix-4d-interim-financial-report-for-the-half-year-ended-31-decembe-immp-20140218monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-3x-initial-director-s-interest-notice-rule-3-19a-1-appendix-3x-initial-director-s-immp-20140214monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-12-february-2014-pete-a-meyers-to-join-prima-bi-immp-20140212monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-6-february-2014-prima-biomed-s-can-004-clinical-immp-20140206monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-31-january-2014-prima-biomed--immp-20140203monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-29-january-2014-prima-biomed--immp-20140130monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-9-january-2014-prima-biomed-ceo-matthew-lehman--immp-20140109monthly0.5https://www.biopharmawatch.com/news/IMMP/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-immp-20131227monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-a-leader-in-developing-immunocellular-therapeutics-for-cancer-analyst-briefin-immp-20131210monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-26-november-2013-expert-panel-immp-20131126monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-3z-final-director-s-interest-notice-see-chapter-19-for-defined-terms-11-3-2002-ap-immp-20131122monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-immp-20131121monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-20-november-2013-prima-biomed-immp-20131120monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-immp-20131119monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-15-november-2013-chairman-s-a-immp-20131115monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-11-november-2013-prima-biomed-immp-20131112monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-discusses-q1-of-fiscal-year-2014-results-and-cvac-program-update-earnings-cal-immp-20131108monthly0.5https://www.biopharmawatch.com/news/IMMP/st-quarter-results-for-fy-2014-period-ended-30-september-2013-supplemental-information-to--immp-20131107monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-06-november-2013-prima-biomed-immp-20131106monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-1-november-2013--immp-20131107monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-4c-quarterly-report-for-entities-admitted-on-the-basis-of-commitments-appendix-4c-immp-20131104monthly0.5https://www.biopharmawatch.com/news/IMMP/annual-report-2013-abn-90-009-237-889-prima-biomed-contents-03-corporate-directory-04-chai-immp-20131001monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-ltd-australian-cancer-treatment-company-acn-009-237-889-notice-of-2013-annual-immp-20131015monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-immp-20131010monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-immp-20131003monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-management-presents-cvac-tm-phase-2-trial-results-call-transcript-prima-biome-immp-20131003monthly0.5https://www.biopharmawatch.com/news/IMMP/can-003-analysis-phase-2-trial-of-cvac-for-the-treatment-of-ovarian-cancer-patients-in-fir-immp-20131002monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-18-september-2013-top-line-an-immp-20130918monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-11-september-2013-prima-biome-immp-20130911monthly0.5https://www.biopharmawatch.com/news/IMMP/company-announcements-australian-stock-exchange-sydney-30-august-2013-announcement-of-resu-immp-20130903monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-21-august-2013-prima-biomed-t-immp-20130821monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-australian-cancer-treatment-company-asx-media-release-code-asx-prr-nasdaq-pbm-immp-20130815monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-14-august-2013-prima-biomed-s-immp-20130814monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-australian-cancer-treatment-company-asx-media-release-code-asx-prr-nasdaq-pbm-immp-20130809monthly0.5https://www.biopharmawatch.com/news/IMMP/th-quarter-results-for-fy-2013-period-ended-30-june-2013-supplemental-information-to-manag-immp-20130806monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-4c-quarterly-report-for-entities-admitted-on-the-basis-of-commitments-appendix-4c-immp-20130726monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-ltd-australian-cancer-treatment-company-asx-media-release-code-asx-prr-nasdaq-immp-20130719monthly0.5https://www.biopharmawatch.com/news/IMMP/level-7-151-macquarie-street-sydney-nsw-2000-australia-11-july-2013-asx-compliance-pty-ltd-immp-20130715monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-immp-20130710monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-4-july-2013-prima-biomed-acti-immp-20130705monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-25-june-2013-prima-biomed-to--immp-20130627monthly0.5https://www.biopharmawatch.com/news/IMMP/market-release-24-june-2013-prima-biomed-limited-trading-halt-the-securities-of-prima-biom-immp-20130625monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-immp-20130620monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-19-june-2013-cvac-can-003-tri-immp-20130620monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-announcement-release-code-prr-18-june-2013-entitlement-offer-top-20-and-distribution-s-immp-20130618monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-announcement-release-code-prr-13-june-2013-prima-biomed-ltd-completion-of-entitlement--immp-20130613monthly0.5https://www.biopharmawatch.com/news/IMMP/investor-update-by-prima-biomed-edition-june-2013-10-message-from-the-ceo-exciting-times-f-immp-20130613monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-immp-20130529monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-24-may-2013-prima-biomed-ltd--immp-20130524monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-immp-20130521monthly0.5https://www.biopharmawatch.com/news/IMMP/level-7-151-macquarie-street-sydney-nsw-2000-australia-17-may-2013-asx-market-announcement-immp-20130517monthly0.5https://www.biopharmawatch.com/news/IMMP/level-7-151-macquarie-street-sydney-nsw-2000-australia-15-may-2013-asx-market-announcement-immp-20130515monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-announcement-release-code-prr-14-may-2013-entitlement-offer-letter-to-shareholders-as--immp-20130515monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-australian-cancer-treatment-company-asx-announcement-release-code-prr-13-may--immp-20130513monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-8-may-2013-russell-j-howard-t-immp-20130508monthly0.5https://www.biopharmawatch.com/news/IMMP/investor-update-by-prima-biomed-national-ovarian-cancer-day-may-8th-special-edition-may-20-immp-20130503monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-australian-cancer-treatment-company-asx-media-release-code-asx-prr-nasdaq-pbm-immp-20130424monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-24-april-2013-prima-biomed-up-immp-20130425monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-19-april-2013-prima-biomed-qu-immp-20130422monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-17-april-2013-prima-biomed-aw-immp-20130417monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-immp-20130412monthly0.5https://www.biopharmawatch.com/news/IMMP/level-7-151-macquarie-street-sydney-nsw-2000-australia-11-april-2013-asx-market-announceme-immp-20130412monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-australian-cancer-treatment-company-asx-announcement-release-code-prr-11-apri-immp-20130412monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-immp-20130410monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-announcement-release-code-prr-8-april-2013-share-purchase-plan-update-prima-biomed-ltd-immp-20130409monthly0.5https://www.biopharmawatch.com/news/IMMP/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-immp-20130404monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-announcement-release-code-prr-2-april-2013-planned-share-purchase-plan-and-entitlement-immp-20130402monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-announcement-release-code-prr-28-march-2013-change-in-senior-management-prima-biomed-l-immp-20130328monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-20-march-2013-3-8-million-eur-immp-20130320monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-11-march-2013-prima-biomed-to-immp-20130313monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-discusses-first-half-of-fiscal-year-2013-results-earnings-call-transcript-exe-immp-20130308monthly0.5https://www.biopharmawatch.com/news/IMMP/important-notice-the-purpose-of-the-presentation-is-to-provide-an-update-of-the-business-o-immp-20130307monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-5-march-2013-prima-biomed-con-immp-20130305monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-28-february-2013-prima-biomed-immp-20130228monthly0.5https://www.biopharmawatch.com/news/IMMP/abn-90-009-237-889-appendix-4d-interim-financial-report-for-the-half-year-ended-31-decembe-immp-20130225monthly0.5https://www.biopharmawatch.com/news/IMMP/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-immp-20130221monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-6-february-2013-r-d-tax-incen-immp-20130206monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-4-february-2013-prima-biomed--immp-20130204monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-29-january-2013-prima-biomed--immp-20130129monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-24-january-2013-prima-biomed--immp-20130125monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-prr-23-january-2013-quarterly-activity-report-for-quarter-ending-31-immp-20130123monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-24-december-2012-announcement-immp-20121226monthly0.5https://www.biopharmawatch.com/news/IMMP/november-2012-the-manager-australian-stock-exchange-company-announcements-office-level-4-e-immp-20121119monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-announcement-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-16-november-2012-ceo-address-p-immp-20121116monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-14-november-2012-prima-biomed-immp-20121115monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-26-october-2012-prima-names-n-immp-20121029monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-prr-26-october-2012-quarterly-activity-report-for-quarter-ending-30-immp-20121029monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-18-october-2012-prima-to-pres-immp-20121018monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-15-october-2012-positive-inte-immp-20121015monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-isin-us74154b2034-04-october-2012-prima-biomed--immp-20121004monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-20th-september-2012-prima-biomed-to-present-at--immp-20120921monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-31-august-2012-remuneration-package-for-incomin-immp-20120904monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-ltd-level-7-151-macquarie-street-sydney-nsw-2000-australia-tel-61-0-2-9276-12-immp-20120831monthly0.5https://www.biopharmawatch.com/news/IMMP/rule-2-7-3-10-3-3-10-4-3-10-5-appendix-3b-new-issue-announcement-application-for-quotation-immp-20120816monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-30-july-2012-prima-biomed-to-release-interim-cv-immp-20120731monthly0.5https://www.biopharmawatch.com/news/IMMP/the-purpose-of-the-presentation-is-to-provide-an-update-of-the-business-of-prima-biomed-lt-immp-20120618monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-13-th-june-2012-prima-biomed-ltd-shareholders-b-immp-20120613monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-8-june-2012-prima-biomed-dubai-update-prima-bio-immp-20120608monthly0.5https://www.biopharmawatch.com/news/IMMP/june-2012-prima-biomed-to-list-on-the-frankfurt-stock-exchange-sydney-australia-australian-immp-20120605monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-31-may-2012-prima-biomed-to-host-shareholder-br-immp-20120531monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-asx-prr-nasdaq-pbmd-24-may-2012-prima-biomed-announces-changes-to-t-immp-20120524monthly0.5https://www.biopharmawatch.com/news/IMMP/source-prima-biomed-immp-20120502monthly0.5https://www.biopharmawatch.com/news/IMMP/asx-media-release-code-prr-27-april-2012-quarterly-activity-report-for-quarter-ending-31-m-immp-20120427monthly0.5https://www.biopharmawatch.com/news/IMMP/important-notice-the-purpose-of-the-presentation-is-to-provide-an-update-of-the-business-o-immp-20120416monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-appoints-accomplished-biopharma-industry-executive-june-almenoff--atnm-20241104monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-provides-regulatory-update-on-planned-bla-filing-and-future-plans-for-iomab-b-in--atnm-20240805monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-positive-full-data-results-from-the-pivotal-phase-3-sierra-trial-in-pat-atnm-20230218monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-positive-top-line-results-from-pivotal-phase-3-sierra-trial-of-iomab-b--atnm-20221031monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-announces-multiple-senior-leadership-appointments-including-chief-business-and-co-atnm-20210923monthly0.5https://www.biopharmawatch.com/news/ATNM/october-2020-dear-actinium-shareholder-in-2020-thus-far-we-have-made-steady-progress-with--atnm-20201028monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-announces-reverse-stock-split-atnm-20200810monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-announces-closing-of-25-0-million-public-offering-atnm-20200619monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-announces-proposed-public-offering-atnm-20200616monthly0.5https://www.biopharmawatch.com/news/ATNM/pharmaceuticals-inc-atnm-20190418monthly0.5https://www.biopharmawatch.com/news/ATNM/pharmaceuticals-reiterates-previously-announced-atnm-20180226monthly0.5https://www.biopharmawatch.com/news/ATNM/form-of-instructions-as-to-use-of-subscription-rights-certificates-actinium-pharmaceutical-atnm-20180215monthly0.5https://www.biopharmawatch.com/news/ATNM/update-and-outlook-for-2018-atnm-20180125monthly0.5https://www.biopharmawatch.com/news/ATNM/announces-pricing-of-public-offering-of-common-stock-and-warrants-to-purchase-common-stock-atnm-20170728monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-appoints-pharmaceutical-atnm-20170328monthly0.5https://www.biopharmawatch.com/news/ATNM/announces-pricing-of-public-offering-of-common-stock-atnm-20160929monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-issues-mid-year-letter-to-shareholders-providing-update-on-compan-atnm-20160804monthly0.5https://www.biopharmawatch.com/news/ATNM/and-memorial-sloan-kettering-cancer-center-sign-atnm-20151224monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-files-orphan-drug-application-for-use-of-iomab-b-in-treating-refractory-and-relap-atnm-20151123monthly0.5https://www.biopharmawatch.com/news/ATNM/submits-iomab-b-ind-application-to-the-u-s-atnm-20151118monthly0.5https://www.biopharmawatch.com/news/ATNM/letter-to-shareholders-atnm-20150729monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-i-n-c-actinium-announces-5-million-registered-direct-offering-of--atnm-20150604monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-actinium-announces-pricing-of-public-offering-of-common-stock-atnm-20150206monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-i-n-c-actinium-announces-proposed-public-offering-of-common-stock-atnm-20150205monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-i-n-c-actinium-pharmaceuticals-actimab-a-phase-i-ii-trial-interim-atnm-20141106monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-actinium-pharmaceuticals-provides-mid-year-update-directed-at-atnm-20140804monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-actinium-prices-12-5-million-public-offering-of-common-shares-atnm-20140625monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-actinium-announces-proposed-public-offering-of-common-shares-atnm-20140624monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-to-list-common-stock-on-nyse-mkt-shares-of-common-stock-will-begin-trading-on-nys-atnm-20140326monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-i-n-c-actinium-closes-on-approximately-6-6-million-in-private-pla-atnm-20140113monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-i-n-c-actinium-presenting-at-the-ld-micro-conference-today-at-12--atnm-20131205monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-i-n-c-actinium-announces-plans-for-iomab-b-phase-3-pivotal-trial--atnm-20131115monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-atnm-20131112monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-receives-3-5m-from-exercise-of-warrants-actinium-pharmaceutic-atnm-20130607monthly0.5https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inc-a-development-stage-company-consolidated-financial-statements-atnm-20130128monthly0.5https://www.biopharmawatch.com/news/ATNM/unaudited-pro-forma-combined-financial-information-of-cactus-ventures-inc-and-actinium-pha-atnm-20130104monthly0.5https://www.biopharmawatch.com/news/ATNM/audited-consolidated-financial-statements-actinium-pharmaceuticals-inc-a-development-stage-atnm-20130102monthly0.5https://www.biopharmawatch.com/news/ATNM/letter-of-intent-atnm-20121217monthly0.5https://www.biopharmawatch.com/news/SDEV/novabay-pharmaceuticals-inc-regains-compliance-with-nyse-american-continued-listing-standa-sdev-20251020monthly0.5https://www.biopharmawatch.com/news/SDEV/novabay-pharmaceuticals-issues-a-reminder-of-sdev-20250918monthly0.5https://www.biopharmawatch.com/news/SDEV/novabay-pharmaceuticals-announces-one-time-special-cash-dividend-of-0-80-per-share-sdev-20250826monthly0.5https://www.biopharmawatch.com/news/SDEV/novabay-pharmaceuticals-enters-into-6-million-securities-purchase-agreement-with-investor--sdev-20250819monthly0.5https://www.biopharmawatch.com/news/SDEV/novabay-pharmaceuticals-announces-cfo-transition-30-year-finance-veteran-jack-mcgovern-joi-sdev-20170710monthly0.5https://www.biopharmawatch.com/news/SDEV/novabay-pharmaceuticals-successfully-regains-compliance-with-nyse-continued-listing-requir-sdev-20161031monthly0.5https://www.biopharmawatch.com/news/SDEV/novabay-pharmaceuticals-completes-11-8-million-private-placement-emeryville-calif-sdev-20160802monthly0.5https://www.biopharmawatch.com/news/SDEV/novabay-pharmaceuticals-appoints-todd-zavodnick-to-its-board-of-directors-closes-first-tra-sdev-20160509monthly0.5https://www.biopharmawatch.com/news/SDEV/novabay-pharmaceuticals-announces-2-83-million-private-placement-investors-include-insider-sdev-20160224monthly0.5https://www.biopharmawatch.com/news/SDEV/novabay-pharmaceuticals-expects-fourth-quarter-2015-avenova-sales-to-exceed-1-5-million-av-sdev-20160111monthly0.5https://www.biopharmawatch.com/news/SDEV/novabay-pharmaceuticals-secures-3-million-bridge-loan-backers-include-novabay-board-member-sdev-20160107monthly0.5https://www.biopharmawatch.com/news/SDEV/novabay-pharmaceuticals-announces-restructuring-to-focus-on-avenova-commercialization-and--sdev-20151119monthly0.5https://www.biopharmawatch.com/news/SDEV/novabay-announces-proposed-public-offering-of-common-stock-and-warrants-emeryville-calif-b-sdev-20151027monthly0.5https://www.biopharmawatch.com/news/SDEV/novabay-pharmaceuticals-provides-update-on-avenova-sales-growth-reports-progress-with-inte-sdev-20151008monthly0.5https://www.biopharmawatch.com/news/SDEV/novabay-pharmaceuticals-appoints-mark-m-sieczkarek-solta-medical-chairman-and-ceo-and-dr-m-sdev-20140109monthly0.5https://www.biopharmawatch.com/news/SDEV/novabay-pharmaceuticals-announces-positive-results-from-phase-2-clinical-study-of-auriclos-sdev-20130916monthly0.5https://www.biopharmawatch.com/news/SDEV/novabay-pharmaceuticals-inc-announces-pricing-of-public-offering-of-common-stock-and-warra-sdev-20121206monthly0.5https://www.biopharmawatch.com/news/SDEV/former-alcon-executive-with-significant-experience-in-ophthalmic-drug-development-to-overs-sdev-20111004monthly0.5https://www.biopharmawatch.com/news/SDEV/exhibit-b-novabay-pharmaceuticals-sdev-20110629monthly0.5https://www.biopharmawatch.com/news/SDEV/novabay-pharmaceuticals-appoints-gail-maderis-baybio-president-and-ceo-and-former-genzyme--sdev-20101011monthly0.5https://www.biopharmawatch.com/news/CELU/celularity-secures-35-million-strategic-license-deal-strengthens-capital-position-to-advan-celu-20260310monthly0.5https://www.biopharmawatch.com/news/CELU/celularity-announces-closing-of-financing-transactions-celu-20251222monthly0.5https://www.biopharmawatch.com/news/CELU/celularity-completes-major-balance-sheet-restructuring-retires-all-41-6-million-in-senior--celu-20250818monthly0.5https://www.biopharmawatch.com/news/CELU/celularity-announces-chief-financial-officer-transition-celularity-retains-financial-and-b-celu-20250610monthly0.5https://www.biopharmawatch.com/news/CELU/celularity-announces-full-year-2024-operating-and-financial-results-net-revenues-for-the-y-celu-20250509monthly0.5https://www.biopharmawatch.com/news/CELU/celularity-enters-strategic-collaboration-agreement-with-clinical-stage-cell-therapy-compa-celu-20250224monthly0.5https://www.biopharmawatch.com/news/CELU/celularity-raises-full-year-2024-guidance-as-expected-net-sales-through-october-reach-44-4-celu-20241107monthly0.5https://www.biopharmawatch.com/news/CELU/celularity-provides-corporate-update-celu-20241022monthly0.5https://www.biopharmawatch.com/news/CELU/celularity-expands-advanced-biomaterial-product-commercial-portfolio-with-acquisition-of-r-celu-20241016monthly0.5https://www.biopharmawatch.com/news/CELU/celularity-appoints-richard-j-berman-to-its-board-of-directors-seasoned-public-company-dir-celu-20240828monthly0.5https://www.biopharmawatch.com/news/CELU/description-of-business-celularity-inc-celularity-is-a-cellular-and-regenerative-medicine--celu-20240212monthly0.5https://www.biopharmawatch.com/news/CELU/celularity-announces-net-sales-and-total-revenue-expectations-for-fourth-quarter-2023-and--celu-20240103monthly0.5https://www.biopharmawatch.com/news/CELU/celularity-appoints-geoffrey-shiu-fei-ling-m-d-ph-d-to-its-board-of-directors-pharmaceutic-celu-20230907monthly0.5https://www.biopharmawatch.com/news/CELU/celularity-investor-contact-carlos-ramirez-senior-vice-president-celularity-inc-carlos-ram-celu-20230829monthly0.5https://www.biopharmawatch.com/news/CELU/celularity-inc-announces-3-million-registered-direct-offering-celu-20230727monthly0.5https://www.biopharmawatch.com/news/CELU/the-next-evolution-in-cellular-medicine-investor-presentation-june-2023-all-statements-in--celu-20230531monthly0.5https://www.biopharmawatch.com/news/CELU/celularity-contact-paul-graves-chief-communications-officer-celularity-inc-paul-graves-cel-celu-20230427monthly0.5https://www.biopharmawatch.com/news/CELU/celularity-inc-announces-6-million-registered-direct-offering-celu-20230405monthly0.5https://www.biopharmawatch.com/news/CELU/in-the-court-of-chancery-of-the-state-of-delaware-in-re-celularity-inc-c-a-no-2023-verifie-celu-20230317monthly0.5https://www.biopharmawatch.com/news/CELU/celularity-media-contact-paul-graves-svp-chief-communications-officer-celularity-inc-paul--celu-20230126monthly0.5https://www.biopharmawatch.com/news/CELU/celularity-reports-third-quarter-2022-financial-results-and-provides-corporate-update-anno-celu-20221110monthly0.5https://www.biopharmawatch.com/news/CELU/celularity-reports-second-quarter-2022-financial-results-and-corporate-update-announced-fi-celu-20220809monthly0.5https://www.biopharmawatch.com/news/CELU/the-next-evolution-in-cellular-medicine-june-2022-page-1-disclaimers-forward-looking-state-celu-20220617monthly0.5https://www.biopharmawatch.com/news/CELU/celularity-inc-announces-30-million-private-placement-priced-at-the-market-under-nasdaq-ru-celu-20220518monthly0.5https://www.biopharmawatch.com/news/CELU/celularity-reports-first-quarter-2022-financial-results-and-provides-corporate-update-ongo-celu-20220516monthly0.5https://www.biopharmawatch.com/news/CELU/celularity-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-corpor-celu-20220331monthly0.5https://www.biopharmawatch.com/news/CELU/placental-derived-cell-type-program-indication-preclinical-ind-submission-phase-i-phase-ii-celu-20220316monthly0.5https://www.biopharmawatch.com/news/CELU/celularity-receives-orphan-drug-designation-from-u-s-fda-for-its-nk-cell-therapy-cynk-101--celu-20220215monthly0.5https://www.biopharmawatch.com/news/CELU/celularity-receives-fast-track-designation-from-u-s-fda-for-its-nk-cell-therapy-cynk-101-i-celu-20220118monthly0.5https://www.biopharmawatch.com/news/CELU/celularity-receives-fast-track-designation-from-u-s-fda-for-its-nk-cell-therapy-cynk-001-i-celu-20211227monthly0.5https://www.biopharmawatch.com/news/CELU/address-3-co-dependent-variables-affecting-cynk-001-potency-and-persistence-in-aml-cynk-00-celu-20211217monthly0.5https://www.biopharmawatch.com/news/CELU/celularity-reports-third-quarter-2021-financial-results-and-corporate-update-florham-park--celu-20211112monthly0.5https://www.biopharmawatch.com/news/CELU/celularity-reports-second-quarter-2021-financial-results-secured-funding-of-approximately--celu-20210816monthly0.5https://www.biopharmawatch.com/news/CELU/celularity-closes-merger-with-gx-acquisition-corp-and-provides-corporate-update-common-sto-celu-20210719monthly0.5https://www.biopharmawatch.com/news/CELU/celularity-and-arthrex-enter-into-exclusive-supply-and-distribution-agreement-for-multiple-celu-20210701monthly0.5https://www.biopharmawatch.com/news/CELU/celularity-announces-expansion-of-human-placental-hematopoietic-stem-cell-derived-natural--celu-20210629monthly0.5https://www.biopharmawatch.com/news/CELU/gx-acquisition-corp-announces-shareholder-approval-of-extension-proposal-new-york-new-york-celu-20210514monthly0.5https://www.biopharmawatch.com/news/CELU/gx-acquisition-corp-announces-additional-contributions-to-trust-account-new-york-new-york-celu-20210510monthly0.5https://www.biopharmawatch.com/news/CELU/source-celularity-inc-celu-20210505monthly0.5https://www.biopharmawatch.com/news/CELU/gx-acquisition-corp-provides-information-regarding-extension-of-deadline-to-complete-celul-celu-20210416monthly0.5https://www.biopharmawatch.com/news/CELU/celularity-announces-fast-track-designation-by-the-fda-for-its-natural-killer-cell-therapy-celu-20210318monthly0.5https://www.biopharmawatch.com/news/CELU/celularity-and-gx-acquisition-corp-announce-merger-agreement-to-create-a-publicly-listed-l-celu-20210108monthly0.5https://www.biopharmawatch.com/news/CELU/gx-acquisition-corp-announces-the-separate-trading-of-its-class-a-common-stock-and-warrant-celu-20190715monthly0.5https://www.biopharmawatch.com/news/CELU/gx-acquisition-corp-index-to-financial-statement-page-report-of-independent-registered-pub-celu-20190523monthly0.5https://www.biopharmawatch.com/news/CELU/gx-acquisition-corp-announces-pricing-of-250-000-000-initial-public-offering-new-york-ny-celu-20190520monthly0.5https://www.biopharmawatch.com/news/SER/serina-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-upd-ser-20260514monthly0.5https://www.biopharmawatch.com/news/SER/serina-therapeutics-secures-up-to-30-million-in-private-placement-to-advance-registrationa-ser-20260320monthly0.5https://www.biopharmawatch.com/news/SER/document-serina-therapeutics-submits-complete-response-to-fda-clinical-hold-letter-for-ser-ser-20251210monthly0.5https://www.biopharmawatch.com/news/SER/serina-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business-hig-ser-20251113monthly0.5https://www.biopharmawatch.com/news/SER/document-serina-therapeutics-provides-regulatory-update-on-ser-252-program-fda-requests-ad-ser-20251103monthly0.5https://www.biopharmawatch.com/news/SER/document-serina-therapeutics-draws-first-5-million-funding-tranche-to-support-registration-ser-20251006monthly0.5https://www.biopharmawatch.com/news/SER/document-serina-therapeutics-secures-up-to-20-million-to-advance-registrational-trial-of-s-ser-20250909monthly0.5https://www.biopharmawatch.com/news/SER/serina-therapeutics-reports-second-quarter-2025-financial-results-and-provides-business-hi-ser-20250811monthly0.5https://www.biopharmawatch.com/news/SER/document-serina-therapeutics-advances-poz-vmat2i-into-development-for-tardive-dyskinesia-t-ser-20250729monthly0.5https://www.biopharmawatch.com/news/SER/document-serina-therapeutics-announces-date-for-2025-annual-stockholders-meeting-huntsvill-ser-20250701monthly0.5https://www.biopharmawatch.com/news/SER/serina-therapeutics-reports-first-quarter-2025-financial-results-and-provides-business-hig-ser-20250508monthly0.5https://www.biopharmawatch.com/news/SER/4thlnpformulationp-highly-confidential-trade-secret-1-ser-20250415monthly0.5https://www.biopharmawatch.com/news/SER/serina-therapeutics-secures-5-million-in-funding-to-support-advancement-of-ser-252-into-cl-ser-20250408monthly0.5https://www.biopharmawatch.com/news/SER/document-serina-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation--ser-20250407monthly0.5https://www.biopharmawatch.com/news/SER/serina-therapeutics-reports-full-year-2024-financial-results-and-recent-business-highlight-ser-20250324monthly0.5https://www.biopharmawatch.com/news/SER/document-serina-therapeutics-to-present-at-the-american-chemistry-society-acs-spring-2025--ser-20250324monthly0.5https://www.biopharmawatch.com/news/SER/serina-therapeutics-receives-second-5-million-tranche-to-strengthen-cash-position-ahead-of-ser-20250203monthly0.5https://www.biopharmawatch.com/news/SER/serina-therapeutics-secures-10-million-financing-to-continue-advancing-lead-ind-candidate--ser-20241202monthly0.5https://www.biopharmawatch.com/news/SER/serina-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-hig-ser-20241112monthly0.5https://www.biopharmawatch.com/news/SER/serina-therapeutics-to-present-at-the-h-c-wainwright-26th-annual-global-investment-confere-ser-20240904monthly0.5https://www.biopharmawatch.com/news/SER/serina-therapeutics-reports-second-quarter-2024-financial-results-and-provides-business-hi-ser-20240809monthly0.5https://www.biopharmawatch.com/news/SER/serina-therapeutics-appoints-srini-tenjarla-ph-d-as-senior-vice-president-of-cmc-and-formu-ser-20240718monthly0.5https://www.biopharmawatch.com/news/SER/serina-therapeutics-reports-first-quarter-2024-financial-results-and-provides-business-hig-ser-20240514monthly0.5https://www.biopharmawatch.com/news/SER/serina-therapeutics-appoints-dr-simba-gill-as-executive-chairman-dr-gill-brings-extensive--ser-20240417monthly0.5https://www.biopharmawatch.com/news/SER/serina-therapeutics-announces-completion-of-merger-with-agex-therapeutics-shares-of-serina-ser-20240327monthly0.5https://www.biopharmawatch.com/news/SER/agex-therapeutics-reports-fourth-quarter-and-annual-2023-financial-results-alameda-calif-g-ser-20240322monthly0.5https://www.biopharmawatch.com/news/SER/filed-by-agex-therapeutics-inc-pursuant-to-rule-425-under-the-securities-act-of-1933-as-am-ser-20231117monthly0.5https://www.biopharmawatch.com/news/SER/agex-therapeutics-reports-third-quarter-2023-financial-results-alameda-calif-business-wire-ser-20231114monthly0.5https://www.biopharmawatch.com/news/SER/serina-therapeutics-and-agex-therapeutics-enter-into-merger-agreement-ser-20230830monthly0.5https://www.biopharmawatch.com/news/SER/agex-therapeutics-reports-second-quarter-2023-financial-results-alameda-calif-business-wir-ser-20230814monthly0.5https://www.biopharmawatch.com/news/SER/agex-therapeutics-closes-36-000-000-debt-exchange-for-preferred-stock-alameda-calif-busine-ser-20230724monthly0.5https://www.biopharmawatch.com/news/SER/agex-therapeutics-announces-36-000-000-debt-exchange-for-preferred-stock-alameda-calif-bus-ser-20230721monthly0.5https://www.biopharmawatch.com/news/SER/agex-therapeutics-announces-appeal-of-nyse-american-determination-alameda-calif-business-w-ser-20230523monthly0.5https://www.biopharmawatch.com/news/SER/agex-therapeutics-reports-first-quarter-2023-financial-results-alameda-calif-business-wire-ser-20230512monthly0.5https://www.biopharmawatch.com/news/SER/agex-therapeutics-receives-stock-exchange-deficiency-letter-alameda-calif-business-wire-ser-20230426monthly0.5https://www.biopharmawatch.com/news/SER/agex-therapeutics-reports-fourth-quarter-and-annual-2022-financial-results-alameda-calif-b-ser-20230331monthly0.5https://www.biopharmawatch.com/news/SER/agex-therapeutics-receives-extension-of-time-to-attain-compliance-with-stock-exchange-cont-ser-20221125monthly0.5https://www.biopharmawatch.com/news/SER/agex-therapeutics-reports-third-quarter-2022-financial-results-alameda-calif-business-wire-ser-20221110monthly0.5https://www.biopharmawatch.com/news/SER/agex-therapeutics-reports-second-quarter-2022-financial-results-alameda-calif-business-wir-ser-20220812monthly0.5https://www.biopharmawatch.com/news/SER/dr-joanne-hackett-appointed-chairperson-of-agex-board-of-directors-alameda-calif-business--ser-20220518monthly0.5https://www.biopharmawatch.com/news/SER/agex-therapeutics-reports-first-quarter-2022-financial-results-alameda-calif-business-wire-ser-20220513monthly0.5https://www.biopharmawatch.com/news/SER/agex-therapeutics-reports-fourth-quarter-and-annual-2021-financial-results-signed-research-ser-20220329monthly0.5https://www.biopharmawatch.com/news/SER/agex-therapeutics-receives-stock-exchange-deficiency-letter-alameda-calif-business-wire-ser-20211123monthly0.5https://www.biopharmawatch.com/news/SER/agex-therapeutics-reports-third-quarter-2021-financial-results-alameda-calif-business-wire-ser-20211112monthly0.5https://www.biopharmawatch.com/news/SER/agex-therapeutics-reports-second-quarter-2021-financial-results-alameda-calif-business-wir-ser-20210813monthly0.5https://www.biopharmawatch.com/news/SER/agex-therapeutics-and-lygenesis-terminate-merger-negotiations-alameda-calif-pittsburgh-bus-ser-20210723monthly0.5https://www.biopharmawatch.com/news/SER/agex-therapeutics-reports-first-quarter-2021-financial-results-and-provides-business-updat-ser-20210517monthly0.5https://www.biopharmawatch.com/news/SER/agex-therapeutics-reports-fourth-quarter-and-annual-2020-financial-results-and-provides-bu-ser-20210331monthly0.5https://www.biopharmawatch.com/news/SER/agex-therapeutics-and-lygenesis-to-negotiate-merger-agreement-merger-would-create-a-clinic-ser-20210302monthly0.5https://www.biopharmawatch.com/news/SER/agex-therapeutics-reports-third-quarter-2020-financial-results-and-provides-business-updat-ser-20201116monthly0.5https://www.biopharmawatch.com/news/SER/agex-therapeutics-reports-second-quarter-2020-financial-results-and-provides-business-upda-ser-20200814monthly0.5https://www.biopharmawatch.com/news/SER/agex-therapeutics-receives-stock-exchange-deficiency-letter-alameda-calif-business-wire-ser-20200605monthly0.5https://www.biopharmawatch.com/news/SER/agex-therapeutics-reports-first-quarter-2020-financial-results-and-provides-business-updat-ser-20200514monthly0.5https://www.biopharmawatch.com/news/SER/agex-therapeutics-reports-fourth-quarter-and-annual-2019-financial-results-and-provides-bu-ser-20200330monthly0.5https://www.biopharmawatch.com/news/SER/agex-therapeutics-reports-third-quarter-2019-financial-results-and-provides-business-updat-ser-20191114monthly0.5https://www.biopharmawatch.com/news/SER/agex-therapeutics-inc-reports-second-quarter-2019-financial-results-and-provides-business--ser-20190814monthly0.5https://www.biopharmawatch.com/news/SER/agex-therapeutics-reports-first-quarter-2019-financial-results-and-provides-business-updat-ser-20190515monthly0.5https://www.biopharmawatch.com/news/SER/agex-therapeutics-reports-fourth-quarter-and-annual-2018-financial-results-and-provides-bu-ser-20190401monthly0.5https://www.biopharmawatch.com/news/SER/agex-therapeutics-inc-shares-commence-trading-on-the-nyse-american-company-s-common-stock--ser-20181129monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-wins-appeal-following-formal-dispute-resolution-process-for-ons-5010--otlk-20260526monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-reports-second-quarter-fiscal-year-2026-financial-results-and-provide-otlk-20260515monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-completes-federal-dispute-resolution-fdr-meeting-with-fda-for-ons-501-otlk-20260421monthly0.5https://www.biopharmawatch.com/news/OTLK/supplemental-risk-factors-except-as-set-forth-below-as-of-otlk-20260316monthly0.5https://www.biopharmawatch.com/news/OTLK/walnut-street-julia-a-haller-md-suite-1510-philadelphia-pa-19107-ophthalmologist-in-chief--otlk-20260306monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-provides-update-following-type-a-meeting-with-fda-regarding-ons-5010--otlk-20260305monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-provides-regulatory-update-on-u-s-food-and-drug-administration-review-otlk-20251231monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-reports-financial-results-for-second-quarter-fiscal-year-2025-and-pro-otlk-20250515monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-reports-financial-results-for-first-quarter-fiscal-year-2025-and-prov-otlk-20250214monthly0.5https://www.biopharmawatch.com/news/OTLK/reports-financial-results-for-fiscal-year-2024-and-provides-corporate-update-otlk-20241227monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-announces-preliminary-topline-results-of-norse-eight-clinical-trial-f-otlk-20241127monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-reports-financial-results-for-third-quarter-fiscal-year-2024-and-prov-otlk-20240814monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-reports-financial-results-for-second-quarter-fiscal-year-2024-and-pro-otlk-20240515monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-announces-uk-submission-of-marketing-authorization-application-maa-fo-otlk-20240513monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-reports-financial-results-for-first-quarter-fiscal-year-2024-and-prov-otlk-20240214monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-receives-fda-agreement-under-special-protocol-assessment-spa-for-90-d-otlk-20240123monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-reports-financial-results-for-fiscal-year-2023-and-reiterates-ons-501-otlk-20231222monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-provides-update-on-type-a-meetings-with-otlk-20231102monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-provides-regulatory-update-on-fda-review-of-ons-5010-lytenava-bevaciz-otlk-20230830monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-reports-financial-results-for-third-quarter-fiscal-year-2023-and-reit-otlk-20230814monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-reports-financial-results-for-second-quarter-fiscal-year-2023-and-pro-otlk-20230515monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-reports-financial-results-for-first-quarter-fiscal-year-2023-and-prov-otlk-20230214monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-reports-financial-results-for-fiscal-year-2022-and-provides-corporate-otlk-20221229monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-announces-25-million-registered-direct-offering-priced-at-the-market--otlk-20221223monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-announces-validation-of-marketing-authorization-application-by-the-eu-otlk-20221222monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-reports-financial-results-for-third-quarter-fiscal-year-2022-and-reit-otlk-20220810monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-provides-update-on-biologics-license-application-bla-submission-for-o-otlk-20220531monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-reports-financial-results-for-second-quarter-fiscal-year-2022-and-pro-otlk-20220513monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-reports-financial-results-for-first-quarter-fiscal-year-2022-and-prov-otlk-20220214monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-reports-financial-results-for-fiscal-year-2021-and-provides-corporate-otlk-20211222monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-announces-10-million-bought-deal-offering-of-common-stock-iselin-n-j-otlk-20211123monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-reports-financial-results-for-third-quarter-of-fiscal-year-2021-and-p-otlk-20210813monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-reports-positive-efficacy-and-safety-data-from-pivotal-phase-3-norse--otlk-20210803monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-inc-logo-outlook-therapeutics-appoints-c-russell-trenary-iii-as-presi-otlk-20210707monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-reports-financial-results-for-second-quarter-of-fiscal-year-2021-and--otlk-20210514monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-reports-financial-results-for-first-quarter-fiscal-year-2021-and-prov-otlk-20210216monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-announces-10-0-million-bought-deal-offering-of-common-stock-otlk-20210128monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-reports-financial-results-for-fiscal-year-2020-and-provides-corporate-otlk-20201223monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-secures-10-million-in-additional-working-capital-otlk-20201105monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-provides-update-on-progress-towards-first-approved-ophthalmic-formula-otlk-20200930monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-reports-topline-results-and-positive-proof-of-concept-for-ons-5010-ly-otlk-20200826monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-reports-financial-results-for-the-third-quarter-of-fiscal-year-2020-a-otlk-20200814monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-announces-11-2-otlk-20200623monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-provides-clinical-update-on-ons-5010-lytenava-bevacizumab-vikg-lead-p-otlk-20200617monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-announces-16-0-million-private-placement-to-advance-the-development-o-otlk-20200526monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-reports-financial-results-for-the-second-quarter-of-fiscal-year-2020--otlk-20200515monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-provides-covid-19-impact-update-on-ongoing-clinical-trials-norse-1-an-otlk-20200414monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-announces-10-2-million-financings-priced-at-the-market-cranbury-n-j-otlk-20200224monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-provides-business-update-and-reports-financial-results-for-the-first--otlk-20200214monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-announces-agreements-to-streamline-capital-structure-and-regain-100-o-otlk-20200128monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-announces-warrant-amendment-and-restructuring-of-senior-secured-notes-otlk-20191223monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-provides-business-update-and-reports-financial-results-for-fiscal-yea-otlk-20191219monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-inc-2015-equity-incentive-plan-adopted-by-the-board-of-directors-otlk-20190913monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-provides-business-update-and-reports-financial-results-for-third-quar-otlk-20190814monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-provides-business-update-and-reports-second-quarter-financial-results-otlk-20190515monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-announces-fda-acceptance-of-ind-for-ons-5010-enrollment-of-u-s-patien-otlk-20190401monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-regains-compliance-with-all-nasdaq-listing-requirements-cranbury-n-j-otlk-20190305monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-provides-business-update-and-reports-first-quarter-financial-results--otlk-20190214monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-announces-exercise-price-reduction-and-term-extension-of-series-a-war-otlk-20190122monthly0.5https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-provides-business-update-and-reports-financial-results-for-fiscal-yea-otlk-20181218monthly0.5https://www.biopharmawatch.com/news/OTLK/oncobiologics-changes-name-to-outlook-therapeutics-announces-next-steps-in-executing-ons-5-otlk-20181203monthly0.5https://www.biopharmawatch.com/news/OTLK/oncobiologics-advances-ons-5010-into-wet-amd-clinical-trial-receives-commitment-for-20-mil-otlk-20181106monthly0.5https://www.biopharmawatch.com/news/OTLK/oncobiologics-inc-2015-equity-incentive-plan-adopted-by-the-board-of-directors-otlk-20180924monthly0.5https://www.biopharmawatch.com/news/OTLK/oncobiologics-provides-business-update-and-reports-third-quarter-financial-results-for-fis-otlk-20180814monthly0.5https://www.biopharmawatch.com/news/OTLK/oncobiologics-appoints-lawrence-a-kenyon-as-president-and-otlk-20180802monthly0.5https://www.biopharmawatch.com/news/OTLK/oncobiologics-completes-exchange-of-series-a-convertible-preferred-stock-for-newly-created-otlk-20180719monthly0.5https://www.biopharmawatch.com/news/OTLK/oncobiologics-regains-compliance-with-applicable-nasdaq-listing-requirements-cranbury-n-j-otlk-20180711monthly0.5https://www.biopharmawatch.com/news/OTLK/oncobiologics-announces-randy-thurman-as-executive-chairman-of-the-board-of-directors-and--otlk-20180618monthly0.5https://www.biopharmawatch.com/news/OTLK/oncobiologics-reports-second-quarter-financial-results-for-fiscal-2018-cranbury-nj-otlk-20180515monthly0.5https://www.biopharmawatch.com/news/OTLK/oncobiologics-appoints-randy-thurman-to-board-of-directors-cranbury-nj-otlk-20180417monthly0.5https://www.biopharmawatch.com/news/OTLK/oncobiologics-appoints-dr-joerg-windisch-to-board-of-directors-cranbury-nj-otlk-20180327monthly0.5https://www.biopharmawatch.com/news/OTLK/oncobiologics-reports-first-quarter-fiscal-year-2018-results-cranbury-nj-otlk-20180214monthly0.5https://www.biopharmawatch.com/news/OTLK/oncobiologics-announces-term-extension-of-series-a-warrants-cranbury-nj-otlk-20180209monthly0.5https://www.biopharmawatch.com/news/OTLK/oncobiologics-announces-closing-of-strategic-partnership-deal-with-gms-tenshi-holdings-cra-otlk-20171031monthly0.5https://www.biopharmawatch.com/news/OTLK/oncobiologics-announces-strategic-partnership-with-gms-tenshi-holdings-pte-limited-up-to-5-otlk-20170908monthly0.5https://www.biopharmawatch.com/news/OTLK/oncobiologics-secures-additional-funding-cranbury-nj-otlk-20170417monthly0.5https://www.biopharmawatch.com/news/OTLK/oncobiologics-announces-term-extension-of-series-a-warrants-cranbury-nj-otlk-20170206monthly0.5https://www.biopharmawatch.com/news/OTLK/oncobiologics-issues-8-35-million-of-senior-secured-notes-and-warrants-to-acquire-1-9-mill-otlk-20161223monthly0.5https://www.biopharmawatch.com/news/OTLK/oncobiologics-announces-separation-of-otlk-20160610monthly0.5https://www.biopharmawatch.com/news/NNVC/nanoviricides-announces-pricing-of-2-million-registered-direct-offering-shelton-ct-friday-nnvc-20260515monthly0.5https://www.biopharmawatch.com/news/NNVC/nanoviricides-announces-pricing-of-6-million-registered-direct-offering-and-concurrent-pri-nnvc-20251111monthly0.5https://www.biopharmawatch.com/news/NNVC/significantly-improved-safety-profile-and-metabolism-of-remdesivir-observed-due-to-encapsu-nnvc-20210921monthly0.5https://www.biopharmawatch.com/news/NNVC/nanoviricides-completes-licensing-for-coronavirus-field-which-includes-current-covid-19-dr-nnvc-20210915monthly0.5https://www.biopharmawatch.com/news/NNVC/nanoviricides-strengthens-its-board-of-directors-with-addition-of-industry-veteran-brian-z-nnvc-20201119monthly0.5https://www.biopharmawatch.com/news/NNVC/nanoviricides-is-developing-drugs-against-sars-cov-2-with-an-integrated-approach-to-combat-nnvc-20200904monthly0.5https://www.biopharmawatch.com/news/NNVC/nanoviricides-closes-on-11-5-million-underwritten-public-offering-of-common-stock-shelton--nnvc-20200713monthly0.5https://www.biopharmawatch.com/news/NNVC/nanoviricides-announces-pricing-of-10-2-million-registered-direct-offering-shelton-connect-nnvc-20200521monthly0.5https://www.biopharmawatch.com/news/NNVC/honorable-ex-congressman-todd-rokita-joins-the-board-of-directors-of-nanoviricides-inc-she-nnvc-20200519monthly0.5https://www.biopharmawatch.com/news/NNVC/nanoviricides-closes-on-8-625-million-underwritten-public-offering-of-common-stock-shelton-nnvc-20200124monthly0.5https://www.biopharmawatch.com/news/NNVC/nanoviricides-president-dr-anil-diwan-provides-responses-to-shareholder-questions-at-the-a-nnvc-20191209monthly0.5https://www.biopharmawatch.com/news/NNVC/nanoviricides-completes-licensing-for-vzv-field-which-includes-shingles-drug-development-s-nnvc-20191104monthly0.5https://www.biopharmawatch.com/news/NNVC/nanoviricides-announces-2-5-million-financing-in-a-registered-direct-offering-shelton-conn-nnvc-20190227monthly0.5https://www.biopharmawatch.com/news/NNVC/dated-february-13-2017-nanoviricides-reports-the-company-s-director-dr-boniuk-converted-se-nnvc-20170213monthly0.5https://www.biopharmawatch.com/news/NNVC/nanoviricides-inc-completes-purchase-of-cgmp-compliant-pilot-production-facility-nnvc-20150107monthly0.5https://www.biopharmawatch.com/news/NNVC/nanoviricides-reports-that-its-director-dr-milton-boniuk-a-director-has-invested-5m-into-t-nnvc-20140702monthly0.5https://www.biopharmawatch.com/news/NNVC/eradicating-viral-diseases-may-2014-marcum-conference-new-york-city-eugene-seymour-md-mph--nnvc-20140602monthly0.5https://www.biopharmawatch.com/news/NNVC/nanoviricides-inc-reports-its-president-chairman-dr-diwan-purchased-its-common-stock-in-th-nnvc-20140226monthly0.5https://www.biopharmawatch.com/news/NNVC/nanoviricides-announces-that-it-has-raised-20-million-in-a-registered-direct-offering-west-nnvc-20140124monthly0.5https://www.biopharmawatch.com/news/NNVC/nanoviricides-announces-that-its-annual-meeting-was-held-on-december-9th-2013-the-ceo-pres-nnvc-20131213monthly0.5https://www.biopharmawatch.com/news/NNVC/nanoviricides-announces-that-it-now-meets-listing-standards-of-major-national-stock-exchan-nnvc-20130910monthly0.5https://www.biopharmawatch.com/news/NNVC/press-release-dated-nnvc-20130719monthly0.5https://www.biopharmawatch.com/news/NNVC/press-release-dated-nnvc-20130708monthly0.5https://www.biopharmawatch.com/news/NNVC/nanoviricides-announces-retirement-of-its-series-c-convertible-preferred-stock-held-by-sea-nnvc-20130227monthly0.5https://www.biopharmawatch.com/news/NNVC/nanoviricides-announces-completion-of-previously-reported-5-million-in-shelf-offering-comp-nnvc-20121224monthly0.5https://www.biopharmawatch.com/news/NNVC/exhibt-99-1-nanoviricides-raises-5-million-in-shelf-offering-the-company-reports-having-mo-nnvc-20120702monthly0.5https://www.biopharmawatch.com/news/NNVC/nanoviricides-raises-5-million-in-shelf-offering-the-company-reports-having-more-than-24-m-nnvc-20120629monthly0.5https://www.biopharmawatch.com/news/NNVC/nanoviricides-completes-a-5-million-raise-in-shelf-offering-the-company-reports-having-mor-nnvc-20120209monthly0.5https://www.biopharmawatch.com/news/NNVC/nanoviricides-raises-an-additional-5-million-in-shelf-offering-the-company-reports-having--nnvc-20111103monthly0.5https://www.biopharmawatch.com/news/NNVC/nanoviricides-raises-2-5m-in-shelf-offering-the-company-reports-having-more-than-24-months-nnvc-20110727monthly0.5https://www.biopharmawatch.com/news/NNVC/nanoviricides-raises-an-additional-2-5m-in-shelf-offering-the-company-reports-having-more--nnvc-20101222monthly0.5https://www.biopharmawatch.com/news/NNVC/nanoviricides-raises-an-additional-2-5m-in-shelf-offering-the-company-reports-it-now-has-m-nnvc-20100922monthly0.5https://www.biopharmawatch.com/news/NNVC/nanoviricides-raises-5m-in-shelf-offering-west-haven-connecticut-may-12-th-2010-nanovirici-nnvc-20100429monthly0.5https://www.biopharmawatch.com/news/NNVC/source-nanoviricides-inc-nanoviricides-inc-herpes-study-results-discussed-on-cbs-news-repo-nnvc-20090814monthly0.5https://www.biopharmawatch.com/news/NNVC/fireside-chat-3-november-13-th-about-nanoviricides-nanoviricides-inc-www-nanoviricides-com-nnvc-20081120monthly0.5https://www.biopharmawatch.com/news/NNVC/e-xh-ibit-99-1-wednesday-nnvc-20080903monthly0.5https://www.biopharmawatch.com/news/NNVC/sublease-agreement-this-sublease-agreement-this-sublease-is-made-and-entered-into-as-of-th-nnvc-20070308monthly0.5https://www.biopharmawatch.com/news/VERU/investor-and-media-contact-samuel-fisch-executive-director-investor-relations-and-corporat-veru-20260513monthly0.5https://www.biopharmawatch.com/news/VERU/investor-and-media-contact-samuel-fisch-executive-director-investor-relations-and-corporat-veru-20260211monthly0.5https://www.biopharmawatch.com/news/VERU/investor-and-media-contact-samuel-fisch-executive-director-investor-relations-and-corporat-veru-20251217monthly0.5https://www.biopharmawatch.com/news/VERU/investor-and-media-contact-samuel-fisch-executive-director-investor-relations-and-corporat-veru-20251029monthly0.5https://www.biopharmawatch.com/news/VERU/investor-and-media-contact-samuel-fisch-executive-director-investor-relations-and-corporat-veru-20250812monthly0.5https://www.biopharmawatch.com/news/VERU/investor-and-media-contact-samuel-fisch-executive-director-investor-relations-and-corporat-veru-20250508monthly0.5https://www.biopharmawatch.com/news/VERU/investor-and-media-contact-samuel-fisch-executive-director-investor-relations-and-corporat-veru-20250210monthly0.5https://www.biopharmawatch.com/news/VERU/investor-and-media-contact-samuel-fisch-executive-director-investor-relations-and-corporat-veru-20240808monthly0.5https://www.biopharmawatch.com/news/VERU/investor-and-media-contact-samuel-fisch-executive-director-investor-relations-and-corporat-veru-20240508monthly0.5https://www.biopharmawatch.com/news/VERU/investor-and-media-contact-samuel-fisch-executive-director-investor-relations-and-corporat-veru-20240208monthly0.5https://www.biopharmawatch.com/news/VERU/veru-announces-proposed-public-offering-of-common-stock-miami-fl-veru-20231213monthly0.5https://www.biopharmawatch.com/news/VERU/currently-approved-glp-1-receptor-agonist-drugs-for-the-treatment-of-obesity-have-demonstr-veru-20231213monthly0.5https://www.biopharmawatch.com/news/VERU/investor-and-media-contact-samuel-fisch-executive-director-investor-relations-and-corporat-veru-20230810monthly0.5https://www.biopharmawatch.com/news/VERU/investor-contact-samuel-fisch-executive-director-investor-relations-and-corporate-communic-veru-20230511monthly0.5https://www.biopharmawatch.com/news/VERU/investor-contact-samuel-fisch-executive-director-investor-relations-and-corporate-communic-veru-20230209monthly0.5https://www.biopharmawatch.com/news/VERU/investor-contact-samuel-fisch-executive-director-investor-relations-and-corporate-communic-veru-20221205monthly0.5https://www.biopharmawatch.com/news/VERU/investor-and-media-contact-samuel-fisch-executive-director-investor-relations-and-corporat-veru-20220811monthly0.5https://www.biopharmawatch.com/news/VERU/investor-and-media-contact-samuel-fisch-executive-director-investor-relations-and-corporat-veru-20220512monthly0.5https://www.biopharmawatch.com/news/VERU/investor-and-media-contact-samuel-fisch-executive-director-investor-relations-and-corporat-veru-20220209monthly0.5https://www.biopharmawatch.com/news/VERU/investor-and-media-contact-samuel-fisch-executive-director-investor-relations-and-corporat-veru-20211202monthly0.5https://www.biopharmawatch.com/news/VERU/sam-fisch-800-972-0538-director-of-investor-relations-veru-sets-another-quarterly-record-i-veru-20210812monthly0.5https://www.biopharmawatch.com/news/VERU/sam-fisch-800-972-0538-director-of-investor-relations-veru-reports-strong-second-quarter-f-veru-20210512monthly0.5https://www.biopharmawatch.com/news/VERU/sam-fisch-800-972-0538-director-of-investor-relations-veru-announces-proposed-public-offer-veru-20210217monthly0.5https://www.biopharmawatch.com/news/VERU/sam-fisch-800-972-0538-director-of-investor-relations-veru-sets-another-quarterly-record-i-veru-20210210monthly0.5https://www.biopharmawatch.com/news/VERU/sam-fisch-director-of-investor-relations-800-972-0538-veru-reports-record-fiscal-2020-four-veru-20201209monthly0.5https://www.biopharmawatch.com/news/VERU/sam-fisch-800-972-0538-director-of-investor-relations-veru-reports-higher-net-revenues-for-veru-20200813monthly0.5https://www.biopharmawatch.com/news/VERU/sam-fisch-800-972-0538-veru-reports-strong-fiscal-2020-second-quarter-results-as-net-reven-veru-20200513monthly0.5https://www.biopharmawatch.com/news/VERU/sam-fisch-800-972-0538-veru-continues-strong-positive-sales-momentum-in-fiscal-2020-first--veru-20200212monthly0.5https://www.biopharmawatch.com/news/VERU/sam-fisch-800-972-0538-veru-reports-fiscal-2019-full-year-net-revenues-doubled-gross-profi-veru-20191212monthly0.5https://www.biopharmawatch.com/news/VERU/sam-fisch-800-972-0538-veru-reports-higher-net-revenues-and-gross-profit-for-its-fiscal-20-veru-20190808monthly0.5https://www.biopharmawatch.com/news/VERU/sam-fisch-800-972-0538-veru-reports-strong-fiscal-2019-second-quarter-financial-results-pr-veru-20190515monthly0.5https://www.biopharmawatch.com/news/VERU/kevin-gilbert-786-322-2213-veru-reports-strong-fiscal-2019-first-quarter-financial-results-veru-20190213monthly0.5https://www.biopharmawatch.com/news/VERU/kevin-gilbert-786-322-2213-veru-reports-strong-net-revenues-and-gross-profit-for-fiscal-20-veru-20181213monthly0.5https://www.biopharmawatch.com/news/VERU/kevin-gilbert-786-322-2213-veru-announces-proposed-public-offering-of-common-stock-miami-veru-20180926monthly0.5https://www.biopharmawatch.com/news/VERU/kevin-gilbert-786-322-2213-veru-reports-fiscal-2018-third-quarter-financial-results-invest-veru-20180814monthly0.5https://www.biopharmawatch.com/news/VERU/kevin-gilbert-786-322-2213-veru-reports-fiscal-2018-second-quarter-financial-results-promi-veru-20180509monthly0.5https://www.biopharmawatch.com/news/VERU/kevin-gilbert-786-322-2213-veru-reports-fiscal-2018-first-quarter-financial-results-compan-veru-20180214monthly0.5https://www.biopharmawatch.com/news/VERU/app-xfeff-xfeff-xfeff-aspen-park-pharmaceuticals-inc-xfeff-f-inancial-s-tatements-xfeff-s--veru-20171025monthly0.5https://www.biopharmawatch.com/news/VERU/xfeff-veru-inc-reports-fiscal-third-quarter-financial-results-xfeff-xfeff-miami-x2013-veru-20170808monthly0.5https://www.biopharmawatch.com/news/VERU/fourth-amendment-to-credit-agreement-xfeff-this-fourth-amendment-to-credit-agreement-herei-veru-20170519monthly0.5https://www.biopharmawatch.com/news/VERU/kevin-gilbert-312-366-2633-veru-healthcare-reports-fiscal-2017-second-quarter-financial-re-veru-20170509monthly0.5https://www.biopharmawatch.com/news/VERU/xfeff-xfeff-contact-xfeff-kevin-gilbert-312-366-2633-xfeff-the-female-health-company-veru--veru-20161212monthly0.5https://www.biopharmawatch.com/news/VERU/the-female-health-companya-leading-men-s-and-women-s-health-and-oncology-companydecember-2-veru-20161208monthly0.5https://www.biopharmawatch.com/news/VERU/xfeff-third-amendment-to-credit-agreement-xfeff-this-third-amendment-to-credit-agreement-h-veru-20161128monthly0.5https://www.biopharmawatch.com/news/VERU/transcript-of-conference-call-edited-transcript-the-female-health-company-third-quarter-of-veru-20160728monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-michele-greco-cfo-312-595-9123-the-female-health-compan-veru-20160728monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-michele-greco-cfo-231-526-1244-312-595-9123-the-female-health-compan-veru-20160715monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-michele-greco-cfo-231-526-1244-312-595-9123-draft-1-the-female-healt-veru-20160706monthly0.5https://www.biopharmawatch.com/news/VERU/this-communication-contains-forward-looking-statements-including-those-regarding-the-propo-veru-20160607monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-michele-greco-cfo-312-595-9123-the-female-health-compan-veru-20160603monthly0.5https://www.biopharmawatch.com/news/VERU/first-amendment-to-lock-up-agreement-this-first-amendment-to-lock-up-agreement-this-amendm-veru-20160518monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-michele-greco-cfo-231-526-1244-312-595-9123-the-female-health-compan-veru-20160505monthly0.5https://www.biopharmawatch.com/news/VERU/transcript-of-conference-call-edited-transcript-the-female-health-company-second-quarter-o-veru-20160428monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-michele-greco-cfo-312-595-9123-the-female-health-compan-veru-20160428monthly0.5https://www.biopharmawatch.com/news/VERU/transcript-of-conference-call-edited-transcript-the-female-health-company-the-female-healt-veru-20160413monthly0.5https://www.biopharmawatch.com/news/VERU/mitchell-steiner-md-william-r-gargiulo-jr-michele-greco-cfo-901-581-5872-231-526-1244-312--veru-20160413monthly0.5https://www.biopharmawatch.com/news/VERU/this-communication-contains-forward-looking-statements-including-those-regarding-the-propo-veru-20160412monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-michele-greco-cfo-231-526-1244-312-595-9123-the-female-health-compan-veru-20160407monthly0.5https://www.biopharmawatch.com/news/VERU/robert-jaffe-424-288-4098-mitchell-steiner-md-901-581-5872-william-r-gargiulo-jr-231-526-1-veru-20160406monthly0.5https://www.biopharmawatch.com/news/VERU/separation-agreement-and-general-release-this-separation-agreement-and-general-release-agr-veru-20160206monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-michele-greco-cfo-312-595-9123-the-female-health-compan-veru-20160202monthly0.5https://www.biopharmawatch.com/news/VERU/execution-version-credit-agreement-dated-as-of-december-29-2015-by-and-between-the-female--veru-20151229monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-michele-greco-cfo-312-595-9123-the-female-health-compan-veru-20151201monthly0.5https://www.biopharmawatch.com/news/VERU/charter-2-ex99-1oct62015form8k-htm-ex99-1oct62015form8k-htm-contacts-william-r-gargiulo-jr-veru-20151006monthly0.5https://www.biopharmawatch.com/news/VERU/charter-2-ex99-1july2015firn8j-htm-ex99-1july2015firn8j-htm-contacts-william-r-gargiulo-jr-veru-20150730monthly0.5https://www.biopharmawatch.com/news/VERU/charter-2-ex-991toform8k-htm-ex-991toform8k-htm-separation-agreement-and-general-release-t-veru-20150710monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-michele-greco-cfo-312-595-9123-the-female-health-compan-veru-20150701monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-michele-greco-cfo-312-595-9123-the-female-health-compan-veru-20150402monthly0.5https://www.biopharmawatch.com/news/VERU/to-march-19-2015-form-8-k-ex99-1tomarch1920158k-htm-contacts-w-illiam-r-gargiulo-jr-231-52-veru-20150323monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-michele-greco-cfo-312-595-9123-the-female-health-compan-veru-20150203monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-michele-greco-cfo-312-595-9123-the-female-health-compan-veru-20141202monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-michele-greco-cfo-312-595-9123-the-female-health-compan-veru-20141002monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-michele-greco-cfo-312-595-9123-the-female-health-compan-veru-20140915monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-michele-greco-cfo-312-595-9123-the-female-health-compan-veru-20140731monthly0.5https://www.biopharmawatch.com/news/VERU/to-form-8-k-ex991toform8k-htm-contacts-william-r-gargiulo-jr-231-526-1244-michele-greco-cf-veru-20140714monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-michele-greco-cfo-312-595-9123-the-female-health-compan-veru-20140501monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-michele-greco-cfo-312-595-9123-the-female-health-compan-veru-20140324monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-michele-greco-cfo-312-595-9123-the-female-health-compan-veru-20140205monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-michele-greco-cfo-312-595-9123-the-female-health-compan-veru-20131216monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-michele-greco-cfo-312-595-9123-the-female-health-compan-veru-20131211monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-michele-greco-cfo-312-595-9123-the-female-health-compan-veru-20131203monthly0.5https://www.biopharmawatch.com/news/VERU/w-illiam-r-gargiulo-jr-231-526-1244-michele-greco-cfo-312-595-9123-the-female-health-compa-veru-20131004monthly0.5https://www.biopharmawatch.com/news/VERU/w-illiam-r-gargiulo-jr-231-526-1244-michele-greco-cfo-312-595-9123-michael-walton-retires--veru-20130910monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-michele-greco-cfo-312-595-9123-the-female-health-compan-veru-20130801monthly0.5https://www.biopharmawatch.com/news/VERU/to-form-8-k-ex991toform8k-htm-contacts-william-r-gargiulo-jr-231-526-1244-michele-greco-cf-veru-20130715monthly0.5https://www.biopharmawatch.com/news/VERU/w-illiam-r-gargiulo-jr-231-526-1244-michele-greco-cfo-312-595-9123-andrew-love-joins-the-f-veru-20130514monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-michele-greco-231-526-1244-312-595-9123-the-female-health-company-re-veru-20130502monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-michele-greco-cfo-312-595-9123-the-female-health-compan-veru-20130327monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-michele-greco-312-595-9123-the-female-health-company-re-veru-20130130monthly0.5https://www.biopharmawatch.com/news/VERU/consulting-agreement-this-consulting-agreement-this-agreement-is-entered-into-as-of-veru-20130101monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-michele-greco-cfo-312-595-9123-the-female-health-compan-veru-20130103monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-donna-felch-312-595-9123-the-female-health-company-repo-veru-20121204monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-donna-felch-312-595-9123-the-female-health-company-anno-veru-20121109monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-donna-felch-cfo-312-595-9123-the-female-health-company--veru-20121005monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-donna-felch-312-595-9123-the-female-health-company-repo-veru-20120731monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-donna-felch-cfo-312-595-9123-the-female-health-company--veru-20120713monthly0.5https://www.biopharmawatch.com/news/VERU/w-illiam-r-gargiulo-jr-231-526-1244-donna-felch-312-595-9123-the-female-health-company-rep-veru-20120501monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-donna-felch-cfo-312-595-9123-the-female-health-company--veru-20120327monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-donna-felch-312-595-9123-the-female-health-company-repo-veru-20120131monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-donna-felch-cfo-312-595-9123-the-female-health-company--veru-20120105monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-donna-felch-312-595-9123-the-female-health-company-repo-veru-20111202monthly0.5https://www.biopharmawatch.com/news/VERU/to-female-health-compant-form-8-k-ex991tofhcoform8k-htm-for-immediate-release-contacts-wil-veru-20111007monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-donna-felch-cfo-312-595-9123-the-female-health-company--veru-20110805monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-donna-felch-cfo-312-595-9123-the-female-health-company--veru-20110715monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-donna-felch-cfo-312-595-9123-the-female-health-company--veru-20110506monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-donna-felch-cfo-312-595-9123-the-female-health-company--veru-20110413monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-donna-felch-cfo-312-595-9123-the-female-health-company--veru-20110204monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-donna-felch-cfo-312-595-9123-the-female-health-company--veru-20110114monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-donna-felch-312-595-9123-the-female-health-company-repo-veru-20101203monthly0.5https://www.biopharmawatch.com/news/VERU/to-fhco-form-8-k-10-8-2010-ex991fhco8k1082010-htm-for-immediate-release-contacts-william-r-veru-20101008monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-donna-felch-cfo-312-595-9123-the-female-health-company--veru-20100806monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-donna-felch-cfo-312-595-9123-the-female-health-company--veru-20100723monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-donna-felch-cfo-312-595-9123-the-female-health-company--veru-20100507monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-donna-felch-cfo-312-595-9123-the-female-health-company--veru-20100412monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-donna-felch-cfo-312-595-9123-the-female-health-company--veru-20100208monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-donna-felch-312-595-9123-the-female-health-company-init-veru-20100119monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-donna-felch-312-595-9123-the-female-health-company-repo-veru-20091130monthly0.5https://www.biopharmawatch.com/news/VERU/dated-2nd-november-2009-o-t-properties-limited-1-and-the-female-health-company-uk-plc-2-an-veru-20091106monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-donna-felch-312-595-9123-the-female-health-company-comp-veru-20091021monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-donna-felch-312-595-9123-the-female-health-company-repo-veru-20090807monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-donna-felch-312-595-9123-the-female-health-company-repo-veru-20090508monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-donna-felch-cfo-312-595-9123-the-female-health-company--veru-20090210monthly0.5https://www.biopharmawatch.com/news/VERU/exbibit-99-1-to-fhc-dec-1-2008-form-8-k-ex991tofhcdec12008form8k-htm-for-immediate-release-veru-20081201monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-donna-felch-312-595-9123-the-female-health-company-conf-veru-20081106monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-donna-felch-312-595-9123-the-female-health-company-repo-veru-20080812monthly0.5https://www.biopharmawatch.com/news/VERU/to-may-14-2008-form-8-k-ex99-1tomay142008form8k-htm-for-immediate-release-contacts-william-veru-20080514monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-donna-felch-312-595-9742-the-female-health-company-doub-veru-20080403monthly0.5https://www.biopharmawatch.com/news/VERU/the-female-health-company-2008-stock-incentive-plan-effective-as-of-veru-20080327monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-donna-felch-cfo-312-595-9123-the-female-health-company--veru-20080213monthly0.5https://www.biopharmawatch.com/news/VERU/william-r-gargiulo-jr-231-526-1244-donna-felch-312-595-9123-the-female-health-company-repo-veru-20071126monthly0.5https://www.biopharmawatch.com/news/LITS/lite-strategy-announces-25m-share-repurchase-program-signalling-shift-from-initial-litecoi-lits-20251029monthly0.5https://www.biopharmawatch.com/news/LITS/lite-strategy-inc-nasdaq-lits-is-the-first-u-s-listed-public-company-to-adopt-litecoin-as--lits-20250910monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-acquires-litecoin-launches-100m-institutional-treasury-strategy-with-charlie-le-lits-20250804monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-announces-100-000-000-private-placement-to-initiate-litecoin-treasury-strategy--lits-20250718monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-reports-third-quarter-fiscal-year-2025-cash-position-evaluation-of-strategic-al-lits-20250513monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-reports-second-quarter-fiscal-year-2025-cash-position-evaluation-of-strategic-a-lits-20250212monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-reports-first-quarter-fiscal-year-2025-cash-position-reaffirms-continuation-of--lits-20241112monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-reports-fiscal-year-end-2024-cash-position-confirms-continuation-of-evaluation--lits-20240919monthly0.5https://www.biopharmawatch.com/news/LITS/voruciclib-an-oral-cdk9-inhibitor-for-aml-and-other-malignancies-july-2024-forward-looking-lits-20240730monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-to-consider-strategic-alternatives-company-commences-a-cash-preservation-plan-i-lits-20240722monthly0.5https://www.biopharmawatch.com/news/LITS/nasdaq-meip-corporate-overview-novel-drug-candidates-to-address-known-resistance-mechanism-lits-20240521monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-reports-third-quarter-fiscal-year-2024-results-and-operational-highlights-ongoi-lits-20240509monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-reports-second-quarter-fiscal-year-2024-results-and-operational-highlights-san--lits-20240213monthly0.5https://www.biopharmawatch.com/news/LITS/inability-to-protect-our-patents-or-proprietary-rights-and-obtain-necessary-rights-to-thir-lits-20231211monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-reports-first-quarter-fiscal-year-2024-results-and-operational-highlights-san-d-lits-20231109monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-enters-into-agreement-with-anson-funds-and-cable-car-capital-commits-to-capital-lits-20231101monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-adopts-limited-duration-stockholder-rights-plan-responds-to-substantial-stock-a-lits-20231002monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-reports-fiscal-year-2023-results-and-operational-highlights-conference-call-tod-lits-20230926monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-announces-results-of-special-meeting-of-stockholders-lits-20230723monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-reminds-shareholders-to-vote-today-for-the-infinity-transaction-lits-20230719monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-encourages-shareholders-to-vote-for-the-infinity-transaction-lits-20230717monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-postpones-special-meeting-of-shareholders-lits-20230713monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-reminds-shareholders-to-vote-for-the-merger-with-infinity-pharmaceuticals-glass-lits-20230707monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-highlights-recommendation-by-leading-independent-proxy-advisory-firm-iss-to-vot-lits-20230705monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-mails-letter-to-shareholders-reiterating-value-creating-potential-of-proposed-t-lits-20230629monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-responds-to-anson-and-cable-car-lits-20230627monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-and-infinity-pharmaceuticals-host-video-webcast-providing-overview-and-update-o-lits-20230619monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-announces-planned-departure-of-chief-financial-officer-brian-drazba-and-appoint-lits-20230613monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-announces-planned-departure-of-ceo-daniel-p-gold-ph-d-and-appointment-of-david--lits-20230602monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-board-of-directors-rejects-unsolicited-proposal-lits-20230601monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-confirms-receipt-of-unsolicited-acquisition-proposal-lits-20230530monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-reports-third-quarter-fiscal-year-2023-results-and-operational-highlights-mei-b-lits-20230511monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-announces-1-for-20-lits-20230414monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-and-infinity-pharmaceuticals-announce-definitive-merger-agreement-to-advance-th-lits-20230223monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-reports-second-quarter-fiscal-year-2023-results-and-operational-highlights-mei--lits-20230209monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-and-kyowa-kirin-announce-discontinuation-of-zandelisib-development-outside-of-j-lits-20221208monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-reports-first-quarter-fiscal-year-2023-results-and-operational-highlights-mei-b-lits-20221114monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-reports-third-quarter-fiscal-year-2022-results-and-operational-highlights-mei-b-lits-20220523monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-and-kyowa-kirin-provide-regulatory-update-on-zandelisib-following-meeting-with--lits-20220325monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-announces-pricing-of-public-offering-of-common-stock-san-diego-lits-20211201monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-and-kyowa-kirin-announce-data-from-the-ongoing-global-phase-2-tidal-study-evalu-lits-20211130monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-appoints-biotechnology-executive-sujay-kango-to-its-board-of-directors-lits-20211123monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-announces-planned-chief-financial-officer-transition-brian-drazba-chief-financi-lits-20210805monthly0.5https://www.biopharmawatch.com/news/LITS/forward-looking-statements-this-presentation-contains-and-our-officers-and-representatives-lits-20210614monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-announces-the-retirement-of-chief-medical-officer-robert-mass-and-promotion-of--lits-20210430monthly0.5https://www.biopharmawatch.com/news/LITS/forward-looking-statements-this-presentation-contains-and-our-officers-and-representatives-lits-20210331monthly0.5https://www.biopharmawatch.com/news/LITS/helsinn-group-and-mei-pharma-discontinue-the-phase-3-study-with-pracinostat-in-aml-after-c-lits-20200702monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-appoints-cheryl-cohen-product-launch-and-commercialization-veteran-to-its-board-lits-20200414monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-and-kyowa-kirin-announce-global-license-development-and-commercialization-agree-lits-20200414monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-announces-pricing-of-public-offering-of-common-stock-san-diego-lits-20191217monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-appoints-longtime-industry-consultant-and-executive-tamar-howson-to-its-board-o-lits-20190703monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-presents-clinical-results-for-me-344-in-combination-with-bevacizumab-in-early-h-lits-20190601monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-presents-preclinical-data-demonstrating-voruciclib-synergistically-induces-apop-lits-20181201monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-and-kyowa-hakko-kirin-announce-license-agreement-to-develop-and-commercialize-m-lits-20181105monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-promotes-david-m-urso-to-chief-operating-officer-lits-20180716monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-presents-phase-1b-clinical-data-for-me-401-in-patients-with-indolent-b-cell-mal-lits-20180604monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-announces-75-million-private-placement-lits-20180514monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-appoints-industry-veteran-frederick-w-driscoll-to-its-board-of-directors-lits-20180226monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-announces-exclusive-license-agreement-with-presage-biosciences-for-voruciclib-a-lits-20170905monthly0.5https://www.biopharmawatch.com/news/LITS/mei-pharma-announces-appointment-of-brian-drazba-as-chief-financial-officer-san-diego-lits-20170403monthly0.5https://www.biopharmawatch.com/news/LITS/helsinn-group-and-mei-pharma-enter-strategic-agreement-for-the-development-and-commerciali-lits-20160808monthly0.5https://www.biopharmawatch.com/news/LITS/pete-de-spain-vice-president-investor-relations-corporate-communications-858-792-3729-pdes-lits-20151210monthly0.5https://www.biopharmawatch.com/news/LITS/aza-pracinostat-in-aml-introduction-elderly-aml-patients-deemed-unsuitable-for-intensive-t-lits-20151208monthly0.5https://www.biopharmawatch.com/news/LITS/pete-de-spain-vice-president-investor-relations-corporate-communications-858-792-3729-pdes-lits-20150902monthly0.5https://www.biopharmawatch.com/news/LITS/pete-de-spain-vice-president-investor-relations-corporate-communications-858-792-3729-pdes-lits-20150323monthly0.5https://www.biopharmawatch.com/news/LITS/pete-de-spain-vice-president-investor-relations-corporate-communications-858-792-3729-pdes-lits-20141212monthly0.5https://www.biopharmawatch.com/news/LITS/forward-looking-statements-these-slides-and-the-accompanying-oral-presentation-contain-for-lits-20141209monthly0.5https://www.biopharmawatch.com/news/LITS/pracinostat-in-combination-with-azacitidine-produces-a-high-rate-and-rapid-onset-of-diseas-lits-20141208monthly0.5https://www.biopharmawatch.com/news/LITS/pete-de-spain-vice-president-investor-relations-corporate-communications-858-792-3729-pdes-lits-20140909monthly0.5https://www.biopharmawatch.com/news/LITS/pete-de-spain-vice-president-investor-relations-corporate-communications-858-792-3729-pdes-lits-20140902monthly0.5https://www.biopharmawatch.com/news/LITS/pete-de-spain-vice-president-investor-relations-corporate-communications-858-792-3729-pdes-lits-20140408monthly0.5https://www.biopharmawatch.com/news/LITS/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pdespai-lits-20131025monthly0.5https://www.biopharmawatch.com/news/LITS/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pdespai-lits-20131021monthly0.5https://www.biopharmawatch.com/news/LITS/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pdespai-lits-20130618monthly0.5https://www.biopharmawatch.com/news/LITS/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pdespai-lits-20130611monthly0.5https://www.biopharmawatch.com/news/LITS/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pdespai-lits-20130405monthly0.5https://www.biopharmawatch.com/news/LITS/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pdespai-lits-20130211monthly0.5https://www.biopharmawatch.com/news/LITS/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pdespai-lits-20130130monthly0.5https://www.biopharmawatch.com/news/LITS/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pdespai-lits-20121219monthly0.5https://www.biopharmawatch.com/news/LITS/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pdespai-lits-20121105monthly0.5https://www.biopharmawatch.com/news/LITS/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pdespai-lits-20120808monthly0.5https://www.biopharmawatch.com/news/LITS/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pete-de-lits-20120306monthly0.5https://www.biopharmawatch.com/news/LITS/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pete-de-lits-20111229monthly0.5https://www.biopharmawatch.com/news/LITS/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pete-de-lits-20110928monthly0.5https://www.biopharmawatch.com/news/LITS/reminder-marshall-edwards-to-host-conference-call-on-thursday-september-29-san-diego-lits-20110927monthly0.5https://www.biopharmawatch.com/news/LITS/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pete-de-lits-20110908monthly0.5https://www.biopharmawatch.com/news/LITS/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pete-de-lits-20110602monthly0.5https://www.biopharmawatch.com/news/LITS/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pete-de-lits-20110510monthly0.5https://www.biopharmawatch.com/news/LITS/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pete-de-lits-20110502monthly0.5https://www.biopharmawatch.com/news/LITS/pete-de-spain-sr-director-investor-relations-corporate-communications-858-792-3729-pete-de-lits-20110316monthly0.5https://www.biopharmawatch.com/news/LITS/execution-version-voting-agreement-this-voting-agreement-this-agreement-dated-as-of-lits-20101221monthly0.5https://www.biopharmawatch.com/news/LITS/marshall-edwards-to-host-conference-call-on-lits-20100908monthly0.5https://www.biopharmawatch.com/news/LITS/marshall-edwards-inc-contact-pete-de-spain-sr-director-investor-relations-corporate-commun-lits-20100810monthly0.5https://www.biopharmawatch.com/news/LITS/marshall-edwards-inc-contacts-warren-lancaster-203-966-2556-warren-lancaster-marshalledwar-lits-20100617monthly0.5https://www.biopharmawatch.com/news/LITS/marshall-edwards-announces-final-results-from-halted-phase-3-clinical-trial-of-phenoxodiol-lits-20100601monthly0.5https://www.biopharmawatch.com/news/LITS/marshall-edwards-inc-contacts-warren-lancaster-1-203-966-2556-usa-warren-lancaster-marshal-lits-20100524monthly0.5https://www.biopharmawatch.com/news/LITS/marshall-edwards-inc-contacts-warren-lancaster-1-203-966-2556-usa-warren-lancaster-marshal-lits-20100506monthly0.5https://www.biopharmawatch.com/news/LITS/marshall-edwards-inc-contacts-warren-lancaster-1-203-966-2556-usa-warren-lancaster-marshal-lits-20100426monthly0.5https://www.biopharmawatch.com/news/LITS/marshall-edwards-inc-contacts-warren-lancaster-1-203-966-2556-usa-warren-lancaster-marshal-lits-20100420monthly0.5https://www.biopharmawatch.com/news/LITS/marshall-edwards-inc-contacts-warren-lancaster-1-203-966-2556-usa-warren-lancaster-marshal-lits-20100319monthly0.5https://www.biopharmawatch.com/news/LITS/marshall-edwards-inc-contact-warren-lancaster-1-203-966-2556-usa-warren-lancaster-marshall-lits-20100208monthly0.5https://www.biopharmawatch.com/news/LITS/marshall-edwards-inc-contacts-warren-lancaster-1-203-966-2556-usa-warren-lancaster-marshal-lits-20091201monthly0.5https://www.biopharmawatch.com/news/LITS/marshall-edwards-inc-contacts-warren-lancaster-1-203-966-2556-usa-warren-lancaster-marshal-lits-20090922monthly0.5https://www.biopharmawatch.com/news/LITS/marshall-edwards-inc-contacts-warren-lancaster-1-203-966-2556-usa-warren-lancaster-marshal-lits-20090805monthly0.5https://www.biopharmawatch.com/news/LITS/biotech-analyst-joins-board-of-directors-of-marshall-edwards-inc-new-canaan-ct-and-sydney--lits-20090324monthly0.5https://www.biopharmawatch.com/news/LITS/marshall-edwards-inc-announces-resignation-of-stephen-breckenridge-from-board-of-directors-lits-20081219monthly0.5https://www.biopharmawatch.com/news/LITS/marshall-edwards-inc-raises-10-000-000-in-public-offering-washington-dc-and-sydney-austral-lits-20080730monthly0.5https://www.biopharmawatch.com/news/LITS/exv99w1-ovature-phase-iii-trial-update-under-u-s-law-a-new-drug-cannot-be-marketed-until-i-lits-20070821monthly0.5https://www.biopharmawatch.com/news/LITS/marshall-edwards-inc-raises-16-4-million-in-private-equity-financing-washington-dc-and-syd-lits-20070806monthly0.5https://www.biopharmawatch.com/news/LITS/marshall-edwards-inc-contact-david-sheon-202-518-6384-usa-mr-christopher-naughton-ceo-mars-lits-20070404monthly0.5https://www.biopharmawatch.com/news/LITS/marshall-edwards-inc-contact-david-sheon-202-518-6384-usa-mr-christopher-naughton-ceo-mars-lits-20070328monthly0.5https://www.biopharmawatch.com/news/LITS/christopher-naughton-ceo-marshall-edwards-inc-612-8877-6196-david-sheon-sciwords-llc-202-5-lits-20061130monthly0.5https://www.biopharmawatch.com/news/LITS/marshall-edwards-inc-raises-a-total-of-approximately-18-million-in-private-equity-financin-lits-20060712monthly0.5https://www.biopharmawatch.com/news/LITS/marshall-edwards-inc-raises-approximately-14-million-in-private-equity-financing-washingto-lits-20060712monthly0.5https://www.biopharmawatch.com/news/LITS/asx-media-release-7-june-2006-novogen-renegotiates-phenoxodiol-licence-payment-novogen-lim-lits-20060609monthly0.5https://www.biopharmawatch.com/news/LITS/blake-dawson-waldron-l-a-w-y-e-r-s-licence-agreement-novogen-research-pty-limited-abn-87-0-lits-20060516monthly0.5https://www.biopharmawatch.com/news/LITS/marshall-edwards-inc-contact-david-sheon-202-518-6384-usa-mr-christopher-naughton-ceo-mars-lits-20060329monthly0.5https://www.biopharmawatch.com/news/LITS/marshall-edwards-inc-fda-grants-fast-track-designation-for-phenoxodiol-in-oral-dosage-form-lits-20050126monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-380-lackawanna-place-south-orange-nj-07079-call-201-343-5202-nephros-com-nephr-neph-20260507monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-380-lackawanna-place-south-orange-nj-07079-call-201-343-5202-nephros-com-nephr-neph-20250807monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-announces-financial-results-for-quarter-ended-neph-20250508monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-380-lackawanna-place-south-orange-nj-07079-call-201-343-5202-nephros-com-nephr-neph-20250306monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-380-lackawanna-place-south-orange-nj-07079-call-201-343-5202-nephros-com-nephr-neph-20241113monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-380-lackawanna-place-south-orange-nj-07079-call-201-343-5202-nephros-com-nephr-neph-20240509monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-380-lackawanna-place-south-orange-nj-07079-call-201-343-5202-nephros-com-nephr-neph-20240307monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-380-lackawanna-place-south-orange-nj-07079-call-201-343-5202-nephros-com-nephr-neph-20231101monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-380-lackawanna-place-south-orange-nj-07079-call-201-343-5202-nephros-com-nephr-neph-20230809monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-380-lackawanna-place-south-orange-nj-07079-call-201-343-5202-nephros-com-nephr-neph-20230508monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-380-lackawanna-place-south-orange-nj-07079-call-201-343-5202-nephros-com-nephr-neph-20230404monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-380-lackawanna-place-south-orange-nj-07079-call-201-343-5202-nephros-com-nephr-neph-20230308monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-380-lackawanna-place-south-orange-nj-07079-call-201-343-5202-nephros-com-nephr-neph-20230111monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-380-lackawanna-place-south-orange-nj-07079-call-201-343-5202-nephros-com-nephr-neph-20221102monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-380-lackawanna-place-south-orange-nj-07079-call-201-343-5202-nephros-com-nephr-neph-20220930monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-380-lackawanna-place-south-orange-nj-07079-call-201-343-5202-nephros-com-nephr-neph-20220908monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-380-lackawanna-place-south-orange-nj-07079-call-201-343-5202-nephros-com-nephr-neph-20220810monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-380-lackawanna-place-south-orange-nj-07079-call-201-343-5202-nephros-com-nephr-neph-20220630monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-380-lackawanna-place-south-orange-nj-07079-call-201-343-5202-nephros-com-nephr-neph-20220517monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-380-lackawanna-place-south-orange-nj-07079-call-201-343-5202-nephros-com-nephr-neph-20220504monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-380-lackawanna-place-south-orange-nj-07079-call-201-343-5202-nephros-com-nephr-neph-20220223monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-announces-preliminary-results-for-fourth-quarter-and-fiscal-year-2021-and-revenue--neph-20220111monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-announces-preliminary-results-for-third-quarter-of-2021-anticipates-net-revenue-of-neph-20211008monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-appoints-wes-lobo-to-chief-commercial-officer-neph-20210901monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-announces-results-for-quarter-ended-neph-20210805monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-announces-acquisition-of-genarraytion-inc-strategic-acquisition-accelerates-pathog-neph-20210712monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-announces-preliminary-results-for-second-quarter-of-2021-anticipates-net-revenue-o-neph-20210708monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-announces-results-for-quarter-ended-neph-20210506monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-announces-preliminary-results-for-first-quarter-of-2021-anticipates-net-revenue-of-neph-20210405monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-reports-2020-fourth-quarter-and-full-year-financial-results-fourth-quarter-net-rev-neph-20210301monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-announces-preliminary-financial-results-for-fourth-quarter-and-fiscal-year-2020-an-neph-20210112monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-appoints-dan-d-agostino-as-cfo-and-reports-third-quarter-financial-results-finance-neph-20201105monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-announces-pricing-of-5-million-registered-direct-offering-of-common-stock-neph-20201016monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-announces-preliminary-third-quarter-revenues-of-2-1-million-neph-20201006monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-names-andy-astor-president-and-chief-executive-officer-daron-evans-to-remain-senio-neph-20200814monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-reports-second-quarter-financial-results-net-revenue-down-32-due-to-covid-19-inter-neph-20200805monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-announces-preliminary-financial-results-for-second-quarter-2020-anticipates-1-6-mi-neph-20200708monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-to-hold-virtual-annual-meeting-of-stockholders-executives-to-present-business--neph-20200511monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-reports-first-quarter-financial-results-product-revenue-up-43-over-q1-2019-neph-20200506monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-announces-preliminary-financial-results-for-first-quarter-2020-anticipates-2-6-mil-neph-20200402monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-reports-2019-fourth-quarter-and-full-year-financial-results-fourth-quarter-net-rev-neph-20200227monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-announces-pricing-of-7-5-million-underwritten-offering-of-common-stock-neph-20200131monthly0.5https://www.biopharmawatch.com/news/NEPH/dear-friends-and-shareholders-with-the-turn-of-the-new-year-we-are-writing-to-provide-a-co-neph-20200127monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-announces-launch-of-plurapath-tm-a-real-time-portable-water-pathogen-detection-sys-neph-20200109monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-announces-preliminary-financial-results-for-fourth-quarter-and-fiscal-year-2019-an-neph-20200106monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-reports-third-quarter-financial-results-product-revenue-up-85-over-q3-2018-reitera-neph-20191106monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-announces-preliminary-financial-results-for-third-quarter-2019-anticipates-3-1-mil-neph-20191007monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-announces-listing-on-nasdaq-capital-market-neph-20190813monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-reports-second-quarter-financial-results-product-revenue-up-88-over-q2-2018-reiter-neph-20190807monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-announces-second-quarter-2019-financial-results-conference-call-and-record-revenue-neph-20190730monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-announces-preliminary-financial-results-for-second-quarter-2019-and-reverse-stock--neph-20190709monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-announces-2-million-private-placement-neph-20190516monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-reports-first-quarter-financial-results-revenues-up-80-over-q1-2018-driven-by-hosp-neph-20190508monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-380-lackawanna-place-south-orange-nj-07079-t-201-343-5202-f-201-343-5207-www-n-neph-20190408monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-reports-2018-fourth-quarter-and-full-year-financial-results-and-provides-corporate-neph-20190312monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-380-lackawanna-place-south-orange-nj-07079-t-201-343-5202-f-201-343-5207-www-n-neph-20190213monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-announces-preliminary-financial-results-for-fiscal-year-2018-anticipates-5-6-5-7-m-neph-20190109monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-announces-acquisition-of-biocon-adds-growing-water-filtration-business-in-food-ser-neph-20190102monthly0.5https://www.biopharmawatch.com/news/NEPH/unaudited-pro-forma-consolidated-balance-sheet-of-nephros-inc-as-of-neph-20181210monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-380-lackawanna-place-south-orange-nj-07079-t-201-343-5202-f-201-343-5207-www-n-neph-20181001monthly0.5https://www.biopharmawatch.com/news/NEPH/specialty-renal-products-announces-3-million-series-a-financing-neph-20180906monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-appoints-oliver-spandow-to-its-board-of-directors-seasoned-executive-adds-signific-neph-20180813monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-announces-preliminary-financial-results-for-second-quarter-2018-anticipates-57-yea-neph-20180709monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-announces-preliminary-financial-results-for-first-quarter-2018-anticipates-39-year-neph-20180416monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-announces-2-9-million-private-placement-neph-20180411monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-41-grand-ave-river-edge-nj-07661-t-201-343-5202-f-201-343-5207-www-nephros-com-neph-20180226monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-380-lackawanna-pl-south-orange-nj-07079-t-201-343-5202-f-201-343-5207-www-neph-neph-20180104monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-41-grand-ave-river-edge-nj-07661-t-201-343-5202-f-201-343-5207-www-nephros-com-neph-20171016monthly0.5https://www.biopharmawatch.com/news/NEPH/dear-friends-and-shareholders-this-is-an-exciting-time-for-nephros-demand-for-our-products-neph-20170927monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-41-grand-ave-river-edge-nj-07661-t-201-343-5202-f-201-343-5207-www-nephros-com-neph-20170710monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-announces-1-2-million-private-placement-neph-20170317monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-announces-appointment-of-andrew-astor-as-chief-financial-officer-technology-indust-neph-20170214monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-provides-corporate-update-and-fourth-quarter-2016-revenue-guidance-projects-positi-neph-20170124monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-receives-fda-510-k-clearance-of-s100-point-of-use-filter-neph-20160414monthly0.5https://www.biopharmawatch.com/news/NEPH/department-of-health-and-human-services-food-and-drug-administration-new-jersey-district-o-neph-20160407monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-reports-preliminary-2015-revenue-and-provides-update-neph-20160201monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-41-grand-ave-river-edge-nj-07661-t-201-343-5202-f-201-343-5207-www-nephros-com-neph-20150930monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-appoints-moshe-pinto-to-its-board-of-directors-neph-20150817monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-neph-20150727monthly0.5https://www.biopharmawatch.com/news/NEPH/attention-mr-neph-20150602monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-appoints-daron-evans-as-president-and-chief-executive-officer-and-lawrence-centell-neph-20150421monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-41-grand-ave-river-edge-nj-07661-t-201-343-5202-f-201-343-5207-www-nephros-com-neph-20150107monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-41-grand-ave-river-edge-nj-07661-t-201-343-5202-f-201-343-5207-www-nephros-com-neph-20141218monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-41-grand-ave-river-edge-nj-07661-t-201-343-5202-f-201-343-5207-www-nephros-com-neph-20141028monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-41-grand-ave-river-edge-nj-07661-t-201-343-5202-f-201-343-5207-www-nephros-com-neph-20140903monthly0.5https://www.biopharmawatch.com/news/NEPH/1-nephros-inc-neph-20140528monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-41-grand-ave-river-edge-nj-07661-t-201-343-5202-f-201-343-5207-www-nephros-com-neph-20140519monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-41-grand-ave-river-edge-nj-07661-t-201-343-5202-f-201-343-5207-www-nephros-com-neph-20140324monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-41-grand-ave-river-edge-nj-07661-t-201-343-5202-f-201-343-5207-www-nephros-com-neph-20140225monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-41-grand-ave-river-edge-nj-07661-t-201-343-5202-f-201-343-5207-www-nephros-com-neph-20131129monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-41-grand-ave-river-edge-nj-07661-t-201-343-5202-f-201-343-5207-www-nephros-com-neph-20131114monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-41-grand-ave-river-edge-nj-07661-t-201-343-5202-f-201-343-5207-www-nephros-com-neph-20130523monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-41-grand-ave-river-edge-nj-07661-t-201-343-5202-f-201-343-5207-www-nephros-com-neph-20130204monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-41-grand-ave-river-edge-nj-07661-t-201-343-5202-f-201-343-5207-www-nephros-com-neph-20121108monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-41-grand-ave-river-edge-nj-07661-t-201-343-5202-f-201-343-5207-www-nephros-com-neph-20120430monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-41-grand-ave-river-edge-nj-07661-t-201-343-5202-f-201-343-5207-www-nephros-com-neph-20120423monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-announces-date-of-its-2012-annual-meeting-of-stockholders-neph-20120210monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-post-effective-amendment-no-2-to-registration-statement-declared-effective-neph-20111018monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-files-510-k-application-for-hemodiafiltration-system-neph-20110811monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-provides-corporate-update-neph-20110726monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-receives-510k-approval-to-market-additional-ultrafiltration-products-neph-20110721monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-and-bellco-s-r-l-announce-license-agreement-for-mid-dilution-dialysis-products-riv-neph-20110627monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-announces-completion-of-3-2-million-financing-through-rights-offering-and-private--neph-20110310monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-announces-3-2-million-financing-through-completion-of-rights-offering-and-private--neph-20110303monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-extends-rights-offering-neph-20110228monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-rights-offering-registration-statement-declared-effective-neph-20110131monthly0.5https://www.biopharmawatch.com/news/NEPH/e-xhibit-99-1-nephros-completes-bridge-financing-and-announces-stockholder-rights-offering-neph-20101001monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-receives-formal-response-from-fda-for-510-k-application-for-hemodiafiltration-syst-neph-20100707monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-and-ameriwater-announce-dual-stage-ultrafilters-to-be-a-standard-component-of-mro--neph-20100706monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-reports-2010-first-quarter-financial-results-river-edge-nj-prnewswire-neph-20100513monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-signs-development-agreement-with-neph-20100323monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-awarded-2-million-contract-expansion-by-the-office-of-naval-research-neph-20090831monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-completes-1-25-million-private-placement-river-edge-n-j-july-30-prnewswire-fir-neph-20090730monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-common-stock-now-quoted-in-pink-sheets-neph-20090126monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-receives-notice-of-intention-to-delist-from-neph-20090114monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-provides-corporate-update-thursday-neph-20081120monthly0.5https://www.biopharmawatch.com/news/NEPH/unassociated-document-nephros-reports-third-quarter-2008-financial-results-neph-20081114monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-receives-non-compliance-neph-20080918monthly0.5https://www.biopharmawatch.com/news/NEPH/for-more-information-on-nephros-please-visit-the-company-s-website-www-nephros-com-forward-neph-20080917monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-reports-second-quarter-2008-financial-results-neph-20080814monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-reports-2008-first-quarter-financial-results-thursday-neph-20080515monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-to-exhibit-at-the-xlv-era-edta-congress-in-stockholm-sweden-may-10-13-2008-company-neph-20080513monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-appoints-gerald-j-kochanski-as-chief-financial-officer-new-york-ny-nephros-inc-ame-neph-20080428monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-substantially-increases-stockholders-equity-and-expects-to-regain-compliance-w-neph-20080116monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-appoints-james-s-scibetta-to-board-of-directors-neph-20071120monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-reports-third-quarter-2007-financial-results-neph-20071113monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-initiates-pivotal-u-s-trial-for-olpur-h2h-hemodiafiltration-module-and-olpur-md-22-neph-20071016monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-receives-non-compliance-notification-from-amex-new-york-ny-neph-20071003monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-raises-12-7-million-in-new-financing-company-to-use-proceeds-for-clinical-trials-p-neph-20070925monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-reports-second-quarter-2007-financial-results-revenues-increase-15-net-loss-is-red-neph-20070813monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-names-new-independent-auditing-firm-neph-20070720monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-reports-departure-of-director-neph-20070523monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-2007-annual-stockholders-meeting-neph-20070522monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-reports-first-quarter-2007-financial-results-revenues-increase-70-net-loss-is-redu-neph-20070515monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-provides-information-regarding-auditor-s-going-concern-report-and-fiscal-2006-resu-neph-20070503monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-reports-departure-of-director-neph-20070501monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-receives-conditional-approval-from-the-fda-of-investigational-device-exemption-app-neph-20070129monthly0.5https://www.biopharmawatch.com/news/NEPH/american-stock-exchange-will-continue-nephros-s-listing-neph-20061120monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-receives-extension-to-submit-amex-plan-of-compliance-neph-20060817monthly0.5https://www.biopharmawatch.com/news/NEPH/norman-barta-ceo-garth-russell-todd-fromer-nephros-inc-kcsa-worldwide-tel-212-781-5113-212-neph-20060804monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-receives-non-compliance-notification-from-neph-20060721monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-inc-2006-annual-stockholders-meeting-neph-20060621monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-completes-5-million-private-placement-company-to-use-proceeds-for-product-developm-neph-20060602monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-appoints-mark-w-lerner-chief-financial-officer-new-york-n-y-neph-20060308monthly0.5https://www.biopharmawatch.com/news/NEPH/norman-barta-ceo-garth-russell-todd-fromer-nephros-inc-kcsa-worldwide-tel-212-781-5113-212-neph-20060112monthly0.5https://www.biopharmawatch.com/news/NEPH/graphic-omitted-graphic-omitted-contact-marc-panoff-cfo-garth-russell-todd-fromer-nephros--neph-20051114monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-for-immediate-release-contacts-marc-panoff-cfo-garth-russell-todd-fromer-nephros-i-neph-20051019monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-contact-marc-panoff-cfo-garth-russell-todd-fromer-nephros-inc-kcsa-worldwide-tel-2-neph-20050815monthly0.5https://www.biopharmawatch.com/news/NEPH/slide-1-nephros-inc-2005-annual-stockholders-meeting-neph-20050623monthly0.5https://www.biopharmawatch.com/news/NEPH/marc-panoff-cfo-garth-russell-todd-fromer-nephros-inc-kcsa-worldwide-tel-212-781-5113-212--neph-20050617monthly0.5https://www.biopharmawatch.com/news/NEPH/garth-russell-todd-fromer-212-896-1250-212-896-1215-grussell-kcsa-com-tfromer-kcsa-com-nep-neph-20050526monthly0.5https://www.biopharmawatch.com/news/NEPH/graphic-omitted-graphic-omitted-contact-marc-panoff-cfo-garth-russell-todd-fromer-nephros--neph-20050516monthly0.5https://www.biopharmawatch.com/news/NEPH/graphic-omitted-graphic-omitted-for-immediate-release-contact-marc-pannoff-todd-fromer-or--neph-20050426monthly0.5https://www.biopharmawatch.com/news/NEPH/graphic-omitted-contact-marc-panoff-cfo-garth-russell-todd-fromer-nephros-inc-kcsa-worldwi-neph-20050331monthly0.5https://www.biopharmawatch.com/news/NEPH/graphic-omitted-graphic-omitted-press-release-nephros-announces-510-k-filing-with-fda-for--neph-20050314monthly0.5https://www.biopharmawatch.com/news/NEPH/nephros-contact-marc-panoff-cfo-nephros-inc-tel-212-781-5113-for-immediate-release-nephros-neph-20050302monthly0.5https://www.biopharmawatch.com/news/NEPH/marc-panoff-cfo-nephros-inc-tel-212-781-5113-for-immediate-release-nephros-inc-reports-thi-neph-20041116monthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-inc-completes-2-15-million-private-placement-financing-strengthens-ba-mlss-20260421monthly0.5https://www.biopharmawatch.com/news/MLSS/following-successful-fda-marketing-clearance-of-the-compuflo-epidural-instrument-milestone-mlss-20170711monthly0.5https://www.biopharmawatch.com/news/MLSS/david-waldman-or-natalya-rudman-crescendo-communications-llc-email-mlss-crescendo-ir-com-t-mlss-20170612monthly0.5https://www.biopharmawatch.com/news/MLSS/david-waldman-or-natalya-rudman-crescendo-communications-llc-email-mlss-crescendo-ir-com-t-mlss-20161216monthly0.5https://www.biopharmawatch.com/news/MLSS/david-waldman-or-natalya-rudman-crescendo-communications-llc-email-mlss-crescendo-ir-com-t-mlss-20160630monthly0.5https://www.biopharmawatch.com/news/MLSS/investor-relations-david-waldman-or-natalya-rudman-crescendo-communications-llc-email-mlss-mlss-20140527monthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-and-tri-anim-health-services-form-strategic-partnership-to-introduce--mlss-20130709monthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-announces-key-leadership-changes-director-leslie-bernhard-appointed-a-mlss-20090901monthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-acquires-additional-patent-rights-for-painless-injections-and-resolve-mlss-20081002monthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-expands-u-s-and-canadian-distribution-network-with-addition-of-patter-mlss-20080605monthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-names-joseph-d-agostino-as-acting-chief-financial-officer-livingston--mlss-20080130monthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-commences-declaratory-judgment-action-with-respect-to-its-single-toot-mlss-20070912monthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-announces-appointment-of-acting-chief-financial-officer-livingston-n--mlss-20070822monthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-secures-1-million-revolving-line-of-credit-livingston-n-j-pr-newswire-mlss-20070709monthly0.5https://www.biopharmawatch.com/news/MLSS/milestone-scientific-announces-plans-to-appoint-new-chief-financial-officer-current-cfo-to-mlss-20070625monthly0.5https://www.biopharmawatch.com/news/MLSS/leonard-osser-chairman-and-ceo-stuart-j-wildhorn-president-milestone-scientific-inc-973-53-mlss-20050401monthly0.5https://www.biopharmawatch.com/news/MLSS/d61801-ex99-1-txt-press-release-for-immediate-release-contact-stuart-wildhorn-president-mi-mlss-20050106monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-announces-return-of-rights-to-ovaprene-phase-3-program-ongoing-positive-int-dare-20251201monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-reports-third-quarter-2025-financial-results-and-provides-corporate-update--dare-20251113monthly0.5https://www.biopharmawatch.com/news/DARE/positive-interim-phase-3-results-highlight-potential-of-ovaprene-novel-hormone-free-contra-dare-20250714monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-reports-first-quarter-2025-financial-results-and-provides-company-update-in-dare-20250513monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-reports-full-year-2024-financial-results-and-provides-company-update-with-i-dare-20250331monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-announces-phase-3-plans-for-sildenafil-cream-3-6-in-the-treatment-of-female-dare-20241216monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-reports-third-quarter-2024-financial-results-and-provides-company-update-co-dare-20241114monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-selected-to-receive-10-million-award-from-arpa-h-s-sprint-for-women-s-healt-dare-20241023monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-announces-common-stock-purchase-agreement-for-up-to-15-million-with-lincoln-dare-20241021monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-reports-second-quarter-2024-financial-results-and-provides-company-update-c-dare-20240812monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-regains-compliance-with-nasdaq-minimum-bid-price-rule-dare-20240719monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-announces-reverse-stock-split-shares-expected-to-begin-trading-on-split-adj-dare-20240627monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-reports-first-quarter-2024-financial-results-and-provides-company-update-co-dare-20240514monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-secures-22-million-in-non-dilutive-strategic-royalty-financing-to-advance-p-dare-20240430monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-reports-full-year-2023-financial-results-and-provides-company-update-confer-dare-20240328monthly0.5https://www.biopharmawatch.com/news/DARE/dare-bioscience-announces-executive-team-and-board-of-directors-changes-san-diego-jan-26-2-dare-20240123monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-secures-12-million-in-royalty-backed-investment-structure-5-million-at-clos-dare-20231226monthly0.5https://www.biopharmawatch.com/news/DARE/dare-bioscience-announces-positive-topline-pharmacokinetic-and-exploratory-efficacy-result-dare-20231220monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-reports-third-quarter-2023-financial-results-and-provides-company-update-co-dare-20231109monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-announces-additional-positive-data-from-phase-2b-respond-study-of-sildenafi-dare-20231101monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-announces-achievement-of-first-commercial-milestone-under-license-agreement-dare-20231016monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-announces-7-0-million-registered-direct-offering-priced-at-the-market-under-dare-20230830monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-reports-second-quarter-2023-financial-results-and-provides-a-company-update-dare-20230810monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-provides-update-on-activities-to-support-commercial-launch-of-xaciato-clind-dare-20230705monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-announces-positive-topline-data-from-the-exploratory-phase-2b-respond-study-dare-20230605monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-reports-first-quarter-2023-financial-results-and-provides-a-company-update--dare-20230511monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-reports-full-year-2022-financial-results-and-provides-a-company-update-conf-dare-20230330monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-announces-positive-pharmacokinetic-pk-results-from-the-dare-hrt1-phase-1-2--dare-20230109monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-announces-new-development-program-dare-pdm1-as-a-potential-first-in-categor-dare-20221212monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-announces-positive-topline-results-from-dare-vva1-phase-1-2-clinical-study--dare-20221114monthly0.5https://www.biopharmawatch.com/news/DARE/bacterial-vaginosis-is-the-most-common-cause-of-vaginitis-worldwide-the-condition-results--dare-20221110monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-announces-positive-efficacy-results-from-the-dare-hrt1-phase-1-2-study-stat-dare-20221017monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-announces-ide-approval-for-a-single-arm-open-label-pivotal-contraceptive-ef-dare-20221010monthly0.5https://www.biopharmawatch.com/news/DARE/forward-looking-statements-disclaimers-2-this-presentation-is-for-informational-purposes-o-dare-20220912monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-announces-interim-analysis-of-phase-2b-respond-study-of-sildenafil-cream-3--dare-20220829monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-reports-second-quarter-2022-financial-results-and-provides-a-company-update-dare-20220809monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-announces-closing-of-global-license-agreement-with-organon-to-commercialize-dare-20220630monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-announces-partial-adjournment-of-annual-meeting-of-stockholders-to-dare-20220624monthly0.5https://www.biopharmawatch.com/news/DARE/forward-looking-statements-disclaimers-2-this-presentation-is-for-informational-purposes-o-dare-20220523monthly0.5https://www.biopharmawatch.com/news/DARE/051222-dar-bioscience-reports-first-quarter-2022-financial-results-and-provides-a-company--dare-20220512monthly0.5https://www.biopharmawatch.com/news/DARE/upsets-the-balance-of-the-natural-vaginal-microbiome-and-can-lead-to-symptoms-of-odor-and--dare-20220331monthly0.5https://www.biopharmawatch.com/news/DARE/organon-media-contacts-karissa-peer-organon-investor-contacts-jennifer-halchak-614-314-809-dare-20220331monthly0.5https://www.biopharmawatch.com/news/DARE/forward-looking-statements-disclaimers-2-this-presentation-is-for-informational-purposes-o-dare-20220307monthly0.5https://www.biopharmawatch.com/news/DARE/forward-looking-statements-disclaimers-2-this-presentation-is-for-informational-purposes-o-dare-20220214monthly0.5https://www.biopharmawatch.com/news/DARE/forward-looking-statements-disclaimers-2-this-presentation-is-for-informational-purposes-o-dare-20220110monthly0.5https://www.biopharmawatch.com/news/DARE/forward-looking-statements-disclaimers-2-this-presentation-is-for-informational-purposes-o-dare-20211207monthly0.5https://www.biopharmawatch.com/news/DARE/forward-looking-statements-disclaimers-2-this-presentation-is-for-informational-purposes-o-dare-20210930monthly0.5https://www.biopharmawatch.com/news/DARE/forward-looking-statements-disclaimers-2-this-presentation-is-for-informational-purposes-o-dare-20210909monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-da-dare-20210809monthly0.5https://www.biopharmawatch.com/news/DARE/forward-looking-statements-disclaimers-2-this-presentation-is-for-informational-purposes-o-dare-20210630monthly0.5https://www.biopharmawatch.com/news/DARE/forward-looking-statements-disclaimers-2-this-presentation-is-for-informational-purposes-o-dare-20210517monthly0.5https://www.biopharmawatch.com/news/DARE/forward-looking-statements-disclaimers-2-this-presentation-is-for-informational-purposes-o-dare-20201209monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-announces-positive-topline-results-from-dare-bvfree-a-phase-3-trial-of-dare-dare-20201207monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-regains-compliance-with-nasdaq-minimum-equity-rule-and-secures-capital-to-a-dare-20200206monthly0.5https://www.biopharmawatch.com/news/DARE/bayer-and-dar-bioscience-announce-exclusive-licensing-agreement-for-u-s-commercial-rights--dare-20200113monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-closes-previously-announced-acquisition-of-microchips-biotech-with-a-first--dare-20191121monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-inc-prices-underwritten-public-offering-of-common-stock-dare-20190409monthly0.5https://www.biopharmawatch.com/news/DARE/forward-looking-statements-this-presentation-is-for-informational-purposes-only-and-is-not-dare-20190107monthly0.5https://www.biopharmawatch.com/news/DARE/forward-looking-statements-this-presentation-is-for-informational-purposes-only-and-is-not-dare-20181210monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-inc-announces-licensing-and-global-rights-to-novel-phase-iii-product-candid-dare-20181206monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-inc-announces-initiation-of-content-validity-study-for-sildenafil-cream-3-6-dare-20181129monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-inc-announces-enrollment-in-thermography-feasibility-study-with-sildenafil--dare-20181127monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-provides-business-update-and-announces-third-quarter-financial-results-san--dare-20181113monthly0.5https://www.biopharmawatch.com/news/DARE/greg-matz-joins-dar-bioscience-board-of-directors-dare-20180917monthly0.5https://www.biopharmawatch.com/news/DARE/forward-looking-statements-this-presentation-is-for-informational-purposes-only-and-is-not-dare-20180905monthly0.5https://www.biopharmawatch.com/news/DARE/forward-looking-statements-this-presentation-is-for-informational-purposes-only-and-is-not-dare-20180615monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-inc-enters-into-exclusive-worldwide-license-agreement-for-juniper-pharmaceu-dare-20180425monthly0.5https://www.biopharmawatch.com/news/DARE/jessica-grossman-m-d-joins-dar-bioscience-board-of-directors-dare-20180411monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-inc-to-raise-approximately-10-25-million-san-diego-ca-dare-20180213monthly0.5https://www.biopharmawatch.com/news/DARE/dar-bioscience-inc-enters-into-license-and-collaboration-agreement-for-a-product-with-the--dare-20180212monthly0.5https://www.biopharmawatch.com/news/DARE/forward-looking-statements-this-presentation-is-for-informational-purposes-only-and-is-not-dare-20180108monthly0.5https://www.biopharmawatch.com/news/DARE/cerulean-and-dar-announce-awards-for-dar-ceo-ms-johnson-received-athena-pinnacle-award-and-dare-20170508monthly0.5https://www.biopharmawatch.com/news/DARE/thomson-reuters-streetevents-www-streetevents-com-contact-us-2017-thomson-reuters-all-righ-dare-20170323monthly0.5https://www.biopharmawatch.com/news/DARE/cerulean-and-dar-to-host-conference-call-on-proposed-transaction-on-march-23-dare-20170320monthly0.5https://www.biopharmawatch.com/news/DARE/cerulean-pharma-and-dar-bioscience-enter-into-stock-purchase-agreement-transaction-to-crea-dare-20170320monthly0.5https://www.biopharmawatch.com/news/DARE/cerulean-reports-third-quarter-2016-financial-results-and-provides-corporate-update-confer-dare-20161103monthly0.5https://www.biopharmawatch.com/news/DARE/cerulean-announces-technology-platform-collaboration-collaboration-will-create-nanoparticl-dare-20161019monthly0.5https://www.biopharmawatch.com/news/DARE/common-stock-purchase-agreement-common-stock-purchase-agreement-the-agreement-dated-as-of-dare-20161014monthly0.5https://www.biopharmawatch.com/news/DARE/cerulean-announces-reduction-in-force-dare-20160818monthly0.5https://www.biopharmawatch.com/news/DARE/cerulean-announces-results-from-phase-2-clinical-trial-of-crlx101-and-avastin-combination--dare-20160817monthly0.5https://www.biopharmawatch.com/news/DARE/cerulean-reports-second-quarter-2016-corporate-highlights-and-financial-results-conference-dare-20160804monthly0.5https://www.biopharmawatch.com/news/DARE/cerulean-reports-first-quarter-2016-corporate-highlights-and-financial-results-conference--dare-20160502monthly0.5https://www.biopharmawatch.com/news/DARE/cerulean-reports-fourth-quarter-2015-corporate-highlights-and-financial-results-conference-dare-20160310monthly0.5https://www.biopharmawatch.com/news/DARE/cerulean-reports-third-quarter-2015-corporate-highlights-and-financial-results-conference--dare-20151116monthly0.5https://www.biopharmawatch.com/news/DARE/cerulean-appoints-adrian-senderowicz-m-d-as-chief-medical-officer-dare-20150908monthly0.5https://www.biopharmawatch.com/news/DARE/cerulean-reports-second-quarter-2015-corporate-highlights-and-financial-results-strengthen-dare-20150806monthly0.5https://www.biopharmawatch.com/news/DARE/cerulean-appoints-interim-chief-financial-officer-dare-20150527monthly0.5https://www.biopharmawatch.com/news/DARE/cerulean-reports-first-quarter-2015-corporate-highlights-and-financial-results-phase-1b-2--dare-20150506monthly0.5https://www.biopharmawatch.com/news/DARE/cerulean-appoints-chris-guiffre-president-chief-executive-officer-paul-friedman-to-continu-dare-20150320monthly0.5https://www.biopharmawatch.com/news/DARE/cerulean-reports-fourth-quarter-2014-corporate-highlights-and-financial-results-phase-1b-2-dare-20150319monthly0.5https://www.biopharmawatch.com/news/DARE/cerulean-secures-debt-facility-from-hercules-technology-growth-capital-of-up-to-26-0-milli-dare-20150108monthly0.5https://www.biopharmawatch.com/news/DARE/cerulean-reports-third-quarter-2014-corporate-highlights-and-financial-results-dare-20141113monthly0.5https://www.biopharmawatch.com/news/DARE/cerulean-reports-second-quarter-2014-corporate-highlights-and-financial-results-dare-20140812monthly0.5https://www.biopharmawatch.com/news/DARE/cerulean-reports-first-quarter-2014-corporate-highlights-and-financial-results-dare-20140527monthly0.5https://www.biopharmawatch.com/news/BTAI/bxcl501-sublingual-dexmedetomidine-for-treatment-of-agitation-associated-with-bipolar-diso-btai-20251110monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-second-quarter-2025-financial-results-and-recent-business-upd-btai-20250812monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-to-participate-in-canaccord-genuity-45th-annual-growth-conference-btai-20250811monthly0.5https://www.biopharmawatch.com/news/BTAI/xae-bioxcel-therapeutics-555-long-wharf-drive-12th-floor-new-haven-ct-06511-www-bioxcelthe-btai-20250811monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-first-quarter-2025-financial-results-and-provides-business-up-btai-20250512monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-financial-results-for-the-fourth-quarter-and-full-year-2024-e-btai-20250327monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-third-quarter-2024-financial-results-advancing-two-pivotal-ph-btai-20241114monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-second-quarter-2024-financial-results-planning-initiation-of--btai-20240806monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-preliminary-estimated-unaudited-second-quarter-net-revenues-btai-20240716monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-first-quarter-2024-financial-results-advancing-tranquility-an-btai-20240509monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-555-long-wharf-drive-12th-floor-new-haven-ct-06511-bioxceltherapeutic-btai-20240422monthly0.5https://www.biopharmawatch.com/news/BTAI/acute-treatment-of-agitation-associated-with-alzheimer-s-dementia-aad-1-tranquility-progra-btai-20240410monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-financial-results-for-the-fourth-quarter-and-full-year-2023-p-btai-20240312monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-555-long-wharf-drive-12th-floor-new-haven-ct-06511-bioxceltherapeutic-btai-20240214monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-aligns-with-fda-recommendation-for-phase-3-trial-for-tranquility-prog-btai-20231114monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-positive-overall-survival-results-from-single-arm-open-label--btai-20231010monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-second-quarter-2023-financial-results-and-announces-strategic-btai-20230814monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-first-quarter-2023-financial-results-and-recent-operational-h-btai-20230508monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-recen-btai-20230309monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-555-long-wharf-drive-12th-floor-new-haven-ct-06511-www-bioxceltherape-btai-20230221monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-third-quarter-2022-financial-results-and-recent-operational-h-btai-20221110monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-second-quarter-2022-financial-results-and-recent-operational--btai-20220809monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-first-quarter-2022-financial-results-and-recent-operational-h-btai-20220509monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-recen-btai-20220310monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-third-quarter-2021-financial-results-and-recent-operational-h-btai-20211110monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-first-quarter-2021-financial-results-and-provides-business-up-btai-20210510monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and-provi-btai-20210311monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-appoints-june-bray-to-board-of-directors-former-allergan-executive-br-btai-20210301monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-third-quarter-2020-financial-results-and-provides-business-up-btai-20201112monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-second-quarter-2020-financial-results-and-provides-business-u-btai-20200814monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-first-quarter-2020-financial-results-and-provides-business-up-btai-20200512monthly0.5https://www.biopharmawatch.com/news/BTAI/nasdaq-btai-next-wave-april-2020-of-medicines-utilizing-ai-bioxcel-therapeutics-555-long-w-btai-20200415monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-and-provi-btai-20200309monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-third-quarter-2019-financial-results-and-provides-business-up-btai-20191114monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-second-quarter-2019-financial-results-and-provides-business-u-btai-20190806monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-bxcl501-met-primary-endpoint-in-phase-1b-placebo-controlled-btai-20190722monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-achieved-targeted-exposures-of-bxcl501-designed-for-non-invasive-acut-btai-20190520monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-first-quarter-2019-results-and-provides-business-update-on-tr-btai-20190507monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-showcases-data-on-bxcl701-in-combination-with-ox40-agonist-in-late-br-btai-20190401monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-files-clinical-trial-application-for-the-development-of-bxcl701-and-p-btai-20190325monthly0.5https://www.biopharmawatch.com/news/BTAI/nasdaq-btai-next-wave-of-medicines-march-2019-bioxcel-therapeutics-555-long-wharf-drive-ne-btai-20190312monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-late-breaking-data-presentation-at-aacr-2019-annual-meeting-btai-20190311monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-fourth-quarter-and-full-year-2018-quarterly-results-and-provi-btai-20190307monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-addition-of-merck-kgaa-darmstadt-germany-and-pfizer-to-clin-btai-20190304monthly0.5https://www.biopharmawatch.com/news/BTAI/nasdaq-btai-next-wave-of-medicines-february-11th-2019-bioxcel-therapeutics-555-long-wharf--btai-20190211monthly0.5https://www.biopharmawatch.com/news/BTAI/nasdaq-btai-bxcl501-an-acute-treatment-btai-20190103monthly0.5https://www.biopharmawatch.com/news/BTAI/conditions-and-the-factors-described-under-the-caption-risk-factors-in-bioxcel-s-form-10q--btai-20181227monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-doses-first-subjects-in-pharmacokinetic-bioavailability-and-safety-st-btai-20181219monthly0.5https://www.biopharmawatch.com/news/BTAI/nasdaq-btai-next-wave-of-medicines-bioxcel-therapeutics-555-long-wharf-drive-new-h-aven-ct-btai-20181212monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-fda-acceptance-of-ind-for-lead-neuroscience-candidate-bxcl5-btai-20181212monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-positive-results-from-study-in-agitated-schizophrenia-patient-btai-20181114monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-third-quarter-2018-quarterly-results-and-provides-business-up-btai-20181109monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-fda-acceptance-of-ind-for-lead-immuno-oncology-candidate-bx-btai-20181105monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-provides-update-on-the-clinical-advancement-of-bxcl501-for-the-acute--btai-20181030monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-expands-immuno-oncology-partnership-with-nektar-into-clinical-develop-btai-20180924monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-second-quarter-2018-financial-results-and-provides-business-u-btai-20180808monthly0.5https://www.biopharmawatch.com/news/BTAI/dpp8-9-inhibition-the-primary-mechanism-of-bioxcel-therapeutics-lead-immuno-oncology-asset-btai-20180724monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-positive-results-from-phase-1b-trial-of-intravenously-dosed-d-btai-20180627monthly0.5https://www.biopharmawatch.com/news/BTAI/next-wave-of-medicines-bioxcel-therapeutics-780-east-main-street-branford-ct-06405-www-bio-btai-20180607monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-appoints-vincent-j-o-neill-m-d-as-senior-vice-president-and-chief-med-btai-20180607monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-and-nektar-therapeutics-present-preclinical-pancreatic-cancer-data-fo-btai-20180604monthly0.5https://www.biopharmawatch.com/news/BTAI/next-wave-of-medicines-bioxcel-therapeutics-780-east-main-street-branford-ct-06405-www-bio-btai-20180521monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-data-presentation-at-asco-2018-annual-meeting-btai-20180517monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-reports-first-quarter-2018-financial-results-and-provides-business-up-btai-20180514monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-acceptance-of-abstract-at-asco-2018-annual-meeting-btai-20180426monthly0.5https://www.biopharmawatch.com/news/BTAI/bioxcel-therapeutics-announces-pricing-of-initial-public-offering-btai-20180308monthly0.5https://www.biopharmawatch.com/news/RKTO/adelina-4702663-rocket-one-appoints-major-general-malcolm-b-frost-ret-to-space-and-defense-rkto-20260603monthly0.5https://www.biopharmawatch.com/news/RKTO/conf-4700878-rocket-one-appoints-dr-supriyo-bandyopadhyay-as-lead-technical-advisor-of-ai--rkto-20260601monthly0.5https://www.biopharmawatch.com/news/RKTO/rocket-one-accepted-into-amd-ai-developer-program-to-advance-simulation-of-next-generation-rkto-20260528monthly0.5https://www.biopharmawatch.com/news/RKTO/hoth-therapeutics-becomes-rocket-one-inc-nasdaq-rkto-targeting-the-space-economy-with-next-rkto-20260527monthly0.5https://www.biopharmawatch.com/news/RKTO/ai-chip-energy-efficiency-hoth-therapeutics-restructures-as-rocket-one-inc-to-enter-the-ai-rkto-20260519monthly0.5https://www.biopharmawatch.com/news/RKTO/hoth-therapeutics-announces-2-0-million-registered-direct-offering-rkto-20260401monthly0.5https://www.biopharmawatch.com/news/RKTO/january-2026-innovating-for-everyone-clinical-stage-biopharmaceutical-company-focused-on-n-rkto-20260116monthly0.5https://www.biopharmawatch.com/news/RKTO/october-2025-innovating-for-everyone-clinical-stage-biopharmaceutical-company-focused-on-n-rkto-20251014monthly0.5https://www.biopharmawatch.com/news/RKTO/ht-001-the-first-therapy-for-egfr-inhibitor-induced-cutaneous-toxicities-innovating-for-ev-rkto-20250624monthly0.5https://www.biopharmawatch.com/news/RKTO/hoth-therapeutics-regains-nasdaq-compliance-clears-key-listing-hurdle-reaffirms-path-towar-rkto-20250618monthly0.5https://www.biopharmawatch.com/news/RKTO/june-2025-innovating-for-everyone-clinical-stage-biopharmaceutical-company-focused-on-next-rkto-20250606monthly0.5https://www.biopharmawatch.com/news/RKTO/hoth-therapeutics-announces-positive-initial-data-in-phase-2a-clinical-trial-reports-50-re-rkto-20250415monthly0.5https://www.biopharmawatch.com/news/RKTO/hoth-therapeutics-regains-compliance-with-nasdaq-listing-requirements-new-york-ny-rkto-20250124monthly0.5https://www.biopharmawatch.com/news/RKTO/december-2024-innovating-for-everyone-clinical-stage-biopharmaceutical-company-focused-on--rkto-20241129monthly0.5https://www.biopharmawatch.com/news/RKTO/hoth-therapeutics-board-of-directors-approves-bitcoin-as-treasury-reserve-asset-rkto-20241120monthly0.5https://www.biopharmawatch.com/news/RKTO/hoth-therapeutics-announces-exercise-of-warrants-for-4-2-million-gross-proceeds-rkto-20240327monthly0.5https://www.biopharmawatch.com/news/RKTO/hoth-therapeutics-announces-2-89-million-registered-direct-offering-priced-at-the-market-u-rkto-20230913monthly0.5https://www.biopharmawatch.com/news/RKTO/hoth-therapeutics-announces-10-million-private-placement-priced-at-the-market-under-nasdaq-rkto-20221229monthly0.5https://www.biopharmawatch.com/news/RKTO/hoth-therapeutics-regains-compliance-with-nasdaq-listing-requirements-rkto-20221109monthly0.5https://www.biopharmawatch.com/news/RKTO/hoth-therapeutics-announces-a-1-25-reverse-stock-split-effective-pre-market-opening-on-rkto-20221026monthly0.5https://www.biopharmawatch.com/news/RKTO/clinical-stage-biopharmaceutical-company-focused-on-next-generation-therapeutics-meeting-u-rkto-20220425monthly0.5https://www.biopharmawatch.com/news/RKTO/hoth-therapeutics-inc-announces-proposed-public-offering-of-common-stock-rkto-20220411monthly0.5https://www.biopharmawatch.com/news/RKTO/hoth-therapeutics-announces-ht-alz-therapeutic-shows-positive-results-reduce-amyloid-in-al-rkto-20220104monthly0.5https://www.biopharmawatch.com/news/RKTO/hoth-therapeutics-licenses-lupus-therapeutic-back-to-zyl-therapeutics-hoth-to-receive-shar-rkto-20211208monthly0.5https://www.biopharmawatch.com/news/RKTO/clinical-stage-biopharmaceutical-company-focused-on-next-generation-therapeutics-meeting-u-rkto-20210901monthly0.5https://www.biopharmawatch.com/news/RKTO/hoth-therapeutics-announces-positive-safety-results-from-ad001-cohort-1-of-phase-1b-clinic-rkto-20210628monthly0.5https://www.biopharmawatch.com/news/RKTO/introduction-to-ht-kit-an-mrna-frame-shifting-therapeutic-significantly-inhibits-tumor-gro-rkto-20210524monthly0.5https://www.biopharmawatch.com/news/RKTO/hoth-therapeutics-announces-15-million-private-placement-priced-at-the-market-under-nasdaq-rkto-20210308monthly0.5https://www.biopharmawatch.com/news/RKTO/hoth-therapeutics-announces-licensing-agreement-and-collaboration-with-u-s-army-medical-re-rkto-20210104monthly0.5https://www.biopharmawatch.com/news/RKTO/hoth-therapeutics-enters-into-sponsored-research-agreement-for-on-the-go-covid-19-testing--rkto-20200921monthly0.5https://www.biopharmawatch.com/news/RKTO/hoth-therapeutics-appoints-dr-stefanie-johns-ph-d-as-chief-scientific-officer-rkto-20200831monthly0.5https://www.biopharmawatch.com/news/RKTO/hoth-therapeutics-licenses-intellectual-property-to-develop-real-time-breath-based-covid-1-rkto-20200810monthly0.5https://www.biopharmawatch.com/news/RKTO/hoth-therapeutics-executes-licensing-agreement-of-vnlg-152-for-treatment-of-dermatological-rkto-20200731monthly0.5https://www.biopharmawatch.com/news/RKTO/hoth-therapeutics-announces-sponsored-research-agreement-with-vcu-for-potential-covid-19-t-rkto-20200630monthly0.5https://www.biopharmawatch.com/news/RKTO/hoth-announces-pricing-of-public-offering-of-shares-of-common-stock-rkto-20200521monthly0.5https://www.biopharmawatch.com/news/RKTO/hoth-announces-proposed-public-offering-of-common-stock-rkto-20200521monthly0.5https://www.biopharmawatch.com/news/RKTO/hoth-therapeutics-announces-additions-to-its-board-of-directors-rkto-20200417monthly0.5https://www.biopharmawatch.com/news/RKTO/hoth-announces-proposed-public-offering-of-common-stock-rkto-20200323monthly0.5https://www.biopharmawatch.com/news/RKTO/hoth-therapeutics-announces-agreement-to-joint-development-for-a-self-assembling-vaccine-s-rkto-20200323monthly0.5https://www.biopharmawatch.com/news/RKTO/nasdaq-hoth-fall-2019-corporate-presentation-rkto-20191021monthly0.5https://www.biopharmawatch.com/news/RKTO/hoth-therapeutics-inc-issues-letter-to-shareholders-rkto-20190904monthly0.5https://www.biopharmawatch.com/news/RKTO/hoth-therapeutics-and-zyl-therapeutics-rkto-20190823monthly0.5https://www.biopharmawatch.com/news/RKTO/may-2019-corporate-presentation-rkto-20190429monthly0.5https://www.biopharmawatch.com/news/RKTO/hoth-therapeutics-inc-announces-pricing-of-initial-public-offering-and-trading-on-the-nasd-rkto-20190215monthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-reports-second-quarter-2025-financial-results-and-business-highlights-bbi-35-bold-20250805monthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-reports-first-quarter-2025-financial-results-and-business-highlights-initial-bold-20250509monthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-reports-fourth-quarter-and-full-year-2024-financial-results-and-business-hig-bold-20250327monthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-announces-pipeline-and-leadership-updates-company-elects-not-to-advance-bbi--bold-20241212monthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-reports-third-quarter-2024-financial-results-and-business-highlights-enrollm-bold-20241107monthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-provides-business-updates-focused-on-key-value-drivers-and-reports-second-qu-bold-20240812monthly0.5https://www.biopharmawatch.com/news/BOLD/boundless-bio-reports-first-quarter-2024-financial-results-and-corporate-highlights-bbi-35-bold-20240513monthly0.5https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-announces-105-million-private-placement-financing-proceeds-expected-to-algs-20250212monthly0.5https://www.biopharmawatch.com/news/ALGS/hello-everyone-at-aligos-we-regularly-evaluate-our-rewards-and-compensation-approach-to-en-algs-20240125monthly0.5https://www.biopharmawatch.com/news/INMB/modulating-the-innate-immune-system-to-transform-inflammation-driven-disease-1-corporate-p-inmb-20260227monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-announces-upcoming-webinar-to-present-new-clinical-data-on-cordstrom-for-rdeb-c-inmb-20260219monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-reports-new-phase-2-grey-matter-imaging-data-at-ctad-conference-reinforcing-xpr-inmb-20251201monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-announces-two-presentations-at-the-upcoming-18th-annual-ctad-conference-boca-ra-inmb-20251118monthly0.5https://www.biopharmawatch.com/news/INMB/corporate-presentation-november-2025-nasdaq-inmb-modulating-the-innate-immune-system-to-tr-inmb-20251110monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-report-third-quarter-2025-financial-results-and-provide-a-corporate-upda-inmb-20251030monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-second-quarter-2025-results-provides-business-update-and-announce-inmb-20250807monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-to-present-phase-2-mindful-trial-findings-of-xpro-at-the-alzheimer-s-associatio-inmb-20250724monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-approximately-19-million-registered-direct-offering-priced-at-the-inmb-20250627monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-reports-key-findings-from-phase-2-mindful-trial-of-xpro-in-early-alzheimer-s-di-inmb-20250629monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-announce-top-line-results-from-mindful-phase-2-trial-in-early-alzheimer--inmb-20250626monthly0.5https://www.biopharmawatch.com/news/INMB/xpro-reduces-amyloid-and-enhances-behavior-post-traumatic-brain-injury-in-an-animal-model--inmb-20250610monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-attendance-at-the-2025-rbc-capital-markets-global-healthcare-conf-inmb-20250514monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-first-quarter-2025-results-and-provides-business-update-conferenc-inmb-20250508monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-report-first-quarter-2025-financial-results-and-provide-corporate-update-inmb-20250505monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-receives-favorable-patentability-opinion-for-cordstrom-platform-technology-boca-inmb-20250415monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-partners-with-cell-and-gene-therapy-catapult-to-scale-up-cordstrom-manufacturin-inmb-20250414monthly0.5https://www.biopharmawatch.com/news/INMB/alzheimer-s-disease-ad-and-inflammation-baseline-demographics-and-disease-characteristics--inmb-20250409monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-presents-baseline-demographics-and-disease-profiles-of-participants-in-the--inmb-20250401monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-year-end-2024-results-and-provides-a-business-update-company-to-h-inmb-20250327monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-report-fourth-quarter-2024-financial-results-and-provide-corporate-updat-inmb-20250327monthly0.5https://www.biopharmawatch.com/news/INMB/inmb-nasdaq-in-vivo-activation-of-mlnk-cells-with-inkmune-preliminary-results-from-a-phase-inmb-20250304monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-opens-phase-ii-in-high-dose-cohort-of-inkmune-trial-in-prostate-cancer-medical--inmb-20250212monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-announces-plan-to-submit-fda-biologics-license-application-bla-seeking-approval-inmb-20250210monthly0.5https://www.biopharmawatch.com/news/INMB/corporate-presentation-inflammation-immunology-platforms-xpro-cordstrom-inkmune-inmb-nasda-inmb-20250210monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-expands-inkmune-trial-in-prostate-cancer-to-veterans-first-patient-treated--inmb-20250128monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-final-enrollment-of-208-patients-in-phase-2-trial-in-early-alzhei-inmb-20241113monthly0.5https://www.biopharmawatch.com/news/INMB/inflammation-and-immunology-repair-two-platforms-in-the-clinic-xpro-and-inkmune-inmb-nasda-inmb-20241113monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-third-quarter-2024-results-and-provides-business-update-inmb-20241031monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-host-webinar-on-cognitive-testing-using-emacc-and-cdr-sb-why-emacc-is-th-inmb-20241028monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-publication-in-cell-reports-demonstrating-xpro-promotes-remyelina-inmb-20241024monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-report-third-quarter-2024-financial-results-and-provide-corporate-update-inmb-20241024monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-participate-in-the-maxim-healthcare-virtual-summit-boca-raton-florida-inmb-20241011monthly0.5https://www.biopharmawatch.com/news/INMB/inkmune-demonstrates-excellent-safety-and-increased-nk-cell-activity-in-first-dosing-cohor-inmb-20240926monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-announces-results-of-additional-blinded-interim-analysis-of-phase-2-alzheimer-s-inmb-20240917monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-announces-13-0-million-registered-direct-offering-boca-raton-florida-inmb-20240912monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-present-at-the-baird-2024-global-healthcare-conference-boca-raton-florid-inmb-20240903monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-second-quarter-2024-results-and-provides-business-update-company--inmb-20240801monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-report-second-quarter-2024-financial-results-and-provide-a-corporate-upd-inmb-20240801monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-completes-blinded-interim-analysis-of-phase-ii-alzheimer-s-disease-trial-th-inmb-20240627monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-join-russell-3000-index-boca-raton-florida-inmb-20240530monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-report-first-quarter-2024-financial-results-and-provide-a-corporate-upda-inmb-20240507monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-completes-first-cohort-and-initiates-second-cohort-of-phase-1-2-study-of-in-inmb-20240429monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-9-7-million-registered-direct-offering-priced-at-the-market-under-inmb-20240425monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-24-month-stability-validation-of-xpro-for-phase-iii-readiness-and-inmb-20240423monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-raises-approximately-4-8-million-in-gross-proceeds-through-registered-direc-inmb-20240422monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-presents-data-on-inb03-s-role-as-an-immune-check-point-modulator-in-the-tre-inmb-20240408monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-year-end-2023-results-and-provides-a-q4-business-update-company-t-inmb-20240328monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-report-fourth-quarter-2023-financial-results-and-provide-a-corporate-upd-inmb-20240326monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-announces-fda-removal-of-clinical-hold-for-alzheimer-s-disease-program-the-phas-inmb-20240130monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-announces-first-patient-dosed-in-a-phase-1-2-study-of-inkmune-in-patients-with--inmb-20240102monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-provides-update-regarding-global-alzheimer-s-phase-ii-clinical-trial-and-clinic-inmb-20231218monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-demonstrates-that-inb03-enhances-the-uptake-of-trastuzumab-deruxtecan-in-he-inmb-20231129monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-receives-ema-s-authorization-in-france-and-spain-for-phase-ii-clinical-trial-of-inmb-20231127monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-expansion-of-phase-ii-clinical-trial-for-alzheimer-s-disease-in-e-inmb-20231115monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-third-quarter-2023-results-and-provides-business-update-company-t-inmb-20231101monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-patent-claims-covering-inb16-cell-line-and-inkmune-therapeutic-composition--inmb-20231031monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-report-third-quarter-2023-financial-results-and-provide-a-corporate-upda-inmb-20231016monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-present-at-baird-global-healthcare-conference-and-h-c-wainwright-25th-an-inmb-20230907monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-approval-of-clinical-trial-application-by-the-u-k-medicines-and-h-inmb-20230905monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-second-quarter-2023-results-and-provides-business-update-company--inmb-20230807monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-present-at-the-btig-virtual-biotechnology-conference-boca-raton-fl-inmb-20230801monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-report-second-quarter-2023-financial-results-and-provide-a-corporate-upd-inmb-20230731monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-data-presented-at-the-16th-european-meeting-on-glial-cells-in-hea-inmb-20230710monthly0.5https://www.biopharmawatch.com/news/INMB/harnessing-the-power-of-the-innate-immune-system-inmb-webinar-phase-i-ii-trial-of-inkmune--inmb-20230512monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-fda-clearance-of-ind-application-for-inkmune-a-natural-killer-the-inmb-20230508monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-first-quarter-2023-results-and-provides-business-update-company-t-inmb-20230503monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-report-first-quarter-2023-financial-results-and-provide-a-corporate-upda-inmb-20230424monthly0.5https://www.biopharmawatch.com/news/INMB/xpro1595-improves-outcomes-in-a-mouse-model-of-tbi-induced-alzheimer-s-disease-tnf-is-invo-inmb-20230419monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-present-preclinical-data-at-the-2023-aacr-annual-meeting-showing-improve-inmb-20230411monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-submission-of-investigational-new-drug-ind-application-for-inkmun-inmb-20230403monthly0.5https://www.biopharmawatch.com/news/INMB/i-n-m-b-in-v-e-s-t-o-r-pres-e-nt-a-tio-n-march-2023-h-a-r-n-e-ss-i-n-g-t-h-e-p-o-w-e-r-o-f-inmb-20230315monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-2022-results-and-provides-business-update-company-to-host-confere-inmb-20230302monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-report-fourth-quarter-and-full-year-2022-results-and-provide-a-corporate-inmb-20230221monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-receives-approximately-6-4-million-in-research-and-development-rebates-from-inmb-20230208monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-pre-clinical-data-that-support-a-pioneering-approach-to-treating--inmb-20230125monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-virginia-commonwealth-university-and-barrow-neurological-institute-receive--inmb-20221222monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-data-at-ash-highlight-innovative-natural-killer-cell-therapeutic-platform-s-inmb-20221208monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-reports-combination-therapy-with-inb03-overcomes-resistance-to-trastuzumab--inmb-20221206monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-focused-on-novel-clinical-trial-designs-to-advance-next-generation-of-alzhe-inmb-20221129monthly0.5https://www.biopharmawatch.com/news/INMB/c-o-r-p-o-r-a-t-e-p-a-r-t-i-c-i-p-a-n-t-s-david-moss-chief-financial-officer-rj-tesi-chief-inmb-20221104monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-third-quarter-2022-results-and-provides-business-update-company-t-inmb-20221102monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-report-third-quarter-2022-financial-results-and-provide-a-corporate-upda-inmb-20221026monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-positive-solid-tumor-efficacy-data-in-multiple-cancer-cell-lines--inmb-20221019monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conference-a-inmb-20220907monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-second-quarter-2022-results-and-provides-business-update-company--inmb-20220803monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-report-second-quarter-2022-financial-results-and-provide-a-corporate-upd-inmb-20220727monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-ceo-raymond-j-tesi-md-to-participate-in-two-upcoming-panels-on-alzheimer-s--inmb-20220725monthly0.5https://www.biopharmawatch.com/news/INMB/uspto-issues-patent-covering-use-of-xpro-for-treatment-of-cns-diseases-boca-raton-florida-inmb-20220622monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-in-pre-clinical-models-of-trastuzumab-resistant-muc4-her2-breast-cancer-tre-inmb-20220616monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-provide-additional-manufacturing-information-to-fda-as-part-of-ind-appli-inmb-20220523monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-present-at-the-h-c-wainwright-global-hybrid-investment-conference-on-may-inmb-20220518monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-presents-data-demonstrating-xpro-promotes-remyelination-in-gray-matter-at-3-inmb-20220510monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-first-quarter-2022-results-and-provides-business-update-company-d-inmb-20220506monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-report-first-quarter-2022-financial-results-and-provide-a-corporate-upda-inmb-20220428monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-participate-at-the-b-riley-neuro-ophthalmology-conference-boca-raton-fl-inmb-20220425monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-announces-first-patient-dosed-in-phase-2-xpro1595-trial-for-treatment-of-neuroi-inmb-20220413monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-present-preclinical-data-on-inb03-at-the-american-association-for-cancer-inmb-20220411monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-highlights-inkmune-data-featured-in-nk-cells-in-solid-tumors-workshop-at-in-inmb-20220404monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-company-s-cso-dr-mark-lowdell-to-co-host-the-nk-cells-in-solid-tu-inmb-20220330monthly0.5https://www.biopharmawatch.com/news/INMB/challenges-of-nk-immunotherapy-of-solid-tumours-potentiation-of-intra-tumoral-nk-function--inmb-20220330monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-spotlights-key-findings-in-presentations-at-ad-pd-2022-inmune-bio-inc-inter-inmb-20220325monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-participate-in-the-32nd-annual-oppenheimer-healthcare-conference-and-the-inmb-20220314monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-inmune-bio-inc-announces-fourth-quarter-and-full-year-2021-results-and-prov-inmb-20220304monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-report-fourth-quarter-2021-financial-results-and-provide-a-corporate-upd-inmb-20220223monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-present-at-the-bio-ceo-investor-conference-inmb-20220208monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-two-presentations-at-the-2021-british-society-of-immunology-congr-inmb-20211201monthly0.5https://www.biopharmawatch.com/news/INMB/c-o-r-p-o-r-a-t-e-p-a-r-t-i-c-i-p-a-n-t-s-david-moss-co-founder-and-chief-financial-office-inmb-20211105monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-third-quarter-2021-results-and-provides-business-update-announces-inmb-20211103monthly0.5https://www.biopharmawatch.com/news/INMB/harnessing-the-power-of-the-innate-immune-system-targeting-innate-immune-dysfunction-inmb--inmb-20211104monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-multiple-oral-and-poster-presentations-at-the-14th-clinical-trial-inmb-20211027monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-report-third-quarter-2021-financial-results-and-provide-a-corporate-upda-inmb-20211025monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-participate-in-the-b-riley-fall-2021-best-ideas-in-oncology-series-boca--inmb-20210927monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-participation-at-upcoming-investor-conferences-inmb-20210920monthly0.5https://www.biopharmawatch.com/news/INMB/h-a-r-n-e-ss-i-n-g-t-h-e-p-o-w-e-r-o-f-t-h-e-i-nn-a-t-e-i-mm-u-n-e-s-y-s-t-e-m-targeting-i-inmb-20210907monthly0.5https://www.biopharmawatch.com/news/INMB/alzheimer-s-patients-treated-with-inmune-bio-s-xpro-show-reduction-in-csf-phospho-tau-and--inmb-20210901monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-biomarker-data-demonstrating-that-the-first-patient-treated-with--inmb-20210825monthly0.5https://www.biopharmawatch.com/news/INMB/inkmune-an-interview-with-inmune-bio-inmb-s-dr-mark-lowdell-tw-research-tw-dr-lowdell-than-inmb-20210823monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-present-at-the-canaccord-genuity-41st-annual-growth-conference-inmb-20210810monthly0.5https://www.biopharmawatch.com/news/INMB/c-o-r-p-o-r-a-t-e-p-a-r-t-i-c-i-p-a-n-t-s-david-j-moss-chief-financial-officer-raymond-j-t-inmb-20210806monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-second-quarter-2021-results-and-provides-business-update-inmb-20210804monthly0.5https://www.biopharmawatch.com/news/INMB/harnessing-the-power-of-the-inn-a-te-immune-system-modulating-an-innate-immune-response-ag-inmb-20210804monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-design-of-upcoming-phase-2-alzheimer-s-disease-clinical-trial-and-inmb-20210726monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-poster-presentation-and-plenary-talk-at-the-alzheimer-s-associati-inmb-20210719monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-40-million-registered-direct-offering-boca-raton-fl-inmb-20210714monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-first-patient-treated-with-nk-cell-priming-pseudokine-inkmune-in--inmb-20210712monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-15-million-credit-facility-to-purchase-xencor-option-to-reduce-fu-inmb-20210614monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-lead-drug-candidate-xpro1595-receives-chemical-drug-name-pegipane-inmb-20210602monthly0.5https://www.biopharmawatch.com/news/INMB/c-o-r-p-o-r-a-t-e-p-a-r-t-i-c-i-p-a-n-t-s-david-moss-chief-financial-officer-treasurer-sec-inmb-20210507monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-first-quarter-2021-results-and-provides-business-update-company-t-inmb-20210505monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-report-first-quarter-2021-financial-results-and-provide-a-corporate-upda-inmb-20210428monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-participation-in-fireside-chat-at-the-b-riley-neurosciences-confe-inmb-20210423monthly0.5https://www.biopharmawatch.com/news/INMB/professor-mark-w-lowdell-cso-1-exploring-the-cellular-interactions-between-nk-cells-tumor--inmb-20210329monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-professor-mark-lowdell-phd-cso-to-deliver-presentations-at-two-up-inmb-20210322monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-participation-at-upcoming-virtual-investor-conferences-in-march-2-inmb-20210308monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-report-fourth-quarter-and-full-year-2020-financial-results-and-provide-a-inmb-20210225monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-xpro1595-found-to-decrease-neuroinflammation-and-neurodegeneratio-inmb-20210121monthly0.5https://www.biopharmawatch.com/news/INMB/harnessing-the-power-of-the-innate-immune-system-modulating-an-innate-immune-response-agai-inmb-20210121monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-host-key-opinion-leader-webinar-on-thursday-january-21-at-8-am-et-webina-inmb-20210112monthly0.5https://www.biopharmawatch.com/news/INMB/harnessing-the-power-of-the-innate-immune-system-modulating-an-innate-immune-response-agai-inmb-20201112monthly0.5https://www.biopharmawatch.com/news/INMB/c-o-r-p-o-r-a-t-e-p-a-r-t-i-c-i-p-a-n-t-s-david-moss-chief-financial-officer-treasurer-sec-inmb-20201109monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-third-quarter-results-and-provides-business-update-company-to-hos-inmb-20201105monthly0.5https://www.biopharmawatch.com/news/INMB/www-roth-com-member-finra-sipc-1-of-15-covid-19-review-october-2020-www-roth-com-member-fi-inmb-20201027monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-presents-preliminary-phase-i-data-at-21st-international-conference-on-alzhe-inmb-20201005monthly0.5https://www.biopharmawatch.com/news/INMB/harnessing-the-power-of-the-innate-immune-system-in-mb-kol-webinar-on-treatment-resistant--inmb-20200929monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-host-key-opinion-leader-webinar-on-treatment-resistant-depression-on-tue-inmb-20200923monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-awarded-2-9-million-nih-small-business-innovation-research-grant-to-support-inmb-20200917monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-participate-in-oppenheimer-s-fall-healthcare-life-science-med-tech-virtu-inmb-20200915monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-issuance-of-patent-from-u-s-patent-trademark-office-covering-inkm-inmb-20200903monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-fda-acceptance-of-ind-application-to-evaluate-quellor-in-a-blinde-inmb-20200901monthly0.5https://www.biopharmawatch.com/news/INMB/european-patent-granted-covering-inmune-bio-s-xpro1595-inmb-20200813monthly0.5https://www.biopharmawatch.com/news/INMB/c-o-r-p-o-r-a-t-e-p-a-r-t-i-c-i-p-a-n-t-s-david-j-moss-chief-financial-officer-raymond-j-t-inmb-20200807monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-second-quarter-2020-results-and-provides-business-update-the-comp-inmb-20200805monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-schedules-conference-call-to-report-2020-second-quarter-financial-results-inmb-20200731monthly0.5https://www.biopharmawatch.com/news/INMB/harnessing-the-power-of-the-innate-immune-system-modulating-an-innate-immune-response-agai-inmb-20200730monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-featured-on-fox-news-video-stnf-and-cytokine-storm-inmb-20200727monthly0.5https://www.biopharmawatch.com/news/INMB/correction-inmune-bio-inc-announces-closing-of-25-million-public-offering-of-common-stock--inmb-20200720monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-closing-of-25-million-public-offering-of-common-stock-including-f-inmb-20200720monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-prices-public-offering-of-common-stock-inmb-20200716monthly0.5https://www.biopharmawatch.com/news/INMB/harnessing-the-power-of-the-innate-immune-system-modulating-an-innate-immune-response-agai-inmb-20200714monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-announce-interim-data-from-phase-ib-clinical-study-of-xpro1595-in-patien-inmb-20200709monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-receives-regulatory-approval-from-uk-mhra-to-initiate-phase-i-trial-of-inkm-inmb-20200611monthly0.5https://www.biopharmawatch.com/news/INMB/killers-at-the-crossroad-a-published-review-of-innate-immune-cell-potential-in-treatment-o-inmb-20200519monthly0.5https://www.biopharmawatch.com/news/INMB/harnessing-the-power-of-the-innate-immune-system-modulating-an-innate-immune-response-agai-inmb-20200518monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-first-quarter-2020-results-and-provides-business-update-the-compa-inmb-20200513monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-host-first-quarter-2020-earnings-conference-call-inmb-20200506monthly0.5https://www.biopharmawatch.com/news/INMB/harnessing-the-power-of-the-innate-immune-system-modulating-the-innate-immune-response-aga-inmb-20200505monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-speak-on-covid-19-therapeutic-panel-at-maxim-group-s-infectious-disease--inmb-20200428monthly0.5https://www.biopharmawatch.com/news/INMB/frontiers-in-oncology-publishes-an-invited-review-highlighting-soluble-tnf-s-impact-on-bre-inmb-20200423monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-announces-allowance-of-u-s-patent-covering-method-for-treating-cancer-by-in-viv-inmb-20200422monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-dn-tnf-clinical-trial-complications-of-cytokine-storm-caused-by-covid-19-inmb-20200420monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-initiation-of-clinical-program-targeting-soluble-tnf-to-determine-inmb-20200420monthly0.5https://www.biopharmawatch.com/news/INMB/harnessing-the-power-of-the-innate-immune-system-modulating-an-innate-immune-response-agai-inmb-20200409monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-reports-fourth-quarter-and-full-year-2019-results-drug-pipeline-expands-to--inmb-20200311monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-present-at-the-32nd-annual-roth-conference-on-march-17-inmb-20200305monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-schedules-conference-call-to-report-2019-fourth-quarter-and-full-year-finan-inmb-20200227monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-awarded-500-000-grant-for-development-of-novel-treatment-to-reprogram-innat-inmb-20200210monthly0.5https://www.biopharmawatch.com/news/INMB/jfif-exif-mm-c-c-m-r-1a-qa-q-2-inmb-20200113monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-data-on-its-lead-compound-which-highlights-the-potential-to-lower-inmb-20200102monthly0.5https://www.biopharmawatch.com/news/INMB/bio-announces-final-phase-i-clinical-data-for-its-soluble-tnf-inhibitor-inb03-demonstrates-inmb-20191217monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-first-alzheimer-s-disease-patient-dosed-in-xpro1595-study-neuroin-inmb-20191202monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-discuss-potential-new-alzheimer-s-disease-treatments-in-ctad-pre-confere-inmb-20191125monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-strengthens-board-of-directors-with-appointment-of-veteran-finance-executiv-inmb-20191119monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-reports-third-quarter-2019-financial-results-and-provides-shareholder-updat-inmb-20191108monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-presentation-of-data-related-to-its-lead-compound-xpro1595-at-the-inmb-20191016monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-present-at-advances-in-immuno-oncology-usa-congress-and-at-world-immunot-inmb-20191008monthly0.5https://www.biopharmawatch.com/news/INMB/ceo-of-inmune-bio-inc-discusses-company-accomplishments-at-nasdaq-s-marketsite-and-announc-inmb-20190924monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-to-present-xpro1595-for-treating-neuroinflammation-in-alzheimer-s-disease-at-20-inmb-20190923monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-invited-to-speak-on-company-s-advancements-in-cancer-treatments-at-the-targetin-inmb-20190916monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-uspto-allowance-of-key-patent-covering-its-dn-tnf-platform-techno-inmb-20190912monthly0.5https://www.biopharmawatch.com/news/INMB/inmb-non-confidential3q19-v5-inmb-20190909monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-to-introduce-neuliv-program-for-treatment-of-nash-at-h-c-wainwright-21-st-a-inmb-20190904monthly0.5https://www.biopharmawatch.com/news/INMB/company-contact-inmune-bio-inc-inmb-20190827monthly0.5https://www.biopharmawatch.com/news/INMB/inmb-non-confidential3q19-v2-inmb-20190815monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-reports-second-quarter-2019-financial-results-and-provides-shareholder-update-l-inmb-20190812monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-appoints-biotechnology-executive-edgardo-baracchini-as-new-board-member-la-joll-inmb-20190806monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-reports-positive-preliminary-data-from-inb03-phase-i-clinical-trial-in-cancer-l-inmb-20190805monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-co-founder-and-ceo-rj-tesi-presents-at-cambridge-healthcare-institute-s-7th-ann-inmb-20190801monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-co-founder-and-ceo-presents-at-17th-annual-congress-of-international-drug-disco-inmb-20190725monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-co-founder-and-ceo-presents-at-maxim-group-s-conference-on-alzheimer-s-disease--inmb-20190703monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-announces-publication-of-data-on-inkmune-primed-nk-cells-in-peer-reviewed-journ-inmb-20190627monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-featured-in-exclusive-networknewswire-broadcast-inmb-20190611monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-to-present-alzheimer-s-drug-candidate-xpro1595-at-the-tnf-conference-la-jolla-c-inmb-20190604monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-to-present-at-the-9th-annual-ld-micro-invitational-on-june-5th-inmb-20190528monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-reports-first-quarter-2019-financial-results-and-provides-shareholder-update-gl-inmb-20190515monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-closes-private-placement-of-approximately-4-1-million-of-common-stock-led-by-in-inmb-20190507monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-presenting-poster-at-the-neuroimmunology-drug-development-summit-inmb-20190417monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-announces-poster-presentation-with-new-data-regarding-neurodegenerative-disease-inmb-20190408monthly0.5https://www.biopharmawatch.com/news/INMB/clinical-trials-xpro1595-xpro1595-development-philosophy-alzheimer-s-disease-was-first-des-inmb-20190313monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-co-founders-to-present-at-world-immunotherapy-congress-during-the-festival-of-b-inmb-20190226monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-awarded-a-1-million-grant-for-the-development-of-xpro1595-for-the-treatment-of--inmb-20190211monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-closing-of-initial-public-offering-and-trading-on-the-nasdaq-capi-inmb-20190204monthly0.5https://www.biopharmawatch.com/news/INMB/inmune-bio-inc-announces-pricing-of-initial-public-offering-inmb-20190115monthly0.5https://www.biopharmawatch.com/news/CRVO/diffusion-pharmaceuticals-reports-second-quarter-2017-financial-results-and-provides-busin-crvo-20170814monthly0.5https://www.biopharmawatch.com/news/CRVO/nasdaq-dffn-diffusion-pharmaceuticals-provides-corporate-highlights-and-reports-financial--crvo-20170515monthly0.5https://www.biopharmawatch.com/news/CRVO/nasdaq-dffn-diffusion-pharmaceuticals-announces-closing-of-oversubscribed-private-placemen-crvo-20170403monthly0.5https://www.biopharmawatch.com/news/CRVO/diffusion-pharmaceuticals-provides-corporate-highlights-and-reports-2016-financial-results-crvo-20170331monthly0.5https://www.biopharmawatch.com/news/CRVO/nasdaq-dffn-diffusion-pharmaceuticals-provides-corporate-highlights-and-reports-financial--crvo-20161114monthly0.5https://www.biopharmawatch.com/news/CRVO/otcqx-dffn-diffusion-pharmaceuticals-announc-es-uplisting-to-nasdaq-capital-market-charlot-crvo-20161109monthly0.5https://www.biopharmawatch.com/news/CRVO/otcqx-dffn-diffusion-pharmaceuticals-provides-corporate-highlights-and-reports-financial-s-crvo-20160815monthly0.5https://www.biopharmawatch.com/news/CRVO/otcqx-dffn-diffusion-pharmaceuticals-provides-corporate-highlights-and-reports-first-quart-crvo-20160516monthly0.5https://www.biopharmawatch.com/news/CRVO/otcqx-dffn-diffusion-pharmaceuticals-appoints-thomas-byrne-as-general-counsel-charlottesvi-crvo-20160401monthly0.5https://www.biopharmawatch.com/news/CRVO/otcqx-dffn-diffusion-pharmaceuticals-announce-s-stock-ticker-symbol-change-to-dffn-charlot-crvo-20160125monthly0.5https://www.biopharmawatch.com/news/CRVO/diffusion-p-harmaceuticals-completes-merger-with-restorgenex-and-becomes-a-publicly-traded-crvo-20160108monthly0.5https://www.biopharmawatch.com/news/CRVO/otcqx-resx-restorgenex-and-diffusion-pharmaceuticals-announce-merger-agreement-proposed-me-crvo-20151215monthly0.5https://www.biopharmawatch.com/news/CRVO/otcqx-resx-restorgenex-reports-third-quarter-2015-financial-results-buffalo-grove-illinois-crvo-20151112monthly0.5https://www.biopharmawatch.com/news/CRVO/otcqx-resx-restorgenex-reports-financial-results-buffalo-grove-illinois-crvo-20150812monthly0.5https://www.biopharmawatch.com/news/CRVO/otcqb-resx-restorgenex-reports-first-quarter-2015-financial-results-buffalo-grove-illinois-crvo-20150511monthly0.5https://www.biopharmawatch.com/news/CRVO/otcqb-resx-restorgenex-reports-corporate-highlights-and-financial-results-for-2014-buffalo-crvo-20150406monthly0.5https://www.biopharmawatch.com/news/CRVO/logo-this-presentation-includes-forward-looking-statements-under-the-private-securities-li-crvo-20150112monthly0.5https://www.biopharmawatch.com/news/CRVO/otcqb-resx-restorgenex-reports-third-quarter-2014-financial-results-buffalo-grove-illinois-crvo-20141112monthly0.5https://www.biopharmawatch.com/news/CRVO/logo-this-presentation-includes-forward-looking-statements-under-the-private-securities-li-crvo-20140909monthly0.5https://www.biopharmawatch.com/news/CRVO/otcqb-resx-restorgenex-reports-second-quarter-2014-financial-results-chicago-illinois-crvo-20140814monthly0.5https://www.biopharmawatch.com/news/CRVO/otc-qb-resx-restorgenex-announces-management-changes-chicago-illinois-crvo-20140708monthly0.5https://www.biopharmawatch.com/news/CRVO/restorgenex-completes-acquisition-of-two-biopharmaceutical-companies-los-angeles-californi-crvo-20140331monthly0.5https://www.biopharmawatch.com/news/CRVO/restorgenex-names-stephen-m-simes-as-chief-executive-officer-chicago-illinois-crvo-20140310monthly0.5https://www.biopharmawatch.com/news/CRVO/stratus-media-group-acquires-paloma-pharmaceuticals-inc-and-vasculomedics-inc-crvo-20140306monthly0.5https://www.biopharmawatch.com/news/CRVO/hygeia-therapeutics-inc-and-canterbury-laboratories-llc-crvo-20131122monthly0.5https://www.biopharmawatch.com/news/CRVO/stratus-media-group-enters-dermatological-and-restorative-medicine-industry-signs-merger-a-crvo-20130929monthly0.5https://www.biopharmawatch.com/news/CRVO/jack-schneider-named-to-board-role-at-stratus-media-group-inc-veteran-allen-company-execut-crvo-20111201monthly0.5https://www.biopharmawatch.com/news/CRVO/stratus-media-group-secures-ninety-five-percent-ownership-of-proelite-inc-stratus-media-gr-crvo-20110615monthly0.5https://www.biopharmawatch.com/news/CRVO/stratus-media-group-closes-14-1-million-financing-funding-and-corporate-realignment-will-f-crvo-20110526monthly0.5https://www.biopharmawatch.com/news/CRVO/proelite-relaunch-under-management-of-stratus-media-group-international-mma-events-planned-crvo-20100223monthly0.5https://www.biopharmawatch.com/news/CRVO/unassociated-document-news-release-contact-gary-s-maier-maier-company-inc-310-442-9852-str-crvo-20080730monthly0.5https://www.biopharmawatch.com/news/CRVO/gary-s-maier-maier-company-inc-310-442-9852-feris-international-adopts-new-corporate-name--crvo-20080714monthly0.5https://www.biopharmawatch.com/news/CRVO/gary-s-maier-maier-company-inc-310-442-9852-crvo-20080423monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-inc-announces-2-0-million-bridge-financing-aplm-20260401monthly0.5https://www.biopharmawatch.com/news/APLM/index-to-unaudited-condensed-consolidated-interim-financial-statements-unaudited-condensed-aplm-20251222monthly0.5https://www.biopharmawatch.com/news/APLM/foster-city-ca-aplm-20251119monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-announces-changes-to-its-board-of-directors-and-composition-of-committees-by-ap-aplm-20251117monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-announces-receipt-of-nasdaq-delisting-notification-and-will-appeal-to-retain-na-aplm-20250921monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-inc-incorporated-in-the-cayman-islands-as-an-exempted-company-with-limited-liab-aplm-20250828monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-announces-top-line-results-for-phase-3-bridging-trial-of-uproleselan-in-china-i-aplm-20241220monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-regains-compliance-with-nasdaq-s-minimum-bid-price-requirement-aplm-20241210monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-inc-incorporated-in-the-cayman-islands-with-limited-liability-nasdaq-aplm-989-e-aplm-20241101monthly0.5https://www.biopharmawatch.com/news/APLM/index-to-condensed-consolidated-interim-financial-statements-condensed-consolidated-interi-aplm-20240814monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-granted-180-day-extension-to-regain-compliance-with-nasdaq-minimum-bid-price-re-aplm-20240716monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-announces-updated-strategic-focus-and-leadership-team-changes-focus-on-vebrelti-aplm-20240703monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-announces-private-placement-financing-and-addition-to-board-of-directors-aplm-20240508monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-announces-approval-of-vebreltinib-in-china-as-a-first-in-class-treatment-for-gl-aplm-20240425monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-highlights-clinical-progress-and-reports-full-year-2023-financial-results-x2022-aplm-20240328monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-appoints-matthew-plunkett-ph-d-as-chief-financial-officer-aplm-20240304monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-receives-nasdaq-notification-regarding-minimum-bid-price-deficiency-apollomics--aplm-20240119monthly0.5https://www.biopharmawatch.com/news/APLM/index-to-condensed-consolidated-interim-financial-statements-condensed-consolidated-interi-aplm-20230928monthly0.5https://www.biopharmawatch.com/news/APLM/apollomics-a-company-developing-novel-oncology-therapies-to-address-difficult-to-treat-can-aplm-20230330monthly0.5https://www.biopharmawatch.com/news/EVAX/of-extraordinary-general-meeting-evax-20241226monthly0.5https://www.biopharmawatch.com/news/EVAX/march-2024-notice-of-annual-general-meeting-evaxion-biotech-a-s-16-april-2024-at-15-00-ces-evax-20240329monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-regains-compliance-with-nasdaq-minimum-bid-price-requirement-evax-20240207monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-announces-closing-of-15-million-public-offering-evax-20240206monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-biotech-announces-pricing-of-15-million-public-offering-evax-20240201monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-to-develop-tailored-novel-cancer-vaccines-based-upon-a-new-untapped-source-of-ai-d-evax-20240124monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-announces-completion-of-ads-ratio-change-evax-20240122monthly0.5https://www.biopharmawatch.com/news/EVAX/december-2023-notice-of-extraordinary-general-meeting-evaxion-biotech-a-s-11-january-2024--evax-20240110monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-announces-plan-to-implement-ads-ratio-change-evax-20240108monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-biotech-announces-closing-of-private-placement-msd-global-health-innovation-fund-m-evax-20231221monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-announces-business-update-and-third-quarter-2023-financial-results-christian-kanst-evax-20231219monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-biotech-announces-private-placement-financing-msd-global-health-innovation-fund-ms-evax-20231219monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-receives-nasdaq-notification-regarding-minimum-bid-price-deficiency-october-5-2023-evax-20231005monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharm-evax-20230918monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-announces-business-update-and-second-quarter-2023-financial-results-promising-clin-evax-20230818monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-biotech-a-s-index-to-unaudited-condensed-consolidated-interim-financial-statements-evax-20230817monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-unveils-proprietary-genetic-adjuvant-technology-to-boost-the-effect-of-dna-and-mrn-evax-20230525monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-announces-promising-clinical-phase-1-data-for-its-personalized-cancer-vaccine-evx--evax-20230525monthly0.5https://www.biopharmawatch.com/news/EVAX/may-2023-notice-of-annual-general-meeting-evaxion-biotech-a-s-24-may-2023-at-14-00-cest-th-evax-20230504monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-announces-promising-clinical-data-for-dna-based-personalized-cancer-immunotherapy--evax-20230418monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-biotech-a-s-vif-proof-1-extraordinary-general-meeting-of-the-shareholders-of-evaxi-evax-20230206monthly0.5https://www.biopharmawatch.com/news/EVAX/january-2023-notice-of-extraordinary-general-meeting-evaxion-biotech-a-s-21-february-2023--evax-20230202monthly0.5https://www.biopharmawatch.com/news/EVAX/important-milestone-reached-for-evaxion-biotech-s-evx-01-personalized-cancer-therapy-copen-evax-20220921monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-biotech-a-s-index-to-unaudited-condensed-consolidated-interim-financial-statements-evax-20220811monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-biotech-announces-second-quarter-2022-financial-results-and-provides-business-upda-evax-20220810monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-biotech-a-s-announces-executive-management-changes-evax-20220802monthly0.5https://www.biopharmawatch.com/news/EVAX/xa9-evaxion-biotech-a-s-all-rights-reserved-worldwide-copenhagen-denmark-2022-anticipated--evax-20220701monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-biotech-announces-gonorrhea-as-second-bacterial-product-target-copenhagen-denmark-evax-20220630monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-biotech-expands-its-evx-03-dna-vaccine-program-into-non-small-cell-lung-cancer-cop-evax-20220623monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-biotech-secures-equity-financing-of-up-to-40-million-from-lincoln-park-capital-cop-evax-20220607monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-biotech-a-s-index-to-unaudited-condensed-consolidated-interim-financial-statements-evax-20220512monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-biotech-announces-first-quarter-2022-financial-results-and-provides-business-updat-evax-20220511monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-biotech-announces-successful-production-of-personalized-cancer-immunotherapies-in--evax-20220510monthly0.5https://www.biopharmawatch.com/news/EVAX/april-2022-notice-of-annual-general-meeting-evaxion-biotech-a-s-3-may-2022-at-4-00-pm-cest-evax-20220412monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-biotech-announces-fourth-quarter-and-full-year-2021-financial-results-and-provides-evax-20220322monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-biotech-strengthens-management-team-with-two-senior-appointments-copenhagen-denmar-evax-20220314monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-biotech-completes-recruitment-for-phase-1-2a-clinical-trial-for-evx-02-copenhagen--evax-20220307monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-biotech-receives-regulatory-clearance-to-initiate-phase-2-trial-of-evx-01-in-combi-evax-20220118monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-biotech-a-s-index-to-unaudited-condensed-consolidated-interim-financial-statements-evax-20211110monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-biotech-announces-closing-of-27-6-million-follow-on-public-offering-including-full-evax-20211109monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-biotech-announces-q3-2021-financial-results-and-provides-business-update-expect-to-evax-20211109monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-biotech-announces-pricing-of-24-0-million-follow-on-public-offering-copenhagen-den-evax-20211105monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-biotech-announces-filing-of-registration-statement-in-the-u-s-for-proposed-follow--evax-20211026monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-biotech-announces-clinical-collaboration-to-evaluate-lead-product-candidate-with-k-evax-20211025monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-biotech-a-s-index-to-unaudited-condensed-consolidated-interim-financial-statements-evax-20210813monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-biotech-announces-q2-2021-financial-results-and-provides-business-update-data-repo-evax-20210812monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-biotech-reports-data-from-phase-1-2a-trials-of-evx-01-and-evx-02-new-clinical-data-evax-20210708monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-develops-method-to-enhance-ai-drug-development-with-deep-probabilistic-programming-evax-20210625monthly0.5https://www.biopharmawatch.com/news/EVAX/june-2021-notice-of-extraordinary-general-meeting-evaxion-biotech-a-s-7-july-2021-at-18-00-evax-20210623monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-biotech-reports-preclinical-proof-of-concept-data-for-evaxion-s-ai-powered-vaccine-evax-20210603monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-biotech-appoints-lars-holtug-to-the-board-of-directors-copenhagen-denmark-evax-20210526monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-biotech-a-s-index-to-unaudited-condensed-consolidated-interim-financial-statements-evax-20210514monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-biotech-announces-q1-2021-financial-results-and-provides-business-update-raised-ne-evax-20210513monthly0.5https://www.biopharmawatch.com/news/EVAX/april-2021-notice-of-annual-general-meeting-evaxion-biotech-a-s-tuesday-25-may-2021-at-15--evax-20210503monthly0.5https://www.biopharmawatch.com/news/EVAX/evaxion-biotech-announces-q4-and-full-year-2020-financial-results-and-provides-business-up-evax-20210406monthly0.5https://www.biopharmawatch.com/news/TVRD/tvardi-therapeutics-announces-first-quarter-tvrd-20260508monthly0.5https://www.biopharmawatch.com/news/TVRD/overview-january-2026-this-presentation-contains-forward-looking-statements-that-involve-s-tvrd-20260116monthly0.5https://www.biopharmawatch.com/news/TVRD/overview-november-2025-this-presentation-contains-forward-looking-statements-that-involve--tvrd-20251119monthly0.5https://www.biopharmawatch.com/news/TVRD/tvardi-therapeutics-announces-third-quarter-2025-results-and-provides-business-update-on-t-tvrd-20251113monthly0.5https://www.biopharmawatch.com/news/TVRD/tvardi-therapeutics-provides-update-on-preliminary-data-from-phase-2-revert-trial-in-idiop-tvrd-20251013monthly0.5https://www.biopharmawatch.com/news/TVRD/tvardi-therapeutics-announces-second-quarter-2025-results-and-provides-business-update-on--tvrd-20250814monthly0.5https://www.biopharmawatch.com/news/TVRD/overview-june-2025-this-presentation-contains-forward-looking-statements-that-involve-subs-tvrd-20250609monthly0.5https://www.biopharmawatch.com/news/TVRD/tvardi-therapeutics-announces-completion-of-enrollment-in-phase-2-clinical-trial-of-tti-10-tvrd-20250527monthly0.5https://www.biopharmawatch.com/news/TVRD/tvardi-therapeutics-announces-first-quarter-2025-results-and-provides-business-update-comp-tvrd-20250513monthly0.5https://www.biopharmawatch.com/news/TVRD/overview-april-2025-this-presentation-and-any-accompanying-oral-commentary-have-been-prepa-tvrd-20250411monthly0.5https://www.biopharmawatch.com/news/TVRD/tvardi-therapeutics-inc-index-to-financial-statements-page-report-of-independent-registere-tvrd-20250401monthly0.5https://www.biopharmawatch.com/news/TVRD/overview-january-2025-2-disclaimer-and-forward-looking-statements-this-presentation-and-an-tvrd-20250121monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-and-tvardi-therapeutics-announce-entry-into-merger-agreement-proposed-me-tvrd-20241218monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-announces-outcome-of-part-a-of-kourage-1-study-evaluating-oral-difelikef-tvrd-20240612monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-first-quarter-2024-financial-results-topline-efficacy-and-safety-tvrd-20240513monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-announces-fourth-quarter-and-full-year-2023-financial-results-announced--tvrd-20240304monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-prioritizes-late-stage-notalgia-paresthetica-program-and-extends-cash-ru-tvrd-20240122monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-announces-outcome-from-dose-finding-part-a-of-kind-1-study-evaluating-or-tvrd-20231218monthly0.5https://www.biopharmawatch.com/news/TVRD/corporate-presentation-november-2023-2-forward-looking-statements-statements-contained-in--tvrd-20231113monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-third-quarter-2023-financial-results-non-dilutive-financing-agre-tvrd-20231113monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-announces-up-to-40-0-million-non-dilutive-financing-agreement-with-healt-tvrd-20231102monthly0.5https://www.biopharmawatch.com/news/TVRD/corporate-presentation-august-2023-2-forward-looking-statements-statements-contained-in-th-tvrd-20230807monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-second-quarter-2023-financial-results-2q23-total-revenue-of-6-9m-tvrd-20230807monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-appoints-helen-m-boudreau-to-board-of-directors-tvrd-20230803monthly0.5https://www.biopharmawatch.com/news/TVRD/corporate-presentation-may-2023-2-forward-looking-statements-statements-contained-in-this--tvrd-20230515monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-first-quarter-2023-financial-results-1q23-total-revenue-of-6-2m--tvrd-20230515monthly0.5https://www.biopharmawatch.com/news/TVRD/corporate-presentation-march-2023-2-forward-looking-statements-statements-contained-in-thi-tvrd-20230323monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-announces-fourth-quarter-and-full-year-2022-financial-results-4q22-total-tvrd-20230306monthly0.5https://www.biopharmawatch.com/news/TVRD/j-p-morgan-healthcare-conference-tvrd-20230109monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-november-2022-forward-looking-statements-statements-contained-in-this-pr-tvrd-20221107monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-third-quarter-2022-financial-results-net-revenue-was-16-2m-for-3-tvrd-20221107monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-announces-appointment-of-lisa-von-moltke-m-d-to-its-board-of-directors-tvrd-20221103monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer-tvrd-20220912monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-corporate-presentation-august-2022-forward-looking-statements-statements-tvrd-20220808monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-second-quarter-2022-financial-results-net-revenue-was-23m-for-2q-tvrd-20220808monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-announces-positive-topline-results-from-komfort-phase-2-trial-of-oral-di-tvrd-20220630monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-first-quarter-2022-financial-results-korsuva-difelikefalin-injec-tvrd-20220509monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-corporate-presentation-march-2022-forward-looking-statements-statements--tvrd-20220311monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-korsuva-dife-tvrd-20220301monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-j-p-morgan-2022-christopher-a-posner-president-ceo-forward-looking-state-tvrd-20220110monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-announces-cms-grants-tdapa-to-korsuva-difelikefalin-injection-korsuva-re-tvrd-20211220monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-third-quarter-2021-financial-results-korsuva-cr845-difelikefalin-tvrd-20211108monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-announces-ceo-transition-current-cara-director-and-accomplished-commerci-tvrd-20211103monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-and-vifor-pharma-announce-u-s-fda-approval-of-korsuva-difelikefalin-inje-tvrd-20210823monthly0.5https://www.biopharmawatch.com/news/TVRD/targeting-pruritus-with-first-in-class-therapeutics-august-12-th-2021-2-confidential-for-i-tvrd-20210812monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-second-quarter-2021-financial-results-new-drug-application-nda-f-tvrd-20210809monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-first-quarter-2021-financial-results-u-s-food-and-drug-administr-tvrd-20210510monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-announces-topline-results-from-kare-phase-2-dose-ranging-trial-of-oral-k-tvrd-20210429monthly0.5https://www.biopharmawatch.com/news/TVRD/vfmcrp-and-cara-therapeutics-announce-european-medicines-agency-has-accepted-to-review-the-tvrd-20210330monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-and-vifor-pharma-announce-u-s-fda-acceptance-and-priority-review-of-nda--tvrd-20210308monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-u-s-fda-acce-tvrd-20210225monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for-kor-tvrd-20201228monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-third-quarter-2020-financial-results-conference-call-toda-y-at-4-tvrd-20201109monthly0.5https://www.biopharmawatch.com/news/TVRD/vifor-pharma-and-cara-therapeutics-sign-us-license-agreement-for-iv-korsuva-to-treat-dialy-tvrd-20201020monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-appoints-thomas-reilly-as-chief-financial-officer-tvrd-20201001monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-second-quarter-2020-financial-results-conference-call-today-at-4-tvrd-20200810monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-announces-completion-of-interim-statistical-assessment-for-kare-phase-2--tvrd-20200617monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-first-quarter-2020-financial-results-conference-call-today-at-4--tvrd-20200511monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-and-vifor-fresenius-medical-care-renal-pharma-announce-positive-results--tvrd-20200421monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-clinical-updates-on-track-to-report-topline-data-for-kalm-2-phas-tvrd-20200325monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-conference-c-tvrd-20200227monthly0.5https://www.biopharmawatch.com/news/TVRD/targeting-pruritus-with-novel-peripherally-restricted-kappa-agonist-therapeutics-jp-morgan-tvrd-20200114monthly0.5https://www.biopharmawatch.com/news/TVRD/targeting-pruritus-with-novel-peripherally-restricted-kappa-agonist-therapeutics-december--tvrd-20191216monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-announces-positive-topline-data-from-phase-2-trial-of-oral-korsuva-in-ch-tvrd-20191203monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-third-quarter-2019-financial-results-conference-call-today-at-4--tvrd-20191105monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-enters-into-commercial-license-agreement-with-enteris-biopharma-inc-for--tvrd-20190821monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-second-quarter-2019-financial-results-conference-call-today-at-4-tvrd-20190807monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-announces-pricing-of-126-5-million-offering-of-common-stock-tvrd-20190724monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-announces-proposed-offering-of-common-stock-tvrd-20190724monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-announces-positive-results-from-kalm-1-pivotal-phase-3-trial-of-korsuva--tvrd-20190529monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-first-quarter-2019-financial-results-conference-call-today-at-4--tvrd-20190507monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-fourth-quarter-and-full-year-2018-financial-results-conference-c-tvrd-20190312monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-third-quarter-2018-financial-results-conference-call-today-at-4--tvrd-20181106monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-appoints-joana-goncalves-m-d-as-chief-medical-officer-former-vp-of-medic-tvrd-20181023monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-second-quarter-2018-financial-results-conference-call-today-at-4-tvrd-20180807monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-announces-pricing-of-85-5-million-offering-of-common-stock-tvrd-20180718monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-announces-proposed-offering-of-common-stock-tvrd-20180717monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-positive-top-line-data-from-adaptive-phase-2-3-trial-of-i-v-cr84-tvrd-20180627monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-and-vifor-fresenius-medical-care-renal-pharma-vfmcrp-enter-into-ex-u-s-l-tvrd-20180523monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-first-quarter-2018-financial-results-conference-call-today-at-4--tvrd-20180509monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-fourth-quarter-and-full-year-2017-financial-results-conference-c-tvrd-20180315monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-third-quarter-2017-financial-results-management-to-host-conferen-tvrd-20171102monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-second-quarter-2017-financial-results-conference-call-today-at-4-tvrd-20170803monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-first-quarter-2017-financial-results-reported-statistically-sign-tvrd-20170504monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-announces-proposed-offering-of-common-stock-tvrd-20170329monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-announces-positive-top-line-data-from-part-a-of-phase-2-3-trial-of-i-v-c-tvrd-20170328monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-fourth-quarter-and-full-year-2016-financial-results-conference-c-tvrd-20170309monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-third-quarter-2016-financial-results-currently-enrolling-three-l-tvrd-20161103monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-second-quarter-2016-financial-results-resumed-patient-enrollment-tvrd-20160804monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-first-quarter-2016-financial-results-conference-call-today-at-4--tvrd-20160505monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-fourth-quarter-and-full-year-2015-financial-results-conference-c-tvrd-20160310monthly0.5https://www.biopharmawatch.com/news/TVRD/forward-looking-statements-this-presentation-contains-certain-forward-looking-statements-t-tvrd-20160111monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-third-quarter-2015-financial-results-initiated-phase-3-program-f-tvrd-20151109monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-second-quarter-2015-financial-results-reported-statistically-sig-tvrd-20150810monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-announces-proposed-offering-of-common-stock-tvrd-20150727monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-announces-positive-results-from-phase-2-trial-in-uremic-pruritus-novel-p-tvrd-20150723monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-first-quarter-2015-financial-results-end-of-phase-2-meeting-with-tvrd-20150512monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-fourth-quarter-and-full-year-2014-financial-results-phase-3-pivo-tvrd-20150326monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-third-quarter-2014-financial-results-reported-positive-top-line--tvrd-20141110monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-second-quarter-2014-financial-results-conference-call-today-at-4-tvrd-20140807monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-first-quarter-2014-financial-results-conference-call-today-at-4--tvrd-20140512monthly0.5https://www.biopharmawatch.com/news/TVRD/cara-therapeutics-reports-fourth-quarter-and-full-year-2013-financial-results-conference-c-tvrd-20140327monthly0.5https://www.biopharmawatch.com/news/QCLS/q-c-technologies-appoints-ai-systems-leader-chelsea-voss-to-board-of-directors-new-york-ny-qcls-20260120monthly0.5https://www.biopharmawatch.com/news/QCLS/quantum-class-computing-developer-q-c-technologies-welcomes-strategic-advisor-martin-shkre-qcls-20251209monthly0.5https://www.biopharmawatch.com/news/QCLS/q-c-technologies-formerly-tnf-pharmaceuticals-commences-trading-on-nasdaq-under-new-ticker-qcls-20250926monthly0.5https://www.biopharmawatch.com/news/QCLS/tnf-pharmaceuticals-announces-closing-of-7-million-private-placement-financing-priced-at-a-qcls-20250904monthly0.5https://www.biopharmawatch.com/news/QCLS/tnf-pharmaceuticals-secures-exclusive-global-rights-to-innovative-light-speed-computing-ac-qcls-20250902monthly0.5https://www.biopharmawatch.com/news/QCLS/tnf-pharmaceuticals-announces-strategic-equity-investment-priced-at-a-premium-to-market-pr-qcls-20241002monthly0.5https://www.biopharmawatch.com/news/QCLS/mymd-pharmaceuticals-announces-corporate-rebranding-to-new-name-tnf-pharmaceuticals-inc-ne-qcls-20240724monthly0.5https://www.biopharmawatch.com/news/QCLS/mymd-pharmaceuticals-appoints-accomplished-biopharmaceutical-leader-and-current-board-memb-qcls-20240617monthly0.5https://www.biopharmawatch.com/news/QCLS/mymd-pharmaceuticals-secures-strategic-investments-up-to-42-million-in-two-part-funding-fr-qcls-20240521monthly0.5https://www.biopharmawatch.com/news/QCLS/mymd-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-requirement-for-cont-qcls-20240305monthly0.5https://www.biopharmawatch.com/news/QCLS/mymd-pharmaceuticals-announces-reverse-stock-split-to-maintain-nasdaq-listing-common-stock-qcls-20240215monthly0.5https://www.biopharmawatch.com/news/QCLS/mymd-pharmaceuticals-plans-fda-cleared-phase-2-clinical-trial-of-mymd-1-in-rheumatoid-arth-qcls-20231206monthly0.5https://www.biopharmawatch.com/news/QCLS/mymd-announces-preclinical-study-results-showing-novel-cannabidiol-analog-supera-cbd-reduc-qcls-20231019monthly0.5https://www.biopharmawatch.com/news/QCLS/mymd-pharmaceuticals-to-present-updated-statistically-significant-phase-2-data-for-mymd-1--qcls-20231004monthly0.5https://www.biopharmawatch.com/news/QCLS/fda-accepts-mymd-pharmaceuticals-investigational-new-drug-application-ind-for-phase-2-stud-qcls-20230814monthly0.5https://www.biopharmawatch.com/news/QCLS/transcript-of-mymd-pharmaceuticals-inc-mymd-pharmaceuticals-phase-2-trial-update-qcls-20230802monthly0.5https://www.biopharmawatch.com/news/QCLS/mymd-pharmaceuticals-reports-statistically-significant-positive-topline-phase-2-results-fo-qcls-20230802monthly0.5https://www.biopharmawatch.com/news/QCLS/mymd-pharmaceuticals-provides-dosing-update-on-phase-2-multi-center-clinical-trial-of-mymd-qcls-20230412monthly0.5https://www.biopharmawatch.com/news/QCLS/mymd-pharmaceuticals-and-charles-river-present-positive-data-for-next-generation-oral-tnf--qcls-20230320monthly0.5https://www.biopharmawatch.com/news/QCLS/mymd-joins-lot-network-in-effort-to-protect-company-and-shareholders-from-patent-trolls-ba-qcls-20230308monthly0.5https://www.biopharmawatch.com/news/QCLS/mymd-announces-u-s-drug-enforcement-administration-dea-determines-supera-cbd-is-not-a-cont-qcls-20230302monthly0.5https://www.biopharmawatch.com/news/QCLS/mymd-pharmaceuticals-announces-upcoming-presentation-of-preclinical-rheumatoid-arthritis-d-qcls-20230228monthly0.5https://www.biopharmawatch.com/news/QCLS/mymd-announces-15-million-offering-with-existing-investors-baltimore-qcls-20230221monthly0.5https://www.biopharmawatch.com/news/QCLS/mymd-pharmaceuticals-to-present-data-on-oral-tnf-a-inhibitor-mymd-1-at-the-british-society-qcls-20221206monthly0.5https://www.biopharmawatch.com/news/QCLS/mymd-pharmaceuticals-announces-upcoming-presentation-of-late-breaking-data-for-mymd-1-at-t-qcls-20221117monthly0.5https://www.biopharmawatch.com/news/QCLS/mymd-pharmaceuticals-announces-publication-of-phase-1-data-for-oral-tnf-alpha-inhibitor-my-qcls-20221114monthly0.5https://www.biopharmawatch.com/news/QCLS/mymd-pharmaceuticals-provides-dosing-update-on-phase-2-multi-center-clinical-trial-of-mymd-qcls-20220920monthly0.5https://www.biopharmawatch.com/news/QCLS/mymd-pharmaceuticals-receives-grant-from-european-patent-office-for-supera-cbd-compound-al-qcls-20220830monthly0.5https://www.biopharmawatch.com/news/QCLS/data-showing-mymd-pharmaceuticals-mymd-1-may-extend-life-and-improve-health-published-in-t-qcls-20220803monthly0.5https://www.biopharmawatch.com/news/QCLS/mymd-pharmaceuticals-advances-phase-2-multi-center-clinical-trial-of-mymd-1-as-a-therapy-f-qcls-20220726monthly0.5https://www.biopharmawatch.com/news/QCLS/mymd-pharmaceuticals-to-collaborate-with-bascom-palmer-eye-institute-to-study-mymd-1-in-op-qcls-20220712monthly0.5https://www.biopharmawatch.com/news/QCLS/mymd-pharmaceuticals-advances-phase-2-multi-center-clinical-trial-of-mymd-1-as-a-therapy-f-qcls-20220621monthly0.5https://www.biopharmawatch.com/news/QCLS/mymd-pharmaceuticals-lead-compound-mymd-1-demonstrates-superior-anti-inflammatory-effects--qcls-20220412monthly0.5https://www.biopharmawatch.com/news/QCLS/mymd-pharmaceuticals-enrolls-first-patient-in-phase-2-clinical-trial-of-mymd-1-as-a-therap-qcls-20220223monthly0.5https://www.biopharmawatch.com/news/QCLS/mymd-pharmaceuticals-announces-positive-clinical-data-in-advance-of-upcoming-phase-2-trial-qcls-20220208monthly0.5https://www.biopharmawatch.com/news/QCLS/mymd-pharmaceuticals-announces-issuance-of-new-u-s-patent-covering-mymd-1-in-a-method-of-t-qcls-20220105monthly0.5https://www.biopharmawatch.com/news/QCLS/mymd-pharmaceuticals-receives-fda-ind-clearance-to-begin-phase-2-trial-of-mymd-1-for-exten-qcls-20211116monthly0.5https://www.biopharmawatch.com/news/QCLS/mymd-pharmaceuticals-president-chris-chapman-m-d-named-medical-honoree-of-the-year-by-the--qcls-20211026monthly0.5https://www.biopharmawatch.com/news/QCLS/mymd-pharmaceuticals-to-discuss-its-novel-therapies-for-aging-and-related-diseases-at-the--qcls-20211019monthly0.5https://www.biopharmawatch.com/news/QCLS/mymd-pharmaceuticals-to-detail-its-two-upcoming-phase-2-trials-at-the-benzinga-rising-star-qcls-20211005monthly0.5https://www.biopharmawatch.com/news/QCLS/mymd-pharmaceuticals-announces-new-data-demonstrating-8-000-times-higher-potency-of-novel--qcls-20210922monthly0.5https://www.biopharmawatch.com/news/QCLS/mymd-pharmaceuticals-announces-fourth-quarter-2021-initiation-of-phase-2-clinical-trial-of-qcls-20210913monthly0.5https://www.biopharmawatch.com/news/QCLS/akers-biosciences-and-mymd-pharmaceuticals-announce-stockholder-approval-of-merger-shares--qcls-20210419monthly0.5https://www.biopharmawatch.com/news/QCLS/reminder-akers-biosciences-schedules-conference-call-to-discuss-merger-with-mymd-pharmaceu-qcls-20201118monthly0.5https://www.biopharmawatch.com/news/QCLS/akers-biosciences-and-mymd-pharmaceuticals-sign-definitive-merger-agreement-immunotherapie-qcls-20201112monthly0.5https://www.biopharmawatch.com/news/QCLS/akers-biosciences-and-premas-biotech-announce-sars-cov-2-positive-proof-of-concept-results-qcls-20200827monthly0.5https://www.biopharmawatch.com/news/QCLS/execution-version-qcls-20200810monthly0.5https://www.biopharmawatch.com/news/QCLS/akers-biosciences-and-premas-biotech-announce-initiation-of-animal-studies-company-intends-qcls-20200707monthly0.5https://www.biopharmawatch.com/news/QCLS/akers-biosciences-closes-4-8-million-registered-direct-offering-priced-at-the-market-under-qcls-20200518monthly0.5https://www.biopharmawatch.com/news/QCLS/akers-biosciences-announces-4-8-million-registered-direct-offering-priced-at-the-market-un-qcls-20200514monthly0.5https://www.biopharmawatch.com/news/QCLS/akers-biosciences-and-premas-biotech-announce-successful-completion-of-vaccine-prototype-o-qcls-20200514monthly0.5https://www.biopharmawatch.com/news/QCLS/akers-biosciences-and-premas-biotech-announce-successful-expression-of-coronavirus-antigen-qcls-20200408monthly0.5https://www.biopharmawatch.com/news/QCLS/execution-version-qcls-20200407monthly0.5https://www.biopharmawatch.com/news/QCLS/akers-biosciences-and-premas-biotech-announce-progress-in-its-vaccine-development-for-covi-qcls-20200406monthly0.5https://www.biopharmawatch.com/news/QCLS/akers-biosciences-acquires-licenses-to-coronavirus-vaccine-candidate-from-premas-biotech-e-qcls-20200324monthly0.5https://www.biopharmawatch.com/news/QCLS/akers-biosciences-inc-provides-notice-of-proposed-settlement-of-derivative-litigation-thor-qcls-20200117monthly0.5https://www.biopharmawatch.com/news/QCLS/akers-biosciences-announces-q3-2018-earnings-sales-of-flagship-pifa-heparin-pf-4-rapid-ass-qcls-20181115monthly0.5https://www.biopharmawatch.com/news/QCLS/akers-biosciences-announces-a-leadership-change-strategic-update-legal-settlement-and-an-a-qcls-20181008monthly0.5https://www.biopharmawatch.com/news/QCLS/akers-biosciences-granted-180-day-extension-by-nasdaq-to-meet-minimum-bid-price-requiremen-qcls-20180530monthly0.5https://www.biopharmawatch.com/news/QCLS/akers-biosciences-receives-notice-of-delinquent-form-10-q-filing-from-nasdaq-thorofare-n-j-qcls-20180525monthly0.5https://www.biopharmawatch.com/news/QCLS/akers-biosciences-announces-closing-of-6-900-000-public-offering-thorofare-n-j-qcls-20171221monthly0.5https://www.biopharmawatch.com/news/QCLS/akers-biosciences-prices-6-000-000-public-offering-thorofare-n-j-qcls-20171218monthly0.5https://www.biopharmawatch.com/news/QCLS/january-2017-this-announcement-contains-inside-information-akers-biosciences-inc-issue-of--qcls-20170110monthly0.5https://www.biopharmawatch.com/news/QCLS/akers-biosciences-announces-pricing-of-public-offering-of-1-667-000-shares-and-833-500-war-qcls-20170109monthly0.5https://www.biopharmawatch.com/news/QCLS/akers-biosciences-appoints-dr-raza-bokhari-as-non-executive-director-thorofare-n-j-qcls-20151112monthly0.5https://www.biopharmawatch.com/news/QCLS/akers-biosciences-appoints-former-congressman-rob-andrews-to-the-board-thorofare-n-j-qcls-20150630monthly0.5https://www.biopharmawatch.com/news/QCLS/akers-biosciences-announces-joint-venture-to-market-rapid-diagnostic-tests-in-china-akers--qcls-20141023monthly0.5https://www.biopharmawatch.com/news/QCLS/akers-biosciences-co-founder-and-executive-chairman-to-assume-duties-of-president-qcls-20140312monthly0.5https://www.biopharmawatch.com/news/CPHI/china-pharma-holdings-inc-announces-1-for-10-reverse-stock-split-haikou-city-china-cphi-20250404monthly0.5https://www.biopharmawatch.com/news/CPHI/china-pharma-announces-the-entry-of-at-the-market-equity-offering-cphi-20241213monthly0.5https://www.biopharmawatch.com/news/CPHI/china-pharma-holdings-inc-announces-1-for-5-reverse-stock-split-haikou-city-china-cphi-20240223monthly0.5https://www.biopharmawatch.com/news/CPHI/china-pharma-holdings-inc-announces-1-for-10-reverse-stock-split-haikou-city-china-cphi-20230224monthly0.5https://www.biopharmawatch.com/news/CPHI/china-pharma-announces-receipt-of-noncompliance-notice-from-nyse-american-cphi-20221202monthly0.5https://www.biopharmawatch.com/news/CPHI/china-pharma-announces-receipt-of-notification-of-nyse-american-listing-deficiency-haikou--cphi-20220930monthly0.5https://www.biopharmawatch.com/news/CPHI/china-pharma-announces-receipt-of-noncompliance-notice-from-nyse-american-cphi-20220622monthly0.5https://www.biopharmawatch.com/news/CPHI/china-pharma-holdings-inc-ms-diana-na-huang-phone-86-898-6681-1730-china-email-hps-chinaph-cphi-20170912monthly0.5https://www.biopharmawatch.com/news/CPHI/china-pharma-holdings-inc-ms-diana-na-huang-phone-86-898-6681-1730-china-email-hps-chinaph-cphi-20170331monthly0.5https://www.biopharmawatch.com/news/CPHI/china-pharma-holdings-inc-announces-approval-for-nyse-amex-listing-cphi-20090928monthly0.5https://www.biopharmawatch.com/news/CPHI/charter-2-cph8kex991082809-htm-china-pharma-holdings-inc-charter-of-the-nominating-and-com-cphi-20090828monthly0.5https://www.biopharmawatch.com/news/CPHI/resignation-letter-dear-cphi-board-members-and-chairwoman-ms-zhilin-li-due-to-my-personal--cphi-20090430monthly0.5https://www.biopharmawatch.com/news/CPHI/china-pharma-holdings-inc-enters-into-private-placement-agreements-to-raise-10-million-hai-cphi-20080528monthly0.5https://www.biopharmawatch.com/news/CPHI/cph8kex991022508-txt-press-release-china-pharma-holdings-inc-receives-5-6-million-in-purch-cphi-20080225monthly0.5https://www.biopharmawatch.com/news/CPHI/crocker-coulson-donald-xu-president-vice-president-strategic-planning-ccg-elite-china-phar-cphi-20070206monthly0.5https://www.biopharmawatch.com/news/CPHI/cph8kex991090606-txt-press-release-dated-august-15-2006-contact-crocker-coulson-donald-xu--cphi-20060920monthly0.5https://www.biopharmawatch.com/news/CPHI/certificate-of-amendment-of-certificate-of-incorporation-of-ts-electronics-inc-pursuant-to-cphi-20060504monthly0.5https://www.biopharmawatch.com/news/CPHI/ts-electronics-inc-index-to-financial-statements-onny-investment-limited-and-subsidiary-re-cphi-20051020monthly0.5https://www.biopharmawatch.com/news/DYAI/dyadic-highlights-accelerated-interest-in-c1-biomanufacturing-platform-amid-ebola-prepared-dyai-20260615monthly0.5https://www.biopharmawatch.com/news/DYAI/dyadic-announces-first-quarter-2026-financial-results-and-highlights-recent-company-progre-dyai-20260513monthly0.5https://www.biopharmawatch.com/news/DYAI/dyadic-announces-2025-financial-results-and-highlights-recent-company-progress-commercial--dyai-20260325monthly0.5https://www.biopharmawatch.com/news/DYAI/dyadic-announces-third-quarter-2025-financial-results-and-highlights-strategic-progress-co-dyai-20251112monthly0.5https://www.biopharmawatch.com/news/DYAI/dyadic-applied-biosolutions-announces-milestone-achievements-and-recent-company-developmen-dyai-20251006monthly0.5https://www.biopharmawatch.com/news/DYAI/dyadic-reports-second-quarter-2025-financial-results-and-highlights-of-recent-company-prog-dyai-20250813monthly0.5https://www.biopharmawatch.com/news/DYAI/dyadic-international-inc-announces-proposed-public-offering-of-common-stock-dyai-20250730monthly0.5https://www.biopharmawatch.com/news/DYAI/document-dyadic-updates-market-on-covid-19-initiatives-c1-expression-of-sars-cov-2-monoclo-dyai-20201012monthly0.5https://www.biopharmawatch.com/news/DYAI/document-dyadic-presents-new-business-opportunities-to-address-covid-19-influenza-and-cont-dyai-20200318monthly0.5https://www.biopharmawatch.com/news/DYAI/document-dyadic-and-the-israel-institute-for-biological-research-iibr-expand-collaboration-dyai-20200225monthly0.5https://www.biopharmawatch.com/news/DYAI/document-dyadic-announces-new-milestone-as-g2-human-like-glycosylation-reached-further-ext-dyai-20200221monthly0.5https://www.biopharmawatch.com/news/DYAI/document-dyadic-to-interview-with-fox-business-network-on-monday-dyai-20200127monthly0.5https://www.biopharmawatch.com/news/DYAI/document-dyadic-reports-continued-positive-business-trends-and-scientific-results-in-fourt-dyai-20200106monthly0.5https://www.biopharmawatch.com/news/DYAI/document-dyadic-announces-achieving-human-like-glycan-structures-from-its-engineered-c1-ce-dyai-20191125monthly0.5https://www.biopharmawatch.com/news/DYAI/dyadic-announces-effectiveness-of-form-10-registration-statement-and-application-to-nasdaq-dyai-20190213monthly0.5https://www.biopharmawatch.com/news/DYAI/codexis-dyadic-in-enzyme-production-system-license-agreement-redwood-city-ca-and-jupiter-f-dyai-20081117monthly0.5https://www.biopharmawatch.com/news/DYAI/harry-z-rosengart-notifies-dyadic-international-inc-of-his-resignation-dyai-20080619monthly0.5https://www.biopharmawatch.com/news/DYAI/dyadic-s-executive-officers-and-key-employees-announce-their-resignation-dyai-20080605monthly0.5https://www.biopharmawatch.com/news/DYAI/dyadic-international-inc-140-intracoastal-pointe-drive-suite-404-jupiter-fl-33477-notice-o-dyai-20080513monthly0.5https://www.biopharmawatch.com/news/DYAI/granted-efiled-apr-15-2008-9-57am-edt-transaction-id-19406728-case-no-3353-vcp-in-the-cour-dyai-20080415monthly0.5https://www.biopharmawatch.com/news/DYAI/dyadic-international-inc-announces-changes-to-its-board-of-directors-dyai-20080314monthly0.5https://www.biopharmawatch.com/news/DYAI/report-of-internal-investigation-to-the-audit-committee-of-the-board-of-directors-of-dyadi-dyai-20080304monthly0.5https://www.biopharmawatch.com/news/DYAI/dyadic-affirms-ownership-of-all-intellectual-property-underlying-its-technologies-and-prov-dyai-20080118monthly0.5https://www.biopharmawatch.com/news/DYAI/levin-ginsburg-80-north-lasalle-street-w-suite-3200-attorneys-at-law-chicago-illinois-6060-dyai-20080102monthly0.5https://www.biopharmawatch.com/news/DYAI/in-the-court-of-chancery-of-the-state-of-delaware-in-and-for-new-castle-county-mark-a-emal-dyai-20071228monthly0.5https://www.biopharmawatch.com/news/DYAI/dyadic-receives-delisting-notice-from-american-stock-exchange-and-provides-updates-regardi-dyai-20071203monthly0.5https://www.biopharmawatch.com/news/DYAI/dyadic-provides-strategic-and-business-update-dyai-20071119monthly0.5https://www.biopharmawatch.com/news/DYAI/levin-ginsburg-180-north-lasalle-street-suite-3200-attorneys-at-law-chicago-illinois-60601-dyai-20071003monthly0.5https://www.biopharmawatch.com/news/DYAI/dyadic-announces-senior-management-changes-and-other-events-dyai-20071001monthly0.5https://www.biopharmawatch.com/news/DYAI/dyadic-announces-termination-of-employment-of-its-president-and-ceo-mark-a-emalfarb-dyai-20070924monthly0.5https://www.biopharmawatch.com/news/DYAI/dyadic-s-receives-notice-of-continuing-failure-to-satisfy-certain-amex-continued-listing-s-dyai-20070828monthly0.5https://www.biopharmawatch.com/news/DYAI/dyadic-s-amex-listing-will-be-continued-pursuant-to-an-extension-dyai-20070709monthly0.5https://www.biopharmawatch.com/news/DYAI/dyadic-updates-progress-of-its-investigation-company-announces-its-intent-to-abandon-its-h-dyai-20070521monthly0.5https://www.biopharmawatch.com/news/DYAI/dyadic-announces-discovery-of-potentially-material-operational-and-financial-improprieties-dyai-20070424monthly0.5https://www.biopharmawatch.com/news/DYAI/dyadic-announces-13-million-private-placement-jupiter-florida-dyai-20061120monthly0.5https://www.biopharmawatch.com/news/DYAI/abengoa-press-release-dyadic-enters-into-research-and-development-agreement-with-abengoa-b-dyai-20061027monthly0.5https://www.biopharmawatch.com/news/DYAI/dyadic-press-release-dated-5-04-06-dyadic-increases-ownership-in-its-asian-subsidiary-to-1-dyai-20060504monthly0.5https://www.biopharmawatch.com/news/DYAI/press-release-dated-dyai-20060502monthly0.5https://www.biopharmawatch.com/news/DYAI/glenn-nedwin-ph-d-mba-co-founder-and-president-of-novozymes-inc-to-join-dyadic-internation-dyai-20060321monthly0.5https://www.biopharmawatch.com/news/DYAI/termination-and-license-agreement-this-termination-and-license-agreement-this-agreement-is-dyai-20051221monthly0.5https://www.biopharmawatch.com/news/DYAI/v017127-ex99-1-txt-dyadic-international-inc-indemnification-agreement-this-indemnification-dyai-20050428monthly0.5https://www.biopharmawatch.com/news/DYAI/v016572-ex99-1-txt-logo-dyadic-international-inc-dyadic-international-inc-140-intracoastal-dyai-20050415monthly0.5https://www.biopharmawatch.com/news/DYAI/1-txt-dyadic-international-inc-indemnification-agreement-this-indemnification-agreement-ag-dyai-20050401monthly0.5https://www.biopharmawatch.com/news/DYAI/1-txt-executive-employment-agreement-this-executive-employment-agreement-agreement-is-made-dyai-20050201monthly0.5https://www.biopharmawatch.com/news/DYAI/v011187-ex99-1-txt-dyadic-international-inc-statement-of-director-compensation-policy-this-dyai-20050110monthly0.5https://www.biopharmawatch.com/news/GRCE/corporate-presentation-june-2026-summary-2-forward-looking-statements-statements-in-this-p-grce-20260618monthly0.5https://www.biopharmawatch.com/news/GRCE/corporate-presentation-april-2026-summary-2-forward-looking-statements-statements-in-this--grce-20260427monthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-announces-first-quarter-2026-financial-results-provides-business-update-grce-20250812monthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-announces-submission-of-new-drug-application-to-u-s-food-and-drug-admin-grce-20250625monthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-announces-2025-fiscal-year-end-results-provides-business-update-held-ty-grce-20250623monthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-announces-alignment-with-the-fda-supporting-the-planned-nda-submission--grce-20250409monthly0.5https://www.biopharmawatch.com/news/GRCE/corporate-presentation-march-2025-summary-2-forward-looking-statements-statements-in-this--grce-20250303monthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-announces-third-fiscal-quarter-2025-financial-results-provides-business-grce-20250213monthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-announces-results-from-pivotal-phase-3-strive-on-safety-trial-of-gtx-10-grce-20250210monthly0.5https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-announces-second-fiscal-quarter-2025-financial-results-provides-busines-grce-20241113monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-announces-corporate-name-change-to-grace-therapeutics-inc-name-change-reflects-exte-grce-20241028monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-announces-completion-of-patient-enrollment-in-pivotal-phase-3-strive-on-safety-tria-grce-20240925monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-inc-condensed-consolidated-statements-of-loss-and-comprehensive-loss-unaudit-grce-20240809monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-announces-achievement-of-50-enrollment-in-pivotal-phase-3-strive-on-safety-trial-co-grce-20240627monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-inc-consolidated-statements-of-operations-and-comprehensive-loss-year-ended-grce-20240621monthly0.5https://www.biopharmawatch.com/news/GRCE/company-overview-nasdaq-acst-april-2024-forward-looking-statements-statements-in-this-pres-grce-20240401monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-announces-third-fiscal-quarter-2024-financial-results-and-business-highlights-x2022-grce-20240212monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-inc-condensed-consolidated-interim-statements-of-loss-and-comprehensive-loss-grce-20231113monthly0.5https://www.biopharmawatch.com/news/GRCE/in-such-forward-looking-statements-as-a-result-of-various-risks-and-uncertainties-includin-grce-20231023monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-announces-7-5-million-private-placement-equity-financing-princeton-nj-grce-20230926monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-announces-first-quarter-2024-financial-results-and-business-highlights-x2022-new-le-grce-20230811monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-announces-1-for-6-reverse-stock-split-laval-qu-bec-grce-20230707monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-announces-alignment-with-fda-on-gtx-104-pivotal-phase-3-safety-trial-protocol-and-c-grce-20230705monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-reports-fiscal-year-2023-operational-results-laval-qu-bec-grce-20230623monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-announces-appointment-of-prashant-kohli-as-ceo-laval-qu-bec-grce-20230404monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-inc-centralizes-marketplace-for-shares-on-the-nasdaq-with-voluntary-delistin-grce-20230313monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-reports-third-quarter-2023-operational-results-company-to-host-conference-ca-grce-20230214monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-reports-second-quarter-2023-operational-results-company-to-host-conference-c-grce-20221114monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-announces-court-dismissal-of-stockholder-litigation-laval-qu-bec-grce-20220930monthly0.5https://www.biopharmawatch.com/news/GRCE/dated-september-29-2022-announcing-voting-results-of-annual-and-special-meeting-ex-99-1-ac-grce-20220929monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-reports-first-quarter-2023-operational-results-company-to-host-conference-ca-grce-20220811monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-reports-fiscal-year-2022-operational-results-company-to-host-conference-call-grce-20220621monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-announces-positive-results-for-pharmacokinetic-bridging-study-with-intraveno-grce-20220518monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-appoints-healthcare-industry-leader-michael-l-derby-to-its-board-of-director-grce-20220325monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-provides-business-update-for-the-third-quarter-of-fiscal-2022-provides-updat-grce-20220214monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-announces-interim-data-meets-all-primary-endpoints-for-pivotal-pk-study-for--grce-20211202monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-announces-annual-stock-option-grants-grce-20211115monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-provides-business-update-for-the-second-quarter-of-fiscal-2022-grce-20211110monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-provides-update-following-acquisition-of-grace-therapeutics-and-regains-comp-grce-20210922monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-provides-business-update-for-the-first-quarter-of-fiscal-2022-grce-20210812monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-provides-fiscal-2021-year-end-business-update-grce-20210622monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-intends-to-request-hearing-before-nasdaq-panel-to-present-plan-of-compliance-grce-20210517monthly0.5https://www.biopharmawatch.com/news/GRCE/lock-up-agreement-this-agreement-is-entered-into-as-of-may-7-2021-by-and-between-acasti-ph-grce-20210507monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-provides-update-on-recent-financing-activities-grce-20210309monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-announces-results-for-third-quarter-of-fiscal-2021-grce-20210209monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-provides-update-on-recent-financing-activities-grce-20210127monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-provides-business-update-for-the-second-quarter-of-fiscal-2021-grce-20201116monthly0.5https://www.biopharmawatch.com/news/GRCE/in-this-by-law-and-all-other-by-laws-of-the-corporation-unless-grce-20201002monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-announces-review-process-of-strategic-alternatives-grce-20200929monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-appoints-seasoned-executive-brian-d-grce-20200918monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-announces-filing-and-mailing-of-information-circular-and-change-in-record-date-grce-20200911monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-reports-topline-triglyceride-results-from-phase-3-trilogy-2-study-of-capre-i-grce-20200831monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-provides-business-update-for-the-first-quarter-of-fiscal-2021-grce-20200813monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-submits-statistical-analysis-plan-to-fda-and-remains-on-track-to-report-tril-grce-20200731monthly0.5https://www.biopharmawatch.com/news/GRCE/jfif-c-0-0-1-a-qa-2q-bb-3rr-8ddu-r-grce-20200630monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-receives-fda-response-to-trilogy-1-briefing-package-grce-20200619monthly0.5https://www.biopharmawatch.com/news/GRCE/special-meeting-of-shareholders-grce-20190806monthly0.5https://www.biopharmawatch.com/news/GRCE/management-s-discussion-and-analysis-of-the-financial-situation-grce-20190214monthly0.5https://www.biopharmawatch.com/news/GRCE/management-s-discussion-and-analysis-of-the-financial-situation-grce-20181114monthly0.5https://www.biopharmawatch.com/news/GRCE/special-meeting-of-shareholders-grce-20170717monthly0.5https://www.biopharmawatch.com/news/GRCE/correction-acasti-pharma-grants-stock-options-laval-qu-bec-canada-grce-20170616monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-grants-stock-options-laval-qu-bec-canada-grce-20170614monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-to-present-at-upcoming-international-industry-conferences-laval-qu-bec-canad-grce-20170612monthly0.5https://www.biopharmawatch.com/news/GRCE/management-discussion-and-analysis-of-the-financial-situation-and-operating-results-thirte-grce-20170606monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-reports-fourth-quarter-and-full-year-2017-financial-results-company-achieves-grce-20170606monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-and-cordenpharma-announce-large-scale-production-of-capre-with-new-continuou-grce-20170531monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-presents-capre-clinical-data-at-national-lipid-association-scientific-sessio-grce-20170518monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-granted-additional-composition-use-patents-in-taiwan-and-australia-safeguards-valua-grce-20170424monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-to-present-capre-omega-3-bridging-study-results-at-national-lipid-associatio-grce-20170412monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-provides-update-on-capre-phase-3-development-program-outcome-of-the-end-of-p-grce-20170330monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-forms-scientific-advisory-board-and-appoints-two-leading-cardiovascular-dise-grce-20170308monthly0.5https://www.biopharmawatch.com/news/GRCE/not-for-distribution-to-u-s-newswire-services-or-for-dissemination-in-the-united-states-ac-grce-20170221monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-grants-incentive-stock-and-options-laval-qu-bec-canada-grce-20170224monthly0.5https://www.biopharmawatch.com/news/GRCE/general-by-law-of-acasti-pharma-inc-the-corporation-table-of-contents-1-definitions-1-1-1--grce-20170221monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-reports-third-quarter-2017-financial-results-key-developments-include-advanc-grce-20170112monthly0.5https://www.biopharmawatch.com/news/GRCE/business-description-of-and-risk-factors-relating-to-acasti-pharma-inc-dated-as-of-grce-20161205monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-appoints-linda-o-keefe-as-chief-financial-officer-laval-qu-bec-canada-grce-20161128monthly0.5https://www.biopharmawatch.com/news/GRCE/source-acasti-pharma-inc-acasti-announces-stock-ticker-symbol-change-to-acst-on-the-tsxv-l-grce-20161103monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-builds-intellectual-property-portfolio-with-newly-issued-u-s-patent-for-capr-grce-20161026monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-reports-second-quarter-2017-financial-results-key-developments-include-new-l-grce-20161011monthly0.5https://www.biopharmawatch.com/news/GRCE/acasti-pharma-reports-positive-capre-omega-3-bridging-study-data-results-support-streamlin-grce-20160914monthly0.5https://www.biopharmawatch.com/news/GRCE/notice-of-change-in-fiscal-year-end-section-4-8-of-national-instrument-51-102-to-autorit-d-grce-20160805monthly0.5https://www.biopharmawatch.com/news/GRCE/source-acasti-pharma-inc-acasti-announces-the-election-of-its-directors-change-of-fiscal-y-grce-20160715monthly0.5https://www.biopharmawatch.com/news/GRCE/notice-of-annual-and-special-meeting-of-shareholders-to-the-shareholders-of-acasti-phama-i-grce-20160614monthly0.5https://www.biopharmawatch.com/news/GRCE/source-acasti-pharma-inc-acasti-announces-grant-of-stock-options-laval-qu-bec-canada-grce-20160530monthly0.5https://www.biopharmawatch.com/news/GRCE/management-discussion-and-analysis-of-the-financial-situation-and-operating-results-years--grce-20160526monthly0.5https://www.biopharmawatch.com/news/GRCE/source-acasti-pharma-inc-acasti-announces-fourth-quarter-and-fiscal-year-results-laval-qu--grce-20160525monthly0.5https://www.biopharmawatch.com/news/GRCE/source-acasti-pharma-inc-jan-d-alvise-appointed-president-ceo-of-acasti-pharma-seasoned-ex-grce-20160512monthly0.5https://www.biopharmawatch.com/news/GRCE/source-acasti-pharma-inc-nasdaq-grants-acasti-cure-period-to-regain-compliance-with-audit--grce-20160322monthly0.5https://www.biopharmawatch.com/news/GRCE/source-acasti-pharma-inc-acasti-announces-management-appointment-and-changes-to-the-board--grce-20160301monthly0.5https://www.biopharmawatch.com/news/GRCE/source-acasti-pharma-inc-acasti-announces-share-for-debt-laval-qu-bec-canada-grce-20160205monthly0.5https://www.biopharmawatch.com/news/GRCE/notice-of-annual-and-special-meeting-of-shareholders-grce-20150617monthly0.5https://www.biopharmawatch.com/news/GRCE/source-neptune-technologies-bioressources-inc-acasti-pharma-inc-and-neurobiopharm-inc-nept-grce-20140530monthly0.5https://www.biopharmawatch.com/news/GRCE/annual-information-form-fiscal-year-ended-grce-20140530monthly0.5https://www.biopharmawatch.com/news/GRCE/jfif-exif-mm-b-j-1-r-2-i-adobe-photoshop-cs2-windows-2014-05-28-09-39-02-j-grce-20140528monthly0.5https://www.biopharmawatch.com/news/GRCE/notice-of-annual-and-special-meeting-of-shareholders-grce-20140528monthly0.5https://www.biopharmawatch.com/news/GRCE/execution-version-acasti-pharma-inc-as-the-corporation-and-computershare-trust-company-of--grce-20131203monthly0.5https://www.biopharmawatch.com/news/GRCE/execution-grce-20131127monthly0.5https://www.biopharmawatch.com/news/GRCE/this-prepayment-agreement-is-made-on-grce-20131029monthly0.5https://www.biopharmawatch.com/news/GRCE/notice-of-annual-and-special-meeting-of-shareholders-grce-20130528monthly0.5https://www.biopharmawatch.com/news/GRCE/jfif-exif-mm-b-j-1-r-2-i-adobe-photoshop-cs-windows-2013-05-28-07-50-22-m-grce-20130528monthly0.5https://www.biopharmawatch.com/news/SNTI/senti-biosciences-holdings-reports-first-quarter-2026-financial-results-and-highlights-adv-snti-20260514monthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-appoints-entrepreneurial-leader-and-investor-bryan-baum-to-board-of-directors-snti-20250718monthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-granted-u-s-fda-orphan-drug-designation-for-use-of-first-in-class-off-the-shelf--snti-20250618monthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-reports-first-quarter-2025-financial-results-and-provides-a-corporate-update-on--snti-20250506monthly0.5https://www.biopharmawatch.com/news/SNTI/snti-conferencecall-nasdaq-snti-sentibio-com-senti-202-positive-preliminary-results-in-the-snti-20250428monthly0.5https://www.biopharmawatch.com/news/SNTI/document-senti-bio-announces-fourth-quarter-and-full-year-2024-financial-results-and-recen-snti-20250320monthly0.5https://www.biopharmawatch.com/news/SNTI/document-senti-bio-strengthens-leadership-team-with-strategic-hires-jay-cross-proven-finan-snti-20250225monthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-announces-additional-11-5-million-of-financing-approximately-10-million-addition-snti-20250106monthly0.5https://www.biopharmawatch.com/news/SNTI/document-senti-bio-announces-first-patient-dosed-in-clinical-trial-of-sn301a-in-hepatocell-snti-20241216monthly0.5https://www.biopharmawatch.com/news/SNTI/senti-202-initial-clinical-data-december-2024-disclaimer-2-forward-looking-statements-this-snti-20241203monthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-appoints-fran-schulz-to-board-of-directors-biotechnology-industry-executive-with-snti-20241202monthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-announces-positive-initial-clinical-data-in-phase-1-clinical-trial-of-senti-202--snti-20241202monthly0.5https://www.biopharmawatch.com/news/SNTI/document-senti-bio-announces-third-quarter-2024-results-and-recent-pipeline-and-corporate--snti-20241114monthly0.5https://www.biopharmawatch.com/news/SNTI/document-senti-bio-announces-second-quarter-2024-results-and-reviews-recent-corporate-and--snti-20240813monthly0.5https://www.biopharmawatch.com/news/SNTI/document-senti-bio-announces-first-quarter-2024-results-and-reviews-recent-corporate-highl-snti-20240509monthly0.5https://www.biopharmawatch.com/news/SNTI/document-senti-bio-reports-fourth-quarter-and-full-year-2023-financial-results-and-reviews-snti-20240321monthly0.5https://www.biopharmawatch.com/news/SNTI/document-senti-bio-announces-strategic-steps-to-prioritize-investment-in-lead-clinical-pro-snti-20240105monthly0.5https://www.biopharmawatch.com/news/SNTI/document-senti-bio-announces-fda-clearance-of-ind-application-for-senti-202-for-the-treatm-snti-20231220monthly0.5https://www.biopharmawatch.com/news/SNTI/document-senti-bio-announces-third-quarter-2023-results-and-pipeline-updates-ind-for-senti-snti-20231113monthly0.5https://www.biopharmawatch.com/news/SNTI/document-senti-bio-announces-new-strategic-collaboration-with-celest-therapeutics-for-clin-snti-20231106monthly0.5https://www.biopharmawatch.com/news/SNTI/document-senti-bio-announces-second-quarter-2023-results-and-pipeline-updates-genefab-tran-snti-20230811monthly0.5https://www.biopharmawatch.com/news/SNTI/document-senti-bio-announces-closing-of-transaction-leveraging-its-cmc-capabilities-into-a-snti-20230810monthly0.5https://www.biopharmawatch.com/news/SNTI/document-senti-bio-announces-first-quarter-2023-results-and-pipeline-updates-new-preclinic-snti-20230509monthly0.5https://www.biopharmawatch.com/news/SNTI/document-senti-bio-reports-fourth-quarter-and-full-year-2022-financial-results-and-reviews-snti-20230322monthly0.5https://www.biopharmawatch.com/news/SNTI/document-senti-bio-announces-pipeline-prioritization-to-focus-on-logic-gated-cell-therapie-snti-20230127monthly0.5https://www.biopharmawatch.com/news/SNTI/document-senti-bio-highlights-preclinical-data-from-logic-gated-gene-circuit-car-nk-cell-t-snti-20221211monthly0.5https://www.biopharmawatch.com/news/SNTI/document-senti-bio-reports-third-quarter-financial-results-and-pipeline-updates-senti-202--snti-20221110monthly0.5https://www.biopharmawatch.com/news/SNTI/document-senti-bio-reports-second-quarter-financial-results-and-business-updates-lead-deve-snti-20220815monthly0.5https://www.biopharmawatch.com/news/SNTI/senti-biosciences-inc-index-to-condensed-consolidated-financial-statements-page-condensed--snti-20220615monthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-debuts-as-publicly-traded-company-focused-on-developing-next-generation-cell-and-snti-20220609monthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-names-dr-kanya-rajangam-to-newly-created-position-of-chief-medical-and-developme-snti-20220525monthly0.5https://www.biopharmawatch.com/news/SNTI/senti-bio-secures-additional-financing-from-leaps-by-bayer-and-provides-update-on-proposed-snti-20220524monthly0.5https://www.biopharmawatch.com/news/SNTI/to-the-company-s-current-report-on-form-8-k-filed-with-the-sec-on-snti-20211220monthly0.5https://www.biopharmawatch.com/news/SNTI/dynamics-special-purpose-corp-index-to-financial-statement-report-of-independent-registere-snti-20210528monthly0.5https://www.biopharmawatch.com/news/SNTI/dynamics-special-purpose-corp-announces-pricing-of-200-million-initial-public-offering-red-snti-20210525monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-medical-technologies-announces-restatement-of-financial-results-for-quarter-endin-nmtc-20260522monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-reports-fiscal-q2-2026-financial-results-and-provides-corporate-business-update-p-nmtc-20260512monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-reports-fiscal-q1-2026-financial-results-expects-product-revenue-of-at-least-10-5-nmtc-20260217monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-appoints-jason-mills-to-the-board-of-directors-veteran-med-tech-research-analyst--nmtc-20251222monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-reports-strong-fourth-quarter-fiscal-2025-financial-results-with-product-revenue--nmtc-20251217monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-announces-preliminary-unaudited-product-revenue-growth-of-163-to-record-9-1-milli-nmtc-20251006monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-reports-second-quarter-fiscal-year-2025-financial-results-gross-margin-improves-s-nmtc-20250513monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-reports-first-quarter-fiscal-year-2025-financial-results-and-provides-corporate-u-nmtc-20250212monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-regains-compliance-with-nasdaq-listing-requirements-nmtc-20250204monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-announces-preliminary-unaudited-first-quarter-fiscal-2025-revenue-increase-to-a-r-nmtc-20250110monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-product-revenue-increases-77-to-3-5-million-in-fiscal-2024-expects-product-revenu-nmtc-20241217monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-announces-expansion-of-existing-distribution-agreement-with-zimmer-biomet-for-com-nmtc-20241031monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-reports-third-quarter-fiscal-year-2024-financial-results-and-provides-corporate-u-nmtc-20240814monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-reports-second-quarter-fiscal-year-2024-financial-results-and-provides-corporate--nmtc-20240514monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-initiates-limited-commercial-launch-of-onerf-ablation-system-first-to-market-fda--nmtc-20240326monthly0.5https://www.biopharmawatch.com/news/NMTC/nasdaq-nmtc-neuroone-medical-technologies-corporation-march-2024-2-safe-harbor-statements--nmtc-20240315monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-reports-first-quarter-fiscal-year-2024-financial-results-and-provides-corporate-u-nmtc-20240213monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-reports-fiscal-fourth-quarter-and-full-fiscal-year-2023-financial-results-and-pro-nmtc-20231214monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-receives-fda-510-k-clearance-to-market-its-onerf-ablation-system-first-fda-cleare-nmtc-20231211monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-announces-patent-allowance-for-drug-delivery-utilizing-a-novel-neural-probe-paten-nmtc-20231116monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-appoints-medtech-executive-christopher-r-volker-as-chief-operating-officer-and-re-nmtc-20231114monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-provides-progress-update-on-fda-510-k-submission-for-onerf-ablation-system-feedba-nmtc-20231107monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-reports-third-quarter-fiscal-year-2023-financial-results-and-provides-corporate-u-nmtc-20230814monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-medical-technologies-corporation-announces-proposed-public-offering-of-common-sto-nmtc-20230724monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-reports-second-quarter-fiscal-year-2023-financial-results-and-provides-corporate--nmtc-20230511monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-reports-first-quarter-fiscal-year-2023-financial-results-and-provides-corporate-u-nmtc-20230214monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-reports-fiscal-fourth-quarter-and-full-fiscal-year-2022-financial-results-nmtc-20221222monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-receives-fda-510-k-clearance-to-market-its-evo-seeg-system-for-less-than-30-day-u-nmtc-20221025monthly0.5https://www.biopharmawatch.com/news/NMTC/fact-sheet-fall-2022-nasdaq-nmtc-https-n1mtc-com-advancing-neuroscience-one-neuron-at-a-ti-nmtc-20220914monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-reports-third-quarter-fiscal-year-2022-financial-results-and-provides-corporate-u-nmtc-20220811monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-announces-3-5-million-accelerated-milestone-payment-from-zimmer-biomet-for-evo-se-nmtc-20220803monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-issues-letter-to-stockholders-in-connection-with-2022-annual-meeting-of-stockhold-nmtc-20220602monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-provides-evo-seeg-update-the-evo-seeg-electrode-510-k-cleared-for-temporary-less--nmtc-20220516monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-reports-second-quarter-fiscal-year-2022-financial-results-and-provides-corporate--nmtc-20220512monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-reports-first-quarter-fiscal-year-2022-financial-results-and-provides-corporate-u-nmtc-20220214monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-reports-fourth-fiscal-quarter-and-full-fiscal-year-2021-financial-results-and-pro-nmtc-20211215monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-medical-technologies-corporation-announces-proposed-public-offering-of-common-sto-nmtc-20211012monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-medical-technologies-corporation-receives-fda-510-k-clearance-for-its-evo-seeg-el-nmtc-20210907monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-reports-third-quarter-fiscal-2021-financial-results-and-corporate-update-eden-pra-nmtc-20210813monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-announces-approval-for-nasdaq-capital-market-listing-trading-expected-to-commence-nmtc-20210525monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-medical-technologies-corporation-announces-reverse-stock-split-as-part-of-uplisti-nmtc-20210331monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-medical-technologies-corporation-announces-successful-completion-of-first-perform-nmtc-20210223monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-medical-technologies-corporation-announces-private-placement-eden-prairie-mn-nmtc-20210112monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-medical-technologies-corporation-appoints-ronald-mcclurg-experienced-financial-in-nmtc-20210107monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-medical-technologies-corporation-provides-commercialization-update-for-evo-cortic-nmtc-20201006monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-medical-technologies-corporation-reduces-debt-by-3-3-million-and-strengthens-bala-nmtc-20200728monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-medical-technologies-corporation-enters-into-exclusive-development-and-distributi-nmtc-20200722monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-medical-technologies-corporation-company-overview-high-definition-minimally-invas-nmtc-20200406monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-medical-technologies-corporation-appoints-edward-andrle-as-new-board-member-eden--nmtc-20200224monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-medical-technologies-corporation-receives-fda-510-k-clearance-for-evo-cortical-el-nmtc-20191202monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-medical-technologies-corporation-announces-first-sale-of-seeg-depth-electrode-com-nmtc-20190923monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-medical-technologies-corporation-announces-fiscal-third-quarter-2019-financial-re-nmtc-20190814monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-medical-technologies-corporation-appoints-neuroscience-expert-kip-ludwig-phd-to-c-nmtc-20180927monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-medical-technologies-corporation-issues-statement-regarding-recent-promotional-ac-nmtc-20180823monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-inc-nmtc-20170814monthly0.5https://www.biopharmawatch.com/news/NMTC/neuroone-inc-nmtc-20170720monthly0.5https://www.biopharmawatch.com/news/ABVC/abvc-biopharma-reports-2025-form-10-k-total-assets-increase-179-to-21-06-million-as-compan-abvc-20260303monthly0.5https://www.biopharmawatch.com/news/ABVC/abvc-biopharma-reports-230-yoy-licensing-revenue-growth-and-181-asset-expansion-in-q3-2025-abvc-20251103monthly0.5https://www.biopharmawatch.com/news/ABVC/abvc-biopharma-inc-reports-103-year-over-year-asset-growth-and-secures-350k-in-post-quarte-abvc-20250814monthly0.5https://www.biopharmawatch.com/news/ABVC/abvc-biopharma-regains-nasdaq-minimum-bid-price-compliance-silicon-valley-ca-abvc-20250514monthly0.5https://www.biopharmawatch.com/news/ABVC/abvc-biopharma-announces-first-quarter-2025-financial-results-and-strategic-planning-for-a-abvc-20250501monthly0.5https://www.biopharmawatch.com/news/ABVC/abvc-biopharma-announces-2024-financial-results-revenue-surges-234-expenses-down-21-eps-im-abvc-20250416monthly0.5https://www.biopharmawatch.com/news/ABVC/abvc-biopharma-inc-granted-additional-180-day-grace-period-to-regain-compliance-with-nasda-abvc-20250113monthly0.5https://www.biopharmawatch.com/news/ABVC/abvc-biopharma-inc-reports-q3-2024-financial-results-and-operational-milestones-abvc-bioph-abvc-20241114monthly0.5https://www.biopharmawatch.com/news/ABVC/corporate-overview-nasdaq-abvc-2024-2-forward-looking-statements-this-presentation-contain-abvc-20240820monthly0.5https://www.biopharmawatch.com/news/ABVC/abvc-biopharma-inc-reports-strong-q2-2024-financial-results-and-strategic-achievements-exe-abvc-20240815monthly0.5https://www.biopharmawatch.com/news/ABVC/immunity-boosting-combination-therapy-for-myelodysplastic-syndrome-treatment-a-milestone-c-abvc-20240524monthly0.5https://www.biopharmawatch.com/news/ABVC/promising-combination-therapy-for-tripple-negative-breast-cancer-treatment-a-milestone-col-abvc-20240516monthly0.5https://www.biopharmawatch.com/news/ABVC/combination-therapy-holds-promise-for-pancreatic-cancer-treatment-a-milestone-collaboratio-abvc-20240509monthly0.5https://www.biopharmawatch.com/news/ABVC/abvc-biopharma-executes-a-global-licensing-definitive-agreement-for-the-treatment-of-nsclc-abvc-20240416monthly0.5https://www.biopharmawatch.com/news/ABVC/abvc-biopharma-entered-into-a-global-licensing-deal-of-vitargus-with-licensing-income-of-3-abvc-20240326monthly0.5https://www.biopharmawatch.com/news/ABVC/abvc-biopharma-reports-annual-2023-financials-and-provides-fiscal-year-2024-first-quarter--abvc-20240314monthly0.5https://www.biopharmawatch.com/news/ABVC/abvc-acquires-2-96-million-worth-of-land-in-asia-with-stocks-priced-at-3-50-per-share-frem-abvc-20240208monthly0.5https://www.biopharmawatch.com/news/ABVC/abvc-biopharma-reports-third-quarter-2023-financial-and-operational-results-fremont-ca-abvc-20231115monthly0.5https://www.biopharmawatch.com/news/ABVC/abvc-executes-cooperation-agreement-for-strategic-investments-fremont-ca-abvc-20230817monthly0.5https://www.biopharmawatch.com/news/ABVC/abvc-biopharma-regains-compliance-with-nasdaq-s-minimum-bid-price-requirement-fremont-ca-abvc-20230810monthly0.5https://www.biopharmawatch.com/news/ABVC/abvc-corporate-update-and-ceo-s-letter-to-shareholders-fremont-ca-abvc-20230807monthly0.5https://www.biopharmawatch.com/news/ABVC/abvc-signs-a-term-sheet-to-earn-licensing-fees-of-up-to-20m-and-royalties-of-5-12-of-net-s-abvc-20230801monthly0.5https://www.biopharmawatch.com/news/ABVC/abvc-biopharma-announces-closing-on-1-75-million-registered-direct-offering-fremont-ca-abvc-20230731monthly0.5https://www.biopharmawatch.com/news/ABVC/abvc-biopharma-announces-pricing-of-1-75-million-registered-direct-offering-fremont-ca-abvc-20230727monthly0.5https://www.biopharmawatch.com/news/ABVC/abvc-biopharma-announces-reverse-stock-split-fremont-ca-abvc-20230724monthly0.5https://www.biopharmawatch.com/news/ABVC/cor-p-orate-overview-n-a-sd-a-q-abvc-2023-this-presentation-contains-summary-information-a-abvc-20230609monthly0.5https://www.biopharmawatch.com/news/ABVC/abvc-biopharma-announces-fiscal-year-2022-financial-and-operational-results-fremont-ca-abvc-20230331monthly0.5https://www.biopharmawatch.com/news/ABVC/abvc-biopharma-receives-3-175-million-investment-from-the-lind-partners-to-continue-clinic-abvc-20230223monthly0.5https://www.biopharmawatch.com/news/ABVC/abvc-biopharma-announces-letter-to-shareholders-fremont-ca-abvc-20220913monthly0.5https://www.biopharmawatch.com/news/ABVC/abvc-biopharma-expands-co-development-partnership-with-rgene-corporation-fremont-ca-abvc-20220621monthly0.5https://www.biopharmawatch.com/news/ABVC/abvc-biopharma-inc-announces-4-22-million-registered-direct-offering-fremont-california-abvc-20220512monthly0.5https://www.biopharmawatch.com/news/ABVC/abvc-biopharma-inc-44370-old-warm-springs-blvd-fremont-ca-94538-notice-of-2022-annual-meet-abvc-20220427monthly0.5https://www.biopharmawatch.com/news/ABVC/abvc-biopharma-announces-fiscal-year-2021-financial-and-operational-results-fremont-ca-abvc-20220331monthly0.5https://www.biopharmawatch.com/news/ABVC/abvc-biopharma-inc-announces-pricing-of-6-875-million-firm-commitment-offering-will-trade--abvc-20210803monthly0.5https://www.biopharmawatch.com/news/ABVC/american-brivision-holding-corporation-44370-old-warm-springs-blvd-fremont-ca-94538-845-29-abvc-20210108monthly0.5https://www.biopharmawatch.com/news/ABVC/http-abvcpharma-com-44370-old-warm-springs-blvd-fremont-ca-94538-dear-shareholder-now-that-abvc-20210107monthly0.5https://www.biopharmawatch.com/news/ABVC/dear-investors-as-the-abvc-team-works-diligently-to-have-our-shares-uplisted-and-trading-o-abvc-20200603monthly0.5https://www.biopharmawatch.com/news/ABVC/american-brivision-announces-two-financial-transactions-to-improve-working-capital-and-red-abvc-20200413monthly0.5https://www.biopharmawatch.com/news/ABVC/american-brivision-initiates-phase-ii-part-i-clinical-trial-for-abv-1505-in-adult-attentio-abvc-20191205monthly0.5https://www.biopharmawatch.com/news/ABVC/american-brivision-highlights-results-from-vitargus-first-in-human-clinical-trial-dr-andre-abvc-20191015monthly0.5https://www.biopharmawatch.com/news/ABVC/american-brivision-announces-vitargus-presentation-at-upcoming-aao-2019-annual-meeting-glo-abvc-20191010monthly0.5https://www.biopharmawatch.com/news/ABVC/of-independent-registered-public-accounting-firm-abvc-20190214monthly0.5https://www.biopharmawatch.com/news/ABVC/co-development-agreement-made-and-entered-as-of-this-26th-day-of-may-2017-the-effective-da-abvc-20170530monthly0.5https://www.biopharmawatch.com/news/ABVC/addendum-this-addendum-this-addendum-dated-january-12-th-2017-the-effective-date-to-the-co-abvc-20170222monthly0.5https://www.biopharmawatch.com/news/ABVC/10-2015-collaborative-agreement-made-and-entered-into-as-of-this-29th-day-of-december-2015-abvc-20160609monthly0.5https://www.biopharmawatch.com/news/ABVC/donald-c-campion-3747-loch-bend-drive-commerce-michigan-48382-248-360-8105-fax-248-360-412-abvc-20080713monthly0.5https://www.biopharmawatch.com/news/ABVC/important-news-from-ecology-coatings-cleantechnology-paper-coatings-achieves-toxic-mold-in-abvc-20080416monthly0.5https://www.biopharmawatch.com/news/ABVC/exv99w1-ecology-coatings-announces-awarding-of-fifth-u-s-patent-latest-patent-protects-man-abvc-20080214monthly0.5https://www.biopharmawatch.com/news/ABVC/presentation-materials-exv99w1-award-winning-technology-stock-symbol-otcbb-ecoc-october-20-abvc-20071016monthly0.5https://www.biopharmawatch.com/news/ABVC/two-key-board-additions-at-ecology-coatings-lend-expertise-in-strategic-financial-growth-a-abvc-20070828monthly0.5https://www.biopharmawatch.com/news/ABVC/press-contact-alanna-gino-antenna-group-for-ecology-coatings-415-977-1918-alanna-antennagr-abvc-20070815monthly0.5https://www.biopharmawatch.com/news/ABVC/ecologycoatings-logo-ecology-coatings-inc-completes-reverse-merger-with-ocis-corporation-g-abvc-20070730monthly0.5https://www.biopharmawatch.com/news/ABVC/press-contact-rosalind-jackson-antenna-group-for-ecology-coatings-415-977-1923-rosalind-an-abvc-20061107monthly0.5https://www.biopharmawatch.com/news/NEUP/description-of-capital-stock-the-following-description-of-the-capital-stock-of-neuphoria-t-neup-20241223monthly0.5https://www.biopharmawatch.com/news/NEUP/supreme-court-of-new-south-wales-approves-bionomics-re-domiciliation-adelaide-australia-an-neup-20241216monthly0.5https://www.biopharmawatch.com/news/NEUP/scheme-implementation-agreement-amending-agreement-date-24-october-2024-parties-bionomics--neup-20241108monthly0.5https://www.biopharmawatch.com/news/NEUP/bionomics-limited-announces-intention-to-re-domicile-to-the-united-states-adelaide-austral-neup-20241001monthly0.5https://www.biopharmawatch.com/news/NEUP/securities-purchase-agreement-this-securities-purchase-agreement-this-x201c-agreement-x201-neup-20240531monthly0.5https://www.biopharmawatch.com/news/NEUP/signed-in-accordance-with-a-resolution-of-the-directors-made-pursuant-to-section-306-3-of--neup-20240315monthly0.5https://www.biopharmawatch.com/news/NEUP/results-of-annual-general-meeting-adelaide-australia-and-neup-20231130monthly0.5https://www.biopharmawatch.com/news/NEUP/bionomics-announces-retirement-of-board-member-adelaide-australia-and-neup-20231128monthly0.5https://www.biopharmawatch.com/news/NEUP/bionomics-limited-acn-075-582-740-notice-of-annual-general-meeting-explanatory-statement-a-neup-20231103monthly0.5https://www.biopharmawatch.com/news/NEUP/bionomics-announces-successful-end-of-phase-2-meeting-with-the-fda-and-solidifies-plans-to-neup-20231016monthly0.5https://www.biopharmawatch.com/news/NEUP/bionomics-limited-abn-55-075-582-740-statutory-accounts-director-s-report-in-accordance-wi-neup-20230929monthly0.5https://www.biopharmawatch.com/news/NEUP/bionomics-announces-positive-topline-results-from-the-phase-2b-attune-clinical-trial-of-bn-neup-20230928monthly0.5https://www.biopharmawatch.com/news/NEUP/factors-affecting-future-performance-this-announcement-contains-x201c-forward-looking-x201-neup-20230731monthly0.5https://www.biopharmawatch.com/news/NEUP/asx-announcement-28-july-2023-shareholder-communication-on-the-de-listing-process-bionomic-neup-20230728monthly0.5https://www.biopharmawatch.com/news/NEUP/for-further-information-please-contact-baker-young-gpo-box-1672-adelaide-south-australia-5-neup-20230725monthly0.5https://www.biopharmawatch.com/news/NEUP/july-2023-lisa-banh-senior-advisor-listings-compliance-asx-compliance-pty-limited-20-bridg-neup-20230724monthly0.5https://www.biopharmawatch.com/news/NEUP/notification-of-cessation-of-securities-part-3-issued-capital-following-changes-following--neup-20230707monthly0.5https://www.biopharmawatch.com/news/NEUP/abn-53-075-582-740-asx-announcement-28-april-2023-quarterly-activities-and-cashflow-report-neup-20230707monthly0.5https://www.biopharmawatch.com/news/NEUP/new-and-recent-appointee-bios-mr-fisher-is-an-experienced-corporate-advisor-and-public-com-neup-20230703monthly0.5https://www.biopharmawatch.com/news/NEUP/abn-53-075-582-740-asx-announcement-27-april-2023-bionomics-announces-the-completion-of-en-neup-20230427monthly0.5https://www.biopharmawatch.com/news/NEUP/abn-53-075-582-740-asx-announcement-9-march-2023-bionomics-reports-promising-update-on-ana-neup-20230309monthly0.5https://www.biopharmawatch.com/news/NEUP/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-neup-20230223monthly0.5https://www.biopharmawatch.com/news/NEUP/abn-53-075-582-740-bionomics-limited-asx-half-year-information-x2013-31-december-2022-lodg-neup-20230223monthly0.5https://www.biopharmawatch.com/news/NEUP/abn-53-075-582-740-21-february-2023-asx-market-announcements-asx-limited-level-4-stock-exc-neup-20230221monthly0.5https://www.biopharmawatch.com/news/NEUP/about-bionomics-limited-bionomics-limited-asx-bno-nasdaq-bnox-is-a-clinical-stage-biopharm-neup-20230130monthly0.5https://www.biopharmawatch.com/news/NEUP/explanatory-statement-purpose-of-information-this-explanatory-statement-explanatory-statem-neup-20230118monthly0.5https://www.biopharmawatch.com/news/NEUP/rule-3-19a-1-appendix-3x-initial-director-s-interest-notice-information-or-documents-not-a-neup-20230109monthly0.5https://www.biopharmawatch.com/news/NEUP/abn-53-075-582-740-asx-announcement-19-december-2022-bionomics-reports-topline-results-in--neup-20221219monthly0.5https://www.biopharmawatch.com/news/NEUP/about-bionomics-limited-bionomics-limited-asx-bno-nasdaq-bnox-is-a-clinical-stage-biopharm-neup-20221216monthly0.5https://www.biopharmawatch.com/news/NEUP/abn-53-075-582-740-16-november-2022-asx-market-announcements-asx-limited-level-4-stock-exc-neup-20221116monthly0.5https://www.biopharmawatch.com/news/NEUP/abn-53-075-582-740-asx-announcement-25-october-2022-quarterly-activities-and-cashflow-repo-neup-20221025monthly0.5https://www.biopharmawatch.com/news/NEUP/abn-53-075-582-740-asx-announcement-18-october-2022-bionomics-receives-r-d-tax-incentive-r-neup-20221018monthly0.5https://www.biopharmawatch.com/news/NEUP/bionomics-limited-acn-075-582-740-notice-of-annual-general-meeting-explanatory-statement-a-neup-20221018monthly0.5https://www.biopharmawatch.com/news/NEUP/bionomics-annual-report-director-s-report-contents-page-executive-chairman-report-1-direct-neup-20221006monthly0.5https://www.biopharmawatch.com/news/NEUP/abn-53-075-582-740-asx-announcement-4-october-2022-bionomics-to-participate-in-the-cantor--neup-20221004monthly0.5https://www.biopharmawatch.com/news/NEUP/dr-charlie-taylor-is-an-associate-professor-of-psychiatry-at-uc-san-diego-he-received-his--neup-20220921monthly0.5https://www.biopharmawatch.com/news/NEUP/released-on-authority-of-the-board-for-further-information-please-contact-general-ms-suzan-neup-20220825monthly0.5https://www.biopharmawatch.com/news/NEUP/abn-53-075-582-740-asx-announcement-8-august-2022-bionomics-receives-r-d-tax-incentive-ref-neup-20220808monthly0.5https://www.biopharmawatch.com/news/NEUP/abn-53-075-582-740-asx-announcement-29-july-2022-quarterly-activities-and-cashflow-report--neup-20220729monthly0.5https://www.biopharmawatch.com/news/NEUP/notification-of-issue-conversion-or-payment-up-of-unquoted-equity-securities-part-5-other--neup-20220720monthly0.5https://www.biopharmawatch.com/news/NEUP/notification-of-cessation-of-securities-part-3-issued-capital-following-changes-following--neup-20220705monthly0.5https://www.biopharmawatch.com/news/NEUP/abn-53-075-582-740-13-june-2022-bionomics-investor-webinar-bionomics-limited-asx-bno-nasda-neup-20220613monthly0.5https://www.biopharmawatch.com/news/NEUP/rule-3-19a-2-appendix-3y-change-of-director-s-interest-notice-information-or-documents-not-neup-20220518monthly0.5https://www.biopharmawatch.com/news/NEUP/bionomics-limited-to-participate-in-upcoming-investor-conferences-neup-20220516monthly0.5https://www.biopharmawatch.com/news/NEUP/abn-53-075-582-740-asx-announcement-29-april-2022-quarterly-activities-and-cashflow-report-neup-20220429monthly0.5https://www.biopharmawatch.com/news/NEUP/abn-53-075-582-740-bionomics-limited-asx-half-year-information-x2013-31-december-2021-lodg-neup-20220223monthly0.5https://www.biopharmawatch.com/news/NEUP/abn-53-075-582-740-asx-announcement-28-january-2022-quarterly-activities-and-cashflow-repo-neup-20220128monthly0.5https://www.biopharmawatch.com/news/NEUP/to-improve-the-lives-of-patients-with-serious-cns-disorders-corporate-presentation-nasdaq--neup-20220112monthly0.5https://www.biopharmawatch.com/news/NEUP/abn-53-075-582-740-asx-announcement-04-january-2022-bionomics-initiates-phase-2-prevail-st-neup-20220104monthly0.5https://www.biopharmawatch.com/news/NEUP/abn-53-075-582-740-asx-announcement-31-december-2021-resignation-of-director-bionomics-lim-neup-20220103monthly0.5https://www.biopharmawatch.com/news/NEUP/appendix-3y-change-of-director-s-interest-notice-rule-3-19a-2-appendix-3y-change-of-direct-neup-20211222monthly0.5https://www.biopharmawatch.com/news/SKYE/developing-innovative-medicines-to-treat-obesity-and-other-metabolic-diseases-february-202-skye-20260202monthly0.5https://www.biopharmawatch.com/news/SKYE/document-skye-completes-17m-financing-and-acquires-novel-phase-2-ready-cb1-inhibiting-mono-skye-20230821monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-announces-7-0-million-registered-direct-offering-skye-20210927monthly0.5https://www.biopharmawatch.com/news/SKYE/skye-bioscience-appoints-biotech-executive-praveen-tyle-ph-d-to-board-of-directors-skye-20210725monthly0.5https://www.biopharmawatch.com/news/SKYE/emerald-bioscience-raises-approximately-7-0-million-in-upsized-registered-offering-long-be-skye-20200804monthly0.5https://www.biopharmawatch.com/news/SKYE/emerald-bioscience-announces-2-0-million-registered-direct-offering-long-beach-ca-skye-20191121monthly0.5https://www.biopharmawatch.com/news/SKYE/emerald-bioscience-secures-all-fields-licenses-for-cannabinoid-derivatives-developed-by-un-skye-20190529monthly0.5https://www.biopharmawatch.com/news/SKYE/douglas-cesario-chief-financial-officer-email-doug-emeraldbio-life-phone-949-336-3437-forw-skye-20190325monthly0.5https://www.biopharmawatch.com/news/SKYE/nemus-bioscience-signs-agreement-with-noramco-to-manufacture-proprietary-cannabidiol-analo-skye-20190304monthly0.5https://www.biopharmawatch.com/news/SKYE/nemus-bioscience-announces-that-emerald-health-sciences-has-provided-a-credit-facility-of--skye-20181008monthly0.5https://www.biopharmawatch.com/news/SKYE/emerald-health-strategic-majority-investor-in-nemus-bioscience-completes-final-closing-of--skye-20180216monthly0.5https://www.biopharmawatch.com/news/SKYE/nemus-secures-emerald-health-as-strategic-majority-investor-to-help-advance-clinical-devel-skye-20180119monthly0.5https://www.biopharmawatch.com/news/SKYE/nemus-bioscience-announces-closing-of-convertible-bridge-loan-and-anticipated-equity-finan-skye-20171229monthly0.5https://www.biopharmawatch.com/news/SKYE/nemus-bioscience-announces-2-000-000-series-f-preferred-stock-financing-costa-mesa-calif-skye-20171101monthly0.5https://www.biopharmawatch.com/news/SKYE/nemus-bioscience-provides-further-update-on-previously-announced-20-million-schneider-fina-skye-20171013monthly0.5https://www.biopharmawatch.com/news/SKYE/n-emus-bioscience-announces-20-million-series-e-preferred-stock-financing-costa-mesa-calif-skye-20170504monthly0.5https://www.biopharmawatch.com/news/SKYE/nemus-bioscience-announces-closing-of-1-200-000-preferred-stock-financing-skye-20170110monthly0.5https://www.biopharmawatch.com/news/SKYE/nemus-bioscience-announces-preferred-stock-financing-costa-mesa-calif-skye-20161229monthly0.5https://www.biopharmawatch.com/news/SKYE/nemus-bioscience-announces-closing-of-500-000-preferred-stock-financing-skye-20161027monthly0.5https://www.biopharmawatch.com/news/SKYE/nemus-bioscience-announces-500-000-preferred-stock-financing-skye-20161026monthly0.5https://www.biopharmawatch.com/news/SKYE/settlement-and-release-of-claims-nmus-ex101-htm-exhibit-10-1-skye-20160812monthly0.5https://www.biopharmawatch.com/news/SKYE/nemus-bioscience-appoints-dr-brian-murphy-as-ceo-costa-mesa-ca-skye-20150825monthly0.5https://www.biopharmawatch.com/news/SKYE/nemus-bioscience-announces-closing-of-5-0-million-series-b-financing-funding-to-finance-de-skye-20150820monthly0.5https://www.biopharmawatch.com/news/SKYE/nemus-bioscience-announces-5m-series-b-financing-funding-to-finance-development-of-nb1111--skye-20150820monthly0.5https://www.biopharmawatch.com/news/SKYE/nemus-bioscience-announces-appointment-of-douglas-s-ingram-former-president-of-allergan-to-skye-20150604monthly0.5https://www.biopharmawatch.com/news/SKYE/nemus-bioscience-inc-audit-committee-charter-i-purpose-the-purpose-of-the-audit-committee--skye-20150227monthly0.5https://www.biopharmawatch.com/news/SKYE/nemus-bioscience-announces-appointment-of-thomas-a-george-cfo-of-deckers-brands-to-its-boa-skye-20150112monthly0.5https://www.biopharmawatch.com/news/SKYE/nemus-balance-sheets-assets-june-30-skye-20141103monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-first-quarter-2025-results-reports-net-sales-of-18-9-million-fo-rmti-20250512monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-fourth-quarter-and-full-year-2024-financial-and-operational-res-rmti-20250320monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-achieves-profitability-on-an-adjusted-ebitda-basis-in-the-fourth-quarter--rmti-20240321monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-amends-loan-and-security-agreement-with-innovatus-life-sciences-lending-f-rmti-20240108monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-third-quarter-2023-results-net-sales-for-the-third-quarter-of-2-rmti-20231114monthly0.5https://www.biopharmawatch.com/news/RMTI/document-rockwell-medical-announces-second-quarter-2023-results-net-sales-for-the-six-mont-rmti-20230814monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-acquires-hemodialysis-concentrates-business-from-evoqua-water-technologie-rmti-20230711monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-appoints-mark-strobeck-ph-d-as-president-and-chief-executive-officer-rmti-20220622monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-transforming-iron-deficiency-therapy-nasdaq-rmti-corporate-presentati-rmti-20220613monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-transforming-iron-deficiency-therapy-nasdaq-rmti-corporate-presentati-rmti-20220520monthly0.5https://www.biopharmawatch.com/news/RMTI/corporate-presentation-january-2022-www-rockwellmed-com-rockwell-medical-inc-transforming--rmti-20220105monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-appointment-of-russell-l-rmti-20200917monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-enters-into-exclusive-license-agreement-with-jeil-pharmaceutical-co-ltd-f-rmti-20200909monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-rmti-20200810monthly0.5https://www.biopharmawatch.com/news/RMTI/united-states-district-court-eastern-district-of-new-york-in-re-rockwell-medical-inc-stock-rmti-20200619monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-rmti-20200511monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-appoints-russell-h-ellison-m-d-m-sc-as-president-and-chief-executive--rmti-20200420monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-receives-fda-approval-for-triferic-avnu-ferric-pyrophosphate-citrate--rmti-20200327monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-announces-35-million-debt-financing-agreement-with-innovatus-capital--rmti-20200317monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-reports-fourth-quarter-and-full-year-2019-financial-results-company-r-rmti-20200312monthly0.5https://www.biopharmawatch.com/news/RMTI/january-2020-certain-statements-in-this-presentation-may-constitute-forward-looking-statem-rmti-20200115monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-enters-into-exclusive-license-and-supply-agreements-with-sun-pharma-f-rmti-20200114monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-reports-third-quarter-2019-financial-results-x2013-company-reports-fi-rmti-20191111monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-provides-business-update-encouraging-progress-for-triferic-portfolio--rmti-20191025monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-reports-second-quarter-2019-financial-results-company-records-first-c-rmti-20190808monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-reports-first-quarter-2019-financial-results-significant-progress-for-rmti-20190509monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-reports-fourth-quarter-and-full-year-2018-financial-results-company-i-rmti-20190314monthly0.5https://www.biopharmawatch.com/news/RMTI/transcript-of-rockwell-medical-lnc-presentation-at-the-2019-bio-ceo-lnvestor-conference-rmti-20190211monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-investor-presentation-january-2019-certain-statements-in-this-presentatio-rmti-20190107monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-reports-third-quarter-2018-financial-results-rmti-20181109monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-provides-business-update-reports-second-quarter-2018-financial-result-rmti-20180814monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-appoints-new-chief-executive-officer-stuart-paul-brings-significant-healt-rmti-20180808monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-engagement-of-marcum-llp-as-new-independent-auditor-rmti-20180730monthly0.5https://www.biopharmawatch.com/news/RMTI/state-of-michigan-in-the-circuit-court-for-the-county-of-oakland-rockwell-medical-inc-plai-rmti-20180711monthly0.5https://www.biopharmawatch.com/news/RMTI/state-of-michigan-in-the-circuit-court-for-the-county-of-oakland-rockwell-medical-inc-plai-rmti-20180619monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-provides-update-on-commercial-strategy-company-to-move-forward-with-comme-rmti-20180607monthly0.5https://www.biopharmawatch.com/news/RMTI/state-of-michigan-in-the-circuit-court-for-the-county-of-oakland-rockwell-medical-inc-plai-rmti-20180523monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-ceo-transition-rmti-20180522monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-inc-appoints-two-independent-and-experienced-life-sciences-executives-to--rmti-20180313monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-1q17-earnings-call-rmti-20170509monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-files-preliminary-proxy-statement-for-annual-meeting-new-director-nominat-rmti-20170404monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-nomination-of-dave-domzalski-to-board-of-directors-wixom-michig-rmti-20170302monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-closes-58-5-million-public-offering-of-common-stock-wixom-mi-11-25-2014-r-rmti-20141120monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-prices-58-5-million-public-offering-of-common-stock-wixom-mi-11-19-2014-r-rmti-20141120monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-55-million-proposed-public-offering-of-common-stock-wixom-mi-ma-rmti-20141117monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-enters-into-exclusive-long-term-agreement-with-baxter-healthcare-to-comme-rmti-20141003monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-sfp-meets-primary-and-key-secondary-endpoints-in-phase-3-cruise-rmti-20130711monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-closes-40-3-million-public-offering-of-common-stock-wixom-mi-globe-newswi-rmti-20130515monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-the-exercise-of-over-allotment-option-wixom-mi-globe-newswire-0-rmti-20130515monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-prices-35-0-million-public-offering-of-common-stock-wixom-mi-globe-newswi-rmti-20130515monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-proposed-public-offering-of-common-stock-wixom-mi-marketwire-05-rmti-20130514monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-closes-12-9-million-registered-direct-common-stock-offering-wixom-michiga-rmti-20130326monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-to-raise-12-9-million-in-registered-direct-common-stock-offering-wixom-mi-rmti-20130320monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-iron-delivery-drug-sfp-meets-primary-endpoint-in-prime-clinical-rmti-20130204monthly0.5https://www.biopharmawatch.com/news/RMTI/source-rockwell-medical-technologies-inc-rockwell-medical-closes-17-5-million-registered-c-rmti-20120215monthly0.5https://www.biopharmawatch.com/news/RMTI/source-rockwell-medical-technologies-inc-rockwell-medical-prices-registered-common-stock-o-rmti-20120209monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-schedules-conference-call-reporting-fourth-quarter-and-year-end-results-w-rmti-20120127monthly0.5https://www.biopharmawatch.com/news/RMTI/rockwell-medical-announces-positive-phase-iib-clinical-data-sfp-well-tolerated-no-apparent-rmti-20100226monthly0.5https://www.biopharmawatch.com/news/RMTI/source-rockwell-medical-technologies-inc-rockwell-medical-technologies-inc-announces-closi-rmti-20091005monthly0.5https://www.biopharmawatch.com/news/RMTI/company-press-release-rockwell-medical-technologies-inc-announces-22-million-registered-di-rmti-20090930monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-provides-business-update-and-reports-full-year-2025-financial-results-data-readou-nxtc-20260305monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-provides-business-update-sim0505-cdh6-adc-phase-1-dose-escalation-data-update-ant-nxtc-20260123monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-announces-closing-of-21-5-million-pipe-financing-in-advance-of-first-half-2026-ph-nxtc-20251117monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-provides-business-update-and-reports-second-quarter-2025-financial-results-announ-nxtc-20250807monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-provides-business-update-and-reports-first-quarter-2025-financial-results-dosing--nxtc-20250501monthly0.5https://www.biopharmawatch.com/news/NXTC/corporate-presentation-nasdaq-nxtc-april-2025-forward-looking-statement-2-to-the-extent-th-nxtc-20250410monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-provides-business-update-and-reports-full-year-2024-financial-results-completed-c-nxtc-20250306monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-announces-first-patient-dosed-in-the-phase-1-study-of-lncb74-b7-h4-adc-as-therape-nxtc-20250110monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-announces-acceptance-of-ind-application-for-lncb74-lncb74-is-a-b7-h4-targeting-an-nxtc-20241210monthly0.5https://www.biopharmawatch.com/news/NXTC/corporate-presentation-nasdaq-nxtc-december-2024-forward-looking-statement-2-to-the-extent-nxtc-20241205monthly0.5https://www.biopharmawatch.com/news/NXTC/corporate-presentation-nasdaq-nxtc-november-2024-forward-looking-statement-2-to-the-extent-nxtc-20241108monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-provides-business-update-and-reports-third-quarter-2024-financial-results-priorit-nxtc-20241107monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-provides-business-update-and-reports-second-quarter-2024-financial-results-lncb74-nxtc-20240801monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-provides-business-update-and-reports-first-quarter-2024-financial-results-phase-1-nxtc-20240502monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-provides-business-update-and-reports-full-year-2023-financial-results-prioritizin-nxtc-20240321monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-provides-year-end-clinical-pipeline-updates-beltsville-md-nxtc-20231214monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-provides-business-update-and-reports-third-quarter-2023-financial-results-phase-1-nxtc-20231102monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-provides-business-update-and-reports-second-quarter-2023-financial-results-phase--nxtc-20230803monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-provides-business-update-and-reports-first-quarter-2023-financial-results-clinica-nxtc-20230504monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-provides-business-update-and-reports-full-year-2022-financial-results-clinical-da-nxtc-20230302monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-provides-update-and-reports-third-quarter-2022-financial-results-discontinuing-de-nxtc-20221103monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-provides-business-update-and-reports-second-quarter-2022-financial-results-on-tra-nxtc-20220804monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-provides-business-update-and-reports-first-quarter-2022-financial-results-on-trac-nxtc-20220505monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-provides-business-update-and-reports-fourth-quarter-and-full-year-2021-financial--nxtc-20220303monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-and-collaborators-provide-clinical-and-research-updates-on-nc318-and-nc410-candid-nxtc-20211113monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-reports-third-quarter-2021-financial-results-and-provides-business-update-beltsvi-nxtc-20211104monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-announces-new-appointments-to-its-board-of-directors-beltsville-md-nxtc-20211004monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-reports-second-quarter-2021-financial-results-beltsville-md-nxtc-20210805monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-provides-business-update-and-reports-fourth-quarter-and-full-year-2020-financial--nxtc-20210304monthly0.5https://www.biopharmawatch.com/news/NXTC/dr-han-myint-appointed-as-nextcure-s-chief-medical-officer-beltsville-md-nxtc-20210114monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-announces-appointment-of-john-g-houston-ph-d-to-its-board-of-directors-beltsville-nxtc-20200914monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-provides-an-interim-update-of-the-phase-2-portion-of-the-nc318-monotherapy-phase--nxtc-20200713monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-announces-appointment-of-veteran-oncology-executive-garry-nicholson-to-its-board--nxtc-20200330monthly0.5https://www.biopharmawatch.com/news/NXTC/nextcure-announces-promotion-of-timothy-mayer-ph-d-to-chief-operating-officer-beltsville-m-nxtc-20191002monthly0.5https://www.biopharmawatch.com/news/BRNS/document-barinthus-bio-reports-first-quarter-2026-financial-results-and-updates-on-corpora-brns-20260430monthly0.5https://www.biopharmawatch.com/news/BRNS/document-barinthus-bio-reports-full-year-2025-financial-results-and-updates-on-corporate-d-brns-20260313monthly0.5https://www.biopharmawatch.com/news/BRNS/document-barinthus-bio-announces-update-on-phase-1-avalon-clinical-trial-of-vtp-1000-for-t-brns-20251210monthly0.5https://www.biopharmawatch.com/news/BRNS/document-barinthus-bio-reports-third-quarter-2025-financial-results-and-updates-on-corpora-brns-20251107monthly0.5https://www.biopharmawatch.com/news/BRNS/barinthus-bio-reports-second-quarter-2025-financial-results-and-updates-on-corporate-devel-brns-20250807monthly0.5https://www.biopharmawatch.com/news/BRNS/document-barinthus-bio-reports-second-quarter-2025-financial-results-and-updates-on-corpor-brns-20250807monthly0.5https://www.biopharmawatch.com/news/BRNS/document-barinthus-bio-reports-first-quarter-2025-financial-results-and-updates-on-corpora-brns-20250507monthly0.5https://www.biopharmawatch.com/news/BRNS/document-barinthus-bio-reports-full-year-2024-financial-results-and-updates-on-corporate-d-brns-20250320monthly0.5https://www.biopharmawatch.com/news/BRNS/document-barinthus-bio-announces-strategic-focus-in-immunology-and-inflammation-i-i-and-pr-brns-20250110monthly0.5https://www.biopharmawatch.com/news/BRNS/document-barinthus-bio-promotes-snap-ti-co-inventor-geoffrey-lynn-m-d-ph-d-to-chief-scient-brns-20241125monthly0.5https://www.biopharmawatch.com/news/BRNS/document-arbutus-and-barinthus-bio-announce-new-data-from-the-im-prove-ii-trial-showing-th-brns-20241115monthly0.5https://www.biopharmawatch.com/news/BRNS/document-barinthus-bio-reports-third-quarter-2024-update-on-corporate-developments-and-fin-brns-20241106monthly0.5https://www.biopharmawatch.com/news/BRNS/document-barinthus-bio-reports-second-quarter-2024-update-on-corporate-developments-and-fi-brns-20240808monthly0.5https://www.biopharmawatch.com/news/BRNS/document-barinthus-bio-s-vtp-300-trials-demonstrate-ability-to-achieve-undetectable-hbsag--brns-20240606monthly0.5https://www.biopharmawatch.com/news/BRNS/document-barinthus-bio-reports-first-quarter-2024-financial-results-and-update-on-corporat-brns-20240513monthly0.5https://www.biopharmawatch.com/news/BRNS/document-barinthus-bio-announces-topline-data-from-phase-1b-2-apollo-trial-of-vtp-200-in-p-brns-20240418monthly0.5https://www.biopharmawatch.com/news/BRNS/document-barinthus-bio-reports-full-year-2023-financial-results-and-update-on-corporate-de-brns-20240320monthly0.5https://www.biopharmawatch.com/news/BRNS/barinthus-bio-provides-a-financial-update-and-announces-anticipated-2024-corporate-milesto-brns-20240105monthly0.5https://www.biopharmawatch.com/news/BRNS/new-partnership-aims-to-advance-vaccine-against-mers-coronavirus-brns-20231221monthly0.5https://www.biopharmawatch.com/news/BRNS/barinthus-bio-presents-interim-data-from-phase-2b-hbv003-trial-and-phase-2a-ab-729-202-tri-brns-20231109monthly0.5https://www.biopharmawatch.com/news/BRNS/barinthus-bio-reports-third-quarter-2023-financial-results-and-recent-corporate-developmen-brns-20231109monthly0.5https://www.biopharmawatch.com/news/BRNS/vaccitech-renames-as-barinthus-biotherapeutics-to-highlight-strategic-evolution-into-a-t-c-brns-20231106monthly0.5https://www.biopharmawatch.com/news/BRNS/vaccitech-reports-second-quarter-2023-financial-results-and-recent-corporate-developments--brns-20230810monthly0.5https://www.biopharmawatch.com/news/BRNS/vaccitech-to-present-positive-final-data-at-easl-congress-for-phase-1b-2-hbv002-study-in-a-brns-20230621monthly0.5https://www.biopharmawatch.com/news/BRNS/vaccitech-reports-first-quarter-2023-financial-brns-20230512monthly0.5https://www.biopharmawatch.com/news/BRNS/vaccitech-reports-full-year-2022-financial-results-and-an-update-on-corporate-developments-brns-20230324monthly0.5https://www.biopharmawatch.com/news/BRNS/vaccitech-reports-third-quarter-2022-financial-results-and-recent-corporate-developments-o-brns-20221110monthly0.5https://www.biopharmawatch.com/news/BRNS/vaccitech-promotes-gemma-brown-as-chief-financial-officer-oxford-united-kingdom-brns-20220920monthly0.5https://www.biopharmawatch.com/news/BRNS/vaccitech-reports-second-quarter-2022-financial-results-and-recent-corporate-developments--brns-20220809monthly0.5https://www.biopharmawatch.com/news/BRNS/vaccitech-s-vtp-300-induced-sustained-reductions-of-surface-antigen-in-patients-with-chron-brns-20220622monthly0.5https://www.biopharmawatch.com/news/BRNS/vaccitech-reports-first-quarter-2022-financial-results-and-recent-corporate-developments-o-brns-20220511monthly0.5https://www.biopharmawatch.com/news/BRNS/vaccitech-reports-full-year-2021-financial-results-and-recent-corporate-developments-oxfor-brns-20220325monthly0.5https://www.biopharmawatch.com/news/BRNS/vaccitech-acquires-avidea-technologies-to-expand-product-pipeline-and-strengthen-scientifi-brns-20211213monthly0.5https://www.biopharmawatch.com/news/BRNS/vaccitech-reports-third-quarter-2021-financial-results-and-recent-corporate-developments-o-brns-20211112monthly0.5https://www.biopharmawatch.com/news/BRNS/vaccitech-reports-second-quarter-2021-financial-results-and-recent-corporate-developments--brns-20210812monthly0.5https://www.biopharmawatch.com/news/BRNS/vaccitech-reports-first-quarter-2021-financial-results-and-recent-corporate-developments-o-brns-20210614monthly0.5https://www.biopharmawatch.com/news/QTEX/qtrex-expands-into-quantum-processor-interface-with-single-build-cryogenic-chip-carrier-ba-qtex-20260618monthly0.5https://www.biopharmawatch.com/news/QTEX/qtrex-awarded-government-grant-to-advance-the-world-s-first-native-rf-dielectric-material--qtex-20260609monthly0.5https://www.biopharmawatch.com/news/QTEX/qtrex-secures-purchase-order-from-a-u-s-based-fortune-500-company-for-an-ame-system-and-re-qtex-20260601monthly0.5https://www.biopharmawatch.com/news/QTEX/qtrex-announces-pricing-of-a-10-million-private-placement-of-ordinary-shares-with-a-new-fu-qtex-20260529monthly0.5https://www.biopharmawatch.com/news/QTEX/additively-manufactured-electronics-and-fabrica-product-lines-product-lines-of-nano-dimens-qtex-20260528monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-to-begin-trading-as-qtrex-quantum-under-nasdaq-ticker-qtex-on-qtex-20260520monthly0.5https://www.biopharmawatch.com/news/QTEX/nyu-langone-issues-580-000-purchase-order-for-inspira-s-fda-cleared-art100-following-multi-qtex-20260518monthly0.5https://www.biopharmawatch.com/news/QTEX/technologies-ceo-issues-letter-to-shareholders-on-strategic-direction-and-value-creation-p-qtex-20260511monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-secures-596-000-ame-system-order-from-leading-irish-technological-university-ra-an-qtex-20260501monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-and-qarakal-sign-joint-development-agreement-qtex-20260430monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-secures-fully-paid-390-000-purchase-order-and-recurring-revenue-strea-qtex-20260428monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-completes-commercial-deployment-of-its-qtex-20260416monthly0.5https://www.biopharmawatch.com/news/QTEX/to-the-company-s-report-of-foreign-private-issuer-on-form-6-k-filed-with-the-sec-on-qtex-20260406monthly0.5https://www.biopharmawatch.com/news/QTEX/technologies-appoints-yoav-rozanovich-as-chief-business-officer-to-drive-immediate-revenue-qtex-20260414monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-enters-quantum-computing-sector-targeting-a-critical-connectivity-bottleneck-with--qtex-20260406monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-announces-acquisition-of-qtex-20260406monthly0.5https://www.biopharmawatch.com/news/QTEX/technologies-terminates-atm-and-sepa-equity-facilities-to-prepare-for-next-strategic-phase-qtex-20260331monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-reports-full-year-2025-qtex-20260326monthly0.5https://www.biopharmawatch.com/news/QTEX/receives-nasdaq-notification-regarding-minimum-market-value-deficiency-qtex-20260225monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-expands-u-s-qtex-20260218monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-announces-receipt-of-nasdaq-notification-regarding-minimum-bid-price--qtex-20260212monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-secures-vendor-approval-from-12-billion-revenue-hmo-world-s-2-nd-largest-enabling--qtex-20260209monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-announces-pricing-of-4-75-million-registered-direct-offering-and-concurrent-privat-qtex-20260205monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-validates-next-gen-standalone-hyla-blood-sensor-with-clinical-grade-a-qtex-20260203monthly0.5https://www.biopharmawatch.com/news/QTEX/art100-becomes-inspira-s-first-system-to-complete-clinical-evaluation-and-enters-budgeted--qtex-20260129monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-advances-to-final-governmental-budgetary-validation-procedures-for-previously-anno-qtex-20260121monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-signs-term-sheet-for-acquisition-of-advanced-liquid-biopsy-cancer-diagnostics-tech-qtex-20260105monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-outlines-strategic-vision-and-transaction-framework-for-breast-cancer-liquid-biops-qtex-20260108monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-reaffirms-49-5-million-in-binding-purchase-orders-and-aligns-executio-qtex-20251223monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-announces-1-8-million-registered-direct-offering-priced-at-the-market-and-addition-qtex-20251215monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-granted-patent-in-japan-for-the-inspira-art-system-s-convertible-dual-qtex-20251209monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-announces-strategic-leap-in-lab-capabilities-accelerating-next-genera-qtex-20251203monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-oxy-b-h-n-ltd-notice-of-annual-and-extraordinary-general-meeting-of-s-qtex-20251125monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-completes-clinical-study-for-hyla-blood-sensor-ahead-of-regulatory-submission-ra-a-qtex-20251113monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-nears-final-regulatory-clearance-for-the-art100-in-the-uae-accelerati-qtex-20251106monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-and-bites-form-strategic-alliance-to-embed-ai-as-a-core-standard-across-inspira-s--qtex-20251022monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-appoints-former-johnson-johnson-senior-business-manager-as-vp-of-global-sales-and--qtex-20251021monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-reports-first-half-2025-financial-results-and-issues-business-update--qtex-20251001monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-to-unveil-hyla-real-time-blood-sensor-at-u-s-elso-97-35-accuracy-confirmed-ra-anan-qtex-20250918monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-announces-97-3-accuracy-results-for-hyla-blood-sensor-advancing-toward-fda-submiss-qtex-20250911monthly0.5https://www.biopharmawatch.com/news/QTEX/top-u-s-honor-roll-hospital-expands-use-of-inspira-art100-system-to-lung-transplant-proced-qtex-20250902monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-receives-u-s-patent-approval-for-the-art500-core-technology-key-patent-positions-t-qtex-20250822monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-secures-27-million-government-binding-purchase-order-for-art100-systems-with-full--qtex-20250819monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-activates-u-s-based-consulting-firm-to-execute-transformational-initiatives-ra-ana-qtex-20250731monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-regains-compliance-with-nasdaq-minimum-bid-price-requirement-ra-anana-israel-qtex-20250718monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-achieves-all-key-objectives-in-previously-announced-government-talks-forging-a-pat-qtex-20250710monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-in-high-level-government-talks-to-advance-national-integration-of-the-art100-and-e-qtex-20250707monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-secures-22-5-million-purchase-order-launches-full-revenue-execution-p-qtex-20250702monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-s-art100-in-use-at-tier-1-u-s-hospitals-generating-strong-clinical-interest-and-ac-qtex-20250611monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-scales-up-art100-production-capabilities-amid-advanced-negotiation-with-european-g-qtex-20250605monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-oxy-b-h-n-ltd-notice-of-extraordinary-general-meeting-of-shareholders-qtex-20250530monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-initiates-global-commercial-rollout-of-fda-cleared-art100-system-foll-qtex-20250529monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-aligns-executive-team-amid-corporate-structuring-initiatives-ra-anana-qtex-20250527monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-art100-system-approved-by-israel-s-largest-healthcare-provider-for-use-in-organ-tr-qtex-20250507monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-achieves-above-99-gas-exchange-efficiency-in-vortx-technology-in-vivo-animal-testi-qtex-20250423monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-generates-first-revenues-from-deployment-of-inspira-art100-systems-th-qtex-20250415monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-oxy-b-h-n-ltd-notice-of-extraordinary-general-meeting-of-shareholders-qtex-20250407monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-announces-successful-treatment-of-first-patient-with-inspira-art100-a-qtex-20250407monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-announces-successful-installation-of-inspira-art100-systems-in-premie-qtex-20250325monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-releases-ceo-update-major-milestones-signal-next-level-respiratory-ca-qtex-20250314monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-receives-nasdaq-notification-regarding-minimum-bid-requirement-ra-ana-qtex-20250313monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-reports-full-year-2024-financial-results-and-provides-business-update-qtex-20250311monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-announces-positive-results-from-clinical-study-of-hyla-blood-sensor-a-qtex-20250304monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-achieves-positive-results-of-above-95-for-preventing-bloodstream-infections-the-ex-qtex-20250211monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-integrates-new-oxygenation-indicator-into-ai-powered-hyla-blood-senso-qtex-20250205monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-introduces-advanced-features-for-inspira-art100-further-amplifying-user-and-system-qtex-20250127monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-announces-the-appointment-of-tal-parnes-as-the-new-chairman-of-the-board-bringing--qtex-20250121monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-collaborates-with-zriha-medical-to-launch-cutting-edge-production-lin-qtex-20250117monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-unveils-modular-configuration-for-revolutionary-vortx-blood-oxygenati-qtex-20250114monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-preparing-production-in-response-to-spread-of-respiratory-virus-in-china-ra-anana--qtex-20250110monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-flagship-technology-to-be-showcased-at-arab-health-expo-2025-in-dubai-qtex-20250107monthly0.5https://www.biopharmawatch.com/news/QTEX/securities-purchase-agreement-this-securities-purchase-agreement-this-agreement-is-dated-a-qtex-20241227monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-delivers-systems-to-leading-distributor-for-u-s-deployment-ra-anana-i-qtex-20241216monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-expands-hyla-blood-sensor-technology-into-personalized-blood-lab-testing-for-rapid-qtex-20241210monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-collaborates-with-new-york-s-westchester-medical-center-to-evaluate-the-inspira-ar-qtex-20241204monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-oxy-b-h-n-ltd-notice-of-annual-general-meeting-of-shareholders-notice-qtex-20241125monthly0.5https://www.biopharmawatch.com/news/QTEX/see-disclaimers-on-slides-1-16-copyright-2018-2024-inspira-technologies-oxy-b-h-n-ltd-all--qtex-20241112monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-announces-establishment-of-distribution-facility-to-support-u-s-deployment-of-insp-qtex-20241024monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-announces-development-of-new-disposable-kit-with-built-in-performance-monitoring-m-qtex-20241009monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-secures-a-second-u-s-patent-approval-for-orbiting-blood-oxygenation-delivery-syste-qtex-20240913monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-to-publish-hyla-clinical-results-in-fourth-quarter-2024-the-clip-on-hyla-blood-sen-qtex-20240828monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-announces-fda-listing-and-market-readiness-of-new-product-ra-anana-is-qtex-20240822monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-oxy-b-h-n-ltd-interim-condensed-financial-statements-as-of-june-30-20-qtex-20240815monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-approached-by-large-medical-company-to-evaluate-operation-of-their-key-product-wit-qtex-20240813monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-introduces-the-inspira-cardi-art-aiming-to-provide-oxygen-to-the-brai-qtex-20240730monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-receives-israeli-regulatory-approval-for-the-inspira-art100-system-approval-follow-qtex-20240711monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-announces-business-plan-targets-company-to-aggressively-promote-inspira-art100-in--qtex-20240620monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-receives-first-ever-purchase-order-for-inspira-art100-systems-in-u-s-first-units-e-qtex-20240613monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-art100-receives-fda-510-k-clearance-ra-anana-israel-qtex-20240528monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-announces-start-of-production-of-the-inspira-art100-ra-anana-israel-qtex-20240502monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-receives-csa-certification-of-compliance-to-u-s-standards-for-the-inspira-art100-r-qtex-20240425monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-signs-term-sheet-for-use-of-inspira-art100-device-in-organ-transplant-procedures-r-qtex-20240416monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-and-ennocure-in-vitro-study-results-show-100-prevention-of-bacterial-growth-that-c-qtex-20240410monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-announces-program-to-pioneer-the-applicable-use-of-the-inspira-art100-device-for-a-qtex-20240403monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-announces-1-65-million-registered-direct-offering-of-ordinary-shares-by-inspira-ce-qtex-20240401monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-reports-full-year-2023-financial-results-fda-submission-for-approval--qtex-20240325monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-announces-amar-regulatory-submission-of-the-inspira-art100-to-enter-the-southeast--qtex-20240318monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-releases-new-data-demonstrating-superiority-of-its-core-technology-across-key-endp-qtex-20240312monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-oxy-b-h-n-ltd-notice-of-extraordinary-general-meeting-of-shareholders-qtex-20240308monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-oxy-b-h-n-ltd-notice-of-extraordinary-general-meeting-of-shareholders-qtex-20240304monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-announces-plans-to-report-the-primary-results-for-a-core-blood-oxygenation-technol-qtex-20240304monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-announces-breakthrough-update-nears-first-fda-510-k-approval-3-u-s-patents-approve-qtex-20240227monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-introduces-high-end-platform-for-bio-mimicking-blood-parameters-for-development-an-qtex-20240222monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-receives-first-ever-u-s-patent-approval-for-an-orbiting-blood-oxygenation-delivery-qtex-20240214monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-collaborates-with-a-leading-israeli-medical-center-for-clinical-evalu-qtex-20240208monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-signs-strategic-agreement-to-enter-gulf-states-with-glo-med-for-deplo-qtex-20240130monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-announces-plans-to-launch-and-target-single-use-disposable-blood-oxygenation-kit-f-qtex-20240109monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-signs-letter-of-intent-with-northwestern-memorial-hospital-in-chicago-qtex-20240102monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-announces-3-88-million-registered-direct-offering-ra-anana-israel-qtex-20231226monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-announces-95-accuracy-results-for-hyla-blood-sensor-planning-fda-submission-for-cl-qtex-20231226monthly0.5https://www.biopharmawatch.com/news/QTEX/in-preparation-for-fda-clearance-and-device-deployment-inspira-has-appointed-dr-dan-gorfil-qtex-20231211monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-collaborates-with-ennocure-for-development-of-proprietary-bio-electronic-treatment-qtex-20231129monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-oxy-b-h-n-ltd-notice-of-annual-general-meeting-of-shareholders-notice-qtex-20231122monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-reports-third-quarter-2023-financial-results-ra-anana-israel-qtex-20231116monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-announces-israeli-innovation-authority-grant-for-new-vortx-disposable-blood-oxygen-qtex-20231106monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-granted-u-s-patent-for-inspira-art500-medical-device-this-new-patent-advances-insp-qtex-20231025monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-terminates-atm-program-and-provides-an-update-ra-anana-israel-qtex-20231024monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-enters-into-a-distribution-agreement-in-central-america-with-cio-med-group-the-agr-qtex-20231010monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-oxy-b-h-n-ltd-interim-condensed-financial-statements-as-of-june-30-20-qtex-20231002monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-unveils-the-inspira-art-line-of-medical-devices-at-the-world-s-larges-qtex-20230928monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-tm-announces-510-k-fda-submission-of-inspira-tm-art100-towards-commercialization-m-qtex-20230913monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-signs-agreement-expansion-with-innovimed-for-clinical-trials-of-inspira-art-respir-qtex-20230829monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-reports-second-quarter-2023-financial-results-as-of-qtex-20230810monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-tm-art100-completes-usability-study-in-boston-massachusetts-u-s-ra-anana-israel-qtex-20230809monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-receives-certification-of-medical-devices-quality-management-systems--qtex-20230724monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-enters-into-collaboration-agreement-with-u-s-based-perfusion-solution-qtex-20230719monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-unveils-investor-deck-showcasing-revolutionary-advancement-in-acute-r-qtex-20230615monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-appoints-dr-nir-as-chief-medical-officer-dr-nir-is-a-clinical-strateg-qtex-20230530monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-reports-first-quarter-2023-financial-results-as-of-qtex-20230518monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-will-reveal-the-new-alice-tm-device-at-the-world-s-largest-extracorpo-qtex-20230516monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-is-developing-the-vortx-tm-blood-oxygenator-a-unique-technology-for-s-qtex-20230511monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-reports-fourth-quarter-2022-and-full-year-financial-results-as-of-qtex-20230404monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-tm-technologies-announces-first-in-human-of-hyla-tm-blood-sensor-in-clinical-study-qtex-20230322monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-tm-technologies-receives-approval-from-sheba-medical-center-to-conduct-clinical-st-qtex-20230213monthly0.5https://www.biopharmawatch.com/news/QTEX/copyright-2018-2023-inspira-technologies-oxy-b-h-n-ltd-all-rights-reserved-1-investor-pres-qtex-20230206monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-tm-technologies-granted-patent-by-u-s-patent-office-for-the-inspira-tm-art-system--qtex-20230123monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-signs-strategic-oem-agreement-with-terumo-cardiovascular-terumo-cardi-qtex-20221227monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-tm-technologies-begins-manufacturing-of-the-alice-tm-cpb-device-ahead-of-planned-2-qtex-20221220monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-signs-agreement-to-conduct-clinical-study-of-hyla-tm-blood-sensor-the-qtex-20221214monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-reports-third-quarter-2022-financial-results-as-of-qtex-20221123monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-tm-technologies-signs-a-strategic-agreement-in-europe-to-potentially-provide-26-1--qtex-20221122monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-tm-technologies-granted-patent-by-the-israeli-patent-office-for-key-safety-compone-qtex-20221110monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-oxy-b-h-n-ltd-interim-condensed-financial-statements-as-of-june-30-20-qtex-20220929monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-oxy-b-h-n-ltd-notice-of-annual-and-extraordinary-general-meeting-of-s-qtex-20220908monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-tm-technologies-performed-hyla-tm-blood-sensor-in-vivo-study-in-preparation-of-pla-qtex-20220907monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-reports-second-quarter-2022-financial-results-as-of-qtex-20220811monthly0.5https://www.biopharmawatch.com/news/QTEX/copyright-2018-2022-inspira-technologies-oxy-b-h-n-ltd-all-rights-reserved-august-2022-inv-qtex-20220808monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-reveals-next-generation-liby-ecmo-an-extracorporeal-membrane-oxygenat-qtex-20220711monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-signs-strategic-agreement-in-u-s-to-potentially-provide-59-million-fo-qtex-20220707monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-develops-a-non-invasive-blood-sensor-designed-to-alert-real-time-chan-qtex-20220706monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-announces-first-quarter-2022-financial-results-as-of-qtex-20220519monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-announces-deployment-agreement-in-the-israeli-market-to-target-15m-th-qtex-20220406monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-releases-q4-fy2021-financial-results-qtex-20220331monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-appointed-an-expert-in-the-field-of-artificial-lung-as-the-new-chief--qtex-20220203monthly0.5https://www.biopharmawatch.com/news/QTEX/revolutionizing-acute-respiratory-care-february-2022-copyright-2018-2022-inspira-technolog-qtex-20220201monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-signs-a-strategic-agreement-in-the-u-s-to-target-212-million-for-insp-qtex-20220131monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-has-listed-an-fda-class-i-510-k-exempt-component-of-the-art-system-ra-qtex-20220128monthly0.5https://www.biopharmawatch.com/news/QTEX/professor-daniel-brodie-the-president-of-the-international-extracorporeal-organization-els-qtex-20220119monthly0.5https://www.biopharmawatch.com/news/QTEX/about-art-system-this-presentation-contains-express-or-implied-forward-looking-statements--qtex-20220106monthly0.5https://www.biopharmawatch.com/news/QTEX/amended-articles-the-companies-law-1999-a-limited-liability-company-articles-of-associatio-qtex-20211220monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-signs-strategic-agreement-with-innovimed-for-the-potential-deployment-qtex-20211209monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-professor-eddy-fan-expert-in-critical-care-medicine-and-extracorporea-qtex-20211130monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-announces-2021-third-quarter-financial-results-in-october-2021-compan-qtex-20211123monthly0.5https://www.biopharmawatch.com/news/QTEX/dr-stephane-ledot-an-expert-in-critical-care-and-anesthesia-has-joined-inspira-technologie-qtex-20211123monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-oxy-b-h-n-ltd-notice-of-extraordinary-general-meeting-of-shareholders-qtex-20211112monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-oxy-b-h-n-ltd-interim-condensed-financial-statements-as-of-june-30-20-qtex-20211027monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-enters-europe-signs-a-strategic-agreement-with-waas-group-for-the-dep-qtex-20211026monthly0.5https://www.biopharmawatch.com/news/QTEX/revolutionizing-acute-respiratory-care-o-c-t-ob-er-2021-copyright-2018-2021-inspira-techno-qtex-20211012monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-artificial-lung-to-acquire-a-digital-edge-the-company-contracted-glob-qtex-20210922monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-oxy-b-h-n-ltd-iinn-iinnw-p-1-roprietary-inspira-technologies-oxy-b-h--qtex-20210913monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-reached-important-milestone-as-it-completed-a-pump-bench-study-the-ex-qtex-20210818monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-announces-first-half-2021-financial-results-and-provides-business-upd-qtex-20210813monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-expands-board-of-directors-to-accelerate-company-s-go-to-market-effor-qtex-20210810monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-expands-medical-advisory-board-as-part-of-future-expansion-into-north-american-mar-qtex-20210726monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-and-ben-gurion-university-have-developed-a-platform-designed-to-preve-qtex-20210719monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-oxy-b-h-n-ltd-announces-closing-of-initial-public-offering-ra-anana-i-qtex-20210716monthly0.5https://www.biopharmawatch.com/news/QTEX/inspira-technologies-oxy-b-h-n-ltd-announces-pricing-of-initial-public-offering-ra-anana-i-qtex-20210713monthly0.5https://www.biopharmawatch.com/news/GRDX/gridai-technologies-corp-announces-receipt-of-nasdaq-notice-regarding-late-form-10-k-filin-grdx-20260428monthly0.5https://www.biopharmawatch.com/news/GRDX/eric-corbett-100-long-branch-avenue-unit-21-etobicoke-ontario-m8w-0c1-canada-via-email-jas-grdx-20251128monthly0.5https://www.biopharmawatch.com/news/GRDX/entero-therapeutics-nasdaq-ento-acquires-100-of-grid-ai-a-grid-edge-ai-platform-optimizing-grdx-20251001monthly0.5https://www.biopharmawatch.com/news/GRDX/entero-therapeutics-inc-announces-reverse-stock-split-grdx-20250814monthly0.5https://www.biopharmawatch.com/news/GRDX/entero-therapeutics-inc-announces-3-0-million-private-placement-priced-at-the-market-under-grdx-20250811monthly0.5https://www.biopharmawatch.com/news/GRDX/entero-therapeutics-announces-signing-of-rescission-agreement-with-immunogenx-grdx-20250324monthly0.5https://www.biopharmawatch.com/news/GRDX/entero-therapeutics-appoints-richard-paolone-as-grdx-20250214monthly0.5https://www.biopharmawatch.com/news/GRDX/entero-therapeutics-announces-proposed-reverse-merger-with-journey-therapeutics-a-clinical-grdx-20241113monthly0.5https://www.biopharmawatch.com/news/GRDX/entero-therapeutics-signs-letter-of-intent-to-license-and-commercialize-remote-patient-and-grdx-20240910monthly0.5https://www.biopharmawatch.com/news/GRDX/entero-therapeutics-inc-receives-nasdaq-notification-regarding-delayed-form-10-q-grdx-20240823monthly0.5https://www.biopharmawatch.com/news/GRDX/entero-therapeutics-chairman-and-ceo-james-sapirstein-provides-business-update-with-focus--grdx-20240731monthly0.5https://www.biopharmawatch.com/news/GRDX/entero-therapeutics-announces-exercise-of-warrants-and-issuance-of-new-warrants-in-a-priva-grdx-20240711monthly0.5https://www.biopharmawatch.com/news/GRDX/first-wave-biopharma-changes-name-to-entero-therapeutics-rebranding-introduced-as-company--grdx-20240517monthly0.5https://www.biopharmawatch.com/news/GRDX/first-wave-biopharma-inc-to-raise-approximately-1-1-million-of-gross-proceeds-priced-at-th-grdx-20240510monthly0.5https://www.biopharmawatch.com/news/GRDX/first-wave-biopharma-announces-two-abstracts-on-celiac-disease-research-accepted-for-prese-grdx-20240318monthly0.5https://www.biopharmawatch.com/news/GRDX/first-wave-biopharma-announces-completion-of-business-combination-with-immunogenx-adding-p-grdx-20240314monthly0.5https://www.biopharmawatch.com/news/GRDX/first-wave-biopharma-inc-to-raise-approximately-4-0-million-of-gross-proceeds-in-registere-grdx-20240304monthly0.5https://www.biopharmawatch.com/news/GRDX/first-wave-biopharma-chairman-and-ceo-issues-letter-to-shareholders-highlighting-recent-ac-grdx-20240104monthly0.5https://www.biopharmawatch.com/news/GRDX/first-wave-biopharma-announces-exercise-of-warrants-and-issuance-of-new-warrants-in-a-priv-grdx-20231227monthly0.5https://www.biopharmawatch.com/news/GRDX/first-wave-biopharma-announces-streamlining-of-clinical-pipeline-with-non-binding-term-she-grdx-20231227monthly0.5https://www.biopharmawatch.com/news/GRDX/first-wave-biopharma-announces-entry-into-term-sheet-for-business-combination-with-immunog-grdx-20231218monthly0.5https://www.biopharmawatch.com/news/GRDX/first-wave-biopharma-announces-1-for-20-reverse-stock-split-and-results-of-the-special-mee-grdx-20231214monthly0.5https://www.biopharmawatch.com/news/GRDX/first-wave-biopharma-announces-exercise-of-warrants-and-issuance-of-new-warrants-in-a-priv-grdx-20230914monthly0.5https://www.biopharmawatch.com/news/GRDX/first-wave-biopharma-announces-exclusive-global-license-agreement-for-capeserod-from-sanof-grdx-20230914monthly0.5https://www.biopharmawatch.com/news/GRDX/first-wave-biopharma-inc-announces-pricing-of-2-1-million-public-offering-grdx-20230719monthly0.5https://www.biopharmawatch.com/news/GRDX/first-wave-biopharma-announces-initial-topline-results-from-phase-2-span-clinical-trial-in-grdx-20230713monthly0.5https://www.biopharmawatch.com/news/GRDX/first-wave-biopharma-announces-exercise-of-warrants-and-issuance-of-new-warrants-in-a-priv-grdx-20230613monthly0.5https://www.biopharmawatch.com/news/GRDX/first-wave-biopharma-announces-4-0-million-private-placement-priced-at-the-market-under-na-grdx-20230313monthly0.5https://www.biopharmawatch.com/news/GRDX/first-wave-biopharma-regains-compliance-with-nasdaq-s-minimum-bid-price-requirement-nasdaq-grdx-20230207monthly0.5https://www.biopharmawatch.com/news/GRDX/first-wave-biopharma-announces-results-of-special-meeting-of-stockholders-grdx-20230113monthly0.5https://www.biopharmawatch.com/news/GRDX/first-wave-biopharma-announces-distribution-of-series-f-grdx-20221125monthly0.5https://www.biopharmawatch.com/news/GRDX/first-wave-biopharma-inc-announces-private-placement-grdx-20221121monthly0.5https://www.biopharmawatch.com/news/GRDX/first-wave-biopharma-inc-announces-pricing-of-6-0-grdx-20221006monthly0.5https://www.biopharmawatch.com/news/GRDX/exbibit-99-1-first-wave-biopharma-inc-announces-reverse-stock-split-grdx-20220825monthly0.5https://www.biopharmawatch.com/news/GRDX/first-wave-biopharma-inc-announces-private-placement-grdx-20220715monthly0.5https://www.biopharmawatch.com/news/GRDX/first-wave-biopharma-inc-announces-9-million-registered-direct-offering-priced-at-the-mark-grdx-20220228monthly0.5https://www.biopharmawatch.com/news/GRDX/first-wave-biopharma-chairman-and-ceo-issues-letter-to-shareholders-boca-raton-fl-december-grdx-20211213monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-to-change-corporate-name-to-first-wave-biopharma-today-company-to-begin-t-grdx-20210921monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-ceo-issues-letter-to-shareholders-regarding-recent-acquisition-of-first-w-grdx-20210914monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-announces-acquisition-of-first-wave-bio-and-its-proprietary-niclosamide-f-grdx-20210913monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-announces-reverse-stock-split-common-stock-will-begin-trading-on-split-ad-grdx-20210913monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-announces-positive-topline-data-for-phase-2-ms1819-combination-therapy-tr-grdx-20210818monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-announces-appointment-of-terry-coelho-to-its-board-of-directors-azurrx-ex-grdx-20210816monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-announces-3-0-million-bought-deal-offering-of-common-stock-grdx-20210722monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-provides-key-takeaways-from-phase-2b-option-2-clinical-trial-topline-resu-grdx-20210331monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-announces-10-million-registered-direct-offering-priced-at-the-market-unde-grdx-20210308monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-appoints-president-and-ceo-james-sapirstein-as-new-chairman-of-the-board--grdx-20210224monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-announces-exclusive-worldwide-license-agreement-with-first-wave-bio-for-u-grdx-20210104monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-requests-protocol-amendment-to-phase-2b-option-2-study-of-ms1819-in-cysti-grdx-20201117monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-ceo-issues-clarifying-statement-to-shareholders-grdx-20200812monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-announces-positive-interim-data-from-first-patient-cohort-in-phase-2-clin-grdx-20200811monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-closes-15-2-million-private-placement-and-6-9-million-convertible-note-ex-grdx-20200720monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-issues-letter-to-shareholders-grdx-20200421monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-appoints-gregory-oakes-to-its-board-of-directors-seasoned-veteran-with-decades-of-s-grdx-20200409monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-receives-1-13-million-in-2018-cir-french-research-tax-credit-x25cf-cir-pr-grdx-20200302monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-announces-closing-of-6-9-million-private-placement-email-grdx-20200113monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-to-present-interim-phase-2-clinical-study-data-for-ms1819-sd-in-combinati-grdx-20200109monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-announces-appointment-of-daniel-schneiderman-as-chief-financial-officer-grdx-20200103monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-inc-announces-equity-purchase-agreement-for-up-to-15-million-with-lincoln-grdx-20191114monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-ceo-issues-letter-to-shareholders-grdx-20191022monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-announces-positive-cff-dsmb-review-of-final-phase-2-option-trial-data-x25-grdx-20191017monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-announces-first-patients-dosed-in-clinical-study-for-ms1819-sd-in-combina-grdx-20191015monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-announces-appointment-of-james-sapirstein-as-chief-executive-officer-foun-grdx-20191010monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-announces-positive-results-from-phase-2-trial-with-ms1819-in-cystic-fibro-grdx-20190925monthly0.5https://www.biopharmawatch.com/news/GRDX/securities-and-exchange-commission-grdx-20190722monthly0.5https://www.biopharmawatch.com/news/GRDX/presentation-untitled-document-grdx-20190710monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-announces-initiation-of-phase-2-clinical-study-for-ms1819-sd-in-combinati-grdx-20190708monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-announces-notice-of-allowance-of-u-s-and-japan-patents-covering-a-mtan-in-grdx-20190607monthly0.5https://www.biopharmawatch.com/news/GRDX/additional-exhibits-untitled-document-grdx-20190606monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-reaches-enrollment-target-for-phase-ii-option-clinical-trial-x25cf-enroll-grdx-20190523monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-presents-positive-secondary-endpoint-data-in-its-phase-ii-ms1819-sd-chron-grdx-20190520monthly0.5https://www.biopharmawatch.com/news/GRDX/jfif-exif-mm-j-i-v-grdx-20190507monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-exceeds-50-enrollment-target-for-phase-ii-option-clinical-trial-x25cf-enr-grdx-20190423monthly0.5https://www.biopharmawatch.com/news/GRDX/presentation-untitled-document-grdx-20190411monthly0.5https://www.biopharmawatch.com/news/GRDX/presentation-untitled-document-grdx-20190328monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-announces-first-patients-dosed-in-phase-ii-option-clinical-trial-initial--grdx-20190220monthly0.5https://www.biopharmawatch.com/news/GRDX/secconnect-com-azurrx-biopharma-announces-initiation-of-phase-ii-option-clinical-trial-of--grdx-20181219monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-to-acquire-payment-rights-to-lead-drug-candidate-ms1819-sd-from-protea-bi-grdx-20181212monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-to-present-at-upcoming-investor-conferences-grdx-20181204monthly0.5https://www.biopharmawatch.com/news/GRDX/corporate-presentation-untitled-document-grdx-20181108monthly0.5https://www.biopharmawatch.com/news/GRDX/secconnect-com-azurrx-biopharma-receives-sanction-of-cystic-fibrosis-therapeutics-developm-grdx-20181101monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-announces-fda-acceptance-of-ind-application-for-phase-2-clinical-trial-of-grdx-20181016monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-announces-positive-outcome-with-ms1819-sd-showing-statistically-significa-grdx-20180924monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-to-present-at-the-rodman-renshaw-20th-annual-global-investment-conference-grdx-20180828monthly0.5https://www.biopharmawatch.com/news/GRDX/blueprint-azurrx-biopharma-announces-successful-phase-iia-trial-of-ms1819-sd-in-exocrine-p-grdx-20180629monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-announces-appointment-of-dr-james-pennington-as-chief-medical-officer-grdx-20180530monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-announces-proposed-public-offering-of-common-stock-brooklyn-ny-globe-news-grdx-20180430monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-and-mayoly-spindler-announce-additional-positive-interim-data-for-ms1819--grdx-20180423monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-announces-positive-preclinical-data-with-azx1103-x25cf-company-is-develop-grdx-20180418monthly0.5https://www.biopharmawatch.com/news/GRDX/corporate-presentation-untitled-document-grdx-20180213monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-to-present-at-the-biotech-showcase-2018-conference-january-8th-brooklyn-n-grdx-20171204monthly0.5https://www.biopharmawatch.com/news/GRDX/presentation-untitled-document-grdx-20171006monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-and-mayoly-spindler-announce-positive-ms1819-sd-phase-ii-data-in-exocrine-grdx-20170927monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-announces-closing-of-5-0-million-private-financing-brooklyn-n-y-grdx-20170608monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-provides-update-on-ms1819-phase-ii-trial-initial-patient-experience-shows-no-safety-grdx-20170411monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-announces-addition-of-charles-j-casamento-to-the-board-of-directors-grdx-20170308monthly0.5https://www.biopharmawatch.com/news/GRDX/azurrx-biopharma-martin-krusin-x2013-vice-president-phone-1-646-699-7855-email-mkrusin-azu-grdx-20161011monthly0.5https://www.biopharmawatch.com/news/IGC/pharma-launches-strategic-national-media-partnership-with-new-to-the-street-to-expand-inve-igc-20260330monthly0.5https://www.biopharmawatch.com/news/IGC/igc-pharma-announces-results-of-2025-annual-igc-20251014monthly0.5https://www.biopharmawatch.com/news/IGC/date-june-16-2025-nyseamerican-igc-1-nyse-american-igc-service-to-humanity-igc-20250617monthly0.5https://www.biopharmawatch.com/news/IGC/igc-announces-updated-life-sciences-presentation-igc-20221220monthly0.5https://www.biopharmawatch.com/news/IGC/igc-announces-adjournment-of-annual-meeting-voting-for-proposal-four-to-igc-20180102monthly0.5https://www.biopharmawatch.com/news/IGC/igc-announces-adjournment-of-annual-meeting-voting-for-proposals-three-and-four-to-igc-20171218monthly0.5https://www.biopharmawatch.com/news/IGC/igc-announces-adjournment-of-annual-meeting-voting-for-proposals-three-and-four-to-igc-20171122monthly0.5https://www.biopharmawatch.com/news/IGC/igc-announces-results-of-annual-shareholders-meeting-bethesda-igc-20171113monthly0.5https://www.biopharmawatch.com/news/IGC/nyse-american-extends-india-globalization-capital-compliance-plan-period-bethesda-md-globe-igc-20171012monthly0.5https://www.biopharmawatch.com/news/IGC/igc-acquires-exclusive-rights-to-thc-based-treatment-for-alzheimer-s-disease-bethesda-igc-20170612monthly0.5https://www.biopharmawatch.com/news/IGC/the-igc-executive-summary-dated-igc-20170525monthly0.5https://www.biopharmawatch.com/news/IGC/india-globalization-capital-inc-igc-engages-networknewswire-for-corporate-communications-s-igc-20170425monthly0.5https://www.biopharmawatch.com/news/IGC/nyse-mkt-extends-india-globalization-capital-compliance-plan-period-bethesda-md-globenewsw-igc-20170421monthly0.5https://www.biopharmawatch.com/news/IGC/india-globalization-capital-receives-letter-from-nyse-mkt-llc-bethesda-md-globenewswire-igc-20170404monthly0.5https://www.biopharmawatch.com/news/IGC/india-globalization-capital-announces-the-extension-of-warrants-expiry-date-and-inducement-igc-20170217monthly0.5https://www.biopharmawatch.com/news/IGC/igc-appoints-john-cherin-as-cfo-treasurer-and-pao-bethesda-igc-20161121monthly0.5https://www.biopharmawatch.com/news/IGC/igc-acquires-10-stake-in-1-000-room-luxury-hotel-development-project-in-genting-highlands--igc-20160804monthly0.5https://www.biopharmawatch.com/news/IGC/igc-invests-in-farming-facility-accelerating-initiative-for-the-legal-cannabis-farming-mar-igc-20160406monthly0.5https://www.biopharmawatch.com/news/IGC/issued-on-igc-20160329monthly0.5https://www.biopharmawatch.com/news/IGC/issued-on-igc-20160317monthly0.5https://www.biopharmawatch.com/news/IGC/igc-completes-satisfactory-settlement-with-sricon-exchanges-minority-interest-for-5-acres--igc-20160308monthly0.5https://www.biopharmawatch.com/news/IGC/issued-on-igc-20160225monthly0.5https://www.biopharmawatch.com/news/IGC/india-globalization-capital-50-strike-warrants-to-be-removed-from-nyse-mkt-bethesda-igc-20160229monthly0.5https://www.biopharmawatch.com/news/IGC/igc-expands-infrastructure-development-capabilities-with-acquisition-accelerates-initiativ-igc-20160216monthly0.5https://www.biopharmawatch.com/news/IGC/igc-inc-announces-third-quarter-financial-results-bethesda-md-globe-newswire-igc-20150213monthly0.5https://www.biopharmawatch.com/news/IGC/igc-expands-legal-cannabis-strategy-through-the-acquisition-of-midtown-partners-will-creat-igc-20141218monthly0.5https://www.biopharmawatch.com/news/IGC/igc-announces-adjournment-of-annual-meeting-seeks-to-obtain-a-quorum-of-voting-stockholder-igc-20140828monthly0.5https://www.biopharmawatch.com/news/IGC/india-globalization-capital-executes-off-take-agreement-to-support-production-growth-of-hi-igc-20140715monthly0.5https://www.biopharmawatch.com/news/IGC/igc-partners-with-terrasphere-to-develop-multiple-vertical-farming-sites-furthers-technolo-igc-20140703monthly0.5https://www.biopharmawatch.com/news/IGC/igc-completes-acquisition-of-hk-based-trading-company-bethesda-igc-20140604monthly0.5https://www.biopharmawatch.com/news/IGC/india-globalization-capital-raises-about-506-thousand-in-registered-direct-offering-bethes-igc-20140402monthly0.5https://www.biopharmawatch.com/news/IGC/india-globalization-capital-provides-update-on-acquisition-and-diversification-strategy-be-igc-20140311monthly0.5https://www.biopharmawatch.com/news/IGC/india-globalization-capital-executes-off-take-agreement-to-support-production-growth-of-hi-igc-20140130monthly0.5https://www.biopharmawatch.com/news/IGC/source-india-globalization-capital-inc-india-globalization-capital-announces-reverse-stock-igc-20130412monthly0.5https://www.biopharmawatch.com/news/IGC/source-india-globalization-capital-inc-igc-20130206monthly0.5https://www.biopharmawatch.com/news/IGC/source-india-globalization-capital-inc-igc-20130114monthly0.5https://www.biopharmawatch.com/news/IGC/india-globalization-capital-announces-a-change-in-its-board-of-directors-bethesda-md-marke-igc-20121227monthly0.5https://www.biopharmawatch.com/news/IGC/source-india-globalization-capital-inc-igc-20121214monthly0.5https://www.biopharmawatch.com/news/IGC/source-india-globalization-capital-inc-igc-20121101monthly0.5https://www.biopharmawatch.com/news/IGC/source-india-globalization-capital-inc-igc-20121018monthly0.5https://www.biopharmawatch.com/news/IGC/source-india-globalization-capital-inc-igc-20120913monthly0.5https://www.biopharmawatch.com/news/IGC/india-globalization-capital-announces-a-change-in-its-board-of-directors-and-the-creation--igc-20120601monthly0.5https://www.biopharmawatch.com/news/IGC/source-india-globalization-capital-inc-igc-20120405monthly0.5https://www.biopharmawatch.com/news/IGC/source-india-globalization-capital-inc-igc-20120207monthly0.5https://www.biopharmawatch.com/news/IGC/source-india-globalization-capital-inc-igc-20120202monthly0.5https://www.biopharmawatch.com/news/IGC/source-india-globalization-capital-inc-igc-20111018monthly0.5https://www.biopharmawatch.com/news/IGC/india-globalization-capital-enters-into-a-partnership-to-provide-iron-ore-to-chinese-steel-igc-20110809monthly0.5https://www.biopharmawatch.com/news/IGC/india-globalization-capital-announces-financial-results-for-end-of-fiscal-year-2011-bethes-igc-20110714monthly0.5https://www.biopharmawatch.com/news/IGC/india-globalization-capital-announces-a-change-in-its-board-of-directors-bethesda-md-marke-igc-20110311monthly0.5https://www.biopharmawatch.com/news/IGC/india-globalization-capital-announces-fiscal-third-quarter-results-bethesda-md-marketwire-igc-20110223monthly0.5https://www.biopharmawatch.com/news/IGC/india-globalization-capital-files-amended-10-k-for-fiscal-year-ended-igc-20110201monthly0.5https://www.biopharmawatch.com/news/IGC/source-india-globalization-capital-inc-igc-20101208monthly0.5https://www.biopharmawatch.com/news/IGC/india-globalization-capital-provides-update-on-its-iron-ore-business-bethesda-md-marketwir-igc-20101203monthly0.5https://www.biopharmawatch.com/news/IGC/india-globalization-capital-announces-35-million-iron-ore-supply-contract-with-chinese-min-igc-20100527monthly0.5https://www.biopharmawatch.com/news/IGC/india-globalization-capital-plan-receives-nyse-amex-acceptance-bethesda-md-igc-20100504monthly0.5https://www.biopharmawatch.com/news/IGC/india-globalization-capital-announces-160-million-5-year-iron-ore-supply-contract-with-lea-igc-20100427monthly0.5https://www.biopharmawatch.com/news/IGC/india-globalization-capital-inc-igc-receives-noncompliance-warning-letter-from-the-amex-be-igc-20100402monthly0.5https://www.biopharmawatch.com/news/IGC/india-globalization-capital-commissions-first-quarry-for-commercial-use-second-expected-to-igc-20100106monthly0.5https://www.biopharmawatch.com/news/IGC/india-globalization-capital-inc-igc-receives-noncompliance-warning-letter-from-the-amex-be-igc-20091112monthly0.5https://www.biopharmawatch.com/news/IGC/india-globalization-capital-to-raise-about-2-million-in-registered-direct-financing-bethes-igc-20090918monthly0.5https://www.biopharmawatch.com/news/IGC/india-globalization-capital-inc-igc-and-its-subsidiaries-file-financial-results-for-fiscal-igc-20080721monthly0.5https://www.biopharmawatch.com/news/IGC/india-globalization-capital-amex-igc-conference-presentation-june-2008-www-indiaglobalcap--igc-20080604monthly0.5https://www.biopharmawatch.com/news/IGC/india-globalization-capital-amex-igc-investor-presentation-january-2008-3-forward-looking--igc-20080129monthly0.5https://www.biopharmawatch.com/news/IGC/ram-mukunda-chief-executive-officer-and-president-india-globalization-capital-inc-301-983--igc-20061201monthly0.5https://www.biopharmawatch.com/news/IGC/ram-mukunda-chief-executive-officer-and-president-india-globalization-capital-inc-301-983--igc-20060818monthly0.5https://www.biopharmawatch.com/news/IGC/ram-mukunda-chief-executive-officer-and-president-india-globalization-capital-inc-301-983--igc-20060404monthly0.5https://www.biopharmawatch.com/news/IGC/the-company-has-agreed-to-pay-integrated-global-network-llc-a-related-party-and-privately--igc-20060317monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-granted-south-korean-patent-covering-primec-composition-for-als-patent-claims-c-nrsn-20260611monthly0.5https://www.biopharmawatch.com/news/NRSN/jama-neurology-publishes-results-from-paradigm-phase-2b-trial-of-primec-in-als-demonstrati-nrsn-20260316monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-announces-statistically-significant-65-reduction-in-risk-of-death-and-greater-t-nrsn-20260218monthly0.5https://www.biopharmawatch.com/news/NRSN/hamenofim-st-building-b-herzliya-4672562-israel-notice-of-special-meeting-of-shareholders--nrsn-20260213monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-confirms-favorable-safety-and-tolerability-of-primec-in-an-alzheimer-s-phase-2--nrsn-20251222monthly0.5https://www.biopharmawatch.com/news/NRSN/hamenofim-st-building-b-herzliya-4672562-israel-notice-of-special-meeting-of-shareholders--nrsn-20251121monthly0.5https://www.biopharmawatch.com/news/NRSN/hamenofim-st-building-b-herzliya-4672562-israel-notice-of-annual-general-meeting-of-shareh-nrsn-20250821monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-regains-compliance-with-nasdaq-s-minimum-equity-requirement-neurosense-in-compl-nrsn-20250106monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-enters-binding-term-sheet-to-advance-primec-for-als-binding-term-s-nrsn-20241223monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-provides-business-update-and-third-quarter-2024-financial-results-nrsn-20241218monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-receives-positive-fda-feedback-on-phase-3-study-design-for-primec-the-type-c-me-nrsn-20241211monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-announces-completion-of-paradigm-study-highlighting-primec-s-significant-effica-nrsn-20241204monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-announces-5-million-private-placement-at-premium-to-market-price-nrsn-20241202monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-secures-key-fda-meeting-to-advance-its-phase-3-als-trial-and-nda-submission-mee-nrsn-20241028monthly0.5https://www.biopharmawatch.com/news/NRSN/new-analysis-shows-primec-significantly-improves-key-mirnas-in-als-patients-groundbreaking-nrsn-20241024monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-advances-plans-for-early-commercialization-of-groundbreaking-als-treatment-in-c-nrsn-20241015monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-plans-to-file-for-early-commercialization-of-als-treatment-in-cana-nrsn-20241009monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-ltd-condensed-interim-unaudited-balance-sheets-u-s-dollars-in-thou-nrsn-20240930monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-regains-compliance-with-nasdaq-minimum-bid-price-rule-nrsn-20240924monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-announces-receipt-of-nasdaq-minimum-bid-price-notification-nrsn-20240830monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-announces-positive-biomarker-data-from-als-phase-2b-clinical-trial-nrsn-20240801monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-s-paradigm-als-clinical-trial-demonstrates-up-to-73-improved-complication-free--nrsn-20240709monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-demonstrates-statistically-significant-efficacy-and-survival-benefits-in-people-nrsn-20240701monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-management-provides-corporate-update-and-first-quarter-2024-financial-results-f-nrsn-20240624monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-receives-delisting-notice-from-nasdaq-and-intends-to-appeal-nrsn-20240621monthly0.5https://www.biopharmawatch.com/news/NRSN/index-to-consolidated-financial-statements-page-report-of-independent-registered-public-ac-nrsn-20240617monthly0.5https://www.biopharmawatch.com/news/NRSN/hamenofim-st-building-b-herzliya-4672562-israel-notice-of-annual-general-meeting-of-shareh-nrsn-20240528monthly0.5https://www.biopharmawatch.com/news/NRSN/hamenofim-st-building-b-herzliya-4672562-israel-notice-of-annual-general-meeting-of-shareh-nrsn-20240523monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-vice-president-of-r-d-shiran-zimri-ph-d-to-participate-in-the-3-rd-annual-als-d-nrsn-20240520monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-partners-with-phasev-to-optimize-upcoming-als-phase-3-trial-using-advanced-caus-nrsn-20240514monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-announces-new-positive-data-analysis-from-paradigm-clinical-trial-demonstrating-nrsn-20240507monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-announces-pricing-of-4-5-million-registered-direct-offering-and-concurrent-priv-nrsn-20240410monthly0.5https://www.biopharmawatch.com/news/NRSN/april-2024-nasdaq-nrsn-forward-looking-statements-this-presentation-and-oral-statements-ma-nrsn-20240410monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-collaborates-with-lonza-to-identify-exosome-based-biomarkers-in-order-to-advanc-nrsn-20240409monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-announces-year-end-2023-financial-results-and-provides-business-update-nrsn-20240405monthly0.5https://www.biopharmawatch.com/news/NRSN/february-2024-nasdaq-nrsn-forward-looking-statements-this-presentation-and-oral-statements-nrsn-20240222monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-regains-compliance-with-nasdaq-minimum-bid-price-rule-nrsn-20240207monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-recaps-positive-2023-achievements-including-statistically-significant-slowing-o-nrsn-20240109monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-announces-receipt-of-nasdaq-notice-regarding-minimum-stockholders-equity-requir-nrsn-20231227monthly0.5https://www.biopharmawatch.com/news/NRSN/december-2023-nasdaq-nrsn-forward-looking-statements-2-this-presentation-and-oral-statemen-nrsn-20231221monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-reports-new-data-statistically-significant-clinical-efficacy-in-phase-2b-als-tr-nrsn-20231214monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-to-report-phase-2b-als-topline-primary-safety-and-tolerability-secondary-clinic-nrsn-20231205monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-announces-third-quarter-2023-financial-results-and-provides-business-update-top-nrsn-20231128monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-receives-u-s-fda-confirmation-of-cmc-strategy-for-primec-in-preparation-for-piv-nrsn-20231113monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-completes-dosing-of-last-patient-in-the-double-blind-segment-of-phase-2b-als-tr-nrsn-20231106monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-ceo-provides-q3-2023-update-phase-2b-als-topline-results-expected-december-2023-nrsn-20231017monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-s-primec-demonstrates-outstanding-effect-on-als-survival-in-innovative-ipsc-mod-nrsn-20231004monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-ends-its-at-the-market-equity-offering-program-company-is-fully-funded-beyond-c-nrsn-20231002monthly0.5https://www.biopharmawatch.com/news/NRSN/european-medicines-agency-grants-neurosense-sme-status-sme-status-offers-regulatory-guidan-nrsn-20230920monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-granted-patents-in-europe-japan-and-israel-for-its-als-drug-primec-patents-vali-nrsn-20230919monthly0.5https://www.biopharmawatch.com/news/NRSN/investor-webinar-september-2023-nasdaq-nrsn-forward-looking-statements-this-presentation-a-nrsn-20230912monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-announces-second-quarter-2023-financial-results-and-provides-business-update-al-nrsn-20230816monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-ceo-provides-q2-2023-update-view-video-here-link-nrsn-20230706monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-announces-pricing-of-4-5-million-registered-direct-offering-and-concurrent-priv-nrsn-20230622monthly0.5https://www.biopharmawatch.com/news/NRSN/corporate-presentation-june-2023-nasdaq-nrsn-disclaimer-this-presentation-and-oral-stateme-nrsn-20230608monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-reports-first-quarter-2023-financial-results-provides-business-update-phase-2b--nrsn-20230601monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-completes-enrollment-in-phase-2b-als-clinical-trial-96-of-participants-who-comp-nrsn-20230515monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-reports-positive-preliminary-results-in-parkinson-s-biomarker-stud-nrsn-20230502monthly0.5https://www.biopharmawatch.com/news/NRSN/hamenofim-st-building-b-herzliya-4672562-israel-notice-of-annual-general-meeting-of-shareh-nrsn-20230426monthly0.5https://www.biopharmawatch.com/news/NRSN/corporate-presentation-march-2023-nasdaq-nrsn-disclaimer-this-presentation-and-oral-statem-nrsn-20230420monthly0.5https://www.biopharmawatch.com/news/NRSN/hamenofim-st-building-b-herzliya-4672562-israel-notice-of-annual-general-meeting-of-shareh-nrsn-20230417monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-ceo-provides-q1-2023-update-phase-2b-als-trial-achieves-80-enrollment-nrsn-20230417monthly0.5https://www.biopharmawatch.com/news/NRSN/corporate-presentation-march-2023-nasdaq-nrsn-disclaimer-this-presentation-and-oral-statem-nrsn-20230320monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-ceo-recaps-2022-achievements-presents-2023-catalysts-view-video-here-nrsn-20230213monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-and-quantalx-collaborate-to-improve-early-detection-and-treatment-of-neurodegen-nrsn-20230209monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-receives-approval-in-germany-to-enroll-patients-in-its-phase-2b-als-trial-parad-nrsn-20230208monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-expands-its-phase-2b-als-paradigm-trial-to-canada-and-withdraws-protocol-from-u-nrsn-20230206monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-announces-second-quarter-2022-financial-results-and-provides-business-update-nrsn-20230119monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-reports-positive-final-results-from-alzheimer-s-biomarker-study-el-nrsn-20230119monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-announces-third-quarter-2022-financial-results-and-provides-business-update-nrsn-20221201monthly0.5https://www.biopharmawatch.com/news/NRSN/corporate-presentation-november-2022-nasdaq-nrsn-disclaimer-2-this-presentation-and-oral-s-nrsn-20221129monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-receives-regulatory-approval-to-commence-patient-enrollment-in-italy-for-its-ph-nrsn-20221116monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-receives-fda-clearance-of-ind-for-its-als-phase-2b-study-neurosense-therapeutic-nrsn-20221115monthly0.5https://www.biopharmawatch.com/news/NRSN/corporate-presentation-november-2022-nasdaq-nrsn-1-disclaimer-2-this-presentation-and-oral-nrsn-20221103monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-to-ring-nasdaq-opening-bell-and-host-the-als-combination-therapy-s-nrsn-20221013monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-announces-positive-primec-pharmacokinetic-study-results-anticipates-phase-iib-a-nrsn-20220928monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-announces-positive-primec-toxicology-data-supportive-of-current-phase-iib-parad-nrsn-20220920monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-announces-second-quarter-2022-financial-results-and-provides-business-update-nrsn-20220831monthly0.5https://www.biopharmawatch.com/news/NRSN/corporate-presentation-august-2022-nasdaq-nrsn-trademarks-in-this-presentation-are-the-pro-nrsn-20220809monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-joins-everythingals-open-innovation-consortium-set-to-enroll-us-and-eu-patients-nrsn-20220803monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-and-neuralight-collaborate-to-detect-als-oculometric-biomarkers-us-nrsn-20220728monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-ceo-provides-key-corporate-update-video-view-video-here-https-yout-nrsn-20220718monthly0.5https://www.biopharmawatch.com/news/NRSN/primec-significantly-alters-key-als-biomarkers-neuroinflammation-tdp-43-accumulation-treat-nrsn-20220713monthly0.5https://www.biopharmawatch.com/news/NRSN/corporate-presentation-july-2022-nasdaq-nrsn-2-disclaimer-this-presentation-and-oral-state-nrsn-20220705monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-reports-positive-preliminary-results-from-novel-alzheimer-s-biomar-nrsn-20220630monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-reports-positive-results-from-stage-iii-als-biomarker-study-preliminary-results-nrsn-20220627monthly0.5https://www.biopharmawatch.com/news/NRSN/corporate-presentation-june-2022-nasdaq-nrsn-2-disclaimer-this-presentation-and-oral-state-nrsn-20220607monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-enrolls-first-patient-in-phase-iib-als-trial-for-its-combination-therapy-primec-nrsn-20220601monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-announces-first-quarter-2022-financial-results-and-provides-business-update-nrsn-20220531monthly0.5https://www.biopharmawatch.com/news/NRSN/hamenofim-st-building-b-herzliya-4672562-israel-notice-of-annual-general-meeting-of-shareh-nrsn-20220519monthly0.5https://www.biopharmawatch.com/news/NRSN/hamenofim-st-building-b-herzliya-4672562-israel-notice-of-annual-general-meeting-of-shareh-nrsn-20220511monthly0.5https://www.biopharmawatch.com/news/NRSN/corporate-presentation-may-2022-nasdaq-nrsn-trademarks-in-this-presentation-are-the-proper-nrsn-20220414monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-commences-enrollment-and-dosing-in-its-pharmacokinetic-study-of-pr-nrsn-20220411monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-ceo-provides-key-corporate-update-video-nrsn-20220330monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-receives-4-million-through-warrant-exercises-warrants-exercised-at-nrsn-20220325monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-receives-fda-clearance-of-ind-for-primec-for-the-treatment-of-als--nrsn-20220321monthly0.5https://www.biopharmawatch.com/news/NRSN/corporate-presentation-march-2022-nasdaq-nrsn-trademarks-in-this-presentation-are-the-prop-nrsn-20220315monthly0.5https://www.biopharmawatch.com/news/NRSN/disclaimer-this-presentation-and-oral-statements-made-regarding-the-subject-of-this-presen-nrsn-20220215monthly0.5https://www.biopharmawatch.com/news/NRSN/hamenofim-st-building-b-herzliya-4672562-israel-notice-of-special-general-meeting-of-share-nrsn-20220131monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-extends-als-biomarker-collaboration-with-massachusetts-general-hos-nrsn-20220127monthly0.5https://www.biopharmawatch.com/news/NRSN/hamenofim-st-building-b-herzliya-4672562-israel-notice-of-special-general-meeting-of-share-nrsn-20220126monthly0.5https://www.biopharmawatch.com/news/NRSN/neurosense-therapeutics-announces-pricing-of-initial-public-offering-of-units-and-approval-nrsn-20211208monthly0.5https://www.biopharmawatch.com/news/CCEL/irene-smith-813-749-2102-ismith-cryo-cell-com-cryo-cell-receives-acceptance-of-compliance--ccel-20260508monthly0.5https://www.biopharmawatch.com/news/CCEL/irene-smith-813-749-2102-ismith-cryo-cell-com-cryo-cell-receives-nyse-american-continued-l-ccel-20260312monthly0.5https://www.biopharmawatch.com/news/CCEL/irene-smith-813-749-2102-ismith-cryo-cell-com-cord-blood-banking-leader-cryo-cell-announce-ccel-20250508monthly0.5https://www.biopharmawatch.com/news/CCEL/irene-smith-813-749-2102-ismith-cryo-cell-com-cord-blood-banking-leader-cryo-cell-declares-ccel-20241030monthly0.5https://www.biopharmawatch.com/news/CCEL/irene-smith-813-749-2102-ismith-cryo-cell-com-cord-blood-banking-leader-cryo-cell-reports--ccel-20241015monthly0.5https://www.biopharmawatch.com/news/CCEL/irene-smith-813-749-2102-ismith-cryo-cell-com-cryo-cell-announces-plans-to-explore-strateg-ccel-20240325monthly0.5https://www.biopharmawatch.com/news/CCEL/irene-smith-813-749-2102-ismith-cryo-cell-com-cord-blood-banking-leader-cryo-cell-announce-ccel-20220316monthly0.5https://www.biopharmawatch.com/news/CCEL/irene-smith-813-749-2102-ismith-cryo-cell-com-cryo-cell-reports-financial-results-for-fisc-ccel-20220222monthly0.5https://www.biopharmawatch.com/news/CCEL/irene-smith-813-749-2102-ismith-cryo-cell-com-cord-blood-banking-leader-cryo-cell-reports--ccel-20211015monthly0.5https://www.biopharmawatch.com/news/CCEL/cryo-cell-international-announces-changes-to-its-board-of-directors-miami-fl-ccel-20210920monthly0.5https://www.biopharmawatch.com/news/CCEL/diane-glanz-rph-pharmd-investor-relations-consultant-813-749-2195-dglanz-cryo-cell-com-cor-ccel-20210715monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-chairman-and-co-chief-executive-officer-cryo-cell-international-inc-813-749--ccel-20210414monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-cryo-cell-international-inc-813-749-2100-dportnoy-cryo-cell-com-cryo-cell-re-ccel-20210224monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-chairman-and-co-ceo-cryo-cell-international-inc-813-749-2100-cord-blood-bank-ccel-20201015monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-chairman-and-co-chief-executive-officer-cryo-cell-international-inc-813-749--ccel-20200710monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-chairman-and-co-ceo-cryo-cell-international-inc-813-749-2100-dportnoy-cryo-c-ccel-20200611monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-chairman-and-co-chief-executive-officer-cryo-cell-international-inc-813-749--ccel-20200506monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-cryo-cell-international-inc-813-749-2100-dportnoy-cryo-cell-com-cryo-cell-re-ccel-20200227monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-chairman-and-co-ceo-cryo-cell-international-inc-813-749-2100-dportnoy-cryo-c-ccel-20191015monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-chairman-and-co-chief-executive-officer-cryo-cell-international-inc-813-749--ccel-20190715monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-chairman-and-co-chief-executive-officer-cryo-cell-international-inc-813-749--ccel-20190415monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-cryo-cell-international-inc-813-749-2100-dportnoy-cryo-cell-com-cryo-cell-re-ccel-20190228monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-chairman-and-co-ceo-cryo-cell-international-inc-813-749-2100-dportnoy-cryo-c-ccel-20181015monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-chairman-and-co-chief-executive-officer-cryo-cell-international-inc-813-749--ccel-20180816monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-chairman-and-co-chief-executive-officer-cryo-cell-international-inc-813-749--ccel-20180716monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-chairman-and-co-chief-executive-officer-cryo-cell-international-inc-813-749--ccel-20180615monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-chairman-and-co-chief-executive-officer-cryo-cell-international-inc-813-749--ccel-20180604monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-chairman-and-co-chief-executive-officer-cryo-cell-international-inc-813-749--ccel-20180416monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-cryo-cell-international-inc-813-749-2100-dportnoy-cryo-cell-com-cryo-cell-re-ccel-20180228monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-chairman-and-co-chief-executive-officer-cryo-cell-international-inc-813-749--ccel-20171016monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-chairman-and-co-chief-executive-officer-cryo-cell-international-inc-813-749--ccel-20170414monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-cryo-cell-international-inc-813-749-2100-dportnoy-cryo-cell-com-cryo-cell-re-ccel-20170228monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-chairman-and-co-chief-executive-officer-cryo-cell-international-inc-813-749--ccel-20160711monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-chairman-and-co-chief-executive-officer-cryo-cell-international-inc-813-749--ccel-20160414monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-cryo-cell-international-inc-813-749-2100-dportnoy-cryo-cell-com-cryo-cell-re-ccel-20160302monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-chairman-and-co-chief-executive-officer-cryo-cell-international-inc-813-749--ccel-20150716monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-chairman-and-co-chief-executive-officer-cryo-cell-international-inc-813-749--ccel-20150415monthly0.5https://www.biopharmawatch.com/news/CCEL/cryo-cell-international-inc-cord-blood-banking-leader-takes-significant-ownership-stake-in-ccel-20150331monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-cryo-cell-international-inc-813-749-2100-dportnoy-cryo-cell-com-cryo-cell-re-ccel-20150303monthly0.5https://www.biopharmawatch.com/news/CCEL/nancy-abramson-special-projects-marketing-manager-cryo-cell-international-inc-813-749-2100-ccel-20141203monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-chairman-and-co-ceo-cryo-cell-international-inc-813-749-2100-dportnoy-cryo-c-ccel-20141015monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-chairman-and-co-chief-executive-officer-cryo-cell-international-inc-813-749--ccel-20140707monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-chairman-and-co-chief-executive-officer-cryo-cell-international-inc-813-749--ccel-20140415monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-cryo-cell-international-inc-813-749-2100-dportnoy-cryo-cell-com-cryo-cell-re-ccel-20140303monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-chairman-and-co-ceo-cryo-cell-international-inc-813-749-2100-dportnoy-cryo-c-ccel-20131015monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-chairman-and-co-chief-executive-officer-cryo-cell-international-inc-813-749--ccel-20130715monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-chairman-and-co-chief-executive-officer-cryo-cell-international-inc-813-749--ccel-20130405monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-cryo-cell-international-inc-813-749-2100-dportnoy-cryo-cell-com-cryo-cell-re-ccel-20130228monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-chairman-and-co-ceo-cryo-cell-international-inc-813-749-2100-dportnoy-cryo-c-ccel-20121015monthly0.5https://www.biopharmawatch.com/news/CCEL/key-stakeholders-support-cryo-cell-international-leadership-in-proxy-contest-oldsmar-fla-ccel-20120705monthly0.5https://www.biopharmawatch.com/news/CCEL/cryo-cell-leadership-sets-the-record-straight-on-efforts-to-date-oldsmar-fla-ccel-20120703monthly0.5https://www.biopharmawatch.com/news/CCEL/david-portnoy-cryo-cell-international-inc-813-749-2100-dportnoy-cryo-cell-com-cryo-cell-in-ccel-20111018monthly0.5https://www.biopharmawatch.com/news/CCEL/source-cryo-cell-international-inc-on-tuesday-ccel-20110830monthly0.5https://www.biopharmawatch.com/news/CCEL/julia-avery-investors-stern-investor-relations-inc-212-362-1200-julia-sternir-com-irene-sm-ccel-20110808monthly0.5https://www.biopharmawatch.com/news/CCEL/julia-avery-investors-stern-investor-relations-inc-212-362-1200-julia-sternir-com-irene-sm-ccel-20110713monthly0.5https://www.biopharmawatch.com/news/CCEL/julia-avery-investors-stern-investor-relations-inc-212-362-1200-julia-sternir-com-irene-sm-ccel-20110621monthly0.5https://www.biopharmawatch.com/news/CCEL/julia-avery-investors-stern-investor-relations-inc-212-362-1200-julia-sternir-com-irene-sm-ccel-20110525monthly0.5https://www.biopharmawatch.com/news/CCEL/julia-avery-investors-investor-relations-212-362-1200-julia-sternir-com-irene-smith-media--ccel-20110413monthly0.5https://www.biopharmawatch.com/news/CCEL/julia-avery-investors-stern-investor-relations-inc-212-362-1200-julia-sternir-com-irene-sm-ccel-20110228monthly0.5https://www.biopharmawatch.com/news/CCEL/lilian-stern-investors-investor-relations-stern-ir-212-362-1200-lilian-sternir-com-wendi-l-ccel-20101014monthly0.5https://www.biopharmawatch.com/news/CCEL/lilian-stern-investors-investor-relations-stern-ir-212-362-1200-lilian-sternir-com-kristin-ccel-20100715monthly0.5https://www.biopharmawatch.com/news/CCEL/dianne-will-investors-investor-relations-518-398-6222-dwill-willstar-net-kristin-boza-medi-ccel-20100413monthly0.5https://www.biopharmawatch.com/news/CCEL/dianne-will-investors-investor-relations-518-398-6222-dwill-willstar-net-kristin-boza-medi-ccel-20100301monthly0.5https://www.biopharmawatch.com/news/CCEL/dianne-will-investors-investor-relations-518-398-6222-dwill-willstar-net-kellie-hotz-media-ccel-20091013monthly0.5https://www.biopharmawatch.com/news/CCEL/dianne-will-investors-investor-relations-518-398-6222-dwill-willstar-net-kellie-hotz-media-ccel-20090709monthly0.5https://www.biopharmawatch.com/news/CCEL/gayatri-narayanan-investors-edelman-212-704-4577-gayatri-narayanan-edelman-com-kellie-hotz-ccel-20090409monthly0.5https://www.biopharmawatch.com/news/CCEL/gayatri-narayanan-investors-edelman-212-704-4577-gayatri-narayanan-edelman-com-kellie-hotz-ccel-20090302monthly0.5https://www.biopharmawatch.com/news/CCEL/mona-j-walsh-investors-edelman-212-704-4598-mona-walsh-edelman-com-kellie-hotz-media-inqui-ccel-20081015monthly0.5https://www.biopharmawatch.com/news/CCEL/mona-j-walsh-investors-edelman-212-704-4598-mona-walsh-edelman-com-kellie-hotz-media-inqui-ccel-20080410monthly0.5https://www.biopharmawatch.com/news/CCEL/cryo-cell-international-to-hold-2008-annual-meeting-on-july-15-2008-oldsmar-fla-ccel-20080227monthly0.5https://www.biopharmawatch.com/news/CCEL/mona-j-walsh-investors-edelman-212-704-4598-mona-walsh-edelman-com-kellie-hotz-media-inqui-ccel-20080211monthly0.5https://www.biopharmawatch.com/news/CCEL/special-stockholders-meeting-to-elect-directors-set-for-march-4-2008-oldsmar-fla-ccel-20080122monthly0.5https://www.biopharmawatch.com/news/CCEL/delaware-chancery-court-rejects-portnoy-request-to-seat-dissident-slate-in-cryo-cell-elect-ccel-20080117monthly0.5https://www.biopharmawatch.com/news/CCEL/mona-j-walsh-investors-edelman-212-704-4598-mona-walsh-edelman-com-kellie-hotz-media-inqui-ccel-20071015monthly0.5https://www.biopharmawatch.com/news/CCEL/katie-wood-edelman-312-240-2827-katie-wood-edelman-com-cryo-cell-international-inc-reports-ccel-20070416monthly0.5https://www.biopharmawatch.com/news/CCEL/denise-roche-the-ruth-group-inc-646-536-7008-droche-theruthgroup-com-cryo-cell-internation-ccel-20070228monthly0.5https://www.biopharmawatch.com/news/CCEL/denise-roche-the-ruth-group-inc-646-536-7008-droche-theruthgroup-com-cryo-cell-internation-ccel-20061016monthly0.5https://www.biopharmawatch.com/news/CCEL/denise-roche-the-ruth-group-inc-646-536-7008-droche-theruthgroup-com-cryo-cell-internation-ccel-20060717monthly0.5https://www.biopharmawatch.com/news/CCEL/denise-roche-the-ruth-group-inc-646-536-7008-droche-theruthgroup-com-cryo-cell-internation-ccel-20060411monthly0.5https://www.biopharmawatch.com/news/CCEL/francesca-demartino-the-ruth-group-inc-646-536-7024-fdemartino-theruthgroup-com-cryo-cell--ccel-20060227monthly0.5https://www.biopharmawatch.com/news/CCEL/francesca-demartino-the-ruth-group-inc-646-536-7024-fdemartino-theruthgroup-com-cryo-cell--ccel-20051011monthly0.5https://www.biopharmawatch.com/news/CCEL/francesca-demartino-the-ruth-group-inc-646-536-7024-fdemartino-theruthgroup-com-cryo-cell--ccel-20051004monthly0.5https://www.biopharmawatch.com/news/CCEL/cryo-cell-board-appoints-mercedes-walton-chief-executive-officer-wednesday-august-17-appoi-ccel-20050819monthly0.5https://www.biopharmawatch.com/news/CCEL/francesca-demartino-the-ruth-group-inc-646-536-7024-fdemartino-theruthgroup-com-cryo-cell--ccel-20050715monthly0.5https://www.biopharmawatch.com/news/CCEL/todd-atenhan-813-749-2100-813-855-4745-fax-investor-relations-cryo-cell-com-cryo-cell-inte-ccel-20050405monthly0.5https://www.biopharmawatch.com/news/CCEL/todd-atenhan-813-749-2100-813-855-4745-fax-investor-relations-cryo-cell-com-cryo-cell-inte-ccel-20050211monthly0.5https://www.biopharmawatch.com/news/CCEL/todd-atenhan-727-450-8000-727-723-0444-fax-investor-relations-cryo-cell-com-cryo-cell-inte-ccel-20041004monthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-announces-gmp-manufacturing-of-clinical-trial-material-ctm-with-eurofins-cdmo-am-plrz-20260310monthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-completes-branding-process-for-pl-14-allergy-blocker-with-brand-name-nasarix-as--plrz-20260108monthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-submits-pre-request-for-designation-to-fda-for-pl-16-viral-blocker-designed-to-r-plrz-20251219monthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-reports-positive-mucoadhesion-results-for-intranasal-naloxone-hydrogel-compared--plrz-20251203monthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-ltd-condensed-financial-statements-as-of-june-30-2025-unaudited-u-s-dollars-in-t-plrz-20250917monthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-reports-successful-intranasal-delivery-of-pl-14-allergy-blocker-in-latest-study--plrz-20250722monthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-reports-successful-safety-study-of-a-formulation-of-pl-14-allergy-blocker-in-hum-plrz-20250425monthly0.5https://www.biopharmawatch.com/news/PLRZ/amended-articles-the-companies-law-1999-a-limited-liability-company-articles-of-associatio-plrz-20250417monthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-receives-nasdaq-notification-regarding-minimum-bid-requirements-raanana-israel-plrz-20250411monthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-engages-leading-branding-firm-for-strategic-brand-development-raanana-israel-plrz-20250402monthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-ltd-announces-17-0-million-private-placement-raanana-israel-plrz-20250331monthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-structures-clinical-strategy-for-its-allergy-blocker-ahead-of-fda-pre-submission-plrz-20250327monthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-expands-drug-delivery-innovation-with-preclinical-studies-for-epilepsy-rescue-tr-plrz-20250325monthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-plrz-20250314monthly0.5https://www.biopharmawatch.com/news/PLRZ/notice-of-annual-general-meeting-of-shareholders-notice-is-hereby-given-that-an-annual-gen-plrz-20250313monthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-initiates-preclinical-studies-for-intranasal-naloxone-targeting-opioid-overdose--plrz-20250310monthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-announces-filing-of-divisional-patent-application-for-its-innovative-trap-target-plrz-20250130monthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-commences-gmp-manufacturing-preliminary-process-for-its-pl-14-allergy-blocker-in-plrz-20250123monthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-announces-publication-of-u-s-national-patent-application-for-its-innovative-hydr-plrz-20241230monthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-appoints-dr-michal-meir-as-senior-director-of-regulatory-and-clinical-affairs-ra-plrz-20241219monthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-announces-appointment-of-vp-of-regulatory-affairs-and-quality-assurance-raanana--plrz-20241213monthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-enters-into-gmp-manufacturing-agreement-for-ctm-supply-of-its-pl-14-allergy-bloc-plrz-20241202monthly0.5https://www.biopharmawatch.com/news/PLRZ/polyrizon-announces-pricing-of-4-2-million-initial-public-offering-and-listing-on-the-nasd-plrz-20241028monthly0.5https://www.biopharmawatch.com/news/KYNB/described-in-kyntra-bio-s-most-recent-annual-report-on-form-10-k-and-quarterly-report-on-f-kynb-20260107monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-third-quarter-2025-financial-results-and-provides-business-update-x2022-c-kynb-20251110monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-completes-sale-of-fibrogen-china-to-astrazeneca-for-approximately-220-million-x20-kynb-20250902monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state-ad-kynb-20250818monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-second-quarter-2025-financial-results-and-provides-business-update-x2022--kynb-20250811monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-appoints-michael-kauffman-m-d-ph-d-to-its-board-of-directors-kynb-20250609monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-first-quarter-2025-financial-results-and-provides-business-update-x2022-t-kynb-20250512monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-announces-publication-of-results-from-phase-1-monotherapy-study-of-fg-3246-in-pat-kynb-20250328monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-fourth-quarter-and-full-year-2024-financial-results-x2022-announced-sale--kynb-20250317monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-announces-the-sale-of-fibrogen-china-to-astrazeneca-for-approximately-160-million-kynb-20250220monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-appoints-david-delucia-as-chief-financial-officer-kynb-20241216monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-third-quarter-2024-financial-results-x2022-topline-results-from-phase-2-p-kynb-20241112monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-second-quarter-2024-financial-results-and-provides-business-update-x2022--kynb-20240806monthly0.5https://www.biopharmawatch.com/news/KYNB/virtual-kol-investor-event-series-part-ii-review-fg-3246-development-program-in-metastatic-kynb-20240626monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-first-quarter-2024-financial-results-x2022-topline-data-from-the-pancreat-kynb-20240506monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-fourth-quarter-and-full-year-2023-financial-results-x2022-topline-data-fr-kynb-20240226monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-third-quarter-2023-financial-results-x2022-topline-data-from-two-pivotal--kynb-20231106monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-announces-topline-results-from-lelantos-2-a-phase-3-clinical-study-of-pamrevlumab-kynb-20230829monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-second-quarter-2023-financial-results-x2022-topline-data-from-three-late--kynb-20230807monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-announces-leadership-transition-appoints-thane-wettig-as-interim-chief-executive--kynb-20230725monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-announces-topline-results-from-phase-3-zephyrus-1-study-of-pamrevlumab-for-the-tr-kynb-20230626monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-announces-topline-results-from-lelantos-1-phase-3-clinical-study-of-pamrevlumab-i-kynb-20230607monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-announces-positive-topline-results-from-china-pivotal-phase-3-clinical-trial-of-r-kynb-20230518monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-first-quarter-2023-financial-results-x2022-topline-data-from-four-phase-3-kynb-20230508monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-fourth-quarter-and-full-year-2022-financial-results-x2022-topline-data-fr-kynb-20230227monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-third-quarter-2022-financial-results-x2022-continued-advancement-of-pamre-kynb-20221107monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-second-quarter-2022-financial-results-x2022-completed-enrollment-of-lelan-kynb-20220808monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-first-quarter-2022-financial-results-completed-enrollment-in-zephyrus-1-p-kynb-20220509monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-fourth-quarter-and-full-year-2021-financial-results-completed-enrollment--kynb-20220228monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-third-quarter-2021-financial-results-roxadustat-receives-eu-approval-for--kynb-20211109monthly0.5https://www.biopharmawatch.com/news/KYNB/astellas-receives-european-commission-approval-for-first-in-class-evrenzo-tm-roxadustat-fo-kynb-20210819monthly0.5https://www.biopharmawatch.com/news/KYNB/expertise-in-hypoxia-inducible-factor-hif-and-connective-tissue-growth-factor-ctgf-biology-kynb-20210816monthly0.5https://www.biopharmawatch.com/news/KYNB/uncertainties-related-to-the-continued-progress-and-timing-of-our-various-programs-includi-kynb-20210811monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-second-quarter-2021-financial-results-roxadustat-net-product-revenue-in-c-kynb-20210809monthly0.5https://www.biopharmawatch.com/news/KYNB/eluminex-biosciences-investors-media-zhenze-john-hu-ph-d-mpd-business-development-john-hu--kynb-20210720monthly0.5https://www.biopharmawatch.com/news/KYNB/astellas-receives-positive-chmp-opinion-for-evrenzo-tm-roxadustat-for-adult-patients-with--kynb-20210625monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-and-hifibio-announce-transformative-partnership-to-advance-next-generation-therap-kynb-20210617monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-first-quarter-2021-financial-results-roxadustat-net-product-revenue-in-ch-kynb-20210510monthly0.5https://www.biopharmawatch.com/news/KYNB/reliance-on-these-forward-looking-statements-which-speak-only-as-of-the-date-of-this-relea-kynb-20210407monthly0.5https://www.biopharmawatch.com/news/KYNB/media-jennifer-harrington-1-610-574-9196-jennifer-harrington-gcihealth-com-kynb-20210406monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-fourth-quarter-and-full-year-2020-financial-results-strong-fourth-quarter-kynb-20210301monthly0.5https://www.biopharmawatch.com/news/KYNB/annual-report-on-form-10-k-for-the-fiscal-year-ended-kynb-20201218monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-third-quarter-2020-financial-results-strong-third-quarter-china-roxadusta-kynb-20201105monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-second-quarter-2020-financial-results-strong-second-quarter-china-roxadus-kynb-20200806monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-inc-media-inquiries-sara-iacovino-1-703-474-4452-sara-iacovino-gcihealth-com-inve-kynb-20200806monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-first-quarter-2020-financial-results-roxadustat-u-s-nda-review-and-e-u-ma-kynb-20200507monthly0.5https://www.biopharmawatch.com/news/KYNB/master-supply-agreement-this-master-supply-agreement-the-agreement-is-effective-as-of-kynb-20200324monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-fourth-quarter-and-full-year-2019-financial-results-x2022-roxadustat-nda--kynb-20200302monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-inc-media-inquiries-sara-iacovino-1-703-474-4452-sara-iacovino-gcihealth-com-inve-kynb-20200211monthly0.5https://www.biopharmawatch.com/news/KYNB/astellas-submits-supplemental-new-drug-application-for-approval-of-evrenzo-roxadustat-for--kynb-20200130monthly0.5https://www.biopharmawatch.com/news/KYNB/this-presentation-contains-forward-looking-statements-that-involve-substantial-risks-and-u-kynb-20200110monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-inc-media-inquiries-sara-iacovino-1-703-474-4452-sara-iacovino-gcihealth-com-inve-kynb-20200106monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-submits-new-drug-application-to-the-u-s-fda-for-roxadustat-in-patients-with-anemi-kynb-20191223monthly0.5https://www.biopharmawatch.com/news/KYNB/zhang-l-wang-f-wang-l-et-al-prevalence-of-chronic-kidney-disease-in-china-a-cross-sectiona-kynb-20191202monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-third-quarter-2019-financial-results-roxadustat-positive-pooled-phase-3-e-kynb-20191111monthly0.5https://www.biopharmawatch.com/news/KYNB/about-fibrogen-fibrogen-inc-headquartered-in-san-francisco-california-with-subsidiary-offi-kynb-20191108monthly0.5https://www.biopharmawatch.com/news/KYNB/predict-potential-continue-and-similar-words-although-some-forward-looking-statements-are--kynb-20191108monthly0.5https://www.biopharmawatch.com/news/KYNB/this-release-contains-forward-looking-statements-regarding-our-strategy-future-plans-and-p-kynb-20191011monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-announces-initiation-of-phase-2-clinical-trial-of-roxadustat-for-the-treatment-of-kynb-20190926monthly0.5https://www.biopharmawatch.com/news/KYNB/roxadustat-approved-in-japan-for-the-treatment-of-anemia-associated-with-chronic-kidney-di-kynb-20190920monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-inc-karen-l-bergman-vice-president-investor-relations-and-corporate-communication-kynb-20190826monthly0.5https://www.biopharmawatch.com/news/KYNB/roxadustat-kynb-20190821monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-second-quarter-2019-financial-results-on-track-to-submit-u-s-nda-for-roxa-kynb-20190808monthly0.5https://www.biopharmawatch.com/news/KYNB/forward-looking-statements-this-release-contains-forward-looking-statements-regarding-our--kynb-20190725monthly0.5https://www.biopharmawatch.com/news/KYNB/about-pamrevlumab-pamrevlumab-is-a-first-in-class-antibody-developed-by-fibrogen-to-inhibi-kynb-20190722monthly0.5https://www.biopharmawatch.com/news/KYNB/pamrevlumab-mechanism-of-action-overall-summary-of-study-fg-3019-079-in-non-ambulatory-sub-kynb-20190628monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-kynb-20190605monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-first-quarter-2019-financial-results-x2022-positive-topline-results-from--kynb-20190509monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-kynb-20190415monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-fourth-quarter-and-full-year-2018-financial-results-roxadustat-approved-i-kynb-20190227monthly0.5https://www.biopharmawatch.com/news/KYNB/this-presentation-contains-forward-looking-statements-that-involve-substantial-risks-and-u-kynb-20190107monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-announces-positive-topline-results-from-three-global-phase-3-trials-of-roxadustat-kynb-20181220monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-announces-approval-of-roxadustat-in-china-for-the-treatment-of-anemia-in-chronic--kynb-20181217monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-appoints-maykin-ho-ph-d-kynb-20181206monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-third-quarter-2018-financial-results-roxadustat-new-drug-applications-und-kynb-20181108monthly0.5https://www.biopharmawatch.com/news/KYNB/asn-kidney-week-2018-data-presented-from-two-japanese-phase-3-studies-on-roxadustat-in-the-kynb-20181030monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-presents-results-from-two-phase-3-studies-of-roxadustat-for-the-treatment-of-anem-kynb-20181025monthly0.5https://www.biopharmawatch.com/news/KYNB/astellas-submits-new-drug-application-in-japan-of-roxadustat-for-the-treatment-of-anemia-a-kynb-20181001monthly0.5https://www.biopharmawatch.com/news/KYNB/astellas-announces-positive-topline-results-for-global-phase-3-trial-of-roxadustat-in-chro-kynb-20180920monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-kynb-20180912monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-second-quarter-2018-financial-results-roxadustat-u-s-phase-3-topline-clin-kynb-20180807monthly0.5https://www.biopharmawatch.com/news/KYNB/my-michael-yee-jefferies-tn-thomas-b-neff-fibrogen-py-k-peony-yu-fibrogen-sp-seth-porter-f-kynb-20180608monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-announces-completion-of-enrollment-in-u-s-phase-3-clinical-program-for-roxadustat-kynb-20180607monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-presents-clinical-results-of-pamrevlumab-treatment-in-patients-with-locally-advan-kynb-20180603monthly0.5https://www.biopharmawatch.com/news/KYNB/astellas-and-fibrogen-announce-topline-results-from-double-blind-japan-phase-3-study-for-r-kynb-20180531monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-presents-latest-data-from-praise-phase-2b-study-of-pamrevlumab-in-idiopathic-pulm-kynb-20180521monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-first-quarter-2018-financial-results-pamrevlumab-data-to-be-presented-at--kynb-20180509monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-fourth-quarter-and-full-year-2017-financial-results-roxadustat-u-s-phase--kynb-20180227monthly0.5https://www.biopharmawatch.com/news/KYNB/this-presentation-the-accompanying-modules-and-in-each-case-the-oral-commentary-contain-fo-kynb-20180108monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-third-quarter-2017-financial-results-roxadustat-nda-filing-accepted-for-c-kynb-20171108monthly0.5https://www.biopharmawatch.com/news/KYNB/astellas-and-fibrogen-announce-positive-topline-results-from-first-japan-phase-3-trial-for-kynb-20171031monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-announces-acceptance-by-china-fda-of-roxadustat-new-drug-application-nda-for-trea-kynb-20171018monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-appoints-gerald-lema-to-board-of-directors-san-francisco-ca-kynb-20170919monthly0.5https://www.biopharmawatch.com/news/KYNB/praise-background-pamrevlumab-fg-3019-a-human-mab-targeting-ctgf-preclinical-data-supporti-kynb-20170913monthly0.5https://www.biopharmawatch.com/news/KYNB/cancer-roxadustat-the-company-s-most-advanced-product-candidate-is-an-oral-small-molecule--kynb-20170816monthly0.5https://www.biopharmawatch.com/news/KYNB/q2-2017-fibrogen-inc-earnings-call-kynb-20170807monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-second-quarter-2017-financial-results-company-announces-positive-topline--kynb-20170807monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-first-quarter-2017-financial-results-conference-call-and-webcast-to-be-he-kynb-20170509monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-inc-announces-pricing-of-follow-on-kynb-20170406monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-announces-china-fda-approval-of-cta-to-conduct-pivotal-phase-2-3-clinical-trial-o-kynb-20170331monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-fiscal-2016-financial-results-conference-call-and-webcast-to-be-held-toda-kynb-20170301monthly0.5https://www.biopharmawatch.com/news/KYNB/this-presentation-the-accompanying-modules-and-in-each-case-the-oral-commentary-contain-fo-kynb-20170216monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-s-roxadustat-fg-4592-meets-primary-endpoints-in-two-phase-3-anemia-studies-in-chi-kynb-20170130monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-financial-results-for-the-third-quarter-of-2016-and-provides-corporate-up-kynb-20161108monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-financial-results-for-the-second-quarter-of-2016-enrollment-completed-in--kynb-20160808monthly0.5https://www.biopharmawatch.com/news/KYNB/astellas-and-fibrogen-announce-first-patient-treated-in-phase-3-studies-and-positive-phase-kynb-20160725monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-announces-initiation-by-astellas-of-phase-3-clinical-study-in-japan-of-roxadustat-kynb-20160609monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-reports-financial-results-for-the-first-quarter-of-2016-continued-progress-in-rox-kynb-20160509monthly0.5https://www.biopharmawatch.com/news/KYNB/fibrogen-announces-fiscal-2015-financial-results-webcast-conference-call-scheduled-for-4-3-kynb-20160229monthly0.5https://www.biopharmawatch.com/news/KYNB/this-presentation-the-accompanying-modules-and-in-each-case-the-oral-commentary-contain-fo-kynb-20160211monthly0.5https://www.biopharmawatch.com/news/AIFF/for-additional-information-contact-richard-s-derose-703-293-7901-for-release-aiff-20180329monthly0.5https://www.biopharmawatch.com/news/AIFF/for-additional-information-contact-richard-s-derose-703-293-7901-for-release-aiff-20171113monthly0.5https://www.biopharmawatch.com/news/AIFF/blueprint-for-additional-information-contact-richard-s-derose-703-293-7901-for-release-aiff-20170814monthly0.5https://www.biopharmawatch.com/news/AIFF/for-additional-information-contact-richard-s-derose-703-293-7901-for-release-aiff-20170511monthly0.5https://www.biopharmawatch.com/news/AIFF/for-additional-information-contact-richard-s-derose-703-293-7901-for-release-aiff-20160330monthly0.5https://www.biopharmawatch.com/news/AIFF/for-additional-information-contact-richard-s-derose-703-293-7901-for-release-aiff-20141112monthly0.5https://www.biopharmawatch.com/news/AIFF/for-additional-information-contact-richard-s-derose-703-293-7901-for-release-aiff-20111110monthly0.5https://www.biopharmawatch.com/news/AIFF/for-additional-information-contact-richard-s-derose-703-293-7901-for-release-aiff-20110811monthly0.5https://www.biopharmawatch.com/news/AIFF/for-additional-information-contact-richard-s-derose-703-293-7901-for-release-aiff-20071113monthly0.5https://www.biopharmawatch.com/news/AIFF/for-additional-information-contact-richard-s-derose-703-293-7901-for-release-aiff-20070813monthly0.5https://www.biopharmawatch.com/news/AIFF/for-additional-information-contact-richard-s-derose-703-293-7901-for-release-aiff-20070510monthly0.5https://www.biopharmawatch.com/news/AIFF/for-additional-information-contact-richard-s-derose-703-293-7901-for-release-aiff-20070329monthly0.5https://www.biopharmawatch.com/news/AIFF/for-additional-information-contact-richard-s-derose-703-293-7901-for-release-aiff-20061109monthly0.5https://www.biopharmawatch.com/news/AIFF/for-additional-information-contact-richard-s-derose-703-293-7901-for-release-aiff-20060808monthly0.5https://www.biopharmawatch.com/news/AIFF/for-additional-information-contact-richard-s-derose-703-293-7901-for-release-aiff-20060511monthly0.5https://www.biopharmawatch.com/news/AIFF/for-additional-information-contact-richard-s-derose-703-293-7901-for-release-aiff-20060329monthly0.5https://www.biopharmawatch.com/news/AIFF/for-additional-information-contact-richard-s-derose-703-293-7901-for-release-aiff-20051110monthly0.5https://www.biopharmawatch.com/news/AIFF/for-additional-information-contact-sandor-rosenberg-703-293-7900-for-release-aiff-20050810monthly0.5https://www.biopharmawatch.com/news/AIFF/for-additional-information-contact-richard-s-derose-703-293-7901-for-release-aiff-20050516monthly0.5https://www.biopharmawatch.com/news/AIFF/for-additional-information-contact-richard-s-derose-703-293-7901-for-release-aiff-20050321monthly0.5https://www.biopharmawatch.com/news/AIFF/for-additional-information-contact-richard-s-derose-703-293-7901-for-release-aiff-20041110monthly0.5https://www.biopharmawatch.com/news/LSTA/waiver-to-agreement-and-plan-of-merger-this-waiver-to-agreement-and-plan-of-merger-this-wa-lsta-20260402monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-enters-into-definitive-agreement-to-be-acquired-by-kuva-labs-inc-each--lsta-20260306monthly0.5https://www.biopharmawatch.com/news/LSTA/forward-looking-statements-advisory-this-presentation-contains-forward-looking-statements--lsta-20251014monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-reports-second-quarter-2025-financial-results-and-provides-business-up-lsta-20250807monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-expands-intellectual-property-portfolio-with-new-composition-of-matter-lsta-20250715monthly0.5https://www.biopharmawatch.com/news/LSTA/positive-preliminary-cohort-b-results-from-the-agitg-led-ascend-trial-to-be-presented-at-e-lsta-20250626monthly0.5https://www.biopharmawatch.com/news/LSTA/forward-looking-statements-advisory-this-presentation-contains-forward-looking-statements--lsta-20250617monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-reports-first-quarter-2025-financial-results-and-provides-business-upd-lsta-20250508monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-reports-full-year-2024-financial-results-and-provides-business-update--lsta-20250227monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-reports-encouraging-preliminary-cohort-a-data-from-the-agitg-led-phase-lsta-20250122monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-upd-lsta-20241112monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-reports-second-quarter-2024-financial-results-and-provides-business-up-lsta-20240812monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-reports-first-quarter-2024-financial-results-and-provides-business-upd-lsta-20240509monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-reports-full-year-2023-financial-results-and-provides-business-update--lsta-20240229monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-reports-third-quarter-2023-financial-results-and-provides-business-upd-lsta-20231102monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-reports-second-quarter-2023-financial-results-and-provides-business-up-lsta-20230814monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-announces-retirement-of-dr-erkki-ruoslahti-from-board-of-directors-las-lsta-20230711monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-reports-first-quarter-2023-financial-results-and-provides-business-upd-lsta-20230509monthly0.5https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-provid-lsta-20230330monthly0.5https://www.biopharmawatch.com/news/LSTA/to-lisata-s-amendment-no-1-to-current-report-on-form-8-k-filed-on-lsta-20221110monthly0.5https://www.biopharmawatch.com/news/LSTA/cend-business-overview-cend-therapeutics-inc-formerly-drugcendr-inc-is-a-delaware-corporat-lsta-20221004monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-and-cend-therapeutics-announce-closing-of-merger-and-the-emergence-o-lsta-20220915monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-announces-approval-of-merger-and-name-change-to-lisata-therapeutics--lsta-20220914monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-reports-second-quarter-2022-financial-results-and-provides-business--lsta-20220805monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-provides-update-on-phase-2b-freedom-trial-of-xowna-in-coronary-micro-lsta-20220523monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-reports-first-quarter-2022-financial-results-and-provides-business-u-lsta-20220505monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-and-cend-therapeutics-announce-definitive-merger-agreement-combined--lsta-20220427monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-reports-fourth-quarter-and-full-year-2021-financial-results-and-prov-lsta-20220322monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-provides-corporate-update-and-reports-2021-third-quarter-financial-r-lsta-20211104monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-reports-second-quarter-2021-financial-results-and-provides-business--lsta-20210805monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-reports-first-quarter-2021-financial-results-and-provides-business-u-lsta-20210506monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-reports-fourth-quarter-and-full-year-2020-financial-results-and-prov-lsta-20210225monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-inc-announces-65-million-registered-direct-offerings-priced-at-the-m-lsta-20210212monthly0.5https://www.biopharmawatch.com/news/LSTA/this-investor-presentation-contains-forward-looking-statements-within-the-meaning-of-the-p-lsta-20210129monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-announces-25-0-million-private-placement-basking-ridge-n-j-lsta-20210121monthly0.5https://www.biopharmawatch.com/news/LSTA/this-investor-presentation-contains-forward-looking-statements-within-the-meaning-of-the-p-lsta-20201214monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-announces-the-resignation-of-dr-douglas-losordo-chief-medical-office-lsta-20201117monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-provides-corporate-update-and-reports-2020-third-quarter-financial-r-lsta-20201105monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-provides-corporate-update-and-reports-2020-second-quarter-financial--lsta-20200813monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-appoints-dr-michael-h-davidson-to-board-of-directors-basking-ridge-n-lsta-20200728monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-announces-4-3-million-registered-direct-offering-priced-at-the-marke-lsta-20200526monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-provides-corporate-update-and-reports-2020-first-quarter-financial-r-lsta-20200507monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-announces-5-0-million-registered-direct-offering-priced-at-the-marke-lsta-20200423monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-to-receive-10-9-million-of-non-dilutive-capital-through-new-jersey-t-lsta-20200422monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-reports-fourth-quarter-and-full-year-2019-financial-results-and-prov-lsta-20200305monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-reports-positive-results-for-clbs16-from-the-escape-cmd-trial-at-ame-lsta-20191116monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-reports-2019-third-quarter-and-nine-month-financial-results-and-prov-lsta-20191106monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-reports-2019-second-quarter-and-first-six-months-financial-results-a-lsta-20190808monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-inc-reports-2019-first-quarter-financial-results-and-provides-corpor-lsta-20190509monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-reports-2018-fourth-quarter-and-year-end-financial-results-conferenc-lsta-20190314monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-reports-2018-third-quarter-financial-results-development-programs-re-lsta-20181108monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-reports-2018-second-quarter-and-first-six-months-financial-results-c-lsta-20180809monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-receives-fda-regenerative-medicine-advanced-therapy-designation-for-cd34-cell-th-lsta-20180619monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-reports-2017-fourth-quarter-and-year-end-financial-results-conferenc-lsta-20180322monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-announces-enrollment-of-the-70-th-subject-in-the-phase-2-t-rex-clini-lsta-20170905monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-announces-2016-fourth-quarter-and-full-year-financial-results-annual-lsta-20170317monthly0.5https://www.biopharmawatch.com/news/LSTA/support-agreement-and-irrevocable-proxy-this-support-agreement-and-irrevocable-proxy-this--lsta-20170316monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-updates-status-of-receipt-of-funds-for-a-portion-of-previously-annou-lsta-20170106monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-reports-2016-third-quarter-financial-results-revenues-increase-58-ve-lsta-20161107monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-appoints-gregory-r-brown-md-to-its-board-of-directors-experienced-in-lsta-20161012monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-inc-enters-into-agreements-to-raise-25-million-in-common-equity-pric-lsta-20160915monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-reports-2016-second-quarter-financial-results-total-quarterly-revenu-lsta-20160809monthly0.5https://www.biopharmawatch.com/news/LSTA/q1-earnings-pr-exhibit-caladrius-biosciences-reports-2016-first-quarter-financial-results--lsta-20160505monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-tightens-strategic-focus-and-provides-2016-revenue-guidance-emphasizes-pct-subsi-lsta-20160106monthly0.5https://www.biopharmawatch.com/news/LSTA/caladrius-biosciences-announces-third-quarter-2015-financial-results-and-provides-corporat-lsta-20151105monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-announces-proposed-public-offering-of-common-stock-lsta-20150527monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-announces-preserve-ami-clinical-trial-one-year-follow-up-results-results-support-p-lsta-20150316monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-strengthens-executive-management-with-appointments-of-david-j-mazzo-phd-as-chief-e-lsta-20150105monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-announces-initial-positive-data-from-phase-2-preserve-ami-clinical-trial-statistic-lsta-20141117monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-announces-third-quarter-2014-financial-results-and-outlines-near-term-milestones-lsta-20141030monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-secures-debt-facility-strengthens-balance-sheet-with-non-dilutive-financing-compan-lsta-20140929monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-announces-second-quarter-2014-financial-results-and-provides-business-update-lsta-20140807monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-appoints-steven-m-klosk-to-board-of-directors-lsta-20140708monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-presents-five-year-survival-data-for-autologous-melanoma-immunotherapy-targeting-c-lsta-20140529monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-announces-closing-of-acquisition-of-california-stem-cell-inc-and-first-quarter-201-lsta-20140508monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-announces-definitive-agreement-to-acquire-california-stem-cell-inc-addition-of-a-p-lsta-20140414monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-announces-conference-call-and-webcast-lsta-20140411monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-announces-2013-year-end-financial-results-and-provides-corporate-update-expanded-c-lsta-20140313monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-completes-patient-enrollment-in-phase-2-amr-001-trial-for-prevention-of-adverse-ca-lsta-20131216monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-announces-third-quarter-2013-financial-results-and-provides-corporate-update-compa-lsta-20131107monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-announces-pricing-of-public-offering-of-common-stock-lsta-20131003monthly0.5https://www.biopharmawatch.com/news/LSTA/exh-99-1-pr-10-3-13-neostem-announces-proposed-public-offering-of-common-stock-lsta-20131003monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-announces-second-quarter-2013-financial-results-highlights-and-developments-compan-lsta-20130808monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-appoints-douglas-w-losordo-as-chief-medical-officer-andrew-l-pecora-to-assume-new--lsta-20130806monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-begins-trading-today-on-nasdaq-stock-market-neostem-to-ring-the-nasdaq-stock-marke-lsta-20130807monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-to-begin-trading-on-nasdaq-stock-market-ticker-symbol-will-remain-nbs-lsta-20130723monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-announces-1-for-10-reverse-split-lsta-20130712monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-ceo-s-letter-to-shareholders-lsta-20130509monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-announces-partial-exercise-of-underwriters-over-allotment-option-lsta-20130430monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-announces-pricing-of-public-offering-of-common-stock-lsta-20130429monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-announces-proposed-public-offering-of-common-stock-lsta-20130429monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-ceo-s-letter-to-shareholders-lsta-20130319monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-announces-2012-year-end-financial-results-and-business-update-revenues-increased-b-lsta-20130311monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-appoints-stephen-w-potter-to-board-of-directors-lsta-20130211monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-announces-quarterly-results-and-business-update-lsta-20121114monthly0.5https://www.biopharmawatch.com/news/LSTA/pr-series-e-redemption-neostem-inc-announces-the-redemption-of-the-outstanding-7-series-e--lsta-20121017monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-announces-quarterly-results-and-business-update-lsta-20120814monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-ceo-s-letter-to-shareholders-lsta-20120709monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-signs-a-definitive-agreement-to-divest-its-51-ownership-interest-in-suzhou-erye-lsta-20120618monthly0.5https://www.biopharmawatch.com/news/LSTA/presentation-investor-presentation-nyse-amex-nbs-april-2012-2-included-in-this-presentatio-lsta-20120420monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-announces-pricing-of-public-offering-for-6-000-000-in-gross-proceeds-lsta-20120329monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-provides-updates-and-reports-year-end-results-lsta-20120320monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-inc-nbs-investor-presentation-january-2012-2-included-in-this-presentation-are-for-lsta-20120126monthly0.5https://www.biopharmawatch.com/news/LSTA/unassociated-document-islet-sciences-inc-selects-neostem-s-manufacturing-subsidiary-progen-lsta-20120112monthly0.5https://www.biopharmawatch.com/news/LSTA/amorcyte-a-neostem-company-announces-expansion-of-intellectual-property-coverage-lsta-20120110monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-inc-nbs-investor-presentation-january-2012-2-included-in-this-presentation-are-for-lsta-20120106monthly0.5https://www.biopharmawatch.com/news/LSTA/unassociated-document-neostem-provides-updates-reports-results-for-third-quarter-and-upcom-lsta-20111111monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-acquires-amorcyte-a-clinical-stage-cardiovascular-disease-cell-therapy-company-lsta-20111017monthly0.5https://www.biopharmawatch.com/news/LSTA/jfif-x-x-6exif-mm-b-j-1-r-2-i-adobe-photoshop-cs3-windows-2011-09-12-17-59-26-lsta-20110912monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-appoints-grant-thornton-llp-as-new-independent-registered-public-accounting-firm-lsta-20110823monthly0.5https://www.biopharmawatch.com/news/LSTA/unassociated-document-neostem-provides-update-on-amorcyte-clinical-progress-and-reports-re-lsta-20110815monthly0.5https://www.biopharmawatch.com/news/LSTA/unassociated-document-neostem-announces-closing-of-public-offering-for-16-500-000-in-gross-lsta-20110722monthly0.5https://www.biopharmawatch.com/news/LSTA/unassociated-document-neostem-announces-pricing-of-public-offering-for-16-500-000-in-gross-lsta-20110719monthly0.5https://www.biopharmawatch.com/news/LSTA/v225802-ex99-2-converted-by-secpublisher-2-1-1-8-created-by-bcl-technologies-inc-for-sec-f-lsta-20110614monthly0.5https://www.biopharmawatch.com/news/LSTA/capacity-constraints-continue-to-loosen-for-suzhou-erye-pharmaceuticals-as-a-new-productio-lsta-20110613monthly0.5https://www.biopharmawatch.com/news/LSTA/unassociated-document-neostem-provides-results-for-2010-and-an-update-on-recent-activities-lsta-20110401monthly0.5https://www.biopharmawatch.com/news/LSTA/neostem-announces-the-addition-of-jason-kolbert-as-vice-president-of-strategic-business-de-lsta-20110308monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-updates-u-s-fda-regulatory-status-of-drugsorb-atr-fda-appeal-decision-found-n-ctso-20250820monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-leads-a-new-era-in-sepsis-treatment-cytosorbents-highlights-the-vital-and-evo-ctso-20250731monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-provides-u-s-fda-and-health-canada-regulatory-update-for-drugsorb-atr-princet-ctso-20250702monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-files-appeal-with-u-s-fda-for-supervisory-review-of-its-de-novo-request-for-d-ctso-20250624monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-first-quarter-2025-financial-results-and-provides-business-update-pri-ctso-20250514monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-provides-regulatory-update-for-drugsorb-atr-princeton-n-j-ctso-20250501monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-appoints-melanie-grossman-cpa-as-vice-president-and-corporate-controller-ms-g-ctso-20250417monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-appoints-thomas-shannon-as-vice-president-of-marketing-for-north-america-prin-ctso-20250414monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-extends-expiration-date-of-outstanding-series-b-right-warrants-princeton-nj-ctso-20250404monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-busine-ctso-20250331monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reschedules-earnings-release-to-ctso-20250321monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-rights-offering-begins-to-participate-eligible-stockholders-should-consult-th-ctso-20241223monthly0.5https://www.biopharmawatch.com/news/CTSO/the-terms-and-conditions-of-the-offering-are-set-forth-in-the-company-s-prospectus-dated-2-ctso-20241209monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-third-quarter-2024-financial-and-operational-results-princeton-n-j-ctso-20241107monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-submits-drugsorb-atr-marketing-application-to-u-s-fda-to-reduce-the-severity--ctso-20241001monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-appoints-peter-j-mariani-chief-financial-officer-cytosorbents-cfo-kathleen-p--ctso-20240813monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-second-quarter-2024-financial-and-operational-results-new-cfo-peter-j-ctso-20240813monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-announces-compliance-with-nasdaq-minimum-bid-price-requirement-princeton-n-j-ctso-20240801monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-secures-20-million-credit-facility-credit-facility-provides-timely-non-diluti-ctso-20240702monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-first-quarter-2024-results-product-sales-up-a-robust-14-over-prior-ye-ctso-20240509monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-fourth-quarter-and-full-year-2023-results-star-t-trial-results-select-ctso-20240314monthly0.5https://www.biopharmawatch.com/news/CTSO/groundbreaking-randomized-controlled-trial-reports-excellent-clinical-outcomes-using-cytos-ctso-20240117monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-provides-update-on-the-star-t-trial-and-reports-final-independent-data-and-sa-ctso-20231228monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-announces-closing-of-10-3-million-registered-direct-offering-company-insiders-ctso-20231213monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-third-quarter-2023-financial-and-operational-results-q3-2023-product--ctso-20231109monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-highlights-upcoming-presentations-at-eacts-2023-focus-on-antithrombotic-remov-ctso-20230927monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-announces-kathleen-p-bloch-to-resume-as-full-time-chief-financial-officer-pri-ctso-20230919monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorb-with-ex-vivo-organ-perfusion-transforming-the-future-of-solid-organ-transplantati-ctso-20230911monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-announces-resignation-of-chief-financial-officer-alexander-d-amico-princeton--ctso-20230901monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-second-quarter-2023-financial-and-operational-results-q2-2023-total-r-ctso-20230801monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-press-release-cytosorbents-appoints-alexander-d-amico-as-chief-financial-offi-ctso-20230719monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-completes-enrollment-of-the-star-t-pivotal-trial-princeton-n-j-ctso-20230707monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-first-quarter-2023-results-pivotal-u-s-and-canada-star-t-trial-enroll-ctso-20230502monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-pivotal-star-t-trial-reaches-second-key-milestone-with-80-patients-enrolled-p-ctso-20230420monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-announces-board-chairman-al-w-kraus-to-retire-princeton-n-j-ctso-20230419monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-fourth-quarter-and-full-year-2022-results-pivotal-u-s-and-canada-star-ctso-20230309monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-issues-stockholder-letter-and-reports-preliminary-fourth-quarter-and-full-yea-ctso-20230131monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-receives-5m-in-non-dilutive-debt-financing-from-bridge-bank-and-extends-loan--ctso-20221229monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-announces-pivotal-star-t-trial-reaches-first-milestone-with-40-patients-enrol-ctso-20221114monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-third-quarter-2022-financial-and-operational-results-cytosorbents-exp-ctso-20221103monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-announces-pending-retirement-of-chief-financial-officer-kathleen-p-bloch-prin-ctso-20221007monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-achieves-iso-13485-certification-of-princeton-manufacturing-facility-in-new-j-ctso-20220927monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-second-quarter-2022-financial-and-operational-results-princeton-n-j-ctso-20220802monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-partners-with-nikkiso-to-distribute-the-pureadjust-hemoperfusion-blood-pump-a-ctso-20220601monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-first-quarter-2022-results-and-revises-2022-outlook-q1-2022-total-rev-ctso-20220503monthly0.5https://www.biopharmawatch.com/news/CTSO/first-patient-enrolled-in-u-s-star-d-pivotal-trial-evaluating-the-drugsorb-atr-antithrombo-ctso-20220429monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-highlights-the-strategy-of-enhanced-lung-rest-using-cytosorb-with-ecmo-to-hel-ctso-20220428monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-to-expand-direct-sales-of-cytosorb-to-the-united-kingdom-the-sixth-largest-me-ctso-20220414monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-receives-approximately-740-000-from-the-new-jersey-business-tax-certificate-t-ctso-20220407monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-appoints-jiny-kim-mba-to-its-board-of-directors-ctso-20220405monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-highlights-activities-at-the-live-41st-international-symposium-on-intensive-c-ctso-20220317monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-fourth-quarter-and-full-year-2021-results-and-provides-2022-outlook-2-ctso-20220308monthly0.5https://www.biopharmawatch.com/news/CTSO/first-patient-enrolled-in-the-procyss-multicenter-randomized-controlled-trial-evaluating-c-ctso-20220201monthly0.5https://www.biopharmawatch.com/news/CTSO/new-publication-reports-significant-reductions-in-perioperative-bleeding-complications-fol-ctso-20220124monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-issues-stockholder-letter-and-reports-preliminary-fourth-quarter-and-full-yea-ctso-20220118monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-announces-publication-of-u-s-ctc-multicenter-registry-results-using-cytosorb--ctso-20211220monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-full-third-quarter-2021-financial-and-operational-results-third-quart-ctso-20211104monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-comments-on-remove-study-presentation-ctso-20211020monthly0.5https://www.biopharmawatch.com/news/CTSO/first-patient-enrolled-in-u-s-star-t-pivotal-trial-evaluating-the-drugsorb-atr-antithrombo-ctso-20211014monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-provides-preliminary-third-quarter-business-update-and-revised-2021-product-r-ctso-20211012monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-announces-availability-of-preliminary-data-abstracts-from-two-endocarditis-st-ctso-20211007monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-to-host-international-webinar-on-the-worldwide-experience-using-cytosorb-in-c-ctso-20210916monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-announces-filing-of-an-investigational-device-exemption-ide-for-the-u-s-clini-ctso-20210910monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-and-aferetica-announce-the-commercial-launch-in-italy-of-the-persorb-adsorber-ctso-20210830monthly0.5https://www.biopharmawatch.com/news/CTSO/second-u-s-fda-breakthrough-device-designation-granted-to-cytosorbents-drugsorb-atr-antith-ctso-20210812monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-second-quarter-2021-financial-and-operational-results-total-revenue-i-ctso-20210803monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-receives-full-fda-approval-of-investigational-device-exemption-ide-for-u-s-st-ctso-20210706monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-first-quarter-2021-financial-and-operational-results-total-revenue-in-ctso-20210504monthly0.5https://www.biopharmawatch.com/news/CTSO/u-s-fda-approves-cytosorbents-to-initiate-u-s-star-t-trial-for-ticagrelor-removal-during-c-ctso-20210419monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-announces-lease-of-new-global-headquarters-in-princeton-new-jersey-ctso-20210329monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-announces-filing-of-an-investigational-device-exemption-ide-for-u-s-trial-on--ctso-20210316monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-announces-2020-financial-and-operational-results-2020-total-revenue-was-41-0--ctso-20210309monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-2021-leadership-and-growth-in-the-new-normal-ctso-20210218monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue-preliminary-ful-ctso-20210112monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-pays-off-15m-term-loans-and-establishes-new-undrawn-15m-loan-commitment-with--ctso-20201210monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-record-third-quarter-2020-financial-results-cytosorbents-reports-reco-ctso-20201104monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-record-second-quarter-2020-financial-results-cytosorbents-posts-recor-ctso-20200804monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-corporation-announces-pricing-of-50-million-public-offering-of-common-stock-ctso-20200722monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-provides-preliminary-q2-2020-financial-results-and-corporate-update-achieved--ctso-20200720monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-announces-commercial-launch-and-immediate-availability-of-cytosorb-to-treat-c-ctso-20200624monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-awarded-2-897-172-phase-iii-sttr-contract-to-advance-hemodefend-bga-plasma-an-ctso-20200609monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorb-is-e-u-approved-to-remove-rivaroxaban-a-leading-factor-xa-inhibitor-and-novel-ora-ctso-20200512monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-first-quarter-2020-financial-and-operational-results-first-quarter-20-ctso-20200505monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-promotes-vincent-j-capponi-to-president-ctso-20200504monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-to-report-q1-2020-operating-and-financial-results-ctso-20200428monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-receives-1-1-million-in-non-dilutive-funding-from-the-new-jersey-business-tax-ctso-20200429monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-appoints-dr-efthymios-n-deliargyris-m-d-ctso-20200427monthly0.5https://www.biopharmawatch.com/news/CTSO/development-update-u-s-fda-grants-breakthrough-designation-to-cytosorb-for-removal-of-tica-ctso-20200420monthly0.5https://www.biopharmawatch.com/news/CTSO/new-study-suggests-cytosorb-improves-clinical-outcomes-in-pneumonia-patients-with-septic-s-ctso-20200415monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-announces-2019-financial-and-operational-results-2019-total-revenue-was-24-9--ctso-20200305monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-preliminary-2019-financial-results-and-issues-stockholder-letter-grow-ctso-20200114monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-changes-contract-research-organizations-and-temporarily-pauses-enrollment-in--ctso-20191125monthly0.5https://www.biopharmawatch.com/news/CTSO/dr-eric-mortensen-to-leave-cytosorbents-at-year-end-ctso-20191106monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-third-quarter-2019-financial-results-ctso-20191105monthly0.5https://www.biopharmawatch.com/news/CTSO/first-study-to-evaluate-cytosorb-in-cytokine-release-syndrome-crs-following-car-t-cell-imm-ctso-20190916monthly0.5https://www.biopharmawatch.com/news/CTSO/nasdaq-ctso-hc-wainwright-21-st-global-investment-conference-ctso-20190910monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-record-second-quarter-2019-financial-results-q2-2019-total-revenue-wa-ctso-20190806monthly0.5https://www.biopharmawatch.com/news/CTSO/cyto-sorbents-corporation-nasdaq-ctso-a-leader-in-critical-care-immunotherapy-cytosorbents-ctso-20190604monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-first-quarter-2019-financial-results-and-provides-second-quarter-2019-ctso-20190507monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-achieves-record-revenue-and-product-sales-growth-in-2018-2018-total-revenue-w-ctso-20190307monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-announces-the-data-safety-monitoring-board-recommends-continuation-of-remove--ctso-20190204monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-announces-expansion-of-cytosorb-partnership-with-fresenius-medical-care-agree-ctso-20190122monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-issues-stockholder-letter-with-preliminary-2018-financial-results-cytosorbent-ctso-20190107monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-third-quarter-2018-financial-results-achieved-record-19-1m-in-trailin-ctso-20181106monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-awarded-up-to-3m-in-sbir-phase-iib-bridge-funding-by-nih-nhlbi-to-accelerate--ctso-20180821monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-achieves-record-total-revenue-and-cytosorb-sales-in-the-second-quarter-2018-q-ctso-20180802monthly0.5https://www.biopharmawatch.com/news/CTSO/aferetica-and-cytosorbents-debut-the-perlife-system-for-organ-preservation-and-rehabilitat-ctso-20180709monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-added-to-the-russell-2000-and-russell-3000-indexes-ctso-20180626monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-officially-opens-new-u-s-cytosorb-manufacturing-facility-new-facility-quadrup-ctso-20180612monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-to-present-at-the-jefferies-2018-global-healthcare-conference-ctso-20180604monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-strong-first-quarter-2018-financial-results-ctso-20180508monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-refinances-existing-debt-with-new-15-million-debt-facility-with-bridge-bank-e-ctso-20180404monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-corporation-nasdaq-ctso-full-year-2017-and-q4-2017-earnings-and-operating-res-ctso-20180308monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-pre-announces-preliminary-fourth-quarter-and-full-year-2017-results-and-issue-ctso-20180108monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-achieves-key-milestone-with-fda-approval-of-the-u-s-refresh-2-pivotal-cardiac-ctso-20171221monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-continues-strong-trajectory-of-growth-in-the-third-quarter-2017-company-achie-ctso-20171109monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-record-quarterly-total-revenue-and-product-sales-in-the-second-quarte-ctso-20170807monthly0.5https://www.biopharmawatch.com/news/CTSO/additional-5-million-in-non-dilutive-debt-financing-from-bridge-bank-ctso-20170706monthly0.5https://www.biopharmawatch.com/news/CTSO/dr-eric-r-mortensen-m-d-ph-d-clinical-trial-veteran-joins-cytosorbents-as-chief-medical-of-ctso-20170530monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-first-quarter-2017-financial-results-strong-performance-leads-to-incr-ctso-20170508monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-announces-positive-refresh-i-trial-results-achieved-the-goals-of-this-safety--ctso-20170505monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-2017-propelling-the-company-to-the-next-level-targeting-significant-annual-sa-ctso-20170419monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-announces-proposed-offering-of-common-stock-ctso-20170330monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-strengthens-intellectual-property-portfolio-with-new-patents-issued-in-the-u--ctso-20170328monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-corporation-nasdaq-ctso-2016-earnings-and-operating-results-conference-call-ctso-20170303monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-pre-announces-q4-2016-and-full-year-2016-results-ctso-20170110monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorb-q3-2016-sales-reach-record-2-14m-doubling-from-a-year-ago-exceeded-2m-in-cytosorb-ctso-20161107monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-announces-positive-top-line-safety-data-from-refresh-i-cardiac-surgery-trial-ctso-20161005monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-achieves-fourth-consecutive-quarter-of-record-cytosorb-sales-q2-2016-cytosorb-ctso-20160809monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-closes-10-million-debt-financing-with-bridge-bank-ctso-20160701monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-continues-strong-growth-in-q1-2016-record-quarterly-sales-up-127-from-a-year--ctso-20160509monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-corporation-nasdaq-ctso-2015-earnings-and-operating-results-conference-call-ctso-20160309monthly0.5https://www.biopharmawatch.com/news/CTSO/cyto-sorbents-corporation-nasdaq-ctso-working-to-save-lives-through-blood-purification-bio-ctso-20160111monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-accelerates-growth-in-q3-2015-ctso-20151113monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-steady-growth-in-q2-2015-ctso-20150813monthly0.5https://www.biopharmawatch.com/news/CTSO/veteran-healthcare-analyst-michael-g-bator-joins-cytosorbents-board-of-directors-ctso-20150715monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-24-year-over-year-increase-in-cytosorb-sales-in-first-quarter-2015-ctso-20150511monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-corporation-nasdaq-cm-ctso-2014-year-end-earnings-and-operating-results-confe-ctso-20150331monthly0.5https://www.biopharmawatch.com/news/CTSO/announces-closing-of-public-offering-ctso-20150114monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-receives-nasdaq-listing-approval-shares-to-trade-on-the-nasdaq-capital-market-ctso-20141218monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-announces-strategic-partnership-with-fresenius-medical-care-monmouth-junction-ctso-20141215monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-reports-temporary-change-of-stock-trading-symbol-monmouth-junction-nj-ctso-20141205monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-corporation-otcbb-ctso-q3-2014-earnings-and-operating-results-conference-call-ctso-20141112monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-announces-appointment-of-new-board-director-monmouth-junction-nj-ctso-20141114monthly0.5https://www.biopharmawatch.com/news/CTSO/cyto-sorbents-corporation-otcqb-ctso-an-emerging-leader-in-critical-care-immunotherapy-q3--ctso-20141112monthly0.5https://www.biopharmawatch.com/news/CTSO/dear-shareholders-and-friends-this-is-an-exciting-time-for-cytosorbents-corporation-cytoso-ctso-20141106monthly0.5https://www.biopharmawatch.com/news/CTSO/preliminary-q3-2014-report-cytosorbents-achieves-its-first-quarter-of-approximately-1m-in--ctso-20141014monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-corporation-otcbb-ctso-q2-2014-earnings-and-operating-results-conference-call-ctso-20140812monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-corporation-otcbb-ctso-q1-2014-earnings-and-operating-results-conference-call-ctso-20140514monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-corporation-otcbb-ctso-2013-earnings-and-operating-results-conference-call-ctso-20140331monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-corporation-announces-10-200-000-registered-direct-offering-by-pr-newswire-ma-ctso-20140307monthly0.5https://www.biopharmawatch.com/news/CTSO/cyto-sorbents-corporation-otcbb-ctso-an-emerging-leader-in-critical-care-immunotherapy-bio-ctso-20140115monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-corporation-otcbb-ctso-2013-third-quarter-earnings-conference-call-transcript-ctso-20131106monthly0.5https://www.biopharmawatch.com/news/CTSO/rodman-renshaw-presentation-otcbb-ctso-dr-phillip-chan-md-phd-ceo-september-2013-working-t-ctso-20130913monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-corporation-otcbb-ctso-2013-shareholder-update-conference-call-transcript-ctso-20130821monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-provides-corporate-update-and-reports-financial-results-for-the-period-ended-ctso-20130814monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-announces-start-of-1m-us-army-phase-ii-sbir-contract-and-closing-of-additiona-ctso-20130627monthly0.5https://www.biopharmawatch.com/news/CTSO/kathleen-p-bloch-appointed-as-chief-financial-officer-of-cytosorbents-monmouth-junction-ne-ctso-20130513monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-corporation-a-critical-care-focused-company-using-blood-purification-to-treat-ctso-20130211monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-2012-end-of-year-shareholder-letter-monmouth-junction-nj-ctso-20130109monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-updates-corporate-progress-and-third-quarter-2012-financial-results-wednesday-ctso-20121121monthly0.5https://www.biopharmawatch.com/news/CTSO/cyto-sorbents-rodman-and-renshaw-presentation-september-2012-otcbb-ctso-cyto-sorbents-corp-ctso-20120914monthly0.5https://www.biopharmawatch.com/news/CTSO/cyto-sorbents-investor-presentation-june-2012-otcbb-ctso-cyto-sorbents-corporation-working-ctso-20120607monthly0.5https://www.biopharmawatch.com/news/CTSO/in-response-to-a-number-of-shareholder-questions-cytosorbents-corporation-posted-the-follo-ctso-20120518monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-strengthens-balance-sheet-through-convertible-note-monmouth-junction-nj-ctso-20120213monthly0.5https://www.biopharmawatch.com/news/CTSO/shareholder-letter-cytosorbents-2011-end-of-year-shareholder-letter-monmouth-junction-nj-ctso-20120111monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-announces-purchase-agreement-for-up-to-8-5-million-with-lincoln-park-capital--ctso-20111209monthly0.5https://www.biopharmawatch.com/news/CTSO/unassociated-document-cytosorbents-corporation-releases-shareholder-letter-monmouth-juncti-ctso-20110606monthly0.5https://www.biopharmawatch.com/news/CTSO/unassociated-document-cytosorbents-corporation-achieves-european-union-regulatory-approval-ctso-20110331monthly0.5https://www.biopharmawatch.com/news/CTSO/v204295-ex99-1-converted-by-secpublisher-2-1-1-8-created-by-bcl-technologies-inc-for-sec-f-ctso-20101201monthly0.5https://www.biopharmawatch.com/news/CTSO/v189448-ex99-1-converted-by-secpublisher-2-1-1-8-created-by-bcl-technologies-inc-for-sec-f-ctso-20100629monthly0.5https://www.biopharmawatch.com/news/CTSO/cytosorbents-corporation-enters-into-funding-agreement-monmouth-junction-new-jersey-ctso-20100510monthly0.5https://www.biopharmawatch.com/news/CTSO/unassociated-document-medasorb-technologies-announces-company-name-change-to-cytosorbents--ctso-20100506monthly0.5https://www.biopharmawatch.com/news/CTSO/jfif-exif-mm-b-j-1-r-2-i-adobe-photoshop-cs2-windows-2010-01-13-19-41-03-ctso-20100113monthly0.5https://www.biopharmawatch.com/news/CTSO/medasorb-technologies-corporation-raises-1-3m-in-series-b-warrant-exercise-monmouth-juncti-ctso-20091009monthly0.5https://www.biopharmawatch.com/news/CTSO/medasorb-technologies-corporation-announces-management-changes-monmouth-junction-nj-ctso-20090109monthly0.5https://www.biopharmawatch.com/news/CTSO/unassociated-document-medasorb-corporation-fka-medasorb-technologies-llc-a-development-sta-ctso-20060706monthly0.5https://www.biopharmawatch.com/news/ALLR/copyright-2023-allarity-therapeutics-all-rights-reserved-nasdaq-allr-dual-inhibition-of-pa-allr-20260508monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-advances-stenoparib-toward-pivotal-development-with-phase-3-manufact-allr-20260506monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-presents-two-aacr-2026-posters-highlighting-stenoparib-s-potential-i-allr-20260421monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-reports-full-year-2025-financial-results-and-corporate-progress-stre-allr-20260331monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-closes-20-million-financing-to-accelerate-the-advance-of-stenoparib--allr-20260306monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-two-patients-now-exceeding-one-year-of-treatment-with-sten-allr-20240916monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-outlines-company-s-2024-progress-and-objectives-current-cash-balance-allr-20240722monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-granted-hearing-before-nasdaq-panel-to-present-plan-of-regaining-compliance-bosto-allr-20240627monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-dual-parp-tankyrase-inhibitor-stenoparib-continues-to-show-extended--allr-20240625monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-regains-compliance-with-nasdaq-s-minimum-stockholders-equity-require-allr-20240520monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-reports-first-quarter-financial-results-and-highlights-including-cle-allr-20240514monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-that-all-series-a-preferred-and-all-variable-priced-warran-allr-20240507monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-exceeds-nasdaq-s-minimum-equity-requirement-requests-voluntarily-wit-allr-20240506monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-stenoparib-shows-clear-clinical-benefit-and-achieves-significant-mil-allr-20240502monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-boston-allr-20240429monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-receives-nasdaq-approved-extension-to-regain-compliance-with-nasdaq--allr-20240417monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-1-for-20-reverse-stock-split-boston-allr-20240404monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-makes-strategic-pivot-to-focus-solely-on-accelerating-stenoparib-tow-allr-20240327monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-receives-extension-from-nasdaq-hearings-panel-to-regain-compliance-w-allr-20240325monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-reports-full-year-2023-financial-results-and-provides-a-business-upd-allr-20240308monthly0.5https://www.biopharmawatch.com/news/ALLR/copyright-2023-allarity-therapeutics-all-rights-reserved-nasdaq-allr-a-gene-expression-bas-allr-20240301monthly0.5https://www.biopharmawatch.com/news/ALLR/rs-uljkw-oodulw-7khudshxwlfv-oouljkwvuhvhuyhg-1dvgdt-5-personalized-cancer-care-realized-j-allr-20231206monthly0.5https://www.biopharmawatch.com/news/ALLR/all-evaluable-participants-with-prior-parp-inhibitor-therapy-and-chemotherapy-showed-signi-allr-20231205monthly0.5https://www.biopharmawatch.com/news/ALLR/copyright-2023-allarity-therapeutics-all-rights-reserved-nasdaq-allr-personalized-cancer-c-allr-20231113monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-ceo-letter-to-shareholders-boston-allr-20230811monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-strengthens-board-of-directors-with-appointment-of-three-accomplishe-allr-20230727monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-inc-announces-pricing-of-11-million-public-offering-boston-ma-allr-20230706monthly0.5https://www.biopharmawatch.com/news/ALLR/initial-data-from-allarity-s-phase-2-trial-of-ixempra-indicate-potential-for-improved-clin-allr-20230705monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-reverse-stock-split-of-common-stock-common-stock-will-begi-allr-20230629monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-adjournment-of-special-meeting-of-stockholders-meeting-adj-allr-20230623monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-inc-announces-pricing-of-7-5-million-public-offering-boston-ma-allr-20230419monthly0.5https://www.biopharmawatch.com/news/ALLR/abstract-evaluating-allarity-s-drp-companion-diagnostic-for-cisplatin-accepted-at-2023-asc-allr-20230411monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-provides-updates-for-ixempra-and-stenoparib-phase-2-monotherapy-clin-allr-20230328monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-reverse-stock-split-of-common-stock-common-stock-will-begi-allr-20230327monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-doses-first-patient-in-phase-1b-clinical-trial-evaluating-dovitinib--allr-20230320monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-adjournment-of-2023-annual-meeting-of-stockholders-boston--allr-20230120monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-reschedules-2022-annual-stockholders-meeting-and-sets-new-record-dat-allr-20221201monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-reports-third-quarter-2022-financial-results-cambridge-ma-u-s-a-allr-20221115monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-adjournment-of-2022-annual-meeting-of-stockholders-cambrid-allr-20221107monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-reports-second-quarter-2022-financial-results-provides-recent-operat-allr-20221011monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-appoints-seasoned-biotechnology-executive-jerry-mclaughlin-to-board--allr-20220926monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-appointment-of-new-auditor-cambridge-ma-u-s-a-allr-20220912monthly0.5https://www.biopharmawatch.com/news/ALLR/copyright-2022-allarity-therapeutics-all-rights-reserved-nasdaq-allr-personalized-cancer-c-allr-20220808monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-receives-nasdaq-notification-of-non-compliance-with-listing-rule-525-allr-20220826monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-refocuses-oncology-pipeline-strategy-towards-combination-therapies-n-allr-20220802monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-bolsters-its-board-of-directors-with-appointment-of-prominent-clinic-allr-20220711monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-announces-executive-leadership-transition-board-appoints-james-g-cul-allr-20220629monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-reports-first-quarter-2022-financial-results-cambridge-ma-u-s-a-allr-20220527monthly0.5https://www.biopharmawatch.com/news/ALLR/copyright-2022-allarity-therapeutics-all-rights-reserved-nasdaq-allr-personalized-cancer-c-allr-20220527monthly0.5https://www.biopharmawatch.com/news/ALLR/correction-notice-to-press-release-announcing-financial-results-for-the-fourth-quarter-and-allr-20220518monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-prov-allr-20220516monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-receives-nasdaq-notification-of-non-compliance-with-listing-rule-525-allr-20220422monthly0.5https://www.biopharmawatch.com/news/ALLR/copyright-2022-allarity-therapeutics-all-rights-reserved-n-a-sdaq-a-l-lr-personalized-canc-allr-20220118monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-and-oncoheroes-biosciences-sign-agreements-to-advance-pediatric-canc-allr-20220103monthly0.5https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-closes-its-recapitalization-share-exchange-and-20m-pipe-investment-l-allr-20211221monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-therapeutics-appoints-drake-richey-and-john-yee-md-mph-to-board-of-directors-brisb-tpst-20260604monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-first-quarter-2026-financial-results-and-provides-business-update-announce-tpst-20260514monthly0.5https://www.biopharmawatch.com/news/TPST/accelerating-the-development-of-advanced-therapies-for-cancer-patients-february-2026-forwa-tpst-20260211monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-second-quarter-2025-financial-results-and-provides-business-update-x2022-r-tpst-20250811monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-first-quarter-2025-financial-results-and-provides-business-update-x2022-pr-tpst-20250513monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-year-end-2024-financial-results-and-provides-business-update-x2022-granted-tpst-20250327monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-third-quarter-2024-financial-results-and-provides-business-update-building-tpst-20241112monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-extends-limited-duration-stockholder-rights-plan-tpst-20241010monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-second-quarter-2024-financial-results-and-provides-business-update-unveile-tpst-20240808monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-unveils-new-survival-data-for-amezalpat-tpst-1120-in-randomized-first-line-hcc-stu-tpst-20240620monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-first-quarter-2024-financial-results-and-provides-business-update-advancin-tpst-20240509monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-year-end-2023-financial-results-and-provides-business-update-announced-pos-tpst-20240319monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-third-quarter-2023-financial-results-and-provides-business-update-tpst-112-tpst-20231108monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-releases-new-data-demonstrating-superiority-of-tpst-1120-arm-across-multiple-study-tpst-20231011monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-second-quarter-2023-financial-results-and-provides-business-update-brisban-tpst-20230810monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-first-quarter-2023-financial-results-and-provides-business-update-brisbane-tpst-20230510monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-announces-positive-early-results-from-global-randomized-phase-1b-2-combination-stu-tpst-20230428monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-therapeutics-inc-consolidated-statements-of-operations-in-thousands-except-per-sha-tpst-20230322monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-provides-asco-kol-feedback-on-tpst-1120-clinical-results-and-updated-financial-gui-tpst-20220609monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-positive-tpst-1120-clinical-data-from-phase-1-trial-in-patients-with-advan-tpst-20220526monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-first-quarter-2022-financial-results-and-provides-corporate-highlights-ann-tpst-20220513monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-announces-private-placement-financing-of-15-million-south-san-francisco-calif-tpst-20220427monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-year-end-2021-financial-results-and-provides-corporate-highlights-first-cl-tpst-20220329monthly0.5https://www.biopharmawatch.com/news/TPST/investor-contacts-sylvia-wheeler-wheelhouse-life-science-advisors-swheeler-wheelhouselsa-c-tpst-20211110monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-reports-second-quarter-2021-financial-results-and-provides-corporate-highlights-cl-tpst-20210812monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-s-business-overview-tempest-is-a-clinical-stage-oncology-company-focused-on-levera-tpst-20210709monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-closes-merger-with-millendo-and-completes-pipe-financing-south-san-francisco-ca-tpst-20210628monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-and-millendo-announce-stockholder-approval-of-merger-tempest-to-trade-on-nasdaq-pu-tpst-20210622monthly0.5https://www.biopharmawatch.com/news/TPST/tempest-and-millendo-announce-proposed-merger-agreement-transaction-to-advance-tempest-s-t-tpst-20210329monthly0.5https://www.biopharmawatch.com/news/TPST/millendo-therapeutics-provides-pipeline-and-business-update-further-investment-in-mle-301--tpst-20210105monthly0.5https://www.biopharmawatch.com/news/TPST/millendo-therapeutics-announces-initiation-of-first-in-human-clinical-trial-of-mle-301-a-s-tpst-20200924monthly0.5https://www.biopharmawatch.com/news/TPST/millendo-therapeutics-provides-corporate-and-pipeline-update-mle-301-a-selective-neurokini-tpst-20200623monthly0.5https://www.biopharmawatch.com/news/TPST/millendo-therapeutics-announces-topline-results-for-pivotal-phase-2b-study-of-livoletide-i-tpst-20200406monthly0.5https://www.biopharmawatch.com/news/TPST/millendo-therapeutics-appoints-christophe-arbet-engels-md-phd-as-chief-medical-officer-com-tpst-20200210monthly0.5https://www.biopharmawatch.com/news/TPST/corporate-presentation-january-2020-cautionary-statement-regarding-forward-looking-stateme-tpst-20200113monthly0.5https://www.biopharmawatch.com/news/TPST/geoff-nichol-appointed-to-millendo-therapeutics-board-of-directors-tpst-20191219monthly0.5https://www.biopharmawatch.com/news/TPST/millendo-therapeutics-announces-proposed-public-offering-of-common-stock-tpst-20191204monthly0.5https://www.biopharmawatch.com/news/TPST/millendo-therapeutics-announces-departure-of-chief-medical-officer-tpst-20190618monthly0.5https://www.biopharmawatch.com/news/TPST/millendo-reports-full-year-2018-operating-and-financial-results-initiated-zephyr-a-pivotal-tpst-20190329monthly0.5https://www.biopharmawatch.com/news/TPST/presentation-to-lorem-ipsum-dolor-may-2018-corporate-presentation-march-2019-2-cautionary--tpst-20190322monthly0.5https://www.biopharmawatch.com/news/TPST/millendo-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ann-arb-tpst-20190117monthly0.5https://www.biopharmawatch.com/news/TPST/presentation-to-lorem-ipsum-dolor-may-2018-corporate-presentation-january-2019-2-cautionar-tpst-20190107monthly0.5https://www.biopharmawatch.com/news/TPST/millendo-therapeutics-announces-successful-merger-completion-completion-of-merger-with-ova-tpst-20181207monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-and-millendo-therapeutics-provide-update-on-merger-agreement-and-financing-new--tpst-20181101monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-and-millendo-therapeutics-announce-merger-to-create-leading-rare-endocrine-dise-tpst-20180809monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-reports-first-quarter-2018-financial-results-and-provides-business-update-tpst-20180503monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-reports-fourth-quarter-and-year-end-2017-financial-results-initial-data-from-fi-tpst-20180315monthly0.5https://www.biopharmawatch.com/news/TPST/corporate-presentation-january-2018-forward-looking-statements-this-presentation-includes--tpst-20180108monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-sm-announces-corporate-update-reporting-safety-data-from-first-20-patients-in-p-tpst-20180103monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-reports-third-quarter-2017-financial-results-initial-safety-data-from-first-20--tpst-20171102monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-reports-second-quarter-2017-financial-results-fertilization-of-bovine-eggpc-cel-tpst-20170803monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-appoints-christopher-kroeger-m-d-m-b-a-as-chief-executive-officer-dr-kroeger-s--tpst-20170621monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-reports-first-quarter-2017-financial-results-fertilization-of-bovine-eggpc-cell-tpst-20170509monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-reports-fourth-quarter-and-year-end-2016-financial-results-ovature-program-on-t-tpst-20170302monthly0.5https://www.biopharmawatch.com/news/TPST/to-our-current-report-on-form-8-k-filed-with-the-securities-and-exchange-commission-on-tpst-20161223monthly0.5https://www.biopharmawatch.com/news/TPST/to-our-current-report-on-form-8-k-filed-with-the-securities-and-exchange-commission-on-tpst-20161103monthly0.5https://www.biopharmawatch.com/news/TPST/to-our-current-report-on-form-8-k-filed-with-the-securities-and-exchange-commission-on-tpst-20160804monthly0.5https://www.biopharmawatch.com/news/TPST/harald-stock-ph-d-commences-role-as-president-and-chief-executive-officer-of-ovascience-be-tpst-20160701monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-announces-pricing-of-public-offering-of-common-stock-tpst-20160526monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-announces-proposed-public-offering-of-common-stock-tpst-20160525monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-reports-first-quarter-2016-financial-results-augment-treatment-gains-traction-i-tpst-20160505monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-reports-fourth-quarter-and-year-end-2015-financial-results-harald-stock-ph-d-ap-tpst-20160225monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-names-harald-f-stock-chief-executive-officer-elect-industry-veteran-brings-prov-tpst-20160106monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-provides-business-update-and-outlines-2015-corporate-progress-company-achieves--tpst-20151207monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-reports-third-quarter-2015-financial-results-tpst-20151105monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-provides-update-on-corporate-goal-for-augment-treatment-tpst-20150928monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-reports-second-quarter-2015-financial-results-healthy-babies-born-with-augment--tpst-20150810monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-welcomes-john-howe-m-d-former-president-and-ceo-of-project-hope-to-board-of-dir-tpst-20150605monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-reports-first-quarter-2015-financial-results-tpst-20150511monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-welcomes-john-sexton-president-of-new-york-university-to-board-of-directors-tpst-20150430monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-reports-fourth-quarter-and-year-end-2014-financial-results-tpst-20150316monthly0.5https://www.biopharmawatch.com/news/TPST/for-the-purpose-of-incorporating-the-information-set-forth-herein-by-reference-into-the-re-tpst-20150108monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-announces-proposed-public-offering-of-common-stock-tpst-20150106monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-advances-all-three-fertility-treatment-options-augment-treatment-available-in-f-tpst-20141217monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-strengthens-management-team-to-support-expanding-global-operations-promotes-art-tpst-20141211monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-reports-third-quarter-2014-financial-results-company-ahead-of-schedule-in-achie-tpst-20141110monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-appoints-jeffrey-young-to-chief-financial-officer-reports-inducement-option-gra-tpst-20140918monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-reports-second-quarter-2014-financial-results-augment-sm-treatment-available-in-tpst-20140807monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-reports-first-quarter-2014-financial-results-company-commenced-international-la-tpst-20140508monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-announces-exercise-of-over-allotment-option-in-public-offering-of-common-stock--tpst-20140318monthly0.5https://www.biopharmawatch.com/news/TPST/for-the-purpose-of-incorporating-the-information-set-forth-herein-by-reference-into-the-re-tpst-20140306monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-reports-fourth-quarter-and-year-end-2013-financial-results-tpst-20140227monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-provides-update-on-pipeline-advancements-and-commercial-plans-new-potential-fer-tpst-20140113monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-announces-global-healthcare-strategist-marc-kozin-joins-company-s-board-of-dire-tpst-20140110monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-appoints-david-stern-to-executive-vice-president-global-commercial-operations-tpst-20140109monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-and-intrexon-collaborate-to-accelerate-development-of-ovascience-s-ovature-sm-t-tpst-20131219monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-reports-third-quarter-fiscal-2013-financial-results-tpst-20131113monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-provides-update-on-tpst-20130910monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-reports-second-quarter-fiscal-2013-financial-results-tpst-20130813monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-appoints-arthur-tzianabos-ph-d-to-chief-scientific-officer-tpst-20130730monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-appoints-mary-fisher-to-company-s-board-of-directors-tpst-20130611monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-reports-first-quarter-fiscal-2013-financial-results-tpst-20130515monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-announces-listing-on-nasdaq-under-ticker-symbol-tpst-20130425monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-announces-agreement-for-35-million-private-placement-tpst-20130313monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-reports-fourth-quarter-and-year-end-2012-financial-results-tpst-20130225monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-appoints-alison-lawton-to-chief-operating-officer-tpst-20130102monthly0.5https://www.biopharmawatch.com/news/TPST/ovascience-announces-third-quarter-fiscal-2012-financial-results-tpst-20121113monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-announces-pricing-of-4-6-million-public-offering-4-6-million-upfront-with-up-to-vnrx-20260607monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-first-quarter-2026-financial-results-and-business-update-conf-vnrx-20260514monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-announces-acceptance-of-compliance-plan-by-nyse-american-vnrx-20260423monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-full-fiscal-year-2025-financial-results-and-business-update-c-vnrx-20260331monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standard-vnrx-20260206monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-secures-2-0-million-in-funding-henderson-nev-january-8-2026-prnewswire-volition-vnrx-20260108monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-proposed-underwritten-public-offering-of-common-stock-and-com-vnrx-20251009monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-second-quarter-2025-financial-results-and-business-update-con-vnrx-20250814monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-announces-pricing-of-1-2-million-registered-direct-offering-vnrx-20250804monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-first-quarter-2025-financial-results-and-business-update-conf-vnrx-20250515monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-full-fiscal-year-2024-financial-results-and-business-update-c-vnrx-20250331monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-announces-pricing-of-up-to-2-3-million-registered-direct-offering-up-to-2-3-mil-vnrx-20250326monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-announces-pricing-of-up-to-1-9-million-registered-direct-offering-up-to-1-9-mil-vnrx-20241206monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-third-quarter-2024-financial-results-and-business-update-conf-vnrx-20241114monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-appoints-timothy-i-still-as-chairman-henderson-nevada-vnrx-20241106monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-appoints-dr-ethel-rubin-as-an-independent-director-henderson-nevada-vnrx-20240930monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-second-quarter-2024-financial-results-and-business-update-con-vnrx-20240814monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-announces-pricing-of-up-to-21-5-million-registered-direct-offering-7-million-up-vnrx-20240809monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-issues-mid-year-review-ahead-of-2024-annual-meeting-henderson-nevada-vnrx-20240627monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-first-quarter-2024-financial-results-and-business-update-conf-vnrx-20240513monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-full-fiscal-year-2023-financial-results-and-business-update-c-vnrx-20240325monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-appoints-dr-andrew-retter-as-chief-medical-officer-henderson-nevada-vnrx-20240319monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-secures-approximately-5-5-million-in-belgium-regional-government-financing-from-vnrx-20231205monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-third-quarter-2023-financial-results-and-business-update-conf-vnrx-20231114monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-second-quarter-2023-financial-results-and-business-update-con-vnrx-20230814monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-proposed-underwritten-public-offering-of-common-stock-vnrx-20230531monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-first-quarter-2023-financial-results-and-business-update-conf-vnrx-20230510monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-full-fiscal-year-2022-financial-results-and-business-update-c-vnrx-20230315monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-proposed-underwritten-public-offering-of-common-stock-vnrx-20230216monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-third-quarter-2022-financial-results-and-business-update-conf-vnrx-20221114monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-appoints-mickie-henshall-as-an-independent-director-henderson-nevada-vnrx-20220816monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-second-quarter-2022-financial-results-and-business-update-con-vnrx-20220810monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-proposed-underwritten-public-offering-of-common-stock-vnrx-20220728monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-first-quarter-2022-financial-results-and-business-update-conf-vnrx-20220511monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-full-fiscal-year-2021-financial-results-and-business-update-c-vnrx-20220330monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-signs-exclusive-28-million-license-and-supply-agreement-with-heska-corporation-to-vnrx-20220329monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-third-quarter-2021-financial-results-and-business-update-conf-vnrx-20211110monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-second-quarter-2021-financial-results-and-business-update-con-vnrx-20210811monthly0.5https://www.biopharmawatch.com/news/VNRX/of-volitionrx-limited-dated-vnrx-20210511monthly0.5https://www.biopharmawatch.com/news/VNRX/of-volitionrx-limited-regarding-appointment-of-directors-dated-vnrx-20210329monthly0.5https://www.biopharmawatch.com/news/VNRX/of-volitionrx-limited-dated-vnrx-20210322monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-pricing-of-20-million-underwritten-public-offering-of-common--vnrx-20210210monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-provides-a-business-update-and-appoints-key-officers-to-drive-commercialization-vnrx-20210202monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-appoints-dr-tom-butera-dvm-to-board-of-directors-vnrx-20201203monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-third-quarter-2020-financial-results-and-business-update-conf-vnrx-20201112monthly0.5https://www.biopharmawatch.com/news/VNRX/of-volitionrx-limited-dated-vnrx-20200813monthly0.5https://www.biopharmawatch.com/news/VNRX/of-volitionrx-limited-issued-vnrx-20200519monthly0.5https://www.biopharmawatch.com/news/VNRX/of-volitionrx-limited-dated-vnrx-20200507monthly0.5https://www.biopharmawatch.com/news/VNRX/issued-vnrx-20200423monthly0.5https://www.biopharmawatch.com/news/VNRX/of-volitionrx-limited-dated-vnrx-20200220monthly0.5https://www.biopharmawatch.com/news/VNRX/form-8-k-press-release-of-volitionrx-limited-dated-november-12-2019-form-8-k-press-release-vnrx-20191112monthly0.5https://www.biopharmawatch.com/news/VNRX/volition-appoints-dr-phillip-barnes-to-board-of-directors-vnrx-20191009monthly0.5https://www.biopharmawatch.com/news/VNRX/of-volitionrx-limited-dated-vnrx-20190812monthly0.5https://www.biopharmawatch.com/news/VNRX/of-volitionrx-limited-dated-vnrx-20190724monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-first-quarter-2019-financial-results-and-business-update-conf-vnrx-20190508monthly0.5https://www.biopharmawatch.com/news/VNRX/of-volitionrx-limited-dated-vnrx-20190313monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-third-quarter-2018-financial-results-and-business-update-vnrx-20181107monthly0.5https://www.biopharmawatch.com/news/VNRX/of-volitionrx-limited-dated-vnrx-20180813monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-announces-9-million-private-placement-vnrx-20180808monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-first-quarter-2018-financial-results-and-business-update-vnrx-20180510monthly0.5https://www.biopharmawatch.com/news/VNRX/issued-vnrx-20180308monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-full-fiscal-year-2017-financial-results-and-business-update-c-vnrx-20180301monthly0.5https://www.biopharmawatch.com/news/VNRX/of-volitionrx-limited-volitionrx-limited-announces-third-quarter-2017-financial-results-an-vnrx-20171109monthly0.5https://www.biopharmawatch.com/news/VNRX/press-release-vnrx-20170809monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-first-quarter-2017-financial-results-and-business-update-vnrx-20170511monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-appoints-david-vanston-as-chief-financial-officer-vnrx-20170411monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-third-quarter-2016-financial-results-and-business-update-vnrx-20161110monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-announces-acquisition-of-new-belgian-facility-and-appointment-of-coo-to-vnrx-20161026monthly0.5https://www.biopharmawatch.com/news/VNRX/092916-volitionrx-limited-announces-proposed-public-offering-of-common-stock-vnrx-20160929monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-announces-second-quarter-2016-financial-results-and-business-update-vnrx-20160811monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-appoints-dr-edward-futcher-to-board-of-directors-appointment-to-help-guide-comp-vnrx-20160624monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-announces-first-quarter-2016-financial-results-and-business-update-namur-belgiu-vnrx-20160513monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-announces-proposed-public-offering-of-common-stock-namur-belgium-vnrx-20160317monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-announces-full-year-2015-financial-results-and-business-update-namur-belgium-vnrx-20160311monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-announces-dr-jason-terrell-s-transition-to-full-time-status-as-chief-medical-of-vnrx-20160105monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-to-present-at-two-conferences-in-november-ceo-to-speak-at-canaccord-genuity-med-vnrx-20151112monthly0.5https://www.biopharmawatch.com/news/VNRX/c-o-r-p-o-r-a-t-e-p-a-r-t-i-c-i-p-a-n-t-s-scott-powell-director-of-investor-relations-came-vnrx-20151110monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-announces-appointment-of-david-kratochvil-as-chief-financial-officer-vnrx-20150817monthly0.5https://www.biopharmawatch.com/news/VNRX/transcript-of-conference-call-c-o-r-p-o-r-a-t-e-p-a-r-t-i-c-i-p-a-n-t-s-scott-powell-direc-vnrx-20150812monthly0.5https://www.biopharmawatch.com/news/VNRX/updated-conference-call-transcript-volitionrx-limited-first-quarter-2015-financial-earning-vnrx-20150512monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-limited-prices-public-offering-of-common-stock-2-475-000-shares-priced-at-3-75--vnrx-20150206monthly0.5https://www.biopharmawatch.com/news/VNRX/volitionrx-completes-3-million-private-placement-namur-belgium-marketwired-vnrx-20140228monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-reports-positive-updated-data-from-briquilimab-studies-in-chronic-spon-jspr-20260108monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-appoints-jeet-mahal-as-chief-executive-officer-to-lead-next-phase-of-c-jspr-20260107monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate-u-jspr-20250813monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-reports-positive-data-from-180mg-cohort-in-spotlight-study-of-briquili-jspr-20250614monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-reports-first-quarter-2025-financial-results-and-provides-corporate-up-jspr-20250512monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-provid-jspr-20250227monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-reports-positive-data-from-beacon-study-of-briquilimab-in-chronic-spon-jspr-20250108monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-reports-third-quarter-2024-financial-results-and-provides-corporate-up-jspr-20241107monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-reports-positive-data-from-spotlight-study-of-briquilimab-in-chronic-i-jspr-20241014monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-appointment-of-svetlana-lucas-ph-d-to-its-board-of-directors-jspr-20240619monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-reports-fiscal-2023-financial-results-and-recent-corporate-development-jspr-20240304monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-pricing-of-50-million-underwritten-offering-of-common-stock-jspr-20240206monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-inc-announces-reverse-stock-split-jspr-20240102monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-reports-third-quarter-2023-financial-results-and-provides-business-upd-jspr-20231109monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-appointment-of-thomas-g-wiggans-as-chairperson-of-the-board--jspr-20231101monthly0.5https://www.biopharmawatch.com/news/JSPR/briquilimab-is-an-investigative-drug-and-is-not-approved-for-any-indication-safe-harbor-st-jspr-20231010monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-ind-clearance-for-phase-1b-2a-study-of-subcutaneous-briquili-jspr-20231009monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-appoints-herb-cross-as-chief-financial-officer-jeet-mahal-continues-as-jspr-20230925monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-to-present-new-positive-data-on-briquilimab-conditioning-in-patients-w-jspr-20230921monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-reports-second-quarter-2023-financial-results-and-provides-a-business--jspr-20230811monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-appoints-scott-brun-m-d-to-its-board-of-directors-dr-brun-also-appoint-jspr-20230620monthly0.5https://www.biopharmawatch.com/news/JSPR/harnessing-the-power-of-jasper-s-differentiated-c-kit-therapeutic-approach-nasdaq-jspr-jun-jspr-20230602monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-reports-first-quarter-2023-financial-results-and-provides-a-business-u-jspr-20230512monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-reports-fiscal-2022-financial-results-and-provides-a-business-update-a-jspr-20230308monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-presents-data-supporting-ongoing-development-of-briquilimab-its-c-kit--jspr-20230217monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-positive-follow-up-clinical-data-from-investigator-sponsored-jspr-20230216monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-closing-of-public-offering-of-common-stock-and-full-exercise-jspr-20230127monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-pricing-of-90-million-public-offering-of-common-stock-jspr-20230125monthly0.5https://www.biopharmawatch.com/news/JSPR/briquilimab-is-an-investigative-drug-and-is-not-approved-for-any-indication-safe-harbor-st-jspr-20230124monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-new-positive-briquilimab-data-to-be-presented-at-the-2023-ta-jspr-20230113monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-development-prioritization-of-briquilimab-in-chronic-disease-jspr-20230110monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-reports-third-quarter-2022-financial-results-and-provides-a-corporate--jspr-20221110monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-reports-second-quarter-2022-financial-results-and-provides-a-corporate-jspr-20220812monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-reports-first-quarter-2022-financial-results-and-provides-a-corporate--jspr-20220512monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-management-changes-to-strengthen-leadership-team-jspr-20220321monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-fiscal-2021-financial-results-and-provides-business-update-jspr-20220318monthly0.5https://www.biopharmawatch.com/news/JSPR/transforming-the-field-of-hematopoietic-stem-cell-therapies-nasdaq-jspr-march-2022-2-jsp19-jspr-20220316monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-appointment-of-ronald-martell-as-chief-executive-officer-wil-jspr-20220228monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-jsp191-phase-1b-mds-aml-late-breaking-data-presentation-at-t-jspr-20220224monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-announces-third-quarter-2021-financial-results-and-provides-business-u-jspr-20211112monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-closes-transaction-with-amplitude-healthcare-acquisition-corporation-c-jspr-20210924monthly0.5https://www.biopharmawatch.com/news/JSPR/amplitude-healthcare-acquisition-corporation-announces-shareholder-approval-of-business-co-jspr-20210922monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-and-amplitude-healthcare-acquisition-corporation-announce-two-new-boar-jspr-20210920monthly0.5https://www.biopharmawatch.com/news/JSPR/enabling-cures-with-hematopoietic-stem-cell-transplants-september-2021-2021-jasper-therape-jspr-20210909monthly0.5https://www.biopharmawatch.com/news/JSPR/presentation-transcript-bill-lis-executive-chairman-and-chief-executive-officer-of-jasper--jspr-20210507monthly0.5https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-and-amplitude-healthcare-acquisition-corporation-announce-merger-to-cr-jspr-20210506monthly0.5https://www.biopharmawatch.com/news/JSPR/amplitude-healthcare-acquisition-corporation-announces-the-separate-trading-of-its-class-a-jspr-20200110monthly0.5https://www.biopharmawatch.com/news/JSPR/index-to-financial-statements-page-report-of-independent-registered-public-accounting-firm-jspr-20191122monthly0.5https://www.biopharmawatch.com/news/JSPR/amplitude-healthcare-acquisition-corporation-announces-pricing-of-100-000-000-initial-publ-jspr-20191119monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-private-placement-of-up-to-15-million-15-million-upfront-with-a-miles-lgvn-20260310monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-appoints-stephen-h-willard-as-chief-executive-officer-mr-willard-has-a-30-year--lgvn-20260213monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-key-leadership-updates-than-powell-chief-business-officer-and-head-of-lgvn-20250903monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-second-quarter-2025-financial-results-and-provides-business-update-fu-lgvn-20250813monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-up-to-17-5-million-public-offering-5-0-million-upfront-with-up-to-an--lgvn-20250808monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-u-s-fda-approval-of-ind-application-for-a-phase-2-pivotal-registratio-lgvn-20250708monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-first-quarter-2025-financial-results-and-provides-business-update-piv-lgvn-20250508monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-full-year-2024-financial-results-and-provides-business-update-pivotal-lgvn-20250228monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-third-quarter-2024-financial-results-and-provides-business-update-pha-lgvn-20241112monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-second-quarter-2024-financial-results-and-provides-business-update-po-lgvn-20240814monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-9-0-million-registered-direct-offering-priced-at-the-market-under-nas-lgvn-20240718monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-u-s-fda-grants-fast-track-designation-for-lomecel-b-tm-for-the-treatm-lgvn-20240709monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-u-s-fda-grants-lomecel-b-tm-regenerative-medicine-advanced-therapy-rm-lgvn-20240710monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-exercise-of-warrants-for-4-4-million-gross-proceeds-miami-lgvn-20240617monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-board-of-directors-planned-transitions-richard-kender-retired-svp-of--lgvn-20240510monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-exercise-of-warrants-for-6-2-million-gross-proceeds-miami-lgvn-20240417monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-pricing-of-5-25-million-public-offering-04-08-2024-miami-lgvn-20240408monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-1-for-10-reverse-stock-split-miami-fl-lgvn-20240319monthly0.5https://www.biopharmawatch.com/news/LGVN/update-longeveron-announces-2-36-million-registered-direct-offering-priced-at-the-market-u-lgvn-20231221monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-4-million-registered-direct-offering-priced-at-the-market-under-nasda-lgvn-20231012monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-positive-top-line-results-for-lomecel-b-tm-in-its-clear-mind-phase-2a-lgvn-20231005monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-rights-offering-declared-effective-and-calendar-finalized-miami-lgvn-20230816monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-pricing-for-rights-offering-and-expected-calendar-miami-lgvn-20230814monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-appoints-lisa-locklear-as-chief-financial-officer-miami-fl-lgvn-20230720monthly0.5https://www.biopharmawatch.com/news/LGVN/cell-based-therapies-a-regenerative-medicine-company-may-2023-2-forward-looking-statements-lgvn-20230623monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-inc-provides-corporate-update-and-reports-first-quarter-2023-financial-results--lgvn-20230512monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-inc-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2022-fin-lgvn-20230310monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-appoints-wa-el-hashad-as-chief-executive-officer-hashad-is-a-former-executive-a-lgvn-20230228monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-provides-corporate-update-and-announces-2023-strategic-priorities-and-anticipat-lgvn-20230106monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-inc-provides-corporate-update-and-reports-third-quarter-2022-financial-results--lgvn-20221114monthly0.5https://www.biopharmawatch.com/news/LGVN/u-s-food-and-drug-administration-fda-grants-fast-track-designation-for-longeveron-s-lomece-lgvn-20220831monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-inc-provides-corporate-update-and-reports-second-quarter-2022-financial-results-lgvn-20220808monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-inc-provides-corporate-update-and-reports-first-quarter-2022-financial-results--lgvn-20220513monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-ceo-transition-geoff-green-stepping-down-as-ceo-effective-lgvn-20220509monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-expands-executive-leadership-team-appoints-k-chris-min-m-d-ph-d-as-chief-medica-lgvn-20220405monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-fourth-quarter-and-full-year-2021-financial-results-and-operational-p-lgvn-20220311monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-adds-seasoned-biotech-executive-todd-girolamo-to-its-board-of-directors-girolam-lgvn-20220217monthly0.5https://www.biopharmawatch.com/news/LGVN/nasdaq-lgvn-www-longeveron-com-h-c-wainwright-bioconnect-2022-virtual-conference-cell-ther-lgvn-20220110monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-granted-orphan-drug-designation-by-fda-for-lomecel-b-to-treat-infants-with-hypo-lgvn-20211206monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-inc-announces-pricing-of-a-20-5-million-private-placement-miami-florida-lgvn-20211201monthly0.5https://www.biopharmawatch.com/news/LGVN/u-s-food-and-drug-administration-approves-longeveron-s-lomecel-b-for-rare-pediatric-diseas-lgvn-20211118monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-inc-provides-corporate-update-and-reports-third-quarter-2021-financial-results--lgvn-20211112monthly0.5https://www.biopharmawatch.com/news/LGVN/nasdaq-lgvn-october-2021-cell-therapy-for-aging-related-disease-life-threatening-condition-lgvn-20211001monthly0.5https://www.biopharmawatch.com/news/LGVN/trial-results-lomecel-b-for-aging-frailty-a-phase-2b-randomized-blinded-and-placebo-contro-lgvn-20210929monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-final-results-of-phase-1-clinical-study-of-lomecel-b-injection-in-hyp-lgvn-20210909monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-topline-results-of-phase-2b-study-of-lomecel-b-for-aging-frailty-stud-lgvn-20210813monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-inc-provides-corporate-update-and-reports-second-quarter-2021-financial-results-lgvn-20210813monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-the-appointment-of-ursula-ungaro-to-its-board-of-directors-miami-flor-lgvn-20210525monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-inc-provides-corporate-update-and-reports-first-quarter-2021-financial-results--lgvn-20210514monthly0.5https://www.biopharmawatch.com/news/LGVN/senior-scientist-anthon-y-oliva-phd-director-of-patient-clinical-services-jessic-a-proteni-lgvn-20210511monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-announces-successful-completion-of-phase-i-ii-clinical-study-of-lomecel-b-infus-lgvn-20210415monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-cell-based-therapies-longeveron-announces-positive-results-of-phase-i-clinical--lgvn-20210413monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2020-financi-lgvn-20210330monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-inc-announces-partial-exercise-of-over-allotment-option-in-initial-public-offer-lgvn-20210315monthly0.5https://www.biopharmawatch.com/news/LGVN/longeveron-and-university-of-miami-expand-exclusive-license-agreement-and-enter-into-crada-lgvn-20210310monthly0.5https://www.biopharmawatch.com/news/NSRX/nasus-pharma-announces-positive-top-line-data-from-phase-2-clinical-study-of-ns002-achieve-nsrx-20260316monthly0.5https://www.biopharmawatch.com/news/NSRX/the-companies-law-1999-a-limited-liability-company-amended-and-restated-articles-of-associ-nsrx-20260306monthly0.5https://www.biopharmawatch.com/news/NSRX/dear-nasus-pharma-ltd-shareholders-we-cordially-invite-you-to-attend-the-special-general-m-nsrx-20260129monthly0.5https://www.biopharmawatch.com/news/NSRX/nasus-pharma-ltd-condensed-financial-statements-as-of-june-30-2025-unaudited-u-s-dollars-i-nsrx-20251229monthly0.5https://www.biopharmawatch.com/news/NSRX/nasus-pharma-strengthens-leadership-team-appointing-eyal-rubin-as-executive-vice-president-nsrx-20251120monthly0.5https://www.biopharmawatch.com/news/NSRX/nasus-pharma-announces-initiation-of-phase-2-clinical-study-of-ns002-with-first-participan-nsrx-20251118monthly0.5https://www.biopharmawatch.com/news/NSRX/nasus-pharma-announces-expanded-agreement-to-support-development-and-commercialization-of--nsrx-20251008monthly0.5https://www.biopharmawatch.com/news/NSRX/nasus-pharma-announces-closing-of-initial-public-offering-tel-aviv-israel-nsrx-20250814monthly0.5https://www.biopharmawatch.com/news/PLUR/leak-out-agreement-this-leak-out-agreement-the-leak-out-agreement-or-the-agreement-is-made-plur-20250313monthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-ceo-issues-letter-to-shareholders-summarizing-the-strategy-change-and-progress-in-20-plur-20221222monthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-ceo-issues-letter-to-shareholders-announcing-new-tech-collaboration-cost-reduction-i-plur-20220929monthly0.5https://www.biopharmawatch.com/news/PLUR/pluri-ceo-issues-shareholder-update-plur-20220725monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-reports-topline-results-from-its-phase-ii-studies-of-acute-respiratory-distress--plur-20211227monthly0.5https://www.biopharmawatch.com/news/PLUR/december-9-2020-pluristem-conference-call-inspired-by-life-2-this-presentation-contains-ex-plur-20201209monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-ceo-issues-shareholder-update-on-clinical-programs-plur-20200721monthly0.5https://www.biopharmawatch.com/news/PLUR/nasdaq-tase-nndm-www-nano-di-com-2020-nano-dimension-all-rights-reserved-nano-dimension-is-plur-20200430monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-reports-preliminary-data-from-its-covid-19-compassionate-use-program-treating-se-plur-20200407monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-provides-update-on-covid-19-preparedness-current-phase-iii-clinical-trials-statu-plur-20200326monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-ceo-issues-shareholder-letter-plur-20190702monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-therapeutics-approved-for-listing-on-nasdaq-capital-market-company-s-common-stoc-plur-20071210monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-s-reverse-stock-split-effective-today-stock-to-trade-under-the-new-symbol-psti-n-plur-20071126monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-announces-a-reverse-stock-split-in-conjunction-with-its-application-for-listing--plur-20071109monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-life-systems-inc-amended-2005-stock-option-plan-this-amended-2005-stock-option-p-plur-20070524monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-announces-private-equity-investment-of-8m-new-york-plur-20070214monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-completes-conversion-of-outstanding-convertible-debentures-98-of-the-3-million-i-plur-20061024monthly0.5https://www.biopharmawatch.com/news/PLUR/consulting-agreement-between-biologics-consulting-group-inc-hereinafter-bcg-address-1317-k-plur-20060615monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-announces-closing-of-7-senior-secured-convertible-debenture-private-placement-ha-plur-20060404monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-strengthens-business-strategy-company-to-focus-on-commercializing-cell-therapy-p-plur-20060314monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-announces-advanced-engineered-cell-graft-to-improve-resurgence-of-the-hematopoie-plur-20060118monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-appoints-arnon-nagler-m-d-msc-to-scientific-advisory-board-pioneer-and-world-acc-plur-20051109monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-announces-joint-projects-product-development-and-worldwide-distributorship-agree-plur-20051020monthly0.5https://www.biopharmawatch.com/news/PLUR/pluristem-board-appoints-john-l-bakos-president-u-s-leadership-by-seasoned-veteran-to-prov-plur-20050224monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-reverse-stock-split-cambridge-mass-pmn-20251124monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-second-quarter-2025-financial-results-corporate-highlights--pmn-20250813monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-0-8-million-registered-direct-offering-priced-at-the-market-pmn-20250724monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-first-quarter-2025-financial-results-first-cohort-completed-pmn-20250512monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-full-year-2024-financial-results-and-recent-highlights-rapi-pmn-20250331monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-doses-first-patients-in-phase-1b-precise-ad-trial-of-pmn310-for-alzhe-pmn-20250225monthly0.5https://www.biopharmawatch.com/news/PMN/nasdaq-pmn-targeting-the-underlying-cause-of-neurodegenerative-diseases-copyright-2025-pro-pmn-20250127monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-initiates-phase-1b-clinical-trial-precise-ad-in-alzheimer-s-disease-t-pmn-20250110monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-third-quarter-2024-financial-results-and-recent-highlights--pmn-20241114monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-second-quarter-2024-financial-results-and-recent-highlights-pmn-20240808monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-up-to-122-7-million-private-placement-financing-30-3-millio-pmn-20240726monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-reports-promising-top-line-data-from-its-phase-1a-alzheimer-s-trial-t-pmn-20240726monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-first-quarter-2024-financial-results-and-recent-highlights--pmn-20240514monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-publishes-study-highlighting-oligomer-selectivity-and-benefit-of-amyl-pmn-20240430monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-full-year-2023-financial-results-and-recent-highlights-top--pmn-20240401monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-inc-announces-leadership-transition-appoints-neil-warma-industry-lead-pmn-20240103monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-doses-first-subjects-in-phase-1a-clinical-trial-of-pmn310-to-treat-al-pmn-20231120monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-third-quarter-2023-financial-results-and-recent-highlights--pmn-20231114monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-20-4-million-private-placement-financing-at-the-market-fund-pmn-20230821monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-second-quarter-2023-financial-results-and-recent-highlights-pmn-20230814monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-consolidate-trading-on-the-nasdaq-exchange-company-to-voluntarily--pmn-20230710monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-first-quarter-2023-financial-results-and-recent-highlights--pmn-20230515monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-fda-clearance-of-investigational-new-drug-ind-application-f-pmn-20230508monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-submission-of-investigational-new-drug-ind-application-for--pmn-20230410monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-full-year-2022-financial-results-and-recent-highlights-comp-pmn-20230308monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-third-quarter-2022-financial-results-and-recent-highlights--pmn-20221114monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-closing-of-us-7-4-million-private-placement-toronto-ontario-pmn-20221012monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-appoints-accomplished-biopharmaceutical-leader-dr-gail-m-farfel-as-ch-pmn-20220913monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-announces-second-quarter-pmn-20220815monthly0.5https://www.biopharmawatch.com/news/PMN/promis-neurosciences-to-commence-trading-on-nasdaq-under-the-symbol-pmn-toronto-ontario-an-pmn-20220708monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-to-begin-trading-on-nasdaq-stock-exchange-princeton-nj-ptn-20260518monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-earns-5-5-million-6-5-million-milestone-payment-in-retinal-disease-collaboration-w-ptn-20250922monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-1-for-50-reverse-stock-split-princeton-nj-ptn-20250808monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-announces-transition-to-otc-pink-following-nyse-american-delisting-no-ptn-20250507monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-announces-receipt-of-nyse-american-notice-of-delisting-and-intent-ptn-20250410monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-positive-topline-results-from-phase-2-ulcerative-colitis-uc-study-of-ora-ptn-20250328monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-4-7-million-registered-direct-offering-and-concurrent-private-placement--ptn-20250207monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-exercise-of-warrants-for-approximately-3-4-million-gross-proceeds-cranbu-ptn-20241216monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-reports-first-quarter-fiscal-year-2025-operating-financial-results-obesity-program-ptn-20241114monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-receives-notice-of-non-compliance-from-nyse-american-cranbury-nj-ptn-20241007monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-reports-fourth-quarter-and-fiscal-year-ended-2024-financial-results-provides-updat-ptn-20241001monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-exercise-of-warrants-for-approximately-6-1-million-gross-proceeds-cranbu-ptn-20240621monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-reports-third-quarter-fiscal-year-2024-financial-results-and-provides-corporate-up-ptn-20240515monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-reports-second-quarter-fiscal-year-2024-financial-results-and-provides-corporate-u-ptn-20240215monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-10-million-registered-direct-offering-cranbury-nj-ptn-20240130monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-completes-sale-of-vyleesi-to-cosette-pharmaceuticals-for-up-to-171-million-palatin-ptn-20231220monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-receives-notice-of-acceptance-of-the-listing-standards-compliance-plan-from-nyse-a-ptn-20231218monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-reports-first-quarter-fiscal-year-2024-financial-results-and-provides-corporate-up-ptn-20231114monthly0.5https://www.biopharmawatch.com/news/PTN/ptn-palatin-announces-5-million-registered-direct-offering-cranbury-n-j-ptn-20231023monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-preliminary-quarter-ended-ptn-20230930monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-receives-notice-of-non-compliance-from-nyse-american-palatin-to-deliver-plan-of-co-ptn-20231013monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-reports-fourth-quarter-and-fiscal-year-ended-2023-financial-results-and-provides-c-ptn-20230928monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-to-present-at-the-h-c-wainwright-25-th-annual-global-investment-conference-cranbur-ptn-20230907monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-completes-enrollment-in-phase-3-melody-1-study-of-pl9643-for-the-treatment-of-pati-ptn-20230907monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-initiates-clinical-program-for-bremelanotide-co-formulated-with-a-pde5i-for-the-tr-ptn-20230810monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-provides-update-on-vyleesi-collaborations-licensee-fosun-pharma-reports-first-comm-ptn-20230808monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-direct-to-consumer-telehealth-partnership-with-upscripthealth-for-vylees-ptn-20230807monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-to-participate-in-canaccord-genuity-s-43-rd-annual-growth-conference-cranbury-nj-ptn-20230804monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-preliminary-fourth-quarter-fiscal-2023-vyleesi-product-revenue-results-4-ptn-20230711monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-presents-preclinical-diabetic-nephropathy-data-at-the-international-podocyte-confe-ptn-20230530monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-reports-third-quarter-fiscal-year-2023-financial-results-and-provides-corporate-up-ptn-20230516monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-to-report-third-quarter-fiscal-year-2023-results-teleconference-and-webcast-to-be--ptn-20230512monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-invites-investors-to-listen-to-replay-of-the-pl9643-dry-eye-disease-key-opinion-le-ptn-20230508monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-to-host-key-opinion-leader-webinar-review-of-phase-3-pl9643-data-for--ptn-20230501monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-presents-initial-dry-eye-disease-phase-3-clinical-data-at-the-association-of-resea-ptn-20230427monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-presents-data-at-the-association-of-research-in-vision-and-ophthalmology-2023-annu-ptn-20230425monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-preliminary-third-quarter-fiscal-2023-vyleesi-product-revenue-results-3--ptn-20230419monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-reports-second-quarter-fiscal-year-2023-financial-results-and-provides-corporate-u-ptn-20230215monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-reports-first-quarter-fiscal-year-2023-financial-results-and-provides-corporate-up-ptn-20221114monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-10-million-registered-direct-offering-cranbury-nj-ptn-20221031monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-reports-fourth-quarter-and-fiscal-year-2022-financial-results-and-provides-corpora-ptn-20220922monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-reports-third-quarter-fiscal-year-2022-financial-results-and-provides-corporate-up-ptn-20220517monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-reports-second-quarter-fiscal-year-2022-financial-results-and-provides-corporate-u-ptn-20220215monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-reports-first-quarter-fiscal-year-2022-results-and-provides-corporate-update-phase-ptn-20211115monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-reports-fourth-quarter-and-full-year-fiscal-year-2021-financial-results-and-provid-ptn-20210929monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-announces-adjournment-of-annual-meeting-of-stockholders-x25cf-limited-to-proposal--ptn-20210708monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-reports-financial-results-for-the-third-fiscal-quarter-of-2021-and-provides-corpor-ptn-20210517monthly0.5https://www.biopharmawatch.com/news/PTN/forward-looking-statements-statements-in-this-press-release-that-are-not-historical-facts--ptn-20210217monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-first-quarter-fiscal-year-2021-results-and-provides-busin-ptn-20201117monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-announces-fourth-quarter-and-fiscal-year-2020-financial-results-a-ptn-20200928monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-announces-mutual-termination-of-license-agreement-with-amag-pharmaceu-ptn-20200727monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-announces-adjournment-of-annual-meeting-of-stockholders-x25cf-limited-ptn-20200629monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-third-quarter-fiscal-year-2020-financial-results-and-rece-ptn-20200512monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-second-quarter-fiscal-year-2020-financial-results-and-rec-ptn-20200211monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-first-quarter-fiscal-year-2020-results-and-provides-corpo-ptn-20191113monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-fourth-quarter-and-fiscal-year-2019-results-teleconferenc-ptn-20190912monthly0.5https://www.biopharmawatch.com/news/PTN/fda-approves-new-drug-application-for-vyleesi-x2122-bremelanotide-injection-first-fda-appr-ptn-20190621monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-third-quarter-fiscal-year-2019-results-teleconference-and-ptn-20190509monthly0.5https://www.biopharmawatch.com/news/PTN/blueprint-palatin-technologies-inc-reports-second-fiscal-quarter-2019-results-and-provides-ptn-20190212monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-first-fiscal-quarter-2019-results-and-provides-corporate--ptn-20181113monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-fourth-quarter-and-fiscal-year-2018-results-vyleesi-x2122-ptn-20180913monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-third-quarter-fiscal-year-2018-results-teleconference-and-ptn-20180515monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-second-quarter-fiscal-year-2018-results-teleconference-an-ptn-20180212monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-first-quarter-fiscal-year-2018-results-teleconference-and-ptn-20171113monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-fourth-quarter-and-fiscal-year-2017-results-teleconferenc-ptn-20170925monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-announces-appointment-of-anthony-m-manning-ph-d-to-board-of-directors-ptn-20170912monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-announces-signing-of-licensing-agreement-with-fosun-pharma-rights-to--ptn-20170906monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-third-quarter-fiscal-year-2017-results-teleconference-and-ptn-20170516monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-second-quarter-fiscal-year-2017-results-teleconference-an-ptn-20170209monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-announces-closing-of-license-agreement-with-amag-pharmaceuticals-for--ptn-20170203monthly0.5https://www.biopharmawatch.com/news/PTN/monday-january-9-8-a-m-amag-pharmaceuticals-and-palatin-technologies-enter-into-exclusive--ptn-20170109monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-announces-proposed-public-offering-of-common-stock-and-warrants-cranb-ptn-20161130monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-first-quarter-fiscal-year-2017-results-teleconference-and-ptn-20161115monthly0.5https://www.biopharmawatch.com/news/PTN/for-immediate-release-ptn-20161101monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-fourth-quarter-and-fiscal-year-2016-results-cranbury-nj-x-ptn-20160920monthly0.5https://www.biopharmawatch.com/news/PTN/for-immediate-release-ptn-20160801monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-ptn-20160517monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-second-quarter-fiscal-year-2016-results-teleconference-an-ptn-20160216monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-first-quarter-fiscal-year-2016-results-teleconference-and-ptn-20151112monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-fourth-quarter-and-fiscal-year-end-2015-results-cranbury--ptn-20150921monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-ptn-20150706monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-ptn-20150513monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-ptn-20150213monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-completes-20-million-equity-and-10-million-debt-financings-cranbury-nj-and-farming-ptn-20141224monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-ptn-20141118monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-ptn-20140909monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-ptn-20140903monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-ptn-20140513monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-ptn-20140218monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-ptn-20131114monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-ptn-20130930monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-ptn-20130514monthly0.5https://www.biopharmawatch.com/news/PTN/for-u-s-media-palatin-technologies-presents-positive-data-for-bremelanotide-in-female-sexu-ptn-20130301monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-ptn-20130214monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-november-2012-carl-spana-ph-d-president-ceo-stephen-t-wills-cpa-mst-c-ptn-20121115monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-first-quarter-fiscal-year-2013-results-teleconference-and-ptn-20121114monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-fourth-quarter-and-fiscal-year-end-2012-results-cranbury--ptn-20120911monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-july-2-2012-at-4-30-p-m-et-palatin-technologies-inc-announces-pricing-of-35-mi-ptn-20120702monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-ptn-20120619monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-ptn-20120514monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-ptn-20120215monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-ptn-20111115monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-ptn-20110922monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-ptn-20110623monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-and-subsidiary-consolidated-balance-sheets-unaudited-ptn-20110526monthly0.5https://www.biopharmawatch.com/news/PTN/press-release-ex99-htm-ptn-20110516monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-announces-pricing-of-public-offering-of-common-stock-and-warrants-ptn-20110224monthly0.5https://www.biopharmawatch.com/news/PTN/dated-february-4-2011-ex99-htm-for-release-february-4-2011-at-4-05-p-m-et-palatin-technolo-ptn-20110204monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-december-2-2010-at-4-00-p-m-et-palatin-technologies-receives-non-compliance-le-ptn-20101202monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-ptn-20101115monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-ptn-20100927monthly0.5https://www.biopharmawatch.com/news/PTN/presentation-on-september-14-2010-ptn-20100914monthly0.5https://www.biopharmawatch.com/news/PTN/press-release-ex99-1-htm-ptn-20100625monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-reports-third-quarter-fiscal-year-2010-results-teleconference-and-ptn-20100513monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-raise-2-6-million-dollars-in-registered-direct-offering-cranbu-ptn-20100224monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-ptn-20100216monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-ptn-20091116monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-september-29-2009-at-7-30-a-m-et-palatin-technologies-to-receive-5-million-fro-ptn-20090929monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-ptn-20090908monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-to-raise-3-1-ptn-20090812monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-ptn-20090515monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-march-5-2009-at-7-30-a-m-et-palatin-technologies-listing-compliance-plan-accep-ptn-20090305monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-february-17-2009-at-7-30-a-m-et-palatin-technologies-inc-reports-fiscal-year-2-ptn-20090217monthly0.5https://www.biopharmawatch.com/news/PTN/press-release-dated-ptn-20081230monthly0.5https://www.biopharmawatch.com/news/PTN/press-release-dated-ptn-20081209monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-september-30-2008-at-7-30-a-m-et-palatin-technologies-inc-reports-fourth-quart-ptn-20080930monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-july-1-2008-at-7-30-a-m-et-palatin-technologies-announces-amendment-expanding--ptn-20080701monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-may-13-2008-at-7-30-a-m-et-palatin-technologies-announces-new-strategic-object-ptn-20080513monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-ptn-20080211monthly0.5https://www.biopharmawatch.com/news/PTN/dated-january-22-2008-for-release-january-22-2008-at-7-30-a-m-et-palatin-technologies-anno-ptn-20080122monthly0.5https://www.biopharmawatch.com/news/PTN/for-release-november-9-2007-at-7-30-a-m-et-palatin-technologies-inc-reports-fiscal-year-20-ptn-20071109monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-press-release-dated-ptn-20070926monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-press-release-dated-ptn-20070918monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-press-release-dated-ptn-20070910monthly0.5https://www.biopharmawatch.com/news/PTN/dated-august-30-2007-n-e-w-s-r-e-l-e-a-s-e-ptn-20070830monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-press-release-dated-ptn-20070509monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-press-release-dated-ptn-20070131monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-press-release-dated-ptn-20070213monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-press-release-dated-ptn-20070209monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-press-release-dated-ptn-20061110monthly0.5https://www.biopharmawatch.com/news/PTN/corporate-presentation-corporate-presentation-ptn-20061106monthly0.5https://www.biopharmawatch.com/news/PTN/dated-september-13-2006-palatin-technologies-inc-press-release-dated-ptn-20060913monthly0.5https://www.biopharmawatch.com/news/PTN/dated-may-9-2006-palatin-technologies-inc-press-release-dated-ptn-20060509monthly0.5https://www.biopharmawatch.com/news/PTN/dated-april-17-2006-palatin-technologies-inc-press-release-dated-ptn-20060417monthly0.5https://www.biopharmawatch.com/news/PTN/dated-april-12-2006-palatin-technologies-inc-press-release-dated-ptn-20060412monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-press-release-dated-ptn-20051202monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-press-release-dated-semptember-20-2005-for-release-semptember-20--ptn-20050920monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-press-release-dated-ptn-20050623monthly0.5https://www.biopharmawatch.com/news/PTN/palatin-technologies-inc-press-release-dated-ptn-20050509monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-positive-phase-1-data-including-partial-response-demonstra-ktta-20251120monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-activation-of-clinical-trial-sites-in-south-korea-for-phas-ktta-20250916monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-pricing-of-5-million-public-offering-miami-fl-globe-newswi-ktta-20250506monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-5-million-private-placement-priced-at-the-market-under-nas-ktta-20240926monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-positive-initial-safety-tolerability-pharmacokinetic-pk-an-ktta-20240926monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-corp-announces-final-results-of-tender-offer-purchases-all-5-323-451-ktta-20230914monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-intention-to-commence-a-4-0-million-tender-offer-for-its-c-ktta-20230720monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-announces-comprehensive-settlement-agreement-with-the-camac-group-ktta-20221212monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-acquires-allomek-therapeutics-expands-cns-product-portfolio-with-add-ktta-20221012monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-acquires-alpha-5-integrin-llc-alpha-5-is-a-potentially-first-in-clas-ktta-20220622monthly0.5https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-corp-announces-pricing-of-a-30-4-million-private-placement-priced-at-ktta-20211124monthly0.5https://www.biopharmawatch.com/news/PLSM/pulsenmore-announces-full-year-2025-financial-results-and-webcast-management-to-host-confe-plsm-20260330monthly0.5https://www.biopharmawatch.com/news/PLSM/pulsenmore-builds-u-s-momentum-with-another-commercial-engagement-following-fda-clearance-plsm-20260209monthly0.5https://www.biopharmawatch.com/news/PLSM/pulsenmore-announces-first-commercial-engagement-with-a-leading-u-s-based-medical-center-plsm-20260202monthly0.5https://www.biopharmawatch.com/news/PLSM/pulsenmore-and-clalit-health-services-launch-first-at-home-follicular-monitoring-service-f-plsm-20260126monthly0.5https://www.biopharmawatch.com/news/PLSM/pulsenmore-to-commence-trading-on-nasdaq-as-it-expands-fda-authorized-home-prenatal-ultras-plsm-20260121monthly0.5https://www.biopharmawatch.com/news/FEMY/confidentail-nasdaq-femy-1-corporate-presentation-may-2026-2026-femasys-inc-redefining-wom-femy-20260513monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-announces-financial-results-for-quarter-ended-femy-20260508monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-appoints-john-canning-as-chief-operating-officer-to-drive-operational-execution-an-femy-20260401monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-secures-u-s-fda-clearance-for-next-generation-femvue-diagnostic-device-innovative--femy-20251218monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-announces-third-quarter-financial-results-for-2025-fda-approval-to-advance-final-f-femy-20251114monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-advances-global-growth-with-second-partner-order-for-fembloc-in-europe-continued-r-femy-20251106monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-secures-fda-approval-to-advance-final-fembloc-trial-phase-and-12-million-financing-femy-20251103monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-secures-uk-regulatory-approval-of-fembloc-permanent-birth-control-advances-europea-femy-20250820monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-announces-second-quarter-financial-results-for-2025-continued-progress-on-regulato-femy-20250808monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-secures-first-european-order-for-fembloc-marking-strategic-milestone-in-global-exp-femy-20250806monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-achieves-australian-and-new-zealand-regulatory-approvals-for-femaseed-for-first-li-femy-20250701monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-announces-historic-milestone-with-european-approval-of-fembloc-the-first-non-surgi-femy-20250625monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-names-new-chief-commercial-officer-to-drive-execution-and-global-growth-new-cco-to-femy-20250617monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-announces-financial-results-for-quarter-ended-femy-20250508monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-announces-financial-results-for-year-ended-femy-20250327monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-secures-distribution-partnerships-for-commercialization-of-fembloc-in-spain-compan-femy-20250318monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-announces-fembloc-delivery-system-approval-in-europe-a-significant-step-towards-fe-femy-20250313monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-announces-financial-results-for-quarter-ended-femy-20241112monthly0.5https://www.biopharmawatch.com/news/FEMY/investor-presentation-october-2024-nasdaq-femy-disrupting-convention-in-women-s-reproducti-femy-20241029monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-secures-strategic-distribution-partnerships-for-commercialization-of-femaseed-for--femy-20240911monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-inc-receives-u-s-fda-clearance-to-market-femchec-an-innovative-diagnostic-solution-femy-20240909monthly0.5https://www.biopharmawatch.com/news/FEMY/investor-presentation-august-2024-nasdaq-femy-disrupting-convention-in-women-s-reproductiv-femy-20240830monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-announces-ce-mark-and-canadian-approval-for-femvue-mini-a-fallopian-tube-assessmen-femy-20240829monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-announces-financial-results-for-quarter-ended-femy-20240808monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-receives-ce-mark-approval-for-four-of-its-women-s-health-products-clearing-the-pat-femy-20240620monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-announces-financial-results-for-quarter-ended-femy-20240509monthly0.5https://www.biopharmawatch.com/news/FEMY/investor-presentation-april-2024-nasdaq-femy-disrupting-convention-in-women-s-reproductive-femy-20240424monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-announces-financial-results-for-year-ended-femy-20240328monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-announces-positive-topline-data-from-pivotal-trial-for-its-fda-cleared-femaseed-fo-femy-20240320monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-completes-the-first-in-office-commercial-procedure-with-the-fda-cleared-femaseed-i-femy-20240306monthly0.5https://www.biopharmawatch.com/news/FEMY/disrupting-convention-in-women-s-health-through-continuous-innovation-february-2024-corpor-femy-20240228monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-inc-advances-commercial-readiness-with-appointment-of-richard-spector-to-new-posit-femy-20240206monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-inc-completes-enrollment-of-femaseed-pivotal-trial-in-support-of-commercial-launch-femy-20231128monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-inc-secures-additional-financing-with-strategic-investment-from-investors-led-by-p-femy-20231115monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-inc-announces-financial-results-for-the-third-quarter-ended-femy-20231114monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-inc-regains-compliance-with-nasdaq-listing-requirements-atlanta-femy-20231011monthly0.5https://www.biopharmawatch.com/news/FEMY/disrupting-convention-in-women-s-health-through-continuous-innovation-september-2023-corpo-femy-20230927monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-inc-announces-financial-results-for-the-second-quarter-ended-femy-20230810monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-initiates-enrollment-in-pivotal-trial-of-its-permanent-birth-control-candidate-fem-femy-20230803monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-announces-notice-of-allowance-for-new-u-s-patent-application-covering-use-of-fembl-femy-20230727monthly0.5https://www.biopharmawatch.com/news/FEMY/disrupting-convention-in-women-s-health-through-continuous-innovation-june-2023-corporate--femy-20230626monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-inc-replaces-two-board-members-with-seasoned-industry-leaders-in-the-life-sciences-femy-20230615monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-femcath-intrauterine-catheter-receives-product-approval-in-canada-femcath-is-the-f-femy-20230608monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-inc-announces-financial-results-for-the-first-quarter-ended-femy-20230511monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-femcerv-endocervical-tissue-sampler-for-cervical-cancer-diagnosis-receives-product-femy-20230503monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-announces-3-9-million-registered-direct-offering-priced-at-the-market-under-nasdaq-femy-20230419monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-femaseed-localized-directional-insemination-for-infertility-receives-product-appro-femy-20230418monthly0.5https://www.biopharmawatch.com/news/FEMY/disrupting-convention-in-women-s-health-through-continuous-innovation-march-2023-corporate-femy-20230331monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-inc-announces-financial-results-for-the-year-ended-femy-20230330monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-inc-announces-commercial-availability-of-its-femcath-intrauterine-device-femcath-i-femy-20221219monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-inc-announces-financial-results-for-the-third-quarter-ended-femy-20221110monthly0.5https://www.biopharmawatch.com/news/FEMY/disrupting-convention-in-women-s-health-through-continuous-innovation-october-2022-corpora-femy-20221020monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-inc-announces-the-appointment-of-christine-thomas-as-senior-vice-president-of-regu-femy-20221012monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-inc-announces-enrollment-completion-for-stage-2-study-of-fembloc-for-permanent-bir-femy-20221006monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-inc-announces-the-commercial-availability-of-femcerv-for-cervical-cancer-screening-femy-20220929monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-inc-announces-financial-results-for-the-second-quarter-ended-femy-20220810monthly0.5https://www.biopharmawatch.com/news/FEMY/disrupting-convention-in-women-s-health-through-continuous-innovation-august-2022-corporat-femy-20220802monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-inc-announces-financial-results-for-the-first-quarter-ended-femy-20220511monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-inc-announces-financial-results-for-the-year-ended-femy-20220324monthly0.5https://www.biopharmawatch.com/news/FEMY/disrupting-convention-in-women-s-health-through-continuous-innovation-february-2022-corpor-femy-20220228monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-inc-announces-the-appointment-of-dov-elefant-to-new-position-of-chief-financial-of-femy-20220224monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-inc-announces-the-appointment-of-wendy-perrow-transformational-biotech-entrepreneu-femy-20220120monthly0.5https://www.biopharmawatch.com/news/FEMY/disrupting-convention-in-women-s-health-through-continuous-innovation-january-2022-corpora-femy-20220105monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-inc-announces-financial-results-for-the-third-quarter-of-2021-up-to-792-patient-pi-femy-20211110monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-inc-to-join-the-russell-microcap-index-atlanta-femy-20210920monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-inc-announces-the-appointment-of-edward-evantash-m-d-as-chief-medical-officer-indu-femy-20210901monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-inc-announces-financial-results-for-the-second-quarter-of-2021-completed-initial-p-femy-20210811monthly0.5https://www.biopharmawatch.com/news/FEMY/femasys-inc-announces-first-patient-treated-in-pivotal-trial-for-femaseed-first-in-class-i-femy-20210720monthly0.5https://www.biopharmawatch.com/news/FEMY/transforming-women-s-healthcare-2021-femasys-inc-corporate-presentationjuly-2021-forward-l-femy-20210713monthly0.5https://www.biopharmawatch.com/news/HBIO/nasdaq-hbio-harvard-bioscience-investor-overview-may-2026-hbio-20260512monthly0.5https://www.biopharmawatch.com/news/HBIO/nasdaq-hbio-harvard-bioscience-investor-overview-march-202-6-hbio-20260317monthly0.5https://www.biopharmawatch.com/news/HBIO/hbio-confidential-1-nasdaq-hbio-hbio-investor-overview-january-202-6-hbio-20260112monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-appoints-john-duke-to-board-of-directors-hbio-20250602monthly0.5https://www.biopharmawatch.com/news/HBIO/jim-green-chairman-president-ceo-january-5-2024-hbio-investor-overview-enabling-discovery--hbio-20240105monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-becomes-pure-play-developer-manufacturer-and-marketer-of-tools-for-life-hbio-20131101monthly0.5https://www.biopharmawatch.com/news/HBIO/copyright-harvard-bioscience-2012-2-safe-harbor-statement-this-presentation-contains-forwa-hbio-20120808monthly0.5https://www.biopharmawatch.com/news/HBIO/excerpts-from-annual-report-dear-fellow-shareholders-2011-was-a-challenging-year-for-hbio--hbio-20120416monthly0.5https://www.biopharmawatch.com/news/HBIO/excerpts-from-annual-report-dear-fellow-shareholders-2010-was-a-landmark-year-for-hbio-wit-hbio-20110415monthly0.5https://www.biopharmawatch.com/news/HBIO/dear-fellow-shareholders-despite-the-tough-economic-conditions-of-2009-revenues-were-up-3--hbio-20100423monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-2009-hbio-20090514monthly0.5https://www.biopharmawatch.com/news/HBIO/david-green-president-dgreen-harvardbioscience-com-tel-508-893-8999-fax-508-429-8478-chane-hbio-20090430monthly0.5https://www.biopharmawatch.com/news/HBIO/david-green-chane-graziano-tom-mcnaughton-president-ceo-cfo-dgreen-harvardbioscience-com-c-hbio-20090226monthly0.5https://www.biopharmawatch.com/news/HBIO/david-green-president-dgreen-harvardbioscience-com-tel-508-893-8999-fax-508-429-8478-chane-hbio-20081105monthly0.5https://www.biopharmawatch.com/news/HBIO/unaudited-pro-forma-financial-information-the-following-unaudited-pro-forma-financial-info-hbio-20081006monthly0.5https://www.biopharmawatch.com/news/HBIO/david-green-president-dgreen-harvardbioscience-com-tel-508-893-8999-fax-508-429-8478-chane-hbio-20080811monthly0.5https://www.biopharmawatch.com/news/HBIO/david-green-president-dgreen-harvardbioscience-com-tel-508-893-8999-fax-508-429-8478-chane-hbio-20080501monthly0.5https://www.biopharmawatch.com/news/HBIO/david-green-chane-graziano-president-ceo-dgreen-harvardbioscience-com-cgraziano-harvardbio-hbio-20080425monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-2008-hbio-20080408monthly0.5https://www.biopharmawatch.com/news/HBIO/dear-fellow-shareholders-two-thousand-seven-was-another-year-of-solid-performance-for-harv-hbio-20080409monthly0.5https://www.biopharmawatch.com/news/HBIO/david-green-chane-graziano-bryce-chicoyne-president-ceo-cfo-dgreen-harvardbioscience-com-c-hbio-20080228monthly0.5https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-inc-adopts-shareholder-rights-plan-holliston-massachusetts-business-wir-hbio-20080206monthly0.5https://www.biopharmawatch.com/news/HBIO/pro-forma-financial-information-unaudited-pro-forma-financial-information-the-following-un-hbio-20071206monthly0.5https://www.biopharmawatch.com/news/HBIO/david-green-president-dgreen-harvardbioscience-com-tel-508-893-8999-fax-508-429-8478-chane-hbio-20071101monthly0.5https://www.biopharmawatch.com/news/HBIO/bryce-chicoyne-chief-financial-officer-bchicoyne-harvardbioscience-com-harvard-bioscience--hbio-20071011monthly0.5https://www.biopharmawatch.com/news/MODD/modular-medical-regains-compliance-with-nasdaq-minimum-bid-price-requirement-san-diego-ca--modd-20260416monthly0.5https://www.biopharmawatch.com/news/MODD/modular-medical-announces-1-for-30-reverse-stock-split-san-diego-ca-accesswire-modd-20260326monthly0.5https://www.biopharmawatch.com/news/MODD/modular-medical-announces-12-0-million-public-offering-priced-at-a-premium-to-market-san-d-modd-20260303monthly0.5https://www.biopharmawatch.com/news/MODD/modular-medical-announces-proposed-public-offering-san-diego-ca-accesswire-modd-20251209monthly0.5https://www.biopharmawatch.com/news/MODD/modular-medical-appoints-industry-veteran-jeff-goldberg-to-board-of-directors-san-diego-ca-modd-20250528monthly0.5https://www.biopharmawatch.com/news/MODD/modular-medical-announces-proposed-public-offering-san-diego-ca-accesswire-modd-20241121monthly0.5https://www.biopharmawatch.com/news/MODD/modular-medical-announces-fda-clearance-of-the-modd1-insulin-pump-modd1-is-a-patch-pump-fo-modd-20240904monthly0.5https://www.biopharmawatch.com/news/MODD/modular-medical-announces-proposed-public-offering-san-diego-modd-20240215monthly0.5https://www.biopharmawatch.com/news/MODD/modular-medical-announces-510-k-submission-of-modd1-insulin-pump-san-diego-ca-accesswire-modd-20240119monthly0.5https://www.biopharmawatch.com/news/MODD/investor-presentation-nasdaq-modd-2-forward-looking-statements-other-disclaimers-this-pres-modd-20231226monthly0.5https://www.biopharmawatch.com/news/MODD/modular-medical-announces-diabetes-industry-veteran-duane-desisto-will-join-the-board-of-d-modd-20230706monthly0.5https://www.biopharmawatch.com/news/MODD/modular-medical-announces-pricing-of-upsized-9-4-million-public-offering-san-diego-ca-acce-modd-20230516monthly0.5https://www.biopharmawatch.com/news/MODD/modular-medical-appoints-kevin-schmid-as-chief-operating-officer-schmid-brings-40-years-of-modd-20220726monthly0.5https://www.biopharmawatch.com/news/MODD/investor-presentation-nasdaq-modd-2-forward-looking-statements-other-disclaimers-this-pres-modd-20220613monthly0.5https://www.biopharmawatch.com/news/MODD/modular-medical-announces-8-million-registered-direct-offering-san-diego-ca-accesswire-modd-20220503monthly0.5https://www.biopharmawatch.com/news/MODD/modular-medical-appoints-james-jeb-besser-as-chief-executive-officer-lynn-vos-to-remain-on-modd-20220224monthly0.5https://www.biopharmawatch.com/news/MODD/modular-medical-investor-presentation-nasdaq-modd-forward-looking-statements-other-disclai-modd-20220214monthly0.5https://www.biopharmawatch.com/news/MODD/modular-medical-announces-pricing-of-15-million-public-offering-and-uplisting-to-the-nasda-modd-20220210monthly0.5https://www.biopharmawatch.com/news/MODD/steven-g-felsher-and-philip-b-sheibley-appointed-to-board-of-directors-of-modular-medical--modd-20211129monthly0.5https://www.biopharmawatch.com/news/MODD/modular-medical-inc-announces-reverse-stock-split-in-connection-with-application-for-uplis-modd-20211126monthly0.5https://www.biopharmawatch.com/news/MODD/investor-presentation-otcqb-modd-forward-looking-statements-other-disclaimers-this-summary-modd-20210930monthly0.5https://www.biopharmawatch.com/news/MODD/modular-medical-expands-executive-team-with-appointment-of-lynn-o-connor-vos-as-new-ceo-o--modd-20210816monthly0.5https://www.biopharmawatch.com/news/MODD/modular-medical-announces-financing-modd-20210512monthly0.5https://www.biopharmawatch.com/news/MODD/forward-looking-statements-other-disclaimers-modd-20210325monthly0.5https://www.biopharmawatch.com/news/MODD/common-stock-purchase-agreement-by-and-among-modular-medical-inc-and-modd-20181119monthly0.5https://www.biopharmawatch.com/news/MODD/lichter-yu-and-associates-inc-certified-public-accountants-21031-ventura-blvd-suite-316-wo-modd-20170728monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-reports-fiscal-year-2026-third-quarter-financial-results-and-provides-corporate-u-vtgn-20260212monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-reports-fiscal-year-2026-second-quarter-financial-results-and-provides-corporate--vtgn-20251113monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-completes-palisade-3-phase-3-public-speaking-challenge-study-for-the-acute-treatm-vtgn-20251103monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-appoints-paul-edick-to-its-board-of-directors-mr-edick-brings-extensive-industry--vtgn-20251029monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-reports-fiscal-year-2026-first-quarter-financial-results-and-corporate-update-top-vtgn-20250807monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-appoints-elissa-cote-as-chief-corporate-development-officer-accomplished-biopharm-vtgn-20250625monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-reports-fiscal-year-2025-financial-results-and-provides-corporate-update-topline--vtgn-20250617monthly0.5https://www.biopharmawatch.com/news/VTGN/document-vistagen-on-track-to-deliver-topline-data-from-fasedienol-palisade-3-phase-3-tria-vtgn-20250602monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagencorporatepr-nasdaq-vtgn-pioneering-neuroscience-with-nose-to-brain-neurocircuitry-vtgn-20250303monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-reports-fiscal-year-2025-third-quarter-financial-results-and-corporate-update-fas-vtgn-20250213monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-receives-u-s-patent-for-av-101-to-treat-neuropathic-pain-vtgn-20250205monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-announces-positive-results-from-exploratory-phase-2a-study-of-ph284-in-cancer-cac-vtgn-20250114monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-reports-fiscal-year-2025-second-quarter-financial-results-and-corporate-update-fa-vtgn-20241107monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-reports-fiscal-year-2025-first-quarter-financial-results-and-corporate-update-pal-vtgn-20240813monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-reports-fiscal-year-2024-financial-results-and-provides-corporate-update-registra-vtgn-20240611monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-reports-fiscal-year-2022-first-quarter-financial-results-and-provide-vtgn-20210812monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-announces-appointment-of-maggie-fitzpatrick-to-its-board-of-director-vtgn-20210722monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-announces-appointment-of-mary-l-rotunno-to-its-board-of-directors-ms-vtgn-20210707monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-reports-fiscal-year-2021-financial-results-and-provides-corporate-up-vtgn-20210629monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-set-to-join-the-russell-2000-xae-index-south-san-francisco-calif-x20-vtgn-20210616monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-initiates-palisade-phase-3-trial-of-ph94b-in-social-anxiety-disorder-vtgn-20210526monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-announces-appointment-of-ann-cunningham-as-chief-commercial-officer--vtgn-20210504monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-announces-appointment-of-joanne-curley-ph-d-to-its-board-of-director-vtgn-20210427monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-reports-fiscal-2021-third-quarter-financial-results-and-provides-upd-vtgn-20210211monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-regains-full-compliance-with-nasdaq-listing-requirements-vtgn-20210106monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-expands-r-d-team-with-appointment-of-louis-monti-m-d-ph-d-pioneer-in-vtgn-20201201monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-reports-fiscal-2021-second-quarter-financial-results-and-provides-hi-vtgn-20201112monthly0.5https://www.biopharmawatch.com/news/VTGN/virtual-annual-meeting-of-stockholders-closing-remarks-from-shawn-k-singh-jd-chief-executi-vtgn-20200918monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-reports-fiscal-2021-first-quarter-financial-results-and-highlights-c-vtgn-20200813monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-announces-pricing-of-12-5-million-underwritten-public-offering-of-co-vtgn-20200802monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-announces-positive-meeting-with-fda-regarding-pivotal-phase-3-study--vtgn-20200723monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-reports-fiscal-year-2020-results-and-provides-cns-pipeline-update-vi-vtgn-20200629monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-and-everinsight-therapeutics-enter-strategic-collaboration-to-develo-vtgn-20200625monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-and-nuformix-announce-agreement-to-develop-novel-patentable-cocrystalline-forms-o-vtgn-20200527monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-submits-ph94b-phase-2a-study-protocol-for-treatment-of-adjustment-disorder-with-a-vtgn-20200518monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-expands-ph94b-clinical-development-to-include-adjustment-disorder-related-to-covi-vtgn-20200428monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-announces-common-stock-purchase-agreement-for-up-to-10-25-million-vtgn-20200325monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-announces-positive-results-of-newly-published-exploratory-phase-2a-study-of-ph10--vtgn-20200220monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-reports-fiscal-2020-third-quarter-financial-results-and-provides-cns-vtgn-20200213monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-receives-fda-clearance-of-ind-for-phase-2-clinical-study-of-av-101-a-vtgn-20200130monthly0.5https://www.biopharmawatch.com/news/VTGN/u-s-fda-grants-vistagen-therapeutics-fast-track-designation-for-ph94b-for-treatment-of-soc-vtgn-20191210monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-reports-topline-phase-2-results-for-av-101-as-an-adjunctive-treatment-of-major-de-vtgn-20191114monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-reports-fiscal-2020-second-quarter-financial-results-and-provides-pi-vtgn-20191107monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-expands-european-patent-protection-for-av-101-for-treatment-of-depre-vtgn-20191028monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-reports-fiscal-2020-first-quarter-financial-results-vtgn-20190813monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-announces-uspto-grant-of-patent-for-treatment-of-depression-with-fas-vtgn-20190723monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-announces-positive-preclinical-data-supporting-av-101-s-potential-for-treating-le-vtgn-20190620monthly0.5https://www.biopharmawatch.com/news/VTGN/positive-pilot-phase-3-data-position-vistagen-s-ph94b-neuroactive-nasal-spray-for-pivotal--vtgn-20190401monthly0.5https://www.biopharmawatch.com/news/VTGN/corporate-presentation-untitled-document-vtgn-20190314monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-receives-notice-of-allowance-for-u-s-patent-for-treatment-of-depress-vtgn-20190213monthly0.5https://www.biopharmawatch.com/news/VTGN/av-101-stimulates-the-formation-of-new-brain-cells-in-nonclinical-studies-vtgn-20190131monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-appoints-pharmaceutical-industry-veteran-ann-cunningham-to-its-board-vtgn-20190115monthly0.5https://www.biopharmawatch.com/news/VTGN/presentation-untitled-document-vtgn-20190111monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-receives-notices-of-allowance-in-australia-and-japan-for-av-101-pate-vtgn-20181112monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-reports-fiscal-2019-second-quarter-financial-results-south-san-franc-vtgn-20181029monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-acquires-worldwide-rights-to-develop-and-commercialize-ph10-a-first--vtgn-20181025monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-receives-fda-fast-track-designation-for-development-of-av-101-as-a-n-vtgn-20181003monthly0.5https://www.biopharmawatch.com/news/VTGN/1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-28-29-vtgn-20180918monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-acquires-worldwide-license-of-phase-3-ready-cns-drug-candidate-from--vtgn-20180913monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-and-baylor-college-of-medicine-collaborate-on-first-step-study-to-te-vtgn-20180813monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-reports-fiscal-year-2018-financial-results-and-provides-year-to-date-vtgn-20180626monthly0.5https://www.biopharmawatch.com/news/VTGN/blueprint-vistagen-therapeutics-issued-two-key-u-s-patents-for-treatment-of-depression-wit-vtgn-20180613monthly0.5https://www.biopharmawatch.com/news/VTGN/secconnect-com-vistagen-therapeutics-receives-notice-of-allowance-for-japanese-patent-for--vtgn-20180611monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-receives-notice-of-allowance-of-u-s-patent-for-treatment-of-osteoart-vtgn-20180523monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-receives-notice-of-allowance-for-japanese-patent-regarding-methods-o-vtgn-20180502monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-receives-european-patent-regarding-methods-of-production-for-av-101--vtgn-20180410monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-initiates-phase-2-study-of-av-101-for-major-depressive-disorder-sout-vtgn-20180405monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-receives-a-notice-of-allowance-for-another-key-u-s-patent-covering-o-vtgn-20180319monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-receives-notice-of-allowance-for-a-key-u-s-patent-covering-treatment-vtgn-20180307monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-reports-third-quarter-fiscal-2018-financial-results-south-san-franci-vtgn-20180212monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-issues-letter-to-stockholders-as-company-prepares-to-initiate-av-101-vtgn-20180129monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-receives-fda-fast-track-designation-for-av-101-for-the-treatment-of--vtgn-20180103monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-announces-closing-of-15-000-000-underwritten-offering-of-common-stock-and-warrant-vtgn-20171213monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-expands-stem-cell-patent-portfolio-with-new-u-s-patent-on-methods-fo-vtgn-20171208monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-granted-u-s-patent-regarding-methods-of-production-for-av-101-south--vtgn-20171206monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-reports-second-fiscal-quarter-2018-financial-results-and-provides-bu-vtgn-20171109monthly0.5https://www.biopharmawatch.com/news/VTGN/secconnect-com-vistagen-therapeutics-receives-european-patent-for-av-101-for-treatment-of--vtgn-20171106monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-announces-fda-authorization-to-initiate-phase-2-study-of-av-101-for-major-depress-vtgn-20171026monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-receives-notice-of-allowance-from-u-s-patent-and-trademark-office-for-u-s-patent--vtgn-20170928monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-announces-pricing-of-underwritten-offering-of-common-stock-and-warrants-to-purcha-vtgn-20170831monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-reports-first-fiscal-quarter-2018-financial-results-and-provides-bus-vtgn-20170814monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-receives-notice-of-allowance-from-u-s-patent-and-trademark-office-for-u-s-patent--vtgn-20170808monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-reports-fiscal-2017-financial-results-and-provides-corporate-update--vtgn-20170629monthly0.5https://www.biopharmawatch.com/news/VTGN/blueprint-vistagen-therapeutics-largest-stockholder-signs-6-month-lock-up-agreement-south--vtgn-20170501monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-announces-peer-reviewed-publication-in-the-journal-of-pain-highlight-vtgn-20170427monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-receives-european-patent-office-notice-of-intention-to-grant-europea-vtgn-20170329monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-grants-exclusive-sublicense-of-cardiac-stem-cell-technologies-to-blu-vtgn-20161214monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-reports-second-quarter-2017-financial-results-and-business-update-so-vtgn-20161114monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-provides-business-outlook-and-sets-corporate-milestones-company-pois-vtgn-20160922monthly0.5https://www.biopharmawatch.com/news/VTGN/secconnect-com-vistagen-therapeutics-appoints-pharmaceutical-cns-drug-development-executiv-vtgn-20160620monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-announces-nasdaq-listing-and-pricing-of-10-0-million-public-offering-company-upli-vtgn-20160511monthly0.5https://www.biopharmawatch.com/news/VTGN/secconnect-com-vistagen-therapeutics-appoints-jerry-gin-ph-d-mba-to-its-board-of-directors-vtgn-20160330monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-bolsters-clinical-and-regulatory-advisory-board-with-appointments-of-vtgn-20160322monthly0.5https://www.biopharmawatch.com/news/VTGN/secconnect-com-2015-letter-to-stockholders-february-2016-dear-fellow-stockholders-2015-was-vtgn-20160211monthly0.5https://www.biopharmawatch.com/news/VTGN/secconnect-com-vistagen-announces-first-patient-dosed-in-nih-sponsored-phase-2a-study-of-o-vtgn-20151103monthly0.5https://www.biopharmawatch.com/news/VTGN/favorable-data-on-vistagen-therapeutics-av-101-for-major-depressive-disorder-published-in--vtgn-20150916monthly0.5https://www.biopharmawatch.com/news/VTGN/secconnect-com-vistagen-receives-fda-and-nih-clearance-to-initiate-nih-funded-phase-2-stud-vtgn-20150701monthly0.5https://www.biopharmawatch.com/news/VTGN/investor-presentation-ex99-1-htm-vtgn-20150316monthly0.5https://www.biopharmawatch.com/news/VTGN/dated-august-13-2014-ex99-1-htm-vistagen-announces-reverse-stock-split-vtgn-20140813monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-provides-update-on-36-million-strategic-financing-agreement-vtgn-20130628monthly0.5https://www.biopharmawatch.com/news/VTGN/ex-hibit-99-1-vistagen-announces-36-million-strategic-financing-agreement-proceeds-will-ac-vtgn-20130410monthly0.5https://www.biopharmawatch.com/news/VTGN/secconnect-com-vistagen-therapeutics-to-present-cardiosafe-3d-tm-developments-at-society-o-vtgn-20130311monthly0.5https://www.biopharmawatch.com/news/VTGN/secconnect-com-vistagen-therapeutics-enters-strategic-collaboration-with-celsis-ivt-to-fur-vtgn-20130304monthly0.5https://www.biopharmawatch.com/news/VTGN/secconnect-com-vistagen-ceo-issues-update-letter-to-stockholders-south-san-francisco-ca-ma-vtgn-20120514monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-updates-pipeline-of-stem-cell-technology-based-drug-rescue-candidates-company-ide-vtgn-20120216monthly0.5https://www.biopharmawatch.com/news/VTGN/secconnect-com-vistagen-therapeutics-and-synterys-sign-strategic-medicinal-chemistry-colla-vtgn-20111207monthly0.5https://www.biopharmawatch.com/news/VTGN/vistagen-therapeutics-and-university-health-network-toronto-extend-broad-stem-cell-allianc-vtgn-20111130monthly0.5https://www.biopharmawatch.com/news/BCTX/briapro-therapeutics-corp-condensed-interim-consolidated-financial-statements-for-the-thre-bctx-20260331monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-and-briapro-enter-into-asset-purchase-agreement-for-exclusive-soluble-cd80-licens-bctx-20260218monthly0.5https://www.biopharmawatch.com/news/BCTX/briapro-therapeutic-corp-condesed-interim-consolidated-financial-statements-for-the-three--bctx-20251229monthly0.5https://www.biopharmawatch.com/news/BCTX/briapro-therapeutic-corp-consolidated-financial-statements-for-the-period-ended-july-31-20-bctx-20251201monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-proposed-effective-date-of-share-consolidation-philadelphia-and-vancouv-bctx-20250821monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-announces-pricing-of-15-million-public-offering-philadelphia-and-van-bctx-20250715monthly0.5https://www.biopharmawatch.com/news/BCTX/briapro-therapeutic-corp-condesed-interim-consolidated-financial-statements-for-the-three--bctx-20250618monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-announces-pricing-of-13-8-million-public-offering-philadelphia-and-v-bctx-20250424monthly0.5https://www.biopharmawatch.com/news/BCTX/briapro-therapeutic-corp-condesed-interim-consolidated-financial-statements-for-the-three--bctx-20250312monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-announces-proposed-public-offering-of-common-shares-philadelphia-and-bctx-20250203monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-completion-of-15-1-share-consolidation-philadelphia-and-vancouver-briti-bctx-20250127monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-proposed-effective-date-of-share-consolidation-philadelphia-and-vancouv-bctx-20250103monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-rescheduling-of-its-annual-general-meeting-of-shareholders-to-bctx-20250103monthly0.5https://www.biopharmawatch.com/news/BCTX/briapro-therapeutic-corp-condesed-interim-consolidated-financial-statements-for-the-three--bctx-20241216monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-announces-proposed-public-offering-philadelphia-and-vancouver-britis-bctx-20241211monthly0.5https://www.biopharmawatch.com/news/BCTX/briapro-therapeutic-corp-consolidated-financial-statements-for-the-period-ended-july-31-20-bctx-20241101monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-announces-5-million-offering-priced-at-the-market-under-nasdaq-rules-bctx-20241001monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-reports-100-resolution-of-brain-metastasis-in-breast-cancer-patient-with-eye-bulg-bctx-20241001monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-announces-8-5-million-offering-priced-at-the-market-under-nasdaq-rul-bctx-20240911monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-presentation-at-the-2024-society-for-immunotherapy-of-cancer-sitc-annua-bctx-20240909monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-quadruples-progression-free-survival-pfs-in-patient-with-eye-bulging-metastatic-b-bctx-20240718monthly0.5https://www.biopharmawatch.com/news/BCTX/briapro-therapeutic-corp-condesed-interim-financial-statements-for-the-three-and-nine-mont-bctx-20240614monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-announces-pricing-of-5-0-million-registered-direct-offering-philadel-bctx-20240515monthly0.5https://www.biopharmawatch.com/news/BCTX/briapro-therapeutic-corp-condesed-interim-financial-statements-for-the-three-and-six-month-bctx-20240402monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-reports-unprecedented-preliminary-survival-and-clinical-benefit-in-antibody-drug--bctx-20231220monthly0.5https://www.biopharmawatch.com/news/BCTX/briapro-therapeutic-corp-condesed-interim-financial-statements-for-the-three-month-period--bctx-20231214monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-records-new-responder-with-remarkable-improvement-of-eye-bulging-metastatic-tumor-bctx-20231130monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-reports-unprecedented-anti-tumor-activity-of-its-next-generation-personalized-bre-bctx-20231103monthly0.5https://www.biopharmawatch.com/news/BCTX/briapro-therapeutic-corp-financial-statements-for-the-period-ended-july-31-2023-expressed--bctx-20231025monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-reports-benchmark-beating-patient-survival-and-clinical-benefit-in-advanced-metas-bctx-20230908monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-corp-announces-closing-of-plan-of-arrangement-spinning-out-briapro-t-bctx-20230831monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-receives-court-approval-for-the-share-arrangement-spinning-out-briapro-therapeuti-bctx-20230825monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-corp-announces-voting-results-from-special-meeting-shareholders-over-bctx-20230821monthly0.5https://www.biopharmawatch.com/news/BCTX/fda-approves-briacell-s-pivotal-registrational-study-design-in-advanced-metastatic-breast--bctx-20230627monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-enters-definitive-arrangement-agreement-for-the-spin-out-of-briapro-therapeutics--bctx-20230525monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-closes-4-million-strategic-investment-by-prevail-partners-llc-at-us-8-63-per-shar-bctx-20230519monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-4-million-strategic-investment-and-clinical-alliance-with-prevail-partn-bctx-20230515monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-presents-positive-data-demonstrating-survival-and-clinical-benefits-in-advanced-m-bctx-20230417monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-intention-to-spin-out-certain-pre-clinical-assets-into-a-newly-created--bctx-20230331monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-reports-positive-survival-data-in-advanced-metastatic-breast-cancer-9-of-11-women-bctx-20230223monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-corp-announces-results-of-shareholder-meeting-philadelphia-pa-and-va-bctx-20230209monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-ceo-letter-to-shareholders-positive-fda-feedback-on-our-pivotal-study-for-lead-cl-bctx-20230124monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-investigate-alleged-illegal-trading-of-public-securities-philadelphia-pa-and-v-bctx-20230123monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-positive-end-of-phase-ii-meeting-with-the-fda-for-bria-imt-combination--bctx-20230118monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-new-patent-issuance-bria-ots-ind-timing-guidance-and-additional-clinica-bctx-20230110monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-positive-clinical-and-quality-of-life-data-in-advanced-metastatic-breas-bctx-20221208monthly0.5https://www.biopharmawatch.com/news/BCTX/ipa-s-subsidiary-biostrand-and-briacell-announce-artificial-intelligence-collaboration-and-bctx-20221130monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-reports-positive-breast-cancer-efficacy-data-with-bria-imt-immunotherapy-treatmen-bctx-20221110monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-corp-condensed-consolidated-financial-statements-as-of-bctx-20221028monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-successful-completion-of-phase-i-portion-of-clinical-study-in-advanced--bctx-20221021monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-partners-with-caris-life-sciences-to-expand-patient-outreach-and-molecular-profil-bctx-20220914monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-secures-license-for-a-promising-novel-anti-cancer-agent-philadelphia-pa-and-vanco-bctx-20220804monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-partners-with-waisman-biomanufacturing-to-manufacture-and-supply-prostate-cancer--bctx-20220705monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-enters-research-agreement-to-identify-novel-targets-for-cancer-treatment-philadel-bctx-20220629monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-anti-cancer-technology-published-in-leading-cancer-drug-discovery-journal-anti-ca-bctx-20220624monthly0.5https://www.biopharmawatch.com/news/BCTX/condensed-interim-consolidated-financial-statements-for-the-three-and-nine-months-ended-bctx-20220613monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-adds-additional-clinical-sites-to-broaden-patient-access-and-further-boost-enroll-bctx-20220518monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-receives-fda-fast-track-approval-for-targeted-breast-cancer-immunotherapy-u-s-foo-bctx-20220413monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-presents-development-details-of-bria-ots-platform-technology-at-the-american-asso-bctx-20220412monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-advances-preparatory-work-for-new-bria-ots-breast-cancer-clinical-trial-bria-ots--bctx-20220407monthly0.5https://www.biopharmawatch.com/news/BCTX/condensed-interim-consolidated-financial-statements-for-the-three-and-six-months-ended-bctx-20220315monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-adds-two-clinical-trial-sites-to-accelerate-patient-enrollment-philadelphia-pa-an-bctx-20220228monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-appoints-leading-immunologist-dr-alexander-kharazi-to-its-scientific-advisory-boa-bctx-20220223monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-appoints-renowned-oncologist-giuseppe-del-priore-md-mph-as-chief-medical-officer--bctx-20220216monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-present-at-the-aacr-2022-provides-corporate-buyback-and-insider-buying-update--bctx-20220210monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-corp-announces-results-of-2022-annual-and-special-meeting-of-shareho-bctx-20220119monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-corp-notice-of-annual-general-and-special-meeting-and-management-inf-bctx-20220105monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-uplist-and-trade-on-the-toronto-stock-exchange-from-tsx-venture-exchange-under-bctx-20211229monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-insiders-intention-to-purchase-up-to-10-of-public-market-securities-ins-bctx-20211217monthly0.5https://www.biopharmawatch.com/news/BCTX/condensed-interim-consolidated-financial-statements-for-the-three-months-ended-bctx-20211215monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-summarizes-clinical-data-poster-presented-at-the-2021-san-antonio-breast-cancer-s-bctx-20211209monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-adds-mary-crowley-cancer-research-center-as-a-clinical-trial-site-for-its-phase-i-bctx-20211118monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-update-on-previously-announced-securities-buyback-program-and-participa-bctx-20211112monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-adds-pioneering-immunologist-and-cancer-immunotherapy-expert-suzanne-ostrand-rose-bctx-20211105monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-appoints-renowned-pharmaceutical-veteran-jane-gross-ph-d-to-its-board-of-director-bctx-20211102monthly0.5https://www.biopharmawatch.com/news/BCTX/consolidated-financial-statements-for-the-years-ended-bctx-20211029monthly0.5https://www.biopharmawatch.com/news/BCTX/october-is-breast-cancer-awareness-month-briacell-is-advancing-the-fight-with-its-immunoth-bctx-20211005monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-tsxv-acceptance-of-normal-course-issuer-bid-berkeley-calif-and-vancouve-bctx-20210922monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-securities-buyback-to-purchase-up-to-10-of-common-shares-and-up-to-10-o-bctx-20210909monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-appoints-marc-lustig-to-its-board-of-directors-berkeley-calif-and-va-bctx-20210901monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference-sep-bctx-20210823monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology--bctx-20210819monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-phase-i-iia-clinical-trial-combination-study-in-advanced-breast-cancer-patients-o-bctx-20210714monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-present-at-three-upcoming-investor-conferences-berkeley-calif-and-vancouver-br-bctx-20210712monthly0.5https://www.biopharmawatch.com/news/BCTX/condensed-interim-consolidated-financial-statements-for-the-three-and-nine-months-ended-bctx-20210630monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-expands-breast-cancer-platform-technology-into-prostate-melanoma-and-bctx-20210616monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-announces-proceeds-of-us-12-88-million-from-warrant-exercises-procee-bctx-20210610monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-hold-corporate-and-clinical-update-conference-call-wednesday-bctx-20210609monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-corp-announces-closing-of-us-27-2-million-private-placement-berkeley-bctx-20210607monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-corp-announces-us-27-2-million-private-placement-berkeley-calif-and--bctx-20210603monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-reports-12-0-months-overall-survival-benefit-in-advanced-breast-cancer-100-resolu-bctx-20210602monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-corp-announces-results-of-shareholder-meeting-berkeley-calif-and-van-bctx-20210519monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-to-participate-at-upcoming-conferences-and-appoints-senior-r-d-director-berkeley--bctx-20210511monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-investor-and-media-outreach-programs-berkeley-calif-and-vancouver-briti-bctx-20210415monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-closing-of-over-allotment-option-in-connection-with-u-s-public-offering-bctx-20210412monthly0.5https://www.biopharmawatch.com/news/BCTX/condensed-interim-consolidated-financial-statements-for-the-three-and-six-months-ended-bctx-20210401monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-therapeutics-to-present-at-the-american-association-for-cancer-research-annual-me-bctx-20210330monthly0.5https://www.biopharmawatch.com/news/BCTX/briacell-announces-pricing-of-us-25-million-public-offering-and-nasdaq-listing-berkeley-ca-bctx-20210223monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-reports-first-quarter-2026-financial-results-and-recent-corporate-up-howl-20260507monthly0.5https://www.biopharmawatch.com/news/HOWL/corporate-presentation-december-2025-1-2025-werewolf-therapeutics-2025-werewolf-therapeuti-howl-20251218monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-reports-second-quarter-2025-financial-results-and-provides-business--howl-20250814monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-reports-first-quarter-2025-financial-results-and-provides-business-u-howl-20250508monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-prov-howl-20250311monthly0.5https://www.biopharmawatch.com/news/HOWL/delivering-the-power-of-immunotherapy-corporate-presentation-november-2024-1-2024-werewolf-howl-20241112monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-u-howl-20241107monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-reports-second-quarter-2024-financial-results-and-provides-business--howl-20240808monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-highlights-initial-safety-and-efficacy-data-from-its-ongoing-phase-1-howl-20240625monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-to-present-data-from-ongoing-phase-1-1b-clinical-trial-of-wtx-124-as-howl-20240603monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-reports-first-quarter-2024-financial-results-and-provides-business-u-howl-20240503monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-prov-howl-20240307monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-provides-business-update-and-highlights-2024-strategic-outlook-prior-howl-20240108monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-reports-third-quarter-2023-financial-results-and-provides-business-u-howl-20231114monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-presents-preliminary-monotherapy-data-from-phase-1-1b-clinical-trial-howl-20231103monthly0.5https://www.biopharmawatch.com/news/HOWL/cautionary-statements-this-presentation-contains-forward-looking-statements-that-involve-s-howl-20230918monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-reports-second-quarter-2023-financial-results-and-provides-business--howl-20230810monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-reports-first-quarter-2023-financial-results-and-provides-business-u-howl-20230511monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-prov-howl-20230323monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-reports-third-quarter-2022-financial-results-and-provides-business-u-howl-20221110monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-reports-second-quarter-2022-financial-results-and-provides-business--howl-20220811monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-reports-first-quarter-2022-financial-results-and-provides-business-h-howl-20220510monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-reports-fourth-quarter-2021-and-full-year-2021-financial-results-and-howl-20220324monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-reports-third-quarter-2021-financial-results-and-business-update-cli-howl-20211110monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-reports-second-quarter-2021-financial-results-and-business-update-ca-howl-20210812monthly0.5https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-reports-first-quarter-2021-financial-results-recently-completed-upsi-howl-20210610monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-reports-fourth-quarter-and-full-year-2019-financial-results-fourth-q-nhtc-20200212monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-reports-third-quarter-2019-financial-results-repurchased-2-9-million-nhtc-20191101monthly0.5https://www.biopharmawatch.com/news/NHTC/notice-of-ratification-of-potentially-defective-corporate-acts-by-the-board-of-directors-o-nhtc-20191010monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-reports-second-quarter-2019-financial-results-revenue-of-23-4-millio-nhtc-20190807monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-reports-first-quarter-2019-financial-results-nhtc-20190507monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-reports-fourth-quarter-and-full-year-2018-financial-results-full-yea-nhtc-20190222monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-announces-fourth-quarter-and-full-year-2018-preliminary-revenue-esti-nhtc-20190117monthly0.5https://www.biopharmawatch.com/news/NHTC/exhibit-natural-health-trends-rejects-false-allegations-and-reiterates-commitment-to-ethic-nhtc-20190107monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-reports-third-quarter-2018-financial-results-total-revenue-increased-nhtc-20181030monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-reports-second-quarter-2018-financial-results-maintained-strong-gros-nhtc-20180801monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-issues-response-to-allegation-nhtc-20180720monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-announces-second-quarter-2018-preliminary-revenue-estimate-nhtc-20180712monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-reports-first-quarter-2018-financial-results-second-sequential-quart-nhtc-20180502monthly0.5https://www.biopharmawatch.com/news/NHTC/faruqi-faruqi-llp-benjamin-heikali-sbn-307466-10866-wilshire-boulevard-suite-1470-los-ange-nhtc-20180413monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-announces-first-quarter-2018-preliminary-revenue-estimate-nhtc-20180412monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-reports-fourth-quarter-and-full-year-2017-financial-results-first-se-nhtc-20180214monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-announces-fourth-quarter-and-full-year-2017-preliminary-revenue-esti-nhtc-20180116monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-reports-third-quarter-2017-financial-results-positive-sales-momentum-nhtc-20171101monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-announces-third-quarter-2017-preliminary-revenue-estimate-nhtc-20171013monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-reports-second-quarter-2017-financial-results-expanded-operating-inc-nhtc-20170802monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-announces-second-quarter-2017-preliminary-financial-results-nhtc-20170714monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-reports-first-quarter-2017-financial-results-expanded-operating-inco-nhtc-20170427monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-announces-first-quarter-2017-preliminary-revenue-estimate-nhtc-20170413monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-reports-fourth-quarter-and-full-year-2016-financial-results-record-q-nhtc-20170208monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-announces-fourth-quarter-and-full-year-2016-preliminary-financial-re-nhtc-20170117monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-reports-third-quarter-2016-financial-results-and-declares-special-ca-nhtc-20161025monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-announces-third-quarter-2016-reporting-date-and-preliminary-revenue--nhtc-20161013monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-reports-strong-second-quarter-2016-financial-results-revenue-increas-nhtc-20160727monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-to-report-second-quarter-2016-financial-results-on-july-27-th-and-an-nhtc-20160712monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-reports-strong-first-quarter-2016-financial-results-revenue-increase-nhtc-20160427monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-to-report-first-quarter-2016-financial-results-on-april-27-th-and-an-nhtc-20160412monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-reports-strong-fourth-quarter-and-full-year-2015-financial-results-f-nhtc-20160202monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-refutes-false-claims-company-takes-action-to-protect-market-integrit-nhtc-20160113monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-announces-fourth-quarter-2015-estimated-revenue-nhtc-20160111monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-reports-strong-third-quarter-2015-financial-results-record-quarterly-nhtc-20151027monthly0.5https://www.biopharmawatch.com/news/NHTC/exhibit-natural-health-trends-to-report-third-quarter-2015-financial-results-on-october-27-nhtc-20151013monthly0.5https://www.biopharmawatch.com/news/NHTC/investor-contact-scott-davidson-brett-maas-chief-financial-officer-managing-partner-natura-nhtc-20150728monthly0.5https://www.biopharmawatch.com/news/NHTC/investor-contact-scott-davidson-brett-maas-chief-financial-officer-managing-partner-natura-nhtc-20150714monthly0.5https://www.biopharmawatch.com/news/NHTC/investor-contact-scott-davidson-brett-maas-chief-financial-officer-managing-partner-natura-nhtc-20150505monthly0.5https://www.biopharmawatch.com/news/NHTC/investor-contact-scott-davidson-brett-maas-chief-financial-officer-managing-partner-natura-nhtc-20150303monthly0.5https://www.biopharmawatch.com/news/NHTC/investor-contact-scott-davidson-brett-maas-chief-financial-officer-managing-partner-natura-nhtc-20150212monthly0.5https://www.biopharmawatch.com/news/NHTC/investor-contact-scott-davidson-brett-maas-chief-financial-officer-managing-partner-natura-nhtc-20141105monthly0.5https://www.biopharmawatch.com/news/NHTC/investor-contact-scott-davidson-brett-maas-chief-financial-officer-managing-partner-natura-nhtc-20140730monthly0.5https://www.biopharmawatch.com/news/NHTC/investor-contact-scott-davidson-brett-maas-chief-financial-officer-managing-partner-natura-nhtc-20140507monthly0.5https://www.biopharmawatch.com/news/NHTC/investor-contact-scott-davidson-brett-maas-chief-financial-officer-managing-partner-natura-nhtc-20140307monthly0.5https://www.biopharmawatch.com/news/NHTC/investor-contact-scott-davidson-brett-maas-chief-financial-officer-managing-partner-natura-nhtc-20131106monthly0.5https://www.biopharmawatch.com/news/NHTC/investor-contact-scott-davidson-brett-maas-chief-financial-officer-managing-partner-natura-nhtc-20130806monthly0.5https://www.biopharmawatch.com/news/NHTC/investor-contact-scott-davidson-brett-maas-chief-financial-officer-managing-partner-natura-nhtc-20130508monthly0.5https://www.biopharmawatch.com/news/NHTC/investor-contact-scott-davidson-brett-maas-chief-financial-officer-managing-partner-natura-nhtc-20130312monthly0.5https://www.biopharmawatch.com/news/NHTC/investor-contact-scott-davidson-brett-maas-chief-financial-officer-managing-partner-natura-nhtc-20121113monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-corp-notified-of-non-compliance-with-nasdaq-independent-director-nhtc-20071119monthly0.5https://www.biopharmawatch.com/news/NHTC/there-be-any-sale-of-any-securities-in-any-jurisdiction-in-which-such-offer-solicitation-o-nhtc-20070509monthly0.5https://www.biopharmawatch.com/news/NHTC/chris-sharng-natural-health-trends-972-241-4080-chris-sharng-nhtglobal-com-nhtc-20070416monthly0.5https://www.biopharmawatch.com/news/NHTC/chris-sharng-natural-health-trends-972-241-4080-chris-sharng-nhtglobal-com-deanna-decker-p-nhtc-20070306monthly0.5https://www.biopharmawatch.com/news/NHTC/deanna-decker-padilla-spear-beardsley-212-752-8338-ddecker-psbpr-com-rick-anderson-padilla-nhtc-20070226monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-appoints-stephanie-s-hayano-president-and-ceo-will-serve-as-a-compan-nhtc-20060731monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-corp-complies-with-nasdaq-listing-requirements-dallas-business-wire-nhtc-20060623monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-corp-chris-sharng-evp-cfo-972-241-4080-for-immediate-release-natural-nhtc-20060526monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-notified-of-non-compliance-with-nasdaq-rule-friday-nhtc-20060421monthly0.5https://www.biopharmawatch.com/news/NHTC/d30501exv99w1-txt-press-release-natural-health-trends-corp-announces-third-quarter-and-nin-nhtc-20051115monthly0.5https://www.biopharmawatch.com/news/NHTC/graphic-omitted-michael-porter-president-investor-relations-porter-levay-rose-inc-linda-de-nhtc-20051018monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-corp-robert-h-hesse-interim-chief-executive-officer-972-241-4080-for-nhtc-20051006monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-corp-announces-fiscal-2004-results-net-sales-up-113-active-distribut-nhtc-20050323monthly0.5https://www.biopharmawatch.com/news/NHTC/natural-health-trends-corp-hires-richard-s-johnson-to-manage-its-entry-into-japan-dallas-b-nhtc-20041123monthly0.5https://www.biopharmawatch.com/news/NHTC/source-natural-health-trends-corp-natural-health-trends-corp-raises-approximately-17-milli-nhtc-20041008monthly0.5https://www.biopharmawatch.com/news/AEON/disrupting-a-3-5b-neurotoxin-market-dominated-by-a-single-brand-for-30-years-corporate-pre-aeon-20260514monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-inc-condensed-consolidated-statements-of-operations-and-comprehensive-loss--aeon-20260514monthly0.5https://www.biopharmawatch.com/news/AEON/complex-currently-approved-and-marketed-for-cosmetic-indications-by-evolus-inc-under-the-n-aeon-20260403monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-inc-consolidated-statements-of-operations-and-comprehensive-loss-income-in--aeon-20260330monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-reports-bpd-type-2a-meeting-with-fda-and-shareholder-approval-of-the-novemb-aeon-20260121monthly0.5https://www.biopharmawatch.com/news/AEON/bringing-biosimilar-competition-to-a-u-s-therapeutic-neurotoxin-market-still-dominated-by--aeon-20260112monthly0.5https://www.biopharmawatch.com/news/AEON/relevant-materials-and-any-other-documents-filed-by-the-company-with-the-sec-may-be-obtain-aeon-20251215monthly0.5https://www.biopharmawatch.com/news/AEON/advancing-a-proven-molecule-toward-full-label-biosimilar-approval-fresh-data-new-capital-s-aeon-20251204monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-inc-condensed-consolidated-statements-of-operations-and-comprehensive-loss--aeon-20251114monthly0.5https://www.biopharmawatch.com/news/AEON/accelerated-access-to-the-3b-u-s-neurotoxin-therapeutic-market-via-biosimilarity-corporate-aeon-20250908monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-inc-condensed-consolidated-statements-of-operations-and-comprehensive-loss--aeon-20250812monthly0.5https://www.biopharmawatch.com/news/AEON/corporate-presentation-aegis-capital-healthcare-conference-may-2025-prabotulinumtoxina-red-aeon-20250520monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-inc-condensed-consolidated-statements-of-operations-and-comprehensive-incom-aeon-20250514monthly0.5https://www.biopharmawatch.com/news/AEON/forward-looking-statements-certain-statements-in-this-press-release-may-be-considered-forw-aeon-20250327monthly0.5https://www.biopharmawatch.com/news/AEON/closing-of-the-merger-the-accompanying-financial-statements-include-successor-periods-for--aeon-20250324monthly0.5https://www.biopharmawatch.com/news/AEON/corporate-presentation-march-2025-prabotulinumtoxina-potential-biosimilar-for-therapeutic--aeon-20250310monthly0.5https://www.biopharmawatch.com/news/AEON/assumptions-prove-incorrect-actual-results-may-differ-significantly-from-those-anticipated-aeon-20250224monthly0.5https://www.biopharmawatch.com/news/AEON/built-a-highly-experienced-management-team-with-specific-experience-in-biopharmaceutical-a-aeon-20250207monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-inc-announces-pricing-of-approximately-20-0-million-underwritten-public-off-aeon-20250106monthly0.5https://www.biopharmawatch.com/news/AEON/unless-the-context-otherwise-requires-the-company-for-periods-prior-to-the-close-of-the-me-aeon-20241113monthly0.5https://www.biopharmawatch.com/news/AEON/corporate-presentation-october-2024-prabotulinumtoxina-potential-biosimilar-for-therapeuti-aeon-20241007monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-inc-condensed-consolidated-statements-of-operations-and-comprehensive-incom-aeon-20240812monthly0.5https://www.biopharmawatch.com/news/AEON/corporate-presentation-august-2024-prabotulinumtoxina-potential-biosimilar-for-therapeutic-aeon-20240806monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-inc-condensed-consolidated-statements-of-operations-and-comprehensive-loss--aeon-20240514monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-announces-preliminary-top-line-results-from-phase-2-interim-analysis-of-abp-aeon-20240503monthly0.5https://www.biopharmawatch.com/news/AEON/about-aeon-biopharma-aeon-is-a-clinical-stage-biopharmaceutical-company-focused-on-develop-aeon-20240329monthly0.5https://www.biopharmawatch.com/news/AEON/predecessor-periods-has-been-placed-in-the-consolidated-financial-statements-and-in-the-ta-aeon-20240329monthly0.5https://www.biopharmawatch.com/news/AEON/negatives-of-these-terms-or-variations-of-them-or-similar-terminology-such-forward-looking-aeon-20240319monthly0.5https://www.biopharmawatch.com/news/AEON/press-release-on-aeon-20231113monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-announces-topline-results-from-phase-2-trial-of-abp-450-prabotulinumtoxina--aeon-20231019monthly0.5https://www.biopharmawatch.com/news/AEON/index-to-financial-statements-table-of-contents-negativethickspace-aeon-biopharma-inc-nega-aeon-20230727monthly0.5https://www.biopharmawatch.com/news/AEON/corporate-presentation-july-2023-2-forward-looking-statements-this-presentation-includes-f-aeon-20230724monthly0.5https://www.biopharmawatch.com/news/AEON/priveterra-acquisition-corp-announces-authorization-to-list-on-nyse-upon-completion-of-bus-aeon-20230717monthly0.5https://www.biopharmawatch.com/news/AEON/priveterra-acquisition-corp-announces-intention-to-transfer-to-nyse-upon-completion-of-bus-aeon-20230711monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-and-priveterra-announce-arrangement-of-up-to-125-million-of-financing-in-co-aeon-20230630monthly0.5https://www.biopharmawatch.com/news/AEON/execution-version-priveterra-sponsor-llc-300-se-2nd-street-suite-600-fort-lauderdale-flori-aeon-20230629monthly0.5https://www.biopharmawatch.com/news/AEON/corporate-presentation-may-2023-2-disclaimer-about-this-presentation-this-investor-present-aeon-20230524monthly0.5https://www.biopharmawatch.com/news/AEON/kol-event-botulinum-toxin-and-migraine-prevention-aeon-20230224monthly0.5https://www.biopharmawatch.com/news/AEON/us-docs-138831380-2-aeon-biopharma-to-host-key-opinion-leader-webinar-on-past-present-and--aeon-20230214monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-and-priveterra-acquisition-corp-announce-additional-capital-commitment-from-aeon-20230110monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-and-priveterra-acquisition-corp-announce-filing-of-s-4-registration-stateme-aeon-20221227monthly0.5https://www.biopharmawatch.com/news/AEON/aeon-biopharma-to-become-publicly-listed-via-merger-with-priveterra-acquisition-corp-accel-aeon-20221213monthly0.5https://www.biopharmawatch.com/news/AEON/priveterra-acquisition-corp-receives-expected-notification-from-nasdaq-related-to-delayed--aeon-20210604monthly0.5https://www.biopharmawatch.com/news/AEON/priveterra-acquisition-corp-announces-the-separate-trading-of-its-common-stock-and-warrant-aeon-20210326monthly0.5https://www.biopharmawatch.com/news/AEON/priveterra-aeon-20210211monthly0.5https://www.biopharmawatch.com/news/AEON/priveterra-acquisition-corp-announces-pricing-of-upsized-240-million-initial-public-offeri-aeon-20210208monthly0.5https://www.biopharmawatch.com/news/VYNE/bringing-life-into-balance-yarrow-bioscience-overview-may-2026-2-disclaimers-the-informati-vyne-20260521monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-reports-2025-second-quarter-financial-results-and-provides-business-upda-vyne-20250814monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-reports-2025-first-quarter-financial-results-and-provides-business-updat-vyne-20250508monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-reports-2024-fourth-quarter-and-year-end-financial-results-and-provides--vyne-20250306monthly0.5https://www.biopharmawatch.com/news/VYNE/corporate-presentation-january-2025-forward-looking-statements-and-important-notes-this-pr-vyne-20250113monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-reports-positive-top-line-phase-1a-mad-data-for-vyn202-its-novel-bd2-sel-vyne-20241223monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-updat-vyne-20241107monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-positive-phase-1a-sad-data-for-vyn202-a-novel-bd2-selective-be-vyne-20240912monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-reports-second-quarter-2024-financial-results-and-provides-business-upda-vyne-20240814monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-reports-first-quarter-2024-financial-results-and-provides-business-update-design-of-p-vyne-20240509monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-reports-2023-fourth-quarter-and-year-end-financial-results-and-provides-business-upda-vyne-20240229monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-appoints-christine-borowski-ph-d-to-its-board-of-directors-bridgewater-n-vyne-20240103monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-reports-third-quarter-2023-financial-results-and-provides-business-updat-vyne-20231113monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-private-placement-of-88-million-transaction-provides-88-millio-vyne-20231030monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-reports-second-quarter-2023-financial-results-and-provides-business-upda-vyne-20230814monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-reports-first-quarter-2023-financial-results-and-provides-business-updat-vyne-20230511monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-selection-of-development-candidate-vyn202-a-potential-best-in--vyne-20230501monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-reports-year-end-2022-financial-results-and-provides-business-update-fir-vyne-20230309monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-rule-bridgewater-n-j-vyne-20230228monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-reports-third-quarter-2022-financial-results-and-provides-business-updat-vyne-20221110monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-reports-second-quarter-2022-financial-results-bridgewater-n-j-vyne-20220812monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-results-from-its-phase-2a-trial-of-fmx114-for-the-treatment-of-vyne-20220810monthly0.5https://www.biopharmawatch.com/news/VYNE/the-inhibet-tm-platform-bromodomain-end-terminal-bet-inhibitors-in-autoimmune-disease-iain-vyne-20220727monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-completes-enrollment-in-phase-2a-trial-of-fmx114-for-the-treatment-of-mi-vyne-20220617monthly0.5https://www.biopharmawatch.com/news/VYNE/kol-event-update-on-the-bet-inhibet-platform-and-vyn201-vyne-20220517monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-reports-first-quarter-2022-financial-results-and-provides-business-updat-vyne-20220512monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-positive-phase-1b-efficacy-data-for-fmx114-from-phase-1b-2a-tr-vyne-20220407monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-reports-positive-preclinical-data-for-intra-articular-injection-of-pan-bet-inhibitor--vyne-20220330monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-reports-year-end-2021-financial-results-and-provides-corporate-update-fm-vyne-20220317monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-reports-positive-preclinical-data-for-lead-bet-inhibitor-vyn201-in-human-skin-model-o-vyne-20220307monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-phase-1b-data-for-fmx114-from-phase-1b-2a-trial-for-the-treatm-vyne-20220119monthly0.5https://www.biopharmawatch.com/news/VYNE/unaudited-pro-forma-condensed-consolidated-financial-information-overview-on-vyne-20220112monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-divests-topical-minocycline-assets-transaction-includes-cash-payments-of-vyne-20220113monthly0.5https://www.biopharmawatch.com/news/VYNE/investor-presentation-january-2022-forward-looking-statements-this-presentation-includes-f-vyne-20220105monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-reports-third-quarter-2021-financial-results-and-provides-business-updat-vyne-20211110monthly0.5https://www.biopharmawatch.com/news/VYNE/lead-bet-inhibitor-vyn201-demonstrates-improvement-in-reducing-fibrotic-tissue-mass-and-ov-vyne-20211104monthly0.5https://www.biopharmawatch.com/news/VYNE/lead-bet-inhibitor-vyn201-significantly-reduces-expression-of-several-key-pro-inflammatory-vyne-20211026monthly0.5https://www.biopharmawatch.com/news/VYNE/have-been-updated-from-the-footnotes-and-the-report-of-our-independent-registered-public-a-vyne-20210812monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-reports-second-quarter-2021-financial-results-and-announces-new-strategi-vyne-20210812monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-reports-first-quarter-2021-financial-results-and-provides-business-updat-vyne-20210506monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-reports-year-end-2020-financial-results-and-provides-business-update-con-vyne-20210304monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-development-program-for-fmx114-combination-topical-gel-for-mil-vyne-20210301monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-reverse-stock-split-bridgewater-n-j-vyne-20210211monthly0.5https://www.biopharmawatch.com/news/VYNE/investor-presentation-january-2021-forward-looking-statements-this-presentation-includes-f-vyne-20210107monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-reports-third-quarter-2020-financial-results-and-provides-business-updat-vyne-20201105monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-covered-status-for-zilxi-minocycline-with-express-scripts-cove-vyne-20201002monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-zilxi-minocycline-topical-foam-1-5-available-in-pharmacies-nat-vyne-20201001monthly0.5https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-announces-the-appointment-of-patrick-g-lepore-to-its-board-of-directors--vyne-20200914monthly0.5https://www.biopharmawatch.com/news/VYNE/menlo-therapeutics-announces-completion-of-corporate-name-change-to-vyne-therapeutics-will-vyne-20200908monthly0.5https://www.biopharmawatch.com/news/VYNE/menlo-therapeutics-announces-corporate-name-change-to-vyne-therapeutics-company-will-comme-vyne-20200902monthly0.5https://www.biopharmawatch.com/news/VYNE/menlo-reports-second-quarter-2020-financial-results-and-provides-business-update-conferenc-vyne-20200806monthly0.5https://www.biopharmawatch.com/news/VYNE/investor-presentation-june-2020-forward-looking-statements-this-presentation-includes-forw-vyne-20200601monthly0.5https://www.biopharmawatch.com/news/VYNE/menlo-therapeutics-announces-positive-results-from-phase-2-trial-of-fcd105-for-the-treatme-vyne-20200602monthly0.5https://www.biopharmawatch.com/news/VYNE/therapeutics-receives-fda-approval-of-zilxi-minocycline-topical-foam-1-5-the-first-topical-vyne-20200529monthly0.5https://www.biopharmawatch.com/news/VYNE/menlo-reports-first-quarter-2020-financial-results-and-provides-business-update-conference-vyne-20200511monthly0.5https://www.biopharmawatch.com/news/VYNE/menlo-therapeutics-announces-results-from-two-phase-3-clinical-trials-of-serlopitant-for-t-vyne-20200406monthly0.5https://www.biopharmawatch.com/news/VYNE/menlo-therapeutics-appoints-andrew-saik-as-chief-financial-officer-bridgewater-n-j-vyne-20200324monthly0.5https://www.biopharmawatch.com/news/VYNE/menlo-reports-financial-results-for-subsidiary-foamix-pharmaceuticals-for-year-ended-vyne-20200312monthly0.5https://www.biopharmawatch.com/news/VYNE/menlo-therapeutics-and-foamix-pharmaceuticals-complete-merger-creating-a-combined-company--vyne-20200309monthly0.5https://www.biopharmawatch.com/news/VYNE/menlo-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-vyne-20200303monthly0.5https://www.biopharmawatch.com/news/VYNE/foamix-and-menlo-announce-shareholder-approval-of-proposed-merger-transaction-on-track-to--vyne-20200206monthly0.5https://www.biopharmawatch.com/news/VYNE/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-vyne-20191112monthly0.5https://www.biopharmawatch.com/news/VYNE/menlo-therapeutics-reports-third-quarter-2019-financial-results-and-provides-program-updat-vyne-20191031monthly0.5https://www.biopharmawatch.com/news/VYNE/menlo-therapeutics-reports-second-quarter-2019-financial-results-and-provides-program-upda-vyne-20190801monthly0.5https://www.biopharmawatch.com/news/VYNE/menlo-therapeutics-reports-first-quarter-2019-financial-results-vyne-20190502monthly0.5https://www.biopharmawatch.com/news/VYNE/menlo-therapeutics-reports-fourth-quarter-and-full-year-2018-financial-results-vyne-20190227monthly0.5https://www.biopharmawatch.com/news/VYNE/menlo-therapeutics-successful-phase-2-clinical-trial-of-serlopitant-demonstrates-reduction-vyne-20181210monthly0.5https://www.biopharmawatch.com/news/VYNE/menlo-therapeutics-reports-third-quarter-2018-financial-results-and-provides-business-upda-vyne-20181107monthly0.5https://www.biopharmawatch.com/news/VYNE/menlo-therapeutics-announces-results-from-a-phase-2-clinical-trial-of-serlopitant-for-the--vyne-20181008monthly0.5https://www.biopharmawatch.com/news/VYNE/menlo-therapeutics-reports-second-quarter-2018-financial-results-and-provides-business-upd-vyne-20180801monthly0.5https://www.biopharmawatch.com/news/VYNE/exhibit-menlo-therapeutics-reports-first-quarter-2018-financial-results-vyne-20180509monthly0.5https://www.biopharmawatch.com/news/VYNE/menlo-therapeutics-reports-fourth-quarter-and-full-year-2017-financial-results-vyne-20180328monthly0.5https://www.biopharmawatch.com/news/VYNE/for-menlo-therapeutics-media-menlotx-com-investor-contact-patti-bank-westwicke-com-vyne-20180129monthly0.5https://www.biopharmawatch.com/news/AIDX/biolabs-reports-first-quarter-2026-financial-results-and-recent-operational-progress-state-aidx-20260520monthly0.5https://www.biopharmawatch.com/news/AIDX/biolabs-reports-full-year-2025-financial-results-and-recent-operational-progress-full-year-aidx-20260331monthly0.5https://www.biopharmawatch.com/news/AIMD/ainos-reports-first-quarter-2026-financial-results-and-highlights-smell-ai-execution-acros-aimd-20260513monthly0.5https://www.biopharmawatch.com/news/AIMD/ainos-reports-full-year-2025-financial-results-and-highlights-commercial-momentum-entering-aimd-20260330monthly0.5https://www.biopharmawatch.com/news/AIMD/ainos-reports-third-quarter-2025-financial-results-digital-olfactory-commercialization-acc-aimd-20251113monthly0.5https://www.biopharmawatch.com/news/AIMD/ainos-reports-second-quarter-2025-financial-results-1h-2025-kicks-off-ai-nose-s-growing-co-aimd-20250813monthly0.5https://www.biopharmawatch.com/news/AIMD/ainos-secures-2-1-million-order-with-ase-for-first-deployment-of-ai-nose-in-semiconductor--aimd-20250806monthly0.5https://www.biopharmawatch.com/news/AIMD/ainos-regains-nasdaq-compliance-sets-90-day-roadmap-to-scale-ai-nose-platform-in-2026-comm-aimd-20250716monthly0.5https://www.biopharmawatch.com/news/AIMD/ainos-and-kenmec-launch-strategic-partnership-to-deploy-ai-powered-scent-intelligence-in-s-aimd-20250624monthly0.5https://www.biopharmawatch.com/news/AIMD/ainos-reports-first-quarter-2025-financial-results-q1-revenues-increased-412-year-over-yea-aimd-20250512monthly0.5https://www.biopharmawatch.com/news/AIMD/ainos-and-ase-partner-to-power-ai-scent-digitization-in-semiconductor-manufacturing-harnes-aimd-20250311monthly0.5https://www.biopharmawatch.com/news/AIMD/ainos-reports-full-year-2024-financial-results-unveiled-revolutionary-ai-nose-for-robotics-aimd-20250307monthly0.5https://www.biopharmawatch.com/news/AIMD/ainos-and-ugo-to-develop-the-world-s-first-robot-with-a-sense-of-smell-a-major-breakthroug-aimd-20250305monthly0.5https://www.biopharmawatch.com/news/AIMD/ainos-inc-announces-strategic-partnership-with-taiwan-tanabe-seiyaku-to-advance-manufactur-aimd-20241202monthly0.5https://www.biopharmawatch.com/news/AIMD/ainos-reports-second-quarter-2024-financial-results-enrolling-first-subject-for-fcgs-clini-aimd-20240805monthly0.5https://www.biopharmawatch.com/news/AIMD/ainos-unveils-critical-progress-in-ainos-flora-clinical-trials-and-next-gen-plans-powered--aimd-20240614monthly0.5https://www.biopharmawatch.com/news/AIMD/ainos-reports-first-quarter-2024-financial-results-strategic-focus-on-veldona-and-ai-power-aimd-20240513monthly0.5https://www.biopharmawatch.com/news/AIMD/ainos-reports-full-year-2023-financial-results-strategic-pivot-towards-veldona-and-ai-powe-aimd-20240308monthly0.5https://www.biopharmawatch.com/news/AIMD/ainos-submits-clinical-hold-complete-response-to-us-fda-to-resolve-the-deficiencies-on-inv-aimd-20240205monthly0.5https://www.biopharmawatch.com/news/AIMD/ainos-inc-announces-stock-consolidation-aimd-20231212monthly0.5https://www.biopharmawatch.com/news/AIMD/ainos-reports-third-quarter-2023-financial-results-product-cycle-transition-approaches-its-aimd-20231109monthly0.5https://www.biopharmawatch.com/news/AIMD/promissory-note-extension-agreement-this-promissory-note-agreement-the-agreement-is-entere-aimd-20230822monthly0.5https://www.biopharmawatch.com/news/AIMD/ainos-reports-second-quarter-2023-financial-results-strategic-focus-continues-to-pivot-fro-aimd-20230811monthly0.5https://www.biopharmawatch.com/news/AIMD/ainos-partners-with-nisshinbo-micro-devices-and-inabata-to-co-develop-voc-sensing-platform-aimd-20230809monthly0.5https://www.biopharmawatch.com/news/AIMD/ainos-appoints-amanda-sung-as-new-chief-financial-officer-current-cfo-celia-wu-announces-h-aimd-20230517monthly0.5https://www.biopharmawatch.com/news/AIMD/ainos-announces-us-3-million-convertible-notes-private-placement-san-diego-ca-accesswire-aimd-20230313monthly0.5https://www.biopharmawatch.com/news/AIMD/ainos-announces-pricing-of-3-3-million-public-offering-uplisting-to-nasdaq-and-reverse-sto-aimd-20220808monthly0.5https://www.biopharmawatch.com/news/AIMD/ainos-announces-strategic-relationship-with-innopharmax-to-jointly-develop-combined-oral-t-aimd-20211207monthly0.5https://www.biopharmawatch.com/news/AIMD/ainos-elects-ms-hui-lan-celia-wu-as-cfo-lawrence-k-lin-as-executive-vice-president-of-oper-aimd-20210816monthly0.5https://www.biopharmawatch.com/news/AIMD/ainos-announces-finra-approval-of-name-change-and-ticker-symbol-change-to-x201c-aimd-x201d-aimd-20210524monthly0.5https://www.biopharmawatch.com/news/AIMD/amarillo-biosciences-inc-announced-closing-under-securities-purchase-agreement-with-majori-aimd-20210421monthly0.5https://www.biopharmawatch.com/news/AIMD/amarillo-biosciences-inc-enters-into-a-securities-purchase-agreement-to-foster-new-growth-aimd-20201230monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-third-quarter-2025-financial-results-boca-raton-fla-business-wire-txmd-20251112monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-second-quarter-2025-financial-results-boca-raton-fla-business-wir-txmd-20250812monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-first-quarter-2025-financial-results-boca-raton-fla-business-wire-txmd-20250513monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-full-year-2024-financial-results-boca-raton-fla-business-wire-txmd-20250327monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-third-quarter-2024-financial-results-boca-raton-fla-business-wire-txmd-20241112monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-second-quarter-2024-financial-results-boca-raton-fla-business-wir-txmd-20240812monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-first-quarter-2024-financial-results-boca-raton-fla-business-wire-txmd-20240510monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-full-year-2023-financial-results-evaluation-of-strategic-alternat-txmd-20240329monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-third-quarter-2023-financial-results-focus-remains-on-cost-contro-txmd-20231114monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-second-quarter-2023-financial-results-txmd-20230814monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-first-quarter-2023-financial-results-txmd-20230515monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-full-year-2022-financial-results-and-provides-update-on-business--txmd-20230407monthly0.5https://www.biopharmawatch.com/news/TXMD/unaudited-pro-forma-condensed-consolidated-financial-information-overview-effective-txmd-20221230monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-completes-transaction-to-license-its-products-to-mayne-pharma-mayne-pharma--txmd-20230103monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-definitive-agreements-to-license-its-products-to-mayne-pharma-txm-txmd-20221204monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-third-quarter-2022-financial-results-q3-total-revenue-of-20-9-mil-txmd-20221114monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-additional-7-million-private-placement-maturity-date-of-financing-txmd-20221031monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-7-million-private-placement-maturity-date-of-financing-agreement--txmd-20221003monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-appoints-dr-brian-bernick-and-mr-mark-glickman-as-interim-co-chief-executiv-txmd-20220912monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-second-quarter-2022-financial-results-quarterly-total-net-revenue-txmd-20220815monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-secures-15-million-equity-investment-from-rubric-capital-company-also-reach-txmd-20220801monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-and-ew-healthcare-partners-announce-definitive-agreement-for-ew-healthcare--txmd-20220531monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-receives-u-s-food-and-drug-administration-fda-approval-for-supplemental-new-txmd-20220520monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-first-quarter-2022-financial-results-quarterly-total-net-product--txmd-20220516monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-completes-the-divestiture-of-vitacare-prescription-services-to-goodrx-in-a--txmd-20220414monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-fourth-quarter-2021-financial-results-reached-definitive-agreemen-txmd-20220310monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-enters-into-a-definitive-agreement-to-divest-vitacare-to-goodrx-goodrx-has--txmd-20220307monthly0.5https://www.biopharmawatch.com/news/TXMD/u-s-food-and-drug-administration-fda-responds-to-request-from-therapeuticsmd-to-revise-cer-txmd-20211210monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-settles-u-s-patent-litigation-with-amneal-for-bijuva-estradiol-and-progeste-txmd-20211208monthly0.5https://www.biopharmawatch.com/news/TXMD/hugh-o-dowd-thank-you-everyone-for-a-wonderful-morning-we-look-forward-to-taking-further-f-txmd-20211116monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-leadership-changes-appointment-of-industry-veteran-hugh-o-dowd-as-txmd-20211112monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-appointment-of-hugh-o-dowd-as-president-o-dowd-brings-25-years-of-txmd-20210808monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-second-quarter-2021-financial-results-2q21-total-net-product-reve-txmd-20210804monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-first-quarter-2021-financial-results-1q21-total-net-revenue-incre-txmd-20210506monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-fourth-quarter-and-full-year-2020-financial-results-full-year-202-txmd-20210302monthly0.5https://www.biopharmawatch.com/news/TXMD/building-the-premier-women-s-health-company-january-2021-2-forward-looking-statements-this-txmd-20210113monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-third-quarter-2020-financial-results-significant-growth-in-net-re-txmd-20201109monthly0.5https://www.biopharmawatch.com/news/TXMD/for-investor-presentation-purposes-only-corporate-presentation-txmd-20200914monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-second-quarter-2020-financial-results-2q20-total-net-product-reve-txmd-20200724monthly0.5https://www.biopharmawatch.com/news/TXMD/building-the-premier-women-s-health-company-june-2020-2-forward-looking-statements-this-pr-txmd-20200623monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-appointment-of-james-c-d-arecca-as-chief-financial-officer-and-re-txmd-20200601monthly0.5https://www.biopharmawatch.com/news/TXMD/building-the-premier-women-s-health-company-bofa-securities-conference-txmd-20200513monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-first-quarter-2020-financial-results-1q20-total-net-product-reven-txmd-20200506monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-further-strengthens-board-with-appointment-of-new-independent-director-kare-txmd-20200422monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-provides-covid-19-related-business-update-strong-preliminary-first-quarter--txmd-20200326monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-strengthens-board-with-appointment-of-industry-leaders-paul-bisaro-and-gail-txmd-20200324monthly0.5https://www.biopharmawatch.com/news/TXMD/building-the-premier-women-s-health-company-cowen-conference-txmd-20200303monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-fourth-quarter-and-full-year-2019-financial-results-4q19-total-ne-txmd-20200220monthly0.5https://www.biopharmawatch.com/news/TXMD/building-the-premier-women-s-health-company-jp-morgan-conference-january-2020-2-forward-lo-txmd-20200102monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-amendment-to-term-loan-financing-facility-with-tpg-sixth-street-p-txmd-20191230monthly0.5https://www.biopharmawatch.com/news/TXMD/investor-update-txmd-20191218monthly0.5https://www.biopharmawatch.com/news/TXMD/investor-presentation-txmd-20191119monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-third-quarter-2019-financial-results-3q19-net-revenue-product-and-txmd-20191106monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-estimated-third-quarter-2019-financial-results-txmd-20191023monthly0.5https://www.biopharmawatch.com/news/TXMD/investor-update-txmd-20191015monthly0.5https://www.biopharmawatch.com/news/TXMD/investor-presentation-october-2019-building-a-premier-women-s-health-portfolio-2-2-forward-txmd-20191001monthly0.5https://www.biopharmawatch.com/news/TXMD/investor-presentation-txmd-20190925monthly0.5https://www.biopharmawatch.com/news/TXMD/investor-presentation-september-2019-building-a-premier-women-s-health-portfolio-2-2-forwa-txmd-20190831monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-second-quarter-2019-financial-results-imvexxy-net-revenue-3-1-mil-txmd-20190806monthly0.5https://www.biopharmawatch.com/news/TXMD/investor-update-txmd-20190709monthly0.5https://www.biopharmawatch.com/news/TXMD/no-image-1-txmd-20190610monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-and-theramex-enter-into-exclusive-license-and-supply-agreement-to-commercia-txmd-20190607monthly0.5https://www.biopharmawatch.com/news/TXMD/investor-update-may-2019-annovera-building-a-premier-women-s-health-portfolio-segesterone--txmd-20190430monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-first-quarter-2019-financial-results-bijuva-commercial-launch-in--txmd-20190506monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-closes-300-million-non-dilutive-term-loan-financing-facility-with-tpg-sixth-txmd-20190424monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-signs-binding-commitment-letter-for-300-million-non-dilutive-term-loan-fina-txmd-20190417monthly0.5https://www.biopharmawatch.com/news/TXMD/imvexxy-update-txmd-20190408monthly0.5https://www.biopharmawatch.com/news/TXMD/investor-presentation-march-2019-2-forward-looking-statements-this-presentation-by-therape-txmd-20190228monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-fourth-quarter-and-full-year-2018-financial-results-successful-la-txmd-20190221monthly0.5https://www.biopharmawatch.com/news/TXMD/investor-update-february-4-2019-2-forward-looking-statements-this-presentation-by-therapeu-txmd-20190131monthly0.5https://www.biopharmawatch.com/news/TXMD/forward-looking-statements-this-presentation-by-therapeuticsmd-inc-referred-to-as-we-and-o-txmd-20181221monthly0.5https://www.biopharmawatch.com/news/TXMD/investor-presentation-january-2019-2-forward-looking-statements-this-presentation-by-thera-txmd-20190108monthly0.5https://www.biopharmawatch.com/news/TXMD/investor-update-december-18-2018-2-forward-looking-statements-this-presentation-by-therape-txmd-20181216monthly0.5https://www.biopharmawatch.com/news/TXMD/investor-presentation-november-2018-2-forward-looking-statements-this-presentation-by-ther-txmd-20181127monthly0.5https://www.biopharmawatch.com/news/TXMD/investor-presentation-november-2018-2-forward-looking-statements-this-presentation-by-ther-txmd-20181113monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-third-quarter-2018-financial-results-strong-early-launch-indicato-txmd-20181107monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-fda-approval-of-tx-001hr-bijuva-estradiol-and-progesterone-capsul-txmd-20181029monthly0.5https://www.biopharmawatch.com/news/TXMD/investor-presentation-october-2018-2-forward-looking-statements-this-presentation-by-thera-txmd-20181002monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-enters-into-label-discussions-for-tx-001hr-txmd-20180927monthly0.5https://www.biopharmawatch.com/news/TXMD/investor-presentation-september-2018-2-forward-looking-statements-this-presentation-by-the-txmd-20180924monthly0.5https://www.biopharmawatch.com/news/TXMD/investor-presentation-september-2018-2-forward-looking-statements-this-presentation-by-the-txmd-20180905monthly0.5https://www.biopharmawatch.com/news/TXMD/investor-presentation-august-2018-2-forward-looking-statements-this-presentation-by-therap-txmd-20180821monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-fda-approval-of-annovera-segesterone-acetate-ethinyl-estradiol-va-txmd-20180810monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-second-quarter-2018-financial-results-imvexxy-early-experience-pr-txmd-20180730monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-draw-down-of-75-million-under-term-loan-with-midcap-financial-txmd-20180607monthly0.5https://www.biopharmawatch.com/news/TXMD/investor-day-txmd-20180604monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-fda-approval-of-tx-004hr-imvexxy-tm-estradiol-vaginal-inserts-the-txmd-20180530monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-first-quarter-2018-financial-results-200-million-non-dilutive-ter-txmd-20180503monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-enters-into-label-negotiations-for-tx-004hr-txmd-20180411monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-expansion-of-board-of-directors-dr-jane-f-barlow-appointed-as-ind-txmd-20180402monthly0.5https://www.biopharmawatch.com/news/TXMD/txmd-overview-march-2018-ther-0086-03-18-2-forward-looking-statements-this-presentation-by-txmd-20180312monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-fda-acceptance-of-new-drug-application-nda-and-prescription-drug--txmd-20180308monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-fourth-quarter-and-full-year-2017-financial-results-pdufa-target--txmd-20180220monthly0.5https://www.biopharmawatch.com/news/TXMD/txmd-overview-january-2018-ther-0086-01-18-2-forward-looking-statements-this-presentation--txmd-20180109monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-fda-acceptance-of-new-drug-application-and-prescription-drug-user-txmd-20171219monthly0.5https://www.biopharmawatch.com/news/TXMD/txmd-overview-november-2017-ther-0086-11-17-2-forward-looking-statements-this-presentation-txmd-20171113monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-third-quarter-2017-financial-results-resubmission-of-new-drug-app-txmd-20171106monthly0.5https://www.biopharmawatch.com/news/TXMD/txmd-overview-october-2017-ther-0086-10-17-2-forward-looking-statements-this-presentation--txmd-20171004monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-move-to-nasdaq-global-select-market-txmd-20170925monthly0.5https://www.biopharmawatch.com/news/TXMD/txmd-overview-september-2017-ther-0086-9-17-2-forward-looking-statements-this-presentation-txmd-20170912monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-provides-tx-004hr-regulatory-update-txmd-20170810monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-second-quarter-2017-financial-results-txmd-20170803monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-provides-tx-004hr-regulatory-update-txmd-20170717monthly0.5https://www.biopharmawatch.com/news/TXMD/txmd-overview-june-2017-ther-0086-6-17-2-forward-looking-statements-this-presentation-by-t-txmd-20170531monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-receives-complete-response-letter-from-fda-for-tx-004hr-new-drug-applicatio-txmd-20170508monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-first-quarter-2017-financial-results-txmd-20170502monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-provides-tx-004hr-regulatory-update-txmd-20170410monthly0.5https://www.biopharmawatch.com/news/TXMD/investor-day-txmd-20170301monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-fourth-quarter-and-full-year-2016-financial-results-pipeline-of-t-txmd-20170223monthly0.5https://www.biopharmawatch.com/news/TXMD/txmd-overview-january-2017-ther-0086-1-17-2-forward-looking-statements-this-presentation-b-txmd-20170109monthly0.5https://www.biopharmawatch.com/news/TXMD/tx-001hr-supplemental-replenish-trial-design-and-topline-phase-3-results-december-2016-2-f-txmd-20161208monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-positive-top-line-results-from-pivotal-phase-3-replenish-trial-in-txmd-20161205monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-third-quarter-2016-financial-results-topline-phase-3-data-for-tx--txmd-20161103monthly0.5https://www.biopharmawatch.com/news/TXMD/txmd-overview-september-2016-ther-0086-8-16-2-forward-looking-statements-this-presentation-txmd-20160926monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-fda-acceptance-of-new-drug-application-nda-and-prescription-drug--txmd-20160919monthly0.5https://www.biopharmawatch.com/news/TXMD/txmd-overview-august-2016-ther-0086-8-16-2-forward-looking-statements-this-presentation-by-txmd-20160822monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-second-quarter-2016-financial-results-new-drug-application-submit-txmd-20160804monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-new-drug-application-submission-for-yuvvexy-tx-004hr-txmd-20160707monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-filing-timeline-for-yuvvexy-tx-004hr-new-drug-application-txmd-20160629monthly0.5https://www.biopharmawatch.com/news/TXMD/txmd-overview-may-2016-ther-0086-5-16-2-forward-looking-statements-this-presentation-by-th-txmd-20160504monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-first-quarter-2016-financial-results-nda-filing-for-tx-004hr-plan-txmd-20160503monthly0.5https://www.biopharmawatch.com/news/TXMD/rejoice-trial-data-presentation-txmd-20160307monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-fourth-quarter-and-full-year-2015-financial-results-company-to-pr-txmd-20160225monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-positive-top-line-results-from-its-phase-3-rejoice-trial-in-postm-txmd-20151207monthly0.5https://www.biopharmawatch.com/news/TXMD/txmd-overview-november-2015-ther-0063-11-15-2-forward-looking-statements-this-presentation-txmd-20151110monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-third-quarter-2015-financial-results-topline-phase-3-data-anticip-txmd-20151104monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-completes-enrollment-in-phase-3-clinical-trial-of-bio-identical-oral-combin-txmd-20151013monthly0.5https://www.biopharmawatch.com/news/TXMD/txmd-overview-august-2015-w-w-w-t-h-e-r-a-p-e-u-t-i-c-s-m-d-c-o-m-a-woman-s-health-company-txmd-20150817monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-second-quarter-2015-financial-results-completed-enrollment-of-700-txmd-20150806monthly0.5https://www.biopharmawatch.com/news/TXMD/txmd-overview-june-2015-w-w-w-t-h-e-r-a-p-e-u-t-i-c-s-m-d-c-o-m-a-woman-s-health-company-t-txmd-20150623monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-completes-enrollment-in-the-rejoice-trial-a-phase-3-clinical-trial-of-tx-00-txmd-20150609monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-first-quarter-2015-financial-results-first-quarter-product-sales--txmd-20150505monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-appoints-biopharmaceutical-senior-executives-angus-c-russell-and-j-martin-c-txmd-20150318monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-fourth-quarter-and-full-year-2014-financial-results-current-women-txmd-20150310monthly0.5https://www.biopharmawatch.com/news/TXMD/investor-overview-january-2015-w-w-w-t-h-e-r-a-p-e-u-t-i-c-s-m-d-c-o-m-2-2-this-presentati-txmd-20150112monthly0.5https://www.biopharmawatch.com/news/TXMD/investor-overview-november-2014-w-w-w-t-h-e-r-a-p-e-u-t-i-c-s-m-d-c-o-m-2-2-this-presentat-txmd-20141118monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-third-quarter-financial-results-company-advances-two-phase-3-prog-txmd-20141106monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-second-quarter-2014-financial-results-company-significantly-stren-txmd-20140806monthly0.5https://www.biopharmawatch.com/news/TXMD/nyse-mkt-txmd-corporate-overview-q2-2014-copyright-2014-by-therapeuticsmd-may-2014-this-pr-txmd-20140506monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-reports-first-quarter-2014-results-management-to-host-conference-call-at-4--txmd-20140505monthly0.5https://www.biopharmawatch.com/news/TXMD/nyse-mkt-txmd-corporate-overview-q2-2014-copyright-2014-by-therapeuticsmd-this-presentatio-txmd-20140408monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-announces-launch-of-secondary-offering-boca-raton-fl-txmd-20140318monthly0.5https://www.biopharmawatch.com/news/TXMD/nyse-mkt-txmd-corporate-overview-q1-2014-copyright-2014-by-therapeuticsmd-this-presentatio-txmd-20140304monthly0.5https://www.biopharmawatch.com/news/TXMD/investor-relations-dan-cartwright-lisa-m-wilson-chief-financial-officer-in-site-communicat-txmd-20140303monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-names-randall-s-stanicky-to-board-of-directors-boca-raton-fl-txmd-20131218monthly0.5https://www.biopharmawatch.com/news/TXMD/txmd-q3-2013-earnings-conference-call-txmd-20131104monthly0.5https://www.biopharmawatch.com/news/TXMD/dan-cartwright-investor-relations-chief-financial-officer-lisa-m-wilson-tel-561-961-1930-i-txmd-20131104monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-inc-presentation-dated-october-2013-txmd-corporate-overview-october-2013-co-txmd-20131008monthly0.5https://www.biopharmawatch.com/news/TXMD/dan-cartwright-investor-relations-chief-financial-officer-lisa-m-wilson-tel-561-961-1900-i-txmd-20130925monthly0.5https://www.biopharmawatch.com/news/TXMD/dan-cartwright-chief-financial-officer-tel-561-961-1930-dan-cartwright-therapeuticsmd-com--txmd-20130806monthly0.5https://www.biopharmawatch.com/news/TXMD/dan-cartwright-chief-financial-officer-tel-561-961-1930-dan-cartwright-therapeuticsmd-com--txmd-20130614monthly0.5https://www.biopharmawatch.com/news/TXMD/investor-presentation-june-2013-copyright-2013-by-therapeuticsmd-txmd-20130604monthly0.5https://www.biopharmawatch.com/news/TXMD/dan-cartwright-investor-relations-chief-financial-officer-lisa-m-wilson-tel-561-961-1930-i-txmd-20130516monthly0.5https://www.biopharmawatch.com/news/TXMD/investor-relations-dan-cartwright-lisa-m-wilson-chief-financial-officer-in-site-communicat-txmd-20130508monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-inc-8-k-exhbit-99-1-1-for-immediate-release-therapeuticsmd-announces-tradin-txmd-20130422monthly0.5https://www.biopharmawatch.com/news/TXMD/symbol-txmd-txmd-20130315monthly0.5https://www.biopharmawatch.com/news/TXMD/symbol-txmd-txmd-20130307monthly0.5https://www.biopharmawatch.com/news/TXMD/unless-the-context-otherwise-requires-the-terms-therapeutics-txmd-company-we-us-or-our-ref-txmd-20130125monthly0.5https://www.biopharmawatch.com/news/TXMD/symbol-txmd-txmd-20120926monthly0.5https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-inc-8-k-for-immediate-release-symbol-txmd-txmd-20120807monthly0.5https://www.biopharmawatch.com/news/TXMD/symbol-txmd-txmd-20120710monthly0.5https://www.biopharmawatch.com/news/TXMD/consent-of-independent-registered-public-accounting-firm-the-board-of-directors-and-stockh-txmd-20111011monthly0.5https://www.biopharmawatch.com/news/TXMD/spectrum-health-network-inc-index-to-financial-statements-financial-statements-report-of-i-txmd-20100614monthly0.5https://www.biopharmawatch.com/news/TXMD/america-s-minority-health-network-inc-index-to-financial-statements-financial-statements-r-txmd-20090730monthly0.5https://www.biopharmawatch.com/news/TXMD/croff-enterprises-inc-agrees-to-merge-with-america-s-minority-health-network-inc-los-angel-txmd-20090709monthly0.5https://www.biopharmawatch.com/news/TXMD/croff-announces-common-share-sale-and-dividend-denver-co-06-12-2008-croff-enterprises-inc--txmd-20080702monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-reports-year-end-2025-corporate-and-financial-results-phase-1-apollo-d-mrkr-20260318monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business-upd-mrkr-20251114monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-reports-year-end-2024-corporate-and-financial-results-lead-program-inv-mrkr-20250331monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-provides-a-clinical-update-on-mt-601-in-patients-with-lymphoma-apollo--mrkr-20241219monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-awarded-9-5-million-grant-from-the-cancer-prevention-research-institut-mrkr-20241217monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-upd-mrkr-20241114monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-reports-second-quarter-2024-financial-results-and-provides-business-up-mrkr-20240814monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-awarded-2-million-grant-from-nih-in-support-of-phase-1-study-investiga-mrkr-20240812monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-reports-first-quarter-2024-financial-results-and-provides-business-upd-mrkr-20240515monthly0.5https://www.biopharmawatch.com/news/MRKR/principal-investigator-from-city-of-hope-national-medical-center-invited-to-present-clinic-mrkr-20240408monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-reports-year-end-2023-corporate-and-financial-results-lead-program-in--mrkr-20240325monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-announces-clinical-program-updates-and-pipeline-prioritization-strateg-mrkr-20240108monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-announces-sustained-complete-response-in-first-lymphoma-patient-treate-mrkr-20231211monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-reports-third-quarter-2023-financial-results-and-provides-business-upd-mrkr-20231109monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-announces-complete-response-in-first-lymphoma-patient-treated-with-mt--mrkr-20230911monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-reports-second-quarter-2023-financial-results-and-provides-business-up-mrkr-20230814monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-reports-non-clinical-proof-of-concept-data-and-update-on-clinical-read-mrkr-20230807monthly0.5https://www.biopharmawatch.com/news/MRKR/european-medicines-agency-grants-orphan-drug-designation-for-mt-401-developed-by-marker-th-mrkr-20230710monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-reports-mt-401-non-clinical-data-in-aml-cells-after-hypomethylating-ag-mrkr-20230626monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-announces-first-lymphoma-patient-treated-with-mt-601-in-phase-1-clinic-mrkr-20230612monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-reports-pre-clinical-data-of-its-mt-601-multitaa-specific-t-cell-produ-mrkr-20230531monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-appoints-monic-stuart-m-d-as-chief-medical-officer-accomplished-health-mrkr-20230508monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-announces-comprehensive-non-dilutive-agreement-with-cellready-structur-mrkr-20230501monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-reports-fiscal-year-2022-corporate-and-financial-results-2022-clinical-mrkr-20230322monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-and-lincoln-park-capital-enter-into-a-common-stock-purchase-agreement--mrkr-20221213monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-announces-fda-clearance-of-ind-for-mt-601-its-six-antigen-t-cell-thera-mrkr-20221122monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-reports-q3-2022-operating-and-financial-results-company-awarded-2-mill-mrkr-20221110monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-awarded-2-million-grant-from-u-s-fda-to-support-marker-s-phase-2-artem-mrkr-20220913monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-reports-q2-2022-operating-and-financial-results-houston-tx-mrkr-20220811monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-announces-fda-clearance-of-ind-for-mt-601-the-six-antigen-targeted-t-c-mrkr-20220804monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-reports-q1-2022-operating-and-financial-results-topline-readout-of-pha-mrkr-20220513monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-announces-entry-into-services-agreement-with-wilson-wolf-houston-april-mrkr-20220426monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-reports-fiscal-year-2021-operating-and-financial-results-enrollment-of-mrkr-20220317monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-announces-clinical-program-updates-and-pipeline-expansion-results-from-mrkr-20220216monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-receives-fda-orphan-drug-designation-for-its-multi-antigen-targeted-t--mrkr-20220119monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-appoints-biotech-executive-katharine-knobil-m-d-to-board-of-directors--mrkr-20211209monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-reports-third-quarter-2021-operating-and-financial-results-enrollment--mrkr-20211110monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-awarded-13-1-million-grant-from-the-cancer-prevention-and-research-ins-mrkr-20210819monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-reports-second-quarter-2021-operating-and-financial-results-marker-con-mrkr-20210810monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-announces-opening-of-new-cgmp-manufacturing-facility-facility-is-now-a-mrkr-20210728monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-announces-completion-of-safety-lead-in-portion-of-phase-2-study-in-pos-mrkr-20210706monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-reports-first-quarter-2021-operating-and-financial-results-marker-cont-mrkr-20210512monthly0.5https://www.biopharmawatch.com/news/MRKR/corporate-presentation-march-2021-forward-looking-statements-certain-statements-contained--mrkr-20210316monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-reports-fiscal-year-2020-operating-and-financial-results-dosed-first-p-mrkr-20210309monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-announces-dosing-of-first-patient-in-phase-2-trial-of-mt-401-in-acute--mrkr-20210303monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-announces-completion-of-new-manufacturing-facility-to-support-clinical-mrkr-20210113monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-announces-fda-lifted-partial-clinical-hold-on-phase-2-aml-clinical-tri-mrkr-20210105monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-reports-third-quarter-2020-operating-and-financial-results-initiated-f-mrkr-20201109monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-reports-second-quarter-2020-operating-and-financial-results-houston-tx-mrkr-20200810monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-announces-new-manufacturing-facility-to-support-clinical-development-o-mrkr-20200630monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-receives-usan-approval-for-zelenoleucel-as-nonproprietary-name-for-mt--mrkr-20200623monthly0.5https://www.biopharmawatch.com/news/MRKR/phase-1-trial-in-pancreatic-mrkr-20200601monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-reports-interim-results-of-its-multitaa-specific-t-cell-therapy-in-pat-mrkr-20200529monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-reports-first-quarter-2020-operating-and-financial-results-company-to--mrkr-20200511monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-receives-fda-orphan-drug-designation-for-its-multi-antigen-targeted-t--mrkr-20200429monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-reports-full-year-2019-operating-and-financial-results-houston-tx-mrkr-20200312monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-and-aspire-capital-enter-into-a-common-stock-purchase-agreement-for-up-mrkr-20200302monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-announces-update-to-its-clinical-program-in-aml-u-s-fda-lifts-clinical-mrkr-20200211monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-reports-third-quarter-2019-operating-and-financial-results-conference--mrkr-20191112monthly0.5https://www.biopharmawatch.com/news/MRKR/6-lymphoma-phase-i-trial-tactal-group-a-active-disease-15-patients-7-complete-responses-cr-mrkr-20190924monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-appoints-nadia-agopyan-ph-d-rac-as-vice-president-of-regulatory-affair-mrkr-20190815monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-reports-second-quarter-2019-operating-and-financial-results-houston-tx-mrkr-20190808monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-appoints-steve-elms-to-its-board-of-directors-houston-tx-mrkr-20190806monthly0.5https://www.biopharmawatch.com/news/MRKR/july-22-nd-2019-peter-hoang-president-chief-executive-officer-1-2-3-brandon-g-smaglo-m-d-f-mrkr-20190722monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-to-report-updated-results-from-phase-1-2-trial-with-multitaa-therapy-i-mrkr-20190620monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-reports-first-quarter-2019-operating-and-financial-results-company-on--mrkr-20190509monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-provides-business-and-clinical-update-multitaa-t-cell-therapies-contin-mrkr-20190328monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-announces-clinical-update-at-the-transplantation-cellular-therapy-meet-mrkr-20190225monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-announces-change-in-corporate-headquarters-and-access-to-new-laborator-mrkr-20190215monthly0.5https://www.biopharmawatch.com/news/MRKR/the-center-for-cell-and-gene-therapy-at-baylor-college-of-medicine-to-present-at-the-trans-mrkr-20190115monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-provides-updates-of-its-lead-clinical-programs-reports-clinical-data-u-mrkr-20190103monthly0.5https://www.biopharmawatch.com/news/MRKR/safety-and-efficacy-of-multi-taa-t-cells-for-myeloma-premal-lulla-ifigeneia-tzannou-george-mrkr-20181204monthly0.5https://www.biopharmawatch.com/news/MRKR/the-center-for-cell-and-gene-therapy-at-baylor-college-of-medicine-to-present-at-the-60-th-mrkr-20181127monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-inc-appoints-anthony-h-kim-as-chief-financial-officer-houston-tx-mrkr-20181127monthly0.5https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-inc-announces-new-executive-appointments-juan-vera-m-d-appointed-chief-mrkr-20181023monthly0.5https://www.biopharmawatch.com/news/MRKR/tapimmune-and-marker-therapeutics-announce-successful-closing-of-previously-announced-merg-mrkr-20181018monthly0.5https://www.biopharmawatch.com/news/MRKR/allison-mickey-713-798-4710-allison-huseman-bcm-edu-www-bcm-edu-news-from-the-labs-to-comm-mrkr-20180808monthly0.5https://www.biopharmawatch.com/news/MRKR/tapimmune-announces-pricing-of-70-million-private-placement-financing-led-by-new-enterpris-mrkr-20180608monthly0.5https://www.biopharmawatch.com/news/MRKR/tapimmune-and-marker-therapeutics-announce-entry-into-merger-agreement-creating-a-transfor-mrkr-20180515monthly0.5https://www.biopharmawatch.com/news/MRKR/tapimmune-appoints-peter-hoang-as-president-and-chief-executive-officer-mrkr-20170925monthly0.5https://www.biopharmawatch.com/news/MRKR/tapimmune-inc-enters-into-definitive-agreements-to-raise-6-82-million-in-a-private-placeme-mrkr-20170622monthly0.5https://www.biopharmawatch.com/news/MRKR/tapimmune-announces-change-in-management-and-board-of-directors-mrkr-20170428monthly0.5https://www.biopharmawatch.com/news/MRKR/tapimmune-announces-reverse-stock-split-in-preparation-for-proposed-uplisting-to-nasdaq-ca-mrkr-20160915monthly0.5https://www.biopharmawatch.com/news/MRKR/tapimmune-appoints-michael-j-loiacono-as-chief-financial-officer-accomplished-financial-di-mrkr-20160825monthly0.5https://www.biopharmawatch.com/news/MRKR/tapimmune-enters-into-definitive-agreements-to-raise-8-5-million-from-the-exercise-of-outs-mrkr-20160811monthly0.5https://www.biopharmawatch.com/news/MRKR/tapimmune-appoints-dr-john-n-bonfiglio-as-president-and-chief-operating-officer-mrkr-20160719monthly0.5https://www.biopharmawatch.com/news/MRKR/tapimmune-appoints-frederick-g-wasserman-to-its-board-of-directors-accomplished-financial--mrkr-20160127monthly0.5https://www.biopharmawatch.com/news/MRKR/u-s-food-drug-administration-grants-orphan-drug-designation-to-tapimmune-s-tpiv-200-in-the-mrkr-20151209monthly0.5https://www.biopharmawatch.com/news/MRKR/international-centre-for-dispute-resolution-international-arbitration-tribunal-tapimmune-i-mrkr-20140723monthly0.5https://www.biopharmawatch.com/news/MRKR/tapimmune-releases-positive-interim-data-on-phase-i-clinical-trial-in-her2-neu-breast-canc-mrkr-20140303monthly0.5https://www.biopharmawatch.com/news/MRKR/and-agree-with-the-statements-made-by-tapimmune-regarding-my-resignations-sincerely-s-deni-mrkr-20120514monthly0.5https://www.biopharmawatch.com/news/MRKR/tapimmune-licenses-her2-neu-antigen-technology-from-mayo-clinic-for-incorporation-into-a-v-mrkr-20120416monthly0.5https://www.biopharmawatch.com/news/MRKR/entitled-tapimmune-closes-1-13-million-funding-company-retires-notes-and-11-2mm-warrants-d-mrkr-20110224monthly0.5https://www.biopharmawatch.com/news/MRKR/glynn-wilson-chairman-ceo-tapimmune-inc-2815-eastlake-avenue-suite-300-seattle-wa-98102-mrkr-20100716monthly0.5https://www.biopharmawatch.com/news/MRKR/glynn-wilson-chairman-ceo-taplmmune-inc-866-359-7541-donald-c-weinberger-adam-lowensteiner-mrkr-20100524monthly0.5https://www.biopharmawatch.com/news/MRKR/tapimmune-inc-executes-a-securities-purchase-agreement-for-the-issuance-of-1-53-million-in-mrkr-20100518monthly0.5https://www.biopharmawatch.com/news/MRKR/tapimmune-inc-signs-r-d-collaboration-letter-of-intent-agreement-with-aeras-global-tb-vacc-mrkr-20100201monthly0.5https://www.biopharmawatch.com/news/MRKR/tapimmune-inc-announces-acquisition-of-core-tap-technologies-and-intellectual-property-fro-mrkr-20070628monthly0.5https://www.biopharmawatch.com/news/MRKR/genemax-corp-appoints-konstantine-sarafis-as-chief-operating-officer-vancouver-canada-augu-mrkr-20040901monthly0.5https://www.biopharmawatch.com/news/APUS/apimeds-pharmaceuticals-receives-notice-from-nyse-regulation-regarding-late-filing-of-annu-apus-20260422monthly0.5https://www.biopharmawatch.com/news/APUS/apimeds-pharmaceuticals-us-inc-announces-material-breach-of-merger-agreement-by-inscobee-i-apus-20260324monthly0.5https://www.biopharmawatch.com/news/APUS/apimeds-and-mindwave-announce-merger-integrating-biotech-growth-with-ai-driven-digital-tre-apus-20251202monthly0.5https://www.biopharmawatch.com/news/APUS/apimeds-expands-leadership-team-with-dr-susan-kramer-to-lead-product-development-and-brian-apus-20250715monthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-announces-antiviral-program-targeting-ongoing-hantavirus-and-ebola-virus-dise-traw-20260527monthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-completes-analysis-of-ratutrelvir-clinical-study-in-paxlovid-eligible-and-ine-traw-20260219monthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-reports-second-quarter-2025-results-and-business-highlights-advancing-novel-p-traw-20250814monthly0.5https://www.biopharmawatch.com/news/TRAW/nasdaq-traw-june-2025-corporate-presentation-forward-looking-statements-2-this-presentatio-traw-20250630monthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-rigosertib-june-2025-forward-looking-statements-this-presentation-contains-an-traw-20250603monthly0.5https://www.biopharmawatch.com/news/TRAW/nasdaq-traw-may-2025-corporate-presentation-forward-looking-statements-2-this-presentation-traw-20250527monthly0.5https://www.biopharmawatch.com/news/TRAW/nasdaq-traw-may-2025-corporate-presentation-forward-looking-statements-2-this-presentation-traw-20250519monthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-reports-first-quarter-2025-results-and-business-highlights-fda-briefing-docum-traw-20250424monthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-reports-full-year-2024-results-and-business-highlights-tivoxavir-marboxil-s-p-traw-20250331monthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-announces-management-updates-werner-cautreels-phd-to-retire-as-ceo-while-cont-traw-20250328monthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-s-covid-19-candidate-ratutrelvir-presented-at-icar-preclinical-and-phase-1-da-traw-20250325monthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-antiviral-bird-flu-program-tivoxavir-marboxil-shows-positive-data-in-non-huma-traw-20250324monthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-s-bird-flu-drug-candidate-tivoxavir-marboxil-presented-at-icar-poster-undersc-traw-20250321monthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-reports-positive-results-from-an-accepted-bird-flu-model-for-anti-viral-candi-traw-20250303monthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-regains-compliance-with-nasdaq-equity-listing-rule-newtown-pa-traw-20250228monthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-announces-completion-of-phase-i-studies-with-tivoxavir-marboxil-a-single-dose-traw-20250123monthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-inc-announces-financing-up-to-72-6-million-from-leading-healthcare-institutio-traw-20241230monthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-provides-business-update-and-reports-q3-2024-financial-results-covid-phase-1--traw-20241114monthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-inc-announces-special-shareholders-meeting-results-three-proposals-including--traw-20240917monthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-reports-q2-2024-financial-results-provides-recent-business-highlights-merger--traw-20240815monthly0.5https://www.biopharmawatch.com/news/TRAW/traws-pharma-reports-first-quarter-2024-financial-results-and-provides-business-update-com-traw-20240516monthly0.5https://www.biopharmawatch.com/news/TRAW/potential-best-in-class-p-roduct-candidates-in-development-for-cancer-respiratory-viral-di-traw-20240416monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-and-trawsfynydd-therapeutics-inc-announce-business-combination-t-traw-20240402monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-reports-corporate-update-and-announces-third-quarter-2023-financial--traw-20231114monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-reports-corporate-update-and-announces-second-quarter-2023-financial-traw-20230810monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-reports-first-quarter-2023-financial-results-and-provides-business-u-traw-20230515monthly0.5https://www.biopharmawatch.com/news/TRAW/by-electronic-delivery-to-mguerin-onconova-us-traw-20230505monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-announces-the-unexpected-passing-of-chief-medical-officer-dr-mark-ge-traw-20230406monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-reports-full-year-2022-financial-results-and-provides-business-updat-traw-20230316monthly0.5https://www.biopharmawatch.com/news/TRAW/sent-via-electronic-delivery-to-mguerin-onconova-us-traw-20230213monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-appoints-drs-peter-atadja-and-trafford-clarke-to-its-board-of-direct-traw-20221219monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-announces-plans-for-a-phase-1-2a-trial-of-narazaciclib-combined-with-traw-20221114monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-reports-second-quarter-2022-financial-results-and-provides-business--traw-20220811monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-announces-key-management-promotions-mark-guerin-promoted-to-chief-op-traw-20220613monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-reports-first-quarter-2022-financial-results-and-provides-business-u-traw-20220511monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-reports-full-year-2021-financial-results-and-provides-business-updat-traw-20220317monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-reports-third-quarter-2021-financial-results-and-provides-business-u-traw-20211111monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-announces-pricing-of-21-million-public-offering-of-common-stock--traw-20210924monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-announces-encouraging-clinical-data-supporting-the-anti-cancer-activ-traw-20210922monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-reports-second-quarter-2021-financial-results-and-provides-business--traw-20210812monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-regains-compliance-with-nasdaq-continued-listing-requirement-newtown-traw-20210622monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-traw-20210520monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-reports-first-quarter-2021-financial-results-and-provides-business-u-traw-20210517monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-reports-full-year-2020-financial-results-provides-business-update-co-traw-20210311monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-regains-compliance-with-nasdaq-continued-listing-requirement-newtown-traw-20210224monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-announces-closing-of-28-75-million-public-offering-of-common-sto-traw-20210216monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-announces-pricing-of-25-million-public-offering-of-common-stock--traw-20210210monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-announces-8-7-million-public-offering-newtown-pa-traw-20210107monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-announces-fda-permission-for-study-to-proceed-under-its-investigatio-traw-20201221monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-files-investigational-new-drug-application-for-multi-kinase-cdk4-6-i-traw-20201123monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-reports-third-quarter-2020-financial-results-and-provides-business-u-traw-20201112monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-announces-topline-results-from-the-pivotal-phase-3-inspire-trial-iv--traw-20200824monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-highlights-corporate-progress-and-reports-second-quarter-2020-financ-traw-20200812monthly0.5https://www.biopharmawatch.com/news/TRAW/by-electronic-delivery-to-mguerin-onconova-us-traw-20200803monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-provides-corporate-update-and-reports-first-quarter-2020-financial-r-traw-20200514monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-announces-completion-of-enrollment-of-phase-3-inspire-trial-provides-traw-20200324monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-announces-10-million-registered-direct-offering-priced-at-the-ma-traw-20191231monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-announces-closing-of-5-0-million-registered-direct-offering-pric-traw-20191219monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-announces-exclusive-license-agreement-with-specialised-therapeutics--traw-20191218monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-announces-5-0-million-registered-direct-offering-priced-at-the-m-traw-20191206monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-announces-data-on-genomic-profiles-of-higher-risk-myelodysplastic-sy-traw-20191209monthly0.5https://www.biopharmawatch.com/news/TRAW/inceptua-medicines-access-and-onconova-therapeutics-announce-pre-approval-access-collabora-traw-20191206monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-announces-11-0-million-public-offering-newtown-pa-traw-20191121monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-affirms-planned-completion-of-pivotal-phase-3-inspire-study-of-rigosertib-in-myel-traw-20191024monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-reports-business-highlights-and-second-quarter-2019-financial-re-traw-20190814monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-announces-license-agreement-with-hanx-biopharmaceuticals-to-develop--traw-20190516monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-reports-business-highlights-and-first-quarter-2019-financial-res-traw-20190514monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-reports-business-highlights-and-full-year-2018-financial-results-traw-20190326monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-promotes-dr-steven-m-fruchtman-to-chief-executive-officer-executive--traw-20190115monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-highlights-results-from-phase-2-trial-of-oral-rigosertib-in-combination-with-azac-traw-20181203monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-announces-business-highlights-and-financial-results-for-third-quarte-traw-20181113monthly0.5https://www.biopharmawatch.com/news/TRAW/by-electronic-delivery-to-mguerin-onconova-us-traw-20181012monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-notice-to-holders-of-tradable-warrants-september-25-2018-you-are-traw-20180925monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-reports-business-highlights-and-financial-results-for-second-quarter-traw-20180814monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-announces-promotion-for-steven-m-fruchtman-m-d-new-role-as-the-presi-traw-20180621monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-reports-business-highlights-and-financial-results-for-first-quar-traw-20180515monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-announces-pricing-of-25-0-million-upsized-underwritten-public-offeri-traw-20180427monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-presents-data-on-dual-inhibitor-of-cdk4-6-ark5-at-american-association-for-cancer-traw-20180419monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-announces-license-agreement-with-pint-pharma-to-commercialize-rigose-traw-20180308monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-reports-business-highlights-and-full-year-2017-financial-results-traw-20180308monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-announces-pricing-of-8-7-million-underwritten-public-offering-newtow-traw-20180208monthly0.5https://www.biopharmawatch.com/news/TRAW/corporate-update-traw-20180129monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-moving-forward-with-phase-3-inspire-pivotal-trial-with-increased-sample-size-foll-traw-20180117monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-announces-pricing-of-public-offering-of-common-stock-traw-20171110monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-reports-business-highlights-and-third-quarter-2017-financial-res-traw-20171109monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-reports-recent-business-highlights-and-second-quarter-2017-finan-traw-20170815monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-reports-recent-business-highlights-and-first-quarter-2017-financ-traw-20170515monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-announces-pricing-of-public-offering-of-common-stock-gross-proceeds--traw-20170421monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-reports-recent-business-highlights-and-year-end-2016-financial-r-traw-20170327monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-presents-phase-2-data-from-oral-rigosertib-and-azacitidine-combination-trial-in-h-traw-20161205monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-reports-recent-business-highlights-and-third-quarter-2016-financ-traw-20161114monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-announces-successful-end-of-phase-2-meeting-with-fda-for-oral-rigosertib-and-azac-traw-20160926monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-reports-recent-business-highlights-and-second-quarter-2016-finan-traw-20160815monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-reports-recent-business-highlights-and-first-quarter-2016-financ-traw-20160511monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-reports-recent-business-highlights-and-year-end-2015-financial-r-traw-20160328monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-announces-listing-transfer-to-nasdaq-capital-market-newtown-pa-traw-20160204monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-announces-registered-direct-offering-gross-proceeds-to-support-phase-traw-20160106monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-presents-positive-data-from-phase-2-combination-trial-of-oral-rigosertib-and-azac-traw-20151207monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-reports-recent-business-highlights-and-third-quarter-2015-financ-traw-20151111monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-announces-data-presentation-from-phase-2-combination-trial-of-oral-rigosertib-and-traw-20151105monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-announces-16-5m-share-purchase-agreement-with-lincoln-park-capital-f-traw-20151008monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-reports-recent-business-highlights-and-second-quarter-2015-finan-traw-20150813monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-reports-recent-business-highlights-and-first-quarter-2015-financ-traw-20150514monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-reports-recent-business-highlights-and-fourth-quarter-and-year-e-traw-20150326monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-announces-data-presentation-from-combination-of-rigosertib-and-azacitidine-in-mds-traw-20141207monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-reports-third-quarter-2014-financial-and-operational-results-nin-traw-20141113monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-announces-ten-presentations-at-the-2014-ash-annual-meeting-phase-3-ontime-trial-d-traw-20141106monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-reports-second-quarter-2014-financial-and-operational-results-ne-traw-20140813monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-reports-first-quarter-2014-financial-and-operational-results-new-traw-20140512monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-reports-fourth-quarter-and-year-end-2013-financial-results-and-o-traw-20140310monthly0.5https://www.biopharmawatch.com/news/TRAW/th-annual-cowen-healthcare-conference-traw-20140305monthly0.5https://www.biopharmawatch.com/news/TRAW/analyst-day-traw-20131219monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-announces-results-of-interim-analysis-of-metastatic-pancreatic-cancer-study-newto-traw-20131217monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-announces-presentation-of-positive-data-from-clinical-trials-of-rigosertib-in-mye-traw-20131209monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-reports-third-quarter-2013-financial-and-operational-results-new-traw-20131112monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-therapeutics-inc-reports-second-quarter-2013-financial-and-operational-results-ne-traw-20130906monthly0.5https://www.biopharmawatch.com/news/TRAW/onconova-appoints-dr-jerome-groopman-and-anne-vanlent-to-board-of-directors-newtown-pa-traw-20130729monthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-reports-third-quarter-2025-results-continued-momentum-toward-pma-submission-adgm-20251112monthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-closes-financing-of-19-million-upfront-positions-company-to-advance-purpose-adgm-20251020monthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-announces-pricing-of-up-to-approximately-50-million-private-placement-of-se-adgm-20251015monthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-unveils-preliminary-acute-results-from-fulcrum-vt-u-s-pivotal-study-in-late-adgm-20251010monthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-inc-announces-completion-of-enrollment-for-fulcrum-vt-pivotal-clinical-tria-adgm-20251001monthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-expands-chief-business-officer-deborah-kaster-s-role-to-include-chief-finan-adgm-20250908monthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-reports-second-quarter-2025-results-adgm-20250813monthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-reports-first-quarter-2025-results-adgm-20250515monthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-reports-fourth-quarter-and-full-year-2024-results-adgm-20250331monthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-provides-clinical-and-business-updates-adgm-20250317monthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-announces-strategic-restructuring-to-accelerate-us-pivotal-ide-trial-and-pr-adgm-20250228monthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-announces-appointment-of-accomplished-medical-device-leader-todd-usen-as-ch-adgm-20241216monthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-adagio-medical-reports-third-quarter-2024-results-adgm-20241114monthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-provides-business-updates-adgm-20240819monthly0.5https://www.biopharmawatch.com/news/ADGM/adagio-medical-announces-the-closing-of-the-business-combination-with-arya-iv-creating-a-p-adgm-20240731monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-reports-fiscal-2024-first-quarter-financial-results-q1-2024-adjusted-ebitda-aytu-20231114monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-announces-approval-of-the-cotempla-xr-odt-manufacturing-site-transfer-prior-aytu-20231026monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-reports-record-revenues-record-prescriptions-and-highest-adjusted-ebitda-in-aytu-20230927monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-announces-exclusive-agreement-with-medomie-pharma-ltd-to-commercialize-adze-aytu-20230731monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-announces-submission-of-cotempla-xr-odt-manufacturing-site-transfer-prior-a-aytu-20230710monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-announces-pricing-of-4-0-million-public-offering-priced-at-the-market-and-t-aytu-20230609monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-reports-third-quarter-of-fiscal-year-2023-financial-results-total-prescript-aytu-20230511monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-subleases-a-portion-of-its-manufacturing-facility-englewood-co-aytu-20230501monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-announces-approval-of-adzenys-xr-odt-manufacturing-site-transfer-u-s-food-d-aytu-20230427monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-reports-second-quarter-of-fiscal-year-2023-second-consecutive-quarter-of-po-aytu-20230221monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-announces-delayed-filing-of-second-quarter-fiscal-2023-financial-results-en-aytu-20230213monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-regains-nasdaq-minimum-bid-price-compliance-englewood-co-aytu-20230125monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-announces-1-for-20-reverse-stock-split-englewood-co-aytu-20230105monthly0.5https://www.biopharmawatch.com/news/AYTU/in-the-court-of-chancery-of-the-state-of-delaware-nd-rafal-aponowicz-derivatively-on-behal-aytu-20221219monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-announces-highest-weekly-adzenys-xr-odt-prescriptions-generated-since-incep-aytu-20221130monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-receives-a-180-day-extension-by-nasdaq-to-regain-compliance-with-bid-price--aytu-20221122monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-announces-the-passing-of-co-founder-and-board-member-michael-macaluso-engle-aytu-20221116monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-reports-record-quarterly-revenue-and-positive-adjusted-ebitda-in-first-quar-aytu-20221114monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-to-report-first-quarter-fiscal-2023-financial-results-on-aytu-20221107monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-announces-agreement-with-avenue-venture-debt-fund-to-extend-interest-only-p-aytu-20221025monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-announces-strategic-shift-to-focus-on-commercial-operations-and-indefinite--aytu-20221013monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-announces-continuing-availability-of-adhd-medication-adzenys-xr-odt-in-resp-aytu-20221005monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-reports-record-fourth-quarter-and-fiscal-year-2022-revenue-record-fourth-qu-aytu-20220927monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-to-report-fourth-quarter-and-fiscal-2022-financial-results-on-aytu-20220920monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-announces-addition-of-fourth-patent-license-for-ar101-enzastaurin-this-four-aytu-20220914monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-announces-issuance-of-its-first-patent-for-ar101-enzastaurin-first-issued-u-aytu-20220816monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-announces-closing-of-10-0-million-registered-public-offering-englewood-co-a-aytu-20220815monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-announces-launch-of-public-offering-englewood-co-aytu-20220808monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-announces-initiation-of-the-ar101-prevent-trial-for-the-treatment-of-vascul-aytu-20220720monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-announces-the-appointment-of-vivian-liu-to-the-company-s-board-of-directors-aytu-20220629monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-reports-third-quarter-2022-financial-results-and-outlines-key-strategic-pri-aytu-20220516monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-announces-positive-preclinical-data-in-ventilator-associated-pneumonia-with-aytu-20220425monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-announces-fast-track-designation-granted-to-ar101-for-the-treatment-of-vasc-aytu-20220419monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-announces-fda-orange-book-listing-of-newly-issued-patent-for-cotempla-xr-od-aytu-20220323monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-announces-pricing-of-7-6-million-registered-offering-englewood-co-aytu-20220302monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-announces-ar101-granted-orphan-designation-in-europe-for-the-treatment-of-e-aytu-20220302monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-announces-business-and-pipeline-progress-and-reports-second-quarter-2022-fi-aytu-20220214monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-completes-15-million-debt-refinancing-englewood-co-aytu-20220131monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-appoints-mark-oki-as-chief-financial-officer-englewood-co-aytu-20220104monthly0.5https://www.biopharmawatch.com/news/AYTU/ex-99-1-aytu-biopharma-announces-fda-clearance-of-investigational-new-drug-ind-application-aytu-20211213monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-reports-first-quarter-2022-financial-results-quarterly-net-revenue-increase-aytu-20211115monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-reports-fourth-quarter-and-full-year-fiscal-2021-financial-results-quarterl-aytu-20210927monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-announces-close-of-merger-with-neos-therapeutics-100m-revenue-specialty-ph-aytu-20210322monthly0.5https://www.biopharmawatch.com/news/AYTU/investor-presentation-dated-december-15-2020-exhitbit-99-1-aytu-bioscience-nasdaq-aytu-ann-aytu-20201215monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-announces-10-0-million-bought-deal-offering-englewood-co-accesswire-aytu-20201210monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-nasdaq-aytu-aytu-bioscience-to-acquire-neos-therapeutics-inc-aytu-20201210monthly0.5https://www.biopharmawatch.com/news/AYTU/part-iv-page-report-of-independent-registered-public-accounting-firm-f-x2011-2-consolidate-aytu-20201210monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-and-neos-therapeutics-announce-definitive-merger-agreement-creating-a-comb-aytu-20201210monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-announces-fiscal-q1-2021-net-revenue-of-13-5-million-an-increase-of-839-ye-aytu-20201112monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-announces-fiscal-q4-2020-net-revenue-of-14-9-million-an-increase-of-82-seq-aytu-20201006monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-announces-15-million-debt-retirement-company-retires-15m-obligation-assume-aytu-20200601monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-reports-third-quarter-fiscal-2020-financial-results-company-reports-revenu-aytu-20200514monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-to-report-fiscal-q3-fy-2020-results-and-business-update-englewood-co-aytu-20200507monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-announces-china-export-clearance-of-company-s-covid-19-igg-igm-rapid-test--aytu-20200430monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-announces-results-from-annual-stockholders-meeting-company-s-board-of-dire-aytu-20200424monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-announces-exclusive-distribution-agreement-for-covid-19-igg-igm-rapid-test-aytu-20200423monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-signs-exclusive-global-license-with-cedars-sinai-for-potential-coronavirus-aytu-20200421monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-confirms-export-and-incoming-delivery-of-covid-19-igg-igm-rapid-tests-chin-aytu-20200417monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-announces-positive-results-from-an-independently-conducted-clinical-study--aytu-20200416monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-provides-update-on-its-licensed-covid-19-igg-igm-rapid-test-supply-and-ong-aytu-20200415monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-announces-first-commercial-shipment-of-its-2-10-minute-covid-19-igg-igm-po-aytu-20200403monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-announces-receipt-of-initial-shipment-of-100-000-covid-19-igg-igm-point-of-aytu-20200401monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-submits-notice-of-commercialization-to-the-fda-allowing-for-company-s-dist-aytu-20200323monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-announces-20-0-million-registered-direct-offering-priced-at-the-market-englewood-co-a-aytu-20200312monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-announces-9-0-million-registered-direct-offering-priced-at-the-market-englewood-co-ac-aytu-20200311monthly0.5https://www.biopharmawatch.com/news/AYTU/to-this-current-report-on-form-8-k-a-are-not-specific-to-the-identified-assets-acquired-an-aytu-20200214monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-reports-q2-revenue-of-3-2m-up-77-year-over-year-and-121-sequentially-englewood-co-acc-aytu-20200213monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-and-innovus-pharmaceuticals-announce-filing-of-form-s-4-registration-state-aytu-20191224monthly0.5https://www.biopharmawatch.com/news/AYTU/products-competing-in-the-40b-consumer-segment-0-05-43m-ltm-revenue-19b-tam-aytu-20191211monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-announces-launch-of-natesto-xae-u-s-co-promotion-with-acerus-pharmaceutica-aytu-20191202monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-reports-first-quarter-2020-financial-results-englewood-co-accesswire-aytu-20191114monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-announces-hiring-of-matthew-phillips-as-executive-vice-president-of-commer-aytu-20191111monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-announces-closing-of-12-4m-prescription-product-portfolio-purchase-asset-p-aytu-20191104monthly0.5https://www.biopharmawatch.com/news/AYTU/blueprint-aytu-bioscience-acquires-12-4-million-prescription-product-portfolio-transaction-aytu-20191014monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-announces-10-million-private-placement-armistice-capital-and-altium-capita-aytu-20191014monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-reports-100-revenue-growth-to-7-3-million-in-fy-2019-results-do-not-includ-aytu-20190926monthly0.5https://www.biopharmawatch.com/news/AYTU/filed-by-aytu-bioscience-inc-pursuant-to-rule-425-under-the-securities-act-of-1933-and-dee-aytu-20190912monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-expands-natesto-xae-partnership-with-acerus-pharmaceuticals-to-accelerate--aytu-20190730monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-reports-291-revenue-growth-in-q3-fy19-company-posts-highest-ever-quarterly-aytu-20190514monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-announces-submission-of-zolpimist-x2122-for-approval-to-australian-therape-aytu-20190424monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-reports-71-revenue-growth-in-q2-fy19-company-posts-highest-ever-quarterly--aytu-20190207monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-announces-positive-interim-results-from-natesto-spermatogenesis-study-fert-aytu-20181115monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-reports-55-sequential-revenue-growth-in-q1-fy19-adds-tuzistra-xr-to-portfo-aytu-20181107monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-enters-3-billion-cough-and-cold-market-and-expands-primary-care-portfolio--aytu-20181105monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-announces-issuance-of-first-u-s-patent-covering-mioxsys-for-male-infertili-aytu-20181011monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-announces-publication-of-manuscript-summarizing-results-from-the-ongoing-n-aytu-20180917monthly0.5https://www.biopharmawatch.com/news/AYTU/natesto-q4-revenue-increases-178-sequentially-q4-product-revenue-increases-52-sequentially-aytu-20180906monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-to-report-fiscal-fourth-quarter-2018-results-and-business-update-live-conf-aytu-20180830monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-enters-1-8-billion-u-s-prescription-sleep-aid-market-with-exclusive-licens-aytu-20180613monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-provides-fiscal-third-quarter-2018-business-update-live-conference-call-an-aytu-20180514monthly0.5https://www.biopharmawatch.com/news/AYTU/dear-aytu-bioscience-shareholders-and-colleagues-in-response-to-multiple-inquiries-from-in-aytu-20180424monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-announces-closing-of-12-000-000-public-offering-aytu-20180306monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-provides-fiscal-second-quarter-2018-business-update-live-conference-call-a-aytu-20180208monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-shareholders-and-colleagues-aytu-20180117monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-announces-appointment-of-david-green-as-chief-financial-officer-englewood--aytu-20171218monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-provides-update-on-the-continued-growth-of-natesto-in-the-u-s-englewood-co-aytu-20171128monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-provides-fiscal-first-quarter-2018-business-update-live-conference-call-an-aytu-20171109monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-inc-proforma-balance-sheet-aytu-20171003monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-provides-fiscal-fourth-quarter-and-year-end-2017-business-update-live-conf-aytu-20170831monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-inc-announces-11-5-million-private-placement-englewood-co-aytu-20170811monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-provides-third-quarter-fiscal-2017-business-update-aytu-20170511monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-announces-the-acquisition-of-nuelle-inc-developer-and-marketer-of-fiera-fe-aytu-20170509monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-announces-divestiture-of-primsol-to-allegis-holdings-sale-price-of-1-75-mi-aytu-20170403monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-biosciences-completes-successful-warrant-tender-offer-and-receives-2-2-million-from-e-aytu-20170301monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-provides-second-quarter-fiscal-2017-business-update-and-financial-results--aytu-20170209monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-provides-first-fiscal-quarter-2017-business-update-live-conference-call-an-aytu-20161107monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-announces-pricing-of-8-6-million-public-offering-of-common-stock-and-warra-aytu-20161027monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-provides-fiscal-fourth-quarter-and-fiscal-year-2016-business-update-live-c-aytu-20160901monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-inc-announces-common-stock-purchase-agreement-for-up-to-10-5-million-equit-aytu-20160727monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-strengthens-board-with-the-appointment-of-two-pharmaceutical-industry-vete-aytu-20160713monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-to-optimize-capitalization-in-support-of-future-anticipated-uplisting-of-i-aytu-20160525monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-provides-third-fiscal-quarter-2016-business-update-live-conference-call-an-aytu-20160511monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-announces-closing-of-public-offering-englewood-co-aytu-20160506monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-announces-pricing-of-7-5-million-public-offering-of-common-stock-and-warra-aytu-20160502monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-enters-2-billion-testosterone-replacement-market-with-acquisition-of-u-s-c-aytu-20160425monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-strengthens-board-with-appointment-of-first-independent-director-veteran-f-aytu-20160413monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-awarded-health-canada-approval-for-its-mioxsys-system-for-male-infertility-aytu-20160331monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-provides-second-fiscal-quarter-business-update-live-conference-call-and-we-aytu-20160216monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-announces-additions-to-board-of-directors-englewood-co-aytu-20160127monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-acquires-second-revenue-generating-urology-product-company-to-begin-market-aytu-20151006monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-provides-first-quarterly-business-update-live-conference-call-and-webcast--aytu-20150928monthly0.5https://www.biopharmawatch.com/news/AYTU/aytu-bioscience-completes-5-175-million-private-placement-englewood-co-aytu-20150902monthly0.5https://www.biopharmawatch.com/news/AYTU/report-of-independent-registered-public-accounting-firm-to-the-board-of-directors-and-stoc-aytu-20150422monthly0.5https://www.biopharmawatch.com/news/OPTH/optimi-health-corp-management-s-discussion-and-analysis-overview-this-management-s-discuss-opth-20260529monthly0.5https://www.biopharmawatch.com/news/OPTH/optimi-health-advances-highest-purity-natural-psilocybin-extract-to-date-the-6-naturally-d-opth-20260526monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-inc-announces-pricing-of-approximately-4-0-million-private-placement-offerin-hcwb-20260521monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-enters-into-4-0-million-warrant-inducement-priced-at-the-market-under-nasdaq-hcwb-20251119monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-announces-initiation-of-first-in-human-clinical-trial-to-evaluate-hcw9302-in-hcwb-20251118monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-reports-third-quarter-2025-business-highlights-and-financial-results-miramar-hcwb-20251114monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-reports-second-quarter-2025-business-highlights-and-financial-results-correc-hcwb-20250818monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-reports-second-quarter-2025-business-highlights-and-financial-results-mirama-hcwb-20250814monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-regains-compliance-with-nasdaq-capital-market-requirements-company-in-full-c-hcwb-20250626monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-announces-pricing-of-5-0-million-follow-on-offering-priced-at-the-market-und-hcwb-20250605monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-completes-deliverable-and-solidifies-license-agreement-with-wy-biotech-hcw-b-hcwb-20250604monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-reports-first-quarter-2025-business-highlights-and-financial-results-miramar-hcwb-20250515monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-announces-pricing-of-5-0-million-follow-on-offering-priced-at-the-market-und-hcwb-20250513monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-announces-1-for-40-reverse-stock-split-miramar-fl-x2013-hcwb-20250401monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-reports-fourth-quarter-and-fiscal-year-2024-business-highlights-and-financia-hcwb-20250328monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-granted-extension-by-the-nasdaq-hearings-panel-to-regain-compliance-with-con-hcwb-20250306monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-granted-fda-clearance-to-evaluate-one-of-the-company-s-lead-product-candidat-hcwb-20250203monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-inc-received-nasdaq-staff-determination-letter-company-expected-notice-for-c-hcwb-20241223monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-announces-pricing-of-6-9-million-registered-direct-offering-and-concurrent-p-hcwb-20241118monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-reports-third-quarter-2024-financial-results-and-business-highlights-miramar-hcwb-20241114monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-reports-second-quarter-2024-financial-results-and-business-highlights-correc-hcwb-20240814monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-reports-first-quarter-2024-financial-results-and-business-highlights-miramar-hcwb-20240515monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-reports-fourth-quarter-2023-and-fiscal-year-end-financial-results-and-busine-hcwb-20240401monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-reports-third-quarter-2023-financial-results-and-recent-business-highlights--hcwb-20231114monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-reports-second-quarter-2023-financial-results-and-recent-business-highlights-hcwb-20230811monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-reports-first-quarter-2023-financial-results-and-recent-business-highlights--hcwb-20230509monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-reports-fourth-quarter-and-full-year-2022-financial-results-and-recent-busin-hcwb-20230328monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-reports-third-quarter-2022-financial-results-and-recent-business-highlights--hcwb-20221107monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-reports-second-quarter-2022-financial-results-and-recent-business-highlights-hcwb-20220812monthly0.5https://www.biopharmawatch.com/news/HCWB/u-s-patent-issued-to-hcw-biologics-for-foundational-platform-technology-issued-claims-for--hcwb-20220803monthly0.5https://www.biopharmawatch.com/news/HCWB/u-of-m-begins-phase-i-of-first-in-human-clinical-trial-for-advanced-solid-tumor-cancers-mi-hcwb-20220519monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-reports-first-quarter-2022-financial-results-and-recent-business-highlights--hcwb-20220513monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-reports-fourth-quarter-and-full-year-2021-financial-results-and-business-hig-hcwb-20220328monthly0.5https://www.biopharmawatch.com/news/HCWB/masonic-cancer-center-at-the-university-of-minnesota-receives-fda-clearance-to-proceed-wit-hcwb-20220124monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-reports-third-quarter-financial-results-and-recent-business-highlights-miram-hcwb-20211112monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-receives-fda-clearance-to-proceed-with-phase-1b-clinical-trial-for-immunothe-hcwb-20211028monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-reports-second-quarter-financial-results-and-recent-business-highlights-mira-hcwb-20210813monthly0.5https://www.biopharmawatch.com/news/HCWB/hcw-biologics-inc-announces-pricing-of-56-0-million-initial-public-offering-miramar-fl-hcwb-20210719monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-reports-first-quarter-2026-financial-results-and-provides-corporate--clrb-20260514monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-reports-second-quarter-2025-financial-results-and-provides-a-corpora-clrb-20250814monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-one-for-thirty-reverse-stock-split-clrb-20250618monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-enters-into-common-stock-agreements-to-raise-2-5-million-priced-at-m-clrb-20250605monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-reports-first-quarter-2025-financial-results-and-provides-a-corporat-clrb-20250513monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-announces-plan-to-explore-strategic-alternatives-florham-park-n-j-clrb-20250430monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-reports-financial-results-for-year-ended-2024-and-provides-a-corpora-clrb-20250313monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-highlight-2025-strategic-initiatives-at-upcoming-biotech-showcase-clrb-20250112monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-reports-financial-results-for-q3-2024-and-provides-a-corporate-updat-clrb-20241118monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-compliance-regarding-filing-of-form-10-q-clrb-20241101monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-to-restate-previously-issued-financial-statements-company-announces-receipt-of-e-clrb-20240823monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-reports-financial-results-for-q2-2024-and-provides-a-corporate-updat-clrb-20240813monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-iopofosine-i-131-exceeds-primary-endpoint-in-waldenstrom-s-macroglob-clrb-20240723monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-exercise-of-tranche-b-warrants-and-purchase-of-new-warrant-clrb-20240722monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-reports-financial-results-for-q1-2024-and-provides-a-corporate-updat-clrb-20240514monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-reports-financial-results-for-year-ended-2023-and-provides-a-corpora-clrb-20240327monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-positive-topline-data-achieving-primary-endpoint-in-pivota-clrb-20240108monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-to-release-top-line-data-from-wm-pivotal-trial-during-the-jp-morgan-healthcare-c-clrb-20231102monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-reports-financial-results-for-second-quarter-2023-and-provides-a-corporate-updat-clrb-20230814monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-provides-a-research-and-development-program-summary-waldenstrom-s-macroglobuline-clrb-20230612monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-reports-financial-results-for-first-quarter-2023-and-provides-a-corporate-update-clrb-20230504monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-reports-financial-results-for-year-ended-2022-and-provides-a-corporate-update-clrb-20230309monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-reports-financial-results-for-third-quarter-2022-and-provides-a-corporate-update-clrb-20221103monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-awarded-2-million-grant-to-expand-its-ongoing-phase-1-study-of-iopofosine-i-131--clrb-20220922monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-announces-publication-of-data-from-its-expansion-cohort-of-the-phase-ii-clover-1-clrb-20220913monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-reports-financial-results-for-second-quarter-2022-clrb-20220805monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-announces-stock-consolidation-florham-park-n-j-clrb-20220721monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-reports-financial-results-for-first-quarter-2022-and-provides-a-corporate-update-clrb-20220510monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-positive-dmc-review-of-pivotal-trial-of-iopofosine-in-wald-clrb-20220426monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-reports-financial-results-for-year-ended-december-2021-and-provides-a-corporate--clrb-20220321monthly0.5https://www.biopharmawatch.com/news/CLRB/corporate-presentation-march-2022-n-a-s-d-a-q-c-l-rb-forward-looking-statements-2-this-pre-clrb-20220315monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-executive-leadership-changes-names-mr-chad-kolean-as-chief-clrb-20220225monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-poster-presentation-at-the-63-rd-american-society-for-hema-clrb-20211211monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-s-iopofosine-i-131-exhibits-signals-of-efficacy-in-phase-i-study-for-pediatric-b-clrb-20211116monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-reports-financial-results-for-the-third-quarter-2021-and-provides-a-corporate-up-clrb-20211108monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-appoints-laurence-reilly-m-d-ll-m-interim-chief-medical-officer-successful-track-clrb-20211102monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-announces-innovative-concierge-service-for-patients-participating-in-its-clinica-clrb-20211025monthly0.5https://www.biopharmawatch.com/news/CLRB/preliminary-data-with-iopofosine-i-131-in-combination-with-external-beam-radiation-suggest-clrb-20210922monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-to-participate-in-the-oppenheimer-fall-healthcare-life-sciences-medtech-summit-clrb-20210915monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-awarded-2-0-million-phase-ii-nih-sbir-grant-to-support-pivotal-study-of-iopofosi-clrb-20210818monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-announces-manufacturing-and-supply-agreement-with-evergreen-theragnostics-for-cl-clrb-20210816monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-reports-financial-results-for-the-second-quarter-2021-and-provides-a-corporate-u-clrb-20210809monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-announces-expansion-of-ongoing-collaboration-agreement-with-intocell-inc-preclin-clrb-20210713monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-announces-a-co-development-and-commercialization-collaboration-with-legochembio--clrb-20210712monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-to-participate-in-the-ladenburg-thalmann-2021-virtual-healthcare-conference-clrb-20210708monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-announces-the-election-of-dr-asher-alban-chanan-khan-to-its-board-of-directors-clrb-20210624monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-presents-data-in-waldenstrom-s-macroglobulinemia-in-poster-at-the-2021-american--clrb-20210604monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-announces-poster-presentation-of-clr-131-data-in-waldenstrom-s-macroglobulinemia-clrb-20210520monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-to-participate-at-the-oppenheimer-rare-orphan-disease-summit-on-clrb-20210514monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-reports-financial-results-for-the-first-quarter-2021-and-provides-a-corporate-up-clrb-20210510monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-strengthens-global-ip-position-with-phospholipid-drug-conjugate-composition-of-m-clrb-20210427monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-to-participate-at-upcoming-institutional-investor-conferences-clrb-20210311monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-granted-japanese-composition-of-matter-patent-for-its-phospholipid-ether-drug-co-clrb-20210309monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-to-participate-at-upcoming-institutional-investor-conferences-clrb-20210305monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-reports-financial-results-for-year-ended-clrb-20210302monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-to-present-at-bio-ceo-investor-digital-conference-florham-park-n-j-february-10-2-clrb-20210212monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-receives-orphan-drug-designation-from-the-european-commission-for-clr-131-in-wal-clrb-20210127monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-initiates-pivotal-trial-of-clr-131-in-waldenstrom-s-macroglobulinemia-florham-pa-clrb-20210112monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-pricing-of-24-5-million-underwritten-public-offering-and-2-clrb-20201223monthly0.5https://www.biopharmawatch.com/news/CLRB/corporate-presentation-december-2020-nasdaq-clrb-forward-looking-statements-2-this-present-clrb-20201223monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-reports-third-quarter-2020-financial-results-and-provides-a-corporate-update-clrb-20201109monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-clr-131-demonstrates-preliminary-activity-in-phase-i-study-for-pedia-clrb-20201106monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-reports-data-on-clr-131-phase-2-clover-1-study-in-triple-class-refractory-multip-clrb-20200909monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-presents-poster-at-the-aacr-virtual-meeting-advances-in-malignant-lymphoma-poste-clrb-20200817monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-reports-second-quarter-2020-financial-results-and-provides-a-corporate-update-clrb-20200810monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-announces-poster-presentation-at-the-international-symposium-on-pediatric-neuro--clrb-20200804monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-announces-poster-presentation-of-clinical-data-at-the-american-association-of-ca-clrb-20200721monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-appoints-dr-john-friend-as-chief-medical-officer-clrb-20200701monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-to-be-granted-eu-patent-for-phospholipid-ether-ple-analogs-as-cancer-targeting-d-clrb-20200611monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-closing-of-20-million-underwritten-public-offering-clrb-20200605monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-pricing-of-20-million-underwritten-public-offering-clrb-20200603monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-granted-sme-status-by-the-european-medicines-agency-designation-comes-with-finan-clrb-20200601monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-receives-fda-fast-track-designation-for-clr-131-in-lymphoplasmacytic-lymphoma-wa-clrb-20200526monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-granted-composition-of-matter-and-use-patent-in-europe-for-clr-131-patent-covers-clrb-20200514monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-reports-first-quarter-2020-financial-results-and-provides-a-corporate-update-clrb-20200507monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-reports-financial-results-for-year-ended-clrb-20200309monthly0.5https://www.biopharmawatch.com/news/CLRB/clinical-data-call-clrb-20200219monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-clr-131-achieves-primary-efficacy-endpoints-from-its-phase-clrb-20200219monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-host-a-clr-131-clinical-data-call-with-its-phase-2-lead-investiga-clrb-20200109monthly0.5https://www.biopharmawatch.com/news/CLRB/e-xhibit-99-1-cellectar-appoints-dr-igor-grachev-as-chief-medical-officer-clrb-20200107monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-receives-orphan-drug-designation-for-clr-131-in-lymphoplasmacytic-lymphoma-lpl-clrb-20200106monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-biotech-showcase-2020-clrb-20191219monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-presents-poster-at-the-american-association-for-cancer-research-aacr-san-antonio-clrb-20191213monthly0.5https://www.biopharmawatch.com/news/CLRB/fractionated-dosing-of-clr-131-in-patients-with-relapsed-or-refractory-multiple-myeloma-pr-clrb-20191209monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-announces-oral-presentation-at-the-61-st-annual-american-society-of-hematology-c-clrb-20191202monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-reports-third-quarter-2019-financial-results-and-provides-a-corporate-update-clrb-20191112monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-presents-a-new-phospholipid-drug-conjugate-pdc-at-the-2019-aacr-nci-eortc-molecu-clrb-20191030monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-announces-poster-at-the-2019-aacr-nci-eortc-molecular-targets-and-cancer-therape-clrb-20191017monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-presents-poster-at-the-cancer-research-uk-aacr-joint-conference-on-engineering-a-clrb-20191015monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-announces-presentation-at-the-cancer-research-uk-aacr-joint-conference-on-engine-clrb-20191008monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-presents-data-from-dlbcl-cohort-of-its-phase-2-clover-1-study-at-the-european-so-clrb-20190930monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-receives-orphan-drug-designation-from-the-european-commission-for-clr-131-in-mul-clrb-20190924monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-presents-data-from-cohort-6-of-its-clr-131-phase-1-study-in-patients-with-relaps-clrb-20190916monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-announces-oral-presentation-at-the-european-society-for-medical-oncology-esmo-co-clrb-20190910monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-announces-late-breaker-poster-presentation-at-the-17-th-international-myeloma-wo-clrb-20190904monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-appoints-dov-elefant-as-chief-financial-officer-seasoned-executive-with-over-two-clrb-20190815monthly0.5https://www.biopharmawatch.com/news/CLRB/clr-131-advances-to-second-malignant-brain-tumor-cohort-of-ongoing-pediatric-phase-1-study-clrb-20190814monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-reports-second-quarter-2019-financial-results-and-provides-a-corporate-update-clrb-20190812monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-receives-fda-fast-track-designation-for-clr-131-in-diffuse-large-b-cell-lymphoma-clrb-20190709monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-expands-third-cohort-of-its-phase-2-clover-1-study-of-clr-131-response-rate-exce-clrb-20190521monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-closing-of-10-0-million-financing-clrb-20190520monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-10-0-million-financing-clrb-20190516monthly0.5https://www.biopharmawatch.com/news/CLRB/clr-131-achieves-50-overall-response-rate-in-cohort-6-of-ongoing-phase-1-study-in-relapsed-clrb-20190515monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-receives-fda-fast-track-designation-for-clr-131-in-relapsed-or-refractory-multip-clrb-20190513monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-reports-first-quarter-2019-financial-results-and-provides-a-corporate-update-rep-clrb-20190506monthly0.5https://www.biopharmawatch.com/news/CLRB/fda-grants-exemption-to-import-alert-for-cellectar-s-clr-131-in-pediatric-and-adolescent-p-clrb-20190319monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-reports-financial-results-for-year-ended-clrb-20190226monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-reports-positive-top-line-response-rate-of-30-from-r-r-multiple-myeloma-cohort-i-clrb-20190225monthly0.5https://www.biopharmawatch.com/news/CLRB/corporate-presentation-january-2019-nasdaq-clrb-forward-looking-statements-this-presentati-clrb-20190129monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-provides-update-on-phase-1-trial-of-clr-131-in-relapsed-refractory-multiple-myel-clrb-20190107monthly0.5https://www.biopharmawatch.com/news/CLRB/corporate-presentation-january-2019-nasdaq-clrb-forward-looking-statements-this-presentati-clrb-20190107monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-granted-japanese-patent-for-clr-131-patent-covers-composition-of-matter-and-use--clrb-20181211monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-initiates-cohort-6-of-phase-1b-trial-evaluating-clr-131-in-relapsed-refractory-m-clrb-20181204monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-reports-third-quarter-2018-financial-results-and-provides-business-update-florha-clrb-20181113monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-announces-fda-grants-exemption-to-import-alert-for-clr-131-hematology-studies-cl-clrb-20181112monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-announces-overall-survival-exceeding-19-months-in-phase-1b-trial-with-clr-131-in-clrb-20181002monthly0.5https://www.biopharmawatch.com/news/CLRB/corporate-presentation-october-2018-nasdaq-clrb-forward-looking-statements-this-presentati-clrb-20181002monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-s-clr-131-receives-fda-orphan-drug-designation-for-the-treatment-of-pediatric-os-clrb-20180925monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-provides-an-update-on-the-fda-import-alert-clrb-20180924monthly0.5https://www.biopharmawatch.com/news/CLRB/fda-grants-rare-pediatric-disease-designation-to-cellectar-biosciences-clr-131-for-the-tre-clrb-20180917monthly0.5https://www.biopharmawatch.com/news/CLRB/corporate-presentation-september-2018-nasdaq-clrb-forward-looking-statements-this-presenta-clrb-20180904monthly0.5https://www.biopharmawatch.com/news/CLRB/fractionated-dosing-improves-tolerability-and-safety-of-cellectar-s-clr-131-in-r-r-multipl-clrb-20180820monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-s-clr-131-receives-fda-rare-pediatric-disease-designation-for-the-treatment-of-e-clrb-20180813monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-reports-2018-second-quarter-financial-results-and-provides-business-update-madis-clrb-20180810monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-and-orano-med-announce-collaboration-to-develop-new-phospholipid-drug-conjugate--clrb-20180801monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-closing-of-16-56-million-underwritten-public-offering-and--clrb-20180731monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-pricing-of-14-4-million-underwritten-public-offering-madis-clrb-20180727monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-reports-positive-phase-2-interim-data-for-clr-131-in-relapsed-refractory-dlbcl-p-clrb-20180718monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-reports-94-reduction-in-overall-tumor-volume-in-waldenstrom-macroglobulinemia-pa-clrb-20180717monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-announces-1-for-10-reverse-stock-split-madison-wis-clrb-20180713monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-s-clr-131-receives-fda-orphan-drug-designation-for-treatment-of-ewing-s-sarcoma--clrb-20180709monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-announces-expansion-of-diffuse-large-b-cell-lymphoma-cohort-in-clr-131-phase-2-t-clrb-20180628monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-granted-u-s-patent-for-the-treatment-of-various-cancers-and-cancer-stem-cells-wi-clrb-20180607monthly0.5https://www.biopharmawatch.com/news/CLRB/fda-grants-rare-pediatric-disease-designation-to-cellectar-biosciences-clr-131-for-the-tre-clrb-20180606monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-reports-recent-corporate-highlights-and-2018-first-quarter-financial-results-clrb-20180511monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-granted-orphan-drug-designation-for-clr-131-to-treat-rhabdomyosarcoma-madison-wi-clrb-20180509monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-receives-rare-pediatric-disease-designation-for-clr-131-to-treat-neuroblastoma-m-clrb-20180502monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-presents-preclinical-data-at-aacr-annual-meeting-demonstrating-efficacy-of-fract-clrb-20180417monthly0.5https://www.biopharmawatch.com/news/CLRB/preclinical-data-highlighting-uptake-and-enhanced-anti-tumor-effects-of-cellectar-s-clr-13-clrb-20180416monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-appoints-brian-m-posner-as-chief-financial-officer-madison-wis-clrb-20180404monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-announces-issuance-of-u-s-patent-covering-clr-131-use-in-multiple-myeloma-madiso-clrb-20180403monthly0.5https://www.biopharmawatch.com/news/CLRB/c-ellectar-granted-seminal-u-s-patent-for-phospholipid-ether-analogs-as-cancer-targeting-d-clrb-20180327monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-reports-2017-financial-results-and-provides-a-corporate-update-conference-call-t-clrb-20180321monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-host-2017-financial-results-and-business-update-conference-call-o-clrb-20180322monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-granted-orphan-drug-designation-for-clr-131-to-treat-neuroblastoma-m-clrb-20180319monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-announces-late-breaking-poster-presentations-at-aacr-2018-featuring-pdcs-and-clr-clrb-20180315monthly0.5https://www.biopharmawatch.com/news/CLRB/phase-1-clinical-data-demonstrating-clr-124-uptake-in-brain-tumors-accepted-for-oral-prese-clrb-20180306monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-upcoming-march-conferences-madison-wis-clrb-20180305monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-the-2018-bio-ceo-investor-conference-madison-wis-clrb-20180208monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-receives-uspto-notice-of-allowance-for-patent-covering-use-of-clr-131-in-multipl-clrb-20180207monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-initiates-dlbcl-cohort-in-phase-2-trial-of-clr-131-in-refractory-b-cell-hematolo-clrb-20180129monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-participate-at-noble-capital-markets-fourteenth-annual-investor-c-clrb-20180122monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-participate-at-biotech-showcase-2018-madison-wis-clrb-20180104monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-files-ind-for-phase-1-trial-of-clr-131-in-pediatric-cancers-madison-wis-clrb-20171214monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-announces-expansion-of-relapsed-refractory-multiple-myeloma-cohort-in-phase-2-tr-clrb-20171206monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-the-10-th-annual-ld-micro-main-event-madison-wisc-clrb-20171120monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-reports-third-quarter-2017-financial-and-corporate-performance-madis-clrb-20171109monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-announces-updated-median-overall-survival-of-26-2-months-from-cohort-1-of-clr-13-clrb-20171107monthly0.5https://www.biopharmawatch.com/news/CLRB/new-preclinical-data-suggest-that-cellectar-biosciences-pdc-platform-provides-enhanced-out-clrb-20171030monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-introduces-multiple-dose-regimen-in-fifth-cohort-of-phase-1-trial-of-clrb-20171024monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-receives-additional-japanese-patent-for-clr-131-and-clr-125-for-the--clrb-20171017monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-7-76-million-registered-direct-offering-priced-at-the-mark-clrb-20171010monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-and-pierre-fabre-extend-collaboration-for-development-of-new-phospho-clrb-20171010monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-the-microcap-conference-madison-wis-clrb-20170929monthly0.5https://www.biopharmawatch.com/news/CLRB/l-cellectar-biosciences-reports-cohort-four-data-and-partial-response-in-relapsed-or-refra-clrb-20170927monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-enters-into-strategic-collaboration-with-onconova-therapeutics-to-de-clrb-20170921monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-the-ladenburg-thalmann-2017-healthcare-conference-madi-clrb-20170920monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-appoints-jarrod-longcor-chief-business-officer-madison-wis-clrb-20170918monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-the-19-th-annual-rodman-and-renshaw-global-investment--clrb-20170906monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-significant-pdc-platform-advancement-demonstrates-potentia-clrb-20170822monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-reports-second-quarter-2017-financial-and-corporate-performance-madi-clrb-20170814monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-clr-131-achieves-overall-survival-of-greater-than-22-months-in-advan-clrb-20170808monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-host-conference-call-on-clrb-20170803monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-signs-collaboration-with-avicenna-oncology-to-develop-new-pdcs-for-s-clrb-20170801monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-the-2017-marcum-microcap-conference-madison-wisc-clrb-20170606monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-the-ld-micro-invitational-conference-madison-wisc-clrb-20170530monthly0.5https://www.biopharmawatch.com/news/CLRB/three-abstracts-on-dosing-regimens-of-cellectar-s-clr-131-in-a-variety-of-tumor-types-publ-clrb-20170518monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-reports-first-quarter-2017-financial-and-corporate-performance-madis-clrb-20170511monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-host-conference-call-on-clrb-20170502monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-receives-additional-u-s-patents-for-pdc-optical-agents-in-the-detect-clrb-20170425monthly0.5https://www.biopharmawatch.com/news/CLRB/updated-cellectar-biosciences-strengthens-management-team-with-appointment-of-john-friend--clrb-20170421monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-receives-japanese-patent-for-clr-131-and-clr-125-for-the-treatment-o-clrb-20170418monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-adds-industry-veterans-douglas-swirsky-and-frederick-driscoll-to-its-clrb-20170410monthly0.5https://www.biopharmawatch.com/news/CLRB/after-much-anticipation-cellectar-biosciences-initiates-nci-supported-phase-ii-trial-of-cl-clrb-20170330monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-further-deepens-intellectual-property-portfolio-with-patent-grant-fo-clrb-20170321monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-reports-2016-company-performance-and-continued-progress-in-first-qua-clrb-20170315monthly0.5https://www.biopharmawatch.com/news/CLRB/newly-issued-japanese-patent-for-pdc-optical-agents-further-strengthens-cellectar-bioscien-clrb-20170314monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-host-conference-call-on-march-15-to-report-fourth-quarter-and-yea-clrb-20170309monthly0.5https://www.biopharmawatch.com/news/CLRB/expanding-its-strategic-relationship-with-wisconsin-alumni-research-foundation-warf-cellec-clrb-20170308monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-29-th-annual-roth-conference-madison-wis-clrb-20170306monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-provides-phase-i-trial-update-of-clr-131-in-multiple-myeloma-median--clrb-20170227monthly0.5https://www.biopharmawatch.com/news/CLRB/upon-successful-completion-of-cohort-3-cellectar-biosciences-initiates-fourth-cohort-of-it-clrb-20170222monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-the-2-nd-annual-disruptive-growth-healthcare-conferenc-clrb-20170209monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-2017-bio-ceo-investor-conference-madison-wis-clrb-20170207monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-two-peer-reviewed-studies-demonstrating-the-capabilities-o-clrb-20170131monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-noblecon13-madison-wis-clrb-20170126monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-additional-us-patent-granted-for-clr-131-and-clr-125-in-a--clrb-20170124monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-the-9-th-annual-biotech-showcase-madison-wis-clrb-20170105monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-us-and-japanese-patent-allowances-for-diagnostic-and-optic-clrb-20161220monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-uspto-grants-patent-allowances-for-radiotherapeutic-pdcs-f-clrb-20161214monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-uspto-grants-patent-for-paclitaxel-pdc-provides-additional-clrb-20161212monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-presents-poster-at-the-58-th-annual-meeting-of-the-american-society--clrb-20161206monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-results-from-the-first-two-cohorts-of-its-clr-131-phase-1--clrb-20161201monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-successful-completion-of-9-2-million-public-offering-which-clrb-20161129monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-partnership-with-radiopharmaceutical-specialists-cpdc-to-e-clrb-20161128monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-successful-conjugation-of-multiple-pierre-fabre-cytotoxic--clrb-20161117monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-inc-research-as-the-cro-for-the-phase-ii-trial-of-clr-131--clrb-20161115monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-recent-key-accomplishments-and-third-quarter-2016-financia-clrb-20161110monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-host-conference-call-on-november-11-to-report-third-quarter-2016--clrb-20161107monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-design-for-nci-supported-phase-ii-study-of-clr-131-in-mult-clrb-20161031monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-data-on-clr-131-accepted-for-poster-presentation-at-the-58-clrb-20161024monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-enrollment-of-first-patient-into-third-cohort-of-its-phase-clrb-20161006monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-uspto-issues-formal-patent-allowance-for-clr-1603-madison--clrb-20161004monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-new-positive-data-from-phase-i-clinical-study-of-clr-131-i-clrb-20160929monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-lead-compound-clr-131-to-be-studied-in-head-and-neck-cance-clrb-20160912monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-recent-key-accomplishments-and-second-quarter-2016-financi-clrb-20160811monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-2-million-nci-sbir-contract-for-a-phase-2-clinical-study-c-clrb-20160803monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-appoints-jarrod-longcor-senior-vice-president-of-corporate-developme-clrb-20160720monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-results-of-nci-sponsored-study-of-clr-125-showing-potentia-clrb-20160623monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-results-of-in-vivo-study-demonstrating-pdc-platform-delive-clrb-20160615monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-uspto-issues-patent-for-its-radiotherapeutic-pdc-portfolio-clrb-20160531monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-the-2016-marcum-microcap-conference-madison-wi-clrb-20160523monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-patent-application-for-phospholipid-ether-analogs-as-cancer-targetin-clrb-20160520monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-satisfies-all-nasdaq-listing-criteria-clrb-20160516monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-first-quarter-2016-financial-results-madison-wi-clrb-20160512monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-successful-completion-of-8-million-public-offering-madison-clrb-20160420monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-year-end-2015-financial-results-madison-wi-clrb-20160310monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-1-for-10-reverse-stock-split-madison-wi-clrb-20160304monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-the-2016-biotech-showcase-madison-wi-clrb-20160107monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-positive-data-from-phase-1-therapeutic-trial-of-clr-131-in-clrb-20160105monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-and-pierre-fabre-laboratories-announce-oncology-research-collaborati-clrb-20151217monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-third-quarter-financial-results-madison-wi-clrb-20151112monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-pricing-of-3-3-million-financing-madison-wi-clrb-20150928monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-2-nd-quarter-financial-results-madison-wi-clrb-20150812monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-appoints-industry-veteran-jim-caruso-president-and-chief-executive-officer-dr-si-clrb-20150616monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-clr1502-development-program-to-be-classified-as-combinatio-clrb-20150611monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-intent-to-adjourn-annual-meeting-of-stockholders-meeting-t-clrb-20150527monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-initiates-proof-of-concept-trial-of-i-131-clr1404-in-multiple-myelom-clrb-20150415monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-full-year-2014-financial-results-and-recent-highlights-management-to-clrb-20150324monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-host-conference-call-on-march-24th-to-discuss-fourth-quarter-and--clrb-20150317monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-27-th-annual-roth-conference-clrb-20150304monthly0.5https://www.biopharmawatch.com/news/CLRB/peer-reviewed-glioma-surgery-study-with-cellectar-biosciences-fluorescence-cancer-targetin-clrb-20150122monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-to-present-at-the-biotech-showcase-2015-conference-clrb-20150109monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-granted-orphan-designation-for-i-131-clr1404-for-the-treatment-of-mu-clrb-20141204monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-names-cameron-szakacs-ph-d-vice-president-of-clinical-development-clrb-20141125monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-reports-third-quarter-2014-financial-results-and-recent-highlights-m-clrb-20141111monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-publication-of-findings-demonstrating-efficacy-of-its-phos-clrb-20141015monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-acceptance-of-investigational-new-drug-application-to-eval-clrb-20140904monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-closing-of-public-offering-and-partial-exercise-of-underwr-clrb-20140820monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-pricing-of-12-500-000-public-offering-and-listing-on-the-n-clrb-20140814monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-files-investigational-new-drug-application-to-evaluate-i-131-clr1404-clrb-20140811monthly0.5https://www.biopharmawatch.com/news/CLRB/article-entitled-alkylphosphocholine-analogs-for-broad-spectrum-cancer-imaging-and-therapy-clrb-20140611monthly0.5https://www.biopharmawatch.com/news/CLRB/biosciences-announces-1-for-20-reverse-stock-split-and-reduction-clrb-20140613monthly0.5https://www.biopharmawatch.com/news/CLRB/background-materials-methods-results-conclusions-funding-source-funding-provided-by-cellec-clrb-20140605monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-appoints-chad-j-kolean-chief-financial-officer-clrb-20140529monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-announces-receipt-of-orphan-designation-of-i-124-clr1404-as-diagnost-clrb-20140505monthly0.5https://www.biopharmawatch.com/news/CLRB/dr-simon-pedder-becomes-president-and-chief-executive-officer-of-cellectar-biosciences-clrb-20140402monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-full-year-2013-financial-results-and-recent-highlights-management-to-clrb-20140325monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-march-2014-safe-harbor-statement-this-slide-presentation-contains-fo-clrb-20140319monthly0.5https://www.biopharmawatch.com/news/CLRB/cellectar-announces-initiation-of-phase-ii-imaging-trial-with-i-124-clr1404-in-patients-wi-clrb-20140304monthly0.5https://www.biopharmawatch.com/news/CLRB/novelos-therapeutics-announces-corporate-name-change-to-cellectar-biosciences-inc-stock-to-clrb-20140212monthly0.5https://www.biopharmawatch.com/news/CLRB/novelos-therapeutics-announces-definitive-agreements-to-raise-4-0-million-in-private-place-clrb-20140206monthly0.5https://www.biopharmawatch.com/news/CLRB/developing-novel-drugs-for-the-diagnosis-and-treatment-of-cancer-novelos-therapeutics-inc--clrb-20131122monthly0.5https://www.biopharmawatch.com/news/CLRB/novelos-appoints-industry-veteran-to-lead-strategic-realignment-madison-wisc-clrb-20131009monthly0.5https://www.biopharmawatch.com/news/CLRB/novelos-therapeutics-announces-leadership-transition-madison-wisc-clrb-20130729monthly0.5https://www.biopharmawatch.com/news/CLRB/novelos-therapeutics-inc-otcqx-nvlt-developing-novel-drugs-for-the-treatment-and-diagnosis-clrb-20130523monthly0.5https://www.biopharmawatch.com/news/CLRB/novelos-therapeutics-provides-product-pipeline-update-to-begin-i-124-clr1404-light-phase-2-clrb-20130516monthly0.5https://www.biopharmawatch.com/news/CLRB/novelos-therapeutics-closes-5-5-million-clrb-20130221monthly0.5https://www.biopharmawatch.com/news/CLRB/novelos-therapeutics-prices-5-5-million-public-offering-madison-wisc-clrb-20130213monthly0.5https://www.biopharmawatch.com/news/CLRB/novelos-therapeutics-announces-positive-initial-imaging-results-in-brain-cancer-trial-with-clrb-20120619monthly0.5https://www.biopharmawatch.com/news/CLRB/novelos-therapeutics-closes-5-4-million-public-offering-announces-dismissal-with-prejudice-clrb-20120614monthly0.5https://www.biopharmawatch.com/news/CLRB/novelos-therapeutics-prices-5-4-clrb-20120608monthly0.5https://www.biopharmawatch.com/news/CLRB/novelos-therapeutics-closes-6-clrb-20111207monthly0.5https://www.biopharmawatch.com/news/CLRB/novelos-therapeutics-prices-5-9-clrb-20111201monthly0.5https://www.biopharmawatch.com/news/CLRB/placement-clrb-20110401monthly0.5https://www.biopharmawatch.com/news/ZJYL/jin-medical-international-ltd-announces-1-for-20-share-combination-as-part-of-strategic-na-zjyl-20260311monthly0.5https://www.biopharmawatch.com/news/ZJYL/jin-medical-ceo-fireside-chat-zjyl-20260205monthly0.5https://www.biopharmawatch.com/news/ZJYL/jin-medical-international-ltd-to-host-management-fireside-chat-zjyl-20260126monthly0.5https://www.biopharmawatch.com/news/ZJYL/jin-medical-announces-the-official-commencement-date-of-chuzhou-facility-changzhou-china-zjyl-20260122monthly0.5https://www.biopharmawatch.com/news/ZJYL/jin-medical-international-ltd-management-plans-for-fireside-chat-changzhou-china-zjyl-20260121monthly0.5https://www.biopharmawatch.com/news/ZJYL/jin-medical-international-ltd-no-33-lingxiang-road-wujin-district-changzhou-city-jiangsu-p-zjyl-20251230monthly0.5https://www.biopharmawatch.com/news/ZJYL/jin-medical-international-ltd-unaudited-condensed-consolidated-balance-sheets-march-31-zjyl-20250820monthly0.5https://www.biopharmawatch.com/news/ZJYL/jin-medical-launches-production-at-plant-no-3-accelerating-global-delivery-from-the-chuzho-zjyl-20250716monthly0.5https://www.biopharmawatch.com/news/ZJYL/jin-medical-international-ltd-nasdaq-minimum-bid-price-non-compliance-changzhou-city-china-zjyl-20250506monthly0.5https://www.biopharmawatch.com/news/ZJYL/jin-medical-accelerates-chuzhou-facility-construction-to-unlock-annual-production-capacity-zjyl-20250424monthly0.5https://www.biopharmawatch.com/news/ZJYL/construction-of-jinmed-s-new-facility-begins-in-chuzhou-china-chuzhou-city-china-zjyl-20241010monthly0.5https://www.biopharmawatch.com/news/ZJYL/jin-medical-international-ltd-and-subsidiaries-unaudited-condensed-consolidated-financial--zjyl-20240726monthly0.5https://www.biopharmawatch.com/news/ZJYL/jin-medical-international-ltd-no-33-lingxiang-road-wujin-district-changzhou-city-jiangsu-p-zjyl-20240111monthly0.5https://www.biopharmawatch.com/news/ZJYL/jin-medical-international-ltd-enters-into-memorandum-of-understanding-to-acquire-medical-e-zjyl-20231214monthly0.5https://www.biopharmawatch.com/news/ZJYL/jin-medical-international-ltd-empowers-lao-le-hui-assisted-bathing-project-with-portable-n-zjyl-20231213monthly0.5https://www.biopharmawatch.com/news/ZJYL/jin-medical-international-ltd-secures-rmb66-million-in-orders-for-innovative-micro-hyperba-zjyl-20231211monthly0.5https://www.biopharmawatch.com/news/ZJYL/index-to-unaudited-condensed-consolidated-financial-statements-jin-medical-international-l-zjyl-20230823monthly0.5https://www.biopharmawatch.com/news/ZJYL/jin-medical-international-ltd-announces-exercise-of-the-underwriters-over-allotment-option-zjyl-20230406monthly0.5https://www.biopharmawatch.com/news/ZJYL/jin-medical-international-ltd-announces-pricing-of-8-000-000-initial-public-offering-chang-zjyl-20230327monthly0.5https://www.biopharmawatch.com/news/LFWD/robotics-reports-fourth-quarter-and-year-end-2019-financial-results-lfwd-20200220monthly0.5https://www.biopharmawatch.com/news/LFWD/robotics-announces-pricing-of-7-0-million-public-offering-lfwd-20200210monthly0.5https://www.biopharmawatch.com/news/LFWD/reports-third-quarter-2019-financial-results-lfwd-20191113monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-reports-second-quarter-2019-financial-lfwd-20190808monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-announces-pricing-of-lfwd-20190612monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-appoints-chunlin-allen-han-to-its-board-of-directors-marlborough-mass-and-lfwd-20190520monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-reports-first-quarter-lfwd-20190507monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-announces-pricing-of-registered-direct-offering-for-4-250-000-yokneam-ilit-lfwd-20190403monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-completes-one-for-twenty-five-reverse-lfwd-20190401monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-announces-proposed-public-lfwd-20190225monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-reports-fourth-quarter-lfwd-20190208monthly0.5https://www.biopharmawatch.com/news/LFWD/announces-preliminary-fiscal-year-2018-revenue-lfwd-20190114monthly0.5https://www.biopharmawatch.com/news/LFWD/human-and-robotic-intersection-take-the-next-step-1-november-2018-rewalk-confidential-lfwd-20181113monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-reports-third-quarter-lfwd-20181108monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-reports-second-quarter-lfwd-20180814monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-receives-first-tranche-of-5-million-as-part-of-20-million-strategic-invest-lfwd-20180515monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-reports-first-quarter-lfwd-20180510monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-appoints-yohanan-engelhardt-to-its-board-of-directors-and-as-chairman-of-t-lfwd-20180503monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-ltd-appoints-ori-gon-as-chief-financial-officer-marlborough-ma-lfwd-20180105monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-reports-third-quarter-2017-financial-results-24-yoy-growth-in-q3-revenue-t-lfwd-20171102monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-reports-second-quarter-2017-financial-results-146-yoy-growth-in-q2-revenue-lfwd-20170803monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-reports-first-quarter-2017-financial-results-record-revenue-of-2-5-million-lfwd-20170504monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-reports-fourth-quarter-and-year-end-2016-financial-results-2016-full-year--lfwd-20170217monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-reports-third-quarter-2016-financial-results-revenue-of-1-4-million-placed-lfwd-20161103monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-announces-pricing-of-public-offering-of-ordinary-shares-and-warrants-yokne-lfwd-20161027monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-reports-preliminary-estimated-revenues-of-1-4-million-for-the-third-quarte-lfwd-20161026monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-reports-second-quarter-2016-financial-results-placed-24-personal-units-18--lfwd-20160804monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-reports-first-quarter-2016-financial-results-growth-driven-by-u-s-veterans-lfwd-20160505monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-appoints-peter-l-wehrly-to-its-board-of-directors-yokneam-ilit-israel-marl-lfwd-20160405monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-reports-fourth-quarter-and-year-end-2015-financial-results-record-23-perso-lfwd-20160225monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-reports-third-quarter-2015-financial-results-yokneam-ilit-israel-marlborou-lfwd-20151105monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-ltd-kochav-yokneam-building-floor-6-yokneam-ilit-20692-israel-tel-972-4-95-lfwd-20151019monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-ltd-interim-consolidated-financial-statements-as-of-june-30-2015-u-s-dolla-lfwd-20151001monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-appoints-deborah-disanzo-to-its-board-of-directors-distinguished-career-in-lfwd-20150916monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-founder-dr-amit-goffer-to-retire-dr-goffer-leaves-lasting-legacy-with-visi-lfwd-20150824monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-reports-second-quarter-2015-financial-results-yokneam-ilit-israel-marlboro-lfwd-20150806monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-reports-first-quarter-2015-financial-results-yokneam-ilit-israel-marlborou-lfwd-20150507monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-reports-fourth-quarter-and-year-end-2014-financial-results-fourth-quarter--lfwd-20150212monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-appoints-kevin-hershberger-as-chief-financial-officer-ami-kraft-will-assum-lfwd-20141218monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-reports-third-quarter-2014-financial-results-revenue-up-277-year-over-year-lfwd-20141113monthly0.5https://www.biopharmawatch.com/news/LFWD/rewalk-robotics-ltd-kochav-yokneam-building-floor-6-yokneam-20692-israel-dear-shareholder--lfwd-20141110monthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-presents-higher-dose-phase-1-results-for-da-1726-at-easl-congress-2026-supporting--mtva-20260527monthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-reports-first-quarter-2026-financial-results-and-provides-corporate-update-48-mg-p-mtva-20260514monthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-inc-transforming-cardiometabolic-diseases-investor-presentation-march-2026-www-met-mtva-20260326monthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-announces-the-pricing-of-8-1-million-underwritten-public-offering-mtva-20260115monthly0.5https://www.biopharmawatch.com/news/MTVA/december-2023-nasdaq-nrbo-1-november-2025-metavia-inc-nasdaq-mtva-2-forward-looking-statem-mtva-20251106monthly0.5https://www.biopharmawatch.com/news/MTVA/december-2023-nasdaq-nrbo-1-august-2025-metavia-inc-nasdaq-mtva-2-forward-looking-statemen-mtva-20250807monthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-reports-second-quarter-2025-financial-results-and-provides-corporate-update-dosed--mtva-20250807monthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indication-mtva-20250804monthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-doses-first-patient-in-the-48-mg-mad-cohort-of-its-phase-1-clinical-trial-evaluati-mtva-20250709monthly0.5https://www.biopharmawatch.com/news/MTVA/december-2023-nasdaq-nrbo-1-may-2025-metavia-inc-nasdaq-mtva-2-forward-looking-statements--mtva-20250521monthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-reports-first-quarter-2025-financial-results-and-provides-corporate-update-announc-mtva-20250514monthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-announces-10-0-million-private-placement-priced-at-the-market-under-nasdaq-rules-mtva-20250509monthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-presents-data-on-da-1241-a-gpr119-agonist-demonstrating-both-hepatoprotective-and--mtva-20250507monthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-reports-additional-positive-top-line-results-from-the-mad-part-2-of-its-phase-1-st-mtva-20250422monthly0.5https://www.biopharmawatch.com/news/MTVA/december-2023-nasdaq-nrbo-1-april-2025-metavia-inc-nasdaq-mtva-2-forward-looking-statement-mtva-20250415monthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-announces-positive-top-line-data-from-the-4-week-phase-1-mad-trial-of-da-1726-a-no-mtva-20250415monthly0.5https://www.biopharmawatch.com/news/MTVA/top-line-data-from-mad-part-2-of-the-phase-1-trial-of-da-1726-expected-in-april-of-2025-an-mtva-20250320monthly0.5https://www.biopharmawatch.com/news/MTVA/december-2023-nasdaq-nrbo-1-jan-2025-nasdaq-mtva-da-1241-phase-2a-topline-data-mash-tag-20-mtva-20250110monthly0.5https://www.biopharmawatch.com/news/MTVA/metavia-announces-positive-top-line-results-from-its-phase-2a-clinical-trial-of-da-1241-in-mtva-20241218monthly0.5https://www.biopharmawatch.com/news/MTVA/december-2023-nasdaq-nrbo-1-november-2024-nasdaq-mtva-metavia-inc-2-forward-looking-statem-mtva-20241129monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-announces-strategic-realignment-ahead-of-important-clinical-milest-mtva-20241118monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides-corporat-mtva-20241107monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-completes-last-patient-last-visit-in-its-phase-2a-clinical-trial-e-mtva-20241104monthly0.5https://www.biopharmawatch.com/news/MTVA/december-2023-nasdaq-nrbo-1-october-2024-neurobo-pharmaceuticals-inc-2-forward-looking-sta-mtva-20241007monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-announces-positive-top-line-data-from-the-sad-part-1-of-its-phase--mtva-20240930monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-reports-second-quarter-2024-financial-results-and-provides-corpora-mtva-20240814monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-completes-enrollment-of-the-sad-part-1-of-its-phase-1-clinical-tri-mtva-20240813monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-announces-joint-research-agreement-together-with-dong-a-st-and-imm-mtva-20240806monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-announces-exclusive-license-agreement-with-mthera-pharma-for-nb-01-mtva-20240730monthly0.5https://www.biopharmawatch.com/news/MTVA/december-2023-nasdaq-nrbo-1-july-2024-neurobo-pharmaceuticals-inc-2-forward-looking-statem-mtva-20240716monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-announces-the-closing-of-up-to-70-million-concurrent-private-place-mtva-20240625monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-announces-up-to-70-million-concurrent-private-placement-and-regist-mtva-20240624monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-da-1726-demonstrated-superiority-in-weight-loss-retention-of-lean--mtva-20240622monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-da-1241-in-combination-with-semaglutide-improves-liver-fibrosis-an-mtva-20240522monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-reports-first-quarter-2024-financial-results-and-provides-corporat-mtva-20240509monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-to-present-latest-pre-clinical-data-on-cardiometabolic-assets-da-1241-and-da-1726--mtva-20240430monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-doses-first-patient-in-its-phase-1-clinical-trial-evaluating-da-17-mtva-20240417monthly0.5https://www.biopharmawatch.com/news/MTVA/december-2023-nasdaq-nrbo-1-april-2024-neurobo-pharmaceuticals-inc-2-forward-looking-state-mtva-20240416monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-completes-enrollment-of-part-1-of-its-phase-2a-clinical-trial-eval-mtva-20240401monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-reports-year-end-2023-financial-results-and-provides-corporate-upd-mtva-20240328monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-receives-safety-review-committee-approval-to-continue-with-its-pha-mtva-20240313monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-appoints-seasoned-life-science-executive-marshall-woodworth-as-chi-mtva-20240304monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-receives-first-site-irb-approval-for-its-phase-1-clinical-trial-ev-mtva-20240229monthly0.5https://www.biopharmawatch.com/news/MTVA/december-2023-nasdaq-nrbo-1-february-2024-neurobo-pharmaceuticals-inc-2-forward-looking-st-mtva-20240214monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-announces-fda-clearance-of-ind-for-a-phase-1-clinical-trial-of-da--mtva-20240201monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-reports-positive-pre-clinical-safety-data-of-da-1241-in-combinatio-mtva-20240118monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-regains-compliance-with-nasdaq-minimum-price-requirement-mtva-20240109monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-submits-ind-application-to-the-fda-for-a-phase-1-clinical-trial-of-mtva-20231228monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-announces-1-for-8-reverse-stock-split-commencement-of-trading-on-s-mtva-20231221monthly0.5https://www.biopharmawatch.com/news/MTVA/nasdaq-nrbo-december-2023-neurobo-pharmaceuticals-inc-2-this-presentation-may-contain-forw-mtva-20231207monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-reports-third-quarter-2023-financial-results-and-provides-corporat-mtva-20231113monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-strengthens-board-of-directors-with-the-appointment-of-james-p-tur-mtva-20231106monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-inc-nasdaq-nrbo-september-2023-0-66-x201d-0-66-x201d-2-forward-loo-mtva-20230922monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-doses-first-patient-in-its-phase-2a-clinical-trial-evaluating-da-1-mtva-20230915monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-reports-second-quarter-2023-financial-results-and-provides-corpora-mtva-20230809monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-receives-first-site-irb-approval-for-its-phase-2a-clinical-trial-e-mtva-20230803monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-novel-glp1r-and-gcgr-dual-agonist-da-1726-shown-to-elicit-superior-mtva-20230627monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-announces-acceptance-of-two-general-posters-and-one-eposter-theate-mtva-20230613monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-inc-appoints-pharmaceutical-industry-executive-mark-a-glickman-to--mtva-20230512monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-announces-fda-clearance-of-ind-for-a-phase-2a-clinical-trial-of-da-mtva-20230502monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-announces-submission-of-ind-application-to-the-fda-for-a-phase-2a--mtva-20230403monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-reports-full-year-2022-financial-results-company-pipeline-to-focus-mtva-20230330monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-appoints-joseph-hooker-as-interim-chief-executive-officer-and-pres-mtva-20230118monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-announces-pricing-of-30-mtva-20221104monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-inc-compliant-with-all-applicable-nasdaq-listing-criteria-boston-m-mtva-20220929monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-inc-and-dong-a-st-co-ltd-announce-strategic-collaboration-to-licen-mtva-20220915monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-announces-reverse-stock-split-boston-mtva-20220912monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-reports-full-year-2021-financial-results-boston-mtva-20220401monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-inc-appoints-d-gordon-strickland-to-its-board-of-directors-boston-mtva-20220128monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-reports-third-quarter-2021-financial-results-boston-mtva-20211115monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-appoints-gil-price-m-d-as-president-and-chief-executive-officer-in-mtva-20211104monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-announces-14-mtva-20211001monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-reports-second-quarter-2021-financial-results-boston-mtva-20210816monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-shareholders-elect-hyung-heon-kim-and-andrew-i-koven-to-neurobo-s--mtva-20210712monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-reports-first-quarter-2021-financial-results-boston-mtva-20210517monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-reports-full-year-2020-financial-results-and-provides-corporate-st-mtva-20210415monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-receives-approval-for-amendment-of-contingent-value-rights-for-gem-mtva-20210324monthly0.5https://www.biopharmawatch.com/news/MTVA/company-presentation-confidential-march-2021-2-disclaimers-this-presentation-includes-forw-mtva-20210305monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-announces-10-0-million-private-placement-boston-mtva-20210119monthly0.5https://www.biopharmawatch.com/news/MTVA/company-presentation-mtva-20210108monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-acquires-ana-therapeutics-for-late-stage-oral-antiviral-developmen-mtva-20210106monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-appoints-douglas-j-swirsky-to-the-board-of-directors-industry-vete-mtva-20200902monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-announces-continuation-of-partial-clinical-hold-of-gemcabene-bosto-mtva-20200526monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-announces-7-5-million-registered-direct-offering-boston-mtva-20200414monthly0.5https://www.biopharmawatch.com/news/MTVA/neurobo-pharmaceuticals-reports-year-end-2019-financial-results-and-provides-corporate-str-mtva-20200330monthly0.5https://www.biopharmawatch.com/news/MTVA/novel-treatments-for-neurodegenerative-and-cardiometabolic-conditions-multi-modal-disease--mtva-20191230monthly0.5https://www.biopharmawatch.com/news/MTVA/gemphire-therapeutics-announces-expected-closing-date-of-merger-with-neurobo-pharmaceutica-mtva-20191230monthly0.5https://www.biopharmawatch.com/news/MTVA/gemphire-therapeutics-announces-stockholder-approval-of-proposals-required-for-merger-with-mtva-20191206monthly0.5https://www.biopharmawatch.com/news/MTVA/novel-treatments-for-neurodegenerative-conditions-multi-modal-disease-modifying-therapies--mtva-20190924monthly0.5https://www.biopharmawatch.com/news/MTVA/gemphire-therapeutics-reports-second-quarter-2019-financial-results-and-provides-corporate-mtva-20190809monthly0.5https://www.biopharmawatch.com/news/MTVA/gemphire-therapeutics-and-neurobo-pharmaceuticals-announce-merger-agreement-to-advance-a-n-mtva-20190725monthly0.5https://www.biopharmawatch.com/news/MTVA/gemphire-announces-top-line-data-from-familial-partial-lipodystrophy-fpld-phase-2a-proof-o-mtva-20190626monthly0.5https://www.biopharmawatch.com/news/MTVA/gemphire-therapeutics-reports-fourth-quarter-and-fiscal-year-2018-financial-results-mtva-20190315monthly0.5https://www.biopharmawatch.com/news/MTVA/safe-harbor-statement-this-presentation-includes-forward-looking-statements-within-the-mea-mtva-20190107monthly0.5https://www.biopharmawatch.com/news/MTVA/gemphire-therapeutics-announces-review-of-strategic-alternatives-and-provides-corporate-up-mtva-20181203monthly0.5https://www.biopharmawatch.com/news/MTVA/gemphire-therapeutics-reports-third-quarter-2018-financial-results-and-provides-corporate--mtva-20181108monthly0.5https://www.biopharmawatch.com/news/MTVA/gemphire-therapeutics-inc-condensed-statements-of-comprehensive-loss-in-thousands-except-s-mtva-20180813monthly0.5https://www.biopharmawatch.com/news/MTVA/gemphire-announces-termination-of-phase-2a-clinical-trial-of-gemcabene-in-pediatric-mtva-20180810monthly0.5https://www.biopharmawatch.com/news/MTVA/gemphire-provides-update-on-development-of-gemcabene-fda-requests-the-company-provide-addi-mtva-20180806monthly0.5https://www.biopharmawatch.com/news/MTVA/gemphire-announces-amended-and-restated-gemcabene-license-agreement-with-pfizer-inc-mtva-20180806monthly0.5https://www.biopharmawatch.com/news/MTVA/advancing-cardiovascular-and-nash-opportunities-indigo-1-trial-top-line-results-june-28th--mtva-20180628monthly0.5https://www.biopharmawatch.com/news/MTVA/who-are-diagnosed-with-nafld-and-abnormal-liver-function-as-assessed-by-liver-transaminase-mtva-20180508monthly0.5https://www.biopharmawatch.com/news/MTVA/diagnostics-molecular-templates-tetraphase-pharmaceuticals-biotrove-acquired-by-lifetechno-mtva-20180503monthly0.5https://www.biopharmawatch.com/news/MTVA/gemphire-therapeutics-inc-condensed-statements-of-comprehensive-loss-in-thousands-except-p-mtva-20180315monthly0.5https://www.biopharmawatch.com/news/MTVA/about-gemphire-gemphire-is-a-clinical-stage-biopharmaceutical-company-that-is-committed-to-mtva-20180212monthly0.5https://www.biopharmawatch.com/news/MTVA/condensed-statements-of-comprehensive-loss-in-thousands-except-per-share-amounts-for-the-t-mtva-20171113monthly0.5https://www.biopharmawatch.com/news/MTVA/nafld-gemcabene-has-demonstrated-proof-of-concept-efficacy-for-nash-in-the-stam-x2122-mode-mtva-20170925monthly0.5https://www.biopharmawatch.com/news/MTVA/including-the-success-and-timing-of-gemphire-s-regulatory-submissions-and-pre-clinical-and-mtva-20170919monthly0.5https://www.biopharmawatch.com/news/MTVA/condensed-statements-of-comprehensive-loss-in-thousands-except-per-share-amounts-for-the-t-mtva-20170814monthly0.5https://www.biopharmawatch.com/news/MTVA/providing-new-treatment-options-for-cardiometabolic-diseases-through-its-complementary-con-mtva-20170807monthly0.5https://www.biopharmawatch.com/news/MTVA/ability-to-successfully-market-and-distribute-its-product-candidate-if-approved-gemphire-s-mtva-20170725monthly0.5https://www.biopharmawatch.com/news/MTVA/with-statins-and-other-drugs-in-903-subjects-across-19-phase-1-and-phase-2-clinical-trials-mtva-20170628monthly0.5https://www.biopharmawatch.com/news/MTVA/gemphire-therapeutics-announces-departure-of-its-chief-executive-officer-mina-sooch-livoni-mtva-20170530monthly0.5https://www.biopharmawatch.com/news/MTVA/gemphire-therapeutics-inc-balance-sheet-data-in-thousands-march-31-mtva-20170509monthly0.5https://www.biopharmawatch.com/news/MTVA/gemphire-announces-fiscal-year-2016-financial-results-and-provides-corporate-update-announ-mtva-20170315monthly0.5https://www.biopharmawatch.com/news/MTVA/gemphire-therapeutics-announces-12-5-million-financing-mtva-20170310monthly0.5https://www.biopharmawatch.com/news/MTVA/advancing-a-class-on-top-of-statins-february-2017-safe-harbor-statement-2-this-presentatio-mtva-20170130monthly0.5https://www.biopharmawatch.com/news/MTVA/gemphire-announces-third-quarter-2016-financial-results-and-provides-corporate-update-livo-mtva-20161102monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-results-for-the-period-ended-march-31-2026-rvp-20260515monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-rvp-20260409monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-results-for-2025-rvp-20260327monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-ii-and-iii-class-b-rvp-20251230monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-results-for-the-periods-ended-september-30-2025-rvp-20251114monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-ii-and-iii-class-b-rvp-20250930monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-results-for-the-periods-ended-june-30-2025-rvp-20250814monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-rvp-20250723monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-ii-and-iii-class-b-rvp-20250630monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-results-for-the-period-ended-march-31-2025-rvp-20250515monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-rvp-20250410monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-results-for-2024-rvp-20250328monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-rvp-20250114monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-ii-and-iii-class-b-rvp-20241230monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-results-for-the-periods-ended-september-30-2024-rvp-20241114monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-results-for-the-periods-ended-june-30-2024-rvp-20240814monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-ii-and-iii-class-b-rvp-20240628monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-results-for-the-period-ended-march-31-2024-rvp-20240515monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-results-for-2023-rvp-20240329monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-ii-and-iii-class-b-rvp-20231229monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-not-impacted-by-fda-safety-communication-rvp-20231201monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-results-for-the-periods-ended-september-30-2023-rvp-20231114monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-ii-and-iii-class-b-rvp-20230929monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-results-for-the-period-ended-june-30-2023-rvp-20230814monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-ii-and-iii-class-b-rvp-20230630monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-results-for-the-period-ended-march-31-2023-rvp-20230515monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-results-for-2022-rvp-20230330monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-rvp-20230327monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-ii-and-iii-class-b-rvp-20221228monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-rvp-20221215monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-results-for-the-periods-ended-september-30-2022-rvp-20221114monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-ii-and-iii-class-b-rvp-20220930monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-results-for-the-periods-ended-june-30-2022-rvp-20220815monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-ii-and-iii-class-b-rvp-20220630monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-rvp-20220606monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-9-7-million-in-operating-income-for-the-first-three-m-rvp-20220517monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-rvp-20220418monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-results-for-2021-rvp-20220331monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-ii-and-iii-class-b-rvp-20211229monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-44-1-million-in-operating-income-for-the-first-nine-m-rvp-20211116monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-ii-class-b-rvp-20210930monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-36-1-million-in-operating-income-for-the-first-six-mo-rvp-20210817monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-rvp-20210607monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-rvp-20210603monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-23-4-million-in-operating-income-for-first-quarter-of-rvp-20210517monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-rvp-20210419monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-results-for-2020-rvp-20210401monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-i-and-ii-class-b-rvp-20210108monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-increased-income-and-sales-for-third-quarter-of-2020-rvp-20201118monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-i-and-ii-class-b-rvp-20200930monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-increased-income-and-sales-for-second-quarter-of-2020-rvp-20200817monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-i-and-ii-class-b-rvp-20200630monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-operating-income-and-increased-sales-for-first-quarte-rvp-20200518monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-rvp-20200430monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-results-for-2019-rvp-20200331monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-i-and-ii-class-b-rvp-20191223monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-operating-income-and-increased-sales-for-third-quarte-rvp-20191115monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-i-and-ii-class-b-rvp-20190930monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-operating-income-and-increased-sales-for-second-quart-rvp-20190815monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-i-and-ii-class-b-rvp-20190628monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-announces-results-as-of-march-31-2019-rvp-20190515monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-rvp-20190507monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-results-for-the-year-2018-rvp-20190329monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-rvp-20190327monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-i-and-ii-class-b-rvp-20181221monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-announces-results-as-of-rvp-20181115monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-i-and-ii-class-b-rvp-20181002monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-results-as-of-rvp-20180815monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-i-and-ii-class-b-rvp-20180629monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-announces-results-as-of-rvp-20180516monthly0.5https://www.biopharmawatch.com/news/RVP/www-vanishpoint-com-rti-vanishpoint-com-p-o-box-9-511-lobo-lane-little-elm-texas-75068-000-rvp-20180412monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-results-for-the-year-2017-rvp-20180402monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-i-and-ii-class-b-rvp-20171227monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-announces-results-as-of-rvp-20171114monthly0.5https://www.biopharmawatch.com/news/RVP/eastern-district-court-denies-motion-to-reconsider-becton-dickinson-and-co-judgment-rvp-20171031monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-i-and-ii-class-b-rvp-20170929monthly0.5https://www.biopharmawatch.com/news/RVP/exhi-bit-99-retractable-technologies-inc-files-motions-in-connection-with-becton-dickinson-rvp-20170915monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-sale-of-common-stock-rvp-20170824monthly0.5https://www.biopharmawatch.com/news/RVP/district-court-issues-final-judgment-retractable-technologies-inc-et-al-v-becton-dickinson-rvp-20170818monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-results-as-of-rvp-20170816monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-i-and-ii-class-b-rvp-20170630monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-announces-litigation-update-and-results-for-the-first-quarter-rvp-20170515monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-results-for-the-year-2016-rvp-20170403monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-announces-litigation-updates-rvp-20170321monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-i-and-ii-class-b-rvp-20161227monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-on-fifth-circuit-s-opinion-rvp-20161206monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-results-as-of-rvp-20161115monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-i-and-ii-class-b-rvp-20160922monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-results-as-of-rvp-20160817monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-i-and-ii-class-b-rvp-20160706monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-results-for-the-first-quarter-of-2016-little-elm-texa-rvp-20160517monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-results-for-the-year-2015-little-elm-texas-rvp-20160401monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-i-and-ii-class-b-rvp-20160401monthly0.5https://www.biopharmawatch.com/news/RVP/oral-argument-calendared-for-retractable-technologies-inc-rvp-20160128monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-i-and-ii-class-b-rvp-20160111monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-results-for-the-third-quarter-of-2015-rvp-20151117monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-i-and-ii-class-b-rvp-20150925monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-results-as-of-rvp-20150817monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-i-and-ii-class-b-rvp-20150626monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-recognition-of-payment-rvp-20150521monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-improved-results-for-the-first-quarter-2015-rvp-20150515monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-rvp-20150427monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-rvp-20150421monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-i-and-ii-class-b-rvp-20150409monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-results-for-the-three-and-twelve-months-ended-rvp-20150402monthly0.5https://www.biopharmawatch.com/news/RVP/court-of-appeals-order-retractable-technologies-inc-et-al-v-becton-dickinson-and-co-rvp-20150205monthly0.5https://www.biopharmawatch.com/news/RVP/district-court-issues-final-judgment-retractable-technologies-inc-et-al-v-becton-dickinson-rvp-20150121monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-quarterly-profits-rvp-20141117monthly0.5https://www.biopharmawatch.com/news/RVP/district-court-issues-order-granting-retractable-technologies-inc-injunctive-relief-under--rvp-20141113monthly0.5https://www.biopharmawatch.com/news/RVP/district-court-issues-order-denying-becton-dickinson-and-company-s-renewed-motion-for-judg-rvp-20141006monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-results-of-operations-rvp-20140814monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-i-and-ii-class-b-rvp-20140625monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-i-and-ii-class-b-rvp-20140401monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-i-and-ii-class-b-rvp-20131220monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-results-of-operations-rvp-20131114monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-i-and-ii-class-b-rvp-20131021monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-announces-verdict-rvp-20130919monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-results-of-operations-rvp-20130815monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-i-and-ii-class-b-rvp-20130626monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-results-of-operations-rvp-20130517monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-i-and-ii-class-b-rvp-20130329monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-i-and-ii-class-b-rvp-20121221monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-s-unit-sales-jumped-in-the-third-quarter-of-2012-rvp-20121115monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-i-and-ii-class-b-rvp-20120928monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-s-gross-profit-increased-6-2-in-the-second-quarter-of-2012-ov-rvp-20120815monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-launches-new-vanishpoint-blood-collection-set-rvp-20120726monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-i-and-ii-class-b-rvp-20120711monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-lower-revenue-for-the-first-quarter-rvp-20120516monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-states-that-its-policy-is-not-to-comment-on-unusual-market-ac-rvp-20120425monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-decreased-its-loss-from-operations-dramatically-for-the-nine--rvp-20111130monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-i-and-ii-class-b-rvp-20110909monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-s-unit-sales-increased-dramatically-in-the-second-quarter-of--rvp-20110815monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-rvp-20110711monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-i-and-ii-class-b-rvp-20110628monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-net-income-of-1-7-million-for-the-first-quarter-of-20-rvp-20110520monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-s-normal-policy-is-not-to-comment-on-unusual-market-activity-rvp-20110425monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-net-income-of-2-4-million-in-2010-rvp-20110406monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-77-gross-profit-increase-for-q3-2010-rvp-20101202monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-61-0-sales-increase-for-the-first-quarter-of-2010-rvp-20100519monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-i-and-ii-class-b-rvp-20100511monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-an-increase-in-revenues-of-39-7-for-2009-rvp-20100407monthly0.5https://www.biopharmawatch.com/news/RVP/court-issues-permanent-injunction-enjoining-omi-from-infringing-a-retractable-technologies-rvp-20100305monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-announces-verdict-in-patent-infringement-suit-rvp-20091223monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-has-3q-2009-revenues-increase-19-5-percent-over-3q-2008-rvp-20091119monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-announces-verdict-in-patent-infringement-suit-rvp-20091110monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-acts-to-reduce-annual-operating-expenses-by-6-million-rvp-20090630monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-first-half-2008-sales-of-11-8-rvp-20080811monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-first-quarter-2008-sales-of-5-3-rvp-20080515monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-2007-sales-of-26-3-million-new-patent-and-recent-liti-rvp-20080403monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-nine-months-2007-sales-of-19-1-rvp-20071116monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-first-half-2007-sales-of-11-0-million-as-unit-sales-r-rvp-20070815monthly0.5https://www.biopharmawatch.com/news/RVP/case-2-07-cv-00250-df-document-1-1-filed-06-15-2007-page-1-of-31-in-the-united-states-dist-rvp-20070619monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-5-8-million-in-first-quarter-revenues-as-unit-sales-i-rvp-20070516monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-announces-record-2006-revenues-of-25-3-million-on-32-6-rvp-20070410monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-declares-dividends-to-series-i-and-ii-class-b-rvp-20070328monthly0.5https://www.biopharmawatch.com/news/RVP/queensland-rvp-20070307monthly0.5https://www.biopharmawatch.com/news/RVP/u-s-gov-t-awards-retractable-technologies-third-safety-syringe-contract-under-bush-global--rvp-20070220monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-reports-30-1-rvp-20060517monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-inc-posts-record-4-th-quarter-full-year-2005-sales-and-316-000-4--rvp-20060403monthly0.5https://www.biopharmawatch.com/news/RVP/wednesday-november-16-9-00-am-et-for-immediate-release-retractable-technologies-inc-posts--rvp-20051116monthly0.5https://www.biopharmawatch.com/news/RVP/u-s-gov-t-awards-retractable-technologies-second-safety-syringe-contract-under-bush-global-rvp-20051102monthly0.5https://www.biopharmawatch.com/news/RVP/retractable-technologies-rvp-20051011monthly0.5https://www.biopharmawatch.com/news/QNCX/quince-therapeutics-announces-clinically-meaningful-improvements-across-functional-hemodyn-qncx-20260518monthly0.5https://www.biopharmawatch.com/news/QNCX/quince-therapeutics-settles-approximately-16-4-million-of-debt-qncx-20260330monthly0.5https://www.biopharmawatch.com/news/QNCX/quince-therapeutics-announces-topline-results-from-pivotal-phase-3-neat-clinical-trial-of--qncx-20260129monthly0.5https://www.biopharmawatch.com/news/QNCX/quince-therapeutics-provides-business-update-and-reports-third-quarter-2025-financial-resu-qncx-20251112monthly0.5https://www.biopharmawatch.com/news/QNCX/quince-therapeutics-provides-business-update-and-reports-second-quarter-2025-financial-res-qncx-20250811monthly0.5https://www.biopharmawatch.com/news/QNCX/quince-therapeutics-completes-enrollment-in-pivotal-phase-3-neat-clinical-trial-in-ataxia--qncx-20250716monthly0.5https://www.biopharmawatch.com/news/QNCX/quince-therapeutics-provides-business-update-and-reports-first-quarter-2025-financial-resu-qncx-20250513monthly0.5https://www.biopharmawatch.com/news/QNCX/quince-therapeutics-provides-business-update-and-reports-fiscal-year-2024-financial-result-qncx-20250324monthly0.5https://www.biopharmawatch.com/news/QNCX/quince-therapeutics-provides-business-update-and-reports-third-quarter-2024-financial-resu-qncx-20241113monthly0.5https://www.biopharmawatch.com/news/QNCX/quince-therapeutics-provides-business-update-and-reports-second-quarter-2024-financial-res-qncx-20240813monthly0.5https://www.biopharmawatch.com/news/QNCX/quince-therapeutics-to-acquire-erydel-qncx-20230724monthly0.5https://www.biopharmawatch.com/news/QNCX/quince-therapeutics-adopts-limited-duration-stockholders-rights-plan-qncx-20230405monthly0.5https://www.biopharmawatch.com/news/QNCX/quince-therapeutics-details-strategic-growth-plan-with-launch-of-new-corporate-name-strate-qncx-20220801monthly0.5https://www.biopharmawatch.com/news/QNCX/cortexyme-announces-agreement-to-acquire-novosteo-expanding-pipeline-with-addition-of-targ-qncx-20220510monthly0.5https://www.biopharmawatch.com/news/QNCX/cortexyme-provides-regulatory-update-on-development-program-for-atuzaginstat-in-alzheimer--qncx-20210215monthly0.5https://www.biopharmawatch.com/news/QNCX/investor-contact-chris-lowe-cortexyme-inc-chief-financial-officer-clowe-cortexyme-com-medi-qncx-20210126monthly0.5https://www.biopharmawatch.com/news/QNCX/investor-contact-chris-lowe-cortexyme-inc-chief-financial-officer-clowe-cortexyme-com-medi-qncx-20200512monthly0.5https://www.biopharmawatch.com/news/QNCX/investor-contact-chris-lowe-cortexyme-inc-chief-financial-officer-clowe-cortexyme-com-medi-qncx-20200317monthly0.5https://www.biopharmawatch.com/news/QNCX/hal-mackins-for-cortexyme-inc-hal-torchcomllc-com-415-994-0040-cortexyme-announces-125-mil-qncx-20200205monthly0.5https://www.biopharmawatch.com/news/QNCX/chris-lowe-chief-financial-officer-cortexyme-inc-clowe-cortexyme-com-hal-mackins-for-corte-qncx-20190508monthly0.5https://www.biopharmawatch.com/news/PIII/document-ex-99-1-p3-health-partners-inc-and-subsidiaries-pro-forma-condensed-consolidated--piii-20260515monthly0.5https://www.biopharmawatch.com/news/PIII/p3-health-partners-announces-fourth-quarter-and-full-year-2025-results-providing-2026-guid-piii-20260326monthly0.5https://www.biopharmawatch.com/news/PIII/p3-health-partners-announces-third-quarter-2025-results-p3-reports-continued-operational-p-piii-20251114monthly0.5https://www.biopharmawatch.com/news/PIII/p3-health-partners-announces-second-quarter-2025-results-core-business-demonstrates-streng-piii-20250814monthly0.5https://www.biopharmawatch.com/news/PIII/p3-health-partners-announces-first-quarter-2025-results-affirming-2025-guidance-management-piii-20250515monthly0.5https://www.biopharmawatch.com/news/PIII/p3-health-partners-announces-fourth-quarter-and-full-year-2024-results-revenue-increased-1-piii-20250327monthly0.5https://www.biopharmawatch.com/news/PIII/p3-health-partners-provides-preliminary-2025-guidance-and-announces-proposed-financing-tra-piii-20250213monthly0.5https://www.biopharmawatch.com/news/PIII/p3-health-partners-announces-third-quarter-2024-results-revenue-increased-26-year-over-yea-piii-20241112monthly0.5https://www.biopharmawatch.com/news/PIII/p3-health-partners-announces-second-quarter-2024-results-management-to-host-conference-cal-piii-20240807monthly0.5https://www.biopharmawatch.com/news/PIII/p3-health-partners-announces-first-quarter-2024-results-dr-aric-coffman-joins-p3-health-pa-piii-20240508monthly0.5https://www.biopharmawatch.com/news/PIII/p3-health-partners-announces-fourth-quarter-and-full-year-2023-results-total-revenue-growt-piii-20240328monthly0.5https://www.biopharmawatch.com/news/PIII/document-p3-health-partners-reaffirms-guidance-for-2023-and-announces-guidance-for-2024-he-piii-20240109monthly0.5https://www.biopharmawatch.com/news/PIII/report-of-independent-registered-public-accounting-firm-to-the-stockholders-and-board-of-d-piii-20231109monthly0.5https://www.biopharmawatch.com/news/PIII/document-p3-health-partners-announces-third-quarter-and-year-to-date-2023-results-ytd-tota-piii-20231108monthly0.5https://www.biopharmawatch.com/news/PIII/document-p3-health-partners-announces-second-quarter-2023-results-management-to-host-confe-piii-20230807monthly0.5https://www.biopharmawatch.com/news/PIII/document-p3-health-partners-announces-first-quarter-2023-results-capitated-revenue-increas-piii-20230510monthly0.5https://www.biopharmawatch.com/news/PIII/p3-health-partners-announces-fourth-quarter-and-full-year-2022-results-affirming-2023-guid-piii-20230331monthly0.5https://www.biopharmawatch.com/news/PIII/p3-health-partners-affirms-2023-outlook-and-schedules-earnings-call-for-2022-results-hende-piii-20230314monthly0.5https://www.biopharmawatch.com/news/PIII/p3-health-partners-reaffirms-guidance-for-2022-and-announces-guidance-for-2023-henderson-n-piii-20230111monthly0.5https://www.biopharmawatch.com/news/PIII/p3-health-partners-provides-third-quarter-and-year-to-date-2022-financial-results-strong-t-piii-20221114monthly0.5https://www.biopharmawatch.com/news/PIII/p3-health-partners-provides-second-quarter-and-year-to-date-2022-financial-results-increas-piii-20221020monthly0.5https://www.biopharmawatch.com/news/PIII/p3-health-partners-announces-receipt-of-nasdaq-notice-of-delisting-and-intention-to-appeal-piii-20221004monthly0.5https://www.biopharmawatch.com/news/PIII/p3-health-partners-announces-receipt-of-nasdaq-notice-regarding-late-filing-of-periodic-re-piii-20220819monthly0.5https://www.biopharmawatch.com/news/PIII/p3-health-partners-announces-receipt-of-nasdaq-notice-regarding-late-filing-of-periodic-re-piii-20220524monthly0.5https://www.biopharmawatch.com/news/PIII/p3-health-partners-to-present-fourth-quarter-and-full-year-2021-financial-results-manageme-piii-20220414monthly0.5https://www.biopharmawatch.com/news/PIII/p3-health-partners-announces-select-preliminary-fourth-quarter-and-full-year-2021-results--piii-20220309monthly0.5https://www.biopharmawatch.com/news/PIII/who-people-with-passion-and-purpose-what-dedicated-to-transforming-healthcare-for-patients-piii-20211228monthly0.5https://www.biopharmawatch.com/news/PIII/p3-health-group-holdings-llc-and-subsidiaries-condensed-consolidated-financial-statements--piii-20211209monthly0.5https://www.biopharmawatch.com/news/PIII/p3-analyst-day-presentation-september-2021-who-people-with-passion-and-purpose-what-dedica-piii-20210922monthly0.5https://www.biopharmawatch.com/news/PIII/p3-health-partners-to-become-publicly-traded-via-merger-with-foresight-acquisition-corp-tr-piii-20210525monthly0.5https://www.biopharmawatch.com/news/PIII/index-to-financial-statement-page-audited-financial-statement-of-foresight-acquisition-cor-piii-20210212monthly0.5https://www.biopharmawatch.com/news/PIII/foresight-acquisition-corp-announces-pricing-of-275-000-000-initial-public-offering-foresi-piii-20210210monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-reports-first-quarter-2026-financial-results-advancing-global-commercializa-codx-20260514monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-reports-full-year-2025-financial-results-advancing-global-commercialization-codx-20260331monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-pricing-of-7-0-million-registered-direct-offering-of-common-s-codx-20251028monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on--codx-20250930monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-pricing-of-3-8-million-registered-direct-offering-of-common-s-codx-20250917monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-reports-second-quarter-2025-financial-results-salt-lake-city-utah-codx-20250814monthly0.5https://www.biopharmawatch.com/news/CODX/plan-of-distribution-we-have-entered-into-the-amended-and-restated-equity-distribution-agr-codx-20250425monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-reports-full-year-2024-financial-results-codx-20250327monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-intention-to-submit-enhanced-version-of-covid-19-test-to-fda--codx-20250221monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-reports-third-quarter-2024-financial-results-codx-20241107monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-reports-second-quarter-2024-financial-results-codx-20240808monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-submits-first-fda-510-k-application-for-co-dx-pcr-pro-platform-the-comp-codx-20240614monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-reports-first-quarter-2024-financial-results-codx-20240509monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-reports-full-year-2023-financial-results-codx-20240314monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-reports-third-quarter-2023-financial-results-receives-grant-award-from--codx-20231109monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-reports-second-quarter-2023-financial-results-co-dx-receives-grant-awar-codx-20230810monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-reports-first-quarter-2023-financial-results-clinical-trials-for-co-dx--codx-20230511monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-reports-full-year-2022-financial-results-full-year-results-impacted-by--codx-20230316monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-reports-third-quarter-2022-financial-results-nearing-commencement-of-cl-codx-20221110monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-reports-second-quarter-2022-financial-results-second-quarter-results-im-codx-20220811monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-reports-solid-first-quarter-2022-financial-results-strong-results-highlight-codx-20220512monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-reports-full-year-2021-financial-results-achieved-record-full-year-revenue--codx-20220324monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-authorization-of-30-million-share-repurchase-program-salt-lak-codx-20220315monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-signs-agreement-to-acquire-all-assets-and-intellectual-property-related-codx-20211222monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-reports-continued-strength-in-third-quarter-2021-financial-results-solid-qu-codx-20211111monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-reports-strong-second-quarter-2021-financial-results-solid-quarterly-result-codx-20210812monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-reports-first-quarter-2021-financial-results-strong-quarterly-results-highl-codx-20210513monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-reports-fourth-quarter-and-full-year-2020-financial-results-record-quarterl-codx-20210325monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-anticipates-reporting-highest-quarterly-revenue-following-demand-for-covid--codx-20210106monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-q3-2020-financial-results-including-ytd-net-income-per-common-codx-20201116monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-to-amend-q2-2020-form-10-q-to-show-0-51-net-income-per-share-salt-lake--codx-20201102monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-q1-2020-results-and-provides-mid-second-quarter-update-compan-codx-20200514monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-announces-4-2-million-registered-direct-offering-priced-at-the-market-salt--codx-20200227monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-announces-closing-of-10-2-million-registered-direct-offering-priced-at-the--codx-20200219monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-announces-10-2-million-registered-direct-offering-priced-at-the-market-salt-codx-20200211monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-announces-5-0-million-registered-direct-offering-priced-at-the-market-salt--codx-20200124monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-new-additions-to-board-of-directors-salt-lake-city-utah-codx-20190627monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-regains-compliance-with-nasdaq-listing-standards-salt-lake-city-utah-codx-20190222monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-closing-of-5-5-million-registered-direct-offering-salt-lake-c-codx-20190204monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-elimination-of-debt-additional-capital-infusion-salt-lake-cit-codx-20190130monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-and-lgc-biosearch-technologies-sign-license-agreement-for-coprimer-tech-codx-20181030monthly0.5https://www.biopharmawatch.com/news/CODX/co-diagnostics-inc-announces-pricing-of-initial-public-offering-salt-lake-city-ut-codx-20170712monthly0.5https://www.biopharmawatch.com/news/OSRH/osr-holdings-executes-definitive-815-million-global-license-agreement-for-vxm01-with-bcm-e-osrh-20260429monthly0.5https://www.biopharmawatch.com/news/OSRH/osr-holdings-eliminates-2-02-million-warrant-overhang-with-premium-priced-convertible-note-osrh-20260409monthly0.5https://www.biopharmawatch.com/news/OSRH/vaximm-an-osr-company-receives-binding-term-sheet-from-bcm-europe-for-global-exclusive-lic-osrh-20260112monthly0.5https://www.biopharmawatch.com/news/OSRH/vaximm-ag-an-osr-company-enters-term-sheet-with-bcm-europe-for-potential-vxm01-license-wit-osrh-20251121monthly0.5https://www.biopharmawatch.com/news/OSRH/osr-holdings-signs-definitive-agreement-to-acquire-woori-io-a-pioneer-in-noninvasive-gluco-osrh-20251014monthly0.5https://www.biopharmawatch.com/news/OSRH/osr-holdings-innovation-headquarters-nasdaq-osrh-investor-update-osrh-20250806monthly0.5https://www.biopharmawatch.com/news/OSRH/osr-holdings-appoints-dr-constance-h-fer-as-chief-scientific-officer-osrh-20250325monthly0.5https://www.biopharmawatch.com/news/OSRH/comparison-of-the-three-months-ended-osrh-20250221monthly0.5https://www.biopharmawatch.com/news/OSRH/osr-holdings-inc-and-osr-holdings-co-ltd-announce-completion-of-business-combination-osr-h-osrh-20250218monthly0.5https://www.biopharmawatch.com/news/OSRH/bellevue-life-sciences-acquisition-corp-announces-approval-of-business-combination-proposa-osrh-20250213monthly0.5https://www.biopharmawatch.com/news/OSRH/bellevue-life-sciences-acquisitions-corp-reminds-stockholders-to-vote-in-favor-of-extensio-osrh-20240514monthly0.5https://www.biopharmawatch.com/news/OSRH/osr-holdings-co-ltd-enters-into-business-combination-agreement-with-bellevue-life-sciences-osrh-20231116monthly0.5https://www.biopharmawatch.com/news/OSRH/bellevue-life-sciences-acquisition-corp-and-osr-holdings-sign-an-exclusive-letter-of-inten-osrh-20230711monthly0.5https://www.biopharmawatch.com/news/OSRH/bellevue-life-sciences-acquisition-corp-announces-separate-trading-of-its-shares-of-common-osrh-20230314monthly0.5https://www.biopharmawatch.com/news/OSRH/bellevue-life-sciences-acquisition-corp-page-report-of-independent-registered-public-accou-osrh-20230214monthly0.5https://www.biopharmawatch.com/news/OSRH/bellevue-life-sciences-acquisition-corp-announces-closing-of-full-over-allotment-option-be-osrh-20230221monthly0.5https://www.biopharmawatch.com/news/OSRH/bellevue-life-sciences-acquisition-corp-announces-pricing-of-60-million-initial-public-off-osrh-20230209monthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-ltd-enters-into-5-1-million-warrant-inducement-maxim-group-llc-is-acting-as-mdcx-20251205monthly0.5https://www.biopharmawatch.com/news/MDCX/filed-by-newsfilecorp-com-medicus-pharma-ltd-appoints-carolyn-bonner-as-chief-financial-of-mdcx-20251201monthly0.5https://www.biopharmawatch.com/news/MDCX/filed-by-newsfilecorp-com-medicus-pharma-ltd-provides-corporate-updates-and-reports-third--mdcx-20251114monthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-ltd-announces-8-0-million-non-dilutive-debenture-financing-the-company-plan-mdcx-20250918monthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-ltd-completes-acquisition-of-antev-limited-antev-is-developing-teverelix-a--mdcx-20250902monthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-ltd-provides-update-on-doxorubicin-containing-novel-microneedle-array-d-mna-mdcx-20250821monthly0.5https://www.biopharmawatch.com/news/MDCX/filed-by-newsfilecorp-com-medicus-pharma-ltd-announces-a-memorandum-of-understanding-mou-w-mdcx-20250804monthly0.5https://www.biopharmawatch.com/news/MDCX/filed-by-newsfilecorp-com-medicus-pharma-ltd-announces-voting-results-following-the-annual-mdcx-20250723monthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-ltd-announces-a-definitive-agreement-to-acquire-antev-ltd-uk-antev-sharehol-mdcx-20250630monthly0.5https://www.biopharmawatch.com/news/MDCX/filed-by-newsfilecorp-com-medicus-pharma-ltd-announces-appointment-of-andrew-smith-as-chie-mdcx-20250623monthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-ltd-announces-pricing-of-7-0-million-public-offering-philadelphia-pa-mdcx-20250529monthly0.5https://www.biopharmawatch.com/news/MDCX/filed-by-newsfilecorp-com-medicus-pharma-ltd-announces-a-binding-letter-of-intent-to-acqui-mdcx-20250428monthly0.5https://www.biopharmawatch.com/news/MDCX/filed-by-newsfilecorp-com-mdcx-20250318monthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-ltd-announces-pricing-of-4-2-million-regulation-a-offering-philadelphia-pa-mdcx-20250306monthly0.5https://www.biopharmawatch.com/news/MDCX/filed-by-newsfilecorp-com-medicus-pharma-ltd-enters-into-standby-equity-purchase-agreement-mdcx-20250211monthly0.5https://www.biopharmawatch.com/news/MDCX/notice-of-change-of-auditor-to-eisneramper-llp-mnp-llp-and-to-ontario-securities-commissio-mdcx-20241219monthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-ltd-announces-minor-use-mums-designation-from-the-fda-for-doxorubicin-conta-mdcx-20241212monthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-ltd-announces-collaboration-agreement-to-expand-phase-2-clinical-study-in-a-mdcx-20241202monthly0.5https://www.biopharmawatch.com/news/MDCX/management-s-discussion-and-analysis-the-following-management-s-discussion-and-analysis-md-mdcx-20241125monthly0.5https://www.biopharmawatch.com/news/MDCX/medicus-pharma-ltd-announces-pricing-of-us-4-0m-initial-public-offering-in-the-united-stat-mdcx-20241113monthly0.5https://www.biopharmawatch.com/news/CRIS/unaudited-financial-information-curis-inc-and-subsidiaries-unaudited-condensed-consolidate-cris-20250328monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-inc-fifth-amended-and-restated-2010-stock-incentive-plan-1-purpose-the-purpose-of-th-cris-20240523monthly0.5https://www.biopharmawatch.com/news/CRIS/fda-allows-patient-enrollment-to-resume-in-monotherapy-dose-escalation-of-emavusertib-in-t-cris-20220830monthly0.5https://www.biopharmawatch.com/news/CRIS/fda-lifts-partial-clinical-hold-on-the-takeaim-lymphoma-study-of-emavusertib-curis-working-cris-20220818monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-second-quarter-2022-financial-results-and-business-update-presented-encourag-cris-20220804monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-first-quarter-2022-financial-results-and-business-update-strong-balance-shee-cris-20220505monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-announces-fda-partial-clinical-hold-for-takeaim-lymphoma-study-of-emavusertib-ca-494-cris-20220411monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-announces-fda-partial-clinical-hold-for-takeaim-leukemia-study-of-emavusertib-ca-494-cris-20220404monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-fourth-quarter-and-year-end-2021-financial-results-presented-positive-update-cris-20220224monthly0.5https://www.biopharmawatch.com/news/CRIS/cautionary-note-regarding-forward-looking-statements-this-presentation-contains-certain-fo-cris-20211216monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-appoints-john-a-hohneker-m-d-to-board-of-directors-cris-20211206monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-third-quarter-2021-financial-results-and-business-update-enrolled-first-pati-cris-20211109monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-second-quarter-2021-financial-results-presented-positive-updated-data-from-p-cris-20210803monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-announces-positive-updated-data-from-ongoing-phase-1-2-study-of-ca-4948-monotherapy--cris-20210611monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-inc-fourth-amended-and-restated-2010-stock-incentive-plan-1-purpose-the-purpose-of-t-cris-20210602monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-first-quarter-2021-financial-results-abstract-with-encouraging-clinical-data-cris-20210512monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-fourth-quarter-and-year-end-2020-financial-results-significantly-expanded-ir-cris-20210316monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-announces-proposed-public-offering-of-common-stock-cris-20201208monthly0.5https://www.biopharmawatch.com/news/CRIS/cautionary-note-regarding-forward-looking-statements-this-presentation-contains-certain-fo-cris-20201130monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-third-quarter-2020-financial-results-clinical-data-in-ca-4948-nhl-and-aml-md-cris-20201110monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-second-quarter-2020-financial-results-clinical-data-expected-in-ca-4948-nhl--cris-20200804monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-announces-17-5-million-registered-direct-offering-cris-20200611monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-inc-third-amended-and-restated-2010-stock-incentive-plan-1-purpose-the-purpose-of-th-cris-20200610monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-first-quarter-2020-financial-results-management-to-host-conference-call-toda-cris-20200512monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-fourth-quarter-and-year-end-2019-financial-results-and-provides-business-upd-cris-20200319monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-announces-30-million-common-stock-purchase-agreement-with-aspire-capital-fund-cris-20200227monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-and-aurigene-announce-amendment-of-collaboration-for-the-development-and-commerciali-cris-20200206monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-announces-option-and-license-agreement-with-immunext-for-the-development-and-commerc-cris-20200107monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-announces-positive-safety-tolerability-and-pharmacokinetic-data-in-ongoing-phase-1-s-cris-20191206monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-third-quarter-2019-financial-results-management-to-host-conference-call-toda-cris-20191105monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-announces-promotion-of-bill-steinkrauss-to-chief-financial-officer-cris-20190912monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-second-quarter-2019-financial-results-anti-tumor-activity-observed-in-multip-cris-20190806monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-inc-third-amended-and-restated-2010-stock-incentive-plan-1-purpose-the-purpose-of-th-cris-20190530monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-first-quarter-2019-financial-results-management-to-host-conference-call-toda-cris-20190514monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-fourth-quarter-and-year-end-2018-financial-results-management-to-host-confer-cris-20190326monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-third-quarter-2018-financial-results-new-leadership-increasing-focus-on-clin-cris-20181101monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-second-quarter-2018-financial-results-management-to-host-conference-call-tod-cris-20180802monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-expands-senior-management-expertise-with-appointment-of-robert-martell-m-d-ph-d-as-h-cris-20180524monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-announces-1-for-5-reverse-stock-split-cris-20180522monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-inc-third-amended-and-restated-2010-stock-incentive-plan-1-purpose-the-purpose-of-th-cris-20180515monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-first-quarter-2018-financial-results-management-to-host-conference-call-toda-cris-20180503monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-fourth-quarter-and-year-end-2017-financial-results-management-to-host-confer-cris-20180308monthly0.5https://www.biopharmawatch.com/news/CRIS/this-presentation-contains-certain-forward-looking-statements-about-curis-inc-we-us-or-the-cris-20171113monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-announces-proposed-public-offering-of-common-stock-cris-20170913monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-inc-2017-all-rights-reserved-this-presentation-contains-certain-forward-looking-stat-cris-20170913monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-second-quarter-2017-financial-results-management-to-host-conference-call-tod-cris-20170803monthly0.5https://www.biopharmawatch.com/news/CRIS/this-presentation-contains-certain-forward-looking-statements-about-curis-inc-we-us-or-the-cris-20170607monthly0.5https://www.biopharmawatch.com/news/CRIS/second-amended-and-restated-2010-stock-incentive-plan-1-purpose-the-purpose-of-this-second-cris-20170522monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-james-e-dentzer-chief-financial-officer-chief-administrative-officer--cris-20170504monthly0.5https://www.biopharmawatch.com/news/CRIS/this-presentation-contains-certain-forward-looking-statements-about-curis-inc-we-us-or-the-cris-20161214monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-james-e-dentzer-chief-financial-officer-chief-administrative-officer--cris-20161114monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-james-e-dentzer-chief-financial-officer-chief-administrative-officer--cris-20161109monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-james-e-dentzer-chief-financial-officer-chief-administrative-officer--cris-20160907monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-mani-mohindru-ph-d-chief-strategy-officer-curis-inc-617-503-6605-mmoh-cris-20160330monthly0.5https://www.biopharmawatch.com/news/CRIS/amendment-no-1-to-amended-and-restated-2010-stock-incentive-plan-the-amended-and-restated--cris-20150528monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-prices-public-offering-of-common-stock-cris-20150225monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-mani-mohindru-ph-d-vice-president-corporate-strategy-and-investor-rel-cris-20150224monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-and-aurigene-announce-collaboration-license-and-option-agreement-to-discover-develop-cris-20150121monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-mani-mohindru-ph-d-vice-president-corporate-strategy-and-investor-rel-cris-20140603monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-mani-mohindru-ph-d-vice-president-corporate-strategy-and-investor-rel-cris-20140220monthly0.5https://www.biopharmawatch.com/news/CRIS/forward-looking-statements-this-presentation-contains-statements-about-curis-future-expect-cris-20140113monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-mani-mohindru-ph-d-vice-president-corporate-strategy-and-investor-rel-cris-20131106monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-mani-mohindru-ph-d-vice-president-corporate-strategy-and-investor-rel-cris-20130813monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-michael-p-gray-chief-financial-officer-curis-inc-617-503-6632-mgray-c-cris-20130311monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-michael-p-gray-chief-financial-officer-curis-inc-617-503-6632-mgray-c-cris-20130219monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-michael-p-gray-chief-financial-and-chief-operating-officer-curis-inc--cris-20121212monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-michael-p-gray-chief-financial-and-chief-operating-officer-curis-inc--cris-20121128monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-michael-p-gray-chief-operating-and-chief-financial-officer-curis-inc--cris-20120208monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-michael-p-gray-chief-financial-and-chief-operating-officer-curis-inc--cris-20120130monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-michael-p-gray-chief-financial-and-chief-operating-officer-curis-inc--cris-20111108monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-third-quarter-2011-financial-results-conference-call-to-be-held-today-at-9-0-cris-20111027monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-michael-p-gray-chief-financial-and-chief-operating-officer-curis-inc--cris-20110915monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-second-quarter-2011-financial-results-conference-call-to-be-held-today-at-9--cris-20110728monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-first-quarter-2011-financial-results-conference-call-to-be-held-today-at-9-0-cris-20110428monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-michael-p-gray-chief-financial-and-chief-operating-officer-curis-inc--cris-20110321monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-fourth-quarter-and-year-end-2010-financial-results-conference-call-to-be-hel-cris-20110210monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-third-quarter-2010-financial-results-conference-call-to-be-held-today-at-9-0-cris-20101028monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-second-quarter-2010-financial-results-conference-call-to-be-held-today-at-9--cris-20100803monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-michael-p-gray-chief-financial-and-chief-operating-officer-curis-inc--cris-20100616monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-michael-p-gray-chief-financial-officer-curis-inc-617-503-6632-mgray-c-cris-20100604monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-michael-p-gray-chief-financial-officer-and-chief-operating-officer-cu-cris-20100506monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-fourth-quarter-and-year-end-2009-financial-results-conference-call-to-be-hel-cris-20100225monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-michael-p-gray-chief-financial-and-chief-operating-officer-curis-inc--cris-20100122monthly0.5https://www.biopharmawatch.com/news/CRIS/forward-looking-statements-this-presentation-contains-statements-about-curis-future-expect-cris-20100108monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-third-quarter-2009-financial-results-conference-call-to-be-held-today-at-9-0-cris-20091029monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-second-quarter-2009-financial-results-and-provides-pipeline-update-conferenc-cris-20090730monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-first-quarter-2009-financial-results-conference-call-to-be-held-today-at-9-0-cris-20090505monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-fourth-quarter-and-year-end-2008-financial-results-conference-call-to-be-hel-cris-20090210monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-michael-p-gray-chief-financial-and-chief-operating-officer-curis-inc--cris-20081028monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-michael-p-gray-cfo-coo-curis-inc-617-503-6632-mgray-curis-com-curis-r-cris-20080730monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-michael-p-gray-cfo-coo-curis-inc-617-503-6632-mgray-curis-com-curis-r-cris-20080430monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-michael-p-gray-chief-financial-officer-and-chief-operating-officer-cu-cris-20080214monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-michael-p-gray-chief-financial-officer-curis-inc-617-503-6632-mgray-c-cris-20071219monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-michael-p-gray-cfo-coo-curis-inc-617-503-6632-mgray-curis-com-curis-r-cris-20071030monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-michael-p-gray-cfo-coo-curis-inc-617-503-6632-mgray-curis-com-curis-a-cris-20070806monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-michael-p-gray-cfo-coo-curis-inc-617-503-6632-mgray-curis-com-curis-r-cris-20070731monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-michael-p-gray-jenny-viscarolasaga-cfo-coo-for-curis-inc-curis-inc-61-cris-20070502monthly0.5https://www.biopharmawatch.com/news/CRIS/forward-looking-statements-this-presentation-contains-statements-about-curis-future-expect-cris-20070309monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-michael-p-gray-jenny-viscarolasaga-cfo-coo-for-curis-inc-curis-inc-61-cris-20070214monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-michael-p-gray-jenny-viscarolasaga-chief-financial-officer-for-curis--cris-20061220monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-michael-p-gray-jenny-viscarolasaga-chief-financial-officer-for-curis--cris-20061109monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-inc-nasdaq-cris-corporate-presentation-cris-20060912monthly0.5https://www.biopharmawatch.com/news/CRIS/for-more-information-michael-p-gray-jenny-viscarolasaga-chief-financial-officer-for-curis--cris-20060901monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-second-quarter-2006-financial-results-cambridge-ma-cris-20060727monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-first-quarter-2006-financial-results-cambridge-ma-cris-20060509monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-fourth-quarter-and-year-end-2005-financial-results-cambridge-ma-cris-20060214monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-third-quarter-2005-results-cambridge-ma-cris-20051114monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-logo-for-immediate-release-curis-announces-delay-in-filing-form-10-q-for-third-quart-cris-20051109monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-second-quarter-2005-results-cambridge-ma-cris-20050809monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-tm-curis-inc-nasdaq-cris-corporate-overview-cris-20050620monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-first-quarter-2005-results-cambridge-ma-cris-20050426monthly0.5https://www.biopharmawatch.com/news/CRIS/second-amendment-to-collaborative-research-development-and-license-agreement-between-curis-cris-20050411monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-reports-fourth-quarter-and-year-end-2004-financial-results-cambridge-ma-cris-20050215monthly0.5https://www.biopharmawatch.com/news/CRIS/curis-to-co-develop-cancer-drug-with-genentech-in-the-united-states-agreement-provides-for-cris-20050201monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-oncology-highlights-phase-1-data-in-an-investigator-initiated-study-of-lymphir-deni-ctxr-20260530monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-reports-fiscal-second-quarter-2026-financial-results-and-provid-ctxr-20260515monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-oncology-ships-first-international-order-of-lymphir-to-europe-order-fulfilment-expa-ctxr-20260429monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-announces-a-registered-direct-offering-of-5-million-priced-at-the-m-ctxr-20260424monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-oncology-provides-commercial-update-on-lymphir-launch-highlighting-early-adoption-a-ctxr-20260331monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-oncology-announces-positive-topline-results-from-investigator-initiated-phase-1-stu-ctxr-20260310monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-oncology-announces-preliminary-topline-phase-1-data-from-study-of-lymphir-e7777-dos-ctxr-20260304monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-announces-first-reported-revenue-following-successful-launch-of-ctxr-20260213monthly0.5https://www.biopharmawatch.com/news/CTXR/nasdaq-ctxr-citius-pharmaceuticals-inc-nasdaq-ctxr-corporate-overview-december-2025-forwar-ctxr-20251201monthly0.5https://www.biopharmawatch.com/news/CTXR/this-presentation-has-been-prepared-by-citius-pharmaceuticals-inc-the-company-for-informat-ctxr-20251023monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-announces-a-registered-direct-offering-of-6-0-million-priced-at-the-ctxr-20251021monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-reports-fiscal-third-quarter-2025-financial-results-and-provide-ctxr-20250812monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-requirement-cranfo-ctxr-20250708monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-announces-a-registered-direct-offering-of-up-to-15-8-million-priced-ctxr-20250610monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-reports-fiscal-second-quarter-2025-financial-results-and-provid-ctxr-20250514monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-announces-2-million-registered-direct-offering-of-common-stock-cran-ctxr-20250401monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-reports-fiscal-first-quarter-2025-financial-results-and-provide-ctxr-20250214monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-and-citius-oncology-announce-unique-permanent-j-code-issued-for-lym-ctxr-20250206monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-announces-3-million-registered-direct-offering-priced-at-the-market-ctxr-20250108monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-and-citius-oncology-highlight-lymphir-commercial-launch-planned-for-ctxr-20250107monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-reports-fiscal-full-year-2024-financial-results-and-provides-bu-ctxr-20241227monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-announces-1-for-25-reverse-stock-split-cranford-n-j-ctxr-20241122monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-reports-productive-fda-type-c-meeting-to-discuss-phase-3-mino-lok-p-ctxr-20241125monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-announces-3-million-registered-direct-offering-cranford-nj-ctxr-20241115monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-and-citius-oncology-inc-announce-promising-preliminary-results--ctxr-20241111monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-and-citius-oncology-inc-announce-lymphir-denileukin-diftitox-cx-ctxr-20240905monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-completes-merger-of-subsidiary-with-tenx-keane-to-form-citius-oncol-ctxr-20240813monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-reports-fiscal-third-quarter-2024-financial-results-and-provide-ctxr-20240813monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-receives-fda-approval-for-lymphir-denileukin-diftitox-cxdl-immunoth-ctxr-20240808monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-achieves-primary-and-secondary-endpoints-in-phase-3-trial-of-mino-l-ctxr-20240521monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-reports-fiscal-second-quarter-2024-financial-results-and-provid-ctxr-20240514monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-announces-15-million-registered-direct-offering-cranford-nj-ctxr-20240426monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-announces-fda-acceptance-of-the-bla-resubmission-of-lymphir-denileu-ctxr-20240318monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-reports-fiscal-first-quarter-2024-financial-results-and-provide-ctxr-20240214monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-resubmits-the-biologics-license-application-of-lymphir-denileukin-d-ctxr-20240214monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-announces-nomination-of-pharmaceutical-executive-robert-j-smith-to--ctxr-20240123monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-reports-fiscal-full-year-2023-financial-results-and-provides-bu-ctxr-20240102monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-executes-definitive-agreement-to-merge-wholly-owned-subsidiary-with-ctxr-20231024monthly0.5https://www.biopharmawatch.com/news/CTXR/nasdaq-ctxr-click-to-edit-master-title-style-citius-pharmaceuticals-inc-nasdaq-ctxr-corpor-ctxr-20230911monthly0.5https://www.biopharmawatch.com/news/CTXR/press-release-exhibiti-99-1-citius-pharmaceuticals-inc-ctxr-20230908monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-reports-fiscal-third-quarter-2023-financial-results-and-provide-ctxr-20230815monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-reaches-92-event-milestone-in-mino-lok-phase-3-trial-cranford-n-j-ctxr-20230810monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-receives-a-complete-response-letter-from-the-u-s-food-and-drug--ctxr-20230729monthly0.5https://www.biopharmawatch.com/news/CTXR/nasdaq-ctxr-click-to-edit-master-title-style-citius-pharmaceuticals-inc-nasdaq-ctxr-corpor-ctxr-20230629monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-announces-positive-results-from-the-phase-2b-study-of-halo-lido-cit-ctxr-20230620monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-reports-fiscal-second-quarter-2023-financial-results-and-provid-ctxr-20230512monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-announces-15-million-registered-direct-offering-cranford-nj-ctxr-20230504monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-advances-mino-lok-phase-3-trial-achieving-85-of-92-events-to-date-c-ctxr-20230424monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-completes-enrollment-in-phase-2b-study-of-halo-lido-for-the-prescri-ctxr-20230403monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-reports-fiscal-first-quarter-2023-financial-results-and-provide-ctxr-20230210monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-reports-fiscal-full-year-2022-financial-results-and-provides-bu-ctxr-20221222monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-announces-u-s-food-and-drug-administration-acceptance-of-biolog-ctxr-20221201monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-secures-3-6-million-through-new-jersey-economic-development-pro-ctxr-20221121monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-submits-biologics-license-application-to-the-u-s-food-and-drug--ctxr-20220928monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-announces-a-clinical-collaboration-with-the-university-of-pittsburg-ctxr-20220922monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-reports-fiscal-third-quarter-2022-financial-results-and-provide-ctxr-20220811monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-holds-pre-bla-meeting-with-the-fda-for-i-ontak-denileukin-difti-ctxr-20220712monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-announces-intention-to-spinoff-late-stage-oncology-asset-i-onta-ctxr-20220525monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-reports-fiscal-second-quarter-2022-financial-results-and-provid-ctxr-20220512monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-to-accelerate-phase-3-mino-lok-trial-by-expanding-trial-sites-inter-ctxr-20220506monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-enrolls-first-patient-in-phase-2b-study-of-halo-lido-for-the-prescr-ctxr-20220426monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-announces-key-management-realignment-to-support-commercialization-o-ctxr-20220413monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-reports-topline-data-from-the-pivotal-phase-3-study-of-cancer-immun-ctxr-20220406monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-announces-fda-acceptance-of-ind-application-for-its-phase-2b-study--ctxr-20220215monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-reports-fiscal-first-quarter-2022-financial-results-and-provide-ctxr-20220210monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-reports-fiscal-full-year-2021-financial-results-and-provides-bu-ctxr-20211215monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-completes-enrollment-in-the-pivotal-phase-3-study-of-its-cancer-imm-ctxr-20211206monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-acquires-dr-reddy-s-laboratories-license-for-late-phase-3-oncology--ctxr-20210907monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-reports-third-fiscal-quarter-2021-financial-results-and-provide-ctxr-20210812monthly0.5https://www.biopharmawatch.com/news/CTXR/nasdaq-ctxr-click-to-edit-master-title-style-citius-pharmaceuticals-inc-nasdaq-ctxr-corpor-ctxr-20210707monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-announces-positive-recommendation-by-independent-data-monitorin-ctxr-20210701monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-achieves-next-interim-analysis-milestone-in-its-mino-lok-phase-3-tr-ctxr-20210608monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-to-be-added-to-russell-2000-index-cranford-n-j-ctxr-20210607monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-reports-second-fiscal-quarter-2021-financial-results-and-provid-ctxr-20210513monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-announces-76-5-million-registered-direct-offering-priced-at-the-mar-ctxr-20210217monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-corporate-presentation-winter-2020-21-nasdaq-ctxr-2-nasdaq-ctxr-ctxr-20210216monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-announces-20-0-million-private-placement-priced-at-the-market-cranf-ctxr-20210125monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-corporate-presentation-winter-2020-21-nasdaq-ctxr-2-nasdaq-ctxr-ctxr-20210111monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-receives-fda-response-and-guidance-to-pre-ind-consultation-submissi-ctxr-20201209monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-subsidiary-novecite-announces-data-from-a-study-of-induced-mesenchy-ctxr-20201208monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-announces-results-of-study-that-mino-lok-eradicates-s-aureus-biofilm-more-effective-ctxr-20201130monthly0.5https://www.biopharmawatch.com/news/CTXR/908-967-6677-x105-ascott-citiuspharma-com-letter-to-shareholders-october-2020-dear-fellow--ctxr-20201026monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-signs-an-exclusive-worldwide-licensing-agreement-with-novellus-ther-ctxr-20201007monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-reports-positive-results-from-recent-data-monitoring-committee-meet-ctxr-20200929monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-achieves-chemical-manufacturing-and-control-milestones-for-mino-lok-ctxr-20200922monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-files-addendum-to-mino-lok-phase-3-trial-record-keeping-protocol-to-advance-trials--ctxr-20200915monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-announces-improved-design-and-expansion-of-intellectual-property-fo-ctxr-20200826monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-corporate-presentation-fall-2020-nasdaq-ctxr-disclaimer-this-pr-ctxr-20200826monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-announces-6-0-million-bought-deal-offering-cranford-n-j-ctxr-20200805monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-submits-mino-wrap-briefing-package-to-fda-for-pre-ind-consult-mino-wrap-being-devel-ctxr-20200804monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-brings-on-myron-s-czuczman-m-d-as-chief-medical-officer-cmo-and-exe-ctxr-20200714monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-receives-fda-response-on-pre-investigational-new-drug-pind-application-for-its-indu-ctxr-20200626monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-receives-positive-fda-feedback-on-its-submitted-plan-to-study-catheter-compatibilit-ctxr-20200602monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-announces-expanded-access-program-for-investigational-phase-3-mino-lok-the-covid-19-ctxr-20200526monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-announces-7-5-million-registered-direct-offering-priced-at-the-market-under-nasdaq--ctxr-20200514monthly0.5https://www.biopharmawatch.com/news/CTXR/908-967-6677-x105-ascott-citiuspharma-com-letter-to-shareholders-may-2020-dear-fellow-shar-ctxr-20200512monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-corporate-presentation-summer-2020-nasdaq-ctxr-disclaimer-this--ctxr-20200429monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-announces-pre-ind-submission-to-fda-under-the-coronavirus-treatment-acceleration-pr-ctxr-20200427monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-signs-exclusive-option-with-novellus-to-license-novel-stem-cell-therapy-for-acute-r-ctxr-20200401monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-cites-independent-estimates-of-total-available-world-market-for-min-ctxr-20200225monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-achieves-50-patient-enrollment-in-phase-3-mino-lok-pivotal-trial-next-major-milesto-ctxr-20200204monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements-cranford-n-j-ctxr-20200203monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-ctxr-20200122monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-announces-positive-outcome-of-interim-futility-analysis-for-its-phase-3-mino-lok-pi-ctxr-20191219monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-corporate-update-november-2019-dear-investors-citius-pharmaceuticals-inc-company-ha-ctxr-20191105monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-reaches-first-interim-analysis-milestone-for-mino-lok-pivotal-trial-study-reaches-4-ctxr-20191007monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-announces-pricing-of-7-0-million-underwritten-offering-priced-at-the-market-cranfor-ctxr-20190925monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-ctxr-20190919monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-announces-change-to-primary-endpoint-in-mino-lok-phase-3-study-new-endpoint-improve-ctxr-20190904monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-presents-data-on-mino-lok-showing-98-clinical-efficacy-the-data-pro-ctxr-20190430monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-announces-5-3-million-registered-direct-offering-priced-at-the-market-cranford-n-j-ctxr-20190401monthly0.5https://www.biopharmawatch.com/news/CTXR/2-disclaimer-this-presentation-has-been-prepared-by-citius-pharmaceuticals-inc-ctxr-20190219monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-licenses-mino-wrap-from-md-anderson-cancer-center-new-technology-designed-to-reduce-ctxr-20190108monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-ctxr-20181212monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-announces-pricing-of-10-0-million-underwritten-offering-priced-at-the-market-cranfo-ctxr-20180809monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-ctxr-20180801monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-provides-clinical-update-and-progress-of-the-mino-lok-phase-3-trial-pivotal-trial-a-ctxr-20180709monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-announces-2-0-million-registered-direct-offering-priced-at-the-market-cranford-nj-ctxr-20180329monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-announces-enrollment-of-first-patient-in-the-mino-lok-phase-3-trial-pivotal-trial-t-ctxr-20180215monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-announces-6-million-registered-direct-offering-priced-at-the-market-cranford-nj-ctxr-20171218monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-corporate-presentation-winter-2017-nasdaq-ctxr-2-disclaimer-thi-ctxr-20171201monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-corporate-presentation-winter-2017-nasdaq-ctxr-2-disclaimer-thi-ctxr-20171107monthly0.5https://www.biopharmawatch.com/news/CTXR/international-study-at-md-anderson-sister-institutions-supports-mino-lok-phase-2b-results--ctxr-20171107monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-receives-fast-track-designation-by-fda-for-mino-lok-tm-investig-ctxr-20171031monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-shareholder-letter-october-2017-dear-citius-pharmaceuticals-inc-sha-ctxr-20171010monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-announces-closing-of-public-offering-cranford-nj-august-8-2017--ctxr-20170802monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-prices-6-800-000-public-offering-and-listing-on-the-nasdaq-capi-ctxr-20170804monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharma-announces-addition-of-south-america-to-world-license-worldwide-license-for-m-ctxr-20170323monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-discontinues-suprenza-to-focus-on-core-assets-ctxr-20160701monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-announces-appointment-of-dr-eugene-holuka-to-its-board-of-direc-ctxr-20160628monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-completes-acquisition-of-leonard-meron-biosciences-acquisition-prov-ctxr-20160405monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-signs-letter-of-intent-to-acquire-leonard-meron-biosciences-merger--ctxr-20160307monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-announces-results-from-phase-2a-trial-of-hydrocortisone-and-lidocai-ctxr-20160201monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-inc-announces-appointment-of-mr-suren-dutia-to-its-board-of-directo-ctxr-20151008monthly0.5https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-announces-myron-holubiak-former-president-of-roche-laboratories-inc-ctxr-20151006monthly0.5https://www.biopharmawatch.com/news/CTXR/unaudited-pro-forma-condensed-financial-statements-the-following-unaudited-condensed-pro-f-ctxr-20140918monthly0.5https://www.biopharmawatch.com/news/EUDA/euda-health-expands-helix-product-line-with-launch-of-regenix-ipsc-derived-skin-stem-cell--euda-20260601monthly0.5https://www.biopharmawatch.com/news/EUDA/euda-health-holdings-limited-has-regained-compliance-with-nasdaq-capital-market-s-continue-euda-20260601monthly0.5https://www.biopharmawatch.com/news/EUDA/euda-highlights-shenzhen-inno-s-approval-under-shenzhen-key-industry-r-d-program-for-tcr-t-euda-20260428monthly0.5https://www.biopharmawatch.com/news/EUDA/euda-health-holdings-limited-has-received-notice-from-nasdaq-that-it-has-failed-to-maintai-euda-20260427monthly0.5https://www.biopharmawatch.com/news/EUDA/euda-announces-reverse-stock-split-of-its-ordinary-shares-singapore-euda-20260319monthly0.5https://www.biopharmawatch.com/news/EUDA/euda-health-holdings-limited-announces-repurchase-and-cancellation-of-streeterville-warran-euda-20260304monthly0.5https://www.biopharmawatch.com/news/EUDA/euda-health-announces-second-amendment-to-streeterville-warrant-agreement-singapore-euda-20260115monthly0.5https://www.biopharmawatch.com/news/EUDA/euda-enters-into-convertible-loan-agreement-with-shenzhen-inno-further-expanding-stem-cell-euda-20260113monthly0.5https://www.biopharmawatch.com/news/EUDA/euda-health-holdings-limited-announces-amendment-to-streeterville-warrant-agreement-singap-euda-20260107monthly0.5https://www.biopharmawatch.com/news/EUDA/euda-launches-nationwide-stem-cell-extraction-cryostorage-and-clinical-delivery-platform-i-euda-20251230monthly0.5https://www.biopharmawatch.com/news/EUDA/euda-health-to-launch-euda-helix-2-0-in-january-2026-singapore-euda-20251229monthly0.5https://www.biopharmawatch.com/news/EUDA/euda-accelerates-longevity-strategy-with-launch-of-comprehensive-stem-cell-therapy-platfor-euda-20251223monthly0.5https://www.biopharmawatch.com/news/EUDA/euda-integrates-qb-utility-token-to-create-a-digital-health-and-rewards-platform-across-it-euda-20251222monthly0.5https://www.biopharmawatch.com/news/EUDA/euda-plans-to-integrate-qb-utility-token-into-its-healthcare-ecosystem-singapore-euda-20251208monthly0.5https://www.biopharmawatch.com/news/EUDA/euda-health-holdings-limited-announces-execution-of-securities-purchase-agreement-singapor-euda-20251205monthly0.5https://www.biopharmawatch.com/news/EUDA/euda-subsidiary-ck-health-plus-expands-into-india-in-strategic-partnership-with-saferock-i-euda-20251023monthly0.5https://www.biopharmawatch.com/news/EUDA/euda-subsidiary-ck-health-plus-secures-malaysia-direct-selling-license-strengthening-its-l-euda-20251020monthly0.5https://www.biopharmawatch.com/news/EUDA/euda-health-holdings-limited-and-subsidiaries-unaudited-condensed-consolidated-balance-she-euda-20251001monthly0.5https://www.biopharmawatch.com/news/EUDA/euda-signs-letter-of-intent-to-potentially-acquire-euda-20250910monthly0.5https://www.biopharmawatch.com/news/EUDA/euda-strategically-expands-into-t-cell-immunotherapy-strengthening-its-stem-cell-therapy-p-euda-20250904monthly0.5https://www.biopharmawatch.com/news/EUDA/euda-signs-letter-of-intent-to-potentially-acquire-chemokine-pte-ltd-singapore-euda-20250828monthly0.5https://www.biopharmawatch.com/news/EUDA/euda-expands-wellness-product-portfolio-with-a-next-generation-immune-health-supplement-si-euda-20250826monthly0.5https://www.biopharmawatch.com/news/EUDA/euda-partners-with-authorized-distributor-of-guangdong-cell-biotech-to-offer-stem-cell-the-euda-20250424monthly0.5https://www.biopharmawatch.com/news/EUDA/euda-holdings-and-guangdong-cell-biotech-explore-potential-strategic-partnership-to-advanc-euda-20241216monthly0.5https://www.biopharmawatch.com/news/EUDA/euda-health-holdings-limited-and-subsidiaries-unaudited-condensed-consolidated-balance-she-euda-20241018monthly0.5https://www.biopharmawatch.com/news/EUDA/fortress-cove-limited-index-of-financial-statements-financial-statements-report-of-indepen-euda-20241010monthly0.5https://www.biopharmawatch.com/news/EUDA/euda-health-holdings-limited-completes-acquisition-of-ck-health-plus-sdn-bhd-expanding-int-euda-20240508monthly0.5https://www.biopharmawatch.com/news/EUDA/euda-health-expands-into-direct-selling-holistic-wellness-products-with-acquisition-of-ck--euda-20240506monthly0.5https://www.biopharmawatch.com/news/EUDA/euda-health-holdings-limited-has-received-nasdaq-notification-regarding-minimum-market-val-euda-20240116monthly0.5https://www.biopharmawatch.com/news/EUDA/euda-health-holdings-limited-announces-receipt-of-nasdaq-listing-delinquency-letter-singap-euda-20230519monthly0.5https://www.biopharmawatch.com/news/EUDA/euda-health-holdings-limited-announces-receipt-of-nasdaq-listing-delinquency-letter-singap-euda-20230410monthly0.5https://www.biopharmawatch.com/news/EUDA/euda-health-holdings-limited-board-of-director-officer-letter-euda-20230215monthly0.5https://www.biopharmawatch.com/news/EUDA/euda-health-limited-and-subsidiaries-index-to-unaudited-condensed-consolidated-financial-s-euda-20221123monthly0.5https://www.biopharmawatch.com/news/EUDA/i-acquisition-2-corp-announces-approval-of-business-combination-and-ability-of-shareholder-euda-20221110monthly0.5https://www.biopharmawatch.com/news/EUDA/i-acquisition-2-corp-and-euda-health-limited-announce-amendment-to-share-purchase-agreemen-euda-20220610monthly0.5https://www.biopharmawatch.com/news/EUDA/i-acquisition-2-corp-and-euda-health-limited-announce-extension-of-due-diligence-review-pe-euda-20220531monthly0.5https://www.biopharmawatch.com/news/EUDA/i-acquisition-2-corp-to-combine-with-euda-health-limited-to-bring-a-leading-digital-health-euda-20220412monthly0.5https://www.biopharmawatch.com/news/EUDA/i-acquisition-2-corp-announces-the-separate-trading-of-its-ordinary-shares-warrants-and-ri-euda-20211214monthly0.5https://www.biopharmawatch.com/news/EUDA/i-acquisition-2-corp-index-to-financial-statement-page-report-of-independent-registered-pu-euda-20211124monthly0.5https://www.biopharmawatch.com/news/EUDA/i-acquisition-2-corp-announces-pricing-of-75-million-initial-public-offering-singapore-euda-20211122monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-all-rights-reserved-corporate-presentation-redefining-the-course-of-neurodegen-pasg-20251231monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-reports-second-quarter-2025-financial-results-and-provides-recent-business-hig-pasg-20250812monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-reports-first-quarter-2025-financial-results-and-provides-recent-business-high-pasg-20250513monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-recen-pasg-20250304monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-interim-data-from-uplift-d-study-in-ftd-grn-and-provides-business-up-pasg-20250110monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-reports-third-quarter-2024-financial-results-and-provides-recent-business-high-pasg-20241113monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-presents-preclinical-and-interim-clinical-data-for-pbft02-in-ftd-grn-at-the-eu-pasg-20241024monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-to-present-positive-interim-data-from-cohort-1-patients-with-ftd-grn-in-uplift-pasg-20240916monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-reports-second-quarter-2024-financial-results-and-provides-recent-business-hig-pasg-20240808monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-out-licenses-three-pediatric-gene-therapy-programs-to-gemma-biotherapeutics-an-pasg-20240801monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-positive-feedback-from-fda-on-expansion-of-uplift-d-trial-of-pbft02--pasg-20240716monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-reports-first-quarter-2024-financial-results-and-provides-recent-business-high-pasg-20240514monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-recen-pasg-20240304monthly0.5https://www.biopharmawatch.com/news/PASG/nasdaq-pasg-xa9-2024-passage-bio-all-rights-reserved-corporate-presentation-january-2024-2-pasg-20240105monthly0.5https://www.biopharmawatch.com/news/PASG/in-the-court-of-chancery-of-the-state-of-delaware-tara-m-williams-derivatively-on-behalf-o-pasg-20231213monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-promising-initial-data-from-phase-1-2-clinical-trial-of-pbft02-in-ft-pasg-20231220monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-reports-third-quarter-2023-financial-results-and-provides-recent-business-high-pasg-20231113monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-reports-second-quarter-2023-financial-results-and-provides-recent-business-hig-pasg-20230807monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-reports-first-quarter-2023-financial-results-and-provides-recent-business-high-pasg-20230511monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-recen-pasg-20230306monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-presents-additional-interim-data-from-imagine-1-study-for-gm1-gangliosidosis-a-pasg-20230224monthly0.5https://www.biopharmawatch.com/news/PASG/xa9-2023-passagebio-all-rights-reserved-nasdaq-pasg-fulfilling-the-promise-of-genetic-medi-pasg-20230109monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-positive-interim-clinical-data-from-first-six-patients-with-gm1-gang-pasg-20221214monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-reports-third-quarter-2022-financial-results-and-provides-business-updates-dos-pasg-20221110monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-reports-second-quarter-2022-financial-results-and-provides-recent-business-hig-pasg-20220804monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-presents-new-interim-clinical-and-biomarker-data-for-patients-with-gm1-ganglio-pasg-20220518monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-reports-first-quarter-2022-financial-results-and-provides-recent-business-high-pasg-20220516monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-recen-pasg-20220303monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-presents-new-interim-clinical-data-for-patients-with-gm1-gangliosidosis-in-ima-pasg-20220211monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-2022-research-and-clinical-development-goals-to-advance-robust-cns-p-pasg-20220110monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-positive-interim-safety-and-biomarker-data-and-advances-phase-1-2-tr-pasg-20211217monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-reports-third-quarter-2021-financial-results-and-provides-recent-business-high-pasg-20211104monthly0.5https://www.biopharmawatch.com/news/PASG/fulfilling-the-promise-of-genetic-medicines-for-central-nervous-system-disorders-corporate-pasg-20211004monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-reports-second-quarter-2021-financial-results-and-provides-recent-business-hig-pasg-20210805monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-reports-first-quarter-2021-financial-results-and-recent-business-highlights-do-pasg-20210505monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-reports-fourth-quarter-and-full-year-2020-financial-results-and-recent-busines-pasg-20210303monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-announces-plan-to-deliver-on-multiple-meaningful-catalysts-in-2021-investigati-pasg-20210111monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-reports-third-quarter-2020-financial-results-and-recent-business-highlights-do-pasg-20201110monthly0.5https://www.biopharmawatch.com/news/PASG/corporate-presentation-september-2020-forward-looking-statements-this-presentation-include-pasg-20200909monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-reports-second-quarter-2020-financial-results-and-recent-business-highlights-s-pasg-20200813monthly0.5https://www.biopharmawatch.com/news/PASG/passage-bio-reports-first-quarter-2020-financial-results-and-recent-business-highlights-ex-pasg-20200511monthly0.5https://www.biopharmawatch.com/news/XCUR/united-states-district-court-northern-district-of-illinois-eastern-division-in-re-exicure--xcur-20260318monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-reports-second-quarter-2025-financial-results-xcur-20250808monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-nasdaq-xcur-regains-compliance-with-nasdaq-filing-requirements-redwood-city-ca-xcur-20250804monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q-redwood-cit-xcur-20250528monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-reports-full-year-2024-financial-results-chicago-il-xcur-20250318monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-announces-purchase-agreement-with-gpcr-therapeutics-inc-chicago-il-xcur-20250122monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-announces-shareholders-approve-the-8-7-million-equity-financing-and-reports-ex-xcur-20241220monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-unaudited-proforma-consolidated-balance-sheets-in-thousands-xcur-20241217monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-enters-into-purchase-agreements-for-1-3-million-and-8-7-million-equity-financi-xcur-20241114monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-receives-extension-from-nasdaq-hearings-panel-chicago-il-xcur-20240918monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-announces-1-for-5-reverse-stock-split-chicago-il-xcur-20240826monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-announces-additional-adjournment-of-special-meeting-and-information-for-reconv-xcur-20240819monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-announces-adjournment-of-special-meeting-and-information-for-reconvened-specia-xcur-20240815monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-receives-positive-listing-determination-from-nasdaq-chicago-il-xcur-20240801monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-reports-first-quarter-2024-financial-results-chicago-il-xcur-20240617monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-reports-full-year-2023-financial-results-chicago-il-xcur-20240606monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-received-nasdaq-notice-of-a-delisting-determination-chicago-il-xcur-20240523monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-reports-third-quarter-2023-financial-results-chicago-il-xcur-20240516monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-k-chicago-il-xcur-20240422monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-and-bluejay-therapeutics-inc-enter-into-a-patent-license-agreement-to-develop--xcur-20240205monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q-chicago-il-xcur-20231128monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-announces-appointment-of-new-ceo-and-cfo-and-changes-to-board-of-directors-chi-xcur-20230823monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-reports-second-quarter-2023-financial-results-and-provides-corporate-update-ch-xcur-20230811monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-reports-first-quarter-2023-financial-results-and-provides-corporate-update-chi-xcur-20230714monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-announces-support-of-ceo-in-its-ongoing-exploration-of-strategic-alternatives--xcur-20230526monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q-chicago-il-xcur-20230519monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-announces-investment-in-korean-sns-platform-cyworld-chicago-il-xcur-20230504monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-announces-appointment-of-new-ceo-and-cfo-and-changes-to-board-of-directors-chi-xcur-20230427monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-reports-full-year-2022-financial-results-and-provides-corporate-update-chicago-xcur-20230327monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-announces-termination-of-abbvie-and-ipsen-collaboration-agreements-exicure-and-xcur-20221214monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-reports-third-quarter-2022-financial-results-and-provides-corporate-update-chi-xcur-20221114monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-enters-into-definitive-agreement-with-cbi-usa-inc-for-5-4-million-equity-finan-xcur-20220926monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-reports-second-quarter-2022-financial-results-and-corporate-progress-company-a-xcur-20220815monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-regains-compliance-with-nasdaq-minimum-bid-price-requirement-chicago-il-xcur-20220720monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-announces-receipt-of-nasdaq-notice-of-non-compliance-and-implementation-of-one-xcur-20220629monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-announces-adjournment-of-annual-meeting-of-stockholders-chicago-il-xcur-20220527monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-reports-first-quarter-2022-financial-results-and-corporate-progress-recently-a-xcur-20220516monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-announces-5-million-raise-in-private-placement-transaction-priced-at-market-premiu-xcur-20220510monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-reports-full-year-2021-financial-results-and-corporate-progress-continues-to-a-xcur-20220325monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-announces-leadership-transition-and-changes-to-the-board-of-directors-brian-c--xcur-20220204monthly0.5https://www.biopharmawatch.com/news/XCUR/execution-version-xcur-20211210monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-announces-results-of-internal-investigation-and-implementation-of-strategic-me-xcur-20211210monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-reports-third-quarter-2021-financial-results-and-corporate-progress-chicago-il-xcur-20211119monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-reports-second-quarter-2021-financial-results-and-corporate-progress-entered-e-xcur-20210812monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-provides-interim-results-from-ongoing-phase-1b-2-clinical-trial-of-cavrotolimod-as-xcur-20210805monthly0.5https://www.biopharmawatch.com/news/XCUR/about-exicure-inc-exicure-inc-is-a-clinical-stage-biotechnology-company-developing-therape-xcur-20210513monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-reports-first-quarter-2021-financial-results-and-corporate-progress-company-ad-xcur-20210512monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-reports-full-year-2020-financial-results-and-corporate-progress-granted-two-fa-xcur-20210311monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-granted-orphan-drug-designation-by-the-u-s-food-and-drug-administration-for-cavrot-xcur-20210303monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-granted-two-fast-track-designations-for-cavrotolimod-ast-008-from-the-u-s-food-and-xcur-20210111monthly0.5https://www.biopharmawatch.com/news/XCUR/8k-010721-xcur-20210107monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-reports-third-quarter-2020-financial-results-and-corporate-progress-chicago-an-xcur-20201112monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-reports-second-quarter-2020-financial-results-and-corporate-progress-chicago-a-xcur-20200812monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-announces-first-patient-dosed-in-phase-2-merkel-cell-carcinoma-trial-of-cavrotolim-xcur-20200616monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-reports-first-quarter-2020-financial-results-and-corporate-progress-chicago-an-xcur-20200514monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-provides-business-update-amid-covid-19-pandemic-phase-2-stage-of-its-phase-1b-2-cl-xcur-20200330monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-reports-full-year-2019-financial-results-and-corporate-progress-friedreich-s-a-xcur-20200303monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-announces-proposed-public-offering-of-common-stock-published-xcur-20191218monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-reports-third-quarter-2019-financial-results-and-recent-developments-chicago-xcur-20191107monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-reports-second-quarter-2019-financial-results-and-recent-developments-chicago-xcur-20190808monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-appoints-dr-bali-muralidhar-of-abingworth-llp-and-bosun-hau-of-tybourne-capital-ma-xcur-20190807monthly0.5https://www.biopharmawatch.com/news/XCUR/trial-in-patients-with-advanced-solid-tumors-exicure-is-based-outside-of-chicago-il-and-in-xcur-20190802monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-appoints-jeffrey-l-cleland-and-tim-walbert-to-board-of-directors-chicago-ill-cambr-xcur-20190722monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-announces-preclinical-data-supporting-development-of-sna-technology-in-the-central-xcur-20190627monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-reports-first-quarter-2019-financial-results-and-reviews-corporate-progress-ch-xcur-20190508monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-reports-full-year-2018-financial-results-and-corporate-progress-completed-phas-xcur-20190308monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-provides-update-on-corporate-progress-and-third-quarter-2018-financial-results-xcur-20181106monthly0.5https://www.biopharmawatch.com/news/XCUR/also-contains-projections-and-other-information-concerning-our-industry-our-business-and-t-xcur-20181010monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-provides-update-on-corporate-progress-and-second-quarter-2018-financial-result-xcur-20180806monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-reports-first-quarter-2018-financial-results-and-reviews-corporate-progress-re-xcur-20180515monthly0.5https://www.biopharmawatch.com/news/XCUR/exhibit-exicure-announces-data-for-topical-anti-tnf-compound-ast-005-in-patients-with-mild-xcur-20180430monthly0.5https://www.biopharmawatch.com/news/XCUR/exhibit-exicure-inc-reports-full-year-2017-financial-results-and-corporate-progress-launch-xcur-20180309monthly0.5https://www.biopharmawatch.com/news/XCUR/exhibit-exicure-inc-reports-third-quarter-2017-financial-results-and-provides-business-upd-xcur-20171114monthly0.5https://www.biopharmawatch.com/news/XCUR/exicure-inc-formerly-aurasense-therapeutics-llc-index-to-financial-statements-page-audited-xcur-20171002monthly0.5https://www.biopharmawatch.com/news/BFRG/bullfrog-ai-regains-compliance-with-nasdaq-shareholders-equity-requirement-strengthened-ba-bfrg-20260422monthly0.5https://www.biopharmawatch.com/news/BFRG/bullfrog-ai-provides-business-update-strengthened-balance-sheet-supports-continued-executi-bfrg-20260413monthly0.5https://www.biopharmawatch.com/news/BFRG/bullfrog-ai-announces-commercial-agreement-with-top-5-global-pharmaceutical-company-to-ide-bfrg-20260330monthly0.5https://www.biopharmawatch.com/news/BFRG/bullfrog-ai-publishes-annual-letter-to-shareholders-highlights-significant-progress-in-202-bfrg-20251230monthly0.5https://www.biopharmawatch.com/news/BFRG/bullfrog-ai-announces-strategic-collaboration-with-sygnature-discovery-to-introduce-bullfr-bfrg-20250612monthly0.5https://www.biopharmawatch.com/news/BFRG/bullfrog-ai-and-eleison-pharmaceuticals-enter-agreement-to-collaborate-to-optimize-pivotal-bfrg-20250227monthly0.5https://www.biopharmawatch.com/news/BFRG/bullfrog-ai-issues-letter-to-stockholders-gaithersburg-md-bfrg-20241227monthly0.5https://www.biopharmawatch.com/news/BFRG/bullfrog-ai-announces-appointment-of-chief-financial-officer-gaithersburg-md-bfrg-20241217monthly0.5https://www.biopharmawatch.com/news/BFRG/bullfrog-ai-announces-pricing-of-registered-direct-offering-and-concurrent-private-placeme-bfrg-20241018monthly0.5https://www.biopharmawatch.com/news/BFRG/bullfrog-ai-strengthens-scientific-advisory-board-with-the-addition-of-gsk-veteran-and-ind-bfrg-20241015monthly0.5https://www.biopharmawatch.com/news/BFRG/bullfrog-ai-announces-publication-of-data-supporting-potential-of-liver-disease-treatment--bfrg-20241009monthly0.5https://www.biopharmawatch.com/news/BFRG/bullfrog-ai-and-lieber-institute-for-brain-development-reveal-new-insights-into-bipolar-di-bfrg-20240725monthly0.5https://www.biopharmawatch.com/news/BFRG/bullfrog-ai-and-lieber-institute-for-brain-development-collaboration-identifies-novel-drug-bfrg-20240516monthly0.5https://www.biopharmawatch.com/news/BFRG/bullfrog-ai-s-cso-tom-chittenden-to-present-at-the-quantum-computing-symposium-at-bio-it-w-bfrg-20240409monthly0.5https://www.biopharmawatch.com/news/BFRG/bullfrog-ai-announces-availability-of-fireside-chat-recording-featuring-ceos-of-bullfrog-a-bfrg-20240307monthly0.5https://www.biopharmawatch.com/news/BFRG/bullfrog-ai-appoints-globally-renowned-biomedical-ai-expert-dr-thomas-w-chittenden-as-chie-bfrg-20240226monthly0.5https://www.biopharmawatch.com/news/BFRG/bullfrog-ai-to-discuss-findings-from-its-collaboration-with-lieber-institute-for-brain-dev-bfrg-20240209monthly0.5https://www.biopharmawatch.com/news/BFRG/bullfrog-ai-strengthens-scientific-advisory-board-with-the-addition-of-dr-gwenn-smith-and--bfrg-20240126monthly0.5https://www.biopharmawatch.com/news/BFRG/bullfrog-ai-s-collaboration-with-lieber-institute-for-brain-development-yields-potentially-bfrg-20240117monthly0.5https://www.biopharmawatch.com/news/BFRG/bullfrog-ai-announces-issuance-of-australian-patent-protecting-novel-prodrugs-of-mebendazo-bfrg-20240116monthly0.5https://www.biopharmawatch.com/news/BFRG/bullfrog-ai-issues-letter-to-shareholders-gaithersburg-md-bfrg-20231229monthly0.5https://www.biopharmawatch.com/news/BFRG/bullfrog-ai-announces-identification-of-novel-potential-drug-targets-for-colorectal-cancer-bfrg-20231005monthly0.5https://www.biopharmawatch.com/news/BFRG/healthcare-investor-relations-corporate-communications-clinical-trial-patient-recruitment--bfrg-20230926monthly0.5https://www.biopharmawatch.com/news/BFRG/healthcare-investor-relations-corporate-communications-clinical-trial-patient-recruitment--bfrg-20230920monthly0.5https://www.biopharmawatch.com/news/BFRG/healthcare-investor-relations-corporate-communications-clinical-trial-patient-recruitment--bfrg-20230913monthly0.5https://www.biopharmawatch.com/news/BFRG/bullfrog-ai-announces-issuance-of-u-s-patent-protecting-novel-prodrugs-of-mebendazole-and--bfrg-20230725monthly0.5https://www.biopharmawatch.com/news/BFRG/bullfrog-ai-announces-appointment-of-enrique-garc-a-rivera-as-vice-president-of-artificial-bfrg-20230711monthly0.5https://www.biopharmawatch.com/news/BFRG/bullfrog-ai-ceo-vin-singh-to-present-at-the-gujarati-physicians-convention-2023-more-than--bfrg-20230609monthly0.5https://www.biopharmawatch.com/news/BFRG/bullfrog-ai-strengthens-capabilities-of-its-ai-platform-through-expansion-of-licensing-agr-bfrg-20230605monthly0.5https://www.biopharmawatch.com/news/BFRG/bullfrog-ai-files-quarterly-report-on-form-10-q-gaithersburg-md-bfrg-20230526monthly0.5https://www.biopharmawatch.com/news/BFRG/bullfrog-ai-files-2022-annual-report-on-form-10-k-gaithersburg-md-bfrg-20230425monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-schedules-2025-annual-meeting-of-shareholders-beijing-ccm-20251202monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-reports-financial-results-for-the-first-half-of-2025-beijing-ccm-20250926monthly0.5https://www.biopharmawatch.com/news/CCM/concord-healthcare-announces-completion-of-china-s-first-proton-therapy-for-choroidal-mali-ccm-20250714monthly0.5https://www.biopharmawatch.com/news/CCM/concord-healthcare-announces-official-release-of-the-proton-therapy-large-model-beijing-ccm-20250529monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-changes-in-management-beijing-ccm-20250411monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-result-of-2024-annual-general-meeting-beijing-ccm-20250106monthly0.5https://www.biopharmawatch.com/news/CCM/concord-healthcare-announces-approval-granted-to-the-application-for-the-proton-therapy-eq-ccm-20241209monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-schedules-2024-annual-meeting-of-shareholders-beijing-ccm-20241113monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-reports-financial-results-for-the-first-half-of-2024-beijing-ccm-20240927monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-obtaining-large-medical-equipment-procurement-license-for-its-pr-ccm-20240916monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-regains-compliance-with-nyse-minimum-price-requirement-beijing-ccm-20240807monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-receipt-of-nyse-non-compliance-letter-regarding-ads-trading-pric-ccm-20240220monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-listing-of-its-subsidiary-on-the-stock-exchange-of-hong-kong-lim-ccm-20240109monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-schedules-2023-annual-meeting-of-shareholders-beijing-ccm-20231120monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-schedules-2022-annual-meeting-of-shareholders-beijing-ccm-20221125monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-changes-in-management-beijing-ccm-20220930monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-reports-financial-results-for-the-first-half-of-2022-beijing-ccm-20220923monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-its-subsidiary-s-application-filing-for-potential-listing-on-the-ccm-20220601monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-reports-financial-results-for-the-first-half-of-2021-beijing-ccm-20211210monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-schedules-2020-annual-meeting-of-shareholders-beijing-ccm-20211129monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-completes-rmb-400-million-funding-round-led-by-consortium-investors-beijin-ccm-20210823monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-receives-notification-from-nyse-regarding-delayed-filing-of-2020-annual-re-ccm-20210525monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-changes-in-board-of-directors-beijing-ccm-20210521monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-divestment-of-singapore-concord-international-hospital-beijing-ccm-20201228monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-schedules-2020-annual-meeting-of-shareholders-beijing-ccm-20201120monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-reports-financial-results-for-the-first-half-of-2020-beijing-ccm-20200826monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-changes-to-the-board-beijing-ccm-20191202monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-schedules-2019-annual-meeting-of-shareholders-beijing-ccm-20191128monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-reports-financial-results-for-the-first-half-of-2019-beijing-ccm-20190823monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-new-appointments-to-management-team-beijing-ccm-20190319monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-schedules-2018-annual-meeting-of-shareholders-beijing-ccm-20181207monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-reports-financial-results-for-the-first-half-of-2018-beijing-ccm-20180829monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-welcomes-investment-led-by-china-international-capital-corporation-limited-ccm-20180403monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-holds-2017-annual-meeting-of-shareholders-beijing-ccm-20171221monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-schedules-2017-annual-meeting-of-shareholders-beijing-ccm-20171116monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-withdrawal-of-buyer-parties-going-private-proposal-beijing-ccm-20171113monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-changes-to-the-board-beijing-ccm-20170918monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-reports-financial-results-for-the-first-half-of-2017-beijing-ccm-20170825monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-changes-to-the-board-beijing-ccm-20170724monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-reports-financial-results-for-the-first-half-of-2016-beijing-ccm-20160824monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-receipt-of-preliminary-non-binding-going-private-proposal-beijin-ccm-20160711monthly0.5https://www.biopharmawatch.com/news/CCM/for-more-information-please-contact-concord-medical-services-mr-adam-j-sun-chinese-and-eng-ccm-20160524monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-reports-fourth-quarter-and-full-year-2015-financial-results-beijing-ccm-20160329monthly0.5https://www.biopharmawatch.com/news/CCM/corrections-to-certain-disclosures-in-the-company-s-2014-annual-report-on-form-20-f-in-its-ccm-20160127monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-to-hold-annual-general-meeting-on-ccm-20151215monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-declares-special-dividend-beijing-ccm-20151211monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-reports-third-quarter-2015-financial-results-beijing-ccm-20151118monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-plan-to-establish-beijing-allcure-medical-information-technology-ccm-20150908monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-reports-financial-results-for-the-second-quarter-of-2015-beijing-ccm-20150817monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-acquires-additional-ownership-interest-in-md-anderson-cancer-center-proton-ccm-20150812monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-services-announces-share-repurchase-program-beijing-ccm-20150810monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-results-of-special-general-meeting-beijing-ccm-20150603monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-reports-financial-results-for-the-first-quarter-of-2015-beijing-ccm-20150520monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-2015-extraordinary-general-meeting-of-shareholders-beijing-ccm-20150504monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-reports-fourth-quarter-and-full-year-2014-financial-results-meets-full-yea-ccm-20150323monthly0.5https://www.biopharmawatch.com/news/CCM/hereof-about-concord-medical-concord-medical-services-holdings-limited-is-a-leading-specia-ccm-20150130monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-divestment-of-chang-an-hospital-sells-outstanding-52-equity-inte-ccm-20141216monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-reports-third-quarter-2014-financial-results-reiterates-fy14-financial-for-ccm-20141117monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-receives-government-approval-to-establish-free-standing-radiotherapy-cance-ccm-20141027monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-reports-second-quarter-2014-financial-results-reiterates-fy14-financial-fo-ccm-20140813monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-declares-special-dividend-beijing-ccm-20140728monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-new-appointments-to-management-team-beijing-ccm-20140625monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-reports-first-quarter-2014-financial-results-and-reiterates-full-year-2014-ccm-20140521monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-reports-fourth-quarter-and-full-year-2013-financial-results-beijing-ccm-20140331monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-changes-to-the-board-beijing-ccm-20140306monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-declares-special-dividend-beijing-ccm-20140107monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-results-of-2013-annual-general-meeting-appoints-new-board-member-ccm-20131226monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-reports-third-quarter-2013-financial-results-and-reiterates-financial-year-ccm-20131112monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-acquisition-of-its-shares-by-ceo-and-coo-from-other-shareholders-ccm-20130815monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-reports-second-quarter-2013-financial-results-2q13-total-net-revenue-incre-ccm-20130812monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-reports-first-quarter-2013-financial-results-beijing-ccm-20130521monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-the-signing-of-us-50-million-ifc-loan-agreement-beijing-ccm-20130515monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-reports-fourth-quarter-and-full-year-2012-financial-results-beijing-china-ccm-20130320monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-services-announces-successful-closing-of-the-acquisition-of-ownership-inte-ccm-20130104monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-shareholder-resolutions-adopted-at-2012-annual-general-meeting-b-ccm-20121224monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-services-holdings-limited-the-company-notice-of-annual-general-meeting-not-ccm-20121121monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-reports-third-quarter-2012-financial-results-beijing-ccm-20121121monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-extension-of-existing-share-repurchase-program-beijing-ccm-20121009monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-reports-second-quarter-2012-financial-results-and-updates-guidance-for-ful-ccm-20120820monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-its-successful-closing-of-the-acquisition-of-52-ownership-in-cha-ccm-20120618monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-reports-first-quarter-2012-financial-results-beijing-ccm-20120521monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-acquisition-of-controlling-equity-interest-in-chang-an-hospital--ccm-20120321monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-shareholder-resolutions-adopted-at-2011-annual-general-meeting-b-ccm-20111202monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-reports-third-quarter-2011-financial-results-beijing-ccm-20111114monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-services-holdings-limited-the-company-notice-of-annual-general-meeting-not-ccm-20111101monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-services-announces-share-repurchase-program-ccm-20110930monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-services-announces-the-appointment-of-mr-adam-sun-as-acting-chief-financia-ccm-20110831monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-higher-revenues-net-income-and-earnings-per-ads-for-the-second-q-ccm-20110816monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-declares-special-dividend-ccm-20110728monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-first-quarter-2011-financial-results-beijing-ccm-20110518monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-fourth-quarter-and-fiscal-year-2010-financial-results-full-year--ccm-20110328monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-to-acquire-a-52-equity-interest-in-chang-an-hospital-updates-on-progress-o-ccm-20110106monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-re-designates-elaine-zong-as-independent-director-beijing-ccm-20101223monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-third-quarter-2010-financial-results-beijing-ccm-20101118monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-services-holdings-limited-the-company-notice-of-annual-general-meeting-not-ccm-20101112monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-second-quarter-2010-financial-results-beijing-aug-18-prnewswire--ccm-20100908monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-second-quarter-2010-financial-results-beijing-aug-18-prnewswire--ccm-20100819monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-share-repurchase-program-beijing-ccm-20100630monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-first-quarter-2010-financial-results-beijing-ccm-20100527monthly0.5https://www.biopharmawatch.com/news/CCM/amended-and-as-defined-in-the-u-s-private-securities-litigation-reform-act-of-1995-these-f-ccm-20100428monthly0.5https://www.biopharmawatch.com/news/CCM/concord-medical-announces-fourth-quarter-and-fiscal-year-2009-financial-results-dr-hongbin-ccm-20100319monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-reports-second-quarter-2025-financial-results-and-recent-business-highlights-x2022--inab-20250807monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-reports-first-quarter-2025-financial-results-and-recent-business-highlights-x2022-p-inab-20250507monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-unveils-promising-new-data-from-next-generation-gamma-delta-t-cell-engager-tce-plat-inab-20250428monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-business-hig-inab-20250313monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-announces-advanced-gamma-delta-t-cell-engager-tce-platform-for-oncology-and-autoimm-inab-20250303monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-reports-updated-positive-results-from-phase-1-trial-of-inb-100-in-leukemia-patients-inab-20250211monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-reports-continued-progression-free-survival-in-phase-1-investigator-sponsored-trial-inab-20241210monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-reports-continued-durable-remissions-in-phase-1-trial-of-inb-200-in-plenary-oral-pr-inab-20241125monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-reports-third-quarter-2024-financial-results-and-recent-corporate-highlights-report-inab-20241112monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-announces-clinical-pipeline-prioritization-to-focus-on-inb-100-for-acute-myeloid-le-inab-20240830monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-solidifies-position-as-a-clinical-leader-of-gamma-delta-t-cell-therapy-in-oncology--inab-20240812monthly0.5https://www.biopharmawatch.com/news/INAB/v3-in8bio-reports-second-quarter-2024-financial-results-and-recent-corporate-highlights-pr-inab-20240808monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-presents-positive-data-demonstrating-durable-1-year-complete-remission-in-100-of-ev-inab-20240613monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-presents-progression-free-survival-update-from-phase-1-study-of-inb-200-at-2024-ame-inab-20240603monthly0.5https://www.biopharmawatch.com/news/INAB/v3-in8bio-reports-first-quarter-2024-financial-results-and-recent-corporate-highlights-pre-inab-20240509monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-reports-fourth-quarter-and-full-year-2023-financial-results-and-recent-business-hig-inab-20240314monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-announces-pricing-of-financing-totaling-up-to-46-9-million-in-private-placement-ini-inab-20231211monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-s-inb-200-demonstrates-extended-progression-free-survival-in-patients-with-newly-di-inab-20231120monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-reports-third-quarter-2023-financial-results-and-provides-corporate-update-x2022-co-inab-20231109monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-completes-dose-escalation-in-phase-1-trial-of-inb-100-a-potential-first-in-class-ga-inab-20231012monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-reports-second-quarter-2023-financial-results-and-provides-corporate-update-x2022-p-inab-20230810monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-announces-positive-inb-200-phase-1-data-update-in-glioblastoma-at-the-2023-asco-ann-inab-20230605monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-s-deltex-gamma-delta-t-cells-show-promise-in-targeting-ovarian-cancer-preclinical-r-inab-20230517monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-reports-first-quarter-2023-financial-results-and-provides-corporate-update-x2022-pr-inab-20230512monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-presents-positive-new-inb-100-data-showing-long-term-complete-remissions-and-elevat-inab-20230424monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-announces-positive-preclinical-data-for-gamma-delta-car-platform-and-launches-new-c-inab-20230417monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-corporate--inab-20230330monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-presents-preclinical-data-showing-non-signaling-car-platform-targets-cancer-cells-w-inab-20230223monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-provides-inb-200-clinical-update-and-outlines-2023-pipeline-goals-all-three-patient-inab-20230105monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-announces-new-data-at-ash-showing-100-percent-of-cohort-1-patients-maintained-durab-inab-20221212monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-announces-fda-clearance-to-initiate-a-phase-2-clinical-trial-of-inb-400-gamma-delta-inab-20221208monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-reports-third-quarter-2022-financial-results-and-highlights-recent-company-progress-inab-20221206monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-reports-second-quarter-2022-financial-results-and-provides-corporate-update-x2022-i-inab-20221110monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-announces-closing-of-exercise-option-to-purchase-additional-shares-in-public-offeri-inab-20220819monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-announces-pricing-of-10-25-million-underwritten-public-offering-of-common-stock-inab-20220811monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-reports-second-quarter-2022-financial-results-and-provides-corporate-update-x2022-u-inab-20220812monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-observes-durable-morphologic-complete-responses-in-ongoing-phase-1-clinical-trial-o-inab-20220727monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-reports-first-quarter-2022-financial-results-and-provides-corporate-update-x2022-ph-inab-20220512monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-presents-clinical-update-from-the-ongoing-phase-1-trial-of-inb-100-an-allogeneic-ga-inab-20220328monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-corporate--inab-20220317monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-provides-update-from-the-ongoing-phase-1-clinical-trial-of-its-allogeneic-gamma-del-inab-20211216monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-reports-third-quarter-2021-financial-results-and-provides-corporate-update-xf0b7-cl-inab-20211110monthly0.5https://www.biopharmawatch.com/news/INAB/in8bio-reports-second-quarter-2021-financial-results-and-provides-corporate-update-xf0b7-f-inab-20210910monthly0.5https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-inc-announces-new-multi-year-exclusive-manufacturing-ag-naii-20170811monthly0.5https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-naii-20160321monthly0.5https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-naii-20151001monthly0.5https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-inc-files-unfair-competition-false-advertising-and-disp-naii-20150918monthly0.5https://www.biopharmawatch.com/news/NAII/nai-press-release-naii-20140703monthly0.5https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-inc-settles-patent-infringement-dispute-with-bpi-sports-naii-20120315monthly0.5https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-inc-announces-resolution-of-patent-litigation-case-and--naii-20110812monthly0.5https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-inc-announces-stock-repurchase-plan-san-marcos-calif-naii-20110603monthly0.5https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-inc-announces-supply-agreement-with-nestl-nutrition-naii-20101005monthly0.5https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-inc-announces-carnosyn-beta-alanine-licensing-agreement-naii-20090309monthly0.5https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-inc-announces-fiscal-2008-results-naii-20080922monthly0.5https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-inc-announces-sale-of-as-we-change-assets-and-provides--naii-20080805monthly0.5https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-inc-appoints-new-chief-financial-officer-naii-20080212monthly0.5https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-inc-announces-annual-loss-of-5-3-million-and-fourth-qua-naii-20071015monthly0.5https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-inc-announces-late-filing-of-its-annual-report-on-form--naii-20070928monthly0.5https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-inc-announces-retirement-of-chief-scientific-officer-an-naii-20070706monthly0.5https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-inc-announces-third-quarter-results-highlights-third-qu-naii-20070427monthly0.5https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-inc-receives-additional-swiss-pharmaceutical-license-an-naii-20070316monthly0.5https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-inc-announces-20-increase-in-second-quarter-net-income--naii-20070122monthly0.5https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-inc-announces-15-increase-in-first-quarter-revenue-naii-20061023monthly0.5https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-inc-announces-fourth-quarter-net-income-of-0-16-per-dil-naii-20060911monthly0.5https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-inc-announces-record-fourth-quarter-net-sales-and-chang-naii-20060706monthly0.5https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-inc-announces-third-quarter-results-naii-20060501monthly0.5https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-inc-announces-second-quarter-results-naii-20060214monthly0.5https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-inc-announces-first-quarter-results-naii-20051024monthly0.5https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-inc-announces-record-breaking-revenue-for-fiscal-2005-naii-20050906monthly0.5https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-inc-announces-third-quarter-results-naii-20050503monthly0.5https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-inc-reports-68-increase-in-second-quarter-pre-tax-earni-naii-20050209monthly0.5https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-inc-reports-36-net-sales-increase-and-net-income-of-0-1-naii-20041025monthly0.5https://www.biopharmawatch.com/news/NAII/natural-alternatives-international-inc-reports-record-breaking-net-sales-for-fiscal-2004-naii-20040830monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-first-quarter-2026-financial-results-2026-guidance-affirmed-irix-20260519monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-irix-20260112monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-second-quarter-2025-financial-results-irix-20250812monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-first-quarter-2025-financial-results-irix-20250513monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-fourth-quarter-and-full-year-2024-financial-results-irix-20250327monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-strategic-investment-in-the-company-irix-20250319monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-irix-20250114monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-third-quarter-2024-financial-results-irix-20241112monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-appoints-patrick-mercer-as-chief-executive-officer-irix-20241003monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-second-quarter-2024-financial-results-irix-20240808monthly0.5https://www.biopharmawatch.com/news/IRIX/mountain-irix-20240805monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-first-quarter-2024-financial-results-irix-20240514monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-corporation-announces-successful-appeal-for-revision-of-recent-medicare-lcds-to-pro-irix-20231127monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-third-quarter-2023-financial-results-and-business-update-irix-20231114monthly0.5https://www.biopharmawatch.com/news/IRIX/granted-in-the-court-of-chancery-of-the-state-of-delaware-in-re-iridex-corp-c-a-no-2023-pr-irix-20231107monthly0.5https://www.biopharmawatch.com/news/IRIX/in-the-court-of-chancery-of-the-state-of-delaware-in-re-iridex-corp-c-a-no-2023-verified-p-irix-20231018monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-second-quarter-2023-financial-results-irix-20230810monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-first-quarter-2023-financial-results-irix-20230511monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-fourth-quarter-and-full-year-2022-financial-results-achieves-record-quarter-irix-20230309monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-irix-20230110monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-record-third-quarter-2022-financial-results-company-announces-fda-clearan-irix-20221110monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-second-quarter-2022-financial-results-irix-20220815monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-first-quarter-2022-financial-results-achieved-record-first-quarter-revenu-irix-20220512monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-the-appointment-of-beverly-huss-to-its-board-of-directors-irix-20220321monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-fourth-quarter-and-full-year-2021-financial-results-exceeds-prior-guidanc-irix-20220310monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-irix-20220111monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-third-quarter-2021-financial-results-achieved-51-year-over-year-revenue-g-irix-20211111monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-second-quarter-2021-financial-results-achieved-116-year-over-year-revenue-irix-20210812monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-first-quarter-2021-financial-results-irix-20210511monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-fourth-quarter-and-full-year-2020-financial-results-irix-20210322monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-completes-transaction-with-topcon-corporation-mountain-view-ca-irix-20210310monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-strategic-collaboration-with-topcon-corporation-transaction-provides-19-5-irix-20210302monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-irix-20210111monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-third-quarter-2020-financial-results-irix-20201109monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-second-quarter-2020-financial-results-irix-20200806monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-first-quarter-2020-financial-results-irix-20200511monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-the-appointment-of-doris-engibous-to-its-board-of-directors-mountain-view-irix-20200421monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-retirement-of-vp-finance-names-prior-cfo-coo-as-interim-cfo-mountain-view-irix-20200330monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-fourth-quarter-and-full-year-2019-financial-results-irix-20200312monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-preliminary-operational-and-financial-results-for-fourth-quarter-and-full-irix-20200113monthly0.5https://www.biopharmawatch.com/news/IRIX/mountain-irix-20191107monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-appointment-of-robert-gunst-as-chairman-of-the-board-of-directors-and-dep-irix-20191028monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-2019-second-quarter-financial-results-irix-20190806monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-leadership-transition-david-bruce-appointed-president-and-ceo-mountain-vi-irix-20190521monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-2019-first-quarter-financial-results-irix-20190502monthly0.5https://www.biopharmawatch.com/news/IRIX/scott-shuda-appointed-to-iridex-board-of-directors-mountain-view-calif-irix-20190429monthly0.5https://www.biopharmawatch.com/news/IRIX/ken-ludlum-appointed-to-iridex-board-of-directors-mountain-view-calif-irix-20190402monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-corporation-condensed-consolidated-balance-sheets-in-thousands-and-unaudited-decemb-irix-20190305monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-resolution-of-its-dispute-with-quantel-medical-mountain-view-calif-irix-20190212monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-preliminary-operational-and-financial-results-for-2018-fourth-quarter-and-irix-20190108monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-departure-of-chief-financial-officer-and-reiterates-full-year-2018-guidan-irix-20181204monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-appointment-of-robert-e-grove-ph-d-to-its-board-of-directors-mountain-vie-irix-20181015monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-proposed-public-offering-of-common-stock-mountain-view-california-irix-20180913monthly0.5https://www.biopharmawatch.com/news/IRIX/june-30-december-30-2018-2017-assets-current-assets-cash-and-cash-equivalents-16-045-21-70-irix-20180802monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-corporation-condensed-consolidated-balance-sheets-in-thousands-and-unaudited-march--irix-20180503monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-appointment-of-maria-sainz-and-david-bruce-to-its-board-of-directors-moun-irix-20180416monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-corporation-condensed-consolidated-balance-sheets-in-thousands-and-unaudited-decemb-irix-20180308monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-issues-voluntary-recall-of-trufocus-lio-premiere-laser-indirect-ophthalmoscope-upda-irix-20180223monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-infringement-lawsuit-against-quantel-irix-20180109monthly0.5https://www.biopharmawatch.com/news/IRIX/which-was-filed-with-the-securities-and-exchange-commission-forward-looking-statements-con-irix-20180108monthly0.5https://www.biopharmawatch.com/news/IRIX/forward-looking-statements-participation-in-this-presentation-requires-that-you-be-aware-o-irix-20171102monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-corporation-condensed-consolidated-balance-sheets-in-thousands-and-unaudited-septem-irix-20171102monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-corporation-condensed-consolidated-balance-sheets-in-thousands-and-unaudited-july-1-irix-20170803monthly0.5https://www.biopharmawatch.com/news/IRIX/number-of-factors-please-see-a-detailed-description-of-these-and-other-risks-contained-in--irix-20170719monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-first-quarter-2017-financial-results-updates-guidance-for-full-year-2017-irix-20170503monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-fourth-quarter-and-2016-financial-results-and-provides-full-year-2017-fin-irix-20170308monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-preliminary-unaudited-revenues-for-2016-fourth-quarter-and-full-year-moun-irix-20170109monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-corporation-prices-public-offering-of-common-stock-irix-20161209monthly0.5https://www.biopharmawatch.com/news/IRIX/irix-ex991-6-pptx-htm-iridex-corporation-corporate-presentation-november-2016-nasdaq-irix--irix-20161109monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-2016-third-quarter-nine-month-results-cyclo-g6-glaucoma-laser-platform-thir-irix-20161103monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-preliminary-revenues-for-2016-third-quarter-mountain-view-ca-irix-20161011monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-2016-second-quarter-six-month-results-total-revenues-up-32-percent-year-ove-irix-20160804monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-atabak-mokari-will-be-chief-financial-officer-and-vp-corporate-developmen-irix-20160711monthly0.5https://www.biopharmawatch.com/news/IRIX/safe-harbor-participation-in-this-presentation-requires-that-you-be-aware-of-the-federal-l-irix-20160601monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-2016-first-quarter-results-record-first-quarter-revenues-revenues-up-11-per-irix-20160505monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-2015-fourth-quarter-full-year-results-revenues-up-3-percent-versus-fourth-q-irix-20160303monthly0.5https://www.biopharmawatch.com/news/IRIX/safe-harbor-participation-in-this-presentation-requires-that-you-be-aware-of-the-federal-l-irix-20160112monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-preliminary-unaudited-revenues-for-2015-fourth-quarter-and-full-year-year-irix-20160111monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-2015-third-quarter-nine-month-results-mountain-view-ca-irix-20151105monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-2015-second-quarter-six-month-results-mountain-view-ca-irix-20150806monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-chief-financial-officer-resigns-to-accept-another-opportunity-irix-20150804monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-preliminary-revenues-for-2015-second-quarter-irix-20150716monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-2015-first-quarter-results-record-q1-revenues-mountain-view-ca-irix-20150507monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-2014-fourth-quarter-year-end-results-record-revenues-for-the-quarter-and-th-irix-20150305monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-preliminary-unaudited-revenues-for-2014-fourth-quarter-and-full-year-2015-irix-20150112monthly0.5https://www.biopharmawatch.com/news/IRIX/medical-laser-veteran-george-r-marcellino-ph-d-appointed-to-iridex-board-of-directors-moun-irix-20141231monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-2014-third-quarter-nine-month-results-mountain-view-ca-irix-20141030monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-2014-second-quarter-six-month-results-revenue-up-15-year-over-year-for-both-irix-20140731monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-2014-first-quarter-results-revenue-up-16-to-10-3-million-year-over-year-mou-irix-20140501monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-2013-fourth-quarter-results-record-revenue-of-10-6-million-in-quarter-mount-irix-20140227monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-preliminary-unaudited-revenues-for-2013-fourth-quarter-and-year-end-irix-20140128monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-2013-third-quarter-results-record-revenue-of-9-5-million-in-quarter-mountai-irix-20131031monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-2013-second-quarter-results-9-2-million-record-q2-revenue-mountain-view-cal-irix-20130801monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-2013-first-quarter-results-profits-increase-as-commercial-progress-and-oper-irix-20130502monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-record-2012-fourth-quarter-results-board-approves-new-3-0-million-stock-rep-irix-20130228monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-2012-third-quarter-results-mountain-view-calif-irix-20121101monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-appoints-chairman-william-m-moore-as-interim-president-ceo-cfo-james-mackaness-to-a-irix-20120828monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-2012-second-quarter-results-mountain-view-calif-irix-20120802monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-2012-first-quarter-results-mountain-view-calif-irix-20120503monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-2011-fourth-quarter-and-year-end-results-mountain-view-calif-irix-20120301monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-corporation-executive-management-bonus-plan-summary-effective-date-january-1st-2012-irix-20120221monthly0.5https://www.biopharmawatch.com/news/IRIX/cutera-and-iridex-announce-acquisition-of-iridex-aesthetic-business-unit-purchase-position-irix-20120103monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-2011-third-quarter-and-nine-month-results-mountain-view-calif-irix-20111103monthly0.5https://www.biopharmawatch.com/news/IRIX/execution-copy-iridex-corporation-employment-agreement-this-employment-agreement-the-agree-irix-20111012monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-growing-revenue-and-profits-in-2011-second-quarter-mountain-view-calif-irix-20110804monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-growing-revenue-and-profits-in-2011-first-quarter-announces-stock-repurchas-irix-20110505monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-corporation-2011-senior-staff-bonus-plan-summary-objective-to-provide-cash-incentiv-irix-20110310monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-reports-strong-growth-and-profits-in-2010-fourth-quarter-quarterly-profit-increases-irix-20110303monthly0.5https://www.biopharmawatch.com/news/IRIX/jim-mackaness-chief-financial-officer-650-940-4700-irix-20101104monthly0.5https://www.biopharmawatch.com/news/IRIX/jim-mackaness-chief-financial-officer-650-940-4700-irix-20100805monthly0.5https://www.biopharmawatch.com/news/IRIX/jim-mackaness-chief-financial-officer-650-940-4700-irix-20100506monthly0.5https://www.biopharmawatch.com/news/IRIX/jim-mackaness-chief-financial-officer-650-940-4700-irix-20100329monthly0.5https://www.biopharmawatch.com/news/IRIX/jim-mackaness-chief-financial-officer-650-940-4700-irix-20100304monthly0.5https://www.biopharmawatch.com/news/IRIX/jim-mackaness-chief-financial-officer-650-940-4700-irix-20091218monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-corporation-2010-employee-incentive-program-summary-objective-to-provide-cash-incen-irix-20091215monthly0.5https://www.biopharmawatch.com/news/IRIX/jim-mackaness-chief-financial-officer-650-940-4700-irix-20091112monthly0.5https://www.biopharmawatch.com/news/IRIX/jim-mackaness-chief-financial-officer-650-940-4700-irix-20090813monthly0.5https://www.biopharmawatch.com/news/IRIX/jim-mackaness-chief-financial-officer-650-940-4700-irix-20090514monthly0.5https://www.biopharmawatch.com/news/IRIX/jim-mackaness-chief-financial-officer-650-940-4700-irix-20090310monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-corporation-2009-employee-incentive-program-summary-objective-to-provide-cash-incen-irix-20081216monthly0.5https://www.biopharmawatch.com/news/IRIX/jim-mackaness-chief-financial-officer-650-940-4700-irix-20081104monthly0.5https://www.biopharmawatch.com/news/IRIX/jim-mackaness-chief-financial-officer-650-940-4700-irix-20080812monthly0.5https://www.biopharmawatch.com/news/IRIX/jim-mackaness-chief-financial-officer-650-940-4700-irix-20080513monthly0.5https://www.biopharmawatch.com/news/IRIX/jim-mackaness-chief-financial-officer-650-940-4700-irix-20080410monthly0.5https://www.biopharmawatch.com/news/IRIX/theodore-a-boutacoff-chief-executive-officer-650-940-4700-irix-20071217monthly0.5https://www.biopharmawatch.com/news/IRIX/theodore-a-boutacoff-president-and-ceo-650-940-4700-irix-20071119monthly0.5https://www.biopharmawatch.com/news/IRIX/theodore-a-boutacoff-appointed-president-ceo-of-irix-20071017monthly0.5https://www.biopharmawatch.com/news/IRIX/larry-tannenbaum-chief-business-officer-650-940-4700-irix-20071015monthly0.5https://www.biopharmawatch.com/news/IRIX/larry-tannenbaum-chief-business-officer-650-940-4700-irix-20070912monthly0.5https://www.biopharmawatch.com/news/IRIX/iridex-announces-closing-of-5-0-million-private-placement-irix-20070905monthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-reports-first-quarter-2026-financial-results-and-provides-phase-3-de-cvkd-20260507monthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-announces-end-of-phase-2-meeting-with-the-fda-and-pivotal-phase-3-re-cvkd-20260430monthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-reports-fourth-quarter-2025-financial-results-provides-corporate-upd-cvkd-20260331monthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-highlights-research-supporting-12-lox-inhibition-in-reducing-inflamm-cvkd-20260312monthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-acquires-vlx-1005-a-first-in-class-phase-2-12-lox-inhibitor-for-pati-cvkd-20251211monthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-appoints-dr-lee-golden-to-board-of-directors-cvkd-20251201monthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-reports-third-quarter-2025-financial-results-and-provides-corporate--cvkd-20251110monthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-enhances-anticoagulation-pipeline-through-acquisition-of-exithera-s--cvkd-20250915monthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate-cvkd-20250811monthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-announces-clinical-trial-initiation-plans-for-tecarfarin-in-patients-cvkd-20250805monthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-reports-first-quarter-2025-financial-results-and-provides-corporate--cvkd-20250508monthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-reports-full-year-2024-results-business-highlights-and-path-forward--cvkd-20250313monthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-announces-collaboration-agreement-with-abbott-in-support-of-pivotal--cvkd-20250304monthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-announces-chief-medical-officer-transition-to-advance-clinical-devel-cvkd-20250206monthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-provides-third-quarter-cvkd-20241107monthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-announces-exercise-of-warrants-for-4-7-million-gross-proceeds-cvkd-20241101monthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-raises-5-1-million-via-at-the-market-facility-cvkd-20241024monthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-inc-nasdaq-cvkd-september-2024-2-caution-concerning-forward-looking--cvkd-20240925monthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-provides-second-quarter-2024-corporate-update-cvkd-20240807monthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-and-abbott-initiate-collaborative-effort-to-advance-novel-anticoagul-cvkd-20240806monthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-receives-fda-orphan-drug-designation-for-tecarfarin-for-prevention-o-cvkd-20240409monthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-provides-fourth-quarter-2023-corporate-update-cvkd-20240311monthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-appoints-jeff-cole-as-chief-operating-officer-in-advance-of-tecarfar-cvkd-20240208monthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-provides-third-quarter-2023-corporate-update-cvkd-20231109monthly0.5https://www.biopharmawatch.com/news/CVKD/create-a-cover-slide-cadrenal-therapeutics-inc-nasdaq-cvkd-august-2023-2-cautionary-statem-cvkd-20230818monthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-provides-second-quarter-2023-corporate-update-cvkd-20230810monthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-announces-appointment-of-robert-lisicki-to-board-of-directors-cvkd-20230724monthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-announces-7-5-million-private-placement-priced-at-the-market-under-n-cvkd-20230712monthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-provides-first-quarter-2023-corporate-update-cvkd-20230510monthly0.5https://www.biopharmawatch.com/news/CVKD/create-a-cover-slide-cadrenal-therapeutics-inc-nasdaq-cvkd-march-2023-2-cautionary-stateme-cvkd-20230327monthly0.5https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-announces-pricing-of-initial-public-offering-ipo-cvkd-20230120monthly0.5https://www.biopharmawatch.com/news/HIND/vt-1953-in-treating-symptoms-of-malignant-fungating-wounds-mfw-phase-2-ist-study-results-n-hind-20260213monthly0.5https://www.biopharmawatch.com/news/HIND/u-s-market-product-assessment-and-valuation-of-vt-1953-for-the-treatment-of-symptoms-of-ma-hind-20260128monthly0.5https://www.biopharmawatch.com/news/HIND/vyome-holdings-announces-transformational-first-quarter-following-nasdaq-listing-quarter-e-hind-20251119monthly0.5https://www.biopharmawatch.com/news/HIND/vyome-holdings-acquires-mit-ai-spinout-oculo-health-launches-business-unit-to-create-ai-ps-hind-20250929monthly0.5https://www.biopharmawatch.com/news/HIND/vyome-therapeutics-inc-and-subsidiary-condensed-consolidated-balance-sheets-as-of-amount-i-hind-20250902monthly0.5https://www.biopharmawatch.com/news/HIND/vyome-a-us-india-healthcare-platform-with-clinical-stage-immuno-inflammation-assets-pendin-hind-20250707monthly0.5https://www.biopharmawatch.com/news/HIND/reshape-lifesciences-announces-pricing-of-2-6-million-public-offering-hind-20250609monthly0.5https://www.biopharmawatch.com/news/HIND/vyome-therapeutics-inc-and-subsidiary-vyome-therapeutics-inc-and-subsidiary-consolidated-f-hind-20250528monthly0.5https://www.biopharmawatch.com/news/HIND/reshape-lifesciences-announces-1-for-25-reverse-stock-split-effective-as-of-commencement-o-hind-20250509monthly0.5https://www.biopharmawatch.com/news/HIND/reshape-lifesciences-announces-pricing-of-upsized-6-0-million-public-offering-hind-20250215monthly0.5https://www.biopharmawatch.com/news/HIND/vyome-a-us-india-healthcare-platform-with-clinical-stage-immuno-inflammation-assets-pendin-hind-20241211monthly0.5https://www.biopharmawatch.com/news/HIND/reshape-lifesciences-reports-third-quarter-ended-hind-20241114monthly0.5https://www.biopharmawatch.com/news/HIND/reshape-lifesciences-announces-1-for-58-reverse-stock-split-effective-as-of-commencement-o-hind-20240923monthly0.5https://www.biopharmawatch.com/news/HIND/reshape-lifesciences-reports-second-quarter-ended-hind-20240814monthly0.5https://www.biopharmawatch.com/news/HIND/reshape-lifesciences-enters-into-merger-agreement-with-vyome-therapeutics-and-asset-purcha-hind-20240709monthly0.5https://www.biopharmawatch.com/news/HIND/reshape-lifesciences-reports-first-quarter-ended-hind-20240520monthly0.5https://www.biopharmawatch.com/news/HIND/reshape-lifesciences-reports-year-ended-hind-20240404monthly0.5https://www.biopharmawatch.com/news/HIND/reshape-lifesciences-enters-into-warrant-exercise-transaction-for-1-2-million-in-gross-pro-hind-20231121monthly0.5https://www.biopharmawatch.com/news/HIND/reshape-lifesciences-reports-third-quarter-ended-hind-20231109monthly0.5https://www.biopharmawatch.com/news/HIND/reshape-lifesciences-announces-pricing-of-3-0-million-public-offering-hind-20230929monthly0.5https://www.biopharmawatch.com/news/HIND/reshape-lifesciences-signs-exclusive-license-agreement-with-biorad-medisys-for-obalon-gast-hind-20230921monthly0.5https://www.biopharmawatch.com/news/HIND/reshape-lifesciences-reports-second-quarter-ended-hind-20230807monthly0.5https://www.biopharmawatch.com/news/HIND/reshape-lifesciences-reports-first-quarter-ended-hind-20230516monthly0.5https://www.biopharmawatch.com/news/HIND/reshape-lifesciences-announces-pricing-of-2-5-million-registered-direct-offering-and-concu-hind-20230420monthly0.5https://www.biopharmawatch.com/news/HIND/reshape-lifesciences-announces-pricing-of-upsized-10-2-million-underwritten-public-offerin-hind-20230206monthly0.5https://www.biopharmawatch.com/news/HIND/business-our-company-reshape-lifesciences-inc-is-a-worldwide-premier-weight-loss-solutions-hind-20230127monthly0.5https://www.biopharmawatch.com/news/HIND/reshape-lifesciences-announces-1-for-50-reverse-stock-split-effective-as-of-commencement-o-hind-20221223monthly0.5https://www.biopharmawatch.com/news/HIND/reshape-lifesciences-reports-third-quarter-2022-financial-results-and-provides-corporate-u-hind-20221114monthly0.5https://www.biopharmawatch.com/news/HIND/reshape-lifesciences-announces-750-000-registered-direct-offering-hind-20221108monthly0.5https://www.biopharmawatch.com/news/HIND/reshape-lifesciences-reports-second-quarter-2022-financial-results-and-provides-corporate--hind-20220815monthly0.5https://www.biopharmawatch.com/news/HIND/reshape-lifesciences-announces-appointment-of-paul-f-hickey-as-president-and-chief-executi-hind-20220727monthly0.5https://www.biopharmawatch.com/news/HIND/reshape-lifesciences-reports-first-quarter-2022-financial-results-and-provides-corporate-u-hind-20220523monthly0.5https://www.biopharmawatch.com/news/HIND/reshape-lifesciences-reports-year-ended-2021-financial-and-operating-results-and-provides--hind-20220328monthly0.5https://www.biopharmawatch.com/news/HIND/reshape-lifesciences-to-announce-financial-results-for-the-year-ended-hind-20220322monthly0.5https://www.biopharmawatch.com/news/HIND/reshape-lifesciences-to-announce-financial-results-for-the-year-ended-hind-20220317monthly0.5https://www.biopharmawatch.com/news/HIND/reshape-lifesciences-reports-third-quarter-and-nine-month-2021-financial-and-operational-r-hind-20211111monthly0.5https://www.biopharmawatch.com/news/HIND/reshape-reports-second-quarter-2021-financial-results-and-provides-business-update-webinar-hind-20210816monthly0.5https://www.biopharmawatch.com/news/HIND/reshape-lifesciences-inc-and-obalon-therapeutics-inc-announce-anticipated-closing-of-merge-hind-20210615monthly0.5https://www.biopharmawatch.com/news/HIND/obalon-therapeutics-continues-to-urge-stockholders-to-vote-for-all-proposals-related-to-me-hind-20210520monthly0.5https://www.biopharmawatch.com/news/HIND/obalon-therapeutics-stockholders-special-meeting-adjourned-to-hind-20210518monthly0.5https://www.biopharmawatch.com/news/HIND/obalon-announces-first-quarter-2021-financial-results-san-diego-ca-may-12-2021-globe-newsw-hind-20210512monthly0.5https://www.biopharmawatch.com/news/HIND/obalon-announces-fourth-quarter-and-full-year-2020-financial-results-hind-20210312monthly0.5https://www.biopharmawatch.com/news/HIND/voting-and-support-agreement-among-obalon-therapeutics-inc-and-certain-stockholders-of-res-hind-20210119monthly0.5https://www.biopharmawatch.com/news/HIND/exhibit-william-plovanic-resigns-as-president-and-chief-executive-officer-and-will-continu-hind-20200508monthly0.5https://www.biopharmawatch.com/news/HIND/obalon-therapeutics-inc-announces-pricing-of-15-000-000-public-offering-san-diego-ca-hind-20190802monthly0.5https://www.biopharmawatch.com/news/HIND/obalon-announces-reverse-stock-split-effective-today-obln-common-stock-expected-to-begin-t-hind-20190725monthly0.5https://www.biopharmawatch.com/news/HIND/summary-business-description-this-summary-highlights-selected-information-about-us-this-of-hind-20190103monthly0.5https://www.biopharmawatch.com/news/NCEL/to-the-shareholders-of-newcelx-ag-kloten-switzerland-zurich-june-x00a0-5-2026-invitation-t-ncel-20260605monthly0.5https://www.biopharmawatch.com/news/NCEL/newcelx-announces-pricing-of-1-35-million-equity-financing-at-30-premium-pricing-financing-ncel-20260401monthly0.5https://www.biopharmawatch.com/news/NCEL/newcelx-announces-strategic-collaboration-with-eledon-pharmaceuticals-nasdaq-eldn-to-advan-ncel-20260309monthly0.5https://www.biopharmawatch.com/news/NCEL/newcelx-reports-peer-reviewed-publication-supporting-mazindol-ir-sr-and-advances-cvr-monet-ncel-20260212monthly0.5https://www.biopharmawatch.com/news/NCEL/newcelx-announces-updated-corporate-presentation-ahead-of-key-spring-2026-investor-and-par-ncel-20260129monthly0.5https://www.biopharmawatch.com/news/NCEL/newcelx-announce-positive-results-from-international-collaborative-study-exploring-advance-ncel-20260112monthly0.5https://www.biopharmawatch.com/news/NCEL/newcelx-appoints-dr-julien-boisdron-a-swiss-big-pharma-leader-in-diabetes-innovation-to-it-ncel-20260105monthly0.5https://www.biopharmawatch.com/news/NCEL/newcelx-expands-intellectual-property-footprint-with-publication-of-doxa-patent-applicatio-ncel-20251211monthly0.5https://www.biopharmawatch.com/news/NCEL/newcelx-strengthens-scientific-advisory-board-with-appointment-of-jeremy-shefner-md-phd-ch-ncel-20251117monthly0.5https://www.biopharmawatch.com/news/NCEL/newcelx-ceo-issues-letter-to-shareholders-zurich-switzerland-ncel-20251104monthly0.5https://www.biopharmawatch.com/news/NCEL/newcelx-provides-business-and-strategic-roadmap-update-following-closing-of-merger-with-nl-ncel-20251103monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-ltd-and-kadimastem-ltd-announce-completion-of-merger-combined-company-re-ncel-20251031monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-expands-cns-pipeline-with-aex-6xx-series-developed-by-aexon-labs-doxa-pl-ncel-20251030monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-and-kadimastem-highlight-continued-bird-foundation-support-for-itol-102--ncel-20251029monthly0.5https://www.biopharmawatch.com/news/NCEL/statuten-der-newcelx-ag-newcelx-sa-newcelx-ltd-die-gesellschaft-articles-of-association-of-ncel-20251029monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-and-kadimastem-announce-completion-of-material-conditions-precedent-for--ncel-20251028monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-and-kadimastem-announce-strategic-collaboration-between-kadimastem-and-t-ncel-20251027monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-and-kadimastem-announce-receipt-of-nasdaq-approval-merger-expected-to-close-on-ncel-20251023monthly0.5https://www.biopharmawatch.com/news/NCEL/kadimastem-ltd-interim-condensed-financial-statements-as-of-ncel-20251010monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-ltd-unaudited-interim-condensed-financial-statements-as-of-june-30-2025--ncel-20251006monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-shareholders-approve-merger-with-kadimastem-and-related-proposals-at-ext-ncel-20250930monthly0.5https://www.biopharmawatch.com/news/NCEL/kadimastem-and-nls-pharmaceutics-announce-effectiveness-of-sec-registration-statement-in-c-ncel-20250910monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-and-kadimastem-announce-a-hong-kong-patent-covering-cell-selection-and-e-ncel-20250904monthly0.5https://www.biopharmawatch.com/news/NCEL/seventh-amendment-to-agreement-of-merger-and-plan-of-reorganization-this-seventh-amendment-ncel-20250829monthly0.5https://www.biopharmawatch.com/news/NCEL/execution-version-exchange-agreement-this-exchange-agreement-this-agreement-dated-as-of-ncel-20250805monthly0.5https://www.biopharmawatch.com/news/NCEL/sixth-amendment-to-agreement-of-merger-and-plan-of-reorganization-this-sixth-amendment-to--ncel-20250718monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-highlights-continued-progress-in-itol-102-diabetes-program-as-bird-found-ncel-20250717monthly0.5https://www.biopharmawatch.com/news/NCEL/fifth-amendment-to-agreement-of-merger-and-plan-of-reorganization-this-fifth-amendment-to--ncel-20250701monthly0.5https://www.biopharmawatch.com/news/NCEL/amendment-to-the-securities-purchase-agreement-this-amendment-to-the-securities-purchase-a-ncel-20250626monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-ceo-issues-letter-to-shareholders-zurich-june-16-2025-prnewswire-nls-pha-ncel-20250616monthly0.5https://www.biopharmawatch.com/news/NCEL/to-the-shareholders-of-nls-pharmaceutics-ltd-zurich-switzerland-zurich-ncel-20250606monthly0.5https://www.biopharmawatch.com/news/NCEL/fourth-amendment-to-agreement-of-merger-and-plan-of-reorganization-this-fourth-amendment-t-ncel-20250605monthly0.5https://www.biopharmawatch.com/news/NCEL/amendment-no-3-to-the-agreement-of-merger-and-plan-of-reorganization-this-amendment-is-mad-ncel-20250505monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-positive-results-from-study-ko-943-demonstrating-mazindol-redu-ncel-20250415monthly0.5https://www.biopharmawatch.com/news/NCEL/neither-this-security-nor-the-securities-for-which-this-security-is-exercisable-have-been--ncel-20250326monthly0.5https://www.biopharmawatch.com/news/NCEL/to-form-6-k-file-no-001-39957-filed-on-ncel-20250331monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-ceo-issues-letter-to-shareholders-z-uuml-rich-switzerland-ncel-20250310monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-new-preclinical-data-for-aex-2-expanding-the-therapeutic-poten-ncel-20250227monthly0.5https://www.biopharmawatch.com/news/NCEL/kadimastem-and-itolerance-successfully-complete-pre-ind-meeting-with-the-fda-for-its-type--ncel-20250225monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-and-kadimastem-unveil-multi-target-approach-to-diabetes-expanding-beyond-ncel-20250210monthly0.5https://www.biopharmawatch.com/news/NCEL/amendment-to-the-agreement-of-merger-and-plan-of-reorganization-this-amendment-dated-ncel-20250130monthly0.5https://www.biopharmawatch.com/news/NCEL/kadimastem-shareholders-approved-the-merger-with-nls-pharmaceutics-zurich-switzerland-and-ncel-20250131monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-the-submission-of-three-research-abstracts-to-the-2025-ascp-an-ncel-20250130monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-the-launch-of-a-preclinical-program-for-mazindol-er-in-the-tre-ncel-20250128monthly0.5https://www.biopharmawatch.com/news/NCEL/kadimastem-calls-for-a-special-general-meeting-of-shareholders-to-approve-the-merger-with--ncel-20250116monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-ltd-and-kadimastem-ltd-announce-the-initial-closing-of-500-000-of-the-pr-ncel-20250106monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-ltd-and-kadimastem-ltd-announce-filing-of-f-4-registration-statement-wit-ncel-20241230monthly0.5https://www.biopharmawatch.com/news/NCEL/to-the-shareholders-of-nls-pharmaceutics-ltd-zurich-switzerland-zurich-23-december-2024-in-ncel-20241223monthly0.5https://www.biopharmawatch.com/news/NCEL/to-the-shareholders-of-nls-pharmaceutics-ltd-zurich-switzerland-zurich-16-december-2024-in-ncel-20241204monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-and-kadimastem-announce-the-submission-of-a-request-by-kadimastem-and-it-ncel-20241219monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-ceo-issues-letter-to-shareholders-z-rich-switzerland-ncel-20241211monthly0.5https://www.biopharmawatch.com/news/NCEL/to-form-6-k-file-no-001-39957-filed-on-ncel-20241204monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-promising-preclinical-data-for-first-in-class-non-sulfonamide--ncel-20241203monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-highlights-innovative-preclinical-program-for-first-in-class-non-sulfona-ncel-20241118monthly0.5https://www.biopharmawatch.com/news/NCEL/statuten-articles-of-association-der-of-nls-pharmaceutics-ag-nls-pharmaceutics-ag-nls-phar-ncel-20241115monthly0.5https://www.biopharmawatch.com/news/NCEL/kadimastem-ltd-financial-statements-as-of-ncel-20241112monthly0.5https://www.biopharmawatch.com/news/NCEL/category-notifications-issued-to-company-members-sub-category-invitation-to-the-general-me-ncel-20241106monthly0.5https://www.biopharmawatch.com/news/NCEL/agreement-of-merger-and-plan-of-reorganization-by-and-among-nls-pharmaceutics-ltd-nls-phar-ncel-20241104monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-and-kadimastem-enter-into-a-definitive-merger-agreement-zurich-switzerla-ncel-20241104monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-ltd-regains-full-compliance-with-nasdaq-listing-requirements-zurich-swit-ncel-20241028monthly0.5https://www.biopharmawatch.com/news/NCEL/statuten-der-nls-pharmaceutics-ag-nls-pharmaceutics-sa-nls-pharmaceutics-ltd-die-gesellsch-ncel-20241022monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-ltd-unaudited-interim-condensed-financial-statements-as-of-june-30-2024--ncel-20241018monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-ltd-announces-closing-of-private-placement-and-expected-compliance-with--ncel-20241015monthly0.5https://www.biopharmawatch.com/news/NCEL/neither-this-security-nor-the-securities-for-which-this-security-is-exercisable-have-been--ncel-20241009monthly0.5https://www.biopharmawatch.com/news/NCEL/statuten-der-nls-pharmaceutics-ag-nls-pharmaceutics-sa-nls-pharmaceutics-ltd-die-gesellsch-ncel-20240925monthly0.5https://www.biopharmawatch.com/news/NCEL/to-the-shareholders-of-nls-pharmaceutics-ltd-zurich-switzerland-zurich-10-september-2024-i-ncel-20240913monthly0.5https://www.biopharmawatch.com/news/NCEL/to-the-shareholders-of-nls-pharmaceutics-ltd-zurich-switzerland-zurich-26-august-2024-invi-ncel-20240826monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-and-kadimastem-announce-binding-term-sheet-to-merge-the-proposed-transac-ncel-20240729monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-ag-nls-pharmaceutics-announces-registered-direct-offering-zurich-switzer-ncel-20240628monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-promising-preclinical-results-for-parkinson-s-disease-treatmen-ncel-20240627monthly0.5https://www.biopharmawatch.com/news/NCEL/to-the-shareholders-of-nls-pharmaceutics-ltd-zurich-switzerland-zurich-ncel-20240625monthly0.5https://www.biopharmawatch.com/news/NCEL/nasdaq-panel-grants-nls-pharmaceutics-request-for-extension-to-comply-with-continued-listi-ncel-20240625monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-publication-of-new-patent-application-for-next-gen-dual-non-su-ncel-20240611monthly0.5https://www.biopharmawatch.com/news/NCEL/to-the-shareholders-of-nls-pharmaceutics-ltd-zurich-switzerland-zurich-ncel-20240605monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-reports-positive-results-from-study-ko-874-on-mazindol-s-neuroprotective-ncel-20240528monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-receipt-of-additional-staff-delisting-determination-from-nasda-ncel-20240524monthly0.5https://www.biopharmawatch.com/news/NCEL/addendum-to-the-loan-agreement-agreement-of-ncel-20240522monthly0.5https://www.biopharmawatch.com/news/NCEL/second-addendum-to-the-loan-agreement-agreement-of-ncel-20240514monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-receipt-of-staff-delisting-determination-from-nasdaq-intends-t-ncel-20240419monthly0.5https://www.biopharmawatch.com/news/NCEL/statuten-der-nls-pharmaceutics-ag-nls-pharmaceutics-sa-nls-pharmaceutics-ltd-die-gesellsch-ncel-20240415monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-1-75-million-registered-direct-offering-zurich-switzerland-acc-ncel-20240320monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-secures-exclusive-global-license-for-next-generation-non-sulfonamide-dua-ncel-20240320monthly0.5https://www.biopharmawatch.com/news/NCEL/second-addendum-to-the-loan-agreement-agreement-of-ncel-20240320monthly0.5https://www.biopharmawatch.com/news/NCEL/statuten-der-nls-pharmaceutics-ag-nls-pharmaceutics-sa-nls-pharmaceutics-ltd-die-gesellsch-ncel-20240314monthly0.5https://www.biopharmawatch.com/news/NCEL/nasdaq-accepts-nls-pharmaceutics-plan-to-regain-listing-compliance-z-rich-switzerland-ncel-20240311monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-submits-plan-to-regain-listing-compliance-with-nasdaq-z-rich-switzerland-ncel-20240223monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-receipt-of-notice-of-deficiency-with-nasdaq-continued-listing--ncel-20240112monthly0.5https://www.biopharmawatch.com/news/NCEL/z-rich-switzerland-ncel-20231229monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-ltd-unaudited-interim-condensed-financial-statements-as-of-june-30-2023--ncel-20231206monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-election-of-additional-board-members-professor-claudio-l-a-bas-ncel-20231128monthly0.5https://www.biopharmawatch.com/news/NCEL/to-the-shareholders-of-nls-pharmaceutics-ag-zurich-switzerland-zurich-1-december-2023-invi-ncel-20231204monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-exclusive-option-agreement-to-develop-and-commercialize-next-g-ncel-20231201monthly0.5https://www.biopharmawatch.com/news/NCEL/loan-agreement-agreement-of-ncel-20231115monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-receipt-of-nasdaq-minimum-bid-price-notification-z-rich-switze-ncel-20231025monthly0.5https://www.biopharmawatch.com/news/NCEL/loan-agreement-agreement-of-28-september-2023-between-nls-pharmaceutics-ag-the-circle-6-80-ncel-20231025monthly0.5https://www.biopharmawatch.com/news/NCEL/re-defining-central-nervous-system-therapies-nls-pharmaceutics-september-2023-2-forward-lo-ncel-20230913monthly0.5https://www.biopharmawatch.com/news/NCEL/z-rich-switzerland-ncel-20230828monthly0.5https://www.biopharmawatch.com/news/NCEL/thank-you-for-joining-the-presentation-will-begin-shortly-nls-pharmaceutics-company-update-ncel-20230706monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-releases-the-results-from-its-annual-general-meeting-z-rich-switzerland-ncel-20230630monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-positive-safety-data-from-in-vitro-cyp450-and-transporter-medi-ncel-20230614monthly0.5https://www.biopharmawatch.com/news/NCEL/to-the-shareholders-of-nls-pharmaceutics-ag-zurich-switzerland-zurich-8-june-2023-invitati-ncel-20230609monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-appoints-keith-harrison-dewedoff-as-interim-chief-financial-officer-z-ri-ncel-20230508monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-receives-green-light-from-the-u-s-fda-to-proceed-with-phase-3-clinical-p-ncel-20230502monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-open-label-extension-study-six-month-data-for-quilience-mazind-ncel-20230327monthly0.5https://www.biopharmawatch.com/news/NCEL/statuten-der-nls-pharmaceutics-ag-nls-pharmaceutics-sa-nls-pharmaceutics-ltd-die-gesellsch-ncel-20230221monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-completion-of-open-label-extension-study-with-quilience-mazind-ncel-20230130monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-regains-compliance-with-nasdaq-stockholders-equity-requirement-z-rich-sw-ncel-20230125monthly0.5https://www.biopharmawatch.com/news/NCEL/to-the-shareholders-of-nls-pharmaceutics-ltd-zurich-switzerland-zurich-ncel-20230120monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-new-in-vitro-data-reconfirming-quilience-s-mazindol-er-unique--ncel-20230123monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-an-r-d-update-webcast-to-review-the-company-s-growing-portfoli-ncel-20230112monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-technology-patent-grant-covering-mazindol-for-treatment-of-att-ncel-20230110monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-ceo-issues-letter-to-shareholders-to-our-shareholders-and-friends-just-u-ncel-20221222monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-israeli-patent-grant-covering-mazindol-for-treatment-of-attent-ncel-20221220monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-closing-of-initial-tranche-of-us-10-0-million-purchase-agreeme-ncel-20221214monthly0.5https://www.biopharmawatch.com/news/NCEL/statuten-der-nls-pharmaceutics-ag-nls-pharmaceutics-sa-nls-pharmaceutics-ltd-die-gesellsch-ncel-20221214monthly0.5https://www.biopharmawatch.com/news/NCEL/neither-this-security-nor-the-securities-for-which-this-security-is-exercisable-has-been-r-ncel-20221208monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-receipt-of-nasdaq-minimum-bid-price-notification-z-rich-switze-ncel-20221207monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-notice-of-allowance-for-u-s-patent-covering-mazindol-for-opioi-ncel-20221201monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-launch-of-paid-for-named-patient-program-with-mazindol-er-for--ncel-20221123monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-successfully-appeals-nasdaq-delisting-notice-switzerland-zurich-ncel-20221114monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-provides-open-label-extension-study-update-for-quilience-mazindol-er-in--ncel-20221107monthly0.5https://www.biopharmawatch.com/news/NCEL/u-s-fda-grants-orphan-drug-designation-odd-for-quilience-ograve-mazindol-er-for-the-treatm-ncel-20221102monthly0.5https://www.biopharmawatch.com/news/NCEL/statuten-der-nls-pharmaceutics-ag-nls-pharmaceutics-sa-nls-pharmaceutics-ltd-die-gesellsch-ncel-20221028monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-ltd-unaudited-interim-condensed-financial-statements-as-of-and-for-the-s-ncel-20221011monthly0.5https://www.biopharmawatch.com/news/NCEL/to-the-shareholders-of-nls-pharmaceutics-ag-zurich-switzerland-zurich-ncel-20221005monthly0.5https://www.biopharmawatch.com/news/NCEL/neither-this-security-nor-the-securities-for-which-this-security-is-exercisable-have-been--ncel-20220930monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-positive-top-line-results-from-its-phase-2a-clinical-trial-of--ncel-20220927monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-appoints-dr-george-apostol-as-chief-medical-officer-and-global-head-of-r-ncel-20220908monthly0.5https://www.biopharmawatch.com/news/NCEL/short-term-note-agreement-dated-as-of-ncel-20220819monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-decision-by-japanese-patent-office-to-grant-patent-in-japan-fo-ncel-20220728monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-positive-opinion-from-european-regulators-to-grant-orphan-drug-ncel-20220721monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-receipt-of-nasdaq-minimum-bid-price-notification-switzerland-z-ncel-20220610monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-appoints-chad-c-hellmann-as-chief-financial-officer-switzerland-zurich-ncel-20220606monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-over-enrollment-in-its-phase-2a-clinical-trial-evaluating-quil-ncel-20220602monthly0.5https://www.biopharmawatch.com/news/NCEL/to-the-shareholders-of-nls-pharmaceutics-ag-zurich-switzerland-zurich-9-may-2022-invitatio-ncel-20220511monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-achieves-90-enrollment-milestone-in-quilience-phase-2a-clinical-trial-fo-ncel-20220504monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-ltd-announces-closing-of-us-4-4-million-registered-direct-offering-zuric-ncel-20220426monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-ltd-announces-us-4-4-million-registered-direct-offering-priced-at-the-ma-ncel-20220413monthly0.5https://www.biopharmawatch.com/news/NCEL/investor-presentation-april-2022-alexander-zwyer-ceo-co-founder-defining-central-nervous-s-ncel-20220401monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-receipt-of-notice-of-deficiency-with-nasdaq-continued-listing--ncel-20220401monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-retains-lifesci-partners-as-financial-advisor-to-evaluate-strategic-part-ncel-20220331monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-early-access-program-eap-allowing-patients-with-idiopathic-hyp-ncel-20220328monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-positive-interim-top-line-data-for-quilience-mazindol-er-in-pa-ncel-20220316monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-to-present-interim-top-line-data-for-quilience-mazindol-er-in-patients-w-ncel-20220207monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-patent-issuance-in-the-united-states-for-its-mazindol-extended-ncel-20220104monthly0.5https://www.biopharmawatch.com/news/NCEL/share-option-plan-regulation-2021-of-nls-pharmaceutics-ltd-company-table-of-content-1-intr-ncel-20211214monthly0.5https://www.biopharmawatch.com/news/NCEL/standby-equity-distribution-amendment-agreement-this-amendment-agreement-dated-as-of-ncel-20211214monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-preclinical-results-confirming-the-potential-benefit-and-safet-ncel-20211130monthly0.5https://www.biopharmawatch.com/news/NCEL/to-the-shareholders-of-nls-pharmaceutics-ag-stans-switzerland-stans-9-november-2021-invita-ncel-20211118monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-ceo-issues-letter-to-shareholders-switzerland-stans-ncel-20211101monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-preclinical-data-demonstrating-the-potential-of-nls-4-lauflumi-ncel-20211014monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-ltd-unaudited-interim-condensed-financial-statements-as-of-and-for-the-s-ncel-20210928monthly0.5https://www.biopharmawatch.com/news/NCEL/standby-equity-distribution-agreement-this-standby-equity-distribution-agreement-this-agre-ncel-20210927monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-initiates-phase-2-trial-for-quilience-in-narcolepsy-and-announces-first-patient-enroll-ncel-20210914monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-notice-of-allowance-for-u-s-patent-application-covering-its-pr-ncel-20210819monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-the-appointment-of-eric-konofal-m-d-ph-d-as-chief-scientific-o-ncel-20210719monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-announces-fda-acceptance-of-ind-application-to-initiate-clinical-trials--ncel-20210715monthly0.5https://www.biopharmawatch.com/news/NCEL/investor-presentation-july-2021-alexander-zwyer-ceo-co-founder-defining-central-nervous-sy-ncel-20210701monthly0.5https://www.biopharmawatch.com/news/NCEL/to-the-shareholders-of-nls-pharmaceutics-ag-stans-switzerland-stans-21-may-2021-invitation-ncel-20210525monthly0.5https://www.biopharmawatch.com/news/NCEL/con-f-i-d-e-n-t-i-a-l-redefining-central-nervous-system-therapies-investor-presentation-ma-ncel-20210401monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-appoints-silvia-panigone-ph-d-as-chief-operating-officer-switzerland-sta-ncel-20210405monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-obtains-license-to-full-regulatory-data-package-and-proprietary-know-how-ncel-20210312monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-ltd-announces-closing-of-20-0-million-initial-public-offering-ncel-20210202monthly0.5https://www.biopharmawatch.com/news/NCEL/nls-pharmaceutics-ltd-announces-pricing-of-20-0-million-initial-public-offering-ncel-20210128monthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-reports-third-quarter-2025-financial-results-and-provides-corporate-update-ph-gtbp-20251114monthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-announces-first-patient-dosed-in-phase-1-trial-of-gtb-3650-second-generation--gtbp-20250127monthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-announces-fda-clearance-of-investigational-new-drug-ind-application-for-gtb-3-gtbp-20240627monthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-inc-announces-3-2-million-registered-direct-offering-priced-at-the-market-und-gtbp-20240521monthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-inc-announces-1-for-30-reverse-stock-split-brisbane-california-gtbp-20240201monthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-announces-ind-submission-for-gtb-3650-for-treatment-of-cd33-leukemia-brisbane-gtbp-20231205monthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-names-charles-j-casamento-to-the-board-of-directors-brisbane-california-gtbp-20230504monthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-inc-announces-6-5-million-registered-direct-offering-priced-at-premium-to-mar-gtbp-20221230monthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-announces-adjournment-of-special-shareholders-meeting-meeting-adjourned-to-gtbp-20221004monthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-announces-expanded-trike-partnership-with-cytovance-biologics-sign-6-000-000--gtbp-20201006monthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-announces-the-sale-of-its-fixed-dose-combination-tablet-gtb-004-for-myastheni-gtbp-20190924monthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-reports-third-quarter-2018-financial-results-and-provides-business-update-x20-gtbp-20181115monthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-announces-dr-raymond-w-gtbp-20180514monthly0.5https://www.biopharmawatch.com/news/GTBP/former-sucampo-chief-scientific-officer-dr-peter-kiener-joins-gt-biopharma-s-board-of-dire-gtbp-20180424monthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-gtbp-otcqb-announces-appointment-of-shawn-m-cross-as-chairman-and-chief-execu-gtbp-20180215monthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-announces-7-1-million-convertible-debt-financing-gtbp-20180123monthly0.5https://www.biopharmawatch.com/news/GTBP/geoffrey-b-davis-joins-gt-biopharma-s-gtbp-20180116monthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-inc-announces-shawn-m-cross-20-year-healthcare-investment-banking-industry-ve-gtbp-20171116monthly0.5https://www.biopharmawatch.com/news/GTBP/gt-biopharma-announces-stock-sales-agreement-with-holders-of-converted-securities-washingt-gtbp-20171012monthly0.5https://www.biopharmawatch.com/news/GTBP/jfif-c-0-0-c-x-v-gtbp-20151026monthly0.5https://www.biopharmawatch.com/news/GTBP/oxis-international-reports-october-revenues-match-total-3-rd-quarter-revenues-gtbp-20121106monthly0.5https://www.biopharmawatch.com/news/GTBP/oxis-international-announces-significant-revenues-during-the-3rd-quarter-from-the-launch-o-gtbp-20121024monthly0.5https://www.biopharmawatch.com/news/GTBP/oxis-international-forms-joint-venture-to-develop-ergothioneine-based-treatment-for-acute--gtbp-20110711monthly0.5https://www.biopharmawatch.com/news/GTBP/oxis-international-names-former-wal-mart-executive-ken-eaton-to-board-of-directors-gtbp-20110627monthly0.5https://www.biopharmawatch.com/news/GTBP/letterhead-of-oxis-international-inc-oxis-international-inc-announces-the-appointment-of-b-gtbp-20100311monthly0.5https://www.biopharmawatch.com/news/GTBP/assignment-and-assumption-agreement-this-assignment-and-assumption-agreement-this-agreemen-gtbp-20090407monthly0.5https://www.biopharmawatch.com/news/GTBP/oxis-international-inc-323-vintage-park-drive-suite-b-foster-city-california-94404-gtbp-20080616monthly0.5https://www.biopharmawatch.com/news/GTBP/unassociated-document-gtbp-20070503monthly0.5https://www.biopharmawatch.com/news/GTBP/oxis-international-inc-2003-stock-incentive-plan-notice-of-stock-option-award-optionee-s-n-gtbp-20070111monthly0.5https://www.biopharmawatch.com/news/GTBP/oxis-international-reports-financial-results-for-first-quarter-2006-product-revenues-incre-gtbp-20060509monthly0.5https://www.biopharmawatch.com/news/GTBP/gary-post-managing-director-and-investment-principal-of-ambient-advisors-llc-joins-oxis-bo-gtbp-20060321monthly0.5https://www.biopharmawatch.com/news/GTBP/stock-purchase-agreement-this-stock-purchase-agreement-this-agreement-is-made-as-of-gtbp-20050919monthly0.5https://www.biopharmawatch.com/news/GTBP/execution-copy-oxis-international-inc-conversion-agreement-this-conversion-agreement-this--gtbp-20050523monthly0.5https://www.biopharmawatch.com/news/GTBP/will-anderson-obidicut-llc-503-452-7621-will-obidicut-net-gtbp-20050228monthly0.5https://www.biopharmawatch.com/news/GTBP/securities-purchase-agreement-this-securities-purchase-agreement-this-agreement-is-dated-a-gtbp-20041230monthly0.5https://www.biopharmawatch.com/news/GTBP/marvin-s-hausman-md-rejoins-oxis-international-inc-board-of-directors-portland-ore-busines-gtbp-20040823monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-reports-second-quarter-2025-financial-results-and-provides-business-update-icu-20250813monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-announces-4-million-registered-direct-offering-priced-at-the-market-under--icu-20250710monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-announces-positive-nasdaq-listing-determination-denver-co-july-2-2025-x201-icu-20250702monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-announces-pricing-of-up-to-8-million-public-offering-4-million-upfront-wit-icu-20250620monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-reports-first-quarter-2025-financial-results-and-provides-business-updates-icu-20250514monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-b-icu-20250327monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-announces-6-million-registered-direct-offering-priced-at-the-market-denver-icu-20250131monthly0.5https://www.biopharmawatch.com/news/ICU/january-2025-www-seastarmedical-com-nasdaq-icu-investor-presentation-bringing-organ-restor-icu-20250108monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-reports-third-quarter-2024-financial-results-and-provides-a-business-updat-icu-20241113monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-announces-10-million-registered-direct-offering-priced-at-the-market-under-icu-20240710monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-strengthens-board-of-directors-and-transitions-to-commercial-stage-company-icu-20240610monthly0.5https://www.biopharmawatch.com/news/ICU/may-14-2024-seastar-medical-reports-first-quarter-2024-financial-results-and-provides-a-bu-icu-20240514monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-reports-2023-financial-results-and-provides-a-business-update-denver-icu-20240417monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-to-restate-financials-sets-business-update-call-for-april-17-restatement-o-icu-20240327monthly0.5https://www.biopharmawatch.com/news/ICU/fda-grants-humanitarian-device-exemption-approval-to-seastar-medical-s-selective-cytophere-icu-20240222monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-announces-pricing-of-9-0-million-registered-direct-offering-priced-at-the--icu-20240126monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-appoints-david-a-green-as-chief-financial-officer-denver-icu-20240111monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-reports-third-quarter-2023-financial-results-and-provides-a-business-updat-icu-20231114monthly0.5https://www.biopharmawatch.com/news/ICU/fda-issues-approvable-letter-for-seastar-medical-s-selective-cytopheretic-device-for-pedia-icu-20231030monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-provides-regulatory-update-regarding-selective-cytopheretic-device-use-in--icu-20231003monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-reports-second-quarter-2023-financial-results-and-provides-a-business-upda-icu-20230814monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-reports-first-quarter-2023-financial-results-and-provides-a-business-updat-icu-20230515monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-provides-regulatory-update-related-to-its-hde-application-for-pediatric-se-icu-20230509monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-reports-2022-financial-results-and-provides-a-business-update-denver-icu-20230330monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-holding-corporation-closes-initial-3-3-million-tranche-of-9-8-million-priv-icu-20230316monthly0.5https://www.biopharmawatch.com/news/ICU/forward-looking-statements-this-presentation-contains-certain-forward-looking-statements-w-icu-20230215monthly0.5https://www.biopharmawatch.com/news/ICU/draft-3-lha-clean-al-comments-february-8-2023-seastar-medical-receives-fda-approval-to-beg-icu-20230209monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-submits-investigational-device-exemption-ide-application-to-fda-to-study-a-icu-20230109monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-and-nuwellis-enter-into-a-u-s-license-and-distribution-agreement-for-seast-icu-20221229monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-completes-business-combination-with-lmf-acquisition-opportunities-lmf-acqu-icu-20221028monthly0.5https://www.biopharmawatch.com/news/ICU/lmf-acquisition-opportunities-inc-stockholders-approve-previously-announced-business-combi-icu-20221018monthly0.5https://www.biopharmawatch.com/news/ICU/lmf-acquisition-opportunities-and-seastar-medical-announce-effectiveness-of-registration-s-icu-20220928monthly0.5https://www.biopharmawatch.com/news/ICU/lmf-acquisition-opportunities-inc-announces-extension-of-deadline-to-complete-business-com-icu-20220729monthly0.5https://www.biopharmawatch.com/news/ICU/investor-presentation-2022-05-03-investor-presentation-seastar-medical-inc-lmf-acquisition-icu-20220503monthly0.5https://www.biopharmawatch.com/news/ICU/seastar-medical-to-become-publicly-listed-on-nasdaq-via-business-combination-with-lmf-acqu-icu-20220422monthly0.5https://www.biopharmawatch.com/news/ICU/lmf-acquisition-opportunities-inc-index-to-financial-statements-page-report-of-independent-icu-20210601monthly0.5https://www.biopharmawatch.com/news/ICU/lmf-acquisition-opportunities-inc-announces-separate-trading-of-its-class-a-common-stock-a-icu-20210318monthly0.5https://www.biopharmawatch.com/news/ICU/lmf-acquisition-opportunities-inc-index-to-financial-statements-page-report-of-independent-icu-20210128monthly0.5https://www.biopharmawatch.com/news/ICU/lmf-acquisition-opportunities-inc-announces-pricing-of-upsized-90-million-initial-public-o-icu-20210125monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-reports-70-growth-in-active-u-s-commercial-install-base-for-breast-cancer-cryoabla-iccm-20260617monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-reports-first-quarter-2026-financial-results-prosense-sales-increase-substantially-iccm-20260512monthly0.5https://www.biopharmawatch.com/news/ICCM/dear-icecure-medical-ltd-shareholder-we-cordially-invite-you-to-attend-the-special-general-iccm-20260422monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-participates-in-society-of-breast-imaging-symposium-2026-as-u-s-prosense-revenue-i-iccm-20260421monthly0.5https://www.biopharmawatch.com/news/ICCM/u-s-fda-approves-icecure-s-post-marketing-choice-study-for-prosense-cryoablation-in-the-lo-iccm-20260311monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-ceo-issues-letter-to-shareholders-reports-record-fourth-quarter-and-full-year-2025-iccm-20260112monthly0.5https://www.biopharmawatch.com/news/ICCM/amended-and-restated-articles-of-association-of-icecure-medical-ltd-the-company-table-of-c-iccm-20260108monthly0.5https://www.biopharmawatch.com/news/ICCM/dear-icecure-medical-ltd-shareholder-we-cordially-invite-you-to-attend-the-special-general-iccm-20251203monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-receives-fda-marketing-authorization-for-prosense-cryoablation-for-the-treatment-o-iccm-20251003monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-s-prosense-at-the-european-society-of-breast-imaging-congress-2025-unlocking-de-es-iccm-20250930monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-s-prosense-featured-at-cirse-2025-annual-meeting-positive-clinical-results-with-cr-iccm-20250922monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-granted-notice-of-allowance-for-u-s-patent-for-its-next-generation-xsense-cryoprob-iccm-20250918monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-receives-regulatory-approval-in-israel-for-its-next-generation-xsense-cryoablation-iccm-20250915monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-s-prosense-substantially-reduces-abdominal-wall-endometriosis-pain-with-high-proce-iccm-20250904monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-ltd-unaudited-interim-condensed-consolidated-balance-sheet-u-s-dollars-in--iccm-20250813monthly0.5https://www.biopharmawatch.com/news/ICCM/dear-icecure-medical-ltd-shareholder-we-cordially-invite-you-to-attend-the-special-general-iccm-20250801monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-announces-expiration-and-results-of-approximately-two-times-over-subscribed-rights-iccm-20250729monthly0.5https://www.biopharmawatch.com/news/ICCM/dear-icecure-medical-ltd-shareholder-we-cordially-invite-you-to-attend-the-special-general-iccm-20250728monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-s-prosense-featured-at-japanese-breast-cancer-society-conference-updated-positive--iccm-20250725monthly0.5https://www.biopharmawatch.com/news/ICCM/dear-icecure-medical-ltd-shareholder-we-cordially-invite-you-to-attend-the-annual-and-spec-iccm-20250716monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-announces-commencement-of-rights-offering-iccm-20250710monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-reports-preliminary-financial-results-for-the-three-and-six-months-ended-iccm-20250630monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-announces-record-date-for-rights-offering-for-up-to-10-million-iccm-20250625monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-receives-notice-of-patent-allowance-in-u-s-for-a-novel-cryogen-flow-control-to-opt-iccm-20250609monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-reports-first-quarter-2025-financial-results-recently-finalized-and-delive-iccm-20250528monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-announces-positive-fda-development-understanding-on-path-forward-for-marketing-aut-iccm-20250430monthly0.5https://www.biopharmawatch.com/news/ICCM/dear-icecure-medical-ltd-shareholders-we-cordially-invite-you-to-attend-the-special-genera-iccm-20250410monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-reports-2024-financial-results-42-growth-in-prosense-cryoablation-sales-in-iccm-20250327monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-reports-updated-timeline-and-progress-with-fda-regarding-marketing-authorization-f-iccm-20250320monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-s-prosense-cryoablation-featured-in-six-studies-presented-at-st-gallen-internation-iccm-20250318monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-receives-notice-of-allowance-in-china-for-novel-cryogenic-pump-for-next-generation-iccm-20250317monthly0.5https://www.biopharmawatch.com/news/ICCM/breast-cancer-patients-who-underwent-icecure-s-prosense-cryoablation-in-japan-reported-sig-iccm-20250310monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-submits-filing-for-regulatory-approval-of-its-next-generation-xsense-cryoablation--iccm-20250224monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-s-prosense-in-the-spotlight-at-society-of-interventional-oncology-sio-annual-meeti-iccm-20250204monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-files-for-regulatory-approval-of-prosense-cryoablation-system-in-china-seeks-to-ex-iccm-20250127monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-ceo-issues-letter-to-shareholders-reports-increase-of-42-in-prosense-sales-iccm-20250113monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-regains-full-nasdaq-compliance-with-nasdaq-minimum-closing-bid-price-rule-iccm-20250106monthly0.5https://www.biopharmawatch.com/news/ICCM/european-patent-office-issues-intention-to-grant-notice-to-icecure-for-its-next-generation-iccm-20250103monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-s-prosense-cryoablation-safe-and-effective-in-destruction-of-kidney-tumors-with-88-iccm-20241205monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-reports-36-sales-growth-in-the-first-nine-months-of-2024-driven-by-global--iccm-20241126monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-s-next-generation-multiprobe-cryoablation-technology-issued-notice-of-allowance-fr-iccm-20241125monthly0.5https://www.biopharmawatch.com/news/ICCM/fda-advisory-panel-votes-in-favor-of-icecure-s-prosense-cryoablation-benefit-risk-profile--iccm-20241108monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-receives-notice-of-allowance-from-u-s-patent-and-trademark-office-for-its-next-gen-iccm-20241021monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-s-prosense-featured-in-6-global-studies-on-cryoablation-of-breast-tumors-at-the-20-iccm-20241007monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-s-ice3-5-year-trial-results-published-in-the-peer-reviewed-annals-of-surgical-onco-iccm-20240924monthly0.5https://www.biopharmawatch.com/news/ICCM/study-published-in-the-british-journal-of-radiology-demonstrates-icecure-s-prosense-is-a-s-iccm-20240916monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-announces-fda-advisory-panel-meeting-date-for-marketing-authorization-of-prosense--iccm-20240912monthly0.5https://www.biopharmawatch.com/news/ICCM/uspto-grants-notice-of-allowance-for-additional-patent-on-icecure-s-novel-cryogenic-pump-t-iccm-20240828monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-ltd-unaudited-interim-condensed-consolidated-balance-sheet-u-s-dollars-in--iccm-20240820monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-s-prosense-destroyed-100-of-breast-cancer-tumors-in-independent-study-of-patients--iccm-20240814monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-announces-positive-data-from-the-largest-multi-institutional-study-of-its-kind-cry-iccm-20240807monthly0.5https://www.biopharmawatch.com/news/ICCM/recurrence-free-rate-for-women-with-breast-cancer-treated-with-icecure-s-prosense-cryoabla-iccm-20240722monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-announces-receipt-of-nasdaq-minimum-bid-price-notification-caesarea-israel-iccm-20240719monthly0.5https://www.biopharmawatch.com/news/ICCM/dear-icecure-medical-ltd-shareholders-we-cordially-invite-you-to-attend-the-special-genera-iccm-20240716monthly0.5https://www.biopharmawatch.com/news/ICCM/european-study-provides-more-evidence-supporting-icecure-s-prosense-is-safe-effective-cryo-iccm-20240709monthly0.5https://www.biopharmawatch.com/news/ICCM/u-s-food-and-drug-administration-grants-regulatory-clearance-to-icecure-for-next-gen-xsens-iccm-20240701monthly0.5https://www.biopharmawatch.com/news/ICCM/fda-to-convene-advisory-panel-for-review-of-icecure-s-de-novo-marketing-clearance-request--iccm-20240604monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-maintains-positive-momentum-and-reports-sales-growth-for-cryoablation-syst-iccm-20240528monthly0.5https://www.biopharmawatch.com/news/ICCM/independent-study-results-in-japan-demonstrate-zero-0-breast-cancer-local-recurrence-5-yea-iccm-20240507monthly0.5https://www.biopharmawatch.com/news/ICCM/dear-icecure-medical-ltd-shareholders-we-cordially-invite-you-to-attend-the-annual-and-spe-iccm-20240415monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-reports-final-ice3-breast-cancer-cryoablation-trial-results-of-100-patient-iccm-20240415monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-reports-full-year-2023-financial-results-global-prosense-and-disposables-s-iccm-20240403monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-submits-fda-regulatory-filing-for-new-xsense-cryoablation-system-with-cryoprobes-c-iccm-20240402monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-reports-positive-topline-results-from-ice3-cryoablation-breast-cancer-stud-iccm-20240319monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-receives-notice-of-patent-allowance-in-japan-for-a-novel-cryogen-flow-control-to-o-iccm-20240312monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-s-prosense-a-promising-alternative-treatment-for-extra-pelvis-endometriosis-indepe-iccm-20240304monthly0.5https://www.biopharmawatch.com/news/ICCM/study-using-icecure-s-prosense-treatment-results-in-100-tumor-reduction-in-early-stage-bre-iccm-20240226monthly0.5https://www.biopharmawatch.com/news/ICCM/u-s-fda-grants-icecure-medical-s-appeal-reopens-de-novo-classification-request-for-marketi-iccm-20240130monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-ceo-issues-letter-to-shareholders-reports-increase-in-sales-in-preliminary-iccm-20240110monthly0.5https://www.biopharmawatch.com/news/ICCM/study-using-icecure-s-prosense-finds-cryoablation-allows-the-ultimate-de-escalation-of-sur-iccm-20231213monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-system-successfully-treated-kidney-cancer-tumor-with-92-disease-free-survival-rate-iccm-20231128monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-files-appeal-with-u-s-fda-requesting-a-review-of-its-de-novo-classificatio-iccm-20231115monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-announces-receipt-of-nasdaq-minimum-bid-price-notification-caesarea-israel-iccm-20231103monthly0.5https://www.biopharmawatch.com/news/ICCM/women-deemed-inoperable-for-breast-cancer-benefitted-from-icecure-medical-s-prosense-as-an-iccm-20231005monthly0.5https://www.biopharmawatch.com/news/ICCM/independent-study-validates-icecure-s-prosense-cryoablation-is-safe-effective-outpatient-p-iccm-20231002monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-receives-fda-response-to-de-novo-classification-request-for-breast-cancer-iccm-20230920monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-s-prosense-cryoablation-system-receives-regulatory-approval-in-brazil-6-6--iccm-20230905monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-takes-next-major-initiative-as-it-prepares-to-accelerate-the-commercializa-iccm-20230828monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-ltd-unaudited-interim-condensed-consolidated-balance-sheet-u-s-dollars-in--iccm-20230814monthly0.5https://www.biopharmawatch.com/news/ICCM/health-canada-approves-icecure-medical-s-minimally-invasive-prosense-cryoablation-system-s-iccm-20230724monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-reports-first-quarter-2023-financial-operational-results-physician-interes-iccm-20230522monthly0.5https://www.biopharmawatch.com/news/ICCM/dear-icecure-medical-ltd-shareholders-we-cordially-invite-you-to-attend-the-annual-and-spe-iccm-20230427monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-s-prosense-system-used-in-endometriosis-cryoablation-study-that-demonstrated-effic-iccm-20230420monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-ordinary-shares-to-trade-exclusively-on-nasdaq-company-to-voluntarily-deli-iccm-20230419monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-reports-2022-full-year-financial-results-recent-corporate-developments-mil-iccm-20230329monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-receives-regulatory-approval-in-china-for-commercial-use-of-its-icesense3--iccm-20230328monthly0.5https://www.biopharmawatch.com/news/ICCM/dear-icecure-medical-ltd-shareholders-we-cordially-invite-you-to-attend-the-special-genera-iccm-20230301monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-announces-preliminary-unaudited-2022-year-end-financial-results-recent-ope-iccm-20230209monthly0.5https://www.biopharmawatch.com/news/ICCM/u-s-patent-office-grants-notice-of-allowance-to-icecure-for-novel-cryogenic-pump-for-next--iccm-20230123monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-receives-notice-of-patent-allowance-in-japan-for-a-novel-cryogenic-pump-for-its-ne-iccm-20230118monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-ceo-issues-letter-to-shareholders-iccm-20230104monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-ltd-announces-closing-of-14-5-million-public-offering-priced-at-the-market-iccm-20221223monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-ltd-announces-pricing-of-14-5-million-public-offering-priced-at-the-market-iccm-20221221monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-s-prosense-safe-and-effective-in-treating-kidney-tumors-with-89-5-recurrence-free--iccm-20221219monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-appoints-vincent-chun-hung-chan-to-serve-as-an-independent-director-on-its-board-o-iccm-20221206monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-reports-financial-results-for-the-nine-months-ended-iccm-20221205monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-s-prosense-featured-in-poster-presentation-at-radiological-society-of-north-americ-iccm-20221130monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-s-prosense-achieves-significant-milestone-in-medicare-coverage-of-breast-cancer-pr-iccm-20221108monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-files-de-novo-classification-request-with-the-fda-for-marketing-authorization-of-p-iccm-20221019monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-ltd-unaudited-interim-condensed-consolidated-balance-sheet-u-s-dollars-in--iccm-20220922monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-submits-regulatory-filing-in-vietnam-for-approval-of-prosense-company-is-rapidly-e-iccm-20220829monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-reports-financial-results-for-the-first-half-of-2022-and-recent-operationa-iccm-20220815monthly0.5https://www.biopharmawatch.com/news/ICCM/dear-icecure-medical-ltd-shareholders-we-cordially-invite-you-to-attend-the-special-genera-iccm-20220727monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-announces-regulatory-filing-submission-for-approval-of-prosense-in-canada-for-indi-iccm-20220725monthly0.5https://www.biopharmawatch.com/news/ICCM/corporate-presentation-july-2022-freezing-cancer-in-its-tracks-nasdaq-tase-iccm-icecure-me-iccm-20220711monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-shanghai-medtronic-turing-medical-sign-distribution-agreement-in-mainland--iccm-20220613monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-s-prosense-cryoablation-system-submitted-for-regulatory-approval-in-brazil-iccm-20220609monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-reports-first-quarter-2022-financial-results-and-operational-highlights-co-iccm-20220518monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-ltd-the-company-compensation-policy-for-company-s-office-holders-dated-mar-iccm-20220307monthly0.5https://www.biopharmawatch.com/news/ICCM/corporate-presentation-february-2022-freezing-cancer-in-its-tracks-nasdaq-tase-iccm-icecur-iccm-20220228monthly0.5https://www.biopharmawatch.com/news/ICCM/corporate-presentation-february-2022-nasdaq-tase-iccm-icecure-medical-com-freezing-cancer--iccm-20220224monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-announces-preliminary-unaudited-2021-year-end-financial-results-revenue-in-iccm-20220131monthly0.5https://www.biopharmawatch.com/news/ICCM/dear-icecure-medical-ltd-shareholders-we-cordially-invite-you-to-attend-the-annual-and-spe-iccm-20220127monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-ceo-issues-letter-to-shareholders-caesarea-israel-january-5-th-2022-icecur-iccm-20220105monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-receives-notice-of-intention-to-grant-a-european-patent-covering-its-cryog-iccm-20211220monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-ltd-closes-17-million-underwritten-public-offering-and-partial-exercise-of-iccm-20211213monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-ltd-announces-pricing-of-15-million-underwritten-public-offering-caesarea--iccm-20211209monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-announces-appointment-of-merav-nir-dotan-to-vice-president-human-resources-iccm-20211129monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-reports-financial-results-as-of-and-for-the-first-nine-months-of-2021-and--iccm-20211123monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-announces-updated-regulatory-strategy-in-china-for-the-icesense3-system-to-iccm-20211012monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-reports-financial-results-for-the-first-half-of-2021-and-recent-operating--iccm-20210923monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-announces-exclusive-distribution-agreement-to-sell-prosense-cryoablation-s-iccm-20210901monthly0.5https://www.biopharmawatch.com/news/ICCM/icecure-medical-shares-to-begin-trading-on-nasdaq-capital-market-on-iccm-20210826monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-ads-ratio-change-tampa-fl-and-london-aktx-20260317monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-5-million-financing-including-concurrent-registered-direct-of-aktx-20251216monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-reports-first-quarter-2025-financial-results-and-provides-corporate-upd-aktx-20250515monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-reports-full-year-2024-financial-results-and-provides-corporate-update--aktx-20250416monthly0.5https://www.biopharmawatch.com/news/AKTX/corporate-presentation-january-2025-nasdaq-aktx-akaritx-com-next-generation-precision-bi-f-aktx-20250113monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-successful-completion-of-merger-of-akari-therapeutics-and-pea-aktx-20241114monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-shareholder-approval-in-connection-with-peak-bio-inc-merger-b-aktx-20241108monthly0.5https://www.biopharmawatch.com/news/AKTX/business-of-akari-overview-akari-is-a-biotechnology-company-focused-on-developing-advanced-aktx-20240911monthly0.5https://www.biopharmawatch.com/news/AKTX/peak-bio-consolidated-financial-statements-as-of-and-for-the-years-ended-aktx-20240906monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-reports-second-quarter-2024-financial-results-and-recent-highlights-sam-aktx-20240819monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-reports-first-quarter-2024-financial-results-and-recent-highlights-ente-aktx-20240516monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-and-peak-bio-announce-portfolio-prioritization-plan-for-combined-go-for-aktx-20240501monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-reports-full-year-2023-financial-results-and-recent-highlights-boston-a-aktx-20240401monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-and-peak-bio-announce-definitive-agreement-to-merge-as-equals-creating--aktx-20240305monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-existing-investors-support-the-company-through-a-2-million-pr-aktx-20240102monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-appoints-experienced-life-sciences-entrepreneur-samir-r-patel-m-d-to-bo-aktx-20231201monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-presents-poster-on-progress-in-pre-clinical-development-of-long-acting--aktx-20231116monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-plc-for-the-six-month-period-ended-aktx-20230929monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-existing-investors-support-the-company-through-a-2-million-pr-aktx-20230921monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-new-york-a-aktx-20230905monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-establishment-of-boston-u-s-headquarters-office-to-support-ex-aktx-20230818monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-plc-announces-ads-ratio-change-new-york-and-london-aktx-20230815monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-the-appointment-of-beth-anne-lang-as-senior-vice-president-re-aktx-20230802monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-granted-nomacopan-orphan-drug-designation-from-the-european-commission--aktx-20230727monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-july-2023-2-certain-statements-in-this-presentation-constitute-forward--aktx-20230724monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-appoints-experienced-life-sciences-executive-wendy-dicicco-as-interim-c-aktx-20230719monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-provides-updates-on-development-of-nomacopan-in-pediatric-and-adult-hsc-aktx-20230713monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-provides-update-on-development-of-long-acting-pas-nomacopan-for-treatme-aktx-20230711monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-receives-positive-opinion-on-orphan-drug-designation-from-the-european--aktx-20230706monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-appoints-industry-veteran-wa-el-hashad-to-board-of-directors-new-york-a-aktx-20230705monthly0.5https://www.biopharmawatch.com/news/AKTX/this-document-is-important-and-requires-your-immediate-attention-if-you-are-in-any-doubt-a-aktx-20230606monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-may-2023-2-certain-statements-in-this-presentation-constitute-forward-l-aktx-20230522monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-reports-full-year-2022-financial-results-and-highlights-development-of--aktx-20230501monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-granted-180-day-extension-by-nasdaq-to-meet-minimum-bid-price-requireme-aktx-20230425monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-plc-announces-4-million-registered-direct-offering-offering-includes-10-aktx-20230330monthly0.5https://www.biopharmawatch.com/news/AKTX/poland-and-u-k-regulatory-authorities-urpl-and-mhra-approve-use-of-new-higher-yielding-man-aktx-20230329monthly0.5https://www.biopharmawatch.com/news/AKTX/the-company-except-as-otherwise-indicated-herein-or-as-the-context-otherwise-requires-refe-aktx-20230328monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-presentation-of-a-case-study-from-phase-3-part-a-clinical-tri-aktx-20230221monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-february-2023-2-certain-statements-in-this-presentation-constitute-forw-aktx-20230215monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-pre-clinical-development-progress-toward-potential-ind-on-lon-aktx-20230215monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-acceleration-of-the-phase-3-clinical-trial-of-nomacopan-for-t-aktx-20230213monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-granted-fda-rare-pediatric-disease-designation-of-nomacopan-for-the-tre-aktx-20221110monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-the-appointment-of-john-f-neylan-iii-md-as-executive-vice-pre-aktx-20221108monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-receipt-of-nasdaq-minimum-bid-price-notification-new-york-and-aktx-20221028monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-plc-quarterly-report-for-the-period-ended-aktx-20220927monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-12-75-million-registered-direct-offering-new-york-and-london-aktx-20220912monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-narrows-pipeline-focus-new-york-and-london-aktx-20220801monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-positive-results-from-recent-pre-clinical-studies-of-investig-aktx-20220728monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-plc-quarterly-report-for-the-period-ended-aktx-20220720monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-first-patient-to-complete-course-of-treatment-in-the-phase-ii-aktx-20220707monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-the-appointment-of-accomplished-biotech-executive-melissa-bra-aktx-20220613monthly0.5https://www.biopharmawatch.com/news/AKTX/this-document-is-important-and-requires-your-immediate-attention-if-you-are-in-any-doubt-a-aktx-20220607monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-presents-results-from-the-cascade-and-coronet-studies-in-covid-19-at-th-aktx-20220519monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-reports-full-year-2021-financial-results-and-highlights-clinical-progre-aktx-20220516monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-publication-of-phase-ii-data-of-investigational-nomacopan-for-aktx-20220510monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-presents-results-from-two-preclinical-development-programs-of-long-acting-pas-nomaco-aktx-20220509monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-plc-announces-9-0-million-registered-direct-offering-new-york-and-londo-aktx-20220308monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-appoints-rachelle-jacques-as-president-and-chief-executive-officer-indu-aktx-20220302monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-new-data-showing-a-significant-role-for-complement-activation-aktx-20220228monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-advances-lung-program-with-inhaled-nomacopan-focused-on-early-treatment-of-severe-ex-aktx-20220126monthly0.5https://www.biopharmawatch.com/news/AKTX/fda-agrees-to-use-of-new-higher-yielding-manufacturing-process-for-nomacopan-in-pivotal-cl-aktx-20220119monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-plc-announces-6-0-million-registered-direct-offering-new-york-and-londo-aktx-20211230monthly0.5https://www.biopharmawatch.com/news/AKTX/december-2021-combined-inhibition-of-complement-leukotriene-pathways-to-treat-inflammatory-aktx-20211221monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-plc-quarterly-report-for-the-period-ended-aktx-20211203monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-presents-new-data-revealing-potential-mechanism-of-action-driving-serio-aktx-20211201monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-new-data-with-nomacopan-from-its-surface-of-the-eye-program-n-aktx-20211025monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-plc-quarterly-report-for-the-period-ended-aktx-20210922monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-private-placement-new-york-and-london-aktx-20210707monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-plc-quarterly-report-for-the-period-ended-aktx-20210629monthly0.5https://www.biopharmawatch.com/news/AKTX/this-document-is-important-and-requires-your-immediate-attention-if-you-are-in-any-doubt-a-aktx-20210607monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-receives-fda-fast-track-designation-for-nomacopan-for-the-treatment-of--aktx-20210428monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-reports-full-year-2020-financial-results-and-highlights-recent-clinical-aktx-20210420monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-initiation-of-pivotal-phase-iii-trial-of-nomacopan-in-bullous-aktx-20210412monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-a-cooperative-research-and-development-agreement-crada-with-t-aktx-20210304monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-presents-new-preclinical-data-highlighting-potential-of-long-acting-pas-aktx-20210225monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-adds-histamine-inhibitor-votucalis-to-pipeline-to-treat-neuropathic-pai-aktx-20210202monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-plc-quarterly-report-for-the-period-ended-aktx-20201211monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-new-clinical-data-that-show-long-term-self-administered-nomac-aktx-20201211monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-publication-in-american-journal-of-pathology-highlighting-pot-aktx-20201203monthly0.5https://www.biopharmawatch.com/news/AKTX/this-document-is-important-and-requires-your-immediate-attention-if-you-are-in-any-doubt-a-aktx-20201116monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-further-clinical-trial-progress-using-nomacopan-to-treat-covi-aktx-20201006monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-successful-scientific-advice-meeting-with-the-european-medici-aktx-20201001monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-plc-quarterly-report-for-the-period-ended-aktx-20200901monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-international-clinical-development-program-of-nomacopan-for-t-aktx-20200831monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-successful-end-of-phase-ii-meeting-with-fda-to-initiate-pivot-aktx-20200812monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-enters-into-a-securities-purchase-agreement-for-up-to-30-million-with-a-aktx-20200701monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-appointment-of-chief-financial-officer-new-york-and-london-aktx-20200701monthly0.5https://www.biopharmawatch.com/news/AKTX/this-document-is-important-and-requires-your-immediate-attention-if-you-are-in-any-doubt-a-aktx-20200601monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-plc-quarterly-report-for-the-period-ended-aktx-20200529monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-receives-positive-ema-opinion-on-orphan-designation-for-nomacopan-for-b-aktx-20200521monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-positive-topline-results-from-aktx-20200501monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-and-busines-aktx-20200331monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-plc-announces-closing-of-9-5-million-private-placement-new-york-and-lon-aktx-20200304monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-plc-announces-private-placement-new-york-and-london-aktx-20200220monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-preclinical-ophthalmic-data-showing-nomacopan-reduces-both-va-aktx-20200127monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-positive-interim-data-from-phase-iii-paroxysmal-nocturnal-hem-aktx-20200110monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-initiation-of-pivotal-phase-iii-trial-of-nomacopan-in-pediatr-aktx-20191223monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-pivotal-phase-iii-trial-design-of-nomacopan-in-pediatric-hema-aktx-20191202monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-plc-quarterly-report-for-the-period-ended-aktx-20191127monthly0.5https://www.biopharmawatch.com/news/AKTX/revised-press-release-akari-therapeutics-reports-revised-third-quarter-2019-financial-resu-aktx-20191127monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-new-data-from-atopic-keratoconjunctivitis-akc-patients-suppor-aktx-20191014monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-positive-phase-ii-clinical-data-in-orphan-blistering-skin-dis-aktx-20191010monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-nomacopan-granted-u-s-orphan-drug-designation-for-bullous-pemphigoid-ne-aktx-20190913monthly0.5https://www.biopharmawatch.com/news/AKTX/september-2019-investor-presentation-copyright-akari-therapeutics-plc-2019-aktx-20190910monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-nomacopan-granted-u-s-orphan-drug-designation-for-hematopoietic-stem-ce-aktx-20190830monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-plc-quarterly-report-for-the-period-ended-aktx-20190829monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-receives-fda-fast-track-designation-for-nomacopan-for-paediatric-hemato-aktx-20190814monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-new-data-demonstrating-synergistic-benefits-of-nomacopan-s-bi-aktx-20190809monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-plc-announces-4-5-million-registered-direct-offering-new-york-and-londo-aktx-20190628monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-nomacopan-demonstrates-positive-early-safety-and-efficacy-in-phase-i-ii-aktx-20190619monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-plc-consolidated-annual-report-and-financial-statements-for-the-year-en-aktx-20190606monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-plc-quarterly-report-for-the-period-ended-aktx-20190529monthly0.5https://www.biopharmawatch.com/news/AKTX/this-document-is-important-and-requires-your-immediate-attention-if-you-are-in-any-doubt-a-aktx-20190529monthly0.5https://www.biopharmawatch.com/news/AKTX/or-targeting-the-leukotriene-b4-pathway-and-or-complement-c5-via-dual-functional-recombina-aktx-20190429monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-expanded-ophthalmology-program-based-on-positive-emerging-dat-aktx-20190426monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-reports-fourth-quarter-and-full-year-2018-financial-results-and-business-highlights--aktx-20190423monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-positive-initial-phase-ii-clinical-data-in-orphan-skin-diseas-aktx-20190423monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-provide-update-on-its-eye-disease-program-during-association-for-res-aktx-20190327monthly0.5https://www.biopharmawatch.com/news/AKTX/positive-fda-meeting-outlines-path-ahead-for-akari-therapeutics-s-coversin-in-hematopoieti-aktx-20190313monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-new-data-highlighting-differentiation-of-drug-candidate-cover-aktx-20181130monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-announces-coversin-data-to-be-presented-at-2018-complement-based-drug-development-su-aktx-20181115monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-plc-quarterly-report-for-the-period-ended-aktx-20181115monthly0.5https://www.biopharmawatch.com/news/AKTX/october-2018-investor-presentation-copyright-akari-therapeutics-plc-2018-2-disclaimers-cer-aktx-20181001monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-new-clinical-data-in-post-transplant-thrombotic-microangiopat-aktx-20180930monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-announces-second-quarter-2018-financial-results-and-business-highlights-announced-se-aktx-20180927monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-plc-quarterly-report-for-the-period-ended-aktx-20180927monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-enters-into-a-securities-purchase-agreement-for-up-to-20-million-with-a-aktx-20180927monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-new-preclinical-rheumatoid-arthritis-data-and-new-clinical-da-aktx-20180912monthly0.5https://www.biopharmawatch.com/news/AKTX/this-document-is-important-and-requires-your-immediate-attention-if-you-are-in-any-doubt-a-aktx-20180817monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-announces-first-quarter-2018-financial-results-and-update-on-its-growing-pipeline-of-aktx-20180817monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-plc-quarterly-report-for-the-period-ended-aktx-20180816monthly0.5https://www.biopharmawatch.com/news/AKTX/this-document-is-important-and-requires-your-immediate-attention-if-you-are-in-any-doubt-a-aktx-20180807monthly0.5https://www.biopharmawatch.com/news/AKTX/median-and-range-ldh-x-uln-days-since-first-dose-of-coversin-0-0-5-1-1-5-2-2-5-3-3-5-4-4-5-aktx-20180615monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-receives-notice-related-to-delay-in-20-f-filing-new-york-and-london-aktx-20180521monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-fourth-quarter-and-full-year-2017-financial-results-and-highl-aktx-20180321monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-completion-of-phase-ii-cobalt-trial-of-coversin-in-patients-w-aktx-20180206monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-strengthens-board-with-two-senior-industry-appointments-aktx-20180123monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-phase-ii-cobalt-trial-of-coversin-tm-in-patients-with-pnh-met-aktx-20171210monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-plc-quarterly-report-for-the-period-ended-aktx-20171113monthly0.5https://www.biopharmawatch.com/news/AKTX/the-company-except-as-otherwise-indicated-herein-or-as-the-context-otherwise-requires-refe-aktx-20171017monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-further-clinical-progress-completion-of-enrollment-into-cobal-aktx-20171011monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-regulatory-progress-following-fda-meeting-plans-to-start-cove-aktx-20170921monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-appointment-of-david-horn-solomon-as-ceo-new-york-and-london-aktx-20170821monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-plc-quarterly-report-for-the-period-ended-aktx-20170810monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-plc-company-no-05252842-articles-of-association-the-companies-act-2006--aktx-20170718monthly0.5https://www.biopharmawatch.com/news/AKTX/july-2017-nasdaq-aktx-copyright-akari-therapeutics-plc-2017-1-cautionary-note-regarding-fo-aktx-20170712monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-to-present-data-from-phase-2-pnh-trial-of-coversin-at-the-22nd-congress-aktx-20170623monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-resignation-of-ceo-executive-chairman-to-continue-to-fulfill--aktx-20170530monthly0.5https://www.biopharmawatch.com/news/AKTX/this-document-is-important-and-requires-your-immediate-attention-if-you-are-in-any-doubt-a-aktx-20170516monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-plc-quarterly-report-for-the-period-ended-aktx-20170515monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-edison-s-withdrawal-of-edison-report-titled-akari-s-coversin--aktx-20170427monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-demonstrates-positive-response-with-coversin-in-ongoing-phase-2-pnh-tri-aktx-20170424monthly0.5https://www.biopharmawatch.com/news/AKTX/january-2017-nasdaq-aktx-cautionary-note-regarding-forward-looking-statements-certain-stat-aktx-20170109monthly0.5https://www.biopharmawatch.com/news/AKTX/december-2016-nasdaq-aktx-copyright-akari-therapeutics-plc-2016-cautionary-note-regarding--aktx-20161206monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-pharmaceuticals-plc-quarterly-report-for-the-period-ended-aktx-20161110monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-pharmaceuticals-plc-quarterly-report-for-the-period-ended-aktx-20160811monthly0.5https://www.biopharmawatch.com/news/AKTX/july-2016-nasdaq-aktx-cautionary-note-regarding-forward-looking-statements-copyright-2016--aktx-20160712monthly0.5https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-announces-positive-preliminary-results-from-first-pnh-patient-treated-w-aktx-20160331monthly0.5https://www.biopharmawatch.com/news/AKTX/volution-immuno-pharmaceuticals-sa-and-affiliate-table-of-contents-as-of-and-for-the-six-m-aktx-20151016monthly0.5https://www.biopharmawatch.com/news/AKTX/securities-and-exchange-commission-aktx-20150922monthly0.5https://www.biopharmawatch.com/news/AKTX/celsus-therapeutics-and-volution-immuno-pharmaceuticals-announce-completion-of-acquisition-aktx-20150918monthly0.5https://www.biopharmawatch.com/news/AKTX/celsus-therapeutics-and-volution-immuno-pharmaceuticals-announce-75-million-private-placem-aktx-20150818monthly0.5https://www.biopharmawatch.com/news/AKTX/celsus-therapeutics-plc-to-be-renamed-akari-therapeutics-plc-celsus-therapeutics-cltx-and--aktx-20150715monthly0.5https://www.biopharmawatch.com/news/AKTX/celsus-therapeutics-announces-that-the-phase-ii-trial-of-mrx-6-cream-2-in-pediatric-atopic-aktx-20150217monthly0.5https://www.biopharmawatch.com/news/AKTX/equity-incentive-plan-celsus-therapeutics-plc-2014-equity-incentive-plan-1-definitions-unl-aktx-20140619monthly0.5https://www.biopharmawatch.com/news/AKTX/celsus-therapeutics-plc-company-number-05252842-notice-of-annual-general-meeting-12-may-20-aktx-20140512monthly0.5https://www.biopharmawatch.com/news/AKTX/celsus-therapeutics-announces-the-closing-of-9-2-million-public-offering-and-full-exercise-aktx-20140205monthly0.5https://www.biopharmawatch.com/news/AKTX/celsus-therapeutics-announces-pricing-of-public-offering-and-listing-on-nasdaq-american-de-aktx-20140130monthly0.5https://www.biopharmawatch.com/news/AKTX/celsus-therapeutics-announces-appointment-of-pablo-jimenez-m-d-to-chief-medical-officer-ap-aktx-20131024monthly0.5https://www.biopharmawatch.com/news/AKTX/celsus-therapeutics-names-allan-shaw-to-board-of-directors-new-york-and-london-globe-newsw-aktx-20131002monthly0.5https://www.biopharmawatch.com/news/AKTX/celsus-therapeutics-announces-12-5-million-private-placement-new-york-aktx-20130919monthly0.5https://www.biopharmawatch.com/news/AKTX/celsus-therapeutics-announces-adr-ticker-symbol-change-to-clsxy-new-york-aktx-20130916monthly0.5https://www.biopharmawatch.com/news/AKTX/celsus-therapeutics-announces-positive-phase-ii-interim-results-for-mrx-6-in-the-treatment-aktx-20130508monthly0.5https://www.biopharmawatch.com/news/AKTX/celsus-therapeutics-strengthens-board-of-directors-with-addition-of-dermatology-industry-v-aktx-20130501monthly0.5https://www.biopharmawatch.com/news/AKTX/celsus-therapeutics-strengthens-board-of-directors-with-addition-of-pharma-biotech-industr-aktx-20130430monthly0.5https://www.biopharmawatch.com/news/AKTX/morria-announces-corporate-trade-name-change-to-celsus-therapeutics-and-the-appointment-of-aktx-20130305monthly0.5https://www.biopharmawatch.com/news/AKTX/morria-biopharmaceuticals-announces-full-time-appointment-of-alan-harris-m-d-ph-d-as-chief-aktx-20130123monthly0.5https://www.biopharmawatch.com/news/PMI/medical-announces-pricing-of-5-million-offering-pmi-20260505monthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-syncardia-reports-revenue-growth-based-on-top-line-results-for-the-first-qu-pmi-20260422monthly0.5https://www.biopharmawatch.com/news/PMI/opening-and-strategic-overview-patrick-nj-schnegelsberg-ceo-pmi-20260327monthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-syncardia-highlight-second-successful-total-artificial-heart-bridge-to-tran-pmi-20260319monthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-syncardia-announce-successful-four-year-bridge-to-transplant-with-syncardia-pmi-20260317monthly0.5https://www.biopharmawatch.com/news/PMI/syncardia-featured-on-the-cruxx-of-medtech-podcast-pmi-20260113monthly0.5https://www.biopharmawatch.com/news/PMI/always-seek-the-advice-of-your-physician-or-a-qualified-health-care-provider-with-any-ques-pmi-20260113monthly0.5https://www.biopharmawatch.com/news/PMI/medical-announces-up-to-50-million-senior-secured-debt-financing-pmi-20251230monthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-marks-public-company-milestone-by-ringing-the-nyse-opening-bell-picard-medi-pmi-20251218monthly0.5https://www.biopharmawatch.com/news/PMI/securities-and-exchange-commission-pmi-20251209monthly0.5https://www.biopharmawatch.com/news/PMI/dcvicc-csign-figure-1-pmi-20251204monthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-inc-pmi-20251203monthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-to-present-the-next-generation-fully-implantable-syncardia-total-artificial-pmi-20251126monthly0.5https://www.biopharmawatch.com/news/PMI/syncardia-completes-first-in-vivo-implantations-of-pmi-20251119monthly0.5https://www.biopharmawatch.com/news/PMI/reports-third-quarter-2025-financial-results-pmi-20251114monthly0.5https://www.biopharmawatch.com/news/PMI/picard-issues-statement-on-intraday-stock-price-pmi-20251027monthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-inc-announces-exercise-of-underwriters-over-allotment-option-in-connection--pmi-20250909monthly0.5https://www.biopharmawatch.com/news/PMI/picard-medical-inc-announces-pricing-of-17-million-initial-public-offering-tucson-arizona-pmi-20250828monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-presentation-at-icar-2026-highlights-mechanism-of-action-and-clinical-adv-cocp-20260430monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-s-first-oral-norovirus-protease-inhibitor-cdi-988-to-be-featured-at-the-i-cocp-20260219monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-receives-irb-approval-from-emory-university-school-of-medicine-for-phase--cocp-20251218monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-third-quarter-2025-financial-results-and-provides-updates-on-its--cocp-20251114monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-presents-data-from-phase-1-study-of-first-in-class-norovirus-protease--cocp-20250710monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-s-novel-norovirus-antiviral-to-be-presented-at-department-of-defense-medi-cocp-20250605monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-s-investigational-drug-candidate-cc-42344-demonstrates-strong-antiviral-p-cocp-20250529monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-first-quarter-2025-financial-results-and-provides-updates-on-its--cocp-20250515monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-s-norovirus-oral-antiviral-candidate-demonstrates-potent-activity-against-cocp-20250424monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-2024-financial-results-and-provides-updates-on-its-antiviral-drug-cocp-20250331monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-phase-1-results-with-oral-broad-acting-antiviral-drug-cdi-988-for-cocp-20250108monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-extend-phase-2a-influenza-challenge-study-with-oral-pb2-inhibitor-cc-4-cocp-20241231monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-third-quarter-2024-financial-results-and-provides-updates-on-its--cocp-20241113monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-s-co-ceos-highlight-pioneering-approach-to-antiviral-drug-candidates-targ-cocp-20241031monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-to-highlight-near-term-clinical-milestones-during-presentations-at-two-up-cocp-20240819monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-second-quarter-2024-financial-results-and-provides-updates-on-its-cocp-20240814monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-favorable-results-from-single-ascending-dose-cohorts-of-phase-1-s-cocp-20240718monthly0.5https://www.biopharmawatch.com/news/COCP/new-broad-spectrum-antiviral-currently-in-a-phase-2a-clinical-trial-in-influenza-a-may-be--cocp-20240620monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-first-quarter-2024-financial-results-and-provides-updates-on-its--cocp-20240513monthly0.5https://www.biopharmawatch.com/news/COCP/enrollment-completed-in-phase-2a-study-with-cocrystal-pharma-s-oral-antiviral-candidate-cc-cocp-20240501monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-2023-financial-results-and-provides-updates-on-its-antiviral-drug-cocp-20240328monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-receives-pre-ind-responses-from-the-fda-on-oral-cc-42344-for-treating-inf-cocp-20240319monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-provides-an-update-on-the-clinical-development-of-its-novel-broad-spectru-cocp-20240104monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-announces-first-patient-in-for-phase-2a-human-challenge-study-evaluating--cocp-20231206monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-third-quarter-2023-financial-results-and-provides-updates-on-its--cocp-20231113monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-receives-uk-mhra-authorization-to-initiate-its-phase-2a-influenza-human-c-cocp-20231031monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-first-quarter-2023-financial-results-and-provides-updates-on-its--cocp-20230515monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-appoints-pharma-industry-veteran-fred-hassan-to-its-board-of-directors-bo-cocp-20230424monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-completes-4-million-private-placement-priced-at-the-market-under-nasdaq-r-cocp-20230410monthly0.5https://www.biopharmawatch.com/news/COCP/enrollment-completed-in-phase-1-influenza-a-study-with-cocrystal-pharma-s-oral-antiviral-c-cocp-20221026monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-second-quarter-2022-financial-results-and-provides-updates-on-its-cocp-20220815monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-first-quarter-2022-financial-results-and-provides-updates-on-its--cocp-20220511monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-2021-financial-results-and-provides-updates-on-development-progra-cocp-20220323monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-s-covid-19-oral-and-intranasal-pulmonary-protease-inhibitors-exhibit-powe-cocp-20211222monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-third-quarter-financial-results-and-provides-an-update-on-develop-cocp-20211115monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-announces-the-passing-of-chairman-ceo-and-co-founder-dr-gary-wilcox-bothe-cocp-20210528monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-announces-40-million-bought-deal-offering-of-common-stock-cocp-20210504monthly0.5https://www.biopharmawatch.com/news/COCP/united-states-district-court-district-of-new-jersey-trent-nichols-and-sharon-nichols-deriv-cocp-20201002monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-increases-previously-announced-bought-deal-to-15-0-million-bothell-wa-cocp-20200826monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-announces-10-0-million-bought-deal-offering-bothell-wa-cocp-20200826monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-expands-exclusive-license-agreement-with-kansas-state-university-research-cocp-20200422monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-announces-appointment-of-nobel-laureate-and-scientific-advisor-roger-d-ko-cocp-20200420monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-reports-2019-financial-results-and-outlines-expected-value-driving-milest-cocp-20200330monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-announces-closing-of-6-8-million-registered-direct-offering-priced-at-the-cocp-20200311monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-announces-plans-to-advance-coronavirus-program-company-has-immediately-in-cocp-20200306monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-announces-closing-of-11-0-million-registered-direct-offering-priced-at-th-cocp-20200228monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-cocp-20191030monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-announces-closing-of-private-placement-bothell-wa-cocp-20190311monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-announces-exclusive-worldwide-license-and-collaboration-agreement-with-me-cocp-20190103monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-inc-prices-8-000-000-common-stock-offering-tucker-ga-and-bothell-wa-cocp-20180501monthly0.5https://www.biopharmawatch.com/news/COCP/presentation-untitled-document-cocp-20170109monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-receives-health-canada-approval-to-conduct-phase-i-clinical-study-for-cc--cocp-20160425monthly0.5https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-announces-in-licensing-of-crispr-cas-technologies-for-hepatitis-b-virus-a-cocp-20160210monthly0.5https://www.biopharmawatch.com/news/COCP/biozone-pharmaceuticals-inc-acquires-biozone-laboratories-cocp-20110707monthly0.5https://www.biopharmawatch.com/news/COCP/international-surf-resorts-inc-isfr-enters-binding-letter-of-intent-to-acquire-biozone-lab-cocp-20110302monthly0.5https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-announces-first-quarter-2021-financial-results-and-provides-a-busine-cmmb-20210513monthly0.5https://www.biopharmawatch.com/news/CMMB/first-amendment-to-asset-purchase-and-assignment-agreement-this-first-amendment-to-asset-p-cmmb-20210316monthly0.5https://www.biopharmawatch.com/news/CMMB/anchiano-announces-shareholder-approval-of-the-merger-with-chemomab-and-prices-45-5m-priva-cmmb-20210315monthly0.5https://www.biopharmawatch.com/news/CMMB/anchiano-therapeutics-and-chemomab-announce-entry-into-definitive-merger-agreement-merger--cmmb-20201215monthly0.5https://www.biopharmawatch.com/news/CMMB/anchiano-appoints-steve-dipalma-as-chief-financial-officer-cmmb-20200505monthly0.5https://www.biopharmawatch.com/news/CMMB/targeting-genetically-defined-cancers-corporate-presentation-february-2020-cmmb-20200204monthly0.5https://www.biopharmawatch.com/news/CMMB/anchiano-therapeutics-ltd-consolidated-interim-financial-statements-cmmb-20191121monthly0.5https://www.biopharmawatch.com/news/CMMB/anchiano-discontinues-phase-2-codex-study-evaluating-inodiftagene-vixteplasmid-in-patients-cmmb-20191115monthly0.5https://www.biopharmawatch.com/news/CMMB/anchiano-therapeutics-chairman-stephen-hoffmann-steps-down-from-board-cmmb-20191024monthly0.5https://www.biopharmawatch.com/news/CMMB/anchiano-therapeutics-enters-into-an-exclusive-option-to-license-agreement-for-novel-pan-r-cmmb-20190924monthly0.5https://www.biopharmawatch.com/news/CMMB/anchiano-therapeutics-ltd-consolidated-interim-financial-statements-cmmb-20190813monthly0.5https://www.biopharmawatch.com/news/CMMB/anchiano-therapeutics-reports-second-quarter-2019-financial-results-cmmb-20190805monthly0.5https://www.biopharmawatch.com/news/CMMB/anchiano-therapeutics-delists-ordinary-shares-from-the-tel-aviv-stock-exchange-cmmb-20190618monthly0.5https://www.biopharmawatch.com/news/CMMB/anchiano-therapeutics-ltd-the-company-our-or-us-notice-of-annual-general-meeting-of-shareh-cmmb-20190528monthly0.5https://www.biopharmawatch.com/news/CMMB/anchiano-therapeutics-reports-first-quarter-2019-financial-results-closed-30-5-million-u-s-cmmb-20190522monthly0.5https://www.biopharmawatch.com/news/CMMB/anchiano-therapeutics-initiates-process-to-voluntarily-delist-its-ordinary-shares-from-the-cmmb-20190314monthly0.5https://www.biopharmawatch.com/news/CMMB/anchiano-therapeutics-reports-fourth-quarter-and-full-year-2018-financial-results-successf-cmmb-20190312monthly0.5https://www.biopharmawatch.com/news/CMMB/anchiano-therapeutics-announces-closing-of-30-5-million-initial-public-offering-cmmb-20190214monthly0.5https://www.biopharmawatch.com/news/CMMB/anchiano-therapeutics-announces-pricing-of-30-5-million-initial-public-offering-cmmb-20190212monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-reports-first-quarter-2026-results-and-provides-a-business-update-conference-call--bngo-20260513monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-reports-preliminary-fourth-quarter-and-full-year-2025-results-bngo-20260112monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-10-million-registered-direct-offering-priced-at-the-market-under-nasdaq--bngo-20250103monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-amendment-to-senior-secured-bngo-20250103monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-3-million-registered-direct-offering-priced-at-the-market-under-nasdaq-r-bngo-20241031monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-preliminary-3q-2024-revenues-and-cash-bngo-20241010monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-up-to-30-million-registered-direct-offering-priced-at-the-market-under-n-bngo-20240705monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-private-placement-of-senior-secured-notes-in-debt-restructuring-that-imp-bngo-20240528monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-10-million-registered-direct-offering-priced-at-the-market-under-nasdaq--bngo-20240404monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-amendment-to-debt-financing-arrangement-to-extend-cash-runway-amendment--bngo-20240228monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-reports-preliminary-fourth-quarter-and-full-year-2023-results-preliminary-q4-2023--bngo-20240108monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-prices-80-0-million-financing-in-convertible-notes-and-warrants-announces-prelimin-bngo-20230930monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-announces-cfo-transition-and-appointment-of-g-lsen-kama-as-chief-financial-officer-bngo-20230814monthly0.5https://www.biopharmawatch.com/news/BNGO/update-bionano-announces-preliminary-q1-2023-results-and-business-updates-preliminary-q1-t-bngo-20230424monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-reports-preliminary-fourth-quarter-and-full-year-2022-results-preliminary-bngo-20230105monthly0.5https://www.biopharmawatch.com/news/BNGO/investor-call-and-webcast-bngo-20221129monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-acquire-purigen-biosystems-to-enable-further-simplified-and-accelerate-bngo-20221128monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-reports-preliminary-fourth-quarter-and-full-year-2021-results-preliminary-bngo-20220112monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-acquire-biodiscovery-furthering-bionano-s-vision-of-creating-the-most--bngo-20211012monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-proposed-underwritten-public-offering-of-common-stock-bngo-20210119monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-announces-proposed-underwritten-public-offering-of-common-stock-bngo-20210107monthly0.5https://www.biopharmawatch.com/news/BNGO/january-2021r-erik-holmlin-ceochris-stewart-cfo-corporate-overview-legal-disclaimerthis-pr-bngo-20210107monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-report-third-quarter-2020-financial-results-and-host-a-conference-call-bngo-20201015monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-appoints-tech-executive-christopher-stewart-as-its-chief-financial-office-bngo-20200826monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-acquires-diagnostics-services-provider-lineagen-inc-to-accelerate-clinica-bngo-20200824monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-to-report-first-quarter-2020-financial-results-on-bngo-20200514monthly0.5https://www.biopharmawatch.com/news/BNGO/bionano-genomics-releases-operating-results-for-third-quarter-2018-completed-recent-ipo-ra-bngo-20181107monthly0.5https://www.biopharmawatch.com/news/GNTA/genenta-signs-definitive-agreements-with-sophia-high-tech-genenta-enters-aerospace-as-it-c-gnta-20260423monthly0.5https://www.biopharmawatch.com/news/GNTA/genenta-science-s-p-a-registered-office-milan-via-dell-annunciata-31-subscribed-and-paid-u-gnta-20260325monthly0.5https://www.biopharmawatch.com/news/GNTA/genenta-announces-pricing-of-15-0-million-registered-direct-offering-of-american-depositar-gnta-20251026monthly0.5https://www.biopharmawatch.com/news/GNTA/genenta-science-s-p-a-consolidated-statements-of-operations-and-comprehensive-loss-2025-20-gnta-20251010monthly0.5https://www.biopharmawatch.com/news/GNTA/genenta-science-s-p-a-registered-office-milano-via-olgettina-n-58-share-capital-subscribed-gnta-20250910monthly0.5https://www.biopharmawatch.com/news/GNTA/genenta-announces-20-million-20-9m-financing-to-expand-pipeline-as-brain-tumor-trial-is-sh-gnta-20250319monthly0.5https://www.biopharmawatch.com/news/GNTA/genenta-science-s-p-a-consolidated-statements-of-operations-and-comprehensive-loss-2024-20-gnta-20241029monthly0.5https://www.biopharmawatch.com/news/GNTA/genenta-science-s-p-a-registered-office-milano-via-olgettina-n-58-share-capital-subscribed-gnta-20240402monthly0.5https://www.biopharmawatch.com/news/GNTA/genenta-science-s-p-a-consolidated-statements-of-operations-and-comprehensive-loss-2023-20-gnta-20231020monthly0.5https://www.biopharmawatch.com/news/GNTA/genenta-science-s-p-a-registered-office-milano-via-olgettina-n-58-share-capital-subscribed-gnta-20230510monthly0.5https://www.biopharmawatch.com/news/GNTA/genenta-provides-first-half-2022-business-update-and-financial-results-gnta-20221024monthly0.5https://www.biopharmawatch.com/news/GNTA/genenta-science-s-p-a-formerly-genenta-science-s-r-l-consolidated-statements-of-operations-gnta-20221025monthly0.5https://www.biopharmawatch.com/news/GNTA/genenta-science-s-p-a-registered-office-milan-via-olgettina-n-58-subscribed-and-paid-up-sh-gnta-20220511monthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-announces-transformational-relaunch-as-a-neuropsychiatric-company-cyclerion-rela-cycn-20250924monthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-s-sgc-stimulator-portfolio-generates-revenues-to-enable-company-growth-cyclerion-cycn-20241217monthly0.5https://www.biopharmawatch.com/news/CYCN/regina-graul-ph-d-promoted-to-chief-executive-officer-cycn-20240807monthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-appoints-regina-graul-ph-d-as-president-dr-graul-will-lead-the-rebuild-of-cycler-cycn-20231204monthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-strengthens-board-of-directors-with-experienced-company-builder-and-cutting-edge-cycn-20231130monthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-regains-compliance-with-nasdaq-minimum-bid-price-requirement-cycn-20230601monthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-announces-reverse-stock-split-cycn-20230515monthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-announces-definitive-agreement-for-zagociguat-and-cy3018-certain-cyclerion-share-cycn-20230511monthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-therapeutics-enters-into-exclusive-negotiation-period-and-binding-equity-investm-cycn-20230403monthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-reports-corporate-update-and-full-year-2022-financial-results-cycn-20230322monthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-concludes-unsolicited-proposal-is-not-in-the-best-interest-of-the-company-cycn-20221122monthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-announces-mitochondrial-disease-focused-corporate-strategy-recent-positive-melas-cycn-20221006monthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-announces-cy6463-clinical-pipeline-progress-and-second-quarter-2022-financial-re-cycn-20220809monthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-therapeutics-announces-positive-topline-clinical-data-for-cy6463-in-patients-wit-cycn-20220728monthly0.5https://www.biopharmawatch.com/news/CYCN/steven-e-hyman-m-d-appointed-to-cyclerion-therapeutics-board-of-directors-renowned-neurosc-cycn-20220726monthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-therapeutics-announces-positive-topline-clinical-data-for-cy6463-in-melas-patien-cycn-20220610monthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-announces-cy6463-clinical-pipeline-progress-and-first-quarter-2022-financial-res-cycn-20220504monthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-announces-cy6463-clinical-pipeline-and-corporate-updates-phase-2a-study-in-mitoc-cycn-20220224monthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-therapeutics-reports-third-quarter-2021-financial-results-and-corporate-update-f-cycn-20211109monthly0.5https://www.biopharmawatch.com/news/CYCN/on-a-mission-to-develop-treatments-that-restore-cognitive-function-corporate-presentation--cycn-20210930monthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-therapeutics-reports-second-quarter-2021-financial-results-and-corporate-update--cycn-20210729monthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-therapeutics-announces-global-licensing-agreement-with-akebia-therapeutics-for-p-cycn-20210604monthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-therapeutics-hosted-webinar-to-discuss-pipeline-progress-provided-updates-on-dev-cycn-20210427monthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-therapeutics-appoints-errol-de-souza-ph-d-to-board-of-directors-s-enior-cns-expe-cycn-20210426monthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-therapeutics-announces-departure-of-chief-medical-officer-cycn-20210318monthly0.5https://www.biopharmawatch.com/news/CYCN/this-document-contains-forward-looking-statements-within-the-meaning-of-section-27a-of-the-cycn-20210113monthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-announces-positive-data-from-iw-6463-cns-translational-pharmacology-study-in-hea-cycn-20201014monthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-therapeutics-reports-second-quarter-2020-financial-results-and-recent-corporate--cycn-20200803monthly0.5https://www.biopharmawatch.com/news/CYCN/delivering-impact-in-cns-diseases-investor-webinar-cycn-20200709monthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-to-host-webcast-investor-event-on-cycn-20200618monthly0.5https://www.biopharmawatch.com/news/CYCN/safe-harbor-statement-2-this-presentation-contains-forward-looking-statements-any-statemen-cycn-20200414monthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-announces-iw-6463-phase-1-healthy-volunteer-study-results-that-support-further-d-cycn-20200115monthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-therapeutics-announces-praliciguat-topline-phase-2-results-in-diabetic-nephropat-cycn-20191030monthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-therapeutics-reports-second-quarter-2019-financial-results-and-progress-on-four--cycn-20190812monthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-therapeutics-provides-a-corporate-and-pipeline-overview-as-a-newly-launched-publ-cycn-20190513monthly0.5https://www.biopharmawatch.com/news/CYCN/cyclerion-announces-the-appointment-of-andreas-busch-ph-d-as-chief-innovation-officer-dr-b-cycn-20190409monthly0.5https://www.biopharmawatch.com/news/CYCN/information-statement-cyclerion-therapeutics-inc-this-information-statement-is-being-furni-cycn-20190319monthly0.5https://www.biopharmawatch.com/news/GDTC/cytomed-therapeutics-limited-1-commonwealth-lane-08-22-singapore-149544-proxy-statement-an-gdtc-20260414monthly0.5https://www.biopharmawatch.com/news/GDTC/cytomed-therapeutics-announces-novel-first-in-human-clinical-trial-collaborations-with-ren-gdtc-20251208monthly0.5https://www.biopharmawatch.com/news/GDTC/cytomed-therapeutics-completes-acquisition-of-t-cell-technology-from-uk-to-treat-cancers-i-gdtc-20251118monthly0.5https://www.biopharmawatch.com/news/GDTC/cytomed-therapeutics-secures-non-dilutive-investment-for-subsidiary-longevitybank-from-ich-gdtc-20251106monthly0.5https://www.biopharmawatch.com/news/GDTC/cytomed-therapeutics-chairman-increases-effective-holdings-to-21-95-singapore-singapore-gdtc-20251022monthly0.5https://www.biopharmawatch.com/news/GDTC/cytomed-makes-cash-bid-for-potential-acquisition-of-tc-biopharm-limited-s-relevant-assets--gdtc-20251014monthly0.5https://www.biopharmawatch.com/news/GDTC/cytomed-therapeutics-announces-publication-of-collaborative-research-with-the-university-o-gdtc-20251002monthly0.5https://www.biopharmawatch.com/news/GDTC/cytomed-therapeutics-limited-and-subsidiaries-unaudited-interim-condensed-consolidated-fin-gdtc-20250930monthly0.5https://www.biopharmawatch.com/news/GDTC/update-on-recent-acquisition-cytomed-therapeutics-expands-into-auto-immune-diseases-buildi-gdtc-20250828monthly0.5https://www.biopharmawatch.com/news/GDTC/cytomed-therapeutics-limited-announces-at-the-market-atm-offering-program-singapore-gdtc-20250818monthly0.5https://www.biopharmawatch.com/news/GDTC/update-on-clinical-trial-milestone-cytomed-therapeutics-achieves-completion-of-dose-level--gdtc-20250721monthly0.5https://www.biopharmawatch.com/news/GDTC/cytomed-therapeutics-limited-1-commonwealth-lane-08-22-singapore-149544-proxy-statement-an-gdtc-20250516monthly0.5https://www.biopharmawatch.com/news/GDTC/cytomed-therapeutics-reports-full-year-ended-gdtc-20250428monthly0.5https://www.biopharmawatch.com/news/GDTC/cytomed-therapeutics-signs-business-research-collaboration-agreement-with-india-s-sunact-c-gdtc-20250106monthly0.5https://www.biopharmawatch.com/news/GDTC/update-on-clinical-milestone-cytomed-therapeutics-announces-first-patient-dosed-in-its-fir-gdtc-20241120monthly0.5https://www.biopharmawatch.com/news/GDTC/cytomed-therapeutics-first-in-human-phase-i-angelica-clinical-trial-using-its-patented-don-gdtc-20241007monthly0.5https://www.biopharmawatch.com/news/GDTC/cytomed-therapeutics-completes-cash-acquisition-of-cord-blood-banking-licence-and-assets-e-gdtc-20241003monthly0.5https://www.biopharmawatch.com/news/GDTC/cytomed-therapeutics-limited-and-subsidiaries-unaudited-interim-condensed-consolidated-fin-gdtc-20240930monthly0.5https://www.biopharmawatch.com/news/GDTC/cytomed-therapeutics-limited-1-commonwealth-lane-08-22-singapore-149544-proxy-statement-an-gdtc-20240425monthly0.5https://www.biopharmawatch.com/news/GDTC/cytomed-therapeutics-limited-1-commonwealth-lane-08-22-singapore-149544-proxy-statement-an-gdtc-20240419monthly0.5https://www.biopharmawatch.com/news/GDTC/cytomed-therapeutics-to-launch-complimentary-cell-banking-for-qualified-shareholders-for-f-gdtc-20240318monthly0.5https://www.biopharmawatch.com/news/GDTC/cytomed-therapeutics-limited-announces-research-collaboration-with-singapore-sengkang-gene-gdtc-20240304monthly0.5https://www.biopharmawatch.com/news/GDTC/malaysian-patent-granted-for-cytomed-therapeutics-licensed-allogeneic-car-gamma-delta-t-ce-gdtc-20240129monthly0.5https://www.biopharmawatch.com/news/GDTC/cytomed-therapeutics-limited-and-subsidiaries-unaudited-interim-condensed-consolidated-fin-gdtc-20231117monthly0.5https://www.biopharmawatch.com/news/GDTC/chinese-patent-granted-for-cytomed-therapeutics-licensed-ipsc-based-technology-singapore-s-gdtc-20230925monthly0.5https://www.biopharmawatch.com/news/GDTC/chinese-patent-granted-for-a-star-spinoff-cytomed-therapeutics-licensed-allogeneic-car-gam-gdtc-20230801monthly0.5https://www.biopharmawatch.com/news/GDTC/a-star-spinoff-cytomed-therapeutics-announce-a-patent-for-its-licensed-car-gamma-delta-t-c-gdtc-20230706monthly0.5https://www.biopharmawatch.com/news/GDTC/cytomed-therapeutics-limited-announces-pricing-of-initial-public-offering-singapore-gdtc-20230413monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-ints-20260507monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-regains-compliance-with-nasdaq-s-minimum-bid-price-requirement-shel-ints-20260306monthly0.5https://www.biopharmawatch.com/news/INTS/updated-as-of-ints-20260305monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporat-ints-20250807monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-inc-raises-6-6-million-from-at-the-market-offering-atm-stock-sales--ints-20250804monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-inc-announces-proposed-public-offering-of-common-stock-shelton-conn-ints-20250611monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-reports-first-quarter-2025-financial-results-and-provides-corporate-ints-20250513monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-inc-announces-2-35-million-public-offering-ints-20250425monthly0.5https://www.biopharmawatch.com/news/INTS/this-presentation-contains-forward-looking-statements-within-the-meaning-of-the-private-se-ints-20250423monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-reports-2024-year-end-financial-results-and-provides-corporate-upda-ints-20250313monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-inc-announces-pricing-of-3-million-registered-direct-offering-and-c-ints-20241121monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-reports-third-quarter-2024-financial-results-and-provides-corporate-ints-20241113monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-reports-second-quarter-2024-financial-results-and-provides-corporat-ints-20240808monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-inc-announces-the-appointment-of-thomas-dubin-to-its-board-of-direc-ints-20240515monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-reports-first-quarter-2024-financial-results-and-provides-corporate-ints-20240509monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-reports-full-year-2023-financial-results-and-provides-corporate-upd-ints-20240314monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-appoints-joseph-talamo-cpa-as-chief-financial-officer-mr-talamo-bri-ints-20231212monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-reports-third-quarter-financial-results-and-provides-corporate-upda-ints-20231113monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-to-present-at-the-h-c-wainwright-25-th-annual-global-investment-con-ints-20230905monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-reports-second-quarter-financial-results-and-provides-corporate-upd-ints-20230814monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-inc-announces-the-closing-and-full-exercise-of-the-over-allotment-o-ints-20230710monthly0.5https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-inc-announces-pricing-of-upsized-initial-public-offering-raising-ap-ints-20230629monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-host-virtual-kol-event-highlighting-unmet-needs-in-postpartum-depression-and-t-lpcn-20260604monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-inc-lipocine-announces-financial-results-for-the-first-quarter-ended-lpcn-20260507monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-results-for-the-full-year-ended-lpcn-20260310monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-last-patient-last-visit-in-pivotal-phase-3-trial-of-lpcn-1154-for-postp-lpcn-20260218monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-reports-encouraging-progress-post-second-interim-safety-review-in-phase-3-trial-o-lpcn-20260112monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-provides-progress-update-on-lpcn-1154-phase-3-clinical-trial-in-postpartum-depres-lpcn-20250930monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-h-c-wainwright-27-th-annual-global-investment-conference-lpcn-20250905monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-results-for-the-second-quarter-ended-lpcn-20250805monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-first-patient-dosed-in-phase-3-clinical-trial-for-lpcn-1154-in-postpart-lpcn-20250626monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-s-lpcn-1148-highlighted-in-the-june-2025-edition-of-hepatology-lpcn-20250522monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-a-g-p-s-annual-healthcare-company-showcase-lpcn-20250514monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-results-for-the-first-quarter-ended-lpcn-20250508monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-license-and-supply-agreement-for-tlando-in-brazil-lpcn-20250506monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-initiation-of-outpatient-phase-3-postpartum-depression-trial-of-lpcn-11-lpcn-20250326monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-results-for-the-full-year-ended-lpcn-20250313monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-fda-labeling-changes-for-testosterone-products-lpcn-20250312monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-receives-updated-regulatory-guidance-on-lpcn-1154-lpcn-20250206monthly0.5https://www.biopharmawatch.com/news/LPCN/fda-grants-fast-track-designation-to-lipocine-for-lpcn-1148-as-a-treatment-for-sarcopenia--lpcn-20241217monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-publication-and-discussion-of-lpcn-1148-manuscript-at-the-liver-meeting-lpcn-20241118monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-results-for-the-third-quarter-ended-lpcn-20241107monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-distribution-and-license-agreement-with-spc-korea-to-commercialize-tlan-lpcn-20241031monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-positive-oral-brexanolone-quantitative-eeg-results-quantitative-electro-lpcn-20241010monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-supply-and-distribution-agreement-with-pharmalink-to-commercialize-tlan-lpcn-20241008monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-host-virtual-kol-event-on-lpcn-2401-for-improved-body-composition-in-obesity-m-lpcn-20241002monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-h-c-wainwright-8-th-annual-mash-investor-conference-lpcn-20240930monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-phase-2-data-on-lpcn-2401-to-be-presented-at-obesityweek-study-evaluate-lpcn-20240905monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-h-c-wainwright-26th-annual-global-investment-conference-lpcn-20240827monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-results-for-the-second-quarter-ended-lpcn-20240808monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-results-for-the-first-quarter-ended-lpcn-20240509monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-late-breaking-oral-presentation-of-data-from-the-phase-2-study-of-lpcn--lpcn-20240508monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-completion-of-dosing-in-pivotal-study-of-postpartum-depression-candidat-lpcn-20240501monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-positive-lpcn-2401-clinical-results-showing-improved-body-composition-i-lpcn-20240411monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-positive-week-52-results-from-lpcn-1148-phase-2-study-in-patients-with--lpcn-20240328monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-first-cohort-dosed-in-pivotal-study-of-lpcn-1154-company-anticipates-to-lpcn-20240325monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-results-for-the-full-year-ended-lpcn-20240307monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-36-th-annual-roth-conference-lpcn-20240306monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-confirmation-of-dosing-regimen-for-pivotal-study-of-lpcn-1154-positive--lpcn-20240206monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-and-verity-pharma-enter-into-license-agreement-for-tlando-franchise-in-the-u-s-an-lpcn-20240118monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-biotech-showcase-2024-company-management-will-also-host-meetings-at-lpcn-20231219monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-releases-late-breaking-presentation-on-lpcn-1148-phase-2-results-at-the-liver-mee-lpcn-20231113monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-results-for-the-third-quarter-ended-lpcn-20231108monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-clinical-data-on-lpcn-1148-at-the-liver-meeting-2023-late-breaking-abs-lpcn-20231101monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-completes-successful-meeting-with-fda-on-lpcn-1154-in-postpartum-depression-lipoc-lpcn-20231026monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-lpcn-20230919monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-results-for-the-second-quarter-ended-lpcn-20230810monthly0.5https://www.biopharmawatch.com/news/LPCN/lpcn-1148-phase-2-study-meets-primary-endpoint-in-patients-with-cirrhosis-met-primary-endp-lpcn-20230727monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-h-c-wainwright-annual-neuropsychiatry-virtual-conference-lpcn-20230614monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-lpcn-1148-and-lpcn-1144-at-the-easl-congress-2023-phase-2-proof-of-con-lpcn-20230607monthly0.5https://www.biopharmawatch.com/news/LPCN/positive-topline-clinical-results-support-streamlined-development-pathway-for-lpcn-1154-li-lpcn-20230516monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-results-for-the-first-quarter-ended-lpcn-20230511monthly0.5https://www.biopharmawatch.com/news/LPCN/first-subject-dosed-in-the-clinical-bridge-study-with-lipocine-depression-candidate-lpcn-1-lpcn-20230403monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-pro-rata-distribution-of-series-b-preferred-stock-to-its-holders-of-com-lpcn-20230310monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-results-for-the-year-ended-lpcn-20230310monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-at-biotech-showcase-company-management-will-also-host-meetings-at-life-lpcn-20230105monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-completes-enrollment-of-lpcn-1148-phase-2-study-for-decompensated-cirrhosis-top-l-lpcn-20221219monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-results-for-the-third-quarter-ended-lpcn-20221109monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-senior-leadership-appointments-to-advance-its-cns-focused-pipeline-salt-lpcn-20221103monthly0.5https://www.biopharmawatch.com/news/LPCN/efficacy-safety-and-tolerability-of-continued-lpcn-1144-treatment-in-nonalcoholic-steatohe-lpcn-20221027monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-strategic-realignment-and-forward-focus-on-treating-cns-disorders-compa-lpcn-20220926monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-favorable-regulatory-pathway-on-oral-lpcn-1154-for-post-partum-depressi-lpcn-20220915monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-results-for-the-second-quarter-ended-lpcn-20220808monthly0.5https://www.biopharmawatch.com/news/LPCN/fda-clears-lpcn-2101-ind-for-adult-epilepsy-treatment-phase-2-photosensitive-epilepsy-stud-lpcn-20220711monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-lpcn-20220614monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-presentation-at-2022-lpcn-20220606monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-positive-lpcn-1144-nash-open-label-extension-study-results-lpcn-1144-wa-lpcn-20220512monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-results-for-the-first-quarter-ended-lpcn-20220509monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-board-of-director-appointments-industry-veterans-jill-m-jene-ph-d-and-s-lpcn-20220411monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-its-partner-received-fda-approval-of-tlando-commercial-launch-expected--lpcn-20220329monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-results-for-the-year-ended-lpcn-20220309monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-regulatory-guidance-on-lpcn-1144-in-non-cirrhotic-lpcn-20220301monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-its-partner-received-fda-acceptance-of-nda-resubmission-for-tlando-pduf-lpcn-20220203monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-peer-reviewed-publication-of-phase-3-study-results-for-lpcn-20220127monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-patient-dosed-in-its-phase-2-study-with-lpcn-1148-for-management-of-liv-lpcn-20211222monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-results-for-the-third-quarter-ended-lpcn-20211110monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-fda-grants-fast-track-designation-to-lpcn-1144-for-treatment-of-non-cir-lpcn-20211104monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-multiple-poster-presentations-at-the-american-association-for-the-study-lpcn-20211101monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-and-antares-pharma-enter-into-u-s-licensing-agreement-to-commercialize-tlando-und-lpcn-20211018monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-fda-affirmation-of-class-1-lpcn-20210928monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-s-lpcn-1144-met-non-alcoholic-steatohepatitis-nash-resolution-regulatory-endpoint-lpcn-20210825monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-settlement-with-clarus-therapeutics-lpcn-20210714monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-presentations-at-the-international-liver-congress-2021-digital-event-lpcn-20210623monthly0.5https://www.biopharmawatch.com/news/LPCN/fda-clears-lpcn-1154-ind-application-for-a-phase-2-postpartum-depression-study-lpcn-20210614monthly0.5https://www.biopharmawatch.com/news/LPCN/forward-looking-statements-this-presentation-contains-forward-looking-statements-about-lip-lpcn-20210614monthly0.5https://www.biopharmawatch.com/news/LPCN/background-and-aims-non-alcoholic-steatohepatitis-nash-is-lpcn-20210609monthly0.5https://www.biopharmawatch.com/news/LPCN/summary-judgment-ruling-in-patent-infringement-lawsuit-lpcn-20210526monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-results-for-the-first-quarter-ended-lpcn-20210506monthly0.5https://www.biopharmawatch.com/news/LPCN/forward-looking-statements-this-presentation-contains-forward-looking-statements-about-lip-lpcn-20210330monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-results-for-the-year-ended-lpcn-20210311monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-publication-in-journal-of-endocrinological-investigation-highlighting-t-lpcn-20210304monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-presentations-on-tlando-at-endo-2021-conference-lpcn-20210303monthly0.5https://www.biopharmawatch.com/news/LPCN/forward-looking-statements-this-presentation-contains-forward-looking-statements-about-lip-lpcn-20210301monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-closes-underwritten-public-offering-of-common-stock-salt-lake-city-lpcn-20210128monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-prices-25-million-underwritten-public-offering-of-common-stock-salt-lake-city-lpcn-20210126monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-launch-of-public-offering-of-common-stock-salt-lake-city-lpcn-20210125monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-lpcn-20210114monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-positive-topline-phase-2-results-from-lpcn-1144-ongoing-lift-study-in-b-lpcn-20210112monthly0.5https://www.biopharmawatch.com/news/LPCN/enabling-oral-drug-delivery-to-improve-patient-compliance-january-2021-corporate-presentat-lpcn-20210104monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-open-label-extension-to-ongoing-lpcn-1144-lift-study-lpcn-20201230monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-update-on-jury-trial-in-patent-infringement-lawsuit-against-clarus-ther-lpcn-20201229monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-deletion-of-unauthorized-changes-to-company-s-website-lpcn-20201208monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-provides-new-regulatory-update-on-lpcn-20201204monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-third-quarter-2020-financial-and-operational-results-lpcn-20201110monthly0.5https://www.biopharmawatch.com/news/LPCN/tlando-oral-testosterone-replacement-therapy-without-dose-titration-requirement-in-hypogon-lpcn-20201109monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-provides-regulatory-update-on-lpcn-20201106monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-present-preclinical-data-on-therapeutic-potential-of-lpcn-1144-in-hepatic-fibr-lpcn-20201105monthly0.5https://www.biopharmawatch.com/news/LPCN/lpcn-1144-treatment-potential-assessment-in-a-high-fat-diet-induced-rabbit-model-of-hepati-lpcn-20201014monthly0.5https://www.biopharmawatch.com/news/LPCN/tlando-oral-testosterone-replacement-therapy-without-dose-titration-requirement-introducti-lpcn-20201013monthly0.5https://www.biopharmawatch.com/news/LPCN/forward-looking-statements-this-presentation-contains-forward-looking-statements-about-lip-lpcn-20201005monthly0.5https://www.biopharmawatch.com/news/LPCN/forward-looking-statements-this-presentation-contains-forward-looking-statements-about-lip-lpcn-20200921monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-completion-of-enrollment-in-the-lpcn-1144-lift-study-phase-2-clinical-s-lpcn-20200921monthly0.5https://www.biopharmawatch.com/news/LPCN/forward-looking-statements-this-presentation-contains-forward-looking-statements-about-lip-lpcn-20200914monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-provides-regulatory-update-for-lpcn-20200828monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-second-quarter-2020-financial-and-operational-results-lpcn-20200806monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-publication-of-lpcn-1144-liver-fat-study-lfs-results-lpcn-20200803monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-derivative-suit-was-dismissed-lpcn-20200731monthly0.5https://www.biopharmawatch.com/news/LPCN/forward-looking-statements-this-presentation-contains-forward-looking-statements-about-lip-lpcn-20200720monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-lpcn-20200713monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-presentations-on-tlando-at-aua-virtual-experience-2020-lpcn-20200515monthly0.5https://www.biopharmawatch.com/news/LPCN/treatment-potential-of-lpcn-1144-demonstrated-in-a-pre-clinical-nash-and-hepatic-fibrosis--lpcn-20200513monthly0.5https://www.biopharmawatch.com/news/LPCN/enabling-oral-drug-delivery-to-improve-patient-compliance-may-2020-corporate-presentation--lpcn-20200511monthly0.5https://www.biopharmawatch.com/news/LPCN/fda-clears-lpcn-1148-ind-application-for-phase-2-cirrhosis-trial-lpcn-20200505monthly0.5https://www.biopharmawatch.com/news/LPCN/u-s-fda-denies-clarus-s-oral-testosterone-ester-citizen-petition-lpcn-20200417monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-us-court-of-appeals-for-the-federal-circuit-affirms-decision-of-lpcn-20200409monthly0.5https://www.biopharmawatch.com/news/LPCN/impact-of-a-new-oral-testosterone-undecanoate-on-blood-pressure-and-cardiovascular-risk-in-lpcn-20200401monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-outcome-of-markman-hearing-in-patent-infringement-suit-against-clarus-lpcn-20200326monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-2019-year-end-financial-and-operational-results-lpcn-20200313monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-tlando-pdufa-date-of-lpcn-20200304monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-closing-of-registered-direct-offering-of-common-stock-and-warrants-salt-lpcn-20200227monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-6-million-registered-direct-offering-priced-at-the-market-salt-lake-cit-lpcn-20200225monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-regulatory-path-forward-for-tlando-resubmission-lpcn-20200224monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-streamlines-its-infringement-lawsuit-against-clarus-therapeutics-lpcn-20200211monthly0.5https://www.biopharmawatch.com/news/LPCN/a-novel-oral-testosterone-therapy-tlando-safely-restores-testosterone-to-eugonadal-levels--lpcn-20200205monthly0.5https://www.biopharmawatch.com/news/LPCN/enabling-oral-drug-delivery-to-improve-patient-compliance-january-2020-corporate-presentat-lpcn-20200113monthly0.5https://www.biopharmawatch.com/news/LPCN/lpcn-1144-oral-testosterone-undecanoate-resolves-non-alcoholic-fatty-liver-disease-michael-lpcn-20200110monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-closing-of-public-offering-of-common-stock-and-warrants-salt-lake-city-lpcn-20191118monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-pricing-of-public-offering-of-common-stock-and-warrants-salt-lake-city-lpcn-20191114monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-launch-of-public-offering-of-common-stock-and-warrants-salt-lake-city-lpcn-20191113monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-third-quarter-2019-financial-and-operational-results-lpcn-20191112monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-receives-complete-response-letter-for-tlando-from-lpcn-20191111monthly0.5https://www.biopharmawatch.com/news/LPCN/lpcn-1144-resolves-non-alcoholic-fatty-liver-disease-introduction-r-esults-soar-hypogonadi-lpcn-20191108monthly0.5https://www.biopharmawatch.com/news/LPCN/confidential-1-smsna-2019-lpcn-20191025monthly0.5https://www.biopharmawatch.com/news/LPCN/1-confidential-1-smsna-2019-october-25-2019-lpcn-oral-t-tlando-reduces-liver-fat-in-men-wi-lpcn-20191021monthly0.5https://www.biopharmawatch.com/news/LPCN/forward-looking-statements-this-presentation-contains-forward-looking-statements-about-lip-lpcn-20191021monthly0.5https://www.biopharmawatch.com/news/LPCN/lpcn-1144-resolves-non-alcoholic-fatty-liver-disease-somaya-albhaisi-1-kilyoung-kim-3-jona-lpcn-20191001monthly0.5https://www.biopharmawatch.com/news/LPCN/first-biopsy-confirmed-nash-patient-dosed-in-lipocine-lift-study-of-lpcn-1144-lpcn-20190930monthly0.5https://www.biopharmawatch.com/news/LPCN/tlando-lpcn-1144-reduces-liver-fat-in-men-with-fatty-liver-irwin-goldstein-1-kilyoung-kim--lpcn-20190923monthly0.5https://www.biopharmawatch.com/news/LPCN/forward-looking-statements-this-presentation-contains-forward-looking-statements-about-lip-lpcn-20190923monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-trial-date-in-lipocine-s-infringement-lawsuit-against-clarus-therapeuti-lpcn-20190827monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-second-quarter-2019-financial-and-operational-results-lpcn-20190807monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-receives-fda-clearance-for-clinical-testing-its-nash-candidate-lpcn-1144-in-expan-lpcn-20190723monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-set-to-join-russell-microcap-index-lpcn-20190625monthly0.5https://www.biopharmawatch.com/news/LPCN/forward-looking-statements-this-presentation-contains-forward-looking-statements-about-lip-lpcn-20190528monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-tlando-nda-pdufa-action-date-of-lpcn-20190514monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-first-quarter-2019-financial-and-operational-results-lpcn-20190508monthly0.5https://www.biopharmawatch.com/news/LPCN/forward-looking-statements-this-presentation-contains-forward-looking-statements-about-lip-lpcn-20190501monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-seeks-injunction-against-the-marketing-of-clarus-therapeutics-jatenzo-for-testost-lpcn-20190403monthly0.5https://www.biopharmawatch.com/news/LPCN/forward-looking-statements-this-presentation-contains-forward-looking-statements-about-lip-lpcn-20190328monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-abpm-labeling-study-results-consistent-with-recently-approved-testoster-lpcn-20190327monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-late-breaker-presentation-at-easl-meeting-to-detail-lpcn-1144-mri-pdff-based-clin-lpcn-20190326monthly0.5https://www.biopharmawatch.com/news/LPCN/forward-looking-statements-this-presentation-contains-forward-looking-statements-about-lip-lpcn-20190318monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-s-lpcn-1144-for-nash-demonstrates-substantial-fatty-liver-resolution-and-meaningf-lpcn-20190312monthly0.5https://www.biopharmawatch.com/news/LPCN/therapeutic-potential-of-lpcn-1144-in-nafld-nash-background-aims-male-hypogonadism-is-an-u-lpcn-20190307monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-and-operational-results-for-the-year-ended-lpcn-20190306monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-inc-announces-fda-clearance-of-ind-to-commence-phase-2-study-of-lpcn-1144-in-biop-lpcn-20190214monthly0.5https://www.biopharmawatch.com/news/LPCN/forward-looking-statements-this-presentation-contains-forward-looking-statements-about-lip-lpcn-20190128monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-files-ind-to-evaluate-lpcn-1144-in-biopsy-confirmed-nash-subjects-lpcn-20190123monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-s-nash-therapy-candidate-achieves-meaningful-liver-fat-reduction-based-on-interim-lpcn-20190117monthly0.5https://www.biopharmawatch.com/news/LPCN/uspto-grants-priority-motion-to-lipocine-and-enters-judgment-against-clarus-salt-lake-city-lpcn-20190114monthly0.5https://www.biopharmawatch.com/news/LPCN/forward-looking-statements-this-presentation-contains-forward-looking-statements-about-lip-lpcn-20181230monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-successful-ex-vivo-conversion-assessment-of-lpcn-20181231monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-lpcn-1144-clinical-trial-results-selected-for-presentation-at-2019-nash-lpcn-20181221monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-lpcn-1144-mri-pdff-clinical-results-selected-for-presentation-at-keysto-lpcn-20181220monthly0.5https://www.biopharmawatch.com/news/LPCN/author-disclosures-are-on-file-at-aasld-this-study-was-funded-by-lipocine-inc-contact-info-lpcn-20181109monthly0.5https://www.biopharmawatch.com/news/LPCN/forward-looking-statements-this-presentation-contains-forward-looking-statements-about-lip-lpcn-20181108monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-and-operational-results-for-the-three-and-nine-months-ended-lpcn-20181107monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-completion-of-enrollment-in-lpcn-1144-liver-imaging-study-in-subjects-a-lpcn-20181105monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-completion-of-enrollment-in-ambulatory-blood-pressure-study-for-lpcn-20181101monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-lpcn-1144-clinical-trial-results-selected-for-late-breaker-presentation-lpcn-20181011monthly0.5https://www.biopharmawatch.com/news/LPCN/enabling-oral-drug-delivery-to-improve-patient-compliance-october-2018-corporate-presentat-lpcn-20181001monthly0.5https://www.biopharmawatch.com/news/LPCN/non-alcoholic-fatty-liver-disease-nafld-and-its-clinical-progression-fatty-liver-is-a-reve-lpcn-20180829monthly0.5https://www.biopharmawatch.com/news/LPCN/forward-looking-statements-this-presentation-contains-forward-looking-statements-about-lip-lpcn-20180807monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-dosing-in-ambulatory-blood-pressure-study-for-lpcn-20180607monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-receives-complete-response-letter-for-tlando-from-u-s-food-and-drug-administratio-lpcn-20180509monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-and-operational-results-for-the-first-quarter-ended-lpcn-20180507monthly0.5https://www.biopharmawatch.com/news/LPCN/forward-looking-statements-this-presentation-contains-forward-looking-statements-about-lip-lpcn-20180312monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-settlement-of-securities-class-action-lawsuit-lpcn-20180216monthly0.5https://www.biopharmawatch.com/news/LPCN/forward-looking-statements-this-presentation-contains-forward-looking-statements-about-lip-lpcn-20180213monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-10-million-loan-and-security-agreement-with-silicon-valley-bank-lpcn-20180208monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-outcome-of-fda-advisory-committee-meeting-for-tlando-testosterone-repla-lpcn-20180110monthly0.5https://www.biopharmawatch.com/news/LPCN/u-s-fda-extends-review-for-tlando-advisory-committee-meeting-date-of-lpcn-20171117monthly0.5https://www.biopharmawatch.com/news/LPCN/forward-looking-statements-this-presentation-contains-forward-looking-statements-about-lip-lpcn-20171108monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-and-operational-results-for-the-third-quarter-and-nine-months-lpcn-20171108monthly0.5https://www.biopharmawatch.com/news/LPCN/of-oral-testosterone-replacement-therapy-lpcn-1021-analysis-of-two-fixed-dose-regimens-exh-lpcn-20171025monthly0.5https://www.biopharmawatch.com/news/LPCN/fda-advisory-committee-scheduled-to-review-tlando-on-lpcn-20171018monthly0.5https://www.biopharmawatch.com/news/LPCN/enabling-oral-drug-delivery-to-improve-patient-compliance-september-26-2017-ladenburg-thal-lpcn-20170925monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-motions-decision-by-uspto-in-interference-against-clarus-salt-lake-city-lpcn-20170921monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-fda-advisory-committee-meeting-for-lpcn-20170920monthly0.5https://www.biopharmawatch.com/news/LPCN/forward-looking-statements-this-presentation-contains-forward-looking-statements-about-lip-lpcn-20170908monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-fda-acknowledgement-of-tlando-lpcn-1021-nda-resubmission-pdufa-goal-dat-lpcn-20170814monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-resubmits-nda-for-its-oral-testosterone-product-candidate-lpcn-1021-for-treatment-lpcn-20170809monthly0.5https://www.biopharmawatch.com/news/LPCN/forward-looking-statements-this-presentation-contains-forward-looking-statements-about-lip-lpcn-20170808monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-and-operational-results-for-the-second-quarter-and-six-months-lpcn-20170807monthly0.5https://www.biopharmawatch.com/news/LPCN/forward-looking-statements-this-presentation-contains-forward-looking-statements-about-lip-lpcn-20170710monthly0.5https://www.biopharmawatch.com/news/LPCN/forward-looking-statements-this-presentation-contains-forward-looking-statements-about-lip-lpcn-20170628monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-submission-of-spa-on-lpcn-1107-an-oral-alternative-for-the-prevention-o-lpcn-20170626monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-validates-no-titration-dosing-regimen-with-positive-topline-efficacy-results-for--lpcn-20170619monthly0.5https://www.biopharmawatch.com/news/LPCN/forward-looking-statements-this-presentation-contains-forward-looking-statements-about-lip-lpcn-20170526monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-and-operational-results-for-the-first-quarter-2017-lpcn-20170508monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-completes-enrollment-in-the-lpcn-1021-fixed-dose-clinical-trials-top-line-data-fr-lpcn-20170424monthly0.5https://www.biopharmawatch.com/news/LPCN/forward-looking-statements-this-presentation-contains-forward-looking-statements-about-lip-lpcn-20170404monthly0.5https://www.biopharmawatch.com/news/LPCN/th-annual-roth-conference-lpcn-20170313monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-and-operational-results-for-the-full-year-of-2016-salt-lake-c-lpcn-20170306monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-the-promotion-of-gregory-bass-to-chief-commercial-officer-salt-lake-cit-lpcn-20170215monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-receives-fda-guidance-on-the-phase-3-program-for-lpcn-1107-an-oral-alternative-fo-lpcn-20170109monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-initiates-a-dosing-flexibility-study-for-lpcn-1021-its-oral-testosterone-replacem-lpcn-20170105monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-initiate-dosing-validation-study-for-lpcn-1021-oral-testosterone-replacement-p-lpcn-20161205monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-and-operational-results-for-the-third-quarter-of-2016-salt-la-lpcn-20161108monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-issuance-of-us-patent-9-480-690-salt-lake-city-lpcn-20161107monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-completes-post-action-meeting-lpcn-20161017monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-wins-dismissal-of-patent-infringement-lawsuit-related-to-lpcn-1021-salt-lake-city-lpcn-20161007monthly0.5https://www.biopharmawatch.com/news/LPCN/forward-looking-statements-this-presentation-contains-forward-looking-statements-about-lip-lpcn-20160927monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-positive-top-line-phase-2b-study-results-for-lpcn-1111-a-next-generatio-lpcn-20160926monthly0.5https://www.biopharmawatch.com/news/LPCN/forward-looking-statements-2-this-presentation-contains-forward-looking-statements-about-l-lpcn-20160810monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-and-operational-results-for-the-second-quarter-of-2016-salt-l-lpcn-20160809monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-receives-complete-response-letter-crl-for-lpcn-1021-from-u-s-food-and-drug-admini-lpcn-20160629monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-added-to-russell-3000-and-russell-global-indexes-salt-lake-city-lpcn-20160627monthly0.5https://www.biopharmawatch.com/news/LPCN/hypogonadal-men-with-diabetes-benefit-from-lpcn-1021-oral-testosterone-christina-wang-md-1-lpcn-20160527monthly0.5https://www.biopharmawatch.com/news/LPCN/forward-looking-statements-2-this-presentation-contains-forward-looking-statements-about-l-lpcn-20160516monthly0.5https://www.biopharmawatch.com/news/LPCN/long-term-safety-and-tolerability-of-oral-testosterone-lpcn-1021-in-hypogonadal-men-result-lpcn-20160510monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-and-operational-results-for-the-first-quarter-of-2016-salt-la-lpcn-20160509monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-the-presentation-of-clinical-data-for-oral-testosterone-replacement-the-lpcn-20160502monthly0.5https://www.biopharmawatch.com/news/LPCN/corporate-presentation-april-2016-exhibit-99-1-lpcn-20160412monthly0.5https://www.biopharmawatch.com/news/LPCN/subjects-with-the-following-pre-existing-cardiovascular-conditions-reported-in-medical-his-lpcn-20160401monthly0.5https://www.biopharmawatch.com/news/LPCN/hypogonadal-men-with-and-without-cardiovascular-disorders-benefit-from-lpcn-1021-oral-test-lpcn-20160329monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-the-presentation-of-clinical-data-for-lpcn-1021-its-oral-testosterone-r-lpcn-20160328monthly0.5https://www.biopharmawatch.com/news/LPCN/forward-looking-statements-2-this-presentation-contains-forward-looking-statements-about-l-lpcn-20160311monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-and-operational-results-for-the-full-year-of-2015-salt-lake-c-lpcn-20160310monthly0.5https://www.biopharmawatch.com/news/LPCN/february-2016-exhibit-99-1-lpcn-20160216monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-reports-positive-results-of-multi-dose-pharmacokinetic-study-of-lpcn-1107-for-the-lpcn-20160216monthly0.5https://www.biopharmawatch.com/news/LPCN/forward-looking-statements-2-this-presentation-contains-forward-looking-statements-about-l-lpcn-20160111monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-first-patient-dosed-in-phase-2b-clinical-study-for-lpcn-1111-a-novel-te-lpcn-20160104monthly0.5https://www.biopharmawatch.com/news/LPCN/piper-jaffray-2015-healthcare-conference-december-2015-exhibit-99-1-lpcn-20151130monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-adopts-stockholder-rights-plan-salt-lake-city-lpcn-20151113monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-and-operational-results-for-the-third-quarter-of-2015-salt-la-lpcn-20151112monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-pdufa-goal-date-for-lpcn-1021-nda-salt-lake-city-lpcn-20151112monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-presentation-of-lpcn-1021-clinical-data-at-21st-annual-smsna-meeting-sa-lpcn-20151111monthly0.5https://www.biopharmawatch.com/news/LPCN/fda-accepts-for-filing-lipocine-s-new-drug-application-for-its-oral-testosterone-replaceme-lpcn-20151029monthly0.5https://www.biopharmawatch.com/news/LPCN/corporate-presentation-october-2015-exhibit-99-1-lpcn-20151013monthly0.5https://www.biopharmawatch.com/news/LPCN/forward-looking-statements-2-this-presentation-contains-forward-looking-statements-about-l-lpcn-20150929monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-first-subject-dosed-in-multi-dose-pk-study-for-its-oral-product-candida-lpcn-20150928monthly0.5https://www.biopharmawatch.com/news/LPCN/click-to-edit-master-title-style-2-forward-looking-statements-this-presentation-contains-f-lpcn-20150827monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-submits-new-drug-application-to-fda-for-its-oral-testosterone-replacement-product-lpcn-20150831monthly0.5https://www.biopharmawatch.com/news/LPCN/click-to-edit-master-title-style-2-forward-looking-statements-this-presentation-contains-f-lpcn-20150812monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-and-operational-results-for-the-second-quarter-of-2015-salt-l-lpcn-20150811monthly0.5https://www.biopharmawatch.com/news/LPCN/click-to-edit-master-title-style-2-forward-looking-statements-this-presentation-contains-f-lpcn-20150803monthly0.5https://www.biopharmawatch.com/news/LPCN/click-to-edit-master-title-style-2-forward-looking-statements-this-presentation-contains-f-lpcn-20150713monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-s-oral-testosterone-well-tolerated-in-phase-3-study-lpcn-1021-was-well-tolerated--lpcn-20150629monthly0.5https://www.biopharmawatch.com/news/LPCN/click-to-edit-master-title-style-2-forward-looking-statements-this-presentation-contains-f-lpcn-20150623monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-successful-completion-of-food-effect-study-for-lpcn-1021-an-oral-testos-lpcn-20150615monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-development-plans-for-lpcn-1107-salt-lake-city-lpcn-20150608monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-receives-fda-orphan-drug-designation-for-lpcn-1107-an-oral-product-candidate-for--lpcn-20150602monthly0.5https://www.biopharmawatch.com/news/LPCN/forward-looking-statements-2-this-presentation-contains-forward-looking-statements-about-l-lpcn-20150511monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-appoints-dr-jyrki-mattila-as-chief-business-officer-salt-lake-city-lpcn-20150518monthly0.5https://www.biopharmawatch.com/news/LPCN/this-study-was-supported-by-lipocine-inc-j-c-kaminetsky-research-funding-principal-investi-lpcn-20150518monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-presentation-of-additional-lpcn-1021-clinical-data-at-american-urologic-lpcn-20150511monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-and-operational-results-for-the-first-quarter-of-2015-salt-la-lpcn-20150507monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-completion-of-lpcn-1021-oral-testosterone-phase-3-clinical-trial-salt-l-lpcn-20150430monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-closing-of-34-8-million-common-stock-offering-salt-lake-city-lpcn-20150429monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-prices-30-2-million-public-offering-of-common-stock-salt-lake-city-lpcn-20150424monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-proposed-public-offering-of-common-stock-salt-lake-city-lpcn-20150423monthly0.5https://www.biopharmawatch.com/news/LPCN/adrian-dobs-research-funding-clinical-researcher-clarus-endo-honoraria-advisory-group-abbv-lpcn-20150331monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-presentation-of-additional-lpcn-1021-clinical-data-at-american-society--lpcn-20150410monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-results-from-pre-nda-meeting-for-lpcn-1021-an-oral-testosterone-product-lpcn-20150324monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-and-operational-results-for-the-full-year-2014-salt-lake-city-lpcn-20150311monthly0.5https://www.biopharmawatch.com/news/LPCN/this-study-was-supported-by-lipocine-inc-cw-research-funding-clinical-researcher-antares-c-lpcn-20150309monthly0.5https://www.biopharmawatch.com/news/LPCN/this-presentation-contains-and-our-discussions-during-this-conference-may-include-forward--lpcn-20150306monthly0.5https://www.biopharmawatch.com/news/LPCN/this-presentation-contains-and-our-discussions-during-this-conference-may-include-forward--lpcn-20150302monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-presentation-of-lpcn-1021-clinical-data-at-endo-2015-salt-lake-city-lpcn-20150227monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-presentation-of-lpcn-1107-clinical-data-at-the-society-for-maternal-fet-lpcn-20150130monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-positive-phase-1b-top-line-results-with-lpcn-1107-in-pregnant-women-fir-lpcn-20150112monthly0.5https://www.biopharmawatch.com/news/LPCN/fda-confirms-lipocine-s-previously-agreed-clinical-development-plan-for-lpcn-1021-salt-lak-lpcn-20141215monthly0.5https://www.biopharmawatch.com/news/LPCN/corporate-presentation-december-2014-exhibit-99-1-lpcn-20141126monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-management-changes-salt-lake-city-lpcn-20141117monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-and-operational-results-for-the-third-quarter-of-2014-salt-la-lpcn-20141110monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-positive-top-line-results-in-phase-2a-study-of-lpcn-1111-candidate-for--lpcn-20141013monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-positive-top-line-results-in-its-phase-3-study-of-lpcn-1021-for-oral-te-lpcn-20140924monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-first-patient-dosed-in-phase-1-study-in-pregnant-women-of-lpcn-1107-pot-lpcn-20140908monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-financial-and-operational-results-for-the-second-quarter-of-2014-salt-l-lpcn-20140813monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-issuance-of-u-s-patent-for-lpcn-1021-salt-lake-city-lpcn-20140715monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-first-patient-dosed-in-phase-2a-study-of-lpcn-1111-a-novel-testosterone-lpcn-20140527monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-successful-phase-1-results-with-lpcn-1107-potentially-the-first-oral-pr-lpcn-20140515monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-completion-of-enrollment-in-its-soar-phase-3-study-for-oral-testosteron-lpcn-20140429monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-to-begin-trading-on-the-nasdaq-capital-market-salt-lake-city-lpcn-20140318monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-first-patient-dosed-in-phase-3-study-for-oral-testosterone-replacement--lpcn-20140210monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-announces-new-appointments-to-its-board-of-directors-salt-lake-city-lpcn-20140107monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-inc-condensed-balance-sheets-unaudited-lpcn-20130905monthly0.5https://www.biopharmawatch.com/news/LPCN/lipocine-inc-financial-statements-lpcn-20130725monthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-reports-q1-2026-results-revenue-up-31-to-17-9m-new-q1-record-total-liabiliti-cosm-20260521monthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-reports-full-year-2025-results-revenue-hits-all-time-record-of-65-3m-up-20-g-cosm-20260415monthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-reports-record-q3-2025-results-with-all-time-high-revenue-gross-profit-and-g-cosm-20251117monthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-regains-compliance-with-nasdaq-minimum-bid-price-requirement-chicago-il-glob-cosm-20251016monthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-ceo-issues-letter-to-shareholders-building-a-global-healthcare-powerhouse-wi-cosm-20250929monthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-secures-up-to-300-million-financing-facility-to-launch-ethereum-treasury-str-cosm-20250806monthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-receives-additional-180-day-compliance-period-from-nasdaq-chicago-il-accessw-cosm-20250506monthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-announces-it-will-not-proceed-with-an-offering-under-its-form-s-1-chicago-il-cosm-20250218monthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-regains-compliance-with-nasdaq-minimum-bid-price-rule-chicago-il-accesswire-cosm-20240719monthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-receives-additional-delinquency-letter-from-nasdaq-regarding-late-filings-of-cosm-20240524monthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-receives-nasdaq-notice-on-late-filing-of-its-form-10-k-chicago-il-accesswire-cosm-20240419monthly0.5https://www.biopharmawatch.com/news/COSM/related-party-transaction-policies-and-procedures-policy-it-is-the-policy-of-the-board-of--cosm-20240322monthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-bolsters-presence-in-400bn-global-generic-drugs-market-with-3-5m-acquisition-cosm-20240118monthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-set-for-substantial-growth-from-acquisitions-completed-in-2023-in-2023-cosmo-cosm-20231227monthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-reports-q3-2023-results-revenue-increased-7-yoy-total-assets-reached-record--cosm-20231121monthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-ceo-issues-letter-to-shareholders-company-reaches-major-strategic-inflection-cosm-20231005monthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-introduces-guidance-expects-to-achieve-over-180m-in-gross-annual-revenue-and-cosm-20230912monthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-reports-q2-2023-financial-results-adjusted-net-income-increases-by-3550-to-s-cosm-20230815monthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-inc-announces-pricing-of-5-25-million-registered-direct-offering-and-concurr-cosm-20230720monthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-ends-2022-with-transformed-balance-sheet-and-achieves-positive-adjusted-ebit-cosm-20230413monthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-announces-the-appointment-of-nikos-bardakis-an-experienced-executive-in-the--cosm-20230201monthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-inc-announces-pricing-of-32-5-million-registered-direct-offering-and-concurr-cosm-20221219monthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-holdings-inc-changes-its-name-to-cosmos-health-inc-and-announces-a-1-for-25-reverse-cosm-20221216monthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-reports-third-quarter-2022-financial-results-chicago-cosm-20221115monthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-health-reports-202-42-increase-in-adjusted-ebitda-and-positive-operating-income-for-cosm-20220822monthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-holdings-announces-agreement-to-acquire-cana-laboratories-a-legacy-european-pharmac-cosm-20220720monthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-holdings-reports-12-5-increase-in-revenue-88-9-increase-in-gross-profit-and-achieve-cosm-20220518monthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-holdings-announces-closing-of-6-million-private-placement-of-convertible-preferred--cosm-20220228monthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-holdings-announces-shareholder-approval-of-private-offering-cosmos-holdings-cosm-20211220monthly0.5https://www.biopharmawatch.com/news/COSM/pro-forma-balance-sheet-as-of-cosm-20211208monthly0.5https://www.biopharmawatch.com/news/COSM/pro-forma-balance-sheet-as-of-cosm-20210921monthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-holdings-provides-first-quarter-2021-business-update-reports-89-year-over-year-and--cosm-20210518monthly0.5https://www.biopharmawatch.com/news/COSM/cosmos-holdings-1-312-536-3102-info-cosmoshold-com-141-west-jackson-blvd-suite-4236-chicag-cosm-20201117monthly0.5https://www.biopharmawatch.com/news/COSM/financial-statements-amplerissimo-ltd-a-development-stage-company-index-to-financial-state-cosm-20140218monthly0.5https://www.biopharmawatch.com/news/COSM/financial-statements-amplerissimo-ltd-a-development-stage-company-index-to-financial-state-cosm-20140103monthly0.5https://www.biopharmawatch.com/news/COSM/financial-statements-amplerissimo-ltd-a-development-stage-company-index-to-financial-state-cosm-20131114monthly0.5https://www.biopharmawatch.com/news/COSM/financial-statements-amplerissimo-ltd-a-development-stage-company-index-to-financial-state-cosm-20131003monthly0.5https://www.biopharmawatch.com/news/COSM/share-contribution-agreement-this-share-contribution-agreement-the-agreement-is-made-and-e-cosm-20120927monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-reports-record-fourth-quarter-and-full-year-2025-financial-results-and-pro-bfri-20260319monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-reports-second-quarter-2025-financial-results-and-provides-a-business-upda-bfri-20250813monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-major-restructuring-of-relationship-with-biofrontera-ag-backed-b-bfri-20250630monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-is-negotiating-fundamental-changes-to-its-cooperation-with-biofrontera-ag--bfri-20250611monthly0.5https://www.biopharmawatch.com/news/BFRI/supplement-dated-june-3-2025-to-the-proxy-statement-for-the-2025-annual-meeting-of-stockho-bfri-20250603monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-reports-first-quarter-2025-financial-results-and-provides-a-business-updat-bfri-20250516monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-reports-record-fiscal-year-2024-financial-results-and-provides-a-business--bfri-20250321monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-closes-a-4-2-million-senior-secured-convertible-note-woburn-mass-bfri-20241122monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-reports-third-quarter-and-nine-month-2024-financial-results-and-provides-b-bfri-20241113monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-highly-significant-results-in-phase-3-study-of-ameluz-photodynam-bfri-20241031monthly0.5https://www.biopharmawatch.com/news/BFRI/fda-approves-use-of-up-to-three-tubes-of-biofrontera-inc-s-ameluz-aminolevulinic-acid-hci--bfri-20241007monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-reports-second-quarter-2024-financial-results-and-provides-a-business-upda-bfri-20240814monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-announces-the-launch-of-a-new-fda-approved-red-light-source-the-rhodoled-xl-la-bfri-20240610monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-reports-first-quarter-2024-financial-results-and-provides-a-business-updat-bfri-20240515monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-announces-achievement-of-two-milestones-associated-with-series-b-3-convertible-bfri-20240503monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-2024-annual-meeting-of-stockholders-and-deadlines-for-submission-bfri-20240326monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-reports-record-fiscal-year-2023-financial-results-and-provides-a-business--bfri-20240318monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-closing-of-private-placement-of-up-to-16-0-million-priced-at-mar-bfri-20240223monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-restructuring-of-supply-agreement-with-biofrontera-ag-oslash-ame-bfri-20240220monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-fda-filing-of-supplemental-new-drug-application-for-ameluz-to-pe-bfri-20240205monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-preliminary-revenues-for-the-fourth-quarter-and-full-year-2023-bfri-20240111monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-reports-third-quarter-2023-financial-results-and-provides-a-business-updat-bfri-20231110monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-4-5-million-registered-direct-offering-priced-at-the-market-unde-bfri-20231031monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-receives-fda-approval-for-new-formulation-of-ameluz-patent-application-fil-bfri-20231010monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-preliminary-third-quarter-revenues-revenues-increased-101-to-108-bfri-20231004monthly0.5https://www.biopharmawatch.com/news/BFRI/index-to-financial-statements-page-audited-financial-statements-as-of-and-for-the-years-en-bfri-20231003monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-reports-second-quarter-2023-financial-results-and-provides-a-business-upda-bfri-20230811monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-preliminary-second-quarter-revenues-are-up-26-to-31-management-r-bfri-20230713monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-appoints-dr-heikki-lanckriet-to-its-board-of-directors-woburn-mass-bfri-20230712monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-1-for-20-reverse-stock-split-woburn-mass-bfri-20230703monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-begins-development-of-a-portable-photodynamic-therapy-lamp-for-use-with-am-bfri-20230601monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-names-founder-and-executive-chairman-hermann-luebbert-as-chief-executive-o-bfri-20230530monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-reports-first-quarter-2023-financial-results-and-provides-a-business-updat-bfri-20230512monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-reports-fourth-quarter-and-record-full-year-2022-financial-results-bfri-20230308monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-preliminary-revenues-for-the-fourth-quarter-and-full-year-2022-w-bfri-20230109monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-reports-third-quarter-2022-financial-results-and-provides-a-business-updat-bfri-20221114monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-fully-exercises-recently-acquired-options-to-purchase-shares-of-biofronter-bfri-20221108monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-enters-into-agreements-to-purchase-options-of-biofrontera-ag-sets-company--bfri-20221031monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-names-fred-leffler-as-chief-financial-officer-woburn-mass-bfri-20221024monthly0.5https://www.biopharmawatch.com/news/BFRI/press-release-bfri-20221014monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-preliminary-product-revenues-for-the-third-quarter-of-2022-wobur-bfri-20221005monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-reports-second-quarter-2022-financial-results-and-provides-a-business-upda-bfri-20220812monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-exercise-of-existing-warrants-and-issuance-of-warrants-in-privat-bfri-20220727monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-preliminary-product-revenues-for-the-second-quarter-of-2022-wobu-bfri-20220712monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-pricing-of-9-4-million-private-placement-woburn-ma-bfri-20220516monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-reports-first-quarter-2022-financial-results-and-provides-a-business-updat-bfri-20220513monthly0.5https://www.biopharmawatch.com/news/BFRI/april-8-2022-biofrontera-inc-reports-fourth-quarter-and-full-year-2021-financial-results-a-bfri-20220408monthly0.5https://www.biopharmawatch.com/news/BFRI/press-release-bfri-20220406monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-preliminary-revenue-for-the-fourth-quarter-and-full-year-2021-bfri-20220113monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-pricing-of-15-million-private-placement-priced-at-the-market-under-nasdaq--bfri-20211129monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-reports-third-quarter-2021-financial-results-and-provides-business-update--bfri-20211130monthly0.5https://www.biopharmawatch.com/news/BFRI/biofrontera-inc-announces-pricing-of-18-0-million-initial-public-offering-woburn-ma-bfri-20211028monthly0.5https://www.biopharmawatch.com/news/WGRX/wellgistics-health-announces-lock-up-agreement-with-holders-of-a-majority-of-its-common-st-wgrx-20260528monthly0.5https://www.biopharmawatch.com/news/WGRX/wellgistics-health-releases-letter-to-our-shareholders-why-vertical-integration-and-blockc-wgrx-20260521monthly0.5https://www.biopharmawatch.com/news/WGRX/wellgistics-health-announces-reverse-stock-split-tampa-fl-wgrx-20260520monthly0.5https://www.biopharmawatch.com/news/WGRX/wellgistics-health-reports-first-quarter-2026-financials-and-provides-wellgistics-pharmacy-wgrx-20260519monthly0.5https://www.biopharmawatch.com/news/WGRX/wellgistics-health-to-announce-first-quarter-2026-financials-on-tuesday-wgrx-20260519monthly0.5https://www.biopharmawatch.com/news/WGRX/wellgistics-health-and-kare-pharmtech-execute-joint-venture-expanding-access-to-200-000-pa-wgrx-20260414monthly0.5https://www.biopharmawatch.com/news/WGRX/wellgistics-strengthens-pharmacychain-with-insurance-eligibility-benefits-verification-cap-wgrx-20260311monthly0.5https://www.biopharmawatch.com/news/WGRX/wellgistics-targets-70b-market-breakthrough-addressing-ozempic-glp-1-muscle-loss-with-forz-wgrx-20260309monthly0.5https://www.biopharmawatch.com/news/WGRX/wellgistics-health-to-add-telehealth-mental-health-ai-capabilities-via-tollo-health-partne-wgrx-20260211monthly0.5https://www.biopharmawatch.com/news/WGRX/nfl-alumni-health-partners-with-wellgistics-health-to-deploy-technology-to-improve-health--wgrx-20260203monthly0.5https://www.biopharmawatch.com/news/WGRX/wellgistics-health-provides-2026-corporate-outlook-integration-of-prescription-drug-dispen-wgrx-20260107monthly0.5https://www.biopharmawatch.com/news/WGRX/wellgistics-health-reminds-shareholders-of-wgrx-20251219monthly0.5https://www.biopharmawatch.com/news/WGRX/wellgistics-health-announces-launch-of-diabetes-drug-brenzavvy-to-wellgistics-pharmacy-net-wgrx-20251208monthly0.5https://www.biopharmawatch.com/news/WGRX/wellgistics-health-announces-that-it-will-distribute-a-dream-bowl-2026-meme-coin-to-wellgi-wgrx-20251203monthly0.5https://www.biopharmawatch.com/news/WGRX/wellgistics-health-announces-sponsorship-of-dream-bowl-2026-and-participation-in-datavault-wgrx-20251126monthly0.5https://www.biopharmawatch.com/news/WGRX/datavault-ai-licenses-patents-covering-digital-ledger-enabled-smart-contracts-for-commerci-wgrx-20251125monthly0.5https://www.biopharmawatch.com/news/WGRX/datavault-ai-completes-exclusive-license-of-patents-covering-use-of-blockchain-enabled-sma-wgrx-20251125monthly0.5https://www.biopharmawatch.com/news/WGRX/wellgistics-health-reports-third-quarter-2025-financial-results-and-provides-business-upda-wgrx-20251120monthly0.5https://www.biopharmawatch.com/news/WGRX/wellgistics-health-enters-into-smart-contract-services-agreement-with-datavault-ai-to-deve-wgrx-20251027monthly0.5https://www.biopharmawatch.com/news/WGRX/datavault-ai-and-wellgistics-health-announce-plans-for-pharmacychain-to-implement-manufact-wgrx-20251022monthly0.5https://www.biopharmawatch.com/news/WGRX/wellgistics-health-announces-executive-management-and-board-changes-tampa-fl-wgrx-20251013monthly0.5https://www.biopharmawatch.com/news/WGRX/wellgistics-health-announces-pricing-of-5-million-public-offering-thursday-25-september-20-wgrx-20250925monthly0.5https://www.biopharmawatch.com/news/WGRX/wellgistics-health-inc-to-present-at-september-investor-conferences-friday-05-september-20-wgrx-20250905monthly0.5https://www.biopharmawatch.com/news/WGRX/wellgistics-health-introduces-hubrx-ai-advancing-the-ai-powered-prescription-ecosystem-tam-wgrx-20250827monthly0.5https://www.biopharmawatch.com/news/WGRX/wellgistics-health-achieves-stability-in-first-half-2025-and-executes-growth-initiatives-t-wgrx-20250820monthly0.5https://www.biopharmawatch.com/news/WGRX/wellgistics-health-nasdaq-wgrx-launches-xrp-payment-program-for-independent-pharmacies-tam-wgrx-20250813monthly0.5https://www.biopharmawatch.com/news/WGRX/wellgistics-health-converts-8-1m-debt-to-equity-tampa-florida-access-newswire-wgrx-20250725monthly0.5https://www.biopharmawatch.com/news/WGRX/ceo-of-wellgistics-health-converts-1-5-million-of-debt-to-equity-at-ipo-price-tampa-fl-acc-wgrx-20250415monthly0.5https://www.biopharmawatch.com/news/WGRX/wellgistics-health-inc-announces-agreement-to-acquire-peek-healthcare-technologies-inc-to--wgrx-20250410monthly0.5https://www.biopharmawatch.com/news/WGRX/wellgistics-health-annual-letter-to-shareholders-from-the-office-of-the-ceo-march-2025-tam-wgrx-20250327monthly0.5https://www.biopharmawatch.com/news/WGRX/wellgistics-health-achieves-soc-2-type-1-compliance-strengthening-security-for-ai-driven-p-wgrx-20250318monthly0.5https://www.biopharmawatch.com/news/WGRX/protega-pharmaceuticals-collaborates-with-wellgistics-to-support-pharmacist-education-and--wgrx-20250304monthly0.5https://www.biopharmawatch.com/news/WGRX/wellgistics-expands-healthcare-ecosystem-with-tollo-health-agreement-targeting-multi-billi-wgrx-20250226monthly0.5https://www.biopharmawatch.com/news/WGRX/wellgistics-health-inc-announces-pricing-of-4-0-million-initial-public-offering-tampa-flor-wgrx-20250221monthly0.5https://www.biopharmawatch.com/news/SCNX/commack-ny-scnx-20250814monthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-announces-the-divestiture-of-its-legacy-subsidiaries-for-a-total-consideration-o-scnx-20250408monthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-announces-the-u-s-fda-approval-of-its-nda-for-scn-102-to-be-launched-as-arblitm--scnx-20250318monthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-to-commercially-launch-rezenopy-a-life-saving-opioid-overdose-emergency-treatmen-scnx-20250306monthly0.5https://www.biopharmawatch.com/news/SCNX/scienture-holdings-inc-announces-private-placement-of-3-million-of-10-secured-convertible--scnx-20241126monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-health-inc-announces-name-change-to-scienture-holdings-inc-tampa-fl-and-commack-ny-scnx-20240920monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-health-inc-announces-business-combination-with-scienture-inc-in-a-transaction-value-scnx-20240726monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-health-inc-announces-special-cash-dividend-tampa-fl-scnx-20240709monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-health-inc-announces-receipt-of-notice-from-nasdaq-regarding-late-filing-of-quarter-scnx-20240529monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-health-inc-announces-special-cash-dividend-tampa-fl-scnx-20240306monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-health-inc-files-its-3q-10q-tampa-fl-scnx-20240117monthly0.5https://www.biopharmawatch.com/news/SCNX/superlatus-announces-distribution-partnership-with-north-america-s-leading-wholesale-distr-scnx-20231012monthly0.5https://www.biopharmawatch.com/news/SCNX/superlatus-newly-merged-with-trxade-health-acquires-the-assets-of-spero-foods-a-plant-base-scnx-20231004monthly0.5https://www.biopharmawatch.com/news/SCNX/superlatus-innovates-151-billion-us-snacking-market-with-pulse-based-protein-twists-under--scnx-20230824monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-health-inc-announces-closing-of-acquisition-of-superlatus-inc-scnx-20230731monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-health-inc-amends-definitive-merger-agreement-with-superlatus-inc-scnx-20230714monthly0.5https://www.biopharmawatch.com/news/SCNX/superlatus-inc-and-trxade-health-inc-sign-definitive-merger-agreement-to-create-a-global-s-scnx-20230630monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-health-inc-issues-correction-to-press-release-announcing-its-anticipated-combinatio-scnx-20230623monthly0.5https://www.biopharmawatch.com/news/SCNX/superlatus-inc-to-combine-with-trxade-health-inc-to-create-a-global-food-consolidation-pla-scnx-20230623monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-health-inc-s-board-of-directors-approves-reverse-stock-split-lutz-florida-scnx-20230621monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-health-reports-first-quarter-gross-margin-of-69-and-q1-2023-financial-results-conti-scnx-20230515monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-health-reports-16-revenue-growth-and-year-end-2022-financial-results-continues-nati-scnx-20230327monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-health-reports-third-quarter-gross-margin-of-58-and-q3-2022-financial-results-conti-scnx-20221107monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-health-announces-pricing-of-1-8-million-registered-direct-offering-lutz-fl-accesswi-scnx-20221004monthly0.5https://www.biopharmawatch.com/news/SCNX/tr-x-ade-health-inc-taps-advisory-board-member-and-leading-pharmaceutical-industry-expert--scnx-20221003monthly0.5https://www.biopharmawatch.com/news/SCNX/correction-notice-to-trxade-health-press-release-reporting-second-quarter-revenue-growth-o-scnx-20220725monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-health-reports-second-quarter-revenue-growth-of-73-and-q2-2022-financial-results-co-scnx-20220725monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-health-reports-first-quarter-revenue-growth-of-6-and-q1-2022-financial-results-cont-scnx-20220509monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-health-reports-year-end-2021-financial-results-continues-nationwide-expansion-of-br-scnx-20220328monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-health-inc-to-participate-in-the-2022-virtual-growth-conference-presented-by-maxim--scnx-20220315monthly0.5https://www.biopharmawatch.com/news/SCNX/coborn-s-inc-and-bonum-health-a-trxade-health-company-ink-telemedicine-deal-to-deploy-deep-scnx-20220223monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-health-forms-joint-venture-sosrx-com-to-expand-medication-accessibility-via-manufac-scnx-20220215monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-health-to-present-at-aegis-virtual-conference-tampa-fl-accesswire-scnx-20220209monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-health-inc-announces-resumption-of-modified-stock-repurchase-program-tampa-fl-acces-scnx-20211213monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-health-reports-third-quarter-2021-financial-results-third-quarter-2021-revenue-incr-scnx-20211025monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-health-reports-second-quarter-2021-financial-results-q2-2021-gross-profit-margin-ex-scnx-20210726monthly0.5https://www.biopharmawatch.com/news/SCNX/winn-dixie-southeastern-grocers-inc-and-bonum-health-trxade-health-company-ink-telemedicin-scnx-20210721monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-group-inc-announces-name-change-to-trxade-health-inc-tampa-fl-accesswire-scnx-20210528monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-group-reports-record-first-quarter-2021-financial-results-first-quarter-revenues-in-scnx-20210426monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-group-to-present-at-planet-microcap-showcase-ceo-suren-ajjarapu-to-present-wednesda-scnx-20210409monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-group-reports-annual-revenue-growth-of-130-and-year-end-2020-financial-results-cont-scnx-20210329monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-group-to-present-at-the-diamond-equity-research-emerging-growth-invitational-tampa--scnx-20201118monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-group-to-present-at-the-virtual-fall-investor-summit-tampa-fl-scnx-20201110monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-group-reports-record-third-quarter-2020-financial-results-revenues-increase-174-to--scnx-20201026monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-group-announces-launch-of-bonum-b2b-platform-bonum-bundles-telehealth-a-covid-19-ri-scnx-20200811monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-group-to-report-second-quarter-2020-results-of-operations-on-monday-scnx-20200715monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-group-announces-addition-to-the-russell-microcap-index-company-provides-reminder-re-scnx-20200623monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-group-to-deliver-virtual-presentation-on-june-24th-2020-at-11-30-a-m-eastern-time-m-scnx-20200615monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-group-inc-withdraws-its-previously-filed-fda-emergency-use-authorization-for-rapid--scnx-20200507monthly0.5https://www.biopharmawatch.com/news/SCNX/tr-x-ade-group-reports-first-quarter-2020-financial-results-q1-2020-revenues-increase-46-t-scnx-20200504monthly0.5https://www.biopharmawatch.com/news/SCNX/tr-x-ade-group-inc-sets-date-for-2020-annual-meeting-of-stockholders-tampa-fl-accesswire-a-scnx-20200402monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-group-inc-files-fda-emergency-use-authorization-for-rapid-covid-19-testing-kit-tamp-scnx-20200401monthly0.5https://www.biopharmawatch.com/news/SCNX/tr-x-ade-group-inc-reports-2019-results-delivered-2019-annual-revenues-of-7-43-million-94--scnx-20200330monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-group-inc-announces-exercise-of-overallotment-option-by-underwriters-tampa-fl-scnx-20200224monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-group-inc-announces-closing-of-firm-commitment-common-stock-offering-tampa-fl-scnx-20200218monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-group-inc-announces-uplisting-to-nasdaq-capital-market-pricing-of-5-2-million-firm--scnx-20200213monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-group-inc-s-wholly-owned-bonum-health-subsidiary-teams-up-with-benzer-pharmacy-plan-scnx-20191121monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-group-inc-charter-of-the-nominating-and-corporate-governance-committee-effective-scnx-20191120monthly0.5https://www.biopharmawatch.com/news/SCNX/trxade-group-generates-record-revenues-in-third-quarter-of-2019-revenue-growth-of-173-to-2-scnx-20191031monthly0.5https://www.biopharmawatch.com/news/SCNX/charter-of-audit-committee-trxade-group-inc-the-company-audit-committee-charter-role-the-a-scnx-20191028monthly0.5https://www.biopharmawatch.com/news/SCNX/tr-x-ade-group-inc-announces-acquisition-of-independent-specialty-pharmacy-tampa-fl-octobe-scnx-20181017monthly0.5https://www.biopharmawatch.com/news/SCNX/proforma-financial-statements-year-ending-scnx-20170303monthly0.5https://www.biopharmawatch.com/news/SCNX/tr-x-ade-group-inc-completes-restructuring-tampa-fl-january-6-th-2017-trxade-group-inc-otc-scnx-20161231monthly0.5https://www.biopharmawatch.com/news/SCNX/tr-x-ade-group-inc-appointments-independent-director-tampa-fl-august-24-th-2016-trxade-gro-scnx-20160825monthly0.5https://www.biopharmawatch.com/news/SCNX/tr-x-ade-group-inc-expands-its-board-of-directors-with-appointment-of-independent-director-scnx-20150318monthly0.5https://www.biopharmawatch.com/news/SCNX/tr-x-ade-group-inc-expands-its-board-of-directors-with-appointment-of-independent-director-scnx-20141223monthly0.5https://www.biopharmawatch.com/news/ERNA/eterna-therapeutics-announces-9-2-million-convertible-debt-and-warrant-financing-erna-20231214monthly0.5https://www.biopharmawatch.com/news/ERNA/eterna-therapeuticsinvestor-presentation-august-2023-1-eterna-therapeutics-inc-this-presen-erna-20230802monthly0.5https://www.biopharmawatch.com/news/ERNA/eterna-therapeutics-reports-financial-results-for-fourth-quarter-and-full-year-2022-and-re-erna-20230320monthly0.5https://www.biopharmawatch.com/news/ERNA/eterna-therapeuticscompany-overview-november-2022-1-eterna-therapeutics-inc-legal-notices--erna-20221109monthly0.5https://www.biopharmawatch.com/news/ERNA/brooklyn-immunotherapeutics-announces-receipt-of-nasdaq-notification-regarding-minimum-bid-erna-20220617monthly0.5https://www.biopharmawatch.com/news/ERNA/brooklyn-immunotherapeutics-announces-changes-to-executive-management-matt-angel-ph-d-appo-erna-20220531monthly0.5https://www.biopharmawatch.com/news/ERNA/brooklyn-immunotherapeutics-announces-receipt-of-notice-from-nasdaq-regarding-delayed-fili-erna-20220527monthly0.5https://www.biopharmawatch.com/news/ERNA/brooklyn-immunotherapeutics-announces-fourth-quarter-and-full-year-2021-financial-results--erna-20220415monthly0.5https://www.biopharmawatch.com/news/ERNA/brooklyn-immunotherapeutics-announces-closing-of-12-million-private-placement-new-york-erna-20220309monthly0.5https://www.biopharmawatch.com/news/ERNA/mrna-engineered-cell-genetic-medicines-november-2021-a-platform-company-in-cell-gene-editi-erna-20211112monthly0.5https://www.biopharmawatch.com/news/ERNA/brooklyn-immunotherapeutics-to-move-stock-exchange-listing-to-nasdaq-ticker-symbol-to-rema-erna-20211014monthly0.5https://www.biopharmawatch.com/news/ERNA/brooklyn-immunotherapeutics-provides-highlights-of-shareholder-update-call-from-erna-20210920monthly0.5https://www.biopharmawatch.com/news/ERNA/dear-brooklyn-immunotherapeutics-inc-brooklyn-shareholder-we-are-pleased-to-announce-that--erna-20210914monthly0.5https://www.biopharmawatch.com/news/ERNA/september-2021-mrna-engineered-cell-cytokine-medicines-a-platform-company-in-cell-gene-edi-erna-20210909monthly0.5https://www.biopharmawatch.com/news/ERNA/brooklyn-immunotherapeutics-announces-adjournment-of-annual-meeting-of-stockholders-due-to-erna-20210820monthly0.5https://www.biopharmawatch.com/news/ERNA/brooklyn-immunotherapeutics-announces-second-quarter-2021-financial-results-erna-20210812monthly0.5https://www.biopharmawatch.com/news/ERNA/brooklyn-immunotherapeutics-welcomes-jay-sial-as-chief-administrative-officer-brooklyn-ny-erna-20210713monthly0.5https://www.biopharmawatch.com/news/ERNA/brooklyn-immunotherapeutics-completes-acquisition-of-novellus-therapeutics-acquisition-adv-erna-20210719monthly0.5https://www.biopharmawatch.com/news/ERNA/brooklyn-immunotherapeutics-welcomes-dr-kevin-a-d-amour-as-chief-scientific-officer-brookl-erna-20210608monthly0.5https://www.biopharmawatch.com/news/ERNA/howard-j-federoff-md-phd-appointed-chief-executive-officer-of-brooklyn-immunotherapeutics--erna-20210406monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-announces-proposed-reverse-stock-split-ratio-and-anticipated-closing-of-merge-erna-20210323monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-announces-approval-of-merger-with-brooklyn-immunotherapeutics-by-stockholders-erna-20210315monthly0.5https://www.biopharmawatch.com/news/ERNA/independent-advisory-firm-iss-recommends-ntn-stockholders-vote-for-proposed-merger-and-ass-erna-20210308monthly0.5https://www.biopharmawatch.com/news/ERNA/brooklyn-immunotherapeutics-announces-initiation-of-phase-2-trial-of-irx-2-in-combination--erna-20210209monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-announces-date-of-special-meeting-of-stockholders-to-vote-on-proposed-merger--erna-20210203monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-inc-receives-noncompliance-notice-from-nyse-american-erna-20210115monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-inc-reports-third-quarter-2020-results-erna-20201113monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-enters-asset-purchase-agreement-to-sell-entertainment-and-advertising-assets--erna-20200918monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-inc-and-brooklyn-immunotherapeutics-llc-enter-into-definitive-merger-agreemen-erna-20200813monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-inc-receives-noncompliance-notice-from-nyse-american-erna-20200812monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-inc-reports-second-quarter-2020-results-erna-20200807monthly0.5https://www.biopharmawatch.com/news/ERNA/nyse-regulation-accepts-plan-for-ntn-buzztime-inc-to-regain-compliance-by-september-2021-erna-20200615monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-inc-reports-first-quarter-2020-results-erna-20200519monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-inc-receives-noncompliance-notice-from-nyse-american-erna-20200330monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-inc-reports-fourth-quarter-and-full-year-2019-results-erna-20200317monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-signs-definitive-agreement-to-sell-stump-trivia-for-1-4-million-continues-emp-erna-20200114monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-appoints-game-development-expert-michael-gottlieb-to-the-board-jeff-berg-and--erna-20191126monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-inc-reports-third-quarter-2019-results-grew-cash-flow-from-operations-to-1-8--erna-20191030monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-announces-ceo-transition-ram-krishnan-to-depart-cfo-allen-wolff-to-act-as-interim-ceo-erna-20190917monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-announces-board-transition-erna-20190903monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-inc-reports-second-quarter-2019-results-signs-repeat-customer-for-3-million-d-erna-20190809monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-inc-reports-first-quarter-2019-results-launches-buzztime-entertainment-app-in-erna-20190513monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-inc-reports-fourth-quarter-and-full-year-2018-results-grew-q4-2018-revenue-12-erna-20190320monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-exploring-strategic-alternatives-erna-20181207monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-inc-reports-third-quarter-2018-results-grew-revenue-15-5-to-6-0-million-up-fr-erna-20181107monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-inc-reports-second-quarter-2018-results-grew-revenue-to-5-7-million-up-from-5-erna-20180802monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-announces-1-6-million-registered-direct-offering-of-common-stock-erna-20180627monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-inc-reports-first-quarter-2018-results-grew-revenue-to-5-8-million-up-10-from-erna-20180509monthly0.5https://www.biopharmawatch.com/news/ERNA/nyse-regulation-accepts-plan-for-ntn-buzztime-inc-to-regain-compliance-by-march-2019-erna-20180430monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-inc-receives-noncompliance-notice-from-nyse-american-erna-20180323monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-inc-reports-fourth-quarter-and-full-year-2017-results-annual-gross-margins-of-erna-20180306monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-inc-reports-third-quarter-2017-results-gross-margin-reaches-70-erna-20171107monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-inc-reports-second-quarter-2017-results-erna-20170802monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-appoints-two-new-independent-members-to-the-board-of-directors-erna-20170710monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-inc-reports-first-quarter-2017-results-records-gaap-net-loss-of-90-000-a-1-mi-erna-20170503monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-announces-registered-direct-offering-of-common-stock-erna-20170425monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-announces-registered-direct-offering-of-common-stock-erna-20170327monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-inc-expands-partnership-with-buffalo-wild-wings-and-reports-fourth-quarter-an-erna-20170306monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-inc-reports-third-quarter-2016-results-receives-2-7-million-in-net-proceeds-s-erna-20161108monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-announces-registered-direct-offering-of-common-stock-erna-20161101monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-inc-reports-second-quarter-2016-results-improves-net-loss-by-1-8-million-to-8-erna-20160803monthly0.5https://www.biopharmawatch.com/news/ERNA/buzztime-announces-anticipated-effective-date-of-reverse-forward-stock-split-carlsbad-ca-erna-20160607monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-inc-reports-first-quarter-2016-results-launches-order-and-payment-at-buffalo--erna-20160506monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-inc-amends-credit-agreement-increasing-access-to-short-term-capital-erna-20160311monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-inc-reports-fourth-quarter-2015-results-achieves-adjusted-ebitda-positive-for-erna-20160311monthly0.5https://www.biopharmawatch.com/news/ERNA/presentation-safe-harbor-this-presentation-contains-forward-looking-statements-which-refle-erna-20160211monthly0.5https://www.biopharmawatch.com/news/ERNA/nyse-accepts-plan-for-ntn-buzztime-inc-to-regain-compliance-by-may-2017-erna-20160202monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-inc-preannounces-fourth-quarter-2015-metrics-increased-site-count-for-the-thi-erna-20160128monthly0.5https://www.biopharmawatch.com/news/ERNA/safe-harbor-this-presentation-contains-forward-looking-statements-which-reflect-management-erna-20151202monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-inc-receives-noncompliance-notice-from-erna-20151116monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-inc-reports-third-quarter-2015-results-increased-site-count-for-the-second-qu-erna-20151105monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-inc-reports-second-quarter-2015-results-grew-revenue-8-sequentially-erna-20150806monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-inc-reports-first-quarter-2015-results-the-beond-platform-reaches-43-of-the-i-erna-20150507monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-inc-secures-new-credit-agreement-increases-financial-flexibility-and-reduces--erna-20150416monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-inc-reports-fourth-quarter-and-full-year-2014-results-the-beond-platform-reac-erna-20150326monthly0.5https://www.biopharmawatch.com/news/ERNA/ntn-buzztime-names-allen-wolff-chief-financial-officer-erna-20141219monthly0.5https://www.biopharmawatch.com/news/ERNA/we-entertain-consumers-in-ways-that-create-long-term-value-for-merchants-we-put-play-to-wo-erna-20140311monthly0.5https://www.biopharmawatch.com/news/ERNA/press-release-ntn-8kex99-1-htm-erna-20130328monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-corp-announces-3-5-million-registered-direct-offering-priced-at-the-mar-lexx-20251215monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-corp-announces-4-0-million-registered-direct-offering-priced-at-the-mar-lexx-20250926monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-announces-2-million-registered-direct-offering-of-common-stock-kelowna-british-col-lexx-20250425monthly0.5https://www.biopharmawatch.com/news/LEXX/kelowna-bc-accesswire-lexx-20241015monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-releases-strategic-letter-from-the-outgoing-ceo-kelowna-british-columbia-lexx-20240905monthly0.5https://www.biopharmawatch.com/news/LEXX/positive-interim-body-weight-results-from-lexaria-s-diabetes-animal-study-dehydratech-appe-lexx-20240717monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-announces-3-6-million-registered-direct-offering-priced-at-the-market-under-nasdaq-lexx-20240215monthly0.5https://www.biopharmawatch.com/news/LEXX/ceo-letter-to-stakeholders-according-to-the-wall-street-journal-near-the-end-of-2023-there-lexx-20240124monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-s-patented-technology-improved-the-oral-performance-of-the-rybelsus-branded-glp-1--lexx-20240104monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-enters-new-global-exclusive-collaboration-and-license-agreement-with-sulfosyn-glob-lexx-20231013monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-granted-two-new-patents-in-canada-lexaria-now-holds-37-granted-patents-world-wide--lexx-20231012monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-incorporates-new-subsidiary-for-cpg-products-and-updates-human-nicotine-study-kelo-lexx-20230728monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-announces-pricing-of-2-0-million-public-offering-kelowna-bc-accesswire--lexx-20230511monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-s-dehydratech-cbd-diabetes-study-demonstrates-weight-loss-improved-triglyceride-an-lexx-20230302monthly0.5https://www.biopharmawatch.com/news/LEXX/ceo-letter-to-stakeholders-as-2022-came-to-a-close-it-isn-t-news-that-nearly-all-companies-lexx-20230117monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-s-human-clinical-hypertension-study-a-success-hyper-h21-4-using-dehydratech-cbd-ev-lexx-20221027monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-provides-annual-letter-from-the-ceo-kelowna-british-columbia-lexx-20220127monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-s-human-clinical-study-delivers-effective-and-safe-blood-pressure-reduction-result-lexx-20210907monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-s-dehydratech-cbd-lowers-blood-pressure-human-clinical-study-hyper-h21-1-evidences-lexx-20210729monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-drug-delivery-platform-enables-up-to-three-fold-increase-in-oral-delivery-of-antiv-lexx-20210615monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-s-dehydratech-tm-enabled-remdesivir-and-ebastine-effectively-inhibit-the-covid-19--lexx-20210603monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-issues-successful-results-from-first-2021-study-hyper-a21-1-up-to-2-178-more-cbd-d-lexx-20210506monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-appoints-new-chief-financial-officer-and-issues-consultant-warrants-kelowna-britis-lexx-20210415monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-corp-announces-uplisting-to-nasdaq-capital-market-and-pricing-of-9-6-mi-lexx-20210112monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-corp-otcqx-lxrp-lxx-cse-drug-delivery-platform-innovator-investor-prese-lexx-20201231monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-expands-covid-19-drug-research-program-utilizing-proprietary-dehydratech-remdesivi-lexx-20201222monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-s-patented-technology-significantly-enhances-oral-delivery-of-antiviral-drugs-demo-lexx-20201201monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-sells-non-pharmaceutical-thc-related-assets-for-cdn-3-85m-asset-sale-in-lexx-20201119monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-advances-2021-strategic-initiatives-lexaria-focusing-on-four-core-busin-lexx-20201105monthly0.5https://www.biopharmawatch.com/news/LEXX/altria-and-lexaria-conclude-phase-i-research-and-development-program-r-d-program-utilized--lexx-20200716monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-engages-investor-relations-and-capital-markets-advisory-firm-for-its-sh-lexx-20200629monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-announces-over-us-2-000-000-private-placement-kelowna-bc-accesswire-lexx-20200504monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-begins-coronavirus-covid-19-drug-delivery-program-kelowna-british-colum-lexx-20200319monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-provides-update-on-two-licensed-clients-kelowna-british-columbia-lexx-20200304monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-corp-and-cannadips-cbd-announce-definitive-technology-licensing-agreeme-lexx-20200114monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-ceo-discusses-strategic-outlook-lexaria-bioscience-corp-lexaria-or-the--lexx-20200109monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-announces-2-nd-tranche-closing-of-non-brokered-private-placement-kelowna-british-c-lexx-20191129monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-announces-closing-of-non-brokered-private-placement-kelowna-british-columbia-lexx-20191114monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-and-hill-street-beverage-co-enter-global-manufacturing-licensing-partne-lexx-20190724monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-enters-cbd-beverage-license-agreement-with-nic-s-beverages-kelowna-brit-lexx-20190710monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-announces-new-dehydratech-innovation-files-new-patents-new-enhanced-deh-lexx-20190604monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-s-dehydratech-tm-formulation-delivers-475-more-cbd-to-bloodstream-after-15-minutes-lexx-20190515monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-announces-cbd-beverage-formulation-license-agreement-with-nevada-based--lexx-20190507monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-engages-oak-hill-financial-inc-to-provide-investor-relations-services-k-lexx-20190415monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-renews-contracts-with-senior-management-and-cancels-options-kelowna-bri-lexx-20190409monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-begins-largest-cannabinoid-r-d-program-in-its-history-kelowna-british-c-lexx-20190320monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-warrant-exercises-kelowna-british-columbia-lexx-20190125monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-announces-partnership-with-altria-to-fund-research-and-development-of-d-lexx-20190115monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-issues-options-kelowna-british-columbia-lexx-20181214monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-expands-staff-issues-options-kelowna-british-columbia-lexx-20181207monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-submits-application-to-health-canada-for-research-license-and-appoints--lexx-20181126monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-launches-chrgd-kelowna-british-columbia-lexx-20181113monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-announces-increased-size-and-closing-of-private-placement-kelowna-briti-lexx-20181031monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-arranges-private-placement-financing-to-fund-new-laboratory-kelowna-bri-lexx-20181016monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-creates-and-brands-subsidiary-companies-kelowna-british-columbia-lexx-20181010monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-receives-three-patent-grants-and-two-notices-of-allowance-provides-patent-portfoli-lexx-20180907monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-announces-positive-blood-brain-barrier-results-lexaria-s-technology-del-lexx-20180830monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-announces-further-advancement-of-edibles-nicotine-testing-delivery-meas-lexx-20180809monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-and-hill-street-beverage-company-announce-definitive-agreement-for-cann-lexx-20180731monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-announces-2018-agm-results-and-corporate-update-kelowna-british-columbia-lexx-20180703monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-files-new-patent-application-for-enhancement-of-delivery-of-lipophilic-agents-acro-lexx-20180629monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-announces-exercises-of-existing-warrants-and-options-kelowna-british-columbia-lexx-20180619monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-announces-exercises-of-existing-warrants-enters-consulting-agreement-kelowna-briti-lexx-20180528monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-corp-receives-new-granted-patents-kelowna-british-columbia-lexx-20180523monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-announces-loi-with-hill-street-beverage-co-for-cannabis-infused-alcohol-free-beer--lexx-20180427monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-announces-human-clinical-study-on-cbd-absorption-underway-kelowna-british-columbia-lexx-20180423monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-achieves-significant-breakthrough-in-alternative-nicotine-delivery-technology-kelo-lexx-20180417monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-corp-receives-new-u-s-patent-allowance-for-cannabinoid-delivery-and-upd-lexx-20180411monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-announces-exercises-of-existing-warrants-enters-investor-relations-agreement-kelow-lexx-20180323monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-files-new-patent-application-for-enhanced-transdermal-delivery-system-kelowna-brit-lexx-20180320monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-and-neutrisci-enter-global-licensing-agreement-kelowna-british-columbia-lexx-20180226monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-announces-exercises-of-existing-warrants-kelowna-british-columbia-lexx-20180202monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-enters-licensing-agreement-with-canadian-cannabis-chocolate-manufacturer-kelowna-b-lexx-20180125monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-announces-exercises-of-existing-warrants-kelowna-british-columbia-lexx-20180117monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-upgrades-to-the-otcqx-market-kelowna-british-columbia-lexx-20180104monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-announces-exercises-of-existing-warrants-kelowna-british-columbia-lexx-20171222monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-announces-new-research-including-cannabinoid-topical-creams-and-nicotin-lexx-20171215monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-receives-u-s-patent-award-for-its-dehydratech-tm-delivery-of-thc-nsaids-lexx-20171213monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-announces-option-and-warrant-transactions-kelowna-british-columbia-lexx-20171201monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-announces-upcoming-investment-event-and-warrant-exercise-kelowna-british-columbia-lexx-20171127monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-bioscience-acquires-100-ownership-of-poviva-tea-llc-kelo-lexx-20171102monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-announces-upcoming-public-events-and-warrant-exercise-kelowna-british-columbia-lexx-20170922monthly0.5https://www.biopharmawatch.com/news/LEXX/university-of-british-columbia-to-perform-clinical-study-on-the-cardiovascular-and-cogniti-lexx-20170831monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-announces-attendance-at-two-cannabis-investment-conferences-and-issues-shares-for--lexx-20170829monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-announces-exercised-warrants-and-options-kelowna-bc-lexx-20170816monthly0.5https://www.biopharmawatch.com/news/LEXX/national-research-council-and-lexaria-bioscience-commence-laboratory-work-kelowna-british--lexx-20170720monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-awarded-australian-patent-for-cannabinoid-infused-edibles-kelowna-briti-lexx-20170718monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-s-appoints-new-acting-cfo-vancouver-british-columbia-lexx-20170605monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-s-ambarii-corporation-announces-loi-with-naturally-splendid-to-distribute-cbd-melt-lexx-20170530monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-featured-on-television-kelowna-bc-lexx-20170518monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-announces-research-on-nonsteroidal-anti-inflammatory-drugs-kelowna-bc-lexx-20170510monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-announces-r-d-on-nicotine-kelowna-bc-lexx-20170504monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-announces-million-dollar-research-and-development-program-kelowna-bc-lexx-20170502monthly0.5https://www.biopharmawatch.com/news/LEXX/existing-warrants-exercised-for-lexaria-kelowna-bc-lexx-20170427monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-welcomes-canada-s-proposed-cannabis-legislation-kelowna-bc-lexx-20170418monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-and-neutrisci-enter-cannabinoid-joint-venture-kelowna-bc-lexx-20170410monthly0.5https://www.biopharmawatch.com/news/LEXX/existing-stock-option-and-warrant-exercises-for-lexaria-kelowna-bc-lexx-20170324monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-introduces-turbocbd-brand-of-high-absorption-full-spectrum-hemp-oil-capsules-kelow-lexx-20170322monthly0.5https://www.biopharmawatch.com/news/LEXX/design-phase-underway-for-studies-to-be-conducted-by-national-research-council-and-lexaria-lexx-20170314monthly0.5https://www.biopharmawatch.com/news/LEXX/existing-stock-option-and-warrant-exercises-for-lexaria-kelowna-bc-lexx-20170310monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-receives-notice-of-its-first-patent-to-be-granted-in-australia-for-cannabinoid-inf-lexx-20170227monthly0.5https://www.biopharmawatch.com/news/LEXX/stock-option-exercises-and-debt-settlement-for-lexaria-kelowna-bc-lexx-20170217monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-signs-master-collaborative-research-agreement-kelowna-bc-lexx-20170208monthly0.5https://www.biopharmawatch.com/news/LEXX/ceo-clips-features-lexaria-on-the-bnn-channel-kelowna-bc-lexx-20170131monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-receives-us-98-000-from-exercise-of-options-and-warrants-kelowna-bc-lexx-20170126monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-and-neutrisci-announce-successful-cannabinoid-tablet-development-and-positive-resu-lexx-20170119monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-receives-us-33-029-25-from-exercise-of-options-and-warrants-kelowna-bc-lexx-20170110monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-extends-investor-relations-agreement-kelowna-bc-lexx-20161222monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-files-international-cannabinoid-patent-applications-kelowna-bc-lexx-20161219monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-receives-us-737-500-from-exercise-of-warrants-kelowna-bc-lexx-20161202monthly0.5https://www.biopharmawatch.com/news/LEXX/hempco-food-and-fibre-inc-to-utilize-lexaria-s-patented-technology-kelowna-bc-lexx-20161129monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-enters-memorandum-of-understanding-establishing-a-joint-venture-with-neutrisci-int-lexx-20161122monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-announces-price-cuts-on-vipova-tm-tea-products-kelowna-bc-lexx-20161115monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-option-and-warrant-exercise-and-issuance-kelowna-bc-lexx-20161102monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-bioscience-announces-issuance-of-u-s-patent-for-cannabinoid-infused-edibles-kelown-lexx-20161026monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-engages-consultants-and-issues-options-kelowna-bc-lexx-20161011monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-appoints-new-auditors-kelowna-bc-lexx-20161006monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-closes-final-tranche-of-fully-subscribed-financing-kelowna-bc-lexx-20160831monthly0.5https://www.biopharmawatch.com/news/LEXX/new-loi-signed-to-out-license-lexaria-s-technology-kelowna-bc-lexx-20160830monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-closes-financing-enhances-investor-relations-agreement-k-lexx-20160811monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-signs-letter-of-intent-for-second-technology-out-licensing-agreement-including-pla-lexx-20160810monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-enters-loan-agreement-kelowna-bc-lexx-20160725monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-engages-respected-consulting-and-finance-firms-kelowna-bc-lexx-20160721monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-receives-notice-of-allowance-of-first-patent-by-us-patent-office-kelowna-bc-lexx-20160712monthly0.5https://www.biopharmawatch.com/news/LEXX/for-canadian-distribution-only-lexaria-intends-to-complete-an-equity-financing-of-us-300-0-lexx-20160705monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-closes-financing-enters-investor-relations-agreement-iss-lexx-20160606monthly0.5https://www.biopharmawatch.com/news/LEXX/for-canadian-distribution-only-lexaria-intends-to-complete-an-equity-financing-of-cdn-100--lexx-20160531monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-definitive-technology-licensing-agreement-reached-kelowna-bc-lexx-20160520monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-confirms-name-change-kelowna-bc-lexx-20160509monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-announces-change-of-cfo-and-director-and-corporate-updat-lexx-20160427monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-closes-tranche-of-financing-and-issues-shares-to-preside-lexx-20160415monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-closes-first-tranche-of-financing-and-reports-results-of-lexx-20160329monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-announces-groundbreaking-technology-licensing-agreement--lexx-20160322monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-operations-update-kelowna-bc-lexx-20160308monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-proposes-to-change-name-to-lexaria-bioscience-corp-kelow-lexx-20160219monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-signs-distribution-agreement-with-telluride-coffee-kelow-lexx-20160128monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-s-technology-demonstrates-positive-test-results-for-nitr-lexx-20160120monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-buyins-net-consults-to-lexaria-corp-to-surveil-short-sellers-and-lexx-20160115monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-studies-nitric-oxide-levels-in-human-subjects-kelowna-bc-lexx-20160113monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-forward-stock-split-kelowna-bc-lexx-20151216monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-news-release-lexaria-files-additional-new-patent-pendings-kelown-lexx-20151214monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-enters-investors-relations-contract-with-radius-kelowna--lexx-20151214monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-financing-close-kelowna-bc-lexx-20151210monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-news-release-lexaria-forward-stock-split-kelowna-bc-lexx-20151207monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-news-release-lexaria-and-vipova-tm-holiday-sale-kelowna-bc-lexx-20151125monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-news-release-lexaria-forward-stock-split-kelowna-bc-lexx-20151118monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-news-release-lexaria-products-sold-out-in-vegas-coffee-and-cocoa-lexx-20151117monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-news-release-lexaria-protein-bar-available-now-kelowna-bc-lexx-20151103monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-news-release-lexaria-announces-product-update-and-international--lexx-20151008monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-corp-to-present-on-cannabis-investor-webcast-tomorrow-ke-lexx-20151007monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-news-release-lexaria-energy-protein-bar-available-november-3-kel-lexx-20151006monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-partners-with-mjic-media-for-media-outreach-vancouver-lexx-20150923monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-news-release-ted-mckechnie-joins-lexaria-board-of-directors-kelo-lexx-20150916monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-s-technology-achieves-cannabidiol-absorption-rate-499-gr-lexx-20150824monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-issues-shares-as-per-management-contract-kelowna-bc-lexx-20150817monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-introduces-new-vipova-tm-prodcuts-kelowna-bc-lexx-20150812monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-hires-investor-relations-firm-kelowna-bc-lexx-20150811monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-laboratory-testing-and-sales-distribution-update-kelowna-bc-lexx-20150728monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-issues-shares-as-per-management-contract-kelowna-bc-lexx-20150722monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-lowers-prices-kelowna-bc-lexx-20150714monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-announces-definitive-agreement-kelowna-bc-lexx-20150626monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-supreme-court-of-canada-rules-in-favour-of-cannabis-edibles-kelo-lexx-20150623monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-focuses-on-technology-sells-burlington-mmpr-license-appl-lexx-20150612monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-files-u-s-utility-and-international-patent-applications--lexx-20150611monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-enters-services-contract-with-tdm-financial-kelowna-bc-m-lexx-20150608monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-updates-sales-channels-efforts-kelowna-bc-lexx-20150605monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-bioavailability-testing-to-commence-on-lexaria-s-patent-pending--lexx-20150520monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-closes-financing-and-announces-conference-participation--lexx-20150515monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-intellectual-property-update-kelowna-bc-lexx-20150515monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-launches-new-corporate-website-kelowna-bc-lexx-20150430monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-s-vipova-tm-tea-available-soon-at-amazon-com-kelowna-bc-lexx-20150408monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-updates-operations-kelowna-bc-lexx-20150407monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-s-new-president-from-biopharmaceutical-industry-kelowna--lexx-20150326monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lower-prices-for-vipova-tm-tea-due-to-production-efficiencies-ke-lexx-20150324monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-corp-to-present-at-cannabis-investor-webcast-kelowna-bc-lexx-20150311monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-letter-from-the-president-kelowna-bc-lexx-20150224monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-vipova-tm-by-lexaria-launches-national-sales-initiative-kelowna--lexx-20150223monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-hires-national-sales-strategist-and-sponsors-first-sales-lexx-20150213monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-updates-operations-kelowna-bc-lexx-20150204monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-maintains-otcqb-marketplace-status-kelowna-bc-lexx-20150202monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-announces-vipova-tm-website-for-cbd-research-and-direct--lexx-20150115monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-commissions-cannabinoid-education-series-kelowna-bc-lexx-20150108monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-vipova-tm-by-lexaria-announces-new-president-kelowna-bc-december-lexx-20141222monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-announces-name-change-of-poviva-tea-to-vipova-tm-tea-and-lexx-20141222monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-corp-to-present-at-cannabis-investor-webcast-kelowna-bc-lexx-20141215monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-closes-51-acquisition-of-poviva-tea-llc-kelowna-bc-lexx-20141212monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-oilfield-sale-completed-kelowna-bc-lexx-20141210monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-updates-burlington-license-application-kelowna-bc-lexx-20141209monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-enters-agreement-to-sell-belmont-lake-oil-assets-kelowna-lexx-20141201monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-and-enertopia-launch-medical-advisory-board-kelowna-bc-lexx-20141120monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-updates-medical-marijuana-and-cannabidiol-policies-kelow-lexx-20141118monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-health-wellness-business-plan-by-lexaria-kelowna-bc-lexx-20141113monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-continues-transformation-into-alternative-health-sector--lexx-20141112monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-closes-second-tranche-of-financing-kelowna-bc-lexx-20140926monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-news-release-national-medical-marihuana-outreach-plan-kelowna-bc-lexx-20140918monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-news-release-health-canada-marijuana-license-application-submitt-lexx-20140917monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-news-release-excellent-results-at-new-lexaria-oil-well-kelowna-b-lexx-20140916monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-announces-responsible-marijuana-policy-kelowna-bc-lexx-20140828monthly0.5https://www.biopharmawatch.com/news/LEXX/progress-at-lexaria-s-belmont-lake-oil-field-kelowna-bc-lexx-20140827monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-closes-first-tranche-of-financing-kelowna-bc-lexx-20140812monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-news-release-corporate-update-kelowna-bc-lexx-20140805monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-news-release-lexaria-issues-stock-options-kelowna-bc-lexx-20140724monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-news-release-municipal-approval-for-lexaria-enertopia-joint-vent-lexx-20140714monthly0.5https://www.biopharmawatch.com/news/LEXX/overwhelming-support-at-2014-lexaria-agm-kelowna-bc-lexx-20140617monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-news-release-lexaria-and-enertopia-update-loi-with-signed-defini-lexx-20140529monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-news-release-lexaria-announces-second-production-facility-and-ve-lexx-20140527monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-news-release-lexaria-appoints-former-chief-of-police-as-security-lexx-20140505monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-news-release-lexaria-adds-to-management-team-kelowna-bc-lexx-20140424monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-news-release-resignation-of-director-kelowna-bc-lexx-20140425monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-news-release-lexaria-welcomes-jeff-paikin-to-advisory-board-kelo-lexx-20140414monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-news-release-lexaria-s-first-marijuana-production-facility-kelow-lexx-20140410monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-news-release-lexaria-eliminates-193-333-in-debts-kelowna-bc-lexx-20140331monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-welcomes-new-medical-marijuana-expert-advisor-kelowna-bc-lexx-20140325monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-closes-1-272-000-financing-kelowna-bc-marketwired-lexx-20140321monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexaria-launches-awareness-program-via-agoracom-kelowna-bc-marke-lexx-20140312monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-enters-social-media-contract-kelowna-bc-lexx-20140310monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-news-release-lexaria-enters-joint-venture-with-enertopia-corp-in-lexx-20140305monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexx-20140228monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexx-20140129monthly0.5https://www.biopharmawatch.com/news/LEXX/successful-new-oil-well-kelowna-bc-lexx-20131206monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-corp-announces-permits-received-for-drilling-of-new-well-kelowna-bc-lexx-20131127monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-news-release-debt-successfully-refinanced-kelowna-bc-lexx-20131113monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-news-release-new-well-to-be-drilled-at-belmont-lake-field-kelown-lexx-20131104monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-news-release-lexaria-announces-well-recompletion-kelowna-bc-lexx-20131003monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-corp-provides-mississippi-oil-field-update-kelowna-bc-lexx-20130923monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-corp-provides-third-quarter-results-kelowna-bc-lexx-20130912monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-corp-engages-corporate-communications-firm-kelowna-bc-lexx-20130826monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-corp-grants-options-kelowna-bc-lexx-20130618monthly0.5https://www.biopharmawatch.com/news/LEXX/lexaria-corp-annual-general-meeting-results-vancouver-lexx-20130501monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexx-20130213monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexx-20121010monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexx-20120928monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexx-20120627monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexx-20120504monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexx-20110713monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexx-20110629monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexx-20110622monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexx-20110202monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexx-20110105monthly0.5https://www.biopharmawatch.com/news/LEXX/filed-by-newsfilecorp-com-lexx-20101105monthly0.5https://www.biopharmawatch.com/news/LEXX/announcing-closing-of-private-placement-md-filed-by-filing-services-canada-inc-403-717-389-lexx-20091229monthly0.5https://www.biopharmawatch.com/news/KAPA/kairos-pharma-recaps-important-acquisitions-and-details-plans-for-the-balance-of-2026-in-l-kapa-20260604monthly0.5https://www.biopharmawatch.com/news/KAPA/kairos-pharma-to-present-positive-safety-and-efficacy-data-from-phase-2-prostate-cancer-tr-kapa-20251007monthly0.5https://www.biopharmawatch.com/news/KAPA/kairos-pharma-announces-positive-interim-efficacy-analysis-of-phase-2-trial-of-env105-in-a-kapa-20250918monthly0.5https://www.biopharmawatch.com/news/KAPA/kairos-pharma-announces-virtual-kol-event-to-provide-perspectives-on-env105-interim-effica-kapa-20250911monthly0.5https://www.biopharmawatch.com/news/KAPA/kairos-pharma-announces-presentation-of-new-phase-1-data-on-env105-combination-therapy-in--kapa-20250903monthly0.5https://www.biopharmawatch.com/news/KAPA/kairos-pharma-announces-positive-safety-results-from-phase-2-trial-of-env-105-in-advanced--kapa-20250715monthly0.5https://www.biopharmawatch.com/news/KAPA/dr-john-yu-chief-executive-officer-kairos-pharma-ltd-2355-westwood-boulevard-suite-139-los-kapa-20250609monthly0.5https://www.biopharmawatch.com/news/KAPA/kairos-pharma-ltd-announces-new-data-on-small-molecule-gitr-ligand-agonist-kros-101-as-pro-kapa-20250603monthly0.5https://www.biopharmawatch.com/news/KAPA/kairos-pharma-ltd-provides-letter-to-stockholders-kapa-20250424monthly0.5https://www.biopharmawatch.com/news/KAPA/kairos-pharma-ltd-announces-peer-reviewed-publication-highlighting-potentially-groundbreak-kapa-20250320monthly0.5https://www.biopharmawatch.com/news/KAPA/kairos-pharma-presents-preclinical-data-on-its-investigational-compounds-kros-101-and-kros-kapa-20250226monthly0.5https://www.biopharmawatch.com/news/KAPA/kairos-pharma-oral-presentation-on-its-investigational-compound-kros-101-at-the-13-th-aacr-kapa-20250206monthly0.5https://www.biopharmawatch.com/news/KAPA/kairos-pharma-approved-to-dual-list-on-upstream-trading-to-begin-kapa-20241119monthly0.5https://www.biopharmawatch.com/news/KAPA/kairos-pharma-enters-agreement-with-precheck-health-services-to-develop-biomarkers-to-iden-kapa-20240924monthly0.5https://www.biopharmawatch.com/news/KAPA/kairos-pharma-closing-of-6-2-million-initial-public-offering-kapa-20240917monthly0.5https://www.biopharmawatch.com/news/RGNT/regentis-biomaterials-announces-pricing-of-a-6-5-million-private-placement-herzliya-il-rgnt-20260617monthly0.5https://www.biopharmawatch.com/news/RGNT/regentis-to-commence-european-surgeon-training-for-gelrinc-in-knee-cartilage-repair-as-com-rgnt-20260608monthly0.5https://www.biopharmawatch.com/news/RGNT/notice-of-an-annual-general-meeting-of-the-shareholders-to-be-held-on-thursday-july-2-2026-rgnt-20260604monthly0.5https://www.biopharmawatch.com/news/RGNT/notice-of-an-annual-general-meeting-of-the-shareholders-to-be-held-on-thursday-july-2-2026-rgnt-20260528monthly0.5https://www.biopharmawatch.com/news/RGNT/regentis-biomaterials-reports-2025-financial-results-and-provides-business-update-7-4-mill-rgnt-20260224monthly0.5https://www.biopharmawatch.com/news/RGNT/regentis-expands-its-european-clinical-site-network-to-support-its-commercial-and-clinical-rgnt-20260217monthly0.5https://www.biopharmawatch.com/news/RGNT/regentis-gelrinc-establishes-long-term-durability-of-cartilage-repair-through-quantitative-rgnt-20260106monthly0.5https://www.biopharmawatch.com/news/RGNT/regentis-biomaterials-granted-new-u-s-patent-for-its-off-the-shelf-regenerative-cartilage--rgnt-20251218monthly0.5https://www.biopharmawatch.com/news/RGNT/regentis-biomaterials-ltd-announces-pricing-of-initial-public-offering-herzliya-israel-rgnt-20251203monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-reports-2017-third-quarter-financial-results-a-nd-development-program-update-s-prog-govx-20171109monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-reports-2017-second-quarter-financial-results-and-provides-corporate-update-continu-govx-20170807monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-reports-2017-first-quarter-financial-results-and-development-program-updates-zika-v-govx-20170508monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-reports-2016-year-end-financial-results-atlanta-ga-govx-20170324monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-reports-2016-third-quarter-financial-results-and-provides-corporate-update-updates--govx-20161114monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-reports-2016-second-quarter-financial-results-and-provides-corporate-update-ongoing-govx-20160805monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-reports-2016-first-quarter-financial-results-atlanta-ga-govx-20160504monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-reports-2015-year-end-financial-results-and-provides-corporate-update-atlanta-ga-govx-20160316monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-to-develop-vaccine-against-zika-virus-collaboration-with-university-of-georgia-infe-govx-20160201monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-begins-oncology-immunotherapy-program-geovax-to-apply-its-mva-vlp-vaccine-technolog-govx-20151209monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-reports-2015-third-quarter-financial-results-atlanta-ga-govx-20151112monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-reports-2015-second-quarter-financial-results-and-provides-corporate-update-ebola-v-govx-20150804monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-reports-2015-first-quarter-financial-results-and-provides-corporate-update-ebola-ma-govx-20150514monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-appoints-industry-veteran-to-its-board-of-directors-randal-d-chase-ph-d-brings-exte-govx-20150323monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-reports-2014-year-end-financial-results-progress-report-outlined-on-ebola-marburg-a-govx-20150320monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-announces-equity-financing-of-up-to-6-million-funds-to-be-used-to-advance-the-compa-govx-20150226monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-reports-2014-third-quarter-financial-results-atlanta-g-a-govx-20141111monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-announces-initiation-of-ebola-vaccine-development-program-geovax-developing-vaccine-govx-20141002monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-reports-2014-second-quarter-financial-results-and-provides-corporate-update-atlanta-govx-20140807monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-reports-2014-first-quarter-financial-results-and-provides-corporate-update-atlanta--govx-20140501monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-labs-reports-2013-financial-results-and-provides-corporate-update-atlanta-ga-govx-20140305monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-announces-1-65m-private-placement-atlanta-ga-govx-20131212monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-reports-2013-third-quarter-financial-results-completion-of-phase-1-therapeutic-hiv--govx-20131112monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-dna-mva-vaccine-elicits-sustained-antibody-responses-to-hiv-new-clinical-data-from--govx-20131009monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-reports-financial-results-for-the-second-quarter-and-first-half-2013-and-provides-c-govx-20130812monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-labs-reports-2013-first-quarter-financial-results-and-provides-clinical-development-govx-20130502monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-labs-reports-2012-financial-results-and-progress-two-ongoing-clinical-trials-for-pr-govx-20130311monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-reports-2012-third-quarter-financial-results-atlanta-ga-govx-20121114monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-reports-2012-second-quarter-financial-results-three-hiv-aids-vaccine-human-clinical-govx-20120813monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-labs-reports-2012-first-quarter-financial-results-data-from-phase-2a-preventive-hiv-govx-20120515monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-labs-reports-2011-financial-results-two-ongoing-clinical-trials-for-hiv-aids-vaccin-govx-20120328monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-announces-private-placement-of-2-2-million-atlanta-govx-20120320monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-labs-inc-announces-private-offering-of-common-stock-and-warrants-offering-expected--govx-20120104monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-labs-inc-announces-nine-month-2011-govx-20111110monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-labs-inc-announces-second-quarter-financial-results-clinical-development-with-hiv-a-govx-20110812monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-labs-inc-announces-first-quarter-financial-results-atlanta-ga-govx-20110427monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-labs-reports-fourth-quarter-and-year-end-2010-financial-results-atlanta-ga-govx-20110225monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-labs-inc-announces-nine-month-2010-govx-20101109monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-labs-inc-announces-six-month-2010-govx-20100805monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-labs-govx-20100728monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-labs-announces-postponement-of-public-offering-atlanta-ga-govx-20100630monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-labs-inc-announces-first-quarter-financial-results-atlanta-ga-govx-20100505monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-labs-announces-reverse-stock-split-applies-for-listing-on-nasdaq-1-50-reverse-split-govx-20100427monthly0.5https://www.biopharmawatch.com/news/GOVX/at-the-company-robert-mcnally-president-ceo-678-384-7220-or-rmcnally-geovax-com-at-the-inv-govx-20100330monthly0.5https://www.biopharmawatch.com/news/GOVX/at-the-company-robert-mcnally-president-ceo-678-384-7220-or-rmcnally-geovax-com-at-the-inv-govx-20100323monthly0.5https://www.biopharmawatch.com/news/GOVX/at-the-company-robert-mcnally-678-384-7220-or-rmcnally-geovax-com-at-financial-relations-b-govx-20100301monthly0.5https://www.biopharmawatch.com/news/GOVX/at-the-company-robert-mcnally-678-384-7220-or-rmcnally-geovax-com-at-financial-relations-b-govx-20091106monthly0.5https://www.biopharmawatch.com/news/GOVX/at-the-company-robert-mcnally-404-727-0971-or-rmcnally-geovax-com-at-financial-relations-b-govx-20090921monthly0.5https://www.biopharmawatch.com/news/GOVX/at-the-company-robert-mcnally-404-727-0971-or-rmcnally-geovax-com-at-financial-relations-b-govx-20090807monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-signs-hiv-aids-vaccine-proposal-with-health-and-hospital-system-of-cook-county-govx-20090618monthly0.5https://www.biopharmawatch.com/news/GOVX/financial-relations-board-leslie-loyet-312-640-6672-or-lloyet-mww-com-at-the-company-rober-govx-20090507monthly0.5https://www.biopharmawatch.com/news/GOVX/financial-relations-board-leslie-loyet-312-640-6672or-lloyet-mww-com-at-the-company-bob-mc-govx-20090312monthly0.5https://www.biopharmawatch.com/news/GOVX/financial-relations-board-tim-grace-312-640-6667-or-tgrace-mww-com-at-the-company-bob-mcna-govx-20090220monthly0.5https://www.biopharmawatch.com/news/GOVX/geo-vax-labs-inc-add-1-contacts-at-financial-relations-board-tim-grace-312-640-6667-or-tgr-govx-20090211monthly0.5https://www.biopharmawatch.com/news/GOVX/melanie-nimrodi-media-contact-312-546-3508-mnimrodi-frbir-com-at-the-company-robert-mcnall-govx-20081110monthly0.5https://www.biopharmawatch.com/news/GOVX/financial-relations-board-melanie-nimrodi-312-546-3508-or-mnimrodi-frbir-com-at-the-compan-govx-20081020monthly0.5https://www.biopharmawatch.com/news/GOVX/melanie-nimrodi-media-contact-312-546-3508-mnimrodi-frbir-com-at-the-company-robert-mcnall-govx-20080820monthly0.5https://www.biopharmawatch.com/news/GOVX/melanie-nimrodi-media-contact-312-546-3508-mnimrodi-frbir-com-at-the-company-robert-mcnall-govx-20080811monthly0.5https://www.biopharmawatch.com/news/GOVX/geovax-vivalis-media-contact-melanie-nimrodi-media-contact-steve-grobet-emmanuel-huynh-1-3-govx-20080722monthly0.5https://www.biopharmawatch.com/news/GOVX/melanie-nimrodi-media-contact-312-546-3508-mnimrodi-frbir-com-at-the-company-robert-mcnall-govx-20080707monthly0.5https://www.biopharmawatch.com/news/GOVX/media-information-for-immediate-release-contact-information-at-geovax-labs-inc-at-financia-govx-20080512monthly0.5https://www.biopharmawatch.com/news/GOVX/at-the-company-donald-hildebrand-jennifer-nelms-404-727-0971-info-geovax-com-for-immediate-govx-20080324monthly0.5https://www.biopharmawatch.com/news/GOVX/tim-grace-investor-contact-312-640-6667-melanie-nimrodi-media-contact-312-546-3508-mnimrod-govx-20080314monthly0.5https://www.biopharmawatch.com/news/GOVX/at-the-company-donald-hildebrand-jennifer-nelms-404-727-0971-for-immediate-release-02-nove-govx-20071106monthly0.5https://www.biopharmawatch.com/news/CVM/boone-boulevard-suite-802-vienna-va-22182-usa-telephone-703-506-9460-www-cel-sci-com-compa-cvm-20260614monthly0.5https://www.biopharmawatch.com/news/CVM/boone-boulevard-suite-802-company-contact-vienna-va-22182-usa-gavin-de-windt-telephone-703-cvm-20260511monthly0.5https://www.biopharmawatch.com/news/CVM/boone-boulevard-suite-802-vienna-va-22182-usa-telephone-703-506-9460-www-cel-sci-com-compa-cvm-20260511monthly0.5https://www.biopharmawatch.com/news/CVM/8229-boone-boulevard-suite-802-company-contact-vienna-va-22182-usa-gavin-de-windt-telephon-cvm-20250827monthly0.5https://www.biopharmawatch.com/news/CVM/8229-boone-boulevard-suite-802-vienna-va-22182-usa-telephone-703-506-9460-www-cel-sci-com--cvm-20250711monthly0.5https://www.biopharmawatch.com/news/CVM/8229-boone-boulevard-suite-802-vienna-va-22182-usa-telephone-703-506-9460-www-cel-sci-com--cvm-20250521monthly0.5https://www.biopharmawatch.com/news/CVM/boone-boulevard-suite-802-vienna-va-22182-usa-telephone-703-506-9460-www-cel-sci-com-compa-cvm-20250317monthly0.5https://www.biopharmawatch.com/news/CVM/8229-boone-boulevard-suite-802-vienna-va-22182-usa-telephone-703-506-9460-www-cel-sci-com--cvm-20241229monthly0.5https://www.biopharmawatch.com/news/CVM/cel-sci-s-multikine-increased-5-year-survival-rate-to-82-6-in-locally-advanced-resectable--cvm-20240917monthly0.5https://www.biopharmawatch.com/news/CVM/boone-boulevard-suite-802-company-contact-vienna-va-22182-usa-gavin-de-windt-telephone-703-cvm-20240726monthly0.5https://www.biopharmawatch.com/news/CVM/news-8229-boone-boulevard-suite-802-vienna-va-22182-usa-telephone-703-506-9460-www-cel-sci-cvm-20240726monthly0.5https://www.biopharmawatch.com/news/CVM/boone-boulevard-suite-802-vienna-va-22182-usa-telephone-703-506-9460-www-cel-sci-com-compa-cvm-20240618monthly0.5https://www.biopharmawatch.com/news/CVM/boone-boulevard-suite-802-vienna-va-22182-usa-telephone-703-506-9460-www-cel-sci-com-compa-cvm-20240209monthly0.5https://www.biopharmawatch.com/news/CVM/boone-boulevard-suite-802-vienna-va-22182-usa-telephone-703-506-9460-www-cel-sci-com-compa-cvm-20231116monthly0.5https://www.biopharmawatch.com/news/CVM/8229-boone-boulevard-suite-802-vienna-va-22182-usa-telephone-703-506-9460-www-cel-sci-com--cvm-20231030monthly0.5https://www.biopharmawatch.com/news/CVM/8229-boone-boulevard-suite-802-vienna-va-22182-usa-telephone-703-506-9460-www-cel-sci-com--cvm-20231023monthly0.5https://www.biopharmawatch.com/news/CVM/boone-boulevard-suite-802-vienna-va-22182-usa-telephone-703-506-9460-www-cel-sci-com-compa-cvm-20230720monthly0.5https://www.biopharmawatch.com/news/CVM/8229-boone-boulevard-suite-802-company-contact-vienna-va-22182-usa-gavin-de-windt-telephon-cvm-20230717monthly0.5https://www.biopharmawatch.com/news/CVM/8229-boone-boulevard-suite-802-vienna-va-22182-usa-telephone-703-506-9460-www-cel-sci-com--cvm-20230714monthly0.5https://www.biopharmawatch.com/news/CVM/boone-boulevard-suite-802-company-contact-vienna-va-22182-usa-gavin-de-windt-telephone-703-cvm-20230711monthly0.5https://www.biopharmawatch.com/news/CVM/boone-boulevard-suite-802-vienna-va-22182-usa-telephone-703-506-9460-www-cel-sci-com-compa-cvm-20230427monthly0.5https://www.biopharmawatch.com/news/CVM/8229-boone-boulevard-suite-802-vienna-va-22182-usa-telephone-703-506-9460-www-cel-sci-com--cvm-20230419monthly0.5https://www.biopharmawatch.com/news/CVM/boone-boulevard-suite-802-vienna-va-22182-usa-telephone-703-506-9460-www-cel-sci-com-compa-cvm-20230308monthly0.5https://www.biopharmawatch.com/news/CVM/8229-boone-boulevard-suite-802-company-contact-vienna-va-22182-usa-gavin-de-windt-telephon-cvm-20220912monthly0.5https://www.biopharmawatch.com/news/CVM/8229-boone-boulevard-suite-802-vienna-va-22182-usa-telephone-703-506-9460-www-cel-sci-com--cvm-20220819monthly0.5https://www.biopharmawatch.com/news/CVM/8229-boone-boulevard-suite-802-vienna-va-22182-usa-telephone-703-506-9460-www-cel-sci-com--cvm-20210707monthly0.5https://www.biopharmawatch.com/news/CVM/n-ews-release-8229-boone-boulevard-suite-802-company-contact-vienna-va-22182-usa-gavin-de--cvm-20210608monthly0.5https://www.biopharmawatch.com/news/CVM/n-ews-release-8229-boone-boulevard-suite-802-vienna-va-22182-usa-telephone-703-506-9460-ww-cvm-20201208monthly0.5https://www.biopharmawatch.com/news/CVM/boone-boulevard-suite-802-company-contact-vienna-va-22182-usa-gavin-de-windt-telephone-703-cvm-20200323monthly0.5https://www.biopharmawatch.com/news/CVM/n-ews-release-8229-boone-boulevard-suite-802-company-contact-vienna-va-22182-usa-gavin-de--cvm-20191015monthly0.5https://www.biopharmawatch.com/news/CVM/cel-sci-corporation-releases-letter-to-shareholders-vienna-va-cvm-20190508monthly0.5https://www.biopharmawatch.com/news/CVM/n-ews-release-8229-boone-boulevard-suite-802-vienna-va-22182-usa-telephone-703-506-9460-ww-cvm-20181023monthly0.5https://www.biopharmawatch.com/news/CVM/n-ews-release-8229-boone-boulevard-suite-802-vienna-va-22182-usa-telephone-703-506-9460-ww-cvm-20180817monthly0.5https://www.biopharmawatch.com/news/CVM/n-ews-release-8229-boone-boulevard-suite-802-vienna-va-22182-usa-telephone-703-506-9460-ww-cvm-20180628monthly0.5https://www.biopharmawatch.com/news/CVM/gavin-de-windt-investor-relations-manager-phone-703-506-9460-email-address-gdewindt-cel-sc-cvm-20180627monthly0.5https://www.biopharmawatch.com/news/CVM/n-ews-release-8229-boone-boulevard-suite-802-vienna-va-22182-usa-telephone-703-506-9460-ww-cvm-20180403monthly0.5https://www.biopharmawatch.com/news/CVM/boone-boulevard-suite-802-company-contact-vienna-va-22182-placecountry-regionusa-gavin-de--cvm-20171207monthly0.5https://www.biopharmawatch.com/news/CVM/gavin-de-windt-investor-relations-manager-phone-703-506-9460-email-address-gdewindt-cel-sc-cvm-20170823monthly0.5https://www.biopharmawatch.com/news/CVM/boone-boulevard-suite-802-company-contact-vienna-va-22182-usa-gavin-de-windt-telephone-703-cvm-20170814monthly0.5https://www.biopharmawatch.com/news/CVM/n-ews-release-8229-boone-boulevard-suite-802-company-contact-vienna-va-22182-usa-gavin-de--cvm-20170605monthly0.5https://www.biopharmawatch.com/news/CVM/boone-boulevard-suite-802-company-contact-vienna-va-22182-usa-gavin-de-windt-telephone-703-cvm-20170512monthly0.5https://www.biopharmawatch.com/news/CVM/cel-sci-corporation-8229-boone-boulevard-suite-802-company-contact-vienna-va-22182-usa-gav-cvm-20170501monthly0.5https://www.biopharmawatch.com/news/CVM/n-ews-release-8229-boone-boulevard-suite-802-company-contact-vienna-va-22182-usa-gavin-de--cvm-20170309monthly0.5https://www.biopharmawatch.com/news/CVM/cel-sci-corporation-8229-boone-boulevard-suite-802-company-contact-vienna-va-22182-usa-gav-cvm-20170306monthly0.5https://www.biopharmawatch.com/news/CVM/boone-boulevard-suite-802-company-contact-vienna-va-22182-usa-gavin-de-windt-telephone-703-cvm-20170227monthly0.5https://www.biopharmawatch.com/news/CVM/8229-boone-boulevard-suite-802-company-contact-vienna-va-22182-usa-gavin-de-windt-telephon-cvm-20170217monthly0.5https://www.biopharmawatch.com/news/CVM/gavin-de-windt-investor-relations-manager-phone-703-506-9460-email-address-gdewindt-cel-sc-cvm-20161201monthly0.5https://www.biopharmawatch.com/news/CVM/cel-sci-corporation-contact-gavin-de-windt-investor-relations-manager-phone-703-506-9460-e-cvm-20160926monthly0.5https://www.biopharmawatch.com/news/CVM/n-ews-release-8229-boone-boulevard-suite-802-company-contact-vienna-va-22182-usa-gavin-de--cvm-20160823monthly0.5https://www.biopharmawatch.com/news/CVM/gavin-de-windt-cel-sci-corporation-703-506-9460-cel-sci-announces-5-million-registered-dir-cvm-20160518monthly0.5https://www.biopharmawatch.com/news/CVM/gavin-de-windt-cel-sci-corporation-703-506-9460-cel-sci-announces-proposed-public-offering-cvm-20151022monthly0.5https://www.biopharmawatch.com/news/CVM/boone-boulevard-suite-802-company-contact-vienna-va-22182-usa-gavin-de-windt-telephone-703-cvm-20150521monthly0.5https://www.biopharmawatch.com/news/CVM/n-ews-release-8229-boone-boulevard-suite-802-vienna-va-22182-usa-telephone-703-506-9460-ww-cvm-20150513monthly0.5https://www.biopharmawatch.com/news/CVM/boone-boulevard-suite-802-company-contact-vienna-va-22182-usa-gavin-de-windt-telephone-703-cvm-20150511monthly0.5https://www.biopharmawatch.com/news/CVM/n-ews-release-8229-boone-boulevard-suite-802-vienna-va-22182-usa-telephone-703-506-9460-ww-cvm-20141020monthly0.5https://www.biopharmawatch.com/news/CVM/boone-boulevard-suite-802-company-contact-vienna-va-22182-usa-gavin-de-windt-telephone-703-cvm-20141021monthly0.5https://www.biopharmawatch.com/news/CVM/cel-sci-corporation-news-8229-boone-boulevard-suite-802-company-contact-vienna-va-22182-us-cvm-20140415monthly0.5https://www.biopharmawatch.com/news/CVM/cel-sci-corporation-news-8229-boone-boulevard-suite-802-company-contact-vienna-va-22182-us-cvm-20131218monthly0.5https://www.biopharmawatch.com/news/CVM/cel-sci-corporation-news-release-8229-boone-boulevard-suite-802-company-contact-vienna-va--cvm-20131031monthly0.5https://www.biopharmawatch.com/news/CVM/boone-boulevard-suite-802-company-contact-vienna-va-22182-usa-gavin-de-windt-telephone-703-cvm-20131007monthly0.5https://www.biopharmawatch.com/news/CVM/cel-sci-corporation-8229-boone-boulevard-suite-802-company-contact-vienna-va-22182-usa-gav-cvm-20130903monthly0.5https://www.biopharmawatch.com/news/CVM/boone-boulevard-suite-802-company-contact-vienna-va-22182-usa-gavin-de-windt-telephone-703-cvm-20130719monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-to-present-at-the-h-c-wainwright-27-th-annual-global-investment-confe-phio-20250903monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides-business-u-phio-20250814monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-exercise-of-warrants-for-approximately-2-5-million-gross-pr-phio-20250725monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-agreement-with-u-s-manufacturing-source-for-drug-substance--phio-20250725monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-positive-safety-monitoring-committee-recommendation-to-adva-phio-20250625monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-strategic-initiative-to-create-awareness-of-the-comprehensi-phio-20250606monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-reports-first-quarter-2025-financial-results-and-provides-business-up-phio-20250515monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-positive-pathology-results-in-third-cohort-in-intasyl-ph-76-phio-20250507monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-positive-safety-monitoring-committee-recommendation-to-adva-phio-20250409monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-reports-2024-year-end-financial-results-and-provides-business-update--phio-20250331monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-appointment-of-david-h-deming-to-board-of-directors-phio-20250220monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-1-83-million-registered-direct-offering-priced-at-the-marke-phio-20250116monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-2-5-million-registered-direct-offering-priced-at-the-market-phio-20250115monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-3-19-million-registered-direct-offering-priced-at-the-marke-phio-20250114monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-promising-results-of-second-cohort-from-its-ongoing-clinica-phio-20250113monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-registered-direct-offering-priced-at-the-market-under-nasda-phio-20241223monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-1-15-million-registered-direct-offering-priced-at-the-marke-phio-20241219monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-positive-safety-monitoring-committee-smc-recommendation-to--phio-20241219monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides-business-up-phio-20241114monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-upcoming-presentation-at-the-39-th-annual-meeting-of-the-so-phio-20241107monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-reports-second-quarter-2024-financial-results-and-provides-business-u-phio-20240814monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-new-chief-financial-officer-marlborough-massachusetts-newsf-phio-20240801monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-exercise-of-warrants-for-3-1-million-gross-proceeds-marlbor-phio-20240712monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-terminates-share-purchase-agreement-with-triton-funds-marlborough-mas-phio-20240705monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-reverse-stock-split-marlborough-mass-newsfile-corp-phio-20240702monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-positive-recommendation-from-safety-monitoring-committee-sm-phio-20240528monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-secures-new-investor-fund-invests-in-microcap-equities-phio-20240517monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-reports-q1-2024-results-and-provides-business-update-four-sites-acros-phio-20240509monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-reports-2023-year-end-financial-results-and-provides-business-update--phio-20240402monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-exercise-of-warrants-for-2-8-million-gross-proceeds-phio-20231207monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-reports-third-quarter-2023-financial-results-and-provides-business-up-phio-20231109monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-dosing-of-first-patient-in-collaborative-clinical-trial-wit-phio-20230821monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-reports-second-quarter-2023-financial-results-and-provides-business-u-phio-20230810monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-4-million-concurrent-registered-direct-offering-and-private-phio-20230531monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-initiation-of-collaborative-clinical-trial-with-ph-762-agon-phio-20230524monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-fda-clearance-to-initiate-clinical-trial-of-ph-762-for-trea-phio-20230516monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-reports-first-quarter-2023-financial-results-and-provides-business-up-phio-20230511monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-2-million-registered-direct-offering-priced-at-the-market-u-phio-20230418monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-presents-preclinical-data-demonstrating-synergy-enhanced-in-vivo-anti-phio-20230418monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-presents-preclinical-study-showing-ph-762-induces-systemic-memory-t-c-phio-20230417monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-reports-2022-year-end-financial-results-and-provides-business-update--phio-20230322monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-appoints-robert-bitterman-as-president-and-chief-executive-officer-phio-20230222monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-reverse-stock-split-phio-20230125monthly0.5https://www.biopharmawatch.com/news/PHIO/www-phiopharma-com-i-ticker-phio-nasdaq-phio-pharmaceuticals-proprietary-innovations-in-im-phio-20230106monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-new-clinical-program-to-study-ph-762-for-the-treatment-of-c-phio-20221221monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-announces-new-appointments-to-leadership-team-reports-on-third-quarter-2022-financial-phio-20221110monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman-phio-20220929monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-reports-second-quarter-2022-financial-results-and-provides-business-u-phio-20220811monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-reports-first-quarter-2022-financial-results-and-provides-business-up-phio-20220512monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-reports-2021-year-end-financial-results-and-provides-business-update--phio-20220322monthly0.5https://www.biopharmawatch.com/news/PHIO/sent-via-electronic-delivery-to-gdispersyn-phiopharma-com-ckontulis-phiopharma-com-phio-20220225monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-reports-third-quarter-2021-financial-results-and-provides-business-up-phio-20211110monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-reports-second-quarter-2021-financial-results-and-provides-business-u-phio-20210812monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-reports-first-quarter-2021-financial-results-and-provides-business-up-phio-20210513monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-reports-2020-year-end-financial-results-and-provides-business-update--phio-20210325monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-reports-third-quarter-2020-financial-results-and-provides-business-up-phio-20201110monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-reports-second-quarter-2020-financial-results-and-provides-business-u-phio-20200812monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-reports-year-end-2019-financial-results-and-provides-business-update--phio-20200326monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-and-helmholtz-zentrum-m-nchen-announce-collaboration-and-option-agree-phio-20200310monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-pricing-of-8-0-million-underwritten-public-offering-phio-20200211monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-reverse-stock-split-phio-20200114monthly0.5https://www.biopharmawatch.com/news/PHIO/stanley-higgins-senior-director-listing-qualifications-the-nasdaq-stock-market-llc-1-301-9-phio-20191203monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-reports-third-quarter-2019-financial-results-and-provides-business-up-phio-20191112monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-reports-second-quarter-2019-financial-results-and-provides-business-u-phio-20190812monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-reports-first-quarter-2019-financial-results-and-corporate-highlights-phio-20190514monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-reports-fourth-quarter-and-year-end-2018-financial-results-and-corpor-phio-20190327monthly0.5https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-appoints-gerrit-dispersyn-as-new-chief-executive-officer-effective-ma-phio-20190215monthly0.5https://www.biopharmawatch.com/news/PHIO/rxi-pharmaceuticals-corporation-changes-name-to-phio-pharmaceuticals-corp-reflects-company-phio-20181119monthly0.5https://www.biopharmawatch.com/news/PHIO/rxi-pharmaceuticals-reports-third-quarter-2018-financial-results-and-recent-corporate-high-phio-20181114monthly0.5https://www.biopharmawatch.com/news/PHIO/rxi-pharmaceuticals-announces-pricing-of-15-million-upsized-underwritten-public-offering-phio-20181001monthly0.5https://www.biopharmawatch.com/news/PHIO/the-use-of-self-delivering-rnai-to-enhance-nk-cell-cytotoxicity-melissa-maxwell-dingxue-ya-phio-20180926monthly0.5https://www.biopharmawatch.com/news/PHIO/rxi-pharmaceuticals-reports-second-quarter-2018-financial-results-and-recent-corporate-hig-phio-20180814monthly0.5https://www.biopharmawatch.com/news/PHIO/rxi-pharmaceuticals-reports-first-quarter-2018-financial-results-and-recent-corporate-high-phio-20180510monthly0.5https://www.biopharmawatch.com/news/PHIO/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-phio-20180327monthly0.5https://www.biopharmawatch.com/news/PHIO/rxi-pharmaceuticals-reports-fourth-quarter-and-year-end-2017-financial-results-and-recent--phio-20180326monthly0.5https://www.biopharmawatch.com/news/PHIO/rxi-pharmaceuticals-announces-reverse-stock-split-phio-20180105monthly0.5https://www.biopharmawatch.com/news/PHIO/rxi-pharmaceuticals-reports-third-quarter-2017-financial-results-and-recent-corporate-high-phio-20171108monthly0.5https://www.biopharmawatch.com/news/PHIO/rxi-pharmaceuticals-reports-second-quarter-2017-financial-results-and-recent-corporate-hig-phio-20170810monthly0.5https://www.biopharmawatch.com/news/PHIO/rxi-pharmaceuticals-reports-first-quarter-2017-financial-results-and-recent-corporate-high-phio-20170511monthly0.5https://www.biopharmawatch.com/news/PHIO/rxi-pharmaceuticals-topical-application-of-self-delivering-rnai-sd-rxrna-compounds-for-red-phio-20170429monthly0.5https://www.biopharmawatch.com/news/PHIO/rxi-pharmaceuticals-reports-fourth-quarter-and-year-end-2016-financial-results-and-recent--phio-20170330monthly0.5https://www.biopharmawatch.com/news/PHIO/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-phio-20170329monthly0.5https://www.biopharmawatch.com/news/PHIO/rxi-pharmaceuticals-announces-closing-of-11-5-million-underwritten-public-offering-and-ful-phio-20161221monthly0.5https://www.biopharmawatch.com/news/PHIO/rxi-pharmaceuticals-announces-pricing-of-10-million-underwritten-public-offering-phio-20161216monthly0.5https://www.biopharmawatch.com/news/PHIO/forward-looking-statements-this-presentation-contains-forward-looking-statements-within-th-phio-20161130monthly0.5https://www.biopharmawatch.com/news/PHIO/rxi-pharmaceuticals-reports-third-quarter-2016-financial-results-and-highlights-recent-cor-phio-20161110monthly0.5https://www.biopharmawatch.com/news/PHIO/rxi-pharmaceuticals-reports-second-quarter-2016-financial-results-and-highlights-recent-co-phio-20160811monthly0.5https://www.biopharmawatch.com/news/PHIO/rxi-pharmaceuticals-reports-first-quarter-2016-financial-results-and-highlights-recent-cor-phio-20160512monthly0.5https://www.biopharmawatch.com/news/PHIO/rxi-pharmaceuticals-announces-reverse-stock-split-phio-20160415monthly0.5https://www.biopharmawatch.com/news/PHIO/rxi-pharmaceuticals-reports-fourth-quarter-and-year-end-2015-financial-results-and-recent--phio-20160330monthly0.5https://www.biopharmawatch.com/news/PHIO/property-of-rxi-pharmaceuticals-forward-looking-statements-forward-looking-statements-this-phio-20150929monthly0.5https://www.biopharmawatch.com/news/PHIO/rxi-pharmaceuticals-reports-financial-results-for-the-first-quarter-of-2014-phio-20140514monthly0.5https://www.biopharmawatch.com/news/PHIO/rxi-pharmaceuticals-reports-full-year-2013-financial-results-phio-20140328monthly0.5https://www.biopharmawatch.com/news/PHIO/rxi-pharmaceuticals-reports-financial-results-for-the-third-quarter-of-2013-westborough-ma-phio-20131114monthly0.5https://www.biopharmawatch.com/news/PHIO/rxi-pharmaceuticals-reports-financial-results-for-the-second-quarter-of-2013-westborough-m-phio-20130814monthly0.5https://www.biopharmawatch.com/news/PHIO/rxi-pharmaceuticals-announces-application-for-nasdaq-capital-market-listing-and-reverse-st-phio-20130722monthly0.5https://www.biopharmawatch.com/news/PHIO/rxi-pharmaceuticals-reports-financial-results-for-the-first-quarter-of-2013-acquired-subst-phio-20130515monthly0.5https://www.biopharmawatch.com/news/PHIO/rxi-pharmaceuticals-reports-full-year-2012-financial-results-cash-burn-of-approximately-4--phio-20130329monthly0.5https://www.biopharmawatch.com/news/PHIO/rxi-pharmaceuticals-corporation-march-2013-otc-rxii-next-generation-in-rnai-forward-lookin-phio-20130307monthly0.5https://www.biopharmawatch.com/news/PHIO/rxi-pharmaceuticals-reports-financial-results-for-the-third-quarter-of-2012-appointment-of-phio-20121114monthly0.5https://www.biopharmawatch.com/news/PHIO/rxi-pharmaceuticals-receives-fda-clearance-to-begin-clinical-trial-with-rxi-109-first-stud-phio-20120531monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-inc-announces-closing-of-registered-direct-offering-carson-city-nevada-bivi-20241029monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-inc-announces-pricing-of-registered-direct-offering-priced-at-the-market-under-nasd-bivi-20241028monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-inc-announces-closing-of-registered-direct-offering-and-concurrent-private-placemen-bivi-20241024monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-inc-announces-pricing-of-registered-direct-offering-and-concurrent-private-placemen-bivi-20241023monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-inc-announces-pricing-of-registered-direct-offering-and-concurrent-private-placemen-bivi-20241021monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-inc-announces-closing-of-public-offering-carson-city-nevada-bivi-20240925monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-inc-announces-proposed-public-offering-carson-city-nevada-bivi-20240923monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-announces-pipeline-update-and-near-term-clinical-priorities-recently-completed-fina-bivi-20240311monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-inc-announces-closing-of-public-offering-carson-city-nevada-bivi-20240306monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-inc-announces-proposed-public-offering-of-common-stock-carson-city-nevada-bivi-20240301monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-s-ne3107-demonstrates-potential-improvements-in-motor-and-non-motor-symptoms-for-pa-bivi-20240301monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-announces-efficacydata-from-phase-3-trial-of-ne3107-in-patientswith-mild-to-moderat-bivi-20231129monthly0.5https://www.biopharmawatch.com/news/BIVI/for-release-october-25-2023-at-12-20pm-et-blinded-data-presented-at-ctad-suggest-that-ne31-bivi-20231018monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-announces-positive-results-for-ne3107-in-parkinson-s-and-alzheimer-s-phase-2-trials-bivi-20221205monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-issues-letter-to-shareholders-positive-preliminary-data-from-investigator-sponsored-bivi-20221004monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-and-dr-sheldon-jordan-jointly-announce-topline-results-from-an-investigator-sponsor-bivi-20220907monthly0.5https://www.biopharmawatch.com/news/BIVI/developing-transformative-therapies-to-overcome-chronic-debilitating-diseases-corporate-pr-bivi-20220613monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-secures-up-to-a-25-0-million-debt-facility-with-avenue-venture-opportunities-fund-l-bivi-20211201monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-inc-announces-pricing-of-public-offering-of-common-stock-bivi-20210808monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-announces-first-patient-enrolled-in-phase-3-study-of-ne3107-in-alzheimer-s-disease-bivi-20210805monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-announces-closing-of-acquisition-of-biopharma-assets-from-privately-held-neurmedix--bivi-20210611monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-announces-amended-terms-for-asset-acquisition-from-privately-held-neurmedix-bivi-20210510monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-acquires-biopharma-assets-from-privately-held-neurmedix-includes-pivotal-phase-3-al-bivi-20210427monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-announces-closing-of-public-offering-of-common-stock-includes-full-exercise-of-unde-bivi-20200923monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-s-new-drug-candidate-biv201-receives-fda-orphan-drug-designation-for-the-treatment--bivi-20181129monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-receives-fda-clearance-of-ind-application-for-phase-2a-clinical-trial-in-refractory-bivi-20170403monthly0.5https://www.biopharmawatch.com/news/BIVI/biovie-enters-into-a-12-million-common-stock-purchase-agreement-with-aspire-capital-fund-b-bivi-20170105monthly0.5https://www.biopharmawatch.com/news/BIVI/lat-pharma-llc-audited-financial-statements-december-31-2014-and-december-31-2015-1095-eve-bivi-20160415monthly0.5https://www.biopharmawatch.com/news/MBAI/mbody-ai-corp-inc-index-to-financial-statements-table-of-contents-page-report-of-independe-mbai-20260512monthly0.5https://www.biopharmawatch.com/news/MBAI/mbody-ai-corp-expands-fortune-500-deployment-advancing-national-robotics-rollout-proven-pi-mbai-20260326monthly0.5https://www.biopharmawatch.com/news/MBAI/mbody-ai-and-check-cap-ltd-mbai-submit-nasdaq-listing-application-for-merger-close-propose-mbai-20260224monthly0.5https://www.biopharmawatch.com/news/MBAI/mbody-ai-corp-inc-index-to-financial-statements-table-of-contents-page-report-of-independe-mbai-20260130monthly0.5https://www.biopharmawatch.com/news/MBAI/check-cap-clears-key-nasdaq-requirement-advancing-mbody-ai-merger-toward-completion-milest-mbai-20260126monthly0.5https://www.biopharmawatch.com/news/MBAI/consolidated-unaudited-financial-statements-of-check-cap-ltd-a-s-of-and-for-the-six-months-mbai-20251230monthly0.5https://www.biopharmawatch.com/news/MBAI/mbody-ai-to-begin-trading-under-new-nasdaq-ticker-symbol-mbai-mbai-ticker-change-for-check-mbai-20251201monthly0.5https://www.biopharmawatch.com/news/MBAI/mbody-ai-chek-secures-98-shareholder-approval-to-become-leading-nasdaq-embodied-ai-company-mbai-20251117monthly0.5https://www.biopharmawatch.com/news/MBAI/check-cap-ltd-check-cap-building-29-abba-hushi-avenue-p-o-box-1271-isfiya-3009000-israel-n-mbai-20250912monthly0.5https://www.biopharmawatch.com/news/MBAI/check-cap-ltd-consolidated-unaudited-balance-sheets-u-s-dollars-in-thousands-except-share--mbai-20241231monthly0.5https://www.biopharmawatch.com/news/MBAI/check-cap-ltd-check-cap-building-29-abba-hushi-avenue-p-o-box-1271-isfiya-3009000-israel-a-mbai-20240415monthly0.5https://www.biopharmawatch.com/news/MBAI/check-cap-ltd-check-cap-building-29-abba-hushi-avenue-p-o-box-1271-isfiya-3009000-israel-a-mbai-20240320monthly0.5https://www.biopharmawatch.com/news/MBAI/business-combination-agreement-between-nobul-ai-corp-and-check-cap-ltd-dated-as-of-march-2-mbai-20240325monthly0.5https://www.biopharmawatch.com/news/MBAI/proxy-statement-extraordinary-general-meeting-of-shareholders-this-proxy-statement-is-furn-mbai-20240328monthly0.5https://www.biopharmawatch.com/news/MBAI/graham-schmidt-mbai-20240122monthly0.5https://www.biopharmawatch.com/news/BMGL/bmgl-to-effect-reverse-share-split-on-bmgl-20260610monthly0.5https://www.biopharmawatch.com/news/BMGL/receipt-of-delinquency-notification-from-nasdaq-singapore-bmgl-20260123monthly0.5https://www.biopharmawatch.com/news/BMGL/receipt-of-delinquency-notification-from-nasdaq-singapore-bmgl-20251201monthly0.5https://www.biopharmawatch.com/news/BMGL/singapore-bmgl-20250717monthly0.5https://www.biopharmawatch.com/news/BMGL/basel-medical-obtains-waiver-of-lock-up-for-potential-strategic-fund-raising-singapore-bmgl-20250626monthly0.5https://www.biopharmawatch.com/news/BMGL/basel-medical-group-ltd-and-its-subsidiaries-unaudited-consolidated-financial-statements-f-bmgl-20250618monthly0.5https://www.biopharmawatch.com/news/BMGL/basel-medical-group-ltd-reaffirms-strong-financial-position-amid-market-volatility-singapo-bmgl-20250529monthly0.5https://www.biopharmawatch.com/news/BMGL/basel-medical-group-subsidiary-awarded-s-375-million-contract-to-supply-healthcare-product-bmgl-20250520monthly0.5https://www.biopharmawatch.com/news/BMGL/basel-medical-group-ltd-kicks-off-us-1-0-billion-bitcoin-btc-acquisition-strategy-move-sin-bmgl-20250516monthly0.5https://www.biopharmawatch.com/news/BMGL/basel-medical-group-completes-acquisition-of-bethesda-medical-to-strengthen-healthcare-eco-bmgl-20250430monthly0.5https://www.biopharmawatch.com/news/BMGL/basel-medical-group-signs-agreement-to-acquire-bethesda-medical-to-strengthen-healthcare-e-bmgl-20250411monthly0.5https://www.biopharmawatch.com/news/BMGL/basel-medical-group-ltd-announces-exercise-of-overallotment-option-singapore-bmgl-20250319monthly0.5https://www.biopharmawatch.com/news/BMGL/basel-medical-group-ltd-announces-closing-of-us-8-820-000-initial-public-offering-singapor-bmgl-20250303monthly0.5https://www.biopharmawatch.com/news/BMGL/basel-medical-group-ltd-prices-us-8-820-000-initial-public-offering-singapore-bmgl-20250225monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-announces-upcoming-presentation-of-additional-data-from-the-virage-phase-tovx-20260420monthly0.5https://www.biopharmawatch.com/news/TOVX/unique-oncolytic-virus-therapies-for-multiple-solid-tumors-january-2026-2-forward-looking--tovx-20260112monthly0.5https://www.biopharmawatch.com/news/TOVX/content-of-this-presentation-is-copyright-and-responsibility-of-the-author-permission-is-r-tovx-20251020monthly0.5https://www.biopharmawatch.com/news/TOVX/virotherapy-with-armed-oad-declaration-of-interest-honoraria-shares-and-funding-from-theri-tovx-20251008monthly0.5https://www.biopharmawatch.com/news/TOVX/p-161-a-phase-i-dose-escalation-study-to-assess-the-oncolytic-virus-vcn-01-safety-and-effi-tovx-20250602monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-reports-first-quarter-2025-operational-highlights-and-financial-results--tovx-20250508monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-announces-pricing-of-7-5-million-public-offering-rockville-md-tovx-20250507monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-announces-primary-endpoints-for-efficacy-and-safety-achieved-in-virage-p-tovx-20250507monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-announces-positive-outcomes-from-the-second-meeting-of-the-independent-d-tovx-20250331monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-reports-full-year-2024-operational-highlights-and-financial-results-enro-tovx-20250306monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-announces-u-s-fda-guidance-on-design-of-phase-3-study-of-vcn-01-for-the--tovx-20241205monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-reports-third-quarter-2024-operational-highlights-and-financial-results--tovx-20241112monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-announces-orphan-medicinal-product-designation-granted-by-the-european-c-tovx-20241016monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-announces-positive-outcome-of-data-and-safety-monitoring-committee-dsmc--tovx-20241003monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-announces-pricing-of-2-5-million-public-offering-rockville-md-tovx-20240926monthly0.5https://www.biopharmawatch.com/news/TOVX/corporate-overview-september-2024-2-forward-looking-statements-this-presentation-includes--tovx-20240923monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-awarded-manufacturing-funding-from-the-spanish-government-s-national-kno-tovx-20240916monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-announces-reverse-stock-split-rockville-md-tovx-20240816monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-reports-second-quarter-2024-operational-highlights-and-financial-results-tovx-20240813monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-receives-rare-pediatric-drug-designation-by-the-u-s-fda-for-vcn-01-for-t-tovx-20240731monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-announces-fast-track-designation-granted-by-the-u-s-fda-for-vcn-01-for-t-tovx-20240523monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-reports-first-quarter-2024-operational-highlights-and-financial-results--tovx-20240507monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-announces-positive-topline-data-from-investigator-sponsored-phase-1-tria-tovx-20240423monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-to-present-preclinical-data-supporting-the-potential-synergy-of-vcn-01-a-tovx-20240422monthly0.5https://www.biopharmawatch.com/news/TOVX/corporate-overview-april-2024-2-forward-looking-statements-this-presentation-includes-forw-tovx-20240416monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-reports-full-year-2023-operational-highlights-and-financial-results-the--tovx-20240325monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-announces-positive-recommendation-tovx-20240207monthly0.5https://www.biopharmawatch.com/news/TOVX/corporate-overview-08-january-2024-2-forward-looking-statements-this-presentation-includes-tovx-20240108monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-reports-third-quarter-2023-operational-highlights-and-financial-results--tovx-20231113monthly0.5https://www.biopharmawatch.com/news/TOVX/e-xhibit-99-1-theriva-biologics-presents-survival-outcomes-data-from-phase-1-study-evaluat-tovx-20231023monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-announces-presentation-at-esmo-congress-2023-featuring-survival-outcomes-tovx-20231017monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-reports-second-quarter-2023-operational-highlights-and-financial-results-tovx-20230808monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-announces-key-progress-in-virage-an-ongoing-multinational-phase-2b-trial-tovx-20230802monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-announces-orphan-drug-designation-granted-by-the-u-s-fda-for-vcn-01-for--tovx-20230627monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-reports-first-quarter-2023-operational-highlights-and-financial-results--tovx-20230511monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-reports-fourth-quarter-and-full-year-2022-operational-highlights-and-fin-tovx-20230330monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-announces-presentation-of-safety-and-pharmacokinetic-data-from-cohort-1--tovx-20230216monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-announces-first-patient-dosed-in-virage-a-phase-2b-trial-of-systemically-tovx-20230117monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-announces-dosing-of-first-patient-in-the-investigator-sponsored-phase-1--tovx-20230109monthly0.5https://www.biopharmawatch.com/news/TOVX/theriva-biologics-reports-third-quarter-2022-operational-highlights-and-financial-results--tovx-20221110monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-rebrands-as-theriva-biologics-rebrand-solidifies-sharpened-clinical-de-tovx-20221012monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-announces-presentation-at-siop-international-society-of-pediatric-onco-tovx-20220930monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-announces-positive-outcome-of-data-and-safety-monitoring-committee-dsm-tovx-20220927monthly0.5https://www.biopharmawatch.com/news/TOVX/c-o-nc-o-m-ita-n-t-se-q-u-e-nti-al-1-2-p-0-022-value-k-ep-k-ep-marker-t2-relaxation-time-n-tovx-20220912monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-announces-presentation-at-esmo-congress-2022-describing-phase-1-invest-tovx-20220905monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-second-quarter-2022-operational-highlights-and-financial-resul-tovx-20220801monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-announces-3-million-private-placement-of-convertible-preferred-stock-r-tovx-20220729monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-announces-reverse-stock-split-rockville-md-tovx-20220715monthly0.5https://www.biopharmawatch.com/news/TOVX/oncolytic-adenovirus-with-hyaluronidase-activity-that-evades-neutralizing-antibodies-and-a-tovx-20220516monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-first-quarter-2022-operational-highlights-and-financial-result-tovx-20220516monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-positive-safety-data-on-syn-020-intestinal-alkaline-phosphatas-tovx-20220510monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-announces-management-transitions-in-support-of-strategic-transformatio-tovx-20220323monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-2021-year-end-operational-highlights-and-financial-results-com-tovx-20220316monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-completes-acquisition-of-vcn-biosciences-expands-pipeline-into-oncolog-tovx-20220311monthly0.5https://www.biopharmawatch.com/news/TOVX/january-2022-b-riley-securities-oncology-investor-conference-forward-looking-statements-th-tovx-20220127monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-announces-planned-transformative-acquisition-of-vcn-biosciences-develo-tovx-20211214monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-third-quarter-2021-operational-highlights-and-financial-result-tovx-20211103monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-announces-second-adjournment-of-annual-meeting-of-shareholders-due-to--tovx-20211006monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-announces-adjournment-of-annual-meeting-of-shareholders-due-to-lack-of-tovx-20210921monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-second-quarter-2021-operational-highlights-and-financial-resul-tovx-20210805monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-provides-update-on-syn-020-intestinal-alkaline-phosphatase-phase-1-sin-tovx-20210629monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-regains-compliance-with-nyse-american-continued-listing-standards-rock-tovx-20210526monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-2021-first-quarter-operational-highlights-and-financial-result-tovx-20210505monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-announces-first-patient-dosed-in-phase-1b-2a-clinical-trial-of-syn-004-tovx-20210414monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-announces-first-six-participants-dosed-in-phase-1a-clinical-trial-of-s-tovx-20210401monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-2020-year-end-operational-highlights-and-financial-results-ann-tovx-20210304monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-announces-extension-of-compliance-plan-period-by-nyse-american-rockvil-tovx-20201124monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-welcomes-senior-biotech-executive-john-monahan-phd-to-board-of-directo-tovx-20201112monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-2020-third-quarter-operational-highlights-and-financial-result-tovx-20201110monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-provides-update-on-investigator-sponsored-phase-2b-clinical-study-of-s-tovx-20201002monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-2020-second-quarter-operational-highlights-and-financial-resul-tovx-20200806monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-2020-first-quarter-operational-highlights-and-financial-result-tovx-20200505monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-2019-year-end-operational-highlights-and-financial-results-rec-tovx-20200220monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-announces-acceptance-of-compliance-plan-by-nyse-american-rockville-md-tovx-20200207monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-receives-fda-guidance-at-type-c-meeting-for-syn-004-ribaxamase-phase-1-tovx-20200107monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-on-nyse-american-noncompliance-notice-and-compliance-plan-rock-tovx-20191127monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-third-quarter-2019-operational-highlights-and-financial-result-tovx-20191104monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-second-quarter-2019-operational-highlights-and-financial-resul-tovx-20190808monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-regains-compliance-with-nyse-american-continued-listing-standards-for--tovx-20190701monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-first-quarter-2019-operational-highlights-and-financial-result-tovx-20190508monthly0.5https://www.biopharmawatch.com/news/TOVX/march-2019-company-overview-updated-3-4-2019-tovx-20190304monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-2018-year-end-operational-highlights-and-financial-results-enr-tovx-20190227monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-announces-first-two-patients-enrolled-in-phase-2b-investigator-sponsor-tovx-20190103monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-announces-positive-outcome-of-end-of-phase-2-meeting-with-fda-on-syn-0-tovx-20181121monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-third-quarter-2018-operational-highlights-and-financial-result-tovx-20181108monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-prices-18-000-000-public-offering-rockville-md-tovx-20181011monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-announces-agreement-with-cedars-sinai-medical-center-for-an-investigat-tovx-20180906monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-second-quarter-2018-operational-highlights-and-financial-resul-tovx-20180808monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-announces-acceptance-of-compliance-plan-by-nyse-american-rockville-md-tovx-20180522monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-first-quarter-2018-operational-highlights-and-financial-result-tovx-20180508monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-provides-update-on-development-of-syn-004-ribaxamase-for-the-preventio-tovx-20180423monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-on-nyse-american-noncompliance-notice-and-compliance-plan-for--tovx-20180307monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-2017-year-end-operational-highlights-and-financial-results-com-tovx-20180222monthly0.5https://www.biopharmawatch.com/news/TOVX/biotech-showcase-2018-steven-shallcross-interim-ceo-cfo-tovx-20180109monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-announces-management-changes-rockville-md-tovx-20171205monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-third-quarter-2017-operational-highlights-and-financial-result-tovx-20171101monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-announces-closing-of-12-million-convertible-preferred-stock-financing--tovx-20170912monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-second-quarter-2017-operational-highlights-and-financial-resul-tovx-20170803monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-announces-allowance-of-key-u-s-patent-covering-syn-010-intended-for-th-tovx-20170627monthly0.5https://www.biopharmawatch.com/news/TOVX/syn-004-ribaxamase-receives-breakthrough-therapy-designation-from-u-s-food-and-drug-admini-tovx-20170511monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-first-quarter-tovx-20170504monthly0.5https://www.biopharmawatch.com/news/TOVX/phase-2b-clinical-trial-results-syn-004-ribaxamase-tovx-20170504monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-2016-year-end-operational-highlights-and-financial-results-com-tovx-20170302monthly0.5https://www.biopharmawatch.com/news/TOVX/investor-presentation-february-2017-forward-looking-statements-this-presentation-includes--tovx-20170210monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-confirms-key-features-of-pivotal-phase-2b-3-trial-of-syn-010-pursuant--tovx-20170118monthly0.5https://www.biopharmawatch.com/news/TOVX/biotech-showcase-investor-presentation-tovx-20170109monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-syn-004-ribaxamase-tovx-20170105monthly0.5https://www.biopharmawatch.com/news/TOVX/announces-commencement-of-public-offering-of-common-stock-and-warrants-tovx-20161115monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-third-quarter-2016-operational-highlights-and-financial-result-tovx-20161101monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-second-quarter-2016-operational-highlights-and-financial-resul-tovx-20160803monthly0.5https://www.biopharmawatch.com/news/TOVX/investor-slide-deck-june-2016-forward-looking-statements-this-presentation-includes-forwar-tovx-20160627monthly0.5https://www.biopharmawatch.com/news/TOVX/mark-pimentel-md-frcp-c-results-from-two-phase-2-clinical-trials-of-syn-010-a-proprietary--tovx-20160523monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-first-quarter-2016-operational-highlights-and-financial-result-tovx-20160505monthly0.5https://www.biopharmawatch.com/news/TOVX/investor-slide-deck-march-2016-forward-looking-statements-this-presentation-includes-forwa-tovx-20160314monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-2015-year-end-operational-highlights-and-financial-results-rep-tovx-20160310monthly0.5https://www.biopharmawatch.com/news/TOVX/investor-slide-deck-january-11-2016-tovx-20160111monthly0.5https://www.biopharmawatch.com/news/TOVX/new-york-city-microbiome-clinical-program-seminar-tovx-20151210monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-third-quarter-2015-financial-results-and-operational-highlight-tovx-20151105monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-second-quarter-2015-financial-results-and-operational-highligh-tovx-20150810monthly0.5https://www.biopharmawatch.com/news/TOVX/intrexon-and-synthetic-biologics-enter-ecc-to-develop-novel-biotherapeutics-for-treatment--tovx-20150810monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-first-quarter-2015-financial-results-and-operational-highlight-tovx-20150511monthly0.5https://www.biopharmawatch.com/news/TOVX/steven-shallcross-named-chief-financial-officer-of-synthetic-biologics-executive-brings-si-tovx-20150504monthly0.5https://www.biopharmawatch.com/news/TOVX/march-2015-nyse-mkt-syn-forward-looking-statements-this-presentation-includes-forward-look-tovx-20150323monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-year-end-2014-financial-results-and-operational-highlights-ste-tovx-20150316monthly0.5https://www.biopharmawatch.com/news/TOVX/february-2015-nyse-mkt-syn-forward-looking-statements-this-presentation-includes-forward-l-tovx-20150209monthly0.5https://www.biopharmawatch.com/news/TOVX/january-2015-nyse-mkt-syn-forward-looking-statements-this-presentation-includes-forward-lo-tovx-20150112monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-third-quarter-2014-financial-results-and-operational-highlight-tovx-20141114monthly0.5https://www.biopharmawatch.com/news/TOVX/november-2014-nyse-mkt-syn-forward-looking-statements-this-presentation-includes-forward-l-tovx-20141103monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-to-raise-20-7-million-in-registered-direct-offering-for-immediate-rele-tovx-20141010monthly0.5https://www.biopharmawatch.com/news/TOVX/september-2014-nyse-mkt-syn-tovx-20140909monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-second-quarter-2014-financial-results-and-operational-highligh-tovx-20140814monthly0.5https://www.biopharmawatch.com/news/TOVX/may-2014-nyse-mkt-syn-forward-looking-statements-this-presentation-includes-forward-lookin-tovx-20140527monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-first-quarter-2014-financial-results-and-operational-highlight-tovx-20140515monthly0.5https://www.biopharmawatch.com/news/TOVX/a-combination-trial-of-estriol-plus-glatiramer-acetate-in-rrms-rhonda-voskuhl-m-d-professo-tovx-20140430monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-year-end-2013-financial-results-and-operational-update-confere-tovx-20140331monthly0.5https://www.biopharmawatch.com/news/TOVX/forward-looking-statements-this-presentation-includes-forward-looking-statements-on-synthe-tovx-20140304monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-board-of-directors-accepts-resignation-of-long-standing-founder-and-bo-tovx-20140226monthly0.5https://www.biopharmawatch.com/news/TOVX/january-2014-nyse-mkt-syn-forward-looking-statements-this-presentation-includes-forward-lo-tovx-20140113monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-announces-proposed-public-offering-of-common-stock-rockville-md-tovx-20131211monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-and-intrexon-corporation-tovx-20131210monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-enters-into-license-with-cedars-sinai-medical-center-to-develop-novel--tovx-20131207monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-third-quarter-tovx-20131114monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-initiates-manufacturing-of-syn-004-for-use-in-preclinical-and-clinical-tovx-20131015monthly0.5https://www.biopharmawatch.com/news/TOVX/nyse-mkt-syn-september-2013-forward-looking-statements-this-presentation-includes-forward--tovx-20130909monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-second-quarter-2013-financial-results-and-operational-update-p-tovx-20130814monthly0.5https://www.biopharmawatch.com/news/TOVX/nyse-mkt-syn-june-2013-forward-looking-statements-this-presentation-includes-forward-looki-tovx-20130627monthly0.5https://www.biopharmawatch.com/news/TOVX/may-20-2013-nyse-mkt-syn-tovx-20130520monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-first-quarter-2013-financial-results-for-immediate-release-roc-tovx-20130515monthly0.5https://www.biopharmawatch.com/news/TOVX/may-14-2013-nyse-mkt-syn-tovx-20130514monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-year-end-tovx-20130416monthly0.5https://www.biopharmawatch.com/news/TOVX/nyse-mkt-syn-tovx-20130211monthly0.5https://www.biopharmawatch.com/news/TOVX/nyse-mkt-syn-january-7-2013-tovx-20130108monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-and-intrexon-corporation-initiate-development-of-monoclonal-antibodies-tovx-20121220monthly0.5https://www.biopharmawatch.com/news/TOVX/nyse-mkt-syn-december-2012-forward-looking-statements-this-presentation-includes-forward-l-tovx-20121206monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-closes-deal-for-acquisition-of-c-difficile-infectious-disease-program--tovx-20121203monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-third-quarter-2012-financial-results-accelerating-development--tovx-20121114monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-to-acquire-clinical-stage-c-difficile-infectious-disease-program-novel-tovx-20121112monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-completes-10-8-million-private-placement-financing-for-immediate-relea-tovx-20121031monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-second-quarter-2012-financial-results-addition-of-monoclonal-a-tovx-20120814monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-and-intrexon-corporation-enter-worldwide-exclusive-collaboration-for-i-tovx-20120808monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-first-quarter-2012-financial-results-preclinical-and-clinical--tovx-20120515monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-appoints-jeffrey-j-kraws-as-independent-chairman-for-immediate-release-tovx-20120511monthly0.5https://www.biopharmawatch.com/news/TOVX/nyse-amex-syn-tovx-20120424monthly0.5https://www.biopharmawatch.com/news/TOVX/synthetic-biologics-reports-2011-year-end-financial-results-company-prioritizes-focus-on-s-tovx-20120330monthly0.5https://www.biopharmawatch.com/news/TOVX/v302228-ex99-1-converted-by-secpublisher-2-1-1-8-created-by-bcl-technologies-inc-for-sec-f-tovx-20120213monthly0.5https://www.biopharmawatch.com/news/TOVX/adeona-appoints-c-evan-ballantyne-as-chief-financial-officer-former-cfo-of-clinical-data-i-tovx-20120207monthly0.5https://www.biopharmawatch.com/news/TOVX/adeona-announces-executive-management-transitions-and-board-of-directors-appointments-to-s-tovx-20120206monthly0.5https://www.biopharmawatch.com/news/TOVX/adeona-pharmaceuticals-and-intrexon-announce-worldwide-exclusive-collaboration-for-synthet-tovx-20111121monthly0.5https://www.biopharmawatch.com/news/TOVX/unassociated-document-adeona-reports-third-quarter-2011-financial-results-clinical-trial-f-tovx-20111114monthly0.5https://www.biopharmawatch.com/news/TOVX/unassociated-document-adeona-appoints-jeff-lucero-riley-as-independent-chairman-for-immedi-tovx-20111102monthly0.5https://www.biopharmawatch.com/news/TOVX/unassociated-document-adeona-reports-second-quarter-2011-financial-results-planning-to-ini-tovx-20110815monthly0.5https://www.biopharmawatch.com/news/TOVX/adeona-reports-1st-quarter-2011-financial-results-adeona-clinical-laboratory-a-wholly-owne-tovx-20110516monthly0.5https://www.biopharmawatch.com/news/TOVX/adeona-executes-manufacturing-and-supply-agreement-with-tg-united-for-reazin-tm-contract-p-tovx-20110420monthly0.5https://www.biopharmawatch.com/news/TOVX/adeona-s-clinical-study-of-reazin-tm-meets-primary-outcomes-of-increasing-serum-zinc-and-d-tovx-20110415monthly0.5https://www.biopharmawatch.com/news/TOVX/unassociated-document-adeona-to-raise-3-5-million-in-registered-direct-offering-for-immedi-tovx-20110407monthly0.5https://www.biopharmawatch.com/news/TOVX/unassociated-document-adeona-reports-2010-year-end-financial-results-3-2-million-net-reven-tovx-20110331monthly0.5https://www.biopharmawatch.com/news/TOVX/adeona-to-raise-4-million-in-registered-direct-offering-for-immediate-release-ann-arbor-mi-tovx-20110128monthly0.5https://www.biopharmawatch.com/news/TOVX/v207771-ex99-1-converted-by-secpublisher-2-1-1-8-created-by-bcl-technologies-inc-for-sec-f-tovx-20110110monthly0.5https://www.biopharmawatch.com/news/TOVX/adeona-announces-third-quarter-2010-financial-results-and-achievements-ann-arbor-mi-tovx-20101115monthly0.5https://www.biopharmawatch.com/news/TOVX/adeona-announces-second-quarter-2010-profitability-and-achievements-company-achieves-979-7-tovx-20100816monthly0.5https://www.biopharmawatch.com/news/TOVX/adeona-announces-equity-financing-and-clinical-update-ann-arbor-mi-tovx-20100706monthly0.5https://www.biopharmawatch.com/news/TOVX/adeona-completes-a-17-5-million-corporate-partnership-with-meda-ab-for-the-development-and-tovx-20100507monthly0.5https://www.biopharmawatch.com/news/TOVX/adeona-announces-fourth-quarter-2009-results-and-achievements-investor-call-scheduled-for--tovx-20100401monthly0.5https://www.biopharmawatch.com/news/TOVX/adeona-appoints-james-s-kuo-m-d-m-b-a-as-chairman-ceo-and-president-company-intends-to-lau-tovx-20100209monthly0.5https://www.biopharmawatch.com/news/TOVX/powerpoint-presentation-ex99-1-htm-amex-aen-onemedforum-2010-tovx-20100113monthly0.5https://www.biopharmawatch.com/news/TOVX/adeona-completes-hartlab-acquisition-ann-arbor-mi-market-wire-tovx-20090713monthly0.5https://www.biopharmawatch.com/news/TOVX/adeona-announces-appointment-of-max-lyon-as-chief-executive-officer-and-president-ann-arbo-tovx-20090629monthly0.5https://www.biopharmawatch.com/news/TOVX/this-release-includes-forward-looking-statements-on-adeona-s-current-expectations-and-proj-tovx-20090604monthly0.5https://www.biopharmawatch.com/news/TOVX/adeona-pharmaceuticals-announces-first-quarter-2009-results-ann-arbor-michigan-tovx-20090515monthly0.5https://www.biopharmawatch.com/news/TOVX/adeona-announces-acquisition-of-colwell-clinical-laboratories-a-southern-california-clia-c-tovx-20090416monthly0.5https://www.biopharmawatch.com/news/TOVX/adeona-pharmaceuticals-announces-stock-repurchase-program-ann-arbor-michigan-tovx-20090407monthly0.5https://www.biopharmawatch.com/news/TOVX/adeona-pharmaceuticals-announces-fourth-quarter-and-year-end-2008-results-68-reduction-in--tovx-20090331monthly0.5https://www.biopharmawatch.com/news/TOVX/adeona-pharmaceuticals-announces-clinical-update-and-third-quarter-2008-results-ann-arbor--tovx-20081114monthly0.5https://www.biopharmawatch.com/news/TOVX/pipex-pharmaceuticals-announces-clinical-update-and-second-quarter-2008-results-43-reducti-tovx-20080814monthly0.5https://www.biopharmawatch.com/news/TOVX/pipex-pharmaceuticals-announces-results-of-eighty-patient-six-month-prospective-randomized-tovx-20080709monthly0.5https://www.biopharmawatch.com/news/TOVX/pipex-pharmaceuticals-appoints-co-founder-and-vice-chairman-nicholas-stergis-as-chief-exec-tovx-20080708monthly0.5https://www.biopharmawatch.com/news/TOVX/pipex-pharmaceuticals-announces-clinical-update-and-first-quarter-2008-results-conference--tovx-20080515monthly0.5https://www.biopharmawatch.com/news/TOVX/pipex-pharmaceuticals-announces-fourth-quarter-and-year-end-2007-results-webcast-conferenc-tovx-20080331monthly0.5https://www.biopharmawatch.com/news/TOVX/pipex-pharmaceuticals-completes-type-a-meeting-with-fda-for-oral-tetrathiomolybdate-new-dr-tovx-20080229monthly0.5https://www.biopharmawatch.com/news/TOVX/pipex-pharmaceuticals-anti-copper-coprexa-demonstrates-40-reduction-of-insoluble-amyloid-b-tovx-20071105monthly0.5https://www.biopharmawatch.com/news/TOVX/pipex-pharmaceuticals-appoints-david-a-newsome-m-d-as-chief-scientific-officer-pioneer-of--tovx-20071015monthly0.5https://www.biopharmawatch.com/news/TOVX/pipex-pharmaceuticals-receives-equipment-loan-from-bank-of-ann-arbor-supports-pipex-s-new--tovx-20071003monthly0.5https://www.biopharmawatch.com/news/TOVX/pipex-pharmaceuticals-plans-november-nda-filing-for-coprexa-based-on-pre-nda-meetings-with-tovx-20070921monthly0.5https://www.biopharmawatch.com/news/TOVX/pipex-pharmaceuticals-acquires-late-stage-oral-candidate-for-dry-age-related-macular-degen-tovx-20070710monthly0.5https://www.biopharmawatch.com/news/TOVX/pipex-pharmaceuticals-to-begin-trading-today-on-the-american-stock-exchange-tovx-20070626monthly0.5https://www.biopharmawatch.com/news/TOVX/pipex-pharmaceuticals-announces-fourth-quarter-and-year-end-2006-results-webcast-conferenc-tovx-20070402monthly0.5https://www.biopharmawatch.com/news/TOVX/pipex-pharmaceuticals-inc-announces-the-appointment-of-daniel-j-dorman-and-james-s-kuo-m-d-tovx-20070220monthly0.5https://www.biopharmawatch.com/news/TOVX/pipex-pharmaceuticals-completes-13-7-million-in-private-equity-financings-ann-arbor-michig-tovx-20061128monthly0.5https://www.biopharmawatch.com/news/TOVX/pipex-therapeutics-coprexa-pivotal-clinical-trial-results-presented-at-nih-sponsored-wilso-tovx-20061107monthly0.5https://www.biopharmawatch.com/news/VSEE/vsee-health-inc-unaudited-pro-forma-condensed-consolidated-financial-statements-on-vsee-20260531monthly0.5https://www.biopharmawatch.com/news/VSEE/vsee-health-inc-announces-postponement-of-annual-meeting-of-stockholders-until-vsee-20251212monthly0.5https://www.biopharmawatch.com/news/VSEE/september-30-convertible-debt-transactions-warrant-conversion-transaction-pipe-investment--vsee-20251211monthly0.5https://www.biopharmawatch.com/news/VSEE/december-31-vsee-20251128monthly0.5https://www.biopharmawatch.com/news/VSEE/vsee-health-receives-expected-additional-notice-of-deficiency-from-nasdaq-related-to-delay-vsee-20250822monthly0.5https://www.biopharmawatch.com/news/VSEE/vsee-health-inc-receives-nasdaq-delisting-determination-and-plans-to-request-reconsiderati-vsee-20250808monthly0.5https://www.biopharmawatch.com/news/VSEE/vsee-health-announces-870k-contract-with-national-mental-health-services-company-san-jose--vsee-20250127monthly0.5https://www.biopharmawatch.com/news/VSEE/vsee-health-announces-935k-contracts-with-major-medical-device-manufacturers-san-jose-cali-vsee-20250121monthly0.5https://www.biopharmawatch.com/news/VSEE/vsee-health-secures-major-contract-with-leading-florida-health-system-to-deliver-home-heal-vsee-20250110monthly0.5https://www.biopharmawatch.com/news/VSEE/vsee-health-awarded-teleradiology-services-agreement-with-premier-inc-san-jose-calif-vsee-20241218monthly0.5https://www.biopharmawatch.com/news/VSEE/vsee-health-announces-partnership-with-tele911-to-create-first-virtual-emergency-departmen-vsee-20241216monthly0.5https://www.biopharmawatch.com/news/VSEE/vsee-health-partners-with-abundabox-to-launch-abundalife-transforming-health-record-manage-vsee-20241206monthly0.5https://www.biopharmawatch.com/news/VSEE/vsee-health-and-the-teledentists-bring-the-first-virtual-oral-health-compliance-services-t-vsee-20241121monthly0.5https://www.biopharmawatch.com/news/VSEE/vsee-health-health-tech-without-borders-and-idocta-expand-clinton-global-initiative-telehe-vsee-20241119monthly0.5https://www.biopharmawatch.com/news/VSEE/vsee-health-reports-third-quarter-2024-revenue-up-131-year-over-year-san-jose-calif-vsee-20241115monthly0.5https://www.biopharmawatch.com/news/VSEE/vsee-health-and-babyliveadvice-partner-to-reduce-maternal-care-disparities-through-innovat-vsee-20241029monthly0.5https://www.biopharmawatch.com/news/VSEE/vsee-health-expands-its-telehealth-service-offering-with-new-glp-1-program-to-address-obes-vsee-20241021monthly0.5https://www.biopharmawatch.com/news/VSEE/vsee-health-kwajalein-atoll-government-us-coast-guard-cadets-launch-sea-ambulance-teleheal-vsee-20241016monthly0.5https://www.biopharmawatch.com/news/VSEE/vsee-health-co-ceo-and-star-tides-chair-to-discuss-digital-health-transformation-and-cyber-vsee-20241011monthly0.5https://www.biopharmawatch.com/news/VSEE/vsee-health-provides-a-business-update-and-reports-second-quarter-2024-financial-results-vsee-20240923monthly0.5https://www.biopharmawatch.com/news/VSEE/vsee-health-inc-receives-nasdaq-notice-regarding-delayed-form-10-q-filing-vsee-20240911monthly0.5https://www.biopharmawatch.com/news/VSEE/vsee-health-and-stand-together-partner-to-launch-aimee-telehealth-service-vsee-20240806monthly0.5https://www.biopharmawatch.com/news/VSEE/vsee-health-and-ava-robotics-partner-to-develop-telepresence-solutions-for-the-hospital-in-vsee-20240801monthly0.5https://www.biopharmawatch.com/news/VSEE/vsee-health-to-provide-telehealth-and-billing-services-to-skywardrx-clients-vsee-20240724monthly0.5https://www.biopharmawatch.com/news/VSEE/vsee-health-now-providing-outpatient-telehealth-services-to-the-federal-bureau-of-prisons--vsee-20240709monthly0.5https://www.biopharmawatch.com/news/VSEE/vsee-lab-inc-unaudited-condensed-consolidated-financial-statements-for-the-three-months-en-vsee-20240628monthly0.5https://www.biopharmawatch.com/news/VSEE/digital-health-acquisition-corp-announces-listing-transfer-to-the-nasdaq-capital-market-bo-vsee-20231027monthly0.5https://www.biopharmawatch.com/news/VSEE/digital-health-acquisition-corp-announces-extension-of-deadline-to-complete-initial-busine-vsee-20230801monthly0.5https://www.biopharmawatch.com/news/VSEE/digital-health-acquisition-corp-announces-extension-of-deadline-to-complete-initial-busine-vsee-20230508monthly0.5https://www.biopharmawatch.com/news/VSEE/digital-health-acquisition-corp-announces-extension-of-deadline-to-complete-initial-busine-vsee-20230202monthly0.5https://www.biopharmawatch.com/news/VSEE/digital-health-acquisition-corp-announces-filing-of-a-preliminary-extension-proxy-statemen-vsee-20221011monthly0.5https://www.biopharmawatch.com/news/VSEE/digital-health-to-acquire-vsee-labs-and-idoc-telehealth-solutions-with-new-entity-valued-a-vsee-20220616monthly0.5https://www.biopharmawatch.com/news/VSEE/digital-health-acquisition-corp-announces-the-separate-trading-of-its-shares-of-common-sto-vsee-20211230monthly0.5https://www.biopharmawatch.com/news/VSEE/index-to-financial-statement-page-report-of-independent-registered-public-accounting-firm--vsee-20211108monthly0.5https://www.biopharmawatch.com/news/VSEE/digital-health-acquisition-corp-prices-100-million-initial-public-offering-new-york-new-yo-vsee-20211103monthly0.5https://www.biopharmawatch.com/news/BON/bon-partners-with-chang-an-pilot-to-launch-world-class-joint-laboratory-for-natural-ingred-bon-20260217monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-and-subsidiaries-condensed-consolidated-balance-sheets-unaudited--bon-20250929monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-registered-company-no-358246-the-company-notice-of-extraodinary-g-bon-20250401monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-announces-pricing-of-12-million-best-efforts-offering-xi-an-china-bon-20250317monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-registered-company-no-358246-the-company-notice-of-extraodinary-g-bon-20250106monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-and-subsidiaries-condensed-consolidated-balance-sheets-unaudited--bon-20240927monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-announces-brand-strategic-cooperation-with-guangdong-juwo-xi-an-c-bon-20240514monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-registered-company-no-358246-the-company-notice-of-extraodinary-g-bon-20240223monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-incentive-compensation-recovery-policy-effective-date-bon-20231122monthly0.5https://www.biopharmawatch.com/news/BON/memorandum-of-understanding-bon-natural-life-limited-nasdaq-bon-bon-party-a-bon-natural-li-bon-20231005monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-and-subsidiaries-condensed-consolidated-balance-sheets-unaudited--bon-20230911monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-registered-company-no-358246-the-company-notice-of-extraodinary-g-bon-20221031monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-and-subsidiaries-condensed-consolidated-balance-sheets-unaudited-bon-20220801monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-announces-change-to-board-composition-xian-china-bon-20220630monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-bon-natural-life-limited-announces-record-setting-full-fiscal-year-2021-r-bon-20220203monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-announces-fy2021-earnings-release-date-and-webcast-earnings-to-be-bon-20220131monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-and-subsidiaries-condensed-consolidated-balance-sheets-unaudited--bon-20210817monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-announces-land-acquisition-to-construct-its-third-production-faci-bon-20210706monthly0.5https://www.biopharmawatch.com/news/BON/bon-natural-life-limited-announces-pricing-of-upsized-11-million-initial-public-offering-x-bon-20210623monthly0.5https://www.biopharmawatch.com/news/LABT/lakewood-amedex-biotherapeutics-appoints-joseph-tucker-ph-d-to-board-of-directors-appointm-labt-20260428monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-paul-murphy-353-1-2769800-redchip-companies-inc-dave-gentry-ceo-1-407--trib-20260616monthly0.5https://www.biopharmawatch.com/news/TRIB/trinity-biotech-plc-paul-murphy-353-1-2769800-redchip-companies-inc-dave-gentry-ceo-1-407--trib-20260501monthly0.5https://www.biopharmawatch.com/news/TRIB/press-release-dated-trib-20161121monthly0.5https://www.biopharmawatch.com/news/TRIB/press-release-dated-trib-20150409monthly0.5https://www.biopharmawatch.com/news/TRIB/press-release-dated-trib-20150402monthly0.5https://www.biopharmawatch.com/news/TRIB/dear-shareholder-you-have-received-notification-of-an-extraordinary-general-meeting-of-the-trib-20120906monthly0.5https://www.biopharmawatch.com/news/ZSTK/filed-by-newsfilecorp-com-transparency-first-an-update-on-zerostack-s-financials-and-progr-zstk-20251009monthly0.5https://www.biopharmawatch.com/news/ZSTK/filed-by-newsfilecorp-com-flora-growth-corp-unaudited-pro-forma-consolidated-financial-sta-zstk-20250923monthly0.5https://www.biopharmawatch.com/news/ZSTK/filed-by-newsfilecorp-com-flora-growth-corp-announces-pricing-of-2-7-million-registered-di-zstk-20230919monthly0.5https://www.biopharmawatch.com/news/ZSTK/filed-by-newsfilecorp-com-flora-growth-corp-to-acquire-australian-vaporizers-expects-immed-zstk-20230918monthly0.5https://www.biopharmawatch.com/news/ZSTK/filed-by-newsfilecorp-com-flora-growth-corp-unaudited-pro-forma-consolidated-statement-of--zstk-20230825monthly0.5https://www.biopharmawatch.com/news/ZSTK/filed-by-newsfilecorp-com-flora-growth-corp-reports-second-quarter-2023-financial-results-zstk-20230810monthly0.5https://www.biopharmawatch.com/news/ZSTK/filed-by-newsfilecorp-com-flora-growth-corp-announces-update-on-sale-of-colombian-assets-e-zstk-20230725monthly0.5https://www.biopharmawatch.com/news/ZSTK/flora-growth-corp-appoints-clifford-starke-as-chief-executive-officer-and-dany-vaiman-as-c-zstk-20230627monthly0.5https://www.biopharmawatch.com/news/ZSTK/flora-growth-corp-to-effect-reverse-stock-split-fort-lauderdale-florida-toronto-zstk-20230607monthly0.5https://www.biopharmawatch.com/news/ZSTK/flora-growth-reports-first-quarter-2023-financial-results-flora-generated-20-1-million-in--zstk-20230515monthly0.5https://www.biopharmawatch.com/news/ZSTK/flora-growth-corp-announces-the-appointment-of-hussein-rakine-as-ceo-and-member-of-the-boa-zstk-20230418monthly0.5https://www.biopharmawatch.com/news/ZSTK/flora-growth-reports-2022-year-end-financial-results-37-2m-in-revenue-314-growth-year-over-zstk-20230331monthly0.5https://www.biopharmawatch.com/news/ZSTK/flora-growth-issues-2023-revenue-guidance-of-90-million-to-105-million-reflecting-anticipa-zstk-20230130monthly0.5https://www.biopharmawatch.com/news/ZSTK/flora-growth-receives-additional-180-day-extension-by-nasdaq-to-regain-compliance-with-min-zstk-20230106monthly0.5https://www.biopharmawatch.com/news/ZSTK/flora-growth-closes-acquisition-of-franchise-global-health-cementing-foothold-in-germany-a-zstk-20221227monthly0.5https://www.biopharmawatch.com/news/ZSTK/flora-growth-corp-announces-pricing-of-5-0-million-registered-direct-offering-fort-lauderd-zstk-20221209monthly0.5https://www.biopharmawatch.com/news/ZSTK/flora-growth-reports-third-quarter-2022-financial-results-revenue-for-the-three-month-peri-zstk-20221128monthly0.5https://www.biopharmawatch.com/news/ZSTK/arrangement-agreement-flora-growth-corp-and-zstk-20221021monthly0.5https://www.biopharmawatch.com/news/ZSTK/flora-growth-corp-interim-condensed-consolidated-financial-statements-for-the-six-months-e-zstk-20220919monthly0.5https://www.biopharmawatch.com/news/ZSTK/flora-growth-reports-h1-2022-financial-results-h1-2022-revenue-increased-to-15-0-million-u-zstk-20220815monthly0.5https://www.biopharmawatch.com/news/ZSTK/executive-employment-agreement-this-executive-employment-agreement-agreement-is-made-as-of-zstk-20220707monthly0.5https://www.biopharmawatch.com/news/ZSTK/flora-growth-announces-results-of-annual-meeting-of-shareholders-appointment-of-brandon-ko-zstk-20220706monthly0.5https://www.biopharmawatch.com/news/ZSTK/flora-growth-corp-the-corporation-by-law-no-1-a-a-by-law-relating-generally-to-the-transac-zstk-20220701monthly0.5https://www.biopharmawatch.com/news/ZSTK/flora-growth-corp-announces-5-million-share-repurchase-program-fort-lauderdale-florida-tor-zstk-20220616monthly0.5https://www.biopharmawatch.com/news/ZSTK/flora-growth-corporation-notice-of-annual-and-special-meeting-of-shareholders-dear-flora-g-zstk-20220606monthly0.5https://www.biopharmawatch.com/news/ZSTK/flora-growth-reports-fiscal-year-end-2021-results-flora-reports-9-0-million-in-revenue-for-zstk-20220510monthly0.5https://www.biopharmawatch.com/news/ZSTK/of-flora-growth-corp-dated-march-17-2022-flora-growth-appoints-former-amazon-executive-tim-zstk-20220317monthly0.5https://www.biopharmawatch.com/news/ZSTK/of-flora-growth-corp-dated-february-28-2022-exhihbit-99-1-flora-growth-completes-acquisiti-zstk-20220228monthly0.5https://www.biopharmawatch.com/news/ZSTK/of-flora-growth-corp-dated-november-23-2021-flora-growth-closes-34-5-million-public-offeri-zstk-20211123monthly0.5https://www.biopharmawatch.com/news/ZSTK/of-flora-growth-corp-dated-november-19-2021-flora-growth-announces-pricing-of-30-million-p-zstk-20211119monthly0.5https://www.biopharmawatch.com/news/ZSTK/of-flora-growth-corp-dated-november-15-2021-flora-growth-completes-acquisition-of-vessel-b-zstk-20211115monthly0.5https://www.biopharmawatch.com/news/ZSTK/of-flora-growth-corp-dated-september-17-2021-flora-growth-announces-unaudited-financial-re-zstk-20210917monthly0.5https://www.biopharmawatch.com/news/ZSTK/of-flora-growth-corp-dated-august-19-2021-flora-growth-reports-h1-2021-financial-results-a-zstk-20210819monthly0.5https://www.biopharmawatch.com/news/ZSTK/mr-stan-bharti-resignation-letter-effective-as-of-august-5-2021-resignation-to-the-board-o-zstk-20210813monthly0.5https://www.biopharmawatch.com/news/ZSTK/dated-july-22-2021-flora-growth-announces-warrant-extensions-toronto-ontario-zstk-20210722monthly0.5https://www.biopharmawatch.com/news/ZSTK/dated-may-13-2021-flora-growth-corp-announces-closing-of-initial-public-offering-toronto-o-zstk-20210513monthly0.5https://www.biopharmawatch.com/news/ZSTK/dated-may-11-2021-flora-growth-corp-announces-pricing-of-initial-public-offering-toronto-o-zstk-20210511monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-inc-reports-financial-results-for-the-quarter-ended-mbrx-20200812monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-new-independent-in-vitro-testing-confirms-antiviral-activity-of-wp1122-mbrx-20200721monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-agreement-to-produce-wp1122-for-expanded-development-of-potential-covi-mbrx-20200715monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-provides-update-on-annamycin-clinical-development-houston-mbrx-20200702monthly0.5https://www.biopharmawatch.com/news/MBRX/new-publication-finds-combination-of-wp1066-and-radiation-resulted-in-long-term-survival-i-mbrx-20200701monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-preclinical-data-confirms-efficacy-of-annamycin-in-lung-metastases-dat-mbrx-20200625monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-confirmatory-in-vitro-analysis-of-wp1122-receives-feedback-from-fda-on-mbrx-20200616monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-common-stock-will-resume-trading-on-the-nasdaq-on-mbrx-20200528monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-provides-update-on-coronavirus-drug-development-fda-grants-pre-ind-meeting-reque-mbrx-20200527monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-nasdaq-trading-halt-pending-receipt-of-additional-information-houston-mbrx-20200518monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-provides-additional-comments-regarding-trading-halt-houston-mbrx-20200511monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-head-of-niaid-antiviral-drug-discovery-and-development-center-joins-co-mbrx-20200422monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-leading-virologist-joins-development-team-follows-discovery-that-activ-mbrx-20200415monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-investor-conference-call-to-discuss-covid-19-potential-for-drug-candid-mbrx-20200414monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-active-compound-in-wp1122-reduces-coronavirus-replication-in-vitro-by--mbrx-20200408monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-additional-positive-safety-data-in-eu-aml-trial-a-total-of-19-patients-mbrx-20200402monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-inc-reports-financial-results-for-the-year-ended-mbrx-20200319monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-signs-agreement-with-utmb-to-test-wp1122-on-a-range-of-viruses-including-coronav-mbrx-20200317monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-dr-hongbo-zhai-joins-science-advisory-board-to-explore-oncologic-derma-mbrx-20200310monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-issues-video-shareholder-letter-houston-mbrx-20200304monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-positive-independent-report-of-no-cardiotoxicity-in-annamycin-phase-1--mbrx-20200220monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-presents-clinical-trial-data-demonstrating-a-median-reduction-of-56-in-skin-canc-mbrx-20200218monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-to-seek-accelerated-fda-approval-and-plans-for-pivotal-phase-2-aml-trial-followi-mbrx-20200205monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-successful-completion-of-us-phase-1-aml-trial-of-annamycin-no-evidence-mbrx-20200203monthly0.5https://www.biopharmawatch.com/news/MBRX/mbrxexh991q12020investor-developing-ground-breaking-therapies-for-highly-resistant-cancers-mbrx-20200112monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-new-data-shows-reversal-of-tumor-activity-in-animal-models-annamycin-s-mbrx-20191219monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-additional-positive-interim-results-from-phase-1-2-clinical-studies-of-mbrx-20191204monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-positive-trial-data-with-100-safe-delivery-of-p-stat3-inhibitor-and-ef-mbrx-20191119monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-fda-approval-of-ind-for-its-stat3-inhibitor-in-emory-university-clinic-mbrx-20191112monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-inc-reports-financial-results-for-the-third-quarter-ended-mbrx-20191112monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-new-data-confirms-anti-tumor-efficacy-of-annamycin-in-both-human-and-m-mbrx-20191029monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-increases-annamycin-production-due-to-positive-clinical-trial-activity-and-expan-mbrx-20191022monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-inc-reports-financial-results-for-the-second-quarter-ended-mbrx-20190816monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-completion-of-lymphoma-trial-enrollment-houston-mbrx-20190813monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-breakthrough-discovery-wp1066-potentially-capable-of-immune-reprogramm-mbrx-20190806monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-annamycin-in-acute-myeloid-leukemia-in-poland-advances-to-3-rd-cohort--mbrx-20190718monthly0.5https://www.biopharmawatch.com/news/MBRX/mbrxexhibit991q22019inve-developing-breakthrough-therapies-for-highly-resistant-cancers-ma-mbrx-20190531monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-inc-reports-financial-results-for-the-first-quarter-ended-mbrx-20190514monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-additional-positive-interim-results-in-first-cohort-of-phase-1-2-clini-mbrx-20190507monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-inc-general-corporate-update-call-wednesday-mbrx-20190424monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-15-0-million-registered-direct-offering-houston-mbrx-20190423monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-agreement-with-emory-university-to-conduct-pediatric-brain-tumor-trial-mbrx-20190411monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-proposed-underwritten-public-offering-houston-mbrx-20190326monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-positive-interim-results-in-first-cohort-of-phase-1-2-clinical-studies-mbrx-20190326monthly0.5https://www.biopharmawatch.com/news/MBRX/nasdaq-mbrx-non-confidential-information-mbrx-20190318monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-first-patients-treated-in-european-annamycin-clinical-trial-houston-mbrx-20190314monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-inc-reports-financial-results-for-the-year-ended-mbrx-20190221monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-approval-for-third-drug-to-commence-clinical-trials-mbrx-will-now-have-mbrx-20190207monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-the-fda-has-granted-orphan-drug-designation-for-its-brain-tumor-drug-h-mbrx-20190205monthly0.5https://www.biopharmawatch.com/news/MBRX/nasdaq-mbrx-non-confidential-information-january-14-201-9-1-disclaimer-all-statements-cont-mbrx-20190115monthly0.5https://www.biopharmawatch.com/news/MBRX/nasdaq-mbrx-non-confidential-information-january-7-201-9-1-disclaimer-all-statements-conta-mbrx-20190107monthly0.5https://www.biopharmawatch.com/news/MBRX/call-to-discuss-recent-breakthrough-discovery-and-fda-filing-on-wednesday-mbrx-20181212monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-inc-reports-financial-results-for-the-third-quarter-ended-mbrx-20181113monthly0.5https://www.biopharmawatch.com/news/MBRX/prospectus-summary-this-summary-highlights-information-contained-elsewhere-in-this-prospec-mbrx-20181015monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-inc-reports-financial-results-for-the-second-quarter-ended-mbrx-20180813monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-receives-approval-for-leukemia-clinical-trial-houston-mbrx-20180620monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-inc-reports-financial-results-for-the-first-quarter-ended-mbrx-20180515monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-inc-unaudited-condensed-balance-sheets-in-thousands-mbrx-20180328monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-breakthrough-discovery-of-a-new-molecule-for-cancer-treatment-cutting--mbrx-20180215monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-activity-with-pancreatic-cancer-drug-houston-mbrx-20180207monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-inc-reports-financial-results-for-the-third-quarter-ended-mbrx-20171114monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-md-anderson-has-filed-an-ind-with-the-fda-on-its-drug-wp1066-for-the-t-mbrx-20171101monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-requests-authorization-from-the-polish-government-to-advance-annamycin-houston-mbrx-20171024monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-fda-approval-of-annamycin-mbrx-20170926monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-inc-reports-financial-results-for-the-second-quarter-ended-mbrx-20170814monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-s-new-drug-for-the-treatment-of-glioblastoma-nears-clinical-trials-at-md-anderso-mbrx-20170725monthly0.5https://www.biopharmawatch.com/news/MBRX/jon-disclaimer-hello-this-is-jon-foster-cfo-of-moleculin-biotech-inc-and-i-would-like-to-w-mbrx-20170630monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-significant-discovery-with-potential-to-treat-pancreatic-cancer-metabo-mbrx-20170621monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-preparation-to-file-an-ind-with-the-fda-for-wp1220-for-treatment-of-cu-mbrx-20170613monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-issues-shareholder-update-on-fda-designation-of-orphan-drug-and-ind-stat-mbrx-20170523monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-inc-reports-financial-results-for-the-first-quarter-ended-mbrx-20170516monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-appoints-theradex-systems-as-cro-to-manage-phase-i-ii-annamycin-trial-ho-mbrx-20170411monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-inc-reports-financial-results-for-the-fourth-quarter-and-year-ended-mbrx-20170403monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-receives-orphan-drug-designation-for-annamycin-for-the-treatment-of-acute-myeloi-mbrx-20170322monthly0.5https://www.biopharmawatch.com/news/MBRX/nasdaq-mbrx-mbrx-20170315monthly0.5https://www.biopharmawatch.com/news/MBRX/nasdaq-mbrx-mbrx-20170228monthly0.5https://www.biopharmawatch.com/news/MBRX/announces-pricing-of-5-million-underwritten-mbrx-20170209monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-inc-reports-financial-results-for-the-third-quarter-ended-mbrx-20161121monthly0.5https://www.biopharmawatch.com/news/MBRX/operator-welcome-to-the-moleculin-biotech-inc-s-conference-call-to-provide-a-general-corpo-mbrx-20161021monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-accelerated-plan-for-clinical-trial-drug-production-secures-assistance-mbrx-20161007monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-to-present-at-oktoberinvestfest-new-york-and-houston-mbrx-20160923monthly0.5https://www.biopharmawatch.com/news/MBRX/august-2016-disclaimer-all-statements-contained-herein-other-than-statements-of-historical-mbrx-20160912monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-appoints-new-chief-financial-officer-seasoned-financial-executive-jonathan-p-fos-mbrx-20160822monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-inc-reports-financial-results-for-the-second-quarter-ended-mbrx-20160818monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-expands-research-sponsorship-at-md-anderson-cancer-center-facilitates-access-to--mbrx-20160809monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-data-on-wp1122-presented-at-the-28-th-annual-international-carbohydrat-mbrx-20160728monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-announces-successful-engineering-run-for-production-of-annamycin-houston-mbrx-20160719monthly0.5https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-inc-reports-financial-results-for-the-first-quarter-ended-mbrx-20160617monthly0.5https://www.biopharmawatch.com/news/CURX/curanex-reports-first-quarter-2026-business-progress-as-phyto-n-advances-toward-planned-fd-curx-20260514monthly0.5https://www.biopharmawatch.com/news/CURX/curanex-expands-its-drug-development-pipeline-to-include-cancer-cachexia-representing-a-mu-curx-20260402monthly0.5https://www.biopharmawatch.com/news/CURX/curanex-pharmaceuticals-inc-announces-exercise-of-the-over-allotment-option-by-underwriter-curx-20250912monthly0.5https://www.biopharmawatch.com/news/CURX/curanex-pharmaceuticals-inc-announces-closing-of-its-initial-public-offering-jericho-new-y-curx-20250827monthly0.5https://www.biopharmawatch.com/news/CURX/curanex-pharmaceuticals-inc-announces-pricing-of-its-initial-public-offering-jericho-new-y-curx-20250826monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-reports-second-quarter-2025-financial-results-and-provides-business-u-bolt-20250814monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-reports-first-quarter-2025-financial-results-and-provides-business-up-bolt-20250512monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-provi-bolt-20250324monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-reports-third-quarter-2024-financial-results-and-provides-business-up-bolt-20241112monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-reports-second-quarter-2024-financial-results-and-provides-business-u-bolt-20240813monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-reports-first-quarter-2024-results-announces-strategic-pipeline-prior-bolt-20240514monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-provi-bolt-20240321monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-reports-third-quarter-2023-financial-results-and-provides-business-up-bolt-20231109monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-reports-second-quarter-2023-financial-results-and-provides-business-u-bolt-20230807monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-reports-first-quarter-2023-financial-results-and-provides-business-up-bolt-20230511monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-provi-bolt-20230329monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-reports-third-quarter-2022-financial-results-and-provides-business-up-bolt-20221110monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-reports-second-quarter-2022-financial-results-and-provides-business-u-bolt-20220810monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-reports-first-quarter-2022-financial-results-and-provides-business-hi-bolt-20220512monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-reports-four-quarter-and-full-year-2021-financial-results-and-provide-bolt-20220330monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-reports-interim-bdc-1001-phase-1-2-data-demonstrating-a-safe-and-well-bolt-20211206monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-reports-third-quarter-2021-financial-results-and-provides-business-hi-bolt-20211109monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-reports-second-quarter-2021-financial-results-and-provides-business-h-bolt-20210812monthly0.5https://www.biopharmawatch.com/news/BOLT/genmab-and-bolt-biotherapeutics-announce-oncology-research-and-development-collaboration-m-bolt-20210602monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-reports-first-quarter-2021-financial-results-and-provides-business-hi-bolt-20210513monthly0.5https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and-provi-bolt-20210331monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-reports-its-ion-channel-modulator-kio-300-suppressed-seizure-activit-kprx-20260618monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provides-corporate--kprx-20260508monthly0.5https://www.biopharmawatch.com/news/KPRX/in-addition-to-news-releases-and-sec-filings-we-expect-to-post-information-on-our-website--kprx-20260325monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-announces-management-team-changes-encinitas-california-kprx-20260402monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-results-company-advances-r-kprx-20260325monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-reports-third-quarter-2025-results-company-advances-pipeline-with-tw-kprx-20251107monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-reports-second-quarter-2025-results-company-advances-pipeline-with-t-kprx-20250808monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-and-senju-pharmaceutical-partner-on-kio-301-for-the-treatment-of-ret-kprx-20250603monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-reports-first-quarter-results-initiating-two-phase-2-trials-for-trea-kprx-20250509monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-reports-2024-results-retinal-disease-drug-development-pipeline-conti-kprx-20250325monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-reports-third-quarter-results-retinal-disease-pipeline-advancing-two-kprx-20241108monthly0.5https://www.biopharmawatch.com/news/KPRX/document-kiora-pharmaceuticals-receives-investigational-new-drug-approval-to-initiate-abac-kprx-20241029monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-reports-second-quarter-results-retinal-disease-drug-development-pipe-kprx-20240809monthly0.5https://www.biopharmawatch.com/news/KPRX/document-kiora-pharmaceuticals-receives-european-orphan-medicinal-product-designation-for--kprx-20240730monthly0.5https://www.biopharmawatch.com/news/KPRX/document-biotech-executive-lisa-walters-hoffert-joins-kiora-pharmaceuticals-board-of-direc-kprx-20240701monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-reports-first-quarter-results-update-on-pipeline-of-drugs-targeting--kprx-20240510monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-reports-2023-results-continues-to-advance-pipeline-of-treatments-for-kprx-20240325monthly0.5https://www.biopharmawatch.com/news/KPRX/expectations-with-regard-thereto-or-any-changes-in-the-events-conditions-or-circumstances--kprx-20240201monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-and-th-a-open-innovation-enter-strategic-agreement-to-develop-and-co-kprx-20240131monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-reports-q3-2023-results-expanding-clinical-development-of-kio-301-fo-kprx-20231109monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-appoints-praveen-tyle-phd-as-new-chairman-succeeds-paul-chaney-who-i-kprx-20230921monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-adjourns-special-meeting-of-stockholders-to-september-27-encinitas-c-kprx-20230901monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-announces-q2-2023-earnings-and-business-update-highlighting-pipeline-kprx-20230808monthly0.5https://www.biopharmawatch.com/news/KPRX/biotech-leader-carmine-stengone-joins-kiora-pharmaceuticals-board-of-directors-kprx-20230801monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-and-sentrx-animal-care-amend-existing-manufacturing-licensing-agreem-kprx-20230615monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-announces-pricing-of-5-5-million-underwritten-public-offering-encini-kprx-20230602monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-reports-first-quarter-results-positive-clinical-data-driving-signifi-kprx-20230509monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-s-investigational-treatment-for-retinitis-pigmentosa-kio-301-demonstrates-visual-fun-kprx-20230427monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-reports-2022-financial-results-provides-update-on-clinical-developme-kprx-20230323monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-receives-approval-for-phase-2-study-of-kio-101-for-treatment-of-ocul-kprx-20230207monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-inc-nasdaq-kprx-january-2023-corporate-outlook-2-forward-looking-sta-kprx-20230109monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-enters-into-agreements-to-raise-3-12-million-from-the-exercise-of-pr-kprx-20221118monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements-salt-lake-city-u-kprx-20221013monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-to-implement-1-for-40-reverse-split-salt-lake-city-utah-kprx-20220926monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-appoints-melissa-tosca-as-executive-vice-president-of-finance-salt-l-kprx-20220913monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-announces-pricing-of-5-2-million-underwritten-public-offering-salt-l-kprx-20220722monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-receives-nasdaq-notification-of-non-compliance-with-listing-rule-525-kprx-20220531monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-appoints-erin-parsons-to-its-board-of-directors-stephen-from-to-reti-kprx-20220201monthly0.5https://www.biopharmawatch.com/news/KPRX/corporate-overview-january-2022-2-forward-looking-statements-some-of-the-statements-in-thi-kprx-20220111monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-appoints-david-hollander-md-mba-to-its-board-of-directors-kprx-20211215monthly0.5https://www.biopharmawatch.com/news/KPRX/kiora-reports-kio-101-is-safe-and-tolerable-topline-data-supports-advancing-kio-101-to-a-p-kprx-20211214monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-is-now-kiora-pharmaceuticals-provides-update-on-company-s-sharpened-clinical-devel-kprx-20211108monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-pharmaceuticals-appoints-eric-j-daniels-md-mba-as-chief-development-officer-and-cl-kprx-20211026monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-pharmaceuticals-nasdaq-eyeg-sept-2021-2-forward-looking-statements-some-of-the-sta-kprx-20210914monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-announces-10-75-million-registered-direct-offering-priced-at-the-market-under-nasd-kprx-20210810monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-pharmaceuticals-announces-appointment-of-brian-m-strem-ph-d-as-president-and-chief-kprx-20210726monthly0.5https://www.biopharmawatch.com/news/KPRX/treating-inflammatory-and-immune-diseases-may-2021-2-forward-looking-statements-some-of-th-kprx-20210527monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-o-kprx-20210401monthly0.5https://www.biopharmawatch.com/news/KPRX/lead-independent-director-charter-if-the-chairman-of-the-board-of-eyegate-pharmaceutical-i-kprx-20210201monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-enters-into-agreement-for-8-0-million-private-placement-waltham-ma-kprx-20210106monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-pharma-announces-transformative-acquisition-of-panoptes-pharma-expands-pipeline-be-kprx-20201221monthly0.5https://www.biopharmawatch.com/news/KPRX/nasdaq-eyeg-corporate-presentation-september-2020-tb-d-2-some-of-the-matters-discussed-in--kprx-20200914monthly0.5https://www.biopharmawatch.com/news/KPRX/nasdaq-eyeg-corporate-presentation-2-some-of-the-matters-discussed-in-this-presentation-co-kprx-20200601monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-pharma-announces-positive-topline-data-in-follow-on-dry-eye-pilot-study-waltham-ma-kprx-20200331monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-announces-5-0-million-registered-direct-offering-priced-at-the-market-under-nasdaq-kprx-20191231monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-pharma-receives-1-9-million-from-exercised-warrants-waltham-ma-kprx-20191217monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-pharma-announces-additional-positive-top-line-data-in-prk-pivotal-study-waltham-ma-kprx-20191202monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-pharma-hits-primary-endpoint-in-prk-pivotal-study-waltham-ma-kprx-20191122monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-enters-into-agreement-for-1-9-million-private-placement-waltham-ma-kprx-20190930monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-pharma-regains-nasdaq-listing-compliance-kprx-20190923monthly0.5https://www.biopharmawatch.com/news/KPRX/nasdaq-eyeg-corporate-presentation-some-of-the-matters-discussed-in-this-presentation-cont-kprx-20190830monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-pharma-announces-reverse-stock-split-effective-august-30-2019-waltham-ma-kprx-20190829monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-pharma-receives-positive-nasdaq-listing-determination-kprx-20190514monthly0.5https://www.biopharmawatch.com/news/KPRX/nasdaq-eyeg-corporate-presentation-two-versatile-platforms-moving-towards-commercializatio-kprx-20181212monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-pharma-announces-positive-results-in-second-prk-study-data-confirms-results-from-e-kprx-20181113monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-pharmaceuticals-signs-technology-transfer-and-license-agreement-with-sentrx-animal-kprx-20181002monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-pharmaceuticals-granted-additional-180-days-to-comply-with-nasdaq-listing-rules-kprx-20180925monthly0.5https://www.biopharmawatch.com/news/KPRX/nasdaq-eyeg-investor-presentation-two-versatile-platforms-moving-towards-commercialization-kprx-20180905monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-announces-top-line-results-for-phase-3-trial-of-egp-437-in-anterior-uveitis-waltha-kprx-20180904monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-pharmaceuticals-announces-new-board-member-steven-boyd-kprx-20180516monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-announces-completion-of-11-25-million-public-offering-kprx-20180417monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-announces-11-25-million-public-offering-kprx-20180413monthly0.5https://www.biopharmawatch.com/news/KPRX/nasdaq-eyeg-eyegate-pharmaceuticals-inc-271-waverley-oaks-road-suite-108-waltham-ma-02452--kprx-20180312monthly0.5https://www.biopharmawatch.com/news/KPRX/www-eyegatepharma-com-nasdaq-eyeg-nasdaq-eyeg-eyegate-pharmaceuticals-inc-271-waverley-oak-kprx-20180226monthly0.5https://www.biopharmawatch.com/news/KPRX/nasdaq-eyeg-eyegate-pharmaceuticals-inc-271-waverley-oaks-road-suite-108-waltham-ma-02452--kprx-20180212monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-announces-top-line-results-for-phase-2b-trial-of-egp-437-in-cataract-surgery-egp-4-kprx-20180205monthly0.5https://www.biopharmawatch.com/news/KPRX/corporate-presentation-eyegate-pharmaceuticals-inc-271-waverley-oaks-road-suite-108-waltha-kprx-20180108monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-promotes-sarah-romano-to-chief-financial-officer-sarah-romano-elevated-from-interi-kprx-20180104monthly0.5https://www.biopharmawatch.com/news/KPRX/two-versatile-platforms-moving-towards-commercialization-some-of-the-matters-discussed-in--kprx-20171109monthly0.5https://www.biopharmawatch.com/news/KPRX/providing-innovative-products-that-enhance-drug-efficacy-and-patient-compliance-to-improve-kprx-20170912monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-launches-social-media-pages-to-enhance-investor-and-trade-relationships-waltham-ma-kprx-20170911monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-announces-completion-of-10-0-million-public-offering-kprx-20170614monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-announces-10-0-million-public-offering-kprx-20170609monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-submits-investigational-device-exemption-ide-filing-for-second-pilot-study-of-ocul-kprx-20170504monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-pharmaceuticals-inc-providing-innovative-products-that-enhance-drug-efficacy-and-p-kprx-20170223monthly0.5https://www.biopharmawatch.com/news/KPRX/international-headquarters-2150-st-elz-ar-blvd-west-laval-quebec-h7l-4a8-phone-514-744-679-kprx-20170221monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-pharmaceuticals-announces-executive-promotions-sarah-romano-named-interim-chief-fi-kprx-20170206monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-pharmaceuticals-inc-kprx-20170130monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-pharmaceuticals-inc-kprx-20170109monthly0.5https://www.biopharmawatch.com/news/KPRX/fda-confirms-a-510-k-de-novo-path-for-eyegate-s-device-the-ocular-bandage-gel-following-pr-kprx-20161117monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-pharmaceuticals-inc-providing-innovative-products-that-enhance-drug-efficacy-and-p-kprx-20160912monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-announces-positive-top-line-data-from-phase-1b-2a-clinical-trial-of-egp-437-for-tr-kprx-20160801monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-announces-completion-of-3-77-million-registered-direct-offering-kprx-20160630monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-announces-3-77-million-registered-direct-offering-kprx-20160627monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-pharmaceuticals-inc-providing-innovative-products-that-enhance-drug-efficacy-and-p-kprx-20160601monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-pharma-announces-at-the-market-issuance-program-waltham-mass-kprx-20160524monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-pharmaceuticals-inc-providing-innovative-products-that-enhance-drug-efficacy-and-p-kprx-20160307monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-pharmaceuticals-inc-providing-innovative-products-that-enhance-drug-efficacy-and-p-kprx-20160119monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-pharmaceuticals-inc-providing-innovative-products-that-enhance-drug-efficacy-and-p-kprx-20150908monthly0.5https://www.biopharmawatch.com/news/KPRX/c-o-m-p-a-n-y-i-n-t-e-r-v-i-e-w-eyegate-pharmaceuticals-inc-eyeg-stephen-from-has-served-a-kprx-20150814monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-pharmaceuticals-announces-pricing-of-10-000-000-public-offering-of-common-stock-an-kprx-20150730monthly0.5https://www.biopharmawatch.com/news/KPRX/eyegate-signs-licensing-agreement-with-valeant-pharmaceuticals-for-egp-437-combination-pro-kprx-20150710monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-reports-first-quarter-2026-financial-results-and-provides-clinical-corporate-u-calc-20260512monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-reports-second-quarter-2025-financial-results-and-provides-clinical-corporate--calc-20250812monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-reports-first-quarter-2025-financial-results-and-provides-clinical-corporate-u-calc-20250514monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-reports-2024-financial-results-and-provides-clinical-corporate-updates-enrollm-calc-20250327monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-secures-credit-facility-for-up-to-32-5-million-10-million-funded-at-close-exte-calc-20250305monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-presents-aki-data-from-a-post-hoc-analysis-of-the-phase-2-cardea-trial-of-auxo-calc-20250304monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-reports-third-quarter-2024-financial-results-and-provides-clinical-corporate-u-calc-20241113monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-announces-pricing-of-public-offering-of-common-stock-calc-20241030monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-announces-proposed-public-offering-of-common-stock-calc-20241030monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-to-present-late-breaking-positive-data-including-a-win-ratio-analysis-from-pha-calc-20241030monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-reports-second-quarter-2024-financial-results-and-provides-clinical-corporate--calc-20240812monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-announces-positive-topline-data-from-phase-2b-carpo-trial-of-auxora-in-acute-p-calc-20240627monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-reports-first-quarter-2024-financial-results-and-provides-clinical-corporate-u-calc-20240513monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-reports-2023-financial-results-and-provides-clinical-corporate-updates-enrollm-calc-20240328monthly0.5https://www.biopharmawatch.com/news/CALC/developing-novel-therapies-for-acute-inflammatory-and-immunologic-diseases-february-2024-1-calc-20240213monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-announces-private-placement-of-up-to-approximately-55-million-20-4-million-in--calc-20240122monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-reports-third-quarter-2023-financial-results-and-provides-clinical-corporate-u-calc-20231109monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-announces-presentation-of-initial-data-from-the-crspa-study-of-auxora-at-the-6-calc-20231102monthly0.5https://www.biopharmawatch.com/news/CALC/business-section-overview-company-overview-we-are-a-clinical-stage-biopharmaceutical-compa-calc-20230731monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-reports-second-quarter-2023-financial-results-and-provides-clinical-corporate--calc-20230810monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-developing-first-in-class-therapies-for-acute-inflammatory-diseases-with-high--calc-20230615monthly0.5https://www.biopharmawatch.com/news/CALC/calcimedica-reports-first-quarter-2023-financial-results-and-provides-clinical-corporate-u-calc-20230515monthly0.5https://www.biopharmawatch.com/news/CALC/note-purchase-agreement-t-his-n-ote-p-urchase-a-greement-this-agreement-is-made-as-of-calc-20230210monthly0.5https://www.biopharmawatch.com/news/CALC/operator-ladies-and-gentlemen-thank-you-for-standing-by-and-welcome-to-the-graybug-and-cal-calc-20221122monthly0.5https://www.biopharmawatch.com/news/CALC/graybug-vision-inc-203-redwood-shores-parkway-suite-620-redwood-city-ca-94065-www-graybug--calc-20221110monthly0.5https://www.biopharmawatch.com/news/CALC/graybug-vision-reports-financial-results-for-the-three-and-six-months-ended-calc-20220811monthly0.5https://www.biopharmawatch.com/news/CALC/graybug-vision-reports-first-quarter-2022-financial-results-and-recent-corporate-developme-calc-20220510monthly0.5https://www.biopharmawatch.com/news/CALC/graybug-vision-inc-6411-beckley-street-suite-north-200-n200-baltimore-md-21224-www-graybug-calc-20220413monthly0.5https://www.biopharmawatch.com/news/CALC/graybug-vision-reports-full-year-2021-financial-results-and-recent-corporate-developments--calc-20220310monthly0.5https://www.biopharmawatch.com/news/CALC/graybug-vision-inc-6411-beckley-street-suite-north-200-n200-baltimore-md-21224-www-graybug-calc-20211112monthly0.5https://www.biopharmawatch.com/news/CALC/graybug-vision-inc-275-shoreline-drive-suite-450-redwood-city-ca-94065-www-graybug-vision--calc-20210811monthly0.5https://www.biopharmawatch.com/news/CALC/graybug-vision-announces-first-quarter-2021-financial-results-and-recent-corporate-develop-calc-20210512monthly0.5https://www.biopharmawatch.com/news/CALC/graybug-vision-announces-full-year-2020-financial-results-and-recent-corporate-development-calc-20210304monthly0.5https://www.biopharmawatch.com/news/CALC/graybug-vision-announces-financial-results-for-the-three-and-nine-months-ended-calc-20201112monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-closes-28-75-million-underwritten-public-offering-of-its-american-depositary-sha-blrx-20170405monthly0.5https://www.biopharmawatch.com/news/BLRX/confidential-property-not-to-be-used-without-written-authorization-from-health-science-com-blrx-20170330monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-ltd-announces-closing-of-15-million-private-placement-to-institutional-investors-blrx-20120227monthly0.5https://www.biopharmawatch.com/news/BLRX/biolinerx-to-place-15-million-in-securities-with-institutional-investors-jerusalem-israel-blrx-20120215monthly0.5https://www.biopharmawatch.com/news/LNAI/lunai-bioworks-lnai-20260617monthly0.5https://www.biopharmawatch.com/news/LNAI/lunai-bioworks-lnai-20260520monthly0.5https://www.biopharmawatch.com/news/LNAI/lunai-bioworks-inc-announces-postponement-of-special-meeting-of-stockholders-to-lnai-20260428monthly0.5https://www.biopharmawatch.com/news/LNAI/lunai-bioworks-executes-20m-strategic-transaction-at-fixed-1-50-conversion-acquiring-bbb-d-lnai-20260326monthly0.5https://www.biopharmawatch.com/news/LNAI/lunai-bioworks-regains-compliance-with-nasdaq-minimum-bid-price-requirement-lnai-20251016monthly0.5https://www.biopharmawatch.com/news/LNAI/exchange-agreement-this-exchange-agreement-this-agreement-is-entered-into-as-of-2025-the-e-lnai-20250709monthly0.5https://www.biopharmawatch.com/news/LNAI/renovaro-and-biosymetrics-announce-definitive-merger-agreement-to-advance-ai-driven-biomar-lnai-20250226monthly0.5https://www.biopharmawatch.com/news/LNAI/renovaro-to-acquire-predictive-oncology-in-all-stock-transaction-acquisition-provides-acce-lnai-20250106monthly0.5https://www.biopharmawatch.com/news/LNAI/renovaro-inc-announces-10-million-in-equity-committed-los-angeles-lnai-20240614monthly0.5https://www.biopharmawatch.com/news/LNAI/renovaro-inc-and-amsterdam-umc-cancer-center-poised-to-advance-cancer-immunotherapy-los-an-lnai-20240524monthly0.5https://www.biopharmawatch.com/news/LNAI/renovarocube-to-acquire-100-ownership-of-cyclomics-reinforcing-cutting-edge-cancer-diagnos-lnai-20240424monthly0.5https://www.biopharmawatch.com/news/LNAI/ai-pioneer-gedi-cube-and-biotech-innovator-renovaro-biosciences-combine-forces-to-accelera-lnai-20240213monthly0.5https://www.biopharmawatch.com/news/LNAI/renovaro-biosciences-announces-results-of-special-meeting-of-shareholders-los-angeles-lnai-20240125monthly0.5https://www.biopharmawatch.com/news/LNAI/message-from-renovaro-bioscience-inc-s-ceo-the-hon-mark-dybul-md-accelerating-healthcare-w-lnai-20240116monthly0.5https://www.biopharmawatch.com/news/LNAI/renovaro-biosciences-appoints-two-finance-industry-experts-to-board-of-directors-los-angel-lnai-20231010monthly0.5https://www.biopharmawatch.com/news/LNAI/ai-company-gedicube-and-renovaro-biosciences-sign-definitive-agreement-to-combine-message--lnai-20231002monthly0.5https://www.biopharmawatch.com/news/LNAI/renovaro-biosciences-and-ai-health-company-gedi-cube-sign-definitive-agreement-to-combine--lnai-20230929monthly0.5https://www.biopharmawatch.com/news/LNAI/letter-of-intent-lnai-20230801monthly0.5https://www.biopharmawatch.com/news/LNAI/enochian-biosciences-inc-announces-adjournment-of-2023-lnai-20230623monthly0.5https://www.biopharmawatch.com/news/LNAI/enochian-biosciences-announces-that-its-cancer-platform-remains-on-track-for-trials-in-hum-lnai-20230608monthly0.5https://www.biopharmawatch.com/news/LNAI/enochian-biosciences-ceo-letter-to-shareholders-turning-the-page-a-promising-future-los-an-lnai-20230403monthly0.5https://www.biopharmawatch.com/news/LNAI/enochian-biosciences-announces-a-scientific-presentation-of-proof-of-concept-studies-for-a-lnai-20230329monthly0.5https://www.biopharmawatch.com/news/LNAI/enochian-biosciences-achieves-full-compliance-with-nasdaq-filing-requirements-lnai-20230313monthly0.5https://www.biopharmawatch.com/news/LNAI/enochian-biosciences-announces-receipt-of-notice-from-nasdaq-regarding-delayed-filing-of-f-lnai-20230223monthly0.5https://www.biopharmawatch.com/news/LNAI/enochian-biosciences-announces-receipt-of-notice-from-nasdaq-regarding-delayed-filing-of-f-lnai-20221130monthly0.5https://www.biopharmawatch.com/news/LNAI/enochian-biosciences-forges-ahead-with-focused-approach-promising-future-lnai-20221024monthly0.5https://www.biopharmawatch.com/news/LNAI/enochian-biosciences-announces-receipt-of-notice-from-nasdaq-regarding-delayed-filing-of-a-lnai-20221021monthly0.5https://www.biopharmawatch.com/news/LNAI/ceo-s-letter-to-shareholders-06-01-2022-updated-09-23-2022-dear-shareholders-i-have-spoken-lnai-20220923monthly0.5https://www.biopharmawatch.com/news/LNAI/enochian-biosciences-inc-nasdaq-enob-lnai-20220706monthly0.5https://www.biopharmawatch.com/news/LNAI/enochian-biosciences-announces-findings-from-a-rigorous-internal-review-of-scientific-data-lnai-20220701monthly0.5https://www.biopharmawatch.com/news/LNAI/01-2022-updated-06-06-2022-dear-shareholders-i-have-spoken-to-some-of-you-about-the-seriou-lnai-20220607monthly0.5https://www.biopharmawatch.com/news/LNAI/dear-shareholders-i-have-spoken-to-some-of-you-about-the-serious-and-disturbing-news-that--lnai-20220602monthly0.5https://www.biopharmawatch.com/news/LNAI/scientific-leaders-agree-on-promise-of-enochian-biosciences-los-angeles-lnai-20220531monthly0.5https://www.biopharmawatch.com/news/LNAI/enochian-biosciences-board-learns-of-arrest-of-co-founder-and-inventor-and-expresses-stron-lnai-20220525monthly0.5https://www.biopharmawatch.com/news/LNAI/enochian-biosciences-announces-the-appointment-of-executive-vice-president-of-research-and-lnai-20220420monthly0.5https://www.biopharmawatch.com/news/LNAI/enochian-biosciences-announces-appointment-of-senior-vice-president-for-clinical-operation-lnai-20220407monthly0.5https://www.biopharmawatch.com/news/LNAI/enochian-biosciences-inventor-and-co-founder-presents-data-on-novel-clinical-approaches-as-lnai-20220405monthly0.5https://www.biopharmawatch.com/news/LNAI/enochian-biosciences-and-caring-cross-announce-a-partnership-to-potentially-increase-the-e-lnai-20220315monthly0.5https://www.biopharmawatch.com/news/LNAI/update-enochian-biosciences-at-the-cutting-edge-the-future-of-biotech-is-disruptive-scienc-lnai-20220124monthly0.5https://www.biopharmawatch.com/news/LNAI/distinguished-scientific-and-public-health-leaders-to-join-enochian-biosciences-scientific-lnai-20210830monthly0.5https://www.biopharmawatch.com/news/LNAI/enochian-biosciences-names-the-hon-dr-mark-dybul-as-chief-executive-officer-dr-dybul-s-dee-lnai-20210720monthly0.5https://www.biopharmawatch.com/news/LNAI/enochian-biosciences-announces-29-million-registered-direct-offering-priced-at-the-market--lnai-20210614monthly0.5https://www.biopharmawatch.com/news/LNAI/enochian-biosciences-elegant-simplicity-integrating-diverse-scientific-approaches-to-devel-lnai-20210216monthly0.5https://www.biopharmawatch.com/news/LNAI/securities-and-exchange-commission-lnai-20200915monthly0.5https://www.biopharmawatch.com/news/LNAI/enochian-biosciences-announces-three-scientific-presentations-on-potential-hiv-and-hbv-cur-lnai-20200513monthly0.5https://www.biopharmawatch.com/news/LNAI/wolfe-axelrod-weinberger-associates-llc-stephen-d-axelrod-cfa-don-weinberger-212-370-4500--lnai-20160405monthly0.5https://www.biopharmawatch.com/news/LNAI/wolfe-axelrod-weinberger-associates-llc-stephen-d-axelrod-cfa-donald-c-weinberger-212-370--lnai-20140930monthly0.5https://www.biopharmawatch.com/news/LNAI/wolfe-axelrod-weinberger-associates-llc-stephen-d-axelrod-cfa-donald-c-weinberger-212-370--lnai-20140814monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-closing-of-oversubscribed-30-million-private-placement-fundin-apre-20260401monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provide-apre-20260316monthly0.5https://www.biopharmawatch.com/news/APRE/xa9-2026-aprea-therapeutics-inc-all-rights-reserved-precision-oncology-through-synthetic-l-apre-20260109monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-3-1-million-private-placement-priced-at-the-market-under-nasd-apre-20251209monthly0.5https://www.biopharmawatch.com/news/APRE/precision-oncology-through-synthetic-lethality-transforming-ddr-inhibition-into-patient-be-apre-20250908monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-reports-second-quarter-2025-financial-results-and-provides-a-clinical-u-apre-20250812monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-reports-first-quarter-2025-financial-results-and-provides-a-clinical-up-apre-20250514monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-provide-apre-20250325monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-strategic-ip-portfolio-evolution-in-dna-damage-response-ddr-c-apre-20250205monthly0.5https://www.biopharmawatch.com/news/APRE/precision-oncology-through-synthetic-lethality-january-2025-2-xa9-2024-aprea-therapeutics--apre-20250113monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-upda-apre-20241107monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-presents-preliminary-findings-on-oral-wee1-inhibitor-apr-1051-at-eortc--apre-20241023monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-engages-philippe-pultar-md-to-serve-as-senior-medical-advisor-and-lead--apre-20241009monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-reports-second-quarter-2024-financial-results-and-provides-business-upd-apre-20240812monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-first-patient-dosed-in-acesot-1051-phase-1-trial-evaluating-o-apre-20240617monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-reports-first-quarter-2024-financial-results-and-provides-a-business-up-apre-20240514monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-presentations-on-its-next-generation-wee1-inhibitor-apr-1051--apre-20240410monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-provide-apre-20240326monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-private-placement-financing-of-up-to-34-0-million-financing-l-apre-20240311monthly0.5https://www.biopharmawatch.com/news/APRE/precision-oncology-through-synthetic-lethality-february-2024-2-xa9-2024-aprea-therapeutics-apre-20240206monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-provides-corporate-update-and-announces-development-plans-for-2024-doyl-apre-20240104monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-reports-third-quarter-2023-financial-results-and-provides-a-business-up-apre-20231109monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-unveils-initial-clinical-data-on-atri-atrn-119-and-pre-clinical-data-on-wee1i-atrn-1-apre-20231016monthly0.5https://www.biopharmawatch.com/news/APRE/precision-oncology-through-synthetic-lethality-october-2023-forward-looking-statements-cer-apre-20230922monthly0.5https://www.biopharmawatch.com/news/APRE/precision-oncology-through-synthetic-lethality-september-2023-forward-looking-statements-c-apre-20230911monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-reports-second-quarter-2023-financial-results-and-provides-update-on-bu-apre-20230810monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-reports-first-quarter-2023-financial-results-and-provides-update-on-bus-apre-20230515monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-appoints-gabriela-gruia-m-d-to-board-of-directors-doylestown-pa-may-8-2-apre-20230505monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-provide-apre-20230330monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-doylestown-apre-20230301monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-proposed-public-offering-of-common-stock-doylestown-pa-apre-20230222monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-one-for-twenty-reverse-stock-split-doylestown-pa-apre-20230213monthly0.5https://www.biopharmawatch.com/news/APRE/precision-oncology-through-synthetic-lethality-february-2023-forward-looking-statements-ce-apre-20230210monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-appoints-john-hamill-as-chief-financial-officer-doylestown-pa-apre-20230130monthly0.5https://www.biopharmawatch.com/news/APRE/xa9-2023-aprea-therapeutics-inc-all-rights-reserved-1-january-24-26-2023-boston-ma-ddr-inh-apre-20230126monthly0.5https://www.biopharmawatch.com/news/APRE/precision-oncology-through-synthetic-lethality-january-2023-forward-looking-statements-cer-apre-20230109monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-reports-third-quarter-2022-financial-results-and-provides-update-on-bus-apre-20221109monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-reports-second-quarter-2022-financial-results-and-provides-update-on-bu-apre-20220811monthly0.5https://www.biopharmawatch.com/news/APRE/precision-oncology-through-synthetic-lethality-may-2022-forward-looking-statements-certain-apre-20220517monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-acquisition-of-atrin-pharmaceuticals-inc-and-reports-first-qu-apre-20220516monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-provide-apre-20220315monthly0.5https://www.biopharmawatch.com/news/APRE/j-p-morgan-40-th-annual-healthcare-conference-january-2022-forward-looking-statements-cert-apre-20220113monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-removal-of-fda-clinical-hold-on-eprenetapopt-in-lymphoid-mali-apre-20211209monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-reports-third-quarter-2021-financial-results-and-provides-update-on-bus-apre-20211108monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-reports-second-quarter-2021-financial-results-and-provides-update-on-bu-apre-20210812monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-a-partial-clinical-hold-on-myeloid-malignancy-programs-boston-apre-20210805monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-reports-first-quarter-2021-financial-results-and-provides-update-on-bus-apre-20210506monthly0.5https://www.biopharmawatch.com/news/APRE/j-p-morgan-39-th-annual-healthcare-conference-january-2021-forward-looking-statements-cert-apre-20201231monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-announces-results-of-primary-endpoint-from-phase-3-trial-of-eprenetapop-apre-20201228monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-reports-third-quarter-2020-financial-results-and-provides-update-on-bus-apre-20201105monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-appoints-michael-a-kelly-to-board-of-directors-boston-ma-apre-20200929monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-promotes-gregory-s-wessels-to-chief-commercial-officer-and-announces-go-apre-20200918monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-reports-second-quarter-2020-financial-results-and-provides-update-on-bu-apre-20200811monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-appoints-fouad-namouni-m-d-and-richard-peters-m-d-ph-d-to-board-of-dire-apre-20200629monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-reports-first-quarter-2020-financial-results-and-provides-update-on-bus-apre-20200515monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-and-provide-apre-20200326monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-inc-january-2020-j-p-morgan-38-th-annual-healthcare-conference-2-2020-a-apre-20200102monthly0.5https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-reports-third-quarter-2019-financial-results-boston-ma-apre-20191114monthly0.5https://www.biopharmawatch.com/news/BCDA/ex-3-1-2-ex-99489-htm-exhibit-3-1-ex-99489-htm-exhibit-3-1-certificate-of-amendment-of-ame-bcda-20171107monthly0.5https://www.biopharmawatch.com/news/BCDA/cardiamp-pivotal-heart-failure-trial-initiated-at-two-us-centers-san-carlos-ca-december-29-bcda-20161229monthly0.5https://www.biopharmawatch.com/news/BCDA/attached-to-our-current-report-on-form-8-k-filed-with-the-securities-and-exchange-commissi-bcda-20161027monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-inc-index-bcda-20161027monthly0.5https://www.biopharmawatch.com/news/BCDA/biocardia-inc-signs-merger-agreement-with-tiger-x-medical-inc-secures-funding-to-support-f-bcda-20160823monthly0.5https://www.biopharmawatch.com/news/BCDA/pro-forma-unaudited-consolidated-financial-information-the-following-unaudited-pro-forma-c-bcda-20110616monthly0.5https://www.biopharmawatch.com/news/BCDA/pro-forma-unaudited-consolidated-financial-information-the-following-unaudited-pro-forma-c-bcda-20110404monthly0.5https://www.biopharmawatch.com/news/BCDA/cardo-medical-inc-announces-layoffs-bcda-20101007monthly0.5https://www.biopharmawatch.com/news/BCDA/cardo-medical-inc-announces-closing-of-6-2-million-private-placement-proceeds-will-fund-wo-bcda-20091119monthly0.5https://www.biopharmawatch.com/news/BCDA/clicknsettle-com-inc-and-cardo-medical-llc-announce-completion-of-merger-miami-fl-and-los--bcda-20080902monthly0.5https://www.biopharmawatch.com/news/BCDA/clicknsettle-com-inc-and-cardo-medical-llc-announce-merger-agreement-miami-fl-and-los-ange-bcda-20080618monthly0.5https://www.biopharmawatch.com/news/BCDA/clicknsettle-com-inc-closes-sale-of-51-of-the-company-to-investor-group-led-by-dr-phillip--bcda-20080318monthly0.5https://www.biopharmawatch.com/news/BCDA/clicknsettle-com-inc-announces-proposed-sale-of-51-of-the-company-to-investor-group-led-by-bcda-20071220monthly0.5https://www.biopharmawatch.com/news/BCDA/glenn-halpryn-and-jerry-glauser-purchase-control-of-clicknsettle-com-inc-miami-florida-bcda-20070926monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-announces-raise-of-approximately-5-0-million-of-capital-including-a-4-5-sint-20260603monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-signs-supply-agreement-with-evonik-to-manufacture-silicon-nitride-peek--sint-20251201monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-reports-pivotal-third-quarter-business-update-and-financial-highlights-driven-by-fda-sint-20251113monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-submits-fda-510-k-for-silicon-nitride-foot-ankle-medical-devices-advanc-sint-20250722monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-acquires-sinaptic-surgical-assets-and-ip-to-expand-into-1-3b-foot-and-a-sint-20250624monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-announces-patent-issuance-and-formation-of-subsidiary-to-advance-antimi-sint-20250522monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-provides-business-update-highlighting-strategic-focus-to-medical-device-sint-20250515monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-announces-5-million-private-placement-priced-at-the-market-under-nasdaq-sint-20250226monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-appoints-gregg-r-honigblum-as-chief-strategy-officer-seasoned-healthcar-sint-20241119monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-announces-stock-repurchase-program-salt-lake-city-ut-sint-20241118monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-announces-appointment-of-eric-k-olson-as-chief-executive-officer-salt-l-sint-20240806monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-regains-compliance-with-nasdaq-bid-price-requirement-salt-lake-city-uta-sint-20240612monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-announces-reverse-stock-split-effective-sint-20240523monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-announces-proposed-public-offering-of-common-stock-sint-20240329monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-announces-proposed-public-offering-of-common-stock-sint-20240322monthly0.5https://www.biopharmawatch.com/news/SINT/e-xhibit-99-1-sintx-technologies-announces-pricing-of-4-0-sint-20240131monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-shares-select-preliminary-q4-2023-and-full-year-2023-sint-20240123monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-enters-a-long-term-sint-20231107monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-awarded-phase-ii-nih-grant-for-silicon-nitride-peek-3d-printed-composit-sint-20231011monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-announces-pricing-of-12-0-million-public-offering-sint-20230207monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-shares-select-preliminary-q4-2022-and-full-year-2022-revenue-update-sint-20230119monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-announces-reverse-stock-split-effective-december-20-2022-sintx-common-s-sint-20221220monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-informs-stockholders-of-key-dates-and-terms-related-to-announced-rights-sint-20220912monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-acquires-technology-assessment-and-transfer-inc-the-acquisition-broaden-sint-20220706monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-ends-patent-license-agreement-with-o2today-sint-20211105monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-shares-q3-2021-revenue-update-sint-20211014monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-announces-adjournment-of-annual-meeting-of-stockholders-due-to-lack-of--sint-20210915monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-reassesses-exclusive-patent-license-with-o2today-sint-20210805monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-enters-ceramic-armor-market-through-purchase-of-assets-from-b4c-llc-and-technology-l-sint-20210722monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-announces-the-sale-of-first-silicon-nitride-antipathogenic-powder-to-o2-sint-20210630monthly0.5https://www.biopharmawatch.com/news/SINT/o2today-and-sintx-technologies-enter-commercialization-agreement-to-fight-covid-19-caption-sint-20210225monthly0.5https://www.biopharmawatch.com/news/SINT/e-xhibit-99-1-share-purchase-agreement-this-share-purchase-agreement-this-agreement-is-dat-sint-20200804monthly0.5https://www.biopharmawatch.com/news/SINT/o2today-announces-agreement-to-develop-antimicrobial-face-masks-with-sintx-technologies-in-sint-20200804monthly0.5https://www.biopharmawatch.com/news/SINT/share-purchase-agreement-this-share-purchase-agreement-this-agreement-is-dated-as-of-sint-20200716monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement-sint-20200714monthly0.5https://www.biopharmawatch.com/news/SINT/share-purchase-agreement-this-share-purchase-agreement-this-agreement-is-dated-as-of-sint-20200626monthly0.5https://www.biopharmawatch.com/news/SINT/share-purchase-agreement-this-share-purchase-agreement-this-agreement-is-dated-as-of-sint-20200623monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-announces-sars-cov-2-testing-results-sint-20200620monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-releases-preliminary-2019-year-end-earnings-report-and-a-sint-20200304monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-announces-agreement-toward-a-collaboration-with-nissin-manufacturing-co-sint-20200130monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-informs-stockholders-of-key-dates-and-terms-related-to-announced-rights-sint-20191227monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-releases-2019-third-quarter-and-year-to-date-sint-20191118monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-releases-2019-ytd-earnings-report-company-also-announced-that-it-has-re-sint-20190815monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-announces-reverse-stock-split-effective-today-sintx-common-stock-expect-sint-20190729monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-announces-stockholders-approve-reverse-stock-split-sintx-also-announces-sint-20190715monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-announces-adjournment-of-annual-meeting-of-stockholders-until-july-3-20-sint-20190627monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-renews-lease-with-portfolio-investments-at-centrepointe-business-park-s-sint-20190610monthly0.5https://www.biopharmawatch.com/news/SINT/sintx-technologies-announces-adjournment-of-annual-meeting-of-stockholders-until-may-23-20-sint-20190424monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-receives-nasdaq-listing-determination-plans-to-request-hearing-sint-20170825monthly0.5https://www.biopharmawatch.com/news/SINT/amending-and-replacing-amedica-releases-2016-preliminary-unaudited-earnings-report-and-bus-sint-20170609monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-releases-2016-preliminary-earnings-report-and-business-update-salt-lake-city-ut-ma-sint-20170608monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-announces-delayed-filing-of-quarterly-report-on-form-10-q-and-receipt-of-nasdaq-le-sint-20170526monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-announces-delayed-filing-of-annual-report-on-form-10-k-and-receipt-of-nasdaq-lette-sint-20170419monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-announces-results-of-independent-femoral-head-wear-testing-sint-20170227monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-minimum-bid-price-ru-sint-20170215monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-announces-pricing-of-public-offering-to-raise-4-5-million-salt-lake-city-ut-01-19--sint-20170120monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-announces-proposed-public-offering-of-common-stock-and-warrants-salt-lake-city-ut--sint-20170118monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-announces-positive-scientific-data-and-re-files-fda-submission-sint-20161219monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-announces-new-sales-leadership-and-provides-regulatory-updates-salt-lake-city-mark-sint-20161122monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-corporation-reports-third-quarter-2016-financial-results-year-to-date-operational--sint-20161110monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-announces-workforce-reduction-salt-lake-city-marketwired-10-05-16-amedica-corporat-sint-20161003monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-receives-fda-clearance-for-additional-valeo-ii-lateral-lumbar-interbody-fusion-dev-sint-20160824monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-announces-receipt-of-nasdaq-notice-of-bid-price-deficiency-sint-20160819monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-corporation-reports-second-quarter-2016-financial-results-year-to-date-operational-sint-20160811monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-announces-closing-of-12-7-million-public-offering-and-full-exercise-of-over-allotm-sint-20160708monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-announces-pricing-of-11-million-public-offering-sint-20160705monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-submits-response-to-fda-for-clearance-of-composite-interbody-spinal-device-porous--sint-20160613monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-corporation-reports-first-quarter-2016-financial-results-q1-operational-cash-burn--sint-20160512monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-completes-debt-exchange-and-reduces-debt-obligations-by-47-year-over-year-sint-20160503monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-signs-exclusive-chinese-silicon-nitride-distribution-agreement-10-year-exclusive-a-sint-20160418monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-enters-debt-exchange-agreement-agreement-to-unlock-additional-working-capital-and--sint-20160405monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-first-to-3d-print-silicon-nitride-for-medical-applications-company-plans-to-use-3d-sint-20160323monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-corporation-reports-fourth-quarter-and-full-year-2015-financial-results-2015-reven-sint-20160317monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-to-present-advantages-of-silicon-nitride-implants-at-2016-brazilian-spine-congress-sint-20160223monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-regains-compliance-with-nasdaq-listing-requirements-and-announces-capitalization-i-sint-20160209monthly0.5https://www.biopharmawatch.com/news/SINT/exhibit-united-states-securities-and-exchange-commission-washington-d-c-20549-form-8-k-cur-sint-20160128monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-enhances-valeo-ii-product-family-with-the-addition-of-its-second-generation-cervic-sint-20160125monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-signs-international-private-label-supply-agreement-with-chinese-orthopedic-company-sint-20151230monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-corporation-amends-series-a-and-c-warrants-amended-terms-fix-exercise-prices-and-c-sint-20151214monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-submits-24-month-clinical-data-to-fda-for-clearance-of-composite-interbody-spinal--sint-20151110monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-corporation-signs-additional-silicon-nitride-private-label-agreement-newest-allian-sint-20151105monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-launches-innovative-articulating-inserter-for-minimally-invasive-tlif-procedures-s-sint-20151013monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-breaks-into-the-dental-market-with-recent-joint-development-agreement-marks-first--sint-20151012monthly0.5https://www.biopharmawatch.com/news/SINT/exhibit-amedica-corporation-adds-giuseppe-pezzotti-phd-to-its-scientific-advisory-board-dr-sint-20150909monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-enters-into-definitive-agreements-to-raise-15-0-million-in-equity-financing-sint-20150908monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-announces-preliminary-q2-2015-financial-results-and-update-on-recent-fda-response--sint-20150727monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-corporation-provides-update-on-fda-inquiries-and-femoral-head-testing-protocol-fee-sint-20150707monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-corporation-reports-fourth-quarter-and-full-year-2014-financial-results-full-year--sint-20150305monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-announces-receipt-of-nasdaq-notice-of-bid-price-deficiency-sint-20150220monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-submits-510-k-application-to-fda-for-composite-spinal-interbody-spacers-with-porou-sint-20150212monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-becomes-first-to-receive-fda-clearance-for-two-level-cervical-interbody-cage-indic-sint-20150203monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-announces-steps-to-simplify-organization-and-align-financial-objectives-sint-20150112monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-s-spinal-interbody-spacers-with-porous-silicon-nitride-center-provide-equivalent-f-sint-20150105monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-announces-preliminary-q4-fy-2014-financial-results-and-update-on-cascade-clinical--sint-20141218monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-corporation-reports-third-quarter-2014-financial-results-q3-silicon-nitride-cerami-sint-20141106monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-corporation-announces-private-label-agreement-with-spinal-kinetics-strategic-agree-sint-20141014monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-corporation-appoints-eric-a-stookey-to-the-board-of-directors-sint-20141007monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-corporation-appoints-new-president-and-chief-executive-officer-sint-20140930monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-corporation-reports-second-quarter-2014-financial-results-proprietary-silicon-nitr-sint-20140807monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-secures-26-million-in-funding-20-million-debt-facility-with-hercules-technology-gr-sint-20140701monthly0.5https://www.biopharmawatch.com/news/SINT/06-05-14-amedica-announces-termination-of-biologic-distribution-agreement-new-strategy-all-sint-20140605monthly0.5https://www.biopharmawatch.com/news/SINT/05-15-14-amedica-corporation-reports-first-quarter-2014-financial-results-proprietary-sili-sint-20140515monthly0.5https://www.biopharmawatch.com/news/SINT/amedica-reports-fourth-quarter-and-full-year-2013-financial-results-fourth-quarter-2013-to-sint-20140331monthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-secures-100m-term-sheet-for-exclusive-u-s-rights-to-ala-002-a-next-g-juns-20260520monthly0.5https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-inc-announces-pricing-of-11-million-initial-public-offering-and-list-juns-20241202monthly0.5https://www.biopharmawatch.com/news/AMS/raymond-c-stachowiak-c-o-american-shared-hospital-services-two-embarcadero-center-suite-41-ams-20200422monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-making-the-best-healthcare-technology-accessible-septemb-ams-20190924monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-first-quarter-2019-results-proton-revenue-increa-ams-20190509monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-fourth-quarter-and-year-end-2018-results-proton--ams-20190328monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-third-quarter-2018-results-proton-revenue-increa-ams-20181108monthly0.5https://www.biopharmawatch.com/news/AMS/september-2018-making-the-best-healthcare-technology-accessible-this-presentation-may-be-d-ams-20180927monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-second-quarter-2018-results-revenue-increased-4--ams-20180809monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-first-quarter-net-income-increased-33-1-san-francisco-ca-ams-20180510monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-fourth-quarter-net-income-is-0-24-per-share-after-income-ams-20180326monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-third-quarter-results-san-francisco-ca-ams-20171113monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-second-quarter-results-san-francisco-ca-ams-20170810monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-higher-first-quarter-revenue-and-net-income-san--ams-20170515monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-fourth-quarter-net-income-increased-63-2-as-revenue-incr-ams-20170323monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-2016-third-quarter-results-san-francisco-ca-ams-20161110monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-2016-second-quarter-results-san-francisco-ca-ams-20160810monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-2016-first-quarter-results-san-francisco-ca-ams-20160510monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-fourth-quarter-and-2015-results-san-francisco-ca-ams-20160329monthly0.5https://www.biopharmawatch.com/news/AMS/american-ams-20151112monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-second-quarter-results-san-francisco-ca-ams-20150819monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-first-quarter-results-san-francisco-ca-ams-20150514monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-provides-update-on-form-10-k-san-francisco-ca-ams-20150401monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-fourth-quarter-and-2014-results-san-francisco-ca-ams-20150330monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-third-quarter-results-san-francisco-ca-ams-20141113monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-second-quarter-results-san-francisco-ca-ams-20140814monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-first-quarter-results-san-francisco-ca-ams-20140515monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-fourth-quarter-and-2013-results-san-francisco-ca-ams-20140327monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-third-quarter-and-nine-months-results-san-franci-ams-20131113monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-second-quarter-and-first-half-results-san-franci-ams-20130814monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-first-quarter-results-san-francisco-ca-ams-20130514monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-fourth-quarter-and-2012-results-and-updates-stat-ams-20130401monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-2012-third-quarter-results-san-francisco-ca-nove-ams-20121107monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-second-quarter-results-san-francisco-ca-ams-20120809monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-first-quarter-results-san-francisco-ca-ams-20120514monthly0.5https://www.biopharmawatch.com/news/AMS/correcting-and-replacing-american-shared-hospital-services-reports-fourth-quarter-and-2011-ams-20120315monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-fourth-quarter-and-2011-results-san-francisco-ca-ams-20120315monthly0.5https://www.biopharmawatch.com/news/AMS/unassociated-document-american-shared-hospital-services-reports-third-quarter-results-san--ams-20111114monthly0.5https://www.biopharmawatch.com/news/AMS/unassociated-document-american-shared-hospital-services-reports-second-quarter-results-san-ams-20110808monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-first-quarter-results-san-francisco-ca-ams-20110510monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-fourth-quarter-and-2010-results-san-francisco-ca-ams-20110303monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-third-quarter-results-san-francisco-ca-ams-20101104monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-second-quarter-results-san-francisco-ca-ams-20100810monthly0.5https://www.biopharmawatch.com/news/AMS/unassociated-document-american-shared-hospital-services-reports-first-quarter-results-san--ams-20100514monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-fourth-quarter-and-2009-results-san-francisco-ca-ams-20100323monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-2009-third-quarter-results-san-francisco-ca-ams-20091105monthly0.5https://www.biopharmawatch.com/news/AMS/ray-stachowiak-elected-to-board-of-directors-of-american-shared-hospital-services-san-fran-ams-20090915monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-2009-second-quarter-results-san-francisco-ca-ams-20090804monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-announces-termination-of-negotiations-to-sell-its-intere-ams-20090528monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-announces-contract-to-supply-a-leksell-gamma-knife-perfe-ams-20090527monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-2009-first-quarter-results-san-francisco-ca-ams-20090513monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-fourth-quarter-and-2008-results-san-francisco-ca-ams-20090313monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-announces-contract-to-supply-a-leksell-gamma-knife-perfe-ams-20081218monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-2008-third-quarter-results-san-francisco-ca-ams-20081104monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-2008-second-quarter-results-san-francisco-ca-ams-20080729monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-2008-first-quarter-results-san-francisco-ca-ams-20080501monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-contracts-to-supply-a-leksell-gamma-knife-perfexion-syst-ams-20080331monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-fourth-quarter-and-2007-results-san-francisco-ca-ams-20080303monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-third-quarter-and-nine-months-results-san-franci-ams-20071114monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-increases-its-equity-investment-in-still-river-systems-d-ams-20070910monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-second-quarter-and-first-half-results-san-franci-ams-20070808monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-first-quarter-results-san-francisco-ca-ams-20070514monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-higher-revenue-and-pre-tax-income-for-the-fourth-ams-20070306monthly0.5https://www.biopharmawatch.com/news/AMS/exv99w1-american-shared-hospital-services-orders-four-leksell-gamma-knife-perfexion-system-ams-20061106monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-19-increase-in-revenue-and-15-increase-in-operat-ams-20061103monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-further-growth-in-revenue-and-earnings-for-the-s-ams-20060727monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-13-increase-in-operating-income-and-19-increase--ams-20060504monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-announces-2-million-equity-investment-in-developer-of-pr-ams-20060411monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-fourth-quarter-revenue-increased-19-operating-income-inc-ams-20060222monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-higher-revenue-and-operating-income-for-the-thir-ams-20051027monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-15-revenue-growth-and-8-increase-in-operating-in-ams-20050726monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-2004-fourth-quarter-and-annual-results-san-franc-ams-20050131monthly0.5https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-reports-2004-third-quarter-and-nine-month-results-operat-ams-20041026monthly0.5https://www.biopharmawatch.com/news/TNON/tenon-medical-reports-first-quarter-2026-financial-results-first-quarter-2026-revenue-of-1-tnon-20260512monthly0.5https://www.biopharmawatch.com/news/TNON/tenon-medical-reports-fourth-quarter-and-full-year-2025-financial-results-fourth-quarter-2-tnon-20260319monthly0.5https://www.biopharmawatch.com/news/TNON/tenon-medical-announces-closing-of-private-placement-of-senior-convertible-notes-offering--tnon-20260312monthly0.5https://www.biopharmawatch.com/news/TNON/tenon-medical-announces-pricing-of-at-the-market-pipe-financing-strategically-placed-pipe--tnon-20251111monthly0.5https://www.biopharmawatch.com/news/TNON/tenon-medical-expands-sacro-pelvic-fusion-portfolio-with-strategic-asset-acquisition-sivan-tnon-20250801monthly0.5https://www.biopharmawatch.com/news/TNON/tenon-medical-inc-announces-a-2-5-million-registered-direct-offering-and-concurrent-privat-tnon-20250325monthly0.5https://www.biopharmawatch.com/news/TNON/tenon-medical-inc-announces-a-registered-direct-offering-and-concurrent-private-placement--tnon-20250325monthly0.5https://www.biopharmawatch.com/news/TNON/tenon-medical-inc-announces-pricing-of-4-5-million-public-offering-priced-at-the-market-un-tnon-20240912monthly0.5https://www.biopharmawatch.com/news/TNON/tenon-medical-appoints-medical-device-veteran-kevin-williamson-chief-financial-officer-los-tnon-20240827monthly0.5https://www.biopharmawatch.com/news/TNON/experienced-medical-devices-industry-executive-joins-tenon-s-board-of-directors-los-gatos--tnon-20240328monthly0.5https://www.biopharmawatch.com/news/TNON/tenon-medical-reports-fourth-quarter-and-full-year-2023-financial-results-fourth-quarter-2-tnon-20240312monthly0.5https://www.biopharmawatch.com/news/TNON/tenon-medical-inc-issues-approximately-3-85-million-in-series-a-preferred-stock-raises-app-tnon-20240221monthly0.5https://www.biopharmawatch.com/news/TNON/tenon-medical-inc-announces-second-adjournment-of-special-meeting-of-stockholders-meeting--tnon-20240110monthly0.5https://www.biopharmawatch.com/news/TNON/tenon-medical-inc-announces-adjournment-of-special-meeting-of-stockholders-tenon-medical-i-tnon-20231226monthly0.5https://www.biopharmawatch.com/news/TNON/tenon-medical-announces-1-10-reverse-split-los-gatos-ca-accesswire-tnon-20231101monthly0.5https://www.biopharmawatch.com/news/TNON/tenon-medical-announces-pricing-of-5-6-million-public-offering-tnon-20230614monthly0.5https://www.biopharmawatch.com/news/TNON/tenon-medical-accelerates-commercial-scale-with-own-infrastructure-to-support-top-line-gro-tnon-20221011monthly0.5https://www.biopharmawatch.com/news/TNON/tenon-medical-inc-reports-first-quarter-2022-financial-results-closes-16-million-ipo-and-c-tnon-20220607monthly0.5https://www.biopharmawatch.com/news/TNON/investor-presentation-june-2022-2-safe-harbor-this-presentation-contains-forward-looking-s-tnon-20220531monthly0.5https://www.biopharmawatch.com/news/TNON/tenon-medical-inc-announces-pricing-of-16-million-initial-public-offering-los-gatos-ca-tnon-20220426monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-announces-1-85-million-registered-direct-offering-pri-celz-20241023monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-regains-compliance-with-nasdaq-listing-requirements-p-celz-20230628monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-announces-reverse-stock-split-phoenix-az-celz-20230609monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-inc-prices-16-million-public-offering-and-uplisting-t-celz-20211203monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-announces-implementation-of-reverse-stock-split-in-pr-celz-20211109monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-inc-to-launch-virtual-physician-focused-on-telehealth-celz-20210323monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-inc-begins-recruitment-of-stemspine-clinical-sites-celz-20210310monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-provides-update-on-immcelz-fda-application-celz-20210303monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-files-patent-on-prevention-of-organ-transplant-reject-celz-20210216monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-recruits-internationally-renowned-kidney-expert-to-sc-celz-20210208monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-identifies-and-files-patent-on-novel-mechanism-of-imm-celz-20210201monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-files-investigational-new-drug-application-ind-with-f-celz-20210112monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-identifies-mechanism-of-action-of-immcelz-stroke-rege-celz-20201222monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-reports-completion-and-submission-of-clinical-trial-d-celz-20190904monthly0.5https://www.biopharmawatch.com/news/CELZ/patients-treated-for-erectile-dysfunction-utilizing-company-s-patented-caverstem-stem-cell-celz-20190620monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-inc-april-2019-shareholder-update-9-15-am-et-4-30-19--celz-20190430monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-inc-celz-20190328monthly0.5https://www.biopharmawatch.com/news/CELZ/shareholder-update-creative-medical-technology-holdings-inc-phoenix-az-2-12-19-otcqb-celz--celz-20190219monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-inc-december-2018-shareholder-update-phoenix-celz-20181227monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-inc-announces-new-design-to-caverstem-website-includi-celz-20181106monthly0.5https://www.biopharmawatch.com/news/CELZ/shareholder-update-creative-medical-technology-holdings-inc-phoenix-celz-20181017monthly0.5https://www.biopharmawatch.com/news/CELZ/shareholder-update-creative-medical-technology-holdings-inc-phoenix-az-8-14-18-otcqb-celz--celz-20180816monthly0.5https://www.biopharmawatch.com/news/CELZ/securities-purchase-agreement-this-securities-purchase-agreement-this-agreement-is-dated-a-celz-20180808monthly0.5https://www.biopharmawatch.com/news/CELZ/company-sees-possible-access-to-amniostemtm-for-cancer-patients-under-right-to-try-law-pho-celz-20180706monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-forms-caverstem-international-llc-subsidiary-to-conce-celz-20180619monthly0.5https://www.biopharmawatch.com/news/CELZ/stem-cell-clinical-trial-expert-to-join-scientific-advisory-board-celz-20180604monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-files-patent-on-anti-aging-technology-using-amniostem-celz-20180510monthly0.5https://www.biopharmawatch.com/news/CELZ/shareholder-update-creative-medical-technology-holdings-inc-continues-to-extinguish-debt-p-celz-20180430monthly0.5https://www.biopharmawatch.com/news/CELZ/amendment-to-8-promissory-note-this-amendment-to-the-8-promissory-note-this-amendment-date-celz-20180411monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-inc-to-unveil-its-patented-caverstem-procedure-for-er-celz-20180326monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-inc-announces-continued-recruitment-of-physicians-for-celz-20180131monthly0.5https://www.biopharmawatch.com/news/CELZ/stem-cells-as-medicine-the-promise-of-universal-donor-adult-stem-cells-continues-to-attrac-celz-20171220monthly0.5https://www.biopharmawatch.com/news/CELZ/urologist-to-the-stars-dr-alexander-gershman-begins-treating-patients-with-patented-cavers-celz-20171218monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-recruits-top-urologists-for-caverstem-tm-stem-cell-tr-celz-20171213monthly0.5https://www.biopharmawatch.com/news/CELZ/management-reimbursement-agreement-this-management-reimbursement-agreement-this-agreement--celz-20171117monthly0.5https://www.biopharmawatch.com/news/CELZ/amendment-and-waiver-to-the-patent-purchase-agreement-this-amendment-and-waiver-dated-as-o-celz-20171114monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-announces-commercialization-of-patented-stem-cell-pro-celz-20171018monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-expands-personalized-minimally-manipulated-stem-cell--celz-20171011monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-achieves-100-patient-enrollment-in-caverstem-tm-clini-celz-20170828monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-demonstrates-amniostem-derived-exosomes-inhibit-gliom-celz-20170725monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-adds-immune-modulatory-cells-for-stimulation-of-peris-celz-20170621monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-develops-platform-aimed-at-augmenting-all-mesenchymal-celz-20170607monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-inc-files-patent-on-amniostem-mediated-immune-reprogr-celz-20170524monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-to-expand-into-10-billion-dollar-per-year-lower-back--celz-20170518monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-files-patent-on-reducing-radiation-toxicity-using-amn-celz-20170404monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-appoints-internationally-renowned-stem-cell-pioneer-a-celz-20170308monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-announces-initiation-of-in-house-research-program-at--celz-20170222monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-files-patent-on-amniostem-stroke-therapy-collaboratio-celz-20161213monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-recruits-internationally-renowned-neurologist-to-assi-celz-20161206monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-announces-creation-of-amniotic-fluid-stem-cell-focuse-celz-20161116monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technologies-receives-exclusive-license-to-key-amniotic-fluid-stem-cell-p-celz-20161102monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-inc-recruits-internationally-renowned-urologic-surger-celz-20161101monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technology-holdings-expands-adult-stem-cell-therapeutic-platform-to-comba-celz-20160824monthly0.5https://www.biopharmawatch.com/news/CELZ/creative-medical-technologies-completes-proof-of-concept-studies-at-preventing-miscarriage-celz-20160621monthly0.5https://www.biopharmawatch.com/news/CELZ/agreement-agreement-this-agreement-is-entered-into-by-and-between-middle-east-general-cons-celz-20150715monthly0.5https://www.biopharmawatch.com/news/PMCB/pharmacyte-biotech-inc-increases-stake-in-tnf-pharmaceuticals-around-recent-license-for-br-pmcb-20250902monthly0.5https://www.biopharmawatch.com/news/PMCB/pharmacyte-biotech-inc-announces-7-million-capital-raise-led-by-existing-investors-pmcb-20250818monthly0.5https://www.biopharmawatch.com/news/PMCB/new-investment-marks-expansion-of-corporate-strategy-to-utilize-significant-cash-position--pmcb-20231116monthly0.5https://www.biopharmawatch.com/news/PMCB/pharmacyte-biotech-announces-cash-tender-offer-for-up-to-7-750-000-shares-at-3-25-per-shar-pmcb-20230511monthly0.5https://www.biopharmawatch.com/news/PMCB/pharmacyte-biotech-to-implement-second-10-million-share-repurchase-plan-pmcb-20230202monthly0.5https://www.biopharmawatch.com/news/PMCB/pharmacyte-biotech-board-of-directors-announces-business-review-committee-to-evaluate-oppo-pmcb-20221007monthly0.5https://www.biopharmawatch.com/news/PMCB/pharmacyte-biotech-reaches-cooperation-agreement-with-iroquois-capital-company-appoints-fi-pmcb-20220815monthly0.5https://www.biopharmawatch.com/news/PMCB/pharmacyte-biotech-rebukes-iroquois-commencement-of-consent-solicitation-7-owner-attemptin-pmcb-20220728monthly0.5https://www.biopharmawatch.com/news/PMCB/pharmacyte-biotech-commences-first-phase-of-two-phase-pig-study-pmcb-20220721monthly0.5https://www.biopharmawatch.com/news/PMCB/pharmacyte-biotech-reports-positive-interim-results-in-malignant-ascites-mouse-model-study-pmcb-20220719monthly0.5https://www.biopharmawatch.com/news/PMCB/pharmacyte-biotech-announces-preliminary-unaudited-financial-results-for-fiscal-year-2022-pmcb-20220711monthly0.5https://www.biopharmawatch.com/news/PMCB/pharmacyte-biotech-issues-follow-up-response-to-iroquois-capital-s-second-letter-on-june-9-pmcb-20220615monthly0.5https://www.biopharmawatch.com/news/PMCB/pharmacyte-biotech-appoints-dr-matthias-l-hr-to-board-of-directors-pmcb-20220405monthly0.5https://www.biopharmawatch.com/news/PMCB/this-document-may-include-statements-by-pharmacyte-biotech-that-constitute-forward-looking-pmcb-20220309monthly0.5https://www.biopharmawatch.com/news/PMCB/this-document-may-include-statements-by-pharmacyte-biotech-that-constitute-forward-looking-pmcb-20210910monthly0.5https://www.biopharmawatch.com/news/PMCB/pharmacyte-biotech-announces-70-million-registered-direct-offering-priced-at-the-market-un-pmcb-20210819monthly0.5https://www.biopharmawatch.com/news/PMCB/pharmacyte-biotech-announces-uplist-date-to-nasdaq-and-pricing-of-15-million-public-offeri-pmcb-20210809monthly0.5https://www.biopharmawatch.com/news/PMCB/business-entity-filing-acknowledgement-07-09-2021-work-order-item-number-filing-number-fil-pmcb-20210713monthly0.5https://www.biopharmawatch.com/news/PMCB/business-entity-filing-acknowledgement-07-02-2021-work-order-item-number-filing-number-fil-pmcb-20210706monthly0.5https://www.biopharmawatch.com/news/PMCB/pharmacyte-biotech-announces-adjournment-of-annual-meeting-of-stockholders-recording-of-st-pmcb-20210618monthly0.5https://www.biopharmawatch.com/news/PMCB/pharmacyte-biotech-inc-supplement-dated-june-4-2021-to-definitive-proxy-statement-dated-ma-pmcb-20210604monthly0.5https://www.biopharmawatch.com/news/PMCB/pharmacyte-biotech-inc-23046-avenida-de-la-carlota-suite-600-laguna-hills-california-92653-pmcb-20210505monthly0.5https://www.biopharmawatch.com/news/PMCB/pharmacyte-biotech-enters-into-license-agreement-for-covid-19-diagnostic-kits-pmcb-20200408monthly0.5https://www.biopharmawatch.com/news/PMCB/pharmacyte-biotech-inc-23046-avenida-de-la-carlota-suite-600-laguna-hills-california-92653-pmcb-20190823monthly0.5https://www.biopharmawatch.com/news/PMCB/pharmacyte-biotech-appoints-dr-raymond-tong-to-board-of-directors-pmcb-20171010monthly0.5https://www.biopharmawatch.com/news/PMCB/pharmacyte-restructures-agreements-with-austrianova-to-strengthen-partnership-pmcb-20170906monthly0.5https://www.biopharmawatch.com/news/PMCB/pharmacyte-biotech-appoints-dr-michael-m-abecassis-to-board-of-directors-pmcb-20170710monthly0.5https://www.biopharmawatch.com/news/PMCB/pharmacyte-biotech-appoints-thomas-yuen-to-board-of-directors-pmcb-20170502monthly0.5https://www.biopharmawatch.com/news/PMCB/nuvilex-announces-name-change-to-pharmacyte-biotech-company-s-shares-will-trade-under-new--pmcb-20150109monthly0.5https://www.biopharmawatch.com/news/PMCB/nuvilex-obtains-exclusive-worldwide-license-to-develop-disease-treatments-that-combine-cel-pmcb-20141201monthly0.5https://www.biopharmawatch.com/news/PMCB/nuvilex-inc-audit-committee-charter-this-audit-committee-charter-charter-was-adopted-by-th-pmcb-20140919monthly0.5https://www.biopharmawatch.com/news/PMCB/nuvilex-enters-into-an-at-the-market-banking-agreement-with-chardan-capital-markets-pmcb-20140529monthly0.5https://www.biopharmawatch.com/news/PMCB/nuvilex-contracts-with-austrianova-for-cgmp-compliant-cell-in-a-box-encapsulation-of-cells-pmcb-20140320monthly0.5https://www.biopharmawatch.com/news/PMCB/nuvilex-announces-27-million-funding-commitment-with-institutional-investor-to-advance-lat-pmcb-20140220monthly0.5https://www.biopharmawatch.com/news/PMCB/nuvilex-s-completes-acquisition-of-exclusive-worldwide-rights-to-live-cell-encapsulation-t-pmcb-20131202monthly0.5https://www.biopharmawatch.com/news/PMCB/nuvilex-accelerates-development-of-treatments-for-cancer-and-diabetes-with-new-corporate-m-pmcb-20131125monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-appoints-john-n-bonfiglio-phd-to-board-of-directors-experienced-biotech-executive--gnpx-20190219monthly0.5https://www.biopharmawatch.com/news/GNPX/genprex-announces-10-million-private-placement-austin-texas-gnpx-20180507monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-announces-binding-agreement-for-senior-debt-to-equity-exchange-of-up-to-vvos-20260605monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-announces-grand-opening-of-affiliated-sleep-center-near-detroit-michiga-vvos-20251216monthly0.5https://www.biopharmawatch.com/news/VVOS/r-d-prabhu-lata-k-shete-m-d-s-financial-statements-december-31-2024-and-2023-r-d-prabhu-la-vvos-20250825monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-completes-acquisition-of-the-sleep-center-of-nevada-transaction-brings--vvos-20250613monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-reports-first-quarter-2025-financial-results-and-provides-operational-u-vvos-20250515monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-signs-definitive-agreement-to-acquire-largest-sleep-center-operator-in--vvos-20250416monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-reports-full-year-2024-financial-results-and-provides-operational-updat-vvos-20250331monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-announces-3-5-million-registered-direct-offering-priced-at-the-market-u-vvos-20241223monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-reports-third-quarter-2024-financial-results-and-provides-operational-u-vvos-20241114monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-announces-pricing-of-4-3-million-registered-direct-offering-of-common-s-vvos-20240919monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-receives-groundbreaking-fda-510-k-clearance-to-treat-moderate-to-severe-vvos-20240918monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-reports-second-quarter-2024-financial-results-and-provides-operational--vvos-20240814monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-closes-7-5-million-at-the-market-private-equity-backed-investment-and-l-vvos-20240612monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-reports-first-quarter-2024-financial-results-and-provides-operational-u-vvos-20240514monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-provide-vvos-20240328monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-reports-second-quarter-2023-financial-results-and-provides-operational--vvos-20230816monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-reports-first-quarter-2023-financial-results-and-provides-operational-u-vvos-20230608monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-announces-additional-strategic-initiatives-aimed-at-accelerating-antici-vvos-20230509monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-provide-vvos-20230330monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-expands-product-line-and-revenue-potential-with-acquisition-of-product--vvos-20230301monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-announces-pricing-of-8-million-private-placement-vvos-20230105monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-reports-second-and-third-quarter-2022-financial-results-and-provides-op-vvos-20221220monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-announces-receipt-of-notice-from-nasdaq-regarding-late-filing-of-third--vvos-20221128monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-provides-update-on-revenue-recognition-review-detailed-analysis-finds-m-vvos-20221122monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-announces-multiple-regulatory-clearances-in-australia-for-its-entire-li-vvos-20220718monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-sleep-2022-annual-meeting-presentation-highlights-retrospective-study-d-vvos-20220606monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-reports-first-quarter-2022-financial-results-and-operational-update-fir-vvos-20220516monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-operati-vvos-20220331monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-reports-third-quarter-2021-financial-results-and-operational-update-thi-vvos-20211115monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-reports-second-quarter-2021-financial-results-and-operational-update-se-vvos-20210812monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-reports-first-quarter-2021-financial-results-and-operational-update-man-vvos-20210517monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-announces-closing-of-follow-on-offering-and-exercise-in-full-of-the-und-vvos-20210511monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-to-launch-myocorrect-orofacial-myofunctional-therapy-service-vivos-to-o-vvos-20210330monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and-operati-vvos-20210325monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-launches-vivoscore-diagnostic-technology-for-home-sleep-apnea-testing-i-vvos-20210216monthly0.5https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-announces-closing-of-initial-public-offering-and-exercise-in-full-of-th-vvos-20201215monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-acquires-ai-integrated-digital-health-platform-behind-halo-clarity-and-nexalin-neu-nxl-20260519monthly0.5https://www.biopharmawatch.com/news/NXL/technology-advances-pivotal-clinical-trial-of-halo-clarity-nxl-20260422monthly0.5https://www.biopharmawatch.com/news/NXL/technology-receives-nasdaq-listing-status-notification-nxl-20260123monthly0.5https://www.biopharmawatch.com/news/NXL/harnessing-the-power-of-advanced-frequency-neurostimulation-to-improve-mental-health-inves-nxl-20251205monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-appoints-highly-experienced-financial-leader-justin-van-fleet-nxl-20250804monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-announces-pricing-of-5-0-million-public-offering-of-common-stock-housto-nxl-20250505monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-regains-compliance-with-nasdaq-continued-listing-requirements-nxl-20241101monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-announces-closing-of-5-2-million-public-offering-houston-nxl-20240701monthly0.5https://www.biopharmawatch.com/news/NXL/nexalin-technology-announces-pricing-of-5-2-million-public-offering-houston-nxl-20240627monthly0.5https://www.biopharmawatch.com/news/NXL/announces-regulatory-approval-to-sell-nexalin-s-gen-2-15-ma-neurostimulation-device-by-the-nxl-20240618monthly0.5https://www.biopharmawatch.com/news/NXL/techn-ology-regains-compliance-with-nasdaq-continued-listing-requirements-nxl-20240426monthly0.5https://www.biopharmawatch.com/news/NXL/technology-ceo-provides-letter-to-shareholders-nxl-20240411monthly0.5https://www.biopharmawatch.com/news/NXL/technology-inc-nxl-20230602monthly0.5https://www.biopharmawatch.com/news/NXL/technology-inc-nxl-20220920monthly0.5https://www.biopharmawatch.com/news/NXL/technology-inc-nxl-20220916monthly0.5https://www.biopharmawatch.com/news/PHGE/zorronet-delivers-98-success-in-israel-railways-pilot-awarded-framework-supply-agreement-f-phge-20260416monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-acquires-zorronet-autonomous-ai-command-and-control-platform-for-real-time-defense-a-phge-20260410monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-inc-received-nyse-american-notification-letter-regarding-stockholders-equity-deficie-phge-20260327monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-ceo-issues-letter-to-stockholders-ceo-letter-to-stockholders-highlights-the-company--phge-20260319monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-inc-unaudited-pro-forma-condensed-consolidated-financial-information-on-phge-20260210monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-reports-second-quarter-2025-financial-results-and-provides-program-updates-positive--phge-20250813monthly0.5https://www.biopharmawatch.com/news/PHGE/corporate-presentation-june-2025-clinical-stage-programs-addressing-urgent-need-for-overco-phge-20250609monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-reports-first-quarter-2025-financial-results-and-provides-business-and-program-updat-phge-20250515monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-announces-positive-topline-results-from-phase-2-trial-evaluating-bx211-for-the-treat-phge-20250403monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-business-an-phge-20250325monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-announces-a-series-of-financings-for-aggregate-gross-proceeds-of-12-million-proceeds-phge-20250226monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-announces-third-quarter-2024-financial-results-and-provides-business-and-program-upd-phge-20241114monthly0.5https://www.biopharmawatch.com/news/PHGE/r-e-v-ol-u-tioni-z-i-n-g-the-t-r-e-a-tme-n-t-of-i-n-f-e-c-t-i-o-n-s-a-s-s-oci-a-t-e-d-wit--phge-20240926monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-business-up-phge-20240403monthly0.5https://www.biopharmawatch.com/news/PHGE/form-of-parent-stockholder-support-agreement-biomx-inc-support-agreement-this-support-agre-phge-20240306monthly0.5https://www.biopharmawatch.com/news/PHGE/item-8-financial-statements-and-supplementary-data-consolidated-financial-statements-decem-phge-20231207monthly0.5https://www.biopharmawatch.com/news/PHGE/revolutionizing-the-treatment-of-cystic-fibrosis-through-our-unique-bolt-phage-therapy-pla-phge-20231129monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-reports-third-quarter-2023-financial-results-and-provides-business-update-analysis-o-phge-20231114monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-reports-second-quarter-2023-financial-results-and-provides-business-update-patient-s-phge-20230809monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-reports-first-quarter-2023-financial-results-and-provides-business-update-announced--phge-20230515monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-business-up-phge-20230329monthly0.5https://www.biopharmawatch.com/news/PHGE/revolutionizing-the-treatment-of-cystic-fibrosis-through-our-unique-bolt-phage-therapy-pla-phge-20230222monthly0.5https://www.biopharmawatch.com/news/PHGE/revolutionizing-the-treatment-of-cystic-fibrosis-through-our-unique-bolt-phage-therapy-pla-phge-20230126monthly0.5https://www.biopharmawatch.com/news/PHGE/dated-november-9-2022-e-xhibit-99-1-biomx-reports-third-quarter-2022-financial-results-and-phge-20221109monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-reports-second-quarter-2022-financial-results-and-provides-business-update-enrollmen-phge-20220810monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-ltd-all-rights-reserved-company-introduction-safe-harbor-statement-this-presentation-phge-20220614monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-reports-first-quarter-2022-financial-results-and-provides-business-update-upcoming-k-phge-20220511monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-business-up-phge-20220330monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-reports-third-quarter-2021-financial-results-and-provides-business-update-announces--phge-20211115monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-reports-second-quarter-2021-financial-results-and-provides-business-update-up-to-45--phge-20210816monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-reports-first-quarter-2021-financial-results-and-provides-business-updates-company-a-phge-20210524monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-business-up-phge-20210331monthly0.5https://www.biopharmawatch.com/news/PHGE/to-we-us-and-our-refer-to-biomx-inc-and-its-wholly-owned-israeli-subsidiary-biomx-ltd-and--phge-20201204monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-reports-third-quarter-2020-financial-results-and-announces-expanded-portfolio-of-pha-phge-20201112monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-reports-second-quarter-2020-financial-results-and-provides-business-update-expect-to-phge-20200813monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-reports-first-quarter-2020-financial-results-and-provides-business-update-positive-p-phge-20200514monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-announces-date-of-2020-annual-meeting-of-stockholders-ness-ziona-israel-phge-20200407monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-announces-positive-topline-data-from-phase-1-study-for-lead-candidate-bx001-for-acne-phge-20200331monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-announces-dual-listing-on-the-tel-aviv-phge-20200203monthly0.5https://www.biopharmawatch.com/news/PHGE/jfif-6-6-424-lddl-z-6-6-424-lddl-z-1-aq-a-phge-20200109monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-ltd-index-to-financial-statements-page-interim-consolidated-balance-sheets-as-of-phge-20191113monthly0.5https://www.biopharmawatch.com/news/PHGE/biomx-appoints-russell-g-phge-20191104monthly0.5https://www.biopharmawatch.com/news/PHGE/chardan-healthcare-acquisition-corp-completes-merger-with-biomx-ltd-combined-company-renam-phge-20191029monthly0.5https://www.biopharmawatch.com/news/PHGE/chardan-healthcare-acquisition-corp-shareholders-approve-definitive-merger-agreement-with--phge-20191023monthly0.5https://www.biopharmawatch.com/news/PHGE/chardan-healthcare-acquisition-corp-announces-amendment-to-merger-agreement-with-biomx-ltd-phge-20191014monthly0.5https://www.biopharmawatch.com/news/PHGE/chardan-healthcare-acquisition-corp-announces-amendment-to-merger-agreement-with-biomx-ltd-phge-20191011monthly0.5https://www.biopharmawatch.com/news/PHGE/chardan-advises-health-sciences-acquisitions-corporation-on-merger-with-immunovant-phge-20191003monthly0.5https://www.biopharmawatch.com/news/PHGE/chardan-healthcare-acquisition-chac-to-merge-with-biomx-ltd-phge-20190923monthly0.5https://www.biopharmawatch.com/news/PHGE/jfif-6-6-424-lddl-z-6-6-424-lddl-z-1a-q-phge-20190919monthly0.5https://www.biopharmawatch.com/news/PHGE/chardan-healthcare-acquisition-corp-announces-merger-agreement-with-biomx-ltd-combined-com-phge-20190717monthly0.5https://www.biopharmawatch.com/news/PHGE/chardan-healthcare-acquisition-corp-index-to-balance-sheet-page-report-of-independent-regi-phge-20181218monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-receives-notification-from-nasdaq-related-to-annual-re-mrm-20260529monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-group-reports-q1-2026-results-tokyo-mrm-20260528monthly0.5https://www.biopharmawatch.com/news/MRM/annex-a-to-notice-of-convocation-note-this-document-has-been-translated-from-the-japanese--mrm-20260416monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-december-2025-key-performance-indicators-kpi-mrm-20260130monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-forms-new-special-mission-team-to-drive-world-id-adoption-across-3-000-locations-t-mrm-20260123monthly0.5https://www.biopharmawatch.com/news/MRM/world-co-founded-by-sam-altman-and-alex-blania-accelerates-expansion-in-japan-via-medirom--mrm-20251228monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-november-2025-key-performance-indicators-kpi-mrm-20251222monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-mother-labs-partners-with-td-synnex-to-accelerate-national-adoption-of-mother-brac-mrm-20251204monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-october-2025-key-performance-indicators-kpis-mrm-20251203monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-mother-labs-inc-receives-capital-investment-from-internal-investors-completion-of--mrm-20251030monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-to-launch-new-treasury-strategy-utilizing-cryptocurrency-aimed-at-incentivize-larg-mrm-20251029monthly0.5https://www.biopharmawatch.com/news/MRM/more-than-10-000-people-receive-verified-world-ids-at-medirom-locations-medirom-is-a-locat-mrm-20251028monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-reports-financial-results-for-the-six-months-ended-mrm-20251021monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-september-2025-key-performance-indicators-kp-mrm-20251020monthly0.5https://www.biopharmawatch.com/news/MRM/series-a-round-valuation-9-billion-medirom-mother-labs-inc-decides-to-make-an-investment-f-mrm-20251009monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-decides-to-double-installation-of-authentication-device-orb-to-200-stores-in-colla-mrm-20250925monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-august-2025-key-performance-indicators-kpis--mrm-20250924monthly0.5https://www.biopharmawatch.com/news/MRM/japan-ground-self-defense-force-adopts-medirom-mother-labs-remony-for-advanced-health-moni-mrm-20250918monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-s-remony-certified-by-mlit-as-a-fatigue-driving-prevention-device-august-28th-2025-mrm-20250828monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-launches-cryptocurrency-strategy-with-next-generation-proof-of-human-technology-wo-mrm-20250822monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-july-2025-key-performance-indicators-kpis-to-mrm-20250820monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-joins-the-world-network-embracing-next-generation-proof-of-human-concept-led-by-ch-mrm-20250731monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-june-2025-key-performance-indicators-kpis-to-mrm-20250721monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-may-2025-key-performance-indicators-kpis-tot-mrm-20250620monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-regains-compliance-with-nasdaq-continued-listing-requi-mrm-20250605monthly0.5https://www.biopharmawatch.com/news/MRM/may-2025-medirom-group-specific-health-guidance-service-utilizing-the-lav-healthcare-app-s-mrm-20250530monthly0.5https://www.biopharmawatch.com/news/MRM/note-this-document-has-been-translated-from-the-japanese-original-for-reference-purposes-o-mrm-20250530monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-2-2-rise-in-revenue-and-20-improvement-in-ea-mrm-20250520monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-april-2025-key-performance-indicators-kpis-t-mrm-20250520monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-march-2025-key-performance-indicators-kpis-t-mrm-20250426monthly0.5https://www.biopharmawatch.com/news/MRM/notice-this-is-a-translation-of-the-japanese-original-for-reference-purposes-only-and-in-t-mrm-20250423monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-february-2025-key-performance-indicators-kpi-mrm-20250228monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-new-jpy350-million-approximately-2-4-million-mrm-20250318monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-mother-labs-executive-makes-additional-invest-ment-in-mother-labs-series-a-financi-mrm-20250313monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-january-2025-key-performance-indicators-kpis-mrm-20250222monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-preliminary-unaudited-financial-results-for--mrm-20250218monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-december-2024-key-performance-indicators-kpi-mrm-20250129monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-mother-labs-provides-mother-bracelet-device-and-remote-health-monitoring-system-re-mrm-20250121monthly0.5https://www.biopharmawatch.com/news/MRM/completion-of-offering-and-increase-in-registered-capital-january-21-2025-tokyo-japan-medi-mrm-20250114monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-november-2024-key-performance-indicators-kpi-mrm-20241223monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technology-s-subsidiary-medirom-mother-labs-raises-an-aggregate-total-o-mrm-20241213monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-pricing-of-public-offering-tokyo-japan-mrm-20241209monthly0.5https://www.biopharmawatch.com/news/MRM/two-senior-medirom-mother-labs-executives-invest-in-mother-labs-series-a-f-inancing-at-a-p-mrm-20241201monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-has-received-orders-for-over-25-000-mother-bracelet-units--mrm-20241209monthly0.5https://www.biopharmawatch.com/news/MRM/m3-group-joins-medirom-mother-labs-series-a-financing-round-at-jpy9-billion-as-of-mrm-20241201monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-october-2024-key-performance-indicators-kpis-mrm-20241121monthly0.5https://www.biopharmawatch.com/news/MRM/index-to-unaudited-condensed-consolidated-financial-statements-unaudited-condensed-consoli-mrm-20241108monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-september-2024-key-performance-indicators-kp-mrm-20241024monthly0.5https://www.biopharmawatch.com/news/MRM/elematec-corporation-forms-a-business-alliance-with-and-agrees-to-make-a-strategic-investm-mrm-20241015monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-august-2024-key-performance-indicators-kpis--mrm-20240924monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-july-2024-key-performance-indicators-kpis-to-mrm-20240827monthly0.5https://www.biopharmawatch.com/news/MRM/capital-and-business-alliance-formed-between-medirom-mother-labs-and-nfes-technologies-nfe-mrm-20240823monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-june-2024-key-performance-indicators-kpis-to-mrm-20240723monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-announces-acquisition-of-japan-gene-medicine-corporation-n-mrm-20240710monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-may-2024-key-performance-indicators-kpis-tot-mrm-20240625monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-receives-notification-from-nasdaq-related-to-annual-re-mrm-20240521monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-march-2024-key-performance-indicators-kpis-t-mrm-20240424monthly0.5https://www.biopharmawatch.com/news/MRM/announcement-execution-of-memorandum-of-understanding-for-share-acquisition-subsidiarizati-mrm-20240402monthly0.5https://www.biopharmawatch.com/news/MRM/note-this-document-has-been-translated-from-the-japanese-original-for-reference-purposes-o-mrm-20240329monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-february-2024-key-performance-indicators-kpi-mrm-20240321monthly0.5https://www.biopharmawatch.com/news/MRM/notice-this-is-a-translation-of-the-japanese-original-for-reference-purposes-only-and-in-t-mrm-20240311monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-january-2024-key-performance-indicators-kpis-mrm-20240222monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-december-2023-key-performance-indicators-kpi-mrm-20240125monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-reports-financial-results-for-the-six-months-ended-mrm-20231229monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-november-2023-key-performance-indicators-kpi-mrm-20231222monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-october-2023-key-performance-indicators-kpis-mrm-20231124monthly0.5https://www.biopharmawatch.com/news/MRM/nasdaq-mrm-september-2023-important-notices-important-notices-and-disclaimers-this-investo-mrm-20231025monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-september-2023-key-performance-indicators-kp-mrm-20231024monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-august-2023-key-performance-indicators-kpis--mrm-20230920monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-july-2023-key-performance-indicators-kpis-to-mrm-20230822monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-june-2023-key-performance-indicators-kpis-to-mrm-20230720monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-may-2023-key-performance-indicators-kpis-tot-mrm-20230620monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-group-reorganization-new-york-mrm-20230602monthly0.5https://www.biopharmawatch.com/news/MRM/to-a-report-on-form-6-k-filed-by-the-company-with-the-sec-on-mrm-20230524monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-april-2023-key-performance-indicators-kpis-t-mrm-20230522monthly0.5https://www.biopharmawatch.com/news/MRM/to-a-report-on-form-6-k-filed-by-the-company-with-the-sec-on-march-16-2023-about-medirom-h-mrm-20230501monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-march-2023-key-performance-indicators-kpis-t-mrm-20230420monthly0.5https://www.biopharmawatch.com/news/MRM/note-this-document-has-been-translated-from-the-japanese-original-for-reference-purposes-o-mrm-20230331monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-february-2023-key-performance-indicators-kpi-mrm-20230327monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-successfully-appeals-nasdaq-delisting-notice-new-york-mrm-20230316monthly0.5https://www.biopharmawatch.com/news/MRM/english-translation-of-convocation-notice-originally-issued-in-the-japanese-language-note--mrm-20230316monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-january-2023-key-performance-indicators-kpis-mrm-20230222monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-up-to-jpy-50-million-stock-repurchase-plan-b-mrm-20230119monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-preliminary-unaudited-financial-results-for--mrm-20230118monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-receipt-of-nasdaq-delisting-notice-and-inten-mrm-20221230monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-closing-of-sale-and-issuance-of-convertible--mrm-20221229monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-sets-full-year-2021-earnings-call-for-thursday-mrm-20221222monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-november-2022-key-performance-indicators-kpi-mrm-20221220monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-proposed-sale-of-convertible-corporate-bonds-mrm-20221209monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-preliminary-interim-half-year-financial-resu-mrm-20221209monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-october-2022-key-performance-indicators-kpis-mrm-20221123monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-september-2022-key-performance-indicators-kp-mrm-20221020monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-august-2022-key-performance-indicators-kpis--mrm-20220920monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-july-2022-key-performance-indicators-kpis-to-mrm-20220822monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-june-2022-key-performance-indicators-kpis-to-mrm-20220722monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-receives-nasdaq-notification-regarding-minimum-market--mrm-20220701monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-may-2022-key-performance-indicators-kpis-tot-mrm-20220621monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-april-2022-key-performance-indicators-kpis-t-mrm-20220519monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-receives-notification-from-nasdaq-related-to-delayed-f-mrm-20220518monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-preliminary-2021-financial-results-revenue-g-mrm-20220506monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-regains-compliance-with-nasdaq-listing-standard-new-yo-mrm-20220422monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-march-2022-key-performance-indicators-kpis-t-mrm-20220418monthly0.5https://www.biopharmawatch.com/news/MRM/note-this-document-has-been-translated-from-the-japanese-original-for-reference-purposes-o-mrm-20220329monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-its-latest-key-performance-indicators-kpis-n-mrm-20220318monthly0.5https://www.biopharmawatch.com/news/MRM/this-is-an-english-translation-of-the-original-issued-in-japanese-note-this-document-has-b-mrm-20220314monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-its-latest-key-performance-indicators-kpis-n-mrm-20220304monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-its-latest-key-performance-indicators-kpis-n-mrm-20220124monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-receives-nasdaq-notification-regarding-minimum-market--mrm-20220121monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-business-alliance-with-juju-holdings-kabushi-mrm-20211221monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-its-latest-key-performance-indicators-kpis-n-mrm-20211213monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-its-latest-key-performance-indicators-kpis-n-mrm-20211119monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-group-announces-changes-of-directors-and-corporate-names-of-subsidiaries-to-streng-mrm-20211103monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-its-latest-key-performance-indicators-kpis-n-mrm-20211020monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-to-present-at-the-benzinga-healthcare-small-cap-conference-mrm-20210924monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-acquisition-of-zacc-kabushiki-kaisha-new-yor-mrm-20210922monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-the-timing-of-its-release-of-2021-interim-ea-mrm-20210819monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-its-latest-key-performance-indicators-kpis-n-mrm-20210719monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-its-latest-key-performance-indicators-kpis-n-mrm-20210622monthly0.5https://www.biopharmawatch.com/news/MRM/note-this-document-has-been-translated-from-the-japanese-original-for-reference-purposes-o-mrm-20210608monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-partners-with-sanei-electronics-for-manufacture-of-mother-tracker-with-canon-elect-mrm-20210521monthly0.5https://www.biopharmawatch.com/news/MRM/preventative-healthcare-enabled-earnings-presentation-may-2021-medirom-healthcare-technolo-mrm-20210519monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-its-latest-key-performance-indicators-kpis-n-mrm-20210517monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-enters-into-strategic-partnership-with-zacc-kabushiki--mrm-20210415monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-its-latest-key-performance-indicators-kpis-n-mrm-20210318monthly0.5https://www.biopharmawatch.com/news/MRM/note-the-company-assumes-no-responsibility-for-this-translation-or-for-direct-indirect-or--mrm-20210302monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-exercise-and-closing-of-over-allotment-optio-mrm-20210201monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-closing-of-12-000-000-initial-public-offerin-mrm-20201231monthly0.5https://www.biopharmawatch.com/news/MRM/medirom-healthcare-technologies-inc-announces-pricing-of-upsized-12-0-million-initial-publ-mrm-20201228monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-announces-up-to-10-million-cash-financing-includes-up-front-issuance-of-preferred-s-imnn-20260604monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-reports-first-quarter-2026-financial-results-and-provides-business-update-imnn-001--imnn-20260512monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-reports-2025-financial-results-and-provides-business-update-highlighting-significan-imnn-20260331monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-successfully-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement-l-imnn-20250828monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-reports-second-quarter-2025-financial-results-and-provides-business-update-stock-di-imnn-20250805monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-announces-stock-dividend-boosting-shareholder-value-stock-dividend-reflects-company-imnn-20250728monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-announces-reverse-stock-split-lawrenceville-n-j-imnn-20250723monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-announces-up-to-9-75-million-private-placement-priced-at-the-market-under-nasdaq-ru-imnn-20250523monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-reports-first-quarter-2025-financial-results-and-provides-business-update-first-sit-imnn-20250512monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-finalizes-phase-3-study-design-with-fda-for-imnn-001-in-newly-diagnosed-advanced-ov-imnn-20250325monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-reports-2024-financial-results-and-provides-business-update-highlighting-significan-imnn-20250227monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-appoints-douglas-v-faller-m-d-ph-d-as-chief-medical-officer-dr-faller-joins-imunon--imnn-20250210monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-reports-third-quarter-2024-financial-results-and-provides-business-updates-conferen-imnn-20241107monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-lawrenceville-n-j-imnn-20241007monthly0.5https://www.biopharmawatch.com/news/IMNN/final-august-12-2024-imunon-reports-second-quarter-2024-financial-results-and-provides-a-b-imnn-20240814monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-announces-10-million-registered-direct-offering-priced-at-the-market-under-nasdaq-r-imnn-20240731monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-announces-11-1-month-increase-in-overall-survival-in-patients-with-newly-diagnosed--imnn-20240730monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-reports-first-quarter-2024-financial-results-and-provides-business-update-conferenc-imnn-20240513monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-appoints-director-dr-stacy-r-lindborg-as-president-and-ceo-assumes-leadership-role--imnn-20240508monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-reports-compliance-with-nasdaq-listing-requirements-lawrenceville-n-j-imnn-20240411monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-reports-2023-financial-results-and-provides-business-update-conference-call-begins--imnn-20240328monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-announces-leadership-change-executive-chairman-to-lead-day-to-day-operations-active-imnn-20240312monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-appoints-dr-sebastien-hazard-as-chief-medical-officer-and-reports-inducement-grant--imnn-20231211monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-reports-third-quarter-2023-financial-results-and-provides-a-business-update-advance-imnn-20231114monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-reports-second-quarter-2023-financial-results-and-provides-business-update-advances-imnn-20230810monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-reports-first-quarter-2023-financial-results-and-provides-business-update-non-viral-imnn-20230511monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-reports-2022-financial-results-and-provides-business-update-conference-call-begins--imnn-20230330monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-inc-third-quarter-2022-conference-call-monday-imnn-20221114monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-reports-third-quarter-2022-financial-results-and-provides-business-update-conferenc-imnn-20221114monthly0.5https://www.biopharmawatch.com/news/IMNN/imunon-appoints-james-e-dentzer-to-its-board-of-directors-ceo-of-curis-brings-extensive-bi-imnn-20221003monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-second-quarter-2022-financial-results-and-provides-business-up-imnn-20220815monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-appoints-dr-corinne-le-goff-as-president-and-chief-executive-officer-michael-h-tar-imnn-20220719monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-first-quarter-2022-financial-results-and-provides-business-upd-imnn-20220516monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-announces-7-0-million-registered-direct-offering-priced-at-the-market-imnn-20220406monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-2021-financial-results-and-provides-business-update-focus-on-c-imnn-20220331monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-announces-stock-consolidation-lawrenceville-n-j-imnn-20220228monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-announces-pricing-of-30-million-registered-direct-offerings-of-convert-imnn-20220113monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-announces-pricing-of-30-million-registered-direct-offerings-of-convert-imnn-20220110monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-third-quarter-2021-financial-results-and-provides-business-upd-imnn-20211115monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-second-quarter-2021-financial-results-and-provides-business-up-imnn-20210812monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-enters-into-10-million-strategic-loan-facility-with-silicon-valley-ban-imnn-20210621monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-appoints-dr-stacy-r-lindborg-to-its-board-of-directors-25-year-pharmac-imnn-20210608monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-announces-adjournment-of-annual-meeting-a-quorum-has-been-achieved-to--imnn-20210610monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-announces-adjournment-of-annual-meeting-49-of-shares-voted-quorum-not--imnn-20210604monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-first-quarter-2021-financial-results-and-provides-business-upd-imnn-20210514monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-announces-15-million-registered-direct-offering-lawrenceville-nj-imnn-20210331monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-2020-financial-results-and-provides-business-update-entered-20-imnn-20210319monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-issues-letter-to-stockholders-discusses-broad-based-dna-vaccine-initia-imnn-20210211monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-announces-35-million-registered-direct-offering-priced-at-the-market-u-imnn-20210122monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-third-quarter-2020-financial-results-and-provides-business-upd-imnn-20201116monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-announces-common-stock-purchase-agreement-with-lincoln-park-capital-and-provides-u-imnn-20200908monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-second-quarter-2020-financial-results-and-provides-business-up-imnn-20200814monthly0.5https://www.biopharmawatch.com/news/IMNN/william-j-o-connor-derivatively-on-behalf-of-celsion-corporation-and-individually-and-on-b-imnn-20200803monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-receives-recommendation-from-independent-data-monitoring-committee-to--imnn-20200713monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-announces-pricing-of-10-million-underwritten-offering-of-common-stock--imnn-20200622monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-first-quarter-2020-financial-results-and-provides-business-upd-imnn-20200515monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-receives-2-5-million-in-non-dilutive-funding-from-the-sale-of-its-new-jersey-state-imnn-20200423monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-2019-financial-results-and-provides-business-update-enters-202-imnn-20200326monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-prices-4-8-million-registered-direct-offering-lawrenceville-nj-imnn-20200228monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-third-quarter-2019-financial-results-and-provides-business-upd-imnn-20191115monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-second-quarter-2019-financial-results-and-provides-business-up-imnn-20190815monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-first-quarter-2019-financial-results-and-provides-business-upd-imnn-20190515monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-2018-financial-results-celsion-enters-2019-with-a-strong-balan-imnn-20190329monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-third-quarter-2018-financial-results-and-provides-business-upd-imnn-20181115monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-second-quarter-2018-financial-results-and-provides-business-up-imnn-20180814monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-first-quarter-2018-financial-results-and-provides-business-upd-imnn-20180511monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-second-quarter-2017-financial-results-and-provides-business-up-imnn-20170815monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-announces-5-million-registered-direct-offering-lawrenceville-n-j-imnn-20170706monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-announces-cancellation-of-registered-direct-offering-lawrenceville-n-j-imnn-20170622monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-announces-5-4-million-registered-direct-offering-lawrenceville-n-j-imnn-20170619monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-regains-compliance-with-nasdaq-listing-requirements-lawrenceville-n-j-imnn-20170614monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-announces-stock-consolidation-strategic-move-to-attract-a-broader-rang-imnn-20170526monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-first-quarter-2017-financial-results-and-provides-business-upd-imnn-20170512monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-year-end-201-6-financial-results-and-provides-business-update--imnn-20170316monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-announces-5-0-million-public-offering-lawrenceville-n-j-imnn-20170215monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-announces-1-8-million-registered-direct-offering-lawrenceville-n-j-imnn-20161220monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-third-quarter-2016-financial-results-and-provides-business-upd-imnn-20161110monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-second-quarter-2016-financial-results-and-provides-business-up-imnn-20160815monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-announces-6-million-registered-direct-offering-lawrenceville-n-j-imnn-20160613monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-first-quarter-2016-financial-results-and-provides-business-upd-imnn-20160516monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-year-end-2015-financial-results-and-provides-business-update-c-imnn-20160330monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-announces-appointment-of-two-new-members-to-its-board-of-directors-lawrenceville-n-imnn-20151217monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-third-quarter-2015-financial-results-and-provides-business-upd-imnn-20151105monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-second-quarter-2015-financial-results-and-provides-business-up-imnn-20150810monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-announces-8-million-at-the-market-registered-direct-offering-lawrencev-imnn-20150528monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-first-quarter-2015-financial-results-and-provides-business-upd-imnn-20150512monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-year-end-2014-financial-results-and-provides-business-update-c-imnn-20150312monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-and-mytomorrows-partner-to-introduce-thermodox-early-access-program-in-imnn-20150120monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-third-quarter-2014-financial-results-company-completes-acquisi-imnn-20141111monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-announces-appointment-of-michael-h-tardugno-to-executive-chairman-of-the-board-of--imnn-20141007monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-second-quarter-2014-financial-results-company-completes-acquis-imnn-20140807monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-completes-acquisition-of-egen-inc-transaction-forms-fully-integrated-o-imnn-20140620monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-to-acquire-egen-inc-transaction-forms-fully-integrated-oncology-discov-imnn-20140610monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-first-quarter-2014-financial-results-and-provides-business-upd-imnn-20140508monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-year-end-2013-financial-results-and-provides-business-update-o-imnn-20140313monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-announces-15-million-at-the-market-registered-direct-offering-lawrence-imnn-20140115monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-third-quarter-2013-financial-results-and-provides-business-upd-imnn-20131112monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-announces-stock-consolidation-strategic-move-to-attract-a-broader-rang-imnn-20131028monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-second-quarter-2013-financial-results-and-provides-heat-study--imnn-20130808monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-announces-jeffrey-w-church-reappointed-to-cfo-company-completes-previously-announc-imnn-20130702monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-announces-9-83-million-registered-direct-offering-lawrenceville-n-j-imnn-20130531monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-first-quarter-2013-financial-results-and-provides-business-upd-imnn-20130509monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-year-end-2012-financial-results-and-provides-business-update-d-imnn-20130318monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-announces-15-million-registered-direct-offering-lawrenceville-n-j-imnn-20130222monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-provides-an-update-regarding-thermodox-agreements-with-zhejiang-hisun--imnn-20130205monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-announces-results-of-phase-iii-heat-study-of-thermodox-in-primary-liver-cancer-com-imnn-20130131monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-and-zhejiang-hisun-pharmaceutical-company-enter-into-technology-develo-imnn-20130122monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-selected-balance-sheet-information-in-thousands-imnn-20121113monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-second-quarter-2012-financial-results-and-business-update-comp-imnn-20120814monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-reports-first-quarter-2012-financial-results-company-to-hold-conference-call-on-tu-imnn-20120515monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-reports-year-end-2011-financial-results-and-provides-business-update-company-to-ho-imnn-20120315monthly0.5https://www.biopharmawatch.com/news/IMNN/the-investor-presentation-of-celsion-corporation-is-contained-in-the-corresponding-pdf-fil-imnn-20120307monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-to-raise-15-million-in-private-placement-investment-by-leading-life-sc-imnn-20111201monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-announces-unanimous-recommendation-by-independent-data-monitoring-committee-to-con-imnn-20111128monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-reports-third-quarter-2011-financial-results-and-provides-business-updates-company-imnn-20111110monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-reports-second-quarter-2011-financial-results-and-provides-business-updates-compan-imnn-20110809monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-announces-closing-of-18-4-million-in-financing-triggers-conversion-of-all-preferre-imnn-20110725monthly0.5https://www.biopharmawatch.com/news/IMNN/exhibit-lease-exhibit99-1-htm-exhibit-10-1-tenant-celsion-suite-no-100-997-lenox-drive-law-imnn-20110711monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-announces-closing-of-6-6-million-registered-direct-offering-columbia-m-imnn-20110706monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-announces-6-6-million-registered-direct-offering-columbia-md-imnn-20110701monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-announces-8-6-million-equity-offering-of-common-stock-and-warrants-col-imnn-20110527monthly0.5https://www.biopharmawatch.com/news/IMNN/celsion-corporation-reports-year-end-2010-financial-results-and-provides-business-update-c-imnn-20110325monthly0.5https://www.biopharmawatch.com/news/ELAB/financial-statements-of-a-b-aerospace-inc-for-the-three-and-nine-months-ended-elab-20260513monthly0.5https://www.biopharmawatch.com/news/ELAB/northstrive-biosciences-files-new-u-s-patent-application-for-el-22-targeting-muscle-preser-elab-20260428monthly0.5https://www.biopharmawatch.com/news/ELAB/northstrive-defense-tech-acquires-patented-gps-denied-autonomous-drone-navigation-technolo-elab-20260423monthly0.5https://www.biopharmawatch.com/news/ELAB/svm-machining-inc-signs-long-term-agreement-to-supply-mission-critical-aerospace-and-defen-elab-20260421monthly0.5https://www.biopharmawatch.com/news/ELAB/pmgc-holdings-inc-nasdaq-elab-secures-40-million-equity-purchase-facility-agreement-announ-elab-20260417monthly0.5https://www.biopharmawatch.com/news/ELAB/aga-precision-systems-signs-second-long-term-supply-agreement-to-manufacture-aerospace-and-elab-20260409monthly0.5https://www.biopharmawatch.com/news/ELAB/pmgc-holdings-inc-nasdaq-elab-pmgc-holdings-fully-utilizes-all-available-in-20m-equity-fin-elab-20260408monthly0.5https://www.biopharmawatch.com/news/ELAB/northstrive-defense-tech-acquires-multi-domain-drone-payload-technology-option-for-defense-elab-20260406monthly0.5https://www.biopharmawatch.com/news/ELAB/pmgc-holdings-inc-announces-the-formation-of-new-subsidiary-northstrive-defense-tech-to-ta-elab-20260402monthly0.5https://www.biopharmawatch.com/news/ELAB/aga-precision-systems-signs-long-term-agreement-to-supply-mission-critical-aerospace-and-d-elab-20260331monthly0.5https://www.biopharmawatch.com/news/ELAB/svm-machining-inc-secures-itar-registration-enabling-entry-into-u-s-defense-manufacturing--elab-20260324monthly0.5https://www.biopharmawatch.com/news/ELAB/pmgc-holdings-inc-announces-anticipated-reverse-stock-split-elab-20260304monthly0.5https://www.biopharmawatch.com/news/ELAB/northstrive-biosciences-files-10-u-s-patent-applications-for-el-22-and-el-32-targeting-mus-elab-20260218monthly0.5https://www.biopharmawatch.com/news/ELAB/northstrive-biosciences-signs-definitive-license-agreement-for-commercialization-of-el-22--elab-20260211monthly0.5https://www.biopharmawatch.com/news/ELAB/pmgc-holdings-inc-announces-the-acquisition-of-svm-machining-inc-elab-20260203monthly0.5https://www.biopharmawatch.com/news/ELAB/pmgc-holdings-inc-announces-reverse-stock-split-effective-elab-20260106monthly0.5https://www.biopharmawatch.com/news/ELAB/northstrive-biosciences-advances-to-phase-iii-of-ai-driven-drug-discovery-program-toward-v-elab-20251217monthly0.5https://www.biopharmawatch.com/news/ELAB/pmgc-holdings-inc-announces-aga-precision-systems-llc-s-itar-international-traffic-in-arms-elab-20251030monthly0.5https://www.biopharmawatch.com/news/ELAB/pmgc-holdings-inc-s-subsidiary-aga-precision-systems-llc-completes-acquisition-of-indarg-e-elab-20251028monthly0.5https://www.biopharmawatch.com/news/ELAB/pmgc-holdings-inc-announces-anticipated-reverse-stock-split-elab-20250828monthly0.5https://www.biopharmawatch.com/news/ELAB/pmgc-holdings-inc-terminates-loi-to-focus-on-acquiring-high-growth-cnc-acquisitions-in-aer-elab-20250730monthly0.5https://www.biopharmawatch.com/news/ELAB/pmgc-holdings-inc-completes-acquisition-of-cnc-machining-company-aga-precision-systems-llc-elab-20250718monthly0.5https://www.biopharmawatch.com/news/ELAB/pmgc-holdings-inc-completes-acquisition-of-customer-it-packaging-company-pacific-sun-packa-elab-20250710monthly0.5https://www.biopharmawatch.com/news/ELAB/pmgc-holdings-inc-signs-non-binding-loi-to-acquire-cnc-aerospace-manufacturer-generating-4-elab-20250624monthly0.5https://www.biopharmawatch.com/news/ELAB/pmgc-holdings-inc-signs-letter-of-intent-to-acquire-profitable-u-s-based-as9100d-iso-9001--elab-20250616monthly0.5https://www.biopharmawatch.com/news/ELAB/pmgc-holdings-inc-signs-letter-of-intent-to-acquire-profitable-u-s-based-electronics-manuf-elab-20250609monthly0.5https://www.biopharmawatch.com/news/ELAB/northstrive-biosciences-signs-binding-term-sheet-with-modulant-biosciences-for-exclusive-g-elab-20250513monthly0.5https://www.biopharmawatch.com/news/ELAB/northstrive-biosciences-strengthens-ip-portfolio-with-new-us-patent-filings-for-el-22-and--elab-20250429monthly0.5https://www.biopharmawatch.com/news/ELAB/northstrive-biosciences-announces-positive-fda-response-supporting-a-submission-of-ind-for-elab-20250424monthly0.5https://www.biopharmawatch.com/news/ELAB/pmgc-holdings-inc-signs-letter-of-intent-to-acquire-profitable-u-s-based-custom-it-packagi-elab-20250416monthly0.5https://www.biopharmawatch.com/news/ELAB/northstrive-biosciences-signs-partnership-with-yuva-biosciences-to-develop-ai-powered-ther-elab-20250410monthly0.5https://www.biopharmawatch.com/news/ELAB/pmgc-holdings-inc-announces-1-48-million-registered-direct-offering-priced-at-the-market-u-elab-20250321monthly0.5https://www.biopharmawatch.com/news/ELAB/pmgc-holdings-announces-share-repurchases-from-existing-shareholders-elab-20250321monthly0.5https://www.biopharmawatch.com/news/ELAB/securities-purchase-agreement-this-securities-purchase-agreement-this-agreement-dated-as-o-elab-20250311monthly0.5https://www.biopharmawatch.com/news/ELAB/pmgc-holdings-inc-announces-reverse-stock-split-to-maintain-nasdaq-listing-compliance-newp-elab-20250306monthly0.5https://www.biopharmawatch.com/news/ELAB/northstrive-biosciences-inc-a-subsidiary-of-pmgc-holdings-inc-announces-successful-submiss-elab-20250218monthly0.5https://www.biopharmawatch.com/news/ELAB/a-pmgc-holdings-c-ompany-na-sdaq-elab-the-information-in-this-presentation-is-being-provid-elab-20250207monthly0.5https://www.biopharmawatch.com/news/ELAB/pmgc-holdings-inc-announces-closing-of-elevai-skincare-divestiture-subtitle-1-strategic-di-elab-20250116monthly0.5https://www.biopharmawatch.com/news/ELAB/resignation-letter-to-the-shareholders-and-board-of-directors-of-elevai-labs-inc-ladies-an-elab-20241231monthly0.5https://www.biopharmawatch.com/news/ELAB/elevai-labs-inc-announces-reverse-stock-split-to-maintain-nasdaq-listing-compliance-novemb-elab-20241122monthly0.5https://www.biopharmawatch.com/news/ELAB/knotus-co-ltd-study-no-21-ke-1021-efficacy-study-of-new-drug-candidate-for-sarcopenia-expe-elab-20241024monthly0.5https://www.biopharmawatch.com/news/ELAB/elevai-labs-inc-announces-pricing-of-8-0-million-public-offering-elab-20240923monthly0.5https://www.biopharmawatch.com/news/ELAB/nation-a-n-l-hair-loss-medical-aesthetics-president-carly-klein-today-the-1-leading-cause--elab-20240904monthly0.5https://www.biopharmawatch.com/news/ELAB/elevai-labs-inc-subsidiary-elevai-skincare-inc-announces-positive-data-results-with-comple-elab-20240826monthly0.5https://www.biopharmawatch.com/news/ELAB/next-generation-skin-scalp-rejuvenation-stem-cell-exosomes-mitochondrial-biogenesis-techno-elab-20240716monthly0.5https://www.biopharmawatch.com/news/ELAB/elevai-labs-acquires-exclusive-license-to-two-myostatin-muscle-loss-prevention-assets-with-elab-20240501monthly0.5https://www.biopharmawatch.com/news/ELAB/elevai-labs-inc-acquires-worldwide-license-agreement-for-proprietary-stem-cell-manufacturi-elab-20240116monthly0.5https://www.biopharmawatch.com/news/ELAB/elevai-labs-enters-into-licensing-agreement-with-yuva-biosciences-to-combine-exosome-and-m-elab-20231129monthly0.5https://www.biopharmawatch.com/news/ELAB/elevai-labs-inc-announces-closing-of-6-000-000-initial-public-offering-newport-beach-ca-elab-20231124monthly0.5https://www.biopharmawatch.com/news/ELAB/elevai-labs-inc-announces-pricing-of-6-000-000-initial-public-offering-newport-beach-ca-elab-20231120monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-japan-s-mhlw-grants-orphan-drug-designation-for-qrx003-in--qnrx-20260604monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-provides-corporate-update-and-reports-first-quarter-2026-financial-r-qnrx-20260507monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-fda-grants-fast-track-designation-for-qrx003-for-the-treat-qnrx-20260311monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-second-quarter-2025-financial-results-and-corporate-update-qnrx-20250807monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-fda-clearance-to-initiate-second-pivotal-whole-body-qrx003-qnrx-20250522monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-european-medicines-agency-ema-grants-orphan-drug-designati-qnrx-20250520monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-provides-corporate-update-and-announces-first-quarter-2025-financial-qnrx-20250513monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2-qnrx-20250313monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-pricing-of-6-8-million-public-offering-ashburn-va-qnrx-20241220monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-provides-corporate-update-and-announces-third-quarter-2024-financial-qnrx-20241107monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-provides-corporate-update-and-announces-second-quarter-2024-financia-qnrx-20240808monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-provides-corporate-update-and-announces-fourth-quarter-and-2023-fina-qnrx-20240313monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-fda-clearance-to-recruit-teen-subjects-into-both-ongoing-n-qnrx-20240304monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-fda-clearance-of-clinical-optimization-plan-for-qrx003-for-qnrx-20231218monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-provides-corporate-update-and-announces-third-quarter-2023-financial-qnrx-20231108monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-provides-corporate-update-and-announces-second-quarter-2023-financia-qnrx-20230802monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-provides-corporate-update-and-announces-first-quarter-2023-financial-qnrx-20230508monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-provides-corporate-update-and-announces-fourth-quarter-and-full-year-qnrx-20230308monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-pricing-of-7-0-million-public-offering-ashburn-va-qnrx-20230222monthly0.5https://www.biopharmawatch.com/news/QNRX/x200b-x200b-x200b-x200b-x200b-x200b-x200b-x200b-x200b-quoin-pharmaceuticals-ltd-x200b-cond-qnrx-20221110monthly0.5https://www.biopharmawatch.com/news/QNRX/to-the-company-s-form-6-k-furnished-to-the-sec-on-qnrx-20220921monthly0.5https://www.biopharmawatch.com/news/QNRX/x200b-x200b-x200b-x200b-x200b-x200b-x200b-x200b-x200b-quoin-pharmaceuticals-ltd-x200b-cond-qnrx-20220818monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-announces-pricing-of-16-8-million-upsized-public-offering-ashburn-va-qnrx-20220805monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-ltd-condensed-consolidated-financial-statements-as-of-qnrx-20220523monthly0.5https://www.biopharmawatch.com/news/QNRX/notice-of-annual-general-meeting-of-shareholders-to-be-held-on-april-12-2022-notice-is-her-qnrx-20220308monthly0.5https://www.biopharmawatch.com/news/QNRX/notice-of-special-general-meeting-of-shareholders-to-be-held-on-february-28-2022-notice-is-qnrx-20220208monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-ltd-the-company-convening-of-a-special-general-meeting-of-the-compan-qnrx-20220131monthly0.5https://www.biopharmawatch.com/news/QNRX/unaudited-pro-forma-condensed-combined-financial-information-introduction-on-qnrx-20220112monthly0.5https://www.biopharmawatch.com/news/QNRX/financial-statements-as-of-qnrx-20211220monthly0.5https://www.biopharmawatch.com/news/QNRX/financial-statements-as-of-qnrx-20211123monthly0.5https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-completes-merger-and-will-commence-trading-on-nasdaq-capital-market--qnrx-20211029monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-announces-record-date-and-distribution-date-for-cvrs-in-connection-w-qnrx-20211015monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-announces-shareholder-approval-of-strategic-merger-with-quoin-pharma-qnrx-20210927monthly0.5https://www.biopharmawatch.com/news/QNRX/amendment-agreement-amendment-agreement-this-agreement-dated-as-of-september-2021-by-and-a-qnrx-20210917monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-announces-the-apograft-tm-bone-marrow-transplantation-of-first-patie-qnrx-20210902monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-reports-second-quarter-2021-financial-and-operating-results-strategi-qnrx-20210824monthly0.5https://www.biopharmawatch.com/news/QNRX/the-securities-and-exchange-commission-declared-cellect-biotechnology-s-registration-state-qnrx-20210813monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-files-registration-statement-in-connection-with-proposed-strategic-m-qnrx-20210616monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-reports-top-line-data-from-phase-1-2-clinical-trial-results-support--qnrx-20210419monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-reports-fourth-quarter-and-full-year-2020-financial-and-operating-re-qnrx-20210328monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-and-quoin-pharmaceuticals-announce-strategic-merger-up-to-25-25-mill-qnrx-20210324monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-reports-third-quarter-financial-and-operating-results-recent-develop-qnrx-20201120monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-commences-collaboration-with-xnk-therapeutics-to-advance-novel-nk-ce-qnrx-20201029monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-initiates-u-s-clinical-trial-of-apograft-tel-aviv-israel-qnrx-20201022monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-ltd-notice-of-annual-general-meeting-of-shareholders-notice-is-hereb-qnrx-20201020monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-ltd-notice-of-annual-general-meeting-of-shareholders-notice-is-hereb-qnrx-20201013monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-ltd-notice-of-annual-general-meeting-of-shareholders-notice-is-hereb-qnrx-20200925monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-to-present-at-the-2020-cell-gene-meeting-on-the-mesa-management-to-h-qnrx-20200921monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biothechnology-ltd-interim-consolidated-financial-statements-as-of-june-30-2020-ni-qnrx-20200812monthly0.5https://www.biopharmawatch.com/news/QNRX/european-patent-office-grants-cellect-biotechnology-pivotal-patent-for-stem-cells-activati-qnrx-20200806monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-reports-first-quarter-2020-financial-and-operating-results-continues-qnrx-20200521monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-s-apograft-to-empower-cellular-treatment-of-covid-19-related-pulmona-qnrx-20200518monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-announces-positive-data-demonstrating-robust-engraftment-using-apogr-qnrx-20200511monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-continues-to-achieve-milestones-receives-new-patent-allowance-in-can-qnrx-20200427monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-ltd-notice-of-special-general-meeting-of-shareholders-notice-is-here-qnrx-20200422monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-reports-fourth-quarter-and-full-year-2019-results-achieved-primary-i-qnrx-20200403monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-receives-new-patent-allowance-in-china-qnrx-20200402monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-and-canndoc-ltd-to-enter-into-strategic-pharma-grade-cannabis-commer-qnrx-20200304monthly0.5https://www.biopharmawatch.com/news/QNRX/of-special-general-meeting-of-shareholders-qnrx-20200127monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-ltd-prices-3m-qnrx-20200108monthly0.5https://www.biopharmawatch.com/news/QNRX/biotechnology-strengthens-ip-portfolio-receives-intention-to-grant-patents-from-european-a-qnrx-20200107monthly0.5https://www.biopharmawatch.com/news/QNRX/receives-approval-for-u-s-qnrx-20191223monthly0.5https://www.biopharmawatch.com/news/QNRX/of-special-general-meeting-of-shareholders-qnrx-20191125monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-reports-third-quarter-2019-financial-and-operating-results-tel-aviv--qnrx-20191119monthly0.5https://www.biopharmawatch.com/news/QNRX/regains-compliance-with-nasdaq-minimum-bid-price-requirement-qnrx-20191107monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biothechnology-ltd-interim-consolidated-financial-statements-as-of-june-30-2019-ni-qnrx-20190813monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-announces-positive-qnrx-20190812monthly0.5https://www.biopharmawatch.com/news/QNRX/biotechnology-and-washington-university-wu-qnrx-20190708monthly0.5https://www.biopharmawatch.com/news/QNRX/general-meeting-of-shareholders-qnrx-20190625monthly0.5https://www.biopharmawatch.com/news/QNRX/biotechnology-reports-first-quarter-2019-financial-and-operating-results-qnrx-20190521monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-to-explore-strategic-alternatives-to-maximize-shareholder-value-tel--qnrx-20190516monthly0.5https://www.biopharmawatch.com/news/QNRX/enabling-regenerative-medicine-may-2019-qnrx-20190430monthly0.5https://www.biopharmawatch.com/news/QNRX/announces-positive-phase-i-ii-mid-study-results-of-its-apograft-technology-qnrx-20190327monthly0.5https://www.biopharmawatch.com/news/QNRX/biotechnology-reports-fourth-quarter-and-full-year-2018-results-and-recent-corporate-progr-qnrx-20190318monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-announces-positive-results-from-cell2in-collaboration-showing-significant-improvem-qnrx-20190311monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-announces-closing-of-6-5-million-underwritten-public-offering-tel-aviv-israel-qnrx-20190213monthly0.5https://www.biopharmawatch.com/news/QNRX/announces-pricing-of-6-5-million-public-offering-qnrx-20190208monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-begins-collaboration-with-washington-qnrx-20190205monthly0.5https://www.biopharmawatch.com/news/QNRX/of-manufacturing-of-clinical-grade-fasl-enables-cellect-to-expedite-qnrx-20190128monthly0.5https://www.biopharmawatch.com/news/QNRX/the-risks-and-uncertainties-not-presently-known-to-us-or-that-we-currently-deem-immaterial-qnrx-20190124monthly0.5https://www.biopharmawatch.com/news/QNRX/biotechnology-reports-clinical-and-regulatory-milestone-targets-qnrx-20190123monthly0.5https://www.biopharmawatch.com/news/QNRX/approves-cellect-s-grant-application-qnrx-20181217monthly0.5https://www.biopharmawatch.com/news/QNRX/biotechnology-provides-corporate-update-and-reports-third-quarter-2018-financial-results-qnrx-20181113monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-receives-multiple-patent-grants-following-us-eu-russia-and-south-korean-approval-c-qnrx-20181105monthly0.5https://www.biopharmawatch.com/news/QNRX/announces-a-major-technological-breakthrough-for-qnrx-20181022monthly0.5https://www.biopharmawatch.com/news/QNRX/positive-results-of-orthopedic-treatment-with-the-use-of-apograft-enriched-stem-cells-deri-qnrx-20181018monthly0.5https://www.biopharmawatch.com/news/QNRX/announces-positive-clinical-results-qnrx-20181015monthly0.5https://www.biopharmawatch.com/news/QNRX/general-meeting-of-shareholders-qnrx-20180920monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-receives-notice-of-allowance-for-stem-cell-selection-technology-patent-in-korea-in-qnrx-20180820monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-and-cell2in-launch-collaboration-to-significantly-improve-stem-cell-selection-and--qnrx-20180813monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biothechnology-ltd-interim-consolidated-financial-statements-as-of-june-30-2018-ni-qnrx-20180809monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-granted-key-european-patent-for-its-stem-cell-selection-technology-covers-use-of-t-qnrx-20180807monthly0.5https://www.biopharmawatch.com/news/QNRX/of-extraordinary-general-meeting-of-shareholders-qnrx-20180725monthly0.5https://www.biopharmawatch.com/news/QNRX/signed-strategic-agreement-qnrx-20180709monthly0.5https://www.biopharmawatch.com/news/QNRX/signs-collaboration-agreement-qnrx-20180705monthly0.5https://www.biopharmawatch.com/news/QNRX/of-annual-general-meeting-of-shareholders-qnrx-20180524monthly0.5https://www.biopharmawatch.com/news/QNRX/biotechnology-ltd-qnrx-20180517monthly0.5https://www.biopharmawatch.com/news/QNRX/former-ge-healthcare-executive-to-join-cellect-as-chief-business-officer-andrew-sabatier-f-qnrx-20180510monthly0.5https://www.biopharmawatch.com/news/QNRX/major-milestone-for-enabling-stem-cells-production-qnrx-20180409monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2-qnrx-20180319monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-announces-4-million-qnrx-20180129monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-announces-opening-of-a-second-clinical-trial-site-and-approval-from-safety-board-d-qnrx-20180116monthly0.5https://www.biopharmawatch.com/news/QNRX/group-of-patients-in-clinical-trial-with-cellect-s-apograft-stem-cell-transplant-follow-up-qnrx-20180104monthly0.5https://www.biopharmawatch.com/news/QNRX/of-extraordinary-general-meeting-of-shareholders-qnrx-20171128monthly0.5https://www.biopharmawatch.com/news/QNRX/biotechnology-ltd-provides-corporate-update-and-reports-third-quarter-2017-financial-resul-qnrx-20171122monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-ltd-notice-of-extraordinary-general-meeting-of-shareholders-notice-i-qnrx-20171107monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-announces-a-major-breakthrough-of-its-apograft-technology-reporting-today-positive-qnrx-20171025monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-appoints-dr-ronit-bakimer-kleiner-as-chief-development-officer-tel-aviv-israel-qnrx-20171019monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-s-apograft-for-acute-gvhd-and-chronic-gvhd-qnrx-20170905monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biothechnology-ltd-interim-consolidated-financial-statements-as-of-june-30-2017-ni-qnrx-20170821monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-ltd-notice-of-extraordinary-general-meeting-of-shareholders-notice-i-qnrx-20170626monthly0.5https://www.biopharmawatch.com/news/QNRX/unofficial-translation-into-english-from-hebrew-cellect-biotechnology-ltd-the-company-re-u-qnrx-20170626monthly0.5https://www.biopharmawatch.com/news/QNRX/following-the-us-cellect-receives-russian-patent-covering-any-device-and-method-using-cell-qnrx-20170614monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-receives-notice-of-allowance-from-the-us-patent-trademark-office-patent-covers-any-qnrx-20170612monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-is-moving-to-trade-exclusively-on-the-nasdaq-cellect-shareholders-can-now-exchange-qnrx-20170609monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-ltd-provides-corporate-update-and-reports-first-quarter-2017-financi-qnrx-20170529monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-gets-green-light-from-fda-for-apograft-ind-submission-in-the-u-s-cellect-s-ceo-dr--qnrx-20170503monthly0.5https://www.biopharmawatch.com/news/QNRX/general-meeting-of-shareholders-and-series-1-stock-options-qnrx-20170404monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-receives-notice-of-intention-to-grant-from-european-patent-office-for-patent-prote-qnrx-20170403monthly0.5https://www.biopharmawatch.com/news/QNRX/successful-first-cancer-patient-stem-qnrx-20170327monthly0.5https://www.biopharmawatch.com/news/QNRX/enabling-stem-cells-corporate-presentation-2017-this-presentation-includes-statements-that-qnrx-20170323monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2-qnrx-20170323monthly0.5https://www.biopharmawatch.com/news/QNRX/general-meeting-of-shareholders-qnrx-20170322monthly0.5https://www.biopharmawatch.com/news/QNRX/former-head-clinical-development-and-qnrx-20170302monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-announces-positive-clinical-trial-results-apograft-tm-cellect-s-flagship-technolog-qnrx-20170221monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-receives-patent-notice-of-allowance-from-us-patent-trademark-office-protecting-com-qnrx-20170112monthly0.5https://www.biopharmawatch.com/news/QNRX/general-meeting-of-shareholders-and-series-1-stock-options-qnrx-20161130monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-ltd-provides-corporate-update-and-reports-third-quarter-2016-financi-qnrx-20161128monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-ltd-the-company-qnrx-20160925monthly0.5https://www.biopharmawatch.com/news/QNRX/receives-israeli-ministry-of-health-approval-to-initiate-phase-i-ii-qnrx-20160913monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-ltd-provides-corporate-update-and-reports-second-quarter-2016-financ-qnrx-20160831monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-ltd-to-present-at-18-th-annual-rodman-renshaw-global-investment-conf-qnrx-20160825monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-ltd-the-company-qnrx-20160811monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-ltd-qnrx-20160811monthly0.5https://www.biopharmawatch.com/news/QNRX/cellect-biotechnology-ltd-announces-pricing-of-u-s-initial-public-offering-and-nasdaq-list-qnrx-20160729monthly0.5https://www.biopharmawatch.com/news/ACXP/c-o-r-r-e-c-t-i-o-n-acurx-pharmaceuticals-inc-pr-newswire-acxp-20250618monthly0.5https://www.biopharmawatch.com/news/ACXP/7-01-am-et-on-tuesday-acxp-20250513monthly0.5https://www.biopharmawatch.com/news/ACXP/7-01-am-et-on-tuesday-acxp-20250318monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-inc-announces-1-1-million-registered-direct-offering-staten-island-n-acxp-20250307monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-inc-announces-2-5-million-registered-direct-offering-priced-at-the-m-acxp-20250106monthly0.5https://www.biopharmawatch.com/news/ACXP/7-01-am-et-on-wednesday-acxp-20241113monthly0.5https://www.biopharmawatch.com/news/ACXP/7-01-am-et-on-friday-acxp-20240809monthly0.5https://www.biopharmawatch.com/news/ACXP/7-01-am-et-on-wednesday-acxp-20240515monthly0.5https://www.biopharmawatch.com/news/ACXP/7-01-am-et-on-monday-acxp-20230814monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-inc-announces-pricing-of-4-0-million-registered-direct-offering-acxp-20230516monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-inc-reports-fourth-quarter-and-full-year-2022-results-and-provides-b-acxp-20230316monthly0.5https://www.biopharmawatch.com/news/ACXP/7-01-am-et-on-monday-acxp-20221114monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-inc-announces-4-225-million-registered-direct-offering-acxp-20220725monthly0.5https://www.biopharmawatch.com/news/ACXP/7-01-am-et-on-wednesday-acxp-20220511monthly0.5https://www.biopharmawatch.com/news/ACXP/7-01-am-et-on-thursday-acxp-20220317monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-inc-reports-third-quarter-2021-results-and-provides-business-update--acxp-20211112monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-inc-reports-second-quarter-2021-results-and-provides-business-update-acxp-20210816monthly0.5https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-inc-announces-pricing-of-15-million-underwritten-initial-public-offe-acxp-20210625monthly0.5https://www.biopharmawatch.com/news/LIMN/liminatus-pharma-announces-receipt-of-nasdaq-listing-delinquency-letter-limn-20250825monthly0.5https://www.biopharmawatch.com/news/LIMN/iba101-the-strategic-answer-to-the-pd-1-l1-patent-cliff-liminatus-pharma-inc-the-company-b-limn-20250814monthly0.5https://www.biopharmawatch.com/news/LIMN/liminatus-pharma-charts-dual-front-attack-on-cancer-with-iba101-next-generation-cd47-inhib-limn-20250624monthly0.5https://www.biopharmawatch.com/news/LIMN/crafting-the-future-of-healing-for-patients-next-generation-cd47-blockade-with-liminatus-p-limn-20250624monthly0.5https://www.biopharmawatch.com/news/LIMN/liminatus-pharma-announces-compliance-with-nasdaq-filing-requirements-limn-20250604monthly0.5https://www.biopharmawatch.com/news/LIMN/report-of-independent-registered-public-accounting-firm-to-the-board-of-directors-and-stoc-limn-20250506monthly0.5https://www.biopharmawatch.com/news/HWH/unaudited-pro-forma-condensed-combined-financial-information-introduction-the-following-un-hwh-20250916monthly0.5https://www.biopharmawatch.com/news/HWH/hwh-international-inc-announces-reverse-stock-split-bethesda-md-hwh-20250220monthly0.5https://www.biopharmawatch.com/news/HWH/alset-capital-acquisition-corp-balance-sheets-unaudited-august-31-hwh-20240112monthly0.5https://www.biopharmawatch.com/news/HWH/united-states-securities-and-exchange-commission-washington-d-c-20549-schedule-14a-proxy-s-hwh-20230731monthly0.5https://www.biopharmawatch.com/news/HWH/alset-capital-acquisition-corp-announces-postponement-of-special-meeting-of-stockholders-b-hwh-20230721monthly0.5https://www.biopharmawatch.com/news/HWH/alset-capital-acquisition-corp-announces-execution-of-merger-agreement-with-hwh-internatio-hwh-20220912monthly0.5https://www.biopharmawatch.com/news/HWH/report-of-independent-registered-public-accounting-firm-to-the-shareholders-and-board-of-d-hwh-20220203monthly0.5https://www.biopharmawatch.com/news/HWH/alset-capital-acquisition-corp-announces-pricing-of-75-000-000-initial-public-offering-bet-hwh-20220131monthly0.5https://www.biopharmawatch.com/news/CNSP/cnspharma-com-nasdaq-cnsp-march-2026-investor-presentation-2-forward-looking-statements-th-cnsp-20260311monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-announces-reverse-stock-split-houston-tx-cnsp-20250718monthly0.5https://www.biopharmawatch.com/news/CNSP/nasdaq-cnsp-july-2025-2-forward-looking-statements-this-presentation-incorporates-informat-cnsp-20250715monthly0.5https://www.biopharmawatch.com/news/CNSP/nasdaq-cnsp-april-2025-2-forward-looking-statements-this-presentation-incorporates-informa-cnsp-20250409monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-announces-reverse-stock-split-houston-tx-cnsp-20250219monthly0.5https://www.biopharmawatch.com/news/CNSP/nasdaq-cnsp-january-2025-forward-looking-statements-2-this-presentation-incorporates-infor-cnsp-20250103monthly0.5https://www.biopharmawatch.com/news/CNSP/nasdaq-cnsp-cnsp-20241211monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-announces-pricing-of-3-million-registered-direct-offering-of-common-st-cnsp-20241023monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-expands-pipeline-with-in-license-of-late-stage-novel-potential-blood-b-cnsp-20240730monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-announces-pricing-of-registered-direct-offering-and-concurrent-private-cnsp-20240703monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-announces-pricing-of-registered-direct-offering-and-concurrent-private-cnsp-20240626monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-announces-pricing-of-registered-direct-offering-and-concurrent-private-cnsp-20240614monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-announces-reverse-stock-split-houston-tx-cnsp-20240603monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-reports-first-quarter-2024-financial-results-enrollment-completed-in-p-cnsp-20240516monthly0.5https://www.biopharmawatch.com/news/CNSP/investor-presentation-april-2024-www-cnspharma-com-nasdaq-cnsp-nasdaq-cnsp-this-presentati-cnsp-20240415monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-reports-full-year-2023-financial-results-and-highlights-recent-corpora-cnsp-20240401monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-announces-successful-interim-analysis-of-efficacy-and-safety-data-in-p-cnsp-20231218monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-reports-third-quarter-2023-financial-results-and-reiterates-company-is-cnsp-20231115monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-reports-second-quarter-2023-financial-results-and-reiterates-upcoming--cnsp-20230814monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-reports-first-quarter-2023-financial-results-and-provides-corporate-up-cnsp-20230515monthly0.5https://www.biopharmawatch.com/news/CNSP/bettina-m-cockroft-m-d-m-b-a-pharmaceutical-and-biotech-industry-veteran-joins-cns-pharmac-cnsp-20230508monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-appoints-faith-l-charles-jd-as-chair-of-the-board-of-directors-over-30-cnsp-20230103monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-announces-pricing-of-6-0-million-public-offering-at-a-premium-to-the-m-cnsp-20221130monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-announces-reverse-stock-split-houston-tx-cnsp-20221128monthly0.5https://www.biopharmawatch.com/news/CNSP/prospectus-summary-this-summary-highlights-information-contained-elsewhere-in-this-prospec-cnsp-20221024monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-reports-second-quarter-2022-financial-results-and-provides-corporate-u-cnsp-20220815monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-reports-first-quarter-2022-financial-results-and-provides-corporate-up-cnsp-20220516monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-reports-full-year-2021-financial-results-and-provides-corporate-update-cnsp-20220303monthly0.5https://www.biopharmawatch.com/news/CNSP/www-cnspharma-com-2100-west-loop-south-suite-900-houston-tx-77027-800-946-9185-nasdaq-cnsp-cnsp-20220106monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-announces-11-5-million-private-placement-priced-at-the-market-under-na-cnsp-20220106monthly0.5https://www.biopharmawatch.com/news/CNSP/www-cnspharma-com-2100-west-loop-south-suite-900-houston-tx-77027-800-946-9185-nasdaq-cnsp-cnsp-20211130monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-reports-second-quarter-2021-financial-results-and-provides-business-ou-cnsp-20210813monthly0.5https://www.biopharmawatch.com/news/CNSP/www-cnspharma-com-2100-west-loop-south-suite-900-houston-tx-77027-800-946-9185-nasdaq-cnsp-cnsp-20210630monthly0.5https://www.biopharmawatch.com/news/CNSP/www-cnspharma-com-2100-west-loop-south-suite-900-houston-tx-77027-800-946-9185-nasdaq-cnsp-cnsp-20210516monthly0.5https://www.biopharmawatch.com/news/CNSP/www-cnspharma-com-2100-west-loop-south-suite-900-houston-tx-77027-800-946-9185-nasdaq-cnsp-cnsp-20210312monthly0.5https://www.biopharmawatch.com/news/CNSP/www-cnspharma-com-2100-west-loop-south-suite-900-houston-tx-77027-800-946-9185-nasdaq-cnsp-cnsp-20210225monthly0.5https://www.biopharmawatch.com/news/CNSP/www-cnspharma-com-2100-west-loop-south-suite-900-houston-tx-77027-800-946-9185-nasdaq-cnsp-cnsp-20210107monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-announces-pricing-of-10-0-million-public-offering-houston-cnsp-20201223monthly0.5https://www.biopharmawatch.com/news/CNSP/prospectus-summary-this-summary-highlights-information-contained-elsewhere-in-this-prospec-cnsp-20201217monthly0.5https://www.biopharmawatch.com/news/CNSP/www-cnspharma-com-2100-west-loop-south-suite-900-houston-tx-77027-800-946-9185-nasdaq-cnsp-cnsp-20201211monthly0.5https://www.biopharmawatch.com/news/CNSP/www-cnspharma-com-2100-west-loop-south-suite-900-houston-tx-77027-800-946-9185-nasdaq-cnsp-cnsp-20201112monthly0.5https://www.biopharmawatch.com/news/CNSP/www-cnspharma-com-2100-west-loop-south-suite-900-houston-tx-77027-800-946-9185-nasdaq-cnsp-cnsp-20200916monthly0.5https://www.biopharmawatch.com/news/CNSP/amendment-to-employment-agreement-this-amendment-amendment-is-entered-into-effective-as-of-cnsp-20200901monthly0.5https://www.biopharmawatch.com/news/CNSP/www-cnspharma-com-2100-west-loop-south-suite-900-houston-tx-77027-800-946-9185-nasdaq-cnsp-cnsp-20200625monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-announces-the-fda-has-granted-orphan-drug-designation-for-brain-cancer-drug-berubicin--cnsp-20200611monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-announces-common-stock-will-resume-trading-on-the-nasdaq-on-cnsp-20200528monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-provides-update-on-development-agreement-for-wp1122-houston-may-27-2020-prnewswire-cns-cnsp-20200527monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-announces-nasdaq-trading-halt-pending-receipt-of-additional-information-houston-may-18-cnsp-20200518monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-announces-business-highlights-and-2019-fourth-quarter-financial-result-cnsp-20200312monthly0.5https://www.biopharmawatch.com/news/CNSP/www-cnspharma-com-2100-west-loop-south-suite-900-houston-tx-77027-800-946-9185-nasdaq-cnsp-cnsp-20200310monthly0.5https://www.biopharmawatch.com/news/CNSP/www-cnspharma-com-2100-west-loop-south-suite-900-houston-tx-77027-800-946-9185-nasdaq-cnsp-cnsp-20200302monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-licenses-dna-binding-agent-from-md-anderson-doubling-its-drug-pipeline-cnsp-20200113monthly0.5https://www.biopharmawatch.com/news/CNSP/nasdaq-cnsp-www-cnspharma-com-2100-west-loop-south-suite-900-houston-tx-77027-800-946-9185-cnsp-20200116monthly0.5https://www.biopharmawatch.com/news/CNSP/nasdaq-cnsp-www-cnspharma-com-2100-west-loop-south-suite-900-houston-tx-77027-800-946-9185-cnsp-20200113monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-announces-full-exercise-of-over-allotment-option-houston-tx-cnsp-20191121monthly0.5https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-announces-closing-of-initial-public-offering-of-common-stock-houston-t-cnsp-20191113monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-plc-unaudited-condensed-consolidated-statements-of-operations-for-the-three-months--ncna-20260514monthly0.5https://www.biopharmawatch.com/news/NCNA/a-new-era-in-oncology-notice-of-2026-annual-general-meeting-monday-8th-june-2026-at-11-00a-ncna-20260506monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-business-up-ncna-20260319monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-appoints-theresa-bruce-as-chief-operating-officer-edinburgh-united-kingdom-ncna-20260106monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-presents-latest-data-demonstrating-clinical-activity-and-favorable-safety-for-nuc-7-ncna-20251210monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-plc-unaudited-condensed-consolidated-statements-of-operations-for-the-three-months--ncna-20251113monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-china-edinburgh-uni-ncna-20251105monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-presents-encouraging-data-on-nuc-7738-in-combination-with-pd-1-inhibitors-using-pri-ncna-20251018monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-announces-encouraging-data-for-nuc-3373-in-combination-with-anti-pd-1-therapy-nuc-3-ncna-20251014monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-compliant-with-all-nasdaq-continued-listing-criteria-anticipated-cash-runway-into-2-ncna-20250905monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-to-present-data-on-nuc-7738-s-synergy-with-pd-1-inhibitors-at-the-esmo-congress-202-ncna-20250903monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-plc-unaudited-condensed-consolidated-statements-of-operations-for-the-three-months--ncna-20250820monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-announces-ads-ratio-change-edinburgh-united-kingdom-ncna-20250801monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-cancels-all-outstanding-series-a-warrants-following-strategic-atm-execution-edinbur-ncna-20250721monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-announces-plan-to-implement-ads-ratio-change-edinburgh-united-kingdom-ncna-20250711monthly0.5https://www.biopharmawatch.com/news/NCNA/notice-of-2025-annual-general-meeting-friday-27th-june-2025-at-11-00am-venue-lochside-hous-ncna-20250605monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-plc-unaudited-condensed-consolidated-statements-of-operations-for-the-three-months--ncna-20250602monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-reports-fourth-quarter-and-year-end-2024-financial-results-and-provides-business-up-ncna-20250320monthly0.5https://www.biopharmawatch.com/news/NCNA/notice-of-general-meeting-monday-7th-april-2025-at-11-00am-venue-lochside-house-3-lochside-ncna-20250318monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-plc-unaudited-condensed-consolidated-statements-of-operations-for-the-three-months--ncna-20241125monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-announces-encouraging-initial-data-from-phase-1b-2-modular-study-of-nuc-3373-in-com-ncna-20241111monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-the-united-states-e-ncna-20240925monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-presents-encouraging-data-on-nuc-7738-in-combination-with-pembrolizumab-in-pd-1-inh-ncna-20240914monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-announces-update-for-phase-2-randomized-colorectal-cancer-study-nutide-323-study-to-ncna-20240829monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-plc-unaudited-condensed-consolidated-statements-of-operations-for-the-three-months--ncna-20240815monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-plc-unaudited-condensed-consolidated-statements-of-operations-for-the-three-months--ncna-20240516monthly0.5https://www.biopharmawatch.com/news/NCNA/notice-f-2024-annual-general-meeting-tuesday-18th-june-2024-at-11-00am-venue-lochside-hous-ncna-20240513monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-regains-compliance-with-nasdaq-minimum-bid-price-requirement-edinburgh-united-kingd-ncna-20240501monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-announces-completion-of-ads-ratio-change-edinburgh-united-kingdom-ncna-20240416monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-presents-data-at-the-aacr-2024-annual-meeting-highlighting-the-ability-of-nuc-7738--ncna-20240409monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-announces-plan-to-implement-ads-ratio-change-edinburgh-united-kingdom-ncna-20240327monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-reports-fourth-quarter-and-year-end-2023-financial-results-and-provides-business-up-ncna-20240320monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-plc-unaudited-condensed-consolidated-statements-of-operations-for-the-three-months--ncna-20231116monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-announces-listing-transfer-to-nasdaq-capital-market-edinburgh-united-kingdom-ncna-20231110monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-presents-promising-data-on-nuc-7738-at-the-aacr-nci-eortc-international-conference--ncna-20231016monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-presents-encouraging-data-on-nuc-3373-in-colorectal-cancer-at-the-aacr-nci-eortc-in-ncna-20231013monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-announces-presentations-at-the-aacr-nci-eortc-international-conference-on-molecular-ncna-20230918monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-plc-unaudited-condensed-consolidated-statements-of-operations-for-the-three-months--ncna-20230816monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-plc-unaudited-condensed-consolidated-statements-of-operations-for-the-three-months--ncna-20230517monthly0.5https://www.biopharmawatch.com/news/NCNA/notice-of-2023-annual-general-meeting-nucana-plc-77-78-cannon-street-london-england-ec4n-6-ncna-20230515monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-announces-receipt-of-nasdaq-notice-edinburgh-united-kingdom-ncna-20230512monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-presents-data-at-the-aacr-2023-annual-meeting-highlighting-novel-nuc-7738-mechanism-ncna-20230414monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-reports-fourth-quarter-and-year-end-2022-financial-results-and-provides-business-up-ncna-20230404monthly0.5https://www.biopharmawatch.com/news/NCNA/technical-board-of-appeal-of-the-european-patent-office-issues-oral-ruling-that-nucana-s-1-ncna-20230324monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-regains-compliance-with-nasdaq-minimum-bid-price-requirement-edinburgh-united-kingd-ncna-20230123monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-announces-receipt-of-nasdaq-notice-edinburgh-united-kingdom-ncna-20230106monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-plc-unaudited-condensed-consolidated-statements-of-operations-for-the-three-months--ncna-20221116monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-presents-positive-data-on-nuc-3373-at-the-34-th-eortc-nci-aacr-annual-meeting-2022--ncna-20221026monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-presents-promising-data-on-nuc-7738-at-the-european-society-of-medical-oncology-esm-ncna-20220912monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-presents-favorable-data-on-nuc-3373-at-the-european-society-of-medical-oncology-esm-ncna-20220912monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-announces-presentations-at-the-european-society-for-medical-oncology-esmo-congress--ncna-20220906monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-plc-unaudited-condensed-consolidated-statements-of-operations-for-the-three-months--ncna-20220817monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-regains-compliance-with-nasdaq-minimum-bid-price-requirement-edinburgh-united-kingd-ncna-20220727monthly0.5https://www.biopharmawatch.com/news/NCNA/german-court-rules-that-gilead-s-sofosbuvir-infringes-nucana-s-190-patent-edinburgh-united-ncna-20220711monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-announces-presentation-on-nuc-7738-at-the-european-hematology-association-eha-2022--ncna-20220610monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-announces-receipt-of-nasdaq-notice-edinburgh-united-kingdom-ncna-20220603monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-plc-unaudited-condensed-consolidated-statements-of-operations-for-the-three-months--ncna-20220602monthly0.5https://www.biopharmawatch.com/news/NCNA/notice-of-2022-annual-general-meeting-nucana-plc-77-78-cannon-street-london-england-ec4n-6-ncna-20220523monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-reports-fourth-quarter-and-year-ended-2021-financial-results-and-provides-business--ncna-20220427monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-announces-upcoming-presentations-on-nuc-3373-at-the-american-association-for-cancer-ncna-20220308monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-announces-update-for-phase-3-biliary-tract-cancer-study-independent-data-monitoring-ncna-20220302monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-announces-enrollment-of-required-number-of-patients-to-conduct-second-interim-analy-ncna-20220222monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-plc-unaudited-condensed-consolidated-statements-of-operations-for-the-three-months--ncna-20211118monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-appoints-elliott-m-levy-m-d-to-its-board-of-directors-former-amgen-svp-of-global-de-ncna-20211101monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-receives-fast-track-designation-from-the-u-s-food-and-drug-administration-for-acela-ncna-20210929monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-announces-four-poster-presentations-at-the-esmo-congress-2021-nuc-3373-continues-to-ncna-20210916monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-announces-enrollment-of-required-number-of-patients-to-conduct-first-interim-analys-ncna-20210915monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-plc-unaudited-condensed-consolidated-statements-of-operations-for-the-three-months--ncna-20210819monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-appoints-jeffrey-d-bloss-m-d-as-chief-medical-officer-seasoned-physician-executive--ncna-20210810monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-nucana-plc-notice-of-annual-general-meeting-thursday-24-june-2021-at-11-00am-venue--ncna-20210524monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-plc-unaudited-condensed-consolidated-statements-of-operations-for-the-three-months--ncna-20210519monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-announces-five-poster-presentations-at-the-american-association-for-cancer-research-ncna-20210410monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-reports-fourth-quarter-and-year-end-2020-financial-results-and-provides-business-up-ncna-20210304monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-presents-encouraging-data-at-asco-gi-for-nuc-3373-in-heavily-pre-treated-patients-w-ncna-20210115monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-appoints-andrew-kay-as-board-chairman-pharmaceutical-executive-brings-a-wealth-of-e-ncna-20201221monthly0.5https://www.biopharmawatch.com/news/NCNA/final-data-from-the-phase-ib-study-of-acelarin-plus-cisplatin-in-patients-with-advanced-bi-ncna-20201130monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-plc-unaudited-condensed-consolidated-statements-of-operations-for-the-three-months--ncna-20201119monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-expands-its-board-of-directors-with-the-appointment-of-bali-muralidhar-abingworth-m-ncna-20201013monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-announces-closing-of-public-offering-of-american-depositary-shares-and-full-exercis-ncna-20200921monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-announces-pricing-of-a-public-offering-of-american-depositary-shares-edinburgh-unit-ncna-20200917monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-announces-proposed-public-offering-of-american-depositary-shares-edinburgh-united-k-ncna-20200916monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-plc-unaudited-condensed-consolidated-statements-of-operations-for-the-three-months--ncna-20200819monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-plc-notice-of-annual-general-meeting-thursday-25-june-2020-at-11-00am-venue-lochsid-ncna-20200602monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-plc-unaudited-condensed-consolidated-statements-of-operations-for-the-three-months--ncna-20200519monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-announces-the-re-opening-of-enrollment-in-multiple-clinical-studies-after-temporary-ncna-20200518monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-to-present-two-abstracts-at-the-american-association-for-cancer-research-aacr-annua-ncna-20200515monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-announces-re-opening-of-global-phase-iii-study-of-acelarin-plus-cisplatin-in-patien-ncna-20200505monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-provides-update-on-impact-of-covid-19-on-clinical-studies-edinburgh-united-kingdom-ncna-20200402monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-reports-preliminary-data-from-phase-ii-study-of-single-agent-acelarin-nuc-1031-in-p-ncna-20200310monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-receives-positive-opinion-for-orphan-drug-designation-in-the-european-union-for-ace-ncna-20200304monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-announces-first-patients-dosed-in-both-us-and-europe-in-phase-iii-study-of-acelarin-ncna-20200127monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-plc-unaudited-condensed-consolidated-statements-of-operations-for-the-three-months--ncna-20191113monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-presents-data-at-aacr-nci-eortc-international-conference-on-molecular-targets-and-c-ncna-20191029monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-announces-fda-clearance-to-commence-phase-iii-study-of-acelarin-nuc-1031-for-the-fi-ncna-20191025monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-plc-unaudited-condensed-consolidated-statements-of-operations-for-the-three-months--ncna-20190821monthly0.5https://www.biopharmawatch.com/news/NCNA/enrollment-in-the-independent-investigator-sponsored-phase-iii-metastatic-pancreatic-study-ncna-20190820monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-announces-first-patients-dosed-in-phase-i-study-of-nuc-7738-nuc-7738-is-nucana-s-th-ncna-20190717monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-receives-orphan-drug-designation-from-the-u-s-food-and-drug-administration-for-acel-ncna-20190612monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-plc-77-78-cannon-street-london-england-ec4n-6af-company-number-03308778-notice-of-2-ncna-20190529monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-plc-unaudited-condensed-consolidated-statements-of-operations-for-the-three-months--ncna-20190514monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-reports-fourth-quarter-and-year-end-2018-financial-results-and-provides-business-up-ncna-20190307monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-plc-announces-withdrawal-of-public-offering-of-adss-edinburgh-united-kingdom-ncna-20190125monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-plc-unaudited-condensed-consolidated-statements-of-operations-for-the-three-months--ncna-20181128monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-announces-first-patients-enrolled-in-phase-ib-study-of-nuc-3373-in-advanced-colorec-ncna-20181101monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-reports-additional-promising-clinical-data-on-nuc-1031-acelarin-as-front-line-treat-ncna-20181021monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-to-present-new-data-from-its-protide-portfolio-at-the-european-society-for-medical--ncna-20181009monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-plc-unaudited-condensed-consolidated-statements-of-operations-for-the-three-months--ncna-20181001monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-reports-second-quarter-2018-financial-results-and-provides-business-update-addition-ncna-20180828monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-plc-company-number-03308778-77-78-cannon-street-london-england-ec4n-6af-notice-of-2-ncna-20180601monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-reports-first-quarter-2018-financial-results-edinburgh-united-kingdom-ncna-20180523monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-announces-appointment-of-cyrille-leperlier-to-its-board-of-directors-edinburgh-unit-ncna-20180521monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-plc-announces-appointment-of-adam-george-to-its-board-of-directors-edinburgh-united-ncna-20180409monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-reports-financial-results-for-the-year-ended-ncna-20180321monthly0.5https://www.biopharmawatch.com/news/NCNA/nucana-announces-promising-clinical-data-at-asco-gi-on-nuc-1031-acelarin-as-front-line-tre-ncna-20180119monthly0.5https://www.biopharmawatch.com/news/BMRA/news-for-immediate-release-gary-huff-former-ceo-of-labcorp-diagnostics-appointed-to-biomer-bmra-20251008monthly0.5https://www.biopharmawatch.com/news/BMRA/news-for-immediate-release-biomerica-appoints-eric-b-chin-to-board-of-directors-and-audit--bmra-20250606monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-reverse-stock-split-shares-expected-to-begin-trading-on-split-adjusted-bmra-20250416monthly0.5https://www.biopharmawatch.com/news/BMRA/news-for-immediate-release-diagnostics-industry-leader-jack-kenny-joins-biomerica-s-board--bmra-20230828monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-proposed-underwritten-public-offering-of-common-stock-bmra-20230302monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-positive-topline-results-from-the-endpoint-clinical-trial-of-its-infoo-bmra-20220208monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-preliminary-second-quarter-revenue-increase-of-approximately-238-to-ap-bmra-20211216monthly0.5https://www.biopharmawatch.com/news/BMRA/news-biomerica-signs-exclusive-distribution-agreement-in-canada-for-its-new-and-proprietar-bmra-20210624monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-s-fast-15-minute-simple-to-use-covid-19-antigen-rapid-test-receives-ce-mark-biom-bmra-20210112monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-retirement-of-chief-financial-officer-cfo-hiring-of-new-cfo-and-appoin-bmra-20200831monthly0.5https://www.biopharmawatch.com/news/BMRA/the-university-of-texas-health-science-center-at-houston-joins-biomerica-s-infoods-irritab-bmra-20200629monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-files-for-fda-emergency-use-authorization-eua-of-its-unique-laboratory-antibody--bmra-20200616monthly0.5https://www.biopharmawatch.com/news/BMRA/mayo-clinic-joins-biomerica-s-infoods-irritable-bowel-syndrome-ibs-diagnostic-guided-thera-bmra-20200601monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-receives-ce-mark-for-new-high-volume-version-of-10-minute-test-for-covid-19-expo-bmra-20200507monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-signs-two-definitive-agreements-with-mount-sinai-medical-school-in-new-york-to-s-bmra-20200402monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-begins-shipping-samples-of-10-minute-test-for-covid-19-virus-exposure-10-minute--bmra-20200317monthly0.5https://www.biopharmawatch.com/news/BMRA/biomerica-announces-2-0-million-investment-by-palm-global-small-cap-master-fund-bmra-20200226monthly0.5https://www.biopharmawatch.com/news/BMRA/news-for-immediate-release-mexico-s-cofepris-mexico-s-equivalent-of-the-fda-approves-biome-bmra-20180308monthly0.5https://www.biopharmawatch.com/news/BMRA/news-for-immediate-release-contact-zackary-irani-949-645-2111-biomerica-announces-third-qu-bmra-20060414monthly0.5https://www.biopharmawatch.com/news/BMRA/amendment-of-the-note-loan-and-modification-agreement-this-writing-effective-as-of-bmra-20041124monthly0.5https://www.biopharmawatch.com/news/NVNO/envveno-medical-receives-first-ever-fda-ide-approval-for-a-u-s-pivotal-study-of-a-non-surg-nvno-20260429monthly0.5https://www.biopharmawatch.com/news/NVNO/envveno-receives-unfavorable-appeal-decision-from-the-fda-for-the-venovalve-nvno-20251113monthly0.5https://www.biopharmawatch.com/news/NVNO/envveno-receives-not-approvable-letter-from-the-fda-for-the-venovalve-nvno-20250820monthly0.5https://www.biopharmawatch.com/news/NVNO/positive-11-month-topline-efficacy-data-showing-significant-clinical-improvement-from-envv-nvno-20240424monthly0.5https://www.biopharmawatch.com/news/NVNO/positive-topline-efficacy-data-showing-significant-clinical-improvement-from-envveno-medic-nvno-20240306monthly0.5https://www.biopharmawatch.com/news/NVNO/envveno-medical-presents-positive-preliminary-device-related-material-adverse-event-mae-da-nvno-20231116monthly0.5https://www.biopharmawatch.com/news/NVNO/hancock-jaffe-announces-corporate-rebranding-to-reflect-prioritization-of-its-development--nvno-20210922monthly0.5https://www.biopharmawatch.com/news/NVNO/hancock-jaffe-laboratories-announces-pricing-of-upsized-36-million-offering-nvno-20210209monthly0.5https://www.biopharmawatch.com/news/NVNO/hancock-jaffe-deemed-compliant-with-all-nasdaq-continued-listing-requirements-company-rega-nvno-20201221monthly0.5https://www.biopharmawatch.com/news/NVNO/hancock-jaffe-laboratories-announces-pricing-of-5-6-million-offering-nvno-20200717monthly0.5https://www.biopharmawatch.com/news/NVNO/hancock-jaffe-reports-early-positive-results-from-first-in-human-venovalve-study-reflux-si-nvno-20190607monthly0.5https://www.biopharmawatch.com/news/NVNO/hancock-jaffe-mourns-the-loss-of-director-marc-robins-nvno-20190430monthly0.5https://www.biopharmawatch.com/news/NVNO/hancock-jaffe-completes-2-7-million-private-placement-of-common-stock-company-strengthens--nvno-20190313monthly0.5https://www.biopharmawatch.com/news/NVNO/hancock-jaffe-appoints-three-new-independent-directors-accomplished-medical-device-profess-nvno-20181002monthly0.5https://www.biopharmawatch.com/news/NVNO/hancock-jaffe-appoints-bob-rankin-as-chief-financial-officer-irvine-calif-nvno-20180713monthly0.5https://www.biopharmawatch.com/news/NVNO/hancock-jaffe-laboratories-inc-announces-full-exercise-of-1-125-000-underwriter-s-over-all-nvno-20180612monthly0.5https://www.biopharmawatch.com/news/NVNO/hancock-jaffe-laboratories-inc-announces-pricing-of-initial-public-offering-irvine-calif-nvno-20180531monthly0.5https://www.biopharmawatch.com/news/ACON/aclarion-inc-adopts-limited-duration-stockholder-rights-plan-acon-20260319monthly0.5https://www.biopharmawatch.com/news/ACON/aclarion-appoints-greg-gould-as-chief-financial-officer-healthtech-cfo-with-extensive-publ-acon-20250903monthly0.5https://www.biopharmawatch.com/news/ACON/aclarion-inc-announces-adjournment-of-annual-meeting-of-stockholders-meeting-adjourned-to--acon-20250707monthly0.5https://www.biopharmawatch.com/news/ACON/aclarion-releases-updated-investor-presentation-in-connection-with-appearance-at-planet-mi-acon-20250423monthly0.5https://www.biopharmawatch.com/news/ACON/aclarion-inc-announces-adjournment-of-special-meeting-of-stockholders-meeting-adjourned-to-acon-20250228monthly0.5https://www.biopharmawatch.com/news/ACON/aclarion-announces-pricing-of-registered-direct-offering-of-common-stock-priced-at-the-mar-acon-20250130monthly0.5https://www.biopharmawatch.com/news/ACON/aclarion-announces-pricing-of-registered-direct-offering-of-common-stock-priced-at-the-mar-acon-20250103monthly0.5https://www.biopharmawatch.com/news/ACON/aclarion-announces-initial-payer-coverage-of-nociscan-by-axa-throughout-greater-london-uk--acon-20240626monthly0.5https://www.biopharmawatch.com/news/ACON/index-to-financial-statements-aclarion-inc-page-financial-statements-report-of-independent-acon-20240221monthly0.5https://www.biopharmawatch.com/news/ACON/better-data-better-care-october-2023-nasdaq-acon-aclarion-2023-2-disclaimer-the-informatio-acon-20230928monthly0.5https://www.biopharmawatch.com/news/ACON/aclarion-inc-announces-filing-of-delayed-10-q-quarterly-report-broomfield-co-acon-20230825monthly0.5https://www.biopharmawatch.com/news/ACON/aclarion-inc-announces-delayed-10-q-filing-broomfield-co-acon-20230519monthly0.5https://www.biopharmawatch.com/news/ACON/aclarion-inc-releases-updated-investor-presentation-in-connection-with-appearance-at-ld-mi-acon-20221025monthly0.5https://www.biopharmawatch.com/news/ACON/aclarion-inc-announces-listing-on-nasdaq-and-pricing-of-9-4-million-initial-public-offerin-acon-20220421monthly0.5https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-announces-signing-of-definitive-share-purchase-agreement-to-acquire-dura--asbp-20260612monthly0.5https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-announces-closing-of-second-and-final-tranche-of-21-million-private-place-asbp-20260420monthly0.5https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-has-entered-into-a-letter-of-intent-to-acquire-a-leading-global-automotiv-asbp-20260416monthly0.5https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-holdings-inc-announces-michael-c-howe-with-decades-of-experience-at-leadi-asbp-20250610monthly0.5https://www.biopharmawatch.com/news/ASBP/unaudited-pro-forma-condensed-combined-financial-information-defined-terms-included-below--asbp-20250221monthly0.5https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-holdings-inc-announces-public-listing-on-nasdaq-the-closing-of-the-busine-asbp-20250220monthly0.5https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-inc-and-powerup-acquisition-corp-announce-business-combination-agreement--asbp-20240903monthly0.5https://www.biopharmawatch.com/news/ASBP/powerup-acquisition-corp-announces-postponement-of-extraordinary-general-meeting-of-shareh-asbp-20240520monthly0.5https://www.biopharmawatch.com/news/ASBP/powerup-acquisition-corp-announces-postponement-of-extraordinary-general-meeting-of-shareh-asbp-20240516monthly0.5https://www.biopharmawatch.com/news/ASBP/visiox-pharmaceuticals-inc-a-commercial-stage-biopharmaceutical-company-to-be-listed-on-na-asbp-20231227monthly0.5https://www.biopharmawatch.com/news/ASBP/powerup-acquisition-corp-announces-the-separate-trading-of-its-class-a-ordinary-shares-and-asbp-20220411monthly0.5https://www.biopharmawatch.com/news/ASBP/report-of-independent-registered-public-accounting-firm-to-the-shareholders-and-board-of-d-asbp-20220223monthly0.5https://www.biopharmawatch.com/news/ASBP/powerup-acquisition-corp-announces-pricing-of-250-million-initial-public-offering-new-york-asbp-20220217monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-research-collaboration-for-novel-thyroid-beta-agonists-as-po-vktx-20150202monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-inc-announces-pricing-of-initial-public-offering-vktx-20150429monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-inc-announces-closing-of-initial-public-offering-vktx-20150505monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-signs-broad-licensing-deal-with-ligand-pharmaceuticals-for-rights-to-five-novel-the-vktx-20150522monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-submits-investigational-new-drug-ind-application-for-vk5211-a-selectiv-vktx-20150714monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-upcoming-investor-conferences-vktx-20151005monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-upcoming-life-science-industry-events-vktx-20151112monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-submits-investigational-new-drug-ind-application-to-conduct-phase-2-cl-vktx-20151117monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-and-kennedy-krieger-institute-sign-collaboration-agreement-to-evaluate-vktx-20151123monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-presents-new-data-on-vk5211-demonstrating-robust-weight-gain-in-primat-vktx-20151207monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-biotech-showcase-2016-vktx-20160107monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-upcoming-investor-conferences-vktx-20160202monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-presents-positive-phase-1b-clinical-data-on-vk2809-in-hypercholesterol-vktx-20160411monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-the-2016-marcum-microcap-conference-vktx-20160524monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-positive-top-line-results-from-proof-of-concept-study-of-vk0-vktx-20160726monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-presents-phase-1-data-and-highlights-ongoing-phase-2-study-of-vk5211-a-vktx-20160901monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-upcoming-investor-conferences-vktx-20160907monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-presents-positive-proof-of-concept-data-for-vk0214-in-in-vivo-model-of-vktx-20160926monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-the-2016-bio-investor-forum-vktx-20161013monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-host-conference-call-to-discuss-third-quarter-2016-financial-result-vktx-20161103monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-presents-new-clinical-data-on-vk2809-in-subjects-with-elevated-cholest-vktx-20161115monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-the-ld-micro-main-event-vktx-20161129monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-receives-orphan-drug-designation-for-vk0214-from-the-u-s-food-and-drug-vktx-20161206monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-biotech-showcase-2017-vktx-20161221monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-senior-level-appointments-to-management-team-vktx-20170105monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-2017-bio-ceo-investor-conference-vktx-20170207monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-initial-results-from-in-vivo-proof-of-concept-study-of-vk280-vktx-20170209monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-and-poc-capital-enter-agreement-to-fund-clinical-development-of-vk2809-vktx-20170214monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-upcoming-investor-conferences-vktx-20170228monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-fourth-quarter-and-year-end-2016-after-vktx-20170302monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-h-c-wainwright-co-s-1st-annual-nash-investor-conference-vktx-20170328monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-first-quarter-2017-after-market-close--vktx-20170503monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-upcoming-investor-conferences-vktx-20170531monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-promising-top-line-results-from-in-vivo-study-of-vk2809-in-n-vktx-20170606monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-completes-enrollment-in-phase-2-study-of-vk5211-in-patients-recovering-vktx-20170712monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2017-after-market-close-vktx-20170802monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-rodman-renshaw-s-19th-annual-global-investment-conferenc-vktx-20170905monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-presentation-of-data-from-in-vivo-proof-of-concept-study-of--vktx-20170907monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-results-of-gene-expression-analysis-from-in-vivo-study-of-vk-vktx-20170911monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-host-key-opinion-leader-event-to-discuss-musculoskeletal-therapeuti-vktx-20170925monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-top-line-results-from-proof-of-concept-study-of-vk0214-in-in-vktx-20171004monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-presents-results-from-proof-of-concept-study-of-vk0214-in-in-vivo-mode-vktx-20171023monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-presents-results-from-in-vivo-study-of-vk2809-in-biopsy-confirmed-non--vktx-20171024monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-third-quarter-2017-on-november-8-2017-vktx-20171101monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-proposed-public-offering-of-common-stock-vktx-20171205monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-biotech-showcase-2018-vktx-20180102monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-proposed-public-offering-of-common-stock-vktx-20180201monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-2018-bio-ceo-investor-conference-vktx-20180207monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-fourth-quarter-and-year-end-2017-on-ma-vktx-20180228monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-upcoming-investor-conferences-vktx-20180306monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-first-quarter-2018-on-may-9-2018-vktx-20180502monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-completes-enrollment-in-phase-2-study-of-vk2809-in-patients-with-hyper-vktx-20180605monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-proposed-public-offering-of-common-stock-vktx-20180606monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-vk5211-phase-2-study-results-selected-for-plenary-oral-prese-vktx-20180717monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2018-on-august-9-2018-vktx-20180802monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-participate-in-upcoming-investor-conferences-vktx-20180828monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-proposed-public-offering-of-common-stock-vktx-20180919monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-participate-in-upcoming-investor-conferences-vktx-20180926monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-presents-results-from-phase-2-study-of-vk5211-in-patients-recovering-f-vktx-20181001monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-vk2809-phase-2-study-results-selected-for-oral-late-breaker--vktx-20181004monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-data-from-in-vivo-study-of-vk2809-presented-at-oral-plenary--vktx-20181008monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-third-quarter-2018-on-november-7-2018-vktx-20181031monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-presents-results-from-phase-2-study-of-vk2809-in-patients-with-non-alc-vktx-20181112monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-biotech-showcase-2019-vktx-20190102monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-participate-in-upcoming-investor-conferences-and-events-vktx-20190226monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-fourth-quarter-and-year-end-2018-on-ma-vktx-20190306monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-participate-in-upcoming-investor-conferences-vktx-20190328monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-new-data-from-phase-2-study-of-vk2809-in-patients-with-non--vktx-20190404monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-presents-new-data-from-phase-2-study-of-vk2809-in-patients-with-non-al-vktx-20190411monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-first-quarter-2019-on-may-2-2019-vktx-20190425monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-participate-in-upcoming-investor-conferences-vktx-20190430monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-participate-in-upcoming-investor-conferences-vktx-20190528monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2019-on-august-1-2019-vktx-20190725monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-participate-in-upcoming-investor-conferences-vktx-20190828monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-2019-cantor-global-healthcare-conference-vktx-20190925monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-third-quarter-2019-on-november-5-2019-vktx-20191031monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-participate-in-upcoming-investor-conferences-vktx-20191112monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-initiation-of-phase-2b-voyage-study-of-vk2809-in-patients-wi-vktx-20191119monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-biotech-showcase-2020-vktx-20200106monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-fourth-quarter-and-year-end-2019-on-fe-vktx-20200219monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-participate-in-upcoming-investor-conferences-vktx-20200224monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-reports-fourth-quarter-and-year-end-2019-financial-results-and-provide-vktx-20200226monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-participate-in-19th-annual-needham-healthcare-conference-vktx-20200407monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-first-quarter-2020-on-april-30-2020-vktx-20200423monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-participate-in-upcoming-investor-conferences-vktx-20200428monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-2020-annual-meeting-of-stockholders-to-be-held-as-virtual-me-vktx-20200512monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-participate-in-upcoming-investor-conferences-vktx-20200527monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2020-on-july-29-2020-vktx-20200722monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-participate-in-upcoming-investor-conferences-vktx-20200728monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-new-data-from-phase-2-study-of-vk2809-in-patients-with-non--vktx-20200820monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-presents-new-data-from-phase-2-study-of-vk2809-in-patients-with-non-al-vktx-20200828monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-participate-in-upcoming-investor-conferences-vktx-20200902monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-initiation-of-phase-1-clinical-trial-of-vk0214-vktx-20200909monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-third-quarter-2020-on-october-28-2020-vktx-20201021monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-stifel-healthcare-conference-2020-vktx-20201110monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-h-c-wainwright-bioconnect-2021-conference-vktx-20210105monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-senior-management-team-appointments-vktx-20210106monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-fourth-quarter-and-year-end-2020-on-fe-vktx-20210210monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-participate-at-upcoming-investor-conferences-vktx-20210304monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-20th-annual-needham-virtual-healthcare-conference-vktx-20210407monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-first-quarter-2021-on-april-28-2021-vktx-20210421monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-participate-in-upcoming-investor-conferences-vktx-20210610monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-results-from-phase-1-clinical-trial-of-novel-oral-thyroid-re-vktx-20210617monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-initiation-of-phase-1b-clinical-trial-of-vk0214-in-patients--vktx-20210624monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2021-on-july-28-2021-vktx-20210721monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-participate-in-upcoming-investor-conferences-vktx-20210902monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-h-c-wainwright-s-5th-annual-nash-investor-conference-vktx-20211005monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-preclinical-data-on-novel-dual-glp-1-gip-agonists-at-obesit-vktx-20211025monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-third-quarter-2021-on-november-3-2021-vktx-20211027monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-presents-preclinical-data-on-novel-dual-glp-1-gip-agonists-at-obesityw-vktx-20211101monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-stifel-2021-virtual-healthcare-conference-vktx-20211109monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-h-c-wainwright-bioconnect-2022-conference-vktx-20220103monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-initiation-of-phase-1-clinical-trial-of-vk2735-company-s-lea-vktx-20220110monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-clinical-hold-on-phase-1b-trial-of-vk0214-in-patients-with-x-vktx-20220124monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-fourth-quarter-and-year-end-2021-on-fe-vktx-20220202monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-svb-leerink-11th-annual-global-healthcare-conference-vktx-20220207monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-upcoming-investor-conferences-vktx-20220308monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-the-21st-annual-needham-virtual-healthcare-conference-vktx-20220406monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-first-quarter-2022-on-april-27-2022-vktx-20220420monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-h-c-wainwright-global-investment-conference-vktx-20220516monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-william-blair-biotech-focus-conference-2022-vktx-20220706monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-fda-has-lifted-clinical-hold-on-phase-1b-trial-of-vk0214-in--vktx-20220719monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2022-on-july-27-2022-vktx-20220720monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-participate-in-fireside-chat-at-btig-biotechnology-conference-2022-vktx-20220802monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-participate-at-upcoming-investor-conferences-vktx-20220906monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-third-quarter-2022-on-october-26-2022-vktx-20221019monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-stifel-2022-healthcare-conference-vktx-20221108monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-completion-of-enrollment-in-phase-2b-voyage-study-of-vk2809--vktx-20230109monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-fourth-quarter-and-year-end-2022-on-fe-vktx-20230201monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-svb-securities-global-biopharma-conference-vktx-20230207monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-participate-at-upcoming-investor-conferences-vktx-20230307monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-proposed-public-offering-of-common-stock-vktx-20230329monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-22nd-annual-needham-healthcare-conference-vktx-20230411monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-first-quarter-2023-on-april-26-2023-vktx-20230420monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-positive-top-line-results-from-phase-2b-voyage-study-of-vk28-vktx-20230516monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2023-on-july-26-2023-vktx-20230719monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-initiation-of-phase-2-venture-trial-of-dual-glp-1-gip-recept-vktx-20230906monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-participate-at-upcoming-investor-conferences-vktx-20230907monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-highlight-data-from-phase-1-clinical-trial-of-dual-glp-1-gip-recept-vktx-20231010monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-presents-new-data-from-phase-1-clinical-trial-of-dual-glp-1-gip-recept-vktx-20231017monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-third-quarter-2023-on-october-25-2023-vktx-20231018monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-completion-of-enrollment-in-phase-2-venture-trial-of-dual-gl-vktx-20231023monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-participate-at-upcoming-investor-conferences-vktx-20231102monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-presents-new-data-from-phase-2b-voyage-study-of-vk2809-in-patients-wit-vktx-20231113monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-fourth-quarter-and-year-end-2023-on-fe-vktx-20240131monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-proposed-public-offering-of-common-stock-vktx-20240227monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-first-quarter-2024-on-april-24-2024-vktx-20240417monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-participate-at-upcoming-investor-conferences-vktx-20240530monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-positive-52-week-histologic-data-from-phase-2b-voyage-study--vktx-20240604monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-presents-preclinical-data-on-novel-dual-amylin-and-calcitonin-receptor-vktx-20240624monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2024-on-july-24-2024-vktx-20240717monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-participate-at-morgan-stanley-22nd-annual-global-healthcare-confere-vktx-20240828monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-results-from-phase-1b-clinical-trial-of-vk0214-in-patients-w-vktx-20241009monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-third-quarter-2024-on-october-23-2024-vktx-20241016monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-highlight-clinical-data-from-vk2735-obesity-program-in-presentation-vktx-20241028monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-participate-at-upcoming-investor-conferences-vktx-20241031monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-data-from-phase-2b-voyage-study-of-vk2809-in-patients-with--vktx-20241112monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-presents-results-from-phase-2b-voyage-study-of-vk2809-in-biopsy-confir-vktx-20241119monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-43rd-annual-j-p-morgan-healthcare-conference-vktx-20250106monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-initiation-of-phase-2-venture-oral-dosing-trial-of-vk2735-ta-vktx-20250108monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-fourth-quarter-and-year-end-2024-on-fe-vktx-20250129monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-participate-at-upcoming-investor-conferences-vktx-20250304monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-completion-of-enrollment-in-phase-2-venture-oral-dosing-tria-vktx-20250326monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025-vktx-20250416monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-participate-at-upcoming-investor-conferences-vktx-20250528monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-initiation-of-phase-3-obesity-clinical-program-with-glp-1-gi-vktx-20250625monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2025-on-july-23-2025-vktx-20250716monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-participate-at-upcoming-investor-conferences-vktx-20250828monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-third-quarter-2025-on-october-22-2025-vktx-20251015monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-initiation-of-vk2735-maintenance-dosing-clinical-trial-in-pa-vktx-20251021monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-highlight-clinical-data-from-vk2735-obesity-program-in-presentation-vktx-20251029monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-participate-at-upcoming-investor-conferences-vktx-20251104monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-highlights-clinical-data-from-vk2735-obesity-program-in-presentation-a-vktx-20251106monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-completion-of-enrollment-in-phase-3-vanquish-1-trial-of-vk27-vktx-20251119monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-participate-at-the-piper-sandler-37th-annual-healthcare-conference-vktx-20251125monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-vktx-20260105monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-appointment-of-neil-aubuchon-as-chief-commercial-officer-vktx-20260107monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-completion-of-enrollment-in-maintenance-dosing-clinical-tria-vktx-20260108monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-announces-publication-of-results-from-phase-2-venture-trial-of-dual-gl-vktx-20260112monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-fourth-quarter-and-year-end-2025-on-fe-vktx-20260204monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-participate-at-upcoming-investor-conferences-vktx-20260410monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-presents-data-from-its-13-week-phase-2-venture-oral-dosing-trial-of-vk-vktx-20260512monthly0.5https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-to-participate-at-upcoming-investor-conferences-vktx-20260521monthly0.5https://www.biopharmawatch.com/news/ALT/vaxin-changes-company-name-to-altimmune-alt-20150901monthly0.5https://www.biopharmawatch.com/news/ALT/pharmathene-reports-year-end-2015-financial-and-operational-results-provides-update-on-lit-alt-20160311monthly0.5https://www.biopharmawatch.com/news/ALT/pharmathene-receives-20-million-payment-from-siga-to-extend-payment-deadline-alt-20160708monthly0.5https://www.biopharmawatch.com/news/ALT/pharmathene-reports-second-quarter-2016-financial-and-operational-results-alt-20160804monthly0.5https://www.biopharmawatch.com/news/ALT/pharmathene-files-protest-against-hhs-over-anthrax-vaccine-bidding-process-alt-20160805monthly0.5https://www.biopharmawatch.com/news/ALT/pharmathene-withdraws-protest-against-hhs-over-anthrax-vaccine-bidding-process-alt-20160825monthly0.5https://www.biopharmawatch.com/news/ALT/pharmathene-announces-receipt-of-payments-from-siga-alt-20160916monthly0.5https://www.biopharmawatch.com/news/ALT/pharmathene-reports-third-quarter-2016-financial-and-operational-results-alt-20161104monthly0.5https://www.biopharmawatch.com/news/ALT/pharmathene-receives-final-payment-from-siga-of-83-9-million-alt-20161116monthly0.5https://www.biopharmawatch.com/news/ALT/pharmathene-declares-2-91-special-cash-dividend-on-common-stock-alt-20161117monthly0.5https://www.biopharmawatch.com/news/ALT/pharmathene-and-altimmune-announce-merger-to-create-immunotherapeutics-company-targeting-i-alt-20170119monthly0.5https://www.biopharmawatch.com/news/ALT/pharmathene-announces-record-date-and-meeting-date-for-special-meeting-of-stockholders-reg-alt-20170313monthly0.5https://www.biopharmawatch.com/news/ALT/pharmathene-reports-year-end-2016-financial-and-operational-results-alt-20170314monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-appoints-vipin-k-garg-ph-d-as-president-and-chief-executive-officer-alt-20181127monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-presentation-of-heptcell-phase-1-results-at-the-international-liver-co-alt-20190129monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-closing-of-14-million-registered-direct-offering-alt-20190312monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-participate-at-31st-annual-roth-conference-alt-20190314monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-positive-results-from-nasovax-extension-study-alt-20190319monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-announce-year-end-2018-financial-results-on-april-2-alt-20190321monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-present-nasovax-phase-2-data-at-the-world-vaccine-congress-in-washington-d-c-alt-20190411monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-announce-first-quarter-2019-financial-results-on-may-15-alt-20190508monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-important-additions-to-its-patent-portfolio-for-heptcell-and-alt-702-p-alt-20190605monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-successful-pre-ind-meeting-with-fda-alt-20190610monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-announce-second-quarter-2019-financial-results-on-august-14-alt-20190805monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-appoints-m-scott-harris-m-d-as-chief-medical-officer-alt-20190909monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-participate-in-upcoming-investor-conferences-alt-20191010monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-announce-third-quarter-2019-financial-results-on-november-14-alt-20191106monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-host-key-opinion-leader-call-on-alt-801-for-the-treatment-of-nash-alt-20191121monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-present-at-the-2020-nash-tag-conference-alt-20200107monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-positive-results-for-alt-702-in-preclinical-model-of-colorectal-cancer-alt-20200123monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-present-at-upcoming-investor-and-scientific-conferences-alt-20200204monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-present-at-the-cowen-40th-annual-health-care-conference-alt-20200219monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-completes-first-development-milestone-toward-a-single-dose-intranasal-covid-19-v-alt-20200228monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-announce-year-end-2019-financial-results-on-march-27-alt-20200325monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-and-the-university-of-alabama-at-birmingham-to-collaborate-on-development-of-sin-alt-20200330monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-announce-first-quarter-2020-financial-results-on-may-14-alt-20200508monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-launches-clinical-trial-of-t-covid-an-investigational-intranasal-immune-modulato-alt-20200601monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-ind-clearance-for-a-phase-2-trial-of-heptcell-immunotherapeutic-for-th-alt-20200622monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-receives-award-from-u-s-department-of-defense-to-fund-phase-1-2-clinical-trial-o-alt-20200629monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-dosing-of-first-patient-in-phase-1b-clinical-trial-of-nasoshield-a-sin-alt-20200630monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-signs-teaming-agreement-with-dynport-vaccine-company-on-u-s-government-funding-e-alt-20200709monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-pricing-of-a-public-offering-of-115-million-of-common-stock-and-pre-fu-alt-20200713monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-closing-of-132-million-public-offering-of-common-stock-and-pre-funded--alt-20200716monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-manufacturing-agreement-with-vigene-biosciences-for-adcovid-its-single-alt-20200722monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-announce-second-quarter-2020-financial-results-on-august-12-alt-20200805monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-completes-enrollment-in-phase-1b-clinical-trial-of-nasoshield-a-single-dose-intr-alt-20200807monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-data-presentation-on-alt-801-its-balanced-and-long-acting-glp-1-glucag-alt-20200826monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-successful-completion-of-multiple-dose-toxicity-and-toxicokinetic-stud-alt-20200901monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-presents-highlights-of-intranasal-covid-19-vaccine-and-therapeutic-programs-adco-alt-20200928monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-present-at-upcoming-investor-conferences-alt-20200930monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-and-uab-announce-publication-of-compelling-pre-clinical-data-for-adcovid-intrana-alt-20201012monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-present-at-two-upcoming-virtual-investor-conferences-alt-20201015monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-announce-third-quarter-2020-financial-results-on-november-10-alt-20201103monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-adds-lonza-as-a-manufacturing-partner-for-supply-of-adcovid-its-single-dose-intr-alt-20201110monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-present-at-upcoming-virtual-investor-conferences-alt-20201116monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-submission-of-investigational-new-drug-application-for-adcovid-a-singl-alt-20201125monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-commences-dosing-in-phase-1-clinical-trial-of-alt-801-a-long-acting-glp-1-glucag-alt-20201208monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-present-at-the-4th-annual-nash-summit-2020-digital-conference-alt-20201211monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-begins-multinational-phase-2-clinical-trial-of-heptcell-a-novel-immunotherapeuti-alt-20201230monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-fda-clearance-of-adcovid-ind-application-alt-20210217monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-announce-year-end-2020-financial-results-on-february-25-2021-alt-20210222monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-commences-enrollment-in-phase-1-clinical-trial-of-adcovid-a-needle-free-single-d-alt-20210225monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-present-at-upcoming-conferences-alt-20210308monthly0.5https://www.biopharmawatch.com/news/ALT/adcovid-altimmune-s-single-dose-intranasal-covid-19-vaccine-candidate-prevents-sars-cov-2--alt-20210315monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-partners-with-summit-biosciences-to-produce-a-multidose-nasal-spray-presentation-alt-20210322monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-present-at-upcoming-scientific-conferences-alt-20210429monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-new-preclinical-data-for-adcovid-demonstrating-sterilizing-immunity-af-alt-20210510monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-announce-first-quarter-2021-financial-results-on-may-17-2021-alt-20210511monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-demonstrates-strong-neutralization-of-south-african-variant-in-preclinical-study-alt-20210526monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-present-at-the-2021-jefferies-virtual-healthcare-conference-alt-20210527monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-update-on-adcovid-phase-1-clinical-trial-alt-20210629monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-announce-second-quarter-2021-financial-results-on-august-11-2021-alt-20210804monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference-septem-alt-20210907monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-announce-12-week-data-from-alt-801-phase-1-trial-on-september-28-2021-alt-20210927monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-host-key-opinion-leader-call-with-dr-stephen-harrison-on-pemvidutide-phase-1--alt-20210929monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-initiation-of-12-week-phase-1b-trial-of-pemvidutide-in-subjects-with-n-alt-20211004monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-present-at-upcoming-h-c-wainwright-investor-conferences-october-12-13-2021-alt-20211006monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-announce-third-quarter-2021-financial-results-on-november-10-2021-alt-20211103monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-present-pemvidutide-clinical-data-at-upcoming-nash-tag-conference-january-8-2-alt-20220103monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-fda-clearance-of-pemvidutide-alt-801-ind-for-obesity-alt-20220131monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-report-fourth-quarter-and-full-year-2021-financial-results-on-march-15-2022-alt-20220308monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-initiation-of-48-week-phase-2-momentum-trial-of-pemvidutide-in-obesity-alt-20220401monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-report-first-quarter-2022-financial-results-and-provide-business-update-on-ma-alt-20220505monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-oral-presentation-of-pemvidutide-clinical-data-at-upcoming-easl-intern-alt-20220617monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-report-second-quarter-2022-financial-results-and-provide-business-update-on-a-alt-20220804monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-first-dosing-of-all-subjects-in-phase-2-momentum-trial-of-pemvidutide--alt-20220928monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-present-pemvidutide-clinical-data-at-the-upcoming-aha-scientific-sessions-and-alt-20221028monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-report-third-quarter-2022-financial-results-and-provide-business-update-on-no-alt-20221103monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-participate-at-two-upcoming-investor-conferences-alt-20221122monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-appoints-raymond-jordt-as-chief-business-officer-alt-20230104monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-busine-alt-20230221monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-completes-enrollment-in-phase-2-clinical-trial-of-heptcell-an-immunotherapeutic--alt-20230411monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-ma-alt-20230504monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-participate-in-the-healthcare-virtual-conference-presented-by-maxim-group-llc-alt-20230616monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-initiation-of-phase-2b-impact-trial-evaluating-the-efficacy-and-safety-alt-20230801monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-report-second-quarter-2023-financial-results-and-provide-business-update-on-a-alt-20230803monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-completion-of-dosing-in-the-phase-2-momentum-trial-of-pemvidutide-in-s-alt-20230912monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-present-new-data-on-the-anti-inflammatory-and-anti-fibrotic-properties-of-pem-alt-20231025monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-granted-fast-track-designation-by-fda-for-pemvidutide-for-the-treatment-of-non-a-alt-20231026monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-report-third-quarter-2023-financial-results-and-provide-business-update-on-no-alt-20231031monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-presentation-of-pemvidutide-clinical-data-at-upcoming-nash-tag-confere-alt-20240102monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-report-fourth-quarter-and-full-year-2023-financial-results-and-provide-busine-alt-20240320monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-statement-on-the-passing-of-dr-stephen-harrison-alt-20240425monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-participate-at-two-upcoming-conferences-alt-20240501monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-report-first-quarter-2024-financial-results-and-provide-business-update-on-ma-alt-20240502monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-present-clinical-data-from-pemvidutide-at-upcoming-easl-international-liver-c-alt-20240529monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-presents-data-at-easl-international-liver-congress-2024-supporting-the-disease-m-alt-20240605monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-oral-presentations-of-pemvidutide-clinical-data-at-upcoming-american-d-alt-20240618monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-participate-in-the-piper-sandler-2nd-annual-virtual-obesity-investor-day-to-d-alt-20240620monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-presents-data-on-the-effect-of-pemvidutide-on-cardioinflammatory-lipids-during-o-alt-20240622monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-presents-data-from-phase-2-momentum-trial-of-pemvidutide-in-obesity-during-oral--alt-20240623monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-participate-at-leerink-partners-therapeutics-forum-alt-20240702monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-report-second-quarter-2024-financial-results-and-provide-business-update-on-a-alt-20240801monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-presents-results-of-a-phase-2-mri-based-body-composition-sub-study-at-60th-annua-alt-20240910monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-completes-enrollment-in-phase-2b-impact-trial-of-pemvidutide-in-metabolic-dysfun-alt-20240930monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-present-new-data-on-the-lipidomic-profile-in-subjects-treated-with-pemvidutid-alt-20241015monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-successful-completion-of-end-of-phase-2-meeting-with-fda-for-pemviduti-alt-20241107monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-presents-new-data-on-the-effect-of-pemvidutide-on-inflammatory-lipids-in-subject-alt-20241115monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-present-at-the-cachexia-regulatory-trials-update-workshop-of-the-17th-interna-alt-20241202monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-added-to-nasdaq-biotechnology-index-alt-20241219monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-participate-in-the-guggenheim-smid-cap-biotech-conference-alt-20250129monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-participate-in-the-leerink-global-healthcare-conference-alt-20250303monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-host-virtual-r-d-day-on-march-13-2025-alt-20250306monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-participate-in-the-citizens-life-sciences-conference-alt-20250430monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-present-at-upcoming-easl-international-liver-congress-2025-alt-20250501monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-secures-up-to-100-million-in-credit-facility-from-hercules-capital-alt-20250513monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-initiation-of-reclaim-phase-2-trial-evaluating-the-efficacy-and-safety-alt-20250519monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-multiple-presentations-at-upcoming-american-diabetes-association-s-sci-alt-20250613monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-initiation-of-restore-phase-2-trial-evaluating-the-efficacy-and-safety-alt-20250709monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-board-of-directors-appoints-jerry-durso-as-chairman-alt-20250811monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-announces-fda-fast-track-designation-for-pemvidutide-in-alcohol-use-disorder-aud-alt-20250819monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-participate-in-two-upcoming-investor-conferences-alt-20250923monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-no-alt-20251030monthly0.5https://www.biopharmawatch.com/news/ALT/altimmune-to-participate-in-upcoming-investor-conferences-alt-20260527monthly0.5https://www.biopharmawatch.com/news/ALT/pemvidutide-demonstrates-significant-metabolic-improvements-in-patients-with-mash-in-new-4-alt-20260528monthly0.5https://www.biopharmawatch.com/news/SGMT/3-v-biosciences-expands-leadership-team-opens-new-facility-and-integrates-operations-sgmt-20100513monthly0.5https://www.biopharmawatch.com/news/SGMT/3-v-biosciences-appoints-edward-m-connor-jr-md-chief-medical-officer-sgmt-20100603monthly0.5https://www.biopharmawatch.com/news/SGMT/james-f-young-joins-3-v-biosciences-board-of-directors-sgmt-20100720monthly0.5https://www.biopharmawatch.com/news/SGMT/3-v-biosciences-appoints-merdad-v-parsey-md-phd-as-chief-executive-officer-sgmt-20100930monthly0.5https://www.biopharmawatch.com/news/SGMT/3-v-biosciences-promotes-stephen-r-brady-to-chief-business-officer-sgmt-20110210monthly0.5https://www.biopharmawatch.com/news/SGMT/3-v-biosciences-appoints-dr-george-w-kemble-phd-as-chief-scientific-officer-sgmt-20110815monthly0.5https://www.biopharmawatch.com/news/SGMT/3-v-biosciences-appoints-douglas-i-buckley-phd-as-vice-president-of-biology-sgmt-20120629monthly0.5https://www.biopharmawatch.com/news/SGMT/3-v-biosciences-closes-preferred-stock-financing-and-designates-novel-host-factor-hepatiti-sgmt-20120709monthly0.5https://www.biopharmawatch.com/news/SGMT/3-v-biosciences-to-present-at-the-seventh-annual-jmp-securities-healthcare-conference-sgmt-20120710monthly0.5https://www.biopharmawatch.com/news/SGMT/3-v-biosciences-to-present-data-on-hcv-product-candidates-at-the-american-association-for--sgmt-20121001monthly0.5https://www.biopharmawatch.com/news/SGMT/3-v-biosciences-presents-positive-preclinical-data-on-hcv-product-candidates-targeting-fas-sgmt-20121112monthly0.5https://www.biopharmawatch.com/news/SGMT/3-v-biosciences-completes-20-million-series-c-financing-sgmt-20130621monthly0.5https://www.biopharmawatch.com/news/SGMT/3-v-biosciences-presents-positive-data-for-novel-fasn-inhibitor-at-the-aacr-nci-eortc-inte-sgmt-20131023monthly0.5https://www.biopharmawatch.com/news/SGMT/3-v-biosciences-names-dr-william-mcculloch-chief-medical-officer-sgmt-20131121monthly0.5https://www.biopharmawatch.com/news/SGMT/3-v-biosciences-commences-patient-dosing-in-phase-1-clinical-study-of-fasn-inhibitor-tvb-2-sgmt-20131204monthly0.5https://www.biopharmawatch.com/news/SGMT/3-v-biosciences-to-present-clinical-and-preclinical-data-for-fasn-inhibitors-at-eortc-nci--sgmt-20141002monthly0.5https://www.biopharmawatch.com/news/SGMT/3-v-biosciences-announces-presentation-of-first-human-clinical-data-for-lead-oral-fasn-inh-sgmt-20141119monthly0.5https://www.biopharmawatch.com/news/SGMT/3-v-biosciences-to-present-at-the-25th-annual-oppenheimer-healthcare-conference-sgmt-20141204monthly0.5https://www.biopharmawatch.com/news/SGMT/3-v-biosciences-announces-closing-of-28-5m-financing-round-sgmt-20141230monthly0.5https://www.biopharmawatch.com/news/SGMT/3-v-biosciences-appoints-rekha-hemrajani-as-chief-financial-officer-sgmt-20150219monthly0.5https://www.biopharmawatch.com/news/SGMT/diacylglycerol-metabolism-and-signaling-is-a-driving-force-underlying-fasn-inhibitor-sensi-sgmt-20150415monthly0.5https://www.biopharmawatch.com/news/SGMT/3-v-biosciences-provides-clinical-update-on-tvb-2640-at-aacr-metabolism-and-cancer-confere-sgmt-20150609monthly0.5https://www.biopharmawatch.com/news/SGMT/3-v-biosciences-to-present-at-the-2015-wedbush-pacgrow-healthcare-conference-on-august-12--sgmt-20150804monthly0.5https://www.biopharmawatch.com/news/SGMT/3-v-biosciences-to-present-data-at-the-aacr-nci-eortc-international-conference-on-molecula-sgmt-20151102monthly0.5https://www.biopharmawatch.com/news/SGMT/3-v-biosciences-to-present-data-at-the-american-association-for-the-study-of-liver-disease-sgmt-20161108monthly0.5https://www.biopharmawatch.com/news/SGMT/3-v-biosciences-to-present-clinical-data-demonstrating-tvb-2640-inhibits-fatty-acid-synthe-sgmt-20171016monthly0.5https://www.biopharmawatch.com/news/SGMT/ascletis-and-3-v-biosciences-announce-nash-strategic-license-and-series-e-financing-sgmt-20190213monthly0.5https://www.biopharmawatch.com/news/SGMT/3-v-biosciences-commences-dosing-in-phase-2-clinical-study-of-the-fasn-inhibitor-tvb-2640--sgmt-20190430monthly0.5https://www.biopharmawatch.com/news/SGMT/3-v-biosciences-changes-name-to-sagimet-biosciences-and-closes-25-million-financing-sgmt-20190802monthly0.5https://www.biopharmawatch.com/news/SGMT/fasn-inhibitor-tvb-2640-shows-pharmacodynamic-effect-and-evidence-of-clinical-activity-in--sgmt-20190924monthly0.5https://www.biopharmawatch.com/news/SGMT/data-on-sagimet-s-lead-candidate-tvb-2640-to-be-presented-at-easl-ilc-2020-sgmt-20200331monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-announces-positive-topline-results-in-12-week-nash-phase-2-clinical-trial-of-fasn--sgmt-20200617monthly0.5https://www.biopharmawatch.com/news/SGMT/fatty-acid-synthase-inhibitor-tvb-2640-reduces-hepatic-de-novo-lipogenesis-in-males-with-m-sgmt-20200727monthly0.5https://www.biopharmawatch.com/news/SGMT/novel-first-in-class-fatty-acid-synthase-inhibitor-tvb-2640-versus-placebo-demonstrates-cl-sgmt-20200820monthly0.5https://www.biopharmawatch.com/news/SGMT/tvb-2640-with-bevacizumab-in-relapsed-high-grade-astrocytoma-sgmt-20200930monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-to-present-data-from-phase-2-fascinate-1-trial-of-tvb-2640-in-nash-at-aasld-s-the--sgmt-20201006monthly0.5https://www.biopharmawatch.com/news/SGMT/asc40-tvb-2640-phase-2-nash-trial-completed-patient-enrollment-in-china-sgmt-20201119monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-raises-80-million-in-crossover-financing-sgmt-20210211monthly0.5https://www.biopharmawatch.com/news/SGMT/fasn-inhibitor-asc40-demonstrates-positive-phase-2-topline-clinical-results-from-china-coh-sgmt-20210308monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-names-dr-eduardo-bruno-martins-as-chief-medical-officer-sgmt-20210310monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-receives-fast-track-designation-from-u-s-food-and-drug-administration--sgmt-20210316monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-to-present-phase-2-data-on-lead-candidate-tvb-2640-at-the-international-liver-cong-sgmt-20210422monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-appoints-life-sciences-industry-veteran-elizabeth-grammer-to-board-of--sgmt-20210503monthly0.5https://www.biopharmawatch.com/news/SGMT/tvb-2640-fasn-inhibitor-for-the-treatment-of-nonalcoholic-steatohepatitis-fascinate-1-a-ra-sgmt-20210723monthly0.5https://www.biopharmawatch.com/news/SGMT/published-results-from-sagimet-s-fascinate-1-phase-2a-trial-demonstrate-fasn-inhibitor-tvb-sgmt-20210725monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-doses-first-patient-in-fascinate-2-phase-2b-trial-in-nash-patients-wit-sgmt-20210815monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-to-present-data-from-phase-2-fascinate-1-trial-of-tvb-2640-in-nash-at-aasld-s-the--sgmt-20211004monthly0.5https://www.biopharmawatch.com/news/SGMT/new-data-from-sagimet-s-phase-2-fascinate-1-clinical-trial-demonstrate-tvb-2640-s-positive-sgmt-20211112monthly0.5https://www.biopharmawatch.com/news/SGMT/therapeutic-efficacy-of-fasn-inhibition-in-preclinical-models-of-hcc-sgmt-20220130monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-to-present-additional-biomarker-phase-2-data-on-denifanstat-tvb-2640-i-sgmt-20220504monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-announces-presentation-of-additional-phase-2-data-on-denifanstat-ident-sgmt-20220608monthly0.5https://www.biopharmawatch.com/news/SGMT/targeting-de-novo-lipogenesis-and-the-lands-cycle-induces-ferroptosis-in-kras-mutant-lung--sgmt-20220701monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-announces-oral-presentation-on-denifanstat-at-keystone-symposia-in-non-sgmt-20220804monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-announces-completion-of-patient-enrollment-in-phase-2b-fascinate-2-cli-sgmt-20220913monthly0.5https://www.biopharmawatch.com/news/SGMT/fasn-inhibition-targets-multiple-drivers-of-nash-by-reducing-steatosis-inflammation-and-fi-sgmt-20220930monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-announces-appointment-of-david-happel-to-chief-executive-officer-dr-ge-sgmt-20221024monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-announces-late-breaking-oral-and-poster-presentations-for-denifanstat--sgmt-20221031monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-announces-positive-interim-phase-2b-clinical-trial-data-with-denifanst-sgmt-20221103monthly0.5https://www.biopharmawatch.com/news/SGMT/phase-ii-investigation-of-tvb-2640-denifanstat-with-bevacizumab-in-patients-with-first-rel-sgmt-20230401monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-to-present-interim-data-from-phase-2b-trial-of-denifanstat-in-nash-at--sgmt-20230607monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-presents-positive-phase-2b-fascinate-2-clinical-trial-interim-data-for-sgmt-20230623monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-announces-pricing-of-upsized-initial-public-offering-sgmt-20230713monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-announces-leadership-changes-sgmt-20230720monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-announces-closing-of-underwriters-option-to-purchase-additional-shares-sgmt-20230815monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-announces-completion-of-enrollment-of-120-patients-for-phase-3-clinica-sgmt-20230927monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-to-present-at-the-h-c-wainwright-7th-annual-nash-investor-conference-sgmt-20231018monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-announces-acceptance-of-two-abstracts-at-aasld-the-liver-meeting-2023-sgmt-20231024monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-presents-preclinical-results-supporting-the-therapeutic-potential-of-i-sgmt-20231110monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-to-present-at-the-35th-annual-piper-sandler-healthcare-conference-sgmt-20231122monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-announces-oral-presentation-of-preclinical-results-of-fasn-inhibitor-i-sgmt-20231128monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-to-participate-in-the-first-annual-goldman-sachs-catalyst-clinic-sgmt-20231204monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-announces-positive-topline-results-from-phase-2b-fascinate-2-clinical--sgmt-20240122monthly0.5https://www.biopharmawatch.com/news/SGMT/gannex-s-strategic-partner-sagimet-biosciences-announces-positive-topline-results-from-pha-sgmt-20240122monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-announces-proposed-public-offering-of-series-a-common-stock-sgmt-20240123monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-to-participate-in-two-upcoming-investor-conferences-sgmt-20240229monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-reports-full-year-2023-financial-results-and-provides-corporate-update-sgmt-20240325monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-announces-appointment-of-tim-walbert-and-paul-hoelscher-to-its-board-o-sgmt-20240325monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-announces-completion-of-phase-1-hepatic-impairment-study-with-fasn-inh-sgmt-20240327monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-to-host-virtual-investor-and-analyst-day-on-inhibiting-fatty-acid-synt-sgmt-20240422monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-announces-appointment-of-thierry-chauche-as-chief-financial-officer-sgmt-20240506monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-announces-oral-presentation-of-data-from-the-phase-2b-fascinate-2-study-of-denifan-sgmt-20240507monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-to-host-virtual-investor-and-analyst-day-on-inhibiting-fatty-acid-synt-sgmt-20240516monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-to-host-conference-call-and-webcast-to-discuss-recently-presented-data-sgmt-20240610monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-announces-appointment-of-anne-phillips-and-jennifer-jarrett-to-its-boa-sgmt-20240801monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-reports-second-quarter-2024-financial-results-and-provides-corporate-u-sgmt-20240814monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-to-participate-in-two-upcoming-investor-conferences-sgmt-20240904monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-announces-oral-presentation-at-the-8th-annual-mash-drug-development-summit-sgmt-20240912monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-receives-fda-breakthrough-therapy-designation-for-denifanstat-in-mash-sgmt-20241001monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-to-present-at-the-h-c-wainwright-8th-annual-mash-virtual-conference-an-sgmt-20241001monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-announces-publication-of-results-from-phase-2b-fascinate-2-clinical-tr-sgmt-20241011monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-announces-upcoming-presentations-at-aasld-the-liver-meeting-2024-sgmt-20241016monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-announces-successful-completion-of-end-of-phase-2-interactions-with-fd-sgmt-20241029monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-to-participate-in-the-ubs-global-healthcare-conference-sgmt-20241107monthly0.5https://www.biopharmawatch.com/news/SGMT/ascletis-completes-enrollment-of-phase-iii-trial-of-asc40-denifanstat-once-daily-oral-tabl-sgmt-20241112monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-presents-clinical-denifanstat-and-preclinical-fasn-inhibitor-data-at-a-sgmt-20241118monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-to-participate-in-the-piper-sandler-36th-annual-healthcare-conference-sgmt-20241126monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-announces-oral-presentation-at-the-9th-annual-mash-tag-2025-conference-sgmt-20250106monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-announces-oral-presentation-at-the-mash-pathogenesis-and-therapeutic-a-sgmt-20250219monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-announces-upcoming-presentations-at-easl-congress-2025-sgmt-20250423monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-to-host-virtual-kol-event-evaluating-the-synergistic-potential-of-a-co-sgmt-20250522monthly0.5https://www.biopharmawatch.com/news/SGMT/ascletis-announces-phase-iii-trial-of-denifanstat-asc40-a-first-in-class-once-daily-oral-f-sgmt-20250603monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-to-host-virtual-kol-event-a-new-mechanism-of-action-in-treating-acne-u-sgmt-20250609monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference-sgmt-20250805monthly0.5https://www.biopharmawatch.com/news/SGMT/ascletis-presented-phase-iii-study-results-of-first-in-class-fasn-inhibitor-denifanstat-as-sgmt-20250917monthly0.5https://www.biopharmawatch.com/news/SGMT/ascletis-completes-denifanstat-asc40-pre-nda-consultation-with-china-national-medical-prod-sgmt-20251014monthly0.5https://www.biopharmawatch.com/news/SGMT/ascletis-announces-china-national-medical-products-administration-acceptance-of-new-drug-a-sgmt-20251210monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-announces-positive-results-from-the-phase-1-pk-clinical-trial-of-denif-sgmt-20251218monthly0.5https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-announces-poster-presentation-at-the-10th-annual-mash-tag-2026-confere-sgmt-20260108monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-series-a-financing-rare-20110620monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-initiates-phase-1-clinical-study-of-ux001-in-hereditary-inclusion-body-myopathy-rare-20110815monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-granted-orphan-drug-designation-for-ux001-sa-er-for-the-treatment-of-hereditary-rare-20111005monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-appoints-tom-kassberg-as-chief-business-officer-and-announces-management-team-rare-20111121monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-in-licenses-therapeutic-program-for-rare-genetic-disease-mucopolysaccharidosis--rare-20120105monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-granted-orphan-drug-designation-for-ux003-for-the-treatment-of-mucopolysacchari-rare-20120228monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-the-completion-of-the-phase-1-clinical-study-of-ux001-in-hereditary-i-rare-20120308monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-granted-orphan-designations-in-europe-for-two-lead-product-candidates-ux001-for-rare-20120328monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-appoints-shalini-sharp-as-chief-financial-officer-and-senior-vice-president-fin-rare-20120418monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-relocates-company-headquarters-to-support-operational-expansion-rare-20120423monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-phase-1-results-of-ux001-in-hereditary-inclusion-body-myopathy-hibm-a-rare-20120501monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-initiates-phase-2-study-of-ux001-in-hereditary-inclusion-body-myopathy-a-rare-n-rare-20120705monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-2012-wedbush-pacgrow-life-sciences-management-access-conferen-rare-20120807monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-canaccord-genuity-32nd-annual-growth-conference-on-august-16--rare-20120809monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-stifel-nicolaus-weisel-healthcare-conference-2012-in-boston-rare-20120830monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-11th-annual-bio-investor-forum-in-san-francisco-rare-20121003monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-three-abstracts-accepted-for-poster-presentation-at-17th-annual-world-rare-20121010monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-completion-of-phase-2-study-enrollment-for-ux001-in-hereditary-inclus-rare-20121030monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-raises-75-million-in-oversubscribed-crossover-financing-rare-20121220monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-2013-31st-annual-j-p-morgan-healthcare-conference-rare-20130102monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-in-licensing-of-clinical-stage-product-triheptanoin-rare-20130110monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-cowen-and-company-33rd-annual-health-care-conference-rare-20130304monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-barclays-global-healthcare-conference-rare-20130306monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-20th-annual-future-leaders-in-the-biotech-industry-conference-rare-20130329monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-initiates-novel-disease-monitoring-program-for-hereditary-inclusion-body-myopat-rare-20130408monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-advances-clinical-development-of-ux003-for-the-treatment-of-mucopolysaccharidos-rare-20130515monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-a-positive-signal-in-interim-data-from-phase-2-study-of-ux001-in-here-rare-20130703monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-gains-worldwide-rights-to-triheptanoin-ux007-rare-20130711monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-initiates-new-development-program-studying-triheptanoin-ux007-for-the-treatment-rare-20130805monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-upcoming-healthcare-investor-conferences-rare-20130807monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-receives-approval-of-clinical-trial-application-cta-for-a-phase-1-2-trial-testi-rare-20130814monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-investigational-new-drug-application-for-ux007-is-active-rare-20130826monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-presentation-of-three-abstracts-at-the-12th-international-congress-of-rare-20130828monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-collaboration-with-kyowa-hakko-kirin-to-develop-and-commercialize-pha-rare-20130903monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-positive-data-from-retrospective-study-of-ux007-triheptanoin-in-patie-rare-20130916monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-three-abstracts-accepted-for-poster-presentation-at-18th-annual-world-rare-20130926monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-the-presentation-of-data-from-a-single-dose-phase-1-study-conducted-b-rare-20131006monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-initiation-of-phase-1-2-study-of-recombinant-human-beta-glucuronidase-rare-20131204monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-investigational-new-drug-application-for-triheptanoin-for-the-treatment-of-gluc-rare-20131217monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-granted-eu-orphan-drug-designation-for-krn23-for-the-treatment-of-x-linked-hypo-rare-20141030monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-j-p-morgan-healthcare-conference-rare-20150105monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-license-of-intellectual-property-related-to-the-treatment-of-huntingt-rare-20150107monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-pricing-of-public-offering-of-common-stock-rare-20150204monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-positive-36-week-data-from-phase-1-2-study-of-recombinant-human-beta--rare-20150210monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-full-exercise-of-underwriters-option-to-purchase-additional-shares-rare-20150217monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-appoints-daniel-g-welch-to-board-of-directors-rare-20150413monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-positive-data-from-investigator-sponsored-trial-of-triheptanoin-in-gl-rare-20150422monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-appoints-dennis-huang-as-chief-technical-operations-officer-and-senior-vice-pre-rare-20150604monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-completion-of-enrollment-in-phase-3-study-of-recombinant-human-beta-g-rare-20150608monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-jmp-securities-healthcare-conference-rare-20150617monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-upcoming-investor-conferences-rare-20150804monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-initiation-of-phase-2-study-of-recombinant-human-beta-glucuronidase-i-rare-20150805monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-aceneuramic-acid-prolonged-release-marketing-authorization-applicatio-rare-20151002monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-positive-interim-data-from-phase-2-study-of-ux007-in-long-chain-fatty-rare-20151013monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-pharmaceutical-and-arcturus-therapeutics-announce-a-research-collaboration-and--rare-20151029monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-upcoming-investor-conferences-rare-20151111monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-positive-interim-40-week-data-from-pediatric-phase-2-study-of-krn23-in--rare-20151202monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-and-saint-louis-university-s-center-for-world-health-and-medicine-announce-rese-rare-20160323monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-positive-interim-data-from-phase-2-study-of-krn23-for-the-treatment-of--rare-20160421monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-and-takeda-enter-into-a-collaboration-to-develop-and-commercialize-therapies-fo-rare-20160607monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-appoints-karah-parschauer-as-executive-vice-president-general-counsel-rare-20160620monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-receives-breakthrough-therapy-designation-for-krn23-in-pediatric-patients-with--rare-20160628monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-phase-3-data-for-recombinant-human-beta-glucuronidase-in-mucopolysac-rare-20160713monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-positive-topline-data-from-phase-3-study-of-recombinant-human-beta-gl-rare-20160714monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-completion-of-enrollment-in-phase-3-study-of-aceneuramic-acid-extende-rare-20160727monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-second-quarter-2016-financial-results-and-corporate-rare-20160801monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-krn23-data-presentations-at-asbmr-2016-annual-meeting-rare-20160823monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-positive-interim-data-from-phase-2-study-of-krn23-for-the-treatment-of--rare-20160918monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-withdrawal-of-marketing-authorization-application-for-aceneuramic-aci-rare-20161111monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-positive-data-from-phase-2-study-of-ux007-in-long-chain-fatty-acid-ox-rare-20161130monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-fourth-quarter-and-full-year-2016-financial-results-and-corporate-updat-rare-20170216monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-topline-data-from-phase-2-ux007-glucose-transporter-type-1-deficiency-rare-20170322monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-and-kyowa-kirin-international-announce-positive-data-from-pediatric-phase-2-stu-rare-20170406monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-appoints-deborah-dunsire-m-d-to-board-of-directors-rare-20170410monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-kyowa-hakko-kirin-and-kyowa-kirin-international-announce-positive-24-week-data--rare-20170418monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-first-quarter-2017-financial-results-and-corporate-update-rare-20170504monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-recombinant-human-beta-glucuronidase-biologics-license-application-an-rare-20170523monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-second-quarter-2017-financial-results-and-corporate-update-rare-20170727monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-top-line-results-from-phase-3-study-of-ace-er-in-gne-myopathy-rare-20170822monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-and-kyowa-hakko-kirin-announce-submission-of-burosumab-s-biologics-license-appl-rare-20170824monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-morgan-stanley-global-healthcare-conference-rare-20170906monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-and-kyowa-hakko-kirin-announce-additional-burosumab-data-in-x-linked-hypophosph-rare-20170911monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-acquire-dimension-therapeutics-rare-20171003monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-and-kyowa-hakko-kirin-announce-fda-not-currently-planning-to-hold-advisory-comm-rare-20171101monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-third-quarter-2017-financial-results-and-corporate-update-rare-20171102monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-completes-tender-offer-and-acquisition-of-dimension-therapeutics-rare-20171107monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-fda-approval-of-mepsevii-vestronidase-alfa-the-first-therapy-for-prog-rare-20171115monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-completion-of-patient-dosing-in-first-cohort-of-phase-1-2-clinical-st-rare-20171116monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-highlight-pipeline-at-analyst-and-investor-day-on-december-4-rare-20171130monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-and-kyowa-kirin-announce-positive-48-week-data-from-adult-phase-3-study-of-buro-rare-20171204monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-sells-priority-review-voucher-for-130-million-rare-20171218monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-update-to-ux007-development-program-in-long-chain-fatty-acid-oxidatio-rare-20180104monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-j-p-morgan-healthcare-conference-rare-20180104monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-positive-interim-topline-results-from-first-cohort-of-phase-1-2-clini-rare-20180107monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-proposed-public-offering-of-common-stock-rare-20180122monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-pricing-of-public-offering-of-common-stock-rare-20180123monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-appoints-camille-l-bedrosian-m-d-as-chief-medical-officer-and-executive-vice-pr-rare-20180129monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-fourth-quarter-and-full-year-2017-financial-results-and-corporate-updat-rare-20180220monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-positive-topline-results-and-dmc-review-from-first-cohort-of-phase-1--rare-20180307monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-upcoming-investor-conferences-rare-20180308monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-filing-and-fda-clearance-of-an-investigational-new-drug-application-f-rare-20180423monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-and-kyowa-kirin-announce-crysvita-burosumab-twza-now-launched-in-the-u-s-for-th-rare-20180430monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-first-quarter-2018-financial-results-and-corporate--rare-20180501monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-first-quarter-2018-financial-results-and-corporate-update-rare-20180507monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-and-kyowa-kirin-announce-topline-phase-3-study-results-demonstrating-superiorit-rare-20180517monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-and-kyowa-kirin-announce-publication-of-phase-2-study-results-demonstrating-tha-rare-20180523monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-first-patient-dosed-in-phase-1-2-study-of-dtx401-a-gene-therapy-for-t-rare-20180726monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-second-quarter-2018-financial-results-and-corporate-update-rare-20180802monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-fda-accepts-proposal-to-submit-an-nda-for-ux007-for-the-treatment-of--rare-20180829monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-jefferies-gene-therapy-summit-rare-20180926monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-positive-topline-cohort-2-results-from-phase-1-2-clinical-study-of-dt-rare-20180927monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-approval-of-mepsevii-vestronidase-alfa-in-brazil-for-the-treatment-of-rare-20181018monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-negative-topline-results-from-phase-3-study-of-ux007-in-patients-with-rare-20181026monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-third-quarter-2018-financial-results-and-corporate-update-rare-20181105monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-intent-to-submit-new-drug-application-to-u-s-fda-for-ux007-for-the-tr-rare-20181114monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-and-kyowa-kirin-announce-health-canada-approval-of-crysvita-burosumab-injection-rare-20181206monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-j-p-morgan-healthcare-conference-rare-20190103monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-positive-topline-results-from-first-cohort-of-phase-1-2-clinical-stud-rare-20190104monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-positive-topline-data-from-ongoing-long-term-extension-study-of-ux007-rare-20190122monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-appoints-shehnaaz-suliman-m-d-to-board-of-directors-rare-20190204monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-and-kyowa-kirin-announce-positive-64-week-results-for-crysvita-burosumab-from-p-rare-20190214monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-fourth-quarter-and-full-year-2018-financial-results-and-corporate-updat-rare-20190219monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-positive-24-week-data-from-first-cohort-of-phase-1-2-study-of-dtx401--rare-20190221monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-proposed-public-offering-of-common-stock-rare-20190225monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-pricing-of-public-offering-of-common-stock-rare-20190226monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-upcoming-investor-conferences-rare-20190311monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-approval-of-crysvita-burosumab-in-brazil-for-the-treatment-of-x-linke-rare-20190326monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-corporate-update-at-analyst-and-investor-day-on-april-17-in-new-york-rare-20190411monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-ux007-granted-fast-track-designation-and-rare-pediatric-disease-desig-rare-20190416monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-first-quarter-2019-financial-results-and-corporate--rare-20190430monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-first-quarter-2019-financial-results-and-corporate-update-rare-20190506monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-bank-of-america-merrill-lynch-healthcare-conference-rare-20190510monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-emil-d-kakkis-m-d-ph-d-as-recipient-of-bio-s-2019-henri-a-termeer-bio-rare-20190529monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-upcoming-investor-conferences-rare-20190531monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-expands-leadership-team-and-promotes-erik-harris-to-chief-commercial-officer-rare-20190617monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-second-quarter-2019-financial-results-and-corporate-rare-20190723monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-submission-of-new-drug-application-to-fda-for-ux007-triheptanoin-for--rare-20190801monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-second-quarter-2019-financial-results-and-corporate-update-rare-20190801monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-wedbush-pacgrow-healthcare-conference-rare-20190813monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-upcoming-investor-conferences-rare-20190830monthly0.5https://www.biopharmawatch.com/news/RARE/genetx-and-ultragenyx-announce-orphan-drug-designation-and-rare-pediatric-disease-designat-rare-20190903monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-positive-data-from-phase-1-2-study-of-dtx401-gene-therapy-in-glycogen-rare-20190904monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-and-kyowa-kirin-announce-intent-to-submit-supplemental-biologics-license-applic-rare-20190910monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-and-kyowa-kirin-announce-u-s-fda-approves-label-update-for-crysvita-burosumab-f-rare-20190930monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-jefferies-gene-therapy-editing-summit-rare-20191002monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-fda-accepts-new-drug-application-for-ux007-triheptanoin-for-treatment-rare-20191014monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-third-quarter-2019-financial-results-and-corporate-update-rare-20191105monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-upcoming-investor-conferences-rare-20191108monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-piper-jaffray-31st-annual-healthcare-conference-rare-20191126monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-sale-of-future-european-royalties-on-crysvita-burosumab-for-320-milli-rare-20191218monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-positive-topline-cohort-3-results-and-improved-longer-term-cohort-2-r-rare-20200109monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-preliminary-2019-revenue-and-provides-2020-crysvita-revenue-guidance-rare-20200113monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-and-kyowa-kirin-announce-submission-of-supplemental-biologics-license-applicati-rare-20200113monthly0.5https://www.biopharmawatch.com/news/RARE/genetx-and-ultragenyx-announce-investigational-new-drug-ind-application-active-for-gtx-102-rare-20200115monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-fourth-quarter-and-full-year-2019-financial-results-rare-20200206monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-fourth-quarter-and-full-year-2019-financial-results-and-corporate-updat-rare-20200213monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-svb-leerink-global-healthcare-conference-rare-20200221monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-planned-transition-of-chief-financial-officer-rare-20200303monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-barclays-global-healthcare-conference-rare-20200309monthly0.5https://www.biopharmawatch.com/news/RARE/genetx-and-ultragenyx-announce-first-patient-dosed-in-phase-1-2-clinical-trial-of-gtx-102--rare-20200316monthly0.5https://www.biopharmawatch.com/news/RARE/genetx-and-ultragenyx-announce-gtx-102-granted-fast-track-designation-by-u-s-fda-for-treat-rare-20200504monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-bofa-securities-global-health-care-conference-rare-20200511monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-positive-longer-term-results-from-first-three-cohorts-of-phase-1-2-st-rare-20200513monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-positive-data-from-confirmatory-cohort-of-phase-1-2-study-of-dtx401-g-rare-20200515monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-exercise-of-option-to-purchase-additional-stock-of-arcturus-therapeut-rare-20200521monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-upcoming-investor-conferences-rare-20200528monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-u-s-commercial-launch-of-dojolvi-triheptanoin-the-first-fda-approved--rare-20200722monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-second-quarter-2020-financial-results-and-corporate-rare-20200724monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-second-quarter-2020-financial-results-and-corporate-update-rare-20200730monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-upcoming-investor-conferences-rare-20200804monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-expands-leadership-team-and-appoints-ernie-meyer-as-chief-human-resources-offic-rare-20200901monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-appoints-mardi-c-dier-as-chief-financial-officer-rare-20200902monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-upcoming-investor-conferences-rare-20200903monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-jefferies-gene-therapy-editing-summit-rare-20200925monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-third-quarter-2020-financial-results-and-corporate--rare-20201021monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-third-quarter-2020-financial-results-and-corporate-update-rare-20201027monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-pricing-of-public-offering-of-common-stock-rare-20201028monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-proposed-public-offering-of-common-stock-rare-20201028monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-under-rare-20201102monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-upcoming-investor-conferences-rare-20201105monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-plans-to-build-large-scale-gene-therapy-manufacturing-facility-to-sup-rare-20201109monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-upcoming-healthcare-conferences-rare-20201124monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-orphan-drug-designation-for-ux701-for-the-treatment-of-wilson-disease-rare-20201209monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-39th-annual-j-p-morgan-virtual-healthcare-conference-rare-20210105monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-progress-across-broad-gene-therapy-portfolio-and-positive-longer-term-rare-20210108monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-fourth-quarter-and-full-year-2020-financial-results-rare-20210204monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-fourth-quarter-and-full-year-2020-financial-results-and-corporate-updat-rare-20210211monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-approval-of-dojolvi-ux007-triheptanoin-in-canada-for-the-treatment-of-rare-20210217monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-upcoming-investor-conferences-rare-20210217monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-barclays-global-healthcare-conference-rare-20210303monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-fda-clearance-of-investigational-new-drug-ind-application-for-ux053-a-rare-20210308monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-completes-successful-end-of-phase-2-meeting-with-fda-and-finalizes-phase-3-stud-rare-20210422monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-upcoming-data-presentations-at-american-society-of-gene-cell-therapy--rare-20210427monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-first-quarter-2021-financial-results-and-corporate--rare-20210428monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-truist-securities-life-sciences-summit-rare-20210428monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-first-quarter-2021-financial-results-and-corporate-update-rare-20210504monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-bank-of-america-securities-healthcare-conference-rare-20210510monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20210518monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-jefferies-virtual-healthcare-conference-rare-20210526monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-goldman-sachs-42nd-annual-healthcare-conference-rare-20210603monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-appoints-corsee-sanders-ph-d-to-board-of-directors-rare-20210630monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-receives-orphan-drug-designation-from-fda-and-european-commission-for-ux053-an--rare-20210727monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-second-quarter-2021-financial-results-and-corporate-update-rare-20210802monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-participate-in-gene-therapy-panel-at-wedbush-pacgrow-healthcare-conference-rare-20210804monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20210817monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-approval-of-dojolvi-triheptanoin-in-brazil-for-the-treatment-of-long--rare-20210823monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-participate-in-panel-at-citi-s-16th-annual-biopharma-healthcare-conference-rare-20210901monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-crysvita-burosumab-and-ux143-setrusumab-data-presentations-at-upcomin-rare-20210927monthly0.5https://www.biopharmawatch.com/news/RARE/mereo-biopharma-and-ultragenyx-present-data-from-the-phase-2b-asteroid-study-of-ux143-setr-rare-20211001monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20211004monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-jefferies-gene-therapy-editing-summit-rare-20211025monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-third-quarter-2021-financial-results-and-corporate--rare-20211026monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-additional-positive-multi-year-durability-data-from-phase-1-2-aav-gen-rare-20211129monthly0.5https://www.biopharmawatch.com/news/RARE/genetx-and-ultragenyx-announce-presentations-at-upcoming-2021-fast-global-summit-gala-rare-20211201monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-first-patient-dosed-in-phase-1-2-clinical-study-of-ux053-an-mrna-ther-rare-20211201monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-40th-annual-jp-morgan-healthcare-conference-rare-20220103monthly0.5https://www.biopharmawatch.com/news/RARE/genetx-and-ultragenyx-provide-preliminary-update-on-phase-1-2-clinical-study-of-gtx-102-in-rare-20220105monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20220202monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-fourth-quarter-and-full-year-2021-financial-results-rare-20220203monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-fourth-quarter-and-full-year-2021-financial-results-and-corporate-updat-rare-20220210monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-first-patient-dosed-in-pivotal-phase-2-3-clinical-study-of-setrusumab-rare-20220420monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-appoints-amrit-ray-m-d-m-b-a-to-board-of-directors-rare-20220422monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-acquires-global-rights-to-aav-gene-therapy-abo-102-for-sanfilippo-syndrome-type-rare-20220517monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-positive-longer-term-durability-data-from-two-phase-1-2-gene-therapy--rare-20220519monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-jefferies-global-healthcare-conference-rare-20220601monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-goldman-sachs-global-healthcare-conference-rare-20220610monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20220720monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-second-quarter-2022-financial-results-and-corporate-rare-20220725monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-second-quarter-2022-financial-results-and-corporate-update-rare-20220728monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20220803monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-participate-at-citi-biopharma-conference-rare-20220901monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-and-mereo-biopharma-to-present-setrusumab-data-update-at-asbmr-rare-20220909monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-third-quarter-2022-financial-results-and-corporate--rare-20221027monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-third-quarter-2022-financial-results-and-corporate-update-rare-20221102monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-upcoming-healthcare-conferences-rare-20221109monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-departure-of-chief-financial-officer-rare-20221110monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20221118monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-piper-sandler-healthcare-conference-rare-20221122monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20221221monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-rare-20230104monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-preliminary-2022-revenue-guidance-for-2023-revenue-and-cash-usage-pipel-rare-20230106monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-fourth-quarter-and-full-year-2022-financial-results-rare-20230209monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-fourth-quarter-and-full-year-2022-financial-results-and-corporate-updat-rare-20230216monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-participate-in-orphan-neuro-panel-at-cowen-healthcare-conference-rare-20230228monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-appoints-dr-eric-crombez-chief-medical-officer-and-executive-vice-president-rare-20230314monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20230321monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-guggenheim-s-genomic-medicines-and-rare-disease-days-rare-20230328monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20230419monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-first-quarter-2023-financial-results-and-corporate--rare-20230427monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-first-quarter-2023-financial-results-and-corporate-update-rare-20230504monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-bank-of-america-s-2023-health-care-conference-rare-20230505monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-upcoming-data-presentations-at-american-society-of-gene-cell-therapy--rare-20230508monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-receives-fda-agreement-to-expand-ongoing-global-phase-1-2-trial-evaluating-gtx--rare-20230517monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-issues-2022-environmental-social-and-governance-esg-report-rare-20230524monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-opens-new-gene-therapy-manufacturing-facility-in-bedford-continuing-its-expansi-rare-20230621monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-initiation-of-dosing-in-second-cohort-of-pivotal-phase-1-2-3-cyprus2--rare-20230731monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-program-and-pipeline-updates-at-analyst-day-including-interim-data-fr-rare-20231016monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-proposed-public-offering-of-common-stock-rare-20231017monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-participate-in-the-jefferies-london-healthcare-conference-rare-20231107monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20231117monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-participate-at-investor-conferences-in-november-rare-20231120monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-rare-20240102monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-completion-of-enrollment-in-global-phase-1-2-trial-of-gtx-102-in-pedi-rare-20240103monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-receives-positive-recommendation-from-nice-in-the-u-k-for-evkeeza-evinacumab-fo-rare-20240104monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-preliminary-2023-revenue-guidance-for-2024-revenue-and-cash-usage-pipel-rare-20240107monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20240119monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-completion-of-dosing-across-stage-1-cohorts-in-pivotal-phase-1-2-3-cy-rare-20240125monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-receives-prime-designation-from-european-medicines-agency-ema-for-gtx-102-for-t-rare-20240205monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-data-demonstrating-treatment-with-ux111-results-in-significant-reduct-rare-20240206monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-fourth-quarter-and-full-year-2023-financial-results-rare-20240208monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-fourth-quarter-and-full-year-2023-financial-results-and-corporate-updat-rare-20240215monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20240223monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-participate-at-investor-conferences-in-march-rare-20240227monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20240322monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-upcoming-data-presentations-at-american-academy-of-neurology-aan-2024-rare-20240412monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-update-to-conference-call-timing-to-discuss-new-data-from-gtx-102-in--rare-20240412monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-positive-interim-phase-1-2-data-in-patients-with-angelman-syndrome-af-rare-20240415monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20240419monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-first-quarter-2024-financial-results-and-corporate--rare-20240425monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-completion-of-enrollment-in-phase-3-orbit-and-cosmic-studies-evaluati-rare-20240430monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-issues-2023-corporate-responsibility-report-showcasing-commitment-to-improving--rare-20240430monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-first-quarter-2024-financial-results-and-corporate-update-rare-20240502monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-participate-at-bank-of-america-s-2024-healthcare-conference-rare-20240507monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20240517monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-positive-top-line-results-from-phase-3-study-of-dtx401-gene-therapy-f-rare-20240530monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-participate-at-goldman-sachs-45th-annual-global-healthcare-conference-rare-20240604monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-and-mereo-biopharma-announce-new-phase-2-data-from-phase-2-3-orbit-study-demons-rare-20240611monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-plans-to-file-for-accelerated-approval-of-ux111-for-the-treatment-of--rare-20240612monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants-rare-20240612monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20240620monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-successful-end-of-phase-2-meeting-with-fda-for-gtx-102-angelman-syndr-rare-20240717monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20240719monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-gtx-102-angelman-syndrome-program-update-at-the-asf-family-conferenc-rare-20240724monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-second-quarter-2024-financial-results-and-corporate-update-rare-20240801monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20240821monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-participate-in-investor-conferences-in-september-rare-20240829monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20240918monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-upcoming-setrusumab-ux143-presentations-at-the-asbmr-2024-annual-meet-rare-20240926monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-provides-update-on-stage-1-cohorts-in-pivotal-phase-1-2-3-cyprus2-study-evaluat-rare-20241003monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-receives-breakthrough-therapy-designation-for-setrusumab-ux143-in-osteogenesis--rare-20241007monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20241018monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-third-quarter-2024-financial-results-and-corporate--rare-20241029monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-third-quarter-2024-financial-results-and-corporate-update-rare-20241105monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-presents-positive-update-on-gtx-102-angelman-syndrome-program-at-fast-s-17th-an-rare-20241109monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20241120monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-participate-in-investor-conferences-in-december-rare-20241126monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-first-patient-dosed-in-pivotal-phase-3-aspire-study-evaluating-gtx-10-rare-20241219monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-submits-biologics-license-application-to-the-u-s-fda-for-ux111-aav-gene-therapy-rare-20241219monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20241220monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-rare-20250106monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-preliminary-2024-revenue-financial-guidance-for-2025-pipeline-updates-a-rare-20250112monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20250117monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-fda-acceptance-and-priority-review-of-the-biologics-license-applicati-rare-20250218monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20250219monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-participate-at-investor-conferences-in-march-rare-20250224monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20250319monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-first-quarter-2025-financial-results-and-corporate-update-rare-20250506monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-underscores-continued-commitment-to-rare-disease-innovation-with-2024-impact-re-rare-20250514monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20250520monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-participate-at-goldman-sachs-46th-annual-global-healthcare-conference-rare-20250603monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-receives-breakthrough-therapy-designation-for-gtx-102-in-angelman-syndrome-rare-20250627monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-receives-complete-response-letter-from-fda-for-ux111-aav-gene-therapy-to-treat--rare-20250711monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20250718monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-host-conference-call-for-second-quarter-2025-financial-results-and-corporate-rare-20250730monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-completes-enrollment-of-phase-3-aspire-study-evaluating-gtx-102-for-the-treatme-rare-20250731monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-second-quarter-2025-financial-results-and-corporate-update-rare-20250805monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-initiates-rolling-submission-of-biologics-license-application-bla-to-u-s-fda-fo-rare-20250818monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20250821monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-to-participate-at-investor-conferences-in-september-rare-20250829monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20251003monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-completes-rolling-submission-of-biologics-license-application-bla-to-u-s-fda-fo-rare-20251230monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-provides-financial-and-business-updates-at-j-p-morgan-annual-healthcare-confere-rare-20260112monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20260123monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-positive-longer-term-data-demonstrating-treatment-with-ux111-gene-the-rare-20260203monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20260320monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-announces-u-s-fda-acceptance-of-bla-resubmission-for-ux111-aav-gene-therapy-to--rare-20260402monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20260424monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20260522monthly0.5https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rare-20260619monthly0.5https://www.biopharmawatch.com/news/IONS/isis-initiates-phase-1-clinical-trial-of-isis-sod1rx-in-patients-with-als-ions-20100305monthly0.5https://www.biopharmawatch.com/news/IONS/isis-earns-6-million-milestone-payment-from-bristol-myers-squibb-for-bms-pcsk9rx-ions-20100308monthly0.5https://www.biopharmawatch.com/news/IONS/isis-improves-financial-guidance-and-reports-financial-results-and-highlights-for-second-q-ions-20100809monthly0.5https://www.biopharmawatch.com/news/IONS/isis-reports-financial-results-and-highlights-for-third-quarter-2010-ions-20101104monthly0.5https://www.biopharmawatch.com/news/IONS/isis-and-xenon-collaborate-to-develop-antisense-drugs-against-hemojuvelin-and-hepcidin-ions-20101116monthly0.5https://www.biopharmawatch.com/news/IONS/isis-pharmaceuticals-adds-two-new-drugs-to-development-pipeline-ions-20110106monthly0.5https://www.biopharmawatch.com/news/IONS/isis-pharmaceuticals-to-discuss-productive-regulatory-discussions-regarding-the-mipomersen-ions-20110110monthly0.5https://www.biopharmawatch.com/news/IONS/isis-initiates-phase-1-clinical-trial-of-isis-fxirx-to-treat-clotting-disorders-ions-20110202monthly0.5https://www.biopharmawatch.com/news/IONS/isis-reports-financial-results-and-highlights-for-2010-ions-20110228monthly0.5https://www.biopharmawatch.com/news/IONS/isis-initiates-phase-1-study-of-isis-ttrrx-and-earns-5-million-milestone-payment-from-glax-ions-20110519monthly0.5https://www.biopharmawatch.com/news/IONS/isis-reports-financial-results-and-highlights-for-second-quarter-2011-ions-20110804monthly0.5https://www.biopharmawatch.com/news/IONS/isis-pharmaceuticals-files-patent-infringement-suit-against-santaris-pharma-ions-20110923monthly0.5https://www.biopharmawatch.com/news/IONS/isis-reports-financial-results-and-highlights-for-third-quarter-2011-ions-20111107monthly0.5https://www.biopharmawatch.com/news/IONS/isis-to-receive-up-to-14-million-from-pfizer-for-its-acquisition-of-excaliard-pharmaceutic-ions-20111122monthly0.5https://www.biopharmawatch.com/news/IONS/isis-reports-positive-phase-1-data-demonstrating-isis-apociiirx-produces-significant-reduc-ions-20111206monthly0.5https://www.biopharmawatch.com/news/IONS/isis-reports-positive-phase-1-data-demonstrating-isis-fxirx-reduces-factor-xi-activity-wit-ions-20111212monthly0.5https://www.biopharmawatch.com/news/IONS/isis-adds-three-new-drugs-to-its-development-pipeline-ions-20111214monthly0.5https://www.biopharmawatch.com/news/IONS/isis-updates-kynamro-submission-timeline-ions-20111215monthly0.5https://www.biopharmawatch.com/news/IONS/isis-initiates-phase-1-clinical-study-of-isis-smnrx-in-patients-with-spinal-muscular-atrop-ions-20111219monthly0.5https://www.biopharmawatch.com/news/IONS/isis-reports-phase-1-data-demonstrating-isis-ttrrx-produces-significant-reductions-in-ttr--ions-20120105monthly0.5https://www.biopharmawatch.com/news/IONS/isis-reports-financial-results-and-highlights-for-2011-ions-20120229monthly0.5https://www.biopharmawatch.com/news/IONS/isis-initiates-phase-1-study-in-patients-with-cancer-with-the-first-generation-2-5-antisen-ions-20120307monthly0.5https://www.biopharmawatch.com/news/IONS/isis-initiates-phase-2-study-of-isis-apociiirx-in-patients-with-hypertriglyceridemia-ions-20120504monthly0.5https://www.biopharmawatch.com/news/IONS/isis-reports-financial-results-and-highlights-for-second-quarter-2012-ions-20120806monthly0.5https://www.biopharmawatch.com/news/IONS/isis-pharmaceuticals-prices-offering-of-201-25-million-of-2-3-4-convertible-senior-notes-i-ions-20120808monthly0.5https://www.biopharmawatch.com/news/IONS/isis-investment-in-regulus-valued-at-28-million-at-completion-of-regulus-initial-public-of-ions-20121011monthly0.5https://www.biopharmawatch.com/news/IONS/isis-reports-financial-results-and-highlights-for-third-quarter-2012-ions-20121106monthly0.5https://www.biopharmawatch.com/news/IONS/isis-pharmaceuticals-reports-positive-phase-1-data-on-three-drugs-in-development-to-treat--ions-20121207monthly0.5https://www.biopharmawatch.com/news/IONS/biogen-idec-and-isis-pharmaceuticals-announce-collaboration-for-antisense-programs-to-trea-ions-20121210monthly0.5https://www.biopharmawatch.com/news/IONS/isis-pharmaceuticals-and-astrazeneca-form-strategic-alliance-on-rna-therapeutics-for-cance-ions-20121211monthly0.5https://www.biopharmawatch.com/news/IONS/isis-announces-that-isis-ttr-rx-was-granted-fast-track-designation-for-the-treatment-of-pa-ions-20121213monthly0.5https://www.biopharmawatch.com/news/IONS/isis-pharmaceuticals-to-provide-update-on-fda-approval-of-kynamro-mipomersen-ions-20130129monthly0.5https://www.biopharmawatch.com/news/IONS/isis-initiates-phase-2-3-study-of-isis-ttr-rx-and-earns-7-5-million-milestone-payment-from-ions-20130219monthly0.5https://www.biopharmawatch.com/news/IONS/isis-reports-financial-results-and-highlights-for-2012-ions-20130228monthly0.5https://www.biopharmawatch.com/news/IONS/isis-reports-financial-results-and-highlights-for-first-quarter-2013-ions-20130507monthly0.5https://www.biopharmawatch.com/news/IONS/isis-pharmaceuticals-prices-public-offering-of-common-stock-ions-20130508monthly0.5https://www.biopharmawatch.com/news/IONS/isis-pharmaceuticals-earns-10-million-milestone-payment-from-astrazeneca-for-isis-ar-rx-to-ions-20130603monthly0.5https://www.biopharmawatch.com/news/IONS/isis-reports-financial-results-and-highlights-for-second-quarter-2013-ions-20130806monthly0.5https://www.biopharmawatch.com/news/IONS/isis-reports-phase-2-data-on-isis-apociii-rx-showing-substantial-reductions-of-triglycerid-ions-20130921monthly0.5https://www.biopharmawatch.com/news/IONS/isis-reports-financial-results-and-highlights-for-third-quarter-2013-ions-20131105monthly0.5https://www.biopharmawatch.com/news/IONS/isis-pharmaceuticals-reports-positive-phase-1-data-demonstrating-isis-apo-a-rx-produces-si-ions-20131116monthly0.5https://www.biopharmawatch.com/news/IONS/isis-pharmaceuticals-to-receive-7-5-million-from-alnylam-ions-20140113monthly0.5https://www.biopharmawatch.com/news/IONS/joseph-loscalzo-m-d-ph-d-joins-isis-pharmaceuticals-board-of-directors-ions-20140203monthly0.5https://www.biopharmawatch.com/news/IONS/isis-announces-positive-opinion-on-european-orphan-drug-designation-for-isis-ttr-rx-ions-20140214monthly0.5https://www.biopharmawatch.com/news/IONS/isis-reports-financial-results-and-highlights-for-2013-ions-20140228monthly0.5https://www.biopharmawatch.com/news/IONS/isis-reports-updated-results-from-isis-smn-rx-clinical-studies-in-infants-and-children-wit-ions-20140429monthly0.5https://www.biopharmawatch.com/news/IONS/isis-pharmaceuticals-licenses-isis-fxi-rx-to-bayer-to-develop-and-commercialize-for-the-pr-ions-20140504monthly0.5https://www.biopharmawatch.com/news/IONS/isis-pharmaceuticals-reports-final-phase-2-data-on-isis-gcgr-rx-showing-significant-reduct-ions-20140616monthly0.5https://www.biopharmawatch.com/news/IONS/isis-pharmaceuticals-initiates-phase-3-study-of-isis-smn-rx-in-infants-with-spinal-muscula-ions-20140801monthly0.5https://www.biopharmawatch.com/news/IONS/isis-reports-financial-results-and-highlights-for-second-quarter-2014-ions-20140804monthly0.5https://www.biopharmawatch.com/news/IONS/isis-pharmaceuticals-initiates-phase-3-study-of-isis-apociii-rx-in-patients-with-fcs-ions-20140828monthly0.5https://www.biopharmawatch.com/news/IONS/isis-pharmaceuticals-reports-financial-results-and-highlights-for-third-quarter-2014-ions-20141107monthly0.5https://www.biopharmawatch.com/news/IONS/isis-pharmaceuticals-prices-offering-of-425-million-of-1-00-convertible-senior-notes-ions-20141112monthly0.5https://www.biopharmawatch.com/news/IONS/astrazeneca-and-isis-pharmaceuticals-to-co-develop-targeted-oligonucleotide-delivery-metho-ions-20141113monthly0.5https://www.biopharmawatch.com/news/IONS/isis-pharmaceuticals-initiates-phase-3-study-of-isis-smn-rx-in-children-with-spinal-muscul-ions-20141125monthly0.5https://www.biopharmawatch.com/news/IONS/isis-apociii-rx-phase-2-study-in-patients-with-familial-chylomicronemia-published-in-the-n-ions-20141203monthly0.5https://www.biopharmawatch.com/news/IONS/isis-pharmaceuticals-announces-collaboration-with-janssen-to-discover-and-develop-rna-targ-ions-20150105monthly0.5https://www.biopharmawatch.com/news/IONS/isis-pharmaceuticals-appoints-paula-soteropoulos-as-president-and-chief-executive-officer--ions-20150106monthly0.5https://www.biopharmawatch.com/news/IONS/isis-pharmaceuticals-reports-positive-phase-1-data-demonstrating-isis-pkk-rx-produces-sign-ions-20150224monthly0.5https://www.biopharmawatch.com/news/IONS/isis-reports-financial-results-and-highlights-for-2014-ions-20150227monthly0.5https://www.biopharmawatch.com/news/IONS/isis-pharmaceuticals-reports-positive-phase-1-data-on-isis-angptl3-rx-ions-20150323monthly0.5https://www.biopharmawatch.com/news/IONS/isis-pharmaceuticals-reports-positive-data-from-isis-ttr-rx-in-patients-with-ttr-amyloidos-ions-20150422monthly0.5https://www.biopharmawatch.com/news/IONS/isis-reports-financial-results-and-highlights-for-first-quarter-2015-ions-20150505monthly0.5https://www.biopharmawatch.com/news/IONS/isis-pharmaceuticals-reports-data-from-isis-smn-rx-phase-2-study-in-infants-with-spinal-mu-ions-20150611monthly0.5https://www.biopharmawatch.com/news/IONS/isis-pharmaceuticals-promoted-to-the-large-cap-russell-1000-index-ions-20150629monthly0.5https://www.biopharmawatch.com/news/IONS/akcea-therapeutics-receives-orphan-drug-designation-from-the-us-fda-for-volanesorsen-isis--ions-20150706monthly0.5https://www.biopharmawatch.com/news/IONS/isis-pharmaceuticals-initiates-clinical-study-of-isis-htt-rx-in-patients-with-huntington-s-ions-20150721monthly0.5https://www.biopharmawatch.com/news/IONS/positive-clinical-data-from-lp-a-lowering-drug-isis-apo-a-rx-published-in-the-lancet-ions-20150722monthly0.5https://www.biopharmawatch.com/news/IONS/positive-clinical-data-from-volanesorsen-published-in-the-new-england-journal-of-medicine-ions-20150729monthly0.5https://www.biopharmawatch.com/news/IONS/isis-pharmaceuticals-collaboration-to-discover-and-develop-antisense-drugs-for-cardiovascu-ions-20150911monthly0.5https://www.biopharmawatch.com/news/IONS/isis-pharmaceuticals-initiates-shine-study-to-provide-isis-smn-rx-for-patients-with-sma-wh-ions-20151015monthly0.5https://www.biopharmawatch.com/news/IONS/isis-reports-financial-results-and-highlights-for-third-quarter-2015-ions-20151109monthly0.5https://www.biopharmawatch.com/news/IONS/isis-pharmaceuticals-announces-initiation-of-phase-1-2-clinical-study-of-isis-sod1-rx-in-p-ions-20151211monthly0.5https://www.biopharmawatch.com/news/IONS/isis-pharmaceuticals-changes-name-to-ionis-pharmaceuticals-ions-20151218monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-pharmaceuticals-earns-5-million-milestone-payment-from-biogen-for-advancing-a-new-pr-ions-20151222monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-pharmaceuticals-receives-orphan-drug-designation-from-the-us-fda-for-ionis-htt-rx-fo-ions-20160105monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-pharmaceuticals-completes-target-enrollment-for-nusinersen-phase-3-study-cherish-in--ions-20160112monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-2015-financial-results-outperform-projections-ions-20160225monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-pharmaceuticals-reports-data-update-from-nusinersen-phase-2-study-in-infants-with-sp-ions-20160420monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-pharmaceuticals-and-kastle-therapeutics-announce-acquisition-of-kynamro-ions-20160503monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-pharmaceuticals-and-md-anderson-form-strategic-alliance-to-advance-novel-cancer-ther-ions-20160523monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-pharmaceuticals-provides-update-on-ionis-ttr-rx-program-ions-20160526monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-pharmaceuticals-reports-positive-clinical-data-on-ionis-ttr-rx-at-the-xv-internation-ions-20160707monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-pharmaceuticals-announces-publication-in-nature-biotechnology-of-a-novel-mechanism-o-ions-20160712monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-pharmaceuticals-licenses-first-oral-antisense-drug-acting-locally-in-the-gi-tract-to-ions-20160719monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-pharmaceuticals-reports-financial-results-and-highlights-for-second-quarter-2016-ions-20160809monthly0.5https://www.biopharmawatch.com/news/IONS/akcea-announces-publication-in-the-lancet-of-clinical-results-with-lp-a-lowering-drugs-des-ions-20160922monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-pharmaceuticals-reports-financial-results-and-highlights-for-third-quarter-2016-ions-20161109monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-pharmaceuticals-reports-positive-clinical-data-from-ionis-angptl3-l-rx-ions-20161115monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-earns-28-million-from-astrazeneca-for-a-new-drug-to-treat-cancer-ions-20161216monthly0.5https://www.biopharmawatch.com/news/IONS/spinraza-nusinersen-approved-in-u-s-to-treat-broad-range-of-patients-with-spinal-muscular--ions-20161223monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-pharmaceuticals-reports-positive-data-from-phase-2-study-of-ionis-gcgr-rx-in-patient-ions-20170104monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-and-akcea-enter-into-strategic-collaboration-with-global-pharmaceutical-company-to-d-ions-20170106monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-earns-75-million-from-bayer-for-advancing-ionis-fxi-rx-and-ionis-fxi-l-rx-ions-20170214monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-2016-financial-results-outperform-financial-guidance-ions-20170228monthly0.5https://www.biopharmawatch.com/news/IONS/akcea-and-ionis-announce-positive-results-from-pivotal-study-of-volanesorsen-in-patients-w-ions-20170306monthly0.5https://www.biopharmawatch.com/news/IONS/akcea-therapeutics-files-registration-statement-for-proposed-initial-public-offering-ions-20170327monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-pharmaceuticals-announces-phase-3-neuro-ttr-study-of-inotersen-ionis-ttr-rx-meets-bo-ions-20170515monthly0.5https://www.biopharmawatch.com/news/IONS/spinraza-nusinersen-approved-in-the-european-union-ions-20170601monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-to-independently-advance-inotersen-and-ionis-fb-l-rx-ions-20170811monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-earns-40-million-spinraza-regulatory-milestone-payment-from-biogen-ions-20170830monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-pharmaceuticals-initiates-clinical-study-of-ionis-mapt-rx-in-patients-with-alzheimer-ions-20171013monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-submission-of-new-drug-application-nda-for-inotersen-to-the-u-s-fda-ions-20171106monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-management-transitions-ions-20171107monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-pharmaceuticals-licenses-second-orally-delivered-antisense-drug-to-janssen-ions-20171116monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-pharmaceuticals-licenses-ionis-htt-rx-to-partner-following-successful-phase-1-2a-stu-ions-20171211monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-inotersen-nda-accepted-for-priority-review-by-the-fda-ions-20180108monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-licences-new-antisense-drug-for-kidney-disease-to-astrazeneca-ions-20180220monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-reports-fourth-quarter-and-full-year-2017-financial-results-ions-20180227monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-htt-rx-rg6042-top-line-data-demonstrate-significant-reductions-of-disease-causing-mu-ions-20180301monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-closes-strategic-collaboration-with-biogen-to-develop-drugs-for-a-broad-range-of-neu-ions-20180605monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-pharmaceuticals-appoints-damien-mcdevitt-as-chief-business-officer-ions-20180618monthly0.5https://www.biopharmawatch.com/news/IONS/new-england-journal-of-medicine-publishes-results-from-pivotal-study-of-tegsedi-inotersen--ions-20180705monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-htt-rx-rg6042-granted-prime-designation-by-the-european-medicines-agency-for-the-tre-ions-20180802monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-the-appointment-of-two-new-board-members-ions-20180924monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-enters-new-collaboration-with-partner-to-develop-ionis-fb-l-rx-for-complement-mediat-ions-20181010monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-reports-third-quarter-2018-financial-results-ions-20181106monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-plans-for-management-transitions-in-2020-ions-20181220monthly0.5https://www.biopharmawatch.com/news/IONS/first-patient-enrolled-in-pivotal-study-of-rg6042-ionis-htt-rx-for-people-with-huntington--ions-20190128monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-exceeds-2018-financial-guidance-ions-20190227monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-appointment-of-brett-p-monia-ph-d-to-its-board-of-directors-ions-20190325monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-launches-new-corporate-brand-that-reflects-company-s-industry-leading-innovation-and-ions-20190506monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-appointment-of-joan-e-herman-to-its-board-of-directors-ions-20190612monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-reports-second-quarter-2019-financial-results-ions-20190807monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-licenses-hepatitis-b-program-to-gsk-ions-20190827monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-factor-xi-anti-thrombotic-medicine-advances-with-bayer-following-positive-clinical-r-ions-20191009monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-provides-third-quarter-financial-results-and-improved-2019-guidance-ions-20191106monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-pharmaceuticals-announces-private-placement-of-507-5-million-principal-amount-of-0-1-ions-20191212monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-appoints-c-frank-bennett-ph-d-to-chief-scientific-officer-and-promotes-eric-e-swayze-ions-20191218monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-licenses-investigational-alzheimer-s-therapy-ions-20191219monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-appoints-onaiza-cadoret-manier-as-chief-corporate-development-and-commercial-officer-ions-20200109monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-treatment-for-alexander-disease-granted-orphan-drug-status-from-ema-ions-20200211monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-and-partner-announce-enrollment-completion-of-global-phase-3-generation-hd1-study-fo-ions-20200420monthly0.5https://www.biopharmawatch.com/news/IONS/new-england-journal-of-medicine-publishes-study-results-evaluating-ionis-antisense-therapy-ions-20200902monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-treatment-for-alexander-disease-receives-orphan-drug-designation-from-u-s-fda-ions-20200930monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-reports-third-quarter-2020-financial-results-and-recent-business-achievements-ions-20201104monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-astrazeneca-s-initiation-of-the-phase-2b-clinical-study-of-its-antisense-m-ions-20201130monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-initiation-of-the-global-phase-3-balance-study-for-akcea-apociii-lrx-in-pa-ions-20201201monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-appoints-eugene-schneider-m-d-as-executive-vice-president-and-chief-clinical-develop-ions-20210107monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-reports-positive-topline-phase-2-study-results-of-its-novel-antisense-treatment-for--ions-20210329monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-initiates-phase-3-trial-of-novel-antisense-medicine-to-treat-leading-cause-of-juveni-ions-20210405monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-prices-private-placement-of-convertible-senior-notes-ions-20210408monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-completes-enrollment-in-pivotal-neuro-ttransform-study-of-eplontersen-ions-20210729monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-initiates-pivotal-phase-3-clinical-study-of-olezarsen-in-patients-with-severe-hypert-ions-20211102monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-initiates-phase-3-clinical-program-of-donidalorsen-in-patients-with-hereditary-angio-ions-20211118monthly0.5https://www.biopharmawatch.com/news/IONS/biogen-exercises-option-with-ionis-to-develop-and-commercialize-investigational-aso-for-sm-ions-20220104monthly0.5https://www.biopharmawatch.com/news/IONS/pfizer-and-ionis-announce-discontinuation-of-vupanorsen-clinical-development-program-ions-20220131monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-publication-of-positive-phase-2-data-for-donidalorsen-in-new-england-journ-ions-20220316monthly0.5https://www.biopharmawatch.com/news/IONS/biogen-and-ionis-announce-topline-phase-1-study-results-of-investigational-drug-in-c9orf72-ions-20220328monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-partner-biogen-announces-that-results-from-phase-3-valor-study-and-open-label-extens-ions-20220603monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-that-fda-accepts-new-drug-application-and-grants-priority-review-of-tofers-ions-20220726monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-provides-update-on-development-program-evaluating-pcsk9-antisense-medicine-for-the-t-ions-20220923monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-plan-for-new-manufacturing-facility-in-oceanside-calif-ions-20221012monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-positive-data-from-gsk-s-phase-2b-clinical-study-of-bepirovirsen-ions-20221108monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-reports-third-quarter-financial-results-ions-20221109monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-partners-with-metagenomi-to-add-gene-editing-to-its-broad-technology-platform-ions-20221114monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-european-medicines-agency-accepts-marketing-authorization-application-of-t-ions-20221205monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-and-royalty-pharma-enter-into-royalty-agreement-for-up-to-1-1-billion-to-further-adv-ions-20230109monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-receives-fda-fast-track-designation-for-olezarsen-in-patients-with-familial-chylomic-ions-20230131monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-gsk-has-advanced-bepirovirsen-into-phase-3-development-ions-20230201monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-fda-advisory-committee-voted-unanimously-for-a-potential-accelerated-appro-ions-20230322monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-positive-donidalorsen-late-stage-clinical-progress-in-hae-ions-20230601monthly0.5https://www.biopharmawatch.com/news/IONS/eplontersen-phase-3-results-published-in-jama-show-consistent-and-sustained-benefit-ions-20230928monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-poised-for-continued-momentum-in-2024-with-product-launches-and-key-advances-in-robu-ions-20240108monthly0.5https://www.biopharmawatch.com/news/IONS/eplontersen-granted-u-s-fda-fast-track-designation-for-patients-with-transthyretin-mediate-ions-20240208monthly0.5https://www.biopharmawatch.com/news/IONS/olezarsen-receives-orphan-drug-designation-from-u-s-fda-for-familial-chylomicronemia-syndr-ions-20240215monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-new-chief-global-product-strategy-officer-to-lead-next-phase-of-commercial-ions-20240229monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-positive-results-from-phase-2-study-of-ion224-an-investigational-medicine--ions-20240313monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-positive-topline-results-from-phase-1-2a-trial-of-ion582-for-angelman-synd-ions-20240516monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-and-biogen-announce-topline-phase-1-2-study-results-of-investigational-drug-in-amyot-ions-20240516monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-olezarsen-fcs-new-drug-application-accepted-for-priority-review-and-enroll-ions-20240625monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-positive-detailed-results-from-the-halos-study-of-ion582-in-people-with-an-ions-20240722monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-pricing-of-500-3-million-public-offering-ions-20240909monthly0.5https://www.biopharmawatch.com/news/IONS/zilganersen-granted-u-s-fda-fast-track-designation-for-people-living-with-alexander-diseas-ions-20241001monthly0.5https://www.biopharmawatch.com/news/IONS/wainzua-eplontersen-recommended-for-approval-in-the-eu-by-chmp-for-the-treatment-of-adults-ions-20241021monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-fda-acceptance-of-new-drug-application-for-donidalorsen-for-prophylactic-t-ions-20241104monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-announces-pivotal-phase-3-trial-design-for-ion582-in-angelman-syndrome-ions-20241106monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-enters-new-chapter-in-2025-as-commercial-stage-biotech-with-multiple-independent-pro-ions-20250113monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-and-ono-pharmaceutical-announce-global-license-agreement-for-sapablursen-for-polycyt-ions-20250311monthly0.5https://www.biopharmawatch.com/news/IONS/ionis-to-present-new-analyses-from-core-and-core2-pivotal-studies-supporting-olezarsen-for-ions-20260604monthly0.5https://www.biopharmawatch.com/news/BBIO/pellepharm-launches-with-financing-from-bridgebio-pharma-to-develop-topical-therapy-for-ba-bbio-20161208monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-launches-with-a-focus-on-precision-medicines-for-genetic-diseases-bbio-20170103monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-launches-eidos-therapeutics-to-develop-targeted-therapy-for-fatal-heart-d-bbio-20170427monthly0.5https://www.biopharmawatch.com/news/BBIO/pellepharm-announces-topline-results-from-phase-2-study-of-topical-patidegib-in-gorlin-syn-bbio-20170731monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-expands-investor-base-raising-an-additional-135-million-and-discloses-gen-bbio-20170913monthly0.5https://www.biopharmawatch.com/news/BBIO/eidos-therapeutics-initiates-first-clinical-study-for-ag10-targeting-transthyretin-amyloid-bbio-20170928monthly0.5https://www.biopharmawatch.com/news/BBIO/md-anderson-and-bridgebio-pharma-launch-navire-pharma-to-develop-targeted-therapy-for-pati-bbio-20171004monthly0.5https://www.biopharmawatch.com/news/BBIO/eidos-therapeutics-to-present-data-on-its-potential-treatment-for-transthyretin-amyloidosi-bbio-20171109monthly0.5https://www.biopharmawatch.com/news/BBIO/preclinical-data-demonstrates-potential-of-eidos-therapeutics-lead-compound-for-the-treatm-bbio-20171115monthly0.5https://www.biopharmawatch.com/news/BBIO/fda-grants-breakthrough-therapy-designation-and-orphan-drug-designation-to-pellepharm-for--bbio-20171120monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-appoints-sanuj-ravindran-m-d-and-eric-michael-david-m-d-as-ceos-in-reside-bbio-20180104monthly0.5https://www.biopharmawatch.com/news/BBIO/pellepharm-appoints-sanuj-k-ravindran-m-d-as-president-and-chief-executive-officer-bbio-20180104monthly0.5https://www.biopharmawatch.com/news/BBIO/eidos-therapeutics-to-present-at-36th-annual-j-p-morgan-healthcare-conference-bbio-20180105monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-licenses-late-stage-oncology-drug-infigratinib-to-tackle-fgfr-driven-mala-bbio-20180130monthly0.5https://www.biopharmawatch.com/news/BBIO/eidos-therapeutics-to-host-symposium-on-ttr-stabilization-at-the-16th-international-sympos-bbio-20180320monthly0.5https://www.biopharmawatch.com/news/BBIO/eidos-therapeutics-completes-64m-series-b-financing-bbio-20180405monthly0.5https://www.biopharmawatch.com/news/BBIO/eidos-therapeutics-initiates-phase-2-clinical-trial-for-ag10-targeting-transthyretin-amylo-bbio-20180503monthly0.5https://www.biopharmawatch.com/news/BBIO/pellepharm-to-present-topical-patidegib-and-skin-cancer-epidemiological-data-at-the-7th-in-bbio-20180516monthly0.5https://www.biopharmawatch.com/news/BBIO/pellepharm-to-present-at-the-2018-ubs-global-healthcare-conference-bbio-20180521monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-enters-into-agreement-to-acquire-late-stage-therapy-for-ultra-rare-disord-bbio-20180611monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-launches-coa-therapeutics-to-target-coenzyme-a-for-rare-genetic-disorders-bbio-20180613monthly0.5https://www.biopharmawatch.com/news/BBIO/pellepharm-to-participate-in-the-cantor-fitzgerald-dermatology-and-aesthetics-summit-bbio-20180613monthly0.5https://www.biopharmawatch.com/news/BBIO/neurovive-out-licenses-targeted-lhon-therapy-to-bridgebio-pharma-s-new-subsidiary-fortify--bbio-20180618monthly0.5https://www.biopharmawatch.com/news/BBIO/eidos-therapeutics-announces-pricing-of-initial-public-offering-bbio-20180620monthly0.5https://www.biopharmawatch.com/news/BBIO/eidos-therapeutics-announces-closing-of-initial-public-offering-and-exercise-in-full-of-th-bbio-20180622monthly0.5https://www.biopharmawatch.com/news/BBIO/eidos-therapeutics-reports-second-quarter-2018-financial-results-and-provides-corporate-up-bbio-20180807monthly0.5https://www.biopharmawatch.com/news/BBIO/qed-tx-a-new-company-working-on-a-treatment-for-achondroplasia-bbio-20180815monthly0.5https://www.biopharmawatch.com/news/BBIO/eidos-therapeutics-announces-publication-of-ag10-molecular-design-in-journal-of-medicinal--bbio-20180823monthly0.5https://www.biopharmawatch.com/news/BBIO/eidos-therapeutics-presents-data-from-its-phase-1-clinical-trial-of-ag10-at-the-22nd-annua-bbio-20180917monthly0.5https://www.biopharmawatch.com/news/BBIO/eidos-therapeutics-to-present-at-the-leerink-partners-roundtable-series-rare-disease-oncol-bbio-20180925monthly0.5https://www.biopharmawatch.com/news/BBIO/pellepharm-to-present-at-cantor-fitzgerald-global-healthcare-conference-bbio-20180925monthly0.5https://www.biopharmawatch.com/news/BBIO/fda-grants-orphan-drug-designation-to-eidos-therapeutics-product-candidate-ag10-for-treatm-bbio-20181003monthly0.5https://www.biopharmawatch.com/news/BBIO/eidos-therapeutics-to-present-phase-2-data-for-ag10-in-ttr-amyloidosis-cardiomyopathy-at-t-bbio-20181005monthly0.5https://www.biopharmawatch.com/news/BBIO/pellepharm-presents-updated-data-from-two-phase-2-studies-demonstrating-the-potential-of-p-bbio-20181015monthly0.5https://www.biopharmawatch.com/news/BBIO/qed-therapeutics-presents-data-for-infigratinib-in-cholangiocarcinoma-in-late-breaking-abs-bbio-20181019monthly0.5https://www.biopharmawatch.com/news/BBIO/data-published-in-nature-communications-demonstrates-coa-therapeutics-potential-to-treat-g-bbio-20181023monthly0.5https://www.biopharmawatch.com/news/BBIO/eidos-therapeutics-receives-positive-opinion-for-orphan-designation-from-the-european-medi-bbio-20181026monthly0.5https://www.biopharmawatch.com/news/BBIO/eidos-therapeutics-to-host-conference-call-and-webcast-to-discuss-phase-2-clinical-trial-r-bbio-20181029monthly0.5https://www.biopharmawatch.com/news/BBIO/eidos-therapeutics-reports-third-quarter-2018-financial-results-and-provides-corporate-upd-bbio-20181106monthly0.5https://www.biopharmawatch.com/news/BBIO/eidos-therapeutics-announces-positive-phase-2-data-for-ag10-in-symptomatic-patients-with-m-bbio-20181110monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-llc-signs-joint-collaboration-agreement-with-cincinnati-children-s-to-acc-bbio-20181112monthly0.5https://www.biopharmawatch.com/news/BBIO/eidos-therapeutics-to-present-at-two-upcoming-investor-conferences-bbio-20181114monthly0.5https://www.biopharmawatch.com/news/BBIO/leo-pharma-and-pellepharm-announce-760-million-collaboration-to-advance-innovative-therapi-bbio-20181120monthly0.5https://www.biopharmawatch.com/news/BBIO/pellepharm-to-present-at-piper-jaffray-healthcare-conference-bbio-20181121monthly0.5https://www.biopharmawatch.com/news/BBIO/eidos-therapeutics-appoints-william-lis-to-board-of-directors-bbio-20181206monthly0.5https://www.biopharmawatch.com/news/BBIO/qed-therapeutics-announces-a-collaboration-with-foundation-medicine-to-develop-companion-d-bbio-20181210monthly0.5https://www.biopharmawatch.com/news/BBIO/eidos-therapeutics-to-present-at-37th-annual-j-p-morgan-healthcare-conference-bbio-20190102monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-closes-299-2-million-financing-round-to-support-its-efforts-to-target-gen-bbio-20190123monthly0.5https://www.biopharmawatch.com/news/BBIO/phoenix-tissue-repair-doses-first-patient-in-phase-1-2-clinical-trial-of-ptr-01-bbp-589-fo-bbio-20190222monthly0.5https://www.biopharmawatch.com/news/BBIO/eidos-therapeutics-initiates-attribute-cm-a-phase-3-study-of-ag10-in-attr-cm-with-registra-bbio-20190227monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-announces-filing-of-registration-statement-for-proposed-initial-public-of-bbio-20190524monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-announces-pricing-of-its-initial-public-offering-bbio-20190626monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-expands-its-research-into-neuromuscular-disease-to-include-limb-girdle-mu-bbio-20190905monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-s-origin-biosciences-presents-new-data-on-the-natural-history-of-molybden-bbio-20190905monthly0.5https://www.biopharmawatch.com/news/BBIO/alexion-and-bridgebio-announce-japanese-license-agreement-for-eidos-transthyretin-amyloido-bbio-20190909monthly0.5https://www.biopharmawatch.com/news/BBIO/ivy-brain-tumor-center-and-bridgebio-subsidiary-qed-therapeutics-announce-collaboration-to-bbio-20190924monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-terminates-merger-process-with-its-subsidiary-eidos-therapeutics-bbio-20191014monthly0.5https://www.biopharmawatch.com/news/BBIO/qed-and-parent-company-bridgebio-announce-preclinical-data-supporting-tolerability-and-act-bbio-20191017monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-gene-therapy-subsidiaries-present-data-demonstrating-potential-in-two-rar-bbio-20191022monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-third-quarter-2019-financial-results-and-highlights-portfolio-pro-bbio-20191107monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20191127monthly0.5https://www.biopharmawatch.com/news/BBIO/pellepharm-completes-enrollment-of-pivotal-phase-3-clinical-trial-of-patidegib-topical-gel-bbio-20191202monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-s-origin-biosciences-initiates-rolling-submission-of-new-drug-application-bbio-20191203monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20191205monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-appoints-eli-wallace-as-chief-scientific-officer-in-residence-for-onc-bbio-20191209monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-s-origin-biosciences-enters-partnership-with-medison-to-commercialize-bbp-bbio-20191218monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-to-present-at-upcoming-investor-conference-bbio-20191219monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-s-qed-therapeutics-receives-fast-track-designation-for-infigratinib-in-ad-bbio-20200106monthly0.5https://www.biopharmawatch.com/news/BBIO/pellepharm-initiates-phase-2-clinical-trial-of-patidegib-topical-gel-for-people-with-high--bbio-20200108monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-s-gene-therapy-subsidiaries-enter-strategic-partnership-with-catalent-for-bbio-20200110monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-grows-pipeline-to-20-genetic-medicines-with-four-assets-focused-on-treati-bbio-20200113monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20200205monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-and-eidos-therapeutics-to-present-at-upcoming-investor-conferences-bbio-20200221monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-appoints-ronald-j-daniels-to-its-board-of-directors-bbio-20200224monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20200303monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-prices-upsized-offering-of-475-million-convertible-senior-notes-bbio-20200304monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-s-qed-therapeutics-announces-dosing-of-first-patients-in-phase-3-and-phas-bbio-20200312monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20200403monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20200505monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-to-present-at-upcoming-investor-conference-bbio-20200506monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-s-qed-therapeutics-announces-preclinical-data-demonstrating-potential-of--bbio-20200511monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-and-eidos-therapeutics-announce-definitive-merger-agreement-bbio-20200615monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-s-origin-biosciences-announces-fda-approval-of-nulibry-fosdenopterin-for--bbio-20200713monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-reports-second-quarter-2020-financial-results-and-business-update-bbio-20200806monthly0.5https://www.biopharmawatch.com/news/BBIO/ucsf-and-bridgebio-pharma-collaborate-to-accelerate-the-development-of-therapies-for-genet-bbio-20201223monthly0.5https://www.biopharmawatch.com/news/BBIO/leading-independent-proxy-advisory-firm-iss-recommends-bridgebio-pharma-and-eidos-therapeu-bbio-20210104monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20210106monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-and-eidos-therapeutics-inc-announce-january-21-2021-election-deadline-bbio-20210113monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-prices-upsized-offering-of-650-million-convertible-senior-notes-bbio-20210125monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20210208monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-fourth-quarter-and-full-year-2020-financial-results-and-business--bbio-20210225monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-s-origin-biosciences-announces-fda-approval-of-nulibry-fosdenopterin-for--bbio-20210309monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20210330monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-s-qed-therapeutics-and-helsinn-group-announce-fda-approval-of-truseltiq-i-bbio-20210409monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20210504monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-reports-first-quarter-2021-financial-results-and-business-update-bbio-20210511monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-and-lianbio-announce-strategic-collaboration-to-develop-and-commercialize-bbio-20210513monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-announces-topline-results-from-phase-3-attribute-cm-study-bbio-20210712monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20210805monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-reports-second-quarter-2021-financial-results-and-business-update-bbio-20210810monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20210930monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-reports-third-quarter-2021-financial-results-and-business-update-bbio-20211109monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-announces-clinical-collaboration-with-amgen-to-study-bbp-398-a-potentially-best--bbio-20220113monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-announces-dosing-of-first-patient-in-phase-1-2-trial-of-investigational-g-bbio-20220127monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-and-sentynl-therapeutics-announce-asset-purchase-agreement-for-bridgebio--bbio-20220308monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-to-host-investor-call-to-discuss-phase-2-data-for-limb-girdle-muscula-bbio-20220311monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-announces-positive-phase-2-data-for-limb-girdle-muscular-dystrophy-type-2-bbio-20220314monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20220330monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-inc-reports-first-quarter-2022-financial-results-and-business-update-bbio-20220510monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-to-present-at-the-j-p-morgan-healthcare-conference-bbio-20230104monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-to-participate-in-february-and-march-investor-events-bbio-20230208monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-to-host-educational-roundtable-with-esteemed-achondroplasia-expert-bbio-20230213monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20230217monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-to-host-investor-call-to-discuss-phase-2-cohort-5-data-for-achondroplasia-bbio-20230303monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-announces-positive-phase-2-data-for-infigratinib-in-children-with-achondr-bbio-20230306monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-announces-positive-topline-results-from-phase-3-attribute-cm-study-bbio-20230717monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-announces-acoramidis-phase-3-attribute-cm-data-presented-at-aha-and-publi-bbio-20231113monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-to-participate-in-the-j-p-morgan-healthcare-conference-bbio-20240103monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-announces-fda-clearance-of-ind-application-for-bbo-8520-a-first-in-class-direct--bbio-20240103monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-announces-publication-of-positive-results-from-phase-3-attribute-cm-study-bbio-20240110monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20240110monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-secures-up-to-1-25-billion-of-capital-from-blue-owl-and-cpp-investments-t-bbio-20240118monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-shares-positive-results-of-single-arm-phase-3-study-of-acoramidis-in-japa-bbio-20240202monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-fourth-quarter-and-full-year-2023-financial-results-and-business--bbio-20240226monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-announces-u-s-fda-acceptance-of-new-drug-application-for-acoramidis-for-t-bbio-20240321monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-first-quarter-2024-financial-results-and-business-update-bbio-20240508monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-announces-positive-data-from-phase-1-2-study-of-encaleret-in-autosomal-do-bbio-20240603monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-third-quarter-2024-financial-results-and-business-update-bbio-20241104monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-to-participate-in-the-j-p-morgan-healthcare-conference-bbio-20250108monthly0.5https://www.biopharmawatch.com/news/BBIO/beyonttra-acoramidis-the-first-near-complete-ttr-stabilizer-90-approved-by-the-european-co-bbio-20250211monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-to-report-fourth-quarter-and-full-year-2024-financial-results-and-busines-bbio-20250213monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-fourth-quarter-and-full-year-2024-financial-results-and-commercia-bbio-20250220monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-first-quarter-2025-financial-results-and-business-update-bbio-20250506monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-second-quarter-2025-financial-results-and-business-update-bbio-20250804monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-third-quarter-2025-financial-results-and-business-update-bbio-20251103monthly0.5https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bbio-20251222monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-raises-over-5-million-to-complete-multiple-late-phase-2-clinical-trials-ird-20190722monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-announces-completion-of-the-first-of-two-phase-2b-clinical-trials-for-nyxo-ird-20190904monthly0.5https://www.biopharmawatch.com/news/IRD/rexahn-to-explore-strategic-alternatives-ird-20190924monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-announces-results-from-two-phase-2-clinical-studies-of-nyxol-eye-drops-ird-20191107monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-announces-in-license-of-phase-2-oral-small-molecule-drug-candidate-for-dia-ird-20200122monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-to-participate-in-upcoming-virtual-healthcare-investor-conferences-in-september-ird-20200909monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-to-host-key-opinion-leader-event-on-nyxol-and-apx3330-ird-20201103monthly0.5https://www.biopharmawatch.com/news/IRD/rexahn-pharmaceuticals-announces-expected-effectiveness-of-reverse-stock-split-and-merger--ird-20201105monthly0.5https://www.biopharmawatch.com/news/IRD/industry-veteran-susan-benton-joins-the-ocuphire-pharma-board-of-directors-ird-20201106monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-to-participate-in-upcoming-virtual-hcw-conference-in-november-ird-20201110monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-announces-two-publications-supporting-the-apx3330-program-ird-20201112monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-announces-expansion-of-global-patents-for-nyxol-and-1-7-million-nih-grants-ird-20201116monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-announces-first-patient-enrolled-in-mira-2-phase-3-clinical-trial-investig-ird-20201119monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-to-be-featured-in-cantor-fitzgerald-fireside-chat-with-equity-research-analyst-kr-ird-20201208monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-to-present-at-the-lifesci-partners-10th-annual-healthcare-corporate-access-event--ird-20201230monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-initiates-lynx-1-phase-3-study-investigating-nyxol-in-night-vision-disturb-ird-20210105monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-completes-enrollment-in-mira-2-phase-3-clinical-trial-investigating-nyxol-for-rev-ird-20210106monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-announces-publication-of-orion-1-phase-2-results-for-nyxol-in-clinical-ophthalmol-ird-20210120monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-to-participate-in-the-2021-bio-ceo-investor-conference-and-cantor-fitzgerald-s-pa-ird-20210211monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-initiates-enrollment-in-vega-1-phase-2-trial-investigating-nyxol-in-presbyopia-ird-20210218monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-to-participate-in-march-investor-conferences-ird-20210304monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-announces-publication-of-mira-1-phase-2b-results-in-optometry-and-visual-science--ird-20210305monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-announces-mira-2-phase-3-registration-trial-for-the-reversal-of-mydriasis-meets-p-ird-20210315monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ird-20210401monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-initiates-zeta-1-phase-2-clinical-trial-investigating-apx3330-in-diabetic-retinop-ird-20210408monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-s-apx3330-for-retinal-diseases-to-be-presented-at-the-2021-association-for-resear-ird-20210422monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-completes-enrollment-in-vega-1-phase-2-clinical-trial-investigating-nyxol-in-comb-ird-20210512monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-granted-two-new-u-s-patents-covering-late-stage-drug-candidate-nyxol-including-fo-ird-20210518monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-to-host-key-opinion-leader-event-on-nyxol-as-a-potential-new-treatment-option-for-ird-20210520monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-announces-appointment-of-jay-s-pepose-m-d-ph-d-to-its-board-of-directors-ird-20210608monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-announces-addition-to-the-russell-microcap-index-ird-20210611monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-s-vega-1-phase-2-trial-in-presbyopia-meets-primary-and-secondary-endpoints-ird-20210630monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ird-20210709monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-selected-to-present-at-multiple-ophthalmic-conferences-in-july-ird-20210713monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-announces-publication-in-the-journal-of-cellular-signaling-featuring-its-oral-ref-ird-20210722monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-presenting-at-two-conferences-in-august-ird-20210806monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-presenting-at-four-conferences-in-september-ird-20210902monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ird-20210903monthly0.5https://www.biopharmawatch.com/news/IRD/rd-fund-launches-opus-genetics-with-19m-seed-funding-to-advance-gene-therapy-treatments-fo-ird-20210922monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-presenting-at-three-upcoming-healthcare-conferences-this-fall-ird-20210927monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-s-clinical-phase-2b-oral-drug-candidate-apx3330-for-retina-to-be-featured-at-the--ird-20211001monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-announces-publications-featuring-the-ref-1-protein-a-transcription-factor-regulat-ird-20211007monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-announces-two-key-leadership-appointments-ird-20211020monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-invited-to-present-clinical-data-on-nyxol-and-apx3330-at-the-american-academy-of--ird-20211101monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-announces-presence-at-eyecelerator-aao-2021-ird-20211108monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-announces-agreement-with-massachusetts-eye-and-ear-and-harvard-medical-schoo-ird-20211111monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-announces-enrollment-of-first-patients-in-second-phase-3-pivotal-trial-mira-3-for-ird-20211123monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-expands-prestigious-medical-advisory-board-with-six-new-kols-to-support-advanceme-ird-20211208monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-to-host-virtual-investor-r-d-day-on-january-31st-ird-20220125monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-completes-enrollment-in-mira-3-pivotal-phase-3-clinical-trial-for-nyxol-in-rm-and-ird-20220208monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-appoints-brian-leising-vice-president-manufacturing-ird-20220215monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-completes-enrollment-in-mira-4-pediatric-safety-trial-evaluating-nyxol-for-revers-ird-20220308monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-to-present-at-oppenheimer-annual-healthcare-conference-ird-20220310monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-completes-enrollment-of-over-100-subjects-in-24-week-zeta-1-phase-2b-trial-of-ora-ird-20220316monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-announces-positive-topline-results-from-mira-3-phase-3-fda-registration-trial-for-ird-20220329monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-to-present-at-wet-amd-dme-drug-development-summit-in-boston-ma-ird-20220406monthly0.5https://www.biopharmawatch.com/news/IRD/opus-enters-strategic-collaboration-with-resilience-for-aav-based-gene-therapy-development-ird-20220411monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-announces-upcoming-clinical-presentations-at-arvo-2022-medical-meeting-and-modliv-ird-20220426monthly0.5https://www.biopharmawatch.com/news/IRD/new-data-on-potential-of-opus-aav-based-gene-therapies-for-rare-inherited-retinal-diseases-ird-20220428monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-announces-promising-new-data-highlighting-potential-of-aav-based-gene-therap-ird-20220504monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-appoints-jennifer-hunt-chief-development-officer-ird-20220511monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-announces-upcoming-presentations-at-the-retina-world-congress-clinical-tri-ird-20220511monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-announces-positive-topline-results-from-lynx-1-phase-3-trial-evaluating-nyxol-eye-ird-20220519monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-to-present-new-interim-masked-safety-data-for-oral-apx3330-in-diabetics-at-annual-ird-20220608monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-appoints-ben-yerxa-ph-d-as-permanent-chief-executive-officer-ird-20220621monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-granted-new-u-s-patent-for-late-stage-oral-drug-candidate-apx3330-for-use-in-diab-ird-20220629monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-announces-late-breaking-paper-for-nyxol-for-reversal-of-dilation-indication-at-an-ird-20220707monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-to-present-at-ois-retina-innovation-summit-2022-ird-20220711monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-expands-its-leadership-team-ird-20220721monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-extends-u-s-patent-protection-for-late-stage-drug-candidate-nyxol-for-reversal-of-ird-20220803monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-announces-upcoming-presentations-at-two-conferences-in-august-ird-20220808monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-hosts-inaugural-patient-advocacy-outreach-webinar-on-inherited-retinal-disea-ird-20220901monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conference-ird-20220906monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-announces-last-patient-completes-final-visit-in-zeta-1-phase-2b-24-week-tr-ird-20220908monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-leadership-to-present-at-3rd-annual-gene-therapy-for-ophthalmic-disorders-co-ird-20220912monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-receives-pdfua-fee-waiver-for-nyxol-new-drug-application-from-fda-ird-20220912monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-announces-upcoming-presentations-at-european-forum-2022-eyecelerator-aao-2022-and-ird-20220915monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-expands-board-of-directors-with-appointment-of-global-ophthalmology-leader-d-ird-20220927monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-expands-medical-advisory-board-with-seven-new-kols-and-strengthens-leadership-tea-ird-20220929monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-hosting-key-opinion-leader-event-on-oral-apx3330-for-diabetic-eye-disease-ird-20221006monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-to-present-at-the-microcap-rodeo-windy-city-roundup-2022-conference-ird-20221007monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-announces-six-poster-presentations-on-nyxol-and-apx3330-at-the-american-academy-o-ird-20221024monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-announces-peer-reviewed-publication-in-bmc-ophthalmology-for-nyxol-and-strategic--ird-20221102monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-sponsors-uni-rare-natural-history-study-for-people-with-inherited-retinal-di-ird-20221114monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-to-present-at-five-upcoming-investor-industry-conferences-ird-20221121monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-receives-fda-clearance-of-ind-application-for-opgx-001-a-gene-therapy-candid-ird-20221201monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-announces-acquisition-of-the-rights-to-two-gene-therapy-product-candidates-f-ird-20221228monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-announces-first-patient-enrolled-in-vega-2-pivotal-phase-3-trial-of-nyxol--ird-20230109monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-announces-topline-results-from-zeta-1-phase-2-trial-of-oral-apx3330-in-diabetic-r-ird-20230125monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-announces-fda-acceptance-of-new-drug-application-and-pdufa-date-of-september-28-2-ird-20230213monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-announces-apx3330-phase-2-data-presentations-at-retina-meetings-ird-20230216monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-announces-apx3330-and-nyxol-data-presentations-at-arvo-2023-annual-meeting-ird-20230323monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-provides-corporate-update-and-reiterates-previous-guidance-on-clinical-programs-ird-20230425monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-announces-apx3330-and-nyxol-data-presentations-at-ascrs-2023-and-eyecelerator-ird-20230502monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ird-20230524monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-presents-apx3330-zeta-1-data-at-clinical-trials-at-the-summit-cts-2023-ird-20230612monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-announces-late-breaking-presentation-on-apx3330-zeta-1-clinical-data-at-american--ird-20230621monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-presents-apx3330-zeta-1-clinical-data-in-late-breaker-session-at-the-american-dia-ird-20230627monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ird-20230710monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-to-present-at-american-society-of-retina-specialists-annual-meeting-and-ois-retin-ird-20230726monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-to-present-at-the-canaccord-43rd-annual-growth-conference-and-the-h-c-wain-ird-20230808monthly0.5https://www.biopharmawatch.com/news/IRD/abstract-on-zeta-1-study-of-apx3330-receives-award-at-women-in-ophthalmology-wio-summer-sy-ird-20230828monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-to-present-at-escrs-2023-and-modlive-conferences-in-september-ird-20230907monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-announces-first-patient-dosed-in-phase-1-2-trial-of-gene-therapy-opgx-lca5-i-ird-20230907monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-to-participate-in-three-upcoming-investment-bank-conferences-ird-20230911monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-to-present-at-euretina-and-retina-society-conferences-in-october-ird-20231006monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-to-present-at-aao-2023-and-eyecelerator-retina-showcase-ird-20231026monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ird-20231101monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-announces-successful-end-of-phase-2-meeting-with-fda-for-oral-apx3330-in-d-ird-20231102monthly0.5https://www.biopharmawatch.com/news/IRD/new-preliminary-clinical-data-on-potential-of-opus-aav-based-gene-therapy-for-rare-inherit-ird-20231103monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ird-20231127monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-announces-presentation-at-ophthalmology-innovation-summit-ois-xiii-ird-20231130monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-receives-fda-agreement-under-special-protocol-assessment-for-lynx-2-phase--ird-20240104monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ird-20240124monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-announces-presentation-on-apx3330-at-the-annual-angiogenesis-exudation-and-ird-20240205monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ird-20240215monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-to-present-in-the-bio-ceo-investor-conference-ird-20240223monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-announces-completion-of-dosing-in-first-cohort-of-phase-1-2-trial-of-gene-th-ird-20240326monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-announces-the-u-s-commercial-launch-of-ryzumvl-phentolamine-ophthalmic-solution-0-ird-20240401monthly0.5https://www.biopharmawatch.com/news/IRD/first-patient-enrolled-in-lynx-2-phase-3-study-evaluating-phentolamine-ophthalmic-solution-ird-20240411monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-announces-apx3330-presentation-at-arvo-2024-annual-meeting-ird-20240422monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-to-present-at-the-aegis-virtual-conference-ird-20240503monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-announces-presentation-on-apx3330-at-the-arvo-2024-annual-meeting-ird-20240506monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-announces-presentations-on-the-development-of-apx3330-for-diabetic-retinop-ird-20240606monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-announces-1-7-million-in-project-based-funding-from-the-foundation-fighting--ird-20240613monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-to-highlight-apx3330-for-diabetic-retinopathy-at-two-scientific-meetings-i-ird-20240710monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-to-present-at-two-investor-conferences-in-august-ird-20240808monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-receives-rare-pediatric-disease-designation-from-the-u-s-fda-for-ocular-gene-ird-20240820monthly0.5https://www.biopharmawatch.com/news/IRD/update-ocuphire-pharma-initiates-vega-3-phase-3-trial-evaluating-phentolamine-ophthalmic-s-ird-20240905monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-initiates-vega-3-phase-3-trial-evaluating-phentolamine-ophthalmic-solution-ird-20240905monthly0.5https://www.biopharmawatch.com/news/IRD/ocuphire-pharma-announces-publication-of-full-phase-3-results-of-phentolamine-ophthalmic-s-ird-20240930monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ird-20241112monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-to-host-virtual-kol-event-on-opgx-lca5-as-a-treatment-for-lca5-associated-in-ird-20241203monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-receives-fda-agreement-under-special-protocol-assessment-for-phase-3-trial-o-ird-20241219monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-announces-updates-on-opgx-lca5-clinical-program-ird-20250218monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-announces-fda-fast-track-and-enrollment-updates-for-phentolamine-ophthalmic--ird-20250226monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-announces-presentations-at-association-for-research-in-vision-and-ophthalmol-ird-20250305monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ird-20250319monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-announces-presentation-on-phentolamine-ophthalmic-solution-0-75-in-dim-light-ird-20250321monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-announces-pricing-of-public-offering-and-concurrent-private-placement-with-p-ird-20250321monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-to-participate-in-upcoming-investor-conference-in-april-ird-20250402monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-files-definitive-proxy-statement-and-sends-letter-to-stockholders-highlighti-ird-20250407monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-announces-one-month-clinical-data-from-pediatric-patient-in-phase-1-2-trial--ird-20250408monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-announces-presentation-of-opgx-lca5-gene-therapy-data-at-arvo-12-month-phase-ird-20250505monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-granted-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-opgx-ird-20250506monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-announces-presentations-on-inherited-retinal-disease-programs-at-medical-con-ird-20250512monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-announces-lynx-2-phase-3-trial-met-its-primary-endpoint-for-phentolamine-oph-ird-20250602monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ird-20250703monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-to-participate-in-the-h-c-wainwright-5th-annual-ophthalmology-virtual-confer-ird-20250805monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-announces-fda-clearance-of-ind-application-for-gene-therapy-candidate-opgx-b-ird-20250818monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-inherited-retinal-disease-programs-featured-at-medical-and-industry-conferen-ird-20250827monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conferenc-ird-20250903monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-doses-first-patient-in-pivotal-lynx-3-phase-3-trial-evaluating-phentolamine--ird-20250904monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ird-20250912monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ird-20251202monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-announces-positive-recommendation-from-independent-data-monitoring-committee-ird-20251209monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ird-20251216monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-solidifies-leadership-position-in-gene-therapy-development-for-inherited-ret-ird-20260406monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-announces-data-presentations-at-the-2026-american-society-of-cataract-and-re-ird-20260410monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-announces-fda-acceptance-of-opgx-lca5-into-rare-disease-evidence-principles--ird-20260504monthly0.5https://www.biopharmawatch.com/news/IRD/opus-genetics-completes-enrollment-in-cohort-1-of-phase-1-2-opgx-best1-gene-therapy-study-ird-20260507monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-raises-46-million-series-a-and-recruits-leadership-and-advisory-board-idya-20160503monthly0.5https://www.biopharmawatch.com/news/IDYA/fiercebiotech-names-ideaya-biosciences-as-one-of-its-fierce-15-biotech-companies-of-2016-idya-20160916monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-emerging-innovators-panel-at-citis-12th-annual-biotec-idya-20170906monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-present-at-the-36th-annual-j-p-morgan-healthcare-conference-idya-20180105monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-and-cancer-research-uk-announce-partnership-agreement-to-develop-small--idya-20180313monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-raises-94-million-crossover-series-b-financing-idya-20180315monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-appoints-julie-hambleton-m-d-as-senior-vice-president-and-chief-medical-idya-20180318monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-appoints-paul-stone-j-d-as-senior-vice-president-and-general-counsel-he-idya-20180605monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-present-at-the-2018-jefferies-global-healthcare-conference-idya-20180606monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-licenses-phase-1-compound-lxs196-for-the-treatment-of-cancers-with-gnaq-and-gna11-m-idya-20181003monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-appoints-bao-truong-as-vice-president-head-of-regulatory-affairs-idya-20181204monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-on-tuesd-idya-20190102monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-appoints-leading-cancer-researchers-frank-mccormick-ph-d-frs-and-willia-idya-20190213monthly0.5https://www.biopharmawatch.com/news/IDYA/updated-phase-1-clinical-trial-monotherapy-data-for-ide196-in-metastatic-uveal-melanoma-to-idya-20190329monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-receives-authorization-to-proceed-with-phase-1-2-tissue-type-agnostic-basket-trial--idya-20190508monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-pricing-of-initial-public-offering-idya-20190522monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-strengthens-management-with-internal-appointments-of-paul-stone-j-d-as--idya-20190709monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-first-patient-dosing-of-pkc-inhibitor-ide196-in-phase-1-2-tis-idya-20190711monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-first-patient-dosing-of-ide196-for-solid-tumors-outside-of-uveal-melanoma-idya-20191008monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-present-at-upcoming-investor-conferences-idya-20191025monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-reports-end-of-phase-1-meeting-with-fda-for-ide196-confirms-acceptabili-idya-20191031monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-leadership-updates-in-research-organization-idya-20191105monthly0.5https://www.biopharmawatch.com/news/IDYA/phase-1-2-clinical-trial-progress-for-ide196-to-be-presented-at-society-for-melanoma-resea-idya-20191115monthly0.5https://www.biopharmawatch.com/news/IDYA/ide196-program-updates-targeting-initiation-of-potentially-registration-enabling-phase-2-s-idya-20191209monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-appoints-wendy-yarno-to-its-board-of-directors-idya-20191218monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-on-wedne-idya-20200106monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-and-boston-childrens-hospital-collaborate-on-preclinical-evaluation-of--idya-20200110monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-synthetic-lethality-research-highlights-and-target-milestones-idya-20200115monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-and-pfizer-enter-clinical-trial-collaboration-and-supply-agreement-to-evaluate-clin-idya-20200318monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-ide196-monotherapy-phase-2-dose-selection-and-clinical-progra-idya-20200318monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-addition-of-julie-patel-as-vice-president-human-resources-enh-idya-20200421monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-aacr-abstracts-for-ide196-targeting-gnaq-11-tumors-and-precli-idya-20200515monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-jefferies-virtual-healthcare-conference-on-tuesday-ju-idya-20200519monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-nomination-of-development-candidate-ide397-for-mat2a-synthetic-lethality--idya-20200608monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-selected-to-join-russell-3000-r-index-idya-20200611monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-proposed-public-offering-of-common-stock-idya-20200616monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-pricing-of-public-offering-of-common-stock-idya-20200617monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-appoints-garret-hampton-ph-d-to-the-board-of-directors-an-industry-leader-in-precis-idya-20200630monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-doses-first-patient-in-a-phase-1-combination-study-of-ide196-and-binime-idya-20200709monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-to-participate-in-fireside-chat-at-btig-biotechnology-conference-and-wedbush-pacgro-idya-20200714monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-ide196-program-update-and-clinical-protocol-criteria-met-for-cohort-expan-idya-20200716monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-to-participate-in-upcoming-september-2020-investor-relations-events-idya-20200831monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-partnership-with-the-broad-institute-and-advancement-of-synthetic-lethali-idya-20201022monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-to-participate-in-upcoming-november-2020-investor-relations-events-idya-20201102monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-addition-to-nasdaq-biotechnology-index-idya-20201214monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-to-participate-in-upcoming-january-2021-investor-relations-events-and-scientific-co-idya-20210104monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-doses-first-patient-in-a-phase-1-combination-study-of-ide196-and-crizot-idya-20210105monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-submission-of-ind-application-for-mat2a-development-candidate-idya-20210111monthly0.5https://www.biopharmawatch.com/news/IDYA/spelman-college-and-ideaya-biosciences-announce-partnership-for-professional-development-o-idya-20210119monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-to-participate-in-upcoming-february-2021-investor-relations-events-idya-20210201monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-ide397-ind-clearance-by-u-s-fda-to-initiate-phase-1-and-appointment-of-ma-idya-20210208monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inaugural-synthetic-lethality-investor-day-idya-20210222monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-to-participate-in-upcoming-march-2021-investor-relations-events-idya-20210301monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-presentations-at-aacr-annual-meeting-2021-for-synthetic-lethality-program-idya-20210311monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-dose-expansion-in-phase-1-2-study-of-ide196-and-binimetinib-combination-i-idya-20210323monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-dosing-of-first-patient-of-mat2a-inhibitor-ide397-in-phase-1-clinical-tri-idya-20210415monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-investor-day-webcast-to-review-clinical-data-from-phase-1-2-trial-of-daro-idya-20210415monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-reports-darovasertib-ide196-monotherapy-overall-survival-data-and-observes-early-pa-idya-20210416monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tues-idya-20210419monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-to-participate-in-upcoming-may-2021-investor-relations-event-idya-20210506monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-dose-expansion-in-phase-1-2-study-of-darovasertib-and-crizotinib-combinat-idya-20210510monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-present-at-2021-jefferies-virtual-healthcare-conference-idya-20210524monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-ide397-phase-1-clinical-pharmacodynamic-data-and-phase-2-initiation-of-da-idya-20210628monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-proposed-public-offering-of-common-stock-idya-20210706monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-pricing-of-public-offering-of-common-stock-idya-20210707monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwrit-idya-20210712monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-panel-discussion-at-2021-wedbush-pacgrow-healthcare-v-idya-20210802monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-investor-conferences-in-september-2021-idya-20210830monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-appoints-michael-white-ph-d-as-chief-scientific-officer-idya-20211018monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-investor-conferences-in-november-2021-idya-20211101monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-investor-webcast-to-review-clinical-data-from-phase-1-2-trial-of-darovase-idya-20211129monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-investor-conferences-in-december-2021-idya-20211130monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-reports-clinical-data-from-phase-2-expansion-dose-of-darovasertib-and-crizotinib-sy-idya-20211207monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-investor-conferences-in-january-2022-idya-20220103monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-appoints-dr-frank-mccormick-as-chair-of-scientific-advisory-board-idya-20220104monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-acquisition-of-proprietary-inquire-tm-chemical-library-to-enh-idya-20220105monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-corporate-and-portfolio-update-for-j-p-morgan-40th-annual-hea-idya-20220110monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-advances-first-in-class-parg-development-candidate-ide161-into-ind-enabling-studies-idya-20220131monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-investor-conferences-in-february-2022-idya-20220201monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-investor-conferences-in-march-2022-idya-20220301monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-investor-webcast-to-report-interim-ide397-phase-1-clinical-da-idya-20220308monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-and-pfizer-expand-clinical-trial-collaboration-and-supply-agreements-for-evaluation-idya-20220314monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-reports-ide397-interim-phase-1-clinical-data-idya-20220315monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-receives-orphan-drug-designation-for-darovasertib-a-pkc-inhibitor-for-t-idya-20220502monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-investor-conferences-in-may-2022-idya-20220503monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-present-at-the-2022-jefferies-global-healthcare-conference-idya-20220608monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-development-candidate-nomination-of-a-potential-first-in-class-pol-theta--idya-20220628monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-ide397-clinical-program-update-and-ctdna-molecular-responses-demonstratin-idya-20220727monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-achievement-of-first-milestone-in-ongoing-collaboration-with-gsk-for-pote-idya-20220829monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-investor-conferences-in-september-2022-idya-20220830monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-first-patient-in-for-phase-i-clinical-trial-to-evaluate-darovasertib-mono-idya-20220906monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-reports-positive-interim-phase-2-clinical-results-for-darovasertib-and-crizotinib-s-idya-20220911monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-pricing-of-public-offering-of-common-stock-idya-20220914monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-proposed-public-offering-of-common-stock-idya-20220914monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwrit-idya-20220919monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-phase-2-mat2a-inhibitor-ide397-achieves-first-patient-in-for-multiple-com-idya-20221018monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-plans-for-investor-r-d-day-and-participation-in-upcoming-inve-idya-20221101monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-appoints-darrin-m-beaupre-m-d-ph-d-as-chief-medical-officer-to-lead-cli-idya-20221128monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-agenda-topics-and-key-opinion-leader-presenters-for-investor--idya-20221129monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-receives-fast-track-designation-for-darovasertib-combination-therapy-wi-idya-20221205monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-submission-of-ind-application-to-the-u-s-fda-for-parg-develop-idya-20221212monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-appoints-dr-karlene-cimprich-ph-d-and-dr-kornelia-polyak-m-d-ph-d-to-sc-idya-20221219monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-on-tuesd-idya-20230103monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-ind-clearance-by-u-s-fda-enabling-phase-1-initiation-for-first-in-class-p-idya-20230109monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-darovasertib-phase-2-initiation-in-neoadjuvant-and-adjuvant-uveal-melanom-idya-20230123monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-the-2023-guggenheim-oncology-conference-idya-20230201monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-citis-2023-virtual-oncology-leadership-summit-idya-20230216monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-investor-conferences-in-march-2023-idya-20230301monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-presentations-at-aacr-annual-meeting-2023-for-potential-first-in-class-sy-idya-20230314monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-idya-20230331monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-upcoming-april-2023-investor-relations-event-idya-20230403monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-first-patient-dosed-in-phase-1-clinical-trial-for-ide161-as-potential-fir-idya-20230419monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-positive-interim-phase-2-data-for-darovasertib-and-crizotinib-combination-idya-20230423monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-proposed-public-offering-of-common-stock-idya-20230424monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-pricing-of-public-offering-idya-20230425monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-closing-of-public-offering-including-full-exercise-of-underwriters-option-idya-20230427monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-idya-20230428monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-upcoming-may-2023-investor-relations-event-idya-20230501monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-ind-clearance-enabling-phase-1-2-clinical-trial-for-combination-of-ide397-idya-20230522monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-idya-20230526monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-upcoming-june-2023-investor-relations-events-idya-20230530monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-selection-of-ide397-phase-2-monotherapy-expansion-dose-for-global-enrollm-idya-20230612monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-first-reported-case-of-uveal-melanoma-patient-spared-enucleation-in-phase-idya-20230622monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-idya-20230630monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-idya-20230728monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-upcoming-august-2023-investor-relations-event-idya-20230801monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-and-amgen-achieve-first-patient-in-for-clinical-evaluation-of-ide397-mat2a-and-amg--idya-20230802monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-reports-second-quarter-2023-financial-results-and-provides-business-idya-20230810monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-first-patient-in-for-company-sponsored-phase-2-clinical-trial-evaluating--idya-20230816monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-clearance-of-ind-application-for-pol-theta-helicase-developme-idya-20230821monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-upcoming-september-2023-investor-relations-events-idya-20230905monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-phase-1-expansion-and-preliminary-clinical-proof-of-concept-for-potential-idya-20230911monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-receives-fast-track-designation-for-potential-first-in-class-parg-inhibitor-ide161--idya-20230926monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-receives-fast-track-designation-for-ide161-in-a-second-indication-for-t-idya-20230927monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-idya-20231006monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-development-candidate-nomination-of-a-werner-helicase-inhibit-idya-20231009monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-phase-2-expansion-of-darovasertib-and-crizotinib-combination--idya-20231016monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-proffered-paper-oral-presentation-at-esmo-2023-for-phase-2-cl-idya-20231017monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-top-line-phase-2-results-at-esmo-2023-of-darovasertib-and-crizotinib-comb-idya-20231023monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-pricing-of-public-offering-idya-20231024monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants-idya-20231024monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-closing-of-public-offering-including-full-exercise-of-underwriters-option-idya-20231027monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-idya-20231027monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-plans-for-investor-r-d-day-and-participation-in-jefferies-lon-idya-20231101monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-reports-third-quarter-2023-financial-results-and-provides-business--idya-20231107monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-agenda-for-investor-r-d-day-webcast-on-december-4-2023-idya-20231203monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-clinical-study-collaboration-with-gilead-sciences-to-evaluate-trodelvy-r--idya-20231204monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-upcoming-december-2023-investor-relations-event-idya-20231205monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-idya-20231208monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-idya-20231229monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-participation-at-the-42nd-annual-j-p-morgan-healthcare-confer-idya-20240107monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-idya-20240126monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-upcoming-february-2024-investor-relations-events-idya-20240201monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-reports-fourth-quarter-and-full-year-2023-financial-results-and-pro-idya-20240220monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-upcoming-march-2024-investor-relations-events-idya-20240304monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-clinical-collaboration-to-evaluate-ide161-in-combination-with-keytruda-r--idya-20240312monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-upcoming-april-2024-investor-relations-event-idya-20240401monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-idya-20240405monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-selection-of-move-forward-phase-2-expansion-dose-for-ide397-m-idya-20240422monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-asco-2024-oral-presentation-for-darovasertib-in-neoadjuvant-u-idya-20240424monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-idya-20240426monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-upcoming-may-2024-investor-relations-event-idya-20240501monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-reports-first-quarter-2024-financial-results-and-provides-business--idya-20240507monthly0.5https://www.biopharmawatch.com/news/IDYA/c-o-r-r-e-c-t-i-o-n-ideaya-biosciences-inc-idya-20240523monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-appoints-daniel-a-simon-as-chief-business-officer-to-lead-corporate-str-idya-20240528monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-upcoming-june-2024-investor-relations-events-idya-20240529monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-idya-20240531monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-results-for-darovasertib-phase-2-ist-in-neoadjuvant-uveal-melanoma-at-asc-idya-20240603monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-clinical-program-updates-for-ide397-a-potential-first-in-clas-idya-20240624monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-first-patient-in-for-phase-1-clinical-trial-evaluating-ide397-idya-20240625monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-idya-20240628monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-investor-webcast-to-report-clinical-data-update-for-ide397-phase-2-monoth-idya-20240705monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-positive-interim-phase-2-monotherapy-expansion-data-for-ide397-a-potentia-idya-20240708monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-pricing-of-public-offering-idya-20240709monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants-idya-20240709monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-closing-of-public-offering-including-full-exercise-of-underwriters-option-idya-20240711monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-upcoming-august-2024-investor-relations-event-idya-20240729monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-option-and-license-agreement-for-potential-first-in-class-b7h-idya-20240731monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-idya-20240823monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-the-morgan-stanley-22nd-annual-global-healthcare-conf-idya-20240826monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-idya-20240830monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-appoints-douglas-b-snyder-as-senior-vice-president-general-counsel-idya-20240918monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-webcast-to-report-interim-phase-2-data-for-darovasertib-and-regulatory-up-idya-20240922monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-positive-interim-phase-2-data-for-darovasertib-and-successful-idya-20240923monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-idya-20240927monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-positive-interim-phase-1-expansion-data-of-ide397-in-mtap-deletion-urothe-idya-20241025monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-ind-clearance-for-werner-helicase-development-candidate-ide27-idya-20241028monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-idya-20241101monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-development-candidate-nomination-of-ide034-a-potential-first-in-class-b7h-idya-20241111monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-participation-in-jefferies-london-healthcare-conference-and-p-idya-20241112monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-appoints-stu-dorman-as-chief-commercial-officer-idya-20241118monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-idya-20241129monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-participation-in-upcoming-december-2024-investor-relations-ev-idya-20241202monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-idya-20241206monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-development-candidate-nomination-of-ide892-a-potential-best-i-idya-20241209monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-first-patient-in-for-phase-1-clinical-trial-evaluating-ide161-in-combinat-idya-20241210monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-agenda-for-investor-r-d-day-webcast-on-december-16-2024-idya-20241211monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-development-candidate-nomination-of-ide251-a-potential-first-in-class-kat-idya-20241216monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-idmc-recommendation-of-move-forward-dose-in-part-2a-of-registration-enabl-idya-20241217monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-idya-20241227monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-participation-at-the-43rd-annual-j-p-morgan-healthcare-confer-idya-20250112monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-upcoming-february-2025-investor-relations-events-idya-20250127monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-idya-20250131monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-appointment-of-healthcare-investment-banking-veteran-joshua-b-idya-20250210monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-further-gilead-sciences-clinical-study-collaboration-evaluating-combinati-idya-20250213monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-reports-fourth-quarter-and-full-year-2024-financial-results-and-pro-idya-20250213monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-idya-20250228monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-collaboration-with-attmos-to-accelerate-ai-ml-enabled-drug-di-idya-20250303monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-oral-presentation-at-the-new-drugs-on-the-horizon-series-at-aacr-2025-for-idya-20250326monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-idya-20250328monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-receives-us-fda-breakthrough-therapy-designation-for-darovasertib-monot-idya-20250331monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-participation-in-upcoming-april-2025-investor-relations-event-idya-20250401monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-phase-1-2-expansion-for-ide397-and-trodelvy-r-combination-in--idya-20250410monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-successful-fda-type-d-meeting-on-phase-3-registrational-trial-idya-20250414monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-idya-20250425monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-upcoming-may-2025-investor-relations-events-idya-20250428monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-us-fda-ind-clearance-for-ide849-a-potential-first-in-class-dl-idya-20250506monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-reports-first-quarter-2025-financial-results-and-provides-business--idya-20250506monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-idya-20250530monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-upcoming-june-2025-investor-relations-events-idya-20250602monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-idya-20250627monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-upcoming-july-2025-investor-relations-event-idya-20250721monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-and-hengrui-pharmaceuticals-announce-oral-presentation-at-iaslc-2025-wo-idya-20250722monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-10-year-anniversary-r-d-day-on-september-8-2025-to-present-mu-idya-20250723monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-proffered-paper-oral-presentation-at-esmo-2025-for-phase-2-cl-idya-20250724monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-idya-20250801monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-inc-reports-second-quarter-2025-financial-results-and-provides-business-idya-20250805monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-agenda-for-10-year-anniversary-r-d-day-on-september-8-2025-idya-20250818monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-upcoming-september-2025-investor-relations-events-idya-20250825monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-idya-20250829monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-present-first-median-overall-survival-data-from-phase-2-trial-of-the-idya-20250829monthly0.5https://www.biopharmawatch.com/news/IDYA/servier-and-ideaya-biosciences-partner-to-bring-darovasertib-a-promising-uveal-melanoma-tr-idya-20250902monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-ind-submission-for-ide892-a-potential-best-in-class-prmt5-inh-idya-20250903monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-first-patient-in-for-phase-1-2-combination-trial-of-ide397-a--idya-20250904monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-positive-interim-phase-2-data-for-darovasertib-in-the-neoadju-idya-20250908monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-idya-20250926monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-upcoming-november-2025-investor-relations-events-idya-20251027monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-idya-20251031monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-provides-a-business-update-and-outlines-2026-corporate-objectives-at-th-idya-20260111monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-first-patient-in-for-phase-1-trial-of-ide892-a-potential-best-idya-20260309monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-upcoming-presentations-at-aacr-2026-highlighting-multiple-cli-idya-20260318monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-first-patient-in-for-phase-1-trial-of-ide574-a-potential-firs-idya-20260406monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-idya-20260501monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-idya-20260529monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-closes-34-6-million-series-a-financing-in-rare-endocrine-diseases-mbx-20200727monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-appoints-james-cornelius-to-its-board-of-directors-mbx-20201027monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-appoints-mary-jane-geiger-m-d-ph-d-as-chief-medical-officer-mbx-20210105monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-appoints-ora-hirsch-pescovitz-m-d-to-board-of-directors-mbx-20220405monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-appoints-richard-b-bartram-as-chief-financial-officer-mbx-20220411monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-receives-orphan-drug-designation-for-lead-candidate-mbx-2109-for-the-treat-mbx-20220726monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-advances-phase-1-clinical-trial-of-long-acting-parathyroid-hormone-peptide-mbx-20221005monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-closes-115-million-series-b-financing-to-advance-development-of-endocrine--mbx-20221114monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-mbx-20230104monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-to-participate-in-the-svb-securities-global-biopharma-conference-mbx-20230124monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-to-participate-in-the-needham-22nd-annual-healthcare-conference-mbx-20230410monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-to-participate-in-may-investor-conferences-mbx-20230508monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-appoints-steven-j-prestrelski-ph-d-m-b-a-as-chief-scientific-officer-mbx-20230710monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-announces-u-s-fda-clearance-of-ind-application-for-mbx-1416-for-the-treatm-mbx-20230807monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-to-participate-in-morgan-stanley-global-healthcare-conference-mbx-20230829monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-announces-positive-phase-1-multiple-ascending-dose-data-for-mbx-2109-a-lon-mbx-20230911monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-to-showcase-results-from-phase-1-study-of-mbx-2109-in-late-breaking-oral-p-mbx-20231003monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-doses-first-participant-in-phase-1-2-clinical-trial-of-mbx-1416-for-the-tr-mbx-20231009monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-presents-positive-results-from-phase-1-study-of-mbx-2109-in-late-breaking--mbx-20231016monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-to-participate-in-stifel-2023-healthcare-conference-mbx-20231031monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-announces-appointment-of-michelle-graham-as-chief-human-resources-officer-mbx-20231101monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-to-participate-in-42nd-annual-j-p-morgan-healthcare-conference-mbx-20231220monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-to-participate-in-oppenheimer-34th-annual-healthcare-life-sciences-confere-mbx-20240131monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-appoints-steven-ryder-m-d-to-board-of-directors-mbx-20240205monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-appoints-salomon-azoulay-m-d-as-chief-medical-officer-mbx-20240625monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-raises-63-5-million-in-series-c-financing-to-advance-precision-endocrine-p-mbx-20240805monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-doses-first-patient-in-phase-2-avail-trial-of-mbx-2109-for-the-treatment-o-mbx-20240812monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-announces-launch-of-initial-public-offering-mbx-20240909monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-announces-pricing-of-initial-public-offering-mbx-20240912monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-announces-closing-of-upsized-initial-public-offering-including-full-exerci-mbx-20240916monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-to-participate-in-upcoming-november-investor-conferences-mbx-20241028monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-announces-last-subject-last-visit-in-phase-1-trial-of-mbx-1416-for-the-tre-mbx-20241118monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-announces-mbx-2109-phase-1-study-results-published-in-the-journal-of-clini-mbx-20241202monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-to-participate-in-43rd-annual-j-p-morgan-healthcare-conference-mbx-20241218monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-announces-positive-topline-results-from-phase-1-trial-of-mbx-1416-for-the--mbx-20250107monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-to-participate-in-upcoming-february-investor-conferences-mbx-20250123monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-to-participate-in-march-investor-conferences-mbx-20250218monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-completes-enrollment-in-phase-2-avail-trial-of-mbx-2109-canvuparatide-for--mbx-20250303monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference-mbx-20250326monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-to-participate-in-citizens-and-rbc-may-investor-conferences-mbx-20250422monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-to-participate-in-june-investor-conferences-mbx-20250520monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-to-participate-in-the-37th-annual-piper-sandler-healthcare-conference-mbx-20251118monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-to-provide-2026-outlook-and-business-update-at-44th-annual-j-p-morgan-heal-mbx-20260111monthly0.5https://www.biopharmawatch.com/news/MBX/mbx-biosciences-appoints-karen-basbaum-as-chief-business-officer-mbx-20260310monthly0.5https://www.biopharmawatch.com/news/GLUE/versant-ventures-strengthens-global-team-and-discovery-engine-infrastructure-glue-20200310monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-discloses-32-5-million-financing-glue-20200526monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-96-million-series-b-financing-to-advance-small-molecule--glue-20200924monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-strengthens-executive-leadership-team-with-new-appointments-glue-20201027monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-formation-of-scientific-advisory-board-glue-20201116monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-to-present-at-piper-sandler-32nd-annual-virtual-healthcare-confere-glue-20201120monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference-glue-20210107monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-expands-senior-management-team-glue-20210208monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-glue-20210216monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-strengthens-leadership-with-key-executive-and-board-appointments-glue-20210225monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-95-million-series-c-financing-to-accelerate-next-generat-glue-20210312monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-expands-leadership-team-with-appointment-of-filip-janku-m-d-ph-d-a-glue-20210610monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-pricing-of-initial-public-offering-glue-20210623monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-to-participate-in-morgan-stanley-19th-annual-global-healthcare-con-glue-20210908monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-addition-to-russell-2000-and-russell-3000-indexes-glue-20210910monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-to-present-late-breaking-preclinical-data-on-targeting-gspt1-for-m-glue-20210930monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-presents-preclinical-data-at-aacr-nci-eortc-highlighting-potential-glue-20211007monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-to-present-at-4th-annual-targeted-protein-degradation-summit-glue-20211020monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-to-participate-in-piper-sandler-33rd-annual-virtual-healthcare-con-glue-20211122monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-appoints-jullian-g-jones-ph-d-j-d-mba-as-chief-business-officer-glue-20211202monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-glue-20220104monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-and-yeda-the-commercial-arm-of-the-weizmann-institute-of-science-a-glue-20220125monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-participation-in-upcoming-investor-conferences-glue-20220203monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-presents-preclinical-data-highlighting-potential-of-gspt1-directed-glue-20220408monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-fo-glue-20220906monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-to-present-at-5th-annual-targeted-protein-degradation-summit-and-3-glue-20221020monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-participation-in-upcoming-investor-conferences-glue-20221031monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-first-patient-dosed-in-phase-1-2-clinical-trial-evaluati-glue-20221101monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-glue-20230104monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-outlines-progress-across-portfolio-of-molecular-glue-degraders-and-glue-20230109monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences-glue-20230203monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-appoints-dr-jan-skvarka-to-board-of-directors-glue-20230323monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-presents-preclinical-data-from-gspt1-degrader-program-focused-on-m-glue-20230417monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-advances-second-development-candidate-mrt-6160-a-novel-highly-sele-glue-20230523monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-to-present-at-upcoming-investor-and-industry-conferences-glue-20230530monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-appoints-dr-anthony-m-manning-to-board-of-directors-glue-20230726monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-interim-pk-pd-and-clinical-data-for-mrt-2359-in-phase-1--glue-20231017monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-glue-20231027monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-presents-preclinical-data-at-acr-convergence-2023-demonstrating-po-glue-20231107monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-to-present-at-piper-sandler-healthcare-conference-glue-20231121monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-glue-20240103monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-provides-corporate-update-and-key-anticipated-milestones-for-2024-glue-20240108monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-glue-20240131monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-initiation-of-ind-enabling-studies-for-mrt-8102-a-first--glue-20240311monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-proposed-public-offering-of-common-stock-and-pre-funded--glue-20240515monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-presents-preclinical-data-at-digestive-disease-week-2024-highlight-glue-20240521monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-to-present-at-the-jefferies-global-healthcare-conference-glue-20240530monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-presents-preclinical-data-at-eular-2024-demonstrating-therapeutic--glue-20240614monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-to-present-at-the-ubs-targeted-protein-degradation-day-glue-20240708monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-first-participants-dosed-in-mrt-6160-phase-1-study-glue-20240819monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-glue-20240828monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-presents-preclinical-data-at-the-36th-eortc-nci-aacr-symposium-on--glue-20241023monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-to-participate-in-the-jefferies-london-healthcare-conference-glue-20241113monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-to-participate-in-the-piper-sandler-healthcare-conference-glue-20241126monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-presents-preclinical-data-at-the-2024-san-antonio-breast-cancer-sy-glue-20241211monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-closing-of-global-license-agreement-with-novartis-to-adv-glue-20241211monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-appoints-dr-eric-a-hughes-to-board-of-directors-glue-20241213monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-glue-20250106monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-provides-corporate-update-and-key-anticipated-milestones-for-2025-glue-20250110monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference-glue-20250224monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-to-present-pipeline-update-and-release-fourth-quarter-and-full-yea-glue-20250311monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-presents-preclinical-data-at-american-association-for-cancer-resea-glue-20250428monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-to-participate-in-the-jefferies-global-healthcare-conference-glue-20250528monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-fda-clearance-of-ind-application-for-mrt-8102-a-nek7-dir-glue-20250610monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-glue-20250902monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-to-present-interim-mrt-8102-phase-1-study-results-glue-20260106monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-proposed-public-offering-of-common-stock-and-pre-funded--glue-20260107monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-announces-clinical-supply-agreement-to-support-phase-2-trial-evalu-glue-20260316monthly0.5https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-glue-20260520monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-to-present-update-on-ptx-022-at-pachyonychia-congenita-project-patie-pvla-20181019monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-appoints-rare-disease-senior-executive-elaine-j-heron-phd-to-board-o-pvla-20180905monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-announces-fda-fast-track-designation-for-ptx-022-for-treatment-of-pa-pvla-20181112monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-announces-10-million-in-funding-from-ligand-pharmaceuticals-to-accel-pvla-20181218monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-commences-phase-3-portion-of-phase-2-3-pivotal-study-of-ptx-022-in-p-pvla-20191113monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-completes-enrollment-in-phase-2-3-pivotal-study-of-ptx-022-for-treat-pvla-20200306monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-completes-45-million-series-c-financing-pvla-20200528monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-reports-top-line-results-from-pivotal-phase-2-3-valo-trial-of-qtorin-pvla-20201223monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-announces-series-d-financing-of-up-to-37-7-million-to-accelerate-lat-pvla-20230105monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-announces-positive-topline-results-from-phase-2-study-of-qtorin-3-9--pvla-20230309monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-reports-topline-results-from-pivotal-phase-3-vapaus-study-of-qtorin--pvla-20230720monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-announces-u-s-fda-breakthrough-therapy-designation-granted-to-qtorin-pvla-20231116monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-awarded-up-to-2-6-million-grant-from-the-u-s-food-and-drug-administr-pvla-20241003monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-announces-presentations-at-the-12th-pediatric-dermatology-research-a-pvla-20241015monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-appoints-matthew-e-korenberg-as-chief-financial-officer-pvla-20241017monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-announces-first-patient-dosed-in-selva-phase-3-clinical-trial-of-qto-pvla-20241107monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-announces-closing-of-merger-with-pieris-pharmaceuticals-and-concurre-pvla-20241213monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-announces-publication-of-results-from-phase-2-clinical-trial-of-qtor-pvla-20250110monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-to-expand-phase-3-selva-clinical-trial-of-qtorin-3-9-rapamycin-anhyd-pvla-20250210monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-to-present-at-the-td-cowen-45th-annual-healthcare-conference-pvla-20250225monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-to-host-full-year-2024-financial-results-conference-call-on-march-31-pvla-20250318monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-to-present-at-the-jones-healthcare-and-technology-innovation-confere-pvla-20250404monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-announces-qtorin-rapamycin-3-9-anhydrous-gel-for-the-treatment-of-mi-pvla-20250411monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-granted-additional-u-s-patent-for-qtorin-rapamycin-for-the-treatment-pvla-20250422monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-to-host-first-quarter-2025-financial-results-and-corporate-update-co-pvla-20250508monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-strengthens-executive-leadership-team-with-appointment-of-rare-disea-pvla-20250527monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-granted-sixth-u-s-patent-covering-0-1-20-anhydrous-compositions-of-r-pvla-20250618monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-completes-enrollment-in-phase-3-selva-trial-of-qtorin-rapamycin-for--pvla-20250623monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-to-participate-in-the-canaccord-genuity-45th-annual-growth-conferenc-pvla-20250805monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-announces-positive-topline-results-from-phase-2-toiva-clinical-trial-pvla-20251215monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-granted-fda-fast-track-designation-for-qtorin-3-9-rapamycin-anhydrou-pvla-20251216monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-launches-beyond-mlm-disease-awareness-campaign-for-microcystic-lymph-pvla-20260310monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-announces-issuance-of-european-patent-covering-anhydrous-composition-pvla-20260316monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-announces-new-data-from-the-phase-2-toiva-trial-of-qtorin-rapamycin--pvla-20260515monthly0.5https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-presents-new-selva-and-toiva-data-at-the-2026-international-society--pvla-20260520monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-receives-regulatory-scientific-advice-on-cvac-phase-iii-trial-immp-20110218monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-announces-strategic-acquisition-of-immutep-sa-immp-20141002monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-to-prioritize-immuno-oncology-programs-targeting-immune-checkpoint-lag-3-immp-20150302monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-receives-a-research-tax-credit-cash-rebate-in-france-immp-20150611monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-announces-commencement-of-milestones-for-imp701-program-immp-20150814monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-announces-first-safety-pharmacokinetics-and-immuno-monitoring-data-from-phase-immp-20160622monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-collaborates-in-investigator-sponsored-new-clinical-trial-for-imp321-in-solid-immp-20160712monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-receives-uk-approval-for-aipac-study-immp-20161220monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-announces-data-from-imp321-aipac-clinical-trial-in-breast-cancer-immp-20161221monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-announces-new-product-candidate-imp761-a-lag-3-agonist-antibody-immp-20170102monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-enters-new-material-transfer-agreement-with-cytlimic-immp-20170105monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-commences-recruitment-for-second-cohort-of-melanoma-trial-immp-20170112monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-to-maintain-nasdaq-listing-immp-20170118monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-commences-randomised-phase-iib-clinical-trial-for-imp321-in-breast-cancer-immp-20170120monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-to-present-at-2nd-annual-cancer-immunotherapy-conference-immp-20170123monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-receives-a-860-000-tax-credit-payment-from-french-government-immp-20170213monthly0.5https://www.biopharmawatch.com/news/IMMP/first-half-2017-operational-update-immp-20170224monthly0.5https://www.biopharmawatch.com/news/IMMP/usa-patent-grants-for-imp321-in-cancer-immp-20170301monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-completes-recruitment-for-second-patient-cohort-in-melanoma-trial-and-will-pr-immp-20170315monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-receives-a-492-144-tax-refund-from-australian-government-immp-20170411monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-receives-approval-for-third-cohort-of-phase-i-melanoma-trial-immp-20170417monthly0.5https://www.biopharmawatch.com/news/IMMP/data-from-prima-biomed-aipac-clinical-trial-to-be-presented-at-2017-asco-conference-immp-20170516monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-announces-formation-of-clinical-advisory-board-immp-20170530monthly0.5https://www.biopharmawatch.com/news/IMMP/lag-3ig-imp321-demonstrates-positive-safety-and-efficacy-qualities-in-breast-cancer-clinic-immp-20170603monthly0.5https://www.biopharmawatch.com/news/IMMP/asco-poster-2017-immp-20170605monthly0.5https://www.biopharmawatch.com/news/IMMP/operational-update-immp-20170625monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-announces-pricing-of-us-5-0-million-registered-direct-offering-of-its-america-immp-20170628monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-announces-approval-for-the-initiation-of-the-insight-clinical-trial-immp-20170708monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-announces-second-milestone-payment-for-imp701-program-immp-20170715monthly0.5https://www.biopharmawatch.com/news/IMMP/financial-update-2h17-immp-20170718monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-receives-a-1-3-million-tax-refund-from-french-government-immp-20170814monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-appoints-non-executive-director-to-the-board-immp-20170819monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-and-monash-university-receive-funding-grant-for-lag-3-research-project-immp-20170829monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-secures-japanese-patent-grant-for-lead-product-imp321-in-infectious-disease-immp-20170905monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-secures-japanese-patent-grant-for-imp731-antibody-immp-20170907monthly0.5https://www.biopharmawatch.com/news/IMMP/imp321-new-data-accepted-for-presentation-at-the-society-for-immunotherapy-of-cancer-sitc--immp-20171016monthly0.5https://www.biopharmawatch.com/news/IMMP/dr-fre-de-ric-triebel-presenting-at-the-world-immunotherapy-congress-2017-immp-20171018monthly0.5https://www.biopharmawatch.com/news/IMMP/dr-fre-de-ric-triebel-presented-at-the-world-immunotherapy-congress-2017-immp-20171030monthly0.5https://www.biopharmawatch.com/news/IMMP/new-eftilagimod-alpha-lag-3ig-or-imp321-data-for-presentation-at-the-society-for-immunothe-immp-20171107monthly0.5https://www.biopharmawatch.com/news/IMMP/eftilagimod-alpha-lag-3ig-or-imp321-pre-ind-meeting-with-the-fda-immp-20171114monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-changes-its-name-to-immutep-ltd-immp-20171119monthly0.5https://www.biopharmawatch.com/news/IMMP/faq-change-of-company-name-from-prima-biomed-limited-to-immutep-limited-immp-20171120monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-secures-european-patent-grant-for-lead-product-imp321-in-cancer-immp-20171120monthly0.5https://www.biopharmawatch.com/news/IMMP/prima-biomed-becomes-immutep-immp-20171128monthly0.5https://www.biopharmawatch.com/news/IMMP/operational-update-immp-20171211monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-limited-announces-milestone-payment-from-chinese-partner-eoc-pharma-immp-20180131monthly0.5https://www.biopharmawatch.com/news/IMMP/outcome-from-dsmb-safety-review-and-extension-of-tacti-mel-phase-i-clinical-trial-immp-20180208monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-receives-a-686-704-r-d-tax-incentive-immp-20180304monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-united-states-patent-grant-for-imp701-antibody-immp-20180305monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-raises-a-6-85m-through-institutional-placement-immp-20180311monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-enters-into-clinical-trial-collaboration-and-supply-agreement-with-msd-immp-20180311monthly0.5https://www.biopharmawatch.com/news/IMMP/updated-tacti-mel-data-presented-at-the-cambridge-healthtech-institute-s-immuno-oncology-s-immp-20180321monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-commences-patient-dosing-in-additional-tacti-mel-cohort-immp-20180321monthly0.5https://www.biopharmawatch.com/news/IMMP/operational-update-immp-20180402monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-completes-6-31-million-share-purchase-plan-raises-total-of-13-16-million-immp-20180412monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-present-at-2018-asco-annual-meeting-immp-20180504monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-present-interim-results-from-tacti-mel-clinical-trial-in-global-webcast-immp-20180516monthly0.5https://www.biopharmawatch.com/news/IMMP/positive-new-data-from-ongoing-tacti-mel-study-in-unresectable-or-metastatic-melanoma-pres-immp-20180529monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-submits-investigational-new-drug-ind-application-with-fda-immp-20180702monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-s-lag-3-immunostimulant-product-candidate-efti-receives-ind-approval-from-u-s-fda-immp-20180730monthly0.5https://www.biopharmawatch.com/news/IMMP/tacti-mel-patient-recruitment-complete-and-operational-update-immp-20180807monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-present-at-the-biocentury-25th-annual-newsmakers-in-the-biotech-industry-confer-immp-20180815monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-receives-a-1-9-million-research-and-development-related-tax-rebate-from-french-gov-immp-20180821monthly0.5https://www.biopharmawatch.com/news/IMMP/progress-towards-clinical-development-of-imp761-a-lag-3-agonist-antibody-immp-20180903monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-enters-into-clinical-trial-collaboration-and-supply-agreement-with-merck-kgaa-darm-immp-20180923monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-present-at-ladenburg-thalmann-2018-healthcare-conference-immp-20180926monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-presentations-at-society-for-immunotherapy-of-cancer-sitc-2018-annual-me-immp-20181002monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-data-presentations-at-upcoming-industry-conferences-immp-20181023monthly0.5https://www.biopharmawatch.com/news/IMMP/operational-update-immp-20181031monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-presents-positive-new-data-from-ongoing-tacti-mel-study-at-society-for-immunothera-immp-20181111monthly0.5https://www.biopharmawatch.com/news/IMMP/new-data-from-ongoing-tacti-mel-study-in-unresectable-or-metastatic-melanoma-presented-at--immp-20181127monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-us-5-2-million-financing-led-by-u-s-specialist-healthcare-investor-altiu-immp-20181219monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-enters-into-clinical-trial-collaboration-service-and-supply-agreement-with-cytlimi-immp-20190107monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-present-at-upcoming-industry-conferences-immp-20190226monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-present-at-oppenheimer-s-29th-annual-healthcare-conference-immp-20190303monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-data-from-ongoing-tacti-mel-phase-i-clinical-trial-in-unresectable-or-me-immp-20190305monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-presents-positive-imp761-preclinical-results-at-14th-congress-of-european-crohn-s--immp-20190306monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-doses-first-patient-in-tacti-002-phase-ii-trial-immp-20190306monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-present-imp761-preclinical-results-in-global-webcast-immp-20190317monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-united-states-patent-grant-for-eftilagimod-alpha-in-cancer-immp-20190320monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-host-eftilagimod-alpha-clinical-development-update-global-webcast-immp-20190326monthly0.5https://www.biopharmawatch.com/news/IMMP/operational-update-immp-20190430monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-upcoming-industry-conference-participation-immp-20190510monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-data-from-ongoing-tacti-mel-phase-i-clinical-trial-in-unresectable-or-me-immp-20190516monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-european-patent-grant-for-eftilagimod-alpha-in-chemo-immunotherapy-immp-20190522monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-presentation-at-asco-2019-immp-20190602monthly0.5https://www.biopharmawatch.com/news/IMMP/insight-first-patient-dosed-in-the-4th-arm-called-insight-004-immp-20190605monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-completes-recruitment-of-initial-cohort-in-1st-line-nsclc-patients-for-tacti-002-t-immp-20190613monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-australian-patent-granted-for-eftilagimod-alpha-in-chemo-immunotherapy-immp-20190620monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-host-key-opinion-leader-call-immp-20190624monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-completes-patient-enrolment-of-the-aipac-phase-iib-clinical-trial-in-metastatic-br-immp-20190625monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-raises-a-10-million-via-private-placement-and-underwritten-entitlement-offer-immp-20190709monthly0.5https://www.biopharmawatch.com/news/IMMP/operational-update-immp-20190726monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-completes-a-6m-entitlement-offer-immp-20190806monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-granted-european-patent-for-eftilagimod-alpha-in-cancer-immp-20190821monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-japanese-patent-grant-for-lag525-antibody-immp-20190916monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-receive-4m-milestone-payment-from-gsk-immp-20190922monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-expansion-of-part-a-of-tacti-002-phase-ii-clinical-trial-due-to-positive-immp-20190925monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-data-presentations-at-upcoming-industry-conferences-immp-20191009monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-receives-a-2-5-million-r-d-tax-incentive-from-french-government-immp-20191009monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-reports-positive-final-efficacy-data-from-tacti-mel-trial-in-melanoma-immp-20191014monthly0.5https://www.biopharmawatch.com/news/IMMP/operational-update-immp-20191028monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-presents-positive-interim-data-from-phase-ii-tacti-002-trial-at-sitc-immp-20191107monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-european-patent-grant-for-lag525-antibody-immp-20191113monthly0.5https://www.biopharmawatch.com/news/IMMP/insight-004-clinical-trial-update-immp-20191218monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-expands-part-c-of-tacti-002-due-to-positive-data-immp-20200108monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-activities-report-immp-20200129monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-present-tacti-002-interim-data-at-german-cancer-congress-immp-20200204monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-reports-positive-tacti-002-data-immp-20200218monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-receives-second-ind-approval-for-efti-from-us-fda-immp-20200308monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-s-partner-eoc-pharma-reports-completion-of-recruitment-of-phase-i-study-of-efti-immp-20200318monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-reports-supportive-efficacy-data-from-the-phase-iib-aipac-study-overall-survival-d-immp-20200324monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-s-partner-eoc-pharma-continues-to-advance-efti-in-breast-cancer-immp-20200408monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-advances-cell-line-development-for-imp761-immp-20200414monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-tacti-002-data-presentation-at-the-aacr-virtual-annual-meeting-2020-immp-20200414monthly0.5https://www.biopharmawatch.com/news/IMMP/enrollment-completed-for-the-insight-004-study-immp-20200420monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-quarterly-activities-report-immp-20200420monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-reports-positive-phase-ii-tacti-002-data-immp-20200428monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-first-insight-004-data-and-new-tacti-002-data-to-be-included-in-poster-p-immp-20200429monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-granted-japanese-patent-for-eftilagimod-alpha-in-chemo-immunotherapy-combination-immp-20200506monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-global-webcast-to-present-new-data-from-2020-asco-annual-meeting-immp-20200525monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-receives-us-2-4-million-r-d-tax-incentive-from-french-government-immp-20200527monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-improving-data-from-the-phase-ii-tacti-002-study-immp-20200530monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-reports-first-results-from-insight-004-study-immp-20200530monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-receives-a-1-437-826-r-d-tax-incentive-immp-20200621monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-completes-recruitment-for-part-a-of-phase-ii-tacti-002-study-immp-20200628monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-united-states-patent-grant-for-imp701-antibody-immp-20200713monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-quarterly-activities-report-immp-20200722monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-granted-united-states-patent-for-eftilagimod-alpha-in-chemo-immunotherapy-combinat-immp-20200811monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-completes-recruitment-for-stage-1-of-part-b-in-tacti-002-study-immp-20200817monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-issues-newsletter-update-to-shareholders-immp-20200817monthly0.5https://www.biopharmawatch.com/news/IMMP/new-data-from-immutep-s-efti-to-be-presented-at-esmo-immp-20200825monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-and-monash-university-receive-grant-funding-for-lag-3-project-immp-20200830monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-improving-results-from-stage-i-of-phase-ii-tacti-002-study-immp-20200916monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-reports-improving-results-from-insight-004-trial-immp-20200916monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-present-aipac-overall-survival-data-at-the-san-antonio-breast-cancer-symposium--immp-20201018monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-granted-european-patent-for-imp761-immp-20201021monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-activities-report-for-the-first-quarter-of-fiscal-year-2021-immp-20201021monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-the-start-of-an-investigator-initiated-phase-ii-study-in-covid-19-patien-immp-20201022monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-collaborate-with-labcorp-to-develop-oncology-services-and-products-immp-20201029monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-s-tacti-002-data-to-be-presented-at-society-for-immunotherapy-of-cancer-2020-annua-immp-20201101monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-s-phase-ii-tacti-002-study-reports-encouraging-data-at-sitc-immp-20201108monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-australian-patent-grant-for-imp701-antibody-immp-20201108monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-expansion-of-tacti-002-collaboration-trial-immp-20201117monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-completes-a-a-29-6-million-placement-to-accelerate-and-broaden-its-clinical-develo-immp-20201117monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-s-chinese-partner-eoc-pharma-to-start-phase-ii-metastatic-breast-cancer-study-immp-20201208monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-reports-statistically-significant-survival-benefit-for-key-patient-groups-in-the-o-immp-20201208monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-operational-update-immp-20201215monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-upscales-efti-manufacturing-immp-20201216monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-secures-united-states-patent-for-eftilagimod-alpha-in-combination-with-a-pd-1-path-immp-20201228monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-completes-recruitment-of-head-and-neck-cancer-patients-of-phase-ii-tacti-002-study-immp-20210105monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-quarterly-activities-report-immp-20210121monthly0.5https://www.biopharmawatch.com/news/IMMP/ulcerative-colitis-phase-ii-study-of-gsk2831781-discontinued-immp-20210121monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-advancement-of-phase-ii-trial-for-eftilagimod-alpha-in-covid-19-patients-immp-20210126monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-expands-part-b-of-tacti-002-study-immp-20210305monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-secures-second-united-states-patent-grant-for-eftilagimod-alpha-in-combination-wit-immp-20210309monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-enters-second-collaboration-with-msd-for-a-new-randomised-phase-iib-trial-in-head--immp-20210316monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-participate-in-a-fireside-chat-at-the-inaugural-m-vest-and-maxim-group-emerging-immp-20210317monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-european-patent-grant-for-lag525-antibody-in-combination-therapy-immp-20210406monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-achieves-fast-track-designation-from-us-fda-for-efti-a-soluble-lag-3-protein-in-fi-immp-20210407monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-receives-a-1-155-055-r-d-tax-incentive-immp-20210416monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-quarterly-activities-report-immp-20210418monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-announce-new-tacti-002-and-insight-004-data-in-poster-presentations-and-discuss-immp-20210427monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-operational-update-immp-20210506monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-publication-of-tacti-002-and-insight-004-abstracts-for-asco-2021-annual--immp-20210520monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-present-at-the-jefferies-virtual-healthcare-conference-immp-20210524monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-granted-chinese-patent-for-eftilagimod-alpha-in-chemo-immunotherapy-combination-immp-20210526monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-enters-into-a-new-collaboration-with-merck-kgaa-darmstadt-germany-for-lag-3-therap-immp-20210531monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-secures-second-european-patent-for-eftilagimod-alpha-a-soluble-lag-3-protein-in-co-immp-20210602monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-reports-positive-data-from-its-tacti-002-phase-ii-study-of-lag-3-therapy-efti-at-a-immp-20210604monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-reports-positive-final-data-from-the-insight-004-phase-i-study-of-lag-3-therapy-ef-immp-20210604monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-reveals-a-new-anti-lag-3-research-program-immp-20210607monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-completes-a-a-60-million-placement-to-expand-its-clinical-development-and-manufact-immp-20210621monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-evaluate-efti-in-triple-combination-therapy-phase-i-study-with-chemotherapy-and-immp-20210621monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-receives-fda-and-irb-approval-in-the-us-for-phase-iib-tacti-003-trial-in-hnscc-immp-20210705monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-quarterly-activities-report-immp-20210713monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-reports-dosing-of-first-patient-for-triple-combination-efti-anti-pd-1-chemo-in-ins-immp-20210804monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-chinese-patent-grant-for-lag-3-antagonist-antibody-lag525-immp-20210826monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-s-chinese-partner-eoc-pharma-expands-efti-trial-pipeline-immp-20210830monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-completes-recruitment-of-2nd-line-pd-1-pd-l1-refractory-nsclc-patients-in-tacti-00-immp-20210901monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-present-final-overall-survival-data-from-phase-iib-aipac-as-a-late-breaking-pos-immp-20210920monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-receives-a-3-4-million-r-d-tax-incentive-from-french-government-immp-20210928monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-present-at-healthcare-investor-conferences-immp-20210928monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-present-phase-ii-tacti-002-data-at-sitc-2021-immp-20210930monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-quarterly-activities-report-immp-20211027monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-receives-positive-ema-scientific-advice-for-further-clinical-development-of-efti-i-immp-20211028monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-granted-chinese-patent-for-eftilagimod-alpha-a-soluble-lag-3-protein-in-combinatio-immp-20211102monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-reports-improved-and-statistically-significant-survival-benefit-for-three-key-pati-immp-20211108monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-publication-of-aipac-tacti-002-and-tacti-003-abstracts-for-sitc-2021-ann-immp-20211108monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-publishes-aipac-tacti-002-and-tacti-003-trial-posters-at-sitc-with-positive-new-da-immp-20211114monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-granted-chinese-patent-for-eftilagimod-alpha-a-soluble-lag-3-fusion-protein-in-com-immp-20211114monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-successfully-completes-recruitment-for-phase-ii-tacti-002-study-of-lag-3-therapy-e-immp-20211119monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-reports-good-safety-from-first-five-patients-in-triple-combination-therapy-efti-st-immp-20211201monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-advances-imp761-manufacturing-immp-20211215monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-quarterly-activities-report-immp-20220124monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-present-at-february-investor-conferences-immp-20220131monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-granted-australian-patent-for-eftilagimod-alpha-a-soluble-lag-3-protein-in-combina-immp-20220211monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-present-new-data-from-the-phase-ii-tacti-002-study-of-efti-at-esmo-s-european-l-immp-20220217monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-present-at-healthcare-investor-conferences-immp-20220223monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-appoints-lucy-turnbull-as-non-executive-director-immp-20220224monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-receives-constructive-feedback-from-us-fda-on-its-clinical-development-program-for-immp-20220309monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-present-biomarker-and-multivariate-analysis-from-phase-iib-aipac-study-in-metas-immp-20220318monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-second-japanese-patent-grant-for-lag-3-antagonist-antibody-lag525-immp-20220318monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-publication-of-tacti-002-abstract-at-esmo-s-european-lung-cancer-congres-immp-20220323monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-s-efti-in-combination-with-msd-s-pembrolizumab-shows-encouraging-antitumor-activit-immp-20220329monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-announce-new-tacti-002-data-in-an-oral-presentation-at-the-asco-2022-annual-mee-immp-20220427monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-quarterly-activities-report-immp-20220428monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-presents-new-and-significant-data-from-the-aipac-study-immp-20220504monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-publication-of-tacti-002-and-tacti-003-abstracts-at-asco-2022-immp-20220527monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-global-webcast-to-discuss-tacti-002-data-presented-at-asco-2022-immp-20220601monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-reports-positive-overall-response-rate-in-its-phase-ii-clinical-trial-in-1st-line--immp-20220603monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-announce-new-tacti-002-data-at-the-2022-world-conference-on-lung-cancer-immp-20220626monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-granted-japanese-patent-for-imp761-a-first-in-class-immunosuppressive-antibody-tar-immp-20220705monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-quarterly-activities-report-immp-20220728monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-reports-new-positive-interim-data-from-its-phase-ii-study-of-lag-3-candidate-eftil-immp-20220731monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-granted-japanese-patent-for-eftilagimod-alpha-a-soluble-lag-3-protein-in-combinati-immp-20220829monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-investigator-initiated-phase-ii-trial-evaluating-lag-3-candidate-eftilag-immp-20220905monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-appoints-lag-3-pioneer-dr-fre-de-ric-triebel-to-board-immp-20220912monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-clinical-development-update-for-its-first-in-class-lag-3-antigen-presenting-cell-a-immp-20220913monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-receives-a-2-7-million-r-d-tax-incentive-from-french-government-immp-20220922monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-participate-in-two-upcoming-investor-conferences-immp-20220926monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-receives-fda-fast-track-designation-for-lag-3-therapeutic-eftilagimod-alpha-for-fi-immp-20221003monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-abstracts-accepted-for-presentation-at-the-society-for-immunotherapy-of--immp-20221004monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-independent-data-monitoring-committee-positive-recommendation-to-continu-immp-20221025monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-quarterly-activities-report-immp-20221025monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-late-breaking-abstract-accepted-for-oral-presentation-on-first-in-class-lag-3-ther-immp-20221101monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-participate-in-two-upcoming-investor-conferences-immp-20221102monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-abstract-highlighting-eftilagimod-alpha-selected-for-sitc-2022-annual-me-immp-20221103monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-compelling-clinical-results-from-phase-ii-trial-utilizing-its-first-in-c-immp-20221109monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-promising-initial-clinical-data-from-insight-003-at-sitc-2022-immp-20221109monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-granted-new-patents-in-japan-and-south-korea-for-first-in-class-lag-3-candidate-ef-immp-20221109monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-receives-australian-r-d-tax-incentive-immp-20221113monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-participate-in-the-jmp-securities-hematology-and-oncology-summit-immp-20221201monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-gmp-manufacturing-process-developed-for-imp761-a-first-in-class-lag-3-ag-immp-20221205monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-successfully-achieves-commercial-scale-in-manufacturing-of-eftilagimod-alpha-immp-20221207monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-successful-meeting-with-the-fda-on-eftilagimod-alpha-plus-chemotherapy-f-immp-20221222monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-achieves-50-enrollment-milestone-in-randomised-phase-iib-tacti-003-trial-for-first-immp-20230103monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-quarterly-activities-report-immp-20230129monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-reaches-enrolment-target-for-insight-003-trial-in-1st-line-nsclc-immp-20230206monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-initiation-of-phase-ii-iii-trial-for-eftilagimod-alpha-plus-paclitaxel-i-immp-20230313monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-abstract-accepted-for-mini-oral-presentation-at-esmo-s-european-lung-can-immp-20230322monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-expansion-of-triple-combination-therapy-in-1st-line-non-small-cell-lung--immp-20230330monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-positive-final-data-in-2nd-line-metastatic-nsclc-patients-refractory-to--immp-20230331monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-changes-to-the-board-immp-20230411monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-initiation-of-investigator-initiated-phase-ii-trial-in-soft-tissue-sarco-immp-20230416monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-quarterly-activities-report-immp-20230426monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-presentation-of-new-tacti-002-data-at-the-2023-asco-annual-meeting-immp-20230426monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-appoints-dr-florian-vogl-as-chief-medical-officer-immp-20230426monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-receives-approval-to-initiate-insight-005-trial-evaluating-eftilagimod-alpha-and-a-immp-20230430monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-kol-event-focused-on-eftilagimod-alpha-in-non-small-cell-lung-cancer-and-immp-20230502monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-participate-in-the-jmp-securities-life-sciences-conference-immp-20230509monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-receives-positive-feedback-from-fda-on-late-stage-clinical-development-of-eftilagi-immp-20230515monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-s-efti-in-combination-with-pembrolizumab-achieves-excellent-initial-overall-surviv-immp-20230516monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-doses-first-patient-in-aipac-003-phase-ii-iii-trial-for-metastatic-breast-cancer-immp-20230524monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-promising-new-clinical-data-from-triple-combination-therapy-in-insight-0-immp-20230524monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-publication-of-abstracts-for-asco-2023-annual-meeting-immp-20230525monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-selects-charles-river-laboratories-for-imp761-s-glp-toxicology-study-immp-20230529monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-successfully-completes-institutional-placement-and-institutional-component-of-its--immp-20230602monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-reports-final-positive-data-in-2nd-line-head-and-neck-squamous-cell-carcinoma-at-a-immp-20230605monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-participate-at-the-jefferies-healthcare-conference-immp-20230607monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-granted-united-states-patent-for-imp761-a-first-in-class-agonist-antibody-targetin-immp-20230620monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-secures-third-united-states-patent-for-eftilagimod-alpha-in-combination-with-a-pd--immp-20230627monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-completes-a-80-million-capital-raise-immp-20230627monthly0.5https://www.biopharmawatch.com/news/IMMP/first-patient-dosed-in-chemotherapy-free-triple-combination-phase-ii-trial-targeting-soft--immp-20230728monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-present-overall-survival-data-in-1st-line-non-small-cell-lung-cancer-accepted-f-immp-20230731monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-quarterly-activities-report-q4-fy23-immp-20230731monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-receives-positive-scientific-advice-from-european-medicines-agency-immp-20230801monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-participate-in-september-investor-conferences-immp-20230905monthly0.5https://www.biopharmawatch.com/news/IMMP/commercial-manufacturing-of-eftilagimod-alpha-at-2000l-scale-granted-authorization-for-cli-immp-20230920monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-abstract-accepted-for-presentation-at-the-society-for-immunotherapy-of-c-immp-20231002monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-publication-of-abstracts-at-esmo-congress-2023-immp-20231015monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-s-efti-in-combination-with-keytruda-generates-excellent-overall-survival-benefit-i-immp-20231022monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-reports-promising-clinical-data-from-insight-003-trial-at-esmo-congress-2023-immp-20231024monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-receives-a-1-13-million-r-d-tax-incentive-immp-20231025monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-quarterly-activities-report-q1-fy24-immp-20231030monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-participate-in-november-investor-events-immp-20231101monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-new-biomarker-data-from-tacti-002-phase-ii-in-first-line-non-small-cell--immp-20231102monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-completion-of-the-safety-lead-in-and-opening-of-the-randomized-phase-ii--immp-20231106monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-completes-enrollment-in-tacti-003-phase-iib-trial-of-efti-and-keytruda-in-first-li-immp-20231109monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-site-expansion-for-insight-003-phase-i-trial-immp-20231122monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-receives-a-2-6-million-r-d-tax-incentive-from-french-government-immp-20231207monthly0.5https://www.biopharmawatch.com/news/IMMP/first-patient-dosed-in-trial-evaluating-efti-and-the-anti-pd-l1-therapy-bavencio-in-metast-immp-20240104monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-quarterly-activities-report-q2-fy24-immp-20240130monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-receives-positive-feedback-from-the-spanish-medicines-agency-for-upcoming-tacti-00-immp-20240417monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-appoints-leading-research-institute-to-conduct-first-in-human-phase-i-study-of-imp-immp-20240418monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-quarterly-activities-report-q3-fy24-immp-20240428monthly0.5https://www.biopharmawatch.com/news/IMMP/positive-initial-clinical-data-reported-from-immutep-s-efti-combined-with-radiotherapy-and-immp-20240502monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-successfully-completes-institutional-placement-and-institutional-component-of-enti-immp-20240605monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-signs-exclusive-license-agreement-with-cardiff-university-for-next-generation-anti-immp-20240624monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-receives-regulatory-clearance-for-phase-i-study-of-first-in-class-lag-3-agonist-an-immp-20240717monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-successful-meeting-with-fda-on-phase-iii-design-in-non-small-cell-lung-c-immp-20240721monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-quarterly-activities-report-q4-fy24-immp-20240731monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-participate-in-upcoming-investor-conferences-immp-20240807monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-first-participant-dosed-in-phase-i-study-of-imp761-a-first-in-class-agon-immp-20240814monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-late-breaking-abstract-in-head-neck-cancer-selected-for-oral-presentatio-immp-20240820monthly0.5https://www.biopharmawatch.com/news/IMMP/new-data-to-be-presented-from-eftisarc-neo-phase-ii-evaluating-novel-triple-combination-in-immp-20240917monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-receives-a-3-6-million-r-d-tax-incentive-from-french-government-immp-20240924monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-participate-in-the-2024-maxim-healthcare-virtual-summit-immp-20241010monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-first-in-human-phase-i-study-of-imp761-progresses-to-dose-escalation-por-immp-20241017monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-quarterly-activities-report-q1-fy25-immp-20241028monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-present-new-phase-iib-data-in-pd-l1-negative-cps-1-head-and-neck-cancer-at-esmo-immp-20241028monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-and-monash-university-announce-first-publication-detailing-how-human-lag-3-binds-t-immp-20241215monthly0.5https://www.biopharmawatch.com/news/IMMP/patient-enrolment-completed-for-insight-003-immp-20250106monthly0.5https://www.biopharmawatch.com/news/IMMP/patient-enrolment-completed-for-eftisarc-neo-phase-ii-trial-immp-20250121monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-quarterly-activities-report-q2-fy25-immp-20250130monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-present-pivotal-tacti-004-trial-in-progress-poster-at-the-european-lung-cancer--immp-20250319monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-quarterly-activities-report-q3-fy25-immp-20250429monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-announces-abstracts-accepted-for-presentation-at-the-european-society-for-medical--immp-20250728monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-to-present-pivotal-tacti-004-trial-in-progress-poster-at-the-2025-world-conference-immp-20250729monthly0.5https://www.biopharmawatch.com/news/IMMP/immutep-quarterly-activities-report-q4-fy25-immp-20250730monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-management-announces-pricing-of-upsized-initial-public-offering-cgem-20210108monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-management-announces-closing-of-initial-public-offering-and-full-exercise-of-unde-cgem-20210112monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-to-provide-cln-081-clinical-update-at-asco-2021-cgem-20210519monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-announces-management-transition-cgem-20210521monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-receives-investigational-new-drug-ind-clearance-from-the-fda-for-cln-049-cgem-20210607monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-receives-fda-clearance-of-investigational-new-drug-ind-application-for-c-cgem-20210629monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-to-present-data-demonstrating-breadth-and-progress-of-its-immuno-oncolog-cgem-20220308monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-to-present-updated-data-demonstrating-the-therapeutic-potential-of-cln-0-cgem-20220531monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-and-taiho-pharmaceutical-complete-agreement-for-strategic-collaboration--cgem-20220623monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-announces-the-appointment-of-david-p-ryan-m-d-to-its-board-of-directors-cgem-20221102monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-to-present-new-preclinical-data-for-cln-619-and-cln-617-at-the-2023-amer-cgem-20230314monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-oncology-to-present-first-clinical-data-evaluating-novel-anti-mica-b-antibody-cln-cgem-20230426monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-receives-approval-from-european-medicines-agency-to-initiate-phase-1-cgem-20250416monthly0.5https://www.biopharmawatch.com/news/CGEM/taiho-oncology-and-cullinan-therapeutics-announce-acceptance-of-abstracts-for-zipalertinib-cgem-20250722monthly0.5https://www.biopharmawatch.com/news/CGEM/taiho-oncology-and-cullinan-therapeutics-present-data-on-zipalertinib-at-the-iaslc-2025-wo-cgem-20250909monthly0.5https://www.biopharmawatch.com/news/CGEM/taiho-oncology-and-cullinan-therapeutics-present-data-on-zipalertinib-in-patients-with-nsc-cgem-20251012monthly0.5https://www.biopharmawatch.com/news/CGEM/taiho-oncology-taiho-pharmaceutical-and-cullinan-therapeutics-initiate-rolling-submission--cgem-20251120monthly0.5https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-provides-corporate-update-and-highlights-anticipated-2026-milestones-cgem-20260108monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-closes-120-million-financing-to-advance-targeted-protein-modulation-dru-nrix-20200312monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-addition-of-immuno-oncology-clinical-experts-to-its-managemen-nrix-20200616monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-pricing-of-209-million-initial-public-offering-nrix-20200723monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-present-at-3rd-annual-targeted-protein-degradation-summit-nrix-20201006monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-expansion-of-its-strategic-collaboration-with-sanofi-to-devel-nrix-20210107monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-pricing-of-upsized-public-offering-of-common-stock-nrix-20210305monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-presentation-of-nx-1607-preclinical-data-at-aacr-nrix-20210310monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-upcoming-presentation-of-nx-5948-preclinical-data-at-the-eula-nrix-20210521monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-regulatory-clearance-to-initiate-phase-1-clinical-trial-of-nx-nrix-20211212monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-advances-clinical-and-preclinical-pipeline-and-outlines-2022-catalysts-nrix-20220110monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-present-preclinical-data-from-its-novel-btk-degrader-nx-2127-and-cbl-nrix-20220308monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-detil-0255-a-drug-enha-nrix-20220405monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-presents-new-preclinical-data-supporting-nx-2127-and-detil-0255-clinica-nrix-20220408monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-initiation-of-phase-1b-expansion-cohorts-in-ongoing-phase-1-t-nrix-20220526monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-will-present-trial-in-progress-posters-for-three-clinical-programs-at-t-nrix-20220603monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-40-million-registered-direct-offering-nrix-20220708monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-six-poster-presentations-at-the-upcoming-society-for-immunoth-nrix-20221005monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-reports-case-study-of-patient-with-aggressive-non-hodgkin-s-lymphoma-nh-nrix-20221026monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-presentations-at-the-64th-american-society-of-hematology-ash--nrix-20221103monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-present-at-41st-annual-j-p-morgan-healthcare-conference-nrix-20230104monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-advances-promising-targeted-protein-modulation-pipeline-and-outlines-20-nrix-20230109monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-presentations-at-the-american-association-for-cancer-research-nrix-20230314monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-presents-data-at-the-american-association-for-cancer-research-aacr-annu-nrix-20230417monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-presentations-at-the-65th-american-society-of-hematology-ash--nrix-20231102monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-webcast-to-review-data-from-its-phase-1-clinical-trials-of-bt-nrix-20231204monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-presents-positive-clinical-data-from-its-novel-bruton-s-tyrosine-kinase-nrix-20231211monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-outlines-2024-strategic-priorities-with-advancement-of-targeted-protein-nrix-20240108monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-reports-fourth-quarter-and-fiscal-year-2023-financial-results-and-provi-nrix-20240215monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-u-s-fda-lifts-partial-clinical-hold-on-nx-2127-phase-1-trial-nrix-20240311monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-extension-of-strategic-collaboration-with-gilead-sciences-nrix-20240402monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-extension-of-strategic-collaboration-with-sanofi-to-develop-n-nrix-20240409monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-host-a-webcast-and-conference-call-to-discuss-data-from-the-ongoing--nrix-20240610monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-presentations-at-discovery-on-target-conference-nrix-20240930monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-reports-third-quarter-fiscal-2024-financial-results-and-provides-a-corp-nrix-20241011monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-appoints-anil-kapur-to-its-board-of-directors-nrix-20241016monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-presents-preclinical-data-from-two-autoimmune-and-inflammatory-disease--nrix-20241117monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-webcast-to-review-new-data-from-its-phase-1-clinical-trial-of-nrix-20241202monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-receives-u-s-fda-fast-track-designation-for-nx-5948-for-the-treatment-o-nrix-20241219monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference-nrix-20250106monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-outlines-2025-goals-and-objectives-for-advancement-of-its-robust-pipeli-nrix-20250113monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences--nrix-20250204monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-nrix-20250304monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-multiple-presentations-at-the-american-association-for-cancer-nrix-20250325monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-licenses-a-drug-discovery-program-to-sanofi-targeting-a-novel-transcription-factor-f-nrix-20250402monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-reports-first-quarter-2025-financial-results-and-provides-a-corporate-u-nrix-20250408monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-presents-positive-preclinical-data-at-the-aacr-2025-annual-meeting-from-nrix-20250425monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-presents-data-at-the-aacr-2025-annual-meeting-highlighting-the-transfor-nrix-20250428monthly0.5https://www.biopharmawatch.com/news/NRIX/sanofi-exercises-license-extension-option-to-nurix-s-stat6-program-nrix-20250602monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-presents-updated-positive-data-demonstrating-durable-deepening-response-nrix-20250612monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-reports-second-quarter-2025-financial-results-and-provides-a-corporate--nrix-20250709monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-presents-new-data-demonstrating-durable-deepening-responses-in-phase-1--nrix-20251206monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-reports-first-quarter-2026-financial-results-and-provides-a-corporate-u-nrix-20260408monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-new-preclinical-data-highlighting-breadth-of-targeted-protein-nrix-20260422monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-nrix-20260513monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-presents-new-preclinical-and-phase-1-translational-data-supporting-bexo-nrix-20260514monthly0.5https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-announces-global-collaboration-with-roche-to-co-develop-and-co-commerci-nrix-20260608monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-125-million-underwritten-offering-imtx-20251205monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-third-quarter-2025-financial-results-and-business-update-imtx-20251117monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-first-quarter-2025-financial-results-and-business-update-imtx-20250513monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-full-year-2024-financial-results-and-business-update-imtx-20250327monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-third-quarter-2024-financial-results-business-update-and-first-clinical-imtx-20241118monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-multiple-presentations-at-the-39th-annual-meeting-of-the-society-for-im-imtx-20241108monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-pricing-of-150-million-public-offering-imtx-20241011monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-proposed-150-million-public-offering-imtx-20241010monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-upcoming-oral-and-poster-presentations-at-the-society-for-immunotherapy-imtx-20241004monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-upcoming-oral-presentation-at-the-society-for-melanoma-research-congres-imtx-20240906monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-second-quarter-2024-financial-results-and-business-update-imtx-20240813monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-appoints-alise-reicin-to-board-of-directors-imtx-20240731monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-upcoming-oral-presentation-at-esmo-congress-2024-imtx-20240718monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-first-quarter-2024-financial-results-and-business-update-imtx-20240514monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-pricing-of-175-million-public-offering-imtx-20240117monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-proposed-public-offering-imtx-20240117monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-third-quarter-2023-financial-results-and-business-update-imtx-20231114monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-second-quarter-2023-financial-results-and-business-update-imtx-20230817monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-35-million-equity-investment-from-bristol-myers-squibb-imtx-20230724monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-first-quarter-2023-financial-results-and-business-update-imtx-20230516monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-third-quarter-2022-financial-results-and-business-update-imtx-20221117monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-110-million-underwritten-offering-of-ordinary-shares-imtx-20221010monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-second-quarter-2022-financial-results-and-business-update-imtx-20220809monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-first-quarter-2022-financial-results-and-business-update-imtx-20220602monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-full-year-2021-financial-results-and-corporate-update-imtx-20220323monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-third-quarter-2021-financial-results-and-provides-business-update-imtx-20211116monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-reports-clinical-responses-across-multiple-solid-tumor-types-in-ongoing-actengine-imtx-20211109monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-second-quarter-2021-financial-results-and-provides-business-update-imtx-20210810monthly0.5https://www.biopharmawatch.com/news/IMTX/biocopy-ag-and-immatics-enter-into-a-collaboration-to-characterize-t-cell-receptor-peptide-imtx-20210707monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-changes-to-its-board-of-directors-imtx-20210526monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-first-quarter-2021-financial-results-and-business-update-imtx-20210518monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-full-year-2020-financial-results-and-corporate-update-imtx-20210330monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-third-quarter-2020-financial-results-and-business-update-imtx-20201202monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-presents-phase-i-data-from-actolog-multi-target-pilot-study-ima101-at-the-35th-an-imtx-20201110monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-presents-preclinical-proof-of-concept-data-for-tcr-bispecifics-program-ima401-tar-imtx-20201029monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-appoints-arnd-christ-as-chief-financial-officer-imtx-20200929monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-appoints-biotech-executive-eliot-forster-to-board-of-directors-imtx-20200915monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-second-quarter-2020-financial-results-and-business-update-imtx-20200903monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-european-clinical-expansion-of-its-adoptive-cell-therapy-programs-imtx-20200818monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-extends-cell-therapy-manufacturing-collaboration-with-uthealth-imtx-20200806monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-board-of-directors-additions-following-public-listing-on-nasdaq-imtx-20200709monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-completion-of-business-combination-and-listing-on-nasdaq-imtx-20200702monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-and-gsk-partner-to-develop-novel-adoptive-cell-therapies-imtx-20200220monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-and-celgene-enter-strategic-collaboration-to-develop-novel-adoptive-cell-therapie-imtx-20190828monthly0.5https://www.biopharmawatch.com/news/IMTX/genmab-enters-strategic-partnership-with-immatics-to-discover-and-develop-next-generation--imtx-20180712monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-receives-58-million-in-financing-to-develop-t-cell-receptor-based-immunotherapies-imtx-20171004monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-initiates-personalized-adoptive-cellular-therapy-in-patients-with-relapsed-and-or-imtx-20170821monthly0.5https://www.biopharmawatch.com/news/IMTX/amgen-and-immatics-enter-strategic-collaboration-to-develop-novel-bispecific-cancer-immuno-imtx-20170109monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-and-md-anderson-announce-launch-of-immatics-us-inc-to-develop-multiple-t-cell-and-imtx-20150826monthly0.5https://www.biopharmawatch.com/news/IMTX/eu-funded-consortium-led-by-immatics-and-biontech-to-advance-a-novel-class-of-fully-person-imtx-20141014monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-receives-eur-22-million-final-tranche-of-series-d-fundraising-imtx-20140716monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-and-roche-sign-cancer-vaccine-and-immunotherapy-collaboration-imtx-20131113monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-closes-eur-34-million-financing-to-complete-phase-3-development-of-ima901-for-ren-imtx-20131015monthly0.5https://www.biopharmawatch.com/news/IMTX/new-eu-funded-consortium-to-develop-fully-personalized-cancer-vaccines-for-brain-cancer-pa-imtx-20130704monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-appoints-peter-chambre-as-chairman-imtx-20121112monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-renal-cancer-vaccine-ima901-completes-phase-3-patient-recruitment-and-is-granted--imtx-20121108monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-announces-publication-of-ima901-cancer-vaccine-data-in-nature-medicine-immune-res-imtx-20120729monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-wins-2012-tie50-award-imtx-20120525monthly0.5https://www.biopharmawatch.com/news/IMTX/first-patients-are-vaccinated-in-imprint-immatics-pivotal-phase-iii-trial-with-ima901-in-p-imtx-20110615monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-to-receive-support-from-pfizer-for-its-pivotal-phase-iii-study-imprint-with-ima90-imtx-20110411monthly0.5https://www.biopharmawatch.com/news/IMTX/immatics-raises-eur-54-million-to-advance-its-late-stage-clinical-therapeutic-cancer-vacci-imtx-20100921monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-announces-new-employment-inducement-grants-fdmt-20260612monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-to-participate-in-upcoming-investor-conferences-fdmt-20260527monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-announces-new-employment-inducement-grants-fdmt-20260515monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-announces-new-employment-inducement-grants-fdmt-20260417monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-to-participate-in-upcoming-investor-conferences-fdmt-20260219monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-announces-new-employment-inducement-grants-fdmt-20260213monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-announces-new-employment-inducement-grants-fdmt-20251212monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-announces-new-employment-inducement-grants-fdmt-20250912monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-to-participate-in-upcoming-investor-conferences-fdmt-20250825monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-announces-new-employment-inducement-grants-fdmt-20250815monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-reports-second-quarter-2025-financial-results-operational-highlights-and-expected-upc-fdmt-20250811monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-to-participate-in-the-h-c-wainwright-5th-annual-ophthalmology-virtual-conference-fdmt-20250806monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-presents-positive-60-week-results-from-4d-150-spectra-clinical-trial-in-dme-and-regul-fdmt-20250731monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-announces-presentations-at-43rd-annual-scientific-meeting-of-the-american-society-of--fdmt-20250724monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-announces-new-employment-inducement-grants-fdmt-20250711monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-announces-accelerated-4d-150-phase-3-development-in-wet-amd-and-streamlined-organizat-fdmt-20250702monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-to-participate-in-upcoming-investor-conferences-fdmt-20250528monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-announces-new-employment-inducement-grants-fdmt-20250516monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-reports-first-quarter-2025-financial-results-operational-highlights-and-expected-upco-fdmt-20250508monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-to-participate-in-upcoming-investor-conferences-fdmt-20250505monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-announces-rmat-designation-granted-by-fda-for-4d-150-for-dme-fdmt-20250501monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-announces-new-employment-inducement-grants-fdmt-20250411monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-to-participate-in-upcoming-investor-conferences-fdmt-20250327monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-announces-first-patients-enrolled-in-4front-1-phase-3-clinical-trial-evaluating-4d-15-fdmt-20250310monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-reports-full-year-2024-financial-results-operational-highlights-and-expected-upcoming-fdmt-20250228monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-to-participate-in-upcoming-investor-conferences-fdmt-20250219monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-presents-positive-52-week-results-from-phase-2b-cohort-of-prism-wet-amd-study-and-lon-fdmt-20250208monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-announces-corporate-webcast-to-review-interim-52-week-results-from-the-phase-2b-cohor-fdmt-20250129monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-announces-positive-interim-data-from-4d-150-spectra-clinical-trial-in-dme-and-alignme-fdmt-20250110monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-focuses-pipeline-to-prioritize-4d-150-in-wet-amd-dme-and-4d-710-in-cf-and-extends-cas-fdmt-20250110monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-announces-landmark-publication-of-4d-150-preclinical-data-for-the-treatment-of-neovas-fdmt-20241216monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-to-participate-in-upcoming-investor-conferences-and-ophthalmology-innovation-summit-x-fdmt-20241114monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-reports-third-quarter-2024-financial-results-operational-highlights-and-expected-upco-fdmt-20241113monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-announces-presentation-at-the-2024-north-american-cystic-fibrosis-conference-fdmt-20240923monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-highlights-robust-and-durable-clinical-activity-for-4d-150-and-design-of-4front-phase-fdmt-20240918monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-announces-presentations-at-upcoming-retina-conferences-fdmt-20240905monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-to-participate-in-the-2024-cantor-global-healthcare-conference-fdmt-20240903monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-to-host-4d-150-wet-amd-development-day-on-september-18-2024-fdmt-20240827monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-to-participate-in-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference-fdmt-20240812monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-reports-second-quarter-2024-financial-results-and-operational-highlights-fdmt-20240808monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-advances-leadership-in-large-market-ophthalmology-with-senior-management-hires-and-fo-fdmt-20240805monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-announces-positive-phase-2-prism-interim-results-for-intravitreal-4d-150-in-a-broad-w-fdmt-20240717monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-announces-fda-clearance-of-ind-application-for-4d-175-genetic-medicine-for-the-treatm-fdmt-20240624monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-to-present-initial-interim-24-week-landmark-analysis-from-the-4d-150-phase-2-prism-po-fdmt-20240618monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-presents-injection-free-subgroup-analyses-from-4d-150-phase-2-prism-randomized-dose-e-fdmt-20240608monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-presents-positive-interim-data-from-phase-1-2-aerow-clinical-trial-of-aerosolized-4d--fdmt-20240606monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-announces-presentations-at-clinical-trials-at-the-summit-2024-meeting-fdmt-20240604monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-to-participate-in-upcoming-investor-conferences-fdmt-20240603monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-to-present-interim-data-from-aerosolized-4d-710-phase-1-2-aerow-clinical-trial-for-cy-fdmt-20240530monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-reports-first-quarter-2024-financial-results-and-operational-highlights-fdmt-20240509monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-to-participate-in-upcoming-investor-conference-fdmt-20240507monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-announces-presentations-at-arvo-2024-annual-meeting-fdmt-20240501monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-announces-update-on-regulatory-interactions-and-development-path-for-4d-710-for-treat-fdmt-20240328monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-to-participate-in-upcoming-investor-conferences-fdmt-20240304monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-reports-full-year-2023-financial-results-and-operational-highlights-fdmt-20240229monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-presents-interim-data-from-4d-310-inglaxa-phase-1-2-clinical-trials-for-fabry-disease-fdmt-20240212monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-announces-pricing-of-upsized-public-offering-of-common-stock-fdmt-20240207monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-announces-proposed-public-offering-of-common-stock-fdmt-20240205monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-presents-positive-interim-data-from-randomized-phase-2-prism-clinical-trial-of-intrav-fdmt-20240203monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-to-host-corporate-webcast-to-discuss-interim-data-from-phase-2-prism-clinical-trial-o-fdmt-20240129monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-receives-rare-pediatric-disease-designation-from-fda-for-aerosolized-4d-710-for-treat-fdmt-20240123monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-highlights-recent-clinical-pipeline-progress-near-term-milestones-and-organizational--fdmt-20240104monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-and-arbor-biotechnologies-establish-partnership-to-co-develop-and-co-commercialize-ne-fdmt-20240103monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-4d-150-genet-fdmt-20231221monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-to-present-interim-24-week-data-from-randomized-phase-2-prism-clinical-trial-of-4d-15-fdmt-20231204monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-to-participate-in-upcoming-investor-conferences-fdmt-20231115monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-reports-third-quarter-2023-financial-results-and-operational-highlights-fdmt-20231109monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-presents-positive-interim-data-from-phase-1-2-aerow-clinical-trial-of-aerosolized-4d--fdmt-20231101monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-gains-alignment-with-fda-on-plan-to-lift-clinical-hold-on-phase-1-2-inglaxa-clinical--fdmt-20231030monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-to-present-interim-data-from-aerosolized-4d-710-phase-1-2-aerow-clinical-trial-for-cy-fdmt-20231025monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-receives-ema-priority-medicines-prime-designation-for-4d-150-clinical-stage-genetic-m-fdmt-20231023monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-appoints-uneek-mehra-as-chief-financial-and-business-officer-fdmt-20230912monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-to-participate-in-upcoming-investor-conferences-fdmt-20230907monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-announces-first-patient-enrolled-in-4d-150-phase-2-spectra-clinical-trial-in-dme-and--fdmt-20230907monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-reports-second-quarter-2023-financial-results-and-operational-hi-fdmt-20230809monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-presents-additional-positive-interim-data-from-intravitreal-4d-150-phase-1-2-prism-cl-fdmt-20230729monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-completes-enrollment-of-phase-2-prism-clinical-trial-for-intravitreal-4d-150-in-patie-fdmt-20230717monthly0.5https://www.biopharmawatch.com/news/FDMT/astellas-and-4d-molecular-therapeutics-4dmt-enter-into-license-agreement-to-use-4dmt-s-pro-fdmt-20230710monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-presents-positive-interim-data-from-aerosolized-4d-710-phase-1-2-aerow-clinical-trial-fdmt-20230607monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-to-participate-in-upcoming-investor-conferences-fdmt-20230601monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-to-present-interim-data-from-4d-710-phase-1-2-aerow-clinical-trial-for-cystic-fibrosi-fdmt-20230524monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-announces-presentation-on-aerosolized-4d-710-for-treatment-of-cystic-fibrosis-at-the--fdmt-20230511monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-reports-first-quarter-2023-financial-results-and-operational-hig-fdmt-20230510monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-announces-closing-of-upsized-public-offering-of-common-stock-and-fdmt-20230509monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-to-participate-in-upcoming-investor-conferences-fdmt-20230508monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-announces-pricing-of-upsized-public-offering-of-common-stock-fdmt-20230505monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-announces-proposed-public-offering-of-common-stock-fdmt-20230504monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-presents-positive-interim-data-from-intravitreal-4d-150-phase-1-2-prism-clinical-tria-fdmt-20230427monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-acquires-complement-pathway-inhibitor-payload-for-4d-175-product-candidate-for-geogra-fdmt-20230424monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-to-present-interim-data-from-4d-150-phase-1-2-prism-clinical-trial-for-wet-amd-at-arv-fdmt-20230413monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-reports-full-year-2022-financial-results-and-operational-highlig-fdmt-20230315monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-presents-interim-data-from-4d-310-inglaxa-phase-1-2-clinical-tri-fdmt-20230222monthly0.5https://www.biopharmawatch.com/news/FDMT/4dmt-to-present-interim-clinical-data-from-inglaxa-phase-1-2-trials-of-4d-310-for-fabry-di-fdmt-20230216monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-to-participate-in-the-svb-securities-global-biopharma-conference-fdmt-20230208monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-announces-fda-clearance-of-ind-application-for-4d-150-genetic-me-fdmt-20230202monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-announces-updates-on-clinical-pipeline-and-additional-preclinica-fdmt-20230109monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-to-participate-in-the-upcoming-evercore-isi-healthconx-2022-conf-fdmt-20221121monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-announces-interim-clinical-data-from-on-going-phase-1-2-clinical-fdmt-20221114monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-interim-clinical-data-from-the-on-going-phase-1-2-clinical-trial-fdmt-20221110monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-reports-third-quarter-2022-financial-results-fdmt-20221109monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-announces-interim-clinical-data-from-phase-1-2-clinical-trial-of-fdmt-20221103monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-interim-clinical-data-from-the-on-going-phase-1-2-clinical-trial-fdmt-20221026monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-appoints-noriyuki-kasahara-md-phd-to-the-board-of-directors-and--fdmt-20220927monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-to-participate-in-upcoming-investor-conferences-fdmt-20220920monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-reports-second-quarter-2022-financial-results-and-provides-4d-31-fdmt-20220811monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-to-participate-in-upcoming-june-investor-conferences-fdmt-20220602monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-reports-first-quarter-2022-financial-results-and-provides-corpor-fdmt-20220512monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-to-participate-in-the-bofa-securities-2022-healthcare-conference-fdmt-20220505monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-announces-first-patient-dosed-in-phase-1-2-clinical-trial-of-4d--fdmt-20220404monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-reports-full-year-2021-financial-results-and-operational-highlig-fdmt-20220328monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-announces-resignation-of-professor-david-schaffer-ph-d-from-the--fdmt-20220222monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-to-participate-in-the-11th-annual-svb-leerink-global-healthcare--fdmt-20220211monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-announces-updated-interim-results-from-the-4d-310-phase-1-2-clin-fdmt-20220209monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-to-present-updated-clinical-data-with-4d-310-in-fabry-disease-pa-fdmt-20220202monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-announces-fda-fast-track-designation-granted-to-4d-125-for-the-t-fdmt-20220110monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-announces-first-patient-dosed-in-phase-1-2-clinical-trial-of-4d--fdmt-20220106monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-to-participate-in-the-upcoming-evercore-isi-healthconx-2021-conf-fdmt-20211123monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-reports-financial-results-for-the-third-quarter-of-2021-and-prov-fdmt-20211110monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-announces-pricing-of-public-offering-of-common-stock-fdmt-20211029monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-announces-proposed-public-offering-of-common-stock-fdmt-20211026monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-reports-interim-results-from-the-4d-310-phase-1-2-clinical-trial-fdmt-20211025monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-presents-interim-results-from-the-ongoing-4d-125-phase-1-2-clini-fdmt-20211010monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-announces-fda-clearance-of-ind-application-for-4d-710-an-a101-ve-fdmt-20211006monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-to-participate-in-chardan-s-5th-annual-genetic-medicines-confere-fdmt-20210929monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-announces-late-breaking-presentation-of-4d-125-clinical-data-at--fdmt-20210924monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-reports-financial-results-for-the-second-quarter-of-2021-and-pro-fdmt-20210812monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-announces-rare-disease-ophthalmology-product-candidate-portfolio-fdmt-20210624monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-appoints-carolyne-zimmermann-as-chief-business-officer-fdmt-20210607monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-co-fdmt-20210603monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-reports-financial-results-for-the-first-quarter-of-2021-and-prov-fdmt-20210513monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-presents-non-human-primate-preclinical-data-at-asgct-on-the-4d-1-fdmt-20210512monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-announces-collaboration-on-leading-machine-learning-technology-a-fdmt-20210504monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-to-participate-in-bofa-securities-2021-virtual-health-care-confe-fdmt-20210430monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-announces-preclinical-data-presentations-at-asgct-and-ats-annual-fdmt-20210427monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-reports-financial-results-for-the-year-ended-december-31-2020-an-fdmt-20210325monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-announces-first-patient-dosed-in-phase-1-2-clinical-trial-of-4d--fdmt-20210309monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-announces-closing-of-initial-public-offering-and-full-exercise-o-fdmt-20201215monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-announces-upsized-pricing-of-initial-public-offering-fdmt-20201210monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-strengthens-leadership-team-with-key-appointments-in-clinical-re-fdmt-20201202monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-appoints-susannah-gray-to-board-of-directors-fdmt-20200827monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-announces-first-patient-dosed-in-phase-1-2-clinical-trial-of-4d--fdmt-20200819monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-receives-fda-fast-track-designation-for-4d-310-gene-therapy-for--fdmt-20200813monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-of-4d-11-fdmt-20200727monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-announces-new-agreement-with-cystic-fibrosis-foundation-fdmt-20200617monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-raises-75-million-in-series-c-financing-fdmt-20200616monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-announces-presentation-of-preclinical-data-at-the-6th-internatio-fdmt-20190530monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-raises-90-million-series-b-financing-fdmt-20180905monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-announces-collaboration-with-pfizer-inc-for-cardiac-gene-therapy-fdmt-20160107monthly0.5https://www.biopharmawatch.com/news/FDMT/4d-molecular-therapeutics-and-roche-sign-collaboration-agreement-for-gene-therapy-vector-d-fdmt-20150427monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-ag-appoints-sean-marett-as-coo-chief-operating-officer-bntx-20121030monthly0.5https://www.biopharmawatch.com/news/BNTX/new-eu-funded-consortium-to-develop-fully-personalized-cancer-vaccines-for-brain-cancer-pa-bntx-20130704monthly0.5https://www.biopharmawatch.com/news/BNTX/sierk-po-tting-to-be-the-new-cfo-chief-financial-officer-of-biontech-group-bntx-20140901monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-ag-and-ganymed-pharmaceuticals-ag-open-new-research-headquarters-in-mainz-germany-bntx-20141001monthly0.5https://www.biopharmawatch.com/news/BNTX/eu-funded-consortium-led-by-immatics-and-biontech-to-advance-a-novel-class-of-fully-person-bntx-20141014monthly0.5https://www.biopharmawatch.com/news/BNTX/breakthrough-development-in-cancer-immunology-published-in-nature-bntx-20150422monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-signs-co-development-and-commercialization-agreement-in-immuno-oncology-bntx-20150519monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-launches-mammatyper-breast-cancer-diagnostic-test-in-europe-bntx-20150611monthly0.5https://www.biopharmawatch.com/news/BNTX/siemens-and-biontech-cooperate-on-production-of-personalized-cancer-vaccines-bntx-20150625monthly0.5https://www.biopharmawatch.com/news/BNTX/bayer-and-biontech-join-forces-to-develop-innovative-new-mrna-vaccines-and-therapeutics-fo-bntx-20160510monthly0.5https://www.biopharmawatch.com/news/BNTX/nature-publication-describes-first-example-of-a-clinically-applicable-and-systemic-mrna-ca-bntx-20160601monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-enter-into-worldwide-strategic-collaboration-with-genentech-to-develop-individ-bntx-20160921monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-present-at-35th-annual-j-p-morgan-healthcare-conference-2017-bntx-20161222monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-present-at-cowen-and-company-s-37th-annual-health-care-conference-bntx-20170222monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-present-interim-phase-i-ii-data-for-investigational-mrna-vaccine-in-melanoma-p-bntx-20170307monthly0.5https://www.biopharmawatch.com/news/BNTX/nature-medicine-reports-elimination-of-large-tumors-in-mice-by-messenger-rna-encoded-bispe-bntx-20170612monthly0.5https://www.biopharmawatch.com/news/BNTX/nature-publication-reports-favorable-clinical-trial-results-of-biontech-s-individualized-c-bntx-20170705monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-ag-enters-into-licensing-agreement-with-cellscript-llc-as-it-advances-development-bntx-20170906monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-secures-usd-270-million-in-series-a-financing-bntx-20180104monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-appoints-dr-o-zlem-tu-reci-as-chief-medical-officer-bntx-20180529monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-and-smp-to-evaluate-smp-s-next-generation-technology-for-biontech-products-bntx-20180801monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-commencement-of-initial-public-offering-bntx-20190924monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-pricing-of-initial-public-offering-bntx-20191010monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-report-third-quarter-2019-financial-results-and-operational-progress-on-novemb-bntx-20191107monthly0.5https://www.biopharmawatch.com/news/BNTX/european-investment-bank-provides-funding-of-50-million-to-biontech-as-part-of-the-investm-bntx-20191217monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-bntx-20191218monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-publication-of-preclinical-data-for-first-in-kind-car-t-cell-therapy-ap-bntx-20200102monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-reports-rapid-progress-on-covid-19-vaccine-program-to-address-global-public-healt-bntx-20200316monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-report-full-year-financial-results-for-2019-and-provide-corporate-update-on-th-bntx-20200323monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-and-pfizer-announce-regulatory-approval-from-german-authority-paul-ehrlich-instit-bntx-20200422monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-report-first-quarter-2020-financial-results-and-operational-update-on-may-12-2-bntx-20200505monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-first-quarter-2020-financial-results-and-corporate-progress-bntx-20200512monthly0.5https://www.biopharmawatch.com/news/BNTX/investment-plan-for-europe-european-investment-bank-to-provide-biontech-with-up-to-100-mil-bntx-20200611monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-hold-webcast-to-present-early-positive-data-from-ongoing-phase-1-2-study-of-mr-bntx-20200701monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-report-second-quarter-2020-financial-results-and-operational-update-on-august--bntx-20200806monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-second-quarter-2020-financial-results-and-corporate-progress-bntx-20200811monthly0.5https://www.biopharmawatch.com/news/BNTX/biopharma-leaders-unite-to-stand-with-science-bntx-20200908monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-propose-expansion-of-pivotal-covid-19-vaccine-trial-bntx-20200912monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-present-data-from-bnt311-gen1046-and-bnt131-sar441000-programs-at-sitc-35th-an-bntx-20201014monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-report-third-quarter-2020-financial-results-and-operational-update-on-november-bntx-20201103monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-reach-an-agreement-to-supply-the-eu-with-200-million-doses-of-their-bn-bntx-20201111monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-conclude-phase-3-study-of-covid-19-vaccine-candidate-meeting-all-prima-bntx-20201118monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-to-submit-emergency-use-authorization-request-today-to-the-u-s-fda-for-bntx-20201120monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-and-instadeep-announce-strategic-collaboration-and-form-ai-innovation-lab-to-deve-bntx-20201125monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-submitted-application-for-conditional-marketing-authorization-for-covi-bntx-20201201monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-hold-press-conference-to-provide-an-update-on-covid-19-vaccine-development-pro-bntx-20201202monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-achieve-first-authorization-in-the-world-for-a-vaccine-to-combat-covid-bntx-20201202monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-achieve-health-canada-authorization-for-their-vaccine-to-combat-covid--bntx-20201209monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-announce-publication-of-results-from-landmark-phase-3-trial-of-bnt162b-bntx-20201210monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-receive-fda-advisory-committee-vote-supporting-potential-first-emergen-bntx-20201210monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-celebrate-historic-first-authorization-in-the-u-s-of-vaccine-to-preven-bntx-20201212monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-provide-data-from-german-phase-1-2-study-further-characterizing-immune-bntx-20201214monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-and-fosun-pharma-to-supply-china-with-mrna-based-covid-19-vaccine-bntx-20201216monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-hold-press-conference-to-provide-an-update-on-covid-19-vaccine-development-pro-bntx-20201221monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-receive-authorization-in-the-european-union-for-covid-19-vaccine-bntx-20201221monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-receive-chmp-positive-opinion-for-their-covid-19-vaccine-bntx-20201221monthly0.5https://www.biopharmawatch.com/news/BNTX/correction-pfizer-and-biontech-to-supply-the-u-s-with-100-million-additional-doses-of-covi-bntx-20201223monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-to-supply-the-u-s-with-100-million-additional-doses-of-covid-19-vaccin-bntx-20201223monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-to-supply-the-european-union-with-100-million-additional-doses-of-comi-bntx-20201229monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-bntx-20210105monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-publishes-data-on-novel-mrna-vaccine-approach-to-treat-autoimmune-diseases-in-sci-bntx-20210107monthly0.5https://www.biopharmawatch.com/news/BNTX/an-in-vitro-study-shows-pfizer-biontech-covid-19-vaccine-elicits-antibodies-that-neutraliz-bntx-20210108monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-publish-results-of-study-showing-covid-19-vaccine-elicits-antibodies-t-bntx-20210120monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-reach-agreement-with-covax-for-advance-purchase-of-vaccine-to-help-com-bntx-20210122monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-publish-preclinical-data-from-investigational-covid-19-vaccine-program-bntx-20210201monthly0.5https://www.biopharmawatch.com/news/BNTX/update-on-vaccine-production-at-biontech-s-manufacturing-site-in-marburg-bntx-20210210monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-to-supply-the-united-states-with-100-million-additional-doses-of-covid-bntx-20210212monthly0.5https://www.biopharmawatch.com/news/BNTX/in-vitro-study-published-in-the-new-england-journal-of-medicine-demonstrates-sera-from-ind-bntx-20210217monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-to-supply-the-european-union-with-200-million-additional-doses-of-comi-bntx-20210217monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-commence-global-clinical-trial-to-evaluate-covid-19-vaccine-in-pregnan-bntx-20210218monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-submit-covid-19-vaccine-stability-data-at-standard-freezer-temperature-bntx-20210219monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-initiate-a-study-as-part-of-broad-development-plan-to-evaluate-covid-1-bntx-20210225monthly0.5https://www.biopharmawatch.com/news/BNTX/real-world-evidence-confirms-high-effectiveness-of-pfizer-biontech-covid-19-vaccine-and-pr-bntx-20210311monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-report-full-year-financial-results-for-2020-and-provide-corporate-update-on-th-bntx-20210323monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-provides-update-on-vaccine-production-status-at-marburg-manufacturing-site-bntx-20210326monthly0.5https://www.biopharmawatch.com/news/BNTX/ema-approves-new-storage-option-for-pfizer-biontech-vaccine-easing-distribution-and-storag-bntx-20210326monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-full-year-2020-financial-results-and-corporate-update-bntx-20210330monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-report-first-quarter-2021-financial-results-and-operational-update-on-may-10-2-bntx-20210504monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-first-quarter-2021-financial-results-and-corporate-update-bntx-20210510monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-acquire-kite-s-neoantigen-tcr-cell-therapy-r-d-platform-and-manufacturing-faci-bntx-20210719monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-announce-collaboration-with-biovac-to-manufacture-and-distribute-covid-bntx-20210721monthly0.5https://www.biopharmawatch.com/news/BNTX/fighting-infectious-diseases-on-the-african-continent-bntx-20210723monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-report-second-quarter-financial-results-and-operational-update-on-august-9-202-bntx-20210802monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-completes-acquisition-of-kite-s-neoantigen-tcr-cell-therapy-r-d-platform-and-manu-bntx-20210804monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-second-quarter-2021-financial-results-and-corporate-update-bntx-20210809monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-initiate-rolling-submission-of-supplemental-biologics-license-applicat-bntx-20210825monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-announce-collaboration-with-brazil-s-eurofarma-to-manufacture-covid-19-bntx-20210826monthly0.5https://www.biopharmawatch.com/news/BNTX/fda-advisory-committee-votes-unanimously-in-favor-of-comirnaty-booster-for-emergency-use-i-bntx-20210918monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-announce-positive-topline-results-from-pivotal-trial-of-covid-19-vacci-bntx-20210920monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-expand-collaboration-with-u-s-to-provide-500-million-additional-covid--bntx-20210922monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-present-new-clinical-and-preclinical-data-across-multiple-immuno-oncology-prog-bntx-20211001monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-announce-phase-3-trial-data-showing-high-efficacy-of-a-booster-dose-of-bntx-20211021monthly0.5https://www.biopharmawatch.com/news/BNTX/fda-advisory-committee-votes-in-favor-of-granting-emergency-use-authorization-for-the-pfiz-bntx-20211026monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-report-third-quarter-financial-results-and-operational-update-on-november-9-20-bntx-20211027monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-present-new-clinical-data-from-first-in-class-car-t-program-bnt211-in-late-bre-bntx-20211101monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-third-quarter-2021-financial-results-and-corporate-update-bntx-20211109monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-hold-digital-press-conference-to-provide-an-update-on-omicron-variant-bntx-20211208monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-bntx-20211227monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-join-high-level-meeting-with-partners-in-marburg-and-to-hold-press-conference--bntx-20220215monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-report-full-year-and-fourth-quarter-2021-financial-results-and-operational-upd-bntx-20220316monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-fourth-quarter-and-full-year-2021-financial-results-and-corporate-updat-bntx-20220330monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-ads-repurchase-program-bntx-20220331monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-granted-pandemic-preparedness-contract-by-german-federal-ministry-of-health-bntx-20220408monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-and-matinas-biopharma-announce-exclusive-research-collaboration-to-evaluate-novel-bntx-20220411monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-report-first-quarter-2022-financial-results-and-operational-update-on-may-9-20-bntx-20220426monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-first-quarter-financial-results-and-corporate-update-bntx-20220509monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-provide-an-update-on-manufacturing-and-development-plans-of-mrna-vaccines-in-a-bntx-20220609monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-host-first-edition-of-innovation-series-on-diversified-pipeline-latest-technol-bntx-20220620monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-starts-construction-of-first-mrna-vaccine-manufacturing-facility-in-africa-bntx-20220623monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-report-second-quarter-2022-financial-results-and-operational-update-on-august--bntx-20220725monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-and-genmab-expand-global-strategic-collaboration-to-develop-and-commercialize-nov-bntx-20220805monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-second-quarter-financial-results-and-corporate-update-bntx-20220808monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-ceo-ugur-sahin-visited-israel-to-discuss-cooperation-on-pandemic-preparedness-and-bntx-20220907monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-and-australia-s-state-of-victoria-form-strategic-partnership-to-establish-mrna-re-bntx-20221006monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-report-third-quarter-2022-financial-results-and-operational-update-on-november-bntx-20221024monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-third-quarter-2022-financial-results-and-corporate-update-bntx-20221107monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-expands-global-footprint-by-acquiring-gmp-manufacturing-site-to-establish-first-m-bntx-20221114monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-starts-phase-1-clinical-trial-for-prophylactic-herpes-simplex-virus-2-vaccine-can-bntx-20221221monthly0.5https://www.biopharmawatch.com/news/BNTX/update-on-first-biontainer-for-african-based-mrna-manufacturing-facility-bntx-20221221monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-initiates-phase-1-clinical-trial-for-malaria-vaccine-program-bnt165-bntx-20221223monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-bntx-20221228monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-strategic-partnership-with-uk-government-to-provide-up-to-10-000-patien-bntx-20230106monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-strengthens-manufacturing-capabilities-with-first-in-house-plasmid-dna-manufactur-bntx-20230202monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-establishment-of-interdisciplinary-mrna-excellence-center-to-conduct-re-bntx-20230301monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-report-full-year-and-fourth-quarter-2022-financial-results-and-operational-upd-bntx-20230313monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-fourth-quarter-and-full-year-2022-financial-results-and-corporate-updat-bntx-20230327monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-and-dualitybio-form-global-strategic-partnership-to-accelerate-development-of-dif-bntx-20230403monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-report-first-quarter-2023-financial-results-and-operational-update-on-may-8-20-bntx-20230424monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-and-oncoc4-present-positive-phase-1-2-data-for-antibody-candidate-bnt316-onc-392--bntx-20230602monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-and-oncoc4-initiate-pivotal-phase-3-trial-of-bnt316-onc-392-program-in-metastatic-bntx-20230629monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-report-second-quarter-2023-financial-results-and-operational-update-on-august--bntx-20230724monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-completes-acquisition-of-instadeep-bntx-20230731monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-receive-positive-chmp-opinion-for-omicron-xbb-1-5-adapted-covid-19-vac-bntx-20230830monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-and-cepi-announce-partnership-to-advance-mrna-mpox-vaccine-development-and-suppor-bntx-20230918monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-receive-health-canada-authorization-for-xbb-1-5-adapted-monovalent-cov-bntx-20230928monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-present-multiple-program-updates-across-modalities-at-esmo-congress-2023-bntx-20231016monthly0.5https://www.biopharmawatch.com/news/BNTX/update-regarding-pfizer-s-statement-on-comirnaty-related-write-offs-bntx-20231016monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-expands-late-stage-clinical-oncology-portfolio-with-initiation-of-further-phase-2-bntx-20231019monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-presents-positive-phase-1-2-data-update-for-car-t-cell-therapy-candidate-bnt211-i-bntx-20231023monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-report-third-quarter-financial-results-and-corporate-update-on-november-6-2023-bntx-20231023monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-announce-positive-topline-data-for-mrna-based-combination-vaccine-prog-bntx-20231026monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-third-quarter-2023-financial-results-and-corporate-update-bntx-20231106monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-inaugurate-first-african-site-on-december-18-2023-bntx-20231212monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-achieves-milestone-at-mrna-based-vaccine-manufacturing-site-in-rwanda-bntx-20231218monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-and-dualitybio-receive-fda-breakthrough-therapy-designation-for-antibody-drug-con-bntx-20231221monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-outlines-2024-strategic-priorities-at-the-42nd-annual-j-p-morgan-healthcare-confe-bntx-20240109monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-and-dualitybio-initiate-pivotal-phase-3-trial-of-antibody-drug-conjugate-candidat-bntx-20240122monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-and-dualitybio-receive-fda-fast-track-designation-for-next-generation-antibody-dr-bntx-20240131monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-and-autolus-announce-strategic-car-t-cell-therapy-collaboration-to-advance-pipeli-bntx-20240208monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-report-fourth-quarter-and-full-year-2023-financial-results-and-provide-corpora-bntx-20240306monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-planned-retirement-of-sean-marett-bntx-20240307monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-present-clinical-data-updates-for-personalized-mrna-based-and-targeted-oncolog-bntx-20240311monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-fourth-quarter-and-full-year-2023-financial-results-and-corporate-updat-bntx-20240320monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-report-first-quarter-2024-financial-results-and-corporate-update-on-may-6-2024-bntx-20240422monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-first-quarter-2024-financial-results-and-corporate-update-bntx-20240506monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-present-clinical-data-updates-for-next-generation-immunotherapy-candidates-at--bntx-20240521monthly0.5https://www.biopharmawatch.com/news/BNTX/investigational-acasunlimab-duobody-pd-l1x4-1bb-in-combination-with-pembrolizumab-demonstr-bntx-20240601monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-report-second-quarter-2024-financial-results-and-corporate-update-on-august-5--bntx-20240722monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-positive-topline-phase-2-results-for-mrna-immunotherapy-candidate-bnt11-bntx-20240730monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-second-quarter-2024-financial-results-and-corporate-update-bntx-20240805monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-present-clinical-data-updates-across-mrna-and-immunomodulatory-oncology-portfo-bntx-20240905monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-host-ai-day-as-an-edition-of-its-innovation-series-on-october-1-2024-bntx-20240917monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-receive-positive-chmp-opinion-for-omicron-kp-2-adapted-covid-19-vaccin-bntx-20240920monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-report-third-quarter-2024-financial-results-and-corporate-update-on-november-4-bntx-20241021monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-host-innovation-series-r-d-day-on-november-14-2024-bntx-20241031monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-third-quarter-2024-financial-results-and-corporate-update-bntx-20241104monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-acquire-biotheus-to-boost-oncology-strategy-bntx-20241113monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-provides-business-and-pipeline-updates-at-43rd-annual-j-p-morgan-healthcare-confe-bntx-20250114monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-completes-acquisition-of-biotheus-bntx-20250203monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-report-fourth-quarter-and-full-year-2024-financial-results-and-corporate-updat-bntx-20250224monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-fourth-quarter-and-full-year-2024-financial-results-and-corporate-updat-bntx-20250310monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-report-first-quarter-2025-financial-results-and-corporate-update-on-may-5-2025-bntx-20250422monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-present-clinical-and-preclinical-data-across-mrna-and-next-generation-immuno-o-bntx-20250424monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-first-quarter-2025-financial-results-and-corporate-update-bntx-20250505monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-present-progress-across-diversified-oncology-pipeline-at-the-2025-asco-annual--bntx-20250527monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-and-bristol-myers-squibb-announce-global-strategic-partnership-to-co-develop-and--bntx-20250602monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-ryan-richardson-to-step-down-from-the-management-board-bntx-20250717monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-report-second-quarter-2025-financial-results-and-corporate-update-on-august-4--bntx-20250721monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-receive-positive-chmp-opinion-for-lp-8-1-adapted-covid-19-vaccine-in-t-bntx-20250725monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-second-quarter-2025-financial-results-and-corporate-update-bntx-20250804monthly0.5https://www.biopharmawatch.com/news/BNTX/pfizer-and-biontech-s-comirnaty-receives-u-s-fda-approval-for-adults-65-and-older-and-indi-bntx-20250827monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-to-report-third-quarter-2025-financial-results-and-corporate-update-on-november-3-bntx-20251027monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-and-oncoc4-announce-clinically-meaningful-overall-survival-benefit-for-selective--bntx-20251206monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-and-bristol-myers-squibb-present-first-global-phase-2-data-for-pd-l1xvegf-a-bispe-bntx-20251209monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-provides-strategic-business-update-and-outlines-2026-areas-of-focus-at-44th-annua-bntx-20260112monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-and-co-founders-announce-plan-to-pursue-next-generation-mrna-innovations-in-co-fo-bntx-20260310monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-announces-fourth-quarter-and-full-year-2025-financial-results-and-corporate-updat-bntx-20260310monthly0.5https://www.biopharmawatch.com/news/BNTX/biontech-and-dualitybio-s-antibody-drug-conjugate-trastuzumab-pamirtecan-demonstrated-clin-bntx-20260411monthly0.5https://www.biopharmawatch.com/news/BNTX/global-data-for-biontech-and-bristol-myers-squibb-s-pd-l1xvegf-a-bispecific-pumitamig-show-bntx-20260530monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-inc-announces-pricing-of-initial-public-offering-rytm-20171005monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-presentation-of-genetic-epidemiology-of-lepr-pomc-and-pcs-rytm-20180319monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-provide-an-update-on-genetic-sequencing-efforts-and-expansion-of-rytm-20190909monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-inc-announces-pricing-of-public-offering-rytm-20191016monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-late-breaking-data-presentations-at-obesityweek-2019-rytm-20191030monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-completes-rolling-submission-of-new-drug-application-to-u-s-food-an-rytm-20200330monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-fda-acceptance-of-new-drug-application-for-setmelanotide--rytm-20200513monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-receives-rare-pediatric-disease-designation-from-u-s-food-and-drug--rytm-20200701monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-appointment-of-david-meeker-m-d-as-chief-executive-office-rytm-20200720monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-clinical-data-on-setmelanotide-at-obesityweek-2020-rytm-20201104monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-fda-approval-of-imcivree-setmelanotide-as-first-ever-ther-rytm-20201127monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-appointments-of-camille-l-bedrosian-m-d-and-lynn-tetrault-rytm-20201211monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-positive-data-with-setmelanotide-in-additional-mc4r-pathw-rytm-20210126monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-inc-announces-pricing-of-public-offering-rytm-20210205monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-late-breaking-data-presentations-at-endo-2021-rytm-20210309monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-european-commission-authorization-of-imcivree-setmelanoti-rytm-20210723monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-comprehensive-expansion-of-clinical-development-program-w-rytm-20210803monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-marketing-authorisation-of-imcivree-setmelanotide-in-grea-rytm-20210921monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-presents-first-ever-data-showing-improvements-in-health-related-qua-rytm-20211101monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-fda-acceptance-for-filing-and-priority-review-of-suppleme-rytm-20211115monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-first-patients-dosed-in-daybreak-and-weekly-trials-evalua-rytm-20220113monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-at-cowen-co-42nd-annual-health-care-conference-rytm-20220301monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-fda-approval-of-imcivree-setmelanotide-for-use-in-patient-rytm-20220616monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-launches-imcivree-setmelanotide-in-germany-for-the-treatment-of-obe-rytm-20220622monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-positive-interim-results-from-phase-2-clinical-trial-eval-rytm-20220712monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-inc-announces-proposed-public-offering-rytm-20220914monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-presents-data-from-phase-2-and-long-term-extension-trials-evaluatin-rytm-20221102monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-imcivree-setmelanotide-granted-marketing-authorization-in-rytm-20221121monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-present-at-22nd-annual-needham-virtual-healthcare-conference-rytm-20230410monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-health-canada-approval-of-imcivree-setmelanotide-injectio-rytm-20230508monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-and-genpharm-announce-collaboration-to-provide-imcivree-setmelanoti-rytm-20230522monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-presents-data-demonstrating-bmi-reduction-in-patients-with-hypothal-rytm-20230617monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-six-abstracts-to-be-presented-at-the-obesity-society-s-an-rytm-20231010monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-presents-data-from-its-long-term-extension-study-of-setmelanotide-s-rytm-20231017monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-first-patient-dosed-in-phase-1-trial-evaluating-rm-718-a--rytm-20240325monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-publication-of-results-from-phase-2-study-of-setmelanotid-rytm-20240429monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-reports-first-quarter-2024-financial-results-and-business-update-rytm-20240507monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-presents-patient-reported-experiences-with-hyperphagia-in-hypothala-rytm-20240603monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-appointment-of-alastair-garfield-ph-d-as-chief-scientific-rytm-20240708monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-first-patients-dosed-in-phase-2-trial-evaluating-oral-mc4-rytm-20240723monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-european-commission-expands-imcivree-setmelanotide-market-rytm-20240731monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-fda-acceptance-for-priority-review-of-supplemental-new-dr-rytm-20240826monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-five-new-data-presentations-at-obesityweek-2024-rytm-20241104monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-publication-of-results-from-phase-3-study-of-setmelanotid-rytm-20241113monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-fda-approval-of-imcivree-setmelanotide-for-patients-as-yo-rytm-20241220monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-orphan-drug-designation-granted-to-setmelanotide-for-trea-rytm-20250319monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-announce-topline-results-from-pivotal-phase-3-transcend-trial-ev-rytm-20250406monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-new-data-presentations-on-patients-with-acquired-or-conge-rytm-20250514monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-to-announce-topline-results-from-phase-2-trial-evaluating-oral-mc4r-rytm-20250708monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-inc-announces-proposed-public-offering-of-common-stock-rytm-20250709monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-inc-announces-pricing-of-upsized-public-offering-of-common-stock-rytm-20250710monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-presents-data-on-mc4r-agonists-setmelanotide-and-bivamelagon-at-end-rytm-20250712monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-rytm-20260526monthly0.5https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-presents-positive-interim-six-month-data-from-phase-2-trial-of-setm-rytm-20260615monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-operating-results-regn-20010125monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-offering-of-convertible-senior-subordinated-notes-in-a-144a-offering-regn-20011012monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-sells-200-million-of-convertible-senior-subordinated-notes-regn-20011012monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-granted-license-by-amgen-and-immunex-to-interleukin-1-inhibitor-patents-regn-20020708monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-initiates-phase-ii-clinical-trial-of-il1-trap-in-patients-with-rheumatoid-arthri-regn-20020725monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-completes-enrollment-of-phase-iii-studies-for-short-term-treatment-regimens-with-regn-20020725monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-completes-12-month-efficacy-phase-of-axokine-r-phase-iii-pivotal-trial-for-the-t-regn-20030121monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-receives-fast-track-designation-from-u-s-food-and-drug-administration-for-aspect-regn-20030121monthly0.5https://www.biopharmawatch.com/news/REGN/arthur-f-ryan-elected-to-regeneron-s-board-of-directors-regn-20030121monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-fourth-quarter-and-full-year-2002-financial-and-operating-results-regn-20030206monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-novartis-form-strategic-collaboration-to-develop-and-commercialize-the-il-1--regn-20030401monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-results-of-phase-iii-obesity-study-regn-20030401monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-s-axokine-promotes-weight-loss-in-study-of-overweight-and-obese-people-with-type-regn-20030416monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-first-quarter-financial-and-operating-results-regn-20030505monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-second-quarter-financial-and-operating-results-regn-20030801monthly0.5https://www.biopharmawatch.com/news/REGN/aventis-and-regeneron-enter-global-partnership-to-develop-and-commericalize-the-vegf-trap--regn-20030909monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-phase-ii-results-for-il-1-trap-clinical-program-in-rheumatoid-arthritis--regn-20031008monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-third-quarter-financial-and-operating-results-regn-20031031monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-fourth-quarter-and-full-year-2003-financial-and-operating-results-regn-20040224monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-plans-for-phase-iib-study-of-il-1-trap-and-end-of-novartis-participati-regn-20040301monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-first-quarter-financial-and-operating-results-regn-20040427monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-second-quarter-financial-and-operating-results-regn-20040727monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-third-quarter-financial-and-operating-results-fda-grants-fast-track-desi-regn-20041028monthly0.5https://www.biopharmawatch.com/news/REGN/sanofi-aventis-reaffirms-commitment-to-alliance-with-regeneron-pharmaceuticals-partners-ap-regn-20050111monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-fourth-quarter-and-full-year-2004-financial-and-operating-results-regn-20050223monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-s-vegf-trap-demonstrates-positive-preliminary-results-from-single-agent-phase-1--regn-20050517monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-second-quarter-financial-and-operating-results-regn-20050804monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-third-quarter-financial-and-operating-results-regn-20051103monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-s-vegf-trap-demonstrates-positive-preliminary-results-in-patients-with-age-relat-regn-20060203monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-fourth-quarter-and-full-year-2005-financial-and-operating-results-regn-20060224monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-completes-enrollment-for-il-1-trap-phase-3-trial-in-autoinflammatory-disease-eff-regn-20060419monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-positive-phase-1-data-for-the-vegf-trap-in-age-related-macular-degenerat-regn-20060502monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-first-quarter-financial-and-operating-results-regn-20060505monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-receives-fast-track-designation-for-the-il-1-trap-in-cias-1-associated-periodic--regn-20060601monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-pharmaceuticals-inc-annual-shareholders-meeting-regn-20060609monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-second-quarter-financial-and-operating-results-bla-filing-for-auto-infla-regn-20060803monthly0.5https://www.biopharmawatch.com/news/REGN/nih-selects-regeneron-for-knockout-mouse-project-regeneron-will-use-its-velocigene-technol-regn-20060908monthly0.5https://www.biopharmawatch.com/news/REGN/bayer-healthcare-and-regeneron-to-collaborate-on-vegf-trap-for-the-treatment-of-eye-diseas-regn-20061018monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-positive-phase-3-data-for-il-1-trap-in-caps-il-1-trap-rilonacept-markedl-regn-20061031monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-third-quarter-financial-and-operating-results-regn-20061107monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-closing-of-public-offering-of-shares-of-common-stock-regn-20061120monthly0.5https://www.biopharmawatch.com/news/REGN/lease-ex-99-1-exhibit-99-1-lease-by-and-between-bmr-landmark-at-eastview-llc-a-delaware-li-regn-20061222monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-signs-lease-for-new-headquarters-facility-to-be-built-in-westchester-county-ny-regn-20061222monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-blocking-new-angiogenesis-target-may-offer-novel-approach-to-slowing-tum-regn-20061222monthly0.5https://www.biopharmawatch.com/news/REGN/astrazeneca-licenses-regeneron-s-velocimmune-technology-for-discovering-human-monoclonal-a-regn-20070206monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-fourth-quarter-and-full-year-2006-financial-and-operating-results-regn-20070302monthly0.5https://www.biopharmawatch.com/news/REGN/astellas-licenses-regeneron-s-velocimmune-technology-for-discovering-human-monoclonal-anti-regn-20070403monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-first-quarter-financial-and-operating-results-regn-20070503monthly0.5https://www.biopharmawatch.com/news/REGN/annual-meeting-of-shareholders-regn-20070608monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-second-quarter-financial-and-operating-results-regn-20070801monthly0.5https://www.biopharmawatch.com/news/REGN/rilonacept-il-1-trap-granted-fda-priority-review-for-the-treatment-of-caps-regeneron-s-fir-regn-20070814monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-receives-20-million-milestone-payment-for-initiation-of-phase-3-study-of-vegf-tr-regn-20070814monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-positive-primary-endpoint-results-from-a-phase-2-study-of-vegf-trap-ey-regn-20071001monthly0.5https://www.biopharmawatch.com/news/REGN/pdufa-date-for-rilonacept-il-1-trap-extended-three-months-by-fda-action-date-on-biologics--regn-20071102monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-third-quarter-financial-and-operating-results-regn-20071106monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-initiates-major-global-collaboration-with-sanofi-aventis-to-develop-and-commerci-regn-20071129monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-closes-312-million-common-stock-sale-in-connection-with-sanofi-aventis-collabora-regn-20071221monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-fourth-quarter-and-full-year-2007-financial-and-operating-results-regn-20080228monthly0.5https://www.biopharmawatch.com/news/REGN/fda-approves-regeneron-s-arcalyst-rilonacept-for-treatment-of-cryopyrin-associated-periodi-regn-20080229monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-first-quarter-2008-financial-and-operating-results-regn-20080502monthly0.5https://www.biopharmawatch.com/news/REGN/sanofi-aventis-and-regeneron-update-aflibercept-vegf-trap-clinical-development-program-in--regn-20080521monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-second-quarter-2008-financial-and-operating-results-regn-20080731monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-s-arcalyst-rilonacept-reduced-incidence-of-gout-flares-by-81-percent-in-a-phase--regn-20080904monthly0.5https://www.biopharmawatch.com/news/REGN/top-line-results-of-a-multi-center-randomized-double-blind-placebo-controlled-study-of-the-regn-20080904monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-third-quarter-2008-financial-and-operating-results-regn-20081104monthly0.5https://www.biopharmawatch.com/news/REGN/27th-annual-j-p-morgan-healthcare-conference-january-2009-except-for-historical-informatio-regn-20090109monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-full-year-and-fourth-quarter-2008-financial-and-operating-results-regn-20090226monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-first-quarter-2009-financial-and-operating-results-regn-20090501monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-converts-interleukin-1-antibody-opt-in-rights-to-royalty-agreement-regn-20090611monthly0.5https://www.biopharmawatch.com/news/REGN/sanofi-aventis-and-regeneron-announce-results-from-phase-2-study-with-aflibercept-vegf-tra-regn-20090611monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-second-quarter-2009-financial-and-operating-results-regn-20090804monthly0.5https://www.biopharmawatch.com/news/REGN/phase-3-trial-of-aflibercept-in-metastatic-pancreatic-cancer-discontinued-phase-3-studies--regn-20090914monthly0.5https://www.biopharmawatch.com/news/REGN/enrollment-completed-in-regeneron-and-bayer-healthcare-phase-3-studies-of-vegf-trap-eye-in-regn-20090914monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-third-quarter-2009-financial-and-operating-results-regn-20091104monthly0.5https://www.biopharmawatch.com/news/REGN/sanofi-aventis-and-regeneron-expand-strategic-antibody-collaboration-new-agreements-expand-regn-20091112monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-28th-annual-j-p-morgan-healthcare-conference-regn-20100107monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-full-year-and-fourth-quarter-2009-financial-and-operating-results-regn-20100218monthly0.5https://www.biopharmawatch.com/news/REGN/vegf-trap-eye-shows-positive-results-in-a-phase-2-study-in-patients-with-diabetic-macular--regn-20100218monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-participation-in-a-panel-discussion-at-rbc-capital-markets-healthcare--regn-20100225monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-cowen-and-company-30th-annual-healthcare-conferenc-regn-20100304monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-barclays-capital-global-2010-healthcare-conference-regn-20100318monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-appointment-of-michael-aberman-m-d-as-vice-president-strategy-and-inve-regn-20100322monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-first-quarter-2010-financial-and-operating-results-regn-20100429monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-bank-of-america-merrill-lynch-2010-healthcare-conf-regn-20100507monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-participation-in-j-p-morgan-biotech-ceo-cfo-conference-call-series-regn-20100511monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-provides-initial-data-on-two-antibody-product-candidates-regn-20100512monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-2010-citi-investment-research-global-healthcare-co-regn-20100520monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-9th-annual-needham-healthcare-conference-regn-20100604monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-schedules-june-9-2010-teleconference-and-webcast-to-discuss-phase-3-trial-result-regn-20100608monthly0.5https://www.biopharmawatch.com/news/REGN/arcalyst-rilonacept-meets-primary-and-all-secondary-endpoints-in-phase-3-trial-of-preventi-regn-20100609monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-goldman-sachs-31st-annual-global-healthcare-confer-regn-20100611monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-webcast-investor-day-on-july-15-2010-regn-20100713monthly0.5https://www.biopharmawatch.com/news/REGN/astellas-to-pay-295-million-to-extend-license-of-regeneron-s-velocimmune-antibody-technolo-regn-20100728monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-second-quarter-2010-financial-and-operating-results-regn-20100728monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-bank-of-america-merrill-lynch-2010-specialty-pharm-regn-20100805monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-morgan-stanley-global-healthcare-conference-regn-20100903monthly0.5https://www.biopharmawatch.com/news/REGN/phase-3-trial-of-aflibercept-in-second-line-metastatic-colorectal-cancer-to-continue-as-pl-regn-20100908monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-ubs-global-life-sciences-conference-regn-20100913monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-panel-discussion-at-citi-s-5th-annual-biotech-day-regn-20100928monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-pharmaceuticals-inc-announces-the-sale-of-4-500-000-shares-of-common-stock-regn-20101006monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-increases-size-of-public-offering-of-common-stock-regn-20101008monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-exercise-of-over-allotment-option-and-closing-of-underwritten-offering-regn-20101013monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-17th-annual-newsmakers-in-the-biotech-industry-con-regn-20101015monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-third-quarter-2010-financial-results-and-business-highlights-regn-20101028monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-2010-credit-suisse-annual-healthcare-conference-regn-20101102monthly0.5https://www.biopharmawatch.com/news/REGN/christine-a-poon-elected-to-regeneron-board-of-directors-regn-20101115monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-schedules-november-22-2010-teleconference-and-webcast-to-discuss-results-of-two--regn-20101119monthly0.5https://www.biopharmawatch.com/news/REGN/bayer-and-regeneron-report-positive-top-line-results-of-two-phase-3-studies-with-vegf-trap-regn-20101122monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-22nd-annual-piper-jaffray-healthcare-conference-regn-20101123monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-2010-deutsche-bank-biofest-regn-20101206monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-bayer-report-positive-results-for-vegf-trap-eye-in-phase-3-study-in-central--regn-20101220monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-schedules-december-20-2010-teleconference-and-webcast-to-discuss-results-of-vegf-regn-20101220monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-29th-annual-j-p-morgan-healthcare-conference-regn-20110103monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-isi-annual-conference-regn-20110208monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-webcast-investor-briefing-on-vegf-trap-eye-clinical-program-on-sunday-februar-regn-20110209monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-full-year-and-fourth-quarter-2010-financial-and-operating-results-regn-20110217monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-march-2011-investor-conference-presentations-regn-20110223monthly0.5https://www.biopharmawatch.com/news/REGN/arcalyst-rilonacept-meets-primary-and-all-secondary-endpoints-in-second-phase-3-trial-for--regn-20110228monthly0.5https://www.biopharmawatch.com/news/REGN/sanofi-aventis-and-regeneron-report-top-line-results-from-phase-iii-study-with-aflibercept-regn-20110310monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-10th-annual-needham-healthcare-conference-regn-20110330monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-bayer-announce-start-of-phase-3-clinical-program-in-diabetic-macular-edema-regn-20110408monthly0.5https://www.biopharmawatch.com/news/REGN/fda-grants-priority-review-for-vegf-trap-eye-for-the-treatment-of-wet-age-related-macular--regn-20110418monthly0.5https://www.biopharmawatch.com/news/REGN/sanofi-aventis-and-regeneron-report-positive-phase-iii-results-with-zaltrap-aflibercept-in-regn-20110426monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-bayer-report-positive-results-for-vegf-trap-eye-in-second-phase-3-study-in-c-regn-20110427monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-bank-of-america-merrill-lynch-2011-health-care-con-regn-20110502monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-first-quarter-2011-financial-and-operating-results-regn-20110503monthly0.5https://www.biopharmawatch.com/news/REGN/fda-schedules-advisory-committee-meeting-to-discuss-bla-for-vegf-trap-eye-for-the-treatmen-regn-20110523monthly0.5https://www.biopharmawatch.com/news/REGN/zaltrap-aflibercept-significantly-improved-survival-in-previously-treated-metastatic-color-regn-20110606monthly0.5https://www.biopharmawatch.com/news/REGN/vegf-trap-eye-submitted-for-eu-marketing-authorization-for-treatment-of-wet-age-related-ma-regn-20110607monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-eylea-aflibercept-ophthalmic-solution-receives-unanimous-recommendatio-regn-20110617monthly0.5https://www.biopharmawatch.com/news/REGN/trading-in-regeneron-common-stock-halted-regn-20110617monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-aflibercept-injection-submitted-in-japan-for-marketing-authorization-for-the-treatme-regn-20110628monthly0.5https://www.biopharmawatch.com/news/REGN/phase-3-trial-of-zaltrap-aflibercept-in-advanced-prostate-cancer-to-continue-as-planned-at-regn-20110707monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-second-quarter-2011-financial-and-operating-results-regn-20110728monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-review-of-biologics-license-application-for-eylea-aflibercept-injectio-regn-20110816monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-september-2011-investor-conference-presentations-regn-20110831monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-appointment-of-joseph-j-larosa-as-senior-vice-president-general-counse-regn-20110906monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-third-quarter-2011-financial-and-operating-results-regn-20111027monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-2011-credit-suisse-annual-healthcare-conference-regn-20111107monthly0.5https://www.biopharmawatch.com/news/REGN/sanofi-and-regeneron-report-positive-preliminary-phase-2-program-results-for-anti-pcsk9-an-regn-20111110monthly0.5https://www.biopharmawatch.com/news/REGN/multimedia-regeneron-announces-fda-approval-of-eylea-aflibercept-injection-for-the-treatme-regn-20111118monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-fda-approval-of-eylea-aflibercept-injection-for-the-treatment-of-wet-a-regn-20111121monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-fda-acceptance-of-arcalyst-rilonacept-supplemental-biologics-license-a-regn-20111122monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-investor-conference-presentations-regn-20111123monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-bayer-initiate-phase-3-clinical-program-for-the-treatment-of-wet-age-related-regn-20111128monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-time-change-at-the-2011-deutsche-bank-biofest-regn-20111201monthly0.5https://www.biopharmawatch.com/news/REGN/two-year-results-of-phase-3-studies-with-eylea-aflibercept-injection-in-wet-amd-show-susta-regn-20111205monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-host-conference-call-on-january-3-at-8-30-a-m-eastern-time-to-discuss-ongoing-regn-20120102monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-30th-annual-j-p-morgan-healthcare-conference-regn-20120103monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-settlement-of-patent-litigation-with-genentech-for-u-s-ophthalmic-sale-regn-20120103monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-full-year-2011-financial-and-operating-results-and-host-conference-cal-regn-20120126monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-february-13-2012-as-date-of-full-year-2011-financial-and-operating-res-regn-20120210monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-leerink-swann-2012-global-healthcare-conference-regn-20120213monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-february-2012-investor-conference-presentations-regn-20120221monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-march-2012-investor-conference-presentations-regn-20120228monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-bayer-announce-approval-of-eylea-aflibercept-injection-for-the-treatment-of--regn-20120308monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-change-in-date-for-presentation-at-barclays-capital-2012-global-health-regn-20120309monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-data-publication-and-presentations-with-potential-first-in-class-lipid-regn-20120321monthly0.5https://www.biopharmawatch.com/news/REGN/sanofi-and-regeneron-announce-regulatory-and-clinical-update-for-zaltrap-aflibercept-regn-20120405monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-first-quarter-2012-financial-and-operating-results-and-host-conference-regn-20120412monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-first-quarter-2012-financial-and-operating-results-regn-20120426monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-bayer-announce-co-promotion-agreement-with-santen-for-eylea-aflibercept-inje-regn-20120508monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-provides-update-on-fda-advisory-committee-discussion-of-arcalyst-rilonacept-inje-regn-20120508monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-participation-in-j-p-morgan-biotech-ceo-cfo-conference-call-series-regn-20120509monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-bank-of-america-merrill-lynch-2012-healthcare-conf-regn-20120510monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-june-2012-investor-conference-presentations-regn-20120530monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-second-quarter-2012-financial-and-operating-results-and-host-conferenc-regn-20120711monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-second-quarter-2012-financial-and-operating-results-regn-20120725monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-receives-complete-response-letter-from-fda-for-arcalyst-rilonacept-sbla-for-the--regn-20120730monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-september-2012-investor-conference-presentations-regn-20120829monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-aflibercept-injection-recommended-for-approval-for-the-treatment-of-wet-age-related--regn-20120921monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-fda-approval-of-eylea-aflibercept-injection-for-macular-edema-followin-regn-20120921monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-named-world-s-1-biopharmaceutical-employer-in-science-magazine-annual-survey-regn-20120921monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-third-quarter-2012-financial-and-operating-results-and-host-conference-regn-20121010monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-publication-of-eylea-aflibercept-injection-phase-3-view-1-and-view-2-s-regn-20121018monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-third-quarter-2012-financial-and-operating-results-regn-20121024monthly0.5https://www.biopharmawatch.com/news/REGN/sanofi-and-regeneron-announce-publication-of-phase-2-results-with-ldl-cholesterol-lowering-regn-20121031monthly0.5https://www.biopharmawatch.com/news/REGN/sanofi-and-regeneron-announce-patient-enrollment-in-cardiovascular-outcomes-trial-with-ant-regn-20121105monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-november-2012-investor-conference-presentations-regn-20121106monthly0.5https://www.biopharmawatch.com/news/REGN/zaltrap-ziv-aflibercept-receives-chmp-positive-opinion-in-the-european-union-for-previousl-regn-20121116monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-aflibercept-injection-approved-for-the-treatment-of-wet-age-related-macular-degenera-regn-20121127monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-deutsche-bank-2012-dbaccess-biofest-regn-20121127monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-named-biotechnology-company-of-the-year-regn-20121129monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-january-2013-investor-conference-presentations-regn-20121220monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-recommends-rejection-of-mini-tender-offer-by-trc-capital-corporation-regn-20130104monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-fourth-quarter-and-full-year-2012-financial-and-operating-results-and--regn-20130128monthly0.5https://www.biopharmawatch.com/news/REGN/zaltrap-ziv-aflibercept-approved-in-the-eu-for-patients-with-previously-treated-metastatic-regn-20130205monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-receipt-of-hart-scott-rodino-notice-regn-20130211monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-fourth-quarter-and-full-year-2012-financial-and-operating-results-regn-20130214monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-bayer-initiate-phase-3-trial-of-eylea-aflibercept-injection-for-the-treatmen-regn-20130219monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-2013-investor-conference-presentations-regn-20130219monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-pharmaceuticals-announces-expansion-in-new-york-s-hudson-valley-regn-20130404monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-first-quarter-2013-financial-and-operating-results-and-host-conference-regn-20130411monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-2013-investor-conference-presentations-regn-20130418monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-acquires-full-rights-to-two-novel-ophthalmology-development-programs-regn-20130503monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-first-quarter-2013-financial-and-operating-results-regn-20130503monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-2013-investor-conference-presentations-regn-20130508monthly0.5https://www.biopharmawatch.com/news/REGN/sanofi-and-regeneron-announce-patient-enrollment-in-two-phase-3-trials-with-sarilumab-in-r-regn-20130515monthly0.5https://www.biopharmawatch.com/news/REGN/sanofi-and-regeneron-announce-publication-of-positive-phase-2a-results-of-dupilumab-in-ast-regn-20130521monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-bayer-report-positive-phase-3-results-for-eylea-aflibercept-injection-in-myo-regn-20130606monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-first-recipients-of-annual-regeneron-prize-for-creative-innovation-regn-20130627monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-second-quarter-2013-financial-and-operating-results-and-host-conferenc-regn-20130702monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-aflibercept-injection-recommended-for-approval-for-the-treatment-of-visual-impairmen-regn-20130726monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-bayer-report-positive-one-year-results-from-two-phase-3-trials-of-eylea-afli-regn-20130806monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-second-quarter-2013-financial-and-operating-results-regn-20130806monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-granted-fundamental-patents-covering-mouse-antibody-technology-used-in-velocimmu-regn-20130807monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-2013-investor-conference-presentations-regn-20130827monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-appointment-of-robert-e-landry-as-senior-vice-president-finance-and-ch-regn-20130910monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-present-phase-3-data-for-eylea-aflibercept-injection-in-diabetic-macular-edem-regn-20130917monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-third-quarter-2013-financial-and-operating-results-and-host-conference-regn-20131010monthly0.5https://www.biopharmawatch.com/news/REGN/sanofi-and-regeneron-report-positive-top-line-results-with-alirocumab-from-first-phase-3-s-regn-20131016monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-positive-phase-3-data-for-eylea-aflibercept-injection-in-macular-edema-f-regn-20131021monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-named-top-employer-in-the-global-biopharmaceutical-industry-for-the-second-year--regn-20131024monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-2013-investor-conference-presentations-regn-20131101monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-third-quarter-2013-financial-and-operating-results-regn-20131105monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-aflibercept-injection-submitted-for-eu-marketing-authorization-for-the-treatment-of--regn-20131107monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-highlights-eylea-aflibercept-injection-data-to-be-presented-at-american-academy--regn-20131112monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-aflibercept-injection-approved-for-the-treatment-of-macular-edema-following-central--regn-20131122monthly0.5https://www.biopharmawatch.com/news/REGN/sanofi-and-regeneron-report-positive-results-with-sarilumab-in-first-phase-3-rheumatoid-ar-regn-20131122monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-s-chief-executive-officer-and-chief-scientific-officer-named-management-team-of--regn-20131125monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-2013-investor-conference-presentation-regn-20131204monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-32nd-annual-j-p-morgan-healthcare-conference-regn-20131217monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-fda-acceptance-of-eylea-aflibercept-injection-supplemental-biologics-l-regn-20131218monthly0.5https://www.biopharmawatch.com/news/REGN/sanofi-and-regeneron-announce-collaboration-with-american-college-of-cardiology-for-pcsk9--regn-20131219monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-geisinger-health-system-announce-major-human-genetics-research-collaboration-regn-20140113monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-amendment-to-investor-agreement-with-sanofi-regn-20140113monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-launches-new-human-genetics-initiative-regn-20140113monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-fourth-quarter-and-full-year-2013-financial-and-operating-results-and--regn-20140121monthly0.5https://www.biopharmawatch.com/news/REGN/two-year-results-from-phase-3-vista-trial-of-eylea-aflibercept-injection-for-the-treatment-regn-20140210monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-fourth-quarter-and-full-year-2013-financial-and-operating-results-regn-20140211monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-2014-investor-conference-presentations-regn-20140214monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-fda-acceptance-of-eylea-aflibercept-injection-supplemental-biologics-l-regn-20140224monthly0.5https://www.biopharmawatch.com/news/REGN/bayer-healthcare-and-regeneron-announce-regulatory-submission-of-eylea-aflibercept-injecti-regn-20140303monthly0.5https://www.biopharmawatch.com/news/REGN/sanofi-and-regeneron-to-present-alirocumab-clinical-data-at-the-american-college-of-cardio-regn-20140327monthly0.5https://www.biopharmawatch.com/news/REGN/sanofi-and-regeneron-report-positive-results-with-alirocumab-from-phase-2-japanese-study-regn-20140401monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-initiative-for-stem-education-in-hudson-valley-regn-20140403monthly0.5https://www.biopharmawatch.com/news/REGN/robert-a-ingram-elected-to-regeneron-board-of-directors-regn-20140404monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-first-quarter-2014-financial-and-operating-results-and-host-conference-regn-20140411monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-first-quarter-2014-financial-and-operating-results-regn-20140508monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-update-to-upcoming-2014-investor-conference-presentations-regn-20140530monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-winners-of-the-2014-regeneron-prize-for-creative-innovation-regn-20140602monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-aflibercept-injection-submitted-for-eu-marketing-authorization-for-the-treatment-of--regn-20140611monthly0.5https://www.biopharmawatch.com/news/REGN/sanofi-and-regeneron-announce-new-detailed-data-from-positive-sarilumab-phase-3-rheumatoid-regn-20140612monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-aflibercept-injection-recommended-for-approval-for-the-treatment-of-visual-impairmen-regn-20140627monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-positive-results-from-phase-2b-study-of-dupilumab-in-patient-regn-20140709monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-second-quarter-2014-financial-and-operating-results-and-host-conferenc-regn-20140718monthly0.5https://www.biopharmawatch.com/news/REGN/two-year-results-from-phase-3-vivid-dme-trial-of-eylea-aflibercept-injection-for-the-treat-regn-20140718monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-aflibercept-injection-receives-fda-approval-for-the-treatment-of-diabetic-macular-ed-regn-20140729monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-plan-to-use-priority-review-voucher-for-alirocumab-u-s-fda-s-regn-20140730monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-report-positive-top-line-results-from-nine-phase-3-trials-of-alirocum-regn-20140730monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-second-quarter-2014-financial-and-operating-results-regn-20140805monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-aflibercept-injection-receives-eu-approval-for-the-treatment-of-diabetic-macular-ede-regn-20140811monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-2014-investor-conference-presentations-regn-20140819monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-to-present-results-from-four-phase-3-alirocumab-trials-in-hot-line-se-regn-20140825monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-presentation-of-detailed-positive-results-from-four-pivotal--regn-20140831monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-submission-of-application-for-eylea-aflibercept-injection-in-japan-for-regn-20140904monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-aflibercept-injection-receives-fda-breakthrough-therapy-designation-for-diabetic-ret-regn-20140916monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-eylea-aflibercept-injection-approved-for-the-treatment-of-patients-wit-regn-20140922monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-positive-phase-2-top-line-dupilumab-results-in-patients-with-regn-20140930monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-aflibercept-injection-receives-fda-approval-for-macular-edema-following-retinal-vein-regn-20141006monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-third-quarter-2014-financial-and-operating-results-and-host-conference-regn-20141015monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-genetics-center-fully-operational-announces-new-collaborations-and-key-appointme-regn-20141016monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-ranked-number-one-biopharmaceutical-employer-by-science-magazine-for-third-conse-regn-20141016monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-aflibercept-injection-demonstrates-significantly-greater-gains-in-visual-acuity-than-regn-20141017monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-start-of-phase-3-study-of-dupilumab-in-patients-with-atopic--regn-20141020monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-2014-investor-conference-presentations-regn-20141103monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-third-quarter-2014-financial-and-operating-results-regn-20141104monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-positive-results-from-phase-2b-study-of-dupilumab-in-patient-regn-20141111monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-eylea-aflibercept-injection-approved-for-the-treatment-of-diabetic-mac-regn-20141118monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-new-results-from-six-phase-3-trials-showing-that-alirocumab--regn-20141119monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-that-dupilumab-has-received-fda-breakthrough-therapy-designa-regn-20141120monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-aflibercept-injection-accepted-for-priority-review-by-fda-for-diabetic-retinopathy-i-regn-20141201monthly0.5https://www.biopharmawatch.com/news/REGN/have-you-been-counted-regeneron-and-sanofi-us-join-forces-with-leading-cardiovascular-orga-regn-20141215monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-and-panel-discussion-at-the-33rd-annual-j-p-morgan-health-regn-20141219monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-positive-topline-results-from-first-phase-3-trials-evaluatin-regn-20150109monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-fourth-quarter-and-full-year-2014-financial-and-operating-results-and--regn-20150109monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-praluent-alirocumab-marketing-authorization-application-has--regn-20150112monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-aflibercept-injection-recommended-for-approval-for-the-treatment-of-visual-impairmen-regn-20150123monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-praluent-alirocumab-biologics-license-application-has-been-a-regn-20150126monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-fourth-quarter-and-full-year-2014-financial-and-operating-results-regn-20150210monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-2015-investor-conference-presentations-regn-20150213monthly0.5https://www.biopharmawatch.com/news/REGN/new-results-from-cholesterol-counts-show-most-americans-polled-do-not-know-their-bad-chole-regn-20150218monthly0.5https://www.biopharmawatch.com/news/REGN/nih-sponsored-comparative-effectiveness-trial-in-diabetic-macular-edema-shows-eylea-aflibe-regn-20150218monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-aflibercept-injection-receives-eu-approval-for-the-treatment-of-visual-impairment-du-regn-20150226monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-18-month-results-of-odyssey-long-term-trial-with-praluent-al-regn-20150315monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-aflibercept-injection-receives-fda-approval-for-the-treatment-of-diabetic-retinopath-regn-20150325monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-first-quarter-2015-financial-and-operating-results-and-host-conference-regn-20150410monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-2015-investor-conference-presentations-regn-20150429monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-first-quarter-2015-financial-and-operating-results-regn-20150507monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-positive-pivotal-phase-2b-dupilumab-data-in-asthma-presented-regn-20150518monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-positive-topline-results-from-phase-3-studies-with-sarilumab-regn-20150521monthly0.5https://www.biopharmawatch.com/news/REGN/fda-advisory-committee-recommends-approval-of-regeneron-and-sanofi-s-praluent-alirocumab-i-regn-20150609monthly0.5https://www.biopharmawatch.com/news/REGN/trading-in-regeneron-common-stock-halted-regn-20150609monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-2015-winners-of-the-regeneron-prize-for-creative-innovation-regn-20150625monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-aflibercept-injection-receives-approval-in-japan-for-the-treatment-of-retinal-vein-o-regn-20150626monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-rapid-response-platform-for-emerging-infectious-diseases-described-in-proceeding-regn-20150629monthly0.5https://www.biopharmawatch.com/news/REGN/new-film-documents-heart-felt-stories-of-people-living-with-high-ldl-cholesterol-regn-20150630monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-phase-3-results-showing-ldl-c-reductions-of-more-than-60-per-regn-20150708monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-second-quarter-2015-financial-and-operating-results-and-host-conferenc-regn-20150708monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-chmp-recommends-european-approval-of-praluent-alirocumab-for-regn-20150724monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-fda-approval-of-praluent-alirocumab-injection-the-first-pcsk-regn-20150724monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-launch-major-new-immuno-oncology-collaboration-regn-20150728monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-2015-investor-conference-presentations-regn-20150831monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-new-positive-praluent-alirocumab-phase-3-data-presented-at-e-regn-20150901monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-agreement-with-barda-for-the-development-of-new-antibody-treatment-for-regn-20150921monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-icahn-school-of-medicine-at-mount-sinai-announce-new-antibody-research-agree-regn-20150924monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-approval-of-praluent-alirocumab-for-the-treatment-of-hyperch-regn-20150928monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-collaboration-with-mitsubishi-tanabe-pharma-for-investigational-pain-t-regn-20151001monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-third-quarter-2015-financial-and-operating-results-and-host-conference-regn-20151008monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-24th-annual-credit-suisse-healthcare-conference-regn-20151023monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-eu-approval-of-eylea-aflibercept-injection-for-the-treatment-of-visual-regn-20151030monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-third-quarter-2015-financial-and-operating-results-regn-20151104monthly0.5https://www.biopharmawatch.com/news/REGN/new-survey-of-u-s-adults-with-diabetes-reveals-less-than-half-understand-their-risk-for-vi-regn-20151105monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-present-results-from-pivotal-phase-3-study-of-sarilumab-at-american-c-regn-20151108monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-new-praluent-alirocumab-injection-analyses-presented-at-aha--regn-20151110monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-18-000-patient-odyssey-outcomes-trial-of-praluent-injection--regn-20151124monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-unitedhealth-group-selects-praluent-alirocumab-injection-for-regn-20151211monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-mourns-passing-of-dr-alfred-g-gilman-board-member-and-nobel-laureate-regn-20151227monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-34th-annual-j-p-morgan-healthcare-conference-regn-20160107monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-sarilumab-biologics-license-application-accepted-for-review--regn-20160108monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-fourth-quarter-and-full-year-2015-financial-and-operating-results-and--regn-20160126monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-2016-investor-conference-presentation-regn-20160202monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-fourth-quarter-and-full-year-2015-financial-and-operating-results-regn-20160209monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-2016-investor-conference-presentation-regn-20160229monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-genetics-center-publication-in-new-england-journal-of-medicine-links-angptl4-inh-regn-20160302monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-topline-results-of-phase-3-monotherapy-study-demonstrating-s-regn-20160311monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-strongly-disagree-with-u-s-jury-verdict-in-ongoing-patent-litigation--regn-20160316monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-positive-topline-results-from-phase-3-praluent-alirocumab-st-regn-20160323monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-bayer-to-jointly-develop-novel-combination-therapy-for-eye-diseases-regn-20160324monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-positive-dupilumab-topline-results-from-two-phase-3-trials-i-regn-20160401monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-intellia-therapeutics-announce-collaboration-to-discover-and-develop-crispr--regn-20160411monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-first-quarter-2016-financial-and-operating-results-and-host-conference-regn-20160415monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-2016-investor-conference-presentations-regn-20160429monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-positive-topline-results-from-phase-2-3-fasinumab-study-in-patients-wi-regn-20160502monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-first-quarter-2016-financial-and-operating-results-regn-20160505monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-selected-by-society-for-science-the-public-as-new-sponsor-of-the-science-talent--regn-20160526monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-presents-positive-interim-data-from-phase-2-proof-of-concept-study-of-evinacumab-regn-20160531monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-that-dupilumab-used-with-topical-corticosteroids-tcs-was-sup-regn-20160606monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-approval-of-praluent-alirocumab-for-the-treatment-of-hyperch-regn-20160705monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-second-quarter-2016-financial-and-operating-results-and-host-conferenc-regn-20160708monthly0.5https://www.biopharmawatch.com/news/REGN/award-winning-chef-elizabeth-falkner-reveals-her-struggle-with-atopic-dermatitis-to-highli-regn-20160712monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-2016-winners-of-the-regeneron-prize-for-creative-innovation-regn-20160713monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-2016-investor-conference-presentation-regn-20160718monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-agreement-with-barda-for-the-manufacturing-and-testing-of-new-antibodi-regn-20160822monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-present-positive-phase-3-investigational-data-for-praluent-alirocumab-regn-20160829monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-2016-investor-conference-presentations-regn-20160901monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-election-of-bonnie-bassler-ph-d-and-huda-zoghbi-m-d-to-board-of-direct-regn-20160912monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-teva-announce-global-collaboration-to-develop-and-commercialize-fasinumab-an-regn-20160920monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-dupilumab-biologics-license-application-accepted-for-priorit-regn-20160926monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-phase-2-study-of-aflibercept-co-formulated-with-rinucumab-anti-pdgfr-b-regn-20160930monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-positive-dupixent-dupilumab-phase-3-atopic-dermatitis-data-p-regn-20161001monthly0.5https://www.biopharmawatch.com/news/REGN/new-survey-reveals-the-widespread-and-serious-impact-of-moderate-to-severe-atopic-dermatit-regn-20161005monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-third-quarter-2016-financial-and-operating-results-and-host-conference-regn-20161007monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-teva-provide-update-on-fasinumab-clinical-development-programs-regn-20161017monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-25th-annual-credit-suisse-healthcare-conference-regn-20161021monthly0.5https://www.biopharmawatch.com/news/REGN/science-magazine-once-again-names-regeneron-the-best-company-to-work-for-regn-20161027monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-receive-complete-response-letter-from-fda-for-sarilumab-an-investigat-regn-20161028monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-third-quarter-2016-financial-and-operating-results-regn-20161104monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-to-present-data-from-phase-3-praluent-alirocumab-injection-clinical-t-regn-20161111monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-present-results-from-phase-3-monarch-study-of-investigational-sarilum-regn-20161116monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-praluent-alirocumab-cardiovascular-outcomes-trial-will-conti-regn-20161117monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-ceo-leonard-schleifer-and-cso-george-yancopoulos-named-ey-2016-national-life-sci-regn-20161121monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-marketing-authorization-application-for-dupixent-dupilumab-a-regn-20161208monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-35th-annual-j-p-morgan-healthcare-conference-regn-20161222monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-genetics-center-and-geisinger-study-finds-life-threatening-genetic-disorder-is-s-regn-20161222monthly0.5https://www.biopharmawatch.com/news/REGN/science-publication-highlights-the-precision-medicine-approach-of-the-regeneron-genetics-c-regn-20161222monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-hires-jay-markowitz-m-d-as-senior-vice-president-of-portfolio-management-regn-20170104monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-to-appeal-u-s-district-court-rulings-in-ongoing-patent-litigation-reg-regn-20170105monthly0.5https://www.biopharmawatch.com/news/REGN/forty-of-nation-s-brightest-young-scientists-named-regeneron-science-talent-search-2017-fi-regn-20170124monthly0.5https://www.biopharmawatch.com/news/REGN/tony-coles-m-d-elected-to-regeneron-board-of-directors-regn-20170131monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-first-approval-of-kevzara-sarilumab-for-the-treatment-of-mod-regn-20170201monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-fourth-quarter-and-full-year-2016-financial-and-operating-results-and--regn-20170207monthly0.5https://www.biopharmawatch.com/news/REGN/appeals-court-grants-stay-of-permanent-injunction-for-praluent-alirocumab-during-appeals-p-regn-20170208monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-fourth-quarter-and-full-year-2016-financial-and-operating-results-regn-20170209monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-2017-investor-conference-presentations-regn-20170213monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-to-present-new-data-on-dupixent-dupilumab-for-moderate-to-severe-atop-regn-20170227monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-presentation-of-positive-data-from-long-term-pivotal-phase-3-regn-20170304monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-to-present-new-phase-3-praluent-alirocumab-injection-clinical-trial-a-regn-20170307monthly0.5https://www.biopharmawatch.com/news/REGN/teen-scientist-researches-new-approach-to-neurological-damage-wins-regeneron-science-talen-regn-20170314monthly0.5https://www.biopharmawatch.com/news/REGN/u-k-biobank-regeneron-and-gsk-announce-largest-gene-sequencing-initiative-on-world-s-most--regn-20170322monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-fda-approval-of-dupixent-dupilumab-the-first-targeted-biolog-regn-20170328monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-to-host-investor-conference-call-to-discuss-dupixent-dupilumab-approv-regn-20170328monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-evinacumab-has-received-fda-breakthrough-therapy-designation-for-homoz-regn-20170406monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-first-quarter-2017-financial-and-operating-results-and-host-conference-regn-20170414monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-receive-positive-chmp-opinion-for-kevzara-sarilumab-to-treat-adult-pa-regn-20170424monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-fda-approval-of-a-new-once-monthly-dosing-option-for-praluen-regn-20170425monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-kevzara-sarilumab-biologics-license-application-resubmission-regn-20170428monthly0.5https://www.biopharmawatch.com/news/REGN/survey-results-show-eighty-percent-of-rheumatoid-arthritis-patients-report-life-altering-p-regn-20170502monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-first-quarter-2017-financial-and-operating-results-regn-20170504monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-investor-conference-presentations-regn-20170505monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-inovio-enter-immuno-oncology-clinical-study-agreement-for-glioblastoma-combi-regn-20170508monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sillajen-announce-immuno-oncology-clinical-study-agreement-for-combination-t-regn-20170508monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-investor-conference-presentations-regn-20170518monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-fda-approval-of-kevzara-sarilumab-for-the-treatment-of-moder-regn-20170522monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-angptl3-evinacumab-publication-in-new-england-journal-of-medicine-and--regn-20170524monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-present-positive-study-results-for-investigational-pd-1-antibody-regn-regn-20170604monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-positive-results-from-first-dedicated-studies-evaluating-pra-regn-20170611monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-recognized-on-the-civic-50-list-of-the-most-community-minded-companies-in-the-un-regn-20170621monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-details-royalty-agreement-with-novartis-for-canakinumab-acz885-regn-20170622monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-approval-of-kevzara-sarilumab-to-treat-adult-patients-with-m-regn-20170627monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-the-2017-winners-of-the-regeneron-prize-for-creative-innovation-regn-20170713monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-second-quarter-2017-financial-and-operating-results-and-host-conferenc-regn-20170713monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-receive-positive-chmp-opinion-for-dupixent-dupilumab-to-treat-adult-p-regn-20170721monthly0.5https://www.biopharmawatch.com/news/REGN/accessing-the-regeneron-second-quarter-2017-financial-and-operating-results-webcast-regn-20170803monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-second-quarter-2017-financial-and-operating-results-regn-20170803monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-discontinue-development-of-suptavumab-for-respiratory-syncytial-virus-regn-20170814monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-to-present-new-analyses-from-praluent-alirocumab-injection-trials-at--regn-20170825monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-investor-conference-presentations-regn-20170831monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-cemiplimab-regn2810-has-received-fda-breakthrough-therapy-de-regn-20170908monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-positive-dupilumab-topline-results-from-phase-3-trial-in-unc-regn-20170911monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-positive-study-results-for-dupixent-dupilumab-in-patients-wi-regn-20170916monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-approval-of-dupixent-dupilumab-to-treat-adult-patients-with--regn-20170928monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-new-collaborations-with-hhs-to-develop-antibodies-against-ebola-influe-regn-20171002monthly0.5https://www.biopharmawatch.com/news/REGN/appellate-court-orders-a-new-trial-and-vacates-permanent-injunction-in-ongoing-patent-case-regn-20171005monthly0.5https://www.biopharmawatch.com/news/REGN/internationally-acclaimed-writer-and-executive-producer-of-hbo-s-the-night-of-reveals-his--regn-20171011monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-third-quarter-2017-financial-and-operating-results-and-host-conference-regn-20171011monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-positive-phase-2-study-results-for-dupilumab-in-patients-wit-regn-20171016monthly0.5https://www.biopharmawatch.com/news/REGN/science-magazine-ranks-regeneron-1-biopharma-employer-for-fifth-time-regn-20171019monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-s-first-global-day-of-service-supports-over-100-non-profit-and-community-organiz-regn-20171027monthly0.5https://www.biopharmawatch.com/news/REGN/dupilumab-significantly-reduced-steroid-use-asthma-attacks-and-improved-lung-function-in-p-regn-20171031monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-share-clinical-progress-of-regn1979-and-cemiplimab-regn2810-in-b-cell-lymphom-regn-20171101monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-to-present-new-analyses-from-the-praluent-alirocumab-injection-odysse-regn-20171107monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-third-quarter-2017-financial-and-operating-results-regn-20171108monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-investor-conference-presentation-regn-20171115monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-provides-update-on-eylea-aflibercept-injection-and-nesvacumab-ang2-antibody-comb-regn-20171127monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-fda-acceptance-of-sbla-filing-for-12-week-dosing-of-eylea-aflibercept--regn-20171211monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-positive-topline-pivotal-results-for-pd-1-antibody-cemiplima-regn-20171213monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-collaboration-programs-highlighted-during-sanofi-analyst-day-regn-20171213monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-isa-pharmaceuticals-announce-strategic-immuno-oncology-collaboration-regn-20171218monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-36th-annual-j-p-morgan-healthcare-conference-regn-20171227monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-to-accelerate-and-expand-investment-for-cemiplimab-and-dupilumab-deve-regn-20180108monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-forms-consortium-of-leading-life-sciences-companies-to-accelerate-largest-widely-regn-20180108monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-approval-of-dupixent-dupilumab-in-japan-for-the-treatment-of-atopic-de-regn-20180122monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-fourth-quarter-and-full-year-2017-financial-and-operating-results-and--regn-20180123monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-fourth-quarter-and-full-year-2017-financial-and-operating-results-regn-20180208monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-appointment-of-marion-mccourt-as-senior-vice-president-and-head-of-com-regn-20180212monthly0.5https://www.biopharmawatch.com/news/REGN/fda-to-review-dupixent-dupilumab-as-potential-treatment-for-moderate-to-severe-asthma-regn-20180302monthly0.5https://www.biopharmawatch.com/news/REGN/praluent-alirocumab-injection-significantly-reduced-risk-of-cardiovascular-events-in-high--regn-20180310monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-plans-to-make-praluent-alirocumab-more-accessible-and-afford-regn-20180310monthly0.5https://www.biopharmawatch.com/news/REGN/teen-scientists-win-1-8-million-at-regeneron-science-talent-search-2018-with-top-awards-fo-regn-20180313monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-aflibercept-injection-demonstrates-positive-topline-results-in-phase-3-non-prolifera-regn-20180319monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-genetics-center-publication-in-new-england-journal-of-medicine-identifies-new-ge-regn-20180321monthly0.5https://www.biopharmawatch.com/news/REGN/ema-to-review-cemiplimab-as-a-potential-treatment-for-advanced-cutaneous-squamous-cell-car-regn-20180403monthly0.5https://www.biopharmawatch.com/news/REGN/ema-to-review-dupixent-dupilumab-as-potential-treatment-for-inadequately-controlled-modera-regn-20180403monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-first-quarter-2018-financial-and-operating-results-and-host-conference-regn-20180409monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-investor-conference-presentations-regn-20180423monthly0.5https://www.biopharmawatch.com/news/REGN/fda-to-conduct-priority-review-of-cemiplimab-as-a-potential-treatment-for-advanced-cutaneo-regn-20180430monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-to-lower-net-price-of-praluent-alirocumab-injection-in-exchange-for-s-regn-20180501monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-first-quarter-2018-financial-and-operating-results-regn-20180503monthly0.5https://www.biopharmawatch.com/news/REGN/positive-phase-3-trial-of-dupixent-dupilumab-in-adolescents-with-inadequately-controlled-m-regn-20180516monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-share-first-positive-clinical-data-for-cemiplimab-in-advanced-non-sma-regn-20180516monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-investor-conference-presentation-regn-20180518monthly0.5https://www.biopharmawatch.com/news/REGN/new-england-journal-of-medicine-publishes-two-positive-phase-3-trials-showing-dupixent-dup-regn-20180521monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-s-investigational-ebola-treatment-shipping-to-democratic-republic-of-the-congo-f-regn-20180531monthly0.5https://www.biopharmawatch.com/news/REGN/new-england-journal-of-medicine-publishes-pivotal-cemiplimab-trials-showing-positive-resul-regn-20180604monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-zoetis-announce-collaboration-to-research-antibody-therapies-for-use-in-anim-regn-20180606monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-second-quarter-2018-financial-and-operating-results-and-host-conferenc-regn-20180709monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-second-quarter-2018-financial-and-operating-results-regn-20180802monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-the-2018-winners-of-the-regeneron-prize-for-creative-innovation-regn-20180803monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-bluebird-bio-announce-collaboration-to-discover-develop-and-commercialize-ne-regn-20180806monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-provides-regulatory-update-on-eylea-aflibercept-injection-sbla-in-wet-age-relate-regn-20180813monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-teva-announce-positive-topline-phase-3-fasinumab-results-in-patients-with-ch-regn-20180816monthly0.5https://www.biopharmawatch.com/news/REGN/fda-approves-eylea-aflibercept-injection-sbla-in-wet-age-related-macular-degeneration-regn-20180817monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-investor-conference-presentation-regn-20180824monthly0.5https://www.biopharmawatch.com/news/REGN/fda-to-review-supplemental-biologics-license-application-for-praluent-alirocumab-injection-regn-20180912monthly0.5https://www.biopharmawatch.com/news/REGN/fda-to-review-eylea-aflibercept-injection-for-the-treatment-of-diabetic-retinopathy-regn-20180913monthly0.5https://www.biopharmawatch.com/news/REGN/positive-phase-3-results-presented-for-dupixent-dupilumab-show-significant-improvement-on--regn-20180915monthly0.5https://www.biopharmawatch.com/news/REGN/fda-approves-libtayo-cemiplimab-rwlc-as-first-and-only-treatment-for-advanced-cutaneous-sq-regn-20180928monthly0.5https://www.biopharmawatch.com/news/REGN/libtayo-cemiplimab-rwlc-data-at-esmo-2018-congress-provide-new-insights-in-six-tumor-types-regn-20181008monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-third-quarter-2018-financial-and-operating-results-and-host-conference-regn-20181008monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-showed-positive-topline-results-in-two-phase-3-trials-of-patients-with--regn-20181016monthly0.5https://www.biopharmawatch.com/news/REGN/fda-approves-asthma-indication-for-dupixent-dupilumab-regn-20181019monthly0.5https://www.biopharmawatch.com/news/REGN/kevzara-sarilumab-data-at-the-2018-acr-arhp-annual-meeting-provide-additional-insight-on-s-regn-20181019monthly0.5https://www.biopharmawatch.com/news/REGN/fda-approves-asthma-indication-for-dupixent-dupilumab-regn-20181022monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-aflibercept-injection-improves-diabetic-retinopathy-and-reduces-vision-threatening-c-regn-20181025monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-ranked-1-biopharma-employer-for-sixth-time-by-science-magazine-regn-20181026monthly0.5https://www.biopharmawatch.com/news/REGN/fda-grants-priority-review-for-dupixent-dupilumab-as-potential-treatment-for-adolescents-w-regn-20181106monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-third-quarter-2018-financial-and-operating-results-regn-20181106monthly0.5https://www.biopharmawatch.com/news/REGN/new-england-journal-of-medicine-publishes-positive-detailed-results-from-praluent-alirocum-regn-20181107monthly0.5https://www.biopharmawatch.com/news/REGN/odyssey-outcomes-investigators-highlight-at-aha-that-praluent-alirocumab-injection-was-ass-regn-20181111monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-investor-conference-presentation-regn-20181120monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-presents-positive-data-at-ash-for-regn1979-cd20xcd3-bispecific-antibody-in-relap-regn-20181201monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-37th-annual-j-p-morgan-healthcare-conference-regn-20181218monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-restructure-immuno-oncology-collaboration-for-discovery-and-developme-regn-20190107monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-fourth-quarter-and-full-year-2018-financial-and-operating-results-and--regn-20190118monthly0.5https://www.biopharmawatch.com/news/REGN/forty-of-the-nation-s-most-brilliant-young-scientists-named-finalists-in-regeneron-science-regn-20190123monthly0.5https://www.biopharmawatch.com/news/REGN/chmp-recommends-approval-of-praluent-alirocumab-injection-to-reduce-cardiovascular-risk-in-regn-20190204monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-fourth-quarter-and-full-year-2018-financial-and-operating-results-regn-20190206monthly0.5https://www.biopharmawatch.com/news/REGN/one-year-results-from-positive-phase-3-eylea-trial-in-diabetic-retinopathy-presented-at-an-regn-20190209monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-offer-praluent-alirocumab-at-a-new-reduced-u-s-list-price-regn-20190211monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-investor-conference-presentation-regn-20190214monthly0.5https://www.biopharmawatch.com/news/REGN/u-s-and-eu-patent-office-decisions-invalidate-amgen-subsidiary-immunex-s-patents-claiming--regn-20190215monthly0.5https://www.biopharmawatch.com/news/REGN/positive-results-presented-from-two-phase-3-trials-of-dupixent-dupilumab-in-severe-chronic-regn-20190225monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-strongly-disagree-with-verdict-upholding-three-of-five-amgen-u-s-pate-regn-20190225monthly0.5https://www.biopharmawatch.com/news/REGN/chmp-recommends-approval-of-dupixent-dupilumab-for-asthma-indication-regn-20190301monthly0.5https://www.biopharmawatch.com/news/REGN/new-analyses-to-be-presented-at-aad-for-dupixent-dupilumab-and-the-burden-of-atopic-dermat-regn-20190301monthly0.5https://www.biopharmawatch.com/news/REGN/fda-to-undertake-priority-review-of-dupixent-dupilumab-for-adults-with-inadequately-contro-regn-20190308monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-investor-conference-call-regn-20190308monthly0.5https://www.biopharmawatch.com/news/REGN/fda-approves-dupixent-dupilumab-for-moderate-to-severe-atopic-dermatitis-in-adolescents-regn-20190311monthly0.5https://www.biopharmawatch.com/news/REGN/new-genetic-data-from-regeneron-and-gsk-on-50-000-uk-biobank-participants-made-available-t-regn-20190311monthly0.5https://www.biopharmawatch.com/news/REGN/teen-scientists-win-1-8-million-at-regeneron-science-talent-search-2019-with-innovative-id-regn-20190312monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-to-present-new-praluent-alirocumab-data-at-acc-19-regn-20190313monthly0.5https://www.biopharmawatch.com/news/REGN/praluent-alirocumab-now-approved-in-european-union-to-reduce-the-risk-of-cardiovascular-ev-regn-20190315monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-alnylam-announce-broad-collaboration-to-discover-develop-and-commercialize-r-regn-20190408monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-first-quarter-2019-financial-and-operating-results-and-host-conference-regn-20190408monthly0.5https://www.biopharmawatch.com/news/REGN/chmp-issues-positive-opinion-for-libtayo-cemiplimab-in-advanced-cutaneous-squamous-cell-ca-regn-20190426monthly0.5https://www.biopharmawatch.com/news/REGN/fda-approves-praluent-alirocumab-to-prevent-heart-attack-stroke-and-unstable-angina-requir-regn-20190426monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-investor-conference-presentations-regn-20190429monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-approved-for-severe-asthma-by-european-commission-regn-20190507monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-first-quarter-2019-financial-and-operating-results-regn-20190507monthly0.5https://www.biopharmawatch.com/news/REGN/fda-approves-eylea-aflibercept-injection-for-diabetic-retinopathy-regn-20190513monthly0.5https://www.biopharmawatch.com/news/REGN/updated-libtayo-cemiplimab-rwlc-results-reinforce-durable-and-substantial-response-rates-i-regn-20190516monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-investor-conference-presentation-regn-20190523monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-cd20xcd3-bispecific-regn1979-shows-positive-results-in-patients-with-relapsed-or-regn-20190614monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-positive-topline-phase-2-results-for-il-33-antibody-in-asthm-regn-20190621monthly0.5https://www.biopharmawatch.com/news/REGN/fda-approves-dupixent-dupilumab-for-chronic-rhinosinusitis-with-nasal-polyposis-regn-20190626monthly0.5https://www.biopharmawatch.com/news/REGN/chmp-recommends-approval-of-dupixent-dupilumab-for-moderate-to-severe-atopic-dermatitis-in-regn-20190628monthly0.5https://www.biopharmawatch.com/news/REGN/libtayo-cemiplimab-approved-for-advanced-cutaneous-squamous-cell-carcinoma-in-the-european-regn-20190701monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-second-quarter-2019-financial-and-operating-results-and-host-conferenc-regn-20190708monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-the-2019-winners-of-the-regeneron-prize-for-creative-innovation-regn-20190718monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-approved-by-european-commission-for-adolescents-with-moderate-to-severe-regn-20190806monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-showed-positive-topline-results-in-phase-3-trial-of-children-aged-6-to--regn-20190806monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-second-quarter-2019-financial-and-operating-results-regn-20190806monthly0.5https://www.biopharmawatch.com/news/REGN/palm-ebola-clinical-trial-stopped-early-as-regeneron-s-regn-eb3-therapy-shows-superiority--regn-20190812monthly0.5https://www.biopharmawatch.com/news/REGN/fda-approves-eylea-aflibercept-injection-prefilled-syringe-regn-20190813monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-positive-topline-results-from-phase-3-trial-of-evinacumab-in-patients--regn-20190814monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-investor-conference-presentation-regn-20190815monthly0.5https://www.biopharmawatch.com/news/REGN/u-s-district-court-invalidates-amgen-patent-claims-targeting-pcsk9-regn-20190828monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-debuts-on-prestigious-dow-jones-sustainability-world-index-of-most-sustainable-c-regn-20190917monthly0.5https://www.biopharmawatch.com/news/REGN/educational-campaign-helps-teens-and-their-caregivers-tackle-everyday-challenges-of-living-regn-20190918monthly0.5https://www.biopharmawatch.com/news/REGN/chmp-recommends-approval-of-dupixent-dupilumab-for-severe-chronic-rhinosinusitis-with-nasa-regn-20190920monthly0.5https://www.biopharmawatch.com/news/REGN/the-lancet-publishes-results-from-two-positive-phase-3-trials-of-dupixent-dupilumab-in-sev-regn-20190920monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-third-quarter-2019-financial-and-operating-results-and-host-conference-regn-20191010monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-investor-conference-presentations-regn-20191018monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-colleagues-support-150-community-organizations-during-third-annual-day-for-doing-regn-20191025monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-ranked-2-in-science-magazine-s-top-biopharma-companies-to-work-for-regn-20191025monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-now-approved-in-european-union-for-severe-chronic-rhinosinusitis-with-n-regn-20191029monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-provides-updates-on-phase-3-libtayo-cemiplimab-development-program-in-advanced-n-regn-20191105monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-third-quarter-2019-financial-and-operating-results-regn-20191105monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-vyriad-announce-strategic-agreement-for-discovery-and-development-of-new-onc-regn-20191106monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-results-from-cd20xcd3-and-bcmaxcd3-bispecifics-and-c5-antibody-program-regn-20191106monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-investor-conference-presentations-regn-20191112monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-s-yancopoulos-receives-columbia-college-s-alexander-hamilton-award-regn-20191122monthly0.5https://www.biopharmawatch.com/news/REGN/new-england-journal-of-medicine-publishes-results-of-ebola-clinical-trial-confirming-super-regn-20191127monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-positive-topline-phase-2-data-with-anti-c5-antibody-pozelimab-in-patie-regn-20191205monthly0.5https://www.biopharmawatch.com/news/REGN/first-clinical-data-for-regn5458-bcmaxcd3-show-positive-preliminary-results-in-multiple-my-regn-20191208monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-announce-intent-to-restructure-antibody-collaboration-for-kevzara-sar-regn-20191210monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-cold-spring-harbor-laboratory-unveil-new-dedicated-laboratories-for-student--regn-20191212monthly0.5https://www.biopharmawatch.com/news/REGN/society-for-science-the-public-announces-regeneron-as-new-title-sponsor-of-the-internation-regn-20191212monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-38th-annual-j-p-morgan-healthcare-conference-regn-20191220monthly0.5https://www.biopharmawatch.com/news/REGN/publication-highlights-regeneron-s-costimulatory-bispecific-antibodies-an-emerging-class-o-regn-20200108monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-encouraging-garetosmab-phase-2-results-in-patients-with-ultra-rare-deb-regn-20200109monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-fourth-quarter-and-full-year-2019-financial-and-operating-results-and--regn-20200110monthly0.5https://www.biopharmawatch.com/news/REGN/forty-of-the-nation-s-brightest-young-scientists-named-finalists-in-regeneron-science-tale-regn-20200122monthly0.5https://www.biopharmawatch.com/news/REGN/fda-accepts-for-priority-review-dupixent-dupilumab-for-children-aged-6-to-11-years-with-mo-regn-20200128monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-expanded-collaboration-with-hhs-to-develop-antibody-treatments-for-new-regn-20200204monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-fourth-quarter-and-full-year-2019-financial-and-operating-results-regn-20200206monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-aflibercept-injection-reduced-risk-of-developing-vision-threatening-events-by-75-aft-regn-20200208monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-investor-conference-presentations-regn-20200212monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-important-advances-in-novel-covid-19-antibody-program-regn-20200317monthly0.5https://www.biopharmawatch.com/news/REGN/first-patient-outside-u-s-treated-in-global-kevzara-sarilumab-clinical-trial-program-for-p-regn-20200330monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-american-college-of-cardiology-presentation-of-positive-phase-3-evinac-regn-20200330monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-phase-3-data-at-revolutionizing-atopic-dermatitis-conference-show-signi-regn-20200403monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-finalizes-praluent-alirocumab-restructuring-and-updates-accounting-presentation-regn-20200406monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-zai-lab-announce-regional-strategic-collaboration-for-regn1979-cd20xcd3-bisp-regn-20200408monthly0.5https://www.biopharmawatch.com/news/REGN/fda-accepts-for-priority-review-biologics-license-application-for-regn-eb3-to-treat-ebola-regn-20200416monthly0.5https://www.biopharmawatch.com/news/REGN/phase-3-trial-of-libtayo-cemiplimab-as-monotherapy-for-first-line-advanced-non-small-cell--regn-20200427monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-provide-update-on-u-s-phase-2-3-adaptive-designed-trial-of-kevzara-sa-regn-20200427monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-upcoming-investor-conference-presentations-regn-20200429monthly0.5https://www.biopharmawatch.com/news/REGN/libtayo-cemiplimab-shows-clinically-meaningful-and-durable-responses-in-second-line-advanc-regn-20200505monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-colorado-center-for-personalized-medicine-announce-major-new-human-genetics--regn-20200511monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-presentations-at-asco-2020-showcase-diverse-clinical-oncology-portfolio-regn-20200513monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-eosinophilic-esophagitis-trial-meets-both-co-primary-endpoints-regn-20200522monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-secondary-offering-of-its-common-stock-held-by-sanofi-and-5-billion-st-regn-20200525monthly0.5https://www.biopharmawatch.com/news/REGN/fda-approves-dupixent-dupilumab-as-first-biologic-medicine-for-children-aged-6-to-11-years-regn-20200526monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-pricing-of-secondary-offering-of-its-common-stock-held-by-sanofi-regn-20200526monthly0.5https://www.biopharmawatch.com/news/REGN/libtayo-cemiplimab-rwlc-longer-term-results-in-advanced-cutaneous-squamous-cell-carcinoma--regn-20200529monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-completes-secondary-offering-of-common-stock-held-by-sanofi-regn-20200529monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-intellia-therapeutics-expand-collaboration-to-develop-crispr-cas9-based-trea-regn-20200601monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-virtual-only-format-for-2020-annual-meeting-of-shareholders-regn-20200608monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-recognized-as-healthcare-sector-leader-on-the-civic-50-list-of-the-most-communit-regn-20200610monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-begins-first-clinical-trials-of-anti-viral-antibody-cocktail-regn-cov2-for-the-t-regn-20200611monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-collaborations-on-dupixent-dupilumab-highlighted-during-sanofi-r-d-investor-even-regn-20200611monthly0.5https://www.biopharmawatch.com/news/REGN/two-science-publications-highlight-potential-of-regn-cov2-anti-viral-antibody-cocktail-to--regn-20200611monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-approved-in-china-for-adults-with-moderate-to-severe-atopic-dermatitis-regn-20200619monthly0.5https://www.biopharmawatch.com/news/REGN/fda-approves-new-dupixent-dupilumab-pre-filled-pen-designed-to-support-more-convenient-sel-regn-20200619monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-the-2020-winners-of-the-regeneron-prize-for-creative-innovation-regn-20200622monthly0.5https://www.biopharmawatch.com/news/REGN/new-publication-highlights-preclinical-research-showing-potential-to-enhance-cancer-treatm-regn-20200624monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-vigorously-defend-allegations-related-to-contributions-to-a-patient-assistanc-regn-20200624monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-provide-update-on-kevzara-sarilumab-phase-3-u-s-trial-in-covid-19-pat-regn-20200702monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-start-of-regn-cov2-phase-3-covid-19-prevention-trial-in-collaboration--regn-20200706monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-manufacturing-and-supply-agreement-for-barda-and-u-s-department-of-def-regn-20200707monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-second-quarter-2020-financial-and-operating-results-and-host-conferenc-regn-20200708monthly0.5https://www.biopharmawatch.com/news/REGN/barda-procures-regeneron-s-regn-eb3-investigational-ebola-treatment-for-national-preparedn-regn-20200729monthly0.5https://www.biopharmawatch.com/news/REGN/teen-scientists-win-1-8-million-at-virtual-regeneron-science-talent-search-2020-for-exempl-regn-20200729monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-pricing-of-public-offering-of-senior-unsecured-notes-regn-20200807monthly0.5https://www.biopharmawatch.com/news/REGN/fda-accepts-evinacumab-biologics-license-application-for-priority-review-as-a-treatment-fo-regn-20200812monthly0.5https://www.biopharmawatch.com/news/REGN/new-england-journal-of-medicine-publishes-positive-phase-3-evinacumab-results-in-patients--regn-20200819monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-roche-collaborate-to-significantly-increase-global-supply-of-regn-cov2-inves-regn-20200819monthly0.5https://www.biopharmawatch.com/news/REGN/late-breaking-libtayo-cemiplimab-pivotal-data-in-advanced-non-small-cell-lung-cancer-and-b-regn-20200903monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-long-term-data-show-sustained-improvement-in-lung-function-and-reductio-regn-20200908monthly0.5https://www.biopharmawatch.com/news/REGN/fda-grants-dupixent-dupilumab-breakthrough-therapy-designation-for-eosinophilic-esophagiti-regn-20200914monthly0.5https://www.biopharmawatch.com/news/REGN/recovery-covid-19-phase-3-trial-to-evaluate-regeneron-s-regn-cov2-investigational-antibody-regn-20200914monthly0.5https://www.biopharmawatch.com/news/REGN/positive-pivotal-data-for-libtayo-cemiplimab-monotherapy-in-locally-advanced-basal-cell-ca-regn-20200918monthly0.5https://www.biopharmawatch.com/news/REGN/late-breaking-esmo-presentation-shows-libtayo-cemiplimab-monotherapy-increases-overall-sur-regn-20200921monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-s-regn-cov2-antibody-cocktail-reduced-viral-levels-and-improved-symptoms-in-non--regn-20200929monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-third-quarter-2020-financial-and-operating-results-and-host-conference-regn-20201006monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-significantly-reduced-severe-asthma-attacks-in-children-and-is-the-only-regn-20201013monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-s-antibody-cocktail-regn-eb3-inmazeb-is-first-fda-approved-treatment-for-ebola-z-regn-20201014monthly0.5https://www.biopharmawatch.com/news/REGN/chmp-recommends-approval-of-dupixent-dupilumab-for-children-aged-6-to-11-years-with-severe-regn-20201016monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-late-breaking-pivotal-data-showing-significant-improvement-in-eosinophi-regn-20201026monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-investor-conference-presentations-regn-20201027monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-s-covid-19-outpatient-trial-prospectively-demonstrates-that-regn-cov2-antibody-c-regn-20201028monthly0.5https://www.biopharmawatch.com/news/REGN/fda-accepts-for-priority-review-libtayo-cemiplimab-rwlc-for-advanced-non-small-cell-lung-c-regn-20201029monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-once-again-earns-1-ranking-in-science-magazine-s-top-biopharma-companies-to-work-regn-20201029monthly0.5https://www.biopharmawatch.com/news/REGN/regn-cov2-independent-data-monitoring-committee-recommends-holding-enrollment-in-hospitali-regn-20201030monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-third-quarter-2020-financial-and-operating-results-regn-20201105monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-included-on-dow-jones-sustainability-world-index-for-second-consecutive-year-regn-20201116monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-s-regen-cov2-is-first-antibody-cocktail-for-covid-19-to-receive-fda-emergency-us-regn-20201121monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-approved-by-european-commission-as-first-and-only-biologic-medicine-for-regn-20201130monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-investor-webcast-at-american-society-of-hematology-2020-annual-meeting-regn-20201130monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-s-bcmaxcd3-bispecific-antibody-regn5458-shows-deep-and-durable-responses-in-pati-regn-20201205monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-39th-annual-j-p-morgan-healthcare-conference-regn-20201216monthly0.5https://www.biopharmawatch.com/news/REGN/new-england-journal-of-medicine-publishes-positive-initial-regeneron-antibody-cocktail-res-regn-20201217monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-encouraging-initial-data-from-covid-19-antibody-cocktail-trial-in-hosp-regn-20201229monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-u-s-government-agreement-to-purchase-additional-covid-19-antibody-cock-regn-20210112monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-fourth-quarter-and-full-year-2020-financial-and-operating-results-and--regn-20210119monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-positive-interim-data-with-regen-cov-antibody-cocktail-used-as-passive-v-regn-20210126monthly0.5https://www.biopharmawatch.com/news/REGN/regen-cov-antibody-cocktail-is-active-against-sars-cov-2-variants-first-identified-in-the--regn-20210127monthly0.5https://www.biopharmawatch.com/news/REGN/new-dupixent-dupilumab-data-showcasing-improvements-across-four-type-2-inflammatory-diseas-regn-20210201monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-fourth-quarter-and-full-year-2020-financial-and-operating-results-regn-20210205monthly0.5https://www.biopharmawatch.com/news/REGN/fda-approves-libtayo-cemiplimab-rwlc-as-first-immunotherapy-indicated-for-patients-with-ad-regn-20210209monthly0.5https://www.biopharmawatch.com/news/REGN/fda-approves-first-in-class-evkeeza-evinacumab-dgnb-for-patients-with-ultra-rare-inherited-regn-20210211monthly0.5https://www.biopharmawatch.com/news/REGN/u-s-federal-circuit-court-of-appeals-rules-in-favor-of-regeneron-and-sanofi-in-praluent-al-regn-20210211monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-investor-conference-presentations-regn-20210212monthly0.5https://www.biopharmawatch.com/news/REGN/the-lancet-publishes-libtayo-cemiplimab-data-showing-extended-overall-survival-in-patients-regn-20210212monthly0.5https://www.biopharmawatch.com/news/REGN/fda-approves-libtayo-cemiplimab-rwlc-monotherapy-for-patients-with-first-line-advanced-non-regn-20210222monthly0.5https://www.biopharmawatch.com/news/REGN/independent-data-monitoring-committee-finds-clear-efficacy-for-regen-cov-casirivimab-with--regn-20210225monthly0.5https://www.biopharmawatch.com/news/REGN/ema-issues-advice-on-regeneron-s-antibody-cocktail-casirivimab-with-imdevimab-for-certain--regn-20210226monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-positive-phase-2-data-evaluating-fel-d-1-antibody-cocktail-in-cat-alle-regn-20210227monthly0.5https://www.biopharmawatch.com/news/REGN/fda-accepts-dupixent-dupilumab-for-review-in-children-with-moderate-to-severe-asthma-regn-20210304monthly0.5https://www.biopharmawatch.com/news/REGN/phase-3-trial-of-libtayo-cemiplimab-monotherapy-in-advanced-cervical-cancer-stopped-early--regn-20210315monthly0.5https://www.biopharmawatch.com/news/REGN/phase-3-trial-shows-regen-cov-casirivimab-with-imdevimab-antibody-cocktail-reduced-hospita-regn-20210323monthly0.5https://www.biopharmawatch.com/news/REGN/nih-sponsored-trial-finds-eylea-aflibercept-injection-reduced-vision-threatening-complicat-regn-20210330monthly0.5https://www.biopharmawatch.com/news/REGN/nih-covid-19-treatment-guidelines-strongly-recommend-use-of-regen-cov-casirivimab-with-imd-regn-20210409monthly0.5https://www.biopharmawatch.com/news/REGN/phase-3-prevention-trial-showed-81-reduced-risk-of-symptomatic-sars-cov-2-infections-with--regn-20210412monthly0.5https://www.biopharmawatch.com/news/REGN/phase-3-treatment-trial-in-recently-infected-asymptomatic-patients-showed-regen-cov-casiri-regn-20210412monthly0.5https://www.biopharmawatch.com/news/REGN/new-dupixent-dupilumab-analyses-at-two-upcoming-dermatology-congresses-reinforce-long-term-regn-20210423monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-investor-conference-presentations-regn-20210423monthly0.5https://www.biopharmawatch.com/news/REGN/ats-2021-breaking-news-session-to-feature-pivotal-data-on-regen-cov-casirivimab-with-imdev-regn-20210503monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-first-quarter-2021-financial-and-operating-results-regn-20210506monthly0.5https://www.biopharmawatch.com/news/REGN/positive-phase-3-libtayo-cemiplimab-results-in-advanced-cervical-cancer-presented-at-esmo--regn-20210512monthly0.5https://www.biopharmawatch.com/news/REGN/phase-3-data-presented-at-ats-2021-show-regen-cov-casirivimab-with-imdevimab-reduced-risk--regn-20210517monthly0.5https://www.biopharmawatch.com/news/REGN/pivotal-data-at-ats-2021-show-dupixent-dupilumab-significantly-reduced-asthma-attacks-and--regn-20210517monthly0.5https://www.biopharmawatch.com/news/REGN/libtayo-cemiplimab-rwlc-presentations-at-asco-highlight-expanding-clinical-data-in-diverse-regn-20210519monthly0.5https://www.biopharmawatch.com/news/REGN/libtayo-cemiplimab-receives-positive-chmp-opinion-for-the-treatment-in-europe-of-two-advan-regn-20210524monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-investor-conference-presentations-regn-20210525monthly0.5https://www.biopharmawatch.com/news/REGN/fda-authorizes-lower-1-200-mg-intravenous-and-subcutaneous-dose-of-regen-cov-casirivimab-a-regn-20210604monthly0.5https://www.biopharmawatch.com/news/REGN/regen-cov-casirivimab-and-imdevimab-phase-3-recovery-trial-meets-primary-outcome-improving-regn-20210616monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-participate-in-guggenheim-biopharma-strategy-series-regn-20210622monthly0.5https://www.biopharmawatch.com/news/REGN/libtayo-cemiplimab-approved-by-the-european-commission-as-the-first-immunotherapy-indicate-regn-20210625monthly0.5https://www.biopharmawatch.com/news/REGN/intellia-and-regeneron-announce-landmark-clinical-data-showing-deep-reduction-in-disease-c-regn-20210626monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-smpc-updated-with-long-term-data-reinforcing-well-established-safety-pr-regn-20210628monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-genetics-center-discovers-gpr75-gene-mutations-that-protect-against-obesity-regn-20210701monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-second-quarter-2021-financial-and-operating-results-and-host-conferenc-regn-20210707monthly0.5https://www.biopharmawatch.com/news/REGN/japan-becomes-first-country-to-approve-regeneron-antibody-cocktail-casirivimab-and-imdevim-regn-20210720monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-astrazeneca-to-research-develop-and-commercialize-new-small-molecule-medicin-regn-20210727monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-significantly-improved-itch-and-hives-in-patients-with-chronic-spontane-regn-20210729monthly0.5https://www.biopharmawatch.com/news/REGN/fda-expands-authorized-use-of-regen-cov-casirivimab-and-imdevimab-regn-20210730monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-the-2021-winners-of-the-regeneron-prize-for-creative-innovation-regn-20210803monthly0.5https://www.biopharmawatch.com/news/REGN/new-england-journal-of-medicine-publishes-positive-phase-3-trial-results-for-regen-cov-cas-regn-20210804monthly0.5https://www.biopharmawatch.com/news/REGN/phase-3-trial-of-libtayo-cemiplimab-rwlc-combined-with-chemotherapy-stopped-early-due-to-s-regn-20210805monthly0.5https://www.biopharmawatch.com/news/REGN/uk-authorizes-regeneron-antibody-cocktail-to-prevent-and-treat-acute-covid-19-infection-regn-20210820monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-encouraging-topline-phase-2-data-of-high-dose-aflibercept-in-wet-age-r-regn-20210824monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-pivotal-trial-meets-all-primary-and-secondary-endpoints-becoming-first--regn-20210830monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-new-u-s-government-agreement-to-purchase-additional-doses-of-regen-cov-regn-20210914monthly0.5https://www.biopharmawatch.com/news/REGN/esmo-late-breaking-data-show-libtayo-cemiplimab-and-chemotherapy-first-line-treatment-comb-regn-20210919monthly0.5https://www.biopharmawatch.com/news/REGN/new-dupixent-dupilumab-data-in-patients-as-young-as-six-years-old-with-moderate-to-severe--regn-20210921monthly0.5https://www.biopharmawatch.com/news/REGN/fda-accepts-libtayo-cemiplimab-rwlc-for-priority-review-for-advanced-cervical-cancer-regn-20210928monthly0.5https://www.biopharmawatch.com/news/REGN/new-england-journal-of-medicine-publishes-positive-phase-3-trial-results-for-regen-cov-cas-regn-20210929monthly0.5https://www.biopharmawatch.com/news/REGN/new-regen-cov-casirivimab-and-imdevimab-data-show-supportive-results-in-patients-hospitali-regn-20210930monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-third-quarter-2021-financial-and-operating-results-and-host-conference-regn-20211011monthly0.5https://www.biopharmawatch.com/news/REGN/fda-accepts-regen-cov-casirivimab-and-imdevimab-for-priority-review-for-treatment-and-prop-regn-20211014monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-is-the-first-biologic-to-significantly-reduce-itch-and-skin-lesions-in--regn-20211022monthly0.5https://www.biopharmawatch.com/news/REGN/second-dupixent-dupilumab-phase-3-eosinophilic-esophagitis-trial-to-demonstrate-significan-regn-20211025monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-presentations-at-ash-highlight-expanding-clinical-research-in-blood-cancers-and--regn-20211104monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-third-quarter-2021-financial-and-operating-results-regn-20211104monthly0.5https://www.biopharmawatch.com/news/REGN/new-phase-3-analyses-show-that-a-single-dose-of-regen-cov-casirivimab-and-imdevimab-provid-regn-20211108monthly0.5https://www.biopharmawatch.com/news/REGN/chmp-recommends-eu-approval-of-regeneron-antibody-cocktail-to-treat-and-prevent-covid-19-regn-20211111monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-3-billion-share-repurchase-program-regn-20211112monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-antibody-cocktail-approved-by-european-commission-to-treat-and-prevent-covid-19-regn-20211112monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-listed-on-dow-jones-sustainability-world-index-for-third-consecutive-year-regn-20211115monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-investor-conference-presentations-regn-20211116monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-participate-in-h-c-wainwright-co-virtual-event-regn-20211203monthly0.5https://www.biopharmawatch.com/news/REGN/new-england-journal-of-medicine-publishes-positive-phase-3-dupixent-dupilumab-results-in-c-regn-20211208monthly0.5https://www.biopharmawatch.com/news/REGN/new-regn5458-bcmaxcd3-phase-1-data-show-75-response-rate-at-highest-dose-levels-studied-in-regn-20211211monthly0.5https://www.biopharmawatch.com/news/REGN/positive-phase-3-dupixent-dupilumab-data-in-children-6-months-to-5-years-with-moderate-to--regn-20211213monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-40th-annual-j-p-morgan-healthcare-conference-regn-20211222monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-ultragenyx-collaborate-to-commercialize-evkeeza-evinacumab-outside-the-unite-regn-20220107monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-fourth-quarter-and-full-year-2021-financial-and-operating-results-and--regn-20220113monthly0.5https://www.biopharmawatch.com/news/REGN/fda-accepts-for-review-libtayo-cemiplimab-rwlc-in-combination-with-chemotherapy-for-first--regn-20220119monthly0.5https://www.biopharmawatch.com/news/REGN/second-positive-phase-3-dupixent-dupilumab-trial-confirms-significant-improvements-for-pat-regn-20220119monthly0.5https://www.biopharmawatch.com/news/REGN/forty-accomplished-young-scientists-named-finalists-in-the-2022-regeneron-science-talent-s-regn-20220120monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-provide-regulatory-update-on-libtayo-cemiplimab-rwlc-in-advanced-cerv-regn-20220128monthly0.5https://www.biopharmawatch.com/news/REGN/chmp-recommends-approval-of-dupixent-dupilumab-for-children-aged-6-to-11-years-with-severe-regn-20220131monthly0.5https://www.biopharmawatch.com/news/REGN/positive-dupixent-dupilumab-data-across-five-diseases-with-underlying-type-2-inflammation--regn-20220201monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-fourth-quarter-and-full-year-2021-financial-and-operating-results-regn-20220204monthly0.5https://www.biopharmawatch.com/news/REGN/fda-accepts-dupixent-dupilumab-for-priority-review-in-children-aged-6-months-to-5-years-wi-regn-20220210monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-presents-encouraging-phase-2-results-for-high-dose-aflibercept-8-mg-in-wet-age-r-regn-20220211monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-investor-conference-presentations-regn-20220217monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-provide-update-on-ongoing-dupixent-dupilumab-chronic-spontaneous-urti-regn-20220218monthly0.5https://www.biopharmawatch.com/news/REGN/late-breaking-data-at-2022-aaaai-annual-meeting-show-dupixent-dupilumab-significantly-impr-regn-20220226monthly0.5https://www.biopharmawatch.com/news/REGN/late-breaking-phase-3-data-at-2022-aaaai-annual-meeting-show-dupixent-dupilumab-significan-regn-20220226monthly0.5https://www.biopharmawatch.com/news/REGN/intellia-and-regeneron-announce-updated-phase-1-data-demonstrating-a-single-dose-of-ntla-2-regn-20220228monthly0.5https://www.biopharmawatch.com/news/REGN/late-breaking-phase-3-data-at-aad-2022-show-dupixent-dupilumab-significantly-improved-sign-regn-20220326monthly0.5https://www.biopharmawatch.com/news/REGN/fda-accepts-dupixent-dupilumab-for-priority-review-in-patients-aged-12-years-and-older-wit-regn-20220404monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-first-quarter-2022-financial-and-operating-results-and-host-conference-regn-20220405monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-approved-by-european-commission-for-children-aged-6-to-11-years-with-se-regn-20220407monthly0.5https://www.biopharmawatch.com/news/REGN/u-s-fda-extends-review-of-biologics-license-application-for-regen-cov-casirivimab-and-imde-regn-20220414monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-acquire-checkmate-pharmaceuticals-and-its-investigational-immune-activator-fo-regn-20220419monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-investor-conference-presentations-regn-20220502monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-first-quarter-2022-financial-and-operating-results-regn-20220504monthly0.5https://www.biopharmawatch.com/news/REGN/fda-approves-dupixent-dupilumab-as-first-treatment-for-adults-and-children-aged-12-and-old-regn-20220520monthly0.5https://www.biopharmawatch.com/news/REGN/evkeeza-evinacumab-phase-3-trial-demonstrates-48-ldl-c-reduction-in-children-with-ultra-ra-regn-20220521monthly0.5https://www.biopharmawatch.com/news/REGN/fda-accepts-dupixent-dupilumab-for-priority-review-in-adults-with-prurigo-nodularis-regn-20220531monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-completes-acquisition-of-checkmate-pharmaceuticals-regn-20220531monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-strengthens-commitment-to-oncology-through-purchase-of-sanofi-s-stake-in-the-reg-regn-20220602monthly0.5https://www.biopharmawatch.com/news/REGN/intellia-and-regeneron-present-updated-interim-data-from-phase-1-study-of-crispr-based-ntl-regn-20220624monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-aflibercept-injection-sbla-for-every-16-week-dosing-regimen-in-patients-with-diabeti-regn-20220629monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-completes-purchase-of-sanofi-s-stake-in-libtayo-cemiplimab-regn-20220701monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-second-quarter-2022-financial-and-operating-results-and-host-conferenc-regn-20220706monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-phase-3-trial-shows-positive-results-in-children-1-to-11-years-of-age-w-regn-20220714monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-the-2022-winners-of-the-regeneron-prize-for-creative-innovation-regn-20220726monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-genetics-center-discovers-rare-mutations-in-the-cideb-gene-that-protect-against--regn-20220727monthly0.5https://www.biopharmawatch.com/news/REGN/novel-costimulatory-bispecific-antibody-shows-encouraging-anti-tumor-activity-when-combine-regn-20220803monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-second-quarter-2022-financial-and-operating-results-regn-20220803monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-investor-conference-presentations-regn-20220825monthly0.5https://www.biopharmawatch.com/news/REGN/esmo-presentations-of-libtayo-cemiplimab-fianlimab-and-novel-bispecific-antibodies-showcas-regn-20220904monthly0.5https://www.biopharmawatch.com/news/REGN/late-breaking-dupixent-dupilumab-data-at-ers-2022-show-consistent-efficacy-and-safety-prof-regn-20220905monthly0.5https://www.biopharmawatch.com/news/REGN/aflibercept-8-mg-meets-primary-endpoints-in-two-global-pivotal-trials-for-dme-and-wamd-wit-regn-20220908monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-late-breaking-phase-3-data-at-the-eadv-2022-congress-showed-significant-regn-20220908monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-investor-call-and-webcast-at-esmo-2022-regn-20220909monthly0.5https://www.biopharmawatch.com/news/REGN/novel-regeneron-bispecific-antibodies-show-encouraging-anti-tumor-activity-in-two-advanced-regn-20220910monthly0.5https://www.biopharmawatch.com/news/REGN/fianlimab-lag-3-inhibitor-combined-with-libtayo-cemiplimab-demonstrates-greater-than-60-re-regn-20220912monthly0.5https://www.biopharmawatch.com/news/REGN/positive-neoadjuvant-libtayo-cemiplimab-monotherapy-data-in-resectable-cutaneous-squamous--regn-20220912monthly0.5https://www.biopharmawatch.com/news/REGN/positive-dupixent-dupilumab-phase-3-data-in-children-aged-6-months-to-5-years-with-moderat-regn-20220915monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-alnylam-report-promising-data-from-ongoing-phase-1-study-of-aln-hsd-in-nash--regn-20220915monthly0.5https://www.biopharmawatch.com/news/REGN/intellia-and-regeneron-announce-initial-data-from-the-cardiomyopathy-arm-of-ongoing-phase--regn-20220916monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-approved-by-fda-as-the-first-and-only-treatment-indicated-for-prurigo-n-regn-20220928monthly0.5https://www.biopharmawatch.com/news/REGN/aflibercept-8-mg-positive-pivotal-results-in-diabetic-macular-edema-and-wet-age-related-ma-regn-20220930monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-elects-dr-craig-b-thompson-to-board-of-directors-regn-20221003monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-third-quarter-2022-financial-and-operating-results-and-host-conference-regn-20221004monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-late-breaking-phase-3-data-presented-at-ueg-week-2022-showed-significan-regn-20221011monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-aflibercept-injection-sbla-for-treatment-of-retinopathy-of-prematurity-rop-accepted--regn-20221012monthly0.5https://www.biopharmawatch.com/news/REGN/libtayo-cemiplimab-receives-positive-chmp-opinion-recommending-approval-to-treat-advanced--regn-20221014monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-receives-six-months-of-u-s-pediatric-exclusivity-for-eylea-aflibercept-injection-regn-20221021monthly0.5https://www.biopharmawatch.com/news/REGN/inmazeb-atoltivimab-maftivimab-and-odesivimab-ebgn-wins-prestigious-2022-prix-galien-usa-b-regn-20221028monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-investor-conference-presentations-regn-20221103monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-presents-new-data-at-ash-from-advancing-hematology-pipeline-across-multiple-bloo-regn-20221103monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-third-quarter-2022-financial-and-operating-results-regn-20221103monthly0.5https://www.biopharmawatch.com/news/REGN/aflibercept-8-mg-late-breaking-data-presented-at-retina-society-in-diabetic-macular-edema--regn-20221104monthly0.5https://www.biopharmawatch.com/news/REGN/libtayo-cemiplimab-rwlc-in-combination-with-chemotherapy-approved-by-the-fda-as-first-line-regn-20221108monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-recommended-for-eu-approval-by-the-chmp-for-the-treatment-of-prurigo-no-regn-20221111monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-cytomx-announce-strategic-research-collaboration-in-the-field-of-conditional-regn-20221117monthly0.5https://www.biopharmawatch.com/news/REGN/libtayo-cemiplimab-approved-by-the-european-commission-as-the-first-immunotherapy-in-secon-regn-20221122monthly0.5https://www.biopharmawatch.com/news/REGN/evkeeza-evinacumab-dgnb-sbla-for-children-with-ultra-rare-inherited-form-of-high-cholester-regn-20221130monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-esmo-io-presentations-highlight-potential-of-fianlimab-and-libtayo-cemiplimab-in-regn-20221201monthly0.5https://www.biopharmawatch.com/news/REGN/pivotal-odronextamab-cd20xcd3-phase-2-data-in-patients-with-relapsed-refractory-diffuse-la-regn-20221211monthly0.5https://www.biopharmawatch.com/news/REGN/linvoseltamab-bcmaxcd3-initial-pivotal-phase-2-data-show-clinically-meaningful-responses-i-regn-20221212monthly0.5https://www.biopharmawatch.com/news/REGN/odronextamab-cd20xcd3-demonstrates-high-and-durable-complete-response-rate-among-patients--regn-20221212monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-named-on-dow-jones-sustainability-world-index-for-fourth-consecutive-year-regn-20221212monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-approved-by-european-commission-as-the-first-and-only-targeted-medicine-regn-20221215monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-recommended-for-eu-approval-by-the-chmp-for-the-treatment-of-eosinophil-regn-20221216monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-41st-annual-j-p-morgan-healthcare-conference-regn-20221219monthly0.5https://www.biopharmawatch.com/news/REGN/positive-dupixent-dupilumab-phase-3-results-in-adults-and-adolescents-with-eosinophilic-es-regn-20221221monthly0.5https://www.biopharmawatch.com/news/REGN/libtayo-cemiplimab-approved-in-japan-for-advanced-or-recurrent-cervical-cancer-regn-20221223monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-fourth-quarter-and-full-year-2022-financial-and-operating-results-and--regn-20230103monthly0.5https://www.biopharmawatch.com/news/REGN/top-40-high-school-scientists-selected-as-finalists-in-the-regeneron-science-talent-search-regn-20230124monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-recommended-for-expanded-eu-approval-by-the-chmp-to-treat-children-as-y-regn-20230127monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-approved-by-european-commission-as-the-first-and-only-targeted-medicine-regn-20230130monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-investor-conference-presentations-regn-20230131monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-fourth-quarter-and-full-year-2022-financial-and-operating-results-regn-20230203monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-aflibercept-injection-approved-as-the-first-pharmacologic-treatment-for-preterm-infa-regn-20230208monthly0.5https://www.biopharmawatch.com/news/REGN/pozelimab-c5-antibody-bla-for-treatment-of-children-and-adults-with-ultra-rare-chaple-dise-regn-20230221monthly0.5https://www.biopharmawatch.com/news/REGN/aflibercept-8-mg-bla-for-treatment-of-wet-age-related-macular-degeneration-and-diabetic-ma-regn-20230223monthly0.5https://www.biopharmawatch.com/news/REGN/libtayo-cemiplimab-in-combination-with-chemotherapy-receives-positive-chmp-opinion-for-the-regn-20230224monthly0.5https://www.biopharmawatch.com/news/REGN/kevzara-sarilumab-approved-by-fda-as-first-and-only-biologic-indicated-for-patients-with-p-regn-20230301monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-application-for-treatment-of-chronic-spontaneous-urticaria-csu-in-adult-regn-20230307monthly0.5https://www.biopharmawatch.com/news/REGN/students-win-more-than-1-8-million-at-2023-regeneron-science-talent-search-for-remarkable--regn-20230315monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-late-breaking-data-at-aad-show-significant-improvements-in-signs-and-sy-regn-20230318monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-approved-by-european-commission-as-first-and-only-targeted-medicine-for-regn-20230321monthly0.5https://www.biopharmawatch.com/news/REGN/fda-approves-first-in-class-evkeeza-evinacumab-dgnb-for-young-children-with-ultra-rare-for-regn-20230322monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-demonstrates-potential-to-become-first-biologic-to-treat-copd-by-showin-regn-20230323monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sonoma-biotherapeutics-announce-collaboration-to-discover-develop-and-commer-regn-20230328monthly0.5https://www.biopharmawatch.com/news/REGN/libtayo-cemiplimab-in-combination-with-chemotherapy-approved-by-european-commission-for-th-regn-20230329monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-first-quarter-2023-financial-and-operating-results-and-host-conference-regn-20230403monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-investor-conference-presentations-regn-20230411monthly0.5https://www.biopharmawatch.com/news/REGN/aflibercept-8-mg-and-eylea-aflibercept-injection-presentations-at-arvo-provide-new-insight-regn-20230417monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-retirement-of-board-chair-dr-p-roy-vagelos-accomplished-physician-busi-regn-20230417monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-alnylam-report-positive-interim-phase-1-clinical-data-on-aln-app-an-investig-regn-20230426monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-highlight-new-and-updated-clinical-data-at-asco-showcasing-breadth-of-cancer--regn-20230502monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-first-quarter-2023-financial-and-operating-results-regn-20230504monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-applauds-supreme-court-s-unanimous-opinion-striking-down-amgen-s-pcsk9-patent-cl-regn-20230518monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-investor-conference-presentations-regn-20230518monthly0.5https://www.biopharmawatch.com/news/REGN/high-school-scientists-and-engineers-win-nearly-9-million-at-the-regeneron-international-s-regn-20230519monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-late-breaking-phase-3-copd-results-presented-at-ats-and-simultaneously--regn-20230521monthly0.5https://www.biopharmawatch.com/news/REGN/fianlimab-lag-3-inhibitor-combined-with-libtayo-cemiplimab-shows-clinically-meaningful-and-regn-20230525monthly0.5https://www.biopharmawatch.com/news/REGN/updated-linvoseltamab-bcmaxcd3-data-from-pivotal-trial-demonstrates-early-deep-and-durable-regn-20230525monthly0.5https://www.biopharmawatch.com/news/REGN/fda-issues-complete-response-letter-crl-for-aflibercept-8-mg-biologics-license-application-regn-20230627monthly0.5https://www.biopharmawatch.com/news/REGN/two-year-results-for-aflibercept-8-mg-from-pivotal-photon-trial-demonstrate-durable-vision-regn-20230627monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-second-quarter-2023-financial-and-operating-results-and-host-conferenc-regn-20230629monthly0.5https://www.biopharmawatch.com/news/REGN/aflibercept-8-mg-two-year-results-from-pivotal-photon-trial-in-diabetic-macular-edema-pres-regn-20230729monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-the-2023-winners-of-the-regeneron-prize-for-creative-innovation-regn-20230801monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-second-quarter-2023-financial-and-operating-results-regn-20230803monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-acquire-decibel-therapeutics-strengthening-gene-therapy-and-hearing-loss-prog-regn-20230809monthly0.5https://www.biopharmawatch.com/news/REGN/two-year-pulsar-trial-results-for-aflibercept-8-mg-demonstrate-durable-vision-gains-at-ext-regn-20230810monthly0.5https://www.biopharmawatch.com/news/REGN/odronextamab-receives-ema-filing-acceptance-for-treatment-of-relapsed-refractory-follicula-regn-20230817monthly0.5https://www.biopharmawatch.com/news/REGN/veopoz-pozelimab-bbfg-receives-fda-approval-as-the-first-treatment-for-children-and-adults-regn-20230818monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-hd-aflibercept-injection-8-mg-approved-by-fda-for-treatment-of-wet-age-related-macul-regn-20230818monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-agreement-with-barda-supporting-development-of-next-generation-antibod-regn-20230822monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-investor-conference-presentations-regn-20230823monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-updates-to-board-of-directors-regn-20230908monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-provides-update-on-planned-chief-financial-officer-transition-regn-20230908monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-completes-acquisition-of-decibel-therapeutics-adding-promising-gene-therapy-prog-regn-20230925monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-sbla-for-treatment-of-eosinophilic-esophagitis-eoe-in-children-aged-1-t-regn-20230926monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-third-quarter-2023-financial-and-operating-results-and-host-conference-regn-20230928monthly0.5https://www.biopharmawatch.com/news/REGN/odronextamab-bla-for-treatment-of-relapsed-refractory-follicular-lymphoma-fl-and-diffuse-l-regn-20230929monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-intellia-announce-expanded-research-collaboration-to-develop-crispr-based-th-regn-20231003monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-hd-aflibercept-injection-8-mg-two-year-results-from-pivotal-pulsar-trial-in-wet-age--regn-20231005monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-showcase-progress-from-innovative-oncology-portfolio-in-several-difficult-to--regn-20231015monthly0.5https://www.biopharmawatch.com/news/REGN/together-for-change-genomics-and-equity-initiative-launched-by-a-coalition-of-meharry-medi-regn-20231018monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-builds-on-together-for-change-initiative-with-five-year-5-million-commitment-to--regn-20231018monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-sanofi-provide-update-on-dupixent-dupilumab-sbla-for-chronic-spontaneous-urt-regn-20231020monthly0.5https://www.biopharmawatch.com/news/REGN/libtayo-cemiplimab-neoadjuvant-treatment-demonstrates-encouraging-event-free-survival-in-p-regn-20231021monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-phase-3-results-show-sustained-efficacy-for-up-to-one-year-in-children--regn-20231022monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-investor-conference-presentations-regn-20231025monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-shares-preliminary-results-showing-gene-therapy-improves-auditory-responses-in-c-regn-20231026monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-hd-aflibercept-injection-8-mg-data-presentations-at-aao-reinforce-efficacy-and-safet-regn-20231101monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-third-quarter-2023-financial-and-operating-results-regn-20231102monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-highlight-scientific-advancements-across-diversified-pipeline-in-difficult-to-regn-20231103monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-commits-34-million-over-five-years-to-continue-to-sponsor-the-regeneron-internat-regn-20231113monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-investor-conference-presentation-regn-20231115monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-significantly-reduced-copd-exacerbations-in-second-positive-phase-3-tri-regn-20231127monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-host-investor-call-and-webcast-on-december-14-2023-to-provide-updates-across--regn-20231130monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-share-progress-of-novel-combination-therapies-in-oncology-at-esmo-io-regn-20231207monthly0.5https://www.biopharmawatch.com/news/REGN/updated-linvoseltamab-pivotal-data-demonstrated-strong-rates-and-depth-of-response-in-pati-regn-20231207monthly0.5https://www.biopharmawatch.com/news/REGN/updated-odronextamab-data-from-relapsed-refractory-diffuse-large-b-cell-lymphoma-pivotal-t-regn-20231210monthly0.5https://www.biopharmawatch.com/news/REGN/latest-odronextamab-data-in-relapsed-refractory-follicular-lymphoma-showed-compelling-resp-regn-20231211monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-named-on-dow-jones-sustainability-world-index-for-fifth-consecutive-year-regn-20231211monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-42nd-annual-j-p-morgan-healthcare-conference-regn-20231218monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-fourth-quarter-and-full-year-2023-financial-and-operating-results-and--regn-20240105monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-u-s-label-updated-with-data-further-supporting-use-in-atopic-dermatitis-regn-20240116monthly0.5https://www.biopharmawatch.com/news/REGN/top-40-high-school-scientists-in-prestigious-regeneron-science-talent-search-to-compete-fo-regn-20240124monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-fda-approved-as-first-and-only-treatment-indicated-for-children-aged-1--regn-20240125monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-formation-of-regeneron-cell-medicines-with-the-acquisition-of-2seventy-regn-20240130monthly0.5https://www.biopharmawatch.com/news/REGN/linvoseltamab-receives-ema-filing-acceptance-for-treatment-of-relapsed-refractory-multiple-regn-20240202monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-fourth-quarter-and-full-year-2023-financial-and-operating-results-regn-20240202monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-investor-conference-presentations-regn-20240206monthly0.5https://www.biopharmawatch.com/news/REGN/japan-first-in-the-world-to-approve-dupixent-dupilumab-for-chronic-spontaneous-urticaria-c-regn-20240216monthly0.5https://www.biopharmawatch.com/news/REGN/linvoseltamab-bla-for-treatment-of-relapsed-refractory-multiple-myeloma-accepted-for-fda-p-regn-20240221monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-sbla-accepted-for-fda-priority-review-for-treatment-of-copd-with-type-2-regn-20240223monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-hd-aflibercept-injection-8-mg-pivotal-data-in-wet-age-related-macular-degeneration-w-regn-20240308monthly0.5https://www.biopharmawatch.com/news/REGN/praluent-alirocumab-injection-receives-fda-approval-to-treat-children-with-genetic-form-of-regn-20240311monthly0.5https://www.biopharmawatch.com/news/REGN/high-school-seniors-win-1-8-million-at-regeneron-science-talent-search-2024-for-innovative-regn-20240313monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-provides-update-on-biologics-license-application-for-odronextamab-regn-20240325monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-first-quarter-2024-financial-and-operating-results-and-host-conference-regn-20240401monthly0.5https://www.biopharmawatch.com/news/REGN/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-ove-regn-20240407monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-highlight-advances-in-genetic-medicine-research-at-american-society-of-gene-a-regn-20240422monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-showcase-progress-in-advancing-novel-investigational-treatment-approaches-for-regn-20240424monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-mammoth-biosciences-collaborate-to-pursue-next-generation-crispr-based-gene--regn-20240425monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-hd-aflibercept-injection-8-mg-presentations-at-arvo-reinforce-sustained-and-clinical-regn-20240429monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-first-quarter-2024-financial-and-operating-results-regn-20240502monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-investor-conference-presentations-regn-20240506monthly0.5https://www.biopharmawatch.com/news/REGN/latest-db-oto-results-show-dramatically-improved-hearing-to-normal-levels-in-a-child-with--regn-20240508monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-sbla-accepted-for-fda-priority-review-for-treatment-of-adolescents-with-regn-20240513monthly0.5https://www.biopharmawatch.com/news/REGN/more-than-9-million-awarded-to-high-school-scientists-and-engineers-at-the-regeneron-inter-regn-20240517monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-late-breaking-data-from-notus-confirmatory-phase-3-copd-trial-presented-regn-20240520monthly0.5https://www.biopharmawatch.com/news/REGN/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd2-regn-20240523monthly0.5https://www.biopharmawatch.com/news/REGN/update-on-fda-priority-review-of-dupixent-dupilumab-for-the-treatment-of-copd-patients-wit-regn-20240531monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-recommended-for-eu-approval-by-the-chmp-to-treat-patients-with-copd-regn-20240531monthly0.5https://www.biopharmawatch.com/news/REGN/kevzara-sarilumab-approved-by-fda-for-the-treatment-of-active-polyarticular-juvenile-idiop-regn-20240611monthly0.5https://www.biopharmawatch.com/news/REGN/updated-linvoseltamab-data-showcase-continued-deepening-of-responses-in-patients-with-heav-regn-20240616monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-positive-phase-3-data-in-children-1-to-11-years-of-age-with-eosinophili-regn-20240626monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-second-quarter-2024-financial-and-operating-results-and-host-conferenc-regn-20240627monthly0.5https://www.biopharmawatch.com/news/REGN/odronextamab-recommended-for-eu-approval-by-the-chmp-to-treat-relapsed-refractory-follicul-regn-20240628monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-approved-in-the-european-union-as-the-first-ever-targeted-therapy-for-p-regn-20240703monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-the-2024-winners-of-the-regeneron-prize-for-creative-innovation-regn-20240731monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-second-quarter-2024-financial-and-operating-results-regn-20240801monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-investor-conference-presentations-and-oncology-investor-webcast-regn-20240807monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-provides-update-on-biologics-license-application-for-linvoseltamab-regn-20240820monthly0.5https://www.biopharmawatch.com/news/REGN/latest-dupixent-dupilumab-and-itepekimab-data-at-ers-highlight-scientific-innovation-and-l-regn-20240826monthly0.5https://www.biopharmawatch.com/news/REGN/ordspono-odronextamab-approved-in-the-european-union-for-the-treatment-of-relapsed-refract-regn-20240826monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-highlight-progress-across-its-differentiated-oncology-portfolio-and-pipeline--regn-20240909monthly0.5https://www.biopharmawatch.com/news/REGN/libtayo-cemiplimab-demonstrates-durable-survival-benefit-at-five-years-in-advanced-non-sma-regn-20240909monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-is-the-first-and-only-biologic-to-achieve-significant-improvements-in-d-regn-20240911monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-phase-3-trial-confirms-significant-improvements-in-itch-and-hives-for-p-regn-20240911monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-hd-aflibercept-injection-8-mg-data-at-euretina-reinforce-long-term-durability-sustai-regn-20240911monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-approved-in-the-u-s-as-first-and-only-treatment-for-adolescents-with-ch-regn-20240913monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-recommended-for-eu-approval-by-the-chmp-to-treat-eosinophilic-esophagit-regn-20240920monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-third-quarter-2024-financial-and-operating-results-and-host-conference-regn-20240926monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-approved-in-china-as-the-first-ever-biologic-medicine-for-patients-with-regn-20240927monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-approved-in-the-u-s-as-the-first-ever-biologic-medicine-for-patients-wi-regn-20240927monthly0.5https://www.biopharmawatch.com/news/REGN/three-year-results-for-eylea-hd-aflibercept-injection-8-mg-demonstrate-continued-durable-v-regn-20241018monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-late-breaking-positive-phase-3-data-in-chronic-spontaneous-urticaria-to-regn-20241024monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-third-quarter-2024-financial-and-operating-results-regn-20241031monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-approved-in-the-european-union-as-the-first-and-only-medicine-for-young-regn-20241106monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-investor-conference-presentations-regn-20241111monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-highlight-pioneering-pipeline-progress-across-multiple-modalities-spanning-10-regn-20241113monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-sbla-accepted-for-fda-review-for-the-treatment-of-chronic-spontaneous-u-regn-20241115monthly0.5https://www.biopharmawatch.com/news/REGN/novel-combination-of-pozelimab-and-cemdisiran-poze-cemdi-achieved-greater-control-of-intra-regn-20241208monthly0.5https://www.biopharmawatch.com/news/REGN/odronextamab-ash-presentations-underscore-impressive-potential-in-earlier-lines-of-treatme-regn-20241209monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-named-to-dow-jones-sustainability-world-index-for-sixth-consecutive-year-regn-20241216monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-hd-aflibercept-injection-8-mg-phase-3-trial-meets-primary-endpoint-showing-improved--regn-20241217monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-43rd-annual-j-p-morgan-healthcare-conference-regn-20241217monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-advance-two-factor-xi-antibodies-into-a-broad-phase-3-program-following-posit-regn-20241219monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-fourth-quarter-and-full-year-2024-financial-and-operating-results-and--regn-20250107monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-collaborates-with-truveta-and-leading-american-health-systems-to-massively-exten-regn-20250113monthly0.5https://www.biopharmawatch.com/news/REGN/adjuvant-libtayo-cemiplimab-significantly-improves-disease-free-survival-dfs-after-surgery-regn-20250113monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-provides-business-updates-and-highlights-from-broad-clinical-pipeline-at-the-43r-regn-20250113monthly0.5https://www.biopharmawatch.com/news/REGN/america-s-top-40-high-school-scientists-to-compete-for-1-8-million-in-awards-at-prestigiou-regn-20250123monthly0.5https://www.biopharmawatch.com/news/REGN/three-year-results-for-eylea-hd-aflibercept-injection-8-mg-in-patients-with-wet-age-relate-regn-20250208monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-hd-aflibercept-injection-8-mg-positive-phase-3-results-in-patients-with-macular-edem-regn-20250208monthly0.5https://www.biopharmawatch.com/news/REGN/linvoseltamab-bla-accepted-for-fda-review-for-the-treatment-of-relapsed-refractory-multipl-regn-20250211monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-investor-conference-presentations-regn-20250211monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-sbla-accepted-for-fda-priority-review-for-the-targeted-treatment-of-bul-regn-20250218monthly0.5https://www.biopharmawatch.com/news/REGN/latest-db-oto-results-demonstrate-clinically-meaningful-hearing-improvements-in-nearly-all-regn-20250224monthly0.5https://www.biopharmawatch.com/news/REGN/odronextamab-bla-accepted-for-fda-review-for-the-treatment-of-relapsed-refractory-follicul-regn-20250226monthly0.5https://www.biopharmawatch.com/news/REGN/linvoseltamab-recommended-for-eu-approval-by-the-chmp-to-treat-relapsed-refractory-multipl-regn-20250228monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-late-breaking-positive-pivotal-data-in-bullous-pemphigoid-presented-at--regn-20250308monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-science-talent-search-2025-awards-more-than-1-8-million-to-high-school-seniors-f-regn-20250312monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-first-quarter-2025-financial-and-operating-results-and-host-conference-regn-20250325monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-approved-as-the-first-ever-biologic-medicine-in-japan-for-patients-with-regn-20250328monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-hd-aflibercept-injection-8-mg-sbla-accepted-for-fda-priority-review-for-both-the-tre-regn-20250417monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-approved-in-the-u-s-as-the-first-new-targeted-therapy-in-over-a-decade--regn-20250418monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-provides-update-on-eylea-hd-aflibercept-injection-8-mg-supplemental-biologics-li-regn-20250418monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-investor-conference-presentations-regn-20250421monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-new-investment-in-manufacturing-of-its-industry-leading-biologic-medic-regn-20250422monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-hd-aflibercept-injection-8-mg-presentations-at-arvo-reinforce-continued-safety-and-e-regn-20250428monthly0.5https://www.biopharmawatch.com/news/REGN/lynozyfic-linvoseltamab-approved-in-the-european-union-for-the-treatment-of-relapsed-refra-regn-20250428monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-first-quarter-2025-financial-and-operating-results-regn-20250429monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-data-presented-at-ats-reinforce-impact-of-targeting-key-type-2-inflamma-regn-20250501monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-highlight-advances-at-asco-with-phase-3-adjuvant-libtayo-cemiplimab-cscc-upda-regn-20250501monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-prevails-over-amgen-in-antitrust-pcsk9-lawsuit-protecting-biotech-innovation-and-regn-20250515monthly0.5https://www.biopharmawatch.com/news/REGN/75th-annual-regeneron-international-science-and-engineering-fair-awards-teen-scientists-fr-regn-20250516monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-enters-into-asset-purchase-agreement-to-acquire-23andme-for-256-million-plans-to-regn-20250519monthly0.5https://www.biopharmawatch.com/news/REGN/linvoseltamab-in-combination-with-carfilzomib-or-bortezomib-shows-promising-initial-result-regn-20250522monthly0.5https://www.biopharmawatch.com/news/REGN/itepekimab-met-primary-endpoint-in-one-of-two-chronic-obstructive-pulmonary-disease-copd-p-regn-20250530monthly0.5https://www.biopharmawatch.com/news/REGN/libtayo-cemiplimab-phase-3-data-in-the-adjuvant-treatment-of-post-surgical-high-risk-cutan-regn-20250531monthly0.5https://www.biopharmawatch.com/news/REGN/interim-results-from-ongoing-phase-2-courage-trial-confirm-potential-to-improve-the-qualit-regn-20250602monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-expands-clinical-stage-obesity-portfolio-with-strategic-in-licensing-of-novel-du-regn-20250602monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-data-at-revolutionizing-atopic-dermatitis-rad-conference-reinforce-use--regn-20250607monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-demonstrated-superiority-over-xolair-omalizumab-in-chronic-rhinosinusit-regn-20250615monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-approved-in-the-u-s-as-the-only-targeted-medicine-to-treat-patients-wit-regn-20250620monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-first-of-its-kind-donation-matching-program-with-independent-charitabl-regn-20250624monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-second-quarter-2025-financial-and-operating-results-and-host-conferenc-regn-20250626monthly0.5https://www.biopharmawatch.com/news/REGN/lynozyfic-linvoseltamab-gcpt-receives-fda-accelerated-approval-for-treatment-of-relapsed-o-regn-20250702monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-the-2025-winners-of-the-regeneron-prize-for-creative-innovation-regn-20250724monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-reports-second-quarter-2025-financial-and-operating-results-regn-20250801monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-investor-conference-presentations-regn-20250807monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-hd-aflibercept-injection-8-mg-applications-for-expanded-u-s-label-and-prefilled-syri-regn-20250820monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-positive-results-from-phase-3-trial-in-generalized-myasthenia-gravis-regn-20250826monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-updated-presentation-time-for-upcoming-investor-conference-regn-20250904monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-advances-allergy-pipeline-with-two-positive-phase-3-trials-evaluating-first-in-c-regn-20250908monthly0.5https://www.biopharmawatch.com/news/REGN/libtayo-cemiplimab-plus-chemotherapy-results-at-five-years-reinforce-significant-and-durab-regn-20250909monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-positive-phase-3-trial-in-adults-with-ultra-rare-genetic-disorder-fibr-regn-20250917monthly0.5https://www.biopharmawatch.com/news/REGN/results-from-phase-2-courage-trial-demonstrating-potential-to-improve-quality-of-glp-1-rec-regn-20250917monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-donates-ebola-treatment-for-use-in-countries-most-at-risk-of-outbreaks-regn-20250919monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-to-treat-chronic-spontaneous-urticaria-csu-advances-in-eu-with-positive-regn-20250922monthly0.5https://www.biopharmawatch.com/news/REGN/evkeeza-evinacumab-dgnb-angptl3-antibody-approved-in-the-u-s-for-children-as-young-as-1-ye-regn-20250926monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-third-quarter-2025-financial-and-operating-results-and-host-conference-regn-20250930monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-presentation-at-the-44th-annual-j-p-morgan-healthcare-conference-regn-20251222monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-approved-in-japan-for-children-aged-6-to-11-years-with-bronchial-asthma-regn-20251223monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-report-fourth-quarter-and-full-year-2025-financial-and-operating-results-and--regn-20260102monthly0.5https://www.biopharmawatch.com/news/REGN/garetosmab-biologics-license-application-accepted-for-fda-priority-review-for-the-treatmen-regn-20260219monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-renews-sponsorship-of-the-regeneron-science-talent-search-through-2036-committin-regn-20260226monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-investor-conference-presentation-regn-20260305monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-science-talent-search-2026-recognizes-america-s-top-young-scientists-awarding-mo-regn-20260311monthly0.5https://www.biopharmawatch.com/news/REGN/eylea-hd-aflibercept-approved-by-fda-as-first-and-only-injectable-anti-vegf-with-dosing-in-regn-20260402monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-collaborates-with-trinetx-to-access-de-identified-electronic-health-records-of-3-regn-20260402monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-and-telix-announce-strategic-radiopharma-collaboration-regn-20260413monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-investor-conference-presentations-regn-20260420monthly0.5https://www.biopharmawatch.com/news/REGN/cemdisiran-dosed-subcutaneously-every-12-weeks-demonstrates-rapid-deep-and-sustained-disea-regn-20260421monthly0.5https://www.biopharmawatch.com/news/REGN/dupixent-dupilumab-approved-in-the-u-s-as-the-first-biologic-medicine-for-young-children-w-regn-20260422monthly0.5https://www.biopharmawatch.com/news/REGN/next-generation-of-scientific-leaders-awarded-more-than-7-million-at-the-2026-regeneron-in-regn-20260515monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-provides-update-on-phase-3-trial-of-fianlimab-lag-3-inhibitor-combination-in-fir-regn-20260516monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-anti-regn-20260518monthly0.5https://www.biopharmawatch.com/news/REGN/regeneron-to-highlight-progress-across-its-metabolic-disease-ophthalmology-and-rare-diseas-regn-20260604monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-therapeutics-announces-pricing-of-initial-public-offering-clym-20210810monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-therapeutics-announces-closing-of-initial-public-offering-with-exercise-in-full-of-t-clym-20210813monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-therapeutics-to-participate-at-four-upcoming-investor-conferences-clym-20211104monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-therapeutics-provides-program-updates-and-an-overview-of-expected-near-term-mileston-clym-20220118monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-therapeutics-to-host-virtual-investor-event-featuring-opinion-leaders-in-chronic-pai-clym-20220207monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-therapeutics-to-present-at-the-11th-annual-svb-leerink-global-healthcare-conference-clym-20220211monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-therapeutics-to-present-at-stifel-s-2022-cns-days-clym-20220321monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-therapeutics-appoints-susan-franks-as-senior-vice-president-and-head-of-regulatory-a-clym-20220405monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-provides-update-on-etx-810-and-etx-155-clinical-programs-clym-20220425monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-therapeutics-announces-last-patient-completed-dosing-in-phase-2a-study-of-etx-810-in-clym-20220627monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-therapeutics-to-host-virtual-investor-event-on-july-21-2022-clym-20220707monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-announces-updated-development-plans-and-the-advancement-of-etx-155-for-the-treatment-clym-20220718monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-therapeutics-provides-etx-810-program-update-clym-20220802monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-therapeutics-to-participate-at-two-upcoming-investor-conferences-clym-20221108monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-therapeutics-at-the-5th-annual-evercore-isi-healthconx-virtual-conference-clym-20221130monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-therapeutics-announces-its-addition-to-the-russell-2000-and-russell-3000-indexes-clym-20240628monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-therapeutics-reports-second-quarter-financial-results-clym-20240814monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-therapeutics-announces-additions-to-its-leadership-team-clym-20240826monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-therapeutics-to-participate-at-the-stifel-2024-virtual-immunology-and-inflammation-s-clym-20240911monthly0.5https://www.biopharmawatch.com/news/CLYM/eliem-therapeutics-announces-rebranding-and-corporate-name-change-to-climb-bio-inc-clym-20241002monthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-announces-abstract-selected-for-presentation-at-the-american-society-of-nephrolo-clym-20241011monthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-to-present-at-upcoming-investor-conferences-clym-20241031monthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-appoints-douglas-e-williams-ph-d-as-chair-of-the-board-clym-20241111monthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-to-be-added-to-the-nasdaq-biotechnology-index-clym-20241219monthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-expands-pipeline-through-an-exclusive-license-to-develop-and-commercialize-an-an-clym-20250109monthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference-clym-20250204monthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-to-present-at-upcoming-investor-conferences-clym-20250225monthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-to-present-at-the-24th-annual-needham-virtual-healthcare-conference-clym-20250327monthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-appoints-seasoned-biotech-leaders-to-board-of-directors-clym-20250401monthly0.5https://www.biopharmawatch.com/news/CLYM/update-climb-bio-to-present-at-upcoming-september-2025-investor-conferences-clym-20250825monthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-announces-fda-fast-track-designation-for-budoprutug-for-the-treatment-of-primary-clym-20260407monthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-hosts-budoprutug-r-d-spotlight-event-highlighting-topline-subcutaneous-formulati-clym-20260505monthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-to-present-at-upcoming-investor-conferences-clym-20260512monthly0.5https://www.biopharmawatch.com/news/CLYM/climb-bio-presents-clym116-initial-phase-1-safety-data-and-translational-modeling-results--clym-20260605monthly0.5https://www.biopharmawatch.com/news/CRVO/eip-pharma-announces-first-patient-dosing-in-phase-2-clinical-studies-of-a-novel-brain-tar-crvo-20150603monthly0.5https://www.biopharmawatch.com/news/CRVO/eip-pharma-announces-scientific-publication-of-results-demonstrating-pro-cognitive-effects-crvo-20151216monthly0.5https://www.biopharmawatch.com/news/CRVO/eip-pharma-announces-issuance-of-multiple-new-patents-covering-vx-745-a-selective-p38-map--crvo-20160928monthly0.5https://www.biopharmawatch.com/news/CRVO/eip-pharma-announces-positive-results-with-neflamapimod-vx-745-in-two-phase-2a-clinical-tr-crvo-20161108monthly0.5https://www.biopharmawatch.com/news/CRVO/eip-pharma-announces-presentation-of-new-positive-clinical-data-with-neflamapimod-vx-745-a-crvo-20170718monthly0.5https://www.biopharmawatch.com/news/CRVO/eip-pharma-announces-presentation-of-new-mechanism-of-action-data-regarding-neflamapimod-v-crvo-20170719monthly0.5https://www.biopharmawatch.com/news/CRVO/eip-pharma-announces-publication-of-positive-alzheimer-s-disease-clinical-study-data-with--crvo-20180307monthly0.5https://www.biopharmawatch.com/news/CRVO/eip-pharma-secures-20-5-million-in-series-b-financing-crvo-20180516monthly0.5https://www.biopharmawatch.com/news/CRVO/eip-pharma-announces-clinical-study-presentations-at-the-11th-clinical-trials-on-alzheimer-crvo-20181024monthly0.5https://www.biopharmawatch.com/news/CRVO/eip-pharma-announces-phase-2b-reverse-sd-study-of-neflamapimod-fully-enrolled-crvo-20181213monthly0.5https://www.biopharmawatch.com/news/CRVO/eip-pharma-to-present-at-bio-ceo-investor-conference-crvo-20190211monthly0.5https://www.biopharmawatch.com/news/CRVO/eip-pharma-closes-11-2-million-financing-round-to-advance-development-of-neflamapimod-in-a-crvo-20190415monthly0.5https://www.biopharmawatch.com/news/CRVO/eip-pharma-to-present-at-upcoming-investor-conferences-in-june-crvo-20190531monthly0.5https://www.biopharmawatch.com/news/CRVO/eip-pharma-to-host-kol-breakfast-briefing-on-potential-of-neflamapimod-in-alzheimer-s-dise-crvo-20190607monthly0.5https://www.biopharmawatch.com/news/CRVO/eip-pharma-appoints-noel-donnelly-as-cfo-crvo-20190708monthly0.5https://www.biopharmawatch.com/news/CRVO/eip-pharma-initiates-new-study-with-neflamapimod-for-the-treatment-of-cognitive-deficits-i-crvo-20190712monthly0.5https://www.biopharmawatch.com/news/CRVO/eip-pharma-announces-presentation-of-preclinical-data-demonstrating-effects-of-p38a-kinase-crvo-20190717monthly0.5https://www.biopharmawatch.com/news/CRVO/eip-pharma-to-present-at-canaccord-genuity-39th-annual-growth-conference-crvo-20190801monthly0.5https://www.biopharmawatch.com/news/CRVO/eip-pharma-announces-clinical-trial-results-of-reverse-sd-a-phase-2b-study-of-neflamapimod-crvo-20191107monthly0.5https://www.biopharmawatch.com/news/CRVO/eip-pharma-announces-u-s-fda-grants-fast-track-designation-to-neflamapimod-as-a-treatment--crvo-20191107monthly0.5https://www.biopharmawatch.com/news/CRVO/eip-pharma-announces-presentation-of-phase-2b-clinical-trial-results-of-neflamapimod-in-ea-crvo-20191205monthly0.5https://www.biopharmawatch.com/news/CRVO/eip-pharma-announces-positive-phase-2-results-for-neflamapimod-in-mild-to-moderate-dementi-crvo-20201006monthly0.5https://www.biopharmawatch.com/news/CRVO/eip-pharma-announces-presentation-of-positive-clinical-trial-results-with-neflamapimod-at--crvo-20201107monthly0.5https://www.biopharmawatch.com/news/CRVO/eip-pharma-announces-publication-of-preclinical-results-demonstrating-potential-of-neflama-crvo-20201216monthly0.5https://www.biopharmawatch.com/news/CRVO/eip-pharma-announces-new-data-presentations-from-phase-2-treatment-trial-in-dementia-with--crvo-20211104monthly0.5https://www.biopharmawatch.com/news/CRVO/eip-pharma-appoints-dr-marwan-sabbagh-to-board-of-directors-crvo-20211104monthly0.5https://www.biopharmawatch.com/news/CRVO/presentation-at-14th-ctad-conference-november-10-2021-crvo-20211110monthly0.5https://www.biopharmawatch.com/news/CRVO/eip-pharma-publishes-translational-data-of-preclinical-and-phase-2a-results-for-neflamapim-crvo-20220921monthly0.5https://www.biopharmawatch.com/news/CRVO/presentation-of-mri-data-at-clinical-trials-and-alzheimer-s-disease-ctad-conference-demons-crvo-20221202monthly0.5https://www.biopharmawatch.com/news/CRVO/national-institute-on-aging-nia-awards-21m-grant-to-support-key-phase-2b-study-of-eip-phar-crvo-20230118monthly0.5https://www.biopharmawatch.com/news/CRVO/eip-pharma-and-diffusion-pharmaceuticals-announce-merger-agreement-to-create-leading-cns-f-crvo-20230330monthly0.5https://www.biopharmawatch.com/news/CRVO/eip-pharma-announces-presentation-of-neuroimaging-data-exhibiting-potential-effects-of-nef-crvo-20230403monthly0.5https://www.biopharmawatch.com/news/CRVO/eip-pharma-to-present-at-canaccord-genuity-43rd-annual-growth-conference-crvo-20230803monthly0.5https://www.biopharmawatch.com/news/CRVO/eip-pharma-announces-first-patient-dosed-in-rewind-lb-phase-2b-clinical-trial-evaluating-n-crvo-20230814monthly0.5https://www.biopharmawatch.com/news/CRVO/diffusion-pharmaceuticals-stockholders-approve-merger-with-eip-pharma-crvo-20230815monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-announces-publication-in-neurology-results-showing-a-blood-test-at-study-entry-id-crvo-20230906monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-announces-publications-in-major-peer-reviewed-journals-that-inform-on-potential-o-crvo-20231025monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-reports-third-quarter-2023-financial-results-and-business-highlights-crvo-20231113monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-to-participate-in-the-emerging-growth-conference-66-crvo-20240105monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-publishes-positive-results-from-ascend-lb-phase-2a-trial-in-peer-reviewed-journal-crvo-20240212monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-announces-presentation-of-biomarker-data-from-the-ascend-lb-phase-2a-trial-and-pr-crvo-20240305monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-announces-up-to-149-4-million-private-placement-financing-joined-by-leading-healt-crvo-20240328monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-reports-first-quarter-2024-financial-results-and-provides-corporate-updates-crvo-20240515monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-to-appoint-william-elder-as-chief-financial-officer-crvo-20240520monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-announces-completion-of-enrollment-in-phase-2b-rewind-lb-clinical-trial-of-neflam-crvo-20240614monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-to-host-virtual-kol-event-on-neflamapimod-for-dementia-with-lewy-bodies-on-july-2-crvo-20240711monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-announces-presentation-at-aaic-2024-on-plasma-biomarker-data-that-are-consistent--crvo-20240729monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-reports-second-quarter-2024-financial-results-and-provides-corporate-updates-crvo-20240812monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-featured-in-fortune-for-advances-in-the-treatment-of-dementia-with-lewy-bodies-crvo-20240822monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-to-deliver-late-breaking-oral-presentations-at-the-17th-clinical-trials-on-alzhei-crvo-20240926monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-announces-last-patient-last-visit-in-phase-2b-rewind-lb-trial-of-neflamapimod-for-crvo-20241015monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-to-deliver-oral-presentation-at-the-8th-international-lewy-body-dementia-conferen-crvo-20241030monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-announces-key-takeaways-from-oral-presentations-at-the-17th-clinical-trials-on-al-crvo-20241104monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-reports-third-quarter-2024-financial-results-and-provides-corporate-updates-crvo-20241112monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-announces-orphan-drug-designation-granted-to-neflamapimod-by-u-s-food-and-drug-ad-crvo-20241127monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-announces-topline-data-from-rewind-lb-phase-2b-clinical-trial-in-patients-with-de-crvo-20241210monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-crvo-20241212monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-provides-update-on-neflamapimod-dlb-program-as-part-of-presentation-at-the-8th-in-crvo-20250131monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-announces-positive-results-from-the-extension-phase-of-its-phase-2b-clinical-stud-crvo-20250310monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-corporat-crvo-20250317monthly0.5https://www.biopharmawatch.com/news/CRVO/investigators-to-present-clinical-trial-results-showing-neflamapimod-slows-clinical-progre-crvo-20250407monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-to-participate-in-h-c-wainwright-3rd-annual-bioconnect-investor-conference-crvo-20250507monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-reports-first-quarter-2025-financial-results-and-provides-corporate-updates-crvo-20250512monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-announces-new-hire-to-support-neflamapimod-development-and-commercialization-crvo-20250610monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-announces-late-breaking-presentations-at-alzheimer-s-association-international-co-crvo-20250708monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-to-present-new-data-from-phase-2b-rewind-lb-study-at-aaic-2025-and-host-conferenc-crvo-20250724monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-announces-32-week-data-from-rewind-lb-trial-extension-phase-showing-neflamapimod--crvo-20250728monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-reports-second-quarter-2025-financial-results-and-provides-corporate-updates-crvo-20250811monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-announces-late-breaking-data-at-the-18th-ctad-conference-demonstrating-neflamapim-crvo-20251204monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporat-crvo-20260317monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-announces-new-data-at-the-ad-pd-2026-scientific-conference-that-reinforce-neflama-crvo-20260319monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-to-provide-neflamapimod-clinical-program-update-and-participate-in-a-panel-on-bio-crvo-20260407monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-announces-new-data-at-the-2026-aan-annual-meeting-that-demonstrated-neflamapimod--crvo-20260422monthly0.5https://www.biopharmawatch.com/news/CRVO/cervomed-reports-first-quarter-2026-financial-results-and-provides-corporate-updates-crvo-20260518monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-launches-with-50-million-series-a-to-develop-targeted-therapies-for-musc-dyn-20190403monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-appoints-catherine-stehman-breen-to-its-board-of-directors-dyn-20190601monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-appointment-of-joshua-brumm-as-president-and-chief-executive-o-dyn-20191001monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-appointment-of-molly-white-as-vice-president-medical-communica-dyn-20200113monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-expands-leadership-team-with-key-hires-dyn-20200206monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-appoints-david-lubner-to-board-of-directors-dyn-20200423monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-demonstrates-force-platform-s-potential-to-deliver-potent-exon-skipping--dyn-20200512monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-accelerates-programs-in-facioscapulohumeral-muscular-dystrophy-fshd-with-dyn-20200519monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-appoints-daniel-wilson-as-vice-president-head-of-intellectual-property-dyn-20200611monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-appointment-of-leading-dmd-expert-francesco-muntoni-to-scienti-dyn-20200720monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-appoints-susanna-high-as-chief-operating-officer-dyn-20200803monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-115-million-financing-to-advance-pipeline-of-modern-oligonucle-dyn-20200810monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-pricing-of-initial-public-offering-dyn-20200916monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-closing-of-initial-public-offering-dyn-20200921monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-present-at-upcoming-investor-conferences-dyn-20201109monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference-dyn-20210105monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-myotonic-dystrophy-type-1-program-achieves-robust-rna-knock-down-of-toxi-dyn-20210110monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-pricing-of-168-million-public-offering-dyn-20210120monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-appoints-ashish-dugar-ph-d-mba-senior-vice-president-global-head-of-medi-dyn-20210208monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-appoints-wildon-farwell-m-d-mph-as-chief-medical-officer-dyn-20210304monthly0.5https://www.biopharmawatch.com/news/DYN/new-preclinical-data-from-dyne-therapeutics-myotonic-dystrophy-type-1-program-to-be-featur-dyn-20210427monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-presents-new-preclinical-data-from-its-myotonic-dystrophy-type-1-program-dyn-20210514monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-dyn-20210526monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-chief-scientific-officer-transition-dyn-20210602monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-presents-preclinical-data-from-its-facioscapulohumeral-muscular-dystroph-dyn-20210625monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-presents-new-in-vivo-data-for-its-myotonic-dystrophy-type-1-candidate-dy-dyn-20210920monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-present-at-chardan-s-virtual-5th-annual-genetic-medicines-conference-dyn-20210927monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-host-virtual-research-and-development-day-on-wednesday-october-13-202-dyn-20210928monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-presents-new-in-vivo-data-for-its-duchenne-muscular-dystrophy-program-du-dyn-20211001monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-highlights-preclinical-data-and-clinical-development-plans-for-dmd-and-d-dyn-20211013monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-submission-of-ind-application-to-initiate-clinical-trial-of-dy-dyn-20211202monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-dyn-20220105monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-fda-clinical-hold-on-ind-application-for-dyne-251-in-duchenne--dyn-20220118monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-appoints-carlo-incerti-m-d-to-its-board-of-directors-dyn-20220303monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-presents-new-in-vivo-data-from-dyne-101-at-asgct-annual-meeting-demonstr-dyn-20220516monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-present-at-jefferies-global-healthcare-conference-dyn-20220603monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-fda-clearance-of-ind-application-for-dyne-251-for-the-treatmen-dyn-20220705monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-clearance-of-clinical-trial-application-for-dyne-101-for-the-t-dyn-20220712monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-breakthrough-article-publication-of-duchenne-muscular-dystroph-dyn-20220810monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-appoints-francesco-bibbiani-m-d-as-senior-vice-president-head-of-develop-dyn-20220829monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-first-patient-dosed-in-phase-1-2-deliver-clinical-trial-of-dyn-dyn-20220906monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-initiation-of-phase-1-2-achieve-clinical-trial-of-dyne-101-for-dyn-20220906monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-present-at-morgan-stanley-20th-annual-global-healthcare-conference-dyn-20220906monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-highlights-dm1-and-dmd-clinical-programs-during-spotlight-on-the-clinic--dyn-20220912monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-present-at-chardan-s-6th-annual-genetic-medicines-conference-dyn-20220927monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-presents-preclinical-data-from-its-duchenne-muscular-dystrophy-programs--dyn-20221011monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-receives-fda-fast-track-designation-for-dyne-251-for-the-treatment-of-du-dyn-20221031monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-present-at-investor-conferences-in-november-dyn-20221102monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-present-at-41st-annual-j-p-morgan-healthcare-conference-dyn-20230103monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-present-at-upcoming-investor-conferences-dyn-20230307monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-presentations-on-its-dm1-and-dmd-programs-at-the-2023-muscular-dyn-20230320monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-receives-fda-orphan-drug-and-rare-pediatric-designations-for-dyne-251-fo-dyn-20230323monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-present-new-preclinical-data-at-asgct-annual-meeting-demonstrating-fo-dyn-20230502monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-present-at-bofa-securities-2023-healthcare-conference-dyn-20230503monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-preclinical-data-demonstrating-force-platform-delivery-to-cns-featured-i-dyn-20230517monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-receives-european-medicines-agency-ema-orphan-drug-designation-for-dyne--dyn-20230525monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-present-at-jefferies-healthcare-conference-dyn-20230601monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-present-at-morgan-stanley-21st-annual-global-healthcare-conference-dyn-20230905monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-receives-fda-orphan-drug-designation-for-dyne-101-for-the-treatment-of-m-dyn-20230920monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-present-at-october-investor-conferences-dyn-20230928monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-present-at-november-investor-conferences-dyn-20231107monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-host-virtual-event-tomorrow-january-3-at-8-00-am-et-to-present-initia-dyn-20240102monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-proposed-public-offering-of-common-stock-dyn-20240103monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-present-at-42nd-annual-j-p-morgan-healthcare-conference-dyn-20240105monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-closing-of-public-offering-of-common-stock-and-full-exercise-b-dyn-20240111monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-present-at-february-investor-conferences-dyn-20240201monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-upcoming-presentations-on-initial-clinical-data-from-its-achie-dyn-20240214monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-present-at-stifel-2024-virtual-cns-days-dyn-20240313monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-ceo-transition-dyn-20240325monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-present-at-the-cantor-virtual-muscular-dystrophy-symposium-dyn-20240327monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-to-newly-app-dyn-20240327monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-host-virtual-investor-event-to-review-new-clinical-data-from-the-achi-dyn-20240519monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-proposed-public-offering-of-common-stock-dyn-20240520monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-closing-of-public-offering-of-common-stock-and-full-exercise-b-dyn-20240528monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-present-at-jefferies-global-healthcare-conference-dyn-20240530monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-presents-new-preclinical-data-for-its-facioscapulohumeral-muscular-dystr-dyn-20240613monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-presents-new-preclinical-data-demonstrating-the-potential-of-the-force-p-dyn-20240624monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-present-at-morgan-stanley-22nd-annual-global-healthcare-conference-dyn-20240829monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-key-leadership-appointments-dyn-20240903monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-present-at-chardan-s-8th-annual-genetic-medicines-conference-dyn-20240923monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-presents-data-at-world-muscle-society-congress-highlighting-promise-of-f-dyn-20241009monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-present-at-upcoming-investor-conferences-dyn-20241107monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-new-clinical-data-dyn-20250108monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-present-at-43rd-annual-j-p-morgan-healthcare-conference-dyn-20250109monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-receives-fda-fast-track-designation-for-dyne-101-for-the-treatment-of-my-dyn-20250121monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conferenc-dyn-20250203monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-upcoming-presentations-at-the-2025-mda-clinical-scientific-con-dyn-20250214monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-present-at-stifel-2025-virtual-cns-forum-dyn-20250311monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-new-long-term-clinical-data-from-phase-1-2-deliver-trial-of-dy-dyn-20250316monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-appointment-of-erick-j-lucera-as-chief-financial-officer-dyn-20250320monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-to-newly-ap-dyn-20250320monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-dyn-20250414monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-chief-business-officer-and-chief-scientific-officer-appointmen-dyn-20250415monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-receives-european-medicines-agency-ema-orphan-drug-designation-for-dyne--dyn-20250424monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-present-new-preclinical-data-in-facioscapulohumeral-muscular-dystroph-dyn-20250605monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-provide-update-on-dyne-1-dyn-20250616monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-secures-up-to-275-million-in-debt-financing-from-hercules-capital-dyn-20250630monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-proposed-public-offering-of-common-stock-dyn-20250630monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-present-at-upcoming-investor-conferences-dyn-20250827monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-proposed-public-offering-of-common-stock-dyn-20251208monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-closing-of-upsized-public-offering-of-common-stock-and-full-ex-dyn-20251211monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-appoints-vikram-karnani-to-board-of-directors-dyn-20251223monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-present-at-44th-annual-j-p-morgan-healthcare-conference-dyn-20260107monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-upcoming-presentations-across-neuromuscular-pipeline-at-2026-m-dyn-20260222monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-participation-at-2026-academy-of-managed-care-pharmacy-amcp-co-dyn-20260401monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-to-participate-in-upcoming-investor-conferences-dyn-20260513monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-initiation-of-phase-3-forzetto-trial-of-z-rostudirsen-in-duche-dyn-20260520monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-announces-submission-of-biologics-license-application-bla-to-u-s-fda-for-dyn-20260526monthly0.5https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-dyn-20260618monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-filing-of-registration-statement-for-proposed-initial-publ-allo-20180914monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-pricing-of-initial-public-offering-allo-20181010monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-november-2018-investor-conference-schedule-allo-20181105monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-presents-data-from-preclinical-study-of-allo-715-anti-bcma-demonstra-allo-20181203monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-and-servier-present-pooled-data-from-phase-1-trials-of-allogeneic-uc-allo-20181204monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-allo-20181219monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-in-collaboration-with-servier-announces-fda-clearance-of-the-ind-for-allo-20190128monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-february-and-march-2019-investor-conference-schedule-allo-20190205monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-enters-lease-to-build-manufacturing-facility-to-develop-and-commerci-allo-20190220monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-to-report-fourth-quarter-and-full-year-2018-financial-results-on-mar-allo-20190227monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-presents-preclinical-data-demonstrating-the-potential-of-allocar-t-t-allo-20190401monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-april-2019-investor-conference-schedule-allo-20190403monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-publication-of-preclinical-study-results-in-molecular-ther-allo-20190415monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-to-report-first-quarter-2019-financial-results-on-may-7-2019-allo-20190430monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-expansion-of-scientific-advisory-board-allo-20190501monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-june-2019-investor-conference-schedule-allo-20190529monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-fda-clearance-of-the-ind-for-allo-715-a-bcma-allogeneic-ca-allo-20190604monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-to-report-second-quarter-2019-financial-results-on-august-7-2019-allo-20190729monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-appoints-rafael-g-amado-m-d-as-executive-vice-president-of-research--allo-20190805monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-september-2019-investor-conference-schedule-allo-20190903monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-enters-research-collaboration-directed-at-enhancing-future-cancer-im-allo-20190919monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-to-report-third-quarter-2019-financial-results-on-november-5-2019-allo-20191029monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-and-notch-therapeutics-announce-collaboration-to-research-and-develo-allo-20191105monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-pre-clinical-data-presentations-supporting-allocar-t-pipel-allo-20191106monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-year-end-2019-media-event-and-investor-conference-schedule-allo-20191111monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-allo-20200102monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-and-springworks-therapeutics-announce-clinical-collaboration-to-eval-allo-20200113monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-february-and-march-2020-investor-conference-schedule-allo-20200206monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-to-report-fourth-quarter-and-full-year-2019-financial-results-on-feb-allo-20200219monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-in-collaboration-with-servier-to-present-initial-results-from-its-ph-allo-20200429monthly0.5https://www.biopharmawatch.com/news/ALLO/american-society-of-clinical-oncology-asco-abstract-reports-initial-allo-501-alpha-phase-1-allo-20200513monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-with-collaborator-servier-reports-positive-results-from-its-phase-1--allo-20200529monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-and-md-anderson-announce-strategic-collaboration-to-accelerate-advan-allo-20201015monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-reports-positive-initial-results-from-phase-1-universal-study-of-all-allo-20201205monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-presents-preclinical-data-on-allo-316-in-acute-myeloid-leukemia-at-t-allo-20201206monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-presents-preclinical-findings-supporting-allo-605-the-first-anti-bcm-allo-20201207monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-and-overland-pharmaceuticals-form-joint-venture-in-greater-china-to--allo-20201215monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-20201223monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-to-present-at-the-virtual-39th-annual-j-p-morgan-healthcare-conferen-allo-20210105monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-ton-schumacher-ph-d-chair-of-scientific-advisory-board-awa-allo-20210126monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-participation-in-four-upcoming-virtual-investor-conference-allo-20210209monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-feb-allo-20210218monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-presents-preclinical-research-highlighting-a-novel-turbocar-t-cell-t-allo-20210410monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-and-springworks-therapeutics-announce-dosing-of-first-patient-in-pha-allo-20210412monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-20210419monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-fda-regenerative-medicine-advanced-therapy-rmat-designatio-allo-20210421monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-to-report-first-quarter-financial-results-on-may-5-2021-allo-20210427monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-to-present-data-from-its-anti-cd19-allocar-t-therapy-program-in-rela-allo-20210428monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-to-host-virtual-cd19-forum-on-may-19-2021-allo-20210512monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-cd19-forum-highlights-positive-results-from-phase-1-studies-of-allo--allo-20210519monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-participation-in-five-upcoming-virtual-investor-conference-allo-20210520monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-presents-positive-phase-1-data-on-allo-501-and-allo-501a-in-relapsed-allo-20210604monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-granted-fda-fast-track-designation-for-allo-605-the-first-turbocar-t-allo-20210630monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-participation-in-two-upcoming-virtual-investor-conferences-allo-20210712monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-to-report-second-quarter-financial-results-on-august-4-2021-allo-20210727monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-appoints-industry-leaders-elizabeth-liz-barrett-and-vicki-sato-ph-d--allo-20210802monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-receives-fda-orphan-drug-designation-odd-for-allo-715-for-the-treatm-allo-20210812monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-participation-in-two-upcoming-virtual-investor-conferences-allo-20210901monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-adds-renowned-car-t-expert-jae-park-m-d-to-its-scientific-advisory-b-allo-20210920monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-reports-fda-clinical-hold-of-allocar-t-trials-based-on-a-single-pati-allo-20211007monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-to-report-third-quarter-financial-results-on-november-4-2021-allo-20211028monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-to-showcase-clinical-data-from-the-alpha-alpha2-and-universal-alloca-allo-20211104monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-participation-in-five-upcoming-virtual-investor-conference-allo-20211112monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-conference-call-to-review-alpha-alpha2-and-universal-phase-allo-20211201monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-reports-positive-phase-1-data-from-the-alpha-trials-in-non-hodgkin-s-allo-20211213monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-reports-positive-results-from-phase-1-universal-study-of-single-dose-allo-20211213monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-expands-headquarters-to-support-company-growth-and-pipeline-innovati-allo-20211215monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-to-present-at-the-virtual-40th-annual-j-p-morgan-healthcare-conferen-allo-20220104monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-removal-of-fda-clinical-hold-across-all-allocar-t-clinical-allo-20220110monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-exclusive-collaboration-and-global-license-agreement-with--allo-20220111monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-receives-fda-fast-track-designation-for-its-first-solid-tumor-candid-allo-20220310monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-publishes-preclinical-data-on-allo-316-an-allocar-t-candidate-target-allo-20220413monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-the-fda-granted-regenerative-medicine-advanced-therapy-rma-allo-20220608monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-r-d-showcase-features-hematologic-and-solid-tumor-advances-across-it-allo-20221129monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-appoints-zachary-j-roberts-m-d-ph-d-as-executive-vice-president-of-research-devel-allo-20230103monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-allo-20230104monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-participation-in-two-upcoming-investor-conferences-allo-20230117monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-publication-in-nature-medicine-of-data-from-its-phase-1-un-allo-20230124monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-publishes-preclinical-data-in-clinical-cancer-research-supporting-dl-allo-20230125monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-presents-data-on-dagger-a-next-generation-allocar-t-platform-technol-allo-20230201monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-to-report-fourth-quarter-and-year-end-2022-financial-results-on-febr-allo-20230221monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-publication-of-industry-advancing-case-study-on-chromosoma-allo-20230301monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-participation-in-two-upcoming-investor-conferences-allo-20230302monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-316-at-the-ameri-allo-20230314monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-publishes-2022-annual-environmental-social-and-governance-esg-report-allo-20230330monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-participation-in-four-upcoming-investor-conferences-allo-20230413monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-presents-interim-phase-1-data-on-allo-316-in-renal-cell-carcinoma-at-allo-20230417monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-appoints-timothy-moore-as-chief-technical-officer-allo-20230420monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-to-report-first-quarter-2023-financial-results-on-may-3-2023-allo-20230425monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-presentation-of-phase-1-data-from-the-allo-501-501a-trials-allo-20230426monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-encore-presentation-of-phase-1-data-from-the-allo-501-501a-allo-20230511monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-participation-in-three-upcoming-investor-conferences-allo-20230524monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-presents-updated-allo-501-501a-phase-1-data-in-large-b-cell-lymphoma-allo-20230603monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-501-501a-in-larg-allo-20230609monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-provides-additional-allo-501-501a-phase-1-data-in-an-oral-presentati-allo-20230615monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-appoints-earl-douglas-as-general-counsel-allo-20230814monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-appoints-geoffrey-parker-as-chief-financial-officer-allo-20231016monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-poster-presentations-at-the-65th-annual-meeting-of-the-ame-allo-20231102monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-presents-preclinical-data-on-next-generation-cloak-and-dagger-techno-allo-20231103monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-and-foresight-diagnostics-announce-partnership-to-develop-mrd-based--allo-20240104monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-2024-platform-vision-to-redefine-the-future-of-car-t-led-b-allo-20240104monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-and-arbor-biotechnologies-announce-global-gene-editing-licensing-agr-allo-20240312monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-q2-investor-conference-participation-allo-20240409monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-pricing-of-110-million-offering-of-common-stock-allo-20240513monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-participation-in-the-td-cowen-5th-annual-oncology-innovati-allo-20240523monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-initiates-pivotal-phase-2-trial-investigating-cemacabtagene-ansegedl-allo-20240620monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-activates-three-community-cancer-centers-as-first-sites-for-the-pivo-allo-20240701monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-to-report-second-quarter-2024-financial-results-and-provide-business-allo-20240731monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences-allo-20240808monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-to-present-pre-clinical-data-highlighting-the-potential-of-allo-329--allo-20240926monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-participation-in-the-goldman-sachs-cell-therapy-day-confer-allo-20240930monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-allo-20241029monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-to-report-third-quarter-2024-financial-results-and-provide-business--allo-20241030monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-participation-in-november-investor-conferences-allo-20241104monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-to-present-new-data-demonstrating-the-potential-of-allo-316-in-heavi-allo-20241105monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-positive-phase-1-data-demonstrating-the-potential-of-allo--allo-20241107monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-presents-preclinical-data-for-allo-329-an-allogeneic-cd19-cd70-dual--allo-20241118monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-participation-in-december-investor-conferences-allo-20241119monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-acknowledges-the-passing-of-founding-board-member-david-bonderman-allo-20241212monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-allo-20241216monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-secures-u-s-fda-ind-clearance-for-allo-329-advancing-its-next-genera-allo-20250128monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-benjamin-m-beneski-as-senior-vice-president-and-chief-tech-allo-20250129monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-participation-in-february-investor-conferences-allo-20250204monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-publication-of-durable-response-data-from-phase-1-alpha-al-allo-20250213monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-expands-strategic-partnership-with-foresight-diagnostics-to-advance--allo-20250225monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-participation-in-march-investor-conference-allo-20250226monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-and-pr-allo-20250303monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-granted-three-u-s-fda-fast-track-designations-ftd-for-allo-329-a-next-generation--allo-20250407monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-to-present-updated-allo-316-clinical-results-in-kidney-cancer-in-ora-allo-20250423monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-business--allo-20250506monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-asco-2025-abstract-publication-featuring-oral-presentation-allo-20250522monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences-allo-20250523monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-to-report-second-quarter-2025-financial-results-and-provide-business-allo-20250806monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-participation-in-upcoming-investor-conference-allo-20250827monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-to-report-third-quarter-2025-financial-results-and-provide-business--allo-20251030monthly0.5https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences-allo-20260526monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-to-present-at-the-2026-jefferies-global-healthcare-conference-in-new-york-alxo-20260601monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-s-evorpacept-in-combination-with-zanidatamab-generates-promising-durable-resp-alxo-20260507monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-reports-inducement-grant-as-permitted-by-the-nasdaq-listing-rules-alxo-20260417monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-to-present-at-upcoming-investor-conferences-in-q1-2026-alxo-20260219monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-27--alxo-20260219monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-to-present-at-upcoming-investor-conferences-alxo-20251118monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-to-report-second-quarter-2025-financial-results-on-august-12-2025-alxo-20250805monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-highlights-differentiated-design-preclinical-data-and-development-plans-for-e-alxo-20250520monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-to-host-r-d-webcast-event-highlighting-its-novel-egfr-targeting-antibody-drug-alxo-20250513monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-to-report-first-quarter-2025-financial-results-on-may-8-2025-alxo-20250502monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-encouraging-final-results-from-phase-1-trial-evaluating-evorpacept--alxo-20250425monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-reports-aspen-03-and-aspen-04-phase-2-trials-evaluating-evorpacept-with-a-che-alxo-20250425monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-receives-ind-clearance-from-u-s-fda-for-alx2004-a-novel-egfr-targeted-antibod-alxo-20250407monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-highlights-focused-evorpacept-development-plan-clinical-progress-and-corporat-alxo-20250305monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025-alxo-20250227monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-to-host-virtual-r-d-day-on-march-5-2025-alxo-20250218monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-presents-positive-updated-data-from-aspen-06-phase-2-trial-demonstrating-evor-alxo-20250123monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-reports-inducement-grant-as-permitted-by-the-nasdaq-listing-rules-alxo-20250122monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-to-host-virtual-company-event-highlighting-updated-data-from-aspen-06-phase-2-alxo-20250121monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-alxo-20250107monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-to-present-updated-results-from-phase-2-aspen-06-clinical-trial-of-evorpacept-alxo-20241218monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-to-host-virtual-company-event-highlighting-new-clinical-data-presented-at-sab-alxo-20241212monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-new-data-demonstrating-evorpacept-in-combination-with-zanidatamab-g-alxo-20241210monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-to-participate-in-the-piper-sandler-36th-annual-healthcare-conference-alxo-20241126monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-november-investor-conference-participation-alxo-20241104monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-results-from-phase-1b-2-trial-of-evorpacept-in-combination-with-zan-alxo-20241101monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-to-present-at-the-2024-cantor-fitzgerald-global-healthcare-conference-alxo-20240909monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-first-patients-dosed-with-evorpacept-and-sarclisa-as-part-of-random-alxo-20240904monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-reports-topline-data-from-aspen-06-phase-2-trial-demonstrating-evorpacept-imp-alxo-20240731monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-to-host-investor-call-and-webcast-to-share-topline-data-results-from-aspen-06-alxo-20240731monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-presents-first-evorpacept-combination-data-with-an-antibody-drug-conjugate-fr-alxo-20240602monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-participation-in-the-jefferies-global-healthcare-conference-alxo-20240529monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-appoints-allison-dillon-as-chief-business-officer-alxo-20240507monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-initiation-of-phase-2-investigator-sponsored-trial-of-neoadjuvant-r-alxo-20240430monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-two-evorpacept-abstracts-accepted-for-poster-presentation-at-2024-a-alxo-20240424monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-reports-encouraging-clinical-data-of-evorpacept-in-combination-with-standard--alxo-20240409monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-two-evorpacept-clinical-abstracts-accepted-for-presentation-at-the--alxo-20240305monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-alxo-20240103monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-november-investor-conference-participation-alxo-20231101monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-closing-of-public-offering-including-full-exercise-of-underwriters--alxo-20231010monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-proposed-public-offering-alxo-20231004monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-to-host-investor-call-and-webcast-on-october-3-2023-to-share-interim-phase-2--alxo-20231002monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-realigns-executive-leadership-team-alxo-20230906monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-september-investor-conference-participation-alxo-20230831monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-receives-orphan-drug-designation-from-the-european-commission-for-evorpacept--alxo-20230626monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-first-patient-dosed-in-phase-2-investigator-sponsored-trial-of-evor-alxo-20230509monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-clinical-trial-collaboration-with-sanofi-to-evaluate-evorpacept-in--alxo-20230425monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-and-quantum-leap-healthcare-collaborative-announce-first-patient-dosed-in-the-alxo-20230313monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-first-patient-dosed-in-aspen-07-a-phase-1-study-of-evorpacept-for-t-alxo-20230216monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-provides-corporate-update-and-highlights-key-milestones-in-2023-alxo-20230105monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-alxo-20230103monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-initial-data-from-aspen-05-study-of-evorpacept-in-combination-with--alxo-20221212monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-to-present-new-clinical-data-on-evorpacept-in-acute-myeloid-leukemia-at-64th--alxo-20221103monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-upcoming-investor-conference-participation-alxo-20221102monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-trials-in-progress-abstracts-accepted-for-poster-presentation-at-th-alxo-20221005monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-alxo-20220921monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-upcoming-investor-conference-participation-alxo-20220901monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-and-quantum-leap-healthcare-collaborative-announce-the-selection-of-evorpacep-alxo-20220816monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-first-patient-dosed-in-phase-2-investigator-sponsored-trial-of-evor-alxo-20220811monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-s-evorpacept-receives-fast-track-designation-from-fda-as-first-line-treatment-alxo-20220801monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-receives-u-s-fda-orphan-drug-designation-for-evorpacept-for-the-treatment-of--alxo-20220629monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-evorpacept-clinical-program-updates-alxo-20220603monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-to-participate-in-the-jefferies-2022-healthcare-conference-alxo-20220601monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-first-patient-dosed-in-aspen-06-a-phase-2-3-study-of-evorpacept-for-alxo-20220302monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-receives-u-s-fda-orphan-drug-designation-for-evorpacept-for-the-treatment-of--alxo-20220127monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-provides-corporate-update-and-highlights-key-milestones-in-2022-alxo-20220110monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-alxo-20220104monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-initial-data-from-aspen-02-the-ongoing-phase-1-2-study-of-evorpacep-alxo-20211212monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-updated-data-from-ongoing-clinical-trial-aspen-01-of-evorpacept-sho-alxo-20211109monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-to-present-new-evorpacept-clinical-data-in-myelodysplastic-syndromes-at-63rd--alxo-20211104monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-upcoming-virtual-investor-conference-participation-alxo-20211102monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-first-patient-dosed-in-aspen-05-a-phase-1-2-study-of-evorpacept-in--alxo-20211021monthly0.5https://www.biopharmawatch.com/news/ALXO/zymeworks-and-alx-oncology-announce-first-patient-dosed-in-phase-1b-2-clinical-trial-of-za-alxo-20211005monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-four-abstracts-accepted-for-presentation-at-the-society-for-immunot-alxo-20211001monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-initiation-of-investigator-sponsored-trial-of-evorpacept-alx148-in--alxo-20210916monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-upcoming-virtual-investor-conference-participation-alxo-20210907monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-first-patient-dosed-in-aspen-04-a-phase-2-study-of-alx148-in-combin-alxo-20210728monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-new-data-from-aspen-01-the-phase-1b-study-of-alx148-showing-robust--alxo-20210703monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-update-on-aspen-03-and-aspen-04-the-alx148-phase-2-head-and-neck-ca-alxo-20210614monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-to-collaborate-with-lilly-to-evaluate-alx148-plus-cyramza-ramucirumab-trastuz-alxo-20210610monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-upcoming-virtual-investor-conference-participation-alxo-20210518monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-first-patient-dosed-in-aspen-03-a-phase-2-study-of-alx148-in-combin-alxo-20210510monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-to-present-alx148-clinical-data-at-the-esmo-23rd-world-congress-on-gastrointe-alxo-20210421monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-strengthens-ip-portfolio-announces-end-of-post-grant-review-period-for-issued-alxo-20210405monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-and-tallac-therapeutics-announce-collaboration-on-novel-class-of-cancer-immun-alxo-20210304monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-to-participate-at-h-c-wainwright-global-life-sciences-conference-alxo-20210302monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-provides-corporate-update-and-highlights-key-milestones-in-2021-alxo-20210111monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-to-present-at-39th-annual-j-p-morgan-healthcare-conference-alxo-20210105monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-added-to-the-nasdaq-biotechnology-index-alxo-20201217monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-closing-of-public-offering-and-full-exercise-of-the-underwriters-op-alxo-20201214monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-pricing-of-upsized-public-offering-of-common-stock-alxo-20201209monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-proposed-public-offering-of-common-stock-alxo-20201207monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-updated-data-from-aspen-01-the-ongoing-phase-1b-study-of-alx148-sho-alxo-20201207monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-updates-on-planned-alx148-phase-2-head-and-neck-cancer-studies-alxo-20201207monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-december-2020-virtual-investor-conference-participation-alxo-20201124monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-new-data-from-aspen-01-the-phase-1b-study-of-alx148-showing-promisi-alxo-20201109monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-to-present-alx148-clinical-data-at-the-62nd-american-society-of-hematology-as-alxo-20201105monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-november-2020-virtual-investor-conference-participation-alxo-20201102monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-first-patient-dosed-in-aspen-02-a-phase-1-2-study-of-alx148-in-comb-alxo-20201028monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-to-present-alx148-clinical-data-at-the-society-for-immunotherapy-of-cancer-si-alxo-20201014monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-names-leading-oncology-experts-to-scientific-advisory-board-alxo-20201006monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-to-collaborate-with-merck-on-phase-2-immuno-oncology-studies-evaluating-alx14-alxo-20200922monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-added-to-russell-2000-and-3000-indexes-alxo-20200917monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-participation-at-upcoming-investor-conferences-alxo-20200908monthly0.5https://www.biopharmawatch.com/news/ALXO/alx-oncology-announces-pricing-of-initial-public-offering-alxo-20200716monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-announces-pricing-of-upsized-initial-public-offering-prax-20201016monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-provides-regulatory-update-on-prax-114-program-prax-20201110monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-participate-in-upcoming-investor-conferences-prax-20201120monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-receives-rare-pediatric-disease-and-orphan-drug-designations-fo-prax-20210107monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-provides-corporate-update-and-reports-first-quarter-2021-financ-prax-20210511monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-announces-proposed-public-offering-of-common-stock-prax-20210511monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-provides-corporate-update-and-reports-second-quarter-2021-finan-prax-20210816monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-present-at-citi-s-16th-annual-biopharma-virtual-conference-prax-20210901monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-provides-corporate-update-and-reports-third-quarter-2021-financ-prax-20211103monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-present-data-from-rare-disease-programs-at-the-american-epil-prax-20211129monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-announces-management-team-appointments-prax-20211202monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-host-movement-disorder-day-on-december-17-2021-prax-20211210monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-announces-publication-of-preclinical-data-highlighting-differen-prax-20220118monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-provides-corporate-update-and-reports-fourth-quarter-and-full-y-prax-20220228monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-present-data-from-prax-944-for-essential-tremor-at-2022-amer-prax-20220401monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-showcases-largest-targeted-epilepsy-portfolio-in-industry-at-20-prax-20220427monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-reports-positive-topline-results-from-prax-944-phase-2a-study-i-prax-20220509monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-provides-corporate-update-and-reports-first-quarter-2022-financ-prax-20220509monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-adds-global-business-expertise-to-board-of-directors-with-appoi-prax-20220523monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-reports-negative-results-from-prax-114-phase-2-3-monotherapy-ar-prax-20220606monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-provides-corporate-update-and-reports-second-quarter-2022-finan-prax-20220808monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-provides-updates-on-clinical-stage-pediatric-epilepsy-programs-prax-20220907monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-provides-corporate-update-and-reports-third-quarter-2022-financ-prax-20221109monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-advance-prax-562-phase-2-study-in-pediatric-patients-with-de-prax-20221128monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-and-ucb-announce-epilepsy-research-collaboration-prax-20221213monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-provides-corporate-update-and-reports-fourth-quarter-and-full-y-prax-20230207monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-announces-topline-results-from-the-essential1-study-of-ulixacal-prax-20230303monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-provides-portfolio-update-at-2023-r-d-day-prax-20231002monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-provides-corporate-update-and-reports-third-quarter-2023-financ-prax-20231107monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-showcase-largest-pipeline-of-precision-epilepsy-programs-and-prax-20231128monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-provides-corporate-update-and-reports-fourth-quarter-and-full-y-prax-20240305monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inc-announces-pricing-of-200-million-public-offering-prax-20240328monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-participate-in-upcoming-april-conferences-prax-20240405monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-present-on-ulixacaltamide-at-the-american-academy-of-neurolo-prax-20240412monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-provides-corporate-update-and-reports-second-quarter-2024-finan-prax-20240813monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-announce-topline-data-from-the-phase-2-embold-study-of-relut-prax-20240902monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-announces-positive-topline-results-from-the-embold-study-in-scn-prax-20240903monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-announce-third-quarter-2024-financial-results-and-host-confe-prax-20241101monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-provides-corporate-update-and-reports-third-quarter-2024-financ-prax-20241106monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-showcase-updates-from-largest-epilepsy-pipeline-of-precision-prax-20241126monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-present-at-upcoming-december-investor-conferences-prax-20241203monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-announces-rare-pediatric-disease-designation-granted-for-relutr-prax-20241218monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-highlights-2025-corporate-strategy-and-business-priorities-prax-20250113monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-present-at-two-february-investor-conferences-prax-20250203monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-provides-update-on-essential3-and-corporate-update-prax-20250228monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-provides-corporate-update-and-reports-first-quarter-2025-financ-prax-20250502monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-participate-in-upcoming-conferences-prax-20250520monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-provides-corporate-update-and-reports-second-quarter-2025-finan-prax-20250804monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inc-announces-pricing-of-575-million-public-offering-prax-20260107monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-enters-its-next-chapter-following-a-pivotal-year-of-progress-prax-20260112monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-provides-corporate-update-and-reports-fourth-quarter-and-full-y-prax-20260219monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-announces-fda-acceptance-and-priority-review-of-new-drug-applic-prax-20260330monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-announces-positive-results-from-the-embrave-part-a-trial-of-els-prax-20260406monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-announces-fda-acceptance-of-new-drug-application-for-ulixacalta-prax-20260414monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-provides-corporate-update-and-reports-first-quarter-2026-financ-prax-20260507monthly0.5https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-to-participate-in-goldmans-sachs-47th-annual-global-healthcare--prax-20260604monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-secures-25-million-series-a-funding-from-key-investors-and-enters-int-kytx-20200113monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-announces-the-appointment-of-james-chung-m-d-ph-d-as-chief-medical-of-kytx-20210413monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-appoints-ian-clark-as-chairman-of-the-board-and-karen-walker-as-chief-kytx-20210915monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-closes-85-million-series-b-financing-led-by-northpond-ventures-kytx-20220126monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-names-cell-therapy-expert-tom-van-blarcom-ph-d-as-senior-vice-preside-kytx-20220823monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-names-georg-schett-m-d-and-peter-a-merkel-m-d-mph-to-scientific-advis-kytx-20220823monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-names-peter-maag-ph-d-as-chief-executive-officer-kytx-20221013monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-submits-ind-for-novel-car-t-cell-therapy-to-treat-lupus-nephritis-kytx-20221018monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-announces-fda-clearance-of-ind-for-kyv-101-a-novel-fully-human-cd19-c-kytx-20221111monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-to-present-new-data-of-kyv-101-in-lupus-at-american-society-of-gene-c-kytx-20230517monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-to-present-new-data-of-kyv-101-in-lupus-at-european-congress-of-rheum-kytx-20230524monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-granted-fda-fast-track-designation-for-kyv-101-in-lupus-nephritis-kytx-20230601monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-announces-first-patient-enrolled-in-phase-1-clinical-trial-of-cd19-ca-kytx-20230629monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-announces-regulatory-approval-of-phase-1-2-clinical-trial-for-kyv-101-kytx-20230706monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-extends-series-b-financing-round-to-145-million-and-brings-in-new-inv-kytx-20230803monthly0.5https://www.biopharmawatch.com/news/KYTX/verily-and-kyverna-therapeutics-announce-collaboration-to-advance-cell-therapy-for-autoimm-kytx-20230907monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-to-participate-in-the-morgan-stanley-21st-annual-global-healthcare-co-kytx-20230908monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-announces-achievement-of-28-day-post-infusion-milestone-for-first-u-s-kytx-20230913monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-and-oxford-biomedica-sign-license-and-supply-agreement-for-lentivecto-kytx-20230920monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-and-elevatebio-to-advance-kyverna-s-ingenui-t-cell-therapy-manufactur-kytx-20230926monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-announces-fda-clearance-of-ind-for-kyv-101-a-novel-fully-human-cd19-c-kytx-20231011monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-announces-collaboration-with-charite-to-fund-research-into-b-cell-and-kytx-20231101monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-hosts-a-car-t-cell-therapy-symposium-in-berlin-to-discuss-investigati-kytx-20231110monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-congratulates-the-teams-at-the-universities-of-bochum-and-magdeburg-f-kytx-20231111monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-congratulates-scientific-advisory-board-member-peter-a-merkel-m-d-m-p-kytx-20231111monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-announces-fda-clearance-of-phase-2-ind-for-kyv-101-a-fully-human-cd19-kytx-20231113monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-announces-publication-in-the-lancet-neurology-of-case-report-of-patie-kytx-20231115monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-granted-fda-fast-track-designation-for-kyv-101-in-the-treatment-of-pa-kytx-20231213monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-s-kyv-101-receives-u-s-fda-clearance-for-treatment-of-patients-with-refractory-pro-kytx-20240103monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-granted-fda-fast-track-designation-for-kyv-101-in-the-treatment-of-pa-kytx-20240119monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-announces-first-publication-of-ingenui-t-a-novel-car-t-cell-vein-to-v-kytx-20240124monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-announces-pricing-of-upsized-initial-public-offering-kytx-20240207monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-announces-closing-of-initial-public-offering-and-full-exercise-of-und-kytx-20240212monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-congratulates-prof-g-schett-et-al-on-the-publication-of-a-case-series-kytx-20240222monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-and-stanford-university-agree-to-evaluate-kyv-101-in-patients-with-no-kytx-20240307monthly0.5https://www.biopharmawatch.com/news/KYTX/first-in-disease-use-of-kyverna-therapeutics-kyv-101-in-patients-with-progressive-multiple-kytx-20240329monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-to-attend-the-2024-american-academy-of-neurology-aan-annual-meeting-i-kytx-20240411monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-to-present-data-on-50-patient-experience-at-symposium-at-eular-2024-kytx-20240607monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-and-national-institutes-of-health-co-author-seminal-review-on-cell-th-kytx-20240610monthly0.5https://www.biopharmawatch.com/news/KYTX/first-in-disease-use-of-kyverna-therapeutics-kyv-101-in-patient-with-severe-stiff-person-s-kytx-20240617monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-s-kyv-101-receives-u-s-fda-ind-clearance-for-treatment-of-patients-with-treatment--kytx-20240620monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-receives-u-s-fda-rmat-designation-for-kyv-101-in-the-treatment-of-pat-kytx-20240812monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-to-participate-in-upcoming-september-investor-conferences-kytx-20240821monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-announces-leadership-update-kytx-20240916monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-presents-patient-data-reinforcing-potential-of-kyv-101-for-treatment--kytx-20240918monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-announces-new-patient-data-highlighting-potential-of-kyv-101-for-trea-kytx-20241114monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-kytx-20250106monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-highlights-neuroimmunology-car-t-franchise-and-registrational-phase-3-kytx-20250828monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-highlights-potential-of-kyv-101-in-multiple-sclerosis-with-data-from--kytx-20250924monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-announces-proposed-public-offering-of-common-stock-kytx-20251215monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-to-present-new-data-from-neuroimmunology-franchise-at-aan-2026-kytx-20260305monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-presents-longer-term-phase-2-data-for-miv-cel-in-generalized-myasthenia-gravis-at--kytx-20260420monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-presents-registrational-trial-primary-analysis-for-miv-cel-in-stiff-person-syndrom-kytx-20260421monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-names-greg-martini-as-chief-financial-officer-kytx-20260518monthly0.5https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-highlights-updated-miv-cel-data-at-eular-demonstrating-substantial-re-kytx-20260603monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-raises-9-5-million-to-put-simple-antibody-platform-to-work-argx-20090909monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-opens-new-r-d-facility-in-flanders-argx-20091109monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-simple-antibody-platform-set-to-transform-therapeutic-antibody-discovery-developme-argx-20100228monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-concludes-eur-12-5-million-series-a-financing-round-argx-20100419monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-granted-broad-patent-covering-its-unique-simple-antibody-platform-argx-20100707monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-awarded-1-5-million-iwt-grant-to-accelerate-pre-clinical-antibody-development-argx-20100926monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-appoints-dr-debbie-allen-as-senior-director-business-development-argx-20101104monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-signs-discovery-and-development-alliance-with-lilly-argx-20110104monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-initiates-a-second-pre-clinical-development-program-in-under-18-months-from-start--argx-20110515monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-announces-non-exclusive-license-with-biowa-for-potelligent-technology-argx-20110725monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-presents-significant-progress-at-biopharm-america-2011-argx-20110906monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-is-awarded-1-3-million-iwt-grant-to-advance-proprietary-simple-antibody-platform-f-argx-20111129monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-raises-eur-27-5-million-usd-37-million-in-oversubscribed-series-b-round-argx-20111130monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-advances-a-third-therapeutic-antibody-program-into-preclinical-development-argx-20120207monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-enters-into-a-therapeutic-antibody-alliance-with-shire-argx-20120227monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-appoints-alain-thibault-as-chief-medical-officer-and-koos-rasser-as-ip-counsel-argx-20120318monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-launches-nhance-technology-to-generate-better-human-antibody-therapies-argx-20120318monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-granted-first-us-patent-covering-its-unique-nhance-technology-argx-20120423monthly0.5https://www.biopharmawatch.com/news/ARGX/cambridge-healthtech-associates-announces-argen-x-as-inaugural-signature-award-winner-argx-20120513monthly0.5https://www.biopharmawatch.com/news/ARGX/ruiyi-formerly-anaphore-and-argen-x-announce-exclusive-worldwide-license-agreement-for-arg-argx-20121003monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-appoints-dr-david-l-lacey-to-its-supervisory-board-argx-20121024monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-reveals-the-target-and-unique-mechanism-of-action-of-its-most-advanced-preclinical-argx-20121105monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-announces-grant-of-broad-us-patent-covering-its-simple-antibody-platform-argx-20121205monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-expands-its-therapeutic-antibody-alliance-with-shire-argx-20130106monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-initiates-phase-ib-study-of-argx-110-in-cancer-argx-20130106monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-announces-preclinical-development-of-argx-112-for-dermatology-argx-20130324monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-to-present-at-upcoming-ninth-annual-pegs-2013-argx-20130425monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-grants-license-to-its-nhance-antibody-half-life-extension-technology-argx-20130805monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-identifies-potent-antibody-antagonists-against-complex-chronic-pain-target-nav1-7-argx-20130911monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-initiates-phase-ib-study-of-argx-111-in-cancer-argx-20130916monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-reaches-milestone-in-simple-antibody-research-and-product-development-collaboratio-argx-20130918monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-and-de-duve-institute-ucl-to-collaborate-on-novel-immunomodulation-therapy-in-canc-argx-20131103monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-raises-eur-5-million-from-pmv-in-extension-of-eur-32-5-million-series-b-argx-20131103monthly0.5https://www.biopharmawatch.com/news/ARGX/argx-110-a-novel-anti-cd70-antibody-meets-translational-development-goals-in-dose-escalati-argx-20131216monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-starts-phase-ib-expansion-cohorts-with-argx-110-a-novel-anti-cd70-antibody-in-canc-argx-20140106monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-receives-two-preclinical-milestone-payments-under-collaboration-with-shire-argx-20140112monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-appoints-dr-werner-lanthaler-to-its-supervisory-board-argx-20140403monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-uses-its-simple-antibody-platform-to-identify-four-hotspots-on-met-as-targets-for--argx-20140406monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-advances-argx-113-into-preclinical-development-for-autoimmune-disorders-argx-20140423monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-announces-collaboration-with-bayer-to-discover-and-develop-therapeutic-antibody-ca-argx-20140527monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-to-present-results-of-phase-1-study-of-argx-110-a-novel-anti-cd70-antibody-in-pati-argx-20140528monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-enters-long-term-strategic-alliance-with-shire-pharmaceuticals-in-therapeutic-anti-argx-20140603monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-announces-intention-to-launch-an-initial-public-offering-on-euronext-brussels-argx-20140609monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-launches-initial-public-offering-on-euronext-brussels-argx-20140619monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-raises-40-million-in-successful-initial-public-offering-on-euronext-brussels-argx-20140707monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-to-present-at-the-wedbush-2014-life-sciences-management-access-conference-argx-20140804monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-raises-additional-1-8-million-via-exercise-of-over-allotment-option-and-announces--argx-20140810monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-announces-positive-preclinical-results-for-argx-113-argx-20140818monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-business-update-and-first-half-2014-results-argx-20140826monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-appoints-petercam-nv-as-liquidity-provider-to-facilitate-trading-on-euronext-bruss-argx-20140914monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-core-patents-protecting-lead-clinical-candidates-argx-110-and-argx-111-receive-acc-argx-20140916monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-completes-recruitment-of-first-cohort-of-15-patients-with-cd70-positive-solid-tumo-argx-20140917monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-completes-recruitment-of-first-cohort-of-15-patients-with-cd70-positive-hematologi-argx-20141014monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-submits-investigational-new-drug-application-to-evaluate-argx-110-in-waldenstro-m--argx-20141102monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-initiates-clinical-efficacy-evaluation-of-argx-110-in-patients-with-relapsed-refra-argx-20141110monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-third-quarter-business-update-argx-20141113monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-reports-preclinical-data-on-argx-110-in-chronic-myelogenous-leukemia-model-argx-20141207monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-announces-advancement-of-therapeutic-antibody-alliance-with-shire-argx-20141210monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-launches-innovative-access-program-argx-20150111monthly0.5https://www.biopharmawatch.com/news/ARGX/lonza-and-argen-x-announce-a-multi-product-gs-xceed-license-agreement-for-therapeutic-anti-argx-20150217monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-presents-argx-111-at-targeted-anticancer-therapies-argx-20150301monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-expands-preclinical-pipeline-with-argx-115-a-novel-simple-antibody-for-cancer-immu-argx-20150303monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-to-host-conference-call-webcast-to-report-fourth-quarter-business-update-and-full--argx-20150310monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-to-present-at-22nd-annual-biocentury-future-leaders-in-the-biotech-industry-confer-argx-20150312monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-reports-fourth-quarter-business-update-and-full-year-2014-financial-results-argx-20150317monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-announces-annual-general-meeting-of-shareholders-13-may-2015-argx-20150331monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-opens-expansion-cohort-in-phase-1b-study-of-argx-111-in-patients-with-met-amplifie-argx-20150408monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-n-v-announces-changes-to-the-board-of-directors-argx-20150413monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-announces-publication-on-therapeutic-potential-of-argx-115-in-cancer-immunotherapy-argx-20150422monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-announces-results-of-annual-general-meeting-2015-argx-20150512monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-first-quarter-2015-financial-results-and-business-update-argx-20150514monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-awarded-1-5-million-iwt-grant-to-advance-the-application-of-nhance-fc-modification-argx-20150518monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-and-leo-pharma-enter-into-alliance-to-develop-antibody-based-treatments-for-skin-c-argx-20150520monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-presents-preliminary-efficacy-and-expanded-safety-data-from-phase-i-trial-of-argx--argx-20150528monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-to-present-at-jefferies-2015-global-healthcare-conference-on-tuesday-2-june-at-8-0-argx-20150531monthly0.5https://www.biopharmawatch.com/news/ARGX/preliminary-phase-i-results-of-argx-110-in-patients-with-t-cell-lymphomas-presented-at-icm-argx-20150617monthly0.5https://www.biopharmawatch.com/news/ARGX/change-to-the-board-of-directors-argx-20150714monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-and-university-of-bern-enter-into-license-agreement-to-develop-argx-110-based-comb-argx-20150729monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-to-present-at-wedbush-pacgrow-healthcare-conference-argx-20150806monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-to-host-conference-call-webcast-to-report-half-year-results-on-26-august-2015-argx-20150818monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-announces-half-year-results-for-2015-argx-20150824monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-partner-ruiyi-inc-announces-first-human-dosing-of-gerilimzumab-a-novel-simple-anti-argx-20150922monthly0.5https://www.biopharmawatch.com/news/ARGX/argen-x-completes-first-dosing-of-argx-113-for-severe-autoimmune-disorders-argx-20151021monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-key-investor-conferences-argx-20151029monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-third-quarter-2015-financial-results-and-provides-business-update-argx-20151116monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-host-workshop-and-webcast-announcing-topline-clinical-tcl-data-and-preclinical-a-argx-20151203monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-initial-results-from-a-phase-1-single-ascending-dose-study-of-argx-113-in-argx-20160104monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-16-m-investment-by-us-funds-advised-by-subsidiaries-of-federated-investor-argx-20160118monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-successfully-closes-transaction-with-us-funds-advised-by-subsidiaries-of-federated--argx-20160121monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-receives-milestone-payment-in-leo-pharma-collaboration-argx-20160131monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-the-leerink-partners-5th-annual-global-healthcare-conference-argx-20160203monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-opens-clinical-trial-sites-in-south-korea-for-argx-111-program-argx-20160216monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-home-member-state-selection-argx-20160224monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-host-conference-call-webcast-to-report-fourth-quarter-business-update-and-full-y-argx-20160301monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-fourth-quarter-business-update-and-full-year-2015-financial-results-argx-20160309monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-s-partner-bird-rock-bio-demonstrates-potential-for-gerilimzumab-a-novel-simple-anti-argx-20160314monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-annual-general-meeting-of-shareholders-28-april-2016-argx-20160315monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-and-abbvie-to-collaborate-on-argx-115-against-novel-immuno-oncology-target-argx-20160419monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-results-of-annual-general-meeting-2016-argx-20160427monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-first-quarter-2016-financial-results-and-provides-business-update-argx-20160509monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-private-placement-of-2-703-000-new-shares-for-an-aggregate-amount-of-30-m-argx-20160531monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-efficacy-and-expanded-safety-data-from-phase-1-trial-of-argx-111-argx-20160601monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-successfully-closes-30-million-private-placement-argx-20160601monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-presentation-of-updated-argx-110-phase-1-data-in-tcl-at-eha-2016-argx-20160608monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-initial-results-from-phase-1-multiple-ascending-dose-mad-study-of-argx-11-argx-20160628monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-host-conference-call-webcast-to-report-second-quarter-2016-business-update-and-h-argx-20160802monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-wedbush-pacgrow-healthcare-conference-argx-20160803monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-second-quarter-business-update-and-half-year-2016-financial-results-argx-20160824monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-host-inaugural-r-d-day-and-webcast-on-september-22-2016-argx-20160913monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-provides-update-on-lead-programs-in-auto-immune-disease-and-oncology-at-r-d-day-in--argx-20160921monthly0.5https://www.biopharmawatch.com/news/ARGX/frost-sullivan-applauds-argenx-for-enhancing-the-therapeutic-qualities-of-human-antibodies-argx-20161003monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-third-quarter-2016-financial-results-and-provides-business-update-argx-20161025monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-upcoming-investor-conferences-argx-20161106monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-provide-updates-on-argx-113-and-argx-110-during-american-society-of-hematology-a-argx-20161130monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-launches-phase-i-ii-study-of-argx-110-in-combination-with-azacitidine-in-newly-diag-argx-20161213monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-publication-of-seminal-data-supporting-the-therapeutic-potential-of-argx--argx-20161227monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-launches-phase-ii-proof-of-concept-study-of-argx-113-for-the-treatment-of-myastheni-argx-20170105monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-leerink-partners-6th-annual-global-healthcare-conference-argx-20170208monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-extension-of-therapeutic-antibody-alliance-with-shire-argx-20170225monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-cowen-co-37th-annual-healthcare-conference-argx-20170226monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-intention-to-conduct-a-registered-public-offering-in-the-united-states-argx-20170228monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-that-staten-biotech-exercised-its-option-to-develop-therapeutic-simple-an-argx-20170302monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-host-conference-call-webcast-to-report-fourth-quarter-business-update-and-full-y-argx-20170308monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-annual-general-meeting-of-shareholders-26-april-2017-argx-20170314monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-fourth-quarter-business-update-and-full-year-2016-financial-results-argx-20170314monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-collaboration-with-broteio-pharma-to-develop-therapeutic-antibody-for-sev-argx-20170320monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-first-patient-dosed-in-phase-ii-proof-of-concept-study-of-argx-113-for-th-argx-20170330monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-launches-phase-ii-study-of-argx-110-as-a-monotherapy-in-relapsed-refractory-ctcl-pa-argx-20170411monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-receives-first-preclinical-milestone-payment-in-abbvie-collaboration-argx-20170412monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-files-registration-statement-for-a-proposed-public-offering-in-the-united-states-argx-20170423monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-results-of-annual-general-meeting-2017-argx-20170425monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-first-quarter-2017-financial-results-and-provides-business-update-argx-20170501monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reaches-50-enrollment-in-phase-2-clinical-trial-of-argx-113-in-myasthenia-gravis-argx-20170503monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-launch-of-proposed-initial-public-offering-in-the-united-states-argx-20170507monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-size-of-initial-public-offering-in-the-united-states-increased-to-5-milli-argx-20170515monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-raises-approximately-100-million-gross-proceeds-with-nasdaq-ipo-argx-20170516monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-full-exercise-of-underwriters-option-to-purchase-additional-adss-argx-20170518monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-closing-of-nasdaq-ipo-argx-20170522monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-jmp-securities-life-sciences-conference-argx-20170612monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-wedbush-pacgrow-healthcare-conference-argx-20170807monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-host-conference-call-webcast-to-report-second-quarter-business-update-and-half-y-argx-20170816monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-orphan-drug-designation-for-argx-113-for-the-treatment-of-myasthenia-grav-argx-20170924monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-host-kol-breakfast-symposium-on-pemphigus-vulgaris-on-november-10-2017-argx-20171101monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-upcoming-investor-conferences-argx-20171112monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-launch-of-proposed-public-offering-in-the-united-states-argx-20171210monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-provide-updates-on-phase-1-2-clinical-trials-of-argx-110-in-acute-myeloid-leukem-argx-20171210monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-size-of-proposed-public-offering-in-the-united-states-updated-to-3-5-mill-argx-20171212monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-raises-approximately-231-million-in-gross-proceeds-in-an-upsized-u-s-public-offerin-argx-20171213monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-closing-of-u-s-public-offering-for-gross-proceeds-of-approximately-266-mi-argx-20171217monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-host-conference-call-webcast-to-report-fourth-quarter-business-update-and-full-y-argx-20180221monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-cowen-company-38th-annual-health-care-conference-argx-20180305monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-annual-general-meeting-of-shareholders-on-may-8-2018-argx-20180325monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-complete-data-from-the-phase-2-clinical-trial-of-efgartigimod-argx-113-i-argx-20180402monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-first-quarter-2018-financial-results-and-provides-business-update-argx-20180508monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-upcoming-investor-conferences-argx-20180516monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-receives-feedback-from-fda-in-end-of-phase-2-meeting-for-efgartigimod-in-myasthenia-argx-20180605monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-host-kol-breakfast-symposium-on-immune-thrombocytopenia-argx-20180611monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-host-conference-call-webcast-to-report-second-quarter-business-update-argx-20180725monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-2018-wedbush-pacgrow-healthcare-conference-argx-20180809monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-launch-of-proposed-public-offering-in-the-united-states-argx-20180916monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-raises-approximately-300-6-million-in-gross-proceeds-in-a-u-s-public-offering-argx-20180918monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-closing-of-u-s-public-offering-argx-20180920monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-new-cusatuzumab-argx-110-aml-data-in-abstracts-published-in-connection-wi-argx-20181031monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-upcoming-investor-conferences-argx-20181106monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-enters-exclusive-global-collaboration-and-license-agreement-with-cilag-gmbh-interna-argx-20181202monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-37th-annual-j-p-morgan-healthcare-conference-argx-20190102monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-host-conference-call-webcast-to-report-fourth-quarter-business-update-and-full-y-argx-20190220monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-cowen-and-company-39th-annual-health-care-conference-argx-20190303monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-bank-of-america-merrill-lynch-2019-health-care-conference-argx-20190507monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-host-r-d-day-on-may-22-2019-argx-20190514monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-upcoming-investor-conferences-argx-20190529monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-report-half-year-2019-financial-results-and-second-quarter-business-update-on-au-argx-20190725monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-2019-wedbush-pacgrow-healthcare-conference-argx-20190806monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-morgan-stanley-17th-annual-global-healthcare-conference-argx-20190903monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-participate-in-upcoming-investor-conferences-argx-20191029monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-launch-of-proposed-global-offering-argx-20191105monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-raises-484-million-in-gross-proceeds-in-a-global-offering-argx-20191106monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-full-exercise-of-underwriters-option-to-purchase-additional-adss-argx-20191107monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-closing-of-global-offering-argx-20191111monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-results-of-extraordinary-general-meeting-of-shareholders-argx-20191124monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-upcoming-investor-events-argx-20191125monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-publication-of-efgartigimod-phase-2-primary-immune-thrombocytopenia-trial-argx-20191209monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-report-full-year-2019-financial-results-and-fourth-quarter-business-update-on-fe-argx-20200219monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-cowen-40th-annual-health-care-conference-argx-20200224monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-full-year-2019-financial-results-argx-20200226monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-data-from-phase-2-trial-of-efgartigimod-in-pemphigus-at-2020-society-for-argx-20200510monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-bofa-securities-virtual-health-care-conference-2020-argx-20200510monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-report-first-quarter-2020-financial-results-and-business-update-on-may-14-2020-argx-20200510monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-positive-topline-phase-3-adapt-trial-results-argx-20200525monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-launch-of-proposed-global-offering-argx-20200526monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-raises-750-million-in-gross-proceeds-in-a-global-offering-argx-20200527monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-full-exercise-of-underwriters-option-to-purchase-additional-adss-argx-20200528monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-closing-of-global-offering-argx-20200601monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-goldman-sachs-41st-annual-global-healthcare-conference-argx-20200603monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-closing-of-global-offering-argx-20200716monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-report-half-year-2020-financial-results-and-second-quarter-business-update-on-ju-argx-20200722monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-2020-wedbush-pacgrow-healthcare-virtual-conference-argx-20200803monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-management-to-present-at-upcoming-virtual-investor-conferences-argx-20200901monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-additional-data-from-global-phase-3-adapt-trial-of-efgartigimod-for-myas-argx-20200918monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-expands-capabilities-in-antibody-engineering-through-key-technology-partnerships-argx-20201006monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-report-third-quarter-2020-financial-results-and-business-update-on-october-22-20-argx-20201014monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-participate-in-upcoming-virtual-investor-conferences-argx-20201108monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-premieres-a-mystery-to-me-a-docuseries-inspired-by-the-myasthenia-gravis-patient-ex-argx-20201117monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-39th-annual-j-p-morgan-healthcare-conference-argx-20210103monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-go-decision-in-adhere-trial-of-efgartigimod-in-chronic-inflammatory-demye-argx-20210131monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-launch-of-proposed-global-offering-argx-20210201monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-issues-statement-concerning-efgartigimod-argx-20210202monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-raises-1-0-billion-in-gross-proceeds-in-a-global-offering-argx-20210202monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-full-exercise-of-underwriters-option-to-purchase-additional-adss-argx-20210203monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-closing-of-global-offering-argx-20210205monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-report-full-year-2020-financial-results-and-fourth-quarter-business-update-on-ma-argx-20210224monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-fda-acceptance-of-bla-filing-for-efgartigimod-for-the-treatment-of-genera-argx-20210302monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-full-year-2020-financial-results-and-provides-fourth-quarter-business-updat-argx-20210303monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-management-to-present-at-upcoming-virtual-investor-conferences-argx-20210427monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-report-first-quarter-2021-financial-results-and-business-update-on-may-14-2021-argx-20210506monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-first-quarter-2021-financial-results-and-provides-business-update-argx-20210513monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-upcoming-investor-conferences-argx-20210531monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-publication-of-phase-3-adapt-trial-results-of-efgartigimod-for-the-treatm-argx-20210616monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-host-virtual-r-d-day-on-july-20-2021-argx-20210713monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-report-half-year-2021-financial-results-and-second-quarter-business-update-on-ju-argx-20210721monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-2021-wedbush-pacgrow-virtual-healthcare-conference-argx-20210803monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-validation-of-european-marketing-authorization-application-for-efgartigim-argx-20210824monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-upcoming-investor-conferences-argx-20210902monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-highlight-potential-first-in-class-fcrn-antagonist-efgartigimod-at-upcoming-neur-argx-20211007monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-report-third-quarter-2021-financial-results-and-business-update-on-october-28-20-argx-20211020monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-third-quarter-2021-financial-results-and-provides-business-update-argx-20211027monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-upcoming-investor-conferences-argx-20211109monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-40th-annual-j-p-morgan-healthcare-conference-argx-20220102monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-highlights-strategic-priorities-for-2022-argx-20220106monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-the-11th-annual-svb-leerink-global-healthcare-conference-argx-20220210monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-report-full-year-2021-financial-results-and-fourth-quarter-business-update-on-ma-argx-20220224monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-the-42nd-annual-cowen-health-care-conference-argx-20220228monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-launch-of-proposed-global-offering-argx-20220322monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-raises-700-million-in-gross-proceeds-in-a-global-offering-argx-20220323monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-closing-of-global-offering-argx-20220328monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-annual-general-meeting-of-shareholders-on-may-10-2022-argx-20220329monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-full-exercise-of-underwriters-option-to-purchase-additional-adss-argx-20220329monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-new-data-from-generalized-myasthenia-gravis-program-at-2022-american-aca-argx-20220331monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-presents-interim-results-from-adapt-open-label-extension-study-evaluating-vyvgart-e-argx-20220404monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-report-first-quarter-2022-financial-results-and-business-update-on-may-5-2022-argx-20220427monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-bofa-securities-2022-healthcare-conference-argx-20220503monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-positive-phase-3-data-from-advance-trial-of-vyvgart-efgartigimod-alfa-fca-argx-20220504monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-results-of-annual-general-meeting-of-shareholders-argx-20220510monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-the-uk-mhra-has-granted-early-access-to-efgartigimod-for-generalized-myas-argx-20220531monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-upcoming-investor-conferences-argx-20220601monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-report-half-year-2022-financial-results-and-second-quarter-business-update-on-ju-argx-20220720monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-wells-fargo-healthcare-conference-argx-20220831monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-highlight-key-programs-from-neuromuscular-franchise-at-upcoming-medical-meetings-argx-20220921monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-report-third-quarter-2022-financial-results-and-business-update-on-october-27-20-argx-20221019monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-extraordinary-general-meeting-of-shareholders-on-december-12-2022-argx-20221028monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-upcoming-investor-conferences-argx-20221106monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-pivotal-advance-trial-data-during-ash-plenary-session-highlighting-vyvga-argx-20221212monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-appoints-ana-cespedes-to-board-of-directors-argx-20221213monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-41st-annual-j-p-morgan-healthcare-conference-argx-20230103monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-extraordinary-general-meeting-of-shareholders-on-february-27-2023-to-appo-argx-20230116monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-report-full-year-2022-financial-results-and-fourth-quarter-business-update-on-ma-argx-20230224monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-appoints-steve-krognes-to-board-of-directors-argx-20230227monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-upcoming-investor-conferences-argx-20230227monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-full-year-2022-financial-results-and-provides-fourth-quarter-business-updat-argx-20230301monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-annual-general-meeting-of-shareholders-on-may-2-2023-argx-20230317monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-report-first-quarter-2023-financial-results-and-business-update-on-may-4-2023-argx-20230427monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-bofa-securities-2023-health-care-conference-argx-20230502monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-upcoming-investor-conferences-argx-20230530monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-u-s-food-and-drug-administration-approval-of-vyvgart-hytrulo-efgartigimod-argx-20230620monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-launch-of-proposed-global-offering-argx-20230717monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-raises-1-1-billion-in-gross-proceeds-in-a-global-offering-argx-20230718monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-full-exercise-of-underwriters-option-to-purchase-additional-adss-argx-20230719monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-report-half-year-2023-financial-results-and-second-quarter-business-update-on-ju-argx-20230719monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-closing-of-global-offering-argx-20230724monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-upcoming-investor-conferences-argx-20230829monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-positive-chmp-opinion-for-subcutaneous-efgartigimod-for-generalized-myast-argx-20230914monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-report-third-quarter-2023-financial-results-and-business-update-on-october-31-20-argx-20231024monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-upcoming-investor-conferences-argx-20231101monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-42nd-annual-j-p-morgan-healthcare-conference-argx-20240101monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-highlights-2024-strategic-priorities-argx-20240107monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-report-full-year-2023-financial-results-and-fourth-quarter-business-update-on-fe-argx-20240221monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-upcoming-investor-conferences-argx-20240225monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-report-first-quarter-2024-financial-results-and-business-update-on-may-9-2024-argx-20240502monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-bofa-securities-2024-health-care-conference-argx-20240507monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-goldman-sachs-45th-annual-global-healthcare-conference-argx-20240604monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-report-half-year-2024-financial-results-and-second-quarter-business-update-on-ju-argx-20240718monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-half-year-2024-financial-results-and-provides-second-quarter-business-updat-argx-20240725monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-upcoming-investor-conferences-argx-20240828monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-report-third-quarter-2024-financial-results-and-business-update-on-october-31-20-argx-20241024monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-third-quarter-2024-financial-results-and-provides-business-update-argx-20241031monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-participate-at-upcoming-investor-conferences-argx-20241105monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-upcoming-investor-conferences-argx-20241126monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-43rd-annual-j-p-morgan-healthcare-conference-argx-20250106monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-highlights-2025-strategic-priorities-argx-20250113monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-full-year-2024-financial-results-and-provides-fourth-quarter-business-updat-argx-20250227monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-announces-annual-general-meeting-of-shareholders-on-may-27-2025-argx-20250411monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-report-first-quarter-2025-financial-results-and-business-update-on-may-8-2025-argx-20250501monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-bofa-securities-2025-health-care-conference-argx-20250506monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-first-quarter-2025-financial-results-and-provides-business-update-argx-20250508monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-goldman-sachs-46th-annual-global-healthcare-conference-argx-20250603monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-report-half-year-2025-financial-results-and-second-quarter-business-update-on-ju-argx-20250724monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-reports-half-year-2025-financial-results-and-provides-second-quarter-business-updat-argx-20250731monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-report-third-quarter-2025-financial-results-and-business-update-on-october-30-20-argx-20251023monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-highlights-2026-strategic-priorities-argx-20260112monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-report-full-year-2025-financial-results-and-fourth-quarter-business-update-on-fe-argx-20260219monthly0.5https://www.biopharmawatch.com/news/ARGX/argenx-to-present-at-upcoming-investor-conferences-argx-20260527monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-presents-first-in-vivo-images-of-brain-tdp-43-pathology-from-phase-1-trial-of-pe-aciu-20260319monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update-aciu-20250805monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-first-quarter-2025-financial-results-and-provides-a-corporate-update-aciu-20250430monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-full-year-2024-financial-results-and-provides-a-corporate-update-aciu-20250313monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-participate-in-upcoming-investor-conferences-aciu-20250304monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-present-at-the-jefferies-2024-london-healthcare-conference-aciu-20241113monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-third-quarter-2024-financial-results-and-provides-a-corporate-update-aciu-20241105monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-receives-second-milestone-payment-following-progress-in-phase-2b-retain-trial-of-aciu-20240917monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-second-quarter-2024-financial-results-and-provides-a-corporate-update-aciu-20240806monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-showcasing-its-novel-morphomer-antibody-drug-conjugate-moradc-platform-for-the-t-aciu-20240716monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-present-at-the-jefferies-global-healthcare-conference-in-june-2024-aciu-20240528monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-first-quarter-2024-financial-results-and-provides-a-corporate-update-aciu-20240513monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-and-takeda-sign-exclusive-option-and-license-agreement-for-active-immunotherapy--aciu-20240513monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-full-year-2023-financial-results-and-provides-a-corporate-update-aciu-20240314monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-announces-upcoming-presentations-at-ad-pd-2024-aciu-20240222monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-regain-global-rights-to-crenezumab-and-semorinemab-aciu-20240122monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-announces-pricing-of-underwritten-offering-of-common-shares-aciu-20231215monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-present-at-the-jefferies-2023-london-healthcare-conference-aciu-20231107monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-third-quarter-2023-financial-results-and-provides-a-corporate-update-aciu-20231103monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-host-kol-webinar-on-amyloid-plaque-pet-imaging-in-alzheimer-s-disease-as-a-su-aciu-20231102monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-clinical-data-published-in-nature-communications-show-alpha-synuclein-pet-tracer-aciu-20231027monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-announces-upcoming-presentations-at-the-16th-ctad-conference-aciu-20231017monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-present-at-the-jefferies-2023-cns-neuro-summit-in-october-2023-aciu-20231005monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference-in-sep-aciu-20230905monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-second-quarter-2023-financial-results-and-provides-a-corporate-update-aciu-20230804monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-present-at-the-btig-virtual-biotechnology-conference-2023-aciu-20230728monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-sa-appoints-new-chief-medical-officer-aciu-20230726monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-showcasing-precision-medicine-programs-at-aaic-2023-aciu-20230703monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-holds-annual-general-meeting-of-shareholders-aciu-20230623monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-first-quarter-2023-financial-results-and-provides-a-corporate-update-aciu-20230428monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-host-key-opinion-leader-webinar-on-early-diagnosis-and-prevention-of-alzheime-aciu-20230405monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-at-ad-pd-2023-to-present-new-clinical-and-preclinical-data-from-its-precision-me-aciu-20230320monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-full-year-2022-financial-results-and-provides-corporate-update-aciu-20230316monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-report-full-year-2022-financial-results-and-provide-corporate-update-on-march-aciu-20230308monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-awarded-new-grants-from-mjff-and-target-als-supporting-programs-targeting-tdp-43-aciu-20230207monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-present-at-the-svb-securities-global-biopharma-conference-aciu-20230202monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-partner-life-molecular-imaging-initiates-phase-3-study-of-tau-pet-diagnostic-pi--aciu-20230118monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-present-progress-of-alzheimer-s-disease-programs-targeting-abeta-and-tau-at-t-aciu-20221123monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-present-at-the-jefferies-london-healthcare-conference-aciu-20221108monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-third-quarter-2022-financial-results-and-provides-a-corporate-update-aciu-20221028monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-opens-new-centers-in-phase-1b-2-trial-evaluating-aci-24-targeting-abeta-in-alzhe-aciu-20221004monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-receives-a-grant-from-the-michael-j-fox-foundation-for-continued-development-of--aciu-20220901monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-kol-webinar-on-the-potential-benefits-of-vaccines-for-alzheimer-s-and-parkinson--aciu-20220824monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-host-key-opinion-leader-webinar-on-vaccinations-to-treat-and-prevent-alzheime-aciu-20220811monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-second-quarter-2022-financial-results-and-provides-corporate-update-aciu-20220728monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-announces-upcoming-presentations-at-the-alzheimer-s-association-international-co-aciu-20220722monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-holds-annual-general-meeting-of-shareholders-aciu-20220624monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-present-at-the-2022-jefferies-healthcare-conference-aciu-20220531monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-ceo-andrea-pfeifer-receives-aenne-burda-award-aciu-20220517monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-s-anti-abeta-vaccine-results-from-phase-1b-study-in-down-syndrome-published-in-j-aciu-20220509monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-first-quarter-2022-financial-results-and-provides-corporate-update-aciu-20220428monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-present-at-the-b-riley-annual-neuro-ophthalmology-virtual-investor-conference-aciu-20220427monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-changes-to-senior-management-aciu-20220408monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-kol-webinar-on-first-clinical-proof-of-concept-for-alpha-synuclein-diagnostic-sh-aciu-20220330monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-full-year-2021-financial-results-and-provides-corporate-update-aciu-20220322monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-host-key-opinion-leader-webinar-on-alpha-synuclein-as-a-target-in-neurodegene-aciu-20220321monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-present-at-the-ad-pd-2022-new-clinical-and-preclinical-data-for-alpha-synucle-aciu-20220228monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-aci-35-030-phase-1b-2a-trial-interim-data-confirm-consistent-safety-and-potent-i-aciu-20220215monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-aci-24-data-in-brain-communications-show-abeta-vaccine-candidate-induces-immunit-aciu-20220204monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-present-at-the-svb-leerink-11th-annual-global-healthcare-conference-aciu-20220202monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-awarded-two-michael-j-fox-foundation-grants-to-advance-small-molecule-parkinson--aciu-20211215monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-announces-late-breaker-presentation-by-genentech-at-ctad-on-phase-2-lauriet-stud-aciu-20211110monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-third-quarter-2021-financial-results-and-provides-corporate-update-aciu-20211108monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-extends-research-collaboration-with-university-of-pennsylvania-focusing-on-the-p-aciu-20211104monthly0.5https://www.biopharmawatch.com/news/ACIU/new-data-on-ac-immune-s-abeta-and-ptau-clinical-programs-in-alzheimer-s-disease-to-be-pres-aciu-20211102monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-present-at-the-jefferies-london-healthcare-conference-aciu-20211025monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-ceo-andrea-pfeifer-receives-first-sef-womenaward-for-ceo-of-the-year-aciu-20210903monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september-aciu-20210902monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-second-quarter-2021-financial-results-and-provides-corporate-update-aciu-20210804monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-presents-full-phase-1b-results-on-anti-abeta-vaccine-and-discusses-its-first-in--aciu-20210729monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-holds-its-annual-general-meeting-of-shareholders-aciu-20210625monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-provides-update-on-alzheimer-s-disease-vaccine-candidates-targeting-pathological-aciu-20210602monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-highlight-first-in-class-alzheimer-s-disease-vaccine-programs-at-upcoming-inv-aciu-20210520monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-announces-expansion-of-phase-1b-2a-phospho-tau-alzheimer-s-vaccine-trial-and-pro-aciu-20210517monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-first-quarter-2021-financial-results-and-provides-corporate-update-aciu-20210428monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-hosts-investor-webinar-highlighting-the-power-of-its-morphomer-platform-to-enabl-aciu-20210331monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-host-webinar-highlighting-its-innovative-morphomer-technology-platform-and-pi-aciu-20210326monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-full-year-2020-financial-results-and-provides-2021-r-d-outlook-aciu-20210323monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-announces-new-clinical-results-in-down-syndrome-and-plans-for-future-development-aciu-20210316monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-presents-new-preclinical-data-for-therapeutic-and-diagnostic-candidates-addressi-aciu-20210309monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-present-new-data-from-alpha-synuclein-and-tdp-43-programs-at-the-ad-pd-2021-v-aciu-20210224monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-highlight-promising-alzheimer-s-vaccine-at-the-svb-leerink-10th-annual-global-aciu-20210217monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-initiates-clinical-study-of-first-in-class-diagnostic-for-parkinson-s-disease-aciu-20210208monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-progress-for-therapeutic-programs-targeting-the-nlrp3-inflammasome-pathw-aciu-20210129monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-receives-competitive-target-als-foundation-grant-to-accelerate-the-development-o-aciu-20201215monthly0.5https://www.biopharmawatch.com/news/ACIU/immunotherapy-pioneer-prof-carl-h-june-joins-ac-immune-s-board-of-directors-aciu-20201120monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-q3-2020-financial-results-and-provides-business-update-aciu-20201113monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-provide-strategy-and-pipeline-update-during-jefferies-virtual-london-healthca-aciu-20201112monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-and-wuxi-biologics-strengthen-strategic-partnership-to-accelerate-ac-immune-s-an-aciu-20201109monthly0.5https://www.biopharmawatch.com/news/ACIU/competitive-eu-grant-supports-collaboration-to-accelerate-development-of-ac-immune-s-first-aciu-20201009monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-showcase-anti-tau-portfolio-at-h-c-wainwright-22nd-annual-global-investment-c-aciu-20200911monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-q2-2020-financial-results-and-provides-business-update-aciu-20200805monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-initiates-ind-enabling-studies-for-first-in-class-antibody-targeting-tdp-43-to-t-aciu-20200803monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-wins-prestigious-award-to-develop-a-game-changing-parkinson-s-diagnostic-tool-aciu-20200730monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-demonstrates-enhanced-performance-of-first-in-class-parkinson-s-diagnostic-agent-aciu-20200728monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-present-advances-in-two-of-the-company-s-world-leading-programs-at-the-upcomi-aciu-20200723monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-advances-phospho-tau-alzheimer-s-vaccine-in-phase-1b-2a-study-aciu-20200716monthly0.5https://www.biopharmawatch.com/news/ACIU/tau-pet-tracer-pi-2620-could-set-new-standards-for-an-improved-diagnosis-of-progressive-su-aciu-20200707monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-announces-results-of-annual-general-meeting-aciu-20200626monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-ceo-to-showcase-novel-target-programs-at-ubs-global-healthcare-conference-aciu-20200515monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-q1-2020-financial-results-and-provides-business-update-aciu-20200504monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-full-year-2019-financial-results-and-provides-2020-r-d-outlook-aciu-20200330monthly0.5https://www.biopharmawatch.com/news/ACIU/internationally-renowned-neurologist-dr-juan-fortea-joins-ac-immune-s-clinical-advisory-bo-aciu-20200320monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-present-new-data-demonstrating-the-depth-of-its-neurodegenerative-programs-at-aciu-20200305monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-present-at-jefferies-2019-london-healthcare-conference-aciu-20191114monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-q3-2019-financial-results-and-business-update-aciu-20191113monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-hosts-key-opinion-leader-event-untangling-tau-pathology-to-treat-alzheimer-s-and-aciu-20191106monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-host-key-opinion-leader-event-untangling-tau-pathology-to-treat-alzheimer-s-a-aciu-20191024monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-receives-milestone-payment-in-connection-with-initiation-of-a-phase-2-trial-of-t-aciu-20190917monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-awarded-michael-j-fox-foundation-grant-to-accelerate-development-of-parkinson-s--aciu-20190904monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-q2-2019-financial-results-business-and-clinical-update-aciu-20190814monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-announces-research-collaboration-with-university-of-pennsylvania-focusing-on-pat-aciu-20190812monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-initiates-ph1b-2a-study-of-anti-phospho-tau-vaccine-in-alzheimer-s-disease-aciu-20190801monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-hosts-kol-event-and-reports-initial-interim-clinical-data-for-aci-24-vaccine-to--aciu-20190711monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-announces-election-of-new-chairman-of-the-board-at-annual-general-meeting-aciu-20190628monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-host-key-opinion-leader-meeting-on-treating-alzheimer-s-in-down-syndrome-aciu-20190627monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-initiation-of-a-phase-2-substudy-to-increase-understanding-of-disease-pr-aciu-20190620monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-q1-2019-financial-results-and-business-update-aciu-20190515monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-present-at-the-h-c-wainwright-global-life-sciences-conference-aciu-20190401monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-presents-new-data-on-alpha-synuclein-pet-tracer-at-ad-pdtm-conference-aciu-20190329monthly0.5https://www.biopharmawatch.com/news/ACIU/new-clinical-data-on-ac-immune-s-novel-next-generation-tau-pet-tracer-presented-by-licensi-aciu-20190327monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-full-year-2018-financial-results-and-provides-business-update-aciu-20190321monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-report-progress-of-early-stage-pipeline-at-ad-pd-tm-congress-aciu-20190304monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-makes-two-appointments-to-executive-committee-to-accelerate-product-development-aciu-20190207monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-announces-appointment-of-dr-marie-kosco-vilbois-as-chief-scientific-officer-aciu-20190103monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-and-wuxi-biologics-to-establish-an-exclusive-strategic-partnership-aciu-20181219monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-and-lilly-announce-license-and-collaboration-agreement-aciu-20181212monthly0.5https://www.biopharmawatch.com/news/ACIU/in-memoriam-dr-andreas-muhs-cso-scientific-leader-and-friend-has-passed-away-aciu-20181207monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-awarded-third-follow-up-grant-from-the-michael-j-fox-foundation-for-first-in-hum-aciu-20181115monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-third-quarter-2018-financial-results-and-corporate-update-aciu-20181113monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-present-at-the-jefferies-2018-london-healthcare-conference-aciu-20181112monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-shares-insights-from-key-opinion-leader-meeting-on-abeta-oligomers-in-alzheimer--aciu-20181109monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-present-at-2018-society-for-neurosciences-meeting-aciu-20181101monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-host-key-opinion-leader-meeting-on-abeta-oligomers-in-alzheimer-s-disease-ad--aciu-20181101monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-partner-life-molecular-imaging-presents-new-clinical-study-results-for-tau-pet-t-aciu-20181029monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-sa-new-data-supporting-crenezumab-as-potential-alzheimer-s-therapy-aciu-20181029monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-selected-to-present-progress-on-its-tau-morphomer-program-in-the-late-breaking-n-aciu-20181025monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-announces-important-clinical-milestones-for-aci-24-vaccine-in-alzheimer-s-diseas-aciu-20180820monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-second-quarter-2018-financial-results-and-corporate-update-aciu-20180808monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-announces-successful-closing-of-second-subscription-rights-offering-aciu-20180731monthly0.5https://www.biopharmawatch.com/news/ACIU/new-phase-2-data-analysis-for-crenezumab-presented-at-global-alzheimer-s-conference-provid-aciu-20180725monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-announces-closing-of-first-subscription-rights-offering-and-primary-offering-as--aciu-20180724monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-announces-price-of-usd-11-75-for-offerings-and-issuance-of-up-to-10-million-comm-aciu-20180718monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-announces-offerings-and-issuance-of-up-to-10-million-common-shares-aciu-20180717monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-announces-results-of-annual-general-meeting-aciu-20180706monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-first-quarter-2018-financial-results-and-corporate-update-aciu-20180502monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-announces-results-of-extraordinary-shareholders-meeting-aciu-20180427monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-announces-the-selection-of-tau-small-molecules-for-clinical-development-in-alzhe-aciu-20180405monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-prepares-for-a-first-in-human-study-of-a-promising-positron-emission-tomography--aciu-20180315monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-participate-in-two-investor-conferences-and-provide-scientific-updates-at-aat-aciu-20180206monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-shares-insights-from-key-opinion-leader-meeting-on-tau-as-a-therapeutic-and-diag-aciu-20171201monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-host-key-opinion-leader-meeting-on-tau-as-a-therapeutic-and-diagnostic-target-aciu-20171121monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-sa-reports-third-quarter-2017-financial-results-and-corporate-update-aciu-20171113monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-sa-to-receive-milestone-payment-for-anti-tau-antibody-moving-into-phase-2-trial--aciu-20171102monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-to-present-at-two-investor-conferences-and-provide-scientific-updates-at-ctad-co-aciu-20171024monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-awarded-continuation-of-2015-grant-from-the-michael-j-fox-foundation-for-parkins-aciu-20171003monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-completes-recruitment-for-low-dose-cohort-in-world-s-first-clinical-trial-for-an-aciu-20170912monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-discovers-next-generation-antibodies-focused-on-neurodegenerative-diseases-aciu-20170822monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-second-quarter-2017-financial-results-aciu-20170809monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-provides-seven-updates-on-its-pipeline-and-technology-at-the-alzheimer-s-associa-aciu-20170710monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-announces-results-of-annual-general-meeting-aciu-20170628monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-and-essex-bio-technology-announce-research-collaboration-for-neurodegenerative-d-aciu-20170522monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-sa-reports-first-quarter-2017-financial-results-aciu-20170511monthly0.5https://www.biopharmawatch.com/news/ACIU/piramal-imaging-and-ac-immune-present-first-clinical-data-for-tau-pet-imaging-tracer-at-in-aciu-20170403monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-provides-twelve-updates-on-its-pipeline-at-the-international-conference-on-alzhe-aciu-20170323monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-full-year-2016-financial-results-and-r-d-update-aciu-20170317monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-partner-genentech-to-start-second-phase-3-clinical-trial-for-alzheimer-s-therapy-aciu-20170228monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-partner-genentech-presents-important-data-on-alzheimer-s-therapy-crenezumab-aciu-20161209monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-sa-announces-results-of-annual-general-meeting-aciu-20161115monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-reports-third-quarter-2016-results-aciu-20161111monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-sa-reports-third-quarter-2016-results-aciu-20161111monthly0.5https://www.biopharmawatch.com/news/ACIU/switzerland-s-ac-immune-opens-for-trading-on-nasdaq-aciu-20160923monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-sa-announces-pricing-of-upsized-initial-public-offering-aciu-20160922monthly0.5https://www.biopharmawatch.com/news/ACIU/ac-immune-sa-commences-proposed-initial-public-offering-of-common-shares-aciu-20160913monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-launches-zbio-20210323monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-announces-new-executive-leadership-appointments-zbio-20210503monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-acquires-exclusive-worldwide-rights-to-obexelimab-from-xencor-zbio-20211121monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-appoints-dr-john-orloff-to-board-of-directors-zbio-20220106monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-submits-investigational-new-drug-application-in-china-for-zb001-for-the-tr-zbio-20220516monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-obtains-ind-approval-in-china-for-phase-1-2-study-of-zb001-for-the-treatme-zbio-20220801monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-secures-118-million-to-advance-its-broad-pipeline-of-autoimmune-disease-th-zbio-20221107monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-announces-first-patient-dosed-in-phase-3-clinical-study-of-obexelimab-for--zbio-20230111monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-announces-publication-of-phase-2-study-of-obexelimab-an-investigational-tr-zbio-20230801monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-announces-strategic-license-and-collaboration-agreement-with-bristol-myers-zbio-20230905monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-strengthens-executive-leadership-with-appointment-of-jennifer-fox-as-chief-zbio-20231204monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-appoints-patricia-allen-to-its-board-of-directors-zbio-20240306monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-announces-upsized-200-million-series-c-financing-to-advance-mid-and-late-s-zbio-20240507monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-appoints-orlando-oliveira-as-chief-commercial-officer-zbio-20240701monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-announces-pricing-of-upsized-initial-public-offering-zbio-20240913monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-announces-closing-of-full-exercise-of-underwriters-option-to-purchase-addi-zbio-20240919monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-to-participate-in-upcoming-healthcare-investor-conferences-zbio-20241107monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-completes-targeted-enrollment-of-the-phase-3-indigo-trial-of-obexelimab-in-zbio-20241112monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-to-present-at-the-guggenheim-smid-cap-biotech-conference-zbio-20250128monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-appoints-haley-laken-ph-d-as-chief-scientific-officer-zbio-20250407monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-to-present-at-the-jefferies-global-healthcare-conference-zbio-20250529monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-to-present-at-upcoming-healthcare-investor-conferences-zbio-20250826monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-to-present-at-upcoming-healthcare-investor-conferences-zbio-20251111monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-s-partner-innocare-pharma-announces-achievement-of-primary-endpoint-in-pha-zbio-20251215monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-zbio-20251219monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-zbio-20260417monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-zbio-20260518monthly0.5https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-zbio-20260617monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-announces-multiple-presentations-across-portfolio-at-the-european-hematology-iron-20260512monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-to-participate-in-upcoming-investor-conferences-iron-20260511monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-appoints-lisa-amaya-price-mba-as-chief-human-resources-officer-iron-20260112monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-presents-positive-initial-data-from-rally-mf-phase-2-trial-in-patients-with--iron-20251206monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-to-participate-in-upcoming-investor-conferences-iron-20250827monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-announces-positive-pre-nda-meeting-and-confirms-plans-to-submit-nda-for-bito-iron-20250721monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-appoints-nadim-ahmed-to-its-board-of-directors-iron-20250714monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-presents-positive-clinical-data-updates-across-portfolio-at-the-european-hem-iron-20250612monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-to-participate-in-upcoming-investor-conferences-iron-20250528monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-announces-multiple-presentations-across-portfolio-at-the-european-hematology-iron-20250514monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-to-participate-in-the-h-c-wainwright-3rd-annual-bioconnect-investor-conferen-iron-20250513monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-to-host-webinar-with-key-opinion-leaders-on-anemia-of-myelofibrosis-mf-iron-20250429monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-to-participate-in-upcoming-investor-conferences-iron-20250226monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-announces-pricing-of-225-5-million-upsized-public-offering-of-common-stock-a-iron-20250122monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-to-host-conference-call-on-type-c-meeting-for-bitopertin-in-erythropoietic-p-iron-20250120monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-iron-20250117monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-presents-positive-clinical-and-translational-data-across-portfolio-at-the-66-iron-20241209monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-presents-positive-updated-results-from-phase-1b-trial-in-patients-with-myelo-iron-20241208monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-to-participate-in-upcoming-investor-conferences-iron-20241113monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-announces-multiple-presentations-across-portfolio-at-the-66th-american-socie-iron-20241105monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-to-host-conference-call-on-end-of-phase-2-fda-meeting-for-bitopertin-in-eryt-iron-20241101monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-appoints-seasoned-industry-executive-rahul-kaushik-ph-d-as-chief-technical-o-iron-20241023monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-announces-presentation-of-new-data-from-phase-1b-trial-of-disc-0974-in-patie-iron-20241011monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-expands-leadership-team-with-appointment-of-industry-veteran-steve-caffe-md--iron-20240919monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-to-participate-in-upcoming-investor-conferences-iron-20240830monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-to-participate-in-the-jefferies-global-healthcare-conference-iron-20240530monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-announces-multiple-presentations-across-portfolio-at-the-european-hematology-iron-20240514monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-to-participate-in-the-h-c-wainwright-bioconnect-investor-conference-iron-20240513monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-to-participate-in-the-leerink-partners-global-biopharma-conference-2024-iron-20240306monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-receives-fda-fast-track-designation-for-disc-0974-for-the-treatment-of-anemi-iron-20240220monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-receives-fda-orphan-drug-designation-for-disc-3405-for-the-treatment-of-poly-iron-20240209monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-iron-20240103monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-announces-retirement-of-brian-macdonald-mb-chb-phd-as-chief-innovation-offic-iron-20231220monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-announces-grant-of-us-patent-for-methods-of-treating-erythropoietic-protopor-iron-20231114monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-to-participate-in-upcoming-investor-conferences-iron-20231108monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-initiates-a-phase-1-study-of-disc-3405-anti-tmprss6-mab-in-healthy-volunteer-iron-20231003monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-receives-fda-fast-track-designation-for-mwtx-003-for-the-treatment-of-polycy-iron-20230920monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-to-participate-in-upcoming-investor-conferences-iron-20230830monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-announces-first-patient-enrolled-in-phase-1-2-clinical-trial-of-bitopertin-i-iron-20230727monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-announces-closing-of-public-offering-of-common-stock-and-pre-funded-warrants-iron-20230622monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-announces-pricing-of-upsized-public-offering-of-common-stock-and-pre-funded--iron-20230613monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-to-participate-in-the-jefferies-healthcare-conference-iron-20230531monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-announces-presentation-of-initial-data-from-phase-2-beacon-trial-in-patients-iron-20230511monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-to-participate-in-h-c-wainwright-bioconnect-investor-conference-iron-20230421monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-to-host-disease-webinar-with-kols-on-erythropoietic-protoporphyria-epp-iron-20230413monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-announces-collaboration-with-national-institutes-of-health-for-phase-2-clini-iron-20230321monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-initiates-a-phase-1b-2-clinical-study-of-disc-0974-in-adults-with-non-dialys-iron-20230216monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-to-participate-in-svb-securities-global-biopharma-conference-iron-20230208monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-announces-multiple-presentations-across-hematology-portfolio-at-the-64th-ame-iron-20221103monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-initiates-beacon-a-phase-2-clinical-study-of-bitopertin-in-patients-with-ery-iron-20220810monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-initiates-phase-1b-2-clinical-study-of-disc-0974-in-myelofibrosis-patients-w-iron-20220623monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-presents-positive-results-from-phase-1-clinical-study-of-disc-0974-in-health-iron-20220610monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-announces-presentation-of-clinical-data-from-first-in-human-phase-1-study-of-iron-20220516monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-appoints-jay-t-backstrom-m-d-m-p-h-to-its-board-of-directors-and-rahul-khara-iron-20220104monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-announces-oral-presentation-on-bitopertin-at-the-63rd-american-society-of-he-iron-20211111monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-announces-90-million-series-b-financing-to-advance-portfolio-of-clinical-sta-iron-20210902monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-appoints-will-savage-md-phd-as-chief-medical-officer-and-jonathan-yu-as-chie-iron-20210823monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-initiates-phase-1-clinical-study-of-disc-0974-a-first-in-class-inhibitor-of--iron-20210728monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-expands-hematology-pipeline-with-worldwide-licensing-agreement-for-bitoperti-iron-20210527monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-to-present-at-the-european-hematology-association-eha-2021-virtual-congress-iron-20210524monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-to-present-at-the-jefferies-virtual-healthcare-conference-iron-20210521monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-appoints-william-white-to-its-board-of-directors-iron-20210113monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-to-present-at-the-virtual-62nd-american-society-of-hematology-annual-meeting-iron-20201202monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-to-present-at-the-piper-sandler-32nd-annual-healthcare-conference-iron-20201123monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-to-present-at-citi-s-15th-annual-biopharma-virtual-conference-iron-20200908monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-expands-leadership-team-with-industry-veterans-to-advance-hepcidin-modulatin-iron-20200803monthly0.5https://www.biopharmawatch.com/news/IRON/john-quisel-jd-phd-joins-disc-medicine-as-president-and-chief-executive-officer-iron-20200128monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-expands-pipeline-focused-on-hepcidin-pathway-iron-20191029monthly0.5https://www.biopharmawatch.com/news/IRON/disc-medicine-completes-50-million-series-a-financing-led-by-novo-holdings-a-s-to-advance--iron-20191029monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-series-a-to-advance-novel-therapeutic-modality-and-develop-i-kymr-20171004monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-appoints-industry-veteran-mark-e-nuttall-ph-d-as-chief-business-office-kymr-20180206monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-discovery-collaboration-with-gsk-to-advance-new-treatment-mo-kymr-20180404monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-65-million-series-b-financing-to-advance-pipeline-of-targete-kymr-20181113monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-presents-first-validation-of-irak4-protein-degraders-in-myd88-mutant-l-kymr-20181203monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-expansion-of-scientific-advisory-board-to-advance-pre-clinic-kymr-20181218monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-present-new-preclinical-data-for-its-first-in-class-oral-irak4-degr-kymr-20190329monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-leadership-transitions-kymr-20190708monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-is-named-one-of-the-fiercebiotech-s-fierce-15-companies-of-2019-kymr-20190923monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-present-preclinical-data-demonstrating-the-potency-and-antitumor-ac-kymr-20191017monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-present-preclinical-data-on-its-first-in-class-irak4-degraders-demo-kymr-20191111monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-promotes-nello-mainolfi-phd-to-chief-executive-officer-kymr-20191120monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-present-preclinical-data-on-its-first-in-class-selective-and-potent-kymr-20200205monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-102-million-series-c-financing-to-advance-its-protein-degrad-kymr-20200312monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-initiates-enrollment-in-non-interventional-trial-evaluating-irak4-role-kymr-20200603monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-disclose-irakimid-degrader-program-and-present-preclinical-data-dem-kymr-20200611monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-and-sanofi-enter-into-strategic-partnership-to-advance-novel-protein-d-kymr-20200709monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-pricing-of-upsized-initial-public-offering-kymr-20200821monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-closing-of-initial-public-offering-with-exercise-in-full-of--kymr-20200825monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-key-leadership-appointments-kymr-20200901monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-presents-preclinical-data-on-irakimid-and-stat3-programs-at-virtual-62-kymr-20201201monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-strengthens-leadership-with-key-appointments-and-promotions-kymr-20201216monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-presents-late-breaking-preclinical-data-highlighting-superiority-of-du-kymr-20210410monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-honored-by-boston-business-journal-as-a-2021-best-places-to-work-compa-kymr-20210419monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-presents-late-breaking-preclinical-data-on-irak4-degrader-kt-474-at-im-kymr-20210510monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-pricing-of-upsized-public-offering-of-common-stock-kymr-20210701monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-ind-fo-kymr-20211130monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-on-janu-kymr-20220104monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-key-2022-goals-and-milestones-to-support-its-evolution-into--kymr-20220110monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-presents-preclinical-data-highlighting-biological-superiority-of-mdm2--kymr-20220408monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-present-pre-clinical-data-at-the-eular-2022-congress-showing-stat3--kymr-20220601monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-doses-first-patients-in-phase-1-oncology-trials-of-stat3-and-irakimid--kymr-20220615monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-presents-preclinical-data-demonstrating-activity-of-kt-253-a-selective-kymr-20221211monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-presents-data-demonstrating-superior-efficacy-of-kt-253-a-potent-and-s-kymr-20230601monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-presents-new-clinical-data-from-the-ongoing-phase-1-trial-of-stat3-deg-kymr-20230601monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-first-patient-dosed-in-phase-2-hidradenitis-suppurativa-clin-kymr-20231027monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-first-patient-dosed-in-phase-2-atopic-dermatitis-clinical-tr-kymr-20231207monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-pricing-of-275-million-public-offering-kymr-20240105monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-outlines-key-2024-objectives-and-strategy-to-progress-leading-portfoli-kymr-20240109monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-scientific-presentations-at-the-american-association-for-can-kymr-20240408monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-pricing-of-225-million-public-offering-kymr-20240820monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-closing-of-upsized-225-million-public-offering-and-full-exer-kymr-20240821monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-three-scientific-presentations-at-the-eortc-nci-aacr-2024-sy-kymr-20241023monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-dosing-of-first-participant-in-phase-1-clinical-trial-of-kt--kymr-20241024monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-on-janu-kymr-20250107monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-appoints-noah-goodman-as-chief-business-officer-kymr-20250409monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-participate-in-fireside-chat-at-the-bofa-securities-2025-health-car-kymr-20250507monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-report-second-quarter-2025-financial-results-on-august-11-2025-kymr-20250804monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-second-quarter-2025-financial-results-and-provides-a-busines-kymr-20250811monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-first-patient-dosed-in-broaden2-phase-2b-atopic-dermatitis-c-kymr-20251125monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-pricing-of-upsized-602-million-public-offering-kymr-20251210monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-closing-of-upsized-602-million-public-offering-and-full-exer-kymr-20251211monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-on-janu-kymr-20260106monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-on-febru-kymr-20260219monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-announces-late-breaking-oral-presentation-of-kt-621-phase-1b-data-at-t-kymr-20260310monthly0.5https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-presents-new-preclinical-lupus-data-for-kt-579-first-in-class-oral-irf-kymr-20260608monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-data-at-the-american-diabetes-association-ada-2026-scientific-sessions-lxrx-20260603monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provides-clinical-lxrx-20260507monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-100-million-loan-facility-with-hercules-capital-lxrx-20260504monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-data-on-effect-of-kidney-function-on-the-long-term-efficacy-and-safety--lxrx-20260311monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-closing-of-approximately-94-6-million-public-offering-and-concurrent-pri-lxrx-20260206monthly0.5https://www.biopharmawatch.com/news/LXRX/viatris-expands-innovative-portfolio-in-cardiovascular-diseases-with-the-company-s-first-l-lxrx-20260120monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-provides-a-business-and-pipeline-update-at-the-44th-annual-j-p-mor-lxrx-20260112monthly0.5https://www.biopharmawatch.com/news/LXRX/clinical-data-on-effect-of-sotagliflozin-on-adipose-distribution-in-non-diabetic-patients--lxrx-20251205monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-participate-in-two-upcoming-december-investor-conferences-lxrx-20251125monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-report-third-quarter-2025-financial-results-on-november-6-2025-lxrx-20251030monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-submission-of-additional-data-to-u-s-fda-supporting-the--lxrx-20250908monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-new-preclinical-data-on-pilavapadin-in-chemotherapy-ind-lxrx-20250904monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-presentation-of-diabetic-peripheral-neuropathic-pain-pat-lxrx-20250903monthly0.5https://www.biopharmawatch.com/news/LXRX/sotagliflozin-provides-consistent-relative-risk-reduction-in-heart-failure-and-major-cardi-lxrx-20250902monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-participate-at-two-upcoming-investor-conferences-lxrx-20250827monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides-busines-lxrx-20250806monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-requirement-lxrx-20250731monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-report-second-quarter-2025-financial-results-on-august-6-2025-lxrx-20250723monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-patient-reported-data-on-diabetic-peripheral-neuropathic-pain-dpnp-at-t-lxrx-20250718monthly0.5https://www.biopharmawatch.com/news/LXRX/data-demonstrating-sotagliflozin-reduces-the-risk-of-clinically-important-hypoglycemic-eve-lxrx-20250623monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-american-diabetes-associati-lxrx-20250618monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-the-2025-jefferies-global-healthcare-conference-lxrx-20250529monthly0.5https://www.biopharmawatch.com/news/LXRX/sonata-hcm-study-design-presented-at-heart-failure-2025-the-annual-congress-of-the-heart-f-lxrx-20250519monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-first-quarter-2025-financial-results-and-provides-business-lxrx-20250513monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-the-3rd-annual-h-c-wainwright-bioconnect-investor-co-lxrx-20250506monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-report-first-quarter-2025-financial-results-on-may-13-2025-lxrx-20250506monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-the-24th-annual-needham-virtual-healthcare-conferenc-lxrx-20250402monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-exclusive-license-agreement-with-novo-nordisk-for-lx9851-lxrx-20250328monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-the-leerink-partners-global-healthcare-conference-20-lxrx-20250307monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-financial-results-and-pr-lxrx-20250306monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-report-fourth-quarter-and-full-year-2024-financial-results-on-m-lxrx-20250304monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-topline-results-from-phase-2b-progress-study-evaluating--lxrx-20250303monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-announce-topline-results-from-phase-2b-progress-study-evaluatin-lxrx-20250302monthly0.5https://www.biopharmawatch.com/news/LXRX/published-data-in-the-lancet-diabetes-endocrinology-highlights-unique-efficacy-benefits-of-lxrx-20250218monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-virtual-webcast-on-lx9211-for-diabetic-peripheral-neuropathic-pain-lxrx-20250121monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-appoints-scott-coiante-as-chief-financial-officer-lxrx-20250102monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-receipt-of-complete-response-letter-for-zynquista-sotagliflozin-lxrx-20241220monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-completion-of-enrollment-in-phase-2b-progress-study-of-lx9211-in-diabeti-lxrx-20241126monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-participate-in-december-investor-conferences-lxrx-20241125monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-reposition-as-clinical-development-focused-company-following-regulatory-update--lxrx-20241122monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-appoints-ivan-h-cheung-to-board-of-directors-lxrx-20241120monthly0.5https://www.biopharmawatch.com/news/LXRX/post-hoc-analysis-demonstrating-sotagliflozin-benefits-across-broad-spectrum-of-heart-fail-lxrx-20241114monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides-business-lxrx-20241112monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-participate-in-the-jefferies-london-global-healthcare-conferenc-lxrx-20241106monthly0.5https://www.biopharmawatch.com/news/LXRX/published-data-in-journal-of-american-society-of-nephrology-highlights-findings-on-efficac-lxrx-20241105monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-third-quarter-2024-financial-results-conference-call-and-w-lxrx-20241105monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-preclinical-in-vivo-efficacy-data-demonstrating-ability-of-new-investig-lxrx-20241104monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-outcome-of-fda-advisory-committee-for-zynquista-sotagliflozin-as-an-adju-lxrx-20241031monthly0.5https://www.biopharmawatch.com/news/LXRX/new-analysis-of-phase-3-data-demonstrating-renal-protective-benefits-of-sotagliflozin-to-b-lxrx-20241023monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-completion-of-screening-in-phase-2b-progress-study-of-lx9211-in-diabetic-lxrx-20241022monthly0.5https://www.biopharmawatch.com/news/LXRX/viatris-announces-exclusive-licensing-agreement-with-lexicon-pharmaceuticals-for-sotaglifl-lxrx-20241016monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-phase-3-trial-design-for-sotagliflozin-in-hypertrophic-cardiomyopathy-h-lxrx-20240927monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-departure-of-president-and-chief-operating-officer-lxrx-20240916monthly0.5https://www.biopharmawatch.com/news/LXRX/new-secondary-analysis-of-phase-3-data-demonstrates-sotagliflozin-improves-time-in-range-t-lxrx-20240910monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-participate-in-upcoming-september-investor-conferences-lxrx-20240903monthly0.5https://www.biopharmawatch.com/news/LXRX/new-secondary-analysis-of-phase-3-data-demonstrates-that-inpefa-sotagliflozin-benefited-he-lxrx-20240903monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-fda-advisory-committee-meeting-for-zynquista-lxrx-20240821monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-strategic-repositioning-to-drive-value-and-growth-of-com-lxrx-20240813monthly0.5https://www.biopharmawatch.com/news/LXRX/efficacy-and-safety-data-of-sotagliflozin-in-patients-with-type-1-diabetes-and-chronic-kid-lxrx-20240807monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-second-quarter-2024-financial-results-and-provides-busines-lxrx-20240801monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-second-quarter-2024-financial-results-conference-call-and--lxrx-20240725monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-receives-december-20-2024-pdufa-goal-date-for-sotagliflozin-type-1-lxrx-20240716monthly0.5https://www.biopharmawatch.com/news/LXRX/new-published-data-highlights-potential-cost-savings-of-inpefa-sotagliflozin-for-heart-fai-lxrx-20240715monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-board-of-directors-appoints-mike-exton-ph-d-as-new-chief-executive-officer-and-dir-lxrx-20240708monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-resubmits-sotagliflozin-nda-for-type-1-diabetes-lxrx-20240621monthly0.5https://www.biopharmawatch.com/news/LXRX/data-from-lexicon-s-relief-dpn-1-phase-2-study-of-lx9211-published-today-in-diabetes-care--lxrx-20240619monthly0.5https://www.biopharmawatch.com/news/LXRX/analysis-of-inpefa-sotagliflozin-cost-effectiveness-published-in-jacc-heart-failure-the-pe-lxrx-20240618monthly0.5https://www.biopharmawatch.com/news/LXRX/findings-on-the-burdens-of-diabetic-peripheral-neuropathic-pain-dpnp-among-three-lexicon-s-lxrx-20240614monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference-2024-lxrx-20240529monthly0.5https://www.biopharmawatch.com/news/LXRX/new-post-hoc-analysis-of-pooled-phase-3-data-shows-that-inpefa-sotagliflozin-reduced-risk--lxrx-20240514monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-participate-in-the-bank-of-america-securities-healthcare-confer-lxrx-20240509monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-first-quarter-2024-financial-results-and-provides-business-lxrx-20240502monthly0.5https://www.biopharmawatch.com/news/LXRX/lonnel-coats-retires-as-chief-executive-officer-and-board-member-of-lexicon-pharmaceutical-lxrx-20240429monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-first-quarter-2024-financial-results-conference-call-and-w-lxrx-20240429monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-2024-investor-day-lxrx-20240418monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-participate-in-the-23rd-annual-needham-virtual-healthcare-confe-lxrx-20240403monthly0.5https://www.biopharmawatch.com/news/LXRX/clinical-data-on-the-impact-of-sotagliflozin-on-stroke-and-heart-attack-risk-among-four-le-lxrx-20240325monthly0.5https://www.biopharmawatch.com/news/LXRX/new-post-hoc-analysis-of-intandem3-study-demonstrates-improvements-in-glycemic-control-wit-lxrx-20240312monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-oversubscribed-250-million-private-placement-of-equity-securities-lxrx-20240311monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-preparing-to-resubmit-sotagliflozin-nda-for-type-1-diabetes-following-feedback-fro-lxrx-20240311monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-provides-business-and-pipeline-update-at-42nd-annual-j-p-morgan-he-lxrx-20240108monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-participate-in-the-42nd-annual-jpmorgan-healthcare-conference-lxrx-20231221monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-enrolls-first-patient-in-phase-2b-progress-study-of-lx9211-in-diabetic-peripheral--lxrx-20231130monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-participate-in-the-35th-annual-piper-sandler-healthcare-confere-lxrx-20231122monthly0.5https://www.biopharmawatch.com/news/LXRX/inpefa-sotagliflozin-use-associated-with-early-clinical-benefit-in-heart-failure-and-ather-lxrx-20231112monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-participate-in-the-jefferies-london-healthcare-conference-lxrx-20231110monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-third-quarter-2023-financial-results-and-provides-business-lxrx-20231108monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-third-quarter-2023-financial-results-conference-call-and-w-lxrx-20231103monthly0.5https://www.biopharmawatch.com/news/LXRX/data-on-early-clinical-benefit-for-inpefa-sotagliflozin-will-be-among-five-lexicon-sponsor-lxrx-20231102monthly0.5https://www.biopharmawatch.com/news/LXRX/inpefa-sotagliflozin-receives-coverage-from-express-scripts-on-its-basic-and-high-performa-lxrx-20231101monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-strengthens-management-team-with-two-new-executives-lxrx-20231031monthly0.5https://www.biopharmawatch.com/news/LXRX/new-data-relating-to-sotagliflozin-to-be-presented-at-the-american-society-of-nephrology-a-lxrx-20231030monthly0.5https://www.biopharmawatch.com/news/LXRX/data-from-two-studies-demonstrating-positive-financial-impact-of-inpefa-sotagliflozin-to-b-lxrx-20231017monthly0.5https://www.biopharmawatch.com/news/LXRX/data-demonstrating-financial-impact-of-inpefa-sotagliflozin-to-be-presented-at-the-academy-lxrx-20231011monthly0.5https://www.biopharmawatch.com/news/LXRX/inpefa-sotagliflozin-receives-preferred-formulary-status-with-express-scripts-for-medicare-lxrx-20231009monthly0.5https://www.biopharmawatch.com/news/LXRX/tom-garner-joins-lexicon-as-senior-vice-president-and-chief-commercial-officer-lxrx-20231009monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-post-hoc-analysis-of-scored-clinical-trial-at-the-heart-failure-society-lxrx-20230928monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-study-results-relating-to-sotagliflozin-and-lx9211-at-the-59th-annual-m-lxrx-20230926monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-participate-in-the-h-c-wainwright-co-25th-annual-global-investm-lxrx-20230907monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-series-of-presentations-relating-to-lx9211-its-investigational-drug-for--lxrx-20230907monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-analyses-of-inpefa-sotagliflozin-clinical-study-results-and-changing-pa-lxrx-20230821monthly0.5https://www.biopharmawatch.com/news/LXRX/published-analysis-of-sotagliflozin-inpefa-tm-clinical-data-demonstrates-significant-reduc-lxrx-20230808monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-second-quarter-2023-financial-results-and-provides-busines-lxrx-20230803monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-second-quarter-2023-financial-results-conference-call-and--lxrx-20230728monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-elects-diane-e-sullivan-to-board-of-directors-lxrx-20230728monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-planned-advancement-of-lx9211-into-late-stage-development-lxrx-20230623monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-study-results-relating-to-lx9211-and-inpefa-sotagliflozin-at-the-americ-lxrx-20230620monthly0.5https://www.biopharmawatch.com/news/LXRX/update-lexicon-announces-fda-approval-of-inpefa-sotagliflozin-for-treatment-of-heart-failu-lxrx-20230615monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-participate-in-the-jefferies-2023-global-healthcare-conference-lxrx-20230606monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-closing-of-public-offering-and-concurrent-private-placement-including-fu-lxrx-20230605monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-pricing-of-125-million-public-offering-and-concurrent-private-placement-lxrx-20230601monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-proposed-public-offering-of-common-stock-lxrx-20230531monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-fda-approval-of-inpefa-sotagliflozin-for-treatment-of-heart-failure-lxrx-20230526monthly0.5https://www.biopharmawatch.com/news/LXRX/new-analysis-finds-sotagliflozin-to-be-a-cost-effective-treatment-at-commonly-accepted-wil-lxrx-20230510monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-first-quarter-2023-financial-results-and-provides-business-lxrx-20230502monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-first-quarter-2023-financial-results-conference-call-and-w-lxrx-20230428monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-results-from-lx9211-phase-2-trial-in-postherpetic-neuralgia-at-the-2023-lxrx-20230421monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-participate-in-the-22nd-annual-needham-virtual-healthcare-confe-lxrx-20230417monthly0.5https://www.biopharmawatch.com/news/LXRX/new-analyses-of-sotagliflozin-showing-time-to-clinical-benefit-presented-at-the-american-c-lxrx-20230304monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-reveals-into-the-dark-awareness-campaign-about-vulnerable-and-dangerous-period-of--lxrx-20230304monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-fourth-quarter-2022-financial-results-and-provides-busines-lxrx-20230302monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-fourth-quarter-2022-financial-results-conference-call-and--lxrx-20230228monthly0.5https://www.biopharmawatch.com/news/LXRX/new-analyses-of-sotagliflozin-to-be-presented-at-the-american-college-of-cardiology-s-72nd-lxrx-20230220monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-participate-in-the-41st-annual-jp-morgan-healthcare-conference-lxrx-20230106monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-topline-results-from-phase-2-proof-of-concept-study-of-lx9211-in-posther-lxrx-20221221monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-participate-in-the-34th-annual-piper-sandler-healthcare-confere-lxrx-20221128monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-s-lx9211-shows-significant-and-consistent-benefits-in-the-treatment-of-painful-dia-lxrx-20221114monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-participate-in-the-13th-annual-jefferies-london-healthcare-conf-lxrx-20221111monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-third-quarter-2022-financial-results-and-provides-business-lxrx-20221109monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-highlights-oral-presentation-of-final-results-from-the-relief-dpn--lxrx-20221108monthly0.5https://www.biopharmawatch.com/news/LXRX/new-analysis-of-soloist-whf-results-demonstrates-sotagliflozin-s-significant-effect-in-red-lxrx-20221106monthly0.5https://www.biopharmawatch.com/news/LXRX/new-analysis-of-scored-trial-demonstrates-sotagliflozin-s-effect-on-reducing-albuminuria-i-lxrx-20221105monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-third-quarter-2022-financial-results-conference-call-and-w-lxrx-20221104monthly0.5https://www.biopharmawatch.com/news/LXRX/new-analyses-of-sotagliflozin-from-the-soloist-whf-and-scored-trials-in-high-cardiovascula-lxrx-20221031monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-oral-presentations-relating-to-its-lx9211-neuropathic-pa-lxrx-20221024monthly0.5https://www.biopharmawatch.com/news/LXRX/new-analysis-of-soloist-whf-trial-underscores-sotagliflozin-s-effect-on-reducing-recurrent-lxrx-20221002monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-highlights-scientific-and-medical-presentations-relating-to-its-su-lxrx-20220920monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-highlights-publications-relating-to-sotagliflozin-s-differentiated-lxrx-20220822monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-full-exercise-and-closing-of-options-to-purchase-additional-shares-in-co-lxrx-20220805monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-second-quarter-2022-financial-results-and-provides-busines-lxrx-20220802monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-second-quarter-2022-financial-results-conference-call-and--lxrx-20220729monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-pricing-of-85-0-million-public-offering-and-concurrent-private-placement-lxrx-20220728monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-proposed-public-offering-of-common-stock-lxrx-20220727monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-fda-acceptance-of-new-drug-application-for-sotagliflozin-to-treat-heart--lxrx-20220727monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-positive-top-line-results-from-phase-2-proof-of-concept-study-of-lx9211--lxrx-20220629monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-participate-in-the-jefferies-2022-healthcare-conference-lxrx-20220601monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-resubmits-new-drug-application-for-sotagliflozin-for-the-treatment-of-heart-failur-lxrx-20220531monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-first-quarter-2022-financial-results-and-provides-clinical-lxrx-20220505monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-first-quarter-2022-financial-results-conference-call-and-w-lxrx-20220429monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-participate-in-the-21st-annual-needham-virtual-healthcare-confe-lxrx-20220407monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-welcomes-new-guidelines-for-the-management-of-heart-failure-lxrx-20220404monthly0.5https://www.biopharmawatch.com/news/LXRX/sotagliflozin-improved-outcomes-in-patients-with-and-without-prior-cardiovascular-disease--lxrx-20220402monthly0.5https://www.biopharmawatch.com/news/LXRX/new-analysis-of-cardiovascular-endpoints-in-the-scored-trial-to-be-presented-at-the-americ-lxrx-20220321monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-enters-into-loan-facility-with-oxford-finance-for-up-to-150-million-to-support-pla-lxrx-20220317monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-fourth-quarter-and-full-year-2021-financial-results-and-pr-lxrx-20220228monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-voluntarily-withdraws-sotagliflozin-new-drug-application-and-plans-prompt-resubmis-lxrx-20220228monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-fourth-quarter-2021-financial-results-conference-call-and--lxrx-20220225monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-outlines-major-potential-value-drivers-for-2022-at-40th-annual-j-p-lxrx-20220113monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-participate-in-the-40th-annual-j-p-morgan-healthcare-conference-lxrx-20220104monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-submits-new-drug-application-for-sotagliflozin-for-the-treatment-of-heart-failure--lxrx-20211230monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-participate-in-the-jefferies-london-healthcare-conference-and-t-lxrx-20211115monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-s-sotagliflozin-demonstrates-benefits-in-heart-failure-and-blood-glucose-control-a-lxrx-20211114monthly0.5https://www.biopharmawatch.com/news/LXRX/new-analysis-to-be-presented-at-the-american-heart-association-scientific-sessions-2021-ev-lxrx-20211109monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-third-quarter-2021-financial-results-and-provides-clinical-lxrx-20211103monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-third-quarter-2021-financial-results-conference-call-and-w-lxrx-20211028monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-the-oppenheimer-fall-healthcare-life-sciences-medtec-lxrx-20210915monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-welcomes-new-esc-heart-failure-treatment-guidelines-establishing-sglt-inhibitors-a-lxrx-20210830monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-s-sotagliflozin-demonstrates-additional-compelling-benefits-in-reducing-cardiovasc-lxrx-20210823monthly0.5https://www.biopharmawatch.com/news/LXRX/craig-granowitz-m-d-ph-d-joins-lexicon-as-senior-vice-president-and-chief-medical-officer-lxrx-20210730monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-second-quarter-2021-financial-results-and-provides-clinica-lxrx-20210730monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-second-quarter-2021-financial-results-conference-call-and--lxrx-20210728monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-symposium-at-the-american-diabetes-association-81st-scie-lxrx-20210625monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-participate-in-the-2021-jefferies-virtual-healthcare-conference-lxrx-20210526monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-two-presentations-at-the-american-college-of-cardiology--lxrx-20210513monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-first-quarter-2021-financial-results-and-provides-clinical-lxrx-20210506monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-first-quarter-2021-financial-results-conference-call-and-w-lxrx-20210429monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-participate-in-the-20th-annual-needham-virtual-healthcare-confe-lxrx-20210408monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-fourth-quarter-and-full-year-2020-financial-results-and-pr-lxrx-20210310monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-fourth-quarter-and-full-year-2020-financial-results-confer-lxrx-20210304monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-provides-regulatory-update-on-sotagliflozin-in-heart-failure-lxrx-20210114monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-participate-in-the-39th-annual-j-p-morgan-healthcare-conference-lxrx-20210106monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-commencement-of-dosing-in-phase-2-clinical-study-of-lx92-lxrx-20201231monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-enters-data-collaboration-with-ac-bioscience-lxrx-20201216monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-offering-of-common-stock-lxrx-20201211monthly0.5https://www.biopharmawatch.com/news/LXRX/results-from-soloist-and-scored-outcomes-studies-presented-at-late-breaking-science-sessio-lxrx-20201116monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-participate-in-the-stifel-2020-virtual-healthcare-conference-lxrx-20201116monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-third-quarter-2020-financial-results-and-provides-clinical-lxrx-20201029monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-third-quarter-2020-financial-results-conference-call-and-w-lxrx-20201027monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reaches-agreements-to-exchange-convertible-notes-reduce-outstandin-lxrx-20200923monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-commencement-of-patient-dosing-in-relief-dpn-1-phase-2-c-lxrx-20200904monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-participate-in-the-citi-15th-annual-biopharma-virtual-conferenc-lxrx-20200903monthly0.5https://www.biopharmawatch.com/news/LXRX/gtcr-and-tersera-therapeutics-announce-acquisition-of-xermelo-lxrx-20200803monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-realigns-business-around-research-and-development-assets-with-focus-on-phase-2-lx9-lxrx-20200730monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-enters-into-agreement-with-tersera-therapeutics-for-the-sale-of-xe-lxrx-20200730monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-second-quarter-2020-financial-results-and-provides-a-busin-lxrx-20200730monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-topline-phase-3-data-from-four-phase-3-sotagliflozin-stu-lxrx-20200721monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-poster-presentations-at-the-virtual-cholangiocarcinoma-f-lxrx-20200720monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-presents-clinical-data-at-80th-american-diabetes-association-scien-lxrx-20200613monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-preclinical-efficacy-data-on-telotristat-ethyl-s-antipro-lxrx-20200513monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-first-quarter-2020-financial-results-and-provides-a-busine-lxrx-20200427monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-fourth-quarter-and-full-year-2019-financial-results-and-pr-lxrx-20200312monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-fourth-quarter-and-full-year-2019-financial-results-confer-lxrx-20200305monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-upcoming-investor-conference-lxrx-20200106monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-topline-phase-3-data-for-sotagliflozin-in-type-2-diabete-lxrx-20191220monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-receives-formal-dispute-resolution-request-decision-from-fda-s-off-lxrx-20191202monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-third-quarter-2019-financial-results-and-provides-a-busine-lxrx-20191107monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-termination-of-alliance-and-settlement-with-sanofi-lxrx-20190910monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-publication-of-positive-data-for-zynquista-sotagliflozin-lxrx-20190808monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-second-quarter-2019-financial-results-and-provides-a-busin-lxrx-20190731monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-provides-preliminary-update-for-zynquista-sotagliflozin-type-2-dia-lxrx-20190726monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-first-quarter-2019-financial-results-and-provides-a-busine-lxrx-20190501monthly0.5https://www.biopharmawatch.com/news/LXRX/fda-issues-complete-response-letter-for-zynquista-sotagliflozin-lxrx-20190322monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-conference-call-and-webcast-today-march-22-2019-to-provide-lxrx-20190322monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-fourth-quarter-and-full-year-2018-financial-results-and-pr-lxrx-20190313monthly0.5https://www.biopharmawatch.com/news/LXRX/fda-advisory-committee-votes-on-zynquista-sotagliflozin-as-treatment-for-adults-with-type--lxrx-20190117monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-stock-trading-halted-today-fda-advisory-committee-to-review-sotagl-lxrx-20190117monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-positive-52-week-results-from-sotagliflozin-intandem1-st-lxrx-20180624monthly0.5https://www.biopharmawatch.com/news/LXRX/fda-to-review-zynquista-sotagliflozin-as-potential-treatment-for-type-1-diabetes-lxrx-20180522monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-publication-of-new-xermelo-telotristat-ethyl-data-in-cli-lxrx-20180504monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-poster-presentation-at-the-15th-annual-enets-conference-lxrx-20180228monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-third-quarter-2017-financial-results-and-provides-a-busine-lxrx-20171108monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-third-quarter-2017-financial-results-conference-call-and-w-lxrx-20171103monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-upcoming-investor-conferences-lxrx-20171102monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-initiates-patient-dosing-in-a-phase-1-study-of-lx9211-lxrx-20170927monthly0.5https://www.biopharmawatch.com/news/LXRX/european-commission-approves-xermelo-telotristat-ethyl-for-the-treatment-of-carcinoid-synd-lxrx-20170919monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-the-2017-cantor-fitzgerald-global-healthcare-confere-lxrx-20170918monthly0.5https://www.biopharmawatch.com/news/LXRX/new-england-journal-of-medicine-publishes-data-from-phase-3-intandem3-study-of-sotaglifloz-lxrx-20170913monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-positive-pooled-continuous-glucose-monitoring-data-lxrx-20170908monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-the-bank-of-america-merrill-lynch-2017-global-health-lxrx-20170907monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-four-data-presentations-at-the-european-society-of-medic-lxrx-20170907monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-new-clinical-data-at-the-european-association-for-the-s-lxrx-20170905monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-additional-positive-data-from-pivotal-phase-3-intandem2-st-lxrx-20170815monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-2017-wedbush-pacgrow-healthcare-conference-lxrx-20170803monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-second-quarter-2017-financial-results-and-provides-a-busin-lxrx-20170801monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-opt-in-decision-for-u-s-co-promotion-of-sotagliflozin-wi-lxrx-20170731monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-second-quarter-2017-financial-results-conference-call-and--lxrx-20170724monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-collaborator-ipsen-receives-positive-chmp-opinion-for-xermelo-lxrx-20170721monthly0.5https://www.biopharmawatch.com/news/LXRX/nccn-guidelines-for-neuroendocrine-tumors-include-xermelo-in-combination-with-somatostatin-lxrx-20170619monthly0.5https://www.biopharmawatch.com/news/LXRX/sotagliflozin-data-from-pivotal-intandem1-and-intandem2-studies-presented-at-ada-2017-lxrx-20170610monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-positive-top-line-results-in-phase-3-intandem3-study-for-s-lxrx-20170609monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-new-clinical-data-at-77th-american-diabetes-association-lxrx-20170605monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-upcoming-investor-conferences-lxrx-20170531monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-additional-positive-data-from-pivotal-intandem1-phase-3-st-lxrx-20170511monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-the-bank-of-america-merrill-lynch-2017-healthcare-co-lxrx-20170504monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-first-quarter-2017-financial-results-and-provides-a-busine-lxrx-20170502monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-first-quarter-2017-financial-results-conference-call-and-w-lxrx-20170428monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-16th-annual-needham-healthcare-conference-lxrx-20170403monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-barclays-global-healthcare-conference-lxrx-20170309monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-cowen-and-company-37th-annual-healthcare-conference-lxrx-20170306monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-provides-clinical-pipeline-update-and-reports-2016-fourth-quarter--lxrx-20170303monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-report-fourth-quarter-and-year-end-2016-financial-results-on-march-3-2017-lxrx-20170301monthly0.5https://www.biopharmawatch.com/news/LXRX/fda-approves-lexicon-drug-xermelo-telotristat-ethyl-250-mg-as-first-and-only-oral-treatmen-lxrx-20170228monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-leerink-partners-6th-annual-global-healthcare-conference-lxrx-20170213monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-begins-phase-1-clinical-trial-of-locally-acting-sglt1-inhibitor-lx2761-for-potenti-lxrx-20170109monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-35th-annual-j-p-morgan-healthcare-conference-lxrx-20170105monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-reports-positive-top-line-results-in-second-pivotal-phase-3-study-for-sotagliflozi-lxrx-20161221monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-the-establishment-of-the-commercial-leadership-team-for-telotristat-ethy-lxrx-20161121monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-stifel-2016-healthcare-conference-and-the-jefferies-2016-global--lxrx-20161114monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-acquires-exclusive-rights-to-development-candidate-for-neuropathic-lxrx-20161107monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-publication-of-telestar-study-results-for-telotristat-ethyl-in-the-journ-lxrx-20161031monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-reports-positive-top-line-results-in-phase-2-dose-ranging-study-for-sotagliflozin--lxrx-20161025monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-report-third-quarter-2016-financial-results-on-november-1-2016-lxrx-20161025monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-agreement-to-buy-out-remaining-obligations-to-symphony-i-lxrx-20161005monthly0.5https://www.biopharmawatch.com/news/LXRX/telecast-data-presented-at-the-2016-north-american-neuroendocrine-tumor-society-annual-sym-lxrx-20161003monthly0.5https://www.biopharmawatch.com/news/LXRX/fda-extends-pdufa-date-for-telotristat-etiprate-for-the-treatment-of-carcinoid-syndrome-lxrx-20160914monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-reports-positive-top-line-results-in-pivotal-phase-3-study-for-sotagliflozin-in-pa-lxrx-20160909monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-bank-of-america-merrill-lynch-global-health-care-conference-lxrx-20160907monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-2016-wedbush-pacgrow-healthcare-conference-lxrx-20160812monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-report-second-quarter-2016-financial-results-on-august-4-2016-lxrx-20160801monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-the-validation-by-the-european-medicine-agency-of-the-marketing-authoriz-lxrx-20160718monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-cantor-fitzgerald-healthcare-conference-lxrx-20160707monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-jefferies-2016-healthcare-conference-lxrx-20160606monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-the-launch-of-aboutcarcinoid-com-to-provide-carcinoid-syndrome-disease-e-lxrx-20160602monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-fda-priority-review-of-new-drug-application-for-telotristat-etiprate-for-lxrx-20160531monthly0.5https://www.biopharmawatch.com/news/LXRX/praveen-tyle-ph-d-joins-lexicon-as-executive-vice-president-of-research-and-development-lxrx-20160510monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-bank-of-america-merrill-lynch-2016-health-care-conference-lxrx-20160505monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-provides-clinical-pipeline-update-and-reports-2016-first-quarter-f-lxrx-20160503monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-report-first-quarter-2016-financial-results-on-may-3-2016-lxrx-20160429monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-15th-annual-needham-healthcare-conference-lxrx-20160407monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-submits-new-drug-application-to-fda-for-telotristat-etiprate-for-the-treatment-of--lxrx-20160330monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-telotristat-etiprate-data-to-be-presented-at-european-neuroendocrine-tum-lxrx-20160308monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-36th-annual-cowen-healthcare-conference-lxrx-20160303monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-provides-clinical-pipeline-update-and-reports-2015-fourth-quarter--lxrx-20160301monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-report-fourth-quarter-and-year-end-2015-financial-results-on-march-1-2016-lxrx-20160225monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-34th-annual-j-p-morgan-healthcare-conference-lxrx-20160107monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-oppenheimer-26th-annual-healthcare-conference-lxrx-20151207monthly0.5https://www.biopharmawatch.com/news/LXRX/telotristat-etiprate-achieves-positive-top-line-results-in-second-phase-3-clinical-trial-lxrx-20151201monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-stifel-2015-healthcare-conference-and-the-jefferies-2015-global--lxrx-20151112monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-reports-3rd-quarter-financial-results-and-discusses-collaboration--lxrx-20151106monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-report-third-quarter-2015-financial-results-on-november-6-2015-lxrx-20151105monthly0.5https://www.biopharmawatch.com/news/LXRX/cancer-patients-treated-with-lexicon-s-telotristat-etiprate-report-improved-function-and-w-lxrx-20151019monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-telotristat-etiprate-data-to-be-presented-at-north-american-neuroendocri-lxrx-20151009monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-s-telotristat-etiprate-shows-clinical-benefit-in-treating-carcinoid-syndrome-in-ca-lxrx-20150929monthly0.5https://www.biopharmawatch.com/news/LXRX/media-alert-lexicon-to-discuss-complete-results-of-pivotal-phase-3-telestar-study-lxrx-20150928monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-sotagliflozin-data-to-be-presented-at-european-association-for-the-study-lxrx-20150908monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-telotristat-etiprate-data-to-be-presented-at-european-cancer-congress-lxrx-20150826monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-presentation-of-manuscript-at-the-american-diabetes-association-diabetes-lxrx-20150606monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-jefferies-2015-healthcare-conference-lxrx-20150528monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-selection-of-manuscript-to-be-presented-at-the-american-diabetes-associa-lxrx-20150512monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-bank-of-america-merrill-lynch-2015-health-care-conference-lxrx-20150507monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-one-for-seven-reverse-stock-split-effective-may-20-2015-lxrx-20150429monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-report-first-quarter-2015-financial-results-on-april-29-2015-lxrx-20150427monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-and-bristol-myers-squibb-select-development-candidate-for-neuropat-lxrx-20150415monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-needham-company-s-14th-annual-healthcare-conference-lxrx-20150409monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-first-patient-screened-in-pivotal-phase-3-clinical-trial-lxrx-20150325monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-and-ipsen-expand-their-licensing-and-commercialization-agreement-for-telotristat-e-lxrx-20150318monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-completes-enrollment-in-pivotal-phase-3-clinical-trial-of-telotris-lxrx-20150309monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-provides-clinical-pipeline-update-and-reports-2014-fourth-quarter--lxrx-20150304monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-report-fourth-quarter-and-year-end-2014-financial-results-on-march-4-2015-lxrx-20150302monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-cowen-35th-annual-health-care-conference-lxrx-20150226monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-management-change-lxrx-20150223monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-bio-ceo-investor-conference-lxrx-20150206monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-33rd-annual-j-p-morgan-healthcare-conference-lxrx-20150107monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-oppenheimer-25th-annual-healthcare-conference-lxrx-20141208monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-completion-of-280-million-in-financing-transactions-lxrx-20141126monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-pricing-of-convertible-senior-notes-offering-lxrx-20141121monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-pricing-of-common-stock-offering-lxrx-20141121monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-proposed-common-stock-offering-lxrx-20141119monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-proposed-convertible-senior-notes-offering-lxrx-20141119monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-strengthens-clincial-operations-and-commercial-readiness-lxrx-20141104monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-report-third-quarter-2014-financial-results-on-november-4-2014-lxrx-20141103monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-and-ipsen-enter-into-ex-north-america-japan-licensing-and-commercialization-agreem-lxrx-20141022monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-a-publication-in-the-american-diabetes-association-s-journal-diabetes-ca-lxrx-20140911monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-morgan-stanley-2014-global-healthcare-conference-lxrx-20140904monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-2014-wedbush-life-sciences-management-access-conference-lxrx-20140808monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-report-second-quarter-2014-financial-results-on-august-7-2014-lxrx-20140805monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-and-jdrf-collaborate-for-phase-2-clinical-trial-of-lx4211-in-type-1-diabetes-lxrx-20140709monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-appointment-of-lonnel-coats-as-president-and-chief-executive-officer-lxrx-20140707monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-presents-lx4211-data-at-american-diabetes-association-meeting-lxrx-20140614monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-jefferies-2014-global-healthcare-conference-lxrx-20140530monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-2014-bank-of-america-merrill-lynch-healthcare-conference-lxrx-20140509monthly0.5https://www.biopharmawatch.com/news/LXRX/lx4211-achieves-positive-results-in-type-1-diabetes-clinical-trial-lxrx-20140414monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-2014-needham-healthcare-conference-lxrx-20140403monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-provides-clinical-pipeline-update-and-reports-2013-fourth-quarter--lxrx-20140228monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-report-fourth-quarter-and-year-end-2013-financial-results-on-february-28-2014-lxrx-20140220monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-bio-ceo-and-investor-conference-lxrx-20140203monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-focus-on-late-stage-development-programs-and-preparation-for-commerciali-lxrx-20140113monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-j-p-morgan-healthcare-conference-lxrx-20140108monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-completes-phase-2-study-of-lx1033-in-ibs-d-lxrx-20131203monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-host-2013-research-and-development-day-lxrx-20131202monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-jefferies-global-healthcare-conference-lxrx-20131115monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-provides-clinical-pipeline-update-and-reports-2013-third-quarter-f-lxrx-20131112monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-credit-suisse-healthcare-conference-lxrx-20131107monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-report-third-quarter-financial-results-on-november-12-2013-lxrx-20131106monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-completes-pilot-study-of-telotristat-etiprate-in-ulcerative-colitis-lxrx-20131009monthly0.5https://www.biopharmawatch.com/news/LXRX/lx4211-achieves-positive-results-in-type-2-diabetes-patients-with-renal-impairment-lxrx-20131001monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-stifel-nicolaus-healthcare-conference-lxrx-20130906monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-morgan-stanley-global-healthcare-conference-lxrx-20130905monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-wedbush-pacgrow-life-sciences-management-access-conference-lxrx-20130807monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-provides-clinical-pipeline-update-and-reports-2013-second-quarter--lxrx-20130730monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-report-second-quarter-financial-results-on-july-30-2013-lxrx-20130723monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-presents-preclinical-data-on-lx2761-a-new-clinical-candidate-for-diabetes-designed-lxrx-20130624monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-presents-data-at-the-american-diabetes-association-meeting-on-blood-pressure-reduc-lxrx-20130624monthly0.5https://www.biopharmawatch.com/news/LXRX/john-northcott-joins-lexicon-as-vice-president-of-marketing-commercial-strategy-and-operat-lxrx-20130618monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-goldman-sachs-global-healthcare-conference-lxrx-20130607monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-jefferies-global-healthcare-conference-lxrx-20130531monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-deutsche-bank-dbaccess-healthcare-conference-lxrx-20130528monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-bank-of-america-merrill-lynch-healthcare-conference-lxrx-20130513monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-advances-lx4211-in-type-1-diabetes-phase-2-trial-lxrx-20130510monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-report-first-quarter-financial-results-on-may-10-2013-lxrx-20130503monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-needham-healthcare-conference-lxrx-20130425monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-rbc-capital-markets-healthcare-conference-lxrx-20130225monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-report-fourth-quarter-and-year-end-2012-financial-results-on-february-21-2013-lxrx-20130218monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-bio-ceo-investor-conference-lxrx-20130206monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-the-j-p-morgan-healthcare-conference-lxrx-20130103monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-s-drug-candidate-for-irritable-bowel-syndrome-receives-fast-track-status-from-the--lxrx-20121217monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-the-piper-jaffray-annual-healthcare-conference-lxrx-20121120monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-the-jefferies-2012-global-healthcare-conference-lxrx-20121112monthly0.5https://www.biopharmawatch.com/news/LXRX/lx4211-phase-2b-results-presented-at-american-heart-association-annual-conference-lxrx-20121106monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-provide-third-quarter-2012-financial-results-lxrx-20121031monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-proposed-common-stock-offering-lxrx-20121017monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-initiates-phase-3-clinical-trial-of-telotristat-etiprate-in-patients-with-carcinoi-lxrx-20121012monthly0.5https://www.biopharmawatch.com/news/LXRX/second-phase-2-trial-of-telotristat-etiprate-shows-positive-results-in-carcinoid-syndrome-lxrx-20121012monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-the-morgan-stanley-global-healthcare-conference-lxrx-20120907monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-the-stifel-nicolaus-2012-healthcare-conference-lxrx-20120831monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-the-wedbush-pacgrow-2012-management-access-conferenc-lxrx-20120810monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-provide-second-quarter-2012-financial-results-lxrx-20120724monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-publication-of-results-of-two-studies-of-lx4211-in-patients-with-type-2--lxrx-20120629monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-presents-data-regarding-the-mechanism-of-action-and-safety-of-lx4211-at-american-d-lxrx-20120608monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-the-jefferies-2012-global-healthcare-conference-lxrx-20120530monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-receives-funding-for-phase-2-clinical-trial-of-lx4211-in-type-1-diabetes-lxrx-20120503monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-provide-first-quarter-2012-financial-results-lxrx-20120425monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-the-11th-annual-needham-healthcare-conference-lxrx-20120327monthly0.5https://www.biopharmawatch.com/news/LXRX/fda-grants-lexicon-orphan-drug-designation-for-telotristat-etiprate-for-the-treatment-of-c-lxrx-20120320monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-the-cowen-and-company-32nd-annual-health-care-confer-lxrx-20120229monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-the-rbc-healthcare-conference-lxrx-20120223monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-report-fourth-quarter-and-year-end-2011-financial-results-on-february-22-2012-lxrx-20120216monthly0.5https://www.biopharmawatch.com/news/LXRX/lx4211-enhances-effects-of-dpp-4-inhibition-in-patients-with-type-2-diabetes-lxrx-20120109monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-the-30th-annual-j-p-morgan-healthcare-conference-lxrx-20120104monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-completion-of-rights-offering-to-stockholders-lxrx-20111223monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-plans-for-rights-offering-to-stockholders-lxrx-20111111monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-lx4211-clinical-and-preclinical-data-at-diabetes-conference-lxrx-20111103monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-provide-clinical-pipeline-update-and-report-third-quarter-2011-financial-result-lxrx-20111027monthly0.5https://www.biopharmawatch.com/news/LXRX/data-from-phase-2-clinical-studies-of-telotristat-etiprate-in-patients-with-carcinoid-synd-lxrx-20111021monthly0.5https://www.biopharmawatch.com/news/LXRX/lx4211-for-diabetes-shown-to-reduce-fasting-and-post-prandial-blood-sugar-in-healthy-subje-lxrx-20110913monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-morgan-stanley-global-healthcare-conference-lxrx-20110906monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-publication-of-lx1031-phase-2-trial-results-in-irritable-bowel-syndrome-lxrx-20110810monthly0.5https://www.biopharmawatch.com/news/LXRX/phase-2-trial-of-lexicon-s-lx1032-telotristat-etiprate-shows-positive-results-in-carcinoid-lxrx-20110809monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-the-jefferies-2011-global-healthcare-conference-lxrx-20110531monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-webcast-of-2011-annual-r-d-day-lxrx-20110509monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-provide-first-quarter-2011-financial-results-lxrx-20110426monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-the-10th-annual-needham-healthcare-conference-lxrx-20110329monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-appoints-dr-pablo-lapuerta-chief-medical-officer-lxrx-20110324monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-the-cowen-and-company-31st-annual-health-care-confer-lxrx-20110301monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-provides-clinical-pipeline-update-and-reports-2010-fourth-quarter--lxrx-20110224monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-report-fourth-quarter-and-year-end-2010-financial-results-on-february-24-2011-lxrx-20110215monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-the-13th-annual-bio-ceo-investor-conference-lxrx-20110208monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-positive-results-from-new-clinical-study-of-lx4211-in-type-2-diabetes-pa-lxrx-20110106monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-the-29th-annual-jpmorgan-healthcare-conference-lxrx-20110104monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-top-line-phase-2a-data-for-lx2931-in-patients-with-rheumatoid-arthritis-lxrx-20101214monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-5th-annual-canaccord-genuity-cardiovascular-diabetes-lxrx-20101130monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-provide-clinical-pipeline-update-and-report-third-quarter-2010-financial-result-lxrx-20101026monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-biocentury-newsmakers-in-the-biotech-industry-confer-lxrx-20101012monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-stifel-nicolaus-healthcare-conference-lxrx-20100909monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-morgan-stanley-global-healthcare-conference-lxrx-20100907monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-provide-clinical-pipeline-update-and-report-second-quarter-2010-financial-resul-lxrx-20100803monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-reacquisition-of-all-rights-to-symphony-icon-programs-lxrx-20100802monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-presents-data-describing-lx4211-positive-phase-2-clinical-results-and-novel-mechan-lxrx-20100621monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-clinical-data-for-diabetes-drug-candidate-lx4211-at-two-major-healthcar-lxrx-20100615monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-two-major-healthcare-investor-conferences-lxrx-20100603monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-presents-positive-outcome-in-ibs-patients-treated-with-lx1031-and-data-supporting--lxrx-20100505monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-provide-clinical-pipeline-update-and-report-first-quarter-2010-financial-result-lxrx-20100503monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-at-bio-international-convention-lxrx-20100428monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-present-phase-2-clinical-data-for-ibs-drug-candidate-at-digestive-disease-week-lxrx-20100427monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-announces-webcast-of-2010-annual-r-d-day-lxrx-20100331monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-2009-annual-report-to-stockholders-available-online-lxrx-20100319monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-completion-of-common-stock-offering-lxrx-20100319monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-announces-proposed-95-million-common-stock-offering-lxrx-20100308monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-provides-clinical-pipeline-update-and-reports-2009-fourth-quarter--lxrx-20100223monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-report-fourth-quarter-and-year-end-2009-financial-results-on-february-23-2010-lxrx-20100216monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-the-12th-annual-bio-ceo-investor-conference-lxrx-20100203monthly0.5https://www.biopharmawatch.com/news/LXRX/lexicon-to-host-conference-call-and-webcast-to-review-top-line-phase-2-results-from-diabet-lxrx-20100126monthly0.5https://www.biopharmawatch.com/news/LXRX/phase-2-trial-of-lx4211-demonstrates-significant-and-rapid-improvements-in-multiple-parame-lxrx-20100120monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-to-participate-in-the-jefferies-global-healthcare-conference-and-gold-rapp-20260520monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-to-participate-in-upcoming-investor-conferences-rapp-20260224monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-rapp-20251218monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-to-announce-topline-results-for-rap-219-phase-2a-trial-in-focal-onset-rapp-20250905monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-to-host-2025-investor-and-analyst-day-rapp-20250521monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-to-participate-in-upcoming-investor-conferences-rapp-20250422monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-to-present-data-at-the-2025-american-academy-of-neurology-annual-meet-rapp-20250321monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-announces-appointment-of-dr-jeffrey-sevigny-as-chief-medical-officer--rapp-20250303monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-to-participate-in-upcoming-investor-conferences-rapp-20250224monthly0.5https://www.biopharmawatch.com/news/RAPP/correction-rapport-therapeutics-announces-new-phase-1-data-further-supporting-rap-219-s-tr-rapp-20250109monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-presents-data-demonstrating-consistent-association-between-decreases--rapp-20241206monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-to-present-data-at-american-epilepsy-society-annual-meeting-rapp-20241114monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-reports-third-quarter-financials-and-provides-business-update-rapp-20241107monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-to-present-at-stifel-healthcare-conference-and-jefferies-london-healt-rapp-20241104monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-to-present-at-upcoming-epilepsy-medical-conferences-rapp-20240905monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-to-present-at-22nd-annual-morgan-stanley-global-healthcare-conference-rapp-20240829monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-to-present-data-for-tarp-8-ampar-negative-modulator-at-iasp-2024-worl-rapp-20240729monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-announces-closing-of-174-million-initial-public-offering-including-fu-rapp-20240612monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-announces-pricing-of-initial-public-offering-rapp-20240606monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-appoints-pioneering-industry-leader-john-maraganore-to-board-of-direc-rapp-20240319monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-appoints-chief-people-officer-rapp-20240228monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-appoints-terry-ann-burrell-to-board-of-directors-rapp-20240116monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-rapp-20240103monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-appoints-chief-financial-officer-rapp-20231030monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-appoints-chief-operating-officer-and-scientific-advisory-board-member-rapp-20230907monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-raises-150-million-in-series-b-funding-round-and-announces-key-board--rapp-20230823monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-names-scientific-advisory-board-rapp-20230629monthly0.5https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-launches-with-100-million-to-transform-the-treatment-of-neurological--rapp-20230307monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-fda-fast-track-designation-for-axs-02-for-the-treatment-of-p-axsm-20150305monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-appointment-of-randall-kaye-m-d-as-chief-medical-officer-axsm-20150409monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-enrollment-of-the-first-patient-in-a-phase-3-trial-of-axs-02-axsm-20150810monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-pricing-of-initial-public-offering-axsm-20151119monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-the-2016-jmp-securities-life-sciences-conference-axsm-20160613monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-at-the-2017-bio-ceo-investor-conference-axsm-20170207monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-receives-fda-fast-track-designation-for-axs-05-for-alzheimer-s-disease-axsm-20170508monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-axs-05-poster-presentation-at-the-2018-annual-meeting-of-the-axsm-20180503monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-axs-05-presentation-at-the-2018-alzheimer-s-association-inte-axsm-20180717monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-added-to-nasdaq-biotechnology-index-axsm-20191217monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-pricing-of-public-offering-of-174-million-of-shares-of-commo-axsm-20191219monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-topline-axsm-20200330monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-report-fourth-quarter-and-full-year-2021-financial-results-on-march-axsm-20220215monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-completes-u-s-acquisition-of-axsm-20220509monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-announces-fda-approval-of-axsm-20220819monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-presents-new-data-from-the-evolve-open-label-trial-demonstrating-effec-axsm-20221207monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-to-present-data-and-post-hoc-analyses-on-auvelity-and-sunosi-at-the-20-axsm-20230530monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-presents-new-data-and-post-hoc-analyses-of-auvelity-in-patients-with-m-axsm-20231211monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-presents-data-from-its-leading-neuroscience-pipeline-at-nei-congress-2-axsm-20241108monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-presents-positive-pivotal-phase-3-results-of-the-accord-2-trial-of-axs-axsm-20250404monthly0.5https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-showcases-innovation-in-sleep-medicine-with-multiple-presentations-for-axsm-20250611monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-launches-to-pioneer-a-new-era-of-precision-medicines-for-brain-diseas-nmra-20211007monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-announces-112-million-series-b-financing-nmra-20221011monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-announces-pricing-of-initial-public-offering-nmra-20230915monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-announces-ind-clearance-and-initiation-of-phase-1-study-of-nmra-266-nmra-20231127monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-to-present-at-42nd-annual-j-p-morgan-healthcare-conference-nmra-20240108monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-announces-clinical-hold-of-phase-1-nmra-266-study-nmra-20240415monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-announces-initiation-of-phase-2-study-of-navacaprant-in-bipolar-depre-nmra-20240514monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-announces-initiation-of-phase-1b-study-of-nmra-511-for-treatment-of-a-nmra-20240620monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-to-report-third-quarter-2024-financial-results-on-tuesday-november-12-nmra-20241029monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-to-participate-in-upcoming-conferences-in-november-nmra-20241106monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-to-present-at-leerink-global-healthcare-conference-nmra-20250304monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-to-report-first-quarter-2025-financial-results-on-monday-may-12-2025-nmra-20250428monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-announces-initiation-of-phase-1-clinical-study-of-m4-positive-alloste-nmra-20250709monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-to-report-second-quarter-2025-financial-results-on-wednesday-august-6-nmra-20250723monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-to-participate-in-upcoming-conferences-in-september-nmra-20250902monthly0.5https://www.biopharmawatch.com/news/NMRA/neumora-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-on-mond-nmra-20260316monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-publication-of-phase-1-gardian1-trial-results-for-ocu410st-modifier-gene--ocgn-20260112monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-ceo-to-present-at-oppenheimer-movers-in-rare-disease-summit-ocgn-20251210monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-first-patient-dosed-in-phase-2-3-gardian3-pivotal-confirmatory-trial--ocgn-20250718monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-host-conference-call-on-friday-august-1-at-8-30-a-m-et-to-discuss-business-updat-ocgn-20250717monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-u-s-fda-clearance-of-investigational-new-drug-amendment-to-initiate-p-ocgn-20250616monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-present-at-bio-international-convention-2025-ocgn-20250611monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-rare-pediatric-disease-designation-granted-for-ocu410st-modifier-gene-the-ocgn-20250527monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-provides-business-update-with-first-quarter-2025-financial-results-ocgn-20250509monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-host-conference-call-on-friday-may-9-at-8-30-a-m-et-to-discuss-business-updates--ocgn-20250502monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-present-on-modifier-gene-therapy-platform-at-association-for-research-in-vision--ocgn-20250429monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-present-at-the-2025-cell-gene-meeting-on-the-med-ocgn-20250408monthly0.5https://www.biopharmawatch.com/news/OCGN/data-and-safety-monitoring-board-reviews-cohort-1-safety-data-and-approves-dosing-cohort-2-ocgn-20250318monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-positive-opinion-of-ema-s-committee-for-advanced-therapies-for-atmp-class-ocgn-20250303monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-fda-alignment-on-phase-2-3-pivotal-confirmatory-clinical-trial-for-mo-ocgn-20250227monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-host-conference-call-on-wednesday-march-5-2025-at-8-30-a-m-et-to-discuss-busines-ocgn-20250221monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-dosing-completion-in-the-phase-2-armada-clinical-trial-for-ocu410-ocgn-20250212monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-positive-opinion-of-european-medicines-agency-s-committee-for-advanced-th-ocgn-20250203monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-investigational-new-drug-application-in-effect-after-review-by-fda-to-ocgn-20250127monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ocu200-a-novel-integ-ocgn-20250116monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-positive-2-year-data-across-multiple-mutations-from-phase-1-2-clinica-ocgn-20250113monthly0.5https://www.biopharmawatch.com/news/OCGN/data-and-safety-monitoring-board-reviews-interim-safety-data-of-phase-2-subjects-of-ocu410-ocgn-20241219monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-ceo-to-present-at-oppenheimer-movers-in-rare-disease-summit-ocgn-20241211monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-ceo-to-present-at-noblecon20-noble-capital-markets-20th-annual-emerging-growth-equi-ocgn-20241127monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-european-medicines-agency-grants-orphan-medicinal-product-designation-for-ocgn-20241120monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-compelling-preliminary-data-for-ocu410-a-single-dose-novel-modifier-gene--ocgn-20241119monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-secures-30-million-in-debt-funding-ocgn-20241107monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-clinical-showcase-highlighting-progress-in-retinal-gene-therapy-clinical-trials-in--ocgn-20241028monthly0.5https://www.biopharmawatch.com/news/OCGN/data-and-safety-monitoring-board-approves-initiation-of-phase-2-of-ocu410st-gardian-clinic-ocgn-20241022monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-host-conference-call-on-friday-november-8-at-8-30-a-m-et-to-discuss-business-upd-ocgn-20241017monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-participate-in-2024-maxim-healthcare-virtual-summit-ocgn-20241010monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-removal-of-clinical-hold-on-investigational-new-drug-application-for--ocgn-20241009monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-present-at-the-2024-cell-gene-meeting-on-the-mesa-ocgn-20241002monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-participate-in-a-fireside-chat-at-chardan-s-8th-annual-genetic-medicines-confere-ocgn-20240924monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-chairman-ceo-co-founder-dr-shankar-musunuri-to-speak-during-u-s-india-initiative-on-ocgn-20240909monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-cso-to-participate-in-5th-annual-gene-therapy-for-ophthalmic-disorders-summit-ocgn-20240905monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-participate-in-a-fireside-chat-at-the-h-c-wainwright-26th-annual-global-investme-ocgn-20240903monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-completion-of-dosing-in-subjects-with-stargardt-disease-in-high-dose-coho-ocgn-20240828monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-health-canada-approval-to-initiate-phase-3-clinical-trial-for-ocu400--ocgn-20240826monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-fda-approval-of-expanded-access-program-for-patients-with-retinitis-p-ocgn-20240805monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-closing-of-35-million-public-offering-of-common-stock-ocgn-20240802monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-pricing-of-35-million-public-offering-of-common-stock-ocgn-20240731monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-host-conference-call-on-thursday-august-8-at-8-30-a-m-et-to-discuss-business-upd-ocgn-20240729monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-completion-of-dosing-in-subjects-with-geographic-atrophy-secondary-to-ocgn-20240725monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-data-and-safety-monitoring-board-approves-enrollment-in-high-dose-cohort--ocgn-20240621monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-first-patient-dosed-in-phase-3-limelight-clinical-trial-for-ocu400-fi-ocgn-20240620monthly0.5https://www.biopharmawatch.com/news/OCGN/data-and-safety-monitoring-board-approves-simultaneous-enrollment-in-cohort-3-and-phase-2--ocgn-20240531monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-present-at-bio-international-convention-2024-ocgn-20240529monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-set-to-join-russell-3000-index-effective-june-28-2024-ocgn-20240528monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-cso-to-present-on-modifier-gene-therapy-at-international-society-for-cell-ocgn-20240520monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-dosing-completion-of-subjects-with-stargardt-disease-in-cohort-2-of-phase-ocgn-20240515monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-distribution-of-series-c-preferred-stock-to-holders-of-its-common-stock-ocgn-20240510monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-present-at-may-2024-investor-conferences-ocgn-20240510monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-host-conference-call-on-tuesday-may-14-at-8-30-a-m-et-to-discuss-business-update-ocgn-20240503monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-cso-to-present-on-modifier-gene-therapy-at-retina-world-congress-ocgn-20240502monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-ocu400-modifier-gene-therapy-phase-1-2-data-presentation-at-retinal-cell--ocgn-20240429monthly0.5https://www.biopharmawatch.com/news/OCGN/update-ocugen-to-present-on-modifier-gene-therapy-platform-at-association-for-research-in--ocgn-20240426monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-present-on-modifier-gene-therapy-platform-at-association-for-research-in-vision--ocgn-20240426monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-dosing-completion-of-subjects-with-geographic-atrophy-in-cohort-2-of-phas-ocgn-20240419monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-participate-in-fireside-chat-at-the-emerging-growth-virtual-healthcare-equity-co-ocgn-20240412monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-positive-scientific-advice-from-the-european-medicines-agency-related-ocgn-20240410monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-positive-data-and-safety-monitoring-board-review-and-initiation-of-enroll-ocgn-20240405monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-positive-data-and-safety-monitoring-board-review-and-initiation-of-enroll-ocgn-20240401monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-host-conference-call-on-tuesday-april-2-at-8-30-a-m-et-to-provide-business-updat-ocgn-20240401monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-dosing-completion-of-subjects-with-geographic-atrophy-in-cohort-1-of--ocgn-20240313monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-present-at-investing-in-cures-summit-ocgn-20240306monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-clinical-showcase-webcast-now-available-ocgn-20240228monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-chairman-and-ceo-to-present-at-abu-dhabi-family-office-summit-ocgn-20240226monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-dosing-completion-of-subjects-with-stargardt-in-cohort-1-of-phase-1-2-ocgn-20240222monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-present-at-2024-bio-ceo-investor-conference-ocgn-20240221monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-host-clinical-showcase-in-new-york-city-on-wednesday-february-21-2024-ocgn-20240214monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-present-at-pharma-market-research-conference-ocgn-20240131monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-bob-smith-joins-business-advisory-board-ocgn-20240116monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-ocu400-receives-regenerative-medicine-advanced-therapy-rmat-designation-f-ocgn-20231219monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-first-patient-dosed-in-phase-1-2-clinical-trial-evaluating-the-safety-ocgn-20231213monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-ceo-to-present-at-noblecon19-noble-capital-markets-nineteenth-annual-emerging-growt-ocgn-20231129monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-first-patient-dosed-in-phase-1-2-clinical-trial-evaluating-the-safety-ocgn-20231110monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-cso-to-participate-in-4th-annual-dry-amd-therapeutic-development-summit-ocgn-20231107monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-host-conference-call-on-thursday-november-9-at-8-30-a-m-et-to-discuss-business-u-ocgn-20231102monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-present-at-the-2023-cell-gene-meeting-on-the-mesa-ocgn-20231004monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-cso-to-participate-in-4th-annual-gene-therapy-for-ophthalmic-disorders-conference-ocgn-20230929monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-participate-in-fireside-chat-at-chardan-s-7th-annual-genetic-medicines-conferenc-ocgn-20230927monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-connie-collingsworth-joins-business-advisory-board-ocgn-20230921monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-participate-in-panel-at-cantor-fitzgerald-global-healthcare-conference-2023-ocgn-20230920monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-host-virtual-investor-analyst-event-on-september-13-2023-ocgn-20230912monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-host-conference-call-on-tuesday-august-22-at-8-30-a-m-et-to-discuss-business-upd-ocgn-20230818monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-ceo-cso-to-present-at-41st-annual-aapi-convention-and-scientific-assembly-ocgn-20230630monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-adjournment-of-annual-meeting-of-shareholders-ocgn-20230609monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-business-advisory-board-ocgn-20230605monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-pricing-of-16-5-million-public-offering-of-common-stock-ocgn-20230524monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-proposed-public-offering-of-common-stock-ocgn-20230523monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-present-at-bio-international-convention-2023-ocgn-20230523monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-host-conference-call-on-friday-may-5-at-8-30-a-m-et-to-discuss-business-updates--ocgn-20230428monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-ocu410st-receives-orphan-drug-designation-for-treatment-of-abca4-associat-ocgn-20230427monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-to-participate-in-fireside-chat-at-the-h-c-wainwright-bioconnect-investor-confe-ocgn-20230426monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-present-at-association-for-research-in-vision-and-ophthalmology-2023-annual-meet-ocgn-20230420monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-host-virtual-investor-analyst-event-on-april-14-2023-ocgn-20230411monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-chief-scientific-officer-to-present-at-2023-world-vaccine-congress-ocgn-20230331monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-fda-approval-for-enrollment-of-pediatric-patients-in-ongoing-ocu400-phase-ocgn-20230327monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-to-participate-in-fireside-chat-at-35th-annual-roth-conference-ocgn-20230307monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-appoints-quan-a-vu-to-chief-financial-officer-chief-business-officer-ocgn-20230306monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-submission-of-investigational-new-drug-application-with-u-s-fda-to-in-ocgn-20230227monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-present-at-retinal-vascular-disease-drug-development-summit-ocgn-20230217monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-host-conference-call-on-tuesday-february-28-at-8-30-a-m-et-to-discuss-business-u-ocgn-20230215monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-appoints-quan-a-vu-as-chief-business-officer-ocgn-20230201monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-to-present-at-2023-bio-ceo-investor-conference-ocgn-20230131monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-phase-3-confirmatory-clinical-trial-agreement-for-neocart-ocgn-20221216monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-to-ring-the-nasdaq-stock-market-closing-bell-ocgn-20221213monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-update-on-ocu400-phase-1-2-clinical-trial-targeting-retinitis-pigmentosa--ocgn-20221207monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-present-at-3rd-annual-dry-amd-therapeutics-summit-ocgn-20221128monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-host-conference-call-on-tuesday-november-8-at-8-30-a-m-et-to-discuss-business-up-ocgn-20221027monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-host-r-d-day-in-new-york-city-on-tuesday-november-1-2022-ocgn-20221019monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-completion-of-dosing-in-ocu400-phase-1-2-cohort-2-ocgn-20221012monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-to-present-at-upcoming-vaccines-cell-gene-therapy-conferences-ocgn-20221006monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-to-present-at-chardan-s-6th-annual-genetic-medicines-conference-ocgn-20220929monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-agreement-with-washington-university-in-st-louis-for-commercialization-of-ocgn-20220928monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ocgn-20220916monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-cso-to-participate-in-3rd-annual-gene-therapy-for-ophthalmic-disorders-conference-ocgn-20220908monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-to-present-at-h-c-wainwright-24th-annual-global-investment-conference-ocgn-20220906monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-appoints-robert-j-hopkins-md-mph-tm-facp-fidsa-as-chief-medical-officer-and-promote-ocgn-20220901monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-ceo-to-present-at-h-c-wainwright-2nd-annual-ophthalmology-virtual-conference-ocgn-20220812monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-host-conference-call-on-friday-august-5-at-8-30-a-m-et-to-discuss-business-updat-ocgn-20220729monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-publication-of-positive-results-of-covid-19-vaccine-trial-for-children-2--ocgn-20220621monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-named-among-philadelphia-s-2022-best-places-to-work-ocgn-20220614monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-issuance-of-u-s-patent-for-treating-retinal-degenerative-diseases-usi-ocgn-20220613monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-to-present-at-bio-international-convention-2022-ocgn-20220609monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-to-present-at-h-c-wainwright-global-investment-conference-ocgn-20220523monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-host-conference-call-on-friday-may-6-at-8-30-a-m-et-to-provide-business-update-a-ocgn-20220502monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-to-present-preclinical-results-at-the-association-for-research-in-vision-and-op-ocgn-20220429monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-positive-dsmb-recommendation-for-ocu400-101-clinical-trial-ocgn-20220425monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-to-present-at-noblecon18-ocgn-20220419monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-to-commercialize-covaxin-in-mexico-rights-now-encompassing-all-of-north-america-ocgn-20220418monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-first-patient-dosed-in-phase-1-2-clinical-trial-for-gene-therapy-cand-ocgn-20220401monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-appointment-of-marna-c-whittington-phd-to-board-of-directors-ocgn-20220323monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-appoints-jessica-crespo-cpa-to-chief-accounting-officer-and-senior-vice-preside-ocgn-20220321monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ocgn-20220318monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-to-present-at-the-34th-annual-roth-conference-ocgn-20220309monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-pricing-of-53-5-million-public-offering-of-common-stock-ocgn-20220222monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-proposed-public-offering-of-common-stock-ocgn-20220222monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-host-conference-call-on-friday-february-25-at-8-30-a-m-et-to-discuss-fourth-quar-ocgn-20220218monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-harris-poll-finds-americans-want-more-covid-19-vaccine-options-ocgn-20220215monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-signs-letter-of-intent-to-acquire-vaccine-manufacturing-r-d-hub-in-ontario-cana-ocgn-20220127monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-nirdosh-jagota-ph-d-as-senior-vice-president-regulatory-affairs-compl-ocgn-20220124monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ocgn-20220121monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-to-present-at-upcoming-h-c-wainwright-bioconnect-conference-ocgn-20220106monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ocgn-20211220monthly0.5https://www.biopharmawatch.com/news/OCGN/new-data-suggest-covaxin-bbv152-vaccine-candidate-generates-robust-immune-memory-to-covid--ocgn-20211215monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ocgn-20211118monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-host-conference-call-on-tuesday-november-9-at-8-30-a-m-et-to-discuss-third-quart-ocgn-20211102monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-to-present-pre-clinical-data-for-ocu410-at-2nd-annual-dry-amd-therapeutic-devel-ocgn-20211019monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ocgn-20211016monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-to-participate-in-fireside-chat-at-the-cantor-virtual-global-healthcare-confere-ocgn-20210923monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ocgn-20210917monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-to-present-at-upcoming-citi-and-h-c-wainwright-investment-conferences-ocgn-20210907monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ocgn-20210820monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-host-conference-call-on-friday-august-6-at-8-30-a-m-et-ocgn-20210730monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ocgn-20210716monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-ken-inchausti-as-head-investor-relations-communications-ocgn-20210621monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ocgn-20210618monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-set-to-join-russell-3000-index-ocgn-20210616monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-secures-manufacturing-partnership-for-us-production-of-covid-19-vaccine-candidate-c-ocgn-20210615monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-michael-shine-as-senior-vice-president-commercial-ocgn-20210610monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-expands-covaxin-commercialization-rights-to-include-canada-ocgn-20210603monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-on-track-to-submit-emergency-use-authorization-application-to-u-s-fda-for-its-covid-ocgn-20210526monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-presents-new-preclinical-ocu200-data-at-the-association-for-research-in-vision-and--ocgn-20210506monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-host-conference-call-on-friday-may-7-at-8-30-a-m-et-to-discuss-first-quarter-202-ocgn-20210503monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-studies-showing-covaxin-potentially-effective-against-three-key-variants--ocgn-20210503monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-closing-of-100-million-registered-direct-offering-of-common-stock-pri-ocgn-20210428monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-100-million-registered-direct-offering-of-common-stock-priced-at-a-pr-ocgn-20210423monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-john-paul-gabriel-as-senior-vice-president-manufacturing-and-supply-c-ocgn-20210414monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-to-participate-in-a-cantor-fitzgerald-fireside-chat-to-discuss-covaxin-covid-19-ocgn-20210329monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-host-conference-call-on-thursday-march-18-at-8-30-a-m-et-to-discuss-2020-financi-ocgn-20210312monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-to-present-at-upcoming-march-investor-conferences-ocgn-20210308monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-closing-of-23-million-registered-direct-offering-of-common-stock-ocgn-20210210monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-23-million-registered-direct-offering-of-common-stock-priced-at-a-pre-ocgn-20210207monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-and-bharat-biotech-announce-execution-of-definitive-agreement-for-the-commercializa-ocgn-20210202monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-the-cancellation-of-stockholder-meeting-previously-adjourned-to-11-00-ocgn-20210112monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-to-present-at-ctic-hc-wainwright-and-noble-capital-investor-conferences-ocgn-20210108monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-establishes-vaccine-scientific-advisory-board-ocgn-20201223monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-plan-to-adjourn-annual-meeting-of-stockholders-modify-proposal-regard-ocgn-20201222monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-inc-announces-plan-to-postpone-annual-meeting-of-stockholders-ocgn-20201210monthly0.5https://www.biopharmawatch.com/news/OCGN/leading-independent-proxy-firms-iss-and-glass-lewis-recommend-ocugen-stockholders-vote-for-ocgn-20201201monthly0.5https://www.biopharmawatch.com/news/OCGN/ceo-dr-shankar-musunuri-to-be-featured-as-a-panelist-at-xconomy-s-xcelerating-life-science-ocgn-20201127monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-present-at-the-gcff-virtual-conference-diversified-investing-strategies-ocgn-20201029monthly0.5https://www.biopharmawatch.com/news/OCGN/ceo-dr-shankar-musunuri-to-discuss-the-importance-of-gene-therapy-strategic-partnerships-a-ocgn-20201022monthly0.5https://www.biopharmawatch.com/news/OCGN/cantor-fitzgerald-and-kristen-kluska-to-host-zoom-fireside-chat-with-ocugen-ocgn-20201016monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-participate-in-a-virtual-fireside-chat-at-the-chardan-genetic-medicines-conferen-ocgn-20200929monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-present-at-the-oppenheimer-fall-healthcare-life-sciences-medtech-summit-ocgn-20200916monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-bid-price-rule-ocgn-20200908monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-present-at-the-h-c-wainwright-22nd-annual-global-investment-conference-ocgn-20200903monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-present-at-the-ld-500-virtual-investor-conference-ocgn-20200828monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-host-conference-call-on-friday-august-14-at-8-30-a-m-et-ocgn-20200806monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-present-at-world-orphan-drug-congress-usa-2020-conference-ocgn-20200721monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-appoints-dr-mohamed-genead-as-chair-of-retina-scientific-advisory-board-ocgn-20200603monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-discontinue-phase-3-ogvhd-trial-ocgn-20200601monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-completion-of-warrant-exchange-ocgn-20200422monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-appoints-kirsten-castillo-and-prabhavathi-fernandes-to-board-of-directors-ocgn-20200407monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-provides-business-update-and-full-year-2019-financial-results-ocgn-20200327monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-host-conference-call-on-friday-march-27-at-8-30-a-m-et-to-discuss-2019-financial-ocgn-20200320monthly0.5https://www.biopharmawatch.com/news/OCGN/nature-gene-therapy-publishes-preclinical-data-of-ocugen-s-ocu400-nr2e3-aav-genetic-modifi-ocgn-20200303monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-present-at-noblecon16-noble-capital-markets-sixteenth-annual-investor-conference-ocgn-20200210monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-provides-business-update-and-third-quarter-2019-financial-highlights-ocgn-20191108monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-warrant-restructuring-ocgn-20191106monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-appointments-to-retina-disease-and-ocular-graft-versus-host-disease-scien-ocgn-20191104monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-host-conference-call-on-friday-november-8-at-8-30-a-m-et-to-discuss-third-quarte-ocgn-20191025monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-appoints-jessica-crespo-cpa-as-controller-ocgn-20191023monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-share-repurchase-program-ocgn-20191009monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-amendment-to-asset-purchase-agreement-ocgn-20191007monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-appoints-sanjay-s-subramanian-mba-as-chief-financial-officer-ocgn-20191001monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-present-at-three-upcoming-conferences-ocgn-20190930monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-granted-fda-orphan-drug-designation-for-ocu400-nr2e3-gene-therapy-for-the-treatment-ocgn-20190918monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-granted-fda-orphan-drug-designation-for-ocu400-gene-therapy-for-the-treatment-of-nr-ocgn-20190214monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-highlight-phase-2-clinical-data-for-ocu310-at-aao-2018-ocgn-20181023monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-initiates-phase-3-clinical-trial-of-ocu310-for-dry-eye-disease-ocgn-20181001monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-present-at-two-upcoming-investor-conferences-ocgn-20180926monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-appoints-james-g-murphy-cpa-as-chief-financial-officer-ocgn-20180813monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-initiates-phase-3-clinical-trial-of-ocu300-for-the-treatment-of-ocular-graft-versus-ocgn-20180702monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-present-at-the-2018-bio-international-convention-ocgn-20180529monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-presents-preclinical-efficacy-data-of-its-proprietary-nanoemulsion-technology-at-ar-ocgn-20180502monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-highlight-potential-efficacy-of-its-proprietary-nanoemulsion-technology-at-arvo--ocgn-20180425monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-ceo-dr-shankar-musunuri-named-a-finalist-for-ernst-young-entrepreneur-of--ocgn-20180423monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-reports-positive-phase-2-clinical-results-demonstrating-proof-of-concept-for-its-no-ocgn-20180320monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-present-at-the-oppenheimer-28th-annual-healthcare-conference-ocgn-20180315monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-to-present-at-2018-bio-ceo-investor-conference-ocgn-20180206monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-expands-focus-on-inherited-retinal-disorders-by-licensing-novel-modifier-gene-thera-ocgn-20171220monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-fda-acceptance-of-investigational-new-drug-application-for-ocu310-brimoni-ocgn-20170925monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-announces-participation-at-the-19th-annual-rodman-renshaw-global-investment-confere-ocgn-20170828monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-receives-fda-orphan-drug-designation-for-ocu300-brimonidine-tartrate-for-the-treatm-ocgn-20170809monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-makes-strategic-appointments-to-management-team-ocgn-20170619monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-closes-7-5-million-series-b-financing-ocgn-20170615monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-expands-global-patent-portfolio-for-ocu200-ocgn-20170508monthly0.5https://www.biopharmawatch.com/news/OCGN/ocugen-closes-6-million-in-series-a-funding-ocgn-20161215monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-raises-25-million-in-series-a-financing-and-announces-founding-team-of-crsp-20140424monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-founding-scientist-emmanuelle-charpentier-awarded-2015-breakthrough-pr-crsp-20141110monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-establish-r-d-operations-in-cambridge-massachusetts-crsp-20150407monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-congratulates-scientific-founder-dr-emmanuelle-charpentier-on-addition-crsp-20150422monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-raises-additional-64-million-to-translate-breakthrough-crispr-cas9-tec-crsp-20150429monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-bolsters-management-team-with-samarth-kulkarni-as-chief-business-offic-crsp-20150811monthly0.5https://www.biopharmawatch.com/news/CRSP/fiercebiotech-names-crispr-therapeutics-as-one-of-its-fierce-15-biotech-companies-of-2015-crsp-20150930monthly0.5https://www.biopharmawatch.com/news/CRSP/vertex-and-crispr-therapeutics-establish-collaboration-to-use-crispr-cas9-gene-editing-tec-crsp-20151026monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-appoints-tony-coles-m-d-to-its-board-of-directors-crsp-20151211monthly0.5https://www.biopharmawatch.com/news/CRSP/ge-ne-thon-and-crispr-therapeutics-announce-research-collaboration-crsp-20151218monthly0.5https://www.biopharmawatch.com/news/CRSP/bayer-and-crispr-therapeutics-ag-join-forces-to-discover-develop-and-commercialize-potenti-crsp-20151221monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-strengthens-its-leadership-team-with-the-appointment-of-marc-becker-as-crsp-20160310monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-adds-pablo-j-cagnoni-m-d-to-board-of-directors-and-names-tony-coles-m--crsp-20160317monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-anagenesis-biotechnologies-announce-strategic-in-licensing-and-col-crsp-20160608monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-raises-additional-38m-as-part-of-series-b-financing-crsp-20160624monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-pricing-of-initial-public-offering-crsp-20161018monthly0.5https://www.biopharmawatch.com/news/CRSP/casebia-therapeutics-press-release-casebia-therapeutics-announces-appointment-of-james-w-b-crsp-20161101monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-the-stifel-2016-healthcare-conference-crsp-20161108monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-two-presentations-demonstrating-the-potential-for-crispr-gen-crsp-20161121monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-the-28th-annual-piper-jaffray-healthcare-conference-crsp-20161122monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-host-conference-call-and-webcast-to-provide-an-update-on-the-crispr-crsp-20170215monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-the-appointment-of-jon-terrett-ph-d-to-head-of-immuno-oncolo-crsp-20170228monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-the-annual-barclays-global-healthcare-conference-crsp-20170302monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-reports-fourth-quarter-and-full-year-2016-financial-results-and-provid-crsp-20170310monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-casebia-therapeutics-announce-commercial-license-agreement-with-ma-crsp-20170314monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-the-16th-annual-needham-healthcare-conference-crsp-20170330monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-casebia-therapeutics-announce-exclusive-development-and-option-agr-crsp-20170417monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-the-42nd-annual-deutsche-bank-health-care-conference-crsp-20170427monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-exclusive-license-of-lipid-nanoparticle-technologies-develop-crsp-20170508monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-investor-conferences-in-may-crsp-20170512monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-collaborators-at-the-university-of-florida-awarded-target-als-gran-crsp-20170516monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-the-presentation-of-data-on-its-lead-program-at-the-upcoming-crsp-20170518monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-masthercell-sa-sign-service-agreement-for-the-development-and-manu-crsp-20170606monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference-crsp-20170614monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-the-piper-jaffray-genomerx-symposium-crsp-20170705monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-neon-therapeutics-enter-research-collaboration-crsp-20170710monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-intellia-therapeutics-caribou-biosciences-and-ers-genomics-announce-ap-crsp-20170725monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-collaboration-with-massachusetts-general-hospital-to-researc-crsp-20170822monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-investor-conferences-in-october-crsp-20171004monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-awarded-grant-from-friedreich-s-ataxia-research-alliance-to-collaborat-crsp-20171013monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-highlights-new-additions-to-portfolio-of-allogeneic-crispr-based-car-t-crsp-20171110monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-casebia-collaborate-with-curevac-on-mrna-for-gene-editing-programs-crsp-20171113monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-upcoming-investor-conferences-crsp-20171128monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-oral-presentation-of-new-data-on-ctx001-a-crispr-gene-edited-crsp-20171205monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-oral-presentation-of-new-data-on-ctx001-a-crispr-gene-edited-crsp-20171210monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-pricing-of-public-offering-of-common-shares-crsp-20180104monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-transition-of-bill-lundberg-md-crsp-20180208monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-four-upcoming-investor-conferences-crsp-20180221monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-the-retirement-of-tyler-dylan-hyde-and-appointment-of-shelby-crsp-20180326monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-the-appointment-of-steve-caffe-as-head-of-regulatory-affairs-crsp-20180404monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-data-on-allogeneic-crispr-based-car-t-cell-therapies-at-aac-crsp-20180413monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-presents-positive-data-on-allogeneic-crispr-based-car-t-cell-therapies-crsp-20180416monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-may-investor-conferences-crsp-20180503monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-presentations-at-the-asgct-21st-annual-meeting-crsp-20180515monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-three-june-conferences-crsp-20180605monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-intellia-therapeutics-and-caribou-biosciences-announce-grant-of-u-s-pa-crsp-20180619monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-upcoming-investor-conferences-crsp-20180830monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-pricing-of-public-offering-of-common-shares-crsp-20180920monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-the-chardan-genetic-medicines-conference-crsp-20181002monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-maxcyte-expand-clinical-and-commercial-license-agreement-into-onco-crsp-20181109monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-upcoming-investor-conferences-crsp-20181121monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-vertex-announce-fda-fast-track-designation-for-ctx001-for-the-trea-crsp-20190104monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-probiogen-sign-collaboration-and-license-agreement-to-develop-nove-crsp-20190122monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-stridebio-expand-exclusive-development-and-option-agreement-crsp-20190219monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-proposes-new-members-to-the-board-of-directors-crsp-20190221monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-presentations-at-the-american-association-for-cancer-researc-crsp-20190227monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-upcoming-investor-conferences-crsp-20190306monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-upcoming-investor-conferences-crsp-20190401monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-vertex-announce-fda-fast-track-designation-for-ctx001-for-the-trea-crsp-20190416monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-upcoming-investor-conferences-crsp-20190501monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-upcoming-investor-conferences-crsp-20190529monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-oral-presentation-at-the-55th-annual-meeting-of-the-european-crsp-20190701monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-upcoming-investor-conferences-crsp-20190731monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-viacyte-present-positive-in-vitro-data-towards-a-potential-immune--crsp-20190917monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-upcoming-investor-conferences-crsp-20191001monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-ksq-therapeutics-announce-license-agreement-to-advance-companies-r-crsp-20191015monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-bayer-announce-an-update-on-casebia-therapeutics-crsp-20191021monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-pricing-of-public-offering-of-common-shares-crsp-20191120monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-upcoming-investor-conferences-crsp-20191127monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-the-goldman-sachs-12th-annual-healthcare-ceos-unscripted-crsp-20200106monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-the-bank-of-america-securities-2020-health-care-conferen-crsp-20200507monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-presentations-at-the-american-association-for-cancer-researc-crsp-20200515monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-upcoming-investor-conferences-crsp-20200526monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-the-build-out-of-new-cell-therapy-manufacturing-facility-crsp-20200625monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-proposed-offering-of-common-shares-crsp-20200629monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-pricing-of-public-offering-of-common-shares-crsp-20200630monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-upcoming-investor-conferences-crsp-20200730monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-the-wells-fargo-2020-virtual-healthcare-conference-crsp-20200903monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-vertex-pharmaceuticals-announce-priority-medicines-prime-designati-crsp-20200922monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-upcoming-investor-conferences-crsp-20200929monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-congratulates-co-founder-emmanuelle-charpentier-on-receiving-the-2020--crsp-20201007monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference-crsp-20201116monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-con-crsp-20201124monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-vertex-to-host-investor-webcast-to-review-data-presented-at-the-62-crsp-20201201monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-receives-grant-to-advance-in-vivo-crispr-cas9-gene-editing-therapies-f-crsp-20201214monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-the-appointment-of-philippe-drouet-as-chief-commercial-offic-crsp-20210201monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-the-guggenheim-healthcare-talks-2021-oncology-day-crsp-20210205monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-upcoming-investor-conferences-crsp-20210303monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-poster-presentation-at-the-american-association-for-cancer-r-crsp-20210310monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-the-20th-annual-needham-virtual-healthcare-conferenc-crsp-20210406monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-presents-preclinical-data-at-aacr-2021-supporting-cd70-knockout-as-a-n-crsp-20210410monthly0.5https://www.biopharmawatch.com/news/CRSP/vertex-and-crispr-therapeutics-announce-priority-medicines-prime-designation-granted-by-th-crsp-20210426monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-trials-in-progress-poster-presentation-at-the-2021-american--crsp-20210428monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-upcoming-investor-conferences-crsp-20210429monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-nkarta-announce-global-collaboration-to-develop-gene-edited-cell-t-crsp-20210506monthly0.5https://www.biopharmawatch.com/news/CRSP/vertex-and-crispr-therapeutics-to-present-new-clinical-data-on-investigational-crispr-cas9-crsp-20210512monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-upcoming-investor-conferences-crsp-20210525monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-capsida-biotherapeutics-announce-strategic-collaboration-to-develo-crsp-20210615monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-the-canaccord-genuity-41st-annual-growth-conference-crsp-20210805monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-the-chardan-s-5th-annual-genetic-medicines-conferenc-crsp-20210928monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-preclinical-data-at-the-society-for-immunotherapy-of-cancer-crsp-20211001monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-host-virtual-event-highlighting-ctx110-clinical-data-crsp-20211005monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-upcoming-investor-conferences-crsp-20211102monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-viacyte-inc-to-start-clinical-trial-of-the-first-gene-edited-cell--crsp-20211116monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-upcoming-investor-conferences-crsp-20211123monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-viacyte-inc-announce-first-patient-dosed-in-phase-1-clinical-trial-crsp-20220202monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-the-11th-annual-svb-leerink-global-healthcare-confer-crsp-20220209monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-upcoming-investor-conferences-crsp-20220228monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-poster-presentation-at-the-american-association-for-cancer-r-crsp-20220308monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-upcoming-investor-conferences-crsp-20220407monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-proposes-new-appointment-to-the-board-of-directors-crsp-20220412monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-the-2022-bank-of-america-healthcare-conference-crsp-20220504monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-host-innovation-day-on-june-21-2022-crsp-20220531monthly0.5https://www.biopharmawatch.com/news/CRSP/vertex-and-crispr-therapeutics-announce-acceptance-of-late-breaking-abstract-for-ctx001-at-crsp-20220602monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-the-goldman-sachs-43rd-annual-global-healthcare-conferen-crsp-20220608monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-presents-positive-results-from-its-phase-1-cobalt-lym-trial-of-ctx130--crsp-20220611monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-upcoming-investor-conferences-crsp-20220831monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-vertex-announce-global-exa-cel-regulatory-submissions-for-sickle-c-crsp-20220927monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-fda-regenerative-medicine-advanced-therapy-rmat-designation--crsp-20220928monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series-gene-editing-and-ther-crsp-20220929monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-crsp-20221005monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-poster-presentation-on-ctx110-at-the-american-society-of-hem-crsp-20221103monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-presents-data-at-the-society-for-immunotherapy-of-cancer-sitc-37th-ann-crsp-20221110monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-the-2022-bmo-growth-esg-conference-crsp-20221201monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-vertex-to-present-at-the-american-society-of-hematology-ash-annual-crsp-20221210monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-update-on-its-ongoing-phase-1-carbon-trial-of-ctx110-crsp-20221212monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-the-appointment-of-alex-harding-m-d-m-b-a-as-head-of-busines-crsp-20221219monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-b-riley-securities-3rd-annual-oncology-conference-crsp-20230111monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-upcoming-investor-conferences-crsp-20230208monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-the-43rd-annual-cowen-health-care-conference-crsp-20230227monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-the-american-association-for-cancer-research-2023-annual-crsp-20230314monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-vertex-announce-licensing-agreement-to-accelerate-development-of-v-crsp-20230327monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-vertex-complete-submission-of-rolling-biologics-license-applicatio-crsp-20230403monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-needham-s-22nd-annual-healthcare-conference-crsp-20230413monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-upcoming-investor-conferences-crsp-20230502monthly0.5https://www.biopharmawatch.com/news/CRSP/positive-results-from-pivotal-trials-of-exa-cel-for-transfusion-dependent-beta-thalassemia-crsp-20230609monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-goldman-sachs-44th-annual-global-healthcare-conferen-crsp-20230613monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-citi-039-s-18th-annual-biopharma-conference-crsp-20230830monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-crsp-20230927monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-proposes-new-appointment-to-the-board-of-directors-crsp-20231016monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-completion-of-fda-advisory-committee-meeting-for-exagamgloge-crsp-20231031monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-trading-halted-today-fda-advisory-committee-to-review-biologics-licens-crsp-20231031monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-third-quarter-2023-financial-resu-crsp-20231106monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-preclinical-data-at-the-american-heart-association-aha-scien-crsp-20231106monthly0.5https://www.biopharmawatch.com/news/CRSP/vertex-and-crispr-therapeutics-announce-authorization-of-the-first-crispr-cas9-gene-edited-crsp-20231116monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-updates-to-immuno-oncology-pipeline-and-expansion-into-autoi-crsp-20231204monthly0.5https://www.biopharmawatch.com/news/CRSP/vertex-and-crispr-therapeutics-announce-us-fda-approval-of-casgevy-exagamglogene-autotemce-crsp-20231208monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-crsp-20240103monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-highlights-strategic-priorities-and-2024-outlook-crsp-20240108monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-u-s-food-and-drug-administration-fda-approval-of-casgevy-exa-crsp-20240116monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-announces-280-million-registered-direct-offering-crsp-20240213monthly0.5https://www.biopharmawatch.com/news/CRSP/european-commission-approves-first-crispr-cas9-gene-edited-therapy-casgevy-exagamglogene-a-crsp-20240213monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-the-citi-2024-virtual-oncology-leadership-summit-crsp-20240215monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-proposes-new-appointment-to-the-board-of-directors-crsp-20240313monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-the-american-society-of-gene-and-cell-therapy-asgct-2024-crsp-20240401monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-the-annual-needham-virtual-healthcare-conference-crsp-20240403monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-oral-presentation-at-the-american-society-of-gene-and-cell--crsp-20240422monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-highlights-asgct-oral-presentation-and-announces-new-programs-utilizin-crsp-20240508monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-the-bank-of-america-securities-health-care-conference-crsp-20240509monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-strengthens-executive-leadership-team-with-key-appointments-crsp-20240523monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-upcoming-investor-conferences-crsp-20240529monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-the-guggenheim-inaugural-healthcare-innovation-conferenc-crsp-20241107monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-the-jefferies-london-healthcare-conference-crsp-20241114monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-presents-data-at-the-2024-american-society-of-hematology-ash-annual-me-crsp-20241209monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-proposes-new-appointment-to-the-board-of-directors-crsp-20250107monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-crsp-20250108monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-highlights-strategic-priorities-and-anticipated-2025-milestones-crsp-20250113monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-the-guggenheim-smid-cap-biotech-conference-crsp-20250129monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference-crsp-20250226monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-present-at-the-24th-annual-needham-virtual-healthcare-conference-crsp-20250403monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-and-sirius-therapeutics-announce-multi-target-collaboration-to-develop-crsp-20250519monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-upcoming-investor-conferences-crsp-20250529monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-prices-upsized-convertible-senior-notes-offering-crsp-20260311monthly0.5https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-to-participate-in-upcoming-investor-conferences-crsp-20260528monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-to-host-conference-call-to-report-part-b-16-week-data-from-the-phase-2-apge-20260526monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-provides-pipeline-progress-and-reports-second-quarter-2025-financial-r-apge-20250811monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-to-host-conference-call-to-report-part-a-16-week-data-from-the-phase-2-apge-20250706monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-to-participate-at-the-jefferies-global-healthcare-conference-apge-20250529monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-announces-positive-interim-results-from-the-phase-1b-trial-of-apg808-i-apge-20250512monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-to-participate-at-the-bank-of-america-2025-health-care-conference-apge-20250501monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-announces-positive-interim-phase-1-results-from-the-apg990-healthy-vol-apge-20250303monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-to-host-conference-call-to-report-interim-results-from-the-phase-1-hea-apge-20250228monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-to-participate-in-upcoming-march-investor-conferences-apge-20250225monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-to-participate-at-the-guggenheim-smid-cap-biotech-conference-apge-20250129monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-announces-agenda-for-virtual-r-d-day-apge-20241129monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-to-host-inaugural-virtual-r-d-day-on-december-2-2024-apge-20241118monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-to-participate-in-upcoming-november-investor-conferences-apge-20241104monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-announces-poster-presentation-at-the-acaai-2024-annual-scientific-meet-apge-20241016monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-to-participate-at-the-stifel-2024-immunology-and-inflammation-summit-apge-20240912monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-appoints-jeff-s-hartness-as-chief-commercial-officer-apge-20240909monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-to-participate-in-upcoming-june-investor-conferences-apge-20240523monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-to-participate-at-the-2024-bank-of-america-healthcare-conference-apge-20240506monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-inc-announces-closing-of-upsized-public-offering-and-full-exercise-of--apge-20240312monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-inc-announces-pricing-of-upsized-420-million-underwritten-public-offer-apge-20240307monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-inc-announces-proposed-underwritten-public-offering-apge-20240305monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-announces-positive-interim-results-from-phase-1-healthy-volunteer-trial-for-apg777--apge-20240305monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-to-host-conference-call-and-webcast-to-report-interim-results-from-phase-1-healthy--apge-20240304monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-apge-20240102monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-to-participate-in-upcoming-november-investor-conferences-apge-20231030monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-announces-two-abstracts-accepted-for-presentation-at-the-2023-european-academy-of-d-apge-20230927monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-to-participate-at-the-2023-stifel-virtual-i-i-day-apge-20230914monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-to-participate-in-upcoming-august-investor-conferences-apge-20230802monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-inc-announces-closing-of-upsized-initial-public-offering-and-full-exer-apge-20230718monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-inc-announces-pricing-of-upsized-initial-public-offering-apge-20230713monthly0.5https://www.biopharmawatch.com/news/APGE/apogee-therapeutics-launches-with-169-million-to-develop-potentially-best-in-class-therapi-apge-20221207monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-upcoming-investor-conferences-wve-20260601monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-supports-alphadetect-to-accelerate-detection-of-alpha-1-wve-20260519monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-at-2025-jefferies-global-healthcare-conference-wve-20250529monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-highlights-strategic-priorities-and-expected-2025-milestones-ahead-of-j-wve-20250113monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-submission-of-first-clinical-trial-application-for-wve-007-si-wve-20241223monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-approval-of-first-clinical-trial-application-for-restoraation-wve-20240430monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-upcoming-presentations-at-mda-conference-that-highlight-best--wve-20240227monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-proof-of-concept-preclinical-data-for-adar-editing-program-in-wve-20210602monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-highlights-pipeline-progress-and-expansion-leveraging-new-pn-backbone-c-wve-20210111monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-webcast-conference-call-of-second-quarter-2020-financial-results-on--wve-20200727monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-provides-timing-update-on-precision-hd-clinical-programs-wve-20190410monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-to-present-new-data-on-its-dmd-exon-53-skipping-program-and-discovery-p-wve-20180920monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-initiates-clinical-development-of-wve-210201-in-patients-with-duchenne--wve-20180711monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-initiates-two-phase-1b-2a-clinical-trials-precision-hd1-and-precision-h-wve-20170724monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-receives-orphan-drug-designation-from-fda-for-its-lead-candidate-design-wve-20160621monthly0.5https://www.biopharmawatch.com/news/WVE/wave-life-sciences-announces-pricing-of-initial-public-offering-wve-20151111monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-pricing-of-initial-public-offering-zyme-20170428monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-closing-of-initial-public-offering-zyme-20170503monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-thanks-resigning-directors-for-their-service-zyme-20170510monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-reports-first-quarter-2017-financial-results-zyme-20170516monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-at-the-2017-american-society-of-clinical-oncology-annual-meeting-zyme-20170518monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-partial-exercise-of-over-allotment-option-for-its-initial-public-offer-zyme-20170526monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-closing-of-partial-exercise-of-over-allotment-option-for-its-initial-p-zyme-20170531monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-presents-safety-and-anti-tumor-activity-data-from-the-ongoing-phase-1-study-of-z-zyme-20170607monthly0.5https://www.biopharmawatch.com/news/ZYME/drug-candidates-developed-using-zymeworks-azymetric-platform-nominated-for-late-stage-prec-zyme-20170612monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-and-daiichi-sankyo-announce-successful-achievement-of-a-research-milestone-in-bi-zyme-20170718monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-at-37-th-annual-canaccord-genuity-growth-conference-zyme-20170804monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-host-second-quarter-2017-financial-results-conference-call-on-august-8-2017-zyme-20170804monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-reports-second-quarter-2017-financial-results-zyme-20170808monthly0.5https://www.biopharmawatch.com/news/ZYME/management-s-discussion-and-analysis-of-zyme-20170809monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-at-the-european-society-for-medical-oncology-2017-congress-and-hold-w-zyme-20170906monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-presents-additional-safety-and-anti-tumor-activity-data-from-the-ongoing-phase-1-zyme-20170911monthly0.5https://www.biopharmawatch.com/news/ZYME/merck-to-advance-bispecific-antibody-drug-candidate-developed-using-zymeworks-azymetric-pl-zyme-20170919monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-reports-third-quarter-2017-financial-results-and-provides-business-update-zyme-20171108monthly0.5https://www.biopharmawatch.com/news/ZYME/management-s-discussion-and-analysis-of-zyme-20171108monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-at-upcoming-2017-stifel-healthcare-conference-zyme-20171113monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-license-agreement-with-johnson-johnson-innovation-to-develop-and-comme-zyme-20171113monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-presents-results-of-the-completed-dose-escalation-portion-of-the-ongoing-phase-1-zyme-20171205monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-highlights-key-2017-accomplishments-and-announces-2018-priorities-lead-asset-zw2-zyme-20180108monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-opening-clinical-sites-in-canada-zyme-20180228monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-at-barclays-2018-global-healthcare-conference-zyme-20180307monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-reports-2017-year-end-financial-results-zyme-20180314monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-presents-preclinical-data-at-the-annual-meeting-of-the-american-association-for--zyme-20180418monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-and-celgene-expand-bispecific-antibody-collaboration-zyme-20180423monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-selection-of-zw25-abstract-for-oral-presentation-at-the-american-socie-zyme-20180425monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-at-bloom-burton-co-healthcare-investor-conference-2018-zyme-20180430monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-reports-2018-first-quarter-financial-results-zyme-20180501monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-at-the-ubs-global-healthcare-conference-2018-zyme-20180510monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-and-daiichi-sankyo-expand-immuno-oncology-collaboration-focused-on-bispecific-an-zyme-20180518monthly0.5https://www.biopharmawatch.com/news/ZYME/clinical-data-for-zymeworks-novel-bispecific-antibody-zw25-presented-at-the-american-socie-zyme-20180601monthly0.5https://www.biopharmawatch.com/news/ZYME/material-change-report-zyme-20180607monthly0.5https://www.biopharmawatch.com/news/ZYME/annual-general-and-special-meeting-of-shareholders-zyme-20180608monthly0.5https://www.biopharmawatch.com/news/ZYME/5-400-000-common-shares-zyme-20180608monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-closes-previously-announced-public-offering-zyme-20180614monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-reports-financial-results-for-the-second-quarter-of-2018-zyme-20180801monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-at-canaccord-genuity-38th-annual-growth-conference-zyme-20180802monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-at-wells-fargo-healthcare-conference-zyme-20180829monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-reports-ind-submission-milestone-achieved-in-lilly-collaboration-zyme-20180904monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-names-anthony-polverino-ph-d-executive-vice-president-of-early-development-and-c-zyme-20180919monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-at-ladenburg-thalmann-2018-healthcare-conference-zyme-20180925monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-webcast-r-d-briefing-zyme-20181004monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-and-leo-pharma-enter-into-bispecific-antibody-licensing-and-research-collaborati-zyme-20181026monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-selection-of-zw25-abstract-for-plenary-session-presentation-at-the-30--zyme-20181030monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-reports-financial-results-for-the-third-quarter-of-2018-zyme-20181106monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-at-upcoming-investor-conferences-zyme-20181107monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-updated-clinical-data-for-novel-bispecific-antibody-zyme-20181114monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-and-beigene-announce-license-and-collaboration-agreement-for-zymeworks-her2-targ-zyme-20181127monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-submits-investigational-new-drug-ind-application-for-zw49-and-presents-ind-enabl-zyme-20181210monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-highlights-2018-achievements-and-announces-2019-priorities-zyme-20190107monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-reports-second-investigational-new-drug-ind-submission-zyme-20190117monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-at-barclays-2019-global-healthcare-conference-zyme-20190305monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-reports-2018-year-end-financial-results-zyme-20190306monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-opens-phase-2-clinical-trial-for-zw25-in-first-line-her2-expressing-metastatic-g-zyme-20190415monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-at-bloom-burton-co-healthcare-investor-conference-2019-zyme-20190423monthly0.5https://www.biopharmawatch.com/news/ZYME/daiichi-sankyo-selects-lead-candidate-built-on-zymeworks-azymetric-bispecific-platform-zyme-20190425monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-adds-experienced-executives-to-management-team-to-support-expanding-clinical-dev-zyme-20190430monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-reports-2019-first-quarter-financial-results-zyme-20190502monthly0.5https://www.biopharmawatch.com/news/ZYME/annual-general-meeting-of-shareholders-zyme-20190503monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-enters-its-first-zymelink-tm-antibody-drug-conjugate-platform-licensing-agreemen-zyme-20190515monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-and-gsk-expand-2016-azymetric-tm-bispecific-agreement-zyme-20190517monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-corporate-update-conference-call-zyme-20190524monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-at-jefferies-2019-global-healthcare-conference-zyme-20190528monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-earns-milestone-payment-in-merck-collaboration-zyme-20190529monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-lead-asset-zw25-granted-fast-track-designation-from-the-fda-zyme-20190530monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-adds-accomplished-biopharmaceutical-executives-to-its-board-of-directors-zyme-20190605monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-at-raymond-james-life-sciences-and-medtech-conference-zyme-20190613monthly0.5https://www.biopharmawatch.com/news/ZYME/5-555-556-common-shares-zyme-20190620monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-closing-of-public-offering-and-exercise-in-full-of-the-underwriters-ov-zyme-20190625monthly0.5https://www.biopharmawatch.com/news/ZYME/celgene-selects-lead-oncology-therapeutic-candidate-under-bispecific-antibody-collaboratio-zyme-20190716monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-reports-2019-second-quarter-financial-results-zyme-20190802monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-participate-in-upcoming-investor-conferences-zyme-20190828monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-new-chair-of-board-of-directors-and-voluntary-delisting-from-the-tsx-zyme-20190918monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-updated-single-agent-data-for-her2-targeted-bispecific-zyme-20190930monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-appoints-chief-people-officer-zyme-20191016monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-phase-1-data-for-zw25-in-combination-with-zyme-20191028monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-at-stifel-2019-healthcare-conference-zyme-20191104monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-reports-2019-third-quarter-financial-results-zyme-20191105monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-files-automatic-shelf-registration-statement-and-enters-into-at-the-market-equit-zyme-20191106monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-selection-of-zw25-abstract-for-mini-oral-presentation-at-the-european--zyme-20191118monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-highlights-advancing-clinical-collaboration-with-beigene-and-zyme-20191122monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-at-the-j-p-morgan-healthcare-conference-2020-zyme-20200107monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-agreement-with-pfizer-and-initiation-of-a-new-phase-2-trial-evaluating-zyme-20200113monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-files-preliminary-prospectus-supplements-for-offering-of-common-shares-and-pre-f-zyme-20200124monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-closing-of-public-offering-and-exercise-in-full-of-the-underwriters-ov-zyme-20200127monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-at-raymond-james-41-st-annual-institutional-investors-conference-zyme-20200224monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-reports-2019-year-end-financial-results-zyme-20200302monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-appoints-dr-kelvin-neu-to-the-board-of-directors-zyme-20200316monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-first-patient-dosed-in-phase-1b-2-trial-of-zw25-in-first-line-her2-pos-zyme-20200401monthly0.5https://www.biopharmawatch.com/news/ZYME/document-zymeworks-reports-2020-first-quarter-financial-results-zyme-20200507monthly0.5https://www.biopharmawatch.com/news/ZYME/annual-general-meeting-of-shareholders-zyme-20200508monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-at-the-jefferies-2020-virtual-healthcare-conference-zyme-20200528monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-corporate-update-webcast-and-conference-call-zyme-20200630monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-new-multispecific-antibody-collaboration-with-merck-zyme-20200708monthly0.5https://www.biopharmawatch.com/news/ZYME/corporate-update-webcast-and-conference-call-summary-zyme-20200709monthly0.5https://www.biopharmawatch.com/news/ZYME/document-zymeworks-reports-2020-second-quarter-financial-results-zyme-20200805monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-at-upcoming-investor-conferences-zyme-20200903monthly0.5https://www.biopharmawatch.com/news/ZYME/document-zymeworks-reports-2020-third-quarter-financial-results-zyme-20201103monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-at-upcoming-investor-conferences-zyme-20201110monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-and-alx-oncology-announce-clinical-collaboration-evaluating-zanidatamab-with-the-zyme-20201116monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-receives-orphan-drug-designation-from-the-european-commission-for-her2-targeted--zyme-20201119monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-receives-fda-breakthrough-therapy-designation-for-her2-targeted-bispecific-antib-zyme-20201130monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-expansion-of-zanidatamab-pivotal-trial-in-her2-amplified-biliary-tract-zyme-20201201monthly0.5https://www.biopharmawatch.com/news/ZYME/exelixis-in-licenses-iconic-therapeutics-tissue-factor-targeting-antibody-drug-conjugate-a-zyme-20201202monthly0.5https://www.biopharmawatch.com/news/ZYME/zanidatamab-clinical-data-selected-for-oral-presentation-at-the-american-society-of-clinic-zyme-20201210monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-at-j-p-morgan-healthcare-conference-and-host-two-webcasts-in-january--zyme-20210107monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-highlights-2020-achievements-and-announces-corporate-priorities-zyme-20210111monthly0.5https://www.biopharmawatch.com/news/ZYME/zanidatamab-data-highlight-durable-antitumor-activity-in-her2-expressing-biliary-tract-and-zyme-20210115monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-advances-her2-bispecific-antibody-drug-conjugate-zw49-into-expansion-cohort-stag-zyme-20210128monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-participate-in-upcoming-investor-conferences-and-events-zyme-20210210monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-expands-commercial-team-and-creates-new-r-d-role-zyme-20210210monthly0.5https://www.biopharmawatch.com/news/ZYME/document-zymeworks-reports-2020-year-end-financial-results-zyme-20210224monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-five-presentations-at-the-american-association-for-cancer-research-aac-zyme-20210311monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-showcases-preclinical-assets-including-new-therapeutic-platform-protect-and-zani-zyme-20210412monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-at-bloom-burton-healthcare-conference-zyme-20210413monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-succession-plan-for-chief-medical-officer-zyme-20210419monthly0.5https://www.biopharmawatch.com/news/ZYME/document-zymeworks-reports-2021-first-quarter-financial-results-zyme-20210505monthly0.5https://www.biopharmawatch.com/news/ZYME/annual-general-meeting-of-shareholders-zyme-20210506monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-at-jefferies-virtual-healthcare-conference-zyme-20210526monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-at-ladenburg-thalmann-healthcare-conference-zyme-20210708monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-first-patient-with-advanced-her2-positive-breast-cancer-dosed-with-zan-zyme-20210728monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-milestone-payment-as-janssen-achieves-first-patient-dosed-for-its-bisp-zyme-20210803monthly0.5https://www.biopharmawatch.com/news/ZYME/document-zymeworks-reports-2021-second-quarter-financial-results-zyme-20210804monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-abstract-for-zanidatamab-in-first-line-her2-expressing-gastroesophagea-zyme-20210913monthly0.5https://www.biopharmawatch.com/news/ZYME/zanidatamab-phase-2-clinical-trial-demonstrates-promising-response-rate-and-durability-in--zyme-20210916monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-and-alx-oncology-announce-first-patient-dosed-in-phase-1b-2-clinical-trial-of-za-zyme-20211005monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-webcast-to-present-herizon-gea-01-pivotal-trial-design-and-zanidatamab-zyme-20211026monthly0.5https://www.biopharmawatch.com/news/ZYME/document-zymeworks-reports-2021-third-quarter-financial-results-zyme-20211103monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-at-upcoming-investor-conferences-zyme-20211108monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-launches-global-phase-3-zanidatamab-trial-in-first-line-her2-positive-gastroesop-zyme-20211109monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-abstract-for-zanidatamab-in-late-line-her2-positive-breast-cancer-at-t-zyme-20211119monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-second-janssen-bispecific-antibody-to-begin-clinical-development-utili-zyme-20211201monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-expansion-of-zanidatamab-pivotal-trial-in-asia-in-collaboration-with-b-zyme-20211209monthly0.5https://www.biopharmawatch.com/news/ZYME/zanidatamab-data-presented-at-the-san-antonio-breast-cancer-symposium-sabcs-demonstrate-en-zyme-20211209monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-names-biotechnology-industry-leader-kenneth-galbraith-as-chair-and-ceo-to-succee-zyme-20220105monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-at-40th-annual-j-p-morgan-healthcare-conference-zyme-20220106monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-provides-corporate-update-on-key-strategic-priorities-and-outlook-for-2022-zyme-20220119monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-host-fourth-quarter-and-full-year-2021-results-conference-call-zyme-20220208monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-provides-corporate-update-and-reports-year-end-2021-financial-results-zyme-20220224monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-participation-in-upcoming-investor-conferences-zyme-20220303monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-participation-in-upcoming-investor-conferences-zyme-20220401monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-host-first-quarter-2022-results-conference-call-zyme-20220419monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-presentations-at-2022-american-society-of-clinical-oncology-asco-annua-zyme-20220427monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-reports-last-patient-enrolled-in-pivotal-study-of-zanidatamab-in-treatment-of-he-zyme-20220428monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-participation-in-upcoming-investor-conferences-zyme-20220502monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-trials-in-progress-poster-for-herizon-gea-01-at-esmo-gi-zyme-20220518monthly0.5https://www.biopharmawatch.com/news/ZYME/clinical-data-demonstrating-promising-antitumor-activity-with-zanidatamab-in-1l-setting-of-zyme-20220526monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-participation-in-upcoming-investor-conference-zyme-20220527monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-appoints-dr-paul-moore-as-chief-scientific-officer-zyme-20220627monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-statement-on-u-s-supreme-court-overturning-roe-v-wade-zyme-20220711monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-host-second-quarter-results-conference-call-zyme-20220721monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-oral-presentation-of-data-from-phase-1-study-of-zanidatamab-zovodotin--zyme-20220725monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-participation-in-upcoming-investor-conferences-zyme-20220801monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-provides-corporate-update-and-reports-second-quarter-2022-financial-results-zyme-20220804monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-release-of-esmo-abstract-for-phase-1-study-of-zanidatamab-zovodotin-zw-zyme-20220904monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-reports-preliminary-phase-1-trial-results-for-zanidatamab-zovodotin-zw49-at-euro-zyme-20220912monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-participation-in-upcoming-investor-conferences-and-early-research-deve-zyme-20221004monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-preclinical-data-at-the-society-for-immunotherapy-of-cancer-sitc-conf-zyme-20221005monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-early-r-d-day-highlights-progress-in-development-of-novel-pipeline-assets-and-ap-zyme-20221020monthly0.5https://www.biopharmawatch.com/news/ZYME/november-is-stomach-cancer-awareness-month-zyme-20221101monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-presents-preclinical-data-on-tlr7-isacs-technology-at-the-society-for-immunother-zyme-20221110monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-abstract-for-zanidatamab-in-late-line-her2-positive-metastatic-breast--zyme-20221121monthly0.5https://www.biopharmawatch.com/news/ZYME/zanidatamab-clinical-data-selected-for-presentation-at-the-american-society-of-clinical-on-zyme-20221214monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-provides-corporate-update-on-key-strategic-priorities-and-outlook-for-2023-zyme-20230104monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-abstract-for-zanidatamab-in-her2-expressing-metastatic-gastroesophagea-zyme-20230117monthly0.5https://www.biopharmawatch.com/news/ZYME/jazz-pharmaceuticals-and-zymeworks-announce-84-overall-survival-at-18-months-from-phase-2--zyme-20230119monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-participation-in-upcoming-investor-conferences-zyme-20230125monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-host-fourth-quarter-and-full-year-2022-results-conference-call-zyme-20230221monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-participation-in-upcoming-investor-conferences-zyme-20230228monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-reports-fourth-quarter-and-full-year-2022-financial-results-zyme-20230307monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-updated-data-on-multiple-product-candidates-at-the-american-associati-zyme-20230314monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-participation-in-upcoming-investor-conferences-zyme-20230403monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-host-first-quarter-2023-results-conference-call-zyme-20230417monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-participation-in-upcoming-investor-conferences-zyme-20230501monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-provides-corporate-update-and-reports-first-quarter-2023-financial-results-zyme-20230508monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-showcases-new-and-updated-clinical-data-for-zanidatamab-at-asco-2023-zyme-20230525monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-participation-in-upcoming-investor-conferences-zyme-20230601monthly0.5https://www.biopharmawatch.com/news/ZYME/jazz-pharmaceuticals-and-zymeworks-present-positive-pivotal-phase-2b-trial-data-at-asco-20-zyme-20230602monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-set-to-join-russell-3000-russell-2000-and-russell-microcap-indexes-zyme-20230626monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-appoints-new-director-zyme-20230629monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-participation-in-upcoming-investor-conference-zyme-20230703monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-host-second-quarter-2023-results-conference-call-zyme-20230719monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-participation-in-upcoming-investor-conferences-zyme-20230801monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-provides-corporate-update-and-reports-second-quarter-2023-financial-results-zyme-20230810monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-on-clinical-and-preclinical-programs-at-multiple-upcoming-medical-con-zyme-20230927monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-new-director-nominee-zyme-20231016monthly0.5https://www.biopharmawatch.com/news/ZYME/jazz-pharmaceuticals-to-showcase-growing-impact-in-solid-tumor-oncology-research-at-esmo-2-zyme-20231016monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-host-third-quarter-2023-results-conference-call-zyme-20231017monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-showcases-updated-clinical-data-for-zanidatamab-at-the-2023-esmo-annual-congress-zyme-20231020monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-participation-in-upcoming-investor-conferences-zyme-20231101monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-presents-preclinical-data-on-trispecific-t-cell-engager-therapeutic-programs-at--zyme-20231104monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-provides-corporate-update-and-reports-third-quarter-2023-financial-results-zyme-20231107monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-participation-in-upcoming-investor-conference-zyme-20231130monthly0.5https://www.biopharmawatch.com/news/ZYME/updated-phase-2a-data-showcasing-potential-of-zanidatamab-in-her2-hr-metastatic-breast-can-zyme-20231208monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-added-to-nasdaq-biotechnology-index-zyme-20231215monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-outlines-strategic-priorities-and-outlook-for-2024-and-2025-zyme-20240104monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-additional-leadership-appointments-zyme-20240104monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-participation-in-upcoming-investor-conferences-zyme-20240131monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-host-fourth-quarter-and-full-year-2023-results-conference-call-zyme-20240214monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-participation-in-upcoming-investor-conferences-zyme-20240227monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-preclinical-data-on-antibody-drug-conjugate-and-multispecific-platfor-zyme-20240305monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-reports-fourth-quarter-and-full-year-2023-financial-results-zyme-20240306monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-participation-in-upcoming-investor-conferences-zyme-20240327monthly0.5https://www.biopharmawatch.com/news/ZYME/zanidatamab-biologics-license-application-for-previously-treated-her2-positive-metastatic--zyme-20240402monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-presents-new-data-from-multiple-preclinical-development-programs-at-2024-america-zyme-20240408monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-report-first-quarter-2024-financial-results-and-host-conference-call-on-may-2-zyme-20240411monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-participation-in-upcoming-investor-conferences-zyme-20240430monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-provides-corporate-update-and-reports-first-quarter-2024-financial-results-zyme-20240502monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-participation-in-upcoming-investor-conferences-zyme-20240528monthly0.5https://www.biopharmawatch.com/news/ZYME/zanidatamab-granted-priority-review-for-her2-positive-metastatic-biliary-tract-cancer-zyme-20240529monthly0.5https://www.biopharmawatch.com/news/ZYME/introducing-pride-in-biotech-zyme-20240529monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-china-nmpa-acceptance-of-biologics-license-application-for-zanidatamab-zyme-20240610monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-fda-clearance-of-investigational-new-drug-application-for-zw171-a-nove-zyme-20240617monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-report-second-quarter-2024-financial-results-and-host-conference-call-on-augu-zyme-20240711monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-fda-clearance-of-investigational-new-drug-application-for-zw191-a-nove-zyme-20240722monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-participation-in-upcoming-investor-conferences-zyme-20240730monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-provides-corporate-update-and-reports-second-quarter-2024-financial-results-zyme-20240801monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-participation-in-upcoming-investor-conferences-zyme-20240822monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-showcases-new-and-updated-clinical-data-for-zanidatamab-at-esmo-2024-zyme-20240909monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-presents-updated-phase-2-data-for-zanidatamab-demonstrating-increased-mpfs-in-he-zyme-20240916monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-preclinical-data-on-antibody-drug-conjugate-programs-at-eortc-nci-aac-zyme-20240918monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-upcoming-scientific-presentation-at-the-society-for-immunotherapy-of-c-zyme-20241007monthly0.5https://www.biopharmawatch.com/news/ZYME/dr-raffaele-colombo-honored-as-a-pharmavoice-100-winner-zyme-20241008monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-presents-new-preclinical-data-on-antibody-drug-conjugate-programs-at-eortc-nci-a-zyme-20241009monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-report-third-quarter-2024-financial-results-and-host-conference-call-on-octob-zyme-20241010monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-first-patient-dosed-in-phase-1-clinical-trial-evaluating-zw171-in-adva-zyme-20241021monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-presents-new-preclinical-data-on-antibody-drug-conjugate-programs-at-eortc-nci-a-zyme-20241025monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-participation-in-upcoming-investor-conferences-zyme-20241029monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-provides-corporate-update-and-reports-third-quarter-2024-financial-results-zyme-20241031monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-first-patient-dosed-in-phase-1-clinical-trial-evaluating-zw191-in-fola-zyme-20241105monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-presents-preclinical-data-on-zw171-at-the-society-for-immunotherapy-of-cancer-si-zyme-20241107monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-participation-in-upcoming-investor-conferences-zyme-20241121monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-hosts-r-d-day-highlighting-continued-clinical-progress-in-oncology-programs-and--zyme-20241212monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-outlines-strategic-priorities-and-outlook-for-2025-and-2026-zyme-20250108monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-participation-in-upcoming-investor-conferences-zyme-20250130monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-report-fourth-quarter-and-full-year-2024-financial-results-and-host-conferenc-zyme-20250213monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-participation-in-upcoming-investor-conferences-zyme-20250225monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-achievement-of-14-million-milestone-from-gsk-collaboration-zyme-20250226monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2024-financia-zyme-20250305monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-preclinical-data-on-t-cell-engager-and-antibody-drug-conjugate-platfo-zyme-20250325monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-participation-in-upcoming-investor-conferences-zyme-20250326monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-preclinical-data-on-zw1528-at-the-american-thoracic-society-annual-me-zyme-20250331monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-report-first-quarter-2025-financial-results-and-host-conference-call-on-may-8-zyme-20250417monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-appoints-dr-sabeen-mekan-as-senior-vice-president-clinical-development-zyme-20250421monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-presents-new-data-from-multiple-development-programs-at-2025-aacr-annual-meeting-zyme-20250425monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-provides-corporate-update-and-reports-first-quarter-2025-financial-results-zyme-20250508monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-presents-preclinical-data-on-zw1528-at-the-american-thoracic-society-internation-zyme-20250519monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-participation-in-upcoming-investor-conferences-zyme-20250521monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-presentations-highlighting-breadth-of-oncology-portfolio-at-upcoming-m-zyme-20250522monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-wins-life-sciences-bc-2025-company-of-the-year-award-zyme-20250710monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-report-second-quarter-2025-financial-results-and-host-conference-call-on-augu-zyme-20250717monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-fda-clearance-of-investigational-new-drug-application-for-zw251-a-nove-zyme-20250728monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-provides-corporate-update-and-reports-second-quarter-2025-financial-results-zyme-20250807monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-participation-in-upcoming-investor-conferences-zyme-20250819monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-presentation-at-the-european-respiratory-society-ers-congress-2025-zyme-20250915monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-presents-preclinical-data-on-zw1528-at-the-european-respiratory-society-annual-c-zyme-20250926monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-upcoming-scientific-presentations-at-the-society-for-immunotherapy-of--zyme-20251007monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-appoints-dr-adam-schayowitz-as-acting-chief-development-officer-zyme-20251009monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-clinical-data-from-the-phase-1-trial-of-zw191-an-antibody-drug-conjug-zyme-20251013monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-report-third-quarter-2025-financial-results-and-host-conference-call-on-novem-zyme-20251016monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-presents-initial-clinical-data-from-the-phase-1-trial-of-zw191-an-antibody-drug--zyme-20251023monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-participation-in-upcoming-investor-conferences-zyme-20251028monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-presents-new-preclinical-data-at-the-society-for-immunotherapy-of-cancer-confere-zyme-20251104monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-provides-corporate-update-and-reports-third-quarter-2025-financial-results-zyme-20251106monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-appoints-scott-platshon-as-acting-chief-investment-officer-zyme-20251118monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-participation-in-upcoming-conferences-zyme-20251202monthly0.5https://www.biopharmawatch.com/news/ZYME/ziihera-zanidatamab-hrii-combinations-achieve-unprecedented-results-in-first-line-her2-loc-zyme-20260106monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-outlines-strategic-priorities-and-outlook-for-2026-zyme-20260111monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-leadership-appointments-and-transitions-to-align-with-evolution-of-cor-zyme-20260112monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-presentations-for-ziihera-zanidatamab-hrii-at-2026-aacr-annual-meeting-zyme-20260318monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-at-the-aacr-oncology-industry-partnering-event-zyme-20260409monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth-zyme-20260409monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-presents-new-preclinical-data-at-aacr-2026-highlighting-broad-antibody-drug-conj-zyme-20260417monthly0.5https://www.biopharmawatch.com/news/ZYME/jazz-pharmaceuticals-announces-fda-acceptance-and-priority-review-of-supplemental-biologic-zyme-20260427monthly0.5https://www.biopharmawatch.com/news/ZYME/u-s-fda-grants-priority-review-to-beone-medicines-tevimbra-in-first-line-her2-gea-zyme-20260429monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-provides-corporate-update-and-reports-first-quarter-2026-financial-results-zyme-20260507monthly0.5https://www.biopharmawatch.com/news/ZYME/zymeworks-to-present-at-respiratory-innovation-summit-zyme-20260508monthly0.5https://www.biopharmawatch.com/news/ZYME/beone-medicines-announces-phase-3-herizon-gea-data-published-in-nejm-and-presented-at-asco-zyme-20260527monthly0.5https://www.biopharmawatch.com/news/ZYME/phase-3-herizon-gea-01-results-published-in-the-new-england-journal-of-medicine-show-durab-zyme-20260527monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-provides-business-update-at-investor-meeting-biib-20080107monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-announces-appointment-of-nancy-l-leaming-to-board-of-directors-biib-20080110monthly0.5https://www.biopharmawatch.com/news/BIIB/fda-approves-tysabri-r-for-the-treatment-of-moderate-to-severe-crohn-039-s-disease-biib-20080114monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-wachovia-2008-healthcare-conference-biib-20080123monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-receives-director-nomination-proposal-biib-20080128monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-announces-webcast-of-presentation-at-the-merrill-lynch-global-pharmaceutical-b-biib-20080131monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-report-fourth-quarter-and-full-year-2007-financial-results-on-february-6-20-biib-20080206monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-reports-full-year-and-fourth-quarter-2007-results-biib-20080206monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-cardiokine-initiate-phase-iii-clinical-trial-for-lixivaptan-in-congestive--biib-20080214monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-prices-1-0-billion-senior-unsecured-notes-offering-biib-20080229monthly0.5https://www.biopharmawatch.com/news/BIIB/researchers-report-neublastin-virtually-restores-complete-long-term-sensory-motor-function-biib-20080324monthly0.5https://www.biopharmawatch.com/news/BIIB/genentech-and-biogen-idec-announce-top-line-results-from-a-phase-ii-iii-clinical-trial-of--biib-20080414monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-elan-present-new-tysabri-r-data-at-the-60th-annual-meeting-of-the-american-biib-20080415monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-announces-multiple-sclerosis-franchise-and-pipeline-presentations-at-the-60th--biib-20080415monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-announces-slate-of-directors-for-annual-meeting-of-shareholders-biib-20080417monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-report-first-quarter-2008-financial-results-on-april-23-2008-biib-20080423monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-reports-first-quarter-2008-results-biib-20080423monthly0.5https://www.biopharmawatch.com/news/BIIB/genentech-and-biogen-idec-announce-top-line-results-from-phase-ii-iii-clinical-study-of-ri-biib-20080429monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-commences-mailing-of-proxy-materials-to-shareholders-biib-20080508monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-celebrates-30-years-of-transforming-discovery-into-care-biib-20080519monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-names-hans-peter-hasler-chief-operating-officer-biib-20080529monthly0.5https://www.biopharmawatch.com/news/BIIB/riskmetrics-and-glass-lewis-endorse-all-four-biogen-idec-director-nominees-biib-20080610monthly0.5https://www.biopharmawatch.com/news/BIIB/proxy-governance-endorses-all-four-biogen-idec-director-nominees-biib-20080611monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-stockholders-elect-company-039-s-board-nominees-biib-20080619monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-announces-certified-stockholder-vote-results-confirming-election-of-all-four-o-biib-20080709monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-elan-celebrate-second-anniversary-of-tysabri-r-for-the-treatment-of-multip-biib-20080722monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-report-second-quarter-2008-financial-results-on-july-22-2008-biib-20080722monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-reports-second-quarter-2008-results-biib-20080722monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-elan-will-host-a-conference-call-for-the-investment-community-biib-20080731monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-initiates-phase-iii-clinical-trial-for-adentri-r-in-acute-decompensated-heart--biib-20080821monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-thomas-weisel-partners-healthcare-conference-biib-20080826monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-3rd-annual-citi-biotech-day-biib-20080904monthly0.5https://www.biopharmawatch.com/news/BIIB/elan-and-biogen-idec-initiate-first-clinical-trial-of-tysabri-r-in-oncology-biib-20080905monthly0.5https://www.biopharmawatch.com/news/BIIB/new-long-term-data-show-that-patients-taking-avonex-r-for-up-to-15-years-experience-reduce-biib-20080918monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-features-data-on-avonex-r-and-tysabri-r-and-showcases-the-company-039-s-multip-biib-20080918monthly0.5https://www.biopharmawatch.com/news/BIIB/phase-iii-study-showed-rituxan-in-combination-with-chemotherapy-improved-progression-free--biib-20081007monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-announces-top-line-results-from-phase-ii-clinical-trial-of-baminercept-in-rheu-biib-20081009monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-reports-third-quarter-2008-results-biib-20081021monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-report-third-quarter-2008-financial-results-on-october-21-2008-biib-20081021monthly0.5https://www.biopharmawatch.com/news/BIIB/phase-iib-data-published-in-the-lancet-show-that-bg-12-biogen-idec-039-s-novel-oral-compou-biib-20081023monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-elects-to-participate-with-genentech-in-the-development-and-commercialization--biib-20081030monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-credit-suisse-2008-healthcare-conference-biib-20081107monthly0.5https://www.biopharmawatch.com/news/BIIB/rituxan-in-combination-with-chemotherapy-improves-progression-free-survival-in-difficult-t-biib-20081206monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-27th-annual-j-p-morgan-healthcare-conference-biib-20090106monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-report-fourth-quarter-and-full-year-2008-financial-results-on-february-6-20-biib-20090206monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-receives-shareholder-proposal-biib-20090206monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-reports-full-year-and-fourth-quarter-2008-results-biib-20090206monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-names-michael-lytton-executive-vice-president-of-business-development-biib-20090223monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-cowen-amp-company-29th-annual-healthcare-conference-biib-20090310monthly0.5https://www.biopharmawatch.com/news/BIIB/phase-iii-study-of-rituxan-in-lupus-nephritis-did-not-meet-primary-endpoint-biib-20090311monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-announces-march-25-webcast-of-research-amp-development-day-biib-20090318monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-highlights-progress-and-breadth-of-pipeline-programs-at-r-amp-d-day-biib-20090325monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-4-th-annual-citi-biotech-day-biib-20090330monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-showcases-leading-multiple-sclerosis-franchise-and-pipeline-at-the-61st-annual-biib-20090415monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-reports-first-quarter-2009-results-biib-20090416monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-board-recommends-shareholders-elect-directors-with-record-of-success-in-enhanc-biib-20090427monthly0.5https://www.biopharmawatch.com/news/BIIB/mri-data-showing-tysabri-promoted-remyelination-presented-at-the-61st-annual-meeting-of-th-biib-20090428monthly0.5https://www.biopharmawatch.com/news/BIIB/first-ten-year-follow-up-shows-that-treatment-with-avonex-leads-to-long-term-benefits-in-e-biib-20090430monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-deutsche-bank-34th-annual-health-care-conference-biib-20090514monthly0.5https://www.biopharmawatch.com/news/BIIB/genentech-and-biogen-idec-submit-applications-to-the-fda-for-rituxan-for-most-common-type--biib-20090519monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-comments-on-proxy-advisory-firms-reports-biib-20090524monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-sends-letter-to-stockholders-biib-20090526monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-joins-with-the-global-ms-community-to-mark-world-ms-day-biib-20090527monthly0.5https://www.biopharmawatch.com/news/BIIB/subset-data-from-two-randomized-phase-3-trials-show-tysabri-significantly-improves-health--biib-20090531monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-announces-preliminary-tabulation-of-stockholder-vote-by-independent-inspector--biib-20090609monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-goldman-sachs-30th-annual-healthcare-conference-biib-20090609monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-announces-conclusion-of-arbitration-with-genentech-biib-20090616monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-announces-first-patient-enrolled-in-the-global-phase-iii-study-of-pegylated-in-biib-20090622monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-acorda-therapeutics-announce-collaboration-agreement-to-develop-and-commer-biib-20090701monthly0.5https://www.biopharmawatch.com/news/BIIB/phillip-a-sharp-to-retire-from-biogen-idec-board-biib-20090716monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-report-second-quarter-2009-financial-results-on-july-16-2009-biib-20090716monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-thomas-weisel-partners-healthcare-conference-biib-20090902monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-announces-proposal-to-acquire-all-outstanding-shares-of-facet-for-14-50-per-sh-biib-20090904monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-foundation-announces-1-million-gift-to-north-carolina-biotechnology-center-biib-20090909monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-morgan-stanley-global-healthcare-unplugged-conference-biib-20090910monthly0.5https://www.biopharmawatch.com/news/BIIB/data-supporting-unique-efficacy-of-tysabri-presented-at-the-25th-congress-of-the-european--biib-20090911monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-commences-tender-offer-for-facet-biotech-biib-20090921monthly0.5https://www.biopharmawatch.com/news/BIIB/elan-to-highlight-tysabri-data-in-crohn-s-disease-at-the-american-college-of-gastroenterol-biib-20091019monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-report-third-quarter-2009-financial-results-on-october-20-2009-biib-20091020monthly0.5https://www.biopharmawatch.com/news/BIIB/subset-data-from-two-randomized-phase-3-trials-show-tysabri-significantly-reduces-rates-of-biib-20091027monthly0.5https://www.biopharmawatch.com/news/BIIB/correcting-and-replacing-biogen-idec-to-present-at-the-2009-annual-credit-suisse-healthcar-biib-20091110monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-lazard-capital-markets-6th-annual-healthcare-conference-biib-20091110monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-increases-offer-to-acquire-facet-biotech-to-17-50-per-share-in-cash-sends-lett-biib-20091203monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-2009-deutsche-bank-biotech-boston-confab-biib-20091210monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-stands-ready-to-close-its-17-50-all-cash-tender-offer-for-facet-biotech-biib-20091215monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-announces-president-and-chief-executive-officer-james-c-mullen-to-retire-biib-20100104monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-goldman-sachs-healthcare-ceos-unscripted-2010-a-view-from-th-biib-20100104monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-28th-annual-j-p-morgan-healthcare-conference-biib-20100105monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-adds-senior-leadership-to-commercial-and-medical-operations-biib-20100107monthly0.5https://www.biopharmawatch.com/news/BIIB/world-renowned-yogi-baron-baptiste-unveils-new-program-to-help-people-with-multiple-sclero-biib-20100111monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-submits-application-in-europe-for-the-approval-of-fampridine-pr-tablets-to-imp-biib-20100112monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-issues-statement-on-u-s-approval-of-ampyra-dalfampridine-biib-20100123monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-receives-notice-of-intention-to-nominate-directors-at-2010-meeting-of-sharehol-biib-20100128monthly0.5https://www.biopharmawatch.com/news/BIIB/multiple-sclerosis-experts-join-biogen-idec-s-research-and-development-team-biib-20100208monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-report-fourth-quarter-and-full-year-2009-financial-results-on-february-9-20-biib-20100209monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-reports-full-year-and-fourth-quarter-2009-results-biib-20100209monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-swedish-orphan-biovitrum-update-hemophilia-partnership-agreement-biib-20100218monthly0.5https://www.biopharmawatch.com/news/BIIB/fda-approves-rituxan-plus-chemotherapy-for-the-most-common-type-of-adult-leukemia-biib-20100218monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-cowen-and-company-30th-annual-health-care-conference-biib-20100305monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-barclays-capital-2010-global-healthcare-conference-biib-20100319monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-appoints-eric-rowinsky-and-stephen-sherwin-to-board-of-directors-pursuant-to-a-biib-20100322monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-elan-enroll-first-patient-in-large-well-controlled-head-to-head-study-of-m-biib-20100325monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-strengthens-position-as-a-leader-in-neurology-with-38-data-presentations-at-62-biib-20100405monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-report-first-quarter-2010-financial-results-on-april-20-2010-biib-20100420monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-reports-first-quarter-2010-results-tysabri-revenues-increase-32-year-over-year-biib-20100420monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-bank-of-america-merrill-lynch-2010-healthcare-conference-biib-20100506monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-2010-citi-investment-research-global-healthcare-conference-biib-20100521monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-abbott-announce-enrollment-of-first-patient-in-global-phase-iii-study-of-d-biib-20100524monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-2010-annual-shareholder-meeting-webcast-biib-20100604monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-provides-update-on-ceo-search-and-management-changes-biib-20100607monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-announces-enrollment-of-first-patient-in-phase-ii-bg-12-combination-trial-in-m-biib-20100615monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-swedish-orphan-biovitrum-announce-decision-to-advance-long-lasting-hemophi-biib-20100709monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-report-second-quarter-2010-financial-results-on-july-20-2010-biib-20100720monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-knopp-neurosciences-announce-license-agreement-for-late-stage-als-drug-can-biib-20100818monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-2010-morgan-stanley-global-healthcare-unplugged-conference-biib-20100908monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-stifel-nicolaus-2010-healthcare-conference-biib-20100909monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-2010-ubs-global-life-sciences-conference-biib-20100915monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-announces-webcast-of-hemophilia-r-amp-d-roundtable-biib-20100921monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-makes-statement-about-u-s-fda-approval-of-gilenya-biib-20100922monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-showcases-global-multiple-sclerosis-leadership-with-more-than-45-data-presenta-biib-20101006monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-report-third-quarter-2010-financial-results-on-october-26-2010-biib-20101026monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-lazard-capital-markets-7th-annual-healthcare-conference-biib-20101110monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-announces-webcast-of-neurodegeneration-amp-repair-r-amp-d-roundtable-biib-20101122monthly0.5https://www.biopharmawatch.com/news/BIIB/phase-iii-study-showed-rituxan-for-initial-use-followed-by-continued-use-delayed-the-need--biib-20101205monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-swedish-orphan-biovitrum-announce-first-patient-dosed-in-global-registrati-biib-20101206monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-awards-clinical-fellowship-program-grants-to-support-education-and-research-fo-biib-20101207monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-2010-deutsche-bank-biofest-biib-20101209monthly0.5https://www.biopharmawatch.com/news/BIIB/amanda-freitag-of-chopped-and-iron-chef-america-teams-up-with-multiple-sclerosis-nutrition-biib-20101217monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-neurimmune-announce-agreement-on-three-neurodegenerative-disease-programs-biib-20101220monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-elan-submit-applications-to-update-tysabri-labeling-that-may-help-stratify-biib-20101222monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-29th-annual-j-p-morgan-healthcare-conference-biib-20110105monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-report-fourth-quarter-and-year-end-2010-financial-results-on-february-1-201-biib-20110201monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-citi-2011-global-healthcare-conference-biib-20110224monthly0.5https://www.biopharmawatch.com/news/BIIB/chmp-recommends-updating-tysabri-labeling-with-anti-jc-virus-antibody-status-as-a-third-fa-biib-20110418monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-receives-positive-opinion-from-the-chmp-and-authorisation-from-health-canada-o-biib-20110419monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-reports-first-quarter-2011-results-biib-20110421monthly0.5https://www.biopharmawatch.com/news/BIIB/correcting-and-replacing-biogen-idec-to-report-first-quarter-2011-financial-results-on-apr-biib-20110421monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-deutsche-bank-36th-annual-healthcare-conference-biib-20110427monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-receives-approval-for-fampyra-in-australia-to-improve-walking-ability-in-adult-biib-20110516monthly0.5https://www.biopharmawatch.com/news/BIIB/european-medicines-agency-s-committee-for-medicinal-products-for-human-use-issues-positive-biib-20110520monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-launches-women-in-ms-educational-initiative-biib-20110524monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-celebrates-world-ms-day-biib-20110525monthly0.5https://www.biopharmawatch.com/news/BIIB/2-700-students-in-greater-boston-and-north-carolina-to-benefit-from-biogen-idec-foundation-biib-20110526monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-2011-annual-shareholder-meeting-webcast-biib-20110526monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-jefferies-2011-global-healthcare-conference-biib-20110601monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-goldman-sachs-32nd-annual-global-healthcare-conference-biib-20110601monthly0.5https://www.biopharmawatch.com/news/BIIB/correcting-and-replacing-biogen-idec-reports-positive-data-from-avonex-dose-titration-stud-biib-20110606monthly0.5https://www.biopharmawatch.com/news/BIIB/european-commission-approves-inclusion-of-anti-jc-virus-antibody-status-as-a-pml-risk-fact-biib-20110622monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-researchers-identify-novel-approach-for-promoting-remyelination-and-inhibiting-biib-20110703monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-report-second-quarter-2011-financial-results-on-july-26-2011-biib-20110726monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-reports-second-quarter-2011-results-biib-20110726monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-strengthens-ms-activesource-for-people-with-multiple-sclerosis-biib-20110727monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-abbott-announce-positive-top-line-results-from-the-first-registrational-tr-biib-20110809monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-stifel-nicolaus-2011-healthcare-conference-biib-20110830monthly0.5https://www.biopharmawatch.com/news/BIIB/more-than-1-000-biogen-idec-employees-across-the-globe-help-patients-communities-in-first--biib-20110930monthly0.5https://www.biopharmawatch.com/news/BIIB/data-presented-at-the-5th-joint-triennial-congress-of-ectrims-and-actrims-demonstrates-bio-biib-20111012monthly0.5https://www.biopharmawatch.com/news/BIIB/data-about-early-use-and-long-term-benefit-of-tysabri-presented-at-5th-joint-triennial-con-biib-20111019monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-elan-receive-notification-of-pdufa-date-extension-biib-20111020monthly0.5https://www.biopharmawatch.com/news/BIIB/oral-bg-12-dimethyl-fumarate-significantly-reduced-multiple-sclerosis-ms-relapses-and-disa-biib-20111021monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-announces-positive-top-line-results-from-second-phase-3-trial-investigating-or-biib-20111026monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-portola-pharmaceuticals-announce-global-collaboration-for-oral-syk-inhibit-biib-20111027monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-reports-third-quarter-2011-results-biib-20111028monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-2011-deutsche-bank-biofest-biib-20111130monthly0.5https://www.biopharmawatch.com/news/BIIB/samsung-and-biogen-idec-announce-joint-venture-to-develop-manufacture-and-market-biosimila-biib-20111205monthly0.5https://www.biopharmawatch.com/news/BIIB/ascend-study-to-evaluate-the-effectiveness-of-tysabri-natalizumab-as-a-treatment-for-secon-biib-20120126monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-appoints-kenneth-dipietro-executive-vice-president-human-resources-biib-20120130monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-acquire-stromedix-biib-20120214monthly0.5https://www.biopharmawatch.com/news/BIIB/samsung-biologics-and-biogen-idec-announce-formation-of-biosimilars-joint-venture-samsung--biib-20120227monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-submits-application-to-fda-for-approval-of-oral-bg-12-to-treat-multiple-sclero-biib-20120228monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-barclays-2012-global-healthcare-conference-biib-20120306monthly0.5https://www.biopharmawatch.com/news/BIIB/new-data-presented-at-64th-aan-annual-meeting-highlights-biogen-idec-s-commitment-to-deliv-biib-20120420monthly0.5https://www.biopharmawatch.com/news/BIIB/new-tysabri-data-presented-at-64th-annual-aan-meeting-highlight-biogen-idec-amp-elan-commi-biib-20120426monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-report-first-quarter-2012-financial-results-on-may-1-2012-biib-20120501monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-increases-revenue-7-to-1-3-billion-in-the-first-quarter-biib-20120501monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-deutsche-bank-37th-annual-healthcare-conference-biib-20120502monthly0.5https://www.biopharmawatch.com/news/BIIB/us-and-eu-regulatory-authorities-accept-oral-bg-12-marketing-applications-for-review-biib-20120509monthly0.5https://www.biopharmawatch.com/news/BIIB/new-avonex-dosing-innovations-for-people-with-multiple-sclerosis-now-available-in-us-biib-20120514monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-announces-collaboration-with-leading-research-institutions-to-sequence-genomes-biib-20120717monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-report-second-quarter-2012-financial-results-on-july-24-2012-biib-20120724monthly0.5https://www.biopharmawatch.com/news/BIIB/correcting-and-replacing-biogen-idec-increases-revenue-18-to-1-4-billion-in-the-second-qua-biib-20120724monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-stifel-nicolaus-healthcare-conference-2012-biib-20120829monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-sells-benlysta-royalty-rights-to-dri-capital-managed-fund-biib-20120910monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-employees-participate-in-80-volunteer-projects-in-22-countries-as-part-of-annu-biib-20120914monthly0.5https://www.biopharmawatch.com/news/BIIB/the-new-england-journal-of-medicine-publishes-pivotal-data-demonstrating-efficacy-and-safe-biib-20120919monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-sobi-announce-positive-top-line-results-from-phase-3-study-investigating-l-biib-20120926monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-s-commitment-to-ms-demonstrated-through-significant-scientific-data-being-pres-biib-20121010monthly0.5https://www.biopharmawatch.com/news/BIIB/tysabri-natalizumab-data-at-ectrims-reaffirm-positive-effects-of-treatment-for-people-with-biib-20121011monthly0.5https://www.biopharmawatch.com/news/BIIB/new-data-from-phase-3-studies-provide-additional-evidence-supporting-treatment-effect-for--biib-20121012monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-receives-notification-of-pdufa-date-extension-biib-20121018monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-increases-revenue-6-percent-to-1-4-billion-in-the-third-quarter-biib-20121025monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-sobi-announce-positive-top-line-results-from-phase-3-study-investigating-l-biib-20121031monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-credit-suisse-2012-annual-healthcare-conference-biib-20121107monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-opens-new-rtp-facility-biib-20121129monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-eisai-announce-manufacturing-alliance-at-research-triangle-park-facilities-biib-20121212monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-forms-first-of-its-kind-research-consortium-to-identify-als-drug-targets-biib-20121220monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-31st-annual-j-p-morgan-healthcare-conference-biib-20130102monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-reports-top-line-results-from-phase-3-trial-investigating-dexpramipexole-in-pe-biib-20130103monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-elan-submit-applications-for-first-line-use-of-tysabri-in-anti-jcv-antibod-biib-20130116monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-2012-revenue-increases-9-to-5-5-billion-biib-20130128monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-acquire-full-rights-and-control-of-tysabri-from-elan-for-upfront-cash-and-c-biib-20130206monthly0.5https://www.biopharmawatch.com/news/BIIB/new-phase-3-data-reinforce-long-lasting-protection-from-bleeding-for-patients-with-hemophi-biib-20130208monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-citi-2013-global-healthcare-conference-biib-20130219monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-2013-rbc-capital-markets-global-healthcare-conference-biib-20130220monthly0.5https://www.biopharmawatch.com/news/BIIB/fda-accepts-biogen-idec-s-biologics-license-application-for-first-long-lasting-factor-ix-t-biib-20130304monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-new-data-on-diverse-neurological-portfolio-at-65th-aan-annual-meeti-biib-20130306monthly0.5https://www.biopharmawatch.com/news/BIIB/adding-multimedia-new-tysabri-data-reaffirm-substantial-efficacy-in-treatment-of-people-wi-biib-20130318monthly0.5https://www.biopharmawatch.com/news/BIIB/us-patent-office-grants-patent-claiming-dosing-regimen-for-tecfidera-dimethyl-fumarate-biib-20130319monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-report-first-quarter-2013-financial-results-on-april-25-2013-biib-20130425monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-submits-application-to-fda-for-approval-of-plegridy-peginterferon-beta-1a-in-m-biib-20130521monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-deutsche-bank-38th-annual-dbaccess-healthcare-conference-biib-20130522monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-appoints-spyros-artavanis-tsakonas-chief-scientific-officer-biib-20130523monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-reinforces-commitment-to-ms-community-on-5th-annual-world-ms-day-biib-20130529monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-2013-annual-shareholder-meeting-webcast-biib-20130604monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-sobi-present-new-data-from-the-phase-3-study-of-their-long-lasting-hemophi-biib-20130702monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-delivers-double-digit-top-amp-bottom-line-growth-in-second-quarter-2013-biib-20130725monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-report-second-quarter-2013-financial-results-on-july-25-2013-biib-20130725monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-morgan-stanley-global-healthcare-conference-biib-20130829monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-stifel-nicolaus-2013-global-healthcare-conference-biib-20130903monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-foundation-awards-250-000-grant-to-citizen-schools-to-invest-in-science-educat-biib-20130904monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-isis-pharmaceuticals-announce-strategic-collaboration-to-advance-treatment-biib-20130909monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-extensive-new-data-from-its-robust-multiple-sclerosis-portfolio-at--biib-20130923monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-becomes-first-u-s-based-biotech-named-to-dow-jones-sustainability-world-index-biib-20130924monthly0.5https://www.biopharmawatch.com/news/BIIB/new-data-analyses-show-significant-clinical-and-mri-improvements-with-plegridy-peginterfer-biib-20131001monthly0.5https://www.biopharmawatch.com/news/BIIB/free-genetic-testing-initiative-to-be-available-nationally-at-hemophilia-treatment-centers-biib-20131002monthly0.5https://www.biopharmawatch.com/news/BIIB/new-tysabri-data-show-earlier-treatment-and-longer-term-use-result-in-significant-reductio-biib-20131003monthly0.5https://www.biopharmawatch.com/news/BIIB/new-tecfidera-dimethyl-fumarate-data-show-sustained-efficacy-and-long-term-safety-in-a-bro-biib-20131004monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-total-revenues-increased-32-to-1-8-billion-in-third-quarter-company-raises-201-biib-20131028monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-credit-suisse-healthcare-conference-biib-20131105monthly0.5https://www.biopharmawatch.com/news/BIIB/leading-hematology-journal-publishes-pivotal-eloctate-data-that-demonstrated-efficacy-and--biib-20131113monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-2013-deutsche-bank-biofest-biib-20131125monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-receives-notification-from-fda-of-pdufa-date-extension-for-alprolix-biib-20131202monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-samsung-bioepis-announce-agreement-to-market-anti-tnf-biosimilar-product-c-biib-20131217monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-32nd-annual-j-p-morgan-healthcare-conference-biib-20140107monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-sangamo-biosciences-announce-global-collaboration-to-develop-treatments-fo-biib-20140109monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-2013-total-revenues-increase-26-percent-to-6-9-billion-biib-20140129monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-report-fourth-quarter-and-year-end-2013-financial-results-on-january-29-201-biib-20140129monthly0.5https://www.biopharmawatch.com/news/BIIB/tecfidera-dimethyl-fumarate-approved-in-the-european-union-as-a-first-line-oral-treatment--biib-20140203monthly0.5https://www.biopharmawatch.com/news/BIIB/eisai-and-biogen-idec-enter-collaboration-to-develop-and-commercialize-alzheimer-s-disease-biib-20140305monthly0.5https://www.biopharmawatch.com/news/BIIB/health-canada-approves-biogen-idec-s-long-acting-alprolix-therapy-for-hemophilia-b-biib-20140321monthly0.5https://www.biopharmawatch.com/news/BIIB/fda-approves-biogen-idec-s-alprolix-the-first-hemophilia-b-therapy-to-reduce-bleeding-epis-biib-20140328monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-new-clinical-data-from-its-robust-neurology-portfolio-at-aan-annual-biib-20140414monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-report-first-quarter-2014-financial-results-on-april-23-2014-biib-20140423monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-new-two-year-data-from-the-plegridy-peginterferon-beta-1a-phase-3-a-biib-20140429monthly0.5https://www.biopharmawatch.com/news/BIIB/new-data-reinforce-efficacy-of-tecfidera-dimethyl-fumarate-in-ms-patients-with-high-diseas-biib-20140430monthly0.5https://www.biopharmawatch.com/news/BIIB/new-tysabri-analysis-at-aan-annual-meeting-shows-improved-walking-speed-in-significant-num-biib-20140501monthly0.5https://www.biopharmawatch.com/news/BIIB/richard-a-rudick-joins-biogen-idec-as-vice-president-development-sciences-value-based-medi-biib-20140512monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-sanford-bernstein-30th-annual-strategic-decisions-conference-biib-20140521monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-announces-official-partnership-with-sailing-sclerosis-oceans-of-hope-to-global-biib-20140528monthly0.5https://www.biopharmawatch.com/news/BIIB/data-from-biogen-idec-s-portfolio-of-multiple-sclerosis-therapies-and-pipeline-featured-at-biib-20140530monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-abbvie-announce-positive-top-line-results-from-phase-3-study-investigating-biib-20140616monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-yahoo-health-spotlight-visionaries-whose-work-benefits-people-with-multipl-biib-20140716monthly0.5https://www.biopharmawatch.com/news/BIIB/plegridy-peginterferon-beta-1a-approved-in-the-european-union-for-the-treatment-of-multipl-biib-20140723monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-s-plegridy-peginterferon-beta-1a-approved-in-the-us-for-the-treatment-of-multi-biib-20140815monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-names-adriana-karaboutis-evp-technology-and-business-solutions-biib-20140821monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-in-panel-at-the-citi-9th-annual-biotech-conference-biib-20140826monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-morgan-stanley-global-healthcare-conference-2014-biib-20140902monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-data-at-joint-actrims-ectrims-meeting-highlight-robust-multiple-sclerosis-port-biib-20140903monthly0.5https://www.biopharmawatch.com/news/BIIB/new-international-survey-finds-ms-patients-and-neurologists-view-communication-positively--biib-20140910monthly0.5https://www.biopharmawatch.com/news/BIIB/plegridy-peginterferon-beta-1a-two-year-data-confirm-maintenance-of-efficacy-and-safety-in-biib-20140911monthly0.5https://www.biopharmawatch.com/news/BIIB/detailed-results-from-biogen-idec-and-abbvie-s-pivotal-phase-3-decide-study-further-define-biib-20140912monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-named-global-biotechnology-industry-leader-on-dow-jones-sustainability-world-i-biib-20140923monthly0.5https://www.biopharmawatch.com/news/BIIB/olivier-danos-joins-biogen-idec-as-senior-vice-president-gene-therapy-biib-20140923monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-gretchen-rubin-unveil-ms-blueprinttm-a-new-online-tool-to-help-people-with-biib-20141015monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-third-quarter-2014-revenues-increase-37-to-2-5-billion-biib-20141022monthly0.5https://www.biopharmawatch.com/news/BIIB/correcting-and-replacing-biogen-idec-to-report-third-quarter-2014-financial-results-on-oct-biib-20141022monthly0.5https://www.biopharmawatch.com/news/BIIB/leading-researchers-join-biogen-idec-to-advance-drug-discovery-for-neurodegenerative-disea-biib-20141023monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-sobi-announce-european-medicines-agency-validates-elocta-rfviiifc-marketin-biib-20141031monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-2014-deutsche-bank-biofest-conference-biib-20141119monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-data-from-hematology-programs-including-eloctate-and-alprolix-at-as-biib-20141203monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-reports-positive-top-line-results-from-phase-2-anti-lingo-1-trial-in-people-wi-biib-20150108monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-and-columbia-university-medical-center-to-conduct-collaborative-genetics-resea-biib-20150109monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-report-fourth-quarter-and-year-end-2014-financial-results-on-january-28-201-biib-20150128monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-fondazione-telethon-and-ospedale-san-raffaele-announce-global-collaboration-to-biib-20150129monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-2014-revenues-increase-40-to-9-7-billion-biib-20150129monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-columbia-university-and-hudsonalpha-institute-identify-new-als-gene-and-signal-biib-20150219monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-to-present-at-the-cowen-and-company-35th-annual-healthcare-conference-biib-20150223monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-idec-becomes-biogen-biib-20150323monthly0.5https://www.biopharmawatch.com/news/BIIB/european-medicines-agency-validates-marketing-authorisation-application-for-zinbryta-dacli-biib-20150327monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-presents-new-anti-lingo-1-phase-2-acute-optic-neuritis-data-demonstrating-neurologi-biib-20150414monthly0.5https://www.biopharmawatch.com/news/BIIB/tecfidera-dimethyl-fumarate-data-reinforce-strong-sustained-efficacy-for-newly-diagnosed-m-biib-20150420monthly0.5https://www.biopharmawatch.com/news/BIIB/international-survey-from-biogen-identifies-opportunities-for-improving-ms-treatment-satis-biib-20150421monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-reports-first-quarter-2015-revenues-of-2-6-billion-biib-20150424monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-5-billion-share-repurchase-program-biib-20150507monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-at-the-bank-of-america-merrill-lynch-2015-health-care-conference-biib-20150507monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-names-matt-griffiths-as-chief-information-officer-biib-20150513monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-at-the-2015-ubs-global-healthcare-conference-biib-20150513monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-2015-annual-shareholder-meeting-webcast-biib-20150528monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-achieves-carbon-neutrality-biib-20150623monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-agtc-enter-collaboration-to-develop-gene-therapies-in-ophthalmology-biib-20150702monthly0.5https://www.biopharmawatch.com/news/BIIB/douglas-williams-to-leave-biogen-for-biotechnology-start-up-biib-20150710monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-presents-new-data-from-phase-1b-study-of-investigational-alzheimer-s-disease-treatm-biib-20150722monthly0.5https://www.biopharmawatch.com/news/BIIB/extension-study-data-supporting-long-term-safety-and-efficacy-of-eloctate-published-in-hae-biib-20150810monthly0.5https://www.biopharmawatch.com/news/BIIB/results-from-b-yond-extension-study-reinforce-long-term-clinical-profile-of-alprolix-for-t-biib-20150817monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-the-als-association-and-columbia-university-medical-center-collaborate-to-drive-und-biib-20150818monthly0.5https://www.biopharmawatch.com/news/BIIB/uspto-dismisses-inter-partes-review-petition-of-biogen-s-patent-514-for-tecfidera-dimethyl-biib-20150902monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-at-the-morgan-stanley-global-healthcare-conference-biib-20150908monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-licenses-mitsubishi-tanabe-pharma-s-phase-2-molecule-for-autoimmune-diseases-biib-20150909monthly0.5https://www.biopharmawatch.com/news/BIIB/correcting-and-replacing-biogen-to-present-at-bank-of-america-merrill-lynch-global-healthc-biib-20150910monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-sobi-receive-positive-opinion-from-chmp-for-elocta-rfviiifc-for-the-treatment-o-biib-20150925monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-highlight-broad-research-commitment-to-ms-care-at-ectrims-congress-including-new-biib-20151001monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-departure-of-tony-kingsley-biib-20151009monthly0.5https://www.biopharmawatch.com/news/BIIB/hemophilia-therapy-from-largest-multi-year-donation-now-available-to-patients-in-developin-biib-20151012monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-report-third-quarter-2015-financial-results-on-october-21-2015-biib-20151021monthly0.5https://www.biopharmawatch.com/news/BIIB/steven-holtzman-to-retire-from-biogen-biib-20151111monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-benepali-etanercept-is-the-first-biosimilar-of-enbrel-to-receive-a-positi-biib-20151120monthly0.5https://www.biopharmawatch.com/news/BIIB/sobi-and-biogen-s-elocta-rfviiifc-approved-in-europe-for-the-treatment-of-haemophilia-a-biib-20151124monthly0.5https://www.biopharmawatch.com/news/BIIB/new-data-show-eloctate-and-alprolix-may-help-control-target-joint-bleeds-in-people-with-he-biib-20151208monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-at-the-34th-annual-j-p-morgan-healthcare-conference-biib-20151218monthly0.5https://www.biopharmawatch.com/news/BIIB/benepali-the-first-etanercept-biosimilar-referencing-enbrel-approved-in-the-european-union-biib-20160116monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-report-fourth-quarter-and-year-end-2015-financial-results-on-january-27-2016-biib-20160127monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-2015-revenues-increase-11-to-10-8-billion-biib-20160127monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-at-the-leerink-partners-5th-annual-global-healthcare-conference-biib-20160204monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-joins-pioneering-target-validation-collaboration-biib-20160208monthly0.5https://www.biopharmawatch.com/news/BIIB/sobi-and-biogen-receive-positive-opinion-from-chmp-for-alprolix-rfixfc-for-the-treatment-o-biib-20160226monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-at-the-cowen-and-company-36th-annual-health-care-conference-biib-20160229monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-at-the-goldman-sachs-alzheimer-s-symposium-biib-20160328monthly0.5https://www.biopharmawatch.com/news/BIIB/flixabi-an-infliximab-biosimilar-candidate-referencing-remicade-receives-positive-chmp-opi-biib-20160401monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-data-at-2016-aan-annual-meeting-highlight-its-expansive-portfolio-of-ms-therapies-t-biib-20160412monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-joins-in-celebration-of-world-hemophilia-day-biib-20160414monthly0.5https://www.biopharmawatch.com/news/BIIB/tecfidera-data-confirm-strong-and-sustained-efficacy-in-newly-diagnosed-ms-patients-and-re-biib-20160418monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-abbvie-receive-positive-opinion-from-the-chmp-on-zinbryta-daclizumab-for-treatm-biib-20160429monthly0.5https://www.biopharmawatch.com/news/BIIB/adam-koppel-executive-vice-president-strategy-and-business-development-to-return-to-bain-c-biib-20160429monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-intent-to-spin-off-its-hemophilia-business-biib-20160503monthly0.5https://www.biopharmawatch.com/news/BIIB/alprolix-rfixfc-approved-in-the-eu-for-the-treatment-of-haemophilia-b-biib-20160513monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-collaboration-with-university-of-pennsylvania-on-multiple-gene-therapy-pr-biib-20160516monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-abbvie-receive-fda-approval-of-once-monthly-zinbryta-daclizumab-for-multiple-sc-biib-20160527monthly0.5https://www.biopharmawatch.com/news/BIIB/flixabi-biogen-s-infliximab-biosimilar-referencing-remicade-approved-in-the-european-union-biib-20160530monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-receives-positive-chmp-opinion-for-tysabri-natalizumab-use-in-highly-active-rrms-pa-biib-20160531monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-names-paul-mckenzie-executive-vice-president-pharmaceutical-operations-amp-technolo-biib-20160621monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-abbvie-s-once-monthly-zinbryta-daclizumab-approved-in-european-union-for-treatm-biib-20160705monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-reports-second-quarter-2016-revenues-of-2-9-billion-biib-20160721monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-ionis-pharmaceuticals-report-nusinersen-meets-primary-endpoint-at-interim-analy-biib-20160801monthly0.5https://www.biopharmawatch.com/news/BIIB/nature-publishes-results-from-pre-clinical-research-and-phase-1b-study-of-biogen-s-investi-biib-20160831monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-s-investigational-alzheimer-s-disease-treatment-aducanumab-granted-fda-fast-track-d-biib-20160901monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-demonstrates-commitment-to-improving-patient-outcomes-with-study-on-burden-of-ms-an-biib-20160908monthly0.5https://www.biopharmawatch.com/news/BIIB/new-data-affirm-strong-efficacy-and-well-characterized-safety-profile-of-tecfidera-in-both-biib-20160914monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-report-third-quarter-2016-financial-results-on-october-26-2016-biib-20161026monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-at-the-25th-annual-credit-suisse-healthcare-conference-biib-20161027monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-s-regulatory-applications-for-nusinersen-as-a-treatment-for-spinal-muscular-atrophy-biib-20161028monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-additional-members-of-management-team-of-hemophilia-spin-off-company-biov-biib-20161115monthly0.5https://www.biopharmawatch.com/news/BIIB/data-reinforcing-the-long-term-safety-and-efficacy-of-extended-half-life-hemophilia-therap-biib-20161203monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-presents-data-from-phase-1b-study-of-investigational-alzheimer-s-disease-treatment--biib-20161208monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-names-michel-vounatsos-chief-executive-officer-biib-20161219monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-s-board-of-directors-approves-separation-of-bioverativ-and-declares-special-dividen-biib-20161220monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-at-the-35th-annual-j-p-morgan-healthcare-conference-biib-20161220monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-spin-off-bioverativ-will-present-at-the-goldman-sachs-healthcare-ceos-unscripte-biib-20161221monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-effectiveness-of-bioverativ-form-10-registration-statement-biib-20161222monthly0.5https://www.biopharmawatch.com/news/BIIB/u-s-fda-approves-biogen-s-spinraza-nusinersen-the-first-treatment-for-spinal-muscular-atro-biib-20161223monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-that-bioverativ-will-host-an-investor-day-on-january-6-2017-biib-20170106monthly0.5https://www.biopharmawatch.com/news/BIIB/new-data-show-spinraza-nusinersen-significantly-reduces-risk-of-death-or-permanent-ventila-biib-20170113monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-forward-pharma-agree-to-enter-into-settlement-and-license-agreement-biib-20170117monthly0.5https://www.biopharmawatch.com/news/BIIB/siemens-healthineers-and-biogen-announce-agreement-to-jointly-develop-new-mri-tools-for-mu-biib-20170117monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-fourth-quarter-and-year-end-2016-financial-results-webcast-adjusted-to-8-00-am-on-j-biib-20170126monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-report-fourth-quarter-and-year-end-2016-financial-results-on-january-26-2017-biib-20170126monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-at-the-2017-rbc-capital-markets-global-healthcare-conference-biib-20170215monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-highlights-advances-from-its-neurology-research-programs-and-portfolio-of-innovativ-biib-20170418monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-s-spinraza-nusinersen-receives-positive-chmp-opinion-for-the-treatment-of-spinal-mu-biib-20170421monthly0.5https://www.biopharmawatch.com/news/BIIB/final-phase-3-study-data-show-spinraza-nusinersen-significantly-improved-motor-function-in-biib-20170424monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-acquires-remedy-pharmaceuticals-cirara-for-large-hemispheric-stroke-biib-20170515monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-at-the-bernstein-33rd-annual-strategic-decisions-conference-biib-20170517monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-s-fampyra-granted-standard-marketing-authorization-in-european-union-for-improvemen-biib-20170524monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-webcast-of-virtual-annual-meeting-of-stockholders-biib-20170531monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-appoints-ginger-gregory-executive-vice-president-chief-human-resources-officer-biib-20170620monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-s-imraldi-an-adalimumab-biosimilar-candidate-referencing-humira-granted-positive-op-biib-20170623monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-appoints-catherine-steele-senior-vice-president-of-corporate-affairs-biib-20170628monthly0.5https://www.biopharmawatch.com/news/BIIB/new-data-reaffirm-clinically-meaningful-benefit-of-spinraza-nusinersen-in-individuals-with-biib-20170629monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-data-at-alzheimer-039-s-association-international-conference-2017-aaic-biib-20170714monthly0.5https://www.biopharmawatch.com/news/BIIB/alisha-a-alaimo-appointed-svp-of-biogen-s-us-therapeutic-operations-biib-20170724monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-report-second-quarter-2017-financial-results-and-strategic-update-on-july-25-201-biib-20170725monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-reports-record-quarterly-revenues-of-3-1-billion-raises-full-year-revenue-guidance-biib-20170725monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-appoints-anabella-villalobos-senior-vice-president-biotherapeutic-amp-medicinal-sci-biib-20170731monthly0.5https://www.biopharmawatch.com/news/BIIB/imraldi-biogen-s-adalimumab-biosimilar-referencing-humira-is-approved-in-the-european-unio-biib-20170824monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-reports-new-data-from-phase-1b-study-of-investigational-alzheimer-s-disease-treatme-biib-20170828monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-at-the-morgan-stanley-15th-annual-global-healthcare-conference-biib-20170906monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-appoints-sanjay-jariwala-as-svp-worldwide-medical-biib-20170912monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-appoints-camille-lee-as-svp-alzheimer-s-disease-therapeutic-area-biib-20170925monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-confirms-commitment-to-tackle-multiple-sclerosis-through-comprehensive-approach-biib-20171018monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-eisai-expand-existing-collaboration-agreement-to-develop-and-commercialize-inve-biib-20171023monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-report-third-quarter-2017-financial-results-on-october-24-2017-biib-20171024monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-affinity-phase-2-trial-initiation-for-opicinumab-anti-lingo-1-in-multiple-biib-20171025monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-ionis-win-prestigious-prix-galien-award-for-spinraza-as-best-biotechnology-prod-biib-20171027monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-presents-new-data-from-long-term-extension-of-phase-1b-study-of-investigational-alz-biib-20171102monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-appoints-chirfi-guindo-as-executive-vice-president-and-head-of-global-marketing-mar-biib-20171102monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-at-the-evercore-isi-biopharma-catalyst-deep-dive-conference-biib-20171120monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-appoints-jeff-capello-as-executive-vice-president-and-chief-financial-officer-biib-20171121monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-appoints-mark-hernon-as-svp-chief-information-officer-biib-20171204monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-at-the-36th-annual-j-p-morgan-healthcare-conference-biib-20171218monthly0.5https://www.biopharmawatch.com/news/BIIB/adaptive-phase-ii-study-of-ban2401-in-early-alzheimer-s-disease-continues-toward-18-month--biib-20171221monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-foundation-commits-10-million-to-stem-education-in-cambridge-and-somerville-biib-20180104monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-report-fourth-quarter-and-year-end-2017-financial-results-on-january-25-2018-upd-biib-20180125monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-reports-record-revenues-for-both-the-full-year-and-fourth-quarter-of-2017-12-3-bill-biib-20180125monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-reports-top-line-results-from-phase-2b-study-of-natalizumab-in-acute-ischemic-strok-biib-20180207monthly0.5https://www.biopharmawatch.com/news/BIIB/the-new-england-journal-of-medicine-publishes-spinraza-nusinersen-phase-3-study-results-in-biib-20180214monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-at-the-cowen-and-company-38th-annual-health-care-conference-biib-20180228monthly0.5https://www.biopharmawatch.com/news/BIIB/new-data-presented-at-mda-clinical-conference-show-benefit-in-motor-function-for-infants-t-biib-20180312monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-acquire-from-pfizer-first-in-class-phase-2b-ready-asset-for-cognitive-impairment-biib-20180312monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-at-the-2018-advances-in-alzheimer-s-and-parkinson-s-therapies-aat-ad-pd--biib-20180315monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-at-the-advances-in-alzheimer-s-and-parkinson-s-therapies-an-aat-ad-pd-fo-biib-20180315monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-builds-on-its-40-year-legacy-in-neuroscience-with-presentation-of-research-from-its-biib-20180417monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-reports-quarterly-revenues-of-3-1-billion-biib-20180424monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-report-first-quarter-2018-financial-results-on-april-24-2018-biib-20180424monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-neurimmune-announce-option-exercise-for-alzheimer-s-disease-investigational-tre-biib-20180501monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-appoints-daniel-karp-as-evp-corporate-development-biib-20180531monthly0.5https://www.biopharmawatch.com/news/BIIB/phase-ii-clinical-study-of-elenbecestat-demonstrates-safety-and-tolerability-in-mci-and-mi-biib-20180604monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-enters-exclusive-option-agreement-to-acquire-tms-phase-2-asset-for-acute-stroke-biib-20180607monthly0.5https://www.biopharmawatch.com/news/BIIB/samsung-bioepis-and-biogen-announce-pooled-analysis-results-of-anti-tnf-biosimilars-benepa-biib-20180613monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-enhances-commitment-to-sma-research-with-data-presented-at-annual-sma-conference-biib-20180613monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-exercises-option-to-increase-ownership-in-samsung-bioepis-biib-20180628monthly0.5https://www.biopharmawatch.com/news/BIIB/data-to-be-presented-from-biogen-s-alzheimer-s-disease-clinical-development-portfolio-at-t-biib-20180718monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-q2-2018-revenues-increase-9-to-3-4-billion-biib-20180724monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-report-second-quarter-2018-financial-results-on-july-24-2018-biib-20180724monthly0.5https://www.biopharmawatch.com/news/BIIB/eisai-and-biogen-announce-detailed-results-of-phase-ii-clinical-study-of-ban2401-in-early--biib-20180725monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-host-investor-webcast-to-discuss-alzheimer-s-disease-portfolio-on-july-25-2018-biib-20180725monthly0.5https://www.biopharmawatch.com/news/BIIB/eisai-and-biogen-present-detailed-results-from-phase-ii-clinical-study-of-elenbecestat-in--biib-20180725monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-enrolls-first-patient-in-global-phase-3-study-of-biib093-iv-glibenclamide-for-large-biib-20180904monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-highlights-at-ectrims-2018-data-on-its-industry-leading-multiple-sclerosis-portfoli-biib-20181002monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-data-from-its-neurology-pipeline-at-the-2018-international-congress-of-p-biib-20181003monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-host-investor-webcasts-from-clinical-trials-on-alzheimer-s-disease-meeting-on-oc-biib-20181004monthly0.5https://www.biopharmawatch.com/news/BIIB/new-spinraza-nusinersen-data-presented-at-annual-congress-of-the-world-muscle-society-demo-biib-20181006monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-advances-research-to-improve-outcomes-for-patients-with-multiple-sclerosis-biib-20181011monthly0.5https://www.biopharmawatch.com/news/BIIB/imraldi-biogen-s-adalimumab-biosimilar-referencing-humira-is-launched-in-the-european-unio-biib-20181017monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-data-from-alzheimer-s-disease-portfolio-at-the-2018-clinical-trials-on-a-biib-20181018monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-report-third-quarter-2018-financial-results-october-23-2018-biib-20181023monthly0.5https://www.biopharmawatch.com/news/BIIB/ucb-and-biogen-announce-topline-results-from-a-phase-2b-study-of-dapirolizumab-pegol-in-sy-biib-20181023monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-q3-2018-revenues-increased-12-to-3-4-billion-biib-20181023monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-eisai-announce-presentation-of-detailed-analyses-from-the-phase-1b-long-term-ex-biib-20181026monthly0.5https://www.biopharmawatch.com/news/BIIB/international-prix-galien-recognizes-spinraza-as-best-biotechnology-product-biib-20181129monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-host-investor-webcast-on-its-multiple-sclerosis-portfolio-on-december-12-2018-biib-20181212monthly0.5https://www.biopharmawatch.com/news/BIIB/alkermes-and-biogen-announce-submission-of-a-new-drug-application-to-u-s-food-and-drug-adm-biib-20181217monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-biib-20181217monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-skyhawk-therapeutics-announce-agreement-to-develop-novel-small-molecule-rna-spl-biib-20190104monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-report-fourth-quarter-and-year-end-2018-financial-results-january-29-2019-biib-20190129monthly0.5https://www.biopharmawatch.com/news/BIIB/alkermes-and-biogen-announce-u-s-food-and-drug-administration-acceptance-of-diroximel-fuma-biib-20190225monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-further-expands-presence-in-china-with-approval-of-spinraza-nusinersen-the-first-an-biib-20190228monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-agreement-to-acquire-nightstar-therapeutics-to-establish-clinical-pipelin-biib-20190304monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-at-the-cowen-39th-annual-health-care-conference-biib-20190305monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-at-the-stifel-first-annual-cns-day-biib-20190327monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-q1-2019-revenues-increased-11-to-3-5-billion-biib-20190424monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-report-first-quarter-2019-financial-results-april-24-2019-biib-20190424monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-three-new-nominees-for-election-to-board-of-directors-biib-20190429monthly0.5https://www.biopharmawatch.com/news/BIIB/data-published-in-neurology-show-that-treatment-with-spinraza-nusinersen-improved-motor-fu-biib-20190430monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-data-at-aan-highlighting-its-innovative-marketed-treatments-and-investig-biib-20190501monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-new-interim-data-from-its-phase-1-2-clinical-study-of-tofersen-biib067-f-biib-20190501monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-presents-data-at-2019-aan-annual-meeting-affirming-longer-term-safety-and-durabilit-biib-20190506monthly0.5https://www.biopharmawatch.com/news/BIIB/data-at-aan-demonstrate-biogen-s-leadership-and-commitment-to-innovation-in-ms-biib-20190507monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-s-spinraza-nusinersen-receives-positive-recommendation-from-nice-for-funding-in-the-biib-20190514monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-recommends-stockholders-reject-the-below-market-mini-tender-offer-by-trc-capital-co-biib-20190520monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-at-bernstein-s-35th-annual-strategic-decisions-conference-biib-20190521monthly0.5https://www.biopharmawatch.com/news/BIIB/new-phase-3-interim-results-support-safety-and-efficacy-of-diroximel-fumarate-in-multiple--biib-20190530monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-webcast-of-annual-meeting-of-stockholders-biib-20190605monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-host-investor-webcast-to-discuss-als-portfolio-on-june-5-2019-biib-20190605monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-completes-acquisition-of-nightstar-therapeutics-for-approximately-800-million-biib-20190607monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-new-safety-and-efficacy-data-on-biosimilars-and-estimates-1-8-billion-eu-biib-20190611monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-new-data-further-establishing-spinraza-nusinersen-as-a-foundation-of-care-biib-20190701monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-q2-2019-revenues-increased-8-to-3-6-billion-biib-20190723monthly0.5https://www.biopharmawatch.com/news/BIIB/diroximel-fumarate-demonstrated-significantly-improved-gastrointestinal-tolerability-profi-biib-20190730monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-at-the-morgan-stanley-17th-annual-global-healthcare-conference-biib-20190827monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-report-third-quarter-2019-financials-october-22-2019-biib-20190911monthly0.5https://www.biopharmawatch.com/news/BIIB/new-data-presented-at-ectrims-reinforce-long-term-benefits-of-tecfidera-dimethyl-fumarate--biib-20190911monthly0.5https://www.biopharmawatch.com/news/BIIB/new-research-demonstrate-biogen-s-continued-commitment-to-improve-care-of-patients-with-mu-biib-20190912monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-advances-spinal-muscular-atrophy-sma-clinical-research-with-new-study-evaluating-a--biib-20190918monthly0.5https://www.biopharmawatch.com/news/BIIB/interferon-beta-treatments-including-plegridy-peginterferon-beta-1a-and-avonex-interferon--biib-20190923monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-leadership-update-biib-20191001monthly0.5https://www.biopharmawatch.com/news/BIIB/landmark-nurture-study-of-infants-with-spinal-muscular-atrophy-sma-treated-pre-symptomatic-biib-20191002monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-samsung-bioepis-to-present-data-for-infliximab-and-adalimumab-biosimilars-at-un-biib-20191021monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-plans-regulatory-filing-for-aducanumab-in-alzheimer-s-disease-based-on-new-analysis-biib-20191022monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-reports-q3-2019-revenues-of-3-6-billion-biib-20191022monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-expand-biosimilars-portfolio-and-gain-access-to-additional-markets-through-new-t-biib-20191106monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-at-the-evercore-isi-2nd-annual-healthconx-conference-biib-20191121monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-presents-data-demonstrating-improved-gastrointestinal-tolerability-with-vumerity-di-biib-20191122monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-host-investor-webcasts-from-clinical-trials-on-alzheimer-s-disease-ctad-congress-biib-20191205monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-reports-top-line-results-from-phase-2-study-in-progressive-supranuclear-palsy-biib-20191213monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-biib-20191217monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-acquire-novel-clinical-stage-asset-with-application-in-alzheimer-s-disease-and-p-biib-20200113monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-reports-full-year-2019-revenues-of-14-4-billion-biib-20200130monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-at-the-cowen-40th-annual-health-care-conference-biib-20200224monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-sangamo-announce-global-collaboration-to-develop-gene-regulation-therapies-for--biib-20200227monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-foundation-commits-10-million-to-support-covid-19-relief-efforts-in-the-u-s-and-aro-biib-20200316monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-statement-business-update-regarding-covid-19-biib-20200318monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-first-patient-treated-with-higher-dose-of-spinraza-nusinersen-in-phase-2--biib-20200402monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-webcast-encore-aducanumab-presentation-from-virtual-aat-ad-pd-meeting-on-april-2-biib-20200402monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-broad-institute-of-mit-and-harvard-partners-healthcare-launch-consortium-to-build-a-biib-20200416monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-report-first-quarter-2020-financial-results-april-22-2020-biib-20200422monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-participate-at-world-medical-innovation-forum-virtual-gathering-covid-19-on-may--biib-20200511monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-webcast-prerecorded-encore-aducanumab-presentation-from-aan-science-highlights-v-biib-20200518monthly0.5https://www.biopharmawatch.com/news/BIIB/new-spinraza-nusinersen-data-reinforce-sustained-efficacy-and-longer-term-safety-across-br-biib-20200518monthly0.5https://www.biopharmawatch.com/news/BIIB/new-data-at-aan-showcase-biogen-s-commitment-to-advancing-innovation-in-ms-biib-20200519monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-webcast-of-annual-meeting-of-stockholders-biib-20200526monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-mit-launch-new-virtual-learning-lab-for-high-school-students-historically-under-biib-20200528monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-statement-about-director-lynn-schenk-biib-20200602monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-presents-positive-phase-2-cutaneous-lupus-erythematosus-cle-data-at-european-e-cong-biib-20200604monthly0.5https://www.biopharmawatch.com/news/BIIB/new-results-from-landmark-nurture-study-show-that-pre-symptomatic-sma-patients-treated-wit-biib-20200610monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-completes-submission-of-biologics-license-application-to-fda-for-aducanumab-as-a-tr-biib-20200708monthly0.5https://www.biopharmawatch.com/news/BIIB/the-new-england-journal-of-medicine-publishes-final-results-from-phase-1-2-study-of-tofers-biib-20200708monthly0.5https://www.biopharmawatch.com/news/BIIB/initiation-of-new-phase-iii-clinical-study-ahead-3-45-of-ban2401-preclinical-asymptomatic--biib-20200713monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-report-second-quarter-2020-financial-results-july-22-2020-biib-20200722monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-data-at-virtual-2020-alzheimer-s-association-international-conference-hi-biib-20200724monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-denali-to-collaborate-on-lrrk2-program-for-parkinson-s-disease-and-certain-tv-p-biib-20200806monthly0.5https://www.biopharmawatch.com/news/BIIB/fda-accepts-biogen-s-aducanumab-biologics-license-application-for-alzheimer-039-s-disease--biib-20200807monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-webcast-prerecorded-encore-aducanumab-presentation-from-61st-annual-meeting-of-t-biib-20200831monthly0.5https://www.biopharmawatch.com/news/BIIB/new-biogen-data-presented-at-actrims-ectrims-advance-understanding-of-clinical-and-health--biib-20200908monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-invest-250-million-in-a-20-year-initiative-to-eliminate-its-use-of-fossil-fuels--biib-20200914monthly0.5https://www.biopharmawatch.com/news/BIIB/statement-to-icer-s-announced-plans-to-conduct-an-assessment-on-the-value-of-aducanumab-biib-20200929monthly0.5https://www.biopharmawatch.com/news/BIIB/statement-about-the-fda-advisory-committee-on-aducanumab-biib-20200929monthly0.5https://www.biopharmawatch.com/news/BIIB/samsung-bioepis-and-biogen-announce-ema-filing-acceptance-of-sb11-a-proposed-biosimilar-re-biib-20201006monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-report-third-quarter-2020-financial-results-october-21-2020-biib-20201021monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-reports-q3-2020-results-biib-20201021monthly0.5https://www.biopharmawatch.com/news/BIIB/european-medicines-agency-accepts-biogen-s-aducanumab-marketing-authorization-application--biib-20201030monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-webcast-prerecorded-presentation-on-aducanumab-embark-study-design-and-live-q-am-biib-20201104monthly0.5https://www.biopharmawatch.com/news/BIIB/update-on-fda-advisory-committee-s-meeting-on-aducanumab-in-alzheimer-s-disease-biib-20201106monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-ranked-1-biotechnology-company-by-dow-jones-sustainability-world-index-for-an-indus-biib-20201116monthly0.5https://www.biopharmawatch.com/news/BIIB/samsung-bioepis-and-biogen-announce-fda-filing-acceptance-of-sb11-a-proposed-biosimilar-re-biib-20201118monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-sage-therapeutics-announce-global-collaboration-to-develop-and-commercialize-po-biib-20201127monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-files-new-drug-application-for-aducanumab-in-japan-biib-20201209monthly0.5https://www.biopharmawatch.com/news/BIIB/the-european-commission-grants-marketing-authorization-for-plegridy-peginterferon-beta-1a--biib-20201221monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-first-patient-treated-in-respond-study-evaluating-benefit-of-spinraza-nus-biib-20210108monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-launch-pioneering-study-to-develop-digital-biomarkers-of-cognitive-health-using--biib-20210111monthly0.5https://www.biopharmawatch.com/news/BIIB/a-statement-about-biogen-political-action-committee-biib-20210113monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-participate-in-webinar-with-alzheimer-039-s-disease-international-on-january-14--biib-20210114monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-eisai-announce-fda-s-3-month-extension-of-review-period-for-the-biologics-licen-biib-20210129monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-fda-approval-of-plegridy-peginterferon-beta-1a-intramuscular-administrati-biib-20210201monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-report-fourth-quarter-and-full-year-2020-financial-results-february-3-2021-biib-20210203monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-the-pricing-terms-of-its-private-exchange-offer-biib-20210210monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-the-expiration-date-results-of-its-cash-tender-offer-biib-20210211monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-participate-in-the-cowen-41st-annual-health-care-conference-biib-20210222monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-participate-in-webinar-with-the-global-alzheimer-039-s-platform-foundation-on-fe-biib-20210223monthly0.5https://www.biopharmawatch.com/news/BIIB/life-science-cares-and-biogen-foundation-help-launch-food-for-free-s-just-eats-program-biib-20210224monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-webcast-aducanumab-presentations-from-ad-pd-2021-virtual-conference-on-march-9-1-biib-20210303monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-plans-to-build-a-new-state-of-the-art-gene-therapy-manufacturing-facility-biib-20210304monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-participate-in-the-stifel-3rd-annual-cns-day-biib-20210322monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-two-new-nominees-for-election-to-board-of-directors-biib-20210409monthly0.5https://www.biopharmawatch.com/news/BIIB/sage-therapeutics-and-biogen-announce-sage-324-phase-2-placebo-controlled-kinetic-study-in-biib-20210412monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2-biib-20210414monthly0.5https://www.biopharmawatch.com/news/BIIB/new-data-at-aan-2021-from-across-biogen-s-ms-portfolio-demonstrate-positive-impact-of-trea-biib-20210416monthly0.5https://www.biopharmawatch.com/news/BIIB/18-month-pre-specified-analysis-showing-consistent-reduction-in-clinical-outcome-measures--biib-20210419monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-advances-leading-research-in-spinal-muscular-atrophy-sma-with-new-data-at-aan-2021--biib-20210419monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-reports-first-quarter-2021-results-biib-20210422monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-report-first-quarter-2021-financial-results-april-22-2021-biib-20210422monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-provides-regulatory-update-on-the-supplemental-biologic-license-application-sbla-fo-biib-20210428monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-releases-2020-year-in-review-demonstrating-its-commitment-to-transparency-and-progr-biib-20210428monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-capsigen-announce-collaboration-to-discover-and-develop-novel-aav-capsids-for-t-biib-20210510monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-envisagenics-announce-collaboration-to-advance-rna-splicing-research-biib-20210513monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-topline-results-from-phase-2-3-gene-therapy-study-for-xlrp-biib-20210514monthly0.5https://www.biopharmawatch.com/news/BIIB/swissmedic-grants-good-manufacturing-practice-multi-product-license-to-biogen-biologics-fa-biib-20210520monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-webcast-of-annual-meeting-of-stockholders-biib-20210525monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-eisai-launch-multiple-initiatives-to-help-patients-with-alzheimer-s-disease-acc-biib-20210607monthly0.5https://www.biopharmawatch.com/news/BIIB/fda-grants-accelerated-approval-for-aduhelm-as-the-first-and-only-alzheimer-s-disease-trea-biib-20210607monthly0.5https://www.biopharmawatch.com/news/BIIB/a-letter-from-biogen-s-ceo-on-aduhelm-biib-20210607monthly0.5https://www.biopharmawatch.com/news/BIIB/new-data-at-cure-sma-2021-highlight-the-long-term-efficacy-of-spinraza-nusinersen-and-biog-biib-20210610monthly0.5https://www.biopharmawatch.com/news/BIIB/sage-therapeutics-and-biogen-announce-positive-pivotal-phase-3-results-for-zuranolone-an-i-biib-20210615monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-topline-results-from-phase-2-study-of-gosuranemab-an-anti-tau-antibody-fo-biib-20210616monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-first-patient-dosed-in-phase-3-systemic-lupus-erythematosus-study-biib-20210617monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-participate-in-svb-leerink-s-3rd-annual-cns-forum-biib-20210622monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-eisai-update-for-the-alzheimer-s-disease-community-biib-20210623monthly0.5https://www.biopharmawatch.com/news/BIIB/eisai-and-biogen-inc-announce-u-s-fda-grants-breakthrough-therapy-designation-for-lecanema-biib-20210623monthly0.5https://www.biopharmawatch.com/news/BIIB/collaboration-between-abbvie-biogen-and-pfizer-creates-world-s-largest-browsable-resource--biib-20210708monthly0.5https://www.biopharmawatch.com/news/BIIB/fda-approves-updated-aduhelm-prescribing-information-to-emphasize-population-studied-in-cl-biib-20210708monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-innocare-announce-license-and-collaboration-agreement-for-orelabrutinib-an-inno-biib-20210712monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-reports-second-quarter-2021-results-biib-20210722monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-report-second-quarter-2021-financial-results-july-22-2021-biib-20210722monthly0.5https://www.biopharmawatch.com/news/BIIB/an-open-letter-to-the-alzheimer-s-disease-community-from-our-head-of-research-and-developm-biib-20210722monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-data-from-aduhelm-and-alzheimer-s-disease-portfolio-at-2021-alzheimer-s--biib-20210723monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-eisai-announce-aduhelm-aducanumab-avwa-data-presentations-at-alzheimer-s-associ-biib-20210726monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-ionis-report-positive-topline-clinical-data-on-investigational-alzheimer-s-dise-biib-20210726monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-eisai-announce-design-of-aduhelm-icare-ad-us-study-the-first-real-world-observa-biib-20210729monthly0.5https://www.biopharmawatch.com/news/BIIB/late-breaking-aaic-presentation-explores-potential-clinical-effects-of-lecanemab-ban2401-biib-20210729monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-results-from-phase-3b-nova-study-evaluating-every-six-week-dosing-with-na-biib-20210802monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-participate-in-the-morgan-stanley-19th-annual-global-healthcare-conference-biib-20210901monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-plans-to-initiate-phase-3b-study-evaluating-potential-benefit-of-a-higher-dose-of-n-biib-20210915monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-positive-topline-results-from-phase-2-convey-study-in-small-fiber-neuropa-biib-20210916monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-agenda-for-virtual-investor-day-r-amp-d-day-on-september-21-2021-biib-20210921monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-r-amp-d-day-to-provide-overview-of-diversified-pipeline-and-capabilities-with-poten-biib-20210921monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-investor-day-on-september-21-2021-biib-20210921monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-issues-first-progress-report-of-its-signature-healthy-climate-healthy-lives-initiat-biib-20210923monthly0.5https://www.biopharmawatch.com/news/BIIB/eisai-initiates-rolling-submission-to-the-u-s-fda-for-biologics-license-application-of-lec-biib-20210927monthly0.5https://www.biopharmawatch.com/news/BIIB/sage-therapeutics-and-biogen-announce-consistent-clinically-meaningful-data-for-zuranolone-biib-20211004monthly0.5https://www.biopharmawatch.com/news/BIIB/new-ms-paths-data-at-ectrims-2021-confirm-biogen-s-disease-modifying-therapies-do-not-redu-biib-20211013monthly0.5https://www.biopharmawatch.com/news/BIIB/new-data-at-ectrims-2021-highlight-biogen-s-focus-on-patient-centered-outcomes-and-improvi-biib-20211013monthly0.5https://www.biopharmawatch.com/news/BIIB/topline-results-from-tofersen-phase-3-study-and-its-open-label-extension-in-sod1-als-to-be-biib-20211014monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-topline-results-from-the-tofersen-phase-3-study-and-its-open-label-extens-biib-20211017monthly0.5https://www.biopharmawatch.com/news/BIIB/sage-therapeutics-and-biogen-announce-plans-to-submit-a-new-drug-application-nda-for-zuran-biib-20211019monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-report-third-quarter-2021-financial-results-october-20-2021-biib-20211020monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-reports-third-quarter-2021-results-biib-20211020monthly0.5https://www.biopharmawatch.com/news/BIIB/a-letter-from-alphonse-galdes-ph-d-head-of-pharmaceutical-operations-and-technology-at-bio-biib-20211102monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-late-breakers-and-additional-new-data-presentations-at-the-2021-clinical--biib-20211103monthly0.5https://www.biopharmawatch.com/news/BIIB/eisai-presents-late-breaker-updates-on-lecanemab-clinical-biomarker-and-safety-data-from-p-biib-20211110monthly0.5https://www.biopharmawatch.com/news/BIIB/new-phase-3-data-show-positive-correlation-between-aduhelm-treatment-effect-on-biomarkers--biib-20211111monthly0.5https://www.biopharmawatch.com/news/BIIB/eisai-presents-new-analysis-of-lecanemab-clinical-efficacy-results-from-phase-2b-study-at--biib-20211111monthly0.5https://www.biopharmawatch.com/news/BIIB/update-on-regulatory-review-of-aducanumab-in-the-european-union-biib-20211117monthly0.5https://www.biopharmawatch.com/news/BIIB/sage-therapeutics-and-biogen-announce-positive-one-year-zuranolone-50-mg-data-in-the-ongoi-biib-20211201monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-therapanacea-announce-new-collaboration-with-the-potential-to-advance-digital-h-biib-20211214monthly0.5https://www.biopharmawatch.com/news/BIIB/update-on-the-phase-4-confirmatory-study-of-aduhelm-biib-20211216monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-reduced-price-for-aduhelm-to-improve-access-for-patients-with-early-alzhe-biib-20211220monthly0.5https://www.biopharmawatch.com/news/BIIB/japan-s-first-committee-on-new-drugs-of-the-pharmaceutical-affairs-and-food-sanitation-cou-biib-20211222monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-biib-20220104monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-exercises-option-with-ionis-to-develop-and-commercialize-investigational-aso-for-sm-biib-20220104monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-host-analyst-q-amp-a-call-biib-20220110monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-s-statement-on-the-draft-national-coverage-determination-ncd-for-monoclonal-antibod-biib-20220111monthly0.5https://www.biopharmawatch.com/news/BIIB/update-on-the-phase-4-envision-confirmatory-study-of-aduhelm-biib-20220127monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-reaches-agreement-with-samsung-biologics-to-sell-equity-stake-in-their-biosimilar-j-biib-20220127monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-exercises-option-to-participate-in-the-development-and-commercialization-of-a-late--biib-20220201monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-submits-response-to-the-centers-for-medicare-and-medicaid-services-cms-proposed-nat-biib-20220210monthly0.5https://www.biopharmawatch.com/news/BIIB/sage-therapeutics-and-biogen-announce-the-phase-3-coral-study-met-its-primary-and-key-seco-biib-20220216monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-at-the-cowen-42nd-annual-health-care-conference-biib-20220218monthly0.5https://www.biopharmawatch.com/news/BIIB/eisai-initiates-submission-of-application-data-under-the-prior-assessment-consultation-sys-biib-20220304monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-new-research-at-the-international-conference-on-alzheimer-s-and-parkinso-biib-20220311monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-eisai-amend-collaboration-agreements-on-alzheimer-s-disease-treatments-biib-20220314monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-new-updates-across-its-sma-research-program-at-2022-mda-conference-biib-20220314monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-peer-reviewed-publication-of-aduhelm-phase-3-emerge-and-engage-data-in-th-biib-20220316monthly0.5https://www.biopharmawatch.com/news/BIIB/long-term-phase-3-data-show-aduhelm-continues-to-reduce-underlying-pathologies-of-alzheime-biib-20220316monthly0.5https://www.biopharmawatch.com/news/BIIB/the-national-minority-quality-forum-and-biogen-highlight-equitable-access-to-research-and--biib-20220318monthly0.5https://www.biopharmawatch.com/news/BIIB/latest-findings-on-lecanemab-clinical-efficacy-aria-rates-biomarkers-relationship-to-clini-biib-20220321monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-ionis-announce-topline-phase-1-study-results-of-investigational-drug-in-c9orf72-biib-20220328monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-submits-final-protocol-for-aduhelm-aducanumab-avwa-phase-4-envision-trial-to-fda-biib-20220330monthly0.5https://www.biopharmawatch.com/news/BIIB/new-data-at-aan-2022-highlight-real-world-evidence-from-biogen-s-ms-portfolio-and-emerging-biib-20220404monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-s-statement-on-the-final-national-coverage-determination-for-amyloid-beta-targeting-biib-20220407monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-completes-sale-of-equity-stake-in-biosimilar-joint-venture-to-samsung-biologics-for-biib-20220420monthly0.5https://www.biopharmawatch.com/news/BIIB/update-on-regulatory-submission-for-aducanumab-in-the-european-union-biib-20220422monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-statement-regarding-updated-aduhelm-aducanumab-avwa-prescribing-information-in-us-biib-20220429monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-report-first-quarter-2022-financial-results-may-3-2022-biib-20220503monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-medrhythms-to-develop-and-commercialize-a-prescription-digital-therapeutic-targ-biib-20220505monthly0.5https://www.biopharmawatch.com/news/BIIB/eisai-completes-rolling-submission-to-the-u-s-fda-for-biologics-license-application-of-lec-biib-20220509monthly0.5https://www.biopharmawatch.com/news/BIIB/denali-therapeutics-and-biogen-announce-initiation-of-phase-2b-study-of-lrrk2-inhibitor-in-biib-20220531monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-samsung-bioepis-byooviz-ranibizumab-nuna-launches-in-the-united-states-biib-20220602monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-appreciation-statement-for-retiring-board-members-nancy-leaming-and-brian-posner-biib-20220615monthly0.5https://www.biopharmawatch.com/news/BIIB/new-data-presented-at-cure-sma-reveal-residual-unmet-needs-in-young-sma-patients-treated-w-biib-20220615monthly0.5https://www.biopharmawatch.com/news/BIIB/european-patent-office-grants-patent-related-to-tecfidera-dimethyl-fumarate-biib-20220621monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-happify-health-collaborate-to-support-multiple-sclerosis-patients-on-digital-pl-biib-20220622monthly0.5https://www.biopharmawatch.com/news/BIIB/the-u-s-fda-accepts-and-grants-priority-review-for-eisai-s-biologics-license-application-o-biib-20220705monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-reports-second-quarter-2022-results-biib-20220720monthly0.5https://www.biopharmawatch.com/news/BIIB/fda-accepts-biogen-s-new-drug-application-and-grants-priority-review-of-tofersen-for-a-rar-biib-20220726monthly0.5https://www.biopharmawatch.com/news/BIIB/the-new-england-journal-of-medicine-publishes-positive-phase-2-data-on-litifilimab-biib059-biib-20220728monthly0.5https://www.biopharmawatch.com/news/BIIB/eisai-presents-new-findings-on-lecanemab-s-investigational-subcutaneous-formulation-and-mo-biib-20220803monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-participate-in-the-morgan-stanley-20th-annual-global-healthcare-conference-biib-20220831monthly0.5https://www.biopharmawatch.com/news/BIIB/statement-on-alzheimer-s-amp-dementia-journal-publication-about-association-between-reduct-biib-20220831monthly0.5https://www.biopharmawatch.com/news/BIIB/the-new-england-journal-of-medicine-publishes-second-manuscript-reporting-positive-phase-2-biib-20220907monthly0.5https://www.biopharmawatch.com/news/BIIB/the-new-england-journal-of-medicine-publishes-pivotal-tofersen-data-that-show-benefits-in--biib-20220921monthly0.5https://www.biopharmawatch.com/news/BIIB/statement-biogen-statement-on-qui-tam-settlement-biib-20220926monthly0.5https://www.biopharmawatch.com/news/BIIB/lecanemab-confirmatory-phase-3-clarity-ad-study-met-primary-endpoint-showing-highly-statis-biib-20220927monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-denali-therapeutics-announce-initiation-of-the-phase-3-lighthouse-study-in-park-biib-20221003monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-first-patient-dosed-in-pivotal-study-of-litifilimab-in-cutaneous-lupus-er-biib-20221010monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-sage-therapeutics-present-further-analyses-from-phase-3-skylark-study-of-zurano-biib-20221017monthly0.5https://www.biopharmawatch.com/news/BIIB/eisai-presents-full-results-of-lecanemab-phase-3-confirmatory-clarity-ad-study-for-early-a-biib-20221129monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-sage-therapeutics-complete-rolling-submission-of-new-drug-application-for-zuran-biib-20221206monthly0.5https://www.biopharmawatch.com/news/BIIB/sage-therapeutics-and-biogen-to-host-investor-webcast-on-december-6-2022-to-discuss-potent-biib-20221206monthly0.5https://www.biopharmawatch.com/news/BIIB/fda-accepts-biogen-biologics-license-application-for-biib800-a-biosimilar-candidate-refere-biib-20221209monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-reaches-agreement-with-genentech-to-receive-royalties-on-the-potential-commercializ-biib-20221219monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-participate-in-the-41st-annual-j-p-morgan-healthcare-conference-biib-20221222monthly0.5https://www.biopharmawatch.com/news/BIIB/eisai-submits-supplemental-biologics-license-application-to-fda-for-traditional-approval-o-biib-20230106monthly0.5https://www.biopharmawatch.com/news/BIIB/eisai-files-marketing-authorization-application-for-anti-amyloid-beta-protofibril-antibody-biib-20230115monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-shares-update-on-fda-advisory-committee-meeting-for-tofersen-biib-20230123monthly0.5https://www.biopharmawatch.com/news/BIIB/marketing-authorization-application-for-lecanemab-as-treatment-for-early-alzheimer-s-disea-biib-20230126monthly0.5https://www.biopharmawatch.com/news/BIIB/lecanemab-receives-priority-review-status-in-japan-biib-20230129monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-sage-therapeutics-announce-fda-accepts-filing-of-new-drug-application-and-grant-biib-20230206monthly0.5https://www.biopharmawatch.com/news/BIIB/biologics-license-application-for-lecanemab-designated-for-priority-review-by-china-nation-biib-20230227monthly0.5https://www.biopharmawatch.com/news/BIIB/fda-accepts-eisai-s-filing-of-a-supplemental-biologics-license-application-and-grants-prio-biib-20230305monthly0.5https://www.biopharmawatch.com/news/BIIB/a-statement-from-biogen-on-access-to-leqembi-biib-20230313monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-appoints-chuck-triano-as-head-of-investor-relations-biib-20230314monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-provides-update-on-fda-advisory-committee-meeting-on-tofersen-for-sod1-als-biib-20230322monthly0.5https://www.biopharmawatch.com/news/BIIB/new-data-presented-at-ad-pd-2023-show-biogen-s-biib080-mapt-aso-substantially-reduced-tau--biib-20230329monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-exercises-option-with-denali-to-develop-and-commercialize-antibody-transport-vehicl-biib-20230412monthly0.5https://www.biopharmawatch.com/news/BIIB/fda-grants-accelerated-approval-for-qalsody-tofersen-for-sod1-als-a-major-scientific-advan-biib-20230425monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-publishes-2022-esg-report-biib-20230501monthly0.5https://www.biopharmawatch.com/news/BIIB/health-canada-accepts-new-drug-submission-for-lecanemab-as-treatment-for-early-alzheimer-s-biib-20230515monthly0.5https://www.biopharmawatch.com/news/BIIB/statement-biogen-provides-update-on-parkinson-s-disease-clinical-development-program-biib-20230605monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-stock-trading-halted-today-fda-advisory-committee-to-review-supplemental-biologics--biib-20230609monthly0.5https://www.biopharmawatch.com/news/BIIB/fda-advisory-committee-votes-unanimously-to-confirm-the-clinical-benefit-of-leqembi-lecane-biib-20230609monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-changes-to-its-board-of-directors-biib-20230612monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-2023-annual-shareholder-meeting-preliminary-results-biib-20230626monthly0.5https://www.biopharmawatch.com/news/BIIB/new-data-at-cure-sma-highlight-potential-benefit-of-spinraza-nusinersen-in-infants-and-tod-biib-20230630monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-acquire-reata-pharmaceuticals-biib-20230728monthly0.5https://www.biopharmawatch.com/news/BIIB/leqembi-intravenous-infusion-lecanemab-approved-for-the-treatment-of-alzheimer-s-disease-i-biib-20230925monthly0.5https://www.biopharmawatch.com/news/BIIB/eisai-presents-new-leqembi-lecanemab-irmb-investigational-subcutaneous-formulation-interim-biib-20231025monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-participate-in-the-6th-annual-evercore-isi-healthconx-conference-biib-20231116monthly0.5https://www.biopharmawatch.com/news/BIIB/leqembi-intravenous-infusion-lecanemab-for-the-treatment-of-alzheimer-s-disease-to-be-laun-biib-20231212monthly0.5https://www.biopharmawatch.com/news/BIIB/chmp-issues-positive-opinion-for-biogen-s-skyclarys-omaveloxolone-the-first-therapy-to-tre-biib-20231215monthly0.5https://www.biopharmawatch.com/news/BIIB/centralized-marketing-authorizations-of-generic-versions-of-tecfidera-are-revoked-by-the-e-biib-20231219monthly0.5https://www.biopharmawatch.com/news/BIIB/leqembi-lecanemab-approved-for-the-treatment-of-alzheimer-s-disease-in-china-biib-20240109monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-report-fourth-quarter-and-full-year-2023-financial-results-february-13-2024-biib-20240112monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-received-european-commission-approval-for-skyclarys-omaveloxolone-the-first-therapy-biib-20240212monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-s-qalsody-tofersen-the-first-therapy-to-treat-rare-genetic-form-of-als-received-pos-biib-20240223monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-participate-in-the-td-cowen-44th-annual-health-care-conference-biib-20240226monthly0.5https://www.biopharmawatch.com/news/BIIB/eisai-to-host-annual-information-meeting-with-update-on-leqembi-lecanemab-irmb-biib-20240307monthly0.5https://www.biopharmawatch.com/news/BIIB/update-on-european-medicines-agency-review-of-lecanemab-marketing-authorization-applicatio-biib-20240322monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-report-first-quarter-2024-financial-results-april-24-2024-biib-20240424monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-reports-first-quarter-2024-results-biib-20240424monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-reports-progress-on-corporate-responsibility-priorities-biib-20240502monthly0.5https://www.biopharmawatch.com/news/BIIB/eisai-initiates-rolling-biologics-license-application-to-us-fda-for-leqembi-lecanemab-irmb-biib-20240514monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-participate-in-the-jefferies-global-healthcare-conference-biib-20240523monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-participate-in-the-goldman-sachs-45th-annual-global-healthcare-conference-biib-20240530monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-receives-european-commission-approval-for-qalsody-tofersen-the-first-therapy-to-tre-biib-20240530monthly0.5https://www.biopharmawatch.com/news/BIIB/fda-accepts-eisai-s-filing-of-leqembi-lecanemab-irmb-supplemental-biologics-license-applic-biib-20240609monthly0.5https://www.biopharmawatch.com/news/BIIB/leqembi-lecanemab-for-the-treatment-of-alzheimer-s-disease-launched-in-china-biib-20240627monthly0.5https://www.biopharmawatch.com/news/BIIB/leqembi-lecanemab-approved-for-the-treatment-of-alzheimer-s-disease-in-hong-kong-biib-20240710monthly0.5https://www.biopharmawatch.com/news/BIIB/sage-therapeutics-and-biogen-announce-topline-results-from-phase-2-kinetic-2-study-of-sage-biib-20240724monthly0.5https://www.biopharmawatch.com/news/BIIB/new-clinical-data-demonstrates-three-years-of-continuous-treatment-with-dual-acting-leqemb-biib-20240730monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-reports-second-quarter-2024-results-biib-20240801monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-report-second-quarter-2024-financial-results-august-1-2024-biib-20240801monthly0.5https://www.biopharmawatch.com/news/BIIB/new-higher-dose-nusinersen-efficacy-and-safety-data-presented-at-world-muscle-society-cong-biib-20241008monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-receives-u-s-fda-breakthrough-therapy-designation-for-felzartamab-for-the-treatment-biib-20241009monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-presents-positive-results-from-phase-2-ignaz-study-of-felzartamab-in-iga-nephropath-biib-20241026monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-appoints-daniel-quirk-md-as-chief-medical-officer-biib-20241029monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-neomorph-announce-multi-target-research-collaboration-to-discover-and-develop-m-biib-20241029monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-report-third-quarter-2024-financial-results-october-30-2024-biib-20241030monthly0.5https://www.biopharmawatch.com/news/BIIB/eisai-presents-data-on-benefits-of-long-term-administration-of-dual-acting-lecanemab-at-th-biib-20241030monthly0.5https://www.biopharmawatch.com/news/BIIB/eisai-receives-positive-opinion-from-the-chmp-in-the-european-union-for-lecanemab-in-early-biib-20241114monthly0.5https://www.biopharmawatch.com/news/BIIB/samsung-bioepis-and-biogen-receive-european-commission-ec-approval-for-aflibercept-biosimi-biib-20241118monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-participate-in-the-7th-annual-evercore-healthconx-conference-biib-20241119monthly0.5https://www.biopharmawatch.com/news/BIIB/leqembi-lecanemab-approved-for-the-treatment-of-early-alzheimer-s-disease-in-mexico-biib-20241205monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-appoints-tim-power-as-head-of-investor-relations-biib-20241209monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-biib-20250107monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-report-fourth-quarter-and-full-year-2024-financial-results-february-12-2025-biib-20250121monthly0.5https://www.biopharmawatch.com/news/BIIB/fda-approves-leqembi-lecanemab-irmb-iv-maintenance-dosing-for-the-treatment-of-early-alzhe-biib-20250126monthly0.5https://www.biopharmawatch.com/news/BIIB/update-on-regulatory-review-of-lecanemab-for-early-alzheimer-s-disease-in-the-european-uni-biib-20250131monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-reports-fourth-quarter-and-full-year-2024-results-biib-20250212monthly0.5https://www.biopharmawatch.com/news/BIIB/the-committee-for-medicinal-products-for-human-use-chmp-reaffirms-positive-opinion-for-lec-biib-20250228monthly0.5https://www.biopharmawatch.com/news/BIIB/eisai-receives-regulatory-review-outcome-for-lecanemab-as-a-treatment-for-early-alzheimer--biib-20250303monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-initiates-phase-3-study-of-felzartamab-for-the-treatment-of-late-antibody-mediated--biib-20250311monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-participate-in-the-stifel-2025-virtual-cns-forum-biib-20250311monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-announces-plans-for-new-global-headquarters-and-innovation-hub-in-kendall-square-biib-20250324monthly0.5https://www.biopharmawatch.com/news/BIIB/update-on-regulatory-review-of-lecanemab-for-early-alzheimer-s-disease-by-the-european-com-biib-20250401monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-s-investigational-tau-targeting-therapy-biib080-receives-fda-fast-track-designation-biib-20250402monthly0.5https://www.biopharmawatch.com/news/BIIB/update-on-regulatory-review-of-lecanemab-for-early-alzheimer-s-disease-by-the-european-com-biib-20250414monthly0.5https://www.biopharmawatch.com/news/BIIB/european-commission-grants-marketing-authorization-for-leqembi-lecanemab-biib-20250415monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-participate-in-the-goldman-sachs-46th-annual-global-healthcare-conference-biib-20250603monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-highlights-the-potential-of-felzartamab-for-a-range-of-immune-mediated-diseases-inc-biib-20250611monthly0.5https://www.biopharmawatch.com/news/BIIB/dapirolizumab-pegol-phase-3-data-in-sle-presented-at-the-annual-european-congress-of-rheum-biib-20250612monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-initiates-phase-3-pediatric-study-of-omaveloxolone-for-the-treatment-of-friedreich--biib-20250618monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-advance-investigational-spinal-muscular-atrophy-asset-to-registrational-studies--biib-20250625monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-initiates-phase-3-study-of-felzartamab-for-the-treatment-of-primary-membranous-neph-biib-20250630monthly0.5https://www.biopharmawatch.com/news/BIIB/two-year-real-world-study-of-leqembi-in-the-united-states-presented-at-alzheimer-039-s-ass-biib-20250730monthly0.5https://www.biopharmawatch.com/news/BIIB/new-data-presented-at-aaic-demonstrates-investigational-leqembi-lecanemab-irmb-360-mg-subc-biib-20250730monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-report-second-quarter-2025-financial-results-july-31-2025-biib-20250731monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-reports-second-quarter-2025-results-biib-20250731monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-and-stoke-therapeutics-announce-presentations-of-clinical-data-from-studies-of-zore-biib-20250825monthly0.5https://www.biopharmawatch.com/news/BIIB/austria-and-germany-to-become-the-first-markets-in-the-european-union-eu-to-launch-leqembi-biib-20250825monthly0.5https://www.biopharmawatch.com/news/BIIB/fda-approves-leqembi-iqlik-lecanemab-irmb-subcutaneous-injection-for-maintenance-dosing-fo-biib-20250829monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-participate-in-upcoming-healthcare-conferences-biib-20250902monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-highlights-multiple-assets-and-indications-in-lupus-biib-20250903monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-report-third-quarter-2025-financial-results-october-30-2025-biib-20251030monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-reports-third-quarter-2025-results-biib-20251030monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-to-participate-in-upcoming-investor-conferences-biib-20251104monthly0.5https://www.biopharmawatch.com/news/BIIB/leqembi-lecanemab-iv-maintenance-dosing-for-the-treatment-of-early-alzheimer-s-disease-app-biib-20251113monthly0.5https://www.biopharmawatch.com/news/BIIB/high-dose-regimen-of-nusinersen-receives-positive-chmp-opinion-for-the-treatment-of-spinal-biib-20251117monthly0.5https://www.biopharmawatch.com/news/BIIB/biogen-issues-statement-in-response-to-the-passing-of-charles-weissmann-md-ph-d-co-founder-biib-20251222monthly0.5https://www.biopharmawatch.com/news/BIIB/the-journal-of-the-american-medical-association-jama-neurology-publishes-long-term-results-biib-20251222monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-sonelokimab-phase-3-vela-results2026-06-21T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-phase-3-emerge-study-results2026-06-21T21:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-pricing-of-initial-public-offering-sldb-20180125monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-closing-initial-public-offering-and-sldb-20180130monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-clinical-hold-on-sgt-001-phase-i-ii-clinical-trial-for-duchenn-sldb-20180314monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-provides-update-on-sgt-001-clinical-development-program-for-duchenne-mus-sldb-20180418monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-new-preclinical-data-at-the-american-society-of-gene-and-cell--sldb-20180518monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-fda-removes-clinical-hold-sgt-001-sldb-20180618monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-present-jp-morgan-healthcare-conference-sldb-20190102monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-preliminary-sgt-001-data-and-intention-to-dose-escalate-in-ign-sldb-20190207monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-upcoming-preclinical-data-presentations-at-the-american-societ-sldb-20190415monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-publication-highlighting-important-sldb-20190905monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-participate-chardan-3rd-annual-genetic-sldb-20191002monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-provides-sgt-001-program-update-sldb-20191112monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-provides-data-update-from-sgt-001-development-program-sldb-20191218monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-organizational-changes-to-prioritize-development-of-sgt-001-sldb-20200109monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-appointment-of-ian-f-smith-to-its-board-of-directors-sldb-20200416monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-provides-update-regarding-sgt-001-phase-i-ii-clinical-hold-on-ignite-dmd-sldb-20200507monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-presents-data-duchenne-muscular-dystrophy-gene-sldb-20200514monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-hold-virtual-annual-meeting-of-stockholders-on-june-16-2020-sldb-20200522monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-hold-virtual-annual-meeting-stockholders-june-sldb-20200616monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-appointment-ian-f-smith-chairman-sldb-20200618monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-provides-update-regarding-the-ignite-dmd-phase-i-ii-clinical-hold-sldb-20200724monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-fda-lifts-clinical-hold-on-ignite-dmd-clinical-trial-sldb-20201001monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-participate-virtual-fireside-chat-chardan-4th-sldb-20201002monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-host-third-quarter-2020-financial-results-and-sldb-20201105monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-present-39th-annual-jp-morgan-healthcare-sldb-20210106monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-present-upcoming-investor-conferences-sldb-20210217monthly0.5https://www.biopharmawatch.com/news/SLDB/efficacy-and-safety-data-from-solid-biosciences-ongoing-ignite-dmd-phase-i-ii-clinical-tri-sldb-20210224monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-appointments-to-management-team-and-board-of-directors-sldb-20210304monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-efficacy-and-safety-data-from-the-ongoing-ignite-dmd-clinical-tr-sldb-20210315monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-proposed-public-offering-of-common-stock-sldb-20210317monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-pricing-public-offering-common-stock-sldb-20210318monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-closing-of-public-offering-and-full-exercise-of-over-allotment-sldb-20210323monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-participate-guggenheim-healthcare-talks-sldb-20210325monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-participate-virtual-fireside-chat-chardan-5th-sldb-20210420monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-highlights-expertise-aav-gene-therapy-multiple-sldb-20210504monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-host-first-quarter-2021-financial-results-and-sldb-20210514monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-present-upcoming-scientific-conferences-sldb-20210525monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-present-jefferies-virtual-healthcare-sldb-20210526monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-inducement-grant-to-new-chief-regulatory-officer-sldb-20210607monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-appointment-iman-barilero-pharmd-phd-sldb-20210607monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-strengthens-management-team-to-advance-programs-for-duchenne-muscular-dy-sldb-20210701monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-inducement-grant-new-senior-vice-sldb-20210702monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-appointment-michael-inbar-cpa-mba-sldb-20210819monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-provide-update-long-term-outcomes-data-sldb-20210920monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-participate-upcoming-investor-conferences-sldb-20210920monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-and-forge-biologics-announce-viral-vector-sldb-20211004monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-participate-jefferies-gene-therapyediting-sldb-20211021monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-provides-third-quarter-2021-business-update-and-financial-results-sldb-20211103monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-inducement-grant-to-new-senior-vice-president-human-resources-sldb-20220104monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-present-40th-annual-jp-morgan-healthcare-sldb-20220106monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-participate-svb-leerink-11th-annual-global-sldb-20220210monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-fourth-quarter-and-full-year-2021-financial-results-and-2-year-e-sldb-20220314monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-management-host-call-april-27-2022-discuss-sldb-20220427monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-participate-jefferies-healthcare-conference-sldb-20220602monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-inducement-grant-new-senior-vice-sldb-20220602monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-present-upcoming-scientific-and-patient-sldb-20220623monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-presents-new-sgt-001-ignite-dmd-study-results-at-world-muscle-society-20-sldb-20221013monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-a-1-for-15-reverse-stock-split-sldb-20221027monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-provides-third-quarter-2022-business-update-and-financial-results-sldb-20221110monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-participate-piper-sandler-34th-annual-sldb-20221122monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-stockholder-approval-acquisition-sldb-20221201monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-inducement-grants-under-nasdaq-listing-sldb-20221205monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-appoints-kevin-tan-cfa-chief-financial-officer-sldb-20230109monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-present-41st-annual-jp-morgan-healthcare-sldb-20230109monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-outlines-strategy-leadership-precision-genetic-sldb-20230110monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-and-phlox-therapeutics-announce-strategic-research-collaboration-focused-sldb-20230111monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-present-svb-securities-global-biopharma-sldb-20230208monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-present-at-barclays-global-healthcare-conference-sldb-20230307monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-participate-bmo-biopharma-spotlight-series-sldb-20230321monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-provides-fourth-quarter-and-full-year-2022-sldb-20230323monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-present-22nd-annual-needham-healthcare-sldb-20230413monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-participate-chardans-7th-annual-genetic-sldb-20230421monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-present-jmp-securities-life-sciences-sldb-20230508monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-provides-first-quarter-business-update-and-sldb-20230511monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-present-american-society-gene-and-cell-therapy-sldb-20230516monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-participate-jefferies-healthcare-conference-sldb-20230601monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-provides-second-quarter-business-update-and-financial-results-sldb-20230814monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-participate-citis-18th-annual-biopharma-sldb-20230831monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-participate-upcoming-investor-conferences-sldb-20230905monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-appoints-gabriel-brooks-m-d-as-chief-medical-officer-sldb-20231002monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-appoints-gabriel-brooks-m-d-chief-medical-sldb-20231002monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-provides-third-quarter-business-update-and-sldb-20231108monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-participate-jefferies-london-healthcare-sldb-20231109monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-participate-35th-annual-piper-sandler-sldb-20231122monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-109-million-private-placement-sldb-20240108monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-granted-fda-orphan-drug-designation-duchenne-sldb-20240116monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-participate-upcoming-investor-conferences-sldb-20240306monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-licensing-agreement-with-armatus-bio-for-the-use-of-aav-slb101-sldb-20240307monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-provides-fourth-quarter-and-full-year-2023-sldb-20240313monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-participate-cantors-virtual-muscular-dystrophy-sldb-20240327monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-receives-rare-pediatric-disease-designation-from-the-fda-for-duchenne-mu-sldb-20240401monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-inducement-grants-under-nasdaq-sldb-20240403monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-present-american-society-gene-and-cell-sldb-20240507monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-provides-first-quarter-2024-business-update-and-financial-results-sldb-20240515monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-joins-the-russell-3000-index-sldb-20240701monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-inducement-grant-under-nasdaq-listing-sldb-20240701monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-second-quarter-2024-financial-results-and-provides-business-upda-sldb-20240813monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-inducement-grants-under-nasdaq-sldb-20241002monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-participate-truist-securities-biopharma-sldb-20241031monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-third-quarter-2024-financial-results-and-provides-business-updat-sldb-20241106monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-collaboration-with-mayo-clinic-to-accelerate-gene-therapy-inno-sldb-20241204monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-added-to-the-nasdaq-biotechnology-index-sldb-20241223monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-fda-ind-clearance-for-first-in-industry-dual-route-of-administ-sldb-20250107monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-outlines-key-priorities-for-advancing-diversified-neuromuscular-and-card-sldb-20250115monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-receives-fda-fast-track-designation-for-sgt-212-dual-route-of-administra-sldb-20250121monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-positive-initial-clinical-data-from-next-generation-duchenne-gen-sldb-20250218monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-sldb-20250306monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-present-2025-muscular-dystrophy-association-sldb-20250312monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-inducement-grants-under-nasdaq-sldb-20250501monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-first-quarter-2025-financial-results-and-provides-business-updat-sldb-20250515monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-inducement-grants-under-nasdaq-sldb-20250701monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-fda-ind-and-health-canada-cta-approval-for-first-in-class-card-sldb-20250708monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-receives-fda-fast-track-designation-for-sgt-501-first-in-class-gene-ther-sldb-20250723monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-inducement-grants-under-nasdaq-sldb-20250801monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-second-quarter-2025-financial-results-and-provides-business-upda-sldb-20250812monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-participate-upcoming-investor-conferences-sldb-20250828monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-present-2025-neuromuscular-study-group-annual-sldb-20250925monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-present-upcoming-scientific-meetings-sldb-20251001monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-inducement-grants-under-nasdaq-sldb-20251001monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-participate-upcoming-investor-conferences-sldb-20251030monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-participate-upcoming-investor-conferences-sldb-20251111monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-duchenne-muscular-dystrophy-added-to-national-recommended-unif-sldb-20251216monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-present-44th-annual-jp-morgan-healthcare-sldb-20260106monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-doses-first-participant-in-first-in-class-phase-1b-falcon-trial-evaluati-sldb-20260112monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-to-present-at-the-2026-muscular-dystrophy-association-mda-clinical-scien-sldb-20260306monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-announces-oversubscribed-240-million-private-placement-sldb-20260306monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-provides-interim-positive-clinical-update-sldb-20260311monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-sldb-20260319monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-sldb-20260501monthly0.5https://www.biopharmawatch.com/news/SLDB/solid-biosciences-doses-first-participant-in-phase-3-impact-duchenne-clinical-trial-evalua-sldb-20260507monthly0.5https://www.biopharmawatch.com/news/RXRX/dr-yolanda-chong-joins-recursion-pharmaceuticals-to-advance-discovery-platform-rxrx-20170418monthly0.5https://www.biopharmawatch.com/news/RXRX/deep-learning-luminary-yoshua-bengio-joins-recursion-pharmaceuticals-as-key-advisor-rxrx-20170428monthly0.5https://www.biopharmawatch.com/news/RXRX/dr-chand-sishta-to-lead-regulatory-affairs-for-recursion-pharmaceuticals-rxrx-20170628monthly0.5https://www.biopharmawatch.com/news/RXRX/pharmaceutical-business-development-leader-dr-kevin-lynch-joins-recursion-as-chief-busines-rxrx-20180501monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-pharmaceuticals-receives-grant-to-leverage-ai-enabled-discovery-platform-in-infe-rxrx-20180507monthly0.5https://www.biopharmawatch.com/news/RXRX/medicinal-chemistry-leaders-drs-phil-carpino-and-mike-genin-form-new-chemistry-team-at-rec-rxrx-20180515monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-receives-fda-clearance-of-investigational-new-drug-application-to-initiate-first-rxrx-20180710monthly0.5https://www.biopharmawatch.com/news/RXRX/veteran-biopharma-operations-leader-tina-m-larson-to-join-recursion-as-chief-operating-off-rxrx-20180710monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-pharmaceuticals-named-one-of-utah-s-2018-top-workplaces-by-the-salt-lake-tribune-rxrx-20181105monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-secures-1-6m-nih-phase-2-sbir-grant-to-identify-therapeutic-candidates-for-senes-rxrx-20181108monthly0.5https://www.biopharmawatch.com/news/RXRX/r-martin-chavez-appointed-chairman-of-recursion-s-board-of-directors-rxrx-20210301monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-pharmaceuticals-announces-pricing-of-initial-public-offering-rxrx-20210416monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-announces-first-internally-developed-nce-advanced-to-ind-enabling-studies-to-pot-rxrx-20210525monthly0.5https://www.biopharmawatch.com/news/RXRX/altitude-lab-launches-investor-coalition-to-fund-and-mentor-healthcare-startups-in-utah-rxrx-20210608monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-is-granted-orphan-drug-designation-for-rec-4881-for-the-potential-treatment-of-f-rxrx-20210929monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-to-participate-in-upcoming-investor-conferences-rxrx-20220302monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-to-participate-in-upcoming-investor-conference-rxrx-20220502monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-is-granted-eu-orphan-drug-designation-for-rec-4881-for-the-potential-treatment-o-rxrx-20220721monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-receives-iss-esg-prime-rating-and-plans-to-participate-in-the-goldman-sachs-glob-rxrx-20220818monthly0.5https://www.biopharmawatch.com/news/RXRX/community-leaders-unite-to-provide-support-and-resources-for-thousands-of-utahns-with-rare-rxrx-20230221monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-to-participate-in-upcoming-investor-conferences-rxrx-20230301monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-publishes-second-annual-environmental-social-and-governance-report-rxrx-20230328monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-to-participate-in-upcoming-investor-conference-rxrx-20230403monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-to-participate-in-upcoming-investor-conferences-rxrx-20230502monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-appoints-david-mauro-m-d-ph-d-as-chief-medical-officer-rxrx-20230516monthly0.5https://www.biopharmawatch.com/news/RXRX/altitude-lab-relocates-to-gateway-s-biohive-hub-rxrx-20230525monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-to-participate-in-upcoming-investor-conferences-rxrx-20230601monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-s-phase-2-trial-for-the-treatment-of-cerebral-cavernous-malformation-has-fully-e-rxrx-20230613monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-celebrates-opening-of-its-canadian-headquarters-in-toronto-with-government-offic-rxrx-20230626monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-announces-collaboration-and-50-million-investment-from-nvidia-to-accelerate-grou-rxrx-20230712monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-launches-valence-labs-at-icml-with-a-commitment-to-open-science-including-1-mill-rxrx-20230726monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-to-participate-in-upcoming-investor-conference-rxrx-20230801monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-bridges-the-protein-and-chemical-space-with-massive-protein-ligand-interaction-p-rxrx-20230808monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-to-participate-in-upcoming-investor-conferences-rxrx-20230905monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-to-participate-in-upcoming-investor-conference-rxrx-20231102monthly0.5https://www.biopharmawatch.com/news/RXRX/bayer-and-recursion-focus-research-collaboration-on-oncology-rxrx-20231109monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-on-january-8-rxrx-20240103monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-unveils-lowe-drug-discovery-software-at-the-j-p-morgan-healthcare-conference-rxrx-20240108monthly0.5https://www.biopharmawatch.com/news/RXRX/altitude-lab-startups-raise-over-120m-in-capital-rxrx-20240124monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-to-host-public-l-earnings-call-on-february-27-rxrx-20240220monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-to-participate-in-upcoming-investor-conferences-rxrx-20240301monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-hosts-second-annual-rare-disease-day-events-for-utah-s-rare-disease-community-rxrx-20240301monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-publishes-annual-environmental-social-and-governance-report-rxrx-20240326monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-to-participate-in-upcoming-investor-conference-rxrx-20240402monthly0.5https://www.biopharmawatch.com/news/RXRX/altitude-lab-secures-small-business-administration-growth-fund-accelerator-grant-to-launch-rxrx-20240430monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-to-participate-in-upcoming-investor-conferences-rxrx-20240501monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-to-report-first-quarter-2024-business-updates-and-financial-results-on-may-9-rxrx-20240502monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-announces-completion-of-nvidia-powered-biohive-2-the-largest-supercomputer-in-ph-rxrx-20240513monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-appoints-robert-hershberg-m-d-ph-d-as-new-chair-of-the-board-rxrx-20240524monthly0.5https://www.biopharmawatch.com/news/RXRX/power-of-recursion-os-on-display-at-genome-scale-in-nature-genetics-paper-detailing-potent-rxrx-20240529monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-to-participate-in-upcoming-investor-conferences-rxrx-20240603monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-announces-pricing-of-200-million-public-offering-of-class-a-common-stock-rxrx-20240627monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-to-report-second-quarter-2024-business-updates-and-financial-results-on-august-8-rxrx-20240805monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-updates-l-earnings-call-on-august-8th-to-8-30-am-et-6-30-am-mt-rxrx-20240808monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-provides-business-updates-and-reports-second-quarter-2024-financial-results-rxrx-20240808monthly0.5https://www.biopharmawatch.com/news/RXRX/correction-recursion-provides-business-updates-and-reports-second-quarter-2024-financial-r-rxrx-20240808monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-to-report-third-quarter-2024-business-updates-and-financial-results-on-november--rxrx-20241030monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-and-exscientia-shareholders-approve-the-proposed-combination-rxrx-20241113monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-pharmaceuticals-reports-grant-of-inducement-awards-as-permitted-by-the-nasdaq-li-rxrx-20241220monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-to-present-at-43rd-annual-jp-morgan-healthcare-conference-rxrx-20250106monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-announces-two-key-investigational-oncology-drugs-advancing-to-clinical-trials-ta-rxrx-20250107monthly0.5https://www.biopharmawatch.com/news/RXRX/altitude-lab-startups-raise-154m-in-capital-rxrx-20250218monthly0.5https://www.biopharmawatch.com/news/RXRX/altitude-lab-launches-pre-seed-venture-fund-anchored-by-recursion-ceo-chris-gibson-enablin-rxrx-20250219monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-to-report-fourth-quarter-and-fiscal-year-2024-business-updates-and-financial-res-rxrx-20250224monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-to-participate-in-upcoming-investor-conference-rxrx-20250401monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-announces-first-patient-dosed-in-phase-1-clinical-study-of-rec-3565-a-selective--rxrx-20250408monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-and-enamine-release-new-ai-enabled-targeted-compound-libraries-rxrx-20250409monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-to-present-preliminary-clinical-data-from-the-ongoing-phase-1b-2-trial-of-rec-48-rxrx-20250423monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-to-report-first-quarter-2025-business-updates-and-financial-results-on-may-5th-rxrx-20250428monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-to-participate-in-upcoming-investor-conferences-rxrx-20250506monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-to-participate-in-upcoming-investor-conferences-rxrx-20250530monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-to-participate-in-upcoming-investor-conferences-rxrx-20250827monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-to-report-third-quarter-2025-business-updates-and-financial-results-on-november--rxrx-20251028monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-to-present-at-44th-annual-j-p-morgan-healthcare-conference-rxrx-20260106monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-to-report-fourth-quarter-and-full-year-2025-business-updates-and-financial-resul-rxrx-20260218monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-to-participate-in-upcoming-investor-conferences-rxrx-20260407monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-to-report-first-quarter-2026-business-updates-and-financial-results-on-may-6-rxrx-20260429monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-reports-grant-of-inducement-awards-as-permitted-by-the-nasdaq-listing-rules-rxrx-20260529monthly0.5https://www.biopharmawatch.com/news/RXRX/recursion-to-participate-in-upcoming-investor-conferences-rxrx-20260602monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-of-shanghai-raises-over-30-million-in-series-a-funding-zlab-20140827monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-secures-over-100m-series-b-financing-from-leading-healthcare-investors-zlab-20160108monthly0.5https://www.biopharmawatch.com/news/ZLAB/paratek-pharmaceuticals-and-zai-lab-announce-collaboration-development-and-license-agreeme-zlab-20170424monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-secures-series-c-financing-zlab-20170628monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-limited-announces-pricing-of-u-s-initial-public-offering-of-adss-zlab-20170920monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-limited-announces-closing-of-u-s-initial-public-offering-of-adss-zlab-20170922monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-added-into-the-nasdaq-biotechnology-index-zlab-20181218monthly0.5https://www.biopharmawatch.com/news/ZLAB/turning-point-therapeutics-granted-fast-track-designation-for-repotrectinib-in-ntrk-positi-zlab-20200825monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-first-patient-dosed-in-china-in-a-potentially-registrational-study-of-re-zlab-20201029monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-upcoming-presentation-at-39th-annual-j-p-morgan-healthcare-conference-zlab-20201230monthly0.5https://www.biopharmawatch.com/news/ZLAB/turning-point-and-zai-lab-broaden-collaboration-zlab-20210111monthly0.5https://www.biopharmawatch.com/news/ZLAB/argenx-announces-go-decision-in-adhere-trial-of-efgartigimod-in-chronic-inflammatory-demye-zlab-20210201monthly0.5https://www.biopharmawatch.com/news/ZLAB/argenx-announces-fda-acceptance-of-bla-filing-for-efgartigimod-for-the-treatment-of-genera-zlab-20210302monthly0.5https://www.biopharmawatch.com/news/ZLAB/turning-point-therapeutics-announces-new-preclinical-data-for-three-drug-candidates-zlab-20210409monthly0.5https://www.biopharmawatch.com/news/ZLAB/amgen-s-investigational-targeted-treatment-bemarituzumab-granted-breakthrough-therapy-desi-zlab-20210419monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-proposed-public-offering-of-american-depositary-shares-zlab-20210419monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-pricing-of-public-offering-of-american-depositary-shares-and-ordinary-sh-zlab-20210420monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-closing-of-public-offering-of-american-depositary-shares-and-full-exerci-zlab-20210423monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-to-announce-first-quarter-2021-financial-results-on-may-10-2021-zlab-20210426monthly0.5https://www.biopharmawatch.com/news/ZLAB/novocure-announces-fda-approval-of-ide-supplement-for-phase-3-pivotal-lunar-trial-of-tumor-zlab-20210518monthly0.5https://www.biopharmawatch.com/news/ZLAB/regeneron-resumes-enrollment-of-fl-and-dlbcl-patients-in-odronextamab-trials-zlab-20210518monthly0.5https://www.biopharmawatch.com/news/ZLAB/paratek-pharmaceuticals-announces-fda-approval-of-nuzyra-omadacycline-oral-only-dosing-reg-zlab-20210601monthly0.5https://www.biopharmawatch.com/news/ZLAB/argenx-announces-publication-of-phase-3-adapt-trial-results-of-efgartigimod-for-the-treatm-zlab-20210616monthly0.5https://www.biopharmawatch.com/news/ZLAB/mirati-therapeutics-adagrasib-receives-breakthrough-therapy-designation-from-u-s-food-and--zlab-20210624monthly0.5https://www.biopharmawatch.com/news/ZLAB/novocure-presents-final-safety-and-efficacy-results-from-its-phase-2-pilot-hepanova-trial--zlab-20210701monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-to-announce-second-quarter-2021-financial-results-zlab-20210722monthly0.5https://www.biopharmawatch.com/news/ZLAB/qinlock-ripretinib-approved-in-taiwan-for-treatment-of-advanced-gastrointestinal-stromal-t-zlab-20210901monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-to-host-virtual-research-and-development-day-on-september-22-2021-zlab-20210909monthly0.5https://www.biopharmawatch.com/news/ZLAB/novocure-announces-clinical-trial-collaboration-with-roche-to-evaluate-tumor-treating-fiel-zlab-20210914monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-expands-u-s-operations-to-join-the-cambridge-biotechnology-community-zlab-20210916monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-holds-virtual-research-and-development-day-zlab-20210922monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-upcoming-presentations-in-october-investor-conferences-zlab-20211011monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-first-patient-treated-in-greater-china-portion-of-potentially-registrati-zlab-20211025monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-third-quarter-2021-financial-results-and-corporate-updates-zlab-20211109monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-and-blueprint-medicines-announce-strategic-collaboration-and-license-agreement-for-zlab-20211109monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-first-patient-dosed-in-greater-china-in-global-registrational-clinical-t-zlab-20211111monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-first-patient-dosed-in-greater-china-in-global-registrational-clinical-t-zlab-20211115monthly0.5https://www.biopharmawatch.com/news/ZLAB/2-the-top-phase-2-trial-reports-positive-top-line-results-in-newly-diagnosed-glioblastoma-zlab-20211116monthly0.5https://www.biopharmawatch.com/news/ZLAB/novocure-announces-last-patient-enrolled-in-phase-3-pivotal-lunar-trial-of-tumor-treating--zlab-20211122monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-partner-argenx-announces-u-s-food-and-drug-administration-fda-approval-of-vyvgart--zlab-20211217monthly0.5https://www.biopharmawatch.com/news/ZLAB/fda-grants-breakthrough-therapy-designation-for-cullinan-oncology-s-cln-081-in-patients-wi-zlab-20220104monthly0.5https://www.biopharmawatch.com/news/ZLAB/argenx-announces-vyvgart-approval-in-japan-for-the-treatment-of-generalized-myasthenia-gra-zlab-20220120monthly0.5https://www.biopharmawatch.com/news/ZLAB/u-s-food-and-drug-administration-fda-accepts-mirati-therapeutics-new-drug-application-for--zlab-20220215monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-breakthrough-therapy-designation-granted-for-repotrectinib-in-china-zlab-20220217monthly0.5https://www.biopharmawatch.com/news/ZLAB/argenx-announces-positive-topline-phase-3-data-from-adapt-sc-study-evaluating-subcutaneous-zlab-20220322monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-statement-on-sec-listing-matter-zai-lab-limited-zlab-20220328monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-to-present-new-oncology-research-at-2022-aacr-annual-meeting-zai-lab-limited-zlab-20220406monthly0.5https://www.biopharmawatch.com/news/ZLAB/turning-point-therapeutics-announces-positive-topline-data-by-blinded-independent-central--zlab-20220413monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-plants-a-tree-for-every-employee-on-earth-day-2022-zai-lab-limited-zlab-20220419monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-to-announce-first-quarter-2022-financial-results-on-may-10-2022-zai-lab-limited-zlab-20220420monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-engagement-of-kpmg-llp-a-u-s-auditor-as-the-company-s-independent-regist-zlab-20220421monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-and-turning-point-therapeutics-announce-topline-analysis-in-china-subpopulation-fo-zlab-20220428monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-to-present-new-prime-subgroup-analysis-for-niraparib-in-ovarian-cancer-at-2022-asc-zlab-20220531monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-breakthrough-therapy-designations-granted-for-repotrectinib-in-china-zai-zlab-20220610monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-primary-listing-on-the-main-board-of-the-stock-exchange-of-hong-kong-lim-zlab-20220627monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-acceptance-by-china-s-nmpa-of-the-bla-for-efgartigimod-for-patients-with-zlab-20220713monthly0.5https://www.biopharmawatch.com/news/ZLAB/argenx-announces-european-commission-approval-of-vyvgart-efgartigimod-alfa-fcab-for-the-tr-zlab-20220812monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-participation-in-september-investor-conferences-zai-lab-limited-zlab-20220823monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-s-statement-regarding-u-s-china-agreement-concerning-pcaob-inspection-and-review-o-zlab-20220826monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-to-present-analysis-of-the-impact-of-timing-for-zejula-niraparib-maintenance-treat-zlab-20220920monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-believes-its-engagement-of-kpmg-llp-is-consistent-with-pcaob-requirements-and-comp-zlab-20220929monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-launches-its-first-trust-report-zai-lab-limited-zlab-20221014monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-the-appointment-of-dr-peter-huang-as-chief-scientific-officer-zai-lab-li-zlab-20221108monthly0.5https://www.biopharmawatch.com/news/ZLAB/argenx-announces-u-s-fda-acceptance-of-biologics-license-application-for-subcutaneous-efga-zlab-20221122monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-partner-mirati-therapeutics-presents-late-breaking-results-evaluating-concurrent-a-zlab-20221205monthly0.5https://www.biopharmawatch.com/news/ZLAB/mirati-therapeutics-announces-u-s-fda-accelerated-approval-of-krazati-adagrasib-as-a-targe-zlab-20221212monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-participation-in-january-investor-conferences-zai-lab-limited-zlab-20221220monthly0.5https://www.biopharmawatch.com/news/ZLAB/mirati-announces-adagrasib-krazati-receives-breakthrough-therapy-designation-from-fda-for--zlab-20221221monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-nda-for-sulbactam-durlobactam-sul-dur-granted-priority-review-by-china-s-zlab-20230130monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-participation-in-february-investor-conferences-zai-lab-limited-zlab-20230131monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-to-present-two-new-phase-3-analyses-for-niraparib-in-ovarian-cancer-at-the-2023-es-zlab-20230222monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-participation-in-march-investor-conferences-zai-lab-limited-zlab-20230228monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-presentation-of-results-of-the-lunar-phase-3-clinical-trial-in-non-small-zlab-20230426monthly0.5https://www.biopharmawatch.com/news/ZLAB/journal-of-clinical-oncology-publishes-rapid-communication-featuring-updated-clinical-data-zlab-20230427monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-to-highlight-new-data-from-its-oncology-pipeline-at-2023-asco-annual-meeting-zai-l-zlab-20230601monthly0.5https://www.biopharmawatch.com/news/ZLAB/argenx-announces-u-s-food-and-drug-administration-approval-of-vyvgart-hytrulo-efgartigimod-zlab-20230620monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-and-argenx-announce-approval-of-vyvgart-efgartigimod-alfa-injection-for-generalize-zlab-20230630monthly0.5https://www.biopharmawatch.com/news/ZLAB/updated-data-from-trident-1-trial-show-durable-efficacy-benefits-with-repotrectinib-for-pa-zlab-20230816monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-breakthrough-therapy-designation-granted-for-repotrectinib-for-treatment-zlab-20230830monthly0.5https://www.biopharmawatch.com/news/ZLAB/argenx-announces-positive-chmp-opinion-for-subcutaneous-efgartigimod-for-generalized-myast-zlab-20230915monthly0.5https://www.biopharmawatch.com/news/ZLAB/tivdak-tisotumab-vedotin-tftv-significantly-prolonged-overall-survival-in-patients-with-re-zlab-20231022monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-the-first-listing-of-vyvgart-efgartigimod-alfa-injection-and-other-updat-zlab-20231212monthly0.5https://www.biopharmawatch.com/news/ZLAB/argenx-announces-approval-of-vyvdura-efgartigimod-alfa-and-hyaluronidase-qvfc-injection-fo-zlab-20240117monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-to-announce-full-year-2023-financial-results-and-recent-corporate-updates-on-febru-zlab-20240125monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-to-present-final-overall-survival-os-data-from-phase-3-nora-study-of-zejula-nirapa-zlab-20240306monthly0.5https://www.biopharmawatch.com/news/ZLAB/argenx-announces-approval-of-vyvgart-efgartigimod-alfa-in-japan-for-adults-with-primary-im-zlab-20240326monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-partner-novocure-announces-metis-phase-3-clinical-trial-met-primary-endpoint-demon-zlab-20240327monthly0.5https://www.biopharmawatch.com/news/ZLAB/argenx-advances-clinical-development-of-efgartigimod-in-primary-sjogren-s-disease-zai-lab--zlab-20240327monthly0.5https://www.biopharmawatch.com/news/ZLAB/bristol-myers-squibb-presents-new-interim-long-term-efficacy-data-from-the-emergent-4-tria-zlab-20240406monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-statement-on-executive-management-team-s-agreement-on-share-activities-zai-lab-lim-zlab-20240411monthly0.5https://www.biopharmawatch.com/news/ZLAB/argenx-data-highlight-evidence-that-vyvgart-and-vyvgart-hytrulo-drive-transformative-outco-zlab-20240416monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-initiates-global-phase-2-clinical-trial-evaluating-zl-1102-as-a-topical-treatment--zlab-20240522monthly0.5https://www.biopharmawatch.com/news/ZLAB/metis-phase-3-clinical-trial-met-primary-endpoint-significantly-delaying-time-to-intracran-zlab-20240603monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-dr-harald-reinhart-to-retire-as-head-of-global-development-for-neuroscie-zlab-20240611monthly0.5https://www.biopharmawatch.com/news/ZLAB/u-s-food-and-drug-administration-approves-augtyro-repotrectinib-a-next-generation-tyrosine-zlab-20240613monthly0.5https://www.biopharmawatch.com/news/ZLAB/argenx-announces-fda-approval-of-vyvgart-hytrulo-for-chronic-inflammatory-demyelinating-po-zlab-20240621monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-to-announce-second-quarter-2024-financial-results-and-recent-corporate-updates-on--zlab-20240710monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-supported-study-published-in-cell-provides-new-insights-with-potential-to-improve--zlab-20240715monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-and-argenx-announce-approval-of-efgartigimod-alfa-injection-subcutaneous-injection-zlab-20240716monthly0.5https://www.biopharmawatch.com/news/ZLAB/paratek-pharmaceuticals-announces-positive-top-line-efficacy-and-safety-data-from-post-mar-zlab-20240718monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-participation-in-september-investor-conferences-zlab-20240822monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-to-present-preliminary-data-from-phase-1-trial-of-zl-1218-an-investigational-anti--zlab-20240827monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-to-present-preclinical-data-of-zl-1503-an-il-13-il-31-bispecific-antibody-for-the--zlab-20240917monthly0.5https://www.biopharmawatch.com/news/ZLAB/u-s-food-and-drug-administration-approves-bristol-myers-squibb-s-cobenfy-xanomeline-and-tr-zlab-20240926monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-to-present-data-from-phase-1-trial-of-zl-1310-its-investigational-antibody-drug-co-zlab-20241009monthly0.5https://www.biopharmawatch.com/news/ZLAB/fda-approves-novocure-s-optune-lua-for-the-treatment-of-metastatic-non-small-cell-lung-can-zlab-20241015monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-to-announce-third-quarter-2024-financial-results-and-recent-corporate-updates-on-n-zlab-20241016monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-to-host-webcast-presentation-to-discuss-data-from-early-clinical-program-evaluatin-zlab-20241017monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-participation-in-november-and-december-investor-conferences-zlab-20241018monthly0.5https://www.biopharmawatch.com/news/ZLAB/zl-1310-an-investigational-dll3-targeted-antibody-drug-conjugate-adc-demonstrates-promisin-zlab-20241024monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-reports-positive-topline-data-from-phase-3-bridging-trial-evaluating-karxt-for-the-zlab-20241029monthly0.5https://www.biopharmawatch.com/news/ZLAB/bristol-myers-squibb-presents-new-long-term-data-from-the-emergent-program-evaluating-cobe-zlab-20241031monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-and-argenx-announce-approval-of-vyvgart-hytrulo-for-chronic-inflammatory-demyelina-zlab-20241111monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-proposed-public-offering-of-american-depositary-shares-zlab-20241113monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-anticipated-closing-of-public-offering-of-american-depositary-shares-and-zlab-20241118monthly0.5https://www.biopharmawatch.com/news/ZLAB/argenx-advances-clinical-development-of-efgartigimod-sc-in-idiopathic-inflammatory-myopath-zlab-20241120monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-and-pfizer-announce-strategic-collaboration-on-the-novel-antibacterial-drug-xacdur-zlab-20241121monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-the-inclusion-of-augtyro-repotrectinib-for-ros1-nsclc-and-other-updates--zlab-20241127monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-and-novocure-announce-positive-topline-results-from-phase-3-panova-3-clinical-tria-zlab-20241202monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-participation-in-investor-conference-in-january-2025-zlab-20241212monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-strategic-partnership-with-medilink-therapeutics-to-develop-a-novel-lrrc-zlab-20250109monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-and-vertex-announce-strategic-agreement-to-develop-and-commercialize-povetacicept--zlab-20250110monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-positive-topline-results-for-tivdak-in-the-china-subpopulation-of-the-gl-zlab-20250115monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-acceptance-of-new-drug-application-for-karxt-for-the-treatment-of-schizo-zlab-20250117monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-receives-orphan-drug-designation-from-the-u-s-fda-for-zl-1310-dll3-adc-for-the-tre-zlab-20250122monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-provide-recent-zlab-20250128monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-participation-in-investor-conferences-in-march-2025-zlab-20250303monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-acceptance-of-biologics-license-application-for-tivdak-for-the-treatment-zlab-20250312monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-to-present-new-data-from-internally-developed-next-generation-oncology-candidates--zlab-20250326monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-complies-with-the-hfcaa-not-subject-to-delisting-zlab-20250410monthly0.5https://www.biopharmawatch.com/news/ZLAB/argenx-announces-fda-approval-of-vyvgart-hytrulo-prefilled-syringe-for-self-injection-in-g-zlab-20250410monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-to-announce-first-quarter-2025-financial-results-and-recent-corporate-updates-on-m-zlab-20250414monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-acceptance-of-supplemental-new-drug-application-for-repotrectinib-for-pa-zlab-20250421monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-to-present-data-from-phase-1-trial-of-dll3-targeted-antibody-drug-conjugate-adc-zl-zlab-20250423monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-presents-data-highlighting-potential-of-internally-developed-next-generation-oncol-zlab-20250425monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-complies-with-the-hfcaa-not-subject-to-delisting-zlab-20250508monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-receives-u-s-fda-fast-track-designation-for-zl-1310-a-dll3-targeted-antibody-drug--zlab-20250519monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-participation-in-investor-conferences-in-june-2025-zlab-20250530monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-and-novocure-announce-results-from-the-phase-3-panova-3-trial-of-tumor-treating-fi-zlab-20250531monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-presents-positive-phase-1-data-for-zl-1310-a-dll3-targeted-adc-demonstrating-robus-zlab-20250602monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-presents-new-preclinical-data-for-zl-1503-an-il-13-il-31r-bispecific-antibody-for--zlab-20250613monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-positive-topline-phase-3-results-for-bemarituzumab-in-fibroblast-growth--zlab-20250630monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-to-announce-second-quarter-2025-financial-results-and-recent-corporate-updates-on--zlab-20250710monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-establishes-oncology-scientific-advisory-board-zlab-20250813monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-china-national-medical-products-administration-grants-innovative-medical-zlab-20250819monthly0.5https://www.biopharmawatch.com/news/ZLAB/argenx-announces-positive-topline-results-from-adapt-seron-study-of-vyvgart-in-patients-wi-zlab-20250825monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-participation-in-investor-conferences-in-september-2025-zlab-20250828monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-approval-of-tivdak-for-patients-with-recurrent-or-metastatic-cervical-ca-zlab-20250901monthly0.5https://www.biopharmawatch.com/news/ZLAB/vertex-announces-key-advancements-across-kidney-portfolio-zlab-20250925monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-oral-presentation-of-updated-data-from-global-phase-1-trial-of-zocilurta-zlab-20251013monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-to-announce-third-quarter-2025-financial-results-and-recent-corporate-updates-on-n-zlab-20251015monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-updated-phase-1-data-for-zocilurtatug-pelitecan-formerly-zl-1310-demonst-zlab-20251024monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-participation-in-investor-conferences-in-november-and-december-2025-zlab-20251031monthly0.5https://www.biopharmawatch.com/news/ZLAB/update-on-amgen-s-bemarituzumab-phase-1b-3-fortitude-102-study-zlab-20251104monthly0.5https://www.biopharmawatch.com/news/ZLAB/vertex-presents-updated-phase-1-2-data-from-ruby-3-study-that-continue-to-demonstrate-best-zlab-20251110monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-dosing-of-first-participant-in-global-phase-1-1b-study-of-zl-1503-an-il--zlab-20251208monthly0.5https://www.biopharmawatch.com/news/ZLAB/argenx-provides-update-on-uplighted-studies-of-efgartigimod-sc-in-thyroid-eye-disease-zlab-20251215monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-announces-national-medical-products-administration-nmpa-approval-of-augtyro-repotr-zlab-20260106monthly0.5https://www.biopharmawatch.com/news/ZLAB/u-s-fda-approves-novocure-s-optune-pax-for-the-treatment-of-locally-advanced-pancreatic-ca-zlab-20260212monthly0.5https://www.biopharmawatch.com/news/ZLAB/argenx-announces-positive-topline-results-from-phase-3-adapt-oculus-trial-of-vyvgart-in-oc-zlab-20260226monthly0.5https://www.biopharmawatch.com/news/ZLAB/vertex-announces-positive-week-36-interim-analysis-results-for-primary-and-all-secondary-e-zlab-20260309monthly0.5https://www.biopharmawatch.com/news/ZLAB/viridian-therapeutics-announces-positive-topline-results-from-elegrobart-phase-3-reveal-1--zlab-20260330monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-presents-new-data-demonstrating-zocilurtatug-pelitecan-zoci-induces-rapid-and-robu-zlab-20260417monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-presents-new-preclinical-data-suggesting-zl-1503-an-il-13-il-31r-bispecific-antibo-zlab-20260418monthly0.5https://www.biopharmawatch.com/news/ZLAB/viridian-therapeutics-announces-positive-topline-results-from-elegrobart-phase-3-reveal-2--zlab-20260505monthly0.5https://www.biopharmawatch.com/news/ZLAB/argenx-announces-u-s-fda-approval-expanding-vyvgart-and-vyvgart-hytrulo-for-use-in-all-adu-zlab-20260508monthly0.5https://www.biopharmawatch.com/news/ZLAB/vertex-announces-us-fda-acceptance-of-biologics-license-application-for-accelerated-approv-zlab-20260601monthly0.5https://www.biopharmawatch.com/news/ZLAB/argenx-presents-new-efgartigimod-data-showing-long-term-sustained-patient-benefit-in-myosi-zlab-20260603monthly0.5https://www.biopharmawatch.com/news/ZLAB/phase-3-nora-data-of-zejula-niraparib-demonstrate-significant-pfs-benefit-in-chinese-women-zlab-20200919monthly0.5https://www.biopharmawatch.com/news/ZLAB/zai-lab-and-novocure-announce-pivotal-lunar-study-in-non-small-cell-lung-cancer-met-primar-zlab-20230105monthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-nasdaq-hura-to-present-at-the-virtual-investor-new-to-the-street-event-hura-20241022monthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-nasdaq-hura-announces-webcast-replay-of-panel-presentation-at-the-2024--hura-20241023monthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-confere-hura-20250219monthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-inc-to-present-at-the-37th-annual-roth-conference-hura-20250310monthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-hura-20250407monthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-inc-announces-abstracts-accepted-for-poster-presentation-at-the-2025-aa-hura-20250408monthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-and-kineta-present-updated-results-from-kineta-s-phase-i-ii-study-of-kv-hura-20250428monthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-inc-initiates-phase-1b-2a-study-of-ifx-hu2-0-as-an-adjunctive-therapy-t-hura-20250505monthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-inc-to-present-at-the-3rd-annual-h-c-wainwright-bioconnect-conference-hura-20250513monthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-presents-ifx-hu2-0-trial-in-progress-poster-at-the-2025-american-societ-hura-20250602monthly0.5https://www.biopharmawatch.com/news/HURA/fda-removes-partial-clinical-hold-on-tuhura-biosciences-phase-3-accelerated-approval-trial-hura-20250609monthly0.5https://www.biopharmawatch.com/news/HURA/tuhura-files-investigational-new-drug-application-for-tbs-2025-in-the-treatment-of-blood-r-hura-20260217monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-announces-the-publication-of-new-long-term-disease-control-dat-mltx-20220509monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-starts-phase-2-trial-of-the-nanobody-sonelokimab-in-patients-w-mltx-20220512monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-signs-development-and-manufacturing-agreement-with-vetter-phar-mltx-20220726monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-to-initiate-global-phase-2-study-of-the-nanobody-sonelokimab-i-mltx-20220926monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-reports-third-quarter-2022-financial-results-and-provides-rece-mltx-20221114monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-screens-first-patient-in-phase-2-study-of-the-nanobody-sonelok-mltx-20221214monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-to-host-capital-markets-day-in-new-york-and-virtually-today-mltx-20230419monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-reports-first-quarter-2023-financial-results-and-provides-a-bu-mltx-20230512monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-announces-pricing-of-400-million-upsized-public-offering-of-cl-mltx-20230628monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-presents-positive-12-week-data-from-the-phase-2-mira-trial-wit-mltx-20231011monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-announces-landmark-phase-2-results-for-nanobody-sonelokimab-in-mltx-20231105monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-reports-third-quarter-2023-financial-results-and-provides-a-bu-mltx-20231114monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-reports-full-year-2023-financial-results-recent-business-highl-mltx-20240229monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-reports-first-quarter-2024-financial-results-and-provides-a-bu-mltx-20240507monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-starts-phase-3-vela-program-of-the-nanobody-sonelokimab-in-pat-mltx-20240516monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-reports-second-quarter-2024-financial-results-and-announces-a--mltx-20240807monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-to-host-a-capital-markets-update-on-wednesday-september-11-mltx-20240909monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-reports-third-quarter-2024-financial-results-and-provides-a-bu-mltx-20241107monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-starts-phase-3-izar-program-of-the-nanobody-sonelokimab-in-pat-mltx-20241113monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-reports-full-year-2024-financial-results-and-provides-a-busine-mltx-20250226monthly0.5https://www.biopharmawatch.com/news/MLTX/moonlake-immunotherapeutics-reports-first-quarter-2025-financial-results-and-provides-a-bu-mltx-20250512monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-names-shirley-edwards-to-board-of-directors-solv-20240415monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-announces-first-quarter-2024-earnings-release-date-and-upcoming-investor-events-solv-20240423monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-cautions-investors-regarding-trc-capital-s-mini-tender-offer-solv-20240607monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-introduces-denials-prevention-solution-an-ai-powered-tool-empowering-health-syst-solv-20240624monthly0.5https://www.biopharmawatch.com/news/SOLV/u-s-news-world-report-expands-use-of-solventum-s-ambulatory-potentially-preventable-compli-solv-20240702monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-to-report-second-quarter-2024-financial-results-and-host-conference-call-on-augu-solv-20240716monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-autonomous-coding-listed-in-epic-toolbox-solv-20240820monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-to-participate-in-upcoming-investor-conferences-solv-20240828monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-launches-all-in-one-extended-wear-wound-dressing-for-v-a-c-therapy-solv-20240910monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-names-surgeon-and-diagnostics-pioneer-dr-ryan-egeland-as-chief-medical-officer-solv-20241010monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-announces-commitment-to-100-renewable-electricity-by-2030-solv-20241014monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-to-report-third-quarter-2024-financial-results-and-host-conference-call-on-novem-solv-20241015monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-launches-first-3d-printed-aligner-attachments-to-revolutionize-aligner-treatment-solv-20241114monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-to-participate-in-the-piper-sandler-healthcare-conference-solv-20241119monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-to-report-fourth-quarter-and-full-year-fiscal-2024-earnings-on-february-27-2025-solv-20250130monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-fluency-for-imaging-clinches-top-spot-again-ranked-1-best-in-klas-for-speech-rec-solv-20250205monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-announces-sale-of-its-purification-filtration-business-to-thermo-fisher-scientif-solv-20250225monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-to-host-investor-day-on-thursday-march-20-2025-in-new-york-city-solv-20250226monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-launches-attest-ebowie-dick-test-system-revolutionizing-sterilization-assurance-solv-20250312monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-to-present-value-creation-formula-and-long-range-plan-at-2025-investor-day-solv-20250320monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-partners-with-sprintray-to-disrupt-the-digital-dentistry-market-with-high-qualit-solv-20250325monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-to-report-first-quarter-fiscal-2025-earnings-on-may-8-2025-solv-20250417monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-to-participate-in-the-2025-bofa-securities-health-care-conference-solv-20250508monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-to-participate-in-the-2025-goldman-sachs-health-care-conference-solv-20250603monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-named-a-best-company-to-work-for-by-u-s-news-world-report-solv-20250618monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-to-report-second-quarter-fiscal-2025-earnings-on-august-7-2025-solv-20250717monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-announces-launch-of-secondary-offering-of-common-stock-solv-20250813monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-to-participate-in-upcoming-investor-conferences-solv-20250828monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-announces-early-tender-results-and-upsizing-of-its-note-tender-offers-solv-20250908monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-to-report-third-quarter-fiscal-2025-earnings-on-november-6-2025-solv-20251016monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-appoints-heather-knight-as-chief-commercial-officer-solv-20251021monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-to-participate-in-the-2025-stifel-healthcare-conference-solv-20251103monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-announces-agreement-to-acquire-acera-surgical-solv-20251120monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-announces-1-billion-share-repurchase-program-solv-20251120monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-to-participate-in-the-2025-piper-sandler-healthcare-conference-solv-20251125monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-earns-diamond-level-hirc-resiliency-badge-demonstrating-best-in-class-supply-cha-solv-20251216monthly0.5https://www.biopharmawatch.com/news/SOLV/global-expert-panel-publishes-new-recommendations-on-advanced-use-of-closed-incision-negat-solv-20251217monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-to-report-fourth-quarter-and-full-year-fiscal-2025-earnings-on-february-26-2026-solv-20260203monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-to-participate-in-the-2026-keybanc-healthcare-forum-solv-20260311monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-foundation-and-america-s-toothfairy-launch-national-effort-to-expand-access-to-p-solv-20260514monthly0.5https://www.biopharmawatch.com/news/SOLV/solventum-to-participate-in-the-2026-jefferies-healthcare-conference-solv-20260527monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-report-fourth-quarter-and-full-year-2024-financial-results-on-thurs-bpmc-20250205monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-third-quarter-2024-results-and-raises-ayvakit-ayvakyt-avapriti-bpmc-20241030monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-report-third-quarter-2024-financial-results-on-wednesday-october-30-bpmc-20241016monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-present-at-upcoming-investor-conferences-blueprint-medicines-corpor-bpmc-20240910monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-second-quarter-2024-results-and-raises-ayvakit-ayvakyt-avaprit-bpmc-20240801monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-report-second-quarter-2024-financial-results-on-thursday-august-1-2-bpmc-20240718monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-data-presentations-at-eaaci-and-eha-annual-meetings-highligh-bpmc-20240530monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-present-the-first-promising-and-most-advanced-clinical-data-for-a-c-bpmc-20240523monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20240506monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-strong-first-quarter-2024-results-and-raises-ayvakit-ayvakyt-a-bpmc-20240502monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-report-first-quarter-2024-financial-results-on-thursday-may-2-2024--bpmc-20240418monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-host-webcast-and-conference-call-highlighting-emerging-opportunitie-bpmc-20240411monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20240404monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20240306monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-highlights-ayvakit-avapritinib-long-term-efficacy-and-safety-data-and--bpmc-20240223monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-fourth-quarter-and-full-year-2023-results-achieved-204-2-milli-bpmc-20240215monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20240205monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-report-fourth-quarter-and-full-year-2023-financial-results-on-thurs-bpmc-20240201monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-highlights-2024-corporate-strategy-and-business-priorities-at-42nd-ann-bpmc-20240108monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20240105monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-present-at-42nd-annual-j-p-morgan-healthcare-conference-blueprint-m-bpmc-20231218monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-ayvakyt-avapritinib-receives-european-commission-approval-as-the-first-bpmc-20231212monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-leadership-in-driving-continued-innovation-in-systemic-mastocytosis-hi-bpmc-20231209monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20231204monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-present-at-jmp-securities-hematology-and-oncology-summit-blueprint--bpmc-20231128monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-ayvakyt-avapritinib-receives-positive-chmp-opinion-as-the-first-and-on-bpmc-20231110monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20231103monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-third-quarter-2023-results-blueprint-medicines-corporation-nas-bpmc-20231026monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-report-third-quarter-2023-financial-results-on-thursday-october-26--bpmc-20231012monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20231005monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20230905monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20230804monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-second-quarter-2023-results-blueprint-medicines-corporation-na-bpmc-20230802monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-report-second-quarter-2023-financial-results-on-wednesday-august-2--bpmc-20230719monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20230705monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20230605monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-highlights-clinical-progress-across-precision-oncology-pipeline-at-202-bpmc-20230603monthly0.5https://www.biopharmawatch.com/news/BPMC/nejm-evidence-publishes-results-from-registrational-pioneer-trial-demonstrating-significan-bpmc-20230523monthly0.5https://www.biopharmawatch.com/news/BPMC/fda-approves-ayvakit-avapritinib-as-the-first-and-only-treatment-for-indolent-systemic-mas-bpmc-20230522monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20230504monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-first-quarter-2023-results-blueprint-medicines-corporation-nas-bpmc-20230504monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-present-new-clinical-data-across-broad-precision-therapy-pipeline-a-bpmc-20230426monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-report-first-quarter-2023-financial-results-on-thursday-may-4-2023--bpmc-20230420monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-present-at-upcoming-investor-conferences-blueprint-medicines-corpor-bpmc-20230411monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20230405monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-lift-of-partial-clinical-hold-on-phase-1-2-vela-trial-of-blu-bpmc-20230328monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20230307monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-presents-registrational-data-from-pioneer-trial-of-ayvakit-avapritinib-bpmc-20230226monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-regain-global-rights-to-gavreto-pralsetinib-from-roche-blueprint-me-bpmc-20230223monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-fourth-quarter-and-full-year-2022-results-achieved-204-0-milli-bpmc-20230216monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-partial-clinical-hold-for-phase-1-2-vela-trial-of-blu-222-bl-bpmc-20230210monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-report-fourth-quarter-and-full-year-2022-financial-results-on-thurs-bpmc-20230209monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20230207monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-present-positive-data-from-pioneer-trial-of-ayvakit-avapritinib-in--bpmc-20230203monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-fda-acceptance-of-supplemental-new-drug-application-for-ayva-bpmc-20230123monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-appoints-john-tsai-m-d-to-its-board-of-directors-blueprint-medicines-c-bpmc-20230106monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-provides-2023-portfolio-goals-to-achieve-precision-at-scale-expect-to--bpmc-20230105monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20230104monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-clinical-data-highlighting-leadership-in-developing-targeted-t-bpmc-20221211monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20221205monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-submits-supplemental-new-drug-application-to-fda-for-ayvakit-avapritin-bpmc-20221122monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-present-at-upcoming-investor-conferences-blueprint-medicines-corpor-bpmc-20221109monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20221104monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-present-new-data-reinforcing-clinical-leadership-in-systemic-mastoc-bpmc-20221103monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-outlines-2027-blueprint-to-achieve-precision-medicine-at-scale-and-rep-bpmc-20221101monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-host-investor-day-and-announce-third-quarter-2022-financial-results-bpmc-20221019monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20221006monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20220906monthly0.5https://www.biopharmawatch.com/news/BPMC/cancer-publishes-study-demonstrating-substantial-disease-burden-for-patients-with-systemic-bpmc-20220824monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-positive-top-line-results-from-pioneer-trial-of-ayvakit-avap-bpmc-20220817monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20220804monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-second-quarter-2022-results-achieved-36-5-million-in-total-rev-bpmc-20220802monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-report-second-quarter-2022-financial-results-on-tuesday-august-2-20-bpmc-20220726monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-publishes-inaugural-corporate-responsibility-report-blueprint-medicine-bpmc-20220714monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20220707monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-transformative-1-25-billion-strategic-financing-collaboratio-bpmc-20220630monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-appoints-habib-dable-to-its-board-of-directors-blueprint-medicines-cor-bpmc-20220623monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-continued-progress-toward-goal-of-transforming-treatment-of-sy-bpmc-20220609monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20220603monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20220505monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-first-quarter-2022-results-achieved-23-8-million-in-ayvakit-av-bpmc-20220503monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-report-first-quarter-2022-financial-results-on-tuesday-may-3-2022-b-bpmc-20220426monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-blu-945-proof-of-concept-data-supporting-initiation-of-compr-bpmc-20220408monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20220406monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-ayvakyt-avapritinib-receives-european-commission-approval-for-the-trea-bpmc-20220325monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-showcase-broad-precision-therapy-pipeline-at-aacr-annual-meeting-20-bpmc-20220308monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20220304monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-and-proteovant-therapeutics-announce-strategic-collaboration-to-advanc-bpmc-20220228monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-fourth-quarter-and-full-year-2021-results-blueprint-medicines--bpmc-20220216monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-present-at-upcoming-investor-conferences-blueprint-medicines-corpor-bpmc-20220211monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-report-fourth-quarter-and-full-year-2021-financial-results-on-wedne-bpmc-20220209monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20220204monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-ayvakyt-avapritinib-receives-positive-chmp-opinion-for-the-treatment-o-bpmc-20220128monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-elevates-two-talented-leaders-to-its-executive-team-blueprint-medicine-bpmc-20220120monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-provides-2022-portfolio-goals-targeting-expanded-precision-therapy-lea-bpmc-20220110monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20220106monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-ceo-and-leadership-transition-plan-blueprint-medicines-corpo-bpmc-20220105monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-completes-acquisition-of-lengo-therapeutics-blueprint-medicines-corpor-bpmc-20211230monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-appoints-daniella-beckman-to-its-board-of-directors-blueprint-medicine-bpmc-20211209monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20211207monthly0.5https://www.biopharmawatch.com/news/BPMC/nature-medicine-publishes-results-from-two-registration-studies-of-ayvakit-avapritinib-sho-bpmc-20211206monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-expand-precision-therapy-leadership-in-lung-cancer-with-acquisition-bpmc-20211129monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-and-zai-lab-announce-strategic-collaboration-and-license-agreement-for-bpmc-20211109monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20211105monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-third-quarter-2021-financial-results-blueprint-medicines-corpo-bpmc-20211028monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-report-third-quarter-2021-financial-results-on-thursday-october-28--bpmc-20211021monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20211005monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20210903monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-present-at-morgan-stanley-19th-annual-global-healthcare-conference--bpmc-20210902monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20210804monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-second-quarter-2021-financial-results-blueprint-medicines-corp-bpmc-20210729monthly0.5https://www.biopharmawatch.com/news/BPMC/md-anderson-and-blueprint-medicines-announce-strategic-collaboration-to-accelerate-blu-222-bpmc-20210728monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-report-second-quarter-2021-financial-results-on-thursday-july-29-20-bpmc-20210722monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20210707monthly0.5https://www.biopharmawatch.com/news/BPMC/fda-approves-blueprint-medicines-ayvakit-avapritinib-for-the-treatment-of-adults-with-adva-bpmc-20210616monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20210604monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-present-at-upcoming-investor-conferences-blueprint-medicines-corpor-bpmc-20210525monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-presents-arrow-trial-data-for-gavreto-pralsetinib-highlighting-durable-bpmc-20210519monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-appoints-percy-carter-mba-ph-d-as-chief-scientific-officer-blueprint-m-bpmc-20210517monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20210505monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-first-quarter-2021-financial-results-blueprint-medicines-corpo-bpmc-20210429monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-report-first-quarter-2021-financial-results-on-thursday-april-29-20-bpmc-20210422monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-data-highlight-clinical-leadership-in-systemic-mastocytosis-at-aacr-an-bpmc-20210411monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-presents-preclinical-data-highlighting-broad-precision-therapy-researc-bpmc-20210410monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20210407monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-host-virtual-investor-event-and-webcast-to-review-new-data-presente-bpmc-20210405monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-showcase-scientific-leadership-in-precision-oncology-and-hematology-bpmc-20210310monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20210305monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-ema-validation-of-type-ii-variation-marketing-authorization--bpmc-20210303monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-fourth-quarter-and-full-year-2020-financial-results-blueprint--bpmc-20210217monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-report-fourth-quarter-and-full-year-2020-financial-results-on-wedne-bpmc-20210210monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20210205monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-r-d-leadership-transitions-blueprint-medicines-corporation-n-bpmc-20210111monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-portfolio-milestones-and-outlines-2021-roadmap-for-precision-m-bpmc-20210111monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20210105monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-submits-supplemental-new-drug-application-to-fda-for-ayvakit-avapritin-bpmc-20201217monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-data-presented-at-62nd-ash-annual-meeting-and-exposition-highlight-bro-bpmc-20201207monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20201204monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-fda-approval-of-gavreto-pralsetinib-for-the-treatment-of-pat-bpmc-20201201monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-present-broad-range-of-data-reinforcing-commitment-to-advance-patie-bpmc-20201123monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20201103monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-third-quarter-2020-financial-results-blueprint-medicines-corpo-bpmc-20201029monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-report-third-quarter-2020-financial-results-on-thursday-october-29--bpmc-20201022monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20201002monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-european-commission-approval-of-ayvakyt-avapritinib-for-the--bpmc-20200925monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-positive-top-line-results-from-explorer-and-pathfinder-trial-bpmc-20200922monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-arrow-trial-data-at-esmo-virtual-congress-2020-demonstrating-d-bpmc-20200920monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-presents-foundational-preclinical-data-for-blu-945-showing-robust-anti-bpmc-20200917monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-present-at-18th-annual-morgan-stanley-global-healthcare-conference--bpmc-20200909monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-fda-approval-of-gavreto-pralsetinib-for-the-treatment-of-adu-bpmc-20200904monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20200904monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-strengthens-leadership-with-appointment-of-fouad-namouni-m-d-as-presid-bpmc-20200901monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20200804monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-second-quarter-2020-financial-results-blueprint-medicines-corp-bpmc-20200730monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-receives-positive-chmp-opinion-for-avapritinib-for-the-treatment-of-ad-bpmc-20200724monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-report-second-quarter-2020-financial-results-on-thursday-july-30-20-bpmc-20200723monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-global-collaboration-with-roche-to-develop-and-commercialize-bpmc-20200714monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20200702monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-submission-of-new-drug-application-to-fda-for-pralsetinib-fo-bpmc-20200701monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-publication-in-the-lancet-oncology-showing-durable-clinical--bpmc-20200629monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-presents-updated-part-1-data-from-pioneer-trial-of-avapritinib-showing-bpmc-20200606monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bluepri-bpmc-20200603monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-data-presentations-at-asco20-highlighting-deep-durable-clini-bpmc-20200529monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-present-at-upcoming-investors-conferences-blueprint-medicines-corpo-bpmc-20200527monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-host-conference-call-to-review-updated-clinical-data-for-pralsetini-bpmc-20200526monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-receives-complete-response-letter-from-fda-for-avapritinib-new-drug-ap-bpmc-20200515monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-data-presentations-highlighting-significant-progress-in-adva-bpmc-20200514monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-first-quarter-2020-financial-results-blueprint-medicines-corpo-bpmc-20200506monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-report-first-quarter-2020-financial-results-on-wednesday-may-6-2020-bpmc-20200429monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-top-line-results-from-phase-3-voyager-trial-of-avapritinib-v-bpmc-20200428monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-the-achievement-of-key-portfolio-milestones-blueprint-medici-bpmc-20200401monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-part-1-results-from-pioneer-trial-showing-broad-activity-of--bpmc-20200316monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-report-updated-data-from-the-phase-2-pioneer-trial-of-avapritinib-i-bpmc-20200309monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-present-updated-data-from-phase-2-pioneer-trial-of-avapritinib-in-p-bpmc-20200224monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-present-at-upcoming-investor-conferences-blueprint-medicines-corpor-bpmc-20200219monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-fourth-quarter-and-full-year-2019-financial-results-blueprint--bpmc-20200213monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-report-fourth-quarter-and-full-year-2019-financial-results-on-thurs-bpmc-20200206monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-pdufa-date-extension-for-new-drug-application-of-avapritinib-bpmc-20200206monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-pricing-of-public-offering-of-shares-of-common-stock-bluepri-bpmc-20200122monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-proposed-public-offering-of-shares-of-common-stock-blueprint-bpmc-20200121monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-2020-corporate-goals-blueprint-medicines-corporation-nasdaq--bpmc-20200113monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-fda-approval-of-ayvakit-avapritinib-for-the-treatment-of-adu-bpmc-20200109monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-top-line-data-for-pralsetinib-and-initiates-rolling-nda-subm-bpmc-20200108monthly0.5https://www.biopharmawatch.com/news/BPMC/cstone-pharmaceuticals-and-blueprint-medicines-initiate-phase-1b-2-clinical-trial-of-fisog-bpmc-20200106monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-initial-data-from-phase-2-pioneer-trial-of-avapritinib-in-pa-bpmc-20191208monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-fda-intent-to-split-avapritinib-new-drug-application-into-se-bpmc-20191028monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-european-medicines-agency-validation-of-marketing-authorizat-bpmc-20190718monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-presents-navigator-trial-data-in-pdgfra-exon-18-mutant-gist-and-fourth-bpmc-20190601monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-present-at-upcoming-investor-conferences-in-june-blueprint-medicine-bpmc-20190529monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-data-presentations-at-asco-and-eha-meetings-from-registratio-bpmc-20190516monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-fourth-quarter-and-full-year-2018-financial-results-blueprint--bpmc-20190226monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-third-quarter-2018-financial-results-blueprint-medicines-corpo-bpmc-20181030monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-strengthens-leadership-with-the-appointments-of-christina-rossi-as-chi-bpmc-20181029monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-updated-data-from-phase-1-arrow-clinical-trial-showing-broad-bpmc-20181006monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-report-second-quarter-2018-financial-results-on-wednesday-august-1--bpmc-20180725monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-updated-data-from-ongoing-phase-1-explorer-clinical-trial-of-bpmc-20180615monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-and-cstone-pharmaceuticals-announce-exclusive-collaboration-and-licens-bpmc-20180604monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-first-quarter-2018-financial-results-blueprint-medicines-corpo-bpmc-20180502monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-present-proof-of-concept-data-from-ongoing-phase-1-clinical-trial-o-bpmc-20180314monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-present-at-cowen-and-company-38th-annual-health-care-conference-blu-bpmc-20180306monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-fourth-quarter-and-full-year-2017-financial-results-blueprint--bpmc-20180221monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-closing-of-public-offering-and-full-exercise-of-option-to-pu-bpmc-20171215monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-pricing-of-public-offering-of-shares-of-common-stock-bluepri-bpmc-20171212monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-new-data-from-ongoing-phase-1-clinical-trial-of-avapritinib--bpmc-20171210monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-report-third-quarter-2017-financial-results-on-tuesday-october-31-2-bpmc-20171024monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-present-at-morgan-stanley-15th-annual-global-healthcare-conference--bpmc-20170906monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-present-at-upcoming-investor-conferences-in-august-blueprint-medici-bpmc-20170803monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-evaluate-opportunities-to-advance-rare-disease-discovery-program-in-bpmc-20170727monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-report-second-quarter-2017-financial-results-on-wednesday-august-2--bpmc-20170726monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-new-phase-1-clinical-data-for-blu-285-in-advanced-gastrointe-bpmc-20170605monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-report-first-quarter-2017-financial-results-on-wednesday-may-3-2017-bpmc-20170426monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-proposed-public-offering-of-shares-of-common-stock-blueprint-bpmc-20170329monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-present-on-blu-285-and-blu-554-at-upcoming-scientific-conferences-b-bpmc-20170327monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-enrollment-of-first-patient-in-phase-1-clinical-trial-for-bl-bpmc-20170320monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-report-fourth-quarter-and-full-year-2016-financial-results-on-thurs-bpmc-20170302monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-present-at-2017-rbc-capital-markets-global-healthcare-conference-bl-bpmc-20170215monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-closing-of-public-offering-and-full-exercise-of-option-to-pu-bpmc-20161213monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-pricing-of-public-offering-of-shares-of-common-stock-bluepri-bpmc-20161207monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-proposed-public-offering-of-shares-of-common-stock-blueprint-bpmc-20161206monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-proof-of-concept-data-from-phase-1-clinical-trial-of-blu-285-bpmc-20161130monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-proof-of-concept-data-from-global-phase-1-clinical-trial-of--bpmc-20161128monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-appointment-of-marion-dorsch-ph-d-as-chief-scientific-office-bpmc-20161114monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-present-preliminary-data-from-ongoing-phase-1-clinical-trial-for-bl-bpmc-20161103monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-new-drug-discovery-program-targeting-prkaca-kinase-fusions-f-bpmc-20160909monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-present-at-morgan-stanley-global-healthcare-conference-blueprint-me-bpmc-20160907monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-appointment-of-tracey-mccain-as-chief-legal-officer-and-exec-bpmc-20160906monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-second-quarter-2016-financial-results-blueprint-medicines-corp-bpmc-20160809monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-present-at-upcoming-investor-conferences-in-august-blueprint-medici-bpmc-20160803monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-report-second-quarter-2016-financial-results-on-tuesday-august-9-20-bpmc-20160802monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-present-at-upcoming-investor-conferences-in-june-blueprint-medicine-bpmc-20160601monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-first-quarter-2016-financial-results-blueprint-medicines-corpo-bpmc-20160510monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-report-first-quarter-2016-financial-results-on-tuesday-may-10-2016--bpmc-20160503monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-appoints-lynn-seely-m-d-to-board-of-directors-blueprint-medicines-corp-bpmc-20160415monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-announces-worldwide-collaboration-to-accelerate-and-expand-its-develop-bpmc-20160315monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-reports-fourth-quarter-and-full-year-2015-financial-results-blueprint--bpmc-20160311monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-present-at-cowen-and-company-36th-annual-health-care-conference-blu-bpmc-20160302monthly0.5https://www.biopharmawatch.com/news/BPMC/blueprint-medicines-to-present-at-rbc-capital-markets-2016-global-healthcare-conference-bl-bpmc-20160216monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-reports-fourth-quarter-and-year-end-2024-financial-results-and-recent-rgls-20250313monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-reports-third-quarter-2024-financial-results-and-recent-updates-regul-rgls-20241107monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-completion-of-enrollment-in-fourth-cohort-of-phase-1b-multi-rgls-20241008monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-participation-at-two-healthcare-investment-conferences-regu-rgls-20240828monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-reports-second-quarter-2024-financial-results-and-recent-updates-regu-rgls-20240808monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-to-present-at-the-canaccord-genuity-44th-annual-growth-conference-reg-rgls-20240806monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-participation-at-two-healthcare-investment-conferences-regu-rgls-20240709monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-positive-topline-data-from-the-third-cohort-of-patients-in--rgls-20240624monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-expected-addition-to-the-russell-3000-and-russell-2000-inde-rgls-20240604monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-promotion-of-rekha-garg-m-d-m-s-to-chief-medical-officer-re-rgls-20240516monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-reports-first-quarter-2024-financial-results-and-recent-updates-regul-rgls-20240509monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-advances-to-cohort-4-of-phase-1b-multiple-ascending-dose-mad-clinical-rgls-20240506monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-to-participate-in-the-canaccord-genuity-genetic-medicine-for-generali-rgls-20240430monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-reports-fourth-quarter-and-year-end-2023-financial-results-and-recent-rgls-20240321monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-oversubscribed-100-million-private-placement-of-equity-regu-rgls-20240312monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-positive-topline-data-from-the-second-cohort-of-patients-in-rgls-20240312monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-completion-of-enrollment-in-third-cohort-of-phase-1b-multip-rgls-20240102monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-to-present-at-the-6th-annual-evercore-isi-healthconx-conference-regul-rgls-20231122monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-reports-third-quarter-2023-financial-results-and-recent-updates-regul-rgls-20231109monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-first-patient-dosed-in-third-cohort-of-phase-1b-multiple-as-rgls-20231102monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-advances-to-cohort-3-of-phase-1b-multiple-ascending-dose-mad-clinical-rgls-20231019monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-positive-topline-data-from-the-first-cohort-of-patients-in--rgls-20230920monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-completion-of-enrollment-in-second-cohort-of-phase-1b-multi-rgls-20230913monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-participation-at-two-healthcare-investment-conferences-regu-rgls-20230905monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-to-host-virtual-investor-event-on-september-6-2023-regulus-therapeuti-rgls-20230823monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-reports-second-quarter-2023-financial-results-and-recent-updates-regu-rgls-20230808monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference-reg-rgls-20230802monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-to-present-at-the-h-c-wainwright-2nd-annual-kidney-conference-regulus-rgls-20230718monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-first-patient-dosed-in-second-cohort-of-phase-1b-multiple-a-rgls-20230627monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-appointment-of-preston-s-klassen-m-d-to-its-board-of-direct-rgls-20230623monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-update-on-preclinical-studies-in-amyotrophic-lateral-sclero-rgls-20230620monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-strengthens-research-development-leadership-regulus-therapeutics-inc--rgls-20230612monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-advances-to-cohort-2-of-phase-1b-multiple-ascending-dose-mad-clinical-rgls-20230516monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-reports-first-quarter-2023-financial-results-and-recent-updates-regul-rgls-20230511monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-15-million-private-placement-of-equity-regulus-therapeutics-rgls-20230413monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-completion-of-enrollment-in-first-cohort-of-phase-1b-multip-rgls-20230412monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-reports-fourth-quarter-and-year-end-2022-financial-results-and-recent-rgls-20230323monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-to-present-at-the-svb-securities-global-biopharma-conference-regulus--rgls-20230209monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-regulus-therapeutics-i-rgls-20230113monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-resignation-of-board-member-regulus-therapeutics-inc-nasdaq-rgls-20221212monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-appointments-of-industry-veterans-drs-rekha-garg-and-claire-rgls-20221129monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-reports-third-quarter-2022-financial-results-and-recent-updates-regul-rgls-20221110monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-timing-for-third-quarter-2022-financial-results-webcast-and-rgls-20221103monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-first-patient-dosed-in-phase-1b-multiple-ascending-dose-mad-rgls-20221102monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-poster-presentation-at-asn-kidney-week-2022-regulus-therape-rgls-20221027monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-positive-topline-safety-and-pharmacokinetic-pk-data-from-th-rgls-20220912monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-reports-second-quarter-2022-financial-results-and-recent-updates-regu-rgls-20220811monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-timing-for-second-quarter-2022-financial-results-webcast-an-rgls-20220804monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-receipt-of-fda-orphan-drug-designation-for-rgls8429-for-the-rgls-20220621monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-first-subject-dosed-in-phase-1-single-ascending-dose-sad-cl-rgls-20220613monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-appoints-amin-kamel-ph-d-as-vice-president-dmpk-regulus-therapeutics-inc-nasdaq-rg-rgls-20220602monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-to-present-at-the-h-c-wainwright-global-investment-conference-regulus-rgls-20220517monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-reports-first-quarter-2022-financial-results-and-recent-updates-regul-rgls-20220512monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-fda-acceptance-of-investigational-new-drug-ind-application--rgls-20220511monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-timing-for-first-quarter-2022-financial-results-webcast-and-rgls-20220505monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-initiation-of-preclinical-studies-in-amyotrophic-lateral-sc-rgls-20220324monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-reports-fourth-quarter-and-year-end-2021-financial-results-and-recent-rgls-20220310monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-timing-for-fourth-quarter-and-year-end-2021-financial-resul-rgls-20220303monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-completion-of-enrollment-in-phase-2-clinical-trial-of-ladem-rgls-20220224monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-to-present-at-the-11th-annual-svb-leerink-global-healthcare-conferenc-rgls-20220210monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-successful-completion-of-pre-ind-meeting-with-fda-for-rgls8-rgls-20220120monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference-regulu-rgls-20220104monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-appoints-mohammad-ahmadian-ph-d-as-vice-president-chemistry-and-pharmaceutical-dev-rgls-20211203monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-presentation-at-the-first-annual-rare-genetic-kidney-diseas-rgls-20211201monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-closing-of-34-6-million-private-placement-of-equity-regulus-rgls-20211130monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-private-placement-of-equity-regulus-therapeutics-inc-nasdaq-rgls-20211124monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-reports-third-quarter-2021-financial-results-and-recent-updates-regul-rgls-20211110monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-timing-for-third-quarter-2021-financial-results-webcast-and-rgls-20211103monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-strategic-prioritization-of-rgls8429-its-next-generation-ca-rgls-20211012monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-director-david-baltimore-receives-2021-lasker-koshland-special-achiev-rgls-20210930monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-confer-rgls-20210909monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-reports-second-quarter-2021-financial-results-and-recent-updates-regu-rgls-20210810monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-timing-for-second-quarter-2021-financial-results-webcast-an-rgls-20210803monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-presents-additional-data-from-its-autosomal-dominant-polycystic-kidne-rgls-20210625monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-to-present-additional-data-from-its-autosomal-dominant-polycystic-kid-rgls-20210621monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-incremental-update-of-autosomal-dominant-polycystic-kidney--rgls-20210521monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-to-present-at-the-oppenheimer-rare-orphan-disease-summit-regulus-ther-rgls-20210514monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-reports-first-quarter-2021-financial-results-and-recent-updates-regul-rgls-20210513monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-timing-for-first-quarter-2021-financial-results-webcast-and-rgls-20210506monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-top-line-data-from-the-first-cohort-of-phase-1b-clinical-tr-rgls-20210503monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-completion-of-dosing-in-the-first-cohort-of-phase-1b-clinic-rgls-20210415monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-to-present-at-the-20th-annual-needham-virtual-healthcare-conference-r-rgls-20210407monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-reports-fourth-quarter-and-year-end-2020-financial-results-and-recent-rgls-20210309monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference-regu-rgls-20210305monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-completion-of-enrollment-in-first-cohort-of-phase-1b-clinic-rgls-20210210monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-addition-to-board-of-directors-regulus-therapeutics-inc-nasdaq-rgls-a-bi-rgls-20210127monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference-regulu-rgls-20210105monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-closing-of-19-4-million-private-placement-of-equity-regulus-rgls-20201208monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-private-placement-of-equity-regulus-therapeutics-inc-nasdaq-rgls-20201201monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-reports-third-quarter-2020-financial-results-and-recent-updates-regul-rgls-20201105monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-achievement-of-interim-enrollment-milestone-under-collabora-rgls-20201102monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-first-patient-dosed-in-phase-1b-clinical-trial-of-rgls4326--rgls-20201015monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-receipt-of-5-million-milestone-and-material-payments-from-s-rgls-20201013monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-to-present-at-the-h-c-wainwright-22nd-annual-virtual-global-investmen-rgls-20200911monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-to-present-at-the-2020-wells-fargo-virtual-healthcare-conference-regu-rgls-20200903monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-restructuring-of-sanofi-and-oxford-loan-agreements-regulus--rgls-20200831monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-reports-second-quarter-2020-financial-results-and-recent-updates-regu-rgls-20200813monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-to-present-at-the-2020-wedbush-pacgrow-healthcare-virtual-conference--rgls-20200806monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-appoints-denis-drygin-ph-d-as-chief-scientific-officer-regulus-therap-rgls-20200803monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-fda-orphan-drug-designation-of-rgls4326-for-the-treatment-o-rgls-20200729monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-completes-dosing-in-phase-1-multiple-ascending-dose-study-of-rgls4326-rgls-20200722monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-reports-first-quarter-2020-financial-results-and-recent-updates-regul-rgls-20200514monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-reports-fourth-quarter-and-year-end-2019-financial-results-and-recent-updates-regu-rgls-20200312monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-reinitiates-multiple-ascending-dose-study-of-rgls4326-for-the-treatme-rgls-20200213monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-fda-removal-of-partial-clinical-hold-for-multiple-ascending-rgls-20191216monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-to-present-at-the-stifel-healthcare-conference-regulus-therapeutics-i-rgls-20191118monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-reports-third-quarter-2019-financial-results-and-recent-updates-regul-rgls-20191112monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-presents-preclinical-data-identifying-rgls4326-as-a-potential-disease-rgls-20191016monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-publication-in-nature-communications-identifying-rgls4326-a-rgls-20190912monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-to-present-at-the-h-c-wainwright-global-investment-conference-regulus-rgls-20190903monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-to-present-at-the-wells-fargo-healthcare-conference-regulus-therapeut-rgls-20190829monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-reports-second-quarter-2019-financial-results-and-recent-updates-regu-rgls-20190808monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-appoints-cris-calsada-as-chief-financial-officer-regulus-therapeutics-rgls-20190730monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-rgls4326-program-update-regulus-therapeutics-inc-nasdaq-rgl-rgls-20190723monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-new-additions-to-board-of-directors-regulus-therapeutics-inc-nasdaq-rgls-rgls-20190611monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-reports-first-quarter-2019-financial-results-and-recent-updates-regul-rgls-20190509monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-closing-of-first-tranche-of-41-8-million-private-placement--rgls-20190507monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-restructuring-of-term-loan-regulus-therapeutics-inc-nasdaq--rgls-20190506monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-private-placement-of-equity-regulus-therapeutics-inc-nasdaq-rgls-20190506monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-preclinical-efficacy-data-highlighting-potential-of-novel-treatment-for-rgls-20190408monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-reports-fourth-quarter-and-year-end-2018-financial-results-and-recent-updates-regu-rgls-20190318monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-transition-of-research-leadership-regulus-therapeutics-inc-nasdaq-rgls-a-rgls-20190315monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-clinical-candidate-nomination-for-the-treatment-of-glioblastoma-multifor-rgls-20190107monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-preliminary-results-of-planned-interim-data-analysis-of-rgls4326-in-new--rgls-20190104monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-presents-preclinical-survival-data-highlighting-potential-of-novel-treatment-for-g-rgls-20181119monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-reports-third-quarter-2018-financial-results-and-recent-updates-regulus-therapeuti-rgls-20181108monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-successful-restructuring-of-sanofi-collaboration-regulus-therapeutics-in-rgls-20181106monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-data-from-athena-a-global-natural-history-of-disease-study-for-alport-s-rgls-20181025monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-preclinical-data-supporting-rgls4326-as-a-novel-therapeutic-in-developm-rgls-20181022monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-regains-compliance-with-nasdaq-listing-requirements-regulus-therapeutics-inc-nasda-rgls-20181018monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-announces-reverse-stock-split-regulus-therapeutics-inc-nasdaq-rgls-a--rgls-20181004monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-participate-in-fireside-chat-at-the-chardan-genetic-medicines-conference-regulu-rgls-20181002monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-regulus-therapeut-rgls-20180927monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-provides-pipeline-updates-regulus-therapeutics-inc-nasdaq-rgls-a-biopharmaceutical-rgls-20180926monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-reports-second-quarter-2018-financial-results-and-recent-updates-regulus-therapeut-rgls-20180809monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-strategic-update-and-corporate-restructuring-regulus-therapeutics-inc-na-rgls-20180705monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-reports-first-quarter-2018-financial-results-and-pipeline-progress-regulus-therape-rgls-20180510monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-provide-first-quarter-2018-financial-results-on-may-10-2018-regulus-therapeutic-rgls-20180503monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-initiates-multiple-ascending-dose-study-in-healthy-volunteers-of-rgls4326-for-the--rgls-20180501monthly0.5https://www.biopharmawatch.com/news/RGLS/kathryn-j-collier-joins-regulus-board-of-directors-regulus-therapeutics-inc-nasdaq-rgls-a--rgls-20180417monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-at-the-needham-healthcare-conference-regulus-therapeutics-inc-nasdaq-rg-rgls-20180320monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-reports-fourth-quarter-and-year-end-2017-financial-results-and-pipeline-update-reg-rgls-20180307monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-at-the-cowen-and-company-38th-annual-health-care-conference-regulus-the-rgls-20180305monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-first-in-human-dosing-for-phase-i-study-of-rgls4326-for-the-treatment-of-rgls-20171219monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-reports-third-quarter-2017-financial-results-and-recent-events-regulus-therapeutic-rgls-20171107monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-provide-third-quarter-2017-financial-results-on-november-7-2017-regulus-therape-rgls-20171031monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-at-the-2017-wells-fargo-healthcare-conference-regulus-therapeutics-inc--rgls-20170830monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-at-the-2017-wedbush-pacgrow-healthcare-conference-regulus-therapeutics--rgls-20170808monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-reports-second-quarter-2017-financial-results-and-recent-events-regulus-therapeuti-rgls-20170801monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-completion-of-public-offering-of-common-stock-and-exercise-in-full-of-un-rgls-20170725monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-provide-second-quarter-2017-financial-results-on-august-1-2017-regulus-therapeu-rgls-20170725monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-pricing-of-public-offering-of-common-stock-regulus-therapeutics-inc-nasd-rgls-20170719monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-commencement-of-public-offering-of-common-stock-regulus-therapeutics-inc-rgls-20170719monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-promotes-mark-deeg-m-d-phd-to-chief-medical-officer-regulus-therapeutics-inc-nasda-rgls-20170613monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-pipeline-updates-and-advancements-regulus-therapeutics-inc-nasdaq-rgls-a-rgls-20170612monthly0.5https://www.biopharmawatch.com/news/RGLS/pascale-witz-joins-regulus-board-of-directors-regulus-therapeutics-inc-nasdaq-rgls-a-bioph-rgls-20170601monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-reports-first-quarter-2017-financial-results-and-corporate-restructuring-regulus-t-rgls-20170504monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-provide-first-quarter-2017-financial-results-on-may-4-2017-regulus-therapeutics-rgls-20170427monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-at-the-16th-annual-needham-healthcare-conference-regulus-therapeutics-i-rgls-20170328monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-reports-fourth-quarter-2016-financial-results-and-pipeline-update-regulus-therapeu-rgls-20170302monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-release-fourth-quarter-and-full-year-2016-financial-results-on-march-2-2017-reg-rgls-20170223monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-publication-in-nature-communications-identifying-mir-17-as-a-promising-d-rgls-20170216monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-at-upcoming-healthcare-conferences-regulus-therapeutics-inc-nasdaq-rgls-rgls-20170208monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-continuation-of-rg-101-clinical-hold-regulus-therapeutics-inc-nasdaq-rgl-rgls-20170127monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-new-drug-development-candidates-regulus-therapeutics-inc-nasdaq-rgls-a-b-rgls-20161206monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-announce-new-drug-development-candidates-at-r-d-day-on-december-6-2016-regulus--rgls-20161122monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-release-third-quarter-financial-results-on-november-1-2016-regulus-therapeutics-rgls-20161025monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-regulus-therapeutics-i-rgls-20161006monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-appoints-timothy-m-wright-m-d-as-chief-research-and-development-officer-regulus-th-rgls-20161005monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-at-the-2016-wells-fargo-healthcare-conference-regulus-therapeutics-inc--rgls-20160831monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-at-the-2016-wedbush-pacgrow-healthcare-conference-regulus-therapeutics--rgls-20160809monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-reports-second-quarter-2016-financial-results-regulus-therapeutics-inc-nasdaq-rgls-rgls-20160802monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-provides-update-on-clinical-hold-of-rg-101-regulus-therapeutics-inc-nasdaq-rgls-a--rgls-20160727monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-release-second-quarter-financial-results-on-august-2-2016-regulus-therapeutics--rgls-20160726monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-at-cantor-fitzgerald-s-2nd-annual-healthcare-conference-regulus-therape-rgls-20160705monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-reports-clinical-hold-of-rg-101-regulus-therapeutics-inc-nasdaq-rgls-a-biopharmace-rgls-20160627monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-secures-30-million-growth-capital-credit-facility-regulus-therapeutics-inc-nasdaq--rgls-20160620monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-reports-positive-top-line-data-regulus-therapeutics-inc-nasdaq-rgls-a-biopharmaceu-rgls-20160607monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-at-the-jefferies-2016-healthcare-conference-regulus-therapeutics-inc-na-rgls-20160603monthly0.5https://www.biopharmawatch.com/news/RGLS/dr-hugh-rosen-joins-regulus-board-of-directors-regulus-therapeutics-inc-nasdaq-rgls-a-biop-rgls-20160602monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-expands-clinical-trial-collaboration-with-gsk-regulus-therapeutics-inc-nasdaq-rgls-rgls-20160601monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-appoints-allison-wey-as-vice-president-investor-relations-corporate-communications-rgls-20160523monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-new-rg-012-data-at-the-53rd-european-renal-association-european-dialysi-rgls-20160520monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-at-the-2016-ubs-global-healthcare-conference-regulus-therapeutics-inc-n-rgls-20160518monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-at-the-bank-of-america-merrill-lynch-2016-healthcare-conference-regulus-rgls-20160504monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-reports-first-quarter-2016-financial-results-and-recent-highlights-regulus-therape-rgls-20160502monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-timing-for-first-quarter-2016-financial-results-webcast-and-conference-c-rgls-20160426monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-presents-additional-interim-data-on-rg-101-at-international-liver-congress-ilc-201-rgls-20160415monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-new-rg-101-data-at-the-international-liver-congress-2016-ilc-2016-regul-rgls-20160316monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-reports-fourth-quarter-and-year-end-2015-financial-results-and-recent-highlights-r-rgls-20160222monthly0.5https://www.biopharmawatch.com/news/RGLS/rg-101-interim-analysis-shows-97-response-at-8-week-follow-up-regulus-therapeutics-inc-nas-rgls-20160217monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-timing-for-fourth-quarter-and-year-end-2015-financial-results-webcast-an-rgls-20160217monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-completes-rg-101-enrollment-in-phase-ii-combination-study-regulus-therapeutics-inc-rgls-20160121monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-regulus-therapeutics-i-rgls-20160106monthly0.5https://www.biopharmawatch.com/news/RGLS/rg-125-azd4076-a-microrna-therapeutic-targeting-microrna-103-107-being-developed-for-the-t-rgls-20151218monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-appoints-joseph-p-hagan-chief-operating-officer-regulus-therapeutics-inc-nasdaq-rg-rgls-20151207monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-grant-of-patents-covering-lead-microrna-therapeutics-regulus-therapeutic-rgls-20151112monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-reports-third-quarter-2015-financial-results-and-recent-highlights-regulus-therape-rgls-20151105monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-expands-development-of-rg-101-through-clinical-trial-collaboration-with-gsk-regulu-rgls-20151103monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-timing-for-third-quarter-2015-financial-results-webcast-and-conference-c-rgls-20151029monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-achieves-all-research-milestones-in-collaboration-with-biogen-to-identify-microrna-rgls-20151028monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-additional-preclinical-data-supporting-rg-012-as-a-novel-microrna-thera-rgls-20151005monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-updated-data-supporting-rg-101-as-novel-microrna-therapeutic-for-the-tr-rgls-20151002monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-appoints-michael-huang-m-d-as-vice-president-clinical-development-regulus-therapeu-rgls-20150825monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-timing-for-second-quarter-2015-financial-results-webcast-and-conference--rgls-20150728monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-initiates-phase-i-clinical-study-of-rg-012-a-microrna-therapeutic-in-development-f-rgls-20150604monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-kleanthis-g-xanthopoulos-ph-d-to-step-down-as-president-and-chief-executive-office-rgls-20150601monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-reports-first-quarter-2015-financial-results-and-recent-highlights-regulus-therape-rgls-20150507monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-timing-for-first-quarter-2015-financial-results-webcast-and-conference-c-rgls-20150430monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-at-the-deutsche-bank-40th-annual-healthcare-conference-regulus-therapeu-rgls-20150429monthly0.5https://www.biopharmawatch.com/news/RGLS/late-breaking-oral-presentation-at-the-international-liver-congress-ilc-2015-highlights-rg-rgls-20150425monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-late-breaking-expanded-rg-101-data-set-for-the-treatment-of-hcv-at-the--rgls-20150409monthly0.5https://www.biopharmawatch.com/news/RGLS/rg-125-azd4076-a-microrna-therapeutic-targeting-microrna-103-107-for-the-treatment-of-nash-rgls-20150407monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-receives-orphan-medicinal-product-designation-from-the-european-commission-for-rg--rgls-20150325monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-at-cowen-and-company-35th-annual-healthcare-conference-regulus-therapeu-rgls-20150226monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-at-2015-rbc-capital-markets-healthcare-conference-regulus-therapeutics--rgls-20150219monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-reports-fourth-quarter-and-year-end-2014-financial-results-and-recent-highlights-r-rgls-20150218monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-timing-for-fourth-quarter-and-year-end-2014-financial-results-webcast-an-rgls-20150212monthly0.5https://www.biopharmawatch.com/news/RGLS/all-hcv-patients-treated-with-a-single-sc-administration-of-4-mg-kg-of-rg-101-responded-wi-rgls-20150209monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-earns-milestone-payment-from-biogen-idec-related-to-the-identification-of-potentia-rgls-20150202monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-at-two-upcoming-investor-conferences-regulus-therapeutics-inc-nasdaq-rg-rgls-20150202monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-key-goals-under-its-clinical-map-initiative-for-2015-regulus-therapeutic-rgls-20150108monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-at-the-26th-annual-piper-jaffray-healthcare-conference-and-genetic-rx-c-rgls-20141126monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-and-sanofi-present-new-data-enhancing-the-preclinical-profile-of-rg-012-an-anti-mi-rgls-20141115monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-at-the-credit-suisse-healthcare-conference-regulus-therapeutics-inc-nas-rgls-20141106monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-reports-third-quarter-2014-financial-results-and-recent-highlights-regulus-therape-rgls-20141105monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-closing-of-public-offering-of-103-5m-of-common-stock-and-full-exercise-o-rgls-20141103monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-timing-for-third-quarter-2014-financial-results-webcast-and-conference-c-rgls-20141030monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-pricing-of-public-offering-of-common-stock-regulus-therapeutics-inc-nasd-rgls-20141028monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-commencement-of-public-offering-of-common-stock-regulus-therapeutics-inc-rgls-20141027monthly0.5https://www.biopharmawatch.com/news/RGLS/a-single-subcutaneous-dose-of-2mg-kg-of-rg-101-regulus-wholly-owned-galnac-conjugated-anti-rgls-20141022monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-presents-new-preclinical-data-on-multiple-programs-and-provides-portfolio-overview-rgls-20141014monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-notice-of-allowance-from-u-s-patent-office-related-to-microrna-103-107-p-rgls-20140924monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-initiates-athena-natural-history-of-disease-study-in-alport-syndrome-patients-regu-rgls-20140918monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-at-the-wedbush-life-sciences-management-access-conference-regulus-thera-rgls-20140807monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-reports-second-quarter-2014-financial-results-and-recent-highlights-regulus-therap-rgls-20140806monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-enters-into-new-collaboration-agreement-with-biogen-idec-to-identify-microrna-biom-rgls-20140805monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-timing-for-second-quarter-2014-financial-results-webcast-and-conference--rgls-20140730monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-receives-orphan-drug-designation-for-rg-012-a-microrna-therapeutic-for-the-treatme-rgls-20140721monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-patent-grant-from-u-s-patent-office-in-sarnow-patent-estate-on-microrna--rgls-20140625monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-appoints-paul-c-grint-m-d-as-chief-medical-officer-regulus-therapeutics-inc-nasdaq-rgls-20140616monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-at-the-bank-of-america-merrill-lynch-2014-healthcare-conference-regulus-rgls-20140509monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-reports-first-quarter-2014-financial-results-and-recent-highlights-regulus-therape-rgls-20140508monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-at-the-deutsche-bank-39th-annual-healthcare-conference-regulus-therapeu-rgls-20140430monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-presents-positive-preclinical-data-on-mir-21-and-mir-221-oncology-programs-in-oral-rgls-20140407monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-at-the-13th-annual-needham-healthcare-conference-regulus-therapeutics-i-rgls-20140404monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-and-alport-syndrome-foundation-raise-awareness-of-life-threatening-genetic-kidney--rgls-20140325monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-commences-dosing-rg-101-in-healthy-volunteers-in-phase-i-study-regulus-therapeutic-rgls-20140305monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-provides-strategic-update-and-reports-fourth-quarter-and-year-end-2013-financial-r-rgls-20140227monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-at-cowen-and-company-34th-annual-healthcare-conference-regulus-therapeu-rgls-20140226monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-timing-for-fourth-quarter-and-year-end-2013-financial-results-webcast-an-rgls-20140220monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-advances-orphan-disease-portfolio-with-nomination-of-rg-012-as-clinical-developmen-rgls-20140219monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-appoints-head-of-regulus-micromarkers-r-d-division-regulus-therapeutics-inc-nasdaq-rgls-20140213monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-renews-strategic-alliance-with-sanofi-to-focus-on-orphan-disease-and-oncology-targ-rgls-20140205monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-strengthens-executive-management-team-with-addition-of-david-szekeres-as-chief-bus-rgls-20140204monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-expands-its-biomarkers-platform-and-establishes-regulus-micromarkers-a-new-r-d-div-rgls-20140113monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-demonstrates-initial-progress-in-microrna-biomarkers-ms-collaboration-and-receives-rgls-20131120monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-reports-third-quarter-2013-financial-results-and-recent-highlights-regulus-therape-rgls-20131113monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-presents-positive-preclinical-data-demonstrating-that-microrna-21-plays-an-importa-rgls-20131108monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-timing-for-third-quarter-2013-financial-results-webcast-and-conference-c-rgls-20131106monthly0.5https://www.biopharmawatch.com/news/RGLS/positive-preclinical-profile-of-rg-101-a-galnac-conjugated-anti-mir-targeting-microrna-122-rgls-20131104monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-significant-progress-in-strategic-alliance-with-astrazeneca-and-selectio-rgls-20131028monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-reports-second-quarter-2013-financial-results-and-recent-highlights-regulus-therap-rgls-20130813monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-timing-for-second-quarter-2013-financial-results-webcast-and-conference--rgls-20130806monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-completion-of-public-offering-and-exercise-in-full-of-overallotment-opti-rgls-20130723monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-pricing-of-public-offering-of-common-stock-regulus-therapeutics-inc-nasd-rgls-20130717monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-names-stelios-papadopoulos-ph-d-as-chairman-of-its-board-of-directors-regulus-ther-rgls-20130611monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-at-deutsche-bank-38th-annual-healthcare-conference-regulus-therapeutics-rgls-20130521monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-timing-for-first-quarter-2013-financial-results-webcast-and-conference-c-rgls-20130507monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-at-12th-annual-needham-healthcare-conference-regulus-therapeutics-inc-n-rgls-20130424monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-appoints-william-h-rastetter-ph-d-to-its-board-of-directors-regulus-therapeutics-i-rgls-20130401monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-at-future-leaders-in-the-biotech-industry-conference-regulus-therapeuti-rgls-20130328monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-at-cowen-and-company-33rd-annual-healthcare-conference-regulus-therapeu-rgls-20130226monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-reports-fourth-quarter-and-year-end-2012-financial-results-and-highlights-regulus--rgls-20130220monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-timing-for-fourth-quarter-and-year-end-2012-financial-results-webcast-an-rgls-20130213monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-at-two-upcoming-investor-conferences-regulus-therapeutics-inc-nasdaq-rg-rgls-20130204monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-appoints-mark-g-foletta-to-its-board-of-directors-regulus-therapeutics-inc-nasdaq--rgls-20130131monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-at-31st-annual-j-p-morgan-healthcare-conference-regulus-therapeutics-in-rgls-20130103monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-addition-to-russell-2000-index-regulus-therapeutics-inc-nasdaq-rgls-a-bi-rgls-20121220monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-host-nasdaq-closing-bell-ceremony-on-december-5-2012-regulus-therapeutics-inc-n-rgls-20121203monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-appoints-victor-knopov-ph-d-as-vice-president-pharmaceutical-development-regulus-t-rgls-20121127monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-reports-third-quarter-2012-financial-results-and-recent-highlights-regulus-therape-rgls-20121119monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-timing-for-third-quarter-2012-financial-results-webcast-and-conference-c-rgls-20121112monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-to-present-at-the-lazard-capital-markets-healthcare-conference-regulus-therapeutic-rgls-20121108monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-appoints-douglas-e-williams-ph-d-to-its-board-of-directors-regulus-therapeutics-in-rgls-20121107monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-80-9-million-in-total-gross-proceeds-from-ipo-and-other-recent-financial-rgls-20121105monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-presents-new-preclinical-data-on-mir-21-at-kidney-week-2012-regulus-therapeutics-i-rgls-20121103monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-pricing-of-initial-public-offering-regulus-therapeutics-inc-nasdaq-rgls--rgls-20121004monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-files-registration-statement-for-proposed-initial-public-offering-regulus-therapeu-rgls-20120820monthly0.5https://www.biopharmawatch.com/news/RGLS/biogen-idec-and-regulus-therapeutics-form-collaboration-to-explore-microrna-biomarkers-for-rgls-20120815monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-forms-strategic-alliance-for-discovery-development-and-commercializat-rgls-20120814monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-appoints-bruce-carter-to-its-board-of-directors-regulus-therapeutics--rgls-20120430monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-receives-allowance-from-japan-and-u-s-patent-offices-for-hcv-intellectual-property-rgls-20120423monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-announces-new-publication-showing-potential-therapeutic-benefit-of-targeting-micro-rgls-20120216monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-to-present-microrna-platform-and-pipeline-updates-at-two-leading-scie-rgls-20120105monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-to-present-new-in-vivo-data-for-microrna-21-in-kidney-fibrosis-regulu-rgls-20111108monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-expands-worldwide-patent-coverage-on-microrna-122-to-treat-hepatitis--rgls-20111102monthly0.5https://www.biopharmawatch.com/news/RGLS/webinar-advisory-regulus-to-host-discussion-about-potential-of-microrna-33-as-target-for-t-rgls-20111026monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-to-present-new-advancements-in-microrna-therapeutics-for-treatment-of-rgls-20110908monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-and-glaxosmithkline-name-a-third-alliance-microrna-target-triggering--rgls-20110720monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-appoints-gregory-hannon-ph-d-to-scientific-advisory-board-regulus-the-rgls-20110714monthly0.5https://www.biopharmawatch.com/news/RGLS/nature-article-implicates-micrornas-in-the-pathogenesis-of-obesity-and-type-2-diabetes-reg-rgls-20110608monthly0.5https://www.biopharmawatch.com/news/RGLS/regulus-therapeutics-and-collaborators-from-nyu-langone-medical-center-publish-new-data-de-rgls-20110606monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-announces-reverse-stock-split-to-maintain-nasdaq-listing-synaptogenix-inc-nas-snpx-20240403monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-president-daniel-l-alkon-m-d-honored-for-scientific-presentation-at-usc-spons-snpx-20231219monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-joins-leading-neuroscientists-and-academics-as-speaker-at-usc-sponsored-forum-snpx-20231206monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-acquires-significant-stake-in-cannasoul-analtyics-ltd-co-founded-by-the-techn-snpx-20231102monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-announces-peer-reviewed-publication-of-nih-sponsored-phase-2-clinical-trial-r-snpx-20230926monthly0.5https://www.biopharmawatch.com/news/SNPX/bryostatin-1-from-synaptogenix-shows-statistically-significant-results-as-an-als-treatment-snpx-20230907monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-and-cleveland-clinic-to-submit-investigational-new-drug-ind-application-to-fd-snpx-20230719monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-abstract-highlighting-bryostatin-1-benefits-in-severe-alzheimer-s-disease-acc-snpx-20230713monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-provides-corporate-update-and-outlines-potential-business-opportunities-synap-snpx-20230307monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-announces-topline-results-from-nih-sponsored-phase-2-clinical-trial-of-bryost-snpx-20221216monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-announces-15-million-private-placement-with-existing-investors-synaptogenix-i-snpx-20221118monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-to-present-at-thinkequity-investor-conference-on-october-26-2022-synaptogenix-snpx-20221019monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-welcomes-lecanemab-phase-3-trial-results-synaptogenix-inc-nasdaq-snpx-synapto-snpx-20220928monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-announces-live-appearance-of-its-president-and-cso-on-streaming-financial-new-snpx-20220812monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-announces-changes-to-scientific-advisory-board-in-preparation-for-phase-2-dat-snpx-20220726monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-announces-corporate-update-conference-call-synaptogenix-inc-nasdaq-snpx-the-c-snpx-20220721monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-advances-dosing-of-first-patient-in-dose-optimization-clinical-trial-in-prepa-snpx-20220720monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-to-present-at-the-cell-symposium-synaptogenix-inc-nasdaq-snpx-synaptogenix-or-snpx-20220517monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-completes-patient-enrollment-in-nih-sponsored-phase-2b-alzheimer-s-disease-tr-snpx-20220419monthly0.5https://www.biopharmawatch.com/news/SNPX/new-peer-reviewed-article-demonstrates-extended-therapeutic-potential-of-synaptogenix-s-br-snpx-20220405monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-to-present-at-hanson-wade-10th-annual-neurodegenerative-drug-development-summ-snpx-20220329monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-to-present-at-sachs-5th-annual-neuroscience-innovation-forum-synaptogenix-inc-snpx-20220322monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-to-present-research-highlighting-potential-broad-applicability-for-lead-compo-snpx-20220315monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-moves-forward-with-clinical-development-plans-for-bryostatin-1-as-a-treatment-snpx-20220223monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-announces-publication-of-peer-reviewed-scientific-article-evidencing-byrostat-snpx-20220201monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-announces-participation-at-the-benzinga-healthcare-small-cap-conference-synap-snpx-20210928monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-announces-participation-at-the-h-c-wainwright-23rd-annual-global-investment-c-snpx-20210910monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-signs-memorandum-of-understanding-with-nemours-a-i-dupont-hospital-to-initiat-snpx-20210805monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-discloses-positive-results-of-further-bryostatin-trial-analyses-in-presentati-snpx-20210726monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-announces-conference-call-to-discuss-aaic-abstract-findings-synaptogenix-inc--snpx-20210721monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-to-present-data-at-alzheimer-s-association-international-conference-2021-high-snpx-20210714monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-announces-regenerative-patent-award-to-treat-alzheimer-s-disease-synaptogenix-snpx-20210707monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-announces-live-appearance-of-its-president-and-cso-on-streaming-financial-new-snpx-20210624monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-announces-12-5-million-private-placement-synaptogenix-inc-nasdaq-snpx-an-emer-snpx-20210614monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-announces-phase-2b-nih-sponsored-alzheimer-s-disease-trial-update-synaptogeni-snpx-20210609monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-responds-to-fda-approval-of-aducanumab-synaptogenix-inc-nasdaq-snpx-an-emergi-snpx-20210607monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-announces-approval-for-nasdaq-stock-market-listing-synaptogenix-inc-otc-snpx--snpx-20210607monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-announces-plan-to-uplist-on-the-nasdaq-stock-market-synaptogenix-inc-otc-snpx-snpx-20210519monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-to-present-at-sachs-4th-annual-neuroscience-innovation-forum-synaptogenix-inc-snpx-20210426monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-announces-phase-2b-bryostatin-1-clinical-trial-update-synaptogenix-inc-otc-sn-snpx-20210401monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-to-present-at-the-h-c-wainwright-global-life-sciences-conference-synaptogenix-snpx-20210305monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-to-present-at-upcoming-scientific-industry-conferences-synaptogenix-inc-otc-s-snpx-20210225monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-to-participate-in-the-winter-wonderland-best-ideas-from-the-buy-side-conferen-snpx-20210212monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-files-application-to-list-on-the-nasdaq-stock-market-synaptogenix-inc-otc-snp-snpx-20210209monthly0.5https://www.biopharmawatch.com/news/SNPX/new-study-demonstrates-bryostatin-normalizes-autistic-spectrum-behaviors-in-mice-synaptoge-snpx-20210126monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-announces-14-0-million-private-placement-synaptogenix-inc-the-company-or-syna-snpx-20210121monthly0.5https://www.biopharmawatch.com/news/SNPX/synaptogenix-schedules-business-update-conference-call-synaptogenix-inc-otc-snpx-formerly--snpx-20201215monthly0.5https://www.biopharmawatch.com/news/BMY/years-of-global-patient-week-bristol-myers-squibb-brings-joy-to-patients-with-toy-making-w-bmy-20251014monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-appoints-osama-braiwish-as-general-manager-for-saudi-arabia-gulf-coun-bmy-20250320monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-marks-10-years-of-global-patient-week-with-community-initiatives-in-t-bmy-20240930monthly0.5https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-amplia-seu-compromisso-de-longa-data-com-a-pesquisa-do-ca-ncer-por-me-bmy-20231202monthly0.5https://www.biopharmawatch.com/news/BMY/dia-nacional-de-combate-ao-ca-ncer-primeiro-bloqueador-de-checagem-imunolo-gica-completa-1-bmy-20231127monthly0.5https://www.biopharmawatch.com/news/BMY/ans-abre-consulta-pu-blica-para-incorporac-a-o-de-tratamentos-do-mieloma-mu-ltiplo-recidiv-bmy-20231017monthly0.5https://www.biopharmawatch.com/news/BMY/imunoterapia-aumenta-a-sobrevida-de-pacientes-com-ca-ncer-de-pulma-o-em-esta-gio-avanc-ado-bmy-20230828monthly0.5https://www.biopharmawatch.com/news/BMY/anvisa-aprova-camzyos-mavacanteno-para-o-tratamento-da-cardiomiopatia-hipertro-fica-obstru-bmy-20230720monthly0.5https://www.biopharmawatch.com/news/BMY/brasil-deve-ter-mais-de-180-mil-novos-casos-de-ca-ncer-de-pele-ate-o-fim-deste-ano-bristol-bmy-20221221monthly0.5https://www.biopharmawatch.com/news/BMY/campanha-sobre-viver-conta-histo-rias-de-superac-a-o-de-pacientes-oncolo-gicos-viver-com-c-bmy-20220110monthly0.5https://www.biopharmawatch.com/news/BMY/anvisa-aprova-dupla-imunoterapia-para-tratamento-de-ca-ncer-de-pulma-o-em-primeira-linha-a-bmy-20210913monthly0.5https://www.biopharmawatch.com/news/BMY/apo-s-dez-anos-sem-inovac-a-o-anvisa-aprova-nova-alternativa-para-o-tratamento-do-ca-ncer--bmy-20210701monthly0.5https://www.biopharmawatch.com/news/BMY/tabagismo-e-um-dos-maiores-responsa-veis-pela-incide-ncia-do-ca-ncer-renal-silenciosamente-bmy-20210617monthly0.5https://www.biopharmawatch.com/news/BMY/maispro-ximosmaisfortes-intensifica-movimento-de-conscientizac-a-o-sobre-mieloma-mu-ltiplo-bmy-20210526monthly0.5https://www.biopharmawatch.com/news/BMY/anvisa-aprova-imunotera-pico-para-tratamento-de-ca-ncer-de-eso-fago-a-age-ncia-nacional-de-bmy-20201217monthly0.5https://www.biopharmawatch.com/news/BMY/me-s-de-conscientizac-a-o-dos-ca-nceres-de-sangue-pacientes-que-enfrentam-ca-nceres-hemato-bmy-20200922monthly0.5https://www.biopharmawatch.com/news/PFE/international-and-regional-experts-focus-on-rsv-prevention-at-pfizer-mera-maternal-immuniz-pfe-20250521monthly0.5https://www.biopharmawatch.com/news/PFE/international-and-regional-experts-address-the-role-of-vaccines-in-disease-management-duri-pfe-20241104monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-appoints-elif-aral-as-regional-president-for-the-middle-east-russia-africa-pfizer-a-pfe-20240905monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-reflects-on-175-year-global-legacy-and-decades-of-regional-breakthroughs-pfizer-com-pfe-20240611monthly0.5https://www.biopharmawatch.com/news/PFE/the-arab-international-women-s-forum-and-pfizer-launch-dei-by-design-report-with-recommend-pfe-20231107monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-holds-mera-vaccines-summit-to-discuss-the-impact-of-vaccines-on-controlling-disease-pfe-20231030monthly0.5https://www.biopharmawatch.com/news/PFE/padecimientos-de-la-piel-la-4a-causa-de-enfermedades-en-el-ser-humano-los-padecimientos-de-pfe-20220920monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-launches-an-accord-for-a-healthier-world-to-improve-health-equity-for-1-2-billion-p-pfe-20220525monthly0.5https://www.biopharmawatch.com/news/PFE/novos-episo-dios-do-canal-de-podcasts-eu-doutor-trazem-reflexo-es-sobre-a-vida-e-a-carreir-pfe-20200415monthly0.5https://www.biopharmawatch.com/news/PFE/novo-canal-de-podcasts-eu-doutor-discute-dilemas-profissionais-e-pessoais-dos-me-dicos-com-pfe-20200317monthly0.5https://www.biopharmawatch.com/news/PFE/coletivo-pink-2019-festival-de-arte-e-cultura-de-sa-o-paulo-e-exposic-a-o-de-fotos-com-de--pfe-20191010monthly0.5https://www.biopharmawatch.com/news/PFE/movimento-desafio-de-fo-lego-mobiliza-artistas-no-combate-ao-ca-ncer-de-pulma-o-o-fo-lego--pfe-20190809monthly0.5https://www.biopharmawatch.com/news/PFE/pediatras-lanc-am-cartilha-digital-para-responder-a-s-principais-du-vidas-dos-pais-sobre-s-pfe-20190619monthly0.5https://www.biopharmawatch.com/news/PFE/a-rvores-viram-gente-na-avenida-paulista-para-dar-visibilidade-a-pacientes-raros-de-quem-s-pfe-20190614monthly0.5https://www.biopharmawatch.com/news/PFE/anvisa-estende-aprovac-a-o-de-medicamento-inovador-para-doenc-as-inflamato-rias-autoimunes-pfe-20190509monthly0.5https://www.biopharmawatch.com/news/PFE/liderado-por-brasileiro-estudo-pode-mudar-a-conduta-cli-nica-para-portadores-de-arritmia-c-pfe-20190508monthly0.5https://www.biopharmawatch.com/news/PFE/programa-da-onu-apoiado-pela-pfizer-recebe-inscric-o-es-ate-30-de-abril-para-projetos-de-d-pfe-20190417monthly0.5https://www.biopharmawatch.com/news/PFE/anticoncepcional-inovador-da-pfizer-com-mecanismo-de-autoaplicac-a-o-trimestral-chega-ao-b-pfe-20190318monthly0.5https://www.biopharmawatch.com/news/PFE/brasil-celebra-primeiro-dia-nacional-das-doenc-as-raras-em-meio-a-desafios-hoje-28-de-feve-pfe-20190228monthly0.5https://www.biopharmawatch.com/news/PFE/sus-passa-a-oferecer-medicamento-inovador-para-doenc-a-reuma-tica-a-partir-de-agora-a-rede-pfe-20190123monthly0.5https://www.biopharmawatch.com/news/PFE/sus-passa-a-oferecer-medicamento-inovador-para-doenc-a-reuma-tica-a-partir-de-agora-a-rede-pfe-20190121monthly0.5https://www.biopharmawatch.com/news/PFE/governo-avalia-inclusa-o-no-sus-de-vacina-que-amplia-a-protec-a-o-contra-pneumonia-bacteri-pfe-20181207monthly0.5https://www.biopharmawatch.com/news/PFE/campanha-digital-da-pfizer-alerta-para-uso-consciente-de-antibio-ticos-em-muitos-pai-ses-a-pfe-20181114monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-s-new-report-shows-how-behavioural-science-can-help-boost-preventative-healthcare-m-pfe-20180731monthly0.5https://www.biopharmawatch.com/news/PFE/anvisa-aprova-medicamento-inovador-da-pfizer-para-reposic-a-o-hormonal-a-anvisa-acaba-de-a-pfe-20180606monthly0.5https://www.biopharmawatch.com/news/PFE/anvisa-estende-indicac-a-o-de-vacina-contra-meningite-da-pfizer-a-age-ncia-nacional-de-vig-pfe-20180604monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-lanc-a-no-brasil-medicamento-inovador-para-ca-ncer-de-mama-a-pfizer-acaba-de-lanc-a-pfe-20180523monthly0.5https://www.biopharmawatch.com/news/PFE/instituic-o-es-brasileiras-recebem-executivos-da-pfizer-de-diferentes-pai-ses-para-trabalh-pfe-20180521monthly0.5https://www.biopharmawatch.com/news/PFE/anvisa-aprova-nova-indicac-a-o-de-medicamento-para-ca-ncer-de-pulma-o-a-age-ncia-nacional--pfe-20180403monthly0.5https://www.biopharmawatch.com/news/PFE/sus-incorpora-medicamento-da-pfizer-para-doenc-a-gene-tica-de-origem-portuguesa-foi-public-pfe-20180118monthly0.5https://www.biopharmawatch.com/news/PFE/estudo-reforc-a-efica-cia-e-seguranc-a-de-medicamento-da-pfizer-para-doenc-a-gene-tica-um--pfe-20171219monthly0.5https://www.biopharmawatch.com/news/PFE/pesquisa-da-pfizer-aponta-que-brasileiros-querem-viver-muito-mas-descuidam-da-sau-de-os-br-pfe-20171213monthly0.5https://www.biopharmawatch.com/news/PFE/te-cnica-inovadora-da-pfizer-revoluciona-o-tratamento-da-hemofilia-uma-te-cnica-capaz-de-i-pfe-20171130monthly0.5https://www.biopharmawatch.com/news/PFE/carlinhos-brown-pausa-show-para-alertar-sobre-doenc-a-gene-tica-em-ac-a-o-da-academia-bras-pfe-20171117monthly0.5https://www.biopharmawatch.com/news/PFE/associac-a-o-pan-americana-de-infectologia-e-pfizer-lanc-am-campanha-para-alertar-sobre-re-pfe-20171114monthly0.5https://www.biopharmawatch.com/news/PFE/neste-outubro-rosa-ac-a-o-educativa-da-pfizer-e-do-oncoguia-mobiliza-metro-e-800-ta-xis-de-pfe-20170929monthly0.5https://www.biopharmawatch.com/news/PFE/national-sickle-cell-disease-poll-of-african-americans-dispels-long-held-views-pfizer-inc--pfe-20170921monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-e-cvv-lanc-am-campanha-de-prevenc-a-o-do-suici-dio-se-por-um-lado-as-discusso-es-re-pfe-20170906monthly0.5https://www.biopharmawatch.com/news/PFE/pesquisa-da-pfizer-revela-que-brasileiros-com-disfunc-a-o-ere-til-planejam-dia-e-hora-para-pfe-20170724monthly0.5https://www.biopharmawatch.com/news/PFE/pesquisa-realizada-pela-pfizer-aponta-que-brasileiros-desconhecem-ca-ncer-de-rim-a-maioria-pfe-20170714monthly0.5https://www.biopharmawatch.com/news/PFE/victor-mezei-presidente-da-pfizer-brasil-e-eleito-uma-das-personalidades-mais-influentes-d-pfe-20170519monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-traz-para-o-mercado-centrum-vitamints-multivitami-nico-em-formato-de-pastilhas-mast-pfe-20170412monthly0.5https://www.biopharmawatch.com/news/PFE/unia-o-internacional-de-controle-do-ca-ncer-e-pfizer-lanc-am-nova-fase-de-projeto-mundial--pfe-20170330monthly0.5https://www.biopharmawatch.com/news/PFE/sus-incorpora-medicamento-inovador-da-pfizer-para-artrite-reumatoide-foi-publicada-no-u-lt-pfe-20170207monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-e-a-empresa-mais-admirada-do-setor-farmace-utico-conhecida-por-seu-intenso-trabalho-pfe-20161221monthly0.5https://www.biopharmawatch.com/news/PFE/ac-a-o-da-pfizer-no-metro-mostra-que-paulistanos-desconhecem-informac-o-es-ba-sicas-sobre--pfe-20161130monthly0.5https://www.biopharmawatch.com/news/PFE/grande-piquenique-da-pfizer-reunira-gerac-o-es-para-um-dia-de-diversa-o-no-parque-villa-lo-pfe-20161124monthly0.5https://www.biopharmawatch.com/news/PFE/estudo-pioneiro-da-pfizer-desmistifica-efeitos-de-anti-inflamato-rios-para-o-corac-a-o-a-r-pfe-20161117monthly0.5https://www.biopharmawatch.com/news/PFE/anvisa-aprova-medicamento-da-pfizer-para-doenc-a-gene-tica-irreversi-vel-a-age-ncia-nacion-pfe-20161108monthly0.5https://www.biopharmawatch.com/news/PFE/ca-lcio-vitamina-d-e-atividade-fi-sica-pfizer-alerta-sobre-trio-fundamental-para-a-sau-de--pfe-20161020monthly0.5https://www.biopharmawatch.com/news/PFE/com-apoio-de-craques-do-futebol-e-da-pfizer-associac-a-o-me-dica-lanc-a-campanha-de-esclar-pfe-20161019monthly0.5https://www.biopharmawatch.com/news/PFE/pesquisa-aponta-pfizer-como-li-der-em-reputac-a-o-do-setor-farmace-utico-no-brasil-a-pfize-pfe-20160926monthly0.5https://www.biopharmawatch.com/news/PFE/pesquisa-da-pfizer-aponta-rui-dos-na-comunicac-a-o-entre-pacientes-e-me-dicos-estabelecer--pfe-20160831monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-lanc-a-no-brasil-novas-terapias-alvo-contra-ca-ncer-de-pulma-o-e-rim-o-ano-de-2016--pfe-20160708monthly0.5https://www.biopharmawatch.com/news/PFE/com-apoio-da-pfizer-pesquisa-trac-a-novo-perfil-sexual-do-brasileiro-as-dificuldades-sexua-pfe-20160617monthly0.5https://www.biopharmawatch.com/news/PFE/medicamento-da-pfizer-e-o-primeiro-anticorpo-monoclonal-biossimilar-aprovado-pelo-fda-o-me-pfe-20160503monthly0.5https://www.biopharmawatch.com/news/PFE/sociedade-me-dica-lanc-a-campanha-contra-pneumonia-e-pesquisa-ine-dita-da-pfizer-mapeia-im-pfe-20160503monthly0.5https://www.biopharmawatch.com/news/PFE/xalkori-crizotinibe-da-pfizer-e-aprovado-no-brasil-para-o-tratamento-de-ca-ncer-de-pulma-o-pfe-20160211monthly0.5https://www.biopharmawatch.com/news/PFE/instituic-o-es-brasileiras-participam-dos-estudos-cli-nicos-de-fase-3-para-novo-medicament-pfe-20160121monthly0.5https://www.biopharmawatch.com/news/PFE/anvisa-aprova-novo-medicamento-da-pfizer-para-tratamento-de-ca-ncer-renal-a-pfizer-acaba-d-pfe-20151214monthly0.5https://www.biopharmawatch.com/news/PFE/brasileiros-acreditam-que-meta-stase-e-rara-em-tumores-de-mama-diz-pesquisa-ine-dita-da-pf-pfe-20151020monthly0.5https://www.biopharmawatch.com/news/PFE/pesquisa-ine-dita-da-pfizer-mostra-que-ali-vio-ra-pido-e-o-principal-pensamento-no-momento-pfe-20151015monthly0.5https://www.biopharmawatch.com/news/PFE/crianc-as-e-jovens-temem-rugas-e-limitac-o-es-na-velhice-mostra-pesquisa-da-pfizer-vergonh-pfe-20151007monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-conclui-aquisic-a-o-de-vacina-contra-meningite-da-glaxosmithkline-a-pfizer-anunciou-pfe-20151001monthly0.5https://www.biopharmawatch.com/news/PFE/trabalhar-ajuda-a-enfrentar-o-tratamento-contra-o-ca-ncer-indica-pesquisa-ine-dita-da-pfiz-pfe-20150924monthly0.5https://www.biopharmawatch.com/news/PFE/campanha-da-pfizer-propo-e-novo-olhar-sobre-o-envelhecimento-com-o-objetivo-de-redefinir-o-pfe-20150731monthly0.5https://www.biopharmawatch.com/news/PFE/doenc-a-incapacitante-afeta-a-vida-profissional-de-adultos-jovens-no-pai-s-aponta-pesquisa-pfe-20150721monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-inaugura-centro-de-excele-ncia-em-medicina-de-precisa-o-no-chile-com-forte-foco-em--pfe-20150708monthly0.5https://www.biopharmawatch.com/news/PFE/pesquisa-da-pfizer-revela-que-94-das-mulheres-se-incomodam-com-a-pele-do-rosto-a-marca-de--pfe-20150625monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-releases-new-report-highlighting-underserved-latino-populations-and-commits-to-help-pfe-20150619monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-pone-en-circulacio-n-nuevo-informe-destacando-las-poblaciones-de-latinos-menos-favo-pfe-20150619monthly0.5https://www.biopharmawatch.com/news/PFE/novo-medicamento-da-pfizer-para-ca-ncer-de-mama-pode-dobrar-sobrevida-livre-de-progressa-o-pfe-20150616monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-traz-ao-brasil-tratamento-inovador-para-artrite-reumatoide-acaba-de-chegar-ao-brasi-pfe-20150507monthly0.5https://www.biopharmawatch.com/news/PFE/anvisa-aprova-indicac-a-o-de-vacina-da-pfizer-para-crianc-as-e-adolescentes-de-6-a-17-anos-pfe-20150402monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-firma-parceria-com-graacc-e-unia-o-internacional-de-controle-do-ca-ncer-para-fortal-pfe-20150327monthly0.5https://www.biopharmawatch.com/news/PFE/estudo-com-85-mil-pessoas-comprova-efica-cia-de-vacina-da-pfizer-contra-pneumonias-pneumoc-pfe-20150319monthly0.5https://www.biopharmawatch.com/news/PFE/pesquisa-ine-dita-da-pfizer-revela-que-77-dos-brasileiros-com-mais-de-50-anos-consideram-a-pfe-20150206monthly0.5https://www.biopharmawatch.com/news/PFE/fda-concede-aprovac-a-o-antecipada-para-novo-medicamento-da-pfizer-contra-ca-ncer-de-mama--pfe-20150205monthly0.5https://www.biopharmawatch.com/news/PFE/apo-s-transac-a-o-com-empresa-sui-c-a-pfizer-amplia-seu-portfo-lio-de-vacinas-a-pfizer-aca-pfe-20150112monthly0.5https://www.biopharmawatch.com/news/PFE/pfizer-recebe-aprovac-a-o-para-lanc-ar-xeljanz-no-brasil-e-inaugura-classe-de-medicamentos-pfe-20141208monthly0.5https://www.biopharmawatch.com/news/PFE/estrate-gias-de-aconselhamento-empresarial-ajudam-colaboradores-da-pfizer-na-carreira-e-no-pfe-20141128monthly0.5https://www.biopharmawatch.com/news/PFE/estudo-mostra-que-antidepressivo-da-pfizer-tem-baixo-risco-de-provocar-disfunc-a-o-sexual--pfe-20141031monthly0.5https://www.biopharmawatch.com/news/PFE/tratamento-da-pfizer-contra-ca-ncer-de-mama-recebe-revisa-o-priorita-ria-do-fda-o-medicame-pfe-20141023monthly0.5https://www.biopharmawatch.com/news/PFE/pesquisa-ine-dita-da-pfizer-revela-que-71-das-mulheres-no-brasil-desconhecem-a-idade-de-in-pfe-20141017monthly0.5https://www.biopharmawatch.com/news/PFE/cientistas-que-desenvolveram-antidepressivo-da-pfizer-sa-o-reconhecidos-como-hero-is-da-qu-pfe-20141002monthly0.5https://www.biopharmawatch.com/news/PFE/nu-mero-de-mulheres-em-cargos-executivos-na-pfizer-dobra-em-seis-anos-se-o-aumento-das-mul-pfe-20140825monthly0.5https://www.biopharmawatch.com/news/PFE/vacina-para-doenc-as-pneumoco-cicas-e-pneumonia-da-pfizer-e-recomendada-nos-estados-unidos-pfe-20140819monthly0.5https://www.biopharmawatch.com/news/PFE/pesquisa-da-pfizer-mostra-que-viagra-e-mais-acessi-vel-do-que-se-imagina-uma-pesquisa-real-pfe-20140722monthly0.5https://www.biopharmawatch.com/news/PFE/parceria-da-bms-e-pfizer-traz-para-o-brasil-a-segunda-indicac-a-o-de-eliquis-apixabana-a-b-pfe-20140718monthly0.5https://www.biopharmawatch.com/news/PFE/los-hispanos-y-el-ca-ncer-el-ca-ncer-es-una-palabra-que-nadie-quiere-escuchar-cuando-habla-pfe-20130528monthly0.5https://www.biopharmawatch.com/news/PFE/hot-flashes-and-fashion-know-your-options-during-the-holiday-season-fashion-stylist-lisa-r-pfe-20111205monthly0.5https://www.biopharmawatch.com/news/PFE/programa-promotores-de-pfizer-ayuda-a-hispanos-no-asegurados-y-con-seguro-insuficiente-de--pfe-20101209monthly0.5https://www.biopharmawatch.com/news/PFE/disparidad-en-la-comunidad-hispana-acceso-a-una-mejor-salud-los-medios-de-comunicacio-n-ha-pfe-20100922monthly0.5https://www.biopharmawatch.com/news/WAT/waters-launches-industry-first-reversed-phase-bioseparation-columns-to-deliver-up-to-3x-fa-wat-20260608monthly0.5https://www.biopharmawatch.com/news/WAT/waters-announces-fda-510-k-clearance-of-bd-bactec-fxi-culture-system-enabling-broader-acce-wat-20260603monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-to-present-at-the-jefferies-global-healthcare-conference-waters-corpora-wat-20260518monthly0.5https://www.biopharmawatch.com/news/WAT/waters-announces-ce-mark-for-next-generation-fully-automated-bd-bactec-fxi-culture-system--wat-20260415monthly0.5https://www.biopharmawatch.com/news/WAT/waters-announces-fda-clearance-of-the-most-comprehensive-at-home-cervical-cancer-screening-wat-20260408monthly0.5https://www.biopharmawatch.com/news/WAT/waters-prices-offering-of-senior-notes-waters-corporation-nyse-wat-the-company-or-waters-t-wat-20260318monthly0.5https://www.biopharmawatch.com/news/WAT/waters-launches-charge-detection-mass-spectrometry-technology-to-accelerate-the-developmen-wat-20251013monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-schedules-third-quarter-2025-earnings-conference-call-waters-corporatio-wat-20251001monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-to-present-at-the-wells-fargo-healthcare-conference-waters-corporation--wat-20250826monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-nyse-wat-reports-second-quarter-2025-financial-results-highlights-sales-wat-20250804monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-schedules-second-quarter-2025-earnings-conference-call-waters-corporati-wat-20250711monthly0.5https://www.biopharmawatch.com/news/WAT/waters-verbessert-alliance-is-hplc-system-software-und-setzt-damit-einen-neuen-standard-fu-wat-20250618monthly0.5https://www.biopharmawatch.com/news/WAT/waters-mejora-el-software-del-sistema-alliance-is-hplc-waters-mejora-el-software-del-siste-wat-20250618monthly0.5https://www.biopharmawatch.com/news/WAT/waters-ame-liore-le-logiciel-du-syste-me-hplc-alliance-is-e-tablissant-ainsi-un-nouveau-st-wat-20250617monthly0.5https://www.biopharmawatch.com/news/WAT/waters-enhances-alliance-is-hplc-system-software-setting-a-new-standard-for-end-to-end-tra-wat-20250617monthly0.5https://www.biopharmawatch.com/news/WAT/waters-e-tablit-une-nouvelle-re-fe-rence-en-matie-re-de-robustesse-et-de-sensibilite-pour--wat-20250602monthly0.5https://www.biopharmawatch.com/news/WAT/waters-sets-a-new-benchmark-for-robustness-and-sensitivity-for-high-throughput-labs-with-t-wat-20250602monthly0.5https://www.biopharmawatch.com/news/WAT/waters-establece-un-nuevo-esta-ndar-de-sensibilidad-con-el-espectro-metro-de-masas-xevo-tq-wat-20250602monthly0.5https://www.biopharmawatch.com/news/WAT/waters-stellt-bioresolve-protein-a-affinity-columns-zur-beschleunigung-der-antiko-rper-tit-wat-20250528monthly0.5https://www.biopharmawatch.com/news/WAT/waters-lance-les-colonnes-d-affinite-bioresolve-pour-la-prote-ine-a-afin-d-acce-le-rer-la--wat-20250528monthly0.5https://www.biopharmawatch.com/news/WAT/waters-presenta-las-columnas-de-afinidad-de-protei-na-a-bioresolve-waters-presenta-las-col-wat-20250528monthly0.5https://www.biopharmawatch.com/news/WAT/waters-introduces-bioresolve-protein-a-affinity-columns-to-accelerate-antibody-titer-measu-wat-20250528monthly0.5https://www.biopharmawatch.com/news/WAT/waters-acquiert-halo-labs-e-largissant-ainsi-son-portefeuille-d-analyses-biologiques-water-wat-20250522monthly0.5https://www.biopharmawatch.com/news/WAT/waters-erwirbt-halo-labs-und-erweitert-damit-das-portfolio-fu-r-biologische-analysen-die-w-wat-20250522monthly0.5https://www.biopharmawatch.com/news/WAT/waters-adquiere-halo-labs-y-ampli-a-su-cartera-de-ana-lisis-biolo-gicos-waters-corporation-wat-20250522monthly0.5https://www.biopharmawatch.com/news/WAT/waters-acquires-halo-labs-expanding-biological-analysis-portfolio-waters-corporation-nyse--wat-20250521monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-to-present-at-the-jefferies-global-healthcare-conference-waters-corpora-wat-20250516monthly0.5https://www.biopharmawatch.com/news/WAT/waters-inte-gre-des-de-tecteurs-de-diffusion-de-lumie-re-multi-angles-au-logiciel-empower--wat-20250506monthly0.5https://www.biopharmawatch.com/news/WAT/waters-integriert-mehrwinkel-lichtstreuungsdetektoren-mit-empower-software-fu-r-verbessert-wat-20250506monthly0.5https://www.biopharmawatch.com/news/WAT/waters-integra-detectores-de-dispersio-n-de-luz-multia-ngulo-con-el-software-empower-water-wat-20250506monthly0.5https://www.biopharmawatch.com/news/WAT/waters-integrates-multi-angle-light-scattering-detectors-with-empower-software-for-improve-wat-20250506monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-nyse-wat-reports-first-quarter-2025-financial-results-highlights-strong-wat-20250506monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-schedules-first-quarter-2025-earnings-conference-call-waters-corporatio-wat-20250408monthly0.5https://www.biopharmawatch.com/news/WAT/waters-expands-alliance-is-bio-hplc-product-line-with-photodiode-array-detector-to-enhance-wat-20250401monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-to-present-at-the-leerink-partners-global-healthcare-conference-waters--wat-20250307monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-nyse-wat-reports-fourth-quarter-and-full-year-2024-financial-results-hi-wat-20250212monthly0.5https://www.biopharmawatch.com/news/WAT/das-waters-electroforce-apex-1-instrument-bietet-mehr-vielseitigkeit-einfachheit-und-schne-wat-20250204monthly0.5https://www.biopharmawatch.com/news/WAT/l-instrument-waters-electroforce-apex-1-offre-une-polyvalence-une-simplicite-et-une-rapidi-wat-20250204monthly0.5https://www.biopharmawatch.com/news/WAT/waters-electroforce-apex-1-instrument-offers-increased-versatility-simplicity-and-speed-to-wat-20250204monthly0.5https://www.biopharmawatch.com/news/WAT/waters-lanza-el-instrumento-electroforce-apex-1-para-pruebas-meca-nicas-de-materiales-poli-wat-20250204monthly0.5https://www.biopharmawatch.com/news/WAT/innovative-waters-tga-smart-seal-pans-enable-lower-cost-more-efficient-benchtop-analysis-o-wat-20250122monthly0.5https://www.biopharmawatch.com/news/WAT/les-nouvelles-cuvettes-tga-smart-seal-de-waters-permettent-de-re-duire-les-cou-ts-et-d-ame-wat-20250122monthly0.5https://www.biopharmawatch.com/news/WAT/las-innovadoras-bandejas-waters-tga-smart-seal-permiten-un-ana-lisis-de-laboratorio-ma-s-e-wat-20250122monthly0.5https://www.biopharmawatch.com/news/WAT/innovative-waters-tga-smart-seal-pans-ermo-glichen-kostengu-nstigere-und-effizientere-benc-wat-20250122monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-schedules-fourth-quarter-2024-earnings-conference-call-waters-corporati-wat-20250117monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-to-host-investor-day-on-march-5-2025-waters-corporation-nyse-wat-announ-wat-20250110monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-inte-gre-l-indice-dow-jones-sustainability-pour-la-quatrie-me-anne-e-co-wat-20241224monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-zum-vierten-mal-in-folge-in-den-dow-jones-sustainability-index-aufgenom-wat-20241224monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-nombrado-en-el-i-ndice-de-sostenibilidad-dow-jones-por-cuarto-an-o-cons-wat-20241223monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-named-to-dow-jones-sustainability-index-for-the-fourth-consecutive-year-wat-20241223monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-waters-c-wat-20241217monthly0.5https://www.biopharmawatch.com/news/WAT/waters-highlights-continued-progress-towards-sustainability-commitments-news-summary-excee-wat-20241210monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-to-present-at-the-evercore-2024-healthconx-conference-waters-corporatio-wat-20241120monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-opens-state-of-the-art-precision-manufacturing-facility-in-longbridge-u-wat-20241113monthly0.5https://www.biopharmawatch.com/news/WAT/waters-new-software-delivers-lab-centric-business-intelligence-and-enables-confident-audit-wat-20241107monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-nyse-wat-reports-third-quarter-2024-financial-results-highlights-sales--wat-20241101monthly0.5https://www.biopharmawatch.com/news/WAT/waters-new-bioseparations-tools-accelerate-and-improve-development-of-rna-based-vaccines-a-wat-20241010monthly0.5https://www.biopharmawatch.com/news/WAT/new-waters-discovery-core-rheometer-brings-the-power-of-rheology-to-routine-quality-contro-wat-20241008monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-schedules-third-quarter-2024-earnings-conference-call-waters-corporatio-wat-20241007monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-appoints-heather-knight-to-board-of-directors-waters-corporation-nyse-w-wat-20240814monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-nyse-wat-reports-second-quarter-2024-financial-results-highlights-sales-wat-20240731monthly0.5https://www.biopharmawatch.com/news/WAT/waters-new-rapid-screening-dsc-enables-up-to-24x-faster-thermal-stability-testing-at-ultra-wat-20240723monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-schedules-second-quarter-2024-earnings-conference-call-waters-corporati-wat-20240702monthly0.5https://www.biopharmawatch.com/news/WAT/waters-sets-new-standards-for-high-resolution-performance-and-speed-with-xevo-mrt-mass-spe-wat-20240603monthly0.5https://www.biopharmawatch.com/news/WAT/waters-becomes-first-liquid-chromatography-column-provider-to-receive-my-green-lab-act-eco-wat-20240603monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-to-present-at-the-jefferies-2024-healthcare-conference-waters-corporati-wat-20240513monthly0.5https://www.biopharmawatch.com/news/WAT/waters-acquity-qda-ii-mass-detector-delivers-wider-range-of-chemical-analysis-within-cost--wat-20240508monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-nyse-wat-reports-first-quarter-2024-financial-results-highlights-sales--wat-20240507monthly0.5https://www.biopharmawatch.com/news/WAT/waters-accelerates-the-development-of-gene-based-therapeutics-with-new-gtxresolve-premier--wat-20240422monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-schedules-first-quarter-2024-earnings-conference-call-waters-corporatio-wat-20240411monthly0.5https://www.biopharmawatch.com/news/WAT/waters-launches-alliance-is-bio-hplc-system-to-help-biopharma-qc-labs-increase-efficiency--wat-20240409monthly0.5https://www.biopharmawatch.com/news/WAT/effizienz-steigern-fehler-reduzieren-waters-bringt-alliance-is-bio-hplc-system-auf-den-mar-wat-20240409monthly0.5https://www.biopharmawatch.com/news/WAT/waters-streamlines-and-expedites-pfas-testing-with-innovative-oasis-dual-phase-cartridges--wat-20240314monthly0.5https://www.biopharmawatch.com/news/WAT/waters-advances-battery-electrode-design-and-performance-analysis-with-new-rheo-is-accesso-wat-20240313monthly0.5https://www.biopharmawatch.com/news/WAT/waters-announces-seamless-hplc-uplc-data-bridge-for-light-scattering-integrating-essential-wat-20240226monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-to-present-at-the-td-cowen-44th-annual-health-care-conference-waters-co-wat-20240222monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-nyse-wat-reports-fourth-quarter-and-full-year-2023-financial-results-hi-wat-20240206monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-schedules-fourth-quarter-2023-earnings-conference-call-waters-corporati-wat-20240118monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-waters-c-wat-20231221monthly0.5https://www.biopharmawatch.com/news/WAT/waters-earns-sustainability-designation-from-my-green-lab-for-xevo-tq-absolute-system-news-wat-20231219monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-named-to-dow-jones-sustainability-index-for-the-third-consecutive-year--wat-20231219monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-board-of-directors-named-2024-public-company-board-of-the-year-by-natio-wat-20231218monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-opens-new-state-of-the-art-global-capability-center-in-bengaluru-india--wat-20231206monthly0.5https://www.biopharmawatch.com/news/WAT/waters-earns-top-score-in-human-rights-campaign-foundation-s-2023-2024-corporate-equality--wat-20231205monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-to-present-at-the-evercore-isi-healthconx-2023-health-care-conference-w-wat-20231116monthly0.5https://www.biopharmawatch.com/news/WAT/waters-2023-esg-report-highlights-continued-progress-towards-sustainability-commitments-ne-wat-20231116monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-nyse-wat-reports-third-quarter-2023-financial-results-highlights-sales--wat-20231107monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-announces-business-unit-leadership-transition-waters-corporation-nyse-w-wat-20231024monthly0.5https://www.biopharmawatch.com/news/WAT/waters-accelerates-oligonucleotide-bioanalysis-with-the-launch-of-oligoworks-spe-workflow--wat-20231019monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-schedules-third-quarter-2023-earnings-conference-call-waters-corporatio-wat-20231010monthly0.5https://www.biopharmawatch.com/news/WAT/l-instrument-zetastar-de-waters-augmente-la-vitesse-et-la-sensibilite-des-mesures-de-diffu-wat-20230920monthly0.5https://www.biopharmawatch.com/news/WAT/el-instrumento-waters-zetastar-aumenta-la-sensibilidad-de-las-mediciones-de-dispersio-n-de-wat-20230920monthly0.5https://www.biopharmawatch.com/news/WAT/messgera-t-zetastar-von-waters-steigert-geschwindigkeit-und-empfindlichkeit-von-lichtstreu-wat-20230920monthly0.5https://www.biopharmawatch.com/news/WAT/waters-zetastar-instrument-boosts-speed-and-sensitivity-of-light-scattering-measurements-f-wat-20230920monthly0.5https://www.biopharmawatch.com/news/WAT/waters-lanza-nuevas-soluciones-que-simplifican-au-n-ma-s-el-ana-lisis-de-productos-biolo-g-wat-20230912monthly0.5https://www.biopharmawatch.com/news/WAT/waters-pre-sente-de-nouvelles-solutions-accessibles-qui-simplifient-davantage-l-analyse-de-wat-20230912monthly0.5https://www.biopharmawatch.com/news/WAT/waters-bringt-neue-walk-up-lo-sungen-auf-den-markt-die-die-analyse-von-biologischen-arznei-wat-20230912monthly0.5https://www.biopharmawatch.com/news/WAT/waters-launches-new-walk-up-solutions-that-further-simplify-the-analysis-of-biologic-drug--wat-20230912monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-to-present-at-the-bank-of-america-global-healthcare-conference-2023-wat-wat-20230830monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-nyse-wat-reports-second-quarter-2023-financial-results-waters-corporati-wat-20230802monthly0.5https://www.biopharmawatch.com/news/WAT/waters-launches-xbridge-premier-gtx-beh-sec-columns-for-gene-therapy-applications-news-sum-wat-20230801monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-schedules-second-quarter-2023-earnings-conference-call-waters-corporati-wat-20230705monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-and-princeton-university-announce-multi-year-research-collaboration-wat-wat-20230626monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-named-to-u-s-news-world-report-s-2023-2024-best-companies-to-work-for-u-wat-20230612monthly0.5https://www.biopharmawatch.com/news/WAT/waters-et-sartorius-e-largissent-le-champ-de-leur-collaboration-afin-d-offrir-une-bioanaly-wat-20230605monthly0.5https://www.biopharmawatch.com/news/WAT/waters-boosts-resolution-and-triples-scan-speed-of-select-series-mrt-for-metabolomics-and--wat-20230605monthly0.5https://www.biopharmawatch.com/news/WAT/waters-takes-targeted-quantitative-imaging-to-the-next-level-with-new-desi-source-for-the--wat-20230605monthly0.5https://www.biopharmawatch.com/news/WAT/waters-und-sartorius-erweitern-ihre-zusammenarbeit-zur-bereitstellung-umfassender-bioanaly-wat-20230605monthly0.5https://www.biopharmawatch.com/news/WAT/waters-y-sartorius-ampli-an-su-colaboracio-n-waters-y-sartorius-ampli-an-su-colaboracio-n--wat-20230605monthly0.5https://www.biopharmawatch.com/news/WAT/waters-and-sartorius-expand-collaboration-to-deliver-comprehensive-bioanalytics-for-downst-wat-20230605monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-to-present-at-the-jefferies-2023-healthcare-conference-waters-corporati-wat-20230523monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-acquiert-le-leader-de-la-diffusion-de-la-lumie-re-wyatt-technology-wate-wat-20230517monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-completa-la-adquisicio-n-del-li-der-en-dispersio-n-de-luz-wyatt-technol-wat-20230517monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-completes-acquisition-of-light-scattering-leader-wyatt-technology-water-wat-20230516monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-nyse-wat-reports-first-quarter-2023-financial-results-highlights-first--wat-202305092023-05-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WAT/joint-open-laboratory-established-in-china-by-waters-the-chinese-pharmacopeia-commission-w-wat-20150128monthly0.5https://www.biopharmawatch.com/news/WAT/waters-progenesis-qi-marks-next-generation-of-lc-ms-omics-analysis-at-analytica-waters-cor-wat-20140402monthly0.5https://www.biopharmawatch.com/news/WAT/waters-acquity-qda-detector-takes-pittcon-editors-award-waters-corporation-nyse-wat-is-pro-wat-20140306monthly0.5https://www.biopharmawatch.com/news/WAT/waters-marks-ten-years-of-acquity-uplc-looks-to-future-with-acquity-qda-and-ionkey-ms-at-p-wat-20140303monthly0.5https://www.biopharmawatch.com/news/WAT/waters-expands-unifi-solutions-with-three-new-applications-glycans-forensic-toxicology-and-wat-20140129monthly0.5https://www.biopharmawatch.com/news/WAT/waters-introduces-uplc-system-for-nano-to-microscale-separations-the-acquity-uplc-m-class--wat-20140128monthly0.5https://www.biopharmawatch.com/news/WAT/the-waters-acquity-qda-detector-named-a-top-innovation-for-2013-waters-corporation-wat-nys-wat-20131218monthly0.5https://www.biopharmawatch.com/news/WAT/waters-teams-with-biochemical-society-on-proteomics-training-day-and-symposium-waters-corp-wat-20131127monthly0.5https://www.biopharmawatch.com/news/WAT/waters-honors-school-of-pharmacy-at-university-of-maryland-discovery-and-education-were-th-wat-20131112monthly0.5https://www.biopharmawatch.com/news/WAT/waters-introduces-the-acquity-qda-detector-bringing-push-button-mass-detection-to-chromato-wat-20131007monthly0.5https://www.biopharmawatch.com/news/WAT/r-d-100-award-goes-to-waters-acquity-upc2-system-waters-corporation-nyse-wat-today-announc-wat-20130729monthly0.5https://www.biopharmawatch.com/news/WAT/waters-introduces-cortecs-columns-featuring-solid-core-particle-technology-waters-corporat-wat-20130617monthly0.5https://www.biopharmawatch.com/news/WAT/waters-introduces-the-synapt-g2-si-to-its-mass-spectrometer-product-line-waters-corporatio-wat-20130610monthly0.5https://www.biopharmawatch.com/news/WAT/waters-honors-flavor-research-and-education-center-at-university-of-minnesota-at-a-ceremon-wat-20130607monthly0.5https://www.biopharmawatch.com/news/WAT/st-john-s-research-institute-honored-by-waters-center-of-innovation-program-at-a-ceremony--wat-20130409monthly0.5https://www.biopharmawatch.com/news/WAT/vicam-s-new-immunoassay-column-detects-seven-mycotoxins-in-single-run-waters-corporation-n-wat-20130402monthly0.5https://www.biopharmawatch.com/news/WAT/waters-and-dow-announce-major-breakthrough-in-advanced-polymer-analysis-at-pittcon-waters--wat-20130318monthly0.5https://www.biopharmawatch.com/news/WAT/waters-and-dani-instruments-announce-integrated-and-compatible-network-waters-corporation--wat-20130314monthly0.5https://www.biopharmawatch.com/news/WAT/waters-updates-alliance-hplc-designs-without-impacting-established-validated-methods-water-wat-20130225monthly0.5https://www.biopharmawatch.com/news/WAT/waters-unveils-industry-s-first-integrated-lc-ms-platform-for-proteins-peptides-and-glycan-wat-20130128monthly0.5https://www.biopharmawatch.com/news/WAT/fera-and-waters-open-international-food-safety-training-laboratory-a-major-new-internation-wat-20130122monthly0.5https://www.biopharmawatch.com/news/WAT/biological-mass-spectrometry-research-laboratory-at-indiana-university-receives-waters-cen-wat-20121213monthly0.5https://www.biopharmawatch.com/news/WAT/automated-online-sample-preparation-comes-to-waters-ultraperformance-liquid-chromatography-wat-20121120monthly0.5https://www.biopharmawatch.com/news/WAT/waters-selects-mtm-research-center-at-orebro-university-for-center-of-innovation-honors-at-wat-20121105monthly0.5https://www.biopharmawatch.com/news/WAT/waters-selects-metabolomics-laboratory-at-university-of-north-texas-for-center-of-innovati-wat-20120925monthly0.5https://www.biopharmawatch.com/news/WAT/waters-and-nonlinear-dynamics-to-co-develop-next-generation-research-solutions-for-large-s-wat-20120802monthly0.5https://www.biopharmawatch.com/news/WAT/vicam-s-new-don-niv-wb-immunoaffinity-column-significantly-enhances-laboratory-analysis-of-wat-20120702monthly0.5https://www.biopharmawatch.com/news/WAT/waters-breaks-ground-on-new-mass-spectrometry-hq-in-wilmslow-uk-waters-corporation-nyse-wa-wat-20120618monthly0.5https://www.biopharmawatch.com/news/WAT/waters-unveils-new-analytical-tools-for-research-and-routine-screening-applications-at-asm-wat-20120521monthly0.5https://www.biopharmawatch.com/news/WAT/waters-brings-awarding-winning-ultraperformance-convergence-chromatography-to-analytica-20-wat-20120417monthly0.5https://www.biopharmawatch.com/news/WAT/vicam-s-new-fumo-v-strip-tests-delivers-accurate-detection-of-fumonisin-mycotoxins-in-minu-wat-20120330monthly0.5https://www.biopharmawatch.com/news/WAT/waters-ireland-s-nibrt-partner-on-training-and-research-to-advance-burgeoning-biopharma-in-wat-20120327monthly0.5https://www.biopharmawatch.com/news/WAT/waters-acquity-ultraperformance-convergence-chromatography-takes-pittcon-editors-gold-awar-wat-20120315monthly0.5https://www.biopharmawatch.com/news/WAT/waters-ultraperformance-convergence-chromatography-ushers-in-new-category-of-separation-sc-wat-20120312monthly0.5https://www.biopharmawatch.com/news/WAT/thomson-mass-spectrometry-laboratory-at-brazil-s-university-of-campinas-selected-as-waters-wat-20120130monthly0.5https://www.biopharmawatch.com/news/WAT/waters-acquity-uplc-and-xevo-tq-s-capable-of-rapid-fungicide-detection-in-orange-juice-usi-wat-20120123monthly0.5https://www.biopharmawatch.com/news/WAT/waters-and-nibrt-complete-work-on-world-s-first-uplc-glycan-database-waters-corporation-wa-wat-20120120monthly0.5https://www.biopharmawatch.com/news/WAT/waters-and-tecan-sign-agreement-for-clinical-assay-platform-to-address-the-growing-need-fo-wat-20120117monthly0.5https://www.biopharmawatch.com/news/WAT/waters-gifts-research-equipment-to-university-at-buffalo-to-combat-hiv-aids-at-a-ceremony--wat-20111221monthly0.5https://www.biopharmawatch.com/news/WAT/future-fuels-institute-at-florida-state-university-recognized-as-a-waters-center-of-innova-wat-20111115monthly0.5https://www.biopharmawatch.com/news/WAT/waters-mars-and-usaid-pledge-1-million-to-create-global-food-safety-capacity-building-fund-wat-20111114monthly0.5https://www.biopharmawatch.com/news/WAT/waters-recognizes-the-dr-ganesh-anand-laboratory-at-the-national-university-of-singapore-a-wat-20111024monthly0.5https://www.biopharmawatch.com/news/WAT/waters-empowers-advantar-laboratories-for-sustained-growth-waters-corporation-nyse-wat-ann-wat-20111005monthly0.5https://www.biopharmawatch.com/news/WAT/waters-honors-university-of-minnesota-s-joseph-dalluge-ph-d-and-department-of-chemistry-ma-wat-20111003monthly0.5https://www.biopharmawatch.com/news/WAT/waters-introduces-new-truview-lcms-certified-vials-for-the-analytical-laboratory-waters-co-wat-20110929monthly0.5https://www.biopharmawatch.com/news/WAT/waters-fda-and-university-of-maryland-open-world-s-first-international-food-safety-trainin-wat-20110915monthly0.5https://www.biopharmawatch.com/news/WAT/waters-introduces-the-sq-detector-2-designed-for-the-routine-prepared-for-the-unexpected-w-wat-20110906monthly0.5https://www.biopharmawatch.com/news/WAT/center-for-proteomics-at-the-translational-genomics-research-institute-tgen-selected-as-wa-wat-20110826monthly0.5https://www.biopharmawatch.com/news/WAT/waters-ce-marks-in-vitro-diagnostic-masstrak-immunosuppressants-xe-kit-waters-corporation--wat-20110725monthly0.5https://www.biopharmawatch.com/news/WAT/waters-showcases-acquity-ultraperformance-lc-and-mass-spectrometry-uplc-ms-tools-for-incre-wat-20110725monthly0.5https://www.biopharmawatch.com/news/WAT/vicam-introduces-vertu-lateral-flow-reader-for-onsite-and-laboratory-mycotoxin-detection-t-wat-20110707monthly0.5https://www.biopharmawatch.com/news/WAT/waters-recognizes-albert-j-fornace-laboratory-at-georgetown-university-medical-center-as-a-wat-20110707monthly0.5https://www.biopharmawatch.com/news/WAT/waters-unveils-ipad-application-at-hplc-conference-to-aid-customer-selection-of-key-consum-wat-20110622monthly0.5https://www.biopharmawatch.com/news/WAT/brandon-ruotolo-of-the-university-of-michigan-receives-asms-research-award-at-a-ceremony-h-wat-20110608monthly0.5https://www.biopharmawatch.com/news/WAT/waters-introduces-synapt-g2-s-mass-spectrometer-combining-revolutionary-stepwave-ion-optic-wat-20110606monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-and-premier-biosoft-international-announce-collaboration-for-advancing--wat-20110606monthly0.5https://www.biopharmawatch.com/news/WAT/waters-introduces-the-new-xevo-tqd-mass-spectrometer-the-most-versatile-technology-platfor-wat-20110606monthly0.5https://www.biopharmawatch.com/news/WAT/arista-laboratories-purchases-waters-nugenesis-scientific-data-management-system-sdms-to-b-wat-20110513monthly0.5https://www.biopharmawatch.com/news/WAT/waters-welcomes-duke-university-proteomics-core-facility-into-centers-of-innovation-progra-wat-20110511monthly0.5https://www.biopharmawatch.com/news/WAT/waters-expands-impact-of-uplc-technology-with-new-sfc-process-development-lc-and-2d-lc-sys-wat-20110314monthly0.5https://www.biopharmawatch.com/news/WAT/frost-sullivan-waters-xevo-ms-systems-offer-unequalled-combination-of-separations-power-an-wat-20110314monthly0.5https://www.biopharmawatch.com/news/WAT/waters-extends-early-registration-deadline-for-6th-international-symposium-on-mass-spectro-wat-20110223monthly0.5https://www.biopharmawatch.com/news/WAT/waters-releases-nugenesis-sdms-7-1-validated-to-support-windows-7-and-empower-3-cds-waters-wat-20110127monthly0.5https://www.biopharmawatch.com/news/WAT/waters-to-build-new-mass-spectrometry-headquarters-near-manchester-u-k-waters-corporation--wat-20110120monthly0.5https://www.biopharmawatch.com/news/WAT/waters-combines-best-in-class-performance-versatility-and-usability-technologies-in-new-xe-wat-20110110monthly0.5https://www.biopharmawatch.com/news/WAT/waters-new-biopharmaceutical-system-solution-uniquely-unites-uplc-ms-analyses-and-workflow-wat-20110110monthly0.5https://www.biopharmawatch.com/news/WAT/waters-empower-3-answers-call-for-a-standardized-chromatography-data-system-at-enterprise--wat-20101130monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-welcomes-king-s-college-london-into-waters-centers-of-innovation-progra-wat-20101110monthly0.5https://www.biopharmawatch.com/news/WAT/supporting-scientific-invention-waters-corporation-launches-centers-of-innovation-program--wat-20101102monthly0.5https://www.biopharmawatch.com/news/WAT/waters-and-hitachi-high-technologies-america-enter-into-distribution-agreement-for-chromat-wat-20100916monthly0.5https://www.biopharmawatch.com/news/WAT/waters-introduces-ostro-sample-preparation-products-waters-corporation-nyse-wat-today-intr-wat-20100914monthly0.5https://www.biopharmawatch.com/news/WAT/waters-corporation-and-ucla-to-convene-leading-life-scientists-waters-corporation-nyse-wat-wat-20100903monthly0.5https://www.biopharmawatch.com/news/WAT/epa-laboratory-publishes-direct-injection-uplc-ms-ms-methods-for-chemical-dispersants-in-s-wat-20100902monthly0.5https://www.biopharmawatch.com/news/WST/eric-m-green-informs-board-of-plans-to-retire-as-president-ceo-and-chair-of-the-board-of-w-wst-20260309monthly0.5https://www.biopharmawatch.com/news/WST/west-signs-agreement-to-sell-the-manufacturing-and-supply-rights-for-smartdose-3-5ml-on-bo-wst-20260112monthly0.5https://www.biopharmawatch.com/news/WST/west-to-participate-in-upcoming-investor-conferences-west-pharmaceutical-services-inc-nyse-wst-20251024monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-second-quarter-2025-conference-call-west-pharmaceutical-services-inc-nyse-wst-wst-20250708monthly0.5https://www.biopharmawatch.com/news/WST/west-to-participate-in-upcoming-investor-conferences-west-pharmaceutical-services-inc-nyse-wst-20250507monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-leadership-changes-west-pharmaceutical-services-inc-nyse-wst-a-global-leade-wst-20250424monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-first-quarter-2025-conference-call-west-pharmaceutical-services-inc-nyse-wst--wst-20250410monthly0.5https://www.biopharmawatch.com/news/WST/west-to-participate-in-upcoming-investor-conferences-west-pharmaceutical-services-inc-nyse-wst-20250305monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-second-quarter-dividend-west-pharmaceutical-services-inc-nyse-wst-a-global--wst-20250220monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-fourth-quarter-and-full-year-2024-results-west-pharmaceutical-services-inc--wst-20250213monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-fourth-quarter-and-full-year-2024-conference-call-west-pharmaceutical-service-wst-20250130monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-first-quarter-dividend-west-pharmaceutical-services-inc-nyse-wst-a-global-l-wst-20250128monthly0.5https://www.biopharmawatch.com/news/WST/west-introduces-daikyo-plascap-ruv-closures-in-new-nested-format-at-pharmapack-west-pharma-wst-20250122monthly0.5https://www.biopharmawatch.com/news/WST/west-pharmaceutical-services-to-present-at-the-cjs-25th-annual-new-ideas-for-the-new-year--wst-20250106monthly0.5https://www.biopharmawatch.com/news/WST/west-elects-new-director-to-the-board-west-pharmaceutical-services-inc-nyse-wst-a-global-l-wst-20241211monthly0.5https://www.biopharmawatch.com/news/WST/west-to-participate-in-upcoming-investor-conferences-west-pharmaceutical-services-inc-nyse-wst-20241029monthly0.5https://www.biopharmawatch.com/news/WST/west-to-present-on-large-volume-delivery-systems-administration-and-transfer-devices-and-p-wst-20241022monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-third-quarter-2024-conference-call-west-pharmaceutical-services-inc-nyse-wst--wst-20241010monthly0.5https://www.biopharmawatch.com/news/WST/west-wins-heart-of-pharma-award-at-2024-cphi-pharma-awards-west-pharmaceutical-services-in-wst-20241009monthly0.5https://www.biopharmawatch.com/news/WST/west-to-attend-and-showcase-industry-leadership-in-packaging-and-containment-at-cphi-world-wst-20241007monthly0.5https://www.biopharmawatch.com/news/WST/west-to-participate-in-upcoming-investor-conference-west-pharmaceutical-services-inc-nyse--wst-20240905monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-second-quarter-2024-results-west-pharmaceutical-services-inc-nyse-wst-today-wst-20240725monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-second-quarter-2024-conference-call-west-pharmaceutical-services-inc-nyse-wst-wst-20240711monthly0.5https://www.biopharmawatch.com/news/WST/west-introduces-daikyo-crystal-zenith-cz-ready-to-use-nested-vials-in-tub-at-the-internati-wst-20240529monthly0.5https://www.biopharmawatch.com/news/WST/west-to-participate-in-upcoming-investor-conference-west-pharmaceutical-services-inc-nyse--wst-20240528monthly0.5https://www.biopharmawatch.com/news/WST/west-to-participate-in-upcoming-investor-conference-west-pharmaceutical-services-inc-nyse--wst-20240430monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-first-quarter-2024-conference-call-west-pharmaceutical-services-inc-nyse-wst--wst-20240411monthly0.5https://www.biopharmawatch.com/news/WST/west-to-participate-in-upcoming-investor-conferences-west-pharmaceutical-services-inc-nyse-wst-20240228monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-second-quarter-2024-dividend-west-pharmaceutical-services-inc-nyse-wst-a-gl-wst-20240220monthly0.5https://www.biopharmawatch.com/news/WST/west-named-to-newsweek-s-america-s-greatest-workplaces-2024-for-diversity-west-pharmaceuti-wst-20240207monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-fourth-quarter-and-full-year-2023-conference-call-west-pharmaceutical-service-wst-20240201monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-first-quarter-2024-dividend-west-pharmaceutical-services-inc-nyse-wst-a-glo-wst-20231206monthly0.5https://www.biopharmawatch.com/news/WST/west-receives-fda-510-k-clearance-for-vial2bag-advanced-13mm-admixture-device-west-pharmac-wst-20231204monthly0.5https://www.biopharmawatch.com/news/WST/west-to-participate-in-upcoming-investor-conferences-west-pharmaceutical-services-inc-nyse-wst-20231101monthly0.5https://www.biopharmawatch.com/news/WST/west-to-attend-and-showcase-industry-leadership-in-packaging-and-containment-at-cphi-world-wst-20231023monthly0.5https://www.biopharmawatch.com/news/WST/west-to-present-on-development-of-large-volume-delivery-systems-self-injection-devices-and-wst-20231016monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-third-quarter-2023-conference-call-west-pharmaceutical-services-inc-nyse-wst--wst-20231012monthly0.5https://www.biopharmawatch.com/news/WST/west-to-participate-in-upcoming-investor-conference-west-pharmaceutical-services-inc-nyse--wst-20230907monthly0.5https://www.biopharmawatch.com/news/WST/west-to-participate-in-upcoming-investor-conference-west-pharmaceutical-services-inc-nyse--wst-20230802monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-second-quarter-2023-results-west-pharmaceutical-services-inc-nyse-wst-today-wst-20230727monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-second-quarter-2023-conference-call-west-pharmaceutical-services-inc-nyse-wst-wst-20230713monthly0.5https://www.biopharmawatch.com/news/WST/west-to-participate-in-upcoming-investor-conferences-west-pharmaceutical-services-inc-nyse-wst-20230524monthly0.5https://www.biopharmawatch.com/news/WST/west-to-participate-in-upcoming-investor-conference-west-pharmaceutical-services-inc-nyse--wst-202305042023-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-s-ready-pack-containment-solution-with-corning-valor-rtu-vials-utilizing-stevanato-gr-wst-202305022023-05-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-announces-first-quarter-2023-results-and-declares-third-quarter-2023-dividend-west-ph-wst-202304272023-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-first-quarter-2023-conference-call-west-pharmaceutical-services-inc-nyse-wst--wst-202304132023-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-announces-second-quarter-2023-dividend-west-pharmaceutical-services-inc-nyse-wst-a-gl-wst-202303032023-03-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-announces-fourth-quarter-and-full-year-2022-results-west-pharmaceutical-services-inc--wst-202302162023-02-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-expands-corning-collaboration-and-launches-first-product-west-pharmaceutical-services-wst-202302082023-02-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-fourth-quarter-and-full-year-2022-conference-call-and-announces-participation-wst-202302022023-02-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-announces-three-new-product-innovations-at-pharmapack-europe-west-pharmaceutical-serv-wst-202301312023-01-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-to-participate-in-upcoming-investor-conference-west-pharmaceutical-services-inc-nyse--wst-202301052023-01-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/WST/west-announces-first-quarter-2023-dividend-and-participation-in-upcoming-investor-conferen-wst-20221213monthly0.5https://www.biopharmawatch.com/news/WST/west-to-participate-in-upcoming-investor-conferences-west-pharmaceutical-services-inc-nyse-wst-20221104monthly0.5https://www.biopharmawatch.com/news/WST/west-to-attend-and-showcase-industry-leadership-in-packaging-and-containment-at-cphi-world-wst-20221031monthly0.5https://www.biopharmawatch.com/news/WST/west-to-present-on-development-of-large-volume-delivery-systems-self-injection-devices-and-wst-20221018monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-third-quarter-2022-conference-call-west-pharmaceutical-services-inc-nyse-wst--wst-20221013monthly0.5https://www.biopharmawatch.com/news/WST/west-announced-as-company-of-the-year-finalist-for-global-generics-and-biosimilar-awards-2-wst-20221006monthly0.5https://www.biopharmawatch.com/news/WST/west-to-participate-in-upcoming-investor-conference-west-pharmaceutical-services-inc-nyse--wst-20220908monthly0.5https://www.biopharmawatch.com/news/WST/west-makes-minority-investment-in-dublin-based-latch-medical-a-developer-of-vaccine-and-bi-wst-20220811monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-second-quarter-2022-results-west-pharmaceutical-services-inc-nyse-wst-today-wst-20220728monthly0.5https://www.biopharmawatch.com/news/WST/west-elects-new-director-to-the-board-west-pharmaceutical-services-inc-nyse-wst-a-global-l-wst-20220727monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-second-quarter-2022-conference-call-west-pharmaceutical-services-inc-nyse-wst-wst-20220714monthly0.5https://www.biopharmawatch.com/news/WST/west-pharmaceutical-services-releases-2021-corporate-responsibility-report-west-pharmaceut-wst-20220712monthly0.5https://www.biopharmawatch.com/news/WST/west-introduces-daikyo-crystal-zenith-2-25ml-insert-needle-syringe-system-at-bio-internati-wst-20220613monthly0.5https://www.biopharmawatch.com/news/WST/west-receives-exhibitor-award-at-interphex-2022-for-proprietary-deltacube-modeling-platfor-wst-20220524monthly0.5https://www.biopharmawatch.com/news/WST/west-to-attend-and-showcase-industry-leadership-in-packaging-and-containment-at-interphex--wst-20220523monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-executive-leadership-appointments-west-pharmaceutical-services-inc-nyse-wst-wst-20220512monthly0.5https://www.biopharmawatch.com/news/WST/west-to-participate-in-upcoming-investor-conferences-west-pharmaceutical-services-inc-nyse-wst-20220503monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-first-quarter-2022-results-and-declares-third-quarter-2022-dividend-west-ph-wst-20220428monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-first-quarter-2022-conference-call-west-pharmaceutical-services-inc-nyse-wst--wst-20220414monthly0.5https://www.biopharmawatch.com/news/WST/west-receives-fred-simon-award-and-edward-smith-packaging-science-award-at-2022-pda-annual-wst-20220404monthly0.5https://www.biopharmawatch.com/news/WST/west-to-showcase-leadership-and-advancements-of-packaging-science-at-the-2022-pda-annual-m-wst-20220331monthly0.5https://www.biopharmawatch.com/news/WST/west-to-participate-in-upcoming-investor-conference-west-pharmaceutical-services-inc-nyse--wst-20220309monthly0.5https://www.biopharmawatch.com/news/WST/west-names-president-and-ceo-eric-m-green-as-chair-of-the-board-west-pharmaceutical-servic-wst-20220228monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-second-quarter-2022-dividend-west-pharmaceutical-services-inc-nyse-wst-a-gl-wst-20220223monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-fourth-quarter-and-full-year-2021-conference-call-west-pharmaceutical-service-wst-20220203monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-landmark-collaboration-with-corning-in-pharmaceutical-injectable-drug-deliv-wst-20220125monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-first-quarter-2022-dividend-and-2022-share-repurchase-program-west-pharmace-wst-20220105monthly0.5https://www.biopharmawatch.com/news/WST/west-to-participate-in-upcoming-investor-conference-west-pharmaceutical-services-inc-nyse--wst-20211227monthly0.5https://www.biopharmawatch.com/news/WST/west-to-participate-in-upcoming-investor-conferences-west-pharmaceutical-services-inc-nyse-wst-20211111monthly0.5https://www.biopharmawatch.com/news/WST/west-s-novaguard-sa-pro-safety-system-recognized-for-best-technologies-innovation-at-inter-wst-20211025monthly0.5https://www.biopharmawatch.com/news/WST/west-introduces-deltacube-modeling-platform-and-novaguard-sa-pro-safety-system-for-0-5-ml--wst-20211019monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-third-quarter-2021-conference-call-west-pharmaceutical-services-inc-nyse-wst--wst-20211014monthly0.5https://www.biopharmawatch.com/news/WST/west-elects-new-director-to-the-board-west-pharmaceutical-services-inc-nyse-wst-a-global-l-wst-20210823monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-second-quarter-2021-results-west-pharmaceutical-services-inc-nyse-wst-today-wst-20210729monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-second-quarter-2021-conference-call-west-pharmaceutical-services-inc-nyse-wst-wst-20210715monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-participation-in-upcoming-investor-conference-west-pharmaceutical-services--wst-20210525monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-third-quarter-dividend-and-participation-in-upcoming-investor-conference-we-wst-20210505monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-first-quarter-2021-results-west-pharmaceutical-services-inc-nyse-wst-today--wst-20210429monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-first-quarter-2021-conference-call-west-pharmaceutical-services-inc-nyse-wst--wst-20210415monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-participation-in-upcoming-investor-conference-west-pharmaceutical-services--wst-20210317monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-second-quarter-2021-dividend-west-pharmaceutical-services-inc-nyse-wst-a-gl-wst-20210224monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-fourth-quarter-and-full-year-2020-results-west-pharmaceutical-services-inc--wst-20210218monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-fourth-quarter-and-full-year-2020-conference-call-west-pharmaceutical-service-wst-20210204monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-increase-to-fourth-quarter-2020-dividend-west-pharmaceutical-services-inc-n-wst-20201028monthly0.5https://www.biopharmawatch.com/news/WST/west-launches-new-vial2bag-advanced-20mm-admixture-device-west-pharmaceutical-services-inc-wst-20201022monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-third-quarter-2020-results-west-pharmaceutical-services-inc-nyse-wst-today--wst-20201022monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-third-quarter-2020-conference-call-west-pharmaceutical-services-inc-nyse-wst--wst-20201008monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-second-quarter-2020-results-west-pharmaceutical-services-inc-nyse-wst-today-wst-20200723monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-third-quarter-2020-dividend-west-pharmaceutical-services-inc-nyse-wst-a-glo-wst-20200715monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-second-quarter-2020-conference-call-west-pharmaceutical-services-inc-nyse-wst-wst-20200709monthly0.5https://www.biopharmawatch.com/news/WST/west-pharmaceutical-services-inc-to-join-s-p-500-index-west-pharmaceutical-services-inc-ny-wst-20200521monthly0.5https://www.biopharmawatch.com/news/WST/west-to-participate-in-upcoming-investor-conferences-west-pharmaceutical-services-inc-nyse-wst-20200507monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-first-quarter-2020-results-west-pharmaceutical-services-inc-nyse-wst-today--wst-20200423monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-virtual-shareholders-meeting-west-pharmaceutical-services-inc-nyse-wst-a-glob-wst-20200420monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-first-quarter-2020-conference-call-west-pharmaceutical-services-inc-nyse-wst--wst-20200409monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-second-quarter-dividend-west-pharmaceutical-services-inc-nyse-wst-a-global--wst-20200225monthly0.5https://www.biopharmawatch.com/news/WST/west-elects-new-director-to-the-board-west-pharmaceutical-services-inc-nyse-wst-a-global-l-wst-20200217monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-fourth-quarter-and-full-year-2019-results-west-pharmaceutical-services-inc--wst-20200213monthly0.5https://www.biopharmawatch.com/news/WST/west-launches-new-product-innovations-at-pharmapack-2020-booth-b58-west-pharmaceutical-ser-wst-20200205monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-fourth-quarter-and-full-year-2019-conference-call-west-pharmaceutical-service-wst-20200130monthly0.5https://www.biopharmawatch.com/news/WST/west-recognized-as-a-top-company-for-corporate-responsibility-west-pharmaceutical-services-wst-20200128monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-first-quarter-dividend-share-repurchase-program-and-participation-in-upcomi-wst-20191213monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-participation-in-upcoming-investor-conference-west-pharmaceutical-services--wst-20191119monthly0.5https://www.biopharmawatch.com/news/WST/west-and-schott-announce-partnership-to-combine-the-schott-iq-platform-with-west-s-ready-p-wst-20191106monthly0.5https://www.biopharmawatch.com/news/WST/west-launches-two-new-elastomer-product-innovations-at-cphi-worldwide-booth-111f62-west-ph-wst-20191105monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-third-quarter-2019-results-west-pharmaceutical-services-inc-nyse-wst-today--wst-20191024monthly0.5https://www.biopharmawatch.com/news/WST/west-introduces-novapure-3ml-cartridge-components-and-features-smartdose-gen-ii-10ml-drug--wst-20191022monthly0.5https://www.biopharmawatch.com/news/WST/west-increases-equity-stake-in-daikyo-seiko-ltd-extending-the-companies-longstanding-partn-wst-20191016monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-third-quarter-2019-conference-call-west-pharmaceutical-services-inc-nyse-wst--wst-20191010monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-participation-in-upcoming-september-investor-conferences-west-pharmaceutica-wst-20190823monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-second-quarter-2019-results-and-announces-an-increase-to-fourth-quarter-201-wst-20190725monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-second-quarter-2019-conference-call-west-pharmaceutical-services-inc-nyse-wst-wst-20190711monthly0.5https://www.biopharmawatch.com/news/WST/west-novaguard-sa-pro-safety-system-recognized-for-excellence-in-design-and-user-experienc-wst-20190522monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-third-quarter-dividend-and-participation-in-upcoming-investor-conferences-w-wst-20190508monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-first-quarter-2019-results-west-pharmaceutical-services-inc-nyse-wst-today--wst-20190425monthly0.5https://www.biopharmawatch.com/news/WST/west-named-as-a-philadelphia-business-journal-2019-faces-of-philanthropy-honoree-west-phar-wst-20190412monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-first-quarter-2019-conference-call-west-pharmaceutical-services-inc-nyse-wst--wst-20190411monthly0.5https://www.biopharmawatch.com/news/WST/west-expands-presence-in-korea-with-new-sales-office-west-pharmaceutical-services-inc-nyse-wst-20190403monthly0.5https://www.biopharmawatch.com/news/WST/west-opens-new-digital-technology-center-in-bengaluru-india-west-pharmaceutical-services-i-wst-20190308monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-quarterly-dividend-and-share-repurchase-program-west-pharmaceutical-service-wst-20190221monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-fourth-quarter-and-full-year-2018-results-west-pharmaceutical-services-inc--wst-20190214monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-fourth-quarter-and-full-year-2018-conference-call-west-pharmaceutical-service-wst-20190131monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-quarterly-dividend-and-participation-in-upcoming-investor-conference-west-p-wst-20181218monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-participation-in-upcoming-november-investor-conferences-west-pharmaceutical-wst-20181101monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-third-quarter-2018-results-west-pharmaceutical-services-inc-nyse-wst-today--wst-20181025monthly0.5https://www.biopharmawatch.com/news/WST/west-receives-excellence-in-pharma-corporate-social-responsibility-award-at-cphi-worldwide-wst-20181011monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-third-quarter-2018-conference-call-west-pharmaceutical-services-inc-nyse-wst--wst-20181011monthly0.5https://www.biopharmawatch.com/news/WST/west-highlights-integrated-solutions-offering-and-related-technical-and-regulatory-experti-wst-20181008monthly0.5https://www.biopharmawatch.com/news/WST/west-s-president-and-ceo-eric-m-green-presented-with-ceo-connection-2018-social-impact-awa-wst-20180926monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-participation-in-upcoming-september-investor-conferences-west-pharmaceutica-wst-20180823monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-second-quarter-2018-results-west-pharmaceutical-services-inc-nyse-wst-today-wst-20180726monthly0.5https://www.biopharmawatch.com/news/WST/west-celebrates-official-opening-of-new-global-manufacturing-facility-in-waterford-ireland-wst-20180719monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-second-quarter-2018-conference-call-west-pharmaceutical-services-inc-nyse-wst-wst-20180712monthly0.5https://www.biopharmawatch.com/news/WST/west-appoints-bernard-birkett-to-chief-financial-officer-west-pharmaceutical-services-inc--wst-20180621monthly0.5https://www.biopharmawatch.com/news/WST/west-s-selfdose-patient-controlled-injector-wins-silver-medical-design-excellence-award-bo-wst-20180613monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-participation-in-upcoming-june-investor-conferences-west-pharmaceutical-ser-wst-20180524monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-first-quarter-2018-results-west-pharmaceutical-services-inc-nyse-wst-today--wst-20180426monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-first-quarter-2018-conference-call-west-pharmaceutical-services-inc-nyse-wst--wst-20180412monthly0.5https://www.biopharmawatch.com/news/WST/west-to-showcase-daikyo-plascap-ruv-one-step-press-fit-vial-closure-solution-at-pda-annual-wst-20180319monthly0.5https://www.biopharmawatch.com/news/WST/west-chief-financial-officer-william-federici-announces-plans-to-retire-west-pharmaceutica-wst-20180302monthly0.5https://www.biopharmawatch.com/news/WST/west-appoints-silji-abraham-chief-digital-and-transformation-officer-west-pharmaceutical-s-wst-20180226monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-fourth-quarter-and-full-year-2017-results-and-announces-quarterly-dividend--wst-20180215monthly0.5https://www.biopharmawatch.com/news/WST/selfdose-patient-controlled-injector-named-as-recipient-of-pharmapack-exhibitor-innovation-wst-20180207monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-fourth-quarter-and-full-year-2017-conference-call-west-pharmaceutical-service-wst-20180201monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-quarterly-dividend-and-participation-in-upcoming-investor-conferences-west--wst-20171222monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-upcoming-investor-conference-west-pharmaceutical-services-inc-nyse-wst-a-gl-wst-20171115monthly0.5https://www.biopharmawatch.com/news/WST/west-to-showcase-new-extensions-of-the-smartdose-drug-delivery-platform-at-the-pda-univers-wst-20171106monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-third-quarter-2017-results-west-pharmaceutical-services-inc-nyse-wst-today--wst-20171026monthly0.5https://www.biopharmawatch.com/news/WST/study-demonstrates-benefit-of-west-s-id-adapter-for-improving-intradermal-administration-o-wst-20171010monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-fall-investor-conference-schedule-west-pharmaceutical-services-inc-nyse-wst-wst-20170825monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-second-quarter-2017-results-west-pharmaceutical-services-inc-nyse-wst-today-wst-20170727monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-increase-to-quarterly-dividend-west-pharmaceutical-services-inc-nyse-wst-a--wst-20170720monthly0.5https://www.biopharmawatch.com/news/WST/west-elects-new-director-to-the-board-west-pharmaceutical-services-inc-nyse-wst-today-anno-wst-20170601monthly0.5https://www.biopharmawatch.com/news/WST/west-to-present-on-biologics-trends-at-innopack-pharma-confex-booth-b-3-west-pharmaceutica-wst-20170530monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-quarterly-dividend-and-participation-in-upcoming-investor-conferences-west--wst-20170515monthly0.5https://www.biopharmawatch.com/news/WST/west-highlights-company-scientific-and-regulatory-expertise-at-notable-industry-meetings-w-wst-20170503monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-first-quarter-2017-results-west-pharmaceutical-services-inc-nyse-wst-today--wst-20170427monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-first-quarter-2017-conference-call-west-pharmaceutical-services-inc-nyse-wst--wst-20170413monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-fourth-quarter-and-full-year-2016-results-and-announces-quarterly-dividend--wst-20170216monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-fourth-quarter-and-full-year-2016-conference-call-west-pharmaceutical-service-wst-20170202monthly0.5https://www.biopharmawatch.com/news/WST/west-introduces-lyoseal-instant-sealing-solution-and-novaguard-sa-pro-safety-system-at-pha-wst-20170201monthly0.5https://www.biopharmawatch.com/news/WST/west-to-present-at-j-p-morgan-healthcare-conference-west-pharmaceutical-services-inc-nyse--wst-20161228monthly0.5https://www.biopharmawatch.com/news/WST/west-pharmaceutical-services-karen-flynn-receives-silver-stevie-award-in-2016-stevie-award-wst-20161220monthly0.5https://www.biopharmawatch.com/news/WST/west-receives-global-industry-recognitions-for-innovative-contributions-to-pharmaceutical--wst-20161215monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-quarterly-dividend-and-share-repurchase-program-west-pharmaceutical-service-wst-20161214monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-expanded-contract-manufacturing-capabilities-in-ireland-west-pharmaceutical-wst-20161129monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-third-quarter-2016-results-west-pharmaceutical-services-inc-nyse-wst-today--wst-20161027monthly0.5https://www.biopharmawatch.com/news/WST/west-to-showcase-expertise-in-injectable-drug-containment-and-delivery-at-pda-universe-of--wst-20161017monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-third-quarter-2016-conference-call-west-pharmaceutical-services-inc-nyse-wst--wst-20161013monthly0.5https://www.biopharmawatch.com/news/WST/west-appoints-david-a-montecalvo-senior-vice-president-global-operations-and-supply-chain--wst-20160926monthly0.5https://www.biopharmawatch.com/news/WST/west-elects-new-director-and-announces-increase-to-quarterly-dividend-west-pharmaceutical--wst-20160912monthly0.5https://www.biopharmawatch.com/news/WST/west-to-present-at-three-healthcare-conferences-in-september-west-pharmaceutical-services--wst-20160902monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-second-quarter-2016-results-west-pharmaceutical-services-inc-nyse-wst-today-wst-20160728monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-second-quarter-2016-conference-call-west-pharmaceutical-services-inc-nyse-wst-wst-20160714monthly0.5https://www.biopharmawatch.com/news/WST/west-s-smartdose-drug-delivery-technology-platform-selected-by-amgen-for-pushtronex-system-wst-20160711monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-quarterly-dividend-west-pharmaceutical-services-inc-nyse-wst-today-announce-wst-20160705monthly0.5https://www.biopharmawatch.com/news/WST/west-introduces-1-3ml-novapure-plunger-for-higher-volume-injections-west-pharmaceutical-se-wst-20160607monthly0.5https://www.biopharmawatch.com/news/WST/west-to-present-at-investor-conference-in-june-west-pharmaceutical-services-inc-nyse-wst-t-wst-20160601monthly0.5https://www.biopharmawatch.com/news/WST/west-to-present-at-two-investor-conferences-in-may-west-pharmaceutical-services-inc-nyse-w-wst-20160504monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-first-quarter-2016-results-west-pharmaceutical-services-inc-nyse-wst-today--wst-20160428monthly0.5https://www.biopharmawatch.com/news/WST/west-makes-investment-in-nanopass-technologies-west-pharmaceutical-services-inc-nyse-wst-a-wst-20160425monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-first-quarter-2016-conference-call-west-pharmaceutical-services-inc-nyse-wst--wst-20160414monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-quarterly-dividend-west-pharmaceutical-services-inc-nyse-wst-today-announce-wst-20160304monthly0.5https://www.biopharmawatch.com/news/WST/west-appoints-eric-resnick-to-chief-technology-officer-west-pharmaceutical-services-inc-ny-wst-20160301monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-analyst-and-investor-day-west-pharmaceutical-services-inc-nyse-wst-a-global-l-wst-20160225monthly0.5https://www.biopharmawatch.com/news/WST/west-s-daikyo-crystal-zenith-cyclic-olefin-polymer-selected-by-amgen-west-pharmaceutical-s-wst-20160212monthly0.5https://www.biopharmawatch.com/news/WST/west-and-noble-collaborate-to-improve-patient-education-and-training-for-self-injection-sy-wst-20160120monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-new-organizational-structure-west-pharmaceutical-services-inc-nyse-wst-a-gl-wst-20160112monthly0.5https://www.biopharmawatch.com/news/WST/west-appoints-george-l-miller-senior-vice-president-general-counsel-and-corporate-secretar-wst-20151119monthly0.5https://www.biopharmawatch.com/news/WST/west-to-showcase-self-injection-systems-and-prefillable-syringe-component-expertise-at-the-wst-20151102monthly0.5https://www.biopharmawatch.com/news/WST/west-launches-new-ready-to-use-validated-components-at-cphi-innopack-2015-booth-4g30-west--wst-20151013monthly0.5https://www.biopharmawatch.com/news/WST/west-appoints-annette-favorite-senior-vice-president-and-chief-human-resources-officer-wes-wst-20150930monthly0.5https://www.biopharmawatch.com/news/WST/west-pharmaceutical-services-inc-and-healthprize-technologies-announce-self-reporting-and--wst-20150917monthly0.5https://www.biopharmawatch.com/news/WST/west-expands-manufacturing-capacity-at-scottsdale-facility-to-support-customer-demand-for--wst-20150720monthly0.5https://www.biopharmawatch.com/news/WST/west-celebrates-groundbreaking-of-waterford-ireland-manufacturing-facility-west-pharmaceut-wst-20150616monthly0.5https://www.biopharmawatch.com/news/WST/west-bolsters-r-d-strategy-with-global-site-expansions-upgrades-west-pharmaceutical-servic-wst-20150512monthly0.5https://www.biopharmawatch.com/news/WST/west-launches-high-quality-flip-off-plusru-seals-west-pharmaceutical-services-inc-nyse-wst-wst-20150211monthly0.5https://www.biopharmawatch.com/news/WST/west-receives-510-k-clearance-for-novaguard-sa-safety-system-west-pharmaceutical-services--wst-20141111monthly0.5https://www.biopharmawatch.com/news/WST/west-s-vial2bag-dc-device-receives-u-s-fda-510-k-clearance-and-ce-mark-west-pharmaceutical-wst-20141021monthly0.5https://www.biopharmawatch.com/news/WST/west-pharmaceutical-services-announces-ceo-retirement-and-succession-plan-west-pharmaceuti-wst-20141015monthly0.5https://www.biopharmawatch.com/news/WST/west-names-new-president-of-pharmaceutical-packaging-systems-west-pharmaceutical-services--wst-20141007monthly0.5https://www.biopharmawatch.com/news/WST/west-pharmaceutical-services-and-healthprize-technologies-join-forces-on-connected-health--wst-20141006monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-plans-for-a-new-pharmaceutical-component-manufacturing-plant-in-ireland-wes-wst-20141002monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-second-quarter-2014-conference-call-west-pharmaceutical-services-inc-nyse-wst-wst-20140724monthly0.5https://www.biopharmawatch.com/news/WST/west-dedicates-pharmaceutical-manufacturing-plant-in-india-west-pharmaceutical-services-in-wst-20140716monthly0.5https://www.biopharmawatch.com/news/WST/west-completes-preliminary-study-evaluating-the-smartdose-electronic-patch-injector-techno-wst-20131107monthly0.5https://www.biopharmawatch.com/news/WST/west-to-co-present-research-findings-on-understanding-the-patient-journey-through-the-phas-wst-20131101monthly0.5https://www.biopharmawatch.com/news/WST/west-expands-novaguard-platform-of-products-for-safe-and-effective-injectable-drug-deliver-wst-20130702monthly0.5https://www.biopharmawatch.com/news/WST/west-to-celebrate-90-years-of-healthcare-innovation-at-the-nyse-today-representatives-from-wst-20130620monthly0.5https://www.biopharmawatch.com/news/WST/west-celebrates-90-years-of-healthcare-innovation-today-west-pharmaceutical-services-inc-n-wst-20130415monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-the-commercial-introduction-of-a-novel-intradermal-adapter-for-disposable-s-wst-20130227monthly0.5https://www.biopharmawatch.com/news/WST/west-pharmaceutical-services-to-share-insights-and-showcase-solutions-for-drug-delivery-sa-wst-20121011monthly0.5https://www.biopharmawatch.com/news/WST/west-increases-quarterly-dividend-to-0-18-west-pharmaceutical-services-inc-nyse-wst-today--wst-20111007monthly0.5https://www.biopharmawatch.com/news/WST/west-to-present-at-upcoming-investor-conferences-west-pharmaceutical-services-inc-nyse-wst-wst-20110907monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-second-quarter-2011-results-west-pharmaceutical-services-inc-nyse-wst-today-wst-20110728monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-2011-second-quarter-conference-call-west-pharmaceutical-services-inc-nyse-wst-wst-20110721monthly0.5https://www.biopharmawatch.com/news/WST/west-to-present-at-jefferies-conference-west-pharmaceutical-services-inc-nyse-wst-today-an-wst-20110531monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-third-quarter-2011-dividend-west-pharmaceutical-services-inc-nyse-wst-today-wst-20110506monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-first-quarter-2011-results-west-pharmaceutical-services-inc-nyse-wst-today--wst-20110428monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-2011-first-quarter-conference-call-west-pharmaceutical-services-inc-nyse-wst--wst-20110421monthly0.5https://www.biopharmawatch.com/news/WST/west-to-present-at-barclays-capital-conference-west-pharmaceutical-services-inc-nyse-wst-t-wst-20110309monthly0.5https://www.biopharmawatch.com/news/WST/west-appoints-two-directors-and-announces-second-quarter-2011-dividend-west-pharmaceutical-wst-20110224monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-fourth-quarter-2010-results-west-pharmaceutical-services-inc-nyse-wst-today-wst-20110217monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-2010-fourth-quarter-conference-call-west-pharmaceutical-services-inc-nyse-wst-wst-20110210monthly0.5https://www.biopharmawatch.com/news/WST/west-to-present-at-ubs-investor-conference-west-pharmaceutical-services-inc-nyse-wst-today-wst-20110201monthly0.5https://www.biopharmawatch.com/news/WST/west-names-new-president-of-pharmaceutical-packaging-systems-west-pharmaceutical-services--wst-20110105monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-first-quarter-2011-dividend-west-pharmaceutical-services-inc-nyse-wst-today-wst-20101216monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-plan-to-consolidate-certain-operations-west-pharmaceutical-services-inc-nys-wst-20101207monthly0.5https://www.biopharmawatch.com/news/WST/west-announces-third-quarter-2010-results-west-pharmaceutical-services-inc-nyse-wst-today--wst-20101102monthly0.5https://www.biopharmawatch.com/news/WST/west-to-host-2010-third-quarter-conference-call-west-pharmaceutical-services-inc-nyse-wst--wst-20101026monthly0.5https://www.biopharmawatch.com/news/WST/west-increases-quarterly-dividend-to-0-17-west-pharmaceutical-services-inc-nyse-wst-today--wst-20101004monthly0.5https://www.biopharmawatch.com/news/WST/west-to-participate-at-upcoming-investor-conferences-west-pharmaceutical-services-inc-nyse-wst-20100909monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20260604monthly0.5https://www.biopharmawatch.com/news/INSM/chmp-recommends-eu-approval-of-brinsupri-brensocatib-for-the-treatment-of-non-cystic-fibro-insm-20251017monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-multiple-abstracts-at-the-european-respiratory-society-congress-2025-ins-insm-20250922monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20250905monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-september-investor-conferences-insmed-incorporated-nasdaq-insm-a-peop-insm-20250821monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-second-quarter-2025-financial-results-conference-call-on-thursday-august-7--insm-20250724monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-pricing-of-750-million-public-offering-of-common-stock-insmed-incorporate-insm-20250611monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20250604monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-2025-goldman-sachs-annual-global-healthcare-conference-insmed-inc-insm-20250528monthly0.5https://www.biopharmawatch.com/news/INSM/brensocatib-shows-consistent-efficacy-and-safety-across-three-prespecified-subgroups-in-ne-insm-20250521monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-bofa-securities-2025-health-care-conference-insmed-incorporated-n-insm-20250429monthly0.5https://www.biopharmawatch.com/news/INSM/new-england-journal-of-medicine-publishes-positive-results-from-insmed-s-pivotal-phase-3-a-insm-20250423monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-first-quarter-2025-financial-results-conference-call-on-thursday-may-8-2025-insm-20250423monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-11-abstracts-from-across-its-respiratory-portfolio-at-the-american-thora-insm-20250325monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20250310monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-march-2025-investor-conferences-insmed-incorporated-nasdaq-insm-a-peo-insm-20250211monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-fourth-quarter-and-full-year-2024-financial-results-conference-call-on-thur-insm-20250210monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20250207monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20250103monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-insmed-incorporated--insm-20250102monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20241206monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-december-2024-investor-conferences-insmed-incorporated-nasdaq-insm-a--insm-20241202monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20241107monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-november-2024-investor-conferences-insmed-incorporated-nasdaq-insm-a--insm-20241106monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-ranks-no-1-on-science-s-2024-top-biopharma-employers-list-insmed-incorporated-nasda-insm-20241024monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-unites-across-communities-around-the-world-during-third-annual-global-day-of-good-i-insm-20241023monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-third-quarter-2024-financial-results-conference-call-on-thursday-october-31-insm-20241017monthly0.5https://www.biopharmawatch.com/news/INSM/new-subgroup-analyses-from-landmark-phase-3-aspen-study-of-brensocatib-in-patients-with-br-insm-20241008monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20241004monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20240906monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20240802monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-second-quarter-2024-financial-results-conference-call-on-thursday-august-8--insm-20240729monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20240705monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20240607monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-goldman-sachs-45th-annual-global-healthcare-conference-insmed-inc-insm-20240605monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-commercial-webinar-on-june-4-2024-insmed-incorporated-nasdaq-insm-a-global--insm-20240530monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-pricing-of-650-million-public-offering-of-common-stock-insmed-incorporate-insm-20240530monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-investor-call-to-discuss-topline-results-from-phase-3-aspen-study-of-brenso-insm-20240527monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-presents-positive-patient-reported-outcomes-and-microbiologic-data-from-phase-3-ari-insm-20240520monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-bofa-securities-health-care-conference-2024-insmed-incorporated-n-insm-20240507monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20240503monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-first-quarter-2024-financial-results-conference-call-on-thursday-may-9-2024-insm-20240425monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20240405monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-new-data-from-across-its-respiratory-portfolio-at-the-american-thoracic--insm-20240327monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20240305monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-three-march-conferences-insmed-incorporated-nasdaq-insm-a-global-biop-insm-20240229monthly0.5https://www.biopharmawatch.com/news/INSM/actress-jane-seymour-and-insmed-raise-awareness-of-unseenism-and-empower-people-to-speak-u-insm-20240228monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-fourth-quarter-and-full-year-2023-financial-results-conference-call-on-thur-insm-20240208monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20240202monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20240104monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-insmed-incorporated--insm-20240102monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20231205monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-nasdaq-49th-investor-conference-insmed-incorporated-nasdaq-insm-a-insm-20231129monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-two-november-conferences-insmed-incorporated-nasdaq-insm-a-global-bio-insm-20231108monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20231103monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-holds-second-annual-global-day-of-good-to-benefit-communities-across-the-globe-insm-insm-20231102monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-ranks-no-1-on-science-s-2023-top-biopharma-employers-list-insmed-incorporated-nasda-insm-20231026monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-and-google-cloud-collaborate-to-transform-the-lives-of-patients-by-harnessing-the-p-insm-20231024monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-third-quarter-2023-financial-results-conference-call-on-thursday-october-26-insm-20231012monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20231006monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-chardan-s-7th-annual-genetic-medicines-conference-insmed-incorporated-insm-20230926monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20230908monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-morgan-stanley-21st-annual-global-healthcare-conference-insmed-in-insm-20230906monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20230804monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-second-quarter-2023-financial-results-conference-call-on-thursday-august-3--insm-20230720monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20230707monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-goldman-sachs-44th-annual-global-healthcare-conference-insmed-inc-insm-20230607monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20230606monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-presents-range-of-new-study-findings-at-american-thoracic-society-2023-internationa-insm-20230522monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-202305052023-05-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-investor-and-analyst-event-on-may-8-2023-insmed-incorporated-nasdaq-insm-a--insm-202304242023-04-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-first-quarter-2023-financial-results-conference-call-on-thursday-may-4-2023-insm-202304202023-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-202304062023-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-completes-enrollment-of-adult-patients-in-phase-3-aspen-study-of-brensocatib-in-bro-insm-202303312023-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-new-clinical-pre-clinical-and-real-world-data-in-serious-and-rare-lung-d-insm-202303242023-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-202303032023-03-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-two-march-conferences-insmed-incorporated-nasdaq-insm-a-global-biopha-insm-202303012023-03-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-fourth-quarter-and-full-year-2022-financial-results-conference-call-on-thur-insm-202302092023-02-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-svb-securities-global-biopharma-conference-insmed-incorporated-na-insm-202302072023-02-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-202302032023-02-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-202301202023-01-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-provides-business-updates-and-near-term-strategic-outlook-at-41st-annual-j-p-morgan-insm-202301062023-01-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-insmed-incorporated--insm-202301032023-01-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20221206monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-nasdaq-47th-investor-conference-insmed-incorporated-nasdaq-insm-a-insm-20221130monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20221104monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-three-november-conferences-insmed-incorporated-nasdaq-insm-a-global-b-insm-20221101monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-ranks-no-1-on-science-s-2022-top-biopharma-employers-list-insmed-incorporated-nasda-insm-20221027monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-third-quarter-2022-financial-results-conference-call-on-thursday-october-27-insm-20221013monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20221007monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-holds-inaugural-global-day-of-good-a-company-wide-day-of-service-insmed-incorporate-insm-20221006monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20220907monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-two-september-conferences-insmed-incorporated-nasdaq-insm-a-global-bi-insm-20220906monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20220805monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-second-quarter-2022-financial-results-conference-call-on-thursday-august-4--insm-20220721monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20220708monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20220603monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-presents-new-data-across-three-pillars-at-american-thoracic-society-2022-internatio-insm-20220517monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-h-c-wainwright-annual-global-life-sciences-conference-insmed-inco-insm-20220517monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20220506monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-first-quarter-2022-financial-results-conference-call-on-thursday-may-5-2022-insm-20220421monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20220407monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-showcase-new-data-across-three-pillars-at-the-american-thoracic-society-2022-int-insm-20220328monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20220304monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-cowen-42nd-annual-health-care-conference-insmed-incorporated-nasd-insm-20220303monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-svb-leerink-virtual-11th-annual-global-healthcare-conference-insm-insm-20220210monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20220204monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-fourth-quarter-and-full-year-2021-financial-results-conference-call-and-pro-insm-20220127monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-insmed-incorporated--insm-20220104monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20211206monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20211105monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-participate-in-three-november-conferences-insmed-incorporated-inc-nasdaq-insm-a--insm-20211103monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-ranks-no-1-on-science-s-2021-top-biopharma-employers-list-insmed-incorporated-nasda-insm-20211028monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-third-quarter-2021-financial-results-conference-call-on-thursday-october-28-insm-20211014monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20211005monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20210903monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-participate-in-five-september-conferences-insmed-incorporated-inc-nasdaq-insm-a--insm-20210901monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20210806monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-second-quarter-2021-financial-results-conference-call-on-thursday-august-5--insm-20210727monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20210708monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20210604monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-two-june-conferences-insmed-incorporated-inc-nasdaq-insm-a-global-bio-insm-20210525monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-presents-broad-range-of-data-across-its-three-programs-at-the-american-thoracic-soc-insm-20210519monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-pricing-of-concurrent-public-offerings-of-common-stock-and-convertible-se-insm-20210511monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20210507monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-first-quarter-2021-financial-results-conference-call-on-thursday-may-6-2021-insm-20210422monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20210407monthly0.5https://www.biopharmawatch.com/news/INSM/arikayce-amikacin-liposome-inhalation-suspension-approved-by-japan-s-ministry-of-health-la-insm-20210323monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20210305monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-two-march-conferences-insmed-incorporated-nasdaq-insm-a-global-biopha-insm-20210224monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-conference-call-to-discuss-topline-data-from-treprostinil-palmitil-inhalati-insm-20210216monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-fourth-quarter-and-full-year-2020-financial-results-conference-call-on-thur-insm-20210212monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20210205monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-insmed-incorporated--insm-20210105monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-initiates-frontline-clinical-trial-program-for-arikayce-amikacin-liposome-inhalatio-insm-20210104monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20201204monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-initiation-of-phase-3-aspen-study-of-brensocatib-in-patients-with-bronchi-insm-20201202monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference-insmed-incorporated-insm-20201124monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-receives-priority-medicines-prime-designation-from-european-medicines-agency-ema-fo-insm-20201113monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20201106monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-two-november-conferences-insmed-incorporated-nasdaq-insm-a-global-bio-insm-20201102monthly0.5https://www.biopharmawatch.com/news/INSM/la-commissione-europea-autorizza-la-commercializzazione-di-alis-amikacin-liposome-inhalati-insm-20201028monthly0.5https://www.biopharmawatch.com/news/INSM/la-comisio-n-europea-concede-la-autorizacio-n-de-marketing-para-arikayce-liposomal-590-mg--insm-20201028monthly0.5https://www.biopharmawatch.com/news/INSM/la-commission-europe-enne-accorde-une-autorisation-de-mise-sur-le-marche-pour-le-ne-bulise-insm-20201028monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-third-quarter-2020-financial-results-conference-call-on-thursday-october-29-insm-20201020monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bridgewater-n-j-oct-2--insm-20201002monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-r-d-day-on-september-30-2020-insmed-incorporated-nasdaq-insm-a-global-bioph-insm-20200916monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-three-september-conferences-insmed-incorporated-nasdaq-insm-a-global--insm-20200909monthly0.5https://www.biopharmawatch.com/news/INSM/new-england-journal-of-medicine-publishes-positive-results-from-phase-2-willow-study-of-br-insm-20200907monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20200904monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20200807monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-second-quarter-2020-financial-results-conference-call-on-thursday-august-6--insm-20200727monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-receives-positive-chmp-opinion-for-arikayce-liposomal-590-mg-nebuliser-dispersion-f-insm-20200724monthly0.5https://www.biopharmawatch.com/news/INSM/new-ntm-treatment-guidelines-recommend-insmed-s-arikayce-amikacin-liposome-inhalation-susp-insm-20200707monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20200706monthly0.5https://www.biopharmawatch.com/news/INSM/positive-results-from-phase-2-willow-study-of-brensocatib-in-patients-with-non-cystic-fibr-insm-20200624monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-receives-fda-breakthrough-therapy-designation-for-brensocatib-in-patients-with-non--insm-20200608monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20200605monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-two-june-conferences-insmed-incorporated-nasdaq-insm-a-global-biophar-insm-20200526monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-showcase-new-brensocatib-data-at-american-thoracic-society-virtual-clinical-tria-insm-20200520monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20200507monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-pricing-of-public-offering-of-common-stock-insmed-incorporated-nasdaq-ins-insm-20200505monthly0.5https://www.biopharmawatch.com/news/INSM/brensocatib-formerly-ins1007-to-be-studied-in-patients-with-severe-covid-19-in-investigato-insm-20200423monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-first-quarter-2020-financial-results-conference-call-on-thursday-april-30-2-insm-20200420monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20200403monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-provides-business-update-insmed-incorporated-nasdaq-insm-a-global-biopharmaceutical-insm-20200316monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20200305monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-publication-discussing-the-clinical-management-of-common-respiratory-even-insm-20200304monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-cowen-and-company-40th-annual-health-care-conference-insmed-incor-insm-20200226monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides-business-u-insm-20200225monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-9th-annual-svb-leerink-global-healthcare-conference-insmed-incorp-insm-20200219monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-fourth-quarter-and-full-year-2019-financial-results-conference-call-on-tues-insm-20200210monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20200205monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-insmed-incorporated--insm-20200109monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20200103monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20191203monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-two-december-conferences-insmed-incorporated-nasdaq-insm-a-global-bio-insm-20191126monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-two-november-conferences-insmed-incorporated-nasdaq-insm-a-global-bio-insm-20191105monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20191104monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-third-quarter-2019-financial-results-and-provides-business-update-insmed-in-insm-20191030monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-third-quarter-2019-financial-results-conference-call-on-wednesday-october-3-insm-20191023monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20191007monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20190905monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-two-september-conferences-insmed-incorporated-nasdaq-insm-a-global-bi-insm-20190903monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20190802monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-second-quarter-2019-financial-results-conference-call-on-thursday-august-1--insm-20190725monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20190702monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-closing-of-public-offering-of-common-stock-insmed-incorporated-nasdaq-ins-insm-20190626monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-goldman-sachs-40th-annual-global-healthcare-conference-insmed-inc-insm-20190606monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20190604monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-pricing-of-public-offering-of-common-stock-insmed-incorporated-nasdaq-ins-insm-20190521monthly0.5https://www.biopharmawatch.com/news/INSM/new-phase-3-data-show-sustainability-and-durability-of-culture-conversion-with-arikayce-am-insm-20190520monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-first-quarter-2019-financial-results-conference-call-on-tuesday-may-7-2019--insm-20190430monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-granted-additional-u-s-patent-for-arikayce-amikacin-liposome-inhalation-suspension--insm-20190409monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20190402monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-showcase-new-arikayce-amikacin-liposome-inhalation-suspension-and-pipeline-data--insm-20190401monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-h-c-wainwright-global-life-sciences-conference-insmed-incorporate-insm-20190401monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-management-changes-insmed-incorporated-nasdaq-insm-a-global-biopharmaceut-insm-20190327monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20190304monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-the-leerink-partners-8th-annual-global-healthcare-conference-insmed-i-insm-20190220monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-fourth-quarter-and-full-year-2018-financial-results-conference-call-on-frid-insm-20190215monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20190204monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-insmed-incorporated-na-insm-20190107monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-31st-annual-j-p-morgan-healthcare-conference-insmed-incorporated-nasd-insm-20121213monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-clear-108-phase-3-clinical-study-of-arikace-in-cystic-fibrosis-patients-w-insm-20121113monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-two-upcoming-investor-conferences-insmed-incorporated-nasdaq-cm-insm--insm-20121112monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-financial-results-for-third-quarter-and-nine-months-ended-september-30-20-insm-20121107monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-appoints-15-year-life-sciences-industry-veteran-andrew-drechsler-as-chief-financial-insm-20121107monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-2012-third-quarter-earnings-conference-call-insmed-incorporated-nasdaq-cm-i-insm-20121024monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-pricing-of-approximately-26-million-direct-public-offering-insmed-incorpo-insm-20120928monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-stifel-nicolaus-2012-healthcare-conference-insmed-incorporated-nasdaq-insm-20120830monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-2012-wedbush-pacgrow-life-sciences-management-access-conference-insme-insm-20120814monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-financial-results-for-second-quarter-and-six-months-ended-june-30-2012-in-insm-20120807monthly0.5https://www.biopharmawatch.com/news/INSM/pharmaceutical-industry-veteran-al-altomari-elected-to-insmed-s-board-of-directors-insmed--insm-20120806monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-receives-second-composition-of-matter-patent-for-arikace-insmed-incorporated-nasdaq-insm-20120802monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-planned-departure-of-chief-financial-officer-insmed-incorporated-nasdaq-c-insm-20120730monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-2012-second-quarter-earnings-conference-call-insmed-incorporated-nasdaq-cm--insm-20120724monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-jmp-securities-7th-annual-healthcare-conference-insmed-incorporated-n-insm-20120710monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-secures-20-million-loan-agreement-with-hercules-technology-growth-capital-insmed-in-insm-20120702monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-first-patient-dosed-in-target-ntm-phase-2-clinical-trial-of-arikace-in-pa-insm-20120627monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-provides-corporate-update-insmed-incorporated-nasdaq-cm-insm-a-biopharmaceutical-co-insm-20120530monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-incorporated-begins-screening-patients-for-target-ntm-u-s-clinical-trial-of-arikace-insm-20120523monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-appoints-donald-j-hayden-jr-as-executive-chairman-insmed-incorporated-nasdaq-cm-ins-insm-20120516monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-first-quarter-2012-financial-results-insmed-incorporated-nasdaq-insm-a-bi-insm-20120508monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-incorporated-announces-lifting-of-clinical-hold-by-u-s-food-and-drug-administration-insm-20120507monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-2012-first-quarter-earnings-conference-call-insmed-incorporated-nasdaq-cm-i-insm-20120424monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-first-patient-dosed-in-pivotal-european-phase-3-clinical-study-of-arikace-insm-20120416monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-fourth-quarter-and-full-year-2011-financial-results-insmed-incorporated-n-insm-20120313monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-fourth-quarter-and-2011-year-end-earnings-conference-call-insmed-incorporat-insm-20120228monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-incorporated-provides-update-on-clinical-program-for-arikace-insmed-incorporated-na-insm-20120210monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-incorporated-provides-corporate-update-insmed-incorporated-nasdaq-cm-insm-a-biophar-insm-20120120monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-lazard-capital-markets-8th-annual-healthcare-conference-insmed-incorp-insm-20111114monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-financial-results-for-third-quarter-and-nine-months-ended-september-30-20-insm-20111108monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-2011-third-quarter-earnings-conference-call-insmed-incorporated-nasdaq-cm-i-insm-20111025monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-incorporated-provides-regulatory-update-on-arikace-in-non-tuberculous-mycobacteria--insm-20111014monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-sixth-annual-jmp-securities-healthcare-conference-insmed-incorporated-insm-20110926monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-present-at-2011-wedbush-securities-life-sciences-management-access-conference-in-insm-20110811monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-financial-results-for-second-quarter-and-six-months-ended-june-30-2011-in-insm-20110808monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-incorporated-announces-clinical-hold-on-arikace-phase-3-clinical-trials-insmed-inco-insm-20110801monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-2011-second-quarter-earnings-conference-call-insmed-incorporated-nasdaq-cm--insm-20110726monthly0.5https://www.biopharmawatch.com/news/INSM/andrea-drucker-joins-insmed-as-general-counsel-insmed-incorporated-nasdaq-cm-insm-a-biopha-insm-20110718monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-its-addition-to-the-russell-3000-index-insmed-incorporated-nasdaq-cm-insm-insm-20110628monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-s-arikace-demonstrates-sustained-benefit-through-six-cycles-of-treatment-for-cystic-insm-20110610monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-first-quarter-2011-financial-results-insmed-incorporated-nasdaq-cm-insm-a-insm-20110510monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-2011-first-quarter-earnings-conference-call-insmed-incorporated-nasdaq-cm-i-insm-20110426monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-fda-clearance-of-ind-for-pivotal-phase-3-trial-of-arikace-in-nontuberculo-insm-20110321monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-regains-nasdaq-compliance-insmed-incorporated-nasdaq-cm-insmd-a-biopharmaceutical-c-insm-20110321monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-announces-european-medicines-agency-acceptance-of-its-pediatric-investigation-plan--insm-20110303monthly0.5https://www.biopharmawatch.com/news/INSM/one-for-10-reverse-stock-split-of-insmed-common-stock-becomes-effective-insmed-incorporate-insm-20110302monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-shareholders-approve-conversion-of-series-b-conditional-convertible-preferred-stock-insm-20110301monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-participate-on-phase-iii-and-beyond-panel-at-2011-rbc-capital-markets-healthcare-insm-20110224monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-to-host-fourth-quarter-and-2010-year-end-earnings-conference-call-insmed-incorporat-insm-20110223monthly0.5https://www.biopharmawatch.com/news/INSM/nasdaq-grants-insmed-incorporated-180-day-extension-to-regain-compliance-with-minimum-bid--insm-20101216monthly0.5https://www.biopharmawatch.com/news/INSM/insmed-incorporated-and-transave-inc-announce-business-combination-insmed-incorporated-nas-insm-20101202monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-ce-mark-for-stealth-axis-surgical-system-medtronic-a-global-leader-in--mdt-20260428monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-key-affera-clinical-study-milestones-for-sphere-9-and-sphere-360-cathe-mdt-20260425monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-to-acquire-scientia-vascular-marrying-access-and-therapeutic-portfolios-for-neur-mdt-20260310monthly0.5https://www.biopharmawatch.com/news/MDT/minimed-to-begin-trading-on-nasdaq-global-select-market-medtronic-plc-nyse-mdt-a-global-le-mdt-20260306monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-first-surgery-with-hugo-robotic-assisted-surgery-system-in-the-u-s-per-mdt-20260217monthly0.5https://www.biopharmawatch.com/news/MDT/study-showed-minimed-780g-system-achieved-ada-recommended-time-in-range-goals-even-on-days-mdt-20260107monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-filing-of-ipo-registration-statement-for-diabetes-business-minimed-med-mdt-20251219monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-secures-fda-approval-for-the-altaviva-device-a-simple-experience-for-treating-ur-mdt-20250919monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-initiates-global-pivotal-study-of-cardiac-pacing-in-a-new-patient-population-med-mdt-20250915monthly0.5https://www.biopharmawatch.com/news/MDT/study-of-medtronic-hugo-robotic-assisted-surgery-system-in-hernia-repair-meets-safety-and--mdt-20250904monthly0.5https://www.biopharmawatch.com/news/MDT/fda-clears-minimed-780g-system-to-enable-integration-with-the-instinct-sensor-made-by-abbo-mdt-20250902monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-executives-to-speak-at-upcoming-investor-conferences-medtronic-plc-nyse-mdt-a-gl-mdt-20250829monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-board-appointments-and-shareholder-value-creation-initiatives-to-advan-mdt-20250819monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-reports-first-quarter-fiscal-2026-financial-results-medtronic-plc-nyse-mdt-a-glo-mdt-20250819monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-cash-dividend-for-second-quarter-of-fiscal-year-2026-the-board-of-dire-mdt-20250814monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-to-announce-financial-results-for-its-first-quarter-of-fiscal-year-2026-medtroni-mdt-20250805monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-secures-ce-mark-for-minimed-780g-system-for-insulin-requiring-people-with-diabet-mdt-20250721monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-appointment-of-minimed-chief-financial-officer-ahead-of-intended-separ-mdt-20250708monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-board-appoints-dr-joon-lee-as-a-new-director-medtronic-plc-nyse-mdt-a-global-lea-mdt-20250623monthly0.5https://www.biopharmawatch.com/news/MDT/studies-show-promising-results-for-individuals-with-type-2-diabetes-and-young-children-wit-mdt-20250620monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-minimed-as-name-for-planned-new-diabetes-company-medtronic-plc-nyse-md-mdt-20250612monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-chairman-and-ceo-geoff-martha-to-speak-at-bernstein-s-strategic-decisions-confer-mdt-20250523monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-intent-to-separate-diabetes-business-medtronic-plc-nyse-mdt-a-global-l-mdt-20250521monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-to-announce-financial-results-for-its-fourth-quarter-and-full-fiscal-year-2025-m-mdt-20250507monthly0.5https://www.biopharmawatch.com/news/MDT/new-survey-1-in-3-women-have-not-talked-to-their-doctor-about-heart-health-the-1-killer-of-mdt-20250507monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-affera-pulsed-field-ablation-technologies-continue-to-demonstrate-promising-evid-mdt-20250426monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-expand-uro-u-s-clinical-trial-meets-safety-and-effectiveness-primary-endpoints-f-mdt-20250426monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-receives-fda-approval-for-smallest-diameter-lumenless-defibrillation-lead-the-om-mdt-20250425monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-advances-abbott-cgm-partnership-with-fda-submission-of-interoperable-insulin-pum-mdt-20250424monthly0.5https://www.biopharmawatch.com/news/MDT/new-simplera-sync-sensor-for-the-minimed-780g-system-now-fda-approved-medtronic-plc-nyse-m-mdt-20250418monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-evolut-tavr-system-shows-durable-clinical-outcomes-and-outstanding-valve-perform-mdt-20250330monthly0.5https://www.biopharmawatch.com/news/MDT/smart-trial-two-year-data-continues-to-demonstrate-superior-valve-performance-for-evolut-t-mdt-20250309monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-cash-dividend-for-fourth-quarter-of-fiscal-year-2025-the-board-of-dire-mdt-20250306monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-earns-u-s-fda-approval-for-the-world-s-first-adaptive-deep-brain-stimulation-sys-mdt-20250224monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-reports-third-quarter-fiscal-2025-financial-results-medtronic-plc-nyse-mdt-today-mdt-20250218monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-to-announce-financial-results-for-its-third-quarter-of-fiscal-year-2025-medtroni-mdt-20250205monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-appoints-thierry-pie-ton-as-chief-financial-officer-medtronic-plc-nyse-mdt-a-glo-mdt-20250121monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-cms-national-coverage-analysis-for-symplicity-spyral-renal-denervation-mdt-20250113monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-achieves-ce-mark-approval-for-brainsense-adaptive-deep-brain-stimulation-and-ele-mdt-20250113monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-chairman-and-ceo-geoff-martha-to-speak-at-j-p-morgan-healthcare-conference-medtr-mdt-20250106monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-cash-dividend-for-third-quarter-of-fiscal-year-2025-the-board-of-direc-mdt-20241205monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-receives-fda-clearance-for-new-inpen-app-paving-the-way-for-its-smart-mdi-system-mdt-20241120monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-reports-second-quarter-fiscal-2025-financial-results-medtronic-plc-nyse-mdt-toda-mdt-20241119monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-to-announce-financial-results-for-its-second-quarter-of-fiscal-year-2025-medtron-mdt-20241105monthly0.5https://www.biopharmawatch.com/news/MDT/cms-grants-transitional-pass-through-payment-for-medtronic-symplicity-spyral-renal-denerva-mdt-20241101monthly0.5https://www.biopharmawatch.com/news/MDT/spyral-htn-on-med-study-shows-significant-consistent-long-term-blood-pressure-lowering-eff-mdt-20241028monthly0.5https://www.biopharmawatch.com/news/MDT/a-new-paradigm-in-electrophysiology-medtronic-receives-fda-approval-of-affera-mapping-and--mdt-20241024monthly0.5https://www.biopharmawatch.com/news/MDT/voluntary-recall-notifying-medtronic-insulin-pump-users-of-potential-risks-of-shortened-pu-mdt-20241004monthly0.5https://www.biopharmawatch.com/news/MDT/new-clinical-data-demonstrate-excellent-lesion-durability-with-pulseselect-pulsed-field-ab-mdt-20240927monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-expands-aible-spine-surgery-ecosystem-with-new-technologies-and-siemens-healthin-mdt-20240925monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-chairman-and-ceo-geoff-martha-to-speak-at-the-wells-fargo-healthcare-conference--mdt-20240827monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-reports-first-quarter-fiscal-2025-financial-results-medtronic-plc-nyse-mdt-today-mdt-20240820monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-cash-dividend-for-second-quarter-of-fiscal-year-2025-the-board-of-dire-mdt-20240816monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-to-announce-financial-results-for-its-first-quarter-of-fiscal-year-2025-medtroni-mdt-20240812monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-fda-approval-of-simplera-cgm-and-global-partnership-with-abbott-medtro-mdt-20240807monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-departure-of-karen-parkhill-chief-financial-officer-medtronic-plc-nyse-mdt-20240626monthly0.5https://www.biopharmawatch.com/news/MDT/new-minimed-780g-system-data-demonstrates-ability-to-address-persistent-blood-sugar-challe-mdt-20240621monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-chairman-and-ceo-geoff-martha-to-speak-at-goldman-sachs-global-healthcare-confer-mdt-20240606monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-closing-of-public-offering-of-3-0-billion-of-senior-notes-medtronic-pl-mdt-20240603monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-pricing-of-3-0-billion-of-senior-notes-medtronic-plc-the-company-nyse--mdt-20240529monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-reports-full-year-and-fourth-quarter-fiscal-2024-financial-results-announces-div-mdt-20240523monthly0.5https://www.biopharmawatch.com/news/MDT/minimed-780g-system-recognized-among-fast-company-s-2024-world-changing-ideas-fast-company-mdt-20240520monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-affera-mapping-and-ablation-system-with-sphere-9-catheter-achieves-endpoints-for-mdt-20240517monthly0.5https://www.biopharmawatch.com/news/MDT/late-breaking-data-show-reliable-performance-of-small-diameter-defibrillation-lead-the-med-mdt-20240517monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-to-announce-financial-results-for-its-fourth-quarter-and-full-fiscal-year-2024-m-mdt-20240509monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-receives-fda-approval-for-inceptiv-closed-loop-spinal-cord-stimulator-medtronic--mdt-20240426monthly0.5https://www.biopharmawatch.com/news/MDT/americans-favor-quality-over-quantity-in-pursuit-of-longevity-americans-overwhelmingly-say-mdt-20240417monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-unveils-the-future-of-ai-in-gi-genius-summit-2024-reveals-innovations-and-collab-mdt-20240410monthly0.5https://www.biopharmawatch.com/news/MDT/the-medtronic-sphere-360-pulse-field-ablation-pfa-catheter-a-new-paradigm-in-single-shot-a-mdt-20240408monthly0.5https://www.biopharmawatch.com/news/MDT/smart-trial-one-year-data-demonstrates-medtronic-evolut-tavr-platform-as-optimal-treatment-mdt-20240407monthly0.5https://www.biopharmawatch.com/news/MDT/new-survey-uncovers-lack-of-awareness-around-heart-valve-disease-and-risk-factors-among-wo-mdt-20240407monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-fda-approval-of-newest-generation-evolut-tavr-system-for-treatment-of--mdt-20240327monthly0.5https://www.biopharmawatch.com/news/MDT/u-s-patent-office-rejects-axonics-latest-challenge-to-medtronic-patents-medtronic-nyse-mdt-mdt-20240321monthly0.5https://www.biopharmawatch.com/news/MDT/new-real-world-data-shows-minimed-780g-system-sustains-strong-global-performance-exceeding-mdt-20240309monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-cash-dividend-for-fourth-quarter-of-fiscal-year-2024-the-board-of-dire-mdt-20240307monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-evp-cfo-karen-parkhill-to-participate-in-the-barclays-healthcare-conference-medt-mdt-20240305monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-files-itc-action-against-axonics-to-stop-unauthorized-use-of-medtronic-innovatio-mdt-20240229monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-reports-third-quarter-fiscal-2024-financial-results-medtronic-plc-nyse-mdt-today-mdt-20240220monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-to-announce-financial-results-for-its-third-quarter-of-fiscal-year-2024-medtroni-mdt-20240206monthly0.5https://www.biopharmawatch.com/news/MDT/fda-approves-medtronic-percept-rc-neurostimulator-with-exclusive-brainsense-technology-med-mdt-20240108monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-diabetes-announces-world-s-first-approval-for-minimed-780g-system-with-simplera--mdt-20240108monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-receives-ce-mark-for-its-next-generation-micra-leadless-pacing-systems-medtronic-mdt-20240105monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-chairman-and-ceo-geoff-martha-to-speak-at-j-p-morgan-healthcare-conference-medtr-mdt-20231218monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-creates-history-with-fda-approval-of-its-novel-pulseselect-pulsed-field-ablation-mdt-20231213monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-and-cosmo-pharmaceuticals-forge-ahead-in-ai-driven-care-medtronic-plc-nyse-mdt-a-mdt-20231211monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-cash-dividend-for-third-quarter-of-fiscal-year-2024-the-board-of-direc-mdt-20231207monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-reports-second-quarter-fiscal-2024-financial-results-medtronic-plc-nyse-mdt-toda-mdt-20231121monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-fda-approval-of-minimally-invasive-device-to-treat-hypertension-medtro-mdt-20231117monthly0.5https://www.biopharmawatch.com/news/MDT/a-majority-of-americans-are-optimistic-that-ai-will-improve-healthcare-in-2024-more-than-h-mdt-20231113monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-to-announce-financial-results-for-its-second-quarter-of-fiscal-year-2024-medtron-mdt-20231107monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-evolut-tavr-platform-outperforms-surgery-with-sustained-valve-performance-for-lo-mdt-20231024monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-receives-fda-approval-for-extravascular-defibrillator-to-treat-abnormal-heart-rh-mdt-20231023monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-diabetes-announces-ce-mark-for-new-simplera-cgm-with-disposable-all-in-one-desig-mdt-20230921monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-receives-ce-mark-approval-for-inceptiv-spinal-cord-stimulator-with-closed-loop-s-mdt-20230825monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-issues-statement-on-the-fda-circulatory-systems-devices-advisory-panel-vote-for--mdt-20230823monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-to-participate-in-upcoming-investor-conferences-medtronic-plc-nyse-mdt-a-global--mdt-20230822monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-reports-first-quarter-fiscal-2024-financial-results-medtronic-plc-nyse-mdt-today-mdt-20230822monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-cash-dividend-for-second-quarter-of-fiscal-year-2024-the-board-of-dire-mdt-20230817monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-to-announce-financial-results-for-its-first-quarter-of-fiscal-year-2024-medtroni-mdt-20230808monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-board-appoints-greg-lewis-as-new-director-medtronic-announced-today-that-its-boa-mdt-20230626monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-presents-new-data-on-minimed-780g-system-on-fixed-meal-dosing-and-real-world-tim-mdt-20230623monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-to-present-new-data-on-its-intelligent-dosing-platforms-at-the-american-diabetes-mdt-20230612monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-names-ken-washington-new-chief-technology-and-innovation-officer-medtronic-plc-n-mdt-20230601monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-chairman-and-ceo-geoff-martha-to-speak-at-goldman-sachs-global-healthcare-confer-mdt-20230530monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-to-acquire-wearable-insulin-patch-maker-eoflow-medtronic-plc-nyse-mdt-a-global-l-mdt-20230525monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-reports-full-year-and-fourth-quarter-fiscal-2023-financial-results-announces-div-mdt-20230525monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-extravascular-icd-global-clinical-trial-results-reinforce-device-safety-and-effe-mdt-20230520monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-accurhythm-ai-technology-receives-2023-medtech-breakthrough-award-as-best-new-mo-mdt-20230516monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-to-announce-financial-results-for-its-fourth-quarter-and-full-fiscal-year-2023-m-mdt-202305112023-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-receives-fda-approval-for-its-next-generation-micra-leadless-pacing-systems-medt-mdt-202305012023-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-diabetes-resolves-warning-letter-clearing-path-for-future-innovations-medtronic--mdt-202304252023-04-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/fda-approves-medtronic-minimed-780g-system-world-s-first-insulin-pump-with-meal-detection--mdt-202304212023-04-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-davita-launch-mozarc-medical-aimed-at-introducing-new-solutions-for-patients-wit-mdt-202304012023-04-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-pricing-of-2-0-billion-of-senior-notes-medtronic-plc-the-company-nyse--mdt-202303232023-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-to-boost-ai-innovation-with-new-platform-introduction-medtronic-plc-nyse-mdt-a-g-mdt-202303222023-03-22T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-receives-ce-mark-approval-for-affera-mapping-and-ablation-system-to-treat-atrial-mdt-202303152023-03-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-erha-lt-ce-kennzeichnung-fu-r-das-affera-mapping-und-ablationssystem-zur-behandl-mdt-202303152023-03-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-named-one-of-world-s-most-ethical-companies-medtronic-plc-nyse-mdt-a-global-lead-mdt-202303132023-03-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-pulseselect-pfa-system-demonstrates-impressive-results-in-landmark-pulsed-af-glo-mdt-202303062023-03-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-cash-dividend-for-fourth-quarter-of-fiscal-year-2023-the-board-of-dire-mdt-202303022023-03-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-executive-vice-president-and-cfo-karen-parkhill-to-speak-at-cowen-healthcare-con-mdt-202302272023-02-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/minimed-780g-system-demonstrates-superiority-over-multiple-daily-injections-with-cgm-for-t-mdt-202302242023-02-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-reports-third-quarter-fiscal-2023-financial-results-medtronic-plc-nyse-mdt-today-mdt-202302212023-02-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-receives-ce-mark-for-extravascular-defibrillator-system-that-treats-abnormal-hea-mdt-202302172023-02-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-to-announce-financial-results-for-its-third-quarter-of-fiscal-year-2023-medtroni-mdt-202302142023-02-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-linq-insertable-cardiac-monitor-detects-10-times-more-atrial-fibrillation-in-isc-mdt-202302082023-02-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-continues-to-make-significant-advances-as-an-inclusion-diversity-equity-leader-m-mdt-202302012023-02-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-recommends-rejection-of-below-market-mini-tender-offer-by-trc-capital-investment-mdt-202301252023-01-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-named-one-of-america-s-most-just-companies-by-just-capital-and-cnbc-medtronic-pl-mdt-202301102023-01-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-chairman-and-ceo-geoff-martha-to-speak-at-j-p-morgan-healthcare-conference-medtr-mdt-20221219monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-first-patient-enrolled-in-u-s-clinical-trial-for-hugo-robotic-assisted-mdt-20221215monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-named-as-a-leading-sustainability-company-medtronic-plc-nyse-mdt-a-global-leader-mdt-20221214monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-cash-dividend-for-third-quarter-of-fiscal-year-2023-the-board-of-direc-mdt-20221208monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-completes-enrollment-in-pivotal-trial-evaluating-first-of-its-kind-pulsed-field--mdt-20221205monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-executives-to-speak-at-the-evercore-isi-5th-annual-healthconx-conference-medtron-mdt-20221123monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-reports-second-quarter-fiscal-2023-financial-results-medtronic-plc-nyse-mdt-toda-mdt-20221122monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-to-announce-financial-results-for-its-second-quarter-of-fiscal-year-2023-medtron-mdt-20221115monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-launches-world-s-first-and-only-infusion-set-for-insulin-pumps-that-doubles-wear-mdt-20221115monthly0.5https://www.biopharmawatch.com/news/MDT/spyral-htn-on-med-study-demonstrates-meaningful-clinical-benefits-consistent-with-other-sp-mdt-20221107monthly0.5https://www.biopharmawatch.com/news/MDT/anku-ndigung-der-plattform-medtronic-neurovascular-co-lab-zur-beschleunigung-der-innovatio-mdt-20221026monthly0.5https://www.biopharmawatch.com/news/MDT/annonce-du-lancement-de-la-plateforme-medtronic-neurovascular-co-lab-pour-acce-le-rer-l-in-mdt-20221026monthly0.5https://www.biopharmawatch.com/news/MDT/la-plataforma-medtronic-neurovascular-co-lab-acelerara-la-innovacio-n-en-el-tratamiento-de-mdt-20221026monthly0.5https://www.biopharmawatch.com/news/MDT/announcing-the-launch-of-medtronic-neurovascular-co-lab-platform-to-accelerate-innovation--mdt-20221026monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-chairman-and-ceo-geoff-martha-to-speak-at-the-cecp-s-ceo-investor-forum-medtroni-mdt-20221024monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-intention-to-separate-its-combined-patient-monitoring-and-respiratory--mdt-20221024monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-expands-global-access-to-the-benefits-of-robotic-assisted-surgery-medtronic-plc--mdt-20221019monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-leverages-data-science-to-launch-first-of-its-kind-personalized-insights-program-mdt-20221018monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-first-to-receive-fda-approval-for-pacing-the-heart-s-natural-conduction-system-m-mdt-20221017monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-to-webcast-renal-denervation-investor-analyst-briefing-on-november-7-medtronic-p-mdt-20221014monthly0.5https://www.biopharmawatch.com/news/MDT/fortune-and-great-place-to-work-name-medtronic-one-of-the-world-s-best-workplaces-in-2022--mdt-20221013monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-releases-2022-integrated-performance-report-medtronic-plc-today-released-its-fis-mdt-20221011monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-closing-of-public-offering-of-3-5-billion-of-senior-notes-medtronic-pl-mdt-20220921monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-receives-fda-clearance-for-expanded-indication-of-linq-ii-insertable-cardiac-mon-mdt-20220920monthly0.5https://www.biopharmawatch.com/news/MDT/tct-2022-symplicity-htn-3-trial-data-show-sustained-long-term-blood-pressure-reductions-wi-mdt-20220918monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-pricing-of-3-5-billion-of-senior-notes-medtronic-plc-the-company-nyse--mdt-20220915monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-to-appear-at-september-investor-conferences-medtronic-plc-nyse-mdt-a-global-lead-mdt-20220907monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-adapt-study-results-published-in-the-lancet-diabetes-endocrinology-show-improved-mdt-20220901monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-partnership-with-biointellisense-for-exclusive-u-s-distribution-of-mul-mdt-20220831monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-completes-acquisition-of-affera-medtronic-plc-nyse-mdt-a-global-leader-in-health-mdt-20220830monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-extravascular-icd-meets-global-pivotal-clinical-trial-s-safety-and-effectiveness-mdt-20220828monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-reports-first-quarter-fiscal-2023-financial-results-medtronic-plc-nyse-mdt-today-mdt-20220823monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-cash-dividend-for-second-quarter-of-fiscal-year-2023-the-board-of-dire-mdt-20220818monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-to-announce-financial-results-for-its-first-quarter-of-fiscal-year-2023-medtroni-mdt-20220810monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-expands-health-equity-assistance-program-for-colon-cancer-screening-with-support-mdt-20220715monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-receives-fda-clearance-for-next-generation-unid-spine-analyzer-with-degenerative-mdt-20220714monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-co-promotion-agreement-with-cathworks-with-path-toward-acquisition-med-mdt-20220712monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-board-appoints-lidia-fonseca-as-a-new-director-medtronic-plc-nyse-mdt-today-anno-mdt-20220627monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-chairman-and-ceo-geoff-martha-to-speak-at-goldman-sachs-global-healthcare-confer-mdt-20220531monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-reports-full-year-and-fourth-quarter-fiscal-year-2022-financial-results-announce-mdt-20220526monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-and-davita-announce-new-kidney-health-technology-company-medtronic-plc-nyse-mdt--mdt-20220526monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-to-announce-financial-results-for-its-fourth-quarter-and-full-fiscal-year-2022-m-mdt-20220519monthly0.5https://www.biopharmawatch.com/news/MDT/europcr-medtronic-renal-denervation-system-shows-better-blood-pressure-control-with-signif-mdt-20220517monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-receives-fda-approval-for-latest-generation-drug-eluting-coronary-stent-system-m-mdt-20220513monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-completes-acquisition-of-intersect-ent-medtronic-plc-nyse-mdt-a-global-leader-in-mdt-20220513monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-and-ge-healthcare-announce-a-collaboration-to-meet-growing-need-for-outpatient-c-mdt-20220428monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-names-new-chief-scientific-medical-and-regulatory-officer-medtronic-plc-nyse-mdt-mdt-20220425monthly0.5https://www.biopharmawatch.com/news/MDT/acc-22-medtronic-renal-denervation-system-demonstrates-significant-blood-pressure-reductio-mdt-20220404monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-first-patient-implants-of-investigational-implantable-tibial-neuromodu-mdt-20220324monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-survey-finds-pandemic-creating-far-reaching-and-negative-impacts-on-those-with-c-mdt-20220323monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-appoints-new-operating-unit-presidents-medtronic-plc-nyse-mdt-a-global-leader-in-mdt-20220317monthly0.5https://www.biopharmawatch.com/news/MDT/first-u-s-trial-using-gi-genius-intelligent-endoscopy-module-shows-50-reduction-in-missed--mdt-20220316monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-contract-with-vizient-for-touch-surgery-enterprise-medtronic-plc-nyse--mdt-20220309monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-cash-dividend-for-fourth-quarter-of-fiscal-year-2022-the-board-of-dire-mdt-20220304monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-executive-vice-president-and-cfo-to-speak-at-cowen-healthcare-conference-medtron-mdt-20220228monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-launch-of-nuvent-eustachian-tube-dilation-balloon-medtronic-plc-nyse-m-mdt-20220228monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-receives-fda-approval-for-interstim-x-system-the-next-generation-of-the-most-per-mdt-20220222monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-to-provide-underserved-communities-with-artificial-intelligence-ai-assisted-colo-mdt-20220222monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-reports-third-quarter-fiscal-2022-financial-results-medtronic-plc-nyse-mdt-today-mdt-20220222monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-receives-fda-expanded-approval-for-cardiac-cryoablation-catheters-for-pediatric--mdt-20220218monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-to-announce-financial-results-for-its-third-quarter-of-fiscal-year-2022-medtroni-mdt-20220208monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-first-procedure-in-europe-with-hugo-robotic-assisted-surgery-system-me-mdt-20220202monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-fda-approval-of-spinal-cord-stimulation-therapy-for-treating-chronic-p-mdt-20220124monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-foundation-launches-new-stem-partnerships-to-serve-over-60-000-underserved-and-u-mdt-20220121monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-results-showing-meaningful-pain-relief-using-dtm-spinal-cord-stimulati-mdt-20220114monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-schedule-for-presentations-at-the-2022-north-american-neuromodulation--mdt-20220112monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-regulatory-approval-and-launch-in-japan-of-micra-av-transcatheter-paci-mdt-20220110monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-approval-of-the-evolut-pro-tavr-system-in-china-medtronic-plc-nyse-mdt-mdt-20220110monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-to-acquire-affera-medtronic-plc-nyse-mdt-a-global-leader-in-healthcare-technolog-mdt-20220110monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-chairman-and-ceo-geoff-martha-to-speak-at-j-p-morgan-healthcare-conference-medtr-mdt-20220104monthly0.5https://www.biopharmawatch.com/news/MDT/cms-expands-diabetes-medicare-coverage-to-include-cgms-that-integrate-with-medtronic-insul-mdt-20211222monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-two-executive-committee-changes-medtronic-plc-nyse-mdt-a-global-leader-mdt-20211216monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-diabetes-receives-fda-warning-letter-medtronic-plc-nyse-mdt-today-announced-it-r-mdt-20211215monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-invos-7100-cerebral-somatic-oximetry-system-receives-510-k-clearance-for-pediatr-mdt-20211214monthly0.5https://www.biopharmawatch.com/news/MDT/new-study-finds-procedures-treating-spinal-fractures-associated-with-reduction-in-opioid-u-mdt-20211213monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-cash-dividend-for-third-quarter-of-fiscal-year-2022-the-board-of-direc-mdt-20211210monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-reports-second-quarter-fiscal-2022-financial-results-medtronic-plc-nyse-mdt-toda-mdt-20211123monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-510-k-clearance-for-pillcam-small-bowel-3-home-endoscopy-procedure-med-mdt-20211115monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-taps-top-digital-and-healthcare-technology-leaders-to-drive-company-transformati-mdt-20211115monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-named-to-the-dow-jones-sustainability-world-index-medtronic-plc-nyse-mdt-a-globa-mdt-20211115monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-to-announce-financial-results-for-its-second-quarter-of-fiscal-year-2022-medtron-mdt-20211109monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-2045-net-zero-emissions-ambition-to-combat-climate-change-medtronic-pl-mdt-20211108monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-early-data-for-the-intrepid-transcatheter-mitral-valve-replacement-tmv-mdt-20211106monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-self-expanding-tavr-platform-shows-excellent-longer-term-performance-at-five-yea-mdt-20211105monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-study-shows-patients-with-high-blood-pressure-are-interested-in-an-interventiona-mdt-20211104monthly0.5https://www.biopharmawatch.com/news/MDT/austin-l-chiang-m-d-m-p-h-joins-medtronic-as-chief-medical-officer-for-gastrointestinal-bu-mdt-20211021monthly0.5https://www.biopharmawatch.com/news/MDT/children-achieve-time-in-range-mirroring-well-controlled-adults-for-the-first-time-in-real-mdt-20211019monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-new-esg-targets-in-its-fy21-integrated-performance-report-and-unveils--mdt-20211012monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-hugo-robotic-assisted-surgery-system-receives-european-ce-mark-approval-medtroni-mdt-20211011monthly0.5https://www.biopharmawatch.com/news/MDT/continuous-rhythm-monitoring-reveals-strong-short-term-risk-association-between-atrial-fib-mdt-20211004monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-expands-minimally-invasive-spine-surgery-ecosystem-with-next-generation-spinal-t-mdt-20210930monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-receives-ce-mark-approval-for-radial-artery-access-portfolio-medtronic-plc-nyse--mdt-20210928monthly0.5https://www.biopharmawatch.com/news/MDT/first-procedure-in-asia-pacific-performed-with-medtronic-hugo-robotic-assisted-surgery-sys-mdt-20210927monthly0.5https://www.biopharmawatch.com/news/MDT/u-s-patent-office-completes-review-of-medtronic-patents-rejects-more-axonics-challenges-me-mdt-20210922monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-begins-pediatric-clinical-trial-of-spinal-tether-for-treatment-of-scoliosis-medt-mdt-20210922monthly0.5https://www.biopharmawatch.com/news/MDT/u-s-patent-and-trademark-office-rejects-axonics-challenge-to-medtronic-patents-medtronic-p-mdt-20210913monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-collaboration-with-mpirik-to-address-disparities-in-care-associated-with-sudden--mdt-20210913monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-executives-to-speak-at-upcoming-investor-conferences-medtronic-plc-nyse-mdt-the--mdt-20210907monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-navablate-study-results-released-in-late-breaking-podium-presentation--mdt-20210907monthly0.5https://www.biopharmawatch.com/news/MDT/real-world-data-demonstrate-significant-reduction-in-complications-and-reinterventions-wit-mdt-20210827monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-fda-approval-of-next-gen-tavr-system-for-treatment-of-symptomatic-seve-mdt-20210824monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-reports-first-quarter-fiscal-2022-financial-results-medtronic-plc-nyse-mdt-today-mdt-20210824monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-cash-dividend-for-second-quarter-of-fiscal-year-2022-the-board-of-dire-mdt-20210823monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-to-announce-financial-results-for-its-first-quarter-of-fiscal-year-2022-medtroni-mdt-20210810monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-to-acquire-intersect-ent-medtronic-plc-nyse-mdt-the-global-leader-in-medical-tec-mdt-20210806monthly0.5https://www.biopharmawatch.com/news/MDT/first-gynecological-procedures-performed-with-medtronic-hugo-robotic-assisted-surgery-syst-mdt-20210729monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-fda-clearance-and-results-of-artificial-intelligence-algorithms-for-ca-mdt-20210728monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-tyrx-absorbable-antibacterial-envelope-is-effective-at-reducing-infections-in-ca-mdt-20210726monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-launches-newest-generation-drug-coated-balloon-catheter-in-europe-for-treatment--mdt-20210726monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-hugo-robotic-assisted-surgery-system-cornerstone-of-new-robotics-program-in-lati-mdt-20210720monthly0.5https://www.biopharmawatch.com/news/MDT/economic-analysis-finds-continuous-monitoring-for-respiratory-depression-may-provide-benef-mdt-20210707monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-launches-app-based-study-to-better-understand-relationship-between-atrial-fibril-mdt-20210629monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-inpen-real-world-data-and-extended-infusion-set-pivotal-trial-results-demonstrat-mdt-20210628monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-real-world-data-on-inpen-and-extended-infusion-set-pivotal-trial-data--mdt-20210623monthly0.5https://www.biopharmawatch.com/news/MDT/first-procedure-in-the-world-with-medtronic-hugo-robotic-assisted-surgery-system-performed-mdt-20210622monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-receives-fda-expanded-approval-for-arctic-front-family-of-cardiac-cryoablation-c-mdt-20210621monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-fda-approval-of-its-next-generation-recharge-free-spinal-cord-stimulat-mdt-20210610monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-insertable-cardiac-monitor-detects-significantly-higher-rates-of-atrial-fibrilla-mdt-20210607monthly0.5https://www.biopharmawatch.com/news/MDT/fda-approves-first-of-its-kind-sensight-directional-lead-system-for-dbs-therapy-medtronic--mdt-20210607monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-gains-fda-clearance-of-unid-patient-specific-rods-for-use-with-cd-horizon-solera-mdt-20210603monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-to-stop-distribution-and-sale-of-hvad-system-medtronic-plc-nyse-mdt-the-global-l-mdt-20210603monthly0.5https://www.biopharmawatch.com/news/MDT/real-world-data-on-over-4-000-patients-using-the-medtronic-minimed-780g-system-demonstrate-mdt-20210602monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-scientific-data-presentations-at-the-14th-international-conference-on--mdt-20210601monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-reports-fourth-quarter-and-fiscal-year-2021-financial-results-announces-9-divide-mdt-20210527monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-secures-two-ce-mark-approvals-for-guardian-4-sensor-for-inpen-mdi-smart-insulin--mdt-20210526monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-executives-to-speak-at-upcoming-investor-conferences-medtronic-plc-nyse-mdt-the--mdt-20210525monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-evolut-tavr-system-shows-strong-performance-at-two-years-in-low-risk-trial-medtr-mdt-20210518monthly0.5https://www.biopharmawatch.com/news/MDT/late-breaking-data-at-europcr-demonstrates-long-term-benefits-of-medtronic-radiofrequency--mdt-20210518monthly0.5https://www.biopharmawatch.com/news/MDT/new-survey-identifies-opportunity-to-improve-shared-decision-making-between-cardiologists--mdt-20210514monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-to-announce-financial-results-for-its-fourth-quarter-and-full-fiscal-year-2021-m-mdt-20210513monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-and-medtronic-foundation-partner-to-address-covid-19-surges-with-focus-on-equity-mdt-20210513monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-launches-new-pediatric-monitor-that-alerts-clinicians-to-potential-airway-obstru-mdt-20210510monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-careguidepro-a-new-mobile-app-and-online-platform-for-patients-to-navi-mdt-20210505monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-ce-mark-of-evolut-pro-tavi-system-for-treatment-of-symptomatic-severe--mdt-20210503monthly0.5https://www.biopharmawatch.com/news/MDT/procedure-related-techniques-and-care-pathways-from-the-optimize-pro-clinical-study-show-p-mdt-20210428monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-receives-fda-breakthrough-designation-for-the-emprint-ablation-catheter-kit-medt-mdt-20210427monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-receives-fda-approval-to-launch-clinical-study-for-implantable-tibial-neuromodul-mdt-20210427monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-partners-with-surgical-theater-to-provide-first-augmented-reality-platform-for-u-mdt-20210426monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-receives-u-s-fda-approval-for-pipeline-flex-embolization-device-with-shield-tech-mdt-20210421monthly0.5https://www.biopharmawatch.com/news/MDT/in-pact-av-drug-coated-balloon-is-first-and-only-to-show-superior-and-sustained-results-th-mdt-20210420monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-european-launch-of-world-s-first-infusion-set-with-wear-up-to-seven-da-mdt-20210414monthly0.5https://www.biopharmawatch.com/news/MDT/u-s-fda-grants-de-novo-clearance-for-first-and-only-artificial-intelligence-system-for-col-mdt-20210412monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-ongoing-initiatives-to-address-health-equity-for-people-of-color-livin-mdt-20210407monthly0.5https://www.biopharmawatch.com/news/MDT/the-medtronic-foundation-and-children-s-heartlink-focus-new-partnership-on-health-equity-f-mdt-20210407monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-receives-fda-approval-for-breakthrough-transcatheter-pulmonary-valve-replacement-mdt-20210326monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-receives-ce-mark-approval-for-sensight-directional-lead-system-for-dbs-therapy-m-mdt-20210322monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-receives-approval-for-u-s-labeling-of-the-intellis-platform-showing-superior-bac-mdt-20210317monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-cash-dividend-for-fourth-quarter-of-fiscal-year-2021-the-board-of-dire-mdt-20210308monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-first-procedures-in-pivotal-trial-to-evaluate-novel-ablation-technolog-mdt-20210304monthly0.5https://www.biopharmawatch.com/news/MDT/new-analysis-of-reverse-trial-reveals-benefits-of-crt-for-more-patients-with-heart-failure-mdt-20210302monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-reports-third-quarter-fiscal-2021-financial-results-medtronic-plc-nyse-mdt-today-mdt-20210223monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-receives-fda-approval-for-expanded-mri-labeling-of-interstim-surescan-mri-leads--mdt-20210218monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-executives-to-speak-at-upcoming-investor-conferences-medtronic-plc-nyse-mdt-the--mdt-20210217monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-voluntary-recall-of-unused-valiant-navion-thoracic-stent-graft-system--mdt-20210217monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-to-announce-financial-results-for-its-third-quarter-of-fiscal-year-2021-medtroni-mdt-20210216monthly0.5https://www.biopharmawatch.com/news/MDT/surgeons-complete-first-procedures-across-the-u-s-utilizing-medtronic-s-midas-rex-drills-a-mdt-20210216monthly0.5https://www.biopharmawatch.com/news/MDT/new-study-in-newborns-finds-nellcor-pulse-oximetry-technology-provides-faster-stable-oxyge-mdt-20210209monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-early-site-release-of-new-radial-artery-access-portfolio-following-fir-mdt-20210201monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-recognized-as-one-of-fortune-s-2021-world-s-most-admired-companies-medtronic-plc-mdt-20210201monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-receives-fda-approval-of-diamondtemp-ablation-system-for-the-treatment-of-patien-mdt-20210129monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-launches-first-of-its-kind-adaptive-deep-brain-stimulation-adbs-trial-in-parkins-mdt-20210114monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-chairman-and-ceo-geoff-martha-to-speak-at-j-p-morgan-healthcare-conference-medtr-mdt-20210104monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-strengthens-leadership-in-navigated-robotic-spine-surgery-with-fda-clearance-of--mdt-20201216monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-s-osteocool-procedure-shows-significant-swift-pain-relief-and-sustained-improvem-mdt-20201215monthly0.5https://www.biopharmawatch.com/news/MDT/sean-salmon-named-evp-president-cardiovascular-portfolio-continues-as-evp-president-diabet-mdt-20201214monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-cash-dividend-for-third-quarter-of-fiscal-year-2021-the-board-of-direc-mdt-20201214monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-launches-the-first-and-only-pediatric-and-neonatal-acute-dialysis-machine-in-the-mdt-20201208monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-svp-of-strategy-mike-weinstein-to-speak-at-evercore-isi-healthcare-conference-me-mdt-20201201monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-evp-president-of-cardiovascular-portfolio-mike-coyle-to-speak-at-piper-sandler-h-mdt-20201130monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-and-the-medtronic-foundation-expand-covid-19-support-to-more-than-46-million-usd-mdt-20201130monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-reports-second-quarter-fiscal-2021-financial-results-medtronic-plc-nyse-mdt-toda-mdt-20201124monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-to-announce-financial-results-for-its-second-quarter-of-fiscal-year-2021-medtron-mdt-20201117monthly0.5https://www.biopharmawatch.com/news/MDT/the-new-england-journal-of-medicine-medtronic-cryoablation-is-a-superior-treatment-option--mdt-20201116monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-completes-acquisition-of-medicrea-medtronic-plc-nyse-mdt-the-global-leader-in-me-mdt-20201116monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-ranked-as-a-leading-sustainability-company-medtronic-plc-nyse-mdt-the-global-lea-mdt-20201113monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-launches-inpen-with-real-time-guardian-connect-cgm-data-the-first-integrated-sma-mdt-20201112monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-expands-ent-portfolio-with-fda-clearance-of-nim-vital-next-generation-intraopera-mdt-20201029monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-venous-stent-receives-u-s-fda-approval-to-treat-venous-outflow-obstruction-medtr-mdt-20201026monthly0.5https://www.biopharmawatch.com/news/MDT/patients-report-superior-sustained-and-profound-back-pain-relief-at-12-months-with-dtm-spi-mdt-20201020monthly0.5https://www.biopharmawatch.com/news/MDT/nine-month-results-from-medtronic-in-pact-btk-study-presented-in-late-breaking-clinical-tr-mdt-20201018monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-partnership-with-the-foundry-to-develop-innovative-mitral-valve-repair-mdt-20201014monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-named-one-of-america-s-most-just-companies-by-forbes-and-just-capital-medtronic--mdt-20201014monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-launches-head-to-head-tavr-study-comparing-the-evolut-tavr-platform-against-the--mdt-20201014monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-outlines-growth-strategy-at-biennial-investor-day-medtronic-plc-nyse-mdt-the-glo-mdt-20201014monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-2020-integrated-performance-report-shares-goal-of-carbon-neutrality-by-fy30-achi-mdt-20201013monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-donates-nearly-1-million-in-personal-protective-equipment-to-international-medic-mdt-20201009monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-adaptix-interbody-system-the-first-navigated-titanium-cage-with-titan--mdt-20201007monthly0.5https://www.biopharmawatch.com/news/MDT/omar-ishrak-to-retire-as-medtronic-executive-chairman-and-chairman-of-the-board-geoff-mart-mdt-20201006monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-first-patient-implanted-in-elite-study-of-interstim-micro-medtronic-pl-mdt-20201006monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-virtual-2020-institutional-investor-and-analyst-event-and-webcast-medt-mdt-20201005monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-resolute-onyx-drug-eluting-stent-des-first-to-receive-one-month-dapt-labeling-in-mdt-20201001monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-to-acquire-avenu-medical-medtronic-plc-nyse-mdt-the-global-leader-in-medical-tec-mdt-20200930monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-closing-of-public-offering-of-6-25-billion-of-senior-notes-and-redempt-mdt-20200929monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-gets-affirmation-of-key-sacral-neuromodulation-patent-medtronic-nyse-mdt-has-won-mdt-20200925monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-pricing-of-6-25-billion-of-senior-notes-medtronic-plc-the-company-nyse-mdt-20200924monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-evaluates-insertable-cardiac-monitor-in-identifying-patients-at-high-risk-of-wor-mdt-20200923monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-receives-fda-breakthrough-device-designation-for-tyrx-driveline-wrap-device-medt-mdt-20200922monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-tyrx-absorbable-antibacterial-envelope-is-cost-effective-for-patients-at-increas-mdt-20200916monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-ceo-geoff-martha-to-speak-at-morgan-stanley-global-healthcare-conference-medtron-mdt-20200911monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-study-finds-opioid-induced-respiratory-depression-in-the-hospital-more-common-an-mdt-20200910monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-receives-breakthrough-device-designation-from-fda-begins-early-feasibility-study-mdt-20200909monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-evp-cfo-karen-l-parkhill-to-participate-in-the-wells-fargo-securities-2020-virtu-mdt-20200904monthly0.5https://www.biopharmawatch.com/news/MDT/medtronic-announces-fda-approval-for-minimed-770g-insulin-pump-system-with-smartphone-conn-mdt-20200901monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-introduces-the-first-distributed-whole-genome-sequencing-solution-for-highly-sens-ilmn-20260528monthly0.5https://www.biopharmawatch.com/news/ILMN/david-p-king-elected-to-illumina-s-board-of-directors-illumina-inc-nasdaq-ilmn-today-confi-ilmn-20260521monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-reports-financial-results-for-first-quarter-of-fiscal-year-2026-illumina-inc-nasd-ilmn-20260430monthly0.5https://www.biopharmawatch.com/news/ILMN/dragen-v4-5-supports-illumina-s-new-trupath-genome-and-5-base-assays-drives-insights-acros-ilmn-20260416monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-webcast-upcoming-investor-conference-illumina-inc-nasdaq-ilmn-today-announced--ilmn-20260217monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-announce-fourth-quarter-and-full-year-2025-financial-results-on-thursday-febru-ilmn-20260112monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-appoints-dr-eric-green-as-chief-medical-officer-today-illumina-inc-nasdaq-ilmn-an-ilmn-20260108monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-launches-powerful-software-for-connected-intuitive-and-scalable-multiomic-analysi-ilmn-20260106monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-launches-new-business-to-accelerate-technology-and-data-driven-discovery-illumina-ilmn-20251001monthly0.5https://www.biopharmawatch.com/news/ILMN/alnylam-pharmaceuticals-joins-alliance-for-genomic-discovery-expanding-diverse-clinical-ge-ilmn-20250918monthly0.5https://www.biopharmawatch.com/news/ILMN/lancement-d-illumina-protein-prep-pour-ame-liorer-les-connaissances-prote-omiques-et-facil-ilmn-20250908monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-protein-prep-daha-iyi-ilac-kes-fi-ve-gelis-tirilmesi-ic-in-daha-fazla-proteomik-i-ilmn-20250907monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-protein-prep-bringt-neue-erkenntnisse-aus-der-proteomik-fu-r-eine-verbesserte-arz-ilmn-20250907monthly0.5https://www.biopharmawatch.com/news/ILMN/se-lanza-illumina-protein-prep-para-impulsar-mayores-conocimientos-proteo-micos-se-lanza-i-ilmn-20250903monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-protein-prep-launches-to-drive-greater-proteomic-insights-for-improved-drug-disco-ilmn-20250903monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-reports-financial-results-for-second-quarter-of-fiscal-year-2025-revenue-of-1-06--ilmn-20250731monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-enhances-flagship-assay-to-accelerate-access-to-comprehensive-tumor-profiling-ill-ilmn-20250730monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-announce-second-quarter-2025-financial-results-on-thursday-july-31-2025-illumi-ilmn-20250710monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-named-to-time-s-world-s-most-sustainable-companies-list-for-the-second-consecutiv-ilmn-20250710monthly0.5https://www.biopharmawatch.com/news/ILMN/lllumina-releases-2024-corporate-social-responsibility-report-as-it-advances-its-vision-to-ilmn-20250610monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-unveils-promoterai-a-groundbreaking-algorithm-to-accelerate-insights-for-rare-dis-ilmn-20250529monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-expands-clinical-oncology-portfolio-unlocking-new-standard-of-care-and-access-to--ilmn-20250528monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-webcast-upcoming-investor-conference-illumina-inc-nasdaq-ilmn-today-announced--ilmn-20250514monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-dragen-v4-4-powers-clinical-oncology-research-and-multiomic-applications-illumina-ilmn-20250513monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-reports-financial-results-for-first-quarter-of-fiscal-year-2025-core-illumina-rev-ilmn-20250508monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-and-ovation-io-launching-first-of-kind-glp-1-dataset-to-accelerate-new-therapy-de-ilmn-20250501monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-and-tempus-partner-to-drive-the-future-of-precision-medicine-through-genomic-ai-i-ilmn-20250415monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-announce-first-quarter-2025-financial-results-on-thursday-may-8-2025-illumina--ilmn-20250410monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-board-of-directors-elects-dr-scott-gottlieb-chair-keith-meister-to-join-board-of--ilmn-20250325monthly0.5https://www.biopharmawatch.com/news/ILMN/alliance-for-genomic-discovery-completes-250-000-whole-genomes-to-accelerate-drug-discover-ilmn-20250319monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-addresses-recent-developments-in-china-illumina-inc-nasdaq-ilmn-illumina-or-the-c-ilmn-20250310monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-named-to-dow-jones-best-in-class-indices-for-sixth-consecutive-year-and-as-a-sust-ilmn-20250306monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-transforms-multiomic-research-with-new-technologies-to-unlock-deeper-understandin-ilmn-20250224monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-and-broad-clinical-labs-usher-in-new-era-of-drug-discovery-with-collaboration-to--ilmn-20250221monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-unveils-first-of-its-kind-spatial-transcriptomics-technology-illumina-inc-nasdaq--ilmn-20250219monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-webcast-upcoming-investor-session-at-the-advances-in-genome-biology-and-techno-ilmn-20250218monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-reports-financial-results-for-fourth-quarter-and-fiscal-year-2024-core-illumina-r-ilmn-20250206monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-announces-preliminary-unaudited-financial-results-for-fourth-quarter-and-fiscal-y-ilmn-20250114monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-and-nvidia-collaborate-to-decode-biology-and-propel-precision-health-illumina-inc-ilmn-20250113monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-launches-pilot-proteomics-program-with-uk-biobank-and-biopharma-collaborators-to--ilmn-20250113monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-announce-fourth-quarter-and-full-year-2024-financial-results-on-thursday-febru-ilmn-20250109monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-advances-novaseq-x-series-delivering-single-flow-cell-system-software-upgrade-and-ilmn-20250107monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-webcast-upcoming-investor-conference-illumina-inc-nasdaq-ilmn-today-announced--ilmn-20241204monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-announces-expansion-of-trusight-oncology-portfolio-illumina-inc-nasdaq-ilmn-a-glo-ilmn-20241119monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-webcast-upcoming-investor-conferences-illumina-inc-nasdaq-ilmn-today-announced-ilmn-20241106monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-reports-financial-results-for-third-quarter-of-fiscal-year-2024-core-illumina-rev-ilmn-20241104monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-preview-newest-innovations-in-ngs-and-multiomic-technologies-at-the-american-s-ilmn-20241031monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-introduces-the-miseq-i100-series-its-simplest-fastest-benchtop-sequencers-illumin-ilmn-20241009monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-announce-third-quarter-2024-financial-results-on-monday-november-4-2024-illumi-ilmn-20241007monthly0.5https://www.biopharmawatch.com/news/ILMN/charles-dadswell-to-step-down-as-general-counsel-illumina-initiates-search-for-successor-i-ilmn-20241003monthly0.5https://www.biopharmawatch.com/news/ILMN/european-court-of-justice-rules-in-favor-of-illumina-in-jurisdictional-appeal-illumina-inc-ilmn-20240903monthly0.5https://www.biopharmawatch.com/news/ILMN/fda-approves-illumina-cancer-biomarker-test-with-two-companion-diagnostics-to-rapidly-matc-ilmn-20240827monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-announces-strategy-to-accelerate-value-creation-company-poised-to-accelerate-reve-ilmn-20240813monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-reports-financial-results-for-second-quarter-of-fiscal-year-2024-core-illumina-re-ilmn-20240806monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-launches-new-oncology-menu-for-novaseq-x-series-customers-illumina-inc-nasdaq-ilm-ilmn-20240805monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-present-upcoming-strategy-update-as-illumina-inc-nasdaq-ilmn-previously-announ-ilmn-20240718monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-announce-second-quarter-2024-financial-results-on-tuesday-august-6-2024-as-ill-ilmn-20240711monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-acquires-fluent-biosciences-to-accelerate-single-cell-analysis-and-discovery-to-a-ilmn-20240709monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-completes-the-divestiture-of-grail-illumina-inc-nasdaq-ilmn-today-announced-the-s-ilmn-20240624monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-dragen-v4-3-powers-most-comprehensive-accurate-genome-with-industry-leading-innov-ilmn-20240611monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-launches-latest-chemistry-across-most-popular-mid-throughput-sequencers-enabling--ilmn-20240604monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-board-of-directors-approves-spin-off-of-grail-declares-spin-off-dividend-of-grail-ilmn-20240603monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-appoints-everett-cunningham-chief-commercial-officer-illumina-inc-nasdaq-ilmn-a-g-ilmn-20240603monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-drives-genomic-testing-as-standard-of-care-in-oncology-through-collaborative-rese-ilmn-20240529monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-releases-2023-corporate-social-responsibility-report-illumina-inc-nasdaq-ilmn-a-g-ilmn-20240528monthly0.5https://www.biopharmawatch.com/news/ILMN/anna-richo-joins-illumina-s-board-of-directors-illumina-inc-nasdaq-ilmn-announced-today-th-ilmn-20240520monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-webcast-upcoming-investor-conference-illumina-inc-nasdaq-ilmn-today-announced--ilmn-20240515monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-publicly-files-form-10-registration-statement-ahead-of-planned-divestiture-of-gra-ilmn-20240506monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-webcast-upcoming-investor-conference-illumina-inc-nasdaq-ilmn-today-announced--ilmn-20240503monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-reports-financial-results-for-first-quarter-of-fiscal-year-2024-core-illumina-rev-ilmn-20240502monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-s-planned-divestment-of-grail-approved-by-the-european-commission-illumina-inc-na-ilmn-20240412monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-appoints-ankur-dhingra-chief-financial-officer-jakob-wedel-chief-strategy-and-cor-ilmn-20240409monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-announce-first-quarter-2024-financial-results-on-thursday-may-2-2024-illumina--ilmn-20240404monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-reports-financial-results-for-fourth-quarter-and-fiscal-year-2023-revenue-of-1-12-ilmn-20240208monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-announces-preliminary-financial-results-for-fourth-quarter-and-fiscal-year-2023-i-ilmn-20240109monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-expands-collaboration-with-janssen-to-advance-molecular-residual-disease-cancer-t-ilmn-20240105monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-announce-fourth-quarter-and-full-year-2023-financial-results-on-thursday-febru-ilmn-20240104monthly0.5https://www.biopharmawatch.com/news/ILMN/the-alliance-for-genomic-discovery-welcomes-bristol-myers-squibb-gsk-and-novo-nordisk-illu-ilmn-20240104monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-webcast-upcoming-investor-conference-illumina-inc-nasdaq-ilmn-today-announced--ilmn-20231219monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-announces-decision-to-divest-grail-today-illumina-inc-nasdaq-ilmn-announced-that--ilmn-20231217monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-submits-form-10-to-the-securities-and-exchange-commission-illumina-inc-nasdaq-ilm-ilmn-20231211monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-webcast-upcoming-investor-conferences-illumina-inc-nasdaq-ilmn-today-announced-ilmn-20231114monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-launches-global-health-access-initiative-to-support-acceleration-of-pathogen-sequ-ilmn-20231113monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-reports-financial-results-for-third-quarter-of-fiscal-year-2023-welcomed-new-ceo--ilmn-20231109monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-launches-advanced-liquid-biopsy-assay-to-enable-comprehensive-genomic-profiling-o-ilmn-20231101monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-responds-to-european-commission-s-divestiture-order-illumina-inc-nasdaq-ilmn-has--ilmn-20231013monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-posted-a-stewardship-focused-presentation-for-investors-illumina-inc-nasdaq-ilmn--ilmn-20231011monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-announce-third-quarter-2023-financial-results-on-thursday-november-9-2023-illu-ilmn-20231005monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-s-board-appoints-jacob-thaysen-ph-d-as-its-new-chief-executive-officer-illumina-i-ilmn-20230905monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-webcast-upcoming-investor-conference-illumina-inc-nasdaq-ilmn-today-announced--ilmn-20230828monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-expands-genomics-capabilities-in-india-with-opening-of-solutions-center-illumina--ilmn-20230817monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-webcast-upcoming-investor-conference-illumina-inc-nasdaq-ilmn-today-announced--ilmn-20230811monthly0.5https://www.biopharmawatch.com/news/ILMN/dr-steven-barnard-appointed-chief-technology-officer-illumina-inc-nasdaq-ilmn-a-global-lea-ilmn-20230809monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-reports-financial-results-for-second-quarter-of-fiscal-year-2023-revenue-of-1-18--ilmn-20230809monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-and-pillar-biosciences-partner-to-improve-access-to-personalized-cancer-treatment-ilmn-20230725monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-announce-second-quarter-2023-financial-results-on-wednesday-august-9-2023-illu-ilmn-20230718monthly0.5https://www.biopharmawatch.com/news/ILMN/the-alliance-for-genomic-discovery-announces-founding-biopharma-members-abbvie-amgen-astra-ilmn-20230718monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-dragen-4-2-delivers-most-accurate-and-comprehensive-coverage-of-the-genome-poweri-ilmn-20230711monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-announces-ceo-transition-plan-illumina-inc-nasdaq-ilmn-a-global-leader-in-dna-seq-ilmn-20230611monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-releases-2022-corporate-social-responsibility-report-illumina-inc-nasdaq-ilmn-a-g-ilmn-20230605monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-s-board-of-directors-elects-two-experienced-independent-directors-to-board-illumi-ilmn-20230602monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-unveils-ai-software-to-predict-disease-causing-genetic-mutations-in-patients-illu-ilmn-20230601monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-host-third-annual-virtual-esg-investor-event-on-monday-june-12-2023-illumina-i-ilmn-20230531monthly0.5https://www.biopharmawatch.com/news/ILMN/real-world-study-data-reveals-better-outcomes-for-cancer-patients-who-receive-comprehensiv-ilmn-20230530monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-board-chair-issues-letter-to-shareholders-and-urges-shareholders-to-vote-the-whit-ilmn-20230518monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-s-genomic-technologies-enable-better-pathogen-preparedness-and-response-illumina--ilmn-20230516monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-sends-letter-to-shareholders-detailing-why-illumina-s-nominees-far-outmatch-icahn-ilmn-202305152023-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/leading-proxy-advisory-firm-iss-recommends-illumina-shareholders-vote-for-eight-of-illumin-ilmn-202305122023-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-sends-letter-to-shareholders-highlighting-board-strength-weakness-of-icahn-s-plan-ilmn-202305082023-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-increases-equitable-access-to-stem-education-reaching-over-1-million-learners-ill-ilmn-202305022023-05-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-issues-shareholder-letter-and-requests-shareholders-vote-for-the-illumina-directo-ilmn-202305012023-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-reports-financial-results-for-first-quarter-of-fiscal-year-2023-announces-commitm-ilmn-202304252023-04-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-urges-shareholders-to-vote-the-white-proxy-card-for-all-nine-of-illumina-s-nomine-ilmn-202304202023-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-s-cloud-based-informatics-programs-recognized-for-robust-international-data-priva-ilmn-202304122023-04-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-and-henry-ford-health-team-up-to-study-impact-of-comprehensive-genomic-testing-fo-ilmn-202304112023-04-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-celebrates-25-years-of-innovation-illumina-inc-nasdaq-ilmn-a-global-leader-in-dna-ilmn-202304052023-04-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-announce-first-quarter-2023-financial-results-on-tuesday-april-25-2023-illumin-ilmn-202304042023-04-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-s-revolutionary-novaseq-x-exceeds-200th-order-milestone-in-first-quarter-2023-ill-ilmn-202304042023-04-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-will-appeal-ftc-decision-in-federal-court-will-seek-us-resolution-by-late-2023-or-ilmn-202304032023-04-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-files-preliminary-proxy-urging-shareholders-to-vote-for-its-director-nominees-and-ilmn-202303302023-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-launches-new-software-to-enable-tertiary-analysis-for-oncology-applications-and-s-ilmn-202303272023-03-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-issues-statement-in-response-to-carl-icahn-s-letter-illumina-inc-nasdaq-ilmn-a-gl-ilmn-202303242023-03-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-underscores-commitment-to-shareholder-value-and-responds-to-carl-icahn-s-statemen-ilmn-202303202023-03-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-launches-its-first-product-enabling-long-and-short-read-sequencing-on-one-instrum-ilmn-202303142023-03-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-responds-to-icahn-partners-nomination-of-directors-illumina-inc-nasdaq-ilmn-a-glo-ilmn-202303132023-03-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-and-myriad-genetics-expand-partnership-to-broaden-access-to-hrd-testing-in-the-un-ilmn-202303022023-03-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-webcast-upcoming-investor-conference-illumina-inc-nasdaq-ilmn-today-announced--ilmn-202302272023-02-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-liefert-erstes-novaseq-x-plus-sequenziergera-t-an-das-broad-institute-illumina-in-ilmn-202302092023-02-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-delivers-first-novaseq-x-plus-sequencer-to-the-broad-institute-illumina-inc-nasda-ilmn-202302082023-02-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-livre-le-premier-se-quenceur-novaseq-x-plus-au-broad-institute-illumina-inc-nasda-ilmn-202302082023-02-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-entrega-el-primer-secuenciador-novaseq-x-plus-al-broad-institute-illumina-inc-nas-ilmn-202302082023-02-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-entrega-primeiro-sequenciador-novaseq-x-plus-para-broad-institute-a-illumina-inc--ilmn-202302082023-02-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-reports-financial-results-for-fourth-quarter-and-fiscal-year-2022-revenue-of-1-08-ilmn-202302072023-02-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-appoints-joydeep-goswami-chief-financial-officer-illumina-inc-nasdaq-ilmn-a-globa-ilmn-202302012023-02-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-announce-fourth-quarter-and-full-year-2022-financial-results-on-tuesday-februa-ilmn-202301102023-01-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-and-nashville-biosciences-announce-sequencing-agreement-with-amgen-illumina-inc-n-ilmn-202301092023-01-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-webcast-upcoming-investor-conference-illumina-inc-nasdaq-ilmn-today-announced--ilmn-20221219monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-ranks-among-top-scores-on-dow-jones-sustainability-index-and-cdp-illumina-inc-nas-ilmn-20221214monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-webcast-upcoming-investor-conferences-illumina-inc-nasdaq-ilmn-today-announced-ilmn-20221115monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-reports-financial-results-for-third-quarter-of-fiscal-year-2022-revenue-of-1-12-b-ilmn-20221103monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-introduces-new-research-test-to-address-one-of-the-most-common-infections-in-the--ilmn-20221101monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-et-genoscreen-font-cause-commune-pour-e-largir-l-acce-s-au-de-pistage-ge-nomique--ilmn-20221018monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-and-genoscreen-partner-to-expand-access-to-genomic-testing-for-multidrug-resistan-ilmn-20221018monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-host-second-annual-virtual-esg-investor-event-on-friday-october-28-2022-illumi-ilmn-20221017monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-launches-strategic-research-collaboration-with-astrazeneca-to-accelerate-drug-tar-ilmn-20221011monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-announce-third-quarter-2022-financial-results-on-thursday-november-3-2022-illu-ilmn-20221006monthly0.5https://www.biopharmawatch.com/news/ILMN/revolutiona-re-novaseq-x-serie-von-illumina-rasche-beschleunigung-genomischer-entdeckungen-ilmn-20220930monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-de-voile-la-se-rie-re-volutionnaire-novaseq-x-pour-acce-le-rer-les-de-couvertes-g-ilmn-20220930monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-revela-la-revolucionaria-novaseq-x-series-para-acelerar-ra-pidamente-los-descubri-ilmn-20220929monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-introduces-multiple-breakthrough-sequencing-innovations-at-inaugural-genomics-for-ilmn-20220929monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-lanc-a-a-revoluciona-ria-se-rie-novaseq-x-para-acelerar-as-descobertas-geno-micas-ilmn-20220929monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-presenta-la-revolucionaria-serie-novaseq-x-para-acelerar-los-descubrimientos-geno-ilmn-20220929monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-unveils-revolutionary-novaseq-x-series-to-rapidly-accelerate-genomic-discoveries--ilmn-20220929monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-genomics-forum-sold-out-announces-opportunity-to-view-innovation-roadmap-session--ilmn-20220926monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-host-upcoming-investor-day-illumina-inc-nasdaq-ilmn-will-host-its-2022-investo-ilmn-20220919monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-genomics-forum-to-feature-nobel-laureate-frances-arnold-as-part-of-distinguished--ilmn-20220919monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-accelerator-invests-in-the-fifth-global-funding-cycle-of-startups-advancing-break-ilmn-20220914monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-genomics-forum-to-convene-leading-visionaries-to-explore-architecting-health-s-ra-ilmn-20220912monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-announces-opportunity-to-view-live-webcast-of-illumina-genomics-forum-innovation--ilmn-20220908monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-genomics-forum-to-feature-diverse-lineup-of-visionary-global-leaders-illumina-inc-ilmn-20220907monthly0.5https://www.biopharmawatch.com/news/ILMN/neueste-forschungsergebnisse-auf-dem-esmo-kongress-2022-zeigen-die-bedeutung-umfassender-g-ilmn-20220907monthly0.5https://www.biopharmawatch.com/news/ILMN/les-dernie-res-recherches-pre-sente-es-lors-de-l-e-dition-2022-du-congre-s-de-l-esmo-mette-ilmn-20220907monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-intends-to-appeal-european-commission-s-decision-in-grail-deal-illumina-inc-nasda-ilmn-20220906monthly0.5https://www.biopharmawatch.com/news/ILMN/congreso-esmo-2022-perfiles-geno-micos-integrales-para-pacientes-con-ca-ncer-illumina-inc--ilmn-20220905monthly0.5https://www.biopharmawatch.com/news/ILMN/administrative-law-judge-rules-in-favor-of-illumina-in-ftc-challenge-of-grail-deal-illumin-ilmn-20220901monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-deepens-commitment-to-customers-in-china-with-new-manufacturing-site-illumina-inc-ilmn-20220830monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-genomics-forum-to-feature-tennis-legend-chris-evert-on-the-role-genomics-played-i-ilmn-20220829monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-genomics-forum-to-feature-23andme-co-founder-and-ceo-anne-wojcicki-illumina-inc-n-ilmn-20220822monthly0.5https://www.biopharmawatch.com/news/ILMN/minderoo-foundation-and-illumina-commit-40m-aud-to-apply-advanced-genomics-to-marine-conse-ilmn-20220816monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-genomics-forum-to-feature-american-cancer-society-ceo-karen-knudsen-on-the-future-ilmn-20220815monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-reports-financial-results-for-second-quarter-of-fiscal-year-2022-revenue-of-1-16--ilmn-20220811monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-genomics-forum-to-feature-bill-gates-and-distinguished-health-leaders-addressing--ilmn-20220808monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-unveils-its-most-accurate-and-comprehensive-secondary-analysis-platform-boosting--ilmn-20220727monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-announces-inaugural-illumina-genomics-forum-with-a-conversation-with-former-u-s-p-ilmn-20220718monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-figure-parmi-les-premie-res-entreprises-au-monde-a-recevoir-l-approbation-de-ses--ilmn-20220714monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-erha-lt-als-eines-der-ersten-unternehmen-weltweit-die-genehmigung-fu-r-das-wissen-ilmn-20220714monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-announce-second-quarter-2022-financial-results-on-thursday-august-11-2022-illu-ilmn-20220714monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-entre-los-primeros-en-el-mundo-en-recibir-la-aprobacio-n-del-science-based-net-ze-ilmn-20220714monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-among-first-in-the-world-to-receive-approval-of-science-based-net-zero-target-ill-ilmn-20220714monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-investit-dans-un-fonds-de-capital-risque-de-30-millions-de-livres-sterling-pour-f-ilmn-20220630monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-investiert-in-einen-30-millionen-pfund-venture-fonds-um-bahnbrechende-entwicklung-ilmn-20220630monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-invierte-en-un-fondo-de-riesgo-de-30-millones-de-libras-esterlinas-illumina-inc-n-ilmn-20220628monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-invests-in-30m-venture-fund-to-advance-breakthroughs-in-human-health-illumina-inc-ilmn-20220628monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-lance-un-test-de-recherche-de-veloppe-en-collaboration-avec-merck-pour-mieux-comp-ilmn-20220622monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-lanc-a-teste-de-pesquisa-desenvolvido-em-conjunto-com-a-merck-para-revelar-dados--ilmn-20220622monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-lanza-una-prueba-de-investigacio-n-desarrollada-en-conjunto-con-merck-illumina-in-ilmn-20220622monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-launches-research-test-codeveloped-with-merck-to-unlock-deeper-insights-into-the--ilmn-20220622monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-bringt-gemeinsam-mit-merck-entwickelten-forschungstest-auf-den-markt-um-tiefere-e-ilmn-20220622monthly0.5https://www.biopharmawatch.com/news/ILMN/joydeep-goswami-appointed-interim-cfo-sam-samad-to-depart-illumina-illumina-inc-nasdaq-ilm-ilmn-20220609monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-announces-next-generation-products-and-data-at-agbt-general-meeting-to-advance-in-ilmn-20220607monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-showcase-the-transformational-impact-of-comprehensive-genomic-profiling-in-unl-ilmn-20220602monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-introduces-new-pan-cancer-companion-diagnostic-to-match-patients-with-rare-geneti-ilmn-20220524monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-and-allegheny-health-network-to-assess-in-house-comprehensive-cancer-genomic-prof-ilmn-20220518monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-reports-financial-results-for-first-quarter-of-fiscal-year-2022-illumina-inc-nasd-ilmn-20220505monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-and-deerfield-management-partner-to-accelerate-drug-development-illumina-inc-nasd-ilmn-20220505monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-webcast-upcoming-investor-conference-illumina-inc-nasdaq-ilmn-today-announced--ilmn-20220428monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-supports-leading-german-hospital-to-accelerate-genetic-disease-diagnosis-in-criti-ilmn-20220425monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-apoya-el-diagno-stico-de-enfermedades-gene-ticas-en-nin-os-gravemente-enfermos-il-ilmn-20220425monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-unterstu-tzt-fu-hrendes-deutsches-krankenhaus-bei-der-beschleunigung-der-diagnose-ilmn-20220425monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-apporte-son-soutien-a-un-grand-ho-pital-allemand-pour-acce-le-rer-le-diagnostic-d-ilmn-20220425monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-announce-first-quarter-2022-financial-results-on-thursday-may-5-2022-illumina--ilmn-20220414monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-ampli-a-el-acceso-a-la-geno-mica-en-latinoame-rica-a-trave-s-de-un-nuevo-centro-d-ilmn-20220413monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-amplia-o-acesso-a-geno-mica-na-ame-rica-latina-por-meio-de-um-novo-e-avanc-ado-ce-ilmn-20220413monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-expands-access-to-genomics-in-latin-america-through-new-state-of-the-art-solution-ilmn-20220412monthly0.5https://www.biopharmawatch.com/news/ILMN/john-frank-joins-illumina-as-chief-public-affairs-officer-illumina-inc-nasdaq-ilmn-a-globa-ilmn-20220411monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-releases-annual-corporate-social-responsibility-report-illumina-inc-nasdaq-ilmn-a-ilmn-20220407monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-de-voile-un-test-re-volutionnaire-de-profilage-ge-nomique-complet-pour-le-cancer--ilmn-20220316monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-stellt-bahnbrechenden-test-fu-r-umfassendes-genomisches-profiling-bei-krebs-in-eu-ilmn-20220316monthly0.5https://www.biopharmawatch.com/news/ILMN/spoloc-nost-illumina-predstavila-prelomovy-komplexny-test-genomicke-ho-profilovania-rakovi-ilmn-20220316monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-svela-un-innovativo-test-completo-per-la-profilazione-genomica-del-tumore-in-euro-ilmn-20220316monthly0.5https://www.biopharmawatch.com/news/ILMN/spolec-nost-illumina-pr-edstavila-v-evrope-pr-elomovy-komplexni-test-pro-genomove-profilov-ilmn-20220316monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-accelerator-invests-in-seven-omics-startups-advancing-breakthrough-therapeutics-d-ilmn-20220316monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-prezentuje-w-europie-prze-omowy-kompleksowy-test-profilowania-genomowego-pod-ka-t-ilmn-20220315monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-presenta-en-europa-una-innovadora-prueba-integral-de-perfilado-geno-mico-para-el--ilmn-20220315monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-unveils-groundbreaking-comprehensive-genomic-profiling-test-for-cancer-in-europe--ilmn-20220315monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-welcomes-carissa-rollins-as-chief-information-officer-illumina-inc-nasdaq-ilmn-an-ilmn-20220314monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-webcast-upcoming-investor-conference-illumina-inc-nasdaq-ilmn-today-announced--ilmn-20220221monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-reports-financial-results-for-fourth-quarter-and-fiscal-year-2021-illumina-inc-na-ilmn-20220210monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-webcast-upcoming-investor-conferences-illumina-inc-nasdaq-ilmn-today-announced-ilmn-20220203monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-partners-with-centers-across-france-to-advance-a-precision-medicine-approach-for--ilmn-20220203monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-collaborates-with-national-cancer-center-japan-to-address-a-leading-cause-of-deat-ilmn-20220124monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-announce-fourth-quarter-full-year-2021-financial-results-on-thursday-february--ilmn-20220120monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-collaborates-with-nashville-biosciences-to-accelerate-medicines-development-illum-ilmn-20220110monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-partners-with-agendia-to-expand-genomic-testing-in-breast-cancer-care-illumina-in-ilmn-20220110monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-and-boehringer-ingelheim-announce-companion-diagnostic-partnership-illumina-inc-n-ilmn-20220110monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-delivers-2021-results-ahead-of-expectations-strong-2022-guidance-and-deep-pipelin-ilmn-20220110monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-enters-co-development-partnership-with-somalogic-illumina-inc-nasdaq-ilmn-today-a-ilmn-20220105monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-webcast-upcoming-investor-conference-illumina-inc-nasdaq-ilmn-today-announced--ilmn-20211223monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-supports-norway-s-pioneering-precision-medicine-study-illumina-inc-nasdaq-ilmn-to-ilmn-20211209monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-and-sequoia-capital-china-select-first-startups-to-join-genomics-incubator-in-chi-ilmn-20211117monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-and-genetic-alliance-launch-120-million-global-initiative-to-increase-equity-and--ilmn-20211116monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-reports-financial-results-for-third-quarter-of-fiscal-year-2021-illumina-inc-nasd-ilmn-20211104monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-supports-canada-s-nationwide-covid-19-genome-sequencing-initiative-illumina-inc-n-ilmn-20211103monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-supports-israel-s-national-program-to-accelerate-diagnoses-of-critically-ill-newb-ilmn-20211027monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-host-inaugural-esg-investor-event-on-tuesday-november-16-2021-illumina-inc-nas-ilmn-20211020monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-appoints-bob-ragusa-as-chief-executive-officer-ceo-of-grail-illumina-inc-nasdaq-i-ilmn-20211014monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-announce-third-quarter-2021-financial-results-on-thursday-november-4-2021-illu-ilmn-20211013monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-ampli-a-su-presencia-en-latinoame-rica-illumina-inc-nasdaq-ilmn-anuncio-la-creaci-ilmn-20210930monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-expands-presence-in-latin-america-illumina-inc-nasdaq-ilmn-announced-the-creation-ilmn-20210930monthly0.5https://www.biopharmawatch.com/news/ILMN/randomized-trial-demonstrates-whole-genome-sequencing-leads-to-precision-care-for-critical-ilmn-20210927monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-accelerator-invests-in-seven-genomics-startups-for-third-global-cycle-illumina-in-ilmn-20210915monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-commits-to-net-zero-global-greenhouse-gas-emissions-by-2050-illumina-inc-nasdaq-i-ilmn-20210909monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-partners-with-merck-to-develop-and-commercialize-companion-diagnostic-and-researc-ilmn-20210907monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-to-webcast-upcoming-investor-conference-illumina-inc-nasdaq-ilmn-today-announced--ilmn-20210830monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-reports-financial-results-for-second-quarter-of-fiscal-year-2021-illumina-inc-nas-ilmn-20210805monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-donates-1-million-in-sequencing-capabilities-to-mumbai-to-support-sequencing-base-ilmn-20210803monthly0.5https://www.biopharmawatch.com/news/ILMN/illumina-celebrates-grand-opening-of-its-solutions-center-in-the-university-of-maryland-bi-ilmn-20191029monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-to-outline-its-vision-for-sustained-revenue-and-earnings-growth-through-2030-growi-vtrs-20260319monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-provides-pipeline-update-on-four-regulatory-milestones-viatris-inc-nasdaq-vtrs-a-g-vtrs-20251218monthly0.5https://www.biopharmawatch.com/news/VTRS/evropska-studie-ukazuje-klesaji-ci-ceny-rostouci-na-klady-a-nedostatek-vy-sledky-neza-visl-vtrs-20251119monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-recognized-as-one-of-the-fortune-world-s-best-workplaces-in-2025-viatris-inc-nasda-vtrs-20251113monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-announces-quarterly-dividend-viatris-inc-nasdaq-vtrs-today-announced-that-on-novem-vtrs-20251104monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-completes-acquisition-of-aculys-pharma-including-exclusive-rights-to-pitolisant-in-vtrs-20251015monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-to-participate-in-upcoming-investor-conferences-viatris-inc-nasdaq-vtrs-a-global-h-vtrs-20251013monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-named-to-forbes-annual-list-of-the-world-s-best-employers-for-the-fifth-year-in-a--vtrs-20251008monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-to-report-third-quarter-2025-financial-results-on-november-6-2025-viatris-inc-nasd-vtrs-20251001monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-appoints-andrew-enrietti-as-chief-administrative-and-transformation-officer-viatri-vtrs-20250819monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-announces-approval-of-first-generic-iron-sucrose-injection-in-the-u-s-viatris-inc--vtrs-20250811monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-reports-second-quarter-2025-results-and-reiterates-2025-financial-guidance-deliver-vtrs-20250807monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-announces-quarterly-dividend-viatris-inc-nasdaq-vtrs-today-announced-that-on-augus-vtrs-20250805monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-announces-five-data-presentations-on-novel-fast-acting-meloxicam-mr-107a-02-at-pai-vtrs-20250801monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-provides-update-on-phase-3-study-of-mr-139-for-blepharitis-viatris-inc-nasdaq-vtrs-vtrs-20250718monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-announces-positive-top-line-results-from-second-pivotal-phase-3-vega-3-trial-of-mr-vtrs-20250626monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-to-report-second-quarter-2025-financial-results-on-august-7-2025-viatris-inc-nasda-vtrs-20250612monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-announces-positive-top-line-results-from-phase-3-lynx-2-trial-of-mr-142-in-kerator-vtrs-20250602monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-to-participate-in-upcoming-investor-conferences-viatris-inc-nasdaq-vtrs-a-global-h-vtrs-20250522monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-reports-first-quarter-2025-results-and-reaffirms-2025-outlook-viatris-inc-nasdaq-v-vtrs-20250508monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-announces-positive-results-from-phase-3-study-of-investigational-xulane-lo-low-dos-vtrs-20250508monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-announces-positive-top-line-results-from-two-pivotal-phase-3-studies-of-novel-fast-vtrs-20250508monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-announces-quarterly-dividend-viatris-inc-nasdaq-vtrs-today-announced-that-on-may-5-vtrs-20250507monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-to-present-at-the-bofa-securities-2025-healthcare-conference-viatris-inc-nasdaq-vt-vtrs-20250425monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-files-supplemental-new-drug-applications-to-japan-s-ministry-of-health-labor-and-w-vtrs-20250421monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-appoints-hemanth-j-varghese-as-chief-strategy-officer-viatris-inc-nasdaq-vtrs-toda-vtrs-20250414monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-statement-on-nationwide-settlement-to-resolve-opioid-related-claims-viatris-inc-na-vtrs-20250407monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-to-report-first-quarter-2025-financial-results-on-may-8-2025-viatris-inc-nasdaq-vt-vtrs-20250328monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-to-present-at-the-barclays-27th-annual-global-healthcare-conference-viatris-inc-na-vtrs-20250305monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-2025-fina-vtrs-20250227monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-maintains-dividend-policy-for-2025-and-announces-quarterly-dividend-viatris-inc-na-vtrs-20250227monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-to-report-fourth-quarter-and-full-year-2024-financial-results-on-february-27-2025--vtrs-20250203monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-viatris-inc-nasdaq--vtrs-20250107monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-announces-publication-of-phase-2b-care-study-data-for-cenerimod-in-lancet-rheumato-vtrs-20241218monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-reports-third-quarter-financial-results-for-2024-total-revenues-of-3-8-billion-and-vtrs-20241107monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-announces-third-quarter-2024-dividend-viatris-inc-nasdaq-vtrs-today-announced-that-vtrs-20241105monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-named-to-forbes-world-s-top-companies-for-women-2024-list-viatris-inc-nasdaq-vtrs--vtrs-20241029monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-to-participate-in-the-ubs-global-healthcare-conference-and-jefferies-london-health-vtrs-20241029monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-announces-exclusive-licensing-agreement-with-lexicon-pharmaceuticals-for-sotaglifl-vtrs-20241016monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-announces-positive-top-line-results-from-phase-3-study-of-effexor-in-japanese-adul-vtrs-20241009monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-named-to-forbes-annual-list-of-the-world-s-best-employers-for-the-fourth-year-in-a-vtrs-20241008monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-announces-the-pricing-terms-of-maximum-tender-offer-viatris-inc-nasdaq-vtrs-viatri-vtrs-20240918monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-announces-early-tender-results-and-increase-of-pending-maximum-tender-offer-viatri-vtrs-20240917monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-to-report-third-quarter-2024-financial-results-on-november-7-2024-viatris-inc-nasd-vtrs-20240916monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-announces-expiration-and-results-of-any-and-all-cash-tender-offers-viatris-inc-nas-vtrs-20240910monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-announces-the-pricing-terms-of-pending-any-and-all-cash-tender-offers-viatris-inc--vtrs-20240910monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-presents-late-breaking-abstract-on-cenerimod-at-the-26th-asia-pacific-league-of-as-vtrs-20240823monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-reports-second-quarter-financial-results-for-2024-strong-results-demonstrate-power-vtrs-20240808monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-announces-second-quarter-2024-dividend-viatris-inc-nasdaq-vtrs-today-announced-tha-vtrs-20240806monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-brings-to-completion-all-previously-announced-divestitures-with-the-closing-of-its-vtrs-20240703monthly0.5https://www.biopharmawatch.com/news/VTRS/u-s-department-of-justice-informs-viatris-that-it-no-longer-considers-mylan-a-subject-of-g-vtrs-20240702monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-named-to-time-s-world-s-most-sustainable-companies-2024-list-viatris-inc-nasdaq-vt-vtrs-20240625monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-to-report-second-quarter-2024-financial-results-on-august-8-2024-viatris-inc-nasda-vtrs-20240607monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-to-participate-in-the-goldman-sachs-45th-annual-global-healthcare-conference-viatr-vtrs-20240604monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-to-participate-in-the-jeffries-global-healthcare-conference-viatris-inc-nasdaq-vtr-vtrs-20240531monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-publishes-2023-sustainability-report-building-sustainable-access-at-scale-viatris--vtrs-20240521monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-reports-strong-first-quarter-2024-financial-results-and-reaffirms-2024-financial-g-vtrs-20240509monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-to-participate-in-the-bofa-securities-2024-health-care-conference-viatris-inc-nasd-vtrs-20240502monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-expands-its-wellbeing-program-with-the-launch-of-unmind-a-leading-workplace-resour-vtrs-20240501monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-to-report-first-quarter-2024-financial-results-on-may-9-2024-viatris-inc-nasdaq-vt-vtrs-20240416monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-appoints-corinne-le-goff-as-chief-commercial-officer-viatris-inc-nasdaq-vtrs-a-glo-vtrs-20240415monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-announces-the-launch-of-ryzumvl-phentolamine-ophthalmic-solution-0-75-in-the-unite-vtrs-20240401monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-hosts-r-d-event-focusing-on-its-collaboration-with-idorsia-phase-3-assets-selatogr-vtrs-20240327monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-2024-fina-vtrs-20240228monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-and-idorsia-enter-into-significant-global-research-and-development-collaboration-e-vtrs-20240228monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-to-announce-fourth-quarter-and-full-year-2023-financial-results-viatris-inc-nasdaq-vtrs-20240205monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-to-participate-in-42nd-annual-j-p-morgan-healthcare-conference-viatris-inc-nasdaq--vtrs-20231221monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-shareholders-re-elect-all-nominated-directors-and-approve-all-voting-matters-at-an-vtrs-20231215monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-to-participate-in-the-jefferies-london-healthcare-conference-viatris-inc-nasdaq-vt-vtrs-20231114monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-and-theravance-biopharma-announce-positive-top-line-results-from-yupelri-revefenac-vtrs-20231113monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-reports-strong-financial-and-operational-results-for-the-third-quarter-2023-and-re-vtrs-20231107monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-to-host-webinar-the-power-of-partnership-to-address-antimicrobial-resistance-viatr-vtrs-20231030monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-named-to-forbes-annual-list-of-the-world-s-best-employers-for-the-third-year-in-a--vtrs-20231023monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-named-to-3bl-s-100-best-corporate-citizens-of-2023-ranking-viatris-inc-nasdaq-vtrs-vtrs-20231018monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-to-release-third-quarter-2023-financial-results-on-november-7-2023-viatris-inc-nas-vtrs-20231010monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-and-ocuphire-pharma-announce-fda-approval-of-ryzumvl-phentolamine-ophthalmic-solut-vtrs-20230927monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-named-to-time-s-world-s-best-companies-2023-list-viatris-inc-nasdaq-vtrs-a-global--vtrs-20230912monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-announces-u-s-fda-tentative-approval-of-a-paediatric-formulation-of-abacavir-abc-d-vtrs-20230905monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-reports-strong-financial-and-operational-results-for-second-quarter-2023-and-reaff-vtrs-20230807monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-and-mapi-pharma-announce-fda-acceptance-of-new-drug-application-filing-for-ga-depo-vtrs-20230807monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-announces-launch-of-breyna-budesonide-and-formoterol-fumarate-dihydrate-inhalation-vtrs-20230731monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-to-report-second-quarter-2023-financial-results-on-august-7-2023-viatris-inc-nasda-vtrs-20230628monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-named-to-usa-today-s-inaugural-list-of-america-s-climate-leaders-2023-viatris-inc--vtrs-20230530monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-announces-appointment-of-leo-groothuis-to-company-s-board-of-directors-viatris-inc-vtrs-20230522monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-to-participate-in-goldman-sachs-44th-annual-global-healthcare-conference-viatris-i-vtrs-20230517monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-publishes-sustainability-report-showcasing-2022-progress-on-building-sustainable-a-vtrs-20230516monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-reports-strong-financial-and-operational-results-for-first-quarter-2023-and-reaffi-vtrs-202305082023-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-and-mapi-pharma-to-highlight-latest-results-of-multiple-sclerosis-research-at-amer-vtrs-202304242023-04-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-nomme-e-au-classement-linkedin-top-companies-2023-en-irlande-viatris-inc-nasdaq-vt-vtrs-202304202023-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-nombrada-en-la-lista-de-las-mejores-empresas-de-linkedin-de-2023-en-irlanda-viatri-vtrs-202304202023-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-auf-der-linkedin-liste-der-top-unternehmen-in-irland-fu-r-2023-aufgefu-hrt-viatris-vtrs-202304202023-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-named-in-2023-linkedin-top-companies-list-in-ireland-viatris-inc-nasdaq-vtrs-a-glo-vtrs-202304192023-04-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-to-report-first-quarter-2023-financial-results-on-may-8-2023-viatris-inc-nasdaq-vt-vtrs-202304122023-04-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/ncd-academy-launches-new-health-equity-and-social-determinants-of-health-course-viatris-in-vtrs-202304062023-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-wins-summary-judgment-in-new-york-securities-class-action-viatris-inc-nasdaq-vtrs--vtrs-202303312023-03-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-reports-strong-fourth-quarter-and-full-year-2022-financial-results-and-provides-20-vtrs-202302272023-02-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023--vtrs-202302152023-02-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-closes-acquisitions-of-oyster-point-pharma-and-famy-life-sciences-establishing-new-vtrs-202301032023-01-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-inc-to-participate-in-41st-annual-j-p-morgan-healthcare-conference-viatris-inc-nas-vtrs-20221223monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-announces-donations-totaling-1-million-to-provide-aid-supporting-access-to-healthc-vtrs-20221214monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-announces-approval-of-emissions-reduction-targets-by-the-science-based-target-init-vtrs-20221214monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-named-u-s-in-house-legal-team-of-the-year-for-intellectual-property-litigation-by--vtrs-20221118monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-wins-court-decision-invalidating-astrazeneca-s-symbicort-patent-viatris-inc-nasdaq-vtrs-20221110monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-reports-strong-third-quarter-2022-results-reaffirms-2022-guidance-ranges-1-across--vtrs-20221107monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-to-report-financial-results-for-the-third-quarter-2022-and-provide-an-update-on-it-vtrs-20221024monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-named-to-forbes-annual-list-of-the-world-s-best-employers-for-the-second-year-in-a-vtrs-20221011monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-inc-to-participate-in-bofa-global-research-global-healthcare-conference-viatris-in-vtrs-20220906monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-reports-strong-second-quarter-2022-results-reports-total-revenues-of-4-12-billion--vtrs-20220808monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-inc-to-release-second-quarter-2022-financial-results-on-august-8-2022-viatris-inc--vtrs-20220701monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-to-participate-in-goldman-sachs-43rd-annual-global-healthcare-conference-viatris-i-vtrs-20220520monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-publishes-sustainability-report-highlighting-2021-progress-achievements-and-goals--vtrs-20220516monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-reports-strong-first-quarter-2022-results-first-quarter-2022-results-reflect-stron-vtrs-20220509monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-inc-to-release-first-quarter-2022-financial-results-on-may-9-2022-viatris-inc-nasd-vtrs-20220408monthly0.5https://www.biopharmawatch.com/news/VTRS/sesame-workshop-and-viatris-launch-new-emotional-health-and-wellbeing-resources-for-famili-vtrs-20220330monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-defeats-biogen-s-attempt-to-revive-tecfidera-patent-viatris-inc-nasdaq-vtrs-today--vtrs-20220317monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-inc-announces-receipt-of-the-first-fda-approval-for-generic-version-of-symbicort-i-vtrs-20220316monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-to-participate-in-upcoming-investor-conferences-viatris-inc-nasdaq-vtrs-today-anno-vtrs-20220301monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-reports-strong-fourth-quarter-and-full-year-2021-financial-results-issues-2022-fin-vtrs-20220228monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-to-host-virtual-investor-event-and-report-fourth-quarter-and-full-year-2021-financ-vtrs-20220204monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-is-first-to-receive-fda-approval-of-generic-restasis-cyclosporine-ophthalmic-emuls-vtrs-20220203monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-announces-9-dividend-increase-fourth-consecutive-quarterly-dividend-viatris-inc-na-vtrs-20220106monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-wins-court-decisions-on-sanofi-appeals-of-lantus-patent-invalidations-viatris-inc--vtrs-20211229monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-to-move-its-investor-event-previously-scheduled-for-january-7-to-no-later-than-feb-vtrs-20211217monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-named-by-newsweek-as-one-of-america-s-most-responsible-companies-viatris-inc-nasda-vtrs-20211206monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-wins-federal-circuit-court-appeal-upholding-district-court-decision-invalidating-b-vtrs-20211201monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-to-participate-in-evercore-isi-4th-annual-healthconx-conference-viatris-inc-nasdaq-vtrs-20211118monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-and-biocon-biologics-announce-launch-of-interchangeable-semglee-insulin-glargine-y-vtrs-20211116monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-donates-1-million-as-founding-champion-to-new-orleans-based-sbp-s-got-your-back-fu-vtrs-20211111monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-reports-strong-third-quarter-results-raises-2021-financial-guidance-and-announces--vtrs-20211108monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-first-ever-interchangeable-insulin-biosimilar-preferred-on-express-scripts-largest-vtrs-20211020monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-inc-to-release-third-quarter-2021-financial-results-on-nov-8-2021-viatris-inc-nasd-vtrs-20211013monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-named-fifth-on-fortune-s-change-the-world-list-viatris-inc-nasdaq-vtrs-a-new-kind--vtrs-20211011monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-inc-to-participate-in-citi-s-16th-annual-biopharma-conference-viatris-inc-nasdaq-v-vtrs-20210830monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-inc-to-participate-in-bofa-global-healthcare-conference-viatris-inc-nasdaq-vtrs-to-vtrs-20210830monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-reports-strong-second-quarter-results-reports-second-quarter-2021-financial-result-vtrs-20210809monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-inc-and-biocon-biologics-receive-historic-approval-for-first-interchangeable-biosi-vtrs-20210728monthly0.5https://www.biopharmawatch.com/news/VTRS/mylan-wins-dismissal-of-kansas-epipen-direct-purchaser-case-viatris-nasdaq-vtrs-today-anno-vtrs-20210727monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-inc-to-release-second-quarter-2021-financial-results-on-aug-9-2021-viatris-inc-nas-vtrs-20210708monthly0.5https://www.biopharmawatch.com/news/VTRS/mylan-wins-significant-summary-judgment-rulings-in-kansas-epipen-class-action-viatris-nasd-vtrs-20210623monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-firma-un-memorando-de-entendimiento-con-defeat-ncd-partnership-en-el-instituto-de--vtrs-20210528monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-inc-to-participate-in-goldman-sachs-42nd-annual-global-healthcare-conference-viatr-vtrs-20210525monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-inc-reports-strong-first-quarter-2021-financial-results-reaffirms-2021-guidance-an-vtrs-20210510monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-inc-releases-inaugural-sustainability-report-reinforcing-its-commitment-to-better--vtrs-20210506monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-inc-to-participate-in-the-2021-rbc-capital-markets-global-healthcare-conference-vi-vtrs-20210430monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-inc-et-atomo-diagnostics-annoncent-un-accord-avec-unitaid-pour-e-largir-l-acce-s-a-vtrs-20210429monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-inc-to-participate-in-bofa-securities-2021-health-care-conference-viatris-inc-nasd-vtrs-20210429monthly0.5https://www.biopharmawatch.com/news/VTRS/un-an-o-despue-s-de-los-confinamientos-en-todo-el-mundo-por-la-covid-19-un-panel-me-dico-a-vtrs-20210420monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-inc-to-release-first-quarter-2021-financial-results-on-may-10-2021-viatris-inc-nas-vtrs-20210412monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-inc-and-kindeva-drug-delivery-announce-fda-tentative-approval-of-the-first-abbrevi-vtrs-20210308monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-inc-to-participate-in-barclays-global-healthcare-conference-viatris-inc-nasdaq-vtr-vtrs-20210304monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-inc-hosts-inaugural-investor-day-outlining-unique-and-differentiated-business-mode-vtrs-20210301monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-inc-announces-2021-financial-guidance-and-reaffirms-strategic-and-financial-commit-vtrs-20210222monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-inc-to-hold-conference-call-on-monday-feb-22-2021-to-discuss-2021-financial-guidan-vtrs-20210209monthly0.5https://www.biopharmawatch.com/news/VTRS/mylan-wins-summary-judgment-in-epipen-litigation-brought-by-sanofi-viatris-inc-nasdaq-vtrs-vtrs-20201218monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-inc-recommends-caution-on-trc-capital-corp-s-attempt-to-acquire-shares-at-a-signif-vtrs-20201215monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-inc-announces-additional-details-of-previously-disclosed-global-restructuring-init-vtrs-20201211monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-inc-to-present-at-the-j-p-morgan-39th-annual-healthcare-conference-january-14-2021-vtrs-20201210monthly0.5https://www.biopharmawatch.com/news/VTRS/sesame-workshop-and-viatris-inc-launch-global-resources-to-help-children-and-caregivers-ma-vtrs-20201207monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-inc-announces-fda-tentative-approval-of-a-pediatric-formulation-of-dolutegravir-dt-vtrs-20201123monthly0.5https://www.biopharmawatch.com/news/VTRS/viatris-inc-launches-as-a-new-kind-of-healthcare-company-positioned-to-meet-the-world-s-ev-vtrs-20201116monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-announces-usda-approval-of-trucan-ultra-lyme-l4-the-first-and-only-1-2-ml-combinati-elan-20260615monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-launches-befrena-tirnovetmab-new-anti-il-31-monoclonal-antibody-a-breakthrough-addi-elan-20260518monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-to-participate-in-upcoming-investor-conferences-elanco-animal-health-incorporated-n-elan-20260219monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-to-participate-in-the-44th-annual-j-p-morgan-healthcare-conference-elanco-animal-he-elan-20260106monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-s-credelio-quattro-ca1-lotilaner-moxidectin-praziquantel-and-pyrantel-chewable-tabl-elan-20251218monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-to-participate-in-morgan-stanley-23rd-annual-global-healthcare-conference-elanco-an-elan-20250826monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-reports-second-quarter-2025-results-raising-full-year-outlook-and-inn-elan-20250807monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-secures-approval-of-zenrelia-ilunocitinib-in-the-european-union-eu-launching-innova-elan-20250724monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-confirms-date-and-conference-call-for-second-quarter-2025-financial-results-announc-elan-20250710monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-receives-usda-approval-for-trucan-ultra-civ-h3n2-h3n8-canine-influenza-vaccine-brin-elan-20250709monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-releases-2024-impact-report-and-introduces-new-framework-today-elanco-animal-health-elan-20250626monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-receives-positive-opinion-on-zenrelia-ilunocitinib-from-eu-s-committee-for-veterina-elan-20250612monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-releases-new-report-highlighting-the-significance-of-america-s-itchy-dogs-and-the-n-elan-20250605monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-appoints-robert-bob-vanhimbergen-as-chief-financial-officer-elanco-animal-health-in-elan-20250528monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-to-participate-in-the-upcoming-investor-conferences-elanco-animal-health-incorporat-elan-20250516monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-reports-first-quarter-2025-results-accelerating-debt-paydown-in-2025--elan-20250507monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-sells-royalty-and-milestone-rights-for-lotilaner-in-human-health-to-blackstone-acce-elan-20250505monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-s-breakthrough-treatment-for-deadly-canine-parvovirus-has-saved-thousands-of-puppie-elan-20250422monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-confirms-date-and-conference-call-for-first-quarter-2025-financial-results-announce-elan-20250410monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-announces-changes-to-board-of-directors-signs-research-agreement-to-explore-novel-t-elan-20250317monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-reports-fourth-quarter-and-full-year-2024-results-fourth-quarter-2024-elan-20250225monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-enters-agreement-with-medgene-to-commercialize-highly-pathogenic-avian-influenza-va-elan-20250225monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-to-participate-in-upcoming-investor-conferences-elanco-animal-health-incorporated-n-elan-20250221monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-launches-pet-protect-from-the-makers-of-advantage-veterinarian-formulated-supplemen-elan-20250220monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-reinforces-commitment-to-veterinary-and-pet-owner-education-elanco-animal-health-in-elan-20250213monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-confirms-date-and-conference-call-for-fourth-quarter-and-full-year-2024-financial-r-elan-20250204monthly0.5https://www.biopharmawatch.com/news/ELAN/meet-the-faces-of-zen-elanco-s-zenrelia-ilunocitinib-tablets-helps-allergic-dogs-get-back--elan-20250127monthly0.5https://www.biopharmawatch.com/news/ELAN/now-available-credelio-quattro-lotilaner-moxidectin-praziquantel-and-pyrantel-chewable-tab-elan-20250123monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference-elanco-animal-he-elan-20241219monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-to-participate-in-the-upcoming-investor-conferences-elanco-animal-health-incorporat-elan-20241125monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-acquires-speke-contract-manufacturing-facility-securing-key-supply-chain-elanco-ani-elan-20241115monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-strengthens-board-of-directors-with-addition-of-stacey-ma-elanco-animal-health-inco-elan-20241112monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-reports-third-quarter-2024-results-third-quarter-2024-financial-resul-elan-20241107monthly0.5https://www.biopharmawatch.com/news/ELAN/new-data-reveals-elanco-s-canine-parvovirus-monoclonal-antibody-treatment-significantly-im-elan-20241015monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-confirms-date-and-conference-call-for-third-quarter-2024-financial-results-announce-elan-20241010monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-receives-fda-approval-for-credelio-quattro-lotilaner-moxidectin-praziquantel-and-py-elan-20241007monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-announces-fda-approval-and-launch-of-zenrelia-ilunocitinib-tablets-offering-an-effe-elan-20240919monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-provides-update-on-contract-manufacturing-partner-elanco-animal-health-incorporated-elan-20240913monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-to-participate-in-morgan-stanley-22nd-annual-global-healthcare-conference-elanco-an-elan-20240828monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-announces-credelio-quattro-moves-to-final-fda-administrative-review-elanco-animal-h-elan-20240820monthly0.5https://www.biopharmawatch.com/news/ELAN/credelio-lotilaner-kills-ticks-2x-as-fast-as-simparica-trio-sarolaner-moxidectin-and-pyran-elan-20240815monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-reports-second-quarter-2024-results-raises-full-year-revenue-and-main-elan-20240808monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-releases-2023-environmental-social-and-governance-report-delivering-healthier-outco-elan-20240730monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-confirms-date-and-conference-call-for-second-quarter-2024-financial-results-announc-elan-20240718monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-completes-sale-of-aqua-business-elanco-animal-health-incorporated-nyse-elan-announc-elan-20240709monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-provides-innovation-update-elanco-animal-health-incorporated-nyse-elan-today-announ-elan-20240627monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-to-participate-in-goldman-sachs-45th-annual-global-healthcare-conference-elanco-ani-elan-20240606monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-announces-fda-has-completed-review-of-bovaer-first-in-class-methane-reducing-feed-i-elan-20240528monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-to-participate-in-stifel-2024-jaws-and-paws-conference-elanco-animal-health-incorpo-elan-20240521monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-reports-first-quarter-2024-results-first-quarter-2024-financial-resul-elan-20240508monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-s-parvo-is-poop-campaign-unleashes-awareness-and-action-on-national-parvo-awareness-elan-20240423monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-confirms-date-and-conference-call-for-first-quarter-2024-financial-results-announce-elan-20240417monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-appoints-two-animal-health-industry-executives-kathy-turner-and-craig-wallace-to-it-elan-20240401monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-appoints-shiv-o-neill-as-general-counsel-and-corporate-secretary-elanco-animal-heal-elan-20240304monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-is-executing-on-plan-to-deliver-for-shareholders-elanco-animal-health-elan-20240229monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-reports-fourth-quarter-and-full-year-2023-results-fourth-quarter-2023-elan-20240226monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-to-participate-in-upcoming-investor-conferences-elanco-animal-health-incorporated-n-elan-20240222monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-confirms-date-and-conference-call-for-fourth-quarter-and-full-year-2023-financial-r-elan-20240208monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-announces-sale-of-aqua-business-for-1-3-billion-elanco-animal-health-incorporated-n-elan-20240205monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-launches-multi-year-mission-to-save-1-million-puppies-from-canine-parvovirus-elanco-elan-20240117monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-announces-planned-board-leadership-changes-and-corporate-governance-a-elan-20240102monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-announces-addition-of-general-counsel-today-elanco-animal-health-a-di-elan-20180510monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-announces-u-s-food-and-drug-administration-fda-approval-of-credelio-l-elan-20180122monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-innovations-named-best-products-for-2017-elanco-animal-health-a-division-of-eli-lil-elan-20180118monthly0.5https://www.biopharmawatch.com/news/ELAN/new-data-highlights-rift-between-consumers-perceptions-science-about-food-choice-conflicti-elan-20170329monthly0.5https://www.biopharmawatch.com/news/ELAN/taking-action-global-animal-protein-leaders-public-and-private-organizations-outline-futur-elan-20160922monthly0.5https://www.biopharmawatch.com/news/ELAN/statement-from-the-participants-of-the-one-health-summit-september-21-22-in-washington-d-c-elan-20160921monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-s-antibiotic-stewardship-plan-yields-innovation-scientific-advancements-today-elanc-elan-20160914monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-launches-new-video-series-illustrating-the-powerful-bond-between-service-dogs-owner-elan-20160811monthly0.5https://www.biopharmawatch.com/news/ELAN/updated-report-reveals-stark-realities-of-feeding-9-7-billion-people-by-2050-today-elanco--elan-20151028monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-expands-parasiticide-portfolio-in-us-with-new-product-for-heartworm-disease-intesti-elan-20151028monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-announces-comprehensive-antibiotic-stewardship-plan-significant-research-effort-tod-elan-20150602monthly0.5https://www.biopharmawatch.com/news/ELAN/elanco-president-food-productivity-falling-behind-population-growth-urgent-action-required-elan-20120518monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-introduces-the-ruby-xl-system-the-longest-largest-and-softest-coil-on-the-market--pen-20250605monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-upcoming-investor-conferences-penumbra-inc-nyse-pen-today-annou-pen-20250520monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-bofa-securities-2025-health-care-conference-penumbra-inc-ny-pen-20250429monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-first-quarter-2025-earnings-release-and-conference-call-for-april-2-pen-20250403monthly0.5https://www.biopharmawatch.com/news/PEN/seven-new-data-sets-demonstrate-penumbra-s-computer-assisted-vacuum-thrombectomy-cavt-tech-pen-20250402monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-announces-don-kassing-will-retire-from-board-of-directors-penumbra-inc-nyse-p-pen-20250221monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-fourth-quarter-and-full-year-2024-earnings-release-and-conference-c-pen-20250121monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-penumbra-inc-n-pen-20241230monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-piper-sandler-36th-annual-healthcare-conference-penumbra-in-pen-20241120monthly0.5https://www.biopharmawatch.com/news/PEN/new-late-breaking-data-show-patients-treated-with-penumbra-s-computer-assisted-vacuum-thro-pen-20241105monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-announces-completion-of-thunder-ide-study-enrollment-for-acute-ischemic-strok-pen-20241014monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-third-quarter-2024-earnings-release-and-conference-call-for-october-pen-20241002monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-receives-ce-mark-for-computer-assisted-vacuum-thrombectomy-technologies-lightning-pen-20240916monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-baird-global-healthcare-conference-penumbra-inc-nyse-pen-to-pen-20240827monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-wells-fargo-healthcare-conference-penumbra-inc-nyse-pen-tod-pen-20240821monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-announces-200-million-share-repurchase-authorization-penumbra-inc-nyse-pen-th-pen-20240813monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-canaccord-genuity-growth-conference-penumbra-inc-nyse-pen-t-pen-20240802monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-second-quarter-2024-earnings-release-and-conference-call-for-july-3-pen-20240702monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-truist-securities-medtech-conference-penumbra-inc-nyse-pen--pen-20240604monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-william-blair-growth-stock-conference-penumbra-inc-nyse-pen-pen-20240523monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-rbc-capital-markets-global-healthcare-conference-penumbra-i-pen-20240501monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-launches-lightning-flash-2-0-latest-cavt-technology-designed-to-rapidly-remove-bl-pen-20240423monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-first-quarter-2024-earnings-release-and-conference-call-for-may-7-2-pen-20240409monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-fourth-quarter-and-full-year-2023-earnings-release-and-conference-c-pen-20240201monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-j-p-morgan-42nd-annual-healthcare-conference-penumbra-inc-n-pen-20231218monthly0.5https://www.biopharmawatch.com/news/PEN/first-patient-in-storm-pe-rct-enrolled-evaluating-penumbra-s-latest-computer-assisted-vacu-pen-20231128monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-piper-sandler-35th-annual-healthcare-conference-penumbra-in-pen-20231114monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-teams-up-with-honor-everywhere-to-bring-us-war-memorials-to-aging-veterans-everyd-pen-20231110monthly0.5https://www.biopharmawatch.com/news/PEN/new-late-breaking-data-demonstrate-penumbra-s-computer-assisted-vacuum-thrombectomy-techno-pen-20231101monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-third-quarter-2023-earnings-release-and-conference-call-for-novembe-pen-20231005monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-upcoming-investor-conferences-penumbra-inc-nyse-pen-today-annou-pen-20230823monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference-penumbra-in-pen-20230726monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-second-quarter-2023-earnings-release-and-conference-call-for-august-pen-20230705monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-expands-computer-aided-thrombectomy-offerings-with-lightning-bolt-7-technology-de-pen-20230601monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-william-blair-s-43rd-annual-growth-stock-conference-penumbra-in-pen-20230524monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-upcoming-investor-conferences-penumbra-inc-nyse-pen-today-annou-pen-202304252023-04-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-first-quarter-2023-earnings-release-and-conference-call-for-may-2-2-pen-202304042023-04-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-and-veterans-health-administration-to-expand-access-to-rehabilitative-care-using--pen-202304042023-04-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-citi-s-2023-healthcare-services-medtech-tools-hcit-conference-p-pen-202302162023-02-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-fourth-quarter-and-full-year-2022-earnings-release-and-conference-c-pen-202301262023-01-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-launches-latest-innovation-in-mechanical-thrombectomy-lightning-flash-penumbra-in-pen-202301102023-01-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-penumbra-inc-n-pen-20221219monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-jefferies-london-healthcare-conference-penumbra-inc-nyse-pe-pen-20221101monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-third-quarter-2022-earnings-release-and-conference-call-for-novembe-pen-20221006monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-upcoming-investor-conferences-penumbra-inc-nyse-pen-today-annou-pen-20220824monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-canaccord-genuity-42nd-annual-growth-conference-penumbra-in-pen-20220727monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-second-quarter-2022-earnings-release-and-conference-call-for-august-pen-20220707monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-bank-of-america-securities-2022-healthcare-conference-penum-pen-20220426monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-first-quarter-2022-earnings-release-and-conference-call-for-may-3-2-pen-20220405monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-21st-annual-needham-virtual-healthcare-conference-penumbra--pen-20220328monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-citi-s-2022-virtual-healthcare-conference-penumbra-inc-nyse-pen-pen-20220210monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-fourth-quarter-and-full-year-2021-earnings-release-and-conference-c-pen-20220201monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-penumbra-inc-n-pen-20211222monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-third-quarter-2021-earnings-release-and-conference-call-for-novembe-pen-20211006monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-morgan-stanley-19th-annual-global-healthcare-conference-pen-pen-20210831monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-2021-wells-fargo-virtual-healthcare-conference-penumbra-inc-pen-20210826monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-canaccord-genuity-41st-annual-growth-conference-penumbra-in-pen-20210728monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-second-quarter-2021-earnings-release-and-conference-call-for-august-pen-20210712monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-william-blair-41st-annual-growth-stock-virtual-conference-p-pen-20210518monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-bofa-securities-2021-virtual-health-care-conference-penumbr-pen-20210427monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-first-quarter-2021-earnings-release-and-conference-call-for-may-4-2-pen-20210413monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-citi-s-2021-healthcare-services-medtech-tools-hcit-virtual-conf-pen-20210210monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-fourth-quarter-and-full-year-2020-earnings-release-and-conference-c-pen-20210202monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-announces-preliminary-unaudited-revenue-for-the-fourth-quarter-and-full-year-2020-pen-20210111monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-penumbra-inc-n-pen-20201229monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-participate-in-ceo-discussion-with-bank-of-america-penumbra-inc-nyse-pen-t-pen-20201204monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-announces-partnership-with-rapidai-to-enable-faster-clinical-decision-making-for--pen-20201110monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-canaccord-genuity-virtual-medtech-diagnostics-forum-penumbr-pen-20201106monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-third-quarter-2020-earnings-release-and-conference-call-for-october-pen-20200929monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-morgan-stanley-18th-annual-global-healthcare-conference-pen-pen-20200903monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-wells-fargo-2020-virtual-healthcare-conference-penumbra-inc-pen-20200826monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-canaccord-genuity-40th-annual-growth-conference-penumbra-in-pen-20200729monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-second-quarter-2020-earnings-release-and-conference-call-for-august-pen-20200720monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-william-blair-40th-annual-growth-stock-conference-penumbra--pen-20200529monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-announces-pricing-of-offering-of-common-stock-penumbra-inc-nyse-pen-a-global--pen-20200527monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-announces-launch-of-offering-of-100-000-000-of-shares-of-its-common-stock-pen-pen-20200527monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-announces-virtual-2020-annual-meeting-of-stockholders-penumbra-inc-nyse-pen-t-pen-20200515monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-announces-management-transition-penumbra-inc-nyse-pen-a-global-healthcare-company-pen-20200512monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-bank-of-america-merrill-lynch-2020-health-care-conference-p-pen-20200429monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-first-quarter-2020-earnings-release-and-conference-call-for-may-7-2-pen-20200423monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-fourth-quarter-and-full-year-2019-financial-results-penumbra-inc-nyse-pen-20200225monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-fourth-quarter-and-full-year-2019-earnings-release-and-conference-c-pen-20200211monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-penumbra-inc-n-pen-20191231monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-announces-investor-day-2019-penumbra-inc-nyse-pen-today-announced-that-it-wil-pen-20191119monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-third-quarter-2019-earnings-release-and-conference-call-for-novembe-pen-20191017monthly0.5https://www.biopharmawatch.com/news/PEN/sri-kosaraju-promoted-to-president-and-cfo-of-penumbra-penumbra-inc-nyse-pen-a-global-heal-pen-20190829monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-morgan-stanley-17th-annual-global-healthcare-conference-pen-pen-20190827monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-2019-wells-fargo-healthcare-conference-penumbra-inc-nyse-pe-pen-20190821monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-canaccord-genuity-39th-annual-growth-conference-penumbra-in-pen-20190717monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-second-quarter-2019-earnings-release-and-conference-call-for-august-pen-20190716monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-bmo-2019-prescriptions-for-success-healthcare-conference-pe-pen-20190611monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-goldman-sachs-40th-annual-global-healthcare-conference-penu-pen-20190529monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-bank-of-america-merrill-lynch-2019-health-care-conference-p-pen-20190501monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-first-quarter-2019-earnings-release-and-conference-call-for-may-7-2-pen-20190417monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-fourth-quarter-and-full-year-2018-earnings-release-and-conference-c-pen-20190130monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-appoints-janet-leeds-and-surbhi-sarna-to-its-board-of-directors-penumbra-inc--pen-20190118monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-penumbra-inc-n-pen-20181220monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-bmo-prescriptions-for-success-healthcare-conference-penumbr-pen-20181129monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-third-quarter-2018-earnings-release-and-conference-call-for-novembe-pen-20181015monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-announces-participation-at-upcoming-investor-conferences-penumbra-inc-nyse-pe-pen-20180822monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-canaccord-genuity-38th-annual-growth-conference-penumbra-in-pen-20180719monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-second-quarter-2018-earnings-release-and-conference-call-for-august-pen-20180717monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-goldman-sachs-39th-annual-global-healthcare-conference-penu-pen-20180529monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-bank-of-america-merrill-lynch-2018-health-care-conference-a-pen-20180502monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-first-quarter-2018-earnings-release-and-conference-call-for-may-8-2-pen-20180418monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-36th-annual-j-p-morgan-healthcare-conference-penumbra-inc-n-pen-20171221monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-third-quarter-2017-earnings-release-and-conference-call-for-novembe-pen-20171024monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-announces-participation-at-upcoming-investor-conferences-penumbra-inc-nyse-pe-pen-20170824monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-canaccord-genuity-37th-annual-growth-conference-penumbra-in-pen-20170725monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-second-quarter-2017-earnings-release-and-conference-call-for-august-pen-20170725monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-promotes-daniel-davis-to-chief-commercial-officer-alameda-calif-july-5-2017-p-pen-20170705monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-bank-of-america-merrill-lynch-2017-health-care-conference-p-pen-20170503monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-first-quarter-2017-earnings-release-and-conference-call-for-may-9-2-pen-20170425monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-appoints-bridget-o-rourke-to-its-board-of-directors-penumbra-inc-nyse-pen-tod-pen-20170421monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-announces-pricing-of-offering-of-1-300-000-shares-of-its-common-stock-penumbr-pen-20170316monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-announces-launch-of-offering-of-1-300-000-shares-of-its-common-stock-penumbra-pen-20170315monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-fourth-quarter-and-full-year-2016-earnings-release-and-conference-c-pen-20170214monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-35th-annual-j-p-morgan-healthcare-conference-penumbra-inc-n-pen-20161220monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-appoints-thomas-c-wilder-to-its-board-of-directors-penumbra-inc-nyse-pen-toda-pen-20161219monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-announces-resignation-of-board-member-penumbra-inc-nyse-pen-today-announced-t-pen-20161115monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-canaccord-genuity-medical-technologies-diagnostics-forum-pe-pen-20161027monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-third-quarter-2016-earnings-release-and-conference-call-for-novembe-pen-20161020monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-announces-participation-at-upcoming-investor-conferences-penumbra-inc-nyse-pe-pen-20160818monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-second-quarter-2016-earnings-release-and-conference-call-for-august-pen-20160715monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-canaccord-genuity-36th-annual-growth-conference-penumbra-in-pen-20160715monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-bank-of-america-merrill-lynch-2016-healthcare-conference-pe-pen-20160427monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-first-quarter-2016-earnings-release-and-conference-call-for-may-9-2-pen-20160425monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-appoints-kevin-sullivan-to-its-board-of-directors-penumbra-inc-nyse-pen-a-glo-pen-20160223monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-fourth-quarter-and-full-year-2015-earnings-release-and-conference-c-pen-20160223monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-34th-annual-j-p-morgan-2016-healthcare-conference-penumbra--pen-20151228monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-reports-third-quarter-2015-financial-results-penumbra-inc-nyse-pen-a-global-i-pen-20151112monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-to-present-at-the-canaccord-genuity-medical-technologies-diagnostics-forum-pe-pen-20151105monthly0.5https://www.biopharmawatch.com/news/PEN/penumbra-inc-schedules-third-quarter-2015-earnings-release-and-conference-call-for-novembe-pen-20151030monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-highlights-upcoming-data-presentations-for-neladalkib-and-zidesamtinib-at-the-202-nuvl-20260521monthly0.5https://www.biopharmawatch.com/news/NUVL/new-clinical-and-preclinical-data-for-investigational-candidate-zidesamtinib-presented-at--nuvl-20260417monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-announces-ontarget-2026-operating-plan-progress-and-outlines-key-anticipated-2026-nuvl-20260112monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-nuvalent-inc-nasda-nuvl-20251222monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-announces-public-offering-of-common-stock-nuvalent-inc-nasdaq-nuvl-a-clinical-sta-nuvl-20251117monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-announces-timing-of-topline-pivotal-data-for-tki-pre-treated-patients-with-advanc-nuvl-20251114monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-presents-preliminary-data-for-neladalkib-in-advanced-alk-positive-solid-tumors-be-nuvl-20251018monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-present-new-preclinical-data-for-her2-selective-inhibitor-nvl-330-at-aacr-nci--nuvl-20251013monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-participate-in-the-ubs-2025-virtual-oncology-day-nuvalent-inc-nasdaq-nuvl-a-cl-nuvl-20250924monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-presents-pivotal-data-from-arros-1-clinical-trial-of-zidesamtinib-for-tki-pre-tre-nuvl-20250907monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-participate-in-the-cantor-global-healthcare-conference-2025-nuvalent-inc-nasda-nuvl-20250828monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-present-pivotal-data-from-arros-1-clinical-trial-of-zidesamtinib-for-tki-pre-t-nuvl-20250813monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-announces-initiation-of-alkazar-phase-3-randomized-controlled-trial-evaluating-ne-nuvl-20250721monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-announces-positive-pivotal-data-from-arros-1-clinical-trial-of-zidesamtinib-for-t-nuvl-20250624monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-announces-timing-of-pivotal-data-for-tki-pre-treated-patients-with-advanced-ros1--nuvl-20250623monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-appoints-christy-oliger-to-board-of-directors-nuvalent-inc-nasdaq-nuvl-a-clinical-nuvl-20250618monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-announces-publication-in-molecular-cancer-therapeutics-reinforcing-rational-molec-nuvl-20250429monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-present-trial-in-progress-posters-for-the-alkazar-trial-of-neladalkib-and-hero-nuvl-20250423monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum-nuvalent-inc-na-nuvl-20250401monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-present-new-preclinical-data-on-alk-selective-inhibitor-neladalkib-and-ros1-se-nuvl-20250325monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-participate-in-upcoming-march-investor-conferences-nuvalent-inc-nasdaq-nuvl-a--nuvl-20250228monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-nuvalent-inc-nasda-nuvl-20241219monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-appoints-grant-bogle-to-board-of-directors-nuvalent-inc-nasdaq-nuvl-a-clinical-st-nuvl-20241209monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-participate-in-the-piper-sandler-36th-annual-healthcare-conference-nuvalent-in-nuvl-20241126monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-announces-closing-of-upsized-public-offering-of-common-stock-nuvalent-inc-nasdaq--nuvl-20240918monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-announces-pricing-of-upsized-public-offering-of-common-stock-nuvalent-inc-nasdaq--nuvl-20240916monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-announces-public-offering-of-common-stock-nuvalent-inc-nasdaq-nuvl-a-clinical-sta-nuvl-20240916monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-highlights-presentation-of-clinical-data-at-esmo-2024-for-parallel-lead-programs--nuvl-20240914monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-announces-publication-in-cancer-discovery-detailing-design-and-characterization-o-nuvl-20240913monthly0.5https://www.biopharmawatch.com/news/NUVL/updated-data-for-nuvalent-s-alk-selective-inhibitor-nvl-655-and-ros1-selective-inhibitor-z-nuvl-20240909monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-participate-in-the-morgan-stanley-22nd-annual-global-healthcare-conference-nuv-nuvl-20240829monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-announces-first-patient-dosed-in-heroex-1-phase-1a-1b-clinical-trial-of-nvl-330-i-nuvl-20240722monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-present-updated-data-for-ros1-selective-inhibitor-zidesamtinib-and-alk-selecti-nuvl-20240716monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-announces-promotion-of-henry-pelish-ph-d-to-chief-scientific-officer-nuvalent-inc-nuvl-20240711monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-participate-in-the-2024-jefferies-global-healthcare-conference-nuvalent-inc-na-nuvl-20240529monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-receives-u-s-fda-breakthrough-therapy-designation-for-nvl-655-nuvalent-inc-nasdaq-nuvl-20240516monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-presents-new-preclinical-data-supporting-profiles-of-her2-selective-inhibitor-nvl-nuvl-20240408monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-present-new-preclinical-data-on-her2-selective-inhibitor-nvl-330-and-ros1-sele-nuvl-20240305monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-receives-u-s-fda-breakthrough-therapy-designation-for-nvl-520-nuvalent-inc-nasdaq-nuvl-20240227monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-initiates-the-phase-2-portion-of-alkove-1-clinical-trial-for-patients-with-alk-po-nuvl-20240212monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-participate-in-the-guggenheim-healthcare-talks-6th-annual-biotechnology-confer-nuvl-20240201monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-announces-ontarget-2026-operating-plan-and-key-anticipated-milestones-nuvalent-in-nuvl-20240108monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-nuvalent-inc-nasda-nuvl-20231221monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-participate-in-the-bmo-virtual-biopharma-spotlight-series-oncology-day-nuvalen-nuvl-20231101monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-announces-public-offering-of-common-stock-nuvalent-inc-nasdaq-nuvl-a-clinical-sta-nuvl-20231016monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-present-preliminary-data-from-alkove-1-phase-1-2-clinical-trial-of-nvl-655-at--nuvl-20230918monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-initiates-the-phase-2-portion-of-arros-1-clinical-trial-for-patients-with-ros1-po-nuvl-20230905monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-participate-in-upcoming-september-investor-conferences-nuvalent-inc-nasdaq-nuv-nuvl-20230831monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-participate-in-upcoming-august-investor-conferences-nuvalent-inc-nasdaq-nuvl-a-nuvl-20230801monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-participate-in-the-td-cowen-4th-annual-oncology-innovation-summit-nuvalent-inc-nuvl-20230524monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-participate-in-the-stifel-2023-virtual-targeted-oncology-days-nuvalent-inc-nas-nuvl-202304192023-04-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-presents-new-preclinical-data-supporting-intracranial-activity-of-nvl-655-at-aacr-nuvl-202304182023-04-18T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-present-alkove-1-trial-in-progress-poster-for-nvl-655-at-the-european-lung-can-nuvl-202303232023-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-present-new-preclinical-data-on-alk-selective-inhibitor-nvl-655-at-aacr-annual-nuvl-202303142023-03-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-participate-in-the-43rd-annual-cowen-healthcare-conference-nuvalent-inc-nasdaq-nuvl-202303012023-03-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-nuvalent-inc-nasda-nuvl-202301042023-01-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-announces-publication-in-cancer-discovery-detailing-design-and-characterization-o-nuvl-20221213monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-announces-closing-of-upsized-public-offering-of-common-stock-nuvalent-inc-nasdaq--nuvl-20221103monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-announces-public-offering-of-common-stock-nuvalent-inc-nasdaq-nuvl-a-clinical-sta-nuvl-20221031monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-announces-new-preclinical-data-for-selective-kinase-inhibitors-nvl-330-and-nvl-65-nuvl-20221026monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-host-conference-call-to-discuss-preliminary-phase-1-data-from-arros-1-clinical-nuvl-20221017monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-appoints-michael-l-meyers-md-phd-to-board-of-directors-nuvalent-inc-nasdaq-nuvl-a-nuvl-20221006monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-present-preliminary-phase-1-data-from-arros-1-clinical-trial-of-nvl-520-at-34t-nuvl-20220907monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-participate-in-the-wells-fargo-2022-healthcare-conference-nuvalent-inc-nasdaq--nuvl-20220901monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-presents-new-preclinical-data-supporting-potential-best-in-class-profile-for-alk--nuvl-20220805monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-present-at-the-canaccord-genuity-42nd-annual-growth-conference-nuvalent-inc-na-nuvl-20220803monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-announces-leadership-promotions-nuvalent-inc-nasdaq-nuvl-a-clinical-stage-biophar-nuvl-20220720monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-present-new-nvl-655-preclinical-data-and-arros-1-trial-in-progress-poster-for--nuvl-20220713monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-announces-clinical-progress-on-parallel-lead-programs-nvl-520-and-nvl-655-for-nsc-nuvl-20220621monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-present-at-the-2022-jefferies-healthcare-conference-nuvalent-inc-nasdaq-nuvl-a-nuvl-20220602monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-presents-new-data-demonstrating-expanded-preclinical-activity-with-ros1-selective-nuvl-20220408monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-participate-in-the-2022-canaccord-genuity-horizons-in-oncology-virtual-confere-nuvl-20220407monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-appoints-anna-protopapas-as-chair-of-board-of-directors-nuvalent-inc-nasdaq-nuvl--nuvl-20220331monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-present-new-preclinical-data-on-ros1-selective-inhibitor-nvl-520-and-alk-selec-nuvl-20220308monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-participate-in-the-cowen-42nd-annual-healthcare-conference-nuvalent-inc-nasdaq-nuvl-20220302monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-appoints-emily-drabant-conley-phd-to-board-of-directors-nuvalent-inc-nasdaq-nuvl--nuvl-20220203monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-announces-first-patient-dosed-in-arros-1-phase-1-2-clinical-trial-of-nvl-520-its--nuvl-20220107monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-nuvalent-inc-nasda-nuvl-20220104monthly0.5https://www.biopharmawatch.com/news/NUVL/new-preclinical-data-supports-nuvalent-lead-programs-in-ros1-positive-alk-positive-nsclc-n-nuvl-20211007monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-announces-closing-of-upsized-initial-public-offering-nuvalent-inc-a-biopharmaceut-nuvl-20210802monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-announces-pricing-of-initial-public-offering-nuvalent-inc-a-biopharmaceutical-com-nuvl-20210728monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-completes-135-million-series-b-financing-to-advance-portfolio-of-novel-precisely--nuvl-20210511monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-presents-preclinical-data-demonstrating-that-ros1-inhibitor-nuv-520-and-alk-inhib-nuvl-20210410monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-appoints-christopher-turner-m-d-as-chief-medical-officer-nuvalent-inc-a-biotechno-nuvl-20210323monthly0.5https://www.biopharmawatch.com/news/NUVL/nuvalent-launches-with-50m-series-a-financing-from-deerfield-management-to-develop-precise-nuvl-20210127monthly0.5https://www.biopharmawatch.com/news/JNJ/new-talvey-talquetamab-tgvs-plus-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-data-d-jnj-20260613monthly0.5https://www.biopharmawatch.com/news/JNJ/imaavy-nipocalimab-aahu-demonstrates-durable-hemoglobin-response-and-rapid-onset-of-effect-jnj-20260611monthly0.5https://www.biopharmawatch.com/news/JNJ/groundbreaking-global-survey-captures-the-significant-patient-burden-experienced-with-curr-jnj-20260514monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-launches-generation-fine-a-new-movement-encouraging-patients-to-expect-mor-jnj-20260507monthly0.5https://www.biopharmawatch.com/news/JNJ/fda-approves-caplyta-lumateperone-snda-with-robust-new-data-supporting-reduced-risk-of-rel-jnj-20260427monthly0.5https://www.biopharmawatch.com/news/JNJ/imaavy-nipocalimab-aahu-shows-over-two-years-of-sustained-disease-control-in-a-broad-popul-jnj-20260422monthly0.5https://www.biopharmawatch.com/news/JNJ/fda-approval-of-icotyde-icotrokinra-ushers-in-new-era-for-first-line-systemic-treatment-of-jnj-20260318monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-highlights-promising-first-in-human-erda-idrs-formerly-tar-210-results-in--jnj-20260313monthly0.5https://www.biopharmawatch.com/news/JNJ/real-world-head-to-head-analysis-shows-51-reduction-in-risk-of-death-for-patients-with-met-jnj-20260202monthly0.5https://www.biopharmawatch.com/news/JNJ/new-clinical-data-highlights-caplyta-lumateperone-as-a-promising-option-for-achieving-remi-jnj-20260116monthly0.5https://www.biopharmawatch.com/news/JNJ/rybrevant-amivantamab-vmjw-longer-term-results-show-promising-and-durable-responses-in-dif-jnj-20260110monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-celebrates-innovation-in-cancer-research-with-2025-dr-paul-janssen-award-j-jnj-20260108monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-unveils-new-data-showing-nipocalimab-is-the-first-and-only-investigational-jnj-20260106monthly0.5https://www.biopharmawatch.com/news/JNJ/darzalex-faspro-is-the-first-and-only-treatment-approved-by-the-u-s-fda-for-patients-with--jnj-20251106monthly0.5https://www.biopharmawatch.com/news/JNJ/tecvayli-plus-darzalex-faspro-combination-regimen-significantly-improves-progression-free--jnj-20251016monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-highlight-breadth-of-its-major-depressive-disorder-portfolio-at-2025-ec-jnj-20251010monthly0.5https://www.biopharmawatch.com/news/JNJ/icotrokinra-data-in-ulcerative-colitis-show-potential-for-a-standout-combination-of-therap-jnj-20251007monthly0.5https://www.biopharmawatch.com/news/JNJ/tremfya-guselkumab-is-first-and-only-il-23-inhibitor-to-demonstrate-sustained-clinical-and-jnj-20251007monthly0.5https://www.biopharmawatch.com/news/JNJ/u-s-fda-approves-tremfya-guselkumab-for-the-treatment-of-pediatric-plaque-psoriasis-and-ac-jnj-20250929monthly0.5https://www.biopharmawatch.com/news/JNJ/tremfya-guselkumab-achieves-u-s-approval-for-subcutaneous-induction-in-adults-with-ulcerat-jnj-20250919monthly0.5https://www.biopharmawatch.com/news/JNJ/tecvayli-and-darzalex-faspro-based-induction-treatment-demonstrates-promising-rates-and-de-jnj-20250919monthly0.5https://www.biopharmawatch.com/news/JNJ/icotrokinra-shows-superiority-to-deucravacitinib-in-first-reported-head-to-head-trials-rei-jnj-20250917monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-showcase-industry-leading-neuropsychiatry-innovations-at-the-2025-psych-jnj-20250915monthly0.5https://www.biopharmawatch.com/news/JNJ/u-s-fda-approval-of-inlexzo-gemcitabine-intravesical-system-set-to-transform-how-certain-b-jnj-20250909monthly0.5https://www.biopharmawatch.com/news/JNJ/data-published-in-the-new-england-journal-of-medicine-demonstrate-rybrevant-amivantamab-vm-jnj-20250907monthly0.5https://www.biopharmawatch.com/news/JNJ/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-prevents-acquired-resistance-versus-os-jnj-20250906monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-files-with-u-s-fda-to-include-new-evidence-in-tremfya-guselkumab-label-as--jnj-20250729monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-showcases-latest-advancements-in-alzheimer-s-research-at-aaic-2025-johnson-jnj-20250724monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-seeks-first-icotrokinra-u-s-fda-approval-aiming-to-revolutionize-treatment-jnj-20250721monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-receives-u-s-fda-priority-review-for-tar-200-nda-in-high-risk-non-muscle-i-jnj-20250717monthly0.5https://www.biopharmawatch.com/news/JNJ/supplemental-new-drug-application-submitted-to-u-s-fda-for-caplyta-lumateperone-with-data--jnj-20250708monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-launches-first-and-only-daily-disposable-multifocal-toric-contact-lens-acu-jnj-20250623monthly0.5https://www.biopharmawatch.com/news/JNJ/imaavy-nipocalimab-aahu-showed-greater-sustained-disease-control-versus-approved-fcrn-bloc-jnj-20250623monthly0.5https://www.biopharmawatch.com/news/JNJ/investigational-combination-of-first-in-class-bispecifics-talvey-and-tecvayli-shows-deep-a-jnj-20250615monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-s-dual-targeting-car-t-cell-therapy-shows-encouraging-first-results-in-lar-jnj-20250613monthly0.5https://www.biopharmawatch.com/news/JNJ/new-results-for-johnson-johnson-s-bleximenib-demonstrate-promising-antileukemic-activity-i-jnj-20250612monthly0.5https://www.biopharmawatch.com/news/JNJ/new-data-show-tremfya-guselkumab-is-the-only-il-23-inhibitor-proven-to-significantly-inhib-jnj-20250611monthly0.5https://www.biopharmawatch.com/news/JNJ/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-based-regimen-shows-95-percent-progress-jnj-20250603monthly0.5https://www.biopharmawatch.com/news/JNJ/single-infusion-of-carvykti-ciltacabtagene-autoleucel-delivered-lasting-treatment-free-rem-jnj-20250603monthly0.5https://www.biopharmawatch.com/news/JNJ/early-results-from-johnson-johnson-s-trispecific-antibody-show-promising-response-in-heavi-jnj-20250603monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-leads-with-first-parp-inhibitor-combo-to-improve-efficacy-in-patients-with-jnj-20250603monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-unveils-first-in-human-results-for-pasritamig-showing-early-anti-tumor-act-jnj-20250601monthly0.5https://www.biopharmawatch.com/news/JNJ/u-s-fda-oncologic-drugs-advisory-committee-votes-in-favor-of-the-benefit-risk-profile-of-d-jnj-20250520monthly0.5https://www.biopharmawatch.com/news/JNJ/icotrokinra-results-show-significant-skin-clearance-in-patients-with-difficult-to-treat-sc-jnj-20250509monthly0.5https://www.biopharmawatch.com/news/JNJ/tremfya-guselkumab-positioned-to-become-the-first-and-only-il-23-inhibitor-to-offer-subcut-jnj-20250505monthly0.5https://www.biopharmawatch.com/news/JNJ/tremfya-guselkumab-delivers-sustained-clinical-and-endoscopic-remission-in-ulcerative-coli-jnj-20250505monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-receives-fda-approval-for-imaavy-nipocalimab-aahu-a-new-fcrn-blocker-offer-jnj-20250430monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-s-tar-200-monotherapy-achieves-high-disease-free-survival-of-more-than-80--jnj-20250426monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-s-tar-200-monotherapy-demonstrates-highest-complete-response-rate-with-sus-jnj-20250426monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-unveils-highly-anticipated-and-potential-practice-changing-data-in-bladder-jnj-20250421monthly0.5https://www.biopharmawatch.com/news/JNJ/icotrokinra-results-show-75-of-adolescents-with-plaque-psoriasis-achieved-completely-clear-jnj-20250410monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-highlights-new-data-that-showcase-the-strength-of-nipocalimab-demonstratin-jnj-20250408monthly0.5https://www.biopharmawatch.com/news/JNJ/tremfya-guselkumab-is-the-first-and-only-il-23-inhibitor-to-significantly-reduce-both-the--jnj-20250404monthly0.5https://www.biopharmawatch.com/news/JNJ/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-outperforms-osimertinib-with-a-signifi-jnj-20250326monthly0.5https://www.biopharmawatch.com/news/JNJ/new-nipocalimab-data-and-real-world-research-at-aan-2025-highlight-positive-phase-3-result-jnj-20250326monthly0.5https://www.biopharmawatch.com/news/JNJ/u-s-fda-approves-tremfya-guselkumab-the-first-and-only-il-23-inhibitor-offering-both-subcu-jnj-20250320monthly0.5https://www.biopharmawatch.com/news/JNJ/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-significantly-outperforms-standard-of--jnj-20250320monthly0.5https://www.biopharmawatch.com/news/JNJ/nipocalimab-the-first-and-only-investigational-treatment-to-be-granted-u-s-fda-breakthroug-jnj-20250318monthly0.5https://www.biopharmawatch.com/news/JNJ/icotrokinra-meets-primary-endpoint-of-clinical-response-in-ulcerative-colitis-study-and-sh-jnj-20250310monthly0.5https://www.biopharmawatch.com/news/JNJ/icotrokinra-results-show-potential-to-set-a-new-standard-of-treatment-in-plaque-psoriasis--jnj-20250308monthly0.5https://www.biopharmawatch.com/news/JNJ/tremfya-guselkumab-subcutaneous-sc-induction-data-support-potential-to-be-the-first-and-on-jnj-20250221monthly0.5https://www.biopharmawatch.com/news/JNJ/new-nipocalimab-data-published-in-mabs-journal-details-differentiated-molecular-design-cli-jnj-20250213monthly0.5https://www.biopharmawatch.com/news/JNJ/findings-from-pivotal-nipocalimab-phase-3-study-in-a-broad-antibody-positive-population-of-jnj-20250123monthly0.5https://www.biopharmawatch.com/news/JNJ/spravato-esketamine-approved-in-the-u-s-as-the-first-and-only-monotherapy-for-adults-with--jnj-20250121monthly0.5https://www.biopharmawatch.com/news/JNJ/new-drug-application-initiated-with-u-s-fda-for-tar-200-the-first-and-only-intravesical-dr-jnj-20250115monthly0.5https://www.biopharmawatch.com/news/JNJ/nipocalimab-granted-u-s-fda-priority-review-for-the-treatment-of-generalized-myasthenia-gr-jnj-20250109monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-s-posdinemab-and-tau-active-immunotherapy-receive-u-s-fda-fast-track-desig-jnj-20250108monthly0.5https://www.biopharmawatch.com/news/JNJ/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-show-statistically-significant-and-cli-jnj-20250107monthly0.5https://www.biopharmawatch.com/news/JNJ/carvykti-ciltacabtagene-autoleucel-demonstrated-significantly-higher-rates-of-minimal-resi-jnj-20241209monthly0.5https://www.biopharmawatch.com/news/JNJ/warm-autoimmune-hemolytic-anemia-waiha-research-presented-by-johnson-johnson-highlights-pr-jnj-20241209monthly0.5https://www.biopharmawatch.com/news/JNJ/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-based-regimens-demonstrate-improved-rat-jnj-20241208monthly0.5https://www.biopharmawatch.com/news/JNJ/tecvayli-teclistamab-cqyv-demonstrates-potential-as-frontline-combination-therapy-for-pati-jnj-20241208monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-seeks-u-s-fda-approval-for-first-pediatric-indications-for-tremfya-guselku-jnj-20241202monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-seeks-u-s-fda-approval-for-subcutaneous-induction-regimen-of-tremfya-gusel-jnj-20241122monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-showcase-strength-of-its-broad-hematology-portfolio-and-pipeline-at-the-jnj-20241119monthly0.5https://www.biopharmawatch.com/news/JNJ/icotrokinra-delivered-an-industry-leading-combination-of-significant-skin-clearance-with-d-jnj-20241118monthly0.5https://www.biopharmawatch.com/news/JNJ/nipocalimab-demonstrates-significant-clinical-improvement-in-disease-activity-and-igg-redu-jnj-20241114monthly0.5https://www.biopharmawatch.com/news/JNJ/nipocalimab-is-the-first-and-only-investigational-therapy-granted-u-s-fda-breakthrough-the-jnj-20241111monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-submits-applications-in-the-u-s-and-eu-seeking-approval-of-darzalex-faspro-jnj-20241108monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-advances-leadership-in-rheumatic-disease-innovation-with-43-abstracts-at-a-jnj-20241107monthly0.5https://www.biopharmawatch.com/news/JNJ/tremfya-guselkumab-is-the-first-and-only-il-23-inhibitor-to-demonstrate-robust-results-wit-jnj-20241028monthly0.5https://www.biopharmawatch.com/news/JNJ/new-spectrem-study-findings-reveal-tremfya-guselkumab-effectively-clears-overlooked-and-un-jnj-20241025monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-highlights-innovative-neuropsychiatry-portfolio-and-pipeline-at-psych-cong-jnj-20241024monthly0.5https://www.biopharmawatch.com/news/JNJ/nipocalimab-demonstrates-sustained-disease-control-in-adolescents-living-with-generalized--jnj-20241015monthly0.5https://www.biopharmawatch.com/news/JNJ/tremfya-guselkumab-demonstrates-impressive-results-across-biologic-nai-ve-and-biologic-ref-jnj-20241010monthly0.5https://www.biopharmawatch.com/news/JNJ/erleada-apalutamide-demonstrates-statistically-significant-and-clinically-meaningful-impro-jnj-20241002monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-files-for-u-s-fda-approval-of-darzalex-faspro-based-quadruplet-regimen-for-jnj-20240930monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-rolls-out-new-tecnis-odyssey-next-generation-intraocular-lens-offering-cat-jnj-20240930monthly0.5https://www.biopharmawatch.com/news/JNJ/carvykti-is-the-first-and-only-cell-therapy-to-significantly-extend-overall-survival-versu-jnj-20240927monthly0.5https://www.biopharmawatch.com/news/JNJ/darzalex-daratumumab-based-maintenance-regimens-show-clinically-meaningful-deep-and-durabl-jnj-20240927monthly0.5https://www.biopharmawatch.com/news/JNJ/darzalex-faspro-based-quadruplet-regimen-significantly-improves-minimal-residual-disease-n-jnj-20240927monthly0.5https://www.biopharmawatch.com/news/JNJ/novel-combination-of-talvey-talquetamab-tgvs-and-tecvayli-teclistamab-cqyv-suggests-high-r-jnj-20240927monthly0.5https://www.biopharmawatch.com/news/JNJ/talvey-talquetamab-tgvs-and-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-based-combi-jnj-20240927monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-celebrates-innovation-in-regulated-rna-and-protein-degradation-with-2024-d-jnj-20240925monthly0.5https://www.biopharmawatch.com/news/JNJ/rybrevant-amivantamab-vmjw-plus-standard-of-care-approved-in-the-u-s-as-first-and-only-tar-jnj-20240919monthly0.5https://www.biopharmawatch.com/news/JNJ/neoadjuvant-tar-200-plus-cetrelimab-nearly-doubles-the-pathological-complete-response-rate-jnj-20240916monthly0.5https://www.biopharmawatch.com/news/JNJ/new-data-from-tar-200-phase-2b-sunrise-1-study-show-84-percent-complete-response-rate-in-p-jnj-20240915monthly0.5https://www.biopharmawatch.com/news/JNJ/rybrevant-amivantamab-vmjw-plus-chemotherapy-show-49-percent-overall-response-rate-in-meta-jnj-20240914monthly0.5https://www.biopharmawatch.com/news/JNJ/rybrevant-amivantamab-vmjw-plus-chemotherapy-shows-positive-overall-survival-trend-versus--jnj-20240914monthly0.5https://www.biopharmawatch.com/news/JNJ/tremfya-guselkumab-receives-u-s-fda-approval-for-adults-with-moderately-to-severely-active-jnj-20240911monthly0.5https://www.biopharmawatch.com/news/JNJ/dexamethasone-reduces-infusion-related-reactions-in-patients-with-egfr-mutated-non-small-c-jnj-20240910monthly0.5https://www.biopharmawatch.com/news/JNJ/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-show-strong-favorable-overall-survival-jnj-20240908monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-seeks-first-approval-of-nipocalimab-to-treat-broadest-population-living-wi-jnj-20240829monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-is-transforming-solid-tumor-cancer-outcomes-with-new-data-at-the-2024-worl-jnj-20240827monthly0.5https://www.biopharmawatch.com/news/JNJ/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-approved-in-the-u-s-as-a-first-line-ch-jnj-20240820monthly0.5https://www.biopharmawatch.com/news/JNJ/groundbreaking-nipocalimab-study-of-pregnant-individuals-at-high-risk-for-early-onset-seve-jnj-20240807monthly0.5https://www.biopharmawatch.com/news/JNJ/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-based-quadruplet-regimen-approved-in-th-jnj-20240730monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-seeks-u-s-fda-approval-of-spravato-esketamine-as-the-first-and-only-monoth-jnj-20240722monthly0.5https://www.biopharmawatch.com/news/JNJ/carvykti-ciltacabtagene-autoleucel-achieved-statistically-significant-and-clinically-meani-jnj-20240702monthly0.5https://www.biopharmawatch.com/news/JNJ/nipocalimab-pivotal-phase-3-trial-demonstrates-longest-sustained-disease-control-in-fcrn-c-jnj-20240628monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-submits-application-to-u-s-fda-seeking-approval-of-tremfya-guselkumab-for--jnj-20240620monthly0.5https://www.biopharmawatch.com/news/JNJ/tremfya-guselkumab-studies-underscore-its-potential-to-be-the-only-il-23-inhibitor-to-offe-jnj-20240620monthly0.5https://www.biopharmawatch.com/news/JNJ/subcutaneous-amivantamab-biologics-license-application-submitted-to-u-s-fda-for-patients-w-jnj-20240617monthly0.5https://www.biopharmawatch.com/news/JNJ/talvey-talquetamab-tgvs-demonstrates-highly-durable-longer-term-responses-in-patients-with-jnj-20240614monthly0.5https://www.biopharmawatch.com/news/JNJ/carvykti-ciltacabtagene-autoleucel-significantly-improved-progression-free-survival-and-de-jnj-20240603monthly0.5https://www.biopharmawatch.com/news/JNJ/darzalex-daratumumab-based-regimens-significantly-improve-clinical-outcomes-in-both-transp-jnj-20240603monthly0.5https://www.biopharmawatch.com/news/JNJ/late-breaking-results-from-paloma-2-study-of-subcutaneous-amivantamab-in-combination-with--jnj-20240603monthly0.5https://www.biopharmawatch.com/news/JNJ/tecvayli-teclistamab-cqyv-shows-sustained-deep-and-durable-responses-in-patients-with-rela-jnj-20240603monthly0.5https://www.biopharmawatch.com/news/JNJ/first-results-from-late-breaking-phase-3-paloma-3-study-show-five-fold-reduction-in-infusi-jnj-20240531monthly0.5https://www.biopharmawatch.com/news/JNJ/rybrevant-amivantamab-vmjw-plus-lazertinib-is-the-only-chemotherapy-free-regimen-showing-l-jnj-20240531monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-pivotal-study-of-seltorexant-shows-statistically-significant-and-clinicall-jnj-20240529monthly0.5https://www.biopharmawatch.com/news/JNJ/tremfya-guselkumab-demonstrates-superiority-versus-stelara-ustekinumab-in-phase-3-crohn-s--jnj-20240521monthly0.5https://www.biopharmawatch.com/news/JNJ/tremfya-guselkumab-quasar-maintenance-study-in-uc-met-its-primary-endpoint-and-all-major-s-jnj-20240520monthly0.5https://www.biopharmawatch.com/news/JNJ/tar-210-results-show-90-recurrence-free-survival-and-90-complete-response-in-patients-with-jnj-20240505monthly0.5https://www.biopharmawatch.com/news/JNJ/phase-2-data-for-erleada-apalutamide-plus-androgen-deprivation-therapy-following-radical-p-jnj-20240503monthly0.5https://www.biopharmawatch.com/news/JNJ/tar-200-monotherapy-shows-greater-than-80-complete-response-rate-in-patients-with-high-ris-jnj-20240503monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-submits-regulatory-applications-to-european-medicines-agency-for-tremfya-g-jnj-20240501monthly0.5https://www.biopharmawatch.com/news/JNJ/unique-molecular-properties-of-nipocalimab-enabling-differentiated-potential-in-treating-g-jnj-20240411monthly0.5https://www.biopharmawatch.com/news/JNJ/findings-presented-at-acc-24-showed-xarelto-rivaroxaban-reduced-the-risk-of-clinically-sig-jnj-20240408monthly0.5https://www.biopharmawatch.com/news/JNJ/carvykti-is-the-first-and-only-bcma-targeted-treatment-approved-by-the-u-s-fda-for-patient-jnj-20240405monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-showcase-its-broad-scientific-leadership-and-latest-innovations-to-comb-jnj-20240404monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-s-nipocalimab-granted-u-s-fda-fast-track-designation-to-reduce-the-risk-of-jnj-20240326monthly0.5https://www.biopharmawatch.com/news/JNJ/u-s-fda-approves-opsynvi-macitentan-and-tadalafil-as-the-first-and-only-once-daily-single--jnj-20240322monthly0.5https://www.biopharmawatch.com/news/JNJ/rybrevant-amivantamab-vmjw-data-at-elcc-advance-johnson-johnson-s-ambition-to-transform-th-jnj-20240318monthly0.5https://www.biopharmawatch.com/news/JNJ/u-s-fda-oncologic-drugs-advisory-committee-recommends-carvykti-ciltacabtagene-autoleucel-f-jnj-20240315monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-submits-supplemental-biologics-license-application-to-u-s-fda-seeking-appr-jnj-20240311monthly0.5https://www.biopharmawatch.com/news/JNJ/new-data-shows-jnj-2113-the-first-and-only-investigational-targeted-oral-peptide-maintaine-jnj-20240309monthly0.5https://www.biopharmawatch.com/news/JNJ/rybrevant-amivantamab-vmjw-in-combination-with-chemotherapy-is-the-first-fda-approved-ther-jnj-20240301monthly0.5https://www.biopharmawatch.com/news/JNJ/tecvayli-teclistamab-cqyv-biweekly-dosing-approved-by-the-u-s-fda-for-the-treatment-of-pat-jnj-20240220monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-s-nipocalimab-granted-u-s-fda-breakthrough-therapy-designation-for-the-tre-jnj-20240209monthly0.5https://www.biopharmawatch.com/news/JNJ/investigational-targeted-oral-peptide-jnj-2113-demonstrated-positive-results-in-moderate-t-jnj-20240207monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-celebrates-innovation-in-novel-drug-delivery-systems-with-2023-dr-paul-jan-jnj-20240207monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-positive-topline-results-for-nipocalimab-from-a-phase-3-pivotal-st-jnj-20240205monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-submits-supplemental-biologics-license-application-to-u-s-fda-seeking-appr-jnj-20240130monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-highlights-ambition-to-transform-the-treatment-of-prostate-cancer-and-blad-jnj-20240124monthly0.5https://www.biopharmawatch.com/news/JNJ/tremfya-guselkumab-demonstrates-significant-and-rapid-scalp-psoriasis-clearance-in-people--jnj-20240122monthly0.5https://www.biopharmawatch.com/news/JNJ/u-s-food-and-drug-administration-grants-full-approval-for-balversa-to-treat-locally-advanc-jnj-20240119monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-submits-supplemental-biologics-license-application-and-new-drug-applicatio-jnj-20231221monthly0.5https://www.biopharmawatch.com/news/JNJ/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-based-quadruplet-therapy-regimen-shows--jnj-20231212monthly0.5https://www.biopharmawatch.com/news/JNJ/new-analyses-demonstrate-versatility-and-continued-efficacy-of-talvey-in-the-treatment-of--jnj-20231211monthly0.5https://www.biopharmawatch.com/news/JNJ/treatment-with-carvykti-ciltacabtagene-autoleucel-resulted-in-clinically-meaningful-improv-jnj-20231211monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-s-investigational-tar-200-granted-u-s-fda-breakthrough-therapy-designation-jnj-20231204monthly0.5https://www.biopharmawatch.com/news/JNJ/applications-open-for-johnson-johnson-s-second-health-equity-innovation-challenge-johnson--jnj-20231002monthly0.5https://www.biopharmawatch.com/news/JNJ/belatina-tv-host-celebrity-dentist-and-former-the-real-housewives-of-miami-star-karent-sie-jnj-20220720monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-opens-first-satellite-center-for-global-health-discovery-in-asia-pacific-a-jnj-20220620monthly0.5https://www.biopharmawatch.com/news/JNJ/los-principales-agentes-de-cambio-locales-que-abordan-las-brechas-de-equidad-en-la-salud-e-jnj-20220616monthly0.5https://www.biopharmawatch.com/news/JNJ/top-local-changemakers-addressing-health-equity-gaps-across-the-u-s-named-johnson-johnson--jnj-20220614monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-releases-2021-health-for-humanity-report-highlighting-performance-on-esg-p-jnj-20220608monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-goldman-sachs-43rd-annual-global-healthcare-conference-j-jnj-20220512monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-appoints-thibaut-mongon-as-ceo-designate-of-planned-new-consumer-health-co-jnj-20220511monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-bernstein-38th-annual-strategic-decisions-conference-jnj-20220502monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-launches-next-satellite-center-for-global-health-discovery-at-holistic-dru-jnj-20220425monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-ubs-global-healthcare-conference-johnson-johnson-nys-jnj-20220420monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-q1-2022-results-total-sales-growth-of-5-0-to-23-4-billion-with-ope-jnj-20220419monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-dividend-increase-of-6-6-johnson-johnson-nyse-jnj-today-announce-jnj-20220419monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-bofa-securities-2022-healthcare-conference-new-bruns-jnj-20220407monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-investor-conference-call-on-first-quarter-results-johnson-johnson--jnj-20220315monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-names-darius-adamczyk-chairman-and-chief-executive-officer-of-honeywell-to-jnj-20220215monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-raymond-james-43rd-annual-institutional-investors-co-jnj-20220209monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-cowen-42nd-annual-health-care-virtual-conference-joh-jnj-20220207monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-citi-s-2022-virtual-healthcare-conference-johnson-johnso-jnj-20220127monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-q4-and-full-year-2021-results-johnson-johnson-nyse-jnj-today-annou-jnj-20220125monthly0.5https://www.biopharmawatch.com/news/JNJ/real-world-evidence-shows-johnson-johnson-covid-19-vaccine-demonstrates-durable-protection-jnj-20220106monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-quarterly-dividend-for-first-quarter-2022-johnson-johnson-nyse-j-jnj-20220104monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-covid-19-vaccine-demonstrates-85-percent-effectiveness-against-hospitaliza-jnj-20211230monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-positive-chmp-opinion-for-a-booster-shot-of-its-covid-19-vaccine-jnj-20211215monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-investor-conference-call-on-fourth-quarter-results-johnson-johnson-jnj-20211210monthly0.5https://www.biopharmawatch.com/news/JNJ/world-health-organization-strategic-advisory-group-of-experts-sage-interim-recommendation--jnj-20211209monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-appoints-senior-leaders-to-executive-committee-johnson-johnson-nyse-jnj-th-jnj-20211209monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-covid-19-booster-administered-six-months-after-two-dose-regimen-of-bnt162b-jnj-20211205monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-plans-to-accelerate-innovation-serve-patients-and-consumers-and--jnj-20211112monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-enters-into-agreement-to-provide-its-single-shot-covid-19-vaccine-for-the--jnj-20211110monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-endows-research-america-outstanding-achievement-in-public-health-awards-jo-jnj-20211109monthly0.5https://www.biopharmawatch.com/news/JNJ/u-s-cdc-advisory-committee-unanimously-recommends-johnson-johnson-covid-19-vaccine-as-a-bo-jnj-20211021monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-quarterly-dividend-for-fourth-quarter-2021-johnson-johnson-nyse--jnj-20211021monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-covid-19-vaccine-booster-shot-authorized-for-emergency-use-by-u-s-fda-john-jnj-20211020monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-q3-2021-results-johnson-johnson-nyse-jnj-today-announced-results-f-jnj-20211019monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-covid-19-vaccine-booster-shot-unanimously-recommended-for-emergency-use-au-jnj-20211015monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-takes-steps-to-equitably-resolve-all-current-and-future-talc-claims-johnso-jnj-20211014monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-business-review-highlighting-pharmaceuticals-johnson-johnson-nyse--jnj-20211013monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-jessica-moore-as-vice-president-of-investor-relations-johnson-jo-jnj-20211012monthly0.5https://www.biopharmawatch.com/news/JNJ/dr-paul-stoffels-vice-chairman-of-the-executive-committee-and-chief-scientific-officer-of--jnj-20211012monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-credit-suisse-30th-annual-healthcare-conference-john-jnj-20211011monthly0.5https://www.biopharmawatch.com/news/JNJ/janssen-announces-novel-mechanism-of-action-that-shows-promise-against-dengue-in-data-publ-jnj-20211006monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-submission-of-emergency-use-authorization-amendment-to-the-u-s-f-jnj-20211005monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-celebrates-covid-19-vaccine-science-superheroes-johnson-johnson-nyse-jnj-t-jnj-20210928monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-real-world-evidence-and-phase-3-data-confirming-strong-and-long--jnj-20210921monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-investor-conference-call-on-third-quarter-results-johnson-johnson--jnj-20210916monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-ebola-vaccine-regimen-demonstrated-robust-and-durable-immune-response-in-a-jnj-20210913monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-and-global-partners-announce-results-from-phase-2b-imbokodo-hiv-vaccine-cl-jnj-20210831monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-seeks-global-nominees-for-award-geared-at-female-researchers-working-in-sc-jnj-20210826monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-cantor-virtual-global-healthcare-conference-johnson--jnj-20210826monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-data-to-support-boosting-its-single-shot-covid-19-vaccine-johnso-jnj-20210825monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-morgan-stanley-19th-annual-global-healthcare-confere-jnj-20210812monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-barclays-global-consumer-staples-virtual-conference-john-jnj-20210809monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-virtual-wells-fargo-healthcare-conference-johnson-jo-jnj-20210727monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-q2-2021-results-johnson-johnson-nyse-jnj-today-announced-results-f-jnj-20210721monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-quarterly-dividend-for-third-quarter-2021-johnson-johnson-nyse-j-jnj-20210719monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-consumer-inc-issues-voluntary-recall-of-specific-neutrogena-and-aveeno-aer-jnj-20210714monthly0.5https://www.biopharmawatch.com/news/JNJ/positive-new-data-for-johnson-johnson-single-shot-covid-19-vaccine-on-activity-against-del-jnj-20210701monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-investor-conference-call-on-second-quarter-results-johnson-johnson-jnj-20210609monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-releases-2020-health-for-humanity-report-highlighting-performance-and-prog-jnj-20210609monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-live-esg-investor-update-webcast-johnson-johnson-nyse-jnj-announce-jnj-20210524monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-joins-world-health-organization-in-efforts-to-prevent-spread-of-ebola-in-w-jnj-20210513monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-single-shot-covid-19-vaccinations-to-resume-in-the-u-s-for-all-adults-aged-jnj-20210423monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-consumer-health-presents-new-data-on-skincare-for-cancer-patients-at-the-a-jnj-20210423monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-consumer-health-reveals-new-skin-health-research-at-american-academy-of-de-jnj-20210423monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-covid-19-vaccine-roll-out-to-resume-in-europe-following-european-medicines-jnj-20210420monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-dividend-increase-of-5-0-johnson-johnson-nyse-jnj-today-announce-jnj-20210420monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-annonce-un-accord-d-achat-anticipe-avec-l-african-vaccine-acquisition-trus-jnj-20210330monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-anuncia-un-acuerdo-de-compra-anticipado-con-el-african-vaccine-acquisition-jnj-20210330monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-anuncia-acordo-de-compra-antecipada-com-o-fundo-africano-de-aquisic-a-o-de-jnj-20210329monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-gibt-vorab-kaufvertrag-mit-dem-african-vaccine-acquisition-trust-fu-r-den--jnj-20210329monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-anuncia-un-acuerdo-de-compra-para-la-vacuna-candidata-de-covid-19-de-la-em-jnj-20210329monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-advance-purchase-agreement-with-the-african-vaccine-acquisition--jnj-20210329monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-single-shot-covid-19-vaccine-granted-emergency-use-listing-by-the-world-he-jnj-20210312monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-u-s-cdc-advisory-committee-recommends-first-single-shot-covid-19-jnj-20210228monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-covid-19-vaccine-authorized-by-u-s-fda-for-emergency-use-johnson-johnson-n-jnj-20210227monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-single-shot-covid-19-vaccine-candidate-unanimously-recommended-for-emergen-jnj-20210226monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-submission-to-world-health-organization-for-emergency-use-listin-jnj-20210219monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-submission-of-application-to-the-u-s-fda-for-emergency-use-autho-jnj-20210204monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpo-jnj-20210129monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-quarterly-dividend-for-first-quarter-2021-johnson-johnson-nyse-j-jnj-20210104monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-names-dr-nadja-west-retired-united-states-army-lieutenant-general-and-form-jnj-20201203monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-fireside-chat-webcast-on-janssen-s-eye-disease-portfolio-the-jan-jnj-20201203monthly0.5https://www.biopharmawatch.com/news/JNJ/new-survey-finds-critical-need-for-education-on-cataracts-and-modern-treatment-options-tod-jnj-20201201monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-address-racial-and-social-injustice-through-platform-that-aims-to-elimi-jnj-20201117monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-and-u-s-department-of-health-human-services-expand-agreement-to-support-ne-jnj-20201114monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-virtual-medical-devices-update-johnson-johnson-nyse-jnj-will-hold--jnj-20201106monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-quarterly-dividend-for-fourth-quarter-2020-johnson-johnson-nyse--jnj-20201022monthly0.5https://www.biopharmawatch.com/news/JNJ/a-johnson-johnson-anuncia-a-aprovac-a-o-pela-comissa-o-europeia-do-contrato-para-fornecer--jnj-20201010monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-annonce-que-la-commission-europe-enne-a-approuve-un-accord-visant-a-fourni-jnj-20201009monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-gibt-die-zustimmung-der-europa-ischen-kommission-zu-vertrag-u-ber-die-lief-jnj-20201009monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-anuncia-aprobacio-n-por-parte-de-la-comisio-n-europea-del-acuerdo-para-pro-jnj-20201009monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-suministrara-200-millones-de-dosis-del-candidato-a-vacuna-de-covid-19-de-j-jnj-20201008monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-european-commission-approval-of-agreement-to-supply-200-million--jnj-20201008monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-completes-acquisition-of-momenta-pharmaceuticals-inc-johnson-johnson-nyse--jnj-20201001monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-startet-globale-phase-3-zulassungsstudie-fu-r-janssens-covid-19-impfstoffk-jnj-20200924monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-entreprend-un-essai-clinique-pivot-de-phase-3-du-vaccin-candidat-contre-la-jnj-20200924monthly0.5https://www.biopharmawatch.com/news/JNJ/a-johnson-johnson-inicia-a-fase-3-do-principal-estudo-cli-nico-global-da-candidata-a-vacin-jnj-20200924monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-inicia-el-ensayo-cli-nico-de-fase-3-de-la-candidata-a-la-vacuna-contra-la--jnj-20200924monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-inicia-el-ensayo-cli-nico-en-fase-3-del-candidato-de-vacuna-para-la-covid--jnj-20200923monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-initiates-pivotal-global-phase-3-clinical-trial-of-janssen-s-covid-19-vacc-jnj-20200923monthly0.5https://www.biopharmawatch.com/news/JNJ/call-for-award-applicants-johnson-johnson-seeks-female-researchers-working-in-science-tech-jnj-20200914monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-celebrates-role-of-scientists-in-society-with-2020-dr-paul-janssen-award-f-jnj-20200820monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-acquire-momenta-pharmaceuticals-inc-expanding-janssen-s-leadership-in-n-jnj-20200819monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-gibt-vereinbarung-mit-der-us-regierung-fu-r-100-millionen-dosen-eines-covi-jnj-20200806monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-annonce-un-accord-avec-le-gouvernement-des-e-tats-unis-pour-100-millions-d-jnj-20200806monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-anuncia-contrato-com-o-governo-dos-eua-para-fornecer-100-milho-es-de-doses-jnj-20200805monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-anuncia-un-acuerdo-con-el-gobierno-de-estados-unidos-johnson-johnson-nyse--jnj-20200805monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-anuncia-acuerdo-con-el-gobierno-de-los-estados-unidos-para-100-millones-de-jnj-20200805monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-agreement-with-u-s-government-for-100-million-doses-of-investiga-jnj-20200805monthly0.5https://www.biopharmawatch.com/news/JNJ/une-dose-unique-du-candidat-vaccin-de-johnson-johnson-de-montre-un-fort-degre-de-protectio-jnj-20200730monthly0.5https://www.biopharmawatch.com/news/JNJ/einzeldosis-des-covid-19-impfstoffkandidaten-von-johnson-johnson-zeigt-in-pra-klinischen-s-jnj-20200730monthly0.5https://www.biopharmawatch.com/news/JNJ/la-vacuna-candidata-de-una-sola-dosis-contra-el-covid-19-de-johnson-johnson-brinda-una-con-jnj-20200730monthly0.5https://www.biopharmawatch.com/news/JNJ/buenos-resultados-del-candidato-a-vacuna-covid-19-de-johnson-johnson-johnson-johnson-nyse--jnj-20200730monthly0.5https://www.biopharmawatch.com/news/JNJ/dose-u-nica-de-candidata-a-vacina-da-johnson-johnson-contra-covid-19-demonstra-protec-a-o--jnj-20200730monthly0.5https://www.biopharmawatch.com/news/JNJ/single-dose-of-johnson-johnson-covid-19-vaccine-candidate-demonstrates-robust-protection-i-jnj-20200730monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-quarterly-dividend-for-third-quarter-2020-johnson-johnson-nyse-j-jnj-20200720monthly0.5https://www.biopharmawatch.com/news/JNJ/stop-tb-partnership-and-johnson-johnson-with-support-from-usaid-and-the-global-fund-announ-jnj-20200706monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-acceleration-of-its-covid-19-vaccine-candidate-phase-1-2a-clinic-jnj-20200610monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-annual-health-for-humanity-investor-webcast-johnson-johnson-nyse-j-jnj-20200604monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-goldman-sachs-41st-annual-global-virtual-healthcare--jnj-20200528monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-provide-webcast-fireside-chat-on-clinical-data-to-be-presented-at-the-a-jnj-20200518monthly0.5https://www.biopharmawatch.com/news/JNJ/federal-judge-excludes-certain-plaintiff-expert-testimony-from-talc-ovarian-cancer-trials--jnj-20200427monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-collaboration-to-expand-manufacturing-capabilities-for-its-covid-jnj-20200423monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-dividend-increase-of-6-3-johnson-johnson-nyse-jnj-today-announce-jnj-20200414monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-postpones-2020-medical-devices-business-review-due-to-the-coronavirus-john-jnj-20200401monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-virtual-annual-meeting-of-shareholders-johnson-johnson-nyse-jnj-to-jnj-20200331monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-gibt-potenziellen-wirkstoffkandidaten-fu-r-covid-19-impfung-bekannt-neue-w-jnj-20200331monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-anuncia-un-candidato-vacunal-li-der-para-el-covid-19-johnson-johnson-anunc-jnj-20200331monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-annonce-un-candidat-vaccin-principal-contre-la-covid-19-un-nouveau-partena-jnj-20200331monthly0.5https://www.biopharmawatch.com/news/JNJ/a-johnson-johnson-anuncia-possi-vel-principal-vacina-para-o-covid-19-histo-rica-parceria-c-jnj-20200330monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-anuncia-una-vacuna-experimental-inicial-para-la-covid-19-una-nueva-colabor-jnj-20200330monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-a-lead-vaccine-candidate-for-covid-19-landmark-new-partnership-w-jnj-20200330monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-investor-conference-call-on-first-quarter-results-johnson-johnson--jnj-20200317monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-collaboration-with-the-beth-israel-deaconess-medical-center-to-a-jnj-20200313monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-barclays-global-healthcare-conference-johnson-johnson-ny-jnj-20200226monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-launches-heartline-the-first-of-its-kind-virtual-study-designed-to-explore-jnj-20200225monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-expand-partnership-with-u-s-department-of-health-human-services-to-acce-jnj-20200218monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-9th-annual-svb-leerink-global-healthcare-conference--jnj-20200212monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-collaboration-with-u-s-department-of-health-human-services-to-ac-jnj-20200211monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-launches-multi-pronged-response-to-coronavirus-global-public-health-threat-jnj-20200129monthly0.5https://www.biopharmawatch.com/news/JNJ/dr-paul-janssen-award-for-biomedical-research-issues-2020-call-for-nominations-to-celebrat-jnj-20200106monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-quarterly-dividend-for-first-quarter-2020-johnson-johnson-nyse-j-jnj-20200102monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-acquires-taris-biomedical-with-focus-on-transforming-the-treatment-of-blad-jnj-20191220monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-agreement-to-acquire-remaining-stake-in-verb-surgical-inc-dedica-jnj-20191220monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-38th-annual-jp-morgan-health-care-conference-johnson-joh-jnj-20191219monthly0.5https://www.biopharmawatch.com/news/JNJ/tre-s-brasileiros-vencem-desafio-latino-americano-de-histo-rias-de-cie-ncia-promovido-pela-jnj-20191217monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-investor-conference-call-on-fourth-quarter-results-johnson-johnson-jnj-20191210monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-commitment-to-support-republic-of-rwanda-s-preparedness-against--jnj-20191208monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-names-hubert-joly-executive-chairman-of-best-buy-and-mark-a-weinberger-for-jnj-20191205monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-donation-of-up-to-500-000-regimens-of-janssen-s-investigational--jnj-20191031monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-quarterly-dividend-for-fourth-quarter-2019-johnson-johnson-nyse--jnj-20191017monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-lanc-a-desafio-de-inovac-a-o-para-startups-startups-da-a-rea-de-sau-de-de--jnj-20191010monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-releases-inaugural-you-belong-diversity-inclusion-impact-review-johnson-jo-jnj-20191007monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-commits-500-million-investment-over-four-years-to-help-end-the-epidemics-o-jnj-20191004monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reaches-settlement-agreement-with-two-ohio-counties-ahead-of-upcoming-opio-jnj-20191001monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-investor-conference-call-on-third-quarter-results-johnson-johnson--jnj-20190918monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-annonce-les-six-laure-ats-du-champions-of-science-africa-innovation-challe-jnj-20190905monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-2019-morgan-stanley-17th-annual-global-healthcare-co-jnj-20190829monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-barclays-global-consumer-staples-conference-johnson-john-jnj-20190808monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-wells-fargo-securities-2019-healthcare-conference-jo-jnj-20190808monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-quarterly-dividend-for-third-quarter-2019-johnson-johnson-nyse-j-jnj-20190715monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-investor-conference-call-on-second-quarter-results-johnson-johnson-jnj-20190618monthly0.5https://www.biopharmawatch.com/news/JNJ/relato-rio-da-johnson-johnson-revela-avanc-os-na-sau-de-para-a-humanidade-a-johnson-johnso-jnj-20190618monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-releases-2018-health-for-humanity-report-johnson-johnson-nyse-jnj-the-worl-jnj-20190605monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-celebrates-scientists-across-generations-and-geographies-with-2019-dr-paul-jnj-20190603monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-bernstein-s-35th-annual-strategic-decisions-conference-j-jnj-20190517monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-outlines-strategy-to-deliver-above-market-growth-at-2019-pharmaceutical-bu-jnj-20190515monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-dividend-increase-of-5-6-johnson-johnson-nyse-jnj-today-announce-jnj-20190425monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-pharmaceutical-business-review-johnson-johnson-nyse-jnj-will-host--jnj-20190424monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-completes-divestiture-of-advanced-sterilization-products-asp-to-fortive-co-jnj-20190401monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-completion-of-acquisition-of-auris-health-inc-johnson-johnson-ny-jnj-20190401monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-investor-conference-call-on-first-quarter-results-johnson-johnson--jnj-20190319monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-barclays-global-healthcare-conference-johnson-johnson-ny-jnj-20190228monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-8th-annual-svb-leerink-global-healthcare-conference--jnj-20190214monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-agreement-to-acquire-auris-health-inc-focused-on-creating-the-ne-jnj-20190213monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-nomeia-pat-smallcombe-como-chairman-do-grupo-emea-consumer-johnson-johnson-jnj-20190213monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-2019-cagny-conference-johnson-johnson-nyse-jnj-will--jnj-20190205monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-nomina-pat-smallcombe-company-group-chairman-emea-consumer-johnson-johnson-jnj-20190124monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-research-study-with-apple-watch-to-help-improve-afib-outcomes-in-jnj-20190117monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-completes-acquisition-of-ci-z-holdings-co-ltd-johnson-johnson-nyse-jnj-tod-jnj-20190117monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-recommends-rejection-of-below-market-mini-tender-offer-by-peer-peri-llc-jo-jnj-20190111monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-completion-of-offer-for-ci-z-holdings-co-ltd-johnson-johnson-nys-jnj-20190111monthly0.5https://www.biopharmawatch.com/news/JNJ/dr-paul-janssen-award-for-biomedical-research-issues-2019-call-for-nominations-to-celebrat-jnj-20190110monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-quarterly-dividend-for-first-quarter-2019-johnson-johnson-nyse-j-jnj-20190102monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-37th-annual-jp-morgan-health-care-conference-johnson-joh-jnj-20181224monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-investor-conference-call-on-fourth-quarter-results-johnson-johnson-jnj-20181219monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-5-billion-share-repurchase-program-johnson-johnson-nyse-jnj-toda-jnj-20181217monthly0.5https://www.biopharmawatch.com/news/JNJ/statement-on-reuters-talc-article-johnson-johnson-nyse-jnj-today-issued-the-following-stat-jnj-20181214monthly0.5https://www.biopharmawatch.com/news/JNJ/actress-playwright-and-advocate-danai-gurira-partners-with-johnson-johnson-to-help-end-hiv-jnj-20181203monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-bmo-prescriptions-for-success-healthcare-conference--jnj-20181126monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-citi-s-2018-global-healthcare-conference-johnson-joh-jnj-20181112monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-lance-le-concours-africa-innovation-challenge-2-0-johnson-johnson-a-lance--jnj-20181108monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-startet-die-africa-innovation-challenge-2-0-johnson-johnson-hat-heute-die--jnj-20181108monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-presenta-el-desafi-o-2-0-innovacio-n-en-a-frica-johnson-johnson-presento-h-jnj-20181108monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-credit-suisse-27th-annual-healthcare-conference-john-jnj-20181106monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-offer-to-acquire-ci-z-holdings-co-ltd-johnson-johnson-nyse-jnj-t-jnj-20181023monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-quarterly-dividend-for-fourth-quarter-2018-johnson-johnson-nyse--jnj-20181018monthly0.5https://www.biopharmawatch.com/news/JNJ/where-will-the-next-big-idea-in-healthcare-come-from-johnson-johnson-is-counting-on-nurses-jnj-20181001monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-investor-conference-call-on-third-quarter-results-johnson-johnson--jnj-20180919monthly0.5https://www.biopharmawatch.com/news/JNJ/update-johnson-johnson-to-host-investor-conference-call-on-the-pharmaceutical-business-joh-jnj-20180827monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-2018-morgan-stanley-16th-annual-global-healthcare-co-jnj-20180827monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-investor-conference-call-on-the-phase-3-mariner-and-commander-hf-s-jnj-20180827monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-investor-conference-call-on-the-pharmaceutical-business-johnson-jo-jnj-20180820monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-chris-delorefice-as-vice-president-of-investor-relations-johnson-jnj-20180808monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-2018-wells-fargo-13th-annual-healthcare-conference-j-jnj-20180807monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-barclays-global-consumer-staples-conference-johnson-john-jnj-20180807monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-quarterly-dividend-for-third-quarter-2018-johnson-johnson-nyse-j-jnj-20180716monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-s-official-statement-in-response-to-today-s-verdict-in-st-louis-trial-john-jnj-20180712monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-appoints-senior-leaders-to-executive-committee-johnson-johnson-nyse-jnj-to-jnj-20180622monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-retirement-of-group-worldwide-chairman-sandra-e-peterson-johnson-jnj-20180622monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-investor-conference-call-on-second-quarter-results-johnson-johnson-jnj-20180619monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-anuncia-la-aceptacio-n-de-la-oferta-vinculante-de-platinum-equity-para-adq-jnj-20180612monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-anuncia-aceitac-a-o-da-proposta-vinculativa-da-platinum-equity-para-aquisi-jnj-20180612monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-acceptance-of-binding-offer-from-platinum-equity-to-acquire-life-jnj-20180612monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-anuncia-la-aceptacio-n-de-una-oferta-vinculante-de-platinum-equity-para-ad-jnj-20180612monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-gibt-annahme-bindenden-angebotes-von-platinum-equity-zum-erwerb-von-lifesc-jnj-20180612monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-annonce-l-acceptation-de-l-offre-irre-vocable-de-platinum-equity-pour-l-ac-jnj-20180612monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-avanc-a-nas-metas-de-sau-de-para-a-humanidade-a-johnson-johnson-divulgou-o-jnj-20180606monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-binding-offer-from-fortive-corporation-to-acquire-advanced-steri-jnj-20180606monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-progress-toward-health-for-humanity-goals-johnson-johnson-nyse-j-jnj-20180605monthly0.5https://www.biopharmawatch.com/news/JNJ/james-allison-ph-d-wins-2018-dr-paul-janssen-award-for-biomedical-research-johnson-johnson-jnj-20180604monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-goldman-sachs-39th-annual-global-healthcare-conferen-jnj-20180529monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-2018-ubs-global-health-care-conference-johnson-johns-jnj-20180503monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-consumer-and-medical-devices-business-review-johnson-johnson-nyse--jnj-20180502monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-presenta-instituto-de-educacio-n-me-dica-continuada-para-latinoame-rica-co-jnj-20180427monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-dividend-increase-of-7-1-johnson-johnson-nyse-jnj-today-announce-jnj-20180426monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-2018-deutsche-bank-43rd-annual-health-care-conferenc-jnj-20180424monthly0.5https://www.biopharmawatch.com/news/JNJ/dominic-j-caruso-to-retire-as-chief-financial-officer-of-johnson-johnson-johnson-johnson-n-jnj-20180320monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-anuncia-una-oferta-vinculante-de-platinum-equity-para-adquirir-lifescan-in-jnj-20180316monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-gibt-verbindliches-angebot-von-platinum-equity-zur-u-bernahme-von-lifescan-jnj-20180316monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-anuncia-oferta-vinculante-de-platinum-equity-para-adquirir-lifescan-inc-jo-jnj-20180316monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-anuncia-proposta-vinculativa-da-platinum-equity-para-aquisic-a-o-da-lifesc-jnj-20180316monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-annonce-une-offre-ferme-de-platinum-equity-pour-acque-rir-lifescan-inc-joh-jnj-20180316monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-barclays-global-healthcare-conference-johnson-johnson-ny-jnj-20180306monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-cowen-38th-annual-healthcare-conference-johnson-johnson--jnj-20180220monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-2018-cagny-conference-johnson-johnson-nyse-jnj-will--jnj-20180208monthly0.5https://www.biopharmawatch.com/news/JNJ/janssen-and-johnson-johnson-to-provide-webcast-presentation-on-phase-3-data-for-apalutamid-jnj-20180208monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-rbc-capital-markets-2018-global-healthcare-conference-jo-jnj-20180207monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-leerink-partners-7th-annual-global-healthcare-confer-jnj-20180131monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2017-fourth-quarter-results-johnson-johnson-nyse-jnj-today-announc-jnj-20180123monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-issues-statement-on-zytiga-inter-partes-reviews-johnson-johnson-nyse-jnj-i-jnj-20180117monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-quarterly-dividend-for-first-quarter-2018-johnson-johnson-nyse-j-jnj-20180102monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-36th-annual-jp-morgan-health-care-conference-johnson-joh-jnj-20171219monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-investor-conference-call-on-fourth-quarter-results-johnson-johnson-jnj-20171219monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-bmo-capital-markets-healthcare-conference-johnson-jo-jnj-20171130monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-citi-2017-global-healthcare-conference-johnson-johns-jnj-20171120monthly0.5https://www.biopharmawatch.com/news/JNJ/new-va-and-johnson-johnson-campaign-encourages-public-to-take-note-of-veterans-at-risk-for-jnj-20171030monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-26th-annual-credit-suisse-health-care-conference-joh-jnj-20171025monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-quarterly-dividend-for-fourth-quarter-2017-johnson-johnson-nyse--jnj-20171019monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2017-third-quarter-results-johnson-johnson-nyse-jnj-today-announce-jnj-20171017monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-completion-of-codman-neurosurgery-divestiture-to-integra-lifesci-jnj-20171002monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-investor-conference-call-on-third-quarter-results-johnson-johnson--jnj-20170914monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-launches-dr-paul-janssen-project-to-catalyze-and-convene-champions-of-scie-jnj-20170913monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-2017-morgan-stanley-global-health-care-conference-johnso-jnj-20170814monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-2017-wells-fargo-12th-annual-healthcare-conference-j-jnj-20170804monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-barclays-global-consumer-staples-conference-johnson-john-jnj-20170804monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2017-second-quarter-results-johnson-johnson-nyse-jnj-today-announc-jnj-20170718monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-quarterly-dividend-for-third-quarter-2017-johnson-johnson-nyse-j-jnj-20170717monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-releases-2016-health-for-humanity-report-johnson-johnson-has-released-its--jnj-20170622monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-investor-conference-call-on-second-quarter-results-johnson-johnson-jnj-20170620monthly0.5https://www.biopharmawatch.com/news/JNJ/douglas-wallace-ph-d-wins-2017-dr-paul-janssen-award-for-biomedical-research-johnson-johns-jnj-20170620monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-completion-of-acquisition-of-actelion-johnson-johnson-nyse-jnj-t-jnj-20170616monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-expected-settlement-of-actelion-tender-offer-on-june-16-2017-joh-jnj-20170609monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-goldman-sachs-38th-annual-global-healthcare-conferen-jnj-20170525monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-showcases-strong-pipeline-of-transformational-medicines-at-its-pharmaceuti-jnj-20170517monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-jefferies-2017-global-healthcare-conference-johnson--jnj-20170511monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-2017-ubs-global-healthcare-conference-johnson-johnso-jnj-20170505monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-introduces-two-new-interactive-experiences-showcasing-more-than-130-years--jnj-20170501monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-dividend-increase-of-5-0-johnson-johnson-nyse-jnj-today-announce-jnj-20170427monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-pharmaceutical-business-review-johnson-johnson-nyse-jnj-will-host--jnj-20170424monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2017-first-quarter-results-johnson-johnson-nyse-jnj-today-announce-jnj-20170418monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-publishes-interim-result-for-actelion-tender-offer-and-declares-the-tender-jnj-20170331monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-investor-conference-call-on-first-quarter-results-johnson-johnson--jnj-20170321monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-gibt-gewinner-der-ersten-africa-innovation-challenge-bekannt-johnson-johns-jnj-20170315monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-names-winners-of-first-africa-innovation-challenge-johnson-johnson-nyse-jn-jnj-20170314monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-completes-acquisition-of-abbott-medical-optics-johnson-johnson-nyse-jnj-to-jnj-20170227monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-publishes-prospectus-for-actelion-tender-offer-today-janssen-holding-gmbh--jnj-20170216monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-barclays-global-healthcare-conference-johnson-johnson-ny-jnj-20170214monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-adds-hospital-medical-devices-to-sandra-peterson-responsibilities-johnson--jnj-20170202monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-rbc-capital-markets-2017-global-healthcare-conference-jo-jnj-20170127monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-acquire-actelion-for-30-billion-with-spin-out-of-new-r-d-company-johnso-jnj-20170126monthly0.5https://www.biopharmawatch.com/news/JNJ/investor-conference-call-johnson-johnson-to-acquire-actelion-for-30-billion-with-spin-out--jnj-20170126monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-2017-cagny-conference-johnson-johnson-nyse-jnj-will--jnj-20170125monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2016-fourth-quarter-results-johnson-johnson-nyse-jnj-today-announc-jnj-20170124monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-leerink-partners-6th-annual-global-healthcare-confer-jnj-20170123monthly0.5https://www.biopharmawatch.com/news/JNJ/the-echelon-flex-gst-system-will-now-feature-a-45mm-endocutter-with-exclusive-gripping-sur-jnj-20170123monthly0.5https://www.biopharmawatch.com/news/JNJ/ethicon-announces-acquisition-of-megadyne-medical-products-inc-ethicon-endo-surgery-inc-an-jnj-20170120monthly0.5https://www.biopharmawatch.com/news/JNJ/dr-paul-janssen-award-for-biomedical-research-issues-2017-call-for-nominations-the-dr-paul-jnj-20170110monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-quarterly-dividend-for-first-quarter-2017-johnson-johnson-nyse-j-jnj-20170103monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-35th-annual-jp-morgan-health-care-conference-johnson-joh-jnj-20161227monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-investor-conference-call-on-fourth-quarter-full-year-2016-results--jnj-20161227monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-confirms-exclusive-negotiations-with-actelion-johnson-johnson-nyse-jnj-tod-jnj-20161221monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-it-has-ended-discussions-with-actelion-johnson-johnson-nyse-jnj--jnj-20161213monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-confirms-discussions-with-actelion-regarding-potential-transaction-johnson-jnj-20161125monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-establishes-susan-lindquist-chair-for-women-in-science-johnson-johnson-nys-jnj-20161116monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-annonce-le-lancement-de-l-africa-innovation-challenge-qui-vise-a-soutenir--jnj-20161101monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-mourns-the-loss-of-susan-lindquist-biomedical-research-pioneer-and-member--jnj-20161028monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-25th-annual-credit-suisse-health-care-conference-joh-jnj-20161026monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-quarterly-dividend-for-fourth-quarter-2016-johnson-johnson-nyse--jnj-20161020monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-opens-new-global-services-center-in-tampa-florida-today-johnson-johnson-ny-jnj-20161019monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2016-third-quarter-results-johnson-johnson-nyse-jnj-today-announce-jnj-20161018monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-investor-conference-call-on-third-quarter-results-johnson-johnson--jnj-20160920monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-advances-commitment-to-improve-global-health-and-well-being-johnson-johnso-jnj-20160920monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-agreement-to-acquire-abbott-medical-optics-johnson-johnson-nyse--jnj-20160916monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-world-health-organization-will-review-ebola-vaccine-regimen-for--jnj-20160912monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-partners-with-global-citizen-to-improve-the-trajectory-of-human-health-aro-jnj-20160907monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-2016-morgan-stanley-global-health-care-conference-johnso-jnj-20160831monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-2016-wells-fargo-11th-annual-healthcare-conference-j-jnj-20160825monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-ruling-related-to-remicade-in-the-district-of-massachusetts-fede-jnj-20160817monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2016-second-quarter-results-johnson-johnson-nyse-jnj-today-announc-jnj-20160719monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-completion-of-acquisition-of-vogue-international-llc-johnson-joh-jnj-20160718monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-quarterly-dividend-for-third-quarter-2016-johnson-johnson-nyse-j-jnj-20160718monthly0.5https://www.biopharmawatch.com/news/JNJ/janssen-and-johnson-johnson-to-provide-webcast-presentation-on-phase-3-data-for-darzalex-d-jnj-20160707monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-retirement-of-louise-mehrotra-and-appointment-of-joseph-wolk-as--jnj-20160622monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-investor-conference-call-on-second-quarter-results-johnson-johnson-jnj-20160621monthly0.5https://www.biopharmawatch.com/news/JNJ/yoshinori-ohsumi-ph-d-wins-2016-dr-paul-janssen-award-for-biomedical-research-as-part-of-a-jnj-20160608monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-partners-with-leading-organizations-to-advance-education-of-young-women-an-jnj-20160606monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-agreement-to-acquire-vogue-international-johnson-johnson-nyse-jn-jnj-20160602monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-goldman-sachs-37th-annual-global-healthcare-conferen-jnj-20160525monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-showcasing-its-broad-innovation-and-technology-strategies-in-consumer-and--jnj-20160518monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-collaboration-with-hp-inc-subsidiary-to-create-personalized-heal-jnj-20160517monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-2016-ubs-global-healthcare-conference-johnson-johnso-jnj-20160509monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-dividend-increase-of-6-7-johnson-johnson-nyse-jnj-today-announce-jnj-20160428monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-consumer-inc-to-acquire-neostrata-company-inc-a-leader-in-dermocosmetics-j-jnj-20160426monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-2016-deutsche-bank-41st-annual-health-care-conferenc-jnj-20160421monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2016-first-quarter-results-johnson-johnson-nyse-jnj-today-announce-jnj-20160419monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-launch-of-new-global-public-health-strategy-at-opening-of-new-op-jnj-20160405monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-webcast-annual-meeting-of-shareholders-johnson-johnson-nyse-jnj-will-we-jnj-20160328monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-investor-conference-call-on-first-quarter-results-johnson-johnson--jnj-20160315monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-barclays-global-healthcare-conference-johnson-johnson-ny-jnj-20160303monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-hace-una-peticio-n-de-ideas-innovadoras-para-reducir-las-infecciones-por-v-jnj-20160218monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-sucht-innovative-ideen-um-hiv-infektionen-in-subsahara-afrika-zu-senken-jo-jnj-20160218monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-lance-un-appel-aux-ide-es-innovantes-afin-de-re-duire-les-infections-au-vi-jnj-20160218monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-issues-call-for-innovative-ideas-to-reduce-hiv-infections-in-sub-saharan-a-jnj-20160217monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-lanc-a-apelo-em-busca-de-ideias-inovadoras-para-reduzir-a-infecc-a-o-do-vi-jnj-20160217monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-lanza-una-convocatoria-para-ideas-innovadoras-para-reducir-las-infecciones-jnj-20160217monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-rbc-capital-markets-global-healthcare-conference-johnson-jnj-20160209monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2015-fourth-quarter-results-johnson-johnson-nyse-jnj-today-announc-jnj-20160126monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-joins-first-industry-wide-call-for-new-collective-action-to-address-antimi-jnj-20160120monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-actions-to-strengthen-medical-devices-leadership-position-in-evo-jnj-20160119monthly0.5https://www.biopharmawatch.com/news/JNJ/janssen-and-johnson-johnson-to-provide-webcast-presentation-on-the-janssen-oncology-hemato-jnj-20160115monthly0.5https://www.biopharmawatch.com/news/JNJ/dr-paul-janssen-award-for-biomedical-research-lanza-su-llamada-a-la-participacio-n-para-20-jnj-20160106monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-partners-with-leading-universities-to-advance-women-s-education-in-science-jnj-20160106monthly0.5https://www.biopharmawatch.com/news/JNJ/le-dr-paul-janssen-award-for-biomedical-research-lance-son-appel-a-nominations-2016-le-dr--jnj-20160105monthly0.5https://www.biopharmawatch.com/news/JNJ/dr-paul-janssen-award-for-biomedical-research-ruft-zur-kandidatennominierung-2016-auf-der--jnj-20160105monthly0.5https://www.biopharmawatch.com/news/JNJ/dr-paul-janssen-award-for-biomedical-research-issues-2016-call-for-nominations-the-dr-paul-jnj-20160105monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-quarterly-dividend-for-first-quarter-2016-johnson-johnson-nyse-j-jnj-20160104monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-34th-annual-jp-morgan-health-care-conference-johnson-jnj-20151228monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-fourth-quarter-full-year-2015-investor-conference-call-on-results--jnj-20151222monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-formation-of-verb-surgical-inc-in-collaboration-with-verily-john-jnj-20151210monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-completion-of-novira-therapeutics-inc-acquisition-johnson-johnso-jnj-20151204monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-marks-world-aids-day-with-major-new-global-commitments-to-end-hiv-infectio-jnj-20151201monthly0.5https://www.biopharmawatch.com/news/JNJ/share-a-photo-give-back-in-a-snap-today-in-times-square-thousands-of-visitors-joined-actor-jnj-20151124monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-1-75-million-donation-to-save-the-children-to-support-syrian-hum-jnj-20151117monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-agreement-to-acquire-novira-therapeutics-inc-johnson-johnson-nys-jnj-20151104monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-24th-annual-credit-suisse-health-care-conference-joh-jnj-20151027monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-quarterly-dividend-for-fourth-quarter-2015-johnson-johnson-nyse--jnj-20151022monthly0.5https://www.biopharmawatch.com/news/JNJ/le-neuroscientifique-en-chef-de-janssen-a-e-te-nomme-au-conseil-consultatif-scientifique-d-jnj-20151021monthly0.5https://www.biopharmawatch.com/news/JNJ/head-janssen-neuroscientist-appointed-to-scientific-advisory-board-of-global-dementia-disc-jnj-20151021monthly0.5https://www.biopharmawatch.com/news/JNJ/leitender-neurowissenschaftler-bei-janssen-in-den-wissenschaftlichen-beirat-des-globalen-d-jnj-20151021monthly0.5https://www.biopharmawatch.com/news/JNJ/el-jefe-de-neurociencias-de-janssen-asesorara-al-fondo-para-el-descubrimiento-de-la-demenc-jnj-20151021monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2015-third-quarter-results-johnson-johnson-nyse-jnj-today-announce-jnj-20151013monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-10-billion-share-repurchase-program-johnson-johnson-nyse-jnj-tod-jnj-20151013monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-start-of-clinical-trial-of-ebola-vaccine-regimen-in-sierra-leone-jnj-20151009monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-completion-of-cordis-divestiture-to-cardinal-health-johnson-john-jnj-20151004monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-investor-conference-call-on-third-quarter-results-johnson-johnson--jnj-20150915monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-2015-morgan-stanley-healthcare-conference-johnson-jo-jnj-20150903monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-2015-wells-fargo-10th-annual-healthcare-conference-j-jnj-20150827monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-quarterly-dividend-for-third-quarter-2015-johnson-johnson-nyse-j-jnj-20150720monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2015-second-quarter-results-johnson-johnson-nyse-jnj-today-announc-jnj-20150714monthly0.5https://www.biopharmawatch.com/news/JNJ/bert-vogelstein-m-d-wins-2015-dr-paul-janssen-award-for-biomedical-research-johnson-johnso-jnj-20150617monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-investor-conference-call-on-second-quarter-results-johnson-johnson-jnj-20150616monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-open-translational-science-project-in-schizophrenia-johnson-john-jnj-20150609monthly0.5https://www.biopharmawatch.com/news/JNJ/ceo-and-director-of-huntsman-cancer-institute-dr-mary-beckerle-joins-johnson-johnson-board-jnj-20150609monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-acceptance-of-binding-offer-from-cardinal-health-to-acquire-cord-jnj-20150528monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-goldman-sachs-36th-annual-global-healthcare-conferen-jnj-20150527monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-pharmaceutical-segment-to-continue-driving-above-industry-growth-with-plan-jnj-20150520monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-expands-ip-policy-to-create-broad-access-in-128-countries-for-development--jnj-20150514monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-ampli-a-poli-tica-de-pi-para-ampliar-el-acceso-a-nin-os-de-128-pai-ses-que-jnj-20150514monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-nyu-school-of-medicine-partnership-to-evaluate-compassionate-use-jnj-20150507monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-2015-deutsche-bank-40th-annual-health-care-conferenc-jnj-20150430monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-further-patent-and-trademark-office-action-related-to-remicade-j-jnj-20150429monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-dividend-increase-of-7-1-johnson-johnson-nyse-jnj-today-announce-jnj-20150423monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-pharmaceutical-business-review-johnson-johnson-nyse-jnj-will-host--jnj-20150420monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2015-first-quarter-results-johnson-johnson-nyse-jnj-today-announce-jnj-20150414monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-webcast-annual-meeting-of-shareholders-johnson-johnson-nyse-jnj-will-we-jnj-20150327monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-investor-conference-call-on-first-quarter-results-johnson-johnson--jnj-20150317monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-strategic-investment-alliance-to-combat-dementia-globally-johnso-jnj-20150317monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-binding-offer-from-cardinal-health-to-acquire-cordis-johnson-joh-jnj-20150302monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-formation-of-new-health-and-wellness-platform-designed-to-transf-jnj-20150226monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-patent-and-trademark-office-action-related-to-remicade-johnson-j-jnj-20150212monthly0.5https://www.biopharmawatch.com/news/JNJ/el-dr-paul-janssen-award-for-biomedical-research-emite-su-llamada-a-los-nominados-para-201-jnj-20150122monthly0.5https://www.biopharmawatch.com/news/JNJ/dr-paul-janssen-award-for-biomedical-research-ruft-zur-kandidatennominierung-2015-auf-ab-h-jnj-20150121monthly0.5https://www.biopharmawatch.com/news/JNJ/le-prix-2015-du-dr-paul-janssen-pour-les-questions-de-recherche-biome-dicale-fait-appel-a--jnj-20150121monthly0.5https://www.biopharmawatch.com/news/JNJ/dr-paul-janssen-award-for-biomedical-research-issues-2015-call-for-nominations-the-dr-paul-jnj-20150121monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2014-fourth-quarter-and-full-year-results-johnson-johnson-nyse-jnj-jnj-20150120monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-annonce-la-cre-ation-d-un-consortium-de-de-veloppement-d-un-vaccin-contre--jnj-20150118monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-formation-of-ebola-vaccine-development-consortia-gains-funding-f-jnj-20150116monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-kondigt-de-start-aan-van-fase-1-klinisch-onderzoek-van-een-vaccinregime-te-jnj-20150106monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-start-of-phase-1-clinical-trial-of-ebola-vaccine-regimen-johnson-jnj-20150106monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-quarterly-dividend-for-first-quarter-2015-johnson-johnson-nyse-j-jnj-20150105monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-33rd-annual-jp-morgan-health-care-conference-johnson-joh-jnj-20141230monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-fourth-quarter-full-year-2014-investor-conference-call-on-results--jnj-20141217monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-collaboration-between-janssen-and-usaid-to-expand-access-to-anti-jnj-20141211monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-partners-with-save-the-children-to-help-millions-of-children-over-the-next-jnj-20141119monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-completion-of-alios-biopharma-acquisition-johnson-johnson-nyse-j-jnj-20141107monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-innovation-launches-asia-pacific-innovation-center-and-announces-new-allia-jnj-20141028monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-major-commitment-to-speed-ebola-vaccine-development-and-signific-jnj-20141022monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-quarterly-dividend-for-fourth-quarter-2014-johnson-johnson-nyse--jnj-20141016monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-family-of-consumer-companies-turns-brands-purple-in-support-of-spirit-day--jnj-20141015monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2014-third-quarter-results-johnson-johnson-nyse-jnj-today-announce-jnj-20141014monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-agreement-to-acquire-alios-biopharma-johnson-johnson-nyse-jnj-to-jnj-20140930monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-investor-conference-call-on-third-quarter-results-johnson-johnson--jnj-20140923monthly0.5https://www.biopharmawatch.com/news/JNJ/pioneering-gene-editing-research-celebrated-this-week-during-2014-dr-paul-janssen-award-fo-jnj-20140909monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-responds-to-ebola-crisis-with-commitment-to-accelerate-vaccine-program-in--jnj-20140904monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-2014-morgan-stanley-health-care-conference-johnson-johns-jnj-20140903monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-quarterly-dividend-for-third-quarter-2014-johnson-johnson-nyse-j-jnj-20140721monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-5-billion-share-repurchase-program-johnson-johnson-nyse-jnj-toda-jnj-20140721monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2014-second-quarter-results-johnson-johnson-nyse-jnj-today-announc-jnj-20140715monthly0.5https://www.biopharmawatch.com/news/JNJ/care-with-pride-on-target-to-deliver-more-than-500k-to-lgbt-charities-johnson-johnson-s-co-jnj-20140625monthly0.5https://www.biopharmawatch.com/news/JNJ/jennifer-doudna-ph-d-and-emmanuelle-charpentier-ph-d-win-2014-dr-paul-janssen-award-for-bi-jnj-20140624monthly0.5https://www.biopharmawatch.com/news/JNJ/ceo-and-chairman-of-ups-d-scott-davis-joins-johnson-johnson-board-of-directors-johnson-joh-jnj-20140619monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-investor-conference-call-on-second-quarter-results-johnson-johnson-jnj-20140617monthly0.5https://www.biopharmawatch.com/news/JNJ/il-marchio-listerine-celebra-il-torneo-della-fifa-world-cup-con-la-sua-maggiore-azione-mon-jnj-20140605monthly0.5https://www.biopharmawatch.com/news/JNJ/la-marca-listerine-celebra-el-torneo-de-la-copa-mundial-fifa-a-trave-s-de-su-mayor-activac-jnj-20140605monthly0.5https://www.biopharmawatch.com/news/JNJ/listerine-brand-celebrates-the-fifa-world-cup-tournament-through-its-largest-global-social-jnj-20140605monthly0.5https://www.biopharmawatch.com/news/JNJ/la-marca-listerine-celebra-el-torneo-de-la-fifa-world-cup-a-trave-s-de-los-medios-sociales-jnj-20140605monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-anuncia-a-la-ganadora-del-programa-campeones-del-carin-o-en-eeuu-como-part-jnj-20140605monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reinforces-importance-of-children-learning-the-value-of-care-from-their-pa-jnj-20140604monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-medical-devices-diagnostics-businesses-expanding-market-leadership-with-in-jnj-20140522monthly0.5https://www.biopharmawatch.com/news/JNJ/sabine-dandiguian-honoured-as-hba-luminary-by-the-healthcare-businesswomen-s-association-h-jnj-20140513monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-and-american-college-of-sports-medicine-form-global-alliance-to-advance-hu-jnj-20140430monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-dividend-increase-of-6-1-johnson-johnson-nyse-jnj-today-announce-jnj-20140424monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-medical-devices-diagnostics-business-review-johnson-johnson-nyse-j-jnj-20140423monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2014-first-quarter-results-johnson-johnson-nyse-jnj-today-announce-jnj-20140415monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-enters-agreement-to-be-official-healthcare-partner-of-the-uso-johnson-john-jnj-20140401monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-acceptance-of-binding-offer-from-the-carlyle-group-to-acquire-or-jnj-20140331monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-webcast-annual-meeting-of-shareholders-johnson-johnson-nyse-jnj-will-we-jnj-20140321monthly0.5https://www.biopharmawatch.com/news/JNJ/the-listerine-brand-supports-the-fdi-world-dental-federation-in-2014-global-oral-health-in-jnj-20140319monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-analyst-conference-call-on-first-quarter-results-johnson-johnson-n-jnj-20140311monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-lanza-campeones-del-carin-o-en-los-estados-unidos-como-parte-de-su-patroci-jnj-20140306monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-launches-champions-of-care-program-in-the-u-s-as-part-of-2014-fifa-world-c-jnj-20140306monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-2014-cowen-34th-annual-health-care-conference-johnson-jo-jnj-20140225monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-2014-citi-global-health-care-conference-johnson-johnson--jnj-20140214monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-and-scientists-without-borders-announce-winners-of-mental-health-awareness-jnj-20140211monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-issues-dr-paul-janssen-award-for-biomedical-research-call-for-nominations--jnj-20140203monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-clinical-trial-data-sharing-agreement-with-yale-school-of-medici-jnj-20140130monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2013-fourth-quarter-and-full-year-results-johnson-johnson-nyse-jnj-jnj-20140121monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-binding-offer-from-the-carlyle-group-to-acquire-ortho-clinical-d-jnj-20140116monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-quarterly-dividend-for-first-quarter-2014-johnson-johnson-nyse-j-jnj-20140102monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-fourth-quarter-full-year-2013-earnings-meeting-johnson-johnson-nys-jnj-20131218monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-credit-suisse-2013-health-care-conference-johnson-johnso-jnj-20131105monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-and-its-subsidiaries-janssen-pharmaceuticals-inc-and-scios-inc-conclude-pr-jnj-20131104monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-quarterly-dividend-for-fourth-quarter-2013-johnson-johnson-nyse--jnj-20131017monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2013-third-quarter-results-johnson-johnson-nyse-jnj-today-announce-jnj-20131015monthly0.5https://www.biopharmawatch.com/news/JNJ/former-fda-commissioner-dr-mark-b-mcclellan-to-join-johnson-johnson-board-of-directors-joh-jnj-20131014monthly0.5https://www.biopharmawatch.com/news/JNJ/future-of-innovation-dependent-on-funding-collaboration-and-idea-exchange-investment-in-ba-jnj-20130919monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-conference-call-on-third-quarter-results-johnson-johnson-nyse-jnj--jnj-20130917monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-morgan-stanley-global-health-care-conference-johnson-joh-jnj-20130904monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-completes-acquisition-of-aragon-pharmaceuticals-inc-johnson-johnson-nyse-j-jnj-20130819monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2013-second-quarter-results-johnson-johnson-nyse-jnj-today-announc-jnj-20130716monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-quarterly-dividend-for-third-quarter-2013-johnson-johnson-nyse-j-jnj-20130715monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-opening-of-boston-innovation-center-johnson-johnson-today-announ-jnj-20130627monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-conference-call-on-second-quarter-results-johnson-johnson-nyse-jnj-jnj-20130625monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-definitive-agreement-to-acquire-aragon-pharmaceuticals-inc-johns-jnj-20130617monthly0.5https://www.biopharmawatch.com/news/JNJ/david-julius-wins-2013-dr-paul-janssen-award-for-biomedical-research-johnson-johnson-today-jnj-20130612monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-pharmaceuticals-segment-poised-to-continue-driving-growth-with-more-than-1-jnj-20130523monthly0.5https://www.biopharmawatch.com/news/JNJ/janssen-and-johnson-johnson-to-provide-webcast-presentation-of-simeprevir-phase-3-clinical-jnj-20130502monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-dividend-increase-of-8-2-johnson-johnson-nyse-jnj-today-announce-jnj-20130425monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-pharmaceuticals-business-review-johnson-johnson-nyse-jnj-will-host-jnj-20130423monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-sale-of-elan-american-depositary-shares-to-elan-johnson-johnson--jnj-20130418monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2013-first-quarter-results-johnson-johnson-nyse-jnj-today-announce-jnj-20130416monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-webcast-annual-meeting-of-shareholders-johnson-johnson-nyse-jnj-will-we-jnj-20130411monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-analyst-conference-call-on-first-quarter-results-johnson-johnson-n-jnj-20130319monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-annonce-l-ouverture-d-un-centre-d-innovation-a-londres-johnson-johnson-a-a-jnj-20130313monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-anuncia-la-apertura-del-centro-de-innovacio-n-de-londres-johnson-johnson-h-jnj-20130313monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-gibt-ero-ffnung-des-innovationszentrums-in-london-bekannt-johnson-johnson--jnj-20130313monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-opening-of-london-innovation-centre-johnson-johnson-today-announ-jnj-20130312monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-comments-on-venezuelan-currency-devaluation-johnson-johnson-nyse-jnj-today-jnj-20130225monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-2013-citi-global-health-care-conference-johnson-johnson--jnj-20130220monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-2013-leerink-swann-global-health-care-conference-johnson-jnj-20130206monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-presents-growth-strategies-for-medical-devices-diagnostics-segment-johnson-jnj-20130122monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2012-fourth-quarter-and-full-year-results-johnson-johnson-nyse-jnj-jnj-20130122monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-issues-dr-paul-janssen-award-for-biomedical-research-call-for-nominations--jnj-20130110monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-quarterly-dividend-for-first-quarter-2013-johnson-johnson-nyse-j-jnj-20130102monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-analyst-meeting-to-discuss-fourth-quarter-full-year-2012-financial-jnj-20121221monthly0.5https://www.biopharmawatch.com/news/JNJ/ceo-alex-gorsky-elected-chairman-of-johnson-johnson-bill-weldon-to-step-down-after-41-year-jnj-20121130monthly0.5https://www.biopharmawatch.com/news/JNJ/health-care-executive-scholar-and-vice-chancellor-from-ucla-dr-a-eugene-washington-appoint-jnj-20121109monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-credit-suisse-2012-healthcare-conference-johnson-johnson-jnj-20121107monthly0.5https://www.biopharmawatch.com/news/JNJ/janssen-and-johnson-johnson-to-provide-webcast-presentation-of-immunology-pivotal-phase-3--jnj-20121102monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-postpones-medical-devices-diagnostics-review-given-the-state-of-emergency--jnj-20121030monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-medical-devices-diagnostics-review-johnson-johnson-nyse-jnj-will-h-jnj-20121025monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-quarterly-dividend-for-fourth-quarter-2012-johnson-johnson-nyse--jnj-20121017monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2012-third-quarter-results-johnson-johnson-nyse-jnj-today-announce-jnj-20121016monthly0.5https://www.biopharmawatch.com/news/JNJ/james-e-burke-former-chairman-and-ceo-of-johnson-johnson-dies-at-87-former-johnson-johnson-jnj-20121001monthly0.5https://www.biopharmawatch.com/news/JNJ/janssen-and-johnson-johnson-to-present-latest-phase-3-results-for-canagliflozin-in-the-tre-jnj-20120926monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-provides-notice-of-adjournment-of-final-settlement-hearing-to-october-18-2-jnj-20120925monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-plans-to-establish-innovation-centers-johnson-johnson-today-anno-jnj-20120918monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-analyst-conference-call-on-third-quarter-results-johnson-johnson-n-jnj-20120918monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-launches-be-vital-challenge-to-reward-college-student-organizations-making-jnj-20120918monthly0.5https://www.biopharmawatch.com/news/JNJ/sandra-e-peterson-to-join-johnson-johnson-as-group-worldwide-chairman-and-member-of-the-ex-jnj-20120913monthly0.5https://www.biopharmawatch.com/news/JNJ/sandra-e-peterson-wird-group-worldwide-chairman-und-mitglied-des-exekutivausschusses-bei-j-jnj-20120913monthly0.5https://www.biopharmawatch.com/news/JNJ/sandra-e-peterson-sur-le-point-de-rejoindre-johnson-johnson-en-tant-que-pre-sidente-ge-ne--jnj-20120913monthly0.5https://www.biopharmawatch.com/news/JNJ/sandra-e-peterson-se-une-a-johnson-johnson-como-presidenta-internacional-del-grupo-y-miemb-jnj-20120913monthly0.5https://www.biopharmawatch.com/news/JNJ/sandra-e-peterson-se-juntara-a-johnson-johnson-como-presidente-global-do-grupo-e-membro-do-jnj-20120913monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-symposium-honors-2012-recipients-of-the-dr-paul-janssen-award-for-biomedic-jnj-20120907monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-morgan-stanley-global-health-care-conference-johnson-joh-jnj-20120905monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-discontinuation-of-phase-3-development-of-bapineuzumab-intraveno-jnj-20120806monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-provides-notice-of-proposed-settlement-of-shareholder-derivative-actions-f-jnj-20120719monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2012-second-quarter-results-sales-of-16-5-billion-decreased-0-7-ve-jnj-20120717monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-quarterly-dividend-for-third-quarter-2012-johnson-johnson-nyse-j-jnj-20120716monthly0.5https://www.biopharmawatch.com/news/JNJ/dr-victor-ambros-and-dr-gary-ruvkun-win-2012-dr-paul-janssen-award-for-biomedical-research-jnj-20120619monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-analyst-conference-call-on-second-quarter-results-johnson-johnson--jnj-20120618monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-completion-of-synthes-acquisition-johnson-johnson-nyse-jnj-today-jnj-20120614monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-receives-u-s-regulatory-clearance-for-synthes-acquisition-closing-date-for-jnj-20120612monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-expects-to-incur-special-charge-in-second-quarter-for-previously-disclosed-jnj-20120608monthly0.5https://www.biopharmawatch.com/news/JNJ/janssen-and-johnson-johnson-to-present-results-from-five-pivotal-phase-3-studies-evaluatin-jnj-20120605monthly0.5https://www.biopharmawatch.com/news/JNJ/janssen-and-johnson-johnson-to-provide-webcast-presentation-of-zytiga-abiraterone-acetate--jnj-20120525monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-2012-deutsche-bank-securities-inc-37th-annual-health-car-jnj-20120502monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-holds-2012-annual-meeting-of-shareholders-after-10-years-presiding-over-jo-jnj-20120426monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-dividend-increase-of-7-0-johnson-johnson-nyse-jnj-today-announce-jnj-20120426monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-webcast-annual-meeting-of-shareholders-johnson-johnson-nyse-jnj-will-we-jnj-20120419monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2012-first-quarter-results-johnson-johnson-nyse-jnj-today-announce-jnj-20120417monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-analyst-conference-call-on-first-quarter-results-johnson-johnson-n-jnj-20120410monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-resignation-of-sheri-s-mccoy-johnson-johnson-nyse-jnj-said-today-jnj-20120409monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-provide-webcast-presentation-of-xarelto-rivaroxaban-phase-3-clinical-da-jnj-20120319monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-cowen-and-company-32nd-annual-health-care-conference-joh-jnj-20120228monthly0.5https://www.biopharmawatch.com/news/JNJ/alex-gorsky-to-succeed-bill-weldon-as-ceo-of-johnson-johnson-johnson-johnson-today-announc-jnj-20120221monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-2012-leerink-swann-global-health-care-conference-johnson-jnj-20120209monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-joins-public-and-private-partners-in-the-largest-coordinated-action-to-dat-jnj-20120130monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2011-fourth-quarter-and-full-year-results-johnson-johnson-today-an-jnj-20120124monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-analyst-meeting-to-discuss-fourth-quarter-and-full-year-2011-finan-jnj-20120117monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-first-quarter-2012-quarterly-dividend-johnson-johnson-nyse-jnj-t-jnj-20120103monthly0.5https://www.biopharmawatch.com/news/JNJ/dr-paul-janssen-award-for-biomedical-research-issues-call-for-nominations-the-dr-paul-jans-jnj-20111209monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-piper-jaffray-23rd-annual-health-care-conference-joh-jnj-20111128monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-piper-jaffray-23rd-annual-health-care-conference-joh-jnj-20111122monthly0.5https://www.biopharmawatch.com/news/JNJ/landmark-study-shows-that-adding-rivaroxaban-to-standard-antiplatelet-therapy-significantl-jnj-20111113monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2011-third-quarter-results-johnson-johnson-nyse-jnj-today-announce-jnj-20111018monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-analyst-conference-call-on-third-quarter-results-johnson-johnson-n-jnj-20111011monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-makes-strong-progress-in-first-year-of-initiative-to-improve-health-of-mil-jnj-20110920monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-symposium-honors-2011-recipient-of-the-dr-paul-janssen-award-for-biomedica-jnj-20110914monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-morgan-stanley-global-health-care-conference-johnson-joh-jnj-20110906monthly0.5https://www.biopharmawatch.com/news/JNJ/the-amazing-nurses-contest-celebrating-america-s-caregivers-the-johnson-johnson-campaign-f-jnj-20110726monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2011-second-quarter-results-johnson-johnson-nyse-jnj-today-announc-jnj-20110719monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-third-quarter-2011-quarterly-dividend-johnson-johnson-nyse-jnj-t-jnj-20110718monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-launches-healthy-future-2015-its-citizenship-and-sustainability-goals-as-2-jnj-20110714monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-analyst-conference-call-on-second-quarter-results-johnson-johnson--jnj-20110712monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-global-sponsorship-of-the-2014-fifa-world-cup-brazil-johnson-joh-jnj-20110707monthly0.5https://www.biopharmawatch.com/news/JNJ/dr-napoleone-ferrara-wins-2011-dr-paul-janssen-award-for-biomedical-research-johnson-johns-jnj-20110628monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-special-charge-related-to-restructuring-plans-for-cordis-corpora-jnj-20110615monthly0.5https://www.biopharmawatch.com/news/JNJ/former-chairman-and-ceo-of-aetna-inc-ronald-williams-appointed-to-johnson-johnson-board-of-jnj-20110614monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-highlights-strategies-for-growth-through-differentiated-medicines-transfor-jnj-20110526monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-pharmaceuticals-business-review-johnson-johnson-nyse-jnj-will-host-jnj-20110519monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-bank-of-america-merrill-lynch-2011-health-care-conferenc-jnj-20110504monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-holds-2011-annual-meeting-of-shareholders-at-johnson-johnson-s-annual-meet-jnj-20110428monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-dividend-increase-of-5-6-johnson-johnson-nyse-jnj-today-announce-jnj-20110428monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-and-synthes-announce-definitive-merger-agreement-to-create-world-s-most-in-jnj-20110427monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-deutsche-bank-36th-annual-health-care-conference-johnson-jnj-20110426monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-webcast-annual-meeting-of-shareholders-johnson-johnson-nyse-jnj-will-we-jnj-20110420monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2011-first-quarter-results-johnson-johnson-nyse-jnj-today-announce-jnj-20110419monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-provides-additional-information-regarding-amended-agreement-with-merck-joh-jnj-20110415monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-analyst-conference-call-on-first-quarter-results-johnson-johnson-n-jnj-20110412monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-settlement-with-u-s-department-of-justice-and-u-s-securities-and-jnj-20110408monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-acquires-98-89-of-issued-crucell-shares-as-of-the-end-of-the-subsequent-of-jnj-20110308monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-2011-rbc-capital-markets-health-care-conference-johnson--jnj-20110223monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-2011-citi-global-health-care-conference-johnson-johnson--jnj-20110222monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-completes-tender-offer-for-crucell-and-declares-offer-unconditional-johnso-jnj-20110222monthly0.5https://www.biopharmawatch.com/news/JNJ/minimum-acceptance-condition-satisfied-johnson-johnson-nyse-jnj-and-crucell-n-v-nyse-euron-jnj-20110217monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-receives-approval-from-european-commission-johnson-johnson-and-crucell-tod-jnj-20110128monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2010-fourth-quarter-and-full-year-results-johnson-johnson-nyse-jnj-jnj-20110125monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-analyst-meeting-to-discuss-fourth-quarter-and-full-year-2010-finan-jnj-20110118monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-provides-update-on-mcneil-consumer-healthcare-remediation-announces-comple-jnj-20110114monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-executive-appointments-alex-gorsky-vice-chairman-executive-commi-jnj-20101215monthly0.5https://www.biopharmawatch.com/news/JNJ/dr-paul-janssen-award-for-biomedical-research-issues-call-for-nominations-the-dr-paul-jans-jnj-20101214monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-launches-recommended-public-offer-to-acquire-crucell-johnson-johnson-nyse--jnj-20101208monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-and-crucell-progress-update-expect-to-commence-public-offer-prior-to-10-de-jnj-20101130monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-the-piper-jaffray-22nd-annual-health-care-conference-joh-jnj-20101124monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-participate-in-credit-suisse-19th-annual-health-care-conference-johnson-jnj-20101104monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-and-crucell-provide-progress-update-on-preparations-for-public-offer-pursu-jnj-20101029monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-reports-2010-third-quarter-results-johnson-johnson-nyse-jnj-today-announce-jnj-20101019monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-to-host-analyst-meeting-to-discuss-third-quarter-financial-results-and-rev-jnj-20101011monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-and-crucell-reach-agreement-on-intended-public-offer-of-euro-24-75-per-ord-jnj-20101006monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-completes-acquisition-of-micrus-endovascular-johnson-johnson-nyse-jnj-toda-jnj-20100927monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-and-crucell-in-advanced-negotiations-for-an-all-cash-public-offer-of-euro--jnj-20100917monthly0.5https://www.biopharmawatch.com/news/JNJ/colleen-goggins-worldwide-chairman-consumer-group-plans-retirement-from-johnson-johnson-in-jnj-20100916monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-aims-to-help-up-to-120-million-women-and-children-each-year-through-five-y-jnj-20100913monthly0.5https://www.biopharmawatch.com/news/JNJ/drs-erik-de-clercq-and-anthony-s-fauci-win-2010-dr-paul-janssen-award-for-biomedical-resea-jnj-20100908monthly0.5https://www.biopharmawatch.com/news/JNJ/johnson-johnson-of-charleston-named-one-of-the-50-best-employers-to-work-for-in-america-jo-jnj-20100908monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-and-abcellera-announce-collaboration-to-discover-next-generation-t-ce-jazz-20260617monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-delivers-extensive-late-breaking-data-at-sleep-2026-demonstrating-rea-jazz-20260616monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatm-jazz-20260604monthly0.5https://www.biopharmawatch.com/news/JAZZ/phase-3-herizon-gea-01-results-published-in-the-new-england-journal-of-medicine-show-durab-jazz-20260527monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-data-at-asco-2026-highlighting-advancements-for-ziihera-za-jazz-20260421monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-compelling-clinical-and-pre-clinical-data-advancing-oncolo-jazz-20260318monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-participate-in-upcoming-investor-conferences-jazz-pharmaceuticals--jazz-20260217monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-appoints-thomas-riga-as-chief-business-officer-jazz-pharmaceuticals-p-jazz-20260108monthly0.5https://www.biopharmawatch.com/news/JAZZ/ziihera-zanidatamab-hrii-combinations-achieve-unprecedented-results-in-first-line-her2-loc-jazz-20260106monthly0.5https://www.biopharmawatch.com/news/JAZZ/modeyso-dordaviprone-included-in-national-comprehensive-cancer-network-nccn-clinical-pract-jazz-20250909monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-participate-in-the-2025-wells-fargo-healthcare-conference-jazz-pha-jazz-20250821monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-host-modeyso-dordaviprone-investor-webcast-on-august-27-2025-jazz--jazz-20250820monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-enters-exclusive-licensing-agreement-with-saniona-to-develop-and-comm-jazz-20250820monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-second-quarter-2025-financial-results-and-updates-2025-fina-jazz-20250805monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-second-quarter-financial-results-on-august-5-2025-jazz-phar-jazz-20250722monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-receives-european-commission-marketing-authorization-for-ziihera-zani-jazz-20250701monthly0.5https://www.biopharmawatch.com/news/JAZZ/zepzelca-lurbinectedin-and-atezolizumab-tecentriq-combination-granted-u-s-fda-priority-rev-jazz-20250610monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-presents-late-breaking-phase-4-data-showcasing-xywav-calcium-magnesiu-jazz-20250609monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-zepzelca-lurbinectedin-and-atezolizumab-tecentriq-combinati-jazz-20250602monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-reports-clinically-meaningful-long-term-median-overall-survival-data--jazz-20250602monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-expansive-research-demonstrating-comprehensive-treatment-b-jazz-20250529monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-participate-in-upcoming-june-investor-conferences-jazz-pharmaceuti-jazz-20250521monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-first-quarter-2025-financial-results-and-updates-2025-finan-jazz-20250506monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-participate-in-the-bofa-securities-2025-healthcare-conference-jazz-jazz-20250430monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-receives-chmp-positive-opinion-for-zanidatamab-for-the-treatment-of-a-jazz-20250425monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-showcases-transformative-data-at-asco-2025-highlighting-advances-in-s-jazz-20250423monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-first-quarter-financial-results-on-may-6-2025-jazz-pharmace-jazz-20250422monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-participate-in-the-24th-annual-needham-virtual-healthcare-conferen-jazz-20250326monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-showcase-research-demonstrating-treatment-benefits-of-xywav-calciu-jazz-20250319monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-full-year-and-fourth-quarter-2024-financial-results-and-pro-jazz-20250225monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-participate-in-td-cowen-s-45th-annual-health-care-conference-jazz--jazz-20250220monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2024-full-year-and-fourth-quarter-financial-results-on-febr-jazz-20250211monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-jazz-p-jazz-20241217monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-ceo-succession-plan-jazz-pharmaceuticals-plc-nasdaq-jazz-to-jazz-20241216monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-showcase-new-real-world-evidence-reinforcing-epidiolex-cannabidiol-jazz-20241206monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-update-to-national-comprehensive-cancer-network-nccn-clinic-jazz-20241205monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-ziihera-zanidatamab-hrii-investor-webcast-on-december-11-20-jazz-20241204monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-advancements-in-solid-tumors-and-blood-cancer-research-at--jazz-20241203monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-participate-in-citi-s-2024-global-healthcare-conference-jazz-pharm-jazz-20241119monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-third-quarter-2024-financial-results-jazz-pharmaceuticals-p-jazz-20241106monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-presents-new-data-at-psych-congress-2024-confirming-xywav-calcium-mag-jazz-20241031monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2024-third-quarter-financial-results-on-november-6-2024-jaz-jazz-20241023monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-statistically-significant-overall-survival-and-progression--jazz-20241015monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-presents-updated-phase-2-data-for-zanidatamab-demonstrating-increased-jazz-20240916monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-advancements-in-solid-tumor-oncology-research-at-esmo-2024-jazz-20240909monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-new-data-demonstrating-improved-epilepsy-outcomes-with-epi-jazz-20240905monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-pricing-of-private-offering-of-850-million-of-3-125-exchang-jazz-20240904monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-provides-update-on-cannabidiol-oral-solution-phase-3-trial-in-japan-i-jazz-20240822monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-participate-in-upcoming-september-investor-conferences-jazz-pharma-jazz-20240821monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-second-quarter-2024-financial-results-and-updates-2024-fina-jazz-20240731monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-shareholders-elect-laura-hamill-to-the-company-s-board-of-directors-a-jazz-20240725monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-successful-completion-of-term-loan-repricing-and-irrevocabl-jazz-20240722monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2024-second-quarter-financial-results-on-july-31-2024-jazz--jazz-20240717monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-promotes-samantha-pearce-to-chief-commercial-officer-jazz-pharmaceuti-jazz-20240709monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-provides-update-on-phase-2b-trial-of-investigational-suvecaltamide-jz-jazz-20240620monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-presents-overall-survival-and-longer-follow-up-data-from-herizon-btc--jazz-20240601monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-showcases-pioneering-research-in-sleep-medicine-at-sleep-2024-jazz-ph-jazz-20240530monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-participate-in-upcoming-june-investor-conferences-jazz-pharmaceuti-jazz-20240529monthly0.5https://www.biopharmawatch.com/news/JAZZ/zanidatamab-granted-priority-review-for-her2-positive-metastatic-biliary-tract-cancer-jazz-jazz-20240529monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-collaboration-with-life-science-cares-to-improve-the-wellbe-jazz-20240522monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-participate-in-the-bofa-securities-2024-health-care-conference-jaz-jazz-20240501monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-first-quarter-2024-financial-results-and-affirms-2024-finan-jazz-20240501monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-data-across-growing-oncology-pipeline-and-portfolio-at-asc-jazz-20240424monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2024-first-quarter-financial-results-on-may-1-2024-jazz-pha-jazz-20240417monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-showcase-expansive-neuroscience-portfolio-at-american-academy-of-n-jazz-20240410monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-completes-zanidatamab-biologics-license-application-for-previously-tr-jazz-20240402monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-host-virtual-zanidatamab-r-d-day-on-tuesday-march-19-2024-jazz-pha-jazz-20240312monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-full-year-and-fourth-quarter-2023-financial-results-and-pro-jazz-20240228monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-appoints-patrick-kennedy-to-its-board-of-directors-jazz-pharmaceutica-jazz-20240227monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences-jazz-pharmaceut-jazz-20240220monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2023-full-year-and-fourth-quarter-financial-results-on-febr-jazz-20240214monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-enters-definitive-agreement-with-redx-pharma-to-acquire-global-rights-jazz-20240207monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-provides-update-on-phase-2-trial-of-investigational-jzp150-in-adult-p-jazz-20231221monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-jazz-p-jazz-20231220monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-presents-updated-phase-2a-data-at-sabcs-2023-showcasing-potential-of--jazz-20231208monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-long-term-and-real-world-data-emphasizing-commitment-to-tr-jazz-20231201monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-new-data-highlighting-advancements-in-solid-tumors-and-rar-jazz-20231130monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-third-quarter-2023-financial-results-and-updates-financial--jazz-20231108monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-and-md-anderson-announce-five-year-collaboration-to-evaluate-zanidata-jazz-20231107monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-participate-in-upcoming-november-investor-conferences-jazz-pharmac-jazz-20231101monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2023-third-quarter-financial-results-on-november-8-2023-jaz-jazz-20231025monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-presents-data-highlighting-the-continued-need-for-low-sodium-treatmen-jazz-20231023monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-latest-advancements-in-sleep-medicine-at-world-sleep-2023--jazz-20231018monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-showcase-growing-impact-in-solid-tumor-oncology-research-at-esmo-2-jazz-20231016monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-receives-european-commission-approval-for-enrylaze-a-recombinant-erwi-jazz-20230921monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-participate-in-three-upcoming-investor-conferences-jazz-pharmaceut-jazz-20230913monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-key-update-to-leadership-team-jazz-pharmaceuticals-plc-nasd-jazz-20230912monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-showcases-impact-of-sleep-medicine-portfolio-at-psych-congress-2023-j-jazz-20230911monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-participate-in-citi-s-18th-annual-biopharma-conference-jazz-pharma-jazz-20230824monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-second-quarter-2023-financial-results-and-raises-2023-full--jazz-20230809monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2023-second-quarter-financial-results-on-august-9-2023-jazz-jazz-20230726monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-receives-chmp-positive-opinion-for-jzp458-a-recombinant-erwinia-aspar-jazz-20230721monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-and-zymeworks-present-positive-pivotal-phase-2b-trial-data-at-asco-20-jazz-20230602monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-demonstrates-continued-leadership-in-sleep-medicine-with-new-data-pre-jazz-20230531monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-participate-in-the-2023-goldman-sachs-global-healthcare-conference-jazz-20230530monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-host-zanidatamab-kol-investor-webcast-on-june-2-2023-jazz-pharmace-jazz-20230525monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-first-quarter-2023-financial-results-and-affirms-2023-finan-jazz-202305102023-05-10T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-participate-in-the-2023-rbc-capital-markets-global-healthcare-conf-jazz-202305022023-05-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-showcase-rapidly-expanding-oncology-pipeline-and-advances-in-curre-jazz-202304272023-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2023-first-quarter-financial-results-on-may-10-2023-jazz-ph-jazz-202304262023-04-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-advancements-in-neuroscience-at-american-academy-of-neurol-jazz-202304192023-04-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-expands-support-of-the-american-heart-association-to-raise-awareness--jazz-202303302023-03-30T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-data-at-2023-aacr-annual-meeting-showcasing-new-zepzelca-l-jazz-202303152023-03-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-full-year-and-fourth-quarter-2022-financial-results-and-pro-jazz-202303012023-03-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences-jazz-pharmaceut-jazz-202302272023-02-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2022-fourth-quarter-and-full-year-financial-results-on-marc-jazz-202302152023-02-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-and-zymeworks-announce-84-overall-survival-at-18-months-from-phase-2--jazz-202301192023-01-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-jazz-p-jazz-202301032023-01-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-presents-new-findings-from-caregiver-survey-on-outcomes-of-epidiolex--jazz-20221205monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-data-demonstrating-advancements-in-epilepsy-outcomes-at-th-jazz-20221128monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-u-s-fda-approval-of-monday-wednesday-friday-intramuscular-d-jazz-20221118monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-third-quarter-2022-financial-results-and-raises-total-reven-jazz-20221109monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-data-at-2022-ash-meeting-showcasing-commitment-to-advancin-jazz-20221103monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-participate-in-upcoming-november-investor-conferences-jazz-pharmac-jazz-20221101monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2022-third-quarter-financial-results-on-november-9-2022-jaz-jazz-20221026monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-participate-in-upcoming-september-investor-conferences-jazz-pharma-jazz-20220831monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-initiation-of-phase-3-trial-evaluating-epidiolex-epidyolex--jazz-20220818monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-second-quarter-2022-financial-results-and-affirms-2022-fina-jazz-20220803monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2022-second-quarter-financial-results-on-august-3-2022-jazz-jazz-20220720monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-top-line-results-from-phase-3-trial-evaluating-nabiximols-o-jazz-20220628monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-presents-positive-data-from-phase-2-3-trial-of-rylaze-asparaginase-er-jazz-20220607monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-participate-in-the-jefferies-healthcare-conference-jazz-pharmaceut-jazz-20220601monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-new-data-at-sleep-2022-reinforcing-leadership-in-sleep-med-jazz-20220601monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-data-showcasing-clinical-advancements-across-oncology-port-jazz-20220512monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-completes-u-s-divestiture-of-sunosi-solriamfetol-to-axsome-therapeuti-jazz-20220509monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-first-quarter-2022-financial-results-and-raises-2022-financ-jazz-20220504monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-participate-in-the-bofa-securities-2022-global-healthcare-conferen-jazz-20220503monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2022-first-quarter-financial-results-on-may-4-2022-jazz-pha-jazz-20220420monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-presents-pre-clinical-data-for-pan-raf-inhibitor-jzp815-including-pha-jazz-20220408monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-participate-in-upcoming-april-investor-conferences-jazz-pharmaceut-jazz-20220329monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-significant-new-investment-in-uk-manufacturing-jazz-pharmac-jazz-20220325monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-first-patient-enrolled-in-emerge-201-phase-2-basket-trial-e-jazz-20220324monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-pan-raf-inhibitor-pre-clinical-data-at-american-associatio-jazz-20220308monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-full-year-and-fourth-quarter-2021-financial-results-jazz-ph-jazz-20220301monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences-jazz-pharmaceut-jazz-20220228monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2021-fourth-quarter-and-full-year-financial-results-on-marc-jazz-20220215monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-completes-u-s-fda-supplemental-biologics-license-application-for-ryla-jazz-20220202monthly0.5https://www.biopharmawatch.com/news/JAZZ/lancet-neurology-publishes-positive-pivotal-phase-3-data-of-xywav-calcium-magnesium-potass-jazz-20220105monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-jazz-p-jazz-20220103monthly0.5https://www.biopharmawatch.com/news/JAZZ/u-s-fda-grants-orphan-drug-exclusivity-ode-for-xywav-calcium-magnesium-potassium-and-sodiu-jazz-20220103monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-first-patient-enrolled-in-phase-2-clinical-trial-evaluating-jazz-20211230monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-first-patient-enrolled-in-phase-2b-clinical-trial-evaluatin-jazz-20211215monthly0.5https://www.biopharmawatch.com/news/JAZZ/pharmamar-and-jazz-pharmaceuticals-announce-initiation-of-confirmatory-phase-3-clinical-tr-jazz-20211213monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-presents-positive-interim-phase-2-3-results-of-rylaze-asparaginase-er-jazz-20211212monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-from-expanding-neuroscience-portfolio-epidiolex-cannabidio-jazz-20211201monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-first-patient-enrolled-in-imforte-phase-3-trial-evaluating--jazz-20211130monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-participate-in-upcoming-november-investor-conferences-jazz-pharmac-jazz-20211109monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-third-quarter-2021-financial-results-and-raises-full-year-e-jazz-20211109monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-data-showcasing-clinical-advances-across-hematology-oncolo-jazz-20211104monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2021-third-quarter-financial-results-on-november-9-2021-jaz-jazz-20211026monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-xywav-calcium-magnesium-potassium-and-sodium-oxybates-inves-jazz-20210913monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-participate-in-upcoming-september-investor-conferences-jazz-pharma-jazz-20210908monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-u-s-fda-approval-of-xywav-calcium-magnesium-potassium-and-s-jazz-20210812monthly0.5https://www.biopharmawatch.com/news/JAZZ/gw-pharmaceuticals-receives-approval-for-epidyolex-cannabidiol-from-the-mhra-for-the-treat-jazz-20210810monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-second-quarter-2021-financial-results-jazz-pharmaceuticals--jazz-20210803monthly0.5https://www.biopharmawatch.com/news/JAZZ/national-comprehensive-cancer-network-adds-newly-approved-rylaze-asparaginase-erwinia-chry-jazz-20210722monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2021-second-quarter-financial-results-on-august-3-2021-jazz-jazz-20210720monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-rylaze-asparaginase-erwinia-chrysanthemi-recombinant-rywn-i-jazz-20210713monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-orphan-drug-exclusivity-for-xywav-calcium-magnesium-potassi-jazz-20210625monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-updates-2021-financial-guidance-to-include-recently-acquired-gw-pharm-jazz-20210617monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-and-leading-cancer-organizations-collaborate-to-launch-first-and-only-jazz-20210614monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-presents-18-abstracts-in-sleep-medicine-at-sleep-2021-jazz-pharmaceut-jazz-20210609monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-participate-in-jefferies-virtual-healthcare-conference-on-june-2-2-jazz-20210526monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-to-present-new-data-at-asco-and-eha-2021-meetings-showcasing-clinical-advances-across-jazz-20210520monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-participate-in-three-investor-conferences-in-may-2021-jazz-pharmac-jazz-20210504monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-first-quarter-2021-financial-results-jazz-pharmaceuticals-p-jazz-20210504monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-prices-1-5-billion-senior-secured-notes-offering-jazz-pharmaceuticals-jazz-20210422monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-presents-phase-3-study-results-of-xywav-calcium-magnesium-potassium-a-jazz-20210420monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2021-first-quarter-financial-results-on-may-4-2021-jazz-pha-jazz-20210419monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-fda-acceptance-and-priority-review-of-supplemental-new-drug-jazz-20210412monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-fda-approval-of-additional-indication-for-vyxeos-daunorubic-jazz-20210330monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-at-the-10th-annual-j-p-morgan-napa-valley-for-jazz-20210322monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-at-cowen-41st-annual-healthcare-conference-ja-jazz-20210223monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-full-year-and-fourth-quarter-2020-financial-results-jazz-ph-jazz-20210223monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-in-the-leerink-10th-annual-global-healthcare--jazz-20210217monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-completes-submission-of-supplemental-new-drug-application-for-xywav-c-jazz-20210216monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2020-fourth-quarter-financial-results-on-february-23-2021-j-jazz-20210209monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-in-the-39th-annual-j-p-morgan-healthcare-conf-jazz-20210104monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-initiation-of-biologics-license-application-submission-for--jazz-20201221monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-and-pharmamar-announce-results-of-atlantis-phase-3-study-evaluating-z-jazz-20201203monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-appoints-jennifer-cook-and-mark-smith-m-d-to-its-board-of-directors-j-jazz-20201117monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-at-jefferies-virtual-london-healthcare-confer-jazz-20201110monthly0.5https://www.biopharmawatch.com/news/JAZZ/data-at-ash-2020-annual-meeting-highlights-jazz-pharmaceuticals-commitment-to-advancing-he-jazz-20201105monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-third-quarter-2020-financial-results-jazz-pharmaceuticals-p-jazz-20201102monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-acquires-springworks-therapeutics-faah-inhibitor-program-jazz-pharmac-jazz-20201026monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-sleep-publication-of-phase-3-xywav-calcium-magnesium-potass-jazz-20201020monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-webcast-for-xywav-investor-update-jazz-pharmaceuticals-plc--jazz-20201019monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2020-third-quarter-financial-results-on-november-2-2020-jaz-jazz-20201019monthly0.5https://www.biopharmawatch.com/news/JAZZ/new-data-for-zepzelca-lurbinectedin-to-be-presented-at-iaslc-2020-north-america-conference-jazz-20201014monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-positive-top-line-results-from-phase-3-study-of-xywav-calci-jazz-20201008monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-launches-initiative-to-help-educate-people-living-with-rare-form-of-l-jazz-20200917monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-new-sleep-health-collaboration-jazz-pharmaceuticals-plc-nas-jazz-20200915monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-new-research-collaboration-with-redx-pharma-to-discover-and-jazz-20200909monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-at-three-upcoming-virtual-investor-conference-jazz-20200908monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-new-data-on-xywav-calcium-magnesium-potassium-and-sodium-o-jazz-20200827monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-second-quarter-2020-financial-results-jazz-pharmaceuticals--jazz-20200804monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-u-s-fda-approval-of-xywav-calcium-magnesium-potassium-and-s-jazz-20200722monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2020-second-quarter-financial-results-on-august-4-2020-jazz-jazz-20200721monthly0.5https://www.biopharmawatch.com/news/JAZZ/national-comprehensive-cancer-network-adds-zepzelca-lurbinectedin-to-clinical-practice-gui-jazz-20200713monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-u-s-fda-accelerated-approval-of-zepzelca-lurbinectedin-for--jazz-20200615monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-pricing-of-private-offering-of-850-million-of-2-000-exchang-jazz-20200609monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-private-offering-of-850-million-of-exchangeable-senior-note-jazz-20200608monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-at-two-upcoming-virtual-investor-conferences--jazz-20200527monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-showcase-new-data-from-its-growing-oncology-portfolio-at-virtual-a-jazz-20200514monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-appointment-of-kim-sablich-as-executive-vice-president-gene-jazz-20200511monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-at-upcoming-virtual-investor-conferences-jazz-jazz-20200506monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-first-quarter-2020-financial-results-jazz-pharmaceuticals-p-jazz-20200505monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-stops-enrollment-in-phase-3-study-evaluating-defibrotide-for-the-prev-jazz-20200429monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2020-first-quarter-financial-results-on-may-5-2020-jazz-pha-jazz-20200421monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-provides-covid-19-business-update-jazz-pharmaceuticals-plc-nasdaq-jaz-jazz-20200331monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-fda-acceptance-of-new-drug-application-for-jzp-258-for-cata-jazz-20200325monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-at-upcoming-investor-conferences-jazz-pharmac-jazz-20200226monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-full-year-and-fourth-quarter-2019-financial-results-jazz-ph-jazz-20200225monthly0.5https://www.biopharmawatch.com/news/JAZZ/pharmamar-and-jazz-pharmaceuticals-announce-fda-acceptance-and-priority-review-of-new-drug-jazz-20200217monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2019-fourth-quarter-and-full-year-financial-results-on-febr-jazz-20200211monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-submits-new-drug-application-for-jzp-258-for-cataplexy-and-excessive--jazz-20200122monthly0.5https://www.biopharmawatch.com/news/JAZZ/pharmamar-and-jazz-pharmaceuticals-announce-the-u-s-license-agreement-for-lurbinectedin-is-jazz-20200122monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-receives-eu-marketing-authorisation-for-sunosi-solriamfetol-for-exces-jazz-20200120monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-jazz-p-jazz-20200106monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-first-patient-enrolled-in-pivotal-phase-2-3-study-evaluatin-jazz-20191230monthly0.5https://www.biopharmawatch.com/news/JAZZ/pharmamar-and-jazz-pharmaceuticals-sign-exclusive-license-agreement-for-lurbinectedin-in-t-jazz-20191219monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-receives-positive-chmp-opinion-for-solriamfetol-to-improve-wakefulnes-jazz-20191115monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-at-upcoming-investor-conferences-jazz-pharmac-jazz-20191114monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-highlight-growing-hematology-oncology-pipeline-at-ash-2019-annual--jazz-20191107monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-third-quarter-2019-financial-results-jazz-pharmaceuticals-p-jazz-20191105monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2019-third-quarter-financial-results-on-november-5-2019-jaz-jazz-20191022monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-first-patient-enrolled-in-phase-2-clinical-trial-evaluating-jazz-20191010monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-survey-highlights-prevalence-of-misinformation-and-misperception-abou-jazz-20190930monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-presents-positive-jzp-258-phase-3-study-data-at-world-sleep-2019-jazz-jazz-20190925monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-webcast-for-world-sleep-congress-investor-update-jazz-pharm-jazz-20190918monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-in-two-upcoming-investor-conferences-jazz-pha-jazz-20190827monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-acquisition-of-cavion-inc-jazz-pharmaceuticals-plc-nasdaq-j-jazz-20190812monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-second-quarter-2019-financial-results-jazz-pharmaceuticals--jazz-20190806monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-advances-recombinant-crisantaspase-development-program-jazz-pharmaceu-jazz-20190806monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2019-second-quarter-financial-results-on-august-6-2019-jazz-jazz-20190723monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-acquires-pre-clinical-pan-raf-inhibitor-program-from-redx-pharma-jazz-jazz-20190710monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-webcast-for-sunosi-investor-update-jazz-pharmaceuticals-plc-jazz-20190625monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-receives-schedule-iv-designation-from-dea-for-sunosi-solriamfetol-jaz-jazz-20190617monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-appoints-dr-robert-iannone-as-executive-vice-president-research-and-d-jazz-20190603monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-new-data-at-upcoming-asco-annual-meeting-and-eha-congress--jazz-20190516monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-data-to-showcase-ongoing-sleep-medicine-research-at-sleep-2019-jazz-p-jazz-20190509monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-first-quarter-2019-financial-results-jazz-pharmaceuticals-p-jazz-20190507monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-in-two-upcoming-investor-conferences-jazz-pha-jazz-20190506monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2019-first-quarter-financial-results-on-may-7-2019-jazz-pha-jazz-20190423monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-positive-top-line-results-from-phase-3-study-of-jzp-258-in--jazz-20190326monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-at-the-cowen-and-company-39th-annual-healthcare-conference-jazz-20190305monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-full-year-and-fourth-quarter-2018-financial-results-jazz-ph-jazz-20190226monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-appointment-of-anne-o-riordan-to-its-board-of-directors-jaz-jazz-20190214monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2018-fourth-quarter-and-full-year-financial-results-on-febr-jazz-20190212monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-and-codiak-biosciences-announce-strategic-collaboration-to-research-d-jazz-20190103monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-at-the-j-p-morgan-healthcare-conference-on-january-7-jazz--jazz-20181219monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-share-repurchase-program-authorization-increase-of-400-mill-jazz-20181210monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-first-patient-enrolled-in-phase-3-clinical-trial-evaluating-jazz-20181129monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-highlight-hematology-research-at-ash-2018-annual-meeting-jazz-phar-jazz-20181128monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-submits-marketing-authorization-application-to-european-medicines-age-jazz-20181109monthly0.5https://www.biopharmawatch.com/news/JAZZ/national-institute-for-health-and-care-excellence-nice-recommends-jazz-pharmaceuticals-vyx-jazz-20181107monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-at-upcoming-investor-conferences-jazz-pharmac-jazz-20181107monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-third-quarter-2018-financial-results-jazz-pharmaceuticals-p-jazz-20181106monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-fda-approval-of-xyrem-sodium-oxybate-for-the-treatment-of-c-jazz-20181029monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2018-third-quarter-financial-results-on-november-6-2018-jaz-jazz-20181023monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-an-informational-webcast-for-investors-related-to-vyxeos-eu-jazz-20180911monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-in-two-upcoming-investor-conferences-jazz-pha-jazz-20180829monthly0.5https://www.biopharmawatch.com/news/JAZZ/vyxeos-receives-marketing-authorisation-in-the-european-union-for-treatment-of-certain-typ-jazz-20180827monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-second-quarter-2018-financial-results-jazz-pharmaceuticals--jazz-20180807monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-and-md-anderson-cancer-center-collaborate-to-evaluate-potential-treat-jazz-20180806monthly0.5https://www.biopharmawatch.com/news/JAZZ/cms-grants-new-technology-add-on-payment-to-vyxeos-daunorubicin-and-cytarabine-liposome-fo-jazz-20180803monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2018-second-quarter-financial-results-on-august-7-2018-jazz-jazz-20180724monthly0.5https://www.biopharmawatch.com/news/JAZZ/journal-of-clinical-oncology-publishes-pivotal-phase-3-data-for-jazz-pharmaceuticals-vyxeo-jazz-20180719monthly0.5https://www.biopharmawatch.com/news/JAZZ/vyxeos-receives-positive-chmp-opinion-for-treatment-of-certain-types-of-high-risk-acute-my-jazz-20180629monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-enters-into-agreement-with-tersera-therapeutics-llc-for-prialt-jazz-p-jazz-20180629monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-fda-acceptance-of-supplemental-new-drug-application-for-xyr-jazz-20180627monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-presents-long-term-safety-and-efficacy-data-from-phase-3-tones-5-stud-jazz-20180603monthly0.5https://www.biopharmawatch.com/news/JAZZ/new-survey-highlights-lack-of-awareness-of-neurologic-effects-related-to-excessive-sleepin-jazz-20180531monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-webcast-discussion-of-data-to-be-presented-at-apss-jazz-pha-jazz-20180524monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-highlight-breadth-of-research-in-narcolepsy-and-excessive-sleepine-jazz-20180510monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-in-three-upcoming-investor-conferences-jazz-p-jazz-20180509monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-first-quarter-2018-financial-results-jazz-pharmaceuticals-p-jazz-20180508monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-submits-supplemental-new-drug-application-for-xyrem-sodium-oxybate-to-jazz-20180501monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2018-first-quarter-financial-results-on-may-8-2018-jazz-pha-jazz-20180424monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-in-two-investor-conferences-in-march-jazz-pha-jazz-20180306monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-full-year-and-fourth-quarter-2017-financial-results-jazz-ph-jazz-20180227monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-first-patient-enrolled-in-phase-2-clinical-trial-evaluating-jazz-20180223monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2017-fourth-quarter-and-full-year-financial-results-on-febr-jazz-20180213monthly0.5https://www.biopharmawatch.com/news/JAZZ/national-comprehensive-cancer-network-adds-jazz-pharmaceuticals-vyxeos-daunorubicin-and-cy-jazz-20180208monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-at-the-j-p-morgan-healthcare-conference-on-january-8-jazz--jazz-20180102monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-submits-new-drug-application-for-solriamfetol-jzp-110-for-excessive-s-jazz-20171221monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-at-the-bmo-capital-markets-healthcare-conference-jazz-phar-jazz-20171207monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-appointment-of-daniel-swisher-as-president-and-chief-operat-jazz-20171204monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-in-three-upcoming-investor-conferences-jazz-p-jazz-20171109monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-third-quarter-2017-financial-results-jazz-pharmaceuticals-p-jazz-20171107monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-submits-vyxeos-marketing-authorization-application-to-european-medici-jazz-20171103monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-highlight-hematology-research-at-ash-2017-annual-meeting-jazz-phar-jazz-20171101monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2017-third-quarter-financial-results-on-november-7-2017-jaz-jazz-20171024monthly0.5https://www.biopharmawatch.com/news/JAZZ/fortune-magazine-names-jazz-pharmaceuticals-78th-fastest-growing-company-for-2017-jazz-pha-jazz-20170912monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-at-the-wells-fargo-securities-healthcare-conference-jazz-p-jazz-20170830monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-and-immunogen-inc-announce-a-strategic-collaboration-and-option-agree-jazz-20170829monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-second-quarter-2017-financial-results-received-fda-approval-jazz-20170808monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-webcast-for-vyxeos-investor-update-jazz-pharmaceuticals-plc-jazz-20170803monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-fda-approval-of-vyxeos-daunorubicin-and-cytarabine-liposome-jazz-20170803monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-and-xl-protein-gmbh-enter-into-a-license-agreement-on-pasylation-tech-jazz-20170726monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2017-second-quarter-financial-results-on-august-8-2017-jazz-jazz-20170724monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-presents-jzp-110-data-in-patients-with-excessive-sleepiness-associate-jazz-20170606monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-presents-data-for-the-phase-3-tones-2-study-of-jzp-110-in-patients-wi-jazz-20170606monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-fda-acceptance-of-nda-for-vyxeos-cpx-351-an-investigational-jazz-20170531monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-webcast-discussion-of-data-to-be-presented-at-apss-jazz-pha-jazz-20170524monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-phase-3-data-on-jzp-110-an-investigational-treatment-for-e-jazz-20170524monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-in-two-upcoming-investor-conferences-jazz-pha-jazz-20170516monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-first-quarter-2017-financial-results-total-revenues-increas-jazz-20170509monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-positive-results-from-the-phase-3-tones-2-study-of-jzp-110--jazz-20170426monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2017-first-quarter-financial-results-on-may-9-2017-jazz-pha-jazz-20170425monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-positive-results-from-the-phase-2-3-express-study-of-xyrem--jazz-20170424monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-completes-rolling-submission-of-new-drug-application-for-vyxeos-cpx-3-jazz-20170403monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-and-nippon-shinyaku-enter-into-license-agreements-for-the-development-jazz-20170330monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-positive-results-from-the-phase-3-tones-3-and-tones-4-studi-jazz-20170320monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-first-patient-enrolled-in-phase-3-clinical-study-evaluating-jazz-20170315monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-in-two-investor-conferences-in-march-jazz-pha-jazz-20170301monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-full-year-and-fourth-quarter-2016-financial-results-jazz-ph-jazz-20170228monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2016-fourth-quarter-and-full-year-financial-results-on-febr-jazz-20170214monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-first-patient-enrolled-in-phase-2-clinical-study-evaluating-jazz-20170208monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-first-patient-enrolled-in-phase-3-clinical-trial-evaluating-jazz-20170117monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-at-the-j-p-morgan-healthcare-conference-on-january-9-jazz--jazz-20170103monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-that-patient-enrollment-is-complete-for-the-phase-3-study-o-jazz-20161128monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-in-three-upcoming-investor-conferences-jazz-p-jazz-20161110monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-new-data-at-the-annual-ash-meeting-jazz-pharmaceuticals-pl-jazz-20161107monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2016-third-quarter-financial-results-on-november-8-2016-jaz-jazz-20161025monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-initiates-rolling-nda-submission-for-vyxeos-cpx-351-expects-to-comple-jazz-20161003monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-that-patient-enrollment-is-complete-for-the-phase-3-studies-jazz-20160926monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-at-the-morgan-stanley-global-healthcare-conference-jazz-ph-jazz-20160907monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-second-quarter-2016-financial-results-jazz-pharmaceuticals--jazz-20160809monthly0.5https://www.biopharmawatch.com/news/JAZZ/cms-grants-new-technology-add-on-payment-to-defitelio-for-the-treatment-of-hepatic-veno-oc-jazz-20160802monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-and-pfenex-enter-into-a-worldwide-license-and-option-agreement-relate-jazz-20160728monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2016-second-quarter-financial-results-on-august-9-2016-jazz-jazz-20160725monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-plc-announces-results-of-tender-offer-to-purchase-all-of-the-outstand-jazz-20160712monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-expiration-of-hsr-waiting-period-for-proposed-celator-pharm-jazz-20160627monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-conference-call-and-webcast-for-jzp-110-investor-update-jaz-jazz-20160614monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-and-celator-pharmaceuticals-announce-agreement-for-jazz-pharmaceutica-jazz-20160531monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-in-two-upcoming-investor-conferences-jazz-pha-jazz-20160518monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-first-quarter-2016-financial-results-jazz-pharmaceuticals-p-jazz-20160510monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2016-first-quarter-financial-results-on-may-10-2016-jazz-ph-jazz-20160426monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-webcast-for-defitelio-defibrotide-sodium-investor-update-ja-jazz-20160330monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-fda-approval-of-defitelio-defibrotide-sodium-for-the-treatm-jazz-20160330monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-in-two-investor-conferences-in-march-jazz-pha-jazz-20160302monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-full-year-and-fourth-quarter-2015-financial-results-jazz-ph-jazz-20160223monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-data-from-ongoing-evaluations-of-defibrotide-at-the-2016-b-jazz-20160218monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2015-fourth-quarter-and-full-year-financial-results-on-febr-jazz-20160209monthly0.5https://www.biopharmawatch.com/news/JAZZ/results-from-phase-3-trial-of-defibrotide-for-the-treatment-of-severe-veno-occlusive-disea-jazz-20160201monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-at-the-j-p-morgan-healthcare-conference-on-january-11-jazz-jazz-20160104monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-in-three-upcoming-investor-conferences-jazz-p-jazz-20151104monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2015-third-quarter-financial-results-on-november-9-2015-jaz-jazz-20151026monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-u-s-fda-acceptance-for-filing-with-priority-review-of-nda-f-jazz-20150930monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2015-second-quarter-financial-results-on-august-5-2015-jazz-jazz-20150722monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-at-cantor-fitzgerald-healthcare-conference-on-july-8-jazz--jazz-20150701monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-first-patients-enrolled-in-phase-3-clinical-development-pro-jazz-20150608monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-abstracts-from-ongoing-evaluations-of-xyrem-sodium-oxybate-jazz-20150604monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-in-two-investor-conferences-jazz-pharmaceutic-jazz-20150515monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-first-quarter-2015-financial-results-jazz-pharmaceuticals-p-jazz-20150507monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2015-first-quarter-financial-results-on-may-7-2015-jazz-pha-jazz-20150423monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-full-year-and-fourth-quarter-2014-financial-results-jazz-ph-jazz-20150224monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-in-two-investor-conferences-in-march-jazz-pha-jazz-20150223monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-data-on-defibrotide-an-investigational-treatment-in-patien-jazz-20150212monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2014-fourth-quarter-and-full-year-financial-results-on-febr-jazz-20150210monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-at-j-p-morgan-healthcare-conference-on-january-12-jazz-pha-jazz-20150105monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-receives-fda-approval-for-intravenous-administration-of-erwinaze-aspa-jazz-20141219monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-initiates-rolling-nda-submission-for-defibrotide-for-the-treatment-of-jazz-20141211monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-first-patients-enrolled-in-phase-3-trial-of-xyrem-sodium-ox-jazz-20141202monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-new-analysis-of-defibrotide-data-in-patients-with-hepatic--jazz-20141202monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-in-two-investor-conferences-jazz-pharmaceutic-jazz-20141125monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-in-two-investor-conferences-jazz-pharmaceutic-jazz-20141106monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-third-quarter-2014-financial-results-and-updated-guidance-j-jazz-20141104monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2014-third-quarter-financial-results-on-november-4-2014-jaz-jazz-20141021monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-pricing-of-500-million-of-exchangeable-senior-notes-jazz-ph-jazz-20140808monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-proposed-offering-of-500-million-of-exchangeable-senior-not-jazz-20140806monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-second-quarter-2014-financial-results-and-updated-guidance--jazz-20140805monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-completes-acquisition-of-rights-to-defibrotide-in-the-americas-from-s-jazz-20140805monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-at-canaccord-genuity-conference-on-august-13--jazz-20140804monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2014-second-quarter-financial-results-on-august-5-2014-jazz-jazz-20140722monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-agreement-to-acquire-rights-to-defibrotide-in-the-americas--jazz-20140702monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-presents-jzp-110-phase-2b-data-for-the-treatment-of-eds-symptoms-in-a-jazz-20140602monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-data-on-compound-in-sleep-pipeline-during-apss-annual-slee-jazz-20140527monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-names-russell-j-cox-to-position-of-chief-operating-officer-jazz-pharm-jazz-20140519monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-in-two-investor-conferences-jazz-pharmaceutic-jazz-20140513monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-first-quarter-2014-financial-results-jazz-pharmaceuticals-p-jazz-20140508monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2014-first-quarter-financial-results-on-may-8-2014-jazz-pha-jazz-20140424monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-in-two-investor-conferences-in-march-jazz-pha-jazz-20140226monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-management-change-jazz-pharmaceuticals-plc-nasdaq-jazz-toda-jazz-20140225monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-full-year-and-fourth-quarter-2013-financial-results-jazz-ph-jazz-20140225monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-plc-completes-tender-offer-for-gentium-s-p-a-shares-jazz-pharmaceutic-jazz-20140221monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2013-fourth-quarter-and-full-year-financial-results-on-febr-jazz-20140211monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-u-s-commercial-availability-of-versacloz-clozapine-usp-oral-jazz-20140211monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-breaks-ground-on-new-manufacturing-and-development-facility-in-irelan-jazz-20140210monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-plc-announces-minimum-tender-condition-exceeded-during-initial-offeri-jazz-20140123monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-acquisition-from-aerial-biopharma-of-rights-to-a-late-stage-jazz-20140113monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-at-j-p-morgan-healthcare-conference-on-january-13-jazz-pha-jazz-20140106monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-and-gentium-s-p-a-announce-agreement-for-jazz-pharmaceuticals-to-acqu-jazz-20131219monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-at-the-piper-jaffray-healthcare-conference-on-jazz-20131120monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-third-quarter-2013-financial-results-jazz-pharmaceuticals-p-jazz-20131105monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-present-at-the-2013-credit-suisse-healthcare-conference-on-novembe-jazz-20131101monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-third-quarter-2013-financial-results-on-november-5-2013-jaz-jazz-20131022monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-second-quarter-2013-financial-results-jazz-pharmaceuticals--jazz-20130806monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-second-quarter-2013-financial-results-on-august-6-2013-jazz-jazz-20130723monthly0.5https://www.biopharmawatch.com/news/JAZZ/new-research-at-sleep-2013-demonstrates-people-with-narcolepsy-face-significant-health-and-jazz-20130605monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-in-upcoming-investor-events-jazz-pharmaceutic-jazz-20130513monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-first-quarter-2013-financial-results-jazz-pharmaceuticals-p-jazz-20130507monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-first-quarter-2013-financial-results-on-may-7-2013-jazz-pha-jazz-20130423monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-pricing-of-public-offering-of-ordinary-shares-by-selling-sh-jazz-20130305monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-at-two-investor-conferences-in-march-jazz-pha-jazz-20130227monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-reports-full-year-and-fourth-quarter-2012-financial-results-jazz-phar-jazz-20130226monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-report-2012-fourth-quarter-and-full-year-financial-results-on-febr-jazz-20130211monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-to-webcast-presentation-at-j-p-morgan-healthcare-conference-jazz-phar-jazz-20130102monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-presentation-of-largest-safety-trial-to-date-of-patients-tr-jazz-20121210monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-issuance-of-additional-xyrem-patent-jazz-pharmaceuticals-pl-jazz-20121204monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-begins-clinical-trial-of-intravenously-administered-erwinaze-in-patie-jazz-20121203monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-in-three-investor-conferences-in-november-jaz-jazz-20121109monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-support-for-national-campaign-designed-to-curb-prescription-jazz-20121105monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-date-to-release-third-quarter-2012-results-jazz-pharmaceuti-jazz-20121029monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-completes-sale-of-its-women-s-health-business-to-meda-jazz-pharmaceut-jazz-20121015monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-participation-at-the-2012-morgan-stanley-global-healthcare--jazz-20120906monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-enters-definitive-agreement-to-sell-its-women-s-health-business-to-me-jazz-20120906monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-second-quarter-2012-results-jazz-pharmaceuticals-plc-nasdaq-jazz-20120807monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-second-quarter-2012-financial-results-conference-call-on-au-jazz-20120731monthly0.5https://www.biopharmawatch.com/news/JAZZ/catherine-sohn-elected-to-jazz-pharmaceuticals-board-of-directors-jazz-pharmaceuticals-plc-jazz-20120730monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-completes-eusa-pharma-acquisition-jazz-pharmaceuticals-plc-nasdaq-jaz-jazz-20120612monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-presentation-at-the-jefferies-2012-global-healthcare-confer-jazz-20120605monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-first-quarter-2012-financial-results-conference-call-on-may-jazz-20120430monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-announces-public-offering-of-ordinary-shares-by-selling-shareholders--jazz-20120305monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-plc-announces-new-executive-appointments-jazz-pharmaceuticals-plc-nas-jazz-20120124monthly0.5https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-and-azur-pharma-combine-to-create-jazz-pharmaceuticals-plc-jazz-pharm-jazz-20120118monthly0.5https://www.biopharmawatch.com/news/BDX/bd-introduce-un-innovazione-tips-di-nuova-generazione-per-migliorare-il-trattamento-dell-i-bdx-20260410monthly0.5https://www.biopharmawatch.com/news/BDX/bd-propose-une-innovation-tips-de-nouvelle-ge-ne-ration-pour-faire-progresser-les-soins-de-bdx-20260408monthly0.5https://www.biopharmawatch.com/news/BDX/bd-ofrece-la-tecnologi-a-tips-para-impulsar-la-atencio-n-de-la-hipertensio-n-portal-en-tod-bdx-20260408monthly0.5https://www.biopharmawatch.com/news/BDX/bd-stellt-die-na-chste-generation-der-tips-technologie-vor-um-die-behandlung-der-portalen--bdx-20260408monthly0.5https://www.biopharmawatch.com/news/BDX/quand-chaque-battement-compte-bd-aide-les-professionnels-de-sante-a-e-liminer-les-zones-d--bdx-20260407monthly0.5https://www.biopharmawatch.com/news/BDX/when-every-beat-matters-bd-helps-clinicians-eliminate-blind-spots-with-continuous-noninvas-bdx-20260407monthly0.5https://www.biopharmawatch.com/news/BDX/cuando-cada-latido-cuenta-bd-ayuda-a-los-me-dicos-a-eliminar-los-puntos-ciegos-bd-becton-d-bdx-20260407monthly0.5https://www.biopharmawatch.com/news/BDX/wenn-jeder-herzschlag-za-hlt-hilft-bd-a-rzten-dabei-blinde-flecken-zu-beseitigen-dank-kont-bdx-20260407monthly0.5https://www.biopharmawatch.com/news/BDX/bd-avanza-en-el-tratamiento-de-la-arteria-ili-aca-en-toda-la-unio-n-europea-bd-becton-dick-bdx-20260306monthly0.5https://www.biopharmawatch.com/news/BDX/lanesha-minnix-named-general-counsel-for-bd-bd-becton-dickinson-and-company-nyse-bdx-a-lea-bdx-20260219monthly0.5https://www.biopharmawatch.com/news/BDX/bd-and-penn-institute-for-immunology-and-immune-health-collaborate-to-advance-immunotherap-bdx-20251218monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-announce-financial-results-for-its-fourth-quarter-and-full-year-of-fiscal-2025-bd-be-bdx-20251009monthly0.5https://www.biopharmawatch.com/news/BDX/bd-reaches-major-milestone-for-rotarex-catheter-system-with-first-patient-enrolled-in-xtra-bdx-20251009monthly0.5https://www.biopharmawatch.com/news/BDX/bd-and-opentrons-collaborate-to-accelerate-single-cell-multiomics-discoveries-with-robotic-bdx-20251008monthly0.5https://www.biopharmawatch.com/news/BDX/bd-celebrates-55-years-of-manufacturing-excellence-and-impact-in-sumter-s-c-bd-becton-dick-bdx-20251003monthly0.5https://www.biopharmawatch.com/news/BDX/bd-and-henry-ford-health-sign-pharmacy-automation-partnership-to-revolutionize-medication--bdx-20250922monthly0.5https://www.biopharmawatch.com/news/BDX/bd-marks-1-000th-bd-rhapsody-system-driving-scientific-breakthroughs-via-single-cell-multi-bdx-20250917monthly0.5https://www.biopharmawatch.com/news/BDX/bd-expands-peripheral-artery-disease-awareness-efforts-with-love-your-limbs-community-scre-bdx-20250902monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-wells-fargo-2025-healthcare-conference-bd-becton-dickinson-and-company-ny-bdx-20250814monthly0.5https://www.biopharmawatch.com/news/BDX/bd-reports-third-quarter-fiscal-2025-financial-results-revenue-of-5-5-billion-increased-10-bdx-20250807monthly0.5https://www.biopharmawatch.com/news/BDX/bd-businesses-become-first-in-medtech-to-achieve-hirc-s-diamond-badge-across-all-supply-ch-bdx-20250805monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-invest-35-million-in-nebraska-facility-to-expand-prefilled-flush-syringe-manufacturi-bdx-20250804monthly0.5https://www.biopharmawatch.com/news/BDX/bd-aims-to-save-lives-by-empowering-women-with-choice-and-access-to-cervical-cancer-screen-bdx-20250731monthly0.5https://www.biopharmawatch.com/news/BDX/bd-receives-fda-510-k-clearance-for-rapid-point-of-care-covid-19-test-bd-becton-dickinson--bdx-20250730monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-first-pharma-sponsored-clinical-trial-using-bd-libertas-wearable-injector-tec-bdx-20250723monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20250722monthly0.5https://www.biopharmawatch.com/news/BDX/bd-appoints-bilal-muhsin-as-executive-vice-president-and-president-of-future-connected-car-bdx-20250707monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-initiate-real-world-patient-data-registry-for-the-rotarex-atherectomy-system-in-trea-bdx-20250528monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-goldman-sachs-46th-annual-global-healthcare-conference-bd-becton-dickinso-bdx-20250527monthly0.5https://www.biopharmawatch.com/news/BDX/cancer-patients-face-elevated-risk-of-carrying-antimicrobial-resistant-superbugs-first-of--bdx-20250521monthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-landmark-cell-analyzer-featuring-breakthrough-spectral-and-real-time-cell-imag-bdx-20250513monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-announce-financial-results-for-its-third-quarter-of-fiscal-2025-bd-becton-dickinson--bdx-20250512monthly0.5https://www.biopharmawatch.com/news/BDX/bd-reports-second-quarter-fiscal-2025-financial-results-bd-becton-dickinson-and-company-ny-bdx-20250501monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-bank-of-america-securities-health-care-conference-bd-becton-dickinson-and-bdx-20250430monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20250429monthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-industry-first-bioabsorbable-mesh-designed-for-umbilical-hernia-repair-bd-bect-bdx-20250423monthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-next-generation-hemodynamic-monitoring-solution-providing-clinicians-with-ai-d-bdx-20250421monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-announce-financial-results-for-its-second-quarter-of-fiscal-2025-bd-becton-dickinson-bdx-20250403monthly0.5https://www.biopharmawatch.com/news/BDX/bd-named-one-of-america-s-most-innovative-companies-by-fortune-bd-becton-dickinson-and-com-bdx-20250331monthly0.5https://www.biopharmawatch.com/news/BDX/bd-names-gregory-j-hayes-to-board-of-directors-bd-becton-dickinson-and-company-nyse-bdx-a--bdx-20250327monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-milestone-in-clinical-trial-for-use-of-bioabsorbable-galaflex-lite-scaffold-i-bdx-20250320monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-investor-healthcare-conferences-bd-becton-dickinson-and-company-nyse-bdx--bdx-20250213monthly0.5https://www.biopharmawatch.com/news/BDX/bd-reports-first-quarter-fiscal-2025-financial-results-bd-becton-dickinson-and-company-nys-bdx-20250205monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-intent-to-separate-biosciences-and-diagnostic-solutions-business-to-enhance-f-bdx-20250205monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-authorizes-10-million-additional-share-repurchases-bd-completed-bdx-20250128monthly0.5https://www.biopharmawatch.com/news/BDX/bd-and-biosero-collaborate-to-enable-robotic-integration-with-flow-cytometers-used-in-drug-bdx-20250123monthly0.5https://www.biopharmawatch.com/news/BDX/carilion-clinic-first-in-virginia-to-offer-needle-free-in-patient-blood-draws-redefining-p-bdx-20250122monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-announce-financial-results-for-its-first-quarter-of-fiscal-2025-bd-becton-dickinson--bdx-20250116monthly0.5https://www.biopharmawatch.com/news/BDX/bd-boosts-u-s-manufacturing-of-critical-medical-devices-bd-becton-dickinson-and-company-ny-bdx-20250115monthly0.5https://www.biopharmawatch.com/news/BDX/new-asccp-guidelines-include-more-precise-method-of-cervical-cancer-screening-bd-becton-di-bdx-20250113monthly0.5https://www.biopharmawatch.com/news/BDX/bd-names-pamela-spikner-as-chief-accounting-officer-and-controller-bd-becton-dickinson-and-bdx-20250110monthly0.5https://www.biopharmawatch.com/news/BDX/new-survey-finds-women-are-skipping-their-ob-gyn-exams-increasing-risks-for-cervical-cance-bdx-20250109monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-host-virtual-2025-annual-meeting-of-shareholders-bd-becton-dickinson-and-company-nys-bdx-20250107monthly0.5https://www.biopharmawatch.com/news/BDX/bd-and-babson-diagnostics-launch-innovative-fingertip-blood-testing-to-health-care-organiz-bdx-20241217monthly0.5https://www.biopharmawatch.com/news/BDX/bd-resolves-previously-disclosed-sec-investigation-bd-becton-dickinson-and-company-nyse-bd-bdx-20241216monthly0.5https://www.biopharmawatch.com/news/BDX/first-of-its-kind-hpv-self-collection-study-launched-to-improve-cervical-cancer-screening--bdx-20241120monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-7th-annual-evercore-isi-healthconx-conference-bd-becton-dickinson-and-bdx-20241119monthly0.5https://www.biopharmawatch.com/news/BDX/bd-reports-fourth-quarter-and-full-year-fiscal-2024-financial-results-strong-growth-and-ma-bdx-20241107monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-increases-dividend-for-53rd-consecutive-year-the-board-of-directors-of-bd-becton--bdx-20241107monthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-enhanced-intraosseous-system-enabling-vascular-access-in-seconds-for-critical--bdx-20241030monthly0.5https://www.biopharmawatch.com/news/BDX/bd-named-among-the-100-best-corporate-citizens-of-2024-bd-becton-dickinson-and-company-nys-bdx-20241025monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-new-robotics-solution-to-automate-standardize-single-cell-research-bd-becton--bdx-20241014monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-announce-its-fiscal-2024-fourth-quarter-and-full-year-financial-results-bd-becton-di-bdx-20241010monthly0.5https://www.biopharmawatch.com/news/BDX/bd-reaches-agreement-to-resolve-vast-majority-of-hernia-litigation-bd-becton-dickinson-and-bdx-20241002monthly0.5https://www.biopharmawatch.com/news/BDX/new-data-reveals-bd-s-artificial-intelligence-software-highly-effective-in-detecting-indic-bdx-20240926monthly0.5https://www.biopharmawatch.com/news/BDX/bd-expands-capacity-for-advanced-prefillable-syringes-and-enhances-injection-experience-fo-bdx-20240918monthly0.5https://www.biopharmawatch.com/news/BDX/bd-completes-acquisition-of-critical-care-from-edwards-lifesciences-expands-bd-s-portfolio-bdx-20240903monthly0.5https://www.biopharmawatch.com/news/BDX/bd-celebrates-75-years-of-u-s-manufacturing-excellence-in-nebraska-bd-becton-dickinson-and-bdx-20240822monthly0.5https://www.biopharmawatch.com/news/BDX/bd-names-michael-feld-as-president-of-life-sciences-segment-bd-becton-dickinson-and-compan-bdx-20240812monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-wells-fargo-2024-healthcare-conference-bd-becton-dickinson-and-company-ny-bdx-20240808monthly0.5https://www.biopharmawatch.com/news/BDX/bd-reports-third-quarter-fiscal-2024-financial-results-strong-margin-execution-drives-perf-bdx-20240801monthly0.5https://www.biopharmawatch.com/news/BDX/bd-quest-diagnostics-join-forces-to-develop-companion-diagnostics-for-cancer-other-disease-bdx-20240725monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20240723monthly0.5https://www.biopharmawatch.com/news/BDX/bd-statement-on-supplier-issue-impacting-bd-bactec-blood-culture-vials-bd-becton-dickinson-bdx-20240710monthly0.5https://www.biopharmawatch.com/news/BDX/bd-surpasses-scope-1-and-2-reduction-milestones-for-fy-2023-bd-becton-dickinson-and-compan-bdx-20240710monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-announce-financial-results-for-its-third-quarter-of-fiscal-2024-bd-becton-dickinson--bdx-20240703monthly0.5https://www.biopharmawatch.com/news/BDX/new-bd-research-tool-helps-scientists-study-cells-that-are-often-key-culprits-in-the-devel-bdx-20240626monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-dates-for-third-quarter-and-fourth-quarter-fiscal-2024-earnings-webcasts-bd-b-bdx-20240620monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-acquire-edwards-lifesciences-critical-care-product-group-for-4-2-billion-to-expand-s-bdx-20240603monthly0.5https://www.biopharmawatch.com/news/BDX/women-in-u-s-can-now-collect-their-own-sample-for-cervical-cancer-screening-bd-becton-dick-bdx-20240515monthly0.5https://www.biopharmawatch.com/news/BDX/bd-reports-second-quarter-fiscal-2024-financial-results-margin-execution-drives-better-per-bdx-20240502monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20240430monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-bank-of-america-securities-health-care-conference-2024-bd-becton-dickinso-bdx-20240429monthly0.5https://www.biopharmawatch.com/news/BDX/bd-named-a-best-employer-for-excellence-in-employee-well-being-bd-becton-dickinson-and-com-bdx-20240409monthly0.5https://www.biopharmawatch.com/news/BDX/bd-increases-access-to-cutting-edge-image-enabled-spectral-cell-sorters-bd-becton-dickinso-bdx-20240405monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-announce-financial-results-for-its-second-quarter-of-fiscal-2024-bd-becton-dickinson-bdx-20240404monthly0.5https://www.biopharmawatch.com/news/BDX/new-survey-reveals-patients-receive-too-many-needlesticks-bd-becton-dickinson-and-company--bdx-20240327monthly0.5https://www.biopharmawatch.com/news/BDX/bd-named-among-fortune-s-most-innovative-companies-bd-becton-dickinson-and-company-nyse-bd-bdx-20240326monthly0.5https://www.biopharmawatch.com/news/BDX/bd-increases-domestic-production-to-support-u-s-health-care-need-for-syringes-bd-becton-di-bdx-20240321monthly0.5https://www.biopharmawatch.com/news/BDX/bd-and-health-care-consortium-in-denmark-find-success-in-medical-waste-recycling-study-bd--bdx-20240318monthly0.5https://www.biopharmawatch.com/news/BDX/new-study-highlights-benefits-of-medication-management-automation-in-long-term-care-facili-bdx-20240313monthly0.5https://www.biopharmawatch.com/news/BDX/bd-initiates-international-study-to-expand-treatment-options-for-patients-with-peripheral--bdx-20240304monthly0.5https://www.biopharmawatch.com/news/BDX/dave-hickey-announces-intent-to-retire-from-bd-bd-becton-dickinson-and-company-nyse-bdx-a--bdx-20240227monthly0.5https://www.biopharmawatch.com/news/BDX/bd-partners-with-camtech-health-to-increase-access-to-cervical-cancer-screening-in-singapo-bdx-20240221monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-investor-healthcare-conferences-bd-becton-dickinson-and-company-nyse-bdx--bdx-20240215monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-next-installment-of-bd-innovates-series-spotlight-on-peripheral-vascular-dis-bdx-20240212monthly0.5https://www.biopharmawatch.com/news/BDX/bd-reports-first-quarter-fiscal-2024-financial-results-bd-becton-dickinson-and-company-nys-bdx-20240201monthly0.5https://www.biopharmawatch.com/news/BDX/bd-techcyte-announce-strategic-collaboration-to-offer-ai-based-digital-cervical-cytology-s-bdx-20240130monthly0.5https://www.biopharmawatch.com/news/BDX/bd-helps-advance-health-equity-for-women-in-kenya-through-critical-cancer-screening-bd-bec-bdx-20240125monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20240123monthly0.5https://www.biopharmawatch.com/news/BDX/bd-hamilton-collaborate-to-standardize-single-cell-multiomics-experiments-using-robotics-b-bdx-20240123monthly0.5https://www.biopharmawatch.com/news/BDX/new-survey-by-the-harris-poll-highlights-gaps-in-cervical-cancer-screening-access-bd-becto-bdx-20240110monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-webcast-of-annual-meeting-of-shareholders-bd-becton-dickinson-and-company-nys-bdx-20240105monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-announce-financial-results-for-its-first-quarter-of-fiscal-2024-bd-becton-dickinson--bdx-20240104monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-bd-becton-dickinson-and--bdx-20231222monthly0.5https://www.biopharmawatch.com/news/BDX/bd-signs-world-economic-forum-s-zero-health-gaps-pledge-bd-becton-dickinson-and-company-ny-bdx-20231211monthly0.5https://www.biopharmawatch.com/news/BDX/bd-receives-fda-510-k-clearance-for-potentially-transformative-fingertip-blood-collection--bdx-20231207monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-next-installment-of-bd-innovates-series-spotlight-on-pharmaceutical-systems--bdx-20231204monthly0.5https://www.biopharmawatch.com/news/BDX/fda-safety-communication-does-not-impact-bd-syringes-bd-becton-dickinson-and-company-nyse--bdx-20231130monthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-advanced-vascular-access-ultrasound-system-designed-to-improve-clinician-effic-bdx-20231130monthly0.5https://www.biopharmawatch.com/news/BDX/bd-names-dr-ronald-silverman-as-chief-medical-officer-bd-becton-dickinson-and-company-nyse-bdx-20231121monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-6th-annual-evercore-isi-healthconx-conference-bd-becton-dickinson-and-bdx-20231114monthly0.5https://www.biopharmawatch.com/news/BDX/bd-reports-fourth-quarter-and-full-year-fiscal-2023-financial-results-execution-of-bd-2025-bdx-20231109monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-increases-dividend-for-52nd-consecutive-year-the-board-of-directors-of-bd-becton--bdx-20231109monthly0.5https://www.biopharmawatch.com/news/BDX/bd-advances-one-stick-hospital-stay-vision-with-launch-of-next-generation-needle-free-bloo-bdx-20231102monthly0.5https://www.biopharmawatch.com/news/BDX/bd-named-among-the-100-best-corporate-citizens-of-2023-bd-becton-dickinson-and-company-nys-bdx-20231018monthly0.5https://www.biopharmawatch.com/news/BDX/bd-names-greg-rodetis-as-senior-vice-president-of-investor-relations-bd-becton-dickinson-a-bdx-20231017monthly0.5https://www.biopharmawatch.com/news/BDX/bd-casella-complete-industry-first-pilot-recycling-40-000-pounds-of-used-medical-devices-b-bdx-20231016monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-announce-fiscal-2023-fourth-quarter-and-full-year-financial-results-bd-becton-dickin-bdx-20231012monthly0.5https://www.biopharmawatch.com/news/BDX/bd-ranks-in-top-10-for-transparency-awarded-best-code-of-conduct-in-2023-u-s-transparency--bdx-20230919monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-investor-healthcare-conferences-bd-becton-dickinson-and-company-nyse-bdx--bdx-20230823monthly0.5https://www.biopharmawatch.com/news/BDX/bd-reports-third-quarter-fiscal-2023-financial-results-continues-strong-performance-and-pr-bdx-20230803monthly0.5https://www.biopharmawatch.com/news/BDX/bd-receives-510-k-clearance-for-covid-19-influenza-a-b-rsv-molecular-combination-test-bd-b-bdx-20230801monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20230725monthly0.5https://www.biopharmawatch.com/news/BDX/bd-names-joanne-waldstreicher-to-board-of-directors-bd-becton-dickinson-and-company-nyse-b-bdx-20230724monthly0.5https://www.biopharmawatch.com/news/BDX/bd-ceo-tom-polen-addresses-fda-510-k-clearance-of-bd-alaris-infusion-system-bd-becton-dick-bdx-20230724monthly0.5https://www.biopharmawatch.com/news/BDX/bd-receives-fda-510-k-clearance-for-updated-bd-alaris-infusion-system-bd-alaris-infusion-s-bdx-20230721monthly0.5https://www.biopharmawatch.com/news/BDX/bd-issues-fy-2022-esg-report-highlights-notable-progress-in-energy-and-waste-reduction-hea-bdx-20230720monthly0.5https://www.biopharmawatch.com/news/BDX/bd-recognized-as-a-best-place-to-work-for-disability-inclusion-bd-becton-dickinson-and-com-bdx-20230711monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-announce-financial-results-for-its-third-quarter-of-fiscal-2023-bd-becton-dickinson--bdx-20230706monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-sell-surgical-instrumentation-platform-to-steris-bd-becton-dickinson-and-company-nys-bdx-20230620monthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-new-robotic-system-to-automate-clinical-flow-cytometry-bd-becton-dickinson-and-bdx-20230612monthly0.5https://www.biopharmawatch.com/news/BDX/bd-advances-prefilled-flush-syringe-with-integrated-scrub-the-hub-innovation-bd-becton-dic-bdx-20230523monthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-world-s-first-spectral-cell-sorter-with-high-speed-cell-imaging-bd-becton-dick-bdx-20230518monthly0.5https://www.biopharmawatch.com/news/BDX/bd-gains-510-k-clearance-of-artificial-intelligence-software-for-mrsa-diagnostics-bd-becto-bdx-20230516monthly0.5https://www.biopharmawatch.com/news/BDX/health-care-collaboration-in-denmark-aims-to-reduce-medical-waste-a-new-health-care-sector-bdx-202305082023-05-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-reports-second-quarter-fiscal-2023-financial-results-bd-2025-strategic-investments-driv-bdx-202305042023-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-recognized-by-diversityinc-as-a-top-u-s-company-for-diversity-in-2023-list-bd-becton-di-bdx-202305032023-05-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-bank-of-america-securities-2023-health-care-conference-bd-becton-dickinso-bdx-202304262023-04-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-202304252023-04-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-recognized-by-forbes-as-a-best-employer-for-diversity-in-2023-list-bd-becton-dickinson--bdx-202304252023-04-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/new-harris-poll-finds-women-want-more-education-on-sexually-transmitted-infections-testing-bdx-202304192023-04-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-introduces-advanced-ultrasound-technology-to-help-drive-first-stick-success-for-iv-inse-bdx-202304112023-04-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-announce-financial-results-for-its-second-quarter-of-fiscal-2023-bd-becton-dickinson-bdx-202304062023-04-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/michelle-quinn-named-general-counsel-for-bd-franklin-lakes-n-j-april-3-2023-bd-becton-dick-bdx-202304032023-04-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-receives-fda-510-k-clearance-for-first-of-its-kind-high-throughput-diagnostic-test-for--bdx-202303162023-03-16T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-barclays-global-healthcare-conference-bd-becton-dickinson-and-company-nys-bdx-202303012023-03-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-cowen-43rd-annual-healthcare-conference-bd-becton-dickinson-and-company-n-bdx-202302212023-02-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-onclarity-hpv-assay-receives-fda-approval-for-use-with-both-bd-surepath-liquid-based-pa-bdx-202302212023-02-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-named-as-one-of-america-s-best-large-employers-bd-becton-dickinson-and-company-nyse-bdx-bdx-202302152023-02-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-receives-fda-emergency-use-authorization-for-covid-19-influenza-a-b-rsv-combination-tes-bdx-202302082023-02-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-introduces-high-throughput-single-cell-multiomics-platform-to-expand-scope-of-scientifi-bdx-202302032023-02-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-reports-first-quarter-fiscal-2023-financial-results-bd-becton-dickinson-and-company-nys-bdx-202302022023-02-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-named-to-bloomberg-gender-equality-index-for-4th-consecutive-year-bd-becton-dickinson-a-bdx-202301312023-01-31T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-publishes-2022-cybersecurity-annual-report-bd-becton-dickinson-and-company-nyse-bdx-a-l-bdx-202301252023-01-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-202301242023-01-24T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-introduces-fully-automated-robotic-track-system-for-microbiology-labs-bd-becton-dickins-bdx-202301112023-01-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-certest-biotec-announce-emergency-use-authorization-for-mpox-diagnostic-test-bd-becton--bdx-202301092023-01-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-webcast-of-annual-meeting-of-shareholders-bd-becton-dickinson-and-company-nys-bdx-202301062023-01-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/michelle-quinn-named-acting-general-counsel-for-bd-bd-becton-dickinson-and-company-nyse-bd-bdx-202301062023-01-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-announce-financial-results-for-its-first-quarter-of-fiscal-2023-bd-becton-dickinson--bdx-202301052023-01-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/new-harris-poll-reveals-significant-gaps-in-women-s-knowledge-about-cervical-cancer-bd-bec-bdx-202301052023-01-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-bd-becton-dickinson-and--bdx-20221220monthly0.5https://www.biopharmawatch.com/news/BDX/bd-releases-2022-global-inclusion-diversity-and-equity-annual-report-bd-becton-dickinson-a-bdx-20221208monthly0.5https://www.biopharmawatch.com/news/BDX/bd-named-in-top-25-of-newsweek-s-2023-list-of-america-s-most-responsible-companies-bd-bect-bdx-20221207monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-evercore-isi-5th-annual-healthconx-conference-bd-becton-dickinson-and-com-bdx-20221115monthly0.5https://www.biopharmawatch.com/news/BDX/bd-reports-fourth-quarter-and-full-year-fiscal-2022-financial-results-execution-of-bd-2025-bdx-20221110monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-increases-dividend-for-51st-consecutive-year-the-board-of-directors-of-bd-becton--bdx-20221110monthly0.5https://www.biopharmawatch.com/news/BDX/bd-magnolia-medical-technologies-announce-commercial-collaboration-to-help-reduce-blood-cu-bdx-20221018monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-announce-fiscal-2022-fourth-quarter-and-full-year-financial-results-bd-becton-dickin-bdx-20221013monthly0.5https://www.biopharmawatch.com/news/BDX/bd-recognized-among-world-s-best-employers-by-forbes-bd-becton-dickinson-and-company-nyse--bdx-20221011monthly0.5https://www.biopharmawatch.com/news/BDX/bd-heart-to-heart-international-nafc-and-henry-schein-cares-award-critical-lab-equipment-t-bdx-20220929monthly0.5https://www.biopharmawatch.com/news/BDX/new-bd-innovation-center-at-the-university-of-maryland-biopark-offers-researchers-and-stud-bdx-20220927monthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-state-of-the-art-cloud-software-solution-to-streamline-flow-cytometry-research-bdx-20220927monthly0.5https://www.biopharmawatch.com/news/BDX/bd-certest-biotec-announce-us-commercial-launch-of-monkeypox-assay-bd-becton-dickinson-and-bdx-20220926monthly0.5https://www.biopharmawatch.com/news/BDX/bd-foundation-advances-health-equity-education-through-support-of-international-council-of-bdx-20220919monthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-next-generation-prefillable-vaccine-syringe-designed-for-reliability-efficienc-bdx-20220913monthly0.5https://www.biopharmawatch.com/news/BDX/bd-promotes-two-senior-executives-to-segment-leadership-roles-bd-becton-dickinson-and-comp-bdx-20220825monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-wells-fargo-2022-healthcare-conference-bd-becton-dickinson-and-compan-bdx-20220824monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-pricing-of-the-tender-offers-becton-dickinson-and-company-nyse-bdx-the-compan-bdx-20220822monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-early-tender-results-and-upsizing-of-offer-subcap-becton-dickinson-and-compan-bdx-20220822monthly0.5https://www.biopharmawatch.com/news/BDX/bd-accelerate-diagnostics-announce-global-commercial-collaboration-bd-becton-dickinson-and-bdx-20220815monthly0.5https://www.biopharmawatch.com/news/BDX/bd-labcorp-collaborate-to-develop-flow-cytometry-based-companion-diagnostics-for-matching--bdx-20220809monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-tender-offers-for-outstanding-debt-securities-becton-dickinson-and-company-ny-bdx-20220808monthly0.5https://www.biopharmawatch.com/news/BDX/bd-direct-relief-and-national-association-of-community-health-centers-advance-health-equit-bdx-20220808monthly0.5https://www.biopharmawatch.com/news/BDX/bd-reports-third-quarter-fiscal-2022-financial-results-bd-becton-dickinson-and-company-nys-bdx-20220804monthly0.5https://www.biopharmawatch.com/news/BDX/bd-acquires-medkeeper-to-offer-cloud-based-connected-pharmacy-software-bd-becton-dickinson-bdx-20220728monthly0.5https://www.biopharmawatch.com/news/BDX/bd-certest-biotec-announce-commercial-launch-of-monkeypox-test-bd-becton-dickinson-and-com-bdx-20220727monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20220726monthly0.5https://www.biopharmawatch.com/news/BDX/bd-earns-recognition-as-a-best-place-to-work-for-disability-inclusion-bd-becton-dickinson--bdx-20220720monthly0.5https://www.biopharmawatch.com/news/BDX/bd-completes-acquisition-of-parata-systems-bd-becton-dickinson-and-company-nyse-bdx-today--bdx-20220718monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-announce-financial-results-for-its-third-quarter-of-fiscal-2022-bd-becton-dickinson--bdx-20220707monthly0.5https://www.biopharmawatch.com/news/BDX/bd-names-rishi-grover-as-chief-integrated-supply-chain-officer-bd-becton-dickinson-and-com-bdx-20220705monthly0.5https://www.biopharmawatch.com/news/BDX/bd-issues-2021-esg-report-bd-becton-dickinson-and-company-nyse-bdx-a-leading-global-medica-bdx-20220705monthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-combination-test-for-covid-19-influenza-a-b-and-respiratory-syncytial-virus-bd-bdx-20220630monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-voluntary-recall-on-intraosseous-products-bd-becton-dickinson-and-company-a-l-bdx-20220622monthly0.5https://www.biopharmawatch.com/news/BDX/bd-collaborates-with-mayo-clinic-platform-leveraging-real-world-clinical-data-to-improve-p-bdx-20220613monthly0.5https://www.biopharmawatch.com/news/BDX/certest-biotec-and-bd-announce-collaboration-on-molecular-diagnostic-test-for-monkeypox-ce-bdx-20220608monthly0.5https://www.biopharmawatch.com/news/BDX/bd-names-simon-campion-as-medical-segment-president-bd-becton-dickinson-and-company-nyse-b-bdx-20220607monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-acquire-parata-systems-to-enter-new-pharmacy-automation-solutions-market-bd-becton-d-bdx-20220606monthly0.5https://www.biopharmawatch.com/news/BDX/bd-unveils-world-s-first-spectral-cell-sorter-with-high-speed-imaging-technology-that-sort-bdx-20220603monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-goldman-sachs-43rd-annual-global-healthcare-conference-bd-becton-dickinso-bdx-20220602monthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-fully-automated-high-throughput-infectious-disease-molecular-diagnostic-platfo-bdx-20220512monthly0.5https://www.biopharmawatch.com/news/BDX/babson-bd-expand-strategic-partnership-to-advance-diagnostic-blood-collection-in-new-care--bdx-20220511monthly0.5https://www.biopharmawatch.com/news/BDX/bd-reports-second-quarter-fiscal-2022-financial-results-bd-becton-dickinson-and-company-ny-bdx-20220505monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-inaugural-members-of-scientific-advisory-board-bd-becton-dickinson-and-compan-bdx-20220502monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-bofa-securities-2022-healthcare-conference-bd-becton-dickinson-and-co-bdx-20220429monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20220426monthly0.5https://www.biopharmawatch.com/news/BDX/bd-named-to-forbes-2022-list-of-best-employers-for-diversity-bd-becton-dickinson-and-compa-bdx-20220426monthly0.5https://www.biopharmawatch.com/news/BDX/new-bd-reagents-enable-researchers-to-break-through-resolution-boundaries-in-flow-cytometr-bdx-20220425monthly0.5https://www.biopharmawatch.com/news/BDX/bd-forms-sustainable-medical-technology-institute-to-reduce-the-environmental-impact-of-it-bdx-20220422monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-announce-financial-results-for-its-second-quarter-of-fiscal-2022-bd-becton-dickinson-bdx-20220407monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-completion-of-embecta-corp-spinoff-bd-becton-dickinson-and-company-nyse-bdx-a-bdx-20220401monthly0.5https://www.biopharmawatch.com/news/BDX/alberto-mas-announces-intent-to-retire-from-bd-at-end-of-fiscal-year-bd-becton-dickinson-a-bdx-20220331monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-early-tender-results-for-cash-tender-offers-by-morgan-stanley-co-ll-bd-becton-bdx-20220330monthly0.5https://www.biopharmawatch.com/news/BDX/bd-named-one-of-america-s-most-trusted-companies-by-newsweek-bd-becton-dickinson-and-compa-bdx-20220325monthly0.5https://www.biopharmawatch.com/news/BDX/bd-provides-update-regarding-the-planned-spinoff-of-embecta-corp-bd-becton-dickinson-and-c-bdx-20220321monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-cash-tender-offers-by-morgan-stanley-co-llc-bd-becton-dickinson-and-company-n-bdx-20220316monthly0.5https://www.biopharmawatch.com/news/BDX/bd-names-william-bill-brown-to-board-of-directors-bd-becton-dickinson-and-company-nyse-bdx-bdx-20220301monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-cowen-42nd-annual-health-care-conference-bd-becton-dickinson-and-comp-bdx-20220224monthly0.5https://www.biopharmawatch.com/news/BDX/bd-appoints-shana-neal-as-chief-people-officer-bd-becton-dickinson-and-company-nyse-bdx-a--bdx-20220223monthly0.5https://www.biopharmawatch.com/news/BDX/embecta-to-host-virtual-investor-event-ahead-of-planned-spinoff-from-bd-bd-becton-dickinso-bdx-20220223monthly0.5https://www.biopharmawatch.com/news/BDX/bd-collaborates-with-returnsafe-to-help-employers-manage-covid-19-testing-bd-becton-dickin-bdx-20220208monthly0.5https://www.biopharmawatch.com/news/BDX/bd-reports-first-quarter-fiscal-2022-financial-results-bd-becton-dickinson-and-company-nys-bdx-20220203monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-of-directors-approves-embecta-spinoff-and-declares-distribution-of-embecta-stock--bdx-20220201monthly0.5https://www.biopharmawatch.com/news/BDX/bd-expands-from-cancer-discovery-and-diagnosis-into-post-treatment-monitoring-with-acquisi-bdx-20220201monthly0.5https://www.biopharmawatch.com/news/BDX/bd-recognized-for-equality-by-bloomberg-human-rights-campaign-bd-becton-dickinson-and-comp-bdx-20220127monthly0.5https://www.biopharmawatch.com/news/BDX/new-study-finds-up-to-one-third-of-women-receive-clinical-misdiagnosis-of-vaginitis-bd-bec-bdx-20220126monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20220125monthly0.5https://www.biopharmawatch.com/news/BDX/bd-innovation-profiled-in-cover-story-of-science-demonstrates-landmark-advancement-in-flow-bdx-20220120monthly0.5https://www.biopharmawatch.com/news/BDX/bd-named-one-of-america-s-most-just-companies-in-annual-just-100-ranking-bd-becton-dickins-bdx-20220111monthly0.5https://www.biopharmawatch.com/news/BDX/bd-pfizer-wellcome-collaborate-to-improve-global-hospital-antimicrobial-stewardship-practi-bdx-20220111monthly0.5https://www.biopharmawatch.com/news/BDX/bd-introduces-smart-connected-robotics-to-automate-microbial-identification-bd-becton-dick-bdx-20220107monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-change-to-virtual-2022-annual-meeting-of-shareholders-bd-becton-dickinson-and-bdx-20220106monthly0.5https://www.biopharmawatch.com/news/BDX/bd-publishes-2021-cybersecurity-annual-report-bd-becton-dickinson-and-company-nyse-bdx-a-l-bdx-20220106monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-announce-financial-results-for-its-first-quarter-of-fiscal-year-2022-bd-becton-dicki-bdx-20220105monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-bd-becton-dickinson-and--bdx-20211222monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-new-distribution-and-retail-partners-for-bd-veritor-at-home-covid-19-test-bd--bdx-20211222monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-board-of-directors-for-embecta-the-planned-spinoff-of-its-diabetes-care-busin-bdx-20211221monthly0.5https://www.biopharmawatch.com/news/BDX/bd-acquires-scanwell-health-inc-to-expand-and-scale-digital-at-home-testing-bd-becton-dick-bdx-20211221monthly0.5https://www.biopharmawatch.com/news/BDX/bd-expands-fully-automated-high-throughput-molecular-diagnostic-platform-for-core-labs-bd--bdx-20211217monthly0.5https://www.biopharmawatch.com/news/BDX/bd-acquires-tissuemed-ltd-to-add-advanced-sealant-to-its-portfolio-of-surgical-solutions-b-bdx-20211209monthly0.5https://www.biopharmawatch.com/news/BDX/bd-selects-embecta-as-name-of-new-company-for-planned-spinoff-of-diabetes-care-business-an-bdx-20211206monthly0.5https://www.biopharmawatch.com/news/BDX/bd-acquires-venclose-inc-to-extend-treatment-innovations-in-chronic-venous-disease-bd-bect-bdx-20211202monthly0.5https://www.biopharmawatch.com/news/BDX/bd-issues-2021-global-inclusion-diversity-and-equity-report-bd-becton-dickinson-and-compan-bdx-20211201monthly0.5https://www.biopharmawatch.com/news/BDX/bd-statement-on-testing-for-the-covid-19-omicron-variant-of-concern-bd-becton-dickinson-an-bdx-20211130monthly0.5https://www.biopharmawatch.com/news/BDX/bd-names-dr-joseph-m-smith-as-chief-scientific-officer-bd-becton-dickinson-and-company-nys-bdx-20211129monthly0.5https://www.biopharmawatch.com/news/BDX/bd-names-francesca-demartino-as-senior-vice-president-of-investor-relations-bd-becton-dick-bdx-20211124monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-highlight-progress-against-bd-2025-strategy-and-plans-for-long-term-growth-bd-becton-bdx-20211112monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-fourth-fiscal-quarter-and-full-year-2021-results-issues-fiscal-year-2022-guid-bdx-20211104monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-increases-dividend-for-50th-consecutive-year-authorizes-10-million-additional-sha-bdx-20211104monthly0.5https://www.biopharmawatch.com/news/BDX/bd-collaborates-with-u-s-government-on-development-of-covid-19-combination-diagnostic-test-bdx-20211028monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-host-investor-day-on-november-12-bd-becton-dickinson-and-company-nyse-bdx-a-leading--bdx-20211026monthly0.5https://www.biopharmawatch.com/news/BDX/bd-begins-shipments-of-first-smartphone-interpreted-over-the-counter-rapid-covid-19-test-b-bdx-20211026monthly0.5https://www.biopharmawatch.com/news/BDX/bd-names-dr-carrie-byington-to-board-of-directors-bd-becton-dickinson-and-company-nyse-bdx-bdx-20211022monthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-new-together-we-advance-environmental-social-governance-strategy-announces-203-bdx-20211018monthly0.5https://www.biopharmawatch.com/news/BDX/bd-unveils-nebraska-based-manufacturing-capacity-to-support-u-s-vaccination-agility-and-pr-bdx-20211007monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-510-k-clearance-of-expanded-indications-for-the-rotarex-atherectomy-system-bd-bdx-20211006monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-announce-fiscal-2021-fourth-quarter-and-full-year-financial-results-bd-becton-dickin-bdx-20211004monthly0.5https://www.biopharmawatch.com/news/BDX/bd-joins-the-race-to-zero-largest-alliance-dedicated-to-achieving-net-zero-emissions-by-20-bdx-20210922monthly0.5https://www.biopharmawatch.com/news/BDX/bd-partners-with-washington-state-in-back-to-school-testing-effort-bd-becton-dickinson-and-bdx-20210921monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-two-upcoming-virtual-healthcare-investor-conferences-in-september-bd-bect-bdx-20210826monthly0.5https://www.biopharmawatch.com/news/BDX/bd-receives-emergency-use-authorization-for-first-at-home-covid-19-test-to-use-smartphone--bdx-20210825monthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-fully-automated-high-throughput-molecular-diagnostic-platform-for-u-s-laborato-bdx-20210825monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-pricing-of-tender-offers-becton-dickinson-and-company-nyse-bdx-the-company-or-bdx-20210819monthly0.5https://www.biopharmawatch.com/news/BDX/new-bd-benchtop-cell-analyzer-enhances-laboratory-access-and-accelerates-scientific-resear-bdx-20210811monthly0.5https://www.biopharmawatch.com/news/BDX/christopher-delorefice-to-join-bd-as-chief-financial-officer-bd-becton-dickinson-and-compa-bdx-20210811monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-upsizing-of-tender-offers-becton-dickinson-and-company-nyse-bdx-the-company-o-bdx-20210810monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-third-fiscal-quarter-results-strong-base-growth-drives-better-performance-in--bdx-20210805monthly0.5https://www.biopharmawatch.com/news/BDX/christopher-reidy-announces-intent-to-retire-from-bd-bd-becton-dickinson-and-company-nyse--bdx-20210805monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-ubs-genomics-2-0-and-medtech-innovations-summit-bd-becton-dickinson-and-c-bdx-20210729monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-begin-remediation-for-bd-alaris-system-software-bd-becton-dickinson-and-company-nyse-bdx-20210729monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20210727monthly0.5https://www.biopharmawatch.com/news/BDX/bd-acquires-tepha-inc-to-drive-new-innovations-in-soft-tissue-repair-and-regeneration-bd-b-bdx-20210727monthly0.5https://www.biopharmawatch.com/news/BDX/bd-seeks-to-transform-patient-experience-through-vision-of-one-stick-hospital-stay-bd-bect-bdx-20210720monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-two-future-directors-for-diabetes-care-spinoff-company-bd-becton-dickinson-an-bdx-20210712monthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-reimagined-digital-marketplace-for-flow-cytometry-bd-becton-dickinson-and-comp-bdx-20210707monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-announce-financial-results-for-its-third-quarter-of-fiscal-2021-bd-becton-dickinson--bdx-20210630monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-expanded-510-k-clearance-for-at-home-system-for-ascites-bd-becton-dickinson-a-bdx-20210623monthly0.5https://www.biopharmawatch.com/news/BDX/bd-highlights-five-year-esg-achievements-in-2020-sustainability-report-setting-the-foundat-bdx-20210622monthly0.5https://www.biopharmawatch.com/news/BDX/usa-swimming-partners-with-bd-to-provide-covid-19-screening-for-the-olympic-trials-and-oth-bdx-20210611monthly0.5https://www.biopharmawatch.com/news/BDX/bd-hits-2-billion-injection-device-milestone-in-support-of-global-covid-19-vaccination-eff-bdx-20210608monthly0.5https://www.biopharmawatch.com/news/BDX/bd-advances-leadership-in-cybersecurity-preparedness-transparency-bd-becton-dickinson-and--bdx-20210602monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-upcoming-investor-conferences-in-june-bd-becton-dickinson-and-company-nys-bdx-20210526monthly0.5https://www.biopharmawatch.com/news/BDX/bd-leverages-artificial-intelligence-to-transform-microbiology-urine-testing-bd-becton-dic-bdx-20210526monthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-industry-first-ready-to-use-iodine-based-surgical-irrigation-system-bd-becton--bdx-20210525monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-build-new-165-million-manufacturing-facility-in-zaragoza-spain-to-support-ongoing-st-bdx-20210518monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-industry-first-ce-marked-assay-for-hpv-screening-from-at-home-self-collected--bdx-20210513monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-intent-to-spin-off-diabetes-care-business-to-enhance-focus-on-innovation-and--bdx-20210506monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-second-fiscal-quarter-results-reaffirms-fiscal-2021-guidance-bd-becton-dickin-bdx-20210506monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-upcoming-investor-health-care-conferences-in-may-bd-becton-dickinson-and--bdx-20210429monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-enrollment-in-post-market-studies-of-the-wavelinq-arteriovenous-endovascular--bdx-20210429monthly0.5https://www.biopharmawatch.com/news/BDX/elizabeth-mccombs-appointed-chief-technology-officer-at-bd-bd-becton-dickinson-and-company-bdx-20210428monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20210427monthly0.5https://www.biopharmawatch.com/news/BDX/certest-biotec-bd-announce-addition-of-saliva-to-the-ce-marked-viasure-sars-cov-2-n1-n2-re-bdx-20210427monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-fda-510-k-submission-for-bd-alaris-system-bd-becton-dickinson-and-company-nys-bdx-20210426monthly0.5https://www.biopharmawatch.com/news/BDX/bd-s-commitment-to-address-climate-change-in-recognition-of-earth-day-bd-becton-dickinson--bdx-20210422monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-the-voluntary-recall-of-specified-lots-of-chloraprep-hi-lite-orange-26-ml-app-bdx-20210420monthly0.5https://www.biopharmawatch.com/news/BDX/bd-commits-1m-to-fight-maternal-and-neonatal-tetanus-bd-becton-dickinson-and-company-nyse--bdx-20210420monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-510-k-clearance-of-pristine-long-term-hemodialysis-catheter-bd-becton-dickins-bdx-20210414monthly0.5https://www.biopharmawatch.com/news/BDX/bd-max-molecular-multi-drug-resistant-tuberculosis-test-to-be-included-in-who-updated-cons-bdx-20210413monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-announce-financial-results-for-its-second-quarter-of-fiscal-2021-bd-becton-dickinson-bdx-20210405monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-invest-65-million-for-key-supply-chain-infrastructure-in-tucson-arizona-to-increase--bdx-20210401monthly0.5https://www.biopharmawatch.com/news/BDX/bd-receives-emergency-use-authorization-for-asymptomatic-screening-for-sars-cov-2-through--bdx-20210401monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-fda-emergency-use-authorization-for-combination-covid-19-flu-rapid-antigen-te-bdx-20210330monthly0.5https://www.biopharmawatch.com/news/BDX/bd-expands-voluntary-recall-of-chloraprep-3-ml-applicator-nationwide-to-include-all-u-s-st-bdx-20210319monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-collaboration-with-imagemover-for-rapid-antigen-test-reporting-bd-becton-dick-bdx-20210309monthly0.5https://www.biopharmawatch.com/news/BDX/bd-acquires-gsl-solutions-inc-broadening-medication-management-offerings-for-retail-outpat-bdx-20210304monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-collaboration-for-at-home-rapid-test-for-covid-19-bd-becton-dickinson-and-com-bdx-20210222monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-upcoming-investor-conferences-bd-becton-dickinson-and-company-nyse-bdx-a--bdx-20210212monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-emergency-use-authorization-ce-mark-for-combination-molecular-diagnostic-to-d-bdx-20210212monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-first-fiscal-quarter-results-raises-fiscal-2021-guidance-bd-becton-dickinson--bdx-20210204monthly0.5https://www.biopharmawatch.com/news/BDX/die-erste-randomisierte-klinische-studie-ihrer-art-die-in-der-fachzeitschrift-the-lancet-i-bdx-20210203monthly0.5https://www.biopharmawatch.com/news/BDX/le-premier-essai-clinique-randomise-du-genre-publie-dans-the-lancet-infectious-diseases-de-bdx-20210202monthly0.5https://www.biopharmawatch.com/news/BDX/primer-ensayo-cli-nico-aleatorio-describe-las-mejores-pra-cticas-para-cate-teres-perife-ri-bdx-20210202monthly0.5https://www.biopharmawatch.com/news/BDX/first-of-its-kind-randomized-clinical-trial-published-in-the-lancet-infectious-diseases-ou-bdx-20210202monthly0.5https://www.biopharmawatch.com/news/BDX/bd-names-ceo-tom-polen-as-chairman-of-the-board-bd-becton-dickinson-and-company-nyse-bdx-a-bdx-20210126monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20210125monthly0.5https://www.biopharmawatch.com/news/BDX/new-clinical-data-shows-bd-antigen-test-may-be-more-selective-in-detecting-infectious-covi-bdx-20210125monthly0.5https://www.biopharmawatch.com/news/BDX/bd-provides-updates-to-its-fiscal-2021-financial-outlook-and-intends-to-comment-on-its-pre-bdx-20210112monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-bd-becton-dickinson-and--bdx-20201222monthly0.5https://www.biopharmawatch.com/news/BDX/bd-de-passe-le-milliard-de-commandes-de-dispositifs-d-injection-afin-de-soutenir-les-effor-bdx-20201217monthly0.5https://www.biopharmawatch.com/news/BDX/bd-u-bertrifft-1-milliarde-bestellungen-fu-r-injektionsgera-te-zur-unterstu-tzung-der-covi-bdx-20201217monthly0.5https://www.biopharmawatch.com/news/BDX/bd-supera-los-mil-millones-de-pedidos-de-dispositivos-de-inyeccio-n-para-la-covid-19-bd-be-bdx-20201217monthly0.5https://www.biopharmawatch.com/news/BDX/bd-surpasses-1-billion-injection-device-orders-in-support-of-covid-19-vaccination-efforts--bdx-20201216monthly0.5https://www.biopharmawatch.com/news/BDX/new-clinical-trial-data-demonstrates-bd-libertas-wearable-injector-as-a-drug-delivery-syst-bdx-20201209monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-invest-1-2-billion-in-pre-fillable-syringe-manufacturing-capacity-over-next-four-yea-bdx-20201202monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-increases-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse-bdx-20201124monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-streamlined-reporting-capabilities-for-covid-19-data-bd-becton-dickinson-and--bdx-20201123monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-evercore-isi-3rd-annual-healthconx-virtual-conference-bd-becton-dickinson-bdx-20201119monthly0.5https://www.biopharmawatch.com/news/BDX/bd-acquires-the-medical-business-assets-of-cubex-llc-broadening-automated-dispensing-portf-bdx-20201112monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-canadian-government-order-of-more-than-7-million-portable-rapid-point-of-care-bdx-20201110monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-investor-virtual-healthcare-conferences-bd-becton-dickinson-and-company-n-bdx-20201109monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-fiscal-fourth-quarter-and-full-year-2020-results-provides-fiscal-2021-guidanc-bdx-20201105monthly0.5https://www.biopharmawatch.com/news/BDX/bd-receives-order-from-dutch-ministry-of-health-for-more-than-nine-million-15-minute-covid-bdx-20201102monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-executive-leadership-appointments-bd-becton-dickinson-and-company-nyse-bdx-a--bdx-20201022monthly0.5https://www.biopharmawatch.com/news/BDX/certest-biotec-und-bd-geben-ce-kennzeichnung-fu-r-kombinationstest-covid-19-influenza-rsv--bdx-20201021monthly0.5https://www.biopharmawatch.com/news/BDX/certest-biotec-y-bd-anuncian-la-ce-mark-para-la-combinacio-n-de-test-de-covid-19-gripe-y-v-bdx-20201021monthly0.5https://www.biopharmawatch.com/news/BDX/certest-biotec-et-bd-pre-sentent-la-marque-ce-pour-la-combinaison-de-test-covid-19-grippe--bdx-20201021monthly0.5https://www.biopharmawatch.com/news/BDX/certest-biotec-and-bd-announce-ce-mark-for-combination-covid-19-influenza-rsv-test-on-bd-m-bdx-20201021monthly0.5https://www.biopharmawatch.com/news/BDX/bd-marks-25-years-with-mercy-ships-donates-1m-to-support-launch-of-world-s-largest-ngo-hos-bdx-20201007monthly0.5https://www.biopharmawatch.com/news/BDX/bd-granted-fda-510-k-clearance-for-bd-facslyric-flow-cytometer-with-newly-integrated-bd-fa-bdx-20201005monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-fourth-fiscal-quarter-earnings-conference-call-bd-becton-dick-bdx-20201002monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-ce-mark-of-portable-rapid-point-of-care-antigen-test-to-detect-sars-cov-2-in--bdx-20200930monthly0.5https://www.biopharmawatch.com/news/BDX/bd-submits-pre-market-approval-supplement-to-fda-to-enable-thinprep-pap-test-preservcyt-so-bdx-20200923monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-fda-classifications-for-august-4th-recalls-of-bd-alaris-system-hardware-for-k-bdx-20200921monthly0.5https://www.biopharmawatch.com/news/BDX/new-head-to-head-study-demonstrates-equivalency-and-accuracy-of-covid-19-rapid-point-of-ca-bdx-20200909monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-investor-healthcare-conferences-bd-becton-dickinson-and-company-nyse-bdx--bdx-20200831monthly0.5https://www.biopharmawatch.com/news/BDX/bd-provides-update-on-previously-disclosed-recall-of-bd-alaris-system-hardware-bd-becton-d-bdx-20200820monthly0.5https://www.biopharmawatch.com/news/BDX/kristen-stewart-to-join-bd-as-senior-vice-president-of-strategy-and-investor-relations-bd--bdx-20200817monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-ubs-genomics-2-0-and-medtech-innovations-virtual-summit-bd-becton-dickins-bdx-20200813monthly0.5https://www.biopharmawatch.com/news/BDX/bd-and-bd-foundation-commit-7-8-million-to-helping-community-health-centers-expand-innovat-bdx-20200810monthly0.5https://www.biopharmawatch.com/news/BDX/bd-anuncia-retiro-voluntario-del-aplicador-chloraprep-3-ml-en-determinados-territorios-est-bdx-20200807monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-voluntary-recall-of-chloraprep-3-ml-applicator-in-specific-u-s-territories-an-bdx-20200807monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2020-third-fiscal-quarter-provides-fiscal-2020-guidance-bd-becton-bdx-20200806monthly0.5https://www.biopharmawatch.com/news/BDX/bd-releases-fy-2019-sustainability-report-bd-becton-dickinson-and-company-nyse-bdx-a-leadi-bdx-20200803monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-24-million-u-s-government-investment-to-support-scale-up-of-u-s-manufacturing-bdx-20200730monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividends-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse-bdx-20200727monthly0.5https://www.biopharmawatch.com/news/BDX/bd-receives-fda-approval-for-hpv-test-with-extended-genotyping-capabilities-bd-becton-dick-bdx-20200722monthly0.5https://www.biopharmawatch.com/news/BDX/bd-receives-additional-orders-for-177-million-injection-devices-for-u-s-canada-covid-19-va-bdx-20200721monthly0.5https://www.biopharmawatch.com/news/BDX/bd-supports-u-s-government-efforts-to-increase-covid-19-testing-capacity-with-point-of-car-bdx-20200715monthly0.5https://www.biopharmawatch.com/news/BDX/bd-partners-with-u-s-government-on-70-million-manufacturing-infrastructure-project-for-mas-bdx-20200708monthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-first-and-only-fully-sterile-povidone-iodine-and-isopropyl-alcohol-skin-prepar-bdx-20200707monthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-portable-rapid-point-of-care-antigen-test-to-detect-sars-cov-2-in-15-minutes-d-bdx-20200706monthly0.5https://www.biopharmawatch.com/news/BDX/cme-america-announces-a-follow-up-on-the-voluntary-recall-of-bodyguard-infusion-system-adm-bdx-20200703monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-third-fiscal-quarter-earnings-conference-call-bd-becton-dicki-bdx-20200702monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-investor-conferences-bd-becton-dickinson-and-company-nyse-bdx-a-leading-g-bdx-20200601monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-jefferies-virtual-healthcare-conference-bd-becton-dickinson-and-company-n-bdx-20200526monthly0.5https://www.biopharmawatch.com/news/BDX/bd-prices-offerings-of-1-5-billion-of-common-stock-and-1-5-billion-of-depositary-shares-re-bdx-20200521monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-offerings-of-1-5-billion-of-common-stock-and-1-5-billion-of-depositary-shares-bdx-20200519monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2020-second-fiscal-quarter-withdraws-fiscal-year-2020-guidance-du-bdx-20200507monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-bank-of-america-securities-virtual-healthcare-conference-2020-bd-bect-bdx-20200505monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20200428monthly0.5https://www.biopharmawatch.com/news/BDX/cme-america-provides-update-on-two-previously-announced-voluntary-recalls-related-to-ambul-bdx-20200427monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-second-fda-emergency-use-authorization-ce-mark-for-new-covid-19-molecular-dia-bdx-20200413monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-second-fiscal-quarter-earnings-conference-call-bd-becton-dick-bdx-20200406monthly0.5https://www.biopharmawatch.com/news/BDX/bd-biogx-announce-fda-emergency-use-authorization-for-new-covid-19-diagnostic-for-use-in-u-bdx-20200403monthly0.5https://www.biopharmawatch.com/news/BDX/bd-biomedomics-announce-launch-of-rapid-serology-test-to-detect-exposure-to-covid-19-bd-be-bdx-20200331monthly0.5https://www.biopharmawatch.com/news/BDX/bd-biogx-announce-fda-emergency-use-authorization-submissions-for-new-covid-19-diagnostics-bdx-20200316monthly0.5https://www.biopharmawatch.com/news/BDX/bd-statement-on-white-house-meeting-on-covid-19-testing-bd-becton-dickinson-and-company-ny-bdx-20200313monthly0.5https://www.biopharmawatch.com/news/BDX/certest-biotec-and-bd-announce-covid-19-diagnostic-test-certest-biotec-along-with-bd-becto-bdx-20200310monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-barclays-global-healthcare-conference-bd-becton-dickinson-and-company-bdx-20200302monthly0.5https://www.biopharmawatch.com/news/BDX/bd-collaborates-with-fleming-fund-to-help-combat-threat-of-antimicrobial-resistance-in-asi-bdx-20200213monthly0.5https://www.biopharmawatch.com/news/BDX/bd-babson-diagnostics-announce-strategic-partnership-agreement-to-enable-small-volume-bloo-bdx-20200212monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2020-first-fiscal-quarter-lowers-fiscal-2020-guidance-bd-becton-d-bdx-20200206monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividends-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse-bdx-20200127monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-webcast-of-annual-meeting-of-shareholders-bd-becton-dickinson-and-company-nys-bdx-20200123monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-first-fiscal-quarter-earnings-conference-call-bd-becton-dicki-bdx-20200109monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-bd-becton-dickinson-and--bdx-20200103monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividends-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse-bdx-20191125monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-evercore-isi-2nd-annual-healthconx-conference-bd-becton-dickinson-and-com-bdx-20191122monthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-enhanced-antimicrobial-stewardship-analytics-capabilities-bd-becton-dickinson--bdx-20191121monthly0.5https://www.biopharmawatch.com/news/BDX/bd-recommends-stockholders-reject-mini-tender-offer-by-trc-capital-investment-corporation--bdx-20191115monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-jefferies-2019-london-healthcare-conference-bd-becton-dickinson-and-compa-bdx-20191114monthly0.5https://www.biopharmawatch.com/news/BDX/bd-submits-pre-market-approval-supplement-to-fda-for-bd-onclarity-hpv-test-with-extended-g-bdx-20191112monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2019-fourth-fiscal-quarter-and-full-year-provides-fiscal-2020-gui-bdx-20191105monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-fourth-fiscal-quarter-earnings-conference-call-bd-becton-dick-bdx-20191003monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-publication-of-an-independent-analysis-of-drug-coated-balloon-safety-data-for-bdx-20190928monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-leadership-succession-plan-bd-becton-dickinson-and-company-nyse-bdx-a-leading-bdx-20190926monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-investor-healthcare-conferences-bd-becton-dickinson-and-company-nyse-bdx--bdx-20190821monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2019-third-fiscal-quarter-reaffirms-fiscal-2019-guidance-bd-becto-bdx-20190806monthly0.5https://www.biopharmawatch.com/news/BDX/bd-releases-2018-sustainability-report-bd-becton-dickinson-and-company-nyse-bdx-a-leading--bdx-20190723monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividends-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse-bdx-20190722monthly0.5https://www.biopharmawatch.com/news/BDX/bd-provides-update-on-voluntary-recalls-of-alaris-pump-module-model-8100-and-certain-alari-bdx-20190718monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-third-fiscal-quarter-earnings-conference-call-bd-becton-dicki-bdx-20190702monthly0.5https://www.biopharmawatch.com/news/BDX/bd-statement-on-fda-circulatory-system-devices-panel-regarding-paclitaxel-coated-devices-b-bdx-20190620monthly0.5https://www.biopharmawatch.com/news/BDX/bd-desvela-una-nueva-solucio-n-para-pruebas-de-diagno-stico-molecular-de-alto-rendimiento--bdx-20190618monthly0.5https://www.biopharmawatch.com/news/BDX/bd-stellt-neues-produkt-fu-r-molekulardiagnostische-tests-mit-hohem-durchsatz-vor-bd-becto-bdx-20190618monthly0.5https://www.biopharmawatch.com/news/BDX/bd-pre-sente-une-nouvelle-solution-pour-les-tests-de-diagnostic-mole-culaire-a-haut-rendem-bdx-20190618monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-pricing-and-upsizing-of-tender-offers-becton-dickinson-and-company-nyse-bdx-t-bdx-20190604monthly0.5https://www.biopharmawatch.com/news/BDX/new-report-sheds-light-on-health-care-s-hidden-epidemic-hospital-drug-diversion-and-its-ro-bdx-20190604monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-early-tender-results-becton-dickinson-and-company-nyse-bdx-the-company-or-bd--bdx-20190603monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-goldman-sachs-40th-annual-global-healthcare-conference-bd-becton-dick-bdx-20190531monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2019-second-fiscal-quarter-updates-fiscal-2019-guidance-bd-becton-bdx-20190509monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-bank-of-america-merrill-lynch-2019-healthcare-conference-bd-becton-di-bdx-20190501monthly0.5https://www.biopharmawatch.com/news/BDX/bd-receives-fda-approval-for-fully-sterile-chlorhexidine-gluconate-antiseptic-skin-prepara-bdx-20190430monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividends-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse-bdx-20190429monthly0.5https://www.biopharmawatch.com/news/BDX/bd-unveils-platelet-quality-control-media-to-help-reduce-the-incidence-of-sepsis-in-patien-bdx-20190408monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-second-fiscal-quarter-earnings-conference-call-bd-becton-dick-bdx-20190404monthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-new-automated-flow-cytometry-sample-preparation-instrument-with-ce-ivd-certifi-bdx-20190326monthly0.5https://www.biopharmawatch.com/news/BDX/bd-statement-on-paclitaxel-coated-devices-bd-becton-dickinson-and-company-nyse-bdx-a-leadi-bdx-20190321monthly0.5https://www.biopharmawatch.com/news/BDX/bd-receives-u-s-fda-approval-for-first-venous-stent-to-treat-iliofemoral-venous-occlusive--bdx-20190314monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-barclays-global-healthcare-conference-bd-becton-dickinson-and-company-bdx-20190304monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-leerink-partners-8th-annual-global-healthcare-conference-bd-becton-dickin-bdx-20190215monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2019-first-fiscal-quarter-reaffirms-fiscal-2019-guidance-bd-becto-bdx-20190205monthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-ergonomic-pen-needle-technology-to-help-optimize-injection-technique-bd-becton-bdx-20190124monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividends-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse-bdx-20190121monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-preliminary-results-for-2019-first-fiscal-quarter-reaffirms-fiscal-2019-guida-bdx-20190117monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-webcast-of-annual-meeting-of-shareholders-bd-becton-dickinson-and-company-nys-bdx-20190115monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-first-fiscal-quarter-earnings-conference-call-bd-becton-dicki-bdx-20190108monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-investor-healthcare-conferences-bd-becton-dickinson-and-company-nyse-bdx--bdx-20181221monthly0.5https://www.biopharmawatch.com/news/BDX/bd-completes-molecular-portfolio-for-gi-infection-with-new-viral-panel-bd-becton-dickinson-bdx-20181220monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-completion-of-enterprise-level-cybersecurity-assessment-from-ul-bd-becton-dic-bdx-20181211monthly0.5https://www.biopharmawatch.com/news/BDX/bd-expands-integrated-medication-management-to-help-tackle-hospital-drug-diversion-bd-bect-bdx-20181129monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividends-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse-bdx-20181119monthly0.5https://www.biopharmawatch.com/news/BDX/new-diagnostic-test-helps-hospitals-more-quickly-identify-and-treat-emerging-antibiotic-re-bdx-20181113monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-clinical-trial-data-for-the-lutonix-014-drug-coated-balloon-below-the-knee-id-bdx-20181107monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-stifel-2018-healthcare-conference-bd-becton-dickinson-and-company-nys-bdx-20181106monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2018-fourth-fiscal-quarter-and-full-year-provides-fiscal-2019-gui-bdx-20181106monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-invest-200-million-in-nebraska-operations-creating-300-more-jobs-bd-becton-dickinson-bdx-20181023monthly0.5https://www.biopharmawatch.com/news/BDX/bd-donates-20-million-syringes-to-support-polio-eradication-bd-becton-dickinson-and-compan-bdx-20181017monthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-molecular-test-for-detecting-tuberculosis-and-multi-drug-resistant-tb-bd-becto-bdx-20181016monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-fourth-fiscal-quarter-earnings-conference-call-bd-becton-dick-bdx-20181003monthly0.5https://www.biopharmawatch.com/news/BDX/bd-breaks-ground-at-i-d-e-a-tempe-campus-officials-from-bd-becton-dickinson-and-company-ny-bdx-20181003monthly0.5https://www.biopharmawatch.com/news/BDX/tom-polen-promoted-to-chief-operating-officer-of-bd-bd-becton-dickinson-and-company-nyse-b-bdx-20181003monthly0.5https://www.biopharmawatch.com/news/BDX/bd-statement-on-divestiture-of-advanced-bioprocessing-business-bd-becton-dickinson-and-com-bdx-20180907monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-morgan-stanley-2018-global-healthcare-conference-bd-becton-dickinson--bdx-20180830monthly0.5https://www.biopharmawatch.com/news/BDX/bd-awards-1-million-in-grants-to-help-community-health-centers-drive-effective-medication--bdx-20180828monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-wells-fargo-securities-2018-healthcare-conference-bd-becton-dickinson-bdx-20180822monthly0.5https://www.biopharmawatch.com/news/BDX/bd-elects-jeffrey-henderson-to-board-of-directors-bd-becton-dickinson-and-company-nyse-bdx-bdx-20180816monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2018-third-fiscal-quarter-raises-fiscal-2018-revenue-guidance-bd--bdx-20180802monthly0.5https://www.biopharmawatch.com/news/BDX/bd-appoints-simon-campion-to-interventional-segment-president-bd-becton-dickinson-and-comp-bdx-20180801monthly0.5https://www.biopharmawatch.com/news/BDX/bd-drives-the-future-of-immunology-research-with-expanded-offerings-for-simultaneous-rna-a-bdx-20180726monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividends-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse-bdx-20180724monthly0.5https://www.biopharmawatch.com/news/BDX/bd-shares-progress-towards-achieving-2020-sustainability-goals-bd-becton-dickinson-and-com-bdx-20180712monthly0.5https://www.biopharmawatch.com/news/BDX/bd-acquires-tva-medical-to-advance-leadership-in-solutions-for-chronic-kidney-disease-bd-b-bdx-20180709monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-third-fiscal-quarter-earnings-conference-call-bd-becton-dicki-bdx-20180705monthly0.5https://www.biopharmawatch.com/news/BDX/bd-fremviser-sit-udvidede-sortiment-til-vaskul-r-adgang-fra-anl-ggelse-til-fjernelse-pa-de-bdx-20180621monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-demonstrate-expanded-vascular-access-offerings-from-insertion-to-removal-during-the--bdx-20180620monthly0.5https://www.biopharmawatch.com/news/BDX/bd-helmer-scientific-collaborate-to-introduce-first-fully-integrated-refrigerated-automate-bdx-20180604monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-investor-healthcare-conferences-bd-becton-dickinson-and-company-nyse-bdx--bdx-20180604monthly0.5https://www.biopharmawatch.com/news/BDX/bd-names-john-deford-chief-technology-officer-bd-becton-dickinson-and-company-nyse-bdx-a-l-bdx-20180601monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2018-second-fiscal-quarter-raises-fiscal-2018-guidance-bd-becton--bdx-20180503monthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-bd-facsymphony-s6-high-parameter-cell-sorter-to-enable-sorting-of-rare-cell-ty-bdx-20180426monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividends-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse-bdx-20180423monthly0.5https://www.biopharmawatch.com/news/BDX/bd-unveils-suite-of-diagnostic-informatics-and-automation-innovations-bd-becton-dickinson--bdx-20180419monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-second-fiscal-quarter-earnings-conference-call-bd-becton-dick-bdx-20180403monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-barclays-global-healthcare-conference-bd-becton-dickinson-and-company-bdx-20180308monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-demonstrate-enhanced-integration-offerings-that-target-key-gaps-across-the-medicatio-bdx-20180305monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-of-offer-to-repurchase-its-3-000-notes-due-2026-bd-becton-dickinson-a-bdx-20180301monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-raymond-james-39th-annual-institutional-investors-conference-bd-becto-bdx-20180228monthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-circulating-cell-free-dna-blood-collection-tube-for-cancer-and-non-invasive-pr-bdx-20180220monthly0.5https://www.biopharmawatch.com/news/BDX/bd-completes-asset-divestitures-to-merit-medical-bd-becton-dickinson-and-company-nyse-bdx--bdx-20180215monthly0.5https://www.biopharmawatch.com/news/BDX/fda-approves-new-hpv-test-that-detects-and-identifies-hpv-genotypes-that-put-women-at-high-bdx-20180213monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-leerink-partners-7th-annual-global-healthcare-conference-bd-becton-dickin-bdx-20180208monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2018-first-fiscal-quarter-provides-fiscal-2018-guidance-updated-f-bdx-20180206monthly0.5https://www.biopharmawatch.com/news/BDX/comparable-historical-revenue-schedules-inclusive-of-c-r-bard-posted-to-bd-website-as-prev-bdx-20180202monthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-new-los-angeles-county-program-to-equip-patients-with-essential-resources-for--bdx-20180201monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20180122monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-completion-of-enrollment-in-the-lutonix-014-drug-coated-balloon-below-the-kne-bdx-20180118monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-webcast-of-annual-meeting-of-shareholders-bd-becton-dickinson-and-company-nys-bdx-20180117monthly0.5https://www.biopharmawatch.com/news/BDX/bd-and-check-points-receive-ce-mark-for-next-generation-resistant-bacteria-screening-test--bdx-20180115monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-first-fiscal-quarter-earnings-conference-call-bd-becton-dicki-bdx-20180111monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-commencement-of-offer-to-repurchase-its-3-000-notes-due-2026-bd-becton-dickin-bdx-20180108monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-36th-annual-j-p-morgan-healthcare-conference-bd-becton-dickinson-and--bdx-20180103monthly0.5https://www.biopharmawatch.com/news/BDX/bd-completes-bard-acquisition-creating-new-global-health-care-leader-bd-becton-dickinson-a-bdx-20171229monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-expiration-and-final-results-of-exchange-offers-and-consent-solicitations-for-bdx-20171229monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-extension-of-exchange-offers-and-consent-solicitations-for-c-r-bard-inc-notes-bdx-20171228monthly0.5https://www.biopharmawatch.com/news/BDX/bd-statement-on-mofcom-clearance-of-bard-acquisition-bd-becton-dickinson-and-company-nyse--bdx-20171228monthly0.5https://www.biopharmawatch.com/news/BDX/bd-statement-on-ftc-clearance-of-bard-acquisition-bd-becton-dickinson-and-company-nyse-bdx-bdx-20171222monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-extension-of-exchange-offers-and-consent-solicitations-for-c-r-bard-inc-notes-bdx-20171221monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-extension-of-exchange-offers-and-consent-solicitations-for-c-r-bard-inc-notes-bdx-20171219monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-extension-of-exchange-offers-and-consent-solicitations-for-c-r-bard-inc-notes-bdx-20171214monthly0.5https://www.biopharmawatch.com/news/BDX/bd-establishes-product-security-partnership-program-to-enhance-cybersecurity-of-medical-te-bdx-20171211monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-new-offerings-to-help-customers-deliver-safer-simpler-and-smarter-medication--bdx-20171204monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-extension-of-exchange-offers-and-consent-solicitations-for-c-r-bard-inc-notes-bdx-20171128monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-increases-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse-bdx-20171120monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-introduce-integrated-medication-management-platform-designed-to-address-hospitals-gr-bdx-20171116monthly0.5https://www.biopharmawatch.com/news/BDX/bd-statement-on-merit-medical-agreement-to-purchase-bd-bard-product-lines-bd-becton-dickin-bdx-20171116monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2017-fourth-fiscal-quarter-and-full-year-provides-fiscal-2018-gui-bdx-20171102monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-extension-of-exchange-offers-and-consent-solicitations-for-c-r-bard-inc-notes-bdx-20171026monthly0.5https://www.biopharmawatch.com/news/BDX/bd-breaks-ground-on-60-million-expansion-of-nebraska-manufacturing-facility-bd-becton-dick-bdx-20171025monthly0.5https://www.biopharmawatch.com/news/BDX/bd-statement-on-european-commission-conditional-clearance-of-bard-acquisition-bd-becton-di-bdx-20171018monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-fourth-fiscal-quarter-earnings-conference-call-bd-becton-dick-bdx-20171005monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-extension-of-exchange-offers-and-consent-solicitations-for-c-r-bard-inc-notes-bdx-20170927monthly0.5https://www.biopharmawatch.com/news/BDX/bd-expands-efforts-to-combat-antimicrobial-resistance-with-new-diagnostic-test-in-europe-b-bdx-20170926monthly0.5https://www.biopharmawatch.com/news/BDX/bd-and-euroclone-announce-development-and-global-distribution-agreement-for-tests-to-detec-bdx-20170920monthly0.5https://www.biopharmawatch.com/news/BDX/bd-introduces-new-6mm-pen-needle-for-injection-pens-bd-becton-dickinson-and-company-nyse-b-bdx-20170919monthly0.5https://www.biopharmawatch.com/news/BDX/bd-expands-genomics-portfolio-with-new-single-cell-platform-for-rna-expression-analysis-bd-bdx-20170912monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-morgan-stanley-global-healthcare-conference-2017-bd-becton-dickinson--bdx-20170908monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-extension-of-exchange-offers-and-consent-solicitations-for-c-r-bard-inc-notes-bdx-20170829monthly0.5https://www.biopharmawatch.com/news/BDX/bard-shareholders-approve-proposed-merger-with-becton-dickinson-c-r-bard-inc-nyse-bcr-bard-bdx-20170808monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2017-third-fiscal-quarter-bd-becton-dickinson-and-company-nyse-bd-bdx-20170803monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-extension-of-exchange-offers-and-consent-solicitations-for-c-r-bard-inc-notes-bdx-20170801monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20170725monthly0.5https://www.biopharmawatch.com/news/BDX/bd-receives-fda-510-k-clearance-for-new-immunological-diagnostic-system-bd-becton-dickinso-bdx-20170719monthly0.5https://www.biopharmawatch.com/news/BDX/bd-transforms-microbiology-urine-testing-bd-becton-dickinson-and-company-nyse-bdx-a-leadin-bdx-20170718monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-third-fiscal-quarter-earnings-conference-call-bd-becton-dicki-bdx-20170706monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-extension-of-exchange-offers-and-consent-solicitations-for-c-r-bard-inc-notes-bdx-20170703monthly0.5https://www.biopharmawatch.com/news/BDX/bd-receives-fda-510-k-clearance-for-new-line-of-customizable-3-0mm-micro-laparoscopic-inst-bdx-20170620monthly0.5https://www.biopharmawatch.com/news/BDX/bd-and-bard-receive-second-requests-from-ftc-under-hsr-act-bd-becton-dickinson-and-company-bdx-20170609monthly0.5https://www.biopharmawatch.com/news/BDX/bd-receives-fda-510-k-clearance-for-molecular-test-for-harmful-intestinal-bacteria-causing-bdx-20170605monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-extension-of-exchange-offers-and-consent-solicitations-for-c-r-bard-inc-notes-bdx-20170605monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20170523monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-of-early-tenders-and-amendments-to-exchange-offers-bd-becton-dickinso-bdx-20170519monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-investor-healthcare-conferences-bd-becton-dickinson-and-company-nyse-bdx--bdx-20170515monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-exercise-of-option-to-purchase-additional-shares-by-underwriters-of-public-eq-bdx-20170512monthly0.5https://www.biopharmawatch.com/news/BDX/bd-prices-offerings-of-2-25-billion-of-common-stock-and-2-25-billion-of-depositary-shares--bdx-20170510monthly0.5https://www.biopharmawatch.com/news/BDX/bd-and-uniteor-join-forces-to-deliver-an-integrated-tracking-solution-for-the-operating-ro-bdx-20170509monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-offerings-of-2-25-billion-of-common-stock-and-2-25-billion-of-depositary-shar-bdx-20170507monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-commencement-of-exchange-offers-and-consent-solicitations-for-c-r-bard-inc-no-bdx-20170505monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2017-second-fiscal-quarter-bd-becton-dickinson-and-company-nyse-b-bdx-20170502monthly0.5https://www.biopharmawatch.com/news/BDX/bd-advances-efforts-to-combat-antimicrobial-resistance-with-enhanced-diagnostic-solution-o-bdx-20170427monthly0.5https://www.biopharmawatch.com/news/BDX/bd-licenses-novel-molecular-indexing-technology-to-roche-bd-becton-dickinson-and-company-n-bdx-20170426monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-appointment-of-tom-polen-as-president-bd-becton-dickinson-and-company-nyse-bd-bdx-20170423monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-acquire-bard-for-24-billion-bd-becton-dickinson-and-company-nyse-bdx-a-leading-globa-bdx-20170423monthly0.5https://www.biopharmawatch.com/news/BDX/bd-receives-fda-510-k-clearance-for-new-flow-cytometer-system-with-leucocount-reagent-assa-bdx-20170406monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-second-fiscal-quarter-earnings-conference-call-bd-becton-dick-bdx-20170404monthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-power-in-prevention-program-to-help-minimize-risk-of-infections-during-surgica-bdx-20170403monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-inaugural-cecp-ceo-investor-forum-bd-becton-dickinson-and-company-nyse-bd-bdx-20170222monthly0.5https://www.biopharmawatch.com/news/BDX/bd-veritor-system-meets-fda-s-new-performance-requirements-for-rapid-influenza-antigen-det-bdx-20170222monthly0.5https://www.biopharmawatch.com/news/BDX/bd-partnership-honored-by-u-s-chamber-of-commerce-foundation-at-the-health-means-business--bdx-20170221monthly0.5https://www.biopharmawatch.com/news/BDX/bd-demonstrates-synchronized-technology-platform-at-himss17-bd-becton-dickinson-and-compan-bdx-20170220monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-investor-healthcare-conferences-bd-becton-dickinson-and-company-nyse-bdx--bdx-20170217monthly0.5https://www.biopharmawatch.com/news/BDX/bd-initiates-new-industry-alliance-to-combat-rising-opioid-crisis-bd-becton-dickinson-and--bdx-20170216monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-early-access-program-for-bd-resolve-single-cell-analysis-platform-bd-becton-d-bdx-20170213monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2017-first-fiscal-quarter-bd-becton-dickinson-and-company-nyse-bd-bdx-20170202monthly0.5https://www.biopharmawatch.com/news/BDX/new-bd-institute-for-medication-management-excellence-aims-to-improve-patient-safety-and-o-bdx-20170126monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20170123monthly0.5https://www.biopharmawatch.com/news/BDX/pleurx-catheter-system-receives-fda-510-k-clearance-for-specific-non-malignant-recurrent-p-bdx-20170123monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-webcast-of-annual-meeting-of-shareholders-bd-becton-dickinson-and-company-nys-bdx-20170118monthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-reagents-to-simplify-single-cell-research-bd-becton-dickinson-and-company-nyse-bdx-20170117monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-first-fiscal-quarter-earnings-conference-call-bd-becton-dicki-bdx-20170111monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-35th-annual-j-p-morgan-healthcare-conference-bd-becton-dickinson-and--bdx-20170109monthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-advanced-prefillable-syringe-for-higher-volume-injection-of-biologics-bd-becto-bdx-20161215monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-adoption-of-windows-10-internet-of-things-for-the-pyxis-es-system-bd-becton-d-bdx-20161201monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-offer-euro-denominated-senior-unsecured-notes-bd-becton-dickinson-and-company-nyse-b-bdx-20161201monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-pricing-of-tender-offers-bd-becton-dickinson-and-company-nyse-bdx-the-company-bdx-20161201monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-early-tender-results-and-upsizing-of-maximum-tender-offers-bd-becton-dickinso-bdx-20161201monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-28th-annual-piper-jaffray-healthcare-conference-bd-becton-dickinson-a-bdx-20161123monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-increases-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse-bdx-20161121monthly0.5https://www.biopharmawatch.com/news/BDX/becton-dickinson-and-company-announces-tender-offers-for-outstanding-debt-securities-becto-bdx-20161116monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-2016-analyst-day-and-webcast-bd-becton-dickinson-and-company-nyse-bdx-announc-bdx-20161114monthly0.5https://www.biopharmawatch.com/news/BDX/bd-collaborates-with-jdrf-to-focus-on-extended-wear-innovations-for-insulin-infusion-deliv-bdx-20161110monthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-first-syringe-designed-for-use-with-humulin-r-u-500-insulin-bd-becton-dickinso-bdx-20161108monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2016-fourth-fiscal-quarter-and-full-year-provides-fiscal-2017-gui-bdx-20161103monthly0.5https://www.biopharmawatch.com/news/BDX/bd-max-vaginal-panel-receives-fda-market-authorization-to-detect-most-common-causes-of-vag-bdx-20161031monthly0.5https://www.biopharmawatch.com/news/BDX/bd-and-apax-partners-announce-closing-of-joint-venture-to-launch-global-respiratory-busine-bdx-20161004monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-fourth-fiscal-quarter-earnings-conference-call-bd-becton-dick-bdx-20161004monthly0.5https://www.biopharmawatch.com/news/BDX/bd-expands-efforts-to-combat-antimicrobial-resistance-with-new-automated-id-ast-system-bd--bdx-20160930monthly0.5https://www.biopharmawatch.com/news/BDX/bd-receives-fda-510-k-clearance-for-innovative-next-generation-blood-collection-and-separa-bdx-20160929monthly0.5https://www.biopharmawatch.com/news/BDX/bd-invests-100-million-in-nebraska-plant-to-expand-insulin-syringe-manufacturing-bd-becton-bdx-20160922monthly0.5https://www.biopharmawatch.com/news/BDX/bd-unveils-next-generation-wireless-point-of-care-diagnostic-device-bd-becton-dickinson-an-bdx-20160921monthly0.5https://www.biopharmawatch.com/news/BDX/bd-and-vancive-medical-technologies-launch-new-vascular-dressings-with-chg-antimicrobial-b-bdx-20160916monthly0.5https://www.biopharmawatch.com/news/BDX/bd-expands-portfolio-of-reproductive-and-sexually-transmitted-infections-solutions-bd-bect-bdx-20160914monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-new-software-release-for-pyxis-enterprise-solution-bd-becton-dickinson-and-co-bdx-20160912monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-morgan-stanley-global-healthcare-conference-2016-bd-becton-dickinson--bdx-20160906monthly0.5https://www.biopharmawatch.com/news/BDX/bd-submits-pre-market-approval-application-to-fda-for-bd-onclarity-hpv-test-bd-becton-dick-bdx-20160906monthly0.5https://www.biopharmawatch.com/news/BDX/mayo-clinic-proceedings-publishes-new-insulin-injection-and-infusion-recommendations-the-p-bdx-20160901monthly0.5https://www.biopharmawatch.com/news/BDX/bd-celebrates-60-years-in-sandy-utah-bd-becton-dickinson-and-company-nyse-bdx-a-leading-gl-bdx-20160818monthly0.5https://www.biopharmawatch.com/news/BDX/bd-cited-as-infusion-pump-emr-integration-leader-in-klas-report-bd-becton-dickinson-and-co-bdx-20160816monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2016-third-fiscal-quarter-bd-becton-dickinson-and-company-nyse-bd-bdx-20160804monthly0.5https://www.biopharmawatch.com/news/BDX/bd-names-r-andrew-eckert-to-board-of-directors-bd-becton-dickinson-and-company-nyse-bdx-a--bdx-20160728monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20160726monthly0.5https://www.biopharmawatch.com/news/BDX/bd-hits-century-mark-with-infusion-pump-interoperability-bd-becton-dickinson-and-company-n-bdx-20160719monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-third-fiscal-quarter-earnings-conference-call-bd-becton-dicki-bdx-20160701monthly0.5https://www.biopharmawatch.com/news/BDX/bd-and-check-points-announce-development-and-global-distribution-agreement-for-bd-max-assa-bdx-20160616monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-investor-healthcare-conferences-bd-becton-dickinson-and-company-nyse-bdx--bdx-20160603monthly0.5https://www.biopharmawatch.com/news/BDX/bd-expands-its-portfolio-of-easy-to-use-cell-sorters-with-introduction-of-bd-facsmelody-sy-bdx-20160526monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20160524monthly0.5https://www.biopharmawatch.com/news/BDX/bd-expands-reproductive-and-sexually-transmitted-infections-portfolio-with-ce-mark-for-the-bdx-20160513monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2016-second-fiscal-quarter-bd-becton-dickinson-and-company-nyse-b-bdx-20160505monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-bank-of-america-merrill-lynch-2016-health-care-conference-bd-becton-d-bdx-20160504monthly0.5https://www.biopharmawatch.com/news/BDX/bd-extends-longstanding-expertise-in-diabetes-management-to-benefit-pets-bd-becton-dickins-bdx-20160426monthly0.5https://www.biopharmawatch.com/news/BDX/bd-introduces-new-low-temperature-sterilization-containers-bd-becton-dickinson-and-company-bdx-20160422monthly0.5https://www.biopharmawatch.com/news/BDX/bd-divests-vertebral-augmentation-solutions-business-to-stryker-bd-becton-dickinson-and-co-bdx-20160421monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-second-fiscal-quarter-earnings-conference-call-bd-becton-dick-bdx-20160401monthly0.5https://www.biopharmawatch.com/news/BDX/medmined-surveillance-advisor-wins-2015-2016-klas-category-leader-award-bd-becton-dickinso-bdx-20160315monthly0.5https://www.biopharmawatch.com/news/BDX/bd-apax-partners-to-form-joint-venture-for-respiratory-solutions-bd-becton-dickinson-and-c-bdx-20160308monthly0.5https://www.biopharmawatch.com/news/BDX/bd-receives-fda-approval-for-new-automated-cervical-cancer-screening-system-bd-becton-dick-bdx-20160307monthly0.5https://www.biopharmawatch.com/news/BDX/alaris-system-named-2015-best-in-klas-for-smart-pumps-bd-becton-dickinson-and-company-nyse-bdx-20160224monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-investor-healthcare-conferences-bd-becton-dickinson-and-company-nyse-bdx--bdx-20160222monthly0.5https://www.biopharmawatch.com/news/BDX/bd-receives-fda-510-k-clearance-for-new-blood-collection-device-to-help-enhance-patient-an-bdx-20160217monthly0.5https://www.biopharmawatch.com/news/BDX/bd-unveils-new-next-generation-sequencing-library-prep-system-at-the-2016-advances-in-geno-bdx-20160212monthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-bd-facsymphony-high-speed-cell-analyzer-to-enable-identification-and-analysis--bdx-20160208monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2016-first-fiscal-quarter-bd-becton-dickinson-and-company-nyse-bd-bdx-20160203monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20160125monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-webcast-of-annual-meeting-of-shareholders-bd-becton-dickinson-and-company-nys-bdx-20160115monthly0.5https://www.biopharmawatch.com/news/BDX/bd-divests-bd-rx-business-adding-iv-solutions-bd-becton-dickinson-and-company-nyse-bdx-a-l-bdx-20160108monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-first-fiscal-quarter-earnings-conference-call-bd-becton-dicki-bdx-20160107monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-34th-annual-j-p-morgan-healthcare-conference-bd-becton-dickinson-and--bdx-20160104monthly0.5https://www.biopharmawatch.com/news/BDX/bd-unveils-new-bd-facscelesta-flow-cytometer-during-the-2015-american-society-for-cell-bio-bdx-20151212monthly0.5https://www.biopharmawatch.com/news/BDX/bd-introduces-simplified-comprehensive-iv-management-bd-becton-dickinson-and-company-nyse--bdx-20151207monthly0.5https://www.biopharmawatch.com/news/BDX/bd-showcases-expanded-portfolio-to-support-enterprise-medication-management-at-the-ashp-20-bdx-20151202monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20151123monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-stifel-2015-healthcare-conference-bd-becton-dickinson-and-company-nys-bdx-20151112monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2015-fourth-fiscal-quarter-and-full-year-provides-fiscal-2016-gui-bdx-20151104monthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-the-bd-facsseq-cell-sorter-with-bd-precise-assays-for-high-precision-single-ce-bdx-20151006monthly0.5https://www.biopharmawatch.com/news/BDX/bd-celebrates-national-health-information-technology-nhit-week-bd-becton-dickinson-and-com-bdx-20151005monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-fourth-fiscal-quarter-earnings-conference-call-bd-becton-dick-bdx-20150930monthly0.5https://www.biopharmawatch.com/news/BDX/bd-max-enteric-parasite-panel-receives-fda-clearance-for-detection-of-common-and-pathogeni-bdx-20150924monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-morgan-stanley-global-healthcare-conference-2015-bd-becton-dickinson--bdx-20150911monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-acquire-cellular-research-to-develop-a-leading-genomics-platform-for-single-cell-ana-bdx-20150825monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20150728monthly0.5https://www.biopharmawatch.com/news/BDX/bd-opens-advance-diabetes-care-headquarters-in-andover-mass-bd-becton-dickinson-and-compan-bdx-20150715monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-sustainability-goals-for-2020-bd-becton-dickinson-and-company-nyse-bdx-a-lead-bdx-20150713monthly0.5https://www.biopharmawatch.com/news/BDX/de-nouvelles-donne-es-cliniques-indiquent-que-le-cathe-ter-de-perfusion-e-quipe-de-la-tech-bdx-20150710monthly0.5https://www.biopharmawatch.com/news/BDX/los-nuevos-datos-cli-nicos-sugieren-que-el-set-de-infusio-n-con-tecnologi-a-bd-flowsmart-p-bdx-20150710monthly0.5https://www.biopharmawatch.com/news/BDX/neue-klinische-daten-weisen-auf-mo-gliche-verbesserung-von-insulinfluss-und-reduzierung-un-bdx-20150710monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-third-fiscal-quarter-earnings-conference-call-bd-becton-dicki-bdx-20150701monthly0.5https://www.biopharmawatch.com/news/BDX/new-study-shows-higher-rates-of-c-difficile-infection-in-hospitals-that-use-reusable-sharp-bdx-20150627monthly0.5https://www.biopharmawatch.com/news/BDX/new-clinical-data-suggest-infusion-set-with-bd-flowsmart-technology-may-improve-insulin-fl-bdx-20150606monthly0.5https://www.biopharmawatch.com/news/BDX/bd-participates-in-white-house-forum-on-antibiotic-stewardship-bd-becton-dickinson-and-com-bdx-20150602monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-investor-healthcare-conferences-bd-becton-dickinson-and-company-nyse-bdx--bdx-20150529monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20150519monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2015-second-fiscal-quarter-bd-becton-dickinson-and-company-nyse-b-bdx-20150507monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-bank-of-america-merrill-lynch-2015-healthcare-conference-bd-becton-di-bdx-20150504monthly0.5https://www.biopharmawatch.com/news/BDX/becton-dickinson-and-company-announces-final-results-of-exchange-offers-becton-dickinson-a-bdx-20150423monthly0.5https://www.biopharmawatch.com/news/BDX/becton-dickinson-and-company-announces-results-of-early-tenders-and-consents-in-exchange-o-bdx-20150409monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-second-fiscal-quarter-earnings-conference-call-bd-becton-dick-bdx-20150406monthly0.5https://www.biopharmawatch.com/news/BDX/becton-dickinson-and-company-to-commence-exchange-offers-becton-dickinson-and-company-nyse-bdx-20150326monthly0.5https://www.biopharmawatch.com/news/BDX/becton-dickinson-completes-acquisition-of-carefusion-becton-dickinson-and-company-nyse-bdx-bdx-20150317monthly0.5https://www.biopharmawatch.com/news/BDX/european-commission-clears-bd-acquisition-of-carefusion-becton-dickinson-and-company-nyse--bdx-20150313monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-barclays-global-healthcare-conference-bd-becton-dickinson-and-company-bdx-20150303monthly0.5https://www.biopharmawatch.com/news/BDX/bd-acquires-crisi-medical-systems-bd-becton-dickinson-and-company-nyse-bdx-a-leading-globa-bdx-20150302monthly0.5https://www.biopharmawatch.com/news/BDX/bd-and-cellular-research-announce-co-marketing-efforts-for-single-cell-sequencing-bd-life--bdx-20150226monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2015-first-fiscal-quarter-bd-becton-dickinson-and-company-nyse-bd-bdx-20150205monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20150127monthly0.5https://www.biopharmawatch.com/news/BDX/carefusion-stockholders-approve-proposed-merger-with-becton-dickinson-becton-dickinson-and-bdx-20150121monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-webcast-of-annual-meeting-of-shareholders-bd-becton-dickinson-and-company-nys-bdx-20150116monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-first-fiscal-quarter-earnings-conference-call-bd-becton-dicki-bdx-20150108monthly0.5https://www.biopharmawatch.com/news/BDX/the-bd-intelliport-medication-management-system-receives-clearance-from-the-food-and-drug--bdx-20150107monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-33rd-annual-j-p-morgan-healthcare-conference-bd-becton-dickinson-and--bdx-20150107monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-total-hospital-pharmacy-solutions-at-the-2014-american-society-of-health-sys-bdx-20141208monthly0.5https://www.biopharmawatch.com/news/BDX/becton-dickinson-and-carefusion-announce-date-of-special-meeting-in-proposed-merger-becton-bdx-20141208monthly0.5https://www.biopharmawatch.com/news/BDX/becton-dickinson-and-company-to-offer-senior-unsecured-notes-becton-dickinson-and-company--bdx-20141204monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-26th-annual-piper-jaffray-healthcare-conference-bd-becton-dickinson-a-bdx-20141201monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20141125monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-26th-annual-piper-jaffray-healthcare-conference-bd-becton-dickinson-a-bdx-20141125monthly0.5https://www.biopharmawatch.com/news/BDX/becton-dickinson-and-carefusion-announce-expiration-of-hsr-act-waiting-period-in-proposed--bdx-20141120monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-stifel-2014-healthcare-conference-bd-becton-dickinson-and-company-nys-bdx-20141111monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2014-fourth-fiscal-quarter-and-full-year-provides-fiscal-2015-gui-bdx-20141104monthly0.5https://www.biopharmawatch.com/news/BDX/bd-acquires-gencell-biosystems-bd-becton-dickinson-and-company-nyse-bdx-a-leading-global-m-bdx-20141013monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-acquire-carefusion-for-12-2-billion-bd-nyse-bdx-and-carefusion-nyse-cfn-announced-to-bdx-20141005monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-fourth-fiscal-quarter-earnings-conference-call-bd-becton-dick-bdx-20141001monthly0.5https://www.biopharmawatch.com/news/BDX/world-health-organization-issues-prequalification-of-bd-facspresto-near-patient-cd4-counte-bdx-20140923monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-morgan-stanley-global-healthcare-conference-bd-becton-dickinson-and-c-bdx-20140904monthly0.5https://www.biopharmawatch.com/news/BDX/bd-ampli-a-la-gama-de-soluciones-de-sistema-abierto-con-la-plataforma-completamente-automa-bdx-20140902monthly0.5https://www.biopharmawatch.com/news/BDX/bd-e-largit-sa-gamme-de-kits-d-extraction-sur-le-syste-me-bd-max-permettant-d-automatiser--bdx-20140902monthly0.5https://www.biopharmawatch.com/news/BDX/bd-erweitert-das-portfolio-an-open-system-lo-sungen-auf-der-voll-automatisierten-bd-max-pl-bdx-20140902monthly0.5https://www.biopharmawatch.com/news/BDX/bd-together-with-direct-relief-and-the-national-association-of-community-health-centers-an-bdx-20140825monthly0.5https://www.biopharmawatch.com/news/BDX/bd-autoshield-duo-pen-needle-now-available-through-retail-pharmacies-for-people-with-diabe-bdx-20140806monthly0.5https://www.biopharmawatch.com/news/BDX/bd-expands-its-suite-of-open-system-solutions-on-the-fully-automated-bd-max-platform-bd-di-bdx-20140804monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2014-third-fiscal-quarter-bd-becton-dickinson-and-company-nyse-bd-bdx-20140731monthly0.5https://www.biopharmawatch.com/news/BDX/neue-tests-fu-r-chlamydien-und-gonorrho-auf-dem-bd-viper-lt-system-erhalten-ce-ivd-kennzei-bdx-20140731monthly0.5https://www.biopharmawatch.com/news/BDX/les-nouveaux-tests-de-de-pistage-de-la-chlamydiae-trachomatis-et-de-la-neisseria-gonorrhe--bdx-20140729monthly0.5https://www.biopharmawatch.com/news/BDX/new-chlamydia-and-gonorrhea-assays-on-the-bd-viper-lt-system-receive-fda-510k-clearance-bd-bdx-20140728monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20140722monthly0.5https://www.biopharmawatch.com/news/BDX/bd-signs-agreement-for-installation-of-the-bd-cato-workflow-solution-in-leading-cancer-cen-bdx-20140617monthly0.5https://www.biopharmawatch.com/news/BDX/low-volume-clinical-laboratories-now-have-access-to-advanced-data-management-with-new-bloo-bdx-20140611monthly0.5https://www.biopharmawatch.com/news/BDX/bd-issues-2013-sustainability-report-bd-becton-dickinson-and-company-nyse-bdx-a-leading-gl-bdx-20140605monthly0.5https://www.biopharmawatch.com/news/BDX/bd-max-enteric-parasite-panel-zur-identifizierung-der-verbreitetsten-pathogenen-darmparasi-bdx-20140604monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-investor-healthcare-conferences-bd-becton-dickinson-and-company-nyse-bdx--bdx-20140529monthly0.5https://www.biopharmawatch.com/news/BDX/le-test-bd-max-parasites-ente-riques-obtient-le-marquage-ce-pour-la-de-tection-des-parasit-bdx-20140523monthly0.5https://www.biopharmawatch.com/news/BDX/el-panel-bd-max-enteric-parasite-obtiene-marcado-ce-para-la-deteccio-n-de-para-sitos-intes-bdx-20140522monthly0.5https://www.biopharmawatch.com/news/BDX/royal-jubilee-hospital-victoria-vancouver-island-to-be-the-first-canadian-hospital-to-inst-bdx-20140520monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20140520monthly0.5https://www.biopharmawatch.com/news/BDX/leading-hospital-shares-how-it-reduced-needlestick-injuries-by-nearly-70-percent-an-articl-bdx-20140513monthly0.5https://www.biopharmawatch.com/news/BDX/the-bd-max-enteric-bacterial-panel-receives-fda-clearance-to-detect-the-most-common-causes-bdx-20140507monthly0.5https://www.biopharmawatch.com/news/BDX/bd-lanza-un-nuevo-sistema-point-of-care-para-los-pacientes-de-vih-sida-bd-biosciences-un-s-bdx-20140506monthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-new-point-of-care-system-for-hiv-aids-patients-bd-biosciences-a-segment-of-bd--bdx-20140424monthly0.5https://www.biopharmawatch.com/news/BDX/nouveau-test-de-de-pistage-des-infections-a-neisseria-gonorrhoeae-gc-inte-grant-une-techno-bdx-20140410monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-second-fiscal-quarter-earnings-conference-call-bd-becton-dick-bdx-20140403monthly0.5https://www.biopharmawatch.com/news/BDX/dr-claire-pomeroy-elected-as-bd-director-bd-becton-dickinson-and-company-nyse-bdx-a-leadin-bdx-20140324monthly0.5https://www.biopharmawatch.com/news/BDX/new-rsv-test-provides-healthcare-providers-objective-results-in-minutes-bd-diagnostics-a-s-bdx-20140319monthly0.5https://www.biopharmawatch.com/news/BDX/le-test-bd-onclarity-hpv-sur-le-syste-me-bd-viper-lt-obtient-le-marquage-ce-ivd-bd-diagnos-bdx-20140311monthly0.5https://www.biopharmawatch.com/news/BDX/healthcare-providers-can-diagnose-group-a-strep-in-minutes-with-new-test-bd-diagnostics-a--bdx-20140225monthly0.5https://www.biopharmawatch.com/news/BDX/der-fu-r-das-bd-viper-lt-system-bestimmte-bd-onclarity-hpv-test-erha-lt-die-ce-ivd-kennzei-bdx-20140219monthly0.5https://www.biopharmawatch.com/news/BDX/el-ensayo-bd-onclarity-hpv-en-el-sistema-bd-viper-lt-consigue-la-marca-ce-ivd-bd-diagnosti-bdx-20140219monthly0.5https://www.biopharmawatch.com/news/BDX/leading-industry-analyst-amit-bhalla-joins-bd-as-vice-president-global-strategy-and-develo-bdx-20140207monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-investor-healthcare-conferences-bd-becton-dickinson-and-company-nyse-bdx--bdx-20140207monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2014-first-fiscal-quarter-bd-becton-dickinson-and-company-nyse-bd-bdx-20140204monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20140128monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-webcast-of-annual-meeting-of-shareholders-bd-becton-dickinson-and-company-nys-bdx-20140114monthly0.5https://www.biopharmawatch.com/news/BDX/new-laboratory-test-helps-hospitals-detect-newly-emerging-strains-of-drug-resistant-superb-bdx-20140113monthly0.5https://www.biopharmawatch.com/news/BDX/bd-acquires-alverix-inc-bd-becton-dickinson-and-company-nyse-bdx-a-leading-global-medical--bdx-20140107monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-first-fiscal-quarter-earnings-conference-call-bd-becton-dicki-bdx-20140107monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-investor-healthcare-conferences-bd-becton-dickinson-and-company-nyse-bdx--bdx-20140103monthly0.5https://www.biopharmawatch.com/news/BDX/novel-molecular-assay-for-patient-screening-detects-s-aureus-and-newly-emerging-mrsa-strai-bdx-20131203monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-25th-annual-piper-jaffray-healthcare-conference-bd-becton-dickinson-a-bdx-20131127monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-increases-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse-bdx-20131126monthly0.5https://www.biopharmawatch.com/news/BDX/neuartiger-molekularer-assay-fu-r-die-aktive-mrsa-u-berwachung-weist-neu-entdeckte-sta-mme-bdx-20131126monthly0.5https://www.biopharmawatch.com/news/BDX/rapid-delivery-program-product-portfolio-expands-to-biopharmaceutical-injectable-market-bd-bdx-20131119monthly0.5https://www.biopharmawatch.com/news/BDX/un-nouveau-test-mole-culaire-pour-la-surveillance-active-du-sarm-de-tecte-les-nouvelles-so-bdx-20131119monthly0.5https://www.biopharmawatch.com/news/BDX/un-nouveau-test-mole-culaire-pour-le-de-pistage-pre-chirurgical-de-tecte-les-souches-mrsa--bdx-20131114monthly0.5https://www.biopharmawatch.com/news/BDX/bd-joins-national-patient-safety-foundation-corporate-council-furthers-commitment-to-safet-bdx-20131113monthly0.5https://www.biopharmawatch.com/news/BDX/nuevo-ensayo-molecular-de-mrsa-detecta-cepas-resistentes-a-medicamentos-bd-diagnostics-un--bdx-20131112monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2013-fourth-fiscal-quarter-and-full-year-provides-fiscal-2014-gui-bdx-20131105monthly0.5https://www.biopharmawatch.com/news/BDX/bd-rx-announces-fda-approval-of-high-demand-injectable-for-pain-management-bd-rx-inc-a-who-bdx-20131104monthly0.5https://www.biopharmawatch.com/news/BDX/el-nuevo-ensayo-molecular-para-exploracio-n-pre-quiru-rgica-detecta-cepas-de-mrsa-reciente-bdx-20131030monthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-bd-helping-build-healthy-communities-with-direct-relief-and-the-national-assoc-bdx-20131028monthly0.5https://www.biopharmawatch.com/news/BDX/world-health-organization-and-bd-announce-new-commitment-to-address-maternal-and-newborn-m-bdx-20130927monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-fourth-fiscal-quarter-earnings-conference-call-bd-becton-dick-bdx-20130927monthly0.5https://www.biopharmawatch.com/news/BDX/jury-returns-verdict-in-rti-vs-bd-lawsuit-bd-becton-dickinson-and-company-nyse-bdx-announc-bdx-20130920monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-investor-healthcare-conferences-bd-becton-dickinson-and-company-nyse-bdx--bdx-20130830monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2013-third-fiscal-quarter-bd-becton-dickinson-and-company-nyse-bd-bdx-20130801monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20130723monthly0.5https://www.biopharmawatch.com/news/BDX/bd-appoints-christopher-reidy-as-chief-financial-officer-bd-becton-dickinson-and-company-n-bdx-20130708monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-third-fiscal-quarter-earnings-conference-call-bd-becton-dicki-bdx-20130703monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-goldman-sachs-34th-annual-global-healthcare-conference-bd-becton-dick-bdx-20130606monthly0.5https://www.biopharmawatch.com/news/BDX/bd-and-heart-to-heart-international-continue-ongoing-collaboration-to-help-improve-healthc-bdx-20130604monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-deutsche-bank-38th-annual-health-care-conference-bd-becton-dickinson--bdx-20130524monthly0.5https://www.biopharmawatch.com/news/BDX/bd-issues-2012-sustainability-report-bd-becton-dickinson-and-company-nyse-bdx-a-leading-gl-bdx-20130522monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20130521monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2013-second-fiscal-quarter-bd-becton-dickinson-and-company-nyse-b-bdx-20130502monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-second-fiscal-quarter-earnings-conference-call-bd-becton-dick-bdx-20130408monthly0.5https://www.biopharmawatch.com/news/BDX/bd-enters-pharmaceutical-industry-with-new-line-of-generic-prefilled-injectable-products-b-bdx-20130327monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-appointment-of-dr-ellen-strahlman-as-chief-medical-officer-and-senior-vice-pr-bdx-20130313monthly0.5https://www.biopharmawatch.com/news/BDX/bd-acquires-cato-software-solutions-bd-becton-dickinson-and-company-nyse-bdx-a-leading-glo-bdx-20130312monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-investor-healthcare-conferences-bd-becton-dickinson-and-company-nyse-bdx--bdx-20130228monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-investor-healthcare-conferences-bd-becton-dickinson-and-company-nyse-bdx--bdx-20130207monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2013-first-fiscal-quarter-bd-becton-dickinson-and-company-nyse-bd-bdx-20130205monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20130129monthly0.5https://www.biopharmawatch.com/news/BDX/catherine-m-burzik-elected-as-bd-director-bd-becton-dickinson-and-company-nyse-bdx-a-leadi-bdx-20130129monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-webcast-of-annual-meeting-of-shareholders-bd-becton-dickinson-and-company-nys-bdx-20130123monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-first-fiscal-quarter-earnings-conference-call-bd-becton-dicki-bdx-20130108monthly0.5https://www.biopharmawatch.com/news/BDX/bd-completes-acquisition-of-safety-syringes-inc-bd-becton-dickinson-and-company-nyse-bdx-a-bdx-20121226monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-investor-healthcare-conferences-bd-becton-dickinson-and-company-nyse-bdx--bdx-20121221monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-24th-annual-piper-jaffray-healthcare-conference-bd-becton-dickinson-a-bdx-20121121monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-increases-dividend-by-10-percent-the-board-of-directors-of-bd-becton-dickinson-an-bdx-20121120monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2012-fourth-fiscal-quarter-and-full-year-bd-becton-dickinson-and--bdx-20121107monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-funding-and-product-support-for-hurricane-sandy-relief-efforts-bd-becton-dick-bdx-20121106monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-appointment-of-william-a-kozy-as-chief-operating-officer-bd-becton-dickinson--bdx-20121106monthly0.5https://www.biopharmawatch.com/news/BDX/bd-completes-sale-of-majority-of-discovery-labware-unit-bd-becton-dickinson-and-company-ny-bdx-20121101monthly0.5https://www.biopharmawatch.com/news/BDX/bd-is-awarded-windmade-certification-ranks-among-top-40-u-s-companies-in-newsweek-s-2012-g-bdx-20121029monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-chief-financial-officer-transition-bd-becton-dickinson-and-company-nyse-bdx-a-bdx-20121010monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-fourth-fiscal-quarter-earnings-conference-call-bd-becton-dick-bdx-20121002monthly0.5https://www.biopharmawatch.com/news/BDX/bd-acquires-sirigen-group-limited-bd-becton-dickinson-and-company-nyse-bdx-a-leading-globa-bdx-20120827monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2012-third-fiscal-quarter-bd-becton-dickinson-and-company-nyse-bd-bdx-20120802monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20120724monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-of-directors-elects-rebecca-w-rimel-bd-becton-dickinson-and-company-nyse-bdx-a-le-bdx-20120723monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-agreement-to-acquire-safety-syringes-inc-bd-becton-dickinson-and-company-nyse-bdx-20120711monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-third-fiscal-quarter-earnings-conference-call-bd-becton-dicki-bdx-20120628monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-goldman-sachs-33rd-annual-global-healthcare-conference-bd-becton-dick-bdx-20120530monthly0.5https://www.biopharmawatch.com/news/BDX/bd-appoints-ceo-vincent-a-forlenza-as-chairman-of-the-board-bd-becton-dickinson-and-compan-bdx-20120522monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20120522monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-investor-healthcare-conferences-bd-becton-dickinson-and-company-nyse-bdx--bdx-20120502monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2012-second-fiscal-quarter-bd-becton-dickinson-and-company-nyse-b-bdx-20120501monthly0.5https://www.biopharmawatch.com/news/BDX/bd-signs-agreement-to-sell-majority-of-discovery-labware-unit-bd-becton-dickinson-and-comp-bdx-20120410monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-second-fiscal-quarter-earnings-conference-call-bd-becton-dick-bdx-20120402monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-barclays-capital-global-healthcare-conference-bd-becton-dickinson-and-bdx-20120309monthly0.5https://www.biopharmawatch.com/news/BDX/bd-acquires-kiestra-lab-automation-bv-bd-becton-dickinson-and-company-nyse-bdx-a-leading-g-bdx-20120213monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-investor-healthcare-conferences-bd-becton-dickinson-and-company-nyse-bdx--bdx-20120210monthly0.5https://www.biopharmawatch.com/news/BDX/mesenchymal-stem-cells-have-new-cell-culture-environment-bd-biosciences-a-segment-of-bd-be-bdx-20120208monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2012-first-fiscal-quarter-bd-becton-dickinson-and-company-nyse-bd-bdx-20120207monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20120131monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-webcast-of-annual-meeting-of-shareholders-bd-becton-dickinson-and-company-nys-bdx-20120124monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-first-fiscal-quarter-earnings-conference-call-bd-becton-dicki-bdx-20120111monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-30th-annual-j-p-morgan-healthcare-conference-bd-becton-dickinson-and--bdx-20120104monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-23rd-annual-piper-jaffray-healthcare-conference-bd-becton-dickinson-a-bdx-20111122monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-increases-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse-bdx-20111122monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2011-fourth-fiscal-quarter-and-full-year-bd-becton-dickinson-and--bdx-20111102monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-2011-analyst-day-and-webcast-bd-becton-dickinson-and-company-nyse-bdx-announc-bdx-20111028monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-fourth-fiscal-quarter-earnings-conference-call-bd-becton-dick-bdx-20111004monthly0.5https://www.biopharmawatch.com/news/BDX/bd-launches-a-new-generation-short-peripheral-iv-catheter-to-reduce-risk-of-blood-exposure-bdx-20110921monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-increase-access-to-vital-cervical-cancer-screening-in-resource-limited-settings-thro-bdx-20110913monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-2011-morgan-stanley-global-healthcare-conference-bd-becton-dickinson--bdx-20110907monthly0.5https://www.biopharmawatch.com/news/BDX/bd-completes-acquisition-of-carmel-pharma-bd-becton-dickinson-and-company-nyse-bdx-a-leadi-bdx-20110816monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2011-third-fiscal-quarter-bd-becton-dickinson-and-company-nyse-bd-bdx-20110802monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-agreement-to-acquire-carmel-pharma-inc-bd-becton-dickinson-and-company-nyse-b-bdx-20110727monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-of-directors-elects-vincent-a-forlenza-as-next-chief-executive-officer-effective--bdx-20110726monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20110726monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-third-fiscal-quarter-earnings-conference-call-bd-becton-dicki-bdx-20110708monthly0.5https://www.biopharmawatch.com/news/BDX/bd-and-heart-to-heart-international-launch-volunteer-service-trip-to-help-build-back-bette-bdx-20110609monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-goldman-sachs-32nd-annual-global-healthcare-conference-bd-becton-dick-bdx-20110603monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20110524monthly0.5https://www.biopharmawatch.com/news/BDX/bd-issues-2010-sustainability-report-bd-becton-dickinson-and-company-nyse-bdx-a-leading-gl-bdx-20110519monthly0.5https://www.biopharmawatch.com/news/BDX/resource-now-available-to-help-clinicians-reduce-risk-of-blood-exposure-from-short-periphe-bdx-20110503monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-investor-healthcare-conferences-bd-becton-dickinson-and-company-nyse-bdx--bdx-20110428monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2011-second-fiscal-quarter-bd-becton-dickinson-and-company-nyse-b-bdx-20110426monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-second-fiscal-quarter-earnings-conference-call-bd-becton-dick-bdx-20110413monthly0.5https://www.biopharmawatch.com/news/BDX/bd-completes-acquisition-of-accuri-cytometers-inc-bd-becton-dickinson-and-company-nyse-bdx-bdx-20110318monthly0.5https://www.biopharmawatch.com/news/BDX/bd-statement-regarding-impact-of-japan-earthquake-bd-becton-dickinson-and-company-nyse-bdx-bdx-20110315monthly0.5https://www.biopharmawatch.com/news/BDX/bd-donates-325-000-for-japan-earthquake-and-tsunami-relief-efforts-bd-becton-dickinson-and-bdx-20110315monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-investor-healthcare-conferences-bd-becton-dickinson-and-company-nyse-bdx--bdx-20110225monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-agreement-to-acquire-accuri-cytometers-inc-bd-becton-dickinson-and-company-ny-bdx-20110207monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2011-first-fiscal-quarter-bd-becton-dickinson-and-company-nyse-bd-bdx-20110207monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-declares-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse--bdx-20110201monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-of-shareholder-votes-at-annual-meeting-bd-becton-dickinson-and-compan-bdx-20110201monthly0.5https://www.biopharmawatch.com/news/BDX/bd-and-rady-children-s-hospital-san-diego-announce-innovative-pilot-project-to-reduce-envi-bdx-20110124monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-first-fiscal-quarter-earnings-conference-call-bd-becton-dicki-bdx-20110111monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-webcast-of-annual-meeting-of-shareholders-bd-becton-dickinson-and-company-nys-bdx-20110105monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-29th-annual-j-p-morgan-healthcare-conference-bd-becton-dickinson-and--bdx-20110104monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-22nd-annual-piper-jaffray-health-care-conference-bd-becton-dickinson--bdx-20101124monthly0.5https://www.biopharmawatch.com/news/BDX/bd-board-increases-dividend-the-board-of-directors-of-bd-becton-dickinson-and-company-nyse-bdx-20101123monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-results-for-2010-fourth-fiscal-quarter-and-full-year-bd-becton-dickinson-and--bdx-20101103monthly0.5https://www.biopharmawatch.com/news/BDX/bd-ranks-among-top-25-u-s-companies-in-newsweek-s-2010-green-rankings-receives-epa-green-p-bdx-20101025monthly0.5https://www.biopharmawatch.com/news/BDX/bd-announces-live-webcast-of-fourth-fiscal-quarter-earnings-conference-call-bd-becton-dick-bdx-20101014monthly0.5https://www.biopharmawatch.com/news/BDX/bd-to-present-at-the-2010-morgan-stanley-global-healthcare-conference-bd-becton-dickinson--bdx-20100908monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-host-investor-event-at-the-75th-annual-scientific-session-of-the-amer-bsx-20260306monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-agreement-to-acquire-valencia-technologies-corporation-boston--bsx-20260112monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-second-quarter-2025-boston-scientific-corporation--bsx-20250723monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-upcoming-investor-conference-schedule-boston-scientific-corpor-bsx-20250501monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-first-quarter-2025-boston-scientific-corporation-n-bsx-20250423monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-conference-call-discussing-first-quarter-2025-results-boston-s-bsx-20250401monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-agreement-to-acquire-sonivie-ltd-boston-scientific-corporation-bsx-20250303monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-completion-of-1-5-billion-offering-of-senior-notes-boston-scie-bsx-20250226monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-td-cowen-s-45th-annual-health-care-conference-boston-s-bsx-20250219monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-fourth-quarter-and-full-year-2024-boston-scientifi-bsx-20250205monthly0.5https://www.biopharmawatch.com/news/BSX/late-breaking-data-presented-at-af-symposium-2025-highlight-key-boston-scientific-therapie-bsx-20250116monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-agreement-to-acquire-bolt-medical-inc-boston-scientific-corpor-bsx-20250108monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-participation-in-the-j-p-morgan-healthcare-conference-and-conf-bsx-20250102monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-agreement-to-acquire-intera-oncology-inc-boston-scientific-cor-bsx-20241125monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-watchman-flx-left-atrial-appendage-closure-device-demonstrates-superior--bsx-20241116monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-the-2024-ubs-global-healthcare-conference-boston-scien-bsx-20241105monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-agreement-to-acquire-cortex-inc-boston-scientific-corporation--bsx-20241104monthly0.5https://www.biopharmawatch.com/news/BSX/acurate-neo2-aortic-valve-system-data-presented-at-late-breaking-clinical-trial-session-at-bsx-20241030monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-third-quarter-2024-boston-scientific-corporation-n-bsx-20241023monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-launches-next-generation-of-cardiac-mapping-for-the-farapulse-pulsed-fie-bsx-20241018monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-conference-call-discussing-third-quarter-2024-results-boston-s-bsx-20241002monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-japanese-regulatory-approval-for-the-farapulse-pulsed-field-abl-bsx-20240927monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-closes-acquisition-of-silk-road-medical-inc-boston-scientific-corporatio-bsx-20240917monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-fda-approval-for-expanded-indication-of-ingevity-pacing-leads-t-bsx-20240917monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-obtains-ce-mark-for-acurate-prime-aortic-valve-system-boston-scientific--bsx-20240827monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-wells-fargo-s-2024-healthcare-conference-boston-scient-bsx-20240813monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-second-quarter-2024-boston-scientific-corporation--bsx-20240724monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-conference-call-discussing-second-quarter-2024-results-boston--bsx-20240701monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-agreement-to-acquire-silk-road-medical-inc-boston-scientific-c-bsx-20240618monthly0.5https://www.biopharmawatch.com/news/BSX/modular-atp-study-of-the-mcrm-system-meets-primary-safety-and-efficacy-endpoints-boston-sc-bsx-20240518monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-upcoming-investor-conference-schedule-boston-scientific-corpor-bsx-20240501monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-first-quarter-2024-boston-scientific-corporation-n-bsx-20240424monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-initiates-navigate-pf-study-of-the-farawave-nav-pulsed-field-ablation-ca-bsx-20240408monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-conference-call-discussing-first-quarter-2024-results-boston-s-bsx-20240401monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-fda-approval-for-the-agent-drug-coated-balloon-boston-scientifi-bsx-20240301monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-completion-of-2-0-billion-offering-of-senior-notes-boston-scie-bsx-20240227monthly0.5https://www.biopharmawatch.com/news/BSX/six-boston-scientific-benefits-that-support-employee-mental-health-one-in-five-american-ad-bsx-20240215monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-td-cowen-s-44th-annual-health-care-conference-boston-s-bsx-20240205monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-fourth-quarter-and-full-year-2023-boston-scientifi-bsx-20240131monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-fda-approval-for-farapulse-pulsed-field-ablation-system-boston--bsx-20240131monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-agreement-to-acquire-axonics-inc-boston-scientific-corporation-bsx-20240108monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-conference-call-discussing-fourth-quarter-2023-results-boston--bsx-20240105monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-initiates-avant-guard-clinical-trial-to-evaluate-farapulse-pulsed-field--bsx-20231228monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-closes-acquisition-of-relievant-medsystems-inc-boston-scientific-corpora-bsx-20231117monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-stifel-s-2023-healthcare-conference-boston-scientific--bsx-20231101monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-third-quarter-2023-boston-scientific-corporation-n-bsx-20231026monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-agent-drug-coated-balloon-demonstrates-superiority-to-uncoated-balloon-a-bsx-20231025monthly0.5https://www.biopharmawatch.com/news/BSX/real-pe-study-demonstrates-statistically-significant-lower-major-bleeding-rates-with-the-e-bsx-20231024monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-conference-call-discussing-third-quarter-2023-results-boston-s-bsx-20231002monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-agreement-to-acquire-relievant-medsystems-inc-boston-scientifi-bsx-20230919monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-fda-approval-for-the-latest-generation-watchman-flx-pro-left-a-bsx-20230906monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-2023-investor-day-meeting-and-conference-call-discussing-third-bsx-20230905monthly0.5https://www.biopharmawatch.com/news/BSX/advent-study-of-the-farapulse-pulsed-field-ablation-system-meets-primary-efficacy-and-safe-bsx-20230827monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-fda-approval-for-the-polarx-cryoablation-system-boston-scientif-bsx-20230808monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-second-quarter-2023-boston-scientific-corporation--bsx-20230727monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-conference-call-discussing-second-quarter-2023-results-boston--bsx-20230628monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-elects-dr-jessica-l-mega-and-susan-e-morano-to-board-of-directors-boston-bsx-20230627monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-conversion-date-of-series-a-mandatory-convertible-preferred-st-bsx-20230530monthly0.5https://www.biopharmawatch.com/news/BSX/data-at-heart-rhythm-2023-highlight-key-boston-scientific-therapies-boston-scientific-corp-bsx-20230520monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-bernstein-s-39th-annual-strategic-decisions-conference-bsx-202305152023-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-first-quarter-2023-boston-scientific-corporation-n-bsx-202304262023-04-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-conference-call-discussing-first-quarter-2023-results-boston-s-bsx-202304032023-04-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-citi-s-2023-healthcare-services-medtech-tools-hcit-con-bsx-202302132023-02-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-fda-clearance-for-lithovue-elite-single-use-digital-flexible-ur-bsx-202302032023-02-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-fourth-quarter-and-full-year-2022-boston-scientifi-bsx-202302012023-02-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-j-p-morgan-healthcare-conference-and-announces-confere-bsx-202301032023-01-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-strategic-investment-to-acquire-majority-stake-of-acotec-scien-bsx-20221211monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-agreement-to-acquire-apollo-endosurgery-inc-boston-scientific--bsx-20221129monthly0.5https://www.biopharmawatch.com/news/BSX/late-breaking-post-market-study-data-reinforce-clinical-procedural-success-and-safety-of-t-bsx-20221127monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-upcoming-conference-schedule-boston-scientific-corporation-nys-bsx-20221101monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-third-quarter-2022-boston-scientific-corporation-n-bsx-20221026monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-conference-call-discussing-third-quarter-2022-results-boston-s-bsx-20221003monthly0.5https://www.biopharmawatch.com/news/BSX/late-breaking-data-from-protected-tavr-trial-demonstrate-reduced-risk-of-disabling-stroke--bsx-20220917monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-fda-approval-for-expanded-labeling-of-watchman-flx-laac-device--bsx-20220906monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-upcoming-conference-schedule-boston-scientific-corporation-nys-bsx-20220816monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-acquisition-of-obsidio-inc-boston-scientific-corporation-nyse--bsx-20220815monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-second-quarter-2022-boston-scientific-corporation--bsx-20220727monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-conference-call-discussing-second-quarter-2022-results-boston--bsx-20220629monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-agreement-to-purchase-majority-stake-of-m-i-tech-co-ltd-from-s-bsx-20220615monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-bank-of-america-global-healthcare-conference-boston-sc-bsx-20220502monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-first-quarter-2022-boston-scientific-corporation-n-bsx-20220427monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-conference-call-discussing-first-quarter-2022-results-boston-s-bsx-20220401monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-pricing-terms-of-its-cash-tender-offer-boston-scientific-corpo-bsx-20220316monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-completion-of-3-0-billion-offering-of-senior-notes-boston-scie-bsx-20220308monthly0.5https://www.biopharmawatch.com/news/BSX/late-breaking-study-results-reinforce-positive-real-world-outcomes-with-the-watchman-flx-l-bsx-20220228monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-closes-acquisition-of-baylis-medical-company-inc-boston-scientific-corpo-bsx-20220215monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-11th-annual-svb-leerink-global-healthcare-conference-b-bsx-20220214monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-fourth-quarter-and-full-year-2021-boston-scientifi-bsx-20220202monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-present-new-data-on-advances-in-chronic-pain-care-at-the-2022-north-a-bsx-20220107monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-j-p-morgan-healthcare-conference-and-announces-confere-bsx-20220104monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-initiates-trial-to-evaluate-industry-s-first-modular-crm-system-boston-s-bsx-20211202monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-upcoming-conference-schedule-boston-scientific-corporation-nys-bsx-20211108monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-third-quarter-2021-boston-scientific-corporation-n-bsx-20211027monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-eluvia-drug-eluting-vascular-stent-system-exhibits-superiority-compared--bsx-20211006monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-agreement-to-acquire-baylis-medical-company-inc-boston-scienti-bsx-20211006monthly0.5https://www.biopharmawatch.com/news/BSX/positive-late-breaking-clinical-trial-data-for-the-ekosonic-endovascular-system-presented--bsx-20211005monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-positive-late-breaking-clinical-trial-data-for-the-ranger-drug-bsx-20211005monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-conference-call-discussing-third-quarter-2021-results-boston-s-bsx-20211004monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-agreement-to-acquire-devoro-medical-inc-today-boston-scientifi-bsx-20210921monthly0.5https://www.biopharmawatch.com/news/BSX/late-breaking-data-demonstrate-improved-progression-free-survival-in-patients-with-metasta-bsx-20210920monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-2021-investor-day-meeting-boston-scientific-corporation-nyse-b-bsx-20210909monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-closes-acquisition-of-lumenis-ltd-surgical-business-from-baring-private--bsx-20210901monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-fda-clearance-for-exalt-model-b-single-use-bronchoscope-boston--bsx-20210810monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-initiates-randomized-controlled-trial-for-the-ekosonic-endovascular-syst-bsx-20210804monthly0.5https://www.biopharmawatch.com/news/BSX/cms-grants-additional-reimbursement-for-exalt-model-d-single-use-duodenoscope-boston-scien-bsx-20210802monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-second-quarter-2021-boston-scientific-corporation--bsx-20210727monthly0.5https://www.biopharmawatch.com/news/BSX/late-breaking-trial-data-at-tvt-demonstrate-sustained-safety-and-performance-of-watchman-f-bsx-20210721monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-conference-call-discussing-second-quarter-2021-results-boston--bsx-20210629monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-elects-david-s-wichmann-to-board-of-directors-boston-scientific-corporat-bsx-20210624monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-exercises-option-to-acquire-farapulse-inc-boston-scientific-corporation--bsx-20210624monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-erha-lt-ce-kennzeichnung-fu-r-exalt-modell-b-einwegbronchoskop-die-bosto-bsx-20210526monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-obtient-le-marquage-ce-pour-le-bronchoscope-a-usage-unique-exalt-model-b-bsx-20210525monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-conclui-a-marca-ce-para-broncosco-pio-de-uso-u-nico-exalt-model-b-a-bost-bsx-20210525monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-completa-el-marcado-ce-para-el-broncoscopio-exalt-modelo-b-de-un-solo-us-bsx-20210525monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-completa-la-marca-ce-para-el-broncoscopio-de-un-solo-uso-exalt-model-b-b-bsx-20210525monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-completes-ce-mark-for-exalt-model-b-single-use-bronchoscope-boston-scien-bsx-20210525monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-bernstein-s-37th-annual-strategic-decisions-conference-bsx-20210524monthly0.5https://www.biopharmawatch.com/news/BSX/late-breaking-registry-data-at-europcr-congress-demonstrate-reduced-paravalvular-leak-and--bsx-20210518monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-may-conference-schedule-boston-scientific-corporation-nyse-bsx-bsx-20210503monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-first-quarter-2021-boston-scientific-corporation-n-bsx-20210428monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-conference-call-discussing-first-quarter-2021-results-and-part-bsx-20210326monthly0.5https://www.biopharmawatch.com/news/BSX/late-breaking-clinical-trial-data-for-therasphere-y-90-glass-microspheres-demonstrates-imp-bsx-20210325monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-fda-approval-for-therasphere-y-90-glass-microspheres-boston-sci-bsx-20210318monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-february-and-march-2021-conference-schedule-boston-scientific--bsx-20210212monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-fourth-quarter-and-full-year-2020-boston-scientifi-bsx-20210203monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-fda-approval-for-the-vercise-genus-deep-brain-stimulation-syste-bsx-20210122monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-launches-wavewriter-alpha-spinal-cord-stimulator-systems-in-u-s-boston-s-bsx-20210114monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-preliminary-unaudited-sales-for-the-fourth-quarter-and-full-ye-bsx-20210112monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-j-p-morgan-healthcare-conference-and-announces-confere-bsx-20210104monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-stipulation-of-dismissal-of-nevro-corporation-s-patent-infring-bsx-20201214monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-signs-definitive-agreement-to-divest-btg-specialty-pharmaceuticals-busin-bsx-20201201monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-evercore-isi-2020-healthcare-conference-boston-scienti-bsx-20201123monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-lotus-edge-aortic-valve-system-voluntary-recall-and-product-di-bsx-20201117monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-november-2020-conference-schedule-boston-scientific-corporatio-bsx-20201105monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-fda-approval-for-the-ranger-drug-coated-balloon-boston-scientif-bsx-20201102monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-initiates-trial-to-evaluate-watchman-flx-left-atrial-appendage-closure-d-bsx-20201029monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-third-quarter-2020-boston-scientific-corporation-n-bsx-20201028monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-transcatheter-cardiovascular-therapeutics-2020-investor-update-bsx-20201001monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-launches-wavewriter-alpha-spinal-cord-stimulator-systems-in-europe-bosto-bsx-20200930monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-launches-acurate-neo2-aortic-valve-system-in-europe-boston-scientific-co-bsx-20200928monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-expanded-investment-and-exclusive-acquisition-option-agreement-bsx-20200921monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-launches-vercise-genus-dbs-system-in-europe-boston-scientific-corporatio-bsx-20200909monthly0.5https://www.biopharmawatch.com/news/BSX/cms-grants-additional-reimbursement-for-the-eluvia-drug-eluting-vascular-stent-system-bost-bsx-20200903monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-september-2020-conference-schedule-boston-scientific-corporati-bsx-20200826monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-second-quarter-2020-boston-scientific-corporation--bsx-20200729monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-fda-approval-for-next-generation-watchman-flx-left-atrial-appen-bsx-20200721monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-conference-call-discussing-second-quarter-2020-financial-resul-bsx-20200630monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-fda-510-k-clearance-for-the-lux-dx-insertable-cardiac-monitor-s-bsx-20200629monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-medicare-transitional-pass-through-payment-for-the-exalt-model--bsx-20200608monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-launches-directsense-technology-boston-scientific-nyse-bsx-announced-the-bsx-20200601monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-completes-approximately-2-0-billion-aggregate-offerings-of-common-stock--bsx-20200527monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-jefferies-2020-healthcare-conference-boston-scientific-bsx-20200526monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-prices-offerings-of-common-stock-and-mandatory-convertible-preferred-sto-bsx-20200521monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-offerings-of-common-stock-and-mandatory-convertible-preferred--bsx-20200520monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-completes-1-7-billion-offering-of-senior-notes-boston-scientific-corpora-bsx-20200518monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-prices-1-7-billion-of-senior-notes-boston-scientific-corporation-nyse-bs-bsx-20200514monthly0.5https://www.biopharmawatch.com/news/BSX/late-breaking-clinical-trial-data-underscore-safety-and-efficacy-of-boston-scientific-s-ic-bsx-20200508monthly0.5https://www.biopharmawatch.com/news/BSX/pinnacle-flx-study-of-the-watchman-flx-left-atrial-appendage-closure-device-presented-as-l-bsx-20200508monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-may-2020-virtual-conference-schedule-boston-scientific-corpora-bsx-20200506monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-first-quarter-2020-boston-scientific-corporation-n-bsx-20200429monthly0.5https://www.biopharmawatch.com/news/BSX/new-renewable-energy-agreements-to-reduce-boston-scientific-carbon-footprint-by-half-bosto-bsx-20200421monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-2020-annual-meeting-of-stockholders-will-be-conducted-in-virtu-bsx-20200410monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-provides-update-on-covid-19-impact-and-response-efforts-the-covid-19-pan-bsx-20200402monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-february-and-march-2020-conference-schedule-boston-scientific--bsx-20200218monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-fourth-quarter-and-full-year-2019-boston-scientifi-bsx-20200205monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-preliminary-unaudited-sales-for-the-fourth-quarter-and-full-ye-bsx-20200114monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-january-conference-schedule-and-conference-call-discussing-fou-bsx-20200102monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-fda-clearance-for-world-s-first-single-use-duodenoscope-exalt-m-bsx-20191213monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-evercore-isi-and-piper-jaffray-healthcare-conferences--bsx-20191121monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-completes-900-million-offering-of-senior-notes-and-1-0-billion-tender-of-bsx-20191112monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-prices-900-000-000-of-senior-notes-boston-scientific-corporation-the-com-bsx-20191106monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-pricing-terms-of-its-cash-tender-offer-for-up-to-1-0-billion-o-bsx-20191105monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-positive-data-for-the-ranger-drug-coated-balloon-and-the-eluvi-bsx-20191105monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-early-results-of-its-cash-tender-offer-for-up-to-1-0-billion-o-bsx-20191105monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-november-2019-conference-schedule-boston-scientific-corporatio-bsx-20191101monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-third-quarter-2019-boston-scientific-corporation-n-bsx-20191023monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-cash-tender-offer-for-up-to-1-0-billion-of-its-outstanding-deb-bsx-20191022monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-conference-call-discussing-third-quarter-2019-financial-result-bsx-20191001monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-positive-data-from-the-evolve-short-dapt-study-with-the-synerg-bsx-20190926monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-scheduled-presentations-at-transcatheter-cardiovascular-therap-bsx-20190918monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-the-2019-wells-fargo-securities-healthcare-conference--bsx-20190820monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-fda-approval-of-imageready-mri-for-vercise-gevia-deep-brain-st-bsx-20190819monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-closes-acquisition-of-btg-plc-boston-scientific-corporation-nyse-bsx-tod-bsx-20190819monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-39th-annual-canaccord-genuity-growth-conference-boston-bsx-20190725monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-second-quarter-2019-boston-scientific-corporation--bsx-20190724monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-conference-call-discussing-second-quarter-2019-financial-resul-bsx-20190701monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-presents-strategies-for-sustained-long-range-growth-targets-at-2019-inve-bsx-20190626monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-closes-acquisition-of-vertiflex-inc-boston-scientific-corporation-nyse-b-bsx-20190611monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-initiates-trial-comparing-left-atrial-appendage-closure-to-direct-oral-a-bsx-20190522monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-bernstein-s-35th-annual-strategic-decisions-conference-bsx-20190515monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-the-2019-ubs-global-healthcare-conference-boston-scien-bsx-20190507monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-scheduled-presentations-at-heart-rhythm-2019-boston-scientific-bsx-20190501monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-first-quarter-2019-boston-scientific-corporation-n-bsx-20190424monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-fda-approval-for-lotus-edge-aortic-valve-system-boston-scientif-bsx-20190423monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-conference-call-discussing-first-quarter-2019-financial-result-bsx-20190327monthly0.5https://www.biopharmawatch.com/news/BSX/late-breaking-clinical-trial-highlights-positive-safety-and-efficacy-data-for-the-luminize-bsx-20190317monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-ce-mark-for-next-generation-watchman-flx-left-atrial-appendage--bsx-20190313monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-anuncia-datos-previstos-en-el-congreso-ehra-2019-boston-scientific-corpo-bsx-20190312monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-vero-ffentlicht-geplante-daten-auf-dem-kongress-ehra-2019-die-boston-sci-bsx-20190312monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-annonce-les-donne-es-programme-es-au-cours-du-congre-s-de-l-ehra-2019-bo-bsx-20190312monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-scheduled-data-at-ehra-2019-congress-boston-scientific-corpora-bsx-20190311monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-the-cowen-and-company-39th-annual-healthcare-conferenc-bsx-20190227monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-completes-4-3-billion-offering-of-senior-notes-and-issues-redemption-not-bsx-20190225monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-prices-4-3-billion-of-senior-notes-boston-scientific-corporation-nyse-bs-bsx-20190221monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-the-8th-annual-svb-leerink-global-healthcare-conferenc-bsx-20190214monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-fourth-quarter-and-full-year-2018-boston-scientifi-bsx-20190206monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-presenta-en-europa-el-sistema-spectra-wavewriter-de-estimulacio-n-de-la--bsx-20190201monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-lanciert-ru-ckenmarksstimulator-system-spectra-wavewriter-in-europa-bost-bsx-20190201monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-lance-le-syste-me-de-stimulation-de-la-moelle-e-pinie-re-spectra-wavewri-bsx-20190201monthly0.5https://www.biopharmawatch.com/news/BSX/new-four-year-data-demonstrate-rezu-m-water-vapor-therapy-offers-significant-durable-impro-bsx-20190125monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-launches-vercise-primary-cell-and-vercise-gevia-deep-brain-stimulation-s-bsx-20190124monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-preliminary-unaudited-sales-for-the-fourth-quarter-and-full-ye-bsx-20190108monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-conference-call-discussing-fourth-quarter-2018-financial-resul-bsx-20190104monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-exercises-option-to-acquire-millipede-inc-boston-scientific-corporation--bsx-20181227monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-37th-annual-j-p-morgan-healthcare-conference-boston-sc-bsx-20181221monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-prevails-in-u-s-edwards-lifesciences-litigation-boston-scientific-corpor-bsx-20181211monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-2018-bmo-capital-markets-prescriptions-for-success-hea-bsx-20181203monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-citi-s-2018-global-healthcare-conference-boston-scient-bsx-20181127monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-the-30th-annual-piper-jaffray-healthcare-conference-bo-bsx-20181121monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-recommended-offer-to-acquire-btg-plc-boston-scientific-nyse-bs-bsx-20181120monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-2018-canaccord-genuity-medical-technologies-diagnostic-bsx-20181107monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-stifel-2018-healthcare-conference-boston-scientific-co-bsx-20181106monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-27th-annual-credit-suisse-healthcare-conference-boston-bsx-20181106monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-third-quarter-2018-boston-scientific-corporation-n-bsx-20181024monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-prevails-in-german-edwards-lifesciences-litigation-boston-scientific-cor-bsx-20181023monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-closes-acquisition-of-augmenix-inc-boston-scientific-corporation-nyse-bs-bsx-20181016monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-conference-call-discussing-third-quarter-2018-financial-result-bsx-20181001monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-u-s-fda-approval-for-the-eluvia-drug-eluting-vascular-stent-sys-bsx-20180924monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-eluvia-drug-eluting-stent-demonstrates-superior-results-in-imperial-tria-bsx-20180922monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-launches-lithovue-empower-retrieval-deployment-device-boston-scientific--bsx-20180921monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-scheduled-presentations-at-transcatheter-cardiovascular-therap-bsx-20180917monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-agreement-to-acquire-augmenix-inc-boston-scientific-nyse-bsx-t-bsx-20180906monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-morgan-stanley-global-healthcare-conference-boston-sci-bsx-20180906monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-13th-annual-wells-fargo-securities-healthcare-conferen-bsx-20180829monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-agreement-to-acquire-veniti-inc-boston-scientific-corporation--bsx-20180808monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-closes-acquisition-of-claret-medical-inc-announces-positive-reimbursemen-bsx-20180802monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-38th-annual-canaccord-genuity-growth-conference-boston-bsx-20180730monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-second-quarter-2018-boston-scientific-corporation--bsx-20180725monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-corporation-recommends-stockholders-reject-mini-tender-offer-by-trc-capi-bsx-20180724monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-agreement-to-acquire-claret-medical-inc-boston-scientific-corp-bsx-20180720monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-acquire-cryterion-medical-inc-boston-scientific-corporation-nyse-bsx--bsx-20180705monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-conference-call-discussing-second-quarter-2018-financial-resul-bsx-20180702monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-scheduled-presentations-at-digestive-disease-week-2018-boston--bsx-20180601monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-lance-heartlogic-un-outil-de-diagnostic-de-l-insuffisance-cardiaque-en-e-bsx-20180529monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-pra-sentiert-das-herzinsuffizienz-diagnosetool-heartlogic-in-europa-bost-bsx-20180529monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-presenta-heartlogic-para-el-diagno-stico-de-insuficiencia-cardiaca-en-eu-bsx-20180529monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-schedule-of-presentations-at-europcr-2018-boston-scientific-co-bsx-20180516monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-34th-annual-strategic-decisions-conference-boston-scie-bsx-20180514monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-bank-of-america-merrill-lynch-2018-health-care-confere-bsx-20180507monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-closes-nxthera-acquisition-boston-scientific-corporation-nyse-bsx-today--bsx-20180430monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-first-quarter-2018-boston-scientific-corporation-n-bsx-20180425monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-positive-late-breaking-data-from-the-intrepid-study-boston-sci-bsx-20180424monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-prevails-in-european-patent-dispute-with-edwards-lifesciences-boston-sci-bsx-20180416monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-acquisition-of-securus-medical-group-inc-boston-scientific-cor-bsx-20180403monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-prevails-in-u-k-edwards-lifesciences-litigation-boston-scientific-corpor-bsx-20180328monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-conference-call-discussing-first-quarter-2018-financial-result-bsx-20180326monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-17th-annual-needham-healthcare-conference-boston-scien-bsx-20180314monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-scheduled-presentations-at-ehra-2018-congress-boston-scientifi-bsx-20180312monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-barclays-global-healthcare-conference-boston-scientifi-bsx-20180305monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-acquisition-of-emcision-limited-boston-scientific-nyse-bsx-tod-bsx-20180305monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-completes-1-0-billion-offering-of-senior-notes-boston-scientific-corpora-bsx-20180226monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-prices-1-0-billion-of-senior-notes-boston-scientific-corporation-nyse-bs-bsx-20180222monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-fourth-quarter-and-full-year-2017-boston-scientifi-bsx-20180201monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-leerink-partners-7th-annual-global-healthcare-conferen-bsx-20180129monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-investment-and-acquisition-option-agreement-with-millipede-inc-bsx-20180124monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-updated-time-for-webcast-conference-call-discussing-fourth-qua-bsx-20180119monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-positive-results-from-whisper-spinal-cord-stimulation-study-bo-bsx-20180112monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-preliminary-unaudited-sales-for-the-fourth-quarter-and-full-ye-bsx-20180109monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-36th-annual-j-p-morgan-healthcare-conference-boston-sc-bsx-20171222monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-goldman-sachs-healthcare-ceos-unscripted-conference-bo-bsx-20171221monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-u-s-fda-approval-for-the-vercise-deep-brain-stimulation-system--bsx-20171211monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-bmo-capital-markets-prescriptions-for-success-healthca-bsx-20171204monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-update-on-lotus-edge-aortic-valve-system-boston-scientific-nys-bsx-20171128monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-citi-2017-global-healthcare-conference-boston-scientif-bsx-20171127monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-piper-jaffray-29th-annual-healthcare-conference-boston-bsx-20171113monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-stifel-2017-healthcare-conference-boston-scientific-co-bsx-20171108monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-26th-annual-credit-suisse-healthcare-conference-boston-bsx-20171106monthly0.5https://www.biopharmawatch.com/news/BSX/five-year-follow-up-data-demonstrate-the-watchman-left-atrial-appendage-closure-device-pro-bsx-20171102monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-third-quarter-2017-boston-scientific-corporation-n-bsx-20171026monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-appoints-desiree-ralls-morrison-general-counsel-and-corporate-secretary--bsx-20171004monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-webcast-conference-call-discussing-third-quarter-2017-financial-resul-bsx-20171002monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-agreement-to-acquire-apama-medical-boston-scientific-corporati-bsx-20171002monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-u-s-fda-approval-for-mri-labeling-on-high-voltage-devices-and--bsx-20170925monthly0.5https://www.biopharmawatch.com/news/BSX/los-datos-pragma-ticos-confirman-la-efectividad-a-largo-plazo-de-la-termoplastia-bronquial-bsx-20170918monthly0.5https://www.biopharmawatch.com/news/BSX/daten-aus-der-praxis-besta-tigen-die-langzeitwirkung-von-bronchialer-thermoplastie-boston--bsx-20170918monthly0.5https://www.biopharmawatch.com/news/BSX/des-donne-es-re-elles-confirment-l-efficacite-a-long-terme-de-la-thermoplastie-bronchique--bsx-20170918monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-morgan-stanley-global-healthcare-conference-boston-sci-bsx-20170828monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-wells-fargo-2017-healthcare-conference-boston-scientif-bsx-20170821monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-2017-canaccord-genuity-growth-conference-boston-scient-bsx-20170731monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-second-quarter-2017-boston-scientific-corporation--bsx-20170727monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-webcast-conference-call-discussing-second-quarter-2017-financial-resu-bsx-20170705monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-outlines-strategy-for-sustained-growth-at-2017-investor-day-updated-bost-bsx-20170627monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-ce-mark-for-vercise-gevia-deep-brain-stimulation-system-boston--bsx-20170606monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-positive-outcomes-from-prospective-study-of-bronchial-thermopl-bsx-20170524monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-2017-ubs-global-healthcare-conference-boston-scientifi-bsx-20170517monthly0.5https://www.biopharmawatch.com/news/BSX/the-boston-scientific-lotus-valve-system-demonstrated-superior-efficacy-to-corevalve-in-gl-bsx-20170516monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-closes-symetis-acquisition-boston-scientific-corporation-nyse-bsx-today--bsx-20170516monthly0.5https://www.biopharmawatch.com/news/BSX/new-data-from-platinum-diversity-study-presented-at-scai-2017-provide-important-insights-b-bsx-20170512monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-schedule-of-presentations-at-europcr-2017-boston-scientific-ny-bsx-20170510monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-u-s-fda-approval-for-resonate-family-of-high-voltage-devices-bo-bsx-20170509monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-scheduled-presentations-at-heart-rhythm-society-2017-boston-sc-bsx-20170503monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-bank-of-america-merrill-lynch-2017-healthcare-conferen-bsx-20170501monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-first-quarter-2017-boston-scientific-corporation-n-bsx-20170427monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-webcast-conference-call-discussing-first-quarter-2017-financial-resul-bsx-20170330monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-agreement-to-acquire-symetis-boston-scientific-corporation-nys-bsx-20170330monthly0.5https://www.biopharmawatch.com/news/BSX/nice-recommends-boston-scientific-crt-d-devices-powered-by-enduralife-battery-technology-f-bsx-20170316monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-favorable-rulings-in-edwards-lifesciences-litigation-boston-sci-bsx-20170309monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-barclays-global-healthcare-conference-boston-scientifi-bsx-20170307monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-six-finalists-in-2nd-annual-connected-patient-challenge-focuse-bsx-20170303monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-cowen-and-company-37th-annual-healthcare-conference-bo-bsx-20170221monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-2017-rbc-capital-markets-global-healthcare-conference--bsx-20170215monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-fourth-quarter-and-full-year-ended-december-31-201-bsx-20170202monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-leerink-partners-6th-annual-global-healthcare-conferen-bsx-20170201monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-webcast-conference-call-discussing-fourth-quarter-2016-financial-resu-bsx-20170103monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-35th-annual-j-p-morgan-healthcare-conference-boston-sc-bsx-20161230monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-closes-acquisition-of-advanced-biological-tissue-capabilities-and-acquir-bsx-20161213monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-citi-2016-global-healthcare-conference-boston-scientif-bsx-20161123monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-closes-endochoice-acquisition-boston-scientific-corporation-nyse-bsx-tod-bsx-20161122monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-2016-shingo-prize-for-operational-excellence-boston-scientific--bsx-20161121monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-acquires-resectr-tissue-resection-device-from-distal-access-llc-boston-s-bsx-20161115monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-extension-of-the-cash-tender-offer-for-all-shares-of-endochoic-bsx-20161104monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-acquisition-of-the-lumenr-tissue-retractor-system-boston-scien-bsx-20161103monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-stifel-2016-healthcare-conference-boston-scientific-co-bsx-20161027monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-third-quarter-2016-boston-scientific-corporation-n-bsx-20161026monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-25th-annual-credit-suisse-healthcare-conference-boston-bsx-20161025monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-launches-resolution-360-clip-boston-scientific-corporation-nyse-bsx-toda-bsx-20161017monthly0.5https://www.biopharmawatch.com/news/BSX/professor-ian-meredith-to-join-boston-scientific-as-executive-vice-president-and-global-ch-bsx-20161010monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-commences-cash-tender-offer-for-all-shares-of-endochoice-for-8-00-per-sh-bsx-20161007monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-webcast-conference-call-discussing-third-quarter-2016-financial-resul-bsx-20161003monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-acquire-endochoice-boston-scientific-nyse-bsx-and-endochoice-holdings-bsx-20160927monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-ce-mark-for-lotus-edge-valve-system-boston-scientific-corporati-bsx-20160919monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-morgan-stanley-global-healthcare-conference-boston-sci-bsx-20160830monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-wells-fargo-2016-healthcare-conference-boston-scientif-bsx-20160824monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-u-s-fda-approval-of-emblem-mri-s-icd-system-boston-scientific--bsx-20160809monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-canaccord-genuity-growth-conference-and-wedbush-pacgro-bsx-20160801monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-second-quarter-2016-boston-scientific-corporation--bsx-20160728monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-acquisition-of-cosman-medical-boston-scientific-corporation-ny-bsx-20160727monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-elects-yoshiaki-fujimori-to-board-of-directors-boston-scientific-corpora-bsx-20160713monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-webcast-conference-call-discussing-second-quarter-2016-financial-resu-bsx-20160701monthly0.5https://www.biopharmawatch.com/news/BSX/national-institute-for-health-and-care-excellence-provides-positive-guidance-for-use-of-bo-bsx-20160614monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-restructuring-program-to-support-long-term-growth-and-innovati-bsx-20160608monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-goldman-sachs-2016-healthcare-conference-boston-scient-bsx-20160526monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-jefferies-2016-healthcare-conference-boston-scientific-bsx-20160524monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-u-s-fda-approval-for-precision-montage-mri-spinal-cord-stimulat-bsx-20160519monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-schedule-of-presentations-at-europcr-2016-boston-scientific-ny-bsx-20160513monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-positive-long-term-outcomes-for-s-icd-system-in-the-effortless-bsx-20160506monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-bank-of-america-2016-healthcare-conference-boston-scie-bsx-20160429monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-scheduled-presentations-at-heart-rhythm-society-2016-boston-sc-bsx-20160428monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-first-quarter-2016-boston-scientific-corporation-n-bsx-20160427monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-deutsche-bank-2016-healthcare-conference-boston-scient-bsx-20160421monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-ce-mark-for-mri-labeling-of-emblem-s-icd-systems-boston-scient-bsx-20160420monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-webcast-conference-call-discussing-first-quarter-2016-financial-resul-bsx-20160401monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-15th-annual-needham-healthcare-conference-boston-scien-bsx-20160329monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-scheduled-presentations-at-american-college-of-cardiology-s-65-bsx-20160324monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-launches-the-axios-stent-and-electrocautery-enhanced-delivery-system-bos-bsx-20160322monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-mayo-clinic-collaborate-to-speed-development-of-medical-devices-boston-s-bsx-20160316monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-u-s-fda-approval-for-blazer-open-irrigated-catheter-boston-scie-bsx-20160310monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-barclays-global-health-care-conference-boston-scientif-bsx-20160301monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-changes-to-board-of-directors-boston-scientific-corporation-ny-bsx-20160225monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-cowen-company-2016-health-care-conference-boston-scien-bsx-20160223monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-u-s-fda-approval-for-quadripolar-leads-and-initiates-global-tri-bsx-20160223monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-ce-mark-for-eluvia-drug-eluting-vascular-stent-and-announces-in-bsx-20160222monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-medicare-will-cover-watchman-left-atrial-appendage-closure-dev-bsx-20160208monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-fourth-quarter-and-full-year-ended-december-31-201-bsx-20160204monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-and-accenture-develop-data-driven-digital-health-solution-to-help-improv-bsx-20160128monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-leerink-partners-2016-healthcare-conference-boston-sci-bsx-20160127monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-launches-the-lithovue-single-use-digital-flexible-ureteroscope-in-u-s-an-bsx-20160112monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-webcast-fourth-quarter-2015-earnings-call-on-february-4-boston-scient-bsx-20160104monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-2016-j-p-morgan-healthcare-conference-boston-scientifi-bsx-20151222monthly0.5https://www.biopharmawatch.com/news/BSX/lumina-data-demonstrate-70-percent-greater-low-back-pain-relief-with-boston-scientific-pre-bsx-20151211monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-oppenheimer-2015-healthcare-conference-boston-scientif-bsx-20151124monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-scores-perfect-100-on-human-rights-campaign-s-2016-corporate-equality-in-bsx-20151118monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-canaccord-genuity-2015-medical-technology-and-diagnost-bsx-20151105monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-stifel-healthcare-conference-boston-scientific-corpora-bsx-20151103monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-third-quarter-2015-boston-scientific-corporation-n-bsx-20151028monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-additional-investment-and-right-to-acquire-mvalve-technologies-bsx-20151008monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-scheduled-presentations-at-tct-2015-boston-scientific-nyse-bsx-bsx-20151007monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-webcast-third-quarter-2015-earnings-call-on-october-28-boston-scienti-bsx-20151001monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-launches-the-captivator-emr-device-to-treat-diseases-of-the-upper-gi-tra-bsx-20150929monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-ce-mark-for-the-vercise-primary-cell-deep-brain-stimulation-sy-bsx-20150910monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-2015-morgan-stanley-global-healthcare-conference-bosto-bsx-20150902monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-the-2015-wells-fargo-healthcare-conference-boston-scie-bsx-20150826monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-ce-mark-for-mri-compatible-labeling-for-icd-and-crt-d-systems--bsx-20150824monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-fda-approval-of-innova-vascular-self-expanding-stent-system-bo-bsx-20150819monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-second-quarter-2015-boston-scientific-corporation--bsx-20150723monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-elects-donna-a-james-to-board-of-directors-boston-scientific-corporation-bsx-20150715monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-bronchial-thermoplasty-treatment-recognized-by-american-college-of-aller-bsx-20150709monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-webcast-second-quarter-2015-earnings-call-on-july-23-boston-scientifi-bsx-20150701monthly0.5https://www.biopharmawatch.com/news/BSX/new-data-demonstrate-greater-pain-relief-with-boston-scientific-precision-spectra-spinal-c-bsx-20150610monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-launches-the-precision-novi-spinal-cord-stimulator-system-in-europe-bost-bsx-20150604monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-the-goldman-sachs-36th-annual-global-healthcare-confer-bsx-20150526monthly0.5https://www.biopharmawatch.com/news/BSX/post-market-study-evaluating-the-boston-scientific-lotus-valve-system-demonstrates-extreme-bsx-20150520monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-completes-1-85-billion-senior-notes-offering-boston-scientific-corporati-bsx-20150512monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-scheduled-presentations-at-heart-rhythm-society-2015-boston-sc-bsx-20150511monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-prices-1-85-billion-of-senior-notes-boston-scientific-corporation-nyse-b-bsx-20150507monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-outlines-growth-and-expansion-strategy-at-2015-investor-day-boston-scien-bsx-20150501monthly0.5https://www.biopharmawatch.com/news/BSX/new-data-evaluating-the-boston-scientific-eluvia-tm-drug-eluting-vascular-stent-system-dem-bsx-20150428monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-first-quarter-2015-boston-scientific-corporation-n-bsx-20150428monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-the-bank-of-america-merrill-lynch-2015-healthcare-conf-bsx-20150427monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-strategic-collaboration-with-brainlab-ag-boston-scientific-cor-bsx-20150427monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-the-deutsche-bank-40th-annual-healthcare-conference-bo-bsx-20150424monthly0.5https://www.biopharmawatch.com/news/BSX/long-term-data-underscore-safety-and-efficacy-of-the-boston-scientific-s-icd-system-today--bsx-20150420monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-enrolls-first-patient-in-new-study-designed-to-demonstrate-the-effect-of-bsx-20150416monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-signs-strategic-alliance-with-frankenman-medical-equipment-company-bosto-bsx-20150414monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-webcast-conference-call-on-first-quarter-2015-financial-results-bosto-bsx-20150401monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-agrees-to-acquire-xlumena-boston-scientific-corporation-nyse-bsx-announc-bsx-20150401monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-first-u-s-commercial-procedures-with-the-watchman-left-atrial--bsx-20150324monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-fda-and-ce-mark-approval-of-the-emblem-s-icd-system-boston-sci-bsx-20150317monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-fda-approval-for-watchman-left-atrial-appendage-closure-device--bsx-20150313monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-elects-charles-j-dockendorff-and-stephen-p-macmillan-to-board-of-directo-bsx-20150303monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-definitive-agreement-to-acquire-american-medical-systems-urolo-bsx-20150302monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-the-barclays-2015-annual-healthcare-conference-boston--bsx-20150227monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-launches-next-generation-spyglass-ds-direct-visualization-system-for-adv-bsx-20150226monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-the-cowen-35th-annual-healthcare-conference-boston-sci-bsx-20150225monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-agreement-with-johnson-johnson-to-resolve-guidant-litigation-b-bsx-20150217monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-the-rbc-capital-markets-2015-global-healthcare-confere-bsx-20150213monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-and-c-r-bard-announce-distribution-agreement-for-lutonix-drug-coated-bal-bsx-20150209monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-the-leerink-2015-global-healthcare-conference-boston-s-bsx-20150209monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-fourth-quarter-and-full-year-ended-december-31-201-bsx-20150204monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-maple-grove-operations-named-a-2014-best-plants-winner-the-boston-scient-bsx-20150203monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-launches-world-s-longest-lasting-icd-boston-scientific-corporation-nyse--bsx-20150202monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-host-and-webcast-investor-day-business-review-may-1-2015-boston-scien-bsx-20150115monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-webcast-conference-call-discussing-fourth-quarter-2014-financial-resu-bsx-20150107monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-33rd-annual-j-p-morgan-healthcare-conference-boston-sc-bsx-20141222monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-goldman-sachs-ceos-unscripted-healthcare-conference-bo-bsx-20141218monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-earns-top-marks-in-corporate-equality-index-boston-scientific-has-scored-bsx-20141119monthly0.5https://www.biopharmawatch.com/news/BSX/first-u-s-procedures-completed-with-the-symphion-hysteroscopic-tissue-removal-system-bosto-bsx-20141117monthly0.5https://www.biopharmawatch.com/news/BSX/subcutaneous-implantable-defibrillator-receives-favorable-coding-and-payment-designations--bsx-20141113monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-2014-stifel-healthcare-conference-boston-scientific-co-bsx-20141105monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-host-and-webcast-investor-event-boston-scientific-corporation-nyse-bs-bsx-20141104monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-schedule-for-presentations-at-the-upcoming-north-american-neur-bsx-20141103monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-2014-credit-suisse-annual-healthcare-conference-boston-bsx-20141030monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-third-quarter-ended-september-30-2014-boston-scien-bsx-20141022monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-fda-and-ce-mark-approval-for-new-coveredge-surgical-leads-for-t-bsx-20141021monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-initiates-study-of-promus-premier-coronary-stent-system-in-underserved-p-bsx-20141020monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-pacemaker-ce-mark-with-options-for-magnetic-resonance-imaging--bsx-20141016monthly0.5https://www.biopharmawatch.com/news/BSX/fda-advisory-committee-panel-votes-in-favor-of-the-watchman-left-atrial-appendage-closure--bsx-20141008monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-webcast-conference-call-discussing-third-quarter-2014-financial-resul-bsx-20141001monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-enrolls-first-patients-in-u-s-trial-of-the-lotus-valve-system-boston-sci-bsx-20140923monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-ce-mark-for-the-vercise-deep-brain-stimulation-dbs-system-for-t-bsx-20140917monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-schedule-for-presentations-at-upcoming-tct-2014-beginning-satu-bsx-20140910monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-2014-bank-of-america-merrill-lynch-global-healthcare-c-bsx-20140903monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-closes-acquisition-of-interventional-business-of-bayer-ag-boston-scienti-bsx-20140902monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-primary-endpoint-results-of-nectar-hf-clinical-trial-boston-sc-bsx-20140830monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-2014-morgan-stanley-global-healthcare-conference-bosto-bsx-20140825monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-and-asahi-intecc-announce-joint-development-and-manufacturing-programs-b-bsx-20140819monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-second-quarter-ended-june-30-2014-boston-scientifi-bsx-20140724monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-ce-mark-for-agent-drug-coated-balloon-continuing-to-advance-the-bsx-20140723monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-launches-polaris-imaging-system-boston-scientific-corporation-nyse-bsx-h-bsx-20140722monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-fda-approval-for-rebel-platinum-chromium-coronary-stent-system--bsx-20140721monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-ce-mark-for-ranger-drug-coated-balloon-demonstrating-its-contin-bsx-20140714monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-ce-mark-for-the-new-25-mm-lotus-valve-system-boston-scientific--bsx-20140714monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-webcast-conference-call-discussing-second-quarter-2014-financial-resu-bsx-20140701monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-one-year-results-in-the-vantage-clinical-study-evaluating-the--bsx-20140611monthly0.5https://www.biopharmawatch.com/news/BSX/clinical-study-results-demonstrate-therapeutic-advantages-of-the-boston-scientific-vercise-bsx-20140610monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-initiates-the-respond-post-market-registry-evaluating-clinical-outcomes--bsx-20140604monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-wells-fargo-2014-healthcare-conference-boston-scientif-bsx-20140603monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-goldman-sachs-35th-annual-global-healthcare-conference-bsx-20140603monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-lotus-valve-system-demonstrates-strong-performance-and-safety-profile-at-bsx-20140521monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-reports-strong-performance-data-for-synergy-stent-system-boston-scientif-bsx-20140521monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-definitive-agreement-to-acquire-interventional-division-of-bay-bsx-20140515monthly0.5https://www.biopharmawatch.com/news/BSX/study-of-boston-scientific-latitude-remote-patient-management-system-presented-at-heart-rh-bsx-20140510monthly0.5https://www.biopharmawatch.com/news/BSX/largest-randomized-clinical-trial-of-implantable-cardioverter-defibrillator-recipients-dem-bsx-20140508monthly0.5https://www.biopharmawatch.com/news/BSX/new-data-presented-at-wip-2014-demonstrate-sustained-low-back-pain-relief-with-the-boston--bsx-20140508monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-first-quarter-ended-march-31-2014-boston-scientifi-bsx-20140429monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-begins-clinical-trial-of-acuity-x4-lv-pacing-leads-and-reliance-4-front--bsx-20140422monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-host-and-webcast-investor-event-boston-scientific-corporation-nyse-bs-bsx-20140417monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-fda-approval-of-innovative-new-defibrillators-and-heart-failur-bsx-20140415monthly0.5https://www.biopharmawatch.com/news/BSX/first-patient-enrolled-in-clinical-registry-assessing-boston-scientific-vercise-deep-brain-bsx-20140410monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-begins-expansion-of-the-s-icd-system-in-asia-boston-scientific-corporati-bsx-20140407monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-introduces-the-expect-slimline-sl-needle-for-use-during-endoscopic-ultra-bsx-20140407monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-reports-key-data-at-acc-2014-for-cardiac-resynchronization-therapy-techn-bsx-20140401monthly0.5https://www.biopharmawatch.com/news/BSX/new-data-illustrate-long-term-safety-and-effectiveness-of-the-boston-scientific-s-icd-syst-bsx-20140401monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-webcast-conference-call-discussing-first-quarter-2014-financial-resul-bsx-20140401monthly0.5https://www.biopharmawatch.com/news/BSX/new-long-term-data-demonstrate-patients-with-mild-heart-failure-sustained-lower-mortality--bsx-20140330monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-schedule-for-presentations-at-american-college-of-cardiology-2-bsx-20140327monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-gibt-ce-kennzeichnung-und-erste-implantation-der-ingevity-mrt-schrittmac-bsx-20140326monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-anuncia-el-marcado-ce-y-primeros-implantes-para-los-electrodos-de-estimu-bsx-20140325monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-annuncia-l-ottenimento-del-marchio-ce-e-l-esecuzione-dei-primi-impianti--bsx-20140324monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-prestigious-shingo-award-for-operational-excellence-boston-scie-bsx-20140319monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-annonce-l-obtention-du-marquage-ce-et-les-premie-res-implantations-des-s-bsx-20140319monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-ce-mark-approval-and-first-implants-of-ingevity-tm-mri-pacing--bsx-20140314monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-ce-mark-approval-for-rebel-platinum-chromium-coronary-stent-sys-bsx-20140312monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-elects-edward-j-ludwig-to-its-board-of-directors-the-board-of-directors--bsx-20140303monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-the-barclays-2014-global-healthcare-conference-boston--bsx-20140228monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-wallflex-esophageal-stent-gains-ce-mark-for-the-treatment-of-refractory--bsx-20140214monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-fourth-quarter-and-full-year-ended-december-31-201-bsx-20140204monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-the-2014-leerink-swann-global-healthcare-conference-bo-bsx-20140203monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-webcast-conference-call-discussing-fourth-quarter-2013-financial-resu-bsx-20140121monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-names-craig-thompson-m-d-as-new-chief-medical-officer-interventional-car-bsx-20140106monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-32nd-annual-j-p-morgan-healthcare-conference-boston-sc-bsx-20140102monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-ce-mark-approval-and-first-implants-of-its-next-generation-x4--bsx-20131217monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-elects-david-roux-to-its-board-of-directors-the-board-of-directors-of-bo-bsx-20131216monthly0.5https://www.biopharmawatch.com/news/BSX/fda-advisory-panel-votes-favorably-on-the-boston-scientific-watchman-left-atrial-appendage-bsx-20131211monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-reports-favorable-results-assessing-real-world-experience-with-the-preci-bsx-20131206monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-and-the-medicines-company-announce-u-s-co-promotion-agreement-for-promus-bsx-20131206monthly0.5https://www.biopharmawatch.com/news/BSX/il-sistema-di-stimolazione-cerebrale-profonda-di-boston-scientific-vercise-riceve-l-approv-bsx-20131126monthly0.5https://www.biopharmawatch.com/news/BSX/el-sistema-de-estimulacio-n-cerebral-profunda-vercise-recibe-el-marcado-ce-para-el-tratami-bsx-20131126monthly0.5https://www.biopharmawatch.com/news/BSX/vercise-systeme-de-stimulation-cerebrale-profonde-de-boston-scientific-obtient-le-marquage-bsx-20131126monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-fda-approval-for-promus-premier-everolimus-eluting-platinum-chr-bsx-20131125monthly0.5https://www.biopharmawatch.com/news/BSX/das-vercise-system-zur-tiefen-hirnstimulation-von-boston-scientific-hat-die-ce-kennzeichnu-bsx-20131125monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-25th-annual-piper-jaffray-healthcare-conference-boston-bsx-20131122monthly0.5https://www.biopharmawatch.com/news/BSX/susan-lisa-named-vice-president-of-investor-relations-of-boston-scientific-boston-scientif-bsx-20131121monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-fda-clearance-and-ce-mark-approval-for-direxion-torqueable-micr-bsx-20131119monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-vercise-deep-brain-stimulation-system-receives-ce-mark-approval-for-trea-bsx-20131119monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-first-commercial-implants-of-the-lotus-valve-system-in-europe--bsx-20131115monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-completes-acquisition-of-bard-electrophysiology-boston-scientific-corpor-bsx-20131101monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-2013-credit-suisse-healthcare-conference-boston-scient-bsx-20131031monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-lotus-valve-system-meets-primary-performance-endpoint-in-reprise-ii-tria-bsx-20131031monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-schedule-of-major-presentations-at-transcatheter-cardiovascula-bsx-20131028monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-ce-mark-for-lotus-valve-system-boston-scientific-corporation-ny-bsx-20131028monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-transition-plan-for-new-chief-financial-officer-boston-scienti-bsx-20131024monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-third-quarter-ended-september-30-2013-boston-scien-bsx-20131024monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-prestigious-2013-prix-galien-award-for-best-medical-technology--bsx-20131023monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-alair-bronchial-thermoplasty-system-approved-in-china-boston-scientific--bsx-20131023monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-webcast-conference-call-discussing-third-quarter-2013-financial-resul-bsx-20131010monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-begins-clinical-trial-of-innova-peripheral-vascular-drug-eluting-stent-s-bsx-20131009monthly0.5https://www.biopharmawatch.com/news/BSX/new-data-published-in-ep-europace-journal-highlights-differences-in-crt-icd-battery-longev-bsx-20131008monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-reports-favorable-clinical-trial-results-assessing-the-offroad-re-entry--bsx-20131008monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-opens-institute-for-advancing-science-innovation-center-in-shanghai-rein-bsx-20130917monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-concludes-enrollment-in-randomized-multicenter-pivotal-study-of-synergy--bsx-20130912monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-2013-stifel-nicolaus-healthcare-conference-boston-scie-bsx-20130904monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-2013-morgan-stanley-global-healthcare-conference-bosto-bsx-20130903monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-fda-approval-for-intellatip-mifi-xp-ablation-catheter-and-510-k-bsx-20130821monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-completes-enrollment-in-supernova-trial-evaluating-innova-self-expanding-bsx-20130819monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-completes-1-05-billion-senior-notes-offering-boston-scientific-corporati-bsx-20130813monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-prices-1-05-billion-of-senior-notes-boston-scientific-corporation-nyse-b-bsx-20130808monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-second-quarter-ended-june-30-2013-boston-scientifi-bsx-20130725monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-launches-opticross-coronary-imaging-catheter-in-u-s-europe-and-japan-the-bsx-20130724monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-fda-510-k-clearance-for-the-rhythmia-mapping-system-boston-scie-bsx-20130724monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-launches-trial-to-evaluate-neurostimulation-for-treatment-of-chronic-mig-bsx-20130719monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-launches-guidezilla-guide-extension-catheter-in-u-s-and-europe-boston-sc-bsx-20130712monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-webcast-conference-call-discussing-second-quarter-2013-financial-resu-bsx-20130711monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-acquire-c-r-bard-electrophysiology-business-in-a-move-that-would-sign-bsx-20130628monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-vercise-dbs-system-demonstrates-improvement-in-motor-function-for-patien-bsx-20130618monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-begins-patient-enrollment-in-u-s-clinical-trial-for-use-of-vercise-dbs-s-bsx-20130617monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-collaboration-with-pelvic-floor-disorders-network-to-study-tre-bsx-20130603monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-ce-mark-approval-for-guide-dbs-system-boston-scientific-corpora-bsx-20130527monthly0.5https://www.biopharmawatch.com/news/BSX/new-data-demonstrate-significant-and-sustained-blood-pressure-reduction-with-boston-scient-bsx-20130522monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-reports-lotus-valve-system-met-primary-performance-endpoint-in-reprise-i-bsx-20130522monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-promus-premier-and-synergy-drug-eluting-stent-systems-provide-exceptiona-bsx-20130522monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-long-term-data-demonstrate-bronchial-thermoplasty-treatment-benefits-per-bsx-20130521monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-presents-clinical-data-at-digestive-disease-week-boston-scientific-corpo-bsx-20130517monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-schedule-of-major-events-and-presentations-at-europcr-2013-boston-scient-bsx-20130517monthly0.5https://www.biopharmawatch.com/news/BSX/first-patient-enrolled-in-boston-scientific-randomized-study-comparing-wallflex-biliary-rx-bsx-20130515monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-ce-mark-approval-for-the-rhythmia-mapping-system-boston-scienti-bsx-20130510monthly0.5https://www.biopharmawatch.com/news/BSX/new-four-year-data-from-boston-scientific-demonstrated-watchman-device-was-superior-to-war-bsx-20130509monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-the-bank-of-america-merrill-lynch-2013-healthcare-conf-bsx-20130508monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-completes-first-in-human-clinical-trial-of-the-intellatip-mifi-xp-ablati-bsx-20130506monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-schedule-of-major-events-and-presentations-at-heart-rhythm-2013-boston-s-bsx-20130503monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-first-quarter-ended-march-31-2013-boston-scientifi-bsx-20130425monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-begins-clinical-trial-to-evaluate-new-pacing-system-in-mri-environment-t-bsx-20130415monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-launches-precision-spectra-spinal-cord-stimulator-system-in-the-united-s-bsx-20130412monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-webcast-conference-call-discussing-first-quarter-2013-financial-resul-bsx-20130410monthly0.5https://www.biopharmawatch.com/news/BSX/the-boston-scientific-promus-element-platinum-chromium-stent-demonstrates-continued-low-ev-bsx-20130310monthly0.5https://www.biopharmawatch.com/news/BSX/presentation-of-preliminary-results-from-boston-scientific-prevail-clinical-trial-now-avai-bsx-20130309monthly0.5https://www.biopharmawatch.com/news/BSX/the-boston-scientific-watchman-device-continues-to-demonstrate-positive-clinical-outcomes--bsx-20130309monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-launches-rubicon-support-catheter-in-0-035-and-0-018-diameters-boston-sc-bsx-20130306monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-updates-prevail-late-breaking-clinical-trials-presentation-the-boston-sc-bsx-20130306monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-2013-rbc-capital-markets-healthcare-conference-boston--bsx-20130221monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-the-citi-2013-global-healthcare-conference-boston-scie-bsx-20130220monthly0.5https://www.biopharmawatch.com/news/BSX/promus-premier-everolimus-eluting-platinum-chromium-stent-system-receives-ce-mark-approval-bsx-20130212monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-2013-leerink-swann-global-healthcare-conference-boston-bsx-20130206monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-fourth-quarter-and-full-year-ended-december-31-201-bsx-20130129monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2012--bsx-20130117monthly0.5https://www.biopharmawatch.com/news/BSX/first-patient-treated-in-the-boston-scientific-zero-af-clinical-trial-to-evaluate-the-safe-bsx-20130116monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-host-and-webcast-investor-day-meeting-on-february-12-2013-boston-scie-bsx-20130108monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-31st-annual-j-p-morgan-healthcare-conference-boston-sc-bsx-20121220monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-begins-clinical-trial-of-patients-implanted-with-ingevity-pacing-leads-t-bsx-20121217monthly0.5https://www.biopharmawatch.com/news/BSX/the-boston-scientific-close-the-gap-crossroads-classic-brings-a-healthy-heart-message-to-b-bsx-20121212monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-european-regulatory-approval-for-new-precision-spectra-spinal-c-bsx-20121207monthly0.5https://www.biopharmawatch.com/news/BSX/first-patient-enrolled-in-boston-scientific-randomized-study-of-removable-wallflex-biliary-bsx-20121204monthly0.5https://www.biopharmawatch.com/news/BSX/first-patient-enrolled-in-the-boston-scientific-multicenter-study-of-the-synergy-coronary--bsx-20121130monthly0.5https://www.biopharmawatch.com/news/BSX/la-marca-ce-certifica-la-larga-duracio-n-de-los-desfibriladores-de-boston-scientific-se-ca-bsx-20121120monthly0.5https://www.biopharmawatch.com/news/BSX/les-defibrillateurs-de-boston-scientific-obtiennent-le-marquage-ce-pour-leur-longevite-ete-bsx-20121120monthly0.5https://www.biopharmawatch.com/news/BSX/defibrillatoren-von-boston-scientific-erhalten-ce-kennzeichnung-fu-r-la-ngere-funktionsdau-bsx-20121120monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-acquire-vessix-vascular-inc-boston-scientific-corporation-nyse-bsx-is-bsx-20121108monthly0.5https://www.biopharmawatch.com/news/BSX/improved-device-programming-reduces-inappropriate-therapy-and-risk-of-death-for-implantabl-bsx-20121106monthly0.5https://www.biopharmawatch.com/news/BSX/michael-f-mahoney-assumes-role-of-chief-executive-officer-and-president-of-boston-scientif-bsx-20121101monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-ce-mark-approval-for-the-synergy-everolimus-eluting-platinum-ch-bsx-20121031monthly0.5https://www.biopharmawatch.com/news/BSX/promus-element-and-promus-element-plus-receive-ce-mark-approval-for-labeling-update-to-inc-bsx-20121024monthly0.5https://www.biopharmawatch.com/news/BSX/the-boston-scientific-epic-stent-continues-to-demonstrate-positive-clinical-outcomes-for-p-bsx-20121023monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-demonstrates-ongoing-structural-heart-advances-at-transcatheter-cardiova-bsx-20121023monthly0.5https://www.biopharmawatch.com/news/BSX/the-boston-scientific-promus-element-platinum-chromium-stent-demonstrates-positive-outcome-bsx-20121023monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-schedule-of-major-presentations-at-transcatheter-cardiovascular-therapie-bsx-20121018monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-third-quarter-2012-results-boston-scientific-corporation-nyse--bsx-20121018monthly0.5https://www.biopharmawatch.com/news/BSX/first-patient-enrolled-in-reprise-ii-tavr-clinical-trial-to-evaluate-the-safety-and-perfor-bsx-20121010monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-launches-victory-guidewire-for-crossing-resistant-lesions-in-peripheral--bsx-20121009monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-announce-third-quarter-2012-financial-results-on-october-18th-boston--bsx-20121008monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-acquire-rhythmia-medical-inc-boston-scientific-corporation-nyse-bsx-h-bsx-20121008monthly0.5https://www.biopharmawatch.com/news/BSX/new-public-awareness-campaign-launched-to-promote-awareness-of-pelvic-floor-disorders-and--bsx-20121003monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-fda-approval-of-first-in-class-s-icd-system-for-patients-at-ris-bsx-20120928monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-launches-vercise-deep-brain-stimulation-system-in-europe-boston-scientif-bsx-20120928monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-launches-emerge-ptca-balloon-dilatation-catheter-in-the-u-s-boston-scien-bsx-20120927monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-launches-new-implantable-defibrillation-lead-in-europe-and-asia-boston-s-bsx-20120924monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-acquire-bridgepoint-medical-inc-boston-scientific-corporation-nyse-bs-bsx-20120919monthly0.5https://www.biopharmawatch.com/news/BSX/bronchial-thermoplasty-awarded-category-i-cpt-procedure-codes-the-american-medical-associa-bsx-20120919monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-the-2012-morgan-stanley-global-healthcare-conference-b-bsx-20120906monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-watchman-left-atrial-appendage-closure-device-receives-ce-mark-approval--bsx-20120826monthly0.5https://www.biopharmawatch.com/news/BSX/la-famiglia-di-pacemaker-ingenio-di-boston-scientific-riceveilmarchio-ce-per-la-sua-compat-bsx-20120801monthly0.5https://www.biopharmawatch.com/news/BSX/la-familia-de-marcapasos-ingenio-de-boston-scientific-obtiene-el-marcado-ce-para-su-uso-du-bsx-20120801monthly0.5https://www.biopharmawatch.com/news/BSX/la-gamme-de-stimulateurs-cardiaques-ingenio-de-boston-scientific-obtient-le-marquage-ce-po-bsx-20120801monthly0.5https://www.biopharmawatch.com/news/BSX/die-familie-der-ingenio-herzschrittmacher-erha-lt-die-ce-kennzeichnung-fu-r-den-einsatz-be-bsx-20120801monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-second-quarter-2012-results-boston-scientific-corporation-nyse-bsx-20120726monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-promising-clinical-data-on-new-products-at-the-international-s-bsx-20120718monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-announce-second-quarter-2012-financial-results-on-july-26-boston-scie-bsx-20120712monthly0.5https://www.biopharmawatch.com/news/BSX/el-sistema-s-icd-de-boston-scientific-reconocido-como-el-producto-ma-s-innovador-en-cardio-bsx-20120704monthly0.5https://www.biopharmawatch.com/news/BSX/s-icd-system-von-boston-scientific-auf-dem-cardiostim-2012-zum-innovativsten-produkt-geku--bsx-20120704monthly0.5https://www.biopharmawatch.com/news/BSX/il-sistema-s-icd-di-boston-scientific-eletto-il-prodotto-piu-innovativo-a-cardiostim-2012--bsx-20120704monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-completes-patient-enrollment-in-prevail-study-for-first-in-class-watchma-bsx-20120702monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-commends-congress-on-passage-of-bill-reauthorizing-medical-device-user-f-bsx-20120626monthly0.5https://www.biopharmawatch.com/news/BSX/el-sistema-de-monitorizacio-n-remota-de-pacientes-latitude-nxt-de-boston-scientific-ya-es--bsx-20120619monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-annonce-la-premie-re-activation-du-systeme-de-suivi-a-distance-latitude--bsx-20120619monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-gibt-den-ersten-einsatz-des-patientenmanagementsystems-latitude-nxt-zur--bsx-20120618monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-annuncia-il-monitoraggio-remoto-del-primo-paziente-con-il-nuovo-sistema--bsx-20120618monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-closes-cameron-health-acquisition-boston-scientific-corporation-nyse-bsx-bsx-20120608monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-present-an-overview-of-its-endoscopy-business-boston-scientific-corpo-bsx-20120606monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-fda-approval-for-32-mm-and-38-mm-lengths-for-promus-element-plu-bsx-20120604monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-increases-longevity-projections-for-its-u-s-defibrillators-the-u-s-food--bsx-20120531monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-expanded-indication-for-cre-wireguided-balloon-dilator-boston--bsx-20120529monthly0.5https://www.biopharmawatch.com/news/BSX/le-stent-promus-element-demontre-une-se-curite-d-emploi-et-une-efficacite-a-long-terme-exc-bsx-20120524monthly0.5https://www.biopharmawatch.com/news/BSX/lo-stent-promus-element-dimostra-ottima-sicurezza-ed-efficacia-a-lungo-termine-nello-studi-bsx-20120522monthly0.5https://www.biopharmawatch.com/news/BSX/platinum-small-vessel-studie-zeigt-hervorragende-langzeitergebnisse-zur-sicherheit-und-wir-bsx-20120521monthly0.5https://www.biopharmawatch.com/news/BSX/el-stent-promus-element-demuestra-una-seguridad-y-efectividad-excelentes-en-el-estudio-pla-bsx-20120521monthly0.5https://www.biopharmawatch.com/news/BSX/les-donnees-a-un-an-de-l-etude-clinique-evolve-confirment-des-resultats-de-securite-et-d-e-bsx-20120521monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-annonce-les-resultats-positifs-de-l-etude-clinique-menee-sur-la-valve-ao-bsx-20120518monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-endoscopy-presents-promising-clinical-data-during-digestive-disease-week-bsx-20120518monthly0.5https://www.biopharmawatch.com/news/BSX/promus-element-stent-demonstrates-excellent-long-term-safety-and-effectiveness-in-platinum-bsx-20120518monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-fda-approval-and-u-s-launch-of-epic-vascular-stent-boston-scie-bsx-20120517monthly0.5https://www.biopharmawatch.com/news/BSX/los-resultados-al-cabo-de-un-an-o-del-estudio-cli-nico-evolve-confirman-que-los-datos-de-s-bsx-20120516monthly0.5https://www.biopharmawatch.com/news/BSX/einjahresdatender-klinischen-studie-evolve-besta-tigen-sicherheit-und-wirksamkeit-des-syne-bsx-20120515monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-annuncia-i-risultati-positivi-dello-studio-sulla-valvola-aortica-transca-bsx-20120515monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-gibt-positive-daten-von-einer-studie-zum-transkatheter-aortenklappen-sys-bsx-20120515monthly0.5https://www.biopharmawatch.com/news/BSX/one-year-evolve-trial-clinical-results-confirm-comparable-safety-and-effectiveness-data-of-bsx-20120515monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-positive-data-from-lotus-transcatheter-aortic-valve-trial-bost-bsx-20120515monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-annonce-le-marquage-ce-et-le-lancement-europeen-de-son-stent-metallique--bsx-20120515monthly0.5https://www.biopharmawatch.com/news/BSX/i-risultati-ad-un-anno-dello-studio-clinico-evolve-confermano-che-lo-stent-synergy-possied-bsx-20120515monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-annuncia-il-ricevimento-della-marcatura-ce-e-il-lancio-in-europa-dello-s-bsx-20120514monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-gibt-ce-kennzeichnung-und-europa-ische-markteinfu-hrung-des-selbstexpand-bsx-20120514monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-ce-mark-and-european-launch-of-innova-self-expanding-bare-meta-bsx-20120514monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-and-philips-healthcare-announce-collaboration-to-enhance-imaging-equipme-bsx-20120514monthly0.5https://www.biopharmawatch.com/news/BSX/study-of-first-in-class-watchman-device-shows-75-percent-reduction-in-stroke-risk-in-patie-bsx-20120511monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-gibt-eine-branchenfu-hrende-garantiezeit-von-10-jahren-fu-r-icd-und-crt--bsx-20120511monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-innove-en-offrant-des-garanties-etendues-jusqua-10ans-pour-ses-dai-et-cr-bsx-20120511monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-presenta-garanti-as-de-hasta-10-an-os-para-los-dai-y-crt-d-li-deres-del--bsx-20120511monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-presenta-la-garanzia-piu-estesa-del-settore-fino-a-10-anni-per-i-disposi-bsx-20120511monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-schedule-for-europcr-2012-boston-scientific-corporation-nyse-b-bsx-20120510monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-fda-approval-and-first-u-s-implant-of-new-devices-to-treat-bra-bsx-20120507monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-schedule-for-heart-rhythm-society-scientific-sessions-boston-s-bsx-20120503monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-deutsche-bank-37th-annual-health-care-conference-on-ma-bsx-20120426monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-ce-mark-and-european-launch-of-emerge-ptca-dilatation-catheter-bsx-20120424monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-completes-enrollment-in-clinical-trial-to-evaluate-lotus-aortic-valve-sy-bsx-20120423monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-first-quarter-2012-results-boston-scientific-corporation-nyse--bsx-20120419monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-annonce-le-lancement-en-europe-de-la-gamme-de-stimulateurs-cardiaques-in-bsx-20120411monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-u-s-launch-of-z-flex-270-steerable-sheath-boston-scientific-co-bsx-20120411monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-anuncia-la-comercializacio-n-en-europa-de-la-familia-de-marcapasos-ingen-bsx-20120410monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-meldet-die-einfu-hrung-der-ingenio-herzschrittmacher-in-europa-die-neuen-bsx-20120410monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-annuncia-la-commercializzazione-in-europa-della-famiglia-di-pacemaker-in-bsx-20120410monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-launch-of-ingenio-family-of-pacemakers-in-europe-boston-scient-bsx-20120410monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-announce-first-quarter-2012-financial-results-on-april-19-boston-scie-bsx-20120410monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-launches-innovative-device-used-to-prevent-stone-migration-in-urologic-p-bsx-20120402monthly0.5https://www.biopharmawatch.com/news/BSX/bronchial-thermoplasty-with-boston-scientific-s-alair-system-meets-all-criteria-of-califor-bsx-20120327monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-supports-new-clinical-trial-to-evaluate-platinum-chromium-coronary-stent-bsx-20120326monthly0.5https://www.biopharmawatch.com/news/BSX/landmark-analysis-of-year-two-data-from-platinum-workhorse-trial-demonstrates-superior-eff-bsx-20120325monthly0.5https://www.biopharmawatch.com/news/BSX/analysis-of-two-randomized-clinical-trials-identify-no-cases-of-longitudinal-stent-deforma-bsx-20120325monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-begins-u-s-and-international-launch-of-wallflex-biliary-transhepatic-ste-bsx-20120322monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-new-clinical-data-to-be-presented-at-acc-2012-on-the-market-le-bsx-20120320monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-welcomes-positive-private-insurance-coverage-decisions-for-bronchial-the-bsx-20120319monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-health-canada-approval-of-blazer-open-irrigated-catheter-bosto-bsx-20120315monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-vor-der-u-bernahme-von-cameron-health-inc-damit-erwirbt-das-unternehmen--bsx-20120313monthly0.5https://www.biopharmawatch.com/news/BSX/acquisition-de-cameron-health-inc-par-boston-scientific-boston-scientific-va-acque-rir-la--bsx-20120313monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-comprara-cameron-health-inc-la-empresa-se-hace-con-la-primera-y-u-nica-t-bsx-20120313monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-annuncia-l-acquisizione-di-cameron-health-inc-l-azienda-ottiene-la-prima-bsx-20120313monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-renews-agreement-with-lumenis-to-deliver-innovative-laser-products-to-tr-bsx-20120308monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-acquire-cameron-health-inc-boston-scientific-corporation-nyse-bsx-ann-bsx-20120308monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-launch-of-promus-element-platinum-chromium-stent-system-in-jap-bsx-20120301monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-first-implants-of-teligen-implantable-defibrillator-in-china-b-bsx-20120223monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-2012-rbc-capital-markets-global-healthcare-conference--bsx-20120222monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-industry-s-first-fda-approval-for-drug-eluting-coronary-stent-u-bsx-20120222monthly0.5https://www.biopharmawatch.com/news/BSX/moody-s-raises-boston-scientific-s-credit-rating-to-investment-grade-boston-scientific-cor-bsx-20120213monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-launches-innovative-crossing-device-to-treat-complete-blockages-in-perip-bsx-20120208monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-wallflex-enteral-stents-shown-to-be-safe-and-effective-in-three-clinical-bsx-20120207monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-leerink-swann-2012-global-healthcare-conference-boston-bsx-20120207monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-global-launch-of-expect-19-flex-endoscopic-ultrasound-aspirati-bsx-20120206monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-fourth-quarter-and-full-year-ended-december-31-201-bsx-20120202monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-anuncia-el-primer-implante-y-la-presentacio-n-en-el-mercado-del-stent-co-bsx-20120201monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-annuncia-il-primo-impianto-e-la-commercializzazione-in-europa-dello-sten-bsx-20120201monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-gibt-erste-implantation-des-stent-systems-promus-element-plus-in-europa--bsx-20120201monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-annonce-la-premie-re-implantation-et-la-commercialisation-du-stent-promu-bsx-20120201monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-first-implant-and-market-launch-of-promus-element-plus-stent-s-bsx-20120201monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-favorable-ruling-in-patent-infringement-case-boston-scientific-bsx-20120123monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2011--bsx-20120120monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-epic-stent-demonstrates-positive-clinical-outcomes-in-orion-trial-boston-bsx-20120116monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-30th-annual-j-p-morgan-healthcare-conference-boston-sc-bsx-20120103monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-launches-charger-pta-balloon-catheter-boston-scientific-corporation-nyse-bsx-20111212monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-fda-approval-for-new-infinion-16-percutaneous-lead-for-precisio-bsx-20111208monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-introduces-industry-leading-icd-and-crt-d-device-warranties-boston-scien-bsx-20111130monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-2011-piper-jaffray-23rd-annual-healthcare-conference-b-bsx-20111118monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-s-watchman-device-implanted-in-first-patients-in-latin-america-boston-sc-bsx-20111116monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-applauds-introduction-of-patient-access-to-medical-innovation-act-boston-bsx-20111115monthly0.5https://www.biopharmawatch.com/news/BSX/cryoplasty-therapy-with-boston-scientific-polarcath-dilatation-system-reduces-restenosis-r-bsx-20111111monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-synergy-stent-demonstrates-comparable-safety-and-effectiveness-outcomes--bsx-20111111monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-cre-wireguided-balloon-dilator-ce-marked-for-expanded-indication-now-ava-bsx-20111109monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-s-promus-element-platinum-chromium-stent-demonstrates-excellent-outcomes-bsx-20111108monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-platinum-chromium-ion-stent-demonstrates-positive-outcomes-in-perseus-cl-bsx-20111108monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-carotid-wallstent-found-safe-in-study-of-high-surgical-risk-patients-in--bsx-20111108monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-spyglass-direct-visualization-system-demonstrates-high-procedural-succes-bsx-20111102monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-schedule-of-events-at-tct-scientific-symposium-boston-scientif-bsx-20111101monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-exceeds-third-quarter-eps-guidance-repurchases-30-million-shares-boston--bsx-20111020monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-completes-enrollment-in-benign-stricture-study-of-wallflex-biliary-rx-st-bsx-20111018monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-launches-promus-element-stent-system-in-china-boston-scientific-corporat-bsx-20111017monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-welcomes-introduction-of-medical-device-regulatory-improvement-act-in-u--bsx-20111014monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-webcast-conference-call-discussing-third-quarter-2011-financial-resul-bsx-20111011monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-begins-clinical-trial-enrollment-for-omega-platinum-chromium-stent-syste-bsx-20111005monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-begins-enrollment-in-nectar-hf-clinical-trial-boston-scientific-corporat-bsx-20110929monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-favorable-appellate-court-ruling-affirming-non-infringement-of-bsx-20110928monthly0.5https://www.biopharmawatch.com/news/BSX/les-donne-es-cliniques-de-montrent-la-se-curite-a-long-terme-du-syste-me-de-thermoplastie--bsx-20110927monthly0.5https://www.biopharmawatch.com/news/BSX/los-datos-cli-nicos-demuestran-la-seguridad-a-largo-plazo-de-alair-el-sistema-de-termoplas-bsx-20110927monthly0.5https://www.biopharmawatch.com/news/BSX/klinische-daten-zeigen-langzeit-sicherheit-des-alair-tm-systems-zur-bronchialen-thermoplas-bsx-20110927monthly0.5https://www.biopharmawatch.com/news/BSX/i-dati-clinici-dimostrano-la-sicurezza-a-lungo-termine-di-alair-tm-il-sistema-di-termoplas-bsx-20110927monthly0.5https://www.biopharmawatch.com/news/BSX/clinical-data-demonstrates-long-term-safety-of-boston-scientific-s-alair-tm-bronchial-ther-bsx-20110927monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-launches-coyote-balloon-catheter-boston-scientific-corporation-nyse-bsx--bsx-20110919monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-sponsors-new-patient-portal-dedicated-to-pelvic-floor-disorders-boston-s-bsx-20110915monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-names-michael-f-mahoney-as-company-president-announces-ceo-transition-pl-bsx-20110913monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-issues-statement-regarding-fda-advisory-committee-meeting-on-surgical-me-bsx-20110909monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-2011-morgan-stanley-global-healthcare-conference-bosto-bsx-20110902monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-launches-neuromodulation-learning-institute-to-enhance-clinical-educatio-bsx-20110810monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-favorable-court-ruling-dismissing-securities-fraud-case-boston-bsx-20110808monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-second-quarter-results-exceed-consensus-sales-and-eps-full-year-guidance-bsx-20110728monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-1-0b-share-repurchase-program-boston-scientific-corporation-s--bsx-20110728monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-five-year-150-million-investment-in-china-to-accelerate-commer-bsx-20110727monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-s-credit-rating-raised-to-investment-grade-boston-scientific-corporation-bsx-20110721monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-webcast-conference-call-discussing-second-quarter-2011-financial-resu-bsx-20110714monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-completes-clinical-trial-enrollment-for-adapt-monorail-carotid-stent-sys-bsx-20110712monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-welcomes-publication-of-landmark-report-on-chronic-pain-boston-scientifi-bsx-20110630monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-u-s-and-european-launch-of-interlock-35-fibered-idc-occlusion--bsx-20110630monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-welcomes-passage-of-patent-reform-bill-boston-scientific-corporation-nys-bsx-20110627monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-global-launch-of-mustang-pta-balloon-catheter-boston-scientifi-bsx-20110620monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-2011-wells-fargo-securities-healthcare-conference-bost-bsx-20110616monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-favorable-appellate-court-ruling-affirming-invalidity-of-j-j-p-bsx-20110607monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-voluntary-recall-of-icross-coronary-imaging-catheters-boston-s-bsx-20110527monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-fda-approval-and-u-s-launch-of-promus-2-25-mm-everolimus-eluti-bsx-20110525monthly0.5https://www.biopharmawatch.com/news/BSX/la-nueva-fijacio-n-click-tm-de-boston-scientific-para-el-sistema-de-estimulacio-n-de-la-me-bsx-20110523monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-obtient-le-marquage-ce-pour-le-nouveau-dispositif-clik-tm-anchor-du-syst-bsx-20110523monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-gibt-ce-kennzeichnung-des-neuen-clik-tm-ankers-fu-r-das-ru-ckenmarkstimu-bsx-20110523monthly0.5https://www.biopharmawatch.com/news/BSX/el-stent-promus-element-tm-demuestra-una-seguridad-y-efectividad-excepcionales-en-el-estud-bsx-20110523monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-riceve-la-marcatura-ce-del-nuovo-sistema-di-ancoraggio-clik-tm-per-il-si-bsx-20110523monthly0.5https://www.biopharmawatch.com/news/BSX/lo-stent-promus-element-tm-dimostra-sicurezza-ed-efficacia-straordinarie-nello-studio-plat-bsx-20110523monthly0.5https://www.biopharmawatch.com/news/BSX/l-e-tude-clinique-platinum-petits-vaisseaux-demontre-une-se-curite-d-emploi-et-une-efficac-bsx-20110523monthly0.5https://www.biopharmawatch.com/news/BSX/platinum-small-vessel-zeigt-hervorragende-sicherheits-und-wirksamkeitsergebnisse-fu-r-den--bsx-20110523monthly0.5https://www.biopharmawatch.com/news/BSX/promus-element-stent-demonstrates-exceptional-safety-and-effectiveness-in-platinum-small-v-bsx-20110520monthly0.5https://www.biopharmawatch.com/news/BSX/favorable-clinical-study-results-reported-with-dual-anti-platelet-therapy-after-laa-closur-bsx-20110518monthly0.5https://www.biopharmawatch.com/news/BSX/long-term-safety-and-effectiveness-of-bronchial-thermoplasty-demonstrated-in-treating-seve-bsx-20110516monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-favorable-jury-verdict-against-cordis-corporation-in-stent-pat-bsx-20110511monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-commercializza-in-tutto-il-mondo-l-ago-per-aspirazione-ecoendoscopica-ex-bsx-20110511monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-retirement-of-ray-elliott-as-president-and-ceo-effective-end-o-bsx-20110510monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-supports-asthma-awareness-month-with-donation-to-asthma-foundation-bosto-bsx-20110510monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-debute-la-commercialisation-mondiale-d-expect-tm-aiguille-d-aspiration-p-bsx-20110510monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-bringt-weltweit-die-aspirationsnadel-expect-tm-fu-r-die-ultraschall-endo-bsx-20110510monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-lanza-al-mercado-en-todo-el-mundo-la-aguja-de-aspiracio-n-guiada-por-eco-bsx-20110509monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-begins-u-s-and-international-launch-of-expect-endoscopic-ultrasound-aspi-bsx-20110509monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-de-bute-la-commercialisation-et-les-premie-res-implantations-internation-bsx-20110509monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-beginnt-mit-der-internationaler-vermarktung-und-dem-einsatz-einer-neuen--bsx-20110509monthly0.5https://www.biopharmawatch.com/news/BSX/presentacio-n-en-el-mercado-internacional-y-primeros-implantes-de-dispositivos-de-nueva-ge-bsx-20110506monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-begins-international-launch-and-first-implants-of-next-generation-device-bsx-20110506monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-offers-new-crt-d-warranty-program-covering-phrenic-nerve-stimulation-bos-bsx-20110505monthly0.5https://www.biopharmawatch.com/news/BSX/altitude-clinical-data-show-icd-therapy-saves-lives-without-mortality-increase-from-device-bsx-20110505monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-s-spyglass-direct-visualization-system-achieves-global-utilization-miles-bsx-20110504monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-ce-mark-approval-and-first-use-of-blazer-open-irrigated-cathet-bsx-20110503monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-its-schedule-for-heart-rhythm-society-scientific-sessions-bost-bsx-20110502monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-bank-of-america-merrill-lynch-2011-health-care-confere-bsx-20110427monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-deutsche-bank-36th-annual-health-care-conference-bosto-bsx-20110426monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-fda-approval-and-u-s-launch-of-ion-platinum-chromium-stent-sys-bsx-20110425monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-first-quarter-ended-march-31-2011-boston-scientifi-bsx-20110420monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-webcast-conference-call-discussing-first-quarter-2011-financial-resul-bsx-20110414monthly0.5https://www.biopharmawatch.com/news/BSX/el-stent-promus-element-tm-de-cromo-platino-de-boston-scientific-demuestra-resultados-de-s-bsx-20110405monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-begins-international-clinical-trial-enrollment-for-innova-self-expanding-bsx-20110405monthly0.5https://www.biopharmawatch.com/news/BSX/l-etude-clinique-platinum-workhorse-de-montre-une-se-curite-d-emploi-et-une-efficacite-com-bsx-20110405monthly0.5https://www.biopharmawatch.com/news/BSX/promus-element-tm-il-sistema-di-stent-in-platino-e-cromo-di-boston-scientific-ha-dimostrat-bsx-20110405monthly0.5https://www.biopharmawatch.com/news/BSX/platinum-studie-zeigt-vergleichbare-sicherheits-und-wirksamkeitsergebnisse-fu-r-das-platin-bsx-20110405monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-s-promus-element-platinum-chromium-stent-system-demonstrates-comparable--bsx-20110404monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-ion-platinum-chromium-stent-system-demonstrates-strong-performance-in-an-bsx-20110403monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-its-acc-2011-schedule-boston-scientific-corporation-nyse-bsx-t-bsx-20110329monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-fda-approval-of-new-clik-tm-anchor-for-precision-plus-tm-spinal-bsx-20110324monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-gibt-erste-implantationen-des-platin-chrom-koronarstentsystems-omega-tm--bsx-20110323monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-webcast-analyst-event-boston-scientific-corporation-nyse-bsx-today-an-bsx-20110322monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-annuncia-i-primi-impianti-dello-stent-omega-tm-in-platino-cromo-lo-stent-bsx-20110321monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-anuncia-los-primeros-implantes-en-espan-a-del-stent-coronario-de-cromo-p-bsx-20110321monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-gibt-europa-ische-zulassung-und-markteinfu-hrung-des-platin-chrom-stents-bsx-20110310monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-present-at-barclays-capital-2011-global-healthcare-conference-boston--bsx-20110308monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-annonce-le-marquage-ce-et-la-commercialisation-en-europe-d-omega-tm-sten-bsx-20110307monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-annuncia-l-approvazione-in-europa-ed-il-lancio-dello-stent-omega-tm-in-p-bsx-20110307monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-anuncia-la-aprobacio-n-y-comercializacio-n-en-europa-del-stent-coronario-bsx-20110307monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-european-approval-and-launch-of-omega-tm-platinum-chromium-ste-bsx-20110307monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-strengthens-structural-heart-product-portfolio-by-completing-acquisition-bsx-20110303monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-launches-promus-element-and-taxus-element-stent-systems-in-india-boston--bsx-20110217monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-2011-rbc-capital-markets-healthcare-conference-boston--bsx-20110216monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-establishes-endowment-for-donald-s-baim-m-d-scholarship-at-yale-school-o-bsx-20110215monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-acquires-two-novel-technologies-to-treat-peripheral-chronic-total-occlus-bsx-20110215monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-welcomes-publication-of-gender-data-highlighting-benefits-women-receive--bsx-20110208monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-fourth-quarter-and-full-year-ended-december-31-201-bsx-20110201monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-fda-approval-of-renegade-hi-flo-fathom-pre-loaded-system-bosto-bsx-20110131monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-responds-to-doj-civil-lawsuit-boston-scientific-corporation-nyse-bsx-tod-bsx-20110128monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-first-use-of-blazer-open-irrigated-catheter-in-u-s-boston-scie-bsx-20110127monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-begins-clinical-trial-enrollment-in-china-for-promus-element-everolimus--bsx-20110126monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-completes-enrollment-in-evolve-clinical-trial-to-evaluate-synergy-drug-e-bsx-20110124monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2010--bsx-20110119monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-acquire-atritech-boston-scientific-corporation-nyse-bsx-today-announc-bsx-20110119monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-agreement-with-fukuda-denshi-for-distribution-of-cardiac-rhyth-bsx-20110119monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-completes-enrollment-in-clinical-trial-evaluating-next-generation-nitino-bsx-20110110monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-acquires-intelect-medical-boston-scientific-corporation-nyse-bsx-today-a-bsx-20110105monthly0.5https://www.biopharmawatch.com/news/BSX/statement-of-kenneth-stein-m-d-chief-medical-officer-cardiac-rhythm-management-boston-scie-bsx-20110104monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-completes-acquisition-of-sadra-medical-boston-scientific-corporation-nys-bsx-20110104monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-completes-sale-of-neurovascular-business-boston-scientific-corporation-n-bsx-20110103monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-present-at-29th-annual-j-p-morgan-healthcare-conference-boston-scient-bsx-20101227monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-election-of-dr-kristina-m-johnson-to-its-board-of-directors-bo-bsx-20101220monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-welcomes-publication-of-analysis-of-patients-monitored-by-the-latitude-p-bsx-20101207monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-piper-jaffray-health-care-conference-boston-scientific-bsx-20101122monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-acquire-sadra-medical-boston-scientific-corporation-nyse-bsx-today-an-bsx-20101119monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-annuncia-l-approvazione-della-marcatura-ce-e-i-primi-impianti-dei-nuovi--bsx-20101119monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-ce-mark-approval-and-first-implants-for-new-devices-to-treat-h-bsx-20101119monthly0.5https://www.biopharmawatch.com/news/BSX/alair-bronchial-thermoplasty-system-named-best-of-what-s-new-by-popular-science-boston-sci-bsx-20101117monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-sponsorship-of-world-diabetes-day-campaign-2010-boston-scienti-bsx-20101111monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-webcast-investor-day-meeting-boston-scientific-corporation-nyse-bsx-t-bsx-20101110monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-begins-patient-enrollment-in-clinical-trial-assessing-deep-brain-stimula-bsx-20101109monthly0.5https://www.biopharmawatch.com/news/BSX/bronchial-thermoplasty-demonstrates-long-term-asthma-control-in-patients-with-severe-asthm-bsx-20101102monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-agrees-to-sell-neurovascular-business-to-stryker-boston-scientific-corpo-bsx-20101028monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-completes-acquisition-of-asthmatx-boston-scientific-corporation-nyse-bsx-bsx-20101026monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-ce-mark-approval-for-expanded-indication-of-wallflex-biliary-r-bsx-20101022monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-annuncia-l-approvazione-della-marcatura-ce-per-l-espansione-dell-indicaz-bsx-20101022monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-annuncia-l-autorizzazione-della-fda-e-l-approvazione-della-marcatura-ce--bsx-20101021monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-fda-clearance-and-ce-mark-approval-for-advanix-biliary-stents--bsx-20101021monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-results-for-third-quarter-ended-september-30-2010-boston-scien-bsx-20101019monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-global-launch-of-journey-guidewire-boston-scientific-corporati-bsx-20101013monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-webcast-conference-call-discussing-third-quarter-financial-results-bo-bsx-20101007monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-annuncia-la-pubblicazione-di-un-analisi-che-dimostra-l-aumento-della-sop-bsx-20100929monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-welcomes-publication-of-analysis-demonstrating-long-term-survival-benefi-bsx-20100928monthly0.5https://www.biopharmawatch.com/news/BSX/horizons-ami-trial-provides-superior-outcomes-data-at-three-years-with-taxus-drug-eluting--bsx-20100925monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-annuncia-i-dati-clinici-a-supporto-della-sicurezza-e-dell-efficacia-dell-bsx-20100923monthly0.5https://www.biopharmawatch.com/news/BSX/bostonscientific-anuncia-los-datos-cli-nicos-que-avalan-la-seguridad-y-eficacia-del-stent--bsx-20100922monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-s-taxus-element-stent-demonstrates-strong-outcomes-in-diabetic-patients--bsx-20100922monthly0.5https://www.biopharmawatch.com/news/BSX/long-term-data-show-advantages-for-taxus-liberte-stent-in-small-vessels-and-long-lesions-b-bsx-20100922monthly0.5https://www.biopharmawatch.com/news/BSX/promus-element-stent-approved-for-use-in-diabetic-and-heart-attack-patients-in-ce-mark-cou-bsx-20100921monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-clinical-data-supporting-safety-and-efficacy-of-platinum-chrom-bsx-20100921monthly0.5https://www.biopharmawatch.com/news/BSX/approvazione-dello-stent-promus-r-element-tm-per-l-utilizzo-in-pazienti-diabetici-e-colpit-bsx-20100921monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-acquire-asthmatx-boston-scientific-corporation-nyse-bsx-today-announc-bsx-20100920monthly0.5https://www.biopharmawatch.com/news/BSX/espansione-delle-indicazioni-per-i-dispositivi-crtd-boston-scientific-l-approvazione-da-pa-bsx-20100920monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-receives-exclusive-expanded-indication-for-its-crt-ds-boston-scientific--bsx-20100916monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-announces-schedule-of-events-at-tct-scientific-symposium-boston-scientif-bsx-20100914monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-to-participate-in-morgan-stanley-global-healthcare-conference-boston-sci-bsx-20100902monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-s-women-s-health-products-featured-in-studies-at-the-joint-annual-meetin-bsx-20100819monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-resolves-corporate-warning-letter-boston-scientific-corporation-nyse-bsx-bsx-20100811monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-inizia-l-arruolamento-per-il-trial-clinico-sul-nuovo-stent-coronarico-co-bsx-20100805monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-lanc-a-sistema-de-stents-neuroform-ez-tm-nos-estados-unidos-e-na-europa--bsx-20100802monthly0.5https://www.biopharmawatch.com/news/BSX/il-sistema-di-stent-neuroform-ez-tm-di-boston-scientific-viene-lanciato-negli-stati-uniti--bsx-20100728monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-annuncia-l-arruolamento-del-primo-paziente-nello-studio-clinico-multisen-bsx-20100708monthly0.5https://www.biopharmawatch.com/news/BSX/secondo-i-dati-dello-studio-madit-crt-le-pazienti-di-sesso-femminile-beneficiano-maggiorme-bsx-20100618monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-inicia-el-estudio-platinum-plus-para-el-stent-promus-r-element-tm-estudi-bsx-20100526monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-da-il-via-allo-studio-platinum-plus-sul-sistema-di-stent-promus-r-elemen-bsx-20100526monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-annuncia-la-disponibilita-di-un-nuovo-connettore-ideato-per-semplificare-bsx-20100324monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-anuncia-la-disponibilidad-de-un-nuevo-sistema-conector-disen-ado-para-si-bsx-20100324monthly0.5https://www.biopharmawatch.com/news/BSX/el-grupo-asesor-de-la-fda-recomienda-una-nimemente-la-ampliacio-n-de-la-indicacio-n-para-l-bsx-20100323monthly0.5https://www.biopharmawatch.com/news/BSX/sulla-base-dell-importante-studio-madit-crt-la-commissione-consultiva-della-fda-raccomanda-bsx-20100323monthly0.5https://www.biopharmawatch.com/news/BSX/i-risultati-dello-studio-perseus-dimostrano-esiti-positivi-in-termini-di-efficacia-e-sicur-bsx-20100316monthly0.5https://www.biopharmawatch.com/news/BSX/i-pazienti-trattati-con-il-sistema-di-gestione-remota-latitude-r-di-boston-scientific-ragg-bsx-20100315monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-annuncia-l-arruolamento-del-primo-paziente-nello-studio-del-sistema-di-s-bsx-20100115monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-annuncia-che-e-stato-completato-l-arruolamento-nello-studio-clinico-sul--bsx-20100105monthly0.5https://www.biopharmawatch.com/news/BSX/boston-scientific-termina-el-reclutamiento-en-el-ensayo-cli-nico-sobre-el-aneurisma-boston-bsx-20100105monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-grants-of-inducement-awards-spyre-therapeutics-inc-nasdaq-syr-syre-20250502monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-grants-of-inducement-awards-spyre-therapeutics-inc-nasdaq-syr-syre-20250404monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-grants-of-inducement-awards-spyre-therapeutics-inc-nasdaq-syr-syre-20250307monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-to-participate-in-upcoming-march-investor-conferences-spyre-therapeutic-syre-20250225monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-poster-presentation-at-the-20th-congress-of-the-european-croh-syre-20250219monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-grants-of-inducement-awards-spyre-therapeutics-inc-nasdaq-syr-syre-20250207monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-highlights-2025-priorities-and-robust-pipeline-of-upcoming-clinical-rea-syre-20250113monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-grants-of-inducement-awards-spyre-therapeutics-inc-nasdaq-syr-syre-20250103monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-added-to-the-nasdaq-biotechnology-index-spyre-therapeutics-inc-nasdaq-s-syre-20241218monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-grants-of-inducement-awards-spyre-therapeutics-inc-nasdaq-syr-syre-20241202monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-first-participants-dosed-in-phase-1-trials-of-novel-half-life-syre-20241202monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-to-participate-in-the-7th-annual-evercore-isi-healthconx-conference-spy-syre-20241125monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-pricing-of-200-million-public-offering-of-common-stock-spyre--syre-20241118monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-proposed-public-offering-of-its-common-stock-and-pre-funded-w-syre-20241118monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-to-host-conference-call-and-webcast-to-report-interim-results-from-phas-syre-20241111monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-grants-of-inducement-awards-spyre-therapeutics-inc-nasdaq-syr-syre-20241101monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-to-participate-in-upcoming-november-investor-conferences-spyre-therapeu-syre-20241030monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-grants-of-inducement-awards-spyre-therapeutics-inc-nasdaq-syr-syre-20241004monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-appoints-dr-sheldon-sloan-as-chief-medical-officer-spyre-therapeutics-i-syre-20241001monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-to-participate-in-upcoming-investor-conference-spyre-therapeutics-inc-n-syre-20240910monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-first-participants-dosed-in-phase-1-trial-of-spy001-its-novel-syre-20240618monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-grants-of-inducement-awards-spyre-therapeutics-inc-nasdaq-syr-syre-20240603monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-to-participate-in-the-jefferies-global-healthcare-conference-spyre-ther-syre-20240529monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-grants-of-inducement-awards-spyre-therapeutics-inc-nasdaq-syr-syre-20240503monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-grants-of-inducement-awards-spyre-therapeutics-inc-nasdaq-syr-syre-20240401monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-grants-of-inducement-awards-spyre-therapeutics-inc-nasdaq-syr-syre-20240301monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-to-participate-in-the-44th-annual-td-cowen-health-care-conference-spyre-syre-20240226monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-three-abstracts-accepted-for-presentation-at-the-19th-annual--syre-20240208monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-appoints-accomplished-biopharma-and-ibd-leader-mark-c-mckenna-former-ch-syre-20240205monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-grants-of-inducement-awards-spyre-therapeutics-inc-nasdaq-syr-syre-20240202monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-grants-of-inducement-awards-spyre-therapeutics-inc-spyre-nasd-syre-20231222monthly0.5https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-to-present-at-upcoming-investor-conference-spyre-therapeutics-inc-spyre-syre-20231128monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-new-three-year-voxzogo-vosoritide-data-in-hypochondroplasia-and-bmn-333-bmrn-20260616monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-provides-update-on-phase-3-trial-for-bmn-401-in-children-aged-1-12-with-enpp1-def-bmrn-20260518monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-presents-new-data-on-the-effect-of-long-term-treatment-with-voxzogo-vosoritide-on-bmrn-20260502monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-fourth-quarter-and-full-year-2025-financial-results-conference-call-and-w-bmrn-20260217monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-acquire-amicus-therapeutics-for-4-8-billion-expanding-position-as-a-leader-in--bmrn-20251219monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-second-quarter-2025-financial-results-conference-call-and-webcast-on-mond-bmrn-20250722monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-completion-of-acquisition-of-inozyme-biomarin-pharmaceutical-inc-nasdaq-bmrn-20250701monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-presents-five-year-phase-3-results-reinforcing-long-term-efficacy-and-safety-of-r-bmrn-20250624monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-strengthens-enzyme-therapy-business-with-acquisition-of-inozyme-pharma-biomarin-p-bmrn-20250516monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-presents-new-data-for-voxzogo-vosoritide-in-children-with-achondroplasia-and-othe-bmrn-20250512monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-reports-first-quarter-2025-results-and-reaffirms-full-year-guidance-biomarin-phar-bmrn-20250501monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-first-quarter-2025-financial-results-conference-call-and-webcast-on-thurs-bmrn-20250417monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-positive-pivotal-data-for-palynziq-pegvaliase-pqpz-in-adolescents-with--bmrn-20250402monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-presents-new-data-demonstrating-favorable-safety-and-strong-adherence-in-real-wor-bmrn-20250320monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-td-cowen-45th-annual-healthcare-conference-on-tuesday-march-4-a-bmrn-20250225monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-appointment-of-timothy-p-walbert-to-board-of-directors-biomarin-pharmac-bmrn-20250224monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-reports-fourth-quarter-and-full-year-2024-results-sets-full-year-2025-guidance-bi-bmrn-20250219monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-fourth-quarter-and-full-year-2024-financial-results-conference-call-and-w-bmrn-20250205monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-legal-action-against-ascendis-pharma-a-s-in-european-unified-patent-cou-bmrn-20250113monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-on-monday-january--bmrn-20250106monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-presents-real-world-evidence-further-supporting-safety-and-efficacy-of-voxzogo-vo-bmrn-20241116monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-three-upcoming-investor-conferences-biomarin-pharmaceutical-inc-bmrn-20241106monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-28-y-y-total-revenue-growth-in-the-third-quarter-and-increase-in-full-y-bmrn-20241029monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-third-quarter-2024-financial-results-conference-call-and-webcast-on-tuesd-bmrn-20241016monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-data-underscoring-sustained-positive-impact-of-voxzogo-vosoritide-on-h-bmrn-20240918monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-holds-investor-day-provides-new-corporate-strategy-and-introduces-2027-financial--bmrn-20240904monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-investor-day-today-at-10-30-a-m-eastern-time-biomarin-pharmaceutical-inc--bmrn-20240904monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-22nd-annual-morgan-stanley-global-healthcare-conference-on-thur-bmrn-20240829monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-new-r-d-and-business-development-leadership-biomarin-pharmaceutical-inc-bmrn-20240821monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-2024-investor-day-on-september-4th-in-new-york-biomarin-pharmaceutical-in-bmrn-20240819monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-20-y-y-total-revenue-growth-in-the-second-quarter-and-increase-in-full--bmrn-20240805monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-updated-strategy-for-roctavian-to-focus-on-u-s-germany-and-italy-biomar-bmrn-20240805monthly0.5https://www.biopharmawatch.com/news/BMRN/u-s-food-and-drug-administration-approves-biomarin-s-brineura-cerliponase-alfa-for-childre-bmrn-20240724monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-second-quarter-2024-financial-results-conference-call-and-webcast-on-mond-bmrn-20240723monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-data-highlighting-significant-impact-of-voxzogo-vosoritide-in-bone-hea-bmrn-20240617monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-presents-new-phase-3-four-year-data-underscoring-long-term-safety-and-efficacy-of-bmrn-20240607monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-bofa-securities-2024-health-care-conference-on-wednesday-may-15-bmrn-20240508monthly0.5https://www.biopharmawatch.com/news/BMRN/new-data-for-biomarin-s-voxzogo-vosoritide-for-multiple-growth-related-conditions-in-child-bmrn-20240504monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-reports-record-financial-results-for-the-first-quarter-2024-first-quarter-2024-to-bmrn-20240424monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-first-quarter-2024-financial-results-conference-call-and-webcast-on-wedne-bmrn-20240410monthly0.5https://www.biopharmawatch.com/news/BMRN/new-data-to-be-presented-for-biomarin-s-voxzogo-vosoritide-in-children-with-hypochondropla-bmrn-20240312monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-appointment-of-cristin-hubbard-as-chief-commercial-officer-biomarin-pha-bmrn-20240307monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-scheduled-to-participate-in-march-investor-conferences-biomarin-pharmaceutical-in-bmrn-20240301monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-reports-record-financial-results-for-the-fourth-quarter-and-full-year-2023-and-pr-bmrn-20240222monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-fourth-quarter-and-full-year-2023-financial-results-conference-call-and-w-bmrn-20240208monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-roctavian-valoctocogene-roxaparvovec-rvox-data-highlighting-long-term--bmrn-20240206monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-on-monday-january--bmrn-20240103monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-governance-enhancements-and-value-creation-initiatives-biomarin-pharmac-bmrn-20231220monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-agreement-with-german-health-insurance-fund-on-reimbursement-amount-for-bmrn-20231128monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-strong-third-quarter-2023-results-including-continued-profitability-and-bmrn-20231101monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-retirement-of-jean-jacques-bienaime-appoints-alexander-hardy-president--bmrn-20231101monthly0.5https://www.biopharmawatch.com/news/BMRN/u-s-food-and-drug-administration-approves-biomarin-s-voxzogo-vosoritide-for-children-under-bmrn-20231020monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-third-quarter-2023-financial-results-conference-call-and-webcast-on-wedne-bmrn-20231017monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-data-showing-long-term-benefit-of-voxzogo-vosoritide-on-growth-in-chil-bmrn-20230921monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-receives-positive-chmp-opinion-in-europe-to-expand-use-of-voxzogo-vosoritide-to-t-bmrn-20230915monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-innovative-pipeline-at-r-d-day-on-september-12th-in-new-york-biomarin--bmrn-20230911monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-pipeline-at-upcoming-r-d-day-on-tuesday-september-12th-biomarin-pharma-bmrn-20230906monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-three-upcoming-investor-conferences-biomarin-pharmaceutical-inc-bmrn-20230905monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-first-person-treated-commercially-with-roctavian-valoctocogene-roxaparv-bmrn-20230830monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-strong-second-quarter-2023-results-and-record-breaking-revenues-for-the-bmrn-20230731monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-second-quarter-2023-financial-results-conference-call-and-webcast-on-mond-bmrn-20230712monthly0.5https://www.biopharmawatch.com/news/BMRN/u-s-food-and-drug-administration-approves-biomarin-s-roctavian-valoctocogene-roxaparvovec--bmrn-20230629monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-roctavian-valoctocogene-roxaparvovec-data-from-longest-and-largest-hem-bmrn-20230622monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-bank-of-america-2023-health-care-conference-biomarin-pharmaceut-bmrn-202305042023-05-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-record-breaking-first-quarter-2023-results-including-15-year-over-year--bmrn-202304262023-04-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-first-quarter-2023-financial-results-conference-call-and-webcast-on-wedne-bmrn-202304132023-04-13T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-share-updated-data-at-2023-american-college-of-medical-genetics-and-genomics-a-bmrn-202303142023-03-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/fda-accepts-biomarin-s-supplemental-new-drug-application-to-expand-use-of-voxzogo-vosoriti-bmrn-202303072023-03-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-provides-update-on-fda-review-of-roctavian-valoctocogene-roxaparvovec-gene-therap-bmrn-202303062023-03-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-three-investor-conferences-in-march-biomarin-pharmaceutical-inc-bmrn-202303022023-03-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-record-fourth-quarter-and-full-year-2022-total-revenues-driven-by-stron-bmrn-202302272023-02-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-virtually-at-svb-securities-global-biopharma-conference-on-februar-bmrn-202302142023-02-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-w-bmrn-202302072023-02-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-stable-and-durable-annualized-bleed-control-for-roctavian-in-largest-ph-bmrn-202301082023-01-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-41st-annual-j-p-morgan-healthcare-conference-on-monday-january-9-at-bmrn-202301042023-01-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/european-medicines-agency-validates-application-for-extension-of-indication-for-voxzogo-vo-bmrn-202301032023-01-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-advancements-in-fda-review-of-roctavian-valoctocogene-roxaparvovec-for--bmrn-20221123monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-incremental-progress-on-biologics-license-application-bla-review-for-va-bmrn-20221107monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-two-upcoming-investor-conferences-biomarin-pharmaceutical-inc-n-bmrn-20221103monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-third-quarter-2022-year-over-year-total-revenue-growth-of-24-31-excludi-bmrn-20221026monthly0.5https://www.biopharmawatch.com/news/BMRN/fda-accepts-biomarin-s-biologics-license-application-bla-for-valoctocogene-roxaparvovec-aa-bmrn-20221012monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-simplifies-organizational-structure-to-increase-efficiency-biomarin-pharmaceutica-bmrn-20221006monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-third-quarter-2022-financial-results-conference-call-and-webcast-on-wedne-bmrn-20221004monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-resubmits-biologics-license-application-bla-for-valoctocogene-roxaparvovec-aav-ge-bmrn-20220929monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-s-gene-therapy-for-adults-with-severe-hemophilia-a-roctavian-valoctocogene-roxapa-bmrn-20220915monthly0.5https://www.biopharmawatch.com/news/BMRN/first-gene-therapy-for-adults-with-severe-hemophilia-a-biomarin-s-roctavian-valoctocogene--bmrn-20220824monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-record-revenues-in-second-quarter-2022-increases-full-year-2022-top-and-bmrn-20220803monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-second-quarter-2022-financial-results-conference-call-and-webcast-on-wedn-bmrn-20220720monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-presents-findings-from-studies-of-valoctocogene-roxaparvovec-investigational-gene-bmrn-20220711monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-receives-positive-chmp-opinion-in-europe-for-valoctocogene-roxaparvovec-gene-ther-bmrn-20220624monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-the-ministry-of-health-labor-and-welfare-mhlw-in-japan-granted-approval-bmrn-20220621monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-favorable-results-from-global-phase-2-study-of-voxzogo-vosoritide-for-i-bmrn-20220613monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-durable-hemostatic-efficacy-maintained-over-6-years-in-ongoing-phase-1--bmrn-20220531monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-hires-pharmaceutical-industry-leaders-in-marketing-and-accounting-to-fill-strateg-bmrn-20220505monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-findings-from-ongoing-studies-of-valoctocogene-roxaparvovec-investigat-bmrn-20220505monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-the-bofa-securities-2022-healthcare-conference-thursday-may-12--bmrn-20220504monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-record-revenues-in-first-quarter-2022-biomarin-reports-record-first-qua-bmrn-20220427monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-first-quarter-2022-financial-results-conference-call-and-webcast-on-wedne-bmrn-20220413monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-publication-in-new-england-journal-of-medicine-of-one-year-results-from-bmrn-20220317monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-fourth-quarter-and-full-year-2021-financial-results-and-corporate-updat-bmrn-20220223monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-provides-updates-on-progress-in-gene-therapy-programs-biomarin-pharmaceutical-inc-bmrn-20220217monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-biomarin-pharmaceutic-bmrn-20220216monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-fourth-quarter-and-full-year-2021-financial-results-conference-call-and-w-bmrn-20220210monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-oral-presentation-of-2-year-analysis-of-largest-phase-3-gene-therapy-st-bmrn-20220204monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-demonstrates-enduring-commitment-to-advancing-the-standard-of-care-in-hemophilia--bmrn-20220202monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-stable-and-durable-annualized-bleed-control-in-the-largest-phase-3-gene-bmrn-20220109monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-two-virtual-investor-conferences-in-january-biomarin-pharmaceut-bmrn-20220104monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-and-skyline-therapeutics-announce-strategic-collaboration-to-develop-novel-gene-t-bmrn-20211216monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-appoints-former-ceo-of-celgene-corporation-mark-alles-to-board-of-directors-bioma-bmrn-20211215monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-hold-virtual-r-d-day-at-11-00am-et-today-biomarin-pharmaceutical-inc-nasdaq-bm-bmrn-20211130monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-biomarin-pharmaceutic-bmrn-20211129monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-receives-fda-approval-for-voxzogo-vosoritide-for-injection-indicated-to-increase--bmrn-20211119monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-third-quarter-2021-financial-results-and-corporate-updates-financial-hi-bmrn-20211027monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-four-upcoming-virtual-investor-conferences-biomarin-pharmaceuti-bmrn-20211025monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-third-quarter-2021-financial-results-conference-call-and-webcast-on-wedne-bmrn-20211012monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-hires-industry-veterans-to-fill-key-roles-in-r-d-and-technical-operations-biomari-bmrn-20211004monthly0.5https://www.biopharmawatch.com/news/BMRN/u-s-fda-placed-a-clinical-hold-on-bmn-307-phearless-phase-1-2-gene-therapy-study-in-adults-bmrn-20210906monthly0.5https://www.biopharmawatch.com/news/BMRN/european-commission-approves-biomarin-s-voxzogo-vosoritide-for-the-treatment-of-children-w-bmrn-20210827monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-three-upcoming-virtual-investor-conferences-biomarin-pharmaceut-bmrn-20210825monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-second-quarter-2021-financial-results-and-corporate-updates-financial-h-bmrn-20210728monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-oral-presentation-at-international-society-on-thrombosis-and-haemostasi-bmrn-20210721monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-oral-presentation-of-positive-one-year-results-from-phase-3-pivotal-tri-bmrn-20210719monthly0.5https://www.biopharmawatch.com/news/BMRN/european-medicines-agency-validates-biomarin-s-marketing-authorization-application-for-val-bmrn-20210715monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-second-quarter-2021-financial-results-conference-call-and-webcast-on-wedn-bmrn-20210714monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-12-presentations-at-the-international-society-on-thrombosis-and-haemost-bmrn-20210702monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-resubmits-marketing-authorization-application-maa-to-european-medicines-agency-fo-bmrn-20210628monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-receives-positive-chmp-opinion-in-europe-for-vosoritide-for-the-treatment-of-chil-bmrn-20210625monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-the-virtual-bofa-securities-2021-napa-biopharma-conference-biom-bmrn-20210615monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-biomarin-pharmaceutic-bmrn-20210527monthly0.5https://www.biopharmawatch.com/news/BMRN/european-medicines-agency-grants-biomarin-s-request-for-accelerated-assessment-of-valoctoc-bmrn-20210524monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-provides-highlights-of-5-years-of-clinical-data-from-ongoing-phase-1-2-study-of-v-bmrn-20210519monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-biomarin-pharmaceutic-bmrn-20210518monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-6-presentations-at-american-society-of-gene-and-cell-therapy-asgct-virt-bmrn-20210512monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-biomarin-pharmaceutic-bmrn-20210503monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-first-quarter-2021-financial-results-and-corporate-updates-financial-hi-bmrn-20210429monthly0.5https://www.biopharmawatch.com/news/BMRN/allen-institute-and-biomarin-team-up-to-develop-gene-therapies-for-rare-brain-diseases-the-bmrn-20210428monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-new-and-updated-data-at-2021-american-college-of-medical-genetics-and-g-bmrn-20210415monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-first-quarter-2021-financial-results-conference-call-and-webcast-on-thurs-bmrn-20210413monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-oral-presentation-at-endo2021-the-endocrine-society-s-annual-meeting-wi-bmrn-20210320monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-fda-regenerative-medicine-advanced-therapy-rmat-designation-granted-to--bmrn-20210308monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-completes-full-enrollment-in-phase-2-study-of-vosoritide-for-treatment-of-infants-bmrn-20210303monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-fourth-quarter-and-record-full-year-2020-financial-results-and-corporat-bmrn-20210225monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-four-upcoming-virtual-investor-conferences-biomarin-pharmaceuti-bmrn-20210224monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-appoints-former-goldman-sachs-partner-and-life-sciences-executive-maykin-ho-ph-d--bmrn-20210218monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-earns-top-marks-in-human-rights-campaign-s-2021-corporate-equality-index-biomarin-bmrn-20210128monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-fourth-quarter-and-full-year-2020-financial-results-conference-call-and-w-bmrn-20210126monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-positive-phase-3-gene-therapy-trial-results-in-adults-with-severe-hemop-bmrn-20210110monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-biomarin-pharmaceutic-bmrn-20210105monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-benefit-maintained-for-over-two-years-in-children-with-achondroplasia-t-bmrn-20201221monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-biomarin-pharmaceutic-bmrn-20201201monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-and-deep-genomics-to-collaborate-on-advancing-programs-identified-using-artificia-bmrn-20201117monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-three-upcoming-virtual-investor-conferences-biomarin-pharmaceut-bmrn-20201112monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-expands-vosoritide-clinical-program-biomarin-pharmaceutical-inc-nasdaq-bmrn-annou-bmrn-20201109monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-third-quarter-2020-total-revenues-of-477-million-financial-highlights-i-bmrn-20201105monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-the-credit-suisse-29th-annual-virtual-healthcare-conference-on--bmrn-20201104monthly0.5https://www.biopharmawatch.com/news/BMRN/food-and-drug-administration-accepts-biomarin-s-new-drug-application-for-vosoritide-to-tre-bmrn-20201102monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-third-quarter-2020-financial-results-conference-call-and-webcast-on-thurs-bmrn-20201022monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-pioneer-in-rare-disease-treatments-for-phenylketonuria-pku-receives-fda-approval--bmrn-20201007monthly0.5https://www.biopharmawatch.com/news/BMRN/scientific-luminary-and-macarthur-fellowship-winner-kevin-eggan-ph-d-joins-biomarin-as-hea-bmrn-20201005monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-pioneer-in-phenylketonuria-pku-and-gene-therapy-receives-fda-fast-track-designati-bmrn-20201002monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-upcoming-virtual-investor-conference-biomarin-pharmaceutical-in-bmrn-20200929monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-pioneer-in-phenylketonuria-pku-and-gene-therapy-doses-first-participant-in-global-bmrn-20200924monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-four-upcoming-virtual-investor-conferences-biomarin-pharmaceuti-bmrn-20200915monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-presentation-of-vosoritide-phase-3-data-in-children-with-achondroplasia-bmrn-20200911monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-the-lancet-publishes-detailed-vosoritide-phase-3-data-demonstrating-sta-bmrn-20200908monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-biomarin-pharmaceutic-bmrn-20200908monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-submits-new-drug-application-to-u-s-food-and-drug-administration-for-vosoritide-t-bmrn-20200820monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-receives-complete-response-letter-crl-from-fda-for-valoctocogene-roxaparvovec-gen-bmrn-20200819monthly0.5https://www.biopharmawatch.com/news/BMRN/european-medicines-agency-validates-biomarin-s-marketing-authorization-application-for-vos-bmrn-20200813monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-biomarin-pharmaceutic-bmrn-20200810monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-second-quarter-2020-total-revenue-growth-of-11-to-430-million-financial-bmrn-20200804monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-submits-marketing-authorization-application-to-european-medicines-agency-for-voso-bmrn-20200723monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-second-quarter-2020-financial-results-conference-call-and-webcast-on-tues-bmrn-20200721monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-promotes-company-veteran-brian-r-mueller-to-executive-vice-president-cfo-biomarin-bmrn-20200629monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-the-virtual-bofa-securities-2020-napa-biopharma-conference-biom-bmrn-20200623monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-provides-additional-data-from-recent-4-year-update-of-ongoing-phase-1-2-study-of--bmrn-20200617monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-biomarin-pharmaceutic-bmrn-20200603monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-provides-highlights-of-4-years-of-clinical-data-from-ongoing-phase-1-2-study-of-v-bmrn-20200531monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-closing-of-exercise-by-initial-purchasers-of-option-to-purchase-an-addi-bmrn-20200519monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-pricing-of-upsized-550-million-senior-subordinated-convertible-notes-of-bmrn-20200511monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-proposed-private-offering-of-500-million-of-senior-subordinated-convert-bmrn-20200511monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-biomarin-pharmaceutic-bmrn-20200506monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-extends-gene-therapy-leadership-with-dinaqor-in-a-preclinical-collaboration-and-l-bmrn-20200503monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-first-quarter-2020-total-revenue-growth-of-25-to-502-million-financial--bmrn-20200429monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-updates-timing-of-first-quarter-2020-financial-results-conference-call-and-webcas-bmrn-20200422monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-appoints-global-pharmaceutical-veteran-c-greg-guyer-ph-d-to-chief-technical-offic-bmrn-20200421monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-first-quarter-2020-financial-results-conference-call-and-webcast-on-thurs-bmrn-20200414monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-plans-regulatory-submissions-for-marketing-authorization-of-vosoritide-to-treat-c-bmrn-20200406monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-s-brinda-balakrishnan-m-d-ph-d-honored-with-2020-40-under-40-award-from-the-san-f-bmrn-20200309monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-fourth-quarter-and-record-full-year-2019-financial-results-financial-hi-bmrn-20200226monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-s-biologics-license-application-for-valoctocogene-roxaparvovec-accepted-for-prior-bmrn-20200220monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-two-upcoming-investor-conferences-biomarin-pharmaceutical-inc-n-bmrn-20200212monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-cfo-succession-biomarin-pharmaceutical-inc-nasdaq-bmrn-today-announced--bmrn-20200203monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-fourth-quarter-and-full-year-2019-financial-results-conference-call-and-w-bmrn-20200129monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-pioneer-in-phenylketonuria-to-begin-clinical-trial-with-bmn-307-gene-therapy-biom-bmrn-20200113monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-goldman-sachs-12th-annual-healthcare-ceos-unscripted-a-view-fro-bmrn-20200108monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-38th-annual-j-p-morgan-healthcare-conference-in-san-francisco-bioma-bmrn-20200106monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-new-england-journal-of-medicine-publishes-3-years-of-follow-up-data-in--bmrn-20200102monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-submits-biologics-license-application-to-u-s-food-and-drug-administration-for-val-bmrn-20191223monthly0.5https://www.biopharmawatch.com/news/BMRN/european-medicines-agency-validates-biomarin-s-marketing-authorization-application-for-val-bmrn-20191223monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-positive-final-results-from-placebo-controlled-phase-3-data-in-children-bmrn-20191216monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-submits-marketing-authorization-application-to-european-medicines-agency-for-valo-bmrn-20191121monthly0.5https://www.biopharmawatch.com/news/BMRN/poised-for-significant-growth-and-profitability-biomarin-shares-company-highlights-during--bmrn-20191114monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-cumulative-additional-height-gain-of-9-0-cm-over-54-months-versus-natur-bmrn-20191114monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-jefferies-london-healthcare-conference-on-november-21-2019-biom-bmrn-20191112monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-highlight-innovative-development-pipeline-at-r-d-day-on-november-14th-biomarin-bmrn-20191106monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-third-quarter-2019-financial-results-financial-highlights-in-millions-o-bmrn-20191023monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-third-quarter-2019-financial-results-conference-call-and-webcast-on-wedne-bmrn-20191009monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-promotes-lon-cardon-ph-d-to-chief-scientific-strategy-officer-biomarin-pharmaceut-bmrn-20191007monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-jefferies-gene-therapy-editing-summit-on-october-8-2019-in-new--bmrn-20191001monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-pioneer-in-phenylketonuria-pku-therapies-submits-clinical-trial-application-cta-i-bmrn-20190926monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-morgan-stanley-17th-annual-global-healthcare-conference-on-sept-bmrn-20190909monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-morgan-stanley-17th-annual-global-healthcare-conference-on-sept-bmrn-20190828monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-second-quarter-2019-financial-results-financial-highlights-in-millions--bmrn-20190801monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-second-quarter-2019-financial-results-conference-call-and-webcast-on-thur-bmrn-20190716monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-appoints-pharmaceutical-veteran-and-former-j-j-executive-liz-mckee-anderson-to-bo-bmrn-20190709monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-plans-regulatory-submissions-for-marketing-authorization-of-valoctocogene-roxapar-bmrn-20190708monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-acceptance-of-late-breaking-abstract-at-the-international-society-on-th-bmrn-20190626monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-earns-milestone-payments-from-pfizer-for-talzenna-talazoparib-for-metastatic-brea-bmrn-20190621monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-new-england-journal-of-medicine-publishes-vosoritide-phase-2-study-show-bmrn-20190618monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-goldman-sachs-40th-annual-global-healthcare-conference-on-tuesd-bmrn-20190605monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-approval-of-vimizim-elosulfase-alfa-in-china-for-treatment-of-morquio-a-bmrn-20190604monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-that-phase-3-cohort-of-valoctocogene-roxaparvovec-gene-therapy-study-in-bmrn-20190528monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-provides-3-years-of-clinical-data-from-ongoing-phase-1-2-study-of-valoctocogene-r-bmrn-20190528monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-conference-call-tuesday-may-28-2019-to-provide-a-valoctocogene-roxaparvov-bmrn-20190527monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-2019-rbc-capital-markets-global-healthcare-conference-on-may-21-bmrn-20190516monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-bank-of-america-merrill-lynch-health-care-conference-on-may-15--bmrn-20190508monthly0.5https://www.biopharmawatch.com/news/BMRN/european-commission-approves-palynziq-pegvaliase-injection-for-treatment-of-phenylketonuri-bmrn-20190506monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-first-quarter-2019-financial-results-financial-highlights-in-millions-o-bmrn-20190425monthly0.5https://www.biopharmawatch.com/news/BMRN/forbes-names-biomarin-4th-best-midsize-employer-in-america-biomarin-pharmaceutical-inc-nas-bmrn-20190417monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-first-quarter-2019-financial-results-conference-call-and-webcast-on-thurs-bmrn-20190402monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-cowen-and-company-39th-annual-health-care-conference-on-march-1-bmrn-20190306monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-receives-positive-chmp-opinion-in-europe-for-palynziq-pegvaliase-injection-for-tr-bmrn-20190301monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-full-year-and-fourth-quarter-2018-results-financial-highlights-in-milli-bmrn-20190221monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-ongoing-study-demonstrates-durable-treatment-benefit-from-brineura-cerl-bmrn-20190207monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-14-presentations-at-15th-annual-worldsymposium-2019-biomarin-pharmaceut-bmrn-20190204monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-fourth-quarter-and-full-year-2018-financial-results-conference-call-and-w-bmrn-20190123monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-highlights-key-milestones-for-2019-at-37th-annual-j-p-morgan-healthcare-conferenc-bmrn-20190107monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-37th-annual-j-p-morgan-healthcare-conference-in-san-francisco-bioma-bmrn-20181218monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-promotes-amy-wireman-to-group-vice-president-human-resources-biomarin-pharmaceuti-bmrn-20181203monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-citi-s-13th-annual-biotech-conference-on-december-5-in-new-york-bmrn-20181203monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-and-believe-limited-announce-the-debut-of-hemophilia-the-musical-biomarin-pharmac-bmrn-20181112monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-two-investor-conferences-in-november-biomarin-pharmaceutical-in-bmrn-20181108monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-highlights-breadth-of-innovative-development-pipeline-at-r-d-day-on-november-7th--bmrn-20181107monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-highlight-breadth-of-innovative-development-pipeline-at-r-d-day-on-november-7t-bmrn-20181101monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-third-quarter-2018-results-financial-highlights-in-millions-of-u-s-doll-bmrn-20181025monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-receives-milestone-payments-from-pfizer-for-talzenna-talazoparib-for-metastatic-b-bmrn-20181016monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-and-believe-limited-announce-selection-of-25-high-school-students-to-perform-in-f-bmrn-20181011monthly0.5https://www.biopharmawatch.com/news/BMRN/forbes-names-biomarin-among-world-s-best-employers-biomarin-pharmaceutical-inc-nasdaq-bmrn-bmrn-20181011monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-third-quarter-2018-financial-results-conference-call-and-webcast-on-thurs-bmrn-20181004monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-two-investor-conferences-in-october-biomarin-pharmaceutical-inc-bmrn-20180919monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-20-poster-presentations-at-society-for-the-study-of-inborn-errors-of-me-bmrn-20180905monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-participate-in-three-investor-conferences-in-september-biomarin-pharmaceutical-bmrn-20180822monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-second-quarter-2018-results-financial-highlights-in-millions-of-u-s-dol-bmrn-20180802monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-second-quarter-2018-financial-results-conference-call-and-webcast-on-thur-bmrn-20180711monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-partners-with-believe-limited-for-breaking-through-musical-theater-intensive-biom-bmrn-20180709monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-first-recipients-of-rare-scholars-scholarship-program-biomarin-pharmace-bmrn-20180628monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-doses-first-participant-in-phase-2-study-of-vosoritide-for-treatment-of-infants-a-bmrn-20180614monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-receives-milestone-payments-from-pfizer-for-talazoparib-biomarin-pharmaceutical-i-bmrn-20180607monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-receives-standard-approval-for-palynziq-pegvaliase-pqpz-injection-for-treatment-o-bmrn-20180524monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-provides-2-years-of-clinical-data-in-6e13-vg-kg-dose-from-ongoing-phase-1-2-study-bmrn-20180522monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-1-platform-and-3-poster-presentations-at-world-federation-of-hemophilia-bmrn-20180517monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-first-patient-dosed-in-phase-1-2-study-evaluating-valoctocogene-roxapar-bmrn-20180515monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-attend-upcoming-investor-conference-biomarin-pharmaceutical-inc-nasdaq-bmrn-to-bmrn-20180502monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-named-to-forbes-list-of-america-s-best-mid-size-employers-biomarin-pharmaceutical-bmrn-20180501monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-first-quarter-2018-financial-results-financial-highlights-in-millions-o-bmrn-20180425monthly0.5https://www.biopharmawatch.com/news/BMRN/new-england-journal-of-medicine-published-open-label-study-showing-brineura-cerliponase-al-bmrn-20180424monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-first-quarter-2018-financial-results-conference-call-and-webcast-on-wedne-bmrn-20180418monthly0.5https://www.biopharmawatch.com/news/BMRN/european-medicines-agency-ema-accepts-biomarin-s-marketing-application-for-pegvaliase-maa--bmrn-20180328monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-s-gene-therapy-manufacturing-facility-recognized-with-industry-award-biomarin-pha-bmrn-20180321monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-attend-upcoming-investor-conference-biomarin-pharmaceutical-inc-nasdaq-bmrn-to-bmrn-20180306monthly0.5https://www.biopharmawatch.com/news/BMRN/rare-disease-day-2018-biomarin-launches-rare-scholars-scholarship-program-biomarin-today-a-bmrn-20180228monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-fourth-quarter-and-full-year-2017-financial-results-financial-highlight-bmrn-20180222monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-presents-interim-data-of-phase-1-2-study-of-bmn-250-for-treatment-of-sanfilippo-b-bmrn-20180207monthly0.5https://www.biopharmawatch.com/news/BMRN/worldsymposium-recognizes-biomarin-s-brineura-cerliponase-alfa-with-2018-new-treatment-awa-bmrn-20180206monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-20-presentations-at-14th-annual-worldsymposium-2018-biomarin-pharmaceut-bmrn-20180205monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-receives-anticipated-notification-of-pdufa-extension-for-pegvaliase-biologics-lic-bmrn-20171222monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-doses-first-patient-in-global-gener8-1-phase-3-study-of-valoctocogene-roxaparvove-bmrn-20171219monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-highlights-new-results-for-gene-therapy-valoctocogene-roxaparvovec-at-the-2017-am-bmrn-20171211monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-provides-1-5-years-of-clinical-data-for-valoctocogene-roxaparvovec-gene-therapy-f-bmrn-20171209monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-presentations-at-59th-american-society-of-hematology-annual-meeting-exp-bmrn-20171206monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-sells-second-priority-review-voucher-for-125-million-biomarin-pharmaceutical-inc--bmrn-20171127monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-attend-three-upcoming-investor-conferences-biomarin-pharmaceutical-inc-nasdaq--bmrn-20171031monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-third-quarter-2017-financial-results-financial-highlights-in-millions-o-bmrn-20171026monthly0.5https://www.biopharmawatch.com/news/BMRN/fda-grants-breakthrough-therapy-designation-for-biomarin-s-valoctocogene-roxaparvovec-form-bmrn-20171026monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-highlights-breadth-of-innovative-development-pipeline-at-r-d-day-on-october-18th--bmrn-20171018monthly0.5https://www.biopharmawatch.com/news/BMRN/popular-science-names-biomarin-s-brineura-cerliponase-alfa-one-of-the-top-health-innovatio-bmrn-20171018monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-highlight-breadth-of-innovative-development-pipeline-at-r-d-day-on-october-18t-bmrn-20171011monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-third-quarter-2017-financial-results-conference-call-and-webcast-on-thurs-bmrn-20171010monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-appoints-robert-j-hombach-former-baxalta-cfo-and-coo-to-board-of-directors-biomar-bmrn-20171003monthly0.5https://www.biopharmawatch.com/news/BMRN/fda-not-currently-planning-to-hold-advisory-committee-meeting-for-biomarin-s-pegvaliase-bi-bmrn-20170914monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-presents-interim-data-of-phase-1-2-study-of-bmn-250-for-treatment-of-sanfilippo-b-bmrn-20170906monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-3-platform-and-15-poster-presentations-at-13th-international-congress-o-bmrn-20170905monthly0.5https://www.biopharmawatch.com/news/BMRN/fda-accepts-biomarin-s-pegvaliase-biologics-license-application-bla-and-grants-priority-re-bmrn-20170829monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-exercise-in-full-of-underwriters-option-to-purchase-additional-0-599-se-bmrn-20170823monthly0.5https://www.biopharmawatch.com/news/BMRN/forbes-ranks-biomarin-12th-most-innovative-company-in-the-world-biomarin-pharmaceutical-in-bmrn-20170821monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-attend-upcoming-investor-conferences-biomarin-pharmaceutical-inc-nasdaq-bmrn-t-bmrn-20170815monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-offering-of-450-million-of-0-599-senior-subordinated-convertible-notes--bmrn-20170807monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-second-quarter-2017-financial-results-financial-highlights-in-millions--bmrn-20170802monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-plans-to-progress-both-the-6e13vg-kg-and-4e13-vg-kg-doses-of-bmn-270-it-bmrn-20170802monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-second-quarter-2017-financial-results-conference-call-and-webcast-on-wedn-bmrn-20170731monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-second-quarter-2017-financial-results-conference-call-and-webcast-on-wedn-bmrn-20170718monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-s-investigational-gene-therapy-for-hemophilia-a-at-6e13-vg-kg-dose-maintains-aver-bmrn-20170711monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-submits-pegvaliase-biologics-license-application-bla-to-the-u-s-fda-for-treatment-bmrn-20170630monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-acceptance-of-late-breaking-abstract-at-the-international-society-on-th-bmrn-20170616monthly0.5https://www.biopharmawatch.com/news/BMRN/european-commission-approves-brineura-cerliponase-alfa-the-first-treatment-for-cln2-diseas-bmrn-20170601monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-attend-upcoming-investor-conference-biomarin-pharmaceutical-inc-nasdaq-bmrn-to-bmrn-20170531monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-first-quarter-2017-financial-results-financial-highlights-in-millions-o-bmrn-20170504monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-attend-two-upcoming-investor-conferences-biomarin-pharmaceutical-inc-nasdaq-bm-bmrn-20170502monthly0.5https://www.biopharmawatch.com/news/BMRN/fda-approves-brineura-cerliponase-alfa-for-the-treatment-of-cln2-disease-a-form-of-batten--bmrn-20170427monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-receives-positive-chmp-opinion-in-europe-for-brineura-cerliponase-alfa-for-first--bmrn-20170421monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-first-quarter-2017-financial-results-conference-call-and-webcast-on-thurs-bmrn-20170420monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-kuvan-sapropterin-dihydrochloride-patent-challenge-settlement-biomarin--bmrn-20170413monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-fourth-quarter-and-full-year-2016-financial-results-financial-highlight-bmrn-20170223monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-11-presentations-at-13th-annual-worldsymposium-2017-biomarin-pharmaceut-bmrn-20170215monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-attend-three-investor-conferences-in-1q17-biomarin-pharmaceutical-inc-nasdaq-b-bmrn-20170208monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-fourth-quarter-and-full-year-2016-financial-results-conference-call-and-w-bmrn-20170207monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-receives-access-to-priority-medicines-prime-regulatory-support-from-ema-for-bmn-2-bmrn-20170201monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-provide-update-to-proof-of-concept-data-for-bmn-270-gene-therapy-in-hemophilia-bmrn-20170108monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-35th-annual-j-p-morgan-healthcare-conference-in-san-francisco-bioma-bmrn-20170103monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-j-p-morgan-healthcare-conference-biomarin-pharmaceutical-inc-na-bmrn-20120103monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-ind-for-bmn-111-for-achondroplasia-is-active-biomarin-pharmaceutical-in-bmrn-20120103monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-receives-positive-opinion-from-european-regulatory-authorities-for-expanded-biolo-bmrn-20111219monthly0.5https://www.biopharmawatch.com/news/BMRN/highlights-from-biomarin-s-research-development-day-biomarin-pharmaceutical-inc-nasdaq-bmr-bmrn-20111208monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-buy-back-of-naglazyme-royalties-from-adelaide-health-authority-biomarin-bmrn-20111130monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-initiates-phase-2-study-for-galns-in-patients-under-five-years-of-age-with-mps-iv-bmrn-20111129monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-fda-approval-of-expanded-biologics-manufacturing-facility-biomarin-phar-bmrn-20111128monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-a-research-and-development-day-on-december-8th-biomarin-pharmaceutical-in-bmrn-20111117monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-credit-suisse-healthcare-conference-biomarin-pharmaceutical-inc-bmrn-20111103monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-third-quarter-2011-financial-results-financial-highlights-in-millions-e-bmrn-20111027monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-third-quarter-2011-financial-results-conference-call-and-webcast-on-thurs-bmrn-20110929monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-jefferies-global-healthcare-conference-biomarin-pharmaceutical--bmrn-20110920monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-ubs-global-life-sciences-conference-biomarin-pharmaceutical-inc-bmrn-20110913monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-morgan-stanley-global-healthcare-conference-biomarin-pharmaceut-bmrn-20110907monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-baird-health-care-conference-biomarin-pharmaceutical-inc-nasdaq-bmrn-20110830monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-wedbush-life-sciences-conference-biomarin-pharmaceutical-inc-na-bmrn-20110809monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-provides-update-on-galns-phase-1-2-extension-study-mor-100-biomarin-pharmaceutica-bmrn-20110728monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-second-quarter-2011-financial-results-financial-highlights-in-millions--bmrn-20110728monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-initiates-phase-1-trial-for-bmn-673-in-patients-with-advanced-hematological-malig-bmrn-20110714monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-second-quarter-2011-financial-results-conference-call-and-webcast-on-thur-bmrn-20110630monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-agrees-to-acquire-biologics-manufacturing-plant-in-ireland-from-pfizer-biomarin-p-bmrn-20110623monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-william-blair-growth-stock-conference-biomarin-pharmaceutical-i-bmrn-20110608monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-initiates-phase-3-trial-for-amifampridine-phosphate-for-the-treatment-of-lems-bio-bmrn-20110607monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-jefferies-global-healthcare-conference-biomarin-pharmaceutical--bmrn-20110531monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-ubs-global-specialty-pharmaceuticals-conference-biomarin-pharma-bmrn-20110518monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-bank-of-america-merrill-lynch-healthcare-conference-biomarin-ph-bmrn-20110503monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-first-quarter-2011-financial-results-financial-highlights-in-millions-e-bmrn-20110428monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-deutsche-bank-healthcare-conference-biomarin-pharmaceutical-inc-bmrn-20110426monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-first-quarter-2011-financial-results-conference-call-and-webcast-on-thurs-bmrn-20110328monthly0.5https://www.biopharmawatch.com/news/BMRN/first-of-its-kind-study-suggests-importance-of-routine-mental-health-screening-in-the-care-bmrn-20110318monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-barclays-global-healthcare-conference-biomarin-pharmaceutical-i-bmrn-20110308monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-cowen-health-care-conference-biomarin-pharmaceutical-inc-nasdaq-bmrn-20110301monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-citi-global-healthcare-conference-biomarin-pharmaceutical-inc-n-bmrn-20110222monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-fourth-quarter-and-full-year-2010-financial-results-financial-highlight-bmrn-20110217monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-initiates-pivotal-phase-3-trial-for-galns-for-the-treatment-of-mps-iva-biomarin-p-bmrn-20110201monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-fourth-quarter-and-full-year-2010-financial-results-biomarin-pharmaceutic-bmrn-20110124monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-initiates-phase-1-2-trial-for-bmn-701-for-the-treatment-of-pompe-disease-biomarin-bmrn-20110119monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-initiates-phase-1-2-trial-for-bmn-673-for-the-treatment-of-genetically-defined-ca-bmrn-20110111monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-j-p-morgan-29th-annual-healthcare-conference-biomarin-pharmaceu-bmrn-20110105monthly0.5https://www.biopharmawatch.com/news/BMRN/mhra-issues-notice-of-acceptance-for-phase-3-trial-of-galns-for-the-treatment-of-mps-iva-b-bmrn-20101214monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-deutsche-bank-2010-biofest-conference-biomarin-pharmaceutical-i-bmrn-20101207monthly0.5https://www.biopharmawatch.com/news/BMRN/mhra-completes-review-of-cta-and-issues-notice-of-acceptance-for-bmn-673-for-genetically-d-bmrn-20101202monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-piper-jaffray-healthcare-conference-biomarin-pharmaceutical-inc-bmrn-20101129monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-completes-partial-exchange-of-convertible-notes-due-2013-for-common-stock-biomari-bmrn-20101109monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-third-quarter-2010-financial-results-financial-highlights-in-millions-e-bmrn-20101028monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-announces-program-for-bmn-111-for-the-treatment-of-achondroplasia-biomarin-pharma-bmrn-20101019monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-a-research-and-development-day-on-october-19th-biomarin-pharmaceutical-in-bmrn-20101014monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-third-quarter-2010-financial-results-conference-call-and-webcast-on-thurs-bmrn-20101007monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-host-a-research-and-development-day-on-october-19th-biomarin-pharmaceutical-in-bmrn-20101005monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-appoints-william-young-and-kenneth-bate-to-its-board-of-directors-biomarin-pharma-bmrn-20100923monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-ubs-global-life-sciences-conference-biomarin-pharmaceutical-inc-bmrn-20100914monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-stifel-nicolaus-healthcare-conference-biomarin-pharmaceutical-i-bmrn-20100909monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-robert-w-baird-healthcare-conference-biomarin-pharmaceutical-in-bmrn-20100908monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-to-present-at-the-morgan-stanley-global-healthcare-conference-biomarin-pharmaceut-bmrn-20100907monthly0.5https://www.biopharmawatch.com/news/BMRN/results-from-investigator-sponsored-trials-presented-at-ssiem-conference-biomarin-pharmace-bmrn-20100901monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-receives-orphan-drug-designation-from-the-fda-for-bmn-701-for-the-treatment-of-po-bmrn-20100830monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-initiates-phase-3b-study-to-evaluate-the-effects-of-kuvan-on-neurophychiatric-sym-bmrn-20100817monthly0.5https://www.biopharmawatch.com/news/BMRN/biomarin-acquires-zystor-therapeutics-inc-biomarin-pharmaceutical-inc-nasdaq-bmrn-announce-bmrn-20100817monthly0.5https://www.biopharmawatch.com/news/NBIX/soleno-therapeutics-presents-new-vykat-xr-diazoxide-choline-data-at-endo-2026-demonstratin-nbix-20260615monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-new-two-year-crenessity-crinecerfont-data-on-key-clinica-nbix-20260603monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-real-world-data-highlighting-functional-impact-of-mild-tar-nbix-20260518monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-du-nbix-20260501monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-publication-establishing-clinically-meaningful-improvemen-nbix-20260429monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-showing-sustaine-nbix-20260422monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-first-real-world-head-to-head-claims-analysis-demonstratin-nbix-20260414monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-stifel-2026-virtual-cns-forum-neurocrine-bioscien-nbix-20260310monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-provides-update-on-phase-3-study-of-valbenazine-in-dyskinetic-cereb-nbix-20251222monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-new-data-from-phase-2-study-of-osavampator-in-adults-wit-nbix-20250916monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-upcoming-investor-conferences-in-september-neurocrine-nbix-20250826monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-canaccord-genuity-45th-annual-growth-conference-n-nbix-20250806monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-second-quarter-2025-financial-results-neurocrine-bioscience-nbix-20250730monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-new-analysis-of-cahtalog-registry-showing-most-patients-wi-nbix-20250715monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presented-one-year-data-from-phase-3-cahtalyst-studies-showing-impr-nbix-20250714monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-one-year-data-showing-sustained-efficacy-of-crenessity-cri-nbix-20250714monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2025-financ-nbix-20250709monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-initiation-of-phase-1-clinical-study-evaluating-nbip-0143-nbix-20250630monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-new-post-hoc-data-analyses-from-kinect-hd-study-demonstrat-nbix-20250627monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-new-data-showing-significant-patient-reported-improvements-nbix-20250620monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-appoints-lewis-choi-as-chief-information-officer-neurocrine-bioscie-nbix-20250609monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-patient-reported-outcomes-from-kinect-pro-study-demonstrat-nbix-20250602monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-new-positive-data-from-phase-2-study-of-nbi-1117568-in-adu-nbix-20250528monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-wide-ranging-one-year-data-from-phase-3-cahtalyst-pediat-nbix-20250516monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-data-adding-to-the-growing-body-of-evidence-demonstrating--nbix-20250516monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-data-on-improvements-in-physiologic-glucocorticoid-dosing--nbix-20250515monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-findings-contributing-to-the-growing-body-of-evidence-on-t-nbix-20250514monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-new-results-from-exploratory-analyses-of-the-phase-3-caht-nbix-20250508monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-upcoming-investor-conferences-in-may-neurocrine-biosc-nbix-20250506monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-and-carnie-wilson-team-up-to-launch-connecting-with-carnie-awarenes-nbix-20250506monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-first-quarter-2025-financial-results-and-reaffirms-2025-fin-nbix-20250505monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-new-survey-revealing-need-for-routine-screening-and-earli-nbix-20250505monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-initiates-phase-3-registrational-program-for-nbi-1117568-as-potenti-nbix-20250430monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-publishes-analysis-showing-long-term-efficacy-and-a-consistent-safe-nbix-20250424monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-first-quarter-2025-financi-nbix-20250414monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-real-world-data-on-therapeutic-dose-attainment-and-dosing--nbix-20250331monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-48-week-remission-data-on-treatment-of-tardive-dyskinesia--nbix-20250320monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-new-kinect-hd-data-showing-significant-reduction-in-chorea-nbix-20250317monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-stifel-2025-virtual-cns-forum-neurocrine-bioscien-nbix-20250311monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-initiation-of-phase-1-clinical-study-evaluating-nbi-11406-nbix-20250305monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-patient-reported-outcome-data-from-kinect-pro-study-for-ing-nbix-20250227monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-upcoming-investor-conferences-in-march-neurocrine-bio-nbix-20250225monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-board-of-directors-authorizes-500-million-share-repurchase-program--nbix-20250221monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-fourth-quarter-and-fiscal-2024-financial-results-and-provid-nbix-20250206monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-fourth-quarter-and-year-en-nbix-20250130monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-initiation-of-phase-3-registrational-program-for-osavampa-nbix-20250128monthly0.5https://www.biopharmawatch.com/news/NBIX/andrew-ratz-ph-d-joins-neurocrine-biosciences-as-senior-vice-president-of-drug-development-nbix-20250123monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-classic-congenital-adrenal-hyperplasia-supplement-publish-nbix-20250121monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-publication-on-traditional-glucocorticoid-treatment-in-cl-nbix-20250108monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-neur-nbix-20250106monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-fda-approval-of-crenessity-crinecerfont-a-first-in-class--nbix-20241213monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-participate-at-investor-conferences-in-december-neurocrine-biosc-nbix-20241126monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-new-kinect-hd-data-showing-consistent-efficacy-across-19-s-nbix-20241107monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-participate-at-investor-conferences-in-november-neurocrine-biosc-nbix-20241105monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-breadth-of-data-demonstrating-holistic-improvements-over-t-nbix-20241104monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-new-data-on-ingrezza-valbenazine-capsules-at-psych-congres-nbix-20241104monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-third-quarter-2024-financial-results-and-raises-2024-ingrez-nbix-20241030monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-third-quarter-2024-financi-nbix-20241009monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-interim-data-demonstrating-robust-and-sustained-improvemen-nbix-20240930monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-participate-at-the-td-cowen-4th-annual-novel-mechanisms-in-neuro-nbix-20240919monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-provides-update-on-erudite-phase-2-data-for-luvadaxistat-in-adults--nbix-20240912monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-participate-at-the-2024-cantor-global-healthcare-conference-neur-nbix-20240910monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-participate-at-investor-conferences-in-september-neurocrine-bios-nbix-20240828monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-canaccord-genuity-44th-annual-growth-conference-n-nbix-20240807monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-second-quarter-2024-financial-results-and-raises-2024-ingre-nbix-20240801monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-launches-ingrezza-sprinkle-valbenazine-capsules-to-ease-administrat-nbix-20240718monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2024-financ-nbix-20240711monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-u-s-fda-accepts-new-drug-applications-and-grants-priority-nbix-20240701monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presented-cahtalyst-phase-3-pediatric-and-adult-studies-cahtalog-re-nbix-20240603monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-publication-of-primary-cahtalyst-pediatric-phase-3-study--nbix-20240603monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-participate-at-investor-conferences-in-june-neurocrine-bioscienc-nbix-20240529monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-ceo-succession-plan-neurocrine-biosciences-inc-nasdaq-nbi-nbix-20240528monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-new-phase-3-cahtalyst-data-in-adult-and-pediatric-patien-nbix-20240528monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-publication-of-phase-3-kinect-4-post-hoc-analysis-demonst-nbix-20240521monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presented-baseline-data-from-the-cahtalyst-program-in-cah-and-study-nbix-20240514monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-cahtalyst-adult-study-baseline-characteristics-and-data-on-nbix-20240509monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-initiation-of-phase-1-clinical-study-evaluating-effects-o-nbix-20240509monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-bofa-securities-2024-health-care-conference-neuro-nbix-20240507monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-phase-3-baseline-characteristics-data-from-the-cahtalyst-nbix-20240507monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-supports-tardive-dyskinesia-awareness-week-by-advocating-for-routin-nbix-20240506monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presented-cahtalyst-pediatric-study-baseline-characteristics-and-ca-nbix-20240503monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-first-quarter-2024-financial-results-neurocrine-biosciences-nbix-20240501monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-u-s-fda-approval-of-ingrezza-sprinkle-valbenazine-capsule-nbix-20240430monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-launches-what-the-c-h-educational-initiative-to-support-congenital--nbix-20240424monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-positive-phase-2-data-for-nbi-1065845-in-adults-with-major--nbix-20240423monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-first-quarter-2024-financi-nbix-20240410monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-first-patient-dosed-in-phase-2-clinical-study-evaluating--nbix-20240403monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-initiation-of-phase-1-clinical-study-evaluating-effects-o-nbix-20240328monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-participate-at-virtual-investor-conferences-in-march-neurocrine--nbix-20240311monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-participate-at-investor-conferences-in-march-neurocrine-bioscien-nbix-20240227monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-fourth-quarter-and-fiscal-2023-financial-results-and-provid-nbix-20240207monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-fourth-quarter-and-year-en-nbix-20240117monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-neur-nbix-20240102monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-receives-breakthrough-therapy-designation-from-u-s-food-and-drug-ad-nbix-20231205monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-host-analyst-day-on-december-5-2023-neurocrine-biosciences-inc-n-nbix-20231201monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-settlement-of-ingrezza-abbreviated-new-drug-application-a-nbix-20231113monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-provides-development-pipeline-update-neurocrine-biosciences-inc-nas-nbix-20231109monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-launches-interactive-digital-tool-for-use-by-healthcare-providers-t-nbix-20231108monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-jefferies-london-healthcare-conference-neurocrine-nbix-20231108monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-ingrezza-valbenazine-capsules-interim-data-demonstrating-s-nbix-20231102monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-third-quarter-2023-financial-results-and-raises-2023-ingrez-nbix-20231031monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-third-quarter-2023-financi-nbix-20231010monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-post-hoc-data-analysis-in-congenital-adrenal-hyperplasia-a-nbix-20230921monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-u-s-fda-accepts-new-drug-application-for-ingrezza-valbena-nbix-20230914monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-initiation-of-phase-1-clinical-study-evaluating-effects-o-nbix-20230911monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-upcoming-investor-conferences-in-september-neurocrine-nbix-20230831monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-data-at-mds-international-congress-of-parkinson-s-disease--nbix-20230829monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-new-ingrezza-valbenazine-capsules-data-demonstrating-early-nbix-20230828monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-fda-approval-of-ingrezza-valbenazine-capsules-for-the-tre-nbix-20230818monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-second-quarter-2023-financial-results-and-raises-2023-ingre-nbix-20230801monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-appointment-of-christine-a-poon-to-board-of-directors-neu-nbix-20230711monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2023-financ-nbix-20230711monthly0.5https://www.biopharmawatch.com/news/NBIX/diurnal-ltd-a-neurocrine-biosciences-company-presents-phase-3-extension-study-data-for-mod-nbix-20230615monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-goldman-sachs-44th-annual-global-healthcare-confe-nbix-20230608monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-ingrezza-valbenazine-capsules-data-on-tardive-dyskinesia-i-nbix-20230602monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-publication-of-full-kinect-hd-phase-3-study-results-of-va-nbix-20230519monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-ingrezza-valbenazine-capsules-data-on-long-term-improvemen-nbix-202305152023-05-15T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-data-on-treatment-of-patients-with-congenital-adrenal-hype-nbix-202305122023-05-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-first-quarter-2023-financial-results-neurocrine-biosciences-nbix-202305032023-05-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-bank-of-america-securities-2023-healthcare-confer-nbix-202305022023-05-02T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-supports-the-mental-health-community-during-tardive-dyskinesia-awar-nbix-202305012023-05-01T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-first-quarter-2023-financi-nbix-202304122023-04-12T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-stifel-2023-cns-days-neurocrine-biosciences-inc-n-nbix-202303212023-03-21T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-results-from-the-real-world-re-kinect-study-published-in--nbix-202303092023-03-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-data-on-in-vitro-dissolution-performance-of-ingrezza-valbe-nbix-202303092023-03-09T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-participate-at-investor-conferences-in-march-neurocrine-bioscien-nbix-202303082023-03-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-data-on-improvements-over-time-with-long-term-use-of-ingre-nbix-202303032023-03-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-svb-securities-global-biopharma-conference-neuroc-nbix-202302072023-02-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-fourth-quarter-and-fiscal-2022-financial-results-and-provid-nbix-202302062023-02-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-fourth-quarter-and-year-en-nbix-202301172023-01-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-neur-nbix-202301032023-01-03T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-u-s-fda-accepts-supplemental-new-drug-application-for-val-nbix-20221222monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-provides-update-on-phase-2-study-of-nbi-827104-in-pediatric-patient-nbix-20221206monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-demographic-and-clinical-characteristics-data-of-pediatric-nbix-20221202monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-upcoming-healthcare-conferences-neurocrine-bioscience-nbix-20221108monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-data-on-in-vitro-dissolution-performance-of-ingrezza-valbe-nbix-20221103monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-additional-phase-3-data-for-kinect-hd-study-evaluating-val-nbix-20221103monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-third-quarter-2022-financial-results-and-raises-2022-ingrez-nbix-20221101monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-initiates-phase-2-clinical-study-evaluating-nbi-1117568-in-adults-w-nbix-20221027monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-real-world-parkinson-s-disease-patient-characteristics-fro-nbix-20221024monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-data-on-benztropine-use-among-people-treated-with-antipsyc-nbix-20221019monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-third-quarter-2022-financi-nbix-20221011monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-appoints-dr-ingrid-delaet-as-chief-regulatory-officer-neurocrine-bi-nbix-20220929monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-ingrezza-valbenazine-data-on-sustained-treatment-response--nbix-20220919monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-study-findings-on-evolving-tardive-dyskinesia-education--nbix-20220915monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-new-post-hoc-analysis-of-ongentys-opicapone-capsules-effec-nbix-20220915monthly0.5https://www.biopharmawatch.com/news/NBIX/parkinson-movement-disorder-pmd-alliance-and-neurocrine-biosciences-announce-new-survey-re-nbix-20220912monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-morgan-stanley-20th-annual-global-healthcare-conf-nbix-20220906monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-second-quarter-2022-financial-results-and-raises-2022-ingre-nbix-20220804monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2022-financ-nbix-20220714monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-data-on-treatment-of-adolescent-patients-with-classic-cong-nbix-20220613monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-goldman-sachs-43rd-annual-global-healthcare-confe-nbix-20220608monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-honored-at-cares-foundation-22nd-anniversary-gala-neurocrine-biosci-nbix-20220606monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-data-on-sleep-disturbances-and-off-time-in-patients-with-p-nbix-20220606monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-new-ingrezza-valbenazine-data-on-tardive-dyskinesia-improv-nbix-20220523monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-receives-orphan-drug-designation-for-valbenazine-as-a-treatment-for-nbix-20220512monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-bank-of-america-securities-2022-healthcare-confer-nbix-20220503monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-honors-mental-health-awareness-month-and-fifth-anniversary-of-tardi-nbix-20220502monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-first-quarter-2022-financi-nbix-20220413monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-phase-3-data-for-kinect-hd-study-evaluating-valbenazine-fo-nbix-20220401monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-regulatory-approval-of-dysval-valbenazine-for-the-treatme-nbix-20220328monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-data-on-treatment-patterns-and-unmet-needs-in-adult-and--nbix-20220328monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-data-from-movement-disorder-portfolio-at-the-american-ac-nbix-20220324monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-stifel-2022-cns-days-neurocrine-biosciences-inc-nasda-nbix-20220321monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-upcoming-healthcare-conferences-neurocrine-bioscience-nbix-20220301monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-fourth-quarter-and-year-en-nbix-20220125monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-neur-nbix-20220103monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-positive-phase-3-data-for-kinect-hd-study-evaluating-valb-nbix-20211207monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-appoints-jude-onyia-ph-d-as-chief-scientific-officer-neurocrine-bio-nbix-20211130monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-upcoming-healthcare-conferences-neurocrine-bioscience-nbix-20211109monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-new-ingrezza-valbenazine-data-at-psych-congress-2021-neuro-nbix-20211101monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-ongentys-opicapone-and-ingrezza-valbenazine-data-at-the--nbix-20211016monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-third-quarter-2021-financi-nbix-20211011monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-expands-monumental-moments-program-with-world-renowned-artist-jorge-nbix-20211008monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-new-ingrezza-valbenazine-and-ongentys-opicapone-data-at--nbix-20210910monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-upcoming-healthcare-conferences-neurocrine-bioscience-nbix-20210902monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-completion-of-enrollment-in-phase-3-kinect-hd-study-evalu-nbix-20210805monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2021-financ-nbix-20210719monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-participate-at-the-william-blair-biotech-focus-conference-neuroc-nbix-20210708monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-goldman-sachs-42nd-annual-global-healthcare-confe-nbix-20210601monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-2021-rbc-global-healthcare-conference-neurocrine--nbix-20210511monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-bank-of-america-2021-healthcare-conference-neuroc-nbix-20210504monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-supports-mental-health-month-and-tardive-dyskinesia-awareness-week--nbix-20210503monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-appointment-of-johanna-mercier-to-board-of-directors-neur-nbix-20210416monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-first-quarter-2021-financi-nbix-20210414monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-data-from-its-neurology-portfolio-at-the-american-academ-nbix-20210408monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-stifel-3rd-annual-cns-day-neurocrine-biosciences-inc--nbix-20210325monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-new-data-analyses-for-crinecerfont-in-adults-with-classi-nbix-20210320monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-oppenheimer-31st-annual-healthcare-conference-neu-nbix-20210309monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-top-line-results-from-phase-ii-interact-study-evaluating--nbix-20210302monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-cowen-41st-annual-health-care-conference-neurocri-nbix-20210223monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-fourth-quarter-and-year-en-nbix-20210120monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-neur-nbix-20210104monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-upcoming-healthcare-conferences-neurocrine-bioscience-nbix-20201119monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-upcoming-healthcare-conferences-neurocrine-bioscience-nbix-20201109monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-and-me2-orchestra-in-partnership-with-mental-health-advocacy-groups-nbix-20201007monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-third-quarter-2020-financi-nbix-20201006monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-new-data-analyses-of-once-daily-ongentys-opicapone-in-pa-nbix-20200928monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-once-daily-ongentys-opicapone-now-available-in-the-u-s-as-nbix-20200914monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-new-data-analyses-demonstrating-efficacy-of-fda-approved-o-nbix-20200911monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-and-voyager-therapeutics-present-new-long-term-three-year-data-demo-nbix-20200911monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-morgan-stanley-18th-annual-global-healthcare-conf-nbix-20200908monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-new-data-from-its-movement-disorder-programs-for-tardive-nbix-20200903monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-citi-15th-annual-biopharma-virtual-conference-neu-nbix-20200902monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-second-quarter-2020-financial-results-neurocrine-bioscience-nbix-20200803monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-participate-at-the-william-blair-biotech-focus-conference-2020-n-nbix-20200730monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2020-financ-nbix-20200713monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-bank-of-america-securities-2020-napa-biopharma-co-nbix-20200615monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-positive-phase-ii-data-for-crinecerfont-in-adults-with-cong-nbix-20200608monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-goldman-sachs-41st-annual-global-healthcare-confe-nbix-20200604monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-jefferies-virtual-healthcare-conference-neurocrin-nbix-20200526monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-rbc-capital-markets-2020-global-healthcare-confer-nbix-20200514monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-data-from-its-movement-disorder-portfolio-on-the-america-nbix-20200513monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-exercises-option-to-license-idorsia-s-novel-treatment-for-rare-pedi-nbix-20200511monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-new-data-published-from-the-largest-real-world-screening--nbix-20200507monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-bank-of-america-merrill-lynch-health-care-conference--nbix-20200505monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-fda-approval-of-once-daily-ongentys-opicapone-as-an-add-o-nbix-20200427monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-first-quarter-2020-financi-nbix-20200415monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-provides-covid-19-business-update-neurocrine-biosciences-inc-nasdaq-nbix-20200403monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-cowen-40th-annual-health-care-conference-neurocrine-b-nbix-20200225monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-appointment-of-shalini-sharp-to-board-of-directors-neuroc-nbix-20200203monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-fourth-quarter-and-year-en-nbix-20200120monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-provides-preliminary-fourth-quarter-and-full-year-2019-net-product--nbix-20200112monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-and-idorsia-amend-option-agreement-to-license-novel-treatment-for-r-nbix-20200110monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-live-nbix-20200106monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-and-xenon-pharmaceuticals-announce-agreement-to-develop-first-in-cl-nbix-20191202monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-evercore-isi-2nd-annual-healthconx-conference-neurocr-nbix-20191126monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-publishes-long-term-ingrezza-valbenazine-data-in-the-journal-of-cli-nbix-20191112monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-upcoming-healthcare-conferences-neurocrine-bioscience-nbix-20191105monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-third-quarter-2019-financi-nbix-20191014monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-new-data-analyses-demonstrating-long-term-effects-of-ingre-nbix-20191004monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-data-analyses-demonstrating-the-long-term-effectiveness--nbix-20191001monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-appoints-david-w-boyer-as-chief-corporate-affairs-officer-neurocrin-nbix-20190930monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-data-on-ingrezza-valbenazine-for-tardive-dyskinesia-opic-nbix-20190917monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-appointment-of-leslie-v-norwalk-to-board-of-directors-neu-nbix-20190911monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-upcoming-healthcare-conferences-neurocrine-bioscience-nbix-20190828monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-fda-acceptance-of-new-drug-application-for-opicapone-as-a-nbix-20190710monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2019-financ-nbix-20190708monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-data-on-ingrezza-valbenazine-and-opicapone-at-the-2019-w-nbix-20190611monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-goldman-sachs-40th-annual-global-healthcare-conferenc-nbix-20190604monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-jefferies-2019-global-healthcare-conference-neurocrin-nbix-20190530monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-new-data-from-re-kinect-the-largest-real-world-screening-s-nbix-20190520monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-new-quality-of-life-data-analysis-from-re-kinect-the-lar-nbix-20190516monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-bank-of-america-merrill-lynch-health-care-conference--nbix-20190507monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-honors-mental-health-month-and-raises-awareness-of-tardive-dyskines-nbix-20190506monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-and-voyager-therapeutics-announce-phase-i-results-for-vy-aadc-in-pa-nbix-20190505monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-phase-iii-data-analysis-demonstrating-that-opicapone-added-nbix-20190505monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-data-analyses-on-ingrezza-valbenazine-and-opicapone-at-t-nbix-20190430monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-first-quarter-2019-financial-results-neurocrine-biosciences-nbix-20190429monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-first-quarter-2019-financi-nbix-20190408monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-positive-interim-results-from-phase-ii-study-of-nbi-74788-i-nbix-20190312monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-upcoming-healthcare-conferences-neurocrine-bioscience-nbix-20190305monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-fourth-quarter-and-year-end-2018-financial-results-neurocri-nbix-20190205monthly0.5https://www.biopharmawatch.com/news/NBIX/new-ingrezza-valbenazine-analysis-published-in-the-journal-of-affective-disorders-demonstr-nbix-20190116monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-fourth-quarter-and-year-en-nbix-20190115monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-neur-nbix-20190102monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-jefferies-2018-london-healthcare-conference-neuro-nbix-20181107monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-third-quarter-2018-financial-results-neurocrine-biosciences-nbix-20181105monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-new-data-analyses-on-the-long-term-effects-of-ingrezza-v-nbix-20181023monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-third-quarter-2018-financi-nbix-20181015monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-and-jnana-therapeutics-enter-strategic-collaboration-to-discover-no-nbix-20181009monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-new-long-term-data-analyses-on-ingrezza-valbenazine-at-t-nbix-20181001monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-morgan-stanley-16th-annual-global-healthcare-conf-nbix-20180905monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-data-on-ingrezza-valbenazine-and-opicapone-at-the-2018-w-nbix-20180815monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-second-quarter-2018-financial-results-neurocrine-bioscience-nbix-20180731monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2018-financ-nbix-20180710monthly0.5https://www.biopharmawatch.com/news/NBIX/chief-executive-officer-of-neurocrine-biosciences-kevin-gorman-ph-d-named-ey-entrepreneur--nbix-20180608monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-bank-of-america-merrill-lynch-2018-healthcare-con-nbix-20180509monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-new-quality-of-life-data-from-re-kinect-the-largest-real-w-nbix-20180508monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-new-data-from-re-kinect-the-largest-real-world-screening-nbix-20180502monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-new-data-analyses-at-aan-annual-meeting-demonstrating-ingr-nbix-20180425monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-first-quarter-2018-financi-nbix-20180423monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-new-data-from-ingrezza-at-the-2018-american-academy-of-n-nbix-20180418monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-upcoming-healthcare-conferences-neurocrine-bioscience-nbix-20180307monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-leerink-partners-7th-annual-global-healthcare-con-nbix-20180208monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-fourth-quarter-and-year-en-nbix-20180206monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-retirement-of-christopher-o-brien-m-d-and-appointment-of--nbix-20180107monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-provides-preliminary-fourth-quarter-and-full-year-2017-sales-result-nbix-20180107monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-36th-annual-j-p-morgan-healthcare-conference-neur-nbix-20180102monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-bmo-capital-markets-2017-prescriptions-for-succes-nbix-20171207monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presents-long-term-data-analyses-from-open-label-kinect-4-phase-iii-nbix-20171204monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-new-long-term-data-evaluating-ingrezza-for-the-treatment-nbix-20171129monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-29th-annual-piper-jaffray-healthcare-conference-n-nbix-20171121monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-appoints-matt-abernethy-as-chief-financial-officer-neurocrine-biosc-nbix-20171120monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-announces-long-term-results-evaluating-ingrezza-for-the-treatment-of-adults-wit-nbix-20171114monthly0.5https://www.biopharmawatch.com/news/NBIX/ingrezza-first-fda-approved-product-for-the-treatment-of-tardive-dyskinesia-receives-outst-nbix-20171109monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-jefferies-2017-london-healthcare-conference-neuro-nbix-20171108monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-to-present-data-on-the-patient-impact-of-tardive-dyskinesia-from-the-re-kinect--nbix-20171107monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-credit-suisse-26th-annual-healthcare-conference-n-nbix-20171031monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-initiates-phase-iib-clinical-study-of-once-daily-ingrezza-in-children-and-adole-nbix-20171025monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-to-report-third-quarter-2017--nbix-20171024monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-granted-fda-orphan-drug-designation-for-valbenazine-for-the-treatment-of-pediat-nbix-20171023monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-announces-fda-approval-of-80-mg-ingrezza-valbenazine-capsules-for-the-treatment-nbix-20171005monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-announces-data-on-the-real-world-patient-impact-of-td-from-the-re-kinect-study--nbix-20170915monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-morgan-stanley-15th-annual-global-healthcare-conf-nbix-20170906monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-baird-2017-global-healthcare-conference-neurocrin-nbix-20170830monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-second-quarter-2017-results-neurocrine-biosciences-inc-nasd-nbix-20170803monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-to-report-second-quarter-2017-nbix-20170728monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-the-appointment-of-julie-cooke-as-chief-people-officer-ne-nbix-20170721monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-goldman-sachs-38th-annual-global-healthcare-confe-nbix-20170609monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-announces-presentations-related-to-ingrezza-valbenazine-capsules-at-the-21st-in-nbix-20170602monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-jefferies-2017-global-healthcare-conference-neuro-nbix-20170601monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-announces-phase-ii-results-of-vmat2-inhibitor-ingrezza-for-treatment-of-tourett-nbix-20170523monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-announces-ingrezza-valbenazine-capsules-pharmacokinetic-profile-and-long-term-d-nbix-20170518monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-bank-of-america-merrill-lynch-2017-healthcare-con-nbix-20170511monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-first-quarter-2017-results-neurocrine-biosciences-inc-nasda-nbix-20170509monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-to-report-first-quarter-2017--nbix-20170503monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-inc-announces-closing-of-offering-of-517-5-million-of-convertible-s-nbix-20170502monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-inc-prices-450-0-million-convertible-senior-notes-offering-neurocri-nbix-20170426monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-announces-proposed-convertible-senior-notes-offering-neurocrine-biosciences-inc-nbix-20170425monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-announces-ingrezza-long-term-safety-and-efficacy-data-to-be-presented-at-the-20-nbix-20170421monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-announces-fda-approval-of-ingrezza-valbenazine-capsules-as-the-first-and-only-a-nbix-20170411monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-announces-fda-approval-of-ingrezza-tm-valbenazine-capsules-as-the-first-and-onl-nbix-20170411monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-announces-american-journal-of-psychiatry-publication-of-positive-results-from-k-nbix-20170321monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-year-end-2016-results-and-provides-investor-update-for-2017-nbix-20170214monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-and-bial-announce-exclusive-north-american-licensing-agreement-for-opicapone-ne-nbix-20170209monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-to-report-fourth-quarter-and--nbix-20170207monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-announces-completion-of-phase-ii-clinical-study-of-vmat2-inhibitor-ingrezza-val-nbix-20170117monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-the-appointment-of-david-alexandre-gros-m-d-president-and-nbix-20170106monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-provides-update-on-fda-advisory-committee-for-ingrezza-valbenazine-for-the-trea-nbix-20170105monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-35th-annual-j-p-morgan-healthcare-conference-neur-nbix-20170103monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-chief-financial-officer-timothy-p-coughlin-to-step-down-n-nbix-20161221monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-2016-bmo-capital-markets-prescription-for-success-nbix-20161207monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-ingrezza-valbenazine-long-term-data-to-be-presented-at-th-nbix-20161205monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-announces-fda-advisory-committee-meeting-to-review-ingrezza-valbenazine-new-dru-nbix-20161129monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-28th-annual-piper-jaffray-healthcare-conference-n-nbix-20161121monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-jefferies-2016-london-healthcare-conference-neuro-nbix-20161110monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-third-quarter-2016-results-neurocrine-biosciences-inc-nasda-nbix-20161102monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-credit-suisse-25th-annual-healthcare-conference-n-nbix-20161031monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-to-report-third-quarter-2016--nbix-20161026monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-announces-ingrezza-valbenazine-new-drug-application-for-the-treatment-of-tardiv-nbix-20161011monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-morgan-stanley-global-healthcare-conference-neuro-nbix-20160907monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-baird-2016-healthcare-conference-neurocrine-biosc-nbix-20160901monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-announces-fda-conditional-acceptance-of-proprietary-name-ingrezza-for-vmat2-inh-nbix-20160831monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-submits-new-drug-application-for-valbenazine-for-treatment-of-tardive-dyskinesi-nbix-20160829monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-second-quarter-2016-results-neurocrine-biosciences-inc-nasd-nbix-20160803monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-announces-initiation-of-a-long-term-phase-ii-clinical-study-of-vmat2-inhibitor--nbix-20160728monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-to-report-second-quarter-2016-nbix-20160727monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-jefferies-2016-healthcare-conference-neurocrine-b-nbix-20160602monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-the-retirement-of-w-thomas-mitchell-from-the-board-of-dir-nbix-20160520monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-additional-valbenazine-nbi-98854-data-to-be-presented-at--nbix-20160506monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-bank-of-america-merrill-lynch-2016-health-care-co-nbix-20160506monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-first-quarter-2016-results-neurocrine-biosciences-inc-nasda-nbix-20160505monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-to-report-first-quarter-2016--nbix-20160429monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-deutsche-bank-41st-annual-health-care-conference--nbix-20160427monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-barclays-global-healthcare-conference-neurocrine--nbix-20160309monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-the-acceptance-of-three-scientific-abstracts-for-valbenaz-nbix-20160302monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-cowen-and-company-36th-annual-health-care-confere-nbix-20160302monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-year-end-2015-results-and-provides-investor-update-for-2016-nbix-20160211monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-to-report-fourth-quarter-and--nbix-20160208monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-leerink-partners-5th-annual-global-healthcare-con-nbix-20160203monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-announces-initiation-of-phase-ii-clinical-study-of-vmat2-inhibitor-valbenazine--nbix-20160202monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-34th-annual-j-p-morgan-healthcare-conference-neur-nbix-20160104monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-announces-successful-completion-of-phase-ib-t-force-study-of-vmat2-inhibitor-nb-nbix-20151216monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-27th-annual-piper-jaffray-healthcare-conference-n-nbix-20151125monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-jefferies-autumn-2015-global-healthcare-conferenc-nbix-20151111monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-expansion-of-its-clinical-pipeline-neurocrine-biosciences-nbix-20151104monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-credit-suisse-s-24th-annual-healthcare-conference-neu-nbix-20151104monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-third-quarter-2015-results-neurocrine-biosciences-inc-nasda-nbix-20151029monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-to-report-third-quarter-2015--nbix-20151022monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-announces-initiation-of-phase-ii-clinical-study-of-vmat2-inhibitor-nbi-98854-in-nbix-20151020monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-announces-positive-results-from-phase-iii-kinect-3-study-of-nbi-98854-in-tardiv-nbix-20151008monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-the-appointment-of-george-j-morrow-to-its-board-of-direct-nbix-20150930monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-morgan-stanley-global-healthcare-conference-neuro-nbix-20150910monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-the-appointment-of-dr-alfred-w-sandrock-to-its-board-of-d-nbix-20150903monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-baird-2015-healthcare-conference-neurocrine-biosc-nbix-20150902monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-second-quarter-2015-results-neurocrine-biosciences-inc-nasd-nbix-20150729monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-to-report-second-quarter-2015-nbix-20150722monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-provides-update-on-nbi-77860-program-for-congenital-adrenal-hyperpl-nbix-20150608monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-inc-announces-appointment-of-eric-benevich-as-chief-commercial-offi-nbix-20150602monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-jefferies-2015-healthcare-conference-neurocrine-b-nbix-20150527monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-host-analyst-and-investor-day-in-new-york-city-on-may-21-2015-ne-nbix-20150512monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-bank-of-america-merrill-lynch-2015-health-care-co-nbix-20150508monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-inc-announces-appointment-of-dr-bill-aurora-as-vice-president-medic-nbix-20150504monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-first-quarter-2015-results-neurocrine-biosciences-inc-nasda-nbix-20150430monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-deutsche-bank-40th-annual-health-care-conference--nbix-20150430monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-to-report-first-quarter-2015--nbix-20150423monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-and-mitsubishi-tanabe-pharma-announce-agreement-to-develop-and-comm-nbix-20150331monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-barclays-global-healthcare-conference-live-audio--nbix-20150303monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-cowen-and-company-s-35th-annual-health-care-conferenc-nbix-20150224monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-inc-announces-exercise-in-full-of-underwriters-option-to-purchase-a-nbix-20150220monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-inc-prices-public-offering-of-common-stock-neurocrine-biosciences-i-nbix-20150219monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-inc-announces-proposed-public-offering-of-225-million-of-common-sto-nbix-20150217monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-year-end-2014-results-and-provides-investor-update-for-2015-nbix-20150209monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-2015-leerink-global-healthcare-conference-neurocr-nbix-20150204monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-to-report-fourth-quarter-and--nbix-20150202monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-oral-presentation-of-nbi-77860-clinical-trial-data-in-cla-nbix-20150120monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-granting-of-orphan-drug-status-for-nbi-77860-in-congenita-nbix-20150116monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-33rd-annual-j-p-morgan-healthcare-conference-euro-nbix-20150108monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-expansion-of-its-clinical-pipeline-neurocrine-biosciences-nbix-20141210monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-25th-annual-oppenheimer-healthcare-conference-neu-nbix-20141204monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-to-present-at-the-2014-deutsche-bank-biofest-and-the-26th-annual-piper-jaffray--nbix-20141125monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-jefferies-2014-global-healthcare-conference-neuro-nbix-20141112monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-inc-announces-appointment-of-darin-lippoldt-as-chief-legal-officer--nbix-20141104monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-nomura-biotechnology-conference-neurocrine-biosci-nbix-20141103monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-third-quarter-2014-results-neurocrine-biosciences-inc-nasda-nbix-20141103monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-receives-breakthrough-therapy-designation-for-nbi-98854-in-tardive--nbix-20141030monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-to-report-third-quarter-2014--nbix-20141027monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-announces-initiation-of-phase-iii-study-for-vmat2-inhibitor-nbi-98854-neurocrin-nbix-20141020monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-announces-expansion-of-vmat2-inhibitor-program-with-initiation-of-tourette-synd-nbix-20141002monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-inc-announces-appointment-of-malcolm-lloyd-smith-as-chief-regulator-nbix-20141001monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-morgan-stanley-global-healthcare-conference-neuro-nbix-20140903monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-second-quarter-2014-results-neurocrine-biosciences-inc-nasd-nbix-20140806monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-to-report-second-quarter-2014-nbix-20140729monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-presenting-nbi-98854-scientific-abstracts-and-posters-at-the-intern-nbix-20140611monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-jefferies-2014-global-healthcare-conference-neuro-nbix-20140529monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-bank-of-america-merrill-lynch-2014-health-care-co-nbix-20140508monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-first-quarter-2014-results-neurocrine-biosciences-inc-nasda-nbix-20140430monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-to-report-first-quarter-2014--nbix-20140425monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-26th-annual-roth-conference-neurocrine-bioscience-nbix-20140304monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-cowen-and-company-34th-annual-health-care-confere-nbix-20140227monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-inc-prices-public-offering-of-common-stock-neurocrine-biosciences-i-nbix-20140226monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-nbi-98854-scientific-presentations-at-the-international-p-nbix-20140225monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-inc-announces-proposed-public-offering-of-common-stock-neurocrine-b-nbix-20140225monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-leerink-global-healthcare-conference-neurocrine-b-nbix-20140207monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-fourth-quarter-and-year-end-2013-results-neurocrine-bioscie-nbix-20140206monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-to-report-fourth-quarter-and--nbix-20140204monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-announces-12-week-safety-results-from-initial-phase-iib-study-of-vmat2-inhibito-nbix-20140109monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-announces-positive-results-of-vmat2-inhibitor-nbi-98854-in-kinect-2-study-neuro-nbix-20140106monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-oppenheimer-s-24th-annual-healthcare-conference-neuro-nbix-20131204monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-deutsche-bank-2013-biofest-and-the-25th-annual-piper--nbix-20131126monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-third-quarter-2013-results-neurocrine-biosciences-inc-nasda-nbix-20131029monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-to-present-third-quarter-2013-nbix-20131022monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-announces-phase-iib-results-of-vmat2-inhibitor-nbi-98854-for-treatment-of-tardi-nbix-20130909monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-morgan-stanley-global-healthcare-conference-neuro-nbix-20130903monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-the-start-of-second-phase-iii-study-of-elagolix-in-endome-nbix-20130829monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-second-quarter-2013-results-neurocrine-biosciences-inc-nasd-nbix-20130725monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-to-present-second-quarter-201-nbix-20130718monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-announces-completion-of-enrollment-into-kinect-study-for-treatment-of-tardive-d-nbix-20130701monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-jefferies-2013-global-healthcare-conference-neuro-nbix-20130529monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-deutsche-bank-38th-annual-dbaccess-health-care-co-nbix-20130523monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-bank-of-america-merrill-lynch-2013-health-care-co-nbix-20130509monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-first-quarter-2013-results-neurocrine-biosciences-inc-nasda-nbix-20130502monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-to-present-first-quarter-2013-nbix-20130426monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-needham-12th-annual-healthcare-conference-neurocr-nbix-20130424monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-the-start-of-phase-iib-study-of-elagolix-in-uterine-fibro-nbix-20130327monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-25th-annual-roth-conference-neurocrine-bioscience-nbix-20130311monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-cowen-and-company-33rd-annual-health-care-confere-nbix-20130227monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-fourth-quarter-and-year-end-2012-results-neurocrine-bioscie-nbix-20130208monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-leerink-swann-global-healthcare-conference-2013-n-nbix-20130206monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-to-present-fourth-quarter-and-nbix-20130201monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-additional-european-and-united-states-patents-issued-on-p-nbix-20130123monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-announces-start-of-second-phase-iib-study-of-vmat2-inhibitor-nbi-98854-for-trea-nbix-20121218monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-deutsche-bank-s-2012-dbaccess-biofest-neurocrine-bios-nbix-20121127monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-24th-annual-piper-jaffray-healthcare-conference-n-nbix-20121120monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-lazard-capitalmarket-s-9th-annual-healthcare-conferen-nbix-20121106monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-third-quarter-2012-results-neurocrine-biosciences-inc-nasda-nbix-20121031monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-to-present-third-quarter-2012-nbix-20121024monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-announces-start-of-phase-iib-study-of-vmat2-inhibitor-nbi-98854-for-treatment-o-nbix-20121001monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-morgan-stanley-global-healthcare-conference-neuro-nbix-20120905monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-second-quarter-2012-results-neurocrine-biosciences-inc-nasd-nbix-20120731monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-to-present-second-quarter-201-nbix-20120725monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-jefferies-2012-global-healthcare-conference-neuro-nbix-20120529monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-urocortin-2-phase-ii-study-results-in-patients-with-acute-nbix-20120517monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-deutsche-bank-37th-annual-health-care-conference--nbix-20120504monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-first-quarter-2012-results-neurocrine-biosciences-inc-nasda-nbix-20120502monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-to-present-first-quarter-2012-nbix-20120501monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-to-present-first-quarter-2012-nbix-20120425monthly0.5https://www.biopharmawatch.com/news/NBIX/elagolix-endometriosis-phase-iii-trials-on-track-to-commence-in-second-quarter-2012-neuroc-nbix-20120327monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-11th-annual-needham-healthcare-conference-neurocr-nbix-20120327monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-announces-phase-ii-results-of-vmat2-inhibitor-nbi-98854-for-treatment-of-tardiv-nbix-20120326monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-24th-annual-roth-conference-neurocrine-bioscience-nbix-20120307monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-32nd-annual-cowen-health-care-conference-neurocri-nbix-20120229monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-citi-2012-global-health-care-conference-neurocrin-nbix-20120221monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-fourth-quarter-and-year-end-2011-results-neurocrine-bioscie-nbix-20120208monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-14th-annual-bio-ceo-investor-conference-neurocrin-nbix-20120206monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-to-present-fourth-quarter-and-nbix-20120202monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-inc-announces-exercise-in-full-of-underwriters-option-to-purchase-a-nbix-20120130monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-the-fda-has-granted-fast-track-designation-for-vmat2-inhi-nbix-20120125monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-inc-prices-public-offering-of-common-stock-neurocrine-biosciences-i-nbix-20120119monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-inc-announces-proposed-public-offering-of-common-stock-neurocrine-b-nbix-20120118monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-mourns-the-passing-of-founder-and-board-member-wylie-vale-ph-d-neurocrine-biosc-nbix-20120107monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-30th-annual-j-p-morgan-healthcare-conference-neur-nbix-20120106monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-23rd-annual-piper-jaffray-health-care-conference--nbix-20111123monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-2011-credit-suisse-annual-health-care-conference--nbix-20111103monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-third-quarter-2011-results-neurocrine-biosciences-inc-nasda-nbix-20111031monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-to-present-third-quarter-2011-nbix-20111026monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-receives-second-milestone-payment-of-20-million-under-abbott-collab-nbix-20111004monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-elagolix-scientific-presentations-at-the-67th-annual-meet-nbix-20110927monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-that-vmat-2-program-begins-enrollment-in-second-phase-ii--nbix-20110919monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-the-start-of-phase-ii-study-of-elagolix-in-uterine-fibroi-nbix-20110913monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-ubs-global-life-sciences-conference-neurocrine-bi-nbix-20110913monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-stifel-nicolaus-2011-healthcare-conference-neuroc-nbix-20110901monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-to-present-second-quarter-201-nbix-20110728monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-second-quarter-2011-results-neurocrine-biosciences-inc-nasd-nbix-20110728monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-to-present-second-quarter-201-nbix-20110721monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-notice-of-allowance-for-composition-of-matter-patent-on-v-nbix-20110623monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-elagolix-scientific-presentations-at-the-11th-world-congr-nbix-20110616monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-jefferies-2011-global-healthcare-conference-neuro-nbix-20110531monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-first-quarter-2011-results-neurocrine-biosciences-inc-nasda-nbix-20110503monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-to-present-first-quarter-2011-nbix-20110429monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-deutsche-bank-36th-annual-healthcare-conference-n-nbix-20110427monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-successful-phase-iia-clinical-trial-for-vmat2-inhibitor-e-nbix-20110405monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-10th-annual-needham-healthcare-conference-neurocr-nbix-20110330monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-roth-23rd-annual-oc-growth-stock-conference-neuro-nbix-20110308monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-cowen-co-31st-annual-health-care-conference-neuro-nbix-20110302monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-citi-s-2011-global-health-care-conference-neurocrine--nbix-20110223monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-to-present-fourth-quarter-and-nbix-20110210monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-fourth-quarter-and-year-end-2010-results-neurocrine-bioscie-nbix-20110210monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-to-present-fourth-quarter-and-nbix-20110203monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-22nd-annual-piper-jaffray-health-care-conference--nbix-20101123monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-successful-completion-of-daisy-petal-study-neurocrine-bio-nbix-20101122monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-reports-third-quarter-2010-results-neurocrine-biosciences-inc-nasda-nbix-20101028monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-the-oppenheimer-21st-annual-healthcare-conference-neu-nbix-20101026monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-that-vmat2-program-will-move-into-phase-ii-clinical-trial-nbix-20101018monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-to-report-third-quarter-2010--nbix-20101018monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-announces-top-line-results-of-corticotropin-releasing-factor-antagonist-gsk5616-nbix-20100914monthly0.5https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-to-present-at-two-upcoming-conferences-on-september-16-and-septembe-nbix-20100909monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-e-ewtx-20260603monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-e-ewtx-20260504monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-announces-positive-long-term-sevasemten-data-demonstrating-sustained-functional-s-ewtx-20260310monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-on-ja-ewtx-20260106monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-e-ewtx-20251112monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-e-ewtx-20251103monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-e-ewtx-20251002monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-e-ewtx-20250903monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-e-ewtx-20250806monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-reports-positive-results-on-sevasemten-program-for-becker-and-duchen-ewtx-20250626monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-to-present-at-the-annual-goldman-sachs-global-healthcare-conference--ewtx-20250603monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference-o-ewtx-20250514monthly0.5https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirru-ewtx-20250326monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-issues-nationwide-recall-of-potassium-chloride-injection-20-meq-and-potassium--icui-20250213monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-inc-and-otsuka-pharmaceutical-factory-inc-a-subsidiary-of-otsuka-holdings-co-l-icui-20241112monthly0.5https://www.biopharmawatch.com/news/ICUI/smiths-medical-issues-urgent-medical-device-correction-letter-notifying-customers-of-poten-icui-20221212monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-s-plum-360-infusion-system-receives-first-ever-best-in-klas-honor-as-top-perfo-icui-20210202monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-broadens-its-non-pvc-non-dehp-iv-solutions-portfolio-by-entering-long-term-u-s-icui-20200810monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-issues-a-voluntary-nationwide-recall-of-lactated-ringer-s-injection-usp-due-to-icui-20200508monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-inc-to-acquire-pursuit-vascular-inc-icu-medical-inc-nasdaq-icui-a-leader-in-th-icui-20191104monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-inc-issues-a-voluntary-nationwide-recall-of-lactated-ringer-s-injection-usp-an-icui-20191030monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-issues-a-voluntary-nationwide-recall-of-certain-lots-of-plum-and-sapphire-micr-icui-20191007monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-issues-a-voluntary-nationwide-recall-of-certain-lots-of-chemolock-and-chemocla-icui-20190225monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-s-plum-360-infusion-system-is-the-first-medical-device-to-earn-ul-cybersecurit-icui-20180619monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-issues-a-voluntary-nationwide-recall-of-one-lot-of-0-9-sodium-chloride-injecti-icui-20170728monthly0.5https://www.biopharmawatch.com/news/ICUI/integrating-icu-medical-infusion-devices-with-hospital-electronic-medical-records-decrease-icui-20170215monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-launches-the-all-new-diana-compounding-workflow-system-at-the-american-society-icui-20161201monthly0.5https://www.biopharmawatch.com/news/ICUI/b-braun-and-icu-medical-sign-expanded-long-term-international-distribution-agreement-icu-m-icui-20160321monthly0.5https://www.biopharmawatch.com/news/ICUI/new-study-shows-icu-medical-s-swabcap-reduced-central-line-associated-bloodstream-infectio-icui-20160113monthly0.5https://www.biopharmawatch.com/news/ICUI/new-clinical-study-shows-icu-medical-infusion-systems-are-associated-with-a-reduction-in-b-icui-20140905monthly0.5https://www.biopharmawatch.com/news/ICUI/new-study-shows-icu-medical-s-microclave-and-neutron-needlefree-iv-connectors-have-signifi-icui-20140618monthly0.5https://www.biopharmawatch.com/news/ICUI/new-peer-reviewed-study-shows-icu-medical-s-tego-needlefree-connector-is-associated-with-a-icui-20140423monthly0.5https://www.biopharmawatch.com/news/ICUI/new-clinical-studies-show-icu-medical-s-chemolock-closed-system-transfer-device-prevents-h-icui-20131212monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-launches-the-chemolock-needlefree-closed-system-transfer-device-cstd-at-the-am-icui-20131209monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-receives-premier-inc-contract-for-the-new-diana-hazardous-drug-compounding-sys-icui-20131202monthly0.5https://www.biopharmawatch.com/news/ICUI/two-new-clinical-studies-show-icu-medical-chemoclave-system-improves-safety-by-reducing-ha-icui-20130919monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-s-new-chemolock-needlefree-closed-system-transfer-device-cstd-receives-first-e-icui-20130909monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-receives-premier-healthcare-alliance-contracts-for-its-complete-line-of-needle-icui-20130822monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-announces-european-launch-of-the-new-diana-automated-hazardous-drug-compoundin-icui-20130312monthly0.5https://www.biopharmawatch.com/news/ICUI/new-u-s-market-data-shows-icu-medical-s-needlefree-iv-connector-technology-chosen-more-tha-icui-20130307monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-inc-to-voluntarily-discontinue-u-s-distribution-of-the-clc2000-positive-displa-icui-20130128monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-launches-cardioflo-minimally-invasive-hemodynamic-monitoring-sensor-system-icu-icui-20130117monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-launches-diana-automated-sterile-compounding-system-for-the-accurate-safe-and--icui-20121129monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-s-diana-system-may-help-compounding-pharmacies-avoid-drug-contamination-a-rece-icui-20121022monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-launches-nanoclave-needlefree-connector-to-help-clinicians-better-manage-neona-icui-20121015monthly0.5https://www.biopharmawatch.com/news/ICUI/safe-handling-presentation-hosted-by-icu-medical-will-teach-nurses-how-to-protect-themselv-icui-20120906monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-inc-signs-agreement-with-roi-for-microclave-clear-needlefree-iv-connector-icu--icui-20120626monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-s-custom-iv-system-with-microclave-needlefree-connector-shown-to-help-reduce-n-icui-20120613monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-s-chemoclave-system-included-in-mobius-therapeutics-mitosol-kit-for-use-in-gla-icui-20120607monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-inc-plans-to-vigorously-seek-to-collect-damages-in-wake-of-patent-infringement-icui-20120514monthly0.5https://www.biopharmawatch.com/news/ICUI/breaking-studies-icu-medical-inc-s-chemoclave-system-shown-to-protect-nurses-from-exposure-icui-20120503monthly0.5https://www.biopharmawatch.com/news/ICUI/breaking-study-icu-medical-s-tego-needlefree-connector-proves-more-cost-effective-than-tra-icui-20111213monthly0.5https://www.biopharmawatch.com/news/ICUI/novation-awards-icu-medical-inc-a-new-contract-to-supply-members-with-a-complete-line-of-c-icui-20111115monthly0.5https://www.biopharmawatch.com/news/ICUI/breaking-study-icu-medical-inc-chemoclave-system-costs-less-to-implement-than-any-closed-s-icui-20111108monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-launches-neutron-needlefree-catheter-patency-device-with-constant-neutral-pres-icui-20111004monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-inc-awarded-hemodynamic-monitoring-agreement-by-the-premier-healthcare-allianc-icui-20110414monthly0.5https://www.biopharmawatch.com/news/ICUI/three-studies-presented-at-the-2011-shea-annual-scientific-meeting-show-that-the-icu-medic-icui-20110404monthly0.5https://www.biopharmawatch.com/news/ICUI/icu-medical-to-launch-microclave-clear-needlefree-connector-at-the-annual-scientific-meeti-icui-20110331monthly0.5https://www.biopharmawatch.com/news/ABT/new-research-shows-even-stronger-health-outcomes-for-participants-in-a-food-is-medicine-pr-abt-20260608monthly0.5https://www.biopharmawatch.com/news/ABT/new-abbott-data-show-many-people-with-diabetes-may-not-recognize-symptoms-of-diabetic-keto-abt-20260606monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-showcases-expanding-evidence-across-its-cancer-diagnostics-portfolio-at-asco-2026-a-abt-20260526monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-showcases-strength-of-its-technologies-to-address-abnormal-heart-rhythms-with-late--abt-20260425monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-real-madrid-launch-nationwide-effort-to-build-the-next-abbott-dream-team-abbott-abt-20260311monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-amplatzer-piccolo-delivery-system-receives-fda-clearance-and-ce-mark-to-optimize--abt-20251218monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-407th-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20250919monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-abt-20250829monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-big-ten-conference-rally-students-alumni-and-fans-to-save-lives-and-win-1-milli-abt-20250818monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-second-quarter-2025-results-abbott-nyse-abt-today-announced-financial-resul-abt-20250717monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-second-quarter-earnings-abbott-nyse-abt-will-announce-its-abt-20250626monthly0.5https://www.biopharmawatch.com/news/ABT/new-research-on-abbott-s-healthy-food-rx-program-shows-food-is-medicine-approach-helps-peo-abt-20250620monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-406th-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20250613monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-approval-for-tendyne-first-of-its-kind-device-to-replace-the-mitral-va-abt-20250527monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-libre-technology-is-first-continuous-glucose-monitor-associated-with-reduced-hosp-abt-20250515monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-real-madrid-kick-off-search-to-empower-young-soccer-talent-abbott-nyse-abt-anno-abt-20250507monthly0.5https://www.biopharmawatch.com/news/ABT/motoamerica-becomes-first-sports-organization-to-use-abbott-s-rapid-blood-test-for-concuss-abt-20250501monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-integrates-libre-s-data-with-epic-s-electronic-health-record-system-providing-healt-abt-20250429monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-highlights-new-aveir-data-initiates-trial-for-the-company-s-conduction-system-pacin-abt-20250427monthly0.5https://www.biopharmawatch.com/news/ABT/new-clinical-study-data-showcase-long-term-sustained-benefits-of-abbott-s-volt-pfa-system--abt-20250426monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-first-quarter-2025-results-and-reaffirms-full-year-guidance-abbott-nyse-abt-abt-20250416monthly0.5https://www.biopharmawatch.com/news/ABT/new-late-breaking-data-reinforce-benefits-of-abbott-s-triclip-for-people-with-leaky-tricus-abt-20250331monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-ce-mark-for-its-volt-pulsed-field-ablation-system-to-treat-patients-with-a-abt-20250327monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-first-quarter-earnings-abbott-nyse-abt-will-announce-its--abt-20250326monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-initiates-new-intravascular-lithotripsy-clinical-trial-to-improve-outcomes-in-patie-abt-20250324monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-405th-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20250221monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-above-the-bias-film-reveals-misconceptions-can-impact-diabetes-care-one-cupcake-w-abt-20250204monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-fourth-quarter-and-full-year-2024-results-issues-2025-financial-outlook-abb-abt-20250122monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-fourth-quarter-earnings-abbott-nyse-abt-will-announce-its-abt-20250102monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-first-in-world-leadless-pacing-procedures-in-the-left-bundle-branch-area--abt-20241217monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-increases-quarterly-dividend-for-53rd-consecutive-year-abbott-nyse-abt-today-announ-abt-20241213monthly0.5https://www.biopharmawatch.com/news/ABT/university-of-nebraska-wins-the-abbott-and-big-ten-conference-s-nationwide-we-give-blood-d-abt-20241207monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-first-step-toward-its-software-guided-balloon-expandable-tavi-system-to-t-abt-20241125monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-opens-state-of-the-art-global-manufacturing-facility-in-kilkenny-ireland-abbott-nys-abt-20241118monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-inaugure-un-site-de-fabrication-de-pointe-a-kilkenny-en-irlande-abbott-nyse-abt-mar-abt-20241118monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-inaugura-una-planta-de-fabricacio-n-global-de-u-ltima-generacio-n-en-kilkenny-irlan-abt-20241118monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-ero-ffnet-eine-hochmoderne-globale-produktionssta-tte-in-kilkenny-irland-abbott-nys-abt-20241118monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-initiates-new-clinical-trial-to-improve-outcomes-in-patients-with-advanced-heart-fa-abt-20241024monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-third-quarter-2024-results-and-raises-midpoint-of-full-year-eps-guidance-ra-abt-20241016monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-advances-pulsed-field-ablation-clinical-studies-and-launches-new-technology-to-supp-abt-20241010monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-the-big-ten-conference-tackle-u-s-blood-shortages-with-first-of-its-kind-nation-abt-20240926monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-third-quarter-earnings-abbott-nyse-abt-will-announce-its--abt-20240925monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-403rd-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20240919monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-lingo-continuous-glucose-monitor-for-health-and-wellness-now-available-in-the-u-s-abt-20240905monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-initiates-clinical-study-to-evaluate-the-use-of-its-deep-brain-stimulation-system-t-abt-20240904monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-expands-its-pure-bliss-line-of-infant-formulas-to-include-european-made-and-organic-abt-20240827monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-enters-global-partnership-to-connect-its-world-leading-continuous-glucose-monitorin-abt-20240807monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-second-quarter-2024-results-and-raises-full-year-guidance-abbott-nyse-abt-t-abt-20240718monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-second-quarter-earnings-abbott-nyse-abt-will-announce-its-abt-20240627monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-teams-up-with-the-national-association-of-community-health-centers-to-expand-access-abt-20240620monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-402nd-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20240614monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-u-s-fda-clearance-for-two-new-over-the-counter-continuous-glucose-monitori-abt-20240610monthly0.5https://www.biopharmawatch.com/news/ABT/el-stent-innovador-que-se-disuelve-de-abbott-recibe-la-aprobacio-n-de-la-fda-para-arterias-abt-20240430monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-breakthrough-dissolving-stent-receives-fda-approval-for-arteries-below-the-knee-a-abt-20240429monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-first-quarter-2024-results-and-raises-midpoint-of-full-year-guidance-ranges-abt-20240417monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-approval-for-triclip-first-of-its-kind-device-to-repair-leaky-tricuspi-abt-20240402monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-clearance-for-whole-blood-rapid-test-to-help-with-assessment-of-concus-abt-20240401monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-first-quarter-earnings-abbott-nyse-abt-will-announce-its--abt-20240327monthly0.5https://www.biopharmawatch.com/news/ABT/real-world-data-show-abbott-s-freestyle-libre-systems-and-glp-1-medicines-work-better-toge-abt-20240306monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-401st-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20240216monthly0.5https://www.biopharmawatch.com/news/ABT/fda-advisory-committee-votes-in-favor-of-abbott-s-first-of-its-kind-triclip-system-to-trea-abt-20240213monthly0.5https://www.biopharmawatch.com/news/ABT/new-study-shows-mixed-reality-technology-for-blood-donation-from-abbott-and-blood-centers--abt-20240201monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-launches-new-protality-brand-to-support-adults-on-their-weight-loss-journey-the-pro-abt-20240131monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-launches-world-s-smallest-rechargeable-system-with-remote-programming-capabilities--abt-20240125monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-fourth-quarter-and-full-year-2023-results-issues-2024-financial-outlook-abb-abt-20240124monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-first-global-procedures-in-a-clinical-trial-of-its-volt-pulsed-field-abla-abt-20240118monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-fourth-quarter-earnings-abbott-nyse-abt-will-announce-its-abt-20240103monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-j-p-morgan-healthcare-conference-abbott-nyse-abt-will-present-at-the--abt-20231218monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-increases-quarterly-dividend-for-52nd-consecutive-year-abbott-nyse-abt-today-announ-abt-20231215monthly0.5https://www.biopharmawatch.com/news/ABT/late-breaking-data-show-an-aspirin-free-medication-regimen-benefits-people-with-abbott-s-h-abt-20231113monthly0.5https://www.biopharmawatch.com/news/ABT/participants-in-abbott-s-food-as-medicine-program-showed-clinically-significant-improvemen-abt-20231108monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-approval-for-hpv-test-to-run-on-alinity-m-offering-primary-hpv-screeni-abt-20231102monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-sherri-shepherd-millions-not-using-affordable-diabetes-technology-abbott-and-sh-abt-20231101monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-damar-hamlin-team-up-to-build-heart-health-community-with-new-heartmates-progra-abt-20231031monthly0.5https://www.biopharmawatch.com/news/ABT/ninety-one-percent-of-young-adults-with-student-loans-say-financial-stress-is-impacting-th-abt-20231026monthly0.5https://www.biopharmawatch.com/news/ABT/late-breaking-data-show-esprit-btk-drug-eluting-resorbable-scaffold-reduces-chronic-limb-t-abt-20231025monthly0.5https://www.biopharmawatch.com/news/ABT/late-breaking-data-showcase-the-benefits-of-abbott-s-minimally-invasive-devices-for-people-abt-20231024monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-third-quarter-2023-results-and-raises-midpoint-of-full-year-eps-guidance-ra-abt-20231018monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-lanc-a-seu-cateter-de-ablac-a-o-tactiflex-para-tratamento-de-ritmo-cardi-aco-anorma-abt-20231016monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-third-quarter-earnings-abbott-nyse-abt-will-announce-its--abt-20230927monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-completes-acquisition-of-bigfoot-biomedical-abbott-nyse-abt-today-announced-it-has--abt-20230922monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-399th-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20230921monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-broadens-access-to-cutting-edge-biosimilars-in-key-emerging-markets-abbott-nyse-abt-abt-20230920monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-weightwatchers-connected-app-experience-is-now-available-for-people-living-with-abt-20230919monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-acquire-bigfoot-biomedical-furthering-efforts-to-develop-personalized-connected--abt-20230905monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-second-quarter-2023-results-increases-outlook-for-underlying-base-business--abt-20230720monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-approval-for-world-s-first-dual-chamber-leadless-pacemaker-abbott-s-br-abt-20230705monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-second-quarter-earnings-abbott-nyse-abt-will-announce-its-abt-20230629monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-freestyle-libre-2-receives-national-reimbursement-in-france-for-all-people-with-d-abt-20230622monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-398th-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20230609monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-real-madrid-and-the-real-madrid-foundation-band-together-to-beat-malnutrition-globa-abt-20230601monthly0.5https://www.biopharmawatch.com/news/ABT/european-study-finds-the-abbott-cardiomems-sensor-results-in-improved-quality-of-life-and--abt-20230524monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-unveils-late-breaking-data-showing-the-world-s-first-dual-chamber-leadless-pacemake-abt-20230520monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-approval-for-tactiflex-ablation-catheter-for-treatment-of-abnormal-hea-abt-20230519monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-clearance-for-assert-iq-insertable-cardiac-monitor-to-help-doctors-mon-abt-20230518monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-approval-for-its-spinal-cord-stimulation-systems-to-treat-chronic-back-abt-20230516monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-new-partnerships-and-programs-to-advance-its-diversity-in-clinical-trials-abt-202305112023-05-11T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-completes-acquisition-of-cardiovascular-systems-inc-abbott-nyse-abt-today-announced-abt-202304272023-04-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-life-support-system-receives-new-fda-clearances-to-help-doctors-treat-more-critic-abt-202304252023-04-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-new-global-consortium-partnership-address-viral-outbreaks-caused-by-climate-cha-abt-202304202023-04-20T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-first-quarter-2023-results-increases-outlook-for-underlying-base-business-a-abt-202304192023-04-19T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-freestyle-libre-continuous-glucose-monitoring-systems-obtain-significantly-expand-abt-202304172023-04-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/fda-clears-reader-for-abbott-s-freestyle-libre-3-system-abbott-nyse-abt-today-announced-th-abt-202304142023-04-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-first-quarter-earnings-abbott-will-announce-its-first-qua-abt-202303292023-03-29T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-recebe-aprovac-a-o-da-anvisa-para-navitor-uma-nova-gerac-a-o-do-sistema-tavi-para-t-abt-202303282023-03-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/don-t-mess-with-your-melon-abbott-and-the-brain-injury-association-of-america-urge-if-you--abt-202303232023-03-23T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/a-abbott-lanc-a-o-autoteste-panbio-hiv-para-oferecer-mais-rapidez-confianc-a-e-a-discric-a-abt-202303142023-03-14T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-clearance-for-first-commercially-available-lab-based-blood-test-to-hel-abt-202303072023-03-07T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/u-s-fda-clears-abbott-s-freestyle-libre-2-and-freestyle-libre-3-sensors-for-integration-wi-abt-202303062023-03-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/late-breaking-data-from-landmark-coapt-trial-show-long-term-benefits-of-abbott-s-mitraclip-abt-202303052023-03-05T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/new-data-show-superiority-of-abbott-s-triclip-device-compared-to-medical-therapy-for-tricu-abt-202303042023-03-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/late-breaking-data-reinforce-benefits-of-abbott-s-minimally-invasive-heart-devices-new-res-abt-202302282023-02-28T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-397th-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-202302172023-02-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-traz-para-o-brasil-panbio-covid-19-flu-a-b-rapid-panel-um-u-nico-teste-ra-pido-para-abt-202302082023-02-08T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-recebe-autorizac-a-o-da-anvisa-para-ultreon-tecnologia-de-imagem-que-usa-intelige-n-abt-202301272023-01-27T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/fda-approves-abbott-s-spinal-cord-stimulation-for-people-living-with-painful-diabetic-peri-abt-202301262023-01-26T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-fourth-quarter-and-full-year-2022-results-issues-2023-financial-outlook-abb-abt-202301252023-01-25T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-approval-for-navitor-a-next-generation-tavi-system-designed-to-treat-a-abt-202301172023-01-17T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-blood-centers-of-america-launch-first-of-its-kind-mixed-reality-experience-for-use--abt-202301062023-01-06T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-fourth-quarter-earnings-abbott-nyse-abt-will-announce-its-abt-202301042023-01-04T00:00:00.000Zmonthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-freestyle-libre-3-integrated-with-automated-insulin-delivery-system-mylife-loop-i-abt-20221221monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-j-p-morgan-healthcare-conference-abbott-nyse-abt-will-present-at-the--abt-20221220monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-launches-the-world-s-smallest-implantable-rechargeable-spinal-cord-stimulation-syst-abt-20221219monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-the-brain-injury-association-of-america-launch-concussion-awareness-now-coaliti-abt-20221213monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-increases-quarterly-dividend-marking-51-consecutive-years-of-dividend-growth-abbott-abt-20221209monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-three-ces-2023-innovation-awards-for-advancements-in-health-technology-abb-abt-20221117monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-freestyle-libre-is-named-best-medical-technology-in-last-50-years-by-the-galien-f-abt-20221028monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-third-quarter-2022-results-and-raises-full-year-eps-guidance-abbott-nyse-ab-abt-20221019monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-lanc-a-no-brasil-novo-sistema-de-mapeamento-cardi-aco-que-melhora-a-forma-como-me-d-abt-20221018monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-the-home-edit-redesign-the-medicine-cabinet-to-help-people-prepare-for-the-upco-abt-20221012monthly0.5https://www.biopharmawatch.com/news/ABT/new-study-published-in-the-new-england-journal-of-medicine-demonstrates-abbott-s-freestyle-abt-20221006monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-third-quarter-earnings-abbott-nyse-abt-will-announce-its--abt-20220928monthly0.5https://www.biopharmawatch.com/news/ABT/late-breaking-data-show-breadth-of-abbott-s-minimally-invasive-structural-heart-technologi-abt-20220917monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-395th-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20220915monthly0.5https://www.biopharmawatch.com/news/ABT/three-year-data-on-world-s-smallest-heart-device-show-benefits-of-fixing-holes-in-newborn--abt-20220908monthly0.5https://www.biopharmawatch.com/news/ABT/new-data-show-abbott-s-heartmate-3-heart-pump-extends-life-beyond-five-years-for-advanced--abt-20220829monthly0.5https://www.biopharmawatch.com/news/ABT/fda-approves-abbott-s-new-spinal-cord-stimulation-device-provides-tailored-relief-to-multi-abt-20220823monthly0.5https://www.biopharmawatch.com/news/ABT/new-study-shows-abbott-s-blood-test-for-concussion-could-predict-outcomes-from-brain-injur-abt-20220811monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-weightwatchers-partner-to-support-people-living-with-diabetes-in-attaining-thei-abt-20220804monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-lanc-a-ensure-advance-suplemento-nutricional-que-ajuda-no-restabelecimento-muscular-abt-20220802monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-second-quarter-2022-results-and-raises-full-year-eps-guidance-abbott-nyse-a-abt-20220720monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-s-breakthrough-device-designation-to-explore-use-of-deep-brain-stimula-abt-20220712monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-second-quarter-earnings-abbott-nyse-abt-will-announce-its-abt-20220629monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-lanc-a-autoteste-de-anti-geno-panbio-no-brasil-aumentando-o-acesso-a-testes-ra-pido-abt-20220629monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-394th-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20220610monthly0.5https://www.biopharmawatch.com/news/ABT/late-breaking-data-demonstrate-abbott-s-freestyle-libre-3-system-is-most-accurate-14-day-c-abt-20220605monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-development-of-novel-continuous-glucose-ketone-monitoring-system-abbott-n-abt-20220603monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-freestyle-libre-3-receives-u-s-fda-clearance-features-world-s-smallest-thinnest-a-abt-20220531monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-release-elecare-amino-acid-based-formulas-to-help-meet-critical-patient-need-abb-abt-20220524monthly0.5https://www.biopharmawatch.com/news/ABT/new-late-breaking-data-highlight-abbott-structural-heart-transcatheter-valve-therapies-dat-abt-20220519monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-enters-into-consent-decree-with-u-s-food-and-drug-administration-for-its-sturgis-mi-abt-20220516monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-women-as-one-partner-to-help-more-underrepresented-physicians-lead-clinical-tri-abt-20220511monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-obtains-fda-clearance-for-first-test-that-simultaneously-detects-four-common-sexual-abt-20220504monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-release-metabolic-nutrition-formulas-at-the-request-of-the-u-s-food-and-drug-adm-abt-20220429monthly0.5https://www.biopharmawatch.com/news/ABT/study-finds-89-of-patients-treated-for-persistent-atrial-fibrillation-using-abbott-s-ablat-abt-20220429monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-strengthens-left-atrial-appendage-closure-leadership-with-u-s-availability-of-ampla-abt-20220428monthly0.5https://www.biopharmawatch.com/news/ABT/new-analysis-shows-that-abbott-s-freestyle-libre-system-provides-similar-and-sustained-red-abt-20220428monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-camdiab-and-ypsomed-unveil-new-automated-insulin-delivery-partnership-for-people-wi-abt-20220427monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-recommends-rejection-of-below-market-mini-tender-offer-by-trc-capital-investment-co-abt-20220426monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-strengthens-its-connected-care-technologies-with-latest-neurosphere-mypath-digital--abt-20220425monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-first-quarter-2022-results-abbott-nyse-abt-today-announced-financial-result-abt-20220420monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-approval-for-aveir-vr-leadless-pacemaker-system-to-treat-patients-with-abt-20220404monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-lisc-team-up-to-address-diversity-and-equity-gaps-in-the-healthcare-industry-su-abt-20220330monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-first-quarter-earnings-abbott-nyse-abt-will-announce-its--abt-20220328monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-freestyle-libre-is-first-and-only-cgm-system-to-gain-expanded-reimbursement-in-ja-abt-20220324monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-cardiomems-hf-system-receives-fda-approval-to-support-patients-battling-earlier-s-abt-20220221monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-393rd-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20220218monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-voluntarily-recalls-powder-formulas-manufactured-at-one-plant-abbott-nyse-abt-is-in-abt-20220217monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-world-s-first-implant-of-dual-chamber-leadless-pacemaker-in-pivotal-trial-abt-20220207monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-strong-fourth-quarter-2021-results-issues-2022-forecast-abbott-nyse-abt-tod-abt-20220126monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-u-s-fda-clearance-for-new-cardiac-mapping-system-to-improve-how-doctors-tr-abt-20220112monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-anuncia-o-futuro-dos-biowearables-no-ces-consumer-electronics-show-a-abbott-e-a-pri-abt-20220106monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-anuncia-el-futuro-de-los-biowearables-en-el-evento-ces-consumer-electronics-show-de-abt-20220106monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-future-of-biowearables-at-consumer-electronics-show-making-ces-history-ab-abt-20220106monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-fourth-quarter-earnings-abbott-nyse-abt-will-announce-its-abt-20220104monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-proclaim-xr-spinal-cord-stimulation-system-now-offers-expanded-mri-compatibility--abt-20220104monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-j-p-morgan-healthcare-conference-abbott-nyse-abt-will-present-virtual-abt-20211221monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-anuncia-dispositivo-amplatzer-amulet-para-tratar-pessoas-com-fibrilac-a-o-atrial-em-abt-20211214monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-increases-quarterly-dividend-for-50th-consecutive-year-abbott-nyse-abt-today-announ-abt-20211210monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-realiza-pesquisa-sobre-o-perfil-do-doador-de-sangue-e-plasma-e-visa-inspirar-ainda--abt-20211125monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-launches-similac-360-total-care-with-exclusive-blend-of-five-hmo-prebiotics-and-des-abt-20211116monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-achieves-highest-score-in-its-industry-for-the-ninth-consecutive-year-on-the-dow-jo-abt-20211115monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-new-leadless-pacemaker-system-meets-primary-endpoints-in-pivotal-trial-abbott-nys-abt-20211112monthly0.5https://www.biopharmawatch.com/news/ABT/pesquisa-da-abbott-revela-que-brasileiros-apostaram-em-ha-bitos-mais-sauda-veis-durante-a--abt-20211111monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-y-la-american-diabetes-association-asociacio-n-americana-de-diabetes-lanzan-la-prim-abt-20211109monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-the-american-diabetes-association-launch-first-of-its-kind-community-initiative-abt-20211109monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-lanza-una-nueva-iniciativa-para-impulsar-la-diversidad-en-la-investigacio-n-me-dica-abt-20211104monthly0.5https://www.biopharmawatch.com/news/ABT/abt-abt-20211104monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-abbott-nyse-abt-abbott-abt-20211103monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-launches-new-initiative-to-drive-diversity-in-medical-research-and-improve-care-amo-abt-20211103monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-y-real-madrid-se-unen-en-apoyo-de-la-salud-y-la-nutricio-n-infantil-a-nivel-mundial-abt-20211018monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-e-real-madrid-se-unem-para-apoiar-a-sau-de-e-a-nutric-a-o-de-crianc-as-em-todo-mund-abt-20211018monthly0.5https://www.biopharmawatch.com/news/ABT/jason-sudeikis-joins-abbott-real-madrid-at-new-york-stock-exchange-to-support-children-s-h-abt-20211018monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-real-madrid-team-up-to-support-the-health-and-nutrition-of-children-globally-ab-abt-20211018monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-traz-para-o-brasil-dispositivo-de-ritmo-cardi-aco-com-conectividade-bluetooth-e-mon-abt-20211007monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-commits-to-reducing-malnutrition-globally-with-launch-of-abbott-center-for-malnutri-abt-20210930monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-third-quarter-earnings-abbott-nyse-abt-will-announce-its--abt-20210923monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-approval-for-minimally-invasive-portico-with-flexnav-tavr-system-to-tr-abt-20210920monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-391st-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20210915monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-expands-peripheral-vascular-offerings-with-acquisition-of-walk-vascular-llc-abbott--abt-20210902monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-recebe-aprovac-a-o-da-anvisa-para-va-lvula-portico-e-sistema-flexnav-para-tratar-de-abt-20210902monthly0.5https://www.biopharmawatch.com/news/ABT/late-breaking-data-shows-abbott-s-amplatzer-amulet-occluder-offers-superior-left-atrial-ap-abt-20210830monthly0.5https://www.biopharmawatch.com/news/ABT/guide-hf-study-data-show-abbott-s-cardiomems-device-can-improve-care-for-more-patients-wit-abt-20210827monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-amplatzer-amulet-device-approved-by-fda-to-treat-people-with-atrial-fibrillation--abt-20210816monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-clearance-for-its-imaging-technology-using-artificial-intelligence-for-abt-20210803monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-freestyle-libre-2-ios-app-cleared-in-u-s-providing-a-seamless-digital-experience--abt-20210802monthly0.5https://www.biopharmawatch.com/news/ABT/new-study-half-of-americans-living-with-diabetes-may-be-consuming-less-than-the-recommende-abt-20210729monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-second-quarter-2021-results-abbott-nyse-abt-today-announced-financial-resul-abt-20210722monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-xience-stent-receives-fda-approval-for-shortest-blood-thinner-course-for-high-ble-abt-20210630monthly0.5https://www.biopharmawatch.com/news/ABT/late-breaking-data-demonstrate-abbott-s-freestyle-libre-system-supports-health-equity-for--abt-20210625monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-second-quarter-earnings-abbott-nyse-abt-will-announce-its-abt-20210625monthly0.5https://www.biopharmawatch.com/news/ABT/people-who-exercise-intensely-could-improve-recovery-by-adjusting-their-hydration-habits-a-abt-20210624monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-earns-first-of-its-kind-recommendation-for-high-school-stem-interns-to-receive-coll-abt-20210622monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-390th-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20210611monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-confirms-capacity-to-support-expanded-use-of-heartmate-3-heart-pump-abbott-nyse-abt-abt-20210603monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-issues-updated-2021-outlook-abbott-nyse-abt-today-announced-an-update-to-its-financ-abt-20210601monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-ce-mark-for-navitor-the-latest-generation-transcatheter-aortic-valve-impla-abt-20210517monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-seeks-better-treatment-options-for-patients-with-both-atrial-fibrillation-and-heart-abt-20210506monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-first-quarter-2021-results-abbott-nyse-abt-today-announced-financial-result-abt-20210420monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-begins-shipping-binaxnow-covid-19-ag-self-test-to-retailers-today-abbott-nyse-abt-a-abt-20210419monthly0.5https://www.biopharmawatch.com/news/ABT/world-s-fastest-marathoner-eliud-kipchoge-uses-abbott-s-libre-sense-at-nn-mission-marathon-abt-20210412monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-ce-mark-approval-for-next-generation-triclip-device-offering-new-innovatio-abt-20210408monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-xience-stent-receives-european-approval-for-one-month-dual-anti-platelet-therapy--abt-20210406monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-binaxnow-rapid-antigen-self-test-receives-fda-emergency-use-authorization-for-asy-abt-20210331monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-first-quarter-earnings-abbott-nyse-abt-will-announce-its--abt-20210329monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-its-pandemic-defense-coalition-a-global-network-of-expert-collaborators-d-abt-20210311monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-lanc-a-teste-ra-pido-de-anti-geno-porta-til-fa-cil-de-usar-e-com-swab-nasal-que-pod-abt-20210309monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-introduces-neurosphere-virtual-clinic-first-of-its-kind-remote-neuromodulation-pati-abt-20210308monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-eua-for-laboratory-pcr-assay-that-detects-and-differentiates-sars-cov--abt-20210305monthly0.5https://www.biopharmawatch.com/news/ABT/investigadores-de-abbott-encuentran-un-grupo-poco-comu-n-de-personas-con-vih-controlado-qu-abt-20210302monthly0.5https://www.biopharmawatch.com/news/ABT/pesquisadores-da-abbott-encontram-grupo-raro-de-pessoas-com-hiv-controlado-e-que-pode-ser--abt-20210302monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-researchers-find-rare-group-of-people-with-controlled-hiv-who-could-be-a-key-to-unl-abt-20210302monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-anuncia-aprovac-a-o-no-brasil-para-uso-de-dois-dispositivos-para-o-corac-a-o-que-po-abt-20210223monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-389th-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20210219monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-panbio-rapid-antigen-test-receives-ce-mark-for-asymptomatic-screening-and-self-ad-abt-20210126monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-expanded-medicare-reimbursement-for-first-of-its-kind-mitraclip-device-abb-abt-20210120monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-launch-the-neurosphere-mypath-digital-health-app-designed-to-track-and-report-pa-abt-20210114monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-fulfillment-of-federal-government-purchase-of-150-million-binaxnow-covid--abt-20210112monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-510-k-clearance-for-the-first-rapid-handheld-blood-test-for-concussion-abt-20210111monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-fourth-quarter-earnings-abbott-nyse-abt-will-announce-its-abt-20210106monthly0.5https://www.biopharmawatch.com/news/ABT/as-vaccines-roll-out-americans-see-covid-19-testing-as-important-partner-the-development-a-abt-20201222monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-j-p-morgan-healthcare-conference-abbott-nyse-abt-will-present-virtual-abt-20201218monthly0.5https://www.biopharmawatch.com/news/ABT/fda-approves-labeling-update-for-abbott-s-heartmate-3-heart-pump-for-use-in-pediatric-pati-abt-20201217monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-binaxnow-covid-19-rapid-test-receives-fda-emergency-use-authorization-for-first-v-abt-20201216monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-ce-mark-for-its-covid-19-igg-quantitative-antibody-blood-test-abbott-nyse--abt-20201215monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-lanza-prueba-de-anti-geno-ra-pida-porta-til-y-fa-cil-de-usar-que-puede-ofrecer-resu-abt-20201215monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-develops-new-pedialyte-hydration-solution-to-help-support-immune-health-because-sup-abt-20201214monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-increases-quarterly-dividend-by-25-abbott-nyse-abt-today-announced-that-its-board-o-abt-20201211monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-freestyle-libre-2-now-approved-for-adults-and-children-with-diabetes-in-canada-fe-abt-20201202monthly0.5https://www.biopharmawatch.com/news/ABT/imip-e-abbott-anunciam-parceria-para-salvar-vidas-de-bebe-s-e-crianc-as-a-iniciativa-littl-abt-20201123monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-becomes-first-anchor-sponsor-of-american-diabetes-association-s-health-equity-now-i-abt-20201118monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-named-industry-sustainability-leader-for-the-eighth-year-in-a-row-on-the-dow-jones--abt-20201116monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-the-u-s-launch-of-the-ionicrf-generator-for-use-in-patients-living-with-c-abt-20201110monthly0.5https://www.biopharmawatch.com/news/ABT/el-revolucionario-sistema-freestyle-libre-de-abbott-recibe-aprobacio-n-invima-en-colombia--abt-20201103monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-wins-prestigious-prix-galien-usa-award-for-first-of-its-kind-mitraclip-device-abbot-abt-20201030monthly0.5https://www.biopharmawatch.com/news/ABT/improved-mental-and-physical-condition-is-directly-linked-to-nutrition-study-shows-researc-abt-20201019monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-emergency-use-authorization-for-its-covid-19-igm-antibody-blood-test-a-abt-20201012monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-releases-id-now-covid-19-interim-clinical-study-results-from-1-003-people-to-provid-abt-20201007monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-lanc-a-teste-ra-pido-de-anti-geno-porta-til-e-fa-cil-de-usar-que-pode-fornecer-resu-abt-20201005monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-freestyle-libre-3-system-receives-ce-mark-features-world-s-smallest-thinnest-sens-abt-20200928monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-ce-mark-for-next-generation-mitraclip-heart-valve-repair-device-to-treat-m-abt-20200921monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-third-quarter-earnings-abbott-nyse-abt-will-announce-its--abt-20200921monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-387th-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20200917monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-introduces-libre-sense-glucose-sport-biosensor-in-europe-world-s-first-glucose-bios-abt-20200917monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-recebe-aprovac-a-o-da-anvisa-para-uso-de-freestyle-libre-em-mulheres-com-diabetes-g-abt-20200914monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-start-of-trial-to-evaluate-the-new-esprit-btk-drug-eluting-resorbable-sca-abt-20200903monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-freestyle-libre-2-icgm-system-now-available-to-medicare-beneficiaries-abbott-nyse-abt-20200901monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-fast-5-15-minute-easy-to-use-covid-19-antigen-test-receives-fda-emergency-use-aut-abt-20200826monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-start-of-study-to-evaluate-new-device-to-treat-recurrent-atrial-fibrillat-abt-20200804monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-approval-for-ios-compatible-app-allowing-people-living-with-chronic-pa-abt-20200723monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-second-quarter-2020-results-exceeds-analysts-expectations-abbott-nyse-abt-t-abt-20200716monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-agrees-to-global-transcatheter-litigation-settlement-with-edwards-lifesciences-abbo-abt-20200713monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-approval-for-new-heart-rhythm-devices-featuring-bluetooth-connectivity-abt-20200706monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-tandem-diabetes-care-advance-development-of-integrated-technologies-for-future--abt-20200629monthly0.5https://www.biopharmawatch.com/news/ABT/new-research-finds-abbott-s-optical-coherence-tomography-imaging-changed-treatment-decisio-abt-20200626monthly0.5https://www.biopharmawatch.com/news/ABT/new-late-breaking-data-highlight-impact-of-abbott-s-minimally-invasive-structural-heart-th-abt-20200625monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-lanc-a-segundo-teste-laboratorial-de-anticorpos-para-covid-19-para-o-sistema-alinit-abt-20200625monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-second-quarter-earnings-abbott-nyse-abt-will-announce-its-abt-20200623monthly0.5https://www.biopharmawatch.com/news/ABT/new-data-show-use-of-abbott-s-freestyle-libre-system-reduces-all-cause-diabetic-ketoacidos-abt-20200616monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-freestyle-libre-2-icgm-cleared-in-u-s-for-adults-and-children-with-diabetes-achie-abt-20200615monthly0.5https://www.biopharmawatch.com/news/ABT/new-late-breaking-data-show-use-of-abbott-s-freestyle-libre-system-significantly-reduces-h-abt-20200613monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-386th-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20200612monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-anuncia-la-obtencio-n-del-registro-sanitario-en-colombia-de-su-prueba-de-anticuerpo-abt-20200525monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-releases-interim-clinical-study-data-on-id-now-covid-19-rapid-test-showing-strong-a-abt-20200521monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-contract-to-supply-millions-of-igg-lab-based-antibody-tests-to-the-uk-gov-abt-20200521monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-anuncia-aprovac-a-o-da-anvisa-e-disponibilidade-imediata-de-testes-de-anticorpos-pa-abt-20200519monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-provides-update-on-id-now-nyse-abt-abbott-s-id-now-is-the-fastest-molecular-point-o-abt-20200514monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-emergency-use-authorization-for-covid-19-molecular-test-on-new-alinity-abt-20200512monthly0.5https://www.biopharmawatch.com/news/ABT/research-from-university-of-washington-demonstrates-high-performance-of-abbott-s-sars-cov--abt-20200508monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-anuncia-la-aprobacio-n-de-su-prueba-de-anticuerpos-covid-19-para-uso-en-laboratorio-abt-20200507monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-lanc-a-librelinkup-aplicativo-que-conecta-remotamente-usua-rios-do-sistema-freestyl-abt-20200420monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-first-quarter-2020-results-abbott-nyse-abt-today-announced-financial-result-abt-20200416monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-launches-third-covid-19-test-a-laboratory-based-antibody-blood-test-that-will-ship--abt-20200415monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-virtual-attendance-at-annual-meeting-of-shareholders-abbott-nyse-abt-anno-abt-20200414monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-triclip-becomes-first-device-of-its-kind-to-receive-ce-mark-for-minimally-invasiv-abt-20200409monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-freestyle-libre-14-day-system-now-available-in-u-s-for-hospitalized-patients-with-abt-20200408monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-launches-molecular-point-of-care-test-to-detect-novel-coronavirus-in-as-little-as-f-abt-20200327monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-first-quarter-earnings-abbott-nyse-abt-will-announce-its--abt-20200319monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-emergency-use-authorization-and-launches-test-to-detect-novel-coronavi-abt-20200318monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-aims-to-optimize-tavi-implants-with-european-approval-of-flexnav-delivery-system-fo-abt-20200305monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-385th-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20200221monthly0.5https://www.biopharmawatch.com/news/ABT/new-real-world-data-show-that-abbott-s-freestyle-libre-system-delivers-positive-health-out-abt-20200220monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-insulet-partner-to-integrate-next-generation-glucose-sensing-and-automated-insu-abt-20200219monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-introduces-next-generation-heart-rhythm-management-devices-in-europe-featuring-stat-abt-20200218monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-in-development-fully-implantable-heart-pump-system-earns-fda-s-breakthrough-devic-abt-20200204monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-first-of-its-kind-trial-to-assess-new-therapy-option-for-people-at-risk-o-abt-20200203monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-tendyne-device-receives-world-s-first-ce-mark-for-transcatheter-mitral-valve-impl-abt-20200130monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-expanded-indication-from-the-u-s-fda-for-directional-deep-brain-stimulatio-abt-20200124monthly0.5https://www.biopharmawatch.com/news/ABT/new-quality-of-life-and-functional-improvement-data-from-abbott-s-bold-and-triumph-studies-abt-20200123monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-fourth-quarter-2019-results-announces-strong-forecast-for-2020-abbott-nyse--abt-20200122monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-initiate-trial-to-study-mitraclip-as-an-option-for-moderate-surgical-risk-patien-abt-20200113monthly0.5https://www.biopharmawatch.com/news/ABT/fda-approves-less-invasive-surgical-approach-for-abbott-s-heart-pump-to-help-patients-avoi-abt-20200107monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-fourth-quarter-earnings-abbott-nyse-abt-will-announce-its-abt-20200102monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-raises-quarterly-dividend-12-5-increasing-payouts-for-48-straight-years-the-board-o-abt-20191213monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-robert-b-ford-to-succeed-miles-d-white-as-chief-executive-officer-on-marc-abt-20191113monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-discovery-of-new-strain-of-hiv-keeping-global-health-community-a-step-ahe-abt-20191106monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-lanc-a-a-campanha-restaure-o-ritmo-da-sua-vida-para-falar-sobre-constipac-a-o-intes-abt-20191022monthly0.5https://www.biopharmawatch.com/news/ABT/the-australian-red-cross-blood-service-selects-abbott-s-alinity-s-solution-for-blood-and-p-abt-20191021monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-third-quarter-2019-results-abbott-nyse-abt-today-announced-financial-result-abt-20191016monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-tandem-diabetes-care-exploring-new-integrated-solutions-to-improve-diabetes-man-abt-20191015monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-omada-health-partner-to-offer-integrated-digital-health-and-coaching-experience-abt-20191014monthly0.5https://www.biopharmawatch.com/news/ABT/helping-kids-stay-healthy-you-probably-have-a-benign-habit-that-you-can-t-explain-and-you--abt-20191008monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-lanc-a-laclev-em-embalagem-com-seis-comprimidos-a-abbott-empresa-global-de-cuidados-abt-20190930monthly0.5https://www.biopharmawatch.com/news/ABT/late-breaking-data-shows-abbott-s-mitraclip-is-cost-effective-increases-life-expectancy-an-abt-20190929monthly0.5https://www.biopharmawatch.com/news/ABT/new-data-demonstrate-strong-outcomes-for-abbott-device-to-repair-leaky-tricuspid-heart-val-abt-20190928monthly0.5https://www.biopharmawatch.com/news/ABT/fda-approves-abbott-s-low-dose-recharge-free-spinal-cord-stimulation-system-with-up-to-ten-abt-20190926monthly0.5https://www.biopharmawatch.com/news/ABT/u-s-fda-clears-abbott-s-high-sensitivity-troponin-i-blood-test-that-aids-doctors-in-diagno-abt-20190925monthly0.5https://www.biopharmawatch.com/news/ABT/nebulizador-inaresp-da-abbott-oferece-opc-a-o-mais-compacta-e-porta-til-para-inalac-a-o-a--abt-20190919monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-third-quarter-earnings-abbott-nyse-abt-will-announce-its--abt-20190918monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-european-approval-of-two-life-saving-heart-devices-for-babies-and-childre-abt-20190917monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-named-the-industry-leader-in-sustainability-for-the-seventh-consecutive-year-on-the-abt-20190916monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-sanofi-partner-to-integrate-glucose-sensing-and-insulin-delivery-technologies-t-abt-20190916monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-revolutionary-freestyle-libre-system-now-reimbursed-in-the-two-largest-provinces--abt-20190913monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-383rd-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20190912monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-new-data-that-shows-artificial-intelligence-technology-can-help-doctors-b-abt-20190910monthly0.5https://www.biopharmawatch.com/news/ABT/ministry-of-health-of-rwanda-society-for-family-health-rwanda-and-abbott-launch-pioneering-abt-20190909monthly0.5https://www.biopharmawatch.com/news/ABT/he-s-back-and-he-s-hydrated-abbott-and-nfl-star-odell-beckham-jr-partner-for-pedialyte-abb-abt-20190906monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-launches-world-s-first-pivotal-trial-to-test-new-approach-for-repairing-leaky-tricu-abt-20190905monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-lanc-a-plataforma-molecular-para-testes-ra-pidos-de-infecc-o-es-respirato-rias-a-ab-abt-20190902monthly0.5https://www.biopharmawatch.com/news/ABT/new-study-finds-abbott-s-blood-test-technology-could-help-detect-brain-injury-quickly-even-abt-20190826monthly0.5https://www.biopharmawatch.com/news/ABT/together-we-can-increase-the-number-of-women-in-stem-here-is-a-tool-to-help-companies-get--abt-20190826monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-intoximeters-partner-to-keep-roads-safer-by-bringing-together-industry-leading--abt-20190814monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-second-quarter-2019-results-abbott-nyse-abt-today-announced-financial-resul-abt-20190717monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-u-s-approval-of-next-generation-mitraclip-bringing-new-enhancements-to-abb-abt-20190715monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-fda-approval-of-the-alinity-s-system-the-latest-technology-for-screening--abt-20190711monthly0.5https://www.biopharmawatch.com/news/ABT/nutrition-is-the-missing-ingredient-in-home-health-today-new-study-shows-new-research-from-abt-20190624monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-second-quarter-earnings-abbott-nyse-abt-will-announce-its-abt-20190619monthly0.5https://www.biopharmawatch.com/news/ABT/care-abbott-and-the-abbott-fund-launch-partnership-to-address-noncommunicable-diseases-ncd-abt-20190617monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-launches-first-ever-rapid-point-of-care-hba1c-test-to-aid-in-the-diagnosis-of-diabe-abt-20190617monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-382nd-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20190614monthly0.5https://www.biopharmawatch.com/news/ABT/new-survey-shows-millennials-can-help-avoid-blood-shortages-a-new-survey-from-abbott-nyse--abt-20190613monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-lanc-a-dupha-kids-e-dupha-active-primeiras-gomas-mastiga-veis-de-lactulose-para-mul-abt-20190610monthly0.5https://www.biopharmawatch.com/news/ABT/new-data-show-use-of-abbott-s-freestyle-libre-system-significantly-reduces-hba1c-levels-in-abt-20190608monthly0.5https://www.biopharmawatch.com/news/ABT/triluminate-study-shows-treatment-with-abbott-s-first-of-its-kind-minimally-invasive-devic-abt-20190521monthly0.5https://www.biopharmawatch.com/news/ABT/espac-o-vida-da-abbott-promove-experie-ncia-interativa-para-apresentar-tecnologias-inovado-abt-20190520monthly0.5https://www.biopharmawatch.com/news/ABT/new-zoneperfect-keto-is-100-trueketo-with-the-proven-blend-of-macros-for-effective-results-abt-20190516monthly0.5https://www.biopharmawatch.com/news/ABT/nearly-9-out-of-10-college-students-with-student-debt-say-it-s-important-to-find-a-company-abt-20190515monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-partners-with-nih-on-brain-initiative-to-advance-research-for-neurological-disorder-abt-20190514monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-ubs-global-healthcare-conference-abbott-nyse-abt-will-present-at-the--abt-20190507monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-launches-next-generation-detection-technology-in-the-u-s-and-europe-offering-a-smar-abt-20190506monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-who-prequalification-approval-for-breakthrough-hiv-point-of-care-test-abbo-abt-20190502monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-the-u-s-department-of-defense-and-track-tbi-partner-to-study-point-of-care-blood-te-abt-20190430monthly0.5https://www.biopharmawatch.com/news/ABT/new-study-finds-abbott-blood-test-can-help-predict-future-cardiac-events-in-adults-with-no-abt-20190429monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-first-quarter-2019-results-abbott-nyse-abt-today-announced-financial-result-abt-20190417monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-the-abbott-fund-support-relief-efforts-for-cyclone-idai-abbott-nyse-abt-and-its-abt-20190411monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-lanza-en-me-xico-la-aplicacio-n-freestyle-librelink-para-la-medicio-n-de-glucosa-de-abt-20190326monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-first-quarter-earnings-abbott-nyse-abt-will-announce-its--abt-20190320monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-ce-mark-for-alinity-m-diagnostics-system-and-assays-the-latest-in-molecul-abt-20190319monthly0.5https://www.biopharmawatch.com/news/ABT/new-data-for-abbott-s-heartmate-3-highlights-unparalleled-performance-of-industry-s-leadin-abt-20190317monthly0.5https://www.biopharmawatch.com/news/ABT/new-late-breaking-analyses-from-landmark-coapt-trial-show-benefits-of-abbott-s-mitraclip-d-abt-20190317monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-approval-for-expanded-indication-for-mitraclip-device-abbott-nyse-abt--abt-20190314monthly0.5https://www.biopharmawatch.com/news/ABT/late-breaking-data-presentations-at-acc-2019-highlight-abbott-s-leading-cardiovascular-por-abt-20190306monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-latest-diagnostics-technology-alinity-selected-by-regional-medical-laboratory-inc-abt-20190305monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-barclays-global-healthcare-conference-abbott-nyse-abt-will-present-at-abt-20190225monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-381st-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20190222monthly0.5https://www.biopharmawatch.com/news/ABT/new-real-world-evidence-analysis-of-nearly-half-a-million-freestyle-libre-system-users-sho-abt-20190221monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-novo-nordisk-enter-partnership-to-provide-integrated-digital-solution-to-people-abt-20190220monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-introduces-the-world-s-most-sensitive-rapid-diagnostic-test-determine-hbsag-2-to-ac-abt-20190220monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-lanc-a-novo-aplicativo-freestyle-librelink-para-monitoramento-da-glicose-em-smartph-abt-20190218monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-lanc-a-aletam-suplemento-de-cola-geno-que-ajuda-no-desempenho-das-articulac-o-es-qu-abt-20190130monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-2018-results-and-issues-strong-forecast-for-2019-abbott-today-announced-fin-abt-20190123monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-offers-a-new-option-for-physicians-treating-patients-with-atrial-fibrillation-abbot-abt-20190121monthly0.5https://www.biopharmawatch.com/news/ABT/japanese-red-cross-society-selects-abbott-technology-to-screen-country-s-blood-and-plasma--abt-20190117monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-acquire-cephea-valve-technologies-inc-abbott-nyse-abt-announced-today-that-it-ha-abt-20190116monthly0.5https://www.biopharmawatch.com/news/ABT/fda-approves-world-s-first-device-for-treatment-of-premature-babies-and-newborns-with-an-o-abt-20190114monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-malaria-no-more-work-together-to-end-malaria-in-odisha-india-abbott-nyse-abt-an-abt-20190111monthly0.5https://www.biopharmawatch.com/news/ABT/get-bubbly-this-new-year-with-abbott-s-new-pedialyte-sparkling-rush-powder-packs-flavored--abt-20181219monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-fourth-quarter-earnings-abbott-nyse-abt-will-announce-its-abt-20181217monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-raises-quarterly-dividend-14-increasing-payouts-for-47-straight-years-the-board-of--abt-20181214monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-j-p-morgan-healthcare-conference-abbott-nyse-abt-will-present-at-the--abt-20181211monthly0.5https://www.biopharmawatch.com/news/ABT/new-approvals-allow-chronic-pain-sufferers-to-try-abbott-s-non-opioid-pain-therapy-before--abt-20181115monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-recommends-rejection-of-below-market-mini-tender-offer-by-baker-mills-llc-abbott-ny-abt-20181114monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-introduces-the-next-generation-of-influenza-a-b-and-strep-a-assays-with-fastest-eve-abt-20181025monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-heartmate-3-heart-pump-now-fda-approved-for-advanced-heart-failure-patients-not-e-abt-20181019monthly0.5https://www.biopharmawatch.com/news/ABT/new-study-shows-abbott-s-novel-diagnostic-test-has-the-potential-to-demonstrate-gold-stand-abt-20181017monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-third-quarter-2018-results-abbott-nyse-abt-today-announced-financial-result-abt-20181017monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-names-robert-b-ford-president-chief-operating-officer-abbott-nyse-abt-announced-tod-abt-20181015monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-freestyle-libre-2-with-optional-real-time-alarms-secures-ce-mark-for-use-in-europ-abt-20181001monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-ce-mark-for-first-troponin-test-to-help-predict-the-chance-of-heart-attack-abt-20180926monthly0.5https://www.biopharmawatch.com/news/ABT/one-year-results-from-real-world-study-showed-abbott-s-portico-transcatheter-aortic-valve--abt-20180925monthly0.5https://www.biopharmawatch.com/news/ABT/landmark-study-shows-treatment-with-abbott-s-mitraclip-is-superior-to-medical-therapy-for--abt-20180923monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-third-quarter-earnings-abbott-nyse-abt-will-announce-its--abt-20180919monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-379th-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20180913monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-is-named-global-industry-leader-in-sustainability-for-the-sixth-consecutive-year-on-abt-20180913monthly0.5https://www.biopharmawatch.com/news/ABT/where-life-changing-technology-meets-sustainability-our-goal-at-abbott-is-not-just-to-help-abt-20180905monthly0.5https://www.biopharmawatch.com/news/ABT/new-coverage-decision-extends-abbott-s-innovative-pain-therapy-option-to-22-million-americ-abt-20180904monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-expands-its-directional-deep-brain-stimulation-therapy-by-offering-new-mr-condition-abt-20180802monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-freestyle-libre-14-day-flash-glucose-monitoring-system-now-approved-in-u-s-abbott-abt-20180727monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-begins-u-s-pivotal-trial-for-the-tendyne-mitral-valve-replacement-system-to-treat-p-abt-20180726monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-second-quarter-2018-results-abbott-nyse-abt-today-announced-financial-resul-abt-20180718monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-approval-for-next-generation-mitraclip-device-to-treat-people-with-lea-abt-20180712monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-freedom-2-save-program-for-employees-to-address-student-debt-historic-lev-abt-20180626monthly0.5https://www.biopharmawatch.com/news/ABT/new-late-breaking-data-at-ada-underscore-significant-benefits-of-abbott-s-freestyle-libre--abt-20180625monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-second-quarter-earnings-abbott-nyse-abt-will-announce-its-abt-20180620monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-378th-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20180608monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-promove-espac-o-vida-um-projeto-multidisciplinar-e-interativo-para-os-cuidados-para-abt-20180604monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-introduces-the-afinion-2-analyzer-rapid-test-system-for-diabetes-management-abbott--abt-20180531monthly0.5https://www.biopharmawatch.com/news/ABT/newest-generation-of-leading-heart-stent-is-now-approved-in-the-u-s-for-people-with-corona-abt-20180523monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-investigational-tendyne-device-for-mitral-valve-replacement-demonstrates-positive-abt-20180523monthly0.5https://www.biopharmawatch.com/news/ABT/five-year-study-data-confirm-positive-outcomes-for-patients-when-abbott-diagnostic-tool-wa-abt-20180522monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-expands-cardiac-arrhythmias-portfolio-with-fda-clearance-of-advanced-mapping-cathet-abt-20180503monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-xience-sierra-heart-stent-receives-national-reimbursement-in-japan-to-treat-peopl-abt-20180502monthly0.5https://www.biopharmawatch.com/news/ABT/levantamento-de-freestyle-libre-da-abbott-revela-reduc-a-o-nos-ni-veis-de-hipo-e-hiperglic-abt-20180423monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-extends-title-sponsorship-of-abbott-world-marathon-majors-through-2023-abbott-nyse--abt-20180420monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-first-quarter-2018-results-abbott-nyse-abt-today-announced-financial-result-abt-20180418monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-new-ensure-max-protein-helps-americans-go-for-their-healthgoals-let-s-be-honest-a-abt-20180417monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-initiates-groundbreaking-study-to-assess-superiority-of-high-resolution-imaging-ver-abt-20180411monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-initiates-trial-to-evaluate-improved-survival-and-outcomes-with-the-cardiomems-moni-abt-20180329monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-first-quarter-earnings-abbott-nyse-abt-will-announce-its--abt-20180321monthly0.5https://www.biopharmawatch.com/news/ABT/new-long-term-data-show-improved-survival-and-lower-rates-of-stroke-and-pump-thrombosis-fo-abt-20180311monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-the-barclays-capital-2018-global-healthcare-conference-abbott-nyse-ab-abt-20180301monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-surmodics-announce-agreement-for-next-generation-drug-coated-balloon-abbott-nys-abt-20180227monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-377th-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20180216monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-app-for-freestyle-libre-system-now-available-in-europe-for-both-iphone-and-androi-abt-20180207monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-fourth-quarter-2017-results-abbott-nyse-abt-today-announced-financial-resul-abt-20180124monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-revolutionary-continuous-glucose-monitoring-system-freestyle-libre-now-available--abt-20180104monthly0.5https://www.biopharmawatch.com/news/ABT/new-fda-mr-conditional-labeling-approvals-further-expand-abbott-s-portfolio-of-mri-ready-d-abt-20180103monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-launches-alinity-h-series-integrated-hematology-system-combining-speed-accuracy-and-abt-20180102monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-fourth-quarter-earnings-abbott-nyse-abt-will-announce-its-abt-20171218monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-raising-quarterly-dividend-for-46th-straight-year-the-board-of-directors-of-abbott--abt-20171215monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-j-p-morgan-healthcare-conference-abbott-nyse-abt-will-present-at-the--abt-20171204monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-apresenta-laclev-primeira-lactase-mastiga-vel-no-brasil-para-intolera-ncia-a-lactos-abt-20171121monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-mitraclip-approved-as-first-transcatheter-mitral-valve-repair-device-in-japan-abb-abt-20171106monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-fda-clearance-for-its-alinity-ci-series-next-generation-diagnostic-system-abt-20171031monthly0.5https://www.biopharmawatch.com/news/ABT/analysis-of-landmark-study-showed-patients-treated-for-left-main-coronary-artery-disease-w-abt-20171030monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-introduces-next-generation-of-most-widely-used-heart-stent-for-people-with-coronary-abt-20171030monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-launches-the-first-and-only-smartphone-compatible-insertable-cardiac-monitor-in-the-abt-20171023monthly0.5https://www.biopharmawatch.com/news/ABT/a-great-place-to-do-great-things-developing-game-changing-technology-at-abbott-science-has-abt-20171019monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-third-quarter-2017-results-abbott-nyse-abt-today-announced-financial-result-abt-20171018monthly0.5https://www.biopharmawatch.com/news/ABT/patients-battling-complex-regional-pain-syndrome-find-a-host-of-new-benefits-in-abbott-s-p-abt-20171016monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-completes-cash-tender-offer-for-series-b-convertible-perpetual-preferred-stock-of-a-abt-20171004monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-extension-of-cash-tender-offer-for-all-outstanding-shares-of-series-b-con-abt-20171002monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-acquisition-of-alere-set-to-close-on-tuesday-october-3-2017-abbott-nyse-abt-announc-abt-20170929monthly0.5https://www.biopharmawatch.com/news/ABT/no-more-routine-finger-sticks-1-for-americans-with-diabetes-abbott-s-freestyle-libre-appro-abt-20170927monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-secures-fda-approval-for-mri-compatibility-for-the-company-s-ellipse-icd-abbott-nys-abt-20170922monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-third-quarter-earnings-abbott-nyse-abt-will-announce-its--abt-20170920monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-extension-of-cash-tender-offer-for-all-outstanding-shares-of-series-b-con-abt-20170918monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-375th-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20170914monthly0.5https://www.biopharmawatch.com/news/ABT/freestyle-libre-flash-glucose-monitoring-technology-gains-reimbursement-approval-from-the--abt-20170913monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-named-industry-leader-for-responsible-and-sustainable-business-for-five-consecutive-abt-20170907monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-extension-of-cash-tender-offer-for-all-outstanding-shares-of-series-b-con-abt-20170901monthly0.5https://www.biopharmawatch.com/news/ABT/revolutionary-glucose-monitoring-technology-freestyle-libre-now-reimbursed-across-japan-ab-abt-20170831monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-initiates-ground-breaking-u-s-pivotal-study-of-amplatzer-device-to-correct-common-c-abt-20170830monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-the-abbott-fund-donate-1-million-to-support-hurricane-harvey-relief-efforts-abb-abt-20170829monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-introduces-heartmate-3-left-ventricular-assist-system-the-latest-milestone-in-thera-abt-20170828monthly0.5https://www.biopharmawatch.com/news/ABT/pessoas-com-diabetes-e-hipertensa-o-consideram-se-empoderadas-em-relac-a-o-a-sua-sau-de-re-abt-20170824monthly0.5https://www.biopharmawatch.com/news/ABT/north-west-london-pathology-and-abbott-partner-for-diagnostics-products-and-services-inclu-abt-20170815monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-extension-of-cash-tender-offer-for-all-outstanding-shares-of-series-b-con-abt-20170814monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-second-quarter-2017-results-abbott-nyse-abt-today-announced-financial-resul-abt-20170720monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-commences-cash-tender-offer-for-all-outstanding-shares-of-series-b-convertible-perp-abt-20170717monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-bigfoot-biomedical-announce-collaboration-to-develop-breakthrough-diabetes-tech-abt-20170713monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-secures-health-canada-license-for-freestyle-libre-system-for-people-with-diabetes-a-abt-20170629monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-second-quarter-earnings-abbott-nyse-abt-will-announce-its-abt-20170621monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-374th-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20170609monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-ce-mark-for-tacticath-contact-force-ablation-catheter-sensor-enabled-abbo-abt-20170509monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-ce-mark-and-first-use-of-the-world-s-first-smartphone-compatible-insertab-abt-20170508monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-national-reimbursement-for-freestyle-libre-in-france-providing-access-to--abt-20170508monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-introduces-science-based-nutrition-drinks-to-help-patients-have-a-better-recovery-f-abt-20170426monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-first-quarter-2017-results-abbott-nyse-abt-today-announced-financial-result-abt-20170419monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-first-quarter-earnings-abbott-nyse-abt-will-announce-its--abt-20170322monthly0.5https://www.biopharmawatch.com/news/ABT/late-breaking-data-shows-the-cardiomems-hf-system-is-effective-in-reducing-heart-failure-h-abt-20170319monthly0.5https://www.biopharmawatch.com/news/ABT/late-breaking-data-on-abbott-s-mitraclip-system-show-continued-benefit-for-people-with-mit-abt-20170318monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-barclays-capital-2017-global-healthcare-conference-abbott-nyse-abt-wi-abt-20170308monthly0.5https://www.biopharmawatch.com/news/ABT/new-study-results-may-lead-to-a-new-standard-of-care-for-in-vitro-fertilization-treatment--abt-20170308monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-results-of-early-tenders-and-consents-in-exchange-offers-and-execution-of-abt-20170307monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-commences-exchange-offers-and-consent-solicitations-for-st-jude-medical-llc-notes-a-abt-20170221monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-373rd-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20170217monthly0.5https://www.biopharmawatch.com/news/ABT/real-world-data-from-abbott-s-freestyle-libre-show-association-between-higher-frequency-of-abt-20170215monthly0.5https://www.biopharmawatch.com/news/ABT/u-s-fda-grants-abbott-the-first-commercial-authorization-for-a-molecular-test-to-detect-zi-abt-20170202monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-u-s-approval-for-its-assurity-mri-pacemaker-the-world-s-smallest-longest--abt-20170201monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-fourth-quarter-2016-results-abbott-nyse-abt-today-announced-financial-resul-abt-20170125monthly0.5https://www.biopharmawatch.com/news/ABT/new-study-demonstrates-spinal-cord-stimulation-can-reduce-or-stabilize-opioid-use-among-ch-abt-20170120monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-european-launch-of-the-proclaim-drg-neurostimulation-system-for-the-manag-abt-20170118monthly0.5https://www.biopharmawatch.com/news/ABT/new-data-confirms-abbott-s-dorsal-root-ganglion-stimulation-offers-greater-treatment-succe-abt-20170117monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-u-s-launch-and-first-commercial-use-of-the-new-ensite-precision-cardiac-m-abt-20170112monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-obtient-la-certification-ce-pour-ses-syste-mes-de-diagnostic-de-la-se-rie-alinity-c-abt-20170110monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-ce-mark-for-its-alinity-s-blood-and-plasma-screening-system-abbott-nyse-a-abt-20170110monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-ce-mark-for-its-alinity-ci-series-diagnostic-systems-abbott-nyse-abt-anno-abt-20170110monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-completes-the-acquisition-of-st-jude-medical-abbott-nyse-abt-announced-today-it-has-abt-20170104monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-acquisition-of-st-jude-medical-set-to-close-on-january-4-2017-abbott-nyse-abt-annou-abt-20161230monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-fourth-quarter-earnings-abbott-nyse-abt-will-announce-its-abt-20161221monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-raising-quarterly-dividend-for-45th-straight-year-the-board-of-directors-of-abbott--abt-20161209monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-seeks-to-terminate-alere-acquisition-abbott-nyse-abt-has-filed-a-complaint-to-termi-abt-20161207monthly0.5https://www.biopharmawatch.com/news/ABT/study-hospital-nutrition-program-shortens-patient-stays-and-reduces-readmissions-while-pro-abt-20161206monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-ce-mark-for-i-stat-alinity-a-pioneering-handheld-blood-testing-platform-a-abt-20161130monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-absorb-bioresorbable-stent-approved-as-the-first-fully-dissolving-heart-stent-in--abt-20161107monthly0.5https://www.biopharmawatch.com/news/ABT/a-great-place-to-work-according-to-science-don-t-trust-us-trust-science-abbott-is-among-th-abt-20161027monthly0.5https://www.biopharmawatch.com/news/ABT/new-study-babies-fed-infant-formula-with-2-fl-human-milk-oligosaccharide-had-immune-respon-abt-20161026monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-third-quarter-2016-results-abbott-nyse-abt-today-announced-financial-result-abt-20161019monthly0.5https://www.biopharmawatch.com/news/ABT/st-jude-medical-and-abbott-to-sell-portion-of-vascular-closure-and-electrophysiology-busin-abt-20161018monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-approval-for-the-freestyle-libre-pro-system-a-revolutionary-diabetes-s-abt-20160928monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-third-quarter-earnings-abbott-nyse-abt-will-announce-its--abt-20160921monthly0.5https://www.biopharmawatch.com/news/ABT/malnutrition-adds-15-5-billion-annually-to-direct-u-s-medical-costs-healthcare-spending-in-abt-20160921monthly0.5https://www.biopharmawatch.com/news/ABT/fueling-performance-with-fat-eas-launches-first-ketogenic-meal-replacement-for-athletes-wh-abt-20160920monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-sell-abbott-medical-optics-to-johnson-johnson-for-4-325-billion-abbott-nyse-abt--abt-20160916monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-371st-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-toda-abt-20160915monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-named-industry-leader-for-responsible-and-sustainable-business-for-four-consecutive-abt-20160908monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-wells-fargo-healthcare-conference-abbott-nyse-abt-will-present-at-the-abt-20160824monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-unveils-alinity-its-unified-family-of-innovative-next-generation-diagnostics-system-abt-20160802monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-second-quarter-2016-results-abbott-nyse-abt-today-announced-financial-resul-abt-20160720monthly0.5https://www.biopharmawatch.com/news/ABT/fda-approves-the-tecnis-symfony-intraocular-lenses-the-first-and-only-extended-depth-of-fo-abt-20160715monthly0.5https://www.biopharmawatch.com/news/ABT/fda-approves-abbott-s-absorb-bioresorbable-stent-the-only-fully-dissolving-heart-stent-abb-abt-20160705monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-second-quarter-earnings-abbott-nyse-abt-will-announce-its-abt-20160622monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-positive-results-from-groundbreaking-study-of-freestyle-libre-system-for--abt-20160613monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-370th-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20160610monthly0.5https://www.biopharmawatch.com/news/ABT/new-curate-kids-combines-wholesome-ingredients-and-kid-friendly-flavors-to-help-parents-wi-abt-20160510monthly0.5https://www.biopharmawatch.com/news/ABT/a-clever-way-to-add-nutrition-to-your-toddler-s-favorite-foods-go-grow-by-similac-food-mix-abt-20160509monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-positive-results-from-pivotal-study-of-tecnis-symfony-iol-for-cataract-su-abt-20160508monthly0.5https://www.biopharmawatch.com/news/ABT/america-s-health-check-up-aarp-and-abbott-survey-finds-half-of-adults-50-plus-wish-they-ha-abt-20160504monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-deutsche-bank-health-care-conference-abbott-nyse-abt-will-present-at--abt-20160504monthly0.5https://www.biopharmawatch.com/news/ABT/what-s-the-secret-to-living-a-full-life-a-new-global-survey-reveals-family-comes-first-if--abt-20160426monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-introduces-new-services-and-tools-to-help-labs-deliver-greater-operational-producti-abt-20160421monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-first-quarter-2016-results-abbott-nyse-abt-today-announced-financial-result-abt-20160420monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-launches-eas-myoplex-sports-nutrition-line-designed-for-performance-abbott-s-nyse-a-abt-20160407monthly0.5https://www.biopharmawatch.com/news/ABT/new-research-shows-abbott-s-high-sensitive-troponin-test-first-to-measure-impact-of-mental-abt-20160404monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-introduces-ensure-enlive-pairing-the-latest-in-science-and-nutrition-to-improve-hea-abt-20160329monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-first-quarter-earnings-abbott-nyse-abt-will-announce-its--abt-20160328monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-absorb-the-first-fully-dissolving-heart-stent-earns-positive-review-by-fda-adviso-abt-20160315monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-barclays-capital-2016-global-healthcare-conference-abbott-nyse-abt-wi-abt-20160314monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hennepin-county-medical-center-and-university-of-minnesota-collaborate-to-launch-th-abt-20160309monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-369th-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20160219monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-approval-in-australia-for-freestyle-libre-the-revolutionary-glucose-monito-abt-20160216monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-introduces-new-foodie-inspired-snack-brand-curate-as-snacks-and-smaller-meals-conti-abt-20160209monthly0.5https://www.biopharmawatch.com/news/ABT/children-in-europe-now-have-access-to-first-of-its-kind-diabetes-sensing-technology-elimin-abt-20160204monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-fourth-quarter-2015-results-abbott-nyse-abt-today-announced-financial-resul-abt-20160128monthly0.5https://www.biopharmawatch.com/news/ABT/specialized-nutrition-supplement-is-associated-with-a-50-percent-lower-death-rate-in-patie-abt-20160118monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-fourth-quarter-earnings-abbott-nyse-abt-will-announce-its-abt-20160107monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-j-p-morgan-healthcare-conference-abbott-will-present-at-the-34th-annu-abt-20151215monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-raising-quarterly-dividend-for-44th-straight-year-the-board-of-directors-of-abbott--abt-20151211monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-uc-san-francisco-discover-new-virus-is-linked-to-hepatitis-c-abbott-and-univers-abt-20151211monthly0.5https://www.biopharmawatch.com/news/ABT/are-we-doing-everything-we-can-for-malnourished-patients-an-apple-a-day-keeps-the-doctor-a-abt-20151208monthly0.5https://www.biopharmawatch.com/news/ABT/pesquisa-ine-dita-da-abbott-revela-que-52-dos-brasileiros-esta-o-felizes-atualmente-apenas-abt-20151126monthly0.5https://www.biopharmawatch.com/news/ABT/health-is-a-marathon-not-a-sprint-well-known-for-its-culture-theater-and-cuisine-new-york--abt-20151030monthly0.5https://www.biopharmawatch.com/news/ABT/science-says-abbott-is-a-top-employer-the-journal-science-today-recognized-abbott-nyse-abt-abt-20151029monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-fait-e-quipe-avec-la-star-du-football-cristiano-ronaldo-pour-inciter-les-jeunes-a-f-abt-20151022monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-se-une-al-astro-de-fu-tbol-cristiano-ronaldo-para-inspirar-a-jo-venes-a-donar-sangr-abt-20151022monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-teams-up-with-soccer-star-cristiano-ronaldo-to-inspire-young-people-to-donate-blood-abt-20151022monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-se-alia-a-estrela-do-futebol-cristiano-ronaldo-para-inspirar-os-jovens-a-doar-sangu-abt-20151022monthly0.5https://www.biopharmawatch.com/news/ABT/cristiano-ronaldo-e-embaixador-do-movimento-mundial-para-a-doac-a-o-de-sangue-bethe1donor--abt-20151021monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-colabora-con-la-estrella-del-fu-tbol-cristiano-ronaldo-para-alentar-a-los-jo-venes--abt-20151021monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-teams-con-la-star-del-calcio-cristiano-ronaldo-uniti-per-stimolare-i-giovani-a-dona-abt-20151021monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-und-cristiano-ronaldo-arbeiten-zusammen-um-junge-menschen-zum-blut-spenden-anzurege-abt-20151021monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-third-quarter-2015-results-abbott-nyse-abt-today-announced-financial-result-abt-20151021monthly0.5https://www.biopharmawatch.com/news/ABT/new-york-road-runners-and-abbott-partner-for-2015-tcs-new-york-city-marathon-new-york-road-abt-20151015monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-positive-clinical-results-of-absorb-the-naturally-dissolving-heart-stent--abt-20151012monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-celebrates-living-fully-through-the-power-of-health-as-an-official-sponsor-of-the-2-abt-20151001monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-third-quarter-earnings-abbott-nyse-abt-will-announce-its--abt-20150930monthly0.5https://www.biopharmawatch.com/news/ABT/what-does-it-mean-to-live-fully-what-does-it-look-like-to-really-live-a-full-life-one-that-abt-20150922monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-marks-15-years-of-helping-career-minded-moms-reach-their-full-professional-potentia-abt-20150922monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-367th-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20150917monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-named-industry-leader-for-responsible-and-sustainable-business-for-three-consecutiv-abt-20150910monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-completes-acquisition-of-tendyne-holdings-inc-abbott-nyse-abt-announced-today-that--abt-20150902monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-positive-results-of-its-naturally-dissolving-stent-from-absorb-japan-stud-abt-20150901monthly0.5https://www.biopharmawatch.com/news/ABT/new-concussion-survey-reveals-majority-of-adults-are-unable-to-recognize-common-concussion-abt-20150824monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-broaden-foundation-in-structural-heart-therapies-with-two-mitral-valve-transacti-abt-20150730monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-partners-with-the-2015-bmw-berlin-marathon-to-celebrate-the-power-of-health-the-org-abt-20150724monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-second-quarter-2015-results-abbott-nyse-abt-today-announced-financial-resul-abt-20150722monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-idesign-system-creates-3-d-map-of-the-eye-for-precise-personalized-lasik-vision-t-abt-20150720monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-second-quarter-earnings-abbott-nyse-abt-will-announce-its-abt-20150701monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-affirms-its-support-for-mylan-standalone-strategy-and-will-vote-its-mylan-shares-in-abt-20150616monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-366th-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20150612monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-ce-mark-for-new-advancement-of-absorb-stent-system-for-people-with-heart--abt-20150519monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-first-of-its-kind-blood-test-to-aid-in-detecting-early-pregnancy-could-help-docto-abt-20150430monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-first-quarter-2015-results-abbott-nyse-abt-today-announced-financial-result-abt-20150422monthly0.5https://www.biopharmawatch.com/news/ABT/new-blood-glucose-meter-provides-people-with-diabetes-an-accurate-affordable-solution-for--abt-20150415monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-sekisui-collaborate-to-offer-coagulation-testing-for-laboratories-worldwide-tod-abt-20150414monthly0.5https://www.biopharmawatch.com/news/ABT/boston-athletic-association-and-abbott-announce-multiple-year-sponsorship-of-the-boston-ma-abt-20150413monthly0.5https://www.biopharmawatch.com/news/ABT/first-of-its-kind-diabetes-technology-revolutionizes-how-glucose-data-is-collected-and-ana-abt-20150402monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-first-quarter-earnings-abbott-nyse-abt-will-announce-its--abt-20150401monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-mitraclip-system-shown-to-mend-hearts-and-improve-lives-in-people-in-the-united-s-abt-20150315monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-365th-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20150220monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-cowen-and-company-35th-annual-health-care-conference-abbott-nyse-abt--abt-20150219monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-leerink-global-healthcare-conference-abbott-nyse-abt-will-present-at--abt-20150204monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-launches-new-options-for-people-with-cataracts-in-the-united-states-two-new-intraoc-abt-20150130monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-fourth-quarter-2014-results-abbott-today-announced-financial-results-for-th-abt-20150129monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-results-of-tender-offer-and-consent-solicitation-for-cfr-international-sp-abt-20150115monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-fourth-quarter-and-full-year-2014-earnings-abbott-nyse-ab-abt-20150108monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-early-results-of-tender-offer-and-consent-solicitation-for-cfr-internatio-abt-20141230monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-completes-acquisition-of-topera-inc-abbott-nyse-abt-today-announced-that-it-has-com-abt-20141222monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-j-p-morgan-healthcare-conference-abbott-nyse-abt-will-present-at-the--abt-20141218monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-commences-tender-offer-and-consent-solicitation-for-cfr-international-spa-5-125-sen-abt-20141215monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-completes-acquisition-of-veropharm-abbott-nyse-abt-today-announced-that-it-has-acqu-abt-20141212monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-increase-in-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt--abt-20141212monthly0.5https://www.biopharmawatch.com/news/ABT/iridica-la-plataforma-de-pruebas-pionera-de-abbott-para-enfermedades-infecciosas-ya-esta-d-abt-20141211monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-pioneering-infectious-disease-testing-platform-iridica-now-available-in-europe-ab-abt-20141211monthly0.5https://www.biopharmawatch.com/news/ABT/abbotts-wegweisende-plattform-fu-r-die-diagnostik-von-infektionskrankheiten-iridica-jetzt--abt-20141211monthly0.5https://www.biopharmawatch.com/news/ABT/la-plate-forme-d-abbott-iridica-pionnie-re-en-matie-re-d-analyses-des-maladies-infectieuse-abt-20141211monthly0.5https://www.biopharmawatch.com/news/ABT/impact-of-malnutrition-in-u-s-at-157-billion-annually-even-in-food-abundant-industrialized-abt-20141204monthly0.5https://www.biopharmawatch.com/news/ABT/people-with-chronic-obstructive-pulmonary-disease-copd-who-received-nutrition-treatment-in-abt-20141117monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-credit-suisse-2014-healthcare-conference-abbott-nyse-abt-will-partici-abt-20141104monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-expands-its-medical-device-business-with-acquisition-in-catheter-based-electrophysi-abt-20141029monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-third-quarter-2014-results-abbott-today-announced-financial-results-for-the-abt-20141022monthly0.5https://www.biopharmawatch.com/news/ABT/new-large-scale-study-will-look-at-how-nutrition-can-help-keep-patients-from-returning-to--abt-20141020monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-acknowledged-by-science-magazine-as-a-top-employer-abbott-nyse-abt-today-was-named--abt-20141016monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-celebrates-the-power-of-health-and-achievement-as-first-ever-title-sponsor-of-world-abt-20141010monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-goes-extra-mile-in-commitment-to-helping-people-live-healthy-lives-as-an-official-s-abt-20141001monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-third-quarter-earnings-abbott-nyse-abt-will-announce-its--abt-20141001monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-culmina-la-adquisicio-n-de-cfr-pharmaceuticals-y-anuncia-los-resultados-de-la-opa-d-abt-20140926monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-completes-acquisition-of-cfr-pharmaceuticals-announces-results-of-tender-offer-for--abt-20140926monthly0.5https://www.biopharmawatch.com/news/ABT/expiration-of-the-u-s-tender-offer-for-cfr-pharmaceuticals-s-a-abbott-today-announced-the--abt-20140924monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-included-in-top-10-best-companies-by-working-mother-magazine-abbott-s-nyse-abt-long-abt-20140916monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-initiates-absorb-iv-trial-to-evaluate-quality-of-life-and-cost-savings-of-dissolvin-abt-20140915monthly0.5https://www.biopharmawatch.com/news/ABT/absorb-ii-study-shows-abbott-s-dissolving-heart-device-comparable-to-the-world-s-leading-h-abt-20140914monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-once-again-named-the-industry-leader-for-responsible-and-sustainable-business-on-th-abt-20140911monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-new-3-billion-share-repurchase-program-declares-dividend-abbott-s-nyse-ab-abt-20140911monthly0.5https://www.biopharmawatch.com/news/ABT/new-abbott-technology-may-uncover-the-root-of-critical-infections-and-cut-health-care-cost-abt-20140908monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-ce-mark-for-freestyle-libre-a-revolutionary-glucose-monitoring-system-for--abt-20140903monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-commences-tender-offer-for-all-outstanding-ordinary-shares-and-american-depositary--abt-20140825monthly0.5https://www.biopharmawatch.com/news/ABT/access-to-abbott-s-mitraclip-system-expands-in-the-u-s-with-medicare-national-coverage-det-abt-20140812monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-showcase-innovations-to-help-labs-solve-health-care-challenges-at-the-american-a-abt-20140728monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-introduces-new-similac-breastfeeding-supplement-with-dha-lutein-and-vitamin-e-nutri-abt-20140724monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-second-quarter-2014-results-abbott-today-announced-financial-results-for-th-abt-20140716monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-sell-its-developed-markets-branded-generics-pharmaceuticals-business-to-mylan-ab-abt-20140714monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-builds-long-term-commitment-in-china-today-s-announcement-of-a-proposed-strategic-a-abt-20140710monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-fonterra-to-form-strategic-alliance-for-dairy-farming-in-china-abbott-nyse-abt--abt-20140710monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-second-quarter-earnings-abbott-nyse-abt-will-announce-its-abt-20140625monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-ce-mark-for-tecnis-symfony-extended-range-of-vision-intraocular-lens-for-c-abt-20140624monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-acquire-veropharm-abbott-nyse-abt-today-announced-a-definitive-agreement-to-acqu-abt-20140623monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-362nd-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20140613monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-william-blair-34th-annual-growth-stock-conference-abbott-nyse-abt-wil-abt-20140604monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-expands-latin-american-presence-and-branded-generics-portfolio-with-acquisition-of--abt-20140516monthly0.5https://www.biopharmawatch.com/news/ABT/promising-preliminary-data-show-abbott-s-innovative-testing-platform-may-identify-life-thr-abt-20140512monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-facility-receives-top-international-award-for-operational-excellence-abbott-nyse-ab-abt-20140508monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-first-quarter-2014-results-abbott-nyse-abt-today-announced-financial-result-abt-20140416monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-fda-clearance-for-a-new-test-to-help-physicians-quickly-and-accurately-di-abt-20140414monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-completes-enrollment-of-absorb-randomized-clinical-trials-in-the-united-states-japa-abt-20140410monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-first-quarter-earnings-abbott-nyse-abt-will-announce-its--abt-20140401monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-fda-approval-of-its-supera-stent-to-treat-people-with-peripheral-artery-d-abt-20140328monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-361st-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20140221monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-fourth-quarter-and-full-year-2013-earnings-abbott-nyse-ab-abt-20140106monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-j-p-morgan-healthcare-conference-abbott-nyse-abt-will-present-at-the--abt-20131219monthly0.5https://www.biopharmawatch.com/news/ABT/a-space-age-view-into-human-vision-abbott-s-idesign-dx-system-now-available-for-u-s-ophtha-abt-20131217monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-named-top-dealmaker-for-sixth-consecutive-year-by-the-deal-the-deal-a-business-unit-abt-20131118monthly0.5https://www.biopharmawatch.com/news/ABT/experience-a-day-in-the-life-of-an-insulin-using-patient-with-diabetes-through-interactive-abt-20131114monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-supports-relief-efforts-in-the-philippines-abbott-nyse-abt-and-its-philanthropic-fo-abt-20131113monthly0.5https://www.biopharmawatch.com/news/ABT/tiesto-teams-up-with-music-saves-lives-and-abbott-to-encourage-young-people-to-donate-bloo-abt-20131112monthly0.5https://www.biopharmawatch.com/news/ABT/similac-partners-with-national-association-of-hispanic-nurses-to-launch-strongmoms-espan-o-abt-20131107monthly0.5https://www.biopharmawatch.com/news/ABT/partners-in-health-abbott-and-the-abbott-fund-open-nutrition-facility-in-haiti-partners-in-abt-20131106monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-mitraclip-treatment-demonstrates-positive-results-for-patients-with-degenerative--abt-20131030monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-first-in-class-mitraclip-device-now-available-for-u-s-patients-abbott-today-annou-abt-20131025monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-again-recognized-by-science-magazine-as-one-of-the-top-employers-in-the-healthcare--abt-20131024monthly0.5https://www.biopharmawatch.com/news/ABT/new-study-demonstrates-importance-of-oral-nutritional-supplements-in-helping-hospitals-ach-abt-20131018monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-third-quarter-2013-results-abbott-today-announced-financial-results-for-the-abt-20131016monthly0.5https://www.biopharmawatch.com/news/ABT/new-study-shows-oral-nutritional-supplement-use-in-pediatric-inpatients-is-associated-with-abt-20131011monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-third-quarter-earnings-abbott-nyse-abt-will-announce-its--abt-20130925monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-ce-mark-for-freestyle-optium-neo-blood-glucose-and-ketone-monitoring-syste-abt-20130917monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-ranked-among-top-10-best-companies-by-working-mother-magazine-abbott-nyse-abt-today-abt-20130917monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-named-the-leading-healthcare-company-on-the-dow-jones-sustainability-index-djsi-abb-abt-20130912monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-359th-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20130912monthly0.5https://www.biopharmawatch.com/news/ABT/new-data-suggests-abbott-s-high-sensitive-troponin-test-may-help-doctors-more-accurately-d-abt-20130904monthly0.5https://www.biopharmawatch.com/news/ABT/oral-nutritional-supplements-in-the-hospital-demonstrate-significant-health-and-cost-benef-abt-20130830monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-completes-acquisition-of-idev-technologies-abbott-nyse-abt-today-announced-that-it--abt-20130821monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-completes-acquisition-of-optimedica-abbott-nyse-abt-today-announced-that-it-has-com-abt-20130819monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-partners-with-music-saves-lives-to-encourage-young-donors-to-give-the-gift-of-blood-abt-20130815monthly0.5https://www.biopharmawatch.com/news/ABT/new-data-for-abbott-s-investigational-high-sensitive-troponin-test-shows-it-may-help-docto-abt-20130730monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-features-solutions-to-help-labs-prepare-for-the-evolving-healthcare-landscape-at-th-abt-20130729monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-clearance-for-freestyle-precision-pro-blood-glucose-and-beta-ketone-mo-abt-20130725monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-second-quarter-2013-results-abbott-nyse-abt-today-announced-financial-resul-abt-20130717monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-enter-laser-cataract-surgery-market-through-acquisition-of-optimedica-abbott-nys-abt-20130715monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-acquire-idev-technologies-to-expand-global-peripheral-technology-portfolio-abbot-abt-20130715monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-approval-of-next-generation-xience-xpedition-drug-eluting-stent-system-in-abt-20130710monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-second-quarter-earnings-abbott-nyse-abt-will-announce-its-abt-20130628monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-new-test-to-help-doctors-determine-personalized-treatment-path-for-patien-abt-20130620monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-new-3-billion-share-repurchase-program-declares-dividend-abbott-s-nyse-ab-abt-20130614monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-initiates-randomized-clinical-trial-in-japan-to-evaluate-the-absorb-bioresorbable-v-abt-20130611monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-wells-fargo-securities-research-economics-2013-healthcare-conference--abt-20130610monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-william-blair-33rd-annual-growth-stock-conference-abbott-nyse-abt-wil-abt-20130604monthly0.5https://www.biopharmawatch.com/news/ABT/two-real-world-european-studies-of-abbott-s-minimally-invasive-mitraclip-device-demonstrat-abt-20130604monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-goldman-sachs-34th-annual-global-healthcare-conference-abbott-nyse-ab-abt-20130531monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-deutsche-bank-38th-annual-health-care-conference-abbott-nyse-abt-will-abt-20130522monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-ce-mark-for-world-s-longest-coronary-drug-eluting-stent-abbott-nyse-abt-t-abt-20130521monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-ce-mark-for-test-to-aid-doctors-with-diagnosing-and-monitoring-diabetes-a-abt-20130509monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-ubs-global-healthcare-conference-abbott-nyse-abt-will-present-at-the--abt-20130508monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-fda-approval-and-u-s-launch-of-the-tecnis-toric-intraocular-lens-for-cata-abt-20130418monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-first-quarter-2013-results-abbott-today-announced-financial-results-for-the-abt-20130417monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-introduces-next-generation-laboratory-automation-solution-to-help-meet-increased-te-abt-20130416monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-initiates-voluntary-recall-of-freestyle-insulinx-blood-glucose-meters-in-the-united-abt-20130415monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-galectin-3-test-provides-doctors-in-europe-with-new-tool-for-assessing-the-progno-abt-20130410monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-first-quarter-earnings-abbott-nyse-abt-will-announce-its--abt-20130401monthly0.5https://www.biopharmawatch.com/news/ABT/new-abbott-test-can-help-doctors-detect-the-presence-of-two-important-health-issues-abbott-abt-20130328monthly0.5https://www.biopharmawatch.com/news/ABT/fda-advisory-committee-votes-favorably-on-abbott-s-minimally-invasive-mitraclip-device-for-abt-20130320monthly0.5https://www.biopharmawatch.com/news/ABT/new-data-reinforce-strong-long-term-clinical-performance-of-abbott-s-absorb-bioresorbable--abt-20130311monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-minimally-invasive-mitraclip-system-for-mitral-regurgitation-demonstrates-positiv-abt-20130310monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-barclays-capital-2013-global-healthcare-conference-abbott-nyse-abt-wi-abt-20130307monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-introduces-nutrition-for-active-kids-kidz-zoneperfect-nutrition-bars-abbott-s-nyse--abt-20130305monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-collaborate-with-janssen-and-pharmacyclics-on-development-of-companion-test-for--abt-20130221monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-357th-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20130215monthly0.5https://www.biopharmawatch.com/news/ABT/new-survey-reveals-eight-in-10-fitness-enthusiasts-are-not-doing-enough-to-aid-recovery-af-abt-20130212monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-fourth-quarter-and-full-year-2012-results-abbott-today-announced-financial--abt-20130123monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-abbvie-named-to-s-p-dividend-aristocrats-indices-abbott-nyse-abt-has-once-again-abt-20130121monthly0.5https://www.biopharmawatch.com/news/ABT/new-abbott-test-available-in-europe-provides-novel-tool-to-aid-doctors-in-evaluating-poten-abt-20130109monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-initiates-clinical-trial-of-absorb-in-the-united-states-abbott-nyse-abt-announced-t-abt-20130108monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-fda-approval-and-u-s-launch-of-next-generation-xience-xpedition-drug-elut-abt-20130103monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-completes-separation-of-research-based-pharmaceuticals-business-abbott-nyse-abt-tod-abt-20130102monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-abbvie-to-present-at-financial-conferences-abbott-nyse-abt-and-abbvie-will-pres-abt-20121221monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-new-testosterone-test-to-measure-the-hormone-at-low-levels-testosterone-i-abt-20121217monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-356th-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20121214monthly0.5https://www.biopharmawatch.com/news/ABT/new-study-shows-promising-results-for-tests-that-can-help-doctors-better-evaluate-potentia-abt-20121213monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-effectiveness-of-abbvie-form-10-registration-statement-abbott-nyse-abt-an-abt-20121207monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-board-of-directors-approves-separation-of-abbvie-and-declares-special-dividend-dist-abt-20121128monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-final-results-for-partial-debt-tender-offers-abbott-nyse-abt-announced-to-abt-20121127monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-results-for-any-and-all-debt-tender-offers-abbott-nyse-abt-announced-toda-abt-20121113monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-phase-3-hepatitis-c-program-details-abbott-nyse-abt-today-released-detail-abt-20121113monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-results-of-analysis-exploring-the-use-of-humira-adalimumab-in-simultaneou-abt-20121112monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-first-long-term-patient-reported-health-outcomes-data-for-investigational-abt-20121112monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-presents-promising-phase-2b-interferon-free-hepatitis-c-results-at-2012-liver-meeti-abt-20121110monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-early-tender-results-for-partial-debt-tender-offers-and-extends-any-and-a-abt-20121109monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-consideration-for-debt-tender-offers-abbott-nyse-abt-announced-today-the--abt-20121108monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-pricing-of-abbvie-s-14-7-billion-private-placement-notes-offering-abbott--abt-20121105monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-the-abbott-fund-donate-1-million-in-funding-and-products-to-support-hurricane-s-abt-20121102monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-introduces-ensure-complete-shakes-for-adults-abbott-nyse-abt-the-global-healthcare--abt-20121030monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-cash-tender-offers-for-notes-abbott-nyse-abt-announced-today-that-it-has--abt-20121026monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-alk-test-is-now-available-in-europe-as-a-companion-diagnostic-test-to-aid-in-iden-abt-20121024monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-three-year-long-term-data-evaluating-efficacy-with-humira-adalimumab-for--abt-20121022monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-double-digit-earnings-per-share-growth-in-the-third-quarter-abbott-nyse-abt-abt-20121017monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-investigational-interferon-free-hepatitis-c-treatment-regimen-achieved-svr12-obse-abt-20121015monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-awards-two-scholarships-to-inspirational-students-living-with-cystic-fibrosis-abbot-abt-20121012monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-third-quarter-earnings-abbott-nyse-abt-will-announce-its--abt-20121003monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-humira-adalimumab-receives-u-s-fda-approval-for-the-treatment-of-adult-patients-w-abt-20120928monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-international-launch-of-the-absorb-bioresorbable-vascular-scaffold-abbott-abt-20120925monthly0.5https://www.biopharmawatch.com/news/ABT/the-journal-science-again-recognizes-abbott-as-one-of-the-top-employers-in-the-biotech-and-abt-20120921monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-named-to-working-mother-magazine-s-best-companies-list-for-twelve-consecutive-years-abt-20120918monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-355th-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20120913monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-recognized-for-leading-citizenship-performance-for-eighth-consecutive-year-by-dow-j-abt-20120913monthly0.5https://www.biopharmawatch.com/news/ABT/according-to-new-survey-most-men-are-not-proactive-about-their-health-despite-the-desire-t-abt-20120912monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-collaborate-with-astellas-in-cmv-vaccine-trial-abbott-nyse-abt-announced-today-t-abt-20120906monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-ce-mark-for-highly-sensitive-testosterone-test-to-measure-the-hormone-at--abt-20120828monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-ce-mark-and-european-launch-of-next-generation-xience-xpedition-drug-elut-abt-20120820monthly0.5https://www.biopharmawatch.com/news/ABT/public-voting-now-open-to-help-grant-two-20-000-abbott-cfcareforward-scholarships-to-stude-abt-20120813monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-omnilink-elite-vascular-balloon-expandable-stent-system-receives-fda-approval-for-abt-20120807monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-strong-second-quarter-results-abbott-nyse-abt-today-announced-financial-res-abt-20120718monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-focuses-on-the-importance-of-information-management-and-automation-at-the-american--abt-20120713monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-introduces-onelab-a-novel-integrated-web-based-software-platform-to-manage-the-vast-abt-20120711monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-new-test-for-the-management-of-patients-with-diabetes-more-than-346-milli-abt-20120710monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-approval-for-healon-endocoat-protective-gel-for-cataract-surgery-abbot-abt-20120703monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-the-abbott-fund-and-direct-relief-international-reach-key-hiv-testing-milestones-20-abt-20120627monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-second-quarter-earnings-abbott-nyse-abt-will-announce-its-abt-20120627monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-introduces-new-limited-ingredient-nutrition-bar-perfectly-simple-by-zoneperfect-abb-abt-20120626monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-again-named-one-of-the-best-workplaces-in-europe-the-great-place-to-work-institute--abt-20120620monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-presents-results-of-clinical-studies-evaluating-its-investigational-treatment-for-a-abt-20120618monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-354th-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20120608monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-presents-phase-3-study-results-for-investigational-use-of-humira-adalimumab-in-pati-abt-20120606monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-10-year-data-evaluating-humira-adalimumab-for-patients-with-long-standing-abt-20120606monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-introduces-ensure-clear-to-help-adults-fill-dietary-gaps-nyse-abt-as-an-alternate-o-abt-20120605monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-initiation-of-phase-3-study-of-elagolix-in-patients-with-endometriosis-ab-abt-20120605monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-again-recognized-as-one-of-the-best-places-to-work-in-industry-by-the-scientist-mag-abt-20120601monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-goldman-sachs-33rd-annual-global-healthcare-conference-abbott-nyse-ab-abt-20120529monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-wide-range-of-investigational-efficacy-safety-and-health-outcomes-data-o-abt-20120529monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-launches-pediasure-sidekicks-clear-for-picky-eaters-all-children-need-proper-nutrie-abt-20120516monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-xience-prime-and-xience-v-drug-eluting-stents-receive-indication-in-europe-for-mi-abt-20120515monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-new-freestyle-insulinx-blood-glucose-monitoring-system-with-insulin-calculator-no-abt-20120509monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reaches-settlement-agreement-on-depakote-abbott-nyse-abt-has-reached-a-settlement-w-abt-20120507monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-acquire-action-pharma-s-investigational-compound-ap214-in-phase-2b-development-f-abt-20120503monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-collaboration-with-syngene-to-open-first-nutrition-r-d-center-in-india-ab-abt-20120503monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-deutsche-bank-37th-annual-health-care-conference-abbott-nyse-abt-will-abt-20120502monthly0.5https://www.biopharmawatch.com/news/ABT/new-products-from-abbott-s-eas-sports-nutrition-brand-help-athletes-improve-post-workout-r-abt-20120425monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-st-jude-medical-broaden-alliance-for-cardiovascular-products-in-the-united-stat-abt-20120423monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-u-s-fda-clearance-to-use-ifs-advanced-femtosecond-laser-technology-for-arc-abt-20120420monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-presents-positive-results-from-phase-2-pilot-study-of-an-interferon-free-combinatio-abt-20120419monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-presents-positive-results-from-interferon-free-phase-2-co-pilot-study-for-the-treat-abt-20120419monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-double-digit-ongoing-earnings-per-share-growth-in-first-quarter-raises-full-abt-20120418monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-licenses-biomarkers-for-use-in-differentiating-aggressive-from-nonaggressive-prosta-abt-20120417monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-investigational-treatment-for-advanced-parkinson-s-disease-demonstrates-positive--abt-20120417monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-approval-for-next-generation-xience-prime-drug-eluting-stent-in-japan-abbo-abt-20120409monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-positive-phase-2-results-from-multiple-interferon-free-studies-of-combin-abt-20120404monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-plex-id-molecular-system-and-tests-for-broad-microbial-identification-obtain-ce-m-abt-20120330monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-first-quarter-earnings-abbott-nyse-abt-will-announce-its--abt-20120328monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-selects-abbvie-as-new-name-for-future-research-based-pharmaceutical-company-abbott--abt-20120321monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reinforces-global-vascular-leadership-with-new-data-on-innovative-technologies-at-a-abt-20120320monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-patient-enrollment-in-two-phase-3-studies-of-humira-adalimumab-for-modera-abt-20120315monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-new-freestyle-insulinx-blood-glucose-monitoring-system-receives-fda-clearance-abb-abt-20120308monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-absolute-pro-vascular-self-expanding-stent-system-receives-fda-approval-for-treat-abt-20120307monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-barclays-capital-2012-global-healthcare-conference-abbott-nyse-abt-wi-abt-20120307monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-merck-collaborate-to-develop-companion-diagnostic-test-for-investigational-canc-abt-20120306monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-collaborate-on-rapid-molecular-test-to-identify-serious-infections-in-bones-and--abt-20120305monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-starlims-business-acquires-distribution-partners-to-build-international-presence--abt-20120302monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-build-nutrition-manufacturing-facility-in-ohio-abbott-nyse-abt-today-announced-p-abt-20120301monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-galapagos-announce-global-collaboration-for-novel-oral-therapy-glpg0634-in-phas-abt-20120229monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-cowen-and-company-32nd-annual-health-care-conference-abbott-nyse-abt--abt-20120223monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-40th-consecutive-annual-increase-in-quarterly-dividend-the-board-of-direc-abt-20120217monthly0.5https://www.biopharmawatch.com/news/ABT/study-shows-abbott-s-tacrolimus-assay-demonstrates-consistent-organ-transplant-drug-monito-abt-20120213monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-creates-new-similac-simplysmart-baby-bottle-with-innovative-features-abbott-nyse-ab-abt-20120208monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-leerink-swann-2012-global-healthcare-conference-abbott-nyse-abt-will--abt-20120201monthly0.5https://www.biopharmawatch.com/news/ABT/dndi-and-abbott-expand-partnership-to-boost-innovation-for-neglected-tropical-diseases-the-abt-20120130monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-double-digit-ongoing-earnings-per-share-growth-in-fourth-quarter-and-full-y-abt-20120125monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-starlims-lims-technology-to-be-installed-in-fda-testing-laboratories-abbott-nyse--abt-20120118monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-fourth-quarter-and-full-year-2011-earnings-abbott-nyse-ab-abt-20120104monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-initiates-clinical-trial-to-study-drug-eluting-bioresorbable-therapy-for-treatment--abt-20111222monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-university-of-illinois-establish-center-for-nutrition-learning-and-memory-abbot-abt-20111219monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-j-p-morgan-healthcare-conference-abbott-nyse-abt-will-present-at-the--abt-20111215monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-reata-pharmaceuticals-announce-agreement-to-develop-and-commercialize-next-gene-abt-20111212monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-352nd-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20111209monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-initiates-clinical-trial-to-evaluate-the-absorb-bioresorbable-vascular-scaffold-com-abt-20111208monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-clearance-for-new-test-to-detect-vitamin-d-levels-abbott-nyse-abt-anno-abt-20111130monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-expands-agreement-with-gsk-to-include-development-of-a-companion-diagnostic-test-fo-abt-20111128monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-introduces-the-first-fda-approved-supplemental-blood-test-for-chagas-disease-abbott-abt-20111121monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-statement-on-the-results-of-the-aim-high-study-presented-at-aha-2011-final-results--abt-20111115monthly0.5https://www.biopharmawatch.com/news/ABT/new-data-reinforce-clinical-performance-of-abbott-s-absorb-bioresorbable-vascular-scaffold-abt-20111114monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-five-year-data-for-humira-adalimumab-in-ankylosing-spondylitis-abbott-nyse--abt-20111108monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-presents-humira-adalimumab-phase-3-study-results-for-patients-with-active-non-radio-abt-20111107monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-new-long-term-data-evaluating-use-of-humira-adalimumab-for-patients-with--abt-20111106monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-honored-with-scrip-award-for-leadership-in-corporate-social-responsibility-scrip-a--abt-20111104monthly0.5https://www.biopharmawatch.com/news/ABT/path-abbott-and-the-abbott-fund-form-innovative-partnership-to-prevent-malnutrition-path-a-abt-20111103monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-new-data-for-key-vascular-products-at-tct-2011-abbott-nyse-abt-today-ann-abt-20111103monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-2011-credit-suisse-annual-health-care-conference-abbott-nyse-abt-will-abt-20111102monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-broad-spectrum-of-compelling-data-for-humira-adalimumab-at-american-coll-abt-20111102monthly0.5https://www.biopharmawatch.com/news/ABT/experts-report-that-abbott-s-new-plex-id-assay-offers-important-testing-capabilities-for-b-abt-20111102monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-u-s-fda-approval-for-next-generation-xience-prime-drug-eluting-stent-abbot-abt-20111101monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-launches-glucerna-hunger-smart-nutrition-products-for-people-with-diabetes-respondi-abt-20111027monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-awards-cfcareforward-scholarships-to-two-students-living-with-cystic-fibrosis-pursu-abt-20111025monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-genetic-test-for-acute-myeloid-leukemia-prognosis-cleared-by-fda-abbott-nyse-abt--abt-20111024monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-honored-with-asian-csr-award-for-leadership-in-science-education-at-the-10th-asian--abt-20111024monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-strong-ongoing-third-quarter-results-confirms-double-digit-ongoing-earnings-abt-20111019monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-separate-into-two-leading-companies-in-diversified-medical-products-and-research-abt-20111019monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-absorb-bioresorbable-vascular-scaffold-honored-with-wall-street-journal-technolog-abt-20111017monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-third-quarter-earnings-abbott-nyse-abt-will-announce-its--abt-20111005monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-enrolls-first-u-s-patient-in-global-excel-trial-comparing-xience-to-coronary-artery-abt-20111004monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-named-top-dealmaker-for-fourth-consecutive-year-by-the-deal-the-deal-magazine-has-n-abt-20110920monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-earns-100-percent-banned-substance-free-certification-for-all-of-its-eas-sports-nut-abt-20110920monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-351st-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20110915monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-named-to-working-mother-magazine-s-best-companies-list-for-the-eleventh-consecutive-abt-20110915monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-again-recognized-as-one-of-the-top-employers-in-the-biotech-and-pharmaceutical-indu-abt-20110915monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-initiates-international-absorb-btk-clinical-trial-for-treatment-of-below-the-knee-c-abt-20110908monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-named-to-the-dow-jones-sustainability-indexes-for-seventh-consecutive-year-in-recog-abt-20110908monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-morgan-stanley-global-healthcare-conference-abbott-nyse-abt-will-pres-abt-20110831monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-awards-cfcareforward-scholarships-to-40-exceptional-graduate-and-undergraduate-stud-abt-20110830monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-approval-for-alk-gene-test-for-lung-cancer-therapy-selection-abbott-ny-abt-20110826monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-ce-mark-for-healon-endocoat-protective-gel-for-cataract-surgery-abbott-nys-abt-20110822monthly0.5https://www.biopharmawatch.com/news/ABT/fda-clears-abbott-s-genetic-fish-panel-for-leukemia-patient-prognosis-abbott-nyse-abt-anno-abt-20110822monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-expanding-manufacturing-capacity-in-china-to-meet-demands-of-fast-growing-nutrition-abt-20110816monthly0.5https://www.biopharmawatch.com/news/ABT/first-patient-in-japan-treated-with-abbott-s-bioresorbable-vascular-scaffold-as-part-of-gl-abt-20110816monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-approval-for-two-three-month-strengths-of-lupron-depot-ped-leuprolide--abt-20110816monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-pediasure-brand-aims-to-help-moms-with-picky-eaters-take-back-the-table-by-buildi-abt-20110811monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-introduces-vector-borne-pathogen-test-to-detect-microorganisms-carried-by-ticks-and-abt-20110810monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-u-s-fda-approval-for-rx-herculink-elite-renal-stent-system-for-treatment-o-abt-20110810monthly0.5https://www.biopharmawatch.com/news/ABT/data-presented-at-american-association-for-clinical-chemistry-meeting-show-many-americans--abt-20110728monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-hiv-combo-test-detects-infections-earlier-provides-valuable-information-to-help-p-abt-20110727monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-feature-acute-hiv-diagnostic-metabolic-function-tests-and-lab-informatics-at-ame-abt-20110721monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-11-percent-ongoing-earnings-per-share-growth-in-second-quarter-raises-2011--abt-20110720monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-second-quarter-earnings-abbott-nyse-abt-will-announce-its-abt-20110629monthly0.5https://www.biopharmawatch.com/news/ABT/new-phase-2-data-published-in-new-england-journal-of-medicine-show-bardoxolone-methyl-sust-abt-20110624monthly0.5https://www.biopharmawatch.com/news/ABT/information-notice-on-stolen-abbott-diabetes-care-blood-glucose-monitoring-products-abbott-abt-20110624monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-biotest-announce-global-agreement-to-develop-and-commercialize-novel-antibody-f-abt-20110621monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-approval-for-a-new-six-month-formulation-of-lupron-depot-leuprolide-ac-abt-20110620monthly0.5https://www.biopharmawatch.com/news/ABT/reata-and-abbott-initiate-global-phase-3-study-of-bardoxolone-methyl-in-patients-with-chro-abt-20110616monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-approval-for-creon-pancrelipase-infant-specific-dosage-for-patients-wi-abt-20110614monthly0.5https://www.biopharmawatch.com/news/ABT/new-national-survey-results-reveal-majority-of-men-find-it-easier-to-care-for-their-car-th-abt-20110613monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-350th-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20110610monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-interim-results-from-phase-iii-open-label-study-of-investigational-treatmen-abt-20110609monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-statement-on-interim-study-results-of-aim-high-the-national-heart-lung-and-blood-in-abt-20110526monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-goldman-sachs-32nd-annual-global-healthcare-conference-abbott-nyse-ab-abt-20110525monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-u-s-fda-approval-for-xience-nano-to-treat-coronary-artery-disease-in-small-abt-20110524monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-completes-submission-of-new-molecular-test-intended-for-non-small-cell-lung-cancer--abt-20110523monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-statement-on-the-fda-advisory-committee-recommendations-on-fenofibric-acid-the-u-s--abt-20110519monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-approval-for-molecular-test-for-hepatitis-c-abbott-nyse-abt-announced--abt-20110518monthly0.5https://www.biopharmawatch.com/news/ABT/study-shows-improved-patient-management-and-outcome-using-abbott-s-sensitive-troponin-assa-abt-20110518monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-humira-adalimumab-meets-primary-endpoints-in-phase-iii-ulcerative-colitis-study-a-abt-20110510monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-new-freestyle-insulinx-blood-glucose-monitoring-system-with-insulin-calculator-re-abt-20110510monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-approval-to-expand-use-of-the-rx-acculink-carotid-stent-system-to-pati-abt-20110506monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-bank-of-america-merrill-lynch-2011-health-care-conference-abbott-nyse-abt-20110503monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-u-s-fda-approval-for-androgel-1-62-to-treat-men-with-low-testosterone-abbo-abt-20110429monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-highlights-top-tier-financial-performance-strong-growth-in-emerging-markets-at-annu-abt-20110429monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-17-4-percent-sales-growth-and-12-3-percent-ongoing-earnings-per-share-growt-abt-20110420monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-chairman-and-ceo-miles-d-white-elected-to-the-american-academy-of-arts-sciences-abb-abt-20110419monthly0.5https://www.biopharmawatch.com/news/ABT/new-fully-automated-vitamin-d-assay-submitted-for-fda-clearance-according-to-a-recent-repo-abt-20110415monthly0.5https://www.biopharmawatch.com/news/ABT/data-from-landmark-clinical-trial-of-abbott-s-mitraclip-system-demonstrate-durable-clinica-abt-20110404monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-enanta-present-positive-12-week-results-and-3-day-resistance-data-from-phase-2--abt-20110404monthly0.5https://www.biopharmawatch.com/news/ABT/analysis-of-data-across-multiple-drug-eluting-stent-trials-reinforces-positive-clinical-pe-abt-20110403monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-absorb-bioresorbable-vascular-scaffold-demonstrates-positive-one-year-safety-and--abt-20110403monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-introduces-hepatitis-b-sequencing-test-in-europe-abbott-molecular-announced-today-t-abt-20110331monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-first-quarter-earnings-abbott-nyse-abt-will-announce-its--abt-20110331monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-launch-of-catheter-based-mitraclip-system-in-australia-for-mitral-regurgi-abt-20110330monthly0.5https://www.biopharmawatch.com/news/ABT/fda-clears-abbott-s-i-stat-1-wireless-point-of-care-testing-system-abbott-announced-today--abt-20110329monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-introduces-micro-implantation-cataract-suite-abbott-nyse-abt-announced-today-that-i-abt-20110328monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-data-on-novel-vascular-technologies-and-xience-v-at-acc-2011-abbott-nyse-abt-20110328monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-new-hiv-1-qualitative-assay-improves-testing-access-in-remote-areas-for-children--abt-20110321monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-supports-relief-efforts-in-japan-abbott-nyse-abt-through-its-philanthropic-foundati-abt-20110314monthly0.5https://www.biopharmawatch.com/news/ABT/positive-results-from-phase-2-study-of-atrasentan-for-treatment-of-diabetic-kidney-disease-abt-20110304monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-barclays-capital-2011-global-healthcare-conference-abbott-nyse-abt-wi-abt-20110301monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-cowen-and-company-31st-annual-health-care-conference-abbott-nyse-abt--abt-20110222monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-increase-in-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt--abt-20110218monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-rbc-capital-markets-healthcare-conference-abbott-nyse-abt-will-presen-abt-20110215monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-introduces-biothreat-assay-for-plex-id-system-abbott-nyse-abt-announced-today-that--abt-20110207monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-ibis-technology-identified-fatal-disease-organism-in-afghanistan-today-at-the-ame-abt-20110207monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-trek-coronary-balloon-system-now-available-in-the-united-states-and-japan-abbott--abt-20110131monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-double-digit-sales-and-ongoing-earnings-growth-in-fourth-quarter-issues-str-abt-20110126monthly0.5https://www.biopharmawatch.com/news/ABT/fda-advisory-committee-votes-favorably-on-expanding-the-indication-for-abbott-s-carotid-st-abt-20110126monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-ce-mark-approval-for-world-s-first-drug-eluting-bioresorbable-vascular-sca-abt-20110110monthly0.5https://www.biopharmawatch.com/news/ABT/partners-in-health-abbott-and-the-abbott-fund-unite-to-combat-severe-childhood-malnutritio-abt-20110107monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-fourth-quarter-and-full-year-2010-earnings-abbott-nyse-ab-abt-20110103monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-j-p-morgan-healthcare-conference-abbott-nyse-abt-will-present-at-the--abt-20101222monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-astrazeneca-end-license-agreement-for-the-development-of-certriad-abbott-nyse-a-abt-20101222monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-diabetes-care-announces-recall-of-certain-lots-of-precision-xtra-precision-xceed-pr-abt-20101222monthly0.5https://www.biopharmawatch.com/news/ABT/epitherapeutics-and-abbott-enter-into-oncology-collaboration-on-epigenetic-targets-epither-abt-20101220monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-348th-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20101210monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-again-recognized-for-leadership-in-workplace-diversity-and-inclusion-abbott-nyse-ab-abt-20101123monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-announces-positive-results-from-phase-2-study-of-low-dose-atrasentan-for-treatment--abt-20101122monthly0.5https://www.biopharmawatch.com/news/ABT/reata-and-abbott-announce-positive-phase-2b-study-results-for-bardoxolone-methyl-reata-pha-abt-20101120monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-named-one-of-america-s-most-generous-companies-sets-company-records-for-employee-gi-abt-20101116monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-awards-scholarships-to-students-living-with-cystic-fibrosis-to-help-them-pursue-the-abt-20101111monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-joins-clinton-health-access-initiative-in-effort-to-improve-infant-testing-for-hiv--abt-20101108monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-presents-data-exploring-relationship-of-physical-function-to-inflammation-and-struc-abt-20101108monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-remains-on-the-dow-jones-sustainability-indexes-for-the-sixth-consecutive-year-in-r-abt-20101108monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-wins-two-scrip-awards-recognizing-excellence-in-pharmaceutical-and-biotech-industri-abt-20101105monthly0.5https://www.biopharmawatch.com/news/ABT/architect-hiv-ag-ab-combo-test-wins-prestigious-chicago-innovation-award-abbott-today-anno-abt-20101103monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-2010-credit-suisse-annual-health-care-conference-abbott-nyse-abt-will-abt-20101102monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-enanta-present-positive-initial-results-from-phase-2-study-of-abt-450-r-for-tre-abt-20101101monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-again-recognized-for-environmental-initiatives-in-illinois-abbott-nyse-abt-announce-abt-20101028monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-new-zoneperfect-cookie-dough-nutrition-bars-a-nutritious-twist-for-cookie-dough-l-abt-20101027monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-statement-abbott-provides-support-for-cholera-relief-efforts-in-haiti-abbott-nyse-a-abt-20101027monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-strong-third-quarter-results-confirms-double-digit-ongoing-earnings-outlook-abt-20101020monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-reports-psoriasis-phase-iii-results-of-its-investigational-il-12-23-inhibitor-briak-abt-20101011monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-voluntarily-withdraw-meridia-sibutramine-in-the-u-s-abbott-nyse-abt-will-volunta-abt-20101008monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-named-one-of-the-top-employers-in-the-biotech-and-pharmaceutical-industry-by-scienc-abt-20101007monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-market-clearance-for-next-generation-contact-lens-disinfecting-solutio-abt-20100929monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-hosts-conference-call-for-third-quarter-earnings-abbott-nyse-abt-will-announce-its--abt-20100929monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-xience-v-shows-outstanding-two-year-clinical-results-versus-taxus-in-key-safety-a-abt-20100923monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-and-reata-pharmaceuticals-announce-agreement-to-develop-and-commercialize-bardoxolo-abt-20100923monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-xience-v-shows-continued-strong-performance-in-key-safety-and-efficacy-measures-a-abt-20100923monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-voluntariamente-recoge-del-mercado-ciertas-unidades-de-fo-rmula-infantil-marca-simi-abt-20100922monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-s-fully-bioresorbable-vascular-scaffold-technology-continues-to-demonstrate-strong--abt-20100922monthly0.5https://www.biopharmawatch.com/news/ABT/the-deal-names-abbott-top-dealmaker-for-third-consecutive-year-the-deal-magazine-has-named-abt-20100920monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-introduces-sports-nutrition-performance-beverage-eas-peak-with-new-p3-technology-ab-abt-20100920monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-declares-347th-consecutive-quarterly-dividend-the-board-of-directors-of-abbott-nyse-abt-20100916monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-launches-new-ensure-shakes-with-focus-on-helping-baby-boomers-regain-muscle-and-str-abt-20100916monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-data-on-market-leading-xience-v-and-promising-vascular-pipeline-at-tct-2-abt-20100916monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-statement-on-the-fda-advisory-committee-recommendation-on-sibutramine-the-u-s-food--abt-20100915monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-honored-for-workplace-leadership-for-the-tenth-consecutive-year-by-working-mother-m-abt-20100914monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-included-on-the-dow-jones-sustainability-indexes-for-six-consecutive-years-in-recog-abt-20100909monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-completes-acquisition-of-piramal-s-healthcare-solutions-business-becomes-leading-ph-abt-20100908monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-receives-fda-approval-for-first-automated-molecular-test-for-assessing-hepatitis-b--abt-20100901monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-to-present-at-morgan-stanley-global-healthcare-unplugged-conference-abbott-nyse-abt-abt-20100830monthly0.5https://www.biopharmawatch.com/news/ABT/abbott-launches-new-psoriasisanswers-com-web-site-august-marks-national-psoriasis-awarenes-abt-20100812monthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-to-report-first-quarter-2024-financial-results-on-april-30-2024-10x-genomics--txg-20240410monthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-outl-txg-20240215monthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-to-showcase-new-cutting-edge-technologies-and-highlight-innovation-roadmap-at-txg-20240205monthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-to-report-fourth-quarter-and-full-year-2023-financial-results-on-february-15--txg-20240124monthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-10x-genomics-i-txg-20231221monthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-launches-xenium-catalyst-network-10x-genomics-inc-nasdaq-txg-a-leader-in-sing-txg-20231220monthly0.5https://www.biopharmawatch.com/news/TXG/integrative-study-conducted-by-10x-genomics-combines-single-cell-spatial-and-in-situ-analy-txg-20231219monthly0.5https://www.biopharmawatch.com/news/TXG/high-sensitivity-and-specificity-of-the-xenium-platform-from-10x-genomics-outperforms-nano-txg-20231213monthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-and-nih-card-to-create-comprehensive-single-cell-atlas-of-the-human-brain-10x-txg-20231207monthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-wins-another-patent-infringement-case-against-nanostring-technologies-10x-gen-txg-20231117monthly0.5https://www.biopharmawatch.com/news/TXG/owkin-integrates-10x-genomics-spatial-omics-and-single-cell-technologies-to-the-mosaic-stu-txg-20231106monthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-reports-third-quarter-2023-financial-results-10x-genomics-inc-nasdaq-txg-a-le-txg-20231102monthly0.5https://www.biopharmawatch.com/news/TXG/study-fueled-by-xenium-analysis-sheds-light-on-resistance-mechanisms-in-model-of-lethal-pe-txg-20231026monthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-to-report-third-quarter-2023-financial-results-on-november-2-2023-10x-genomic-txg-20231011monthly0.5https://www.biopharmawatch.com/news/TXG/10x-genomics-to-report-third-quarter-financial-results-on-november-3-2021-10x-genomics-nas-txg-20211007monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-grail-inc-nasdaq-gral-gral-20260527monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-to-present-at-the-bofa-securities-2026-health-care-conference-grail-inc-nasdaq-gral--gral-20260430monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-to-present-new-data-from-nhs-galleri-and-pathfinder-2-at-2026-asco-annual-meeting-gr-gral-20260421monthly0.5https://www.biopharmawatch.com/news/GRAL/landmark-nhs-galleri-trial-demonstrates-a-substantial-reduction-in-stage-iv-cancer-diagnos-gral-20260219monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-to-announce-third-quarter-2025-financial-results-grail-inc-nasdaq-gral-a-healthcare--gral-20251029monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-to-present-at-bernstein-insights-healthcare-leaders-and-disruptors-2nd-annual-health-gral-20250910monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-grail-inc-nasdaq-gral-gral-20250829monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-to-present-at-morgan-stanley-23rd-annual-global-healthcare-conference-grail-inc-nasd-gral-20250826monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-to-present-at-canaccord-genuity-45th-annual-growth-conference-grail-inc-nasdaq-gral--gral-20250730monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-to-announce-second-quarter-2025-financial-results-grail-inc-nasdaq-gral-a-healthcare-gral-20250729monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-announces-positive-top-line-results-from-the-galleri-pathfinder-2-registrational-stu-gral-20250618monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-grail-inc-nasdaq-gral-gral-20250530monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-to-present-at-jefferies-global-healthcare-conference-2025-grail-inc-nasdaq-gral-a-he-gral-20250521monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-and-athenahealth-team-up-to-offer-healthcare-providers-streamlined-ordering-of-grail-gral-20250512monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-to-announce-first-quarter-2025-financial-results-grail-inc-nasdaq-gral-a-healthcare--gral-20250429monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-to-present-new-data-on-galleri-and-its-methylation-platform-at-american-association--gral-20250422monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-grail-inc-nasdaq-gral-gral-20250226monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-partners-with-actress-kate-walsh-for-generation-possible-to-raise-awareness-of-multi-gral-20250225monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-to-present-at-td-cowen-45th-annual-health-care-conference-grail-inc-nasdaq-gral-a-he-gral-20250221monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-to-announce-fourth-quarter-2024-financial-results-grail-inc-nasdaq-gral-a-healthcare-gral-20250212monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-and-quest-diagnostics-provide-grail-s-galleri-multi-cancer-early-detection-mced-test-gral-20250212monthly0.5https://www.biopharmawatch.com/news/GRAL/patient-reported-outcomes-for-grail-s-galleri-multi-cancer-early-detection-blood-test-publ-gral-20250113monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-grail-inc-nasdaq-gral-gral-20241218monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-grail-inc-nasdaq-gral-gral-20241203monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-to-participate-in-upcoming-investor-conferences-grail-inc-nasdaq-gral-a-healthcare-c-gral-20241119monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-announces-first-patient-tested-with-blood-based-assay-in-global-phase-3-adjuvant-lun-gral-20241118monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-to-present-at-the-canaccord-genuity-medtech-diagnostics-and-digital-health-services--gral-20241104monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-to-announce-third-quarter-2024-financial-results-grail-inc-nasdaq-gral-a-healthcare--gral-20241029monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-presents-initial-results-from-reflection-real-world-evidence-study-of-galleri-multi--gral-20241023monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-appoints-sarah-krevans-to-board-of-directors-grail-inc-nasdaq-gral-a-healthcare-comp-gral-20241021monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-grail-inc-nasdaq-gral-gral-20240830monthly0.5https://www.biopharmawatch.com/news/GRAL/results-of-grail-s-galleri-multi-cancer-early-detection-blood-test-in-prostate-cancer-publ-gral-20240829monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-to-present-at-the-morgan-stanley-22nd-annual-global-healthcare-conference-grail-inc--gral-20240821monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-to-announce-second-quarter-2024-financial-results-grail-inc-nasdaq-gral-a-healthcare-gral-20240731monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-announces-first-participant-enrolled-in-reach-study-evaluating-clinical-impact-of-ga-gral-20240718monthly0.5https://www.biopharmawatch.com/news/GRAL/grail-advances-the-galleri-registrational-clinical-trial-program-grail-inc-nasdaq-gral-a-h-gral-20240715monthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-announces-oral-presentation-at-the-eha-2026-congress-featuring-additi-elvn-20260512monthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-reports-positive-initial-phase-1b-data-for-elvn-001-in-cml-and-outlines-2026-clini-elvn-20260108monthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-announces-proposed-public-offering-of-common-stock-and-pre-funded-war-elvn-20250613monthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-to-present-at-upcoming-investor-conferences-enliven-therapeutics-inc--elvn-20250522monthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-announces-updated-positive-data-from-phase-1-clinical-trial-of-elvn-0-elvn-20250514monthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting-enlive-elvn-20250402monthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-to-present-at-the-td-cowen-45th-annual-health-care-conference-enliven-elvn-20250225monthly0.5https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-to-present-at-the-jefferies-london-healthcare-conference-enliven-ther-elvn-20241107monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-real-world-evidence-study-finds-medications-for-opioid-use-disorder-particularly--indv-20250723monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-to-report-second-quarter-2025-financial-results-and-host-webcast-on-july-31st-ind-indv-20250717monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-appoints-vanessa-procter-as-executive-vice-president-of-corporate-affairs-indivio-indv-20250708monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-presents-new-data-at-cpdd-demonstrating-that-high-buprenorphine-exposure-may-impr-indv-20250619monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-intention-to-cancel-secondary-listing-on-london-stock-exchange-primary--indv-20250602monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-patrick-barry-as-chief-commercial-officer-indivior-plc-nasdaq-lse-indv--indv-20250527monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-to-participate-in-upcoming-investor-events-indivior-plc-nasdaq-lse-indv-today-ann-indv-20250513monthly0.5https://www.biopharmawatch.com/news/INDV/new-study-highlights-monthly-sublocade-as-a-potential-treatment-option-for-opioid-use-diso-indv-20250501monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-q1-2025-financial-results-indivior-plc-nasdaq-lse-indv-today-announced--indv-20250424monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-further-changes-to-board-of-directors-indivior-plc-nasdaq-lse-indv-indi-indv-20250304monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-joseph-ciaffoni-appointed-chief-executive-officer-indivior-plc-nasdaq-l-indv-20250227monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-fda-approval-of-label-changes-for-sublocade-buprenorphine-extended-rele-indv-20250224monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-fy-and-q4-2024-financial-results-indivior-plc-nasdaq-lse-indv-today-ann-indv-20250220monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-statement-re-delayed-fda-approval-of-sublocade-label-changes-indivior-plc-nasdaq--indv-20250212monthly0.5https://www.biopharmawatch.com/news/INDV/rapid-initiation-with-once-monthly-sublocade-superior-to-standard-initiation-for-treating--indv-20241119monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-highlights-growing-body-of-data-on-sublocade-buprenorphine-once-monthly-extended--indv-20241030monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-q3-2024-financial-results-indivior-plc-nasdaq-lse-indv-today-announced--indv-20241024monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-provides-preliminary-q3-2024-results-updates-fy-2024-guidance-group-continues-to--indv-20241010monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-s-sublocade-rapid-induction-alternative-injection-site-prior-approval-supplement--indv-20241007monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-provides-update-on-aelis-farma-s-clinical-phase-2b-study-results-with-aef0117-in--indv-20240904monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-barda-s-first-order-of-opvee-to-combat-opioids-and-aid-in-national-prep-indv-20240826monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-a-new-100-million-share-repurchase-program-new-program-will-be-executed-indv-20240725monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-q2-2024-financial-results-indivior-plc-nasdaq-lse-indv-today-announced--indv-20240725monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-provides-business-update-conference-call-at-8-00-am-u-s-edt-indivior-plc-nasdaq-l-indv-20240709monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-the-publication-of-new-data-on-the-comparative-effectiveness-of-intrana-indv-20240618monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-dosing-of-first-subject-with-indv-2000-in-a-phase-2-study-assessing-the-indv-20240610monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-to-host-analyst-teach-in-event-in-new-york-city-reconfirms-full-year-2024-guidanc-indv-20240523monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-q1-2024-financial-results-indivior-plc-lse-nasdaq-indv-today-announced--indv-20240425monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-publication-demonstrating-that-opvee-nalmefene-nasal-spray-rapidly-reve-indv-20240311monthly0.5https://www.biopharmawatch.com/news/INDV/court-provides-final-approval-of-settlement-with-direct-purchaser-class-in-the-multidistri-indv-20240229monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-q4-fy-2023-financial-results-indivior-plc-lse-nasdaq-indv-today-announc-indv-20240222monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-q3-2023-financial-results-indivior-plc-lse-nasdaq-indv-today-announced--indv-20231109monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-enters-an-exclusive-licensing-agreement-with-alar-pharmaceuticals-indivior-plc-ls-indv-20231011monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-publishes-real-world-data-showing-sublocade-may-reduce-non-fatal-overdoses-among--indv-20230926monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-q2-h1-2023-financial-results-indivior-plc-lse-nasdaq-indv-today-announc-indv-20230727monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-four-abstracts-accepted-for-presentation-at-the-85th-annual-scientific--indv-20230614monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-to-commence-trading-on-nasdaq-indivior-plc-lse-indv-a-global-pharmaceutical-compa-indv-20230612monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-reaches-agreement-with-states-attorneys-general-and-district-of-columbia-to-resol-indv-20230602monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-to-participate-in-upcoming-investor-conferences-indivior-plc-lse-indv-today-annou-indv-20230525monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-plc-form-20-f-registration-statement-for-additional-us-listing-now-available-trad-indv-20230523monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-u-s-food-and-drug-administration-approval-of-opvee-nalmefene-nasal-spra-indv-20230522monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-q1-2023-financial-results-indivior-plc-lse-indv-today-announced-its-fin-indv-20230427monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-to-participate-in-bank-of-america-global-healthcare-conference-2023-indivior-plc--indv-20230425monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-completes-acquisition-of-opiant-pharmaceuticals-inc-indivior-plc-lse-indv-indivio-indv-20230302monthly0.5https://www.biopharmawatch.com/news/INDV/fy-2022-financial-results-announced-indivior-plc-lse-indv-today-announced-2022-full-year-r-indv-20230216monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-first-patient-included-in-aelis-farma-s-phase-2b-study-assessing-the-ef-indv-20220601monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-presents-new-data-at-the-college-on-problems-of-drug-dependence-cpdd-2021-annual--indv-20210624monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-extends-leadership-position-in-substance-use-disorder-treatment-with-exclusive-ag-indv-20210608monthly0.5https://www.biopharmawatch.com/news/INDV/study-examining-impact-of-covid-19-pandemic-on-opioid-use-disorder-oud-finds-greater-barri-indv-20210422monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-recognizes-drug-and-alcohol-facts-week-2021-developed-by-the-national-institute-o-indv-20210323monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-availability-of-third-quarter-and-nine-months-2020-results-indivior-plc-indv-20201029monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-takes-strategic-alignment-actions-indivior-plc-lon-indv-today-announced-that-it-i-indv-20200924monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-first-half-and-second-quarter-2020-results-now-available-conference-call-with-lea-indv-20200730monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-agreement-to-resolve-criminal-charges-and-civil-complaints-related-to-s-indv-20200724monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-q1-2020-results-now-available-conference-call-with-leadership-today-indivior-plc--indv-20200514monthly0.5https://www.biopharmawatch.com/news/INDV/sublocade-long-term-safety-data-published-in-journal-of-clinical-psychopharmacology-indivi-indv-20200416monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-full-year-2019-results-now-available-leadership-presentation-today-indivior-plc-l-indv-20200213monthly0.5https://www.biopharmawatch.com/news/INDV/virginia-tech-and-indivior-announce-new-collaboration-to-study-long-term-recovery-in-peopl-indv-20191210monthly0.5https://www.biopharmawatch.com/news/INDV/new-analysis-from-one-year-study-of-monthly-buprenorphine-extended-release-injections-show-indv-20191202monthly0.5https://www.biopharmawatch.com/news/INDV/announcement-of-national-institutes-of-health-nih-grant-award-through-the-nih-helping-to-e-indv-20190926monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-raises-fy-2019-net-revenue-and-net-income-guidance-cash-at-h1-2019-expected-to-be-indv-20190711monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-first-quarter-2019-results-now-available-conference-call-with-leadership-today-in-indv-20190502monthly0.5https://www.biopharmawatch.com/news/INDV/statement-of-indivior-on-grand-jury-indictment-indivior-plc-lon-indv-issued-the-following--indv-20190409monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-launch-of-perseris-risperidone-for-the-treatment-of-schizophrenia-in-ad-indv-20190227monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-launch-of-suboxone-buprenorphine-and-naloxone-sublingual-film-authorize-indv-20190220monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-provides-legal-and-trading-update-confirms-launch-of-perseris-and-key-elements-of-indv-20181218monthly0.5https://www.biopharmawatch.com/news/INDV/court-of-appeals-for-the-federal-circuit-declines-to-immediately-issue-mandate-after-preli-indv-20181212monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-to-host-conference-call-on-december-18th-previously-scheduled-capital-markets-day-indv-20181127monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-health-canada-approval-of-sublocadea-buprenorphine-extended-release-inj-indv-20181123monthly0.5https://www.biopharmawatch.com/news/INDV/court-of-appeals-for-the-federal-circuit-lifts-preliminary-injunction-on-generic-buprenorp-indv-20181121monthly0.5https://www.biopharmawatch.com/news/INDV/perseris-the-first-once-monthly-risperidone-containing-subcutaneous-long-acting-injectable-indv-20181119monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-upcoming-investor-events-indivior-plc-lon-indv-today-announced-the-foll-indv-20181106monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-nine-month-and-third-quarter-2018-results-indivior-plc-lon-indv-today-a-indv-20181101monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-provides-update-on-key-business-drivers-and-expectations-indivior-plc-lon-indv-to-indv-20180926monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-unable-to-participate-in-morgan-stanley-healthcare-conference-due-to-adverse-weat-indv-20180912monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-prepays-150-million-of-outstanding-debt-indivior-plc-lon-indv-today-announced-tha-indv-20180910monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-preliminary-injunction-on-generic-buprenorphine-and-naloxone-sublingual-film-uphe-indv-20180731monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-h1-2018-results-period-to-june-30th-q2-2018-m-q2-2017-m-actual-fx-const-indv-20180725monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-is-granted-preliminary-injunction-on-generic-buprenorphine-and-naloxone-sublingua-indv-20180713monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-sees-fy-2018-net-revenue-and-adjusted-net-income-below-previous-expectations-indi-indv-20180711monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-to-announce-and-present-half-year-2018-results-on-july-25th-indivior-plc-lon-indv-indv-20180710monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-s-temporary-restraining-order-is-extended-indivior-plc-lon-indv-indivior-or-the-c-indv-20180628monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-responds-to-generic-suboxone-approvals-and-dr-reddy-s-launch-at-risk-indivior-plc-indv-20180615monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-is-granted-temporary-restraining-order-indivior-plc-lon-indv-indivior-or-the-comp-indv-20180615monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-receives-subpoena-from-california-department-of-insurance-indivior-plc-lon-indv-a-indv-20180531monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-regulatory-submission-to-australia-s-therapeutic-goods-administration-t-indv-20180525monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-s-mark-crossley-to-participate-in-jefferies-2018-global-healthcare-conference-on--indv-20180524monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-enters-into-settlement-with-par-pharmaceutical-in-patent-infringement-case-indivi-indv-20180514monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-to-announce-first-quarter-2018-results-on-may-2nd-and-host-conference-call-indivi-indv-20180411monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-enters-into-an-exclusive-global-license-agreement-for-c4x-discovery-s-orexin-1-ox-indv-20180329monthly0.5https://www.biopharmawatch.com/news/INDV/sublocade-buprenorphine-extended-release-is-now-available-as-first-and-only-monthly-inject-indv-20180301monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-files-complaints-asserting-new-suboxone-film-patent-against-anda-filers-indivior--indv-20180208monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-to-announce-full-year-2017-results-on-february-15th-indivior-plc-lon-indv-today-a-indv-20180119monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-s-shaun-thaxter-to-present-at-the-36th-annual-j-p-morgan-healthcare-conference-on-indv-20180104monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-and-addex-enter-strategic-collaboration-to-accelerate-development-of-gaba-b-pams--indv-20180103monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-nda-acceptance-of-rbp-7000-risperidone-monthly-depot-indivior-plc-lon-i-indv-20171212monthly0.5https://www.biopharmawatch.com/news/INDV/fda-advisory-committees-recommend-approval-of-indivior-s-rbp-6000-for-the-treatment-of-opi-indv-20171031monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-plc-announces-fda-acceptance-with-priority-review-designation-of-rbp-6000-bupreno-indv-20170731monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-plc-presents-results-from-the-phase-3-pivotal-study-of-rbp-6000-buprenorphine-mon-indv-20170621monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-applauds-united-states-surgeon-general-dr-vivek-murthy-s-report-on-substance-misu-indv-20161117monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-announces-positive-top-line-phase-3-pivotal-study-results-for-rbp-6000-buprenorph-indv-20160816monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-applauds-congressional-passage-of-bipartisan-comprehensive-addiction-recovery-act-indv-20160713monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-to-present-new-data-at-ispor-and-icoo-that-assess-implications-of-adherence-healt-indv-20160520monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-applauds-recent-momentum-to-address-opioid-dependence-and-overdose-epidemic-indiv-indv-20151021monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-plc-responds-to-court-s-decision-on-motion-to-amend-indivior-plc-lon-indv-today-a-indv-20151012monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-plc-announces-fda-acceptance-of-naloxone-nasal-spray-new-drug-application-with-pr-indv-20150729monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-plc-announces-positive-top-line-results-from-pivotal-phase-3-trial-of-rbp-7000-in-indv-20150505monthly0.5https://www.biopharmawatch.com/news/INDV/toelating-van-indivior-plc-tot-de-officie-le-lijst-en-tot-verhandeling-op-de-london-stock--indv-20141223monthly0.5https://www.biopharmawatch.com/news/INDV/la-socie-te-indivior-plc-est-admise-a-la-cote-officielle-et-a-la-spe-culation-sur-la-bours-indv-20141223monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-plc-e-admitida-na-lista-oficial-para-ser-negociada-na-bolsa-de-valores-de-londres-indv-20141223monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-plc-zum-offiziellen-verzeichnis-und-handelsverkehr-der-london-stock-exchange-zuge-indv-20141223monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-plc-admitida-en-el-listado-oficial-para-cotizar-en-la-bolsa-de-valores-de-londres-indv-20141223monthly0.5https://www.biopharmawatch.com/news/INDV/indivior-plc-admission-to-the-official-list-and-to-trading-on-the-london-stock-exchange-in-indv-20141223monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-and-oruka-announce-global-collaboration-and-license-agreement-to-develop-orka-001-halo-20260506monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-busine-halo-20260120monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-global-collaboration-and-license-agreement-with-takeda-to-develop-and-c-halo-20260108monthly0.5https://www.biopharmawatch.com/news/HALO/u-s-fda-approves-rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-co-formulated-with-en-halo-20251218monthly0.5https://www.biopharmawatch.com/news/HALO/merus-and-halozyme-enter-global-collaboration-and-license-agreement-to-develop-subcutaneou-halo-20251117monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-inc-announces-proposed-offering-of-650-million-of-convertible-senior-halo-20251105monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-participate-at-upcoming-investor-conferences-halozyme-therapeutics-inc-nasdaq--halo-20250828monthly0.5https://www.biopharmawatch.com/news/HALO/european-commission-approved-darzalex-faspro-for-adult-patients-with-smouldering-multiple--halo-20250723monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-report-second-quarter-2025-financial-and-operating-results-halozyme-therapeuti-halo-20250722monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-added-to-russell-1000-index-halozyme-therapeutics-inc-nasdaq-halo-ha-halo-20250630monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-argenx-received-european-commission-approval-for-vyvgart-subcutaneous-i-halo-20250620monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-participate-at-upcoming-investor-conferences-halozyme-therapeutics-inc-nasdaq--halo-20250528monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-bristol-myers-squibb-received-european-commission-approval-for-subcutan-halo-20250528monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference-halozyme-therape-halo-20250505monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-report-first-quarter-2025-financial-and-operating-results-halozyme-therapeutic-halo-20250428monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-argenx-received-positive-chmp-opinion-for-vyvgart-efgartigimod-alfa-sub-halo-20250428monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-sues-merck-for-patent-infringement-over-subcutaneous-keytruda-formulation-halozym-halo-20250424monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-fda-approval-of-argenx-s-vyvgart-hytrulo-prefilled-syringe-co-formulate-halo-20250410monthly0.5https://www.biopharmawatch.com/news/HALO/european-commission-approved-subcutaneous-darzalex-daratumumab-based-quadruplet-regimen-fo-halo-20250409monthly0.5https://www.biopharmawatch.com/news/HALO/european-commission-approves-subcutaneous-rybrevant-amivantamab-co-formulated-with-enhanze-halo-20250407monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-bristol-myers-squibb-received-positive-chmp-opinion-for-the-subcutaneou-halo-20250331monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-participate-in-the-td-cowen-45th-annual-healthcare-conference-halozyme-therape-halo-20250226monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-report-fourth-quarter-and-full-year-2024-financial-and-operating-results-haloz-halo-20250204monthly0.5https://www.biopharmawatch.com/news/HALO/chmp-issues-positive-opinion-for-subcutaneous-rybrevant-amivantamab-co-formulated-with-enh-halo-20250203monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-investor-conference-call-to-provide-updated-2025-financial-guidance-haloz-halo-20250106monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-takeda-received-regulatory-approval-for-hyqvia-10-subcutaneous-injectio-halo-20241230monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-argenx-s-vydura-with-enhanze-was-granted-regulatory-approval-in-japan-f-halo-20241230monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-fda-approval-of-bristol-myers-squibb-s-opdivo-qvantig-with-enhanze-for--halo-20241230monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-present-at-upcoming-investor-conferences-halozyme-therapeutics-inc-nasdaq-halo-halo-20241127monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-withdraws-proposal-to-acquire-evotec-following-evotec-s-unwillingness-to-engage-i-halo-20241122monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-provides-update-on-non-binding-proposal-to-combine-with-evotec-halozyme-therapeut-halo-20241118monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-confirms-proposal-to-combine-with-evotec-for-11-00-per-share-in-an-all-cash-trans-halo-20241114monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-provides-update-on-licensee-co-formulation-patent-hearing-in-europe-halozyme-ther-halo-20241024monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-report-third-quarter-2024-financial-and-operating-results-halozyme-therapeutic-halo-20241023monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-expansion-of-global-collaboration-and-license-agreement-with-argenx-for-halo-20241003monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-fda-approval-of-roche-s-subcutaneous-ocrevus-zunovo-with-enhanze-for-pe-halo-20240913monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-fda-approval-of-roche-s-tecentriq-hybreza-with-enhanze-for-multiple-typ-halo-20240912monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-present-at-upcoming-investor-conferences-halozyme-therapeutics-inc-nasdaq-halo-halo-20240828monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-report-second-quarter-2024-financial-and-operating-results-halozyme-therapeuti-halo-20240723monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-roche-s-ocrevus-sc-with-enhanze-receives-european-commission-approval-f-halo-20240625monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-argenx-receives-fda-approval-for-vyvgart-hytrulo-co-formulated-with-enh-halo-20240621monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-raises-full-year-2024-financial-guidance-and-updates-5-year-financial-outlook-hal-halo-20240606monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-issuance-of-new-european-patent-for-enhanze-drug-delivery-platform-halo-halo-20240605monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-participate-in-the-goldman-sachs-45th-annual-global-healthcare-conference-halo-halo-20240604monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-bristol-myers-squibb-received-updated-action-date-from-the-u-s-food-and-halo-20240521monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-participate-in-upcoming-investor-conferences-halozyme-therapeutics-inc-nasdaq--halo-20240508monthly0.5https://www.biopharmawatch.com/news/HALO/mahesh-krishnan-elected-to-halozyme-s-board-of-directors-halozyme-therapeutics-inc-nasdaq--halo-20240425monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-report-first-quarter-2024-financial-and-operating-results-halozyme-therapeutic-halo-20240423monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-participate-in-upcoming-investor-conferences-halozyme-therapeutics-inc-nasdaq--halo-20240227monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-fourth-quarter-and-full-year-2023-financial-and-operating-results-reitera-halo-20240220monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-report-fourth-quarter-and-full-year-2023-financial-and-operating-results-haloz-halo-20240208monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-takeda-received-european-commission-approval-for-hyqvia-co-formulated-w-halo-20240129monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-argenx-received-approval-in-japan-for-vyvdura-efgartigimod-alfa-and-hya-halo-20240118monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-takeda-receives-fda-approval-for-hyqvia-co-formulated-with-enhanze-as-m-halo-20240116monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-roche-receives-european-commission-approval-of-tecentriq-sc-with-enhanz-halo-20240116monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-investor-business-forum-and-long-term-outlook-call-halozyme-therapeutics--halo-20240112monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-present-at-upcoming-investor-conferences-halozyme-therapeutics-inc-nasdaq-halo-halo-20231127monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-argenx-receives-european-commission-approval-of-vyvgart-sc-with-enhanze-halo-20231116monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-and-acumen-pharmaceuticals-enter-global-collaboration-and-non-exclusive-license-a-halo-20231106monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-report-third-quarter-2023-financial-and-operating-results-halozyme-therapeutic-halo-20231030monthly0.5https://www.biopharmawatch.com/news/HALO/positive-topline-results-reported-from-bristol-myers-squibb-s-phase-3-checkmate-67t-trial--halo-20231019monthly0.5https://www.biopharmawatch.com/news/HALO/update-halozyme-announces-presentation-of-positive-clinical-data-of-its-high-volume-auto-i-halo-20231016monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-positive-clinical-data-of-its-high-volume-auto-injector-demonstrating-s-halo-20231016monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-present-at-upcoming-investor-conferences-halozyme-therapeutics-inc-nasdaq-halo-halo-20230831monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-approval-of-roche-s-tecentriq-subcutaneous-sc-with-enhanze-in-great-bri-halo-20230829monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-report-second-quarter-2023-financial-and-operating-results-halozyme-therapeuti-halo-20230725monthly0.5https://www.biopharmawatch.com/news/HALO/positive-topline-data-reported-from-argenx-s-adhere-study-of-vyvgart-hytrulo-with-halozyme-halo-20230717monthly0.5https://www.biopharmawatch.com/news/HALO/positive-results-announced-from-phase-3-ocarina-ii-trial-evaluating-roche-s-ocrevus-ocreli-halo-20230713monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-argenx-receives-fda-approval-for-vyvgart-hytrulo-with-enhanze-for-subcu-halo-20230620monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-present-at-the-goldman-sachs-44th-annual-global-healthcare-conference-halozyme-halo-20230606monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-present-at-upcoming-investor-conferences-halozyme-therapeutics-inc-nasdaq-halo-halo-20230503monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-report-first-quarter-2023-financial-and-operating-results-halozyme-therapeutic-halo-20230425monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-report-fourth-quarter-and-full-year-2022-financial-and-operating-results-haloz-halo-20230207monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-appoints-barbara-duncan-to-its-board-of-directors-halozyme-therapeutics-inc-nasda-halo-20230206monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-inc-announces-redemption-of-1-25-convertible-senior-notes-due-2024-h-halo-20230111monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-provides-2023-financial-guidance-and-outlook-halozyme-therapeutics-inc-nasdaq-hal-halo-20230110monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-halozyme-therapeut-halo-20230103monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-participate-in-upcoming-investor-conferences-halozyme-therapeutics-inc-nasdaq--halo-20221109monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-report-third-quarter-2022-financial-and-operating-results-halozyme-therapeutic-halo-20221025monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-participate-in-the-2022-wells-fargo-healthcare-conference-halozyme-therapeutic-halo-20220901monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-inc-announces-proposed-offering-of-500-million-of-convertible-senior-halo-20220815monthly0.5https://www.biopharmawatch.com/news/HALO/positive-results-announced-from-phase-iii-imscin001-study-evaluating-subcutaneous-formulat-halo-20220802monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-report-second-quarter-2022-financial-and-operating-results-halozyme-therapeuti-halo-20220726monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-participate-in-the-goldman-sachs-43rd-annual-global-healthcare-conference-halo-halo-20220608monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-commercial-launch-of-tlando-an-oral-treatment-for-testosterone-replacem-halo-20220607monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-completes-antares-pharma-acquisition-halozyme-therapeutics-inc-nasdaq-halo-halozy-halo-20220524monthly0.5https://www.biopharmawatch.com/news/HALO/hart-scott-rodino-waiting-period-expires-for-halozyme-s-acquisition-of-antares-pharma-halo-halo-20220512monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-first-quarter-2022-financial-results-webcast-and-conference-call-halozyme-halo-20220503monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-commences-tender-offer-for-all-outstanding-shares-of-common-stock-of-antares-phar-halo-20220426monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-inc-and-chugai-pharmaceutical-enter-global-collaboration-and-license-halo-20220324monthly0.5https://www.biopharmawatch.com/news/HALO/positive-topline-results-announced-from-adapt-sc-study-evaluating-subcutaneous-efgartigimo-halo-20220322monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-appoints-moni-miyashita-to-board-of-directors-halozyme-therapeutics-inc-nasdaq-ha-halo-20220315monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-fourth-quarter-and-full-year-2021-financial-results-webcast-and-conferenc-halo-20220209monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-appoints-new-chief-financial-officer-halozyme-therapeutics-inc-nasdaq-halo-today--halo-20220202monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-provides-2022-financial-guidance-and-outlook-halozyme-therapeutics-inc-nasdaq-hal-halo-20220110monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-present-virtually-at-the-40th-annual-j-p-morgan-health-care-conference-halozym-halo-20220104monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-appoints-new-general-counsel-halozyme-therapeutics-inc-nasdaq-halo-today-announce-halo-20211213monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-750-million-three-year-share-repurchase-program-halozyme-therapeutics-i-halo-20211209monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-janssen-receives-u-s-fda-approval-of-darzalex-faspro-daratumumab-and-hy-halo-20211201monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-present-at-upcoming-investor-conferences-halozyme-therapeutics-inc-nasdaq-halo-halo-20211118monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-third-quarter-2021-results-halozyme-therapeutics-inc-nasdaq-halo-today-re-halo-20211102monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-third-quarter-2021-financial-results-webcast-and-conference-call-halozyme-halo-20211019monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-participate-in-the-2021-cantor-virtual-global-healthcare-conference-halozyme-t-halo-20210915monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-present-at-wells-fargo-2021-virtual-healthcare-conference-halozyme-therapeutic-halo-20210826monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-second-quarter-2021-results-halozyme-therapeutics-inc-nasdaq-halo-today-r-halo-20210809monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-participate-in-canaccord-genuity-41st-annual-growth-conference-halozyme-therap-halo-20210730monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-second-quarter-2021-financial-results-webcast-and-conference-call-halozym-halo-20210727monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-janssen-receives-u-s-fda-approval-of-darzalex-faspro-daratumumab-and-hy-halo-20210712monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-janssen-receives-european-marketing-authorizations-for-darzalex-daratum-halo-20210622monthly0.5https://www.biopharmawatch.com/news/HALO/viiv-healthcare-and-halozyme-enter-global-collaboration-and-license-agreement-for-enhanze--halo-20210622monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-highlights-data-presentations-by-collaborators-for-therapies-utilizing-enhanze-at-halo-20210601monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-present-at-upcoming-investor-conferences-halozyme-therapeutics-inc-nasdaq-halo-halo-20210528monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-janssen-receives-two-positive-chmp-opinions-for-darzalex-daratumumab-su-halo-20210521monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-first-quarter-2021-results-halozyme-therapeutics-inc-nasdaq-halo-today-re-halo-20210510monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-present-at-bofa-securities-2021-virtual-health-care-conference-halozyme-therap-halo-20210429monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-first-quarter-2021-financial-results-webcast-and-conference-call-halozyme-halo-20210420monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-inc-announces-proposed-offering-of-500-million-of-convertible-senior-halo-20210223monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-fourth-quarter-and-full-year-2020-financial-results-webcast-and-conferenc-halo-20210210monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-janssen-receives-fda-approval-of-darzalex-faspro-daratumumab-and-hyalur-halo-20210115monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-present-virtually-at-the-39th-annual-j-p-morgan-healthcare-conference-halozyme-halo-20210104monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-roche-receives-european-commission-approval-for-phesgo-fixed-dose-combi-halo-20201223monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-raises-full-year-2020-guidance-halozyme-therapeutics-inc-nasdaq-halo-today-announ-halo-20201123monthly0.5https://www.biopharmawatch.com/news/HALO/horizon-therapeutics-plc-and-halozyme-therapeutics-inc-enter-global-collaboration-and-lice-halo-20201123monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-participate-in-fireside-chat-for-the-piper-sandler-32nd-annual-virtual-healthc-halo-20201118monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-chmp-recommends-eu-approval-of-roche-s-phesgo-fixed-dose-combination-of-halo-20201113monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-janssen-submission-of-applications-in-us-and-eu-seeking-approval-of-dar-halo-20201112monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-upcoming-data-presentations-at-american-society-of-hematology-annual-me-halo-20201105monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-third-quarter-2020-financial-results-webcast-and-conference-call-halozyme-halo-20201022monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-expansion-of-collaboration-and-license-agreement-with-argenx-for-enhanz-halo-20201006monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-poster-presentation-of-data-from-roche-s-phase-1b-study-evaluating-atez-halo-20200917monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-janssen-submission-for-fda-approval-of-darzalex-faspro-daratumumab-and--halo-20200910monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-present-at-upcoming-virtual-investor-conferences-halozyme-therapeutics-inc-nas-halo-20200909monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-participate-in-2020-wells-fargo-virtual-healthcare-conference-halozyme-therape-halo-20200902monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-present-at-canaccord-genuity-40th-annual-growth-conference-halozyme-therapeuti-halo-20200804monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-second-quarter-2020-financial-results-webcast-and-conference-call-halozym-halo-20200729monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-roche-receives-fda-approval-for-phesgo-fixed-dose-combination-of-perjet-halo-20200629monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-receive-10-million-milestone-payment-from-janssen-halozyme-therapeutics-inc-na-halo-20200622monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-participate-in-the-bmo-2020-prescriptions-for-success-healthcare-conference-ha-halo-20200617monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-findings-from-janssen-s-phase-3-andromeda-study-evaluating-subcutaneous-halo-20200613monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-janssen-receives-european-marketing-authorization-for-subcutaneous-darz-halo-20200604monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-present-at-upcoming-virtual-investor-conferences-halozyme-therapeutics-inc-nas-halo-20200528monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-receive-15-million-milestone-payment-from-janssen-halozyme-therapeutics-inc-na-halo-20200514monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-first-quarter-2020-results-halozyme-therapeutics-inc-nasdaq-halo-today-re-halo-20200511monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-present-at-the-bank-of-america-securities-2020-healthcare-conference-halozyme--halo-20200507monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-janssen-receives-fda-approval-of-darzalex-faspro-utilizing-halozyme-s-e-halo-20200501monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-janssen-s-receipt-of-chmp-positive-opinion-for-darzalex-subcutaneous-fo-halo-20200430monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-first-quarter-2020-financial-results-webcast-and-conference-call-halozyme-halo-20200428monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-janssen-submits-new-drug-application-in-japan-for-daratumumab-subcutane-halo-20200426monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-change-of-location-of-annual-stockholders-meeting-halozyme-therapeutics-halo-20200403monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-cowen-40th-annual-health-care-conference-halozyme--halo-20200226monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-fda-has-accepted-biologics-license-application-for-fixed-dose-subcutane-halo-20200225monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-cfo-transition-halozyme-therapeutics-inc-nasdaq-halo-today-announced-th-halo-20200224monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-fourth-quarter-and-full-year-2019-financial-results-webcast-and-conferenc-halo-20200210monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-provides-2020-business-update-and-financial-guidance-halozyme-therapeutics-inc-na-halo-20200114monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-haloz-halo-20200103monthly0.5https://www.biopharmawatch.com/news/HALO/data-from-phase-3-trial-evaluating-fixed-dose-subcutaneous-combination-of-perjeta-and-herc-halo-20191212monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-inc-announces-proposed-offering-of-400-million-of-convertible-senior-halo-20191112monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-third-quarter-2019-results-halozyme-therapeutics-inc-nasdaq-halo-today-re-halo-20191112monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-halo-301-phase-3-study-fails-to-meet-primary-endpoint-halozyme-therapeu-halo-20191104monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-actions-to-focus-strategy-on-enhanze-drug-delivery-technology-halozyme--halo-20191104monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-third-quarter-2019-financial-results-webcast-and-conference-call-halozyme-halo-20191021monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-participate-in-2019-cantor-global-healthcare-conference-halozyme-therapeutics--halo-20190923monthly0.5https://www.biopharmawatch.com/news/HALO/positive-results-announced-from-phase-3-trial-evaluating-fixed-dose-subcutaneous-combinati-halo-20190913monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-participate-in-2019-wells-fargo-healthcare-conference-halozyme-therapeutics-in-halo-20190826monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-second-quarter-2019-results-halozyme-therapeutics-inc-nasdaq-halo-a-biote-halo-20190806monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-participate-in-39th-annual-canaccord-genuity-growth-conference-halozyme-therap-halo-20190725monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-second-quarter-2019-financial-results-webcast-and-conference-call-halozym-halo-20190723monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-janssen-submits-extension-application-to-european-medicines-agency-for--halo-20190719monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-first-clinical-dosing-in-argenx-s-phase-1-trial-of-efgartigimod-argx-11-halo-20190717monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-janssen-submits-bla-to-fda-for-subcutaneous-formulation-of-darzalex-uti-halo-20190712monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-crada-with-national-institute-of-allergy-and-infectious-diseases-for-us-halo-20190625monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-participate-in-upcoming-investor-conferences-halozyme-therapeutics-inc-nasdaq--halo-20190604monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-argenx-has-selected-second-target-under-enhanze-technology-collaboratio-halo-20190522monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-participate-in-bank-of-america-merrill-lynch-health-care-conference-2019-haloz-halo-20190513monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-first-quarter-2019-results-halozyme-therapeutics-inc-nasdaq-halo-a-biotec-halo-20190507monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-names-dr-alison-a-armour-as-senior-vice-president-of-research-and-development-hal-halo-20190506monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-first-quarter-2019-financial-results-webcast-and-conference-call-halozyme-halo-20190423monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-participate-in-upcoming-investor-conferences-halozyme-therapeutics-inc-nasdaq--halo-20190304monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-fda-approval-of-herceptin-hylecta-halozyme-therapeutics-inc-nasdaq-halo-halo-20190228monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-fourth-quarter-and-full-year-2018-financial-results-webcast-and-conferenc-halo-20190207monthly0.5https://www.biopharmawatch.com/news/HALO/argenx-and-halozyme-enter-global-collaboration-and-license-agreement-for-enhanze-technolog-halo-20190204monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-provides-2019-pipeline-update-and-financial-guidance-at-37th-annual-jp-morgan-hea-halo-20190109monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-haloz-halo-20181226monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-change-in-primary-endpoint-for-halo-301-to-overall-survival-halozyme-th-halo-20181126monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-names-albert-kildani-as-vice-president-investor-relations-and-corporate-communica-halo-20181106monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-licenses-new-enhanze-targets-for-25-million-upfront-payment-future-milestones-and-halo-20181030monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-first-clinical-dosing-in-bristol-myers-squibb-s-phase-1-trial-of-bms-98-halo-20181025monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-provides-summary-results-of-data-for-pegph20-combination-treatments-presented-at--halo-20181022monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-third-quarter-2018-financial-results-conference-call-halozyme-therapeutic-halo-20181010monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-publication-in-the-journal-clinical-cancer-research-highlights-new-nonclinical-da-halo-20181004monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-participate-in-upcoming-investor-conference-halozyme-therapeutics-halo-20180920monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-approval-of-subcutaneous-formulation-of-trastuzumab-herceptin-in-canada-halo-20180917monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-appoints-bernadette-connaughton-to-board-of-directors-halozyme-therapeutics-inc-n-halo-20180910monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-names-benjamin-hickey-as-chief-commercial-officer-halozyme-therapeutics-inc-nasda-halo-20180905monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-participate-in-upcoming-investor-conferences-halozyme-therapeutic-halo-20180822monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-second-quarter-2018-results-halozyme-therapeutics-inc-nasdaq-halo-a-biote-halo-20180807monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-participate-in-upcoming-healthcare-conference-halozyme-therapeuti-halo-20180726monthly0.5https://www.biopharmawatch.com/news/HALO/phase-3-study-of-subcutaneous-pertuzumab-and-trastuzumab-initiated-using-halozyme-s-enhanz-halo-20180726monthly0.5https://www.biopharmawatch.com/news/HALO/fda-accepts-biologics-license-application-for-subcutaneous-formulation-of-herceptin-halozy-halo-20180711monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-second-quarter-2018-financial-results-conference-call-halozyme-therapeuti-halo-20180706monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-president-and-chief-executive-officer-dr-helen-torley-named-ey-entrepreneur-of-th-halo-20180611monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-identifies-plasma-biomarkers-as-potential-predictors-of-survival-in-pancreatic-ca-halo-20180601monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-participate-in-upcoming-healthcare-conferences-halozyme-therapeut-halo-20180529monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-first-quarter-2018-results-halozyme-therapeutics-inc-nasdaq-halo-a-biotec-halo-20180510monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-first-quarter-2018-financial-results-conference-call-halozyme-therapeutic-halo-20180410monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-nomination-of-directors-for-reelection-at-2018-stockholder-meeting-halo-halo-20180322monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-present-data-from-six-nonclinical-studies-at-american-association-of-cancer-re-halo-20180314monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-upcoming-healthcare-conference-halozyme-therapeutics-i-halo-20180227monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-fourth-quarter-and-full-year-2017-results-halozyme-therapeutics-inc-nasda-halo-20180220monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-fourth-quarter-and-full-year-2017-financial-results-conference-call-haloz-halo-20180122monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-projects-25-to-30-percent-enhanze-royalty-growth-in-2018-halozyme-therapeutics-in-halo-20180109monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-36th-annual-j-p-morgan-healthcare-conference-haloz-halo-20171227monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-participate-in-upcoming-healthcare-conferences-halozyme-therapeut-halo-20171115monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-present-nonclinical-data-at-sitc-2017-supporting-combination-of-pegph20-with-c-halo-20171110monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-third-quarter-2017-results-halozyme-therapeutics-inc-nasdaq-halo-a-biotec-halo-20171107monthly0.5https://www.biopharmawatch.com/news/HALO/phase-3-study-of-subcutanous-daratumumab-initiated-using-halozyme-s-enhanze-technology-hal-halo-20171031monthly0.5https://www.biopharmawatch.com/news/HALO/first-gastric-cancer-patient-dosed-in-clinical-trial-collaboration-evaluating-halozyme-s-p-halo-20171024monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-initiates-clinical-trial-of-pegph20-with-anti-pdl1-immunotherapy-in-cholangiocarc-halo-20171016monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-third-quarter-2017-financial-results-conference-call-halozyme-therapeutic-halo-20171010monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-licenses-new-enhanze-target-for-30-million-upfront-payment-future-milestones-and--halo-20170914monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-increases-2017-financial-guidance-halozyme-therapeutics-inc-nasdaq-halo-a-biotech-halo-20170914monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-upcoming-healthcare-conferences-halozyme-therapeutics--halo-20170825monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-second-quarter-2017-results-halozyme-therapeutics-inc-nasdaq-halo-a-biote-halo-20170808monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-upcoming-healthcare-conference-halozyme-therapeutics-i-halo-20170804monthly0.5https://www.biopharmawatch.com/news/HALO/initiation-of-clinical-trial-collaboration-evaluating-halozyme-s-pegph20-in-combination-wi-halo-20170713monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-second-quarter-2017-financial-results-conference-call-halozyme-therapeuti-halo-20170710monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-phase-2-data-in-advanced-pancreas-cancer-presented-at-european-society-for-medica-halo-20170628monthly0.5https://www.biopharmawatch.com/news/HALO/fda-approves-genentech-s-rituxan-hycela-a-subcutaneous-rituximab-coformulated-with-halozym-halo-20170622monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-phase-2-data-in-advanced-pancreas-cancer-featured-in-an-oral-presentation-at-asco-halo-20170604monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-upcoming-healthcare-conferences-halozyme-therapeutics--halo-20170525monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-announces-completion-of-public-offering-and-full-exercise-of-underwr-halo-20170524monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-prices-public-offering-of-common-stock-halozyme-therapeutics-inc-nas-halo-20170518monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-announces-public-offering-of-common-stock-halozyme-therapeutics-inc--halo-20170518monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-phase-2-data-in-advanced-pancreas-cancer-to-be-featured-in-an-oral-presentation-a-halo-20170517monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-first-quarter-2017-financial-results-halozyme-therapeutics-inc-nasdaq-hal-halo-20170509monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-first-quarter-2017-financial-results-conference-call-halozyme-therapeutic-halo-20170410monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-s-pegph20-increases-immune-response-and-effectiveness-of-immunotherapies-in-precl-halo-20170403monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-provides-update-on-swog-collaborative-group-clinical-study-halozyme-therapeutics--halo-20170330monthly0.5https://www.biopharmawatch.com/news/HALO/fda-advisory-committee-provides-unanimous-recommendation-for-subcutaneous-rituximab-coform-halo-20170329monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-fourth-quarter-and-full-year-2016-financial-results-halozyme-therapeutics-halo-20170228monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-upcoming-healthcare-conferences-halozyme-therapeutics--halo-20170223monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-fourth-quarter-2016-financial-results-conference-call-halozyme-therapeuti-halo-20170201monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-provides-program-updates-2017-financial-guidance-at-35th-annual-jp-morgan-healthc-halo-20170109monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-phase-2-study-in-advanced-pancreas-cancer-meets-key-endpoints-halozyme--halo-20170105monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-35th-annual-j-p-morgan-healthcare-conference-haloz-halo-20161222monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-provides-update-on-abbvie-collaboration-halozyme-therapeutics-inc-nasdaq-halo-tod-halo-20161121monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-broad-clinical-collaboration-agreement-to-evaluate-pegph20-and-tecentri-halo-20161110monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-third-quarter-2016-financial-results-halozyme-therapeutics-inc-nasdaq-hal-halo-20161107monthly0.5https://www.biopharmawatch.com/news/HALO/fda-accepts-genentech-s-biologics-license-application-for-subcutaneous-formulation-of-ritu-halo-20161103monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-third-quarter-2016-financial-results-conference-call-halozyme-therapeutic-halo-20161013monthly0.5https://www.biopharmawatch.com/news/HALO/pegph20-selected-for-inclusion-in-groundbreaking-clinical-trial-initiative-designed-to-tra-halo-20161004monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-bank-of-america-merrill-lynch-2016-global-health-c-halo-20160908monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-names-mark-j-gergen-as-chief-operating-officer-halozyme-therapeutics-inc-nasdaq-h-halo-20160901monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-upcoming-healthcare-conferences-halozyme-therapeutics--halo-20160831monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-second-quarter-2016-financial-results-halozyme-therapeutics-inc-nasdaq-ha-halo-20160809monthly0.5https://www.biopharmawatch.com/news/HALO/eisai-and-halozyme-initiate-phase-1b-2-clinical-trial-with-first-patient-dosing-of-eribuli-halo-20160726monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-resumes-patient-enrollment-and-dosing-in-pegph20-clinical-trial-with-keytruda-hal-halo-20160725monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-second-quarter-2016-financial-results-conference-call-halozyme-therapeuti-halo-20160711monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-agreement-to-refinance-debt-increases-2016-guidance-for-year-end-cash-b-halo-20160608monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-presents-stage-one-efficacy-and-safety-analysis-of-phase-2-clinical-study-in-meta-halo-20160604monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-ubs-2016-global-health-care-conference-halozyme-th-halo-20160517monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-first-quarter-2016-financial-results-halozyme-therapeutics-inc-nasdaq-hal-halo-20160509monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-first-quarter-2016-financial-results-conference-call-halozyme-therapeutic-halo-20160420monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-expands-oncology-pipeline-with-two-compounds-designed-for-activity-in-the-tumor-m-halo-20160418monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-present-data-from-five-preclinical-studies-at-american-association-of-cancer-r-halo-20160317monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-doses-first-patient-in-phase-3-clinical-trial-of-pegph20-in-combination-with-abra-halo-20160316monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-appoints-jim-daly-to-board-of-directors-halozyme-therapeutics-inc-nasdaq-halo-a-b-halo-20160307monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-upcoming-healthcare-conferences-halozyme-therapeutics--halo-20160302monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-fourth-quarter-and-full-year-2015-financial-results-halozyme-therapeutics-halo-20160229monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-fourth-quarter-and-2015-year-end-financial-results-conference-call-halozy-halo-20160201monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-closing-of-150-million-royalty-backed-debt-financing-halozyme-therapeut-halo-20160126monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-first-clinical-dosing-of-adalimumab-humira-using-enhanze-technology-hal-halo-20160121monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-provides-key-program-updates-2016-financial-guidance-at-34th-annual-jp-morgan-hea-halo-20160111monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-34th-annual-j-p-morgan-healthcare-conference-haloz-halo-20160105monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-enters-into-agreement-for-150-million-non-dilutive-royalty-backed-debt-financing--halo-20160104monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-enters-into-global-collaboration-and-licensing-agreement-with-lilly-halozyme-ther-halo-20151221monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-upcoming-healthcare-conferences-halozyme-therapeutics--halo-20151124monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-expand-with-a-satellite-office-in-san-francisco-halozyme-therapeutics-inc-nasd-halo-20151117monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-third-quarter-2015-financial-results-halozyme-therapeutics-inc-nasdaq-hal-halo-20151109monthly0.5https://www.biopharmawatch.com/news/HALO/first-patient-dosed-in-clinical-trial-of-halozyme-investigational-drug-pegph20-in-combinat-halo-20151105monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-first-clinical-dosing-of-janssen-s-daratumumab-using-enhanze-technology-halo-20151104monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-credit-suisse-healthcare-conference-halozyme-thera-halo-20151103monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-first-clinical-dosing-of-pfizer-s-rivipansel-using-enhanze-technology-h-halo-20151029monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-third-quarter-2015-financial-results-conference-call-halozyme-therapeutic-halo-20151019monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-appoints-michael-j-labarre-as-chief-scientific-officer-halozyme-therapeutics-inc--halo-20150824monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-second-quarter-2015-financial-results-halozyme-therapeutics-inc-nasdaq-ha-halo-20150810monthly0.5https://www.biopharmawatch.com/news/HALO/ucsf-to-study-halozyme-pegph20-in-pancreatic-cancer-patients-who-are-candidates-for-potent-halo-20150806monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-appoints-jeffrey-w-henderson-to-board-halozyme-therapeutics-inc-nasdaq-halo-a-bio-halo-20150805monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-second-quarter-2015-financial-results-conference-call-halozyme-therapeuti-halo-20150803monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-jmp-securities-2015-life-sciences-conference-haloz-halo-20150619monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-plans-for-cfo-transition-names-laurie-stelzer-cfo-halozyme-therapeutics-halo-20150605monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-enters-into-global-collaboration-and-licensing-agreement-with-abbvie-halozyme-the-halo-20150603monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-phase-2-clinical-study-of-investigational-drug-pegph20-shows-doubling-of-progress-halo-20150531monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-ubs-2015-global-health-care-conference-halozyme-th-halo-20150512monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-first-quarter-2015-financial-results-halozyme-therapeutics-inc-nasdaq-hal-halo-20150511monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-bank-of-america-merrill-lynch-2015-health-care-con-halo-20150507monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-first-quarter-2015-financial-results-conference-call-halozyme-therapeutic-halo-20150504monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-presents-new-preclinical-data-at-the-american-association-for-cancer-research-ann-halo-20150420monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-appoints-harry-j-leonhardt-esq-as-senior-vice-president-general-coun-halo-20150413monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-provides-update-following-type-b-fda-meeting-halozyme-therapeutics-inc-nasdaq-hal-halo-20150408monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-appoints-james-mazzola-to-lead-corporate-communications-investor-rel-halo-20150323monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-reports-selection-of-first-product-candidate-under-janssen-collabora-halo-20150310monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-barclays-2015-global-healthcare-conference-halozym-halo-20150303monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-fourth-quarter-and-full-year-2014-financial-results-halozyme-therapeutics-halo-20150302monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-fourth-quarter-and-2014-year-end-financial-results-conference-call-alozym-halo-20150223monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-preclinical-study-results-of-pegph20-published-in-molecular-cancer-ther-halo-20150217monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-appoints-jean-pierre-bizzari-m-d-to-board-of-directors-halozyme-therapeutics-inc--halo-20150121monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-provides-an-update-on-anticipated-milestones-for-2015-at-the-33rd-an-halo-20150112monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-provides-agenda-highlights-for-analyst-and-investor-meeting-halozyme-therapeutics-halo-20150107monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-33rd-annual-j-p-morgan-healthcare-conference-haloz-halo-20150106monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-appoints-athena-countouriotis-m-d-as-chief-medical-officer-halozyme--halo-20150105monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-host-analyst-and-investor-meeting-halozyme-therapeutics-inc-nasda-halo-20141230monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-receives-european-orphan-drug-designation-for-pegylated-recombinant-human-hyaluro-halo-20141219monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-enters-a-global-collaboration-with-janssen-to-develop-and-commercial-halo-20141217monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-presentations-of-preclinical-data-at-the-san-antonio-breast-cancer-symp-halo-20141212monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-25th-annual-oppenheimer-healthcare-conference-halo-halo-20141203monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-piper-jaffray-healthcare-conference-halozyme-thera-halo-20141125monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-third-quarter-2014-financial-results-halozyme-therapeutics-inc-nasdaq-hal-halo-20141110monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-credit-suisse-healthcare-conference-halozyme-thera-halo-20141105monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-third-quarter-2014-financial-results-conference-call-halozyme-therapeutic-halo-20141103monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-receives-fda-approval-for-additional-manufacturing-facilities-for-hylenex-recombi-halo-20141020monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-podium-presentation-on-pegph20-at-the-new-york-academy-of-sciences-halo-halo-20141009monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-issuance-of-u-s-patent-for-companion-diagnostic-for-pegph20-halozyme-th-halo-20141007monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-receives-orphan-drug-designation-for-pegylated-recombinant-human-hyaluronidase-ph-halo-20141003monthly0.5https://www.biopharmawatch.com/news/HALO/swog-to-resume-clinical-trial-of-halozyme-s-pegph20-in-combination-with-modified-folfirino-halo-20140918monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-s-pegph20-program-in-metastatic-pancreatic-cancer-receives-fast-track-designation-halo-20140903monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-second-quarter-2014-financial-results-halozyme-therapeutics-inc-nasdaq-ha-halo-20140811monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-second-quarter-2014-financial-results-conference-call-halozyme-therapeuti-halo-20140804monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-resumes-patient-enrollment-and-dosing-in-pegph20-clinical-program-in-pancreatic-c-halo-20140722monthly0.5https://www.biopharmawatch.com/news/HALO/roche-s-commercial-launch-of-mabthera-sc-triggers-milestone-payment-to-halozyme-halozyme-t-halo-20140625monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-jmp-securities-2014-healthcare-conference-halozyme-halo-20140617monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-presentation-of-clinical-data-at-the-american-diabetes-association-74th-halo-20140615monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-resume-pegph20-clinical-program-in-pancreatic-cancer-halozyme-therapeutics-inc-halo-20140604monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-jefferies-2014-global-health-care-conference-haloz-halo-20140529monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-ubs-2014-global-health-care-conference-halozyme-th-halo-20140514monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-first-quarter-2014-financial-results-halozyme-therapeutics-inc-nasdaq-hal-halo-20140512monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-temporary-halt-of-phase-2-trial-enrollment-and-dosing-for-pegph20-haloz-halo-20140404monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-appointment-of-oncology-product-team-leader-and-other-executive-transit-halo-20140402monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-that-consistent-1-trial-of-hylenex-recombinant-met-primary-endpoint-hal-halo-20140331monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-roche-marketing-authorization-for-mabthera-sc-for-patients-with-common--halo-20140328monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-barclays-2014-global-healthcare-conference-halozym-halo-20140305monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-fourth-quarter-and-year-end-2013-financial-results-halozyme-therapeutics--halo-20140227monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-cowen-and-company-34th-annual-healthcare-conferenc-halo-20140225monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-fourth-quarter-and-2013-year-end-financial-results-conference-call-halozy-halo-20140220monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-announces-closing-of-public-offering-of-common-stock-and-full-exerci-halo-20140210monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-prices-public-offering-of-common-stock-halozyme-therapeutics-inc-nas-halo-20140204monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-announces-public-offering-of-common-stock-halozyme-therapeutics-inc--halo-20140203monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-positive-opinion-from-chmp-for-european-approval-of-roche-s-mabthera-sc-halo-20140124monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-provides-an-update-on-anticipated-milestones-for-2014-at-the-32nd-an-halo-20140113monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-32nd-annual-j-p-morgan-healthcare-conference-haloz-halo-20140109monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-secures-additional-20-million-term-loan-halozyme-therapeutics-inc-nasdaq-halo-tod-halo-20140106monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-announces-executive-transitions-halozyme-therapeutics-inc-nasdaq-hal-halo-20131217monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-piper-jaffray-healthcare-conference-halozyme-thera-halo-20131126monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-third-quarter-2013-financial-results-halozyme-therapeutics-inc-nasdaq-hal-halo-20131108monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-credit-suisse-healthcare-conference-halozyme-thera-halo-20131106monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-third-quarter-2013-financial-results-conference-call-halozyme-therapeutic-halo-20131101monthly0.5https://www.biopharmawatch.com/news/HALO/swog-initiates-randomized-phase-2-clinical-trial-of-halozyme-s-pegph20-in-combination-with-halo-20131022monthly0.5https://www.biopharmawatch.com/news/HALO/yale-researchers-initiate-clinical-trial-evaluating-halozyme-s-recombinant-hyaluronidase-i-halo-20131015monthly0.5https://www.biopharmawatch.com/news/HALO/commercial-launch-of-herceptin-sc-in-eu-triggers-milestone-payment-to-halozyme-from-roche--halo-20130926monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-biocentury-newsmakers-in-the-biotech-industry-conf-halo-20130920monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-present-new-data-on-pegph20-in-pancreatic-cancer-at-european-cancer-congress-h-halo-20130912monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-roche-receives-marketing-authorization-for-herceptin-sc-in-european-uni-halo-20130902monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-second-quarter-2013-financial-results-halozyme-therapeutics-inc-nasdaq-ha-halo-20130807monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-provides-update-on-viropharma-phase-2-trial-of-subcutaneous-cinryze-c1-esterase-i-halo-20130801monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-second-quarter-2013-financial-results-conference-call-halozyme-therapeuti-halo-20130731monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-presents-new-hti-501-data-halozyme-therapeutics-inc-nasdaq-halo-today-announced-i-halo-20130630monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-positive-opinion-from-chmp-on-roche-s-herceptin-sc-for-european-approva-halo-20130628monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-s-phase-1b-clinical-trial-of-pegph20-with-gemcitabine-indicates-positive-activity-halo-20130603monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-present-new-data-on-pegph20-in-pancreatic-cancer-at-american-society-of-clinic-halo-20130515monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-first-quarter-2013-financial-results-halozyme-therapeutics-inc-nasdaq-hal-halo-20130508monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-bank-of-america-merrill-lynch-2013-health-care-con-halo-20130507monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-first-quarter-2013-financial-results-conference-call-halozyme-therapeutic-halo-20130501monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-initiates-randomized-phase-2-trial-of-pegph20-in-pancreatic-cancer-halozyme-thera-halo-20130423monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-names-matt-posard-to-board-of-directors-halozyme-therapeutics-inc-na-halo-20130328monthly0.5https://www.biopharmawatch.com/news/HALO/baxter-and-halozyme-announce-positive-opinion-for-hyqvia-for-treatment-of-primary-and-seco-halo-20130322monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-fourth-quarter-and-year-end-2012-financial-results-halozyme-therapeutics--halo-20130225monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-fourth-quarter-and-2012-year-end-financial-results-conference-call-halozy-halo-20130219monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-issues-financial-guidance-for-2013-halozyme-therapeutics-inc-nasdaq--halo-20130107monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-31st-annual-j-p-morgan-healthcare-conference-haloz-halo-20130103monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-and-pfizer-enter-into-a-collaboration-to-develop-and-commercialize-s-halo-20121221monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announced-roche-filed-a-marketing-authorization-application-for-subcutaneous-mabt-halo-20121208monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-third-quarter-2012-financial-results-halozyme-therapeutics-inc-nasdaq-hal-halo-20121108monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-lazard-capital-markets-9th-annual-healthcare-confe-halo-20121106monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-third-quarter-financial-results-conference-call-halozyme-therapeutics-inc-halo-20121101monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-host-analyst-investor-meeting-on-october-2nd-in-new-york-halozyme-halo-20120925monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-second-quarter-2012-financial-results-halozyme-therapeutics-inc-nasdaq-ha-halo-20120806monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-second-quarter-financial-results-conference-call-halozyme-therapeutics-in-halo-20120802monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-s-ultrafast-insulin-formulations-improved-postprandial-glycemic-control-in-patien-halo-20120611monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-presents-positive-data-from-two-ultrafast-insulin-clinical-trials-with-human-hyal-halo-20120609monthly0.5https://www.biopharmawatch.com/news/HALO/interim-data-from-pre-administration-of-hylenex-in-analog-insulin-pump-therapy-demonstrate-halo-20120609monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-new-data-on-the-company-s-ultrafast-insulin-programs-at-a-halo-20120601monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-jefferies-2012-global-healthcare-conference-halozy-halo-20120531monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-bank-of-america-merrill-lynch-2012-health-care-con-halo-20120509monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-first-quarter-2012-financial-results-halozyme-therapeutics-inc-nasdaq-hal-halo-20120507monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-first-quarter-2012-financial-results-conference-call-halozyme-therapeutic-halo-20120430monthly0.5https://www.biopharmawatch.com/news/HALO/baxter-and-halozyme-provide-update-on-hyq-biologics-license-application-baxter-internation-halo-20120416monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-reports-fourth-quarter-and-year-end-2011-financial-results-and-provides-guidance--halo-20120309monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-two-upcoming-investor-conferences-in-march-halozyme-th-halo-20120307monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-to-host-fourth-quarter-and-2011-year-end-financial-results-conference-call-halozy-halo-20120301monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-citi-2012-global-healthcare-conference-halozyme-th-halo-20120222monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-exercise-in-full-of-over-allotment-option-and-completion-of-public-offe-halo-20120215monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-pricing-of-public-offering-of-common-stock-halozyme-therapeutics-inc-na-halo-20120210monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-proposed-public-offering-of-common-stock-halozyme-therapeutics-inc-nasd-halo-20120209monthly0.5https://www.biopharmawatch.com/news/HALO/hti-501-data-support-commencement-of-phase-2-portion-of-clinical-trial-halozyme-therapeuti-halo-20120131monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-oppenheimer-annual-healthcare-conference-on-decemb-halo-20111207monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-host-third-quarter-2011-financial-results-conference-call-on-nove-halo-20111102monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-announces-data-from-two-phase-1-studies-of-pegph20-demonstrating-tar-halo-20111027monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-data-on-pegph20-at-the-upcoming-2011-eortc-nci-asco-annua-halo-20111024monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-positive-results-from-phase-2-ultrafast-insulin-trials-in-patients-with-halo-20111021monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-begins-clinical-trial-with-hti-501-in-women-with-edematous-fibrosclerotic-pannicu-halo-20110928monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-jmp-securities-healthcare-conference-on-september--halo-20110922monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-upcoming-financial-conferences-halozyme-therapeutics-i-halo-20110901monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-wedbush-2011-global-healthcare-conference-on-augus-halo-20110812monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-reports-second-quarter-2011-financial-results-halozyme-therapeutics--halo-20110805monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-host-second-quarter-2011-financial-results-conference-call-on-aug-halo-20110801monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-s-ultrafast-insulin-demonstrates-reduced-variability-of-insulin-absorption-for-ty-halo-20110624monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-data-on-its-ultrafast-insulin-programs-at-the-upcoming-am-halo-20110620monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-and-intrexon-announce-collaboration-to-develop-first-subcutaneous-recombinant-alp-halo-20110606monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-jefferies-2011-global-healthcare-conference-on-jun-halo-20110602monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-and-viropharma-announce-83-million-global-licensing-agreement-to-dev-halo-20110511monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-reports-first-quarter-2011-financial-results-halozyme-therapeutics-i-halo-20110506monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-the-bank-of-america-merrill-lynch-health-care-conferen-halo-20110505monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-host-first-quarter-2011-financial-results-conference-call-on-may--halo-20110429monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-s-ultrafast-insulin-generates-faster-in-and-faster-out-profile-for-type-1-diabete-halo-20110414monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-reports-fourth-quarter-and-year-end-2010-financial-results-halozyme--halo-20110311monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-host-fourth-quarter-and-2010-financial-results-conference-call-on-halo-20110304monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-two-investor-conferences-in-march-halozyme-therapeutic-halo-20110301monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-roche-doses-first-patient-in-phase-3-clinical-trial-with-subcutaneous-m-halo-20110216monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-roche-completes-patient-enrollment-in-phase-3-clinical-trial-with-subcu-halo-20101207monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-realigns-management-halozyme-therapeutics-inc-nasdaq-halo-a-biopharm-halo-20101203monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-upcoming-investor-conference-halozyme-therapeutics-inc-halo-20101201monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-s-rhuph20-with-recombinant-human-insulin-demonstrates-glycemic-control-comparable-halo-20101112monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-reports-third-quarter-2010-financial-results-halozyme-therapeutics-i-halo-20101105monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-awarded-four-qualifying-therapeutic-discovery-project-grants-halozym-halo-20101104monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-announces-hiring-of-new-leadership-for-business-development-halozyme-halo-20101028monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-host-third-quarter-conference-call-on-november-5-and-present-at-t-halo-20101026monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-announces-implementation-of-development-focused-strategy-halozyme-th-halo-20101011monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-host-analyst-meeting-on-october-14-in-new-york-halozyme-therapeut-halo-20101007monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-to-present-at-two-upcoming-investor-conferences-halozyme-therapeutic-halo-20100915monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-announces-pricing-of-public-offering-of-common-stock-halozyme-therap-halo-20100909monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-announces-public-offering-of-common-stock-halozyme-therapeutics-inc--halo-20100908monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-begins-phase-2-clinical-trials-with-insulin-analogs-lispro-and-aspart-with-rhuph2-halo-20100902monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-provides-hylenex-product-reintroduction-update-halozyme-therapeutics-inc-nasdaq-h-halo-20100831monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-announces-issuance-of-u-s-patent-for-rhuph20-enzyme-platform-halozyme-therapeutic-halo-20100812monthly0.5https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-reports-second-quarter-2010-financial-results-halozyme-therapeutics--halo-20100806monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-transmedics-group-tmdx-20260521monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-announces-intent-to-create-the-first-dedicated-european-transplant-logis-tmdx-20260429monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-provide-update-on-ongoing-clinical-programs-at-the-international-society-of-tmdx-20260423monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-report-first-quarter-2026-financial-results-on-may-5-2026-transmedics-group-tmdx-20260421monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-present-at-upcoming-march-investor-conferences-transmedics-group-inc-transm-tmdx-20260217monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-announces-new-global-headquarters-and-expansion-at-assembly-innovation-park-in-tmdx-20260112monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-transmedics-group-tmdx-20251224monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-report-third-quarter-2025-financial-results-on-october-29-2025-transmedics--tmdx-20251015monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-transmedics-group-tmdx-20250801monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-present-at-the-canaccord-genuity-45th-annual-growth-conference-transmedics--tmdx-20250729monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-report-second-quarter-2025-financial-results-on-july-30-2025-transmedics-gr-tmdx-20250716monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-transmedics-group-tmdx-20250527monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-present-at-upcoming-june-investor-conferences-transmedics-group-inc-transme-tmdx-20250520monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-report-first-quarter-2025-financial-results-on-may-8-2025-transmedics-group-tmdx-20250424monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-transmedics-group-tmdx-20250402monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-present-at-upcoming-march-investor-conferences-transmedics-group-inc-transm-tmdx-20250218monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-february-27-2-tmdx-20250213monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-transmedics-group-tmdx-20250203monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-responds-to-inaccurate-and-misleading-claims-in-recent-short-seller-report-tra-tmdx-20250113monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference-transmedics-tmdx-20241223monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-transmedics-group-tmdx-20241212monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-host-investor-analyst-day-on-december-10-2024-transmedics-group-inc-transme-tmdx-20241126monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-participate-in-the-piper-sandler-36th-annual-healthcare-conference-transmed-tmdx-20241119monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-transmedics-group-tmdx-20241029monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-report-third-quarter-2024-financial-results-on-october-28-2024-transmedics--tmdx-20241015monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-transmedics-group-tmdx-20240927monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-participate-in-the-morgan-stanley-22nd-annual-global-healthcare-conference--tmdx-20240821monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-transmedics-group-tmdx-20240820monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-present-at-the-canaccord-genuity-44th-annual-growth-conference-transmedics--tmdx-20240729monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-transmedics-group-tmdx-20240718monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-report-second-quarter-2024-financial-results-on-july-31-2024-transmedics-gr-tmdx-20240717monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-transmedics-group-tmdx-20240621monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-transmedics-group-tmdx-20240517monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-report-first-quarter-2024-financial-results-on-april-30-2024-transmedics-gr-tmdx-20240416monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-transmedics-group-tmdx-20240408monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-transmedics-group-tmdx-20240319monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-present-at-upcoming-march-investor-conferences-transmedics-group-inc-transm-tmdx-20240228monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-transmedics-group-tmdx-20240228monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-transmedics-group-tmdx-20240216monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-report-fourth-quarter-and-full-year-2023-financial-results-on-february-26-2-tmdx-20240212monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-transmedics-group-tmdx-20240116monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-participate-in-the-42nd-annual-j-p-morgan-healthcare-conference-transmedics-tmdx-20231218monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-transmedics-group-tmdx-20231212monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-present-at-the-piper-sandler-35th-annual-healthcare-conference-transmedics--tmdx-20231114monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-transmedics-group-tmdx-20231103monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-report-third-quarter-2023-financial-results-on-november-6-2023-transmedics--tmdx-20231023monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-transmedics-group-tmdx-20231010monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-participate-in-the-morgan-stanley-21st-annual-global-healthcare-conference--tmdx-20230828monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-transmedics-group-tmdx-20230807monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-acquires-warm-perfusion-evoss-and-cold-perfusion-lifecradle-technologies-from--tmdx-20230802monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-signs-definitive-agreement-to-acquire-summit-aviation-to-expand-transmedics-av-tmdx-20230801monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-appoints-anil-ranganath-as-senior-vice-president-general-counsel-and-corporate-tmdx-20230726monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference-transmedics--tmdx-20230726monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-report-second-quarter-2023-financial-results-on-august-3-2023-transmedics-g-tmdx-20230720monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-transmedics-group-tmdx-20230530monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-inc-prices-400-million-of-convertible-senior-notes-due-2028-transmedics--tmdx-20230508monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-group-inc-announces-proposed-offering-of-300-million-of-convertible-senior-not-tmdx-20230508monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-releases-inaugural-environmental-social-governance-esg-report-transmedics-grou-tmdx-20230501monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-report-first-quarter-2023-financial-results-on-may-1-2023-transmedics-group-tmdx-20230417monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-transmedics-group-tmdx-20230224monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2-tmdx-20230208monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-appoints-nick-corcoran-as-senior-vice-president-of-supply-chain-and-operations-tmdx-20230202monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-participate-in-the-41st-annual-j-p-morgan-healthcare-conference-transmedics-tmdx-20221221monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-transmedics-group-tmdx-20221107monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-report-third-quarter-2022-financial-results-on-november-3-2022-transmedics--tmdx-20221020monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-participate-in-the-morgan-stanley-20th-annual-global-healthcare-conference--tmdx-20220829monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-announces-upsize-and-pricing-of-public-offering-of-common-stock-transmedics-gr-tmdx-20220804monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-announces-proposed-public-offering-of-common-stock-transmedics-group-inc-trans-tmdx-20220803monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-present-at-the-canaccord-genuity-42nd-annual-growth-conference-transmedics--tmdx-20220726monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-report-second-quarter-2022-financial-results-on-august-1-2022-transmedics-g-tmdx-20220718monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-transmedics-group-tmdx-20220603monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-receives-fda-pma-approval-of-ocs-dcd-heart-indication-transmedics-group-inc-tr-tmdx-20220428monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-transmedics-group-tmdx-20220421monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-report-first-quarter-2022-financial-results-on-may-3-2022-transmedics-group-tmdx-20220419monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-announces-the-presentation-of-new-ocs-heart-and-ocs-lung-clinical-data-at-the--tmdx-20220419monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-present-at-the-oppenheimer-s-32nd-annual-healthcare-conference-transmedics--tmdx-20220301monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-transmedics-group-tmdx-20220225monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-present-at-the-cowen-42nd-annual-healthcare-conference-transmedics-group-in-tmdx-20220222monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-report-fourth-quarter-and-full-year-2021-financial-results-on-february-23-2-tmdx-20220209monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-announces-publication-of-ocs-liver-protect-trial-results-in-jama-surgery-trans-tmdx-20220105monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-transmedics-gro-tmdx-20211222monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-transmedics-group-tmdx-20211111monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-third-quarter-2021-financial-results-transmedics-group-inc-transmedics-tmdx-20211109monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-participate-in-the-canaccord-genuity-virtual-medtech-diagnostics-and-digita-tmdx-20211104monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-announces-positive-top-line-results-from-the-u-s-randomized-ocs-dcd-heart-tria-tmdx-20211104monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-report-third-quarter-2021-financial-results-on-november-9-2021-transmedics--tmdx-20211026monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-receives-fda-approval-for-its-ocs-liver-system-for-preservation-and-assessment-tmdx-20210929monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-receives-fda-approval-for-its-ocs-heart-system-enabling-broader-utilization-of-tmdx-20210907monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-participate-in-the-morgan-stanley-19th-annual-global-healthcare-conference--tmdx-20210826monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-transmedics-group-tmdx-20210809monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-second-quarter-2021-financial-results-transmedics-group-inc-transmedic-tmdx-20210805monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-receives-fda-clearance-of-ocs-lung-solution-for-cold-preservation-of-lungs-tra-tmdx-20210729monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-participate-in-the-canaccord-genuity-41st-annual-growth-conference-transmed-tmdx-20210728monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-report-second-quarter-2021-financial-results-on-august-5-2021-transmedics-g-tmdx-20210722monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-stock-trading-halted-today-fda-advisory-committee-to-review-premarket-approval-tmdx-20210714monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-announces-scheduling-of-ocs-liver-fda-advisory-committee-meeting-transmedics-g-tmdx-20210610monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-announces-presentation-of-ocs-liver-protect-trial-results-and-is-recognized-as-tmdx-20210608monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-report-first-quarter-2021-financial-results-on-may-4-2021-transmedics-group-tmdx-20210420monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-appoints-stephanie-lovell-to-board-of-directors-transmedics-group-inc-transmed-tmdx-20210324monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-reports-fourth-quarter-and-full-year-2020-financial-results-transmedics-group--tmdx-20210302monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-announces-scheduling-of-ocs-heart-fda-advisory-committee-meeting-transmedics-g-tmdx-20210301monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-present-at-the-cowen-41st-annual-healthcare-conference-transmedics-group-in-tmdx-20210216monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-march-2-2021--tmdx-20210216monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-transmedics-gro-tmdx-20201224monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-appoints-merilee-raines-to-board-of-directors-transmedics-group-inc-transmedic-tmdx-20201223monthly0.5https://www.biopharmawatch.com/news/TMDX/transmedics-to-participate-in-upcoming-virtual-investor-conferences-transmedics-group-inc--tmdx-20201029monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-present-at-44th-annual-j-p-morgan-healthcare-conference-kodiak-sciences-kod-20260107monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-closing-of-184-million-public-offering-of-common-stock-including-kod-20251218monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-pricing-of-upsized-public-offering-of-common-stock-kodiak-scienc-kod-20251216monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-data-at-arvo-2025-highlight-power-and-versatility-of-abc-platform-in-addre-kod-20250501monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-completes-enrollment-in-second-registrational-trial-of-tarcocimab-in-patie-kod-20250310monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-present-at-glaucoma-360-new-horizons-forum-2025-kodiak-sciences-inc-nas-kod-20250204monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-present-at-43rd-annual-j-p-morgan-healthcare-conference-kodiak-sciences-kod-20250107monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-participate-in-upcoming-investor-conferences-kodiak-sciences-inc-nasdaq-kod-20241111monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-present-at-innovate-retina-2024-kodiak-sciences-inc-nasdaq-kod-a-biopha-kod-20241014monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-host-investor-r-d-day-today-at-10-30am-eastern-time-kodiak-sciences-inc-kod-20240923monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-host-investor-r-d-day-on-september-23-2024-in-new-york-city-kodiak-scie-kod-20240917monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-present-at-upcoming-investor-and-clinical-conferences-kodiak-sciences-i-kod-20240529monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-treatment-of-first-patients-in-phase-3-glow2-study-of-tarcocimab-kod-20240513monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-data-at-arvo-2024-highlight-depth-of-early-and-late-phase-retina-pipeline--kod-20240502monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-report-fourth-quarter-and-full-year-2023-financial-results-and-host-bus-kod-20240326monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-upcoming-presentation-of-first-time-results-of-ksi-501abc-phase--kod-20240130monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-kodiak-scie-kod-20240104monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-present-at-the-6th-annual-evercore-isi-healthconx-conference-kodiak-sci-kod-20231121monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-reboots-tarcocimab-tedromer-development-program-following-strong-positive-results-i-kod-20231106monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-first-time-presentation-of-primary-endpoint-data-from-tarcocimab-kod-20231101monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-upcoming-presentations-at-the-56th-annual-scientific-meeting-of--kod-20231011monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-present-at-the-morgan-stanley-21st-annual-global-healthcare-conference--kod-20230908monthly0.5https://www.biopharmawatch.com/news/KOD/new-one-year-results-for-kodiak-s-tarcocimab-tedromer-in-the-pivotal-beacon-trial-reinforc-kod-20230907monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-topline-results-from-its-phase-3-studies-of-tarcocimab-tedromer--kod-20230724monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-present-at-upcoming-investor-conferences-kodiak-sciences-inc-nasdaq-kod-kod-20230530monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-upcoming-presentations-on-its-product-and-research-pipeline-at-a-kod-20230421monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-expands-development-pipeline-with-treatment-of-first-patient-in-phase-1-cl-kod-20230403monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-upcoming-presentation-of-ksi-301-tarcocimab-tedromer-clinical-da-kod-20230209monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-kodiak-scie-kod-20230104monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-present-at-the-evercore-isi-5th-annual-healthconx-conference-kodiak-sci-kod-20221116monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-present-at-the-2022-morgan-stanley-healthcare-conference-kodiak-science-kod-20220907monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-upcoming-presentations-of-tarcocimab-tedromer-ksi-301-phase-3-be-kod-20220818monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-reports-positive-topline-results-from-beacon-phase-3-study-of-tarcocimab-t-kod-20220808monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-completes-enrollment-in-glow-phase-3-clinical-trial-of-tarcocimab-tedromer-kod-20220805monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-present-at-the-jefferies-global-healthcare-conference-palo-alto-calif-m-kod-20220527monthly0.5https://www.biopharmawatch.com/news/KOD/grand-opening-of-kodiak-sciences-purpose-built-bioconjugation-facility-to-support-potentia-kod-20220519monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-presentation-of-ksi-301-phase-2b-3-study-data-in-wet-amd-at-upco-kod-20220429monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-top-line-results-from-its-initial-phase-2b-3-study-of-ksi-301-in-kod-20220223monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-completes-enrollment-in-gleam-and-glimmer-phase-3-clinical-trials-of-ksi-3-kod-20220203monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-kodiak-scie-kod-20220103monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-completes-enrollment-in-beacon-phase-3-clinical-trial-of-ksi-301-in-patien-kod-20211216monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-present-at-upcoming-conferences-kodiak-sciences-inc-nasdaq-kod-a-biopha-kod-20211108monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-present-at-the-morgan-stanley-19th-annual-global-healthcare-conference--kod-20210831monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-present-at-upcoming-conferences-kodiak-sciences-inc-nasdaq-kod-a-biopha-kod-20210520monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-present-at-upcoming-conferences-kodiak-sciences-inc-nasdaq-kod-a-biopha-kod-20210421monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-present-at-upcoming-conferences-kodiak-sciences-inc-nasdaq-kod-a-biopha-kod-20210302monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-1-year-durability-efficacy-and-safety-data-from-ongoing-phase-1b-kod-20210213monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-upcoming-presentation-of-ksi-301-phase-1b-clinical-study-data-at-kod-20210202monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-present-at-the-j-p-morgan-healthcare-conference-kodiak-sciences-inc-nas-kod-20210105monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-closing-of-645-0-million-public-offering-of-common-stock-and-ful-kod-20201120monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-pricing-of-560-9-million-public-offering-of-common-stock-kodiak--kod-20201117monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-proposed-offering-of-common-stock-kodiak-sciences-inc-nasdaq-kod-kod-20201116monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-completes-enrollment-of-dazzle-phase-2b-3-pivotal-study-of-ksi-301-in-pati-kod-20201116monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-present-at-upcoming-conferences-kodiak-sciences-inc-nasdaq-kod-a-biopha-kod-20201112monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-presentation-of-ksi-301-phase-1b-clinical-study-data-focused-on--kod-20201111monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-treats-first-patients-in-three-phase-3-studies-of-ksi-301-two-studies-in-d-kod-20201005monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-present-at-upcoming-conferences-kodiak-sciences-inc-nasdaq-kod-a-biopha-kod-20200902monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-host-r-d-webcast-to-review-recent-data-from-the-ongoing-phase-1b-study--kod-20200716monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-new-longer-term-safety-efficacy-and-durability-data-from-ongoing-kod-20200710monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-upcoming-presentation-of-ksi-301-clinical-study-data-at-american-kod-20200707monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-present-at-upcoming-conferences-kodiak-sciences-inc-nasdaq-kod-a-clinic-kod-20200528monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-present-at-the-bank-of-america-merrill-lynch-health-care-conference-kod-kod-20200511monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-host-first-quarter-2020-business-highlights-webcast-on-may-12-2020-kodi-kod-20200508monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-appoints-charles-bancroft-to-board-of-directors-kodiak-sciences-inc-nasdaq-kod-20200402monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-and-kodiak-sciences-trademarks-registered-to-kodiak-sciences-inc-for-its-exclusive--kod-20200324monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-present-at-upcoming-conferences-kodiak-sciences-inc-nasdaq-kod-a-clinic-kod-20200227monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-additional-safety-efficacy-and-durability-data-from-ongoing-phas-kod-20200208monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-upcoming-presentation-of-additional-ksi-301-phase-1b-clinical-st-kod-20200205monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-present-at-38th-annual-j-p-morgan-healthcare-conference-kodiak-sciences-kod-20200108monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-appoints-taiyin-yang-ph-d-to-board-of-directors-kodiak-sciences-inc-nasdaq-kod-20191219monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-closing-of-317-4-million-public-offering-of-common-stock-and-ful-kod-20191206monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-pricing-of-276-0-million-public-offering-of-common-stock-kodiak--kod-20191203monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-proposed-offering-of-common-stock-kodiak-sciences-inc-nasdaq-kod-kod-20191202monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-present-at-the-evercore-isi-healthconx-conference-kodiak-sciences-inc-n-kod-20191202monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-sale-of-future-royalties-on-ksi-301-for-225-million-to-baker-bro-kod-20191202monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-report-third-quarter-2019-results-and-host-business-highlights-webcast--kod-20191108monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-host-r-d-day-on-october-14-in-san-francisco-to-highlight-recent-clinica-kod-20191011monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-treats-first-patients-in-dazzle-pivotal-study-of-ksi-301-in-wet-age-relate-kod-20191010monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-upcoming-presentation-of-durability-data-from-clinical-developme-kod-20191007monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-emerging-durability-data-from-ongoing-phase-1b-study-of-ksi-301--kod-20190915monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-release-durability-data-from-clinical-development-program-of-ksi-301-fo-kod-20190912monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-present-at-the-morgan-stanley-global-healthcare-conference-kodiak-scien-kod-20190906monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-upcoming-presentations-at-euretina-meeting-kodiak-sciences-inc-n-kod-20190904monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-present-at-wedbush-pacgrow-healthcare-conference-kodiak-sciences-inc-na-kod-20190808monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-upcoming-presentation-at-american-society-of-retina-specialists--kod-20190724monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-present-at-the-jefferies-2019-healthcare-conference-kodiak-sciences-inc-kod-20190530monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-present-at-the-bank-of-america-merrill-lynch-health-care-conference-201-kod-20190509monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-presentations-at-arvo-2019-annual-meeting-kodiak-sciences-inc-na-kod-20190425monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-to-present-at-the-barclays-global-healthcare-conference-kodiak-sciences-in-kod-20190307monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-upcoming-presentation-of-ksi-301-12-week-phase-1a-study-data-at--kod-20190208monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-added-to-russell-2000-3000-and-microcap-indexes-kodiak-sciences-inc-nasdaq-kod-20181224monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-completion-of-12-week-phase-1a-study-of-ksi-301-in-patients-with-kod-20181221monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-inc-announces-closing-of-initial-public-offering-kodiak-sciences-inc-nasda-kod-20181010monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-inc-announces-pricing-of-initial-public-offering-kodiak-sciences-inc-kodia-kod-20181003monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-inc-announces-launch-of-initial-public-offering-kodiak-sciences-inc-kodiak-kod-20180924monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-expands-leadership-with-industry-veterans-including-appointment-of-jason-e-kod-20180917monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-files-registration-statement-for-proposed-initial-public-offering-kodiak-s-kod-20180907monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-announces-completion-of-enrollment-in-the-company-s-phase-1-safety-and-tol-kod-20180831monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-appoints-bassil-i-dahiyat-ph-d-robert-a-profusek-j-d-and-richard-s-levy-m--kod-20180718monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-inc-announces-presentations-at-arvo-2018-annual-meeting-kodiak-sciences-in-kod-20180427monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-completes-33-million-mezzanine-private-financing-kodiak-sciences-inc-a-dev-kod-20180426monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-inc-and-lonza-announce-agreements-for-the-development-and-manufacture-of-m-kod-20160208monthly0.5https://www.biopharmawatch.com/news/KOD/kodiak-sciences-inc-closes-series-b-financing-to-fuel-retina-pipeline-kodiak-sciences-inc--kod-20160112monthly0.5https://www.biopharmawatch.com/news/TYRA/tyra-announces-pricing-of-upsized-initial-public-offering-tyra-biosciences-inc-nasdaq-tyra-tyra-20210914monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-provides-strategic-updates-ahead-of-annual-lifesci-partners-corporate-a-trvi-20260108monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-report-third-quarter-2025-financial-results-and-provide-a-corporate--trvi-20251106monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-report-second-quarter-2025-financial-results-and-provide-a-corporate-trvi-20250731monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-participate-in-upcoming-august-conferences-trevi-therapeutics-inc-na-trvi-20250729monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-attend-leerink-partners-therapeutics-forum-i-i-and-metabolism-trevi--trvi-20250701monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-closing-of-115-million-underwritten-offering-and-full-exercis-trvi-20250605monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-proposed-public-offering-of-common-stock-trevi-therapeutics-i-trvi-20250602monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-positive-topline-results-from-the-phase-2b-coral-trial-of-had-trvi-20250602monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-host-conference-call-and-webcast-on-june-2nd-to-share-topline-result-trvi-20250601monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-participate-in-upcoming-june-conferences-trevi-therapeutics-inc-nasd-trvi-20250529monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-additional-analyses-from-phase-2a-river-trial-of-haduvio-in-p-trvi-20250520monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-report-first-quarter-2025-financial-results-and-provide-a-corporate--trvi-20250501monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences-trevi-therapeutic-trvi-20250403monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-report-fourth-quarter-and-year-end-2024-financial-results-and-provid-trvi-20250311monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-positive-topline-results-from-the-phase-2a-river-trial-of-had-trvi-20250310monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-host-conference-call-and-webcast-on-march-10th-to-share-topline-resu-trvi-20250309monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences-trevi-therapeutic-trvi-20250227monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-completes-enrollment-for-phase-2b-coral-trial-of-haduvio-in-idiopathic--trvi-20250225monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-participate-in-upcoming-february-investor-conferences-trevi-therapeu-trvi-20250130monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-positive-outcome-from-sample-size-re-estimation-resulting-in--trvi-20241212monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-positive-topline-results-from-human-abuse-potential-study-of--trvi-20241203monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-participate-in-piper-sandler-36th-annual-healthcare-conference-trevi-trvi-20241121monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-report-third-quarter-2024-financial-results-and-provide-a-corporate--trvi-20241030monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-completes-enrollment-for-phase-2a-river-trial-in-refractory-chronic-cou-trvi-20241021monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-participate-in-upcoming-commercial-and-investor-conferences-trevi-th-trvi-20241015monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-provides-update-on-haduvio-s-clinical-development-program-trevi-therape-trvi-20241003monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-additional-analyses-of-cough-relief-time-from-ph2a-canal-tria-trvi-20240926monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-oral-presentation-on-data-from-ph2a-canal-trial-at-the-europe-trvi-20240904monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-participate-in-september-investor-and-medical-conferences-trevi-ther-trvi-20240828monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-report-second-quarter-2024-financial-results-and-provide-a-corporate-trvi-20240801monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-participate-in-upcoming-investor-and-healthcare-events-trevi-therape-trvi-20240702monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-participate-in-upcoming-conferences-trevi-therapeutics-inc-nasdaq-tr-trvi-20240509monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-report-first-quarter-2024-financial-results-and-provide-a-corporate--trvi-20240501monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-abstract-presentation-at-the-american-thoracic-society-2024-i-trvi-20240409monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-participate-in-upcoming-april-events-trevi-therapeutics-inc-nasdaq-t-trvi-20240404monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-adds-clinical-development-expertise-in-chronic-cough-to-leadership-team-trvi-20240402monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-report-q4-and-year-end-2023-financial-results-and-provide-a-corporat-trvi-20240313monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-participate-in-upcoming-march-events-trevi-therapeutics-inc-nasdaq-t-trvi-20240228monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-participate-in-the-oppenheimer-34th-annual-healthcare-life-sciences--trvi-20240206monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-provides-business-updates-trevi-therapeutics-inc-nasdaq-trvi-a-clinical-trvi-20240104monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-the-initiation-of-its-phase-2b-coral-clinical-trial-of-haduvi-trvi-20231205monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-the-initiation-of-its-phase-2a-river-clinical-trial-of-haduvi-trvi-20231102monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-report-q3-2023-financial-results-and-provide-a-corporate-update-on-n-trvi-20231101monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-results-from-phase-2b-3-prism-open-label-extension-study-of-h-trvi-20231013monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-participate-in-upcoming-september-events-trevi-therapeutics-inc-nasd-trvi-20230906monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-report-q2-2023-financial-results-and-provide-a-corporate-update-on-a-trvi-20230803monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-participate-in-upcoming-august-events-trevi-therapeutics-inc-nasdaq--trvi-20230801monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-participate-in-upcoming-july-investor-events-trevi-therapeutics-inc--trvi-20230706monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-participate-in-upcoming-june-conferences-trevi-therapeutics-inc-nasd-trvi-20230530monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-publication-of-positive-data-from-the-canal-trial-in-ipf-chro-trvi-20230522monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-present-at-upcoming-yale-innovation-summit-2023-trevi-therapeutics-i-trvi-20230509monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-report-q1-2023-financial-results-and-provide-a-corporate-update-on-m-trvi-20230504monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-two-presentations-on-the-phase-2-canal-data-at-the-ats-2023-i-trvi-20230502monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-participate-in-upcoming-may-investor-events-trevi-therapeutics-inc-n-trvi-20230427monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-participate-in-the-22nd-annual-needham-virtual-healthcare-conference-trvi-20230411monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-report-q4-and-year-end-2022-financial-results-and-provide-a-corporat-trvi-20230309monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-notice-of-allowance-for-u-s-patent-application-covering-use-o-trvi-20230308monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-participate-in-upcoming-march-conferences-trevi-therapeutics-inc-nas-trvi-20230306monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-present-at-the-emerging-growth-conference-on-february-22-2023-trevi--trvi-20230216monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-present-and-participate-in-upcoming-february-conferences-trevi-thera-trvi-20230202monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-provides-business-update-ahead-of-upcoming-conferences-trevi-therapeuti-trvi-20230105monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-present-and-participate-in-upcoming-conferences-in-san-francisco-dur-trvi-20221219monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-appoints-pharma-industry-veteran-as-chief-medical-officer-trevi-therape-trvi-20221114monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-participate-at-the-stifel-2022-healthcare-conference-trevi-therapeut-trvi-20221108monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-report-q3-2022-financial-results-and-provide-a-corporate-update-on-n-trvi-20221103monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-present-final-data-from-phase-2-trial-of-oral-nalbuphine-extended-re-trvi-20221027monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-proposed-public-offering-trevi-therapeutics-inc-nasdaq-trvi-a-trvi-20220922monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-positive-data-from-full-set-of-subjects-in-phase-2-canal-tria-trvi-20220919monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-present-at-h-c-wainwright-24th-annual-global-investment-conference-t-trvi-20220907monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-host-virtual-r-d-day-on-september-19-2022-trevi-therapeutics-inc-nas-trvi-20220830monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-multiple-late-breaking-abstracts-accepted-for-presentation-at-trvi-20220824monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-present-at-upcoming-august-conferences-trevi-therapeutics-inc-nasdaq-trvi-20220809monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-report-q2-2022-financial-results-and-provide-a-corporate-update-on-a-trvi-20220804monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-attend-the-twelfth-london-international-cough-symposium-12th-lics-tr-trvi-20220707monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-reports-positive-results-from-the-ph2b-3-prism-trial-of-haduvio-in-the--trvi-20220629monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-present-and-participate-in-partnership-meetings-at-upcoming-2022-bio-trvi-20220607monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-report-q1-2022-financial-results-and-provide-a-corporate-update-on-m-trvi-20220505monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-present-at-upcoming-may-meetings-trevi-therapeutics-inc-nasdaq-trvi--trvi-20220503monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-participate-at-21st-annual-needham-virtual-healthcare-conference-tre-trvi-20220411monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-55-million-private-placement-priced-at-the-market-trevi-thera-trvi-20220407monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-participate-at-21st-annual-needham-virtual-healthcare-conference-tre-trvi-20220405monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-hosting-key-opinion-leader-webinar-on-the-seriousness-of-chronic-cough--trvi-20220322monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-concludes-enrollment-for-phase-2-canal-trial-in-ipf-chronic-cough-trevi-trvi-20220315monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-report-q4-and-year-end-2021-financial-results-and-provide-a-corporat-trvi-20220309monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-reports-statistically-significant-result-on-interim-analysis-from-the-p-trvi-20220224monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-completes-enrollment-for-phase-2b-3-prism-study-in-chronic-pruritus-in--trvi-20220201monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-clinical-trial-updates-for-lead-indications-trevi-therapeutic-trvi-20220105monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-attend-multiple-conferences-in-january-2022-trevi-therapeutics-inc-n-trvi-20211216monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-present-at-5th-annual-dermatology-drug-development-summit-for-inflam-trvi-20211115monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-present-at-stifel-2021-virtual-healthcare-conference-trevi-therapeut-trvi-20211109monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-report-q3-2021-financial-results-and-provide-a-corporate-update-on-w-trvi-20211103monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-present-at-11th-world-congress-on-itch-wci-trevi-therapeutics-inc-na-trvi-20211013monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-participating-in-alliance-global-partners-virtual-biotech-specialty-pha-trvi-20211007monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-11-8-million-private-placement-priced-at-the-market-trevi-the-trvi-20210930monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-announces-additions-to-the-senior-leadership-team-trevi-therapeutics-in-trvi-20210809monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-report-q2-2021-financial-results-on-august-12-trevi-therapeutics-inc-trvi-20210805monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-present-at-2021-bio-digital-conference-trevi-therapeutics-inc-nasdaq-trvi-20210609monthly0.5https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-to-report-q1-2021-financial-results-on-may-13-trevi-therapeutics-inc-na-trvi-20210506monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-receives-u-s-fda-approval-for-skinvive-by-juve-derm-for-the-improvemen-abbv-20260616monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-releases-the-aesthetics-evolution-what-consumers-really-want-highlight-abbv-20260610monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-receives-positive-chmp-opinion-for-boey-trenibotulinumtoxine-for-the-t-abbv-20260521monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-first-quarter-2026-financial-results-reports-first-quarter-diluted-eps-of-0-abbv-20260429monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-provides-update-on-trenibotulinumtoxine-trenibote-biologics-license-application-in--abbv-20260423monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-selects-north-carolina-for-new-1-4-billion-manufacturing-campus-abbvie-nyse-abbv-to-abbv-20260422monthly0.5https://www.biopharmawatch.com/news/ABBV/erin-lichy-gets-real-about-her-natrelle-breast-augmentation-allergan-aesthetics-an-abbvie--abbv-20260414monthly0.5https://www.biopharmawatch.com/news/ABBV/botox-cosmetic-onabotulinumtoxina-empowers-women-entrepreneurs-through-the-confidence-coll-abbv-20260408monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-releases-findings-on-the-safety-and-efficacy-of-repeat-trenibote-treat-abbv-20260330monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-reinforces-scientific-differentiation-and-leadership-with-21-evidence--abbv-20260326monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-ushers-in-a-new-age-of-hyaluronic-acid-ha-injectables-with-juve-derm-a-abbv-20260326monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-reveals-evolution-in-approach-to-modern-aesthetic-treatments-with-comp-abbv-20260319monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-redefines-skin-quality-communication-with-launch-of-skin-quality-index-abbv-20260316monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-highlights-medical-weight-loss-mwl-data-and-the-changing-profile-of-pa-abbv-20260304monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-today-de-abbv-20260219monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-trump-administration-reach-agreement-to-improve-access-and-affordability-for-am-abbv-20260112monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-remegen-announce-exclusive-licensing-agreement-to-develop-a-novel-bispecific-an-abbv-20260112monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-acquire-arizona-manufacturing-facility-further-strengthening-manufacturing-capab-abbv-20260112monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-and-girls-inc-in-partnership-with-skinspirit-inspire-future-women-lead-abbv-20251028monthly0.5https://www.biopharmawatch.com/news/ABBV/the-confidence-project-by-botox-cosmetic-onabotulinumtoxina-unveils-this-year-s-grant-reci-abbv-20251021monthly0.5https://www.biopharmawatch.com/news/ABBV/skinmedica-debuts-reimagined-packaging-and-unveils-new-ha5-hydra-collagen-water-burst-mois-abbv-20251009monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-positive-topline-results-from-phase-2-elate-trial-evaluating-onabotulinum-abbv-20251006monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-third-quarter-2025-earnings-conference-call-abbvie-nyse-abbv-will-announce--abbv-20251002monthly0.5https://www.biopharmawatch.com/news/ABBV/natrelle-awarded-supplier-agreement-from-vizient-allergan-aesthetics-an-abbvie-company-nys-abbv-20251001monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-begins-construction-on-70-million-expansion-to-further-increase-biologics-manufactu-abbv-20250930monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-biologics-license-application-bla-to-u-s-fda-for-pivekimab-sunirine-pvek-an-abbv-20250930monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-breaks-ground-on-new-north-chicago-active-pharmaceutical-ingredient-manufacturing-f-abbv-20250929monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-uk-pricing-strategy-for-elahere-mirvetuximab-soravtansine-gynx-abbvie-nys-abbv-20250929monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-new-drug-application-to-u-s-fda-for-tavapadon-for-the-treatment-of-parkinso-abbv-20250926monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-to-showcase-multimodal-treatment-approach-and-continued-commitment-to--abbv-20250925monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-announces-expansion-of-skinvive-by-juve-derm-into-35-new-markets-reinf-abbv-20250923monthly0.5https://www.biopharmawatch.com/news/ABBV/botox-cosmetic-onabotulinumtoxina-unveils-the-one-only-campaign-featuring-real-people-and--abbv-20250909monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-quarterly-dividend-north-chicago-ill-sept-5-2025-the-board-of-directors-of-abbv-20250905monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-updated-results-from-phase-2-epcore-nhl-6-study-evaluating-the-potential--abbv-20250903monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-launches-campaign-to-educate-consumers-about-hyaluronic-acid-ha-inject-abbv-20250903monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-morgan-stanley-23rd-annual-global-healthcare-conference-abbvie-ny-abbv-20250902monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-acquire-gilgamesh-pharmaceuticals-bretisilocin-a-novel-investigational-therapy-f-abbv-20250825monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-positive-topline-results-from-second-phase-3-up-aa-trial-evaluating-upada-abbv-20250821monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-completes-acquisition-of-capstan-therapeutics-abbvie-nyse-abbv-announced-today-that-abbv-20250819monthly0.5https://www.biopharmawatch.com/news/ABBV/skinmedica-unveils-its-newest-hydration-hero-allergan-aesthetics-an-abbvie-company-nyse-ab-abbv-20250819monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-195-million-investment-to-expand-active-pharmaceutical-ingredient-manufac-abbv-20250812monthly0.5https://www.biopharmawatch.com/news/ABBV/get-ready-juve-derm-day-is-calling-allergan-aesthetics-an-abbvie-company-nyse-abbv-today-a-abbv-20250806monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-unveils-the-new-faces-of-natrelle-and-real-stories-of-empowerment-and--abbv-20250805monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-second-quarter-2025-financial-results-reports-second-quarter-diluted-eps-of-abbv-20250731monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-positive-topline-results-from-phase-3-up-aa-trial-evaluating-upadacitinib-abbv-20250730monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-for-u-s-fda-approval-of-combination-treatment-of-venclexta-venetoclax-and-a-abbv-20250729monthly0.5https://www.biopharmawatch.com/news/ABBV/botox-cosmetic-onabotulinumtoxina-selects-this-year-s-entrepreneurs-for-the-confidence-pro-abbv-20250722monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-pa-abbv-20250630monthly0.5https://www.biopharmawatch.com/news/ABBV/u-s-food-and-drug-administration-accepts-for-review-allergan-aesthetics-premarket-approval-abbv-20250630monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-second-quarter-2025-earnings-conference-call-abbvie-nyse-abbv-will-announce-abbv-20250630monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-today-de-abbv-20250620monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-new-data-demonstrating-atogepant-qulipta-aquipta-achieves-superiority-acr-abbv-20250618monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-provides-update-on-verona-trial-for-newly-diagnosed-higher-risk-myelodysplastic-syn-abbv-20250616monthly0.5https://www.biopharmawatch.com/news/ABBV/u-s-fda-approves-expanded-indication-for-abbvie-s-mavyret-glecaprevir-pibrentasvir-as-firs-abbv-20250611monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-invites-people-living-with-migraine-to-enter-the-second-annual-abbvie-migraine-care-abbv-20250603monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-goldman-sachs-46th-annual-global-healthcare-conference-abbvie-nys-abbv-20250603monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-partners-with-chicago-cubs-on-striking-out-cancer-abbvie-nyse-abbv-announced-a-mult-abbv-20250530monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-features-new-data-across-difficult-to-treat-solid-tumors-and-blood-cancers-at-asco--abbv-20250527monthly0.5https://www.biopharmawatch.com/news/ABBV/u-s-fda-approves-emrelis-telisotuzumab-vedotin-tllv-for-adults-with-previously-treated-adv-abbv-20250514monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-adarx-pharmaceuticals-announce-collaboration-and-license-option-agreement-to-de-abbv-20250514monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-bank-of-america-securities-healthcare-conference-abbvie-nyse-abbv-abbv-20250506monthly0.5https://www.biopharmawatch.com/news/ABBV/botox-cosmetic-onabotulinumtoxina-continues-its-mission-of-empowering-entrepreneurs-throug-abbv-20250501monthly0.5https://www.biopharmawatch.com/news/ABBV/rinvoq-upadacitinib-receives-u-s-fda-approval-for-giant-cell-arteritis-gca-abbvie-nyse-abb-abbv-20250429monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-first-quarter-2025-financial-results-reports-first-quarter-diluted-eps-of-0-abbv-20250425monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-biologics-license-application-to-u-s-fda-for-trenibotulinumtoxine-trenibote-abbv-20250424monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of--abbv-20250408monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-first-quarter-2025-earnings-conference-call-abbvie-nyse-abbv-will-announce--abbv-20250331monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-showcases-early-pipeline-and-scientific-advances-in-oncology-at-aacr-annual-meeting-abbv-20250326monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-emphasizes-commitment-to-innovation-science-and-a-patient-centric-appr-abbv-20250324monthly0.5https://www.biopharmawatch.com/news/ABBV/elahere-mirvetuximab-soravtansine-gynx-shows-consistent-survival-benefit-in-long-term-anal-abbv-20250315monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-leerink-partners-global-healthcare-conference-abbvie-nyse-abbv-wi-abbv-20250304monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-gubra-announce-license-agreement-to-develop-an-amylin-analog-for-the-treatment--abbv-20250303monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-positive-chmp-opinion-for-upadacitinib-rinvoq-for-the-treatment-of-adults--abbv-20250228monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-td-cowen-s-45th-annual-health-care-conference-abbvie-nyse-abbv-wi-abbv-20250226monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-appoints-ceo-robert-a-michael-as-chairman-of-the-board-of-directors-abbvie-nyse-abb-abbv-20250214monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-today-de-abbv-20250213monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-to-launch-three-new-state-of-the-art-training-centers-in-the-u-s-expan-abbv-20250212monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-xilio-therapeutics-announce-collaboration-and-option-agreement-to-develop-novel-abbv-20250212monthly0.5https://www.biopharmawatch.com/news/ABBV/u-s-fda-approves-emblaveo-aztreonam-and-avibactam-for-the-treatment-of-adults-with-complic-abbv-20250207monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-invites-consumers-to-join-the-faces-of-natrelle-campaign-allergan-aest-abbv-20250206monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-the-american-society-of-plastic-surgeons-asps-and-the-aesthetic-societ-abbv-20250205monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-full-year-and-fourth-quarter-2024-financial-results-reports-full-year-dilut-abbv-20250131monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-launches-new-aa-signature-program-at-imcas-2025-to-redefine-patient-ce-abbv-20250129monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-unveils-new-aa-signature-program-and-immersive-booth-at-imcas-world-co-abbv-20250124monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-completes-acquisition-of-nimble-therapeutics-abbvie-nyse-abbv-announced-today-that--abbv-20250123monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncolog-abbv-20250123monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-simcere-zaiming-announce-partnership-to-develop-a-novel-trispecific-antibody-ca-abbv-20250113monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-regenxbio-announce-updates-on-the-abbv-rgx-314-clinical-program-abbvie-nyse-abb-abbv-20250113monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-abbvie-nyse-abbv-wil-abbv-20250109monthly0.5https://www.biopharmawatch.com/news/ABBV/coolmonth-is-back-with-deals-on-coolsculpting-elite-by-allergan-aesthetics-allergan-aesthe-abbv-20250107monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-full-year-and-fourth-quarter-2024-earnings-conference-call-abbvie-nyse-abbv-abbv-20250103monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-acquire-nimble-therapeutics-further-strengthening-immunology-pipeline-abbvie-nys-abbv-20241213monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-completes-acquisition-of-aliada-therapeutics-abbvie-nyse-abbv-announced-today-that--abbv-20241211monthly0.5https://www.biopharmawatch.com/news/ABBV/two-data-analyses-from-clinical-trials-show-epcoritamab-duobody-cd3xcd20-induces-durable-c-abbv-20241209monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-positive-topline-results-for-the-phase-3-tempo-2-trial-evaluating-tavapad-abbv-20241209monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-emotional-impact-report-on-mental-health-of-underrepresented-cll-cancer-p-abbv-20241208monthly0.5https://www.biopharmawatch.com/news/ABBV/investigational-epcoritamab-duobody-cd3xcd20-combination-therapy-shows-high-response-rates-abbv-20241207monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-citi-s-2024-global-healthcare-conference-abbvie-nyse-abbv-will-partic-abbv-20241125monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-offers-free-business-education-courses-online-to-support-growing-pract-abbv-20241118monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-european-commission-approval-of-elahere-mirvetuximab-soravtansine-for-the--abbv-20241118monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-awards-20-individuals-living-with-migraine-to-support-career-aspirations-abbvie-nys-abbv-20241114monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-provides-update-on-phase-2-results-for-emraclidine-in-schizophrenia-abbvie-nyse-abb-abbv-20241111monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-celebrates-annual-botox-cosmetic-onabotulinumtoxina-day-allergan-aesth-abbv-20241107monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-evolveimmune-therapeutics-announce-collaboration-and-option-to-license-agreemen-abbv-20241031monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-third-quarter-2024-financial-results-reports-third-quarter-diluted-eps-of-0-abbv-20241030monthly0.5https://www.biopharmawatch.com/news/ABBV/skinspirit-joins-allergan-aesthetics-in-supporting-girls-inc-and-empowering-the-new-genera-abbv-20241029monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-acquire-aliada-therapeutics-strengthening-focus-in-alzheimer-s-disease-and-neuro-abbv-20241028monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-gedeon-richter-announce-new-collaboration-for-the-discovery-and-development-of--abbv-20241024monthly0.5https://www.biopharmawatch.com/news/ABBV/botox-cosmetic-onabotulinumtoxina-receives-fda-approval-for-moderate-to-severe-vertical-ba-abbv-20241018monthly0.5https://www.biopharmawatch.com/news/ABBV/u-s-fda-approves-vyalev-foscarbidopa-and-foslevodopa-for-adults-living-with-advanced-parki-abbv-20241017monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-to-present-new-data-at-2024-american-society-for-dermatologic-surgery--abbv-20241016monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-and-girls-inc-celebrate-six-years-and-challenge-you-to-take-the-pledge-abbv-20241004monthly0.5https://www.biopharmawatch.com/news/ABBV/available-nationwide-juve-derm-voluma-xc-for-moderate-to-severe-temple-hollowing-allergan--abbv-20241002monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-third-quarter-2024-earnings-conference-call-abbvie-nyse-abbv-will-announce--abbv-20241001monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-biologics-license-application-to-the-fda-for-telisotuzumab-vedotin-teliso-v-abbv-20240927monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-positive-topline-results-from-phase-3-tempo-1-trial-evaluating-tavapadon--abbv-20240926monthly0.5https://www.biopharmawatch.com/news/ABBV/new-analysis-demonstrates-the-efficacy-of-rinvoq-upadacitinib-in-atopic-dermatitis-with-va-abbv-20240925monthly0.5https://www.biopharmawatch.com/news/ABBV/empowering-women-entrepreneurs-2024-botox-onabotulinumtoxina-cosmetic-grant-recipients-kic-abbv-20240924monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-positive-chmp-opinion-for-mirvetuximab-soravtansine-elahere-for-the-treatm-abbv-20240920monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-launches-botox-cosmetic-onabotulinumtoxina-for-masseter-muscle-promine-abbv-20240911monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-showcases-advancement-of-solid-tumor-pipeline-at-esmo-2024-with-new-data-in-tumor-t-abbv-20240909monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-today-de-abbv-20240906monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-awards-scholarships-to-45-u-s-students-living-with-chronic-immune-mediated-diseases-abbv-20240827monthly0.5https://www.biopharmawatch.com/news/ABBV/skinmedica-revolutionizes-skin-hydration-with-the-introduction-of-ha5-hydra-collagen-reple-abbv-20240827monthly0.5https://www.biopharmawatch.com/news/ABBV/european-commission-grants-second-indication-approval-for-tepkinly-epcoritamab-for-the-tre-abbv-20240819monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-completes-acquisition-of-cerevel-therapeutics-cerevel-s-clinical-stage-assets-compl-abbv-20240801monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-celebrates-the-second-annual-juve-derm-day-allergan-aesthetics-an-abbv-abbv-20240730monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-european-commission-approval-of-skyrizi-risankizumab-for-the-treatment-of-abbv-20240726monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-second-quarter-2024-financial-results-reports-second-quarter-diluted-eps-of-abbv-20240725monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-regulatory-applications-to-fda-and-ema-for-upadacitinib-rinvoq-in-giant-cel-abbv-20240712monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-appointment-of-roopal-thakkar-m-d-as-executive-vice-president-research-de-abbv-20240710monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-second-quarter-2024-earnings-conference-call-abbvie-nyse-abbv-will-announce-abbv-20240702monthly0.5https://www.biopharmawatch.com/news/ABBV/robert-a-michael-assumes-role-as-abbvie-chief-executive-officer-abbvie-nyse-abbv-today-ann-abbv-20240701monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-positive-chmp-opinion-for-epcoritamab-tepkinly-for-the-treatment-of-adults-abbv-20240628monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-acquires-celsius-therapeutics-abbvie-nyse-abbv-announced-today-the-acquisition-of-c-abbv-20240627monthly0.5https://www.biopharmawatch.com/news/ABBV/introducing-alle-payment-plans-powered-by-cherry-allergan-aesthetics-an-abbvie-company-nys-abbv-20240627monthly0.5https://www.biopharmawatch.com/news/ABBV/u-s-food-and-drug-administration-grants-second-approval-for-epkinly-epcoritamab-bysp-to-tr-abbv-20240626monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-provides-u-s-regulatory-update-on-abbv-951-foscarbidopa-foslevodopa-u-s-food-and-dr-abbv-20240625monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-today-de-abbv-20240621monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-appoints-roxanne-s-austin-as-lead-independent-director-of-the-board-of-directors-ab-abbv-20240620monthly0.5https://www.biopharmawatch.com/news/ABBV/u-s-fda-approves-skyrizi-risankizumab-rzaa-for-ulcerative-colitis-expanding-abbvie-s-portf-abbv-20240618monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-recommends-shareholders-reject-tutanota-s-mini-tender-offer-abbvie-nyse-abbv-has-be-abbv-20240614monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-futuregen-announce-license-agreement-to-develop-next-generation-therapy-for-inf-abbv-20240613monthly0.5https://www.biopharmawatch.com/news/ABBV/botox-cosmetic-onabotulinumtoxina-reveals-2024-women-entrepreneur-grant-recipients-today-a-abbv-20240611monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-positive-topline-results-from-phase-2-piccolo-trial-evaluating-mirvetuxim-abbv-20240606monthly0.5https://www.biopharmawatch.com/news/ABBV/skinmedica-celebrates-25-years-of-empowering-radiant-skin-allergan-aesthetics-an-abbvie-co-abbv-20240606monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-launches-first-of-its-kind-contest-to-empower-people-living-with-migraine-in-their--abbv-20240606monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-advances-oncology-pipeline-with-start-of-multiple-myeloma-phase-3-clinical-trial-fo-abbv-20240605monthly0.5https://www.biopharmawatch.com/news/ABBV/rinvoq-upadacitinib-now-available-for-pediatric-patients-two-years-and-older-with-polyarti-abbv-20240604monthly0.5https://www.biopharmawatch.com/news/ABBV/refer-your-friends-to-alle-the-loyalty-rewards-program-by-allergan-aesthetics-and-earn-50--abbv-20240604monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-goldman-sachs-45th-annual-global-healthcare-conference-abbvie-nys-abbv-20240603monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-positive-chmp-opinion-for-risankizumab-skyrizi-for-the-treatment-of-adults-abbv-20240531monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-showcases-robust-solid-tumor-pipeline-at-asco-2024-with-new-data-from-its-innovativ-abbv-20240528monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-completes-acquisition-of-landos-biopharma-abbvie-nyse-abbv-announced-today-that-it--abbv-20240523monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-new-data-supporting-leading-gastroenterology-portfolio-at-2024-digestive-d-abbv-20240517monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-gilgamesh-pharmaceuticals-announce-collaboration-and-option-to-license-agreemen-abbv-20240513monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-bank-of-america-securities-healthcare-conference-abbvie-nyse-abbv-abbv-20240506monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-first-quarter-2024-financial-results-reports-first-quarter-diluted-eps-of-0-abbv-20240426monthly0.5https://www.biopharmawatch.com/news/ABBV/new-data-show-rinvoq-upadacitinib-demonstrated-superiority-versus-dupixent-dupilumab-acros-abbv-20240425monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-invites-consumers-to-be-the-face-of-botox-cosmetic-onabotulinumtoxina--abbv-20240423monthly0.5https://www.biopharmawatch.com/news/ABBV/phase-3-select-gca-study-of-upadacitinib-rinvoq-showed-positive-results-in-patients-with-g-abbv-20240418monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-late-breaking-data-at-aan-supporting-long-term-safety-and-efficacy-of-ato-abbv-20240412monthly0.5https://www.biopharmawatch.com/news/ABBV/skinmedica-empowers-clear-skin-confidence-with-a-new-modern-approach-to-acne-allergan-aest-abbv-20240409monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-first-quarter-2024-earnings-conference-call-abbvie-nyse-abbv-will-announce--abbv-20240404monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-announces-the-return-of-coolmonth-with-coolsculpting-allergan-aestheti-abbv-20240403monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-launches-moving-the-needle-on-ethics-to-elevate-the-conversation-aroun-abbv-20240325monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-acquire-landos-biopharma-further-strengthening-its-portfolio-in-inflammatory-and-abbv-20240325monthly0.5https://www.biopharmawatch.com/news/ABBV/u-s-food-and-drug-administration-fda-grants-full-approval-for-elahere-mirvetuximab-soravta-abbv-20240322monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-continues-to-champion-individuality-drive-innovation-and-lead-with-int-abbv-20240321monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-barclays-26th-annual-global-healthcare-conference-abbvie-nyse-abb-abbv-20240307monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-allergan-aesthetics-to-present-new-data-at-2024-annual-aad-meeting-showcasing-d-abbv-20240306monthly0.5https://www.biopharmawatch.com/news/ABBV/juve-derm-voluma-xc-for-temple-hollows-receives-u-s-fda-approval-today-allergan-aesthetics-abbv-20240305monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-ose-immunotherapeutics-announce-partnership-to-develop-a-novel-monoclonal-antib-abbv-20240228monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-td-cowen-44th-annual-health-care-conference-abbvie-nyse-abbv-will-abbv-20240227monthly0.5https://www.biopharmawatch.com/news/ABBV/u-s-food-and-drug-administration-fda-grants-priority-review-of-epcoritamab-epkinly-for-dif-abbv-20240227monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-tentarix-announce-collaboration-to-develop-conditionally-active-multi-specific--abbv-20240222monthly0.5https://www.biopharmawatch.com/news/ABBV/botox-cosmetic-onabotulinumtoxina-announces-its-2024-grant-program-supporting-women-entrep-abbv-20240221monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-appointment-of-robert-a-michael-as-chief-executive-officer-abbvie-nyse-ab-abbv-20240220monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-unveils-new-data-from-robust-gastroenterology-portfolio-at-the-19th-congress-of-eur-abbv-20240219monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-today-de-abbv-20240215monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-completes-acquisition-of-immunogen-adds-flagship-antibody-drug-conjugate-adc-elaher-abbv-20240212monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-full-year-and-fourth-quarter-2023-financial-results-reports-full-year-dilut-abbv-20240202monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-releases-decoding-the-future-of-aesthetic-individuality-exploring-the--abbv-20240131monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-showcases-commitment-to-individuality-innovation-and-integrity-at-imca-abbv-20240125monthly0.5https://www.biopharmawatch.com/news/ABBV/alle-by-allergan-aesthetics-is-the-leading-aesthetics-loyalty-rewards-program-in-the-u-s-t-abbv-20240123monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-launches-produodopa-foslevodopa-foscarbidopa-for-people-living-with-advanced-parkin-abbv-20240109monthly0.5https://www.biopharmawatch.com/news/ABBV/lutikizumab-showed-positive-results-in-a-phase-2-trial-of-adults-with-moderate-to-severe-h-abbv-20240108monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-umoja-biopharma-announce-strategic-collaboration-to-develop-novel-in-situ-car-t-abbv-20240104monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-full-year-and-fourth-quarter-2023-earnings-conference-call-abbvie-nyse-abbv-abbv-20240104monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-abbvie-nyse-abbv-wil-abbv-20240102monthly0.5https://www.biopharmawatch.com/news/ABBV/new-data-for-bispecific-antibody-epcoritamab-duobody-cd3xcd20-shows-strong-durable-treatme-abbv-20231209monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-bighat-biosciences-announce-research-collaboration-to-leverage-artificial-intel-abbv-20231205monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-positive-topline-results-from-phase-2-luminosity-trial-evaluating-telisot-abbv-20231129monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-u-s-food-and-drug-administration-fda-and-european-medicines-agency-ema-up-abbv-20231127monthly0.5https://www.biopharmawatch.com/news/ABBV/fifth-annual-botox-cosmetic-onabotulinumtoxina-day-makes-history-as-the-biggest-day-ever-a-abbv-20231120monthly0.5https://www.biopharmawatch.com/news/ABBV/results-published-in-the-lancet-show-ubrelvy-ubrogepant-reduces-the-headache-phase-of-a-mi-abbv-20231116monthly0.5https://www.biopharmawatch.com/news/ABBV/natrelle-unveils-new-for-every-body-campaign-allergan-aesthetics-an-abbvie-company-nyse-ab-abbv-20231108monthly0.5https://www.biopharmawatch.com/news/ABBV/botox-cosmetic-onabotulinumtoxina-day-is-back-like-never-before-allergan-aesthetics-an-abb-abbv-20231101monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-third-quarter-2023-financial-results-reports-third-quarter-diluted-eps-of-1-abbv-20231027monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-announces-positive-topline-results-from-two-pivotal-phase-3-studies-of-abbv-20231024monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-supports-breast-cancer-patients-and-celebrates-breast-reconstruction-p-abbv-20231019monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-skyrizi-risankizumab-versus-stelara-ustekinumab-head-to-head-study-in-crohn-s-dis-abbv-20231015monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-upadacitinib-rinvoq-met-the-primary-endpoint-in-phase-2-clinical-trial-of-abbv-20231012monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-long-term-data-further-supporting-the-efficacy-and-safety-profile-of-rinvo-abbv-20231011monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-showcases-breadth-and-depth-of-research-in-crohn-s-disease-and-ulcerative-colitis-a-abbv-20231010monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-exercises-exclusive-right-to-acquire-mitokinin-further-strengthening-neuroscience-p-abbv-20231005monthly0.5https://www.biopharmawatch.com/news/ABBV/nature-publishes-discovery-and-preclinical-results-for-abbv-cls-484-a-potential-first-in-c-abbv-20231004monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-third-quarter-2023-earnings-conference-call-abbvie-nyse-abbv-will-announce--abbv-20231004monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-and-girls-inc-partner-to-speed-the-entry-of-young-women-into-positions-abbv-20231003monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-results-from-phase-3-canova-study-of-venetoclax-in-patients-with-relapsed--abbv-20230929monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-european-commission-approval-of-tepkinly-epcoritamab-for-adults-with-rela-abbv-20230925monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-announces-positive-topline-results-from-second-phase-3-study-of-onabot-abbv-20230918monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-calls-on-public-to-vote-for-the-2023-abbvie-cystic-fibrosis-scholarship-thriving-st-abbv-20230913monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-skyrizi-risankizumab-met-all-primary-and-secondary-endpoints-versus-stelara-ustek-abbv-20230912monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-today-de-abbv-20230908monthly0.5https://www.biopharmawatch.com/news/ABBV/join-botox-cosmetic-onabotulinumtoxina-and-ifundwomen-in-supporting-women-entrepreneurs-al-abbv-20230906monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-morgan-stanley-healthcare-conference-abbvie-nyse-abbv-will-partic-abbv-20230906monthly0.5https://www.biopharmawatch.com/news/ABBV/journal-of-cosmetic-dermatology-publishes-data-demonstrating-patient-satisfaction-with-nat-abbv-20230830monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-regulatory-applications-to-fda-and-ema-for-risankizumab-skyrizi-in-ulcerati-abbv-20230828monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-european-commission-approval-of-aquipta-atogepant-for-the-preventive-trea-abbv-20230817monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-announces-first-ever-juve-derm-day-allergan-aesthetics-an-abbvie-compa-abbv-20230801monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-second-quarter-2023-financial-results-reports-second-quarter-diluted-eps-of-abbv-20230727monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-calibr-expand-strategic-collaboration-to-advance-several-preclinical-and-early--abbv-20230726monthly0.5https://www.biopharmawatch.com/news/ABBV/skyrizi-risankizumab-achieved-superiority-versus-apremilast-for-co-primary-endpoints-among-abbv-20230726monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-advances-immunology-pipeline-with-first-patient-dosed-in-global-phase-3-trial-of-up-abbv-20230724monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-positive-chmp-opinion-for-epcoritamab-tepkinly-for-the-treatment-of-adults-abbv-20230721monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-second-quarter-2023-earnings-conference-call-abbvie-nyse-abbv-will-announce-abbv-20230706monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-genmab-announce-positive-topline-results-from-phase-1-2-epcore-nhl-1-trial-eval-abbv-20230627monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-employees-volunteer-during-8th-annual-week-of-possibilities-to-support-communities--abbv-20230626monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-secures-positive-chmp-opinion-for-atogepant-for-the-preventive-treatment-of-adults--abbv-20230623monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-today-de-abbv-20230622monthly0.5https://www.biopharmawatch.com/news/ABBV/risankizumab-skyrizi-met-primary-and-key-secondary-endpoints-in-52-week-phase-3-maintenanc-abbv-20230615monthly0.5https://www.biopharmawatch.com/news/ABBV/botox-cosmetic-onabotulinumtoxina-announces-the-winners-of-the-ifundwomen-grant-program-al-abbv-20230613monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-venclyxto-venclexta-venetoclax-continues-to-show-sustained-progression-free-survi-abbv-20230609monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-goldman-sachs-44th-annual-global-healthcare-conference-abbvie-nys-abbv-20230606monthly0.5https://www.biopharmawatch.com/news/ABBV/phase-2-study-of-upadacitinib-rinvoq-alone-or-as-a-combination-therapy-meets-primary-and-k-abbv-20230531monthly0.5https://www.biopharmawatch.com/news/ABBV/new-england-journal-of-medicine-publishes-results-from-phase-3-induction-and-maintenance-p-abbv-20230525monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-long-term-data-further-supporting-the-efficacy-and-safety-profile-of-rinvo-abbv-20230524monthly0.5https://www.biopharmawatch.com/news/ABBV/epkinly-epcoritamab-bysp-approved-by-u-s-fda-as-the-first-and-only-bispecific-antibody-to--abbv-20230519monthly0.5https://www.biopharmawatch.com/news/ABBV/u-s-fda-approves-rinvoq-upadacitinib-as-a-once-daily-pill-for-moderately-to-severely-activ-abbv-20230518monthly0.5https://www.biopharmawatch.com/news/ABBV/skinvive-by-juve-derm-receives-u-s-fda-approval-today-allergan-aesthetics-an-abbvie-compan-abbv-20230515monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-releases-new-data-demonstrating-breadth-of-its-gastroenterology-portfolio-at-2023-d-abbv-20230506monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-bank-of-america-securities-healthcare-conference-abbvie-nyse-abbv-abbv-20230502monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-first-quarter-2023-financial-results-reports-first-quarter-diluted-eps-of-0-abbv-20230427monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-late-breaking-results-from-phase-3-trial-evaluating-atogepant-qulipta-for-abbv-20230421monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-celebrates-the-journeys-of-women-surgeons-with-limitless-allergan-aest-abbv-20230418monthly0.5https://www.biopharmawatch.com/news/ABBV/u-s-fda-approves-qulipta-atogepant-for-adults-with-chronic-migraine-qulipta-now-the-first--abbv-20230417monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of--abbv-20230417monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-invites-college-students-living-with-cystic-fibrosis-to-apply-for-the-abbvie-cf-sch-abbv-20230412monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-avanc-a-estudo-cli-nico-de-fase-3-com-upadacitinibe-para-tratamento-de-lu-pus-erite-abbv-20230404monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-first-quarter-2023-earnings-conference-call-abbvie-nyse-abbv-will-announce--abbv-20230404monthly0.5https://www.biopharmawatch.com/news/ABBV/coolsculpting-elite-announces-first-ever-coolmonth-allergan-aesthetics-an-abbvie-company-n-abbv-20230403monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-to-showcase-360-approach-to-clinical-practice-aesthetic-products-and-p-abbv-20230329monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-advances-upadacitinib-rinvoq-to-phase-3-clinical-trials-in-systemic-lupus-erythemat-abbv-20230323monthly0.5https://www.biopharmawatch.com/news/ABBV/risankizumab-skyrizi-achieves-primary-and-all-secondary-endpoints-in-phase-3-induction-stu-abbv-20230323monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-provides-regulatory-update-on-abbv-951-foscarbidopa-foslevodopa-new-drug-applicatio-abbv-20230322monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-late-breaking-results-of-study-evaluating-52-week-efficacy-and-safety-of--abbv-20230318monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-partners-with-award-winning-redglass-pictures-on-new-film-shedding-light-on-the-hid-abbv-20230315monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-showcases-strength-of-dermatology-portfolio-with-new-data-presented-at-the-2023-aad-abbv-20230313monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-e-capsida-biotherapeutics-ampliam-parceria-estrate-gia-para-desenvolvimento-de-medi-abbv-20230309monthly0.5https://www.biopharmawatch.com/news/ABBV/botox-cosmetic-onabotulinumtoxina-partners-with-ifundwomen-to-help-close-the-confidence-ga-abbv-20230308monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-barclays-global-healthcare-conference-abbvie-nyse-abbv-will-parti-abbv-20230308monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-cowen-43rd-annual-health-care-conference-abbvie-nyse-abbv-will-pa-abbv-20230228monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-highlights-robust-gastroenterology-portfolio-with-new-analyses-and-data-in-inflamma-abbv-20230227monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-positive-chmp-opinion-for-upadacitinib-rinvoq-for-the-treatment-of-adults--abbv-20230227monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-capsida-biotherapeutics-expand-strategic-collaboration-to-develop-targeted-gene-abbv-20230223monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-today-de-abbv-20230216monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submete-o-anticorpo-biespecifico-epcoritamabe-duobody-cd3xcd20-a-ana-lise-da-anvisa-abbv-20230215monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-full-year-and-fourth-quarter-2022-financial-results-reports-full-year-dilut-abbv-20230209monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-takes-a-360-approach-to-non-surgical-aesthetic-treatments-to-improve-p-abbv-20230125monthly0.5https://www.biopharmawatch.com/news/ABBV/juve-derm-volux-xc-for-improvement-of-jawline-definition-now-available-nationwide-today-al-abbv-20230118monthly0.5https://www.biopharmawatch.com/news/ABBV/skinmedica-launches-even-correct-today-allergan-aesthetics-an-abbvie-company-nyse-abbv-ann-abbv-20230117monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-anima-biotech-announce-collaboration-for-the-discovery-and-development-of-mrna--abbv-20230110monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-immunome-announce-strategic-collaboration-to-discover-multiple-novel-oncology-t-abbv-20230106monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-fourth-quarter-2022-earnings-conference-call-abbvie-nyse-abbv-will-announce-abbv-20230105monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-abbvie-nyse-abbv-wil-abbv-20230103monthly0.5https://www.biopharmawatch.com/news/ABBV/u-s-fda-approves-vraylar-cariprazine-as-an-adjunctive-treatment-for-major-depressive-disor-abbv-20221216monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-supplemental-new-drug-application-to-u-s-fda-to-support-new-indication-of-l-abbv-20221216monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-firma-colaborac-a-o-estrate-gica-com-hotspot-therapeutics-para-expandir-portfo-lio--abbv-20221215monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-apresenta-inovac-o-es-para-o-tratamento-de-enxaqueca-cro-nica-durante-16o-congresso-abbv-20221215monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-named-to-dow-jones-sustainability-world-index-for-10th-straight-year-abbvie-nyse-ab-abbv-20221212monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-data-at-the-64th-american-society-of-hematology-ash-annual-meeting-evaluat-abbv-20221211monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-launches-strategic-collaboration-with-hotspot-therapeutics-to-further-expand-immuno-abbv-20221206monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-showcase-migraine-portfolio-and-pipeline-during-the-16th-european-headache-feder-abbv-20221206monthly0.5https://www.biopharmawatch.com/news/ABBV/fda-aceita-submissa-o-de-ana-lise-priorita-ria-de-epcoritamabe-duobody-cd3xcd20-para-o-tra-abbv-20221205monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-evercore-isi-healthconx-conference-abbvie-nyse-abbv-will-particip-abbv-20221123monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-european-commission-approval-of-skyrizi-risankizumab-for-the-treatment-of-abbv-20221123monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-highlights-blood-cancer-data-from-its-growing-oncology-pipeline-at-the-64th-ash-ann-abbv-20221122monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-piper-sandler-healthcare-conference-abbvie-nyse-abbv-will-partici-abbv-20221122monthly0.5https://www.biopharmawatch.com/news/ABBV/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-epcoritamab-duob-abbv-20221121monthly0.5https://www.biopharmawatch.com/news/ABBV/fourth-annual-botox-cosmetic-onabotulinumtoxina-day-most-successful-one-yet-yesterday-alle-abbv-20221117monthly0.5https://www.biopharmawatch.com/news/ABBV/north-chicago-s-new-neal-math-and-science-academy-opens-funded-by-a-donation-from-abbvie-a-abbv-20221116monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-wolfe-research-healthcare-conference-abbvie-nyse-abbv-will-partic-abbv-20221109monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-data-from-extensive-portfolio-at-the-american-college-of-rheumatology-conv-abbv-20221108monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-late-breaking-results-from-phase-2-exploratory-nova-trial-of-novel-invest-abbv-20221107monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-anuncia-resultados-financeiros-globais-do-terceiro-trimestre-de-2022-a-abbvie-nyse--abbv-20221107monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-reaffirms-commitment-to-breast-health-advocacy-with-yearlong-program-f-abbv-20221103monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-celebrates-fourth-annual-botox-cosmetic-onabotulinumtoxina-day-allerga-abbv-20221102monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-submissions-of-regulatory-applications-for-epcoritamab-duobody-cd3xcd20-f-abbv-20221028monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-third-quarter-2022-financial-results-reports-third-quarter-diluted-eps-of-2-abbv-20221028monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-adquire-a-companhia-djs-antibodies-fortalecendo-seu-pipeline-em-imunologia-a-abbvie-abbv-20221025monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-data-from-extensive-portfolio-at-american-college-of-gastroenterology-an-abbv-20221024monthly0.5https://www.biopharmawatch.com/news/ABBV/rinvoq-upadacitinib-receives-its-sixth-u-s-fda-approval-abbvie-nyse-abbv-today-announces-t-abbv-20221021monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-acquires-djs-antibodies-further-strengthening-immunology-pipeline-abbvie-nyse-abbv--abbv-20221020monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-and-girls-inc-partner-to-bridge-the-gender-gap-in-stem-today-allergan--abbv-20221018monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-to-present-data-from-its-leading-aesthetic-portfolio-at-the-2022-ameri-abbv-20221007monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-third-quarter-2022-earnings-conference-call-abbvie-nyse-abbv-will-announce--abbv-20221004monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-highlights-robust-gastroenterology-portfolio-with-new-data-in-crohn-s-disease-and-u-abbv-20220929monthly0.5https://www.biopharmawatch.com/news/ABBV/the-forces-of-beauty-report-from-the-dream-initiative-reveals-demand-for-new-standards-of--abbv-20220922monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-secures-positive-chmp-opinion-for-risankizumab-skyrizi-for-the-treatment-of-adults--abbv-20220919monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-data-from-growing-neuroscience-and-movement-disorders-portfolio-at-2022--abbv-20220915monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-public-voting-open-for-30th-annual-cystic-fibrosis-scholarship-thriving-s-abbv-20220914monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-and-botox-cosmetic-onabotulinumtoxina-reveal-new-see-yourself-campaign-abbv-20220913monthly0.5https://www.biopharmawatch.com/news/ABBV/new-late-breaking-results-from-phase-3-trials-of-skyrizi-risankizumab-evaluating-long-term-abbv-20220910monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-today-de-abbv-20220909monthly0.5https://www.biopharmawatch.com/news/ABBV/new-measure-ad-analyses-evaluate-clinical-psychosocial-and-economic-burdens-in-atopic-derm-abbv-20220908monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-data-from-its-robust-migraine-portfolio-at-the-migraine-trust-internatio-abbv-20220908monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-celebrates-100-million-syringes-of-juve-derm-today-allergan-aesthetics-abbv-20220907monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-morgan-stanley-healthcare-conference-abbvie-nyse-abbv-will-partic-abbv-20220907monthly0.5https://www.biopharmawatch.com/news/ABBV/skinmedica-launches-firm-tone-lotion-for-body-today-allergan-aesthetics-an-abbvie-company--abbv-20220831monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-publishes-the-future-of-aesthetics-global-trends-report-allergan-aesth-abbv-20220830monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-showcases-new-analyses-and-real-world-data-across-multiple-immune-mediated-skin-dis-abbv-20220829monthly0.5https://www.biopharmawatch.com/news/ABBV/children-with-chronic-graft-versus-host-disease-cgvhd-may-now-be-prescribed-imbruvica-ibru-abbv-20220824monthly0.5https://www.biopharmawatch.com/news/ABBV/experience-the-juve-derm-difference-with-allergan-aesthetics-allergan-aesthetics-an-abbvie-abbv-20220817monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-anuncia-resultados-financeiros-do-segundo-trimestre-de-2022-a-abbvie-nyse-abbv-anun-abbv-20220810monthly0.5https://www.biopharmawatch.com/news/ABBV/fda-approves-juve-derm-volux-xc-for-improvement-of-jawline-definition-today-allergan-aesth-abbv-20220803monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-second-quarter-2022-financial-results-reports-second-quarter-diluted-eps-of-abbv-20220729monthly0.5https://www.biopharmawatch.com/news/ABBV/rinvoq-upadacitinib-approved-by-european-commission-as-an-oral-treatment-for-adults-with-a-abbv-20220729monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-regulatory-applications-to-fda-and-ema-for-upadacitinib-rinvoq-in-crohn-s-d-abbv-20220727monthly0.5https://www.biopharmawatch.com/news/ABBV/european-commission-approves-rinvoq-upadacitinib-for-the-treatment-of-adults-with-moderate-abbv-20220726monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-allergan-aesthetics-to-present-new-data-from-leading-neurotoxin-portfolio-at-to-abbv-20220725monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-istar-medical-announce-strategic-alliance-for-the-treatment-of-glaucoma-abbvie--abbv-20220720monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-marketing-authorization-application-to-ema-for-atogepant-for-the-preventive-abbv-20220718monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-second-quarter-2022-earnings-conference-call-abbvie-nyse-abbv-will-announce-abbv-20220708monthly0.5https://www.biopharmawatch.com/news/ABBV/approximately-15-000-abbvie-employees-to-volunteer-globally-to-support-local-communities-i-abbv-20220627monthly0.5https://www.biopharmawatch.com/news/ABBV/chmp-recommends-approval-of-upadacitinib-rinvoq-for-the-treatment-of-adults-with-active-no-abbv-20220627monthly0.5https://www.biopharmawatch.com/news/ABBV/new-survey-offers-perspective-on-mental-and-emotional-journey-for-patients-diagnosed-with--abbv-20220624monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-today-de-abbv-20220623monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-supplemental-new-drug-application-to-u-s-fda-for-atogepant-qulipta-to-suppo-abbv-20220621monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-publishes-the-future-of-aesthetics-global-trends-report-providing-unri-abbv-20220617monthly0.5https://www.biopharmawatch.com/news/ABBV/skyrizi-risankizumab-rzaa-receives-fda-approval-as-the-first-and-only-specific-interleukin-abbv-20220617monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-late-breaking-results-from-phase-2-trial-of-investigational-epcoritamab-d-abbv-20220611monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-investigational-navitoclax-preliminary-data-in-jak-inhibitor-nai-ve-myelof-abbv-20220610monthly0.5https://www.biopharmawatch.com/news/ABBV/new-data-demonstrates-abbvie-s-venclyxto-venclexta-combination-sustained-progression-free--abbv-20220610monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-extensive-data-from-its-migraine-portfolio-at-the-2022-american-headache-abbv-20220607monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-positive-results-from-phase-3-select-axis-2-trials-of-upadacitinib-rinvoq--abbv-20220601monthly0.5https://www.biopharmawatch.com/news/ABBV/the-lancet-publishes-results-from-phase-3-induction-and-maintenance-programs-evaluating-up-abbv-20220527monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-bernstein-38th-annual-strategic-decisions-conference-abbvie-nyse--abbv-20220525monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-showcases-its-leadership-in-rheumatology-research-with-new-data-across-multiple-inf-abbv-20220524monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-positive-data-from-phase-3-study-of-cariprazine-vraylar-for-the-adjunctive-abbv-20220523monthly0.5https://www.biopharmawatch.com/news/ABBV/chmp-recommends-european-commission-approval-of-upadacitinib-rinvoq-for-the-treatment-of-a-abbv-20220523monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-new-drug-application-to-u-s-fda-for-investigational-abbv-951-foscarbidopa-f-abbv-20220520monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-showcase-depth-of-gastroenterology-portfolio-and-pipeline-at-digestive-disease-w-abbv-20220516monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-cugene-announce-collaboration-in-autoimmune-diseases-abbvie-nyse-abbv-and-cugen-abbv-20220516monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-showcase-oncology-portfolio-and-pipeline-during-the-2022-asco-and-eha-annual-con-abbv-20220512monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-awards-45-scholarships-to-u-s-students-living-with-chronic-immune-mediated-diseases-abbv-20220512monthly0.5https://www.biopharmawatch.com/news/ABBV/upadacitinib-rinvoq-achieved-clinical-remission-and-endoscopic-response-at-one-year-in-pha-abbv-20220511monthly0.5https://www.biopharmawatch.com/news/ABBV/rinvoq-upadacitinib-approved-by-u-s-fda-as-an-oral-treatment-for-adults-with-active-ankylo-abbv-20220429monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-first-quarter-2022-financial-results-reports-first-quarter-diluted-eps-of-2-abbv-20220429monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-an-abbvie-company-to-present-new-data-from-its-leading-portfolio-of-eye-care-trea-abbv-20220428monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-an-abbvie-company-to-present-new-data-from-its-eye-care-portfolio-at-the-2022-ame-abbv-20220419monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-first-quarter-2022-earnings-conference-call-abbvie-nyse-abbv-will-announce--abbv-20220414monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-genmab-announce-topline-results-for-epcoritamab-duobody-cd3xcd20-from-phase-1-2-abbv-20220413monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-celebrates-30th-anniversary-of-cf-scholarship-with-opening-of-application-period-fo-abbv-20220413monthly0.5https://www.biopharmawatch.com/news/ABBV/botox-cosmetic-onabotulinumtoxina-celebrates-20-years-since-first-u-s-fda-approval-allerga-abbv-20220413monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-positive-investigational-navitoclax-combination-data-in-phase-2-refine-stu-abbv-20220412monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-an-abbvie-company-announces-positive-topline-phase-3-results-evaluating-investiga-abbv-20220405monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-showcase-breadth-of-neuroscience-portfolio-and-pipeline-at-american-academy-of-n-abbv-20220329monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-brings-data-innovation-industry-expertise-to-the-2022-aesthetic-and-an-abbv-20220329monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-allergan-aesthetics-to-present-new-research-across-dermatology-portfolio-at-202-abbv-20220321monthly0.5https://www.biopharmawatch.com/news/ABBV/rinvoq-upadacitinib-receives-fda-approval-for-the-treatment-of-adults-with-moderately-to-s-abbv-20220316monthly0.5https://www.biopharmawatch.com/news/ABBV/now-available-over-the-counter-lastacaft-provides-eye-allergy-itch-relief-in-minutes-that--abbv-20220315monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-scripps-research-announce-collaboration-to-develop-antiviral-treatments-for-cov-abbv-20220315monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-gedeon-richter-announce-collaboration-in-neuropsychiatric-diseases-abbvie-nyse--abbv-20220311monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-positive-phase-3-atogepant-qulipta-data-for-the-preventive-treatment-of-c-abbv-20220310monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-resolves-humira-adalimumab-u-s-litigation-with-alvotech-abbvie-nyse-abbv-announced--abbv-20220308monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-cowen-42nd-annual-health-care-conference-abbvie-nyse-abbv-will-pa-abbv-20220301monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-acquires-syndesi-therapeutics-strengthening-neuroscience-portfolio-abbvie-nyse-abbv-abbv-20220301monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-provides-update-regarding-skyrizi-risankizumab-rzaa-for-the-treatment-of-moderate-t-abbv-20220228monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-seeks-new-indication-for-imbruvica-ibrutinib-in-pediatric-patients-with-chronic-gra-abbv-20220228monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-an-abbvie-company-to-present-data-from-its-leading-portfolio-of-eye-care-treatmen-abbv-20220224monthly0.5https://www.biopharmawatch.com/news/ABBV/second-phase-3-induction-study-confirms-upadacitinib-rinvoq-improved-clinical-and-endoscop-abbv-20220224monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-supplemental-new-drug-application-to-u-s-fda-for-cariprazine-vraylar-for-th-abbv-20220222monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-today-de-abbv-20220217monthly0.5https://www.biopharmawatch.com/news/ABBV/fda-approves-juve-derm-volbella-xc-for-undereye-hollows-allergan-aesthetics-an-abbvie-comp-abbv-20220208monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-full-year-and-fourth-quarter-2021-financial-results-abbvie-nyse-abbv-announ-abbv-20220202monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-showcases-its-leadership-in-research-in-inflammatory-bowel-diseases-with-new-analys-abbv-20220201monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-announces-open-casting-call-for-botox-cosmetic-onabotulinumtoxina-alle-abbv-20220124monthly0.5https://www.biopharmawatch.com/news/ABBV/u-s-fda-approves-second-indication-for-skyrizi-risankizumab-rzaa-to-treat-adults-with-acti-abbv-20220121monthly0.5https://www.biopharmawatch.com/news/ABBV/u-s-fda-approves-rinvoq-upadacitinib-to-treat-adults-and-children-12-years-and-older-with--abbv-20220114monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-anuncia-que-fda-outorgou-ao-telisotuzumabe-vedotin-a-classificac-a-o-de-terapia-ino-abbv-20220111monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-confirms-guidance-of-greater-than-15-billion-in-combined-risk-adjusted-sales-for-ri-abbv-20220111monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-applications-for-upadacitinib-rinvoq-in-non-radiographic-axial-spondyloarth-abbv-20220107monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-fourth-quarter-and-full-year-2021-earnings-conference-call-abbvie-nyse-abbv-abbv-20220105monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-u-s-fda-granted-breakthrough-therapy-designation-btd-to-telisotuzumab-ved-abbv-20220104monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-abbvie-nyse-abbv-wil-abbv-20220104monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-completes-acquisition-of-soliton-allergan-aesthetics-an-abbvie-company-abbv-20211216monthly0.5https://www.biopharmawatch.com/news/ABBV/rinvoq-upadacitinib-receives-u-s-fda-approval-for-active-psoriatic-arthritis-abbvie-nyse-a-abbv-20211214monthly0.5https://www.biopharmawatch.com/news/ABBV/upadacitinib-rinvoq-achieved-primary-and-key-secondary-endpoints-in-first-phase-3-inductio-abbv-20211206monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-provides-update-on-rinvoq-upadacitinib-for-the-treatment-of-rheumatoid-arthritis-in-abbv-20211203monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-application-for-risankizumab-skyrizi-in-moderate-to-severe-crohn-s-disease--abbv-20211130monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-evercore-isi-conference-abbvie-nyse-abbv-will-participate-in-the--abbv-20211123monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-piper-sandler-healthcare-conference-abbvie-nyse-abbv-will-partici-abbv-20211123monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-to-present-data-from-its-leading-aesthetic-portfolio-at-the-2021-ameri-abbv-20211119monthly0.5https://www.biopharmawatch.com/news/ABBV/new-literature-review-highlights-economic-benefits-associated-with-achieving-rheumatoid-ar-abbv-20211118monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-expands-immunology-portfolio-in-the-european-union-with-the-european-commission-app-abbv-20211117monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-celebrates-third-annual-botox-cosmetic-onabotulinumtoxina-day-let-the--abbv-20211115monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-university-of-chicago-extend-research-collaboration-to-support-preclinical-oncology-abbv-20211110monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-wolfe-research-healthcare-conference-abbvie-nyse-abbv-will-partic-abbv-20211110monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-new-efficacy-data-on-upadacitinib-rinvoq-in-people-with-active-psoriatic-a-abbv-20211109monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-new-long-term-analysis-evaluating-the-sustainability-of-response-to-rinv-abbv-20211109monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-an-abbvie-company-to-present-new-data-from-its-leading-eye-care-portfolio-at-the--abbv-20211108monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-integrated-efficacy-and-safety-data-from-two-phase-3-trials-on-risankizuma-abbv-20211105monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-highlight-new-advances-in-blood-cancer-research-and-expanding-oncology-pipeline--abbv-20211104monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-highlights-innovative-research-from-its-rheumatology-portfolio-at-acr-convergence-2-abbv-20211101monthly0.5https://www.biopharmawatch.com/news/ABBV/u-s-food-and-drug-administration-approves-vuity-pilocarpine-hci-ophthalmic-solution-1-25-t-abbv-20211029monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-cariprazine-vraylar-met-primary-endpoint-in-phase-3-study-as-an-adjunctive-treatm-abbv-20211029monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-third-quarter-2021-financial-results-abbvie-nyse-abbv-announced-financial-r-abbv-20211029monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-abbv-951-foslevodopa-foscarbidopa-showed-improvement-in-controlling-motor-abbv-20211028monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-an-abbvie-company-to-present-new-data-on-investigational-agn-190584-for-the-treat-abbv-20211026monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-chmp-positive-opinion-for-risankizumab-skyrizi-for-the-treatment-of-adults-abbv-20211015monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-launches-series-of-initiatives-to-support-breast-cancer-awareness-alle-abbv-20211011monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-upadacitinib-rinvoq-met-primary-and-most-ranked-secondary-endpoints-in-phase-3-st-abbv-20211007monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-rinvoq-upadacitinib-met-primary-and-all-ranked-secondary-endpoints-in-phase-3-stu-abbv-20211007monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-third-quarter-2021-earnings-conference-call-abbvie-nyse-abbv-will-announce--abbv-20211005monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-showcase-new-data-at-the-united-european-gastroenterology-ueg-week-virtual-2021--abbv-20211002monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-late-breaking-data-on-risankizumab-skyrizi-in-psoriatic-arthritis-at-the-3-abbv-20210930monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-new-analyses-evaluating-rinvoq-upadacitinib-in-atopic-dermatitis-across-pa-abbv-20210930monthly0.5https://www.biopharmawatch.com/news/ABBV/dream-initiative-releases-the-full-spectrum-of-dermatology-a-diverse-and-inclusive-atlas-a-abbv-20210929monthly0.5https://www.biopharmawatch.com/news/ABBV/fda-approves-qulipta-atogepant-the-first-and-only-oral-cgrp-receptor-antagonist-specifical-abbv-20210928monthly0.5https://www.biopharmawatch.com/news/ABBV/americans-are-frustrated-by-unexpected-blurry-near-vision-issues-a-new-survey-reveals-from-abbv-20210927monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-new-data-analyses-for-growing-dermatology-portfolio-at-the-30th-european-a-abbv-20210923monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-regulatory-application-to-fda-for-risankizumab-rzaa-skyrizi-for-the-treatme-abbv-20210920monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-regulatory-applications-to-fda-and-ema-for-upadacitinib-rinvoq-for-the-trea-abbv-20210916monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-today-de-abbv-20210910monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-highlight-its-leadership-in-movement-disorders-at-the-international-parkinson-an-abbv-20210910monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-morgan-stanley-healthcare-conference-abbvie-nyse-abbv-will-partic-abbv-20210909monthly0.5https://www.biopharmawatch.com/news/ABBV/clinical-trial-of-investigational-epcoritamab-duobody-cd3xcd20-in-patients-with-relapsed-r-abbv-20210909monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-data-from-its-migraine-portfolio-at-the-2021-international-headache-cong-abbv-20210908monthly0.5https://www.biopharmawatch.com/news/ABBV/european-commission-approves-rinvoq-upadacitinib-as-first-jak-inhibitor-in-the-european-un-abbv-20210824monthly0.5https://www.biopharmawatch.com/news/ABBV/new-england-journal-of-medicine-publishes-12-week-results-from-study-evaluating-atogepant--abbv-20210818monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-kicks-off-two-week-public-voting-open-for-the-2021-abbvie-cf-scholarship-thriving-s-abbv-20210818monthly0.5https://www.biopharmawatch.com/news/ABBV/skyrizi-risankizumab-rzaa-now-available-in-the-u-s-as-a-single-150-mg-injection-for-adults-abbv-20210809monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-e-calico-anunciam-nova-extensa-o-de-colaborac-a-o-em-doenc-as-relacionadas-ao-envel-abbv-20210805monthly0.5https://www.biopharmawatch.com/news/ABBV/jama-dermatology-publishes-data-showing-rinvoq-upadacitinib-achieved-superiority-versus-du-abbv-20210804monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-second-quarter-2021-financial-results-abbvie-nyse-abbv-announced-financial--abbv-20210730monthly0.5https://www.biopharmawatch.com/news/ABBV/fda-approves-expanded-botox-onabotulinumtoxina-label-to-include-eight-new-muscles-to-treat-abbv-20210729monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-calico-announce-second-extension-of-collaboration-focused-on-aging-and-age-rela-abbv-20210727monthly0.5https://www.biopharmawatch.com/news/ABBV/new-data-presented-on-the-safety-and-efficacy-of-investigational-agn-190584-as-a-potential-abbv-20210725monthly0.5https://www.biopharmawatch.com/news/ABBV/dalvance-dalbavancin-receives-fda-approval-to-treat-acute-bacterial-skin-and-skin-structur-abbv-20210723monthly0.5https://www.biopharmawatch.com/news/ABBV/venetoclax-venclexta-granted-us-fda-breakthrough-therapy-designation-btd-in-higher-risk-my-abbv-20210721monthly0.5https://www.biopharmawatch.com/news/ABBV/resultados-de-estudo-de-fase-3-indicam-que-pacientes-com-doenc-a-de-crohn-tratados-com-ris-abbv-20210720monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-an-abbvie-company-to-present-new-data-from-its-leading-eye-care-portfolio-at-the--abbv-20210720monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-provides-update-regarding-rinvoq-upadacitinib-for-the-treatment-of-moderate-to-seve-abbv-20210716monthly0.5https://www.biopharmawatch.com/news/ABBV/novos-dados-sobre-venclexta-venetoclax-da-abbvie-em-combinac-a-o-fixa-de-tratamento-demons-abbv-20210707monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-apresenta-ana-lise-de-dados-que-indicam-que-risanquizumabe-obte-m-remissa-o-cli-nic-abbv-20210707monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-second-quarter-2021-earnings-conference-call-abbvie-nyse-abbv-will-announce-abbv-20210707monthly0.5https://www.biopharmawatch.com/news/ABBV/aberta-consulta-pu-blica-para-atualizac-a-o-de-protocolo-cli-nico-de-diretrizes-terape-uti-abbv-20210630monthly0.5https://www.biopharmawatch.com/news/ABBV/upadacitinib-rinvoq-met-the-primary-and-all-secondary-endpoints-in-the-52-week-phase-3-mai-abbv-20210629monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-gastroenterology-pipeline-to-be-featured-at-the-16th-congress-of-european-crohn-s-a-abbv-20210628monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-provides-update-regarding-rinvoq-upadacitinib-in-psoriatic-arthritis-and-ankylosing-abbv-20210625monthly0.5https://www.biopharmawatch.com/news/ABBV/chmp-recommends-approval-of-rinvoq-upadacitinib-for-the-treatment-of-atopic-dermatitis-abb-abbv-20210625monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-exercises-right-to-acquire-teneoone-and-lead-asset-tnb-383b-for-the-potential-treat-abbv-20210624monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-today-de-abbv-20210617monthly0.5https://www.biopharmawatch.com/news/ABBV/imbruvica-ibrutinib-plus-venclexta-venclyxto-venetoclax-combination-shows-superior-progres-abbv-20210612monthly0.5https://www.biopharmawatch.com/news/ABBV/new-data-shows-abbvie-s-venclyxto-venclexta-fixed-duration-combination-demonstrates-sustai-abbv-20210611monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-and-botox-cosmetic-onabotulinumtoxina-put-real-stories-at-the-forefron-abbv-20210608monthly0.5https://www.biopharmawatch.com/news/ABBV/captivate-study-shows-an-imbruvica-ibrutinib-plus-venclexta-venclyxto-venetoclax-chemother-abbv-20210607monthly0.5https://www.biopharmawatch.com/news/ABBV/results-from-imbruvica-ibrutinib-resonate-2-study-provide-up-to-seven-years-of-progression-abbv-20210604monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-goldman-sachs-42nd-annual-global-healthcare-conference-abbvie-nys-abbv-20210602monthly0.5https://www.biopharmawatch.com/news/ABBV/phase-3-maintenance-results-show-patients-with-crohn-s-disease-receiving-risankizumab-skyr-abbv-20210602monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-analysis-evaluating-continuous-rinvoq-upadacitinib-treatment-in-psoriati-abbv-20210602monthly0.5https://www.biopharmawatch.com/news/ABBV/new-long-term-efficacy-and-safety-analyses-evaluating-rinvoq-upadacitinib-in-patients-with-abbv-20210602monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-bernstein-s-37th-annual-strategic-decisions-conference-abbvie-nyse-ab-abbv-20210526monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-s-abbv-20210526monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-showcases-the-depth-of-its-rheumatology-portfolio-with-new-data-presented-at-the-eu-abbv-20210525monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-european-commission-approval-of-venclyxto-venetoclax-in-combination-with-a-abbv-20210525monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-new-late-breaking-data-analyses-showing-risankizumab-skyrizi-achieves-clin-abbv-20210524monthly0.5https://www.biopharmawatch.com/news/ABBV/the-lancet-publishes-results-from-pivotal-global-phase-3-program-evaluating-rinvoq-upadaci-abbv-20210524monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-ubs-global-healthcare-virtual-conference-abbvie-nyse-abbv-will-pa-abbv-20210520monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-showcase-breadth-of-oncology-portfolio-and-pipeline-at-the-2021-asco-and-eha-ann-abbv-20210519monthly0.5https://www.biopharmawatch.com/news/ABBV/fda-aceita-submissa-o-de-atogepant-novo-medicamento-da-abbvie-para-o-tratamento-preventivo-abbv-20210513monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-rbc-capital-markets-global-healthcare-conference-abbvie-nyse-abbv-abbv-20210512monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-to-acquire-soliton-expanding-body-contouring-portfolio-allergan-aesthe-abbv-20210510monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-anuncia-resultados-financeiros-do-primeiro-trimestre-de-2021-a-companhia-farmace-ut-abbv-20210507monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-first-quarter-2021-financial-results-abbvie-nyse-abbv-announced-financial-r-abbv-20210430monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-an-abbvie-company-to-share-new-data-highlighting-latest-advancements-in-eye-care--abbv-20210427monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-positive-chmp-opinion-for-venclyxto-venetoclax-as-a-combination-regimen-fo-abbv-20210423monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-regulatory-applications-for-skyrizi-risankizumab-in-psoriatic-arthritis-to--abbv-20210407monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-data-across-its-robust-neuroscience-portfolio-at-the-2021-american-acade-abbv-20210407monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-extension-of-review-for-supplemental-new-drug-application-of-upadacitinib-abbv-20210402monthly0.5https://www.biopharmawatch.com/news/ABBV/skinmedica-launches-neck-correct-cream-for-neck-and-de-collete-today-allergan-aesthetics-a-abbv-20210401monthly0.5https://www.biopharmawatch.com/news/ABBV/new-england-journal-of-medicine-publishes-24-week-results-from-phase-3-study-evaluating-ri-abbv-20210401monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-first-quarter-2021-earnings-conference-call-abbvie-nyse-abbv-will-announce--abbv-20210331monthly0.5https://www.biopharmawatch.com/news/ABBV/u-s-fda-accepts-abbvie-s-new-drug-application-for-atogepant-for-the-preventive-treatment-o-abbv-20210330monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-calls-on-students-with-cystic-fibrosis-to-apply-for-the-abbvie-cf-scholarship-for-t-abbv-20210317monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-extension-of-review-for-supplemental-new-drug-application-of-upadacitinib-abbv-20210317monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-an-abbvie-company-submits-new-drug-application-for-investigational-agn-190584-for-abbv-20210225monthly0.5https://www.biopharmawatch.com/news/ABBV/humira-adalimumab-receives-fda-approval-to-treat-pediatric-patients-living-with-moderately-abbv-20210224monthly0.5https://www.biopharmawatch.com/news/ABBV/new-refresh-digital-lubricant-eye-drops-tackle-eye-dryness-due-to-everyday-screen-use-from-abbv-20210223monthly0.5https://www.biopharmawatch.com/news/ABBV/second-phase-3-induction-study-confirms-upadacitinib-rinvoq-improved-clinical-endoscopic-a-abbv-20210222monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-evolus-and-medytox-announce-resolution-of-intellectual-property-litigation-abbvie-n-abbv-20210219monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-cowen-41st-annual-health-care-conference-abbvie-nyse-abbv-will-pa-abbv-20210219monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-today-de-abbv-20210218monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-10th-annual-svb-leerink-global-healthcare-conference-abbvie-nyse--abbv-20210212monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-caribou-biosciences-announce-collaboration-and-license-agreement-for-car-t-cell-abbv-20210210monthly0.5https://www.biopharmawatch.com/news/ABBV/botox-onabotulinumtoxina-receives-fda-approval-for-pediatric-detrusor-overactivity-associa-abbv-20210210monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-full-year-and-fourth-quarter-2020-financial-results-abbvie-nyse-abbv-announ-abbv-20210203monthly0.5https://www.biopharmawatch.com/news/ABBV/coolsculpting-by-allergan-aesthetics-expands-body-contouring-portfolio-with-coolsculpting--abbv-20210126monthly0.5https://www.biopharmawatch.com/news/ABBV/european-commission-approves-abbvie-s-rinvoq-upadacitinib-for-the-treatment-of-psoriatic-a-abbv-20210125monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-and-allergan-an-abbvie-company-to-present-16-neurotoxin-research-abstr-abbv-20210115monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-enters-into-option-to-acquire-cypris-medical-today-allergan-aesthetics-abbv-20210112monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-fourth-quarter-and-full-year-2020-earnings-conference-call-abbvie-nyse-abbv-abbv-20210112monthly0.5https://www.biopharmawatch.com/news/ABBV/risankizumab-skyrizi-demonstrates-significant-improvements-in-clinical-remission-and-endos-abbv-20210107monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-abbvie-nyse-abbv-wil-abbv-20210106monthly0.5https://www.biopharmawatch.com/news/ABBV/risankizumab-skyrizi-phase-3-results-demonstrate-improvements-in-disease-activity-across-j-abbv-20210105monthly0.5https://www.biopharmawatch.com/news/ABBV/imbruvica-ibrutinib-u-s-prescribing-information-updated-to-include-long-term-data-for-wald-abbv-20201223monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-apresenta-novos-dados-de-venclexta-venetoclax-para-tratamento-com-durac-a-o-fixa-de-abbv-20201214monthly0.5https://www.biopharmawatch.com/news/ABBV/chmp-recommends-the-approvals-of-rinvoq-upadacitinib-for-the-treatment-of-adults-with-acti-abbv-20201211monthly0.5https://www.biopharmawatch.com/news/ABBV/rinvoq-upadacitinib-achieved-superiority-versus-dupixent-dupilumab-for-primary-and-all-ran-abbv-20201210monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-partners-in-50-million-program-to-promote-health-and-education-equity-in--abbv-20201209monthly0.5https://www.biopharmawatch.com/news/ABBV/upadacitinib-rinvoq-meets-primary-and-all-ranked-secondary-endpoints-in-first-phase-3-indu-abbv-20201209monthly0.5https://www.biopharmawatch.com/news/ABBV/combined-data-from-multiple-phase-3-studies-of-imbruvica-ibrutinib-show-efficacy-and-safet-abbv-20201206monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-extended-follow-up-data-for-fixed-duration-treatment-venclexta-venclyxto-v-abbv-20201205monthly0.5https://www.biopharmawatch.com/news/ABBV/imbruvica-ibrutinib-plus-venclexta-venclyxto-venetoclax-combination-shows-high-rates-of-di-abbv-20201205monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-frontier-medicines-establish-global-partnership-to-discover-and-develop-novel-t-abbv-20201202monthly0.5https://www.biopharmawatch.com/news/ABBV/conitec-avalia-incorporac-a-o-de-novo-tratamento-para-pacientes-adultos-com-artrite-reumat-abbv-20201201monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-virtual-immunology-strategic-update-abbvie-nyse-abbv-will-host-a-virtual-im-abbv-20201201monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-anuncia-resultados-financeiros-do-terceiro-trimestre-2020-a-abbvie-companhia-biofar-abbv-20201124monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-evercore-isi-conference-and-piper-sandler-healthcare-conference-a-abbv-20201124monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-celebrates-second-annual-botox-cosmetic-onabotulinumtoxina-day-allerga-abbv-20201116monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-wolfe-research-healthcare-conference-abbvie-nyse-abbv-will-partic-abbv-20201112monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-highlight-blood-cancer-leadership-and-advancing-oncology-pipeline-at-the-ash-62n-abbv-20201105monthly0.5https://www.biopharmawatch.com/news/ABBV/novos-dados-demonstram-que-skyrizi-risanquizumabe-mante-m-a-pele-sem-leso-es-por-mais-de-t-abbv-20201103monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-third-quarter-2020-financial-results-abbvie-nyse-abbv-announced-financial-r-abbv-20201030monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-new-analyses-from-pivotal-phase-3-studies-for-rinvoq-upadacitinib-in-ato-abbv-20201029monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-highlights-innovative-research-for-people-with-rheumatic-diseases-with-new-data-at--abbv-20201028monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-an-abbvie-company-announces-positive-phase-3-topline-results-for-investigational--abbv-20201028monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-e-i-mab-firmam-parceria-global-estrate-gica-para-terapia-diferenciada-de-imuno-onco-abbv-20201023monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-regulatory-applications-to-fda-and-ema-for-rinvoq-upadacitinib-in-atopic-de-abbv-20201019monthly0.5https://www.biopharmawatch.com/news/ABBV/venclexta-venetoclax-receives-fda-full-approval-for-acute-myeloid-leukemia-aml-abbvie-nyse-abbv-20201016monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-to-present-data-from-4-abstracts-at-the-2020-american-society-for-derm-abbv-20201009monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-an-abbvie-company-and-von-miller-encourage-people-with-glaucoma-to-design-their-d-abbv-20201008monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-an-abbvie-company-acquires-innovative-luminera-dermal-filler-business--abbv-20201007monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-third-quarter-2020-earnings-conference-call-abbvie-nyse-abbv-will-announce--abbv-20201006monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-new-data-from-15-abstracts-at-the-2020-virtual-migraine-trust-internatio-abbv-20201002monthly0.5https://www.biopharmawatch.com/news/ABBV/skinmedica-launches-tns-advanced-pro-infusion-serum-for-diamondglow-today-allergan-aesthet-abbv-20200930monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-orphan-drug-and-fast-track-designations-from-the-u-s-food-and-drug-adminis-abbv-20200928monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submete-upadacitinibe-para-pacientes-adultos-com-espondilite-anquilosante-a-avaliac-abbv-20200925monthly0.5https://www.biopharmawatch.com/news/ABBV/conitec-recomenda-incorporac-a-o-de-skyrizi-risanquizumabe-da-abbvie-pelo-sus-para-tratame-abbv-20200923monthly0.5https://www.biopharmawatch.com/news/ABBV/voting-for-the-2020-abbvie-cf-scholarship-thriving-student-awards-is-open-to-the-public-un-abbv-20200916monthly0.5https://www.biopharmawatch.com/news/ABBV/malin-akerman-joins-coolsculpting-and-cooltone-as-u-s-ambassador-for-the-allergan-aestheti-abbv-20200916monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-and-skinbetter-science-announce-the-dream-initiative-to-advance-health-abbv-20200914monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-new-data-from-18-abstracts-at-the-international-congress-of-parkinson-s--abbv-20200911monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-today-de-abbv-20200911monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-i-mab-enter-into-global-strategic-partnership-for-differentiated-immuno-oncolog-abbv-20200904monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-morgan-stanley-healthcare-conference-abbvie-nyse-abbv-will-partic-abbv-20200903monthly0.5https://www.biopharmawatch.com/news/ABBV/the-lancet-oncology-publica-ana-lise-que-acompanhou-por-tre-s-anos-pacientes-de-leucemia-l-abbv-20200902monthly0.5https://www.biopharmawatch.com/news/ABBV/new-england-journal-of-medicine-publica-dados-positivos-de-estudo-de-fase-3-de-regime-comb-abbv-20200901monthly0.5https://www.biopharmawatch.com/news/ABBV/say-no-to-chronic-migraine-monday-urges-people-living-with-chronic-migraine-to-seek-help-f-abbv-20200831monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-regulatory-application-to-fda-for-rinvoq-upadacitinib-for-the-treatment-of--abbv-20200825monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-harvard-university-form-research-alliance-to-address-emergent-viral-diseases-abbvie-abbv-20200825monthly0.5https://www.biopharmawatch.com/news/ABBV/new-england-journal-of-medicine-publishes-positive-phase-3-data-of-venetoclax-combination--abbv-20200812monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-destina-us-35-milho-es-para-apoiar-sistema-de-sau-de-e-comunidades-afetadas-pela-co-abbv-20200804monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-second-quarter-2020-financial-results-abbvie-nyse-abbv-announced-financial--abbv-20200731monthly0.5https://www.biopharmawatch.com/news/ABBV/upadacitinibe-da-abbvie-em-monoterapia-demonstra-reduc-a-o-das-leso-es-de-pele-e-do-prurid-abbv-20200730monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-positive-phase-3-data-for-atogepant-in-migraine-prevention-abbvie-nyse-ab-abbv-20200729monthly0.5https://www.biopharmawatch.com/news/ABBV/third-pivotal-phase-3-study-shows-rinvoq-upadacitinib-plus-topical-corticosteroids-improve-abbv-20200728monthly0.5https://www.biopharmawatch.com/news/ABBV/rinvoq-upadacitinib-monotherapy-meets-all-primary-and-secondary-endpoints-in-second-phase--abbv-20200721monthly0.5https://www.biopharmawatch.com/news/ABBV/fda-approves-expanded-botox-onabotulinumtoxina-label-for-the-treatment-of-pediatric-patien-abbv-20200709monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-second-quarter-2020-earnings-conference-call-abbvie-nyse-abbv-will-announce-abbv-20200707monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-apresenta-dados-de-estudo-que-indicam-superioridade-de-skyrizi-risanquizumabe-na-me-abbv-20200701monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-an-abbvie-company-and-molecular-partners-receive-complete-response-letter-from-fd-abbv-20200626monthly0.5https://www.biopharmawatch.com/news/ABBV/imbruvica-ibrutinib-seeks-to-expand-u-s-label-with-long-term-data-in-waldenstro-m-s-macrog-abbv-20200623monthly0.5https://www.biopharmawatch.com/news/ABBV/fda-accepts-supplemental-biologics-license-application-sbla-for-botox-onabotulinumtoxina-f-abbv-20200622monthly0.5https://www.biopharmawatch.com/news/ABBV/rinvoq-upadacitinib-monotherapy-shows-improvement-in-skin-clearance-and-itch-in-first-phas-abbv-20200618monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-today-de-abbv-20200617monthly0.5https://www.biopharmawatch.com/news/ABBV/fda-approves-juve-derm-voluma-xc-for-enhancement-of-the-chin-region-today-allergan-aesthet-abbv-20200615monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-showcase-27-studies-at-the-virtual-2020-annual-scientific-meeting-of-the-america-abbv-20200615monthly0.5https://www.biopharmawatch.com/news/ABBV/venclexta-venclyxto-venetoclax-plus-azacitidine-demonstrates-statistically-significant-ove-abbv-20200613monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-recommends-shareholders-reject-trc-capital-s-mini-tender-offer-abbvie-nyse-abbv-has-abbv-20200612monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-new-late-breaking-data-showing-skyrizi-risankizumab-rzaa-achieves-superior-abbv-20200612monthly0.5https://www.biopharmawatch.com/news/ABBV/novel-antibody-drug-conjugate-abbv-3373-shows-improvement-in-disease-activity-in-phase-2a--abbv-20200610monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-genmab-announce-broad-oncology-collaboration-abbvie-nyse-abbv-and-genmab-a-s-na-abbv-20200610monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-data-showing-rinvoq-upadacitinib-meets-primary-and-key-secondary-endpoints-abbv-20200606monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-harbour-biomed-utrecht-university-and-erasmus-medical-center-announce-collaboration-abbv-20200605monthly0.5https://www.biopharmawatch.com/news/ABBV/new-long-term-data-from-rinvoq-upadacitinib-15-mg-phase-3-studies-in-rheumatoid-arthritis--abbv-20200604monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-virtual-goldman-sachs-41st-annual-global-healthcare-conference-ab-abbv-20200603monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-regulatory-applications-to-fda-and-ema-for-rinvoq-upadacitinib-for-the-trea-abbv-20200601monthly0.5https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-launches-dedicated-multi-channel-campaign-to-contact-patients-who-may--abbv-20200601monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-jacobio-announce-strategic-collaboration-to-advance-shp2-inhibitors-abbvie-nyse-abbv-20200601monthly0.5https://www.biopharmawatch.com/news/ABBV/fda-approves-the-first-oral-medication-for-the-management-of-heavy-menstrual-bleeding-due--abbv-20200529monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-new-data-at-the-european-e-congress-of-rheumatology-eular-2020-showcasing--abbv-20200527monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-26-nonprofits-selected-for-the-covid-19-community-resilience-fund-abbvie--abbv-20200521monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-data-at-eha-annual-congress-highlight-depth-and-breadth-of-transformative-blood-can-abbv-20200515monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-ubs-virtual-healthcare-conference-abbvie-nyse-abbv-a-research-bas-abbv-20200514monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-completes-transformative-acquisition-of-allergan-abbvie-nyse-abbv-a-research-based--abbv-20200508monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-extension-of-expiration-date-for-exchange-offers-for-allergan-notes-and-e-abbv-20200505monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-first-quarter-2020-financial-results-abbvie-nyse-abbv-announced-financial-r-abbv-20200501monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-rule-2-10-announcement-relevant-securities-in-issue-in-accordance-with-rule-2-1-abbv-20200429monthly0.5https://www.biopharmawatch.com/news/ABBV/imbruvica-ibrutinib-receives-11th-fda-approval-abbvie-nyse-abbv-a-research-based-global-bi-abbv-20200421monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-rule-2-10-announcement-relevant-securities-in-issue-in-accordance-with-rule-2-1-abbv-20200415monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-invites-students-with-cystic-fibrosis-to-apply-for-the-abbvie-cf-scholarship-for-th-abbv-20200408monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-form-8-1-dealings-by-offerors-offerees-or-parties-acting-in-concert-with-them-f-abbv-20200402monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-first-quarter-2020-earnings-conference-call-abbvie-nyse-abbv-a-research-bas-abbv-20200402monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-rule-2-10-announcement-relevant-securities-in-issue-in-accordance-with-rule-2-1-abbv-20200401monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-donates-35-million-for-covid-19-relief-to-support-healthcare-systems-patients-and-c-abbv-20200331monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-anuncia-resultados-positivos-de-estudo-de-fase-3-de-venclexta-venetoclax-em-combina-abbv-20200331monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-form-8-1-statement-of-stock-purchase-by-director-abbvie-issued-the-following-fo-abbv-20200330monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-positive-topline-results-from-phase-3-trial-of-venclexta-venetoclax-in-co-abbv-20200323monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-rule-2-10-announcement-relevant-securities-in-issue-in-accordance-with-rule-2-1-abbv-20200318monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-allergan-sign-consent-decree-agreement-with-federal-trade-commission-staff-on-p-abbv-20200317monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-european-commission-approval-of-venclyxto-combination-regimen-for-patients-abbv-20200312monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-partnering-with-global-authorities-to-determine-efficacy-of-hiv-drug-in-treating-co-abbv-20200309monthly0.5https://www.biopharmawatch.com/news/ABBV/european-commission-grants-abbvie-marketing-authorization-shortening-maviret-glecaprevir-p-abbv-20200306monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-form-8-1-statement-of-stock-purchase-by-director-abbvie-issued-the-following-fo-abbv-20200304monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-rule-2-10-announcement-relevant-securities-in-issue-in-accordance-with-rule-2-1-abbv-20200304monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-form-8-1-share-buyback-abbvie-issued-the-following-forms-today-irish-takeover-p-abbv-20200303monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-allergan-receive-final-european-approval-to-close-pending-transaction-abbvie-ny-abbv-20200303monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-form-8-1-statement-of-stock-purchase-by-director-abbvie-issued-the-following-fo-abbv-20200302monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-provides-update-from-phase-3-study-evaluating-venclexta-venetoclax-in-combination-w-abbv-20200228monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-rule-2-10-announcement-relevant-securities-in-issue-in-accordance-with-rule-2-1-abbv-20200225monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-today-de-abbv-20200220monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-cowen-40th-annual-health-care-conference-abbvie-nyse-abbv-a-resea-abbv-20200219monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-rule-2-10-announcement-relevant-securities-in-issue-in-accordance-with-rule-2-1-abbv-20200219monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-svb-leerink-9th-annual-global-healthcare-conference-abbvie-nyse-a-abbv-20200211monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-full-year-and-fourth-quarter-2019-financial-results-abbvie-nyse-abbv-announ-abbv-20200207monthly0.5https://www.biopharmawatch.com/news/ABBV/rinvoq-upadacitinib-meets-primary-and-key-secondary-endpoints-in-phase-3-study-in-psoriati-abbv-20200205monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-rule-2-10-announcement-relevant-securities-in-issue-in-accordance-with-rule-2-1-abbv-20200205monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-positive-chmp-opinion-for-maviret-glecaprevir-pibrentasvir-to-shorten-trea-abbv-20200131monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-positive-chmp-opinion-for-venclyxto-as-a-chemotherapy-free-combination-reg-abbv-20200131monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-anuncia-aprovac-a-o-da-anvisa-para-venclexta-venetoclax-como-tratamento-livre-de-qu-abbv-20200129monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-allergan-announce-agreements-to-divest-brazikumab-and-zenpep-abbvie-nyse-abbv-a-abbv-20200127monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-rule-2-10-announcement-relevant-securities-in-issue-in-accordance-with-rule-2-1-abbv-20200122monthly0.5https://www.biopharmawatch.com/news/ABBV/new-head-to-head-phase-3-data-show-skyrizi-risankizumab-superior-to-cosentyx-secukinumab-a-abbv-20200114monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-fourth-quarter-and-full-year-2019-earnings-conference-call-abbvie-nyse-abbv-abbv-20200113monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-form-8-1-statement-of-stock-purchase-by-director-abbvie-issued-the-following-fo-abbv-20200109monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-leadership-team-and-creation-of-new-business-allergan-aesthetics-upon-com-abbv-20200108monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-rule-2-10-announcement-relevant-securities-in-issue-in-accordance-with-rule-2-1-abbv-20200108monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-abbvie-nyse-abbv-a-r-abbv-20200103monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-rule-2-10-announcement-relevant-securities-in-issue-in-accordance-with-rule-2-1-abbv-20191220monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-a-abbv-20191218monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-form-8-1-statement-of-stock-purchase-by-director-abbvie-issued-the-following-fo-abbv-20191216monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-rule-2-10-announcement-relevant-securities-in-issue-in-accordance-with-rule-2-1-abbv-20191211monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-scripps-research-announce-collaboration-to-develop-a-broad-range-of-new-therape-abbv-20191209monthly0.5https://www.biopharmawatch.com/news/ABBV/new-long-term-data-continues-to-demonstrate-progression-free-survival-and-overall-survival-abbv-20191208monthly0.5https://www.biopharmawatch.com/news/ABBV/more-than-seven-year-analysis-of-early-treatment-with-imbruvica-ibrutinib-monotherapy-show-abbv-20191207monthly0.5https://www.biopharmawatch.com/news/ABBV/extended-follow-up-phase-3-data-underscore-sustained-efficacy-and-safety-of-imbruvica-ibru-abbv-20191207monthly0.5https://www.biopharmawatch.com/news/ABBV/imbruvica-ibrutinib-plus-venclexta-venclyxto-venetoclax-combination-data-show-high-rates-o-abbv-20191207monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-rule-2-10-announcement-relevant-securities-in-issue-in-accordance-with-rule-2-1-abbv-20191127monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-latest-clinical-research-in-the-treatment-of-leukemias-lymphomas-and-oth-abbv-20191121monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-extension-of-expiration-date-for-exchange-offers-for-allergan-notes-abbvi-abbv-20191118monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-rule-2-10-announcement-relevant-securities-in-issue-in-accordance-with-rule-2-1-abbv-20191113monthly0.5https://www.biopharmawatch.com/news/ABBV/new-positive-data-for-rinvoq-upadacitinib-on-signs-and-symptoms-in-patients-with-ankylosin-abbv-20191112monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-supplemental-new-drug-application-to-u-s-fda-for-imbruvica-ibrutinib-in-com-abbv-20191108monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-rule-2-10-announcement-relevant-securities-in-issue-in-accordance-with-rule-2-1-abbv-20191108monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-launch-of-private-offering-of-senior-unsecured-notes-abbvie-inc-nyse-abbv-abbv-20191106monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-showcase-depth-of-immunology-portfolio-and-pipeline-at-the-2019-acr-arp-annual-m-abbv-20191104monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-third-quarter-2019-financial-results-abbvie-nyse-abbv-announced-financial-r-abbv-20191101monthly0.5https://www.biopharmawatch.com/news/ABBV/rinvoq-upadacitinib-meets-primary-and-all-ranked-secondary-endpoints-in-phase-3-study-in-p-abbv-20191031monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-rule-2-10-announcement-relevant-securities-in-issue-in-accordance-with-rule-2-1-abbv-20191030monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-launches-let-me-be-clear-to-empower-people-with-psoriasis-to-speak-up-and-seek-free-abbv-20191029monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-wolfe-research-inaugural-healthcare-conference-abbvie-nyse-abbv-a-abbv-20191024monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-collaboration-with-cystic-fibrosis-foundation-abbvie-nyse-abbv-a-research-abbv-20191024monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-chmp-positive-opinion-for-upadacitinib-rinvoq-for-the-treatment-of-adults--abbv-20191018monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-rule-2-10-announcement-relevant-securities-in-issue-in-accordance-with-rule-2-1-abbv-20191016monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-new-data-from-its-dermatology-portfolio-and-pipeline-at-the-28th-european-abbv-20191009monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-third-quarter-2019-earnings-conference-call-abbvie-nyse-abbv-a-research-bas-abbv-20191008monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-rule-2-10-announcement-relevant-securities-in-issue-in-accordance-with-rule-2-1-abbv-20191002monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-allergan-receive-second-request-from-federal-trade-commission-on-pending-transa-abbv-20190927monthly0.5https://www.biopharmawatch.com/news/ABBV/upadacitinibe-inibidor-oral-da-jak-da-abbvie-e-aprovado-pelo-fda-eua-para-o-tratamento-de--abbv-20190927monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-fda-approval-of-mavyret-glecaprevir-pibrentasvir-to-shorten-treatment-dura-abbv-20190926monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-public-voting-open-for-the-2019-abbvie-cf-scholarship-thriving-student-aw-abbv-20190925monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-new-and-updated-data-from-22-abstracts-including-two-late-breaking-abstr-abbv-20190923monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-despatch-of-option-holder-proposal-letters-in-accordance-with-rule-15-c-of-the--abbv-20190920monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-rule-2-10-announcement-relevant-securities-in-issue-in-accordance-with-rule-2-1-abbv-20190918monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-declared-abbv-20190906monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-rule-2-10-announcement-relevant-securities-in-issue-in-accordance-with-rule-2-1-abbv-20190904monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-discontinues-rovalpituzumab-tesirine-rova-t-research-and-development-program-abbvie-abbv-20190829monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-morgan-stanley-healthcare-conference-abbvie-nyse-abbv-a-research--abbv-20190827monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-rule-2-10-announcement-relevant-securities-in-issue-in-accordance-with-rule-2-1-abbv-20190821monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-fda-approval-of-rinvoq-upadacitinib-an-oral-jak-inhibitor-for-the-treatmen-abbv-20190816monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-rule-2-10-announcement-relevant-securities-in-issue-in-accordance-with-rule-2-1-abbv-20190807monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-new-drug-application-to-us-fda-for-investigational-elagolix-for-management--abbv-20190805monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-second-quarter-2019-financial-results-abbvie-nyse-abbv-announced-financial--abbv-20190726monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-rule-2-10-announcement-relevant-securities-in-issue-in-accordance-with-rule-2-1-abbv-20190724monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-enhances-early-stage-oncology-pipeline-with-acquisition-of-mavupharma-abbvie-nyse-a-abbv-20190715monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-second-quarter-2019-earnings-conference-call-abbvie-nyse-abbv-a-research-ba-abbv-20190711monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-rule-2-10-announcement-relevant-securities-in-issue-in-accordance-with-rule-2-1-abbv-20190710monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-form-8-1-statement-of-stock-purchase-by-director-abbvie-issued-the-following-fo-abbv-20190627monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-apresenta-resultados-de-va-rios-estudos-cli-nicos-com-medicamentos-em-fase-de-pesqu-abbv-20190627monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inc-rule-2-10-announcement-relevant-securities-in-issue-in-accordance-with-rule-2-1-abbv-20190626monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-acquire-allergan-in-transformative-move-for-both-companies-abbvie-inc-nyse-abbv--abbv-20190625monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-us-fda-lifts-partial-clinical-hold-on-phase-3-study-of-venetoclax-in-pati-abbv-20190624monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-declared-abbv-20190620monthly0.5https://www.biopharmawatch.com/news/ABBV/new-long-term-data-from-upadacitinib-phase-3-studies-in-rheumatoid-arthritis-including-res-abbv-20190612monthly0.5https://www.biopharmawatch.com/news/ABBV/new-two-year-data-at-the-24th-world-congress-of-dermatology-shows-skyrizi-risankizumab-mai-abbv-20190611monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-employees-to-help-underserved-communities-in-sixth-annual-week-of-possibilities-abb-abbv-20190610monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-goldman-sachs-global-healthcare-conference-abbvie-nyse-abbv-a-res-abbv-20190607monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-data-from-venetoclax-chemotherapy-free-combination-regimen-for-patients-wi-abbv-20190604monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-results-from-several-studies-and-clinical-trials-investigating-medicines-a-abbv-20190530monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-provides-update-on-depatuxizumab-mafodotin-depatux-m-an-investigational-medicine-fo-abbv-20190517monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-us-fda-approval-of-venclexta-venetoclax-as-a-chemotherapy-free-combinatio-abbv-20190515monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-resolves-humira-adalimumab-u-s-patent-litigation-with-boehringer-ingelheim-abbvie-n-abbv-20190514monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-ubs-global-healthcare-conference-abbvie-nyse-abbv-a-research-base-abbv-20190514monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-bank-of-america-merrill-lynch-healthcare-conference-abbvie-nyse-a-abbv-20190507monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-apresenta-resultados-financeiros-do-primeiro-trimestre-de-2019-a-abbvie-nyse-abbv-c-abbv-20190430monthly0.5https://www.biopharmawatch.com/news/ABBV/european-commission-approves-skyrizi-risankizumab-for-the-treatment-of-moderate-to-severe--abbv-20190430monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-new-and-updated-data-of-investigational-medicines-for-parkinson-s-diseas-abbv-20190430monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-first-quarter-2019-financial-results-abbvie-nyse-abbv-announced-financial-r-abbv-20190425monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-expands-immunology-portfolio-in-the-u-s-with-fda-approval-of-skyrizi-risankizumab-r-abbv-20190423monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-call-for-entries-for-the-abbvie-cf-scholarship-for-the-2019-2020-academic-abbv-20190417monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-first-quarter-2019-earnings-conference-call-abbvie-nyse-abbv-a-research-bas-abbv-20190403monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-first-regulatory-approval-of-skyrizi-risankizumab-for-the-treatment-of-pl-abbv-20190326monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-donates-40-million-to-rebuild-north-chicago-middle-school-abbvie-a-research-based-g-abbv-20190321monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-provides-update-on-venclexta-venclyxto-venetoclax-multiple-myeloma-program-abbvie-n-abbv-20190319monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-multiple-milestones-for-phase-3-cll14-venetoclax-study-of-fixed-duration--abbv-20190307monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-barclays-global-healthcare-conference-abbvie-nyse-abbv-a-research-abbv-20190301monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-chmp-positive-opinion-for-risankizumab-skyrizi-for-the-treatment-of-modera-abbv-20190301monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-cowen-health-care-conference-abbvie-nyse-abbv-a-research-based-gl-abbv-20190228monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-showcase-scientific-innovation-and-research-advancements-across-dermatology-port-abbv-20190225monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-voyager-therapeutics-announce-collaboration-to-develop-vectorized-antibodies-to-abbv-20190222monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-declared-abbv-20190221monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-new-drug-application-accepted-for-priority-review-by-u-s-fda-for-upadacit-abbv-20190219monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-teneobio-announce-a-strategic-transaction-to-develop-a-new-treatment-for-multip-abbv-20190211monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-u-s-fda-approval-of-imbruvica-ibrutinib-plus-obinutuzumab-gazyva-first-ch-abbv-20190128monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-full-year-and-fourth-quarter-2018-financial-results-abbvie-nyse-abbv-announ-abbv-20190125monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-provides-update-on-phase-3-study-of-ibrutinib-imbruvica-in-metastatic-pancreatic-ca-abbv-20190118monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-tizona-therapeutics-announce-strategic-collaboration-to-develop-first-in-class--abbv-20190103monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-fourth-quarter-and-full-year-2018-earnings-conference-call-abbvie-nyse-abbv-abbv-20190103monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-new-drug-application-to-u-s-fda-and-marketing-authorization-application-to--abbv-20181220monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-abbvie-nyse-abbv-a-r-abbv-20181220monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-executive-leadership-changes-abbvie-nyse-abbv-a-research-based-global-bio-abbv-20181217monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-5-billion-increase-to-stock-repurchase-program-the-board-of-directors-of--abbv-20181213monthly0.5https://www.biopharmawatch.com/news/ABBV/phase-3-trial-of-rova-t-as-second-line-therapy-for-advanced-small-cell-lung-cancer-tahoe-s-abbv-20181205monthly0.5https://www.biopharmawatch.com/news/ABBV/imbruvica-ibrutinib-combination-regimen-significantly-improved-survival-versus-the-chemoim-abbv-20181204monthly0.5https://www.biopharmawatch.com/news/ABBV/imbruvica-ibrutinib-phase-3-combination-data-with-obinutuzumab-finds-significant-improveme-abbv-20181203monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-donates-50-million-to-st-jude-children-s-research-hospital-to-expand-family-centere-abbv-20181203monthly0.5https://www.biopharmawatch.com/news/ABBV/imbruvica-ibrutinib-data-in-chronic-lymphocytic-leukemia-cll-show-up-to-seven-years-of-pro-abbv-20181202monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-new-data-from-phase-3-murano-trial-of-venclexta-venclyxto-venetoclax-in-co-abbv-20181201monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-humira-adalimumab-global-patent-license-with-pfizer-abbvie-nyse-abbv-anno-abbv-20181130monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-us-fda-accelerated-approval-for-venclexta-venetoclax-for-treatment-of-newl-abbv-20181121monthly0.5https://www.biopharmawatch.com/news/ABBV/updated-abbvie-to-highlight-breadth-of-innovative-science-and-ongoing-commitment-to-blood--abbv-20181120monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-donates-55-million-to-three-education-nonprofits-supporting-underserved-youth-in-ch-abbv-20181116monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-positive-phase-3-data-demonstrating-investigational-elagolix-reduces-heavy-abbv-20181114monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-mavyret-glecaprevir-pibrentasvir-shows-high-virologic-cure-rates-in-treatment-nai-abbv-20181113monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-evercore-isi-conference-abbvie-nyse-abbv-a-research-based-global--abbv-20181113monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-characterizes-evolving-hepatitis-c-hcv-patient-landscape-in-the-united-states-using-abbv-20181109monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-humira-adalimumab-global-patent-license-with-momenta-abbvie-nyse-abbv-ann-abbv-20181106monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-third-quarter-2018-financial-results-abbvie-nyse-abbv-announced-financial-r-abbv-20181102monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-european-commission-approval-of-venclyxto-venetoclax-plus-rituximab-for-th-abbv-20181101monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-positive-results-from-cll14-a-phase-3-trial-evaluating-a-venetoclax-combi-abbv-20181031monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-assume-full-development-and-commercial-control-of-cystic-fibrosis-research-progr-abbv-20181024monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-upadacitinib-shows-significant-improvements-in-physical-function-pain-and-quality-abbv-20181023monthly0.5https://www.biopharmawatch.com/news/ABBV/positive-phase-2b-data-for-abbvie-s-upadacitinib-show-significant-induction-of-clinical-re-abbv-20181022monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-global-resolution-of-humira-adalimumab-patent-disputes-with-fresenius-kab-abbv-20181018monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-morphic-therapeutic-announce-collaboration-targeting-fibrotic-diseases-abbvie-n-abbv-20181018monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-supplemental-new-drug-application-accepted-for-priority-review-by-u-s-fda-abbv-20181017monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reinforces-leadership-in-gastroenterology-with-new-data-showcasing-research-advance-abbv-20181016monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-global-resolution-of-humira-adalimumab-patent-disputes-with-sandoz-abbvie-abbv-20181011monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-new-data-for-upadacitinib-and-humira-adalimumab-at-the-2018-acr-arhp-ann-abbv-20181008monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-5-million-donation-to-family-reach-to-support-children-battling-cancer-an-abbv-20180921monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-positive-chmp-opinion-for-a-novel-chemotherapy-free-combination-of-venclyx-abbv-20180921monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-third-quarter-2018-earnings-conference-call-abbvie-nyse-abbv-a-research-bas-abbv-20180917monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-upadacitinib-longer-term-32-week-and-patient-reported-outcomes-data-from-p-abbv-20180913monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-patient-reported-outcomes-data-from-three-pivotal-phase-3-studies-of-risa-abbv-20180913monthly0.5https://www.biopharmawatch.com/news/ABBV/minimal-residual-disease-negativity-data-a-measure-of-undetectable-disease-added-to-vencle-abbv-20180911monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-declared-abbv-20180907monthly0.5https://www.biopharmawatch.com/news/ABBV/public-voting-is-open-for-the-2018-abbvie-cf-scholarship-thriving-student-awards-given-to--abbv-20180905monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reinforces-leadership-in-dermatology-with-new-data-showcasing-research-advancements-abbv-20180904monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-morgan-stanley-16th-annual-global-healthcare-conference-abbvie-ny-abbv-20180828monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-imbruvica-ibrutinib-plus-rituximab-approval-by-u-s-fda-as-first-chemother-abbv-20180827monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-positive-topline-results-from-phase-3-extension-study-evaluating-investig-abbv-20180822monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-100-million-donation-to-ronald-mcdonald-house-charities-to-support-hospit-abbv-20180820monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-second-quarter-2018-financial-results-abbvie-nyse-abbv-announced-financial--abbv-20180727monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-u-s-fda-approval-of-orilissa-elagolix-for-the-management-of-moderate-to-se-abbv-20180724monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-humira-adalimumab-patent-license-with-mylan-abbvie-nyse-abbv-announced-to-abbv-20180717monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-submission-of-supplemental-new-drug-application-to-us-fda-for-venetoclax--abbv-20180712monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-provides-update-on-phase-3-study-of-ibrutinib-imbruvica-in-blood-cancer-diffuse-lar-abbv-20180711monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-second-quarter-2018-earnings-conference-call-abbvie-nyse-abbv-a-research-ba-abbv-20180710monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-calico-announce-extension-of-groundbreaking-collaboration-abbvie-nyse-abbv-a-re-abbv-20180626monthly0.5https://www.biopharmawatch.com/news/ABBV/imbruvica-ibrutinib-supplemental-new-drug-application-accepted-for-review-by-u-s-fda-with--abbv-20180625monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-calibr-announce-collaboration-for-next-generation-t-cell-therapies-abbvie-nyse--abbv-20180625monthly0.5https://www.biopharmawatch.com/news/ABBV/8-000-abbvie-employees-volunteer-across-five-continents-during-fifth-annual-week-of-possib-abbv-20180619monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-new-undetectable-minimal-residual-disease-data-from-phase-3-relapsed-refr-abbv-20180615monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-declared-abbv-20180614monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-additional-outcomes-data-from-three-upadacitinib-phase-3-studies-in-rheuma-abbv-20180612monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-u-s-fda-approval-of-venclexta-venetoclax-tablets-in-combination-with-ritu-abbv-20180608monthly0.5https://www.biopharmawatch.com/news/ABBV/upadacitinib-monotherapy-meets-all-primary-and-ranked-secondary-endpoints-versus-methotrex-abbv-20180605monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-teams-up-with-hidradenitis-suppurativa-patients-around-the-world-to-raise-awareness-abbv-20180604monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-final-results-of-tender-offer-abbvie-nyse-abbv-today-announced-the-final--abbv-20180604monthly0.5https://www.biopharmawatch.com/news/ABBV/phase-2-imbruvica-ibrutinib-plus-venclexta-venetoclax-early-data-show-high-rates-of-respon-abbv-20180603monthly0.5https://www.biopharmawatch.com/news/ABBV/phase-3-imbruvica-ibrutinib-data-suggest-improved-treatment-outcomes-in-waldenstro-m-s-mac-abbv-20180601monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-new-data-from-several-investigational-studies-of-venetoclax-as-monothera-abbv-20180531monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-preliminary-results-of-tender-offer-abbvie-nyse-abbv-today-announced-the--abbv-20180530monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-updated-preliminary-results-of-tender-offer-abbvie-nyse-abbv-today-announ-abbv-20180530monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-goldman-sachs-39th-annual-global-healthcare-conference-abbvie-nys-abbv-20180529monthly0.5https://www.biopharmawatch.com/news/ABBV/imbruvica-ibrutinib-plus-gazyva-obinutuzumab-phase-3-illuminate-trial-for-first-line-thera-abbv-20180524monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-donates-100-million-to-strengthen-access-to-healthcare-housing-for-hurricane-ravage-abbv-20180522monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-dona-100-millones-de-do-lares-para-reforzar-el-acceso-a-la-atencio-n-me-dica-y-a-la-abbv-20180522monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-jefferies-2018-global-healthcare-conference-abbvie-nyse-abbv-a-re-abbv-20180522monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-show-progress-and-growth-in-oncology-research-at-the-american-society-of-clinica-abbv-20180516monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-ubs-global-healthcare-conference-abbvie-nyse-abbv-a-research-base-abbv-20180508monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-2018-bank-of-america-merrill-lynch-health-care-conference-abbvie--abbv-20180502monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-marketing-authorization-application-to-the-european-medicines-agency-for-in-abbv-20180501monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-commences-self-tender-offer-for-up-to-7-5-billion-of-its-common-stock-abbvie-nyse-a-abbv-20180501monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-rice-university-establish-k-c-nicolaou-research-accelerator-to-advance-therapie-abbv-20180430monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-new-investigational-data-for-elagolix-at-the-2018-american-college-of-obst-abbv-20180427monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-first-quarter-2018-financial-results-abbvie-nyse-abbv-announced-financial-r-abbv-20180426monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-upadacitinib-meets-primary-and-key-efficacy-endpoints-in-phase-2b-3-rheumatoid-ar-abbv-20180425monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-deutsche-bank-s-43rd-annual-health-care-conference-abbvie-nyse-ab-abbv-20180418monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-neurocrine-biosciences-announce-pdufa-target-date-of-q3-2018-for-elagolix-in-en-abbv-20180410monthly0.5https://www.biopharmawatch.com/news/ABBV/upadacitinib-meets-all-primary-and-ranked-secondary-endpoints-including-superiority-versus-abbv-20180409monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-global-resolution-of-humira-adalimumab-patent-disputes-with-samsung-bioep-abbv-20180405monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-is-now-accepting-cf-scholarship-applications-from-students-with-cystic-fibrosis-for-abbv-20180328monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-the-international-myeloma-foundation-announce-partnership-to-study-the-role-of--abbv-20180321monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-positive-topline-results-from-second-phase-3-study-evaluating-investigati-abbv-20180313monthly0.5https://www.biopharmawatch.com/news/ABBV/julianne-hough-encourages-women-to-speak-up-for-endo-during-endometriosis-awareness-month--abbv-20180305monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-barclays-global-healthcare-conference-abbvie-nyse-abbv-will-parti-abbv-20180226monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-cowen-and-company-38th-annual-health-care-conference-abbvie-nyse--abbv-20180222monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-positive-topline-results-from-phase-3-study-evaluating-investigational-el-abbv-20180221monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-voyager-therapeutics-announce-global-strategic-collaboration-to-develop-potenti-abbv-20180220monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-new-positive-late-breaking-data-from-two-phase-3-psoriasis-trials-of-risan-abbv-20180217monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-new-late-breaking-phase-2b-data-on-upadacitinib-in-atopic-dermatitis-at-th-abbv-20180217monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-new-phase-2-data-for-upadacitinib-showing-clinical-and-endoscopic-outcome-abbv-20180216monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-increases-dividend-and-announces-new-stock-repurchase-program-the-board-of-director-abbv-20180215monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-showcases-new-late-breaking-investigational-data-at-2018-american-academy-of-dermat-abbv-20180212monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-full-year-and-fourth-quarter-2017-financial-results-abbvie-nyse-abbv-announ-abbv-20180126monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-fourth-quarter-2017-earnings-conference-call-abbvie-nyse-abbv-will-announce-abbv-20180112monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-upadacitinib-granted-breakthrough-therapy-designation-from-the-u-s-food-and-drug--abbv-20180108monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-36th-annual-j-p-morgan-healthcare-conference-abbvie-nyse-abbv-wil-abbv-20171220monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-upadacitinib-shows-positive-results-as-monotherapy-in-phase-3-rheumatoid-arthriti-abbv-20171220monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-goldman-sachs-10th-annual-healthcare-ceos-unscripted-a-view-from--abbv-20171219monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-anuncia-estudo-de-fase-3-com-venetoclax-em-combinac-a-o-com-rituximabe-atinge-objet-abbv-20171214monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-phase-3-study-of-venclexta-venclyxto-venetoclax-in-combination-with-ritux-abbv-20171212monthly0.5https://www.biopharmawatch.com/news/ABBV/imbruvica-ibrutinib-data-provide-insights-into-its-potential-treatment-benefits-for-previo-abbv-20171211monthly0.5https://www.biopharmawatch.com/news/ABBV/imbruvica-ibrutinib-pooled-analysis-suggests-benefit-in-progression-free-survival-pfs-at-3-abbv-20171209monthly0.5https://www.biopharmawatch.com/news/ABBV/imbruvica-ibrutinib-plus-rituximab-phase-3-innovate-trial-in-rare-waldenstro-m-s-macroglob-abbv-20171205monthly0.5https://www.biopharmawatch.com/news/ABBV/risankizumab-meets-all-primary-endpoints-reporting-positive-results-in-fourth-pivotal-phas-abbv-20171204monthly0.5https://www.biopharmawatch.com/news/ABBV/phase-3-murano-study-of-venetoclax-chosen-as-late-breaking-abstract-at-the-2017-american-s-abbv-20171121monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-evercore-isi-2017-biopharma-catalyst-deep-dive-conference-abbvie--abbv-20171115monthly0.5https://www.biopharmawatch.com/news/ABBV/hackathon-na-campus-party-minas-gerais-premia-soluc-o-es-inovadoras-em-sau-de-em-benefi-ci-abbv-20171103monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-jefferies-2017-london-healthcare-conference-abbvie-nyse-abbv-will-abbv-20171103monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-positive-phase-3-extension-study-data-for-investigational-oral-treatment--abbv-20171101monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-third-quarter-2017-financial-results-abbvie-nyse-abbv-announced-financial-r-abbv-20171027monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-increases-quarterly-dividend-by-11-percent-the-board-of-directors-of-abbvie-inc-nys-abbv-20171027monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-u-s-fda-priority-review-for-investigational-oral-treatment-elagolix-for-th-abbv-20171027monthly0.5https://www.biopharmawatch.com/news/ABBV/risankizumab-meets-all-co-primary-and-ranked-secondary-endpoints-achieving-significantly-g-abbv-20171026monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-showcase-robust-immunology-portfolio-with-new-and-late-breaking-data-at-the-2017-abbv-20171024monthly0.5https://www.biopharmawatch.com/news/ABBV/alector-and-abbvie-announce-collaboration-to-advance-a-novel-class-of-immune-therapies-for-abbv-20171024monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-harpoon-therapeutics-announce-immuno-oncology-research-collaboration-abbvie-nys-abbv-20171018monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-2017-credit-suisse-health-care-conference-abbvie-nyse-abbv-will-p-abbv-20171018monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-demonstrates-leadership-in-hcv-with-new-mavyret-glecaprevir-pibrentasvir-data-to-be-abbv-20171011monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-turnstone-biologics-announce-global-collaboration-on-viral-immunotherapies-in-o-abbv-20171010monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-third-quarter-2017-earnings-conference-call-abbvie-nyse-abbv-will-announce--abbv-20171009monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-global-resolution-of-humira-adalimumab-patent-disputes-with-amgen-abbvie--abbv-20170928monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-approval-of-maviret-glecaprevir-pibrentasvir-for-the-treatment-of-chronic-abbv-20170927monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-bristol-myers-squibb-announce-clinical-research-collaboration-to-evaluate-a-the-abbv-20170922monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-positive-topline-results-from-phase-3-trial-evaluating-venclexta-venclyxt-abbv-20170918monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-25th-annual-cystic-fibrosis-scholarship-program-including-2017-thriving-s-abbv-20170913monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-upadacitinib-abt-494-meets-all-primary-and-ranked-secondary-endpoints-in-second-p-abbv-20170911monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-declared-abbv-20170908monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-leads-biotechnology-industry-on-dow-jones-sustainability-index-for-second-consecuti-abbv-20170907monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-upadacitinib-abt-494-meets-primary-endpoint-in-phase-2b-study-in-atopic-dermatiti-abbv-20170907monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-morgan-stanley-15th-annual-global-health-care-conference-abbvie-n-abbv-20170907monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-new-drug-application-to-u-s-fda-for-investigational-oral-treatment-elagolix-abbv-20170906monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-e-sociedades-me-dicas-lanc-am-campanha-para-incentivar-diagno-stico-dos-quase-1-5-m-abbv-20170828monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-u-s-fda-approval-of-mavyret-glecaprevir-pibrentasvir-for-the-treatment-of--abbv-20170803monthly0.5https://www.biopharmawatch.com/news/ABBV/tratamento-para-hepatite-c-da-abbvie-estara-disponi-vel-pelo-sus-o-tratamento-para-hepatit-abbv-20170728monthly0.5https://www.biopharmawatch.com/news/ABBV/european-commission-grants-abbvie-s-maviret-glecaprevir-pibrentasvir-marketing-authorizati-abbv-20170728monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-second-quarter-2017-financial-results-abbvie-nyse-abbv-announced-financial--abbv-20170728monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-chmp-positive-opinion-for-humira-adalimumab-for-the-treatment-of-pediatric-abbv-20170721monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-second-quarter-2017-earnings-conference-call-abbvie-nyse-abbv-will-announce-abbv-20170710monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-e-a-companhia-farmace-utica-com-melhor-reputac-a-o-segundo-estudo-do-reputation-ins-abbv-20170628monthly0.5https://www.biopharmawatch.com/news/ABBV/funciona-rios-da-abbvie-doam-mais-de-26-000-horas-de-trabalho-em-uma-u-nica-semana-em-bene-abbv-20170626monthly0.5https://www.biopharmawatch.com/news/ABBV/6-000-employees-in-more-than-50-countries-join-together-as-abbviegivesback-abbvie-a-global-abbv-20170626monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-chmp-positive-opinion-for-maviret-glecaprevir-pibrentasvir-for-the-treatme-abbv-20170623monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-declared-abbv-20170622monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-principia-announce-collaboration-on-oral-immunoproteasome-inhibitors-abbvie-nys-abbv-20170613monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-upadacitinib-abt-494-meets-all-primary-and-ranked-secondary-endpoints-in-phase-3--abbv-20170607monthly0.5https://www.biopharmawatch.com/news/ABBV/new-data-presented-at-asco-2017-finds-imbruvica-ibrutinib-may-offer-a-more-targeted-approa-abbv-20170605monthly0.5https://www.biopharmawatch.com/news/ABBV/long-term-imbruvica-ibrutinib-efficacy-and-safety-data-at-asco-2017-show-sustained-surviva-abbv-20170605monthly0.5https://www.biopharmawatch.com/news/ABBV/cerca-de-25-milho-es-de-brasileiros-te-m-dor-de-barriga-frequente-para-tratar-a-maioria-se-abbv-20170602monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-goldman-sachs-38th-annual-global-healthcare-conference-abbvie-nys-abbv-20170524monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-jefferies-2017-global-healthcare-conference-abbvie-nyse-abbv-will-abbv-20170519monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-latest-clinical-study-results-in-hematology-and-solid-tumor-research-at--abbv-20170517monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-pivotal-phase-3-data-on-investigational-treatment-elagolix-at-the-world-co-abbv-20170517monthly0.5https://www.biopharmawatch.com/news/ABBV/imbruvica-ibrutinib-pooled-outcomes-data-from-three-phase-3-studies-suggest-potential-clin-abbv-20170514monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-ubs-global-healthcare-conference-abbvie-nyse-abbv-will-participat-abbv-20170505monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-demonstrates-leadership-in-gastroenterology-and-hepatology-with-new-data-and-late-b-abbv-20170504monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-first-quarter-2017-financial-results-abbvie-nyse-abbv-announced-financial-r-abbv-20170427monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-deutsche-bank-42nd-annual-health-care-conference-abbvie-nyse-abbv-abbv-20170421monthly0.5https://www.biopharmawatch.com/news/ABBV/eight-weeks-of-treatment-with-abbvie-s-investigational-pan-genotypic-regimen-of-glecaprevi-abbv-20170421monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-investigational-pan-genotypic-ribavirin-free-regimen-of-glecaprevir-pibrentasvir--abbv-20170420monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-topline-results-from-two-phase-3-studies-investigating-veliparib-in-combi-abbv-20170419monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-positive-phase-2b-data-demonstrating-investigational-medicine-elagolix-si-abbv-20170407monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-first-quarter-earnings-conference-call-abbvie-nyse-abbv-will-announce-its-f-abbv-20170406monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-ibrutinib-imbruvica-supplemental-new-drug-application-for-previously-trea-abbv-20170404monthly0.5https://www.biopharmawatch.com/news/ABBV/u-s-fda-approves-addition-of-moderate-to-severe-fingernail-psoriasis-data-to-abbvie-s-humi-abbv-20170330monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-m2gen-announce-new-collaboration-for-the-oncology-research-information-exchange-abbv-20170328monthly0.5https://www.biopharmawatch.com/news/ABBV/julianne-hough-empowers-women-to-get-in-the-know-about-endometriosis-abbvie-a-global-bioph-abbv-20170323monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-granted-priority-review-in-japan-for-its-investigational-regimen-of-glecaprevir-pib-abbv-20170314monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-barclays-global-healthcare-conference-abbvie-nyse-abbv-will-parti-abbv-20170301monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-chmp-positive-opinion-for-eight-week-treatment-option-with-viekirax-ombita-abbv-20170227monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-5-billion-increase-to-stock-repurchase-program-the-board-of-directors-of--abbv-20170217monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-cowen-and-company-37th-annual-health-care-conference-abbvie-nyse--abbv-20170215monthly0.5https://www.biopharmawatch.com/news/ABBV/u-s-fda-grants-priority-review-to-abbvie-for-its-investigational-regimen-of-glecaprevir-pi-abbv-20170202monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-full-year-and-fourth-quarter-2016-financial-results-abbvie-nyse-abbv-announ-abbv-20170127monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-initiates-phase-2-clinical-trial-programs-for-abbv-8e12-an-investigational-anti-tau-abbv-20170125monthly0.5https://www.biopharmawatch.com/news/ABBV/european-medicines-agency-grants-accelerated-assessment-validates-marketing-authorization--abbv-20170124monthly0.5https://www.biopharmawatch.com/news/ABBV/u-s-fda-approves-imbruvica-ibrutinib-as-first-treatment-specifically-indicated-for-relapse-abbv-20170119monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-fourth-quarter-2016-earnings-conference-call-abbvie-nyse-abbv-will-announce-abbv-20170110monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-four-new-global-research-collaborations-focused-on-advancing-next-generat-abbv-20170109monthly0.5https://www.biopharmawatch.com/news/ABBV/eight-weeks-of-treatment-with-abbvie-s-investigational-pan-genotypic-ribavirin-free-regime-abbv-20170109monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-35th-annual-j-p-morgan-healthcare-conference-abbvie-nyse-abbv-wil-abbv-20161222monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-new-drug-application-to-u-s-fda-for-its-investigational-regimen-of-glecapre-abbv-20161219monthly0.5https://www.biopharmawatch.com/news/ABBV/late-breaking-ibrutinib-imbruvica-data-show-complete-or-partial-response-in-two-thirds-of--abbv-20161206monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-johns-hopkins-to-collaborate-on-cancer-research-abbvie-nyse-abbv-a-global-bioph-abbv-20161205monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-northwestern-university-s-lurie-cancer-center-to-collaborate-on-multi-year-canc-abbv-20161205monthly0.5https://www.biopharmawatch.com/news/ABBV/favorable-response-rates-suggest-promise-of-ibrutinib-imbruvica-combination-therapy-in-two-abbv-20161204monthly0.5https://www.biopharmawatch.com/news/ABBV/imbruvica-ibrutinib-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-5-year-analysi-abbv-20161203monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-orphan-drug-designation-for-investigational-il-23-inhibitor-risankizumab-f-abbv-20161130monthly0.5https://www.biopharmawatch.com/news/ABBV/ca-ncer-e-a-doenc-a-mais-temida-por-mais-de-dois-terc-os-da-populac-a-o-brasileira-revela--abbv-20161117monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-investigational-pan-genotypic-regimen-of-glecaprevir-pibrentasvir-g-p-shows-high--abbv-20161115monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-humira-adalimumab-receives-chmp-positive-opinion-to-treat-adolescents-with-hidrad-abbv-20161114monthly0.5https://www.biopharmawatch.com/news/ABBV/eight-weeks-of-treatment-with-abbvie-s-investigational-pan-genotypic-regimen-of-glecaprevi-abbv-20161111monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-fda-orphan-drug-designation-for-investigational-medicine-veliparib-for-the-abbv-20161104monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-showcase-growing-oncology-portfolio-and-commitment-to-treating-blood-cancers-at--abbv-20161103monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-european-fixed-income-investor-meetings-abbvie-nyse-abbv-today-announced--abbv-20161102monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-25th-annual-credit-suisse-healthcare-conference-abbvie-nyse-abbv--abbv-20161031monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-increases-quarterly-dividend-by-12-3-percent-the-board-of-directors-of-abbvie-inc-n-abbv-20161028monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-third-quarter-2016-financial-results-abbvie-nyse-abbv-announced-financial-r-abbv-20161028monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-positive-pivotal-phase-3-data-demonstrating-investigational-medicine-elag-abbv-20161019monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-third-quarter-earnings-conference-call-abbvie-nyse-abbv-will-announce-its-t-abbv-20161010monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-pivotal-phase-3-data-on-investigational-treatment-elagolix-and-research-on-abbv-20161006monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-investigational-hcv-regimen-receives-u-s-fda-breakthrough-therapy-designation-abb-abbv-20160930monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-opens-first-phase-of-its-global-manufacturing-facility-in-singapore-to-support-the--abbv-20160928monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-showcases-commitment-to-research-and-innovation-in-dermatology-at-the-25th-european-abbv-20160926monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-data-on-eight-week-treatment-of-viekirax-ombitasvir-paritaprevir-ritonavir-abbv-20160923monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-launches-2016-thriving-student-scholarship-contest-to-award-two-inspirational-stude-abbv-20160913monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-declared-abbv-20160909monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-morgan-stanley-global-healthcare-conference-abbvie-nyse-abbv-will-abbv-20160830monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-second-quarter-2016-financial-results-abbvie-nyse-abbv-announced-financial--abbv-20160729monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-initiation-of-phase-3-study-of-venetoclax-in-patients-with-relapsed-or-re-abbv-20160728monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-bristol-myers-squibb-announce-oncology-clinical-collaboration-to-evaluate-the-c-abbv-20160725monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-u-s-fda-approval-of-once-daily-viekira-xr-dasabuvir-ombitasvir-paritaprevi-abbv-20160725monthly0.5https://www.biopharmawatch.com/news/ABBV/chmp-grants-positive-opinion-for-shorter-treatment-duration-with-abbvie-s-viekirax-ombitas-abbv-20160725monthly0.5https://www.biopharmawatch.com/news/ABBV/world-renowned-soccer-player-brandi-chastain-partners-with-abbvie-to-raise-awareness-about-abbv-20160719monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-u-s-fda-rare-pediatric-disease-designation-for-investigational-abt-414-for-abbv-20160711monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-initial-data-from-pivotal-phase-3-trial-evaluating-the-efficacy-and-safety-abbv-20160707monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-second-quarter-earnings-conference-call-abbvie-nyse-abbv-will-announce-its--abbv-20160701monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-humira-adalimumab-receives-u-s-food-and-drug-administration-approval-to-treat-adu-abbv-20160630monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-fourth-breakthrough-therapy-designation-granted-by-the-u-s-food-and-drug--abbv-20160629monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-teams-up-with-leading-nonprofit-organizations-to-give-back-to-underserved-local-com-abbv-20160620monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-declared-abbv-20160616monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-scholarship-programs-recognize-exceptional-students-living-with-chronic-inflammator-abbv-20160616monthly0.5https://www.biopharmawatch.com/news/ABBV/new-abbvie-global-campaign-aims-to-provide-educational-resources-for-millions-living-with--abbv-20160607monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-builds-upon-robust-body-of-imbruvica-ibrutinib-data-with-phase-3-longer-term-studie-abbv-20160606monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-encouraging-phase-1-data-for-investigational-medicine-abt-414-as-monothera-abbv-20160605monthly0.5https://www.biopharmawatch.com/news/ABBV/results-of-phase-1a-1b-study-of-abbvie-s-investigational-medicine-rovalpituzumab-tesirine--abbv-20160605monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-highlight-its-innovative-pipeline-to-the-investment-community-at-an-r-d-day-meet-abbv-20160603monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-research-and-commitment-to-helping-people-living-with-rheumatologic-diseases-high-abbv-20160602monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-goldman-sachs-37th-annual-global-healthcare-conference-abbvie-nys-abbv-20160531monthly0.5https://www.biopharmawatch.com/news/ABBV/european-commission-approves-imbruvica-ibrutinib-for-first-line-treatment-of-patients-with-abbv-20160531monthly0.5https://www.biopharmawatch.com/news/ABBV/biogen-and-abbvie-receive-fda-approval-of-once-monthly-zinbryta-daclizumab-for-multiple-sc-abbv-20160527monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-humira-adalimumab-receives-chmp-positive-opinion-to-treat-certain-forms-of-non-in-abbv-20160527monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-jefferies-2016-healthcare-conference-abbvie-nyse-abbv-will-partic-abbv-20160526monthly0.5https://www.biopharmawatch.com/news/ABBV/il-23-inhibitor-risankizumab-induces-remission-in-phase-ii-study-in-patients-with-moderate-abbv-20160524monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-leadership-in-gastroenterology-showcased-at-digestive-disease-week-with-new-humir-abbv-20160519monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-demonstrates-progress-in-oncology-research-at-asco-2016-annual-meeting-with-multipl-abbv-20160518monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-ubs-global-health-care-conference-abbvie-nyse-abbv-will-participa-abbv-20160512monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submete-a-aprovac-a-o-da-anvisa-venetoclax-o-primeiro-inibidor-da-protei-na-bcl-2-p-abbv-20160511monthly0.5https://www.biopharmawatch.com/news/ABBV/u-s-fda-expands-imbruvica-ibrutinib-label-to-include-overall-survival-data-in-previously-u-abbv-20160509monthly0.5https://www.biopharmawatch.com/news/ABBV/european-medicines-agency-issues-positive-opinion-for-the-use-of-imbruvica-ibrutinib-as-a--abbv-20160429monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-bank-of-america-merrill-lynch-2016-global-health-care-conference--abbv-20160429monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-first-quarter-2016-financial-results-abbvie-nyse-abbv-announced-financial-r-abbv-20160428monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-expand-oncology-presence-through-acquisition-of-stemcentrx-and-its-novel-late-st-abbv-20160428monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-u-s-fda-approval-of-supplemental-new-drug-application-for-viekira-pak-ombi-abbv-20160425monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-cytomx-announce-strategic-collaboration-for-probody-drug-conjugates-abbvie-nyse-abbv-20160421monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-argenx-to-collaborate-on-argx-115-against-novel-immuno-oncology-target-abbvie-n-abbv-20160421monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-university-of-chicago-collaborate-to-advance-cancer-research-the-university-of-chic-abbv-20160420monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-deutsche-bank-41st-annual-health-care-conference-abbvie-nyse-abbv-abbv-20160420monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-new-phase-2-data-for-investigational-once-daily-ribavirin-free-pan-genotyp-abbv-20160416monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-investigational-pan-genotypic-regimen-of-abt-493-and-abt-530-shows-high-svr-rates-abbv-20160415monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-real-world-data-with-viekirax-ombitasvir-paritaprevir-ritonavir-tablets-a-abbv-20160415monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-high-svr-rates-with-viekirax-ombitasvir-paritaprevir-ritonavir-tablets-ex-abbv-20160414monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-fda-accelerated-approval-of-venclexta-venetoclax-tablets-the-first-bcl-2-i-abbv-20160412monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-first-quarter-earnings-conference-call-abbvie-nyse-abbv-will-announce-its-f-abbv-20160407monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-cf-scholarship-now-accepting-applications-from-students-with-cystic-fibrosis-for-20-abbv-20160406monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-partners-with-nutrition-expert-joy-bauer-to-launch-new-resource-for-people-with-oft-abbv-20160405monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-chmp-positive-opinion-for-humira-adalimumab-for-the-treatment-of-pediatric-abbv-20160404monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-data-on-viekirax-ombitasvir-paritaprevir-ritonavir-tablets-and-exviera-d-abbv-20160330monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-barclays-global-healthcare-conference-abbvie-nyse-abbv-will-participa-abbv-20160308monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-boehringer-ingelheim-announce-global-collaboration-on-promising-immunology-comp-abbv-20160307monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-new-dermatology-research-from-more-than-35-presentations-on-humira-adalim-abbv-20160302monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-cowen-and-company-36th-annual-health-care-conference-abbvie-nyse-abbv-abbv-20160229monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-chmp-positive-opinion-for-viekirax-ombitasvir-paritaprevir-ritonavir-table-abbv-20160226monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-ema-orphan-drug-designation-for-investigational-compound-venetoclax-for-th-abbv-20160226monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-launches-scholarship-to-support-students-living-with-rheumatologic-diseases-abbvie--abbv-20160211monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-positive-top-line-results-from-second-phase-3-study-investigating-elagoli-abbv-20160210monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-full-year-2015-and-fourth-quarter-financial-results-abbvie-nyse-abbv-today--abbv-20160129monthly0.5https://www.biopharmawatch.com/news/ABBV/venetoclax-receives-3rd-breakthrough-therapy-designation-from-the-fda-for-the-combination--abbv-20160128monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-initiates-enrollment-in-phase-3-clinical-program-for-elagolix-in-patients-with-uter-abbv-20160128monthly0.5https://www.biopharmawatch.com/news/ABBV/md-anderson-abbvie-connect-to-advance-cancer-immunotherapy-the-immunotherapy-platform-at-t-abbv-20160121monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-venetoclax-receives-breakthrough-therapy-designation-from-fda-in-combination-with-abbv-20160120monthly0.5https://www.biopharmawatch.com/news/ABBV/u-s-and-european-regulators-accept-applications-for-abbvie-s-venetoclax-the-first-potentia-abbv-20160112monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-initiates-enrollment-of-six-global-phase-3-clinical-studies-for-once-daily-pan-geno-abbv-20160111monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-the-launch-of-robust-phase-3-clinical-trial-program-evaluating-abt-494-an-abbv-20160108monthly0.5https://www.biopharmawatch.com/news/ABBV/fda-grants-priority-review-to-abbvie-for-supplemental-new-drug-application-for-viekira-pak-abbv-20160107monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-fourth-quarter-and-full-year-2015-earnings-conference-call-abbvie-nyse-abbv-abbv-20160107monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-the-34th-annual-j-p-morgan-healthcare-conference-abbvie-nyse-abbv-wil-abbv-20151216monthly0.5https://www.biopharmawatch.com/news/ABBV/imbruvica-ibrutinib-phase-3-ray-data-show-significant-reductions-in-disease-progression-ve-abbv-20151207monthly0.5https://www.biopharmawatch.com/news/ABBV/combination-ibrutinib-imbruvica-demonstrates-a-strong-response-rate-in-treatment-naive-pat-abbv-20151207monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-new-england-journal-of-medicine-online-publication-of-venetoclax-phase-1--abbv-20151206monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-phase-2-results-of-venetoclax-in-relapsed-refractory-chronic-lymphocytic-le-abbv-20151206monthly0.5https://www.biopharmawatch.com/news/ABBV/ibrutinib-imbruvica-improves-survival-in-treatment-naive-chronic-lymphocytic-leukemia-pati-abbv-20151206monthly0.5https://www.biopharmawatch.com/news/ABBV/ibrutinib-imbruvica-combination-data-show-promise-in-patients-with-relapsed-refractory-mul-abbv-20151206monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-launches-crohn-s-colitis-scholarship-to-support-students-living-with-inflammatory-b-abbv-20151204monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-fda-acceptance-of-new-drug-application-for-a-once-daily-formulation-of-vi-abbv-20151202monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-launches-good-morning-hypothyroidism-to-help-hypothyroid-patients-manage-their-life-abbv-20151130monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-high-sustained-virologic-response-rates-in-phase-2-studies-with-pan-genot-abbv-20151116monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-new-data-on-viekira-pak-ombitasvir-paritaprevir-ritonavir-tablets-dasabuv-abbv-20151114monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-imbruvica-ibrutinib-phase-iii-combination-data-to-u-s-fda-abbvie-nyse-abbv--abbv-20151113monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-commitment-to-oncology-demonstrated-at-the-57th-american-society-of-hematology-an-abbv-20151105monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-jefferies-autumn-2015-global-healthcare-conference-in-london-abbvie-n-abbv-20151105monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-leadership-and-innovation-in-immunology-showcased-at-the-american-college-of-rheu-abbv-20151103monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-credit-suisse-24th-annual-healthcare-conference-abbvie-nyse-abbv-will-abbv-20151102monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-third-quarter-2015-financial-results-abbvie-nyse-abbv-announced-financial-r-abbv-20151030monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-outlines-long-term-strategic-and-financial-objectives-company-positioned-for-strong-abbv-20151030monthly0.5https://www.biopharmawatch.com/news/ABBV/imbruvica-ibrutinib-awarded-prix-galien-2015-best-pharmaceutical-agent-abbvie-nyse-abbv-a--abbv-20151028monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-apresenta-primeiros-resultados-de-estudo-ine-dito-no-brasil-que-avalia-a-qualidade--abbv-20151028monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-updates-u-s-labels-for-viekira-pak-and-technivie-in-consultation-with-the-u-s-food--abbv-20151022monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-revela-resultados-de-estudo-que-demonstra-impacto-da-artrite-reumatoide-na-qualidad-abbv-20151007monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-third-quarter-earnings-conference-call-abbvie-nyse-abbv-will-announce-its-t-abbv-20151006monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-demonstrates-leadership-in-dermatology-with-26-abstracts-at-the-european-academy-of-abbv-20151005monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-demonstrates-commitment-to-hepatitis-c-patients-with-new-data-on-viekira-pak-ombita-abbv-20151001monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-viekirax-ombitasvir-paritaprevir-ritonavir-tablets-receives-approval-in-japan-for-abbv-20150928monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-advance-once-daily-abt-494-to-phase-3-in-rheumatoid-arthritis-by-year-end-abbvie-abbv-20150925monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-abt-494-meets-primary-endpoint-in-two-phase-2-studies-in-rheumatoid-arthritis-abb-abbv-20150925monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-plans-to-proceed-to-phase-3-evaluation-of-elagolix-in-patients-with-uteri-abbv-20150916monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-submission-of-a-supplemental-new-drug-application-for-imbruvica-ibrutinib-abbv-20150914monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-declared-abbv-20150911monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-2015-morgan-stanley-global-healthcare-conference-abbvie-nyse-abbv-wil-abbv-20150910monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-humira-adalimumab-receives-first-and-only-u-s-food-and-drug-administration-approv-abbv-20150910monthly0.5https://www.biopharmawatch.com/news/ABBV/cast-your-vote-for-the-2015-thriving-undergraduate-and-graduate-scholars-to-help-grant-two-abbv-20150909monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-second-quarter-2015-financial-results-abbvie-nyse-abbv-announced-financial--abbv-20150724monthly0.5https://www.biopharmawatch.com/news/ABBV/technivie-ombitasvir-paritaprevir-and-ritonavir-tablets-receives-fda-approval-as-the-first-abbv-20150724monthly0.5https://www.biopharmawatch.com/news/ABBV/imbruvica-ibrutinib-now-approved-to-treat-waldenstrom-s-macroglobulinemia-in-europe-today--abbv-20150710monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-apresenta-resultados-de-estudos-para-hidradenite-supurativa-doenc-a-inflamato-ria-c-abbv-20150707monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-second-quarter-earnings-conference-call-abbvie-nyse-abbv-will-announce-its--abbv-20150702monthly0.5https://www.biopharmawatch.com/news/ABBV/humira-adalimumabe-da-abbvie-e-aprovado-no-brasil-para-tratamento-de-espondiloartrite-axia-abbv-20150701monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-holkira-pak-now-reimbursed-in-ontario-common-drug-review-grants-positive-recommen-abbv-20150629monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-anuncia-resultados-de-fase-3b-de-estudo-com-pacientes-cro-nicos-com-hepatite-c-geno-abbv-20150629monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-new-phase-3b-results-in-genotype-1b-chronic-hepatitis-c-patients-with-com-abbv-20150624monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-declared-abbv-20150618monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-mobilizes-3-100-employees-for-week-of-service-projects-to-transform-schools-and-com-abbv-20150608monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-data-from-studies-of-the-company-s-oncology-pipeline-at-the-20th-europea-abbv-20150608monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-goldman-sachs-36th-annual-global-healthcare-conference-abbvie-nyse-ab-abbv-20150605monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-research-in-immunology-to-be-featured-at-the-european-league-against-rheumatism-a-abbv-20150604monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-jefferies-2015-healthcare-conference-abbvie-nyse-abbv-will-participat-abbv-20150601monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-phase-2-results-from-study-of-investigational-medicine-veliparib-in-patien-abbv-20150601monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-results-from-phase-1-studies-of-investigational-compound-venetoclax-in-pat-abbv-20150531monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-apresenta-estudos-sobre-novos-tratamentos-em-pesquisa-para-ca-ncer-no-51o-encontro--abbv-20150528monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-completes-acquisition-of-pharmacyclics-abbvie-nyse-abbv-a-global-biopharmaceutical--abbv-20150526monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-new-data-for-its-investigational-hepatitis-c-treatment-in-japanese-patient-abbv-20150526monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-offer-consideration-for-acquisition-of-pharmacyclics-abbvie-nyse-abbv-ann-abbv-20150521monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-orphan-drug-designation-for-humira-adalimumab-from-the-u-s-food-and-drug-a-abbv-20150515monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-extends-exchange-offer-to-acquire-pharmacyclics-inc-abbvie-inc-abbvie-nyse-chx-euro-abbv-20150515monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-ubs-global-healthcare-conference-abbvie-nyse-abbv-will-participate-in-abbv-20150513monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-commitment-to-gastroenterology-and-hepatology-showcased-at-digestive-disease-week-abbv-20150512monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-new-data-from-studies-of-five-oncology-pipeline-assets-in-multiple-cance-abbv-20150511monthly0.5https://www.biopharmawatch.com/news/ABBV/investigational-medicine-venetoclax-receives-breakthrough-therapy-designation-in-relapsed--abbv-20150506monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-bank-of-america-merrill-lynch-2015-health-care-conference-abbvie-nyse-abbv-20150506monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-pivotal-phase-3-data-evaluating-efficacy-and-safety-of-humira-adalimumab--abbv-20150505monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-deutsche-bank-40th-annual-health-care-conference-abbvie-nyse-abbv-wil-abbv-20150429monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-late-breaking-preliminary-phase-3b-data-with-viekirax-exviera-in-chronic-h-abbv-20150425monthly0.5https://www.biopharmawatch.com/news/ABBV/u-s-fda-grants-priority-review-to-abbvie-for-investigational-all-oral-interferon-free-ther-abbv-20150424monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-first-quarter-2015-financial-results-abbvie-nyse-abbv-announced-financial-r-abbv-20150423monthly0.5https://www.biopharmawatch.com/news/ABBV/anvisa-aprova-viekira-pak-da-abbvie-para-o-tratamento-de-pacientes-brasileiros-com-hepatit-abbv-20150423monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-extends-exchange-offer-to-acquire-pharmacyclics-inc-abbvie-inc-abbvie-nyse-chx-euro-abbv-20150417monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-first-quarter-earnings-conference-call-abbvie-nyse-abbv-will-announce-its-f-abbv-20150415monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-investigational-chronic-hepatitis-c-treatment-granted-priority-review-in-japan-ab-abbv-20150415monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-new-data-from-hepatitis-c-clinical-development-program-at-the-internatio-abbv-20150408monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-cf-scholarship-application-for-students-with-cystic-fibrosis-now-available-for-2015-abbv-20150401monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-c2n-enter-into-a-worldwide-license-agreement-for-alzheimer-s-disease-therapy-ab-abbv-20150319monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-dermatology-leadership-showcased-with-humira-adalimumab-data-at-american-academy--abbv-20150317monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-inicia-no-brasil-estudos-cli-nicos-com-novo-tratamento-para-hepatite-c-totalmente-o-abbv-20150317monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-barclays-global-health-care-conference-abbvie-nyse-abbv-will-particip-abbv-20150306monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-acquire-pharmacyclics-including-its-blockbuster-product-imbruvica-creating-an-in-abbv-20150304monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-launches-sigueelguion-com-to-educate-spanish-speaking-americans-about-hypothyroidis-abbv-20150226monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-lanza-sigueelguion-com-para-instruir-a-los-estadounidenses-de-habla-hispana-acerca--abbv-20150226monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-ongoing-research-in-neuroscience-and-oncology-will-be-featured-at-the-2015-americ-abbv-20150226monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-cowen-35th-annual-health-care-conference-abbvie-nyse-abbv-will-partic-abbv-20150225monthly0.5https://www.biopharmawatch.com/news/ABBV/results-from-abbvie-s-study-of-viekira-pak-ombitasvir-paritaprevir-ritonavir-tablets-dasab-abbv-20150223monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-increases-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-increas-abbv-20150219monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-new-drug-application-in-japan-for-its-investigational-all-oral-treatment-fo-abbv-20150211monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-fourth-quarter-and-full-year-2014-financial-results-abbvie-nyse-abbv-today--abbv-20150130monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-top-line-results-from-phase-3-study-of-all-oral-treatment-for-hepatitis-c-abbv-20150130monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-u-s-fda-approval-of-duopa-carbidopa-and-levodopa-enteral-suspension-for-t-abbv-20150116monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-fourth-quarter-and-full-year-2014-earnings-conference-call-abbvie-nyse-abbv-abbv-20150116monthly0.5https://www.biopharmawatch.com/news/ABBV/european-commission-grants-marketing-authorizations-for-abbvie-s-viekirax-ombitasvir-parit-abbv-20150116monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-u-s-fda-approval-of-duopa-carbidopa-and-levodopa-enteral-suspension-for-t-abbv-20150112monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-positive-top-line-results-from-phase-3-study-of-investigational-medicine--abbv-20150108monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-issues-strong-outlook-for-2015-abbvie-nyse-abbv-today-issued-earnings-per-share-gui-abbv-20150108monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-33rd-annual-j-p-morgan-healthcare-conference-abbvie-nyse-abbv-will-pa-abbv-20141230monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-goldman-sachs-healthcare-ceos-unscripted-conference-abbvie-nyse-abbv--abbv-20141223monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-u-s-fda-approval-of-viekira-pak-ombitasvir-paritaprevir-ritonavir-tablets--abbv-20141219monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-results-from-phase-2-study-of-investigational-compound-venetoclax-abt-199--abbv-20141207monthly0.5https://www.biopharmawatch.com/news/ABBV/chmp-grants-positive-opinions-of-abbvie-s-viekirax-ombitasvir-paritaprevir-ritonavir-exvie-abbv-20141121monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-data-on-investigational-oncology-compounds-at-the-56th-american-society--abbv-20141117monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-jefferies-2014-global-healthcare-conference-abbvie-nyse-abbv-will-par-abbv-20141117monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-results-from-study-of-abt-414-in-patients-with-glioblastoma-multiforme-at--abbv-20141114monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-leadership-in-immunology-featured-at-2014-american-college-of-rheumatology-annual-abbv-20141113monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-results-from-studies-in-chronic-hepatitis-c-patients-with-hiv-1-co-infec-abbv-20141111monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-results-from-phase-2-pearl-i-study-in-genotype-4-chronic-hepatitis-c-pat-abbv-20141111monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-credit-suisse-2014-healthcare-conference-abbvie-nyse-abbv-will-partic-abbv-20141105monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-third-quarter-2014-financial-results-abbvie-nyse-abbv-today-announced-finan-abbv-20141031monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-named-a-top-employer-in-science-magazine-s-annual-survey-for-second-consecutive-yea-abbv-20141023monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-new-5-billion-stock-repurchase-program-and-increases-dividend-the-board-o-abbv-20141020monthly0.5https://www.biopharmawatch.com/news/ABBV/announcement-of-termination-of-proposed-abbvie-and-shire-transaction-abbvie-inc-abbvie-and-abbv-20141020monthly0.5https://www.biopharmawatch.com/news/ABBV/announcement-of-notice-to-shire-of-abbvie-board-intention-to-reconsider-recommendation-abb-abbv-20141014monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-late-breaking-results-from-phase-3-trial-of-humira-adalimumab-in-hidraden-abbv-20141013monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-humira-adalimumab-receives-u-s-fda-approval-for-extension-of-polyarticular-juveni-abbv-20141006monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-demonstrates-commitment-to-continued-research-in-hepatitis-c-with-investigational-d-abbv-20141001monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-results-from-multiple-studies-of-investigational-compound-veliparib-in-pat-abbv-20140927monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-humira-adalimumab-receives-u-s-fda-approval-for-the-treatment-of-pediatric-patien-abbv-20140925monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-clinical-study-data-on-potential-new-oncology-medicines-at-the-2014-euro-abbv-20140922monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-declared-abbv-20140919monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-pivotal-phase-3-data-evaluating-efficacy-of-humira-adalimumab-in-patients-abbv-20140911monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-morgan-stanley-global-healthcare-conference-abbvie-nyse-abbv-will-par-abbv-20140905monthly0.5https://www.biopharmawatch.com/news/ABBV/infinity-and-abbvie-announce-global-strategic-collaboration-to-develop-and-commercialize-d-abbv-20140903monthly0.5https://www.biopharmawatch.com/news/ABBV/revised-gaap-earnings-guidance-for-abbvie-inc-for-the-financial-year-ending-december-31-20-abbv-20140903monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-calico-announce-a-novel-collaboration-to-accelerate-the-discovery-development-a-abbv-20140903monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-cystic-fibrosis-scholarship-program-awards-40-student-scholars-with-annual-academic-abbv-20140818monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-ema-and-fda-orphan-drug-designation-for-investigational-compound-abt-414-i-abbv-20140804monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-cystic-fibrosis-research-inc-cfri-team-up-to-raise-awareness-of-the-nutritional-abbv-20140801monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-second-quarter-2014-financial-results-not-for-release-publication-or-distri-abbv-20140725monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-second-quarter-earnings-conference-call-not-for-release-publication-or-dist-abbv-20140723monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-inaugural-week-of-possibilities-volunteer-program-to-support-six-schools--abbv-20140716monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-initiation-of-pivotal-phase-iii-study-of-veliparib-abt-888-in-patients-wi-abbv-20140626monthly0.5https://www.biopharmawatch.com/news/ABBV/not-for-release-publication-or-distribution-in-whole-or-in-part-directly-or-indirectly-in--abbv-20140625monthly0.5https://www.biopharmawatch.com/news/ABBV/not-for-release-publication-or-distribution-in-whole-or-in-part-directly-or-indirectly-in--abbv-20140623monthly0.5https://www.biopharmawatch.com/news/ABBV/not-for-release-publication-or-distribution-in-whole-or-in-part-directly-or-indirectly-in--abbv-20140619monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-declared-abbv-20140619monthly0.5https://www.biopharmawatch.com/news/ABBV/european-medicines-agency-validates-marketing-authorization-applications-for-abbvie-s-inve-abbv-20140617monthly0.5https://www.biopharmawatch.com/news/ABBV/u-s-fda-grants-priority-review-to-abbvie-for-investigational-all-oral-interferon-free-ther-abbv-20140613monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-results-from-large-global-study-of-patient-attitudes-and-adherence-across--abbv-20140611monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-goldman-sachs-35th-annual-global-healthcare-conference-abbvie-nyse-ab-abbv-20140610monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-jefferies-2014-global-healthcare-conference-abbvie-nyse-abbv-will-par-abbv-20140603monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-new-results-from-studies-of-investigational-oncology-compound-abt-199-gdc--abbv-20140531monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-results-from-study-of-investigational-compound-in-patients-with-glioblasto-abbv-20140530monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-2014-ubs-global-healthcare-conference-abbvie-nyse-abbv-will-participa-abbv-20140520monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-receives-orphan-drug-designation-for-humira-adalimumab-from-the-u-s-food-and-drug-a-abbv-20140520monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-michael-severino-m-d-to-lead-r-d-organization-and-drive-continued-pipelin-abbv-20140515monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-bank-of-america-merrill-lynch-2014-health-care-conference-abbvie-nyse-abbv-20140513monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-for-eu-marketing-authorization-its-investigational-all-oral-interferon-free-abbv-20140508monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-first-quarter-2014-financial-results-abbvie-nyse-abbv-announced-financial-r-abbv-20140425monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-data-on-investigational-compounds-at-the-2014-american-society-of-clinic-abbv-20140423monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-submits-new-drug-application-to-u-s-fda-for-its-investigational-all-oral-interferon-abbv-20140422monthly0.5https://www.biopharmawatch.com/news/ABBV/application-now-open-for-students-with-cystic-fibrosis-for-the-2014-abbvie-cf-scholarship--abbv-20140416monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-initiation-of-pivotal-phase-iii-study-of-veliparib-abt-888-for-patients-w-abbv-20140415monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-late-breaking-results-from-turquoise-ii-study-in-chronic-hepatitis-c-pat-abbv-20140412monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-detailed-phase-iii-results-from-sapphire-i-and-sapphire-ii-studies-in-ch-abbv-20140411monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-detailed-results-from-phase-iii-studies-in-patients-with-chronic-hepatit-abbv-20140324monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-initiates-new-clinical-trial-to-evaluate-humira-adalimumab-for-the-treatment-of-fin-abbv-20140320monthly0.5https://www.biopharmawatch.com/news/ABBV/largest-global-survey-of-people-with-rheumatoid-arthritis-reveals-need-for-increased-educa-abbv-20140318monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-supports-educational-initiatives-in-latin-america-to-impact-standards-of-care-and-r-abbv-20140312monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-late-breaker-pearl-iii-study-in-patients-with-chronic-hepatitis-c-at-the-abbv-20140303monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-barclays-global-healthcare-conference-2014-abbvie-nyse-abbv-will-part-abbv-20140226monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-increases-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-increas-abbv-20140220monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-new-art-gallery-designed-to-provide-perspectives-on-the-impact-of-chronic-abbv-20140220monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-cowen-34th-annual-health-care-conference-abbvie-nyse-abbv-will-partic-abbv-20140219monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-expands-manufacturing-presence-with-us-320-million-investment-in-singapore-abbvie-i-abbv-20140205monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-fourth-quarter-and-full-year-2013-financial-results-abbvie-nyse-abbv-today--abbv-20140131monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-completes-largest-phase-iii-program-of-an-all-oral-interferon-free-therapy-for-the--abbv-20140131monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-initiation-of-pivotal-phase-3-study-of-veliparib-abt-888-for-patients-wit-abbv-20140115monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-fourth-quarter-and-full-year-2013-earnings-conference-call-abbvie-nyse-abbv-abbv-20140113monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-32nd-annual-j-p-morgan-healthcare-conference-abbvie-nyse-abbv-will-pa-abbv-20131220monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-releases-first-of-six-phase-iii-results-from-investigational-all-oral-interferon-fr-abbv-20131118monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-credit-suisse-2013-healthcare-conference-abbvie-nyse-abbv-will-partic-abbv-20131107monthly0.5https://www.biopharmawatch.com/news/ABBV/new-survey-reveals-more-than-half-of-americans-are-living-with-gastrointestinal-symptoms-a-abbv-20131106monthly0.5https://www.biopharmawatch.com/news/ABBV/canadian-psoriasis-network-launches-on-world-psoriasis-day-national-organization-will-advo-abbv-20131028monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-third-quarter-2013-financial-results-reports-third-quarter-adjusted-eps-of--abbv-20131025monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-named-a-science-top-employer-the-journal-science-named-abbvie-as-one-of-its-2013-to-abbv-20131024monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-third-quarter-earnings-conference-call-abbvie-nyse-abbv-will-announce-its-t-abbv-20131004monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-phase-ii-data-evaluating-the-efficacy-of-humira-adalimumab-in-patients-wit-abbv-20131003monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-galapagos-to-co-develop-cystic-fibrosis-therapies-galapagos-nv-euronext-glpg-an-abbv-20130924monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-quarterly-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-declared-abbv-20130919monthly0.5https://www.biopharmawatch.com/news/ABBV/new-treatment-option-available-for-canadian-children-living-with-severely-active-pediatric-abbv-20130827monthly0.5https://www.biopharmawatch.com/news/ABBV/vote-to-help-award-a-21-000-abbvie-cf-scholarship-to-two-inspirational-students-with-cysti-abbv-20130819monthly0.5https://www.biopharmawatch.com/news/ABBV/stacy-london-launches-uncover-your-confidence-campaign-to-empower-people-living-with-psori-abbv-20130708monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-second-quarter-earnings-conference-call-abbvie-nyse-abbv-will-announce-its--abbv-20130708monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-preliminary-results-from-phase-i-study-of-investigational-oncology-compoun-abbv-20130617monthly0.5https://www.biopharmawatch.com/news/ABBV/largest-global-survey-of-rheumatoid-arthritis-patients-shows-opportunity-for-increased-col-abbv-20130611monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-participate-in-34th-annual-goldman-sachs-global-healthcare-conference-abbvie-nys-abbv-20130605monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-presents-results-from-phase-i-study-of-investigational-oncology-compound-abt-199-at-abbv-20130603monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-announces-market-availability-of-new-creon-pancrelipase-36-000-lipase-unit-capsules-abbv-20130530monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-investigational-hcv-regimen-receives-breakthrough-therapy-designation-from-the-u--abbv-20130530monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-participate-in-2013-jeffries-global-healthcare-conference-abbvie-nyse-abbv-will--abbv-20130528monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-initiates-phase-3-study-of-its-investigational-compound-atrasentan-on-renal-outcome-abbv-20130520monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-galapagos-extend-glpg0634-collaboration-to-include-crohn-s-disease-galapagos-nv-abbv-20130517monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-data-on-investigational-anti-cancer-compounds-at-american-society-of-cli-abbv-20130515monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-and-alvine-to-collaborate-on-investigational-oral-therapy-for-celiac-disease-abbvie-abbv-20130514monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-bank-of-america-merrill-lynch-2013-health-care-conference-abbvie-nyse-abbv-20130507monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-s-investigational-hcv-regimen-receives-breakthrough-therapy-designation-from-the-u--abbv-20130506monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-cf-scholarship-application-now-available-for-exceptional-undergraduate-and-graduate-abbv-20130501monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-reports-first-quarter-2013-financial-results-abbvie-nyse-abbv-today-announced-finan-abbv-20130426monthly0.5https://www.biopharmawatch.com/news/ABBV/new-data-from-abbvie-s-phase-iib-aviator-trial-demonstrate-high-sustained-viral-response-r-abbv-20130423monthly0.5https://www.biopharmawatch.com/news/ABBV/sofia-vergara-encourages-individuals-with-hypothyroidism-to-follow-the-script-nyse-abbv-em-abbv-20130417monthly0.5https://www.biopharmawatch.com/news/ABBV/sofi-a-vergara-alienta-a-las-personas-con-hipotiroidismo-a-seguir-el-guio-n-nyse-abbv-la-a-abbv-20130417monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-host-first-quarter-earnings-conference-call-abbvie-nyse-abbv-will-announce-its-f-abbv-20130408monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-barclays-global-health-care-conference-abbvie-nyse-abbv-will-present--abbv-20130227monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-to-present-at-cowen-and-company-33rd-annual-health-care-conference-abbvie-nyse-abbv-abbv-20130220monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-issues-inaugural-full-year-outlook-for-2013-abbvie-today-confirmed-it-delivered-str-abbv-20130130monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-named-to-s-p-500-dividend-aristocrat-index-abbvie-nyse-abbv-a-global-biopharmaceuti-abbv-20130121monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-declares-inaugural-dividend-the-board-of-directors-of-abbvie-inc-nyse-abbv-a-global-abbv-20130104monthly0.5https://www.biopharmawatch.com/news/ABBV/abbvie-celebrates-launch-as-new-biopharmaceutical-company-with-employees-patients-abbvie-n-abbv-20130102monthly0.5https://www.biopharmawatch.com/news/TLX/telix-manufacturing-solutions-belgium-delivers-first-gmp-grade-commercial-doses-telix-phar-tlx-20250625monthly0.5https://www.biopharmawatch.com/news/TLX/telix-s-illuccix-psma-pet-imaging-agent-approved-in-germany-telix-pharmaceuticals-limited--tlx-20250605monthly0.5https://www.biopharmawatch.com/news/TLX/telix-s-illuccix-psma-pet-imaging-agent-approved-in-france-telix-pharmaceuticals-limited-a-tlx-20250428monthly0.5https://www.biopharmawatch.com/news/TLX/ipax-linz-study-reports-promising-efficacy-for-tlx101-glioma-therapy-candidate-telix-pharm-tlx-20250415monthly0.5https://www.biopharmawatch.com/news/TLX/illuccix-psma-pet-beeldvormingsagens-voor-prostaatkanker-goedgekeurd-in-nederland-telix-ph-tlx-20250319monthly0.5https://www.biopharmawatch.com/news/TLX/illuccix-approved-for-prostate-cancer-imaging-in-brazil-first-marketing-authorization-in-l-tlx-20250317monthly0.5https://www.biopharmawatch.com/news/TLX/telix-adds-lead-212-isotope-production-capability-telix-pharmaceuticals-limited-asx-tlx-na-tlx-20250312monthly0.5https://www.biopharmawatch.com/news/TLX/telix-2024-full-year-results-record-financial-performance-and-investment-in-future-growth--tlx-20250220monthly0.5https://www.biopharmawatch.com/news/TLX/illuccix-approved-in-the-united-kingdom-telix-pharmaceuticals-limited-asx-tlx-nasdaq-tlx-t-tlx-20250212monthly0.5https://www.biopharmawatch.com/news/TLX/illuccix-receives-european-approval-telix-pharmaceuticals-limited-asx-tlx-nasdaq-tlx-telix-tlx-20250116monthly0.5https://www.biopharmawatch.com/news/TLX/scintimun-commercialization-partnership-with-curium-pharma-telix-pharmaceuticals-limited-a-tlx-20250113monthly0.5https://www.biopharmawatch.com/news/TLX/telix-to-acquire-next-generation-therapeutic-assets-and-innovative-biologics-technology-pl-tlx-20250112monthly0.5https://www.biopharmawatch.com/news/TLX/noble-registry-update-tlx599-cdx-psma-spect-imaging-of-prostate-cancer-published-in-ejnmmi-tlx-20241230monthly0.5https://www.biopharmawatch.com/news/TLX/telix-manufacturing-solutions-brussels-south-update-cyclotron-installation-complete-telix--tlx-20241219monthly0.5https://www.biopharmawatch.com/news/TLX/telix-to-add-fap-targeting-candidates-to-theranostic-pipeline-telix-pharmaceuticals-limite-tlx-20241118monthly0.5https://www.biopharmawatch.com/news/TLX/telix-partners-with-subtle-medical-on-ai-enabled-subtlepet-software-for-faster-pet-imaging-tlx-20241030monthly0.5https://www.biopharmawatch.com/news/TLX/telix-spins-off-rhine-pharma-to-expand-global-access-to-radiopharmaceuticals-telix-pharmac-tlx-20241022monthly0.5https://www.biopharmawatch.com/news/TLX/telix-featured-in-13-abstracts-at-the-annual-congress-of-the-european-association-of-nucle-tlx-20241016monthly0.5https://www.biopharmawatch.com/news/TLX/highly-accurate-telix-s-phase-iii-zircon-trial-for-kidney-cancer-imaging-published-in-the--tlx-20240910monthly0.5https://www.biopharmawatch.com/news/TLX/ipax-1-study-of-tlx101-investigational-glioblastoma-therapy-published-in-neuro-oncology-ad-tlx-20240903monthly0.5https://www.biopharmawatch.com/news/TLX/telix-submits-nda-for-tlx101-cdx-pixclara-brain-cancer-imaging-agent-telix-pharmaceuticals-tlx-20240827monthly0.5https://www.biopharmawatch.com/news/TLX/telix-announces-reorganisation-to-deliver-on-strategic-priorities-telix-pharmaceuticals-li-tlx-20240826monthly0.5https://www.biopharmawatch.com/news/TLX/telix-successfully-prices-a-650-million-convertible-bonds-telix-pharmaceuticals-limited-as-tlx-20240723monthly0.5https://www.biopharmawatch.com/news/TLX/telix-announces-a-600-million-convertible-bonds-offering-telix-pharmaceuticals-limited-asx-tlx-20240723monthly0.5https://www.biopharmawatch.com/news/TLX/telix-completes-tlx250-cdx-zircaix-bla-submission-for-kidney-cancer-imaging-telix-pharmace-tlx-20240602monthly0.5https://www.biopharmawatch.com/news/TLX/telix-announces-positive-rpfs-data-from-prostact-select-trial-of-tlx591-radc-therapy-candi-tlx-20240530monthly0.5https://www.biopharmawatch.com/news/TLX/telix-completes-proof-of-concept-study-of-tlx592-targeted-alpha-therapy-in-prostate-cancer-tlx-20240520monthly0.5https://www.biopharmawatch.com/news/TLX/first-patient-dosed-in-italian-named-patient-early-access-program-for-tlx250-cdx-telix-s-k-tlx-20240325monthly0.5https://www.biopharmawatch.com/news/TLX/qdose-platform-partnership-for-personalised-dosimetry-in-radiopharmaceutical-therapy-telix-tlx-20240318monthly0.5https://www.biopharmawatch.com/news/TLX/appointment-of-dr-darren-patti-to-group-chief-operating-officer-telix-pharmaceuticals-limi-tlx-20240311monthly0.5https://www.biopharmawatch.com/news/TLX/telix-to-acquire-artms-inc-and-its-advanced-isotope-production-platform-telix-pharmaceutic-tlx-20240304monthly0.5https://www.biopharmawatch.com/news/TLX/telix-expands-u-s-development-and-manufacturing-infrastructure-with-acquisition-of-isother-tlx-20240226monthly0.5https://www.biopharmawatch.com/news/TLX/telix-2023-full-year-results-inaugural-profit-achieved-strong-revenue-growth-underpins-inv-tlx-20240222monthly0.5https://www.biopharmawatch.com/news/TLX/telix-submits-biologics-license-application-bla-for-tlx250-cdx-zircaix-for-imaging-of-kidn-tlx-20231218monthly0.5https://www.biopharmawatch.com/news/TLX/first-patient-dosed-in-u-s-expanded-access-program-for-tlx250-cdx-telix-s-breakthrough-kid-tlx-20231211monthly0.5https://www.biopharmawatch.com/news/TLX/positive-topline-results-from-phase-ii-opalescence-study-of-tlx250-cdx-in-triple-negative--tlx-20231206monthly0.5https://www.biopharmawatch.com/news/TLX/first-patient-dosed-in-european-named-patient-early-access-program-for-tlx250-cdx-telix-s--tlx-20231204monthly0.5https://www.biopharmawatch.com/news/TLX/phase-ii-opalescence-study-of-tlx250-cdx-in-triple-negative-breast-cancer-to-be-presented--tlx-20231129monthly0.5https://www.biopharmawatch.com/news/TLX/telix-announces-proposed-acquisition-of-qsam-biosciences-and-its-lead-therapy-candidate-cy-tlx-20231113monthly0.5https://www.biopharmawatch.com/news/TLX/telix-and-mauna-kea-technologies-to-expand-collaboration-in-urologic-oncology-surgery-teli-tlx-20231113monthly0.5https://www.biopharmawatch.com/news/TLX/first-patient-dosed-in-phase-iii-prostact-global-study-of-antibody-based-prostate-cancer-t-tlx-20231112monthly0.5https://www.biopharmawatch.com/news/TLX/telix-to-present-at-jefferies-london-healthcare-conference-2023-telix-pharmaceuticals-limi-tlx-20231108monthly0.5https://www.biopharmawatch.com/news/TLX/telix-and-wiik-pharma-sign-distribution-agreement-for-illuccix-in-the-nordic-region-telix--tlx-20231108monthly0.5https://www.biopharmawatch.com/news/TLX/prostact-select-study-of-tlx591-interim-readout-positive-results-confirm-safety-and-tolera-tlx-20231018monthly0.5https://www.biopharmawatch.com/news/TLX/telix-reports-fourth-consecutive-quarter-of-positive-operating-cash-flow-telix-pharmaceuti-tlx-20231018monthly0.5https://www.biopharmawatch.com/news/TLX/hrh-princess-astrid-of-belgium-visits-telix-s-new-european-manufacturing-facility-in-bruss-tlx-20230927monthly0.5https://www.biopharmawatch.com/news/TLX/telix-to-showcase-new-zircon-phase-iii-kidney-cancer-imaging-data-and-theranostic-pipeline-tlx-20230906monthly0.5https://www.biopharmawatch.com/news/TLX/telix-2023-half-year-results-revenue-and-earnings-growth-marks-transition-to-a-sustainable-tlx-20230823monthly0.5https://www.biopharmawatch.com/news/TLX/first-patient-dosed-in-pivotal-phase-iii-study-of-tlx591-cdx-illuccix-for-prostate-cancer--tlx-20230810monthly0.5https://www.biopharmawatch.com/news/TLX/first-patient-dosed-in-ipax-2-study-of-tlx101-brain-cancer-therapy-candidate-in-patients-w-tlx-20230807monthly0.5https://www.biopharmawatch.com/news/TLX/telix-reports-continued-double-digit-revenue-growth-and-positive-operating-cash-flow-telix-tlx-20230719monthly0.5https://www.biopharmawatch.com/news/TLX/first-patient-dosed-in-starstruck-study-of-tlx250-targeted-radiation-therapy-in-combinatio-tlx-20230718monthly0.5https://www.biopharmawatch.com/news/TLX/new-zircon-phase-iii-data-presented-at-snmmi-potential-utility-of-tlx250-cdx-in-staging-an-tlx-20230626monthly0.5https://www.biopharmawatch.com/news/TLX/telix-to-showcase-zircon-phase-iii-kidney-cancer-imaging-data-and-theranostic-pipeline-dev-tlx-20230622monthly0.5https://www.biopharmawatch.com/news/TLX/telix-to-expand-late-stage-urologic-pipeline-with-acquisition-of-lightpoint-medical-telix--tlx-20230621monthly0.5https://www.biopharmawatch.com/news/TLX/telix-urology-innovation-showcase-to-be-held-at-the-yale-club-new-york-city-telix-pharmace-tlx-20230620monthly0.5https://www.biopharmawatch.com/news/TLX/first-patient-dosed-in-phase-ii-starburst-study-of-tlx250-cdx-exploring-indication-expansi-tlx-20230618monthly0.5https://www.biopharmawatch.com/news/TLX/telix-briefing-innovation-in-urology-to-feature-key-opinion-leaders-in-prostate-and-kidney-tlx-20230615monthly0.5https://www.biopharmawatch.com/news/TLX/telix-opens-european-radiopharmaceutical-production-facility-telix-pharmaceuticals-limited-tlx-20230608monthly0.5https://www.biopharmawatch.com/news/TLX/telix-to-present-at-jefferies-healthcare-conference-telix-pharmaceuticals-limited-asx-tlx--tlx-20230605monthly0.5https://www.biopharmawatch.com/news/TLX/telix-to-host-briefing-with-u-s-leadership-team-and-key-opinion-leaders-to-highlight-innov-tlx-20230525monthly0.5https://www.biopharmawatch.com/news/TLX/telix-to-supply-bayer-with-illuccix-for-global-phase-iii-prostate-cancer-study-telix-pharm-tlx-20230507monthly0.5https://www.biopharmawatch.com/news/TLX/first-patients-in-canada-imaged-with-illuccix-now-commercially-available-nationwide-telix--tlx-20230501monthly0.5https://www.biopharmawatch.com/news/TLX/zircon-phase-iii-kidney-cancer-imaging-study-presented-at-aua-new-data-confirms-efficacy-i-tlx-20230430monthly0.5https://www.biopharmawatch.com/news/TLX/telix-accelerates-artificial-intelligence-ai-development-program-with-acquisition-of-dedic-tlx-20230426monthly0.5https://www.biopharmawatch.com/news/TLX/telix-reports-q1-2023-financial-results-delivers-first-100m-revenue-quarter-telix-pharmace-tlx-20230417monthly0.5https://www.biopharmawatch.com/news/TLX/olaratumab-antibody-licensed-from-lilly-demonstrates-proof-of-concept-as-a-theranostic-rad-tlx-20230416monthly0.5https://www.biopharmawatch.com/news/TLX/fda-approves-expanded-indication-for-telix-s-illuccix-to-include-patient-selection-for-psm-tlx-20230316monthly0.5https://www.biopharmawatch.com/news/TLX/telix-s-zircon-phase-iii-kidney-cancer-imaging-study-presented-in-game-changing-session-at-tlx-20230313monthly0.5https://www.biopharmawatch.com/news/TLX/telix-to-showcase-additional-zircon-phase-iii-data-in-kidney-cancer-imaging-and-theranosti-tlx-20230308monthly0.5https://www.biopharmawatch.com/news/TLX/telix-2022-full-year-results-revenue-up-20x-in-first-year-of-commercial-sales-underpins-tr-tlx-20230227monthly0.5https://www.biopharmawatch.com/news/TLX/detailed-results-from-telix-s-zircon-phase-iii-kidney-cancer-imaging-study-presented-at-as-tlx-20230219monthly0.5https://www.biopharmawatch.com/news/TLX/telix-collaboration-on-next-generation-urologic-oncology-theranostic-published-in-journal--tlx-20230214monthly0.5https://www.biopharmawatch.com/news/TLX/telix-reports-fourth-quarter-2022-financial-results-18-january-2023-telix-pharmaceuticals--tlx-20230117monthly0.5https://www.biopharmawatch.com/news/TLX/presentation-to-j-p-morgan-healthcare-conference-and-q4-2022-illuccix-revenue-update-telix-tlx-20230108monthly0.5https://www.biopharmawatch.com/news/TLX/zircon-phase-iii-renal-cancer-study-to-be-presented-at-asco-gu-along-with-theranostic-pipe-tlx-20221221monthly0.5https://www.biopharmawatch.com/news/TLX/telix-announces-executive-leadership-appointments-telix-pharmaceuticals-limited-asx-tlx-te-tlx-20221204monthly0.5https://www.biopharmawatch.com/news/TLX/illuccix-available-on-high-activity-gallium-generator-technology-to-meet-high-demand-telix-tlx-20221122monthly0.5https://www.biopharmawatch.com/news/TLX/first-patient-dosed-in-phase-ii-ipax-linz-study-of-tlx101-for-glioblastoma-therapy-telix-p-tlx-20221121monthly0.5https://www.biopharmawatch.com/news/TLX/telix-acquires-optimal-tracers-telix-pharmaceuticals-limited-asx-tlx-telix-the-company-tod-tlx-20221113monthly0.5https://www.biopharmawatch.com/news/TLX/telix-to-present-at-jefferies-london-healthcare-conference-2022-telix-pharmaceuticals-limi-tlx-20221111monthly0.5https://www.biopharmawatch.com/news/TLX/telix-announces-positive-topline-results-of-zircon-phase-iii-kidney-cancer-imaging-study-s-tlx-20221106monthly0.5https://www.biopharmawatch.com/news/TLX/telix-reports-third-quarter-2022-financial-results-telix-pharmaceuticals-limited-asx-tlx-t-tlx-20221019monthly0.5https://www.biopharmawatch.com/news/TLX/tlx250-cdx-indication-expansion-preliminary-data-presented-at-eanm-opalescence-phase-ii-fe-tlx-20221017monthly0.5https://www.biopharmawatch.com/news/TLX/telix-partnership-expands-ge-healthcare-immuno-diagnostics-offering-to-the-global-clinical-tlx-20221017monthly0.5https://www.biopharmawatch.com/news/TLX/chinese-nmpa-approves-pivotal-phase-iii-study-of-tlx591-cdx-for-prostate-cancer-imaging-te-tlx-20221016monthly0.5https://www.biopharmawatch.com/news/TLX/health-canada-approves-illuccix-for-prostate-cancer-imaging-telix-pharmaceuticals-limited--tlx-20221013monthly0.5https://www.biopharmawatch.com/news/TLX/eanm-presentations-to-showcase-new-data-and-developments-in-telix-s-theranostics-pipeline--tlx-20221010monthly0.5https://www.biopharmawatch.com/news/TLX/chinese-nmpa-approves-study-of-telix-kidney-cancer-imaging-candidate-telix-pharmaceuticals-tlx-20220927monthly0.5https://www.biopharmawatch.com/news/TLX/first-patient-enrolled-in-prostact-target-study-telix-pharmaceuticals-limited-asx-tlx-teli-tlx-20220926monthly0.5https://www.biopharmawatch.com/news/TLX/final-ipax-1-study-data-confirms-safety-and-tolerability-profile-for-tlx101-preliminary-ef-tlx-20220920monthly0.5https://www.biopharmawatch.com/news/TLX/telix-apac-report-regulatory-progress-for-prostate-and-kidney-cancer-imaging-telix-pharmac-tlx-20220801monthly0.5https://www.biopharmawatch.com/news/TLX/bamf-health-and-telix-complete-first-total-body-pet-scans-with-illuccix-for-prostate-cance-tlx-20220727monthly0.5https://www.biopharmawatch.com/news/TLX/telix-reports-second-quarter-2022-financial-results-telix-pharmaceuticals-limited-asx-tlx--tlx-20220720monthly0.5https://www.biopharmawatch.com/news/TLX/zircon-phase-iii-kidney-cancer-imaging-study-completes-enrolment-telix-pharmaceuticals-lim-tlx-20220710monthly0.5https://www.biopharmawatch.com/news/TLX/kevin-richardson-appointed-as-ceo-telix-americas-telix-pharmaceuticals-limited-asx-tlx-tel-tlx-20220710monthly0.5https://www.biopharmawatch.com/news/TLX/telix-and-invicro-advance-ai-partnership-telix-pharmaceuticals-limited-asx-tlx-telix-the-c-tlx-20220614monthly0.5https://www.biopharmawatch.com/news/TLX/jubilant-radiopharma-joins-illuccix-pharmacy-partner-network-telix-pharmaceuticals-limited-tlx-20220613monthly0.5https://www.biopharmawatch.com/news/TLX/telix-and-reflexion-expand-partnership-for-prostate-cancer-treatment-telix-pharmaceuticals-tlx-20220610monthly0.5https://www.biopharmawatch.com/news/TLX/telix-to-present-at-jefferies-healthcare-conference-telix-pharmaceuticals-limited-asx-tlx--tlx-20220607monthly0.5https://www.biopharmawatch.com/news/TLX/telix-showcasing-innovation-in-theranostics-at-snmmi-telix-pharmaceuticals-limited-asx-tlx-tlx-20220606monthly0.5https://www.biopharmawatch.com/news/TLX/illuccix-granted-transitional-pass-through-payment-status-telix-pharmaceuticals-limited-as-tlx-20220531monthly0.5https://www.biopharmawatch.com/news/TLX/first-patient-dosed-in-phase-ii-renal-cancer-theranostics-study-telix-pharmaceuticals-limi-tlx-20220504monthly0.5https://www.biopharmawatch.com/news/TLX/first-patients-dosed-with-illuccix-telix-s-approved-prostate-cancer-imaging-agent-telix-ph-tlx-20220414monthly0.5https://www.biopharmawatch.com/news/TLX/prostact-update-target-study-ethics-approval-telix-pharmaceuticals-limited-asx-tlx-telix-t-tlx-20220411monthly0.5https://www.biopharmawatch.com/news/TLX/telix-pharmaceuticals-announces-licence-agreement-with-lilly-for-olaratumab-telix-pharmace-tlx-20220410monthly0.5https://www.biopharmawatch.com/news/TLX/commercial-launch-illuccix-now-available-to-order-in-the-united-states-telix-pharmaceutica-tlx-20220404monthly0.5https://www.biopharmawatch.com/news/TLX/change-of-composition-of-the-telix-board-of-directors-telix-pharmaceuticals-limited-asx-tl-tlx-20220330monthly0.5https://www.biopharmawatch.com/news/TLX/new-video-series-psma-pet-ct-today-discusses-the-future-of-prostate-cancer-care-with-leadi-tlx-20220329monthly0.5https://www.biopharmawatch.com/news/TLX/telix-granted-fda-orphan-drug-designation-for-bone-marrow-conditioning-treatment-telix-pha-tlx-20220328monthly0.5https://www.biopharmawatch.com/news/TLX/telix-advances-development-of-glioblastoma-therapy-program-telix-pharmaceuticals-limited-a-tlx-20220322monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-reports-first-in-human-dosing-of-oral-pkm2-modulator-bhv-8100-targeting-metabolic-bhvn-20260601monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-reports-new-clinical-data-in-epilepsy-with-opakalim-a-selective-kv7-2-7-3-activat-bhvn-20260526monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-s-phase-2-obesity-study-with-taldefgrobep-alfa-a-novel-myostatin-activin-pathway--bhvn-20260319monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-highlights-portfolio-progress-positive-early-patient-data-from-priority-degrader--bhvn-20260112monthly0.5https://www.biopharmawatch.com/news/BHVN/fda-extends-pdufa-date-of-biohaven-s-troriluzole-nda-for-rare-disease-spinocerebellar-atax-bhvn-20250514monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-reports-first-quarter-2025-financial-results-and-recent-business-developments-cas-bhvn-20250512monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-announces-investment-up-to-600-million-by-oberland-capital-biohaven-ltd-nyse-bhvn-bhvn-20250428monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-presents-data-across-innovative-neuroscience-portfolio-at-the-2025-american-acade-bhvn-20250405monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-reports-positive-degrader-data-achieving-80-sustained-reductions-in-total-igg-wit-bhvn-20250303monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-reports-recent-business-developments-and-fourth-quarter-and-full-year-2024-financ-bhvn-20250303monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-announces-fda-acceptance-and-priority-review-of-troriluzole-new-drug-application--bhvn-20250211monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-highlights-portfolio-progress-innovation-and-anticipated-milestones-at-the-43rd-a-bhvn-20250113monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-biohaven-ltd-nyse--bhvn-20250107monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-reports-positive-phase-1-degrader-data-achieving-deep-targeted-igg-reductions-in--bhvn-20241216monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-presents-new-data-with-bhv-7000-once-daily-extended-release-formulation-demonstra-bhvn-20241206monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-provides-update-on-taldefgrobep-alfa-development-program-for-spinal-muscular-atro-bhvn-20241125monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-reports-third-quarter-2024-financial-results-and-recent-business-developments-cas-bhvn-20241112monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-announces-closing-of-public-offering-and-full-exercise-of-the-underwriters-option-bhvn-20241002monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-announces-pricing-of-250-million-public-offering-of-common-shares-biohaven-ltd-ny-bhvn-20241001monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-announces-proposed-public-offering-of-common-shares-biohaven-ltd-nyse-bhvn-a-glob-bhvn-20240930monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-initiates-pivotal-trial-of-novel-investigational-drug-for-treatment-of-migraine-b-bhvn-20240930monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-announces-conference-call-to-discuss-topline-pivotal-study-results-in-spinocerebe-bhvn-20240920monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-reports-second-quarter-2024-financial-results-and-recent-business-developments-ca-bhvn-20240808monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-showcases-broad-innovative-portfolio-and-pipeline-updates-across-multiple-therape-bhvn-20240529monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-doses-first-patient-with-its-novel-trop-2-directed-antibody-drug-conjugate-adc-bh-bhvn-20240529monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-reports-first-quarter-2024-financial-results-and-recent-business-developments-cas-bhvn-20240509monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-announces-closing-of-public-offering-and-full-exercise-of-the-underwriters-option-bhvn-20240422monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-announces-pricing-of-230-million-public-offering-of-common-shares-biohaven-ltd-ny-bhvn-20240418monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-announces-proposed-public-offering-of-common-shares-biohaven-ltd-nyse-bhvn-a-biop-bhvn-20240417monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-showcases-innovative-neuroscience-portfolio-with-20-presentations-at-the-2024-ame-bhvn-20240413monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-reports-fourth-quarter-and-full-year-2023-financial-results-and-recent-business-d-bhvn-20240229monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-highlights-progress-across-innovative-portfolio-and-outlines-2024-anticipated-mil-bhvn-20240108monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-biohaven-ltd-nyse--bhvn-20240102monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-presents-expanded-eeg-and-safety-data-for-bhv-7000-at-the-american-epilepsy-socie-bhvn-20231201monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-reports-third-quarter-2023-financial-results-and-recent-business-developments-cas-bhvn-20231114monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-presents-preclinical-data-demonstrating-taldefgrobep-alfa-reduces-fat-and-improve-bhvn-20231016monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-announces-closing-of-public-offering-and-full-exercise-of-the-underwriters-option-bhvn-20231005monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-announces-pricing-of-225-million-public-offering-of-common-shares-biohaven-ltd-ny-bhvn-20231002monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-announces-proposed-public-offering-of-common-shares-biohaven-ltd-nyse-bhvn-a-glob-bhvn-20231002monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-announces-positive-data-from-its-exploratory-electroencephalogram-eeg-biomarker-s-bhvn-20230905monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-s-taldefgrobep-alfa-receives-eu-orphan-drug-designation-for-spinal-muscular-atrop-bhvn-20230731monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-reports-second-quarter-2023-financial-results-and-recent-business-developments-ca-bhvn-20230731monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-provides-preliminary-eeg-data-update-for-kv7-platform-regulatory-update-on-troril-bhvn-20230727monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-provides-overview-of-clinical-progress-regulatory-updates-and-pipeline-developmen-bhvn-20230531monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-to-present-r-d-day-at-yale-school-of-management-biohaven-ltd-nyse-bhvn-biohaven-a-bhvn-20230525monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-reports-first-quarter-2023-financial-results-and-reports-recent-business-developm-bhvn-20230512monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-expands-executive-leadership-team-with-appointment-of-nick-kozauer-m-d-as-senior--bhvn-20230417monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-reports-fourth-quarter-and-full-year-2022-financial-results-and-reports-recent-bu-bhvn-20230323monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-announces-closing-of-public-offering-and-full-exercise-of-the-underwriters-option-bhvn-20221025monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-advances-development-of-the-mode-platform-technology-licensed-from-yale-universit-bhvn-20221025monthly0.5https://www.biopharmawatch.com/news/BHVN/biohaven-announces-launch-of-public-offering-of-common-shares-biohaven-ltd-nyse-bhvn-bioha-bhvn-20221018monthly0.5https://www.biopharmawatch.com/news/INBX/inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-o-inbx-20251022monthly0.5https://www.biopharmawatch.com/news/INBX/inhibrx-prevails-in-trade-secret-case-reaffirming-its-commitment-to-integrity-and-innovati-inbx-20241104monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characteriz-tech-20260604monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20260506monthly0.5https://www.biopharmawatch.com/news/TECH/scaleready-announces-a-g-rex-grant-has-been-awarded-to-sonoma-biotherapeutics-scaleready-i-tech-20251103monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-launches-proximityscope-assay-on-the-bond-rx-platform-from-leica-biosystems-to--tech-20251028monthly0.5https://www.biopharmawatch.com/news/TECH/scaleready-announces-multiple-g-rex-grants-have-been-awarded-to-leading-investigators-at-c-tech-20251023monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-and-oxford-nanopore-technologies-expand-agreement-to-accelerate-development-of--tech-20251009monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-advances-spatial-biology-solutions-bridging-translational-research-to-clinical--tech-20250926monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-highlights-progress-on-climate-innovation-and-culture-in-2025-sustainability-re-tech-20250924monthly0.5https://www.biopharmawatch.com/news/TECH/scaleready-awards-g-rex-grants-to-support-cell-and-gene-therapy-manufacturing-in-californi-tech-20250909monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-upcoming-investor-conferences-bio-techne-corporation-nasdaq-tech--tech-20250827monthly0.5https://www.biopharmawatch.com/news/TECH/scaleready-announces-award-of-a-g-rex-grant-to-the-gates-institute-s-translational-science-tech-20250814monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20250806monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-exosome-diagnostics-divestiture-bio-techne-corporation-nasdaq-tech-to-tech-20250805monthly0.5https://www.biopharmawatch.com/news/TECH/scaleready-announces-a-g-rex-grant-has-been-awarded-to-sidra-medicine-scaleready-in-collab-tech-20250805monthly0.5https://www.biopharmawatch.com/news/TECH/scaleready-announces-multiple-g-rex-grants-have-been-awarded-to-investigators-at-universit-tech-20250731monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-august-6-2025-to-announce-fourth-quarter-and-fiscal--tech-20250717monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-and-spear-bio-announce-strategic-partnership-to-advance-therapeutic-development-tech-20250715monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-s-simple-western-technology-utilized-in-recent-fda-approval-of-zevaskyn-cell-ba-tech-20250714monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-and-usp-announce-collaboration-to-accelerate-monoclonal-antibody-and-gene-thera-tech-20250624monthly0.5https://www.biopharmawatch.com/news/TECH/scaleready-announces-a-g-rex-grant-has-been-awarded-to-immuneel-therapeutics-scaleready-in-tech-20250610monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-investor-conferences-bio-techne-corporation-nasdaq-tech-today-ann-tech-20250529monthly0.5https://www.biopharmawatch.com/news/TECH/scaleready-awards-multiple-g-rex-grants-to-leading-investigators-at-the-university-of-sout-tech-20250514monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-showcase-next-generation-solutions-for-gene-and-cell-therapy-at-american-soc-tech-20250512monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-bofa-securities-2025-health-care-conference-bio-techne-corpor-tech-20250508monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-and-new-share-repurchase-program-bio-techne-corporation-nasda-tech-20250507monthly0.5https://www.biopharmawatch.com/news/TECH/scaleready-awards-a-300-000-g-rex-grant-to-a2-biotherapeutics-inc-scaleready-in-collaborat-tech-20250506monthly0.5https://www.biopharmawatch.com/news/TECH/scaleready-announces-march-biosciences-as-recipient-of-g-rex-grant-to-advance-manufacturin-tech-20250429monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-early-access-program-for-next-generation-spatial-protein-proximity-de-tech-20250424monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-showcase-cutting-edge-solutions-at-the-2025-american-association-for-cancer--tech-20250423monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-may-7-2025-to-announce-third-quarter-fiscal-2025-fin-tech-20250415monthly0.5https://www.biopharmawatch.com/news/TECH/leica-biosystems-and-bio-techne-expand-partnership-to-enable-protease-free-workflows-for-a-tech-20250402monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-new-customer-experience-centre-in-du-sseldorf-germany-bio-techne-corp-tech-20250326monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-highlight-advances-in-the-detection-of-clinically-relevant-biomarkers-using--tech-20250324monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-begins-shipping-leo-a-next-generation-high-throughput-simple-western-system-bio-tech-20250310monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-launches-new-panel-resolving-hard-to-decipher-carrier-screening-genes-bio-techn-tech-20250303monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-investor-conferences-bio-techne-corporation-nasdaq-tech-today-ann-tech-20250227monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-launches-expanded-menu-of-rnascope-probes-for-human-and-mouse-transcriptome-to--tech-20250220monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-release-of-gmp-tcbuster-non-viral-genome-engineering-system-bio-techn-tech-20250218monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20250205monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-appoints-dr-amy-e-herr-to-board-of-directors-bio-techne-corporation-nasdaq-tech-tech-20250204monthly0.5https://www.biopharmawatch.com/news/TECH/scaleready-announces-a-g-rex-grant-has-been-awarded-to-brainchild-bio-scaleready-in-collab-tech-20250121monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-february-5-2025-to-announce-second-quarter-fiscal-20-tech-20250121monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-expands-r-d-systems-ai-engineered-designer-protein-portfolio-to-advance-cell-th-tech-20250110monthly0.5https://www.biopharmawatch.com/news/TECH/scaleready-announces-a-g-rex-grant-has-been-awarded-to-seattle-children-s-therapeutics-sca-tech-20250108monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-phacilitate-advanced-therapies-week-2025-bio-techne-corporation-n-tech-20250108monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-successful-on-second-claim-of-reverse-engineering-by-miltenyi-biotec-bio-techne-tech-20250107monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-bio-techne-corpo-tech-20241220monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-biotherapeutic-characterization-strategic-co-marketing-and-co-promoti-tech-20241219monthly0.5https://www.biopharmawatch.com/news/TECH/scaleready-awards-a-g-rex-grant-to-moonlight-bio-scaleready-in-collaboration-with-wilson-w-tech-20241218monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-new-distribution-agreement-with-medsantek-to-expand-access-to-portfol-tech-20241212monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-launches-esr1-mutation-monitoring-assay-bio-techne-corporation-nasdaq-tech-toda-tech-20241210monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-citi-2024-global-healthcare-conference-bio-techne-corporation-tech-20241127monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-new-distribution-agreement-with-leader-life-sciences-bio-techne-corpo-tech-20241120monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-and-alzpath-announce-strategic-partnership-to-advance-neurodegenerative-disease-tech-20241118monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-highlight-novel-solutions-for-cancer-and-carrier-screening-at-amp-2024-annua-tech-20241114monthly0.5https://www.biopharmawatch.com/news/TECH/updated-bio-techne-announces-ivdr-certified-hematology-controls-and-calibrators-bio-techne-tech-20241111monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-ivdr-certified-hematology-controls-and-calibrators-bio-techne-corpora-tech-20241111monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-investor-conferences-bio-techne-corporation-nasdaq-tech-today-ann-tech-20241108monthly0.5https://www.biopharmawatch.com/news/TECH/scaleready-announces-multiple-g-rex-grants-have-been-awarded-to-leading-investigators-at-t-tech-20241107monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-39th-annual-meeting--tech-20241106monthly0.5https://www.biopharmawatch.com/news/TECH/lunaphore-comet-platform-paves-the-way-for-spatial-biology-adoption-in-clinical-research-b-tech-20241105monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20241030monthly0.5https://www.biopharmawatch.com/news/TECH/scaleready-announces-a-g-rex-grant-has-been-awarded-to-luminary-therapeutics-scaleready-in-tech-20241029monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-october-30-2024-to-announce-first-quarter-fiscal-202-tech-20241010monthly0.5https://www.biopharmawatch.com/news/TECH/scaleready-announces-a-g-rex-grant-has-been-awarded-to-lift-biosciences-scaleready-in-coll-tech-20241009monthly0.5https://www.biopharmawatch.com/news/TECH/scaleready-announces-a-g-rex-grant-has-been-awarded-to-renowned-cancer-immunologist-dr-chr-tech-20241007monthly0.5https://www.biopharmawatch.com/news/TECH/lunaphore-partners-with-discovery-life-sciences-to-bring-innovative-spatial-biology-soluti-tech-20240926monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-neuroscience-2024-the-society-for-neuroscience-sfn-annual-meeting-tech-20240924monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-issues-2024-corporate-sustainability-report-bio-techne-corporation-nasdaq-tech--tech-20240918monthly0.5https://www.biopharmawatch.com/news/TECH/scaleready-announces-a-g-rex-grant-has-been-awarded-to-immunoscape-scaleready-in-collabora-tech-20240918monthly0.5https://www.biopharmawatch.com/news/TECH/scaleready-and-bio-techne-announce-optimal-closed-system-cytokine-packaged-for-single-step-tech-20240916monthly0.5https://www.biopharmawatch.com/news/TECH/scaleready-announces-the-inaugural-g-rex-grant-has-been-awarded-to-stanford-medicine-labor-tech-20240827monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-investor-healthcare-conferences-bio-techne-corporation-nasdaq-tec-tech-20240826monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20240807monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-next-generation-high-throughput-simple-western-system-bio-techne-corp-tech-20240731monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-strategic-investment-in-spear-bio-bio-techne-corporation-nasdaq-tech--tech-20240729monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-august-7-2024-to-announce-fourth-quarter-and-fiscal--tech-20240715monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-upcoming-investor-conferences-bio-techne-corporation-nasdaq-tech--tech-20240531monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-highlight-multiple-applications-of-the-mauriceflex-system-at-the-annual-asms-tech-20240530monthly0.5https://www.biopharmawatch.com/news/TECH/scaleready-announces-20-million-g-rex-grant-program-for-the-advancement-of-cell-and-gene-t-tech-20240529monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-2024-leerink-partners-healthcare-crossroads-conference-bio-te-tech-20240523monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-highlights-recently-announced-top-line-biomarker-data-from-partner-regulus-ther-tech-20240522monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-bofa-securities-health-care-conference-2024-bio-techne-corpor-tech-20240508monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-27th-annual-meeting-of-the-american-society-of-gene-cell-ther-tech-20240507monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20240501monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-new-distribution-agreement-with-thermo-fisher-scientific-bio-techne-c-tech-20240429monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-and-novomol-dx-announce-point-of-care-ocular-biomarker-assay-bio-techne-corpora-tech-20240426monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-files-patent-infringement-lawsuit-against-molecular-instruments-bio-techne-corp-tech-20240423monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-may-1-2024-to-announce-third-quarter-fiscal-2024-fin-tech-20240410monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-surpasses-10-000-peer-reviewed-publications-citing-rnascope-technology-bio-tech-tech-20240408monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-2024-american-association-for-cancer-research-aacr-conference-tech-20240403monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-receives-citeab-s-elisa-kit-supplier-of-the-year-and-spatial-biology-innovation-tech-20240401monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-and-nikon-instruments-inc-announce-partnership-to-expand-access-to-innovative-s-tech-20240328monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-receives-european-ivdr-certification-for-diagnostic-test-to-monitor-chronic-mye-tech-20240322monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-keybanc-life-sciences-medtech-investor-forum-bio-techne-corpo-tech-20240312monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-barclays-26th-annual-global-healthcare-conference-bio-techne--tech-20240306monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20240201monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-s-advanced-cell-diagnostics-acd-sets-new-standard-in-spatial-biology-with-prote-tech-20240129monthly0.5https://www.biopharmawatch.com/news/TECH/lunaphore-and-acd-revolutionize-spatial-biology-research-with-the-launch-of-the-first-full-tech-20240125monthly0.5https://www.biopharmawatch.com/news/TECH/scientists-at-the-wcbp-conference-highlight-advancements-in-protein-biotherapeutic-charge--tech-20240124monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-february-1-2024-to-announce-second-quarter-fiscal-20-tech-20240116monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-showcase-cell-and-gene-therapy-manufacturing-tools-at-phacilitate-advanced-t-tech-20240104monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-bio-techne-corpo-tech-20231221monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-submission-of-fda-drug-master-file-for-excellerate-gmp-ipsc-expansion-tech-20231220monthly0.5https://www.biopharmawatch.com/news/TECH/lunaphore-and-sib-awarded-innosuisse-funding-to-develop-innovative-ai-based-assay-developm-tech-20231214monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-6th-annual-evercore-isi-healthconx-conference-bio-techne-corp-tech-20231127monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-investor-healthcare-conferences-bio-techne-corporation-nasdaq-tec-tech-20231113monthly0.5https://www.biopharmawatch.com/news/TECH/asuragen-to-present-novel-clinical-testing-data-at-amp-2023-conference-bio-techne-corporat-tech-20231102monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20231031monthly0.5https://www.biopharmawatch.com/news/TECH/leading-research-institutes-to-present-new-data-using-lunaphore-s-comet-technology-at-the--tech-20231025monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-appoints-kim-kelderman-as-chief-executive-officer-bio-techne-corporation-nasdaq-tech-20231019monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-achieves-iso-13485-certification-for-its-wallingford-ct-manufacturing-facility--tech-20231016monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-october-31-2023-to-announce-first-quarter-fiscal-202-tech-20231010monthly0.5https://www.biopharmawatch.com/news/TECH/dr-jordan-laser-awarded-amp-meritorious-service-award-bio-techne-corporation-nasdaq-tech-t-tech-20230928monthly0.5https://www.biopharmawatch.com/news/TECH/scientists-at-ce-pharm-conference-describe-how-maurice-and-mauriceflex-systems-transform-t-tech-20230927monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-integrates-its-maurice-system-with-the-thermo-scientific-chromeleon-chromatogra-tech-20230926monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-issues-2023-corporate-sustainability-report-bio-techne-corporation-nasdaq-tech--tech-20230925monthly0.5https://www.biopharmawatch.com/news/TECH/cizzle-and-bio-techne-announce-completion-of-evaluation-programme-for-detection-of-ciz1b-u-tech-20230919monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-investor-healthcare-conferences-bio-techne-corporation-nasdaq-tec-tech-20230828monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-2023-investor-day-and-webcast-bio-techne-corporation-nasdaq-tech-toda-tech-20230824monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-ubs-medtech-tools-and-genomics-summit-2023-bio-techne-corpora-tech-20230815monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-ends-collaboration-program-with-akoya-to-automate-rnascope-on-the-phenocycler-f-tech-20230814monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20230808monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-august-8-2023-to-announce-fourth-quarter-and-fiscal--tech-20230713monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-completes-lunaphore-acquisition-bio-techne-corporation-nasdaq-tech-today-announ-tech-20230710monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-acquire-lunaphore-bio-techne-corporation-nasdaq-tech-a-global-life-sciences--tech-20230622monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-successful-on-claim-of-reverse-engineering-by-miltenyi-biotec-bio-techne-corpor-tech-20230601monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-2023-jefferies-healthcare-conference-bio-techne-corporation-n-tech-20230525monthly0.5https://www.biopharmawatch.com/news/TECH/exosome-diagnostics-releases-interim-results-from-clinical-study-of-prostate-cancer-risk-t-tech-20230518monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-commercializes-rnascope-spatial-biology-workflow-for-the-standard-biotools-hype-tech-20230516monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-2023-rbc-capital-markets-global-healthcare-conference-bio-tec-tech-20230512monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-launch-of-kappa-and-lambda-rnascope-ish-probes-as-analyte-specific-re-tech-20230510monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-third-quarter-fiscal-2023-results-bio-techne-corporation-nasdaq-tech-t-tech-20230503monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20230503monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-bofa-securities-2023-health-care-conference-bio-techne-corpor-tech-20230502monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-and-lunaphore-establish-strategic-partnership-to-develop-the-first-fully-automa-tech-20230417monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-showcase-innovative-cancer-research-cell-therapy-and-manufacturing-tools-at--tech-20230413monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-may-3-2023-to-announce-third-quarter-2023-financial--tech-20230412monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-celebrates-milestone-with-more-than-1-000-ella-instruments-now-in-operation-bio-tech-20230405monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-completes-investment-in-wilson-wolf-manufacturing-bio-techne-corporation-nasdaq-tech-20230403monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-completion-of-cell-and-gene-therapy-catapult-process-analytical-techn-tech-20230315monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-barclays-global-healthcare-conference-bio-techne-corporation--tech-20230310monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-investment-in-wilson-wolf-bio-techne-corporation-nasdaq-tech-today-an-tech-20230301monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-cowen-43rd-annual-health-care-conference-bio-techne-corporati-tech-20230228monthly0.5https://www.biopharmawatch.com/news/TECH/exodx-prostate-test-granted-expanded-coverage-by-medicare-bio-techne-corporation-nasdaq-te-tech-20230224monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-citi-2023-healthcare-services-medtech-tools-hcit-conference-b-tech-20230222monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-and-cell-signaling-technology-announce-partnership-to-validate-simple-western-a-tech-20230214monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20230202monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-launches-the-mauriceflex-system-adding-cief-fractionation-capability-to-the-gol-tech-20230126monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-february-2-2023-to-announce-second-quarter-2023-fina-tech-20230117monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-launches-rnascope-plus-assay-to-advance-gene-therapy-development-bio-techne-cor-tech-20230110monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-bio-techne-corpo-tech-20221221monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-mitobrilliant-fluorescent-dyes-providing-a-next-generation-tool-for-im-tech-20221205monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-and-oxford-nanopore-technologies-partner-to-bring-innovative-reproductive-healt-tech-20221201monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-fifth-annual-evercore-isi-healthconx-conference-bio-techne-co-tech-20221128monthly0.5https://www.biopharmawatch.com/news/TECH/namocell-highlighted-in-nature-publication-for-efficient-single-cell-cloning-of-human-plur-tech-20221117monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-opening-of-new-immunoassay-manufacturing-facility-bio-techne-corporat-tech-20221115monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-stephens-annual-investment-conference-bio-techne-corporation--tech-20221110monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-stifel-2022-healthcare-conference-bio-techne-corporation-nasd-tech-20221108monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-credit-suisse-31st-annual-healthcare-conference-bio-techne-co-tech-20221103monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-cash-dividend-and-stock-dividend-bio-techne-corporation-nasdaq-tech-an-tech-20221101monthly0.5https://www.biopharmawatch.com/news/TECH/asuragen-to-showcase-innovative-diagnostic-lab-solutions-at-amp-2022-conference-bio-techne-tech-20221031monthly0.5https://www.biopharmawatch.com/news/TECH/new-publication-from-exosome-diagnostics-demonstrates-proof-of-concept-for-monitoring-astr-tech-20221018monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-sets-a-new-standard-in-highly-sensitive-rna-imaging-with-the-introduction-of-vi-tech-20221012monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-introduces-new-simple-plex-aav-viral-titer-assays-bio-techne-corporation-nasdaq-tech-20221011monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-november-1-2022-to-announce-first-quarter-2023-finan-tech-20221010monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-commercializes-automated-multi-omic-rnascope-assays-for-spatial-visualization-o-tech-20221006monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-files-patent-infringement-lawsuit-against-molecular-instruments-bio-techne-corp-tech-20220926monthly0.5https://www.biopharmawatch.com/news/TECH/maurice-flex-icief-analysis-adds-fractionation-enabling-mass-spec-peak-characterization-bi-tech-20220921monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-issues-2022-corporate-sustainability-report-bio-techne-corporation-nasdaq-tech--tech-20220919monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-presents-initial-data-on-sjo-gren-s-syndrome-monitoring-assay-bio-techne-corpor-tech-20220908monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-baird-2022-global-healthcare-conference-bio-techne-corporatio-tech-20220906monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-seek-approval-to-implement-four-for-one-stock-split-bio-techne-corporation-n-tech-20220901monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-morgan-stanley-20th-annual-global-healthcare-conference-bio-t-tech-20220830monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-2022-wells-fargo-healthcare-conference-bio-techne-corporation-tech-20220829monthly0.5https://www.biopharmawatch.com/news/TECH/maurice-icief-established-as-a-green-method-for-characterization-of-aav-identity-and-stabi-tech-20220825monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-included-in-the-forbes-best-in-state-employers-2022-list-bio-techne-corporation-tech-20220824monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-release-of-quantist-luminex-data-analysis-software-bio-techne-corpora-tech-20220818monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-ceo-transition-plan-bio-teche-corporation-nasdaq-tech-today-announced-tech-20220804monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20220804monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-fourth-quarter-fiscal-2022-results-bio-techne-corporation-nasdaq-tech--tech-20220804monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-licensing-agreement-and-partnership-with-university-of-dundee-bio-tec-tech-20220728monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-august-4-2022-to-announce-fourth-quarter-2022-financ-tech-20220714monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-launches-new-turbo-ce-sds-cartridge-accelerating-protein-purity-analysis-throug-tech-20220712monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-launch-of-the-ce-ivd-rnascope-ish-probe-high-risk-hpv-assay-for-head--tech-20220706monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-completion-of-namocell-acquisition-bio-techne-corporation-nasdaq-tech-tech-20220705monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-acquire-namocell-bio-techne-corporation-nasdaq-tech-a-global-life-sciences-c-tech-20220622monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-celebrates-40-000-unique-rnascope-in-situ-hybridization-probes-targeting-any-ge-tech-20220526monthly0.5https://www.biopharmawatch.com/news/TECH/global-study-demonstrates-ice3-and-maurice-capillary-isoelectric-focusing-comparability-in-tech-20220525monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-jefferies-healthcare-conference-bio-techne-corporation-nasdaq-tech-20220519monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-and-nonagen-bioscience-announce-exclusive-supply-agreement-for-nonagen-s-oncuri-tech-20220512monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-annual-american-urological-association-conference-in-new-orleans--tech-20220510monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20220504monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-bofa-securities-healthcare-conference-bio-techne-corporation--tech-20220502monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-included-on-the-forbes-best-employers-for-diversity-2022-list-bio-techne-corpor-tech-20220426monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-may-4-2022-to-announce-third-quarter-2022-financial--tech-20220413monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-and-cygnus-technologies-part-of-maravai-lifesciences-introduce-new-simple-plex--tech-20220412monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-keybanc-life-sciences-medtech-investor-forum-bio-techne-corpo-tech-20220317monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-barclays-global-healthcare-conference-bio-techne-corporation--tech-20220309monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-cowen-42nd-annual-health-care-conference-bio-techne-corporati-tech-20220228monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-citi-2022-virtual-healthcare-conference-bio-techne-corporatio-tech-20220222monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-exclusive-development-and-license-agreement-with-thermo-fisher-scient-tech-20220222monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-publication-of-new-data-demonstrating-exodx-prostate-test-correlation-tech-20220214monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-11th-annual-svb-leerink-global-healthcare-conference-bio-tech-tech-20220211monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-awarded-on-the-forbes-america-s-best-employers-2022-list-bio-techne-corporation-tech-20220210monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-second-quarter-fiscal-2022-results-bio-techne-corporation-nasdaq-tech--tech-20220201monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-and-new-share-repurchase-program-bio-techne-corporation-nasda-tech-20220201monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-commercial-release-of-high-sensitivity-fluorescent-detection-stellar--tech-20220118monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-february-1-2022-to-announce-second-quarter-2022-fina-tech-20220117monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-updated-presentation-time-at-the-j-p-morgan-healthcare-conference-bio-tech-20220107monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-and-akoya-biosciences-partner-to-deliver-automated-spatial-multiomics-workflow--tech-20220105monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-j-p-morgan-healthcare-conference-bio-techne-corporation-nasda-tech-20220103monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-appointment-of-brenda-everson-as-svp-human-resources-bio-techne-corpo-tech-20211227monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-appointment-of-will-geist-as-president-protein-sciences-segment-bio-t-tech-20211221monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-future-wilson-wolf-purchase-agreement-bio-techne-corporation-nasdaq-t-tech-20211214monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-publication-of-lateral-flow-technology-proof-of-concept-data-bio-tech-tech-20211208monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-upcoming-investor-conferences-bio-techne-corporation-nasdaq-tech--tech-20211122monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-stifel-2021-virtual-healthcare-conference-bio-techne-corporat-tech-20211109monthly0.5https://www.biopharmawatch.com/news/TECH/asuragen-launches-new-kit-to-enable-broader-coverage-of-gene-variants-linked-to-cystic-fib-tech-20211108monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-credit-suisse-30th-annual-healthcare-conference-bio-techne-co-tech-20211104monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-commercial-availability-of-gmp-grade-proteins-from-dedicated-gmp-faci-tech-20211103monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-named-in-inc-s-first-annual-best-led-companies-bio-techne-corporation-nasdaq-te-tech-20211102monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-first-quarter-fiscal-2022-results-bio-techne-corporation-nasdaq-tech-t-tech-20211102monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20211102monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-exodx-prostate-test-data-publication-in-the-journal-of-prostate-cance-tech-20211013monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-november-2-2021-to-announce-first-quarter-2022-finan-tech-20211011monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-launches-excellerate-ipsc-expansion-medium-bio-techne-corporation-nasdaq-tech-b-tech-20210914monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-and-carterra-initiate-a-clinical-research-collaboration-for-covid-19-variant-an-tech-20210908monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-2021-virtual-wells-fargo-healthcare-conference-bio-techne-cor-tech-20210902monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-fourth-quarter-fiscal-2021-results-bio-techne-corporation-nasdaq-tech--tech-20210805monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20210805monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-s-rnascope-technology-aids-in-the-retrospective-tissue-diagnosis-of-covid-19-in-tech-20210804monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-2021-investor-day-and-webcast-bio-techne-corporation-nasdaq-tech-toda-tech-20210803monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-and-progen-introduce-new-simple-plex-aav2-immunoassay-bio-techne-corporation-na-tech-20210728monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-commercial-release-of-rnascope-hiplex-v2-assay-for-single-cell-valida-tech-20210727monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-august-5-2021-to-announce-fourth-quarter-2021-financ-tech-20210713monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-opening-of-new-ireland-facility-bio-techne-corporation-nasdaq-tech-to-tech-20210628monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-and-catamaran-bio-announce-expanded-collaboration-for-car-nk-cell-manufacturing-tech-20210624monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-further-enhances-its-gene-engineering-cell-gene-therapy-manufacturing-capabilit-tech-20210610monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-joins-cell-and-gene-therapy-catapult-process-analytical-technology-consortium-b-tech-20210608monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-jefferies-virtual-healthcare-conference-bio-techne-corporatio-tech-20210519monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder--tech-20210518monthly0.5https://www.biopharmawatch.com/news/TECH/multisite-study-demonstrates-utility-of-asuragen-kit-for-identifying-variants-linked-to-sp-tech-20210510monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-third-quarter-fiscal-2021-results-bio-techne-corporation-nasdaq-tech-t-tech-20210506monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20210506monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-and-908-devices-announce-joint-collaboration-bio-techne-corporation-nasdaq-tech-tech-20210504monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-commercial-release-of-novel-dnascope-in-situ-hybridization-assays-for-tech-20210427monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-launch-of-professional-assay-services-dedicated-source-for-rna-in-sit-tech-20210415monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-licensing-of-proprietary-antibody-to-xencor-for-therapeutic-developme-tech-20210414monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-commercial-release-of-abby-automated-western-system-for-simple-wester-tech-20210408monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-completes-acquisition-of-asuragen-inc-bio-techne-corporation-nasdaq-tech-today--tech-20210406monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-may-6-2021-to-announce-third-quarter-2021-financial--tech-20210406monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-launch-of-cultrex-ultimatrix-bme-to-support-organoid-and-pluripotent--tech-20210329monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-receipt-of-covid-19-innovation-award-from-citeab-bio-techne-corporati-tech-20210326monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-s-exosome-diagnostics-laboratory-announces-ce-ivd-certification-for-exodx-prost-tech-20210323monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-iso-9001-2015-certification-for-its-bristol-manufacturing-facility-bi-tech-20210315monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-exotru-kidney-transplant-rejection-assay-data-publication-bio-techne--tech-20210308monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-acquire-asuragen-bio-techne-corporation-nasdaq-tech-a-global-life-sciences-c-tech-20210303monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-barclays-global-healthcare-conference-bio-techne-corporation--tech-20210302monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-s-exosome-diagnostics-laboratory-announces-reimbursement-contract-with-humana-b-tech-20210301monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-iso-14001-2015-certification-for-the-emea-region-of-bio-techne-bio-te-tech-20210225monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-and-luminary-therapeutics-sign-license-agreement-for-use-of-bio-techne-s-tcbust-tech-20210223monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-citi-s-2021-healthcare-services-medtech-tools-hcit-virtual-confer-tech-20210216monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-paper-publication-in-annals-of-oncology-bio-techne-corporation-nasdaq-tech-20210211monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-2021-svb-leerink-global-healthcare-conference-bio-techne-corp-tech-20210210monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-expanded-simple-plex-immunoassay-cartridge-portfolio-bio-techne-corpo-tech-20210203monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20210202monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-second-quarter-fiscal-2021-results-bio-techne-corporation-nasdaq-tech--tech-20210202monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-strategic-investment-in-eminence-bio-techne-corporation-nasdaq-tech-a-tech-20210128monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-february-2-2021-to-announce-second-quarter-2021-fina-tech-20210114monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-bio-techne-corpo-tech-20201221monthly0.5https://www.biopharmawatch.com/news/TECH/regulus-therapeutics-collaborates-with-bio-techne-for-biomarker-development-bio-techne-cor-tech-20201202monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-stephens-annual-investment-conference-2020-bio-techne-corpora-tech-20201111monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20201105monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-first-quarter-fiscal-2021-results-bio-techne-corporation-nasdaq-tech-t-tech-20201105monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-stifel-2020-virtual-healthcare-conference-bio-techne-corporat-tech-20201104monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-29th-annual-credit-suisse-virtual-healthcare-conference-bio-t-tech-20201102monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-commercial-release-of-new-sars-cov-2-multi-antigen-serology-assay-kit-tech-20201019monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-iso-13485-2016-certification-for-the-woburn-ma-manufacturing-facility-tech-20201015monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-november-5-2020-to-announce-first-quarter-2021-finan-tech-20201013monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-opening-of-new-canadian-facility-bio-techne-corporation-nasdaq-tech-t-tech-20201001monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-grand-opening-of-gmp-manufacturing-facility-bio-techne-corporation-na-tech-20200930monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-publication-of-exodx-prostate-test-study-in-patients-with-prior-negat-tech-20200923monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-commercial-release-of-new-co-detection-assays-for-simultaneous-detect-tech-20200922monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-rebrands-b-mogen-biotechnologies-as-part-of-the-r-d-systems-product-portfolio-b-tech-20200921monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-and-qiagen-announce-expansion-and-extension-of-exosome-partnership-bio-techne-c-tech-20200917monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-and-hall-of-famer-cal-ripken-jr-announce-partnership-to-raise-awareness-and-edu-tech-20200908monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-2020-wells-fargo-virtual-healthcare-conference-bio-techne-cor-tech-20200903monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-corporation-and-leica-biosystems-are-accelerating-disease-research-with-rnascop-tech-20200819monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-release-of-a-new-sars-cov-1-2-spike-rbd-llamabody-recombinant-antibod-tech-20200811monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-and-nanostring-announce-offering-of-rnascope-reagents-validated-for-use-with-th-tech-20200806monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-fourth-quarter-fiscal-2020-results-bio-techne-corporation-nasdaq-tech--tech-20200804monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20200804monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-and-kantaro-biosciences-to-launch-a-quantitative-research-use-only-covid-19-ser-tech-20200803monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-appointment-of-julie-l-bushman-to-its-board-of-directors-bio-techne-c-tech-20200803monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-launch-of-exocovid-19-test-for-detection-of-sars-cov-2-in-patient-sam-tech-20200721monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-commercial-release-of-new-assay-for-detecting-asos-mirnas-and-sirnas--tech-20200720monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-august-4-2020-to-announce-fourth-quarter-2020-financ-tech-20200713monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-and-zero-the-end-of-prostate-cancer-announce-partnership-to-fund-education-and--tech-20200611monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-continues-to-expand-its-portfolio-to-support-sars-cov-2-and-covid-19-research-a-tech-20200609monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-release-of-gmp-prodots-proteins-to-support-cell-and-gene-therapy-manu-tech-20200608monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-jefferies-virtual-healthcare-conference-bio-techne-corporatio-tech-20200527monthly0.5https://www.biopharmawatch.com/news/TECH/leica-biosystems-and-bio-techne-announce-european-launch-of-the-ce-ivd-rnascope-in-situ-hy-tech-20200526monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-and-kantaro-biosciences-announce-partnership-to-develop-and-scale-production-of-tech-20200519monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-release-of-gmp-cloudz-human-t-cell-activation-kit-bio-techne-corporat-tech-20200511monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-publication-of-exodx-prostate-intelliscore-epi-test-clinical-utility--tech-20200507monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-bofa-securities-2020-health-care-conference-bio-techne-corpor-tech-20200505monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-third-quarter-fiscal-2020-results-bio-techne-corporation-nasdaq-tech-t-tech-20200430monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20200430monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-introduces-replex-capabilities-for-simple-western-assays-on-jess-bio-techne-cor-tech-20200416monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-s-exosome-diagnostics-launches-exodx-prostate-at-home-collection-kit-bio-techne-tech-20200415monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-april-30-2020-to-announce-third-quarter-2020-financi-tech-20200408monthly0.5https://www.biopharmawatch.com/news/TECH/dr-roeland-nusse-gairdner-award-recipient-and-bio-techne-board-of-directors-member-bio-tec-tech-20200401monthly0.5https://www.biopharmawatch.com/news/TECH/extracellular-vesicles-from-plasma-have-higher-tumor-rna-fraction-than-platelets-bio-techn-tech-20200330monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-s-ella-on-the-front-lines-in-fight-against-covid-19-bio-techne-corporation-nasd-tech-20200325monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-s-exosome-diagnostics-laboratory-announces-reimbursement-contract-with-general--tech-20200318monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-barclays-global-healthcare-conference-bio-techne-corporation--tech-20200227monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-cowen-40th-annual-health-care-conference-bio-techne-corporati-tech-20200224monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-svb-leerink-9th-annual-global-healthcare-conference-bio-techn-tech-20200217monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-availability-of-next-generation-elisa-kits-bio-techne-corporation-nas-tech-20200205monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-second-quarter-fiscal-2020-results-bio-techne-corporation-nasdaq-tech--tech-20200204monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20200204monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-february-4-2020-to-announce-second-quarter-2020-fina-tech-20200109monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-rebrands-atlanta-biologicals-serum-and-media-as-part-of-the-r-d-systems-product-tech-20200107monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-bio-techne-corpo-tech-20200102monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-s-exosome-diagnostics-lab-receives-accreditation-from-college-of-american-patho-tech-20191217monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-evercore-isi-2nd-annual-healthconx-conference-bio-techne-corp-tech-20191125monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-2019-stifel-healthcare-conference-bio-techne-corporation-nasd-tech-20191107monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-licenses-atag-technology-from-c4-therapeutics-inc-bio-techne-corporation-nasdaq-tech-20191106monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-stephens-nashville-investment-conference-bio-techne-corporati-tech-20191105monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-first-quarter-fiscal-2020-results-bio-techne-corporation-nasdaq-tech-t-tech-20191029monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20191029monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-investment-for-new-gmp-manufacturing-facility-bio-techne-corporation--tech-20191028monthly0.5https://www.biopharmawatch.com/news/TECH/medicare-issues-final-local-coverage-decision-for-bio-techne-s-exodx-prostate-intelliscore-tech-20191010monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-october-29-2019-to-announce-first-quarter-2020-finan-tech-20191008monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-leverages-the-rnascope-technology-to-advance-a-multiomic-approach-to-antibody-v-tech-20191007monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-attains-iso-9001-2015-certification-for-fetal-bovine-serum-manufacturing-facili-tech-20190916monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-introduces-maurice-empower-control-kit-for-the-maurice-system-bio-techne-corpor-tech-20190820monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-baird-2019-global-healthcare-conference-bio-techne-corporatio-tech-20190815monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-and-cygnus-technologies-announce-partnership-for-3g-cho-hcp-assay-bio-techne-co-tech-20190813monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20190806monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-fourth-quarter-fiscal-2019-results-bio-techne-corporation-nasdaq-tech--tech-20190806monthly0.5https://www.biopharmawatch.com/news/TECH/uman-diagnostics-and-bio-techne-announce-license-and-supply-agreement-for-neurofilament-li-tech-20190723monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-august-6-2019-to-announce-fourth-quarter-2019-financ-tech-20190718monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-32x8-cartridge-for-the-ella-platform-bio-techne-corporation-nasdaq-tec-tech-20190717monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-commercial-release-of-rnascope-hiplex-assay-a-multiplex-in-situ-hybri-tech-20190711monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-ceo-chuck-kummeth-wins-entrepreneur-of-the-year-2019-award-in-the-heartland-bio-tech-20190709monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-china-recognized-with-decade-of-contribution-award-bio-techne-corporation-nasda-tech-20190626monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-appoints-rupert-vessey-to-board-of-directors-bio-techne-corporation-today-annou-tech-20190625monthly0.5https://www.biopharmawatch.com/news/TECH/fda-grants-breakthrough-device-designation-to-bio-techne-s-exodx-prostate-intelliscore-epi-tech-20190617monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-receives-approval-to-offer-the-exodx-prostate-intelliscore-epi-test-in-new-york-tech-20190613monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-acquire-b-mogen-biotechnologies-inc-bio-techne-corporation-nasdaq-tech-annou-tech-20190604monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-goldman-sachs-40th-annual-global-healthcare-conference-bio-te-tech-20190603monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-s-new-exosome-based-liquid-biopsies-helping-to-advance-personalized-care-in-lun-tech-20190528monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-jefferies-2019-global-healthcare-conference-bio-techne-corpor-tech-20190521monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-ubs-global-healthcare-conference-bio-techne-corporation-nasda-tech-20190514monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-bank-of-america-merrill-lynch-2019-health-care-conference-bio-tech-20190502monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-third-quarter-fiscal-2019-results-bio-techne-corporation-nasdaq-tech-t-tech-20190430monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20190430monthly0.5https://www.biopharmawatch.com/news/TECH/elpiscience-and-bio-techne-announce-strategic-collaboration-elpiscience-biopharma-and-bio--tech-20190422monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-april-30-2019-to-announce-third-quarter-2019-financi-tech-20190409monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-and-nanostring-partner-to-co-develop-integrated-workflow-for-rna-spatial-profil-tech-20190328monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-scores-a-trio-of-citeab-2019-awards-bio-techne-a-global-life-sciences-company-p-tech-20190305monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-barclays-global-healthcare-conference-bio-techne-corporation--tech-20190305monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-signs-strategic-cooperation-agreement-with-lisen-imprinting-diagnostics-bio-tec-tech-20190226monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-8th-annual-svb-leerink-global-healthcare-conference-bio-techn-tech-20190220monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20190205monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-second-quarter-fiscal-2019-results-bio-techne-corporation-nasdaq-tech--tech-20190205monthly0.5https://www.biopharmawatch.com/news/TECH/exodx-prostate-intelliscore-epi-recommended-in-national-comprehensive-cancer-network-guide-tech-20190131monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-introduces-48-digoxigenin-cartridge-for-the-ella-platform-bio-techne-today-anno-tech-20190129monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-introduces-ce-sds-plus-for-maurice-system-bio-techne-today-announced-the-launch-tech-20190128monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-launches-cell-and-gene-therapy-portfolio-bio-techne-announces-the-launch-of-the-tech-20190124monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-february-5-2019-to-announce-second-quarter-2019-fina-tech-20190116monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-bio-techne-corpo-tech-20181220monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-gmp-rock-inhibitor-and-chir-99021-for-stem-cell-therapy-bio-techne-has-tech-20181204monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-citi-2018-global-healthcare-conference-bio-techne-corporation-tech-20181120monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20181030monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-first-quarter-fiscal-2019-results-bio-techne-corporation-nasdaq-tech-t-tech-20181030monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-2018-stephens-ny-investment-conference-bio-techne-corporation-tech-20181026monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-signs-strategic-cooperation-agreement-with-micropoint-bioscience-bio-techne-has-tech-20181012monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-october-30-2018-to-announce-first-quarter-2019-finan-tech-20181011monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-scientist-presented-with-the-casss-ce-pharm-award-bio-techne-is-proud-to-announ-tech-20181002monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-cell-and-gene-therapy-initiative-bio-techne-a-global-leader-of-resear-tech-20180927monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-supports-international-antibody-validation-meetings-bio-techne-is-proud-to-be-s-tech-20180919monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-publication-of-data-demonstrating-additional-clinical-validation-of-i-tech-20180918monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-fills-a-need-for-simple-tools-to-study-glycobiology-bio-techne-researchers-publ-tech-20180906monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-morgan-stanley-16th-annual-global-healthcare-conference-bio-t-tech-20180905monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-baird-2018-global-healthcare-conference-bio-techne-corporatio-tech-20180828monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-introduces-gmp-small-molecules-for-stem-cell-therapy-development-bio-techne-has-tech-20180808monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-fourth-quarter-fiscal-2018-results-bio-techne-corporation-nasdaq-tech--tech-20180807monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20180807monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-2018-investor-day-and-webcast-bio-techne-corporation-nasdaq-tech-toda-tech-20180802monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-corporation-completed-its-acquisition-of-exosome-diagnostics-inc-bio-techne-cor-tech-20180801monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-introduces-new-member-of-the-simple-western-family-with-ir-nir-detection-capabi-tech-20180724monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-august-7-2018-to-announce-fourth-quarter-2018-financ-tech-20180712monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-scales-antibody-validation-initiative-using-crispr-gene-editing-technology-acro-tech-20180710monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-expands-rnascope-assay-services-portfolio-to-shorten-development-times-and-save-tech-20180626monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-acquire-exosome-diagnostics-inc-bio-techne-corporation-nasdaq-tech-announced-tech-20180625monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-acquire-quad-technologies-bio-techne-corporation-nasdaq-tech-announced-today-tech-20180607monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-william-blair-38th-annual-growth-stock-conference-bio-techne--tech-20180604monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-jefferies-2018-healthcare-conference-bio-techne-corporation-n-tech-20180524monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-ubs-global-healthcare-conference-bio-techne-corporation-nasda-tech-20180510monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20180502monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-third-quarter-fiscal-2018-results-bio-techne-corporation-nasdaq-tech-t-tech-20180502monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-deutsche-bank-43rd-annual-health-care-conference-bio-techne-c-tech-20180501monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-leads-the-way-in-scientific-support-for-autophagy-research-bio-techne-a-family--tech-20180426monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-new-leadership-appointment-bio-techne-corporation-announced-today-tha-tech-20180424monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-expands-rnascope-ish-automation-facilitating-drug-discovery-and-development-bio-tech-20180321monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-launches-mimex-gi-an-accessible-3-d-cell-culturing-platform-for-the-gastrointes-tech-20180314monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-named-researchers-choice-by-citeab-bio-techne-a-global-life-sciences-company-pr-tech-20180207monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20180206monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-second-quarter-fiscal-2018-results-bio-techne-corporation-nasdaq-tech--tech-20180206monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-leerink-partners-7th-annual-global-healthcare-conference-bio--tech-20180205monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-s-ella-added-to-bioagilytix-portfolio-of-industry-leading-immunoassay-platforms-tech-20180130monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-february-6-2018-to-announce-second-quarter-2018-fina-tech-20180118monthly0.5https://www.biopharmawatch.com/news/TECH/advanced-immunolabeling-reagents-and-tools-from-vector-laboratories-now-from-bio-techne-bi-tech-20180115monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-36th-annual-j-p-morgan-healthcare-conference-bio-techne-corpo-tech-20171228monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-s-rnascope-technology-enabling-robust-gene-expression-and-biomarker-analysis-ad-tech-20171128monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-offers-updated-novus-panel-builder-facilitating-multicolor-flow-cytometry-panel-tech-20171120monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-awards-40-000-usd-research-grant-to-innovative-cancer-researcher-advanced-cell--tech-20171114monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-first-quarter-fiscal-2018-results-bio-techne-corporation-nasdaq-tech-t-tech-20171031monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20171031monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-stephens-fall-investment-conference-bio-techne-corporation-na-tech-20171027monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-adds-two-new-directors-to-its-board-bio-techne-corporation-nasdaq-tech-announce-tech-20171026monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-october-31-2017-to-announce-first-quarter-2018-finan-tech-20171011monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-unveils-a-new-multi-analyte-cartridge-format-for-the-ella-immunoassay-platform--tech-20170920monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-introduces-a-new-luminex-multi-analyte-assay-kit-r-d-systems-a-bio-techne-brand-tech-20170913monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-releases-a-highly-sensitive-and-specific-serological-assay-to-detect-zika-virus-tech-20170906monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-acquires-trevigen-inc-bio-techne-corporation-nasdaq-tech-announced-today-that-i-tech-20170905monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-wells-fargo-healthcare-conference-bio-techne-corporation-nasd-tech-20170828monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-baird-2017-global-healthcare-conference-bio-techne-corporatio-tech-20170822monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20170810monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-august-8-2017-to-announce-fourth-quarter-financial-r-tech-20170712monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-jefferies-2017-global-healthcare-conference-bio-techne-corpor-tech-20170524monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-bank-of-america-merrill-lynch-health-care-conference-bio-tech-tech-20170508monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20170502monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-deutsche-bank-42nd-annual-health-care-conference-bio-techne-c-tech-20170424monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-may-2-2017-to-announce-third-quarter-financial-resul-tech-20170418monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-signs-exclusive-license-agreement-with-multiclonal-therapeutics-for-adult-groun-tech-20170307monthly0.5https://www.biopharmawatch.com/news/TECH/innovative-veterinary-diagnostic-setting-a-new-standard-bio-techne-corporation-has-partner-tech-20170301monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-present-at-the-leerink-partners-6th-annual-global-healthcare-conference-bio--tech-20170213monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-named-company-of-the-year-by-instrument-business-outlook-bio-techne-has-been-na-tech-20170209monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20170207monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-february-7-2017-to-announce-second-quarter-financial-tech-20170125monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-congratulates-astute-medical-on-clinical-trial-results-in-a-major-study-release-tech-20170124monthly0.5https://www.biopharmawatch.com/news/TECH/copd-biomarker-qualification-consortium-partners-with-bio-techne-to-identify-copd-indicato-tech-20170111monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-and-astute-medical-form-strategic-partnership-bio-techne-corporation-nasdaq-tec-tech-20161214monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20161031monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-october-31-2016-to-announce-first-quarter-financial--tech-20161017monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-investor-day-and-webcast-bio-techne-corporation-nasdaq-tech-today-ann-tech-20160831monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20160817monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-august-17-2016-to-announce-fourth-quarter-financial--tech-20160803monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-corporation-completed-its-acquisition-of-advanced-cell-diagnostics-bio-techne-c-tech-20160801monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-acquires-space-import-export-and-strengthens-european-leadership-team-bio-techn-tech-20160701monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20160503monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-may-3-2016-to-announce-third-quarter-financial-resul-tech-20160411monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-corporation-agrees-to-acquire-zephyrus-biosciences-inc-bio-techne-corporation-n-tech-20160321monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20160202monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-february-2-2016-to-announce-second-quarter-financial-tech-20160112monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20151029monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-certifies-over-1-000-antibodies-for-simple-western-bio-techne-corporation-annou-tech-20151026monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-october-28-2015-to-announce-first-quarter-financial--tech-20151014monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-august-6-2015-to-announce-fourth-quarter-financial-r-tech-20150714monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20150505monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-may-5-2015-to-announce-third-quarter-financial-resul-tech-20150423monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-bio-techne-corporation-nasdaq-tech-announced-that-its-board-o-tech-20150203monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-to-host-conference-call-on-february-3-2015-to-announce-second-quarter-financial-tech-20150127monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-launches-simple-plex-platform-bio-techne-corporation-nasdaq-tech-announced-toda-tech-20150122monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-appointment-of-robert-gavin-as-leader-of-new-protein-platforms-divisi-tech-20141125monthly0.5https://www.biopharmawatch.com/news/TECH/bio-techne-announces-agreement-to-acquire-cyvek-bio-techne-corporation-nasdaq-tech-announc-tech-20141104monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-pricing-of-public-offering-ideaya-biosciences-inc-nasdaq-idya-today-annou-idya-20240709monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-abstract-summary-results-of-asco-2024-oral-presentation-for-p-idya-20240523monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-pricing-of-public-offering-ideaya-biosciences-inc-nasdaq-idya-today-annou-idya-20231024monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-announces-pricing-of-public-offering-ideaya-biosciences-inc-nasdaq-idya-today-annou-idya-20230425monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-to-participate-in-citi-s-2023-virtual-oncology-leadership-summit-ideaya-idya-20230216monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-selected-to-join-russell-3000-index-ideaya-biosciences-inc-nasdaq-idya--idya-20200611monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-and-boston-children-s-hospital-collaborate-on-preclinical-evaluation-of-idya-20200110monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-licenses-phase-1-compound-lxs196-for-the-treatment-of-cancers-with-gnaq-and-gna11-m-idya-20181023monthly0.5https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-appoints-julie-hambleton-m-d-as-senior-vice-president-and-chief-medical-idya-20180313monthly0.5https://www.biopharmawatch.com/news/IDYA/fiercebiotech-names-ideaya-biosciences-as-one-of-its-fierce-15-biotech-companies-of-2016-i-idya-20160919monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-announce-full-year-2025-financial-results-and-provide-business-updates-on-marc-pgen-20260311monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-showcases-rapid-commercialization-momentum-and-growing-market-adoption-of-first-a-pgen-20260112monthly0.5https://www.biopharmawatch.com/news/PGEN/fda-grants-priority-review-to-precigen-s-bla-for-prgn-2012-for-the-treatment-of-adults-wit-pgen-20250225monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-present-plans-for-realizing-commercial-vision-for-prgn-2012-at-the-43rd-annual-pgen-20250113monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-precigen-inc-nasda-pgen-20250109monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-completes-submission-of-bla-with-request-for-priority-review-to-the-fda-for-prgn--pgen-20241230monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-participate-in-the-stifel-2024-healthcare-conference-precigen-inc-nasdaq-pgen--pgen-20241112monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-participate-in-the-2024-cantor-global-healthcare-conference-precigen-inc-nasda-pgen-20240916monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-announce-second-quarter-and-first-half-2024-financial-results-on-august-14th-p-pgen-20240809monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-pricing-of-30-0-million-public-offering-of-common-stock-precigen-inc-na-pgen-20240807monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-proposed-30-million-public-offering-of-common-stock-precigen-inc-nasdaq-pgen-20240806monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-appoints-phil-tennant-as-chief-commercial-officer-to-spearhead-first-potential-ge-pgen-20240723monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-groundbreaking-pivotal-study-data-for-prgn-2012-in-patients-with-recurr-pgen-20240603monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-host-a-webcast-on-june-3rd-to-detail-pivotal-study-results-of-prgn-2012-in-rec-pgen-20240523monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-announce-first-quarter-2024-financial-results-on-may-14th-and-host-a-conferenc-pgen-20240508monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-present-late-breaking-abstract-for-pivotal-phase-2-study-data-for-prgn-2012-ad-pgen-20240424monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-and-recurrent-respiratory-papillomatosis-foundation-to-hold-inaugural-internation-pgen-20240328monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-participate-in-a-fireside-chat-hosted-by-cantor-fitzgerald-to-discuss-prgn-201-pgen-20240312monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-announce-fourth-quarter-and-full-year-2023-financial-results-on-march-19th-pre-pgen-20240305monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-participate-in-the-oppenheimer-34th-annual-healthcare-life-sciences-conference-pgen-20240206monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-receives-orphan-drug-designation-for-prgn-2012-for-the-treatment-of-recurrent-res-pgen-20240116monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-precigen-inc-nasda-pgen-20231218monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-participate-in-the-jmp-securities-hematology-and-oncology-summit-precigen-inc--pgen-20231129monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-participate-in-the-stifel-2023-healthcare-conference-precigen-inc-nasdaq-pgen--pgen-20231107monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-participate-in-upcoming-leading-investor-and-industry-conferences-precigen-inc-pgen-20230919monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-fda-confirmation-that-the-ongoing-phase-1-2-study-of-prgn-2012-adenover-pgen-20230809monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-announce-second-quarter-and-first-half-2023-financial-results-on-august-9th-pr-pgen-20230803monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-receives-breakthrough-therapy-designation-for-prgn-2012-adenoverse-immunotherapy--pgen-20230620monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-positive-phase-1-data-for-prgn-3005-autologous-ultracar-t-cells-manufac-pgen-20230605monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-positive-phase-1-data-for-off-the-shelf-prgn-2009-adenoverse-immunother-pgen-20230603monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-receives-fda-clearance-of-ind-to-initiate-phase-2-study-of-prgn-2009-off-the-shel-pgen-20230531monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-announce-first-quarter-2023-financial-results-on-may-10th-precigen-inc-nasdaq--pgen-20230503monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-present-latest-clinical-advancements-for-prgn-3005-ultracar-t-and-prgn-2009-of-pgen-20230426monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-presents-preclinical-data-for-the-next-generation-mesothelin-ultracar-t-with-intr-pgen-20230417monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-regains-exclusive-rights-to-proven-car-t-targets-cd19-and-bcma-to-enable-unencumb-pgen-20230403monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-further-advancement-of-ultracar-t-platform-with-first-patient-dosed-in--pgen-20230329monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-participate-in-a-virtual-fireside-chat-at-cantor-s-the-future-of-oncology-virt-pgen-20230328monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-closing-of-public-offering-of-common-stock-precigen-inc-nasdaq-pgen-ann-pgen-20230127monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-pricing-of-75-0-million-public-offering-of-common-stock-precigen-inc-na-pgen-20230124monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-proposed-75-0-million-public-offering-of-common-stock-precigen-inc-nasd-pgen-20230124monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-host-a-virtual-r-d-event-on-january-24th-to-share-safety-and-efficacy-data-fro-pgen-20230104monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-precigen-inc-nasda-pgen-20221219monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-positive-phase-1-dose-escalation-data-for-autologous-prgn-3006-ultracar-pgen-20221212monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-announce-third-quarter-2022-financial-results-on-november-9th-precigen-inc-nas-pgen-20221102monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-participate-in-the-2022-wells-fargo-healthcare-conference-precigen-inc-nasdaq--pgen-20220901monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-announce-second-quarter-and-first-half-2022-financial-results-on-august-8th-pr-pgen-20220801monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-participate-in-the-stifel-2022-virtual-cell-therapy-summit-precigen-inc-nasdaq-pgen-20220627monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-participate-in-the-2022-h-c-wainwright-global-investment-conference-precigen-i-pgen-20220517monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-receives-fast-track-designation-for-prgn-3006-ultracar-t-in-patients-with-relapse-pgen-20220404monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-provides-pipeline-and-corporate-updates-at-the-40th-annual-j-p-morgan-healthcare--pgen-20220112monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-precigen-inc-nasda-pgen-20220105monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-positive-interim-phase-1-data-for-prgn-3006-ultracar-t-in-relapsed-or-r-pgen-20211213monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-present-at-the-stifel-2021-virtual-healthcare-conference-precigen-inc-nasdaq-p-pgen-20211110monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-host-r-d-update-virtual-event-on-november-4th-to-share-clinical-developments-p-pgen-20211027monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-clearance-of-ind-to-initiate-phase-1-1b-study-for-prgn-3007-ultracar-t--pgen-20211026monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-present-at-the-2021-wells-fargo-virtual-healthcare-conference-and-the-h-c-wain-pgen-20210901monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-announce-second-quarter-and-first-half-2021-financial-results-on-august-9th-pr-pgen-20210802monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-present-at-the-jmp-securities-life-sciences-conference-precigen-inc-nasdaq-pge-pgen-20210610monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-first-patient-dosed-for-prgn-2012-adenoverse-immunotherapy-in-patients--pgen-20210323monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-receives-fda-orphan-drug-designation-for-prgn-2012-adenoverse-immunotherapy-in-pa-pgen-20210318monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-announce-fourth-quarter-and-full-year-2020-financial-results-on-march-1st-prec-pgen-20210222monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-participate-in-guggenheim-healthcare-talks-oncology-day-precigen-inc-nasdaq-pg-pgen-20210204monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-option--pgen-20210126monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-pricing-of-112-5-million-public-offering-of-common-stock-precigen-inc-n-pgen-20210122monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-proposed-public-offering-of-common-stock-precigen-inc-nasdaq-pgen-today-pgen-20210121monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-provides-pipeline-updates-at-the-39th-annual-j-p-morgan-healthcare-conference-pre-pgen-20210113monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-precigen-inc-nasda-pgen-20210106monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-clearance-of-ind-to-initiate-phase-i-study-of-prgn-2012-adenoverse-immu-pgen-20210105monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-provides-latest-clinical-developments-at-virtual-r-d-update-event-precigen-inc-na-pgen-20201215monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-host-r-d-update-virtual-event-on-december-15th-to-share-latest-clinical-develo-pgen-20201208monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-presents-new-data-supporting-the-safety-clinical-activity-expansion-and-persisten-pgen-20201207monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-dosing-of-first-patients-with-ultracar-t-cells-manufactured-using-propr-pgen-20201116monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-reports-third-quarter-2020-and-year-to-date-financial-results-precigen-inc-nasdaq-pgen-20201109monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-announce-third-quarter-2020-financial-results-on-november-9th-will-host-pipeli-pgen-20201102monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-strengthens-focus-on-strategic-partnerships-and-names-gaurav-vij-head-of-business-pgen-20201020monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-s-ultraporator-receives-fda-clearance-for-manufacturing-ultracar-t-cells-in-clini-pgen-20201015monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-present-at-h-c-wainwright-22nd-annual-global-investment-conference-precigen-in-pgen-20200908monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-first-patient-dosed-in-phase-i-ii-study-of-first-in-class-prgn-2009-ade-pgen-20200817monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-announce-second-quarter-and-first-half-2020-financial-results-on-august-10th-p-pgen-20200803monthly0.5https://www.biopharmawatch.com/news/PGEN/preclinical-data-for-prgn-3005-ultracar-t-demonstrate-superior-expansion-and-persistence-o-pgen-20200622monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-participate-in-upcoming-jmp-securities-hematology-and-oncology-forum-precigen--pgen-20200611monthly0.5https://www.biopharmawatch.com/news/PGEN/notice-precigen-announces-date-and-location-change-for-its-2020-annual-meeting-of-sharehol-pgen-20200604monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-present-preclinical-data-for-prgn-3005-ultracar-t-at-the-aacr-virtual-annual-m-pgen-20200515monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-announce-first-quarter-2020-financial-results-on-may-6th-precigen-inc-nasdaq-p-pgen-20200429monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-clearance-of-ind-to-initiate-phase-i-ii-study-for-first-in-class-prgn-2-pgen-20200420monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-announce-fourth-quarter-and-full-year-2019-financial-results-on-march-2nd-prec-pgen-20200224monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-receives-fda-orphan-drug-designation-for-prgn-3006-ultracar-t-in-patients-with-ac-pgen-20200106monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-first-patient-dosed-in-phase-1-study-of-prgn-3005-ultracar-t-in-patient-pgen-20190805monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-first-patient-dosed-in-phase-1-1b-study-of-prgn-3006-ultracar-t-in-pati-pgen-20190626monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-opens-gene-and-cell-therapy-manufacturing-facility-in-germantown-maryland-precige-pgen-20190425monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-clearance-of-ind-to-initiate-phase-1-study-for-first-in-class-prgn-3005-pgen-20190211monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-debut-portfolio-at-investor-event-during-the-37th-annual-j-p-morgan-healthcare-pgen-20181231monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-to-host-conference-call-to-provide-business-updates-precigen-inc-a-wholly-owned-s-pgen-20181224monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-clearance-of-ind-to-initiate-phase-1-1b-study-for-first-in-class-prgn-3-pgen-20181221monthly0.5https://www.biopharmawatch.com/news/PGEN/precigen-announces-first-patient-dosed-in-phase-1-clinical-study-of-inxn-4001-precigen-inc-pgen-20180521monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-second-quarter-earnings-release-date-neogen-corporation-nasdaq-neog-will--neog-20241219monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-to-participate-in-2024-ubs-global-healthcare-conference-neogen-corporation-nasdaq-n-neog-20241105monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-first-quarter-2025-results-neogen-corporation-nasdaq-neog-announced-today-neog-20241010monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-the-appointment-of-new-board-member-neogen-corporation-nasdaq-neog-an-inn-neog-20241001monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-first-quarter-earnings-release-date-neogen-corporation-nasdaq-neog-will-i-neog-20240919monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-to-participate-in-2024-wells-fargo-healthcare-conference-neogen-corporation-nasdaq--neog-20240829monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announced-as-an-official-sponsor-of-us-equestrian-neogen-corporation-nasdaq-neog-an-neog-20240822monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-fourth-quarter-2024-results-neogen-corporation-nasdaq-neog-announced-toda-neog-20240730monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-fourth-quarter-earnings-release-date-neogen-corporation-nasdaq-neog-will--neog-20240711monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-petrifilm-automated-feeder-to-improve-efficiency-of-high-throughput-food-s-neog-20240627monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-mds-awarded-contract-from-usda-food-safety-and-inspection-service-neogen-corporatio-neog-20240610monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-releases-cellusmart-technology-for-biofuel-industry-neogen-corporation-nasdaq-neog--neog-20240607monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-to-participate-in-the-goldman-sachs-45th-annual-global-healthcare-conference-neogen-neog-20240605monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-to-participate-in-the-44th-annual-william-blair-growth-stock-conference-neogen-corp-neog-20240530monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-to-participate-in-the-bank-of-america-2024-health-care-conference-neogen-corporatio-neog-20240508monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-to-participate-in-2024-rbc-capital-markets-global-healthcare-conference-neogen-corp-neog-20240507monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-petrifilm-celebrates-40-years-neogen-corporation-nasdaq-neog-is-celebrating-40-year-neog-20240501monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-new-molecular-method-for-detection-of-two-salmonella-serotypes-neogen-corp-neog-20240430monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-forms-genomics-relationship-with-performance-food-group-neogen-corporation-nasdaq-n-neog-20240418monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-farm-fluid-max-disinfectant-launches-across-great-britain-livestock-poultry-markets-neog-20240411monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-third-quarter-2024-results-neogen-corporation-nasdaq-neog-announced-today-neog-20240409monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-third-quarter-earnings-release-date-neogen-corporation-nasdaq-neog-will-i-neog-20240319monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-james-walter-as-vice-president-global-operations-neogen-corporation-nasda-neog-20240206monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-releases-surekill-gel-bait-pro-applicator-neogen-corporation-nasdaq-neog-announced--neog-20240117monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-releases-provecta-pro-flea-tick-collar-for-dogs-neogen-corporation-nasdaq-neog-anno-neog-20240115monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-second-quarter-2024-results-neogen-corporation-nasdaq-neog-announced-toda-neog-20240109monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-to-participate-in-the-42nd-annual-j-p-morgan-healthcare-conference-neogen-corporati-neog-20231221monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-second-quarter-earnings-release-date-neogen-corporation-nasdaq-neog-will--neog-20231219monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-cat-fanciers-association-collaborate-to-advance-feline-dna-testing-neogen-corporati-neog-20231214monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-biosecurity-partnership-with-terranova-neogen-corporation-nasdaq-neog-ann-neog-20231205monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-highly-sensitive-quantitative-elisa-assay-for-the-detection-of-walnut-alle-neog-20231130monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-to-participate-in-the-piper-sandler-35th-annual-healthcare-conference-neogen-corpor-neog-20231121monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-first-quarter-2024-results-neogen-corporation-nasdaq-neog-announced-today-neog-20231010monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-first-quarter-earnings-release-date-neogen-corporation-nasdaq-neog-will-i-neog-20230926monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-releases-new-professional-pest-management-solution-neogen-corporation-nasdaq-neog-a-neog-20230901monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-to-participate-in-2023-wells-fargo-healthcare-conference-neogen-corporation-nasdaq--neog-20230831monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-wins-best-innovative-luminol-based-substrate-award-neogen-corporation-nasdaq-neog-a-neog-20230830monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-igenity-enhanced-dairy-neogen-corporation-nasdaq-neog-announced-today-that-neog-20230815monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-unveils-over-100-new-genetic-tests-neogen-corporation-nasdaq-neog-announced-today-t-neog-20230808monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-fourth-quarter-2023-results-neogen-corporation-nasdaq-neog-announced-toda-neog-20230727monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-fourth-quarter-earnings-release-date-neogen-corporation-nasdaq-neog-will--neog-20230711monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-wins-red-dot-product-design-award-neogen-corporation-nasdaq-neog-is-proud-to-announ-neog-20230619monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-enhanced-genomic-test-for-cats-neogen-corporation-nasdaq-neog-announced-to-neog-20230613monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-dna-test-for-beef-on-dairy-cattle-neogen-corporation-nasdaq-neog-announced-neog-20230606monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-new-assays-for-histamine-detection-neogen-corporation-nasdaq-neog-announce-neog-20230531monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-to-participate-in-the-43rd-annual-william-blair-growth-stock-conference-neogen-corp-neog-20230530monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-new-assays-for-natural-toxin-detection-neogen-corporation-nasdaq-neog-anno-neog-20230509monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-third-quarter-2023-results-neogen-corporation-nasdaq-neog-announced-today-neog-20230330monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-viroxide-super-receives-new-label-claims-in-u-s-and-canada-neogen-corporation-nasda-neog-20230321monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-third-quarter-earnings-release-date-neogen-corporation-nasdaq-neog-will-i-neog-20230316monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-advances-food-safety-data-analytics-strategy-neogen-corporation-nasdaq-neog-has-con-neog-20230224monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-national-ffa-announce-2022-partnership-sae-grant-recipients-neogen-corporation-nasd-neog-20230217monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-second-quarter-2023-results-neogen-corporation-nasdaq-neog-announced-toda-neog-20230105monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-to-participate-in-the-41st-annual-j-p-morgan-healthcare-conference-neogen-corporati-neog-20221229monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-second-quarter-earnings-release-date-neogen-corporation-nasdaq-neog-will--neog-20221222monthly0.5https://www.biopharmawatch.com/news/NEOG/aoac-certifies-neogen-s-reveal-3-d-for-gluten-neogen-corporation-nasdaq-neog-announced-tod-neog-20221220monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference-neogen-corpor-neog-20221123monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-releases-new-dual-detection-needle-for-production-farmers-neogen-corporation-nasdaq-neog-20221115monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-synergize-disinfectant-in-europe-the-middle-east-africa-neogen-corporation-neog-20221115monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-ffa-announce-2023-sponsorship-agreement-neogen-corporation-nasdaq-neog-announced-to-neog-20221101monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-ready-to-use-chemiluminescent-substrate-neogen-corporation-nasdaq-neog-ann-neog-20221031monthly0.5https://www.biopharmawatch.com/news/NEOG/aoac-approves-neogen-s-megazyme-rapid-integrated-total-dietary-fiber-assay-as-the-standard-neog-20221025monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-adds-companion-ready-to-use-disinfectant-to-biosecurity-portfolio-neogen-corporatio-neog-20221010monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-new-genomic-management-technology-neogen-corporation-nasdaq-neog-has-launc-neog-20220929monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-cfo-transition-neogen-corporation-nasdaq-neog-announced-today-that-steve--neog-20220927monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-first-quarter-results-neogen-corporation-nasdaq-neog-announced-today-the--neog-20220927monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-quantitative-cashew-elisa-assay-neogen-corporation-nasdaq-neog-announced-t-neog-20220919monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-the-appointment-of-two-new-board-members-neogen-corporation-nasdaq-neog-a-neog-20220912monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-completes-3m-food-safety-business-merger-neogen-corporation-nasdaq-neog-announced-t-neog-20220901monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-record-revenues-for-fiscal-2022-neogen-corporation-nasdaq-neog-announced--neog-20220726monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-ceremonially-breaks-ground-on-70-million-lansing-expansion-neogen-corporation-nasda-neog-20220720monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-acquires-distributor-in-thailand-neogen-corporation-nasdaq-neog-announced-today-tha-neog-20220706monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-viroxide-super-approved-for-canadian-distribution-neogen-corporation-nasdaq-neog-an-neog-20220606monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-prozap-gamma-defense-insect-control-solution-neogen-corporation-nasdaq-neo-neog-20220601monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-enhanced-quantitative-peanut-elisa-assay-neogen-corporation-nasdaq-neog-an-neog-20220518monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-and-gencove-launch-infiniseek-the-first-whole-genome-and-genotyping-sequencing-solu-neog-20220512monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-and-foxo-technologies-combine-on-epigenetic-research-project-neogen-corporation-nas-neog-20220429monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-genomics-earns-clia-certificate-of-compliance-neogen-corporation-nasdaq-neog-announ-neog-20220427monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-prozap-protectus-pour-on-insecticide-igr-neogen-corporation-nasdaq-neog-an-neog-20220411monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-s-genetic-veterinary-sciences-inc-facility-earns-iso-17025-accreditation-neogen-cor-neog-20220405monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-third-quarter-results-neogen-corporation-nasdaq-neog-announced-today-the--neog-20220324monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-adds-synergize-ready-to-use-disinfectant-to-biosecurity-portfolio-neogen-corporatio-neog-20220301monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-k-blue-luminescent-substrate-neogen-corporation-nasdaq-neog-announced-toda-neog-20220201monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-second-quarter-results-neogen-corporation-nasdaq-neog-announced-today-the-neog-20211221monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-to-combine-3m-s-food-safety-business-with-its-existing-operations-creating-a-global-neog-20211214monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-acquires-genetic-veterinary-sciences-inc-dba-paw-print-genetics-neogen-corporation--neog-20211209monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-acquires-delf-uk-ltd-neogen-corporation-nasdaq-neog-announced-today-that-it-has-acq-neog-20211201monthly0.5https://www.biopharmawatch.com/news/NEOG/omri-lists-neogen-s-aquaprime-neoklor-aquaprime-activator-for-use-in-canada-neogen-corpora-neog-20211006monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-ffa-announce-2022-sponsorship-agreement-neogen-corporation-nasdaq-neog-announced-to-neog-20211004monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-partners-with-hendrix-genetics-to-improve-genetic-performance-in-africa-neogen-corp-neog-20210928monthly0.5https://www.biopharmawatch.com/news/NEOG/igenity-branded-calves-top-livestock-sales-throughout-us-neogen-corporation-nasdaq-neog-ha-neog-20210923monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-record-revenue-in-first-quarter-neogen-corporation-nasdaq-neog-announced--neog-20210921monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-acquires-capinnovet-inc-neogen-corporation-nasdaq-neog-announced-today-that-it-has--neog-20210920monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-reveal-q-for-9-thc-in-hemp-neogen-corporation-nasdaq-neog-announced-today--neog-20210728monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-record-revenues-for-fiscal-2021-neogen-corporation-nasdaq-neog-announced-to-neog-20210720monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-gencove-extend-animal-genomics-partnership-neogen-corporation-nasdaq-neog-announced-neog-20210628monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-center-for-aquaculture-technologies-partner-to-develop-aquaculture-genotyping-tools-neog-20210624monthly0.5https://www.biopharmawatch.com/news/NEOG/aoac-approves-neogen-soleris-direct-yeast-and-mold-for-use-in-cannabis-neogen-corporation--neog-20210617monthly0.5https://www.biopharmawatch.com/news/NEOG/epa-approves-neogen-viroxide-super-for-u-s-distribution-neogen-corporation-nasdaq-neog-ann-neog-20210602monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-2-for-1-stock-split-neogen-corporation-nasdaq-neog-announced-today-that-i-neog-20210512monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-improved-sanitation-monitoring-system-neogen-corporation-nasdaq-neog-annou-neog-20210503monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-donates-25-000-to-national-ffa-organization-neogen-corporation-nasdaq-neog-announce-neog-20210326monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-third-quarter-results-neogen-corporation-nasdaq-neog-announced-today-that-i-neog-20210323monthly0.5https://www.biopharmawatch.com/news/NEOG/papesh-retires-from-neogen-s-board-after-27-years-neogen-corporation-nasdaq-neog-announced-neog-20210302monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-wastewater-detection-screening-for-covid-19-neogen-corporation-nasdaq-neog-neog-20210215monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-relaunches-fda-approved-thyrokare-tablets-for-dogs-neogen-corporation-nasdaq-neog-a-neog-20210201monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-reveal-q-for-aflatoxin-m1-neogen-corporation-nasdaq-neog-announced-today-t-neog-20210112monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-acquires-food-quality-diagnostics-company-neogen-corporation-nasdaq-neog-announced--neog-20210104monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-second-quarter-results-neogen-corporation-nasdaq-neog-announced-today-that--neog-20201222monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-quick-easy-tests-for-meat-speciation-neogen-corporation-nasdaq-neog-has-de-neog-20201214monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-new-preventative-care-dna-test-igenity-canine-wellness-neogen-corporation--neog-20201208monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-igenity-feeder-a-new-commercial-dna-sorting-tool-neogen-corporation-nasdaq-neog-20201028monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-reveal-3-d-food-extraction-buffer-neogen-corporation-nasdaq-neog-announced-neog-20201015monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-first-quarter-results-neogen-corporation-nasdaq-neog-announced-today-that-r-neog-20200922monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-improved-test-for-gluten-neogen-corporation-nasdaq-neog-announced-today-th-neog-20200916monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-ffa-partner-to-support-organization-fight-covid-19-neogen-corporation-nasdaq-neog-a-neog-20200903monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-s-biosentry-904-disinfectant-proven-effective-against-sars-cov-2-the-virus-that-cau-neog-20200813monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-completes-acquisition-of-u-s-rights-and-related-assets-of-elanco-s-standguard-insec-neog-20200803monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-fiscal-2020-results-neogen-corporation-nasdaq-neog-announced-today-that-rev-neog-20200721monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-plans-to-acquire-u-s-rights-and-related-assets-to-elanco-s-standguard-insecticide-n-neog-20200716monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-advanced-soleris-ng-microbial-testing-system-neogen-corporation-nasdaq-neo-neog-20200715monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-enhanced-igenity-beef-genomic-profile-neogen-corporation-nasdaq-neog-annou-neog-20200518monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-viroxide-super-granted-canadian-approval-to-fight-covid-19-neogen-corporation-nasda-neog-20200506monthly0.5https://www.biopharmawatch.com/news/NEOG/herbert-resigns-as-neogen-s-chairman-borel-named-as-successor-neogen-corporation-nasdaq-ne-neog-20200410monthly0.5https://www.biopharmawatch.com/news/NEOG/epa-adds-neogen-s-synergize-and-companion-to-list-of-approved-disinfectants-to-fight-covid-neog-20200407monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-acquires-chilean-food-and-animal-safety-company-neogen-corporation-nasdaq-neog-anno-neog-20200331monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-third-quarter-results-neogen-corporation-nasdaq-neog-announced-today-that-i-neog-20200324monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-increasing-production-of-sanitizers-and-disinfectants-to-fight-coronavirus-neogen-c-neog-20200312monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-acquires-australian-food-safety-assets-neogen-corporation-nasdaq-neog-announced-tod-neog-20200302monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-partners-with-ripe-io-to-bring-blockchain-to-food-safety-and-animal-genomics-neogen-neog-20200205monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-acquires-u-k-based-culture-media-company-neogen-corporation-nasdaq-neog-announced-t-neog-20200203monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-angus-genetics-launch-improved-angus-gs-sm-neogen-corporation-nasdaq-neog-announced-neog-20200130monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-acquires-italian-food-safety-company-neogen-corporation-nasdaq-neog-announced-today-neog-20200113monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-gencove-partner-to-advance-animal-genomics-neogen-corporation-nasdaq-neog-announced-neog-20200109monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-first-crossbred-beef-heterosis-test-neogen-corporation-nasdaq-neog-announc-neog-20200107monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-acquires-its-distributors-in-argentina-and-uruguay-neogen-corporation-nasdaq-neog-a-neog-20200106monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-second-quarter-results-neogen-corporation-nasdaq-neog-announced-today-that--neog-20191223monthly0.5https://www.biopharmawatch.com/news/NEOG/aoac-approves-neogen-s-soleris-for-enterobacteriaceae-neogen-corporation-nasdaq-neog-has-r-neog-20191219monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-first-rapid-test-for-ergot-alkaloids-neogen-corporation-nasdaq-neog-announ-neog-20191212monthly0.5https://www.biopharmawatch.com/news/NEOG/aoac-approves-neogen-s-reveal-3-d-for-peanut-neogen-corporation-nasdaq-neog-has-received-a-neog-20191125monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-first-quarter-results-neogen-corporation-nasdaq-neog-announced-today-that-r-neog-20190924monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-partners-with-igs-to-enhance-igenity-beef-profile-neogen-corporation-nasdaq-neog-to-neog-20190919monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-s-neoseek-for-stec-receives-aoac-validation-neogen-corporation-nasdaq-neog-announce-neog-20190821monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-licenses-food-safety-data-analytics-platform-from-corvium-neogen-corporation-nasdaq-neog-20190819monthly0.5https://www.biopharmawatch.com/news/NEOG/aoac-approves-neogen-s-reveal-q-for-don-neogen-corporation-nasdaq-neog-has-received-perfor-neog-20190801monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-fiscal-2019-results-neogen-corporation-nasdaq-neog-announced-today-that-rev-neog-20190723monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-awarded-usda-contract-neogen-corporation-nasdaq-neog-announced-today-that-it-had-ag-neog-20190722monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-third-quarter-results-neogen-corporation-nasdaq-neog-announced-today-that-i-neog-20190326monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-coconut-food-allergen-test-kits-neogen-s-comprehensive-line-of-tests-to-de-neog-20190325monthly0.5https://www.biopharmawatch.com/news/NEOG/adent-completes-transition-as-neogen-s-ceo-neogen-corporation-nasdaq-neog-announced-today--neog-20190129monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-names-lilly-vp-of-international-business-neogen-corporation-nasdaq-neog-announced-t-neog-20190109monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-acquires-canadian-animal-genomics-laboratory-neogen-corporation-nasdaq-neog-announc-neog-20190102monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-second-quarter-results-neogen-corporation-nasdaq-neog-announced-today-that--neog-20181220monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-board-approves-stock-buyback-neogen-corporation-neog-announced-today-that-its-board-neog-20181010monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-first-quarter-results-neogen-corporation-nasdaq-neog-announced-today-that-n-neog-20180925monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-acquires-livestock-genetic-services-neogen-corporation-nasdaq-neog-announced-today--neog-20180904monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-s-one-hour-listeria-right-now-receives-aoac-approval-neogen-s-revolutionary-listeri-neog-20180820monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-acquires-water-microbiology-testing-technology-neogen-corporation-nasdaq-neog-annou-neog-20180801monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-fiscal-2018-results-neogen-corporation-nasdaq-neog-announced-today-that-rev-neog-20180717monthly0.5https://www.biopharmawatch.com/news/NEOG/acumedia-and-lab-m-brands-become-neogen-culture-media-neogen-corporation-nasdaq-neog-today-neog-20180626monthly0.5https://www.biopharmawatch.com/news/NEOG/hagedorn-named-neogen-vp-of-food-safety-operations-neogen-corporation-nasdaq-neog-announce-neog-20180406monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-record-revenues-and-earnings-neogen-corporation-nasdaq-neog-announced-today-neog-20180103monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-4-for-3-stock-split-neogen-corporation-nasdaq-neog-today-announced-that-i-neog-20171208monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-bradley-retirement-neogen-corporation-nasdaq-neog-announced-today-that-ed-neog-20171206monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-science-change-neogen-corporation-nasdaq-neog-announced-today-that-dr-dan-neog-20171031monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-management-change-neogen-corporation-nasdaq-neog-announced-today-that-ric-neog-20170922monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-21-net-income-increase-neogen-corporation-nasdaq-neog-announced-today-that--neog-20170919monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-acquires-australian-animal-genomics-laboratory-neogen-corporation-nasdaq-neog-annou-neog-20170901monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-record-revenues-and-earnings-neogen-corporation-nasdaq-neog-announced-today-neog-20170718monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-names-new-ceo-neogen-corporation-nasdaq-neog-announced-today-the-company-has-named--neog-20170717monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-develops-fastest-listeria-test-with-no-enrichment-neogen-corporation-nasdaq-neog-ha-neog-20170710monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-expands-food-safety-genomic-testing-neogen-corporation-nasdaq-neog-today-announced--neog-20170619monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-sesame-food-allergen-test-kit-neogen-corporation-nasdaq-neog-has-expanded--neog-20170605monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-neonet-multi-facility-atp-reporting-and-analysis-system-neogen-corporation-neog-20170509monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-24-increase-in-net-income-neogen-corporation-nasdaq-neog-announced-today-th-neog-20170321monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-revolutionary-new-mycotoxin-tests-neogen-corporation-nasdaq-neog-has-annou-neog-20170131monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-senestech-agreement-cancellation-neogen-corporation-nasdaq-neog-announced-neog-20170124monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-acquires-brazil-based-rogama-neogen-corporation-nasdaq-neog-announced-today-that-it-neog-20161227monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-23-increase-in-net-income-neogen-corporation-nasdaq-neog-announced-today-th-neog-20161221monthly0.5https://www.biopharmawatch.com/news/NEOG/fischer-resigns-as-neogen-director-neogen-corporation-nasdaq-neog-announced-today-that-a-c-neog-20161214monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-names-kephart-as-chief-science-officer-neogen-corporation-nasdaq-neog-announced-tod-neog-20161207monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-acquires-u-k-based-quat-chem-neogen-corporation-nasdaq-neog-announced-today-that-it-neog-20161201monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-named-commercialization-partner-of-the-year-the-university-of-nebraska-has-announce-neog-20161108monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-selected-by-scottish-gov-t-for-beef-herd-improvement-program-neogen-corporation-nas-neog-20161027monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-12-revenue-increase-neogen-corporation-nasdaq-neog-announced-today-that-rev-neog-20160927monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-s-accupoint-advanced-receives-aoac-approval-neogen-corporation-nasdaq-neog-announce-neog-20160919monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-record-revenues-and-earnings-neogen-corporation-nasdaq-neog-announced-today-neog-20160719monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-acquires-preserve-international-and-tetradyne-neogen-corporation-nasdaq-neog-announ-neog-20160502monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-acquires-brazilian-animal-genomics-company-neogen-corporation-nasdaq-neog-announced-neog-20160427monthly0.5https://www.biopharmawatch.com/news/NEOG/crowder-resigns-as-neogen-director-neogen-corporation-nasdaq-neog-announced-today-that-dr--neog-20160418monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-water-based-line-of-mycotoxin-tests-neogen-corporation-nasdaq-neog-has-dev-neog-20160405monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-12-increase-in-net-income-neogen-corporation-nasdaq-neog-announced-today-th-neog-20160323monthly0.5https://www.biopharmawatch.com/news/NEOG/donofrio-joins-neogen-as-director-of-microbiology-neogen-corporation-nasdaq-neog-announced-neog-20160222monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-s-ansr-for-listeria-receives-afnor-validation-neogen-s-ansr-for-listeria-has-been-n-neog-20160215monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-acquires-rodenticide-assets-neogen-corporation-nasdaq-neog-announced-today-that-it--neog-20151223monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-16-increase-in-net-income-neogen-corporation-nasdaq-neog-announced-today-th-neog-20151221monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-s-ansr-for-e-coli-o157-h7-receives-aoac-approval-neogen-has-received-approval-from--neog-20151209monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-ansr-for-e-coli-o157-h7-neogen-corporation-has-developed-the-quickest-and--neog-20151103monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-first-high-volume-water-based-aflatoxin-test-neogen-has-developed-the-firs-neog-20151020monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-11-revenue-increase-neogen-corporation-nasdaq-neog-announced-today-that-rev-neog-20150921monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-acquires-u-k-based-lab-m-holdings-neogen-corporation-nasdaq-neog-announced-today-th-neog-20150827monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-neoseek-salmonella-serotyping-service-neogen-corporation-nasdaq-neog-today-neog-20150727monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-record-revenues-and-earnings-neogen-corporation-nasdaq-neog-announced-today-neog-20150721monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-s-ansr-for-listeria-monocytogenes-receives-aoac-approval-neogen-corporation-has-rec-neog-20150709monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-signs-commercialization-agreement-with-illumina-neogen-corporation-nasdaq-neog-anno-neog-20150707monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-accupoint-advanced-neogen-has-released-an-enhanced-version-of-its-popular--neog-20150609monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-acquires-india-food-safety-company-neogen-corporation-nasdaq-neog-announced-today-t-neog-20150601monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-reveal-for-multi-treenut-food-allergen-test-neogen-has-developed-a-rapid-t-neog-20150331monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-ceo-adopts-10b5-1-trading-plan-neogen-corporation-nasdaq-neog-announced-today-that--neog-20150327monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-13-increase-in-net-income-neogen-corporation-nasdaq-neog-announced-today-th-neog-20150326monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-26-increase-in-net-income-neogen-corporation-nasdaq-neog-announced-today-th-neog-20141218monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-acquires-assets-of-its-chinese-distributor-neogen-corporation-nasdaq-neog-announced-neog-20141208monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-names-coo-neogen-corporation-nasdaq-neog-announced-today-that-it-has-named-richard--neog-20141204monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-acquires-biolumix-neogen-corporation-nasdaq-neog-announced-today-that-effective-sep-neog-20141001monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-13-net-income-increase-neogen-corporation-nasdaq-neog-announced-today-that--neog-20140922monthly0.5https://www.biopharmawatch.com/news/NEOG/merck-animal-health-to-market-neogen-s-dairy-genomic-program-neogen-corporation-nasdaq-neo-neog-20140918monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-comments-on-senestech-neogen-corporation-nasdaq-neog-advised-market-analysts-today--neog-20140724monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-19-increase-in-annual-revenues-neogen-corporation-nasdaq-neog-announced-tod-neog-20140722monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-coo-resigns-neogen-corporation-nasdaq-neog-announced-today-that-stephen-snyder-neog-neog-20140718monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-licenses-innovative-senestech-rodent-control-technology-neogen-corporation-nasdaq-n-neog-20140616monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-disinfectants-proven-effective-against-deadly-pig-virus-neogen-corporation-nasdaq-n-neog-20140528monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-third-quarter-results-neogen-corporation-nasdaq-neog-announced-today-that-i-neog-20140325monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-third-quarter-results-conference-call-neogen-corporation-nasdaq-neog-anno-neog-20140324monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-third-quarter-results-conference-call-neogen-corporation-nasdaq-neog-anno-neog-20140320monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-licenses-cargill-patents-neogen-corporation-nasdaq-neog-announced-today-that-it-has-neog-20140113monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-acquires-chem-tech-neogen-corporation-nasdaq-neog-announced-today-that-it-has-acqui-neog-20140102monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-second-quarter-results-neogen-corporation-nasdaq-neog-announced-today-that--neog-20131219monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-introduces-neofilm-for-simple-microbial-tests-neogen-corporation-nasdaq-neog-announ-neog-20131202monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-acquires-prima-tech-neogen-corporation-nasdaq-neog-announced-today-that-it-has-acqu-neog-20131101monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-shares-to-be-priced-oct-31-neogen-corporation-nasdaq-neog-today-announced-that-a-mi-neog-20131030monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-shares-begin-post-split-trading-neogen-corporation-nasdaq-neog-today-announced-that-neog-20131030monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-3-for-2-stock-split-neogen-corporation-nasdaq-neog-today-announced-that-i-neog-20131003monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-18-revenue-increase-neogen-corporation-nasdaq-neog-announced-today-that-its-neog-20130924monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-1st-quarter-results-conference-call-neogen-corporation-nasdaq-neog-announ-neog-20130923monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-1st-quarter-results-conference-call-neogen-corporation-nasdaq-neog-announ-neog-20130917monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-21-increase-in-annual-net-income-neogen-corporation-nasdaq-neog-announced-t-neog-20130723monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-year-end-results-conference-call-neogen-corporation-nasdaq-neog-announces-neog-20130722monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-year-end-results-conference-call-neogen-corporation-nasdaq-neog-announces-neog-20130716monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-acquires-syrvet-incorporated-neogen-corporation-nasdaq-neog-announced-today-that-it-neog-20130701monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-comprehensive-dairy-heifer-genomic-test-neogen-corporation-nasdaq-neog-ann-neog-20130620monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-announces-bohannon-retirement-successor-named-neogen-corporation-nasdaq-neog-announ-neog-20130610monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-comprehensive-cattle-genomic-test-neogen-corporation-nasdaq-neog-announced-neog-20130506monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-27-increase-in-quarterly-net-income-neogen-corporation-nasdaq-neog-announce-neog-20130326monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-corporation-announces-3rd-quarter-results-conference-call-neogen-corporation-nasdaq-neog-20130325monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-rapid-tests-for-ractopamine-as-international-debate-continues-on-the-use-o-neog-20130321monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-corporation-announces-3rd-quarter-results-conference-call-neogen-corporation-nasdaq-neog-20130320monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-responding-to-horse-meat-in-beef-concerns-neogen-corporation-nasdaq-neog-has-seen-a-neog-20130312monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-acquires-scidera-genomics-neogen-corporation-nasdaq-neog-announced-today-that-it-ha-neog-20130102monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-30-increase-in-quarterly-net-income-neogen-corporation-nasdaq-neog-announce-neog-20121220monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-corporation-announces-2nd-quarter-results-conference-call-neogen-corporation-nasdaq-neog-20121219monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-corporation-announces-2nd-quarter-results-conference-call-neogen-corporation-nasdaq-neog-20121217monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-acquires-macleod-pharmaceuticals-neogen-corporation-nasdaq-neog-announced-today-tha-neog-20121002monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-record-first-quarter-revenue-and-net-income-neogen-corporation-nasdaq-neog--neog-20120925monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-corporation-announces-1st-quarter-results-conference-call-neogen-corporation-nasdaq-neog-20120924monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-corporation-announces-1st-quarter-results-conference-call-neogen-corporation-nasdaq-neog-20120918monthly0.5https://www.biopharmawatch.com/news/NEOG/usda-issues-letter-of-no-objection-for-neogen-s-neoseek-stec-detection-system-neogen-corpo-neog-20120912monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-ansr-for-listeria-neogen-corporation-nasdaq-neog-has-developed-the-quickes-neog-20120806monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-year-end-results-neogen-corporation-nasdaq-neog-announced-today-that-its-re-neog-20120724monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-corporation-announces-year-end-results-conference-call-neogen-corporation-nasdaq-ne-neog-20120723monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-corporation-announces-year-end-results-conference-call-neogen-corporation-nasdaq-ne-neog-20120718monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-acquires-igenity-from-merial-neogen-corporation-nasdaq-neog-announced-today-that-it-neog-20120501monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-third-quarter-revenue-and-net-income-increases-neogen-corporation-nasdaq-ne-neog-20120327monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-develops-simple-precise-test-for-mold-toxin-zearalenone-neogen-corporation-nasdaq-n-neog-20120116monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-fully-quantitative-lateral-flow-test-for-don-neogen-corporation-has-develo-neog-20120103monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-second-quarter-results-neogen-corporation-nasdaq-neog-announced-today-that--neog-20111222monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-corporation-announces-2nd-quarter-results-conference-call-neogen-corporation-nasdaq-neog-20111221monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-develops-quicker-test-for-yeast-and-mold-neogen-corporation-nasdaq-neog-has-develop-neog-20111107monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-first-quarter-revenue-and-net-income-increases-neogen-corporation-nasdaq-ne-neog-20110927monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-fully-quantitative-lateral-flow-test-for-aflatoxin-neogen-corporation-nasd-neog-20110922monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-1st-quarter-results-conference-call-neogen-corporation-nasdaq-neog-announces-the-fo-neog-20110921monthly0.5https://www.biopharmawatch.com/news/NEOG/geneseek-partners-with-researchers-to-combat-e-coli-neogen-corporation-nasdaq-neog-has-ann-neog-20110822monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-30-increase-in-net-income-neogen-corporation-nasdaq-neog-announced-today-th-neog-20110726monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-corporation-announces-year-end-results-conference-call-neogen-corporation-nasdaq-ne-neog-20110725monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-launches-breakthrough-neoseek-system-for-rapid-genomic-detection-and-identification-neog-20110721monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-corporation-announces-year-end-results-conference-call-neogen-corporation-nasdaq-ne-neog-20110714monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-s-betastar-plus-dairy-antibiotic-test-approved-by-fda-ncims-neogen-corporation-nasd-neog-20110606monthly0.5https://www.biopharmawatch.com/news/NEOG/william-t-boehm-joins-neogen-s-board-of-directors-neogen-corporation-nasdaq-neog-announced-neog-20110517monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-27-increase-in-quarterly-net-income-neogen-corporation-nasdaq-neog-announce-neog-20110322monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-corporation-announces-3rd-quarter-results-conference-call-neogen-corporation-nasdaq-neog-20110321monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-corporation-announces-3rd-quarter-results-conference-call-neogen-corporation-nasdaq-neog-20110315monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-s-tests-for-salmonella-in-feed-meet-fda-draft-guidance-neogen-corporation-nasdaq-ne-neog-20110125monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-s-rapid-test-for-salmonella-enteritidis-receives-fda-approval-neogen-corporation-na-neog-20110112monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-names-quinlan-as-cfo-neogen-corporation-nasdaq-neog-announced-today-that-it-has-nam-neog-20110106monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-reports-33-increase-in-net-income-neogen-corporation-nasdaq-neog-announced-today-th-neog-20110104monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-corporation-announces-2nd-quarter-results-conference-call-neogen-corporation-nasdaq-neog-20110103monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-corporation-announces-2nd-quarter-results-conference-call-neogen-corporation-nasdaq-neog-20101222monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-s-creagh-named-director-of-michigan-s-dept-of-agriculture-rural-development-neogen--neog-20101201monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-s-rapid-test-for-salmonella-enteritidis-receives-aoac-approval-neogen-corporation-n-neog-20101108monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-again-named-to-forbes-list-of-best-small-companies-forbes-magazine-has-named-neogen-neog-20101021monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-s-revenues-and-net-income-increase-33-neogen-corporation-nasdaq-neog-announced-toda-neog-20100923monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-corporation-announces-1st-quarter-results-conference-call-neogen-corporation-nasdaq-neog-20100922monthly0.5https://www.biopharmawatch.com/news/NEOG/neogen-corporation-announces-1st-quarter-results-conference-call-neogen-corporation-nasdaq-neog-20100916monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-new-data-across-its-cardiometabolic-portfolio-at-american-diabetes-associat-amgn-20260607monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-goldman-sachs-47th-annual-global-healthcare-conference-amgen-nasda-amgn-20260604monthly0.5https://www.biopharmawatch.com/news/AMGN/europa-ische-kommission-erteilt-zulassung-fu-r-imdylltra-von-amgen-fu-r-die-behandlung-von-amgn-20260603monthly0.5https://www.biopharmawatch.com/news/AMGN/la-commission-europe-enne-approuve-imdylltra-d-amgen-pour-le-traitement-du-cancer-du-poumo-amgn-20260603monthly0.5https://www.biopharmawatch.com/news/AMGN/euro-pska-komisia-schva-lila-liek-imdylltra-spoloc-nosti-amgen-na-liec-bu-pokroc-ile-ho-s--amgn-20260603monthly0.5https://www.biopharmawatch.com/news/AMGN/evropska-komise-schva-lila-pr-i-pravek-imdylltra-od-spolec-nosti-amgen-k-le-c-be-extenzivn-amgn-20260603monthly0.5https://www.biopharmawatch.com/news/AMGN/komisja-europejsa-zatwierdza-preparat-imdylltra-firmy-amgen-do-leczenia-drobnokomo-rkowego-amgn-20260603monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-imdylltra-amgen-nasdaq-amgn-imdylltra-amgn-20260603monthly0.5https://www.biopharmawatch.com/news/AMGN/la-ce-aprueba-imdylltra-de-amgen-para-el-ca-ncer-de-pulmo-n-de-ce-lulas-pequen-as-en-estad-amgn-20260603monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-new-data-across-rare-autoimmune-and-inflammatory-diseases-at-eular-2026-a-amgn-20260603monthly0.5https://www.biopharmawatch.com/news/AMGN/european-commission-approves-amgen-s-imdylltra-for-the-treatment-of-extensive-stage-small--amgn-20260601monthly0.5https://www.biopharmawatch.com/news/AMGN/repatha-cuts-risk-of-first-major-cardiovascular-events-by-31-in-high-risk-patients-without-amgn-20260328monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-amgen-nasdaq-amgn-wil-amgn-20260107monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline-amgen-nasdaq-amgn-today-amgn-20260106monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-takes-action-with-the-u-s-government-to-lower-the-cost-of-medicines-for-american-pat-amgn-20251219monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2025-fourth-quarter-dividend-amgen-nasdaq-amgn-today-announced-that-its-bo-amgn-20251031monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-tezspire-for-chronic-rhinosinusitis-with-nasal-polyps-amgen-nasdaq-amgn-and-a-amgn-20251017monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-makes-repatha-available-through-amgennow-a-direct-to-patient-program-in-the-u-s-amge-amgn-20251006monthly0.5https://www.biopharmawatch.com/news/AMGN/landmark-phase-3-trial-vesalius-cv-meets-primary-endpoints-in-a-cardiovascular-primary-pre-amgn-20251002monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-650m-expansion-of-u-s-manufacturing-creating-hundreds-of-new-jobs-amgen-na-amgn-20250926monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-kyowa-kirin-announce-top-line-results-from-rocatinlimab-phase-3-ascend-long-term-amgn-20250908monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-morgan-stanley-23rd-annual-global-healthcare-conference-amgen-nasd-amgn-20250904monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-investing-more-than-half-a-billion-dollars-in-new-state-of-the-art-center-for-scienc-amgn-20250902monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-2025-wells-fargo-healthcare-conference-amgen-nasdaq-amgn-will-pres-amgn-20250829monthly0.5https://www.biopharmawatch.com/news/AMGN/repatha-now-indicated-for-adults-at-increased-risk-for-major-adverse-cardiovascular-events-amgn-20250825monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-second-quarter-2025-financial-results-amgen-nasdaq-amgn-today-announced-fina-amgn-20250805monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2025-third-quarter-dividend-amgen-nasdaq-amgn-today-announced-that-its-boa-amgn-20250801monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2025-second-quarter-financial-results-amgen-nasdaq-amgn-today-a-amgn-20250731monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-positive-topline-phase-3-results-for-bemarituzumab-in-fibroblast-growth-fa-amgn-20250630monthly0.5https://www.biopharmawatch.com/news/AMGN/results-from-amgen-s-phase-2-obesity-study-of-monthly-maritide-presented-at-the-american-d-amgn-20250623monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-phase-2-maritide-data-to-be-presented-at-the-american-diabetes-association-85th-sc-amgn-20250618monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-football-legend-barry-sanders-highlight-dangers-of-bad-cholesterol-in-new-docume-amgn-20250613monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-goldman-sachs-46th-annual-global-healthcare-conference-amgen-nasdaq-am-amgn-20250605monthly0.5https://www.biopharmawatch.com/news/AMGN/imdelltra-significantly-reduced-risk-of-death-by-40-in-small-cell-lung-cancer-patients-amg-amgn-20250602monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-jefferies-global-healthcare-conference-amgen-nasdaq-amgn-will-present--amgn-20250530monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-2025-rbc-capital-markets-global-healthcare-conference-amgen-nasdaq-amgn-20250516monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference-amgen-n-amgn-20250509monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-first-quarter-2025-financial-results-amgen-nasdaq-amgn-today-announced-finan-amgn-20250501monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2025-first-quarter-financial-results-amgen-nasdaq-amgn-today-an-amgn-20250428monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-900-million-manufacturing-expansion-creation-of-350-new-jobs-in-ohio-amgen-amgn-20250425monthly0.5https://www.biopharmawatch.com/news/AMGN/imdelltra-demonstrated-superior-overall-survival-in-small-cell-lung-cancer-amgen-nasdaq-am-amgn-20250411monthly0.5https://www.biopharmawatch.com/news/AMGN/uplizna-inebilizumab-cdon-is-now-the-first-and-only-fda-approved-treatment-for-igg4-relate-amgn-20250403monthly0.5https://www.biopharmawatch.com/news/AMGN/uplizna-inebilizumab-cdon-significantly-improves-generalized-myasthenia-gravis-symptoms-in-amgn-20250313monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-kyowa-kirin-provide-top-line-results-from-rocatinlimab-phase-3-ignite-study-in-a-amgn-20250308monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2025-second-quarter-dividend-amgen-nasdaq-amgn-today-announced-that-its-bo-amgn-20250304monthly0.5https://www.biopharmawatch.com/news/AMGN/positive-results-from-tezspire-tezepelumab-ekko-phase-3-waypoint-trial-highlight-rapid-sus-amgn-20250301monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-45th-annual-td-cowen-health-care-conference-amgen-nasdaq-amgn-will-amgn-20250228monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-citi-s-2025-virtual-oncology-leadership-summit-amgen-nasdaq-amgn-will--amgn-20250214monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-35th-annual-oppenheimer-healthcare-life-sciences-conference-amgen--amgn-20250207monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-fourth-quarter-and-full-year-2024-financial-results-amgen-nasdaq-amgn-today--amgn-20250204monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2024-fourth-quarter-and-full-year-financial-results-amgen-nasda-amgn-20250131monthly0.5https://www.biopharmawatch.com/news/AMGN/evropska-komise-schva-lila-pr-i-pravek-blincyto-pro-le-c-bu-philadelphia-chromozom-negativ-amgn-20250131monthly0.5https://www.biopharmawatch.com/news/AMGN/europa-ische-kommission-genehmigt-blincyto-bei-philadelphia-chromosom-negativer-cd19-posit-amgn-20250130monthly0.5https://www.biopharmawatch.com/news/AMGN/blincyto-cd19-b-amgen-nasdaq-amgn-blincyto-amgn-20250130monthly0.5https://www.biopharmawatch.com/news/AMGN/la-commission-europeenne-approuve-blincyto-pour-la-leuce-mie-lymphoblastique-aigue-a-pre-c-amgn-20250130monthly0.5https://www.biopharmawatch.com/news/AMGN/euro-pska-komisia-schva-lila-liek-blincyto-na-liec-bu-aku-tnej-lymfoblastovej-leuke-mie-ne-amgn-20250130monthly0.5https://www.biopharmawatch.com/news/AMGN/komisja-europejska-zatwierdza-blincyto-w-terapii-konsoliduja-cej-stosowanej-u-pacjento-w-z-amgn-20250130monthly0.5https://www.biopharmawatch.com/news/AMGN/la-comisio-n-europea-aprueba-blincyto-amgen-nasdaq-amgn-anuncio-hoy-que-la-comisio-n-europ-amgn-20250130monthly0.5https://www.biopharmawatch.com/news/AMGN/european-commission-approves-blincyto-in-philadelphia-chromosome-negative-cd19-positive-b--amgn-20250129monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-lumakras-sotorasib-in-combination-with-vectibix-panitumumab-for-chemorefracto-amgn-20250117monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-43rd-annual-j-p-morgan-healthcare-conference-amgen-nasdaq-amgn-will-pr-amgn-20250108monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2025-first-quarter-dividend-amgen-nasdaq-amgn-today-announced-that-its-boa-amgn-20241210monthly0.5https://www.biopharmawatch.com/news/AMGN/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagn-amgn-20241207monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-1-billion-manufacturing-expansion-in-north-carolina-amgen-nasdaq-amgn-toda-amgn-20241205monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-citi-s-2024-global-healthcare-conference-amgen-nasdaq-amgn-will-presen-amgn-20241202monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-7th-annual-evercore-healthconx-conference-amgen-nasdaq-amgn-will-p-amgn-20241129monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-robust-weight-loss-with-maritide-in-people-living-with-obesity-or-overweig-amgn-20241126monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-host-webcast-to-discuss-maritide-phase-2-results-and-progress-on-development-prog-amgn-20241126monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-senior-executive-research-appointment-amgen-nasdaq-amgn-today-announced-th-amgn-20241120monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-new-data-across-rare-inflammatory-diseases-at-acr-2024-amgen-nasdaq-amgn-to-amgn-20241114monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-provides-statement-on-maritide-phase-1-data-amgen-nasdaq-amgn-today-issued-the-follo-amgn-20241113monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-2024-ubs-global-healthcare-conference-amgen-nasdaq-amgn-will-prese-amgn-20241108monthly0.5https://www.biopharmawatch.com/news/AMGN/tezspire-met-both-co-primary-endpoints-in-phase-3-trial-for-chronic-rhinosinusitis-with-na-amgn-20241108monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-third-quarter-2024-financial-results-amgen-nasdaq-amgn-today-announced-finan-amgn-20241030monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2024-fourth-quarter-dividend-amgen-nasdaq-amgn-today-announced-that-its-bo-amgn-20241025monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2024-third-quarter-financial-results-amgen-nasdaq-amgn-today-an-amgn-20241024monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-positive-phase-3-data-for-uplizna-inebilizumab-cdon-in-generalized-myasthen-amgn-20241015monthly0.5https://www.biopharmawatch.com/news/AMGN/la-la-anthony-partners-with-amgen-to-share-candid-behind-the-scenes-look-at-how-plaque-pso-amgn-20241001monthly0.5https://www.biopharmawatch.com/news/AMGN/tepezza-teprotumumab-receives-approval-in-japan-for-the-treatment-of-active-thyroid-eye-di-amgn-20240924monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-host-conference-call-to-discuss-new-topline-data-in-inflammation-and-rare-disease-amgn-20240923monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-data-from-multiple-early-stage-clinical-trials-at-esmo-2024-amgen-nasdaq--amgn-20240913monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-new-data-for-first-in-class-imdelltra-tarlatamab-dlle-in-small-cell-lung-ca-amgn-20240909monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-2024-wells-fargo-healthcare-conference-amgen-nasdaq-amgn-will-pres-amgn-20240830monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-morgan-stanley-22nd-annual-global-healthcare-conference-amgen-nasd-amgn-20240829monthly0.5https://www.biopharmawatch.com/news/AMGN/otezla-apremilast-now-available-in-the-u-s-for-moderate-to-severe-pediatric-plaque-psorias-amgn-20240820monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-second-quarter-2024-financial-results-amgen-nasdaq-amgn-today-announced-fina-amgn-20240806monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2024-third-quarter-dividend-amgen-nasdaq-amgn-today-announced-that-its-boa-amgn-20240802monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2024-second-quarter-financial-results-amgen-nasdaq-amgn-today-a-amgn-20240801monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-blincyto-blinatumomab-in-cd19-positive-philadelphia-chromosome-negative-b-cel-amgn-20240614monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-innovative-rheumatology-research-at-eular-2024-amgen-nasdaq-amgn-today-an-amgn-20240612monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-goldman-sachs-45th-annual-global-healthcare-conference-amgen-nasdaq-am-amgn-20240605monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-positive-results-for-phase-3-registrational-trial-evaluating-uplizna-inebi-amgn-20240605monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-jefferies-global-healthcare-conference-amgen-nasdaq-amgn-will-present--amgn-20240603monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-innovative-research-from-its-robust-oncology-portfolio-at-asco-2024-amgen-amgn-20240528monthly0.5https://www.biopharmawatch.com/news/AMGN/new-data-presented-at-ats-2024-show-the-potential-of-tezspire-to-help-patients-living-with-amgn-20240519monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-imdelltra-tarlatamab-dlle-the-first-and-only-t-cell-engager-therapy-for-the-t-amgn-20240516monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-host-conference-call-following-ats-2024-amgen-nasdaq-amgn-will-host-a-webcasted-c-amgn-20240515monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference-amgen-n-amgn-20240509monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-first-quarter-2024-financial-results-amgen-nasdaq-amgn-today-announced-finan-amgn-20240502monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-highlights-new-copd-asthma-and-vasculitis-research-at-ats-2024-amgen-nasdaq-amgn-tod-amgn-20240501monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2024-first-quarter-financial-results-amgen-nasdaq-amgn-today-an-amgn-20240429monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-submit-teprotumumab-marketing-authorization-application-to-the-european-medicines-amgn-20240426monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-tezspire-phase-2a-copd-data-at-ats-2024-amgen-nasdaq-amgn-today-provided--amgn-20240416monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-new-research-on-otezla-apremilast-at-aad-2024-amgen-nasdaq-amgn-today-annou-amgn-20240309monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2024-second-quarter-dividend-amgen-nasdaq-amgn-today-announced-that-its-bo-amgn-20240306monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-44th-annual-td-cowen-health-care-conference-amgen-nasdaq-amgn-will-amgn-20240229monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-opens-state-of-the-art-biomanufacturing-site-in-central-ohio-amgen-nasdaq-amgn-today-amgn-20240226monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-host-conference-call-on-rare-disease-amgen-nasdaq-amgn-will-host-a-webcasted-call-amgn-20240219monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-34th-annual-oppenheimer-healthcare-life-sciences-conference-amgen--amgn-20240209monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-fourth-quarter-and-full-year-2023-financial-results-amgen-nasdaq-amgn-today--amgn-20240206monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2023-fourth-quarter-and-full-year-financial-results-amgen-nasda-amgn-20240201monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-amgen-nasdaq-amgn-wil-amgn-20240103monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-provides-regulatory-update-on-status-of-lumakras-sotorasib-amgen-nasdaq-amgn-announc-amgn-20231226monthly0.5https://www.biopharmawatch.com/news/AMGN/sus-incorpora-tratamento-para-mieloma-mu-ltiplo-1-o-sus-devera-fornecer-em-breve-um-novo-t-amgn-20231220monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-executive-appointments-to-accelerate-innovation-amgen-nasdaq-amgn-today-an-amgn-20231214monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-sponsor-the-irish-open-amgen-nasdaq-amgn-today-announced-it-will-serve-as-the-tit-amgn-20231214monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-grants-priority-review-to-amgen-s-tarlatamab-application-for-advanced-small-cell-lung--amgn-20231213monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-aposta-em-flexibilizac-a-o-de-local-de-trabalho-para-melhorar-a-produtividade-e-a-sa-amgn-20231213monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2024-first-quarter-dividend-increase-to-2-25-per-share-amgen-nasdaq-amgn-t-amgn-20231212monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-highlights-hematology-portfolio-at-ash-2023-amgen-nasdaq-amgn-today-announced-the-pr-amgn-20231208monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-evercore-isi-healthconx-conference-amgen-nasdaq-amgn-will-present--amgn-20231122monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-new-cardiovascular-research-at-aha-2023-amgen-nasdaq-amgn-today-announced-n-amgn-20231110monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-new-research-in-early-psoriatic-arthritis-at-acr-2023-amgen-nasdaq-amgn-tod-amgn-20231107monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-new-data-from-phase-2-trial-of-dazodalibep-in-sjo-gren-s-syndrome-at-acr-20-amgn-20231107monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-new-data-that-show-blood-pressure-decreases-for-adults-treated-with-krystex-amgn-20231102monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-data-at-acr-2023-across-expanded-rheumatology-pipeline-and-portfolio-amge-amgn-20231101monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-third-quarter-financial-results-amgen-nasdaq-amgn-today-announced-financial--amgn-20231031monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2023-third-quarter-financial-results-amgen-nasdaq-amgn-today-an-amgn-20231025monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2023-fourth-quarter-dividend-amgen-nasdaq-amgn-today-announced-that-its-bo-amgn-20231024monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-new-lumakras-sotorasib-plus-vectibix-panitumumab-data-in-patients-with-kras-amgn-20231022monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-new-tarlatamab-data-in-small-cell-lung-cancer-amgen-nasdaq-amgn-today-annou-amgn-20231020monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-webcast-investor-call-at-esmo-2023-amgen-nasdaq-amgn-today-announced-that-it-will-amgn-20231019monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-new-research-from-oncology-portfolio-and-pipeline-at-esmo-2023-amgen-nasd-amgn-20231016monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-completes-acquisition-of-horizon-therapeutics-plc-amgen-nasdaq-amgn-today-announced--amgn-20231006monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-launches-partners-of-choice-network-of-eight-leading-oncology-academic-centers-amgen-amgn-20230920monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference-amgen-n-amgn-20230911monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-new-lumakras-sotorasib-plus-chemotherapy-data-in-first-line-kras-g12c-nsclc-amgn-20230910monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-morgan-stanley-global-healthcare-conference-amgen-nasdaq-amgn-will-amgn-20230907monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-horizon-therapeutics-plc-resolve-ftc-lawsuit-clearing-path-to-close-acquisition--amgn-20230901monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-2023-wells-fargo-healthcare-conference-and-the-citi-global-healthc-amgn-20230831monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-late-breaking-phase-2-olpasiran-data-at-esc-2023-amgen-nasdaq-amgn-today-an-amgn-20230826monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-discuss-application-for-lumakras-sotorasib-for-the-treatment-of-kras-g12c-positiv-amgn-20230821monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-second-quarter-financial-results-amgen-nasdaq-amgn-today-announced-financial-amgn-20230803monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2023-third-quarter-dividend-amgen-nasdaq-amgn-today-announced-that-its-boa-amgn-20230801monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2023-second-quarter-financial-results-amgen-nasdaq-amgn-today-a-amgn-20230731monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-amplia-o-nu-mero-de-mulheres-na-lideranc-a-a-amgen-anuncia-promoc-o-es-internas-que--amgn-20230731monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-amplia-o-nu-mero-de-mulheres-na-lideranc-a-a-amgen-anuncia-promoc-o-es-internas-que--amgn-20230724monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-grants-full-approval-for-blincyto-blinatumomab-to-treat-minimal-residual-disease-posit-amgn-20230621monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-goldman-sachs-44th-annual-global-healthcare-conference-amgen-nasda-amgn-20230609monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-new-lumakras-sotorasib-codebreak-200-cns-data-at-asco-2023-amgen-nasdaq-amg-amgn-20230604monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-new-scientific-and-clinical-research-across-its-diverse-oncology-portfolio--amgn-20230601monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-new-research-on-otezla-apremilast-in-psoriatic-arthritis-at-eular-2023-amge-amgn-20230530monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-td-cowen-4th-annual-oncology-innovation-summit-amgen-nasdaq-amgn-w-amgn-20230526monthly0.5https://www.biopharmawatch.com/news/AMGN/maio-roxo-alerta-para-as-doenc-as-inflamato-rias-intestinais-dii-e-ca-ncer-colorretal-de-a-amgn-20230524monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-responds-to-ftc-action-re-proposed-acquisition-of-horizon-therapeutics-amgen-nasdaq--amgn-20230516monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-tscan-therapeutics-announce-collaboration-to-identify-novel-targets-in-crohn-s-d-amgn-20230509monthly0.5https://www.biopharmawatch.com/news/AMGN/new-data-from-amgen-s-prolia-denosumab-demonstrates-significant-reduction-in-osteoporotic--amgn-20230508monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-2023-bank-of-america-merrill-lynch-global-healthcare-conference-am-amgn-20230503monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-first-quarter-financial-results-amgen-nasdaq-amgn-today-announced-financial--amgn-20230427monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2023-first-quarter-financial-results-amgen-nasdaq-amgn-today-an-amgn-20230421monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-wins-patent-appeal-on-otezla-apremilast-amgen-nasdaq-amgn-today-announced-that-the-u-amgn-20230419monthly0.5https://www.biopharmawatch.com/news/AMGN/fundac-a-o-amgen-apoia-ensina-brasil-no-fomento-a-formac-a-o-de-cientistas-o-ensina-brasil-amgn-20230410monthly0.5https://www.biopharmawatch.com/news/AMGN/mulheres-respondem-por-70-das-promoc-o-es-de-cargo-dentro-da-amgen-uma-das-principais-empr-amgn-20230327monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-33rd-annual-oppenheimer-healthcare-conference-amgen-nasdaq-amgn-wi-amgn-20230309monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2023-second-quarter-dividend-amgen-nasdaq-amgn-today-announced-that-its-bo-amgn-20230307monthly0.5https://www.biopharmawatch.com/news/AMGN/sus-incorpora-tratamento-para-mulheres-com-osteoporose-na-po-s-menopausa-1-o-brasil-tera-u-amgn-20230307monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-43rd-annual-td-cowen-healthcare-conference-amgen-nasdaq-amgn-will--amgn-20230303monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-new-repatha-evolocumab-and-olpasiran-data-at-acc-amgen-nasdaq-amgn-today--amgn-20230301monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-cardiovascular-study-to-evaluate-association-between-lipoprotein-a-and-car-amgn-20230222monthly0.5https://www.biopharmawatch.com/news/AMGN/na-contrama-o-do-mercado-e-na-mesma-ma-o-da-empresa-afirma-diretora-promovida-a-s-ve-spera-amgn-20230213monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-2023-svb-securities-global-biopharma-conference-amgen-nasdaq-amgn--amgn-20230209monthly0.5https://www.biopharmawatch.com/news/AMGN/tezspire-approved-for-self-administration-in-the-u-s-with-a-new-pre-filled-pen-amgen-nasda-amgn-20230202monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-posts-full-transcript-and-audio-replay-of-fourth-quarter-and-full-year-2022-earnings-amgn-20230131monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-fourth-quarter-and-full-year-2022-financial-results-amgen-nasdaq-amgn-today--amgn-20230131monthly0.5https://www.biopharmawatch.com/news/AMGN/amjevita-adalimumab-atto-first-biosimilar-to-humira-now-available-in-the-united-states-amg-amgn-20230131monthly0.5https://www.biopharmawatch.com/news/AMGN/rule-15-c-announcement-rule-15-proposal-to-horizon-equity-award-holders-and-participants-i-amgn-20230127monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2022-fourth-quarter-and-full-year-financial-results-amgen-nasda-amgn-20230126monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-biolabs-la-at-the-lundquist-institute-announce-nammi-therapeutics-to-receive-the-amgn-20230106monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-amgen-nasdaq-amgn-wil-amgn-20230104monthly0.5https://www.biopharmawatch.com/news/AMGN/blincyto-blinatumomab-added-to-consolidation-chemotherapy-significantly-improves-survival--amgn-20221213monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-10-increase-in-2023-first-quarter-dividend-amgen-nasdaq-amgn-today-announc-amgn-20221212monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-host-webcast-investor-call-following-announced-acquisition-of-horizon-therapeutic-amgn-20221212monthly0.5https://www.biopharmawatch.com/news/AMGN/rule-2-7-announcement-amgen-inc-to-acquire-horizon-therapeutics-plc-not-for-release-public-amgn-20221212monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-new-amg-133-phase-1-clinical-data-at-wcirdc-2022-amgen-nasdaq-amgn-today-an-amgn-20221201monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-webcast-investor-call-at-wcirdc-2022-amgen-nasdaq-amgn-will-host-a-webcast-call-f-amgn-20221128monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2022-evercore-isi-healthcare-conference-amgen-nasdaq-amgn-will--amgn-20221123monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-entra-em-conso-rcio-que-une-farmace-uticas-pela-ampliac-a-o-do-diagno-stico-do-ca-nc-amgn-20221121monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-new-repatha-evolocumab-data-at-aha-2022-amgen-nasdaq-amgn-today-presented-a-amgn-20221107monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-new-research-across-serious-inflammatory-and-bone-diseases-at-acr-2022-am-amgn-20221107monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-new-phase-2-data-that-show-olpasiran-delivers-significant-reduction-in-lipo-amgn-20221106monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2022-credit-suisse-global-healthcare-conference-amgen-nasdaq-am-amgn-20221104monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-third-quarter-2022-financial-results-amgen-nasdaq-amgn-today-announced-finan-amgn-20221103monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-webcast-investor-call-at-aha-2022-amgen-nasdaq-amgn-will-host-a-webcast-call-for--amgn-20221102monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2022-third-quarter-financial-results-amgen-nasdaq-amgn-today-an-amgn-20221031monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2022-fourth-quarter-dividend-amgen-nasdaq-amgn-today-announced-that-its-bo-amgn-20221028monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-successfully-completes-acquisition-of-chemocentryx-amgen-nasdaq-amgn-today-announced-amgn-20221020monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-annual-trends-report-finds-competition-created-by-biosimilars-contributed-21-billi-amgn-20221012monthly0.5https://www.biopharmawatch.com/news/AMGN/estudo-mostra-benefi-cios-de-novo-tratamento-para-ca-ncer-de-pulma-o-de-ce-lulas-na-o-pequ-amgn-20221010monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-opens-new-state-of-the-art-research-and-development-laboratory-site-in-san-francisco-amgn-20221006monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2022-bank-of-america-merrill-lynch-global-healthcare-conference-amgn-20220912monthly0.5https://www.biopharmawatch.com/news/AMGN/lumakras-sotorasib-combined-with-vectibix-panitumumab-shows-confirmed-30-objective-respons-amgn-20220912monthly0.5https://www.biopharmawatch.com/news/AMGN/lumakras-lumykras-sotorasib-demonstrates-superior-progression-free-survival-over-docetaxel-amgn-20220911monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2022-morgan-stanley-global-healthcare-conference-amgen-nasdaq-a-amgn-20220908monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-positive-new-data-at-eadv-2022-for-otezla-apremilast-amgen-nasdaq-amgn-tod-amgn-20220908monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-webcast-investor-call-at-esmo-2022-amgen-nasdaq-amgn-will-host-a-webcast-call-for-amgn-20220907monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2022-wells-fargo-healthcare-conference-amgen-nasdaq-amgn-will-p-amgn-20220902monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2022-citi-global-healthcare-conference-amgen-nasdaq-amgn-will-p-amgn-20220902monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-topline-data-from-lumakras-sotorasib-phase-3-trial-in-non-small-cell-lung--amgn-20220830monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-new-positive-clinical-and-real-world-data-across-inflammation-portfolio-a-amgn-20220830monthly0.5https://www.biopharmawatch.com/news/AMGN/new-amgen-data-at-esc-2022-show-long-term-ldl-c-lowering-with-repatha-evolocumab-was-well--amgn-20220829monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-positive-top-line-results-from-phase-3-study-of-abp-959-biosimilar-candida-amgn-20220823monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-new-data-at-esc-congress-2022-highlighting-up-to-8-5-years-of-repatha-evo-amgn-20220822monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-new-tarlatamab-clinical-data-at-wclc-2022-amgen-nasdaq-amgn-today-announced-amgn-20220808monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-data-at-wclc-2022-highlights-potential-to-deliver-transformative-medicines-for-histo-amgn-20220807monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-second-quarter-2022-financial-results-amgen-nasdaq-amgn-today-announced-fina-amgn-20220804monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-acquire-chemocentryx-for-4-billion-in-cash-amgen-nasdaq-amgn-and-chemocentryx-inc-amgn-20220804monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-appoints-michael-v-drake-to-board-of-directors-amgen-nasdaq-amgn-today-announced-the-amgn-20220803monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2022-third-quarter-dividend-amgen-nasdaq-amgn-today-announced-that-its-boa-amgn-20220803monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-webcast-investor-meeting-at-wclc-2022-amgen-nasdaq-amgn-will-host-a-webcast-call--amgn-20220802monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2022-second-quarter-financial-results-amgen-nasdaq-amgn-today-a-amgn-20220801monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-foundation-more-than-doubles-commitment-to-labxchange-free-virtual-science-education-amgn-20220620monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-goldman-sachs-43rd-annual-healthcare-conference-amgen-nasdaq-am-amgn-20220610monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-riabni-rituximab-arrx-a-biosimilar-to-rituxan-rituximab-for-adults-with-moder-amgn-20220606monthly0.5https://www.biopharmawatch.com/news/AMGN/new-head-to-head-data-show-vectibix-panitumumab-demonstrated-superior-overall-survival-com-amgn-20220605monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2022-jefferies-healthcare-conference-amgen-nasdaq-amgn-will-pre-amgn-20220603monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-positive-topline-phase-2-data-for-investigational-olpasiran-in-adults-with-amgn-20220531monthly0.5https://www.biopharmawatch.com/news/AMGN/new-data-showcases-how-amgen-is-advancing-all-angles-of-cancer-care-through-innovative-onc-amgn-20220526monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-lance-bass-partner-to-encourage-people-to-do-a-double-take-to-recognize-the-earl-amgn-20220512monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2022-bank-of-america-healthcare-conference-amgen-nasdaq-amgn-wi-amgn-20220506monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-releases-annual-environmental-social-governance-report-amgen-nasdaq-amgn-today-relea-amgn-20220502monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-first-quarter-2022-financial-results-amgen-nasdaq-amgn-today-announced-finan-amgn-20220427monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-results-from-two-open-label-extension-studies-of-repatha-evolocumab-amgen--amgn-20220427monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2022-first-quarter-financial-results-amgen-nasdaq-amgn-today-an-amgn-20220422monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-positive-top-line-results-from-phase-3-study-of-abp-654-biosimilar-candida-amgn-20220418monthly0.5https://www.biopharmawatch.com/news/AMGN/lumakras-sotorasib-codebreak-100-study-shows-two-year-overall-survival-of-32-5-in-patients-amgn-20220410monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-new-otezla-apremilast-data-at-aad-congress-2022-amgen-nasdaq-amgn-today-an-amgn-20220325monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-32nd-annual-oppenheimer-healthcare-conference-amgen-nasdaq-amgn-wi-amgn-20220310monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-long-term-outcomes-for-lumakras-sotorasib-in-kras-g12c-mutated-nsclc-at-a-amgn-20220308monthly0.5https://www.biopharmawatch.com/news/AMGN/global-biotechnology-leader-amgen-breaks-ground-on-new-manufacturing-facility-in-north-car-amgn-20220307monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-42nd-annual-cowen-healthcare-conference-amgen-nasdaq-amgn-will-vir-amgn-20220302monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2022-second-quarter-dividend-amgen-nasdaq-amgn-today-announced-that-its-bo-amgn-20220302monthly0.5https://www.biopharmawatch.com/news/AMGN/new-data-further-reinforce-efficacy-of-tezspire-tezepelumab-ekko-in-a-broad-population-of--amgn-20220226monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-issues-inaugural-green-bond-to-advance-esg-goals-amgen-nasdaq-amgn-today-announced-t-amgn-20220222monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-recognized-for-outstanding-esg-performance-amgen-nasdaq-amgn-today-announced-that-it-amgn-20220216monthly0.5https://www.biopharmawatch.com/news/AMGN/lumakras-sotorasib-shows-encouraging-and-clinically-meaningful-anticancer-activity-in-pati-amgn-20220214monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-outlines-growth-strategy-through-2030-at-virtual-business-review-amgen-nasdaq-amgn-t-amgn-20220208monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-provides-long-term-guidance-through-2030-during-business-review-meeting-in-connectio-amgn-20220208monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-fourth-quarter-and-full-year-2021-financial-results-amgen-nasdaq-amgn-today--amgn-20220207monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-host-virtual-business-review-meeting-amgen-nasdaq-amgn-will-host-a-virtual-busine-amgn-20220203monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-plexium-announce-multi-year-drug-discovery-collaboration-to-identify-novel-targe-amgn-20220203monthly0.5https://www.biopharmawatch.com/news/AMGN/lumakras-sotorasib-receives-approval-in-japan-for-patients-with-kras-g12c-mutated-advanced-amgn-20220120monthly0.5https://www.biopharmawatch.com/news/AMGN/tezspire-tezepelumab-ekko-now-available-in-the-united-states-for-the-treatment-of-severe-a-amgn-20220113monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-arrakis-therapeutics-announce-multi-target-collaboration-to-identify-novel-rna-d-amgn-20220111monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-biolabs-la-at-the-lundquist-institute-announce-that-karma-biotechnologies-will-r-amgn-20220110monthly0.5https://www.biopharmawatch.com/news/AMGN/european-commission-approves-lumykras-sotorasib-for-patients-with-kras-g12c-mutated-advanc-amgn-20220110monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-amgen-nasdaq-amgn-wil-amgn-20220106monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-generate-biomedicines-announce-multi-target-multi-modality-research-collaboratio-amgn-20220106monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-goldman-sachs-14th-annual-healthcare-ceos-unscripted-conference-am-amgn-20211223monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-otezla-apremilast-for-the-treatment-of-adult-patients-with-plaque-psoriasis-r-amgn-20211220monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-tezspire-tezepelumab-ekko-in-the-u-s-for-severe-asthma-amgen-nasdaq-amgn-toda-amgn-20211217monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-new-data-being-presented-at-ash-2021-amgen-nasdaq-amgn-today-announced-new-amgn-20211206monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-10-increase-in-2022-first-quarter-dividend-amgen-nasdaq-amgn-today-announc-amgn-20211203monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-positive-top-line-results-from-otezla-apremilast-phase-3-discreet-study-in-amgn-20211201monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-new-kyprolis-carfilzomib-combination-regimen-with-darzalex-faspro-daratumumab-amgn-20211201monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-named-to-dow-jones-sustainability-world-index-for-eighth-consecutive-year-amgen-nasd-amgn-20211129monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-2021-evercore-isi-healthcare-conference-amgen-nasdaq-amgn-will-pre-amgn-20211124monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-2021-piper-sandler-healthcare-conference-amgen-nasdaq-amgn-will-pr-amgn-20211124monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-awards-the-bath-institute-of-rheumatic-diseases-25-000-through-uplift-innovation-cha-amgn-20211117monthly0.5https://www.biopharmawatch.com/news/AMGN/lumykras-sotorasib-receives-positive-opinion-from-ema-chmp-for-patients-with-kras-g12c-mut-amgn-20211112monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-2021-annual-cowen-io-summit-amgen-nasdaq-amgn-will-present-at-the--amgn-20211110monthly0.5https://www.biopharmawatch.com/news/AMGN/first-and-only-randomized-double-blind-head-to-head-study-comparing-aimovig-erenumab-aooe--amgn-20211108monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-begins-construction-on-new-biomanufacturing-plant-in-central-ohio-amgen-nasdaq-amgn--amgn-20211105monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-third-quarter-2021-financial-results-amgen-nasdaq-amgn-today-announced-finan-amgn-20211102monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2021-third-quarter-financial-results-amgen-nasdaq-amgn-today-an-amgn-20211028monthly0.5https://www.biopharmawatch.com/news/AMGN/fortune-and-great-place-to-work-name-amgen-one-of-the-world-s-best-workplaces-in-2021-amge-amgn-20211026monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2021-fourth-quarter-dividend-amgen-nasdaq-amgn-today-announced-that-its-bo-amgn-20211021monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-successfully-completes-acquisition-of-teneobio-inc-amgen-nasdaq-amgn-today-announced-amgn-20211019monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-new-lumakras-sotorasib-combination-data-from-phase-1b-codebreak-101-study--amgn-20211007monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-neumora-therapeutics-announce-strategic-r-d-collaboration-to-accelerate-novel-pr-amgn-20211007monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-new-data-highlighting-global-trends-in-hip-fracture-incidence-and-treatmen-amgn-20211004monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-kyowa-kirin-present-positive-late-breaking-data-from-phase-2-study-of-amg-451-kh-amgn-20211002monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-webcast-investor-call-at-eadv-2021-amgen-nasdaq-amgn-will-host-a-webcast-call-for-amgn-20210929monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-repatha-evolocumab-in-pediatric-patients-age-10-and-older-with-heterozygous-f-amgn-20210924monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-2021-cantor-global-healthcare-conference-amgen-nasdaq-amgn-will-pr-amgn-20210922monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-releases-8th-edition-of-biosimilar-trends-report-amgen-nasdaq-amgn-today-released-th-amgn-20210922monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-wins-patent-case-on-otezla-apremilast-amgen-today-announced-that-the-u-s-district-co-amgn-20210920monthly0.5https://www.biopharmawatch.com/news/AMGN/lumakras-sotorasib-combined-with-vectibix-panitumumab-showed-encouraging-efficacy-and-safe-amgn-20210916monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-the-lundquist-institute-announce-that-diadem-therapeuctics-will-receive-the-firs-amgn-20210914monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-2021-bank-of-america-merrill-lynch-global-healthcare-conference-am-amgn-20210913monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-webcast-investor-call-at-esmo-2021-amgen-nasdaq-amgn-will-host-a-webcast-call-for-amgn-20210913monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-showcase-new-data-from-inflammation-portfolio-at-eadv-virtual-congress-2021-amgen-amgn-20210913monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-19th-annual-morgan-stanley-global-healthcare-conference-amgen-nasd-amgn-20210909monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-new-data-from-thoracic-oncology-portfolio-at-wclc21-amgen-nasdaq-amgn-today-amgn-20210908monthly0.5https://www.biopharmawatch.com/news/AMGN/new-tezepelumab-data-show-86-reduction-in-exacerbations-in-patients-with-severe-asthma-and-amgn-20210905monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-16th-annual-citi-biopharma-conference-amgen-nasdaq-amgn-will-prese-amgn-20210903monthly0.5https://www.biopharmawatch.com/news/AMGN/new-data-at-esc-congress-2021-shows-repatha-evolocumab-improves-features-of-plaque-stabili-amgn-20210827monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-second-quarter-2021-financial-results-amgen-nasdaq-amgn-today-announced-fina-amgn-20210803monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2021-third-quarter-dividend-amgen-nasdaq-amgn-today-announced-that-its-boa-amgn-20210730monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-appoints-s-omar-ishrak-to-board-of-directors-amgen-nasdaq-amgn-today-announced-the-a-amgn-20210729monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2021-second-quarter-financial-results-amgen-nasdaq-amgn-today-a-amgn-20210729monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-the-international-federation-of-psoriasis-associations-launch-uplift-innovation--amgn-20210714monthly0.5https://www.biopharmawatch.com/news/AMGN/tezepelumab-granted-priority-review-by-u-s-fda-amgen-nasdaq-amgn-today-announced-that-the--amgn-20210708monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-approval-of-aimovig-erenumab-in-japan-for-the-suppression-of-onset-of-migr-amgn-20210623monthly0.5https://www.biopharmawatch.com/news/AMGN/acclaimed-makeup-artist-allan-avendan-o-opens-up-about-personal-skin-condition-provides-in-amgn-20210615monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-goldman-sachs-42nd-annual-global-healthcare-conference-amgen-nasda-amgn-20210604monthly0.5https://www.biopharmawatch.com/news/AMGN/results-from-phase-2-codebreak-100-show-lumakras-sotorasib-is-the-first-and-only-kras-g12c-amgn-20210604monthly0.5https://www.biopharmawatch.com/news/AMGN/phase-2-fight-trial-continues-to-show-improved-overall-survival-with-bemarituzumab-plus-ch-amgn-20210604monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-webcast-investor-meeting-at-asco-2021-amgen-nasdaq-amgn-will-host-a-webcast-call--amgn-20210601monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-kyowa-kirin-to-jointly-develop-and-commercialize-khk4083-a-phase-3-ready-potenti-amgn-20210601monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-2021-jefferies-healthcare-conference-amgen-nasdaq-amgn-will-presen-amgn-20210528monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-lumakras-sotorasib-the-first-and-only-targeted-treatment-for-patients-with-kr-amgn-20210528monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-cowen-2nd-annual-virtual-oncology-innovation-summit-amgen-nasdaq-a-amgn-20210519monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-showcase-new-data-from-oncology-portfolio-at-asco-2021-amgen-nasdaq-amgn-today-an-amgn-20210519monthly0.5https://www.biopharmawatch.com/news/AMGN/new-tezepelumab-data-continue-to-strengthen-profile-for-a-broad-population-of-severe-asthm-amgn-20210513monthly0.5https://www.biopharmawatch.com/news/AMGN/efficacy-of-repatha-evolocumab-across-high-risk-patient-populations-reinforced-at-acc-21-a-amgn-20210511monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-tezepelumab-biologics-license-application-submitted-to-u-s-fda-amgen-nasda-amgn-20210510monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-2021-bank-of-america-merrill-lynch-healthcare-conference-amgen-nas-amgn-20210506monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-accepts-amgen-s-supplemental-new-drug-application-for-otezla-apremilast-for-adults-wit-amgn-20210505monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-provides-updated-information-on-lumakras-sotorasib-1-dose-comparison-study-amgen-nas-amgn-20210428monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-first-quarter-2021-financial-results-amgen-nasdaq-amgn-today-announced-finan-amgn-20210427monthly0.5https://www.biopharmawatch.com/news/AMGN/otezla-apremilast-significantly-improved-measures-of-disease-severity-in-adults-with-mild--amgn-20210423monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2021-first-quarter-financial-results-amgen-nasdaq-amgn-today-an-amgn-20210422monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-investigational-targeted-treatment-bemarituzumab-granted-breakthrough-therapy-desi-amgn-20210419monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-launches-biomarker-assist-a-program-to-help-more-patients-with-non-small-cell-lung-c-amgn-20210419monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-successfully-completes-acquisition-of-five-prime-therapeutics-amgen-nasdaq-amgn-toda-amgn-20210416monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-acquire-rodeo-therapeutics-corporation-amgen-inc-nasdaq-amgn-and-rodeo-therapeuti-amgn-20210330monthly0.5https://www.biopharmawatch.com/news/AMGN/marc-o-o-me-s-de-conscientizac-a-o-e-prevenc-a-o-ca-ncer-colorretal-uma-doenc-a-recorrente-amgn-20210325monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-oppenheimer-31st-annual-healthcare-conference-amgen-nasdaq-amgn-wi-amgn-20210311monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-acquire-five-prime-therapeutics-for-1-9-billion-in-cash-amgen-nasdaq-amgn-and-fiv-amgn-20210304monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2021-second-quarter-dividend-amgen-nasdaq-amgn-today-announced-that-its-bo-amgn-20210303monthly0.5https://www.biopharmawatch.com/news/AMGN/blincyto-blinatumomab-demonstrated-significantly-prolonged-event-free-survival-compared-wi-amgn-20210302monthly0.5https://www.biopharmawatch.com/news/AMGN/tezepelumab-is-the-first-biologic-to-significantly-reduce-exacerbations-in-broad-populatio-amgn-20210226monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-cowen-41st-annual-healthcare-conference-amgen-nasdaq-amgn-will-pre-amgn-20210224monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-webcast-investor-meeting-at-aaaai-virtual-annual-meeting-amgen-nasdaq-amgn-will-h-amgn-20210222monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-submits-supplemental-new-drug-application-for-otezla-apremilast-for-adults-with-mild-amgn-20210222monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-grants-sotorasib-priority-review-designation-for-the-treatment-of-patients-with-kras-g-amgn-20210216monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-guggenheim-healthcare-talks-oncology-day-amgen-nasdaq-amgn-today-annou-amgn-20210209monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-sponsors-golden-ticket-at-biolabs-la-at-the-lundquist-institute-to-help-accelerate-l-amgn-20210203monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-fourth-quarter-and-full-year-2020-financial-results-amgen-nasdaq-amgn-today--amgn-20210202monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-breakthrough-therapy-designation-granted-for-sotorasib-in-china-amgen-nasd-amgn-20210129monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2020-fourth-quarter-and-full-year-financial-results-amgen-nasda-amgn-20210128monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-investigational-kras-g12c-inhibitor-sotorasib-demonstrated-rapid-deep-and-durable--amgn-20210128monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-webcast-investor-meeting-at-2020-world-conference-on-lung-cancer-amgen-nasdaq-amg-amgn-20210126monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-showcase-next-frontier-of-innovation-in-lung-cancer-therapies-at-wclc-2020-amgen--amgn-20210112monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-achieve-carbon-neutrality-by-2027-amgen-nasdaq-amgn-today-announced-the-launch-of-amgn-20210111monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-amgen-nasdaq-amgn-wil-amgn-20210106monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-soumet-une-demande-d-autorisation-de-mise-sur-le-marche-du-sotorasib-a-l-agence-euro-amgn-20201223monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-envi-a-solicitud-de-comercializacio-n-de-sotorasib-a-la-agencia-europea-del-medicame-amgn-20201223monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reicht-antrag-auf-marktzulassung-von-sotorasib-bei-der-europa-ischen-arzneimittelage-amgn-20201223monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presenta-all-agenzia-europea-per-i-medicinali-richiesta-di-autorizzazione-all-immiss-amgn-20201223monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-licenses-amg-634-an-investigational-treatment-for-tuberculosis-and-leprosy-to-medici-amgn-20201222monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-submits-sotorasib-marketing-authorization-application-to-the-european-medicines-agen-amgn-20201222monthly0.5https://www.biopharmawatch.com/news/AMGN/update-on-source-phase-3-trial-for-tezepelumab-in-patients-with-severe-oral-corticosteroid-amgn-20201222monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-awards-two-local-biotech-start-ups-with-golden-ticket-to-labcentral-amgen-nasdaq-amg-amgn-20201217monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-amgen-s-riabni-rituximab-arrx-a-biosimilar-to-rituxan-rituximab-amgen-nasdaq--amgn-20201217monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-transfer-listing-of-debt-securities-to-nasdaq-amgen-inc-nasdaq-amgn-today-announc-amgn-20201216monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-10-increase-in-2021-first-quarter-dividend-amgen-nasdaq-amgn-today-announc-amgn-20201216monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-submits-sotorasib-new-drug-application-to-u-s-fda-for-advanced-or-metastatic-non-sma-amgn-20201216monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-sotorasib-granted-breakthrough-therapy-designation-for-advanced-or-metastatic-non--amgn-20201208monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-novartis-partner-with-karamo-brown-to-support-and-empower-people-living-with-mig-amgn-20201207monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-first-clinical-data-for-bcma-targeted-half-life-extended-bite-therapy-amg-amgn-20201205monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-webcast-investor-call-at-ash-2020-amgen-nasdaq-amgn-will-host-a-webcast-call-for--amgn-20201203monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-new-data-being-presented-at-ash-2020-amgen-nasdaq-amgn-today-announced-sev-amgn-20201130monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-evercore-isi-virtual-healthconx-conference-amgen-nasdaq-amgn-will--amgn-20201125monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-transition-development-and-commercial-rights-for-omecamtiv-mecarbil-and-amg-594-t-amgn-20201123monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-jefferies-virtual-london-healthcare-conference-amgen-nasdaq-amgn-w-amgn-20201113monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-cowen-4th-annual-io-summit-amgen-nasdaq-amgn-will-present-at-the-c-amgn-20201110monthly0.5https://www.biopharmawatch.com/news/AMGN/tezepelumab-navigator-phase-3-trial-met-primary-endpoint-of-a-statistically-significant-an-amgn-20201110monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-showcases-new-data-across-cardiovascular-portfolio-at-aha-scientific-sessions-2020-a-amgn-20201109monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-first-clinical-data-for-amg-757-at-sitc-2020-amgen-nasdaq-amgn-today-announ-amgn-20201109monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-29th-annual-credit-suisse-healthcare-conference-amgen-nasdaq-amgn--amgn-20201104monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-third-quarter-2020-financial-results-amgen-nasdaq-amgn-today-announced-finan-amgn-20201028monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-fomenta-doac-a-o-de-medula-o-ssea-entre-seus-colaboradores-em-prol-dos-pacientes-com-amgn-20201028monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2020-third-quarter-financial-results-amgen-nasdaq-amgn-today-an-amgn-20201027monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-participation-of-systemic-lupus-erythematosus-sle-adaptive-clinical-trial--amgn-20201027monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2020-fourth-quarter-dividend-amgen-nasdaq-amgn-today-announced-that-its-bo-amgn-20201021monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-cytokinetics-and-servier-announce-topline-results-from-galactic-hf-a-phase-3-trial-o-amgn-20201008monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-positive-topline-phase-2-results-for-investigational-kras-g12c-inhibitor-s-amgn-20201005monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-five-year-data-that-reinforce-the-safety-and-efficacy-profile-of-aimovig-e-amgn-20201003monthly0.5https://www.biopharmawatch.com/news/AMGN/clinical-data-from-full-phase-1-cohort-of-investigational-sotorasib-published-in-new-engla-amgn-20200920monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-webcast-investor-calls-at-esmo-2020-amgen-nasdaq-amgn-will-host-two-webcast-calls-amgn-20200916monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-showcase-data-from-oncology-pipeline-during-esmo-virtual-congress-2020-amgen-nasd-amgn-20200916monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-mbc-biolabs-announce-winners-of-the-amgen-golden-ticket-amgen-nasdaq-amgn-and-mb-amgn-20200915monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-2020-bank-of-america-virtual-global-healthcare-conference-amgen-na-amgn-20200914monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-18th-annual-morgan-stanley-global-healthcare-conference-amgen-nasd-amgn-20200911monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-15th-annual-citi-biopharma-conference-amgen-nasdaq-amgn-will-prese-amgn-20200904monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-positive-data-from-phase-3b-study-of-repatha-evolocumab-in-pediatric-patie-amgn-20200829monthly0.5https://www.biopharmawatch.com/news/AMGN/new-amgen-data-to-be-presented-at-esc-congress-2020-highlighting-repatha-evolocumab-effica-amgn-20200825monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-new-kyprolis-carfilzomib-combination-regimen-with-darzalex-daratumumab-and-de-amgn-20200820monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-pricing-terms-for-senior-notes-exchange-offers-increases-the-maximum-notes-amgn-20200813monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-early-tender-results-of-senior-notes-exchange-offers-amgen-inc-nasdaq-amgn-amgn-20200813monthly0.5https://www.biopharmawatch.com/news/AMGN/dia-nacional-de-combate-ao-colesterol-brasileiros-negligenciam-as-doenc-as-cardiovasculare-amgn-20200806monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-commences-exchange-offers-for-certain-series-of-outstanding-senior-notes-from-exchan-amgn-20200730monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-second-quarter-2020-financial-results-amgen-nasdaq-amgn-today-announced-fina-amgn-20200728monthly0.5https://www.biopharmawatch.com/news/AMGN/anvisa-aprova-autoinjetor-para-diminuir-exposic-a-o-hospitalar-de-pacientes-em-tratamento--amgn-20200727monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2020-second-quarter-financial-results-amgen-nasdaq-amgn-today-a-amgn-20200723monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2020-third-quarter-dividend-amgen-nasdaq-amgn-today-announced-that-its-boa-amgn-20200723monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-appoints-amy-e-miles-to-board-of-directors-amgen-today-announced-the-appointment-of--amgn-20200723monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-foundation-awards-khan-academy-an-additional-3-million-to-support-science-learning-a-amgn-20200721monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-additional-investment-in-beigene-amgen-nasdaq-amgn-today-announced-an-addi-amgn-20200712monthly0.5https://www.biopharmawatch.com/news/AMGN/appeals-court-affirms-validity-of-enbrel-etanercept-patents-injunction-against-sandoz-s-in-amgn-20200701monthly0.5https://www.biopharmawatch.com/news/AMGN/permanecer-sem-fraturas-e-essencial-para-pacientes-com-osteoporose-durante-a-pandemia-a-os-amgn-20200626monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-is-supporting-advancement-of-amg-634-for-global-health-diseases-in-developing-countr-amgn-20200622monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-bmo-capital-markets-2020-prescriptions-for-success-healthcare-conf-amgn-20200618monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-goldman-sachs-41st-annual-global-healthcare-conference-amgen-nasda-amgn-20200605monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-new-amg-510-clinical-data-across-multiple-solid-tumors-during-asco20-virtua-amgn-20200529monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-jefferies-2020-virtual-healthcare-conference-amgen-nasdaq-amgn-wil-amgn-20200528monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-webcast-investor-meeting-at-56th-annual-meeting-of-the-american-society-of-clinic-amgn-20200526monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-voting-results-of-annual-meeting-of-stockholders-amgen-nasdaq-amgn-today-a-amgn-20200520monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-showcases-oncology-pipeline-at-asco-2020-amgen-nasdaq-amgn-today-announced-that-data-amgn-20200513monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-bank-of-america-merrill-lynch-virtual-global-healthcare-conference-amgn-20200512monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-grants-fast-track-designation-for-omecamtiv-mecarbil-in-heart-failure-amgen-nasdaq-amg-amgn-20200508monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-positive-top-line-results-from-otezla-apremilast-phase-3-advance-study-in--amgn-20200506monthly0.5https://www.biopharmawatch.com/news/AMGN/kyprolis-carfilzomib-patents-upheld-against-generic-manufacturer-amgen-nasdaq-amgn-today-a-amgn-20200505monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-suntrust-robinson-humphrey-life-sciences-summit-virtual-meeting-se-amgn-20200504monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-first-quarter-2020-financial-results-amgen-nasdaq-amgn-today-announced-finan-amgn-20200430monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2020-first-quarter-financial-results-amgen-nasdaq-amgn-today-an-amgn-20200427monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-e-adaptive-biotecnologies-anunciam-parceria-para-desenvolver-anticorpos-com-potencia-amgn-20200409monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-adaptive-biotechnologies-to-participate-in-webinar-on-covid-19-strategic-collabo-amgn-20200407monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-adaptive-biotechnologies-announce-strategic-partnership-to-develop-a-therapeutic-amgn-20200402monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-establishes-wholly-owned-affiliate-in-japan-amgen-nasdaq-amgn-today-announced-that-i-amgn-20200331monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-positive-results-at-acc-20-wcc-from-phase-3b-study-of-repatha-evolocumab-i-amgn-20200328monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-the-amgen-foundation-commit-up-to-12-5-million-to-support-covid-19-relief-effort-amgn-20200323monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2020-second-quarter-dividend-amgen-nasdaq-amgn-today-announced-that-its-bo-amgn-20200304monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-cowen-40th-annual-healthcare-conference-amgen-nasdaq-amgn-will-pre-amgn-20200227monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-cytokinetics-and-servier-announce-continuation-of-galactic-hf-following-planned-inte-amgn-20200226monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-lanc-a-biossimilar-para-tratamento-de-doenc-as-inflamato-rias-a-amgen-uma-das-maiore-amgn-20200203monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-fourth-quarter-and-full-year-2019-financial-results-amgen-nasdaq-amgn-today--amgn-20200130monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2019-fourth-quarter-and-full-year-financial-results-amgen-nasda-amgn-20200127monthly0.5https://www.biopharmawatch.com/news/AMGN/free-labxchange-science-education-accelerator-launched-by-amgen-foundation-and-harvard-s-f-amgn-20200122monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-global-diagnostic-collaborations-to-expand-molecular-testing-for-patients--amgn-20200113monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-amgen-nasdaq-amgn-wil-amgn-20200109monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-goldman-sachs-12th-annual-healthcare-ceos-unscripted-conference-am-amgn-20200107monthly0.5https://www.biopharmawatch.com/news/AMGN/nova-combinac-a-o-terape-utica-diminui-37-do-risco-de-progressa-o-ou-morte-em-pacientes-co-amgn-20200106monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-commences-strategic-collaboration-with-beigene-to-expand-oncology-presence-in-china--amgn-20200102monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-allergan-submit-biologics-license-application-for-abp-798-biosimilar-candidate-t-amgn-20191219monthly0.5https://www.biopharmawatch.com/news/AMGN/european-commission-approves-evenity-romosozumab-for-the-treatment-of-severe-osteoporosis--amgn-20191212monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-10-increase-in-2020-first-quarter-dividend-amgen-nasdaq-amgn-today-announc-amgn-20191211monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-data-from-phase-3-candor-study-combining-kyprolis-carfilzomib-and-darzalex-daratumum-amgn-20191210monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-selects-location-for-r-d-facility-in-the-south-san-francisco-biotechnology-hub-amgen-amgn-20191209monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-amgen-s-avsola-infliximab-axxq-for-the-same-indications-as-remicade-inflixima-amgn-20191206monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-data-being-presented-at-ash-2019-amgen-nasdaq-amgn-today-announced-new-cli-amgn-20191202monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-completes-acquisition-of-otezla-apremilast-amgen-nasdaq-amgn-today-announced-the-suc-amgn-20191121monthly0.5https://www.biopharmawatch.com/news/AMGN/new-results-from-cosmic-hf-presented-at-aha-2019-show-treatment-of-heart-failure-patients--amgn-20191118monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-new-fourier-analysis-showing-benefit-of-repatha-evolocumab-in-high-risk-pa-amgn-20191116monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-the-duke-clinical-research-institute-announce-initiation-of-first-large-scale-re-amgn-20191115monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-highlights-data-to-be-presented-at-aha-2019-across-cardiovascular-portfolio-amgen-na-amgn-20191111monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-28th-annual-credit-suisse-healthcare-conference-amgen-nasdaq-amgn--amgn-20191107monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-enters-into-strategic-collaboration-with-beigene-to-expand-oncology-presence-in-chin-amgn-20191031monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-entra-no-mercado-de-biossimilares-com-o-lanc-amento-de-kanjinti-para-ca-ncer-de-mama-amgn-20191031monthly0.5https://www.biopharmawatch.com/news/AMGN/the-discovery-of-amgen-s-novel-investigational-kras-g12c-inhibitor-amg-510-published-in-na-amgn-20191030monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-third-quarter-2019-financial-results-amgen-nasdaq-amgn-today-announced-finan-amgn-20191029monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2019-third-quarter-financial-results-amgen-nasdaq-amgn-today-an-amgn-20191024monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-make-repatha-evolocumab-available-exclusively-at-its-lower-list-price-option-in-2-amgn-20191024monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-recommends-rejection-of-mini-tender-offer-from-trc-capital-corporation-amgen-nasdaq--amgn-20191023monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2019-fourth-quarter-dividend-amgen-nasdaq-amgn-today-announced-that-its-bo-amgn-20191022monthly0.5https://www.biopharmawatch.com/news/AMGN/nplate-romiplostim-now-approved-for-earlier-use-in-adults-with-immune-thrombocytopenia-amg-amgn-20191018monthly0.5https://www.biopharmawatch.com/news/AMGN/evenity-romosozumab-receives-positive-chmp-opinion-for-the-treatment-of-severe-osteoporosi-amgn-20191018monthly0.5https://www.biopharmawatch.com/news/AMGN/sports-anchor-and-multiple-myeloma-patient-rod-gilmore-joins-amgen-s-myeloma-mvp-team-amge-amgn-20191015monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-foundation-launches-amgen-biotech-experience-in-pittsburgh-the-amgen-foundation-toda-amgn-20191009monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-new-clinical-data-evaluating-novel-investigational-kras-g12c-inhibitor-in--amgn-20190928monthly0.5https://www.biopharmawatch.com/news/AMGN/heart-attack-survivors-are-taking-steps-to-reduce-their-cardiovascular-risk-but-are-they-t-amgn-20190926monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-webcast-investor-call-at-esmo-2019-amgen-nasdaq-amgn-will-host-a-webcast-call-for-amgn-20190925monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-positive-results-from-two-phase-3-blincyto-blinatumomab-studies-in-pediatr-amgn-20190924monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-showcases-new-data-from-oncology-pipeline-and-portfolio-at-esmo-2019-amgen-nasdaq-am-amgn-20190917monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference-amgen-n-amgn-20190913monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-phase-3-candor-study-combining-kyprolis-carfilzomib-and-darzalex-daratumum-amgn-20190913monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-highlights-new-data-from-kyprolis-carfilzomib-and-oncology-pipeline-at-imw-2019-amge-amgn-20190912monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-new-clinical-data-evaluating-novel-investigational-kras-g12c-inhibitor-in--amgn-20190908monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-morgan-stanley-global-healthcare-conference-amgen-nasdaq-amgn-will-amgn-20190905monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-webcast-investor-call-at-iaslc-2019-world-conference-on-lung-cancer-amgen-nasdaq--amgn-20190904monthly0.5https://www.biopharmawatch.com/news/AMGN/new-amgen-data-to-be-presented-at-esc-congress-2019-highlight-additional-evidence-for-repa-amgn-20190828monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-acquire-otezla-for-13-4-billion-in-cash-or-approximately-11-2-billion-net-of-anti-amgn-20190826monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-allergan-announce-positive-top-line-results-from-comparative-clinical-study-of-a-amgn-20190822monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-wins-patent-case-on-enbrel-etanercept-amgen-nasdaq-amgn-today-announced-that-the-u-s-amgn-20190809monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2019-third-quarter-dividend-amgen-nasdaq-amgn-today-announced-that-its-boa-amgn-20190802monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-second-quarter-2019-financial-results-amgen-nasdaq-amgn-today-announced-fina-amgn-20190730monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-kontroluje-98-udzia-o-w-w-nuevolution-po-zakon-czeniu-przed-uz-onego-okresu-przyje-c-amgn-20190728monthly0.5https://www.biopharmawatch.com/news/AMGN/spolec-nost-amgen-po-ukonc-eni-prodlouz-ene-ho-akceptac-ni-ho-obdobi-vlastni-98-akcii-spol-amgn-20190728monthly0.5https://www.biopharmawatch.com/news/AMGN/spoloc-nost-amgen-zi-skala-na-konci-predl-z-enej-lehoty-na-akcepta-ciu-kontrolu-nad-98-akc-amgn-20190727monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-ha-lt-nach-ablauf-der-verla-ngerten-annahmefrist-98-der-anteile-an-nuevolution-das-a-amgn-20190727monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-controla-el-98-de-las-acciones-de-nuevolution-una-vez-finalizado-el-plazo-de-aceptac-amgn-20190727monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-contro-le-98-des-actions-de-nuevolution-a-la-fin-de-la-pe-riode-d-acceptation-prolon-amgn-20190727monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-98-nuevolution-amgn-20190726monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-controls-98-of-the-shares-in-nuevolution-after-the-end-of-the-extended-acceptance-pe-amgn-20190726monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2019-second-quarter-financial-results-amgen-nasdaq-amgn-today-a-amgn-20190725monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-allergan-s-mvasi-bevacizumab-awwb-and-kanjinti-trastuzumab-anns-now-available-in-amgn-20190718monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-novartis-and-banner-alzheimer-s-institute-discontinue-clinical-research-program-with-amgn-20190711monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-annonce-le-re-sultat-de-l-offre-publique-d-achat-recommande-e-aux-actionnaires-de-nu-amgn-20190709monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-gibt-das-ergebnis-des-empfohlenen-o-ffentlichen-barangebots-bekannt-das-den-anteilse-amgn-20190709monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-og-asza-wyniki-rekomendowanej-publicznej-oferty-goto-wkowej-dla-akcjonariuszy-nuevol-amgn-20190709monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-anuncia-el-resultado-de-la-oferta-pu-blica-en-efectivo-consensuada-a-los-accionistas-amgn-20190709monthly0.5https://www.biopharmawatch.com/news/AMGN/spolec-nost-amgen-ozna-mila-vy-sledky-ver-ejne-nabi-dky-na-hotovostni-odkup-vs-ech-akcii-o-amgn-20190709monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-nuevolution-amgn-20190709monthly0.5https://www.biopharmawatch.com/news/AMGN/spoloc-nost-amgen-oznamuje-vy-sledok-odporu-c-anej-verejnej-ponuky-predaja-akciona-rom-spo-amgn-20190709monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-the-outcome-of-the-recommended-public-cash-offer-to-the-shareholders-of-nu-amgn-20190708monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-ucb-provide-regulatory-update-on-status-of-evenity-romosozumab-in-the-eu-amgen-n-amgn-20190628monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-mbc-biolabs-announce-winners-of-the-amgen-golden-ticket-amgen-nasdaq-amgn-and-mb-amgn-20190625monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-the-institute-for-protein-design-ipd-at-university-of-washington-announce-unique-amgn-20190619monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-blincyto-blinatumomab-five-year-overall-survival-data-at-eha-2019-amgen-na-amgn-20190616monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-publie-le-document-d-offre-concernant-l-offre-publique-d-achat-au-comptant-recommand-amgn-20190614monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-amgen-and-allergan-s-kanjinti-trastuzumab-anns-a-biosimilar-to-herceptin-tras-amgn-20190613monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-publica-el-documento-de-oferta-con-respecto-a-la-oferta-pu-blica-en-efectivo-para-lo-amgn-20190613monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-vero-ffentlicht-angebotsunterlagen-zum-empfohlenen-o-ffentlichen-barangebot-an-die-a-amgn-20190613monthly0.5https://www.biopharmawatch.com/news/AMGN/spolec-nost-amgen-zver-ejnila-nabi-dkovy-dokument-pro-doporuc-enou-ver-ejnou-nabi-dku-na-h-amgn-20190613monthly0.5https://www.biopharmawatch.com/news/AMGN/spoloc-nost-amgen-zverejn-uje-dokument-ponuky-s-ohl-adom-na-odporu-c-anu-verejnu-ponuku-pr-amgn-20190612monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-publikuje-oferte-dotycza-ca-rekomendowanej-publicznej-oferty-goto-wkowej-dla-akcjona-amgn-20190612monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-nuevolution-amgn-20190612monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-publishes-offer-document-with-respect-to-the-recommended-public-cash-offer-to-the-sh-amgn-20190612monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-goldman-sachs-40th-annual-global-healthcare-conference-amgen-nasda-amgn-20190607monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-first-clinical-data-evaluating-novel-investigational-krasg12c-inhibitor-am-amgn-20190603monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-highlights-the-versatility-of-the-bite-immuno-oncology-platform-in-multiple-tumor-ty-amgn-20190602monthly0.5https://www.biopharmawatch.com/news/AMGN/dodatkowe-nieodwo-alne-zobowia-zania-do-przyje-cia-zalecanej-publicznej-oferty-goto-wkowej-amgn-20190530monthly0.5https://www.biopharmawatch.com/news/AMGN/dals-i-neodvolatelne-za-vazky-k-pr-ijeti-doporuc-ene-ver-ejne-nabi-dky-spolec-nosti-amgen--amgn-20190529monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-webcast-investor-meeting-at-55th-annual-meeting-of-the-american-society-of-clinic-amgn-20190529monthly0.5https://www.biopharmawatch.com/news/AMGN/dodatoc-ne-neodvolatel-ne-za-va-zky-spoloc-nosti-amgen-vzt-ahuju-ce-sa-na-akcepta-ciu-odpo-amgn-20190529monthly0.5https://www.biopharmawatch.com/news/AMGN/zusa-tzliche-unwiderrufliche-verpflichtungserkla-rungen-zur-annahme-von-amgens-empfohlenem-amgn-20190529monthly0.5https://www.biopharmawatch.com/news/AMGN/nuevolution-amgen-amgn-20190529monthly0.5https://www.biopharmawatch.com/news/AMGN/engagements-a-caracte-re-irre-vocable-supple-mentaires-en-vue-d-accepter-l-offre-publique--amgn-20190529monthly0.5https://www.biopharmawatch.com/news/AMGN/compromisos-irrevocables-para-aceptar-la-oferta-pu-blica-en-efectivo-recomendada-de-amgen--amgn-20190529monthly0.5https://www.biopharmawatch.com/news/AMGN/additional-irrevocable-undertakings-to-accept-amgen-s-recommended-public-cash-offer-to-the-amgn-20190529monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-joins-with-community-oncology-networks-for-new-research-collaboration-amgen-nasdaq-a-amgn-20190528monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-anuncia-una-oferta-pu-blica-en-efectivo-consensuada-a-los-accionistas-de-nuevolution-amgn-20190525monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-annonce-une-offre-publique-d-achat-au-comptant-recommande-e-aux-actionnaires-de-nuev-amgn-20190524monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-gibt-empfohlenes-o-ffentliches-barangebot-an-die-aktiona-re-von-nuevolution-bekannt--amgn-20190524monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-publikuje-rekomendowana-oferte-goto-wkowa-dla-akcjonariuszy-nuevolution-niniejsza-of-amgn-20190523monthly0.5https://www.biopharmawatch.com/news/AMGN/spoloc-nost-amgen-oznamuje-akciona-rom-spoloc-nosti-nuevolution-verejnu-ponuku-predaja-za--amgn-20190523monthly0.5https://www.biopharmawatch.com/news/AMGN/spolec-nost-amgen-oznamuje-doporuc-enou-ver-ejnou-nabi-dku-na-hotovostni-odkup-vs-ech-akci-amgn-20190523monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-nuevolution-amgn-20190522monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-a-recommended-public-cash-offer-to-the-shareholders-of-nuevolution-the-off-amgn-20190522monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-voting-results-of-annual-meeting-of-stockholders-amgen-nasdaq-amgn-today-a-amgn-20190521monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-rbc-healthcare-conference-and-the-ubs-global-healthcare-conference-amgn-20190516monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-showcases-oncology-pipeline-at-asco-2019-amgen-nasdaq-amgn-today-announced-that-data-amgn-20190515monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-bank-of-america-merrill-lynch-2019-health-care-conference-amgen-na-amgn-20190510monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-highlight-extensive-long-term-safety-and-efficacy-data-of-aimovig-erenumab-aooe-a-amgn-20190502monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-syapse-enter-precision-medicine-collaboration-in-oncology-amgen-nasdaq-amgn-a-wo-amgn-20190502monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-ignites-a-social-fitness-movement-to-support-the-fight-against-heart-disease-and-can-amgn-20190501monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-first-quarter-2019-financial-results-amgen-nasdaq-amgn-today-announced-finan-amgn-20190430monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2019-first-quarter-financial-results-amgen-nasdaq-amgn-today-an-amgn-20190425monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-foundation-launches-amgen-biotech-experience-in-tampa-florida-the-amgen-foundation-t-amgn-20190417monthly0.5https://www.biopharmawatch.com/news/AMGN/evenity-romosozumab-aqqg-now-available-in-the-united-states-for-the-treatment-of-osteoporo-amgn-20190415monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-evenity-romosozumab-aqqg-for-the-treatment-of-osteoporosis-in-postmenopausal--amgn-20190409monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-new-data-at-wco-iof-esceo-2019-revealing-osteoporosis-treatment-gap-in-euro-amgn-20190407monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-cytokinetics-and-servier-announce-continuation-of-galactic-hf-following-planned-inte-amgn-20190320monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-new-four-year-outcomes-study-to-examine-long-term-effects-of-repatha-evolo-amgn-20190315monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-jay-leno-partner-to-sound-the-alarm-on-high-cholesterol-and-its-link-to-heart-at-amgn-20190312monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2019-second-quarter-dividend-amgen-nasdaq-amgn-today-announced-that-its-bo-amgn-20190307monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-cowen-and-company-39th-annual-healthcare-conference-amgen-nasdaq-a-amgn-20190307monthly0.5https://www.biopharmawatch.com/news/AMGN/new-data-from-amgen-to-be-presented-at-acc-19-continues-to-build-evidence-for-repatha-evol-amgn-20190306monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-highlights-progress-of-innovative-early-oncology-pipeline-with-new-data-at-aacr-2019-amgn-20190228monthly0.5https://www.biopharmawatch.com/news/AMGN/jury-upholds-amgen-s-patents-on-repatha-evolocumab-amgen-nasdaq-amgn-today-announced-that--amgn-20190225monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-cytokinetics-and-servier-announce-start-of-meteoric-hf-the-second-phase-3-clinical-t-amgn-20190221monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-fourth-quarter-and-full-year-2018-financial-results-amgen-nasdaq-amgn-today--amgn-20190129monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2018-fourth-quarter-and-full-year-financial-results-amgen-nasda-amgn-20190124monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-receives-nmpa-approval-for-repatha-evolocumab-in-china-to-reduce-the-risk-of-cardiov-amgn-20190124monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-allergan-announce-positive-top-line-results-from-phase-1-phase-3-study-of-abp-79-amgn-20190124monthly0.5https://www.biopharmawatch.com/news/AMGN/european-commission-approves-blincyto-blinatumomab-in-patients-with-philadelphia-chromosom-amgn-20190122monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-ucb-receive-positive-vote-from-fda-advisory-committee-in-favor-of-approval-for-e-amgn-20190116monthly0.5https://www.biopharmawatch.com/news/AMGN/evenity-romosozumab-receives-approval-in-japan-for-the-treatment-of-osteoporosis-in-patien-amgn-20190108monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-makes-all-repatha-evolocumab-device-options-available-in-the-us-at-a-60-percent-redu-amgn-20190107monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-amgen-nasdaq-amgn-wil-amgn-20190103monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-submits-supplemental-biologics-license-application-for-nplate-romiplostim-amgen-nasd-amgn-20181219monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-molecular-partners-announce-strategic-collaboration-in-immuno-oncology-amgen-nas-amgn-20181218monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-engages-cambridge-biotech-community-to-select-2018-labcentral-golden-ticket-winners--amgn-20181218monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-submits-biologics-license-application-for-abp-710-biosimilar-infliximab-to-us-food-a-amgn-20181217monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-nplate-romiplostim-for-use-in-pediatric-patients-with-immune-thrombocytopenia-amgn-20181214monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-direct-relief-partner-to-aid-cancer-patients-in-18-developing-countries-amgen-na-amgn-20181213monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-magellan-rx-management-collaborate-to-improve-patient-care-for-chronic-difficult-amgn-20181211monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-lazarex-cancer-foundation-team-up-to-allow-more-diversity-in-clinical-trials-amg-amgn-20181210monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-10-percent-increase-in-2019-first-quarter-dividend-amgen-nasdaq-amgn-today-amgn-20181207monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-first-in-human-data-evaluating-investigational-novel-bite-immunotherapies--amgn-20181203monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-citi-global-healthcare-conference-amgen-nasdaq-amgn-will-present-a-amgn-20181203monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-ucb-announce-fda-advisory-committee-meeting-to-review-evenity-romosozumab-for-th-amgn-20181130monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-webcast-investor-call-at-ash-2018-amgen-nasdaq-amgn-will-host-a-webcast-call-for--amgn-20181128monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-piper-jaffray-and-evercore-isi-healthcare-conferences-amgen-nasdaq-amgn-20181121monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-receives-chmp-positive-opinion-to-expand-use-of-blincyto-blinatumomab-in-patients-wi-amgn-20181116monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-results-highlighting-the-long-term-safety-and-efficacy-of-repatha-evolocuma-amgn-20181112monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-foundation-pledges-500-000-in-relief-to-victims-of-ventura-and-los-angeles-county-wi-amgn-20181112monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-presentation-of-research-reinforcing-the-long-term-safety-and-efficacy-of--amgn-20181105monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-provention-bio-announce-co-development-collaboration-in-celiac-disease-amgen-nas-amgn-20181105monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-new-data-showcasing-extensive-portfolio-and-exciting-early-oncology-pipel-amgn-20181101monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-foundation-deepens-commitment-to-aspiring-scientists-worldwide-by-expanding-amgen-sc-amgn-20181101monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-third-quarter-2018-financial-results-amgen-nasdaq-amgn-today-announced-finan-amgn-20181030monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-new-fourier-analysis-showing-benefit-with-repatha-evolocumab-in-high-risk--amgn-20181026monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2018-third-quarter-financial-results-amgen-nasdaq-amgn-today-an-amgn-20181026monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-makes-repathaa-evolocumab-available-in-the-us-at-a-60-percent-reduced-list-price-amg-amgn-20181024monthly0.5https://www.biopharmawatch.com/news/AMGN/first-head-to-head-trial-of-a-tnf-inhibitor-versus-methotrexate-monotherapy-in-psoriatic-a-amgn-20181024monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2018-fourth-quarter-dividend-amgen-nasdaq-amgn-today-announced-that-its-bo-amgn-20181023monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-invests-50-million-66-million-in-oxford-nanopore-technologies-amgen-nasdaq-amgn-and--amgn-20181018monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-launches-amgevita-biosimilar-adalimumab-in-markets-across-europe-amgen-nasdaq-amgn-t-amgn-20181016monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-kyprolis-carfilzomib-once-weekly-70-mg-m2-in-combination-with-dexamethasone-k-amgn-20181001monthly0.5https://www.biopharmawatch.com/news/AMGN/blincyto-blinatumomab-approved-in-japan-for-the-treatment-of-relapsed-or-refractory-b-cell-amgn-20180924monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-los-angeles-county-announce-collaboration-to-support-life-science-innovation-hub-amgn-20180920monthly0.5https://www.biopharmawatch.com/news/AMGN/world-s-largest-alzheimer-s-survey-reveals-most-adults-believe-a-cure-will-be-developed-in-amgn-20180917monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference-amgen-n-amgn-20180911monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-morgan-stanley-global-healthcare-conference-amgen-nasdaq-amgn-will-amgn-20180907monthly0.5https://www.biopharmawatch.com/news/AMGN/tezepelumab-granted-breakthrough-therapy-designation-by-us-fda-for-the-treatment-of-patien-amgn-20180907monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-labcentral-open-nomination-process-for-lab-residency-amgen-nasdaq-amgn-and-labce-amgn-20180905monthly0.5https://www.biopharmawatch.com/news/AMGN/european-commission-approves-blincyto-blinatumomab-for-use-in-pediatric-patients-with-phil-amgn-20180829monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-submits-supplemental-new-drug-application-for-kyprolis-carfilzomib-once-weekly-70-mg-amgn-20180827monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-robust-data-exploring-the-impact-of-treatment-with-repatha-evolocumab-acr-amgn-20180821monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-breaks-ground-on-next-generation-biomanufacturing-plant-in-rhode-island-amgen-nasdaq-amgn-20180731monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2018-third-quarter-dividend-amgen-nasdaq-amgn-today-announced-that-its-boa-amgn-20180731monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-succession-plans-for-two-executive-officers-as-part-of-amgen-s-nasdaq-amgn-amgn-20180726monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-second-quarter-2018-financial-results-amgen-nasdaq-amgn-today-announced-fina-amgn-20180726monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2018-second-quarter-financial-results-amgen-nasdaq-amgn-today-a-amgn-20180724monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-cedars-sinai-partner-for-improved-healthcare-quality-amgen-nasdaq-amgn-and-cedar-amgn-20180719monthly0.5https://www.biopharmawatch.com/news/AMGN/former-major-league-baseball-mlb-all-stars-dave-winfield-and-steve-garvey-team-up-with-amg-amgn-20180718monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-ucb-resubmit-biologics-license-application-bla-for-evenity-romosozumab-to-the-us-amgn-20180713monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-novartis-present-new-data-demonstrating-long-term-efficacy-safety-and-tolerabili-amgn-20180628monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-top-line-results-from-phase-3-study-of-abp-710-biosimilar-candidate-to-inf-amgn-20180627monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-health-and-benefits-consultant-piper-jordan-partner-on-first-migraine-project-wi-amgn-20180627monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-novartis-highlight-findings-from-a-large-global-patient-survey-revealing-that-wo-amgn-20180627monthly0.5https://www.biopharmawatch.com/news/AMGN/new-data-show-amgen-s-repatha-evolocumab-significantly-reduced-ldl-c-and-non-hdl-c-in-high-amgn-20180623monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-receives-european-commission-approval-to-add-overall-survival-data-to-blincyto-blina-amgn-20180619monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-addition-of-positive-overall-survival-data-from-phase-3-aspire-trial-to-kypro-amgn-20180611monthly0.5https://www.biopharmawatch.com/news/AMGN/european-commission-approves-prolia-denosumab-for-patients-with-glucocorticoid-induced-ost-amgn-20180608monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-goldman-sachs-39th-annual-global-healthcare-conference-amgen-nasda-amgn-20180608monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-oklahoma-health-care-authority-and-university-of-oklahoma-s-pharmacy-management-cons-amgn-20180606monthly0.5https://www.biopharmawatch.com/news/AMGN/phase-3-a-r-r-o-w-interim-analysis-shows-once-weekly-70-mg-m2-kyprolis-carfilzomib-regimen-amgn-20180601monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-md-anderson-announce-collaboration-to-accelerate-early-stage-treatments-for-leuk-amgn-20180531monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-foundation-and-harvard-team-up-to-offer-free-online-science-education-platform-the-a-amgn-20180530monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-enters-groundbreaking-collaboration-to-improve-symptom-management-during-cancer-trea-amgn-20180523monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-voting-results-of-annual-meeting-of-stockholders-amgen-nasdaq-amgn-today-a-amgn-20180522monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-prolia-denosumab-for-glucocorticoid-induced-osteoporosis-amgen-nasdaq-amgn-to-amgn-20180521monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-aimovig-erenumab-aooe-a-novel-treatment-developed-specifically-for-migraine-p-amgn-20180517monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-receives-european-commission-approval-for-repatha-evolocumab-to-prevent-heart-attack-amgn-20180516monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-bank-of-america-merrill-lynch-2018-health-care-conference-amgen-na-amgn-20180510monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-receives-positive-chmp-opinion-to-add-overall-survival-results-from-the-phase-3-aspi-amgn-20180430monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-receives-positive-chmp-opinion-to-expand-use-of-prolia-denosumab-to-patients-with-gl-amgn-20180427monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-first-quarter-2018-financial-results-amgen-nasdaq-amgn-today-announced-finan-amgn-20180424monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2018-first-quarter-financial-results-amgen-nasdaq-amgn-today-an-amgn-20180419monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-first-of-its-kind-data-at-aan-annual-meeting-reinforcing-robust-and-consist-amgn-20180417monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-rhode-island-will-be-location-of-first-us-next-generation-biomanufacturing-amgn-20180410monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-new-pre-clinical-data-showcasing-robust-approach-to-evaluating-potential--amgn-20180409monthly0.5https://www.biopharmawatch.com/news/AMGN/european-commission-approves-expanded-indication-for-amgen-s-xgeva-denosumab-for-the-preve-amgn-20180403monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-blincyto-blinatumomab-to-treat-minimal-residual-disease-positive-b-cell-precu-amgn-20180329monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-receives-positive-chmp-opinion-recognizing-that-repatha-evolocumab-prevents-heart-at-amgn-20180323monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-allergan-receive-positive-chmp-opinion-for-abp-980-biosimilar-herceptin-for-the--amgn-20180323monthly0.5https://www.biopharmawatch.com/news/AMGN/new-analyses-show-payer-utilization-management-criteria-deny-access-to-pcsk9-inhibitors-fo-amgn-20180309monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-final-results-of-tender-offer-amgen-nasdaq-amgn-today-announced-the-final--amgn-20180308monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2018-second-quarter-dividend-amgen-nasdaq-amgn-today-announced-that-its-bo-amgn-20180307monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-cowen-and-company-38th-annual-health-care-conference-amgen-nasdaq--amgn-20180307monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-preliminary-results-of-tender-offer-amgen-nasdaq-amgn-today-announced-the--amgn-20180306monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-receives-positive-chmp-opinion-for-delivery-system-of-neulasta-pegfilgrastim-amgen-n-amgn-20180227monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-new-data-from-repatha-evolocumab-clinical-trials-at-acc-18-amgen-nasdaq-a-amgn-20180226monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-receives-positive-opinion-expanding-use-of-xgeva-denosumab-to-cover-prevention-of-sk-amgn-20180223monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-fda-advisory-committee-meeting-to-review-potential-new-use-of-blincyto-bli-amgn-20180214monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-fourth-quarter-and-full-year-2017-financial-results-amgen-nasdaq-amgn-today--amgn-20180201monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-receives-chmp-positive-opinion-to-add-updated-overall-survival-data-to-kyprolis-carf-amgn-20180130monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2017-fourth-quarter-and-full-year-financial-results-amgen-nasda-amgn-20180129monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-aimovig-erenumab-met-all-primary-and-secondary-endpoints-in-unique-phase-3b--amgn-20180122monthly0.5https://www.biopharmawatch.com/news/AMGN/european-commission-approves-amgen-and-allergan-s-mvasi-biosimilar-bevacizumab-for-the-tre-amgn-20180118monthly0.5https://www.biopharmawatch.com/news/AMGN/overall-survival-analysis-from-kyprolis-carfilzomib-phase-3-aspire-trial-published-in-the--amgn-20180117monthly0.5https://www.biopharmawatch.com/news/AMGN/european-medicines-agency-accepts-filing-for-evenity-romosozumab-amgen-nasdaq-amgn-and-ucb-amgn-20180108monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-xgeva-denosumab-for-the-prevention-of-skeletal-related-events-in-patients-wit-amgn-20180105monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-36th-annual-j-p-morgan-healthcare-conference-amgen-nasdaq-amgn-wil-amgn-20180104monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-teams-up-with-cambridge-biotech-community-to-select-two-startups-to-receive-golden-t-amgn-20171214monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-15-percent-increase-in-2018-first-quarter-dividend-amgen-nasdaq-amgn-today-amgn-20171212monthly0.5https://www.biopharmawatch.com/news/AMGN/kyprolis-carfilzomib-extended-overall-survival-in-patients-with-relapsed-or-refractory-mul-amgn-20171211monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-foundation-pledges-up-to-500-000-in-relief-to-victims-of-the-southern-california-wil-amgn-20171211monthly0.5https://www.biopharmawatch.com/news/AMGN/new-data-to-be-presented-at-ash-2017-underscore-amgen-s-commitment-to-improving-lives-and--amgn-20171207monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-webcast-investor-call-at-ash-2017-amgen-nasdaq-amgn-will-host-a-webcast-call-for--amgn-20171206monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-amgen-s-repatha-evolocumab-to-prevent-heart-attack-and-stroke-amgen-nasdaq-am-amgn-20171201monthly0.5https://www.biopharmawatch.com/news/AMGN/aimovig-erenumab-phase-3-strive-data-published-in-the-new-england-journal-of-medicine-demo-amgn-20171129monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-evercore-isi-2017-biopharma-catalyst-deep-dive-conference-amgen-na-amgn-20171127monthly0.5https://www.biopharmawatch.com/news/AMGN/estudo-mostra-que-repatha-evolocumabe-reduz-pela-metade-o-risco-relativo-de-eventos-cardio-amgn-20171123monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-launches-the-enbrel-mini-single-dose-prefilled-cartridge-with-autotouch-reusable-aut-amgn-20171117monthly0.5https://www.biopharmawatch.com/news/AMGN/new-analyses-presented-at-aha-2017-show-repatha-evolocumab-significantly-reduced-cardiovas-amgn-20171113monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-receives-positive-chmp-opinion-to-expand-use-of-nplate-romiplostim-in-pediatric-pati-amgn-20171110monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-allergan-receive-positive-chmp-opinion-for-abp-215-biosimilar-bevacizumab-for-th-amgn-20171110monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-new-analyses-of-high-risk-patient-subgroups-from-repatha-evolocumab-cardio-amgn-20171106monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-novartis-announce-expanded-collaboration-with-banner-alzheimer-s-institute-in-pi-amgn-20171102monthly0.5https://www.biopharmawatch.com/news/AMGN/kirin-amgen-joint-venture-to-become-wholly-owned-subsidiary-of-amgen-amgen-nasdaq-amgn-tod-amgn-20171031monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-third-quarter-2017-financial-results-amgen-nasdaq-amgn-today-announced-finan-amgn-20171025monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-appointment-of-wanda-m-austin-to-board-of-directors-amgen-nasdaq-amgn-toda-amgn-20171024monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2017-fourth-quarter-dividend-amgen-nasdaq-amgn-today-announced-that-its-bo-amgn-20171024monthly0.5https://www.biopharmawatch.com/news/AMGN/award-winning-journalist-and-cancer-survivor-joan-lunden-partners-with-amgen-to-launch-at--amgn-20171024monthly0.5https://www.biopharmawatch.com/news/AMGN/phase-3-a-r-r-o-w-study-of-once-weekly-kyprolis-carfilzomib-regimen-meets-primary-endpoint-amgn-20171023monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2017-third-quarter-financial-results-amgen-nasdaq-amgn-today-an-amgn-20171020monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-boston-children-s-hospital-enter-a-collaboration-to-find-new-genes-and-drug-targ-amgn-20171016monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-foundation-awards-khan-academy-3-million-to-support-development-of-free-comprehensiv-amgn-20171012monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-accepts-supplemental-biologics-license-application-for-prolia-denosumab-in-glucocortic-amgn-20171009monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-labcentral-open-nomination-process-for-lab-residency-amgen-nasdaq-amgn-and-labce-amgn-20171006monthly0.5https://www.biopharmawatch.com/news/AMGN/first-randomized-study-to-evaluate-imlygic-talimogene-laherparepvec-an-oncolytic-viral-the-amgn-20171005monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-cytomx-therapeutics-announce-strategic-collaboration-in-immuno-oncology-amgen-na-amgn-20171003monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-abbvie-agree-to-settlement-allowing-commercialization-of-amgevita-amgen-nasdaq-a-amgn-20170928monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-simcere-announce-strategic-collaboration-to-co-develop-and-commercialize-biosimi-amgn-20170926monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-provides-update-on-hurricane-maria-amgen-nasdaq-amgn-today-provided-an-update-on-hur-amgn-20170925monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-foundation-pledges-up-to-5-million-to-hurricane-maria-relief-efforts-amgen-nasdaq-am-amgn-20170922monthly0.5https://www.biopharmawatch.com/news/AMGN/new-fourier-analysis-shows-repatha-evolocumab-reduces-cardiovascular-events-in-patients-wi-amgn-20170915monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-amgen-and-allergan-s-mvasi-bevacizumab-awwb-for-the-treatment-of-five-types-o-amgn-20170914monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference-amgen-n-amgn-20170911monthly0.5https://www.biopharmawatch.com/news/AMGN/evenity-romosozumab-arch-study-results-published-in-the-new-england-journal-of-medicine-am-amgn-20170911monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-allergan-present-phase-3-data-on-biosimilar-trastuzumab-candidate-abp-980-at-the-amgn-20170909monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-highlights-the-latest-evenity-romosozumab-and-prolia-denosumab-research-at-the-ameri-amgn-20170908monthly0.5https://www.biopharmawatch.com/news/AMGN/new-data-demonstrate-aimovig-erenumab-reduced-monthly-migraine-days-in-patients-who-failed-amgn-20170907monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-morgan-stanley-global-healthcare-conference-amgen-nasdaq-amgn-will-amgn-20170907monthly0.5https://www.biopharmawatch.com/news/AMGN/tezepelumab-significantly-reduced-asthma-exacerbations-for-a-broad-population-of-patients--amgn-20170906monthly0.5https://www.biopharmawatch.com/news/AMGN/european-commission-approves-expanded-use-of-mimpara-cinacalcet-for-the-treatment-of-secon-amgn-20170831monthly0.5https://www.biopharmawatch.com/news/AMGN/long-term-analysis-of-phase-3-head-to-head-study-confirms-kyprolis-carfilzomib-regimen-ext-amgn-20170830monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-accepts-amgen-s-filing-of-a-supplemental-new-drug-application-to-add-overall-survival--amgn-20170830monthly0.5https://www.biopharmawatch.com/news/AMGN/el-tratamiento-con-carfilzomib-mejora-significativamente-la-supervivencia-de-pacientes-con-amgn-20170830monthly0.5https://www.biopharmawatch.com/news/AMGN/new-virtual-histology-sub-study-evaluates-impact-of-repatha-evolocumab-on-coronary-artery--amgn-20170829monthly0.5https://www.biopharmawatch.com/news/AMGN/new-analysis-shows-repatha-evolocumab-reduces-cardiovascular-events-in-patients-with-histo-amgn-20170829monthly0.5https://www.biopharmawatch.com/news/AMGN/new-repatha-evolocumab-analysis-demonstrates-cardiovascular-outcomes-efficacy-and-safety-o-amgn-20170828monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-foundation-expands-the-amgen-biotech-experience-bringing-total-program-reach-to-900--amgn-20170824monthly0.5https://www.biopharmawatch.com/news/AMGN/overall-survival-analysis-from-kyprolis-carfilzomib-phase-3-endeavor-trial-published-in-th-amgn-20170823monthly0.5https://www.biopharmawatch.com/news/AMGN/new-economic-analysis-based-on-repatha-evolocumab-outcomes-data-published-in-jama-cardiolo-amgn-20170823monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-new-data-from-the-repatha-evolocumab-cardiovascular-outcomes-study-at-esc-amgn-20170821monthly0.5https://www.biopharmawatch.com/news/AMGN/repatha-evolocumab-phase-3-cognitive-function-study-results-published-in-the-new-england-j-amgn-20170816monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-submits-supplemental-biologics-license-application-for-prolia-denosumab-in-glucocort-amgn-20170731monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-allergan-submit-biosimilar-biologics-license-application-for-abp-980-to-us-food--amgn-20170731monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2017-third-quarter-dividend-amgen-nasdaq-amgn-today-announced-that-its-boa-amgn-20170728monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-grants-priority-review-for-amgen-s-supplemental-biologics-license-application-for-repa-amgn-20170727monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-second-quarter-2017-financial-results-amgen-nasdaq-amgn-today-announced-fina-amgn-20170725monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-accepts-biologics-license-application-for-aimovig-erenumab-amgen-nasdaq-amgn-today-ann-amgn-20170720monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2017-second-quarter-financial-results-amgen-nasdaq-amgn-today-a-amgn-20170720monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-ucb-provide-update-on-regulatory-status-of-evenity-romosozumab-in-the-us-amgen-n-amgn-20170716monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-submits-regulatory-applications-in-us-and-europe-to-include-overall-survival-data-in-amgn-20170714monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-allergan-to-discuss-data-supporting-biologics-license-application-for-abp-215-a--amgn-20170713monthly0.5https://www.biopharmawatch.com/news/AMGN/second-phase-3-study-shows-kyprolis-carfilzomib-regimen-significantly-improves-overall-sur-amgn-20170712monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-grants-full-approval-for-blincyto-blinatumomab-to-treat-relapsed-or-refractory-b-cell--amgn-20170711monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-qb3-953-announce-winners-of-the-amgen-golden-ticket-amgen-nasdaq-amgn-and-qb3-95-amgn-20170711monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-vectibix-panitumumab-for-use-in-wild-type-ras-metastatic-colorectal-cancer-am-amgn-20170629monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-receives-positive-chmp-opinion-to-expand-use-of-mimpara-cinacalcet-for-the-treatment-amgn-20170623monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-new-data-at-22nd-congress-of-the-european-hematology-association-amgen-na-amgn-20170621monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-accepts-amgen-s-supplemental-biologics-license-application-to-expand-indication-for-xg-amgn-20170619monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-erenumab-data-at-the-59th-annual-scientific-meeting-of-the-american-headach-amgn-20170608monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-goldman-sachs-38th-annual-global-healthcare-conference-amgen-nasda-amgn-20170608monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-allergan-announce-fda-advisory-committee-meeting-to-review-abp-215-a-biosimilar--amgn-20170607monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-submits-regulatory-applications-for-repatha-evolocumab-cardiovascular-outcomes-data--amgn-20170605monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-new-data-from-phase-3-xgeva-denosumab-study-in-patients-with-multiple-myelo-amgn-20170604monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-new-phase-2-data-on-imlygic-talimogene-laherparepvec-investigational-combin-amgn-20170603monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-showcases-a-legacy-of-science-innovation-and-collaboration-in-cambridge-when-amgen-n-amgn-20170602monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-ucb-announce-top-line-phase-3-data-from-active-comparator-study-of-evenity-romos-amgn-20170521monthly0.5https://www.biopharmawatch.com/news/AMGN/repatha-evolocumab-reduced-cardiovascular-events-in-patients-with-baseline-ldl-c-levels-be-amgn-20170520monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-voting-results-of-annual-meeting-of-stockholders-amgen-nasdaq-amgn-today-a-amgn-20170519monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-submits-biologics-license-application-to-the-fda-for-erenumab-amgen-nasdaq-amgn-toda-amgn-20170518monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-bank-of-america-merrill-lynch-2017-health-care-conference-amgen-na-amgn-20170512monthly0.5https://www.biopharmawatch.com/news/AMGN/blinatumomab-mejoro-significativamente-la-supervivencia-global-en-pacientes-con-leucemia-l-amgn-20170504monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-harvard-pilgrim-agree-to-first-cardiovascular-outcomes-based-refund-contract-for-amgn-20170502monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-participate-in-the-2017-world-medical-innovation-forum-focused-on-cardiovascular--amgn-20170427monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-first-quarter-2017-financial-results-amgen-nasdaq-amgn-today-announced-finan-amgn-20170426monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-expanded-commercial-collaboration-with-novartis-for-erenumab-in-migraine-a-amgn-20170424monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2017-first-quarter-financial-results-amgen-nasdaq-amgn-today-an-amgn-20170421monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-launches-neulasta-pegfilgrastim-onpro-narratives-amgen-nasdaq-amgn-today-announced-t-amgn-20170418monthly0.5https://www.biopharmawatch.com/news/AMGN/repatha-demonstrou-em-estudos-ine-ditos-evitar-20-dos-eventos-cardiovasculares-em-paciente-amgn-20170406monthly0.5https://www.biopharmawatch.com/news/AMGN/estudio-cli-nico-comparativo-cara-a-cara-fase-3-demostro-que-carfilzomib-mejoro-significat-amgn-20170406monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-submits-applications-in-the-us-and-europe-to-expand-current-indication-for-xgeva-den-amgn-20170404monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-ucb-report-new-data-at-endo-2017-examining-the-option-of-a-second-course-of-trea-amgn-20170401monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-highlight-new-preclinical-data-at-the-american-association-for-cancer-research-aa-amgn-20170331monthly0.5https://www.biopharmawatch.com/news/AMGN/estudio-de-resultados-demuestra-que-evolocumab-reduce-el-colesterol-ldl-a-niveles-sin-prec-amgn-20170330monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-grants-priority-review-for-amgen-s-blincyto-blinatumomab-supplemental-biologics-licens-amgn-20170329monthly0.5https://www.biopharmawatch.com/news/AMGN/journal-of-clinical-oncology-publishes-data-on-blincyto-blinatumomab-in-high-risk-patients-amgn-20170329monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-awards-three-golden-tickets-for-labcentral-residency-amgen-nasdaq-amgn-and-labcentra-amgn-20170328monthly0.5https://www.biopharmawatch.com/news/AMGN/european-commission-approves-amgevita-biosimilar-adalimumab-for-the-treatment-of-certain-i-amgn-20170323monthly0.5https://www.biopharmawatch.com/news/AMGN/analyses-of-pcsk9-inhibitor-prescription-rejection-rates-demonstrate-significant-access-ba-amgn-20170319monthly0.5https://www.biopharmawatch.com/news/AMGN/lowering-ldl-levels-with-repatha-evolocumab-did-not-adversely-affect-cognitive-function-in-amgn-20170318monthly0.5https://www.biopharmawatch.com/news/AMGN/landmark-outcomes-study-shows-that-repatha-evolocumab-decreases-ldl-c-to-unprecedented-low-amgn-20170317monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-oppenheimer-global-health-care-conference-amgen-nasdaq-amgn-will-p-amgn-20170316monthly0.5https://www.biopharmawatch.com/news/AMGN/repatha-evolocumab-four-year-open-label-follow-up-study-published-in-jama-cardiology-amgen-amgn-20170314monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-webcast-investor-meeting-at-upcoming-american-college-of-cardiology-scientific-se-amgn-20170314monthly0.5https://www.biopharmawatch.com/news/AMGN/repatha-evolocumab-demonstrates-reduced-need-for-apheresis-in-patients-with-high-ldl-chole-amgn-20170313monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2017-second-quarter-dividend-amgen-nasdaq-amgn-today-announced-that-its-bo-amgn-20170307monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-highlights-landmark-repatha-evolocumab-cardiovascular-outcomes-study-amongst-data-to-amgn-20170306monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-new-data-from-phase-3-xgeva-denosumab-study-in-multiple-myeloma-patients-at-amgn-20170303monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-overall-survival-data-from-kyprolis-carfilzomib-phase-3-endeavor-trial-at-1-amgn-20170303monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-cowen-and-company-37th-annual-health-care-conference-amgen-nasdaq--amgn-20170302monthly0.5https://www.biopharmawatch.com/news/AMGN/blincyto-blinatumomab-significantly-improved-overall-survival-in-patients-with-b-cell-prec-amgn-20170301monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-new-kyprolis-carfilzomib-and-xgeva-denosumab-data-at-the-16th-internation-amgn-20170301monthly0.5https://www.biopharmawatch.com/news/AMGN/phase-3-head-to-head-trial-showed-kyprolis-carfilzomib-significantly-improved-overall-surv-amgn-20170228monthly0.5https://www.biopharmawatch.com/news/AMGN/repatha-evolocumab-receives-european-commission-approval-for-new-420-mg-single-dose-delive-amgn-20170221monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-submits-supplemental-biologics-license-application-for-blincyto-blinatumomab-in-rela-amgn-20170214monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-anuncia-que-evolocumab-disminuyo-significativamente-el-riesgo-de-eventos-cardiovascu-amgn-20170208monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-amgen-s-parsabiv-etelcalcetide-first-new-treatment-in-more-than-a-decade-for--amgn-20170207monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-appointment-of-charles-m-holley-jr-to-board-of-directors-amgen-nasdaq-amgn-amgn-20170203monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-fourth-quarter-and-full-year-2016-financial-results-amgen-nasdaq-amgn-today--amgn-20170202monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-repatha-evolocumab-significantly-reduced-the-risk-of-cardiovascular-events-amgn-20170202monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2016-fourth-quarter-and-full-year-financial-results-amgen-nasda-amgn-20170130monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-receives-positive-chmp-opinion-for-abp-501-biosimilar-adalimumab-for-the-treatment-o-amgn-20170127monthly0.5https://www.biopharmawatch.com/news/AMGN/study-results-published-in-the-journal-of-the-american-medical-association-show-amgen-s-pa-amgn-20170110monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-statement-on-january-9-2017-u-s-district-court-decision-amgen-nasdaq-amgn-issued-the-amgn-20170109monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-davita-enter-into-new-sourcing-and-supply-agreement-amgen-nasdaq-amgn-today-anno-amgn-20170109monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-immatics-enter-strategic-collaboration-to-develop-novel-bispecific-cancer-immuno-amgn-20170109monthly0.5https://www.biopharmawatch.com/news/AMGN/court-grants-permanent-injunction-for-infringement-of-amgen-s-repatha-patents-amgen-nasdaq-amgn-20170105monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-35th-annual-j-p-morgan-healthcare-conference-amgen-nasdaq-amgn-wil-amgn-20170104monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-15-percent-increase-in-2017-first-quarter-dividend-amgen-nasdaq-amgn-today-amgn-20161220monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-ucb-announce-submission-of-application-for-investigational-osteoporosis-medicati-amgn-20161219monthly0.5https://www.biopharmawatch.com/news/AMGN/new-repatha-evolocumab-dose-delivery-option-receives-positive-chmp-opinion-amgen-nasdaq-am-amgn-20161216monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-citi-2016-global-healthcare-conference-amgen-nasdaq-amgn-will-pres-amgn-20161201monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-presentation-of-new-data-in-acute-lymphoblastic-leukemia-multiple-myeloma--amgn-20161130monthly0.5https://www.biopharmawatch.com/news/AMGN/the-lancet-publishes-results-from-cosmic-hf-trial-showing-omecamtiv-mecarbil-significantly-amgn-20161130monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-erenumab-significantly-reduces-monthly-migraine-days-in-patients-with-epis-amgn-20161116monthly0.5https://www.biopharmawatch.com/news/AMGN/repatha-evolocumab-regresses-atherosclerosis-in-patients-with-coronary-artery-disease-amge-amgn-20161115monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-allergan-submit-biosimilar-biologics-license-application-for-abp-215-to-u-s-food-amgn-20161115monthly0.5https://www.biopharmawatch.com/news/AMGN/new-ten-to-watch-list-highlights-top-amgen-scholars-poised-to-impact-the-future-of-science-amgn-20161114monthly0.5https://www.biopharmawatch.com/news/AMGN/results-from-phase-3-bridge-study-show-romosozumab-significantly-increases-bone-mineral-de-amgn-20161112monthly0.5https://www.biopharmawatch.com/news/AMGN/european-commission-approves-parsabiv-etelcalcetide-for-the-treatment-of-secondary-hyperpa-amgn-20161111monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-collaboration-with-janssen-to-co-fund-studies-with-kyprolis-carfilzomib-an-amgn-20161110monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-webcast-investor-meeting-at-upcoming-american-heart-association-scientific-sessio-amgn-20161110monthly0.5https://www.biopharmawatch.com/news/AMGN/data-to-be-presented-at-acr-arhp-2016-annual-meeting-show-amgen-s-ongoing-commitment-to-th-amgn-20161107monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-expanded-use-of-enbrel-etanercept-to-treat-children-with-chronic-moderate-to--amgn-20161104monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-credit-suisse-25th-annual-healthcare-conference-amgen-nasdaq-amgn--amgn-20161103monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-appoints-lori-johnston-as-senior-vice-president-human-resources-amgen-nasdaq-amgn-to-amgn-20161102monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-highlights-repatha-evolocumab-glagov-imaging-study-amongst-data-to-be-presented-at-a-amgn-20161031monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-third-quarter-2016-financial-results-amgen-nasdaq-amgn-today-announced-finan-amgn-20161027monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-invest-in-israel-based-ehealth-ventures-amgen-europe-gmbh-an-affiliate-of-amgen-i-amgn-20161025monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2016-third-quarter-financial-results-amgen-nasdaq-amgn-today-an-amgn-20161024monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-positive-top-line-results-from-xgeva-denosumab-phase-3-trial-for-delay-of--amgn-20161020monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2016-fourth-quarter-dividend-amgen-nasdaq-amgn-today-announced-that-its-bo-amgn-20161014monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-appointment-of-ellen-j-kullman-to-board-of-directors-amgen-nasdaq-amgn-tod-amgn-20161014monthly0.5https://www.biopharmawatch.com/news/AMGN/new-retrospective-analyses-confirm-vectibix-panitumumab-treatment-provided-survival-benefi-amgn-20161010monthly0.5https://www.biopharmawatch.com/news/AMGN/new-amgen-data-in-melanoma-and-metastatic-colorectal-cancer-to-be-presented-at-the-europea-amgn-20161005monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-participate-in-citi-biotech-r-d-conference-call-amgen-nasdaq-amgn-will-participat-amgn-20161004monthly0.5https://www.biopharmawatch.com/news/AMGN/study-results-published-in-journal-of-clinical-oncology-show-blincyto-blinatumomab-induced-amgn-20161003monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-arrowhead-pharmaceuticals-announce-two-cardiovascular-collaborations-amgen-nasda-amgn-20160929monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-erenumab-significantly-reduces-monthly-migraine-days-in-patients-with-epis-amgn-20160928monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-top-line-results-from-phase-3-kyprolis-carfilzomib-clarion-study-in-newly--amgn-20160927monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-opens-nomination-process-for-labcentral-residency-amgen-nasdaq-amgn-today-announced--amgn-20160926monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-ucb-announce-u-s-fda-acceptance-of-biologics-license-application-for-romosozumab-amgn-20160926monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-amgen-s-amjevita-adalimumab-atto-for-treatment-of-seven-inflammatory-diseases-amgn-20160923monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-anuncia-resultados-preliminares-positivos-do-estudo-de-imagem-glagov-de-fase-3-com-r-amgn-20160922monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-positive-top-line-results-from-phase-3-glagov-imaging-study-of-repatha-evo-amgn-20160920monthly0.5https://www.biopharmawatch.com/news/AMGN/results-from-phase-3-frame-study-of-romosozumab-showed-significant-reductions-in-both-new--amgn-20160918monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-receives-positive-chmp-opinion-for-parsabiv-etelcalcetide-for-the-treatment-of-secon-amgn-20160916monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-positive-data-at-ehmtic-2016-demonstrating-erenumab-significantly-reduces-m-amgn-20160915monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-webcast-investor-call-amgen-nasdaq-amgn-today-announced-that-the-company-will-hos-amgn-20160914monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference-amgen-n-amgn-20160913monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-morgan-stanley-global-healthcare-conference-amgen-nasdaq-amgn-will-amgn-20160908monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-highlight-19-abstracts-on-osteoporosis-disease-state-and-treatment-at-american-so-amgn-20160907monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-obtains-global-development-and-commercial-rights-from-boehringer-ingelheim-for-inves-amgn-20160901monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-servier-extend-omecamtiv-mecarbil-collaboration-in-chronic-heart-failure-amgen-n-amgn-20160901monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-blincyto-blinatumomab-for-use-in-pediatric-patients-with-philadelphia-chromos-amgn-20160901monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-positive-top-line-results-from-phase-3-study-of-prolia-denosumab-in-patien-amgn-20160829monthly0.5https://www.biopharmawatch.com/news/AMGN/new-repatha-evolocumab-analyses-show-efficacy-and-safety-across-risk-groups-in-results-pre-amgn-20160829monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-provides-update-on-status-of-parsabiv-etelcalcetide-new-drug-application-nda-submitt-amgn-20160824monthly0.5https://www.biopharmawatch.com/news/AMGN/new-data-add-to-understanding-of-repatha-evolocumab-in-multiple-patient-populations-amgen--amgn-20160822monthly0.5https://www.biopharmawatch.com/news/AMGN/repatha-evolocumabe-primeiro-medicamento-de-uma-classe-ine-dita-para-tratar-colesterol-alt-amgn-20160818monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-advaxis-enter-global-cancer-immunotherapies-collaboration-amgen-nasdaq-amgn-and--amgn-20160802monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reports-second-quarter-2016-financial-results-amgen-nasdaq-amgn-today-announced-fina-amgn-20160727monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2016-second-quarter-financial-results-amgen-nasdaq-amgn-today-a-amgn-20160722monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2016-third-quarter-dividend-amgen-nasdaq-amgn-today-announced-that-its-boa-amgn-20160722monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-ucb-submit-biologics-license-application-for-romosozumab-to-the-fda-amgen-nasdaq-amgn-20160722monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-allergan-announce-top-line-results-from-phase-3-study-evaluating-abp-980-compare-amgn-20160721monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-settlement-of-securities-litigation-amgen-nasdaq-amgn-today-announced-that-amgn-20160720monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-daiichi-sankyo-announce-agreement-to-commercialize-biosimilars-in-japan-amgen-na-amgn-20160713monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-discuss-data-supporting-biologics-license-application-for-abp-501-a-biosimilar-ca-amgn-20160712monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-first-and-only-single-monthly-injection-for-a-pcsk9-inhibitor-amgen-nasdaq-am-amgn-20160711monthly0.5https://www.biopharmawatch.com/news/AMGN/european-commission-approves-extended-indication-for-amgen-s-kyprolis-carfilzomib-for-the--amgn-20160704monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-sponsors-qb3-953-incubator-for-life-science-startups-amgen-nasdaq-amgn-today-announc-amgn-20160622monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-appoints-esteban-santos-executive-vice-president-operations-amgen-nasdaq-amgn-today--amgn-20160617monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-fda-advisory-committee-meeting-to-review-abp-501-a-biosimilar-candidate-to-amgn-20160613monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-expiration-and-final-results-of-senior-notes-exchange-offers-amgen-nasdaq--amgn-20160610monthly0.5https://www.biopharmawatch.com/news/AMGN/new-analyses-from-pivotal-phase-3-studies-show-kyprolis-carfilzomib-allows-patients-with-r-amgn-20160610monthly0.5https://www.biopharmawatch.com/news/AMGN/blincyto-blinatumomab-improved-overall-survival-in-patients-with-b-cell-precursor-acute-ly-amgn-20160610monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-erenumab-amg-334-significantly-reduces-patients-monthly-migraine-days-in-p-amgn-20160608monthly0.5https://www.biopharmawatch.com/news/AMGN/new-national-survey-sheds-light-on-how-to-better-engage-students-in-science-education-the--amgn-20160607monthly0.5https://www.biopharmawatch.com/news/AMGN/new-phase-3-secondary-analysis-shows-progression-free-survival-benefit-in-early-relapsing--amgn-20160606monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-launch-of-kyprolis-carfilzomib-central-an-online-news-resource-demonstrati-amgn-20160603monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-goldman-sachs-37th-annual-global-healthcare-conference-amgen-nasda-amgn-20160603monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-receives-positive-chmp-opinion-to-extend-indication-of-kyprolis-carfilzomib-for-the--amgn-20160527monthly0.5https://www.biopharmawatch.com/news/AMGN/kyprolis-carfilzomib-demonstrates-economic-value-in-relapsed-or-refractory-multiple-myelom-amgn-20160526monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-early-tender-results-of-senior-notes-exchange-offers-amgen-nasdaq-amgn-ann-amgn-20160525monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-pricing-terms-of-senior-notes-exchange-offers-amgen-nasdaq-amgn-announced--amgn-20160525monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-voting-results-of-annual-meeting-of-stockholders-amgen-nasdaq-amgn-today-a-amgn-20160519monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-highlights-data-to-be-presented-at-21st-congress-of-the-european-hematology-associat-amgn-20160519monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-data-to-be-presented-at-asco-2016-demonstrates-more-insights-into-treatment-options--amgn-20160518monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-breakaway-from-cancer-public-service-announcement-delivers-message-that-education--amgn-20160517monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-commences-exchange-offers-for-certain-series-of-outstanding-senior-notes-from-exchan-amgn-20160512monthly0.5https://www.biopharmawatch.com/news/AMGN/hall-of-fame-quarterback-joe-montana-and-amgen-team-up-to-launch-breakaway-from-heart-dise-amgn-20160511monthly0.5https://www.biopharmawatch.com/news/AMGN/platelet-biogenesis-wins-amgen-golden-ticket-for-labcentral-amgen-nasdaq-amgn-and-labcentr-amgn-20160509monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-bank-of-america-merrill-lynch-2016-health-care-conference-amgen-na-amgn-20160506monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-grants-priority-review-for-amgen-s-supplemental-biologics-license-application-for-blin-amgn-20160503monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-first-quarter-2016-revenues-increased-10-percent-to-5-5-billion-and-adjusted-earni-amgn-20160428monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-participate-in-the-2016-world-medical-innovation-forum-on-cancer-amgen-nasdaq-amg-amgn-20160425monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2016-first-quarter-financial-results-amgen-nasdaq-amgn-today-an-amgn-20160425monthly0.5https://www.biopharmawatch.com/news/AMGN/nplate-romiplostim-study-in-the-lancet-shows-significant-increase-in-durable-platelet-resp-amgn-20160419monthly0.5https://www.biopharmawatch.com/news/AMGN/positive-efficacy-and-tolerability-study-of-repatha-evolocumab-in-statin-intolerant-patien-amgn-20160403monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-ucb-present-positive-data-at-endo-2016-comparing-romosozumab-with-teriparatide-a-amgn-20160401monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-repatha-evolocumab-data-at-acc-16-amgen-nasdaq-amgn-today-announced-that--amgn-20160321monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-ucb-announce-positive-top-line-results-from-phase-3-study-evaluating-romosozumab-amgn-20160321monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-wins-patent-case-on-repatha-evolocumab-amgen-nasdaq-amgn-today-announced-that-a-dela-amgn-20160316monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-accepts-amgen-s-supplemental-biologics-license-application-for-the-expanded-use-of-enb-amgn-20160310monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-cowen-and-company-36th-annual-health-care-conference-amgen-nasdaq--amgn-20160303monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2016-second-quarter-dividend-amgen-nasdaq-amgn-today-announced-that-its-bo-amgn-20160302monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-submits-supplemental-biologics-license-application-for-blincyto-blinatumomab-amgen-n-amgn-20160301monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-ucb-announce-positive-top-line-results-from-the-phase-3-study-of-romosozumab-in--amgn-20160222monthly0.5https://www.biopharmawatch.com/news/AMGN/phase-3-study-demonstrates-aranesp-darbepoetin-alfa-reduces-red-blood-cell-transfusions-in-amgn-20160215monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-leerink-partners-5th-annual-global-healthcare-conference-amgen-nas-amgn-20160205monthly0.5https://www.biopharmawatch.com/news/AMGN/phase-3-study-of-blincyto-blinatumomab-met-primary-endpoint-of-overall-survival-in-patient-amgn-20160204monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-positive-top-line-results-from-phase-3-gauss-3-trial-of-repatha-evolocumab-amgn-20160204monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-2015-revenues-increased-8-percent-to-21-7-billion-and-adjusted-earnings-per-share--amgn-20160128monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-accepts-amgen-s-biosimilar-biologics-license-application-for-abp-501-amgen-nasdaq-amgn-amgn-20160125monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2015-fourth-quarter-and-full-year-financial-results-amgen-nasda-amgn-20160125monthly0.5https://www.biopharmawatch.com/news/AMGN/vectibix-panitumumab-and-best-supportive-care-improves-overall-survival-compared-to-best-s-amgn-20160123monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-repatha-evolocumab-approved-as-first-pcsk9-inhibitor-in-japan-for-the-treatment-of-amgn-20160122monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-new-kyprolis-carfilzomib-combination-therapy-for-the-treatment-of-patients-wi-amgn-20160121monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-34th-annual-j-p-morgan-healthcare-conference-amgen-nasdaq-amgn-wil-amgn-20160107monthly0.5https://www.biopharmawatch.com/news/AMGN/european-commission-approves-amgen-s-imlygic-talimogene-laherparepvec-as-first-oncolytic-i-amgn-20151218monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-27-percent-increase-in-2016-first-quarter-dividend-amgen-nasdaq-amgn-today-amgn-20151215monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-reacquires-all-product-rights-to-prolia-denosumab-xgeva-denosumab-and-vectibix-panit-amgn-20151214monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-data-from-three-trials-evaluating-blincyto-blinatumomab-in-acute-lymphoblas-amgn-20151207monthly0.5https://www.biopharmawatch.com/news/AMGN/new-analyses-presented-at-ash-2015-demonstrate-the-potential-of-kyprolis-carfilzomib-as-ba-amgn-20151205monthly0.5https://www.biopharmawatch.com/news/AMGN/pivotal-head-to-head-endeavor-study-results-published-in-the-lancet-oncology-demonstrate-s-amgn-20151205monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-submits-application-in-europe-to-expand-indication-of-kyprolis-carfilzomib-for-the-t-amgn-20151205monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-merck-announce-cancer-immunotherapy-collaboration-for-patients-with-non-hodgkin--amgn-20151204monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-first-biosimilar-marketing-authorization-application-submitted-to-european-medicin-amgn-20151204monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-first-biosimilar-biologics-license-application-for-abp-501-submitted-to-u-s-food-a-amgn-20151125monthly0.5https://www.biopharmawatch.com/news/AMGN/european-commission-approves-amgen-s-blincyto-blinatumomab-for-the-treatment-of-adults-wit-amgn-20151124monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-repatha-preferred-position-on-cvs-health-commercial-formularies-amgen-nasd-amgn-20151123monthly0.5https://www.biopharmawatch.com/news/AMGN/european-commission-approves-kyprolis-carfilzomib-for-combination-use-in-the-treatment-of--amgn-20151119monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-imlygic-talimogene-laherparepvec-data-at-the-2015-international-congress--amgn-20151116monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-detailed-results-from-phase-3-study-demonstrating-clinical-equivalence-of-b-amgn-20151109monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-cytokinetics-announce-late-breaking-presentation-of-cosmic-hf-trial-at-aha-scien-amgn-20151108monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-detailed-data-comparing-etelcalcetide-with-cinacalcet-in-patients-with-seco-amgn-20151107monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-accepts-amgen-s-new-drug-application-for-novel-intravenous-calcimimetic-etelcalcetide--amgn-20151106monthly0.5https://www.biopharmawatch.com/news/AMGN/key-data-for-amgen-medicines-in-relapsed-multiple-myeloma-and-acute-lymphoblastic-leukemia-amgn-20151105monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-credit-suisse-24th-annual-healthcare-conference-amgen-nasdaq-amgn--amgn-20151105monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-highlights-data-to-be-presented-at-2015-american-college-of-rheumatology-and-associa-amgn-20151104monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-highlight-cardiovascular-portfolio-at-american-heart-association-scientific-sessi-amgn-20151102monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-third-quarter-2015-revenues-increased-14-percent-to-5-7-billion-and-adjusted-earni-amgn-20151028monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-cytokinetics-announce-positive-top-line-results-from-cosmic-hf-a-phase-2-trial-o-amgn-20151027monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-imlygic-talimogene-laherparepvec-as-first-oncolytic-viral-therapy-in-the-us-a-amgn-20151027monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-receives-chmp-positive-opinion-for-imlygic-talimogene-laherparepvec-amgen-nasdaq-amg-amgn-20151023monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2015-third-quarter-financial-results-amgen-nasdaq-amgn-today-an-amgn-20151023monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-foundation-announces-new-4-million-commitment-to-bring-hands-on-biotechnology-labs-t-amgn-20151021monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2015-fourth-quarter-dividend-amgen-nasdaq-amgn-announced-that-its-board-of-amgn-20151014monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-labcentral-announce-2015-golden-ticket-winners-amgen-nasdaq-amgn-and-labcentral--amgn-20151013monthly0.5https://www.biopharmawatch.com/news/AMGN/new-data-show-consistent-safety-profile-for-up-to-10-years-with-prolia-denosumab-in-postme-amgn-20151012monthly0.5https://www.biopharmawatch.com/news/AMGN/new-exploratory-analysis-showed-romosozumab-increased-estimated-bone-strength-more-than-te-amgn-20151012monthly0.5https://www.biopharmawatch.com/news/AMGN/new-data-show-greater-bone-mineral-density-gains-with-prolia-denosumab-compared-with-zoled-amgn-20151011monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-give-23-presentations-on-osteoporosis-disease-and-treatment-at-american-society-f-amgn-20151006monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-repatha-co-preferred-position-on-express-scripts-national-formulary-amgen--amgn-20151006monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-barclays-biosimilars-symposium-amgen-nasdaq-amgn-will-present-at-t-amgn-20151002monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-receives-chmp-positive-opinions-for-two-new-treatment-options-for-patients-with-bloo-amgn-20150925monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-new-kyprolis-carfilzomib-data-at-15th-international-myeloma-workshop-amge-amgn-20150923monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-allergan-announce-positive-top-line-results-from-phase-3-study-of-biosimilar-can-amgn-20150923monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-grants-priority-review-for-amgen-s-supplemental-new-drug-application-for-expanded-labe-amgn-20150918monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-acquire-privately-held-dezima-pharma-amgen-nasdaq-amgn-and-dezima-pharma-b-v-dezi-amgn-20150916monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-xencor-announce-strategic-collaboration-in-cancer-immunotherapy-and-inflammation-amgn-20150916monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference-amgen-n-amgn-20150915monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-highlights-key-clinical-data-to-be-presented-at-european-cancer-congress-2015-amgen--amgn-20150914monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-submits-application-to-fda-for-new-delivery-option-for-monthly-administration-of-rep-amgn-20150911monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-morgan-stanley-global-healthcare-conference-amgen-nasdaq-amgn-will-amgn-20150911monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-submits-marketing-authorization-application-for-novel-intravenous-calcimimetic-etelc-amgn-20150902monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-enters-into-neuroscience-collaboration-with-novartis-for-alzheimer-s-disease-and-mig-amgn-20150901monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-ucb-announce-positive-top-line-results-from-open-label-phase-3-study-of-romosozu-amgn-20150901monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-amgen-s-new-cholesterol-lowering-medication-repatha-evolocumab-amgen-nasdaq-a-amgn-20150827monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-new-long-term-repatha-evolocumab-data-analysis-at-esc-congress-2015-amgen-amgn-20150825monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-submits-new-drug-application-for-novel-intravenous-calcimimetic-etelcalcetide-amg-41-amgn-20150825monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-university-of-california-berkeley-announce-multi-year-partnership-to-assist-canc-amgn-20150818monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-appointment-of-fred-hassan-to-board-of-directors-amgen-nasdaq-amgn-today-a-amgn-20150730monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-second-quarter-2015-revenues-increased-4-percent-to-5-4-billion-and-adjusted-earni-amgn-20150730monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2015-third-quarter-dividend-amgen-nasdaq-amgn-announced-that-its-board-of--amgn-20150728monthly0.5https://www.biopharmawatch.com/news/AMGN/european-commission-approves-amgen-s-new-cholesterol-lowering-medication-repatha-tm-evoloc-amgn-20150727monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2015-second-quarter-financial-results-amgen-nasdaq-amgn-today-a-amgn-20150727monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-kyprolis-carfilzomib-for-combination-use-in-the-treatment-of-patients-with-re-amgn-20150724monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-submits-supplemental-new-drug-application-for-kyprolis-carfilzomib-in-relapsed-multi-amgn-20150723monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-positive-blincyto-blinatumomab-phase-2-study-results-in-patients-with-rela-amgn-20150716monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-open-label-extension-data-from-ongoing-phase-2-study-of-amg-334-in-the-prev-amgn-20150619monthly0.5https://www.biopharmawatch.com/news/AMGN/results-from-phase-3-trial-show-vectibix-panitumumab-improves-overall-survival-in-chemoref-amgn-20150618monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-discuss-details-of-repatha-evolocumab-biologics-license-application-for-the-treat-amgn-20150610monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-goldman-sachs-global-healthcare-conference-amgen-nasdaq-amgn-will--amgn-20150608monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-completes-enrollment-in-large-cardiovascular-outcomes-trial-of-repatha-evolocumab-in-amgn-20150605monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-collaboration-with-roche-on-cancer-immunotherapy-study-with-investigationa-amgn-20150602monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-phase-3-data-at-asco-showing-prolia-denosumab-significantly-reduced-bone-fr-amgn-20150601monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-initiates-phase-3-study-evaluating-once-weekly-kyprolis-carfilzomib-in-patients-with-amgn-20150531monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-merck-announce-expansion-of-collaboration-to-support-studies-of-talimogene-laher-amgn-20150529monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-pooled-phase-3-amg-416-data-for-the-treatment-of-secondary-hyperparathyroid-amgn-20150529monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-launches-program-to-further-advance-basic-biology-research-amgen-nasdaq-amgn-today-a-amgn-20150528monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-jefferies-2015-global-healthcare-conference-amgen-nasdaq-amgn-will-amgn-20150527monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-advance-understanding-of-the-treatment-of-blood-cancers-at-20th-congress-of-europ-amgn-20150527monthly0.5https://www.biopharmawatch.com/news/AMGN/pivotal-study-results-published-in-journal-of-clinical-oncology-showed-talimogene-laherpar-amgn-20150526monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-receives-positive-chmp-opinion-for-use-of-repatha-evolocumab-for-the-treatment-of-hi-amgn-20150522monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-terminate-participation-in-co-development-and-commercialization-of-brodalumab-amg-amgn-20150522monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-appoints-jonathan-p-graham-senior-vice-president-general-counsel-and-secretary-amgen-amgn-20150518monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-first-phase-2-data-for-amg-334-in-the-prevention-of-episodic-migraine-amgen-amgn-20150515monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-voting-results-of-annual-meeting-of-stockholders-amgen-nasdaq-amgn-today-a-amgn-20150514monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-data-at-asco-2015-highlight-oncology-pipeline-and-portfolio-amgen-nasdaq-amgn-today--amgn-20150513monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-breakaway-from-cancer-announces-winners-of-its-nationwide-search-for-champions-in--amgn-20150512monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-amg-334-data-at-17th-congress-of-the-international-headache-society-amgen-amgn-20150511monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-deutsche-bank-40th-annual-healthcare-conference-amgen-nasdaq-amgn--amgn-20150504monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-fda-advisory-committee-meeting-to-review-repatha-evolocumab-as-a-treatment-amgn-20150429monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-discuss-details-of-the-biologics-license-application-for-talimogene-laherparepvec-amgn-20150429monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-first-quarter-2015-revenues-increased-11-percent-to-5-0-billion-and-adjusted-earni-amgn-20150421monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2015-first-quarter-financial-results-amgen-nasdaq-amgn-today-an-amgn-20150416monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-corlanor-ivabradine-to-reduce-the-risk-of-hospitalization-for-worsening-heart-amgn-20150415monthly0.5https://www.biopharmawatch.com/news/AMGN/european-commission-approves-amgen-s-vectibix-panitumumab-as-first-line-treatment-in-combi-amgn-20150406monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-grants-amgen-priority-review-for-kyprolis-carfilzomib-supplemental-new-drug-applicatio-amgn-20150330monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-goldman-sachs-key-debates-in-biosimilars-conference-amgen-nasdaq-a-amgn-20150330monthly0.5https://www.biopharmawatch.com/news/AMGN/cancer-survivor-joan-lunden-named-2015-honorary-breakaway-from-cancer-champion-and-joins-n-amgn-20150326monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-webcast-investor-call-at-the-73rd-annual-meeting-of-the-american-academy-of-derma-amgn-20150323monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-submits-application-for-investigational-ldl-cholesterol-lowering-medication-repatha--amgn-20150320monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-10-abstracts-from-its-dermatology-portfolio-at-the-73rd-annual-meeting-of-amgn-20150317monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-publishes-safety-analysis-of-investigational-cholesterol-lowering-medication-repatha-amgn-20150315monthly0.5https://www.biopharmawatch.com/news/AMGN/new-detailed-data-from-phase-3-study-show-amgen-s-repatha-evolocumab-in-combination-with-s-amgn-20150314monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2015-second-quarter-dividend-amgen-nasdaq-amgn-announced-that-its-board-of-amgn-20150304monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-showcases-cardiovascular-pipeline-at-acc-15-with-new-cholesterol-lowering-and-chroni-amgn-20150302monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-launch-of-new-neulasta-pegfilgrastim-delivery-kit-amgen-nasdaq-amgn-today--amgn-20150302monthly0.5https://www.biopharmawatch.com/news/AMGN/phase-3-head-to-head-endeavor-study-demonstrates-superiority-of-kyprolis-carfilzomib-over--amgn-20150301monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-receives-positive-chmp-opinion-for-use-of-vectibix-panitumumab-as-first-line-treatme-amgn-20150227monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-the-european-medicines-agency-acceptance-of-kyprolis-carfilzomib-marketing-amgn-20150226monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-positive-results-from-head-to-head-study-comparing-the-efficacy-and-safety-amgn-20150225monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-cowen-and-company-35th-annual-health-care-conference-amgen-nasdaq--amgn-20150225monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-fda-advisory-committees-to-review-talimogene-laherparepvec-for-the-treatme-amgn-20150211monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-positive-top-line-results-from-phase-3-study-evaluating-the-efficacy-and-s-amgn-20150203monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-the-familial-hypercholesterolemia-foundation-and-stanford-medicine-launch-find-fh-in-amgn-20150129monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-submits-applications-in-the-us-and-europe-for-kyprolis-carfilzomib-for-the-treatment-amgn-20150127monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-2014-revenues-increased-7-percent-to-20-1-billion-and-adjusted-earnings-per-share--amgn-20150127monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2014-fourth-quarter-and-full-year-financial-results-amgen-nasda-amgn-20150122monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-new-data-supporting-first-line-use-of-vectibix-panitumumab-in-combination-w-amgn-20150115monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-md-anderson-announce-agreement-to-develop-bite-therapies-for-myelodysplastic-syn-amgn-20150112monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-33rd-annual-j-p-morgan-healthcare-conference-amgen-nasdaq-amgn-wil-amgn-20150108monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-kite-pharma-announce-strategic-cancer-immunotherapy-collaboration-to-advance-the-amgn-20150105monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-30-percent-increase-in-2015-first-quarter-dividend-amgen-nasdaq-amgn-today-amgn-20141217monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-astrazeneca-to-present-results-from-phase-3-amagine-1-study-evaluating-brodaluma-amgn-20141211monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-data-from-pivotal-phase-2-study-of-blincyto-blinatumomab-immunotherapy-in-p-amgn-20141208monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-amgen-s-xgeva-denosumab-for-the-treatment-of-hypercalcemia-of-malignancy-refr-amgn-20141208monthly0.5https://www.biopharmawatch.com/news/AMGN/new-trial-initiated-evaluating-amgen-s-talimogene-laherparepvec-in-combination-with-merck--amgn-20141208monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-onyx-announce-detailed-results-from-phase-3-aspire-study-of-kyprolis-carfilzomib-amgn-20141208monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-new-data-from-phase-2-blincyto-blinatumomab-immunotherapy-study-in-patient-amgn-20141206monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-webcast-investor-meeting-at-upcoming-american-society-of-hematology-ash-56th-annu-amgn-20141203monthly0.5https://www.biopharmawatch.com/news/AMGN/actriz-adamari-lo-pez-y-amgen-lanzan-quimioterapia-mitos-y-realidades-sitio-web-y-recursos-amgn-20141203monthly0.5https://www.biopharmawatch.com/news/AMGN/actress-adamari-lo-pez-and-amgen-launch-spanish-language-chemotherapy-myths-or-facts-websi-amgn-20141203monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-blincyto-blinatumomab-immunotherapy-for-the-treatment-of-relapsed-or-refracto-amgn-20141203monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-astrazeneca-announce-positive-results-from-third-and-final-pivotal-phase-3-study-amgn-20141125monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-termination-of-all-amgen-sponsored-clinical-studies-of-rilotumumab-in-adva-amgn-20141124monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-long-term-data-showing-efficacy-and-safety-of-investigational-cholesterol-l-amgn-20141118monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-jefferies-global-healthcare-conference-amgen-nasdaq-amgn-will-part-amgn-20141114monthly0.5https://www.biopharmawatch.com/news/AMGN/the-amgen-foundation-expands-amgen-scholars-program-to-17-top-educational-institutions-wor-amgn-20141112monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-webcast-investor-call-at-upcoming-american-heart-association-scientific-sessions--amgn-20141112monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-highlight-new-data-for-investigational-cholesterol-lowering-medication-evolocumab-amgn-20141112monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-astrazeneca-announce-positive-results-from-second-pivotal-phase-3-study-of-broda-amgn-20141111monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-accepts-amgen-s-biologics-license-application-for-ldl-cholesterol-lowering-medication--amgn-20141110monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-credit-suisse-annual-healthcare-conference-amgen-nasdaq-amgn-will--amgn-20141106monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-highlights-new-data-in-the-treatment-of-blood-cancers-at-ash-2014-amgen-nasdaq-amgn--amgn-20141106monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-top-line-secondary-endpoint-results-of-phase-3-trebananib-trinova-1-trial--amgn-20141104monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-outlines-strategy-growth-objectives-and-capital-allocation-plans-amgen-nasdaq-amgn-t-amgn-20141028monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-third-quarter-2014-revenues-increased-6-percent-to-5-0-billion-and-adjusted-earnin-amgn-20141027monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-webcast-2014-business-review-meeting-on-october-28-amgen-nasdaq-amgn-today-announ-amgn-20141023monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2014-third-quarter-financial-results-amgen-nasdaq-amgn-today-an-amgn-20141023monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-statement-regarding-third-point-investment-amgen-nasdaq-amgn-issued-the-following-st-amgn-20141021monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-files-lawsuit-against-sanofi-and-regeneron-for-patent-infringement-amgen-nasdaq-amgn-amgn-20141017monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-appointment-of-r-sanders-williams-to-board-of-directors-amgen-nasdaq-amgn--amgn-20141017monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2014-fourth-quarter-dividend-amgen-nasdaq-amgn-announced-that-its-board-of-amgn-20141017monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-bite-immunotherapy-blinatumomab-receives-fda-priority-review-designation-in-acute--amgn-20141009monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-positive-top-line-results-from-phase-3-study-evaluating-the-efficacy-and-s-amgn-20141008monthly0.5https://www.biopharmawatch.com/news/AMGN/the-lancet-publishes-two-phase-3-studies-showing-cholesterol-lowering-medication-evolocuma-amgn-20141001monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-moderate-to-severe-plaque-psoriasis-data-to-be-presented-at-the-23rd-congr-amgn-20141001monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-host-summary-webcast-of-kyprolis-carfilzomib-for-injection-data-presented-at-the--amgn-20140924monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-submits-biologics-license-application-for-investigational-bite-immunotherapy-blinatu-amgn-20140922monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-results-from-several-new-exploratory-analyses-evaluating-long-term-impact--amgn-20140915monthly0.5https://www.biopharmawatch.com/news/AMGN/new-analyses-of-phase-2-study-presented-at-asbmr-show-romosozumab-treatment-resulted-in-co-amgn-20140915monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-analyses-of-phase-3-ivabradine-data-for-the-treatment-of-chronic-heart-fail-amgn-20140914monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-23-abstracts-to-be-presented-at-the-american-society-for-bone-and-mineral--amgn-20140910monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-morgan-stanley-global-healthcare-conference-amgen-nasdaq-amgn-will-amgn-20140905monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-submits-marketing-authorization-application-for-talimogene-laherparepvec-to-the-euro-amgn-20140902monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-positive-top-line-results-from-phase-3-yukawa-2-trial-of-evolocumab-in-com-amgn-20140828monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-submits-biologics-license-application-for-novel-investigational-ldl-cholesterol-lowe-amgn-20140828monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-grants-amgen-priority-review-designation-for-ivabradine-for-the-treatment-of-chronic-h-amgn-20140827monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-positive-top-line-results-from-second-phase-3-study-of-amg-416-for-the-tre-amgn-20140818monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-issues-voluntary-recall-of-aranesp-darbepoetin-alfa-500-mcg-prefilled-syringes-in-se-amgn-20140813monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-top-line-results-from-phase-3-focus-trial-of-kyprolis-in-patients-with-rel-amgn-20140813monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-phase-3-aspire-trial-of-kyprolis-in-patients-with-relapsed-multiple-myelom-amgn-20140804monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-second-quarter-2014-revenues-increased-11-percent-to-5-2-billion-and-adjusted-earn-amgn-20140729monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2014-third-quarter-dividend-amgen-nasdaq-amgn-announced-that-its-board-of--amgn-20140725monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2014-second-quarter-financial-results-amgen-nasdaq-amgn-today-a-amgn-20140724monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-positive-phase-3-results-for-amg-416-for-the-treatment-of-secondary-hyperp-amgn-20140717monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-receives-fda-breakthrough-therapy-designation-for-investigational-bite-antibody-blin-amgn-20140701monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-joins-the-national-cancer-institute-and-research-partners-to-help-accelerate-develop-amgn-20140616monthly0.5https://www.biopharmawatch.com/news/AMGN/brodalumab-treatment-improved-clinical-signs-and-symptoms-in-phase-2-psoriatic-arthritis-s-amgn-20140611monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-appoints-david-w-meline-executive-vice-president-and-chief-financial-officer-amgen-n-amgn-20140609monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-goldman-sachs-global-healthcare-conference-amgen-nasdaq-amgn-will--amgn-20140606monthly0.5https://www.biopharmawatch.com/news/AMGN/new-detailed-phase-3-data-show-amgen-s-novel-investigational-cholesterol-lowering-medicati-amgn-20140601monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-highlights-phase-2-results-of-vectibix-panitumumab-versus-bevacizumab-in-combination-amgn-20140531monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-jefferies-2014-global-healthcare-conference-amgen-nasdaq-amgn-will-amgn-20140530monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-host-post-american-society-of-clinical-oncology-asco-summary-webcast-amgen-nasdaq-amgn-20140529monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-onyx-data-at-asco-2014-highlight-oncology-pipeline-and-portfolio-amgen-nasdaq-am-amgn-20140527monthly0.5https://www.biopharmawatch.com/news/AMGN/the-new-england-journal-of-medicine-publishes-positive-proof-of-concept-data-for-new-asthm-amgn-20140520monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-voting-results-of-annual-meeting-of-stockholders-amgen-nasdaq-amgn-today-a-amgn-20140515monthly0.5https://www.biopharmawatch.com/news/AMGN/journal-of-the-american-medical-association-publishes-phase-3-laplace-2-study-showing-evol-amgn-20140513monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-breakaway-from-cancer-honors-four-california-cancer-survivors-during-the-ninth-ann-amgn-20140512monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-names-steven-k-galson-senior-vice-president-global-regulatory-affairs-and-safety-amg-amgn-20140512monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-astrazeneca-announce-positive-results-from-phase-3-study-of-brodalumab-amg-827-i-amgn-20140509monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-first-quarter-2014-revenues-increased-7-percent-to-4-5-billion-amgen-nasdaq-amgn-t-amgn-20140422monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2014-first-quarter-financial-results-amgen-nasdaq-amgn-today-an-amgn-20140417monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-provides-update-on-phase-3-study-of-talimogene-laherparepvec-in-patients-with-metast-amgn-20140404monthly0.5https://www.biopharmawatch.com/news/AMGN/data-from-phase-3-pivotal-studies-show-amgen-s-novel-investigational-cholesterol-lowering--amgn-20140330monthly0.5https://www.biopharmawatch.com/news/AMGN/new-detailed-data-from-three-phase-3-pivotal-studies-show-amgen-s-novel-investigational-ch-amgn-20140329monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-webcast-investor-meeting-at-upcoming-american-college-of-cardiology-s-63rd-annual-amgn-20140326monthly0.5https://www.biopharmawatch.com/news/AMGN/phase-3-pivotal-data-on-amgen-s-novel-investigational-cholesterol-lowering-medicine-to-be--amgn-20140324monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-positive-top-line-results-from-phase-3-tesla-trial-of-evolocumab-amg-145-i-amgn-20140317monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-talimogene-laherparepvec-reduced-size-of-melanoma-tumors-in-new-phase-3-retrospect-amgn-20140314monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2014-second-quarter-dividend-amgen-nasdaq-amgn-announced-that-its-board-of-amgn-20140305monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-cowen-and-company-34th-annual-healthcare-conference-amgen-nasdaq-a-amgn-20140301monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-rbc-capital-markets-global-healthcare-conference-amgen-nasdaq-amgn-amgn-20140221monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-merck-announce-collaboration-to-evaluate-investigational-combination-treatment-f-amgn-20140205monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-positive-top-line-results-from-phase-3-rutherford-2-trial-of-evolocumab-am-amgn-20140130monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-positive-top-line-results-from-phase-3-laplace-2-trial-of-evolocumab-amg-1-amgn-20140128monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-2013-revenues-increased-8-percent-to-18-7-billion-and-adjusted-earnings-per-share--amgn-20140128monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-positive-top-line-results-from-phase-3-gauss-2-trial-of-evolocumab-amg-145-amgn-20140123monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2013-fourth-quarter-and-full-year-financial-results-amgen-nasda-amgn-20140123monthly0.5https://www.biopharmawatch.com/news/AMGN/mass-general-broad-institute-and-amgen-will-work-to-discover-new-drugs-for-inflammatory-bo-amgn-20140115monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-32nd-annual-j-p-morgan-healthcare-conference-amgen-nasdaq-amgn-wil-amgn-20140109monthly0.5https://www.biopharmawatch.com/news/AMGN/chief-financial-officer-jonathan-m-peacock-to-leave-amgen-company-appoints-michael-a-kelly-amgn-20140109monthly0.5https://www.biopharmawatch.com/news/AMGN/romosozumab-phase-2-data-published-in-new-england-journal-of-medicine-show-significant-inc-amgn-20140101monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-positive-top-line-results-from-52-week-phase-3-descartes-study-of-evolocum-amgn-20131219monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-positive-top-line-results-from-phase-3-mendel-2-trial-of-evolocumab-amg-14-amgn-20131217monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2014-first-quarter-dividend-amgen-nasdaq-amgn-announced-that-its-board-of--amgn-20131213monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-host-post-american-society-of-hematology-ash-summary-webcast-amgen-nasdaq-amgn-an-amgn-20131210monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-oppenheimer-24th-annual-healthcare-conference-amgen-nasdaq-amgn-wi-amgn-20131205monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-evolocumab-amg-145-results-from-first-52-week-study-of-a-pcsk9-inhibitor-t-amgn-20131119monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-interim-overall-survival-data-from-phase-3-study-of-talimogene-laherparepve-amgn-20131118monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-webcast-investor-meeting-at-upcoming-american-heart-association-scientific-sessio-amgn-20131114monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-highlight-new-evolocumab-amg-145-data-at-upcoming-american-heart-association-scie-amgn-20131112monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-foundation-commits-2-5-million-in-new-grants-to-engage-50-000-students-each-year-in--amgn-20131107monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-acquires-filgrastim-franchise-rights-from-roche-in-100-markets-amgen-nasdaq-amgn-tod-amgn-20131022monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-third-quarter-2013-revenues-increased-10-percent-to-4-7-billion-and-adjusted-earni-amgn-20131022monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2013-third-quarter-financial-results-amgen-nasdaq-amgn-today-an-amgn-20131017monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-appointment-of-greg-c-garland-to-board-of-directors-amgen-nasdaq-amgn-toda-amgn-20131016monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2013-fourth-quarter-dividend-amgen-nasdaq-amgn-announced-that-its-board-of-amgn-20131016monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-nearly-two-dozen-abstracts-from-romosozumab-and-prolia-denosumab-at-asbmr-a-amgn-20131004monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-astrazeneca-highlight-data-to-be-presented-at-22nd-congress-of-the-european-acad-amgn-20131003monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-successfully-completes-onyx-pharmaceuticals-tender-offer-amgen-nasdaq-amgn-today-ann-amgn-20131001monthly0.5https://www.biopharmawatch.com/news/AMGN/phase-3-trial-comparing-vectibix-panitumumab-to-erbitux-cetuximab-meets-primary-endpoint-o-amgn-20130928monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-shanghaitech-university-announce-plans-for-amgen-china-r-d-center-to-open-on-sha-amgn-20130924monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-onyx-pharmaceuticals-announce-early-termination-of-hsr-waiting-period-for-amgen--amgn-20130918monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-highlights-data-to-be-presented-at-2013-european-cancer-congress-amgen-nasdaq-amgn-t-amgn-20130912monthly0.5https://www.biopharmawatch.com/news/AMGN/analysis-published-in-new-england-journal-of-medicine-highlights-discovery-of-new-predicti-amgn-20130911monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference-amgen-n-amgn-20130910monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-morgan-stanley-global-healthcare-conference-amgen-nasdaq-amgn-will-amgn-20130906monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-cytokinetics-announce-the-first-presentation-of-data-from-phase-2-atomic-ahf-stu-amgn-20130903monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-pooled-analysis-showing-amg-145-significantly-reduced-ldl-cholesterol-in-ov-amgn-20130901monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-participate-at-citi-s-8th-annual-biotech-conference-amgen-nasdaq-amgn-will-partic-amgn-20130830monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-highlight-new-data-at-upcoming-esc-congress-2013-amgen-nasdaq-amgn-today-announce-amgn-20130827monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-acquire-onyx-pharmaceuticals-for-125-per-share-in-cash-amgen-nasdaq-amgn-and-onyx-amgn-20130825monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-servier-complete-product-collaboration-transaction-amgen-nasdaq-amgn-and-servier-amgn-20130812monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-second-quarter-2013-revenues-increased-5-percent-to-4-7-billion-and-adjusted-earni-amgn-20130730monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2013-third-quarter-dividend-amgen-nasdaq-amgn-announced-that-its-board-of--amgn-20130726monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2013-second-quarter-financial-results-amgen-nasdaq-amgn-today-a-amgn-20130725monthly0.5https://www.biopharmawatch.com/news/AMGN/the-lancet-oncology-publishes-results-of-xgeva-denosumab-in-patients-with-giant-cell-tumor-amgn-20130715monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-award-for-science-teaching-excellence-honors-outstanding-teachers-amgen-is-pleased-t-amgn-20130619monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-amgen-s-xgeva-denosumab-for-the-treatment-of-giant-cell-tumor-of-bone-amgen-n-amgn-20130613monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-top-line-results-of-phase-3-trebananib-amg-386-trinova-1-trial-in-recurren-amgn-20130612monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-astrazeneca-highlight-data-to-be-presented-at-european-league-against-rheumatism-amgn-20130612monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-goldman-sachs-34th-annual-global-healthcare-conference-amgen-nasda-amgn-20130606monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-positive-results-from-talimogene-laherparepvec-phase-3-study-in-patients-wi-amgn-20130601monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-astellas-announce-japan-alliance-amgen-nasdaq-amgn-the-world-s-largest-independe-amgn-20130529monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-webcast-investor-meeting-at-upcoming-american-society-of-clinical-oncology-annual-amgn-20130529monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-deutsche-bank-38th-annual-healthcare-conference-amgen-nasdaq-amgn--amgn-20130523monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-voting-results-of-annual-meeting-of-stockholders-amgen-nasdaq-amgn-today-a-amgn-20130522monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-ubs-global-life-sciences-conference-amgen-nasdaq-amgn-will-partici-amgn-20130516monthly0.5https://www.biopharmawatch.com/news/AMGN/new-analyses-identify-predictive-biomarkers-for-vectibix-panitumumab-in-patients-with-meta-amgn-20130515monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-highlights-data-to-be-presented-at-american-society-of-clinical-oncology-annual-meet-amgn-20130515monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-zhejiang-beta-pharma-announce-planned-joint-venture-in-china-amgen-nasdaq-amgn-a-amgn-20130509monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-top-line-results-of-vectibix-panitumumab-phase-3-head-to-head-study-agains-amgn-20130507monthly0.5https://www.biopharmawatch.com/news/AMGN/four-californians-selected-as-breakaway-from-cancer-champions-to-be-honored-during-amgen-t-amgn-20130501monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-first-quarter-2013-revenues-increased-5-percent-to-4-2-billion-and-adjusted-earnin-amgn-20130423monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2013-first-quarter-financial-results-amgen-nasdaq-amgn-today-an-amgn-20130418monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-top-line-results-of-phase-3-talimogene-laherparepvec-trial-in-melanoma-amg-amgn-20130319monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2013-second-quarter-dividend-amgen-nasdaq-amgn-announced-that-its-board-of-amgn-20130306monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-statement-on-government-budget-analysis-for-oral-only-treatments-for-dialysis-patien-amgn-20130222monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-call-for-nominations-for-2013-breakaway-from-cancer-champions-amgen-nasdaq-amgn-20130208monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-outlines-long-term-strategy-amgen-nasdaq-amgn-today-outlined-the-company-s-long-term-amgn-20130207monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-webcast-2013-business-review-meeting-on-february-7-amgen-nasdaq-amgn-today-announ-amgn-20130131monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-results-from-phase-3-paves-study-evaluating-neulasta-pegfilgrastim-in-pati-amgn-20130126monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-backs-states-efforts-to-enact-biosimilar-legislation-that-allows-for-substitution-an-amgn-20130125monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-full-year-2012-revenues-increased-11-percent-to-17-3-billion-and-adjusted-earnings-amgn-20130123monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2012-fourth-quarter-and-full-year-financial-results-amgen-nasda-amgn-20130118monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-top-line-results-of-phase-3-aranesp-darbepoetin-alfa-red-hf-trial-amgen-na-amgn-20130116monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-build-state-of-the-art-manufacturing-facility-in-singapore-amgen-nasdaq-amgn-toda-amgn-20130116monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-31st-annual-j-p-morgan-global-healthcare-conference-amgen-nasdaq-a-amgn-20130103monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-finalizes-agreement-resolving-previously-announced-federal-investigations-amgen-nasd-amgn-20121219monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-appointment-of-robert-a-eckert-to-board-of-directors-amgen-nasdaq-amgn-tod-amgn-20121213monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-names-robert-a-bradway-chairman-of-the-board-of-directors-amgen-nasdaq-amgn-today-an-amgn-20121213monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-31-percent-increase-in-2013-first-quarter-dividend-and-increase-in-its-sha-amgn-20121213monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-acquire-decode-genetics-a-global-leader-in-human-genetics-amgen-nasdaq-amgn-and-d-amgn-20121210monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-highlights-data-to-be-presented-at-american-society-of-hematology-annual-meeting-amg-amgn-20121205monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-24th-annual-piper-jaffray-healthcare-conference-amgen-nasdaq-amgn--amgn-20121120monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-pfizer-highlight-data-to-be-presented-at-american-college-of-rheumatology-meetin-amgn-20121112monthly0.5https://www.biopharmawatch.com/news/AMGN/the-lancet-publication-of-laplace-timi-57-and-mendel-studies-showed-amg-145-significantly--amgn-20121106monthly0.5https://www.biopharmawatch.com/news/AMGN/circulation-publishes-results-from-rutherford-study-which-showed-amg-145-significantly-red-amgn-20121105monthly0.5https://www.biopharmawatch.com/news/AMGN/journal-of-the-american-medical-association-publishes-amg-145-phase-2-gauss-study-showing--amgn-20121105monthly0.5https://www.biopharmawatch.com/news/AMGN/phase-3-sensipar-mimpara-evolve-trial-published-in-the-new-england-journal-of-medicine-amg-amgn-20121103monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-data-from-four-phase-2-studies-at-upcoming-american-heart-association-sci-amgn-20121102monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-webcast-investor-meeting-at-upcoming-american-heart-association-scientific-sessio-amgn-20121101monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-supports-assistance-for-patients-affected-by-hurricane-sandy-amgen-and-the-amgen-fou-amgn-20121101monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-third-quarter-2012-revenues-increased-10-percent-to-4-3-billion-and-adjusted-earni-amgn-20121023monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2012-third-quarter-financial-results-amgen-nasdaq-amgn-today-an-amgn-20121018monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-several-sub-analyses-at-asbmr-from-the-ongoing-open-label-extension-study-o-amgn-20121014monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-appoints-cynthia-patton-senior-vice-president-and-chief-compliance-officer-amgen-nas-amgn-20121012monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2012-fourth-quarter-dividend-amgen-nasdaq-amgn-announced-that-on-oct-10-20-amgn-20121011monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-new-indication-for-prolia-denosumab-for-the-treatment-of-bone-loss-in-men-wit-amgn-20120920monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-names-ray-jordan-senior-vice-president-corporate-affairs-amgen-nasdaq-amgn-today-ann-amgn-20120910monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference-amgen-n-amgn-20120910monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-morgan-stanley-global-healthcare-conference-amgen-nasdaq-amgn-will-amgn-20120907monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-baird-healthcare-conference-amgen-nasdaq-amgn-will-participate-in--amgn-20120831monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-termination-of-ganitumab-phase-3-study-for-futility-in-metastatic-pancreat-amgn-20120808monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-second-quarter-2012-revenues-increased-13-percent-to-4-5-billion-and-adjusted-earn-amgn-20120726monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2012-second-quarter-financial-results-amgen-nasdaq-amgn-today-a-amgn-20120723monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2012-third-quarter-dividend-amgen-nasdaq-amgn-announced-that-its-board-of--amgn-20120719monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-completes-acquisition-of-kai-pharmaceuticals-amgen-nasdaq-amgn-today-announced-the-c-amgn-20120705monthly0.5https://www.biopharmawatch.com/news/AMGN/actress-maura-tierney-and-amgen-launch-the-chemotherapy-myths-or-facts-campaign-amgen-nasd-amgn-20120625monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-completes-acquisition-of-mustafa-nevzat-pharmaceuticals-amgen-nasdaq-amgn-today-anno-amgn-20120612monthly0.5https://www.biopharmawatch.com/news/AMGN/20th-annual-amgen-award-for-science-teaching-excellence-honors-nine-outstanding-teachers-a-amgn-20120611monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-top-line-results-of-phase-3-sensipar-mimpara-evolve-trial-amgen-nasdaq-amg-amgn-20120608monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-voting-results-of-annual-meeting-of-stockholders-amgen-nasdaq-amgn-today-a-amgn-20120523monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-bite-antibody-blinatumomab-amg-103-achieved-high-rate-of-complete-response-in-adul-amgn-20120518monthly0.5https://www.biopharmawatch.com/news/AMGN/analysis-of-rilotumumab-amg-102-data-identifies-a-potential-predictive-biomarker-for-patie-amgn-20120516monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-provide-testimony-at-fda-stakeholder-hearing-on-biosimilars-amgen-nasdaq-amgn-ann-amgn-20120511monthly0.5https://www.biopharmawatch.com/news/AMGN/cancer-support-community-launches-national-program-to-assist-patients-with-cancer-make-inf-amgn-20120509monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-baird-growth-stock-conference-amgen-nasdaq-amgn-will-present-at-th-amgn-20120504monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-deutsche-bank-37th-annual-healthcare-conference-amgen-nasdaq-amgn--amgn-20120503monthly0.5https://www.biopharmawatch.com/news/AMGN/four-californians-selected-as-breakaway-from-cancer-champions-to-be-honored-during-amgen-t-amgn-20120501monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-receives-complete-response-letter-from-fda-for-xgeva-sbla-for-prevention-of-bone-met-amgn-20120426monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-acquire-mustafa-nevzat-a-leading-privately-held-turkish-pharmaceutical-company-am-amgn-20120425monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-first-quarter-2012-revenue-increased-9-percent-to-4-0-billion-and-adjusted-earning-amgn-20120424monthly0.5https://www.biopharmawatch.com/news/AMGN/a-tribute-to-george-rathmann-amgen-s-founding-ceo-1927-2012-amgen-nasdaq-amgn-today-announ-amgn-20120423monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2012-first-quarter-financial-results-amgen-nasdaq-amgn-today-an-amgn-20120419monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-acquire-privately-held-kai-pharmaceuticals-amgen-nasdaq-amgn-and-kai-pharmaceutic-amgn-20120410monthly0.5https://www.biopharmawatch.com/news/AMGN/ucb-and-amgen-initiate-sclerostin-antibody-phase-3-program-in-patients-with-postmenopausal-amgn-20120404monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-astrazeneca-announce-collaboration-to-jointly-develop-and-commercialize-clinical-amgn-20120402monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-phase-2-study-results-for-brodalumab-in-moderate-to-severe-plaque-psoriasi-amgn-20120328monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-pcsk9-inhibitor-reduced-ldl-cholesterol-up-to-81-percent-in-phase-1b-study-amgen-n-amgn-20120325monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2012-second-quarter-dividend-amgen-nasdaq-amgn-announced-that-its-board-of-amgn-20120315monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-completes-tender-offer-for-outstanding-shares-of-micromet-inc-amgen-inc-amgen-nasdaq-amgn-20120307monthly0.5https://www.biopharmawatch.com/news/AMGN/schwartz-center-receives-500-000-grant-from-the-amgen-foundation-the-schwartz-center-for-c-amgn-20120306monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-initial-results-of-tender-offer-for-outstanding-shares-of-micromet-inc-and-amgn-20120302monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-cowen-and-company-32nd-annual-healthcare-conference-amgen-nasdaq-a-amgn-20120229monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-micromet-announce-early-termination-of-hsr-waiting-period-for-amgen-s-acquisitio-amgn-20120215monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-names-michael-severino-m-d-senior-vice-president-global-development-and-corporate-ch-amgn-20120214monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-leerink-swann-global-healthcare-conference-amgen-nasdaq-amgn-will--amgn-20120213monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-discuss-application-for-new-use-of-xgeva-denosumab-at-fda-oncologic-drugs-advisor-amgn-20120208monthly0.5https://www.biopharmawatch.com/news/AMGN/u-bernahme-von-micromet-durch-amgen-die-u-bernahme-umfasst-auch-neuartige-medikamente-gege-amgn-20120126monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-acquire-micromet-amgen-nasdaq-amgn-and-micromet-inc-nasdaq-miti-today-announced-t-amgn-20120126monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-full-year-2011-revenue-increased-4-percent-to-15-6-billion-and-adjusted-earnings-p-amgn-20120126monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2011-fourth-quarter-and-full-year-financial-results-amgen-nasda-amgn-20120124monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-30th-annual-j-p-morgan-global-healthcare-conference-amgen-nasdaq-a-amgn-20120104monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-to-review-potential-new-use-of-xgeva-denosumab-at-oncologic-drugs-advisory-committee-m-amgn-20111229monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-watson-announce-collaboration-to-develop-and-commercialize-oncology-biosimilars--amgn-20111219monthly0.5https://www.biopharmawatch.com/news/AMGN/kevin-sharer-amgen-chairman-and-ceo-announces-plan-to-retire-with-robert-bradway-to-become-amgn-20111215monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2012-first-quarter-dividend-amgen-nasdaq-amgn-announced-that-its-board-of--amgn-20111215monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-final-results-of-its-tender-offer-amgen-nasdaq-amgn-today-announced-the-fi-amgn-20111214monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-final-results-from-the-largest-phase-3-open-label-study-assessing-the-safet-amgn-20111213monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-22nd-annual-oppenheimer-healthcare-conference-amgen-nasdaq-amgn-wi-amgn-20111209monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-fda-agree-to-modify-nplate-romiplostim-risk-evaluation-and-mitigation-strategy-a-amgn-20111206monthly0.5https://www.biopharmawatch.com/news/AMGN/enbrel-etanercept-patent-issued-amgen-nasdaq-amgn-today-issued-the-following-statement-amg-amgn-20111122monthly0.5https://www.biopharmawatch.com/news/AMGN/the-lancet-publishes-results-demonstrating-xgeva-significantly-prolonged-bone-metastasis-f-amgn-20111115monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-plan-to-launch-tender-offer-and-launch-of-senior-notes-offering-amgen-nasd-amgn-20111107monthly0.5https://www.biopharmawatch.com/news/AMGN/prolia-denosumab-open-label-extension-trial-showed-continued-increase-in-bone-mineral-dens-amgn-20111105monthly0.5https://www.biopharmawatch.com/news/AMGN/treatment-with-enbrel-etanercept-shows-significant-and-sustained-clinical-benefits-in-rheu-amgn-20111105monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-appoints-anthony-tony-hooper-executive-vice-president-global-commercial-operations-a-amgn-20111019monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2011-third-quarter-financial-results-amgen-nasdaq-amgn-today-an-amgn-20111019monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-2011-fourth-quarter-dividend-amgen-nasdaq-amgn-announced-that-its-board-of-amgn-20111013monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-highlights-data-to-be-presented-at-2011-european-multidisciplinary-cancer-congress-a-amgn-20110923monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-new-indications-for-prolia-denosumab-for-the-treatment-of-bone-loss-in-patien-amgn-20110919monthly0.5https://www.biopharmawatch.com/news/AMGN/prolia-denosumab-phase-2-extension-study-showed-continued-increase-in-bone-mineral-density-amgn-20110917monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-ubs-global-life-sciences-conference-amgen-nasdaq-amgn-will-partici-amgn-20110915monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-staff-volunteer-efforts-result-in-5-000-for-each-of-their-favorite-nonprofits-each-y-amgn-20110915monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference-amgen-n-amgn-20110912monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-morgan-stanley-global-healthcare-conference-amgen-nasdaq-amgn-will-amgn-20110908monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-baird-healthcare-conference-amgen-nasdaq-amgn-will-participate-in--amgn-20110906monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-stifel-nicolaus-healthcare-conference-amgen-nasdaq-amgn-will-prese-amgn-20110902monthly0.5https://www.biopharmawatch.com/news/AMGN/award-winning-actress-blythe-danner-and-amgen-launch-act-2-reduce-fractures-tm-educational-amgn-20110826monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-pdufa-date-for-xgeva-supplemental-biologics-license-application-amgen-nasd-amgn-20110822monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-highlights-data-to-be-presented-at-american-society-for-bone-and-mineral-research-me-amgn-20110818monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-second-quarter-2011-revenue-increased-4-percent-to-4-0-billion-amgen-nasdaq-amgn-r-amgn-20110729monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2011-second-quarter-financial-results-amgen-nasdaq-amgn-today-a-amgn-20110725monthly0.5https://www.biopharmawatch.com/news/AMGN/xgeva-denosumab-granted-marketing-authorization-in-the-european-union-amgen-nasdaq-amgn-to-amgn-20110715monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-resolves-g-csf-patent-litigation-with-teva-amgen-nasdaq-amgn-announced-today-that-th-amgn-20110715monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-ucb-team-up-with-nasa-on-final-space-shuttle-mission-to-conduct-preclinical-test-amgn-20110705monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-submits-application-to-expand-indication-for-xgeva-denosumab-to-prevent-or-delay-spr-amgn-20110627monthly0.5https://www.biopharmawatch.com/news/AMGN/notice-to-investors-regarding-2011-and-2015-guidance-today-amgen-nasdaq-amgn-issued-the-fo-amgn-20110624monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-modifications-to-u-s-prescribing-information-for-use-of-erythropoiesis-sti-amgn-20110624monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-receives-positive-chmp-opinion-for-vectibix-panitumumab-in-combination-with-chemothe-amgn-20110624monthly0.5https://www.biopharmawatch.com/news/AMGN/teachers-and-schools-across-north-america-receive-10-000-amgen-award-for-science-teaching--amgn-20110621monthly0.5https://www.biopharmawatch.com/news/AMGN/data-presented-at-two-global-medical-congresses-reinforce-benefit-of-enbrel-etanercept-for-amgn-20110525monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-receives-chmp-positive-opinion-for-xgeva-denosumab-in-the-european-union-amgen-nasda-amgn-20110520monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-voting-results-of-annual-meeting-of-stockholders-amgen-nasdaq-amgn-today-a-amgn-20110520monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-oncology-data-to-be-presented-at-asco-annual-meeting-amgen-nasdaq-amgn-today-announc-amgn-20110518monthly0.5https://www.biopharmawatch.com/news/AMGN/phase-3-data-demonstrate-xgeva-denosumab-is-first-bone-targeted-therapy-to-prevent-spread--amgn-20110517monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-webcast-investor-meeting-at-upcoming-american-urological-association-conference-a-amgn-20110513monthly0.5https://www.biopharmawatch.com/news/AMGN/patrick-dempsey-teams-up-with-breakaway-from-cancer-to-help-connect-cancer-patients-to-fre-amgn-20110511monthly0.5https://www.biopharmawatch.com/news/AMGN/five-californians-selected-as-breakaway-from-cancer-champions-to-be-honored-during-amgen-t-amgn-20110510monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-deutsche-bank-36th-annual-healthcare-conference-amgen-nasdaq-amgn--amgn-20110428monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-outlines-strategy-growth-objectives-and-capital-allocation-plans-amgen-nasdaq-amgn-t-amgn-20110421monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-ucb-announce-positive-phase-2-results-of-amg-785-cdp7851-in-patients-with-postme-amgn-20110421monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-first-quarter-2011-revenue-increased-3-percent-to-3-7-billion-amgen-nasdaq-amgn-re-amgn-20110420monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-webcast-2011-business-review-meeting-on-april-21-amgen-nasdaq-amgn-today-announce-amgn-20110414monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2011-first-quarter-financial-results-amgen-nasdaq-amgn-today-an-amgn-20110413monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-establishes-commercial-operations-in-brazil-amgen-nasdaq-amgn-the-world-s-largest-bi-amgn-20110408monthly0.5https://www.biopharmawatch.com/news/AMGN/top-line-results-announced-of-pivotal-phase-3-motesanib-trial-in-advanced-non-squamous-non-amgn-20110330monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-appeal-chmp-opinion-on-vectibix-panitumumab-use-with-chemotherapy-in-metastatic-c-amgn-20110330monthly0.5https://www.biopharmawatch.com/news/AMGN/prolia-denosumab-open-label-extension-trial-showed-continued-increase-in-bone-mineral-dens-amgn-20110323monthly0.5https://www.biopharmawatch.com/news/AMGN/treatment-with-prolia-denosumab-associated-with-significantly-greater-adherence-compliance-amgn-20110323monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-statement-on-chmp-opinion-on-vectibix-panitumumab-use-with-chemotherapy-in-metastati-amgn-20110318monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-donates-1-million-to-help-japanese-disaster-victims-amgen-nasdaq-amgn-today-announce-amgn-20110314monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-completes-acquisition-of-biovex-amgen-nasdaq-amgn-today-announced-the-completion-of--amgn-20110304monthly0.5https://www.biopharmawatch.com/news/AMGN/breakaway-from-cancer-launches-newly-enhanced-website-offering-comprehensive-tailored-supp-amgn-20110303monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-cowen-and-company-31st-annual-healthcare-conference-amgen-nasdaq-a-amgn-20110303monthly0.5https://www.biopharmawatch.com/news/AMGN/world-class-professional-golfer-phil-mickelson-launches-on-course-with-phil-for-people-wit-amgn-20110302monthly0.5https://www.biopharmawatch.com/news/AMGN/nbpts-and-amgen-foundation-join-to-bolster-science-education-the-national-board-for-profes-amgn-20110301monthly0.5https://www.biopharmawatch.com/news/AMGN/results-published-in-the-lancet-demonstrate-superiority-of-xgeva-denosumab-in-the-preventi-amgn-20110224monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-citi-2011-global-healthcare-conference-amgen-nasdaq-amgn-will-part-amgn-20110224monthly0.5https://www.biopharmawatch.com/news/AMGN/the-journal-of-clinical-oncology-publishes-phase-3-xgeva-denosumab-results-in-advanced-can-amgn-20110222monthly0.5https://www.biopharmawatch.com/news/AMGN/enbrel-etanercept-significantly-improved-scalp-involvement-in-patients-with-moderate-to-se-amgn-20110204monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-acquire-biovex-a-privately-held-biotechnology-company-headquartered-in-woburn-mas-amgn-20110124monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-fourth-quarter-2010-adjusted-earnings-per-share-increased-11-percent-to-1-17-full--amgn-20110124monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2010-fourth-quarter-and-full-year-financial-results-amgen-nasda-amgn-20110124monthly0.5https://www.biopharmawatch.com/news/AMGN/boehringer-ingelheim-to-purchase-amgen-s-fremont-california-facility-amgen-inc-nasdaq-amgn-amgn-20110118monthly0.5https://www.biopharmawatch.com/news/AMGN/sensipar-patents-upheld-by-district-court-a-u-s-district-court-in-delaware-today-granted-a-amgn-20110107monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-29th-annual-jp-morgan-healthcare-conference-amgen-nasdaq-amgn-will-amgn-20110106monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-xencor-enter-option-deal-to-co-develop-xencor-s-novel-antibody-for-autoimmune-di-amgn-20110106monthly0.5https://www.biopharmawatch.com/news/AMGN/teach-for-america-and-the-amgen-foundation-renew-partnership-to-improve-math-and-science-e-amgn-20101216monthly0.5https://www.biopharmawatch.com/news/AMGN/xgeva-denosumab-significantly-improved-bone-metastasis-free-survival-in-men-with-prostate--amgn-20101213monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-presents-new-xgeva-denosumab-breast-cancer-skeletal-related-event-prevention-data-at-amgn-20101210monthly0.5https://www.biopharmawatch.com/news/AMGN/three-innovative-ideas-receive-10-000-prizes-in-patients-choices-empowerment-competition-t-amgn-20101208monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-deutsche-bank-s-2010-biofest-amgen-nasdaq-amgn-will-participate-in-deu-amgn-20101208monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-nplate-maintains-platelet-counts-for-more-than-five-years-in-adults-with-chronic-i-amgn-20101205monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-highlights-data-to-be-presented-at-american-society-of-hematology-annual-meeting-amg-amgn-20101202monthly0.5https://www.biopharmawatch.com/news/AMGN/fda-approves-amgen-s-xgeva-denosumab-for-the-prevention-of-skeletal-related-events-in-pati-amgn-20101118monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-foundation-and-ashoka-s-changemakers-announce-finalists-in-patients-choices-empowerm-amgn-20101117monthly0.5https://www.biopharmawatch.com/news/AMGN/call-for-applications-the-amgen-award-for-science-teaching-excellence-amgen-nasdaq-amgn-to-amgn-20101116monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-scholars-undergraduate-summer-research-program-begins-phase-2-today-amgen-scholars-t-amgn-20101115monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-foundation-recognizes-outstanding-staff-volunteers-and-contributes-55-000-to-their-f-amgn-20101111monthly0.5https://www.biopharmawatch.com/news/AMGN/study-published-in-new-england-journal-of-medicine-shows-nplate-significantly-reduces-trea-amgn-20101110monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-19th-annual-credit-suisse-healthcare-conference-amgen-nasdaq-amgn-will-amgn-20101109monthly0.5https://www.biopharmawatch.com/news/AMGN/published-results-show-denosumab-superior-to-zometa-in-delaying-or-preventing-bone-complic-amgn-20101108monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-pfizer-and-world-class-professional-golfer-phil-mickelson-announce-partnership-amgen-amgn-20101106monthly0.5https://www.biopharmawatch.com/news/AMGN/prolia-denosumab-receives-best-new-drug-honor-at-scrip-awards-amgen-nasdaq-amgn-is-pleased-amgn-20101105monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-foundation-awards-4-5-million-grant-to-mla-partner-schools-to-invest-in-la-s-promise-amgn-20101103monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-provide-testimony-at-fda-hearing-on-biosimilars-amgen-nasdaq-amgn-senior-vice-pre-amgn-20101101monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-s-third-quarter-2010-revenue-unchanged-at-3-8-billion-versus-prior-year-amgen-nasdaq-amgn-20101025monthly0.5https://www.biopharmawatch.com/news/AMGN/breakaway-from-cancer-launches-striking-the-balance-podcast-series-to-inspire-action-and-c-amgn-20101020monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-webcast-of-2010-third-quarter-financial-results-amgen-nasdaq-amgn-today-an-amgn-20101020monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-review-results-from-treat-and-propose-updates-to-esa-labeling-for-chronic-renal-f-amgn-20101018monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-highlights-data-to-be-presented-at-american-society-for-bone-and-mineral-research-as-amgn-20101014monthly0.5https://www.biopharmawatch.com/news/AMGN/integrated-analysis-demonstrates-that-denosumab-delays-the-onset-of-bone-complications-com-amgn-20101010monthly0.5https://www.biopharmawatch.com/news/AMGN/updated-amg-386-data-demonstrate-promising-antitumor-activity-in-patients-with-recurrent-o-amgn-20101009monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-highlights-key-clinical-data-to-be-presented-at-european-society-for-medical-oncolog-amgn-20101005monthly0.5https://www.biopharmawatch.com/news/AMGN/two-pivotal-vectibix-phase-3-studies-in-first-and-second-line-treatment-of-metastatic-colo-amgn-20101004monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-initiates-voluntary-nationwide-recall-of-certain-lots-of-epogen-and-procrit-epoetin--amgn-20100924monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-and-pfizer-introduce-psophisticated-style-a-guide-to-everyday-style-and-psoriasis-ho-amgn-20100922monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-ubs-global-life-sciences-conference-amgen-nasdaq-amgn-will-partici-amgn-20100920monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference-amgen-n-amgn-20100914monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-to-present-at-the-baird-healthcare-conference-amgen-nasdaq-amgn-will-participate-in--amgn-20100913monthly0.5https://www.biopharmawatch.com/news/AMGN/amgen-announces-top-line-results-of-phase-3-head-and-neck-cancer-trial-amgen-nasdaq-amgn-t-amgn-20100811monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-reports-first-quarter-2026-financial-results-and-announces-exercise-of-option-to--aort-20260507monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-reports-second-quarter-2025-financial-results-second-quarter-highlights-achieved--aort-20250807monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-announces-release-date-and-teleconference-call-details-for-second-quarter-2025-fi-aort-20250724monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-to-participate-in-upcoming-investor-conferences-artivion-inc-nyse-aort-a-leading--aort-20250603monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-announces-closing-of-transactions-to-exchange-99-5-million-in-principal-amount-of-aort-20250528monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-announces-agreements-to-exchange-95-million-in-principal-amount-of-its-4-250-conv-aort-20250514monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-reports-first-quarter-2025-financial-results-first-quarter-highlights-achieved-re-aort-20250505monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-announces-presentation-of-new-clinical-data-from-nexus-triomphe-ide-trial-at-the--aort-20250505monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-announces-release-date-and-teleconference-call-details-for-first-quarter-2025-fin-aort-20250421monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-reports-fourth-quarter-and-full-year-2024-financial-results-fourth-quarter-highli-aort-20250224monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-announces-release-date-and-teleconference-call-details-for-fourth-quarter-and-ful-aort-20250210monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-announces-presentation-of-late-breaking-data-from-amds-persevere-trial-at-the-61s-aort-20250127monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-granted-fda-humanitarian-device-exemption-for-the-amds-hybrid-prosthesis-artivion-aort-20241209monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-reports-third-quarter-2024-financial-results-third-quarter-highlights-achieved-re-aort-20241107monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-to-participate-in-upcoming-investor-conferences-artivion-inc-nyse-aort-a-leading--aort-20241105monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-announces-release-date-and-teleconference-call-details-for-third-quarter-2024-fin-aort-20241024monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-announces-presentation-of-late-breaking-clinical-data-at-the-38th-european-associ-aort-20241010monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-reports-second-quarter-2024-financial-results-second-quarter-highlights-achieved--aort-20240808monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-to-participate-in-upcoming-investor-conferences-artivion-inc-nyse-aort-a-leading--aort-20240805monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-announces-release-date-and-teleconference-call-details-for-second-quarter-2024-fi-aort-20240725monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-amends-agreements-with-endospan-artivion-inc-nyse-aort-a-leading-cardiac-and-vasc-aort-20240701monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-reports-first-quarter-2024-financial-results-first-quarter-highlights-achieved-re-aort-20240506monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-to-participate-in-the-oppenheimer-34th-annual-healthcare-medtech-services-confere-aort-20240306monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-announces-release-date-and-teleconference-call-details-for-fourth-quarter-and-ful-aort-20240201monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-announces-presentation-of-late-breaking-data-from-amds-persevere-trial-at-the-60t-aort-20240129monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-obtains-350-million-in-senior-secured-credit-facilities-artivion-inc-nyse-aort-a--aort-20240118monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-appoints-lance-a-berry-as-executive-vice-president-chief-financial-officer-announ-aort-20231206monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-announces-completion-of-enrollment-in-persevere-trial-artivion-inc-nyse-aort-a-le-aort-20231109monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-to-participate-in-upcoming-investor-conferences-artivion-inc-nyse-aort-a-leading--aort-20231108monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-reports-third-quarter-2023-financial-results-third-quarter-and-recent-business-hi-aort-20231102monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-announces-release-date-and-teleconference-call-details-for-third-quarter-2023-fin-aort-20231019monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-announces-presentation-of-real-world-data-from-post-market-study-of-on-x-aortic-h-aort-20231005monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-announces-presentation-of-late-breaking-interim-data-from-amds-persevere-trial-at-aort-20231005monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-to-present-at-the-deutsche-bank-31st-annual-leveraged-finance-conference-artivion-aort-20230926monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-to-present-at-the-gilmartin-group-emerging-growth-company-showcase-artivion-inc-n-aort-20230914monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-reports-second-quarter-2023-financial-results-second-quarter-and-recent-business--aort-20230803monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-to-participate-in-upcoming-investor-conferences-artivion-inc-nyse-aort-a-leading--aort-20230801monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-announces-release-date-and-teleconference-call-details-for-second-quarter-2023-fi-aort-20230720monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-announces-fda-pma-approval-of-perclot-and-transfer-of-pma-to-baxter-artivion-inc--aort-20230523monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-reports-first-quarter-2023-financial-results-first-quarter-and-recent-business-hi-aort-20230504monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-announces-release-date-and-teleconference-call-details-for-first-quarter-2023-fin-aort-20230420monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-to-participate-in-the-22nd-annual-needham-virtual-healthcare-conference-artivion--aort-20230410monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference-artivion-inc--aort-20230306monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-reports-fourth-quarter-and-full-year-2022-financial-results-fourth-quarter-and-re-aort-20230216monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-announces-release-date-and-teleconference-call-details-for-fourth-quarter-and-ful-aort-20230202monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-to-participate-in-upcoming-investor-conferences-artivion-inc-nyse-aort-a-leading--aort-20221108monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-reports-third-quarter-2022-financial-results-artivion-inc-nyse-aort-a-leading-car-aort-20221103monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-announces-release-date-and-teleconference-call-details-for-third-quarter-2022-fin-aort-20221020monthly0.5https://www.biopharmawatch.com/news/AORT/elizabeth-hoff-joins-artivion-board-of-directors-artivion-inc-nyse-aort-a-leading-cardiac--aort-20220929monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-follows-recommendation-to-stop-proact-xa-clinical-trial-artivion-inc-nyse-aort-a--aort-20220923monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-to-present-at-the-deutsche-bank-30th-annual-leveraged-finance-conference-artivion-aort-20220914monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-to-participate-in-upcoming-investor-conferences-artivion-inc-nyse-aort-a-leading--aort-20220906monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-to-present-at-the-gilmartin-group-emerging-growth-company-showcase-artivion-inc-n-aort-20220824monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-reports-second-quarter-2022-financial-results-second-quarter-and-recent-business--aort-20220804monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-to-participate-in-upcoming-investor-conferences-artivion-inc-nyse-aort-a-leading--aort-20220803monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-initiates-enrollment-in-persevere-clinical-trial-artivion-inc-nyse-aort-a-leading-aort-20220727monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-announces-release-date-and-teleconference-call-details-for-second-quarter-2022-fi-aort-20220721monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-to-participate-in-the-ubs-2022-global-healthcare-conference-artivion-inc-nyse-aor-aort-20220516monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-reports-first-quarter-2022-financial-results-artivion-inc-nyse-aort-a-leading-car-aort-20220505monthly0.5https://www.biopharmawatch.com/news/AORT/artivionannounces-release-date-and-teleconference-call-details-for-first-quarter-2022-fina-aort-20220421monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-to-participate-in-the-21st-annual-needham-virtual-healthcare-conference-artivion--aort-20220331monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-publishes-inaugural-corporate-responsibility-report-artivion-inc-nyse-aort-a-lead-aort-20220314monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-to-host-investor-analyst-day-on-march-23-2022-artivion-inc-nyse-aort-a-leading-ca-aort-20220309monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-to-participate-in-the-oppenheimer-32nd-annual-healthcare-conference-artivion-inc--aort-20220303monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-reports-fourth-quarter-and-full-year-2021-financial-results-fourth-quarter-and-re-aort-20220217monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-announces-release-date-and-teleconference-call-details-for-fourth-quarter-and-ful-aort-20220203monthly0.5https://www.biopharmawatch.com/news/AORT/artivion-announces-publication-of-on-x-mitral-heart-valve-proact-study-results-in-the-anna-aort-20220131monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-nektar-th-nktr-20260603monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-nektar-th-nktr-20260501monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-proposed-public-offering-nektar-therapeutics-nasdaq-nktr-a-c-nktr-20260420monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-nektar-th-nktr-20260306monthly0.5https://www.biopharmawatch.com/news/NKTR/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral--nktr-20251022monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-announces-rezolve-ad-phase-2b-results-for-rezpegaldesleukin-selected-for-late-break-nktr-20250909monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-second-quarter-on-thursday-august-7-2025-afte-nktr-20250731monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-receives-fast-track-designation-for-rezpegaldesleukin-for-the-treatmen-nktr-20250729monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-closing-of-115-million-public-offering-including-full-exerci-nktr-20250702monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-proposed-public-offering-nektar-therapeutics-nasdaq-nktr-a-c-nktr-20250630monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-top-line-data-from-the-16-week-induction-period-in-rezolve-ad-phase-2b--nktr-20250623monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-bioconnect-investor-co-nktr-20250513monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-first-quarter-on-thursday-may-8-2025-after-cl-nktr-20250501monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammator-nktr-20250320monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-fourth-quarter-and-year-ended-2024-on-wednesd-nktr-20250305monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-completion-of-target-enrollment-in-rezolve-aa-phase-2b-clini-nktr-20250226monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-to-host-virtual-investor-analyst-event-with-type-1-diabetes-experts-on-nktr-20250224monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-receives-fast-track-designation-for-rezpegaldesleukin-for-the-treatmen-nktr-20250210monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-completion-of-target-enrollment-in-rezolve-ad-phase-2b-clini-nktr-20250110monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-nktr-255-following-cd19-directed-car-t-therapy-enhanced-comp-nktr-20241207monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-presents-first-preclinical-data-from-novel-csf-1-program-nktr-422-at-2-nktr-20241118monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-and-collaborators-present-late-breaking-results-from-phase-2-study-of-nktr-255-for--nktr-20241107monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-to-participate-in-upcoming-investor-conferences-nektar-therapeutics-na-nktr-20241106monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-announces-definitive-agreement-with-ampersand-capital-partners-to-sell-its-commerci-nktr-20241104monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-third-quarter-2024-on-thursday-november-7-202-nktr-20241031monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-announces-publication-in-nature-communications-of-results-from-phase-1b-studies-of--nktr-20241029monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-announces-publication-in-blood-of-phase-1-data-for-novel-il-15-agonist-nktr-255-in--nktr-20241017monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-multiple-presentations-for-rezpegaldesleukin-at-eadv-2024-ne-nktr-20240925monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-management-to-present-at-upcoming-investor-conferences-nektar-therapeutics-nasdaq-n-nktr-20240903monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-second-quarter-2024-on-thursday-august-8-2024-nktr-20240801monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-presents-first-preclinical-data-on-nktr-0165-a-tnfr2-agonist-antibody--nktr-20240612monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-management-to-present-at-upcoming-investor-conferences-nektar-therapeutics-nasdaq-n-nktr-20240530monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-first-quarter-2024-on-thursday-may-9-2024-aft-nktr-20240502monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-management-to-present-at-the-h-c-wainwright-2nd-annual-autoimmune-inflammatory-dise-nktr-20240322monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-initiation-of-phase-2b-clinical-study-evaluating-rezpegaldes-nktr-20240305monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-30-million-private-placement-financing-with-tcgx-nektar-ther-nktr-20240304monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-management-to-present-at-the-td-cowen-44th-annual-health-care-conference-nektar-the-nktr-20240227monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-fourth-quarter-and-year-ended-2023-on-monday--nktr-20240226monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-management-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-in-san-fr-nktr-20240103monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-and-collaborators-present-preclinical-data-on-nktr-255-combined-with-obinutuzumab-i-nktr-20231211monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-third-quarter-2023-on-tuesday-november-7-2023-nktr-20231031monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-presents-new-responder-data-for-rezpegaldesleukin-a-first-in-class-selective-regula-nktr-20231013monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-two-abstracts-accepted-at-eadv-congress-2023-for-rezpegaldes-nktr-20231002monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-new-clinical-study-collaboration-with-cellular-biomedicine-g-nktr-20230927monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-promising-new-data-from-phase-1b-study-of-rezpegaldesleukin--nktr-20230913monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-to-host-virtual-investor-analyst-event-with-dermatology-experts-on-sep-nktr-20230906monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-announces-promising-new-and-corrected-rezpegaldesleukin-efficacy-data-which-were-pr-nktr-20230807monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-second-quarter-2023-on-tuesday-august-8-2023--nktr-20230801monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-to-participate-in-fireside-chat-at-the-goldman-sachs-44th-annual-globa-nktr-20230612monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-phase-2-topline-data-for-rezpegaldesleukin-in-patients-with--nktr-20230223monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-president-and-ceo-howard-robin-to-present-at-the-41st-annual-j-p-morga-nktr-20230104monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-announces-poster-presentations-at-the-64th-american-society-of-hematology-ash-annua-nktr-20221212monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-to-host-investor-analyst-event-on-december-12th-nektar-therapeutics-na-nktr-20221205monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-presents-preclinical-data-from-novel-pegylated-interferon-gamma-progra-nktr-20221110monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-and-collaborators-announce-publication-in-blood-advances-of-preclinical-data-demons-nktr-20221109monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-third-quarter-2022-on-thursday-november-3-202-nktr-20221025monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-presents-data-for-rezpegaldesleukin-ly3471851-in-patients-with-atopic--nktr-20220907monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-and-collaborators-announce-preclinical-publication-of-data-for-nktr-255-and-its-obs-nktr-20220816monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-second-quarter-2022-on-thursday-august-4-2022-nktr-20220726monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-announces-promotion-of-jillian-b-thomsen-to-senior-vice-president-chief-financial-o-nktr-20220701monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-and-collaborators-present-preclinical-data-on-nktr-255-a-novel-il-15-receptor-agoni-nktr-20220423monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-to-host-webcast-conference-call-for-analysts-investors-to-outline-new--nktr-20220422monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-to-host-webcast-conference-call-for-analysts-investors-following-annou-nktr-20220314monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-fourth-quarter-and-year-ended-2021-on-monday--nktr-20220217monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-president-and-ceo-howard-robin-to-present-at-the-40th-annual-j-p-morga-nktr-20220105monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-phase-1b-data-for-novel-t-regulatory-cell-stimulator-nktr-35-nktr-20211215monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-presents-clinical-data-for-nktr-255-in-patients-with-relapsed-refracto-nktr-20211213monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-data-presentations-for-its-immuno-oncology-programs-at-the-e-nktr-20211130monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-strengthens-board-of-directors-with-appointment-of-diana-m-brainard-m--nktr-20211115monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-data-presentations-for-its-immuno-oncology-pipeline-at-the-2-nktr-20211112monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-to-host-webcast-conference-call-for-analysts-investors-with-cancer-spe-nktr-20211109monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-third-quarter-2021-on-thursday-november-4-202-nktr-20211026monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-announces-new-clinical-collaboration-with-merck-kgaa-darmstadt-germany-and-pfizer-i-nktr-20210921monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-second-quarter-2021-on-thursday-august-5-2021-nktr-20210727monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-appoints-dimitry-s-a-nuyten-m-d-ph-d-as-senior-vice-president-and-chief-medical-off-nktr-20210719monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-to-participate-in-fireside-chat-at-the-goldman-sachs-42nd-annual-globa-nktr-20210607monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-first-publication-of-nktr-358-a-novel-molecule-designed-to-s-nktr-20210520monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-its-first-publication-of-preclinical-data-highlighting-anti--nktr-20210518monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-first-quarter-2021-on-thursday-may-6-2021-aft-nktr-20210427monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-fourth-quarter-and-year-ended-2020-on-thursda-nktr-20210218monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-announces-agreement-for-phase-2-3-study-of-il-2-pathway-agonist-bempegaldesleukin-i-nktr-20210217monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-announces-collaboration-with-sfj-pharmaceuticals-for-bempegaldesleukin-in-head-and--nktr-20210217monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-president-and-ceo-howard-robin-to-present-at-the-39th-annual-j-p-morga-nktr-20210106monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-appoints-dr-brian-kotzin-as-interim-chief-medical-officer-and-head-of-development-n-nktr-20210105monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-agreement-with-healthcare-royalty-to-sell-adynovate-and-mova-nktr-20201222monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-dosing-of-first-patients-in-phase-1-2-study-of-its-il-15-ago-nktr-20201215monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-presentation-of-preclinical-data-for-nktr-255-its-novel-il-1-nktr-20201207monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-presents-new-data-from-its-immuno-oncology-pipeline-at-the-2020-societ-nktr-20201111monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-to-host-webcast-conference-call-for-analysts-investors-with-expert-onc-nktr-20201109monthly0.5https://www.biopharmawatch.com/news/NKTR/new-clinical-data-presented-from-phase-1b-study-of-nktr-358-a-novel-t-regulatory-cell-stim-nktr-20201104monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-to-host-webcast-conference-call-for-analysts-investors-for-2020-americ-nktr-20201029monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-third-quarter-2020-on-thursday-november-5-202-nktr-20201028monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-phase-1b-clinical-study-to-evaluate-bempegaldesleukin-for-tr-nktr-20201027monthly0.5https://www.biopharmawatch.com/news/NKTR/vaccibody-as-and-nektar-therapeutics-announce-first-patient-dosed-in-a-phase-1-2a-study-ar-nktr-20200812monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-second-quarter-2020-on-thursday-august-6-2020-nktr-20200728monthly0.5https://www.biopharmawatch.com/news/NKTR/data-presented-from-phase-1b-study-of-nktr-358-a-novel-t-regulatory-cell-stimulator-at-ann-nktr-20200604monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-to-host-webcast-conference-call-for-analysts-investors-during-2020-vir-nktr-20200529monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-publication-of-results-from-phase-1-dose-escalation-study-fo-nktr-20200522monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-first-quarter-2020-on-thursday-may-7-2020-aft-nktr-20200428monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-to-webcast-presentation-at-the-cowen-and-company-40th-annual-health-ca-nktr-20200228monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-fourth-quarter-and-year-ended-2019-on-thursda-nktr-20200218monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-publication-of-two-manuscripts-on-lead-immuno-oncology-candi-nktr-20200203monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-issues-statement-regarding-fda-advisory-committee-vote-for-oxycodegol-nektar-therap-nktr-20200114monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-president-and-ceo-howard-robin-to-present-at-the-38th-annual-j-p-morga-nktr-20200107monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-strengthens-board-of-directors-with-appointment-of-myriam-j-curet-m-d--nktr-20191217monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-presentation-of-new-preclinical-data-for-its-il-15-agonist-n-nktr-20191209monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-appoints-john-northcott-as-chief-commercial-officer-nektar-therapeutics-nasdaq-nktr-nktr-20191203monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-webcast-presentation-at-jefferies-2019-london-healthcare-conference-nektar-thera-nktr-20191113monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-presents-data-from-first-in-human-phase-1a-study-on-novel-t-regulatory-nktr-20191110monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-presents-new-clinical-and-preclinical-data-from-its-immuno-oncology-pi-nktr-20191109monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-financial-results-for-the-third-quarter-of-2019-nektar-therape-nktr-20191106monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-to-host-webcast-conference-call-with-melanoma-specialist-for-analysts--nktr-20191101monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-third-quarter-2019-on-wednesday-november-6-20-nktr-20191030monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-initiation-of-first-in-human-phase-1-clinical-study-of-nktr--nktr-20191016monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-initiation-of-two-clinical-studies-of-novel-t-regulatory-cel-nktr-20191007monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-five-abstracts-accepted-for-presentation-at-the-2019-society-nktr-20191002monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-announces-key-executive-promotions-nektar-therapeutics-nasdaq-nktr-announced-today--nktr-20191001monthly0.5https://www.biopharmawatch.com/news/NKTR/clinical-data-presented-from-pivot-02-study-of-bempegaldesleukin-nktr-214-with-nivolumab-i-nktr-20190926monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-abstract-accepted-for-presentation-at-the-5th-cri-cimt-eati--nktr-20190923monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-second-quarter-2019-on-thursday-august-8-2019-nktr-20190730monthly0.5https://www.biopharmawatch.com/news/NKTR/first-in-human-data-presented-from-phase-1a-study-of-nktr-358-a-novel-t-regulatory-cell-st-nktr-20190613monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-to-host-webcast-conference-call-with-immunology-expert-for-analysts-in-nktr-20190611monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-presents-biomarker-and-clinical-data-from-pivot-02-phase-2-study-of-be-nktr-20190601monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-announces-the-launch-of-inheris-biopharma-inc-nektar-therapeutics-nasdaq-nktr-today-nktr-20190523monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-five-accepted-abstracts-at-2019-american-society-of-clinical-nktr-20190515monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-first-quarter-2019-on-wednesday-may-8-2019-af-nktr-20190501monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-presents-preclinical-data-on-its-immuno-oncology-pipeline-candidates-a-nktr-20190402monthly0.5https://www.biopharmawatch.com/news/NKTR/vaccibody-as-and-nektar-therapeutics-present-new-preclinical-data-from-their-immuno-oncolo-nktr-20190401monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-to-webcast-presentation-at-the-cowen-and-company-39th-annual-health-ca-nktr-20190306monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-several-preclinical-data-presentations-for-its-immuno-oncolo-nktr-20190227monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-to-webcast-conference-call-for-analysts-and-investors-at-the-2019-asco-nktr-20190225monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-fourth-quarter-and-year-ended-2018-on-thursda-nktr-20190221monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-to-webcast-conference-call-with-urothelial-cancer-specialist-for-analy-nktr-20190211monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-president-and-ceo-howard-robin-to-present-at-the-37th-annual-j-p-morga-nktr-20181227monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-appoints-wei-lin-m-d-as-senior-vice-president-of-clinical-development-and-head-of-n-nktr-20181114monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-presents-new-clinical-and-preclinical-data-for-its-immuno-oncology-pip-nktr-20181109monthly0.5https://www.biopharmawatch.com/news/NKTR/new-clinical-oncology-collaboration-between-nektar-and-pfizer-to-evaluate-combination-of-n-nktr-20181106monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-to-host-webcast-conference-call-with-melanoma-specialists-for-analysts-nktr-20181106monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-third-quarter-2018-on-wednesday-november-7-20-nktr-20181030monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-ten-abstracts-accepted-for-presentation-at-the-2018-society--nktr-20181002monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-strengthens-board-of-directors-with-appointment-of-veteran-biotechnolo-nktr-20181001monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-second-quarter-2018-on-wednesday-august-8-201-nktr-20180801monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-new-drug-application-for-nktr-181-accepted-for-review-by-fda-nktr-20180730monthly0.5https://www.biopharmawatch.com/news/NKTR/new-data-for-nktr-181-a-first-in-class-investigational-opioid-to-treat-chronic-low-back-pa-nktr-20180614monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-webcast-presentation-at-the-jefferies-2018-healthcare-conference-in-new-york-nek-nktr-20180605monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-submission-of-a-new-drug-application-to-the-u-s-fda-for-nktr-nktr-20180531monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-six-abstracts-accepted-for-presentation-at-the-2018-american-nktr-20180516monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-initiation-of-a-phase-1b-clinical-study-of-nktr-358-a-first--nktr-20180508monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-first-quarter-2018-on-thursday-may-10-2018-af-nktr-20180503monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-to-host-analyst-investor-event-at-2018-asco-annual-meeting-nektar-ther-nktr-20180430monthly0.5https://www.biopharmawatch.com/news/NKTR/new-oncology-clinical-collaboration-between-nektar-and-takeda-to-evaluate-combination-of-n-nktr-20180424monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-presents-new-preclinical-data-for-its-immuno-oncology-programs-at-the--nktr-20180415monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-webcast-presentation-at-the-cowen-and-company-38th-annual-health-care-conference-nktr-20180307monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-fourth-quarter-and-year-ended-2017-on-thursda-nktr-20180221monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-webcast-presentation-at-the-piper-jaffray-29th-annual-healthcare-conference-in-n-nktr-20171127monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-announces-key-executive-promotions-to-drive-the-continued-growth-of-the-company-s-i-nktr-20171122monthly0.5https://www.biopharmawatch.com/news/NKTR/first-data-for-nktr-214-in-combination-with-opdivo-nivolumab-for-patients-with-stage-iv-me-nktr-20171111monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-webcast-presentation-at-jefferies-2017-london-healthcare-conference-nektar-thera-nktr-20171110monthly0.5https://www.biopharmawatch.com/news/NKTR/new-data-featuring-nektar-therapeutics-wholly-owned-immuno-oncology-pipeline-to-be-present-nktr-20171107monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-third-quarter-of-2017-on-tuesday-november-7-2-nktr-20171031monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-seven-abstracts-accepted-for-presentation-at-2017-society-fo-nktr-20170920monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-initiates-propel-clinical-study-to-evaluate-combination-of-nktr-214-a--nktr-20170912monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-presents-clinical-data-from-phase-3-summit-07-study-of-nktr-181-a-firs-nktr-20170906monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-president-and-ceo-howard-w-robin-to-present-at-the-2017-morgan-stanley-nktr-20170906monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-to-present-clinical-data-from-phase-3-summit-07-study-of-nktr-181-a-fi-nktr-20170830monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-second-quarter-of-2017-on-tuesday-august-8-20-nktr-20170802monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-presents-new-preclinical-data-for-nktr-358-a-first-in-class-regulatory-t-cell-stimu-nktr-20170710monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-webcast-presentation-at-jefferies-2017-global-healthcare-conference-in-new-york--nktr-20170606monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-presents-new-clinical-data-from-two-studies-of-nktr-214-a-cd122-biased-agonist-at-2-nktr-20170605monthly0.5https://www.biopharmawatch.com/news/NKTR/new-research-collaboration-between-nektar-and-takeda-to-explore-combination-cancer-therapy-nktr-20170522monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-data-presentations-at-asco-2017-nektar-therapeutics-nasdaq-n-nktr-20170518monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-webcast-presentation-at-ubs-global-healthcare-conference-2017-in-new-york-nektar-nktr-20170515monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-appoints-brian-l-kotzin-m-d-as-head-of-clinical-development-for-nektar-s-immunology-nktr-20170503monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-first-quarter-of-2017-on-tuesday-may-9-2017-a-nktr-20170502monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-to-host-analyst-investor-event-at-2017-asco-annual-meeting-nektar-ther-nktr-20170420monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-presents-new-preclinical-data-for-its-immuno-oncology-programs-at-the--nktr-20170404monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-initiates-clinical-study-of-nktr-358-a-first-in-class-regulatory-t-cel-nktr-20170327monthly0.5https://www.biopharmawatch.com/news/NKTR/nktr-181-meets-primary-and-secondary-endpoints-in-phase-3-summit-07-study-in-chronic-pain--nktr-20170320monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-webcast-presentation-at-cowen-and-company-s-37th-annual-health-care-conference-i-nktr-20170302monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-upcoming-presentations-at-the-american-association-for-cance-nktr-20170301monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-fourth-quarter-and-year-ended-2016-on-wednesd-nktr-20170222monthly0.5https://www.biopharmawatch.com/news/NKTR/clinical-data-from-phase-1-dose-escalation-study-of-single-agent-nktr-214-in-patients-with-nktr-20170218monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-president-and-ceo-howard-w-robin-to-present-at-the-35th-annual-j-p-mor-nktr-20170105monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-to-present-at-jefferies-2016-global-healthcare-conference-in-london-ne-nktr-20161114monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-presents-new-clinical-data-from-ongoing-phase-1-dose-escalation-study--nktr-20161109monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-hold-investor-analyst-event-at-2016-society-for-immunotherapy-of-cancer-annual-m-nktr-20161028monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-upcoming-presentations-at-the-2016-society-for-immunotherapy-nktr-20161028monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-third-quarter-2016-on-thursday-november-3-201-nktr-20161027monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-prices-public-offering-of-shares-of-common-stock-nektar-therapeutics-n-nktr-20161019monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-to-host-investor-analyst-conference-call-to-discuss-new-clinical-colla-nktr-20160927monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-second-quarter-2016-on-wednesday-august-3-201-nktr-20160727monthly0.5https://www.biopharmawatch.com/news/NKTR/preclinical-data-presented-at-asco-2016-annual-meeting-demonstrate-that-single-agent-nktr--nktr-20160606monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-president-and-ceo-howard-w-robin-to-present-at-the-jefferies-2016-glob-nktr-20160602monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-and-daiichi-sankyo-europe-gmbh-sign-european-licensing-agreement-for-o-nktr-20160601monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-first-quarter-2016-on-tuesday-may-3-2016-afte-nktr-20160428monthly0.5https://www.biopharmawatch.com/news/NKTR/preclinical-data-presented-at-aacr-demonstrate-that-combining-nktr-214-with-checkpoint-blo-nktr-20160418monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-to-present-at-cowen-and-company-s-36th-annual-health-care-conference-i-nktr-20160303monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-fourth-quarter-and-year-ended-2015-on-tuesday-nktr-20160226monthly0.5https://www.biopharmawatch.com/news/NKTR/baxalta-announces-submission-of-supplemental-blas-to-expand-use-of-adynovate-to-pediatric--nktr-20160225monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-publishes-pre-clinical-results-for-nktr-214-an-investigational-cd122-biased-immune--nktr-20160201monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-president-and-ceo-howard-w-robin-to-present-at-the-34th-annual-j-p-mor-nktr-20160106monthly0.5https://www.biopharmawatch.com/news/NKTR/baxalta-s-adynovate-meets-endpoints-in-phase-3-study-of-hemophilia-a-patients-under-12-yea-nktr-20151221monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-announces-first-patient-dosed-in-phase-1-2-clinical-study-of-nktr-214-a-cd122-biase-nktr-20151208monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-to-present-at-oppenheimer-26th-annual-healthcare-conference-in-new-yor-nktr-20151208monthly0.5https://www.biopharmawatch.com/news/NKTR/baxalta-presents-additional-data-on-newly-approved-adynovate-and-plans-for-new-indications-nktr-20151207monthly0.5https://www.biopharmawatch.com/news/NKTR/baxalta-announces-u-s-availability-of-adynovate-a-new-treatment-for-adult-patients-with-he-nktr-20151130monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-to-present-at-jefferies-autumn-2015-global-healthcare-conference-in-lo-nktr-20151117monthly0.5https://www.biopharmawatch.com/news/NKTR/baxalta-to-advance-care-for-hemophilia-a-patients-with-fda-approval-of-adynovate-a-simple--nktr-20151116monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-third-quarter-2015-on-thursday-november-5-201-nktr-20151029monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-reports-on-advancements-with-pain-and-oncology-clinical-pipeline-at-investor-and-an-nktr-20151008monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-submits-investigational-new-drug-application-ind-for-nktr-214-to-treat-solid-tumor--nktr-20151007monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-host-research-development-day-for-analysts-and-investors-on-october-8th-nektar-t-nktr-20151001monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-presents-data-demonstrating-that-nktr-214-a-cd122-biased-immunostimulatory-cytokine-nktr-20150921monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-announces-receipt-of-40-million-milestone-payment-resulting-from-first-commercial-s-nktr-20150901monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-second-quarter-2015-on-wednesday-august-5-201-nktr-20150729monthly0.5https://www.biopharmawatch.com/news/NKTR/baxalta-s-bax-855-pivotal-data-published-in-blood-shows-potential-to-provide-strong-bleed--nktr-20150716monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-and-md-anderson-cancer-center-announce-phase-1-2-clinical-research-collaboration-fo-nktr-20150602monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-president-and-ceo-howard-w-robin-to-present-at-the-jefferies-2015-glob-nktr-20150528monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-financial-results-for-the-first-quarter-of-2015-nektar-therape-nktr-20150430monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-first-quarter-2015-on-thursday-april-30-2015--nktr-20150423monthly0.5https://www.biopharmawatch.com/news/NKTR/baxter-submits-application-to-japan-s-mhlw-for-approval-of-bax-855-extended-half-life-reco-nktr-20150416monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-to-present-at-the-14th-annual-needham-healthcare-conference-nektar-the-nktr-20150413monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-announces-receipt-of-100-million-milestone-payment-from-astrazeneca-nektar-therapeu-nktr-20150402monthly0.5https://www.biopharmawatch.com/news/NKTR/movantik-naloxegol-tablets-for-the-treatment-of-opioid-induced-constipation-in-adult-patie-nktr-20150331monthly0.5https://www.biopharmawatch.com/news/NKTR/astrazeneca-and-daiichi-sankyo-to-jointly-commercialise-movantik-in-the-us-nektar-therapeu-nktr-20150319monthly0.5https://www.biopharmawatch.com/news/NKTR/etirinotecan-pegol-nktr-102-prolonged-median-overall-survival-by-2-1-months-versus-active--nktr-20150317monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-announces-start-of-phase-3-summit-07-study-of-nktr-181-in-patients-with-chronic-low-nktr-20150225monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-fourth-quarter-and-year-end-2014-financial-results-nektar-ther-nktr-20150224monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-fourth-quarter-and-year-ended-2014-on-tuesday-nktr-20150217monthly0.5https://www.biopharmawatch.com/news/NKTR/baxter-presents-additional-data-from-pivotal-study-of-bax-855-extended-half-life-investiga-nktr-20150211monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-president-and-ceo-howard-w-robin-to-present-at-the-33rd-annual-j-p-mor-nktr-20150106monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-presents-data-on-target-specific-biomarkers-from-circulating-tumor-cell-sub-study-o-nktr-20141211monthly0.5https://www.biopharmawatch.com/news/NKTR/moventig-approved-in-the-european-union-for-opioid-induced-constipation-nektar-therapeutic-nktr-20141209monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-presents-preclinical-study-findings-for-etirinotecan-pegol-nktr-102-in-combination--nktr-20141120monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-financial-results-for-the-third-quarter-of-2014-nektar-therape-nktr-20141106monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-third-quarter-2014-on-thursday-november-6-201-nktr-20141030monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-moventig-naloxegol-receives-positive-chmp-opinion-in-eu-for--nktr-20140926monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-presents-positive-preclinical-data-on-oral-peripherally-acting-kappa-agonist-molecu-nktr-20140919monthly0.5https://www.biopharmawatch.com/news/NKTR/fda-approves-movantik-naloxegol-tablets-for-the-treatment-of-opioid-induced-constipation-i-nktr-20140916monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-financial-results-for-the-second-quarter-of-2014-nektar-therap-nktr-20140731monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-second-quarter-2014-on-thursday-july-31-2014--nktr-20140722monthly0.5https://www.biopharmawatch.com/news/NKTR/data-published-in-the-new-england-journal-of-medicine-demonstrate-that-naloxegol-improved--nktr-20140619monthly0.5https://www.biopharmawatch.com/news/NKTR/us-fda-advisory-committee-recommends-no-cardiovascular-outcomes-trial-for-peripherally-act-nktr-20140612monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-stock-trading-halted-today-fda-advisory-committee-to-discuss-periphera-nktr-20140611monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-presents-positive-preclinical-data-for-nktr-214-a-novel-cancer-immunotherapy-at-50t-nktr-20140601monthly0.5https://www.biopharmawatch.com/news/NKTR/positive-data-from-phase-2-trial-of-nktr-102-in-patients-with-avastin-refractory-high-grad-nktr-20140531monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-appoints-ivan-gergel-m-d-as-senior-vice-president-drug-development-chief-medical-of-nktr-20140519monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-to-present-at-the-ubs-2014-global-healthcare-conference-in-new-york-ci-nktr-20140516monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-reports-positive-preclinical-data-for-two-oncology-programs-at-2014-aacr-nektar-the-nktr-20140409monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-fourth-quarter-and-year-end-2013-financial-results-nektar-ther-nktr-20140226monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-fourth-quarter-and-year-end-of-2013-on-wednes-nktr-20140219monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-prices-public-offering-of-common-stock-nektar-therapeutics-nasdaq-nktr-nktr-20140122monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-public-offering-of-8-500-000-shares-of-common-stock-nektar-t-nktr-20140121monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-presents-positive-clinical-data-from-a-phase-1-study-of-etirinotecan-pegol-nktr-102-nktr-20140118monthly0.5https://www.biopharmawatch.com/news/NKTR/etirinotecan-pegol-nktr-102-passes-interim-efficacy-analysis-for-beacon-pivotal-phase-3-cl-nktr-20140114monthly0.5https://www.biopharmawatch.com/news/NKTR/first-subjects-dosed-in-phase-1-clinical-study-of-nktr-171-a-new-peripherally-restricted-s-nktr-20140114monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-president-and-ceo-howard-w-robin-to-present-at-the-32nd-annual-j-p-mor-nktr-20140108monthly0.5https://www.biopharmawatch.com/news/NKTR/new-drug-application-for-naloxegol-accepted-by-united-states-food-and-drug-administration--nktr-20131119monthly0.5https://www.biopharmawatch.com/news/NKTR/baxter-completes-enrollment-in-phase-iii-clinical-trial-of-bax-855-extended-half-life-reco-nktr-20131113monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-financial-results-for-the-third-quarter-of-2013-nektar-therape-nktr-20131107monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-third-quarter-of-2013-on-thursday-november-7--nktr-20131030monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-and-roswell-park-cancer-institute-announce-initiation-of-investigator-sponsored-tri-nktr-20131024monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-reports-on-advancements-with-clinical-pipeline-and-introduces-new-preclinical-candi-nktr-20131008monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-host-investor-and-analyst-r-d-day-in-new-york-city-nektar-therapeutics-nasdaq-nk-nktr-20131002monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-announces-preliminary-topline-results-from-phase-2-efficacy-study-for-nktr-181-in-c-nktr-20130926monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-financial-results-for-the-second-quarter-of-2013-nektar-therap-nktr-20130808monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-completes-enrollment-in-phase-3-beacon-study-of-etirinotecan-pegol-in-women-with-me-nktr-20130730monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-presents-positive-data-from-human-abuse-liability-study-for-nktr-181-a-nktr-20130619monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-presents-positive-preclinical-data-for-nktr-214-a-novel-cancer-immunotherapy-at-the-nktr-20130603monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-presents-target-specific-biomarkers-being-assessed-in-ongoing-phase-3-beacon-study--nktr-20130601monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-president-and-ceo-howard-w-robin-to-present-at-the-jefferies-2013-glob-nktr-20130530monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-president-and-ceo-howard-w-robin-to-present-at-the-2013-ubs-global-hea-nktr-20130516monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-financial-results-for-the-first-quarter-of-2013-nektar-therape-nktr-20130509monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-first-quarter-of-2013-on-thursday-may-9-2013--nktr-20130502monthly0.5https://www.biopharmawatch.com/news/NKTR/positive-preclinical-data-for-nktr-214-an-investigational-cancer-immunotherapy-targeting-t-nktr-20130407monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-fourth-quarter-and-year-end-2012-financial-results-nektar-ther-nktr-20130228monthly0.5https://www.biopharmawatch.com/news/NKTR/astrazeneca-announces-results-from-long-term-safety-trial-of-naloxegol-in-patients-with-op-nktr-20130226monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-fourth-quarter-and-year-end-of-2012-on-thursd-nktr-20130213monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-announces-initiation-of-investigator-initiated-trial-evaluating-etirinotecan-pegol--nktr-20130205monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-president-and-ceo-howard-w-robin-to-present-at-the-31st-annual-j-p-mor-nktr-20130104monthly0.5https://www.biopharmawatch.com/news/NKTR/astrazeneca-announces-top-line-phase-iii-results-from-naloxegol-pivotal-trials-in-patients-nktr-20121112monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-host-conference-call-to-discuss-the-positive-phase-3-clinical-results-for-naloxe-nktr-20121112monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-announces-that-fda-grants-fast-track-designation-to-etirinotecan-pegol-nktr-102-for-nktr-20121107monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-third-quarter-of-2012-on-tuesday-november-13--nktr-20121106monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-presents-positive-preclinical-data-for-nktr-171-a-novel-sodium-channel-blocker-to-t-nktr-20121015monthly0.5https://www.biopharmawatch.com/news/NKTR/nktr-192-a-new-short-acting-mu-opioid-analgesic-molecule-achieves-desired-pharmacokinetic--nktr-20120918monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-president-and-ceo-howard-w-robin-to-present-at-the-ubs-2012-global-lif-nktr-20120913monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-financial-results-for-the-second-quarter-of-2012-nektar-therap-nktr-20120809monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-announces-initiation-of-investigator-sponsored-trial-evaluating-etirinotecan-pegol--nktr-20120807monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-second-quarter-of-2012-on-thursday-august-9-2-nktr-20120802monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-announces-start-of-enrollment-in-phase-2-study-of-nktr-181-a-novel-opioid-analgesic-nktr-20120724monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-private-placement-of-125-million-of-senior-secured-notes-due-nktr-20120710monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-announces-that-fda-grants-fast-track-designation-to-nktr-181-a-new-oral-opioid-anal-nktr-20120607monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-financial-results-for-the-first-quarter-of-2012-nektar-therape-nktr-20120502monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-first-quarter-of-2012-on-wednesday-may-2-2012-nktr-20120425monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-host-investor-and-analyst-r-d-day-in-new-york-city-nektar-therapeutics-nasdaq-nk-nktr-20120410monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-doses-first-subjects-in-phase-1-clinical-study-evaluating-nktr-192-a-new-short-acti-nktr-20120402monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-reports-that-partner-affymax-has-announced-fda-approval-of-omontys-peginesatide-inj-nktr-20120328monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-webcast-of-presentation-at-the-32nd-annual-cowen-and-company-nktr-20120302monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-agreement-to-sell-cimzia-and-mircera-royalties-to-royalty-ph-nktr-20120229monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-presents-positive-proof-of-concept-clinical-data-for-its-new-opioid-molecule-nktr-1-nktr-20120227monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-fourth-quarter-and-year-end-of-2011-on-wednes-nktr-20120224monthly0.5https://www.biopharmawatch.com/news/NKTR/baxter-initiates-phase-i-clinical-trial-of-longer-acting-recombinant-fviii-treatment-for-h-nktr-20120105monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-president-and-ceo-howard-w-robin-to-present-at-the-30th-annual-j-p-mor-nktr-20120104monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-reports-affymax-announced-fda-advisory-committee-voted-in-favor-of-benefit-risk-pro-nktr-20111208monthly0.5https://www.biopharmawatch.com/news/NKTR/positive-data-for-nektar-s-new-mu-opioid-analgesic-molecule-to-treat-acute-pain-highlighte-nktr-20111114monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-third-quarter-2011-financial-results-nektar-therapeutics-nasda-nktr-20111102monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-third-quarter-of-2011-on-wednesday-november-2-nktr-20111026monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-presents-positive-data-for-novel-opioid-analgesic-nktr-181-at-the-2011-american-aca-nktr-20110921monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-president-and-ceo-howard-w-robin-to-present-at-the-ubs-2011-global-lif-nktr-20110914monthly0.5https://www.biopharmawatch.com/news/NKTR/positive-results-from-phase-2-clinical-study-of-nktr-102-in-metastatic-breast-cancer-prese-nktr-20110909monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-initiates-second-phase-1-clinical-study-evaluating-nktr-181-a-novel-opioid-molecule-nktr-20110908monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-second-quarter-2011-financial-results-nektar-therapeutics-nasd-nktr-20110804monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-second-quarter-of-2011-on-thursday-august-4-2-nktr-20110727monthly0.5https://www.biopharmawatch.com/news/NKTR/data-from-phase-1-study-of-nktr-181-demonstrate-proof-of-concept-for-nektar-s-novel-opioid-nktr-20110607monthly0.5https://www.biopharmawatch.com/news/NKTR/nktr-102-shows-high-response-rate-and-sustained-duration-of-response-in-women-with-platinu-nktr-20110605monthly0.5https://www.biopharmawatch.com/news/NKTR/nktr-102-demonstrates-sustained-clinical-benefit-in-46-of-patients-with-metastatic-breast--nktr-20110604monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-announces-new-phase-2-data-for-nktr-102-to-be-presented-at-2011-asco-annual-meeting-nktr-20110518monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-first-quarter-2011-financial-results-nektar-therapeutics-nasda-nktr-20110427monthly0.5https://www.biopharmawatch.com/news/NKTR/fda-grants-orphan-drug-designation-for-nektar-s-investigational-drug-nktr-102-for-treatmen-nktr-20110421monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-first-quarter-of-2011-on-wednesday-april-27-2-nktr-20110418monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-initiates-phase-1-clinical-study-evaluating-nktr-181-a-novel-opioid-molecule-for-tr-nktr-20110321monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-president-and-ceo-howard-w-robin-to-present-at-the-31st-annual-cowen-a-nktr-20110301monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-fourth-quarter-and-year-end-2010-financial-results-nektar-ther-nktr-20110301monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-fourth-quarter-and-year-end-of-2010-on-tuesda-nktr-20110217monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-completes-public-offering-of-common-stock-nektar-therapeutics-nasdaq-n-nktr-20110124monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-prices-public-offering-of-common-stock-nektar-therapeutics-nasdaq-nktr-nktr-20110119monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-announces-proposed-public-offering-of-common-stock-nektar-therapeutics-nktr-20110118monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-president-and-ceo-howard-w-robin-to-present-at-the-29th-annual-j-p-mor-nktr-20110105monthly0.5https://www.biopharmawatch.com/news/NKTR/nktr-102-demonstrates-significant-efficacy-as-single-agent-in-second-or-third-line-treatme-nktr-20101212monthly0.5https://www.biopharmawatch.com/news/NKTR/phase-2-clinical-data-on-nktr-102-in-metastatic-breast-cancer-to-be-presented-at-33rd-annu-nktr-20101209monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-announces-two-preclinical-data-presentations-at-society-for-neuroscience-40th-annua-nktr-20101113monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-reports-third-quarter-2010-financial-results-nektar-therapeutics-nasda-nktr-20101104monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-to-announce-financial-results-for-the-third-quarter-of-2010-on-thursday-november-4--nktr-20101028monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-presents-new-preclinical-data-on-nktr-181-at-anesthesiology-2010-nektar-therapeutic-nktr-20101017monthly0.5https://www.biopharmawatch.com/news/NKTR/nktr-181-a-mu-opioid-analgesic-with-a-novel-molecular-structure-demonstrates-slower-entry--nktr-20101015monthly0.5https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-to-present-at-the-ubs-2010-global-life-sciences-conference-nektar-ther-nktr-20100918monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-makes-grants-to-new-employees-under-inducement-plan-adc-therapeutics-sa-n-adct-20260501monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides--adct-20260310monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-participate-in-the-44th-annual-j-p-morgan-healthcare-conference-adc-th-adct-20260108monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-makes-grants-to-new-employees-under-inducement-plan-adc-therapeutics-sa-n-adct-20251001monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-makes-grants-to-new-employees-under-inducement-plan-adc-therapeutics-sa-n-adct-20250902monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-reports-second-quarter-2025-financial-results-and-provides-operational-up-adct-20250812monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-host-second-quarter-2025-financial-results-conference-call-on-august-1-adct-20250805monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-makes-grants-to-new-employees-under-inducement-plan-adc-therapeutics-sa-n-adct-20250801monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-makes-grant-to-new-employee-under-inducement-plan-adc-therapeutics-sa-nys-adct-20250701monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-updated-zynlonta-investigator-initiated-trial-data-in-r-r-margi-adct-20250616monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-100-million-private-placement-extending-expected-cash-runway-in-adct-20250612monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-updated-data-from-lotis-7-clinical-trial-presented-at-the-europ-adct-20250612monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-makes-grants-to-new-employees-under-inducement-plan-adc-therapeutics-sa-n-adct-20250602monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-present-at-upcoming-investor-conferences-adc-therapeutics-sa-nyse-adct-adct-20250515monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-reports-first-quarter-2025-financial-results-and-provides-operational-upd-adct-20250514monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-presentation-of-lotis-7-clinical-trial-data-at-the-european-hem-adct-20250514monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-host-first-quarter-2025-financial-results-conference-call-on-may-14-20-adct-20250508monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-preclinical-data-highlighted-at-the-american-association-for-ca-adct-20250428monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-makes-grants-to-new-employees-under-inducement-plan-adc-therapeutics-sa-n-adct-20250401monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference-a-adct-20250401monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides--adct-20250327monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-abstracts-accepted-for-presentation-at-the-american-association-adct-20250325monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-host-fourth-quarter-and-year-end-2024-financial-results-conference-cal-adct-20250320monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-makes-grants-to-new-employees-under-inducement-plan-adc-therapeutics-sa-n-adct-20250203monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-participate-in-the-guggenheim-smid-cap-biotech-conference-adc-therapeu-adct-20250130monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-makes-grants-to-new-employees-under-inducement-plan-adc-therapeutics-sa-n-adct-20250102monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-completion-of-enrollment-of-phase-3-confirmatory-clinical-trial-adct-20241230monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-positive-initial-data-from-lotis-7-clinical-trial-evaluating-zy-adct-20241211monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-the-lancet-haematology-publication-of-data-from-investigator-in-adct-20241209monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-provide-initial-data-update-on-lotis-7-clinical-trial-adc-therapeutics-adct-20241206monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-makes-grants-to-new-employees-under-inducement-plan-adc-therapeutics-sa-n-adct-20241202monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-reports-third-quarter-and-year-to-date-2024-financial-results-and-provide-adct-20241107monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-investigator-initiated-study-abstracts-accepted-for-presentatio-adct-20241105monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-present-at-november-investor-conferences-adc-therapeutics-sa-nyse-adct-adct-20241104monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-makes-grants-to-new-employees-under-inducement-plan-adc-therapeutics-sa-n-adct-20241101monthly0.5https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-to-host-third-quarter-2024-financial-results-conference-call-on-november--adct-20241031monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-jaypirca-pirtobrutinib-significantly-reduced-the-risk-of-disease-progression-or-de-lly-20260614monthly0.5https://www.biopharmawatch.com/news/LLY/zepbound-tirzepatide-and-shaquille-o-neal-launch-national-campaign-after-nba-legend-learns-lly-20260610monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-oral-glp-1-foundayo-orforglipron-delivered-superior-a1c-control-and-weight-loss-in-lly-20260608monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-foundayo-orforglipron-the-only-oral-glp-1-taken-without-food-or-water-restrictions-lly-20260607monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-triple-agonist-retatrutide-drove-substantial-improvements-in-weight-a1c-knee-osteo-lly-20260606monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-new-data-on-foundayo-mounjaro-and-retatrutide-at-the-american-diabetes-as-lly-20260528monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-three-acquisitions-to-build-infectious-disease-portfolio-eli-lilly-and-com-lly-20260526monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesi-lly-20260521monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-caitlin-clark-foundation-and-musco-lighting-open-three-community-sports-courts-in-in-lly-20260516monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-unicef-collaborate-to-give-millions-of-children-a-healthier-start-eli-lilly-and--lly-20260514monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-acquire-ajax-therapeutics-to-advance-outcomes-for-patients-with-myelofibrosis-and-lly-20260427monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-acquire-kelonia-therapeutics-to-advance-in-vivo-car-t-cell-therapies-eli-lilly-an-lly-20260420monthly0.5https://www.biopharmawatch.com/news/LLY/foundayo-orforglipron-la-nueva-pastilla-glp-1-de-lilly-que-se-administra-por-vi-a-oral-par-lly-20260409monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-acquire-centessa-pharmaceuticals-to-advance-treatments-for-sleep-wake-disorders-e-lly-20260331monthly0.5https://www.biopharmawatch.com/news/LLY/phase-3b-data-presented-at-aad-annual-meeting-show-lilly-s-taltz-ixekizumab-plus-zepbound--lly-20260328monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-triple-agonist-retatrutide-demonstrated-significant-reductions-in-a1c-and-weight-i-lly-20260319monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-ebglyss-lebrikizumab-lbkz-is-the-first-and-only-selective-il-13-inhibitor-to-deliv-lly-20260316monthly0.5https://www.biopharmawatch.com/news/LLY/patients-with-crohn-s-disease-maintained-steroid-free-remission-for-three-years-with-lilly-lly-20260219monthly0.5https://www.biopharmawatch.com/news/LLY/usopc-announces-the-team-usa-athlete-recovery-program-in-partnership-with-eli-lilly-and-co-lly-20260216monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-acquire-ventyx-biosciences-to-advance-oral-therapies-targeting-inflammatory-media-lly-20260107monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-orforglipron-helped-people-maintain-weight-loss-after-switching-from-injectable-in-lly-20251218monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-citi-s-2025-global-healthcare-conference-eli-lilly-and-company-nys-lly-20251118monthly0.5https://www.biopharmawatch.com/news/LLY/queer-eye-s-tan-france-helps-unthread-obesity-bias-as-part-of-zepbound-s-tirzepatide-chang-lly-20251110monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-plans-to-build-a-new-3-billion-facility-to-boost-oral-medicine-manufacturing-capacit-lly-20251103monthly0.5https://www.biopharmawatch.com/news/LLY/lillydirect-and-walmart-pharmacy-launch-first-retail-pick-up-option-with-direct-to-consume-lly-20251029monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-partners-with-nvidia-to-build-the-industry-s-most-powerful-ai-supercomputer-supercha-lly-20251028monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-roster-of-team-usa-athletes-for-the-olympic-and-paralympic-games-milano-co-lly-20251028monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-omvoh-mirikizumab-mrkz-approved-by-u-s-fda-as-a-single-injection-maintenance-regim-lly-20251027monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-fourth-quarter-2025-dividend-the-board-of-directors-of-eli-lilly-and-compan-lly-20251027monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-drafts-shaquille-o-neal-to-raise-awareness-for-moderate-to-severe-obstructive-sleep--lly-20251027monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-omvoh-mirikizumab-mrkz-demonstrated-early-and-sustained-improvement-in-bowel-urgen-lly-20251027monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-acquire-adverum-biotechnologies-eli-lilly-and-company-nyse-lly-and-adverum-biotec-lly-20251024monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-ebglyss-lebrikizumab-lbkz-delivered-durable-disease-control-when-administered-once-lly-20251024monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-baricitinib-delivered-near-complete-scalp-hair-regrowth-at-one-year-for-adolescent-lly-20251024monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-verzenio-abemaciclib-prolonged-survival-in-hr-her2-high-risk-early-breast-cancer-w-lly-20251017monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-third-quarter-2025-financial-results-announcem-lly-20251016monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-oral-glp-1-orforglipron-demonstrated-superior-glycemic-control-in-two-successful-p-lly-20251015monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-new-clinical-data-for-verzenio-abemaciclib-and-multiple-novel-pipeline-pr-lly-20251013monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-omvoh-mirikizumab-mrkz-is-the-first-and-only-il-23p19-antagonist-to-show-four-year-lly-20251007monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-opens-newest-gateway-labs-site-in-san-diego-to-boost-local-biotechnology-ecosystem-e-lly-20250926monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-kisunla-donanemab-receives-marketing-authorization-by-european-commission-for-the--lly-20250925monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-fda-approves-inluriyo-imlunestrant-for-adults-with-er-her2-esr1-mutated-advanced-or-me-lly-20250925monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-plans-to-build-a-new-6-5-billion-facility-to-manufacture-active-pharmaceutical-ingre-lly-20250923monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-mounjaro-tirzepatide-a-gip-glp-1-dual-receptor-agonist-reduced-a1c-by-an-average-o-lly-20250917monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-oral-glp-1-orforglipron-superior-to-oral-semaglutide-in-head-to-head-trial-eli-lil-lly-20250917monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-oral-glp-1-orforglipron-demonstrated-meaningful-weight-loss-and-cardiometabolic-im-lly-20250916monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-plans-to-build-5-billion-manufacturing-facility-in-virginia-eli-lilly-and--lly-20250916monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-bernstein-s-2nd-annual-healthcare-forum-eli-lilly-and-company-nyse-lly-20250911monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-launches-new-brain-health-matters-campaign-in-partnership-with-julianne-moore-empowe-lly-20250909monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-launches-tunelab-platform-to-give-biotechnology-companies-access-to-ai-enabled-drug--lly-20250909monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-jaypirca-pirtobrutinib-the-first-and-only-approved-non-covalent-reversible-btk-inh-lly-20250908monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-olomorasib-receives-u-s-fda-s-breakthrough-therapy-designation-for-the-treatment-o-lly-20250904monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-verzenio-abemaciclib-increases-overall-survival-in-hr-her2-high-risk-early-breast--lly-20250827monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-oral-glp-1-orforglipron-is-successful-in-third-phase-3-trial-triggering-global-reg-lly-20250826monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-morgan-stanley-23rd-annual-global-healthcare-conference-eli-lilly--lly-20250825monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-wells-fargo-20th-annual-healthcare-conference-eli-lilly-and-compan-lly-20250822monthly0.5https://www.biopharmawatch.com/news/LLY/anne-white-to-retire-as-executive-vice-president-and-president-lilly-neuroscience-eli-lill-lly-20250820monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-second-quarter-2025-financial-results-and-raises-guidance-revenue-in-q2-2025-lly-20250807monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-oral-glp-1-orforglipron-delivers-weight-loss-of-up-to-an-average-of-27-3-lbs-in-fi-lly-20250807monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-mounjaro-tirzepatide-a-gip-glp-1-dual-agonist-demonstrated-cardiovascular-protecti-lly-20250731monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-kisunla-donanemab-azbt-showed-growing-benefit-over-three-years-in-early-symptomati-lly-20250730monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-jaypirca-pirtobrutinib-the-first-and-only-approved-non-covalent-reversible-btk-inh-lly-20250729monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-completes-acquisition-of-verve-therapeutics-to-advance-one-time-treatments-for-peopl-lly-20250725monthly0.5https://www.biopharmawatch.com/news/LLY/donanemab-receives-positive-opinion-from-the-committee-for-medicinal-products-for-human-us-lly-20250725monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-second-quarter-2025-financial-results-announce-lly-20250724monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-verve-announce-expiration-of-verve-tender-offer-eli-lilly-and-company-nyse-lly-a-lly-20250724monthly0.5https://www.biopharmawatch.com/news/LLY/fda-approves-updated-label-for-lilly-s-kisunla-donanemab-azbt-with-new-dosing-in-early-sym-lly-20250709monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-third-quarter-2025-dividend-the-board-of-directors-of-eli-lilly-and-company-lly-20250623monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-once-weekly-insulin-efsitora-alfa-demonstrated-a1c-reduction-and-a-safety-profile--lly-20250622monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-oral-glp-1-orforglipron-showed-compelling-efficacy-and-a-safety-profile-consistent-lly-20250621monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-acquire-verve-therapeutics-to-advance-one-time-treatments-for-people-with-high-ca-lly-20250617monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-offer-all-approved-doses-of-zepbound-tirzepatide-single-dose-vials-through-lillyd-lly-20250616monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-goldman-sachs-46th-annual-global-health-care-conference-eli-lilly--lly-20250602monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-presents-first-clinical-data-for-its-investigational-next-generation-fr-targeting-ad-lly-20250602monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-details-of-presentations-at-american-diabetes-association-s-ada-85th-scien-lly-20250529monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-expand-its-pain-pipeline-with-acquisition-of-siteone-therapeutics-eli-lilly-and-c-lly-20250527monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-details-of-presentations-at-2025-american-society-of-clinical-oncology-asc-lly-20250522monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-kisunla-donanemab-receives-marketing-authorization-in-australia-for-the-treatment--lly-20250521monthly0.5https://www.biopharmawatch.com/news/LLY/zepbound-tirzepatide-showed-superior-weight-loss-over-wegovy-semaglutide-in-complete-surmo-lly-20250511monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-plans-to-expand-purdue-university-collaboration-with-up-to-a-250-million-investment--lly-20250509monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-transitions-in-executive-leadership-eli-lilly-and-company-nyse-lly-today-a-lly-20250508monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-second-quarter-2025-dividend-the-board-of-directors-of-eli-lilly-and-compan-lly-20250505monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-bank-of-america-securities-2025-healthcare-conference-eli-lilly-an-lly-20250502monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum-revenu-lly-20250501monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-first-quarter-2025-financial-results-announcem-lly-20250417monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-oral-glp-1-orforglipron-demonstrated-statistically-significant-efficacy-results-an-lly-20250417monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-lepodisiran-reduced-levels-of-genetically-inherited-heart-disease-risk-factor-lipo-lly-20250330monthly0.5https://www.biopharmawatch.com/news/LLY/lillydirect-platform-expands-to-facilitate-access-to-alzheimer-s-disease-care-eli-lilly-an-lly-20250327monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-details-of-presentations-at-2025-american-association-for-cancer-research--lly-20250325monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-baricitinib-delivered-high-rates-of-hair-regrowth-for-adolescents-with-severe-alop-lly-20250308monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-ebglyss-lebrikizumab-lbkz-single-monthly-maintenance-injection-achieved-completely-lly-20250307monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-leerink-partners-global-healthcare-conference-eli-lilly-and-compan-lly-20250228monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-jaypirca-pirtobrutinib-recommended-by-chmp-for-approval-in-the-european-union-for--lly-20250228monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-plans-to-more-than-double-u-s-manufacturing-investment-since-2020-exceeding-50-billi-lly-20250226monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-launches-additional-zepbound-vial-doses-and-offers-new-savings-for-self-pay-patients-lly-20250225monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-td-cowen-s-45th-annual-health-care-conference-eli-lilly-and-compan-lly-20250218monthly0.5https://www.biopharmawatch.com/news/LLY/most-patients-on-lilly-s-omvoh-mirikizumab-mrkz-for-crohn-s-disease-achieved-sustained-cli-lly-20250207monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-full-q4-2024-financial-results-and-provides-2025-guidance-revenue-in-q4-2024-lly-20250206monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-fourth-quarter-2024-financial-results-and-2025-lly-20250123monthly0.5https://www.biopharmawatch.com/news/LLY/fda-approves-lilly-s-omvoh-mirikizumab-mrkz-for-crohn-s-disease-expanding-its-use-to-the-s-lly-20250115monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-provides-update-on-2024-revenue-guidance-announces-2025-revenue-guidance-eli-lilly-a-lly-20250114monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-acquire-scorpion-therapeutics-mutant-selective-pi3k-inhibitor-program-eli-lilly-a-lly-20250113monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-j-p-morgan-healthcare-conference-eli-lilly-and-company-nyse-lly-wi-lly-20250107monthly0.5https://www.biopharmawatch.com/news/LLY/fda-approves-zepbound-tirzepatide-as-the-first-and-only-prescription-medicine-for-moderate-lly-20241220monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-kisunla-donanemab-azbt-approved-in-china-for-the-treatment-of-early-symptomatic-al-lly-20241217monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-eva-pharma-announce-regulatory-approval-and-release-of-locally-manufactured-insu-lly-20241217monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-omvoh-mirikizumab-recommended-by-chmp-for-approval-in-the-european-union-for-adult-lly-20241213monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-imlunestrant-an-oral-serd-significantly-improved-progression-free-survival-as-mono-lly-20241211monthly0.5https://www.biopharmawatch.com/news/LLY/phase-3-results-for-lilly-s-jaypirca-pirtobrutinib-in-covalent-btk-inhibitor-pre-treated-c-lly-20241209monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-new-15-billion-share-repurchase-program-and-seventh-consecutive-15-dividen-lly-20241209monthly0.5https://www.biopharmawatch.com/news/LLY/core-kidney-boehringer-ingelheim-and-lilly-are-turning-up-the-volume-on-kidney-health-at-t-lly-20241209monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-3-billion-expansion-of-its-recently-acquired-manufacturing-facility-in-wis-lly-20241205monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-zepbound-tirzepatide-superior-to-wegovy-semaglutide-in-head-to-head-trial-showing--lly-20241204monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-changes-on-board-of-directors-eli-lilly-and-company-nyse-lly-announced-tod-lly-20241119monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-muvalaplin-lowered-lipoprotein-a-levels-in-adults-with-high-risk-for-cardiovascula-lly-20241118monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-tirzepatide-reduced-the-risk-of-worsening-heart-failure-events-by-38-in-adults-wit-lly-20241116monthly0.5https://www.biopharmawatch.com/news/LLY/treatment-with-tirzepatide-in-adults-with-pre-diabetes-and-obesity-or-overweight-resulted--lly-20241113monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-details-of-presentations-at-the-2024-american-society-of-hematology-ash-an-lly-20241105monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-results-from-phase-3-ember-3-study-of-imlunestrant-an-oral-serd-and-addit-lly-20241101monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-q3-2024-financial-results-highlighted-by-strong-volume-driven-revenue-growth-lly-20241030monthly0.5https://www.biopharmawatch.com/news/LLY/modified-titration-of-donanemab-demonstrated-reduction-of-aria-e-in-early-symptomatic-alzh-lly-20241029monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-fourth-quarter-2024-dividend-the-board-of-directors-of-eli-lilly-and-compan-lly-20241028monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-mirikizumab-is-first-and-only-il23p19-antagonist-to-report-long-term-multi-year-su-lly-20241028monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-ebglyss-lebrikizumab-lbkz-demonstrated-meaningful-improvement-in-skin-clearance-an-lly-20241025monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-kisunla-donanemab-azbt-receives-marketing-authorization-in-great-britain-for-the-t-lly-20241023monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-third-quarter-2024-financial-results-announcem-lly-20241016monthly0.5https://www.biopharmawatch.com/news/LLY/survey-reveals-8-in-10-americans-with-ulcerative-colitis-struggle-to-find-a-public-restroo-lly-20241016monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-one-year-histologic-outcomes-in-phase-3-study-of-mirikizumab-compared-to-ust-lly-20241014monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-new-4-5-billion-site-the-lilly-medicine-foundry-to-drive-innovation-in-dru-lly-20241002monthly0.5https://www.biopharmawatch.com/news/LLY/new-data-show-lilly-s-ebglyss-lebrikizumab-lbkz-provided-sustained-disease-control-for-up--lly-20240925monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-kisunla-donanemab-azbt-approved-in-japan-for-the-treatment-of-early-symptomatic-al-lly-20240924monthly0.5https://www.biopharmawatch.com/news/LLY/fda-approves-lilly-s-ebglyss-lebrikizumab-lbkz-for-adults-and-children-12-years-and-older--lly-20240913monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-expands-manufacturing-footprint-in-ireland-with-1-8-billion-investment-eli-lilly-and-lly-20240912monthly0.5https://www.biopharmawatch.com/news/LLY/with-once-a-week-dosing-insulin-efsitora-alfa-delivers-similar-a1c-reduction-compared-to-d-lly-20240910monthly0.5https://www.biopharmawatch.com/news/LLY/once-weekly-dose-of-insulin-efsitora-alfa-delivers-a1c-reduction-consistent-with-the-most--lly-20240910monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-appoints-lucas-montarce-as-executive-vice-president-and-chief-financial-officer-eli--lly-20240909monthly0.5https://www.biopharmawatch.com/news/LLY/in-a-first-of-its-kind-fixed-dose-study-once-weekly-insulin-efsitora-alfa-leads-to-a1c-red-lly-20240905monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-eva-pharma-collaborate-to-expand-access-to-baricitinib-in-low-to-middle-income-c-lly-20240904monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-releases-zepbound-tirzepatide-single-dose-vials-expanding-supply-and-access-for-adul-lly-20240827monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-morgan-stanley-22nd-annual-global-healthcare-conference-eli-lilly--lly-20240822monthly0.5https://www.biopharmawatch.com/news/LLY/tirzepatide-reduced-the-risk-of-developing-type-2-diabetes-by-94-in-adults-with-pre-diabet-lly-20240820monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-retirement-of-marschall-s-runge-from-its-board-of-directors-eli-lilly-and--lly-20240816monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-completes-acquisition-of-morphic-to-improve-outcomes-and-expand-options-for-people-l-lly-20240816monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-opens-state-of-the-art-research-and-development-center-in-the-boston-seaport-eli-lil-lly-20240813monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-q2-2024-financial-results-raises-full-year-revenue-guidance-by-3-billion-rev-lly-20240808monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-tirzepatide-successful-in-phase-3-study-showing-benefit-in-adults-with-heart-failu-lly-20240801monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-second-quarter-2024-financial-results-announce-lly-20240725monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-acquire-morphic-to-improve-outcomes-for-patients-with-inflammatory-bowel-disease--lly-20240708monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-kisunla-donanemab-azbt-approved-by-the-fda-for-the-treatment-of-early-symptomatic--lly-20240702monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-collaborates-with-openai-to-discover-novel-medicines-to-treat-drug-resistant-bacteri-lly-20240625monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-third-quarter-2024-dividend-the-board-of-directors-of-eli-lilly-and-company-lly-20240624monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-tirzepatide-reduced-obstructive-sleep-apnea-osa-severity-with-up-to-51-5-of-partic-lly-20240621monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-tirzepatide-was-superior-to-placebo-for-mash-resolution-and-more-than-half-of-pati-lly-20240608monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-departure-of-anat-ashkenazi-chief-financial-officer-eli-lilly-and-company--lly-20240605monthly0.5https://www.biopharmawatch.com/news/LLY/melissa-seymour-to-join-lilly-as-executive-vice-president-of-global-quality-eli-lilly-and--lly-20240604monthly0.5https://www.biopharmawatch.com/news/LLY/updated-data-from-the-phase-1-2-study-of-olomorasib-in-kras-g12c-mutant-advanced-solid-tum-lly-20240601monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-unicef-expand-support-to-help-millions-of-young-people-at-risk-of-noncommunicable-di-lly-20240529monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-goldman-sachs-45th-annual-global-healthcare-conference-eli-lilly-a-lly-20240528monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-increases-manufacturing-investment-to-9-billion-at-newest-indiana-site-to-boost-api--lly-20240524monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-details-of-presentations-at-2024-american-society-of-clinical-oncology-asc-lly-20240523monthly0.5https://www.biopharmawatch.com/news/LLY/more-than-one-half-of-patients-with-crohn-s-disease-treated-with-lilly-s-mirikizumab-achie-lly-20240521monthly0.5https://www.biopharmawatch.com/news/LLY/with-once-a-week-dosing-insulin-efsitora-alfa-delivers-a1c-reduction-and-safety-profile-co-lly-20240516monthly0.5https://www.biopharmawatch.com/news/LLY/alonzo-weems-to-retire-as-executive-vice-president-of-enterprise-risk-management-and-chief-lly-20240515monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-second-quarter-2024-dividend-the-board-of-directors-of-eli-lilly-and-compan-lly-20240506monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-first-quarter-2024-financial-results-and-raises-full-year-revenue-guidance-b-lly-20240430monthly0.5https://www.biopharmawatch.com/news/LLY/tirzepatide-reduced-sleep-apnea-severity-by-up-to-nearly-two-thirds-in-adults-with-obstruc-lly-20240417monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-first-quarter-2024-financial-results-announcem-lly-20240416monthly0.5https://www.biopharmawatch.com/news/LLY/more-than-two-thirds-of-people-with-atopic-dermatitis-and-skin-of-color-experienced-skin-i-lly-20240310monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-food-and-drug-administration-to-convene-advisory-committee-meeting-to-discuss-the-trai-lly-20240308monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-newest-phase-of-get-better-campaign-challenges-misperceptions-about-obesity-care-e-lly-20240307monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-details-of-presentations-at-2024-american-association-for-cancer-research--lly-20240305monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-cowen-s-44th-annual-health-care-conference-eli-lilly-and-company-n-lly-20240220monthly0.5https://www.biopharmawatch.com/news/LLY/philip-johnson-to-retire-as-lilly-treasurer-eli-lilly-and-company-nyse-lly-today-announced-lly-20240209monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-strong-fourth-quarter-2023-financial-results-and-provides-2024-guidance-reve-lly-20240206monthly0.5https://www.biopharmawatch.com/news/LLY/johna-norton-to-retire-as-lilly-executive-vice-president-of-global-quality-eli-lilly-and-c-lly-20240125monthly0.5https://www.biopharmawatch.com/news/LLY/positive-phase-1-2-clinical-trial-data-for-an-investigational-gene-therapy-for-genetic-hea-lly-20240123monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-fourth-quarter-2023-financial-results-and-2024-lly-20240123monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-launches-end-to-end-digital-healthcare-experience-through-lillydirect-eli-lilly-and--lly-20240104monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-j-p-morgan-healthcare-conference-eli-lilly-and-company-nyse-lly-wi-lly-20240102monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-completes-acquisition-of-point-biopharma-eli-lilly-and-company-nyse-lly-today-announ-lly-20231227monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-extends-tender-offer-to-acquire-point-biopharma-to-dec-22-2023-eli-lilly-and-company-lly-20231218monthly0.5https://www.biopharmawatch.com/news/LLY/updated-data-from-the-bruin-phase-1-2-study-of-pirtobrutinib-in-chronic-lymphocytic-leukem-lly-20231211monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-zepbound-tirzepatide-achieved-additional-6-7-weight-loss-following-a-36-week-open--lly-20231211monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-15-dividend-increase-first-quarter-2024-dividend-the-board-of-directors-of-lly-20231208monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-final-overall-survival-analysis-from-the-monarch-3-study-of-verzenio-abem-lly-20231205monthly0.5https://www.biopharmawatch.com/news/LLY/zepbound-tirzepatide-is-now-available-in-u-s-pharmacies-for-adults-living-with-obesity-eli-lly-20231205monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-extends-tender-offer-to-acquire-point-biopharma-to-dec-15-2023-eli-lilly-and-company-lly-20231204monthly0.5https://www.biopharmawatch.com/news/LLY/jaypirca-pirtobrutinib-now-approved-by-u-s-fda-for-the-treatment-of-adult-patients-with-ch-lly-20231201monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-plans-to-open-its-first-ever-gateway-labs-site-in-san-diego-eli-lilly-and--lly-20231128monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-expand-injectable-manufacturing-capacity-with-planned-2-5-billion-site-in-germany-lly-20231117monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-extends-tender-offer-to-acquire-point-biopharma-to-dec-1-2023-eli-lilly-and-company--lly-20231117monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-the-receipt-of-nrc-consent-in-connection-with-its-proposed-acquisition-of--lly-20231114monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-evercore-isi-healthconx-conference-eli-lilly-and-company-nyse-lly--lly-20231114monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-extension-of-tender-offer-to-acquire-point-biopharma-eli-lilly-and-company-lly-20231108monthly0.5https://www.biopharmawatch.com/news/LLY/fda-approves-lilly-s-zepbound-tirzepatide-for-chronic-weight-management-a-powerful-new-opt-lly-20231108monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-details-of-pirtobrutinib-presentations-in-b-cell-malignancies-at-2023-ash--lly-20231102monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-third-quarter-2023-financial-results-highlights-strong-sales-growth-and-busi-lly-20231102monthly0.5https://www.biopharmawatch.com/news/LLY/hip-hop-classic-it-takes-two-takes-on-new-meaning-in-remix-to-elevate-importance-of-testin-lly-20231101monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-fourth-quarter-2023-dividend-the-board-of-directors-of-eli-lilly-and-compan-lly-20231101monthly0.5https://www.biopharmawatch.com/news/LLY/fda-approves-lilly-s-omvoh-mirikizumab-mrkz-a-first-in-class-treatment-for-adults-with-mod-lly-20231026monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-ubs-biopharma-conference-2023-eli-lilly-and-company-nyse-lly-will--lly-20231026monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-retevmo-selpercatinib-phase-3-results-in-ret-fusion-positive-non-small-cell-lung-c-lly-20231021monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-third-quarter-2023-financial-results-announcem-lly-20231020monthly0.5https://www.biopharmawatch.com/news/LLY/landmark-5-year-monarche-outcome-data-demonstrate-verzenio-abemaciclib-s-long-term-impact--lly-20231020monthly0.5https://www.biopharmawatch.com/news/LLY/nearly-80-of-patients-with-moderate-to-severe-atopic-dermatitis-maintained-clear-or-almost-lly-20231020monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-tirzepatide-shows-additional-21-1-weight-loss-after-12-weeks-of-intensive-lifestyl-lly-20231015monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-mirikizumab-helped-patients-with-crohn-s-disease-achieve-long-term-remission-in-ph-lly-20231012monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-details-of-presentations-at-esmo-congress-2023-eli-lilly-and-company-nyse--lly-20231006monthly0.5https://www.biopharmawatch.com/news/LLY/loxo-lilly-unveils-three-new-oncology-programs-at-2023-aacr-nci-eortc-international-confer-lly-20231004monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-leadership-transitions-eli-lilly-and-company-nyse-lly-today-announced-chan-lly-20231004monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-acquire-point-biopharma-to-expand-oncology-capabilities-into-next-generation-radi-lly-20231003monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-food-and-drug-administration-issues-complete-response-letter-for-lebrikizumab-based-on-lly-20231002monthly0.5https://www.biopharmawatch.com/news/LLY/us-fda-approves-jardiance-for-the-treatment-of-adults-with-chronic-kidney-disease-the-u-s--lly-20230922monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-morgan-stanley-21st-annual-global-healthcare-conference-eli-lilly--lly-20230829monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-retevmo-selpercatinib-demonstrates-superior-progression-free-survival-compared-to--lly-20230822monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-completes-acquisition-of-versanis-bio-eli-lilly-and-company-nyse-lly-today-announced-lly-20230814monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-completes-acquisition-of-sigilon-therapeutics-eli-lilly-and-company-nyse-lly-today-a-lly-20230814monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-completes-acquisition-of-dice-therapeutics-eli-lilly-and-company-nyse-lly-today-anno-lly-20230809monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-second-quarter-2023-financial-results-highlights-accelerating-revenue-growth-lly-20230808monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-retevmo-selpercatinib-is-the-first-targeted-therapy-to-demonstrate-superior-progre-lly-20230804monthly0.5https://www.biopharmawatch.com/news/LLY/tirzepatide-demonstrated-significant-and-superior-weight-loss-compared-to-placebo-in-two-p-lly-20230727monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-second-quarter-2023-financial-results-announce-lly-20230725monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-extension-of-tender-offer-to-acquire-dice-eli-lilly-and-company-nyse-lly-t-lly-20230725monthly0.5https://www.biopharmawatch.com/news/LLY/results-from-lilly-s-landmark-phase-3-trial-of-donanemab-presented-at-alzheimer-s-associat-lly-20230717monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-acquire-versanis-to-improve-patient-outcomes-in-cardiometabolic-diseases-eli-lill-lly-20230714monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-webcast-to-provide-alzheimer-s-disease-update-at-aaic-eli-lilly-and-compan-lly-20230711monthly0.5https://www.biopharmawatch.com/news/LLY/new-england-journal-of-medicine-publishes-bruin-phase-1-2-trial-data-for-pirtobrutinib-in--lly-20230706monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-acquire-sigilon-therapeutics-eli-lilly-and-company-nyse-lly-and-sigilon-therapeut-lly-20230629monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-phase-2-retatrutide-results-published-in-the-new-england-journal-of-medicine-show--lly-20230626monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-third-quarter-2023-dividend-the-board-of-directors-of-eli-lilly-and-company-lly-20230626monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-surmount-2-results-published-in-the-lancet-show-tirzepatide-achieved-a-mean-weight-lly-20230624monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-phase-2-results-published-in-the-new-england-journal-of-medicine-show-orforglipron-lly-20230623monthly0.5https://www.biopharmawatch.com/news/LLY/us-fda-approves-jardiance-empagliflozin-for-the-treatment-of-type-2-diabetes-in-children-1-lly-20230621monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-new-research-in-the-treatment-of-diabetes-and-obesity-at-the-american-dia-lly-20230620monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-teams-up-with-the-american-diabetes-association-and-adam-duvall-to-launch-tap-the-ca-lly-20230620monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-acquire-dice-therapeutics-to-advance-innovation-in-immunology-eli-lilly-and-compa-lly-20230620monthly0.5https://www.biopharmawatch.com/news/LLY/first-of-its-kind-head-to-head-clinical-trial-reaffirms-the-efficacy-of-emgality-in-episod-lly-20230616monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-highlights-verzenio-abemaciclib-and-jaypirca-pirtobrutinib-data-at-2023-asco-annual--lly-20230602monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-goldman-sachs-global-healthcare-conference-eli-lilly-and-company-n-lly-20230530monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-esg-report-highlights-progress-towards-sustainability-goals-eli-lilly-and-company-ny-lly-20230522monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-peresolimab-phase-2a-rheumatoid-arthritis-trial-published-in-the-new-england-journ-lly-20230518monthly0.5https://www.biopharmawatch.com/news/LLY/loxo-lilly-announces-details-of-presentations-at-2023-european-hematology-association-eha--lly-20230511monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-social-impact-venture-capital-portfolio-poised-to-grow-to-300-million-with-new-50--lly-20230509monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-discloses-first-in-class-interim-phase-2-data-in-pediatric-patients-and-new-analysis-lly-20230509monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-bank-of-america-securities-2023-healthcare-conference-eli-lilly-an-lly-20230503monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-donanemab-significantly-slowed-cognitive-and-functional-decline-in-phase-3-study-o-lly-20230503monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-provides-500-000-in-grants-to-support-equitable-access-to-education-for-dreamers-in--lly-20230502monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-second-quarter-2023-dividend-the-board-of-directors-of-eli-lilly-and-compan-lly-20230501monthly0.5https://www.biopharmawatch.com/news/LLY/up-to-73-of-atopic-dermatitis-patients-taking-lilly-s-lebrikizumab-had-improved-or-cleared-lly-20230501monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-first-quarter-2023-financial-results-highlights-continued-core-business-grow-lly-20230427monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-tirzepatide-achieved-up-to-15-7-weight-loss-in-adults-with-obesity-or-overweight-a-lly-20230427monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-divest-baqsimi-to-amphastar-in-an-effort-to-continue-expanding-the-availability-o-lly-20230424monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-make-record-breaking-investment-in-indiana-manufacturing-facilities-eli-lilly-and-lly-20230417monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-food-and-drug-administration-issues-complete-response-letter-for-mirikizumab-eli-lilly-lly-20230413monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-first-quarter-2023-financial-results-announcem-lly-20230413monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-details-of-presentations-at-2023-american-association-for-cancer-research--lly-20230314monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-provides-update-on-a4-study-of-solanezumab-for-preclinical-alzheimer-s-disease-eli-l-lly-20230308monthly0.5https://www.biopharmawatch.com/news/LLY/us-fda-accepts-supplemental-new-drug-application-for-jardiance-for-children-10-years-and-o-lly-20230308monthly0.5https://www.biopharmawatch.com/news/LLY/intensive-education-at-clinics-about-multidisciplinary-care-improved-likelihood-that-adult-lly-20230306monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-fda-broadens-indication-for-verzenio-abemaciclib-in-hr-her2-node-positive-high-risk-ea-lly-20230303monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-cuts-insulin-prices-by-70-and-caps-patient-insulin-out-of-pocket-costs-at-35-per-mon-lly-20230301monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-cowen-s-43rd-annual-health-care-conference-eli-lilly-and-company-n-lly-20230221monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-svb-securities-global-biopharma-conference-eli-lilly-and-company-n-lly-20230207monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-guggenheim-oncology-conference-eli-lilly-and-company-nyse-lly-will-lly-20230203monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-fourth-quarter-2022-financial-results-core-business-growth-and-pipeline-adva-lly-20230202monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-fda-approves-jaypirca-pirtobrutinib-the-first-and-only-non-covalent-reversible-btk-inh-lly-20230127monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-supports-direct-relief-s-efforts-to-expand-access-to-medicines-by-improving-cold-cha-lly-20230126monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-plans-to-invest-additional-450-million-at-manufacturing-site-in-research-triangle-pa-lly-20230124monthly0.5https://www.biopharmawatch.com/news/LLY/us-fda-accepts-supplemental-new-drug-application-for-jardiance-for-adults-with-chronic-kid-lly-20230120monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-food-and-drug-administration-issues-complete-response-letter-for-accelerated-approval--lly-20230119monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-fourth-quarter-2022-financial-results-announce-lly-20230119monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-the-j-p-morgan-healthcare-conference-eli-lilly-and-company-nyse-ll-lly-20230104monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-proqr-to-expand-rna-editing-collaboration-eli-lilly-and-company-nyse-lly-and-pro-lly-20221222monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-eva-pharma-announce-collaboration-to-enhance-sustainable-access-to-affordable-in-lly-20221214monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-2023-financial-guidance-plans-to-launch-up-to-four-new-medicines-lilly-exp-lly-20221213monthly0.5https://www.biopharmawatch.com/news/LLY/loxo-lilly-presents-updated-pirtobrutinib-data-from-the-phase-1-2-bruin-clinical-trial-at--lly-20221212monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-15-dividend-increase-first-quarter-2023-dividend-the-board-of-directors-of-lly-20221212monthly0.5https://www.biopharmawatch.com/news/LLY/phase-iii-trial-demonstrated-jardiance-is-the-first-sglt2-inhibitor-to-show-statistically--lly-20221207monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-updated-data-from-the-verzenio-abemaciclib-phase-3-monarche-trial-presente-lly-20221206monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-completes-acquisition-of-akouos-expanding-efforts-to-help-people-with-genetic-diseas-lly-20221201monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-shares-positive-donanemab-data-in-first-active-comparator-study-in-early-symptomatic-lly-20221130monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-akouos-announce-expiration-of-akouos-tender-offer-eli-lilly-and-company-nyse-lly-lly-20221130monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-2023-financial-guidance-announcement-eli-lilly-lly-20221129monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-details-of-presentations-at-2022-san-antonio-breast-cancer-symposium-eli-l-lly-20221121monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-evercore-isi-healthconx-conference-eli-lilly-and-company-nyse-lly--lly-20221116monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-begin-rollout-of-tempo-personalized-diabetes-management-platform-centralized-expe-lly-20221107monthly0.5https://www.biopharmawatch.com/news/LLY/landmark-empa-kidney-trial-showed-significant-benefit-of-jardiance-in-reducing-kidney-dise-lly-20221104monthly0.5https://www.biopharmawatch.com/news/LLY/loxo-lilly-announces-details-of-presentations-at-the-2022-american-society-of-hematology-a-lly-20221103monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-solid-third-quarter-2022-financial-results-and-continued-pipeline-progress-l-lly-20221101monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-commits-92-5-million-to-purdue-to-establish-an-innovative-pharmaceutical-manufacturi-lly-20221027monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-third-quarter-2022-financial-results-announcem-lly-20221019monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-acquire-akouos-to-discover-and-develop-treatments-for-hearing-loss-eli-lilly-and--lly-20221018monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-fourth-quarter-2022-dividend-the-board-of-directors-of-eli-lilly-and-compan-lly-20221017monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-receives-u-s-fda-fast-track-designation-for-tirzepatide-for-the-treatment-of-adults--lly-20221006monthly0.5https://www.biopharmawatch.com/news/LLY/fda-approves-lilly-s-retevmo-selpercatinib-the-first-and-only-ret-inhibitor-for-adults-wit-lly-20220921monthly0.5https://www.biopharmawatch.com/news/LLY/lebrikizumab-dosed-every-four-weeks-maintained-durable-skin-clearance-in-lilly-s-phase-3-m-lly-20220908monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-details-of-presentations-at-esmo-congress-2022-eli-lilly-and-company-nyse--lly-20220907monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-morgan-stanley-20th-annual-global-healthcare-conference-eli-lilly--lly-20220831monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-citi-s-17th-annual-biopharma-conference-eli-lilly-and-company-nyse-lly-20220825monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-leadership-transition-in-human-resources-and-new-chief-commercial-officer--lly-20220811monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-taltz-ixekizumab-now-available-in-new-citrate-free-formulation-to-reduce-injection-lly-20220808monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-updates-conference-call-start-time-for-second-quarter-2022-financial-results-eli-lil-lly-20220804monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-second-quarter-financial-results-highlights-momentum-of-new-medicines-and-pi-lly-20220804monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-second-quarter-2022-financial-results-announce-lly-20220721monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-will-supply-an-additional-150-000-doses-of-bebtelovimab-to-u-s-government-in-ongoing-lly-20220629monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-third-quarter-2022-dividend-the-board-of-directors-of-eli-lilly-and-company-lly-20220627monthly0.5https://www.biopharmawatch.com/news/LLY/eight-out-of-ten-patients-maintained-skin-clearance-at-one-year-in-lilly-s-lebrikizumab-at-lly-20220607monthly0.5https://www.biopharmawatch.com/news/LLY/new-analyses-of-mounjaro-tirzepatide-injection-for-the-treatment-of-adults-with-type-2-dia-lly-20220606monthly0.5https://www.biopharmawatch.com/news/LLY/jardiance-decreased-relative-risk-of-hospitalization-for-heart-failure-by-50-versus-dpp-4--lly-20220605monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-award-peds-trial-investigating-use-of-trulicity-dulaglutide-in-youth-and-adolescen-lly-20220604monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-surmount-1-results-published-in-the-new-england-journal-of-medicine-show-tirzepati-lly-20220604monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-goldman-sachs-global-healthcare-conference-eli-lilly-and-company-n-lly-20220603monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-details-of-presentations-at-2022-american-society-of-clinical-oncology-asc-lly-20220526monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-plans-to-invest-2-1-billion-in-new-manufacturing-sites-in-indiana-eli-lilly-and-comp-lly-20220525monthly0.5https://www.biopharmawatch.com/news/LLY/fifty-percent-of-patients-with-ulcerative-colitis-treated-with-mirikizumab-achieved-clinic-lly-20220524monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-webcast-to-provide-diabetes-and-obesity-portfolio-update-at-ada-eli-lilly--lly-20220523monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-ubs-global-healthcare-conference-2022-eli-lilly-and-company-nyse-l-lly-20220516monthly0.5https://www.biopharmawatch.com/news/LLY/fda-approves-lilly-s-mounjaro-tirzepatide-injection-the-first-and-only-gip-and-glp-1-recep-lly-20220513monthly0.5https://www.biopharmawatch.com/news/LLY/fda-approves-lilly-and-incyte-s-olumiant-baricitinib-for-the-treatment-of-certain-hospital-lly-20220511monthly0.5https://www.biopharmawatch.com/news/LLY/mary-lynne-hedley-elected-to-lilly-board-of-directors-the-board-of-directors-of-eli-lilly--lly-20220506monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-bank-of-america-securities-2022-healthcare-conference-eli-lilly-an-lly-20220503monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-second-quarter-2022-dividend-the-board-of-directors-of-eli-lilly-and-compan-lly-20220502monthly0.5https://www.biopharmawatch.com/news/LLY/solid-first-quarter-financial-results-reflect-lilly-s-continued-momentum-into-2022-lilly-s-lly-20220428monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-tirzepatide-delivered-up-to-22-5-weight-loss-in-adults-with-obesity-or-overweight--lly-20220428monthly0.5https://www.biopharmawatch.com/news/LLY/tackling-health-disparities-and-inequities-for-women-with-heart-failure-new-program-encour-lly-20220420monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-first-quarter-2022-financial-results-announcem-lly-20220419monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-lebrikizumab-combined-with-topical-corticosteroids-showed-significant-improvements-lly-20220411monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-presents-updated-data-on-retevmo-selpercatinib-in-advanced-ret-fusion-positive-non-s-lly-20220401monthly0.5https://www.biopharmawatch.com/news/LLY/nearly-40-of-adults-with-alopecia-areata-taking-olumiant-4-mg-saw-at-least-80-scalp-hair-c-lly-20220326monthly0.5https://www.biopharmawatch.com/news/LLY/majority-of-patients-treated-with-lebrikizumab-achieved-skin-clearance-in-lilly-s-pivotal--lly-20220326monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-complete-response-letter-for-sintilimab-in-combination-with-pemetrexed-and-lly-20220324monthly0.5https://www.biopharmawatch.com/news/LLY/jardiance-phase-iii-empa-kidney-trial-will-stop-early-due-to-clear-positive-efficacy-in-pe-lly-20220316monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-details-of-presentations-at-2022-american-association-for-cancer-research--lly-20220308monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-barclays-global-healthcare-conference-eli-lilly-and-company-nyse-l-lly-20220303monthly0.5https://www.biopharmawatch.com/news/LLY/jardiance-provided-a-significant-clinical-benefit-in-adults-stabilized-in-hospital-followi-lly-20220301monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-cowen-health-care-conference-eli-lilly-and-company-nyse-lly-will-p-lly-20220228monthly0.5https://www.biopharmawatch.com/news/LLY/us-fda-approves-jardiance-empagliflozin-to-treat-adults-with-heart-failure-regardless-of-l-lly-20220224monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-the-institute-for-genetic-medicine-and-700-million-investment-in-boston-se-lly-20220222monthly0.5https://www.biopharmawatch.com/news/LLY/nearly-two-thirds-of-patients-respond-to-mirikizumab-treatment-at-12-weeks-in-lilly-s-firs-lly-20220218monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-breast-cancer-advocacy-organizations-collaborate-to-drive-awareness-of-the-compl-lly-20220216monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-bebtelovimab-receives-emergency-use-authorization-for-the-treatment-of-mild-to-mod-lly-20220211monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-will-supply-up-to-600-000-doses-of-bebtelovimab-to-u-s-government-in-ongoing-effort--lly-20220210monthly0.5https://www.biopharmawatch.com/news/LLY/cynthia-cardona-elected-as-president-of-the-lilly-foundation-the-eli-lilly-and-company-fou-lly-20220210monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-solid-fourth-quarter-and-full-year-2021-financial-results-recent-late-stage--lly-20220203monthly0.5https://www.biopharmawatch.com/news/LLY/unicef-and-lilly-collaborate-to-help-improve-health-outcomes-for-10-million-children-and-a-lly-20220202monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-guggenheim-oncology-conference-eli-lilly-and-company-nyse-lly-will-lly-20220201monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-1-billion-investment-in-new-manufacturing-facility-in-north-carolina-eli-l-lly-20220128monthly0.5https://www.biopharmawatch.com/news/LLY/updates-on-olumiant-baricitinib-phase-3-lupus-program-and-fda-review-for-atopic-dermatitis-lly-20220128monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-fourth-quarter-and-full-year-2021-financial-re-lly-20220120monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-the-j-p-morgan-healthcare-conference-eli-lilly-and-company-nyse-ll-lly-20220106monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-entos-pharmaceuticals-enter-into-research-and-collaboration-agreement-to-support-lly-20220106monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-lebrikizumab-demonstrated-significant-skin-improvement-and-itch-relief-when-combin-lly-20211221monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-highlights-innovation-based-growth-strategy-and-pipeline-developments-announces-2022-lly-20211215monthly0.5https://www.biopharmawatch.com/news/LLY/mirikizumab-demonstrates-superiority-over-placebo-in-phase-3-maintenance-study-in-ulcerati-lly-20211214monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-15-percent-dividend-increase-first-quarter-2022-dividend-the-board-of-dire-lly-20211213monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-foghorn-announce-strategic-collaboration-for-novel-oncology-targets-using-foghor-lly-20211213monthly0.5https://www.biopharmawatch.com/news/LLY/loxo-oncology-at-lilly-announces-updated-data-from-the-phase-1-2-bruin-clinical-trial-for--lly-20211212monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-regor-therapeutics-group-enter-into-strategic-collaboration-to-discover-and-deve-lly-20211210monthly0.5https://www.biopharmawatch.com/news/LLY/new-lilly-study-reveals-underappreciation-of-bowel-urgency-as-a-symptom-of-ulcerative-coli-lly-20211209monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-bamlanivimab-with-etesevimab-authorized-as-the-first-and-only-neutralizing-antibod-lly-20211203monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-announce-initial-2022-financial-guidance-provide-r-d-overview-at-investment-commu-lly-20211201monthly0.5https://www.biopharmawatch.com/news/LLY/emgality-versus-nurtec-odt-head-to-head-migraine-preventive-treatment-study-now-enrolling--lly-20211118monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-fourth-annual-evercore-isi-healthconx-conference-eli-lilly-and-com-lly-20211117monthly0.5https://www.biopharmawatch.com/news/LLY/us-fda-accepts-supplemental-new-drug-application-and-grants-priority-review-for-jardiance--lly-20211111monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-winners-of-inaugural-leonard-award-a-global-program-celebrating-100-years--lly-20211111monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-wolfe-research-virtual-healthcare-conference-eli-lilly-and-company-lly-20211109monthly0.5https://www.biopharmawatch.com/news/LLY/olumiant-long-term-safety-profile-established-up-to-9-3-years-in-integrated-analysis-of-mo-lly-20211109monthly0.5https://www.biopharmawatch.com/news/LLY/jardiance-shows-consistent-cardio-renal-benefits-in-adults-with-heart-failure-with-left-ve-lly-20211105monthly0.5https://www.biopharmawatch.com/news/LLY/loxo-oncology-at-lilly-announces-details-of-presentations-at-the-2021-american-society-of--lly-20211104monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-supply-614-000-additional-doses-of-bamlanivimab-and-etesevimab-to-the-u-s-governm-lly-20211102monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-bernstein-s-second-annual-operational-decisions-conference-eli-lil-lly-20211101monthly0.5https://www.biopharmawatch.com/news/LLY/additional-verzenio-abemaciclib-phase-3-monarche-trial-data-published-in-the-annals-of-onc-lly-20211028monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-robust-third-quarter-2021-financial-results-as-pipeline-success-strengthens--lly-20211026monthly0.5https://www.biopharmawatch.com/news/LLY/tirzepatide-results-published-in-the-lancet-show-superior-a1c-and-body-weight-reductions-c-lly-20211019monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-fourth-quarter-2021-dividend-the-board-of-directors-of-eli-lilly-and-compan-lly-20211018monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-updated-verzenio-abemaciclib-phase-3-monarche-trial-data-presented-at-esmo-lly-20211014monthly0.5https://www.biopharmawatch.com/news/LLY/fda-approves-verzenio-abemaciclib-as-the-first-and-only-cdk4-6-inhibitor-for-certain-peopl-lly-20211013monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-third-quarter-2021-financial-results-announcem-lly-20211012monthly0.5https://www.biopharmawatch.com/news/LLY/loxo-oncology-at-lilly-announces-details-of-presentations-at-2021-aacr-nci-eortc-virtual-i-lly-20211007monthly0.5https://www.biopharmawatch.com/news/LLY/ready-for-the-challenge-boehringer-ingelheim-and-eli-lilly-and-company-launch-first-ever-o-lly-20211004monthly0.5https://www.biopharmawatch.com/news/LLY/at-week-104-75-of-patients-with-ulcerative-colitis-taking-mirikizumab-maintained-symptomat-lly-20211001monthly0.5https://www.biopharmawatch.com/news/LLY/olumiant-significantly-improved-hair-regrowth-to-at-least-80-scalp-coverage-as-early-as-24-lly-20210930monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-tirzepatide-led-to-greater-improvements-in-liver-fat-content-compared-to-insulin-d-lly-20210930monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-tirzepatide-led-to-greater-time-in-range-compared-to-insulin-degludec-in-adults-wi-lly-20210930monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-susan-g-komen-partner-to-address-disparities-in-breast-cancer-outcomes-experienc-lly-20210929monthly0.5https://www.biopharmawatch.com/news/LLY/fda-expands-lilly-s-erbitux-cetuximab-label-with-combination-of-braftovi-encorafenib-for-t-lly-20210928monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-again-reduces-list-price-of-insulin-lispro-injection-as-latest-change-to-affordabili-lly-20210928monthly0.5https://www.biopharmawatch.com/news/LLY/new-data-from-verzenio-abemaciclib-monarche-study-to-be-featured-in-esmo-virtual-plenary-n-lly-20210927monthly0.5https://www.biopharmawatch.com/news/LLY/eli-lilly-and-company-issues-voluntary-nationwide-recall-of-one-lot-of-glucagon-emergency--lly-20210924monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-the-pricing-terms-of-its-cash-tender-offer-for-up-to-1-5-billion-combined--lly-20210921monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-procurement-agreement-with-european-commission-to-supply-bamlanivimab-and--lly-20210921monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-the-early-tender-results-of-its-pending-cash-tender-offer-for-up-to-1-5-bi-lly-20210921monthly0.5https://www.biopharmawatch.com/news/LLY/emergency-use-authorization-for-lilly-s-bamlanivimab-and-etesevimab-administered-together--lly-20210916monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-supply-388-000-doses-of-etesevimab-to-u-s-government-for-treatment-of-covid-19-el-lly-20210915monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-the-2021-cantor-virtual-global-healthcare-conference-eli-lilly-and-lly-20210913monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-new-data-from-oncology-portfolio-at-esmo-congress-new-data-from-various-s-lly-20210913monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-prices-first-sustainability-bond-to-advance-global-esg-strategy-eli-lilly-and-compan-lly-20210909monthly0.5https://www.biopharmawatch.com/news/LLY/fda-grants-jardiance-breakthrough-therapy-designation-for-heart-failure-with-preserved-eje-lly-20210909monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-diabetes-joins-the-leona-m-and-harry-b-helmsley-charitable-trust-to-pledge-significa-lly-20210907monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-cash-tender-offer-for-up-to-1-5-billion-combined-aggregate-principal-amoun-lly-20210907monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-the-morgan-stanley-19th-annual-global-healthcare-conference-eli-li-lly-20210903monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-citi-s-16th-annual-biopharma-virtual-conference-eli-lilly-and-comp-lly-20210831monthly0.5https://www.biopharmawatch.com/news/LLY/landmark-trial-demonstrates-jardiance-empagliflozin-is-the-first-therapy-to-show-statistic-lly-20210827monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-lycia-therapeutics-enter-into-strategic-collaboration-to-discover-and-develop-no-lly-20210825monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-that-professor-carolyn-bertozzi-has-resigned-from-its-board-of-directors-t-lly-20210825monthly0.5https://www.biopharmawatch.com/news/LLY/us-fda-approves-jardiance-empagliflozin-to-treat-adults-living-with-heart-failure-with-red-lly-20210818monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-leadership-changes-and-formation-of-neuroscience-and-immunology-business-u-lly-20210817monthly0.5https://www.biopharmawatch.com/news/LLY/fda-approves-lyumjev-insulin-lispro-aabc-injection-100-units-ml-for-use-in-insulin-pumps-t-lly-20210816monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-lebrikizumab-significantly-improved-skin-clearance-and-itch-in-people-with-moderat-lly-20210816monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-delivers-strong-second-quarter-2021-financial-results-updates-2021-financial-guidanc-lly-20210803monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-incyte-s-baricitinib-reduced-deaths-among-patients-with-covid-19-receiving-invas-lly-20210803monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-releases-donanemab-data-that-demonstrated-relationship-between-reduction-of-amyloid--lly-20210729monthly0.5https://www.biopharmawatch.com/news/LLY/fda-broadens-existing-emergency-use-of-lilly-and-incyte-s-baricitinib-in-patients-hospital-lly-20210729monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-kumquat-biosciences-announce-collaboration-to-discover-and-develop-novel-small-m-lly-20210729monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-second-quarter-2021-financial-results-announce-lly-20210722monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-incyte-provide-update-on-supplemental-new-drug-application-for-baricitinib-for-t-lly-20210716monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-banner-alzheimer-s-institute-collaborate-on-planned-phase-3-prevention-trial-of--lly-20210715monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-acquisition-of-protomer-technologies-eli-lilly-and-company-nyse-lly-today--lly-20210714monthly0.5https://www.biopharmawatch.com/news/LLY/breakthrough-results-for-jardiance-empagliflozin-confirm-emperor-preserved-as-first-and-on-lly-20210706monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-surpass-1-results-published-in-the-lancet-show-tirzepatide-s-superior-a1c-and-body-lly-20210626monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-call-for-leonard-award-nominations-as-part-of-global-initiative-celebratin-lly-20210624monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-donanemab-receives-u-s-fda-s-breakthrough-therapy-designation-for-treatment-of-alz-lly-20210624monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-launches-think-talk-treat-migraine-to-help-improve-diagnosis-and-treatment-of-migrai-lly-20210617monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-head-to-head-study-comparing-once-monthly-emgality-with-every-other-day-nu-lly-20210615monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-guggenheim-biopharma-strategy-series-eli-lilly-and-company-nyse-ll-lly-20210614monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-webcast-to-provide-diabetes-portfolio-update-at-ada-eli-lilly-and-company--lly-20210611monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-new-clinical-data-from-verzenio-and-oral-serd-programs-at-the-american-soc-lly-20210604monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-goldman-sachs-healthcare-conference-eli-lilly-and-company-nyse-lly-lly-20210603monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reveals-critical-barriers-to-optimal-migraine-care-and-insights-from-novel-clinical--lly-20210603monthly0.5https://www.biopharmawatch.com/news/LLY/taltz-showed-consistent-long-term-improvement-in-key-signs-and-symptoms-of-axial-spondyloa-lly-20210601monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-details-of-presentations-at-2021-american-society-of-clinical-oncology-asc-lly-20210519monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-ubs-global-healthcare-virtual-conference-eli-lilly-and-company-nys-lly-20210513monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-mina-therapeutics-announce-sarna-research-collaboration-eli-lilly-and-company-ny-lly-20210511monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-collaborates-internationally-with-leading-diabetes-technology-companies-to-integrate-lly-20210506monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-bank-of-america-securities-2021-health-care-conference-eli-lilly-a-lly-20210505monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-plans-donation-of-covid-19-therapies-to-direct-relief-for-use-in-low-and-lower-middl-lly-20210504monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-outlines-robust-plans-to-strengthen-esg-commitments-across-the-globe-eli-lilly-and-c-lly-20210504monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-accelerating-baricitinib-s-availability-in-india-following-receipt-of-permission-for-lly-20210504monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-second-quarter-2021-dividend-and-announces-additional-share-repurchase-auth-lly-20210503monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-commit-5-million-to-direct-relief-s-fund-for-health-equity-eli-lilly-and-company--lly-20210503monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-delivers-first-quarter-2021-financial-results-adjusts-2021-financial-guidance-eli-li-lly-20210427monthly0.5https://www.biopharmawatch.com/news/LLY/olumiant-showed-significant-improvements-in-the-severity-and-extent-of-atopic-dermatitis-a-lly-20210423monthly0.5https://www.biopharmawatch.com/news/LLY/taltz-delivers-more-cumulative-days-with-completely-clear-skin-for-adults-with-psoriasis-c-lly-20210423monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-incyte-s-baricitinib-improved-hair-regrowth-for-alopecia-areata-patients-in-seco-lly-20210420monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-requests-revocation-of-emergency-use-authorization-for-bamlanivimab-alone-to-complet-lly-20210416monthly0.5https://www.biopharmawatch.com/news/LLY/diogo-rau-to-join-lilly-as-senior-vice-president-and-chief-information-and-digital-officer-lly-20210413monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-modified-covid-19-purchase-agreement-for-bamlanivimab-alone-with-the-u-s-government--lly-20210412monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-presents-new-data-on-retevmo-selpercatinib-in-advanced-ret-fusion-positive-gastroint-lly-20210411monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hos-lly-20210408monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-first-quarter-2021-financial-results-announcem-lly-20210406monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-host-sustainability-webcast-to-provide-overview-of-environmental-social-and-gover-lly-20210401monthly0.5https://www.biopharmawatch.com/news/LLY/survey-reveals-healthcare-professionals-believe-greater-collaboration-is-needed-to-improve-lly-20210331monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-vir-biotechnology-and-gsk-announce-positive-topline-data-from-the-phase-2-blaze-4-tr-lly-20210329monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-presents-patient-reported-outcomes-from-the-positive-phase-3-monarche-trial-for-verz-lly-20210317monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-mirikizumab-helps-patients-achieve-clinical-remission-and-improves-symptoms-in-adu-lly-20210316monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-donanemab-slowed-alzheimer-s-disease-progression-in-phase-2-trial-full-data-presen-lly-20210313monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-details-of-presentations-at-2021-american-association-for-cancer-research--lly-20210310monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-bamlanivimab-and-etesevimab-together-reduced-hospitalizations-and-death-in-phase-3-lly-20210310monthly0.5https://www.biopharmawatch.com/news/LLY/data-from-lilly-at-international-conference-on-alzheimer-s-parkinson-diseases-2021-ad-pd-2-lly-20210309monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-leadership-transitions-in-manufacturing-and-ethics-and-compliance-organiza-lly-20210309monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-biolojic-design-announce-research-collaboration-to-discover-and-develop-antibody-lly-20210308monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-barclays-global-healthcare-conference-eli-lilly-and-company-nyse-l-lly-20210308monthly0.5https://www.biopharmawatch.com/news/LLY/ema-issues-advice-on-lilly-s-bamlanivimab-ly-cov555-alone-and-administered-together-with-e-lly-20210305monthly0.5https://www.biopharmawatch.com/news/LLY/loxo-oncology-at-lilly-announces-publication-of-pirtobrutinib-loxo-305-phase-1-2-data-in-t-lly-20210305monthly0.5https://www.biopharmawatch.com/news/LLY/tirzepatide-achieved-superior-a1c-and-body-weight-reductions-across-all-three-doses-compar-lly-20210304monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-additional-doses-of-neutralizing-antibody-therapy-purchased-by-u-s-governm-lly-20210226monthly0.5https://www.biopharmawatch.com/news/LLY/welldoc-and-lilly-collaborate-to-integrate-bluestar-app-capabilities-into-lilly-s-connecte-lly-20210225monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-cowen-health-care-conference-eli-lilly-and-company-nyse-lly-will-p-lly-20210224monthly0.5https://www.biopharmawatch.com/news/LLY/tirzepatide-significantly-reduced-a1c-and-body-weight-in-people-with-type-2-diabetes-in-tw-lly-20210217monthly0.5https://www.biopharmawatch.com/news/LLY/kimberly-h-johnson-elected-to-lilly-board-of-directors-the-board-of-directors-of-eli-lilly-lly-20210217monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-svb-leerink-global-healthcare-conference-eli-lilly-and-company-nys-lly-20210211monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-bamlanivimab-ly-cov555-administered-with-etesevimab-ly-cov016-receives-fda-emergen-lly-20210209monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-appoints-anat-ashkenazi-chief-financial-officer-eli-lilly-and-company-nyse-lly-today-lly-20210209monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-webcast-to-provide-alzheimer-s-disease-update-at-ad-pd-conference-eli-lill-lly-20210204monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-guggenheim-healthcare-talks-2021-oncology-day-eli-lilly-and-compan-lly-20210203monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-partners-with-area-health-systems-to-help-enable-access-to-important-antibody-infusi-lly-20210201monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-strong-fourth-quarter-and-full-year-2020-financial-results-eli-lilly-and-com-lly-20210129monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-life-for-a-child-and-beyond-type-1-advance-partnership-to-improve-diabetes-care-in-r-lly-20210128monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-asahi-kasei-pharma-announce-license-agreement-for-chronic-pain-drug-candidate-el-lly-20210128monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-vir-biotechnology-and-gsk-announce-first-patient-dosed-in-expanded-blaze-4-trial-eva-lly-20210127monthly0.5https://www.biopharmawatch.com/news/LLY/new-data-show-treatment-with-lilly-s-neutralizing-antibodies-bamlanivimab-ly-cov555-and-et-lly-20210126monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-completes-acquisition-of-prevail-therapeutics-eli-lilly-and-company-nyse-lly-today-a-lly-20210122monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-neutralizing-antibody-bamlanivimab-ly-cov555-prevented-covid-19-at-nursing-homes-i-lly-20210121monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-merus-nv-announce-collaboration-to-discover-novel-t-cell-re-directing-bispecific-lly-20210119monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-fourth-quarter-2020-financial-results-announce-lly-20210115monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-30-million-limited-partner-investment-in-unseen-capital-health-fund-eli-li-lly-20210115monthly0.5https://www.biopharmawatch.com/news/LLY/gabrielle-sulzberger-elected-to-lilly-board-of-directors-the-board-of-directors-of-eli-lil-lly-20210114monthly0.5https://www.biopharmawatch.com/news/LLY/us-fda-accepts-supplemental-new-drug-application-for-jardiance-empagliflozin-for-adults-wi-lly-20210111monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-donanemab-slows-clinical-decline-of-alzheimer-s-disease-in-positive-phase-2-trial--lly-20210111monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-j-p-morgan-healthcare-conference-eli-lilly-and-company-nyse-lly-wi-lly-20210104monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-begin-pragmatic-study-of-neutralizing-antibody-bamlanivimab-ly-cov555-for-covid-1-lly-20201218monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-2021-financial-guidance-updates-2020-guidance-eli-lilly-and-company-nyse-l-lly-20201215monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-agreement-to-acquire-prevail-therapeutics-eli-lilly-and-company-nyse-lly-a-lly-20201215monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-15-percent-dividend-increase-the-board-of-directors-of-eli-lilly-and-compa-lly-20201214monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-opening-of-patient-enrollment-for-new-ideas-imaging-dementia-evidence-for--lly-20201214monthly0.5https://www.biopharmawatch.com/news/LLY/data-from-actt-2-trial-of-baricitinib-in-hospitalized-covid-19-patients-supportive-of-the--lly-20201211monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-presents-positive-primary-outcome-data-from-monarche-that-builds-on-previous-definit-lly-20201209monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-tirzepatide-significantly-reduced-a1c-and-body-weight-in-people-with-type-2-diabet-lly-20201209monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-2021-financial-guidance-announcement-eli-lilly-lly-20201208monthly0.5https://www.biopharmawatch.com/news/LLY/loxo-oncology-at-lilly-announces-updated-data-from-the-phase-1-2-bruin-clinical-trial-for--lly-20201207monthly0.5https://www.biopharmawatch.com/news/LLY/loxo-oncology-at-lilly-announces-updated-data-from-the-phase-1-2-bruin-clinical-trial-for--lly-20201205monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-unitedhealth-group-partner-on-pragmatic-study-of-neutralizing-antibody-bamlanivi-lly-20201204monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-650-000-additional-doses-of-neutralizing-antibody-bamlanivimab-ly-cov555-p-lly-20201202monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-evercore-isi-3rd-annual-healthconx-conference-eli-lilly-and-compan-lly-20201124monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-neutralizing-antibody-bamlanivimab-ly-cov555-receives-interim-authorization-from-h-lly-20201120monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-precision-biosciences-announce-genome-editing-research-collaboration-and-license-lly-20201120monthly0.5https://www.biopharmawatch.com/news/LLY/baricitinib-receives-emergency-use-authorization-from-the-fda-for-the-treatment-of-hospita-lly-20201119monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-ypsomed-collaborate-to-advance-an-automated-insulin-delivery-system-for-people-w-lly-20201119monthly0.5https://www.biopharmawatch.com/news/LLY/jardiance-reduced-the-risk-of-first-plus-recurrent-cardiovascular-events-in-adults-with-ty-lly-20201118monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-wolfe-research-virtual-healthcare-conference-eli-lilly-and-company-lly-20201112monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-bernstein-operational-decisions-conference-eli-lilly-and-company-n-lly-20201112monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program-eli-lly-20201111monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-neutralizing-antibody-bamlanivimab-ly-cov555-receives-fda-emergency-use-authorizat-lly-20201109monthly0.5https://www.biopharmawatch.com/news/LLY/loxo-oncology-at-lilly-announces-details-of-loxo-305-presentations-at-the-2020-american-so-lly-20201105monthly0.5https://www.biopharmawatch.com/news/LLY/aarti-shah-to-retire-as-lilly-chief-information-and-digital-officer-eli-lilly-and-company--lly-20201105monthly0.5https://www.biopharmawatch.com/news/LLY/acr-2020-lilly-and-incyte-highlight-positive-data-for-olumiant-in-rheumatoid-arthritis-eli-lly-20201102monthly0.5https://www.biopharmawatch.com/news/LLY/eadv-2020-lilly-and-incyte-showcase-new-data-for-baricitinib-for-the-treatment-of-moderate-lly-20201031monthly0.5https://www.biopharmawatch.com/news/LLY/fall-clinical-dermatology-2020-lilly-and-incyte-showcase-positive-new-data-for-baricitinib-lly-20201030monthly0.5https://www.biopharmawatch.com/news/LLY/new-data-at-eadv-2020-confirm-taltz-ixekizumab-demonstrates-sustained-long-term-efficacy-i-lly-20201029monthly0.5https://www.biopharmawatch.com/news/LLY/data-for-lilly-s-bamlanivimab-ly-cov555-in-covid-19-outpatients-published-in-new-england-j-lly-20201028monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-agreement-with-u-s-government-to-supply-300-000-vials-of-investigational-n-lly-20201028monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-third-quarter-financial-results-updates-guidance-eli-lilly-and-company-nyse--lly-20201027monthly0.5https://www.biopharmawatch.com/news/LLY/new-jardiance-findings-showed-improved-cardio-renal-outcomes-in-adults-with-heart-failure--lly-20201023monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-fourth-quarter-2020-dividend-the-board-of-directors-of-eli-lilly-and-compan-lly-20201019monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-agreement-to-acquire-disarm-therapeutics-eli-lilly-and-company-nyse-lly-to-lly-20201015monthly0.5https://www.biopharmawatch.com/news/LLY/mirikizumab-shows-continued-symptom-improvement-and-reduction-of-intestinal-inflammation-i-lly-20201012monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-overcome-study-reveals-nearly-80-of-people-reported-improvement-in-their-migraine--lly-20201009monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-third-quarter-2020-financial-results-announcem-lly-20201008monthly0.5https://www.biopharmawatch.com/news/LLY/baricitinib-has-significant-effect-on-recovery-time-most-impactful-in-covid-19-patients-re-lly-20201008monthly0.5https://www.biopharmawatch.com/news/LLY/indy-racial-equity-pledge-launches-to-drive-accountability-action-and-progress-on-racial-e-lly-20201008monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-arrangement-for-supply-of-potential-covid-19-antibody-therapy-for-low-and--lly-20201008monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-provides-comprehensive-update-on-progress-of-sars-cov-2-neutralizing-antibody-progra-lly-20201007monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-dexcom-team-up-on-new-program-to-help-improve-diabetes-management-eli-lilly-and--lly-20201007monthly0.5https://www.biopharmawatch.com/news/LLY/reyvow-lasmiditan-c-v-demonstrated-superior-pain-freedom-at-2-hours-in-at-least-2-of-3-mig-lly-20201006monthly0.5https://www.biopharmawatch.com/news/LLY/verzenio-significantly-reduced-the-risk-of-cancer-recurrence-by-25-for-people-with-hr-her2-lly-20200920monthly0.5https://www.biopharmawatch.com/news/LLY/chmp-recommends-approval-of-lilly-s-baricitinib-for-the-treatment-of-adults-with-moderate--lly-20200918monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-amgen-announce-manufacturing-collaboration-for-covid-19-antibody-therapies-eli-l-lly-20200917monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-proof-of-concept-data-for-neutralizing-antibody-ly-cov555-in-the-covid-19--lly-20200916monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-launches-digital-health-open-innovation-challenge-to-help-transform-atopic-dermatiti-lly-20200915monthly0.5https://www.biopharmawatch.com/news/LLY/us-fda-grants-fast-track-designation-to-jardiance-empagliflozin-to-improve-outcomes-follow-lly-20200915monthly0.5https://www.biopharmawatch.com/news/LLY/baricitinib-in-combination-with-remdesivir-reduces-time-to-recovery-in-hospitalized-patien-lly-20200914monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-cantor-fitzgerald-virtual-global-healthcare-conference-eli-lilly-a-lly-20200911monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-morgan-stanley-global-healthcare-conference-eli-lilly-and-company--lly-20200911monthly0.5https://www.biopharmawatch.com/news/LLY/reyvow-lasmiditan-c-v-demonstrated-pain-freedom-from-migraine-attacks-at-60-minutes-and-up-lly-20200911monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-webcast-to-discuss-esmo-2020-presentations-eli-lilly-and-company-nyse-lly--lly-20200910monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-commits-insulin-value-program-featuring-35-copay-card-to-suite-of-affordability-solu-lly-20200910monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-oncology-to-showcase-new-data-from-robust-cancer-research-pipeline-at-esmo-virtual-c-lly-20200910monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-leadership-changes-eli-lilly-and-company-nyse-lly-announced-today-that-pat-lly-20200909monthly0.5https://www.biopharmawatch.com/news/LLY/fda-approves-additional-doses-of-trulicity-dulaglutide-for-the-treatment-of-type-2-diabete-lly-20200903monthly0.5https://www.biopharmawatch.com/news/LLY/jardiance-reduced-the-combined-relative-risk-of-cardiovascular-death-and-hospitalization-f-lly-20200829monthly0.5https://www.biopharmawatch.com/news/LLY/new-england-journal-of-medicine-publishes-phase-1-2-data-for-retevmo-selpercatinib-in-adva-lly-20200827monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-innovent-announce-global-expansion-of-tyvyt-licensing-agreement-eli-lilly-and-co-lly-20200818monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-initiates-phase-3-trial-of-ly-cov555-for-prevention-of-covid-19-at-long-term-care-fa-lly-20200803monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-second-quarter-financial-results-raises-eps-guidance-eli-lilly-and-company-n-lly-20200730monthly0.5https://www.biopharmawatch.com/news/LLY/jardiance-meets-primary-endpoint-in-reducing-risk-of-cardiovascular-death-or-hospitalizati-lly-20200730monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-p-tau217-blood-test-shows-high-accuracy-in-diagnosis-of-alzheimer-s-disease-in-dat-lly-20200728monthly0.5https://www.biopharmawatch.com/news/LLY/data-from-lilly-at-alzheimer-s-association-international-conference-2020-aaic-2020-to-show-lly-20200721monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-second-quarter-2020-financial-results-announce-lly-20200717monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-mirikizumab-superior-to-cosentyx-secukinumab-in-a-phase-3-study-for-patients-with--lly-20200717monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-third-quarter-2020-dividend-the-board-of-directors-of-eli-lilly-and-company-lly-20200715monthly0.5https://www.biopharmawatch.com/news/LLY/central-indiana-racial-equity-fund-launches-with-more-than-2-2-million-in-initial-commitme-lly-20200625monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-launches-program-about-what-people-with-diabetes-should-know-before-the-low-about-34-lly-20200624monthly0.5https://www.biopharmawatch.com/news/LLY/full-results-from-emperial-exercise-ability-trials-presented-boehringer-ingelheim-and-eli--lly-20200619monthly0.5https://www.biopharmawatch.com/news/LLY/emgality-demonstrates-reduction-in-frequency-duration-and-pain-severity-in-patients-with-e-lly-20200617monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-overcome-study-reveals-less-than-30-percent-of-people-living-with-migraine-take-re-lly-20200616monthly0.5https://www.biopharmawatch.com/news/LLY/verzenio-abemaciclib-significantly-reduced-the-risk-of-cancer-returning-in-people-with-hig-lly-20200616monthly0.5https://www.biopharmawatch.com/news/LLY/fda-approves-lyumjev-insulin-lispro-aabc-injection-lilly-s-new-rapid-acting-insulin-the-u--lly-20200615monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-begins-a-phase-3-clinical-trial-with-baricitinib-for-hospitalized-covid-19-patients--lly-20200615monthly0.5https://www.biopharmawatch.com/news/LLY/once-weekly-trulicity-dulaglutide-demonstrates-significantly-higher-adherence-and-more-per-lly-20200613monthly0.5https://www.biopharmawatch.com/news/LLY/eli-lilly-and-company-foundation-pledges-25-million-to-combat-racial-injustice-eli-lilly-a-lly-20200613monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-dermira-present-new-lebrikizumab-phase-2b-clinical-data-showing-patients-with-at-lly-20200612monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-highlights-the-evolution-of-its-dermatology-portfolio-at-annual-american-academy-of--lly-20200612monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-partners-with-indianapolis-recorder-newspaper-radio-one-and-wish-tv-for-a-day-of-sol-lly-20200612monthly0.5https://www.biopharmawatch.com/news/LLY/first-patient-dose-delivered-for-lilly-s-tirzepatide-cardiovascular-outcomes-trial-the-fir-lly-20200609monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-goldman-sachs-global-healthcare-conference-eli-lilly-and-company-n-lly-20200608monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-start-of-a-phase-1-study-for-its-second-potential-covid-19-antibody-treatm-lly-20200608monthly0.5https://www.biopharmawatch.com/news/LLY/eular-2020-lilly-s-taltz-ixekizumab-continues-to-show-robust-and-consistent-efficacy-in-ps-lly-20200603monthly0.5https://www.biopharmawatch.com/news/LLY/eular-2020-lilly-shares-new-data-for-olumiant-in-rheumatoid-arthritis-and-systemic-lupus-e-lly-20200603monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-taltz-ixekizumab-is-the-first-il-17a-antagonist-to-receive-u-s-fda-approval-for-th-lly-20200601monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-begins-world-s-first-study-of-a-potential-covid-19-antibody-treatment-in-humans-eli--lly-20200601monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-cyramza-ramucirumab-receives-fda-approval-as-first-line-treatment-for-metastatic-e-lly-20200529monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-receives-u-s-fda-approval-of-tauvid-flortaucipir-f-18-injection-for-use-in-patients--lly-20200528monthly0.5https://www.biopharmawatch.com/news/LLY/statement-from-lilly-chairman-and-ceo-dave-ricks-on-new-part-d-senior-savings-model-presid-lly-20200526monthly0.5https://www.biopharmawatch.com/news/LLY/boehringer-ingelheim-and-lilly-to-collaborate-with-duke-clinical-research-institute-on-a-p-lly-20200526monthly0.5https://www.biopharmawatch.com/news/LLY/emgality-shows-improvement-in-work-productivity-and-health-and-well-being-between-attacks--lly-20200526monthly0.5https://www.biopharmawatch.com/news/LLY/results-of-geras-us-study-demonstrate-societal-cost-burden-for-patients-and-caregivers-dur-lly-20200519monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-oncology-showcases-innovation-in-cancer-research-at-asco-2020-data-from-23-studies-a-lly-20200513monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-receives-u-s-fda-approval-for-retevmo-selpercatinib-the-first-therapy-specifically-f-lly-20200508monthly0.5https://www.biopharmawatch.com/news/LLY/higher-investigational-doses-of-trulicity-dulaglutide-meaningfully-reduced-a1c-and-body-we-lly-20200508monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-ubs-virtual-global-healthcare-conference-eli-lilly-and-company-nys-lly-20200505monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-second-quarter-2020-dividend-the-board-of-directors-of-eli-lilly-and-compan-lly-20200504monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-junshi-biosciences-to-co-develop-antibody-therapies-for-the-prevention-and-treat-lly-20200504monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-bank-of-america-securities-health-care-conference-eli-lilly-and-co-lly-20200430monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-strong-first-quarter-financial-results-adjusts-eps-guidance-eli-lilly-and-co-lly-20200423monthly0.5https://www.biopharmawatch.com/news/LLY/lower-priced-versions-of-humalog-mix75-25-kwikpen-and-humalog-junior-kwikpen-now-available-lly-20200416monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-begins-clinical-testing-of-therapies-for-covid-19-eli-lilly-and-company-nyse-lly-ann-lly-20200410monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-first-quarter-2020-financial-results-announcem-lly-20200408monthly0.5https://www.biopharmawatch.com/news/LLY/eli-lilly-and-company-to-hold-2020-annual-meeting-of-shareholders-virtually-eli-lilly-and--lly-20200407monthly0.5https://www.biopharmawatch.com/news/LLY/new-35-co-pay-now-available-through-lilly-insulin-value-program-in-response-to-covid-19-cr-lly-20200407monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-sitryx-announce-licensing-and-research-collaboration-to-discover-and-develop-new-lly-20200331monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-taltz-ixekizumab-receives-u-s-fda-approval-for-the-treatment-of-pediatric-patients-lly-20200330monthly0.5https://www.biopharmawatch.com/news/LLY/updates-from-lilly-about-insulin-supply-and-affordability-to-keep-the-diabetes-community-i-lly-20200324monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-provides-update-on-clinical-trial-activities-during-covid-19-pandemic-eli-lilly-and--lly-20200323monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-provide-drive-through-covid-19-testing-for-indianapolis-health-care-workers-eli-l-lly-20200322monthly0.5https://www.biopharmawatch.com/news/LLY/us-fda-issues-complete-response-letter-for-empagliflozin-2-5-mg-as-adjunct-to-insulin-for--lly-20200320monthly0.5https://www.biopharmawatch.com/news/LLY/kathryn-beiser-to-join-lilly-as-vice-president-global-communications-eli-lilly-and-company-lly-20200320monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-indiana-state-department-of-health-partner-to-accelerate-covid-19-testing-using-lill-lly-20200318monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-receives-fda-breakthrough-therapy-designation-for-baricitinib-for-the-treatment-of-a-lly-20200316monthly0.5https://www.biopharmawatch.com/news/LLY/abcellera-and-lilly-to-co-develop-antibody-therapies-for-the-treatment-of-covid-19-abcelle-lly-20200312monthly0.5https://www.biopharmawatch.com/news/LLY/us-fda-grants-fast-track-designation-to-jardiance-for-the-treatment-of-chronic-kidney-dise-lly-20200312monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-new-model-designed-to-make-insulins-more-affordable-for-seniors-in-lly-20200311monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-barclays-global-healthcare-conference-eli-lilly-and-company-nyse-l-lly-20200309monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-statement-on-novel-coronavirus-and-the-reliable-supply-of-the-company-s-medicines-el-lly-20200303monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-fda-accepts-regulatory-submission-for-tanezumab-a-potential-first-in-class-treatment-f-lly-20200302monthly0.5https://www.biopharmawatch.com/news/LLY/fda-advisory-committee-votes-in-favor-of-lilly-s-cyramza-ramucirumab-as-first-line-treatme-lly-20200226monthly0.5https://www.biopharmawatch.com/news/LLY/trulicity-dulaglutide-is-the-first-and-only-type-2-diabetes-medicine-approved-to-reduce-ca-lly-20200221monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-cowen-health-care-conference-eli-lilly-and-company-nyse-lly-will-p-lly-20200221monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-svb-leerink-global-healthcare-conference-eli-lilly-and-company-nys-lly-20200221monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-completes-acquisition-of-dermira-eli-lilly-and-company-nyse-lly-today-announced-the--lly-20200220monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-topline-results-for-solanezumab-from-the-dominantly-inherited-alzheimer-ne-lly-20200210monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-guggenheim-healthcare-talks-idea-forum-eli-lilly-and-company-nyse--lly-20200207monthly0.5https://www.biopharmawatch.com/news/LLY/chmp-recommends-approval-of-lilly-s-new-fast-acting-mealtime-insulin-to-improve-glycemic-c-lly-20200131monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-strong-fourth-quarter-and-full-year-2019-financial-results-updates-2020-guid-lly-20200130monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-incyte-announce-positive-top-line-results-from-the-north-american-breeze-ad5-pha-lly-20200130monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-receives-fda-priority-review-for-the-selpercatinib-new-drug-application-eli-lilly-an-lly-20200129monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-plans-donation-of-200-000-insulin-kwikpens-over-next-three-years-to-support-lower-in-lly-20200128monthly0.5https://www.biopharmawatch.com/news/LLY/us-fda-approves-only-triple-combination-tablet-with-jardiance-for-adults-with-type-2-diabe-lly-20200127monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-incyte-announce-top-line-results-from-phase-3-study-breeze-ad4-of-oral-selective-lly-20200127monthly0.5https://www.biopharmawatch.com/news/LLY/anat-hakim-to-join-lilly-as-general-counsel-eli-lilly-and-company-nyse-lly-announced-today-lly-20200124monthly0.5https://www.biopharmawatch.com/news/LLY/governor-cooper-announces-over-460-jobs-in-durham-as-eli-lilly-and-company-selects-north-c-lly-20200121monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-fourth-quarter-2019-financial-results-announce-lly-20200116monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-anna-kaiser-launch-30-day-thriver-challenge-to-increase-awareness-of-daily-stress-of-lly-20200115monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-expands-insulin-affordability-options-with-lower-priced-versions-of-humalog-mix75-25-lly-20200114monthly0.5https://www.biopharmawatch.com/news/LLY/tyvyt-sintilimab-injection-combined-with-alimta-pemetrexed-and-platinum-met-predefined-pri-lly-20200113monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-agreement-to-acquire-dermira-eli-lilly-and-company-nyse-lly-and-dermira-in-lly-20200110monthly0.5https://www.biopharmawatch.com/news/LLY/eli-lilly-and-company-in-collaboration-with-strateos-inc-launch-remote-controlled-robotic--lly-20200109monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-j-p-morgan-healthcare-conference-eli-lilly-and-company-nyse-lly-wi-lly-20200102monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-district-court-rules-in-favor-of-lilly-in-alimta-vitamin-regimen-patent-lawsuit-eli-li-lly-20191230monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-opens-phase-3-clinical-trial-in-ret-mutant-medullary-thyroid-cancer-eli-lilly-and-co-lly-20191230monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-launches-campaign-to-increase-awareness-of-insulin-cost-saving-options-in-an-open-le-lly-20191219monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-the-launch-of-triumph-the-first-long-term-real-world-evidence-study-of-emg-lly-20191218monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-2020-financial-guidance-updates-2019-guidance-eli-lilly-and-company-nyse-l-lly-20191217monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-15-percent-dividend-increase-the-board-of-directors-of-eli-lilly-and-compa-lly-20191216monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-integrate-dexcom-cgm-into-personalized-diabetes-management-system-eli-lilly-and-c-lly-20191216monthly0.5https://www.biopharmawatch.com/news/LLY/boehringer-ingelheim-and-lilly-provide-update-on-jardiance-phase-iii-exercise-ability-stud-lly-20191213monthly0.5https://www.biopharmawatch.com/news/LLY/chmp-issues-positive-opinion-to-expand-cyramza-ramucirumab-label-to-include-results-from-r-lly-20191213monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-opens-first-ever-randomized-phase-3-clinical-trial-in-treatment-nai-ve-ret-fusion-po-lly-20191211monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-presents-interim-clinical-data-from-loxo-305-dose-escalation-trial-in-b-cell-leukemi-lly-20191208monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-new-leadership-and-strategy-in-oncology-research-and-development-eli-lilly-lly-20191205monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-evercore-isi-2nd-annual-healthconx-conference-eli-lilly-and-compan-lly-20191202monthly0.5https://www.biopharmawatch.com/news/LLY/eli-lilly-and-company-unveils-shared-innovation-laboratory-in-south-san-francisco-eli-lill-lly-20191202monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-names-healthvoyager-as-winner-of-digital-health-innovation-challenge-for-inflammator-lly-20191202monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-400-million-capital-investment-in-manufacturing-facilities-in-indianapolis-lly-20191120monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-2020-financial-guidance-announcement-eli-lilly-lly-20191119monthly0.5https://www.biopharmawatch.com/news/LLY/interim-analysis-from-emprise-real-world-study-shows-jardiance-decreased-risk-of-hospitali-lly-20191117monthly0.5https://www.biopharmawatch.com/news/LLY/boehringer-ingelheim-and-lilly-announce-outcome-of-fda-advisory-committee-meeting-for-empa-lly-20191113monthly0.5https://www.biopharmawatch.com/news/LLY/boehringer-ingelheim-and-lilly-initiate-first-ever-study-to-assess-jardiance-in-people-hos-lly-20191112monthly0.5https://www.biopharmawatch.com/news/LLY/acr-2019-lilly-presents-52-week-head-to-head-spirit-h2h-data-from-taltz-ixekizumab-versus--lly-20191112monthly0.5https://www.biopharmawatch.com/news/LLY/acr-2019-lilly-presents-positive-new-data-from-coast-x-a-phase-3-study-of-taltz-ixekizumab-lly-20191112monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reinforces-its-commitment-to-rheumatology-through-data-showcased-at-the-acr-arp-annu-lly-20191108monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-the-pricing-terms-of-its-cash-tender-offer-for-up-to-2-000-006-000-aggrega-lly-20191107monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-the-early-tender-results-and-upsizing-of-its-pending-cash-tender-offer-to--lly-20191107monthly0.5https://www.biopharmawatch.com/news/LLY/eli-lilly-and-company-to-present-multiple-abstracts-for-loxo-305-at-ash-2019-eli-lilly-and-lly-20191106monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-credit-suisse-28th-annual-healthcare-conference-eli-lilly-and-comp-lly-20191104monthly0.5https://www.biopharmawatch.com/news/LLY/boehringer-ingelheim-and-lilly-modernise-alliance-to-focus-full-expertise-on-jardiance-in--lly-20191104monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-cash-tender-offer-for-up-to-2-0-billion-aggregate-principal-amount-of-its--lly-20191024monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-strong-third-quarter-2019-financial-results-raises-2019-eps-guidance-eli-lil-lly-20191023monthly0.5https://www.biopharmawatch.com/news/LLY/enrique-conterno-senior-vice-president-and-president-of-lilly-diabetes-and-lilly-usa-to-re-lly-20191023monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-fourth-quarter-2019-dividend-the-board-of-directors-of-eli-lilly-and-compan-lly-20191021monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-phase-3-study-in-patients-with-metastatic-pancreatic-cancer-did-not-meet-p-lly-20191016monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-presents-positive-results-for-taltz-ixekizumab-in-pediatric-patients-with-moderate-t-lly-20191012monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-reyvow-lasmiditan-the-first-and-only-medicine-in-a-new-class-of-acute-treatment-fo-lly-20191011monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-unveil-new-data-for-the-treatments-of-complex-dermatological-conditions-at-the-28-lly-20191008monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-cyramza-ramucirumab-phase-3-data-in-first-line-egfr-mutated-non-small-cell-lung-ca-lly-20191007monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-voluntary-delisting-from-euronext-paris-eli-lilly-and-company-nyse-lly-ann-lly-20191003monthly0.5https://www.biopharmawatch.com/news/LLY/new-head-to-head-data-show-taltz-ixekizumab-superiority-versus-tremfya-guselkumab-in-peopl-lly-20191003monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-third-quarter-2019-financial-results-announcem-lly-20191002monthly0.5https://www.biopharmawatch.com/news/LLY/verzenio-abemaciclib-significantly-extends-life-by-a-median-of-9-4-months-for-women-with-h-lly-20190929monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-positive-registrational-data-for-selpercatinib-loxo-292-in-heavily-pretrea-lly-20190929monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-oncology-to-present-robust-data-across-its-growing-portfolio-at-esmo-2019-eli-lilly--lly-20190923monthly0.5https://www.biopharmawatch.com/news/LLY/chmp-issues-positive-opinion-to-expand-trulicity-dulaglutide-label-to-include-results-from-lly-20190920monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-webcast-to-discuss-esmo-2019-presentations-eli-lilly-and-company-nyse-lly--lly-20190919monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-positive-results-for-selpercatinib-loxo-292-demonstrating-a-68-percent-obj-lly-20190909monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-pain-clinical-trial-protocol-selected-for-fda-complex-innovative-trial-designs-pil-lly-20190905monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-morgan-stanley-global-healthcare-conference-eli-lilly-and-company--lly-20190904monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-top-line-phase-3-results-for-oral-jak-inhibitor-baricitinib-in-combination-lly-20190823monthly0.5https://www.biopharmawatch.com/news/LLY/arbitration-panel-rules-in-favor-of-lilly-in-complaint-filed-by-adocia-a-chicago-based-arb-lly-20190822monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-webcast-to-discuss-world-conference-on-lung-cancer-presentation-eli-lilly--lly-20190819monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-launches-open-innovation-challenge-to-help-transform-inflammatory-bowel-disease-ibd--lly-20190814monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-superiority-of-taltz-ixekizumab-versus-tremfya-guselkumab-in-delivering-to-lly-20190813monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-court-of-appeals-rules-in-favor-of-lilly-in-alimta-alternate-salt-form-patent-lawsuit--lly-20190809monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-evidation-health-and-apple-study-shows-personal-digital-devices-may-help-in-the-iden-lly-20190808monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-leadership-changes-in-corporate-business-development-oncology-r-d-and-mana-lly-20190807monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-positive-results-for-emgality-galcanezumab-gnlm-from-the-conquer-study-in--lly-20190805monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-second-quarter-2019-financial-results-raises-2019-eps-guidance-eli-lilly-and-lly-20190730monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-verzenio-abemaciclib-significantly-extended-life-in-women-with-hr-her2-advanced-br-lly-20190730monthly0.5https://www.biopharmawatch.com/news/LLY/baqsimi-glucagon-nasal-powder-3-mg-the-first-and-only-nasally-administered-glucagon-to-tre-lly-20190724monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-overcome-observational-study-reveals-inconsistent-and-sub-optimal-treatment-landsc-lly-20190712monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-changes-in-senior-leadership-eli-lilly-and-company-nyse-lly-today-announce-lly-20190711monthly0.5https://www.biopharmawatch.com/news/LLY/new-england-journal-of-medicine-publishes-positive-phase-3-data-for-emgality-galcanezumab--lly-20190711monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-upcoming-presentation-of-new-data-indicating-rise-in-opioid-use-for-migrai-lly-20190710monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-second-quarter-2019-financial-results-announce-lly-20190709monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-award-11-trial-studying-higher-investigational-doses-of-trulicity-dulaglutide-demo-lly-20190626monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-fda-grants-fast-track-designation-to-empagliflozin-for-the-treatment-of-chronic-heart--lly-20190626monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-third-quarter-2019-dividend-the-board-of-directors-of-eli-lilly-and-company-lly-20190619monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-presents-positive-results-for-taltz-ixekizumab-vs-humira-adalimumab-in-a-head-to-hea-lly-20190614monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-5-year-sustained-efficacy-and-safety-results-for-taltz-ixekizumab-in-pati-lly-20190611monthly0.5https://www.biopharmawatch.com/news/LLY/detailed-findings-from-carolina-outcome-trial-support-long-term-cardiovascular-safety-prof-lly-20190610monthly0.5https://www.biopharmawatch.com/news/LLY/new-analysis-shows-cardiorenal-risk-reductions-of-jardiance-are-consistent-in-adults-with--lly-20190610monthly0.5https://www.biopharmawatch.com/news/LLY/trulicity-dulaglutide-significantly-reduced-major-cardiovascular-events-for-broad-range-of-lly-20190609monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-ultra-rapid-lispro-provided-similar-a1c-reductions-compared-to-humalog-insulin-lis-lly-20190609monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-tirzepatide-demonstrates-benefits-in-data-presented-at-the-american-diabetes-assoc-lly-20190608monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-new-data-and-commitment-to-patient-centered-solutions-at-the-annual-europ-lly-20190606monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-showcase-scientific-innovation-within-dermatology-portfolio-at-24th-world-congres-lly-20190605monthly0.5https://www.biopharmawatch.com/news/LLY/fda-approves-emgality-galcanezumab-gnlm-as-the-first-and-only-medication-for-the-treatment-lly-20190604monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-fda-accepts-new-drug-application-for-triple-combination-tablet-for-adults-with-type-2--lly-20190604monthly0.5https://www.biopharmawatch.com/news/LLY/hurricane-season-is-almost-here-are-you-ready-the-2019-atlantic-hurricane-season-begins-ju-lly-20190531monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-goldman-sachs-global-healthcare-conference-eli-lilly-and-company-n-lly-20190530monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-webcast-to-discuss-ada-presentations-and-diabetes-portfolio-eli-lilly-and--lly-20190529monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-licensing-agreement-for-non-opioid-pain-asset-from-centrexion-therapeutics-lly-20190528monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-lower-priced-insulin-now-available-eli-lilly-and-company-s-nyse-lly-insulin-lispro-lly-20190522monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-ubs-global-healthcare-conference-eli-lilly-and-company-nyse-lly-wi-lly-20190516monthly0.5https://www.biopharmawatch.com/news/LLY/data-presentations-at-asco-2019-highlight-lilly-s-targeted-approach-to-developing-treatmen-lly-20190515monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-bank-of-america-merrill-lynch-health-care-conference-eli-lilly-and-lly-20190515monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-cyramza-ramucirumab-becomes-first-fda-approved-biomarker-driven-therapy-in-patient-lly-20190513monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-second-quarter-2019-dividend-the-board-of-directors-of-eli-lilly-and-compan-lly-20190506monthly0.5https://www.biopharmawatch.com/news/LLY/aan-2019-pooled-analyses-of-two-emgality-galcanezumab-gnlm-phase-3-studies-show-reduction--lly-20190506monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-new-data-at-aan-2019-on-emgality-galcanezumab-gnlm-and-lasmiditan-reinfor-lly-20190502monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-solid-first-quarter-2019-financial-results-updates-2019-guidance-to-reflect--lly-20190430monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-court-of-appeals-rules-in-favor-of-lilly-in-alimta-vitamin-regimen-patent-lawsuit-eli--lly-20190426monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-establish-an-access-program-for-patients-as-it-prepares-to-withdraw-lartruvo-from-lly-20190425monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-sale-of-legacy-antibiotics-brands-and-manufacturing-facility-in-china-eli--lly-20190422monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-positive-top-line-results-for-coast-x-a-52-week-placebo-controlled-study-o-lly-20190422monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-avidity-biosciences-announce-licensing-and-research-collaboration-eli-lilly-and--lly-20190422monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-first-quarter-2019-financial-results-announcem-lly-20190410monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-immunext-announce-licensing-and-research-collaboration-eli-lilly-and-company-nys-lly-20190326monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-final-results-of-elanco-exchange-offer-eli-lilly-and-company-nyse-lly-toda-lly-20190313monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-cyramza-ramucirumab-phase-3-relay-trial-met-primary-endpoint-significantly-improvi-lly-20190312monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-preliminary-results-of-elanco-exchange-offer-eli-lilly-and-company-nyse-ll-lly-20190311monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-barclays-global-healthcare-conference-eli-lilly-and-company-nyse-l-lly-20190308monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-cowen-health-care-conference-eli-lilly-and-company-nyse-lly-will-p-lly-20190307monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-final-exchange-ratio-of-4-5121-for-elanco-exchange-offer-eli-lilly-and-com-lly-20190307monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-receives-fda-priority-review-designation-for-emgality-galcanezumab-gnlm-injection-fo-lly-20190305monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-introduce-lower-priced-insulin-reinforcing-our-commitment-to-lower-out-of-pocket--lly-20190304monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-data-demonstrating-continued-scientific-advancements-in-broad-dermatology-lly-20190301monthly0.5https://www.biopharmawatch.com/news/LLY/pfizer-and-lilly-announce-top-line-results-from-phase-3-study-of-tanezumab-in-chronic-low--lly-20190219monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-completes-acquisition-of-loxo-oncology-eli-lilly-and-company-nyse-lly-today-announce-lly-20190215monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-leerink-partners-global-healthcare-conference-eli-lilly-and-compan-lly-20190214monthly0.5https://www.biopharmawatch.com/news/LLY/boehringer-ingelheim-and-lilly-announce-the-carolina-cardiovascular-outcome-trial-of-tradj-lly-20190214monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-guggenheim-healthcare-talks-idea-forum-eli-lilly-and-company-nyse--lly-20190208monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-will-initiate-divestiture-of-its-remaining-interest-in-elanco-animal-health-eli-lill-lly-20190208monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-strong-fourth-quarter-and-full-year-2018-financial-results-lowers-2019-eps-g-lly-20190206monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-loxo-oncology-announce-expiration-of-hsr-act-waiting-period-in-connection-with-p-lly-20190201monthly0.5https://www.biopharmawatch.com/news/LLY/fda-expands-lilly-s-alimta-pemetrexed-label-with-combination-of-keytruda-pembrolizumab-and-lly-20190131monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-revises-date-for-fourth-quarter-2018-financial-results-announcement-eli-lilly-and-co-lly-20190130monthly0.5https://www.biopharmawatch.com/news/LLY/government-employees-affected-by-federal-shutdown-encouraged-to-contact-lilly-diabetes-sol-lly-20190123monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-fourth-quarter-2018-financial-results-announce-lly-20190121monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-phase-3-reach-2-trial-data-published-in-the-lancet-oncology-shows-improvement-in-ove-lly-20190118monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-results-of-phase-3-soft-tissue-sarcoma-study-of-lartruvo-eli-lilly-and-compa-lly-20190118monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-agreement-to-acquire-loxo-oncology-acquisition-will-broaden-the-scope-of-l-lly-20190107monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-j-p-morgan-healthcare-conference-eli-lilly-and-company-nyse-lly-wi-lly-20190103monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-financial-guidance-reviews-commercial-performance-and-highlights-promising-lly-20181219monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-15-percent-dividend-increase-the-board-of-directors-of-eli-lilly-and-compa-lly-20181219monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-aduro-biotech-announce-research-collaboration-and-license-agreement-to-develop-n-lly-20181218monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-publication-of-analyses-showing-benefit-of-the-addition-of-verzenio-abemac-lly-20181218monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-positive-top-line-results-for-taltz-ixekizumab-vs-humira-adalimumab-in-a-h-lly-20181217monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-acquire-pre-clinical-pain-program-from-hydra-biosciences-eli-lilly-and-company-ny-lly-20181214monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-evidation-health-expand-collaboration-to-analyze-data-from-smartphones-and-conne-lly-20181214monthly0.5https://www.biopharmawatch.com/news/LLY/boehringer-ingelheim-and-lilly-partner-with-duke-clinical-research-institute-to-advance-mu-lly-20181213monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-ac-immune-announce-license-and-collaboration-agreement-multi-year-agreement-focu-lly-20181212monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-clinical-data-for-verzenio-abemaciclib-and-real-world-evidence-across-hr--lly-20181129monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-announce-2019-financial-guidance-highlight-late-stage-pipeline-opportunities-and--lly-20181127monthly0.5https://www.biopharmawatch.com/news/LLY/jardiance-recommended-as-preferred-sglt2-inhibitor-for-adults-with-type-2-diabetes-and-est-lly-20181126monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-credit-suisse-27th-annual-healthcare-conference-eli-lilly-and-comp-lly-20181108monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-delivers-solid-third-quarter-2018-results-revises-eps-guidance-eli-lilly-and-company-lly-20181106monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-nextcure-announce-collaboration-to-discover-and-develop-novel-immuno-oncology-me-lly-20181105monthly0.5https://www.biopharmawatch.com/news/LLY/trulicitya-dulaglutide-demonstrates-superiority-in-reduction-of-cardiovascular-events-for--lly-20181105monthly0.5https://www.biopharmawatch.com/news/LLY/initial-results-from-emprise-real-world-evidence-study-show-jardiance-was-associated-with--lly-20181105monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-dicerna-announce-rnai-licensing-and-research-collaboration-eli-lilly-and-company-lly-20181029monthly0.5https://www.biopharmawatch.com/news/LLY/acr-2018-lilly-announces-positive-results-for-two-phase-3-studies-of-taltz-ixekizumab-in-a-lly-20181022monthly0.5https://www.biopharmawatch.com/news/LLY/acr-2018-lilly-shares-updated-safety-analysis-of-olumiant-baricitinib-in-patients-with-mod-lly-20181021monthly0.5https://www.biopharmawatch.com/news/LLY/karen-walker-elected-to-lilly-board-of-directors-the-board-of-directors-of-eli-lilly-and-c-lly-20181016monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-fourth-quarter-2018-dividend-the-board-of-directors-of-eli-lilly-and-compan-lly-20181015monthly0.5https://www.biopharmawatch.com/news/LLY/new-data-showcasing-lilly-s-growing-commitment-in-rheumatology-to-be-featured-at-the-acr-a-lly-20181015monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-metastatic-breast-cancer-advocates-launch-thriver-movement-to-elevate-understand-lly-20181012monthly0.5https://www.biopharmawatch.com/news/LLY/new-analysis-estimates-the-positive-impact-of-jardiance-on-life-expectancy-in-adults-with--lly-20181010monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-new-data-from-oncology-portfolio-at-esmo-2018-congress-showcasing-patient-lly-20181008monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-investigational-dual-gip-and-glp-1-receptor-agonist-shows-significant-reduction-in-lly-20181004monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-third-quarter-2018-financial-results-announcem-lly-20181003monthly0.5https://www.biopharmawatch.com/news/LLY/results-from-two-phase-3-studies-show-lilly-s-ultra-rapid-lispro-urli-met-primary-efficacy-lly-20181002monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-emgality-galcanezumab-gnlm-receives-u-s-fda-approval-for-the-preventive-treatment--lly-20180927monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-receives-positive-chmp-opinion-for-emgality-galcanezumab-for-the-prophylaxis-of-migr-lly-20180921monthly0.5https://www.biopharmawatch.com/news/LLY/new-lilly-diabetes-center-of-excellence-established-at-the-indiana-bioscience-research-ins-lly-20180913monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-initiation-of-ixora-r-head-to-head-trial-comparing-taltz-and-tremfya-in-pa-lly-20180910monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-webcast-to-discuss-easd-presentations-eli-lilly-and-company-nyse-lly-will--lly-20180906monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-positive-phase-3-results-in-study-of-flortaucipir-pet-imaging-agent-eli-li-lly-20180905monthly0.5https://www.biopharmawatch.com/news/LLY/anne-white-promoted-to-president-of-lilly-oncology-eli-lilly-and-company-nyse-lly-today-an-lly-20180830monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-morgan-stanley-global-healthcare-conference-eli-lilly-and-company--lly-20180827monthly0.5https://www.biopharmawatch.com/news/LLY/elanco-animal-health-announces-pricing-of-2-0-billion-of-senior-notes-eli-lilly-and-compan-lly-20180814monthly0.5https://www.biopharmawatch.com/news/LLY/elanco-animal-health-files-ipo-registration-statement-eli-lilly-and-company-nyse-lly-today-lly-20180802monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-diabetes-solution-center-now-open-to-help-people-with-insulin-affordability-the-lill-lly-20180801monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-extension-of-cancer-research-collaboration-with-dana-farber-cancer-institu-lly-20180730monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-delivers-strong-second-quarter-2018-results-revises-eps-guidance-eli-lilly-and-compa-lly-20180724monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-separate-elanco-animal-health-with-initial-public-offering-eli-lilly-and-company--lly-20180724monthly0.5https://www.biopharmawatch.com/news/LLY/highlights-from-lilly-s-alzheimer-s-disease-pipeline-at-the-alzheimer-s-association-intern-lly-20180720monthly0.5https://www.biopharmawatch.com/news/LLY/study-published-in-the-lancet-shows-benefit-of-baricitinib-4-mg-for-the-treatment-of-syste-lly-20180719monthly0.5https://www.biopharmawatch.com/news/LLY/boehringer-ingelheim-and-lilly-announce-tradjenta-s-carmelina-cardiovascular-outcome-trial-lly-20180719monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-once-weekly-trulicity-dulaglutide-label-updated-to-include-data-showing-benefits-f-lly-20180719monthly0.5https://www.biopharmawatch.com/news/LLY/new-lilly-diabetes-helpline-to-assist-people-seeking-solutions-to-insulin-affordability-st-lly-20180712monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-initiation-of-the-observational-survey-of-the-epidemiology-treatment-and-c-lly-20180629monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-positive-top-line-results-for-second-phase-3-study-of-taltz-ixekizumab-in--lly-20180628monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-second-quarter-2018-financial-results-announce-lly-20180628monthly0.5https://www.biopharmawatch.com/news/LLY/ahs-2018-lilly-s-emgality-galcanezumab-gnlm-significantly-reduced-monthly-migraine-headach-lly-20180627monthly0.5https://www.biopharmawatch.com/news/LLY/ahs-2018-lilly-highlights-positive-phase-3-results-from-the-largest-controlled-preventive--lly-20180627monthly0.5https://www.biopharmawatch.com/news/LLY/first-ever-study-of-lilly-s-humulin-r-u-500-administered-in-an-insulin-pump-shows-improved-lly-20180625monthly0.5https://www.biopharmawatch.com/news/LLY/boehringer-ingelheim-and-lilly-announce-positive-top-line-phase-iii-data-results-for-empag-lly-20180625monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-phase-3-data-at-ahs-2018-highlighting-innovative-potential-treatments-for-lly-20180625monthly0.5https://www.biopharmawatch.com/news/LLY/real-world-data-show-advantages-in-people-treated-with-lilly-s-once-weekly-trulicity-dulag-lly-20180624monthly0.5https://www.biopharmawatch.com/news/LLY/new-data-presented-at-the-american-diabetes-association-78th-scientific-sessions-reinforce-lly-20180623monthly0.5https://www.biopharmawatch.com/news/LLY/jardiance-reduced-risk-of-kidney-disease-progression-in-adults-with-type-2-diabetes-and-es-lly-20180623monthly0.5https://www.biopharmawatch.com/news/LLY/investigational-doses-of-lilly-s-once-weekly-trulicity-dulaglutide-show-promise-in-deliver-lly-20180623monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-completes-acquisition-of-armo-biosciences-eli-lilly-and-company-nyse-lly-today-annou-lly-20180622monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-district-court-rules-in-favor-of-lilly-in-alimta-vitamin-regimen-patent-lawsuit-eli-li-lly-20180622monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-third-quarter-2018-dividend-the-board-of-directors-of-eli-lilly-and-company-lly-20180618monthly0.5https://www.biopharmawatch.com/news/LLY/update-on-phase-3-clinical-trials-of-lanabecestat-for-alzheimer-s-disease-eli-lilly-and-co-lly-20180612monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-unveil-new-data-at-the-annual-european-congress-of-rheumatology-furthering-commit-lly-20180611monthly0.5https://www.biopharmawatch.com/news/LLY/ddw-2018-patients-with-moderate-to-severe-ulcerative-colitis-achieved-clinical-and-endosco-lly-20180605monthly0.5https://www.biopharmawatch.com/news/LLY/fda-expands-lilly-s-alimta-pemetrexed-label-to-include-combination-with-keytruda-pembroliz-lly-20180605monthly0.5https://www.biopharmawatch.com/news/LLY/fda-approves-olumiant-baricitinib-2-mg-tablets-for-the-treatment-of-adults-with-moderately-lly-20180601monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-goldman-sachs-global-healthcare-conference-eli-lilly-and-company-n-lly-20180531monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-jefferies-global-healthcare-conference-eli-lilly-and-company-nyse--lly-20180530monthly0.5https://www.biopharmawatch.com/news/LLY/sue-mahony-to-retire-as-president-of-lilly-oncology-eli-lilly-and-company-nyse-lly-announc-lly-20180523monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-taltz-ixekizumab-receives-the-first-u-s-fda-approval-for-label-update-to-include-d-lly-20180522monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-data-at-asco-illustrate-patient-driven-advances-in-cancer-care-eli-lilly-and-company-lly-20180516monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-galcanezumab-meets-primary-endpoint-in-phase-3-study-evaluating-galcanezumab-for-t-lly-20180515monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-acquire-aurka-pharma-eli-lilly-and-company-nyse-lly-today-announced-an-agreement--lly-20180514monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-ubs-global-healthcare-conference-eli-lilly-and-company-nyse-lly-wi-lly-20180511monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-agreement-to-acquire-armo-biosciences-eli-lilly-and-company-nyse-lly-and-a-lly-20180510monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-second-quarter-2018-dividend-the-board-of-directors-of-eli-lilly-and-compan-lly-20180507monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-local-partners-launch-diabetes-prevention-and-management-pilot-in-three-underser-lly-20180501monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-bank-of-america-merrill-lynch-health-care-conference-eli-lilly-and-lly-20180427monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-strong-first-quarter-2018-results-raises-eps-guidance-eli-lilly-and-company--lly-20180424monthly0.5https://www.biopharmawatch.com/news/LLY/fda-advisory-committee-recommends-the-approval-of-baricitinib-2mg-but-not-4mg-for-the-trea-lly-20180423monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-phase-3-data-at-aan-2018-reinforcing-commitment-to-new-innovative-therapi-lly-20180420monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-additional-top-line-results-from-cyramza-ramucirumab-phase-3-range-study-in--lly-20180420monthly0.5https://www.biopharmawatch.com/news/LLY/boehringer-ingelheim-and-lilly-announce-an-academic-collaboration-with-university-of-oxfor-lly-20180416monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-sigilon-therapeutics-announce-strategic-collaboration-to-develop-encapsulated-ce-lly-20180404monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-cyramza-ramucirumab-phase-3-reach-2-study-in-second-line-hepatocellular-ca-lly-20180404monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-first-quarter-2018-financial-results-announcem-lly-20180404monthly0.5https://www.biopharmawatch.com/news/LLY/maura-dickler-m-d-to-become-vice-president-of-late-phase-development-at-lilly-oncology-eli-lly-20180309monthly0.5https://www.biopharmawatch.com/news/LLY/efsd-jdrf-and-lilly-extend-collaboration-supporting-type-1-diabetes-research-the-european--lly-20180308monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-receives-additional-fda-approval-for-verzenio-abemaciclib-as-initial-treatment-for-a-lly-20180226monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-barclays-global-healthcare-conference-eli-lilly-and-company-nyse-l-lly-20180221monthly0.5https://www.biopharmawatch.com/news/LLY/survey-reveals-many-people-with-migraine-live-with-pain-nearly-half-of-every-month-li-lill-lly-20180220monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-cowen-health-care-conference-eli-lilly-and-company-nyse-lly-will-p-lly-20180220monthly0.5https://www.biopharmawatch.com/news/LLY/aad-2018-treatment-with-lilly-s-taltz-ixekizumab-resulted-in-improvement-in-impact-of-geni-lly-20180219monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-showcase-new-data-for-taltz-ixekizumab-and-other-products-across-immunology-pipel-lly-20180214monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-positive-top-line-phase-3-results-for-taltz-ixekizumab-in-ankylosing-spond-lly-20180213monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-strong-fourth-quarter-and-full-year-2017-revenue-growth-increases-2018-eps-g-lly-20180131monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-at-leerink-partners-global-healthcare-conference-eli-lilly-and-company-ny-lly-20180126monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-fourth-quarter-2017-financial-results-announce-lly-20180105monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-at-j-p-morgan-healthcare-conference-eli-lilly-and-company-nyse-lly-will-p-lly-20180102monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-goldman-sachs-healthcare-ceos-unscripted-conference-eli-lilly-and--lly-20171218monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-2018-financial-guidance-and-enhances-outlook-through-2020-eli-lilly-and-co-lly-20171213monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-8-percent-dividend-increase-the-board-of-directors-of-eli-lilly-and-compan-lly-20171211monthly0.5https://www.biopharmawatch.com/news/LLY/fda-accepts-biologics-license-application-bla-to-review-galcanezumab-for-the-prevention-of-lly-20171211monthly0.5https://www.biopharmawatch.com/news/LLY/kimberly-blackwell-m-d-to-become-vice-president-of-early-phase-development-and-immuno-onco-lly-20171211monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-top-line-results-from-cyramza-ramucirumab-phase-3-study-in-first-line-advanc-lly-20171208monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-initiates-clinical-trial-to-evaluate-the-functionality-and-safety-of-its-automated-i-lly-20171205monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-taltz-ixekizumab-receives-u-s-fda-approval-for-the-treatment-of-active-psoriatic-a-lly-20171201monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-2018-financial-guidance-announcement-eli-lilly-lly-20171120monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-evercore-isi-2017-biopharma-catalyst-deep-dive-conference-eli-lill-lly-20171117monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-appoints-philip-johnson-to-senior-vice-president-and-treasurer-eli-lilly-and-company-lly-20171113monthly0.5https://www.biopharmawatch.com/news/LLY/new-data-on-forteo-teriparatide-rdna-origin-injection-showed-reduced-risk-for-new-vertebra-lly-20171109monthly0.5https://www.biopharmawatch.com/news/LLY/acr-arhp-2017-long-term-use-of-lilly-s-taltz-ixekizumab-shows-efficacy-improvements-in-pso-lly-20171108monthly0.5https://www.biopharmawatch.com/news/LLY/acr-arhp-2017-new-analysis-shows-rheumatoid-arthritis-patients-treated-with-baricitinib-re-lly-20171105monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-credit-suisse-26th-annual-healthcare-conference-eli-lilly-and-comp-lly-20171025monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-third-quarter-results-announces-strategic-review-of-elanco-animal-health-eli-lly-20171024monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-72-million-investment-in-diabetes-manufacturing-in-indianapolis-eli-lilly--lly-20171023monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-curevac-announce-global-collaboration-to-develop-mrna-cancer-vaccines-eli-lilly--lly-20171018monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-fourth-quarter-2017-dividend-the-board-of-directors-of-eli-lilly-and-compan-lly-20171016monthly0.5https://www.biopharmawatch.com/news/LLY/rapidly-progressing-advanced-non-small-cell-lung-cancer-patients-shown-to-benefit-in-new-c-lly-20171016monthly0.5https://www.biopharmawatch.com/news/LLY/fda-grants-priority-review-for-potential-new-indication-for-lilly-s-verzenio-abemaciclib-a-lly-20171012monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-topline-results-from-phase-3-juniper-trial-evaluating-verzenio-abemaciclib-i-lly-20171010monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-monarch-3-study-published-in-journal-of-clinical-oncology-demonstrates-benefit-of-ve-lly-20171006monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-patent-and-trademark-office-rules-in-lilly-s-favor-on-alimta-vitamin-regimen-patent-el-lly-20171005monthly0.5https://www.biopharmawatch.com/news/LLY/additional-delivery-of-insulin-ready-for-distribution-in-puerto-rico-today-a-new-shipment--lly-20171005monthly0.5https://www.biopharmawatch.com/news/LLY/humalog-junior-kwikpen-now-available-in-the-u-s-for-people-with-diabetes-humalog-junior-kw-lly-20171004monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-third-quarter-2017-financial-results-announcem-lly-20171002monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-senior-leadership-appointments-for-finance-research-development-and-manufa-lly-20170929monthly0.5https://www.biopharmawatch.com/news/LLY/geisinger-and-boehringer-ingelheim-collaborate-to-create-a-predictive-model-to-help-improv-lly-20170925monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-new-data-for-olumiant-baricitinib-and-taltz-ixekizumab-at-the-european-ac-lly-20170911monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-builds-upon-body-of-clinical-evidence-for-cyramza-ramucirumab-with-phase-3-range-dat-lly-20170910monthly0.5https://www.biopharmawatch.com/news/LLY/ihc-2017-lilly-s-lasmiditan-significantly-reduces-pain-in-patients-with-migraine-eli-lilly-lly-20170909monthly0.5https://www.biopharmawatch.com/news/LLY/ihc-2017-lilly-s-galcanezumab-demonstrates-positive-long-term-safety-results-for-up-to-12--lly-20170908monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-takes-steps-to-streamline-business-invest-in-new-medicines-and-drive-growth-eli-lill-lly-20170907monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-new-data-for-galcanezumab-and-lasmiditan-at-the-18th-congress-of-the-inte-lly-20170906monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-file-baricitinib-resubmission-to-u-s-fda-before-end-of-january-2018-eli-lilly-and-lly-20170830monthly0.5https://www.biopharmawatch.com/news/LLY/new-phase-3-data-for-abemaciclib-and-ramucirumab-presented-at-esmo-2017-congress-eli-lilly-lly-20170829monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-morgan-stanley-global-healthcare-conference-eli-lilly-and-company--lly-20170828monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-positive-results-for-second-phase-3-study-of-lasmiditan-for-the-acute-trea-lly-20170804monthly0.5https://www.biopharmawatch.com/news/LLY/boehringer-ingelheim-and-lilly-to-support-new-american-college-of-cardiology-program-to-hi-lly-20170731monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-second-quarter-results-eli-lilly-and-company-nyse-lly-today-announced-financ-lly-20170725monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-incyte-provide-update-on-baricitinib-eli-lilly-and-company-nyse-lly-and-incyte-c-lly-20170725monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reaches-settlement-agreement-in-u-s-cialis-patent-litigation-eli-lilly-and-company-n-lly-20170712monthly0.5https://www.biopharmawatch.com/news/LLY/eli-lilly-and-company-to-present-more-than-40-abstracts-at-the-alzheimer-s-association-int-lly-20170712monthly0.5https://www.biopharmawatch.com/news/LLY/renowned-television-personality-don-francisco-introduces-new-initiative-to-help-dispel-myt-lly-20170710monthly0.5https://www.biopharmawatch.com/news/LLY/la-popular-estrella-de-televisio-n-don-francisco-presenta-una-nueva-iniciativa-para-ayudar-lly-20170710monthly0.5https://www.biopharmawatch.com/news/LLY/fda-grants-priority-review-for-lilly-s-abemaciclib-for-the-treatment-of-advanced-breast-ca-lly-20170710monthly0.5https://www.biopharmawatch.com/news/LLY/uk-supreme-court-rules-in-lilly-s-favor-on-alimta-vitamin-regimen-patents-eli-lilly-and-co-lly-20170707monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-second-quarter-2017-financial-results-announce-lly-20170706monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-purdue-university-announce-strategic-research-collaboration-eli-lilly-and-compan-lly-20170706monthly0.5https://www.biopharmawatch.com/news/LLY/japan-ministry-of-health-labor-and-welfare-mhlw-grants-marketing-approval-for-olumiant-bar-lly-20170703monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-diabetes-brings-an-extra-splash-of-summertime-fun-and-inspiration-to-diabetes-camps--lly-20170627monthly0.5https://www.biopharmawatch.com/news/LLY/eli-lilly-and-company-unveils-expanded-biotechnology-center-in-san-diego-eli-lilly-and-com-lly-20170621monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-third-quarter-2017-dividend-the-board-of-directors-of-eli-lilly-and-company-lly-20170619monthly0.5https://www.biopharmawatch.com/news/LLY/eular-2017-lilly-s-taltz-ixekizumab-demonstrated-no-progression-or-minimal-progression-of--lly-20170616monthly0.5https://www.biopharmawatch.com/news/LLY/new-safety-and-long-term-efficacy-data-from-baricitinib-clinical-trials-in-patients-with-m-lly-20170616monthly0.5https://www.biopharmawatch.com/news/LLY/eular-2017-lilly-s-taltz-ixekizumab-demonstrated-significant-improvements-in-disease-signs-lly-20170615monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-new-data-on-olumiant-baricitinib-in-rheumatoid-arthritis-and-taltz-ixekiz-lly-20170613monthly0.5https://www.biopharmawatch.com/news/LLY/jardiance-empagliflozin-tablets-to-be-studied-in-chronic-kidney-disease-boehringer-ingelhe-lly-20170612monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-galcanezumab-significantly-reduces-number-of-migraine-headache-days-for-patients-w-lly-20170610monthly0.5https://www.biopharmawatch.com/news/LLY/idf-in-partnership-with-lilly-announces-second-phase-of-bridges-programme-funding-for-tran-lly-20170609monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-late-breaking-data-for-galcanezumab-and-lasmiditan-at-the-american-headac-lly-20170608monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-webcast-to-discuss-pain-management-portfolio-eli-lilly-and-company-nyse-ll-lly-20170608monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-strategic-collaboration-with-keybioscience-ag-eli-lilly-and-company-nyse-l-lly-20170608monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-builds-upon-body-of-data-for-abemaciclib-with-phase-3-monarch-2-data-demonstrating-s-lly-20170603monthly0.5https://www.biopharmawatch.com/news/LLY/boehringer-ingelheim-and-lilly-diabetes-alliance-to-present-33-abstracts-at-the-american-d-lly-20170601monthly0.5https://www.biopharmawatch.com/news/LLY/derica-rice-to-retire-as-lilly-chief-financial-officer-eli-lilly-and-company-nyse-lly-anno-lly-20170601monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-goldman-sachs-global-healthcare-conference-eli-lilly-and-company-n-lly-20170531monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-phase-3-range-urothelial-cancer-trial-of-cyramza-ramucirumab-met-primary-e-lly-20170531monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-results-from-pivotal-breast-cancer-study-of-abemaciclib-and-new-portfolio-lly-20170517monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-positive-results-for-three-phase-3-studies-of-galcanezumab-for-the-prevent-lly-20170512monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-bernstein-strategic-decisions-conference-eli-lilly-and-company-nys-lly-20170510monthly0.5https://www.biopharmawatch.com/news/LLY/leigh-ann-pusey-joins-lilly-as-senior-vice-president-of-corporate-affairs-and-communicatio-lly-20170510monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-ubs-global-healthcare-conference-eli-lilly-and-company-nyse-lly-wi-lly-20170503monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-webcast-to-discuss-oncology-pipeline-eli-lilly-and-company-nyse-lly-will-c-lly-20170502monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-second-quarter-2017-dividend-the-board-of-directors-of-eli-lilly-and-compan-lly-20170501monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-first-quarter-2017-results-eli-lilly-and-company-nyse-lly-today-announced-fi-lly-20170425monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-phase-3-monarch-3-breast-cancer-study-of-abemaciclib-demonstrated-superior-lly-20170424monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-data-for-galcanezumab-for-the-prevention-of-migraine-at-the-american-acad-lly-20170420monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-fda-issues-complete-response-letter-for-baricitinib-eli-lilly-and-company-nyse-lly-and-lly-20170414monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-first-quarter-2017-financial-results-announcem-lly-20170411monthly0.5https://www.biopharmawatch.com/news/LLY/life-with-type-1-diabetes-made-a-little-easier-through-lilly-diabetes-scholarship-donation-lly-20170407monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-ohio-university-heritage-college-of-osteopathic-medicine-partner-on-rotation-pro-lly-20170404monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-850-million-investment-in-u-s-capital-projects-in-2017-eli-lilly-and-compa-lly-20170324monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-the-william-sansum-diabetes-center-announce-a-five-year-research-collaboration-e-lly-20170323monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-phase-3-monarch-2-breast-cancer-study-of-abemaciclib-met-primary-endpoint--lly-20170320monthly0.5https://www.biopharmawatch.com/news/LLY/new-head-to-head-data-shows-significantly-higher-response-rates-for-lilly-s-taltz-ixekizum-lly-20170304monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-diabetes-becomes-official-diabetes-health-partner-of-nascar-nascar-and-lilly-diabete-lly-20170303monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-changes-in-senior-management-eli-lilly-and-company-nyse-lly-today-announce-lly-20170302monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-completes-acquisition-of-colucid-pharmaceuticals-eli-lilly-and-company-nyse-lly-toda-lly-20170301monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-new-data-for-taltz-ixekizumab-in-psoriasis-and-psoriatic-arthritis-at-the-lly-20170228monthly0.5https://www.biopharmawatch.com/news/LLY/additional-results-from-pivotal-ra-beam-study-published-in-new-england-journal-of-medicine-lly-20170215monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-at-leerink-partners-global-healthcare-conference-eli-lilly-and-company-ny-lly-20170209monthly0.5https://www.biopharmawatch.com/news/LLY/carolyn-r-bertozzi-ph-d-elected-to-lilly-board-of-directors-the-board-of-directors-of-eli--lly-20170209monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-at-cowen-health-care-conference-eli-lilly-and-company-nyse-lly-will-prese-lly-20170208monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-trulicity-dulaglutide-label-updated-to-include-use-in-combination-with-basal-insul-lly-20170208monthly0.5https://www.biopharmawatch.com/news/LLY/japan-ip-high-court-rules-in-lilly-s-favor-on-alimta-vitamin-regimen-patents-eli-lilly-and-lly-20170202monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-fourth-quarter-and-full-year-2016-results-eli-lilly-and-company-nyse-lly-tod-lly-20170131monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-revises-time-for-conference-call-for-fourth-quarter-2016-financial-results-announcem-lly-20170130monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-colucid-pharmaceuticals-announce-agreement-for-lilly-to-acquire-colucid-eli-lill-lly-20170118monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-fda-extends-review-period-for-baricitinib-an-investigational-rheumatoid-arthritis-trea-lly-20170113monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-court-of-appeals-rules-in-lilly-s-favor-on-alimta-vitamin-regimen-patent-eli-lilly-and-lly-20170112monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-merck-expand-immuno-oncology-collaboration-eli-lilly-and-company-nyse-lly-today--lly-20170111monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-adjust-organization-and-leadership-structure-to-better-align-with-growth-opportun-lly-20170105monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-fourth-quarter-2016-financial-results-announce-lly-20170105monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-fda-approves-supplemental-new-drug-applications-to-include-landmark-data-in-product-la-lly-20170104monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-at-j-p-morgan-healthcare-conference-eli-lilly-and-company-nyse-lly-will-p-lly-20170103monthly0.5https://www.biopharmawatch.com/news/LLY/chmp-recommends-approval-of-lilly-s-baricitinib-for-the-treatment-of-adults-with-moderate--lly-20161216monthly0.5https://www.biopharmawatch.com/news/LLY/boehringer-ingelheim-and-lilly-welcome-new-recommendation-for-jardiance-empagliflozin-tabl-lly-20161216monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-provides-2017-financial-guidance-and-2016-update-reaffirms-financial-expectations-th-lly-20161215monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-program-to-provide-insulin-at-discounted-prices-eli-lilly-and-company-nyse-lly-20161213monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-dividend-increase-the-board-of-directors-of-eli-lilly-and-company-nyse-lly-lly-20161212monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-fda-approves-synjardy-xr-empagliflozin-metformin-hydrochloride-extended-release-tablet-lly-20161212monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-astrazeneca-to-develop-second-potentially-disease-modifying-treatment-for-alzhei-lly-20161209monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-detailed-results-of-solanezumab-phase-3-expedition3-study-at-the-clinical--lly-20161208monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-presents-neomonarch-phase-2-data-on-abemaciclib-in-early-stage-breast-cancer-eli-lil-lly-20161208monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-introduces-scholars-programs-for-florida-a-m-university-s-and-howard-university-s-bu-lly-20161130monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-top-line-results-of-solanezumab-phase-3-clinical-trial-eli-lilly-and-compa-lly-20161123monthly0.5https://www.biopharmawatch.com/news/LLY/new-analyses-of-phase-3-trials-show-improvements-in-rheumatoid-arthritis-symptoms-followin-lly-20161114monthly0.5https://www.biopharmawatch.com/news/LLY/baricitinib-demonstrates-early-response-compared-to-placebo-and-significant-improvement-co-lly-20161114monthly0.5https://www.biopharmawatch.com/news/LLY/jardiance-empagliflozin-consistently-reduced-the-risk-of-cardiovascular-death-in-adults-wi-lly-20161113monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-presents-clinical-efficacy-safety-and-patient-reported-outcomes-data-of-baricitinib--lly-20161103monthly0.5https://www.biopharmawatch.com/news/LLY/new-data-from-pivotal-ra-beacon-study-show-significant-improvement-in-patient-reported-out-lly-20161102monthly0.5https://www.biopharmawatch.com/news/LLY/new-edition-of-online-tool-to-measure-cancer-progress-to-launch-at-world-cancer-congress-t-lly-20161031monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-third-quarter-2016-results-eli-lilly-and-company-nyse-lly-today-announced-fi-lly-20161025monthly0.5https://www.biopharmawatch.com/news/LLY/fda-approves-lilly-s-lartruvo-olaratumab-in-combination-with-doxorubicin-for-soft-tissue-s-lly-20161019monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-partners-with-the-national-cancer-institute-to-accelerate-cancer-research-through-ne-lly-20161017monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-fourth-quarter-2016-dividend-the-board-of-directors-of-eli-lilly-and-compan-lly-20161017monthly0.5https://www.biopharmawatch.com/news/LLY/eli-lilly-and-company-sponsors-arthritis-foundation-living-your-yes-with-ra-an-initiative--lly-20161012monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-credit-suisse-2016-healthcare-conference-eli-lilly-and-company-nys-lly-20161011monthly0.5https://www.biopharmawatch.com/news/LLY/leading-experts-warn-global-goal-to-cure-or-treat-alzheimer-s-disease-by-2025-is-at-risk-o-lly-20161011monthly0.5https://www.biopharmawatch.com/news/LLY/new-data-on-the-combination-of-lilly-s-alimta-pemetrexed-and-merck-s-keytruda-pembrolizuma-lly-20161009monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-highlights-advancements-in-its-oncology-portfolio-with-new-data-at-esmo-2016-eli-lil-lly-20161005monthly0.5https://www.biopharmawatch.com/news/LLY/elanco-animal-health-enters-agreement-to-acquire-boehringer-ingelheim-vetmedica-s-u-s-feli-lly-20161005monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-third-quarter-2016-financial-results-announcem-lly-20161004monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-latest-data-for-taltz-ixekizumab-in-psoriasis-at-the-european-academy-of--lly-20160927monthly0.5https://www.biopharmawatch.com/news/LLY/chmp-recommends-approval-of-lilly-s-olaratumab-in-combination-with-doxorubicin-for-advance-lly-20160916monthly0.5https://www.biopharmawatch.com/news/LLY/boston-mayor-walsh-and-the-alzheimer-s-association-massachusetts-new-hampshire-chapter-rec-lly-20160915monthly0.5https://www.biopharmawatch.com/news/LLY/levi-garraway-m-d-ph-d-to-become-senior-vice-president-of-global-oncology-at-lilly-succeed-lly-20160914monthly0.5https://www.biopharmawatch.com/news/LLY/jamere-jackson-elected-to-lilly-board-of-directors-the-board-of-directors-of-eli-lilly-and-lly-20160831monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-morgan-stanley-global-healthcare-conference-eli-lilly-and-company--lly-20160824monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-astrazeneca-receive-fda-fast-track-designation-for-azd3293-an-investigational-tr-lly-20160822monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-joshua-smiley-anat-ashkenazi-appointed-to-new-roles-thomas-grein-retires-e-lly-20160810monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-provides-update-on-monarch-2-phase-3-trial-of-abemaciclib-eli-lilly-and-company-nyse-lly-20160810monthly0.5https://www.biopharmawatch.com/news/LLY/john-c-lechleiter-to-retire-as-lilly-ceo-board-elects-david-a-ricks-as-successor-eli-lilly-lly-20160727monthly0.5https://www.biopharmawatch.com/news/LLY/new-studies-suggest-relationship-between-tau-pathology-and-progression-of-alzheimer-s-dise-lly-20160727monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-second-quarter-2016-results-provides-financial-expectations-through-the-rema-lly-20160726monthly0.5https://www.biopharmawatch.com/news/LLY/diversity-of-lilly-s-alzheimer-s-disease-pipeline-showcased-at-the-alzheimer-s-association-lly-20160721monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-boehringer-ingelheim-announce-clinical-trial-collaboration-in-metastatic-breast--lly-20160713monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-howard-university-partner-on-summer-medical-scientific-fellowship-lilly-usa-llc--lly-20160712monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-diabetes-welcomes-acclaimed-singer-songwriter-crystal-bowersox-as-newest-spokesperso-lly-20160706monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-second-quarter-2016-financial-results-announce-lly-20160628monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-convenes-leaders-at-national-mayor-s-conference-to-address-impact-of-alzheimer-s-dis-lly-20160627monthly0.5https://www.biopharmawatch.com/news/LLY/diabetes-scholars-foundation-announces-2016-scholarship-recipients-if-the-caliber-of-stude-lly-20160623monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-third-quarter-2016-dividend-the-board-of-directors-of-eli-lilly-and-company-lly-20160620monthly0.5https://www.biopharmawatch.com/news/LLY/german-supreme-court-grants-lilly-appeal-in-alimta-vitamin-regimen-patent-lawsuit-the-germ-lly-20160614monthly0.5https://www.biopharmawatch.com/news/LLY/aarti-shah-named-chief-information-officer-eli-lilly-and-company-nyse-lly-today-announced--lly-20160613monthly0.5https://www.biopharmawatch.com/news/LLY/new-data-show-lilly-s-once-weekly-trulicity-dulaglutide-in-combination-with-insulin-glargi-lly-20160612monthly0.5https://www.biopharmawatch.com/news/LLY/new-study-findings-underscore-importance-of-physician-patient-communication-on-insulin-adh-lly-20160611monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-american-migraine-foundation-announce-1-million-grant-for-launch-of-first-patien-lly-20160609monthly0.5https://www.biopharmawatch.com/news/LLY/baricitinib-significantly-reduces-joint-damage-progression-in-rheumatoid-arthritis-in-pati-lly-20160609monthly0.5https://www.biopharmawatch.com/news/LLY/patient-reported-outcomes-across-phase-3-studies-of-baricitinib-demonstrate-statistically--lly-20160609monthly0.5https://www.biopharmawatch.com/news/LLY/data-in-the-lancet-show-olaratumab-plus-doxorubicin-offered-11-8-month-increase-in-overall-lly-20160609monthly0.5https://www.biopharmawatch.com/news/LLY/studies-demonstrate-lilly-s-taltz-ixekizumab-maintained-or-achieved-high-levels-of-skin-cl-lly-20160608monthly0.5https://www.biopharmawatch.com/news/LLY/results-of-clinical-and-patient-reported-outcomes-data-for-baricitinib-in-patients-with-rh-lly-20160607monthly0.5https://www.biopharmawatch.com/news/LLY/early-phase-immuno-oncology-studies-of-lilly-s-alimta-pemetrexed-and-cyramza-ramucirumab-w-lly-20160605monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-results-from-monarch-1-trial-of-abemaciclib-monotherapy-eli-lilly-and-comp-lly-20160603monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-diabetes-commercial-update-investor-call-eli-lilly-and-company-nyse-lly-wi-lly-20160601monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-fda-approves-once-daily-jentadueto-xr-linagliptin-and-metformin-hydrochloride-extended-lly-20160531monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-webcast-to-discuss-abemaciclib-data-eli-lilly-and-company-nyse-lly-will-co-lly-20160531monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-goldman-sachs-37th-annual-global-healthcare-conference-eli-lilly-a-lly-20160525monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-details-robust-r-d-pipeline-to-investment-community-in-a-presentation-to-the-investm-lly-20160524monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-bernstein-strategic-decisions-conference-eli-lilly-and-company-nys-lly-20160523monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-first-volunteer-teams-of-2016-depart-in-may-for-thailand-and-ghana-a-team-of-eli-l-lly-20160519monthly0.5https://www.biopharmawatch.com/news/LLY/asco-data-underscore-lilly-s-diverse-oncology-pipeline-and-portfolio-several-studies-will--lly-20160518monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-partners-with-washington-university-school-of-medicine-and-meharry-medical-college-o-lly-20160518monthly0.5https://www.biopharmawatch.com/news/LLY/eli-lilly-and-company-marks-140-years-of-caring-and-discovery-eli-lilly-and-company-nyse-l-lly-20160510monthly0.5https://www.biopharmawatch.com/news/LLY/fda-grants-priority-review-for-lilly-s-olaratumab-an-investigational-medicine-for-advanced-lly-20160504monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-releases-first-ever-integrated-report-eli-lilly-and-company-nyse-lly-today-released--lly-20160502monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-second-quarter-2016-dividend-the-board-of-directors-of-eli-lilly-and-compan-lly-20160502monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-taltz-ixekizumab-now-available-in-the-u-s-for-the-treatment-of-moderate-to-severe--lly-20160502monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-bank-of-america-merrill-lynch-2016-health-care-conference-eli-lill-lly-20160428monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-first-quarter-2016-results-revises-2016-financial-guidance-eli-lilly-and-com-lly-20160426monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-provide-detailed-update-of-pipeline-and-r-d-strategy-at-upcoming-investment-commu-lly-20160412monthly0.5https://www.biopharmawatch.com/news/LLY/eli-lilly-and-company-and-astrazeneca-announce-continuation-of-pivotal-clinical-trial-for--lly-20160408monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-first-quarter-2016-financial-results-announcem-lly-20160404monthly0.5https://www.biopharmawatch.com/news/LLY/new-2016-acc-aha-guideline-focused-update-states-that-it-is-reasonable-to-choose-effient-p-lly-20160331monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-taltz-ixekizumab-receives-u-s-fda-approval-for-the-treatment-of-moderate-to-severe-lly-20160322monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-change-to-primary-endpoint-of-expedition3-study-eli-lilly-and-company-nyse-lly-20160315monthly0.5https://www.biopharmawatch.com/news/LLY/ixekizumab-demonstrates-high-levels-of-skin-clearance-among-patients-with-moderate-to-seve-lly-20160307monthly0.5https://www.biopharmawatch.com/news/LLY/studies-show-ixekizumab-improved-work-productivity-for-patients-with-moderate-to-severe-pl-lly-20160307monthly0.5https://www.biopharmawatch.com/news/LLY/ixekizumab-demonstrates-rapid-clinically-meaningful-improvements-as-early-as-one-week-amon-lly-20160304monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-barclays-global-healthcare-conference-eli-lilly-and-company-nyse-l-lly-20160302monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-phase-3-data-at-the-american-academy-of-dermatology-aad-annual-meeting-fo-lly-20160301monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-receives-positive-chmp-opinion-for-ixekizumab-for-the-treatment-of-moderate-to-sever-lly-20160226monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-at-cowen-health-care-conference-eli-lilly-and-company-nyse-lly-will-prese-lly-20160225monthly0.5https://www.biopharmawatch.com/news/LLY/uk-court-rules-against-lilly-in-alimta-vitamin-regimen-patent-lawsuit-eli-lilly-and-compan-lly-20160212monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-diabetes-helps-inspiring-students-with-type-1-diabetes-attend-college-through-schola-lly-20160211monthly0.5https://www.biopharmawatch.com/news/LLY/american-diabetes-association-survey-shows-summer-camp-can-positively-impact-children-s-di-lly-20160203monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-fourth-quarter-and-full-year-2015-results-eli-lilly-and-company-nyse-lly-tod-lly-20160128monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-roche-diagnostics-to-collaborate-on-alzheimer-s-disease-adjunct-diagnostic-tool--lly-20160127monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-at-leerink-partners-global-healthcare-conference-eli-lilly-and-company-ny-lly-20160127monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-food-and-drug-administration-approves-humulin-r-u-500-kwikpen-the-u-s-food-and-drug-ad-lly-20160121monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-incyte-announce-submission-of-new-drug-application-to-fda-for-oral-once-daily-ba-lly-20160119monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-2016-financial-guidance-updates-2015-expectations-eli-lilly-and-company-ny-lly-20160105monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-at-j-p-morgan-healthcare-conference-eli-lilly-and-company-nyse-lly-will-p-lly-20160104monthly0.5https://www.biopharmawatch.com/news/LLY/fda-approves-basaglar-insulin-glargine-injection-a-long-acting-insulin-treatment-eli-lilly-lly-20151216monthly0.5https://www.biopharmawatch.com/news/LLY/juan-r-luciano-elected-to-lilly-board-of-directors-the-board-of-directors-of-eli-lilly-and-lly-20151215monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-sets-dates-and-conference-calls-for-2016-financial-guidance-and-fourth-quarter-2015--lly-20151215monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-merck-expand-immuno-oncology-collaboration-adding-abemaciclib-and-keytruda-combi-lly-20151210monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-dividend-increase-the-board-of-directors-of-eli-lilly-and-company-nyse-lly-lly-20151208monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-ends-basal-insulin-peglispro-development-program-eli-lilly-and-company-nyse-lly-toda-lly-20151204monthly0.5https://www.biopharmawatch.com/news/LLY/new-data-show-lilly-s-once-weekly-trulicity-dulaglutide-is-effective-as-add-on-treatment-t-lly-20151201monthly0.5https://www.biopharmawatch.com/news/LLY/fda-approves-portrazza-necitumumab-for-specific-type-of-lung-cancer-eli-lilly-and-company--lly-20151124monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-provide-detailed-review-of-elanco-animal-health-and-alzheimer-s-r-d-strategy-at-i-lly-20151120monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-merck-expand-immuno-oncology-collaboration-with-phase-iii-nonsquamous-non-small--lly-20151119monthly0.5https://www.biopharmawatch.com/news/LLY/patients-show-significant-improvement-in-signs-and-symptoms-of-psoriatic-arthritis-less-pr-lly-20151108monthly0.5https://www.biopharmawatch.com/news/LLY/detailed-results-demonstrate-baricitinib-superiority-to-adalimumab-in-improving-signs-and--lly-20151107monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-incyte-announce-patients-treated-with-baricitinib-demonstrated-significant-impro-lly-20151107monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-united-way-celebrate-deepening-partnership-community-impact-representatives-from-lly-20151105monthly0.5https://www.biopharmawatch.com/news/LLY/results-of-two-pivotal-baricitinib-trials-to-be-presented-at-2015-american-college-of-rheu-lly-20151104monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-credit-suisse-2015-healthcare-conference-eli-lilly-and-company-nys-lly-20151104monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-diabetes-and-nascar-xfinity-series-driver-ryan-reed-announce-winners-of-the-my-diabe-lly-20151103monthly0.5https://www.biopharmawatch.com/news/LLY/eli-lilly-and-company-announces-expansion-of-indianapolis-r-d-headquarters-eli-lilly-and-c-lly-20151102monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-incyte-announce-webcast-to-discuss-baricitinib-phase-3-data-eli-lilly-and-compan-lly-20151027monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-third-quarter-2015-results-revises-2015-financial-guidance-eli-lilly-and-com-lly-20151022monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-astrazeneca-expand-immuno-oncology-research-collaboration-with-new-combinations--lly-20151022monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-supports-global-dementia-discovery-fund-eli-lilly-and-company-nyse-lly-announced-it--lly-20151021monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-fourth-quarter-2015-dividend-the-board-of-directors-of-eli-lilly-and-compan-lly-20151019monthly0.5https://www.biopharmawatch.com/news/LLY/baricitinib-demonstrates-superiority-to-adalimumab-in-improving-signs-and-symptoms-of-rheu-lly-20151014monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-brings-drug-development-to-the-classroom-with-new-college-course-offering-graduate-s-lly-20151013monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-imaginab-announce-preclinical-immuno-oncology-collaboration-eli-lilly-and-compan-lly-20151013monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-discontinue-development-of-evacetrapib-for-high-risk-atherosclerotic-cardiovascul-lly-20151012monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-innovent-biologics-expand-their-strategic-alliance-to-include-immuno-oncology-bi-lly-20151011monthly0.5https://www.biopharmawatch.com/news/LLY/eli-lilly-and-company-expands-new-york-city-research-and-development-site-eli-lilly-and-co-lly-20151009monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-acquires-phase-iii-intranasal-glucagon-from-locemia-solutions-eli-lilly-and-company--lly-20151009monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-receives-fda-breakthrough-therapy-designation-for-abemaciclib-a-cdk-4-and-6-inhibito-lly-20151008monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-joins-the-imaging-dementia-evidence-for-amyloid-scanning-ideas-study-eli-lilly-and-c-lly-20151007monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-third-quarter-2015-financial-results-announcem-lly-20151007monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-showcase-data-for-investigational-psoriasis-treatment-at-24th-european-academy-of-lly-20151006monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-sanofi-reach-settlement-agreement-in-u-s-insulin-glargine-litigation-eli-lilly-a-lly-20150928monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-cyramza-ramucirumab-significantly-improves-progression-free-survival-in-phase-ii-b-lly-20150928monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-webcast-to-discuss-empa-reg-outcome-data-eli-lilly-and-company-nyse-lly-wi-lly-20150915monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-morgan-stanley-global-healthcare-conference-eli-lilly-and-company--lly-20150827monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-aace-mark-10th-anniversary-of-hurricane-katrina-with-reminder-of-my-diabetes-emergen-lly-20150825monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-district-court-rules-in-lilly-s-favor-on-alimta-vitamin-regimen-patent-eli-lilly-and-c-lly-20150825monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-humalog-200-units-ml-kwikpen-now-available-in-u-s-pharmacies-humalog-200-units-ml--lly-20150818monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-provides-update-on-evacetrapib-phase-3-trial-eli-lilly-and-company-nyse-lly-has-acce-lly-20150727monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-diabetes-and-nascar-xfinity-series-driver-ryan-reed-want-you-to-think-about-your-dia-lly-20150723monthly0.5https://www.biopharmawatch.com/news/LLY/eli-lilly-and-company-announces-expansion-of-san-diego-biotechnology-center-eli-lilly-and--lly-20150723monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-second-quarter-2015-results-revises-2015-financial-guidance-eli-lilly-and-co-lly-20150723monthly0.5https://www.biopharmawatch.com/news/LLY/new-study-shows-florbetapir-f-18-injection-scans-led-to-change-in-diagnosis-and-management-lly-20150722monthly0.5https://www.biopharmawatch.com/news/LLY/data-using-new-delayed-start-methodology-suggested-benefit-of-early-treatment-with-solanez-lly-20150722monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-diabetes-launches-android-version-of-glucagon-mobile-application-for-those-who-suppo-lly-20150714monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-statement-on-fda-advisory-committee-review-of-necitumumab-the-u-s-food-and-drug-admi-lly-20150709monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-second-quarter-2015-financial-results-announce-lly-20150701monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-immunocore-announce-immunotherapy-based-clinical-trial-collaboration-in-melanoma-lly-20150629monthly0.5https://www.biopharmawatch.com/news/LLY/diabetes-scholars-foundation-announces-2015-scholarship-recipients-attending-college-is-a--lly-20150625monthly0.5https://www.biopharmawatch.com/news/LLY/uk-court-rules-in-favor-of-lilly-in-alimta-vitamin-regimen-patent-lawsuit-eli-lilly-and-co-lly-20150625monthly0.5https://www.biopharmawatch.com/news/LLY/cyramza-ramucirumab-hepatocellular-carcinoma-data-published-by-the-lancet-oncology-eli-lil-lly-20150619monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-investigational-medicine-for-prevention-of-migraine-met-primary-endpoint-in-a-phas-lly-20150617monthly0.5https://www.biopharmawatch.com/news/LLY/eli-lilly-and-company-enters-into-strategic-partnership-with-sarah-cannon-research-institu-lly-20150617monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-dana-farber-cancer-institute-announce-research-collaboration-eli-lilly-and-compa-lly-20150617monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-third-quarter-2015-dividend-the-board-of-directors-of-eli-lilly-and-company-lly-20150615monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-webcast-to-discuss-ixekizumab-phase-iii-data-eli-lilly-and-company-nyse-ll-lly-20150611monthly0.5https://www.biopharmawatch.com/news/LLY/studies-show-psoriasis-patients-achieved-significant-levels-of-skin-clearance-and-improved-lly-20150610monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-incyte-unveil-detailed-data-on-two-pivotal-studies-of-baricitinib-in-rheumatoid--lly-20150610monthly0.5https://www.biopharmawatch.com/news/LLY/new-data-show-superiority-of-lilly-s-once-weekly-trulicity-dulaglutide-to-lantus-insulin-g-lly-20150608monthly0.5https://www.biopharmawatch.com/news/LLY/olympian-kris-freeman-and-nascar-driver-ryan-reed-to-share-their-courageous-stories-with-c-lly-20150608monthly0.5https://www.biopharmawatch.com/news/LLY/study-once-weekly-trulicity-dulaglutide-provides-greater-blood-sugar-reduction-compared-to-lly-20150606monthly0.5https://www.biopharmawatch.com/news/LLY/basal-insulin-peglispro-studies-demonstrate-superiority-to-insulin-glargine-across-multipl-lly-20150606monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-basal-insulin-peglispro-shows-superiority-to-insulin-glargine-in-reducing-hba1c-in-lly-20150606monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-pivotal-phase-3-study-results-for-investigational-psoriasis-treatment-at--lly-20150604monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-commits-780-000-additional-vials-of-insulin-to-life-for-a-child-eli-lilly-and-compan-lly-20150604monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-goldman-sachs-global-healthcare-conference-eli-lilly-and-company-n-lly-20150529monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-astrazeneca-to-collaborate-on-immuno-oncology-combination-clinical-trial-in-soli-lly-20150529monthly0.5https://www.biopharmawatch.com/news/LLY/proclaim-final-trial-results-to-be-presented-at-asco-annual-meeting-eli-lilly-and-company--lly-20150528monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-the-early-results-of-its-cash-tender-offer-eli-lilly-and-company-nyse-lly--lly-20150528monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-cyramza-ramucirumab-data-at-2015-asco-annual-meeting-eli-lilly-and-compan-lly-20150528monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-the-pricing-terms-of-its-cash-tender-offer-for-up-to-1-6-billion-aggregate-lly-20150528monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-incyte-announce-webcast-to-discuss-baricitinib-phase-iii-data-eli-lilly-and-comp-lly-20150528monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-sends-employees-to-serve-in-vulnerable-communities-around-the-world-marcio-donatelli-lly-20150527monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-food-and-drug-administration-approves-humalog-200-units-ml-kwikpen-the-u-s-food-and-dr-lly-20150527monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-new-clinical-data-at-75th-american-diabetes-association-scientific-sessio-lly-20150527monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-cash-tender-offer-for-up-to-1-6-billion-aggregate-principal-amount-of-its--lly-20150512monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-biontech-announce-research-collaboration-on-novel-cancer-immunotherapies-eli-lil-lly-20150511monthly0.5https://www.biopharmawatch.com/news/LLY/eli-lilly-and-company-reveals-plan-for-innovation-center-in-cambridge-massachusetts-eli-li-lly-20150506monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-releases-corporate-responsibility-global-health-reports-eli-lilly-and-company-nyse-l-lly-20150504monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-second-quarter-2015-dividend-the-board-of-directors-of-eli-lilly-and-compan-lly-20150504monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-bank-of-america-merrill-lynch-health-care-conference-eli-lilly-and-lly-20150501monthly0.5https://www.biopharmawatch.com/news/LLY/survey-finds-half-of-heart-stent-patients-don-t-take-their-oral-antiplatelet-medication-as-lly-20150428monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-cyramza-ramucirumab-receives-fourth-fda-approval-eli-lilly-and-company-nyse-lly-ha-lly-20150424monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-first-quarter-2015-results-revenue-declined-1-percent-due-to-the-unfavorable-lly-20150423monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-releases-early-stage-pipeline-data-at-aacr-annual-meeting-2015-eli-lilly-and-company-lly-20150420monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-ixekizumab-met-primary-endpoint-in-a-phase-3-study-investigating-the-treatment-of--lly-20150420monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-first-quarter-2015-financial-results-announcem-lly-20150401monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-date-for-diabetes-investor-meeting-eli-lilly-and-company-nyse-lly-will-con-lly-20150330monthly0.5https://www.biopharmawatch.com/news/LLY/preparation-is-personal-for-those-with-chronic-illnesses-news-highlights-theaace-and-lilly-lly-20150330monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-innovent-biologics-announce-a-strategic-alliance-to-bring-potential-oncology-the-lly-20150320monthly0.5https://www.biopharmawatch.com/news/LLY/german-court-rules-against-lilly-in-alimta-vitamin-regimen-patent-lawsuit-the-german-court-lly-20150306monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-iu-school-of-medicine-partner-on-rotation-program-for-medical-students-students--lly-20150304monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-barclays-global-healthcare-conference-eli-lilly-and-company-nyse-l-lly-20150303monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-at-cowen-health-care-conference-eli-lilly-and-company-nyse-lly-will-prese-lly-20150224monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-update-on-regulatory-submission-timing-for-basal-insulin-peglispro-eli-lil-lly-20150223monthly0.5https://www.biopharmawatch.com/news/LLY/nascar-driver-ryan-reed-takes-first-place-at-daytona-international-speedway-news-highlight-lly-20150221monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-provides-update-on-evacetrapib-phase-3-trial-eli-lilly-and-company-nyse-lly-has-acce-lly-20150219monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-at-leerink-global-healthcare-conference-eli-lilly-and-company-nyse-lly-wi-lly-20150206monthly0.5https://www.biopharmawatch.com/news/LLY/the-lilly-foundation-commits-1-million-to-support-ampath-oncology-institute-in-kenya-in-co-lly-20150204monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-diabetes-donates-92-000-in-camp-scholarships-to-the-american-diabetes-association-ne-lly-20150203monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-fourth-quarter-and-full-year-2014-results-updates-2015-guidance-fourth-quart-lly-20150130monthly0.5https://www.biopharmawatch.com/news/LLY/scoring-progress-against-cancer-new-tool-measures-cancer-progress-to-help-inform-research--lly-20150129monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-provides-update-on-strategy-and-announces-2015-financial-guidance-eli-lilly-and-comp-lly-20150107monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-promotion-of-darren-j-carroll-to-senior-vice-president-of-corporate-busine-lly-20150105monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-at-j-p-morgan-healthcare-conference-eli-lilly-and-company-nyse-lly-will-p-lly-20150105monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-finalizes-novartis-animal-health-acquisition-eli-lilly-and-company-nyse-lly-today-an-lly-20150101monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-diabetes-research-partnership-with-university-of-surrey-eli-lilly-and-comp-lly-20141222monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-adocia-announce-alliance-to-co-develop-ultra-rapid-insulin-based-on-biochaperone-lly-20141219monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-cyramza-ramucirumab-receives-third-fda-approval-eli-lilly-and-company-nyse-lly-has-lly-20141216monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-dividend-increase-the-board-of-directors-of-eli-lilly-and-company-nyse-lly-lly-20141215monthly0.5https://www.biopharmawatch.com/news/LLY/eli-lilly-and-company-and-astrazeneca-initiate-pivotal-clinical-trial-for-patients-with-ea-lly-20141201monthly0.5https://www.biopharmawatch.com/news/LLY/national-alliance-for-hispanic-health-survey-provides-insights-into-hispanic-attitudes-tow-lly-20141119monthly0.5https://www.biopharmawatch.com/news/LLY/encuesta-de-la-national-alliance-for-hispanic-health-brinda-percepciones-sobre-las-actitud-lly-20141119monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-trulicity-dulaglutide-now-available-in-u-s-pharmacies-the-newest-glp-1-receptor-ag-lly-20141110monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-cyramza-ramucirumab-in-combination-with-paclitaxel-granted-fda-approval-for-advanc-lly-20141105monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-shares-insights-from-decade-long-technology-transfer-experience-today-eli-lilly-and--lly-20141030monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-record-breaking-12-7-million-gift-to-united-way-eli-lilly-and-company-nys-lly-20141029monthly0.5https://www.biopharmawatch.com/news/LLY/boehringer-ingelheim-and-lilly-revising-operational-structure-of-diabetes-alliance-in-cert-lly-20141029monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-credit-suisse-2014-healthcare-conference-eli-lilly-and-company-nys-lly-20141028monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-responds-to-decision-in-case-of-terrence-allen-et-al-v-takeda-eli-lilly-and-company--lly-20141027monthly0.5https://www.biopharmawatch.com/news/LLY/the-hope-murals-project-national-art-movement-culminates-in-painting-event-at-grand-centra-lly-20141023monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-third-quarter-2014-results-third-quarter-2014-revenue-declined-16-percent-dr-lly-20141023monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-fourth-quarter-2014-dividend-the-board-of-directors-of-eli-lilly-and-compan-lly-20141020monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-plan-to-realign-puerto-rico-manufacturing-operations-eli-lilly-and-company-lly-20141016monthly0.5https://www.biopharmawatch.com/news/LLY/european-commission-grants-marketing-authorisation-to-humalog-200-units-ml-kwikpen-insulin-lly-20141003monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-third-quarter-2014-financial-results-announcem-lly-20141003monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-discontinue-development-of-tabalumab-based-on-efficacy-results-in-phase-3-lupus-s-lly-20141002monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-seventh-global-day-of-service-rallies-24-000-employees-in-nearly-60-countries-on-o-lly-20140929monthly0.5https://www.biopharmawatch.com/news/LLY/cyramza-in-combination-with-paclitaxel-significantly-improves-overall-survival-in-second-l-lly-20140918monthly0.5https://www.biopharmawatch.com/news/LLY/fda-approves-trulicity-dulaglutide-lilly-s-once-weekly-therapy-for-adults-with-type-2-diab-lly-20140918monthly0.5https://www.biopharmawatch.com/news/LLY/working-mother-names-lilly-to-its-100-best-companies-list-for-20-years-working-mother-maga-lly-20140916monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-astrazeneca-announce-alliance-to-co-develop-potential-treatment-for-alzheimer-s--lly-20140916monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-cyramza-phase-iii-second-line-colorectal-cancer-trial-meets-primary-endpoi-lly-20140912monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-highlights-latest-work-in-diabetes-discovery-and-development-at-2014-european-associ-lly-20140909monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-basal-insulin-peglispro-demonstrated-hba1c-superiority-against-lantus-in-phase-iii-lly-20140904monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-morgan-stanley-2014-global-healthcare-conference-eli-lilly-and-com-lly-20140825monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-ixekizumab-superior-to-etanercept-and-placebo-in-phase-3-psoriasis-studies-ixekizu-lly-20140821monthly0.5https://www.biopharmawatch.com/news/LLY/chmp-recommends-approval-of-lilly-s-humalog-200-units-ml-kwikpen-eli-lilly-and-company-nys-lly-20140730monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-second-quarter-2014-results-second-quarter-2014-revenue-declined-17-percent--lly-20140724monthly0.5https://www.biopharmawatch.com/news/LLY/new-study-shows-beta-amyloid-imaging-is-associated-with-altered-diagnosis-and-management-o-lly-20140716monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-immunocore-enter-immunotherapy-agreement-to-co-discover-and-co-develop-novel-can-lly-20140716monthly0.5https://www.biopharmawatch.com/news/LLY/new-data-shows-cognitive-impairment-precedes-and-predicts-subsequent-functional-impairment-lly-20140715monthly0.5https://www.biopharmawatch.com/news/LLY/new-data-shows-combination-therapy-is-more-effective-than-monotherapy-in-removing-beta-amy-lly-20140713monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-for-better-health-expands-website-s-non-product-branded-health-education-resources-f-lly-20140710monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-por-su-salud-expande-los-recursos-de-educacio-n-sobre-la-salud-en-espan-ol-sin-marca-lly-20140710monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-second-quarter-2014-financial-results-announce-lly-20140709monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-showcase-data-from-its-alzheimer-s-disease-portfolio-at-the-alzheimer-s-associati-lly-20140708monthly0.5https://www.biopharmawatch.com/news/LLY/nascar-driver-ryan-reed-finishes-fourth-at-the-subway-firecracker-250-at-daytona-internati-lly-20140707monthly0.5https://www.biopharmawatch.com/news/LLY/diabetes-scholars-foundation-announces-2014-scholarship-recipients-managing-a-chronic-dise-lly-20140625monthly0.5https://www.biopharmawatch.com/news/LLY/eli-lilly-and-company-collaborates-with-public-and-private-healthcare-organizations-to-pro-lly-20140623monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-detailed-results-from-two-phase-iii-studies-testing-both-doses-of-dulaglut-lly-20140616monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-third-quarter-2014-dividend-the-board-of-directors-of-eli-lilly-and-company-lly-20140616monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-once-weekly-dulaglutide-shows-similar-reductions-in-average-blood-glucose-levels-a-lly-20140614monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-basal-insulin-peglispro-shows-novel-mechanism-of-action-eli-lilly-and-company-nyse-lly-20140614monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-top-line-results-of-phase-iii-hepatocellular-carcinoma-trial-eli-lilly-and-lly-20140611monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-goldman-sachs-global-healthcare-conference-eli-lilly-and-company-n-lly-20140609monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-new-clinical-data-from-diabetes-portfolio-with-76-abstracts-at-the-74th-a-lly-20140609monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-diabetes-adds-nascar-nationwide-series-driver-ryan-reed-to-annual-diabetes-summer-ca-lly-20140609monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-increased-access-to-clinical-trials-data-for-qualified-researchers-eli-lil-lly-20140602monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-cyramza-ramucirumab-significantly-improves-overall-survival-in-phase-iii-non-small-lly-20140602monthly0.5https://www.biopharmawatch.com/news/LLY/thousands-to-create-mural-launching-national-community-art-movement-honoring-those-touched-lly-20140529monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-date-for-investor-web-call-plans-to-share-phase-iii-dulaglutide-data-eli-l-lly-20140527monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-bernstein-strategic-decisions-conference-eli-lilly-and-company-nys-lly-20140522monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-date-for-investor-webcast-to-review-data-presented-at-asco-2014-eli-lilly--lly-20140516monthly0.5https://www.biopharmawatch.com/news/LLY/english-court-rules-against-lilly-in-alimta-vitamin-dosage-regimen-patent-lawsuit-eli-lill-lly-20140515monthly0.5https://www.biopharmawatch.com/news/LLY/abemaciclib-lilly-s-oral-cdk-4-6-inhibitor-shows-single-agent-activity-in-a-phase-i-study--lly-20140514monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-necitumumab-improves-overall-survival-in-largest-ever-phase-iii-study-in-first-lin-lly-20140514monthly0.5https://www.biopharmawatch.com/news/LLY/ready-to-go-the-importance-of-advance-planning-lilly-diabetes-and-the-american-college-of--lly-20140514monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-basal-insulin-peglispro-shows-superiority-in-hba1c-reduction-compared-to-insulin-g-lly-20140512monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-responds-to-brazil-court-ruling-in-labor-case-eli-lilly-and-company-nyse-lly-today-a-lly-20140509monthly0.5https://www.biopharmawatch.com/news/LLY/first-team-of-lilly-s-2014-connecting-hearts-abroad-ambassadors-on-the-ground-in-guatemala-lly-20140507monthly0.5https://www.biopharmawatch.com/news/LLY/eli-lilly-and-company-launches-second-education-program-for-medical-students-eli-lilly-and-lly-20140425monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-first-quarter-2014-results-eli-lilly-and-company-nyse-lly-today-announced-fi-lly-20140424monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-agreement-to-acquire-novartis-animal-health-eli-lilly-and-company-nyse-lly-lly-20140422monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-cyramza-ramucirumab-becomes-first-fda-approved-treatment-for-advanced-gastric-canc-lly-20140421monthly0.5https://www.biopharmawatch.com/news/LLY/american-college-of-endocrinology-ace-focuses-on-emergency-planning-for-people-with-diabet-lly-20140414monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-first-quarter-2014-financial-results-announcem-lly-20140410monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-t1d-exchange-announce-research-collaboration-to-inform-development-of-new-initia-lly-20140409monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-responds-to-verdict-in-case-of-terrence-allen-et-al-v-takeda-eli-lilly-and-company-n-lly-20140408monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-release-early-stage-pipeline-data-targeting-key-cancer-pathways-at-aacr-2014-eli--lly-20140406monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-district-court-upholds-validity-of-lilly-s-alimta-patent-through-2022-eli-lilly-and-co-lly-20140331monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-barclays-healthcare-conference-eli-lilly-and-company-nyse-lly-will-lly-20140305monthly0.5https://www.biopharmawatch.com/news/LLY/elanco-announces-agreement-to-acquire-lohmann-animal-health-elanco-the-animal-health-divis-lly-20140224monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-cowen-healthcare-conference-eli-lilly-and-company-nyse-lly-will-at-lly-20140221monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-ramucirumab-phase-iii-lung-cancer-trial-meets-primary-endpoint-of-overall--lly-20140219monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-usa-llc-launches-new-rotation-program-for-medical-students-lilly-usa-llc-nyse-lly-an-lly-20140212monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-participate-in-leerink-swann-global-healthcare-conference-eli-lilly-and-company-n-lly-20140205monthly0.5https://www.biopharmawatch.com/news/LLY/eli-lilly-and-company-provides-statement-in-response-to-sanofi-u-s-lawsuit-eli-lilly-and-c-lly-20140131monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-fourth-quarter-and-full-year-2013-results-fourth-quarter-2013-revenue-declin-lly-20140130monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-cross-country-skier-kris-freeman-named-to-2014-olympic-team-news-highlights-t1diabetes-lly-20140122monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-acquisition-of-cgrp-antibody-for-migraine-prevention-from-arteaus-therapeu-lly-20140113monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-diabetes-to-contribute-200-000-to-the-diabetes-scholars-foundation-today-lilly-diabe-lly-20140109monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-oncology-on-canvas-expressions-of-a-cancer-journey-reaches-important-milestone-with--lly-20140108monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-2014-financial-guidance-reconfirms-2013-expectations-2014-revenue-anticipa-lly-20140107monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-sets-dates-and-conference-calls-for-2014-financial-guidance-and-fourth-quarter-2013--lly-20140102monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-diabetes-disney-custom-books-for-type-1-diabetes-families-now-available-online-lilly-lly-20131219monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-at-j-p-morgan-healthcare-conference-eli-lilly-and-company-nyse-lly-will-p-lly-20131219monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-first-quarter-2014-dividend-the-board-of-directors-of-eli-lilly-and-company-lly-20131216monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-edivoxetine-did-not-meet-primary-endpoint-of-phase-iii-clinical-studies-as-lly-20131205monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-releases-report-on-corporate-responsibility-efforts-eli-lilly-and-company-nyse-lly-h-lly-20131205monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-diabetes-extends-national-sponsorship-of-the-american-diabetes-association-s-signatu-lly-20131119monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-statement-on-contribution-to-indiana-biosciences-research-institute-following-is-a-s-lly-20131119monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-record-breaking-12-6-million-gift-to-united-way-eli-lilly-and-company-nys-lly-20131119monthly0.5https://www.biopharmawatch.com/news/LLY/cialis-tadalafil-marks-10-years-since-u-s-approval-cialis-is-turning-10-as-cialis-marks-it-lly-20131119monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-significant-global-insulin-manufacturing-capacity-investments-in-response--lly-20131114monthly0.5https://www.biopharmawatch.com/news/LLY/fda-approves-addition-to-cialis-tadalafil-product-label-eli-lilly-and-company-nyse-lly-tod-lly-20131025monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-tapiero-retiring-zulueta-promoted-to-senior-vice-president-and-president-o-lly-20131024monthly0.5https://www.biopharmawatch.com/news/LLY/fda-grants-lilly-s-ramucirumab-priority-review-as-a-potential-single-agent-treatment-for-a-lly-20131023monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-third-quarter-2013-results-worldwide-revenue-increased-6-percent-driven-by-s-lly-20131023monthly0.5https://www.biopharmawatch.com/news/LLY/jackson-tai-elected-to-lilly-board-of-directors-the-board-of-directors-of-eli-lilly-and-co-lly-20131022monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-fourth-quarter-2013-dividend-the-board-of-directors-of-eli-lilly-and-compan-lly-20131021monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-third-quarter-2013-financial-results-announcem-lly-20131015monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-global-day-of-service-supports-indy-do-day-initiative-eli-lilly-and-company-s-nyse-lly-20131009monthly0.5https://www.biopharmawatch.com/news/LLY/single-agent-ramucirumab-significantly-improves-overall-survival-in-advanced-gastric-cance-lly-20131003monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-details-progress-on-achieving-strategic-business-goals-and-its-advancing-pipeline-to-lly-20131003monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reintegration-scholarship-applications-available-for-2014-2015-academic-year-eli-lil-lly-20131001monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-disappointed-in-medicare-decision-to-deny-appropriate-patient-access-to-beta-amyloid-lly-20130927monthly0.5https://www.biopharmawatch.com/news/LLY/data-presented-at-49th-easd-annual-meeting-show-treatment-with-lilly-s-investigational-dul-lly-20130926monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-second-positive-ramucirumab-phase-iii-gastric-cancer-study-meets-primary-e-lly-20130926monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-data-across-its-diabetes-portfolio-at-the-49th-european-association-for-t-lly-20130917monthly0.5https://www.biopharmawatch.com/news/LLY/dr-marschall-s-runge-elected-to-lilly-board-of-directors-the-board-of-directors-of-eli-lil-lly-20130828monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-phase-iii-necitumumab-study-meets-primary-endpoint-of-overall-survival-eli-lly-20130813monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-roswell-park-cancer-institute-partner-to-train-minority-clinical-trial-investigators-lly-20130801monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-second-quarter-2013-results-worldwide-revenue-increased-6-percent-as-growth--lly-20130724monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-second-quarter-2013-financial-results-announce-lly-20130717monthly0.5https://www.biopharmawatch.com/news/LLY/new-study-shows-men-taking-cialis-tadalafil-tablets-once-daily-returned-to-normal-erectile-lly-20130716monthly0.5https://www.biopharmawatch.com/news/LLY/2013-scholarship-recipients-named-by-diabetes-scholars-foundation-news-highlights-lilly-di-lly-20130708monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-dr-lechleiter-s-return-eli-lilly-and-company-nyse-lly-today-announced-that-lly-20130708monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-disappointed-in-draft-medicare-coverage-decision-for-beta-amyloid-imaging-agents-eli-lly-20130708monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-disappointed-in-draft-medicare-coverage-decision-for-beta-amyloid-imaging-agents-eli-lly-20130703monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-host-conference-call-to-discuss-trial-design-of-new-solanezumab-phase-3-study-eli-lly-20130703monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-investigational-glp-1-receptor-agonist-dulaglutide-showed-superior-glycemic-contro-lly-20130622monthly0.5https://www.biopharmawatch.com/news/LLY/follow-up-phase-ii-data-analysis-adds-to-body-of-evidence-for-investigational-novel-basal--lly-20130622monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-issues-alert-for-illegal-scams-involving-fraudulent-checks-and-online-job-requests-e-lly-20130619monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-third-quarter-2013-dividend-the-board-of-directors-of-eli-lilly-and-company-lly-20130618monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-diabetes-kris-freeman-kick-off-summer-with-9th-annual-diabetes-summer-camp-tour-news-lly-20130617monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-voluntarily-terminates-phase-ii-study-for-ly2886721-a-beta-secretase-inhibitor-being-lly-20130613monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-highlight-late-stage-pipeline-molecules-at-the-73rd-american-diabetes-association-lly-20130611monthly0.5https://www.biopharmawatch.com/news/LLY/pronounce-study-does-not-achieve-primary-superiority-endpoint-for-alimta-pemetrexed-for-in-lly-20130603monthly0.5https://www.biopharmawatch.com/news/LLY/new-mobile-app-assists-oncologists-in-navigating-ever-evolving-sea-of-cancer-information-r-lly-20130531monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-statement-on-indiana-biosciences-research-institute-eli-lilly-and-company-nyse-lly-h-lly-20130530monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-at-goldman-sachs-global-healthcare-conference-eli-lilly-and-company-nyse--lly-20130530monthly0.5https://www.biopharmawatch.com/news/LLY/new-data-on-forteo-teriparatide-rdna-origin-injection-show-increased-bone-mineral-density--lly-20130529monthly0.5https://www.biopharmawatch.com/news/LLY/from-research-labs-to-doctors-offices-health-care-providers-at-lilly-play-important-role-i-lly-20130520monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-provides-update-on-ceo-dr-john-lechleiter-eli-lilly-and-company-nyse-lly-today-annou-lly-20130514monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-oncology-to-release-new-pipeline-data-at-asco-2013-eli-lilly-and-company-nyse-lly-wi-lly-20130514monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-enzastaurin-phase-iii-study-did-not-meet-primary-endpoint-in-diffuse-large-lly-20130510monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-ceo-dr-john-lechleiter-to-undergo-scheduled-surgery-eli-lilly-and-company--lly-20130506monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-second-quarter-2013-dividend-the-board-of-directors-of-eli-lilly-and-compan-lly-20130506monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-celebrates-national-volunteer-week-with-deployment-of-global-service-teams-eli-lilly-lly-20130426monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-again-named-one-of-diversityinc-s-top-50-companies-for-diversity-eli-lilly-and-compa-lly-20130424monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-first-quarter-2013-results-worldwide-revenue-was-flat-as-growth-in-key-produ-lly-20130424monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-acquires-novel-tau-tangle-diagnostic-program-to-bolster-alzheimer-s-disease-research-lly-20130417monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-positive-results-of-phase-iii-trials-of-dulaglutide-in-type-2-diabetes-eli-lly-20130416monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-debuts-early-oncology-pipeline-data-at-aacr-annual-meeting-eli-lilly-and-company-nys-lly-20130410monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-first-quarter-2013-financial-results-announcem-lly-20130403monthly0.5https://www.biopharmawatch.com/news/LLY/potential-lilly-investment-would-further-expand-indianapolis-insulin-manufacturing-operati-lly-20130402monthly0.5https://www.biopharmawatch.com/news/LLY/new-study-of-cialis-tadalafil-tablets-co-administered-with-finasteride-meets-primary-endpo-lly-20130318monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-sets-date-for-2013-diabetes-pipeline-update-to-the-media-and-investment-community-el-lly-20130305monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-team-solutions-and-solutions-for-wellness-resources-for-serious-mental-illness-add-lly-20130220monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-discontinues-phase-3-rheumatoid-arthritis-program-for-tabalumab-based-on-efficacy-re-lly-20130207monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-recognized-for-fifth-straight-year-on-nafe-s-top-50-companies-for-executive-women-el-lly-20130205monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-supports-the-medical-community-s-testimony-on-the-clinical-utility-of-beta-amyloid-i-lly-20130130monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-fourth-quarter-and-full-year-2012-results-revises-2013-eps-guidance-fourth-q-lly-20130129monthly0.5https://www.biopharmawatch.com/news/LLY/amyvid-florbetapir-f-18-injection-approved-in-european-union-for-use-in-patients-with-cogn-lly-20130115monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-diabetes-supports-diabetes-scholars-foundation-with-100-000-donation-in-2013-for-a-s-lly-20130108monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-comments-on-2012-financial-guidance-and-announces-2013-financial-guidance-company-re-lly-20130104monthly0.5https://www.biopharmawatch.com/news/LLY/leading-dermatologist-michael-p-heffernan-m-d-and-renowned-rheumatologist-alisa-e-koch-m-d-lly-20130103monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reaches-agreement-with-u-s-securities-and-exchange-commission-eli-lilly-and-company--lly-20121220monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-sets-dates-and-conference-calls-for-2013-financial-guidance-and-fourth-quarter-2012--lly-20121217monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-first-quarter-2013-dividend-announces-new-1-5-billion-share-repurchase-prog-lly-20121217monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-discontinues-one-of-three-phase-3-rheumatoid-arthritis-registration-studies-for-taba-lly-20121213monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-provides-update-on-next-steps-for-solanezumab-eli-lilly-and-company-nyse-lly-today-p-lly-20121212monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-releases-update-on-corporate-responsibility-efforts-eli-lilly-and-company-nyse-lly-h-lly-20121203monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-publica-una-actualizacio-n-sobre-sus-esfuerzos-de-responsabilidad-corporativa-eli-li-lly-20121203monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-publie-une-mise-a-jour-de-ses-efforts-en-matie-re-de-responsabilite-d-entreprise-eli-lly-20121203monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-lanza-la-actualizacio-n-de-los-esfuerzos-de-responsabilidad-corporativa-eli-lilly-an-lly-20121203monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-vero-ffentlicht-aktualisierung-u-ber-ta-tigkeiten-im-corporate-responsibility-bereic-lly-20121203monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-divulga-dados-atualizados-sobre-seus-esforc-os-para-responsabilidade-corporativa-eli-lly-20121203monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-diabetes-joins-the-american-diabetes-association-as-a-national-sponsor-of-the-2013-t-lly-20121127monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-record-breaking-12-4-million-gift-to-united-way-eli-lilly-and-company-nys-lly-20121119monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-recognized-as-one-of-the-best-places-to-work-for-lgbt-equality-for-the-seventh-conse-lly-20121119monthly0.5https://www.biopharmawatch.com/news/LLY/breast-cancer-survivor-awarded-top-prize-in-2012-oncology-on-canvas-sm-art-competition-qui-lly-20121112monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-present-phase-ii-rheumatoid-arthritis-and-biomarker-data-at-acr-for-two-investiga-lly-20121109monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-statement-on-hurricane-sandy-relief-efforts-in-the-aftermath-of-hurricane-sandy-the--lly-20121101monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-expand-indianapolis-insulin-manufacturing-operations-local-and-state-government-o-lly-20121101monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-names-melissa-barnes-chief-ethics-and-compliance-officer-and-senior-vice-president-a-lly-20121030monthly0.5https://www.biopharmawatch.com/news/LLY/european-commission-approves-cialis-tadalafil-tablets-for-the-treatment-of-the-signs-and-s-lly-20121030monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-third-quarter-2012-results-worldwide-revenue-declined-11-percent-to-5-443-bi-lly-20121024monthly0.5https://www.biopharmawatch.com/news/LLY/new-retrospective-studies-of-hospital-readmission-rates-for-subsequent-heart-attack-and-in-lly-20121023monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-diabetes-announces-positive-results-of-phase-iii-trials-of-dulaglutide-in-type-2-dia-lly-20121022monthly0.5https://www.biopharmawatch.com/news/LLY/amyvid-florbetapir-f-18-injection-recommended-for-approval-in-europe-as-a-diagnostic-tool--lly-20121019monthly0.5https://www.biopharmawatch.com/news/LLY/alimta-extends-survival-in-continuation-maintenance-setting-for-specific-lung-cancer-patie-lly-20121017monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-new-data-further-exploring-mechanistic-differences-between-forteo-teripara-lly-20121015monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-positive-results-for-ramucirumab-as-single-agent-in-phase-iii-gastric-canc-lly-20121015monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-fourth-quarter-2012-dividend-the-board-of-directors-of-eli-lilly-and-compan-lly-20121015monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-fifth-global-day-of-service-focuses-on-local-waterways-thousands-of-employees-from-lly-20121011monthly0.5https://www.biopharmawatch.com/news/LLY/diversityinc-names-lilly-the-top-company-for-working-families-eli-lilly-and-company-nyse-l-lly-20121010monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-detailed-results-of-the-phase-3-solanezumab-expedition-studies-following-a-lly-20121008monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reintegration-scholarship-applications-available-for-2013-2014-academic-year-eli-lil-lly-20121001monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-releases-phase-ii-results-for-monoclonal-antibody-ramucirumab-in-lung-cancer-eli-lil-lly-20120929monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-third-quarter-2012-financial-results-announcem-lly-20120924monthly0.5https://www.biopharmawatch.com/news/LLY/cialis-tadalafil-tablets-recommended-for-approval-for-the-treatment-of-the-signs-and-sympt-lly-20120921monthly0.5https://www.biopharmawatch.com/news/LLY/new-international-survey-reveals-multiple-barriers-to-an-accurate-and-timely-alzheimer-s-d-lly-20120919monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-celebrates-18th-consecutive-year-as-one-of-working-mother-s-100-best-companies-eli-l-lly-20120918monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-results-from-lung-cancer-study-eli-lilly-and-company-nyse-lly-announced-to-lly-20120906monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-diabetes-launches-mobile-application-for-those-who-support-people-with-type-1-diabet-lly-20120904monthly0.5https://www.biopharmawatch.com/news/LLY/million-adults-in-the-u-s-have-difficulty-understanding-health-information-lilly-earns-nat-lly-20120830monthly0.5https://www.biopharmawatch.com/news/LLY/noventa-millones-de-adultos-en-los-ee-uu-tienen-dificultad-para-comprender-la-informacio-n-lly-20120830monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-retirement-of-robert-armitage-names-michael-harrington-senior-vice-preside-lly-20120830monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-stops-phase-iii-development-of-pomaglumetad-methionil-for-the-treatment-of-schizophr-lly-20120829monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-court-of-appeals-upholds-validity-of-lilly-s-alimta-compound-patent-eli-lilly-and-comp-lly-20120824monthly0.5https://www.biopharmawatch.com/news/LLY/eli-lilly-and-company-announces-top-line-results-on-solanezumab-phase-3-clinical-trials-in-lly-20120824monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-revises-2012-reported-guidance-to-reflect-income-from-early-payment-of-amylin-obliga-lly-20120809monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-study-results-regarding-postmenopausal-women-with-back-pain-caused-by-vert-lly-20120807monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-supports-research-to-determine-what-a-dog-s-nose-knows-about-people-with-diabetes-an-lly-20120730monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-second-quarter-2012-results-raises-2012-eps-guidance-worldwide-revenue-decli-lly-20120725monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-second-quarter-2012-financial-results-announce-lly-20120712monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-pomaglumetad-methionil-did-not-meet-primary-endpoint-of-clinical-study-eli-lly-20120711monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-obtains-six-months-u-s-pediatric-exclusivity-for-cymbalta-duloxetine-hcl-eli-lilly-a-lly-20120706monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-diabetes-announces-once-upon-a-time-contest-winner-news-highlights-lilly-diabetes-se-lly-20120702monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-statement-on-affordable-care-act-ruling-by-supreme-court-following-is-a-statement-fr-lly-20120628monthly0.5https://www.biopharmawatch.com/news/LLY/diabetes-scholars-foundation-announces-2012-scholarship-recipients-today-the-diabetes-scho-lly-20120626monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-statement-on-pdufa-vote-by-senate-following-is-a-statement-from-john-c-lechleiter-ph-lly-20120626monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-third-quarter-2012-dividend-resumes-share-repurchase-program-the-board-of-d-lly-20120619monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-diabetes-launches-8th-annual-diabetes-summer-camp-tour-with-olympian-kris-freeman-ne-lly-20120618monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-expands-strategic-partnership-with-chinese-manufacturer-novast-to-serve-chinese-pati-lly-20120612monthly0.5https://www.biopharmawatch.com/news/LLY/project-hope-presents-dr-lechleiter-lilly-with-global-health-partner-award-project-hope-pr-lly-20120612monthly0.5https://www.biopharmawatch.com/news/LLY/post-hoc-analysis-of-linagliptin-phase-3-data-in-adults-with-type-2-diabetes-and-albuminur-lly-20120609monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-ceo-calls-for-a-health-care-policy-environment-that-promotes-medical-innovation-rega-lly-20120606monthly0.5https://www.biopharmawatch.com/news/LLY/boehringer-ingelheim-pharmaceuticals-inc-and-eli-lilly-and-company-to-feature-30-presentat-lly-20120605monthly0.5https://www.biopharmawatch.com/news/LLY/lung-cancer-study-showed-encouraging-results-for-alimta-based-regimens-and-full-dose-radia-lly-20120604monthly0.5https://www.biopharmawatch.com/news/LLY/phase-iii-study-patients-with-most-common-type-of-lung-cancer-lived-longer-with-alimta-bas-lly-20120604monthly0.5https://www.biopharmawatch.com/news/LLY/dr-william-g-kaelin-jr-elected-to-lilly-board-of-directors-the-board-of-directors-of-eli-l-lly-20120604monthly0.5https://www.biopharmawatch.com/news/LLY/amyvid-florbetapir-f-18-injection-now-available-in-select-u-s-markets-eli-lilly-and-compan-lly-20120601monthly0.5https://www.biopharmawatch.com/news/LLY/new-mobile-app-helps-doctors-find-clinical-trials-for-cancer-patients-today-eli-lilly-and--lly-20120601monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-commitment-to-global-innovation-reinforced-with-opening-of-new-diabetes-focused-re-lly-20120530monthly0.5https://www.biopharmawatch.com/news/LLY/new-phase-3-data-for-tradjenta-linagliptin-tablets-in-black-or-african-american-patients-w-lly-20120524monthly0.5https://www.biopharmawatch.com/news/LLY/american-college-of-endocrinology-ace-and-lilly-diabetes-offer-new-tips-to-help-people-wit-lly-20120523monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-diabetes-presents-phase-ii-blood-pressure-and-heart-rate-data-on-investigational-glp-lly-20120522monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-oncology-to-disclose-new-pipeline-data-at-asco-2012-eli-lilly-and-company-nyse-lly-w-lly-20120514monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-oncology-to-highlight-final-results-for-phase-iii-study-in-most-common-form-of-lung--lly-20120514monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-sets-date-for-lilly-diabetes-pipeline-update-to-the-investment-community-eli-lilly-a-lly-20120503monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-applauds-law-enforcement-officials-for-their-successful-investigation-and-recovery-o-lly-20120503monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-solid-start-to-the-year-with-first-quarter-2012-results-raises-eps-guidance--lly-20120425monthly0.5https://www.biopharmawatch.com/news/LLY/diversityinc-names-lilly-a-top-company-for-diversity-eli-lilly-and-company-nyse-lly-has-be-lly-20120425monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-diabetes-and-walgreens-launch-diabetes-hypoglycemia-awareness-campaign-lilly-diabete-lly-20120416monthly0.5https://www.biopharmawatch.com/news/LLY/reintegration-awards-recognize-service-to-people-with-mental-illness-sixteen-people-will-b-lly-20120416monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-second-quarter-2012-dividend-the-board-of-directors-of-eli-lilly-and-compan-lly-20120416monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-first-quarter-2012-financial-results-announcem-lly-20120411monthly0.5https://www.biopharmawatch.com/news/LLY/fda-approves-amyvid-florbetapir-f-18-injection-for-use-in-patients-being-evaluated-for-alz-lly-20120409monthly0.5https://www.biopharmawatch.com/news/LLY/fda-approves-amyvid-florbetapir-f-18-injection-for-use-in-patients-being-evaluated-for-alz-lly-20120406monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-diabetes-supports-diabetes-scholars-foundation-with-100-000-donation-in-2012-lilly-d-lly-20120404monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-targets-faulty-c-met-receptor-in-cancer-research-studies-presented-today-at-aacr-mee-lly-20120402monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-anti-il-17-monoclonal-antibody-ixekizumab-met-primary-endpoint-in-phase-ii-study-i-lly-20120328monthly0.5https://www.biopharmawatch.com/news/LLY/fifth-lilly-oncology-on-canvas-art-competition-invites-all-touched-by-cancer-to-share-thei-lly-20120316monthly0.5https://www.biopharmawatch.com/news/LLY/boehringer-ingelheim-and-lilly-s-new-oral-type-2-diabetes-treatment-for-adults-jentadueto--lly-20120307monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-pledges-100-000-to-american-red-cross-tornado-disaster-relief-efforts-the-eli-lilly--lly-20120305monthly0.5https://www.biopharmawatch.com/news/LLY/welcome-back-awards-recognize-outstanding-contributions-in-the-fight-against-depression-fi-lly-20120228monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-introduces-global-innovation-starts-here-initiative-to-foster-innovation-and-quality-lly-20120228monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-releases-its-most-comprehensive-corporate-responsibility-report-eli-lilly-and-compan-lly-20120214monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-recognized-as-a-top-company-for-executive-women-eli-lilly-and-company-nyse-lly-has-e-lly-20120207monthly0.5https://www.biopharmawatch.com/news/LLY/new-study-evaluates-cialis-in-parallel-with-tamsulosin-in-men-with-signs-and-symptoms-sugg-lly-20120207monthly0.5https://www.biopharmawatch.com/news/LLY/partnership-between-lilly-diabetes-and-the-american-diabetes-association-to-send-89-childr-lly-20120201monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-fourth-quarter-and-full-year-2011-results-fourth-quarter-revenue-declined-tw-lly-20120131monthly0.5https://www.biopharmawatch.com/news/LLY/fda-approves-jentadueto-linagliptin-metformin-hydrochloride-tablets-for-the-treatment-of-a-lly-20120130monthly0.5https://www.biopharmawatch.com/news/LLY/elanco-animal-health-announces-lilly-s-agreement-to-acquire-chemgen-corp-elanco-the-animal-lly-20120124monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-comments-on-2011-financial-guidance-and-announces-2012-financial-guidance-company-ex-lly-20120105monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-sets-dates-and-conference-calls-for-2012-financial-guidance-and-fourth-quarter-2011--lly-20111216monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-recognized-as-one-of-the-best-places-to-work-for-lgbt-equality-for-the-sixth-consecu-lly-20111214monthly0.5https://www.biopharmawatch.com/news/LLY/katherine-baicker-elected-to-lilly-board-of-directors-board-of-directors-of-eli-lilly-and--lly-20111212monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-oncology-reveals-findings-from-study-of-jak2-inhibitor-for-blood-cancers-at-ash-meet-lly-20111212monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-first-quarter-2012-dividend-the-board-of-directors-of-eli-lilly-and-company-lly-20111212monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-for-better-health-expands-website-to-include-spanish-health-information-and-interact-lly-20111209monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-for-better-health-expande-su-sitio-web-para-incluir-informacio-n-de-salud-y-herramie-lly-20111209monthly0.5https://www.biopharmawatch.com/news/LLY/taking-sex-off-their-to-do-list-most-couples-prefer-spontaneity-in-the-bedroom-sex-is-spon-lly-20111208monthly0.5https://www.biopharmawatch.com/news/LLY/eli-lilly-and-company-named-a-top-global-company-for-leaders-eli-lilly-and-company-nyse-ll-lly-20111201monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-first-and-only-international-prospective-observational-study-designed-to-u-lly-20111201monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-provides-additional-funding-to-infectious-disease-research-institute-to-identify-new-lly-20111117monthly0.5https://www.biopharmawatch.com/news/LLY/new-analysis-of-data-presented-at-aha-regarding-effect-of-effient-prasugrel-on-cardiovascu-lly-20111116monthly0.5https://www.biopharmawatch.com/news/LLY/f-a-c-e-diabetes-and-anthony-anderson-ask-americans-to-rethink-generation-d-for-the-second-lly-20111111monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-ceo-lechleiter-outlines-opportunities-for-improved-health-and-economic-growth-in-asi-lly-20111110monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-recognize-employees-who-have-served-our-country-through-the-military-u-s-military-lly-20111109monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-surpasses-united-way-2011-campaign-goal-eli-lilly-and-company-nyse-lly-chairman-pres-lly-20111108monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-ceo-says-appropriate-assessment-of-both-benefits-and-risks-critical-in-regulatory-pr-lly-20111102monthly0.5https://www.biopharmawatch.com/news/LLY/alimta-first-chemotherapy-approved-in-europe-as-continuation-maintenance-therapy-for-most--lly-20111028monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-foundation-commits-us-30-million-to-the-lilly-mdr-tb-partnership-the-eli-lilly-and-c-lly-20111027monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-provides-update-on-2011-financial-guidance-due-to-xigris-withdrawal-eli-lilly-and-co-lly-20111025monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-third-quarter-2011-results-third-quarter-2011-revenue-grew-9-percent-to-6-14-lly-20111020monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-fourth-quarter-2011-dividend-the-board-of-directors-of-eli-lilly-and-compan-lly-20111017monthly0.5https://www.biopharmawatch.com/news/LLY/new-study-shows-cialis-significantly-improved-study-endpoints-in-men-with-both-erectile-dy-lly-20111012monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-changes-in-senior-management-eli-lilly-and-company-nyse-lly-today-announce-lly-20111011monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-third-quarter-2011-financial-results-announcem-lly-20111010monthly0.5https://www.biopharmawatch.com/news/LLY/cialis-for-once-daily-use-now-fda-approved-to-treat-men-with-signs-and-symptoms-of-benign--lly-20111007monthly0.5https://www.biopharmawatch.com/news/LLY/2011-lilly-global-day-of-service-focuses-on-healthy-outdoor-living-thousands-of-volunteers-lly-20111004monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-improves-its-environmental-footprint-in-business-operations-and-helps-beautify-commu-lly-20111004monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-launches-open-innovation-drug-discovery-platform-to-help-find-potential-new-medicine-lly-20110927monthly0.5https://www.biopharmawatch.com/news/LLY/alimta-receives-positive-opinion-from-chmp-as-continuation-maintenance-therapy-for-deadly--lly-20110926monthly0.5https://www.biopharmawatch.com/news/LLY/alimta-helped-keep-most-common-form-of-lung-cancer-at-bay-in-elderly-patients-eli-lilly-an-lly-20110926monthly0.5https://www.biopharmawatch.com/news/LLY/lung-cancer-study-reveals-similar-outcomes-for-african-american-and-caucasian-patients-tre-lly-20110920monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-steps-up-efforts-to-improve-diversity-in-clinical-trials-racial-and-ethnic-minoritie-lly-20110920monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-named-one-of-america-s-best-adoption-friendly-workplaces-eli-lilly-and-company-nyse--lly-20110919monthly0.5https://www.biopharmawatch.com/news/LLY/eli-lilly-and-company-bringing-diabetes-education-program-to-the-annual-legislative-confer-lly-20110919monthly0.5https://www.biopharmawatch.com/news/LLY/research-suggests-forteo-significantly-increases-bone-strength-eli-lilly-and-company-nyse--lly-20110919monthly0.5https://www.biopharmawatch.com/news/LLY/new-data-explore-mechanistic-differences-between-forteo-and-zoledronic-acid-eli-lilly-and--lly-20110919monthly0.5https://www.biopharmawatch.com/news/LLY/a-win-for-innovation-president-signs-america-invents-act-today-s-historic-signing-of-the-a-lly-20110916monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-celebrates-17th-consecutive-year-as-one-of-working-mother-100-best-companies-eli-lil-lly-20110916monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-invests-30-million-in-partnership-to-address-non-communicable-diseases-eli-lilly-and-lly-20110913monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-sponsored-summit-to-help-youth-focus-on-their-potential-the-annual-center-for-leader-lly-20110912monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-health-channel-debuts-on-youtube-on-the-heels-of-launching-its-enhanced-lilly-for-be-lly-20110908monthly0.5https://www.biopharmawatch.com/news/LLY/boehringer-ingelheim-and-lilly-to-feature-type-2-diabetes-research-in-presentations-at-the-lly-20110907monthly0.5https://www.biopharmawatch.com/news/LLY/linagliptin-receives-approval-in-europe-for-the-treatment-of-type-2-diabetes-boehringer-in-lly-20110825monthly0.5https://www.biopharmawatch.com/news/LLY/the-american-diabetes-association-and-eli-lilly-and-company-encourage-african-americans-to-lly-20110817monthly0.5https://www.biopharmawatch.com/news/LLY/effient-prasugrel-showed-significant-26-percent-reduction-in-cardiovascular-events-over-cl-lly-20110815monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-review-of-data-on-long-term-raloxifene-treatment-for-postmenopausal-osteop-lly-20110809monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-court-of-appeals-affirms-validity-of-lilly-s-strattera-patent-eli-lilly-and-company-ny-lly-20110729monthly0.5https://www.biopharmawatch.com/news/LLY/eli-lilly-india-and-lupin-announce-strategic-collaboration-to-help-fight-the-battle-agains-lly-20110729monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-launches-physician-payment-registry-eli-lilly-and-company-nyse-lly-today-announced-t-lly-20110727monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-global-gibt-mitarbeitern-mehr-mo-glichkeiten-zu-gemeinnu-tziger-arbeit-durch-ein-neu-lly-20110725monthly0.5https://www.biopharmawatch.com/news/LLY/le-programme-global-giving-de-lilly-fait-de-chaque-employe-un-philanthrope-gra-ce-a-un-nou-lly-20110725monthly0.5https://www.biopharmawatch.com/news/LLY/programa-lilly-global-giving-coloca-o-poder-da-filantropia-em-ma-os-de-funciona-rios-pela--lly-20110725monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-global-giving-situ-a-el-poder-de-la-filantropi-a-en-manos-de-los-empleados-por-medio-lly-20110725monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-global-giving-pone-el-poder-de-la-filantropi-a-en-manos-de-los-empleados-por-primera-lly-20110725monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-global-giving-puts-power-of-philanthropy-in-employees-hands-for-the-first-time-eli-l-lly-20110725monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-second-quarter-2011-results-second-quarter-2011-revenue-grew-9-percent-to-6--lly-20110721monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-presents-follow-up-data-on-semagacestat-to-assist-future-alzheimer-s-disease-researc-lly-20110719monthly0.5https://www.biopharmawatch.com/news/LLY/florbetapir-imaging-to-autopsy-study-awarded-alzheimer-s-association-s-2011-de-leon-prize--lly-20110718monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-argonne-national-laboratory-announce-2-million-upgrade-to-lilly-s-beamline-capab-lly-20110714monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-donation-to-patient-advocate-foundation-expands-services-and-access-for-patients-wit-lly-20110713monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-second-quarter-2011-financial-results-announce-lly-20110712monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-ceo-empfiehlt-einbeziehung-von-biopharmazeutika-in-transatlantische-handels-und-wirt-lly-20110711monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-ceo-says-biopharmaceuticals-should-be-included-in-transatlantic-trade-and-economic-d-lly-20110711monthly0.5https://www.biopharmawatch.com/news/LLY/ceo-von-lilly-ruft-zu-verbessertem-dialog-in-deutschland-zwischen-der-industrie-der-regier-lly-20110707monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-ceo-calls-for-improved-dialogue-in-germany-between-industry-and-the-government-and-h-lly-20110707monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-quality-leader-walsh-appointed-to-company-s-executive-committee-fionnuala-walsh-ph-d-lly-20110701monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-outlines-for-investors-how-its-innovation-based-strategy-and-robust-pipeline-will-dr-lly-20110630monthly0.5https://www.biopharmawatch.com/news/LLY/newly-published-study-showed-axiron-testosterone-topical-solution-restored-testosterone-le-lly-20110628monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-new-investment-to-further-boost-its-biotechnology-capabilities-today-at-th-lly-20110628monthly0.5https://www.biopharmawatch.com/news/LLY/analysis-compares-cost-effectiveness-of-premixed-insulin-analogs-to-long-acting-insulin-an-lly-20110624monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-third-quarter-2011-dividend-the-board-of-directors-of-eli-lilly-and-company-lly-20110620monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-for-better-health-launches-enhanced-multi-channel-patient-education-platform-lilly-f-lly-20110614monthly0.5https://www.biopharmawatch.com/news/LLY/synthes-and-lilly-sign-development-and-collaboration-agreement-synthes-inc-six-syst-vx-and-lly-20110609monthly0.5https://www.biopharmawatch.com/news/LLY/fda-approves-updates-to-lilly-s-humalog-insulin-lispro-injection-rdna-origin-label-eli-lil-lly-20110608monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-district-court-rules-in-favor-of-lilly-in-amylin-litigation-eli-lilly-and-company-nyse-lly-20110608monthly0.5https://www.biopharmawatch.com/news/LLY/new-study-released-today-showed-patients-with-deadly-form-of-lung-cancer-lived-longer-with-lly-20110605monthly0.5https://www.biopharmawatch.com/news/LLY/correction-lilly-presents-data-on-cixutumumab-in-five-subtypes-of-sarcomas-in-the-press-re-lly-20110527monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-comments-on-court-ruling-in-amylin-litigation-eli-lilly-and-company-nyse-lly-today-c-lly-20110525monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-investor-group-form-new-critical-care-company-biocritica-sign-xigris-license-agr-lly-20110523monthly0.5https://www.biopharmawatch.com/news/LLY/study-determined-best-dose-and-showed-55-percent-response-rate-with-lilly-anti-baff-monocl-lly-20110519monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-presents-data-on-cixutumumab-in-five-subtypes-of-sarcoma-eli-lilly-and-company-nyse--lly-20110519monthly0.5https://www.biopharmawatch.com/news/LLY/david-m-kendall-m-d-named-distinguished-medical-fellow-at-lilly-eli-lilly-and-company-nyse-lly-20110518monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-provides-statement-in-response-to-amylin-lawsuit-eli-lilly-and-company-nyse-lly-has--lly-20110516monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-usa-llc-launches-truassist-for-patients-lilly-usa-has-launched-www-lillytruassist-co-lly-20110516monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-oncology-to-present-new-data-on-nine-of-its-pipeline-molecules-at-asco-2011-data-on--lly-20110516monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-oncology-to-unveil-data-from-more-than-30-studies-at-asco-eli-lilly-and-company-nyse-lly-20110516monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-provides-its-perspective-in-response-to-amylin-lawsuit-eli-lilly-and-company-nyse-ll-lly-20110516monthly0.5https://www.biopharmawatch.com/news/LLY/eli-lilly-and-company-invests-2-5-million-to-launch-the-mind-trust-s-grow-what-works-campa-lly-20110505monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-district-court-order-maintains-patent-exclusivity-for-lilly-s-cymbalta-eli-lilly-and-c-lly-20110427monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-medtronic-announce-drug-device-collaboration-for-parkinson-s-disease-eli-lilly-a-lly-20110426monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-first-quarter-2011-results-first-quarter-2011-revenue-grew-6-percent-to-5-8--lly-20110418monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-second-quarter-2011-dividend-the-board-of-directors-of-eli-lilly-and-compan-lly-20110418monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-receives-complete-response-letter-from-fda-for-liprotamase-for-the-treatment-of-exoc-lly-20110415monthly0.5https://www.biopharmawatch.com/news/LLY/american-college-of-endocrinology-ace-and-lilly-diabetes-offer-free-checklist-to-help-peop-lly-20110414monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-first-quarter-2011-financial-results-announcem-lly-20110406monthly0.5https://www.biopharmawatch.com/news/LLY/two-novel-lilly-molecules-target-genetic-mutations-that-can-lead-to-cancer-eli-lilly-and-c-lly-20110404monthly0.5https://www.biopharmawatch.com/news/LLY/axiron-testosterone-topical-solution-ciii-now-available-in-pharmacies-eli-lilly-and-compan-lly-20110401monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-connecting-hearts-abroad-program-sends-employees-on-global-service-assignments-eli-lly-20110331monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-avid-receive-complete-response-letter-from-fda-for-amyvid-florbetapir-f-18-injec-lly-20110318monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-important-action-regarding-recall-of-alcohol-prep-pads-made-by-triad-group-lly-20110317monthly0.5https://www.biopharmawatch.com/news/LLY/nafe-names-lilly-to-top-50-companies-for-executive-women-eli-lilly-and-company-nyse-lly-ha-lly-20110315monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-new-vice-president-of-oncology-research-eli-lilly-and-company-nyse-lly-tod-lly-20110310monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-ceo-calls-for-biopharmaceutical-industry-changes-and-policies-that-encourage-medical-lly-20110309monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-marks-major-milestone-for-mirror-portfolio-with-agreement-by-independent-fund-to-lic-lly-20110215monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-senior-leadership-changes-eli-lilly-and-company-nyse-lly-today-announced-t-lly-20110211monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-ceo-says-industry-public-policy-must-pave-way-for-innovation-a-new-approach-to-resea-lly-20110210monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-the-juvenile-diabetes-research-foundation-partner-to-fund-regenerative-medicine--lly-20110203monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-bristol-myers-squibb-stop-enrollment-in-one-of-two-phase-iii-lung-cancer-trials-of-n-lly-20110202monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-fourth-quarter-and-full-year-2010-results-provides-2011-financial-guidance-h-lly-20110127monthly0.5https://www.biopharmawatch.com/news/LLY/president-of-lilly-oncology-announces-resignation-eli-lilly-and-company-nyse-lly-today-ann-lly-20110125monthly0.5https://www.biopharmawatch.com/news/LLY/statement-from-lilly-and-avid-on-fda-advisory-committee-recommendation-for-amyvid-florbeta-lly-20110120monthly0.5https://www.biopharmawatch.com/news/LLY/new-online-resource-available-specifically-for-patients-and-their-caregivers-following-a-h-lly-20110118monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-confirms-date-and-conference-call-for-fourth-quarter-and-full-year-2010-financial-re-lly-20110118monthly0.5https://www.biopharmawatch.com/news/LLY/statement-from-lilly-on-fda-advisory-committee-recommendation-regarding-liprotamase-new-dr-lly-20110112monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-boehringer-ingelheim-announce-strategic-alliance-to-bring-new-diabetes-treatment-lly-20110111monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-announces-completion-of-avid-acquisition-and-fda-priority-review-for-florbetapir-eli-lly-20101220monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-statement-regarding-president-obama-s-meeting-with-u-s-business-leaders-eli-lilly-an-lly-20101215monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-first-quarter-2011-dividend-the-board-of-directors-of-eli-lilly-and-company-lly-20101213monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-suspends-phase-iii-trial-in-metastatic-melanoma-eli-lilly-and-company-announced-toda-lly-20101213monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-and-acrux-receive-fda-approval-for-axiron-testosterone-topical-solution-ciii-eli-lil-lly-20101123monthly0.5https://www.biopharmawatch.com/news/LLY/mortality-data-presented-for-patients-treated-with-efient-effient-prasugrel-who-underwent--lly-20101116monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-district-court-rules-from-bench-in-lilly-s-favor-confirms-validity-of-alimta-patent-el-lly-20101115monthly0.5https://www.biopharmawatch.com/news/LLY/giving-thanks-and-eating-well-f-a-c-e-diabetes-and-anthony-anderson-encourage-african-amer-lly-20101110monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-to-acquire-avid-radiopharmaceuticals-eli-lilly-and-company-nyse-lly-today-announced--lly-20101108monthly0.5https://www.biopharmawatch.com/news/LLY/fda-approves-cymbalta-for-the-management-of-chronic-musculoskeletal-pain-eli-lilly-and-com-lly-20101104monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-surpasses-united-way-2010-campaign-goal-eli-lilly-and-company-nyse-lly-chairman-pres-lly-20101104monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-ceo-calls-for-a-wave-of-invention-to-reduce-the-toll-of-diabetes-in-a-speech-to-the--lly-20101103monthly0.5https://www.biopharmawatch.com/news/LLY/eli-lilly-and-company-to-open-a-diabetes-focused-research-center-in-china-eli-lilly-and-co-lly-20101102monthly0.5https://www.biopharmawatch.com/news/LLY/the-welcome-back-awards-seeks-nominations-to-honor-leaders-in-the-depression-community-the-lly-20101101monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-ceo-are-we-getting-our-money-s-worth-from-medical-innovation-in-a-speech-to-the-dall-lly-20101029monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-reports-third-quarter-2010-results-total-revenue-growth-of-2-percent-driven-by-highe-lly-20101021monthly0.5https://www.biopharmawatch.com/news/LLY/life-becomes-art-cancer-survivor-awarded-top-prize-in-2010-oncology-on-canvas-sm-art-compe-lly-20101020monthly0.5https://www.biopharmawatch.com/news/LLY/la-vida-se-convierte-en-arte-sobreviviente-del-ca-ncer-recibe-el-primer-premio-del-concurs-lly-20101020monthly0.5https://www.biopharmawatch.com/news/LLY/macrogenics-and-lilly-announce-pivotal-clinical-trial-of-teplizumab-did-not-meet-primary-e-lly-20101020monthly0.5https://www.biopharmawatch.com/news/LLY/health-care-coordination-program-honored-with-urac-national-best-practices-award-urac-a-le-lly-20101018monthly0.5https://www.biopharmawatch.com/news/LLY/eli-lilly-and-company-announces-2010-lilly-reintegration-awards-recipients-for-the-14th-st-lly-20101018monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-declares-fourth-quarter-2010-dividend-the-board-of-directors-of-eli-lilly-and-compan-lly-20101018monthly0.5https://www.biopharmawatch.com/news/LLY/new-forteo-and-evista-data-to-be-presented-at-premiere-scientific-meeting-for-bone-and-min-lly-20101014monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-s-online-interactive-health-education-answers-program-receives-ncqa-recertification--lly-20101011monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-presents-new-data-in-head-and-neck-cancer-a-difficult-to-treat-cancer-with-poor-surv-lly-20101011monthly0.5https://www.biopharmawatch.com/news/LLY/the-interchange-of-art-and-nature-a-greener-welcome-from-sunup-to-sundown-october-7-2010-m-lly-20101006monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-premiada-por-el-consejo-nacional-hispano-de-personas-adultas-mayores-por-su-continuo-lly-20100929monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-recognized-by-the-national-hispanic-council-on-aging-for-ongoing-commitment-to-the-h-lly-20100929monthly0.5https://www.biopharmawatch.com/news/LLY/eli-lilly-and-company-researchers-begin-working-at-new-state-of-the-art-lab-located-in-the-lly-20100928monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-ceo-says-regional-innovation-clusters-can-renew-the-nation-s-economy-in-the-keynote--lly-20100923monthly0.5https://www.biopharmawatch.com/news/LLY/eli-lilly-and-company-encourages-african-americans-to-get-a-check-up-and-face-diabetes-ang-lly-20100923monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-celebrates-16th-consecutive-year-as-one-of-100-best-companies-for-working-mothers-el-lly-20100922monthly0.5https://www.biopharmawatch.com/news/LLY/jeffrey-a-winton-named-vice-president-of-communications-at-eli-lilly-and-company-eli-lilly-lly-20100921monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-recognized-with-world-business-and-development-award-for-tuberculosis-initiative-an--lly-20100921monthly0.5https://www.biopharmawatch.com/news/LLY/phase-ii-study-showed-switching-acs-pci-patients-to-effient-aspirin-from-plavix-aspirin-re-lly-20100913monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-court-of-appeals-reverses-third-party-payor-class-certification-suit-against-lilly-eli-lly-20100910monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-court-of-appeals-upholds-validity-of-lilly-s-evista-patents-through-march-of-2014-eli--lly-20100901monthly0.5https://www.biopharmawatch.com/news/LLY/statement-from-eli-lilly-and-company-regarding-approval-recommendation-from-fda-advisory-c-lly-20100819monthly0.5https://www.biopharmawatch.com/news/LLY/lilly-halts-development-of-semagacestat-for-alzheimer-s-disease-based-on-preliminary-resul-lly-20100817monthly0.5https://www.biopharmawatch.com/news/LLY/u-s-district-court-rules-against-lilly-regarding-strattera-patent-eli-lilly-and-company-ny-lly-20100812monthly0.5https://www.biopharmawatch.com/news/LLY/the-american-diabetes-association-and-eli-lilly-and-company-encourage-african-americans-to-lly-20100805monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20260617monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20260417monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20260313monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20260108monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20251219monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-ptc-therap-ptct-20251218monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20251027monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20251001monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-investor-conferences-ptc-therapeutics-inc-nasd-ptct-20250821monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-second-quarter-2025-financial-results--ptct-20250721monthly0.5https://www.biopharmawatch.com/news/PTCT/sephience-sepiapterin-granted-marketing-authorization-by-the-european-commission-for-the-t-ptct-20250624monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20250619monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20250501monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-receives-positive-chmp-opinion-for-sephience-sepiapterin-for-the-treatmen-ptct-20250425monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-investor-conferences-ptc-therapeutics-inc-nasd-ptct-20250424monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-first-quarter-2025-financial-results-p-ptct-20250417monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20250328monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-presents-new-sepiapterin-data-from-ongoing-studies-ptc-therapeutics-inc-n-ptct-20250320monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-in-upcoming-investor-conferences-ptc-therapeutics-inc-nasd-ptct-20250220monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-fda-acceptance-and-priority-review-for-vatiquinone-nda-for-the--ptct-20250219monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-2024-fina-ptct-20250213monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20250113monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-ptc-therap-ptct-20241223monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-vatiquinone-nda-submission-to-fda-for-the-treatment-of-children-ptct-20241219monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20241217monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-enters-into-agreement-to-sell-priority-review-voucher-for-150-million-ptc-ptct-20241127monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-topline-results-of-cardinals-trial-of-utreloxastat-in-als-patie-ptct-20241126monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20241125monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-fda-approval-of-aadc-deficiency-gene-therapy-ptc-therapeutics-i-ptct-20241113monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-investor-conferences-ptc-therapeutics-inc-nasd-ptct-20241104monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-fda-acceptance-of-translarna-nda-resubmission-ptc-therapeutics--ptct-20241030monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20241025monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-third-quarter-2024-financial-results-p-ptct-20241024monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-fda-target-regulatory-action-date-for-sepiapterin-and-lancet-pu-ptct-20241014monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-positive-results-from-long-term-treatment-studies-and-updates-o-ptct-20241008monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-fda-acceptance-for-filing-of-nda-for-sepiapterin-for-the-treatm-ptct-20241001monthly0.5https://www.biopharmawatch.com/news/PTCT/fda-grants-fast-track-designation-to-ptc518-huntington-s-disease-program-ptc-therapeutics--ptct-20240926monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20240912monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-investor-conferences-ptc-therapeutics-inc-nasd-ptct-20240828monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-sepiapterin-nda-submission-to-fda-ptc-therapeutics-inc-nasdaq-p-ptct-20240730monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-second-quarter-2024-financial-results--ptct-20240725monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20240621monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-investor-conference-ptc-therapeutics-inc-nasda-ptct-20240529monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-validation-of-sepiapterin-european-maa-ptc-therapeutics-inc-nas-ptct-20240528monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-fda-acceptance-and-priority-review-of-the-bla-for-upstaza-ptc-t-ptct-20240514monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-investor-conferences-ptc-therapeutics-inc-nasd-ptct-20240502monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20240423monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-first-quarter-2024-financial-results-p-ptct-20240411monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-announces-submission-of-sepiapterin-maa-for-treatment-of-pku-to-ema-ptc-therapeutics-i-ptct-20240328monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-key-regulatory-updates-ptc-therapeutics-inc-nasdaq-ptct-today-an-ptct-20240319monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-investor-conferences-ptc-therapeutics-inc-nasd-ptct-20240227monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20240222monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-2023-fina-ptct-20240215monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20231214monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-fornece-atualizac-o-es-sobre-atividades-regulato-rias-do-translarna-a-ptc-ptct-20231207monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-ofrece-novedades-sobre-las-actividades-regulatorias-de-translarna-ptc-the-ptct-20231205monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-updates-on-translarna-regulatory-activities-ptc-therapeutics-inc-ptct-20231205monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20231103monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-third-quarter-2023-financial-results-p-ptct-20231016monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-2023-strive-awards-program-funds-initiatives-supporting-the-duchenne-pati-ptct-20230907monthly0.5https://www.biopharmawatch.com/news/PTCT/el-programa-de-2023-premios-strive-de-ptc-therapeutics-financia-iniciativas-de-apoyo-a-la--ptct-20230907monthly0.5https://www.biopharmawatch.com/news/PTCT/o-programa-strive-awards-2023-da-ptc-therapeutics-financia-iniciativas-que-apoiam-a-comuni-ptct-20230907monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-investor-conferences-ptc-therapeutics-inc-nasd-ptct-20230830monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-recent-data-for-sepiapterin-at-the-society-for-the-study-of-in-ptct-20230828monthly0.5https://www.biopharmawatch.com/news/PTCT/chmp-recommends-evrysdi-for-babies-under-two-months-old-with-spinal-muscular-atrophy-ptc-t-ptct-20230721monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-second-quarter-2023-financial-results--ptct-20230720monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20230718monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-appoints-experienced-healthcare-finance-strategist-pierre-gravier-as-chie-ptct-20230717monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-virtual-presentation-on-phenylketonuria-pku-and-sepiapterin-ptc-ptct-20230711monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-results-from-mit-e-clinical-trial-of-vatiquinone-for-the-treatm-ptct-20230629monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20230615monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-investor-conferences-ptc-therapeutics-inc-nasd-ptct-20230602monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-topline-results-from-vatiquinone-move-fa-registration-directed--ptct-20230523monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-anuncia-que-o-estudo-cli-nico-aphenity-atingiu-o-desfecho-prima-rio-com-s-ptct-20230518monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-anuncia-que-el-ensayo-aphenity-logro-el-criterio-de-valoracio-n-primario--ptct-20230518monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20230428monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-first-quarter-2023-financial-results-p-ptct-20230413monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20230328monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-investor-conferences-ptc-therapeutics-inc-nasd-ptct-20230221monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-lanc-a-o-9o-programa-anual-de-pre-mios-strive-para-financiar-iniciativas--ptct-20230207monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-lanza-el-noveno-programa-anual-de-premios-strive-para-financiar-iniciativ-ptct-20230207monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-2022-fina-ptct-20230207monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-receives-2023-eurordis-black-pearl-company-award-for-innovation-ptc-thera-ptct-20230203monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-investor-conference-ptc-therapeutics-inc-nasda-ptct-20230202monthly0.5https://www.biopharmawatch.com/news/PTCT/nice-recomenda-reembolso-para-translarna-ptc-therapeutics-inc-nasdaq-ptct-anunciou-hoje-qu-ptct-20230122monthly0.5https://www.biopharmawatch.com/news/PTCT/nice-recomienda-el-reembolso-de-translarna-ptc-therapeutics-inc-nasdaq-ptct-anuncio-hoy-qu-ptct-20230120monthly0.5https://www.biopharmawatch.com/news/PTCT/nice-recommends-reimbursement-for-translarna-ptc-therapeutics-inc-nasdaq-ptct-today-announ-ptct-20230119monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-launches-9th-annual-strive-awards-program-to-fund-initiatives-benefitting-ptct-20230117monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20230111monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-41st-annual-j-p-morgan-healthcare-conference-ptc-therap-ptct-20230104monthly0.5https://www.biopharmawatch.com/news/PTCT/autoridade-reguladora-brasileira-concede-aprovac-a-o-a-waylivra-para-lipodistrofia-parcial-ptct-20221201monthly0.5https://www.biopharmawatch.com/news/PTCT/la-autoridad-reguladora-brasilen-a-otorga-su-aprobacio-n-a-waylivra-para-tratar-la-lipodis-ptct-20221201monthly0.5https://www.biopharmawatch.com/news/PTCT/brazilian-regulatory-authority-grants-approval-for-waylivra-for-familial-partial-lipodystr-ptct-20221201monthly0.5https://www.biopharmawatch.com/news/PTCT/upstaza-gene-therapy-granted-marketing-authorization-for-aadc-deficiency-by-uk-s-mhra-ptc--ptct-20221117monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-p-ptct-20221013monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-clinical-and-real-world-evidence-on-translarna-at-the-annual-c-ptct-20221011monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-2022-strive-awards-program-funds-initiatives-supporting-the-duchenne-pati-ptct-20220907monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-investor-conferences-ptc-therapeutics-inc-nasd-ptct-20220901monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-second-quarter-2022-financial-results--ptct-20220721monthly0.5https://www.biopharmawatch.com/news/PTCT/upstaza-granted-marketing-authorization-by-european-commission-as-first-disease-modifying--ptct-20220720monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-call-to-review-topline-results-from-study-041-for-translarna-atal-ptct-20220620monthly0.5https://www.biopharmawatch.com/news/PTCT/biotech-investment-veteran-alethia-young-joins-ptc-therapeutics-board-of-directors-ptc-the-ptct-20220609monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-william-blair-42nd-annual-growth-stock-conference-ptc-t-ptct-20220606monthly0.5https://www.biopharmawatch.com/news/PTCT/preliminary-results-presented-at-asco-demonstrated-promising-clinical-efficacy-with-unesbu-ptct-20220603monthly0.5https://www.biopharmawatch.com/news/PTCT/fda-approves-label-extension-for-evrysdi-for-infants-with-spinal-muscular-atrophy-under-2--ptct-20220531monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-recebe-parecer-positivo-do-chmp-para-upstaza-indicada-para-o-tratamento-d-ptct-20220523monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-recibe-una-opinio-n-positiva-del-chmp-para-upstaza-para-el-tratamiento-de-ptct-20220523monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-receives-positive-chmp-opinion-for-upstaza-for-the-treatment-of-aadc-defi-ptct-20220520monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-anuncia-atualizac-a-o-do-ro-tulo-do-translarna-no-brasil-para-pacientes-na-o-ambulator-ptct-20220518monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-anuncia-la-actualizacio-n-de-la-marca-translarna-en-brasil-para-pacientes-no-ambulator-ptct-20220518monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-investor-conferences-ptc-therapeutics-inc-nasd-ptct-20220429monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-first-quarter-2022-financial-results-p-ptct-20220419monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-update-on-ema-regulatory-review-timeline-for-its-aadc-deficiency-ptct-20220414monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20220408monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-initiation-of-pivot-hd-phase-2-clinical-trial-to-evaluate-ptc51-ptct-20220330monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-new-data-at-the-2022-muscular-dystrophy-association-clinical-s-ptct-20220311monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-investor-conferences-ptc-therapeutics-inc-nasd-ptct-20220223monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-fourth-quarter-and-year-end-2021-finan-ptct-20220208monthly0.5https://www.biopharmawatch.com/news/PTCT/fda-concede-ana-lise-priorita-ria-ao-evrysdi-com-base-nos-resultados-do-tratamento-de-bebe-ptct-20220126monthly0.5https://www.biopharmawatch.com/news/PTCT/la-fda-otorga-una-revisio-n-proritaria-a-evrysdi-con-base-en-los-resultados-del-tratamient-ptct-20220126monthly0.5https://www.biopharmawatch.com/news/PTCT/fda-grants-evrysdi-priority-review-based-on-results-from-treating-pre-symptomatic-infants--ptct-20220125monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-annonce-le-lancement-du-8e-programme-annuel-de-prix-strive-pour-financer--ptct-20220118monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-anuncia-los-premios-strive-para-financiar-iniciativas-de-distrofia-muscul-ptct-20220118monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-gibt-den-start-des-8-ja-hrlichen-strive-preisprogramms-zur-finanzierung-v-ptct-20220118monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-anuncia-lanc-amento-do-8o-programa-anual-de-premiac-a-o-strive-para-finan-ptct-20220118monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-anuncia-el-lanzamiento-del-octavo-programa-anual-de-premios-strive-para-f-ptct-20220118monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-launch-of-8th-annual-strive-awards-program-to-fund-initiatives--ptct-20220118monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20220113monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-annonce-le-lancement-du-2022-global-talent-pipeline-program-ptc-therapeut-ptct-20220113monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-anuncia-lanc-amento-do-programa-global-talent-pipeline-de-2022-a-ptc-ther-ptct-20220113monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-anuncia-el-lanzamiento-del-2022-global-talent-pipeline-program-ptc-therap-ptct-20220113monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-gibt-start-des-weltweiten-talent-pipeline-programms-2022-bekannt-ptc-ther-ptct-20220113monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-anuncia-el-lanzamiento-de-su-programa-de-reserva-de-talento-global-2022-p-ptct-20220113monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-launch-of-2022-global-talent-pipeline-program-ptc-therapeutics--ptct-20220113monthly0.5https://www.biopharmawatch.com/news/PTCT/waylivra-recebe-precificac-a-o-na-categoria-de-medicamentos-inovadores-para-tratar-a-si-nd-ptct-20220105monthly0.5https://www.biopharmawatch.com/news/PTCT/waylivra-recibe-asignacio-n-de-precios-en-la-categori-a-de-fa-rmaco-innovador-para-tratar--ptct-20220104monthly0.5https://www.biopharmawatch.com/news/PTCT/waylivra-receives-innovative-drug-category-pricing-to-treat-familial-chylomicronemia-syndr-ptct-20220104monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-at-the-40th-annual-j-p-morgan-virtual-healthcare-conference-pt-ptct-20220103monthly0.5https://www.biopharmawatch.com/news/PTCT/datos-publicados-por-molecular-therapy-demuestran-efectos-sostenidos-de-la-terapia-ge-nica-ptct-20211223monthly0.5https://www.biopharmawatch.com/news/PTCT/dados-publicados-pela-molecular-therapy-demonstram-efeitos-sustentados-da-terapia-gene-tic-ptct-20211223monthly0.5https://www.biopharmawatch.com/news/PTCT/modificadores-de-splicing-administrados-por-via-oral-que-diminuem-sistemicamente-a-protei--ptct-20211220monthly0.5https://www.biopharmawatch.com/news/PTCT/modificadores-de-empalme-orales-que-reducen-de-manera-sistema-tica-la-protei-na-de-la-enfe-ptct-20211220monthly0.5https://www.biopharmawatch.com/news/PTCT/oral-splicing-modifiers-that-systemically-lower-huntington-disease-protein-discovered-thro-ptct-20211220monthly0.5https://www.biopharmawatch.com/news/PTCT/evrysdi-recebe-dois-pre-mios-de-presti-gio-por-inovac-a-o-excepcional-na-descoberta-de-med-ptct-20211207monthly0.5https://www.biopharmawatch.com/news/PTCT/evrysdi-es-reconocida-con-dos-prestigiosos-premios-por-innovacio-n-sobresaliente-en-el-des-ptct-20211207monthly0.5https://www.biopharmawatch.com/news/PTCT/evrysdi-distinguished-by-two-prestigious-awards-for-outstanding-innovation-in-drug-discove-ptct-20211206monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20211202monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-virtual-investor-conference-ptc-therapeutics-i-ptct-20211116monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-virtual-investor-conference-ptc-therapeutics-i-ptct-20211026monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-anuncia-la-ampliacio-n-de-la-indicacio-n-en-la-etiqueta-de-translarna-para-incluir-a-p-ptct-20211025monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-anuncia-ampliac-a-o-do-translarna-para-incluir-pacientes-ambulatoriais-com-ate-dois-an-ptct-20211025monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-announces-expansion-of-translarna-label-to-include-ambulatory-patients-as-young-as-2-y-ptct-20211025monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-third-quarter-2021-financial-results-p-ptct-20211014monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-celebrates-opening-of-gene-therapy-manufacturing-facility-ptc-therapeutic-ptct-20211014monthly0.5https://www.biopharmawatch.com/news/PTCT/tegsedi-recebe-precificac-a-o-inovadora-de-categoria-de-medicamento-no-brasil-a-ptc-therap-ptct-20211011monthly0.5https://www.biopharmawatch.com/news/PTCT/tegsedi-recibe-precio-por-su-categori-a-de-fa-rmacos-innovadores-en-brasil-ptc-therapeutic-ptct-20211011monthly0.5https://www.biopharmawatch.com/news/PTCT/tegsedi-receives-innovative-drug-category-pricing-in-brazil-ptc-therapeutics-inc-nasdaq-pt-ptct-20211011monthly0.5https://www.biopharmawatch.com/news/PTCT/los-resultados-muestran-mejoras-duraderas-y-holi-sticas-en-nin-os-con-deficiencia-de-aadc--ptct-20210930monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20210929monthly0.5https://www.biopharmawatch.com/news/PTCT/os-resultados-mostram-melhorias-duradouras-e-holi-sticas-em-crianc-as-com-deficie-ncia-aad-ptct-20210929monthly0.5https://www.biopharmawatch.com/news/PTCT/results-show-long-lasting-and-holistic-improvements-in-children-with-aadc-deficiency-treat-ptct-20210929monthly0.5https://www.biopharmawatch.com/news/PTCT/os-dados-do-stride-mostram-que-o-translarna-retarda-a-perda-de-ambulac-a-o-por-mais-de-cin-ptct-20210921monthly0.5https://www.biopharmawatch.com/news/PTCT/los-datos-de-stride-muestran-que-translarna-retrasa-la-pe-rdida-de-ambulacio-n-por-ma-s-de-ptct-20210921monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-results-of-ptc518-phase-1-study-for-hu-ptct-20210920monthly0.5https://www.biopharmawatch.com/news/PTCT/stride-data-show-translarna-delays-loss-of-ambulation-by-more-than-five-years-in-boys-with-ptct-20210920monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-recognizes-2021-strive-awards-recipients-for-initiatives-supporting-duche-ptct-20210907monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-virtual-investor-conferences-ptc-therapeutics--ptct-20210827monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-anuncia-aprovac-a-o-do-waylivra-no-brasil-como-primeiro-tratamento-para-s-ptct-20210824monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-anuncia-la-aprobacio-n-de-waylivra-en-brasil-como-primer-tratamiento-para-ptct-20210824monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-waylivra-approval-in-brazil-as-first-treatment-for-familial-chy-ptct-20210823monthly0.5https://www.biopharmawatch.com/news/PTCT/targeting-the-putamen-with-gene-therapy-leads-to-sustained-improvements-in-motor-and-non-m-ptct-20210823monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20210820monthly0.5https://www.biopharmawatch.com/news/PTCT/significant-improvements-in-survival-and-developmental-milestones-demonstrated-in-type-1-s-ptct-20210728monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-second-quarter-2021-financial-results--ptct-20210715monthly0.5https://www.biopharmawatch.com/news/PTCT/results-add-to-body-of-evidence-confirming-emflaza-s-benefit-over-prednisone-ptc-therapeut-ptct-20210624monthly0.5https://www.biopharmawatch.com/news/PTCT/evrysdi-approved-in-japan-for-the-treatment-of-spinal-muscular-atrophy-ptc-therapeutics-in-ptct-20210623monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20210615monthly0.5https://www.biopharmawatch.com/news/PTCT/pre-symptomatic-infants-with-spinal-muscular-atrophy-achieved-same-motor-milestones-as-hea-ptct-20210611monthly0.5https://www.biopharmawatch.com/news/PTCT/health-and-human-services-expert-mary-l-smith-joins-ptc-therapeutics-board-of-directors-pt-ptct-20210609monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-orphan-drug-designations-of-ptc923-for-the-treatment-of-hyperph-ptct-20210526monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-virtual-investor-conference-ptc-therapeutics-i-ptct-20210519monthly0.5https://www.biopharmawatch.com/news/PTCT/new-data-shows-devastating-impact-of-aadc-deficiency-on-caregivers-ptc-therapeutics-inc-na-ptct-20210517monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-virtual-investor-conferences-ptc-therapeutics--ptct-20210427monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-first-quarter-2021-financial-results-p-ptct-20210420monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20210419monthly0.5https://www.biopharmawatch.com/news/PTCT/continued-improvements-in-motor-milestones-in-infants-with-type-1-spinal-muscular-atrophy--ptct-20210415monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-launches-the-ptc-pinpoint-direct-program-for-patient-initiated-genetic-te-ptct-20210414monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-received-gallup-s-don-clifton-strengths-based-culture-award-ptc-therapeut-ptct-20210407monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-ptc518-huntington-disease-deep-dive-webinar-ptc-therapeutics-inc--ptct-20210407monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-commercial-milestone-payment-following-the-recent-european-appr-ptct-20210401monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-the-european-approval-of-evrysdi-for-the-treatment-of-spinal-mu-ptct-20210330monthly0.5https://www.biopharmawatch.com/news/PTCT/results-from-the-second-year-of-evrysdi-risdiplam-treatment-demonstrated-sustained-improve-ptct-20210316monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-presents-results-from-a-real-world-study-of-steroid-switching-in-the-treatment-of-pati-ptct-20210315monthly0.5https://www.biopharmawatch.com/news/PTCT/spinal-muscular-atrophy-sma-foundation-and-ptc-therapeutics-expand-partnership-to-advance--ptct-20210309monthly0.5https://www.biopharmawatch.com/news/PTCT/chmp-adopts-positive-opinion-for-evrysdi-for-the-treatment-of-spinal-muscular-atrophy-in-a-ptct-20210226monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides--ptct-20210225monthly0.5https://www.biopharmawatch.com/news/PTCT/positive-data-from-firefish-study-of-evrysdi-risdiplam-in-infants-with-type-1-spinal-muscu-ptct-20210224monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-the-initiation-of-the-second-stage-of-the-fite19-phase-2-3-clinic-ptct-20210217monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-virtual-investor-conferences-ptc-therapeutics--ptct-20210216monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-fourth-quarter-and-year-end-2020-finan-ptct-20210211monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-opens-applications-for-the-annual-strive-awards-program-and-introduces-a--ptct-20210114monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20210113monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-ptc-therap-ptct-20210104monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20201218monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-translarna-deep-dive-webinar-ptc-therapeutics-inc-nasdaq-ptct-wil-ptct-20201209monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20201204monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-announces-translarna-approval-in-russia-for-the-treatment-of-duchenne-muscular-dystrop-ptct-20201204monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-initiation-of-global-phase-3-clinical-trial-to-evaluate-vatiqui-ptct-20201130monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference-ptc-thera-ptct-20201119monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-key-regulatory-designations-for-ptc596-to-advance-treatment-of--ptct-20201118monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-that-ptc518-has-entered-into-a-phase-1-clinical-trial-for-the-h-ptct-20201117monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-highlights-data-on-high-disease-burden-and-value-of-treatment-across-two--ptct-20201116monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20201028monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-virtual-investor-conferences-ptc-therapeutics--ptct-20201028monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-and-aadc-family-network-announce-first-ever-aadc-deficiency-awareness-day-ptct-20201022monthly0.5https://www.biopharmawatch.com/news/PTCT/evrysdi-risdiplam-continues-to-make-global-progress-for-the-treatment-of-spinal-muscular-a-ptct-20201021monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-third-quarter-2020-financial-results-p-ptct-20201015monthly0.5https://www.biopharmawatch.com/news/PTCT/two-year-data-of-evrysdi-risdiplam-in-infants-with-spinal-muscular-atrophy-demonstrate-con-ptct-20200928monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20200925monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-at-the-jefferies-virtual-gene-therapy-editing-summit-ptc-thera-ptct-20200924monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-launches-ptc-pinpoint-a-genetic-testing-program-for-individuals-suspected-ptct-20200909monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-2020-strive-awards-for-duchenne-muscular-dystrophy-recognize-four-patient-ptct-20200908monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference-ptc-therape-ptct-20200903monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-first-commercial-milestone-payment-following-u-s-fda-approval-o-ptct-20200826monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20200821monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-announces-the-acceptance-of-the-european-marketing-authorization-application-for-evrys-ptct-20200817monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-fda-approval-of-evrysdi-risdiplam-for-the-treatment-of-spinal-m-ptct-20200807monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-mary-frances-harmon-named-one-of-the-most-inspiring-leaders-in-life-scien-ptct-20200806monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-second-quarter-2020-financial-results-and-provides-a-corporate-up-ptct-20200805monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-second-quarter-2020-financial-results--ptct-20200722monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-deep-dive-webinar-on-splicing-platform-ptc-therapeutics-inc-nasda-ptct-20200721monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-agreement-to-monetize-a-portion-of-the-risdiplam-royalty-stream-ptct-20200720monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-first-patient-dosed-in-phase-1-trial-for-ptc857-ptc-therapeutic-ptct-20200708monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-chmp-recommendation-of-translarna-ataluren-label-update-for-non-ptct-20200629monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-the-initiation-of-a-phase-2-3-clinical-trial-to-evaluate-ptc299-ptct-20200617monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20200612monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-2-year-data-from-part-1-of-sunfish-and-new-data-from-jewelfish--ptct-20200612monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-launches-new-talent-pipeline-program-to-help-students-who-graduated-durin-ptct-20200610monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-successfully-completes-acquisition-of-censa-pharmaceuticals-ptc-therapeut-ptct-20200601monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-first-deep-dive-webinar-on-bio-e-platform-ptc-therapeutics-inc-na-ptct-20200528monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-inc-to-hold-virtual-2020-annual-meeting-of-stockholders-ptc-therapeutics--ptct-20200527monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-at-the-jefferies-virtual-healthcare-conference-ptc-therapeutic-ptct-20200526monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20200515monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-investor-conferences-ptc-therapeutics-inc-nasd-ptct-20200505monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-first-quarter-2020-financial-results-and-provides-a-corporate-upd-ptct-20200430monthly0.5https://www.biopharmawatch.com/news/PTCT/confirmatory-part-2-of-firefish-demonstrates-survival-and-motor-milestones-not-seen-in-nat-ptct-20200428monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20200422monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-new-leadership-appointments-ptc-therapeutics-inc-nasdaq-ptct-to-ptct-20200417monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-first-quarter-2020-financial-results-p-ptct-20200416monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-announces-regulatory-update-on-risdiplam-for-spinal-muscular-atrophy-sma-ptc-therapeut-ptct-20200407monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-management-change-ptc-therapeutics-inc-nasdaq-ptct-today-announ-ptct-20200316monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20200311monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-investor-conferences-ptc-therapeutics-inc-nasd-ptct-20200225monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-launches-sixth-annual-strive-awards-program-for-advocacy-organizations-in-ptct-20200218monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-fourth-quarter-and-year-end-2019-finan-ptct-20200217monthly0.5https://www.biopharmawatch.com/news/PTCT/sunfish-pivotal-results-for-risdiplam-rg7916-demonstrate-medically-meaningful-benefit-in-b-ptct-20200206monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20200203monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-a-conference-call-to-review-part-2-of-the-sunfish-clinical-trial--ptct-20200203monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-first-publication-of-real-world-data-showing-translarna-atalure-ptct-20200203monthly0.5https://www.biopharmawatch.com/news/PTCT/risdiplam-rg7916-pivotal-firefish-study-demonstrated-statistically-significant-improvement-ptct-20200123monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-ptc-therap-ptct-20200106monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20191213monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20191129monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-fda-grants-priority-review-to-risdiplam-for-the-treatment-of-sp-ptct-20191125monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-at-the-evercore-isi-2nd-annual-healthconx-conference-ptc-thera-ptct-20191119monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-launches-a-no-cost-testing-program-to-drive-aadc-deficiency-patient-ident-ptct-20191118monthly0.5https://www.biopharmawatch.com/news/PTCT/risdiplam-rg7916-pivotal-sunfish-study-demonstrates-statistically-significant-improvement--ptct-20191111monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20191031monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-third-quarter-2019-financial-results-and-provides-a-corporate-upd-ptct-20191029monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-results-from-long-term-aadc-deficiency-gene-therapy-treatment-d-ptct-20191024monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20191023monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-third-quarter-2019-financial-results-p-ptct-20191015monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-establishes-strategic-collaboration-with-aldevron-to-support-gmp-plasmid--ptct-20191007monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-new-real-world-analysis-demonstrating-translarna-ataluren-slows-ptct-20191004monthly0.5https://www.biopharmawatch.com/news/PTCT/risdiplam-spinal-muscular-atrophy-data-demonstrating-continued-benefit-presented-at-world--ptct-20191002monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-investor-conferences-ptc-therapeutics-inc-nasd-ptct-20190927monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20190920monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-pricing-of-private-offering-of-convertible-senior-notes-ptc-the-ptct-20190918monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-proposed-private-offering-of-convertible-senior-notes-ptc-thera-ptct-20190917monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-proposed-public-offering-of-common-stock-ptc-therapeutics-inc-n-ptct-20190917monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-celebrates-the-fifth-anniversary-of-strive-grant-awards-by-announcing-201-ptct-20190906monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-second-quarter-2019-financial-results-and-provides-a-corporate-up-ptct-20190806monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-expands-presence-in-new-jersey-by-securing-state-of-the-art-biologics-fac-ptct-20190805monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20190731monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-second-quarter-2019-financial-results--ptct-20190723monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-strategic-gene-therapy-licensing-agreement-with-odylia-therapeu-ptct-20190701monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-provides-update-on-translarna-ataluren-application-for-label-expansion-ptc-therapeutic-ptct-20190628monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-receives-fda-approval-for-the-expansion-of-the-emflaza-deflazacort-labeli-ptct-20190607monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-promotes-emily-hill-to-chief-financial-officer-ptc-therapeutics-inc-nasda-ptct-20190603monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20190531monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-investor-conference-ptc-therapeutics-inc-nasda-ptct-20190530monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-first-ever-winners-of-its-priority-program-to-support-research--ptct-20190520monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-and-mri-interventions-announce-strategic-investment-ptc-therapeutics-inc--ptct-20190509monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-investor-conferences-ptc-therapeutics-inc-nasd-ptct-20190508monthly0.5https://www.biopharmawatch.com/news/PTCT/data-from-pivotal-firefish-and-sunfish-studies-demonstrate-clinical-benefit-of-risdiplam-i-ptct-20190507monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20190503monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-first-quarter-2019-financial-results-and-provides-a-corporate-upd-ptct-20190502monthly0.5https://www.biopharmawatch.com/news/PTCT/translarna-ataluren-is-the-first-therapy-approved-in-brazil-for-duchenne-muscular-dystroph-ptct-20190429monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-first-quarter-2019-financial-results-p-ptct-20190418monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-investor-conferences-ptc-therapeutics-inc-nasd-ptct-20190304monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-to-expand-product-portfolio-in-latin-america-with-waylivra-ptc-therapeutics-inc-nasdaq-ptct-20190304monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20190301monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-partial-exercise-of-underwriter-s-option-to-purchase-additional-ptct-20190225monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-fourth-quarter-and-year-end-2018-finan-ptct-20190214monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-launches-fifth-annual-strive-grant-award-program-for-duchenne-muscular-dy-ptct-20190213monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-launches-new-program-to-support-research-projects-in-rare-genetic-disorde-ptct-20190131monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20190125monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-pricing-of-public-offering-of-common-stock-ptc-therapeutics-inc-ptct-20190123monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-proposed-public-offering-of-common-stock-ptc-therapeutics-inc-n-ptct-20190122monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-executive-team-updates-focused-on-accelerating-pipeline-and-bri-ptct-20190107monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-corporate-update-and-outlines-5-year-strategic-plan-at-2019-j-p--ptct-20190107monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-investor-conference-ptc-therapeutics-inc-nasda-ptct-20190102monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20181220monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-deepens-financial-and-commercial-expertise-of-board-with-two-new-appointm-ptct-20181218monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20181207monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20181116monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-third-quarter-2018-financial-results-and-provides-a-corporate-upd-ptct-20181105monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-investor-conference-ptc-therapeutics-inc-nasda-ptct-20181030monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20181023monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-third-quarter-2018-financial-results-p-ptct-20181022monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-initial-data-from-patient-registry-demonstrating-translarna-ata-ptct-20181006monthly0.5https://www.biopharmawatch.com/news/PTCT/risdiplam-demonstrates-preliminary-evidence-of-clinical-benefit-in-type-1-2-3-spinal-muscu-ptct-20181003monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20180928monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-investor-conference-ptc-therapeutics-inc-nasda-ptct-20180925monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-investor-conference-ptc-therapeutics-inc-nasda-ptct-20180913monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-winners-of-global-duchenne-muscular-dystrophy-patient-group-str-ptct-20180907monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20180824monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20180810monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-second-quarter-2018-financial-results-and-provides-a-corporate-up-ptct-20180807monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-second-quarter-2018-financial-results--ptct-20180726monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-publication-of-data-demonstrating-the-clinical-differentiated-b-ptct-20180724monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-positive-data-from-its-translarna-phase-ii-clinical-trial-in-ch-ptct-20180709monthly0.5https://www.biopharmawatch.com/news/PTCT/updated-preliminary-data-from-sma-firefish-program-in-type-1-babies-presented-at-the-cures-ptct-20180616monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20180608monthly0.5https://www.biopharmawatch.com/news/PTCT/chmp-adopts-positive-opinion-for-the-expansion-of-the-translarna-ataluren-label-to-include-ptct-20180601monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-first-quarter-2018-financial-results-and-provides-a-corporate-upd-ptct-20180509monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-first-quarter-2018-financial-results-p-ptct-20180501monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-investor-conference-ptc-therapeutics-inc-nasda-ptct-20180430monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20180427monthly0.5https://www.biopharmawatch.com/news/PTCT/preliminary-clinical-data-from-firefish-trial-in-type-1-sma-patients-presented-at-the-amer-ptct-20180424monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-full-exercise-of-underwriters-option-to-purchase-additional-sha-ptct-20180412monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-r-d-day-to-review-multiple-orphan-disorder-programs-ptc-therape-ptct-20180409monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-proposed-public-offering-of-common-stock-ptc-therapeutics-inc-n-ptct-20180327monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20180319monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-fourth-quarter-and-full-year-2017-financial-results-and-provides--ptct-20180306monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-investor-conferences-ptc-therapeutics-inc-nasd-ptct-20180301monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20180228monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-launches-fourth-annual-strive-grant-award-program-for-duchenne-muscular-d-ptct-20180213monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference-ptc-th-ptct-20180209monthly0.5https://www.biopharmawatch.com/news/PTCT/preliminary-data-from-firefish-trial-in-type-1-sma-infants-presented-at-the-international--ptct-20180127monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-corporate-update-and-outlines-2018-strategic-priorities-ptc-ther-ptct-20180108monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20180105monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-at-the-36th-annual-jp-morgan-healthcare-conference-ptc-therape-ptct-20180103monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20171215monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20171120monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-receives-complete-response-letter-for-ataluren-s-nda-ptc-therapeutics-inc-ptct-20171025monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-at-the-credit-suisse-26th-annual-healthcare-conference-ptc-the-ptct-20171024monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20171023monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-third-quarter-financial-results-ptc-th-ptct-20171019monthly0.5https://www.biopharmawatch.com/news/PTCT/spinal-muscular-atrophy-program-advances-into-pivotal-study-in-sma-patients-ptc-therapeuti-ptct-20171012monthly0.5https://www.biopharmawatch.com/news/PTCT/rg7916-increased-smn-protein-production-in-sunfish-clinical-trial-in-patients-with-type-2--ptct-20171003monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20170921monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-winners-of-global-duchenne-muscular-dystrophy-patient-group-str-ptct-20170907monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20170810monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-second-quarter-financial-results-ptc-t-ptct-20170725monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-promotion-of-dr-joseph-mcintosh-to-senior-vice-president-and-he-ptct-20170724monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-publication-of-data-from-act-dmd-in-the-lancet-ptc-therapeutics-ptct-20170718monthly0.5https://www.biopharmawatch.com/news/PTCT/preliminary-phase-2-data-from-spinal-muscular-atrophy-program-presented-at-curesma-confere-ptct-20170701monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20170630monthly0.5https://www.biopharmawatch.com/news/PTCT/new-analyses-of-translarna-ataluren-data-from-act-dmd-presented-at-the-12th-annual-europea-ptct-20170622monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-fda-advisory-committee-meeting-for-ataluren-for-the-treatment-o-ptct-20170606monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-executive-promotions-ptc-therapeutics-inc-nasdaq-ptct-today-ann-ptct-20170605monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20170602monthly0.5https://www.biopharmawatch.com/news/PTCT/new-analysis-of-act-dmd-placebo-data-on-corticosteroids-presented-at-international-society-ptct-20170523monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20170519monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-first-quarter-2017-financial-results-and-provides-corporate-updat-ptct-20170508monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-first-quarter-financial-results-ptc-th-ptct-20170424monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-fourth-quarter-and-full-year-2016-financial-results-and-provides--ptct-20170316monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-timing-change-for-fourth-quarter-and-year-end-2016-financial-re-ptct-20170313monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-fda-acknowledgment-of-new-drug-application-filing-for-translarn-ptct-20170306monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-fourth-quarter-and-year-end-2016-finan-ptct-20170228monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20170221monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-third-annual-strive-grant-award-program-for-duchenne-muscular-d-ptct-20170208monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-corporate-update-and-outlines-2017-strategic-priorities-to-maxim-ptct-20170109monthly0.5https://www.biopharmawatch.com/news/PTCT/european-commission-ratifies-positive-chmp-opinion-for-the-renewal-of-translarna-marketing-ptct-20170109monthly0.5https://www.biopharmawatch.com/news/PTCT/rg7916-granted-orphan-drug-designation-in-the-u-s-for-the-treatment-of-spinal-muscular-atr-ptct-20170106monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-initiation-of-firefish-study-in-infant-type-i-sma-patients-ptc--ptct-20170105monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20170105monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-2017-corporate-update-at-the-35th-annual-j-p-morgan-healthcare-ptct-20170103monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20161216monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-receives-france-s-2016-prix-galien-for-translarna-south-plainfield-n-j-de-ptct-20161208monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20161118monthly0.5https://www.biopharmawatch.com/news/PTCT/chmp-recommends-renewal-of-translarna-s-marketing-authorization-for-nonsense-mutation-duch-ptct-20161111monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-third-quarter-2016-financial-results-and-provides-corporate-updat-ptct-20161102monthly0.5https://www.biopharmawatch.com/news/PTCT/spinal-muscular-atrophy-program-advances-into-phase-2-clinical-studies-in-sma-patients-wit-ptct-20161020monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-third-quarter-financial-results-ptc-th-ptct-20161019monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-regulatory-update-on-translarna-ataluren-for-nonsense-mutation-d-ptct-20161017monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-new-analyses-that-support-the-potential-benefit-of-ataluren-in--ptct-20161006monthly0.5https://www.biopharmawatch.com/news/PTCT/new-research-validates-translarna-s-ataluren-mechanism-of-action-to-promote-readthrough-of-ptct-20161004monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20160912monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-recognizes-world-duchenne-awareness-day-by-announcing-winners-of-global-d-ptct-20160907monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-regulatory-update-on-translarna-ataluren-ptc-therapeutics-inc-na-ptct-20160725monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-second-quarter-financial-results-ptc-t-ptct-20160721monthly0.5https://www.biopharmawatch.com/news/PTCT/nhs-england-enables-access-to-translarna-ataluren-for-patients-with-nonsense-mutation-duch-ptct-20160707monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-appoints-dawn-svoronos-to-board-of-directors-ptc-therapeutics-inc-nasdaq--ptct-20160613monthly0.5https://www.biopharmawatch.com/news/PTCT/new-analyses-from-phase-3-study-009-of-translarna-ataluren-in-patients-with-cystic-fibrosi-ptct-20160610monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-winners-of-the-global-cystic-fibrosis-patient-group-awards-ptc--ptct-20160516monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-first-quarter-2016-financial-results-and-provides-corporate-updat-ptct-20160505monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20160422monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-first-quarter-financial-results-ptc-th-ptct-20160421monthly0.5https://www.biopharmawatch.com/news/PTCT/nice-recommends-translarna-ataluren-for-the-treatment-of-patients-with-nonsense-mutation-d-ptct-20160415monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-workforce-reduction-as-part-of-operating-expense-management-pla-ptct-20160323monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-update-on-health-canada-review-of-translarna-ataluren-for-the-tr-ptct-20160314monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-presentation-of-results-from-phase-3-act-dmd-clinical-trial-of--ptct-20160314monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20160302monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-fourth-quarter-and-full-year-2015-financial-results-and-provides--ptct-20160229monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-update-on-german-pricing-and-reimbursement-process-for-translarn-ptct-20160226monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-receives-refuse-to-file-letter-from-fda-for-translarna-ataluren-ptc-therapeutics-inc-n-ptct-20160223monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-fourth-quarter-and-year-end-2015-finan-ptct-20160215monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-second-annual-strive-grant-award-program-for-duchenne-muscular--ptct-20160212monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-investor-conferences-ptc-therapeutics-inc-nasd-ptct-20160128monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-outlines-business-priorities-for-the-development-and-commercialization-of-ptct-20160111monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-completes-rolling-nda-submission-to-fda-and-submits-phase-3-act-dmd-clinical-trial-res-ptct-20160108monthly0.5https://www.biopharmawatch.com/news/PTCT/spinal-muscular-atrophy-program-advances-with-additional-product-candidate-entering-clinic-ptct-20160107monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20160106monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-at-the-34th-annual-j-p-morgan-healthcare-conference-ptc-therap-ptct-20151223monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-and-massachusetts-general-hospital-collaborate-on-rare-disease-research-p-ptct-20151209monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20151204monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-completes-enrollment-of-phase-3-clinical-trial-of-translarna-for-patients-with-cystic--ptct-20151119monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-third-quarter-2015-financial-results-provides-corporate-update-an-ptct-20151109monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-investor-conferences-ptc-therapeutics-inc-nasd-ptct-20151103monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-launch-of-strive-grant-award-program-for-cystic-fibrosis-ptc-th-ptct-20151029monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-third-quarter-2015-financial-results-p-ptct-20151027monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-announces-results-from-phase-3-act-dmd-clinical-trial-of-translarna-ataluren-in-patien-ptct-20151015monthly0.5https://www.biopharmawatch.com/news/PTCT/phase-2-data-from-spinal-muscular-atrophy-program-to-be-presented-at-the-20th-internationa-ptct-20151004monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20151002monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-submits-european-application-for-translarna-for-cystic-fibrosis-ptc-thera-ptct-20150930monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-five-winners-in-its-first-ever-global-duchenne-muscular-dystrop-ptct-20150904monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20150821monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-second-quarter-2015-financial-results-and-provides-corporate-upda-ptct-20150730monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-second-quarter-2015-financial-results--ptct-20150716monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-ceo-stuart-w-peltz-ph-d-finalist-for-the-2015-njbiz-innovation-hero-award-ptct-20150623monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-appoints-glenn-d-steele-jr-m-d-ph-d-to-board-of-directors-ptc-therapeutic-ptct-20150615monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-and-biomarin-pharmaceutical-to-host-dmd-industry-symposium-ptc-therapeuti-ptct-20150612monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20150612monthly0.5https://www.biopharmawatch.com/news/PTCT/german-federal-joint-committee-issues-positive-medical-benefit-rating-for-translarna-in-pa-ptct-20150521monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20150515monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-launches-strive-grant-award-program-ptc-therapeutics-inc-nasdaq-ptct-toda-ptct-20150511monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-first-quarter-2015-financial-results-and-provides-corporate-updat-ptct-20150504monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-cancer-stem-cell-program-targeting-bmi1-enters-phase-1-ptc-therapeutics-i-ptct-20150428monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-investor-conferences-ptc-therapeutics-inc-nasd-ptct-20150423monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-first-quarter-2015-financial-results-p-ptct-20150420monthly0.5https://www.biopharmawatch.com/news/PTCT/phase-1-data-from-spinal-muscular-atrophy-program-to-be-presented-at-the-2015-american-aca-ptct-20150420monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20150410monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-names-eric-pauwels-svp-general-manager-commercial-operations-americas-ptc-ptct-20150408monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-and-university-of-pennsylvania-collaborate-on-orphan-disease-research-ptc-ptct-20150319monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-announces-translarna-access-program-in-duchenne-muscular-dystrophy-for-siblings-of-pat-ptct-20150303monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-fourth-quarter-and-2014-full-year-financial-results-and-provides--ptct-20150227monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-march-investor-conferences-ptc-therapeutics-in-ptct-20150216monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-fourth-quarter-and-year-end-2014-finan-ptct-20150213monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20150206monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-investor-conferences-ptc-therapeutics-inc-nasd-ptct-20150205monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-at-the-33rd-annual-j-p-morgan-healthcare-conference-ptc-therap-ptct-20150107monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20150102monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-begins-rolling-nda-submission-to-the-fda-for-translarna-to-treat-duchenne-ptct-20141223monthly0.5https://www.biopharmawatch.com/news/PTCT/translarna-granted-orphan-drug-designation-in-the-u-s-and-europe-for-the-treatment-of-muco-ptct-20141219monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20141217monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-launch-of-translarna-ataluren-in-germany-ptc-therapeutics-inc-n-ptct-20141203monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-ceo-dr-stuart-peltz-recipient-of-the-new-jersey-technology-coun-ptct-20141121monthly0.5https://www.biopharmawatch.com/news/PTCT/spinal-muscular-atrophy-program-enters-phase-1b-2a-trial-in-patients-with-sma-ptc-therapeu-ptct-20141119monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-appoints-dr-tuyen-ong-svp-head-of-clinical-development-and-translational--ptct-20141117monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20141117monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-recognized-for-outstanding-innovation-at-the-2014-rare-orphan-advocacy-an-ptct-20141114monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-webcast-upcoming-science-day-and-investor-conferences-ptc-therapeutics-ptct-20141113monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-third-quarter-financial-results-and-provides-corporate-update-ptc-ptct-20141106monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-expands-access-for-translarna-ataluren-ptc-therapeutics-inc-nasdaq-ptct-t-ptct-20141103monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-at-the-credit-suisse-23rd-annual-healthcare-conference-ptc-the-ptct-20141029monthly0.5https://www.biopharmawatch.com/news/PTCT/translarna-phase-2b-data-published-in-muscle-nerve-ptc-therapeutics-inc-nasdaq-ptct-today--ptct-20141027monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-third-quarter-2014-financial-results-p-ptct-20141023monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-pricing-of-public-offering-of-common-stock-ptc-therapeutics-inc-ptct-20141009monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-proposed-public-offering-of-common-stock-ptc-therapeutics-inc-n-ptct-20141008monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-at-the-leerink-partners-rare-disease-roundtable-ptc-therapeuti-ptct-20140924monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20140924monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-expands-global-presence-in-support-of-translarna-launch-in-duchenne-muscu-ptct-20140917monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-completes-enrollment-of-landmark-trial-in-duchenne-muscular-dystrophy-ptc-ptct-20140909monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-participate-at-upcoming-investor-conferences-ptc-therapeutics-inc-nasd-ptct-20140820monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-second-quarter-financial-results-and-provides-corporate-update-pt-ptct-20140807monthly0.5https://www.biopharmawatch.com/news/PTCT/orally-delivered-compounds-which-selectively-modify-rna-splicing-prevent-deficits-in-mouse-ptct-20140807monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-receives-conditional-approval-in-the-european-union-for-translarna-for-th-ptct-20140804monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20140801monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-at-the-wedbush-life-sciences-management-access-conference-ptc--ptct-20140730monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-second-quarter-2014-financial-results--ptct-20140724monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-expanded-access-program-for-translarna-ataluren-ptc-therapeutic-ptct-20140709monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-at-the-9th-annual-jmp-securities-healthcare-conference-ptc-the-ptct-20140617monthly0.5https://www.biopharmawatch.com/news/PTCT/shane-kovacs-receives-the-2014-new-jersey-technology-council-cfo-deal-of-the-year-award-pt-ptct-20140613monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-appoints-ronald-c-renaud-jr-to-board-of-directors-ptc-therapeutics-inc-na-ptct-20140611monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-receives-positive-opinion-from-chmp-for-translarna-ataluren-ptc-therapeut-ptct-20140523monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-ema-update-ptc-therapeutics-inc-nasdaq-ptct-today-announced-that-ptct-20140523monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-at-the-jefferies-2014-global-healthcare-conference-ptc-therape-ptct-20140521monthly0.5https://www.biopharmawatch.com/news/PTCT/ataluren-phase-3-trial-results-in-nonsense-mutation-cystic-fibrosis-published-in-the-lance-ptct-20140516monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-at-upcoming-investor-conferences-ptc-therapeutics-inc-nasdaq-p-ptct-20140423monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-conference-call-to-discuss-first-quarter-2014-financial-results-p-ptct-20140422monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ptc-therapeu-ptct-20140421monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-fourth-quarter-and-year-end-2013-financial-results-and-provides-c-ptct-20140306monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-at-the-cowen-company-34th-annual-health-care-conference-ptc-th-ptct-20140228monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ptc-therapeut-ptct-20140227monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-fourth-quarter-and-year-end-2013-financial-results-conference-cal-ptct-20140227monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-expands-international-commercial-team-ptc-therapeutics-inc-nasdaq-ptct-to-ptct-20140225monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-at-upcoming-investor-conferences-ptc-therapeutics-inc-nasdaq-p-ptct-20140220monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-closing-of-registered-public-offering-of-common-stock-including-ptct-20140219monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-pricing-of-public-offering-of-common-stock-ptc-therapeutics-inc-ptct-20140212monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-proposed-public-offering-of-common-stock-ptc-therapeutics-inc-n-ptct-20140210monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-that-stuart-w-peltz-ph-d-ceo-is-the-recipient-of-the-2014-dr-so-ptct-20140130monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-provides-update-on-chmp-opinion-for-conditional-approval-of-ataluren-for--ptct-20140124monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-expands-management-team-ptc-therapeutics-inc-nasdaq-ptct-today-announced--ptct-20140124monthly0.5https://www.biopharmawatch.com/news/PTCT/gemeinsames-programm-zu-spinaler-muskelatrophie-geht-in-erste-stufe-der-klinischen-entwick-ptct-20140122monthly0.5https://www.biopharmawatch.com/news/PTCT/un-programme-conjoint-dans-le-domaine-de-l-atrophie-musculaire-spinale-entre-en-premie-re--ptct-20140122monthly0.5https://www.biopharmawatch.com/news/PTCT/joint-program-in-spinal-muscular-atrophy-enters-first-stage-of-clinical-development-ptc-th-ptct-20140122monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-at-the-j-p-morgan-healthcare-conference-ptc-therapeutics-inc-n-ptct-20140106monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-added-to-nasdaq-biotechnology-index-ptc-therapeutics-inc-nasdaq-ptct-toda-ptct-20131223monthly0.5https://www.biopharmawatch.com/news/PTCT/ataluren-clinical-data-demonstrate-an-increase-in-dystrophin-expression-in-duchenne-muscul-ptct-20131212monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-third-quarter-2013-financial-and-corporate-results-ptc-therapeuti-ptct-20131114monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-third-quarter-2013-financial-results-conference-call-and-webcast--ptct-20131107monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-at-credit-suisse-annual-health-care-conference-ptc-therapeutic-ptct-20131105monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-showcase-breadth-of-pipeline-at-upcoming-r-d-day-ptc-therapeutics-inc--ptct-20131018monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-at-the-north-american-cystic-fibrosis-conference-ptc-therapeut-ptct-20131010monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-expands-management-team-ptc-therapeutics-inc-nasdaq-ptct-today-announced--ptct-20131001monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-at-upcoming-investor-conferences-ptc-therapeutics-inc-nasdaq-p-ptct-20130927monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-at-world-muscle-society-congress-ptc-therapeutics-inc-nasdaq-p-ptct-20130925monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-at-european-pediatric-neurology-society-congress-ptc-therapeut-ptct-20130918monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-at-upcoming-investor-conferences-ptc-therapeutics-inc-nasdaq-p-ptct-20130829monthly0.5https://www.biopharmawatch.com/news/PTCT/new-evidence-published-in-muscle-and-nerve-on-measuring-6-minute-walk-distance-in-duchenne-ptct-20130826monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-reports-second-quarter-2013-financial-and-corporate-results-ptc-therapeut-ptct-20130812monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-achievement-of-major-milestone-in-sma-collaboration-ptc-therape-ptct-20130808monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-present-at-wedbush-conference-ptc-therapeutics-inc-nasdaq-ptct-today-a-ptct-20130806monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-to-host-second-quarter-2013-financial-results-conference-call-and-webcast-ptct-20130805monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-closes-initial-public-offering-ptc-therapeutics-inc-ptc-nasdaq-ptct-today-ptct-20130625monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-prices-initial-public-offering-ptc-therapeutics-inc-ptc-today-announced-t-ptct-20130620monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-appoints-shane-kovacs-as-chief-financial-officer-ptc-therapeutics-inc-ptc-ptct-20130603monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-inc-files-registration-statement-for-proposed-initial-public-offering-ptc-ptct-20130516monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-closes-60-million-private-financing-ptc-therapeutics-inc-ptc-today-announ-ptct-20130307monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-european-medicines-agency-validation-of-marketing-authorization-ptct-20121206monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-appoints-geoffrey-mcdonough-m-d-to-board-of-directors-ptc-therapeutics-in-ptct-20121106monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-receives-1-million-grant-award-from-the-national-institutes-of-health-nih-ptct-20121022monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-appoints-jerome-b-zeldis-m-d-ph-d-to-board-of-directors-ptc-therapeutics--ptct-20120928monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-closes-30-million-financing-ptc-therapeutics-inc-ptc-today-announced-the--ptct-20120723monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-achievement-of-major-milestone-in-wellcome-trust-bmi1-collabora-ptct-20120711monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-initiates-open-label-study-for-ataluren-in-patients-with-nonsense-mutatio-ptct-20120627monthly0.5https://www.biopharmawatch.com/news/PTCT/top-line-data-from-phase-3-trial-of-ataluren-in-patients-with-nonsense-mutation-cystic-fib-ptct-20120608monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-announces-executive-promotions-ptc-therapeutics-inc-ptc-today-announced-t-ptct-20120402monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-antibacterial-program-receives-5-million-award-from-the-wellcome-trust-pt-ptct-20111222monthly0.5https://www.biopharmawatch.com/news/PTCT/roche-signs-agreement-with-ptc-therapeutics-to-advance-treatment-for-spinal-muscular-atrop-ptct-20111129monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-receives-grand-challenges-explorations-funding-ptc-therapeutics-inc-annou-ptct-20111107monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-and-genzyme-announce-restructuring-of-collaboration-ptc-therapeutics-inc--ptct-20110902monthly0.5https://www.biopharmawatch.com/news/PTCT/ataluren-phase-2-data-in-nonsense-mutation-cystic-fibrosis-published-in-the-european-respi-ptct-20110701monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-appoints-robert-spiegel-m-d-as-chief-medical-officer-ptc-therapeutics-inc-ptct-20110330monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-and-parent-project-muscular-dystrophy-advance-drug-discovery-program-to-i-ptct-20110201monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-president-and-ceo-elected-aaas-fellow-stuart-w-peltz-ph-d-president-and-c-ptct-20110119monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-completes-enrollment-of-phase-3-trial-of-ataluren-in-patients-with-cystic-ptct-20101221monthly0.5https://www.biopharmawatch.com/news/PTCT/observational-data-from-one-year-follow-up-study-validate-six-minute-walk-distance-as-an-o-ptct-20101201monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-publishes-results-from-phase-2-study-of-ataluren-in-children-with-cystic-fibrosis-ptc--ptct-20101115monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-initiates-phase-2-clinical-trial-of-ataluren-in-patients-with-methylmalon-ptct-20101026monthly0.5https://www.biopharmawatch.com/news/PTCT/pivotal-data-presented-at-the-world-muscle-society-congress-suggest-ataluren-slows-the-los-ptct-20101015monthly0.5https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-awarded-1-6-million-fda-orphan-drug-grant-to-support-an-ongoing-phase-3-s-ptct-20100921monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-that-ceo-dr-deborah-birx-will-deliver-a-presentation-at-t-armp-20250311monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-that-ceo-dr-deborah-birx-will-deliver-a-presentation-at-t-armp-20241119monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-structural-biology-publication-armata-pharmaceuticals-inc-armp-20241030monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-26th-annual-global-investment--armp-20240905monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-presentation-at-the-2024-military-health-system-research--armp-20240826monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-receives-5-25-million-of-additional-non-dilutive-grant-funding-from-armp-20240730monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-completion-of-enrollment-of-phase-2-tailwind-study-of-inh-armp-20240711monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-presentation-at-viruses-of-microbes-2024-armata-pharmaceu-armp-20240710monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-presentation-at-the-6th-annual-bacteriophage-therapy-summ-armp-20240221monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-presentation-of-topline-data-from-swarm-p-a-clinical-stud-armp-20231030monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-presentation-at-phage-futures-global-digital-summit-2023--armp-20231019monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-first-patient-dosed-in-the-phase-2a-portion-of-the-phase--armp-20230926monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-to-participate-in-the-cantor-global-healthcare-conference-armata-ph-armp-20230921monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-oral-presentation-detailing-results-from-the-phase-1b-2a--armp-20230531monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-completion-of-its-phase-1b-2a-swarm-p-a-study-of-inhaled--armp-20221222monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-1st-annual-investor-conference-armp-20221128monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-clearance-of-ind-for-prosthetic-joint-infections-armata-p-armp-20220801monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-first-patient-dosed-in-phase-1b-2a-disarm-study-of-ap-sa0-armp-20220523monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-first-quarter-2022-results-and-provides-corporate-update--armp-20220512monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-fourth-quarter-and-full-year-2021-results-and-provides-co-armp-20220317monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-clearance-of-investigational-new-drug-application-to-init-armp-20220222monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-armata-pharmace-armp-20220217monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-provides-update-on-pseudomonas-respiratory-programs-armata-pharmace-armp-20220105monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-provides-regulatory-and-clinical-update-reflecting-sustained-progre-armp-20211118monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-third-quarter-results-and-provides-general-corporate-upda-armp-20211110monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-to-present-at-the-2021-world-antimicrobial-resistance-congress-arma-armp-20211104monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment--armp-20210908monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-chief-executive-officer-transition-armata-pharmaceuticals-armp-20210802monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2021-healthcare-conference-arm-armp-20210707monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-fourth-quarter-and-full-year-2020-results-and-provides-ge-armp-20210318monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference-arm-armp-20210316monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-third-quarter-2020-results-and-provides-general-corporate-armp-20201112monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-issues-letter-to-shareholders-armata-pharmaceuticals-inc-nyse-ameri-armp-20201029monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-appoints-mina-pastagia-md-ms-as-vice-president-of-clinical-developm-armp-20201026monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-clearance-of-investigational-new-drug-ind-application-to--armp-20201015monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-to-present-at-the-virtual-2020-world-antimicrobial-resistance-congr-armp-20200929monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-armata-pha-armp-20200911monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-second-quarter-2020-results-and-provides-general-corporat-armp-20200813monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-first-quarter-2020-results-and-provides-general-corporate-armp-20200514monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-to-participate-in-the-maxim-group-m-vest-infectious-disease-virtual-armp-20200428monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-third-quarter-results-and-provides-corporate-and-clinical-armp-20191112monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-issues-letter-to-shareholders-armata-pharmaceuticals-inc-nyse-ameri-armp-20191031monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-receipt-of-1-3-million-r-d-tax-incentive-armata-pharmaceu-armp-20191021monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-strengthens-clinical-team-with-appointment-of-dr-heather-dale-jones-armp-20191016monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-to-participate-in-the-ladenburg-thalmann-2019-healthcare-conference-armp-20190919monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-second-quarter-results-and-provides-corporate-and-clinica-armp-20190814monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-to-provide-corporate-update-at-the-39th-annual-canaccord-genuity-gr-armp-20190801monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-to-host-key-opinion-leader-meeting-on-bacteriophage-based-therapeut-armp-20190618monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-strengthens-intellectual-property-portfolio-with-new-patent-allowan-armp-20190603monthly0.5https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-announces-publication-of-successful-adjunctive-phage-treatment-in-c-armp-20190528monthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-presents-real-world-analysis-confirming-muc16-as-a-highly-expressed-whwk-20260410monthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-advances-to-clinical-stage-with-ind-clearance-for-hwk-007-and-annou-whwk-20260108monthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-reports-second-quarter-2025-financial-results-and-recent-highlights-whwk-20250807monthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-to-present-at-the-jefferies-2025-global-healthcare-conference-white-whwk-20250528monthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-to-participate-in-the-td-cowen-6th-annual-oncology-innovation-summi-whwk-20250521monthly0.5https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-completes-strategic-transformation-with-successful-closing-of-sale--whwk-20250326monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025-th-tbph-20251027monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-theravance-biopharm-tbph-20250723monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-theravance-biopharm-tbph-20250513monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-announces-ampreloxetine-presentations-at-the-international-msa-congre-tbph-20250509monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-to-present-analyses-of-ampreloxetine-and-neurogenic-orthostatic-hypotension-at--tbph-20250428monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-first-quarter-2025-financial-results-on-may-8-2025-theravan-tbph-20250424monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-presents-two-new-ampreloxetine-analyses-in-oral-session-at-the-americ-tbph-20250407monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-theravance-biopharm-tbph-20250331monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-present-new-ampreloxetine-analyses-in-neurogenic-orthostatic-hypot-tbph-20250327monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-theravance-biopharm-tbph-20250220monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-febr-tbph-20250212monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-theravance-biopharm-tbph-20250205monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-conduct-investor-meetings-during-the-j-p-morgan-43rd-annual-health-tbph-20241217monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-theravance-biopharm-tbph-20241120monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-third-quarter-2024-financial-results-on-november-12-2024-th-tbph-20241024monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-announces-publication-of-yupelri-revefenacin-area-under-the-curve-spirometry-an-tbph-20241018monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-theravance-biopharm-tbph-20240827monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-second-quarter-2024-financial-results-and-provides-busine-tbph-20240805monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-theravance-biopharm-tbph-20240725monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-second-quarter-2024-financial-results-on-august-5-2024-ther-tbph-20240722monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-theravance-biopharm-tbph-20240509monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-first-quarter-2024-financial-results-on-may-13-2024-therava-tbph-20240429monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-to-host-virtual-key-opinion-leader-kol-event-to-discuss-ampreloxe-tbph-20240410monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-theravance-biopharm-tbph-20240222monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-fourth-quarter-and-full-year-2023-financial-results-on-febr-tbph-20240214monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-announces-appointment-of-jeremy-grant-to-board-of-directors-thera-tbph-20231221monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-conduct-investor-meetings-during-the-j-p-morgan-42nd-annual-health-tbph-20231218monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-present-new-ampreloxetine-data-at-the-34th-international-symposium-tbph-20231116monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-theravance-biopharm-tbph-20230829monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-present-new-ampreloxetine-data-at-the-2023-international-congress--tbph-20230828monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-second-quarter-2023-financial-results-on-august-7-2023-ther-tbph-20230724monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-announces-orphan-drug-designation-granted-to-ampreloxetine-for-th-tbph-20230509monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-first-quarter-2023-financial-results-on-may-8-2023-theravan-tbph-20230424monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-announces-appointment-of-jim-kelly-managing-director-at-weiss-ass-tbph-20230411monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-theravance-biopharm-tbph-20230410monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-theravance-biopharm-tbph-20230302monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-fourth-quarter-and-full-year-2022-financial-results-on-febr-tbph-20230221monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-theravance-biopharm-tbph-20230209monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-announces-final-results-of-tender-offer-theravance-biopharma-inc--tbph-20221122monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-announces-preliminary-results-of-tender-offer-theravance-biopharm-tbph-20221118monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-third-quarter-2022-financial-results-on-november-7-2022-the-tbph-20221031monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-present-new-ampreloxetine-data-in-neurogenic-orthostatic-hypotensi-tbph-20221025monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-announces-tender-offer-for-up-to-95-million-of-its-ordinary-shares-th-tbph-20220928monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-initiates-250-million-capital-return-program-theravance-biopharma-tbph-20220919monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-present-at-upcoming-investor-conferences-theravance-biopharma-inc--tbph-20220906monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-reports-second-quarter-2022-financial-results-and-provides-busine-tbph-20220804monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-second-quarter-2022-financial-results-on-august-4-2022-ther-tbph-20220728monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-announces-tender-offer-for-outstanding-3-25-convertible-senior-notes--tbph-20220726monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-first-quarter-2022-financial-results-on-may-5-2022-theravan-tbph-20220502monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-theravance-biopharm-tbph-20220406monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-theravance-biopharm-tbph-20220222monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-fourth-quarter-and-full-year-2021-financial-results-on-febr-tbph-20220209monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-theravance-biopharm-tbph-20220202monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-announces-enrollment-of-first-patient-in-yupelri-phase-4-study-th-tbph-20220110monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-therav-tbph-20220105monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-theravance-biopharm-tbph-20211118monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-third-quarter-2021-financial-results-november-3-2021-therav-tbph-20211020monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-announces-top-line-results-from-a-phase-3-study-of-ampreloxetine--tbph-20210915monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-second-quarter-2021-financial-results-on-august-3-2021-ther-tbph-20210720monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-inc-announces-pricing-of-public-offering-of-ordinary-shares-theravanc-tbph-20210624monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-theravance-biopharm-tbph-20210506monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-first-quarter-2021-financial-results-on-may-4-2021-theravan-tbph-20210420monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-theravance-biopharm-tbph-20210302monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-participate-in-upcoming-investor-conferences-theravance-biopharma--tbph-20210210monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-fourth-quarter-and-full-year-2020-financial-results-on-febr-tbph-20210209monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-therav-tbph-20210105monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-present-at-the-3rd-annual-evercore-isi-healthconx-conference-thera-tbph-20201117monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-third-quarter-2020-financial-results-on-november-5-2020-the-tbph-20201022monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-present-at-upcoming-investor-conferences-theravance-biopharma-inc--tbph-20200901monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-second-quarter-2020-financial-results-on-august-6-2020-ther-tbph-20200727monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-appoints-deepika-r-pakianathan-ph-d-to-board-of-directors-theravance--tbph-20200702monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-announces-first-patient-dosed-in-phase-2-study-of-td-0903-for-the-tre-tbph-20200625monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-first-quarter-2020-financial-results-on-may-6-2020-theravan-tbph-20200428monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-announces-first-subject-dosed-in-phase-1-study-of-td-0903-in-developm-tbph-20200423monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-announces-peer-reviewed-publication-highlighting-td-1473-program-in-t-tbph-20200420monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-announces-presentations-at-upcoming-investor-conferences-theravance-b-tbph-20200218monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-fourth-quarter-and-full-year-2019-financial-results-on-febr-tbph-20200213monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-announces-pricing-of-public-offering-of-ordinary-shares-theravance-bi-tbph-20200211monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-announces-proposed-public-offering-of-ordinary-shares-theravance-biop-tbph-20200210monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-announces-presentation-at-the-38th-annual-j-p-morgan-healthcare-confe-tbph-20200107monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-announces-dosing-of-first-patient-in-phase-2-allergen-challenge-study-tbph-20191203monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-present-at-two-upcoming-investor-conferences-theravance-biopharma--tbph-20191126monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-present-at-the-2019-credit-suisse-healthcare-conference-november-6-tbph-20191106monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-third-quarter-2019-financial-results-on-november-5-theravan-tbph-20191029monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-present-at-the-2019-cantor-global-healthcare-conference-theravance-tbph-20190925monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-reports-positive-results-from-phase-1-clinical-trial-of-td-8236-an-in-tbph-20190909monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-present-at-two-upcoming-investor-conferences-theravance-biopharma--tbph-20190828monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-second-quarter-2019-financial-results-on-july-31-theravance-tbph-20190725monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-reports-new-data-from-phase-2-study-of-ampreloxetine-td-9855-in-oral--tbph-20190722monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-reports-new-data-from-phase-2-study-of-ampreloxetine-td-9855-in-prese-tbph-20190618monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-and-mylan-expand-yupelri-revefenacin-development-and-commercializatio-tbph-20190614monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-appoints-andrew-hindman-as-senior-vice-president-and-chief-financial--tbph-20190604monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-reports-data-from-phase-1b-study-of-td-1473-in-oral-presentation-at-d-tbph-20190521monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-and-mylan-present-additional-yupelri-revefenacin-phase-3-data-analysi-tbph-20190520monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-announces-data-from-phase-1b-study-of-td-1473-to-be-featured-in-oral--tbph-20190514monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-first-quarter-2019-financial-results-on-may-7-theravance-bi-tbph-20190430monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-present-at-the-18th-annual-needham-healthcare-conference-theravanc-tbph-20190402monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-announces-ampreloxetine-td-9855-phase-2-study-results-selected-for-or-tbph-20190325monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-announces-first-patient-dosed-in-phase-2b-3-study-of-td-1473-in-patie-tbph-20190312monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-present-at-the-8th-annual-svb-leerink-global-healthcare-conference-tbph-20190221monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-fourth-quarter-and-full-year-2018-financial-results-on-febr-tbph-20190219monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-announces-first-patient-dosed-in-registrational-phase-3-study-of-ampr-tbph-20190128monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-announces-alignment-of-workforce-with-focus-on-key-strategic-prioriti-tbph-20190107monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-highlight-innovative-early-research-and-clinical-development-at-r--tbph-20181204monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-announces-first-subject-dosed-in-phase-1-clinical-trial-of-td-8236-a--tbph-20181127monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-announces-first-patient-dosed-in-phase-2-study-of-td-1473-in-patients-tbph-20181120monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-present-at-two-upcoming-investor-conferences-theravance-biopharma--tbph-20181119monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-highlights-expanded-copd-indication-for-trelegy-ellipta-in-europe-the-tbph-20181112monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-present-at-the-credit-suisse-27th-annual-healthcare-conference-the-tbph-20181107monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-announces-sale-of-vibativ-telavancin-to-cumberland-pharmaceuticals-th-tbph-20181106monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-third-quarter-2018-financial-results-on-november-6-theravan-tbph-20181030monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-reports-data-from-td-1473-phase-1b-four-week-study-in-oral-late-break-tbph-20181022monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-announces-data-from-phase-1b-study-of-td-1473-selected-for-oral-late--tbph-20181010monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-reports-positive-new-data-from-multiple-studies-of-vibativ-telavancin-tbph-20181008monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-present-new-data-from-multiple-studies-of-vibativ-telavancin-at-id-tbph-20181001monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-highlights-positive-chmp-opinion-supporting-expanded-copd-indication--tbph-20180924monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-reports-positive-top-line-four-week-data-from-phase-2-trial-of-td-985-tbph-20180801monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-second-quarter-2018-financial-results-on-august-1-theravanc-tbph-20180725monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-highlights-submission-of-regulatory-application-in-japan-for-once-dai-tbph-20180529monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-host-key-opinion-leader-event-focused-on-the-unmet-medical-need-in-tbph-20180517monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-present-at-the-bank-of-america-merrill-lynch-2018-healthcare-confe-tbph-20180510monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-highlights-approval-of-expanded-indication-in-the-us-for-once-daily-t-tbph-20180425monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-highlights-landmark-impact-study-published-in-nejm-showing-significan-tbph-20180419monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-present-new-data-from-multiple-studies-of-vibativ-telavancin-at-20-tbph-20180417monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-present-at-the-17th-annual-needham-healthcare-conference-theravanc-tbph-20180321monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-fourth-quarter-and-full-year-2017-financial-results-on-febr-tbph-20180220monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-and-mylan-announce-fda-acceptance-of-new-drug-application-for-revefen-tbph-20180129monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-highlights-submission-of-landmark-impact-data-to-fda-to-support-expan-tbph-20171128monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-present-at-two-upcoming-investor-conferences-theravance-biopharma--tbph-20171121monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-highlights-marketing-authorization-in-europe-for-trelegy-ellipta-as-o-tbph-20171116monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-and-mylan-submit-new-drug-application-to-fda-for-revefenacin-td-4208--tbph-20171113monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-and-mylan-report-additional-positive-phase-3-data-for-revefenacin-td--tbph-20171101monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-announces-opening-of-company-s-new-corporate-office-in-dublin-ireland-tbph-20171101monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-reports-positive-new-vibativ-telavancin-data-from-tour-observational--tbph-20171031monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-third-quarter-2017-financial-results-on-november-7-2017-the-tbph-20171030monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-present-new-data-from-studies-of-vibativ-telavancin-and-revefenaci-tbph-20171024monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-reports-positive-new-data-from-multiple-studies-of-vibativ-telavancin-tbph-20171009monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-present-new-data-from-multiple-studies-of-vibativ-telavancin-at-id-tbph-20171003monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-highlights-positive-headline-results-from-impact-study-of-trelegy-ell-tbph-20170920monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-ther-tbph-20170919monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-highlights-approval-of-trelegy-ellipta-closed-triple-as-the-first-onc-tbph-20170919monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-highlights-glaxosmithkline-and-innoviva-s-receipt-of-positive-opinion-tbph-20170918monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-present-at-the-morgan-stanley-15th-annual-global-healthcare-confer-tbph-20170905monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-second-quarter-2017-financial-results-and-business-update-o-tbph-20170801monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-appoints-shehnaaz-suliman-md-as-senior-vice-president-of-corporate-de-tbph-20170731monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-and-mylan-announce-positive-results-from-12-month-phase-3-safety-stud-tbph-20170719monthly0.5https://www.biopharmawatch.com/news/TBPH/new-data-highlighting-in-vitro-potency-advantages-for-vibativ-telavancin-against-difficult-tbph-20170605monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-and-mylan-report-additional-phase-3-data-for-revefenacin-td-4208-in-s-tbph-20170523monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-and-mylan-to-present-additional-data-for-revefenacin-td-4208-in-sever-tbph-20170517monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-first-quarter-2017-financial-results-on-may-9-2017-theravan-tbph-20170502monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-present-at-the-deutsche-bank-42nd-annual-health-care-conference-th-tbph-20170427monthly0.5https://www.biopharmawatch.com/news/TBPH/new-data-for-vibativ-telavancin-reported-in-several-presentations-at-eccmid-2017-theravanc-tbph-20170425monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-reports-positive-clinical-response-rates-for-patients-in-tour-observa-tbph-20170424monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-present-new-data-from-multiple-studies-of-vibativ-telavancin-inclu-tbph-20170418monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-present-at-the-16th-annual-needham-healthcare-conference-theravanc-tbph-20170328monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-presents-positive-clinical-data-on-td-1473-at-the-12th-congress-of-th-tbph-20170217monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-report-fourth-quarter-and-full-year-2016-financial-results-on-febr-tbph-20170215monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-present-clinical-data-on-td-1473-at-the-12th-congress-of-the-europ-tbph-20170213monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-present-at-the-leerink-partners-6th-annual-global-healthcare-confe-tbph-20170202monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-reports-new-data-from-ongoing-tour-observational-patient-registry-in--tbph-20170123monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-present-new-data-from-ongoing-tour-observational-patient-registry--tbph-20170117monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-receives-fda-fast-track-designation-for-velusetrag-td-5108-for-idiopa-tbph-20161206monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-to-present-at-the-28th-annual-piper-jaffray-healthcare-conference-the-tbph-20161122monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-highlights-filing-of-u-s-new-drug-application-for-the-closed-triple-i-tbph-20161121monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-presents-interim-data-from-ongoing-telavancin-observational-use-regis-tbph-20161031monthly0.5https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-announces-pricing-of-public-offerings-of-3-850-000-ordinary-shares-an-tbph-20161028monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-to-present-at-the-h-c-wainwright-27th-annual-global-investment-co-plx-20250902monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference-plx-20230801monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-to-hold-fiscal-year-2022-financial-and-business-results-conferenc-plx-20230221monthly0.5https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-hosting-key-opinion-leader-meeting-on-prx-102-drug-candidate-for--plx-20191127monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-completes-divestiture-of-dermacosmetics-business-perrigo-company-plc-nyse-prgo-per-prgo-20260430monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-quarterly-dividend-perrigo-company-plc-nyse-prgo-a-leading-global-provid-prgo-20260219monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-quarterly-dividend-perrigo-company-plc-nyse-prgo-a-leading-global-provid-prgo-20250730monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-present-at-the-canaccord-genuity-45th-annual-growth-conference-perrigo-company--prgo-20250729monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-release-second-quarter-2025-financial-results-on-august-6-2025-perrigo-company--prgo-20250723monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-agreement-to-divest-dermacosmetics-business-for-up-to-327-million-perrig-prgo-20250714monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-attend-the-oppenheimer-25th-annual-consumer-growth-e-commerce-conference-perrig-prgo-20250523monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-quarterly-dividend-perrigo-company-plc-nyse-prgo-a-leading-global-provid-prgo-20250430monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-release-first-quarter-2025-financial-results-on-may-7-2025-perrigo-company-plc--prgo-20250423monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-provides-detailed-plan-to-consumerize-simplify-and-scale-its-unique-global-self-ca-prgo-20250228monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-attend-the-ubs-2025-global-consumer-and-retail-conference-perrigo-company-plc-n-prgo-20250226monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-increases-quarterly-dividend-by-5-perrigo-company-plc-nyse-prgo-a-leading-global-p-prgo-20250219monthly0.5https://www.biopharmawatch.com/news/PRGO/opill-extends-mission-of-breaking-down-birth-control-barriers-with-launch-of-multi-state-c-prgo-20250204monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-release-fourth-quarter-and-fiscal-year-2024-financial-results-on-february-27-20-prgo-20250131monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-expands-its-scientific-office-appoints-abbie-lennox-as-executive-vice-president-an-prgo-20250106monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-quarterly-dividend-perrigo-company-plc-nyse-prgo-a-leading-global-provid-prgo-20241101monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-release-third-quarter-2024-financial-results-on-november-6-2024-perrigo-company-prgo-20241023monthly0.5https://www.biopharmawatch.com/news/PRGO/wnba-star-napheesa-collier-joins-team-opill-for-candid-conversations-on-women-s-health-tod-prgo-20241015monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-good-start-and-dr-browns-brand-partnership-and-launch-of-infant-formula--prgo-20240926monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-the-pricing-of-a-senior-notes-offering-by-its-finance-subsidiary-perrigo-prgo-20240912monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-appoints-industry-veteran-charles-atkinson-as-executive-vice-president-general-cou-prgo-20240904monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-attend-the-piper-sandler-growth-frontiers-conference-perrigo-company-plc-nyse-p-prgo-20240827monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-appoints-david-ball-to-the-newly-created-position-of-executive-vice-president-and--prgo-20240819monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-quarterly-dividend-perrigo-company-plc-nyse-prgo-a-leading-global-provid-prgo-20240801monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-attend-the-canaccord-genuity-44th-annual-growth-conference-perrigo-company-plc--prgo-20240731monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-release-second-quarter-2024-financial-results-on-august-2-2024-perrigo-company--prgo-20240719monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-attend-oppenheimer-24th-annual-consumer-growth-e-commerce-conference-perrigo-co-prgo-20240528monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-executive-transition-for-its-consumer-self-care-international-csci-busin-prgo-20240507monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-quarterly-dividend-perrigo-company-plc-nyse-prgo-a-leading-global-provid-prgo-20240501monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-receives-binding-offer-to-divest-its-hra-pharma-rare-diseases-business-for-up-to-2-prgo-20240425monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-release-first-quarter-2024-financial-results-on-may-7-2024-perrigo-company-plc--prgo-20240423monthly0.5https://www.biopharmawatch.com/news/PRGO/opill-and-wnba-team-up-for-groundbreaking-partnership-today-perrigo-company-plc-a-leading--prgo-20240409monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-commences-shipments-of-opill-to-retailers-nationwide-empowering-millions-to-enter--prgo-20240304monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-attend-ubs-global-consumer-and-retail-conference-perrigo-company-plc-nyse-prgo--prgo-20240229monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-increases-its-quarterly-dividend-perrigo-company-plc-nyse-prgo-a-leading-global-pr-prgo-20240226monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-release-fourth-quarter-and-fiscal-year-2023-financial-results-on-february-27-20-prgo-20240213monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-cash-tender-offer-for-notes-perrigo-company-plc-nyse-prgo-the-company-a--prgo-20231110monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-quarterly-dividend-perrigo-company-plc-nyse-prgo-a-leading-global-provid-prgo-20231102monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-attend-upcoming-consumer-investor-conferences-perrigo-company-plc-nyse-prgo-a-l-prgo-20231031monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-release-third-quarter-2023-financial-results-on-november-7-2023-perrigo-company-prgo-20231024monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-leadership-update-perrigo-company-plc-nyse-prgo-a-leading-provider-of-co-prgo-20230911monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-attend-upcoming-consumer-investor-conferences-perrigo-company-plc-nyse-prgo-a-l-prgo-20230824monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-quarterly-dividend-perrigo-company-plc-nyse-prgo-a-leading-global-provid-prgo-20230802monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-release-second-quarter-2023-financial-results-and-present-at-an-industry-growth-prgo-20230725monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-u-s-fda-approval-for-opill-otc-daily-oral-contraceptive-perrigo-company--prgo-20230713monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-appoints-patrick-lockwood-taylor-as-president-and-ceo-perrigo-company-plc-nyse-prg-prgo-20230608monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-host-1x1-investor-meetings-at-the-23rd-annual-oppenheimer-consumer-growth-e-com-prgo-20230524monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-u-s-fda-approval-for-nicotine-coated-mint-lozenge-perrigo-company-plc-ny-prgo-20230516monthly0.5https://www.biopharmawatch.com/news/PRGO/fda-joint-advisory-committee-votes-in-favor-of-perrigo-s-opill-daily-oral-contraceptive-fo-prgo-20230510monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-quarterly-dividend-perrigo-company-plc-nyse-prgo-a-leading-global-provid-prgo-20230504monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-release-first-quarter-2023-financial-results-on-may-9-2023-perrigo-company-plc--prgo-20230425monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-new-date-for-joint-fda-advisory-committee-meeting-to-review-opill-daily--prgo-20230328monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-present-at-upcoming-12th-annual-ubs-global-consumer-and-retail-conference-perri-prgo-20230302monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-fda-approval-of-the-store-brand-otc-equivalent-of-advil-dual-action-tabl-prgo-20230301monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-launches-its-3-year-optimize-and-accelerate-strategic-plan-issues-fiscal-2023-guid-prgo-20230228monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-increases-its-quarterly-dividend-perrigo-company-plc-nyse-prgo-a-leading-global-pr-prgo-20230221monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-release-fourth-quarter-and-fiscal-year-2022-financial-results-on-february-27-20-prgo-20230214monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-host-virtual-investor-day-on-february-28-2023-perrigo-company-plc-nyse-prgo-a-l-prgo-20221219monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-quarterly-dividend-perrigo-company-plc-nyse-prgo-a-leading-global-provid-prgo-20221103monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-strategic-investment-to-expand-and-strengthen-u-s-manufacturing-of-infan-prgo-20221101monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-receives-notification-of-postponement-for-joint-fda-advisory-committee-to-review-o-prgo-20221026monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-release-third-quarter-2022-financial-results-on-november-8-2022-perrigo-company-prgo-20221025monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-joint-fda-advisory-committee-to-review-opill-daily-oral-contraceptive-fo-prgo-20220912monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-releases-statement-on-recent-market-trading-activity-in-response-to-speculative-co-prgo-20220817monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-quarterly-dividend-perrigo-company-plc-nyse-prgo-a-leading-global-provid-prgo-20220802monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-release-second-quarter-2022-financial-results-on-august-9-2022-perrigo-company--prgo-20220727monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-s-hra-pharma-submits-application-to-fda-for-first-ever-otc-birth-control-pill-perr-prgo-20220711monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-promotes-alison-ives-to-role-of-chief-scientific-officer-perrigo-company-plc-nyse--prgo-20220601monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-u-s-fda-approval-for-omeprazole-magnesium-delayed-release-mini-capsules--prgo-20220526monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-present-at-upcoming-consumer-investor-conferences-perrigo-company-plc-nyse-prgo-prgo-20220519monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-planned-leadership-succession-prgo-20220511monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-quarterly-dividend-prgo-20220505monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-completes-the-acquisition-of-hra-pharma-perrigo-company-plc-nyse-prgo-a-leading-pr-prgo-20220502monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-expected-transaction-close-date-of-hra-pharma-perrigo-company-plc-nyse-p-prgo-20220428monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-release-first-quarter-2022-financial-results-on-may-11-2022-perrigo-company-plc-prgo-20220427monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-launch-of-syndication-of-new-senior-secured-credit-facilities-perrigo-co-prgo-20220328monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-cfo-retirement-and-transition-plan-perrigo-company-plc-nyse-prgo-a-leadi-prgo-20220324monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-u-s-fda-approval-for-otc-use-of-nasonex-24hr-allergy-prgo-20220317monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-completes-divestiture-of-latin-american-businesses-prgo-20220310monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-present-at-upcoming-investor-conferences-prgo-20220225monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-quarterly-dividend-prgo-20220216monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-release-fourth-quarter-and-fiscal-year-2021-financial-results-on-march-1-2022-prgo-20220215monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-present-virtually-at-the-40th-annual-j-p-morgan-healthcare-conference-prgo-20220104monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-voluntary-delisting-from-the-tel-aviv-stock-exchange-tase-prgo-20211122monthly0.5https://www.biopharmawatch.com/news/PRGO/rolf-a-classon-to-not-stand-for-re-election-as-chairman-of-the-perrigo-board-of-directors-prgo-20211108monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-quarterly-dividend-prgo-20211102monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-release-third-quarter-2021-financial-results-on-november-10-2021-prgo-20211027monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-new-consumer-self-care-americas-csca-leadership-prgo-20211005monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-resolves-irish-tax-assessment-for-297-million-prgo-20210929monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-acquire-leading-consumer-self-care-company-hra-pharma-prgo-20210908monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-host-virtual-investor-meetings-at-the-2021-barclays-global-consumer-staples-con-prgo-20210903monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-quarterly-dividend-prgo-20210803monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-release-second-quarter-2021-financial-results-on-august-11-2021-prgo-20210728monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-completes-divestiture-of-generic-rx-business-for-1-55-billion-prgo-20210706monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-present-virtually-at-upcoming-consumer-investor-conferences-prgo-20210521monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-divests-latin-american-businesses-prgo-20210518monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-reports-first-quarter-2021-financial-results-from-continuing-operations-prgo-20210511monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-release-first-quarter-2021-financial-results-on-may-11-2021-prgo-20210427monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-quarterly-dividend-prgo-20210419monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-reports-fourth-quarter-fiscal-year-2020-financial-results-prgo-20210301monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-agreement-to-sell-generic-rx-business-for-1-55-billion-in-total-consider-prgo-20210301monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-increases-quarterly-dividend-by-7-prgo-20210223monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-release-fourth-quarter-and-calendar-year-2020-financial-results-on-march-1-2021-prgo-20210216monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-and-michigan-state-university-announce-partnership-to-advance-consumer-self-care-i-prgo-20210111monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-present-virtually-at-upcoming-investor-conferences-prgo-20201217monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-present-at-the-morgan-stanley-global-consumer-retail-conference-prgo-20201117monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-reports-third-quarter-2020-financial-results-prgo-20201104monthly0.5https://www.biopharmawatch.com/news/PRGO/irish-high-court-rules-perrigo-prgo-20201104monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-completes-acquisition-of-market-leading-otc-self-care-brands-in-eastern-europe-prgo-20201102monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-updates-earnings-conference-call-timing-scheduled-for-november-4-2020-due-to-notif-prgo-20201029monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-quarterly-dividend-prgo-20201022monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-release-third-quarter-2020-financial-results-on-november-4-2020-prgo-20201014monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-voluntarily-recalls-albuterol-sulfate-inhalation-aerosol-reaffirms-2020-guidance-prgo-20200917monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-the-store-brand-equivalent-of-voltaren-arthritis-pain-is-available-at-u--prgo-20200908monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-present-at-upcoming-investor-conferences-prgo-20200825monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-acquires-market-leading-otc-self-care-brands-in-eastern-europe-prgo-20200811monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-second-quarter-2020-financial-results-prgo-20200805monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-quarterly-dividend-prgo-20200729monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-release-second-quarter-2020-financial-results-on-august-5-2020-prgo-20200715monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-furthers-its-consumer-focused-transformation-by-divesting-its-u-k-generic-prescrip-prgo-20200619monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-partners-with-kazmira-llc-to-enter-cbd-market-through-a-two-phased-science-based-a-prgo-20200617monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-the-pricing-of-a-senior-notes-offering-by-its-finance-subsidiary-perrigo-prgo-20200616monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-proposed-public-offering-of-senior-notes-of-its-finance-subsidiary-perri-prgo-20200616monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-present-at-the-20th-annual-oppenheimer-consumer-growth-e-commerce-virtual-confe-prgo-20200602monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-donates-160-000-toothbrushes-to-west-michigan-nonprofit-organizations-prgo-20200602monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-present-at-the-rbc-capital-markets-global-healthcare-conference-prgo-20200508monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-quarterly-dividend-prgo-20200505monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-present-at-the-goldman-sachs-global-staples-forum-webcast-prgo-20200505monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-first-quarter-2020-financial-results-prgo-20200430monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-change-of-venue-and-time-of-the-annual-general-meeting-to-be-held-on-wed-prgo-20200422monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-release-first-quarter-2020-financial-results-on-april-30-2020-prgo-20200416monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-fda-approval-for-the-store-brand-equivalent-of-voltaren-arthritis-pain-prgo-20200406monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-completes-acquisition-of-oral-care-assets-of-high-ridge-brands-prgo-20200402monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-fourth-quarter-fiscal-year-2019-financial-results-prgo-20200227monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-and-catalent-announce-fda-approval-of-perrigo-prgo-20200224monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-acquire-oral-care-assets-of-high-ridge-brands-prgo-20200224monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-increases-its-dividend-by-7-prgo-20200218monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-release-fourth-quarter-and-calendar-year-2019-financial-results-on-february-27--prgo-20200213monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-consumer-self-care-americas-segment-leadership-transition-prgo-20200207monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-advances-consumer-self-care-growth-strategy-with-ranir-subsidiary-acquisition-of-s-prgo-20200106monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-present-at-upcoming-investor-conferences-prgo-20191218monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-closing-of-prevacid-24hr-otc-acquisition-advancing-consumer-self-care-gr-prgo-20191202monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-present-at-the-morgan-stanley-global-consumer-retail-conference-prgo-20191113monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-third-quarter-2019-financial-results-prgo-20191106monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-quarterly-dividend-prgo-20191104monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-issues-voluntary-worldwide-recall-of-ranitidine-due-to-possible-presen-prgo-20191023monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-third-quarter-calendar-year-2019-earnings-date-prgo-20191015monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-hosts-175-west-michigan-students-for-manufacturing-week-celebration-prgo-20191003monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-the-relaunch-of-the-ab-rated-generic-version-of-transderm-scop-1-5-mg-prgo-20191003monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-advances-consumer-self-care-growth-strategy-with-acquisition-of-prevacid-24hr-prgo-20190905monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-present-at-upcoming-investor-conferences-prgo-20190822monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-patent-litigation-settlement-for-the-generic-version-of-nascobal-nasal-s-prgo-20190821monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-resignation-of-jeffrey-c-smith-from-its-board-of-directors-prgo-20190807monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-quarterly-dividend-prgo-20190731monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-second-quarter-calendar-year-2019-earnings-date-prgo-20190725monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-completes-divestiture-of-animal-health-business-for-185-million-prgo-20190708monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-fda-final-approval-and-launch-of-the-ab-rated-generic-version-of-metroge-prgo-20190703monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-completes-acquisition-of-ranir-raises-guidance-prgo-20190702monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-fda-final-approval-for-ab-rated-generic-version-of-voltaren-gel-1-prgo-20190521monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-unveils-self-care-transformation-plan-2019-guidance-and-long-term-growth-targets-a-prgo-20190509monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-expand-into-adjacent-self-care-category-by-acquiring-ranir-global-holdings-llc--prgo-20190509monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-divest-animal-health-business-for-185-million-in-cash-as-part-of-consumer-self--prgo-20190508monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-first-quarter-calendar-year-2019-earnings-date-and-upcoming-conference-p-prgo-20190501monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-increases-its-dividend-by-11-prgo-20190426monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-host-investor-day-prgo-20190418monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-tentative-fda-approval-for-the-generic-version-of-sernivo-spray-0-05-prgo-20190404monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-patent-litigation-settlement-for-the-generic-version-of-finacea-foam-15-prgo-20190402monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-appoints-seasoned-cpg-veteran-ray-silcock-as-chief-financial-officer-prgo-20190320monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-tentative-fda-approval-for-the-generic-version-of-finacea-foam-15-prgo-20190318monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-confirms-patent-challenge-for-generic-version-of-nascobal-prgo-20190305monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-fourth-quarter-and-full-year-2018-financial-results-prgo-20190227monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-receives-leave-to-judicially-review-irish-revenue-tax-assessment-prgo-20190225monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-quarterly-dividend-prgo-20190214monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-patent-litigation-settlement-for-the-generic-version-of-jublia-topical-s-prgo-20190213monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-to-release-fourth-quarter-and-calendar-year-2018-results-on-february-2-prgo-20190213monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-fda-final-approval-for-its-ab-rated-generic-version-of-zovirax-cream-5-prgo-20190206monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-receive-milestone-payment-of-250-million-from-rpi-finance-trust-prgo-20190129monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-appoints-james-dillard-to-role-of-chief-scientific-officer-prgo-20190114monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-present-at-the-j-p-morgan-global-healthcare-conference-prgo-20181220monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-the-launch-of-an-ab-rated-generic-version-of-topicort-topical-spray-0-25-prgo-20181210monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-patent-litigation-settlement-for-the-generic-version-of-sernivo-spray-0--prgo-20181128monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-launches-its-ab-rated-generic-version-of-solaraze-gel-3-prgo-20181127monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-tentative-fda-approval-for-the-first-to-file-generic-version-of-ultravat-prgo-20181126monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-third-quarter-2018-financial-results-prgo-20181108monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-quarterly-dividend-prgo-20181031monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-confirms-patent-challenge-for-generic-version-of-kerydin-prgo-20181029monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-confirms-patent-challenge-for-generic-version-of-narcan-prgo-20181026monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-release-third-quarter-calendar-year-2018-financial-results-on-november-8-2018-prgo-20181025monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-the-launch-of-an-ab-rated-generic-version-of-androgel-topical-gel-1-62-prgo-20181015monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-appoints-murray-s-kessler-as-president-and-chief-executive-officer-in-line-with-sh-prgo-20181008monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-confirms-patent-challenge-for-generic-version-of-jublia-topical-solution-10-prgo-20181001monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-patent-litigation-settlement-for-the-generic-version-of-picato-gel-prgo-20180928monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-final-fda-approval-and-planned-launch-for-the-store-brand-otc-equivalent-prgo-20180907monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-reschedule-investor-event-prgo-20180829monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-expands-otc-growth-strategy-with-rx-to-otc-switch-licensing-for-nasonex-prgo-20180809monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-plan-to-separate-prescription-pharmaceuticals-business-prgo-20180809monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-second-quarter-2018-financial-results-prgo-20180809monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-quarterly-dividend-prgo-20180801monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-release-second-quarter-calendar-year-2018-financial-results-on-august-9-2018-prgo-20180726monthly0.5https://www.biopharmawatch.com/news/PRGO/you-don-t-need-sun-to-feel-the-burn-this-summer-summer-is-the-perfect-time-for-beach-days--prgo-20180605monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-present-at-the-jefferies-2018-healthcare-conference-prgo-20180530monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-confirms-patent-challenge-for-generic-version-of-sernivo-spray-0-05-prgo-20180524monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-confirms-first-to-file-patent-challenge-for-generic-version-of-ultravate-lotion-0--prgo-20180514monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-expects-complete-response-letter-on-generic-version-of-proair-prgo-20180511monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-first-quarter-2018-financial-results-prgo-20180508monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-quarterly-dividend-prgo-20180503monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-release-first-quarter-calendar-year-2018-financial-results-on-may-8-2018-prgo-20180424monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-launches-novel-omeprazole-orally-disintegrating-tablet-to-treat-frequent-heartburn-prgo-20180411monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-present-at-upcoming-investor-conferences-prgo-20180307monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-files-form-10-k-with-sec-will-host-fourth-quarter-and-calendar-year-2017-financial-prgo-20180301monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-fourth-quarter-calendar-year-2017-financial-results-prgo-20180301monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-confirms-patent-challenge-for-generic-version-of-finacea-foam-15-prgo-20180220monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-appoints-ronald-l-winowiecki-as-chief-financial-officer-prgo-20180220monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-quarterly-dividend-prgo-20180215monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-release-fourth-quarter-and-calendar-year-2017-financial-results-on-february-27--prgo-20180208monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-tentative-fda-approval-for-the-generic-version-of-soolantra-cream-1-prgo-20180130monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-tentative-fda-approval-for-the-generic-version-of-onexton-gel-prgo-20180126monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-final-fda-approval-of-a-generic-version-of-estrace-cream-prgo-20180124monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-final-fda-approval-and-launch-of-an-ab-rated-generic-version-of-epiduo-g-prgo-20180124monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-appoints-uwe-ro-hrhoff-as-president-chief-executive-officer-prgo-20180108monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-tentative-fda-approval-for-the-generic-version-of-prolensa-ophthalmic-so-prgo-20180103monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-the-launch-of-an-ab-rated-generic-version-of-mycolog-ii-cream-prgo-20171127monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-completes-divestiture-of-api-business-for-110-million-prgo-20171121monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-to-present-at-the-stifel-2017-healthcare-conference-prgo-20171110monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-third-quarter-2017-financial-results-prgo-20171108monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-announces-quarterly-dividend-prgo-20171102monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-tentative-fda-approval-for-a-first-to-file-generic-version-of-picato-gel-prgo-20171102monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-release-third-quarter-2017-financial-results-on-november-9-2017-prgo-20171026monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-patent-litigation-settlement-for-the-generic-version-of-onexton-gel-prgo-20171026monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-tentative-fda-approval-for-a-first-to-file-generic-version-of-picato-gel-prgo-20171024monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-first-to-market-launch-of-the-otc-store-brand-equivalent-of-nexium-24hr--prgo-20170927monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-fda-final-approval-for-its-ab-rated-generic-version-of-exalgo-32mg-exten-prgo-20170921monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-tentative-fda-approval-for-the-generic-version-of-acanya-gel-prgo-20170918monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-to-present-at-upcoming-investor-conferences-prgo-20170830monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-final-fda-approval-and-settlement-for-the-store-brand-otc-equivalent-of--prgo-20170821monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-fda-final-approval-for-its-ab-rated-generic-version-of-mycolog-ii-cream-prgo-20170816monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-second-quarter-2017-financial-results-prgo-20170810monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-announces-quarterly-dividend-prgo-20170808monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-tentative-fda-approval-for-generic-version-of-mirvaso-gel-prgo-20170804monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-the-launch-of-the-ab-rated-generic-version-of-transderm-scop-1-5-mg-prgo-20170731monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-release-second-quarter-2017-financial-results-on-august-10-2017-prgo-20170727monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-fda-final-approval-for-its-ab-rated-generic-version-of-dermotic-oil-0-01-prgo-20170719monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-confirms-patent-challenge-for-generic-version-of-soolantra-cream-1-prgo-20170717monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-fda-final-approval-for-its-first-to-file-ab-rated-generic-version-of-and-prgo-20170717monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-settlement-of-generic-version-of-dymista-nasal-spray-patent-litigation-prgo-20170717monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-launches-the-generic-version-of-axiron-topical-solution-prgo-20170705monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-retains-spencer-stuart-for-ceo-search-prgo-20170621monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-the-launch-of-generic-equivalents-to-derma-smoothe-fs-scalp-oil-and-body-prgo-20170621monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-the-launch-of-hydrocodone-bitartrate-and-homatropine-methylbromide-oral--prgo-20170619monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-announces-pricing-for-its-cash-tender-offer-prgo-20170614monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-to-present-at-the-17th-annual-oppenheimer-consumer-conference-prgo-20170614monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-to-present-at-the-jefferies-2017-healthcare-conference-prgo-20170602monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-conduct-conference-call-on-may-31-2017-at-8-30-am-et-prgo-20170530monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-files-first-quarter-2017-form-10-q-and-reports-first-quarter-2017-fina-prgo-20170530monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-conduct-conference-call-on-may-23-2017-at-8-30-am-et-prgo-20170522monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-files-2016-form-10-k-with-restated-financial-statements-reports-fourth-quarter-and-prgo-20170522monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-two-new-independent-directors-prgo-20170508monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-announces-quarterly-dividend-prgo-20170503monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-discloses-investigation-prgo-20170502monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-completes-divestiture-of-tysabri-royalty-stream-for-up-to-2-85-billion-prgo-20170327monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-provides-update-on-2016-form-10-k-filing-prgo-20170316monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-first-to-market-launch-of-the-otc-store-brand-equivalent-to-women-prgo-20170308monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-provides-2016-form-10-k-update-prgo-20170307monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-fda-final-approval-for-the-generic-version-of-axiron-topical-solution-30-prgo-20170301monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-select-preliminary-unaudited-calendar-year-2016-financial-resu-prgo-20170227monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-signs-agreement-to-divest-tysabri-royalty-stream-for-up-to-2-85-billion-prgo-20170227monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-leadership-changes-prgo-20170227monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-announces-quarterly-dividend-prgo-20170221monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-fda-final-approval-for-hydrocodone-bitartrate-and-homatropine-methylbrom-prgo-20170217monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-release-fourth-quarter-and-calendar-year-2016-results-on-february-27-2017-prgo-20170214monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-confirms-patent-challenge-for-generic-version-of-onexton-gel-prgo-20170207monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-agreement-with-starboard-prgo-20170207monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-fda-approval-of-its-first-to-file-ab-rated-generic-version-of-topicort-s-prgo-20170124monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-updates-segment-reporting-structure-prgo-20170110monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-fda-approvals-for-the-store-brand-otc-equivalents-to-nicorette-white-ice-prgo-20161220monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-portfolio-review-developments-and-intention-to-restructure-branded-consu-prgo-20161208monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-third-quarter-2016-financial-results-prgo-20161110monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-to-review-strategic-alternatives-for-tysabri-royalty-stream-prgo-20161110monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-announces-appointment-of-two-new-independent-directors-to-board-prgo-20161110monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-announces-quarterly-dividend-prgo-20161108monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-to-release-third-quarter-calendar-year-2016-results-on-november-10-201-prgo-20161026monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-invests-in-tarex-patented-technology-as-a-key-investment-in-the-fight-against-meth-prgo-20160927monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-acknowledges-receipt-of-letter-from-starboard-value-lp-prgo-20160912monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-to-present-at-upcoming-investor-conferences-prgo-20160907monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-tentative-fda-approval-for-generic-version-of-epiduo-gel-prgo-20160901monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-tentative-fda-approval-for-generic-version-of-suprep-oral-solution-and-c-prgo-20160823monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-acquire-u-s-distributor-of-healthcare-consumer-goods-products-geiss-destin-dunn-prgo-20160817monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-second-quarter-2016-financial-results-prgo-20160810monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-completes-the-divestiture-of-its-vitamins-minerals-supplements-business-to-ivc-prgo-20160808monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-announces-quarterly-dividend-prgo-20160802monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-to-release-second-quarter-calendar-year-2016-results-on-august-10-2016-prgo-20160727monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-leadership-change-in-rx-pharmaceuticals-segment-prgo-20160720monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-fda-final-approval-and-launch-of-the-store-brand-equivalent-to-zegerid-o-prgo-20160718monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-fda-clearance-and-launch-of-non-gmo-infant-formulas-for-the-u-s-store-br-prgo-20160621monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-divests-vitamins-minerals-supplements-business-to-ivc-prgo-20160620monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-to-present-at-the-oppenheimer-16th-annual-consumer-conference-prgo-20160616monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-fda-approval-of-the-generic-version-of-ofirmev-acetaminophen-injection-prgo-20160616monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-confirms-first-to-file-patent-challenge-for-generic-version-of-picato-gel-0-015-an-prgo-20160613monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-fda-approval-and-launch-of-the-store-brand-equivalent-to-flonase-prgo-20160531monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-to-present-at-the-ubs-global-healthcare-conference-prgo-20160518monthly0.5https://www.biopharmawatch.com/news/PRGO/correcting-and-replacing-gaap-net-loss-on-consolidated-statement-of-operations-for-first-q-prgo-20160516monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-first-quarter-2016-financial-results-prgo-20160512monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-to-release-first-quarter-calendar-year-2016-results-on-may-12-2016-prgo-20160511monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-fda-approval-and-launch-of-the-generic-version-of-benzaclin-pump-topical-prgo-20160502monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-expands-the-responsibilities-of-sharon-kochan-perrigo-prgo-20160428monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-announces-quarterly-dividend-prgo-20160426monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-appoints-john-t-hendrickson-as-chief-executive-officer-provides-preliminary-first--prgo-20160425monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-responds-to-market-rumors-prgo-20160422monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-first-to-market-launch-of-the-otc-store-brand-equivalent-to-glucerna-ase-prgo-20160412monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-announces-the-closing-of-a-senior-notes-offering-by-its-finance-subsid-prgo-20160310monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-to-present-at-the-barclays-global-healthcare-conference-prgo-20160310monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-to-present-at-upcoming-investor-conferences-prgo-20160301monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-to-present-at-the-rbc-capital-markets-global-healthcare-conference-prgo-20160223monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-furthers-commitment-to-ireland-prgo-20160219monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-announces-quarterly-dividend-prgo-20160216monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-to-announce-calendar-year-fourth-quarter-2015-earnings-results-on-febr-prgo-20160211monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-completes-the-acquisition-of-generic-retin-a-portfolio-further-enhancing-rx-extend-prgo-20160125monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-initiates-voluntary-product-recall-in-the-u-s-of-children-prgo-20160111monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-increases-2016-full-year-adjusted-earnings-per-share-guidance-prgo-20160111monthly0.5https://www.biopharmawatch.com/news/PRGO/allergan-and-perrigo-announce-first-to-market-launch-of-store-brand-equivalent-to-mucinex--prgo-20160104monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-to-present-at-upcoming-investor-conferences-prgo-20151229monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-acquires-generic-retin-a-portfolio-furthering-rx-extended-topicals-strategy-prgo-20151217monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-furthers-rx-extended-topicals-strategy-with-the-acquisition-of-leading-gastrointes-prgo-20151123monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-shareholders-convincingly-reject-mylan-prgo-20151113monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-reaffirms-views-on-mylan-prgo-20151110monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-fda-approval-of-the-ab-rated-generic-version-of-klorcon-extended-release-prgo-20151110monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-issues-shareholder-letter-prgo-20151109monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-responds-to-misleading-statements-prgo-20151109monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-announces-quarterly-dividend-prgo-20151104monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-to-present-at-the-24th-annual-credit-suisse-healthcare-conference-prgo-20151103monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-comments-on-mylan-prgo-20151030monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-taking-actions-to-deliver-shareholder-value-far-superior-to-mylan-offer-prgo-20151022monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-record-third-quarter-highlighted-by-10-organic-net-sales-growt-prgo-20151022monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-to-release-third-quarter-calendar-year-2015-results-on-october-22-2015-prgo-20151019monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-hain-celestial-and-hutchison-china-meditech-bring-earth-prgo-20151008monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-and-flamel-enter-into-exclusive-licensing-agreement-for-liquitime-extended-release-prgo-20151005monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-fda-approval-and-launch-of-the-ab-rated-generic-version-of-benzaclin-top-prgo-20150922monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-board-unanimously-rejects-mylan-prgo-20150917monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announcement-regarding-unsolicited-offer-from-mylan-n-v-prgo-20150914monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-to-present-at-the-morgan-stanley-2015-global-healthcare-conference-prgo-20150910monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-responds-to-misleading-letter-from-mylan-executive-chairman-prgo-20150910monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-acquires-leading-u-s-scar-management-brand-scaraway-prgo-20150831monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-completes-acquisition-of-leading-portfolio-of-otc-brands-from-gsk-prgo-20150828monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-confident-its-shareholders-will-reject-mylan-prgo-20150828monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-to-release-second-quarter-calendar-year-2015-results-on-august-5-2015-prgo-20150724monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-acquire-leading-german-dietary-supplement-brand-yokebe-prgo-20150722monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-to-present-at-upcoming-investor-conferences-prgo-20150616monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-to-acquire-portfolio-of-leading-otc-brands-from-gsk-prgo-20150602monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-to-present-at-the-jefferies-2015-healthcare-conference-prgo-20150527monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-to-present-at-the-ubs-global-healthcare-conference-prgo-20150512monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-to-present-at-upcoming-healthcare-conferences-prgo-20150430monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-rejects-latest-mylan-unsolicited-offer-prgo-20150429monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-announces-quarterly-dividend-prgo-20150428monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-rejects-mylan-unsolicited-offer-prgo-20150424monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-record-fiscal-third-quarter-net-sales-adjusted-net-income-adju-prgo-20150421monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-board-unanimously-rejects-unsolicited-proposal-from-mylan-prgo-20150421monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-fda-approval-and-upcoming-launch-of-the-ab-therapeutic-equivalent-to-exa-prgo-20150408monthly0.5https://www.biopharmawatch.com/news/PRGO/announcement-regarding-possible-offer-prgo-20150408monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-completes-acquisition-of-omega-pharma-invest-n-v-creating-a-top-five-g-prgo-20150330monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-to-present-at-the-2015-rbc-global-healthcare-conference-prgo-20150217monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-record-second-quarter-revenue-adjusted-net-income-and-adjusted-prgo-20150205monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-to-release-second-quarter-fiscal-year-2015-results-on-february-5-2015--prgo-20150129monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-to-release-second-quarter-fiscal-year-2015-results-on-february-5-2015-prgo-20150122monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-launches-ab-therapeutic-equivalent-testosterone-gel-1-0-prgo-20150112monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-partners-with-ferrara-candy-company-to-enter-625-million-gummy-vitamins-and-dietar-prgo-20150112monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-launches-the-generic-version-of-clobex-clobetasol-propionate-spray-0-05-prgo-20150112monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-to-present-at-the-33rd-annual-j-p-morgan-healthcare-conference-prgo-20150106monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-announces-the-closing-of-its-registered-public-offering-of-senior-note-prgo-20141202monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-announces-the-closing-of-its-registered-public-offering-of-ordinary-sh-prgo-20141126monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-announces-underwriters-prgo-20141124monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-announces-proposed-public-offering-of-senior-notes-of-its-finance-subs-prgo-20141124monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-confirms-first-to-file-patent-challenge-for-generic-version-of-aveed-testosterone--prgo-20141124monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-the-launch-of-a-generic-version-of-astellas-prgo-20141124monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-announces-the-pricing-of-senior-notes-offering-by-its-finance-subsidia-prgo-20141124monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-announces-proposed-public-offering-of-ordinary-shares-prgo-20141120monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-reinitiates-shipments-of-guaifenesin-extended-release-600mg-tablets-the-store-bran-prgo-20141106monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-record-first-quarter-revenue-adjusted-net-income-and-adjusted--prgo-20141106monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-to-acquire-omega-pharma-nv-for-eur-3-6-billion-creating-a-top-five-glo-prgo-20141106monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-to-release-first-quarter-fiscal-year-2015-results-on-november-6-2014-prgo-20141023monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-announces-expiration-of-exchange-offer-for-its-1-30-senior-notes-due-2-prgo-20141002monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-announces-extension-of-exchange-offer-for-its-1-30-senior-notes-due-20-prgo-20141001monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-the-out-licensing-of-preclinical-assets-to-imago-pharmaceuticals-prgo-20140929monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-enters-new-therapeutic-category-with-the-acquisition-of-women-prgo-20140929monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-announces-exchange-offer-for-its-1-30-senior-notes-due-2016-2-30-senio-prgo-20140902monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-record-fourth-quarter-and-fiscal-year-revenue-adjusted-operati-prgo-20140814monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-announces-quarterly-dividend-prgo-20140813monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-to-release-fourth-quarter-and-fiscal-year-2014-results-on-august-14-20-prgo-20140731monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-to-present-at-jefferies-2014-global-healthcare-conference-prgo-20140530monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-announces-fda-approval-of-generic-version-of-astepro-nasal-spray-prgo-20140512monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-announces-quarterly-dividend-prgo-20140428monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-to-release-third-quarter-fiscal-year-2014-results-on-may-7-2014-prgo-20140423monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-announces-launch-of-authorized-generic-version-of-taclonex-ointment-calcipotriene--prgo-20140401monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-partners-with-division-of-golden-state-foods-to-manufacture-store-brand-versions-o-prgo-20140326monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-announces-the-transfer-of-development-asset-elnd005-to-transition-ther-prgo-20140228monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-announces-acquisition-of-otc-products-in-australia-prgo-20140228monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-to-present-at-upcoming-healthcare-conference-prgo-20140219monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-reports-record-revenue-adjusted-earnings-and-margins-prgo-20140206monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-announces-quarterly-dividend-prgo-20140129monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-to-release-second-quarter-fiscal-year-2014-results-on-february-6-2014-prgo-20140123monthly0.5https://www.biopharmawatch.com/news/PRGO/perrigo-company-plc-names-board-of-directors-prgo-20131218monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-fourth-quarter-and-full-year-2025-financial-results-and-busine-blfs-20260217monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-preliminary-fourth-quarter-and-full-year-2025-unaudited-revenu-blfs-20260112monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-third-quarter-2025-financial-results-and-business-update-on-no-blfs-20251023monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-reports-second-quarter-2025-financial-results-blfs-20250807monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-participate-in-upcoming-investor-conferences-in-may-and-june-2025-blfs-20250514monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-reports-first-quarter-2025-financial-results-blfs-20250508monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-acquires-panthera-cryosolutions-to-advance-leadership-as-a-pure-play-bio-blfs-20250407monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-appoints-cathy-coste-as-director-and-audit-committee-chair-blfs-20250318monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-reports-fourth-quarter-and-full-year-2024-financial-results-blfs-20250303monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-fourth-quarter-and-full-year-2024-financial-results-and-busine-blfs-20250220monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-preliminary-fourth-quarter-and-full-year-2024-unaudited-revenu-blfs-20250113monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-appoints-tony-j-hunt-to-its-board-of-directors-blfs-20241216monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-6-1-million-sale-of-its-custom-biogenic-systems-freezer-subsid-blfs-20241114monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-reports-third-quarter-2024-financial-results-blfs-20241112monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-73-million-sale-of-its-scisafe-biostorage-subsidiary-blfs-20241112monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-third-quarter-2024-financial-results-and-business-update-on-no-blfs-20241031monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-reports-second-quarter-2024-financial-results-blfs-20240808monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-second-quarter-2024-financial-results-and-business-update-on-a-blfs-20240725monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-introduces-the-cellseal-cryocase-at-international-society-for-cell-gene--blfs-20240529monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-reports-first-quarter-2024-financial-results-blfs-20240509monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-first-quarter-2024-financial-results-and-business-update-on-ma-blfs-20240430monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-the-divestiture-of-its-stirling-freezer-business-blfs-20240418monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-present-at-td-cowen-and-key-bank-investor-conferences-blfs-20240304monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-reports-fourth-quarter-and-full-year-2023-financial-results-blfs-20240229monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-fourth-quarter-and-full-year-2023-financial-results-and-busine-blfs-20240220monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-preliminary-fourth-quarter-and-full-year-2023-unaudited-revenu-blfs-20240108monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-reports-third-quarter-2023-financial-results-blfs-20231109monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-provide-third-quarter-2023-financial-results-and-business-update-on-n-blfs-20231102monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-leadership-transitions-preliminary-third-quarter-revenue-with--blfs-20231019monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-reports-second-quarter-2023-financial-results-updates-full-year-2023-gui-blfs-20230808monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-provide-second-quarter-2023-financial-results-and-business-update-on--blfs-20230727monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-receives-college-of-american-pathologists-cap-bap-accreditation-for-all--blfs-20230614monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-launches-the-intellirate-i67c-liquid-nitrogen-ln2-controlled-rate-freeze-blfs-20230606monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-provide-first-quarter-2023-financial-results-and-business-update-on-m-blfs-20230502monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-reports-preliminary-and-unaudited-2022-fourth-quarter-and-full-year-fina-blfs-20230316monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-reports-immaterial-financial-exposure-to-silicon-valley-bank-blfs-20230310monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provid-blfs-20230309monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-launches-ultraguard-70-c-phase-change-material-pcm-accessory-to-provide--blfs-20230301monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-2023-analyst-day-participation-in-upcoming-investor-conference-blfs-20230117monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-named-one-of-seattle-business-magazine-blfs-20230110monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-2022-fourth-quarter-and-full-year-preliminary-unaudited-revenu-blfs-20230109monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-announce-preliminary-2022-revenue-and-introduce-2023-revenue-guidance-blfs-20221219monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-expands-intellectual-property-estate-blfs-20221121monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-named-in-biospace-best-places-to-work-in-biopharma-2023-report-blfs-20221117monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-reports-third-quarter-2022-financial-results-blfs-20221109monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-third-quarter-2022-financial-results-and-provide-business-upda-blfs-20221102monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-coo-to-retire-and-join-board-of-directors-blfs-20221003monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-appoints-cell-therapy-executive-timothy-l-moore-to-its-board-of-director-blfs-20220825monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-reports-second-quarter-2022-financial-results-and-updates-full-year-2022-blfs-20220809monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-second-quarter-2022-financial-results-and-provide-business-upd-blfs-20220802monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-deploys-scisafe-blfs-20220609monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-reports-first-quarter-2022-financial-results-blfs-20220509monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-executes-co-marketing-agreement-with-coriell-institute-for-medical-resea-blfs-20220509monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-first-quarter-2022-financial-results-and-provide-business-upda-blfs-20220502monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-inc-announces-change-of-auditor-to-grant-thornton-llp-blfs-20220407monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-receives-nasdaq-notice-of-noncompliance-for-delayed-10-k-filing-blfs-20220318monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-additional-delay-in-filing-of-annual-report-on-form-10-k-blfs-20220317monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-secures-strategic-customer-wins-and-plans-2022-expansion-in-400-million--blfs-20220315monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-attend-and-present-at-upcoming-investor-conferences-blfs-20220301monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-reports-unaudited-fourth-quarter-and-full-year-2021-financial-results-blfs-20220228monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-fourth-quarter-and-full-year-2021-financial-results-and-provid-blfs-20220221monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-preliminary-2021-revenue-of-119-million-up-148-over-2020-blfs-20220110monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-collaborates-with-seattle-children-blfs-20220104monthly0.5https://www.biopharmawatch.com/news/BLFS/unicef-selects-ultra-low-temperature-ult-freezers-from-biolife-solutions-to-extend-thermal-blfs-20211216monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-ranks-353-among-fastest-growing-companies-in-north-america-on-the-2021-d-blfs-20211117monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-named-to-inc-magazine-inaugural-list-of-best-led-companies-blfs-20211115monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-third-quarter-2021-financial-results-blfs-20211111monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-executive-management-changes-blfs-20211104monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-third-quarter-2021-financial-results-and-provide-business-upda-blfs-20211104monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-supports-biostorage-best-practices-through-scisafe-blfs-20211026monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-leverages-expanded-bioproduction-tools-and-services-portfolio-in-multipo-blfs-20211004monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-appoints-joydeep-goswami-mba-phd-to-board-of-directors-blfs-20210920monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-cfo-retirement-blfs-20210915monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-files-form-s-3-registration-statement-to-register-shares-from-completed--blfs-20210901monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-closes-acquisition-of-sexton-biotechnologies-blfs-20210901monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-joins-s-p-smallcap-600-index-blfs-20210825monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-second-quarter-2021-financial-results-blfs-20210812monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-acquire-sexton-biotechnologies-to-expand-cell-and-gene-therapy-tools--blfs-20210809monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-second-quarter-2021-financial-results-and-provide-business-upd-blfs-20210805monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-changes-to-board-of-directors-blfs-20210714monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-adopts-new-brand-identity-blfs-20210615monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-promotion-of-caitlin-rice-to-global-vice-president-customer-se-blfs-20210519monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-first-quarter-2021-financial-results-blfs-20210513monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-first-quarter-2021-financial-results-and-provide-business-upda-blfs-20210506monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-closing-of-stirling-ultracold-acquisition-and-expanded-partner-blfs-20210503monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-launches-new-high-capacity-controlled-rate-freezer-line-with-first-shipm-blfs-20210415monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-appoints-two-new-independent-board-directors-blfs-20210406monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-fourth-quarter-and-full-year-2020-financial-results-blfs-20210322monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-acquire-stirling-ultracold-in-an-all-stock-merger-blfs-20210322monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-fourth-quarter-and-full-year-2020-financial-results-and-provid-blfs-20210310monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-promotes-marcus-schulz-to-chief-revenue-officer-blfs-20210216monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-promotes-sarah-aebersold-j-d-to-global-vice-president-human-resources-blfs-20210105monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-casdin-capital-innovation-accelerator-announce-new-investments-in-cell-g-blfs-20201201monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-ranked-403rd-fastest-growing-company-in-north-america-on-deloitte-blfs-20201119monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-third-quarter-2020-financial-results-blfs-20201105monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-third-quarter-2020-financial-results-and-provide-business-upda-blfs-20201029monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-scisafe-division-secures-2-7-million-cold-chain-and-storage-contract-for-blfs-20201014monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-closes-acquisition-of-scisafe-a-high-growth-biostorage-service-provider--blfs-20201001monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-acquire-scisafe-a-high-growth-biostorage-service-provider-to-the-cell-blfs-20200921monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-named-one-of-the-top-100-companies-in-washington-state-blfs-20200825monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-second-quarter-2020-financial-results-blfs-20200806monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-second-quarter-2020-financial-results-and-provide-business-upd-blfs-20200730monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-evo-cold-chain-management-platform-now-supporting-over-100-early-stage-c-blfs-20200715monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-closing-of-86-million-public-offering-of-common-stock-blfs-20200707monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-pricing-of-75-million-public-offering-of-common-stock-blfs-20200702monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-9-6-million-to-9-8-million-in-preliminary-revenue-for-q2-2020-blfs-20200701monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-proposed-public-offering-of-common-stock-blfs-20200701monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-promotes-marcus-schulz-to-vice-president-global-sales-blfs-20200518monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-first-quarter-2020-financial-results-blfs-20200514monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-first-quarter-2020-financial-results-and-provide-business-upda-blfs-20200511monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-preliminary-first-quarter-2020-revenue-blfs-20200501monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-fourth-quarter-and-full-year-2019-financial-results-blfs-20200311monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-awarded-three-new-patents-for-cell-and-gene-therapy-bioproduction-tools-blfs-20200302monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-earnings-call-date-and-upcoming-investor-and-scientific-confer-blfs-20200212monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-executive-appointments-to-support-integration-of-acquired-comp-blfs-20191202monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-acquires-custom-biogenic-systems-blfs-20191112monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-third-quarter-2019-financial-results-blfs-20191112monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-named-one-of-the-fastest-growing-companies-in-north-america-on-deloitte-blfs-20191107monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-third-quarter-2019-financial-results-and-provide-business-upda-blfs-20191031monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-awarded-three-new-patents-for-cryopreservation-thawing-and-cold-chain-tr-blfs-20191014monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-cell-and-gene-therapy-bioproduction-innovation-accelerator-blfs-20190924monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-new-evo-cold-chain-customers-blfs-20190916monthly0.5https://www.biopharmawatch.com/news/BLFS/mustang-bio-adopts-cryostor-freeze-media-and-evo-cold-chain-system-for-cell-and-gene-thera-blfs-20190903monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-strengthens-sales-team-with-key-leadership-additions-blfs-20190828monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-attend-and-present-at-upcoming-scientific-and-investor-conferences-blfs-20190812monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-second-quarter-2019-financial-results-blfs-20190808monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-completes-acquisition-of-savsu-technologies-blfs-20190808monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-second-quarter-2019-financial-results-and-provide-business-upd-blfs-20190731monthly0.5https://www.biopharmawatch.com/news/BLFS/savsu-technologies-expands-ip-portfolio-with-risk-mitigation-technologies-for-shipping-cel-blfs-20190730monthly0.5https://www.biopharmawatch.com/news/BLFS/savsu-technologies-partners-with-united-cargo-to-improve-cold-chain-management-and-deliver-blfs-20190723monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-acquire-savsu-technologies-blfs-20190708monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-join-russell-3000-index-blfs-20190610monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-present-at-the-jefferies-2019-healthcare-conference-blfs-20190530monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-savsu-technologies-selected-by-novartis-to-supply-advanced-col-blfs-20190529monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-first-quarter-2019-financial-results-blfs-20190509monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-first-quarter-2019-financial-results-and-provide-business-upda-blfs-20190502monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-completes-acquisition-of-astero-bio-blfs-20190402monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-fourth-quarter-and-full-year-2018-financial-results-blfs-20190314monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-expands-cell-and-gene-therapy-tools-portfolio-with-acquisition-of-astero-blfs-20190314monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-fourth-quarter-and-full-year-2018-financial-results-and-provid-blfs-20190304monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-attend-and-present-at-upcoming-investor-and-scientific-conferences-blfs-20190219monthly0.5https://www.biopharmawatch.com/news/BLFS/new-policies-to-advance-development-of-cell-and-gene-therapies-announced-by-fda-blfs-20190122monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-completes-redemption-of-series-a-preferred-stock-blfs-20181127monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-attend-and-present-at-upcoming-scientific-and-investor-conferences-blfs-20181113monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-third-quarter-2018-financial-results-blfs-20181108monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-third-quarter-2018-financial-results-and-provide-business-upda-blfs-20181101monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-reports-record-third-quarter-2018-preliminary-revenue-of-5-3-million-up--blfs-20181001monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-increases-ownership-in-savsu-technologies-to-44-with-5-million-investmen-blfs-20180905monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-ring-nasdaq-closing-bell-on-august-29-2018-blfs-20180822monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-second-quarter-2018-financial-results-blfs-20180809monthly0.5https://www.biopharmawatch.com/news/BLFS/casdin-capital-invests-20-million-in-biolife-solutions-to-support-strategic-growth-opportu-blfs-20180809monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-present-and-exhibit-at-fall-investor-and-cell-gene-therapy-conference-blfs-20180806monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-second-quarter-2018-financial-results-and-provide-business-upd-blfs-20180802monthly0.5https://www.biopharmawatch.com/news/BLFS/sandler-capital-funds-to-increase-shareholding-in-biolife-solutions-blfs-20180709monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-reports-second-quarter-2018-preliminary-revenue-of-5-2-million-up-103-ye-blfs-20180702monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-join-russell-microcap-index-blfs-20180611monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-present-at-the-2018-bio-international-convention-blfs-20180529monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-partial-redemption-of-series-a-preferred-stock-blfs-20180517monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-makes-investment-in-savsu-technologies-to-support-growth-and-capture-add-blfs-20180516monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-first-quarter-2018-financial-results-blfs-20180510monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-first-quarter-2018-financial-results-and-provide-business-upda-blfs-20180503monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-receives-2-6-million-from-exercise-of-warrants-blfs-20180430monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-preliminary-first-quarter-2018-revenue-of-3-8-million-up-61-ye-blfs-20180402monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-and-savsu-technologies-to-be-awarded-second-patent-for-next-generation-c-blfs-20180326monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-cryostor-cell-freeze-media-highlighted-in-mayo-clinic-md-anderson-journa-blfs-20180313monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-fourth-quarter-and-full-year-2017-financial-results-blfs-20180308monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-fourth-quarter-and-full-year-2017-financial-results-and-provid-blfs-20180301monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-executes-oem-agreement-with-milliporesigma-blfs-20180213monthly0.5https://www.biopharmawatch.com/news/BLFS/savsu-technologies-and-biolife-solutions-increase-evo-intellectual-property-estate-with-no-blfs-20180118monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-preliminary-2017-revenue-increase-of-34-to-11-million-blfs-20180104monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-executes-supply-agreement-with-iovance-biotherapeutics-blfs-20171213monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-executes-additional-long-term-supply-agreement-with-leading-t-cell-thera-blfs-20171129monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-third-quarter-2017-financial-results-blfs-20171109monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-third-quarter-2017-financial-results-and-provide-business-upda-blfs-20171102monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-and-savsu-providing-enhanced-cold-chain-technologies-for-8-ucsf-clinical-blfs-20171031monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-receives-1-9-million-from-exercise-of-warrants-blfs-20171030monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-customer-kite-pharma-receives-fda-approval-for-yescarta-axicabtagene-cil-blfs-20171019monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-present-at-upcoming-investor-conferences-blfs-20171018monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-cryostor-cell-freeze-media-embedded-in-cellular-biomedicine-group-clinic-blfs-20170919monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-present-at-september-investment-conferences-blfs-20170907monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-second-quarter-2017-financial-results-blfs-20170810monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-second-quarter-2017-financial-results-and-provide-business-upd-blfs-20170803monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-executes-supply-agreement-with-celyad-for-cryostor-use-in-natural-killer-blfs-20170731monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-cryostor-cell-freeze-media-embedded-in-invossa-first-approved-cell-and-g-blfs-20170713monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-modifies-existing-credit-facility-blfs-20170705monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-executes-supply-agreement-with-adaptimmune-for-cryostor-use-in-spear-t-c-blfs-20170614monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-q1-2017-financial-results-blfs-20170511monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-first-quarter-2017-financial-results-and-provide-business-upda-blfs-20170504monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-reports-4th-quarter-and-full-year-2016-results-blfs-20170309monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-fourth-quarter-and-full-year-2016-financial-results-and-provid-blfs-20170302monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-2016-revenue-growth-of-28-blfs-20170112monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-amends-existing-credit-facility-blfs-20170110monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-restructures-biologistex-joint-venture-blfs-20170103monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-executes-10-year-supply-agreement-with-tissuegene-for-cryostor-use-in-in-blfs-20161220monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-reports-record-results-for-third-quarter-2016-blfs-20161110monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-third-quarter-2016-financial-results-and-provide-business-upda-blfs-20161103monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-and-brooks-life-sciences-partner-on-study-of-best-practices-for-shipping-blfs-20161026monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-blfs-20160915monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-blfs-20160824monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-reports-results-for-second-quarter-2016-blfs-20160811monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-executes-10-year-supply-agreement-with-bellicum-pharmaceuticals-for-cryo-blfs-20160810monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-second-quarter-2016-financial-results-and-provide-business-upd-blfs-20160803monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-products-embedded-in-cook-myosite-phase-3-cell-therapy-clinical-trial-fo-blfs-20160718monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-executes-10-year-supply-agreement-with-kite-pharma-for-cryostor-use-in-c-blfs-20160711monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-and-mnx-global-logistics-partner-to-support-immunocellular-therapeutics--blfs-20160519monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-appoints-jim-mathers-as-new-vice-president-of-sales-blfs-20160518monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-reports-first-quarter-2016-results-blfs-20160512monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-first-quarter-2016-financial-results-and-provide-business-upda-blfs-20160506monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-names-roderick-de-greef-chief-financial-officer-secretary-blfs-20160504monthly0.5https://www.biopharmawatch.com/news/BLFS/seattle-business-magazine-names-biolife-solutions-washington-state-manufacturer-of-the-yea-blfs-20160502monthly0.5https://www.biopharmawatch.com/news/BLFS/biologistex-llc-and-mnx-global-logistics-partner-to-offer-enhanced-cold-chain-logistics-se-blfs-20160426monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-names-cord-blood-industry-veteran-karen-foster-vice-president-of-operati-blfs-20160404monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-provides-update-on-customer-cell-therapy-clinical-trials-and-development-blfs-20160314monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-present-at-28th-annual-roth-conference-and-4th-annual-arm-cell-gene-t-blfs-20160309monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-names-roderick-de-greef-interim-chief-financial-officer-blfs-20160307monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-reports-4th-quarter-and-full-year-2015-results-blfs-20160225monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-fourth-quarter-2015-financial-results-and-provide-business-upd-blfs-20160222monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-present-at-18th-annual-bio-ceo-investors-conference-blfs-20160127monthly0.5https://www.biopharmawatch.com/news/BLFS/new-journal-articles-cite-expanded-use-of-biolife-solutions-products-in-clinical-cell-ther-blfs-20160125monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-2015-biopreservation-media-revenue-growth-of-30-blfs-20160107monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-distributor-stemcell-technologies-will-test-the-evo-smart-shipper-and-cl-blfs-20160106monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-customer-capricor-therapeutics-provides-update-on-heart-failure-cell-the-blfs-20151123monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-makes-deloitte-2015-technology-fast-500-blfs-20151116monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-reports-3rd-quarter-2015-results-blfs-20151112monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-third-quarter-2015-financial-results-and-provide-business-upda-blfs-20151102monthly0.5https://www.biopharmawatch.com/news/BLFS/stem-cell-company-cardiocell-utilizes-biolife-solutions-cryostor-in-phase-ii-clinical-tria-blfs-20151022monthly0.5https://www.biopharmawatch.com/news/BLFS/kiadis-pharma-utilizes-biolife-solutions-hypothermosol-to-improve-viability-and-shelf-life-blfs-20151019monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-reports-record-revenue-and-provides-operations-update-for-q3-2015-blfs-20151005monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-present-at-upcoming-investor-conferences-blfs-20150928monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-hemacare-will-validate-the-evo-smart-shipper-and-cloud-based-b-blfs-20150917monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-cryostor-commercial-grade-freeze-media-embedded-in-tc-biopharm-immunicel-blfs-20150914monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-customer-tigenix-phase-3-clinical-trial-meets-primary-endpoint-blfs-20150831monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-second-quarter-2015-financial-results-and-provide-business-upd-blfs-20150729monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-readies-new-bloodstor-27-nacl-cryopreservation-media-to-support-customer-blfs-20150715monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-q2-2015-revenue-of-1-5-million-with-33-growth-in-proprietary-p-blfs-20150713monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-named-one-of-the-100-best-companies-to-work-for-in-washington-state-blfs-20150702monthly0.5https://www.biopharmawatch.com/news/BLFS/savsu-technologies-evo-smart-shipping-container-marketed-by-biolife-solutions-wins-2015-me-blfs-20150618monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-cryostor-cited-in-new-journal-article-on-results-of-phase-i-ii-clinical--blfs-20150615monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-reports-increased-adoption-of-cryostor-and-hypothermosol-clinical-grade--blfs-20150603monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-sponsor-present-and-exhibit-at-the-2015-isct-conference-may-27-30-in--blfs-20150526monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-present-at-the-2015-marcum-microcap-conference-in-new-york-city-blfs-20150522monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-first-quarter-2015-financial-results-and-provide-business-upda-blfs-20150429monthly0.5https://www.biopharmawatch.com/news/BLFS/cord-blood-registry-uses-biolife-solutions-cryostor-clinical-grade-freeze-media-in-the-sto-blfs-20150415monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-preliminary-q1-2015-revenue-of-1-5-million-and-continued-produ-blfs-20150413monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-cryostor-cell-preservation-media-embedded-in-cardio3-biosciences-blfs-20150409monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-fourth-quarter-and-full-year-2014-financial-results-blfs-20150312monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-fourth-quarter-and-full-year-2014-financial-results-and-provid-blfs-20150306monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-cryostor-cell-freeze-media-used-in-mayo-clinic-safety-and-feasibility-st-blfs-20150303monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-wins-washington-state-2015-silver-award-for-achievement-in-medical-techn-blfs-20150302monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-launches-new-cell-thawing-media-products-in-response-to-worldwide-shorta-blfs-20150211monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-reports-preliminary-revenue-for-2014-blfs-20150112monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-biopreservation-media-products-embedded-in-175-cellular-immunotherapy-ot-blfs-20150105monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-sets-date-for-annual-meeting-of-stockholders-blfs-20141224monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-names-pharmaceutical-industry-expert-kevin-o-blfs-20141223monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-present-at-the-ld-micro-main-event-investor-conference-on-wednesday-d-blfs-20141125monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-launches-two-new-product-packaging-options-for-bloodstor-and-cryostor-fr-blfs-20141117monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-named-to-deloitte-blfs-20141113monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-third-quarter-2014-results-blfs-20141106monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-financial-results-for-third-quarter-2014-and-provide-business--blfs-20141030monthly0.5https://www.biopharmawatch.com/news/BLFS/roosterbio-selects-biolife-solutions-cryostor-to-commercialize-human-bone-marrow-derived-s-blfs-20141021monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-biopreservation-media-products-used-at-neostem-subsidiary-progenitor-cel-blfs-20141014monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-preliminary-revenue-for-q3-2014-of-1-2-million-blfs-20141006monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-forms-biologistex-ccm-sm-joint-venture-with-savsu-technologies-to-market-blfs-20140930monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-the-addition-of-jason-acker-mba-phd-and-anthony-davies-phd-to--blfs-20140923monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-present-at-the-16th-annual-rodman-renshaw-global-investment-conferenc-blfs-20140908monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-cryostor-and-hypothermosol-now-embedded-in-130-regenerative-medicine-cli-blfs-20140825monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-second-quarter-2014-results-blfs-20140807monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-cryostor-demonstrates-superior-cell-preservation-in-multicenter-biobanki-blfs-20140804monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-report-financial-results-for-second-quarter-2014-and-provide-business-blfs-20140731monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-manufacturing-agreement-with-somahlution-llc-blfs-20140717monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-cryostor-freeze-media-adopted-by-txcell-for-ovasave-regulatory-t-cell-ba-blfs-20140616monthly0.5https://www.biopharmawatch.com/news/BLFS/frost-sullivan-selects-biolife-solutions-cell-and-tissue-biopreservation-media-for-technol-blfs-20140611monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-present-at-ld-micro-conference-blfs-20140519monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-present-at-third-annual-marcum-microcap-conference-blfs-20140512monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-first-quarter-2014-results-and-provides-business-update-blfs-20140508monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-stock-added-to-the-wilshire-5000-sm-blfs-20140421monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-preliminary-q1-2014-revenue-of-2-million-blfs-20140416monthly0.5https://www.biopharmawatch.com/news/BLFS/adaptimmune-integrates-biolife-solutions-cryostor-cell-freeze-media-in-cancer-immunotherap-blfs-20140402monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-closes-15-4-million-public-offering-and-converts-14-3-million-of-debt-to-blfs-20140325monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-pricing-of-15-4-million-public-offering-blfs-20140320monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-sponsorship-of-alliance-for-regenerative-medicine-2nd-annual-r-blfs-20140310monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-cryostor-freeze-media-adopted-by-parcell-laboratories-for-stem-cells-to--blfs-20140225monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-2013-full-year-results-driven-by-product-adoption-in-regenerat-blfs-20140212monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-be-issued-new-biopreservation-patent-blfs-20140129monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-1-14-reverse-stock-split-blfs-20140121monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-preliminary-2013-revenue-grows-to-9-million-blfs-20140106monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-applies-to-list-its-common-shares-on-the-nasdaq-capital-market-blfs-20131216monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-cryostor-adopted-by-discgenics-for-use-in-novel-injectable-cellular-ther-blfs-20131209monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-appoints-raymond-w-cohen-as-chairman-and-joe-schick-to-board-of-director-blfs-20131119monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-2-2-million-total-revenue-for-the-third-quarter-of-2013-blfs-20131114monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-makes-deloitte-blfs-20131113monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-and-savsu-technologies-announce-exclusive-distribution-agreement-blfs-20130923monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-provides-update-on-clinical-use-of-cryostor-and-hypothermosol-cell-and-t-blfs-20130903monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-hypothermosol-embedded-in-two-intercytex-clinical-trials-of-cell-based-w-blfs-20130822monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-expands-strategic-relationship-with-stemcell-technologies-inc-blfs-20130813monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-record-revenue-of-2-3-million-in-the-second-quarter-of-2013-blfs-20130812monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-the-addition-of-robert-preti-ph-d-to-its-scientific-advisory-b-blfs-20130723monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-strategic-partnership-with-hemacare-blfs-20130625monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-named-one-of-washington-blfs-20130624monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-presentation-at-8th-world-stem-cells-regenerative-medicine-con-blfs-20130523monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-record-revenue-of-2-2-million-in-first-quarter-of-2013-blfs-20130514monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-participation-and-additional-product-citations-at-19th-isct-an-blfs-20130506monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-license-agreement-blfs-20130502monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-2012-full-year-results-10th-consecutive-quarter-of-record-reve-blfs-20130401monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-appoints-rick-stewart-to-board-of-directors-blfs-20130204monthly0.5https://www.biopharmawatch.com/news/BLFS/dhi-global-medical-group-adopts-biolife-solutions-blfs-20130108monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-reports-preliminary-2012-revenue-at-5-7-million-doubled-from-2011-blfs-20130107monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-to-present-at-onemedforum-2013-blfs-20130102monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-tigenix-blfs-20121212monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-2012-third-quarter-results-ninth-straight-quarter-of-record-re-blfs-20121113monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-products-now-used-in-more-than-50-clinical-trial-stage-cellular-therapie-blfs-20121029monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-secures-exclusive-distribution-rights-for-cellenergy-hair-graft-storage--blfs-20121017monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-presentation-at-ibc-inaugural-cell-therapy-clinical-developmen-blfs-20120912monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-2012-second-quarter-results-eighth-straight-quarter-of-record--blfs-20120814monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-completes-corporate-facilities-expansion-build-out-of-additional-cgmp-cl-blfs-20120723monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-completes-first-1-million-revenue-quarter-blfs-20120709monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-restructures-term-debt-secures-3-year-extension-on-maturity-blfs-20120601monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-7th-consecutive-quarter-of-record-revenue-blfs-20120514monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-record-4th-quarter-and-full-year-2011-financial-results-and-pr-blfs-20120326monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-commences-build-out-of-second-gmp-production-suite-and-corporate-office--blfs-20120305monthly0.5https://www.biopharmawatch.com/news/BLFS/improved-cord-blood-processing-research-on-biolife-solutions-cryostor-published-in-transfu-blfs-20120217monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-congratulates-dcprime-on-its-approved-orphan-medicinal-product-applicati-blfs-20120206monthly0.5https://www.biopharmawatch.com/news/BLFS/independent-data-published-on-biolife-solutions-hypothermosol-and-cryostor-blfs-20120127monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-adds-clinical-and-commercialization-experts-to-scientific-advisory-board-blfs-20120123monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-2011-revenue-up-33-blfs-20120110monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-launches-search-engine-optimized-website-and-1-000-free-samples-offer-blfs-20111206monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-q3-2011-revenue-up-36-percent-year-over-year-at-715-000-up-15-percent-ov-blfs-20111003monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-reports-record-quarterly-revenue-blfs-20110706monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-now-the-leading-supplier-of-pre-formulated-gmp-cryopreservation-media-fo-blfs-20110621monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-announces-record-quarterly-revenue-blfs-20110406monthly0.5https://www.biopharmawatch.com/news/BLFS/biolife-solutions-increases-2011-financial-scientific-technical-support-of-the-regenerativ-blfs-20110118monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-enters-exclusive-global-licensing-agreement-for-veppanu-vepdegestrant-an-oral-protac-rigl-20260512monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rigl-20260407monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2025-financial-result-rigl-20250729monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rigl-20250707monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-the-jefferies-global-healthcare-conference-rigl-20250528monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-poster-presentations-at-the-2025-asco-annual-meeting-and-eha2025-congress-rigl-20250522monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-first-quarter-2025-financial-results-rigl-20250429monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rigl-20250404monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-appoints-mark-w-frohlich-m-d-to-board-of-directors-rigl-20250310monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-fourth-quarter-and-full-year-2024-fi-rigl-20250225monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-s-fostamatinib-being-studied-by-national-institute-of-health-in-patients-with-sickle-rigl-20250122monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-provides-business-update-and-2025-outlook-rigl-20250113monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-r289-granted-orphan-drug-designation-by-the-fda-for-mds-rigl-20250109monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-rigl-20250108monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rigl-20250103monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-r289-granted-fast-track-designation-by-the-fda-for-lower-risk-mds-rigl-20241202monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-the-jefferies-london-healthcare-conference-rigl-20241112monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-six-poster-presentations-at-the-66th-american-society-of-hematology-annual-rigl-20241105monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-third-quarter-2024-financial-results-rigl-20241031monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-issues-dear-healthcare-provider-letter-for-gavreto-pralsetinib-rigl-20241024monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rigl-20241004monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-the-2024-cantor-global-healthcare-conference-rigl-20240912monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-first-patient-enrolled-in-phase-1b-2-triplet-therapy-trial-of-rezlidhia-ol-rigl-20240905monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-expands-relationship-with-kissei-to-include-rezlidhia-olutasidenib-in-japan-the-repu-rigl-20240903monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-participate-in-upcoming-september-investor-conferences-rigl-20240829monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2024-financial-result-rigl-20240730monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rigl-20240712monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-reverse-stock-split-rigl-20240625monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-completes-transfer-of-gavreto-pralsetinib-new-drug-application-rigl-20240624monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-five-presentations-at-the-eha2024-hybrid-congress-rigl-20240614monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-highlights-new-data-in-three-poster-presentations-at-the-2024-asco-annual-meeting-rigl-20240603monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-the-jefferies-global-healthcare-conference-rigl-20240530monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-presentations-at-the-upcoming-2024-asco-annual-meeting-and-eha2024-hybrid--rigl-20240523monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-first-quarter-2024-financial-results-rigl-20240430monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rigl-20240410monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-publication-of-data-on-rezlidhia-olutasidenib-in-post-venetoclax-patients--rigl-20240404monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-announces-appointment-of-lisa-rojkjaer-m-d-as-chief-medical-officer-rigl-20240312monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-fourth-quarter-and-full-year-2023-fi-rigl-20240227monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-acquires-u-s-rights-to-gavreto-rigl-20240222monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-provides-business-update-rigl-20240108monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rigl-20240105monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-collaboration-with-connect-to-conduct-a-phase-2-trial-of-olutasidenib-in-g-rigl-20240104monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-rigl-20240103monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-and-md-anderson-announce-strategic-alliance-to-advance-rezlidhia-olu-rigl-20231208monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-the-jefferies-london-healthcare-conference-rigl-20231106monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-poster-presentations-at-the-65th-american-society-of-hematology-annual-mee-rigl-20231102monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-third-quarter-2023-financial-results-rigl-20231031monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-presentation-at-the-upcoming-idweek-2023-rigl-20231011monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rigl-20231006monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-the-2023-cantor-global-healthcare-conference-rigl-20230920monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-participate-in-upcoming-september-investor-conferences-rigl-20230830monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2023-financial-result-rigl-20230725monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rigl-20230705monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-presentation-of-data-from-analysis-of-rezlidhia-olutasidenib-in-post-venet-rigl-20230607monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-second-rezlidhia-olutasidenib-publication-in-blood-advances-rigl-20230606monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-poster-presentation-at-the-upcoming-2023-american-society-of-clinical-onco-rigl-20230601monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-the-jefferies-2023-global-healthcare-conference-rigl-20230531monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-first-quarter-2023-financial-results-rigl-20230425monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rigl-20230406monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-fourth-quarter-and-full-year-2022-fi-rigl-20230228monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-publication-of-rezlidhia-olutasidenib-phase-2-clinical-results-in-blood-ad-rigl-20230202monthly0.5https://www.biopharmawatch.com/news/RIGL/national-comprehensive-cancer-network-adds-newly-approved-rezlidhia-olutasidenib-to-clinic-rigl-20230118monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-provides-business-update-rigl-20230109monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-availability-of-rezlidhia-olutasidenib-in-the-u-s-for-the-treatment-of-adu-rigl-20221222monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-doses-first-patient-in-phase-1b-study-of-r289-for-the-treatment-of-lower-risk-myelod-rigl-20221215monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rigl-20221209monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-publication-of-early-clinical-data-of-olutasidenib-in-the-lancet-haematolo-rigl-20221110monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-five-poster-presentations-at-the-upcoming-64th-american-society-of-hematol-rigl-20221103monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-third-quarter-2022-financial-results-rigl-20221027monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conference-rigl-20220906monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2022-financial-result-rigl-20220726monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-first-quarter-2022-financial-results-rigl-20220426monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rigl-20220408monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-publication-of-data-from-phase-2-clinical-study-of-fostamatinib-for-the-tr-rigl-20220308monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-fourth-quarter-and-year-end-2021-fin-rigl-20220222monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-the-j-p-morgan-healthcare-conference-rigl-20220110monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-provides-business-update-rigl-20220110monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rigl-20220107monthly0.5https://www.biopharmawatch.com/news/RIGL/fostamatinib-meets-primary-endpoint-in-phase-3-trial-in-japan-for-treatment-of-chronic-imm-rigl-20211221monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-appoints-kamil-ali-jackson-to-board-of-directors-rigl-20211216monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-sharpens-focus-on-its-advanced-portfolio-opportunities-rigl-20211115monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-participate-in-two-upcoming-investor-conferences-rigl-20211109monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-third-quarter-2021-financial-results-rigl-20211026monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rigl-20211008monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-participate-in-three-upcoming-investor-conferences-rigl-20210902monthly0.5https://www.biopharmawatch.com/news/RIGL/data-from-nih-nhlbi-sponsored-phase-2-trial-of-fostamatinib-in-hospitalized-covid-19-patie-rigl-20210901monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-reports-second-quarter-2021-financial-results-and-provides-business-update-rigl-20210803monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2021-financial-result-rigl-20210727monthly0.5https://www.biopharmawatch.com/news/RIGL/new-tavalisse-data-analyses-to-be-presented-at-international-society-on-thrombosis-and-hae-rigl-20210714monthly0.5https://www.biopharmawatch.com/news/RIGL/fostamatinib-selected-for-nih-activ-4-covid-19-clinical-trial-rigl-20210629monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-the-jefferies-virtual-healthcare-conference-rigl-20210526monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-appoints-alison-l-hannah-m-d-to-board-of-directors-rigl-20210514monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-first-quarter-2021-financial-results-rigl-20210428monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-closing-of-strategic-collaboration-with-lilly-rigl-20210407monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-completion-of-patient-enrollment-for-nih-nhlbi-sponsored-phase-2-trial-of--rigl-20210311monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-fourth-quarter-and-year-end-2020-fin-rigl-20210223monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-awarded-16-5-million-from-u-s-department-of-defense-for-phase-3-clinical-trial-of-fo-rigl-20210129monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-provides-business-update-rigl-20210111monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-rigl-20210107monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-two-posters-highlighting-tavalisse-at-the-62nd-ash-annual-meeting-expositi-rigl-20201204monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-finalizes-the-study-design-of-its-ongoing-phase-3-clinical-trial-of-fostamatinib-in--rigl-20201117monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-the-jefferies-virtual-london-healthcare-conference-rigl-20201110monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-third-quarter-2020-financial-results-rigl-20201029monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-first-patients-enrolled-in-nih-nhlbi-sponsored-trial-of-fostamatinib-in-ho-rigl-20201009monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-nih-nhlbi-sponsored-trial-of-fostamatinib-in-hospitalized-covid-19-patient-rigl-20200917monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-two-upcoming-investor-conferences-rigl-20200909monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-participate-in-citi-rigl-20200902monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rigl-20200821monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2020-financial-result-rigl-20200728monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-post-hoc-data-analysis-of-tavalisse-in-adult-patients-with-immune-thromboc-rigl-20200727monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-investigator-sponsored-trial-of-fostamatinib-in-patients-with-covid-19-pne-rigl-20200714monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-availability-of-tavlesse-fostamatinib-disodium-hexahydrate-in-europe-rigl-20200709monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-the-bmo-2020-prescriptions-for-success-healthcare-virtual-conference-rigl-20200617monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-poster-highlighting-tavalisse-at-the-virtual-edition-of-the-25th-european-rigl-20200611monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-four-posters-highlighting-irak1-4-inhibitor-at-the-eular-2020-e-congress-rigl-20200603monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-the-jefferies-virtual-healthcare-conference-rigl-20200526monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-reports-first-quarter-2020-financial-results-and-provides-business-update-rigl-20200505monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-change-to-virtual-format-for-2020-annual-meeting-of-stockholders-rigl-20200501monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-first-quarter-2020-financial-results-rigl-20200427monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-fourth-quarter-and-year-end-financia-rigl-20200220monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-provides-business-update-rigl-20200113monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference-rigl-20200109monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-chief-commercial-officer-transition-rigl-20191217monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-jefferies-2019-london-healthcare-conference-rigl-20191113monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-upcoming-data-presentations-at-the-61st-ash-annual-meeting-exposition-rigl-20191107monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-third-quarter-2019-financial-results-rigl-20191029monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-receives-positive-trend-vote-from-chmp-for-fostamatinib-disodium-hexahydrate-for-adu-rigl-20191018monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-host-investor-and-analyst-call-on-october-23-2019-rigl-20191016monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-secures-credit-facility-for-up-to-60-million-rigl-20191002monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-s-fostamatinib-enters-phase-3-clinical-trial-in-japan-with-kissei-pharmaceuticals-fo-rigl-20190923monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-s-ceo-to-participate-in-panel-discussion-at-citi-s-14th-annual-biotech-conference-ri-rigl-20190828monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2019-financial-result-rigl-20190730monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-two-posters-highlighting-fostamatinib-at-the-24th-congress-of-the-europea-rigl-20190613monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-jefferies-2019-healthcare-conference-rigl-20190531monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-enrolls-first-patient-in-phase-3-clinical-trial-of-fostamatinib-disodium-hexahydrate-rigl-20190516monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-first-quarter-2019-financial-results-rigl-20190430monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-welcomes-jane-wasman-to-board-of-directors-rigl-20190326monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-fourth-quarter-and-year-end-financia-rigl-20190221monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-enters-collaboration-and-license-agreement-with-grifols-s-a-to-comme-rigl-20190123monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-provides-business-update-rigl-20190107monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-rigl-20190103monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-the-bmo-capital-markets-2018-prescriptions-for-success-healthcare-conf-rigl-20181205monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-data-on-fostamatinib-in-three-presentations-at-the-60th-american-society--rigl-20181101monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-third-quarter-2018-financial-results-rigl-20181030monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-enters-collaboration-and-license-agreement-with-kissei-pharmaceutica-rigl-20181029monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-receives-ema-validation-of-the-marketing-authorization-application-for-fostamatinib--rigl-20181011monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-host-investor-analyst-day-in-new-york-city-on-october-4-2018-rigl-20180927monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-the-cantor-global-healthcare-conference-rigl-20180924monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-the-20th-annual-global-investment-conference-in-new-york-city-rigl-20180829monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2018-financial-result-rigl-20180801monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-initiates-phase-1-clinical-trial-of-r835-an-irak1-4-inhibitor-for-autoimmune-and-inf-rigl-20180626monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-poster-presentations-at-focis-annual-meeting-rigl-20180620monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-phase-2-results-for-fostamatinib-in-autoimmune-hemolytic-anemia-at-eha-rigl-20180612monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-jefferies-2018-global-healthcare-conference-rigl-20180531monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-appoints-dean-schorno-as-chief-financial-officer-rigl-20180530monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-availability-of-tavalisse-fostamatinib-disodium-hexahydrate-in-the-u-s-rigl-20180529monthly0.5https://www.biopharmawatch.com/news/RIGL/tavalisse-fostamatinib-disodium-hexahydrate-phase-3-data-published-in-the-american-journal-rigl-20180430monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-first-quarter-2018-financial-results-rigl-20180424monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-pricing-of-public-offering-of-common-stock-rigl-20180419monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-fda-approval-of-tavalisse-fostamatinib-disodium-hexahydrate-for-chronic-im-rigl-20180417monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-makes-statement-regarding-website-error-rigl-20180412monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-topline-data-from-proof-of-concept-phase-2-study-of-fostamatinib-in-iga-ne-rigl-20180403monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-two-fostamatinib-presentations-at-the-4th-biennial-summit-of-the-thrombosi-rigl-20180301monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-fourth-quarter-and-year-end-2017-fin-rigl-20180227monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-inc-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rigl-20180216monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-inc-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rigl-20180126monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-inc-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rigl-20180105monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-inc-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-rigl-20171208monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-one-year-efficacy-and-safety-results-for-fostamatinib-in-itp-at-the-2017--rigl-20171208monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rigl-20171117monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-welcomes-gregg-lapointe-to-board-of-directors-rigl-20171102monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-third-quarter-2017-financial-results-rigl-20171031monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-option-to--rigl-20171010monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-pricing-of-public-offering-of-common-stock-rigl-20171004monthly0.5https://www.biopharmawatch.com/news/RIGL/fostamatinib-meets-pre-specified-primary-endpoint-in-stage-1-of-autoimmune-hemolytic-anemi-rigl-20171003monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-proposed-public-offering-of-common-stock-rigl-20171003monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-provides-update-on-fda-review-of-fostamatinib-for-itp-rigl-20171002monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-cantor-fitzgerald-global-healthcare-conference-rigl-20170919monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-welcomes-brian-kotzin-m-d-to-board-of-directors-rigl-20170825monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rigl-20170818monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2017-financial-result-rigl-20170725monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-oral-presentation-of-tavalisse-fostamatinib-disodium-phase-3-clinical-data-rigl-20170622monthly0.5https://www.biopharmawatch.com/news/RIGL/fda-accepts-rigel-rigl-20170619monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-jefferies-2017-global-healthcare-conference-rigl-20170601monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-tavalisse-as-proprietary-name-for-fostamatinib-in-the-united-states-rigl-20170427monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-first-quarter-2017-financial-results-rigl-20170425monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-submits-new-drug-application-to-fda-for-fostamatinib-in-chronic-itp-rigl-20170417monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-fourth-quarter-and-year-end-2016-fin-rigl-20170228monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-option-to--rigl-20170203monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-pricing-of-public-offering-of-common-stock-rigl-20170131monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-proposed-public-offering-of-common-stock-rigl-20170130monthly0.5https://www.biopharmawatch.com/news/RIGL/fostamatinib-study-results-continue-to-trend-positive-rigl-20170130monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rigl-20170116monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-provides-business-updates-and-preliminary-data-in-iga-nephropathy-rigl-20170105monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-jefferies-2016-london-healthcare-conference-rigl-20161110monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-third-quarter-2016-financial-results-rigl-20161028monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rigl-20161010monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-expands-leadership-team-in-research-and-business-development-rigl-20161007monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-s-fostamatinib-meets-primary-endpoint-in-phase-3-study-in-chronic-itp-rigel-pharmace-rigl-20160830monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-press-release-and-conference-call-schedule-on-tuesday-august-30-2016-rigl-20160829monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2016-financial-result-rigl-20160726monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-jefferies-2016-healthcare-conference-rigl-20160602monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-upcoming-american-association-of-immunologists-aai-annual-meeting-rigl-20160505monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-first-quarter-2016-financial-results-rigl-20160426monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-presentations-at-upcoming-american-association-of-cancer-research-aacr-con-rigl-20160412monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-completes-enrollment-of-fit-phase-3-program-for-fostamatinib-in-itp-rigl-20160401monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-fourth-quarter-and-year-end-2015-fin-rigl-20160301monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-cowen-and-company-36th-annual-health-care-conference-rigl-20160229monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-initiates-phase-2-clinical-trial-of-fostamatinib-in-autoimmune-hemolytic-anemia-rigl-20160225monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-completes-enrollment-of-first-phase-3-study-of-fostamatinib-in-itp-fit-rigl-20160128monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-reviews-recent-progress-and-announces-presentation-at-the-34th-annual-j-p-morgan-hea-rigl-20160107monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-third-quarter-2015-financial-results-rigl-20151027monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-and-aclaris-therapeutics-international-sign-license-agreement-for-jak-inhibitors-to--rigl-20150909monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-granted-orphan-drug-designation-for-fostamatinib-in-itp-rigl-20150908monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2015-financial-result-rigl-20150728monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-welcomes-keith-a-katkin-to-board-of-directors-rigl-20150630monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-jefferies-2015-global-healthcare-conference-rigl-20150528monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-first-quarter-2015-financial-results-rigl-20150430monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-and-bristol-myers-squibb-announce-research-and-development-collaboration-for-tgf-bet-rigl-20150223monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-the-33rd-annual-j-p-morgan-healthcare-conference-rigl-20150108monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-executive-management-changes-rigl-20141124monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-initiates-phase-3-studies-of-fostamatinib-in-itp-rigl-20140716monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-jefferies-2014-global-healthcare-conference-rigl-20140529monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-webcast-of-investor-day-on-may-6-2014-rigl-20140430monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-publication-of-r118-ampk-activator-research-rigl-20140306monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-participation-at-two-investor-conferences-rigl-20140227monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-participation-at-two-investor-conferences-rigl-20140206monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-oppenheimer-healthcare-conference-rigl-20131205monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-provides-pipeline-update-rigl-20131024monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-stifel-healthcare-conference-rigl-20130906monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-focus-on-itp-dle-and-dry-eye-rigl-20130905monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-will-resume-responsibility-for-fostamatinib-program-rigl-20130604monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-s-r348-to-initiate-phase-2-clinical-trial-in-dry-eye-rigel-pharmaceuticals-inc-nasda-rigl-20130522monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-participation-at-two-investor-conferences-rigl-20130228monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-bio-ceo-investor-conference-rigl-20130207monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-focus-on-extensive-clinical-pipeline-at-upcoming-j-p-morgan-presentation-rigl-20130103monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-jefferies-2012-global-healthcare-conference-in-london-rigl-20121108monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-proposed-public-offering-of-common-stock-rigl-20121002monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-ubs-global-life-sciences-conference-rigl-20120917monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-initiates-phase-2-clinical-studies-with-r343-for-asthma-and-r333-for-discoid-lupus-rigl-20120905monthly0.5https://www.biopharmawatch.com/news/RIGL/astrazeneca-and-rigel-sign-worldwide-license-agreement-for-a-potential-new-treatment-for-c-rigl-20120619monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-participation-at-two-investor-conferences-rigl-20120531monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-advances-asthma-programs-two-inhaled-drug-candidates-take-aim-at-acute-and-chronic-l-rigl-20120516monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-participation-at-two-investor-conferences-rigl-20120223monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-initiation-of-clinical-trials-in-two-immunology-programs-rigl-20120105monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-oppenheimer-annual-healthcare-conference-rigl-20111207monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-participate-at-two-upcoming-investor-conferences-rigl-20111103monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-webcast-investor-day-on-october-13-2011-rigl-20111006monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-two-upcoming-investor-conferences-rigl-20110825monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-wells-fargo-securities-healthcare-conference-rigl-20110616monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-jefferies-global-healthcare-conference-rigl-20110603monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-pricing-of-public-offering-of-common-stock-rigl-20110526monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-proposed-public-offering-of-common-stock-rigl-20110525monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-assumes-development-responsibility-for-inhaled-asthma-therapy-rigl-20110506monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-bank-of-america-merrill-lynch-health-care-conference-rigl-20110505monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-first-quarter-financial-results-rigl-20110503monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-three-upcoming-investor-conferences-rigl-20110228monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-participation-at-two-investor-conferences-rigl-20110209monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-jp-morgan-healthcare-conference-rigl-20110106monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-and-astrazeneca-awarded-rigl-20101209monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-piper-jaffray-health-care-conference-rigl-20101123monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-announces-presentations-at-two-investor-conferences-rigl-20101028monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-earns-milestone-payments-from-astrazeneca-rigl-20100929monthly0.5https://www.biopharmawatch.com/news/RIGL/rigel-to-present-at-stifel-nicolaus-healthcare-conference-rigl-20100909monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-to-host-investor-call-on-monday-september-8-2025-lucd-20250905monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-to-participate-in-the-cantor-global-healthcare-conference-2025-lucd-20250827monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-to-participate-in-upcoming-investor-conferences-lucd-20250805monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-to-hold-a-business-update-conference-call-and-webcast-on-august-13-2025-lucd-20250730monthly0.5https://www.biopharmawatch.com/news/LUCD/moldx-to-convene-expert-medical-panel-on-medicare-local-coverage-determination-lcd-for-luc-lucd-20250716monthly0.5https://www.biopharmawatch.com/news/LUCD/major-california-health-system-launches-comprehensive-esophageal-precancer-testing-program-lucd-20250618monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-to-join-russell-2000-and-russell-3000-indexes-lucd-20250527monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-to-hold-a-business-update-conference-call-and-webcast-on-may-14-2025-lucd-20250430monthly0.5https://www.biopharmawatch.com/news/LUCD/nci-sponsored-study-shows-positive-data-for-lucid-diagnostics-lucd-20250424monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-announces-pricing-of-public-offering-of-common-stock-lucd-20250409monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-to-participate-in-fireside-chat-at-the-24th-annual-needham-virtual-healt-lucd-20250403monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-launches-embrace-the-future-campaign-showcasing-esocheck-lucd-20250327monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-announces-updated-national-comprehensive-cancer-network-nccn-guidelines--lucd-20250320monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-lucd-20250318monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-secures-first-positive-commercial-insurance-coverage-policy-for-its-esog-lucd-20250313monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-to-hold-a-business-update-conference-call-and-webcast-on-march-24-2025-lucd-20250310monthly0.5https://www.biopharmawatch.com/news/LUCD/renowned-investigators-awarded-8-million-nih-grant-to-study-lucid-diagnostics-lucd-20250227monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-lucd-20250225monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-executes-first-concierge-medicine-contract-with-leaa-health-lucd-20250220monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-to-participate-in-the-12th-annual-btig-medtech-digital-health-life-scien-lucd-20250206monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-announces-record-quarterly-esoguard-test-volume-lucd-20250113monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-minimum-bi-lucd-20241223monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-partners-with-vitalexam-to-enhance-esophageal-precancer-detection-for-fi-lucd-20241219monthly0.5https://www.biopharmawatch.com/news/LUCD/prospective-clinical-utility-study-of-lucid-diagnostics-lucd-20241211monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-completes-convertible-debt-refinancing-to-strengthen-balance-sheet-and-e-lucd-20241203monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-submits-clinical-evidence-package-to-moldx-seeking-medicare-coverage-for-lucd-20241120monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-to-present-at-the-canaccord-genuity-medtech-diagnostics-and-digital-heal-lucd-20241118monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-lucd-20241107monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-expands-direct-contracting-initiative-with-multiple-programs-focused-on--lucd-20241105monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-to-hold-a-business-update-conference-call-and-webcast-on-november-13-202-lucd-20241030monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-receives-notice-of-allowance-for-key-patent-underlying-its-esoguard-esop-lucd-20241015monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-to-participate-in-the-2024-maxim-healthcare-virtual-summit-lucd-20241009monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-to-join-global-medtech-leaders-at-the-medtech-conference-2024-lucd-20241008monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-holds-inaugural-checkyourfoodtube-precancer-testing-event-for-former-nfl-lucd-20241001monthly0.5https://www.biopharmawatch.com/news/LUCD/american-foregut-society-lucd-20240924monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-to-host-symposium-on-non-endoscopic-esophageal-precancer-screening-at-th-lucd-20240910monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-signs-memorandum-of-understanding-with-front-line-mobile-health-lucd-20240903monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-announces-publication-of-analytical-validation-study-of-esoguard-for-ear-lucd-20240820monthly0.5https://www.biopharmawatch.com/news/LUCD/the-american-foregut-society-formally-requests-medical-policy-coverage-of-esoguard-to-enha-lucd-20240813monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-holds-first-major-directly-contracted-esoguard-checkyourfoodtube-precanc-lucd-20240808monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-announces-positive-data-from-envet-be-clinical-utility-study-of-esoguard-lucd-20240806monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-to-participate-in-upcoming-investor-conferences-lucd-20240805monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-to-hold-a-business-update-conference-call-and-webcast-on-august-12-2024-lucd-20240729monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-announces-record-quarterly-esoguard-test-volume-lucd-20240723monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-launches-new-corporate-website-lucd-20240711monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-announces-positive-data-from-its-esoguard-be-1-prospective-international-lucd-20240702monthly0.5https://www.biopharmawatch.com/news/LUCD/4-000th-firefighter-undergoes-lucid-diagnostics-lucd-20240612monthly0.5https://www.biopharmawatch.com/news/LUCD/legacy-sponge-on-a-string-esophageal-cell-collection-device-subject-of-class-ii-fda-recall-lucd-20240509monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-to-hold-a-business-update-conference-call-and-webcast-on-may-13-2024-lucd-20240502monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-partners-with-the-esophageal-cancer-action-network-ecan-to-highlight-eso-lucd-20240429monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-to-participate-in-fireside-chat-at-the-23rd-annual-needham-virtual-healt-lucd-20240408monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-provides-business-update-and-preliminary-fourth-quarter-and-full-year-20-lucd-20240325monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-announces-positive-data-from-the-first-prospective-clinical-validation-s-lucd-20240321monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-announces-multiple-presentations-at-the-upcoming-digestive-disease-week--lucd-20240320monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-to-hold-a-business-update-conference-call-and-webcast-on-march-26-2024-lucd-20240312monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-provides-update-regarding-world-trade-center-health-program-lucd-20240216monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-chairman-ceo-dr-lishan-aklog-highlights-esocheck-esophageal-cell-collect-lucd-20240215monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-executes-contract-to-provide-esoguard-esophageal-precancer-testing-as-a--lucd-20240208monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-announces-peer-reviewed-publication-of-positive-results-from-three-clini-lucd-20231212monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-strengthens-and-expands-market-access-and-direct-contracting-efforts-lucd-20231116monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-launches-next-generation-esoguard-esophageal-dna-test-and-announces-upco-lucd-20231109monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-to-present-at-canaccord-genuity-medtech-diagnostics-and-digital-health-s-lucd-20231102monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-announces-prevent-and-prevent-ff-registries-of-esoguard-esophageal-preca-lucd-20231031monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-to-hold-a-business-update-conference-call-and-webcast-on-november-14-202-lucd-20231031monthly0.5https://www.biopharmawatch.com/news/LUCD/pavmed-and-lucid-diagnostics-to-participate-in-panel-presentation-at-the-2023-cantor-fitzg-lucd-20230921monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-releases-positive-data-from-first-prospective-clinical-utility-study-of--lucd-20230907monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-releases-positive-data-demonstrating-clinical-utility-of-esoguard-esopha-lucd-20230906monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-executes-first-direct-employer-contract-to-provide-esoguard-esophageal-p-lucd-20230824monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-provides-business-update-and-second-quarter-financial-results-lucd-20230814monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-to-hold-a-business-update-conference-call-and-webcast-on-august-15-2023-lucd-20230731monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-to-present-at-the-canaccord-genuity-43rd-annual-growth-conference-lucd-20230726monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-launches-first-esoguard-mobile-test-unit-lucd-20230605monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-provides-business-update-and-first-quarter-financial-results-lucd-20230515monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-and-collaborators-present-new-esoguard-and-esocheck-data-at-digestive-di-lucd-20230511monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-to-hold-a-business-update-conference-call-and-webcast-on-may-16-2023-lucd-20230505monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-reports-publication-of-future-effective-foundational-local-coverage-dete-lucd-20230418monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-to-present-at-22nd-annual-needham-virtual-healthcare-conference-lucd-20230417monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-provides-update-on-newly-published-future-effective-medicare-local-cover-lucd-20230331monthly0.5https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-to-hold-a-business-update-conference-call-and-webcast-on-march-14-2023-lucd-20230303monthly0.5https://www.biopharmawatch.com/news/RNA/the-new-england-journal-of-medicine-publishes-results-from-phase-1-2-marina-trial-of-delpa-rna-20260218monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-participate-in-upcoming-investor-conferences-rna-20250827monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-reports-second-quarter-2025-financial-results-and-recent-highlights-rna-20250807monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-completion-of-enrollment-for-harbor-the-first-global-phase-3-rna-20250728monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-receives-fda-breakthrough-therapy-designation-for-delpacibart-zotadirs-rna-20250723monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-present-topline-data-from-phase-1-2-fortitude-trial-of-del-brax-in--rna-20250611monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-positive-topline-phase-1-2-fortitude-data-demonstrating-cons-rna-20250609monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-the-accelerated-approval-regulatory-pathway-in-the-u-s-is-op-rna-20250609monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rna-20250521monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-reports-first-quarter-2025-financial-results-and-recent-highlights-rna-20250508monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-participate-in-upcoming-investor-conference-rna-20250506monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rna-20250421monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-receives-orphan-drug-designation-in-japan-for-delpacibart-etedesiran-d-rna-20250408monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-participate-in-upcoming-investor-conference-rna-20250401monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-completes-enrollment-in-biomarker-cohort-in-phase-1-2-fortitude-trial--rna-20250331monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rna-20250321monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-positive-topline-del-zota-data-demonstrating-consistent-stat-rna-20250317monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-rna-20250312monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-honors-rare-disease-day-and-global-efforts-to-support-people-and-famil-rna-20250228monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-reports-fourth-quarter-2024-financial-results-and-recent-highlights-rna-20250227monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-participate-in-upcoming-investor-conferences-rna-20250225monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rna-20250221monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rna-20250120monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rna-20250108monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-plans-first-bla-submission-and-accelerates-commercialization-preparati-rna-20250108monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rna-20241220monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-participate-in-upcoming-investor-conference-rna-20241126monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rna-20241121monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-new-precision-cardiology-development-candidates-to-treat-rar-rna-20241112monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-reports-third-quarter-2024-financial-results-and-recent-highlights-rna-20241107monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-host-investor-and-analyst-event-focused-on-precision-cardiology-can-rna-20241031monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-pursues-potential-accelerated-approval-path-with-initiation-of-biomark-rna-20241030monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rna-20241021monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-fda-removed-partial-clinical-hold-on-delpacibart-etedesiran--rna-20241003monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-participate-in-upcoming-investor-conference-rna-20240925monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rna-20240923monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-joins-patient-and-advocacy-communities-in-raising-awareness-during-nat-rna-20240905monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-participate-in-upcoming-investor-conferences-rna-20240828monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rna-20240821monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-closing-of-upsized-public-offering-of-common-stock-including-rna-20240819monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-pricing-of-upsized-public-offering-of-common-stock-rna-20240814monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-proposed-public-offering-of-common-stock-rna-20240813monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-reports-second-quarter-2024-financial-results-and-recent-highlights-rna-20240809monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-positive-aoc-1044-data-demonstrated-significant-increase-of--rna-20240809monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rna-20240805monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-appointment-of-john-b-moriarty-jr-as-chief-legal-officer-rna-20240805monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rna-20240722monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rna-20240621monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-partners-with-the-fshd-society-to-raise-awareness-of-facioscapulohumer-rna-20240620monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-inc-announces-closing-of-upsized-public-offering-of-common-stock-inclu-rna-20240617monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-participate-in-upcoming-investor-conference-rna-20240614monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-inc-announces-pricing-of-public-offering-of-common-stock-rna-20240613monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-inc-announces-proposed-public-offering-of-common-stock-rna-20240612monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-announces-unprecedented-aoc-1020-data-from-phase-1-2-fortitude-trial-demonstrating-rna-20240612monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-present-preliminary-data-from-phase-1-2-fortitude-trial-of-aoc-1020-rna-20240529monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rna-20240521monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-appointment-of-simona-skerjanec-to-board-of-directors-rna-20240515monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-reports-first-quarter-2024-financial-results-and-recent-highlights-rna-20240509monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-participate-in-upcoming-investor-conference-rna-20240508monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-receives-fda-breakthrough-therapy-designation-for-delpacibart-etedesir-rna-20240508monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rna-20240422monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-participate-in-upcoming-investor-conferences-rna-20240327monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rna-20240321monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-positive-aoc-1001-long-term-data-showing-reversal-of-disease-rna-20240304monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-honors-rare-disease-day-rna-20240229monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-oversubscribed-400-million-private-placement-rna-20240229monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-reports-fourth-quarter-and-year-end-2023-financial-results-and-recent--rna-20240228monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-participate-in-upcoming-investor-conferences-rna-20240227monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rna-20240221monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-receives-fda-rare-pediatric-disease-designation-for-aoc-1044-for-treat-rna-20240220monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-present-new-aoc-1001-long-term-efficacy-and-safety-data-from-marina-rna-20240215monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rna-20240122monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-2024-corporate-priorities-and-catalysts-for-next-stage-of-gr-rna-20240105monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rna-20231221monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-reports-positive-data-demonstrating-aoc-1044-delivers-unprecedented-co-rna-20231213monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-expansion-of-cardiovascular-collaboration-with-bristol-myers-rna-20231128monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rna-20231121monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-participate-in-upcoming-investor-conference-rna-20231121monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-reports-third-quarter-2023-financial-results-and-recent-highlights-rna-20231108monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rna-20231023monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-new-positive-aoc-1001-data-demonstrating-improvement-in-mult-rna-20231007monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-upcoming-presentations-at-28th-annual-congress-of-the-world--rna-20230926monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-participate-in-upcoming-investor-conferences-rna-20230925monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rna-20230921monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-joins-with-patient-communities-to-raise-awareness-during-national-musc-rna-20230907monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-upcoming-presentations-at-2023-myotonic-dystrophy-foundation-rna-20230831monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-participate-in-upcoming-investor-conferences-rna-20230830monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rna-20230821monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-receives-fda-orphan-drug-designation-for-aoc-1044-for-treatment-of-duc-rna-20230815monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-reports-second-quarter-2023-financial-results-and-recent-highlights-rna-20230808monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rna-20230721monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-participate-in-upcoming-investor-conference-rna-20230629monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rna-20230621monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-joins-with-patients-caregivers-and-healthcare-providers-globally-to-su-rna-20230620monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-upcoming-presentations-at-the-30th-annual-fshd-society-inter-rna-20230608monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rna-20230522monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-fda-eases-partial-clinical-hold-on-aoc-1001-providing-a-clea-rna-20230517monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-reports-first-quarter-2023-financial-results-and-recent-highlights-rna-20230509monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-positive-topline-data-from-aoc-1001-phase-1-2-marina-trial-d-rna-20230427monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-granted-fda-fast-track-designation-for-aoc-1044-for-treatment-of-duche-rna-20230424monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rna-20230421monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-upcoming-presentations-at-the-75th-american-academy-of-neuro-rna-20230417monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-host-investor-and-analyst-event-focused-on-aoc-1001-topline-data-fr-rna-20230413monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-provides-regulatory-update-on-aoc-1001-for-myotonic-dystrophy-type-1-a-rna-20230330monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rna-20230321monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-upcoming-presentations-at-2023-mda-clinical-scientific-confe-rna-20230313monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-participate-in-upcoming-investor-conference-rna-20230301monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-reports-fourth-quarter-and-year-end-2022-financial-results-and-recent--rna-20230228monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-honors-rare-disease-day-rna-20230228monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-advances-rna-programs-and-expands-into-new-therapeutic-areas-utilizing-its-aoc-pla-rna-20230227monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-arthur-a-levin-to-join-board-of-directors-and-transition-to--rna-20230223monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rna-20230221monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-receives-fda-orphan-drug-designation-for-aoc-1020-for-the-treatment-of-rna-20230214monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-participate-in-upcoming-investor-conference-rna-20230207monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-rna-20230120monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-granted-fda-fast-track-designation-for-aoc-1020-for-the-treatment-of-f-rna-20230118monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-inc-announces-pricing-of-upsized-public-offering-of-common-stock-rna-20221215monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-inc-announces-proposed-public-offering-of-common-stock-rna-20221215monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-announces-positive-aoc-1001-phase-1-2-marina-data-demonstrating-first-ever-success-rna-20221214monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-reports-third-quarter-2022-financial-results-and-recent-highlights-rna-20221108monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-participate-in-upcoming-investor-conferences-rna-20221101monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-phase-1-2-explore44-trial-of-aoc-1044-for-duchenne-muscular--rna-20221011monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-upcoming-presentations-at-27th-international-hybrid-annual-c-rna-20221006monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-the-phase-1-2-fortitude-trial-of-aoc-1020-in-adults-with-fac-rna-20220929monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-fda-partial-clinical-hold-on-new-participant-enrollment-in-p-rna-20220927monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-engages-with-patient-communities-during-national-muscular-dystrophy-aw-rna-20220907monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-participate-in-upcoming-investor-conferences-rna-20220901monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-reports-second-quarter-2022-financial-results-and-recent-highlights-rna-20220809monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-enrolls-patients-in-the-marina-open-label-extension-study-rna-20220802monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-supports-world-facioscapulohumeral-muscular-dystrophy-fshd-day-and-pre-rna-20220617monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-upcoming-presentations-at-the-29th-annual-fshd-society-inter-rna-20220609monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-reports-first-quarter-2022-financial-results-and-recent-highlights-rna-20220510monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-expands-role-of-michael-maclean-to-chief-financial-and-chief-business--rna-20220405monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-upcoming-presentations-at-the-american-academy-of-neurology--rna-20220329monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-upcoming-presentations-at-the-2022-mda-clinical-scientific-c-rna-20220307monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-reports-fourth-quarter-and-year-end-2021-financial-results-and-recent--rna-20220301monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-honors-rare-disease-day-rna-20220228monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-appoints-steve-hughes-m-d-as-chief-medical-officer-rna-20220223monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-participate-in-upcoming-investor-conferences-rna-20220211monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-highlights-fshd-program-at-virtual-investor-and-analyst-event-rna-20211209monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-reports-third-quarter-2021-financial-results-and-recent-highlights-rna-20211109monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-announces-first-person-dosed-with-an-antibody-oligonucleotide-conjugate-aoc-rna-20211104monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-participate-in-upcoming-investor-conferences-rna-20211102monthly0.5https://www.biopharmawatch.com/news/RNA/fda-grants-fast-track-designation-to-aoc-1001-for-the-treatment-of-myotonic-dystrophy-type-rna-20211018monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-participate-in-upcoming-investor-conferences-rna-20210831monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-changes-to-its-board-of-directors-rna-20210825monthly0.5https://www.biopharmawatch.com/news/RNA/european-medicines-agency-ema-grants-orphan-designation-for-aoc-1001-rna-20210824monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-enters-into-collaboration-with-fshd-clinical-trial-network-to-support--rna-20210816monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-reports-second-quarter-2021-financial-results-and-recent-highlights-rna-20210809monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-inc-announces-pricing-of-public-offering-of-common-stock-rna-20210803monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-inc-announces-proposed-public-offering-of-common-stock-rna-20210802monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-receives-ind-clearance-from-fda-to-proceed-with-the-phase-1-2-marina-t-rna-20210802monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-updates-on-the-pipeline-and-platform-at-virtual-investor-and-rna-20210519monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-reports-first-quarter-2021-financial-results-and-recent-highlights-rna-20210512monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-host-virtual-investor-and-analyst-event-on-may-19-2021-rna-20210503monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-present-oral-presentation-on-aoc-1001-for-dm1-at-american-academy-o-rna-20210416monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-participate-in-upcoming-investor-conferences-rna-20210325monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-reports-fourth-quarter-and-year-end-2020-financial-results-and-recent--rna-20210315monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-present-at-the-10th-annual-svb-leerink-global-healthcare-conference-rna-20210217monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-appoints-w-michael-flanagan-ph-d-as-chief-technical-officer-rna-20210121monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-changes-to-its-board-of-directors-rna-20210111monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-2021-pipeline-updates-and-research-collaboration-with-myokar-rna-20210108monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-rna-20201222monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-addition-to-the-nasdaq-biotechnology-index-rna-20201221monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-reports-third-quarter-2020-financial-results-and-recent-highlights-rna-20201110monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-present-at-the-credit-suisse-29th-annual-virtual-healthcare-confere-rna-20201105monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-present-at-the-virtual-chardan-4th-annual-genetic-medicines-confere-rna-20200928monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-present-at-several-upcoming-virtual-scientific-meetings-rna-20200914monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-enters-into-collaboration-to-study-the-natural-history-of-myotonic-dys-rna-20200908monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-present-at-the-2020-wells-fargo-virtual-healthcare-conference-rna-20200903monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-reports-second-quarter-2020-financial-results-and-recent-highlights-rna-20200810monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-appoints-jae-kim-m-d-as-chief-medical-officer-rna-20200727monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-closing-of-initial-public-offering-and-full-exercise-of-unde-rna-20200616monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-pricing-of-initial-public-offering-rna-20200611monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-appoints-michael-maclean-as-chief-financial-officer-rna-20200519monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-appoints-carsten-boess-to-its-board-of-directors-rna-20200413monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-presentations-at-upcoming-investor-conferences-rna-20200224monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-appoints-joseph-baroldi-as-chief-operating-officer-rna-20200212monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-announces-presentation-at-the-38th-annual-j-p-morgan-healthcare-confer-rna-20200107monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-appoints-sarah-boyce-as-chief-executive-officer-rna-20191001monthly0.5https://www.biopharmawatch.com/news/RNA/avidity-biosciences-to-present-at-the-2019-myotonic-annual-conference-rna-20190912monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-upcoming-investor-conferences-rgnx-20260518monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-positive-topline-results-from-pivotal-phase-iii-affinity-duchenne-stud-rgnx-20260514monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-new-positive-interim-data-from-phase-i-ii-affinity-duchenne-trial-of-rgx-rgnx-20260311monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-highlights-key-2026-catalysts-and-announces-positive-long-term-functional-outcom-rgnx-20260111monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-rgnx-20251218monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-upcoming-investor-conferences-rgnx-20251015monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-upcoming-investor-conferences-rgnx-20250828monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-pivotal-program-for-surabgene-lomparvovec-in-diabetic-retinopathy-rgnx-20250807monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-august-7-to-discuss-second-quarter-2025-financial-res-rgnx-20250731monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-publication-of-preclinical-results-demonstrating-functional-benefits-o-rgnx-20250710monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-new-positive-functional-data-from-phase-i-ii-affinity-duchenne-trial-of--rgnx-20250605monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-webcast-discussing-interim-functional-data-from-the-phase-i-ii-affinity--rgnx-20250602monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-fda-acceptance-and-priority-review-of-the-bla-for-rgx-121-for-mps-ii-rgnx-20250513monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentations-at-the-american-society-of-gene-cell-therapy-28th-annual-rgnx-20250508monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-upcoming-investor-conferences-rgnx-20250506monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-may-12-to-discuss-first-quarter-2025-financial-result-rgnx-20250430monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-positive-biomarker-data-from-affinity-duchenne-trial-of-rgx-202-gene-the-rgnx-20250319monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical--rgnx-20250310monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-march-13-to-discuss-fourth-quarter-and-full-year-2024-rgnx-20250226monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-upcoming-investor-conferences-rgnx-20250225monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentations-of-rgx-121-at-the-21st-annual-worldsymposium-2025-rgnx-20250130monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-webcast-discussing-pivotal-program-and-first-functional-data-from-the-af-rgnx-20241114monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-upcoming-investor-conferences-rgnx-20241104monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-november-6-to-discuss-third-quarter-2024-financial-re-rgnx-20241030monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-presents-positive-data-from-the-phase-ii-study-of-subretinal-abbv-rgx-314-in-pat-rgnx-20241021monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentations-at-the-american-academy-of-ophthalmology-2024-annual-mee-rgnx-20241018monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-chardan-rgnx-20240923monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-positive-data-from-pivotal-dose-level-of-rgx-121-demonstrating-long-te-rgnx-20240903monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-upcoming-investor-conferences-rgnx-20240829monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentation-at-the-society-for-the-study-of-inborn-errors-of-metaboli-rgnx-20240827monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-the-h-c-wainwright-4th-annual-ophthalmology-virtual-conference-rgnx-20240808monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-new-positive-data-from-affinity-duchenne-trial-of-rgx-202-rgnx-20240801monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-august-1-to-discuss-second-quarter-2024-financial-res-rgnx-20240725monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-expansion-of-affinity-duchenne-trial-to-include-a-new-cohort-of-younge-rgnx-20240624monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-successful-pre-bla-meeting-with-fda-to-support-accelerated-approval-pa-rgnx-20240618monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-leadership-transition-rgnx-20240612monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-the-goldman-sachs-45th-annual-global-healthcare-conference-rgnx-20240605monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-upcoming-investor-conferences-rgnx-20240510monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-may-8-to-discuss-first-quarter-2024-financial-results-rgnx-20240501monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-chardan-rgnx-20240424monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-lancet-publication-of-phase-i-iia-study-evaluating-abbv-rgx-314-as-a-o-rgnx-20240328monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-cantor-fitzgerald-rgnx-20240327monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-upcoming-investor-conferences-rgnx-20240311monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-proposed-public-offering-of-common-stock-rgnx-20240306monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-new-positive-initial-efficacy-data-from-affinity-duchenne-trial-rgnx-20240305monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-webcast-event-to-discuss-new-interim-clinical-data-from-the-phase-i-ii-a-rgnx-20240229monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-february-27-to-discuss-fourth-quarter-and-full-year-2-rgnx-20240221monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-pivotal-trial-of-rgx-121-for-the-treatment-of-mps-ii-achieves-primary--rgnx-20240207monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-completion-of-enrollment-in-cohort-2-and-additional-positive-interim-d-rgnx-20240207monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentations-at-the-20th-annual-worldsymposium-2024-rgnx-20240131monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-positive-interim-data-from-phase-ii-aaviate-trial-of-abbv-rgx-314-for--rgnx-20240116monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentation-at-the-hawaiian-eye-and-retina-2024-meeting-rgnx-20240110monthly0.5https://www.biopharmawatch.com/news/RGNX/u-s-district-court-issues-decision-on-regenxbio-and-university-of-pennsylvania-nav-technol-rgnx-20240108monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-dose-escalation-in-affinity-duchenne-trial-rgnx-20231129monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-upcoming-investor-conferences-rgnx-20231107monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-presents-positive-one-year-data-from-phase-ii-altitude-trial-of-abbv-rgx-314-for-rgnx-20231103monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-november-8-to-discuss-third-quarter-2023-financial-re-rgnx-20231101monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentations-at-the-american-academy-of-ophthalmology-2023-annual-mee-rgnx-20231030monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-the-jefferies-cns-neuro-summit-rgnx-20231005monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-presents-interim-clinical-data-from-phase-i-ii-affinity-duchenne-trial-of-rgx-20-rgnx-20231003monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentations-at-the-28th-annual-congress-of-the-world-muscle-society-rgnx-20230926monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-upcoming-investor-conferences-rgnx-20230905monthly0.5https://www.biopharmawatch.com/news/RGNX/initial-clinical-data-of-first-pediatric-cln2-patient-dosed-with-rgx-181-presented-at-ssie-rgnx-20230830monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentations-at-the-society-for-the-study-of-inborn-errors-of-metabol-rgnx-20230823monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-participation-at-the-2023-wedbush-pacgrow-healthcare-conference-rgnx-20230801monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-august-2-to-discuss-second-quarter-2023-financial-res-rgnx-20230726monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-upcoming-presentations-at-the-american-society-of-retina-specialists-a-rgnx-20230724monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-highlights-aav-pipeline-with-interim-results-from-retinal-and-duchenne-programs--rgnx-20230711monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-virtual-investor-day-highlighting-aav-pipeline-programs-with-upcoming-in-rgnx-20230627monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-and-university-of-pennsylvania-file-nav-technology-patent-infringement-lawsuit-rgnx-20230620monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentation-at-the-jefferies-global-healthcare-conference-rgnx-20230601monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-rgx-121-rgnx-20230523monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentation-at-the-barclays-gene-editing-therapy-summit-2023-rgnx-20230522monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-nav-technology-platform-will-support-bespoke-gene-therapy-consortium-rgnx-20230516monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-upcoming-investor-conferences-rgnx-20230508monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentations-at-the-american-society-of-gene-cell-therapy-26th-annual-rgnx-20230502monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-may-3-to-discuss-first-quarter-2023-financial-results-rgnx-20230426monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentation-at-chardan-rgnx-20230418monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-receives-fda-fast-track-designation-for-rgx-202-a-novel-gene-therapy-candidate-f-rgnx-20230411monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-upcoming-investor-conferences-rgnx-20230308monthly0.5https://www.biopharmawatch.com/news/RGNX/additional-positive-interim-data-from-phase-i-ii-trial-of-regenxbio-rgnx-20230224monthly0.5https://www.biopharmawatch.com/news/RGNX/additional-positive-interim-data-from-phase-i-ii-iii-campsiite-trial-of-regenxbio-rgnx-20230222monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-february-28-to-discuss-fourth-quarter-and-full-year-2-rgnx-20230221monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentations-at-the-19th-annual-worldsymposium-2023-rgnx-20230217monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-presents-interim-data-from-phase-ii-bridging-study-evaluating-the-clinical-perfo-rgnx-20230211monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentation-at-the-virtual-svb-securities-global-biopharma-conference-rgnx-20230208monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentations-at-the-angiogenesis-exudation-and-degeneration-2023-conf-rgnx-20230206monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-phase-i-ii-trial-of-rgx-202-a-novel-gene-therapy-candidate-for-duchenn-rgnx-20230123monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-senior-leadership-promotions-rgnx-20230109monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentation-at-the-41st-annual-j-p-morgan-healthcare-conference-rgnx-20230103monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-update-on-advancement-of-programs-for-cln2-disease-rgnx-20221221monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-completion-of-dosing-in-the-phase-i-ii-trial-of-rgx-111-for-the-treatm-rgnx-20221208monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-upcoming-investor-conferences-rgnx-20221122monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-presents-positive-interim-data-from-and-the-expansion-of-phase-ii-altitude-trial-rgnx-20221103monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-upcoming-investor-conferences-rgnx-20221102monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-november-3-to-discuss-third-quarter-2022-financial-re-rgnx-20221027monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-additional-positive-interim-data-from-trials-of-rgx-314-for-the-treatm-rgnx-20221003monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentation-at-chardan-rgnx-20220927monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-20-rgnx-20220926monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-upcoming-investor-conferences-rgnx-20220906monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-presents-additional-positive-interim-data-from-the-phase-i-ii-iii-campsiite-tria-rgnx-20220831monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentations-at-the-society-for-the-study-of-inborn-errors-of-metabol-rgnx-20220823monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentation-at-the-h-c-wainwright-2nd-annual-ophthalmology-virtual-co-rgnx-20220810monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-intention-to-file-a-biologics-license-application-using-the-accelerate-rgnx-20220803monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-august-3-to-discuss-second-quarter-2022-financial-res-rgnx-20220801monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-enrollment-complete-in-cohort-5-of-phase-ii-aaviate-trial-rgnx-20220708monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-opens-state-of-the-art-gene-therapy-manufacturing-facility-rgnx-20220609monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-upcoming-investor-conferences-rgnx-20220504monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentations-at-the-american-society-of-gene-cell-therapy-asgct-25th--rgnx-20220503monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-may-4-to-discuss-first-quarter-2022-financial-results-rgnx-20220427monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentation-at-chardan-rgnx-20220420monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-upcoming-investor-conferences-rgnx-20220309monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-march-1-to-discuss-fourth-quarter-and-full-year-2021--rgnx-20220222monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-presents-positive-initial-data-from-phase-i-ii-trial-of-rgx-111-for-the-treatmen-rgnx-20220209monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentations-at-the-11th-annual-svb-leerink-global-healthcare-confere-rgnx-20220208monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentations-at-the-angiogenesis-exudation-and-degeneration-2022-conf-rgnx-20220204monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentations-at-the-18th-annual-worldsymposium-2022-rgnx-20220131monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-initiation-of-second-pivotal-trial-in-rgx-314-clinical-program-for-the-rgnx-20220110monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-fda-clearance-of-ind-for-clinical-trial-of-rgx-202-a-novel-gene-therap-rgnx-20220106monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-orphan-drug-designation-granted-to-rgx-202-a-novel-gene-therapy-candid-rgnx-20211122monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-upcoming-investor-conferences-rgnx-20211108monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-rgx-314-data-presentation-at-the-american-academy-of-ophthalmology-202-rgnx-20211105monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-november-2-to-discuss-third-quarter-2021-financial-re-rgnx-20211026monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-rgx-314-data-presentations-at-american-society-of-retina-specialists-a-rgnx-20211001monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-rgx-314-data-presentations-at-retina-society-54th-annual-scientific-me-rgnx-20210927monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-upcoming-investor-conferences-rgnx-20210907monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-august-9-to-discuss-second-quarter-2021-financial-res-rgnx-20210802monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-upcoming-investor-conferences-rgnx-20210609monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-presents-additional-positive-interim-data-from-phase-i-ii-trial-of-rgx-121-for-t-rgnx-20210514monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-present-at-upcoming-investor-conferences-rgnx-20210506monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-may-5-to-discuss-first-quarter-2021-financial-results-rgnx-20210428monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-rgnx-20210427monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-present-at-the-chardan-5th-annual-genetic-medicines-manufacturing-summit-rgnx-20210421monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-dosing-of-first-patient-in-cohort-3-of-phase-i-ii-trial-of-rgx-121-for-rgnx-20210414monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-upcoming-investor-conferences-rgnx-20210224monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-march-1-to-discuss-fourth-quarter-and-full-year-2020--rgnx-20210222monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-additional-positive-interim-phase-i-iia-and-long-term-follow-up-data-o-rgnx-20210216monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-presents-additional-positive-interim-data-from-phase-i-ii-trial-of-rgx-121-for-t-rgnx-20210208monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentations-at-the-angiogenesis-exudation-and-degeneration-2021-conf-rgnx-20210205monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentations-at-the-17th-annual-worldsymposium-2021-rgnx-20210201monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underw-rgnx-20210112monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-rgnx-20210111monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-pricing-of-public-offering-of-common-stock-rgnx-20210108monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-proposed-public-offering-of-common-stock-rgnx-20210106monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-dosing-of-first-patient-in-phase-ii-altitude-trial-of-rgx-314-for-the--rgnx-20201210monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-positive-interim-data-and-update-for-phase-i-ii-trial-of-rgx-121-for-t-rgnx-20201209monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-dosing-of-first-patient-in-phase-i-ii-trial-of-rgx-111-for-the-treatme-rgnx-20201201monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-present-at-upcoming-investor-conferences-rgnx-20201123monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentations-at-the-american-academy-of-ophthalmology-2020-annual-mee-rgnx-20201110monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-present-at-upcoming-investor-conferences-rgnx-20201105monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-november-4-to-discuss-third-quarter-2020-financial-re-rgnx-20201028monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-continued-progress-and-expansion-of-clinical-development-program-for-r-rgnx-20200930monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-upcoming-investor-conferences-rgnx-20200925monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-dosing-of-first-patient-in-phase-ii-aaviate-trial-of-rgx-314-for-the-t-rgnx-20200909monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-upcoming-investor-conferences-rgnx-20200902monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-fda-clearance-of-ind-for-phase-ii-trial-of-rgx-314-for-the-treatment-o-rgnx-20200825monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-second-quarter-2020-financial-results-and-operational-highlights-rgnx-20200806monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-additional-positive-interim-phase-i-iia-trial-update-and-program-updat-rgnx-20200804monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-august-6-to-discuss-second-quarter-2020-financial-res-rgnx-20200730monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-provides-update-on-progress-of-clinical-programs-for-rare-genetic-neurodegenerat-rgnx-20200708monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-present-at-the-raymond-james-human-health-innovation-conference-rgnx-20200610monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-first-quarter-2020-financial-results-and-operational-highlights-rgnx-20200507monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-may-7-to-discuss-first-quarter-2020-financial-results-rgnx-20200430monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentations-at-the-american-society-of-gene-and-cell-therapy-rgnx-20200428monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-additional-positive-long-term-and-interim-phase-i-iia-trial-update-for-rgnx-20200422monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-and-ultragenyx-announce-new-license-agreement-for-use-of-nav-technology-platform-rgnx-20200331monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-present-at-the-barclays-global-healthcare-conference-rgnx-20200309monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-february-26-to-discuss-fourth-quarter-and-full-year-2-rgnx-20200219monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentations-at-the-16th-annual-worldsymposium-2020-rgnx-20200129monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-interim-data-from-phase-i-ii-trial-of-rgx-121-for-the-treatment-of-muc-rgnx-20191218monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-present-at-the-evercore-isi-2nd-annual-healthconx-conference-rgnx-20191126monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-november-5-to-discuss-third-quarter-2019-financial-re-rgnx-20191029monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentations-at-the-european-society-of-gene-cell-therapy-27th-annual-rgnx-20191017monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-additional-positive-interim-phase-i-iia-trial-update-for-rgx-314-for-t-rgnx-20191011monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-present-at-the-chardan-3rd-annual-genetic-medicines-conference-rgnx-20190930monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-present-at-upcoming-investor-conferences-rgnx-20190828monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-present-interim-phase-i-iia-trial-update-for-rgx-314-for-the-treatment-of-wet-rgnx-20190827monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-new-license-agreement-with-pfizer-for-the-treatment-of-friedreich-rgnx-20190731monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-august-7-to-discuss-second-quarter-2019-financial-res-rgnx-20190730monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-expands-pipeline-using-nav-vectors-to-deliver-therapeutic-antibodies-for-the-tre-rgnx-20190724monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-and-neurimmune-announce-collaboration-to-develop-vectorized-antibodies-for-the-t-rgnx-20190724monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-present-at-the-raymond-james-2019-life-sciences-and-medtech-conference-rgnx-20190611monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-completion-of-dosing-for-phase-i-iia-clinical-trial-of-rgx-314-in-wet--rgnx-20190530monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-first-fda-approval-of-a-gene-therapy-based-on-its-proprietary-nav-tech-rgnx-20190524monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-launch-new-manufacturing-facility-for-nav-technology-based-aav-gene-therapies-rgnx-20190515monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-present-at-the-bank-of-america-merrill-lynch-2019-healthcare-conference-rgnx-20190508monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-may-7-to-discuss-first-quarter-2019-financial-results-rgnx-20190430monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-appoints-dr-steve-pakola-as-chief-medical-officer-rgnx-20190417monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-presentations-at-the-american-society-of-gene-cell-therapy-2019-annual-rgnx-20190415monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-participate-in-upcoming-investor-conferences-rgnx-20190306monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-fourth-quarter-and-full-year-2018-financial-results-and-recent-operation-rgnx-20190227monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-february-27-to-discuss-fourth-quarter-and-full-year-2-rgnx-20190220monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-rgx-314-program-analyst-and-investor-event-with-leading-retina-specialis-rgnx-20190214monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-receives-rare-pediatric-disease-designation-for-rgx-181-gene-therapy-for-the-tre-rgnx-20190131monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference-rgnx-20190104monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-continued-progress-across-programs-in-year-end-2018-corporate-update-rgnx-20190103monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-and-rocket-pharmaceuticals-announce-new-license-agreement-for-the-treatment-of-d-rgnx-20181126monthly0.5https://www.biopharmawatch.com/news/RGNX/fda-grants-orphan-drug-designation-to-rgx-181-gene-therapy-for-the-treatment-of-cln2-form--rgnx-20181114monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-present-at-upcoming-investor-conferences-rgnx-20181106monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-november-7-to-discuss-third-quarter-2018-financial-re-rgnx-20181031monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-additional-positive-interim-phase-i-trial-update-for-rgx-314-for-the-t-rgnx-20181026monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-exclusive-worldwide-license-with-ultragenyx-for-the-treatment-of-cdkl5-rgnx-20181022monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-completion-of-dosing-of-fourth-cohort-in-phase-i-clinical-trial-of-rgx-rgnx-20181004monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-present-at-the-chardan-2nd-annual-genetic-medicines-conference-rgnx-20181002monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-present-at-upcoming-investor-conferences-rgnx-20180906monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-pipeline-expansion-with-rgx-181-gene-therapy-for-cln2-form-of-batten-d-rgnx-20180830monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underw-rgnx-20180814monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-pricing-of-public-offering-of-common-stock-rgnx-20180810monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-announces-proposed-public-offering-of-common-stock-rgnx-20180808monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-and-webcast-on-august-8-to-discuss-second-quarter-2018-f-rgnx-20180807monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-august-8-to-discuss-second-quarter-2018-financial-res-rgnx-20180801monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-receives-fda-fast-track-designation-for-rgx-111-gene-therapy-for-the-treatment-o-rgnx-20180612monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-joins-the-mucopolysaccharidosis-community-to-advance-research-and-innovation-rgnx-20180515monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-present-at-the-bank-of-america-merrill-lynch-2018-healthcare-conference-rgnx-20180509monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-receives-fda-fast-track-designation-for-rgx-121-gene-therapy-for-the-treatment-o-rgnx-20180502monthly0.5https://www.biopharmawatch.com/news/RGNX/regenxbio-to-host-conference-call-on-may-8-to-discuss-first-quarter-2018-financial-results-rgnx-20180501monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-first-quarter-2026-results-cgen-20260518monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-participate-in-upcoming-investor-conferences-cgen-20260219monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-release-fourth-quarter-and-full-year-2025-results-on-monday-march-2-2026-cgen-20260217monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-participate-in-stifel-2025-healthcare-conference-cgen-20251104monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-second-quarter-2025-results-cgen-20250806monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-a-pooled-analysis-of-com701-phase-1-trials-in-platinum-resistant-ovari-cgen-20250728monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-release-second-quarter-2025-results-on-wednesday-august-6-2025-cgen-20250723monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-first-patient-dosed-in-com701-global-platform-trial-in-platinum-sensiti-cgen-20250721monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-ai-ml-driven-predictive-computational-research-at-upcoming-internation-cgen-20250612monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-first-quarter-2025-results-cgen-20250519monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-leadership-transitions-effective-september-2025-cgen-20250513monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-release-first-quarter-2025-results-on-monday-may-19-2025-cgen-20250505monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-participate-in-multiple-virtual-investor-conferences-in-april-2025-cgen-20250326monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-fourth-quarter-and-full-year-2024-results-cgen-20250304monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-participate-in-a-fireside-chat-at-the-2025-leerink-partners-global-healthcare--cgen-20250303monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-enhances-its-ai-ml-predictive-computational-discovery-platform-unigen-with-ultima-cgen-20250226monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-release-fourth-quarter-and-full-year-2024-financial-results-on-tuesday-march-4-cgen-20250218monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference-cgen-20250204monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-first-patient-dosed-in-phase-1-clinical-trial-to-evaluate-com503-as-mon-cgen-20250108monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-expands-its-intellectual-property-portfolio-with-new-u-s-patent-covering-triple-c-cgen-20241127monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-third-quarter-2024-results-cgen-20241112monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-participate-in-stifel-2024-healthcare-conference-cgen-20241111monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-anti-tumor-activity-and-safety-data-of-com701-com902-and-pembrolizumab-cgen-20241105monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-release-third-quarter-2024-financial-results-on-tuesday-november-12-2024-cgen-20241029monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-new-clinical-data-at-sitc-2024-cgen-20241007monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-at-single-cell-genomics-2024-conference-cgen-20240909monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference-cgen-20240829monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-second-quarter-2024-results-cgen-20240806monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-fda-clearance-of-ind-for-com503-for-the-treatment-of-solid-tumors-cgen-20240729monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-release-second-quarter-2024-results-on-tuesday-august-6-2024-cgen-20240723monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-at-upcoming-antibody-industrial-symposium-cgen-20240617monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-receive-milestone-payment-triggered-by-dosing-of-first-patient-in-the-second-p-cgen-20240530monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-first-quarter-2024-results-cgen-20240520monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-publishes-paper-in-cancer-immunology-research-on-unique-biology-of-pvrig-and-its--cgen-20240516monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-appoints-david-silberman-as-chief-financial-officer-cgen-20240515monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-release-first-quarter-2024-results-on-monday-may-20-2024-cgen-20240506monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-new-clinical-data-showing-com701-triple-combination-preliminary-anti-t-cgen-20240425monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-publishes-paper-in-cancer-immunology-research-demonstrating-therapeutic-potential-cgen-20240410monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-participate-in-two-upcoming-investor-conferences-cgen-20240403monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-selected-for-two-oral-presentations-at-the-keystone-symposium-on-cancer-immunothe-cgen-20240311monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-data-reflecting-its-diversified-immuno-oncology-pipeline-at-aacr-2024-cgen-20240306monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-fourth-quarter-and-full-year-2023-results-cgen-20240305monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-at-the-leerink-partners-global-biopharma-conference-2024-cgen-20240226monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-release-fourth-quarter-and-full-year-2023-results-on-tuesday-march-5-2024-cgen-20240220monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-appointment-of-michelle-mahler-m-d-as-chief-medical-officer-cgen-20240215monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-receive-10-million-milestone-payment-following-dosing-of-first-patient-in-astr-cgen-20240108monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-regains-compliance-with-nasdaq-minimum-bid-price-requirement-cgen-20240108monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-will-be-eligible-to-receive-10-million-milestone-payment-upon-dosing-of-first-pat-cgen-20231219monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-host-conference-call-to-discuss-exclusive-license-agreement-with-gilead-for-co-cgen-20231219monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-third-quarter-2023-results-cgen-20231107monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-s-com701-anti-pvrig-mediates-anti-tumor-activity-in-patients-typically-not-respon-cgen-20231106monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-receipt-of-nasdaq-minimum-bid-price-notification-cgen-20231103monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-new-data-at-sitc-2023-suggesting-leading-edge-of-anti-il18-binding-pro-cgen-20231031monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-release-third-quarter-2023-results-on-tuesday-november-7-2023-cgen-20231024monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-at-single-cell-genomics-2023-meeting-cgen-20231003monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-expands-intellectual-property-with-new-japanese-patent-for-the-triple-combination-cgen-20231002monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-new-clinical-and-pre-clinical-data-in-multiple-presentations-at-sitc-2-cgen-20230927monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference-cgen-20230831monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-second-quarter-2023-results-cgen-20230807monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-release-second-quarter-2023-results-on-monday-august-7-2023-cgen-20230724monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-wins-on-pvrig-european-patent-opposition-pursued-by-gsk-and-a-third-party-cgen-20230717monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-doses-first-patient-in-triple-immunotherapy-combination-com701-com902-and-pembrol-cgen-20230622monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-regains-compliance-with-nasdaq-minimum-bid-price-requirement-cgen-20230613monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-s-com701-anti-pvrig-demonstrates-preliminary-durable-anti-tumor-activity-in-tripl-cgen-20230605monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-first-quarter-2023-results-cgen-20230515monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-host-dnam-1-axis-virtual-investor-event-with-kol-drew-pardoll-on-tuesday-may-2-cgen-20230511monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-at-the-jmp-securities-life-sciences-conference-cgen-20230509monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-release-first-quarter-2023-results-on-monday-may-15-2023-cgen-20230501monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-new-clinical-data-showing-preliminary-anti-tumor-activity-of-com701-tr-cgen-20230427monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-data-on-its-lead-pre-clinical-asset-com503-in-an-oral-presentation-at--cgen-20230426monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-new-research-enabling-accurate-detection-and-study-of-novel-target-pvr-cgen-20230315monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-participate-in-a-fireside-chat-at-the-oppenheimer-33rd-annual-healthcare-confe-cgen-20230308monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-doses-first-patient-in-triple-combination-com701-com902-and-pembrolizumab-mss-crc-cgen-20230306monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-fourth-quarter-and-full-year-2022-results-cgen-20230227monthly0.5https://www.biopharmawatch.com/news/CGEN/rilvegostomig-astrazeneca-cgen-20230214monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-release-fourth-quarter-and-full-year-2022-results-on-monday-february-27-2023-cgen-20230213monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-at-the-svb-securities-global-biopharma-conference-cgen-20230209monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-participate-in-the-jmp-securities-c-suite-series-tigit-landscape-overview-cgen-20230123monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-s-com701-anti-pvrig-in-dual-and-triple-combination-demonstrates-preliminary-durab-cgen-20221206monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-s-com701-anti-pvrig-in-dual-and-triple-combination-demonstrates-preliminary-anti--cgen-20221201monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-participate-in-the-jmp-securities-hematology-and-oncology-summit-cgen-20221129monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-receive-milestone-payment-triggered-by-astrazeneca-cgen-20221116monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-third-quarter-2022-results-cgen-20221114monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-participate-in-the-stifel-healthcare-conference-cgen-20221108monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-s-com701-anti-pvrig-in-combination-with-nivolumab-demonstrates-preliminary-anti-t-cgen-20221107monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-receipt-of-nasdaq-delisting-notice-cgen-20221102monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-release-third-quarter-2022-results-on-monday-november-14-2022-cgen-20221031monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-new-clinical-data-at-esmo-io-cgen-20221026monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-new-clinical-and-research-data-in-two-oral-presentations-at-sitc-2022-cgen-20221006monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-letter-to-shareholders-cgen-20220922monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-appointment-of-alberto-sessa-as-chief-financial-officer-cgen-20220912monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-participate-in-upcoming-fierce-biotech-summit-cgen-20220907monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-expands-anti-pvrig-com701-patent-portfolio-with-new-composition-of-matter-and-use-cgen-20220824monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-expands-anti-pvrig-com701-intellectual-property-portfolio-cgen-20220808monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-second-quarter-2022-results-cgen-20220804monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-release-second-quarter-results-on-thursday-august-4-2022-cgen-20220721monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-at-upcoming-industry-conferences-cgen-20220627monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-at-upcoming-investor-conferences-cgen-20220601monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-first-quarter-2022-results-cgen-20220516monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-cfo-departure-cgen-20220510monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-release-first-quarter-2022-on-monday-may-16-2022-cgen-20220502monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-s-computational-discovery-leverages-single-cell-spatial-transcriptomics-to-gain-i-cgen-20220321monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-new-insights-into-the-tumor-microenvironment-using-single-cell-spatial-cgen-20220314monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-at-the-oppenheimer-32nd-annual-global-healthcare-conference-cgen-20220309monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-presents-new-research-suggesting-targeting-dnam-1-axis-holds-promise-for-treatmen-cgen-20220309monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-appointment-of-dr-mathias-hukkelhoven-to-its-board-of-directors-cgen-20220224monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-fourth-quarter-and-full-year-2021-results-cgen-20220224monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-release-fourth-quarter-and-full-year-2021-results-on-thursday-february-24-2022-cgen-20220210monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-at-the-11th-annual-svb-leerink-global-healthcare-conference-cgen-20220209monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-expands-com701-intellectual-property-portfolio-with-new-u-s-patent-covering-tripl-cgen-20220118monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-presents-preliminary-translational-data-demonstrating-immune-activation-in-the-tu-cgen-20211209monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-third-quarter-2021-results-cgen-20211112monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-presents-preliminary-results-from-phase-1-dose-escalation-monotherapy-study-of-co-cgen-20211112monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-presents-initial-translational-data-supporting-the-differentiation-of-pvrig-compa-cgen-20211112monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-collaboration-expansion-with-bristol-myers-squibb-alongside-20-million--cgen-20211111monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-at-upcoming-investor-conferences-cgen-20211108monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-release-third-quarter-2021-results-on-friday-november-12-2021-cgen-20211026monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-milestone-payment-from-astrazeneca-triggered-by-first-patient-dosed-wit-cgen-20211004monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-clinical-data-from-anti-tigit-com902-monotherapy-and-triple-combinatio-cgen-20211001monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-at-the-cantor-global-healthcare-conference-cgen-20210914monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-at-the-morgan-stanley-19th-annual-global-healthcare-conference-cgen-20210826monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-bispecific-antibody-derived-from-com902-to-enter-clinical-development-cgen-20210819monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-second-quarter-2021-results-cgen-20210728monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-doses-first-patient-in-phase-1-2-triple-combination-cohort-expansion-of-com701-wi-cgen-20210719monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-doses-first-patient-in-phase-1-combination-study-of-com902-and-com701-in-patients-cgen-20210715monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-release-second-quarter-2021-results-on-wednesday-july-28-2021-cgen-20210714monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-doses-first-patient-in-com701-opdivo-nivolumab-phase-1b-cohort-expansion-study-cgen-20210630monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-presents-research-supporting-pvrig-as-a-novel-and-differentiated-checkpoint-in-th-cgen-20210629monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-updated-data-from-phase-1-study-of-com701-first-in-class-anti-pvrig-at--cgen-20210608monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-management-to-discuss-com701-data-presented-at-asco-at-event-hosted-by-truist-sec-cgen-20210601monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-first-quarter-2021-results-cgen-20210513monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-participate-at-sitc-cgen-20210511monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-expansion-of-research-collaboration-with-johns-hopkins-university-for-a-cgen-20210510monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-release-first-quarter-2021-results-on-thursday-may-13-2021-cgen-20210503monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-data-update-on-com701-phase-1-clinical-trial-at-the-american-society-o-cgen-20210429monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-publishes-preclinical-data-demonstrating-therapeutic-potential-of-com902-in-cance-cgen-20210427monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-publishes-review-on-biology-and-potential-therapeutic-relevance-of-dnam-1-axis-in-cgen-20210309monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-at-the-oppenheimer-31st-annual-healthcare-conference-cgen-20210308monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-fourth-quarter-and-full-year-2020-results-cgen-20210225monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-data-update-from-com701-phase-1-clinical-trial-cgen-20210225monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-expands-clinical-collaboration-agreement-with-bristol-myers-squibb-with-phase-1b--cgen-20210222monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-release-fourth-quarter-and-full-year-2020-results-on-thursday-february-25-2021-cgen-20210216monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-first-development-milestone-in-license-agreement-with-astrazeneca-for-t-cgen-20201223monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-at-upcoming-investor-conferences-cgen-20201110monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-third-quarter-2020-results-cgen-20201105monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-further-expands-patent-portfolio-for-tigit-inhibitor-com902-with-composition-of-m-cgen-20201102monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-presents-new-research-data-further-supporting-pvrig-as-a-potentially-promising-ta-cgen-20201027monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-release-third-quarter-2020-results-on-thursday-november-5-2020-cgen-20201022monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-addition-of-immuno-oncology-pioneer-dr-nils-lonberg-to-its-scientific-a-cgen-20200930monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-doses-first-patient-in-phase-1-2-triple-combination-study-of-com701-with-bristol--cgen-20200908monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-at-upcoming-september-2020-investor-conferences-cgen-20200903monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-expands-patent-portfolio-for-tigit-inhibitor-com902-with-new-us-composition-of-ma-cgen-20200828monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-second-quarter-2020-results-cgen-20200730monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-release-second-quarter-2020-results-on-thursday-july-30-2020-cgen-20200716monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-fda-clearance-of-ind-application-for-phase-1-2-triple-combination-study-cgen-20200601monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-doses-first-patient-in-com701-phase-1-monotherapy-expansion-cohort-cgen-20200527monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-first-quarter-2020-results-cgen-20200506monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-presents-data-update-from-ongoing-phase-1-trial-of-com701-at-the-2020-aacr-virtua-cgen-20200427monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-release-first-quarter-2020-results-on-wednesday-may-6-2020-cgen-20200423monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-expands-intellectual-property-portfolio-for-com701-with-new-european-composition--cgen-20200422monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-publication-of-bay-1905254-preclinical-data-in-cancer-immunology-resear-cgen-20200420monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-data-update-on-com701-phase-1-clinical-trial-at-the-2020-aacr-virtual--cgen-20200414monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-first-patient-dosed-in-com902-phase-1-trial-for-patients-with-advanced--cgen-20200406monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-closing-of-75-million-public-offering-of-ordinary-shares-cgen-20200317monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-pricing-of-75-million-public-offering-of-ordinary-shares-cgen-20200312monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-commencement-of-public-offering-of-ordinary-shares-cgen-20200311monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-updated-clinical-data-from-ongoing-com701-phase-1-study-cgen-20200309monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-fourth-quarter-and-full-year-2019-results-cgen-20200220monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-phase-1-2-triple-combination-study-to-evaluate-com701-in-combination-wi-cgen-20200220monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-release-fourth-quarter-and-full-year-2019-results-on-thursday-february-20-2020-cgen-20200210monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-presents-update-on-com701-phase-1-trial-at-asco-sitc-clinical-immuno-oncology-sym-cgen-20200207monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-new-u-s-patent-for-methods-of-screening-for-anti-pvrig-antibodies-cgen-20200204monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-further-expands-intellectual-property-portfolio-with-new-european-patent-for-anti-cgen-20200129monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-highlights-recent-accomplishments-and-previews-upcoming-milestones-cgen-20200109monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-appointment-of-dr-oliver-froescheis-as-senior-vice-president-corporate--cgen-20200108monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-added-to-the-nasdaq-biotechnology-index-cgen-20191220monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-third-quarter-2019-results-cgen-20191111monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-expands-patent-portfolio-for-com902-with-new-composition-of-matter-and-use-patent-cgen-20191106monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-presents-preclinical-data-for-com902-anti-tigit-program-at-sitc-2019-cgen-20191105monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-presents-initial-clinical-data-from-ongoing-phase-1-trial-of-com701-in-patients-w-cgen-20191105monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-fda-clearance-of-ind-application-for-com902-cgen-20191104monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-release-third-quarter-2019-results-on-monday-november-11-2019-cgen-20191028monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-data-from-ongoing-com701-phase-1-clinical-trial-at-sitc-2019-cgen-20191002monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-presents-update-on-com701-phase-1-study-at-2019-igcs-cgen-20190919monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-second-quarter-2019-results-cgen-20190805monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-second-quarter-2019-conference-call-scheduled-for-monday-august-5-2019-at-8-30-am-cgen-20190722monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-expands-intellectual-property-portfolio-for-com701-with-new-u-s-patent-covering-c-cgen-20190716monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-appoints-eran-perry-to-its-board-of-directors-cgen-20190702monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-presents-update-on-com701-phase-1-trial-at-the-2019-asco-annual-meeting-cgen-20190603monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-at-the-jefferies-2019-healthcare-conference-cgen-20190522monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-first-quarter-2019-results-cgen-20190520monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-doses-first-patient-in-com701-opdivo-nivolumab-combination-arm-of-phase-1-study-i-cgen-20190520monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-first-quarter-2019-conference-call-scheduled-for-monday-may-20-2019-at-8-30-am-et-cgen-20190506monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-presents-update-on-com701-phase-1-trial-at-the-2019-aacr-annual-meeting-cgen-20190403monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-purchase-of-company-shares-by-its-board-of-directors-and-members-of-man-cgen-20190326monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-issuance-of-two-u-s-composition-of-matter-patents-for-com701-its-lead-i-cgen-20190312monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-at-the-cowen-and-company-39th-annual-health-care-conference-cgen-20190305monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-presents-update-on-com701-phase-1-trial-at-asco-sitc-clinical-immuno-oncology-sym-cgen-20190301monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-fourth-quarter-and-full-year-2018-results-and-announces-corporate-restruc-cgen-20190226monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-fourth-quarter-and-full-year-2018-conference-call-scheduled-for-tuesday-february--cgen-20190214monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-publication-of-two-peer-reviewed-papers-demonstrating-the-role-of-pvrig-cgen-20190122monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-s-phase-1-trial-of-com701-featured-as-a-trial-in-progress-at-the-asco-sitc-clinic-cgen-20190114monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-issuance-of-u-s-patent-for-com902-its-tigit-antibody-product-candidate--cgen-20181113monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-third-quarter-2018-results-cgen-20181107monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-third-quarter-2018-conference-call-scheduled-for-wednesday-november-7-2018-at-8-3-cgen-20181024monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-clinical-milestone-payment-in-cancer-immunotherapy-collaboration-with-b-cgen-20180920monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-first-patient-dosed-with-com701-a-first-in-class-cancer-immunotherapy-a-cgen-20180907monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-appointment-of-dr-jean-pierre-bizzari-to-its-board-of-directors-cgen-20180905monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-second-quarter-2018-results-cgen-20180801monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-second-quarter-2018-conference-call-scheduled-for-wednesday-august-1-2018-at-8-30-cgen-20180718monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-welcomes-fda-clearance-of-bayer-cgen-20180702monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-fda-clearance-of-ind-application-for-com701-a-first-in-class-immuno-onc-cgen-20180702monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-21-million-registered-direct-offering-of-ordinary-shares-and-warrants-cgen-20180615monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-first-quarter-2018-results-cgen-20180509monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-first-quarter-2018-conference-call-scheduled-for-wednesday-may-9-2018-at-10-00-am-cgen-20180430monthly0.5https://www.biopharmawatch.com/news/CGEN/preclinical-data-presented-by-bayer-at-aacr-highlights-bay-1905254-formerly-the-cgen-15001-cgen-20180417monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-appointment-of-henry-adewoye-md-as-chief-medical-officer-cgen-20180326monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-at-the-cowen-and-company-38th-annual-health-care-conference-cgen-20180308monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-fourth-quarter-and-full-year-2017-results-cgen-20180221monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-fourth-quarter-and-full-year-2017-conference-call-scheduled-for-wednesday-februar-cgen-20180208monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-publication-of-the-discovery-of-ildr2-as-a-novel-immune-checkpoint-and--cgen-20180206monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-presents-new-preclinical-data-demonstrating-the-distinctive-features-of-the-pvrig-cgen-20180118monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-presentations-at-three-upcoming-cancer-immunotherapy-conferences-cgen-20180102monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-third-quarter-2017-results-cgen-20171107monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-initiate-manufacturing-of-com902-its-lead-anti-tigit-monoclonal-antibody-cgen-20171106monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-enter-research-collaboration-with-mount-sinai-on-novel-myeloid-immuno-oncology-cgen-20171102monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-at-the-annual-meeting-of-the-society-for-immunotherapy-of-cancer-next--cgen-20171026monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-third-quarter-2017-conference-call-scheduled-for-tuesday-november-7-2017-at-10-00-cgen-20171025monthly0.5https://www.biopharmawatch.com/news/CGEN/a-new-immunomodulatory-target-discovered-by-compugen-demonstrates-potential-for-first-in-c-cgen-20171009monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-at-the-cri-cimt-eati-aacr-international-cancer-immunotherapy-conferenc-cgen-20170807monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-welcomes-paul-sekhri-as-its-new-chairman-of-the-board-cgen-20170802monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-second-quarter-2017-results-cgen-20170802monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-issuance-of-u-s-patent-for-com701-its-lead-immuno-oncology-product-cand-cgen-20170725monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-second-quarter-2017-conference-call-scheduled-for-wednesday-august-2-2017-at-10-0-cgen-20170724monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-presents-at-asco-com701-drug-combination-data-with-tigit-and-pd-1-inhibitors-in-p-cgen-20170605monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-provides-update-on-com701-and-upcoming-presentations-cgen-20170531monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-appointment-of-dr-michal-preminger-to-board-of-directors-cgen-20170525monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-at-two-upcoming-investor-conferences-in-june-cgen-20170523monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-first-quarter-2017-results-cgen-20170509monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-com701-checkpoint-product-candidate-for-immuno-oncology-at-asco-cgen-20170504monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-first-quarter-2017-conference-call-scheduled-for-tuesday-may-9-2017-at-10-00-am-e-cgen-20170426monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-lead-therapeutic-candidate-com902-for-cgen-15137-tigit-immuno-oncology--cgen-20170328monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-cgen-15001-autoimmune-product-candidate-at-upcoming-conferences-cgen-20170322monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-addition-of-prof-miriam-merad-to-its-scientific-advisory-board-cgen-20170308monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-presentations-of-com701-immuno-oncology-pipeline-product-and-predictive-cgen-20170302monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-reports-fourth-quarter-and-calendar-year-2016-results-cgen-20170215monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-fourth-quarter-and-yearend-2016-conference-call-scheduled-for-wednesday-february--cgen-20170130monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-s-cgen-15001-demonstrates-restoration-of-immune-tolerance-in-autoimmunity-compuge-cgen-20170104monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-announces-key-highlights-from-r-d-day-cgen-20161207monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-discloses-its-cancer-immunotherapy-program-targeting-tigit-immune-checkpoint-cgen-20161207monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-appoints-senior-vice-president-corporate-and-business-development-cgen-20161205monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-at-28th-annual-piper-jaffray-healthcare-conference-in-new-york-cgen-20161121monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-immune-checkpoint-program-demonstrates-potential-for-development-of-new-cancer-im-cgen-20161111monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-ltd-reports-3rd-quarter-2016-financial-results-cgen-20161107monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-host-r-d-day-on-december-7-2016-in-new-york-cgen-20161103monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-third-quarter-financial-statements-to-be-released-november-7-2016-cgen-20161010monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-at-the-annual-meeting-of-the-society-for-immunotherapy-of-cancer-next--cgen-20161007monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-discloses-development-of-enhanced-links-platform-utilized-for-the-discovery-of-my-cgen-20160830monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-ltd-reports-2nd-quarter-2016-financial-results-cgen-20160802monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-second-quarter-2016-conference-call-scheduled-for-tuesday-august-2-2016-at-10-00--cgen-20160721monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-discloses-lead-therapeutic-candidate-for-cgen-15029-immuno-oncology-program-cgen-20160622monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-at-jmp-securities-life-sciences-conference-in-new-york-cgen-20160615monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-at-the-jefferies-global-healthcare-conference-in-new-york-cgen-20160523monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-at-the-oppenheimer-annual-israeli-conference-in-tel-aviv-cgen-20160516monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-ltd-reports-first-quarter-2016-financial-results-cgen-20160510monthly0.5https://www.biopharmawatch.com/news/CGEN/steven-holtzman-joins-compugen-as-strategic-business-advisor-cgen-20160510monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-first-quarter-2016-conference-call-and-webcast-scheduled-for-tuesday-may-10-2016--cgen-20160427monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-achieves-preclinical-milestone-in-cancer-immunotherapy-collaboration-with-bayer-cgen-20160418monthly0.5https://www.biopharmawatch.com/news/CGEN/dr-elliott-sigal-joins-compugen-ltd-as-strategic-advisor-and-prof-drew-pardoll-appointed-d-cgen-20160406monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-to-present-at-the-jefferies-immuno-oncology-summit-in-boston-cgen-20160328monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-presents-results-for-cgen-15029-immuno-oncology-therapeutic-program-cgen-20160229monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-ltd-reports-fourth-quarter-and-calendar-2015-results-cgen-20160209monthly0.5https://www.biopharmawatch.com/news/CGEN/compugen-fourth-quarter-and-yearend-2015-conference-call-scheduled-for-tuesday-february-9--cgen-20160126monthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-announces-initiation-of-renew-phase-2-trial-of-lti-03-in-patients-with-i-rntx-20250512monthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-and-qureight-ltd-announce-planned-integration-of-deep-learning-platform--rntx-20250501monthly0.5https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-rntx-20250407monthly0.5https://www.biopharmawatch.com/news/RNTX/aileron-therapeutics-announces-rebranding-to-rein-therapeutics-rntx-20250110monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-to-participate-in-the-oppenheimer-36th-annual-healthcare-life-sciences-conference-qttb-20260218monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-reports-second-quarter-2025-financial-results-and-provides-corporate-update-qttb-20250806monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-doses-first-patients-in-both-part-a-open-label-extension-and-part-b-of-signal-aa-p-qttb-20250416monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-announces-late-breaking-presentation-of-results-from-signal-aa-part-a-clinical-tri-qttb-20250228monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-to-participate-in-upcoming-march-investor-conferences-qttb-20250226monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-to-participate-in-oppenheimer-qttb-20250204monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-to-participate-in-guggenheim-qttb-20241105monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-to-present-tissue-targeted-complement-inhibitor-adx-097-positive-phase-1-clinical--qttb-20241014monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-to-participate-in-upcoming-september-investor-conferences-qttb-20240829monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-joins-russell-3000-index-qttb-20240701monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-appoints-lee-kalowski-as-president-chief-financial-officer-qttb-20240403monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-announces-closing-of-merger-with-homology-medicines-and-concurrent-private-placeme-qttb-20240325monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-announces-publication-of-preclinical-data-in-molecular-therapy-demonstrating-the-t-qttb-20240221monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-regains-worldwide-rights-to-bempikibart-adx-914-from-amgen-qttb-20231116monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-appoints-saul-fink-ph-d-as-chief-technology-officer-qttb-20231024monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-and-horizon-therapeutics-plc-announce-dosing-of-first-patient-in-phase-2-trial-of--qttb-20230913monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-and-horizon-therapeutics-plc-announce-dosing-of-first-patient-in-phase-2-trial-of--qttb-20221027monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-a-clinical-stage-biotechnology-company-focused-on-therapeutics-that-restore-immune-qttb-20220920monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-and-horizon-therapeutics-announce-collaboration-in-autoimmune-diseases-qttb-20220815monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-presents-new-preclinical-data-at-the-international-society-of-nephrology-frontiers-qttb-20220623monthly0.5https://www.biopharmawatch.com/news/QTTB/shelia-violette-founder-and-chief-scientific-officer-of-q32-bio-to-present-at-the-keystone-qttb-20220608monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-initiates-first-in-human-phase-1-clinical-study-of-adx-097-for-the-treatment-of-co-qttb-20220526monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-presents-preclinical-data-highlighting-the-design-and-characterization-of-lead-pro-qttb-20211213monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-presents-preclinical-data-supporting-next-generation-complement-inhibitor-adx-097--qttb-20211108monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-to-present-preclinical-data-on-next-generation-complement-inhibitor-adx-097-at-the-qttb-20211018monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-announces-appointment-of-kathy-laporte-to-its-board-of-directors-qttb-20210803monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-appoints-adam-cutler-as-chief-financial-officer-qttb-20210707monthly0.5https://www.biopharmawatch.com/news/QTTB/q32-bio-to-present-at-the-jefferies-virtual-healthcare-conference-qttb-20210527monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-regains-full-nasdaq-listing-compliance-kzia-20251222monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-highlights-recent-progress-and-provides-business-update-kzia-20250515monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-announces-sale-of-intellectual-property-and-trademarks-rights-for-cantr-kzia-20250331monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-and-the-hebrew-university-of-jerusalem-receives-a-grant-from-the-michae-kzia-20250220monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-announces-closing-of-2-0-million-registered-direct-offering-kzia-20250114monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-provides-update-on-paxalisib-regulatory-pathway-following-type-c-meetin-kzia-20241231monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-to-present-data-highlighting-synergistic-activity-between-paxalisib-and-kzia-20241211monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-announces-granting-of-type-c-meeting-with-fda-to-discuss-potential-next-kzia-20241104monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-announces-presentation-of-promising-phase-i-data-evaluating-concurrent--kzia-20241002monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-announces-presentation-of-evt801-clinical-data-at-15th-biennial-ovarian-kzia-20240923monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-executes-licensing-agreement-with-qimr-berghofer-kzia-20240912monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-announces-upcoming-dipg-data-presentations-at-ispno-and-publication-in-european-jour-kzia-20240627monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-granted-180-day-extension-by-nasdaq-to-meet-the-minimum-bid-price-requirement-kzia-20240523monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-reports-successful-stage-1-completion-of-the-evt801-phase-1-clinical-trial-in-advanc-kzia-20240501monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-licenses-paxalisib-to-sovargen-for-intractable-seizures-in-rare-central-kzia-20240321monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-announces-presentation-of-new-data-at-aacr-annual-meeting-kzia-20240313monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-reports-early-conclusion-of-clinical-trial-after-reaching-primary-endpo-kzia-20240221monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-continues-board-renewal-with-two-new-appointments-kzia-20240118monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-announces-non-binding-letter-of-intent-for-the-proposed-granting-of-rights-to-develo-kzia-20231129monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-provides-overview-of-paxalisib-related-presentations-from-the-society-of-neuro-oncol-kzia-20231121monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-announces-the-release-of-pnoc022-clinical-study-abstract-highlighting-paxalisib-in-d-kzia-20231115monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-announces-publication-in-molecular-cancer-therapeutics-highlighting-paxalisib-precli-kzia-20231110monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-provides-preliminary-update-from-ongoing-phase-2-study-of-paxalisib-in--kzia-20231101monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-announces-clinical-data-at-esmo-2023-from-ongoing-phase-1-evt801-study-kzia-20231023monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-announces-voluntary-delisting-from-asx-kzia-20231011monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-announces-presentations-at-upcoming-scientific-meetings-kzia-20231005monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-announces-acceptance-of-late-breaking-abstract-and-oral-presentation-of-kzia-20230929monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-announces-phase-ii-clinical-study-to-investigate-paxalisib-in-recurrent-kzia-20230608monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-ceo-dr-john-friend-to-participate-in-white-house-cancer-moonshot-kzia-20230525monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-regains-compliance-with-nasdaq-minimum-bid-price-requirement-kzia-20230414monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-presents-new-data-for-paxalisib-and-evt801-at-aacr-annual-meeting-kzia-20230404monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-raises-a-4-5-million-to-progress-r-d-programs-kzia-20230116monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-launches-preclinical-collaboration-with-qimr-berghofer-medical-research-institute-an-kzia-20221215monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-announces-receipt-of-nasdaq-minimum-bid-notification-kzia-20221212monthly0.5https://www.biopharmawatch.com/news/KZIA/compelling-preclinical-data-for-kazia-kzia-20221201monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-to-present-paxalisib-data-in-adult-and-pediatric-brain-cancer-at-society-for-neuro-o-kzia-20221109monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-s-paxalisib-demonstrates-positive-monotherapy-efficacy-signals-in-preclinical-models-kzia-20221027monthly0.5https://www.biopharmawatch.com/news/KZIA/pnoc-clinical-study-of-kazia-kzia-20221006monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-to-present-at-hc-wainwright-24th-annual-global-investment-conference-kzia-20220909monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-to-present-final-data-from-paxalisib-phase-ii-study-in-glioblastoma-at-esmo-kzia-20220908monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-rapporte-des-donne-es-interme-diaires-prometteuses-tire-es-d-kzia-20220806monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-meldet-vielversprechende-zwischenergebnisse-der-kombinationsstudie-von--kzia-20220806monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-informa-de-datos-prometedores-del-estudio-de-paxalisib-con-radioterapia-kzia-20220805monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-reports-promising-interim-data-from-combination-study-of-paxalisib-with-kzia-20220805monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-launches-new-scientific-advisory-board-comprised-of-world-leading-experts-in-brain-c-kzia-20220712monthly0.5https://www.biopharmawatch.com/news/KZIA/us-fda-awards-rare-pediatric-disease-designation-rpdd-to-paxalisib-for-at-rt-a-rare-form-o-kzia-20220706monthly0.5https://www.biopharmawatch.com/news/KZIA/us-fda-awards-orphan-drug-designation-odd-to-paxalisib-for-at-rt-a-rare-form-of-childhood--kzia-20220617monthly0.5https://www.biopharmawatch.com/news/KZIA/positive-data-for-paxalisib-in-two-childhood-brain-cancers-presented-at-20th-ispno-annual--kzia-20220613monthly0.5https://www.biopharmawatch.com/news/KZIA/phase-ii-study-of-paxalisib-in-brain-metastases-advances-to-expansion-stage-in-breast-canc-kzia-20220607monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-presents-positive-final-data-from-phase-ii-study-of-paxalisib-in-newly-diagnosed-gli-kzia-20220603monthly0.5https://www.biopharmawatch.com/news/KZIA/gbm-agile-opens-to-paxalisib-in-europe-kzia-20220531monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-to-present-at-upcoming-investor-conferences-hosted-by-hc-wainwright-and-kzia-20220523monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-marks-dipg-awareness-day-new-preclinical-data-in-dipg-to-be-presented-at-ispno-confe-kzia-20220517monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-to-present-final-data-from-paxalisib-phase-ii-study-in-glioblastoma-at-asco-kzia-20220429monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-announces-preclinical-data-presented-at-aacr-conference-by-johns-hopkin-kzia-20220408monthly0.5https://www.biopharmawatch.com/news/KZIA/two-abstracts-at-aacr-conference-present-detailed-study-design-and-innovative-biomarker-st-kzia-20220408monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-to-present-at-upcoming-investor-conference-and-aacr-annual-scientific-meeting-kzia-20220321monthly0.5https://www.biopharmawatch.com/news/KZIA/phase-ii-clinical-study-at-weill-cornell-medical-center-investigating-paxalisib-in-combina-kzia-20220228monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-to-present-at-bio-ceo-conference-kzia-20220207monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-to-participate-in-edison-group-kzia-20220125monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-to-present-at-hc-wainwright-bioconnect-conference-kzia-20220107monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-appoints-karen-krumeich-as-chief-financial-officer-kzia-20211213monthly0.5https://www.biopharmawatch.com/news/KZIA/gbm-agile-opens-to-paxalisib-in-canada-kzia-20211129monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-appoints-john-friend-md-as-chief-medical-officer-kzia-20211115monthly0.5https://www.biopharmawatch.com/news/KZIA/pnoc-study-in-childhood-brain-cancer-enrols-first-patient-kzia-20211111monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-enrols-first-patient-to-evt801-phase-i-clinical-trial-kzia-20211104monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-to-present-at-ld-micro-main-event-kzia-20211006monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-to-present-at-hc-wainwright-23rd-annual-global-investment-conference-kzia-20210910monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-calls-for-increased-focus-on-brain-cancer-research-this-gbm-awareness-day-kzia-20210721monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-provides-progress-update-on-paxalisib-and-evt801-clinical-programs-kzia-20210630monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-enters-clinical-collaboration-with-cornell-university-for-phase-ii-clinical-study-us-kzia-20210615monthly0.5https://www.biopharmawatch.com/news/KZIA/study-of-paxalisib-in-primary-cns-lymphoma-at-dana-farber-cancer-institute-enrols-first-pa-kzia-20210607monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-to-present-at-ld-micro-invitational-xi-kzia-20210603monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-obtient-de-la-part-d-kzia-20210421monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-lizenziert-globale-rechte-an-evt801-einem-neuartigen-klinisch-einsetzbaren-vegfr3-in-kzia-20210419monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-licencia-los-derechos-globales-de-evt801-un-nuevo-inhibidor-clinic-de-vegfr3-de-evot-kzia-20210419monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-licenses-global-rights-to-evt801-a-novel-first-in-class-clinic-ready-vegfr3-inhibito-kzia-20210419monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-licenses-rights-to-paxalisib-in-greater-china-to-simcere-a-leading-chinese-pharmaceu-kzia-20210329monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-to-collaborate-with-pacific-pediatric-neuro-oncology-consortium-pnoc-for-new-paxalis-kzia-20201210monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-enters-clinical-collaboration-with-dana-farber-cancer-institute-for-primary-cns-lymp-kzia-20200922monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-s-paxalisib-shows-positive-overall-survival-signal-in-phase-ii-glioblastoma-study-ka-kzia-20200407monthly0.5https://www.biopharmawatch.com/news/KZIA/positive-interim-efficacy-data-from-gdc-0084-phase-ii-study-in-glioblastoma-released-at-sn-kzia-20191125monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-calls-for-greater-awareness-of-the-deadliest-brain-cancer-in-the-us-kzia-20190717monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-enters-clinical-collaboration-for-metastatic-brain-cancer-with-alliance-for-clinical-kzia-20190520monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-calls-for-greater-awareness-of-the-deadliest-gynecological-cancer-in-the-us-kzia-20190508monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-presents-positive-cantrixil-phase-i-data-at-aacr-conference-kzia-20190401monthly0.5https://www.biopharmawatch.com/news/KZIA/progress-update-on-gdc-0084-program-kzia-20181029monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-enters-clinical-collaboration-to-investigate-use-of-brain-cancer-drug-gdc-0084-in-br-kzia-20181022monthly0.5https://www.biopharmawatch.com/news/KZIA/cantrixil-phase-i-study-progresses-to-next-stage-kzia-20181010monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-releases-preliminary-cantrixil-phase-i-data-kzia-20180619monthly0.5https://www.biopharmawatch.com/news/KZIA/commencement-de-l-kzia-20180329monthly0.5https://www.biopharmawatch.com/news/KZIA/start-der-klinischen-phase-ii-studie-von-gdc-0084-kzia-20180329monthly0.5https://www.biopharmawatch.com/news/KZIA/commencement-of-phase-ii-clinical-study-of-gdc-0084-kzia-20180328monthly0.5https://www.biopharmawatch.com/news/KZIA/kazie-recibe-de-la-fda-la-designacio-n-de-medicamento-hue-rfano-para-el-gdc-0084-kzia-20180224monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-erha-lt-orphan-kennzeichnung-der-fda-fu-r-gdc-0084-kzia-20180224monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-receives-fda-orphan-designation-for-gdc-0084-kzia-20180223monthly0.5https://www.biopharmawatch.com/news/KZIA/kazia-rec-oit-la-de-signation-de-me-dicament-orphelin-de-la-fda-pour-le-gdc-0084-kzia-20180223monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-announces-grant-of-key-european-patent-protecting-relevant-dosing-regimens-for-vid-imux-20260310monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-to-participate-in-scientific-and-investor-conferences-in-october-imux-20251001monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-to-participate-in-investor-and-scientific-conferences-in-september-imux-20250904monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-closing-of-oversubscribed-65-million-underwritten-public-offering-imux-20250603monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-to-participate-in-investor-scientific-and-industry-conferences-in-june-imux-20250602monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-to-participate-in-scientific-and-industry-conferences-in-may-imux-20250502monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-closing-of-5-1-million-registered-direct-offering-led-by-aberdeen-in-imux-20250410monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-participate-in-scientific-and-industry-conferences-in-april-imux-20250401monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-to-participate-in-scientific-and-investor-conferences-in-march-imux-20250303monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-presents-key-vidofludimus-calcium-data-at-the-actrims-forum-2025-highlighting-its--imux-20250226monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-to-participate-in-investor-and-scientific-conferences-in-february-imux-20250204monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-highlights-2024-accomplishments-and-upcoming-milestones-imux-20250107monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-participate-in-investor-conference-in-december-imux-20241126monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-announces-publication-of-data-from-phase-1-1b-clinical-trial-of-imu-856-in-the-pee-imux-20241113monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2024-an-imux-20241031monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-to-participate-in-industry-scientific-and-investor-conferences-in-november-imux-20241029monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-presents-key-vidofludimus-calcium-data-at-the-40th-congress-of-ectrims-highlightin-imux-20240918monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-announces-first-patient-enrolled-in-investigator-sponsored-phase-2-clinical-trial--imux-20240904monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-to-host-multiple-sclerosis-r-d-day-and-participate-in-scientific-and-investor-conf-imux-20240828monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-announce-financial-results-for-the-second-quarter-ended-june-30-2024-and-pr-imux-20240801monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-to-participate-in-industry-and-scientific-conferences-in-june-imux-20240528monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-to-participate-in-investor-and-scientific-conferences-in-may-imux-20240506monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-announce-financial-results-for-the-first-quarter-ended-march-31-2024-and-pr-imux-20240501monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-announces-publication-of-extended-data-from-phase-2-emphasis-trial-of-vidofludimus-imux-20240430monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-to-host-ms-r-d-day-and-participate-in-investor-conferences-in-april-imux-20240404monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-receives-notice-of-allowance-for-composition-of-matter-patent-of-a-specific-polymo-imux-20240320monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-to-participate-in-investor-and-scientific-conferences-in-march-imux-20240307monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-presents-data-from-phase-2-calliper-and-calvid-1-trials-of-vidofludimus-calcium-at-imux-20240229monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-announce-financial-results-for-the-year-ended-december-31-2023-and-provide--imux-20240215monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-to-participate-in-investor-and-scientific-conferences-in-february-imux-20240201monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-highlights-2023-accomplishments-and-upcoming-milestones-imux-20240105monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-receives-notice-of-allowance-for-united-states-patent-protecting-vidofludimus-calc-imux-20231121monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-to-announce-financial-results-for-the-third-quarter-ended-september-30-2023-and-pr-imux-20231107monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-receives-notice-of-allowance-for-united-states-patent-protecting-the-treatment-of--imux-20231102monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-to-participate-in-scientific-and-industry-conferences-in-november-imux-20231026monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-presents-data-from-phase-2-caldose-1-trial-of-vidofludimus-calcium-in-ulcerative-c-imux-20231016monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-presents-data-from-phase-1b-clinical-trial-of-imu-856-in-celiac-disease-at-the-uni-imux-20231015monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-presents-data-from-phase-2-emphasis-trial-of-vidofludimus-calcium-in-relapsing-rem-imux-20231011monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-to-participate-in-scientific-conferences-in-october-imux-20231004monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-to-participate-in-industry-and-investor-conferences-in-september-imux-20230906monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-completes-enrollment-of-its-phase-2-calliper-trial-of-vidofludimus-calcium-in-prog-imux-20230817monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-to-participate-in-investor-and-scientific-conferences-in-august-imux-20230801monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-announce-financial-results-for-the-second-quarter-ended-june-30-2023-and-pr-imux-20230727monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-to-participate-in-scientific-and-investor-conferences-in-july-imux-20230629monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-to-participate-in-scientific-and-investor-conferences-in-june-imux-20230530monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-announces-that-vidofludimus-calcium-acts-as-potent-nurr1-activator-reinforcing-neu-imux-20230517monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-announce-financial-results-for-the-first-quarter-ended-march-31-2023-and-pr-imux-20230509monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-presents-clinical-and-preclinical-data-for-imu-856-at-digestive-disease-week-2023--imux-20230506monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-strengthens-its-board-of-directors-with-the-appointment-of-richard-rudick-m-d-imux-20230427monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-to-participate-in-investor-and-scientific-conferences-in-may-imux-20230426monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-reports-positive-data-from-maintenance-phase-of-phase-2-caldose-1-trial-of-vidoflu-imux-20230405monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-to-participate-in-investor-and-scientific-conferences-in-march-imux-20230302monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-presents-data-from-phase-2-emphasis-trial-of-vidofludimus-calcium-in-relapsing-rem-imux-20230222monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-announce-financial-results-for-the-year-ended-december-31-2022-and-provide--imux-20230216monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-to-participate-in-scientific-and-investor-conferences-in-february-imux-20230125monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-to-participate-in-investor-and-scientific-conferences-in-november-and-december-imux-20221110monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2022-an-imux-20221027monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-to-participate-in-scientific-and-industry-conferences-in-october-imux-20221004monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-announces-positive-results-from-single-and-multiple-ascending-dose-parts-of-its-ph-imux-20220920monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-participate-in-investor-conferences-in-september-imux-20220901monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-receives-notice-of-allowance-for-composition-of-matter-patent-in-the-united-states-imux-20220816monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-participate-in-the-2022-wedbush-pacgrow-virtual-healthcare-conference-imux-20220802monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-announce-financial-results-for-the-second-quarter-ended-june-30-2022-and-pr-imux-20220728monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-to-participate-in-industry-and-scientific-conferences-in-july-imux-20220628monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-announces-publication-of-data-from-its-phase-2-emphasis-trial-of-vidofludimus-calc-imux-20220615monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-participate-in-scientific-industry-and-investor-conferences-in-june-imux-20220608monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-reports-top-line-data-from-phase-2-caldose-1-trial-of-vidofludimus-calcium-in--imux-20220602monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-announces-start-of-patient-cohorts-in-its-phase-1-clinical-trial-of-imu-856-in-cel-imux-20220505monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-announce-financial-results-for-the-first-quarter-ended-march-31-2022-and-pr-imux-20220503monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-participate-in-upcoming-investor-and-industry-conferences-imux-20220425monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-promotion-of-glenn-whaley-cpa-to-chief-financial-officer-imux-20220316monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-march-imux-20220308monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-announce-financial-results-for-the-year-ended-december-31-2021-and-provide--imux-20220217monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-february-imux-20220208monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-receives-notice-of-allowance-for-composition-of-matter-patents-in-the-united-state-imux-20220202monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-enrollment-of-the-first-patient-in-its-phase-1-trial-of-imu-935-in-m-imux-20211209monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-participate-in-the-piper-sandler-co-33rd-annual-virtual-healthcare-conferen-imux-20211123monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-enrollment-of-first-patient-in-its-phase-3-ensure-program-of-vidoflu-imux-20211118monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2021-an-imux-20211101monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-completion-of-enrollment-of-its-phase-2-caldose-1-trial-of-imu-838-i-imux-20211028monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-first-psoriasis-patient-enrolled-in-ongoing-phase-1-trial-of-imu-935-imux-20211027monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-appoints-patrick-walsh-as-chief-business-officer-imux-20211014monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-enrolls-first-patient-in-its-phase-2-calliper-trial-of-imu-838-in-progressive--imux-20210930monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-participate-in-scientific-and-investor-conferences-in-october-imux-20210928monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-and-the-university-medical-center-goettingen-sign-license-agreement-covering-the-c-imux-20210922monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september-imux-20210908monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-participate-in-investor-conferences-in-august-imux-20210803monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-closing-of-45-0-million-public-offering-imux-20210719monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-pricing-of-45-million-public-offering-of-common-stock-imux-20210715monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-proposed-public-offering-of-common-stock-imux-20210714monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-participate-in-scientific-industry-and-investor-conferences-in-july-imux-20210628monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-participate-in-industry-and-investor-conferences-in-june-imux-20210610monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-appointment-of-inderpal-singh-as-general-counsel-imux-20210601monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-emphasis-interim-analysis-of-10-mg-cohort-confirms-imu-838-imux-20210415monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-participate-in-scientific-investor-and-industry-conferences-in-april-imux-20210413monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-participate-in-industry-and-investor-conferences-in-march-imux-20210302monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-positive-top-line-data-from-investigator-sponsored-phase-2-proof-of--imux-20210218monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-participate-in-the-svb-leerink-10th-annual-global-healthcare-conference-on--imux-20210211monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-participate-in-investor-conferences-in-january-imux-20210105monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-added-to-nasdaq-biotechnology-index-imux-20201214monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-participate-in-investor-conferences-in-december-imux-20201124monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-formation-of-scientific-medical-advisory-board-imux-20201117monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-november-imux-20201110monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-200-patients-enrolled-in-its-phase-2-calvid-1-trial-of-imu-838-for-t-imux-20201102monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-participate-in-scientific-conferences-in-october-imux-20200929monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-results-from-interim-safety-analysis-and-recruitment-update-from-its-imux-20200928monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-publishes-full-unblinded-clinical-data-from-phase-2-emphasis-trial-of-imu-838--imux-20200911monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-participate-in-scientific-and-investor-conferences-in-september-imux-20200908monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-dosing-of-first-healthy-volunteer-in-phase-1-clinical-program-of-imu-imux-20200820monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-closing-of-103-5-million-public-offering-including-full-exercise-of--imux-20200810monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-pricing-of-90-0-million-public-offering-of-common-stock-imux-20200804monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-proposed-public-offering-of-5-million-shares-of-common-stock-imux-20200803monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-report-second-quarter-2020-financial-results-and-provide-corporate-update-imux-20200730monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-participate-in-investor-conferences-in-august-imux-20200729monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-join-russell-3000-index-imux-20200622monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-proposed-public-offering-of-common-stock-imux-20200609monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-u-s-food-and-drug-administration-allowance-of-its-phase-2-calvid-1-c-imux-20200609monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-participate-in-investor-and-industry-conferences-in-june-imux-20200529monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-host-virtual-r-d-day-today-may-19-2020-imux-20200519monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-changes-to-executive-team-imux-20200417monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-participate-in-scientific-and-investor-conferences-in-february-imux-20200211monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-exercises-its-option-for-the-exclusive-worldwide-license-to-imu-856-from-daiichi-s-imux-20200108monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-present-data-on-imu-856-for-the-first-time-at-the-crohn-imux-20191204monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-december-imux-20191125monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-expands-board-of-directors-with-appointment-of-biotechnology-executive-barclay-imux-20191119monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-participate-in-industry-and-investor-conferences-in-november-imux-20191105monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-expands-board-of-directors-with-appointment-of-industry-veteran-tamar-howson-imux-20191015monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-completion-of-enrollment-for-its-phase-2-emphasis-trial-of-imu-838-i-imux-20191010monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-october-imux-20190930monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-doses-first-healthy-volunteer-in-its-phase-1-clinical-program-of-imu-935-a-pot-imux-20190918monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-present-selected-available-and-previously-unpublished-data-regarding-lead-p-imux-20190911monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-participate-in-scientific-and-investor-conferences-in-september-imux-20190903monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-announces-first-patient-enrolled-in-investigator-sponsored-proof-of-concept-cl-imux-20190812monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-ag-awarded-research-grant-by-german-federal-ministry-of-education-and-research-in--imux-20190801monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-present-at-the-canaccord-genuity-39th-annual-growth-conference-on-august-8-imux-20190730monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-appoints-sanjay-s-patel-cfa-as-chief-financial-officer-imux-20190716monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-present-previously-unpublished-data-regarding-lead-program-imu-838-at-the-g-imux-20190624monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-june-imux-20190530monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-to-participate-in-upcoming-may-conferences-imux-20190509monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-inc-appoints-industry-veteran-tamara-a-seymour-as-interim-chief-financial-officer-imux-20190429monthly0.5https://www.biopharmawatch.com/news/IMUX/immunic-therapeutics-and-vital-therapies-complete-transaction-creating-nasdaq-listed-compa-imux-20190412monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026-nvax-20260219monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-report-third-quarter-2025-financial-results-on-november-6-2025-nvax-20251030monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-convertible-debt-refinancing-nvax-20250821monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-second-quarter-2025-financial-results-and-operational-highlights-nvax-20250806monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-report-second-quarter-2025-financial-results-on-august-6-2025-nvax-20250730monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-s-h5n1-vaccine-candidate-demonstrates-immunogenicity-in-preclinical-study-novavax--nvax-20250724monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-upcoming-investor-conferences-nvax-20250529monthly0.5https://www.biopharmawatch.com/news/NVAX/u-s-fda-approves-bla-for-novavax-nvax-20250519monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-first-quarter-2025-financial-results-and-operational-highlights-nvax-20250508monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-bofa-securities-2025-health-care-conference-nvax-20250507monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-significantly-improved-terms-for-collaboration-and-license-agreement-wit-nvax-20250505monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-report-first-quarter-2025-financial-results-on-may-8-2025-nvax-20250501monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-appoints-charles-newton-to-board-of-directors-nvax-20250429monthly0.5https://www.biopharmawatch.com/news/NVAX/shield-utah-study-shows-novavax-nvax-20250415monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-changes-to-board-of-directors-nvax-20250311monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-upcoming-march-investor-conferences-nvax-20250227monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-fourth-quarter-and-full-year-2024-financial-results-and-operational-highli-nvax-20250227monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-2024-financial-res-nvax-20250220monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-advances-corporate-growth-strategy-through-sanofi-partnership-including-achievemen-nvax-20241213monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-initiates-phase-3-trial-for-covid-19-influenza-combination-and-stand-alone-influen-nvax-20241210monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-sale-of-czech-republic-manufacturing-site-to-novo-nordisk-for-200-millio-nvax-20241204monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-grant-of-inducement-awards-pursuant-to-nasdaq-listing-rule-5635-c-4-nvax-20241115monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-jefferies-london-healthcare-conference-nvax-20241113monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-third-quarter-2024-financial-results-and-operational-highlights-nvax-20241112monthly0.5https://www.biopharmawatch.com/news/NVAX/u-s-fda-removes-clinical-hold-on-novavax-nvax-20241111monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-third-quarter-2024-financial-results-and-operat-nvax-20241104monthly0.5https://www.biopharmawatch.com/news/NVAX/update-on-novavax-nvax-20241016monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-s-updated-2024-2025-nuvaxovid-covid-19-vaccine-receives-authorization-in-the-eu-no-nvax-20241009monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-names-dr-ruxandra-draghia-akli-as-new-executive-vice-president-and-head-of-researc-nvax-20240925monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-2024-2025-formula-covid-19-vaccine-available-at-major-pharmacies-across-the-u-s-nvax-20240913monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-upcoming-september-conferences-nvax-20240904monthly0.5https://www.biopharmawatch.com/news/NVAX/la-vacuna-contra-la-covid-19-de-fo-rmula-2024-2025-de-novavax-ya-esta-autorizada-en-ee-uu-nvax-20240902monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-2024-2025-formula-covid-19-impfstoff-jetzt-fu-r-die-verwendung-in-den-usa-zugelass-nvax-20240902monthly0.5https://www.biopharmawatch.com/news/NVAX/l-utilisation-du-vaccin-novavax-2024-2025-formula-covid-19-est-de-sormais-autorise-e-et-re-nvax-20240902monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-2024-2025-formula-covid-19-vaccine-now-authorized-and-recommended-for-use-in-the-u-nvax-20240830monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-second-quarter-2024-financial-results-and-operational-highlights-nvax-20240808monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-second-quarter-2024-financial-results-and-opera-nvax-20240801monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-submits-application-to-european-medicines-agency-for-updated-protein-based-2024-20-nvax-20240624monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-submits-application-to-u-s-fda-for-updated-protein-based-2024-2025-formula-covid-1-nvax-20240614monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-2024-jefferies-global-healthcare-conference-nvax-20240530monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-bofa-securities-2024-health-care-conference-nvax-20240513monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-first-quarter-2024-financial-results-and-operational-highlights-nvax-20240510monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-first-quarter-2024-financial-results-and-operat-nvax-20240507monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-td-cowen-nvax-20240229monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-fourth-quarter-and-full-year-2023-financial-results-and-operational-highli-nvax-20240228monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-2023-financial-res-nvax-20240220monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-grant-of-inducement-awards-pursuant-to-nasdaq-listing-rule-5635-c-4-nvax-20230908monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-upcoming-september-conferences-nvax-20230908monthly0.5https://www.biopharmawatch.com/news/NVAX/le-vaccin-xbb-contre-la-covid-19-de-novavax-a-base-de-prote-ines-a-e-te-ame-liore-pour-ge--nvax-20230823monthly0.5https://www.biopharmawatch.com/news/NVAX/la-vacuna-xbb-covid-de-novavax-indujo-respuestas-neutralizantes-contra-subvariantes-emerge-nvax-20230822monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-s-updated-protein-based-xbb-covid-vaccine-induced-neutralizing-responses-against-e-nvax-20230822monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-second-quarter-2023-financial-results-and-operational-highlights-nvax-20230808monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-second-quarter-2023-financial-results-and-opera-nvax-20230801monthly0.5https://www.biopharmawatch.com/news/NVAX/nuvaxovid-de-novavax-rec-oit-une-autorisation-de-mise-sur-le-marche-comple-te-dans-l-nvax-20230708monthly0.5https://www.biopharmawatch.com/news/NVAX/nuvaxovid-von-novavax-erha-lt-vollsta-ndige-marktzulassung-in-der-eu-zur-pra-vention-von-c-nvax-20230707monthly0.5https://www.biopharmawatch.com/news/NVAX/nuvaxovid-de-novavax-recibe-plena-autorizacio-n-de-comercializacio-n-en-la-ue-para-la-prev-nvax-20230706monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-s-nuvaxovid-receives-full-marketing-authorization-in-the-eu-for-the-prevention-of--nvax-20230706monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-est-pre-t-a-fournir-un-vaccin-monovalent-prote-inique-contre-le-virus-xbb-covid-co-nvax-20230619monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-entregara-la-vacuna-xbb-covid-monovalente-segu-n-la-recomendacio-n-vrbpac-de-la-fd-nvax-20230616monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-prepared-to-deliver-protein-based-monovalent-xbb-covid-vaccine-consistent-with-fda-nvax-20230615monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-adjournment-of-2023-annual-meeting-of-stockholders-to-july-11-2023-nvax-20230615monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-annonce-la-signature-d-nvax-20230605monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-gibt-eine-vereinbarung-mit-dem-bill-melinda-gates-medical-research-institute-u-ber-nvax-20230605monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-agreement-with-bill-melinda-gates-medical-research-institute-to-include--nvax-20230605monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-y-el-instituto-de-investigacio-n-me-dica-bill-melinda-gates-acuerdo-sobre-el-adyuv-nvax-20230605monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-the-jefferies-global-healthcare-conference-nvax-20230601monthly0.5https://www.biopharmawatch.com/news/NVAX/nuvaxovid-de-novavax-recibe-la-opinio-n-positiva-del-chmp-para-la-autorizacio-n-de-comerci-nvax-20230529monthly0.5https://www.biopharmawatch.com/news/NVAX/nuvaxovid-de-novavax-rec-oit-un-avis-positif-du-chmp-pour-l-nvax-20230529monthly0.5https://www.biopharmawatch.com/news/NVAX/nuvaxovid-von-novavax-erha-lt-positive-chmp-stellungnahme-fu-r-vollsta-ndige-marktzulassun-nvax-20230526monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-s-nuvaxovid-receives-positive-chmp-opinion-for-full-marketing-authorization-for-th-nvax-20230526monthly0.5https://www.biopharmawatch.com/news/NVAX/access-to-novavax-nvax-20230512monthly0.5https://www.biopharmawatch.com/news/NVAX/les-re-sultats-positifs-de-premier-ordre-de-l-nvax-20230510monthly0.5https://www.biopharmawatch.com/news/NVAX/resultados-positivos-de-covid-influenza-de-novavax-influenza-independiente-y-dosis-alta-de-nvax-20230509monthly0.5https://www.biopharmawatch.com/news/NVAX/los-resultados-positivos-de-la-fase-2-muestran-que-las-vacunas-candidatas-de-combinacio-n--nvax-20230509monthly0.5https://www.biopharmawatch.com/news/NVAX/resultados-positivos-da-fase-2-mostram-que-as-candidatas-a-vacina-contra-a-combinac-a-o-co-nvax-20230509monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-reports-first-quarter-2023-financial-results-and-operational-highlights-nvax-20230509monthly0.5https://www.biopharmawatch.com/news/NVAX/positive-phase-2-topline-ergebnisse-zeigen-dass-die-covid-influenza-kombination-eigensta-n-nvax-20230509monthly0.5https://www.biopharmawatch.com/news/NVAX/positive-phase-2-topline-results-show-novavax-nvax-20230509monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-the-bofa-securities-2023-health-care-conference-nvax-20230504monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-first-quarter-2023-financial-results-and-operat-nvax-20230502monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-grows-presence-at-world-vaccine-congress-2023-and-33rd-european-congress-of-clinic-nvax-20230404monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-td-cowen-nvax-20230306monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-grant-of-inducement-awards-pursuant-to-nasdaq-listing-rule-5635-c-4-nvax-20230302monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-2022-financial-res-nvax-20230221monthly0.5https://www.biopharmawatch.com/news/NVAX/le-gouvernement-des-e-tats-unis-et-novavax-e-tendent-leur-partenariat-et-garantissent-jusq-nvax-20230213monthly0.5https://www.biopharmawatch.com/news/NVAX/el-gobierno-de-los-estados-unidos-y-novavax-extienden-su-alianza-y-aseguran-hasta-1-5-mill-nvax-20230213monthly0.5https://www.biopharmawatch.com/news/NVAX/governo-dos-eua-e-novavax-ampliam-parceria-garantindo-ate-1-5-milho-es-de-doses-adicionais-nvax-20230213monthly0.5https://www.biopharmawatch.com/news/NVAX/el-gobierno-de-estados-unidos-y-novavax-aseguran-hasta-1-5-millones-de-dosis-ma-s-de-la-va-nvax-20230213monthly0.5https://www.biopharmawatch.com/news/NVAX/verla-ngerung-der-partnerschaft-zwischen-der-us-regierung-und-novavax-zur-bereitstellung-v-nvax-20230213monthly0.5https://www.biopharmawatch.com/news/NVAX/u-s-government-and-novavax-extend-partnership-securing-up-to-1-5-million-additional-doses--nvax-20230213monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-grant-of-inducement-awards-pursuant-to-nasdaq-listing-rule-5635-c-4-nvax-20230125monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-nuvaxovid-covid-19-vaccine-approved-in-south-korea-as-an-adult-booster-nvax-20230118monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-names-john-c-jacobs-as-new-president-chief-executive-officer-nvax-20230109monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-initiation-of-phase-2-trial-for-covid-19-influenza-combination-and-stand-nvax-20221230monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-closing-of-175-25-million-offering-of-convertible-senior-notes-due-2027--nvax-20221228monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-ku-ndigt-preis-fu-r-o-ffentliches-stammaktienangebot-in-ho-he-von-65-millionen-dol-nvax-20221218monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-gibt-die-preisgestaltung-seines-150-millionen-dollar-angebots-von-wandelschuldvers-nvax-20221218monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-annonce-une-offre-propose-e-de-150-millions-de-dollars-d-nvax-20221217monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-annonce-la-fixation-du-prix-de-l-nvax-20221217monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-annonce-une-offre-propose-e-de-125-millions-de-dollars-d-nvax-20221216monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anuncia-valor-de-65-milho-es-para-oferta-pu-blica-de-ac-o-es-ordina-rias-nvax-20221216monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anuncia-el-precio-de-la-oferta-de-150-millones-de-do-lares-de-bonos-preferentes-co-nvax-20221216monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anuncia-prec-o-de-150-milho-es-de-ofertas-de-ti-tulos-seniores-conversi-veis-nvax-20221216monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anuncia-el-precio-de-una-oferta-pu-blica-de-65-millones-de-do-lares-en-acciones-or-nvax-20221216monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anuncia-el-precio-de-una-oferta-de-150-millones-de-bonos-se-nior-convertibles-nvax-20221216monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-annonce-une-proposition-d-nvax-20221216monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-ku-ndigt-geplantes-o-ffentliches-stammaktienangebot-in-ho-he-von-125-millionen-dol-nvax-20221216monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-pricing-of-150-million-offering-of-convertible-senior-notes-nvax-20221215monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-pricing-of-65-million-public-offering-of-common-stock-nvax-20221215monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-ku-ndigt-geplante-emission-von-125-mio-usd-an-wandelbaren-vorrangigen-anleihen-an-nvax-20221215monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anuncia-oferta-proposta-de-us-125-milho-es-em-notas-seniores-conversi-veis-nvax-20221215monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anuncia-oferta-propuesta-de-125-millones-de-do-lares-de-notas-se-nior-convertibles-nvax-20221215monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anuncia-una-propuesta-de-oferta-de-125-millones-de-do-lares-en-bonos-se-nior-conve-nvax-20221215monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anuncia-proposta-de-oferta-pu-blica-de-125-milho-es-em-ac-o-es-ordina-rias-nvax-20221215monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anuncia-propuesta-de-oferta-pu-blica-de-acciones-ordinarias-por-valor-de-125-millo-nvax-20221215monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-anuncia-propuesta-de-oferta-pu-blica-de-125-millones-en-acciones-ordinarias-nvax-20221215monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-proposed-125-million-public-offering-of-common-stock-nvax-20221214monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-proposed-offering-of-125-million-of-convertible-senior-notes-nvax-20221214monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-nuvaxovid-covid-19-vaccine-approved-in-canada-for-use-as-a-primary-series-in-adole-nvax-20221207monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-bofa-securities-2022-virtual-biotech-smid-cap-conference-nvax-20221202monthly0.5https://www.biopharmawatch.com/news/NVAX/weltgesundheitsorganisation-aktualisiert-die-notfallliste-fu-r-covid-19-impfstoff-nuvaxovi-nvax-20221201monthly0.5https://www.biopharmawatch.com/news/NVAX/l-organisation-mondiale-de-la-sante-met-a-jour-la-liste-des-utilisations-d-urgence-du-vacc-nvax-20221201monthly0.5https://www.biopharmawatch.com/news/NVAX/la-oms-actualiza-la-lista-de-uso-de-emergencia-para-la-vacuna-novavax-nuvaxovid-covid-19-nvax-20221130monthly0.5https://www.biopharmawatch.com/news/NVAX/world-health-organization-updates-emergency-use-listing-for-novavax-nuvaxovid-covid-19-vac-nvax-20221129monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-nuvaxovid-covid-19-vaccine-receives-expanded-authorization-in-canada-as-a-booster--nvax-20221118monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-jefferies-london-healthcare-conference-nvax-20221114monthly0.5https://www.biopharmawatch.com/news/NVAX/l-essai-de-phase-3-covid-19-omicron-de-novavax-soutient-l-utilisation-continue-et-future-d-nvax-20221110monthly0.5https://www.biopharmawatch.com/news/NVAX/el-ensayo-o-micron-covid-19-de-fase-3-de-novavax-respalda-el-uso-continuo-y-futuro-de-la-v-nvax-20221109monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-phase-3-studie-covid-19-omikron-unterstu-tzt-den-weiteren-und-zuku-nftigen-einsatz-nvax-20221109monthly0.5https://www.biopharmawatch.com/news/NVAX/estudo-omicron-de-fase-3-da-covid-19-da-novavax-apoia-o-uso-conti-nuo-e-futuro-do-proto-ti-nvax-20221109monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-nuvaxovid-covid-19-vaccine-authorized-in-the-united-kingdom-for-use-as-a-booster-i-nvax-20221109monthly0.5https://www.biopharmawatch.com/news/NVAX/el-ensayo-de-fase-3-covid-19-omicron-de-novavax-apoya-el-uso-de-la-vacuna-prototipo-de-nov-nvax-20221108monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-phase-3-covid-19-omicron-trial-supports-the-continued-and-future-use-of-novavax-pr-nvax-20221108monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-nomme-rick-rodgers-a-son-conseil-d-nvax-20221102monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-beruft-rick-rodgers-in-den-vorstand-nvax-20221102monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-nombra-a-rick-rodgers-miembro-de-la-junta-directiva-nvax-20221102monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-appoints-rick-rodgers-to-board-of-directors-nvax-20221101monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-and-operat-nvax-20221101monthly0.5https://www.biopharmawatch.com/news/NVAX/la-fda-ame-ricaine-accorde-une-autorisation-d-nvax-20221022monthly0.5https://www.biopharmawatch.com/news/NVAX/die-us-amerikanische-arzneimittelbeho-rde-fda-erteilt-eine-notfallzulassung-fu-r-den-novav-nvax-20221022monthly0.5https://www.biopharmawatch.com/news/NVAX/fda-dos-eua-autoriza-uso-emergencial-para-vacina-com-adjuvante-contra-covid-19-da-novavax--nvax-20221022monthly0.5https://www.biopharmawatch.com/news/NVAX/la-fda-de-los-ee-uu-autoriza-el-uso-de-emergencia-de-la-vacuna-adyuvada-contra-la-covid-19-nvax-20221022monthly0.5https://www.biopharmawatch.com/news/NVAX/la-fda-de-ee-uu-otorga-autorizacio-n-de-uso-de-emergencia-para-la-vacuna-novavax-covid-19-nvax-20221021monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-showcases-data-from-expanding-vaccine-portfolio-at-idweek-2022-nvax-20221020monthly0.5https://www.biopharmawatch.com/news/NVAX/u-s-fda-grants-emergency-use-authorization-for-novavax-covid-19-vaccine-adjuvanted-as-a-bo-nvax-20221019monthly0.5https://www.biopharmawatch.com/news/NVAX/le-candidat-vaccin-combine-novavax-covid-19-influenza-a-induit-des-re-ponses-en-anticorps--nvax-20221016monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-covid-19-influenza-kombinationsimpfstoffkandidat-induziert-antiko-rper-und-t-zell--nvax-20221016monthly0.5https://www.biopharmawatch.com/news/NVAX/la-vacuna-combinada-novavax-covid-19-gripe-induce-respuestas-de-anticuerpos-y-ce-lulas-t-nvax-20221014monthly0.5https://www.biopharmawatch.com/news/NVAX/dados-do-proto-tipo-da-vacina-contra-a-covid-19-da-novavax-suportam-reforc-o-homo-logo-e-h-nvax-20221014monthly0.5https://www.biopharmawatch.com/news/NVAX/daten-zum-novavax-prototyp-impfstoff-gegen-covid-19-unterstu-tzen-homologe-und-heterologe--nvax-20221014monthly0.5https://www.biopharmawatch.com/news/NVAX/les-donne-es-sur-le-prototype-du-vaccin-covid-19-de-novavax-confirment-le-rappel-homologue-nvax-20221014monthly0.5https://www.biopharmawatch.com/news/NVAX/los-datos-del-prototipo-de-la-vacuna-de-novavax-contra-la-covid-19-apoyan-el-refuerzo-homo-nvax-20221013monthly0.5https://www.biopharmawatch.com/news/NVAX/los-datos-del-prototipo-de-la-vacuna-covid-19-de-novavax-apoyan-el-refuerzo-homo-logo-y-he-nvax-20221013monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-covid-19-influenza-combination-vaccine-candidate-induced-antibody-and-t-cell-respo-nvax-20221013monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-prototype-covid-19-vaccine-data-support-homologous-and-heterologous-boosting-and-s-nvax-20221012monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-partagera-de-nouvelles-donne-es-sur-son-portefeuille-croissant-de-vaccins-au-congr-nvax-20221010monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-compartira-nuevos-datos-de-la-creciente-cartera-de-vacunas-nvax-20221010monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-pra-sentiert-neue-daten-aus-dem-wachsenden-impfstoffportfolio-auf-dem-world-vaccin-nvax-20221010monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-share-new-data-from-growing-vaccine-portfolio-at-world-vaccine-congress-europe--nvax-20221010monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-makes-one-million-doses-of-nuvaxovid-available-for-use-in-the-united-kingdom-nvax-20220927monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-nuvaxovid-covid-19-vaccine-receives-expanded-emergency-use-authorization-in-taiwan-nvax-20220916monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-nuvaxovid-covid-19-vaccine-now-available-in-israel-for-individuals-aged-12-and-old-nvax-20220916monthly0.5https://www.biopharmawatch.com/news/NVAX/le-vaccin-nuvaxovid-de-novavax-contre-la-covid-19-obtient-une-autorisation-de-mise-sur-le--nvax-20220914monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-nuvaxovid-covid-19-impfstoff-erha-lt-erweiterte-bedingte-marktzulassung-in-der-eur-nvax-20220914monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-and-serum-institute-of-india-announce-full-product-registration-in-south-africa-of-nvax-20220913monthly0.5https://www.biopharmawatch.com/news/NVAX/la-vacuna-novavax-nuvaxovid-covid-19-recibe-autorizacio-n-de-comercializacio-n-condicional-nvax-20220912monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-nuvaxovid-covid-19-vaccine-granted-expanded-conditional-marketing-authorization-in-nvax-20220912monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-upcoming-september-conferences-nvax-20220907monthly0.5https://www.biopharmawatch.com/news/NVAX/swissmedic-autorise-le-vaccin-novavax-nuvaxovid-covid-19-pour-les-adolescents-a-ge-s-de-12-nvax-20220906monthly0.5https://www.biopharmawatch.com/news/NVAX/zulassung-der-swissmedic-fu-r-novavax-nuvaxovid-den-covid-19-impfstoff-fu-r-jugendliche-im-nvax-20220906monthly0.5https://www.biopharmawatch.com/news/NVAX/swissmedic-autoriza-la-vacuna-novavax-nuvaxovid-covid-19-vaccine-para-adolescentes-de-12-a-nvax-20220905monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-nuvaxovid-covid-19-impfstoff-vom-chmp-zur-erweiterten-bedingten-zulassung-als-auff-nvax-20220905monthly0.5https://www.biopharmawatch.com/news/NVAX/le-chmp-recommande-le-vaccin-nuvaxovid-de-novavax-contre-la-covid-19-pour-une-autorisation-nvax-20220905monthly0.5https://www.biopharmawatch.com/news/NVAX/swissmedic-authorizes-novavax-nuvaxovid-covid-19-vaccine-for-adolescents-aged-12-through-1-nvax-20220902monthly0.5https://www.biopharmawatch.com/news/NVAX/la-vacuna-nuvaxovid-covid-19-de-novavax-recomendada-como-refuerzo-para-mayores-de-18-an-os-nvax-20220902monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-nuvaxovid-covid-19-vaccine-recommended-by-chmp-for-expanded-conditional-marketing--nvax-20220901monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-nuvaxovid-covid-19-vaccine-granted-expanded-conditional-marketing-authorization-in-nvax-20220826monthly0.5https://www.biopharmawatch.com/news/NVAX/fda-dos-eua-autoriza-uso-emergencial-para-vacina-com-adjuvante-contra-covid-19-da-novavax--nvax-20220821monthly0.5https://www.biopharmawatch.com/news/NVAX/u-s-fda-erteilt-notfallzulassung-fu-r-novavax-covid-19-impfstoff-adjuvantiert-fu-r-jugendl-nvax-20220821monthly0.5https://www.biopharmawatch.com/news/NVAX/la-fda-ame-ricaine-accorde-une-autorisation-d-nvax-20220821monthly0.5https://www.biopharmawatch.com/news/NVAX/la-fda-de-los-estados-unidos-autoriza-el-uso-de-emergencia-de-la-vacuna-adyuvada-contra-la-nvax-20220821monthly0.5https://www.biopharmawatch.com/news/NVAX/la-fda-concede-la-autorizacio-n-de-uso-de-emergencia-de-la-vacuna-novavax-covid-19-para-ad-nvax-20220821monthly0.5https://www.biopharmawatch.com/news/NVAX/u-s-fda-grants-emergency-use-authorization-for-novavax-covid-19-vaccine-adjuvanted-for-ado-nvax-20220819monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-nuvaxovid-covid-19-vaccine-granted-expanded-provisional-approval-in-new-zealand-fo-nvax-20220818monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-submits-application-to-the-u-s-fda-for-emergency-use-authorization-for-novavax-cov-nvax-20220815monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-nuvaxovid-covid-19-vaccine-approved-in-south-korea-for-use-in-adolescents-aged-12--nvax-20220812monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-participate-in-fireside-chat-at-the-svb-securities-virtual-vaccine-forum-nvax-20220811monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-initiation-of-phase-2b-3-hummingbird-global-clinical-trial-for-the-novav-nvax-20220804monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-to-host-conference-call-to-discuss-second-quarter-2022-financial-results-and-opera-nvax-20220801monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-expanded-approval-of-nuvaxovid-covid-19-vaccine-for-adolescents-aged-12--nvax-20220726monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-nuvaxovid-covid-19-vaccine-granted-provisional-registration-in-australia-for-use-i-nvax-20220726monthly0.5https://www.biopharmawatch.com/news/NVAX/comite-consultivo-do-cdc-dos-eua-recomenda-por-unanimidade-a-vacina-com-adjuvante-da-novav-nvax-20220722monthly0.5https://www.biopharmawatch.com/news/NVAX/el-comite-asesor-de-los-cdc-de-los-estados-unidos-recomienda-por-unanimidad-la-vacuna-adyu-nvax-20220722monthly0.5https://www.biopharmawatch.com/news/NVAX/cdc-beratungsausschuss-empfiehlt-einstimmig-novavax-covid-19-impfstoff-adjuvantiert-als-pr-nvax-20220721monthly0.5https://www.biopharmawatch.com/news/NVAX/le-comite-consultatif-des-cdc-ame-ricains-recommande-a-l-nvax-20220721monthly0.5https://www.biopharmawatch.com/news/NVAX/el-comite-asesor-de-cdc-de-ee-uu-recomienda-la-vacuna-covid-19-de-novavax-para-mayores-de--nvax-20220720monthly0.5https://www.biopharmawatch.com/news/NVAX/u-s-cdc-advisory-committee-unanimously-recommends-novavax-covid-19-vaccine-adjuvanted-as-a-nvax-20220719monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-announces-expanded-agreement-with-sk-bioscience-to-manufacture-covid-19-vaccine-co-nvax-20220719monthly0.5https://www.biopharmawatch.com/news/NVAX/u-s-fda-erteilt-notfallzulassung-fu-r-novavax-covid-19-impfstoff-adjuvantiert-fu-r-persone-nvax-20220718monthly0.5https://www.biopharmawatch.com/news/NVAX/une-autorisation-d-nvax-20220718monthly0.5https://www.biopharmawatch.com/news/NVAX/fda-dos-eua-autoriza-uso-emergencial-para-vacina-com-adjuvante-contra-a-covid-19-da-novava-nvax-20220715monthly0.5https://www.biopharmawatch.com/news/NVAX/la-fda-de-ee-uu-autoriza-el-uso-de-emergencia-de-la-vacuna-adyuvada-contra-la-covid-19-de--nvax-20220715monthly0.5https://www.biopharmawatch.com/news/NVAX/la-fda-concede-una-autorizacio-n-de-uso-de-emergencia-para-la-vacuna-novavax-covid-19-nvax-20220714monthly0.5https://www.biopharmawatch.com/news/NVAX/u-s-fda-grants-emergency-use-authorization-for-novavax-covid-19-vaccine-adjuvanted-for-ind-nvax-20220713monthly0.5https://www.biopharmawatch.com/news/NVAX/governo-dos-eua-garante-3-2-milho-es-de-doses-da-vacina-da-novavax-contra-a-covid-19-nvax-20220712monthly0.5https://www.biopharmawatch.com/news/NVAX/le-gouvernement-ame-ricain-obtient-3-2-millions-de-doses-du-vaccin-novavax-contre-la-covid-nvax-20220712monthly0.5https://www.biopharmawatch.com/news/NVAX/el-gobierno-de-los-estados-unidos-asegura-3-2-millones-de-dosis-de-la-vacuna-contra-la-cov-nvax-20220711monthly0.5https://www.biopharmawatch.com/news/NVAX/us-regierung-sichert-sich-3-2-millionen-dosen-des-novavax-covid-19-impfstoffs-nvax-20220711monthly0.5https://www.biopharmawatch.com/news/NVAX/u-s-government-secures-3-2-million-doses-of-novavax-covid-19-vaccine-nvax-20220711monthly0.5https://www.biopharmawatch.com/news/NVAX/el-gobierno-de-estados-unidos-obtiene-3-2-millones-de-dosis-de-la-vacuna-contra-la-covid-1-nvax-20220711monthly0.5https://www.biopharmawatch.com/news/NVAX/nuvaxovid-vacina-contra-a-covid-19-da-novavax-autorizada-condicionalmente-na-unia-o-europe-nvax-20220706monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-nuvaxovid-covid-19-impfstoff-in-der-europa-ischen-union-fu-r-jugendliche-im-alter--nvax-20220706monthly0.5https://www.biopharmawatch.com/news/NVAX/l-utilisation-du-vaccin-contre-la-covid-19-nuvaxovid-de-novavax-est-autorise-e-sous-condit-nvax-20220706monthly0.5https://www.biopharmawatch.com/news/NVAX/la-vacuna-nuvaxovid-de-novavax-contra-la-covid-19-se-autoriza-de-forma-condicional-en-la-u-nvax-20220706monthly0.5https://www.biopharmawatch.com/news/NVAX/la-vacuna-de-novavax-nuvaxovid-covid-19-autorizada-en-la-unio-n-europea-para-adolescentes--nvax-20220705monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-nuvaxovid-covid-19-vaccine-conditionally-authorized-in-the-european-union-for-adol-nvax-20220705monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-covid-19-data-presented-at-fda-vrbpac-meeting-demonstrates-broad-antibody-response-nvax-20220628monthly0.5https://www.biopharmawatch.com/news/NVAX/novavax-covid-19-impfstoff-nuvaxovid-vom-chmp-zur-erweiterten-bedingten-zulassung-in-der-e-nvax-20220627monthly0.5https://www.biopharmawatch.com/news/NVAX/le-chmp-recommande-le-vaccin-nuvaxovid-de-novavax-contre-la-covid-19-pour-une-autorisation-nvax-20220627monthly0.5